<SEC-DOCUMENT>0001213900-24-097737.txt : 20241114
<SEC-HEADER>0001213900-24-097737.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114063700
ACCESSION NUMBER:		0001213900-24-097737
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		89
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oruka Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-283212
		FILM NUMBER:		241456990

	BUSINESS ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		650-606-7910

	MAIL ADDRESS:	
		STREET 1:		855 OAK GROVE AVE.
		STREET 2:		SUITE 100
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARCA biopharma, Inc.
		DATE OF NAME CHANGE:	20090128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>ea0220567-s1_orukatherap.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:orka="http://www.orukatx.com/20240930" xmlns:srt="http://fasb.org/srt/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif"><b>As
filed with the Securities and Exchange Commission on November 14, 2024 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><b>Registration
No. 333-</b>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>WASHINGTON,
D.C. 20549 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>FORM&#160;<ix:nonNumeric contextRef="c0" name="dei:DocumentType" id="ixv-22658">S-1</ix:nonNumeric></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>REGISTRATION
STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>UNDER</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>THE
SECURITIES ACT OF 1933</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-80"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Oruka
Therapeutics, Inc.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its charter)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-size: 10pt">&#160;</span></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-102"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: top; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>36-3855489</b></span></td></tr> <tr style="font-family: Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer<br/> Identification No.)</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>855
Oak Grove Avenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Suite
100</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Menlo
Park, CA 94025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(650)&#160;606-7910</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Address,
including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Paul
Quinlan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>General
Counsel and Corporate Secretary</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Oruka
Therapeutics, Inc.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>855
Oak Grove Avenue</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Suite
100</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Menlo
Park, CA 94025</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(650)&#160;606-7910</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b><i>Copies
to:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Ryan
A. Murr </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Branden
C. Berns </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Gibson,
Dunn &amp; Crutcher LLP </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>One
Embarcadero Center, Suite 2600 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>San
Francisco, CA 94111 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>(415)
393-8373</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Approximate
date of commencement of proposed sale to the public</b>: From time to time after the effective date of this Registration Statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If any of
the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities
Act of 1933, check the following box.&#8194;&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If this form
is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-299"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</span></ix:nonNumeric></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-312"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-328"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#8194;&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The Registrant
hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant
shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance
with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1pt solid; border-bottom: Black 2pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>The
information in this prospectus is not complete and may be changed. The selling stockholders named in this prospectus may not sell these
securities until the registration statement filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) is effective. This
prospectus is not an offer to sell these securities, and it is not soliciting an offer to buy these securities, in any jurisdiction where
the offer or sale is not permitted. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><b>SUBJECT
TO COMPLETION, DATED NOVEMBER 13, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>PRELIMINARY
PROSPECTUS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_001.jpg"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Oruka
Therapeutics, Inc.</b></span> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>8,719,000
Shares</b></span> </p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Common
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Offered
by the Selling Stockholders </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
relates to the proposed resale or other disposition by the selling stockholders identified herein (the &#8220;Selling Stockholders&#8221;)
of up to (i) 5,600,000 shares (the &#8220;Private Placement Common Shares&#8221;) of our common stock, par value $0.001 per share (&#8220;Common
Stock&#8221;), (ii) 2,439,000 shares of Common Stock (the &#8220;Private Placement Conversion Shares&#8221;) issuable upon the conversion
of 2,439 shares (the &#8220;Private Placement Preferred Shares&#8221;) of Series A preferred stock, par value $0.001 (the &#8220;Series
A Preferred Stock&#8221;) and (iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded warrants (the &#8220;Pre-Funded
Warrants&#8221;). Subject to receiving the requisite stockholder approval and certain beneficial ownership limitations set by each holder
of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert into an aggregate of 1,000 shares of Common
Stock. The shares of Common Stock registered by this prospectus are referred to herein as the &#8220;Resale Shares.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Private
Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants were issued and sold to accredited investors in a
private placement (the &#8220;September 2024 PIPE&#8221;), which closed on September 13, 2024. We are not selling any Resale Shares under
this prospectus and will not receive any of the proceeds from the sale or other disposition of Resale Shares by the Selling Stockholders.
Upon any exercise of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the
holders of the Pre-Funded Warrants. We intend to use those proceeds, if any, for general corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed
or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems,
such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. See the disclosure under the heading
&#8220;Plan of Distribution&#8221; elsewhere in this prospectus for more information about how the Selling Stockholders may sell or otherwise
dispose of their Resale Shares hereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell any, all or none of the securities offered by this prospectus and we do not know when or in what amount the Selling
Stockholders may sell their Resale Shares hereunder following the effective date of the registration statement of which this prospectus
forms a part. Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Resale Shares will be
borne by the Selling Stockholder. We will pay certain fees and expenses (other than discounts, concessions, commissions and similar selling
expenses) incident to the registration of the Resale Shares with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">You should
carefully read this prospectus and any applicable prospectus supplement before you invest in any of the securities being offered.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Common Stock is traded on The Nasdaq Global Market under the symbol
&#8220;ORKA.&#8221; On November 12, 2024, the last reported sale price for our Common Stock was $26.10 per share.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>An investment
in our securities involves a high degree of risk. You should carefully consider the information under the <span style="font-size: 10pt">heading
&#8220;<span style="text-decoration: none">Risk Factors</span>&#8221; beginning on page 6 of this prospectus and any applicable
prospectus supplement. </span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>We are
a &#8220;smaller reporting company&#8221; as defined by Rule 12b-2 of the Exchange Act and are subject to reduced public company reporting
requirements. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Neither
the SEC nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense. </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
date of this prospectus is&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2024 </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; width: 91%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_001"><span style="font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="text-align: center">ii</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_002"><span style="font-size: 10pt">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td style="text-align: center">iii</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_003"><span style="font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_004"><span style="font-size: 10pt">RISK FACTOR SUMMARY</span></a></td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_005"><span style="font-size: 10pt">RISK FACTORS</span></a></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_006"><span style="font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td style="text-align: center">35</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_007"><span style="font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></td>
    <td style="text-align: center">36</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_008"><span style="font-size: 10pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_009"><span style="font-size: 10pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></td>
    <td style="text-align: center">49</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_010"><span style="font-size: 10pt">BUSINESS</span></a></td>
    <td style="text-align: center">50</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_011"><span style="font-size: 10pt">MANAGEMENT</span></a></td>
    <td style="text-align: center">84</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_012"><span style="font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td style="text-align: center">90</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_013"><span style="font-size: 10pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></td>
    <td style="text-align: center">96</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_014"><span style="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</span></a></td>
    <td style="text-align: center">98</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_015"><span style="font-size: 10pt">SELLING STOCKHOLDERS</span></a></td>
    <td style="text-align: center">102</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_016"><span style="font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td style="text-align: center">111</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_017"><span style="font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td style="text-align: center">113</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_018"><span style="font-size: 10pt">LEGAL MATTERS</span></a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_019"><span style="font-size: 10pt">EXPERTS</span></a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_020"><span style="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td style="text-align: center">119</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#a_021"><span style="font-size: 10pt">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td style="text-align: center"><span style="font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ABOUT
THIS PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
is part of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. Under this shelf registration
process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized
anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders
are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized
anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer
to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement
or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is
unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing
prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may
have changed materially since those dates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In this prospectus,
unless the context otherwise requires, the terms &#8220;Oruka,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
and &#8220;our&#8221; refer to Oruka Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience,
trademarks and trade names referred to in this prospectus may appear without the &#174; or TM symbols.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All references
to &#8220;our product candidates,&#8221; &#8220;our programs,&#8221; &#8220;our portfolio&#8221; and &#8220;our pipeline&#8221; in this
prospectus refer to the research programs with respect to which we have exercised the option to acquire intellectual property license
rights to or have the option to acquire intellectual property license rights to pursuant to those certain antibody discovery and option
agreements, each dated March 6, 2024 and subsequently amended and restated on March 28, 2024, by and among Oruka, Paragon Therapeutics,
Inc. (&#8220;Paragon&#8221;) and Paruka Holding LLC (&#8220;Paruka&#8221;) (the &#8220;Paragon Option Agreements&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CAUTIONARY
STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This prospectus
contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking
statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future
performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are
based on current expectations of future events.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All statements,
other than statements of historical facts contained in this prospectus, including, without limitation, statements regarding: stockholder
approval of the conversion rights of the Series A Preferred Stock; our ability to achieve the expected benefits or opportunities and
related timing with respect to the Merger (as defined below), our future results of operations and financial position, business strategy,
the length of time that we believe our existing cash resources will fund our operations, our market size, our potential growth opportunities,
our preclinical and future clinical development activities, the efficacy and safety profile of our product candidates, the potential
therapeutic benefits and economic value of our product candidates, the timing and results of preclinical studies and clinical trials,
the expected impact of macroeconomic conditions, including inflation, increasing interest rates and volatile market conditions, current
or potential bank failures, as well as global events, including ongoing military conflict between Russia and Ukraine, conflict in the
Middle East, and geopolitical tensions in China on our operations, and the receipt and timing of potential regulatory designations, approvals
and commercialization of product candidates. Forward-looking statements generally relate to future events or our future financial or
operating performance. Forward-looking statements generally relate to future events or our future financial or operating performance.
The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221;
&#8220;anticipate,&#8221; &#8220;predict,&#8221; &#8220;target,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;should,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; and similar expressions that convey uncertainty
of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain
these identifying words.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the
impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements we may make. Factors that might cause such a difference are disclosed
in the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results
of Operations.&#8221; You should evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties.
We caution you that the risks, uncertainties and other factors referred to in this prospectus may not contain all of the risks, uncertainties
and other factors that may affect our future results and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In addition,
statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements
are based on information available to us as of the date of this prospectus. While we believe that such information provides a reasonable
basis for these statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have
conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors
are cautioned not to unduly rely on these statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All subsequent
written or oral forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety
by the cautionary statements contained or referred to in this section. We do not undertake any obligation to release publicly any revisions
to these forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence
of unanticipated events, except as may be required under applicable U.S. securities laws. If we do update one or more forward-looking
statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PROSPECTUS
SUMMARY </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>This summary
may not contain all the information that you should consider before investing in securities. You should read the entire prospectus carefully,
including the sections titled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition
and Results of Operations,&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus,
before making an investment decision. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our
mission is to offer patients suffering from chronic skin diseases like psoriasis (&#8220;PsO&#8221;) the greatest possible freedom from
their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. We are advancing
a proprietary portfolio of antibodies that were engineered by Paragon and target the core mechanisms underlying PsO and other dermatologic
and inflammatory diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Our co-lead program,
ORKA-002, is designed to target interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis (&#8220;PsA&#8221;),
and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology
with the aim to increase exposure and decrease dosing frequency. We believe that our focused strategy, differentiated portfolio, and
deep expertise position us to set a new treatment standard in large inflammatory and immunology (&#8220;I&amp;I&#8221;) markets with
continued unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our principal
executive offices are located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910. Our
website address is www.orukatx.com. Information contained on, or accessible through, our website is not incorporated by reference in
this prospectus. We make our periodic and current reports available on our website, free of charge, as soon as reasonably practicable
after such material is electronically filed with, or furnished to, the SEC. No portion of our website is incorporated by reference into
this prospectus. We file our annual, quarterly and special reports, proxy statements and other information with the SEC. Our filings
with the SEC are also available to the public on the SEC&#8217;s website at http://www.sec.gov. Our Common Stock is traded on The Nasdaq
Global Market under the symbol &#8220;ORKA.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Business
Combination of ARCA and Pre-Merger Oruka and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April&#160;3, 2024, we (formerly known as ARCA biopharma, Inc.)
(prior to the Closing Date, unless context otherwise requires, &#8220;ARCA&#8221; and, after the Closing Date, the &#8220;Company&#8221;
or &#8220;Oruka&#8221;) entered into the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;), by and
among ARCA, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas
Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of ARCA (&#8220;Second Merger Sub&#8221;), and Oruka
Therapeutics, a private Delaware corporation (&#8220;Pre-Merger Oruka&#8221;) prior to the consummation of the Merger (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On August
29, 2024 (the &#8220;Closing Date&#8221;), we consummated that previously announced business combination (the &#8220;Closing&#8221;)
pursuant to the Merger Agreement to create a new public company focused on advancing Pre-Merger Oruka&#8217;s pipeline of antibody therapies.
On the Closing Date, First Merger Sub merged with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka merged with and into Second Merger Sub, with Second Merger
Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221; and, together with the First Merger, the &#8220;Merger&#8221;).
In connection with the completion of the Merger, we changed our name from &#8220;ARCA biopharma, Inc.&#8221; to &#8220;Oruka Therapeutics,
Inc.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"></p>
</div><div>
</div><!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement, certain new and existing investors of Oruka (the &#8220;Financing Investors&#8221;)
entered into a subscription agreement with Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the terms and
subject to the conditions of which, immediately prior to the Closing, the Financing Investors purchased 39,873,706 shares of Pre-Merger
Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0 million (which includes
the issuance of 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest
through the conversion date), immediately prior to the Closing and before the effect of the Reverse Stock Split (as defined below) (the
&#8220;Pre-Closing Financing&#8221;). At the Closing, the shares of Pre-Merger Oruka common stock and Pre-Merger Oruka pre-funded warrants
issued in the Pre-Closing Financing were converted into shares of Common Stock in accordance with the Exchange Ratio (as defined herein).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the consummation of the Merger, on the Closing Date (prior to the Reverse Stock Split (as defined below)):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka issued to the Financing Investors an aggregate of 39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka
pre-funded warrants for gross proceeds of approximately $275.0 million (which includes the issuance of 4,764,032 shares of Pre-Merger
Oruka Common Stock on the conversion of Convertible Note, along with the accrued interest through the conversion date); and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.4pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
of the then-outstanding (i) 9,460,019 shares of Pre-Merger Oruka common stock, (ii) 20,000,000 shares of Series A convertible preferred
stock of Pre-Merger Oruka (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), (iii) 2,063,669 options exercisable for shares of
Pre-Merger Oruka common stock, (iv) 5,345,336 Pre-Merger Oruka employee warrants and (v) the Pre-Closing Financing Pre-Merger Oruka common
stock and pre-funded warrants were automatically converted into the right to receive the number of Common Stock, Series B Preferred Stock
or warrants in lieu thereof equal to the exchange ratio calculated in accordance with the Merger Agreement (the &#8220;Exchange Ratio&#8221;),
except for the preferred stock, which was converted at the Exchange Ratio divided by 1,000.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the consummation of the Merger, we effected a 1-for-12 reverse stock split of our Common Stock (the &#8220;Reverse Stock Split&#8221;),
which became effective on September 3, 2024. Our Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the
open of trading on September 3, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Private
Placement of Common Stock, Preferred Stock and Pre-Funded Warrants </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded
Warrants pursuant to the Securities Purchase Agreement dated September 11, 2024 (the &#8220;SPA&#8221;) with the Selling Stockholders.
The Selling Stockholders purchased (i) an aggregate of 5,600,000 shares of the Common Stock, at a price per share of $23.00, (ii) an
aggregate of 2,439 shares of Series A Preferred Stock, at a price per share of $23,000.00, and (iii) Pre-Funded Warrants to purchase
an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents the per share
purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant, for an aggregate
purchase price of approximately $200.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000
shares of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together
with its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date,
which may be increased at the holders&#8217; option (not to exceed 19.99%), effective in accordance with the terms of our Certificate
of Designation of Series A Convertible Preferred Stock (&#8220;Series A Certificate of Designation&#8221;). We filed a definitive proxy
statement with the SEC on October 18, 2024 to solicit such stockholder approval at a special meeting of stockholders to be held on November
14, 2024. Except as otherwise required by law (e.g., voting on a change to the authorized shares of Series A Preferred Stock or the rights
of such shares as required by the General Corporation Law of Delaware (the &#8220;DGCL&#8221;)) and as specified in the Series A Certificate
of Designation, the Series A Preferred Stock does not have voting rights. The Pre-Funded Warrants will be exercisable at any time after
the date of issuance. A holder of Pre-Funded Warrants may not exercise the warrant if the holder, together with its affiliates, would
beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
A holder of Pre-Funded Warrants may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least
61 days&#8217; prior notice to us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The sale
of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants was not registered under the Securities
Act, and such sale was intended to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by
an issuer not involving a public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Corporation
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On August
29, 2024, we completed the Merger, in connection with which Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics
Operating Company, LLC&#8221; and ARCA changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; Our principal executive offices are
located at 855 Oak Grove Ave., Suite 100, Menlo Park, CA 94025, and our telephone number is (650) 606-7910.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><div style="font-family: Times New Roman, Times, Serif; padding: 5; border: Black 1.5pt solid; width: 98%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>The
Offering </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Offered by the Selling Securityholders </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
    to (i) 5,600,000 shares of Common Stock, (ii) 2,439,000 shares of Common Stock issuable upon the conversion of 2,439 shares of Series
    A Preferred Stock and (iii) 680,000 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Terms
    of the Offering </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    selling securityholders will determine when and how they will dispose of the shares of Common Stock, shares of Common Stock issuable
    upon conversion of Series A Preferred Stock and shares of Common Stock issuable upon the exercise of Pre-Funded Warrants registered
    under this prospectus for resale. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 0pt; width: 30%; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
    Outstanding </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of September 30, 2024, there were 34,998,550 of our Common Stock, 2,439 shares of our Series A Preferred Stock and 137,138 shares
    of our Series B Non-Voting Convertible Preferred Stock, par value $0.001 per share (&#8220;Series B Preferred Stock&#8221;), outstanding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholders under this prospectus. The net
    proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders. Upon any exercise
    of the Pre-Funded Warrants by payment of cash, however, we will receive the nominal cash exercise price paid by the holders of the
    Pre-Funded Warrants. See the section titled &#8220;Use of Proceeds.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 0pt; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%; padding-left: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
    the section titled &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors that
    you should consider carefully before deciding to invest in our securities. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Markets and Ticker Symbols </span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 70%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Common Stock is listed on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The number
of issued and outstanding shares of Common Stock does not include the following, as of September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,439,000
shares of Common Stock issuable upon the conversion of 2,439 shares of Series A Preferred Stock;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,428,149
shares of Common Stock issuable upon the conversion of 137,138 shares of Series B Preferred Stock;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,522,207
shares of Common Stock issuable upon the exercise of 5,522,207 pre-funded warrants to acquire shares of Common Stock with an exercise
price of $0.01 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">680,000
shares of Common Stock issuable upon the exercise of 680,000 pre-funded warrants to acquire shares of Common Stock with an exercise price
of $0.001 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,287,760
shares of Common Stock issuable upon the exercise of stock options outstanding under the 2024 Equity Incentive Plan and the 2024 Stock
Incentive Plan with a weighted-average exercise price of 7.97 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,054,358
shares of Common Stock issuable upon the exercise of 3,054,358 warrants to acquire shares of Common Stock with a weighted-average exercise
price of $7.80 per share;</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.2pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,526,324
shares of Common Stock reserved for issuance under our 2024 Stock Incentive Plan; and</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.3pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">463,489
shares of Common Stock reserved for issuance under the ESPP.</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">For additional
information concerning the offering, see the section titled &#8220;<i>Plan of Distribution</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
</div><div>
</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RISK
FACTOR SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The following
summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in
the Risk Factors section below. This summary should be read in conjunction with the Risk Factors section and should not be relied upon
as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial
condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking
statements we have made in this prospectus and those we may make from time to time. You should consider all the risk factors described
in our public filings when evaluating our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, and have no products approved for commercial sale.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have historically incurred losses and we anticipate that we will continue to incur losses for the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never generated revenue from product sales and may never be profitable.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to raise the capital that we need to support our business plans.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Clinical Development and Regulatory Approval</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug
development and obtaining and maintaining regulatory approval for drug products is costly, time-consuming, and highly uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory approval processes are lengthy and time
consuming and we may not be able to obtain or may be delayed in obtaining regulatory approvals for our product candidates.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval, we will be subject to ongoing regulatory obligations.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to achieve our projected development goals in the time frames we announce and expect.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding: 5pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to obtain and protect our patents and other proprietary rights is uncertain.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail in obtaining or maintaining necessary rights to our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to patent infringement claims or may need to file such claims.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patents and our ability to protect our products may be impaired by changes to patent laws.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
patent protection could be reduced or eliminated for non-compliance with legal requirements.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to identify or interpret relevant third-party patents.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become subject to claims challenging the inventorship or ownership of our intellectual property.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
terms may be inadequate to protect our competitive position of our programs.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology licensed from various third-parties may be subject to retained rights.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on agreements with third parties to develop our product candidates. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties we rely on for the execution of nonclinical studies and clinical trials may fail to carry out their contractual duties.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to use third-party manufacturing sites, our third-party manufacturers may encounter difficulties in production or we may
need to switch or create third-party manufacturer redundancies.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Other
Risk Factors - Risks Related to Employee Matters, Managing Growth, Other Risks Related to Our Business, and Owning Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.05pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is dependent on key personnel and we will be harmed if we cannot recruit and retain highly qualified personnel to successfully
implement our business strategy.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
disruptions of information technology systems or breaches of data security could adversely affect our business.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect
our business, operations and consolidated financial performance.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become exposed to costly and damaging liability claims and our insurance may not cover all damages from such claims.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be adversely affected by macroeconomic conditions.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying any dividends in the foreseeable future.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales of shares by existing stockholders could cause our stock price to decline.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
sales and issuances of equity and debt could result in additional dilution to our stockholders and could cause our stock price to decline.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;<b>&#160;</b></span></p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>RISK
FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Financial Condition and Capital Requirements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are a preclinical stage biopharmaceutical company with a limited operating history on which to assess our business; we have not initiated,
conducted or completed any clinical trials, have no products approved for commercial sale, have historically incurred losses, and we
anticipate that we will continue to incur significant losses for the foreseeable future. Moreover, we have never generated revenue from
product sales and may never be profitable.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a preclinical stage biopharmaceutical company with a limited operating history. We will need to raise substantial additional capital
to continue to fund our operations in the future. We have based our estimates on assumptions that may prove to be wrong, and could exhaust
our available financial resources sooner than it currently anticipates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, organizing and staffing
our company, and providing general and administrative support for our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as
our product candidates enter advanced clinical trials. It may be several&#160;years, if ever, before we complete pivotal clinical trials
or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of
our current programs to determine the potential to advance product candidates to regulatory approval. If we obtain regulatory approval
to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive
approval, and our ability to achieve sufficient market acceptance, pricing, coverage and adequate reimbursement from third-party&#160;payors,
and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates,
we may never become profitable despite obtaining such market share and acceptance of our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase
substantially if and as we:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
the preclinical development and initiate the clinical development of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
efforts to discover and develop new product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
the manufacturing of our product candidates or increase volumes manufactured by third parties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
our product candidates into larger, more expensive clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiate
additional preclinical studies or clinical trials for our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
regulatory and marketing approvals and reimbursement for our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
a sales, marketing, and distribution infrastructure to commercialize any products for which it may obtain marketing approval and market
for ourselves;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">make
milestone, royalty, or other payments under third-party&#160;license agreements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
to maintain, protect, and expand our intellectual property portfolio; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -18.45pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
any delays or encounter issues with the development and potential regulatory approval of our clinical and product candidates such as
safety issues, manufacturing delays, clinical trial accrual delays, longer&#160;follow-up&#160;for planned studies or trials, additional
major studies or trials, or supportive trials necessary to support marketing approval.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have no significant experience as a company in initiating, conducting or completing clinical trials. In part because of this lack of
experience, we cannot be certain that our planned clinical trials will begin or be completed on time, if at all. In addition, we have
not yet demonstrated an ability to obtain marketing approvals, manufacture a commercial-scale&#160;product or arrange for a third party
to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization. Consequently,
any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.
Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a&#160;period-to-period&#160;comparison
of our results of operations may not be a good indication of our future performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
will need to continue to raise additional capital in order to fund our operations. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we had $410.9 million of cash. We have incurred significant net losses since our inception. We anticipate that
we will continue to incur significant losses for the foreseeable future. Since February&#160;6, 2024 (inception), we have incurred significant
operating losses. For the period from February&#160;6, 2024 (inception) to September 30, 2024, we reported a net loss of $57.9&#160;million
and net cash used from operating activities of $39.0&#160;million. We will need to raise additional capital to continue to fund our operations
and service our debt obligations in the future. Until such time, if ever, as we can generate substantial revenue from the sale of our
product candidates, we expect to finance our cash needs through a combination of equity offerings, debt financings and licensing, development
or collaboration agreements. If we are unable to raise additional capital when needed, that may raise substantial doubt about our ability
to continue as a going concern. We expect that our existing cash as of $410.9 million as of September 30, 2024 will be sufficient to
fund our operating expenses and capital expenditure requirements for at least 12 months from the date these condensed consolidated financial
statements were issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Developing
our product candidates and operating our company requires a substantial amount of capital. We expect our research and development expenses
to increase in connection with our ongoing activities, particularly as we advance our product candidates through clinical trials. We
may need to raise additional capital to fund our operations and such funding may not be available to us on acceptable terms, or at all,
and such funding may become even more difficult to obtain. Competition for additional capital among biotechnology companies may be particularly
intense during this period of economic instability. We may be unable to raise capital through public offerings of our common stock and
may need to turn to alternative financing arrangements. Such arrangements, if we pursue them, could involve issuances of one or more
types of securities, including common stock, preferred stock, convertible debt, warrants to acquire common stock or other securities.
These securities could be issued at or below the then prevailing market price for our common stock. In addition, if we issue debt securities,
the holders of the debt would have a claim to our assets that would be superior to the rights of stockholders until the principal, accrued
and unpaid interest and any premium or make-whole&#160;has been paid. Interest on any newly-issued&#160;debt securities and/or newly-incurred&#160;borrowings
would increase our operating costs and reduce our net income (or increase our net loss), and these impacts may be material. If the issuance
of new securities results in diminished rights to holders of our common stock, the market price of our common stock could be materially
and adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently have any products approved for sale and do not generate any revenue from product sales. Accordingly, we expect to rely
primarily on equity and/or debt financings to fund our continued operations. Our ability to raise additional funds will depend, in part,
on the success of our preclinical studies and clinical trials and other product development activities, regulatory events, our ability
to identify and enter into licensing or other strategic arrangements, and other events or conditions that may affect our value or prospects,
as well as factors related to financial, economic and market conditions, many of which are beyond our control. There can be no assurances
that sufficient funds will be available to us when required or on acceptable terms, if at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to raise additional capital when required or on acceptable terms, we may be required to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly
delay, scale back, or discontinue the development or commercialization of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    strategic partnerships, or amend existing partnerships, for research and development programs at an earlier stage than otherwise
    would be desirable or that we otherwise would have sought to develop independently, or on terms that are less favorable than might
    otherwise be available in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">dispose
    of technology assets, or relinquish or license on unfavorable terms, our rights to technologies or any of our product candidates
    that we otherwise would seek to develop or commercialize ourselves;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pursue
    the sale of the company to a third party at a price that may result in a loss on investment for our stockholders; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">file
    for bankruptcy or cease operations altogether (and face any related legal proceedings).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
of these events could have a material adverse effect on our business, operating results, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if we are successful in raising new capital, we could be limited in the amount of capital we raise due to investor demand restrictions
placed on the amount of capital we raise, or other reasons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Raising
additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we raise additional capital through the sale of equity securities or convertible debt securities, the ownership interest
of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect
the rights of holders of our common stock. Debt financing and preferred equity financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures,
or declaring dividends.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third
parties, we may be required to relinquish valuable rights to our research programs or product candidates or grant licenses on terms that
may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements with third
parties when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts
or grant rights to third parties to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that we raise additional capital through the sale of equity, including pursuant to any sales under convertible debt or other
securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities
may include liquidation or other preferences that adversely affect the rights of our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, we entered into a Securities Purchase Agreement with certain new institutional and accredited investors, whereby the
investors purchased an aggregate of 5,600,000 shares of Company Common Stock, 2,439 shares of Company Series A Preferred Stock and pre-funded
warrants to purchase an aggregate of 680,000 shares of common stock for an aggregate purchase price of approximately $200.5 million.
Each share of Company Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Debt
financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends.
If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish
valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot
assure you that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates
to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or
more of our development programs or be unable to expand our operations or otherwise capitalize on potential business opportunities, which
could materially harm our business, financial condition, and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Clinical Development, Regulatory Approval and Commercialization</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
face competition from entities that have developed or may develop programs for the diseases addressed by product candidates developed
by us.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
development and commercialization of drugs is highly competitive. Product candidates developed by us, if approved, will face significant
competition and our failure to effectively compete may prevent us from achieving significant market penetration. We compete with a variety
of biopharmaceutical companies as well as academic institutions, governmental agencies, and public and private research institutions,
among others. Many of the companies with which we are currently competing or will compete against in the future have significantly greater
financial resources and expertise in research and development, manufacturing, preclinical testing, clinical trials, regulatory approvals,
and marketing than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources
being concentrated among a smaller number of our competitors. Smaller or early-stage&#160;companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites, recruiting participants
for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
competitors have developed, are developing or will develop programs and processes competitive with our programs and processes. Competitive
therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments. Our
success will depend partially on our ability to develop and commercialize products that have a competitive safety, efficacy, dosing and/or
presentation profile. Our commercial opportunity and success will be reduced or eliminated if competing products are safer, more effective,
have a more attractive dosing profile or presentation or are less expensive than the products we develop, or if our competitors develop
competing products or if biosimilars enter the market more quickly than we do and are able to gain market acceptance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
programs are in preclinical stages of development and may fail in development or suffer delays. We depend on the successful initiation
and completion of clinical trials for our product candidates to advance our product development plans.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have no products on the market, and all of our programs are in preclinical stages of development and have not been tested in humans.
As a result, we expect it will be many&#160;years before we can obtain regulatory approval for and commercialize any product candidate,
if ever. We have not yet demonstrated our ability to initiate or complete any clinical trials, obtain regulatory approvals, manufacture
a clinical or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities
necessary for successful product commercialization. We must initiate and complete clinical trials that demonstrate the safety and efficacy
of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, and can take years to complete
and is uncertain as to outcome. A failure of one or more of our clinical trials can occur at any stage of testing. The outcome of preclinical
testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial
do not necessarily predict final results. Moreover, preclinical and clinical data are often susceptible to varying interpretations and
analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical
trials have nonetheless failed to obtain marketing approval for their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may experience a number of unforeseen events during clinical trials, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
product candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators to suspend or terminate
the trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    supply of our clinical trial materials or other materials necessary to conduct clinical trials of our product candidates may be insufficient,
    delayed, does not meet agreed-upon specifications, or are otherwise inadequate for use in clinical trials;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulators
    or institutional review boards (&#8220;IRBs&#8221;), the FDA or ethics committees may not authorize us or our investigators to commence
    a clinical trial or conduct a clinical trial at a prospective trial site; clinical trials of any product candidates may fail to show
    safety or efficacy, produce negative or inconclusive results, and we may decide, or regulators may require it, to conduct additional
    preclinical studies or clinical trials or we may decide to abandon product development programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and/or contract research
    organizations (&#8220;CROs&#8221;);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    trial sites deviating from trial protocol or dropping out of a trial; we may elect to, or regulators, IRBs or ethics committees may
    require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance
    with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    number of subjects required for clinical trials of any product candidates may be larger than we anticipate, especially if regulatory
    bodies require completion of&#160;non-inferiority&#160;or superiority trials; enrollment in these clinical trials may be slower than
    we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment&#160;follow-up&#160;at a higher
    rate than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    third-party&#160;contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely
    manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical
    trial sites or investigators;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical trials of any of our programs may be greater than we anticipate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reports
    from clinical testing of other therapies may raise safety or efficacy concerns about our programs;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product
    candidates as well as data emerging from other therapies in the same class as our product candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or other regulatory authorities may require us to submit additional data such as long-term&#160;toxicology studies, or impose
    other requirements before permitting us to initiate a clinical trial.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Commencing
clinical trials in the United&#160;States is subject to acceptance by the FDA of an investigational new drug application (&#8220;IND&#8221;),
biologics license application (&#8220;BLA&#8221;) or similar application and finalizing the trial design based on discussions with the
FDA and other regulatory authorities. In the event that the FDA requires us to complete additional preclinical studies or it is required
to satisfy other FDA requests prior to commencing clinical trials, the start of our first clinical trials may be delayed. If our clinical
trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates may be adversely impacted.
Moreover, the combined data from our trials maybe inconclusive or may not be sufficient to ultimately gain marketing approval from the
FDA or other regulatory authorities. There are equivalent processes and risks applicable to clinical trial applications in other countries,
including countries in the European Union (&#8220;EU&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because of the competitive landscape for&#160;immunology and inflammation (commonly referred to as &#8220;I&amp;I&#8221;) indications,
we may also face competition for clinical trial enrollment. Clinical trial enrollment will depend on many factors, including if potential
clinical trial participants choose to undergo treatment with approved products or enroll in competitors&#8217; ongoing clinical trials
for programs that are under development for the same indications as our programs. An increase in the number of approved products for
the indications we are targeting with our programs may further exacerbate this competition. Our inability to enroll a sufficient number
of participants could, among other things, delay our development timeline, which may further harm our competitive position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product
candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates.
Our inability to complete development of, or commercialize our product candidates, or significant delays in doing so, could have a material
and adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are substantially dependent on the success of our two most advanced programs, ORKA-001 and ORKA-002, and our anticipated clinical trials
of such programs may not be successful.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future success is substantially dependent on our ability to develop and timely obtain marketing approval for, and then successfully commercialize,
our two most advanced programs, ORKA-001&#160;and ORKA-002. We are investing a majority of our efforts and financial resources into the
research and development of these programs. We anticipate initiating a Phase&#160;1 clinical trial in healthy volunteers of ORKA-001&#160;in
the first quarter of 2025 and of ORKA-002&#160;in the second half of 2025, each subject to the filing of an IND or foreign equivalent
and regulatory approval. The success of our programs is dependent on observing a longer half-life&#160;of our product candidates in humans
than other extended half-life&#160;monoclonal antibodies (&#8220;mAbs&#8221;) currently marketed and in development as we believe this
longer half-life&#160;has the potential to result in a more favorable dosing schedule for our product candidates, assuming they successfully
complete clinical development and obtain marketing approval. This is based in part on the assumption that the longer half-life&#160;we
have observed in&#160;non-human&#160;primates (&#8220;NHPs&#8221;) will translate into an extended half-life&#160;of our product candidates
in humans. To the extent we do not observe this extended half-life&#160;in humans, it would significantly and adversely affect the clinical
and commercial potential of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
programs will require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, product development,
marketing approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues
from product sales.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
success of our product candidates will depend on a variety of factors. We do not have complete control over many of these factors, including
certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights
and the manufacturing, marketing, distribution and sales efforts of any current or future collaborator.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we do not achieve our projected development goals in the time frames we announce and expect, the development and potential commercialization
of our product candidates may be delayed and our expenses may increase and, as a result, our business may be materially harmed and our
stock price may decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we estimate the timing of the anticipated accomplishment of various scientific, clinical, regulatory and other product
development goals, which it sometimes refers to as milestones. These milestones may include the commencement or completion of scientific
studies and clinical trials, such as the expected timing for the anticipated commencement of our Phase&#160;1 studies, clinical trials
in psoriasis (&#8220;PsO&#8221;) and other target indications, as well as the submission of regulatory filings. From time to time, we
may publicly announce the expected timing of some of these milestones. All of these milestones are and will be based on numerous assumptions.
The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control.
If we do not meet these milestones as publicly announced, or at all, the development and potential commercialization of our product candidates
may be delayed or never achieved and, as a result, our business may be materially harmed and our stock price may decline. Additionally,
delays relative to our projected timelines are likely to cause overall expenses to increase, which may require us to raise additional
capital sooner than expected and prior to achieving targeted development milestones.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
drug delivery device that we may use to deliver our product candidates may have its own regulatory, development, supply and other risks.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to deliver our product candidates via a drug delivery device, such as an injector or other delivery system. There may be unforeseen
technical complications related to the development activities required to bring such a product to market, including primary container
compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving
approval if the devices that we choose to develop do not gain and/or maintain their own regulatory approvals or clearances. Where approval
of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval.
In addition, some drug delivery devices are provided by single-source&#160;unaffiliated third-party&#160;companies. We may be dependent
on the sustained cooperation and effort of those third-party&#160;companies both to supply the devices and, in some cases, to conduct
the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent
on those third-party&#160;companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party&#160;companies
to supply the devices on time and in accordance with the agreed-upon specifications, to successfully complete studies on the devices
in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs,
delays in or failure to obtain regulatory approval and delays in product candidates reaching patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
approach to the discovery and development of our programs is unproven, and we may not be successful in our efforts to build a pipeline
of programs with commercial value.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
approach to the discovery and development of the research programs with respect to which we have the option to acquire intellectual property
license rights to pursuant to those certain antibody discovery and option agreements by and among the Company, Paragon Therapeutics,
Inc. and Paruka Holding, LLC (the &#8220;Option Agreements&#8221;) and leverages clinically validated mechanisms of action and incorporates
advanced antibody engineering to optimize half-life&#160;and other properties designed to overcome limitations of existing therapies.
Our programs are purposefully designed to improve upon existing product candidates and products while maintaining the same, well-established&#160;mechanisms
of action. However, the scientific research that forms the basis of our efforts to develop programs using half-life&#160;extension technologies
is ongoing and may not result in viable programs. There is limited clinical data available on product candidates utilizing half-life&#160;extension
technologies, especially in&#160;I&amp;I indications, demonstrating whether they are safe or effective for long-term&#160;treatment in
humans. The long-term&#160;safety and efficacy of these technologies and the extended half-life&#160;and exposure profile of our programs
compared to currently approved products is unknown.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may ultimately discover that utilizing half-life&#160;extension technologies for our specific targets and indications and any programs
resulting therefrom does not possess certain properties required for therapeutic effectiveness. We currently have only preclinical data
regarding the increased half-life&#160;properties of our programs and the same results may not be seen in humans. In addition, programs
using half-life&#160;extension technologies may demonstrate different chemical and pharmacological properties in participants than they
do in laboratory studies. This technology and any programs resulting therefrom may not demonstrate the same chemical and pharmacological
properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we may in the future seek to discover and develop programs that are based on novel targets and technologies that are unproven.
If our discovery activities fail to identify novel targets or technologies for drug discovery, or such targets prove to be unsuitable
for treating human disease, we may not be able to develop viable additional programs. We and our existing or future collaborators may
never receive approval to market and commercialize any product candidate. Even if we or an existing or future collaborator obtains regulatory
approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired
or may require labeling that includes significant use or distribution restrictions or safety warnings. If the products resulting from
the research programs with respect to which we have the option to acquire intellectual property license rights to pursuant to the Option
Agreements prove to be ineffective, unsafe or commercially unviable, such programs would have little, if any, value, which would have
a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
and clinical development involves a lengthy and expensive process that is subject to delays and uncertain outcomes, and results of earlier
studies and trials may not be predictive of future clinical trial results. If our preclinical studies and clinical trials are not sufficient
to support regulatory approval of any of our product candidates, we may incur additional costs or experience delays in completing, or
ultimately be unable to complete, the development of such product candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies
and then conduct extensive clinical trials to demonstrate the safety and efficacy of such product candidate in humans. Our clinical trials
may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or
clinical trial process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
a failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical studies and early-stage&#160;clinical
trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to
varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical
studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. In addition, we expect
to rely on participants to provide feedback on measures such as measures of quality of life, which are subjective and inherently difficult
to evaluate. These measures can be influenced by factors outside of our control, and can vary widely from&#160;day-to-day&#160;for a
particular participant, and from participant to participant and from site to site within a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot be sure that the FDA will agree with our clinical development plan. We plan to use the data from our planned Phase&#160;1 trials
of our ORKA-001&#160;and ORKA-002&#160;programs in healthy volunteers to support Phase&#160;2 trials in PsO and potentially other&#160;I&amp;I
indications. If the FDA requires us to conduct additional trials or enroll additional participants, our development timelines may be
delayed. We cannot be sure that submission of an IND, BLA or similar application will result in the FDA or comparable foreign regulatory
authorities, as applicable, allowing clinical trials to begin in a timely manner, if at all. Moreover, even if these trials begin, issues
may arise that could cause regulatory authorities to suspend or terminate such clinical trials. Events that may prevent successful or
timely initiation or completion of clinical trials include: inability to generate sufficient preclinical, toxicology or other&#160;<i>in
vivo&#160;</i>or&#160;<i>in vitro&#160;</i>data to support the initiation or continuation of clinical trials; delays in reaching a consensus
with regulatory authorities on study design or implementation of the clinical trials; delays or failure in obtaining regulatory authorization
to commence a trial; delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which
can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites; delays in identifying,
recruiting and training suitable clinical investigators; delays in obtaining required IRB approval at each clinical trial site; delays
in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of our product candidates for use
in clinical trials or the inability to do any of the foregoing; failure by our CROs, other third parties or us to adhere to clinical
trial protocols; failure to perform in accordance with the FDA&#8217;s or any other regulatory authority&#8217;s current Good Clinical
Practice requirements (&#8220;GCPs&#8221;) or applicable regulatory guidelines in other countries; changes to the clinical trial protocols;
clinical sites deviating from trial protocol or dropping out of a trial; changes in regulatory requirements and guidance that require
amending or submitting new clinical protocols; selection of clinical endpoints that require prolonged periods of observation or analyses
of resulting data; transfer of manufacturing processes to facilities operated by a contract manufacturing organization (&#8220;CMO&#8221;)
and delays or failure by our CMOs or us to make any necessary changes to such manufacturing process; and third parties being unwilling
or unable to satisfy their contractual obligations to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
could also encounter delays if a clinical trial is suspended or terminated by it, by the IRBs of the institutions in which such clinical
trials are being conducted, by the Data Safety Monitoring Board, if any, for such clinical trial or by the FDA or comparable foreign
regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical trial protocols, inspection of the clinical trial operations
or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety
issues or adverse side effects, failure to demonstrate a benefit from the programs, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial. If we are required to conduct additional clinical trials or other
testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials
of our product candidates, if the results of these trials are not positive or are only moderately positive or if there are safety concerns,
our business and results of operations may be adversely affected and we may need to adjust or abandon our business plans and we may incur
significant additional costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we encounter difficulties enrolling participants in our future clinical trials, our clinical development activities could be delayed
or otherwise adversely affected.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may experience difficulties in patient participant enrollment in our clinical trials for a variety of reasons. The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of participants
who remain in the trial until conclusion. The enrollment of participants in future trials for any of our programs will depend on many
factors, including if participants choose to enroll in clinical trials, rather than using approved products, or if our competitors have
ongoing clinical trials for programs that are under development for the same indications as our programs, and participants instead enroll
in such clinical trials. Even if we are able to enroll a sufficient number of participants for our clinical trials, it may have difficulty
maintaining participants in our clinical trials. Our inability to enroll or maintain a sufficient number of participants would result
in significant delays in completing clinical trials and increased development costs or may require us to abandon one or more clinical
trials altogether.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preliminary,
&#8220;topline&#8221; or interim data from our clinical trials may change as more participant data becomes available and are subject
to audit and verification procedures.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may publicly disclose preliminary or topline data from our preclinical studies and clinical trials, which are based
on a preliminary analysis of then-available&#160;data, and the results and related findings and conclusions are subject to change following
a more comprehensive review of the data. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of these data without the opportunity to fully and carefully evaluate complete data. As a result, the preliminary or topline results
that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results,
once additional data have been received and fully evaluated or subsequently made subject to audit and verification procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
preliminary or topline data should be viewed with caution until the final data are available. From time to time, we may also disclose
interim data from our preclinical studies and clinical trials. Interim data are subject to the risk that one or more of the clinical
outcomes may materially change as participant enrollment continues and more participant data become available or as participants from
our clinical trials continue other treatments. Further, others, including regulatory agencies, may not accept or agree with our assumptions,
estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the
value of the particular product candidate, the approvability or commercialization of the particular product candidate and our company
in general. In addition, the information we choose to publicly disclose regarding a particular preclinical study or clinical trial is
based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate
information to include in our disclosure. If the preliminary, topline or interim data that we report differ from actual results, or if
others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize,
our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
clinical trials may reveal significant adverse events or undesirable side effects not seen in our preclinical studies and may result
in a safety profile that could halt clinical development, inhibit regulatory approval or limit commercial potential or market acceptance
of any of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Results
of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects, adverse events or unexpected characteristics.
While preclinical studies in NHPs conducted with respect to our programs have not shown any such characteristics to date, we have not
yet initiated any clinical trials in humans. If significant adverse events or other side effects are observed in any of our future clinical
trials, we may have difficulty recruiting participants to such trials, participants may drop out of the trials, or we may be required
to abandon the trials or our development efforts of one or more programs altogether. We, the FDA or other applicable regulatory authorities,
or an IRB, may suspend any clinical trials of any program at any time for various reasons, including a belief that subjects or patients
in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential products developed in the biotechnology
industry that initially showed therapeutic promise in early-stage&#160;studies and trials have later been found to cause side effects
that prevented their further development. However, other potential products have shown side effects in preclinical studies, which side
effects do not present themselves in clinical trials in humans. Even if the side effects do not preclude the product candidate from obtaining
or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to their tolerability
versus other therapies. In addition, an extended half-life&#160;could prolong the duration of undesirable side effects, which could also
inhibit market acceptance. Treatment-emergent&#160;adverse events could also affect participant recruitment or the ability of enrolled
subjects to complete our clinical trials or could result in potential product liability claims. Potential side effects associated with
our product candidates may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from our
product candidates may not be normally encountered in the general patient population and by medical personnel. Any of these occurrences
could harm our business, financial condition, results of operations and prospects significantly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, even if we successfully advance our product candidates or any future product candidates through clinical trials, such trials
will only include a limited number of participants and limited duration of exposure to our product candidates. As a result, we cannot
be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of participants are
exposed to the product candidate after approval. Further, any clinical trials may not be sufficient to determine the effect and safety
consequences of using our product candidates over a multi-year&#160;period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
any of the foregoing events occur or if one or more of the research programs with respect to which we have the option to acquire intellectual
property license rights to pursuant to the Option Agreements prove to be unsafe, our entire pipeline could be affected, which would have
a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may expend our limited resources to pursue a particular program and fail to capitalize on programs that may be more profitable or for
which there is a greater likelihood of success.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
we have limited financial and managerial resources, we focus our research and development efforts on certain selected programs. For example,
we are initially focused on our most advanced programs, ORKA-001&#160;and ORKA-002. As a result, we may forgo or delay pursuit of opportunities
with other programs that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development
programs for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial
potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration,
licensing or other royalty arrangements in cases in which we would have been more advantageous for us to retain sole development and
commercialization rights to such product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Any
approved products resulting from our current programs or any future program may not achieve adequate market acceptance among clinicians,
patients, healthcare third-party payors and others in the medical community necessary for commercial success and we may not generate
any future revenue from the sale or licensing of such products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
if regulatory approval is obtained for a product candidate resulting from one of our current or future programs, they may not gain market
acceptance among physicians, patients, healthcare payors or the medical community. We may not generate or sustain revenue from sales
of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted
in the market. There are several approved products and product candidates in later stages of development for the treatment of PsO.&#160;However,
our programs incorporate advanced antibody engineering to optimize the half-life&#160;and formulation of antibodies; to date, no such
antibody has been approved by the FDA for the treatment of PsO.&#160;Market participants with significant influence over acceptance of
new treatments, such as clinicians and third-party&#160;payors, may not adopt a biologic that incorporates half-life&#160;extension for
our targeted indications, and we may not be able to convince the medical community and third-party&#160;payors to accept and use, or
to provide favorable reimbursement for, any programs developed by us or our existing or future collaborators. An extended half-life&#160;may
make it more difficult for patients to change treatments and there is a perception that half-life&#160;extension could exacerbate side
effects, each of which may adversely affect our ability to gain market acceptance. Market acceptance of our product candidates will depend
on many factors, including factors that are not within our control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Sales
of medical products also depend on the willingness of clinicians to prescribe the treatment. We cannot predict whether clinicians, clinicians&#8217;
organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our product is safe,
therapeutically effective, cost effective or less burdensome as compared with competing treatments. If any of our product candidates
is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from
that product candidate and may not become or remain profitable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Certain
of our programs may compete with our other programs, which could negatively impact our business and reduce our future revenue.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are developing product candidates for the same indication, PsO, and may in the future develop our programs for other&#160;I&amp;I indications.
Each such program targets a different mechanism of action. However, developing multiple programs for a single indication may negatively
impact our business if the programs compete with each other. For example, if multiple programs are conducting clinical trials at the
same time, they could compete for the enrollment of participants. In addition, if multiple product candidates are approved for the same
indication, they may compete for market share, which could limit our future revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may conduct clinical trials for programs at sites outside the United&#160;States, and the FDA may not accept data from trials conducted
in such locations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may choose to conduct one or more of our future clinical trials outside the United&#160;States. Although the FDA may accept data from
clinical trials conducted outside the United&#160;States, acceptance of this data is subject to conditions imposed by the FDA.&#160;For
example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles.
The trial population must also adequately represent the U.S.&#160;population, and the data must be applicable to the U.S.&#160;population
and U.S.&#160;medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject
to the applicable local laws, FDA acceptance of the data will depend upon the determination that the trials also complied with all applicable
U.S.&#160;laws and regulations. If the FDA does not accept the data from any trial that we conduct outside the United&#160;States, it
would likely result in the need for additional trials, which would be costly and time-consuming&#160;and would delay or permanently halt
our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical
trials to receive clearance to initiate such trials in the United&#160;States or to continue such trials once initiated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Further,
conducting clinical trials outside of the U.S. presents additional risks that may delay completion of our clinical trials. These risks
include the failure of enrolled participants in foreign countries to adhere to clinical protocol as a result of differences in healthcare
services or cultural customs that could restrict or limit our ability to conduct our clinical trials, the administrative burdens of conducting
clinical trials under multiple sets of foreign regulations, potential restrictions on data generated from the clinical trial, foreign
exchange fluctuations, diminished protection of intellectual property in some countries, as well as political and economic risks relevant
to foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Government Regulation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently
unpredictable. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates,
we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue
will be materially impaired.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
process of obtaining regulatory approvals, both in the United&#160;States and abroad, is unpredictable, expensive and typically takes
many&#160;years following commencement of clinical trials, if approval is obtained at all, and can vary substantially based upon a variety
of factors, including the type, complexity and novelty of the product candidates involved. Before obtaining regulatory approvals for
the commercial sale of our product candidates, including our most advanced programs, ORKA-001&#160;and ORKA-002, we must demonstrate
through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective
for each targeted indication. Securing regulatory approval also requires the submission of information about the drug manufacturing process
to, and inspection of manufacturing facilities by, the relevant regulatory authority. Further, our product candidates may not be effective,
may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that
may preclude our obtaining marketing approval. The FDA and comparable foreign regulatory authorities have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional
preclinical, clinical or other data. Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for
many reasons, including: the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical
trials; we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate
is safe and effective for our proposed indication; the results of clinical trials may not meet the level of statistical significance
required by the FDA or comparable foreign regulatory authorities for approval; serious and unexpected drug-related&#160;side effects
may be experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates; we may be
unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh our safety risks; the FDA or comparable foreign
regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; the data collected from
clinical trials of our product candidates may not be acceptable or sufficient to support the submission of a BLA or other submission
or to obtain regulatory approval in the United&#160;States or elsewhere, and we may be required to conduct additional clinical trials;
the FDA or the applicable foreign regulatory authority may disagree regarding the formulation, labeling and/or the specifications of
our product candidates; the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities
of third-party&#160;manufacturers with which we contract for clinical and commercial supplies; and the approval policies or regulations
of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient
for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Of
the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes
and are commercialized. The lengthy approval process as well as the unpredictability of future clinical trial results may result in our
failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations
and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than
we request, including failing to approve the most commercially promising indications, may grant approval contingent on the performance
of costly post-marketing&#160;clinical trials, or may approve a product candidate with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that product candidate. If we are not able to obtain, or if there are
delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed
in commercializing, our product candidates and our ability to generate revenue will be materially impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be able to meet requirements for the chemistry, manufacturing and control of our programs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
order to receive approval of our products by the FDA and comparable foreign regulatory authorities, we must show that we and our CMO
partners are able to characterize, control and manufacture our drug products safely and in accordance with regulatory requirements. This
includes manufacturing the active ingredient, developing an acceptable formulation, manufacturing the drug product, performing tests
to adequately characterize the formulated product, documenting a repeatable manufacturing process, and demonstrating that our drug products
meet stability requirements. Meeting these chemistry, manufacturing and control requirements is a complex task that requires specialized
expertise. If we are not able to meet the chemistry, manufacturing and control requirements, we may not be successful in getting our
products approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
product candidates for which we intend to seek approval as biologics may face competition sooner than anticipated.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Patient Protection and Affordable Act, as amended by the Healthcare and Education Reconciliation Act (the &#8220;ACA&#8221;), includes
a subtitle called the Biologics Price Competition and Innovation Act&#160;of&#160;2009 (&#8220;BPCIA&#8221;), which created an abbreviated
approval pathway for biological products that are biosimilar to or interchangeable with an&#160;FDA-licensed&#160;reference biological
product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until
four&#160;years following the date that the reference product was first approved by the FDA.&#160;In addition, the approval of a biosimilar
product may not be made effective by the FDA until 12&#160;years from the date on which the reference product was first approved. During
this&#160;12-year&#160;period of exclusivity, another company may still market a competing version of the reference product if the FDA
approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled&#160;clinical
trials to demonstrate the safety, purity and potency of their product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that any of our product candidates approved as biologics under a BLA should qualify for the&#160;12-year&#160;period of exclusivity.
However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not
consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition
sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject
of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any reference products in a
way that is similar to traditional generic substitution for&#160;non-biological&#160;products is not yet clear, and will depend on a
number of marketplace and regulatory factors that are still developing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we receive regulatory approval of our product candidates, we will be subject to extensive ongoing regulatory obligations and continued
regulatory review and may result in restrictions on the use of the product, which may result in significant additional expense and we
may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities
and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions
for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval&#160;study or risk management
requirements. For example, the FDA may require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) in order to approve our
product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional
elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition,
if the FDA or comparable foreign regulatory authorities approve our product candidates, our product candidates and the activities associated
with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling,
storage, approval, advertising, promotion, sale, distribution, import and export will be subject to comprehensive regulation by the FDA
and other regulatory agencies in the United&#160;States and by comparable foreign regulatory authorities. These requirements include
submissions of safety and other post-marketing&#160;information and reports, registration, as well as&#160;on-going&#160;compliance with
current CGMPs and GCPs for any clinical trials that we conduct following approval. In addition, manufacturers of drug products and their
facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance
with CGMPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or
frequency, or problems with the facilities where the product is manufactured, a regulatory authority may impose restrictions on that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing,
restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials, restrictions
on the manufacturing process, warning or untitled letters, civil and criminal penalties, injunctions, product seizures, detentions or
import bans, voluntary or mandatory publicity requirements and imposition of restrictions on operations, including costly new manufacturing
requirements. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates
and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may face difficulties from healthcare legislative reform measures.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Existing
regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval
of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation
or administrative action, either in the United&#160;States or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors,
patient organizations and customers will be subject to applicable healthcare regulatory laws, including conflicts of interest rules,
which could expose us to penalties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party&#160;payors,
patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These
laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we
research, market, sell and distribute our product candidates, if approved. Principal investigators for our clinical trials may serve
as scientific advisors or consultants to us or may be affiliated with our other service providers, including CROs or site management
organizations, and from time to time may receive cash compensation in connection with such services. If these relationships and any related
compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial
site or in the applicable trial may be questioned or jeopardized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental laws and
regulations that may apply to it, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded&#160;healthcare programs, integrity oversight and reporting obligations to resolve allegations
of&#160;non-compliance,&#160;disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming&#160;and
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we are able to commercialize any product candidates, due to unfavorable pricing regulations and/or third-party coverage and reimbursement
policies, we may not be able to offer such product candidates at competitive prices which would seriously harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
intend to seek approval to market our product candidates in the United&#160;States and in selected foreign jurisdictions. If we obtain
approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions.
Our ability to successfully commercialize any product candidates that we may develop will depend in part on the extent to which reimbursement
for these product candidates and related treatments will be available from government health administration authorities, private health
insurers and other organizations. Government authorities and other third-party&#160;payors, such as private health insurers and health
maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Government authorities and
other third-party&#160;payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
These entities may create preferential access policies for a competitor&#8217;s product, including a branded or generic/biosimilar product,
over our products in an attempt to reduce their costs, which may reduce our commercial opportunity. Additionally, if any of our product
candidates are approved and we are found to have improperly promoted off-label&#160;uses of those product candidates, we may become subject
to significant liability, which would materially adversely affect our business and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to U.S.&#160;and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering
laws and regulations. We can face criminal liability and other serious consequences for violations, which can harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to export control and import laws and regulations, including the U.S.&#160;Export Administration Regulations, U.S.&#160;Customs
regulations, various economic and trade sanctions regulations administered by the U.S.&#160;Treasury Department&#8217;s Office of Foreign
Assets Controls, the U.S.&#160;Foreign Corrupt Practices Act&#160;of&#160;1977, as amended, the U.S.&#160;domestic bribery statute contained
in 18 U.S.C. &#167; 201, the U.S.&#160;Travel Act, the USA PATRIOT Act, and other state and national anti-bribery&#160;and anti-money&#160;laundering
laws in the countries in which we conduct activities. Anti-corruption&#160;laws are interpreted broadly and prohibit companies and their
employees, agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or indirectly,
improper payments or anything else of value to or from recipients in the public or private sector. We may engage third parties to sell
our products outside the United&#160;States, to conduct clinical trials, and/or to obtain necessary permits, licenses, patent registrations,
and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated&#160;hospitals,
universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors,
and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws
and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or
import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Governments
outside the United&#160;States tend to impose strict price controls, which may adversely affect our revenue, if any.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
some countries, particularly member states of the EU (&#8220;EU Member States&#8221;), the pricing of prescription drugs is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt
of marketing approval for a therapeutic. In addition, there can be considerable pressure by governments and other stakeholders on prices
and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further
complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used
by various EU Member States and parallel distribution, or arbitrage between&#160;low-priced&#160;and high-priced&#160;EU Member States,
can further reduce prices. To obtain coverage and reimbursement or pricing approvals in some countries, we or current or future collaborators
may be required to conduct a clinical trial or other studies that compare the cost-effectiveness&#160;of our product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party&#160;payors
or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.
Brexit could lead to legal uncertainty and potentially divergent national laws and regulations, including those related to the pricing
of prescription pharmaceuticals, as the United Kingdom (&#8220;UK&#8221;) determines which EU laws to replicate or replace. If the UK
were to significantly alter its regulations affecting the pricing of prescription pharmaceuticals, we could face significant new costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>A
breakthrough therapy, fast track, or other expedited designation for our product candidates may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that those product candidates will receive marketing approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may seek a breakthrough therapy, fast track, or other designation for appropriate product candidates. Designations such as these are
within the discretion of the FDA, or other comparable regulatory authorities. The receipt of a designation for a product candidate may
not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures
and does not assure ultimate approval by the FDA.&#160;In addition, even if one or more of our product candidates qualifies under one
of FDA&#8217;s designation programs, the FDA may later decide that the products no longer meet the conditions for qualification or decide
that the time period for FDA review or approval will not be shortened.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
ability to obtain and protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive
advantage.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely upon a combination of patents, trademarks, trade secret protection, confidentiality agreements and the Option Agreements to protect
the intellectual property related to our programs and technologies and to prevent third parties from competing unfairly with it. Our
success depends in large part on our ability to obtain and maintain patent protection for our platform technologies, programs and their
uses, as well as our ability to operate without infringing on or violating the proprietary rights of others. Paragon has filed provisional
patent applications and intends to file one or more additional provisional patent applications directed to antibodies that target IL-23,
including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including ORKA-001.
In addition, Paragon has filed provisional patent applications and intends to file one or more additional provisional patent applications
directed to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods
of using such antibodies, including ORKA-002. However, we may not be able to protect our intellectual property rights throughout the
world and the legal systems in certain countries may not favor enforcement or protection of patents, trade secrets and other intellectual
property. Filing, prosecuting and defending patents on programs worldwide would be expensive and our intellectual property rights in
some foreign jurisdictions can be less extensive than those in the United&#160;States; the reverse may also occur. As such, we may not
have patents in all countries or all major markets and may not be able to obtain patents in all jurisdictions even if we apply for them.
Our competitors may operate in countries where we do not have patent protection and can freely use our technologies and discoveries in
such countries to the extent such technologies and discoveries are publicly known or disclosed in countries where we do have patent protection
or pending patent applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
pending and future patent applications may not result in patents being issued. Any issued patents may not afford sufficient protection
of our programs or their intended uses against competitors, nor can there be any assurance that the patents issued will not be infringed,
designed around, invalidated by third parties, or effectively prevent others from commercializing competitive technologies, products
or programs. Even if these patents are granted, they may be difficult to enforce. Further, any issued patents that we may license or
own covering our programs could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies
in the United&#160;States or abroad, including the United&#160;States Patent and Trademark Office (&#8220;USPTO&#8221;). Further, if
we encounter delays in our clinical trials or delays in obtaining regulatory approval, the period of time during which we could market
our product candidates under patent protection would be reduced. Thus, the patents that we may own and license may not afford us any
meaningful competitive advantage.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to seeking patents for some of our technology and programs, we may also rely on trade secrets, including unpatented&#160;know-how,&#160;technology
and other proprietary information, to maintain our competitive position. Any disclosure, either intentional or unintentional, by our
employees, the employees of third parties with whom we share our facilities or third-party&#160;consultants and vendors that we engage
to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity
breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements,
thus eroding our competitive position in our market. In order to protect our proprietary technology and processes, we rely in part on
confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers
and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate
remedy in the event of unauthorized disclosure of confidential information. We may need to share our proprietary information, including
trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft
of trade secrets, including through direct intrusion by private parties or state actors and those affiliated with or controlled by state
actors. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others
may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret
rights against such party. Costly and time-consuming&#160;litigation could be necessary to enforce and determine the scope of our proprietary
rights and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Lastly,
if our trademarks and trade names are not registered or adequately protected, then we may not be able to build name recognition in our
markets of interest and our business may be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not be successful in obtaining or maintaining necessary rights to our programs through acquisitions and&#160;in-licenses.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
our development programs currently do and may in the future require the use of proprietary rights held by third parties, the growth of
our business may depend in part on our ability to acquire,&#160;in-license,&#160;or use these third-party&#160;proprietary rights. We
may be unable to acquire or&#160;in-license&#160;any compositions, methods of use, processes or other third-party&#160;intellectual property
rights from third parties that we identify as necessary for our programs. The licensing and acquisition of third-party&#160;intellectual
property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party&#160;intellectual
property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due
to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party&#160;intellectual
property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully
obtain rights to required third-party&#160;intellectual property rights or maintain the existing intellectual property rights we do obtain,
we may have to abandon development of the relevant program, which could have a material adverse effect on our business, financial condition,
results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we plan to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our programs, there may be
times when the filing and prosecution activities for patents and patent applications relating to our programs are controlled by our current
and future licensors or collaboration partners. If any of our current and future licensors or collaboration partners fail to prosecute,
maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or
our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected
and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the
right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely
affected or prejudiced by actions or inactions of our licensees, our future licensors and our counsel that took place prior to the date
upon which we assumed control over patent prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may rely on third-party&#160;consultants or collaborators or on funds from third parties such that our future licensors
are not the sole and exclusive owners of the patents we&#160;in-license.&#160;If other third parties have ownership rights to our future&#160;in-licensed&#160;patents,
they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This
could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">It
is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain
a license, it may be&#160;non-exclusive,&#160;thereby giving our competitors access to the same technologies licensed to us. In that
event, we may be required to expend significant time and resources to redesign our technology, programs, or the methods for manufacturing
them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are
unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial
condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party&#160;patents do not
exist which might be enforced against our current technology, manufacturing methods, programs, or future methods or products resulting
in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part
to pay royalties and/or other forms of compensation to third parties, which could be significant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Disputes
may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of
rights granted under the license agreement and other interpretation-related&#160;issues; whether and the extent to which our technology
and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense
patents and other rights to third parties; our right to transfer or assign the license; the inventorship and ownership of inventions
and&#160;know-how&#160;resulting from the joint creation or use of intellectual property by our future licensors and us and our partners;
and the priority of invention of patented technology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to patent infringement claims or may need to file claims to protect our intellectual property, which could result in substantial
costs and liability and prevent us from commercializing our potential products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Because
the intellectual property landscape in the biotechnology industry is rapidly evolving and interdisciplinary, it is difficult to conclusively
assess our freedom to operate and guarantee that we can operate without infringing on or violating third-party&#160;rights. If certain
of our product candidates are ultimately granted regulatory approval, patent rights held by third parties, if found to be valid and enforceable,
could be alleged to render one or more of our product candidates infringing. If a third party successfully brings a claim against us,
we may be required to pay substantial damages, be forced to abandon any affected product candidate and/or seek a license from the patent
holder. In addition, any intellectual property claims (e.g., patent infringement or trade secret theft) brought against us, whether or
not successful, may cause us to incur significant legal expenses and divert the attention of our management and key personnel from other
business concerns. We cannot be certain that patents owned or licensed by us will not be challenged by others in the course of litigation.
Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because
they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation
could have a material adverse effect on our ability to raise funds.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Competitors
may infringe or otherwise violate our patents, trademarks, copyrights or other intellectual property. To counter infringement or other
violations, we may be required to file claims, which can be expensive and time-consuming. Any such claims could provoke these parties
to assert counterclaims against us, including claims alleging that we infringe their patents or other intellectual property rights. In
addition, in a patent infringement proceeding, a court or administrative body may decide that one or more of the patents we assert is
invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to prevent the other party from
using the technology at issue on the grounds that our patents do not cover the technology. Similarly, if we assert trademark infringement
claims, a court or administrative body may determine that the marks we have asserted are invalid or unenforceable or that the party against
whom we have asserted trademark infringement has superior rights to the marks in question. In such a case, we could ultimately be forced
to cease use of such marks. In any intellectual property litigation, even if we are successful, any award of monetary damages or other
remedy we receive may not be commercially valuable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Further,
we may be required to protect our patents through procedures created to attack the validity of a patent at the USPTO.&#160;An adverse
determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which
could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S.&#160;federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO
proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, if our programs are found to infringe the intellectual property rights of third parties, these third parties may assert infringement
claims against our future licensees and other parties with whom we have business relationships and we may be required to indemnify those
parties for any damages they suffer as a result of these claims, which may require us to initiate or defend protracted and costly litigation
on behalf of licensees and other parties regardless of the merits of such claims. If any of these claims succeed, we may be forced to
pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings
relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure
during this type of litigation or other proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent
contractors have wrongfully used or disclosed confidential information of third parties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
is common in the biotechnology industry, in addition to our employees, we engage the services of consultants to assist us in the development
of our programs. Many of these consultants, and many of our employees, were previously employed at, or may have previously provided or
may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential
competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged
trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees and
consultants do not use the intellectual property, proprietary information,&#160;know-how&#160;or trade secrets of others in their work
for us, we may become subject to claims that we caused an employee to breach the terms of his or her&#160;non-competition&#160;or&#160;non-solicitation&#160;agreement,
or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information
of a former employer or competitor.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we may litigate to defend ourselves against these claims, even if we are successful, litigation could result in substantial costs and
could be a distraction to management. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court
could prohibit us from using technologies or features that are essential to our programs, if such technologies or features are found
to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation
or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators,
engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results
of operations and financial condition. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Changes
to patent laws in the United&#160;States and other jurisdictions could diminish the value of patents in general, thereby impairing our
ability to protect our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Changes
in either the patent laws or interpretation of patent laws in the United&#160;States, including patent reform legislation such as the
Leahy-Smith&#160;America Invents Act (the &#8220;Leahy-Smith&#160;Act&#8221;) could increase the uncertainties and costs surrounding
the prosecution of our owned and&#160;in-licensed&#160;patent applications and the maintenance, enforcement or defense of our owned and&#160;in-licensed&#160;issued
patents. The Leahy-Smith&#160;Act includes a number of significant changes to United&#160;States patent law. These changes include provisions
that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective&#160;avenues for
competitors to challenge the validity of patents, and enable third-party&#160;submission of prior art to the USPTO during patent prosecution
and additional procedures to attack the validity of a patent at USPTO-administered&#160;post-grant&#160;proceedings, including post-grant&#160;review,
inter partes review and derivation proceedings. Assuming that other requirements for patentability are met, prior to March&#160;2013,
in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United&#160;States,
the first to file a patent application was entitled to the patent. After March&#160;2013, under the Leahy-Smith&#160;Act, the United&#160;States
transitioned to a&#160;first-to-file&#160;system in which, assuming that the other statutory requirements for patentability are met,
the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was
the first to invent the claimed invention. As such, the Leahy-Smith&#160;Act and its implementation could increase the uncertainties
and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could
have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly
uncertain. U.S.&#160;Supreme Court and U.S.&#160;Court of Appeals for the Federal Circuit rulings have narrowed the scope of patent protection
available in certain circumstances and weakened the rights of patent owners in certain situations, including in the antibody arts. For
example, the United&#160;States Supreme Court in&#160;<i>Amgen, Inc. v. Sanofi</i>&#160;(<i>Amgen</i>) recently held that Amgen&#8217;s
patent claims to a class of antibodies functionally defined by their ability to bind a particular antigen were invalid for lack of enablement
where the patent specification provided twenty-six&#160;exemplary antibodies, but the claimed class of antibodies covered a &#8220;vast
number&#8221; of additional antibodies not disclosed in the specification. The Court stated that if patent claims are directed to an
entire class of compositions of matter, then the patent specification must enable a person skilled in the art to make and use the entire
class of compositions. This decision makes it unlikely that we will be granted U.S.&#160;patents with composition of matter claims directed
to antibodies functionally defined by their ability to bind a particular antigen. Even if we are granted claims directed to functionally
defined antibodies, it is possible that a third party may challenge our patents, when issued, relying on the reasoning in&#160;<i>Amgen</i>&#160;or
other recent precedential court decisions. Additionally, there have been proposals for additional changes to the patent laws of the United&#160;States
and other countries that, if adopted, could impact our ability to enforce our proprietary technology. This combination of events has
created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S.&#160;Congress,
the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material
adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Geopolitical
instability in the United&#160;States and in foreign countries could increase the uncertainties and costs surrounding the prosecution
or maintenance of patent applications and the maintenance, enforcement or defense of issued patents. For example, the United&#160;States&#8217;
and foreign governments&#8217; actions related to Russia&#8217;s invasion of Ukraine may limit or prevent filing, prosecution and maintenance
of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result
in abandonment or lapse of patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such
an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government
in March&#160;2022 allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality
in, are registered in, or have predominately primary place of business or profit-making&#160;activities in the United&#160;States and
other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third
parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia.
Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may
be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, a European Unified Patent Court (&#8220;UPC&#8221;) entered into force on June&#160;1, 2023. The UPC is a common patent court
that hears patent infringement and revocation proceedings effective for EU Member States. This could enable third parties to seek revocation
of a European patent in a single proceeding at the UPC rather than through multiple proceedings in each of the jurisdictions in which
the European patent is validated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Although
we do not currently own any European patents or applications, if we obtain such patents and applications in the future, any such revocation
and loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology
and products. Moreover, the controlling laws and regulations of the UPC will develop over time, and may adversely affect our ability
to enforce or defend the validity of any European patents we may obtain. We may decide to opt out from the UPC any future European patent
applications that we may file and any patents we may obtain. If certain formalities and requirements are not met, however, such European
patents and patent applications could be challenged for&#160;non-compliance&#160;and brought under the jurisdiction of the UPC.&#160;We
cannot be certain that future European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide
to opt out of the UPC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Obtaining
and maintaining patent protection depends on compliance with various procedural, document submissions, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for&#160;non-compliance&#160;with these
requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees, renewal fees, annuities fees and various other governmental fees on patents and/or patent applications are due to be
paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent and/or patent application. The USPTO
and various foreign governmental patent agencies also require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late
fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment
or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.&#160;Non-compliance&#160;events
that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits,&#160;non-payment&#160;of fees and failure to properly legalize and submit formal documents. If
we fail to maintain the patents and patent applications covering our programs, our competitive position would be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent,
which might adversely affect our ability to develop and market our products.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party&#160;patent
and pending application in the United&#160;States and abroad that is relevant to or necessary for the commercialization of our product
candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in
a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application
may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party&#160;patent or may incorrectly
predict whether a third-party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration
date of any patent in the United&#160;States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly
interpret relevant patents may negatively impact our ability to develop and market our products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, because some patent applications in the United&#160;States may be maintained in secrecy until the patents are issued, patent
applications in the United&#160;States and many foreign jurisdictions are typically not published until 18&#160;months after filing,
and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent
applications for technology covered by our issued patents or our pending applications, or that we were the first to invent the technology.
Our competitors may have filed, and may in the future file, patent applications covering products or technology similar to ours. Any
such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued
patents covering such technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or&#160;co-inventor.&#160;The failure to name the proper inventors on a patent application can result in the
patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different
individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter
of the patent, conflicting obligations of third parties involved in developing our programs or as a result of questions regarding&#160;co-ownership&#160;of
potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership.
Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we
fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as
exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may rely on third-party&#160;consultants or collaborators or on funds from third parties, such as the U.S.&#160;government,
such that our licensors would not be the sole and exclusive owners of any patents we&#160;in-license.&#160;If other third parties have
ownership rights or other rights to our&#160;in-licensed&#160;patents, they may be able to license such patents to our competitors, and
our competitors could market competing products and technology. This could have a material adverse effect on our competitive position,
business, financial conditions, results of operations, and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Patent
terms may be inadequate to protect the competitive position of our product candidates for an adequate amount of time.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Patents
have a limited lifespan. In the United&#160;States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20&#160;years from its earliest United&#160;States&#160;non-provisional&#160;filing date. Various extensions may be available, but the
life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent
life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time
required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might
expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
technology licensed from various third parties may be subject to retained rights.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future licensors may retain certain rights under the relevant agreements with us, including the right to use the underlying technology
for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make
customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors
limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology
in the event of misuse.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Our Reliance on Third Parties</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely on licensing arrangements with Paragon through the Option Agreements. If we are unable to maintain collaborations or licensing
arrangements, or if our collaborations or licensing arrangements are not successful, our business could be negatively impacted.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
currently rely on our licensing arrangements with Paragon through the Option Agreements for a substantial portion of our discovery capabilities
and&#160;in-licenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Collaborations
or licensing arrangements that we enter into may not be successful, and any success will depend heavily on the efforts and activities
of such collaborators or licensors. If any of our current or future collaborators or licensors experience delays in performance of, or
fails to perform our obligations under their agreement with us, disagrees with our interpretation of the terms of such agreement or terminates
their agreement with us, the research programs with respect to which we have the option to acquire intellectual property license rights
to pursuant to the Option Agreements and development timeline could be adversely affected. If we fail to comply with any of the obligations
under our collaborations or license agreements, including payment terms and diligence terms, our collaborators or licensors may have
the right to terminate such agreements, in which event we may lose intellectual property rights and may not be able to develop, manufacture,
market or sell the products covered by our agreements or may face other penalties under our agreements. Our collaborators and licensors
may also fail to properly maintain or defend the intellectual property we have licensed from them, if required by our agreement with
them, or even infringe upon, our intellectual property rights, leading to the potential invalidation of our intellectual property or
subjecting us to litigation or arbitration, any of which would be time-consuming&#160;and expensive and could harm our ability to commercialize
our product candidates. In addition, collaborators could independently develop, or develop with third parties, products that compete
directly or indirectly with our programs and products if the collaborators believe that the competitive products are more likely to be
successfully developed or can be commercialized under terms that are more economically attractive than ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of our strategy, we plan to evaluate additional opportunities to enhance our capabilities and expand our development pipeline or
provide development or commercialization capabilities that complement ours. We may not realize the benefits of such collaborations, alliances
or licensing arrangements. Any of these relationships may require us to incur&#160;non-recurring&#160;and other charges, increase our
near and long-term&#160;expenditures, issue securities that dilute our existing stockholders or disrupt our management and business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may face significant competition in attracting appropriate collaborators, and more established companies may also be pursuing strategies
to license or acquire third-party&#160;intellectual property rights that we consider attractive. These companies may have a competitive
advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement
for a collaboration will depend upon, among other things, our assessment of the collaborator&#8217;s resources and expertise, the terms
and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Collaborations
are complex and time-consuming&#160;to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology
companies has reduced the number of potential future collaborators. We may not be able to negotiate additional collaborations on a timely
basis, on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake
the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them
to market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely, and plan to rely in the future, on third parties to conduct and support our preclinical studies and clinical trials.
If these third parties do not properly and successfully carry out their contractual duties or meet expected deadlines, we may not be
able to obtain regulatory approval of or commercialize our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have utilized and plan to continue to utilize and depend upon independent investigators and collaborators, such as medical institutions,
CROs, contract testing labs, CMOs and strategic partners, to supply, conduct and support our preclinical studies and clinical trials
under agreements with us. We will rely heavily on these third parties over the course of our preclinical studies and clinical trials,
and we control only certain aspects of their activities. As a result, we will have less direct control over the conduct, timing and completion
of these preclinical studies and clinical trials and the management of data developed through preclinical studies and clinical trials
than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that each of our
studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance
on these third parties does not relieve us of our regulatory responsibilities. We and our third-party&#160;contractors and CROs are required
to comply with GCP regulations, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities
for all of our programs in clinical development. If we or any of these third parties fail to comply with applicable GCP regulations,
the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications or refuse to approve our marketing applications.
We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical
trials comply with GCP regulations. In addition, our clinical trials must be conducted with products produced under cGMP regulations.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws
and regulations or healthcare privacy and security laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
third parties conducting our clinical trials will not be our employees and, except for remedies available to us under our agreements
with such third parties, we cannot control whether they devote sufficient time and resources to our programs. These third parties may
be involved in mergers, acquisitions or similar transactions and may have relationships with other commercial entities, including our
competitors, for whom they may also be conducting clinical trials or other product development activities, which could negatively affect
their performance on our behalf and the timing thereof and could lead to products that compete directly or indirectly with our product
candidates. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere
to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated
and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we currently rely on foreign CROs and CMOs, including WuXi Biologics (Hong&#160;Kong) Limited and its affiliates (&#8220;WuXi
Biologics&#8221;) and will likely continue to rely on foreign CROs and CMOs in the future. WuXi is a subsidiary or affiliate of WuXi
Biologics, which is identified in the proposed U.S. legislation known as the BIOSECURE Act as a biotechnology &#8220;company of concern.&#8221;
The current version of the BIOSECURE Act introduced in the House of Representatives would prohibit federal agencies from entering into
procurement contracts with, as well as providing grants and loans to, an entity that uses biotechnology equipment or services from a
biotechnology company of concern, and includes a grandfathering provision allowing biotechnology equipment and services provided or produced
by named &#8220;biotechnology companies of concern&#8221; under a contract or agreement entered into before the effective date until
January 1, 2032. The pathway and timing for the BIOSECURE Act or its provisions to become law are uncertain, although the bill was passed
in the House of Representatives on September 9, 2024. Depending on whether the BIOSECURE Act becomes law, what the final language of
the BIOSECURE Act includes, and how the law is interpreted by U.S. federal agencies, we could be potentially restricted from pursuing
U.S. federal government business or grants in the future if we continue to use WuXi or other parties identified as &#8220;biotechnology
companies of concern&#8221; beyond the grandfathering period. Foreign CMOs may be subject to U.S.&#160;legislation, including the proposed
BIOSECURE bill, trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material
available to us, delay the procurement or supply of such material or have an adverse effect on our ability to secure significant commitments
from governments to purchase our potential therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
example, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government
policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China
which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#8217;s
public health, economic, political, and social conditions and the uncertainty around China&#8217;s relationship with other governments,
such as the United&#160;States and the UK, could also negatively impact our ability to manufacture our product candidates for our planned
clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition
and cause it to delay our clinical development programs. Furthermore, if the BIOSECURE bill is passed and one or more of our collaborators
in China, including WuXi Biologics, is deemed to be a biotechnology company of concern, our operations and financial condition may be
negatively impacted as a result of any delays or increased costs arising from the trade restrictions and other foreign regulatory requirements
affecting such collaborators. In addition, while we have established relationships with CROs and CMOs outside of China, moving to those
suppliers in the event of a geopolitical instability affecting our collaborators in China could introduce delays into the development
program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
currently rely and expect to rely in the future on the use of manufacturing suites in third-party facilities or on third parties to manufacture
our product candidates, and we may rely on third parties to produce and process our products, if approved. Our business could be adversely
affected if we are unable to use third-party manufacturing suites or if the third-party manufacturers encounter difficulties in production.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own any facility that may be used as our clinical or commercial manufacturing and processing facility and must currently
rely on CMOs to manufacture our product candidates. We have not yet caused any product candidates to be manufactured on a commercial
scale and may not be able to do so for any of our product candidates, if approved. We currently have a sole source relationship for our
supply of the ORKA-001&#160;and ORKA-002&#160;programs. If there should be any disruption in such supply arrangement, including any adverse
events affecting our sole supplier, it could have a negative effect on the clinical development of our programs and other operations
while we work to identify and qualify an alternate supply source. We may not control the manufacturing process of, and may be completely
dependent on, our contract manufacturing partners for compliance with cGMP requirements and any other regulatory requirements of the
FDA or comparable foreign regulatory authorities for the manufacture of our product candidates. Beyond periodic audits, we have limited
control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any approval in the future, we may need to find alternative manufacturing facilities, which would require the incurrence of significant
additional costs, delays, and materially adversely affect our ability to develop, obtain regulatory approval for or market our product
candidates, if approved. Similarly, our failure, or the failure of our CMOs, to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly
and adversely affect supplies of our product candidates or drugs and harm our business and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
our CMOs may experience manufacturing difficulties due to resource constraints, supply chain issues, or as a result of labor disputes
or unstable political environments. If any CMOs on which we will rely fail to manufacture quantities of our product candidates at quality
levels necessary to meet regulatory requirements and at a scale sufficient to meet anticipated demand at a cost that allows us to achieve
profitability, our business, financial condition and prospects could be materially and adversely affected. In addition, our CMOs are
responsible for transporting&#160;temperature-controlled&#160;materials that can be inadvertently degraded during transport due to several
factors, rendering certain batches unsuitable for trial use for failure to meet, among others, our integrity and purity specifications.
We and any of our CMOs may also face product seizure or detention or refusal to permit the import or export of products. Our business
could be materially adversely affected by business disruptions to our third-party&#160;providers that could materially adversely affect
our anticipated timelines, potential future revenue and financial condition and increase our costs and expenses. Each of these risks
could delay or prevent the completion of our preclinical studies and clinical trials or the approval of any of our product candidates
by the FDA, result in higher costs or adversely impact commercialization of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>In
order to successfully implement our plans and strategies, we will need to grow the size of our organization and we may experience difficulties
in managing this growth.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of
preclinical and clinical drug development, technical operations, clinical operations, regulatory affairs and, potentially, sales and
marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial
personnel and systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources and the limited experience of our management team working together in managing a company with such anticipated growth, we may
not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are highly dependent on our key personnel and anticipate hiring new key personnel. If we are not successful in attracting and retaining
highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a preclinical stage biotechnology company with a limited operating history. We have been and will continue to be highly dependent
on the research and development, clinical and business development expertise of our executive officers, as well as the other principal
members of our management, scientific and clinical team. Any of our management team members may terminate their employment with us at
any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Attracting
and retaining qualified personnel will also be critical to our success, including with respect to any strategic transaction that we may
pursue. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development
and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing
executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals
in our industry with the breadth of skills and experience required to successfully develop, facilitate regulatory approval of and commercialize
product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these
key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our discovery
and nonclinical and clinical development and commercialization strategy. Our consultants and advisors may be employed by employers other
than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.
If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
future growth may depend, in part, on our ability to operate in foreign markets, where it would be subject to additional regulatory burdens
and other risks and uncertainties.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we
may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive
regulatory approval from the applicable foreign regulatory authority, and may never receive such regulatory approval for any of our product
candidates. To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements
of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and
distribution of our product candidates, and we cannot predict success in these jurisdictions. If we fail to comply with the regulatory
requirements in international markets and receive applicable marketing approvals, our target market will be reduced and our ability to
realize the full market potential of our product candidates will be harmed and our business will be adversely affected. Moreover, even
if we obtain approval of our product candidates and ultimately commercializes our product candidates in foreign markets, we would be
subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting
and legal requirements and reduced protection of intellectual property rights in some foreign countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we compete
achieve the forecasted growth, our business may not grow at similar rates, or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, CMOs, suppliers and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators,
CROs, CMOs, suppliers and vendors acting for or on our behalf may engage in misconduct or other improper activities. We have adopted
a code of conduct and ethics, but it is not always possible to identify and deter misconduct by these parties and the precautions we
take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
internal information technology systems, or those of any of our CROs, manufacturers, other contractors or consultants, third-party service
providers, or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper
access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, which could result in additional
costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the ordinary course of our business, we and the third parties upon which we rely collect, receive, store, process, generate, use, transfer,
disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) proprietary, confidential, and sensitive
data, including personal data, intellectual property, trade secrets, and other sensitive data (collectively, sensitive information).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and
the increasing amounts of information maintained on our internal information technology systems and those of our third-party&#160;CROs,
other contractors (including sites performing our clinical trials), third-party&#160;service providers and supply chain companies, and
consultants, these systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system
malfunction, natural disasters, terrorism, war and telecommunication and electrical failures, as well as security breaches from inadvertent
or intentional actions by our employees, contractors, consultants, business partners and/or other third parties, or from cyber-attacks&#160;by
malicious third parties, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination
of, or damage to, our data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Some
actors now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state&#160;actors for
geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts,
we, and the third parties upon which we rely, may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks,
that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services.
In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations,
ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Extortion
payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for
example, applicable laws or regulations prohibiting such payments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
the extent that any disruption or security breach were to result in loss, destruction, unavailability, alteration or dissemination of,
or damage to, our data or applications, or for it to be believed or reported that any of these occurred, we could incur liability and
reputational damage and the development and commercialization of our product candidates could be delayed. Further, our insurance policies
may not be adequate to compensate us for the potential losses arising from any such disruption in, or failure or security breach of,
our systems or third-party&#160;systems where information important to our business operations or commercial development is stored.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
fully-remote&#160;workforce may create additional risks for our information technology systems and data because our employees work remotely
and utilize network connections, computers, and devices working at home, while in transit and in public locations. Additionally, business
transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems
could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will
be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and
techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred.
Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.
Applicable data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures
are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
rely on third-party&#160;service providers and technologies to operate critical business systems to process sensitive information in
a variety of contexts. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties
may not have adequate information security measures in place. If our third-party&#160;service providers experience a security incident
or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party&#160;service
providers fail to satisfy their privacy or security-related&#160;obligations to it, any award may be insufficient to cover our damages,
or we may be unable to recover such award. In addition, supply-chain&#160;attacks have increased in frequency and severity, and we cannot
guarantee that third parties&#8217; infrastructure in our supply chain or our third-party&#160;partners&#8217; supply chains have not
been compromised.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may
experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections);
additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions
in our operations (including availability of data); financial loss; management distraction; delays; and other similar harms. Security
incidents and attendant consequences may cause stakeholders (including investors and potential customers) to stop supporting our platform,
deter new customers from products, and negatively impact our ability to grow and operate our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in
our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations.
We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out
of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or
that such coverage will pay future claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
are subject to stringent and changing laws, regulations and standards, and contractual obligations relating to privacy, data protection,
and data security. The actual or perceived failure to comply with such obligations could lead to government enforcement actions (which
could include civil or criminal penalties), fines and sanctions, private litigation and/or adverse publicity and could negatively affect
our operating results and business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
and third parties who we work with are or may become subject to numerous domestic and foreign laws, regulations, and standards relating
to privacy, data protection, and data security, the scope of which is changing, subject to differing applications and interpretations,
and may be inconsistent among countries, or conflict with other rules. We are or may become subject to the terms of contractual obligations
related to privacy, data protection and data security. Our obligations may also change or expand as our business grows. The actual or
perceived failure by us or third parties related to us to comply with such laws, regulations and obligations could increase our compliance
and operational costs, expose us to regulatory scrutiny, actions, fines and penalties, result in reputational harm, lead to a loss of
customers, result in litigation and liability, and otherwise cause a material adverse effect on our business, financial condition, and
results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur
costs that could have a material adverse effect on the success of our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations may involve the use of hazardous and
flammable materials, including chemicals and biological and radioactive materials. In addition, we may incur substantial costs in order
to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations
may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result
in substantial fines, penalties or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
rules dealing with U.S.&#160;federal, state and local income taxation are constantly under review by persons involved in the legislative
process and by the Internal Revenue Service and the U.S.&#160;Treasury Department. Changes to tax laws (which may have retroactive application)
could adversely affect our stockholders or us. We continue to assess the impact of various tax reform proposals and modifications to
existing tax treaties in all jurisdictions where we have operations or employees to determine the potential effect on our business and
any assumptions we make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms
of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. For example, the
United&#160;States enacted the Inflation Reduction Act&#160;of&#160;2022, which implements, among other changes, a 1% excise tax on certain
stock buybacks. In addition, beginning in 2022, the Tax Cuts and&#160;Jobs Act&#160;eliminated the previously available option to deduct
research and development expenditures and requires taxpayers to amortize them generally over five&#160;years for research activities
conducted in the United&#160;States and over 15&#160;years for research activities conducted outside the United&#160;States. The U.S.&#160;Congress
is considering legislation that would restore the current deductibility of research and development expenditures; however, there is no
assurance that the current provision will be repealed or otherwise modified. Such changes, among others, may adversely affect our effective
tax rate, results of operation and general business condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may acquire businesses or products, or form strategic alliances, in the future, and may not realize the benefits of such acquisitions.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may acquire additional businesses or products, form strategic alliances, or create joint ventures with third parties that we believe
will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able
to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and
company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new product candidates or products
resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.
There is no assurance that, following any such acquisition, we will achieve the synergies expected in order to justify the transaction,
which could result in a material adverse effect on our business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
maintain our cash at financial institutions, often in balances that exceed federally-insured limits. The failure of financial institutions
could adversely affect our ability to pay our operational expenses or make other payments.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
cash held in&#160;non-interest-bearing&#160;and interest-bearing&#160;accounts exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;)
insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance
limitations. For example, the FDIC took control of Silicon Valley Bank on March&#160;10, 2023. The Federal Reserve subsequently announced
that account holders would be made whole. We currently hold a small portion of our cash and cash equivalents at Silicon Valley Bank.
However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are
ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their
accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period
to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments,
which could adversely affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>General
Risk Factors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
estimates&#160;of market&#160;opportunity&#160;and forecasts&#160;of market&#160;growth may&#160;prove&#160;to be inaccurate,&#160;and
even if the markets&#160;in which we compete&#160;achieve&#160;the forecasted&#160;growth, our business&#160;may&#160;not grow at similar&#160;rates,
or at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates which
may not prove to be accurate. Our estimates and forecasts relating to size and expected growth of our target market may prove to be inaccurate.
Even if the markets in which we compete meet our size estimates and growth forecasts, our business may not grow at similar rates, or
at all. Our growth is subject to many factors, including our success in implementing our business strategy, which is subject to many
risks and uncertainties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted
price for the product, the ability to obtain coverage and reimbursement and whether we own the commercial rights for that territory.
If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not
generate significant revenue from sales of such products, even if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
may become exposed to costly and damaging liability claims, either when testing a product candidate in the clinical or at the commercial
stage, and our product liability insurance may not cover all damages from such claims.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing, and use of pharmaceutical products. While we currently have no products that have been approved for commercial sale, the future
use of a product candidate in clinical trials, and the sale of any approved products in the future, may expose us to liability claims.
These claims may be made by patients that use the product, healthcare providers, pharmaceutical companies, or others selling such product.
Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially and adversely affect the
market for our products or any prospects for commercialization of our products. Although we intend to obtain product liability insurance
for our future clinical trials, it is possible that any liabilities could exceed our insurance coverage or that in the future we may
not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability
that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess
of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Litigation
costs and the outcome of litigation could have a material adverse effect on our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time&#160;we&#160;may&#160;be&#160;subject&#160;to&#160;litigation&#160;claims through the ordinary course of our business operations
regarding, but not limited to, employment matters, security of patient and employee personal information, contractual relations with
collaborators and intellectual property rights. Litigation to defend ourselves against claims by third parties, or to enforce any rights
that we may have against third parties, may continue to be necessary, which could result in substantial costs and diversion of our resources,
causing a material adverse effect on our business, financial condition, results of operations or cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
business could be adversely affected by economic downturns, inflation, fluctuation in interest rates, natural disasters, public health
crises, political crises, geopolitical events, or other macroeconomic conditions, which could have a material and adverse effect on our
results of operations and financial condition.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including, among other things,
diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, supply chain shortages, increases
in inflation rates, fluctuation in interest rates, and uncertainty about economic stability. For example, the&#160;COVID-19&#160;pandemic
resulted in widespread unemployment, economic slowdown and extreme volatility in the capital markets. The Federal Reserve previously
raised interest rates multiple times in response to concerns about inflation and it may raise them again. Fluctuation in interest rates,
coupled with reduced government spending and volatility in financial markets, may increase economic uncertainty and affect consumer spending.
Similarly, the ongoing military conflict between Russia and Ukraine and in the Middle East and rising tensions with China have created
extreme volatility in the global capital markets and may have further global economic consequences, including disruptions of the global
supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely. If the equity
and credit markets deteriorate, including as a result of political unrest or war, it may make any necessary debt or equity financing
more costly, more dilutive, or more difficult to obtain in a timely manner or on favorable terms, if at all. Increased inflation rates
can adversely affect us by increasing our costs, including materials, operational, labor and employee benefit costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
may in the future experience disruptions as a result of such macroeconomic conditions, including delays or difficulties in initiating
or expanding clinical trials and manufacturing sufficient quantities of materials. Any one or a combination of these events could have
a material and adverse effect on our results of operations and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Risks
Related to Owning Our Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
market price of our common stock may continue to be volatile.</i></b></span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
market price of our common stock may be subject to significant fluctuations. Some of the factors that may cause the market price of our
common stock to fluctuate include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
and results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our existing or future
collaborators;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed financial and development projections that we may provide to the public;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant or potential equity or debt sales by us;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to meet or exceed the financial and development projections of the investment community;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to achieve the perceived benefits of our recent merger as rapidly or to the extent anticipated by financial or industry analysts;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing
    terms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection
    for our technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel, including scientific or management personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including patent or stockholder litigation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions
    regarding our business and stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of similar companies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    market, macroeconomic or geopolitical conditions or market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of securities by us or our securityholders in the future;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we fail to raise an adequate amount of capital to fund our operations or continued development of our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading
    volume of our common stock;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    by competitors of new commercial products, clinical progress or lack thereof, significant contracts, commercial relationships or
    capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    publicity relating to precision medicine product candidates, including with respect to other products in such markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    introduction of technological innovations or new therapies that compete with our products; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">period-to-period
    fluctuations in our financial results.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual
companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In addition, a recession,
depression or other sustained adverse market event could materially and adversely affect our business and the value of our common stock.
In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted
class action securities litigation against such companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective
of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of
our board of directors could have an adverse effect on our operating results, financial condition and cash flows.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
certificate of incorporation and bylaws, as well as provisions under Delaware law, could make an acquisition of the company more difficult
and may prevent attempts by our stockholders to replace or remove management.</i></b></span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Provisions
in our certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the
company that stockholders may consider favorable, including transactions in which our common stockholders might otherwise receive a premium
price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of
our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace
or remove current management by making it more difficult for stockholders to replace members of our board of directors. Among other things,
these provisions:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a classified board of directors such that all members of the board are not elected at one time;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
    the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    the manner in which stockholders can remove directors from the board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on
    at stockholder meetings;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written
    consent;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
    who may call a special meeting of stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
    our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221;
    that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not
    been approved by our board of directors; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-right: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
    the approval of the holders of at least 66 2/3% of the votes that all stockholders would be entitled to cast to amend or repeal certain
    provisions of our charter or bylaws.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;),
which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe
these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with
our board of directors, they would apply even if the offer may be considered beneficial by some stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
governing documents provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will
be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217;
ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
governing documents provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware
is the sole and exclusive forum for state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action
asserting a claim of or based on a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees
or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, the certificate of incorporation
or the bylaws, (iv) any action to interpret, apply, enforce or determine the validity of the certificate of incorporation or bylaws,
or (v) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery
having personal jurisdiction over the indispensable parties named as defendants therein, which for purposes of this risk factor refers
to herein as the &#8220;Delaware Forum Provision.&#8221; Our governing documents further provide that, unless we consent in writing to
an alternative forum, the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting
a cause of action arising under the Securities Act, which for purposes of this risk factor refers to herein as the &#8220;Federal Forum
Provision.&#8221; Neither the Delaware Forum Provision nor the Federal Forum Provision will apply to any causes of action arising under
the Exchange Act. In addition, any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will
be deemed to have notice of and consented to the foregoing Delaware Forum Provision and Federal Forum Provision; provided, however, that
stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations
thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Delaware Forum Provision and the Federal Forum Provision may impose additional litigation costs on our stockholders in pursuing any such
claims, particularly if such stockholders do not reside in or near the State of Delaware. Additionally, these forum selection clauses
may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors,
officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action,
if successful, might benefit our stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Future
sales of shares by existing stockholders could cause our stock price to decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions
on resale lapse, the trading price of our common stock could decline. In addition, shares of our common stock that are subject to our
outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements
and Rules 144 and 701 under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
do not anticipate that we will pay any cash dividends in the foreseeable future</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future
earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock
will be your sole source of gain, if any, for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Our
executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted
to our stockholders for approval.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
executive officers, directors and principal stockholders beneficially own a significant percentage of our outstanding common stock. As
a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters
submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to
act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of
all or substantially all of our assets. This concentration of voting power could delay or prevent our acquisition on terms that other
stockholders may desire.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>If
equity research analysts do not publish research or reports, or publish unfavorable research or reports about us, our business or our
market, our stock price and trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and
our business. Equity research analysts may elect to not provide research coverage of our common stock, and such lack of research coverage
may adversely affect the market price of our common stock. If we do have equity research analyst coverage, we will not have any control
over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity
research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases
coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our
stock price or trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>USE
OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are not selling any securities under this prospectus and we will not receive any proceeds from the sale of the Resale Shares covered
hereby. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholders.
Some of the shares of Common Stock offered hereby are issuable upon the exercise of the Pre-Funded Warrants. Upon exercise of such Pre-Funded
Warrants for cash, we will receive the nominal cash exercise price paid by the holders of the Pre-Funded Warrants. We intend to use those
proceeds, if any, for general corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Subject
to limited exceptions, the Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling
Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing
of any of the Resale Shares. We will bear the costs, fees and expenses incurred in effecting the registration of the Resale Shares covered
by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent
registered public accounting firm. &#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>




</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT&#8217;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>You
should read the following discussion of our financial condition and results of operations in conjunction with the consolidated financial
statements and the related notes thereto and other financial information included elsewhere in this prospectus. This discussion contains
forward-looking statements based upon current beliefs, plans and expectations related to future events and our future financial performance
that involve risks, uncertainties and assumptions. Our actual results could differ materially from those discussed in these forward-looking
statements as a result of various factors. Factors that could cause or contribute to these differences include, but are not limited to,
those discussed below and elsewhere in this prospectus, particularly in the section titled &#8220;Risk Factors.&#8221; Please also see
the section titled &#8220;Cautionary Statement Concerning Forward-Looking Statements.&#8221; As used in this prospectus, unless the context
suggests otherwise, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, &#8220;the Company&#8221;, or &#8220;Oruka&#8221; refers to
Oruka Therapeutics, Inc. and its subsidiaries, including Oruka Therapeutics Operating Company, LLC. </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for psoriasis (&#8220;PsO&#8221;) and other
inflammatory and immunology (&#8220;I&amp;I&#8221;) indications. Our name is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>,
for &#8220;restoration&#8221;&#160;and reflects our mission to deliver therapies for chronic skin diseases that provide patients the
greatest possible freedom from their condition. Our strategy is to apply antibody engineering and format innovations to validated modes
of action, which we believe will enable us to improve meaningfully upon the efficacy and dosing regimens of standard-of-care medicines
while significantly intending to reduce technical and biological risk. Our programs aim to treat and potentially modify disease by targeting
mechanisms with proven efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells.
Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO.
Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of
PsO, psoriatic arthritis (&#8220;PsA&#8221;), and other conditions. These programs each bind their respective targets at high affinity
and incorporate half-life extension technology with the aim to increase exposure and decrease dosing frequency. We believe that our focused
strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large&#160;I&amp;I markets with
continued unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception in February&#160;2024, we have devoted substantially all of our resources to raising capital, organizing and staffing the
company, business and scientific planning, conducting discovery and research activities, establishing arrangements with third parties
for the manufacture of our programs and component materials, and providing general and administrative support for these operations. We
do not have any programs approved for sale and have not generated any revenue from product sales. To date, we have funded our operations
primarily with proceeds from the issuance of convertible preferred stock, common stock, convertible note, pre-funded warrants, and the
proceeds from the reverse recapitalization and merger with ARCA biopharma, Inc., our Pre-Closing Financing and subsequent PIPE Financing
(as defined and further described in &#8220;<i>Recent developments&#8221; </i>below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Since
our inception, we have incurred significant losses and negative cash flows from our operations. Our ability to generate product revenue
sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any programs
we may develop. We generated net losses of $28.6 million for the three months ended September 30, 2024 and $57.9 million for the period
from February&#160;6, 2024 (inception) to September&#160;30, 2024. For the period from February 6 (inception) to September 30, 2024,
we have used net cash of $39.0 million for our operating activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
had cash and cash equivalents of $410.9 million as of September 30, 2024. We expect that our existing cash and cash equivalents will
be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus. We expect to continue
to incur substantial losses for the foreseeable future, and our transition to profitability will depend upon successful development,
approval and commercialization of our product candidates and upon achievement of sufficient revenues to support our cost structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO.&#160;IL-23 is composed of two subunits: a p40 subunit that is
shared with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and
IL-23 signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain to modify the pH-dependent
binding to the neonatal Fc receptor. As a result, it has a pharmacokinetic profile that has the potential to support a SQ injection as
infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease biology of PsO,
possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics of ORKA-001
increase its potential to deliver these disease-modifying benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy data in PsO patients in
the second half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;).&#160;IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa and axial spondyloarthritis.&#160;More recently, the importance of inhibiting the IL-17F isoform along
with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx<sup>&#174;</sup> (bimekizumab) has led
to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar epitopes, or binding
sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more convenient dosing intervals.
We plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim data from the first-in-human
trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional&#160;I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Program</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recent
Developments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>The
Merger</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024, we consummated the previously announced business combination (&#8220;Closing&#8221;) pursuant to that certain Agreement
and Plan of Merger and Reorganization, dated April 3, 2024 (the &#8220;Merger Agreement&#8221;), by and among ARCA, Atlas Merger Sub
Corp, a wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of ARCA
(&#8220;Second Merger Sub&#8221;) and Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;), pursuant to which, among other matters,
Pre-Merger Oruka merged with and into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the
surviving corporation of the merger (&#8220;First Merger&#8221;) and following that, Pre-Merger Oruka then merged with and into Second
Merger Sub, with Second Merger Sub being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with
the First Merger, the &#8220;Merger&#8221;). Following consummation of the Merger, we effected a 1-for-12 reverse stock split (the &#8220;Reverse
Stock Split&#8221;) of the common stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), which became
effective on September 3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening
of trading on September 3, 2024. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221;
and ARCA changed its name to &#8220;Oruka Therapeutics, Inc.&#8221; We are led by the pre-reverse capitalization Pre-Merger Oruka management
team and remains focused on developing biologics to optimize the treatment of inflammatory skin diseases.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Closing
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (refer to Note 6 in our
condensed consolidated financial statements included in this prospectus for additional details) and accrued interest on such note which
converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;). We incurred transaction costs of $20.5
million which was recorded as a reduction to additional paid-in capital in the unaudited condensed consolidated financial statements.
At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded warrants issued pursuant to the Subscription
Agreement were converted into shares of Company Common Stock and pre-funded warrants of Company Common Stock in accordance with the Exchange
Ratio (defined below).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the exchange ratio of 6.8569 shares of Company Common Stock (the &#8220;Exchange Ratio&#8221;),
which were subject to the same vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series
A convertible preferred stock, par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior
to the First Effective Time was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred
stock, par value $0.001 per share, which are convertible into shares of Company Common Stock at a conversion ratio of approximately 83.3332:1,
(iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase shares of Company Common
Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a warrant to purchase shares
of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective Time remain issued and
outstanding in accordance with its terms and such shares Subsequent to the close of the merger, the common stock shares were then, subject
to the reverse stock split of 1-for-12 effected on September 3, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, the investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Merger was accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka
was deemed to be the accounting acquirer for financial reporting purposes. This determination was primarily based on the fact that, immediately
following the Merger: (i) Pre-Merger Oruka stockholders own a substantial majority of the voting rights in the combined company; (ii)
Pre-Merger Oruka&#8217;s largest stockholders retain the largest interest in the combined company; (iii) Pre-Merger Oruka designated
a majority of the initial members of the board of directors of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management
team became the management team of the combined company. Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent
of Pre-Merger Oruka issuing stock to acquire the net assets of ARCA; and (ii) the reported historical operating results of the combined
company prior to the Merger are those of Pre-Merger Oruka. Additional information regarding the Merger is included in Note 3 to the condensed
consolidated financial statements included in this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, we effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value per share
and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common Stock underlying
outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective exercise
prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities. All references
to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share data, and related
information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of
the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 11, 2024, we entered into a Securities
Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors. The
closing of the PIPE Financing occurred on September 13, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Securities Purchase Agreement,
the investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate
of 2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $0.001 per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Components
of Results of Operations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Revenue</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
date, we have not generated revenue from any sources, including product sales, and do not expect to generate any revenue from the sale
of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory
approval, we may generate revenue in the future from product sales or payments from future collaboration or license agreements that we
may enter into with third parties, or any combination thereof. We cannot predict if, when, or to what extent we will generate revenue
from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product
candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Operating
Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Research
and Development</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses consist primarily of costs incurred in connection with the development and research of our programs. These expenses
include costs of funding research performed by third parties, including Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;), that conduct
research and development activities on our behalf, expenses incurred in connection with continuing our current research programs and
discovery-phase development of any programs we may identify, including under future agreements with third parties, such as consultants
and contractors, personnel-related expenses, including salaries, bonuses, employee benefits, stock-based compensation expense, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation
for our leased office space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expense research and development costs as incurred. Our primary focus since inception has been the identification and development of
our pipeline programs. Our research and development expenses primarily consist of external costs, such as fees paid to Paragon under
the Option Agreements. We separately track the amount of costs incurred under the Option Agreements with Paragon between ORKA-001 and
ORKA-002. See &#8220;&#8212;&#160;<i>Contractual Obligations and Commitments</i>&#8221; below for further details on the Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect our research and development expenses to increase substantially for the foreseeable future as we advance our product candidates
into and through preclinical studies and clinical trials, pursue regulatory approval of our product candidates and expand our pipeline
of product candidates.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>General
and Administrative</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses consist primarily of personnel-related expenses, including salaries, bonuses, employee benefits, and stock-based
compensation, for our executive and other administrative personnel. Other significant general and administrative expenses include legal
services, including intellectual property and corporate matters; professional fees for accounting, auditing, tax, insurance, and allocated
human resource costs, information technology costs, and facility-related costs, including rent, utilities, maintenance, and depreciation
for our leased office space.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expect our general and administrative expenses will increase substantially for the foreseeable future as we anticipate an increase in
our personnel headcount to support the expansion of research and development activities, as well as to support our operations generally.
We also expect to continue to incur significant expenses associated with being a public company, including costs related to accounting,
audit, legal, regulatory, and tax-related&#160;services associated with maintaining compliance with applicable Nasdaq and SEC requirements;
additional director and officer insurance costs; and investor and public relations costs. We also expect to incur additional intellectual
property-related expenses as we file patent applications to protect innovations arising from our research and development activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Other
Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
income (expense), net includes interest expense on the convertible note from a related party, interest income, and foreign currency transactions
gains and losses. Interest expense relates to a convertible note (the &#8220;Convertible Note&#8221;) issued to Fairmount Healthcare
Fund&#160;II, L.P. (&#8220;Fairmount&#8221;) in March&#160;2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception)
through September&#160;30, 2024. Deferred tax assets generated from our net operating losses have been fully reserved as we believe it
is not more likely than not that the benefit will be realized due to its cumulative losses generated to date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations for the Three Months Ended September 30, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three&#160;Months<br/>
    Ended&#160;<br/> September&#160;30,<br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,758</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,449</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(29,449</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(504</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">826</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(28,623</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $13,537 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $71 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $504 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended&#160;<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">External research
    and development costs by selected target:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,761</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    research and development costs:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,076</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">707</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,691</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $2,316 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $3,824 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $7,251 for the three months ended September 30, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $146 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses were $25.7&#160;million for the three months ended September 30, 2024 and consisted primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.3&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9.4
    million of research and development expenses on chemistry, manufacturing, and development costs for ORKA-001, including $3.2 million
    of toxicology testing for ORKA-001 with a third-party contract research organization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$3.8&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-002;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$9.1
    million of personnel-related costs related to salaries, benefits and other compensation-related costs, and stock-based compensation
    expense of $7.8 million, including $7.3 million for stock-based compensation related to Paruka Holding LLC (&#8220;Paruka&#8221;)
    warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7
    million of other research expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our general and administrative expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Three
    Months Ended&#160;<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Personnel-related
    (including stock-based compensation)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,435</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional
    and consulting fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">701</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees related to patent<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">116</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">506</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    general and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,758</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $71 for the three months ended September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses were $3.8&#160;million for the three months ended September 30, 2024 and consisted primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.4&#160;million
    of personnel-related costs related to salaries, benefits and other compensation-related costs, including stock-based compensation
    of $1.2&#160;million;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7&#160;million
    of professional and consulting fees associated with accounting, audit, and legal fees to support our business activity and operations
    of a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.1&#160;million
of legal fees due to Paragon associated with patent related activities; and</span></td>
</tr></table><div>

</div><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;
</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.5
million of other business expense and allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities, and depreciation for our leased office space.</span></td>
</tr></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Total
Other Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
income from money market funds was $1.3 million for the three months ended September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
expense was $0.5 million for the three months ended September 30, 2024 relating to the Convertible Note from Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Results
of Operations for the Period of February 6, 2024 (Inception) to September 30, 2024</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our results of operations and comprehensive loss for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from<br/>
    February&#160;6,<br/> 2024<br/> (Inception)&#160;to<br/> September&#160;30,<br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,557</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,248</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    operating expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">57,805</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Loss
    from operations</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,805</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    income (expense)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Interest
    income</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,468</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    other expense, net</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(138</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(57,943</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $33,967 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $1,339 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $1,468 for the period from February&#160;6, 2024 (inception) to September&#160;30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
                                            and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our research and development expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to<br/> September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">External research
    and development costs by selected target:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-001<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">26,939</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ORKA-002<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,987</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other
    research and development costs:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,684</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">947</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Total
    research and development expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">49,557</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $15,478 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $10,662 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $7,681 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $146 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Research
and development expenses were $49.6&#160;million for the period from February&#160;6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$15.5&#160;million
    of research and development expense due to Paragon for services rendered under the Option Agreements for ORKA-001, including $1.5
    million of milestone payment due to Paragon upon exercise of option to enter into a license agreement and achievement of development
    candidate for IL-23, and $5.9 million of research and development expense due to Paragon incurred through March 31, 2024 upon completion
    of IL-23 selection process;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.4
    million of research and development expense on chemistry, manufacturing, and development costs for ORKA-001, including $3.4 million
    in toxicology testing for ORKA-001 with a third-party contract research organization;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$11.0&#160;million
    of research and development expense primarily due to Paragon for services rendered under the Option Agreements for ORKA-002;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$10.7&#160;million
    of personnel-related costs related to salaries, benefits, and other compensation-related costs, and stock-based compensation expense
    of $8.3&#160;million, including $7.7 million for stock-based compensation related to Paruka warrants; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.9
    million of other research expense and allocated human resource costs, information technology costs, and facility-related costs, including
    rent, maintenance, utilities, and depreciation for our leased office space.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our general and administrative expenses for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to<br/> September 30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Personnel-related
    (including stock-based compensation)<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,590</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Professional
    and consulting fees</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees related to patent<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">606</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">722</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    general and administrative expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,248</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $609 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $550 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    related party amount of $180 for the period from February&#160;6, 2024 (inception) to September 30, 2024</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">General
and administrative expenses were $8.2&#160;million for the period from February&#160;6, 2024 (inception) to September 30, 2024 and consisted
primarily of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4.6&#160;million
    of personnel-related costs related to recruiting costs, salaries, benefits and other compensation-related costs, including stock-based
    compensation of $1.5&#160;million and $0.6 million of personnel-related costs are amounts due to Paragon related to recruiting costs
    for hiring our executive team, legal, and finance and accounting functions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$2.3&#160;million
    of professional and consulting fees associated with accounting, audit, and legal fees associated with becoming a public company;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.6&#160;million
    of legal fees due to Paragon associated with patent related activities; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.7
    million of other business expenses and allocated human resource costs, information technology costs, and facility-related costs,
    including rent, maintenance, utilities, and depreciation for our leased office space, including $0.2&#160;million of other business
    expenses due to Paragon.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Total
Other Income (Expense), Net</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
income from money market funds was $1.3 million for the period from February 6, 2024 (inception) to September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Interest
expense was $1.5 million for the period from February 6, 2024 (inception) to September 30, 2024 relating to the Convertible Note from
Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we had $410.9 million of cash and cash equivalents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Since our inception, we have incurred significant
operating losses and negative cash flow from operations. We expect to incur significant expenses and operating losses for the foreseeable
future as we continue the pre-clinical and clinical development of our programs and continue our early-stage research activities. We have
not yet commercialized any products and we do not expect to generate revenue from sales of products for several&#160;years, if at all.
As of September 30, 2024, we had funded our operations primarily with proceeds from issuances of convertible preferred stock, common stock,
convertible note, and pre-funded warrants. In March&#160;2024, we received $3.0&#160;million in gross proceeds from the issuance of Pre-Merger
Oruka Series&#160;A Preferred Stock and $25.0&#160;million in gross proceeds from the issuance of the Convertible Note, both of which
were related party transactions. In August 2024, we raised approximately $228.0 million in net proceeds from Pre-Closing Financing and
received $4.9 million in cash from ARCA upon consummation of the Merger. In September 2024, we received approximately $188.7 million in
net proceeds from the issuance of common stock, Company Series A Preferred Stock, and pre-funded warrants in connection with the PIPE
Financing.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
primary use of cash is to fund the development of our product candidates, and advance our pipeline. This includes both the research and
development costs and the general and administrative expenses required to support those operations. Since we are a clinical stage biotechnology
company, we have incurred significant operating losses since our inception and we anticipate such losses, in absolute dollar terms, to
increase as we continue to pursue clinical development of our product candidates, prepare for the potential commercialization of our
product candidates, and expand our development efforts in our pipeline of nonclinical candidates. We expect that our existing cash and
cash equivalents will be sufficient to fund our operating plans for at least twelve months from the date of filing of this prospectus.
We will need to secure additional financing in the future to fund additional research and development, and before a commercial drug can
be produced, marketed and sold. If we are unable to obtain additional financing or generate license or product revenue, the lack of liquidity
could have a material adverse effect on our company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
Flows</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes our cash flows for the period presented (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Period&#160;from
    <br/> February&#160;6, <br/> 2024<br/> (Inception)&#160;to September&#160;30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(39,019</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(171</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">450,065</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Net
    increase in cash and cash equivalents</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,875</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Operating
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash used in operating activities was $39.0 million, which was primarily
attributable to a net loss of $57.9 million, offset by non-cash charges of $11.3 million and net cash provided by changes in operating
activities of $7.6 million. Non-cash charges primarily consisted of a $9.8 million increase in stock-based compensation expense (primarily
from Paruka Warrant Obligation) and $1.5 million of non-cash interest expense. Net cash provided by changes in our operating activities
primarily consisted of a $1.6 million increase in accounts payable, $1.7 million increase in accrued expenses and other current liabilities,
$6.4 million increase in related parties accounts payable and other current liabilities, partially offset by a $2.0 million increase
in prepaid expenses and other current assets. The increase in amounts due to related parties, accounts payable, and accrued expenses
and other current liabilities was primarily due to an increase in our business activity, as well as vendor invoicing and payments. The
increase in prepaid expenses and other current assets was primarily due to prepaid research and development expenses with our contract
research organization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Investing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash used in investing activities was $0.2 million, which was attributable
to purchases of property and equipment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Financing
Activities</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
February&#160;6, 2024 (inception) to September&#160;30, 2024, net cash provided by financing activities was $450.1 million, consisting
of $2.9&#160;million of net proceeds from the issuance of Series&#160;B Preferred&#160;Stock, $25.0&#160;million of net proceeds from
the issuance of the Convertible Note, $228.1 million of net proceeds from the Pre-Closing Financing, $189.1 million of net proceeds from
the PIPE Financing, and $4.9 million of cash acquired in connection with the reverse recapitalization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Contractual
Obligations and Commitments</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
enter into contracts in the normal course of business with contract research organizations (&#8220;CROs&#8221;)&#160;for clinical trials,
with contract manufacturing organizations (&#8220;CMOs&#8221;) for&#160;clinical supplies manufacturing and with other vendors for preclinical
studies, supplies and other services and products for operating purposes. These contracts generally provide for termination on&#160;notice
or may have a potential termination fee if a purchase order is cancelled within a specified time, and therefore are cancelable contracts.
We do not expect any such contract terminations and did not have any non-cancellable obligations under these agreements as of September
30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Option
Agreements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, we entered into antibody discovery and option agreements with Paragon and Paruka (the &#8220;Option Agreements&#8221;).
Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies directed against certain mutually agreed
therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23 (&#8220;ORKA-001&#8221;) and IL-17 A/F
(&#8220;ORKA-002&#8221;). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program basis,
be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting
from the applicable research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets
(each, an &#8220;Option&#8221;), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If we exercise
our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective
agreement upon the achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon
the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the
first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment
related to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
exclusive Option with respect to each research program for a particular target initiated by the parties (&#8220;Research Program&#8221;)
is exercisable at our sole discretion at any time during the period beginning on the initiation of activities under the associated Research
Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than ORKA-001, the delivery
of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect to ORKA-001, the completion
of the IL-23 antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise
of an Option pursuant to the Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the
expiration of the 30-day period after we exercise our Option with respect to such Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration of the applicable
research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then-existing Research Programs, under the Option Agreements,
the Option Agreements will automatically expire in its entirety. We may terminate the Option Agreements or any Research Program at any
time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that we must pay certain unpaid fees due
to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred by Paragon in connection with its activities
under any terminated Research Program. Paragon may terminate the Option Agreements or a Research Program immediately upon written notice
to us if, as a result of any action or failure to act by us or our affiliates, such Research Program or all material activities under
the applicable Research Plan are suspended, discontinued or otherwise delayed for a certain consecutive number of months. Each party
has the right to terminate the Option Agreements or any Research Program upon (i)&#160;30&#160;days&#8217; prior written notice of the
other party&#8217;s material breach that remains uncured for the 30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, we were required
to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the ORKA-001 program. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In June
2024, pursuant to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody
for ORKA-001 program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process.
We received the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised
our option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research
and development expense in our condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were also required to reimburse Paragon $3.3&#160;million
for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development costs incurred
by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was recognized as a
research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. We are also responsible
for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection process. We recognized
an amount of $0.8&#160;million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the
ORKA-002 research plan. This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September
30, 2024. We accounted for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for
the period from February 6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective
periods. An amount of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares
equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the fair market
value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition, the liability
is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated statement of operations
and comprehensive loss as stock-based compensation expenses under research and development expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
expense the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of on-going development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Note&#160;Payable
with Related Party</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, we entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount, whereby we issued the Convertible Note, with an initial principal amount of $25.0 million that, at the time of issuance,
could be converted into Pre-Merger Oruka Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect
to the shares of preferred shares issued in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate
proceeds of $25.0&#160;million. The Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note
required all unpaid interest and principal to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not
permitted without prior written consent of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible
Note was due in full on the Maturity Date. Pursuant to the Purchase Agreement, we had the right to sell and issue additional convertible
notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million initial principal amount of the Convertible
Note.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the completion of the Merger, the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate
principal amount of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price, which was determined
based upon the Company&#8217;s fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the
Pre-Merger Oruka Common Stock issued upon the conversion of the Convertible Note (including accrued interest) automatically converted
into shares of Company Common Stock. 2,722,207 shares of Company Common Stock were issued on conversion of the Convertible Note and accrued
interest. As of September 30, 2024, there is no note payable to a related party.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
management&#8217;s discussion and analysis of its financial condition and results of operations is based on its financial statements,
which have been prepared in accordance with U.S. GAAP.&#160;The preparation of these condensed consolidated financial statements requires
us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets
and liabilities at the date of the financial statements, as well as the reported revenues recognized and expenses incurred during the
reporting periods. Our estimates are based on its historical experience and on various other factors that we believe are reasonable under
the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are
not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
our significant accounting policies are described in more detail in Note&#160;2 to our consolidated financial statements appearing elsewhere
in this prospectus, we believe the following accounting policies used in the preparation of our financial statements require the most
significant judgments and estimates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Accrued
Research and Development Expenses</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses.
This process involves estimating the level of service performed and the associated cost incurred for the services when we have not yet
been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed,
on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our
accrued expenses as of each balance sheet date in the financial statements based on facts and circumstances known to us at that time.
At each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary. Estimated
accrued research and development expenses include those related to fees paid to vendors in connection with discovery development activities
and any research organizations in connection with studies and testing. Although we do not expect our estimates to be materially different
from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in reporting amounts that are too high or too low in any particular period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
measure stock options granted to employees and non-employees based on the estimated fair values of the awards as of the grant date using
the Black-Scholes option-pricing model. The model requires management to make a number of assumptions, including common stock fair value,
expected volatility, expected term, risk-free interest rate and expected dividend yield. For restricted stock awards and restricted stock
units, the estimated fair value is the fair market value of the underlying stock on the grant date. We expense the fair value of our
equity-based compensation awards on a straight-line basis over the requisite service period, which is the period in which the related
services are received. We account for award forfeitures as they occur. The expense for stock-based awards with performance conditions
is recognized when it is probable that a performance condition is met during the vesting period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Determination
of Fair Value of Common Stock</i>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
public trading market for Company Common Stock has been established in connection with the completion of this Merger. As such, it is
no longer necessary for our board of directors to estimate the fair value of our stock-based awards in connection with its accounting
for granted stock-based awards or other such awards we may grant, as the fair value of Company Common Stock and share-based awards is
determined based on the quoted market price of Company Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior
to the merger, Pre-Merger Oruka&#8217;s common stock valuations were prepared using a hybrid method, including an option pricing method
(&#8220;OPM&#8221;). The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise
prices based on the value thresholds at which the allocation among the various holders of a company&#8217;s securities changes. Under
this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the preferred
stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted
expected return method (&#8220;PWERM&#8221;), where the equity value in one or more of the scenarios is calculated using an OPM. The
PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for the Company,
assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns
considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock
under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to
arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive
at an indication of value for the common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
assumptions underlying these valuations represented management&#8217;s best estimate, which involved inherent uncertainties and the application
of management&#8217;s judgment. As a result, if Pre-Merger Oruka had used significantly different assumptions or estimates, the fair
value of Pre-Merger Oruka&#8217;s incentive shares and its stock-based compensation expense could have been materially different.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Recently
Issued Accounting Pronouncements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">See
Note 2 to the condensed consolidated financial statements included in this prospectus for more information regarding recently issued
accounting pronouncements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, we did not have any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>(a)</i></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><i>Dismissal
                                            of Independent Registered Public Accounting Firm </i></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">KPMG
LLP (&#8220;KPMG&#8221;) served as the independent registered public accounting firm of ARCA prior to the consummation of the Merger.
On August 30, 2024, KPMG was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss KPMG
was approved by the Audit Committee (the &#8220;Audit Committee&#8221;) of the Board of Directors of the Company (the &#8220;Board&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
reports of KPMG on the consolidated financial statements of the Company for the fiscal years ended December&#160;31, 2023 and 2022 did
not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting
principles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the Company&#8217;s two most recent fiscal years and the subsequent period from January&#160;1, 2024 to August 30, 2024, there were (i)&#160;no
disagreements (as defined in Item 304(a)(1)(iv) of Regulation&#160;S-K&#160;and the related instructions thereto) with KPMG on any matter
of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved
to the satisfaction of KPMG, would have caused it to make reference to the subject matter of the disagreement in connection with its
report and (ii)&#160;no reportable events (as described in Item 304(a)(1)(v) of Regulation&#160;S-K).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company provided KPMG with a copy of the disclosures made in this section and requested KPMG to furnish the Company with a letter addressed
to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree.
A copy of KPMG&#8217;s letter to the SEC dated September 5, 2024 regarding these statements was filed as Exhibit 16.1 to the Company&#8217;s
Current Report on Form 8-K filed on September 5, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; "><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>(b)</i></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><i>Appointment
                                            of New Independent Registered Public Accounting Firm</i></span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PricewaterhouseCoopers
LLP (&#8220;PwC&#8221;) served as the independent registered public accounting firm of Oruka prior to the consummation of the Merger.
On August 30, 2024, following the consummation of the Merger, the Audit Committee engaged PwC as the independent registered public accounting
firm of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
ARCA&#8217;s two most recent fiscal years and the subsequent period from January 1, 2024 to August 30, 2024, neither ARCA nor anyone
on its behalf consulted PwC regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on ARCA&#8217;s financial statements, and neither a written report nor oral advice
was provided to the ARCA that PwC concluded was an important factor considered by ARCA in reaching a decision as to any accounting, auditing
or financial reporting issue; or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation
S-K and the related instructions thereto) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;<b>&#160;</b></span></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not
required to provide the information under this item.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>BUSINESS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Company
Overview </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are a biotechnology company focused on developing novel monoclonal antibody therapeutics for PsO and other I&amp;I indications. Our name
is derived from <i>or</i>, for &#8220;skin,&#8221; and <i>arukah</i>, for &#8220;restoration&#8221; and reflects the company&#8217;s
mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition. Our strategy
is to apply antibody engineering and format innovations to validated modes of action, which we believe will enable us to improve meaningfully
upon the efficacy and dosing regimens of standard-of-care medicines while significantly reducing technical and biological risk. Our programs
aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety involved in disease pathology and
the activity of pathogenic tissue-resident memory T cells (&#8220;TRMs&#8221;). Our lead program, ORKA-001, is designed to target the
p19 subunit of interleukin-23 (&#8220;IL-23p19&#8221;) for the treatment of PsO. Our co-lead program, ORKA-002, is designed to target
interleukin-17A and interleukin-17F (&#8220;IL-17A/F&#8221;) for the treatment of PsO, PsA, and other conditions. These programs each
bind their respective targets at high affinity and incorporate half-life extension technology with the aim to increase exposure and decrease
dosing frequency. We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment
standard in large I&amp;I markets with continued unmet need.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Pipeline
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_002.jpg" style="width: 623px; height: 195px"/>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>ORKA-001</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life monoclonal antibody (&#8220;mAb&#8221;) designed to target IL-23p19. IL-23 is a pro-inflammatory
cytokine that plays a critical role in the proliferation and development of T helper 17 (&#8220;Th17&#8221;) cells, which are the primary
drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit that is shared
with IL-12 and a p19 subunit that is specific to IL-23. First-generation IL-23 antibodies bound p40 and inhibited both IL-12 and IL-23
signaling, while more recent IL-23 antibodies targeting the p19 subunit have shown improved efficacy and safety. Based on preclinical
evidence, we believe that ORKA-001 could achieve higher response rates than established therapies in PsO while requiring less frequent
dosing and maintaining the favorable safety profile of therapies targeting IL-23p19. ORKA-001 is engineered with YTE half-life extension
technology, a specific three amino acid change in the fragment crystallizable (&#8220;Fc&#8221;) domain to modify the pH-dependent binding
to the neonatal Fc receptor (&#8220;FcRn&#8221;). As a result, it has a pharmacokinetic profile designed to support a subcutaneous (&#8220;SQ&#8221;)
injection as infrequently as once or twice a year. In addition, emerging evidence suggests that IL-23 blockade can modify the disease
biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;We believe that the expected characteristics
of ORKA-001 increase its potential to deliver these disease-modifying benefits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase 1 trial of ORKA-001 in the first quarter of 2025. We expect to share interim data from the first-in-human trial
in healthy volunteers, including initial pharmacokinetic data, in the second half of 2025 and initial efficacy on psoriasis patients
in the second half of 2026. Based on recent precedent for PsO, we anticipate that the entire development program from first-in-human
to biologics license application (&#8220;BLA&#8221;) filing could take as little as six to seven&#160;years based on the averages for
recently approved medicines. However, we have no control over the length of time needed for FDA review, and this timeline could vary.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A and IL-17F (&#8220;IL-17A/F&#8221;). IL-17 inhibition has become
central to the treatment of psoriatic diseases, including PsO and PsA, and has also shown efficacy in other&#160;I&amp;I indications,
such as hidradenitis suppurativa (&#8220;HS&#8221;) and axial spondyloarthritis (&#8220;axSpA&#8221;). More recently, the importance
of inhibiting the IL-17F isoform along with IL-17A has become appreciated, and dual blockade with the recently approved therapy Bimzelx
(bimekizumab) has led to higher response rates in patients than blockade of IL-17A alone. ORKA-002 is designed to bind IL-17A/F at similar
epitopes, or binding sites, and affinity ranges as bimekizumab, but incorporates half-life extension technology that could enable more
convenient dosing intervals. We plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. We expect to share interim
data from the first-in-human trial in healthy volunteers, including initial pharmacokinetic data, in the first half of 2026.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
view ORKA-002 and ORKA-001 as highly complementary. Patients with moderate-to-severe PsO that have purely skin manifestations are most
often treated with IL-23 inhibitors due to the high efficacy and tolerability of this mechanism. However, for patients who also have
joint involvement, or signs and symptoms of PsA, an IL-17 inhibitor is typically used due to its efficacy in addressing both skin and
joint symptoms. In addition, IL-17 inhibitors are often used in patients with highly resistant skin symptoms that do not adequately resolve
through treatment with an IL-23 inhibitor. Together, ORKA-001 and ORKA-002 provide the potential to offer a highly compelling product
profile for most patients with PsO and/or PsA, as well as the opportunity to address additional I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Additional
Pipeline Programs</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, designed to target an undisclosed pathway. Our strategy as a company is to remain highly focused
on&#160;I&amp;I diseases, and specifically on inflammatory dermatology conditions. Our third program provides the potential for indication
expansion beyond PsO and may create combination opportunities with our more advanced programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Team,
Investors, and Paragon Collaboration</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pre-Merger
Oruka was founded in February&#160;2024 by leading healthcare investor Fairmount Funds Management LLC (&#8220;Fairmount&#8221;). Fairmount
Funds Management has launched other successful biotechnology companies leveraging antibody technologies generated by Paragon, including
Apogee Therapeutics and Spyre Therapeutics. We are led by a management team with significant experience in developing novel treatments
for patients at biopharmaceutical companies such as CRISPR Therapeutics, Celgene, Novartis, CymaBay Therapeutics and Protagonist Therapeutics.
Together, our team has a proven track record of building successful biotech organizations in high-growth environments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
hold options to acquire intellectual property rights with respect to certain research programs, including ORKA-001 and ORKA-002, from
Paragon. Following the exercise of the Options (defined below) under the Paragon Option Agreements and execution of the respective license
agreements, we will have exclusive worldwide development and commercialization rights to our programs, with IL-23 rights for all indications
outside of inflammatory bowel disease (&#8220;IBD&#8221;), pursuant to such agreements, as applicable. Fairmount Funds Management founded
Paragon in 2021 as the firm&#8217;s discovery engine for biologics that potentially overcome limitations of existing therapies. Paragon
leverages a dedicated in-house team of scientific experts in antibody development, as well as its partnership with FairJourney Biologics,
to generate unique therapeutic concepts and enable their rapid proof-of-concept validation. We consider Paragon to be a related party.
See the section titled &#8220;<i>Certain Relationships and Related Transactions</i>&#8221; for additional information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
achieve our goal of developing leading therapeutic antibodies for patients with inflammatory skin diseases, we are applying antibody
engineering to validated modes of action. We believe this approach will enable us to improve meaningfully upon the efficacy and convenience
of standard-of-care medicines while significantly reducing technical and biological risk. The key elements of our strategy include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employ
                                            advanced antibody engineering to build biologics that could significantly improve upon existing
                                            therapies:&#160;&#160;&#160;&#160;</i></b>We and our collaborators at Paragon have optimized
                                            a variety of parameters using a suite of antibody technologies to develop candidates with
                                            the potential to improve upon existing therapies. These parameters include extending half-life
                                            to increase exposure and reduce dosing frequency, enhancing affinity and specificity to maximize
                                            potency and safety, and optimizing developability to ensure consistency and enable convenient,
                                            high-dose formulations. Together, we believe these features have the potential to translate
                                            into more efficacious and convenient medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Target
                                            validated mechanisms of action:&#160;&#160;&#160;&#160;</i></b>Our initial targets, IL-23p19
                                            and IL-17A/F, have established efficacy and safety for the treatment of PsO, PsA, and other
                                            indications. The FDA has approved four biologics in the IL-23 class, including three targeting
                                            IL-23p19, and four biologics in the IL-17 class, including one targeting IL-17A/F.&#160;While
                                            these therapies have advanced the standard of care in PsO and PsA, they have not addressed
                                            these diseases completely, and a significant fraction of patients do not achieve complete
                                            skin clearance. By applying our advanced antibody engineering to these validated targets,
                                            we believe we can maximize our chances of developing superior medicines for patients. In
                                            addition, the reduced technical and biological risk of these validated mechanisms may allow
                                            us to progress our programs more efficiently and rapidly.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leverage
                                            insights from earlier entrants to optimize our approach:&#160;&#160;&#160;&#160;</i></b>We
                                            benefit from a large body of clinical evidence generated by prior therapies targeting IL-23
                                            and IL-17. We continue to extract and apply learnings from this precedent to our programs,
                                            including in development candidate selection, clinical trial design, dosing regimens, formulations
                                            and presentations, regulatory pathway, and indication prioritization. For instance, based
                                            on correlations between affinity and efficacy, we have designed ORKA-001 and ORKA-002 to
                                            bind to similar epitopes and at similar or greater affinities as the leading antibodies in
                                            each class: risankizumab and bimekizumab, respectively, with the aim of maximizing efficacy.
                                            Also, by understanding the exposure-response relationships for efficacy and safety for other
                                            therapies, we plan to select dose levels and regimens that could maximize efficacy and maintenance
                                            of response while maintaining safety.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pursue
                                            opportunities with strong prospects of yielding meaningful new medicines as a &#8220;base
                                            case&#8221; and the potential to shift the treatment paradigm entirely as an &#8220;upside
                                            case&#8221;:&#160;&#160;&#160;&#160;</i></b>Our strategy seeks to maximize the potential
                                            for our programs to reach a base case product profile that could meaningfully advance the
                                            standard of care&#160;&#8212;&#160;for instance, for ORKA-001, SQ dosing one or twice a year
                                            with equal or greater efficacy compared to today&#8217;s standard of care. At the same time,
                                            we aim to deliver an upside case that dramatically improves outcomes for patients&#160;&#8212;&#160;for
                                            instance, significantly increasing rates of complete skin clearance via higher antibody exposures
                                            or offering patients durable remissions free from therapy by introducing patient-specific
                                            dosing intervals.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Build
                                            a preeminent biotechnology company focused on chronic skin disease and other&#160;I&amp;I
                                            indications:&#160;&#160;&#160;&#160;</i></b>We are assembling a team of exceptional people
                                            and helping them reach their full potential and flourish so that together we can bring forward
                                            meaningful new medicines for patients.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that pursuing the focused strategy outlined above will help us to succeed in our mission of offering patients living with PsO,
PsA, and other dermatologic and inflammatory diseases the greatest possible freedom from their condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Targeting
IL-23 and IL-17 to Treat Multiple&#160;I&amp;I Indications</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
programs benefit from significant advances in the understanding of the biology of&#160;I&amp;I diseases over the past four decades. ORKA-001
and ORKA-002 are designed to target two key cytokines that play a related role in multiple indications. IL-23 is an upstream regulator
of Th17 cells, a pro-inflammatory subset of T helper cells characterized by their production of IL-17. IL-23 has a critical role in maintaining
Th17 cells in the tissue as well as activating these cells to secrete IL-17, which acts downstream to trigger inflammation and other
disease symptoms. Th17 cells are involved in PsO, PsA, HS, axSpA, and many other diseases. They play a particularly central role in PsO
and PsA. The diagram below depicting the immunopathogenesis of PsO provides an example of how Th17 cells can mediate disease and how
blocking IL-23 or IL-17 can break the inflammatory cycle that drives disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Immunopathogenesis
of PsO and the role of IL-23 and IL-17</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_003.jpg" style="width: 700px; height: 394px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsO
develops when environmental triggers and a genetic predisposition combine to cause activation of an inflammatory cycle in the skin that
leads to the formation of plaques and other disease manifestations. This process begins with the aberrant activation of the dendritic
cells (&#8220;DCs&#8221;), specifically those producing IL-23 and other cytokines like IL-1&#946;, IL-21, TNF-&#945;, and IL-12. These
cytokines induce the differentiation of Th17 cells, as well as other cell types, such as T helper type 1 (&#8220;Th1&#8221;) cells that
produce IFN&#947; and TNF-&#945; and T helper type 22 (&#8220;Th22&#8221;) cells that produce IL-22. IL-23 plays a key role in the
differentiation and activation of Th17 cells to secrete IL-17, as well as Th22 cells to produce IL-22. IL-17 and these other cytokines
induce keratinocyte hyperproliferation leading to plaque formation and a feedforward inflammatory response, with changes in gene expression
in keratinocytes, the production of antimicrobial peptides, and neutrophil recruitment driving further inflammation. While many cytokines
and cell types contribute to the pathogenesis of PsO, the IL-23/IL-17 axis plays an important role, as supported by the success of therapies
targeting this axis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
the successful treatment of PsO&#160;&#8212;&#160;for instance, with mAbs targeting IL-23 or IL-17 &#8212;&#160;can result in lesional
skin returning to an apparently normal state, disease tends to recur at previously affected sites following cessation of therapy, suggesting
a mechanism of &#8220;immunological memory&#8221; that predisposes individuals to recurrence in the same locations. Evidence suggests
that pathogenic TRMs play a critical role in this memory. TRMs may arise from the Th17 cells and other cells that drove disease in the
first place and remain in their resident tissue, in this case the epidermis and dermis, for long periods of time. Upon a disease trigger,
these TRMs can actively produce proinflammatory cytokines, causing disease recurrence. IL-23 appears to play an important role in maintaining
and potentiating TRMs, as indicated by the depletion of TRMs following treatment with an IL-23 inhibitor but not an IL-17 inhibitor,
which may explain the longer remissions observed with IL-23 inhibitors following withdrawal of therapy. This type of data has raised
the prospect that efficient IL-23 blockade could modify the disease biology of PsO, possibly leading to durable remissions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
scientific discoveries that refined our understanding of the immunopathogenesis of PsO have led to waves of therapeutic advances, ultimately
leading to today&#8217;s standard of care. Before the 1980s, PsO was not even thought of as an immunologic disease, but rather a disease
of keratinocyte dysfunction, leading to treatments such as phototherapy, methotrexate, and retinoids. The discovery in the 1980s that
PsO results from immune dysfunction led to the use of broad immunosuppressants like cyclosporine. From 1990 to 2008, it was believed
that Th1 cells were the predominant mediators of the disease, which led to the use of biologics targeting TNF-&#945; such as Enbrel
(etanercept) and Humira (adalimumab). Finally, the revelation that PsO is driven principally by Th17 cells resulted in the development
of the primary therapies used today, which target IL-23 and IL-17. This increasingly refined understanding of the disease has narrowed
the standard of care from broad immunosuppressive agents (such as cyclosporine) to more specific immunomodulators (TNF-&#945; inhibitors)
to precise biologic therapies targeting the key cytokines involved in disease pathology (IL-23 and IL-17 inhibitors), with each new therapeutic
class raising the bar on both safety and efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biologic
therapies, especially mAbs, are now mainstays in the treatment of a wide variety of&#160;I&amp;I diseases, including PsO and PsA.&#160;Therapies
that have improved upon efficacy and/or reduced dosing frequency have achieved the most commercial success, even when launching many&#160;years
after other biologics. Enbrel was first approved for PsO in 2004 with a weekly maintenance dosing schedule. Four&#160;years later, Humira
was approved for PsO with an every-other-week (Q2W) dosing schedule. Stelara (ustekinumab) was approved a year later with similar Phase&#160;3
data to Humira, but with a significantly improved dosing schedule of every twelve&#160;weeks (Q12W). Several drugs for PsO have been
approved since 2009 that demonstrated higher efficacy in their pivotal studies compared to Stelara, but with more burdensome dosing schedules,
including Tremfya (guselkumab), which has a dosing schedule of every eight&#160;weeks (Q8W), and Cosentyx (secukinumab) and Taltz (ixekizumab),
which have dosing schedules of every four&#160;weeks (Q4W). While these therapies have all become generally successful products, the
most commercially successful drug in the PsO market today is Skyrizi (risankizumab), which combines Stelara&#8217;s Q12W dosing schedule
with improvements in efficacy, as evidenced by a higher psoriasis area severity index (PASI) score of PASI 90 and PASI 100 rates in clinical
trials. In addition, Bimzelx (bimekizumab), approved by the FDA in 2023, has shown evidence of efficacy that exceeds even Skyrizi, though
with a less convenient Q8W dosing schedule. Although many biologics have entered the PsO market over the past two decades, new entrants
have had significant commercial success when they have improved upon efficacy and/or dosing frequency, and room remains to improve in
both areas to set a new standard for the treatment of PsO.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Biologics
have raised the bar on the standard of care in PsO, but leave room for improvement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_004.jpg" style="width: 650px; height: 267px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
biology driving PsO and PsA is well understood today, and the standard of care has progressed dramatically. We believe that it is unlikely
that a novel mechanism will emerge that is as safe and efficacious as targeting the IL-23/IL-17 axis. Therefore, we believe that innovation
now should be focused on optimizing the product profile that can be offered to patients. While much effort is being directed toward daily
oral formats to inhibit this axis, oral medicines have yet to match the efficacy of biologics. We believe that a better biologic with
a longer dosing interval and the potential for improved efficacy will present a more attractive product profile for most patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriasis (PsO)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsO
is a chronic autoimmune skin disorder that affects an estimated 125&#160;million people worldwide with steadily increasing prevalence,
estimated to be around&#160;2&#160;&#8211;&#160;3% of the population currently, according to the World Psoriasis Day consortium. It is
the largest pharmaceutical market within dermatology, with annual sales of approximately $25&#160;billion in 2022, which is estimated
to grow to $32&#160;billion by 2028. The most common form of PsO is plaque psoriasis. Patients with chronic plaque psoriasis have well-demarcated,
erythematous plaques with overlying, coarse, silvery-scaled patches. These plaques can occur anywhere on the body, though are typically
found on the scalp, extensor areas of the knees and elbows, and gluteal cleft. Involvement of the palms, soles, or nails, and intertriginous
areas, including the genitals, can also occur and can be particularly difficult to treat. Between one-quarter and one-half of PsO patients
have moderate disease, defined as having 3% to 10% of the body surface area (&#8220;BSA&#8221;) involved, or severe disease, defined
as having more than 10% BSA involvement. The chronic inflammation in PsO is associated with multiple comorbidities, including PsA, obesity,
metabolic syndrome, hypertension, diabetes, and atherosclerotic cardiovascular disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
discussed earlier, PsO is a complex immune-mediated disease driven primarily by Th17 cells and the cytokines IL-23 and IL-17. The interplay
of environmental and behavioral risk factors and genetics is believed to trigger PsO.&#160;Multiple lines of evidence support a genetic
component to the disease, including the observation that approximately 40% of patients with PsO and PsA have a family history of the
disease and the identification of multiple susceptibility loci, many containing genes related to the regulation of the immune system,
in genome-wide association studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsO Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
patients with mild PsO typically rely on topical corticosteroids or oral therapies like Otezla (apremilast), these agents often do not
provide an adequate response for patients with moderate-to-severe PsO.&#160;As a result, the American Academy of Dermatology-National
Psoriasis Foundation recommends biologics as first-line therapy for moderate-to-severe PsO.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Several
classes of biologic therapies have been approved for PsO over the past 20&#160;years, resulting in progressively more complete symptom
relief. Efficacy in PsO is typically measured via the PASI scoring system. The first biologics approved for PsO were tumor necrosis alpha
(&#8220;TNF-&#945;&#8221;) inhibitors such as Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab), which achieved a
90%&#160;improvement in PASI score (&#8220;PASI 90&#8221;) at 16&#160;weeks in around&#160;25&#160;&#8211;&#160;50% of patients and a
100% improvement in PASI score (&#8220;PASI 100&#8221;) in&#160;around 5&#160;&#8211;&#160;20% of patients. Stelara (ustekinumab), which
targets the p40 subunit of IL-23 that is shared with IL-12, was approved next and achieved efficacy on par with Humira. IL-17 inhibitors
Cosentyx (secukinumab), Taltz (ixekizumab), and Siliq (brodalumab) followed and achieved responses of PASI 90 in around&#160;70% of patients
and PASI 100 in&#160;around 40% of patients with some risk of certain side effects such as oral candidiasis. Most recently, IL-23p19
inhibitors such as Ilumya (tildrakizumab), Tremfya (guselkumab), and Skyrizi (risankizumab) have achieved responses of PASI 90 in&#160;around
70&#160;&#8211;&#160;80% of patients and PASI 100 in around 30&#160;&#8211;&#160;50% of patients with highly tolerable profiles. Finally,
IL-17A/F inhibitors such as Bimzelx (bimekizumab) have recently shown even higher response rates than IL-23 inhibitors, but with slightly
less tolerable profiles.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Treatment
expectations in PsO have evolved progressively with this continued innovation. A 75% improvement in PASI score was previously thought
to be an adequate depth of response, and weekly SQ dosing was viewed as acceptable. With each subsequent generation of innovation, patient
and caregiver expectations have advanced. Today, Skyrizi (risankizumab) is widely viewed as the leader in PsO biologic therapy. In Phase&#160;3
clinical trials, 43% and 58% of patients achieved PASI 100 at 16 and 52&#160;weeks, respectively, with SQ maintenance dosing every three&#160;months.
Most recently, Bimzelx (bimekizumab) has shown evidence of efficacy that exceeds even Skyrizi, achieving a 64% PASI 100 rate at 16&#160;weeks
in Phase&#160;3 trials. However, the increased efficacy comes with a less convenient Q8W dosing schedule and an increased risk of certain
side effects, most notably oral candidiasis. While agents like Skyrizi and Bimzelx reflect the remarkable advancement in PsO treatment,
there remains significant unmet need. Approximately half of moderate-to-severe PsO patients do not achieve full skin clarity, and while
early signs are present, the promise of disease modifying therapy remains unrealized. In addition, a continued desire for more convenient
dosing options has driven significant interest in orally delivered medicines targeting these same pathways. However, oral therapies have
yet to match the efficacy and safety profile of biologics. We believe that ORKA-001 and ORKA-002 could represent the next step in biologic
innovation in PsO, with the potential for higher rates of complete skin clearance, more durable remissions, and markedly more convenient
dosing regimens.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of Psoriatic Arthritis (PsA)</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">PsA
is a chronic inflammatory condition that affects both the skin and joints, and often coexists with PsO.&#160;Around a quarter to a third
of patients with moderate-to-severe PsO also have PsA.&#160;Most individuals develop PsO before being diagnosed with PsA, with a median
gap of seven to eight&#160;years between the diagnosis of skin and joint disease, though in up to 30% of patients with PsA, joint symptoms
appear before or simultaneously with skin manifestations. Patients with PsA present with joint pain, stiffness, and swelling affecting
the peripheral joints, axial skeleton, or both. Enthesitis, dactylitis, nail lesions, fatigue, and ocular inflammation all occur commonly.
PsA can lead to irreversible joint damage, including bony fusion across a joint (ankylosis). The pathogenesis of PsA is likely to be
closely related to the mechanisms that underlie PsO.&#160;Like PsO, the exact cause of PsA remains unknown, but environmental triggers,
including infection and trauma, and genetic factors play a role.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Current
PsA Treatments and Limitations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Effective
treatment of PsA requires a coordinated approach to address the unique combination of disease manifestations each patient has, which
can include peripheral and axial arthritis, enthesitis, dactylitis, and skin and nail involvement. Many patients with milder disease
symptoms will start with nonsteroidal anti-inflammatory drugs (&#8220;NSAIDs&#8221;) and/or local treatments to address specific disease
manifestations. However, those with more moderate or severe disease and/or multidomain involvement will typically receive a biologic
therapy targeting TNF-&#945; or IL-17, or less commonly an oral Janus kinase (&#8220;JAK&#8221;) inhibitor. Comorbid conditions can
also influence treatment selection. For example, an IL-17 inhibitor would be preferred for a patient with significant skin involvement,
but not for patients with IBD or ocular symptoms, where a TNF-&#945; inhibitor would be preferred. The most common endpoint used to
measure the efficacy of TNF-&#945; or IL-17 inhibitors in PsA is ACR response, or the proportion of patients achieving a specified percent
improvement in American College of Rheumatology (&#8220;ACR&#8221;) score, which measures peripheral joint disease. Approved TNF-&#945;
inhibitors, including Humira (adalimumab) and Cimzia (certolizumab), achieved a placebo-adjusted ACR50 response of around&#160;30&#160;&#8211;&#160;35%
at 24&#160;weeks with Q2W dosing. Approved IL-17 inhibitors, including Cosentyx (secukinumab) and Taltz (ixekizumab), achieved a slightly
lower placebo-adjusted ACR50 response of around&#160;25&#160;&#8211;&#160;30% at 24&#160;weeks, but with more convenient Q4W dosing.
Bimzelx (bimekizumab) which was recently approved in the United&#160;States for PsA achieved a placebo-adjusted ACR50 response of approximately
35% at 16&#160;weeks with Q4W dosing. A significant fraction of patients with PsA still do not achieve a satisfactory response with available
therapies, and even the most convenient regimens require monthly SQ dosing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Overview
of additional opportunities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to PsO and PsA, inhibition of IL-23 or IL-17 has demonstrated efficacy in a number of additional&#160;I&amp;I indications, including
HS and axSpA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">HS
is a chronic inflammatory skin disease characterized by lesions that include deep-seated nodules and abscesses, draining tracts, and
fibrotic scars that occur most commonly in intertriginous areas, such as the armpits and groin. Due to the associated pain, sensitive
locations, drainage, odor, and scarring, this condition can have a particularly negative psychosocial impact on affected individuals.
HS is believed to be underdiagnosed and could have a prevalence well above 1% worldwide. Treatment varies depending on severity and can
include topical and systemic antibiotics, hormone therapy, immune modulators, and surgery. Humira (adalimumab) was the only FDA-approved
medication for the treatment of moderate-to-severe HS from its approval in 2015 until the approval of Cosentyx (secukinumab) in October&#160;2023.
However, now multiple other biologics, including Bimzelx (bimekizumab), are advancing through development and have demonstrated encouraging
data in clinical trials, though a significant fraction of patients still do not achieve adequate responses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">axSpA
is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints that comprise the axial skeleton. The disease
causes severe pain, stiffness, and fatigue, and can have additional clinical manifestations like uveitis, enthesitis, peripheral arthritis,
and PsO.&#160;Patients with axSpA may develop further structural damage in their spine, which can lead to the fusion of vertebra (spinal
ankylosis), which has a massive negative impact on mobility, physical function, and quality of life. The overall prevalence of axSpA
is estimated to be around 1% in the United&#160;States. Treatment of axSpA starts with physical therapy and NSAIDs. If patients do not
have an adequate response to NSAIDs, a TNF-&#945; inhibitor is typically used, followed by an IL-17 inhibitor, such as Cosentyx (secukinumab),
Taltz (ixekizumab), or Bimzelx (bimekizumab), or less frequently a JAK inhibitor. Patients often need to cycle through therapies over
time due to inadequate responses or loss of response.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Solution:
Half-Life Extension and Antibody Engineering Technologies</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
antibody engineering campaigns are designed to optimize multiple attributes in parallel: binding affinity, potency in a variety of assays,
developability, and consistently extended serum half-life in non-human primates (&#8220;NHPs&#8221;). Half-life extension is possible
by modifying the pH-dependent binding affinity of the antibody Fc domain for FcRn. A primary mechanism of elimination of antibodies from
the serum is through pinocytosis and degradation in the lysosomes of cells. Throughout this process, antibodies can be recycled back
into the serum by binding to FcRn while they are in endosomes. The interior of the endosome is acidic, and therefore the efficiency of
this recycling process depends on the ability of the antibody Fc domain to bind to FcRn at low pH.&#160;If this low pH binding is efficient
enough, antibody recycling can be favored over degradation, potentially resulting in a much longer serum half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Antibody
engineers have discovered methods of modifying the Fc domain to optimize the efficiency of recycling via FcRn binding. Several engineering
strategies have been identified over the past two decades, with the so-called &#8220;YTE&#8221; mutations (M252Y/S254T/T256E) and &#8220;LS&#8221;
mutations (M428L/N434S) being the most frequently used. Importantly, while these strategies have been known for some time, it was only
relatively recently that enough clinical precedent was established to provide confidence in how these mutations perform in humans. Two
products incorporating YTE modification were approved in 2023 by the FDA, Beyfortus (nirsevimab) and Evusheld (tixagevimab and cilgavimab),
and several more candidates are in clinical trials. Two products using LS mutations were approved in 2021 and 2022, Xevudy (sotrovima)
and Ultomiris (ravulizumab), respectively, and several more candidates are in clinical trials. Based on clinical data in humans, antibodies
with YTE mutations typically have a half-life that is two to four times longer than wildtype antibodies. In addition, preclinical data
in NHPs can be used to predict the approximate half-life in humans, with the human half-life equaling around two to four&#160;times the
NHP half-life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Clinical
experience with YTE-modified mAbs predicts significant half-life extension over wildtype mAbs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><img alt="" src="image_005.jpg" style="width: 446px; height: 368px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">While
this increasing body of clinical precedent serves to validate half-life extension, we do not yet have clinical data showing that the
introduction of these amino acid substitutions in our programs leads to a longer serum half-life. However, we aim to establish this favorable
pharmacokinetic profile early in the clinical development of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-001
is a high affinity, extended half-life mAb designed to target the p19 subunit of IL-23. Based on preclinical data generated to date,
we believe ORKA-001 has the potential to become the leading IL-23 inhibitor and achieve an optimal product profile in PsO consisting
of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>One
to two maintenance doses per year.&#160;&#160;&#160;&#160;</i></b>Standard-of-care therapies targeting IL-23 require maintenance dosing
every eight to twelve&#160;weeks. We engineered the Fc portion of ORKA-001 to include YTE mutations to increase the half-life of ORKA-001
in circulation, which may enable dosing every six to twelve&#160;months&#160;&#8212;&#160;a dosing interval made feasible by half-life
extension technology. In preclinical studies, serum levels from&#160;NHPs indicated an elimination half-life of over 30&#160;days following
SQ administration of ORKA-001. Based on published scientific literature on other antibodies incorporating YTE mutations and pharmacokinetic
modeling, we anticipate this half-life in NHPs to translate to a half-life in humans that could allow subcutaneous dosing every six to
twelve&#160;months while maintaining high antibody exposures.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Higher
PASI 100.&#160;&#160;&#160;&#160;</i></b>ORKA-001 benefits from the robust validation of IL-23 inhibition in PsO by multiple approved
therapies, such as Skyrizi (risankizumab) and Tremfya (guselkumab), while leveraging insights from these therapies to improve upon their
clinical profile. ORKA-001 is designed to bind a similar epitope to the market-leading anti-IL-23 antibody, Skyrizi, with similar or
greater affinity and could achieve much higher exposures in patients due to half-life extension and higher dosing. Skyrizi and Tremfya
both have a robust exposure-response relationship, with higher drug exposures leading to higher response rates. Published data indicates
that these therapies have not saturated this exposure-response relationship, and ORKA-001 could lead to higher response rates, including
higher rates of complete skin clearance, or PASI 100, through increased exposure, even while having more convenient dosing with as few
as one or two maintenance doses per year.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Validated
IL-23p19 safety profile.&#160;&#160;&#160;&#160;</i></b>Existing commercially approved antibodies targeting IL-23 provide a robust precedent
for the safety of IL-23 inhibition. Across thousands of patients dosed in dermatology and IBD indications, no correlations have been
observed at the patient level between exposure and safety. While we are not pursuing IBD, the approved Skyrizi regimens for Crohn&#8217;s
disease and ulcerative colitis supports the safety of high peak exposures. Peak Skyrizi exposures during the&#160;IV induction phase
in Crohn&#8217;s disease and ulcerative colitis are multiple times higher than the peak ORKA-001 exposures at dose levels we currently
plan to evaluate in PsO.&#160;In addition, an exposure-response analysis for Skyrizi in ulcerative colitis showed no relationship between
exposures and evaluated safety endpoints in the 12-week induction or 52-week maintenance periods. In this assessment, the top quartile
of average exposures were significantly higher than the highest anticipated exposures with ORKA-001 in the same periods.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Potential
to offer longer term remission to some patients.&#160;&#160;&#160;&#160;</i></b>Emerging evidence suggests that IL-23 blockade can modify
the disease biology of PsO, possibly leading to durable remissions and preventing the development of PsA.&#160;Dr.&#160;Andrew Blauvelt,
chair of our Scientific Advisory Board, pioneered some of this work by using two- and four-times the approved dose levels of risankizumab
to achieve best-in-indication response rates. This study, called KNOCKOUT, showed a robust depletion of TRMs following high dose IL-23
inhibition, which could lead to longer-lasting remissions in some patients. Additional evidence from a study of guselkumab, called GUIDE,
showed that intervention early in the disease course can lead to longer treatment-free remissions. In addition, retrospective claims
data suggests that treatment with an IL-23 inhibitor could help prevent progression to PsA, though this finding has yet to be confirmed
by a prospective clinical trial. Given the high antibody exposures expected with ORKA-001, we believe that ORKA-001 could lead to durable
remissions for some patients, especially those with short disease duration. We plan to pursue patient-specific dosing intervals to provide
each patient the greatest possible freedom from their disease.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that this target profile for ORKA-001 could offer improved freedom from disease to many patients affected by PsO and represent
a step forward in the standard of care.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
evaluated ORKA-001 in numerous preclinical studies for several key features:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Potency
that matches or exceeds Skyrizi (risankizumab) in vitro</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have tested the potency of ORKA-001 <i>in vitro</i>&#160;in multiple assays, including assays evaluating the inhibition of IL-17 release
from human peripheral mononuclear blood cells, in comparison to risankizumab generated recombinantly based on amino acid sequences from
patent filings. Based on the results of these experiments, we believe ORKA-001 binds a similar epitope as risankizumab with similar potency.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
binds to a similar epitope as risankizumab with similar potency</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<img alt="" src="image_006.jpg" style="width: 592px; height: 253px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Significant
half-life extension in NHPs that could enable a maintenance dosing interval of once or twice a year in humans</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
assessed ORKA-001 in NHPs in comparison to risankizumab generated recombinantly based on amino acid sequences from patent filings. ORKA-001
had a significantly longer half-life, reaching over 30&#160;days with SQ administration. Based on clinical experience with YTE-modified
mAbs and pharmacokinetic modeling, we believe that this half-life extension could enable dosing once or twice per year, as shown in the
figure below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>The incorporation
of YTE mutations significantly extends half-life in NHPs, which could enable once or twice yearly dosing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<img alt="" src="image_007.jpg" style="width: 619px; height: 267px"/></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to enabling less frequent dosing, an extended half-life would increase the exposure of ORKA-001, which has the potential to
increase efficacy. Based on published literature, Skyrizi (risankizumab) demonstrates a clear relationship between antibody exposure
and efficacy, with higher average serum antibody concentration correlating with higher PASI 90 and PASI 100 rates short-term (at 16&#160;weeks)
and long-term (at 52&#160;weeks), as shown for PASI 100 in the figure below. In addition, the KNOCKOUT study, which evaluated two- and
four-times higher doses of Skyrizi than the approved regimen, yielded some of the highest PASI 100 rates observed to date, reaching 67%
at 16&#160;weeks. Based on our pharmacokinetic modeling, ORKA-001 could achieve four-fold higher average exposures than the approved
Skyrizi regimen over the first 16&#160;weeks and over two-fold higher average exposures at steady-state, exceeding even the exposures
in KNOCKOUT.&#160;Based on the exposure-response relationship observed with other IL-23 inhibiting antibodies, we believe that these
increased exposures could result in higher efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-001
is projected to extend the exposure-response relationship established by studies of Skyrizi</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="image_008.jpg" style="width: 613px; height: 246px"/><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Safety
in vitro and in vivo</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have evaluated ORKA-001 in several&#160;<i>in vitro</i>&#160;and&#160;<i>in vivo</i>&#160;preclinical studies to assess safety. In addition,
we have initiated a robust nonclinical program to characterize the toxicology, toxicokinetics, and anti-drug antibody profile of ORKA-001
in NHPs, including a single-dose non-GLP dose-range finding study and one-month and six-month GLP toxicology studies. Collectively, this
nonclinical program is designed to support the initiation of clinical trials. In addition, ORKA-001 benefits from the favorable safety
precedent for IL-23 inhibition provided by the existing commercially approved IL-23-targeted antibodies across several indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Characteristics
that support ease of manufacturing and potentially enable high-concentration formulations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Finally,
we have assessed a variety of attributes essential for manufacturability and high-concentration formulation, including viscosity, solubility,
and stability, among others. ORKA-001 shows evidence of desirable properties across these characteristics, which we believe will enhance
our ability to manufacture ORKA-001 successfully and consistently and to deliver high doses of ORKA-001 subcutaneously using convenient,
low-volume presentations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Based
on these potential advantages and preclinical data, we are advancing ORKA-001 towards a Phase&#160;1 clinical trial in the first quarter
of 2025. This trial will encompass a Phase&#160;1a single-ascending dose portion in healthy volunteers, followed by a Phase&#160;1b,
multiple-dose portion in patients with moderate-to-severe PsO.&#160;Following completion of Phase&#160;1b, patients will become eligible
for an open-label extension study. Initial data from the Phase&#160;1a cohort has the potential to provide key validation of both early
safety and pharmacokinetics, including half-life, to support extended dosing intervals. Initial data from the Phase&#160;1b cohort has
the potential to provide preliminary efficacy data in patients with PsO.&#160;Pending the results from the Phase&#160;1 clinical trial,
we plan to initiate a Phase&#160;2 clinical trial in PsO in 2026. Several aspects of PsO facilitate clinical development, including well-established,
reproducible endpoints based on PASI scores, low placebo rates, particularly with PASI 90 and PASI 100, a rapid efficacy readout at 16&#160;weeks,
and potentially rapid enrollment due to the large patient population. We have not yet submitted an IND with the FDA for our Phase 1 clinical
trial for ORKA-001.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ORKA-002</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Summary</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ORKA-002
is a high affinity, extended half-life mAb designed to target IL-17A/F.&#160;Dual inhibition of both IL-17A and IL-17F has shown superior
efficacy compared to IL-17A inhibition alone in PsO and other indications, as shown by the performance of Bimzelx (bimekizumab) compared
to Cosentyx (secukinumab) and Taltz (ixekizumab) in Phase&#160;3 trials. These therapies all utilize Q4W maintenance dosing in PsO and
PsA, except Bimzelx, where Q8W maintenance dosing in PsO patients &lt;120 kg is recommended.&#160;By binding IL-17A/F at similar epitopes
and affinity ranges as Bimzelx while incorporating half-life extension technology to potentially enable dosing two to three times a year
in PsO and PsA, we believe that ORKA-002 could become the leading therapy in the IL-17 class.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Preclinical
Data</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
preclinical program we are conducting for ORKA-002 mirrors that for ORKA-001 and spans potency, pharmacokinetics, safety, and manufacturing
characteristics. Based on the results of these experiments, we believe ORKA-002 has the potential for comparable potency to bimekizumab,
but with a significantly longer half-life, which we believe could support dosing two or three times per year based on extrapolation from
clinical precedent and pharmacokinetic modeling.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Clinical
Development Plans</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
plan to initiate a Phase&#160;1 trial of ORKA-002 in the third quarter of 2025. As with ORKA-001, initial data on ORKA-002 in healthy
volunteers has the potential to provide key validation of both early safety and pharmacokinetics to support extended dosing intervals.
Though clinical development of ORKA-002 will initially focus on one lead indication, we plan to evaluate ORKA-002 in a range of indications
over time. We see ORKA-002 as highly complementary to ORKA-001, with the potential to provide an optimal therapy for the approximately
one-quarter to one-third of moderate-to-severe PsO patients who have PsA, as well as for PsO patients with highly resistant skin symptoms
that do not respond adequately to an IL-23 inhibitor. Furthermore, ORKA-002 could address indications beyond PsO, including PsA with
limited skin involvement, HS, axSpA, and additional&#160;I&amp;I diseases. We have not yet submitted an IND with the FDA for our Phase
1 clinical trial for ORKA-002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Additional
Pipeline Programs</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
have a third mAb program, ORKA-003, that targets an undisclosed pathway. A core tenet of our strategy is to remain highly focused on&#160;I&amp;I
diseases, and specifically on inflammatory dermatology conditions. ORKA-003 provides the potential for indication expansion beyond PsO
as well as combination opportunities with our more advanced programs. In the future, we may add additional programs to our portfolio
beyond ORKA-001, ORKA-002, and ORKA-003 that fit our strategic focus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
strive to protect the proprietary programs and technologies that we believe are important to our business, including seeking and maintaining
patent protection intended to cover the composition of matter of our programs, their methods of use and manufacture, related technologies,
diagnostics, and other inventions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Paragon
has filed provisional patent applications, and may file additional provisional patent applications directed to antibodies that target
IL-23, including applications covering composition of matter, pharmaceutical formulations, and methods of using such antibodies, including
ORKA-001. In addition, Paragon has filed provisional patent applications, and may file additional provisional patent applications directed
to antibodies that target IL-17, including applications covering composition of matter, pharmaceutical formulations, and methods of using
such antibodies, including ORKA-002. We have exercised our option to acquire exclusive rights to ORKA-001 and the corresponding IL-23
patent applications but have not yet entered into the corresponding license agreement. We have not yet exercised our option to acquire
exclusive rights to any IL-17 patent applications, but retain the right to do so. If the provisional patent applications are pursued
non-provisionally and mature into one or more issued patents covering ORKA-001 or ORKA-002, we would expect those patents to expire in
2045, absent any applicable patent term adjustments or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Commercial</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Should
any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United&#160;States
and other key markets, through internal infrastructure and/or external partnerships in a manner that will enable us to realize the full
commercial value of our programs. Given our stage of development, we have not yet established a commercial organization or distribution
capabilities. We have exercised our option to acquire exclusive worldwide rights to develop and commercialize ORKA-001 but have not entered
into the corresponding license agreement. We also currently hold an exclusive Option (as defined below) to acquire worldwide development
and commercialization rights to ORKA-002.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
do not currently own or operate facilities for product manufacturing, testing, storage, and distribution. We have contracted and expect
to continue to contract with third parties for the manufacture and distribution of our product candidates. Because we rely on contract
manufacturers, we employ personnel with extensive technical, manufacturing, analytical and quality experience. Our team has deep knowledge
and understanding of the regulations that govern manufacturing, documentation, quality assurance, and quality control of drug supply
that are required to support our regulatory filings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
biotechnology and biopharmaceutical industries are characterized by continuing technological advancement and significant competition.
While we believe that our programs, technology, development experience and scientific knowledge provide us with competitive advantages,
we face competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and
private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with
existing therapies and new therapies that may become available in the future. Many of the companies with which we are currently competing
or will compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing,
preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products than we do. Mergers
and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller
number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites, patient enrollment for clinical trials as well as in acquiring technologies
complementary to, or necessary for, our programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Key
competitive factors affecting the success of all our product candidates that we develop, if approved, are likely to be efficacy, safety,
convenience, presentation, price, the level of generic competition, and the availability of reimbursement from government and other third-party
payors. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval
for our products, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Specifically,
there are several companies developing or marketing treatments that may be approved for the same indications and/or diseases as our two
most advanced programs, ORKA-001 and ORKA-002, including major pharmaceutical companies. We do not yet have clinical data for any of
our programs and there can be no assurance that our programs will have similar or comparable results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are several approved biologic therapies for the treatment of moderate-to-severe PsO.&#160;These include mAbs targeting IL-23, such as
Skyrizi (risankizumab) from AbbVie, Tremfya (guselkumab) from Janssen, and Ilumya (tildrakizumab) from Sun Pharma, also marketed as Ilumetri
by Almirall in Europe, which all target the p19 subunit, and Stelara (ustekinumab) from Janssen, which targets the p40 subunit; mAbs
targeting IL-17, such as Bimzelx (bimekizumab) from UCB, which targets IL-17A/F, Cosentyx (secukinumab) from Novartis and Taltz (ixekizumab)
from Eli Lilly, which both target IL-17A, and Siliq (brodalumab) from Ortho Dermatologics, also marketed as Kyntheum by LEO Pharma in
Europe, which targets IL-17 receptor A; and biologics targeting TNF-&#945;, such as Humira (adalimumab) from AbbVie, Enbrel (etanercept)
from Amgen, and Remicade (infliximab) from Janssen, and various biosimilar versions of each. In addition, there are several approved
oral medicines in these indications, including the phosphodiesterase-4 (PDE4) inhibitor Otezla (apremilast) from Amgen and the tyrosine
kinase 2 (TYK2) inhibitor Sotyktu (deucravacitinib) from Bristol-Myers Squibb. Many of these therapies also are approved or in development
for PsA, HS, axSpA, and other&#160;I&amp;I indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we are aware of several product candidates in clinical development for moderate-to-severe PsO, along with PsA, HS, axSpA, and
other indications. These include the biologics picankibart from Innovent Biologics targeting IL-23p19 and sonelokimab from MoonLake Immunotherapeutics
targeting IL-17A/F.&#160;Also, there are several oral agents in development, including JNJ-2113 from Janssen targeting the IL-23 receptor,
DC-806 and DC-853 from Eli Lilly targeting IL-17A, and TAK-279 from Takeda and ESK-001 from Alumis, both targeting TYK2.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>License
Agreements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Paragon
Therapeutics</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
March&#160;6, 2024, we entered into the Paragon Option Agreements. Under the terms of each agreement, Paragon identifies, evaluates,
and develops antibodies directed against certain mutually agreed therapeutic targets of interest to us. Each Paragon Option Agreement
initially included one of two selected targets: IL-23 and IL-17A/F.&#160;Under the Paragon Option Agreements, we have the exclusive option
to, on a research program-by-research program basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title,
and interest in and to the intellectual property resulting from the applicable research program to develop, manufacture, and commercialize
the antibodies and products directed to the selected target(s)&#160;(each, an &#8220;Option&#8221;). In the case of IL-23, our Option
excludes the therapeutic area of IBD.&#160;From time to time, we can choose to add additional targets to the collaboration by mutual
agreement with Paragon and Paruka. In September 2024 we exercised the Option to acquire the rights to ORKA-001 but have not yet entered
into the corresponding license agreement. As of the date hereof, we have not exercised the IL-17A/F Option.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the terms of the Paragon Option Agreements, we initiated certain research programs with Paragon that generally focus on a particular
target (each, a &#8220;Research Program&#8221;). Each Research Program is aimed at discovering, generating, identifying, and/or characterizing
antibodies directed to the respective target. For each Research Program, we established or may establish in the future a research plan
with Paragon that sets forth the activities that will be conducted, and the associated research budget (each, a &#8220;Research Plan&#8221;).
Our exclusive option with respect to each Research Program is exercisable at our sole discretion at any time during the period beginning
on the initiation of activities under the associated Research Program and ending a specified number of&#160;days following (i)&#160;with
respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results of the Research
Plan activities or (ii)&#160;with respect to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement
(the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Paragon Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, each Paragon Option Agreement shall continue in force on a Research Program-by-Research Program basis until the earlier
of: (i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by us; (ii)&#160;the
expiration of the 30-day period after we exercise our Option with respect to a Research Program, subject to mutually agreed extension,
during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii)&#160;the expiration of the
applicable Research Term (as defined under each Paragon Option Agreement) (the &#8220;Term&#8221;). We may terminate any Paragon Option
Agreement or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided
that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate any Paragon Option Agreement
or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us or our affiliates,
such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise delayed
for a certain consecutive number of&#160;months. Each party has the right to terminate the Paragon Option Agreements or any Research
Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the
30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of the date of filing of this prospectus, we have exercised the Option with respect to ORKA-001 but have not yet entered into the corresponding
license agreement. We have not yet exercised the Option with respect to ORKA-002. For each of these agreements, once we enter into the
corresponding license agreements, we will be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million
for each program upon the achievement of certain clinical development milestones, up to $10.0&#160;million for each program upon the
achievement of certain regulatory milestones, as well as tiered royalty payments in the low-to-mid single-digits beginning on the first
commercial sale in each program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
as part of the Paragon Option Agreements, on each of December&#160;31, 2024 and December&#160;31, 2025, we will grant Paruka warrants
to purchase a number of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully-diluted basis, with an exercise
price equal to the fair market value of the underlying shares on the grant date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Option Agreements, on a research program-by-research program basis following the finalization of the research plan for each respective
research program, the Company was required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related
to the ORKA-001 program. This amount was recognized as a research and development expense during the period from February&#160;6 (inception)
to September 30, 2024. In June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its
development candidate for IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred
through the completion of the IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June
2024. During the three months ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone
payment related to the achievement of development candidate as research and development expense in the Company&#8217;s condensed consolidated
statements of operations and comprehensive loss for each of the three months ended September 30, 2024 and for the period from February
6, 2024 (inception) to September 30, 2024. The Company&#8217;s share of development costs incurred during the three months ended September
30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively,
which were recorded as research and development expenses during the respective periods. An amount of $2.3 million is included in related
party accounts payable and other current liabilities as of September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Company was also required to reimburse Paragon $3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through
December&#160;31, 2023 and certain other development costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as
stipulated by the Option Agreements. This amount was recognized as a research and development expense during the period from February&#160;6
(inception) to September 30, 2024. The Company is also responsible for the development costs incurred by Paragon from January&#160;1,
2024 through the completion of the IL-17 selection process. The Company recognized an amount of $0.8&#160;million payable to Paragon
for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan. This was recognized as
research and development expenses in the period from February 6 (inception) to September 30, 2024. The Company accounted for development
costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception)
to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount of $3.8 million is
included in related party accounts payable and other current liabilities as of September 30, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, we recognized
$13.4 million and $33.8 million of expenses, respectively in connection with services provided by Paragon and Paruka under the Paragon
Option Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Government
Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among
other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging,
storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting
of biologics such as those we are developing. We, along with our third-party contractors, will be required to navigate the various preclinical,
clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies
or seek approval or licensure of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>United
States Biologics Regulation </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, biological products are subject to regulation under the FDCA, the Public Health Service Act (&#8220;PHSA&#8221;) and
other federal, state, local, and foreign statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance
with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following
approval may subject an applicant to administrative action and judicial sanctions. The process required by the FDA before biologic product
candidates may be marketed in the United States generally involves the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices (&#8220;GLP&#8221;)
regulation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes
are made;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
by an independent IRB, or ethics committee at each clinical site before the trial is commenced;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
of the proposed biologic candidate in accordance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
of adequate and well-controlled human clinical trials in accordance with current GCP requirements to establish the safety, purity and
potency of the proposed biologic product candidate for its intended purpose;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparation
of and submission to the FDA of a BLA, after completion of all pivotal clinical trials;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
completion of an FDA Advisory Committee review, if applicable;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to
assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s
continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Preclinical
and Clinical Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior
to beginning any clinical trial with a product candidate, in the United States, we must submit an IND to the FDA. An IND is a request
for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is
on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and <i>in vitro</i> studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics
of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the
investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical
trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or
questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical
trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment by an institutional
biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or
synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to
public health or the environment and such review may result in some delay before initiation of a clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Clinical
trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND
must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore,
an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and
its informed consent form before the clinical trial begins at that site, and must monitor the study until completed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Regulatory
authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects
are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include
oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board,
which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from
the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such
as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials
and clinical study results to public registries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
1. The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition.
These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product
in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase
2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically
significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial
sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an
adequate basis for product approval.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain
more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical
trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the
product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements.
The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things,
must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity
and potency. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate
that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted
under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor
must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application
for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by
an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate
the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both
ethical and data integrity standards for clinical studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>BLA Submission
and Review </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Assuming
successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development,
nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or
more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including
negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry,
manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to
test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored
by investigators. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption
applies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA must contain data to assess the
safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and
to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The Food and Drug
Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product
that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial
pediatric study plan within sixty days after an end-of-Phase 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise
required by regulation, PREA does not apply to any biological product for an indication for which orphan designation has been granted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Within
60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before
the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time
of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. Once
a BLA has been accepted for filing, the FDA&#8217;s goal is to review standard applications within ten months after the filing date,
or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and
priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews
a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed,
packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory
committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee,
but it considers such recommendations carefully when making decisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Before
approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically
inspect one or more clinical sites to assure compliance with cGCPs. If the FDA determines that the application, manufacturing process
or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional
testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the
application does not satisfy the regulatory criteria for approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">After
the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing
of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies
that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate
to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted
product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant
might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay
or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">If
regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the
indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of
the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and
to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization
tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls
and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre-&#8201;and post-marketing requirements
is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market
studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may
limit further marketing of the product based on the results of these post-marketing studies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Expedited
Development and Review Programs </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended
to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible
for fast track designation if they are intended to treat a serious or life-threatening disease or condition and data demonstrate the
potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product
and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions
with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast
track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before
the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees
to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission
of the first section of the BLA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation
to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates
that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.
The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as
early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior
managers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough
therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as
priority review and accelerated approval. A product is eligible for priority review if there is evidence it has the potential to provide
a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review
designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as
compared to ten months under standard review).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated
approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit,
or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict
an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of
the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally
require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect
on irreversible morbidity or mortality or other clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 the FDA may require,
as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product
granted accelerated approval. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor
fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the
FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the
timing of the commercial launch of the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Fast
track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the
development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product
no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including,
among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and
distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements,
under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors
are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections
by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon
us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance
of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of
any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with
cGMPs and other aspects of regulatory compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product
reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
warning letters or holds on post-approval clinical studies;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
seizure or detention, or refusal of the FDA to permit the import or export of products;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consent
decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">mandated
modification of promotional materials and labeling and the issuance of corrective information;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety
information about the product; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating
to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with
these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil
and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling
and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians
may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the
behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject
of off-label use of their products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Biosimilars
and Reference Product Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ACA includes a subtitle called the BPCIA, which created an abbreviated approval pathway for biological products that are highly similar,
or &#8220;biosimilar,&#8221; to or interchangeable with an FDA-approved reference biological product. The FDA has issued several guidance
documents outlining an approach to review and approval of biosimilars.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Biosimilarity,
which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of
safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability
requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the
same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual,
the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety
risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A product shown to be biosimilar or interchangeable
with an FDA-approved reference biological product may rely in part on the FDA&#8217;s previous determination of safety and effectiveness
for the reference product for approval, which can potentially reduce the cost and time required to obtain approval to market the product.
Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which
such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked
out by the FDA. In September 2021, the FDA issued two guidance documents intended to inform prospective applicants and facilitate the
development of proposed biosimilars and interchangeable biosimilars, as well as to describe the FDA&#8217;s interpretation of certain
statutory requirements added by the BPCIA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12
years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may
still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s
own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its
product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it
is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which
are governed by state pharmacy law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
reference biologic is granted twelve years of exclusivity from the time of first licensure of the reference product. The first biologic
product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity
against other biologics submitted under the abbreviated approval pathway for the lesser of (i) one year after the first commercial marketing,
(ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of
a lawsuit challenging the biologics&#8217; patents if an application has been submitted, or (iv) 42 months after the application has
been approved if a lawsuit is ongoing within the 42-month period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months
to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection
or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written
Request&#8221; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In July 2018, the FDA
announced an action plan to encourage the development and efficient review of biosimilars, including the establishment of a new office
within the agency that will focus on therapeutic biologics and biosimilars. On December 20, 2020, Congress amended the PHSA as part of
the COVID-19 relief bill to further simplify the biosimilar review process by making it optional to show that conditions of use proposed
in labeling have been previously approved for the reference product, which used to be a requirement of the application. In addition,
government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which
may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation,
and impact of the BPCIA is subject to significant uncertainty.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
discussed below, the IRA is a significant new law that intends to foster generic and biosimilar competition and to lower drug and biologic
costs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Healthcare Laws and Compliance Requirements </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pharmaceutical
companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states
and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute
(&#8220;AKS&#8221;); the federal False Claims Act (&#8220;FCA&#8221;); the Health Insurance Portability and Accountability Act of 1996
(&#8220;HIPAA&#8221;) and similar foreign, federal and state fraud, abuse and transparency laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AKS prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration,
to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which
payment may be made under any federal healthcare program. The term remuneration has been interpreted broadly to include anything of value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and purchasers on
the other. The government often takes the position that to violate the AKS, only one purpose of the remuneration need be to induce referrals,
even if there are other legitimate purposes for the remuneration. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from AKS prosecution, but they are drawn narrowly and practices that involve remuneration, such as
consulting agreements, that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny
if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception
or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated
on a case-by-case basis based on a cumulative review of all of its facts and circumstances. A person or entity does not need to have
actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Civil
and criminal false claims laws, including the FCA, and civil monetary penalty laws, which can be enforced through civil whistleblower
or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims
for payment of federal government funds, including in federal healthcare programs, that are false or fraudulent. Pharmaceutical and other
healthcare companies have been prosecuted under these laws for engaging in a variety of different types of conduct that &#8220;caused&#8221;
the submission of false claims to federal healthcare programs. Under the AKS, for example, a claim resulting from a violation of the
AKS is deemed to be a false or fraudulent claim for purposes of the FCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">HIPAA
created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit
program, including private third-party payors, and making false statements relating to healthcare matters. A person or entity does not
need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order
to have committed a violation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and medical
devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The PHSA
also prohibits the introduction into interstate commerce of unlicensed or mislabeled biological products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which
payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually
report to the Centers for Medicaid &amp; Medicare Services (&#8220;CMS&#8221;) information related to payments or other transfers of
value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists,
certified nurse anesthetists, certified nurse-midwives, and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Beginning on January 1, 2023, California Assembly Bill 1278 requires California physicians
and surgeons to notify patients of the Open Payments database established under the federal Physician Payments Sunshine Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases,
differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations
are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to penalties, including,
without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs,
such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations
to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits
and the curtailment or restructuring of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Data Privacy
and Security </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Numerous
state, federal, and foreign laws govern the collection, dissemination, use, access to, confidentiality, and security of personal information,
including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach
notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations, govern the
collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations
of our partners. For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;),
and their respective implementing regulations imposes data privacy, security, and breach notification obligations on certain health care
providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates and their covered
subcontractors that perform certain services that involve using, disclosing, creating, receiving, maintaining, or transmitting individually
identifiable protected health information (&#8220;PHI&#8221;) for or on behalf of such covered entities. These requirements imposed by
HIPAA and the HITECH Act on covered entities and business associates include entering into agreements that require business associates
protect PHI provided by the covered entity against improper use or disclosure, among other things; following certain standards for the
privacy of PHI, which limit the disclosure of a patient&#8217;s past, present, or future physical or mental health or condition or information
about a patient&#8217;s receipt of health care if the information identifies, or could reasonably be used to identify, the individual;
ensuring the confidentiality, integrity, and availability of all PHI created, received, maintained, or transmitted in electronic form,
to identify and protect against reasonably anticipated threats or impermissible uses or disclosures to the security and integrity of
such PHI; and reporting of breaches of PHI to individuals and regulators. Entities that are found to be in violation of HIPAA may be
subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations
if required to enter into a resolution agreement and corrective action plan with the U.S. Department of Health and Human Services (&#8220;HHS&#8221;)
to settle allegations of HIPAA non-compliance. A covered entity or business associate is also liable for civil money penalties for a
violation that is based on an act or omission of any of its agents, which may include a downstream business associate, as determined
according to the federal common law of agency. HITECH also increased the civil and criminal penalties applicable to covered entities
and business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts
to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. To the extent that we submit
electronic healthcare claims and payment transactions that do not comply with the electronic data transmission standards established
under HIPAA and HITECH, payments to us may be delayed or denied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Even
when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep
consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section
5(a) of the Federal Trade Commission Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, certain state laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California
Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), govern the privacy and security of personal information, including health-related information
in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and
may not have the same effect, thus complicating compliance efforts. The CCPA/CPRA applies to personal data of consumers, business representatives,
and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures
in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s
definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could
reasonably be linked with a particular consumer or household - unless it is subject to HIPAA - and is included under a new category of
personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Failure to comply with these
laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and
security laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts,
and can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on
data processing. Additionally, our use of artificial intelligence and machine learning may be subject to laws and evolving regulations
regarding the use of artificial intelligence/machine learning, controlling for data bias, and antidiscrimination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the CPRA expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal information
and establishing a new regulatory agency to implement and enforce the law. Other states, such as Virginia, Colorado, Connecticut and
Utah, have also passed comprehensive privacy laws, and similar laws are being considered in several other states, as well as at the federal
and local levels. While the laws in these states, like the CCPA, also exempt some data processed in the context of clinical trials, such
developments further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom
we rely.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Coverage
and Reimbursement </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory
approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors,
such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the
level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates,
if approved, the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. Further, no uniform
policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor
to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates,
but also have their own methods and approval process apart from Medicare determinations. As a result, the coverage determination process
is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product
candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained
in the first instance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Third-party
payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety
and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with
existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement
for any product or a decision by a third-party not to cover a product could reduce physician usage and patient demand for the product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment
or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic
tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or
biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products,
will apply to companion diagnostics.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. The IRA provides CMS
with significant new authorities intended to curb drug costs and to encourage market competition. For the first time, CMS will be able
to directly negotiate prescription drug prices and to cap out-of-pocket costs. Each year, CMS will select and negotiate a preset number
of high-spend drugs and biologics that are covered under Medicare Part B and Part D that do not have generic or biosimilar competition.
On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations. These price negotiations
will begin in 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. The IRA also provides
a new &#8220;inflation rebate&#8221; covering Medicare patients that took effect in 2023 and is intended to counter certain price increases
in prescriptions drugs. The inflation rebate provision will require drug manufacturers to pay a rebate to the federal government if the
price for a drug or biologic under Medicare Part B and Part D increases faster than the rate of inflation. To support biosimilar competition,
beginning in October 2022, qualifying biosimilars may receive a Medicare Part B payment increase for a period of five years. Separately,
if a biologic drug for which no biosimilar exists delays a biosimilar&#8217;s market entry beyond two years, CMS will be authorized to
subject the biologics manufacturer to price negotiations intended to ensure fair competition. Notwithstanding these provisions, the IRA&#8217;s
impact on commercialization and competition remains largely uncertain.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Healthcare
Reform </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving
quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement
of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental
control of drug pricing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers
in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import
to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs,
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health
care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the IRA, among other things, extends enhanced
subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the
&#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket
cost and creating a new manufacturer discount program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other
legislative changes have been proposed and adopted since the ACA was enacted, including automatic aggregate reductions of Medicare payments
to providers of on average 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These
reductions went into effect in April 2013 and, due to subsequent legislative amendments, will remain in effect until 2032 unless additional
action is taken by Congress.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the Bipartisan Budget Act of 2018, among other things, amended the Medicare Act (as amended by the ACA) to increase the point-of-sale
discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices
of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient
drugs being covered under Medicare Part D.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things,
reduce the cost of prescription drugs, bring more transparency to product pricing, review the relationship between pricing and manufacturer
patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted
a final rule allowing Medicare Advantage Plans the option to use step therapy for Part B drugs, permitting Medicare Part D plans to apply
certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part
D beneficiaries to disclose drug price increases and lower cost therapeutic alternatives, which went into effect on January 1, 2021.
In response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three
new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility,
and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further,
on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft
Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product
as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised,
it is uncertain if that will continue under the new framework.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Notwithstanding
the IRA, continued legislative and enforcement interest exists in the United States with respect to specialty drug pricing practices.
Specifically, we expect regulators to continue pushing for transparency to drug pricing, reducing the cost of prescription drugs under
Medicare, reviewing the relationship between pricing and manufacturer patient programs, and reforming government program reimbursement
methodologies for drugs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Other
Government Regulation Outside of the United States </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage,
record keeping, distribution, reporting, export and import, advertising, marketing and other promotional practices involving biological
products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced
raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries
prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United
States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement
of human clinical trials. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
requirements and process governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product
licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals, pricing
and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate
approval application has been approved by the regulatory authorities in that country. The current approval process varies from country
to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price
of a product must also be approved. The pricing review period often begins after market approval is granted. Even if a product is approved
by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially
unfeasible in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Regulation
in the European Union </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>European
Data Laws </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data
Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018, and related data protection laws in individual
EU Member States. The GDPR imposes a number of strict obligations and restrictions on the ability to process, including collecting, analyzing
and transferring, personal data of individuals, in particular with respect to health data from clinical trials and adverse event reporting.
The GDPR includes requirements relating to the legal basis of the processing (such as consent of the individuals to whom the personal
data relates), the information provided to the individuals prior to processing their personal data, the notification obligations to the
national data protection authorities, and the security and confidentiality of the personal data. EU Member States may also impose additional
requirements in relation to health, genetic and biometric data through their national legislation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the GDPR imposes specific restrictions on the transfer of personal data to countries outside of the European Economic Area
(&#8220;EEA&#8221;) that are not considered by the European Commission (&#8220;EC&#8221;) to provide an adequate level of data protection.
Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may
use the standard contractual clauses (&#8220;SCCs&#8221;). With regard to the transfer of data from the EEA to the United States, on
July 10, 2023, the EC adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision,
personal data can flow from the EEA to U.S. companies participating in the framework.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Failure
to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in significant
monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever
is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and, in
certain cases, their directors and officers, as well as civil liability claims from individuals whose personal data was processed. Data
protection authorities from the different EU Member States may still implement certain variations, enforce the GDPR and national data
protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing
personal data in the EU. Guidance developed at both the EU level and at the national level in individual EU Member States concerning
implementation and compliance practices are often updated or otherwise revised.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
there is a growing trend towards the required public disclosure of clinical trial data in the EU, which adds to the complexity of obligations
relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials
Regulation No. 536/2014 (&#8220;CTR&#8221;), European Medical Agency (&#8220;EMA&#8221;) disclosure initiatives and voluntary commitments
by industry. Failure to comply with these obligations could lead to government enforcement actions and significant penalties against
us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between
different regulatory frameworks, such as the CTR and the GDPR, further adds to the complexity that we face with regard to data protection
regulation.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">With
regard to the transfer of personal data from the EEA to the UK, personal data may now freely flow from the EEA to the UK since the UK
is deemed to have an adequate data protection level.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">However,
the adequacy decisions include a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after
their entry into force. Additionally, following the UK&#8217;s withdrawal from the EU and the EEA, companies also have to comply with
the UK&#8217;s data protection laws (including the UK GDPR (as defined in section 3(10) (as supplemented by section 205(4)) of the Data
Protection Act 2018 (the &#8220;DPA 2018&#8221;)), the DPA 2018, and related data protection laws in the UK). Separate from the fines
that can be imposed by the GDPR, the UK regime has the ability to fine up to the greater of &#163;17.5 million or 4% of global turnover.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Following
the UK&#8217;s withdrawal from the EU and the EEA, companies are subject to specific transfer rules under the UK regime; personal data
may flow freely from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime.
These UK international transfer rules broadly mirror the GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK
Parliament the international data transfer agreement (&#8220;IDTA&#8221;) and the international data transfer addendum to the EC&#8217;s
standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA
and Addendum came into force on March 21, 2022 and replaced the old SCCs for the purposes of the UK regime. However, the transitional
provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of
any old SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing
operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal
data is subject to appropriate safeguards.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">With
regard to the transfer of personal data from the UK to the United States, the UK government has adopted an adequacy decision for the
United States, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the United States as
offering an adequate level of data protection where the transfer is to a U.S. company participating in the EU-US Data Privacy Framework
and the UK Extension.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Drug and
Biologic Development Process </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Regardless
of where they are conducted, all clinical trials included in applications for marketing authorization (&#8220;MA&#8221;) for human medicines
in the EU/EEA must have been carried out in accordance with EU regulations. This means that clinical trials conducted in the EU/EEA have
to comply with EU clinical trial legislation but also that clinical trials conducted outside the EU/EEA have to comply with ethical principles
equivalent to those set out in the EEA, including adhering to international good clinical practice and the Declaration of Helsinki. The
conduct of clinical trials in the EU is governed by the CTR, which entered into force on January 31, 2022. The CTR replaced the Clinical
Trials Directive 2001/20/EC, (&#8220;Clinical Trials Directive&#8221;) and introduced a complete overhaul of the existing regulation
of clinical trials for medicinal products in the EU.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the former regime, which will expire after a transition period of three years as outlined below in more detail, before a clinical trial
can be initiated it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The
approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;) and one or more Ethics Committees.
NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent
Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before
the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications
must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious
adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees
of the EU member state where they occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">A
more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical
trial through a centralized EU clinical trials portal (the &#8220;CTIS&#8221;). One national regulatory authority (the reporting EU member
state proposed by the applicant) will take the lead in validating and evaluating the application and consult and coordinate with the
other concerned EU Member States. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal.
If an approval is issued, the sponsor may start the clinical trial in all concerned EU Member States. However, a concerned EU member
state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted
in such member state. The CTR also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency
requirements such as mandatory submission of a summary of the clinical trial results to the EU Database. The CTR foresees a three-year
transition period. EU Member States will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission
of initial clinical trial applications via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical
Trials Directive will need to comply with the CTR and have to be transitioned to CTIS. On July 19, 2023, the EC published guidance concerning
the steps to be taken in this transition. This guidance provides, among other things, that (i) documentation which was previously assessed
will not be reassessed, (ii) templates that were developed and endorsed by the EU Clinical Trials Expert Group to provide compliance
with the CTR do not need to be updated and (iii) there is no need to retrospectively create a site suitability form, which are only necessary
for new trial sites.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
both the former regime and the new CTR, national laws, regulations, and the applicable GCP and GLP standards must also be respected during
the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human
Use guidelines on Good Clinical Practice and the ethical principles that have their origin in the Declaration of Helsinki.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the development of a medicinal product, the EMA and national regulators within the EU provide the opportunity for dialogue and guidance
on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee
for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party. A fee is incurred
with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically
provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and
clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing
Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Drug Marketing
Authorization </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EEA, after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining
a MA. To obtain a MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized
or decentralized procedure.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">To
be used or sold in the UK, a drug must have an effective MA obtained by a centralized application through EMA or a national application.
National applications are governed by the Human Medicines Regulations (SI 2012/1916). Applications are made electronically through the
Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) Submissions Portal. The process from application to authorizations
generally takes up to 210 days, excluding time taken to provide any additional information or data required by the MHRA.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
August 30, 2023, the MHRA published detailed guidance on its recently announced new International Reliance Procedure (&#8220;IRP&#8221;)
for MAAs. The IRP applies since January 1, 2024 and replaces existing EU reliance procedures to apply for authorizations from seven international
regulators (e.g. Health Canada, Swiss Medic, FDA, EMA, among others). The IRP allows medicinal products approved in other jurisdictions
that meet certain criteria to undergo a fast-tracked MHRA review to obtain and/or update a MA in the UK or Great Britain.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Applicants
can submit initial MAAs to the IRP but the procedure can also be used throughout the lifecycle of a product for post-authorization procedures
including line extensions, variations and renewals. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Centralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
centralized procedure provides for the grant of a single MA that is issued by the EC following the scientific assessment of the application
by the EMA that is valid for all EU Member States as well as in the three additional member states of the EEA. The centralized procedure
is compulsory for certain types of medicinal products, including for medicines developed by means of certain biotechnological processes,
products designated as orphan medicinal products, advanced therapy medicinal products (&#8220;ATMP&#8221;) and medicinal products with
a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune
and viral diseases). For medicinal products containing a new active substance not yet authorized in the EEA before May 20, 2004 and indicated
for the treatment of other diseases, medicinal products that constitute significant therapeutic, scientific or technical innovations
or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant
may voluntarily submit an application for a MA through the centralized procedure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the centralized procedure, the CHMP established at the EMA, is responsible for conducting the initial assessment of a drug. The CHMP
is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions
to an existing MA. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle,
210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to
be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless
the application is eligible for an accelerated assessment. Accelerated evaluation might be granted by the CHMP in exceptional cases,
when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation.
Upon request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment.
The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements.
This opinion is then transmitted to the EC, which has the ultimate authority for granting MA within 67 days after receipt of the CHMP
opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Decentralized
Authorization Procedure </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Medicines
that fall outside the mandatory scope of the centralized procedure have three routes to authorization: (i) they can be authorized under
the centralized procedure if they concern a significant therapeutic, scientific or technical innovation, or if their authorization would
be in the interest of public health; (ii) they can be authorized under a decentralized procedure where an applicant applies for simultaneous
authorization in more than one EU member state; or (iii) they can be authorized in an EU member state in accordance with that state&#8217;s
national procedures and then be authorized in other EU countries by a procedure whereby the countries concerned agree to recognize the
validity of the original, national MA (mutual recognition procedure).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
decentralized procedure permits companies to file identical MA applications for a medicinal product to the competent authorities in various
EU Member States simultaneously if such medicinal product has not received marketing approval in any EU Member State before. This procedure
is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority
of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The
competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant a MA for their territories
on the basis of this assessment. The only exception to this is where the competent authority of an EU Member State considers that there
are concerns of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually
be referred to the EC, whose decision is binding for all EU Member States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Risk Management
Plan </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;) describing the risk management system that the company will put in place
and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout
the lifetime of the medicine as new information becomes available. An updated RMP must be submitted: (i) at the request of EMA or a national
competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received
that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization
milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20,
2023, all RMPs for centrally authorized products are published by the EMA, subject only to limited redactions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>MA Validity
Period </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">MAs
have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation
of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority
decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for
renewal must be made to the EMA at least nine months before the five-year period expires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw
materials, including all substances coming into contact with the cells or tissues it may contain, can be traced through the sourcing,
manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Any
authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market
of the authorizing member state within three years after authorization ceases to be valid.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
the UK, the period of three years during which the drug has not been marketed in Great Britain will be restarted from the date of conversion
to a Great Britain MA. Conversion refers to the procedure by which, as of January 1, 2021, MAs granted on the basis of a centralized
procedure in the EU are only valid in Northern Ireland but not in Great Britain, whereas, prior EU authorizations have all been automatically
converted into UK MAs effective in Great Britain only.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
the other hand, for the EU, in the case the drug has been marketed in the UK, the placing on the UK market before the end of the period
starting when the UK left the EU on January 31, 2020 and ending on December 31, 2020 (the &#8220;Brexit Transition Period&#8221;) will
be taken into account. If, after the end of the Brexit Transition Period, the drug is not placed on any other market of the remaining
EU Member States, the three-year period will start running from the last date the drug was placed on the UK market before the end of
the Brexit Transition Period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Advanced
Therapy Medicinal Products </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, medicinal products, including ATMPs are subject to extensive pre- and post-market regulation by regulatory authorities at both
the EU and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which
are genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure,
diagnose or prevent diseases or regenerate, repair or replace a human tissue. Pursuant to the ATMP Regulation, the Committee on Advanced
Therapies (&#8220;CAT&#8221;) is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible
for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation
to the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs. Although
such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval for product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the mandatory RMP, the holder of a MA for an ATMP must put in place and maintain a system to ensure that each individual
product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may contain, can
be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where
the product is used.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Exceptional
Circumstances/Conditional Approval </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Similar
to accelerated approval regulations in the United States, conditional MAs can be granted in the EU in exceptional circumstances. A conditional
MA can be granted for medicinal products where, although comprehensive clinical data referring to the safety and efficacy of the medicinal
product have not been supplied, a number of criteria are fulfilled: (i) the benefit/risk balance of the product is positive, (ii) it
is likely that the applicant will be in a position to provide the comprehensive clinical data, (iii) unmet medical needs will be fulfilled
by the grant of the MA and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned
outweighs the risk inherent in the fact that additional data are still required. A conditional MA must be renewed annually.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Data and
Market Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect
of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical
product has already received a MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological
and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the
market. New Chemical Entities (&#8220;NCEs&#8221;) approved in the EU qualify for eight years of data exclusivity and 10 years of marketing
exclusivity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">An
additional non-cumulative one-year period of marketing exclusivity is possible if during the data exclusivity period (the first eight
years of the 10-year marketing exclusivity period), the MA holder obtains an authorization for one or more new therapeutic indications
that are deemed to bring a significant clinical benefit compared to existing therapies.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application
may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years
later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after
the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within
the eight-year data exclusivity period. Additionally, another non-cumulative one-year period of data exclusivity can be added to the
eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant
pre-clinical or clinical studies were carried out in relation to the new indication.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Another
year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized
on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of MA
for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for
one year after the initial change was authorized).</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Products
may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities
to include an NCE. Even if a compound is considered to be an NCE and the MA applicant is able to gain the prescribed period of data exclusivity,
another company nevertheless could also market another version of the medicinal product if such company can complete a full MAA with
their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g.,
a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its
entry into force. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Orphan
Designation and Exclusivity </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
criteria for designating an orphan medicinal product in the EU are similar in principle to those in the U.S. The EMA grants orphan drug
designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, orphan drug designation can be
granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other
satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed
medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is
not a MA, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application
for MA of the medicinal product is submitted. The applicant will receive a fee reduction for the MAA if the orphan drug designation has
been granted, but not if the designation is still pending at the time the MA is submitted, and sponsors must submit an annual report
to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the
duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional MA.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for
a MA; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of MA review by the EMA
and approval by the EC. Additionally, any MA granted for an orphan medicinal product must only cover the therapeutic indication(s) that
are covered by the orphan drug designation. Upon the grant of a MA, orphan drug designation provides up to ten years of market exclusivity
in the orphan indication.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">During
the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU Member States and
the EMA may not accept applications for MA, accept an application to extend an existing MA or grant a MA for other similar medicinal
products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active
substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic
indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition
when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;) addressing the pediatric
population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary
protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation
(EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug
designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market
protection. Additionally, a MA may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject
to certain requirements.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the UK, following the post-Brexit transition period, a system for incentivizing the development of orphan medicines was introduced. Overall,
the requirements for orphan designation largely replicate the requirements in the EU and the benefit of market exclusivity has been retained.
Products with an orphan designation in the EU can be considered for an orphan MA in Great Britain, but a UK-wide orphan MA can only be
considered in the absence of an active EU orphan designation. The MHRA will review applications for orphan designation at the time of
a MA, and will offer incentives, such as market exclusivity and full or partial refunds for MA fees to encourage the development of medicines
in rare diseases. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Pediatric
Development </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, companies developing a new medicinal product are obligated to study their product in children and must therefore submit a PIP
together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric
Committee. Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (e.g. until
enough information to demonstrate its effectiveness and safety in adults is available) or waiver (e.g. because the relevant disease or
condition occurs only in adults) has been granted by the EMA. The MAA for the medicinal product must include the results of all pediatric
clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral
has been granted, in which case the pediatric clinical trials may be completed at a later date. Medicinal products that are granted an
MA on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six-month extension
of the protection under a supplementary protection certificate (if any is in effect at the time of approval), or, in the case of orphan
medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and
is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required
when a MA holder wants to add a new indication, medicinal form or route of administration for a medicine that is already authorized and
covered by intellectual property rights.</span></p><div>

</div><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the MHRA has published guidance on the procedures for UK PIPs which, where possible, mirror the submission format and requirements
of the EU system. EU PIPs remain applicable for Northern Ireland and EU PIPs agreed by the EMA prior to January 1, 2021 have been adopted
as UK PIPs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>PRIME
Designation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few
or no therapies currently exist. The Priority Medicines (&#8220;PRIME&#8221;) scheme is intended to encourage drug development in areas
of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized
procedure. Products from small-and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies
on the basis of compelling non-clinical data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of
product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent
discussions on clinical trial designs and other development program elements, and potentially accelerated MAA assessment once a dossier
has been submitted. Importantly, once a candidate medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur
from the CHMP or CAT are appointed facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting
with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the
overall development plan and regulatory strategy. PRIME eligibility does not change the standards for product approval, and there is
no assurance that any such designation or eligibility will result in expedited review or approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Post-Approval
Regulation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Similar
to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the EC and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of
manufacturing licenses and MAs. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations,
pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting
of medicinal products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Failure
by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related
national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, MA of medicinal products
and marketing of such products, both before and after grant of MA, statutory health insurance, bribery and anti-corruption or other applicable
regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to
authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or
variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions,
injunctions, suspension of licenses, fines and criminal penalties.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
holder of MA for a medicinal product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines,
which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">These
pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks
and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible
requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s
safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability.
MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who
is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission
of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to medicinal products for which they hold MAs. The EMA reviews PSURs
for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product
has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise
that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a
decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the EC&#8217;s decision provides can
undermine the ongoing validity of the MA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">More
generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the MA for the product
or imposition of financial penalties or other enforcement measures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities
that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization
holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC,
Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;).
These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients,
including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical
ingredients into the EU. Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with
the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted
by the competent authorities of the EU Member States. The manufacturer or importer must have a qualified person who is responsible for
certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution
in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for
compliance with GMP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Sales
and Marketing Regulations </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal products, interactions with physicians,
misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member
States may apply to the advertising and promotion of medicinal products and may differ from one country to another. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s SmPC as approved by the
competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective
use of the medicinal product. It forms an intrinsic and integral part of the MA granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities
for the product must be consistent with the approved SmPC and therefore all off-label promotion is prohibited. Direct-to-consumer advertising
of prescription-only medicines is also prohibited in the EU. Violations of the rules governing the promotion of medicinal products in
the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising
and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">EU
regulation with regards to dispensing, sale and purchase of medicines has generally been preserved in the UK following Brexit, through
the Human Medicines Regulations 2012. However, organizations wishing to sell medicines online need to register with the MHRA. Following
Brexit, the requirements to display the common logo no longer apply to UK-based online sellers, except for those established in Northern
Ireland.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Anti-Corruption
Legislation </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation
codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision
of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order
or use of medicinal products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national
anti-bribery laws of the EU Member States. Violation of these laws could result in substantial fines and imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Payments
made to physicians in certain EU Member States also must be publicly disclosed. Moreover, agreements with physicians must often be the
subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the
competent authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional
codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational
risk, public reprimands, administrative penalties, fines or imprisonment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
the UK, the pharmaceutical sector is recognized as being particularly vulnerable to corrupt practices, some of which fall within the
scope of the Bribery Act 2010. Due to the Bribery Act 2010&#8217;s far-reaching territorial application, the potential penalized act
does not have to occur in the UK to become within its scope. If the act or omission does not take place in the UK, but the person&#8217;s
act or omission would constitute an offense if carried out there and the person has a close connection with the UK, an offense will still
have been committed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Bribery Act 2010 is comprised of four offenses that cover (i) individuals, companies and partnerships that give, promise or offer bribes,
(ii) individuals, companies and partnerships that request, agree to receive or accept bribes, (iii) individuals, companies and partnerships
that bribe foreign public officials, and (iv) companies and partnerships that fail to prevent persons acting on their behalf from paying
bribes. The penalties imposed under the Bribery Act 2010 depend on the offence committed, harm and culpability and penalties range from
unlimited fines to imprisonment for a maximum term of ten years and in some cases both.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Regulations
in the UK and Other Markets </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
UK formally left the EU on January 31, 2020 and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol
on Ireland and Northern Ireland and as amended by the Windsor Framework sets out a long-term set of arrangements for the supply of medicines
into Northern Ireland. The EU and the UK agreed on a trade and cooperation agreement (&#8220;TCA&#8221;), which includes provisions affecting
the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including
the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP issued documents. The TCA does
not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
UK government has adopted the Medicines and Medical Devices Act 2021 (the &#8220;MMDA&#8221;) to enable the UK&#8217;s regulatory frameworks
to be updated following the UK&#8217;s departure from the EU. The MMDA introduces regulation-making, delegated powers covering the fields
of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. The MHRA has since been consulting
on future regulations for medicines and medical devices in the UK.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">For
other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct
of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials
must be conducted in accordance with GCPs and the applicable regulatory requirements and the ethical principles that have their origin
in the Declaration of Helsinki.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">If
we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical
trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Employees
and Human Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As
of November 13, 2024, we had 27 full-time employees. We also engage temporary employees and consultants to augment our existing workforce.
None of our employees are represented by a labor union or covered under a collective bargaining agreement. We consider our relationship
with our employees to be good.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
recognize that attracting, motivating, and retaining talent at all levels is vital to continuing our success. We invest in our employees
through high-quality benefits, professional development opportunities, and various health and wellness initiatives and offer competitive
compensation packages (base salary and incentive plans), ensuring fairness in internal compensation practices. The principal purposes
of our incentive plans (bonus and equity) are to align with the long-term interests of our stakeholders and stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Properties
and Facilities </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
maintain a corporate office at 855 Oak Grove Ave., Suite 100, Menlo Park, California. The lease for this office commenced on June 15,
2024 with an initial term of 39.5 months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Legal
Proceedings </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, we may become involved in legal proceedings. We are not currently a party to or aware of any proceedings that we believe
will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources
and other factors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Executive
Officers and Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table and discussion sets forth the names, ages as of November 13, 2024, positions and biographical and other information of
the individuals who currently serve as directors and executive officers of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; width: 33%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 10%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 55%; padding-top: 0.25pt; padding-right: 0.25pt; padding-left: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Executive
    Officers:</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
    Agarwal </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Vice President, Finance and Treasurer </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joana
    Goncalves&#160;&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Quinlan </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    Counsel and Corporate Secretary</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Non-Employee
    Directors:</i></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth
    Kulkarni <sup>(2)(3)&#160;&#160;</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair
    and Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine
    Ball <sup>(1)(3)&#160;&#160;</sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl
    Dambkowski <sup>(1) </sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin <sup>(2)(3) </sup></span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; padding: 0.25pt 0.25pt 0.25pt 10pt; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle <sup>(1)(2)&#160;&#160;</sup>&#160;&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding: 0.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; padding: 0.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Audit Committee.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Compensation Committee.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Member
                                            of the Nominating and Governance Committee (the &#8220;Governance Committee&#8221;).</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each
executive officer serves at the discretion of the of the Board and holds office until their successor is duly appointed and qualified
or until their earlier resignation or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Executive
Officers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Lawrence
Klein, Ph.D.</i></b> Dr.&#160;Klein has served as Chief Executive Officer and as a member of the board of directors of the Company since
the Closing and of Pre-Merger Oruka from February 2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Klein was a Partner
at Versant Venture Management, LLC, a healthcare and biotechnology venture capital firm, from January&#160;2023 to February&#160;2024,
where he invested in and helped to grow early-stage&#160;biotechnology companies. Prior to Versant, Dr.&#160;Klein served in various
positions at CRISPR Therapeutics AG (Nasdaq: CRSP), a biopharmaceutical company, including Chief Operating Officer from January&#160;2020
to October&#160;2022, Chief Business Officer from January&#160;2019 to January&#160;2020, Senior Vice President, Business Development
and Strategy from November&#160;2017 to December&#160;2018 and as Vice President, Strategy from February&#160;2016 to November&#160;2017,
where he helped to initiate and execute on several transformative partnerships, establish the strategic direction of the company, oversee
important pipeline programs and led several functions, including program and portfolio management. Before joining CRISPR, Dr.&#160;Klein
was an Associate Partner at McKinsey&#160;&amp; Company, a global management consulting firm, from October&#160;2014 to February&#160;2016.
Dr.&#160;Klein served as a member of the board of directors of Dyne Therapeutics, Inc. (Nasdaq: DYN) from September&#160;2019 to May&#160;2023
and of Jasper Therapeutics, Inc. (Nasdaq: JSPR) from September&#160;2021 to June&#160;2023. Dr.&#160;Klein received his B.S. in biochemistry
and physics from the University of Wisconsin-Madison&#160;and his Ph.D. in biophysics from Stanford University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Klein is qualified to serve as a member of the Board because of his business development, operational and senior management
experience in the biotechnology industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Arjun
Agarwal.</i>&#160;</b>Mr.&#160;Agarwal has served as the Senior Vice President of Finance of the Company since the Closing and of Pre-Merger
Oruka from March&#160;2024 through the Closing, where he is responsible for overseeing the company&#8217;s finance and accounting functions.
Prior to joining Pre-Merger Oruka, Mr.&#160;Agarwal served as VP of Finance at Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology
company, from June&#160;2021 to March&#160;2024, including through multiple financings and the company&#8217;s successful transition
to become a publicly traded entity. Before joining Jasper, Mr.&#160;Agarwal served as Vice President, Corporate Controller at Protagonist
Therapeutics, Inc. (Nasdaq: PTGX), a biotechnology company, from August&#160;2019 to June&#160;2021, where he was responsible for overseeing
the company&#8217;s finance and accounting functions. Prior to joining Protagonist, Mr.&#160;Agarwal served in various roles of increasing
responsibility at McKesson Corporation (NYSE:&#160;MCK),&#160;an international healthcare services company, from 2009 to 2019. Prior
to McKesson, Mr.&#160;Agarwal worked at PricewaterhouseCoopers LLP, where he managed a portfolio of audit clients. He is a graduate of
Sydenham College of Commerce and Economics at Mumbai University, India. He is a Certified Public Accountant (CPA) and a Chartered Accountant
accredited by the Institute of Chartered Accountants of India.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Joana
Goncalves, MBChB. </i></b>Dr.&#160;Goncalves has served as the Chief Medical Officer of the Company since the Closing and of Pre-Merger
Oruka from April&#160;2024 through the Closing. Prior to joining Pre-Merger Oruka, Dr.&#160;Goncalves served as Chief Medical Officer
of Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company, from October&#160;2018 to April&#160;2024, where she was responsible
for representing Cara Therapeutics in interactions with regulatory agencies, the investor and scientific communities and the board of
directors, building multifunctional terms and developing the clinical development strategy in dermatological conditions. Prior to Cara,
Dr.&#160;Goncalves held various positions at Celgene Corporation, a pharmaceutical company, which was later acquired by Bristol-Myers&#160;Squibb
Company, from April&#160;2014 to October&#160;2018, where she most recently served as Vice President, Medical Affairs for Dermatology
and Neurology and was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA&#174;
for psoriasis. Prior to Celgene, Dr.&#160;Goncalves served as Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc.,
the U.S.&#160;subsidiary of LEO Pharma A/S, a global healthcare company specializing in dermatology and critical care, from February&#160;2012
to April&#160;2014. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic
areas from 2001 to 2012. Dr.&#160;Goncalves received her MBChB from the University of Cape Town, South Africa.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Paul
Quinlan. </i></b>Mr.&#160;Quinlan has served as General Counsel and Corporate Secretary of the Company since the Closing and of Pre-Merger
Oruka since April&#160;2024 through the Closing. Prior to joining Pre-Merger Oruka, Mr.&#160;Quinlan served as General Counsel, Chief
Compliance Officer and Corporate Secretary of CymaBay Therapeutics, Inc., a biopharmaceutical company, from October&#160;2020 to March&#160;2024,
where he was responsible for the general supervision of the company&#8217;s legal affairs. From December&#160;2017 to February&#160;2020,
he served as General Counsel and Corporate Secretary of CymaBay, where he was responsible for the general supervision of the company&#8217;s
legal affairs. Prior to CymaBay, Mr.&#160;Quinlan served as General Counsel and Secretary, from 2010 to January&#160;2018, and Chief
Legal Officer from 2016 to January&#160;2018, of TerraVia Holdings, Inc., a biotechnology company, where he was responsible for the general
supervision of the company&#8217;s legal affairs. Prior to joining TerraVia, Mr.&#160;Quinlan served as General Counsel of Metabolex,
Inc., a biopharmaceutical company, from 2005 to 2010. Prior to joining Metabolex, Mr.&#160;Quinlan held various positions at Maxygen,
Inc., a biopharmaceutical company, from 2000 to 2005. Prior to Maxygen, Mr.&#160;Quinlan practiced law at Cooley LLP and Cravath, Swaine,&#160;&amp;
Moore LLP.&#160;Mr.&#160;Quinlan received a law degree from Columbia Law School and an M.Sc. in Medical Biophysics from the University
of Toronto.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Non-Employee
Directors </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Kristine
Ball. </i></b>Ms. Ball has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka since
May&#160;2024 through the Closing. Ms.&#160;Ball has served as President and Chief Executive Officer of Antiva Biosciences, Inc., a private
biopharmaceutical company, since April&#160;2023. Prior to Antiva, Ms. Ball served as Chief Executive Officer of Soteria Biotherapeutics,
Inc., a private biotechnology company, from September&#160;2020 to August&#160;2022. Prior to joining Soteria, Ms. Ball served as Senior
Vice President, Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., a Nasdaq-listed&#160;biopharmaceutical company,
which later became VYNE Therapeutics Inc. (Nasdaq: VYNE), from September&#160;2017 to March&#160;2020, where she was responsible for
leading all non-R&amp;D functions, including strategic planning, corporate development, commercial, human resources, legal, finance and
information technology. Prior to joining Menlo, Ms. Ball served as Chief Financial Officer and Senior Vice President of Relypsa, Inc.,
a Nasdaq-listed&#160;pharmaceutical company, which was later acquired by Galenica Group, from November&#160;2012 to October&#160;2016.
Prior to Relypsa, Ms. Ball held various other finance roles in the life sciences industry, including Senior Vice President of Finance&#160;&amp;
Administration and Chief Financial Officer of KAI Pharmaceuticals, Inc., a biopharmaceutical company, and Vice President of Finance at
Exelixis, Inc. (Nasdaq: EXEL), a biotechnology company. Prior to that, Ms. Ball served as a senior manager in life sciences audit practice
of Ernst&#160;&amp; Young LLP. Ms.&#160;Ball has previously served on the boards of directors of Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical
company, from 2020 to 2024, Soteria from 2020 to 2022 and Forty Seven, Inc., a Nasdaq-listed&#160;biotechnology company, which was later
acquired by Gilead Sciences, Inc., from 2018 to 2020. Ms. Ball received a B.S. from Babson College.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Ms. Ball is qualified to serve as a member of the Board because of her experience as an executive officer and director of life
sciences companies and her background in finance, corporate development and strategic planning.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Carl
Dambkowski, M.D.</i></b> Dr.&#160;Dambkowski has served as a member of the board of directors of the Company since the Closing and of
Pre-Merger Oruka from February&#160;2024 through the Closing. Dr.&#160;Dambkowski has served as the Chief Medical Officer of Apogee Therapeutics,
Inc. (Nasdaq: APGE), a biotechnology company, since September&#160;2022. Prior to joining Apogee, Dr.&#160;Dambkowski served as a strategic
and clinical leader for a variety of companies, including as Chief Medical Officer of QED Therapeutics, Inc., a private biotechnology
company, from July&#160;2021 to September&#160;2022; Chief Strategy Officer and EVP of Operations of Origin Biosciences, Inc., a private
bioecology company, from March&#160;2018 to June&#160;2021; and Chief Medical Officer of Navire Pharma, Inc., a private biotechnology
company, from January&#160;2020 to September&#160;2022, where he served as the clinical lead starting prior to IND for BBP-398&#160;through
the out licensing of the compound to Bristol-Myers&#160;Squibb based on initial clinical data and for low-dose&#160;infigratinib in achondroplasia
through initial proof-of-concept&#160;data. He was part of the core team that brought TRUSELTIQ<sup>&#174;</sup>&#160;(infigratinib) and
NULIBRY<sup>&#174;</sup>&#160;(fosdenopterin) through regulatory review and FDA approval at QED Therapeutics and Origin Biosciences, respectively.
From July&#160;2016 to March&#160;2018, Dr.&#160;Dambkowski was an associate at McKinsey&#160;&amp; Company, a global management consulting
firm, where he advised biotech and pharmaceutical companies across the world on a range of research and development activities. Dr.&#160;Dambkowski
co-founded&#160;Novonate, Inc., a private medical device company focused on building life-saving&#160;devices for neonates, in January&#160;2015.
Dr.&#160;Dambkowski has coauthored numerous peer-reviewed&#160;publications and scientific abstracts and is a named inventor on multiple
published and granted patents. Dr.&#160;Dambkowski was trained as a physician at Stanford University, where he also received his M.D.
with a concentration in bioengineering. He also received a B.A. (with honors) from Stanford University and an M.A. from Columbia University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Dambkowski is qualified to serve as a member of the Board because of his significant experience and innovations in the biotechnology
industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Peter
Harwin.</i></b> Mr.&#160;Harwin has served as a member of the board of directors of the Company since the Closing and of Pre-Merger Oruka
from February&#160;2024 through the Closing. Mr.&#160;Harwin is a Managing Member at Fairmount Funds Management, a healthcare investment
firm he co-founded&#160;in April&#160;2016. Prior to Fairmount Funds Management, Mr.&#160;Harwin was a member of the investment team
at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Mr.&#160;Harwin also serves as chairman
of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics,
Inc. (Nasdaq: APGE), Viridian Therapeutics, Inc. (Nasdaq: VRDN) and Spyre Therapeutics, Inc. (Nasdaq: SYRE). Mr.&#160;Harwin received
a B.B.A. from Emory University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Mr. Harwin is qualified to serve as a member of the Board because his experience serving as a director of biotechnology companies
and as a manager of funds specializing in the area of life sciences.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Samarth
Kulkarni, Ph.D. </i></b>Dr.&#160;Kulkarni has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February&#160;2024 through the Closing. Dr.&#160;Kulkarni has served as the Chief Executive Officer of CRISPR Therapeutics
AG (Nasdaq: CRSP), a biopharmaceutical company, since December&#160;2017, where he has also served as a member and chair of the board
of directors since June&#160;2018 and September&#160;2023, respectively. Previously, Dr.&#160;Kulkarni served as CRISPR&#8217;s President
and Chief Business Officer from May&#160;2017 to November&#160;2017 and as Chief Business Officer from August&#160;2015. Prior to joining
CRISPR, Dr.&#160;Kulkarni was at McKinsey&#160;&amp; Company, a global management consulting firm, from 2006 to 2015, with various titles,
his most recent being Partner within the Pharmaceuticals and Biotechnology practice. Dr.&#160;Kulkarni has also served as a member of
the boards of directors of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology company, since 2019, including as lead
independent director since September&#160;2023, Repare Therapeutics Inc. (Nasdaq: RPTX), a precision oncology company, since November&#160;2019
and Centessa Pharmaceuticals plc (Nasdaq: CNTA), a biotechnology company, since February&#160;2021. Dr.&#160;Kulkarni received a Ph.D.
in Bioengineering and Nanotechnology from the University of Washington and a B.&#160;Tech. from the Indian Institute of Technology. Dr.&#160;Kulkarni
has authored several publications in leading scientific and business journals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe that Dr. Kulkarni is qualified to serve as a member of the Board because of his experience as a consultant and an executive in
the biopharmaceutical industry and his academic expertise and accomplishments.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cameron
Turtle, D.Phil.</i></b> Dr.&#160;Turtle has served as a member of the board of directors of the Company since the Closing and of Pre-Merger
Oruka from February&#160;2024 through the Closing. Dr.&#160;Turtle has served as Chief Executive Officer and a member of the board of
directors of Spyre Therapeutics, Inc. (formerly Aeglea BioTherapeutics, Inc.) (Nasdaq: SYRE), a biotechnology company, since November&#160;2023
and, before that, as Chief Operating Officer from June&#160;2023 to November&#160;2023. Prior to joining Spyre, Dr.&#160;Turtle was an
advisor to Spyre Therapeutics, Inc., a private biotechnology company, from May&#160;2023 to June&#160;2023. Previously, he served as
Venture Partner at Foresite Labs, a life sciences investment firm, from July&#160;2022 to May&#160;2023; Chief Strategy Officer of BridgeBio
Pharma (Nasdaq: BBIO), a biotechnology company, from January&#160;2021 to April&#160;2022; and Chief Business Officer of Eidos Therapeutics
(Nasdaq: EIDX), a biopharmaceutical company, from November&#160;2018 to January&#160;2021, where he led business development, investor
relations, and multiple operational functions as the company advanced an investigational medicine for a form of heart failure. Prior
to joining BridgeBio and Eidos, he was a consultant at McKinsey&#160;&amp; Company, a global management consulting firm, where he worked
with pharmaceutical and medical device companies on topics including M&amp;A, growth strategy, clinical trial strategy, and sales force
optimization. Dr.&#160;Turtle received his B.S. with honors in Bioengineering from the University of Washington and his D.Phil. in Cardiovascular
Medicine from the University of Oxford, St. John&#8217;s College. He is the recipient of several awards, including a Rhodes Scholarship,
Goldwater Scholarship, Forbes 30 Under&#160;30, San Francisco Business Times 40 Under&#160;40, and the Biocom Life Sciences Catalyst
Award.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
believe Dr. Turtle is qualified to serve as a member of the Board because of his experience as a leader in building, financing, and shaping
biopharmaceutical organizations from preclinical development to late-stage clinical trials and commercialization.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Family
Relationships </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There
are no family relationships among any of our directors or executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Structure and Related Matters</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Structure</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
business and affairs are managed under the direction of our Board. Our Board currently consists of six members. Each of our current directors
will continue to serve until the election and qualification of their successor, or their earlier death, resignation or removal.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
authorized number of directors is determined from time to time solely by resolution of the Board. Our certificate of incorporation and
bylaws provide that our directors may be removed only for cause by the affirmative vote of at least 66 2/3% of the voting power of the
common stock outstanding and entitled to vote thereon. In addition, only our Board is authorized to fill vacancies and any additional
directorships resulting from an increase in the authorized number of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation establishes a classified Board consisting of three classes of directors with staggered three-year terms.
Only one class of directors is elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms
are then expiring, with the other classes continuing for the remainder of their respective three-year terms. The terms of the directors
will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years
2025 for Class I directors, 2026 for Class II directors, and 2027 for Class III directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class I directors are Dr. Dambkowski and Mr. Harwin.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class II directors are Dr. Klein and Dr. Turtle.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Our
                                            Class III directors are Ms. Ball and Dr. Kulkarni.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Director
Independence </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has reviewed the independence of all directors in light of each director&#8217;s (or any family member&#8217;s, if applicable)
affiliations with the Company and members of management, as well as significant holdings of our securities and all other facts and circumstances
that the Board has deemed relevant in determining the independence of each director. The Board has determined that each of the directors
other than Lawrence Klein, our current President and Chief Executive Officer, including Kristine Ball, Carl Dambkowski, Peter Harwin,
Samarth Kulkarni and Cameron Turtle, qualify as &#8220;independent directors&#8221; as defined by the Nasdaq listing rules.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Nasdaq
listing rules have objective tests and a subjective test for determining who is an &#8220;independent director.&#8221; The subjective
test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director. The Board has not established categorical
standards or guidelines to make these subjective determinations but considers all relevant facts and circumstances.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
Leadership Structure</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board has designated Dr. Kulkarni to serve as Chair of the Board. Although our bylaws do not require that we separate the Chief Executive
Officer and Chair positions, our Board believes that having the positions be separate is the appropriate leadership structure for us
at this time, as it helps facilitate independent Board oversight of management and allows the Chief Executive Officer to focus on strategy
execution and managing the business while the Chair focuses on corporate governance and managing the Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our
Board recognizes that, depending on future circumstances, other leadership models, such as combining the roles of Chief Executive Officer
and Chair, might be appropriate. Accordingly, our Board may periodically review its leadership structure. At any time when a non-independent
director is serving as Chair, the independent directors will designate a lead independent director to preside at all meetings of the
Board at which the Chair is not present, preside over executive sessions of the independent directors (which occur regularly throughout
each year), serve as a liaison between the Chair and independent directors, and perform such additional duties as our Board may otherwise
determine and delegate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>Role
of Our Board in Risk Oversight </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
face a number of risks, including those described under the section titled &#8220;Risk Factors&#8221;. Our Board believes that risk management
is an important part of establishing, updating and executing on our business strategy. Our Board, both as a whole and at the committee
level, has oversight responsibility relating to risks that could affect the strategy, business objectives, compliance, operations and
the financial condition and performance of the Company. Our Board focuses its oversight on the most significant risks facing the Company
and on its processes to identify, prioritize, assess, manage and mitigate those risks. Our Board and its committees receive regular reports
from members of our senior management on material risks to the Company, including strategic, operational, financial, legal and regulatory
risks. While our Board has an oversight role, management is principally tasked with direct responsibility for managing and assessing
risks and the implementation of processes and controls to mitigate their effects on the Company. Our Board believes its administration
of its risk oversight function has not significantly impacted its selection of the current leadership structure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Board
Committees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We
currently have an Audit Committee, a Compensation Committee, and a Governance Committee. We believe that the functioning and composition
of these committees complies with the requirements of Nasdaq listing rules and SEC rules and regulations. Each committee has the responsibilities
described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Audit
Committee </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Audit Committee currently comprises Ms. Ball, Dr. Dambkowski, and Dr. Turtle, each of whom qualifies as an independent director for Audit
Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial
and auditing matters to serve the Audit Committee. Ms. Ball chairs the Audit Committee and is an &#8220;audit committee financial expert&#8221;
as defined in Item 407(d)(5)(ii) of Regulation S-K promulgated under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
primary responsibilities of the Audit Committee are to oversee our accounting and financial reporting processes, including the audits
of the financial statements, and the internal and external audit processes. The Audit Committee also oversees the system of internal
controls established by management and our compliance with legal and regulatory requirements. The Audit Committee is also responsible
for the review, consideration and approval or ratification of related party transactions. The Audit Committee further oversees the independent
auditors, including their independence and objectivity. The Audit Committee is empowered to retain outside legal counsel and other advisors
as it deems necessary or appropriate to assist it in fulfilling its responsibilities and to approve the fees and other retention terms
of the advisors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Compensation
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Compensation Committee currently comprises Mr. Harwin, Dr. Kulkarni and Dr. Turtle, each of whom qualifies as an independent director
for Compensation Committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules. Dr. Turtle chairs
the Compensation Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
primary responsibility of the Compensation Committee is to periodically review and approve the compensation and other benefits of our
senior officers and directors. This includes reviewing and approving corporate goals and objectives relevant to the compensation of our
Chief Executive Officer and other executive officers, evaluating the performance of these officers in light of the goals and objectives
and setting or recommending to the Board the officers&#8217; compensation. The Compensation Committee also administers and makes recommendations
to the Board regarding equity incentive plans that are subject to the Board&#8217;s approval, in addition to approving the grant of equity
awards under those plans.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Governance
Committee</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Governance Committee currently comprises Ms. Ball, Dr. Kulkarni and Mr. Harwin, each of whom qualifies as an independent director, as
defined under applicable Nasdaq listing rules. Mr. Harwin chairs the Governance Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Governance Committee is responsible for engaging in succession planning for our Board, developing and recommending to the Board criteria
for identifying and evaluating qualified director candidates and making recommendations to the Board regarding candidates for election
or reelection to the Board at each annual stockholders&#8217; meeting. In addition, the Governance Committee is responsible for overseeing
corporate governance matters. The Governance Committee is also responsible for overseeing the structure, composition and functioning
of the Board and its committees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Compensation
Committee Interlocks and Insider Participation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">None
of the members of our Compensation Committee has at any time been an officer or employee of the Company. None of our executive officers
currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity
that has one or more executive officers serving on our Board or Compensation Committee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>Code
of Conduct and Ethics </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.7pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
Board has adopted a Code of Conduct and Ethics that establishes the standards of ethical conduct applicable to all our directors, officers
and employees. The full text of our Code of Conduct and Ethics is posted on our website at https://ir.orukatx.com/corporate-governance.
It addresses, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting,
external communications, confidentiality requirements, insider trading, proper use of assets and how to report compliance concerns. Any
amendments to the Code of Conduct and Ethics, or any waivers of its requirements, will be posted on our website to the extent required
by applicable rules. The Audit Committee is responsible for applying and interpreting our Code of Conduct and Ethics in situations where
questions are presented to it. Information contained on, or that can be accessed through, our website is not incorporated by reference
into this prospectus, and you should not consider information on our website to be part of this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXECUTIVE
COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of the information contained in the sections below generally relates to ARCA compensation for fiscal years 2023 and 2022 and was included
in the definitive proxy statement/prospectus filed on Form S-4 with the SEC and declared effective on July 24, 2024 (the &#8220;Proxy
Statement/Prospectus&#8221;). Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to our senior management, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
                                            A. Keuer&#8217;s resignation as our President and Chief Operating Officer, effective as of
                                            August 29, 2024, and termination of employment, effective as of September 1, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
                                            Jeffrey Dekker&#8217;s resignation as our Chief Financial Officer, effective as of August
                                            29, 2024, and termination of employment, effective as of September 1, 2024. Mr. Dekker has
                                            entered into a consulting agreement with us, effective as of August 30, 2024, to provide
                                            transition services through August 30, 2025, unless terminated earlier in accordance with
                                            the agreement.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
                                            Klein&#8217;s appointment as our President and Chief Executive Officer, effective as of August
                                            29, 2024. </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
                                            Agarwal&#8217;s appointment as our Senior Vice President, Finance and Treasurer, effective
                                            as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joana
                                            Goncalves&#8217;s appointment as our Chief Medical Officer, effective as of August 29, 2024.
                                            </span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
                                            Quinlan&#8217;s appointment as our General Counsel and Corporate Secretary, effective as
                                            of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>ARCA Executive
Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal&#160;years ended December&#160;31, 2023 and December&#160;31, 2022, compensation awarded to, paid
to, or earned by ARCA&#8217;s principal executive officer and its two most highly compensated executive officers as of December&#160;31,
2023, collectively, the ARCA named executive officers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Summary
Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary
    <br/> ($)<sup>(1)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus
    <br/> ($)<sup>(2)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Stock
    <br/> Awards <br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All&#160;Other
    <br/> Compensation <br/> ($)<sup>(3)</sup></b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 28%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Michael
    R.&#160;Bristow</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">345,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,800</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,800</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former
    President and<br/>
 Chief Executive Officer<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">345,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="vertical-align: top; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Thomas
    A.&#160;Keuer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,802</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,802</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">President
    and Chief Operating Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">88,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,593</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">448,993</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">C.&#160;Jeffrey
    Dekker</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">270,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,072</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">323,072</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Chief
    Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts
                                            paid during the calendar year. Because ARCA&#8217;s actual pay dates do not always coincide
                                            with the first and last&#160;days of the year, these amounts may differ from the base salary
                                            amounts authorized by ARCA&#8217;s board of directors.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Bonus&#8221; in the above table represent retention bonuses
                                            paid to each of Thomas A.&#160;Keuer and C.&#160;Jeffrey Dekker in December&#160;2023. These
                                            amounts were previously reported as &#8220;All Other Compensation&#8221; in ARCA&#8217;s
                                            Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2023.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Represents
                                            401(k)&#160;Company match in the amount of $13,800 for Michael R.&#160;Bristow in each of
                                            2023 and 2022, $15,000 and $13,600 for Thomas A.&#160;Keuer in 2023 and 2022, and $11,579
                                            for C.&#160;Jeffrey Dekker in 2023, Health Savings Account contributions by ARCA in the amount
                                            of $850 for Thomas A.&#160;Keuer in 2022, and $3,960 for C.&#160;Jeffrey Dekker in 2023,
                                            group term life premiums in the amount of $9,602 and $4,989 for Thomas A.&#160;Keuer in 2023
                                            and 2022, and $2,533 for C.&#160;Jeffrey Dekker in 2023, and cell phone reimbursements in
                                            the amount of $1,200 and $1,154 for Thomas A.&#160;Keuer in 2023 and 2022.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Dr.&#160;Bristow
                                            and ARCA mutually agreed to conclude Dr.&#160;Bristow&#8217;s employment effective April&#160;3,
                                            2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Narrative
Disclosure to Summary Compensation Table</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Employment
Agreements or Arrangements</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Michael
R.&#160;Bristow, M.D., Ph.D.</i>&#160;&#160;&#160;&#160;Dr.&#160;Bristow served as ARCA&#8217;s President and Chief Executive Officer
under an Employment and Retention Agreement dated as of June&#160;4, 2008, as amended. Pursuant to such employment agreement, Dr.&#160;Bristow
was permitted to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute,
so long as it did not interfere with his duties as President and Chief Executive Officer of ARCA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Dr.&#160;Bristow&#8217;s separation on April&#160;3, 2024, ARCA and Dr.&#160;Bristow entered into a separation agreement
(the &#8220;Separation Agreement&#8221;) pursuant to which ARCA paid Dr.&#160;Bristow a lump sum amount equal to $370,000, less applicable
tax withholding, which consisted of (i)&#160;12&#160;months of Dr.&#160;Bristow&#8217;s base salary as of the last date of his employment
and (ii)&#160;a $25,000 cash payment. The separation payments were conditioned on Dr.&#160;Bristow not revoking the Separation Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
and Dr.&#160;Bristow also entered into a consulting agreement, effective April&#160;3, 2024 (the &#8220;Consulting Agreement&#8221;),
pursuant to which Dr.&#160;Bristow provided certain consulting services to ARCA through the earlier of (i)&#160;the completion of services
under the Consulting Agreement, (ii)&#160;a termination in accordance with the terms of the Consulting Agreement, and (iii)&#160;a change
of control of ARCA (as defined in ARCA&#8217;s 2020 Equity Incentive Plan (the &#8220;2020 Plan&#8221;)). During the consulting term,
Dr.&#160;Bristow continued to vest in his outstanding equity awards.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>Thomas
A.&#160;Keuer.</i>&#160;&#160;&#160;&#160;Mr.&#160;Keuer served as ARCA&#8217;s President and Chief Operating Officer until August 29,
2024 under an Amended and Restated Employment Agreement that was effective as of January&#160;1, 2015. The potential severance payments
and benefits available under Mr. Keuer&#8217;s employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA&#8217;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Keuer, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Keuer to (i)&#160;increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Keuer&#8217;s retention bonus was paid on
December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus letter
between ARCA and Mr.&#160;Keuer to increase the aggregate amount of the retention bonus by 33.33% to $200,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Mr. Keuer&#8217;s termination of employment, which was considered to be without &#8220;cause&#8221; related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr.&#160;Keuer, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i)&#160;12&#160;months of his base salary, (ii)&#160;the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii)&#160;reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12&#160;months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><i>C.&#160;Jeffrey
Dekker.</i>&#160;&#160;&#160;&#160;Mr.&#160;Dekker served as ARCA&#8217;s Chief Financial Officer until August 29, 2024 under an Employment
Agreement that was effective as of May&#160;10, 2021. Mr.&#160;Dekker served as ARCA&#8217;s Secretary since April&#160;2023 until August
29, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
his employment agreement, Mr.&#160;Dekker was entitled to receive an annual base salary of $270,000, subject to annual increases if approved
by ARCA&#8217;s board of directors or Compensation Committee and was eligible to receive an annual target bonus of 35% of his base salary
as determined by ARCA&#8217;s board of directors or Compensation Committee in its sole discretion. The potential severance payments and
benefits available under Mr. Dekker&#8217;s employment agreement as in effect on December 31, 2023 are set forth in Item 11 of ARCA&#8217;s
Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;8, 2022, the Compensation Committee approved a retention bonus of $100,000 for Mr.&#160;Dekker, subject to continued employment
with ARCA through the earlier of a change in control of ARCA or certain clinical development decisions. On November&#160;29, 2023, the
Compensation Committee approved the amendment of the retention bonus letter between ARCA and Mr.&#160;Dekker to (i)&#160;increase the
aggregate amount of the retention bonus by 50%, to $150,000, and (ii)&#160;in order to assist with tax obligations associated with the
vesting of certain ARCA restricted stock unit awards, provided that $35,000 of&#160;Mr.&#160;Dekker&#8217;s retention bonus was paid
on December&#160;8, 2023. On April&#160;20, 2024, the board of directors of ARCA approved the second amendment of the retention bonus
letter between ARCA and Mr.&#160;Dekker to increase the aggregate amount of the retention bonus by 33.33% to $200,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with Mr. Dekker&#8217;s termination of employment, which was considered to be without &#8220;cause&#8221; related to a change
in control for purposes of his employment agreement, ARCA agreed to pay Mr.&#160;Dekker, in exchange for his execution of a legal release
of claims, a severance payment equivalent to (i)&#160;12&#160;months of his base salary, (ii)&#160;the unpaid portion of his retention
bonus noted above equal to $165,000, and (iii)&#160;reimbursement to cover out-of-pocket costs to continue group health insurance benefits
under COBRA for 12&#160;months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;<span style="font-variant: small-caps"><b>&#160;</b></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Outstanding
Equity Awards at Fiscal Year End</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal year ended December&#160;31, 2023, certain information regarding outstanding equity awards at fiscal
year-end for ARCA named executive officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="10" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    Awards</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> Underlying <br/> Unexercised<br/> Options<br/> (#) <br/> Exercisable</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> Underlying <br/> Unexercised<br/> Options<br/> (#) <br/> Unexercisable</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Option
    <br/> Exercise<br/> Price<br/> ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Option<br/>
    Expiration<br/> Date</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Michael
    R.&#160;Bristow, Former President and Chief Executive Officer</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">408</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245.70</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/26/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">205</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84.42</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/11/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,511</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59.40</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/8/2026</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/15/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">142,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47,500</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/21/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63,334</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,666</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Thomas
    A.&#160;Keuer, President and Chief Operating Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">83</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">245.70</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/26/2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">108</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">84.42</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/11/2025</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">866</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">59.40</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">6/8/2026</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,400</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>&#160;</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45.00</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2/15/2027</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,500</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.27</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/21/2030</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">23,334</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,666</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">C.&#160;Jeffrey
    Dekker, Secretary, Chief Financial Officer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">35,521</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,479</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(3)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.06</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">5/10/2031</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,800</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,900</span></td><td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(2)(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.29</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif">12/14/2031</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vest in 48 monthly installments measured from December&#160;21, 2020.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vest in 36 monthly installments measured from December&#160;14, 2021.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Options
                                            vested 25% after one year, then in 36 monthly installments measured from May&#160;10, 2021.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">In
                                            the event of a change in control of ARCA, 50% of the unvested shares subject to this award
                                            shall become fully and immediately vested upon the closing date of such change in control,
                                            provided, however, that on the earlier of (i)&#160;the one-year anniversary of the closing
                                            date or (ii)&#160;involuntary termination, any options that remain unvested on such earlier
                                            date shall become fully and immediately vested.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>ARCA
Director Compensation</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
of the information contained in the sections below generally relates to compensation for our fiscal year 2023 and was included in the
Proxy Statement/Prospectus. Such information has not been adjusted to reflect the effects of the Reverse Stock Split. Since the date
of the Proxy Statement/Prospectus, there have been several changes to the composition of our Board, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda
                                            Grais, Anders Hove, Robert Conway, James Flynn and Jacob Ma-Weaver resigned from our Board,
                                            effective as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
                                            Klein, Kristine Ball, Carl Dambkowski, Peter Harwin, Samarth Kulkarni and Cameron Turtle
                                            were appointed to our Board, effective as of August 29, 2024.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table shows for the fiscal year ended December&#160;31, 2023, certain information with respect to the compensation of all non-employee
directors of ARCA:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><b>Director
Compensation</b></span><b><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Name</b></span></p></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Fees&#160;Earned
    <br/> or&#160;Paid&#160;in <br/> Cash&#160;<br/> ($)</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option
    <br/> Awards <br/> ($)<sup>(2)</sup></b></span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-top: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total&#160;<br/>
    ($)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linda
    Grais<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">162,500</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raymond
    L.&#160;Woosley<sup>(4)(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">55,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    E.&#160;Conway<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">195,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    J.&#160;Mitchell<sup>(6)(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">52,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anders
    Hove<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jacob
    Ma-Weaver<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">James
    Flynn<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dr.&#160;Bristow,
                                            ARCA&#8217;s former President and Chief Executive Officer, was also a director during the
                                            year ended December&#160;31, 2023, but did not receive any additional compensation for his
                                            service as a director. Dr.&#160;Bristow&#8217;s compensation as an executive officer is set
                                            forth above under &#8220;Executive Compensation&#160;&#8212;&#160;Summary Compensation Table.&#8221;</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            amounts reported under &#8220;Option Awards&#8221; in the above table reflect the grant date
                                            fair value of these awards as determined in accordance with Financial Accounting Standards
                                            Board Accounting Standards Codification Topic&#160;718, Compensation&#160;&#8212;&#160;Stock
                                            Compensation, excluding the effects of estimated forfeitures. The value of stock option awards
                                            was estimated using the Black-Scholes option-pricing model. The valuation assumptions used
                                            in the valuation of option grants may be found in Note&#160;8 to ARCA&#8217;s financial statements
                                            included in this annual report on Form&#160;10-K for the year ended December&#160;31, 2023.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Grais was 19,458, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Woosley was 19,458, all of which were fully vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Conway, Chairman of ARCA&#8217;s board of directors, was 19,458, all of
                                            which were fully vested. Includes $52,500 for Special Committee compensation for 2022 approved
                                            and paid in 2023, as discussed below and $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(6)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Mitchell was 19,577, all of which were fully vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(7)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Dr.&#160;Hove was 18,999, all of which were fully vested. Includes $52,500 for
                                            Special Committee compensation for 2022 approved and paid in 2023, as discussed below and
                                            $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(8)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Ma-Weaver was 18,000, of which 12,000 shares were fully vested. Includes
                                            $37,500 for Special Committee compensation for 2022 approved and paid in 2023, as discussed
                                            below and $52,500 for 2023 approved and paid in 2024.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            aggregate number of shares issuable upon exercise of option awards outstanding at December&#160;31,
                                            2023, for Mr.&#160;Flynn was 12,000, of which 4,000 shares were vested.</span></td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">These
                                            directors resigned from ARCA&#8217;s board of directors effective February&#160;2, 2024.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2021, ARCA revised its compensation plan for non-employee directors to provide that non-employee directors will be compensated for their
service on ARCA&#8217;s board of directors, as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-employee director will receive an annual retainer fee of $40,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">As
                                            additional compensation for their services, each non-employee director will receive (i),
                                            upon joining ARCA&#8217;s board of directors, an initial option grant to purchase 12,000
                                            shares of ARCA&#8217;s Common Stock under the 2020 Plan, (ii), in 2021 the members of the
                                            board of directors received a one-time retention option grant to purchase 12,000 shares of
                                            ARCA&#8217;s Common Stock under the 2020 Plan, and (iii), on an annual basis as of the date
                                            of ARCA&#8217;s annual stockholder meeting, an annual option grant to purchase 6,000 shares
                                            of ARCA&#8217;s Common Stock under the 2020 Plan; provided that such non-employee director
                                            has served on ARCA&#8217;s board of directors for at least six&#160;months prior to the date
                                            of grant (unless such six-month period is modified by recommendation of the Nominating and
                                            Corporate Governance Committee and approved by the Compensation Committee);</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            Chairman of ARCA&#8217;s board of directors will receive an additional annual retainer fee
                                            of $30,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">ARCA&#8217;s
                                            Audit Committee chair will receive an additional annual retainer fee of $15,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
                                            chairs of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance Committee
                                            will each receive an additional annual retainer fee of $10,000;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-chair member of ARCA&#8217;s Audit Committee will receive an additional annual retainer
                                            fee of $7,500; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; text-align: left; width: 0.5in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Each
                                            non-chair member of ARCA&#8217;s Compensation Committee and Nominating and Corporate Governance
                                            Committees will receive an additional annual retainer fee of $5,000.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
January&#160;30, 2024, ARCA approved paying compensation to its existing non-employee directors, pursuant to ARCA&#8217;s Director Compensation
Policy, by granting to Dr.&#160;Linda Grais, Dr.&#160;Anders Hove, Mr.&#160;Robert Conway, Mr.&#160;Daniel Mitchell, Dr.&#160;Raymond
Woosley, Mr.&#160;James Flynn and Mr.&#160;Jacob Ma-Weaver options to purchase 6,000 shares of common stock at an exercise price of $1.64
per share, the closing price of ARCA&#8217;s common stock on January&#160;30, 2024. The options are subject to the terms and conditions
of the 2020 Plan and ARCA&#8217;s standard forms of Stock Option Agreement and Option Grant Notice for the 2020 Plan. The options vest
in 12 equal monthly installments beginning on January&#160;30, 2024, assuming Dr.&#160;Grais&#8217;, Dr.&#160;Hove&#8217;s, Mr.&#160;Conway&#8217;s,
Mr.&#160;Mitchell&#8217;s, Dr.&#160;Woosley&#8217;s, Mr.&#160;Flynn&#8217;s and Mr.&#160;Ma-Weaver&#8217;s continued service on the Board
for such periods.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
2022, ARCA&#8217;s board of directors established a Special Committee to evaluate strategic options for maximizing stockholder value.
The Special Committee includes ARCA board Chairman Robert E.&#160;Conway (chair), and board members Linda Grais, M.D., Anders Hove, M.D.
and Jacob Ma-Weaver. In December&#160;2023, based on the recommendation of the Nominating and Corporate Governance Committee, the board
determined that each member of the Special Committee will be paid $7,500 per month for each month of substantive service on the Special
Committee. In December&#160;2023, payments for 2022 service were made to the members of the Special Committee of $52,500 to each of Robert
E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and $37,500 to Jacob Ma-Weaver (joined the Committee in June&#160;2022). Payments
for 2023 service were paid in 2024 to the members of the Special Committee consisting of $52,500 to each of Robert E.&#160;Conway, Linda
Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver. Payments for 2024 service through April&#160;2024 were paid in 2024 to the members
of the Special Committee consisting of $30,000 to each of Robert E.&#160;Conway, Linda Grais, M.D., Anders Hove, M.D. and Jacob Ma-Weaver.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Director Compensation Program</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September 17, 2024, our Board approved an updated director compensation program for non-employee members of our Board that provides for
the following annual cash retainers:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual
    Cash Retainer</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">40,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Annual
    Board Chair Retainer</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">30,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Audit
    Committee Retainers:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">15,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,500</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation
    Committee Retainers:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Nominating
    and Corporate Governance Committee Retainers</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Chair</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 16.5pt"><span style="font-family: Times New Roman, Times, Serif">Non-Chair
    Member</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In
connection with the Company&#8217;s annual meeting of stockholders, each member of the Board will receive an annual grant of stock options
to purchase 17,500 shares of common stock, which will vest in equal monthly installments over 12 months so long as such director joined
the Board prior to January 1 of the year in which such annual meeting occurs. In addition, in connection with a non-employee director&#8217;s
initial appointment to the Board, they will receive an initial grant of stock options to purchase 35,000 shares of common stock, which
will vest in equal monthly installments over 36 months.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">All
members of the Board are also reimbursed for reasonable and documented out-of-pocket travel and lodging expenses incurred in connection
with attending meetings and activities of the Board and its committees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><b>ARCA
EQUITY COMPENSATION PLAN INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth information as of December&#160;31, 2023, for all of ARCA&#8217;s equity compensation plans and has not been
adjusted to reflect the effects of the Reverse Stock Split:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Plan
    Category</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Securities <br/> to&#160;be&#160;Issued&#160;Upon <br/> Exercise&#160;of <br/> Outstanding <br/> Options&#160;or&#160;Upon <br/>
    Vesting&#160;of <br/> Restricted&#160;Stock <br/> Units<br/> (a)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Weighted
    <br/> Average <br/> Exercise <br/> Price&#160;of <br/> Outstanding <br/> Options<br/> ($)<br/> (b)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of<br/>

    Securities <br/> Remaining <br/> Available&#160;for <br/> Future&#160;Issuance <br/> Under&#160;Equity <br/> Compensation <br/>
    Plans&#160;(Excluding <br/> Securities <br/> Reflected&#160;in<br/> Column(a)) <br/> (c)</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans approved by security holders</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">616,707</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.76</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,718</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Equity
    compensation plans not approved by security holders</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">616,707</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.76</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">459,718</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
December&#160;10, 2020, ARCA stockholders approved the 2020 Plan at ARCA&#8217;s 2020 annual meeting of stockholders. The 2020 Plan is
the successor to the Amended and Restated ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;). A description
of the 2020 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in the Proxy Statement/Prospectus. The 2020
Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan; therefore, all
values in the above table relate solely to the outstanding options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
September&#160;17, 2013, ARCA stockholders approved the 2013 Plan at ARCA&#8217;s 2013 annual meeting of stockholders. On June&#160;9,
2016, ARCA stockholders approved an amendment to the 2013 Plan (as amended, the &#8220;Amended 2013 Plan&#8221;). A description of the
2013 Plan and the Amended 2013 Plan is set forth in Note&#160;8 to ARCA&#8217;s financial statements included in the Proxy Statement/Prospectus.
The Amended 2013 Plan only has options outstanding as of December&#160;31, 2023; no warrants or rights are outstanding under this plan;
therefore, all values in the above table relate solely to the outstanding options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Compensation
Risks</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance
results assist in mitigating excessive risk-taking that could harm the value or reward poor judgment by its executives. ARCA believes
several features of its programs reflect sound risk management practices. ARCA believes it has allocated compensation among base salary
and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting
of equity awards properly accounts for the time horizon of risk. Furthermore, ARCA&#8217;s Compensation Committee assesses and monitors
whether any of ARCA&#8217;s compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis.</span></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND<br/>
 RELATED STOCKHOLDER MATTERS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership
of our Common Stock as of November 1, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
person or group of affiliated persons, who is known by us to be the beneficial owner of more than 5% of Common Stock;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our directors;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
of our named executive officers; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
of our current directors and executive officers as a group.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The column
entitled &#8220;Percentage of Shares Outstanding Beneficially Owned&#8221; is based on a total of 34,998,550 shares of our Common Stock
outstanding as of November 1, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Beneficial
ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect
to the Common Stock. Shares of Common Stock subject to options that are currently exercisable or exercisable within 60 days of the date
of this table are considered outstanding and beneficially owned by the person holding the options for the purpose of calculating the
percentage ownership of that person but not for the purpose of calculating the percentage ownership of any other person. Due to the conversion
limitations on the Series A Preferred Stock, shares of underlying common stock have been excluded from beneficial ownership set forth
below. Except as otherwise noted, the persons and entities in this table have sole voting and investing power with respect to all of
the shares of Common Stock beneficially owned by them, subject to community property laws, where applicable. Except as otherwise indicated
in the table below, addresses of named beneficial owners are in care of Oruka Therapeutics, Inc., 855 Oak Grove Ave., Suite 100, Menlo
Park, CA 94025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Number&#160;of
    <br/> Shares <br/> Beneficially <br/> Owned</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Percentage
    <br/> of&#160;Shares <br/> Outstanding <br/> Beneficially <br/> Owned</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with Fairmount Funds Management LLC<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FMR
    LLC<sup>(2)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,682,300</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">13.38</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with Venrock Healthcare Capital Partners<sup>(3)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,541,941</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.99</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
    affiliated with RTW Investments, LP<sup>(4)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,963,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.61</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Named
    Executive Officers and Directors:</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein<sup>(5)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">852,338</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.44</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Arjun
    Agarwal</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Joana
    Goncalves</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paul
    Quinlan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    R. Bristow<sup>(6)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">399</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    A. Keuer<sup>(7)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,394&#8194;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.
    Jeffrey Dekker<sup>(8)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,333</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle<sup>(9)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,233&#8194;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Samarth
    Kulkarni</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin<sup>(1)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">19.99</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Carl
    Dambkowski</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Kristine
    Ball</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    executive officers and directors as a group (9&#160;persons)<sup>(10)</sup></span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,879,261</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">22.67</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
                                            of (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;)
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days&#8217; notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount
                                            GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.</span></p></td></tr>
</table><div>
</div><p style="margin: 0; font-family: Times New Roman, Times, Serif"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of the shares listed in the table above are owned by funds or accounts managed by direct or indirect subsidiaries of FMR LLC, all
    of which shares are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates,
    and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson
    family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of
    FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
    into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority
    vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217;
    voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group
    with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the exercise of pre-funded warrants held
    by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;), (ii) 668,656 shares of common stock and 95,284 shares of
    common stock issuable upon the exercise of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;),
    and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the exercise of pre-funded warrants held by
    VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;). Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable
    upon the exercise of the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000, 39,000 and 4,000
    shares of common stock issuable upon the conversion of Series A Preferred Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively.
    The pre-funded warrants and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
    restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion of the warrants or Series A Preferred
    Stock that would result in Venrock Healthcare Capital Partners and its affiliates owning, after exercise, a number of shares of common
    stock in excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;) is the sole general partner
    of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG, LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG.
    As voting members of VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any securities beneficially
    owned by VHCPM3 and VHCPM EG. The principal business address of each of these persons and entities is 7 Bryant Park, 23rd Floor,
    New York, NY 10018.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 1,963,147 shares of common stock held in the aggregate by RTW Master Fund, Ltd. (&#8220;RTW Master Fund&#8221;), RTW Innovation
    Master Fund, Ltd. (&#8220;RTW Innovation Master Fund&#8221;), and RTW Biotech Opportunities Operating Ltd. (&#8220;RTW Biotech&#8221;
    and together with RTW Master Fund and RTW Innovation Fund, the &#8220;RTW Funds&#8221;). Excludes 95,000 shares of common stock issuable
    upon the conversion of Series A Preferred Stock held in the aggregate by the RTW Funds. The Series A Preferred Stock is subject to
    a beneficial ownership limitation of 9.99%, which such limitations restrict the RTW Funds and its affiliates from exercising that
    portion of the Series A Preferred Stock that would result in the RTW Funds and its affiliates owning, after exercise, a number of
    shares of common stock in excess of the applicable ownership limitation. RTW Investments, LP (&#8220;RTW&#8221;), in its capacity
    as the investment manager of the RTW Funds, has the power to vote and the power to direct the disposition of the shares held by the
    RTW Funds. Accordingly, RTW may be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing Partner
    of RTW, has the power to direct the vote and disposition of the securities held by RTW. Dr. Wong disclaims beneficial ownership of
    the shares held by the RTW Funds, except to the extent of his pecuniary interest therein. The principal business address of RTW Investments,
    LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong and each of the RTW Funds is c/o RTW Investments,
    LP, 40 10th Avenue, Floor 7, New York, NY 10014.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    852,338 shares of restricted voting common stock.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    (i) 92 shares owned by Investocor Trust, of which Dr. Bristow is the sole trustee and (ii) 117 shares owned by NFS as Custodian for
    Michael Bristow&#8217;s IRA. Dr. Bristow and ARCA mutually agreed to conclude Dr. Bristow&#8217;s employment effective April 3, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Keuer resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Dekker resigned as named executive officer at the Closing and his last day of employment was September 1, 2024, which termination
    was considered to be without &#8220;cause&#8221; related to a change in control for purposes of his employment agreement with ARCA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/>
    <td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            85,233 shares of restricted voting common stock held by the Turtle Family Trust, for which
                                            Mr. Turtle serves as Trustee.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
                                            notes (1), (5) and (9) above.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As discussed
in the &#8220;Certain Relationships and Related Party Transactions of the Combined Company&#8221; section of the Proxy Statement/Prospectus,
the following is a description of each transaction involving (1) the Company since the Closing, including proposed transactions, (2)
Pre-Merger Oruka since February 6, 2024 (its inception) through the Closing, and (3) ARCA, beginning on January 1, 2022, and in which:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company, Pre-Merger Oruka, or ARCA has been, or is to be, a participant;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
amount involved exceeded or will exceed the lesser of $120,000 and 1% of the average of either the Company&#8217;s, Pre-Merger Oruka&#8217;s,
or ARCA&#8217;s assets (as the case may be); and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
which the directors, executive officers, former directors, former executive officers, director nominees and holders of more than 5% of
capital stock of the Company, Pre-Merger Oruka, or ARCA (as the case may be), or other persons as may be required to be disclosed pursuant
to Item 404 of Regulation S-K, had or will have a direct or indirect material interest.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Other than
the compensation agreements and other arrangements disclosed above under the heading &#8220;Executive Compensation,&#8221; and the transactions
described below, since the filing date of the Proxy Statement/Prospectus, there were no transactions or series of similar transactions
to which ARCA, Pre-Merger Oruka, or the Company were a party in which the amount involved exceed $120,000 (or, if less, 1% of the average
of ARCA, Pre-Merger Oruka, or the Company&#8217;s total asset amounts (as the case may be)) and in which any director, executive officer,
holder of 5% or more of any class of ARCA&#8217;s, Pre-Merger Oruka&#8217;s or the Company&#8217;s capital stock (as the case may be)
or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had a direct or indirect material
interest.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>ARCA
Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Transactions
With ARCA&#8217;s Former President and Chief Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
previously entered into unrestricted research grants with its former President and Chief Executive Officer&#8217;s academic research
laboratory at the University of Colorado. Funding of any unrestricted research grants was contingent upon ARCA&#8217;s financial condition,
and could be deferred or terminated at ARCA&#8217;s discretion. There was no expense under these arrangements for the three&#160;months
ended March&#160;31, 2024. Total expense under these arrangements for the three&#160;months ended March&#160;31, 2023 was $108,000. Total
expense under these arrangements for the&#160;years ended December&#160;31, 2023 and 2022 was $(91,000) and $432,000, respectively. In
December&#160;2023, ARCA made a payment of $125,000 for the grant period July&#160;2022 through December&#160;2023 under these arrangements.
In April&#160;2024, the President and Chief Executive Officer resigned.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Cooperation
Agreement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
was a party to a Cooperation Agreement (the &#8220;Cooperation Agreement&#8221;) with Cable Car Capital LLC, The Funicular Fund, LP,
Funicular Funds, LP and Jacob Ma-Weaver&#160;(collectively, &#8220;Cable Car&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Cooperation Agreement, ARCA&#8217;s board of directors appointed Mr.&#160;Ma-Weaver&#160;as a Class&#160;III director with a term
expiring at ARCA&#8217;s 2024 annual meeting of stockholders, effective June&#160;15, 2022 and appointed Mr.&#160;Ma-Weaver&#160;to the
Special Committee of ARCA&#8217;s board of directors (the &#8220;First Director Appointment&#8221;). Mr. Ma-Weaver resigned from ARCA&#8217;s
board of directors immediately prior to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
under the terms of the Cooperation Agreement, ARCA and Cable Car initiated a process and subsequently identified a mutually acceptable
second independent director, Mr.&#160;James Flynn, to join ARCA&#8217;s board of directors. Mr.&#160;Flynn was elected as director at
the 2022 annual meeting of stockholders. Mr. Flynn resigned from ARCA&#8217;s board of directors immediately prior to the Closing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under
the terms of the Cooperation Agreement, Cable Car agreed to abide by customary standstill restrictions from the date of the Cooperation
Agreement until the earlier to occur of (i)&#160;the 180<sup>th</sup>&#160;day after the First Director Appointment is no longer serving
as a director of ARCA and (ii)&#160;the 90<sup>th</sup>&#160;day prior to the 2023 Annual Meeting (such period, the &#8220;Cooperation
Period&#8221;), including that Cable Car would not, among other things, (i)&#160;seek additional representation, or the removal of an
existing director, on ARCA&#8217;s board of directors, (ii)&#160;engage in any solicitation of proxies, or (iii)&#160;initiate, propose
or otherwise solicit, including any solicitations of the type contemplated by Rule&#160;14a-2(b)&#160;promulgated under the Securities
Exchange&#160;Act&#160;of&#160;1934 of ARCA&#8217;s stockholders for the approval of, any stockholder proposal. The Cooperation Period
expired on November&#160;1, 2023, the 90<sup>th&#160;</sup>day prior to the 2023 Annual Meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">ARCA
and Cable Car also agreed to customary mutual non-disparagement&#160;obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Private
Placements of Securities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Series&#160;A Preferred Stock and Convertible Note&#160;Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On March&#160;6,
2024, Oruka entered into a Convertible Note Purchase Agreement with Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount Fund II&#8221;),
whereby Oruka issued and sold to Fairmount Fund II (i)&#160;an aggregate of 20,000,000 shares of Pre-Merger Oruka Series A Preferred
Stock at a purchase price of $0.15 per share and (ii)&#160;a convertible note (the &#8220;Convertible Note&#8221;) with an initial principal
amount of $25.0 million at an interest rate of 12% per annum, for aggregate gross proceeds of $28&#160;million. Fairmount Fund II contributed
the aggregate principal amount of $25.0 million and all accrued interest under the Convertible Note (unpaid accrued interest of $1.5
million divided by the conversion price of $66.62 ($5.55 prior to the impact of the Reverse Stock Split) per share) in exchange for Pre-Merger
Oruka Common Stock and Pre-Merger Oruka pre-funded warrants in connection with the Pre-Closing Financing (as defined below), immediately
prior to the completion of the Merger. Fairmount Funds Management (&#8220;Fairmount&#8221;) is the investment manager of Fairmount Fund
II. Peter Harwin, one of our directors, is a managing member of Fairmount.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Merger
Oruka Pre-Closing Financing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On
April&#160;3, 2024, in connection with the execution of the Merger Agreement, Pre-Merger Oruka entered into the Subscription
Agreement to consummate the Pre-Closing Financing. Pursuant to the Subscription Agreement, the Financing Investors purchased
39,873,706 shares of Pre-Merger Oruka common stock and 9,664,208 Pre-Merger Oruka pre-funded warrants for gross proceeds of
approximately $275.0 million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note
and accrued interest on such note which converted to 4,764,032 shares of Pre-Merger Oruka common stock), immediately prior to the
Closing and before the effect of the Reverse Stock Split. Three of the investors or their affiliates were beneficial
holders of more than 5% of Pre-Merger Oruka&#8217;s capital stock, and the table below sets forth the number of shares of Pre-Merger
Oruka common stock and Pre-Merger Oruka pre-funded warrants purchased by such holders at the closing of the Pre-Closing
Financing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of <br/> Pre-Merger Oruka <br/> Common<br/>
 Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-funded
    <br/> Warrants of <br/> Pre-Merger Oruka</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> Purchase <br/> Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 64%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Fairmount</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,139,797</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,271,241</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">79,907,282</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><sup>(1)</sup></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Venrock Healthcare Capital Partners</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,011,172</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">392,967</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,996,067</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with FMR LLC</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,503,445</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,999,974</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Includes
                                            $25.0 million of proceeds previously received by Pre-Merger Oruka from the issuance of the
                                            Convertible Note and accrued interest on such note, with the remainder of the purchase price
                                            paid in cash.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Company
Transactions </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>September
2024 Private Placement </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 11, 2024, the Company entered into the SPA with the
Selling Stockholders to consummate the Private Placement. Pursuant to the SPA, the Selling Stockholders purchased (i) an aggregate of
5,600,000 shares of Common Stock, at a price per share of $23.00, (ii) an aggregate of 2,439 shares of Series A Preferred Stock (each
Series A Preferred Stock is convertible into 1,000 shares of Company Common Stock), at a price per share of $23,000.00, and (iii) pre-funded
warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per pre-funded warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each pre-funded warrant,
for an aggregate purchase price of approximately $200.5 million. Subject to receiving the requisite stockholder approval and certain beneficial
ownership limitations set by each holder of Series A Preferred Stock, each share of Series A Preferred Stock will automatically convert
into an aggregate of 1,000 shares of Common Stock. Three of the Selling Stockholders or their affiliates were beneficial holders of more
than 5% of the Company&#8217;s capital stock, and the table below sets forth the number of shares of Common Stock, Series A Preferred
Stock and pre-funded warrants purchased by such holders at the closing of the Private Placement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Participant</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Shares
    of <br/> Common Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Series
    A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Pre-Funded
    Warrants</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">Total
    <br/> Purchase <br/> Price</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 52%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with FMR LLC</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,105,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">830</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,505,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Venrock Healthcare Capital Partners</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">300,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,949,700</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Entities
    affiliated with Fairmount</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">275,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">160</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,005,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Our Relationship
with Paragon and Paruka</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are party
to a number of agreements with Paragon and Paruka. Paragon and Paruka beneficially own more than 5% of our capital stock through their
joint holdings of our Common Stock. Fairmount beneficially owns more than 5% of our capital, one of Fairmount&#8217;s employees serves
on our Board, and Fairmount beneficially owns more than 5% of Paragon. Fairmount appointed Paragon&#8217;s board of directors and has
the contractual right to approve the appointment of any executive officers of Paragon, but is not the beneficial owner of Paragon&#8217;s
securities. Paruka is an entity formed by Paragon as a vehicle to hold equity in our Company in order to share profits with certain employees
of Paragon.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March&#160;2024, Pre-Merger Oruka entered into
the Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon identifies, evaluates and develops antibodies
directed against certain mutually agreed therapeutic targets of interest to us. The Option Agreements include two selected targets, IL-23
(ORKA-001) and IL-17A/F (ORKA-002). Under the Option Agreements, we have the exclusive options to, on a research program-by-research program
basis, be granted an exclusive, worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property
resulting from the applicable research program to develop, manufacture, and commercialize the antibodies and products directed to the
selected targets (each, an &#8220;Option&#8221;), with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease.
If we exercise our options, we will be required to make non-refundable milestone payments to Paragon of up to $12.0 million under each
respective agreement upon the achievement of certain clinical development milestones, up to $10.0 million under each respective agreement
upon the achievement of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on
the first commercial sale. From time to time, we can choose to add additional targets to the collaboration by mutual agreement with Paragon.
During the three months ended September 30, 2024, we exercised our option for ORKA-001 and recorded a $1.5 million milestone payment related
to the achievement of development candidate as research and development expense in our condensed consolidated statements of operations
and comprehensive loss for the three months ended September 30, 2024. As of September 30, 2024, this amount is included under related
party accounts payable and other current liabilities on the condensed consolidated balance sheet.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our exclusive Option with respect to each research
program for a particular target initiated by the parties (&#8220;Research Program&#8221;) is exercisable at our sole discretion at any
time during the period beginning on the initiation of activities under the associated Research Program and ending a specified number of&#160;days
following (i) with respect to any Research Program other than ORKA-001, the delivery of the data package from Paragon related to the results
of the Research Plan activities, or (ii) with respect to ORKA-001, the completion of the IL-23 antibody selection process described in
the agreement (the &#8220;Option Period&#8221;). There is no payment due upon exercise of an Option pursuant to the Option Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless terminated earlier, the Option Agreements shall continue in
force on a Research Program-by-Research Program basis until the earlier of: (i)&#160;the end of the Option Period for such Research Program,
as applicable, if such Option is not exercised by us; (ii)&#160;the expiration of the 30-day period after we exercise our Option with
respect to such Research Program, subject to mutually agreed extension, during the Option Period and the parties are unable to finalize
and execute a license agreement, and (iii) the expiration of the applicable research term (the &#8220;Term&#8221;). Upon the expiration
of the Term for all then-existing Research Programs, under the Option Agreements, the Option Agreements will automatically expire in its
entirety. We may terminate the Option Agreements or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior
written notice to Paragon, provided that we must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable
obligations reasonably incurred by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate
the Option Agreements or a Research Program immediately upon written notice to us if, as a result of any action or failure to act by us
or our affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or
otherwise delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research
Program upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the
30-day period and (ii)&#160;the other party&#8217;s bankruptcy.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the Research Plan for each respective research program, we were required
to pay Paragon a one-time nonrefundable research initiation fee of $0.8 million related to the ORKA-001 program. This amount was recognized
as a research and development expense during the period from February 6, 2024 (inception) to September 30, 2024. In June 2024, pursuant
to the Option Agreements with Paragon, we completed the selection process of our development candidate for IL-23 antibody for the ORKA-001
program. We were responsible for 50% of the development costs incurred through the completion of the IL-23 selection process. We received
the rights to at least one selected IL-23 antibody in June 2024. During the three months ended September 30, 2024, we exercised our option
for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement of development candidate as research and development
expense in the Company&#8217;s condensed consolidated statements of operations and comprehensive loss for each of the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024. Our share of development costs incurred
during the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024 was $0.8 million
and $13.2 million, respectively, which were recorded as research and development expenses during the respective periods. An amount of
$2.3 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We were also required to reimburse Paragon $3.3
million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development costs incurred
by Paragon between January 1, 2024 and March 6, 2024 as stipulated by the Option Agreements. This amount was recognized as a research
and development expense during the period from February 6, 2024 (inception) to September 30, 2024. We are also responsible for the development
costs incurred by Paragon from January 1, 2024 through the completion of the IL-17 selection process. We recognized an amount of $0.8
million payable to Paragon for the research initiation fee related to ORKA-002 following the finalization of the ORKA-002 research plan.
This was recognized as research and development expenses in the period from February 6, 2024 (inception) to September 30, 2024. We accounted
for development costs of $3.8 million and $6.6 million during the three months ended September 30, 3024 and for the period from February
6, 2024 (inception) to September 30, 2024, respectively, as research and development expenses during the respective periods. An amount
of $3.8 million is included in related party accounts payable and other current liabilities as of September 30, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As part of the Option Agreements, on each of December
31, 2024 and December 31, 2025, we will grant warrants to purchase a number of shares equal to 1.00% of outstanding shares as of the date
of the grant on a fully diluted basis with an exercise price equal to the fair market value of the underlying shares on the grant date.
The warrants are liability-classified and after the initial recognition, the liability is adjusted to fair value at the end of each reporting
period, with changes in fair value recorded in the consolidated statement of operations and comprehensive loss as stock-based compensation
expenses under research and development expenses.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Indemnification
Agreements and Insurance</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We have entered
into an indemnification agreement with each of the directors and officers and purchased directors&#8217; and officers&#8217; liability
insurance. The indemnification agreements require us to indemnify our directors and officers to the fullest extent permitted under Delaware
law.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Review,
Approval or Ratification of Transactions with Related Parties </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Prior to
the Closing, Pre-Merger Oruka did not have a formal policy regarding approval of transactions with related parties. All disclosable transactions
with related parties which occurred prior to the Closing were approved by the directors not interested in such transactions, pursuant
to Section 144(a)(1) of the DGCL.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Company&#8217;s
Board has adopted a written related person transactions policy. Under this policy, our executive officers, directors, nominees for election
as a director, beneficial owners of more than 5% of our Common Stock, and any members of the immediate family of and any entity affiliated
with any of the foregoing persons, are not permitted to enter into a material related person transaction with us without the review and
approval of our Audit Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit
Committee to review such transaction due to a conflict of interest. The policy provides that, subject to limited exceptions, any transaction,
arrangement or relationship or series of similar transactions, arrangements or relationships in which (1) the aggregate amount involved
since the beginning of the Company&#8217;s last completed fiscal year exceeds or is expected to exceed $120,000, (2) the Company or any
of our subsidiaries is a participant, and (3) any related person has or will have a direct or indirect interest, will be presented to
our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee will consider
the material facts and other factors it deems appropriate, including, but not limited to, whether the transaction is on terms no less
favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the
related person&#8217;s interest in the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SELLING
STOCKHOLDERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">This prospectus
covers the resale or other disposition from time to time by the Selling Stockholders identified in the table below of up to an aggregate
of 8,719,000 shares of our Common Stock. The Selling Stockholders may from time to time offer and sell any or all of the Resale Shares
set forth below pursuant to this prospectus and any accompanying prospectus supplement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On September
11, 2024, we entered into the SPA, pursuant to which we sold an aggregate of (i) 5,600,000 shares of our Common Stock, (ii) 2,439 shares
of our Series A Preferred Stock, which will automatically convert into 1,000 shares of Common Stock, subject to stockholder approval
and certain beneficial ownership limitations set by each holder, pursuant to the Series A Certificate of Designation, and (iii) Pre-Funded
Warrants to purchase an aggregate of 680,000 shares of Common Stock at a purchase price of $22.999 per Pre-Funded Warrant, which represents
the per share purchase price of the Private Placement Common Shares less the $0.001 per share exercise price for each Pre-Funded Warrant,
for an aggregate purchase price of approximately $200.5 million. This prospectus covers the resale or other disposition by the Selling
Stockholders or their pledgees, donees, transferees or other successors-in-interest that receive their shares after the date of this
prospectus of up to the total number of shares of Common Stock, shares of Common Stock issuable upon the conversion of the Series A Preferred
Stock, and shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants sold to the Selling Stockholders pursuant to
the SPA. This prospectus covers the resale or other disposition by the Selling Stockholders or their transferees of up to the total number
of Private Placement Common Shares, Private Placement Preferred Shares and Pre-Funded Warrants issued to the Selling Stockholders upon
conversion of the Private Placement Preferred Shares and exercise of the Pre-Funded Warrants issued pursuant to the SPA. Throughout this
prospectus, when we refer to the &#8220;Selling Stockholders,&#8221; we are referring to the purchasers under the SPA listed in the table
below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are registering
the Resale Shares to permit the Selling Stockholders and their pledgees, donees, transferees or other successors-in interest that receive
their shares after the date of this prospectus to resell or otherwise dispose of the shares in the manner contemplated under &#8220;Plan
of Distribution&#8221; herein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Except as
otherwise disclosed herein, the Selling Stockholders do not have, and within the past three years have not had, any position, office
or other material relationship with us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The following
table sets forth the names of the Selling Stockholders, the number of shares of our Common Stock owned by the Selling Stockholders, the
number of shares of our Common Stock that may be offered under this prospectus and the number of shares of our Common Stock that will
be owned after this offering by the Selling Stockholders assuming all of the shares registered for resale hereby are sold.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell some, all or none of their Resale Shares. We do not know how long the Selling Stockholders will hold the Resale
Shares before selling them, and we currently have no agreements, arrangements or understandings with the Selling Stockholders regarding
the sale or other disposition of any of the Resale Shares. The Resale Shares covered hereby may be offered from time to time by the Selling
Stockholders, provided that Resale Shares issued upon conversion of Series A Preferred Stock may only be offered after such shares of
Series A Preferred Stock are converted to Common Stock pursuant to the terms of the Series A Certificate of Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The information
set forth below is based upon information obtained from the Selling Stockholders and upon information in our possession regarding the
issuance of the Private Placement Common Shares, Private Placement Preferred Shares and shares of Common Stock issuable upon the exercise
of the Pre-Funded Warrants in connection with the September 2024 PIPE. The percentages of Common Stock owned after the offering by each
Selling Stockholder below are based on 34,998,550 shares of Common Stock outstanding as of November 1, 2024, and, for each Selling Stockholder,
assumes the conversion of only the Series A Preferred Stock and exercise of only the Pre-Funded Warrants owned by such Selling Stockholder
but not the Series A Preferred Stock or Pre-Funded Warrants owned by any other Selling Stockholder. The numbers of shares of Common Stock
beneficially owned before and after the offering presented in the table below do not give effect to any Beneficial Ownership Limitations
with respect to the Series A Preferred Stock or Pre-Funded Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-indent: 0pt; padding-left: 0pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Name
    of Selling Stockholders(1)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common<br/>
    Stock<br/> Beneficially<br/> Owned<br/> Before the<br/> Offering (2)</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common<br/>
    Stock that<br/> May<br/> Be Offered<br/> Pursuant to<br/> Prospectus</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Common
    Stock<br/> Beneficially<br/> Owned After the<br/> Offering (2)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Number</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>Percentage<br/>
                                            (%)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 54%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Small Cap Growth Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">555,043</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">179,838</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">375,205</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.07</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Small Cap Growth K6 Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">225,831</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">86,378</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">139,453</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Advisor Series VII:&#160;&#160;Fidelity Advisor Biotechnology Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">609,300</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">197,572</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">411,728</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.18</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Select Portfolios:&#160;&#160;Biotechnology Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">704,983</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">704,883</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Advisor Series VII:&#160;&#160;Fidelity Advisor Health Care Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">629,688</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">67,978</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">561,710</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Select Portfolios:&#160;&#160;Health Care Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">999,710</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">110,356</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">889,354</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.45</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Variable
    Insurance Products Fund IV: VIP Health Care Portfolio (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">159,859</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,109</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">134,750</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Series Growth Company Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78,239</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78,239</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">297,445</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">297,445</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Growth Company Commingled Pool (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,267</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">400,267</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,707</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">92,707</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Capital Trust: Fidelity Stock Selector Small Cap Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">283,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Fidelity
    Securities Fund: Fidelity Series Small Cap Opportunities Fund (3)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,772</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">410,772</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Braidwell
    Partners Master Fund LP (4)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,777,426</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,630,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">147,426</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Venrock Healthcare Capital Partners (5)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,541,941</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">650,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,891,941</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.50</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="padding: 0; font-family: Times New Roman, Times, Serif; text-indent: 0; text-align: left"><p style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
                                            associated with Fairmount Funds Management LLC (6)</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">7,941,690</span></p></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,506,690</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18.90</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">AI
    Biotechnology LLC (7)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,791,052</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,441,052</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.12</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with Blackstone Alternative Asset Management Associates LLC (8)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">590,174</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">350,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">240,174</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Point72
    Associates, LLC (9)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">618,671</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">340,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">278,671</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Frazier Life Sciences (10)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">583,327</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">326,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,327</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with Paradigm BioCapital Advisors LP (11)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">819,660</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">305,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">514,660</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.47</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with RTW Investments, LP (12)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,058,147</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">285,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,773,147</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5.07</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    Associated with T. Rowe Price Associates, Inc. (13)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,244,191</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">215,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,029,191</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2.94</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">SR
    One Capital Opportunities Fund I, LP (14)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">430,330</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">173,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">257,330</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Entities
    associated with Janus Henderson Investors US LLC (15)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">335,456</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">185,456</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Commodore
    Capital Master LP (16)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,419,714</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,269,714</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.62</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Kalehua
    Capital Partners LP (17)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">150,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Avidity
    Private Master Fund I LP (18)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">701,363</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">110,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">591,363</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1.69</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Adage
    Capital Partners LP (19)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">200,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">100,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Affinity
    Healthcare Fund, LP (20)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">284,836</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">45,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">239,836</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Allostery
    Master Fund, LP (21)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
                                            than 1%</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
                                            our knowledge, unless otherwise indicated, all persons named in the table above have sole
                                            voting and investment power with respect to their shares of Common Stock. Unless an address
                                            is provided below, the address for the holder is 855 Oak Grove Ave., Suite 100, Menlo Park,
                                            CA 94025.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Beneficial
                                                                                                                                                                                                                                                         ownership&#8221; is a term broadly defined by the SEC in Rule 13d-3 under the Exchange Act, and includes more than the typical form
                                                                                                                                                                                                                                                         of stock ownership, that is, stock held in the person&#8217;s name. The term also includes what is referred to as &#8220;indirect
                                                                                                                                                                                                                                                         ownership,&#8221; meaning ownership of shares as to which a person has or shares investment power. Notwithstanding the foregoing,
                                                                                                                                                                                                                                                         the beneficial ownership amounts assume the sale of all Common Stock that may be offered pursuant to this prospectus without taking
                                                                                                                                                                                                                                                         into account certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series
                                                                                                                                                                                                                                                         A Preferred Stock into shares of Common Stock (i) prior to the affirmative vote of the holders of a majority of the then outstanding
                                                                                                                                                                                                                                                         shares of the Series A Preferred Stock, or (ii) if, as a result of such conversion, such holder, together with its affiliates, would
                                                                                                                                                                                                                                                         beneficially own more than a specified percentage (established by the holder not to exceed 19.99%) (the &#8220;Beneficial Ownership
                                                                                                                                                                                                                                                         Limitation&#8221;) of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such
                                                                                                                                                                                                                                                         conversion.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
                                            funds and accounts are managed by direct or indirect subsidiaries of FMR LLC.&#160;&#160;Abigail
                                            P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC.&#160;&#160;Members
                                            of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly
                                            or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting
                                            power of FMR LLC. The Johnson family group and all other Series B shareholders have entered
                                            into a shareholders&#8217; voting agreement under which all Series B voting common shares
                                            will be voted in accordance with the majority vote of Series B voting common shares. Accordingly,
                                            through their ownership of voting common shares and the execution of the shareholders&#8217;
                                            voting agreement, members of the Johnson family may be deemed, under the Investment Company
                                            Act of 1940, to form a controlling group with respect to FMR LLC.&#160;&#160;The address
                                            of these funds and accounts is 245 Summer Street, Boston, MA 02210.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 250,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Braidwell Partners Master Fund LP (&#8220;Braidwell Partners&#8221;), (ii) 1,147,426
                                            shares of Common Stock held by Braidwell Partners and (iii) 380,000 shares of Common Stock
                                            issuable upon the exercise of the Pre-Funded Warrants held by Braidwell Partners. Braidwell
                                            LP (the &#8220;Braidwell Investment Manager&#8221;) is the investment manager of Braidwell
                                            Partners. Braidwell GP LLC (the &#8220;Braidwell GP&#8221;) is the general partner of Braidwell
                                            Partners. Braidwell Management LLC (the &#8220;Braidwell IM GP&#8221;) is the general partner
                                            of the Braidwell Investment Manager and the managing member of the Braidwell GP. Messrs.
                                            Alexander T. Karnal and Brian J. Kreiter (together with Braidwell Partners, the Braidwell
                                            Investment Manager, the Braidwell GP and the Braidwell IM GP, the &#8220;Braidwell Parties&#8221;)
                                            together own, directly or indirectly, the Braidwell Investment Manager, the Braidwell GP
                                            and the Braidwell IM GP. The address of Braidwell Partners is c/o Maples Corporate Services
                                            Limited, P.O Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands. The principal
                                            address of the Braidwell Investment Manager, the Braidwell GP and the Co-Founders is One
                                            Harbor Point, 2200 Atlantic Street, 4th Floor, Stamford, Connecticut 06902. The Braidwell
                                            Parties may be deemed to have shared voting and dispositive power with respect to the shares
                                            of Common Stock held by Braidwell Partners. Each of the Braidwell Parties disclaims beneficial
                                            ownership of such shares except to the extent of any pecuniary interest therein.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of
                                            (i) 2,350,074 shares of common stock and 351,506 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by Venrock Healthcare Capital Partners EG, L.P. (&#8220;VHCPEG&#8221;),
                                            (ii) 668,656 shares of common stock and 95,284 shares of common stock issuable upon the exercise
                                            of pre-funded warrants held by Venrock Healthcare Capital Partners III, L.P. (&#8220;VHCP3&#8221;),
                                            and (iii) 66,890 shares of common stock and 9,531 shares of common stock issuable upon the
                                            exercise of pre-funded warrants held by VHCP Co-Investment Holdings III, LLC (&#8220;VHCPCo3&#8221;).
                                            Excludes (i) 54,474, 12,504 and 1,244 shares of common stock issuable upon the exercise of
                                            the pre-funded warrants held by VHCPEG, VHCP3 and VHCPCo3, respectively, and (ii) 157,000,
                                            39,000 and 4,000 shares of common stock issuable upon the conversion of Series A Preferred
                                            Stock held by VHCPEG, VHCP3 and VHCPCo3, respectively. The pre-funded warrants and Series
                                            A Preferred Stock are subject to a beneficial ownership limitation of 9.99%, which such limitations
                                            restrict Venrock Healthcare Capital Partners and its affiliates from exercising that portion
                                            of the warrants or Series A Preferred Stock that would result in Venrock Healthcare Capital
                                            Partners and its affiliates owning, after exercise, a number of shares of common stock in
                                            excess of the applicable ownership limitation. VHCP Management III, LLC (&#8220;VHCPM3&#8221;)
                                            is the sole general partner of VHCP3 and the sole manager of VHCPCo3. VHCP Management EG,
                                            LLC (&#8220;VHCPM EG&#8221;) is the sole general partner of VHCPEG. As voting members of
                                            VHCPM3 and VHCPM EG, Dr. Bong Koh and Nimish Shah may be deemed beneficial owners of any
                                            securities beneficially owned by VHCPM3 and VHCPM EG. The principal business address of each
                                            of these persons and entities is 7 Bryant Park, 23rd Floor, New York, NY 10018.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consists of
                                            (i) (A) 638,614 shares of common stock, (B) 316,025 shares of common stock issuable upon
                                            the exercise of pre-funded warrants and (C) 4,413,743 shares of common stock issuable upon
                                            conversion of 52,965 shares of Series B Preferred Stock held by Fairmount Healthcare Fund
                                            II L.P. (&#8220;Fairmount Fund II&#8221;) and (ii) 2,573,308 shares of common stock held
                                            by Fairmount Healthcare Co-Invest III L.P. (&#8220;Fairmount Fund III&#8221;). Excludes (i)
                                            4,981,639 shares of common stock issuable upon the exercise of the pre-funded warrants, (ii)
                                            7,014,406 shares of common stock issuable upon the conversion of 84,173 shares of Series
                                            B Preferred Stock and (iii) 160,000 shares of common stock issuable upon the conversion of
                                            160 shares of Series A Preferred Stock owned by Fairmount Fund II. The pre-funded warrants
                                            and Series A Preferred Stock are subject to a beneficial ownership limitation of 9.99% and
                                            the shares of Series B Preferred Stock are subject to a beneficial ownership limitation of
                                            19.99%, which such limitations restrict Fairmount Funds Management LLC (&#8220;Fairmount&#8221;)
                                            and its affiliates from exercising that portion of the warrants and converting those shares
                                            of preferred stock that would result in Fairmount and its affiliates owning, after exercise
                                            or conversion, a number of shares of common stock in excess of the applicable ownership limitation.
                                            At such time as Fairmount and its affiliates beneficially own 9.0% or less of the shares
                                            of common stock, the beneficial ownership limitation applicable to the shares of Series B
                                            Preferred Stock will automatically reduce to 9.99%. Fairmount serves as investment manager
                                            for Fairmount Fund II and Fairmount Fund III. Fairmount Fund II and Fairmount Fund III have
                                            delegated to Fairmount the sole power to vote and the sole power to dispose of all securities
                                            held in Fairmount Fund II and Fairmount Fund III&#8217;s portfolios. Because Fairmount Fund
                                            II and Fairmount Fund III have divested themselves of voting and investment power over the
                                            securities they hold and may not revoke that delegation on less than 61 days&#8217; notice,
                                            Fairmount Fund II and Fairmount Fund III disclaim beneficial ownership of the securities
                                            they hold. The general partner of Fairmount is Fairmount Funds Management GP LLC (&#8220;Fairmount
                                            GP&#8221;). As managing members of Fairmount GP, Peter Harwin and Tomas Kiselak may be deemed
                                            to have voting and investment power over the shares held by Fairmount Fund II and Fairmount
                                            Fund III. Fairmount, Fairmount GP, Peter Harwin and Tomas Kiselak disclaim beneficial ownership
                                            of such shares, except to the extent of any pecuniary interest therein. The address of the
                                            entities and individuals listed is 200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
                                            19428.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 1,441,052 shares of Common Stock purchased pursuant to a Subscription Agreement, dated
                                            August 3, 2024, among the Company and the purchasers thereto (including AI Biotechnology
                                            LLC) (ii) 125,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by AI Biotechnology LLC and (ii) 225,000 shares of Common Stock held by AI Biotechnology
                                            LLC. Access Industries Holdings LLC, or AIH, directly controls all of the outstanding voting
                                            interest in AI Biotechnology LLC. Access Industries Management, LLC, or AIM, controls AIH.
                                            Len Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH.
                                            Each of Len Blavatnik, AIM and AIH may be deemed to have voting and investment power over
                                            the shares held by AI Biotechnology LLC and disclaims beneficial ownership of such shares.
                                            The address of each of AI Biotechnology LLC, AIM, AIH and Len Blavatnik is c/o Access Industries,
                                            Inc., 40 West 57th Street, 28th Floor, New York, NY 10019.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 72,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Spruce Street Aggregator L.P. (&#8220;Spruce Street Fund&#8221;), (ii) 130,078 shares
                                            of Common Stock held by Spruce Street Fund, (iii) 53,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Blackstone Annex Master Fund L.P.
                                            (&#8220;Annex Fund&#8221;), and (iv) 335,096 shares of Common Stock held by Annex Fund. Blackstone
                                            Alternative Asset Management Associates LLC is the general partner of Annex Fund and Spruce
                                            Street Fund. Blackstone Holdings II L.P. is the sole member of Blackstone Alternative Asset
                                            Management Associates LLC. Blackstone Holdings I/II GP L.L.C. is the general partner of Blackstone
                                            Holdings II L.P. Blackstone Inc. is the sole member of Blackstone Holdings I/II GP L.L.C.
                                            Blackstone Group Management L.L.C. is the sole holder of the Series II preferred stock of
                                            Blackstone Inc. Blackstone Group Management L.L.C. is wholly owned by its senior managing
                                            directors and controlled by its founder, Stephen A. Schwarzman. Each of such Blackstone entities
                                            and Mr. Schwarzman may be deemed to beneficially own the securities beneficially owned by
                                            the Annex Fund and the Aggregator Fund directly or indirectly controlled by it or him, but
                                            each (other than each of the Annex Fund and the Aggregator Fund to the extent of their respective
                                            direct holdings) disclaims beneficial ownership of such securities. The address of each of
                                            the entities listed is c/o Blackstone Inc., 345 Park Avenue, New York, New York 10154.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 115,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Point72 Associates, LLC (&#8220;Point72 Associates&#8221;) and (ii) 503,671 shares
                                            of Common Stock held by Point72 Associates. Pursuant to an investment management agreement,
                                            Point72 Asset Management, L.P. maintains investment and voting power with respect to the
                                            securities held by certain investment funds it manages, including Point72 Associates. Point72
                                            Capital Advisors, Inc. is the general partner of Point72 Asset Management, L.P. Mr. Steven
                                            A. Cohen controls each of Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc.
                                            By reason of the provisions of Rule 13d-3 of the Exchange Act, each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen may be deemed to beneficially own the
                                            securities held by Point72 Associates reflected herein. Each of Point72 Asset Management,
                                            L.P., Point72 Capital Advisors, Inc., and Mr. Cohen disclaims beneficial ownership of any
                                            such securities. The address for Point72 Associates is c/o Point72 Asset Management, L.P.,
                                            72 Cummings Point Road, Stamford, CT 06902.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 1,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Frazier Life Sciences X, L.P. (&#8220;FLS X&#8221;), (ii) 23,785 shares of Common
                                            Stock held by FLS X, (iii) 1,000 shares of Common Stock issuable upon the conversion of Series
                                            A Preferred Stock held by Frazier Life Sciences XI, L.P. (&#8220;FLS XI&#8221;), (iv) 40,967
                                            shares of Common Stock held by FLS XI, (v) 81,000 shares of Common Stock issuable upon the
                                            conversion of Series A Preferred Stock held Frazier Life Sciences Public Fund, L.P. (&#8220;FLS
                                            Public Fund&#8221;), (vi) 297,560 shares of Common Stock held by FLS Public Fund, (vii) 23,000
                                            shares of Common Stock issuable upon the conversion of Series A Preferred Stock held by Frazier
                                            Life Sciences Public Overage Fund, L.P. (&#8220;FLS Overage Fund&#8221;) and (viii) 115,015
                                            shares of Common Stock held by FLS Overage Fund. FHMLSP, L.P. is the general partner of FLS
                                            Public Fund and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Albert Cha, James N.
                                            Topper, Patrick J. Heron and James Brush are the managing directors of FHMLSP, L.L.C. and
                                            therefore share voting and investment power over the shares held by FLS Public Fund. Dr.
                                            Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim beneficial ownership of the shares held
                                            by FLS Public Fund except to the extent of their pecuniary interests in such shares, if any.
                                            FHMLSP Overage, L.P., is the general partner of FLS Overage Fund and FHMLSP Overage, L.L.C.
                                            is the general partner of FHMLSP Overage, L.P. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush
                                            are the members of FHMLSP Overage, L.L.C. and therefore share voting and investment power
                                            over the shares held by FLS Overage Fund. Dr. Cha, Dr. Topper, Mr. Heron and Dr. Brush disclaim
                                            beneficial ownership of the shares held by FLS Overage Fund except to the extent of their
                                            pecuniary interests in such shares, if any. FHMLS X, L.P. is the general partner of FLS X,
                                            and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Mr. Heron and Dr. Topper are
                                            the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares
                                            held by FLS X. Dr. Topper and Mr. Heron disclaim beneficial ownership of the shares held
                                            by FLS X except to the extent of their pecuniary interests in such shares, if any. FHMLS
                                            XI, L.P. is the general partner of FLS XI, and FHMLS XI, L.L.C. is the general partner of
                                            FHMLS XI, L.P. Mr. Heron, Dr. Topper and Daniel Estes are the members of FHMLS XI, L.L.C.
                                            and therefore share voting and investment power over the shares held by FLS XI. Dr. Topper,
                                            Mr. Heron and Mr. Estes disclaim beneficial ownership of the shares held by FLS XI except
                                            to the extent of their pecuniary interests in such shares, if any. The principal business
                                            address of the above referenced entities and persons is 1001 Page Mill Rd., Building 4, Ste.
                                            B, Palo Alto, CA 94304.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 86,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Paradigm BioCapital International Fund Ltd. (&#8220;Paradigm Fund&#8221;), (ii) 617,323
                                            shares of Common Stock held by Paradigm Fund, (iii) 14,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by Paradigm BioCapital Advisors LP (&#8220;Paradigm
                                            Advisor&#8221;), as discretionary investment manager on behalf of a separate account client
                                            solely with respect to the assets for which Paradigm Advisor acts as its investment manager
                                            (the &#8220;Separate Account&#8221;), and (iv) 102,337 shares of Common Stock held by Paradigm
                                            Advisor, as discretionary investment manager on behalf of the Separate Account. The shares
                                            of Common Stock may be deemed to be indirectly beneficially owned by each of Paradigm Advisor,
                                            Paradigm BioCapital Advisors GP LLC (&#8220;Paradigm Advisor GP&#8221;), and Senai Asefaw,
                                            M.D. Paradigm Advisor GP is the general partner of Paradigm Advisor, and Senai Asefaw, M.D.
                                            is the managing member of Paradigm Advisor GP. Paradigm Advisor is the investment manager
                                            of Paradigm Fund. Paradigm Advisor, Paradigm Advisor GP, and Senai Asefaw, M.D. may be deemed
                                            to have full investment and voting discretion over the shares of Common Stock held by Paradigm
                                            Fund and the Separate Account. The business address for each person and entity named in this
                                            footnote is 767 Third Avenue, 17th Floor, New York, NY 10017.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 95,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock&#160;&#160;and
                                            (ii) 1,963,147 shares of Common Stock, in each case of (i) and (ii) as held in the aggregate
                                            by RTW Master Fund, Ltd. RTW Innovation Master Fund, Ltd., and RTW Biotech Opportunities
                                            Operating Ltd, (collectively, the &#8220;RTW Funds&#8221;). RTW Investments, LP (&#8220;RTW&#8221;),
                                            in its capacity as the investment manager of the RTW Funds, has the power to vote and the
                                            power to direct the disposition of the shares held by the RTW Funds. Accordingly, RTW may
                                            be deemed to be the beneficial owner of such securities. Roderick Wong, M.D., as the Managing
                                            Partner of RTW, has the power to direct the vote and disposition of the securities held by
                                            RTW. Dr. Wong disclaims beneficial ownership of the shares held by the RTW Funds, except
                                            to the extent of his pecuniary interest therein. The address and principal office of RTW
                                            Investments, LP is 40 10th Avenue, Floor 7, New York, NY 10014, and the address of Dr. Wong
                                            and each of the RTW Funds is c/o RTW Investments, LP, 40 10th Avenue, Floor 7, New York,
                                            NY 10014.&#160;&#160;The shares of Common Stock issuable upon conversion of the shares of
                                            Series A Preferred Stock held by the RTW Funds are subject to a Beneficial Ownership Limitation
                                            of 9.99%.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 62,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by T. Rowe Price Health Sciences Fund, Inc., (ii) 1,125,095 shares of Common Stock held
                                            by T. Rowe Price Health Sciences Fund, Inc., (iii) 3,000 shares of Common Stock issuable
                                            upon the conversion of Series A Preferred Stock held by T. Rowe Price Health Sciences Portfolio,
                                            and (iv) 54,096 shares of Common Stock held by T. Rowe Price Health Sciences Portfolio. T.
                                            Rowe Price Associates, Inc. (&#8220;TRPA&#8221;), as investment adviser, has dispositive
                                            and voting power with respect to the shares held by these funds and accounts. For purposes
                                            of the Securities Exchange Act of 1934, TRPA may be deemed to be the beneficial owner of
                                            these aforementioned shares; however, TRPA expressly disclaims that it is, in fact, the beneficial
                                            owner of such securities. TRPA is a wholly owned subsidiary of T. Rowe Price Group, Inc.,
                                            which is a publicly traded financial services holding company. The principal business address
                                            of TRPA is 100 East Pratt Street, Baltimore, MD 21202.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 55,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by SR One Capital Opportunities Fund I, LP (&#8220;Opportunities Fund&#8221;) and (ii)
                                            375,330 shares of Common Stock held by Opportunities Fund. SR One Capital Opportunities Partners
                                            I, LP (&#8220;SR One Partners&#8221;) is the general partner of Opportunities Fund. SR One
                                            Capital Management, LLC (&#8220;SR One Management&#8221;) is the general partner of SR One
                                            Partners. Simeon George, M.D. is the manager of SR One Management. SR One Partners, SR One
                                            Management, and Simeon George share voting and investment power with respect to the shares
                                            directly held by Opportunities Fund. All indirect holders of the above referenced shares
                                            disclaim beneficial ownership of all applicable shares except to the extent of their pecuniary
                                            interest therein. The address of these persons and funds is 985 Old Eagle School Road, Suite
                                            511, Wayne, Pennsylvania 19087.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 30,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Janus Henderson Biotech Innovation Master Fund Limited, (ii) 258,149 shares of Common
                                            Stock held by Janus Henderson Biotech Innovation Master Fund Limited, (iii) 20,000 shares
                                            of Common Stock issuable upon the conversion of Series A Preferred Stock held by Janus Henderson
                                            Biotech Innovation Master Fund II Limited, and (iv) 27,307 shares of Common Stock held by
                                            Janus Henderson Biotech Innovation Master Fund II Limited. Such shares may be deemed to be
                                            beneficially owned by Janus Henderson Investors US LLC (&#8220;Janus&#8221;), an investment
                                            adviser registered under the Investment Advisers Act of 1940, who acts as investment adviser
                                            for Janus Henderson Biotech Innovation Master Fund Limited and Janus Henderson Biotech Innovation
                                            Master Fund II Limited (the &#8220;Janus Funds&#8221;) and has the ability to make decisions
                                            with respect to the voting and deposition of the shares subject to the oversight of the board
                                            of directors of the Janus Funds. Under the terms of its management contract with the Janus
                                            Funds, Janus has overall responsibility for directing the investments of the Janus Funds
                                            in accordance with the Janus Funds&#8217; investment objective, policies and limitations.
                                            The Janus Funds have one or more portfolio managers appointed by and serving at the pleasure
                                            of Janus who make decisions with respect to the disposition of the shares of common stock
                                            offered hereby. The address for Janus is 151 Detroit Street, Denver, CO 80206.&#160;&#160;The
                                            portfolio managers for the Janus Fund are Andrew Acker, Daniel S. Lyons and Agustin Mohedas.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Commodore Capital Master LP and (ii) 1,369,714 shares of Common Stock held by Commodore
                                            Capital Master LP. Commodore Capital LP is the investment manager to Commodore Capital Master
                                            LP and may be deemed to beneficially own the shares held by Commodore Capital Master LP.
                                            Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital LP
                                            and exercise investment discretion with respect to these shares. Commodore Capital LP and
                                            Commodore Capital Master LP have shared voting and dispositive power with respect to these
                                            shares. The address of Commodore Capital LP and Commodore Capital Master LP is 444 Madison
                                            Avenue, 35th Floor, New York, NY 10022.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 50,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Kalehua Capital Partners LP and (ii) 100,000 shares of Common Stock held by Kalehua
                                            Capital Partners LP. Kalehua Capital Partners LP is a buyout fund managed by Kalehua Capital
                                            Management LLC. Tai-Li Chang is the sole member of Kalehua Capital Management LLC. The address
                                            of these persons and funds is 3819 Maple Avenue, Dallas, Texas 75219.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            &#160;(i) 20,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Avidity Private Master Fund I LP and (ii) 681,363 shares of Common Stock held
                                            by Avidity Private Master Fund I LP, which is a Cayman exempted limited partnership. The
                                            general partner of Avidity Private Master Fund I LP is Avidity Capital Partners Fund (GP)
                                            LP, a Delaware limited partnership, whose general partner is Avidity Capital Partners (GP)
                                            LLC, a Delaware limited liability company. Avidity Partners Management LP is the investment
                                            manager of Avidity Private Master Fund I LP. Avidity Partners Management (GP) LLC is the
                                            general partner of Avidity Partners Management LP. David Witzke and Michael Gregory are the
                                            managing members of Avidity Capital Partners (GP) LLC and Avidity Partners Management (GP)
                                            LLC. Each of the entities and individuals referenced in this paragraph may be deemed to beneficially
                                            own the shares held by the Avidity entities. Certain affiliates of the Avidity entities,
                                            which are not selling stockholders, may also own shares. The address of Avidity Private Master
                                            Fund I LP is 2828 N. Harwood Street, Suite 1220, Dallas, Texas 75201.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            &#160;(i) 25,000 shares of Common Stock issuable upon the conversion of Series A Preferred
                                            Stock held by Adage Capital Partners LP (&#8220;Adage&#8221;) and (ii) 175,000 shares of
                                            Common Stock held by Adage. Bob Atchinson and Phillip Gross are the managing members of Adage
                                            Capital Advisors, L.L.C., which is the managing member of Adage Capital Partners GP, L.L.C.,
                                            which is the general partner of Adage, and each such person or entity, as the case may be,
                                            has shared voting and/or investment power over the securities held by Adage Capital Partners,
                                            LP and may be deemed the beneficial owner of such shares, and each such person or entity,
                                            as the case may be, disclaims beneficial ownership of such securities except to the extent
                                            of their respective pecuniary interest therein. The address of these funds and persons is
                                            200 Clarendon St., 52<sup>nd</sup> Floor, Boston, MA 02116.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 10,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Affinity Healthcare Fund, LP (&#8220;Affinity Fund&#8221;) and (ii) 274,836 shares
                                            of Common Stock held by Affinity Fund. Affinity Asset Advisors, LLC (the &#8220;Advisor&#8221;)
                                            is the investment manager of Affinity Healthcare Fund, LP (the &#8220;Fund&#8221;) and exercises
                                            investment discretion with regard to the shares of Common Stock owned by the Fund. The Fund
                                            and the Advisor have the shared power to vote or to direct the vote and to dispose or direct
                                            the disposition of such shares of Common Stock of the Issuer owned by the Fund.&#160;&#160;The
                                            Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer
                                            owned by the Fund by virtue of its position as investment manager of the Fund. The principal
                                            business address of each of the Fund and the Advisor is 767 Third Avenue, 15th Floor, New
                                            York, NY 10017.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.35in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            listed under &#8220;Common Stock Beneficially Owned Before the Offering&#8221; consist of
                                            (i) 8,000 shares of Common Stock issuable upon the conversion of Series A Preferred Stock
                                            held by Allostery Master Fund, LP (&#8220;Allostry Master Fund&#8221;) and (ii) 12,000 shares
                                            of Common Stock held by Allostry Master Fund. Allostery Funds GP LLC (&#8220;Allostery Funds
                                            GP&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master Fund
                                            because it is the general partner of Allostery Master Fund. Allostery Investments LP (&#8220;Allostery
                                            Investments&#8221;) may be deemed the beneficial owner of the shares held by Allostery Master
                                            Fund because it is the investment manager of Allostery Master Fund. Allostery Investments
                                            GP LLC (the &#8220;Investments GP&#8221;) may be deemed the beneficial owner of the shares
                                            beneficially held by Allostery Investments because it is the general partner of Allostery
                                            Investments. Christopher Staral and David Modest may be deemed the beneficial owners of the
                                            shares beneficially held by each of Investments GP and Allostery Funds GP by virtue of their
                                            positions as managing members of Investments GP and Allostery Funds GP. The address of Allostery
                                            Master Fund is c/o Maples Corporate Services Limited, Ugland House, South Church Street,
                                            Grand Cayman KY1-1104, Cayman Islands.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><i>Relationship
with the Selling Stockholders </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In addition
to the SPA, in connection with the Private Placement, we entered into the RRA (as defined below) on September 13, 2024 with the Selling
Stockholders. Certain of the September 2024 investors were, immediately prior to the closing of the September 2024 PIPE, or became holders
of more than 5% of our Common Stock and were parties to the Pre-Closing Financing. See &#8220;<i>Security Ownership of Certain Beneficial
Owners and Management and Related Stockholder Matters.</i>&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Registration
Rights Agreement</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">On September
13, 2024, we entered into a registration rights agreement (the &#8220;RRA&#8221;) with the Private Placement investors. Pursuant to the
RRA, we agreed to file a resale registration statement to register the Registrable Securities (as defined in the RRA) (the &#8220;Registration
Statement&#8221;). This registration statement is being filed to satisfy our obligations under the RRA. We have agreed to use our commercially
reasonable efforts to cause this Registration Statement to be declared effective by the SEC as soon as practicable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We have also
agreed, among other things, to indemnify the Selling Stockholders and each of their respective officers, directors, members, employees,
partners, managers, stockholders, affiliates, investment advisors and agents, each person who controls any such Selling Stockholder and
the officers, directors, members, employees, partners, managers, stockholders, affiliates, investment advisors and agents of each such
controlling person from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any
underwriting discounts and selling commissions) incident to our obligations under the RRA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PLAN
OF DISTRIBUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are registering
the Resale Shares issued to the Selling Stockholders to permit the sale, transfer or other disposition of these shares by the Selling
Stockholders or their donees, pledgees, transferees or other successors-in-interest from time to time after the date of this prospectus.
We will not receive any of the proceeds from the sale by the Selling Stockholders of the Resale Shares. We will, or will procure to,
bear all fees and expenses incident to our obligation to register the Resale Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may sell all or a portion of the Resale Shares beneficially owned by them and offered hereby from time to time, and in the
case of the Private Placement Conversion Shares, may only be offered after such shares are converted to Common Stock pursuant to the
terms of the Series A Certificate of Designation, directly or through one or more underwriters, broker-dealers or agents. If the Resale
Shares are sold through underwriters or broker-dealers, the Selling Stockholders will be responsible for underwriting discounts (it being
understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering)
or commissions or agent&#8217;s commissions. The Resale Shares may be sold on any national securities exchange or quotation service on
which the securities may be listed or quoted at the time of sale, in the over-the-counter market or in transactions otherwise than on
these exchanges or systems or in the over-the-counter market and in one or more transactions at fixed prices, at prevailing market prices
at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions,
which may involve crosses or block transactions. The Selling Stockholders may use any one or more of the following methods when selling
Resale Shares:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">ordinary
brokerage transactions and transactions in which the broker-dealer solicits purchasers;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">block
trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal
to facilitate the transaction;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">to
or through underwriters or purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">an
exchange distribution in accordance with the rules of the applicable exchange;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">privately
negotiated transactions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">settlement
of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">broker-dealers
may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">through
the writing or settlement of options or other hedging transactions, whether such options are listed on an options exchange or otherwise;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
combination of any such methods of sale; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
other method permitted pursuant to applicable law.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders also may resell all or a portion of the Resale Shares in open market transactions in reliance upon Rule 144, as permitted
by that rule, or Section 4(a)(1) under the Securities Act, if available, rather than under this prospectus, provided that they meet the
criteria and conform to the requirements of those provisions. The Selling Stockholders also may dispose of the Resales Shares through
distributions to members, partners, stockholders or other equityholders of the Selling Stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Broker-dealers
engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. If the Selling Stockholders effect
such transactions by selling Resale Shares to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the Selling Stockholders or commissions from
purchasers of the Resale Shares for whom they may act as agent or to whom they may sell as principal. Such commissions will be in amounts
to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction will not be in excess
of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown
in compliance with FINRA IM-2121.01.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In connection
with sales of the Resale Shares or otherwise, the Selling Stockholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the Resale Shares in the course of hedging in positions they assume.
The Selling Stockholders may also sell Resale Shares short and if such short sale takes place after the date that this registration statement
is declared effective by the SEC, the Selling Stockholders may deliver Resale Shares covered by this prospectus to close out short positions
and to return borrowed Resale Shares in connection with such short sales. The Selling Stockholders may also loan or pledge Resale Shares
to broker-dealers that in turn may sell such shares, to the extent permitted by applicable law. The Selling Stockholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
Notwithstanding the foregoing, the Selling Stockholders have been advised that they may not use Resale Shares the resale of which has
been registered on this registration statement to cover short sales of our Common Stock made prior to the date the registration statement,
of which this prospectus forms a part, has been declared effective by the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders may, from time to time, pledge or grant a security interest in some or all of the Resale Shares owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Resale Shares from time
to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities
Act, amending, if necessary, the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling
Stockholders under this prospectus. The Selling Stockholders also may transfer and donate the Resale Shares in other circumstances in
which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this
prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Selling
Stockholders and any broker-dealer or agents participating in the distribution of the Resale Shares may be deemed to be &#8220;underwriters&#8221;
within the meaning of Section 2(11) of the Securities Act in connection with such sales. In such event, any commissions paid, or any
discounts or concessions allowed to, any such broker-dealer or agent and any profit on the resale of the shares purchased by them may
be deemed to be underwriting commissions or discounts under the Securities Act. Selling Stockholders who are &#8220;underwriters&#8221;
within the meaning of Section 2(11) of the Securities Act will be subject to the applicable prospectus delivery requirements of the Securities
Act including Rule 172 thereunder and may be subject to certain statutory liabilities of, including but not limited to, Sections 11,
12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each Selling
Stockholder has informed us that it is not a registered broker-dealer and does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the Resale Shares. Upon us being notified in writing by a Selling Stockholder that
any material arrangement has been entered into with a broker-dealer for the sale of Common Stock through a block trade, special offering,
exchange distribution or secondary distribution or a purchase by a broker or dealer, a supplement to this prospectus will be filed, if
required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such Selling Stockholder and of the participating
broker-dealer(s), (ii) the number of Resale Shares involved, (iii) the price at which such the Resale Shares were sold, (iv) the commissions
paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any
investigation to verify the information set out in this prospectus, and (vi) other facts material to the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under the
securities laws of some U.S. states, the Resale Shares may be sold in such states only through registered or licensed brokers or dealers.
In addition, in some U.S. states the Resale Shares may not be sold unless such shares have been registered or qualified for sale in such
state or an exemption from registration or qualification is available and is complied with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">There can
be no assurance that any Selling Stockholder will sell any or all of the Resale Shares registered pursuant to the shelf registration
statement, of which this prospectus forms a part.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Each Selling
Stockholder and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation M of the Exchange Act, which
may limit the timing of purchases and sales of any of the Resale Shares by the Selling Stockholder and any other participating person.
To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Resale Shares to
engage in market-making activities with respect to the Resale Shares. All of the foregoing may affect the marketability of the Resale
Shares and the ability of any person or entity to engage in market-making activities with respect to the Resale Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We will pay
all expenses of the registration of the Resale Shares pursuant to the September 2024 RRA, including, without limitation, SEC filing fees
and expenses of compliance with state securities or &#8220;blue sky&#8221; laws; provided, however, that each Selling Stockholder will
pay all underwriting discounts and selling commissions, if any and any related legal expenses incurred by it. We will indemnify the Selling
Stockholders against certain liabilities, including some liabilities under the Securities Act, in accordance with the September 2024
RRA, or the Selling Stockholders will be entitled to contribution. We may be indemnified by the Selling Stockholders against certain
civil liabilities set forth in the September 2024 RRA, including liabilities under the Securities Act, that may arise from any written
information furnished to us by the Selling Stockholders specifically for use in this prospectus, in accordance with the related registration
rights agreements, or we may be entitled to contribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>DESCRIPTION
OF CAPITAL STOCK</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>General
</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The following
description summarizes the material terms of our capital stock, as well as other material terms of our amended and restated certificate
of incorporation (&#8220;Certificate of Incorporation&#8221;) and amended and restated bylaws (&#8220;Bylaws&#8221;) and certain provisions
of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Certificate of
Incorporation and Bylaws, copies of which are filed as exhibits to our Current Report on Form 8-K filed on September 5, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our authorized
capital stock consists of 545,000,000 shares of Common Stock, $0.001 par value per share, and 5,000,000 shares of preferred stock, $0.001
par value per share (&#8220;Preferred Stock&#8221;), of which 2,439 shares have been designated as Series A Preferred Stock, $0.001 par
value per share, and 251,504 shares have been designated as Series B Preferred Stock, $0.001 par value per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">As of November
1, 2024, there were 34,998,550 shares of our Common Stock, 2,439 shares of Series A Preferred Stock and 137,138 shares of Series B Preferred
Stock outstanding.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Common
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our Certificate
of Incorporation authorizes the issuance of up to 545,000,000 shares of Common Stock. All outstanding shares of Common Stock are validly
issued, fully paid and nonassessable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Dividend
rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Subject to
preferences that may apply to any shares of Preferred Stock outstanding at the time, the holders of our Common Stock are entitled to
receive dividends out of funds legally available if our Board, in its discretion, determines to issue dividends and then only at the
times and in the amounts that our Board may determine.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Voting
rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to our Bylaws, holders of our Common Stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders.
We have not provided for cumulative voting for the election of directors in our Certificate of Incorporation. Accordingly, pursuant to
our Certificate of Incorporation, holders of a majority of the shares of our Common Stock are able to elect all of our directors. Our
Certificate of Incorporation establishes a classified Board, divided into three classes with staggered three-year terms. Only one class
of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their
respective three-year terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>No preemptive
or similar rights </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Our Common
Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Right
to receive liquidation distributions </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Upon our
liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably
among the holders of our Common Stock and any participating Preferred Stock outstanding at that time, subject to prior satisfaction of
all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding
shares of Preferred Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Preferred
Stock </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Under the
terms of our Certificate of Incorporation, our Board is authorized, subject to limitations prescribed by Delaware law, to issue up to
5,000,000 shares of Preferred Stock in one or more series, to establish from time to time the number of shares to be included in each
series and to fix the designation, powers, preferences and rights of the shares of each series and any of their qualifications, limitations
or restrictions, in each case without further vote or action by our stockholders. Subject to any certificates of designation, the Board
can also increase or decrease the number of shares of any series of Preferred Stock, but not below the number of shares of that series
then outstanding, without any further vote or action by our stockholders. Our Board may authorize the issuance of Preferred Stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of our Common Stock. The issuance
of Preferred Stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other
things, have the effect of delaying, deferring or preventing a change in control of our company and might adversely affect the market
price of our Common Stock and the voting and other rights of the holders of our Common Stock. We issued shares of our Series A Preferred
Stock and shares of our Series B Preferred Stock in connection with the Private Placement and the Merger, respectively, and have no current
plan to issue any additional shares of Preferred Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Series
A Preferred Stock </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Holders of
Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series A Certificate
of Designation or as otherwise required by law, the Series A Preferred Stock does not have voting rights. However, as long as any shares
of Series A Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series A Preferred Stock: (i) alter or change adversely the powers, preferences or rights given to the Series A Preferred
Stock, (ii) alter or amend the Series A Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or its Bylaws in any manner that adversely affects any rights of the holders of Series A Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series A Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise. The Series A Preferred
Stock shall rank on parity with the Common Stock and Series B Preferred Stock upon any liquidation, dissolution or winding-up of the
Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Series
B Preferred Stock </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Certain holders
of our Series B Preferred Stock are entitled to receive dividends on shares of Series B Preferred Stock equal to, on an as-if-converted-to-common-stock
basis, and in the same form as dividends actually paid on shares of our Common Stock. Except as provided in the Series B Certificate
of Designation or as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares
of Series B Preferred Stock are outstanding, we will not, without the affirmative vote of the holders of a majority of the then outstanding
shares of the Series B Preferred Stock: (a) (i) alter or change adversely the powers, preferences or rights given to the Series B Preferred
Stock, (ii) alter or amend the Series B Certificate of Designation, or (iii) amend or repeal any provision of, or add any provision to,
our Certificate of Incorporation or Bylaws in a manner that adversely affects any rights of the holders of the Series B Preferred Stock,
or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of Preferred
Stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for
the benefit of the Series B Preferred Stock, regardless of whether any of the foregoing actions will be by means of amendment to the
Certificate of Incorporation or by merger, consolidation, recapitalization, reclassification, conversion or otherwise, (b) issue further
shares of Series B Preferred Stock beyond those contemplated for issuance in the Merger Agreement or increase or decrease (other than
by conversion) the number of authorized shares of Series B Preferred Stock, (c) at any time while at least 30% of the originally issued
Series B Preferred Stock remains issued and outstanding, consummate either: (x) any Fundamental Transaction (as defined in the Series
B Certificate of Designation) or (y) any merger or consolidation of the Company with or into another entity or any stock sale to, or
other business combination in which the stockholders of the Company immediately before such transaction do not hold at least a majority
of our capital stock immediately after such transaction, or (d) enter into any agreement with respect to any of the foregoing. The Series
B Preferred Stock shall rank on parity with the Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Series B Preferred Stock is convertible at the option of the holder, at any time, and without the payment
of additional consideration by the holder. As of September 30, 2024, each outstanding share of Series B Preferred Stock was convertible
into common stock at a ratio of approximately 83.3332:1.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Registration
Rights </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Holders of
our Series A Preferred Stock are entitled to certain rights with respect to the registration of such securities as further provided under
the heading &#8220;<i>Selling Stockholders - Registration Rights Agreement</i>.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Anti-Takeover
Provisions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The provisions
of Delaware law, our Certificate of Incorporation and our Bylaws could have the effect of delaying, deferring or discouraging another
person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover
bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our Board. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their
terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>&#160;</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>Delaware
law </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">We are subject
to the provisions of Section 203 of the DGCL regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware
corporation from engaging in a business combination with an interested stockholder for a period of three years following the date on
which the person became an interested stockholder unless:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">prior
to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
which resulted in the stockholder becoming an interested stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">upon
completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at
least 85% of the voting stock of the corporation outstanding upon consummation of the transaction, excluding for purposes of determining
the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (1) shares owned by persons who
are directors and also officers and (2) shares owned by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">at
or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized
at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding
voting stock which is not owned by the interested stockholder.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Section 203
defines a &#8220;business combination&#8221; to include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
merger or consolidation involving the corporation and the interested stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">any
sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">subject
to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested
stockholder;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">any
transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of
the corporation beneficially owned by the interested stockholder; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">the
receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided
by or through the corporation.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">In general,
Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and
associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15%
or more of the outstanding voting stock of the corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Certificate
of Incorporation and Bylaw Provisions </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Certificate
of Incorporation and our Bylaws include a number of provisions that could deter hostile takeovers or delay or prevent changes in control
of our company, including the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Board
of Directors vacancies</i></b>. Our Certificate of Incorporation and Bylaws require that the Board, and not stockholders, fill any directorships
that become vacant or are created by an increase in the authorized number of directors by the affirmative vote of a majority of the remaining
directors or by the sole remaining director. In addition, pursuant to our bylaws, the number of directors constituting our Board is permitted
to be set only by a resolution adopted by a majority vote of the entire Board. These provisions prevent a stockholder from increasing
the size of our Board and then gaining control of the Board by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of the Board but promotes continuity of management.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classified
board</i></b>. Our Certificate of Incorporation provides that our Board is classified into three classes of directors, each with staggered
three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is
more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stockholder
action; special meetings of stockholders</i></b>. Our Certificate of Incorporation and Bylaws provide that our stockholders may not take
action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling
a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our Bylaws. Further, our Bylaws provide that special meetings of stockholders may be called only by the Board,
thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force
consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal
of directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Advance
notice requirements for stockholder proposals and director nominations</i></b>. Our Bylaws provide advance notice procedures for stockholders
seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual
meeting of stockholders. Our Bylaws also specify certain requirements regarding the form and content of a stockholder&#8217;s notice.
These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations
for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might
also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors
or otherwise attempting to obtain control of our company.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>No
cumulative voting</i></b>. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors
unless a corporation&#8217;s certificate of incorporation provides otherwise. Our Certificate of Incorporation and Bylaws do not provide
for cumulative voting.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Directors
removed only for cause</i></b>. Our Bylaws provide that stockholders may remove directors only for cause, and only by the affirmative
vote of the holders of at least 66 2/3% of the voting power of the stock outstanding and entitled to vote generally in the election of
directors.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Amendment
of charter provisions</i></b>. Any amendment of the above provisions in our Certificate of Incorporation requires approval by holders
of at least two-thirds of our outstanding Common Stock.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Issuance
of Preferred Stock</i></b>. Our Board has the authority, without further action by the stockholders, to issue up to 5,000,000 shares
of Preferred Stock with rights and preferences, including voting rights, designated from time to time by our Board. The existence of
authorized but unissued shares of Preferred Stock enables our Board to render more difficult or to discourage an attempt to obtain control
of us by merger, tender offer, proxy contest or other means.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b><i>Choice
of forum</i></b>. Our Certificate of Incorporation and Bylaws provide that the Court of Chancery of the State of Delaware is the sole
and exclusive forum for any complaint asserting any internal corporate claims. In addition, our Bylaws also provide that the federal
district courts of the United States are the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act. These choice of forum provisions do not apply to claims brought to enforce a duty or liability created by the
Exchange Act.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Transfer
Agent and Registrar </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The transfer
agent and registrar for our Common Stock, Class A Preferred Stock and Class B Preferred Stock is Computershare Trust Company, N.A. The
transfer agent&#8217;s address is 150 Royall Street, Suite 101, Canton, MA 02021, and its telephone number is (800) 344-5128.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>Exchange
Listing </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Our Common
Stock is listed on The Nasdaq Global Market under the symbol &#8220;ORKA.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>LEGAL
MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Certain legal
matters, including the legality of the securities offered, has been passed upon for us by Gibson, Dunn &amp; Crutcher LLP, San Francisco,
California. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in
the applicable prospectus supplement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">The
financial statement as of February 6, 2024 included in this Prospectus has been so included
in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as
described in Note 1 to the financial statement) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given
on the authority of said firm as experts in auditing and accounting.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;&#160;</b></span></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>WHERE
YOU CAN FIND MORE INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">We are subject
to the informational requirements of the Exchange Act and are required to file annual, quarterly and other reports, proxy statements
and other information with the SEC. The SEC maintains an Internet website (http://www.sec.gov) that contains reports, proxy and information
statements, and various other information about us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Information
about us is also available at our website at http://www.orukatx.com. You may access these materials free of charge as soon as reasonably
practicable after they are electronically filed with, or furnished to, the SEC. However, the information on our website is not a part
of this prospectus and is not incorporated by reference into this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">We have filed
a registration statement on Form S-1 with the SEC relating to the securities covered by this prospectus. This prospectus is a part of
the registration statement and does not contain all of the information in the registration statement. Whenever a reference is made in
this prospectus to a contract or other document of ours, please be aware that the reference is only a summary and that you should refer
to the exhibits that are part of the registration statement for a copy of the contract or other document. You may review a copy of the
registration statement through the SEC&#8217;s website or our website.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INDEX
TO  FINANCIAL STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>As of February 6, 2024</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 90%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheet as of February&#160;6, 2024</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-indent: -10pt"><a href="#aaaa_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statement</span></a></td>
    <td style="padding-left: 10pt; text-align: center; text-indent: -10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; width: 90%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif">Period from February 6, 2024 (Inception) to September 30, 2024</td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_013"><span style="font-size: 10pt">Condensed
    Consolidated Balance Sheets</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-10</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_014"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Operations and Comprehensive Loss</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-11</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_015"><span style="font-size: 10pt">Condensed
    Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-12</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_016"><span style="font-size: 10pt">Condensed
    Consolidated Statement of Cash Flows</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-13</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif"><a href="#b_017"><span style="font-size: 10pt">Notes
    to Condensed Consolidated Financial Statements</span></a></span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-14</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p><div>



</div><!-- Field: Page; Sequence: 125; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><div><a id="aaaa_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of Oruka Therapeutics, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Opinion on the Financial Statement &#8212; Balance Sheet</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have audited the accompanying balance sheet of Oruka Therapeutics,
Inc. (the &#8220;Company&#8221;) as of February 6, 2024, including the related notes (collectively referred to as the &#8220;financial
statement&#8221;). In our opinion, the financial statement presents fairly, in all material respects, the financial position of the Company
as of February 6, 2024 in conformity with accounting principles generally accepted in the United States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Substantial Doubt about the Company&#8217;s Ability to Continue
as a Going Concern</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The accompanying financial statement has been prepared assuming that
the Company will continue as a going concern. As discussed in Note 1 to the financial statement, the Company has not generated any revenue
from product sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception,
which raises substantial doubt about its ability to continue as a going concern. Management&#8217;s plans in regard to these matters are
also described in Note 1. The financial statement does not include any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Basis for Opinion</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The financial statement is the responsibility of the Company&#8217;s
management. Our responsibility is to express an opinion on the Company&#8217;s financial statement based on our audit. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We conducted our audit of this financial statement in accordance with
the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement,
whether due to error or fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit included performing procedures to assess the risks of material
misstatement of the financial statement, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statement. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statement. We believe that our audit provides a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Critical Audit Matters</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical audit matters are matters arising from the current period
audit of the financial statement that were communicated or required to be communicated to the audit committee and that (i) relate to accounts
or disclosures that are material to the financial statement and (ii) involved our especially challenging, subjective, or complex judgments.
We determined there are no critical audit matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 13, 2024, except for the effects of the reverse stock split discussed
in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the effects of the reverse merger exchange
ratio discussed in Note 1 to the financial statement, as to which the date is November 13, 2024.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="aaaa_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ORUKA THERAPEUTICS, INC.<br/>
BALANCE SHEET<br/>
(In thousands, except share amounts)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February 6, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18.25pt">Subscription receivable</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-22659">1</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27.25pt">Total assets</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22660">1</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">Commitments and contingencies (Note 5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9.25pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9.25pt">STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 18.25pt">Series A convertible preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22661">0.001</ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22662">20,000,000</ix:nonFraction> shares authorized, <span style="-sec-ix-hidden: hidden-fact-2"><span style="-sec-ix-hidden: hidden-fact-3">no</span></span> shares issued and outstanding as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 18.25pt">Common stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22663">0.001</ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22664">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22665"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22666">3,197,975</ix:nonFraction></ix:nonFraction> issued and outstanding as of February 6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-22667">3</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 18.25pt">Additional paid-in capital</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" sign="-" unitRef="usd" id="ixv-22668">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 27.25pt">Total stockholders&#8217; equity</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22669">1</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
this financial statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="aaaa_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ORUKA THERAPEUTICS, INC.<br/>
NOTES TO FINANCIAL STATEMENT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c65_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-15142"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business and Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Background and Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or
the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded
by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain
a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory
skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company&#8217;s potential products will require
approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There
can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no
assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February 6, 2024, the Company had no cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c65_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company received $<ix:nonFraction contextRef="c66" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" unitRef="usd" id="ixv-22670">3.0</ix:nonFraction> million
in proceeds from the sale of Series A convertible preferred stock and $<ix:nonFraction contextRef="c38" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="6" unitRef="usd" id="ixv-22671">25.0</ix:nonFraction> million in proceeds from the sale of an unsecured convertible
promissory note, both of which were related party transactions (see Note 7 <i>Subsequent Events</i>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April 3, 2024,
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge
with and into Atlas Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First
Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221;
and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate
name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221;
ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Concurrent with the execution of the Merger Agreement,
the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in
a private placement financing (the &#8220;Private Placement&#8221;) shares and pre-funded warrants of the Company&#8217;s common stock
at an estimated purchase price of $<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22672">9.71</ix:nonFraction> ($<ix:nonFraction contextRef="c67" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-22673">5.55</ix:nonFraction> prior to impact of reverse stock split and reverse merger exchange ratio) per share of
common stock and estimated purchase price of $<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22674">9.70</ix:nonFraction> ($<ix:nonFraction contextRef="c68" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-22675">5.54</ix:nonFraction> prior to the impact of the reverse stock split and reverse merger exchange ratio)
per warrant for gross proceeds of approximately $<ix:nonFraction contextRef="c69" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" unitRef="usd" id="ixv-22676">275.0</ix:nonFraction> million, which will precede the closing of the Merger Agreement. Shares of the
Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private
Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock,
respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private
Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate
purposes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $<ix:nonFraction contextRef="c70" decimals="-5" format="ixt:num-dot-decimal" name="orka:TerminationFee" scale="6" unitRef="usd" id="ixv-22677">0.4</ix:nonFraction> million or Oruka could be required to pay ARCA a termination fee of $<ix:nonFraction contextRef="c65" decimals="-5" format="ixt:num-dot-decimal" name="orka:TerminationFee" scale="6" unitRef="usd" id="ixv-22678">0.4</ix:nonFraction> million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company&#8217;s financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve months from the date the financial statement is available to be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the Merger Agreement discussed
above, the Company effected a one-for-twelve reverse stock split of the Company&#8217;s issued and outstanding shares of common stock
on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Company&#8217;s
common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively
adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of <ix:nonFraction contextRef="c65" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" unitRef="pure" id="ixv-22679">6.8569</ix:nonFraction> as calculated in accordance
with the Merger Agreement for all periods presented.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-15216"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c65" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c65_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-15221"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Subscription receivable</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c65_cont_1"><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="orka:CommonStockTextBlock" id="ixv-15231"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of February 6, 2024, the Company has the authority
to issue a total of <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22680">65,000,000</ix:nonFraction> shares of common stock at a par value of $<ix:nonFraction contextRef="c71" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22681">0.001</ix:nonFraction>. As of February 6, 2024, <ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22682"><ix:nonFraction contextRef="c71" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22683">3,197,975</ix:nonFraction></ix:nonFraction> shares of common stock
were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is
available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such
holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends,
if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders
of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive
the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-15239"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Related Party Transactions</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company issued <ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22684">3,197,975</ix:nonFraction> shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately <ix:nonFraction contextRef="c72" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22685">44.7</ix:nonFraction>%, <ix:nonFraction contextRef="c73" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22686">44.7</ix:nonFraction>% and <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-22687">10.6</ix:nonFraction>%, respectively, of the Company through their common
stock holdings.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-15248"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party,
nor did the Company have knowledge of any proceedings threatened against it.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-15257"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On February 6, 2024, the Company&#8217;s Board of
Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted
stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The
Company reserved <ix:nonFraction contextRef="c75" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-22688">213,085</ix:nonFraction> shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued
under the plan.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c65" continuedAt="_SubsequentEventsTextBlock-c65_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-15266"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company evaluated all events subsequent to February
6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c65_cont_2" id="_SubsequentEventsTextBlock-c65_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In February 2024, the Company&#8217;s Board of Directors
authorized and granted <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-22689">1,184,749</ix:nonFraction> restricted stock awards at a price of $<ix:nonFraction contextRef="c76" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22690">0.0001</ix:nonFraction> per share to employees of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company&#8217;s Board of Directors
authorized and granted <ix:nonFraction contextRef="c77" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" unitRef="shares" id="ixv-22691">1,022,804</ix:nonFraction> restricted stock awards at a price of $<ix:nonFraction contextRef="c77" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22692">0.0001</ix:nonFraction> per share to consultants and a director of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 5, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
<ix:nonFraction contextRef="c78" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22693">213,085</ix:nonFraction> to <ix:nonFraction contextRef="c79" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22694">498,789</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 22, 2024, the Company granted options for
the purchase of an aggregate <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-22695">399,222</ix:nonFraction> shares of common stock, at an exercise price of $5.16 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
<ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22696">498,789</ix:nonFraction> to <ix:nonFraction contextRef="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-22697">1,179,193</ix:nonFraction>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company granted options for
the purchase of an aggregate <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-22698">779,971</ix:nonFraction> shares of common stock, at an exercise price of $6.84 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Antibody Discovery and Option Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into an Antibody
Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company
was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right, title and
interest in and to the intellectual property (&#8220;ORKA-001&#8221;) resulting from the applicable research program to develop, manufacture
and commercialize products directed at the selected target (&#8220;IL-23&#8221;), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research
initiation fee of $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitiationFee" scale="6" unitRef="usd" id="ixv-22699">0.8</ix:nonFraction> million was due to Paragon. This amount was recognized as a research and development expense during the period
ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for <ix:nonFraction contextRef="c84" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-22700">50</ix:nonFraction>% of the development costs incurred prior
to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement
is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $<ix:nonFraction contextRef="c85" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="6" unitRef="usd" id="ixv-22701">5.9</ix:nonFraction> million
of development costs incurred prior to March 31, 2024. The Company will be responsible for <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-22702">50</ix:nonFraction>% of the ORKA-001 development costs incurred
from and after March 31, 2024, through the completion of the IL-23 selection process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company also entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby
the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right,
title and interest in and to the intellectual property (&#8220;ORKA-002&#8221;) resulting from the applicable research program to develop,
manufacture and commercialize products directed at the selected target (&#8220;IL-17&#8221;). The Company was also required to reimburse
Paragon $<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="orka:ReimburseOfDevelopmentCosts" scale="6" unitRef="usd" id="ixv-22703">3.3</ix:nonFraction> million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and
development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company
paid $<ix:nonFraction contextRef="c88" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="6" unitRef="usd" id="ixv-22704">3.3</ix:nonFraction> million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January
1, 2024 to March 31, 2024 of $<ix:nonFraction contextRef="c89" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-22705">0.9</ix:nonFraction> million, which was recognized as a research and development expense in the period from February 6 (inception)
to March 31, 2024. The Company will be required to pay Paragon $<ix:nonFraction contextRef="c90" decimals="-5" format="ixt:num-dot-decimal" name="orka:ResearchInitiationFee" scale="6" unitRef="usd" id="ixv-22706">0.8</ix:nonFraction> million for the research initiation fee related to ORKA-002 within
30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of the date of issuance of the Company&#8217;s
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $<ix:nonFraction contextRef="c91" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-22707">12.0</ix:nonFraction> million upon
the achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c92" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-22708">10.0</ix:nonFraction> million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c65_cont_3" id="_SubsequentEventsTextBlock-c65_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number
of shares equal to <ix:nonFraction contextRef="c93" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-22709">1.00</ix:nonFraction>% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company issued <ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-22710">20,000,000</ix:nonFraction>
shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount&#8221;), a related party of the
Company, at a purchase price of $<ix:nonFraction contextRef="c94" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22711">0.15</ix:nonFraction> per share for gross proceeds of $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-22712">3.0</ix:nonFraction> million. The Company incurred less than $<ix:nonFraction contextRef="c95" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-22713">0.1</ix:nonFraction> million of issuance
costs in connection with this transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The holders of Series A convertible preferred stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding
shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which
the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote
on such matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Each share of Series A convertible preferred stock
is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition,
each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion
ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Company&#8217;s common stock
at a price of at least $<ix:nonFraction contextRef="c96" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22714">12.00</ix:nonFraction> per share resulting in at least $<ix:nonFraction contextRef="c84" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" unitRef="usd" id="ixv-22715">50.0</ix:nonFraction> million of gross proceeds to the Company, or (ii) the vote or written
consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The conversion ratio of Series A convertible preferred
stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue
Price is $<ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22716">0.15</ix:nonFraction> per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any
stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate
of incorporation, as amended and restated). The Conversion Price is approximately $<ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-22717">0.26</ix:nonFraction> per share for Series A convertible preferred stock
and each outstanding share of Series A Preferred Stock was convertible into common stock at a <ix:nonFraction contextRef="c94" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" unitRef="usdPershares" id="ixv-22718">0.5712</ix:nonFraction> conversion ratio.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)
in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series
A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred
stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred
stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series
A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will
share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would
otherwise be payable if it were paid in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c65_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Unless the holders of a majority in voting power
of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger
or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the
surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
Company&#8217;s assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Series A convertible preferred stock does not have
redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into a Series
A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued
a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c99" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22719">25.0</ix:nonFraction> million, that can be converted into
Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its
next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $<ix:nonFraction contextRef="c100" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" unitRef="usd" id="ixv-22720">25.0</ix:nonFraction> million. The Convertible Note will
automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse
recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues
interest at a rate of <ix:nonFraction contextRef="c100" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-22721">12.0</ix:nonFraction>% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not
permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue
additional convertible notes up to an aggregate principal amount equal to $<ix:nonFraction contextRef="c101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22722">30.0</ix:nonFraction> million, in addition to the $<ix:nonFraction contextRef="c102" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22723">25.0</ix:nonFraction> million of initial principal
amount of the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oak Grove Lease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On April 12, 2024, the Company entered into a lease
agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement
date is June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c103" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-22724">39.5</ix:nonNumeric> months. The total lease payment is expected to be $<ix:nonFraction contextRef="c104" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="6" unitRef="usd" id="ixv-22725">1.4</ix:nonFraction> million over the initial lease
term.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c65" escape="true" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="ixv-15380"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Events subsequent to the reissuance of the financial statement
(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be
reissued.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><div><a id="b_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED BALANCE SHEETS<br/>
(UNAUDITED)<br/>
(In thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">February&#160;6,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-22726">410,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">&#8212;</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="orka:SubscriptionReceivables" scale="3" unitRef="usd" id="ixv-22727">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-22728">2,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-22729">412,949</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-22730">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-22731">160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-22732">938</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd" id="ixv-22733">43</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22734">414,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-22735">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-22736">2,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22737">1,710</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating lease liability, current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-22738">146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Related party common stock warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" unitRef="usd" id="ixv-22739">7,681</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Related party accounts payable and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22740">6,357</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-22741">18,039</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability, non-current</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-22742">842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-22743">18,881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Commitment and contingencies (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding: 0 0 0 10pt; text-align: left; text-indent: -10pt">Series&#160;A convertible preferred stock, $<ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22744"><ix:nonFraction contextRef="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22745">0.0001</ix:nonFraction></ix:nonFraction> par value; <span style="-sec-ix-hidden: hidden-fact-22"><span style="-sec-ix-hidden: hidden-fact-24">no</span></span> shares and <ix:nonFraction contextRef="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22746"><ix:nonFraction contextRef="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22747">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of September&#160;30, 2024 and February&#160;6, 2024, respectively; <span style="-sec-ix-hidden: hidden-fact-23"><span style="-sec-ix-hidden: hidden-fact-25">no</span></span>&#160;shares issued and outstanding as of September 30, 2024 and February&#160;6, 2024; liquidation preference of $<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-22748"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-22749">0</ix:nonFraction></ix:nonFraction> as of September 30, 2024 and February&#160;6, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding: 0 0 0 10pt; text-align: left; text-indent: -10pt">Series A non-voting convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22750"><ix:nonFraction contextRef="c10" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22751">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-22752"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-22753">2,439</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-28"><span style="-sec-ix-hidden: hidden-fact-29">no</span></span> shares authorized as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-22754">2,439</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-27">no</span> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-22755">52,841</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Series B non-voting convertible preferred stock, $<ix:nonFraction contextRef="c11" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22756"><ix:nonFraction contextRef="c12" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22757">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22758">251,504</ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-32"><span style="-sec-ix-hidden: hidden-fact-33">no</span></span> shares authorized as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-22759"><ix:nonFraction contextRef="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22760">137,138</ix:nonFraction></ix:nonFraction> and <span style="-sec-ix-hidden: hidden-fact-31">no</span> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-22761">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22762">0.001</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22763">0.001</ix:nonFraction> par value as of September 30, 2024 and February 6, 2024, respectively; <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22764">545,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-22765">65,000,000</ix:nonFraction> shares authorized, <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22766"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22767">34,998,550</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-22768"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-22769">3,197,975</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd" id="ixv-22770">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">&#8212;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-22771">397,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-22772">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-22773">57,943</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22774">342,368</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22775">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total liabilities, convertible preferred stock and stockholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-22776">414,090</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-22777">1</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS<br/>
(UNAUDITED)<br/>
(In thousands, except share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> September&#160;30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period&#160;from <br/> February&#160;6,<br/> 2024 <br/> (Inception)&#160;to<br/> September 30, <br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Operating expenses</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="font-size: 10pt">Research and development<sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">25,691</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">49,557</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">General and administrative<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_2_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,758</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_3_fact" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">8,248</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-22782">29,449</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-22783">57,805</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22784">29,449</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22785">57,805</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-22786">1,330</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-22787">1,330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Interest expense<sup>(3)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" id="ix_4_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">504</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" id="ix_5_fact" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd">1,468</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-22790">826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-22791">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22792">28,623</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22793">57,943</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22794"><ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22795">1.46</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22796"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22797">6.08</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22798"><ix:nonFraction contextRef="c14" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22799">1,461.10</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22800"><ix:nonFraction contextRef="c15" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22801">6,077.25</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net&#160;loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22802"><ix:nonFraction contextRef="c16" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22803">121.76</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-22804"><ix:nonFraction contextRef="c17" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22805">506.44</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22806"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22807">15,013,655</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22808"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22809">7,765,381</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22810"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22811">477</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22812"><ix:nonFraction contextRef="c15" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22813">184</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22814"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22815">49,191</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22816"><ix:nonFraction contextRef="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-22817">19,015</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_0_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_1_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font-family: Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><ix:footnote id="ix_2_footnote" xml:lang="en-US"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024</span></ix:footnote></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED&#160;CONSOLIDATED STATEMENTS&#160;OF&#160;CONVERTIBLE PREFERRED&#160;STOCK&#160;AND&#160;STOCKHOLDERS&#8217;&#160;EQUITY (DEFICIT)<br/>
(UNAUDITED)<br/>
(In thousands, except share data)</b></span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    A<br/>
    Convertible Preferred Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    A<br/>
    Non-Voting<br/>
    Convertible Preferred&#160;Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Series
    B<br/>
    Non-Voting<br/>
    Convertible Preferred&#160;Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Common
    Stock</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Additional
    <br/>
    Paid-in</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Total
    <br/>
    Stockholders&#8217;<br/>
    Equity</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 9pt; text-align: center; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Capital</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Deficit</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>(Deficit)</b></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 34%; padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of February&#160;6, 2024 (inception)</b></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-36; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-37; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-38; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22818">3,197,975</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22819">3</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22820">2</ix:nonFraction>)</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-39; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22821">1</ix:nonFraction></span></td>
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-40; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-41; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-42; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-22822">2,207,553</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-22823">2</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd" id="ixv-22824">2</ix:nonFraction>)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-43; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-44; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance of Series&#160;A convertible preferred stock, net of issuance costs of $<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-22825">69</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-22826">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-22827">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-45; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-46; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-47; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-48; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-49; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-50; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-51; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-52; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22828">17</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22829">17</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22830">7,077</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22831">7,077</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of March&#160;31, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22832">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22833">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22834">5,405,528</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22835">5</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c36" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22836">13</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c37" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22837">7,077</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22838">7,059</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22839">321</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22840">321</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22841">22,243</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22842">22,243</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of June 30, 2024</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22843">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22844">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22845">5,405,528</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22846">5</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22847">334</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22848">29,320</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22849">28,981</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Exchange
    of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="INF" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" scale="0" sign="-" unitRef="shares" id="ixv-22850">20,000,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" sign="-" unitRef="usd" id="ixv-22851">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="INF" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" scale="0" unitRef="shares" id="ixv-22852">137,138</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" unitRef="usd" id="ixv-22853">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" scale="3" unitRef="usd" id="ixv-22854">2,931</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Conversion
    of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-22855">2,722,207</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22856">3</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22857">26,445</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" unitRef="usd" id="ixv-22858">26,448</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock and pre-funded warrants in the Pre-Closing Financing,</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" scale="0" unitRef="shares" id="ixv-22859">20,061,932</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22860">20</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22861">248,437</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" scale="3" unitRef="usd" id="ixv-22862">248,457</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    costs of Pre-Closing Financing and reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-88; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-89; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-90; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" scale="3" sign="-" unitRef="usd" id="ixv-22863">20,480</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-91; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" scale="3" sign="-" unitRef="usd" id="ixv-22864">20,480</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-92; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-93; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-94; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" scale="0" unitRef="shares" id="ixv-22865">1,208,883</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22866">1</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22867">4,999</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-95; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" scale="3" unitRef="usd" id="ixv-22868">5,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-96; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-22869">2,439</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22870">56,097</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-97; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" scale="0" unitRef="shares" id="ixv-22871">5,600,000</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22872">6</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22873">144,433</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-98; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" scale="3" unitRef="usd" id="ixv-22874">144,439</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    cost of PIPE Financing</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22875">3,256</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22876">8,573</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:IssuanceCostOfPIPEFinancing" scale="3" sign="-" unitRef="usd" id="ixv-22877">8,573</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock-based
    compensation expense</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22878">1,750</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" unitRef="usd" id="ixv-22879">1,750</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net loss</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-100; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-101; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-102; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-103; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22880">28,623</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22881">28,623</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Balances
    as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-104; font-family: Times New Roman, Times, Serif; font-size: 8pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22882">2,439</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22883">52,841</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22884">137,138</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22885">2,931</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-22886">34,998,550</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22887">35</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22888">397,345</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-22889">57,943</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd" id="ixv-22890">342,368</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>
</div><p style="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS<br/>
(UNAUDITED)<br/>
(In thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Period&#160;from <br/>
February&#160;6, <br/>
2024 <br/>
(Inception) to <br/>
September&#160;30, <br/>
2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt"><b>Cash flows from operating activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Net loss</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-22891">57,943</ix:nonFraction></span></td>
    <td style="width: 1%"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Depreciation expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-22892">11</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Stock-based compensation expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-22893">9,769</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash interest expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-22894">1,468</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash lease expense</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="3" unitRef="usd" id="ixv-22895">65</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 27pt; text-indent: -0.25in"><span style="font-size: 10pt">Changes in operating assets and liabilities:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Prepaid expenses and other current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" unitRef="usd" id="ixv-22896">1,980</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Other non-current assets</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitRef="usd" id="ixv-22897">43</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Accounts payable</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd" id="ixv-22898">1,621</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" unitRef="usd" id="ixv-22899">1,650</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Operating lease liability</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-22900">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 45pt; text-indent: -0.25in"><span style="font-size: 10pt">Related party accounts payable and other current liabilities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" scale="3" unitRef="usd" id="ixv-22901">6,357</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash used in operating activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-22902">39,019</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Cash flows from investing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Purchases of property and equipment</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-22903">171</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash used in investing activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd" id="ixv-22904">171</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Cash flows from financing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" scale="3" unitRef="usd" id="ixv-22905">2,931</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-22906">24,980</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from the Pre-Closing Financing, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="3" unitRef="usd" id="ixv-22907">228,127</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Proceeds from the PIPE Financing, net</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-22908">189,087</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash acquired in connection with the reverse recapitalization</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CashAssumedInConnectionWithTheReverseRecapitalization" scale="3" unitRef="usd" id="ixv-22909">4,940</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.5in; text-indent: -0.25in"><span style="font-size: 10pt">Net cash provided by financing activities</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-22910">450,065</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Net increase in cash and cash equivalents</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-22911">410,875</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash at beginning of period</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-105; font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Cash and cash equivalents at end of period</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-22912">410,875</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt"><b>Supplemental disclosure of non-cash operating and financing activities:</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Operating lease liability arising from obtaining operating right-of-use asset</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-22913">982</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Assets acquired in connection with the reverse recapitalization</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" scale="3" unitRef="usd" id="ixv-22914">114</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Other liabilities assumed in connection with the reverse recapitalization</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" scale="3" unitRef="usd" id="ixv-22915">54</ix:nonFraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-22916">150</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">PIPE Financing issuance costs included in accounts payable</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-22917">374</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">PIPE Financing issuance costs included in accrued expenses and other current liabilities</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" scale="3" unitRef="usd" id="ixv-22918">6</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash accrued interest on convertible note converted to common stock</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" scale="3" unitRef="usd" id="ixv-22919">1,468</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.25in"><span style="font-size: 10pt">Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" unitRef="usd" id="ixv-22920">2,931</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">The
accompanying notes are an integral part of these condensed consolidated financial statements.<span style="clear: both; display: block;"><br/></span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="b_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>ORUKA
THERAPEUTICS, INC.<br/>
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<br/>
(UNAUDITED)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="ixv-18338"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is an early-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing biologics to optimize the treatment of inflammatory
skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">These
condensed consolidated financial statements reflect, in the opinion of management, all adjustments of a normal and recurring nature that
are necessary for a fair statement of the Company&#8217;s financial position as of September 30, 2024, and its results of operations
for the three months ended September 30, 2024 and from February 6, 2024 (inception) to September 30, 2024, and cash flows for the period
from February 6, 2024 (inception) to September 30, 2024. The condensed balance sheet as of February 6, 2024, included in the condensed
consolidated balance sheets was derived from the Company&#8217;s audited financial statements. The condensed consolidated financial statements
and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;)
for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
results for the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024 are not
necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The condensed consolidated financial
statements include the financial statements of its wholly-owned subsidiaries. All significant intercompany balances and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024, the Company consummated the previously announced business combination (&#8220;Closing&#8221;) pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the &#8220;Merger Agreement&#8221;), by and among ARCA, Atlas Merger
Sub Corp, a wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of
ARCA (&#8220;Second Merger Sub&#8221;) and Pre-Merger Oruka, pursuant to which, among other matters, Pre-Merger Oruka merged with and
into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger
(&#8220;First Merger&#8221;) and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub
being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;).
Following consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of
the common stock, par value $<ix:nonFraction contextRef="c105" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22921">0.001</ix:nonFraction> per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September
3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September
3, 2024. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA changed its
name to &#8220;Oruka Therapeutics, Inc.&#8221; The Company is led by the Pre-Merger Oruka management team and remains focused on developing
biologics to optimize the treatment of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $<ix:nonFraction contextRef="c106" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-22922">275.0</ix:nonFraction>
million (which includes $<ix:nonFraction contextRef="c107" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" unitRef="usd" id="ixv-22923">25.0</ix:nonFraction> million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 6)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $<ix:nonFraction contextRef="c108" decimals="-5" format="ixt:num-dot-decimal" name="orka:AdditionalPaidInCapitalTransacationCost" scale="6" unitRef="usd" id="ixv-22924">20.5</ix:nonFraction> million which was recorded as a reduction to additional paid-in capital in the unaudited
condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded
warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of
Company Common Stock in accordance with the Exchange Ratio (defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2" id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the Exchange Ratio of <ix:nonFraction contextRef="c109" decimals="4" format="ixt:num-dot-decimal" name="orka:ExchangeRatio" scale="0" unitRef="pure" id="ixv-22925">6.8569</ix:nonFraction> shares of Company Common Stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock,
par value $<ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22926">0.0001</ix:nonFraction> (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior to the First Effective Time
was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $<ix:nonFraction contextRef="c111" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22927">0.001</ix:nonFraction> per
share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into shares of Company Common Stock, at a conversion ratio
of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase
shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a
warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective
Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock
shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Net loss per share for periods prior to
the close of the reverse recapitalization has been revised to reflect the exchange ratio. After applying the exchange ratio and the reverse
stock split, net loss per share for the periods from February 6, 2024 (inception) to March 31, 2024 and for three months ended June 30,
2024 and from February 6, 2024 (inception) to June 30, 2024 are $(<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22928">2.21</ix:nonFraction>), $(<ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22929">6.96</ix:nonFraction>), and $(<ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-22930">9.17</ix:nonFraction>), respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, investors in the Pre-Closing Financing received <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd" id="ixv-22931">22,784,139</ix:nonFraction> shares of Company Common
Stock in exchange for <ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="orka:CommomStockExchange" scale="0" unitRef="shares" id="ixv-22932">39,873,706</ix:nonFraction> shares of Pre-Merger Oruka Common Stock (which includes the issuance of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-22933">2,722,207</ix:nonFraction> shares of Company
Common Stock in exchange for <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="orka:CommomStockExchange" scale="0" unitRef="shares" id="ixv-22934">4,764,032</ix:nonFraction> shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="orka:PreFundedWarrantsOfCommonStockShares" scale="0" unitRef="shares" id="ixv-22935">5,522,207</ix:nonFraction> Company pre-funded warrants in exchange for <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightUnissued" scale="0" unitRef="shares" id="ixv-22936">9,664,208</ix:nonFraction> Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka&#8217;s largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger
Oruka. Additional information regarding the Merger is included in Note 3.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect
the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On September 11, 2024, the Company entered into
a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors.
The closing of the PIPE Financing occurred on September 13, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Securities Purchase Agreement, the
investors purchased an aggregate of <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="orka:NumberOfSharesPurchased" scale="0" unitRef="shares" id="ixv-22937">5,600,000</ix:nonFraction> shares of Company Common Stock at a purchase price of $<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22938">23.00</ix:nonFraction> per share, an aggregate of
<ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-22939">2,439</ix:nonFraction> shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $<ix:nonFraction contextRef="c117" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-22940">0.001</ix:nonFraction> per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $<ix:nonFraction contextRef="c119" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SupplementalDeferredPurchasePrice" scale="0" unitRef="usd" id="ixv-22941">23,000.00</ix:nonFraction> per share (each Company Series A Preferred Stock is convertible into <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-22942">1,000</ix:nonFraction>
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22943">680,000</ix:nonFraction> shares of Company Common Stock at a purchase
price of $<ix:nonFraction contextRef="c122" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22944">22.999</ix:nonFraction> per pre-funded warrant, for aggregate net proceeds of approximately $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="6" unitRef="usd" id="ixv-22945">188.7</ix:nonFraction> million (net of issuance costs of $<ix:nonFraction contextRef="c123" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="6" unitRef="usd" id="ixv-22946">11.8</ix:nonFraction> million).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_BusinessDescriptionAndBasisOfPresentationTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. The Company has incurred a net loss of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-22947">28.6</ix:nonFraction> million for the three months ended September
30, 2024 and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="6" sign="-" unitRef="usd" id="ixv-22948">57.9</ix:nonFraction>&#160;million during the period from February&#160;6, 2024 (inception) to September 30, 2024. For the period from February
6, 2024 (inception) to September 30, 2024, the Company used net cash of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="6" unitRef="usd" id="ixv-22949">39.0</ix:nonFraction> million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had cash and cash equivalents of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" unitRef="usd" id="ixv-22950">410.9</ix:nonFraction> million. The Company&#8217;s management expects that the existing
cash and cash equivalents will be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the date these
condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative
costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials
and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general
and administrative support for its operations, including the costs associated with operating as a public company. The Company&#8217;s
ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed,
the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the
commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company&#8217;s business
opportunities, as desired, which could materially harm the Company&#8217;s business, financial condition and results of operations.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-18468"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>2.
Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-18476"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk" id="ixv-18490"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_2" id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ConcentrationRiskCreditRisk-c0_cont_3" id="_ConcentrationRiskCreditRisk-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;10).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-18528"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock" id="ixv-18542"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1" escape="true" name="orka:SubscriptionReceivablePolicyTextBlock" id="ixv-18555"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_SubscriptionReceivablePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-18569"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;1
&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"/><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-18616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-18625"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_PropertyPlantAndEquipmentTextBlock-c0_cont_1"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful&#160;Life</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c124" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22951">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c125" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22952">5</ix:nonNumeric> years</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c126" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22953">3</ix:nonNumeric>-<ix:nonNumeric contextRef="c127" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-22954">5</ix:nonNumeric> years</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1" escape="true" name="orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock" id="ixv-18679"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217; equity (deficit) on the Company&#8217;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#8217; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#8217;
equity (deficit) on the Company&#8217;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1" escape="true" name="orka:NotePayableToRelatedPartyPolicyTextBlock" id="ixv-18697"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Note&#160;Payable to Related Party</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation id="orka_NotePayableToRelatedPartyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1" escape="true" name="orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" id="ixv-18707"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Contract Costs Accruals</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development
expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;),
and the Company&#8217;s related-party Paragon (see Note&#160;10).</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p></ix:continuation></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-18741"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_2" id="_LesseeLeasesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than <ix:nonNumeric contextRef="c3" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-22955">one year</ix:nonNumeric>. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c0_cont_3" id="_LesseeLeasesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-18763"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-18775"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i>&#160;</b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="ixv-18794"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_SellingGeneralAndAdministrativeExpensesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="ixv-18807"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-18839"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments
are classified.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-18872"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss per Share Attributable to Stockholders</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.</p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-18893"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure" id="ixv-22956">50</ix:nonFraction>% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-18926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November&#160;2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting</i> (<i>Topic&#160;280</i>)<i>:
Improvements to Reportable Segment Disclosures</i> (&#8220;ASU&#160;2023-07&#8221;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In December&#160;2023, the FASB issued ASU&#160;2023-09,
<i>Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</i>. This ASU expands disclosures in an entity&#8217;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November 2024, the FASB issued ASU 2024-03, <i>Income
Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.</p></ix:continuation></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-18952"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. Reverse
Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
described within the <i>Reverse Recapitalization and Pre-Closing Financing </i>section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="ixv-18965"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" unitRef="usd" id="ixv-22957">4,940</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" unitRef="usd" id="ixv-22958">114</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="3" unitRef="usd" id="ixv-22959">54</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="3" unitRef="usd" id="ixv-22960">5,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-19017"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsMeasuredOnRecurringBasisTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="ixv-19025"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<ix:continuation id="_FairValueAssetsMeasuredOnRecurringBasisTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value Measurements as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Financial assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Money market funds</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22961">403,322</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c131" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22962">403,322</ix:nonFraction></span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total financial assets</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22963">403,322</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-22964">403,322</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">There
were no transfers between Level&#160;1, Level&#160;2, or Level&#160;3 during the period from February 6, 2024 (inception) to September
30, 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="ixv-19141"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. Accrued
Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-19148"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAccruedLiabilitiesTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    employee compensation and benefits</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" unitRef="usd" id="ixv-22965">933</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional and consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-22966">204</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="orka:AccruedResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-22967">573</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" unitRef="usd" id="ixv-22968">1,710</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-19215"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>6.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible
Note&#8221;), with an initial principal amount of $<ix:nonFraction contextRef="c135" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" unitRef="usd" id="ixv-22969">25.0</ix:nonFraction> million that, at the time of issuance, could be converted into Pre-Merger Oruka
Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued
in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $<ix:nonFraction contextRef="c136" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" unitRef="usd" id="ixv-22970">25.0</ix:nonFraction>&#160;million. The
Convertible Note accrued interest at a rate of <ix:nonFraction contextRef="c137" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-22971">12.0</ix:nonFraction>% per annum. At issuance, the Convertible Note required all unpaid interest and principal
to mature on <ix:nonNumeric contextRef="c66" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-22972">December&#160;31, 2025</ix:nonNumeric> (the &#8220;Maturity Date&#8221;) and prepayment was not permitted without prior written consent
of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, <i>Derivatives and Hedging</i>, and as a result,
did not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company paid debt issuance costs of less than $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" unitRef="usd" id="ixv-22973">0.1</ix:nonFraction>&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the condensed consolidated balance sheet and were being amortized as interest
expense over the term of the Convertible Note using the effective interest method. For the three months ended September 30, 2024 and
the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized interest expenses related to the Convertible
Note of $<ix:nonFraction contextRef="c138" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-22974">0.5</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="6" unitRef="usd" id="ixv-22975">1.5</ix:nonFraction> million, respectively, which includes non-cash interest expense related to the amortization of debt issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Immediately prior to the completion of the Merger
(see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount
of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" unitRef="usd" id="ixv-22976">25.0</ix:nonFraction> million, plus unpaid accrued interest of $<ix:nonFraction contextRef="c139" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="6" unitRef="usd" id="ixv-22977">1.5</ix:nonFraction> million divided by the conversion price which was determined based upon the Company&#8217;s
fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued
upon the conversion of the Convertible Note (including accrued interest) automatically converted into <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-22978">2,722,207</ix:nonFraction> shares of Company Common
Stock. As of September 30, 2024, the Convertible Note is not outstanding.</p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PreferredStockTextBlock-c0_cont_1" escape="true" name="us-gaap:PreferredStockTextBlock" id="ixv-19252"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>7.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for <ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-22979">5,522,207</ix:nonFraction> shares of Company Common Stock at
a purchase price of approximately $<ix:nonFraction contextRef="c141" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22980">9.70</ix:nonFraction> per warrant. After the Merger, there are <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22981">5,522,207</ix:nonFraction> pre-funded warrants outstanding and are exercisable
for <ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares" id="ixv-22982">5,522,207</ix:nonFraction> shares of the Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c143" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22983">0.01</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold <ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22984">680,000</ix:nonFraction> pre-funded warrants, at a purchase price of
$<ix:nonFraction contextRef="c145" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22985">22.999</ix:nonFraction> per warrant, exercisable for <ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-22986">680,000</ix:nonFraction> shares of Company Common Stock at an exercise price of $<ix:nonFraction contextRef="c146" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22987">0.001</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-110">no</span> expiration
date. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-111">none</span> of the pre-funded warrants have been exercised and <ix:nonFraction contextRef="c147" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22988">6,202,207</ix:nonFraction> pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees, directors, and service providers immediately prior to the closing of the Merger. During
the three months ended September 30, 2024, <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-22989">3,054,358</ix:nonFraction> employee warrants were issued at an exercise price of $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-22990">7.80</ix:nonFraction> per warrant. These employee
warrants vest over a period of <ix:nonNumeric contextRef="c149" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="ixv-22991">four years</ix:nonNumeric>. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s employee
warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the
exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued
or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry
custodian. The Company recognizes compensation cost related to employee warrants on a straight-line basis over the requisite service
period, which is the period in which the related services are received. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-112">none</span> of the employee warrants have
been exercised and <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-22992">3,054,358</ix:nonFraction> employee warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, Pre-Merger Oruka issued and
sold an aggregate of <ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22993">20,000,000</ix:nonFraction> shares of Pre-Merger Oruka Series&#160;A Preferred Stock to Fairmount (see Note 13), at a purchase price
of approximately $<ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22994">0.15</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction contextRef="c152" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" unitRef="usd" id="ixv-22995">3.0</ix:nonFraction>&#160;million. Pre-Merger Oruka incurred less than $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" unitRef="usd" id="ixv-22996">0.1</ix:nonFraction>&#160;million
of issuance costs in connection with this transaction. Upon the issuance of the Pre-Merger Oruka Series&#160;A Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not
require the Company to separately account for these features.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleSharesIssuable" scale="0" unitRef="shares" id="ixv-22997">137,138</ix:nonFraction> shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares" id="ixv-22998">2,439</ix:nonFraction> shares of the Company Series
A Preferred Stock at a purchase price of $<ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-22999">23,000.00</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" id="ixv-19312"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Issued and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&#160;Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series A Non-Voting Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23000">2,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23001">2,439</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-23002">52,841</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="3" unitRef="usd" id="ixv-23003">2,439,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series B Non-Voting Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23004">251,504</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-23005">137,138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockValue" scale="3" unitRef="usd" id="ixv-23006">2,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c157" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="3" unitRef="usd" id="ixv-23007">11,428,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_PreferredStockTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Certificate of Designation of Preferences,
Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;)
filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock are entitled to receive dividends on shares of
Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis, and in the same form as, dividends actually
paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law,
the Company Series A Preferred Stock does not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company
Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Subject to the terms
and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing
will not become convertible until the Company&#8217;s stockholders approve the conversion of the Company Series A Preferred Stock into
shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the &#8220;Stockholder Approval&#8221;),
which resulted in the Company Series A Preferred Stock being classified outside of stockholders&#8217; equity (deficit) on the Company&#8217;s
condensed consolidated balance sheet.. Following the Stockholder Approval, each share of Company Series A Preferred Stock will automatically
convert into 1,000 shares of Company Common Stock, subject to certain limitations, including that shares of Company Series A Preferred
Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than
<ix:nonFraction contextRef="c155" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" unitRef="pure" id="ixv-23008">9.99</ix:nonFraction>% of the Company&#8217;s outstanding shares of Company Common Stock as of the applicable conversion date, which may be increased at
the holders&#8217; option (not to exceed <ix:nonFraction contextRef="c156" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" unitRef="pure" id="ixv-23009">19.99</ix:nonFraction>%), effective in accordance with the terms of the Series A Certificate of Designation. If,
at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series A non-voting preferred stock,
the Company fails to deliver to a holder such certificate or certificates, the Company shall, at the request of the holder, pay an amount
equal to the closing price of Company&#8217;s common stock on the trading day immediately prior to the date on which notice to conversion
is received by the Company (the &#8220;Fair Value&#8221;) of such undelivered shares, with such payment to be made within two business
days from the date of request by the holder, whereupon the Company&#8217;s obligations to deliver such shares underlying the notice of
conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request
shall be presumed to have been made by such holder if Stockholder Approval shall not have been obtained prior to the date on which the
notice of conversion is delivered to the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Certificate of Incorporation provides for <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-23010">545,000,000</ix:nonFraction> authorized shares of Company Common Stock. As of September
30, 2024, <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23011">34,988,550</ix:nonFraction> shares of Company Common Stock were issued and outstanding, including <ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-23012">2,207,553</ix:nonFraction> shares of RSAs issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="ixv-23013">As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-23014">2,439,000</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series B Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c159" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-23015">11,428,149</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon
    exercise of pre-funded warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="orka:SharesIssuableUponExerciseOfPrefundedWarrants" scale="0" unitRef="shares" id="ixv-23016">6,202,207</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued stock options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-23017">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued employee warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-23018">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Stock Incentive Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c160" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-23019">4,526,324</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Employee Stock Purchase Plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-23020">463,489</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c161" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares" id="ixv-23021">29,401,287</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-19525"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>8.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options
have been granted with vesting terms less than four&#160;years. As of September 30, 2024, there are no shares of common stock available
for issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:nonNumeric><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is <ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23022">4,634,891</ix:nonFraction> shares
of Company Common Stock and as of September 30, 2024, there are <ix:nonFraction contextRef="c163" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-23023">4,526,324</ix:nonFraction> shares available in the pool. The shares that may be issued
under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase
on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-23024">5</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded
warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective
employees, officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible
to participate in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was approved by the board of directors of ARCA on July 20, 2024, and by ARCA&#8217;s
stockholders on August 22, 2024. The ESPP became effective on August 29, 2024, at which time <ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" unitRef="shares" id="ixv-23025">463,489</ix:nonFraction> shares were reserved for issuance.
The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" unitRef="pure" id="ixv-23026">1</ix:nonFraction>% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee.
As of September 30, 2024, no shares have been issued out of the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock-c0_cont_1" escape="true" name="orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" id="ixv-19592"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three<br/> Months Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from <br/> February&#160;6,<br/> 2024 <br/> (Inception)<br/> to <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c176" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19636"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c177" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-19645"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23027">97.3</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23028">101.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c176" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23029">3.5</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c177" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23030">4.3</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-19715"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Stock Options</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-23031">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23032">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-23033">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23034">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-19935"><span style="font-family: Times New Roman, Times, Serif">9.6</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" unitRef="usd" id="ixv-23035">21,507</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares" id="ixv-23036">1,287,760</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-23037">7.97</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-19971"><span style="font-family: Times New Roman, Times, Serif">9.6</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" unitRef="usd" id="ixv-23038">21,507</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
September 30, 2024 was $<ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23039">6.44</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
February 2024 and March&#160;2024, the Company issued <ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-23040">2,207,553</ix:nonFraction> shares of RSAs to certain employees, directors, and consultants at a
price of $<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" unitRef="usdPershares" id="ixv-23041">0.0001</ix:nonFraction> per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="ixv-20052"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of<br/> RSAs</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
                                            Average<br/> Grant Date<br/> Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested balance
    as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c179" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-23042">2,207,553</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested
    balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c180" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" unitRef="shares" id="ixv-23043">2,207,553</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Option
Agreements and Paruka Warrant Obligation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, the Company entered into antibody
discovery and option agreements with Paragon and Paruka (the &#8220;Option Agreements&#8221;). Under the terms of Option Agreements, Paragon
identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company,
and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license
to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program
to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants
of warrants to purchase a number of shares equal to <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="orka:SharesOutstandingPercentage" scale="-2" unitRef="pure" id="ixv-23044">1.00</ix:nonFraction>% of then outstanding shares of the Company&#8217;s stock, on a fully diluted
basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board (the &#8220;Paruka Warrant
Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for
the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after
the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As
of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $<ix:nonFraction contextRef="c168" decimals="-5" format="ixt:num-dot-decimal" name="orka:EstimatedFairValueOfWarrantsToBeGranted" scale="6" unitRef="usd" id="ixv-23045">11.0</ix:nonFraction> million. For the three months
ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $<ix:nonFraction contextRef="c169" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23046">7.3</ix:nonFraction> million and $<ix:nonFraction contextRef="c170" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23047">7.7</ix:nonFraction> million were recognized
as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As stated above, on July 3, 2024, the Subscription
Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Oruka&#8217;s employees,
directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months
ended September 30, 2024, the Company issued <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-23048">3,054,358</ix:nonFraction> employee warrants at an exercise price of $<ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-23049">7.80</ix:nonFraction> per warrant, which are accounted
as equity in the condensed consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock-c0_cont_1" escape="true" name="orka:ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" id="ixv-23050">The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Warrants</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-23051">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23052">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-23053">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23054">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" id="ixv-20381"><span style="font-family: Times New Roman, Times, Serif">9.8</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" unitRef="usd" id="ixv-23055">51,038</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-23056">3,054,358</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23057">7.80</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" id="ixv-20417"><span style="font-family: Times New Roman, Times, Serif">9.8</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="3" unitRef="usd" id="ixv-23058">51,038</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table></ix:continuation>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of employee warrants granted during the period from February&#160;6, 2024 (inception)
to September 30, 2024 was $<ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-23059">6.27</ix:nonFraction> per share. Aggregate intrinsic value represents the difference between the estimated fair value of the
underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-20487"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from<br/> February&#160;6,<br/> 2024<br/> (Inception) <br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c13" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20530"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-20539"><span style="font-family: Times New Roman, Times, Serif">6.1</span></ix:nonNumeric></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23060">99.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-23061">99.0</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23062">4.2</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-23063">4.2</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-20609"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#8239;Months
                                            Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23064">7,772</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c182" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23065">8,310</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23066">1,229</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c184" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23067">1,459</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23068">9,001</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-23069">9,769</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $<ix:nonFraction contextRef="c172" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23070">7.5</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of approximately <ix:nonNumeric contextRef="c173" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23071">3.4</ix:nonNumeric> years. As of September 30, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $<ix:nonFraction contextRef="c174" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23072">0.1</ix:nonFraction> million, which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c167" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23073">3.4</ix:nonNumeric>
years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $<ix:nonFraction contextRef="c175" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" unitRef="usd" id="ixv-23074">17.8</ix:nonFraction> million, which is expected
to be recognized over a weighted average period of <ix:nonNumeric contextRef="c171" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-23075">3.6</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="ixv-23076">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months
                                            Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka
    warrant obligation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:ParukaWarrantObligation" scale="3" unitRef="usd" id="ixv-23077">7,251</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:ParukaWarrantObligation" scale="3" unitRef="usd" id="ixv-23078">7,681</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee
    warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:EmployeeWarrants" scale="3" unitRef="usd" id="ixv-23079">1,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:EmployeeWarrants" scale="3" unitRef="usd" id="ixv-23080">1,314</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" sign="-" unitRef="usd" id="ixv-23081">427</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" sign="-" unitRef="usd" id="ixv-23082">765</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee
    stock purchase plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23083">9</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23084">9</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23085">9,001</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-23086">9,769</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-20841"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>9.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c185" decimals="0" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd" id="ixv-23087">No</ix:nonFraction>
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of February&#160;6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as
the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated
to date.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="orka_OptionAgreementsTextBlock-c0_cont_1" escape="true" name="orka:OptionAgreementsTextBlock" id="ixv-20868"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>10.
Option Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon
identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company.
The Option Agreements include two selected targets, IL-23 (&#8220;ORKA-001&#8221;) and IL-17 A/F (&#8220;ORKA-002&#8221;). Under the
Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;),
with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will
be required to make non-refundable milestone payments to Paragon of up to $<ix:nonFraction contextRef="c186" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-23088">12.0</ix:nonFraction>&#160;million under each respective agreement upon the
achievement of certain clinical development milestones, up to $<ix:nonFraction contextRef="c187" decimals="-5" format="ixt:num-dot-decimal" name="orka:NonRefundableMilestonePayments" scale="6" unitRef="usd" id="ixv-23089">10.0</ix:nonFraction>&#160;million under each respective agreement upon the achievement
of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial
sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s exclusive Option with respect to each research program for a particular target initiated by the parties (&#8220;Research
Program&#8221;) is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the
associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than
ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect
to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There
is no payment due upon exercise of an Option pursuant to the Option Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the
expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed
extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration
of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then-existing Research Programs, under
the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements
or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the
Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a
Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its
affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise
delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program
upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day
period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="6" unitRef="usd" id="ixv-23090">0.8</ix:nonFraction>&#160;million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In
June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for
IL-23 antibody for ORKA-001 program. The Company was responsible for <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="orka:DevelopmentCostsPercentage" scale="-2" unitRef="pure" id="ixv-23091">50</ix:nonFraction>% of the development costs incurred through the completion of the
IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months
ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $<ix:nonFraction contextRef="c188" decimals="-5" format="ixt:num-dot-decimal" name="orka:MilestonePayment" scale="6" unitRef="usd" id="ixv-23092">1.5</ix:nonFraction> million milestone payment related to the achievement
of development candidate as research and development expense in the Company&#8217;s condensed consolidated statements of operations and
comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September
30, 2024. The Company&#8217;s share of development costs incurred during the three months ended September 30, 3024 and for the period
from February 6, 2024 (inception) to September 30, 2024 was $<ix:nonFraction contextRef="c183" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23093">0.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c184" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23094">13.2</ix:nonFraction> million, respectively, which were recorded as research
and development expenses during the respective periods. An amount of $<ix:nonFraction contextRef="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="6" unitRef="usd" id="ixv-23095">2.3</ix:nonFraction> million is included in related party accounts payable and other
current liabilities as of September 30, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company was also required to reimburse Paragon
$<ix:nonFraction contextRef="c87" decimals="-5" format="ixt:num-dot-decimal" name="orka:OtherDevelopmentCost" scale="6" unitRef="usd" id="ixv-23096">3.3</ix:nonFraction>&#160;million for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development
costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. The Company
is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection
process. The Company recognized an amount of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="6" unitRef="usd" id="ixv-23097">0.8</ix:nonFraction>&#160;million payable to Paragon for the research initiation fee related to ORKA-002
following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from
February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $<ix:nonFraction contextRef="c181" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23098">3.8</ix:nonFraction> million and $<ix:nonFraction contextRef="c182" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" unitRef="usd" id="ixv-23099">6.6</ix:nonFraction> million during
the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as
research and development expenses during the respective periods. An amount of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" scale="6" unitRef="usd" id="ixv-23100">3.8</ix:nonFraction> million is included in related party accounts payable
and other current liabilities as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p></ix:nonNumeric><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:continuation id="orka_OptionAgreementsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number
of shares equal to <ix:nonFraction contextRef="c189" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-23101"><ix:nonFraction contextRef="c190" decimals="4" format="ixt:num-dot-decimal" name="orka:PercentageOfWarrantPurchare" scale="-2" unitRef="pure" id="ixv-23102">1.00</ix:nonFraction></ix:nonFraction>% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the
fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition,
the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note&#160;8) as stock-based compensation expenses under research and development
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized
$<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-23103">13.4</ix:nonFraction> million and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="6" unitRef="usd" id="ixv-23104">33.8</ix:nonFraction> million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-20926"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>11.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of <ix:nonNumeric contextRef="c191" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="ixv-23105">39.5</ix:nonNumeric> months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had $<ix:nonFraction contextRef="c192" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" unitRef="usd" id="ixv-23106">0.9</ix:nonFraction> million of operating lease right-of-use assets, operating lease liability, current of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" unitRef="usd" id="ixv-23107">0.1</ix:nonFraction>
million, and operating lease liability, noncurrent of $<ix:nonFraction contextRef="c3" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" unitRef="usd" id="ixv-23108">0.8</ix:nonFraction> million on its condensed consolidated balance sheets. As of September 30,
2024, the operating lease arrangement had a remaining lease term of <ix:nonNumeric contextRef="c3" format="ixt-sec:durmonth" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-23109">36.0</ix:nonNumeric> months and a discount rate of <ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" unitRef="pure" id="ixv-23110">17.95</ix:nonFraction>%. For the three months ended
September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable
lease expense of $<ix:nonFraction contextRef="c13" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-23111">0.1</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseVariableLeaseIncome" scale="6" unitRef="usd" id="ixv-23112">0.2</ix:nonFraction> million, respectively, in general and administrative expenses in its condensed consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="ixv-20946"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<ix:continuation id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September
    30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for amounts included in the measurement of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    cash flow from operating leases</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-23113">74</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-23114">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    year ending December 31,</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%"><span style="font-family: Times New Roman, Times, Serif">2024
    (remainder)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" unitRef="usd" id="ixv-23115">63</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-23116">369</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd" id="ixv-23117">494</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd" id="ixv-23118">380</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    undiscounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-23119">1,306</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-23120">318</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    discounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-23121">988</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-23122">146</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-23123">842</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EarningsPerShareTextBlock" id="ixv-21131"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>12.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="ixv-23124">Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):</ix:nonNumeric>&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2" id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Shares<br/>
 Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Shares Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23125">21,936</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23126">15,013,655</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c13" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23127">1.46</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23128">47,192</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23129">7,765,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23130">6.08</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series A Preferred Stock<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23131">697</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c193" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23132">477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23133">1,460.62</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23134">1,121</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c120" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23135">184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c120" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23136">6,077.13</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series B Preferred Stock<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c194" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23137">5,990</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c194" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23138">49,191</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction contextRef="c194" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23139">121.77</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c195" decimals="-3" format="ixt:num-dot-decimal" name="orka:CommonStockLossAllocation" scale="3" sign="-" unitRef="usd" id="ixv-23140">9,630</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c195" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-23141">19,015</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(<ix:nonFraction contextRef="c195" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-23142">506.44</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-23143">28,623</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-23144">57,943</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation continuedAt="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_3" id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23145">477,196</ix:nonFraction> and <ix:nonFraction contextRef="c120" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23146">184,462</ix:nonFraction> for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was <ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23147">4,099,227</ix:nonFraction> and <ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" scale="0" unitRef="shares" id="ixv-23148">1,584,575</ix:nonFraction> for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">For the computation of basic net loss per share
attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock
as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding
includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-23149">The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:</ix:nonNumeric>&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c196" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23150">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c197" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23151">3,054,358</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c198" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23152">2,207,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c199" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23153">2,207,553</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23154">1,287,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c201" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23155">1,287,760</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23156">6,549,671</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-23157">6,549,671</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-21382"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>13.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
and Paruka each beneficially own less than <ix:nonFraction contextRef="c202" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23158">5</ix:nonFraction>% of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Fairmount beneficially owns more than <ix:nonFraction contextRef="c203" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23159">5</ix:nonFraction>% of the
Company&#8217;s capital, currently has one representative appointed to the Board, and beneficially owns more than <ix:nonFraction contextRef="c204" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" unitRef="pure" id="ixv-23160">5</ix:nonFraction>% of Paragon. Fairmount
appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1" escape="true" name="srt:ScheduleOfCondensedFinancialStatementsTableTextBlock" id="ixv-23161">The
following is a summary of related party accounts payable and other current liabilities (in thousands):</ix:nonNumeric>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<ix:continuation id="_ScheduleOfCondensedFinancialStatementsTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable Option Agreements&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c205" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23162">6,140</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable other research expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c206" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23163">146</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable patent expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c207" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23164">71</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" unitRef="usd" id="ixv-23165">6,357</ix:nonFraction></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>INFORMATION
NOT REQUIRED IN PROSPECTUS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;13.
Other Expenses of Issuance and Distribution </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The expenses
payable by us in connection with the issuance and distribution of the securities being registered hereunder on Form S-1 (other than underwriting
discounts and commissions, if any) are set forth below. The Selling Stockholders will not bear any portion of such expenses. Each item
listed is estimated, except for the SEC registration fee:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
    registration fee</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33,913</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing
    and engraving</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
    fees and expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"/></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting
    fees and expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous
    expenses</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,087</span></td><td style="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">170,000</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;14.
Indemnification of Officers and Directors </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Section 145
of the DGCL authorizes a court to award, or a corporation&#8217;s board of directors to grant, indemnity to directors and officers under
certain circumstances and subject to certain limitations. The terms of Section 145 of the DGCL are sufficiently broad to permit indemnification
under certain circumstances for liabilities, including reimbursement of expenses incurred, arising under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As permitted
by the DGCL, the Registrant&#8217;s Certificate of Incorporation contains provisions that eliminate the personal liability of its directors
for monetary damages for any breach of fiduciary duties as a director, except liability for the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            breach of the director&#8217;s duty of loyalty to the Registrant or its stockholders;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">acts
                                            or omissions not in good faith or that involve intentional misconduct or a knowing violation
                                            of law;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">under
                                            Section 174 of the DGCL (regarding unlawful dividends and stock purchases); or</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            transaction from which the director derived an improper personal benefit.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">As permitted
by the DGCL, the Registrant&#8217;s Bylaws provide that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant is required to indemnify its directors and executive officers to the fullest extent
                                            permitted by the DGCL, subject to very limited exceptions;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant may indemnify its other employees and agents as set forth in the DGCL;</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Registrant is required to advance expenses, as incurred, to its directors and executive officers
                                            in connection with a legal proceeding to the fullest extent permitted by the DGCL, subject
                                            to very limited exceptions; and</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&#9679;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            rights conferred in the Bylaws are not exclusive.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 155; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Registrant
has entered, and intends to continue to enter, into separate indemnification agreements with its directors and executive officers to
provide these directors and executive officers additional contractual assurances regarding the scope of the indemnification set forth
in the Registrant&#8217;s Certificate of Incorporation and Bylaws and to provide additional procedural protections. At present, there
is no pending litigation or proceeding involving a director or executive officer of the Registrant regarding which indemnification is
sought.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The indemnification
provisions in the Registrant&#8217;s Certificate of Incorporation, Bylaws and the indemnification agreements entered into or to be entered
into between the Registrant and each of its directors and executive officers may be sufficiently broad to permit indemnification of the
Registrant&#8217;s directors and executive officers for liabilities arising under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The Registrant
currently carries liability insurance for its directors and officers. One of the Registrant&#8217;s directors, Peter Harwin, is also
indemnified by his employer with regard to their service on the Registrant&#8217;s board of directors.</span></p><div>

</div><p style="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;15.
Recent Sales of Unregistered Securities </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On September
13, 2024, we completed the Private Placement of Private Placement Common Shares, Private Placement Conversion Shares and Pre-Funded Warrants
pursuant to the SPA with the Selling Stockholders in the September 2024 PIPE. We sold an aggregate of 5,600,000 shares of Common Stock,
2,439 shares of our Series A Preferred Stock and pre-funded warrants to purchase 680,000 shares of Common Stock in the September 2024
PIPE for an aggregate purchase price of approximately $200.5 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Subject to
stockholder approval and certain beneficial ownership limitations, each share of Series A Preferred Stock is convertible into 1,000 shares
of Common Stock. Shares of Series A Preferred Stock shall not be convertible if the conversion would result in a holder, together with
its affiliates, beneficially owning more than 9.99% of our outstanding shares of Common Stock as of the applicable conversion date, which
may be increased at the holders&#8217; option (not to exceed 19.99%), effective in accordance with the terms of our Series A Certificate
of Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The shares
issued pursuant to the September 2024 PIPE were offered and sold in transactions exempt from registration under the Securities Act, in
reliance on Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. Each of the investors represented that it was an &#8220;accredited
investor,&#8221; as defined in Regulation D, and acquired the securities for investment only and not with a view towards, or for resale
in connection with, the public sale or distribution thereof. The shares of Series A Preferred Stock issued pursuant to the September
2024 PIPE have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities Act and any applicable state securities laws.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;16.
Exhibits and Financial Statement Schedules </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT<br/>
    NUMBER</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION
    OF EXHIBIT</b></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex21.htm">Agreement
    and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas
    Merger Sub II, LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of ARCA biopharma, Inc.&#8217;s Form 8-K
    filed on April 3, 2024, File No. 000-22873).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-5_oruka.htm">Amended
    and Restated Certificate of Incorporation of the Company, filed September 3, 2024 (incorporated by reference to Exhibit 3.5 to the
    Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-6_oruka.htm">Amended
    and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.6 to the Registrant&#8217;s Current Report on Form 8-K
    filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex3-1_oruka.htm">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex3-9_oruka.htm">Form
    of Certificate of Designation of Preferences, Rights and Limitations of Series&#160;B Non-Voting Convertible Preferred Stock (incorporated
    by reference to Exhibit 3.9 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-2_oruka.htm">Form
    of Registration Rights Agreement, dated as of September 13, 2024 (incorporated by reference to Exhibit 10.2 to the
    Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex10-1_oruka.htm">Securities
    Purchase Agreement, dated September 11, 2024, by and between Oruka Therapeutics, Inc. and each purchaser identified on Annex A thereto
    (incorporated by reference to Exhibit 10.1 the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 13,
    2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024078549/ea021443901ex4-1_oruka.htm">Form
    of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the
    SEC on September 13, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><a href="ea022056701ex5-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Gibson, Dunn &amp; Crutcher LLP.</span></a></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1*
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex101.htm">Form
    of Oruka Support Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form&#160;8-K filed on April&#160;3,
    2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex102.htm">Form
    of Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April
    3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-1_arcabio.htm">Form
    of Amendment to Oruka Subscription Agreement (incorporated by reference to Exhibit 10.1 to ARCA biopharma, Inc&#8217;s Form 8-K filed
    on July 9, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4*&#8224;
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024060156/ea020913401ex10-2_arcabio.htm">Form
    of Amended &amp; Restated Oruka Subscription Agreement (incorporated by reference to Exhibit 10.2 to ARCA biopharma, Inc&#8217;s
    Form 8-K filed on July 9, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top">10.5*</td>
    <td style="font-family: Times New Roman, Times, Serif">&#160;</td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><a href="https://www.sec.gov/Archives/edgar/data/907654/000121390024097443/ea021692901ex10-4_oruka.htm">Form of Registration Rights Agreement, dated as of August 29, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2024).</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex103.htm">Form
    of ACRA Support Agreement (incorporated by reference to Exhibit 10.3 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7*
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000119312524085437/d794675dex104.htm">Form
    of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to ARCA biopharma, Inc&#8217;s Form 8-K filed on April 3, 2024).</a></span></td>
    </tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8*&#8224;&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_1.htm">Separation
    Agreement and Release, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference
    to Exhibit 10.1 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9*&#8224;&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000095017024041846/abio-ex10_2.htm">Consulting
    Agreement, by and between ARCA biopharma, Inc. and Michael Bristow, dated as of April 3, 2024 (incorporated by reference to Exhibit
    10.2 of ARCA biopharma, Inc.&#8217;s Form 8-K filed on April 4, 2024).</a></span></td></tr>
</table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-45_arcabio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement between Oruka Therapeutics, Inc. and its directors and officers (incorporated by reference to Exhibit
    10.45 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-10_oruka.htm">Oruka
    Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 to the Registrant&#8217;s Current Report
    on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-11_oruka.htm">Oruka
    Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Current
    Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-40_arcabio.htm">Amended
    and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, as amended by the First Amendment dated May 7, 2024 (incorporated
    by reference to Exhibit 10.40 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14*#
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-13_oruka.htm">Second Amendment to Amended and Restated Oruka Therapeutics, Inc. 2024 Equity Incentive Plan, effective as of May 7, 2024 (incorporated by reference to Exhibit 10.13 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).&#160;</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*#
    &#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-41_arcabio.htm">Form
    of Restricted Stock Notice and Restricted Stock Purchase Agreement (incorporated by reference to Exhibit 10.41 to ARCA biopharma,
    Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 91%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-42_arcabio.htm">Form
    of Stock Option Agreement under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.42 to
    ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 91%"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-16_oruka.htm">Form of Employee Warrant Agreement (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-43_arcabio.htm">Amended
    and Restated Director Offer Letter, dated March&#160;22, 2024, between Oruka Therapeutics, Inc. and Samarth Kulkarni (incorporated
    by reference to Exhibit 10.43 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-44_arcabio.htm">Director
    Offer Letter, dated April&#160;24, 2024, between Oruka Therapeutics, Inc. and Kristine Ball (incorporated by reference to Exhibit
    10.44 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-1_oruka.htm">Amended
    and Restated Employment Offer Letter by and between Oruka Therapeutics, Inc. and Lawrence Klein<span style="text-decoration: none">,
    dated as of October 3, 2024</span> (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K
    filed with the SEC on October 4, 2024<span style="text-decoration: none">, File No. 241354944</span>).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea021674601ex10-2_oruka.htm">Amended
    and Restated Employment Letter Agreement by and between the Company and Arjun Agarwal, dated as of October 3, 2024 (incorporated
    by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on October 4, 2024, File No.
    241354944).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-48_arcabio.htm">Employment
    Offer Letter, dated March 15, 2024, by and between Oruka Therapeutics, Inc. and Joana Goncalves (incorporated by reference to Exhibit
    10.48 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23*#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024042529/ea020512201ex10-49_arcabio.htm">Employment
    Offer Letter, dated April&#160;12, 2024, by and between Oruka Therapeutics, Inc. and Paul Quinlan (incorporated by reference to Exhibit
    10.49 to ARCA biopharma, Inc.&#8217;s Form S-4, filed on May 14, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-50_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-17), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.50 to ARCA biopharma, Inc.&#8217;s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).</a></span></td></tr>
</table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25*&#8224;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024053881/ea020512202ex10-51_arcabio.htm">Amended
    and Restated Antibody Discovery and Option Agreement (IL-23), dated March&#160;28, 2024, by and among Paragon Therapeutics, Inc.,
    Paruka Holding LLC and Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 10.51 to ARCA biopharma, Inc.&#8217;s Form
    S-4/A, filed on June 18, 2024, File No. 333-279387).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26*&#8224;#</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex10-25_oruka.htm">Consulting
    Agreement, effective as of August 30, 2024, by and between Oruka Therapeutics, Inc. and Jeff Dekker (incorporated by reference to
    Exhibit 10.25 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>

<tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex16-1_oruka.htm">Letter
    from KPMG LLP, dated September 5, 2024 (incorporated by reference to Exhibit 16.1 to the Registrant&#8217;s Current Report on Form
    8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/907654/000121390024076184/ea021319301ex21-1_oruka.htm">List
    of Subsidiaries of Oruka Therapeutics, Inc (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Current Report on
    Form 8-K filed with the SEC on September 5, 2024).</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex23-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of PricewaterhouseCoopers LLP</span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex5-1_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Gibson, Dunn &amp; Crutcher LLP (included in Exhibit 5.1) </span></a></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#d_001">Power of Attorney (included on the signature page to the registration statement)</a></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Labels Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; ">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><a href="ea022056701ex-fee_oruka.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table. </span></a></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
                                            filed.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
                                            management contract or compensatory plan.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
                                            and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant
                                            hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules
                                            upon request by the SEC; provided, however, that the registrant may request confidential
                                            treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so
                                            furnished. Certain portions of this exhibit (indicated by &#8220;[***]&#8221;) have been
                                            omitted because they are both (i) not material and (ii) is the type of information that the
                                            registrant both customarily and actually treats as private and confidential.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0pt; width: 100%"><tr style="font-family: Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<td style="font-family: Times New Roman, Times, Serif; width: 0.25in"/><td style="font-family: Times New Roman, Times, Serif; width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)</b></span></td><td style="font-family: Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
                                            statement schedules</b></span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item&#8201;17.
Undertakings </b></span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(a) The undersigned
Registrant hereby undertakes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(1) To file,
during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(i) to include
any prospectus required by Section 10(a)(3) of the Securities Act;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(ii) to reflect
in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and
price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Filing Fee Table&#8221;
in the effective registration statement; and</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(iii) to
include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any
material change to such information in the registration statement;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(2) That,
for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial <i>bona fide</i> offering thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(3) To remove
from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">(4) That,
for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as
part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses
filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. <i>Provided, however</i>, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is
part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify
any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such
document immediately prior to such date of first use.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of
the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a
director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted
by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question
whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue. </span><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="d_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act, the Registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Menlo Park, California, on November 13, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ORUKA
    THERAPEUTICS, INC.</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table><div>

</div><p style="font-family: Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and
on the dates indicated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Lawrence Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer &amp; Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lawrence
    Klein</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Arjun Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Vice President, Finance and Treasurer </span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arjun
    Agarwal</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial Officer and Principal Accounting Officer)</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Samarth Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samarth
    Kulkarni</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Kristine Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristine
    Ball</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Carl Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carl
    Dambkowski</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Peter Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Peter
    Harwin</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Cameron Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">November
    13, 2024</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cameron
    Turtle</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">II-7</span></p><div>

</div><!-- Field: Rule-Page --><div style="font-family: Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c1" id="hidden-fact-0" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-2" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-5" name="orka:SubscriptionReceivables" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-7" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-8" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-9" name="us-gaap:OtherAssetsNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-10" name="us-gaap:AccountsPayableCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-11" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-12" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c6" id="hidden-fact-13" name="us-gaap:WarrantsAndRightsOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-14" name="us-gaap:OtherLiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-15" name="us-gaap:LiabilitiesCurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-16" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-17" name="us-gaap:Liabilities" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-18" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-19" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-20" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-21" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-22" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-23" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c7" id="hidden-fact-24" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c8" id="hidden-fact-25" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-26" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-27" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-28" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c10" id="hidden-fact-29" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-30" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-31" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-32" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c12" id="hidden-fact-33" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c4" id="hidden-fact-35" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c18" id="hidden-fact-36" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c19" id="hidden-fact-37" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c20" id="hidden-fact-38" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c23" id="hidden-fact-39" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-40" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-48" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-49" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c31" id="hidden-fact-50" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-51" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-52" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-53" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-54" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c30" id="hidden-fact-55" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c25" id="hidden-fact-56" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c26" id="hidden-fact-57" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c27" id="hidden-fact-58" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c28" id="hidden-fact-59" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c29" id="hidden-fact-60" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c33" id="hidden-fact-61" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c34" id="hidden-fact-62" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-63" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-64" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-65" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-66" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c44" id="hidden-fact-67" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c39" id="hidden-fact-68" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c40" id="hidden-fact-69" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c41" id="hidden-fact-70" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c42" id="hidden-fact-71" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c43" id="hidden-fact-72" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c47" id="hidden-fact-73" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c48" id="hidden-fact-74" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-75" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-76" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-77" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-78" name="orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-79" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-80" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-81" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-82" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-83" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-84" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-85" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-86" name="orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-87" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-88" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-89" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-90" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-91" name="orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-92" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-93" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-94" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-95" name="orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-96" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-97" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c58" id="hidden-fact-98" name="orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c53" id="hidden-fact-99" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c54" id="hidden-fact-100" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c55" id="hidden-fact-101" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c56" id="hidden-fact-102" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c57" id="hidden-fact-103" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c59" id="hidden-fact-104" name="us-gaap:StockholdersEquity" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-105" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c129" id="hidden-fact-106" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c130" id="hidden-fact-107" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c133" id="hidden-fact-108" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c134" id="hidden-fact-109" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-110" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-111" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c149" id="hidden-fact-112" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c176" id="hidden-fact-113" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c177" id="hidden-fact-114" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-115" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-116" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-117" name="orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-118" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-119" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-125" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c3" id="hidden-fact-126" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" id="hidden-fact-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c178" id="hidden-fact-128" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c179" id="hidden-fact-129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c180" id="hidden-fact-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-131" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-132" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-133" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xsi:nil="true"/>
<ix:nonFraction contextRef="c24" id="hidden-fact-134" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-135" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-136" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-137" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-138" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-139" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" unitRef="shares" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-140" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" id="hidden-fact-141" name="orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" unitRef="usd" xsi:nil="true"/>
<ix:nonFraction contextRef="c13" id="hidden-fact-143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonFraction contextRef="c0" id="hidden-fact-144" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="pure" xsi:nil="true"/>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-23313">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-23314">0000907654</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="orka-20240930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship xmlns="" fromRefs="ix_0_fact ix_1_fact" toRefs="ix_0_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_2_fact ix_3_fact" toRefs="ix_1_footnote"/>
<ix:relationship xmlns="" fromRefs="ix_4_fact ix_5_fact" toRefs="ix_2_footnote"/>
<xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:LegalEntityAxis">orka:ARCABIOPHARMAINCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParukaHoldingLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:OrukaAdvisorsLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-22</xbrli:startDate>
    <xbrli:endDate>2024-03-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-07</xbrli:startDate>
    <xbrli:endDate>2024-03-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-30</xbrli:startDate>
    <xbrli:endDate>2024-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-02-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9J5sz1W2sd2giB9Oo7QhM7subWFWiWJSPg=] CSR-->
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-06</xbrli:startDate>
    <xbrli:endDate>2024-03-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-12</xbrli:startDate>
    <xbrli:endDate>2024-04-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaPrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-03</xbrli:startDate>
    <xbrli:endDate>2024-04-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaRestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-01</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-31</xbrli:startDate>
    <xbrli:endDate>2024-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-31</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-29</xbrli:startDate>
    <xbrli:endDate>2024-08-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-02-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-30</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-03-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-12-31</xbrli:startDate>
    <xbrli:endDate>2025-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-06-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-02-06</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0000907654</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea022056701ex5-1_oruka.htm
<DESCRIPTION>OPINION OF GIBSON, DUNN & CRUTCHER LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="text-align: left; width: 70%; vertical-align: middle">&nbsp;<IMG SRC="ex5-1_001.jpg" ALT=""></TD>
  <TD STYLE="width: 30%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gibson, Dunn &amp; Crutcher LLP</P>
                         <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Embarcadero Center<BR>
San Francisco, CA 94111-3715</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tel 415.393.8200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">gibsondunn.com</P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">November 13, 2024</P>

<P STYLE="margin: 0; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 70%">&nbsp;</TD>
  <TD STYLE="width: 30%">Client: 68823-00001</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Oruka Therapeutics, Inc.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">855 Oak Grove Avenue</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suite 100</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Menlo Park, CA 94025</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Oruka Therapeutics, Inc.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Registration Statement on Form S-1&nbsp;</TD></TR>
     </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have acted as counsel to Oruka Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), in connection with the preparation and filing with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
of a Registration Statement on Form S-1 (the &ldquo;<U>Registration Statement</U>&rdquo;) pursuant to the Securities Act of 1933, as amended
(the &ldquo;<U>Securities Act</U>&rdquo;), relating to the resale from time to time by the selling stockholders named therein of (i) up
to 5,600,000 shares (the &ldquo;<U>Common Shares</U>&rdquo;) of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<U>Common
Stock</U>&rdquo;), (ii) 2,439,000 shares (the &ldquo;<U>Conversion Shares</U>&rdquo;) of Common Stock issuable upon the conversion of
2,439 shares of the Company&rsquo;s Series A preferred stock, par value $0.001 per share (the &ldquo;<U>Preferred Stock</U>&rdquo;) and
(iii) 680,000 shares of Common Stock (the &ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo;) issuable upon the exercise of pre-funded warrants
(the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In arriving at the opinion expressed below, we have examined originals,
or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of the specimen common
stock certificates, form of Pre-Funded Warrant and such other documents, corporate records, certificates of officers of the Company and
of public officials and other instruments as we have deemed necessary or advisable to enable us to render these opinions. In our examination,
we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents
submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the foregoing, and subject to the assumptions, exceptions,
qualifications and limitations set forth herein, we are of the opinion that (i) the Common Shares are validly issued, fully paid and non-assessable
and the Conversion Shares, when issued upon the conversion of the Preferred Stock, will be validly issued, fully paid and non-assessable,
(ii) provided that the Pre-Funded Warrants have been duly executed and delivered by the Company and duly delivered to the purchaser thereof
against payment therefor, then the Pre-Funded Warrants, when issued and sold as described in the Registration Statement, assuming a sufficient
number of Pre-Funded Warrant Shares are at the time available for issuance, will be a valid and legally binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or other similar laws relating to or affecting creditors&rsquo; rights generally and by general equitable principles
(regardless of whether such enforceability is considered in a proceeding at law or in equity) and implied covenants of good faith and
fair dealing and (iii) the Pre-Funded Warrant Shares, when issued upon a valid exercise of the Pre-Funded Warrants in accordance with
their terms, will have been duly authorized and validly issued and will be fully paid and non-assessable.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the filing of this opinion as an exhibit to the Registration
Statement, and we further consent to the use of our name under the caption &ldquo;Legal Matters&rdquo; in the Registration Statement and
the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons
whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Gibson, Dunn &amp; Crutcher LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Gibson, Dunn &amp; Crutcher LLP</B><BR>
One Embarcadero Center Suite 2600 | San Francisco, CA 94111-3715 | T: 415.393.8200 | F: 415.393.8306 | gibsondunn.com</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ea022056701ex23-1_oruka.htm
<DESCRIPTION>CONSENT OF PRICEWATERHOUSECOOPERS LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM<SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">We hereby consent to the use in this
Registration Statement on Form S-1 of Oruka Therapeutics, Inc. of our report dated May 13, 2024, except for the effects of the
reverse stock split discussed in Note 1 to the financial statement, as to which the date is September 5, 2024, and except for the
effects of the reverse merger exchange ratio discussed in Note 1 to the financial statement, as to which the date is November 13,
2024 relating to the financial statement of Oruka Therapeutics, Inc., which appears in this Registration Statement. We also consent
to the reference to us under the heading &ldquo;Experts&rdquo; in such Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ PricewaterhouseCoopers LLP<BR>
<BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts<BR>
November 13, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>4
<FILENAME>ea022056701ex-fee_oruka.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 107 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Filing Fee Tables </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Oruka Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table 1: Newly Registered and Carry Forward
Securities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Security
    Type</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Security<BR>

    Class<BR>
 Title</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee
    Calculation or Carry Forward Rule</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount
    Registered</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Proposed
    Maximum Offering Price Per Unit</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Maximum
    Aggregate Offering Price</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fee
    Rate</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount
    of Registration Fee</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Form Type</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward File Number</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry
    Forward Initial effective date</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Filing
    Fee Previously Paid In Connection with Unsold Securities to be Carried Forward</FONT></TD><TD STYLE="font: bold 8pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD COLSPAN="42" STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Newly Registered Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; font: 8pt Times New Roman, Times, Serif; text-align: left; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fees to Be Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; width: 6%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; width: 9%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common stock, par value $0.001 per
    share(1)&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; width: 6%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Rule 457(c)</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">8,719,000</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right">25.405</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">221,506,195&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">0.00015310</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left">$</TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">33,912.60&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; width: 0.5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Fees Previously Paid</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="42" STYLE="font: bold 8pt Times New Roman, Times, Serif; padding-left: 0.125in; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Carry Forward Securities</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">N/A</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="8" STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Offering Amounts&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">221,506,195</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">33,912.60</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="8" STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Fees Previously Paid&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;&thinsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="8" STYLE="padding-bottom: 1.5pt; font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Total Fee Offsets&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&mdash;&thinsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left; font: 8pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: bold 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="8" STYLE="padding-bottom: 4pt; font: bold 8pt Times New Roman, Times, Serif; vertical-align: top; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net Fee Due&thinsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 8pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">33,912.60</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 8pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Pursuant to Rule 416 under
the Securities Act of 1933, as amended, this registration statement also covers such an indeterminate amount of shares of common stock
as may become issuable to prevent dilution resulting from stock splits, stock dividends and similar events.</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">The amount registered consists
of up to (i) 5,600,000 shares of Common Stock held by certain selling stockholders, (ii) 2,439,000 shares of Common Stock issuable upon
the conversion of 2,439 shares of Series A Preferred Stock and (iii) 680,000 shares of Common Stock issuable upon the exercise of pre-funded
warrants held by certain selling stockholders.</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Estimated solely for the purpose
of calculating the registration fee, based on the average of the high and low prices of the shares of common stock on The Nasdaq Global
Market on November 7, 2024 (such date being within five business days of the date that this registration statement was first filed with
the Securities and Exchange Commission, in accordance with Rule 457(c) under the Securities Act).</FONT></TD>
</TR></TABLE>
<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 .X# 2(  A$! Q$!_\0
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M_8ICA$/_  HOPZZC(#RZGXJDF((Q\\S^(C([CKYA8-DY&#@CQ7XA_P#!(/\
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M,_#GXS:=OU3P7XIU4R6^M1#3!9W6I6&B7%E-JNCV_P!KOQF_\$T_B'X(\5>
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(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2J#Z # 2(  A$! Q$!_\0
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M0F)Q%C-3X8$TL<'1\'(U)4/Q_]H # ,!  (1 Q$ /P#ZI@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                    "&4&4 B"7<0 G!( )P2 "<$@
M G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2
M "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!
M( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<
M$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )
MP2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@
MG!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2
M"<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!(
M )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$
M@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P
M2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G
M!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "
M<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!(
M)P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@
M G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2
M "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!( )P2 "<$@ G!
M( )P2 "<$@ G!( )P2 "<$A'<!,"&4&4 B"&4(@         " $0
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MAZNMT;NO)I+W51-3\39$'9;>*Z.D:S^F7WRW#<?GU=VG.,#G.1.*VN68[O\
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MM+<86NP[BQKI&^*KJ.L_.$NRV\4/:-/*_07N&X_/VG:,XR;4D3BIKQ8%^_\
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M\B2'B0]J?C*L:M^-O6Z.]JZBK%_Z0IG3S'Q*ZVMHWX7Z&MPW'YXU[3W&9/\
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M_I'9K>+';:^5T%N&XYV_1->Z>1?]5J^1'>VI?T_?)7:KO2=%NM<C5^^])?\
MZ1V:WB=NKX.B]PW(<V_HKO3796]5VW_"G_Z2/Z,KLJ/7[,5ZHG=_53_])+LU
MO%&=?2/@Z1W$-QS%)Q&N<;U3[,UF?.I?_I/*O6L;[54KG1ZBN%-(G<D5;(G\
M#BRNBO;XJYZ2I7]+K/<@W'&MCO&J*Y[O2-6WB-OA_JC+]8]K[+WF.1$_1->I
M$\KC-]8S.AM'Q5>U:>276&Y!N0Y6BO=\AC=LU)=E<O5%?72O_A<>1<=<W.-R
MQ3ZHO-.[VLK94_YQF-#>8WXDO:E?++L#<@W(<-LXD7VW7*+_ +*KU40.7[^X
M2JGY-Q[=\XPWZV0-EANE<]BIT5:J3_28[#?Q5^UZ>679.X;D.&;9KW7FHZMK
MXM0W6FIU7[RKD^L;#M-XU%21M=4:DNDRIWHZKD7_ )Q"=):/BMKTG2WZ9=1[
MD&Y#DW47$&^0H[E7VX,=[&U<B?YS$W\7M31Y:V\W.1?\,D^L2KH[V^)?I2E.
M^LNWMPW'!=5Q9UC</5AOMSADS\AE;*G_ #CV*+6VJ&TK'U6I;Q&_V+<)>O\
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M"#"'S@J-7\2:75FYNK]0R4CESR_LI/L3\6_!LN+B)JN*G;S+_<]V.]:R1?\
MG#LE_%#VG3RR[5!*SY*$QHNT
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M+;&['(]J'E5L]L6[RNE25:=$^X\I>Y#T+9#?=3:?JD@MGI=+2='RL3JS'M/
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MZ-$<>@CF]4<Q40HK"DTF$3# C6D;N[&?)0BWN(,^2A%O<>?>NKW(@ )
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MNE*5]YRKQ2I*NAN[KG'2N;%(W:KL>*&)VIEMNEKF956U)Y'+GF;D:IN#C)Q
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M_P!9Z5AT#7W1S9(59%2X]>I?T:WWGZ-]C/8A'EM]B%?:?DNCH_:-N)^??1G
M&^:NJ:I]NJ(IK=#ZKJEB^J81JC3];I6^3V^IVN6)<)(WN5#]'W+;[!RF_@HI
MF-5\F/9W/WGYM6TDU4L211NEC<[&YJ9,_MVFHZ2-*&T))+<ZAGKM;W(I^@OE
MM]A'EM]A/MD^"5>CXK\7QIX7<(8-&6&.X794;5N7<N_"(BFKN/-ZMMZNU-!;
ML27.-V.9#\G_ $'WFV-QW$.4SV#MD^"%NC8F=XE\;.$FL*ZQVVEM.H*)$JT9
MS&O<G5&^W)FE?QVL\LC;+;*ETU<C_75J^'XSZP<M/P4'+3V(8[7/@NKHN&-N
M)\U+=?H88F7&IDG?3(SK3-5?E%Y;-:14]4Q6H^)E0O6)_P#UZ'T?V)["/+;[
M"/:?DEV/YOGU0UM'+45<"-=&Y_5'+W9/:TY%2/JI8:JGCW>$C^]3NM&(G@-O
MDAB=1O\ !?33\,;;N.J2F2DI9*>/[F[OP[NV^1X]=0VBP.IWWJI:ULKE5C'+
MW_D.W=OD@V^2&.O^3/4?-R%17R"HMK>1.K6,3[GM7HB>PM+G=:BLJ*%D$J;4
M7UG.5/6.R-J!&I["'7<^XZCYN1*R:@Y*NY$,%1CY>U/67VF,UMTJ&R0\Q-D6
M<-D3&/\ Z'<.$&$)=?\ )GJ7(M'(V-S$Y:R.5.JH9!;84BJ$E<U6^1TWM3V$
M,)["N<NZ5<.SG"MA?<&2N1J-8Y<;347$32M+$Z='R1\N:/:YK\8.[<>PE1J+
MWH65SS51DTL9([WP/XH0W?17$KT?3]=(C7.18F0KZJKY>1O.HU%=K7HVFK+\
M[F57)WJU/EHN.X^OJ1MPO1%'*;[$+NV?)J^SYV]Y\ ]1=H#45ZAJ*>!T<%,B
MJUJ^.#5U5-4UDRS3R.?+(N7;E/TF\MOL",;[$(=IGP0]FQOOQ/S52->U,2*J
M)YEI(Y-V%3H?I@Y;?8A'8WV&.T?)..CXC]3\S#\,^2W^ @M4]S43N_(?IHVI
M^"-C?81Z_P"2SL,>+\S+&OD;\GJ5XH5C\%/TO[4_!(<MOL':)\&)T'[GYJ68
M<["IT_Z^948[Y3>Y/^OF?I3Y;?8GY!RV^Q"SM7R5ST=$_J?FQI)I8E<W<N')
MCKX%S&UCMD?,<[;U5R_P'Z1-C?8@Y;?P3,:J8^"$]&[_ *GYP*:5T>U_3&[H
MW/7WD*F[.CFRJX3S/T@<MOX*#EM_!0SVN?!'V77S/S;25TLTB*Y5V^PG5J52
MHB,VK[3](W+;^"@Y;?P4(]JGP9]F1YGYQXZZ.AQ&GKJW[[VGG5=:ZJJ,JF$]
MQ^DGEM_!0<MOX*&.TSX)1T;$?J?FR9(BN5/^O\)3F<C'*F,>X_2CRT]B#EI[
M$':9\&?9O[GYK)YT=&F,*I*U>6U%5I^E78W\%!L3\%!VF?!GV='F?FM?(CVX
M1,$8(5>F?EI[#]*/+;^"@Y;?P4':9\#V;^Y^:YV]TFQ&*B^P]:P6=UZNU%;%
M?L6HF:U'K[?9D_1WRF^PCRV^PSVJ?!CV;\WQAOVJK7P>TJMH^YR5RQXRU,NS
M[T-!W"^/O;*VKFIG22N5%:KN\_0SRF_@H.4W\%"7;)\%4]%;_J?G):]^Y9G+
ME'+CEE1/NV51VUJ=R*?HQY3?P4(\IOX*$NVSX*YZ'B?U/SI02.RK<JJ%5T+,
MKT_>/T4;&_@H0Y;?P4,SKIGX*_8D>?Z/SMMIXMJ]5R212HOJ*BHT_1/RF_@(
M.4S\%!&NM'P1]A_O^C\\#:=&N]5<(3H]9/55W0_0YRF?@(.5'^"A+M\^5">@
M=_U_1^>ES7-C15^2UV<G8'9^N<VK]')"W$LU+ZB-RB+CVGU52!B=S4)MB)]Z
MA"VNFWP;6#H?J?UOG//;HZ=4C?U7Q7P*24]*UJX?U/H]RV^Q!M3\$K[5/@W^
MQ1XOF]+9(JJ2*3;]S;\IW@-3W2FTM;?2IY6PTK6YYKNB?OGT@1C5]A#EM_!0
MG&LGP4VZ/FW=9\?=0=I/TRS2VNWP\N5RJWGHJ=QJ#EU4U4M0LKGU3USO<O\
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M/H^'EPO5;6QNIX9VQT2+TC;_ /K*5')#21.2:/>GX2__ *S[C\F/\!"/)C_
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M,S%JY'U9C^0GN(M[B$?ZFWW$6]QY)]*K[L(@ PD
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M0J=7^SR;_I+'A[HQ=)VE/29.?<IDW3RKUQ[&IY)^^9>G<N33O;P;M,<>]*8
M%2\
M
M
M
M
M
M
M
M
M                                            2HF0J(3 #3W&CLZ6
M'BQ335B11V[4C8]L-RC;C?CY+943Y2>?>GA[#C2X\"]2:,K:FBKG>AU;%[XU
MRUWL5%\47P/I2B)XF"\5.'L>O;%+'"K8KI3HKZ6;NZ^+'?VKN[]\WM/J;8YV
MGN<G5:''FCBB-I?,6Y:>K8+N^*L=)4/SA/')[MDU;-IF&2DJ+<U6.3'W1N%-
M@:TTE<8[XU&1\JMA>K7,<G5'(O<IBNOJIT;H*6LH5]+7HLS6]/RG?KDBT/(9
MM/6'I\/K-!<JY;HUG+<B_);[?<;S@:L,<**J.;_:]YSEI+5"Z,JV]><UZ8QW
MX-Q:,U_;*S,.[=42?A+W%>2D3')#3Y)QV^\V RG63:J.VL\5\3RM?V">OL,K
M:23F.QU1R%U!4RM?C"X[\GMT5?3M:C'>MGO0T:QPSM+TU+4RTY./:ZUU-AK)
M4E@<QRNRO0M&;Z^3<CW-7V..OM0:!L^IHUFFB9',B83&#4U]X+;9G>B2M8F3
M9C)R:>31Q:V\._X_D)[B+>X-^2@;W'FWK*]R( "0
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M1FMM79=@VM9ZWXB(!HNB
M
M
M
M
M
M
M
M
M
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MUG=$ &JW@
M
M
M
M
M
M
M
M
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M-ON(M[CS;VM>Y$ &$@
M  !( ! YE98H^2K7R(Q"S33].UV$7<G=GV%1MR=-&KID5%\,'FS:E2DW-:Q=
MB=^3MUY]SSF:\5E573W+D7+41GWKT[R]@H;A21[61<Z%?]T<8K2<1[?65;J=
MM1OG8N$BR9?;=15EPI5W,VPITV]WXPECMO&ZXMU#*J^NL3/:U<9/6I6K2JC'
M.PQ?P.IC+JICIE5RN1PGN$L,3W)-RVHGWZD>'B3ZR(9O;*:>34%ID16K$VKA
M7S^6AO#V'(>F>)U+3ZWL%N6J=435-RIX$:G5$5TC4S^^==M^2BG/SUX9AO:/
M)UE93  UG0
M
M
M
M
M
M
M
M
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M[)P :CI
M
M
M
M
M
M
M
M
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MJ1CL)T1%F8BK^0[S.7JHX;0['1\[UM_*< &FZP
M
M
M
M
M
M
M
M
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MW$S>XEC^0WW$S>X\4^QT]V$0 $@
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MD*[7K_#T/0&6V7!:;>*< '*>I
M
M
M
M
M
M
M
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M$\1_VPI/Y.0^@Q\^?@?O]A/$?]L*3^3D/H,
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M3-[B6/Y#?<3-[CPC['3W81  2
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M;;Q5  <AZ\
M
M
M
M
M
M
M
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M4;5?RJ2KCE>C47JNUJKT153J>Z
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M*I9)O[HS-IX6YABN.(XGVAC^0GN(M[B6/]33W$S>X\:^IU]V$0 $@
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MU%;\._\ :8S[.1_(0\UTI_<K_#Z)]F/[.3^50 '%>V
M
M
M
M
M
M
M
M
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MQ]#P!R3V7^P#;^S3Q)EU=3:RJ;_,^@EH?19J!L"(CWL=NRDCOP,=WB=;
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MF]QXU];K[L(@ PD
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MX7W'7_9I[5.D.TYINIK; Z:W7:A<U*^S5BHLU/GN<BIT?&JHN')[.J)W ;K
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M26KKA!!25MXM\=9-#2[DC8YR=S=RJN/>!L
MX!_3>](>LGQ?WOI_YY#^4#OX'!%%\+OH61SDJM#:BA3[WDRP2*J^*+ES3:'"
M;X1K@]Q3NT%J?<J[2-RG<D<46H8&PQ2O7P29CWL3KT3>K,]V,JB =3@IM=N\
M<^/0TQVHNTS:^S#I&TW^ZV:LO<5PKO060T<C8W-=RWR;EW>&&*GXP-U@PSA%
MQ(IN+G#;3^LJ.DEM]+>*9*EE+.Y'/C155,*J=,]"RXP<;M'<"=+.O^L[PRUT
MCG+'!$B*^>ID[]D4:=7+^\F>JHG4#8 /GGJ3X7_3])5R-L/#FY72E1^&RW&Z
M1T;U:G>JM;'*B+G'3./,S7A9\*?PTUE=([?J:UW/1,LS]K*RH<VJI&^'KO:B
M.9UZ9V;4\7(!VN"QM]=3W2BIZVCJ(ZFEJ(VS0SQ/1\<K')EKFJG145%145/:
M7+I&L:YSG81N57*X3H!5!R-QA^$MX5\+[C46JTOK-;W6GD6*7[$HC:1CDSE.
M>]<.[N]B/3S-4VCX8&PS5KDN7#6XTE'N3$M)=HYY-OMV.C8F>_[['<F0/H>#
M5O!'M&Z#[0EDEN&C;PE8^G1OI=OJ6+%5TJN1<))&O@N%]9JJU<+A5PIM( #7
MG&#CIHO@3IW[,ZUO<%J@DW-IX<*^>I<B)EL4:=7=Z97N;E-RHG4XXU)\+]IZ
MEJY&Z?X<W2YTN4V37&Y1T;W-Z]=K(Y43P\5[P/H4#B7AI\*KPTU?<XZ'4UJN
MFBUD5$962JE93(N53#G1HCV^'78J>:=YV3:[K1WRVTU?;:N&OH*IB2P5=+(D
MD<K')E'-<WHY%3Q10/1!S#VD^W+:>S/KVW:;ONDKI<(*^D960W*DF8D2QJ]S
M')A4SN:K5RGL5J^)TG05L-RHX*NEE;/35#&RQ2QKEKV.3+7(OBBIA?Q@78!K
M+M!<<K1V>>&=?K.]02UL-/+%!#10/1LE1)(Y$1C57IE$W.Z^#' ;-!JOLY\<
M&=H3AM!K2FL578*"IJ98*:*LE:]TS8UV.D16IC;O1[4\V*<KU'PNVD*>HEB_
M0!>W*QSFJJ5D.%PN,@=^ X!_3?-(?L?WSZ7#_H'Z;YI#]C^^?2X?] '?P-=\
M!>+U)QXX46+75!;Y[72W7G[*2I<CGQ\J>2%<JG1<K&J^Y3F;B/\ "BZ6X<<0
M-2:4JM$WBLJ+)<9[=)4154362NBD<Q7(B]41=N>H';H. /TW_1WS O7TR$]N
MR?"U<,*RHACN&FM46Z-R>O,V&"9D:]._$J*J>Y,^0'<@,+X7<6-+\8]*4^I-
M(7>*\VN5VU9(\M?$_"*L<C'(CF.1%1<*B=Z+W*BKSU?/A#+!H7C<_AMK/25T
MTS/%7MHIKM45,3Z9C7_J4_@O*<BL7*]41V53HH'7(*;7;TZ+E/(J  <L<=.W
MSIC@UQ3AX?4FG+GK+43DB9+#:9&?<YY51&087JKU16KA$[G)WKT.F+745%7;
M:6:MI?0:N2)CYJ7F(_E/5$W,W)T=A55,IT4"_
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MID#+ #D;M _"+:2X#\3;CHJ?3MQO]9;XXGU-11U$;(XWO8C^7UZY1JM5?-<
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MJ]$0Y$XK?"><*=!5\UOL*7#6U9#(L<C[6Q(Z5N%5%Q+)\OJG>QKFKX.]H=B
M^=5%\,%:Y*Q6U/#&LAI,IB:&\LD>K?%=BPM3/A\KWX.I. '; X<]HM'TVF;E
M-2WR-BRRV2Z1I#5M8G>]J(Y6O;W?(<[&4SC(&\0
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MI:BXST4,KY+W%*QU(Z2)J.D8SKE<*NW=W9:OAA5Z"
M                               ',O%WX0'ACP4XAW;16HX+Z^\6SD\]
MU%1LDA^ZQ,E;ARR(J^K(G@!TT#CC]-9X+?\ X35/[G1?GCW],?"5\"M0U<5/
M-J"OLKI$3#KE;96L15\'.8CT3WJN/,#J@'EV/4%NU+:Z>Z6>X4MTMM4WF05E
M',V6&5OM:]JJBIT7N-.<=^V/H3L\:IM6GM5PW=]=<J9*N!UNI6RLV+(Z/#E5
M[51<M7P WN   -"\1>V7H+ACQ<MW#>]07AVH:Z2FBB=2TK7P(M0Y&QY?O3'?
MUZ>[)OH "FK]F[*X3VG,NB_A"N$FN^)M!H:VSW9MPK:U:"FK)Z9C:267*HS#
MTD551[D1&KMZJYOM Z>   &!<5N->B^"=A2\:TU!3V2D>Y6PLDR^:=R856Q1
M-17O7JF<)T1<KA.IS!<OA9^$U'6I#26#5E? C\/J&TE-&BMZ>LQ'3HJ]Z_*1
MO<!VX#G7@UV\^$7&NZT]GMEZGL=[J7(V"VWZ%*:2557"-8]'.C<Y?!J/W+X(
MIT3YY B#FGC#V^^&G!#B#<]&:C@OTEXH&Q.E6AHV2Q*DD;9&X59$7Y+T\##O
MTUG@M_\ A-4_N=%^> ['!QQ^FL\%O_PFJ?W.B_/&W^SQVJ]&=IAVH?T(1W2+
M[!^C^E?9.F;#^K<S9MVO=G]2?G./ #=    USQ<X_:!X&6R.LUMJ2ELRR_J-
M*N9*F?KC+(FHKW)TZN1,)XJAHVC^%!X&U-P=32U][I(47"5DUK>L2],]$:KG
M?\4#K@&-:(U[I_B1I^FOVE[S2WVSU*9CJJ*3>SVX7Q:Y/%JX5.Y4R9*
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M=P;:;-6U-EU$]JOCM%ZC;%+.B?*Y3FN<R143KM1V['7&$7 ="@
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M,?R$]Q%O<0C^0GN(M[CRKW=>Y$ !(
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M!NQ&Y\5<Y/O5QC'PM4_HW''1$NW=R["U^/%<54O0#ZJ ^;GZ<9_^Z+_^Y_\
M^4'Z<9_^Z+_^Y_\ ^4 PKMH_[8KH[_"[%_+-/JP?$S5W'M>T=VO]#ZT^P7Z'
MN;=K32K0K5^E8Y=0Q,\S8SO]FT^V8&@.W#Q?7@WV<]4W*EGY-VN<:6>W.:N'
M)-.CFJY/-L:2/3S:GM/F-J3L_7#0792X;\9+=S:6[55[J'SS,7UXHU<B4C_8
MB(M-([/BLS3??PCVK*_C1VB=#\&=/R\R2BEACF1.K4K:M6[5=Y,BY;O+F..X
M>)O 6TZO[.%TX5T$+8J)MF;;[:DG='+"QJT[U7RDC8JKX]?:![' 3BI2\:>$
M.E]94NQKKG1L?411KE(:AOJS1^YLC7)[L&Q#YP_!1\6I[?5ZOX27I7P54,CK
MK04\_1[7M5L=5'A>Y47E.V_WQ?:?1X#Y,7JQR=LWX0>]:8U3<*BGT]:*ZLH6
M4L;U1S:2B<YO*CS\E9'MW.7PYCE\$0^A-B[)?!C3]M90TW##2TT+&HU'5UKB
MJY5QTRLDJ.>Y?-5..>UWV1.)&AN-$_&?@PVKJJBHJ%N%12VMJ.K*.J5%25[(
ML+S62*JJK<.ZO>CFJT\+1OPKNN-)S+:^(.@J6YUE.O+GDI7R6ZI;X;GQO:]J
MN\D1B>X#*NWUV(-)Z<X?5/$/AU9OL'<+9-&M?:[<CEBGA>]K$?''GU'M<K5]
M5,*BN5>XZ9[$?$74?$KL]V*KU;!61:AM[Y+952US'MEJ%BQLE=N1%558YF7>
M+D53%N$GPC7!WBE5T]MJ;G5:/NLZHQD%^B;%$YR^"3M<Z-$]F]6Y]G@=0QO;
M*U'M<CD<F45JHJ*GM ^3G:8L-OU3\)K162[4D=?;+A>;'355)*F6RQ/AIFO:
MY/8J*OY3OO[2?@9^QI9/\F_ZQ\\.V%K2#AQ\(E-JNII9*RFLE?9[C)3Q*B.D
M;%3T[]K57HBJB*G7R-__ *;YI#]C^^?2X?\ 0!TA]I/P,_8TLG^3?]8S+AKP
M3T-P@6Y?H+TS0Z>2X\KTKT-JISN7OY><JOR=[_\ A*<>_IOFD/V/[Y]+A_T'
M4_9NX^6_M'<.4UA;;54VBF6KEHUIJI[7OW,1N5RWIA=W[P&URA/.RE@DFE=M
MCC:KG.7KA$3O*Y#:GL ^4G9VX:S=N/M1ZRU;Q,95R6:VM;4NM4F^'<QSU;34
MO3"LC:UCE7"Y<K5ZY55.]]1=D/@UJC3<MEGX;Z=I:5S-C9[?;XJ6ICZ81S9H
MVH]')[^OCDW*:[XW<:M.<!M 7#5FIJML5- BLIZ5JIS:R9479#&GBY5\>Y$R
MJX1%4#Y\=D6LNW9E[<U^X01W.2LTW<ZF:ADYJ?+5D#IZ6;"=$DQABXZ+S'9[
MDQ]2SYA?!^Z U%QR[1FH^.^I:=8J&EJ:F6"7:J1RULS59RX\_>112+[LQ^9]
M/0                                                .9?A(?[$#6
MW]]H/Y[":U^#2X9Z0U7V;6UU[TI9+S6?9BJC])N%NAGDVHD>&[GM5<)E<)YF
MROA(?[$#6W]]H/Y["<P=AKMK<,N _!!-+:KJKG%=4N515[:6A=*SEO1FU=R+
MC/J@=[5O9YX67)&K5\--(5*M^2LMAI7*W/?C,?0^;7PB79XL79WUKH_6G#Z-
M=.4]SED=Z'2/<UM)5P.8]LL*KG:CMZ+M[FJS*=%Z=6S?"C\#H85>RJOU0_PC
MCMBHYWNW.1/WSC3CCQ<U)\(=QLTII?1M@J;=9Z%714C:C[H^%LKV\^LJ%:BH
MQJ-9&FW*XVX1RJ[ 'T(UEK2;B)V&=1ZIJF)'57CAY55T[&IA&R26Y[WHB>S*
MK@YM^!Z_V.<3_P#"Z#^).=6<8=,4VB>R'KG3U(Y74EHT+74$+G)A59%;WQM_
M>:A\L.R5VGM?=GVWZEI]%Z.AU3%=)8'U3YJ:>987,1Z-3[D[IE'.[_8!]LS1
M/;G_ +$WB5^U[?Y:,Y _3*N/'[$=#^YE?]<P?C9VZ^+_ !-X6:CTM?\ AK2V
M>SW*G2&IKF4-8QT34>UR.W/=M3JB)U]H'17P1O\ 6$U7_OFE_FM*=QG#OP1W
M]835?^^:7^:TQT3VH^+;>"7 K5NJV2I'7T](M/;\KU6JE^YPX3QPYR.7R:H'
M"]Y6E[8?PCS;551_9+1VF$EIG1HNZ-8*5K]RY3HJ/JG]_BUS?87/P?>J:S@+
MVF]=<$[[*K8*ZIFAI5D]5'55,KE8YOL26#<OGMC3Q,\^";X3/M6AM3\1Z^)R
MU=]J?L?122)ZRT\2YE>BKWH^5=J^<!KSX2K1UPX0<?=$\9-.IZ//6OB>^9J=
M$KJ16JQ7>U'QI&W"]Z1N ^GYQM\*;K:Z:5[.5+;;;+)3Q7Z\14%9)&JIF!(I
M95CRG=N=&SWHCD\3J+AOKFW\2]"6'5=K?NH+Q1QUD77*M1[456+YM7+5\VJ8
MIVBN!MI[1'"N[:-NLKJ1TRMJ**N:B*M)4LW;),>*=7-<GBUSD145<H&D.P/V
M<>'MAX#Z7U;]@[=?=1WNF]+J;I6P,G?'N>Y.5'N148UNU$7;C+FJJK[.A]:\
M%]"\1K1/;=2:2M%VI)F[7-FI&;VI[6/1$<U4RN'-5%ZGS)MEA[5O8BFJJ*RT
M-===)QS/EQ1TRW.UR(JY=)M1JO@15QE5Y:KDV)H'X7>MAF93ZYX?Q287$U78
M:ET:MQ[()=V?\H@%GV>^"/$CLQ]MRKMEAT]J*X<.YZEU!47=U#*M)-1RL1\3
MW2HFQSXGJQ%=GHK7IA-RHG4WPB_]AQQ"_P#=_P#^<:8SC@3VFN'_ &B+7-4Z
M/N_-JX&(^IM58Q(JRG1>F71Y7+?#<U7-RN,YZ&$?"+_V&_$+_P!W_P#YQI@-
M1_!D<--(ZL[.=377S2MEO-8E]J8TJ;A;H9Y$8D<*HW<]JKA%5>GFIUM\1O#C
M]C[2W[BTWU#Y1]E[M_5_9IX;3:0IM&T]_B?7RUWI4MP= J+(UB;=J1KT39WY
M\3;_ .G"7C]C"B_=A_YD#OU.!_#AKMR: TNCD7**EFILY_X!FYP%P.^$YN?%
MWBUI?1DV@*2UQWFL2E=5QW-\CHT5%57(WE)GJB>)WZ .0/A&-"<5>)_#JS::
MX=6*JO%KFJ)*J]^B544;G-8C>3$K'/:Z1%<KG*B(N%C8=?D-J>P#2_9R[-^E
MN!/#:T6:ELM$Z]NI6+=+C)"Q\]54.;]UR]4RK457(C>Y$1/:JKP[\)OPQL/!
M[B#H+76BH8=,7RYOJ))V6UJ0?=J=T+XZEK6XVOS*J.5._:U<9R=B]K#M ZXX
M)Q:9IM"</:O7MSO'I2R)34\\[:5L21JBN;"Q57=S%QU3Y*GSKMFO(>TCVE*&
MI[2.I9])4-$^.**SNH)8(&Y<CDIL+E:=CEPKI7Y54QER='('UXT#?ZC5&AM.
MWJJBY%3<;=35DL2=S'R1->YJ>Y55#(BTHTA]%A2EY:4VQO*2'&S;A-NW'3&.
M['3!=@                                                <._"X?
MU@]+?[YHOYK5&Z^PO_8G<-OVO=_+2&E/A</ZPFE?]\T7\UJC=G87_L3>&W[7
MN_EI /G5VP]!U7%+X034VDJ&>.EKKO46ZE@EF^0V1;=3[4=Y*N$5?#.4R;C^
M#A[1-PT%JFOX#Z\62WU$-5*RT-K'(BTU4CE6:C7/@YR.<SVN1R)E7M,8XH?[
M;51_MW:/_P WTQG_ ,)=V:*N%]/QMT>Q]/=+<Z+[-)1Y;(B,5J0UC53JBL5&
MM<J=41&.^]<H'T0/ES__ +<?_>W_ /S#L/L9=IBG[1W">FKZJ5D>JK7LH[S3
M,PF9<>K.UO@R1$5?)4>G7;DX\_\ ]N/_ +V__P"8!U[\(/\ V('$3RBH\?38
M#5?P4]GH*_LX7>2JHZ>ID34M4U'S1-<N/1Z;IE4[NJ_E-J?"#_V(/$3^]4?\
M]@-<?!-_V-=X_P!\U5_-Z8#K&X:$TU=Z9:>OT]:ZZ!<YBJ***1JYZ+T5N#YR
M_"%=CZR\++53<6.&])^AV"FK(VW.WT&614\CG_<JF%$_4O7PQ6MPB*YBM1.N
M?IR:7[9-OBN?9:XGPSX1C++-,F4^^C3F-_XS4 LNQAQNGX\\ +!J&ODYM[I=
MUMN<C51>941(B+(N/%['1R*B=ROQX'#GPE/]F5HC]J;;_/:DVS\$)6RR\.-?
MTCE=R8KM#,WKTW/B5KOQX8TU-\)3_9E:(_:FV_SVI ^I]34Q45/+43R-AAB:
MKWR/7#6M1%555?!$ZGR4TI0W/X17M@5E1>YZB#1-M9),L4#E:M/;HW[8H6*J
M=))7N3<O]L]4^2B'TH[2];+;.SMQ.J8&N6:/35QV;>]%]&D1%_%G/XCC'X'R
MU0-MO%"Y*C5JG34%.GX2,:D[OWU7_B@=ZZ*T'IWAW8H;)IBRT-BMD*)MI:"!
ML;<XQN7">L[IU<N57Q,5X[< -)=H+1E98=3VZ%\SXW-I+HR)JU-#)]Z^)ZIE
M.N,MSAR=%-GD-J>P#Y__  <_#CC%P5UMJK2VJ=+W*ET14+)RZNHE8V"*KB?M
M22)KG;G,E:B^LQ%SM8J]$R?0$&,<2==4/#30.H=5W-<4-GH9:R1N<*_8U51B
M+[7*B-3S<@'SO[9UZD[1O;7T%P@HGK/9[/40TU8V/K]TE5LU6[I^# QJ=>Y6
MN3Q/*J:Q.QS\(Y+*Y$H=(:HG1ST_4XDI*UW5?8C8:EJKCP;$OD9#\&#HBOXD
M<5=?\:-0M])J^;)3P3N3U75E2Y9:A[?8K6*UONF,Y^%>X1_HCX86/7]'#NJ]
M.U7HM8YJ=?1)UPUSE3P;*C$3^^N4#NUS&R,5KD1S')A6JF45/]!8_H9M'ZU4
M/T9G^@TWV+.,OQV]GK3-ZJ)^?>:*/[%W-<Y<M1"B(KW><C.7)_ZPWN!\J/A5
M+?2T''?0L=+30TS'61BJV&-&HO\ 54J=R'U$_0S:/UJH?HS/]!\P_A8?Z_F@
M_P!I&?SJ8^IX%I26VDM^Y*2EAIMRY=R8T9GWX0^679+_ -LLU?\ MMJ#^4F/
MJP?*?LE_[99J_P#;;4'\I,!]".TCQ@AX%\&-4:R>UDE50T^RAAD15;+52*C(
M6JB=5;O<BNQ]ZBG O8.[+D/:.O=]XO\ %+F:BI%N+VP4M9W7"KZ.DEE[MT;-
MS41O<J[D[FX7=?PM-UGINS_IRBC<YL=9J.'FX[G(RGJ'(U?\;:O^*;:[ =LA
MM/9)X>L@:C>=33U#U\5<^IE<JK[LX_$!O>V6NBLM!#0V^D@H:*G:C(::FB;'
M'&U.B(UK41$1/8AI#M/]D?1_:+TK7-GM]+;-8-C5U!?X8D9,V5$]1LSD3,D2
MKA%:N51%56X4WZ0VI[ /FQ\&7QJONDM>W_@3JISF+3/J9+?#,_+Z2KA<J5-,
MG]JJ(]^$[EC>O>Y39WPMR)]KCISI_P#:NF_F=:<[ZTVZ.^%9IO0&(U)=34&Y
ML73K54\/-7_EGJOXSHCX6W^QQTY_OKIOYG6@<-\++SK#L>:MX<\48&R5FG-3
M4//?'%ZK*NF1ZLJ*9R]R2-5K7MST15C=[4/L]HW6=IU_I:UZBL58VOL]S@94
MTM3&O1S')GK[%3N5%[E147JBH<I\+^ ]J[0WP?6B=)W';3UC[>Z>VUSFJJTE
M6V679)_<KE6N3Q:Y43K@TE\'QQXN_!+B7=> ^OU=;XY:^2"@2I=THZ]%]>%%
M[N7+C+53HKE14SS -G?"Z?UE=&_[X4_FTYT?V2/[&3A=_O>H_P"20YP^%U_K
M*:-_WPI_-ICH[LC_ -C)PN_WO4?\D@'SPTU:+5QU^$LU!;N(KHZJWQ7RX00V
M^K5$CJ$I-[*:!4[E:K8V*K>Y^%3KN/K!;[;26FAAHZ&EAHJ2!B,BIZ>-&1L:
MG<UK43")Y(<1]LGL 7'BGJV7B)PVN$5MU>]625EOFF6!E3(Q$VS12I^IR^JW
M.<-=C.6KG.A&]I3M>=F^)L&K[5<;G;*9,<W4=K]+@Z>"U<2HKU\UE4#JKM\]
MD^CXU<.ZC4&EM/15'$2@EB=!)1L9%-7Q*]K'QR.7"/VM7>U7+TV814W*9UV'
MK'KO279^L^G.(5LGM=ZL\\M'3QU,L<CW4B*CH5RQSDPB.5B=>YB'//"+X6C3
MUZK:>AXAZ5ET]S'(UUVM4BU,#5\7/B5$>UO]RLB^1W=IW45LU;8Z*]66NBN5
MJK8VSTU93/1T<K')T<B_C]X'K@                                 "
M3/13YY]H#0-54:NU+5T4_+22Y5,CTSURLKE/H=]Z<=\3(63:EU#&]BOW5M1X
M?^4<=#0S$7G=S=;7BK#DRDFOEE1[*69TKF]_550O6ZMDEH5],3%0WP7O4O;E
M6+:+M4TT<:^N[")@RVR<)4U!)#5U;=K4;G"]#OSM$;O!Y]^MX89#H*XTNIM*
MRT51&Q[7)M<JHAKZ]<,+E1U\T%-(]+<]<IM7H9KJ31\NF=/[K-*M.YBJZ16^
M)C&CN)E17/6W5<JRN1V"KB^,.AO./%P[,7MW *Y5EX9)-4M6C:N=INN@MU!8
M:**B@VI(Q,9P@K;?5.H4?;WK$_;G"&K-1<1)K%,ZGJ&;ZM%QN,>_".FTWWN.
MSZHQ_(3W$6]Q!GR4(M[CRSWU>Y$ !(
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M8KIJCLR\0+39K?57:YU5"UD%'0P.FFE7FL7#6-155<(O<B]P'.'P4ND;%?\
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M]R_^4B]3"^$2GTO-(]LCA#\=/9[U788(>==H(%N-M:B9<M3"BO:UOF]N^/\
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MD5/!.C6M3O1K6HN<*IM0#YX<#^#W:^LO%K2E=K745VJ=*4]?')<X9M1QSL?
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MED?)3MB3#*.H^7)3=.B-SAS$Q\G*)G8JG=WP::_]R/I?'_XJN7O_ /.I,?O
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MOW89^9 ^B -3=F?CU!VC>&$.LZ>SR6**6JFI?0Y:A)E18U1%=N1K>BY]AMD
M  /F%V9/]L_XB?MA??Y9Q]/3Y@]F;+?A/.(?BOV0OOA_Y5W4^GP
M                                        ^1/:9T9;>(?PF-5I>\-D
M?:[M=K/1U+8GJQZQOH:5KD1R=RX\3Z['RGXO_P"VQ4'^^"Q_S.D ZA_2O>!O
M_P" O7[J.^J>SI7X.3@1IFM95NTI/>96*CF-NE?-+&WVY8CD:Y/)R*=/ "PM
M-IH;%;*:W6VBIZ"WTK$B@I:6)L443$3"-:QJ(C41/!$/E_\ "Q?U^]!)X?81
MG\ZF/J>?+#X6'^OYH/\ :1G\ZF ^GGZ&;1^M5#]&9_H'Z&;1^M5#]&9_H/3
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MN=ERMJ'.1,-7N:IU@
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M<T313>E-M<"I-4JF.?.][I)9/<KW.5$\$PG@;%
M                           X=^%P_K":5_WS1?S6J-V=A?\ L3>&W[7N
M_EI#2WPL5OJKCP*TO'24TU5*FI8G*R%CGJB>BU2*N$1?+R[C=/8@IY:7LJ\.
M8IXW0RLM[MS)$5%3[M)WHO=T_A XFXH?[;51_MW:/_S?3'U!N5NI;O05=!6T
M[*NCJ8G0ST\S4<R2-R*US7(O145%5%1>]%/F-Q+M5=)\*[25;:2H=2I>K2Y9
MFQ.5B(E!3)\K&,(N<K^(^HX'R/U);K[\'#VL(+I;&5%9H*\*Y8XE7*5=O<].
M9 J^,L+E:J+WKABKA'JAZVF=26S67PIUNOMFJXZ^U7&N954U5$N6R1NM2*UR
M?]>_HIWEVJ^SW;^T=PFN&G*CE4]XAS56BO>G6GJ6M7&5_ >GJN3V+GO1#Y>]
MBG1%_P!*=LC15!>+-6V^JH+C54]2V:!R)$]M/,US57N[_'/N ^D/P@_]B#Q$
M_O5'_/8#7'P3?]C7>/\ ?-5?S>F-C]OV":K[(_$&"GBDGE?%289&U7.7^K8,
MX1$7NP?/GLR=LW6_9HX?U6D[9H".\T]1<)+@M15I.QZ.?'&S;AK<8^Y=_F!]
MCSESX1?B;1Z![,>HJ!\[67/4CH[31PY3+]SD=,['?M2)K^OM<U/%#FYOPH'%
MNZQ24]IX34<E<J99]RK)T3JG56-PJI_C(8UIKLT\>NVMQ#H-3\6UK=-Z7B<O
MK5T/HKHX%<BK#24JIEJNPGW1R87HJN>J84.BO@J]!U&E^SQ67VJC=')J*[2U
M,"NRFZGB:V)JX_NVS=?%,*<[?"4_V96B/VIMO\]J3Z?:4TU;=&:;MU@M%*RB
MM5MIV4M-3QIT9&Q$1$\^G>OBN3YE?"/6BOK.V#HF>GHZBHB;:K<CI(XG/:W%
M;/GJB=^%\>[O ^EVOM*Q:XT-J/3<S^5#>+=46Y[\9PV6)T:K^1RGS9^"OUHF
M@.,.NN&]\<VWW.Z1MY4,_1RU=&Z1)(D_MMLDCL>R)3ZCG ';:[%.J+IKKXX.
M$#IVZG;+'4U]LH7I%4+,Q/5JJ=V4]?HFYG>JHJIE55 ._P I.?MSEV$1,Y4^
M9^COA5=9:&A?8>)G#I:Z_46(IIHIGVZHW)T^ZT[XW8<O3*MVIGN;U0QSB;V\
M.*_:FH:C0/#+0]59Z>YM6"K2W/?6UDL;EPJ+*C&-AC<GREV]RKZZ)E .F>!O
M;SFXT=H>[\.;5H]E59H9ZMU-J*GKUQZ+"JHDSXE8N4>[8B*CD^6WH8?\*[Q?
M337#"QZ HIMM7J.J]*K&L7JE+ J.1KD]CY58J>WE.-D=AOL@1=FS2=1=+ZZ.
MIUW>8VI7.B<CV4<*+EM.QWBN417.3HKD1$RC45>2=4VRO[7OPAE-!44-5+I&
MVUZ4K9)H7)#Z!1Y>_JJ)ZLTB/Q_?T]@'H\->P?VG+'HVW.TSQ0I=(6VNB;7?
M8FFU'<J-87RL:J\R.*':DB=$=C/5N,JA[5\[!7:KU/::FUWGC/27:V53=D]%
M7:INLT,K<HN',= K7)E$7JG@?3( ?+'X-'B%7\(>/>JN$6H_ZD?='RPI#(N$
MCN-*KD<U,_A,;(F?'EL]J'U./E1\(-PZOO!OM0:?XHZ2HYFONCH;HR2GB5S6
MUU,YC9$5$ST<B0N7/RM[\^)],M ZPI.(&BK'J6A8^*DNU'%6,BDRCX][4=L<
MF.CD5<+YHH'S5^%A_K^:#_:1G\ZF/J>?+GX5.TUUQXZZ%DI:.HJ8VV5B.?#$
MYZ(J54JXRB+A<?PGU& 'RG[)?^V6:O\ VVU!_*3'U8/EAV4[17T_PD.KZF6C
MJ(J=UUO[DF=$J,7,LV.N,8Q_#T ZE^$FX;U6O^S#=JBA:Z:ITY60WM8VHF71
ML:^.7P[DCF<]?)AXOP8?%>AUGV>:?2O/:EYTK42TT\#E3>L$DCY8I,>SUWL_
M]6==U-+#64TM//$R>"5JQOBD:CFO:J85JHO145/ ^9W%3LF<5NR;Q3EXC<"$
MJ[O8YGR.?:Z2)9YJ:-R[EII8$7,\/1-JM17)M15PJ(Y0^G195M;!;J2>JJ9X
MZ:G@C=-+-,]&L8QJ9<Y57N1$[U7N0^=EF^%WJ+?1I2ZFX8.;>(5V3K17)86*
MOMY;XW.9X^JKG>\P?77:(X\]NV"32.@M&3V#2%3(D5:ZC>]T;TSU;4UKFM8C
M$3JK&HBN1%3#NX"R[/<DO:9^$5N&MJ-'.LU!7SWGFN;A4I86I#2Y3P55Y'3^
MZQW'1?PMO]CCIS_?73?S.M-O=D3LM6KLPZ!EMK9X[IJ.Y/;-=+HR/:DCD3#8
MF(O5(V9=CVJYRKC.$U+\*]0U5P[/&G8J6GFJI$U53.5D+%>Y$]$K.JHB+XJG
M[R>(&X.PO_8F\-OVO=_+2'/?PF/9CFU%9X^+VEH'MOUDC:EW;3HK7RTK/D5"
M;>N^)<95.NS"]$8="=B"GEI>RKPYBGC=#*RWNW,D145/NTG>B]W3^$W;54D-
M7334\\,<U/,Q8Y(I&HYKVJF%:J+T5%3I@#Y#]HGM01]HCLAZ,BNE2S]&=BO\
M=-=(LHCIV^C3(RJ1/8]$7=['H[P5#Z.=EF66F[*W#B6"!:B:/35*]D*+A7N2
M%%1N?-3Y:=M/LIW#@)Q8J([%0555HZ\J^LM4D,3GI"B+Z].JIGK&JHB9ZJU6
MKU7./JIV3H7T_9JX912L=%(RP4;7QO145JI$F4PO7HH&N.R9VX[=VHM5:AL;
M-,NTO5VVECJZ=LMP2H=5QJ]6R+CELV[%6/N5V>9X8Z]1GS'[2W92XF< ^,M5
MQ?X)0UE30S3OK9:6UQ<VHH9)'*LL:P(GW6!RJY>B*C4545$1J.6OISX7.^VB
MF;1:MX905=UARV::AN3Z-%<B+TY+XI%:JJGX?X@.D>USV2N'?$OA?JJ]?8&W
MV/4]MH)[A37JB@; ]7Q,<_;-LPDC7(W"[LJF<IA4-0_!$ZONETX>ZZT]52R2
MVRTUU/446_JUBSMDYC6+[,PM=CVO5?$U#Q![8?&CMFT-3H#AUH22TVJY)R*Y
MMO>^IE=&O>R:J<UC(HUQURC47Y*NPN%[D['?9PB[-/":&PS5$5;J"X3>GW:I
MA3U%G5C6\IB]ZL8B(B*O>JN=A-V$#?
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M-[B$?R$]Q%O<>9>QKW0B  D
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MM-;:"FM].KE>L-+"V)FY>]<-1$ST0]
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M7O7#41,E^    'CTFE;-1W.6Y4UHH(+C*KEDK(Z9C9GJJY55>B97*]_4]@
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MHG8QEKVL1S5PJ]47Q,]
M         L;E:Z.\T;Z2X4<%;2O5%=!4Q-D8["Y3+5147"HBDMJLMOL5-Z-;
M:&FM]-E7<FEA;$S*]ZX:B)GHAZ    "UJJ6"MIYJ>HACGIY6.CDBD:CF/:J*
MBM5%Z*BHJY1?:6MHTW:-/ME;:K716QLJHLC:.G9$CU3N5=J)G!Z@ %G76ZEN
MM+)2UM-#64TB8?#41H]CDSG"M5,+U1/R%X /(H=+V:V6^>@H[314E%492:F@
MIF,CDRFU=S43"Y3IU\"-FTS9]/<];5::&V<['-]#IF1;\9QNVHF<97O]JGK
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MLUOL= WY-+;:6.GB3W-8B)^\>P
M                  AM3V#:GL(@         0VI["(    0VI["( L:^TT5
MWIW05])3UL*HJ+'41-D:N4PO14\4*E#;J6VP)!24T-+"BY2."-&-_(GN0N@
M(;4]A$   !#:GL&U/81 $/Q$0      "PK;);KG)&^LH*6K?'\AT\+7JWW93
MH7K6(UJ(B(B)W(B=Q,    AM3V$0    'EU^F[3=E<ZNME%6N=A7+44[)%7'
M=G*>&$_(>H +>DHX**'E4\$=/$G5&1,1K?R(5_Q$0
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ML]7:.*FF$D8NU]VI-RJG_EF'TT9W(>;UT_?A[[HC?JIB4X .<[X
M  (808]X$00Q[QCW@1!#'O&/>!$$,>\8]X$00Q[QCW@1!#'O&/>!$$,>\8]X
M$00Q[QCW@1!#'O&/>!$$,>\8]X$00Q[QCW@1!#'O&/>!$$,>\8]X$00Q[QCW
M@1!#'O&/>!$$,>\8]X$00Q[QCW@1!#'O&/>!$$,>\8]X$00Q[QCW@1!#'O&/
M>!$$,>\A^4"8$.OD1       (-[B&XQN)@0Z^0Z^1D1!#KY#KY 1!#KY#KY
M1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#
MKY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#
MKY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY
M1!#KY#KY 1!#KY#KY 1!#KY#KY 1!#KY#KY 1!+T[R".50)P        2$?Q
M@3 AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\
MAU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@
MAU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\
M@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\AU\@(@AU\
MB'X@)@2_E)@      "5JY\2 $X(=?(=?("((=?(=?("((=?(=?("((=?(=?(
M"((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(
M=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((
M=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?("((=?(=?(
M"((=?(=?("((=?(=?("((=?(=?("((=?(97V 1        !( )P0SY#/D!$$
M,^0SY 1!#/D,^0$00SY#/D!$$,^0SY 1!#/D,^0$00SY#/D!$$,^0SY 1!#/
MD,^0$00SY#/D!$$,^0SY 1!#/D,^0$00SY#/D!$$,^0SY 1!#/D,^0$00SY#
M/D!$$,^0SY 1!#/D,^0$00SY#/D!$$,^0SY 1!#/D,^0$00SY#/D!$$,^0SY
M 1!#/D,^0$00SY#/D!$$,^0SY 1!#/D,^0$0"&X"(        )"/XP)@0Z^0
MZ^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00
MZ^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0
M$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0
MZ^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^0Z^0$00Z^1#\0$P)
M?RDP         $.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.
MOD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!
M$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.
MOD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.OD.OD!$$.
MOD.OD!$$.OD.OD!$$.OD.OD!$$O5 WQ F          $BGSRXGW&63B7JR-D
MBHU+K5-VYZ=)GH?0QW<I\\.)=OE=Q*U8K6.3-WJW(OOF>=#0^_.SA=+;SBB(
M8G);9]JO=#NC7O<A0IH>35L:CG;57JP]JFKYJ>1()L*UW3J7+].5CT]*CB79
MW]QWMI>-B+5GDR>DM--2V>2>)GW21N,$-%V&"HJW2/B3FHO<6.F[^Z.=U-5M
MPQ.B&5:=J(X[RY8UPUQKVW=+#-=OO,AJ:1JTZQ]&M[MN.I+IZCEM[E<UG,8O
M@I</AWMEW+ZV<I@JVZ1L<>QS]J^:FO9TJ1$>ZZS9\E"+>X@SY*$6]QP7J:]R
M( "0                                             D)7?J;O<3$K
M_D/]QF$;>[+XP5=5#;:M8X</1?;U*D3II-ST>UC<?)3ID\B7E\Q)HV\S]\NW
M3.F2-S45F#W%.==GQ:UK\<V9GI?7]?I.-[:5R-W=^[J7T?%^^.DD:Q^]DG16
MN[C V.Z9<],E.:X\EJX8U_LP57K#9C-DRQM+.J"N^[+5W&ROJF+U]5Z(9U;.
M+#[?;7PQ:<]'HE3U7JJ*IIJDDN%=1N8M3RV?@M4N;MJSDV>*WQK(DS5PKL9R
M.'DW,&>*3PNC^#.HJ*]:STW.]K8YW76E1K?-9FX/H$G1#Y;=F#?5<3--0212
M(L=TI9-SDPG25JGU'\%/-ZV/OP]WT57;',^,J@()W$3GNV        AX=3 =
M3<;-(:3O-1:;I=?1J^#;S8?1IG[=S4<G5K%3Y*HO>9\B80D?!&_O:B_B*<D7
MF/N3M*59K$_>C>&L_MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@I^0<B/\
M!3\AJ\&J\T>G^UW%A\L^O^FM/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@
MI^0<B/\ !3\@X-5YH]/]G%A\L^O^FM/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9
MLOD1_@I^0<B/\%/R#@U7FCT_V<6'RSZ_Z:T^V1X??KX[Z%4?FQ]LCP^_7QWT
M*H_-FR^1'^"GY!R(_P %/R#@U7FCT_V<6'RSZ_Z:T^V1X??KX[Z%4?FQ]LCP
M^_7QWT*H_-FR^1'^"GY!R(_P4_(.#5>:/3_9Q8?+/K_IK3[9'A]^OCOH51^;
M'VR/#[]?'?0JC\V;+Y$?X*?D'(C_  4_(.#5>:/3_9Q8?+/K_IK3[9'A]^OC
MOH51^;'VR/#[]?'?0JC\V;+Y$?X*?D'(C_!3\@X-5YH]/]G%A\L^O^FM/MD>
M'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@I^0<B/\ !3\@X-5YH]/]G%A\L^O^
MFM/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@I^0<B/\%/R#@U7FCT_V<6'
MRSZ_Z:T^V1X??KX[Z%4?FQ]LCP^_7QWT*H_-FR^1'^"GY!R(_P %/R#@U7FC
MT_V<6'RSZ_Z:T^V1X??KX[Z%4?FQ]LCP^_7QWT*H_-FR^1'^"GY!R(_P4_(.
M#5>:/3_9Q8?+/K_IK3[9'A]^OCOH51^;'VR/#[]?'?0JC\V;+Y$?X*?D'(C_
M  4_(.#5>:/3_9Q8?+/K_IK3[9'A]^OCOH51^;'VR/#[]?'?0JC\V;+Y$?X*
M?D'(C_!3\@X-5YH]/]G%A\L^O^FM/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LO
MD1_@I^0<B/\ !3\@X-5YH]/]G%A\L^O^FM/MD>'WZ^.^A5'YL?;(\/OU\=]"
MJ/S9LOD1_@I^0<B/\%/R#@U7FCT_V<6'RSZ_Z:T^V1X??KX[Z%4?FQ]LCP^_
M7QWT*H_-FR^1'^"GY!R(_P %/R#@U7FCT_V<6'RSZ_Z:T^V1X??KX[Z%4?FQ
M]LCP^_7QWT*H_-FR^1'^"GY!R(_P4_(.#5>:/3_9Q8?+/K_IK3[9'A]^OCOH
M51^;'VR/#[]?'?0JC\V;+Y$?X*?D'(C_  4_(.#5>:/3_9Q8?+/K_IK3[9'A
M]^OCOH51^;'VR/#[]?'?0JC\V;+Y$?X*?D'(C_!3\@X-5YH]/]G%A\L^O^FM
M/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@I^0<B/\ !3\@X-5YH]/]G%A\
ML^O^FM/MD>'WZ^.^A5'YL?;(\/OU\=]"J/S9LOD1_@I^0<B/\%/R#@U7FCT_
MV<6'RSZ_Z:U^V2X?_KX[Z%4?FR'VR/#_ /7QWT*H_-FR^1'^"GY!R(_P4_(.
M#5>:/3_9Q8?+/K_IB>C>*FF==5,]-8[CZ9-"SF2-Y$L>UN<9R]J&8)A"1D+&
M9VM1/Q$V3;QQ:*_?G>5-MM_NQM"8 %J(  +.JK(+?32U-3,R"GA:KY))'(UK
M&HF5557N1$/ 3BCH]-V=4V9?_;XOK&05E'!74LM-4PLGIY6+')%(U'->U4PK
M51>BHJ+C!X'Q6Z-^:MF^@1?5-7+U^\=5MM\UM.KY\>__  C\:6COG59_I\7U
MA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U2C\Y^WZK/P/G]#XTM'
M?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'
MS^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^
M<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1OS5L
M_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5
M'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-
M6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59OI\7U
MA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WS
MJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5F^GQ
M?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'
M?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'
MS^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^
M<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1OS5L
M_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5
M'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-
M6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59OI\7U
MA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WS
MJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5F^GQ
M?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'
M?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'
MS^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^
M<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1OS5L
M_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5
M'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-
M6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59OI\7U
MA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WS
MJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5F^GQ
M?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'
M?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'
MS^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^
M<_;]3\#Y_1+\:.C_ )U6;Z?']8]"R:HLVI%F2TW6CN7)QS/1*ALNS.<9VJN,
MX7O]AYZ\+-'?-6S?0(OJGI632MFTWSEM-JHK8LJ-23T2G9%OVYVYVHF<97&?
M:I9C[3Q?B;;?+?=&W4[3P[[_ #VV>R #=4     #&[CK_3EGJY*6NO\ ;*.K
MCQO@J*N-CVY3*9:KLIWI^4HIQ1T=\ZK-].B^L5[EP_TU=ZR2KK]/VRLJY,;Y
MYZ.-\CL(B)ERIE>B(GXD*"<+-&_-6S_0(OJFA/:>*>';;_EL5ZG:-]]_^$?C
M2T=\ZK-]/B^L/C2T=\ZK-]/B^L/BLT;\U;/] B^J/BLT;\U;/] B^J1_.?M^
MK/X'S^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$
M7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1
MOS5L_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^
M@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK
M-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59O
MI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-
M+1WSJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5
MF^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#
MXTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^W
MZGX'S^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$
M7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1
MOS5L_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^
M@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK
M-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59O
MI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-
M+1WSJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5
MF^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#
MXTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^W
MZGX'S^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$
M7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1
MOS5L_P! B^J/SG[?J?@?/Z'QI:.^=5F^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^
M@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#XTM'?.JS?3XOK#XTM'?.JS?3XOK#XK
M-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA\:6COG59O
MI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-
M+1WSJLWT^+ZP^*S1OS5L_P! B^J/BLT;\U;/] B^J/SG[?J?@?/Z'QI:.^=5
MF^GQ?6'QI:.^=5F^GQ?6'Q6:-^:MG^@1?5'Q6:-^:MG^@1?5'YS]OU/P/G]#
MXTM'?.JS?3XOK#XTM'?.JS?3XOK#XK-&_-6S_0(OJCXK-&_-6S_0(OJC\Y^W
MZGX'S^A\:6COG59OI\7UA\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$
M7U1^<_;]3\#Y_0^-+1WSJLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1
MOS5L_P! B^J/SG[?J?@?/Z%)Q'TK65$4%/J6TU$\SD9'%%6Q.<]RKA$1$<N5
M5<&2HNY.AC=-PXTI25$<]/IJTP31/;)'+'11-<QR+E'(J-Z*BHBHIDJ(B)T_
M>-G#UNT]9MO\M_\ RIOP;_<W_P"4X -A   %-N40\B]ZHL^G%B2[76CMJ39Y
M:U<[8]^,9V[EZXRGY3VL=#Q[WI6S:C6);M::*YK#N2/TN!DNS=C=C<BXSA,X
M]B%5^/AG@VW^?<S7AW^]OM\N]Y_QI:.^=5F^GQ?6'QI:.^=5F^GQ?6(?%9HW
MYJV?Z!%]4C\5FC?FK9_H$7U33_-_M^K8_ ^?T/C2T=\ZK-]/B^L/C2T=\ZK-
M]/B^L/BLT;\U;/\ 0(OJCXK-&_-6S_0(OJC\Y^WZGX'S^A\:6COG59OI\7UA
M\:6COG59OI\7UA\5FC?FK9_H$7U1\5FC?FK9_H$7U1^<_;]3\#Y_0^-+1WSJ
MLWT^+ZP^-+1WSJLWT^+ZP^*S1OS5L_T"+ZH^*S1OS5L_T"+ZH_.?M^I^!\_H
M?&EH[YU6;Z?%]8?&EH[YU6;Z?%]8?%9HWYJV?Z!%]4?%9HWYJV?Z!%]4?G/V
M_4_ ^?T/C2T=\ZK-]/B^L/C2T=\ZK-]/B^L/BLT;\U;/] B^J/BLT;\U;/\
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M_4_ ^?T/C2T=\ZK-]/B^L/C2T=\ZK-]/B^L/BLT;\U;/] B^J/BLT;\U;/\
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M_4_ ^?T/C2T=\ZK-]/B^L/C2T=\ZK-]/B^L/BLT;\U;/] B^J/BLT;\U;/\
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M%$SNGU.T[LOLE<ZX4D<O>]4Z]">KC7F=>B^1=VFV-M].K6_)1>A<24B3?=/
MHLV\/>ZM;W$2#>XB<%ZN.X  9
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MUU/M>[OZR-.[SDCAW;EHZC1<2)C^K:9RICV2-.N6IT4\EKI_$?7-'6*TF(1
M!H.@
M
M
M
M
M                                  "5&H,>1, )?R#\A, )?R#\A, )
M?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\
MA, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )
M?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\A, )?R#\
MA, )?R#\A, )?R#\A, )>GM"-]RDP
M
M
M                               )?!QS+JMVW5=X1>B>F3?RCCIIW1''
M+6JYG+JV](O<E=-_*.-S2^]+F:Z=JPK0>CR1JUR->I;K2>L[8F&EJV5(F[DS
MD].WS)*U47]\Z+D5M'@M4VM:YKFY0DI+52/<Z5D+$5"\J8DC5>GRBE$BTN5[
MT]F3/P)G=<1M2159L]5":&%K-V5RW\$IT<R.W=,%W1.A:YRRB6:][I-GR4(M
M[B#/DH1;W'!>GKW(@ )
M    "0E=\AWN)B#OD.,PC;W9?,2X4^G]&H^L6AYM9CU7-7)J?56N+U<:MTD5
M5/31N7$<:=Y4TZZ]WRN93HKZY,_*7J;PLW#BED@IY*VEC=/&F[UD\3U=*UK7
MO?->SWM:6F=.\3-::=J*65U1(^D:J;DD0R[7'$/36MZ-C;E3)#5*WK-&B=YL
M6^:59J:C?;Z2BC5W<KHT,:L_8TKKTY9I;HD$6?DYPJ%U<D5^*B_1M[?!H%]O
M?15;F,C;/32.]17=_4W[P5[/-?<ZRGO-:K8J5BHZ)IN;A[V2M(:3C;4WRJEN
MDK4W-:J]#-KA=*>VL2@M=*R"DCZ1MC3"K[RC)J-W?T71U,->*>]ZVGZ&.GU'
M8H6JUW)JH43'D]IT2WN.<=$4<T^H;94/RF*J)V%_NT.C4\#SVIG>T/3:7W93
M  U6\
M
M
M
M
M
M
M
M
M                                                      )'=SCE
MS5>YNK+UAN4]-G_E''4CNXYPU!1I-J6\KS&I_5LW3_UCC<TL_>ER];&]88\K
M4DBPK<?B*:U'+<B-RAZ7H<L4FYWK1]W1"UDIFN<[[W\1T7*K6%W#5I+'M?U*
M4D*N]9%_$6M/ ]LCD5?53N+A*A6Y3&0Q/)%E1R6JBMZE-:Y),^KA21>;428:
MGXBM%;Y<=6AFO>ZH9\E"+>X@SY*$6]QPGIZ]R( "0
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MU<V.9JG !HNL
M
M
M
M
M
M
M
M
M
M )7=QSOJ.C=)J2[*U4;_ %9,O?\ VZG1#NXY[U$V&34UU1TKF+Z5-W?W:FWI
MN^7-UGNPLTJN1#RE:CBBLE/+T<F%)_1T;)EKT>TD6WI,JN3U7'0<E,E#$[.'
M="@ZVMST4JTE._G*Q%7WYZ%XZG;3N1LCVJY?8H.^5*V6='2;FN^Z>"+W%2X4
M=='N1[48WVH7W)=3*B,Z*K<HIY;_ $Z29^][I&^PPMI#I).XB03N(G%>C@
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MTPWB?%4 !R7K@
M
M
M
M
M
M
M
M
M
M !*J=#0VI;6R2]W.3=ZZU4J_\=3?7X1HR[P2U&HKICY*54OC_;J;6FY3+G:R
M/NPQEM'*URXZDKJJ=[EC1JH9"Z%&1*_&'-/*14GF7EMVJBG0W<A-3U"T[</9
MG/B49X8IG\Q)%W^Q3W:2WQ\G=.N?+!:K34LE1A&[>HW6UJITE3)-'E5VJU,)
MDNJ1/6<Y^%+FIM\436O1V$QG!0^R%)%$K=F7&-UM8;X3N(D$[B)QG>@
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MT[:/-:ZTVO$R]]T;BC'2VWBG !SG9
M
M                                    @!$$,C($0   ( 1!#(R!$
M                                " $00R,@1!#(R!$$,C($00R,@1!#
M(R!$$,C($00R,@1!#(R!$   0R,@1!#(R!$
M
M
M
M
M
M                                                          $/
M!325^I9/L]<71R;4=4R9_P"&INW\(TIJ-KUN]Q5'8:E1)W?W:FQ@[Y:.I]V%
ME*WDPO:YVZ54/.MT<L;I'JWH1J:ASV]5RJ?@]Y3BK7K3N;&B[O,WH<>5S1WW
M%1(V5F6%_4U$4S>9"Q-QCU$SF+(US7*\K0LJ*63:C'*Q26T$6FO)?K5OJEP]
M,(G0M):#[HKDZIY%Q3R-:U['-5'JN>I68Z2-/DHK5\AM"VDS+?J=Q$@G<1..
M]#                                                "0@[Y#B)!W
MR5$,6]V7R^U-I"2VQ87?)^^8'=K'4(U%:W8GL-D6[B57W21:6NMD;Y'=$<>R
M_1[;O1SS3(Z)-O3:G5I["EHX7S3+IYO:=FAV6]K),U,FU/9DN(5LT,F53#O%
MZID]_46A:FGE<K8)I8TZH]S5,<6%;;(K74K9/!<YR71>-]G,R8YQ3ML]RFNE
MCIW,>E,DZIWX;@S:S<<+=::1\$%E?'(B=%:_&34\RR.ERQ&Q(O@6\L<M/-O<
MJ2(O=@E--TYUEJUX8;ZX8\8;G?.*ND:?T=T=/+>*.)4<N>CIV-7]X^DK>[)\
ME."5<^3C%H=NW;F^T*+](C/K6GR40\UTA'#DA[3H#)?)AOQ3OS3@ YCU
M
M              @B_C(>X\V\W>EL=KK+C6R+!1T<+YYI-JNVL:U5<N$157"(
MO<BFN4[4/#5,_P#9 [W^@U/YLG7'>_NQNU,VJP8)B,MXKOXSLVQ^,8\S4WVT
MG#;YP.^@U/YL?;3<-OG OT&I_-EO9\WDGT:_M'1_Y8]6V<>8QYFIOMIN&WS@
M7Z#4_FQ]M-PV^<"_0:G\V.SYO)/H>T='_DCU;9QYC'F:F^VGX:_.!?H-3^;'
MVT_#7YP+]!J?S8[/F\D^A[1T?^6/5MG'F,>9J7[:CAK\X%^@U/YLA]M5PT^<
M"_0:G\V.SYO)/H>T='_ECU;;QYC'F:D^VJX:?.!?H-3^;'VU7#3YPK]!J?S8
M[/F\D^A[1T?^6/5MO'F,>9J/[:KAG\X7?0:G\V/MJN&?SA=]!J?S8[/F\D^A
M[1T?^6/5MSH1Z&H_MJ>&?SB=]!J?S8^VJX9_.%?H-3^;'9\WDGT9]HZ/_+'J
MVWCS&/,U)]M5PS^<*_0:G\V0^VKX9_.%?H-3^;'9\WDGT8]HZ/\ RQZMN="/
M0U%]M9PR^<7_ ,#4_FQ]M;PR^<2_0:G\V8[/F\D^C/M+1_Y(]6W>@Z&HOMKN
M&/SC_P#@:G\V/MKN&/SC_P#@:G\V.SYO)/H>TM'_ )(]6W,>8QYFH?MKN&'S
MC7Z#4_FQ]M=PP^<B_0:G\V9[/F\L^A[1T?\ ECU;>Z$>AJ#[;#AA\XU^@U/Y
ML?;8<,/G&OT&I_-CL^;R3Z'M+1_Y(]6WL>8QYFH?ML>&'SC_ /@:G\V/ML.&
M/SC_ /@:G\V.SYO)/HQ[1T?^6/5M[H1Z&G_ML^%_SC_^!J?S8^VSX7_./_X&
MI_-CLV;R2S[2T?\ DCU;@Z#H:?\ ML^%_P X_P#X&I_-C[;/A?\ ./\ ^!J?
MS8[-F\DGM+1_Y(]6X.@Z&G_ML^%_SC7Z#4_FR'VVG"_YQN^@57YH=FS>6?0]
MHZ/_ "1ZMP]!T-/?;:<+_G&[Z!5?FB'VV?"_YR.^@57YH=FS>6?0]HZ/_)'J
MW#CS&/,T]]MGPN^<COH%5^:'VV?"[YR.^@57YH=GS>6?0]H:/_+'JW#@8-/_
M &VW"[YQN_<^J_-$/MMN%WSD7]SZK\T.S9O)/H>T=)_DCU;AQYC'F:>^VVX6
M_.1W[GU7YH?;<<+?G([]SZK\T.SYO)/HS[0TG^6/5N''F,>9I[[;GA;\Y7?N
M?5?FA]MSPM^<KOW/JOS0[/F\D^A[0TG^6/5N'"$<(:=^VZX6?.1W[GU7YH?;
M=<+/G([]SZK\T.S9O+/H>T=)_DCU;AQYC'F:>^VZX6?.1W[GU7YHA]MSPL^<
MKOW/JOS0[/F\D^A[0TG^2/5N+'F,>9IS[;OA7\Y7?N?5?FA]MWPK^<KOW/JO
MS0[/F\D^A[0TG^6/5N/\8_&:<^V\X5_.9W[GU7YH?;><*_G,[]SZK\T.S9O)
M/H=OTG^6/5N/'F,>9IO[;SA5\YG?N?5?FA]MYPJ^<SOW/JOS0[-F\D^A[0TG
M^6/5N3'F,>9IO[;SA5\YG?N?5?FA]MYPJ^<SOW/JOS1GLV;R3Z'M#2?Y8]6Y
M,>8QYFFOMO>%/SF=^Y]5^:'VWW"GYS._<ZJ_-#LV;R3Z'M#2?Y8]6Y<>8QYF
MF_MO>%7SF=^Y]5^:(?;?<*?G.[]SZK\T8[/F\D^A[0TG^6/5N7'F,>9IK[;_
M (4_.=?W/JOS0^V_X4_.=?W/JOS0[/F\D^A[0TG^6/5N7'F,>9IG[<#A1\YW
M?N?5?FA]N%PH^<Z_N?5?FAV?-Y)]#VAI/\L>K<V/,8\S3/VX7"CYSK^Y]5^:
M(?;A\*/G.[]SJO\ -#L^;R3Z,>T-)_DCU;GQYC'F:8^W#X4?.=W[G5?YH?;A
M\)_G0O[GU7YH=GS>2?1GVAI/\D>K<^/,8\S2_P!N%PG^<Z_N=5_FA]N%PG^<
MZ_N=5_FAV?-Y)]#VAI/\D>K=&/,8\S2_VXO"?YT+^YU7^:(?;B<)OG0O[G5?
MYH=GS>2?0]H:3_)'JW3CS&/,TM]N)PF^="_N=5_FB/VXG"7YT+^Y]5^:'9\W
MDGT/:&D_R1ZMT80=#2WVXW"7YTK^YU7^:'VY'"3YTK^YU7^:,=GS>2?1GVAI
M?\D>K=/0=#2WVY'"3YTK^YU7^:'VY'"3YTK^YU7^:'9\WDGT/:&D_P D>K=/
M0=#2WVX_"/YTK^Y]7^:(?;E<(_G2O[G5?YH=GS>6?0]H:3_)'JW5T'0TK]N5
MPC^=*_N=5_FB'VY7"/YU+^YU7^:'9\WDGT/:&E_R1ZMU]!T-*?;E<(_G4O[G
M5?YH?;E\(OG5_P#+JO\ -#L^;R3Z'M#2_P"2/5NOH.AI3[<OA%\ZE_<ZK_-#
M[<OA%\ZE_<ZK_-#L^;R3Z'M#2_Y(]6Z^@Z&E/MR^$7SJ7]SJO\T/MR^$?SJ7
M]SJO\T.SYO)/H>T-+_DCU;KZ#H:3^W,X1?.O_P"75?YH?;F<(OG7_P#+JO\
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M
M
M
M
M
M
M                $/::1OE1&Z]W.)R]?29?XZF[?PC1FI(X?LY<G;MC_29?
MXZFSI^<RT-7/W8>:Z&"*3HO5?:7#E@C1&Q*U7N/,F1\CO5192K#:FO<E1SN4
MB=[<F^Y,O3H:1S:KU5;N<>C);*EU0U/5VJ>'3S-YZOCD<['B9-157,A:YTBJ
MI5;?<K7>5&JL*MD:]V%=CP$5$BIM<G0]?<DB(YS_ %0UM,Y?EE4VF&[2L0V:
MG<1()W$31=B                                                $
MA!WR5(A>Y1",]SYH4UE?;KJB5#'1N]KD,OL,S_2%S5M<QG^Y+XF67.V4=R<Z
M1B?=.Y$5"II[A-4W7?.Z1L.U,IX'H8R<GD:89BW-2=>4N#6T<UMC6!W3<U$,
M5U5PVMWI"2P4+E1R97'7J;+IK#0:9RROK&/?X)E,F26BVPUD'.:S?3KW9ZF.
MMVYK;Z2EX<7ZKT'5>EN6*E>C$ZXP8/412TE4Z%T2L5OX1W)J^RT%KIJNLJH/
M71B[6-0XQU<Z6X7JLF9$Z*/<NU,8-S!FFSQVNT_5VY/6X-X;QBT+TPOV?H>[
M_"8SZUM[D/DKP0HU;Q>T.]RJJI?J'O7_ ,X8?6QJ>K^(Y/2?]R'K/LUOU%]_
M%, #DO8
M                        ##N+J?\ :LU?^U%7_(O/F_E#Z/\ %_\ K6:P
M_:>K_D7GS=W'INB/=N^5?;'^]C_B4^4(;BGN]XW>\[[YWS5-Q+N)-Q+N\P<U
M7<0W^93W$,J&4^X;BEN&X"?=YD-Q)N\R&[WAG:53*DNXDW$-X95-Q*2;B3<!
M5W#<4MQ#=YAG>57=YD-Q2W>\;O>#>53<0W^:E/<0RIG9+FGW#?YE/*$-PV.:
M?<-RDFXEW&=CFJ[E]I+E"3<2[O,;,[0J[B&]?:4]WO(;AL;RJ;_-2&]2EN\Q
MN,\)O*IO\R&[WE/<2[API*NXEW>93W$-WF.$5=Q#<4]WO(;APB?<0SY%/=YD
M-QGFSO*IN\R&4]A)N)=QGF;RJ[B&[S*>XEW>8V-Y5-PW%/=[R&X;&\I]PW%+
M=YC<-F>:?=[QN]Y3W#*@YI]Q#=YE/<-QD3;AGR)-WF0W>\"<AN)-PW!G>4^X
MAN\RGN(;@;RGW#*>PI;AN,)<U7<2[O,I[O,AN]X.:?=[AO\ -2GN&X,[0GWJ
M0W>93W>9#<#>%3=[R&XDWH2[@SLJ[B7=YE+=YC=[PRJ[B',*6XEW>8%;?YJ0
MW%+<0WK[0SNJ;O>0W%+<-P-Y3[O,;BGN&5!O*?<2[B3<-P9YI]Q#<2[B7=Y@
M5,J2[B7<0W 5-WO(;BEN&XELSNJ;O,EW%/=YC=[QL;JFXEW$FXEW>8V-U7<0
MW+[2GN(;AL;JF[WD/Q%+<-PV-T^[S&[O*>[S(;O>-C=4W$U-52TDS)8)7PRL
M7<U\;E:YJ^U%3N*&X;C'#68YIQ-JSO#<>@.UIQ*T"YC(KZ^\T:=?1KSFI:OD
MCU7F(GN<==\'>VMI#B%-#;KXBZ5O,F&HVJD1:65W=ADO3"^3D;[$5RGS?W?*
MZC<<[/T=@S1RC:?%WM%TUJM),1Q<5?"7VK9(CTRBY3O)V]ZGS5[/7:_OG"::
MGLU]?+>]*;D;RWNW5%&WVQ*O>U$^\7ITZ*F3Z'Z7U5:]8V.CO5FKHKC;JMB/
MAG@<BHY/%/:BHN45J]45%14RAY'5:3)I;;7CEXOI?1_2>'7TWI.UH[X>\"0&
MF[*<
M
M
M
M
M
M                !#P4T;>Z*+[/W)T[E3-5*J>Y7J;R_"--7]K77NX95,^D
M2=_]TILZ?E,M#51O6'DI2XRL/5%)&T:0YCD]9SOO2]AIU[F.V_P$[J1[4RYR
M9]IO;N;PK=L4=/ ]B0XPF<^TK6RO1T>-OXB6+^IW.6=>8CNC2S61C:IJ1M5$
MR5[\]F:\I9#/42>AJYC,(G3)9456CFJKTQ^,J7BJ6GLZ1(BMW]<X/*I9(9:5
M$654=[C'#Q+9MLWVG<1(-[B)S7:@  9
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M^.-W;Z"K%<5XCQ3@ YKTX
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MX*^F944T[*FGD3+)8W(YKNN.BIT+K'>71,3SA7W<I3  D
M
M
M
M
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M4C6IRKG3.3'E*TZY.=J[<=H=?HG%U5+1\TZ  T7>
M  $"(    0(@
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M\RGN(;O,,JFX;BGN]Y#<&=D^XAN)-WF0R@9V3[O,;O>4]PW!E/N(;O,I[AN
MGW>9#<4]WO&[W@5-Q+N*6[S&X"KN)=WF4]Z^TEW!G96W>\EW>93W$-P-E3=Y
MD-Z^TI[O,AN,[&SV]):KK]$ZGM=^M<G)K[=4,J(G>&YJHN%]J*B85/%%5#[&
M:)U32:WTE:+_ $2_U+<J6.JC15RK4>U%VKYIG"^:'Q8W'TA^#YUJNH.#=199
MI=T]CKGPL:JY5(9/NC%_X2R)[FGG>E\/%CKE^,<GM?LSJ9IEMIY[K<W4P /)
MOI0                          ('FW_\ UCKO."3^*IZ1YU__ -9*[^\2
M?Q5*<O\ ;LGB]^'S[L%EGU%>J*UTKHV5%7*V*-TRJC$5RXZJB*N/<BFVF]DW
M6*M1?3K-_EY?S1K'0UWI]/ZOL]SJT?Z-25,<TG+3+E1JYZ(=0)VKM'(B)R;E
M]';]8^4]%X.C\U;SK+[6W\=GTSI//TAAO2NEKO&WANU9]J9K'_\ '6;Z1+^:
M-\\;T6/A%?V+U5*9J?\ &:6FB^/NF]<W^*T6^.MCJIFN<SGPM1OJHJKU1R^"
M%]QT_K4:C_O"?QD/88=)H\&CS7T=MXF)WY[]T/)Y=3J\^JPTU<;3$QMRV[Y<
MY]F#^NE3X_\ PLW^8V1VO?\ 8_8?#^JG_P 136_9?_KIP?X++_ ALCM??['K
M#_A4G\0X&DF?8>7^?_3O:F(]M8H^7_M;=CSK0ZE_OD'\5YT6B]_B<<\".,-I
MX7TUWBN5+6U+JQ\;F>B,8[&U'(N=SF^U.[)M1.USI5/_  5>/Q10_G3L=#])
MZ3%HJ4R9(BT;[^LN3TMT?JLNMR7QXYFO+_M#2O:(7'&#42?VU/\ R$9U?PF7
M/#32_P"UU/\ R;3C3BCJNFUQKN[7RCCFBIJKE[&5#41Z;(FL7*(JIWM7Q.R^
M$WJ\--+_ +74_P#)M-/H+)7+TAJ+TGE,SS\>;:Z9I;%H=/2\;3$1_P!F7>90
MFG931/ED>UD;45SG.7"(GM5?<7"F-:_M=1>]&7RWT;4?55=%-!$U7(W<YS%:
MB97S4]SDM-:3-><P\;2(M:(EJ+C#VC**W4<]HTM4-K;A)ECZV-=T4">.U?OG
M>S&43S[C1O"!57B=IMRKZWIC.OO4W3H?LPP6*FEN.I)XKC4QQJZ.CB1>0Q41
M>KE7"O7NZ81$]BFE>#_]<W3?^&1_PGS+73J[:O#DU7*)M&T>'.'T30]DKI,^
M/3<YB)WF?CREWDUW1$7V'/?:&XU5=AG=IFPSN@K%:CJRKC^7$CDRUC5\'8ZJ
MO@BICRZ">GW)W7[T^?FJJ^;4VL[I4JNZ:KK7HU%7/1S\-;^),?D0]-]H-9DT
MVGKCQ3M:\[?\//= Z3'J,]LF6-XISV9!P^X/:CXF/EJZ9B0T6[U[A5JNUZHN
M%V]%5R]_ETZJ95J'LLZGM5"^HH:FENKFIET,>Z.3']JCDP[\J?C.IM.66FTW
M9*&V4C493TT+8V],9PB)E?->J^\];:F"K#]G--.'\29F\]\[_%9E^T.IZW?%
M$16.Z-O@X>X7\5[QPQO3(97336I9$95T$F?5PN'*U%^2]/8G?CJ=GMO5(^QK
M=8YFNHN1Z1SD7ILV[MWY.IR1VG-.P67B0^HIXDC9<*9M0]&IA.9ES7+^/:U5
M\U7VF[>SO5MU%PCI:.L:V>*-9J-[']=T>5PU?+:Y$Q[$-7H;-FP:C+T?>V^W
M=+8Z7PX<^GQ:^D;3;OAS?J75.H.,NM8X$?)*ZJG2.CH5?]RA;UQT_N>JN[^F
M>XR35G9LU#I73L]W],I*Y*:-9IX(=R.:U$17*F4]9$ZKX=#I&S\(M)V&\P7>
M@L\5)6P*[EOB<],;FJU?5SA>BKX>9YO'36U'I'0EQBE>U:VOB?34T&>KG.;M
M5V/8U%ROXO:8R="TQX<N?6WWMW[[_P#WQ9ITQ>^;'@T5-J\N6S479DXFU\.H
M8]*UU1)4T54URTBR.55A>UNY6IG[U6HO3P5/-3=W&6[_ &$X8ZBJ$=M<M*Z%
M%SW.D78G[[CFOLS:=GN_$REKXV+Z/;8Y)I'X]7+FN8U,^W+U7']JIM_M67;T
M#A]!1M=UKJV-CF^UK4<]?^,C?RF>CM3FKT1DR9)[M]I^6VT(Z_38[=*TICCG
M.V\?/?FYKT7H"]Z^JJFGLU,VIEIF(^3=(UB(BJJ(O54_ZH9:O9MUZG_@N'Z3
M']8\;ASQ6N7#.GN7V*I*::IK5CW2U2.<C&MW+A$:J=?6]OXC9NC^UC<&US(M
M26^G=1O7#JFB:YCHNO>K7*NY/<J?C[CSFAQ]'9*5[3:T7GT>BUN3I+'>W9Z5
MFD>K>'"BPUFF- VBV7%B15E/"K)&M<CD1=RKWIT\3+TZH6=LN$%UHH*VEE;-
M33L;)'(Q<M<U4145/?DO5Z9\CZQ@K6F*M:3O$0^7Y+6ODM:\<YE. "]
M
M
M
M
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MF0V2Y14;58V5)/QE-N3:QWAO9.XB0;W$3DO00
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M0_T')_#_ %J[4]]L4L[4B5:^!$1?%>8W!U@WY*&AJ(VF&[HYWK*8 &LZ(
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M+%>J+ZJ*Y<9PB]/)2,1-IVB.:5K16-[2R5%R,=YJ=.U/PB5<?&1IO/E<HO\
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M.7^W9/'[\. ]'6-FI-46NU2RNBCK)VPND8B*K=RHF4]IT0SL@VE6Y6^UB?\
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MJ  ZC0
M
M
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M-6,J)J97OI6I2[HH73.]??G&QBX]7O WJ
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M?)0BWN.*]97N1  2
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M%:B(C45/!<9-FY\QM1>XHIT;I*7ZRN.(E?;7ZJ].KMDG9!K=N 380B=-H@
M
M
M
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M(5%174\7]1R.5)896N>U97Q]7M5K>_9YGT8
M                             )7=QRYK-S)=57=B^IMKIO63Q^Z..HW=
MQRGK)R/U9?,?>UTR+_E'&WIN^7+UT[5A-!7(QS$>]58B8+*Z57I.6Q^HGM1"
MC'NDCVHFYWL0K,F9"S#V=3H.)N\V:E6JIU:U$<YO<KE);=)-2LVR81$[B[=/
M$Z=N6N1,^!8W*=G.5D2+^,LV5VGF]BEOB,=A$1/,N7:@IW+B1=_F:]K]0?8]
M59)U<>?%JR*9RJO<9V5QGX9=_L^2A%O<0C^0GN(M[CS[VM>Y$ !(
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M3Y[\-8XXN(VE&,J%RV[4GJ(JX7[LP^@R?).)K/?AZK09..D_). #1=0
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M)=QV:1M2(>4M;BR39V_QL=_W$VD%_P#,[7_)M.(]WF=L\;'?]Q'I'V^A6O\
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M;D1?%,KC)TDBY-W1:[#KJ3?#.\1.S3U6CRZ.\4S1M,JH()W$3HM,
M
M
M
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MB)ER(?6>CI64-+#3QYY<+&QMSU7")A +D
M                         !*XY2U?"L>J;[(J^IZ=4=/_ %CCJU>J''^L
M[LOZ-K_ J^JVX5"?\JXW=)&]I<CI"=J1*G%6/I6^D0-W*BXVJ7#Y'UD/,6/8
MIY,57M>C&JC4]JEYZ4Z&/UI$5JG4X7!XH21U21N1J.17^.4/-KGN2579]8N5
MDI]SI%7#E+-(GUDKG-ZI[S/Q1M/)A]]H:FOJ,QKZI82V-U# USNBKWF8Q;I*
MI6JW&WQ+"\4\M8CF,)SW-2<<VM#ON/Y">XBWN(1_(3W$6]QYI] KW(@ )
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MW.WFL1V,]^,D*6U45 YSZ:DA@>Y,*Z*-&JJ?B0JKK>'3=FV76Z.XM9&JXO\
MC_C9=>\X,^$L[/JW:STW%*RTV:VWHVDN[(V]9*=5Q',N/P'+M5>J[7-[D8=Z
M*B%*:GBJ(GQRQMDC<F'-<F45/8J&II\]M/EC)5O:K35U6&<5OB^)79IX[5W
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M  >A<8
M
M
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M543S)3W*NLX;/H#'\A/<1;W$(_D)[B+>X\T]]7N1  2
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MYSMF:O\ F/H1&F&GG==[\/:]&UFE)B4P .>[
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MB-:U$PB(G@F#RW3.>-JX(_F7M_LYI9WMJ)CY1_Y78 /*O>
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M(VW3@ ]<\T
M
M
M
M
M"3P4X?U_(R;7FIX7]&_9*I3_ )5QW O<<.:\@1VOM3.5<)]DZK^6<;VB]^7"
MZ5]RO\L7HH7V^1S8D]1?$]%C7Q1+(JX)&R,;)R\^K[22LJ&0PJV:78G@=IY=
M?LK(W0L5_7:4EJ&3R)L7!94"-D@D5J\QF,Y+BDID=N<CB,]Z5;?!7N6GVW2E
M1=Z9[BRH-+Q6M-RKU\CV*-[H8U145R9R7KZB.=K4Y>Y4[S$^ZMICXK<W;L?R
M$]Q%O<09\E"+>X\T]Y7N1  2
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MNE-'ER=419FID[8;W'%U6_%&[T6AM%JSLG !IND
M                                                        ,%XX
M_P!9G7?[1UW\W>?)O=YGUDXY?UF=>_M%7?S>0^2^X]1T-[MWS7[5?W<?\2GW
M#<2;B7<>EAX14W>9#=YE/<0W>9C85-PW%/=[R3=YC85=PW%+=YD-Z^T;"IN\
MQN]Y1W#<9%7<2[O,I[B&[S J;U]HW%+<-P$^X;BGN\R&X,[)]WF-WO*>XEW
MV5=Q#=YE/<0W>895-WF0W%/=[QN]X9V3;AN)-Q+N\PSLJ;O,AN\RGN&X&RIN
M]Y#<4MPW!E/N\R&XI[O,;O>!4W$NXDW$N[S J[B7=YDFXAN#.RIN]Y#<4MPW
M V3[O,;BGN\R&[S!LJ;B7<2;AN);))]Q#=YE/=YD-PV%3=YD-Q)O0EW#9G95
MW$N[S)-Q#=YF39/N&XI[O>0W V3[AN)-Q+N\PRJ;O,AN]Y3W#<!/N&XI;AN
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M&U$3&.A-G!\^RY+9KSDMWR^K:?!73XHQ4[H1 !6V0
M         !28B=^.I,380B!)^((B8Z(3D-J>P"4*U%\R<AA (-:B)W$%]Q.
M   D5OE^0CAOL)B&$,;0(@ R)'83/3]XBQ$ZDP&PD(*U%[D3VD^$7P&U/8!*
MUOC@CM[R.$(@2$,)["H#&T"3"9[AA/$G V@2=/8";:GL&$,B7&[P(;6XQ@J
M"78GXB.$]A$&-H$F$7P0AA,]Q4(80;"4AL3OP5 -H$JM($X,@
M
M
M
M
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M*$6]QYM[.O<B  D
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M;:'C?2:XT\L:[FR7&G1W7N^ZM.R$[\G,U4SQ1NZ/1\1%;;*@ --U@
M
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MV34?XY])8;N\R&XS+XD.(WS U1^XU3]0E^)#B-\P-4_N-4_4':,/F@[)J/\
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M^('BA^QOJ[]P:K\V0^(#BC^QMJW]P:K\V.OQ>:/6&>RY_)/I+!MQ+N\S._B
MXH_L;:M_<&J_-D/B XH_L;:N_<*J_-CK\7FCU@[+G\D^DL%W$-QG?Q <4?V-
M]7?N%5?FR7X@.*/[&VKOW!J_S8Z_%YH]89[+F\D^DL$W#<9W]K_Q0_8VU?\
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M:G7H>6RYKY[S?).\O;Z?38M+2,>*-H3 @A$I;8
M
M
M
M
M
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M Y[T@
M                      D(83P0J$,(&-D,>2$-OD3@&T)<>2#'DA, ;0DV
M^0V>2$X!M"3;Y#;Y$X!M"39[AM\B< VA)M\AM\B< VA)L\D(X\D)@#:$N/)!
MCR0F -H2X\D&/)"8 VA+CR08\D)@#:$N/)!CR0F -H2[?<-ON)@#:$N/)!CR
M0F -H280CA/8A, ;0EQY(,>2$P!M"78GD-B>1, QPPEV)Y#8GD3 '#"78GD-
MB>1, <,)=B#8A, <,)=B>P;$]A, <,)=J#:A, SM"3;Y#;Y$X#&T)=J#:A,
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M
M
M
M
M
M
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MN)%/K"DGM]2W8L?5GGDTZ\5N<NCJ+QMM#'="PU+>.G#UT,#HZ+]$%!ZV,?\
M[3&?6)OR4/E_HVLJI.,.A*)(,01W^WKS,>RIC/J%'\DY6N]^'7Z B8QWW\4P
M .:]4
M
M
M
M
M
M
M
M
M                                                      )5_P Q
M\]>(>UO$O5S?OEN]6O\ RSSZ$^"GSQXG(K>)>JU1>OV6J_Y9YT=#[\N!TO\
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ME:G^<^C#4Z'!UW.\/7]#_P!JW\H@ Y[O@
M
M
M
M
M
M
M
M
M
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M*XF8O4^FC>[!Q];[\/2=%TFN*=_BF !H.T
M
M
M
M
M
M
M
M
M
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M%Q['3-13MY%_@.3JO>AWM!/W)CP3@ TG4
M
M
M
M
M
M
M
M
M
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M1JO>AV]+3@B4P -)O@
M                                   "0+T G!#*#* 1!#*#* 1
M 0R@R@$00R@R@$00R@R@$00R@R@$0        2]/;^^.GM_? F!#*#* 1!#*
M#* 1!#*#* 1!#/D,K[ (@AGR&0(@A^(?B B"'XA^("(     "&5]@_$!$$/Q
M#\0$0     $,^0R!$$,K[!E?8!$$,K[!E?8!$$-PW 1!#<-P$00ROL&5]@$0
M0ROL&5]@$00ROL&5]@$00ROL&5]@$0     $A'<!,"7\8V@3 EVC $P)<# $
MP) !.
M
M
M
M
M
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M[B+>X\J^C5]V$0 $@
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M.0/D19);E3,1/?*U#NEO<<?6<K0[VBR3DK.ZH #2=(
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MOW^1@_/'%.X@KA[+P>$^K/\ 572/C7T=K_;N:*_6B_?Y&#\\/MWM%?K1??\
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M#;PEO9 2(O3*=0<YZ%.
M
M
M
M
M
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MSDZ)]V:?61GR3EZ^-KPZ_0N3CQV_E4 0'.>C
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M#H^(B<V*/YA[[H/IJ>*--J)[^Z?_  [L!+N#?$\R^A)@
M
M
M
M
M
M
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M^*< ',>L
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M0
M
M
M
M
M !J/CSVG=$]G*.RRZSGK867=9FTOH=*L_6)&*_=CN_5&FI/TT/@;_P#C[W^Y
M;OK&G/AA_P#6SA3_ 'VY_P 6E-R\%^Q-P2U)P@T-=[GH&CJ[C<+%0U=34.JJ
ME%DEDIV.>Y423&5<J]W<!7MWPF_ BLJ.7-?+G;V=/NU3:IE9WX^\1R_O&_\
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M3W1)^\Q#S735(FE+_'=[?[+Y)C)DQ_"8W]&X0 >5?10
M                               $A'/_ %R!,"'XR( $A%/,"8$K?$=>
MH$P)47VKU'EX>T"8   2Y4;@)@2]?,AU[@)P0R@Z^0$0""]R@1!+N(&-Q."1
MN<J#(G   $O7(^] F
M
M
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MG;"]K4>R5<9:JJJ*N$]7.3I'L'14L?9*X<)1KNA6BE<[I_NBU$JR)_PU<;]
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MY6QU*M8BMC?')E'N[E1KO+'TT**.:YVU53<G7'3_ *X_T 5@
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M<[F+$Y6+W=%0G,5M7FHK?)ASQ6L<GV<C^0GN(M[B6+]3;[B9O<>,?8Z>["(
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M%2M'0U%0B;EBC<_;[<(JX+P\V_\ ^LE=_>)/XJE5YVI,I8^=HASDO; K5_\
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MK!1VBC=(ZFI6;(UD7<[&57JN/,]A4/>X>.,=8R>]M&_\O$Y.&;SU?N[\OX5
M03N(EZ
M
M
M                                        ^<OPP_\ K9PI_OMS_BTI
MVSV>OZPG#7_>S;/YK&>AKSA/H[B@VB;J_3%KU(VB5ZTS;E2LF2'?C=MW(N,[
M6YQWX3V&0VJV4EDM=);K?3QT=!1PLIZ>GA:C8XHV(C6L:B=R(B(B(G@@'H
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MGC?%(YRR>&>[WFO$<GJ*4QS;CN^I,?R$]Q%O<0C^0GN(M[CRSWM>Y$ !(
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M]9.PI_8MZ,]];_/9S@=-?V*_S_X>N^S7_56__/\ Y;] !XU]*
M                                   \W4'^LE=_>)/XJGI'FZ@_UDKO
M[Q)_%4IR^Y*>+WX?/>SW6IL5UI;E1O2.JI9$EC>YJ*B.1?8O14\C8:=I'7K>
MZZ0_18_]!C'"Z)E1Q%T['(QLD;JV)'-<F45%<F45#N5NEK-M3-KI%_\ 4-_T
M'S#HC0ZK54O;%FX(B?@^C]+ZW3:;)2N;#%IV<]<%.,^K-7\0J&UW2MCGI)F2
MJ]C8&,5=K'*G5$SWHAMWCK_6GU%_>$_C(9;2:?MM%,V:GH*:"5N</CB:UR9[
M^J(8EQV7_M4ZB_O*?QD/9QILNFT.6F6_'.T\_P#AX[KL>?6X[X:<,;QR_P"7
M.?9?_KIP?X++_ ALGM?_ .QZP?X5)_$4UMV8<_&E3_X-)_ ALGM??['[#_A,
MG\0\KI/_ .%E_G_S#U.IY=-8OX_]M Z0XBZBT+'4ML5Q6A94JUTN(8Y-RMSA
M?7:N,9\._)D2]H?B$O\ ]H7?1*?\V;0['\39*'4JN1'?=(/XKSHCT>-47+&E
MW1?1FISZ2N2F>:Q._+X?%1TETCI\.JOCMIZVF-N<]_=#YXWZ_5^I[O47.YU'
MI5;/MYDNQK-VUJ-3HU$3N:G<G4[GX3(B<--,8\;;3_R;3DWM",;'Q>U C4PB
M+!C_ "$1UEPFZ<,]+_M=3_R;2S[/TG%K<]+3OM\?'FATW>,FAT]ZQM$_#_AE
MJ(B$,(13!C>LM;VO0=L;<+Q.ZGIGR)$US8GR9>J*J)ZJ+CHB]^$\SWM\E<=9
MO>=HAXBM;7M%:QO,O+XO7:ZV70%TJ[&V9;JWEMIVT\?,?ETC454;A<^KN7N.
M.;S/<JW5,<VMW76-[U:LJR0JDZ1HJ_(:_"(G?Y)E>BG9FA.*%BXB+6I9YGRI
M1JULG,C5GRLX5,]Z>JIK_M64-!)H2EJ96-2LAJVI ['K=47<GN5$S^)#Q_3.
MGKJ\$ZO'DWK6.[X3L]3T1GMI,W9LF/[UI[_C&\-@<,ZW3U9HRB33+V+:H8^6
MQK<[F+WJCL]=W7*Y[\Y\3B*;-VU3(LZK_5%8O,5>_+G]3>/9#JZE]9J2B17.
MI>7#*K?O6ORY,IYJG\5/8:@XBV.?2FO;S0N1T:PU;I(57_Q:JKF.1?<J?P>!
MQ.DL\ZK1:?/-=HB>;N=&8(TVLU&GXMYVY.^*>-(XF(UJ-:B81$3"(5>ABN@=
M:4NM-+4=VI7M<V6-.8QJIF)Z)ZS%3VHN4_?[E0UG:.U39I]15=!<:62BHFSN
MCIZ]KE>U[47".>S&6YZ=V>_P/>3KM-AQTO>VT6[GAZZ+/EM>M*[S7O:_[6<$
M46O;=,Q<2R4#4>U/*1^%_'E?R&T^RQ4OFX8(Q_R8JR5C,^SH[^%RG/W''6D&
MN-?U=71NYE'3,;212M<BI(C5<NY,>"N<["^)TWV?[!)IWA=:HYV+'/4(ZJ>C
MNBIO55;_ ,7:>1Z,M&?IC-FQ^[M//T>IZ0K.'HC#BR>]O#8KDZ*O=[3G7M#\
M::9*.LTE99$GJ)?N==51KE(VYZQ-7Q5>Y?9U3OSBY[0''.6RNGTUI^?%<K<5
M=9&O6!%3.QBI]]CO7P\.O=K[@IP0FU[.R[WAKX;#&Y<-ZM=5KG"M1>]&]^7=
MZKT3RW.DND+ZG)V#1<YGE:?"&IT?H,>GQQKM9RK'.L>,LG[+'#V=]QFU961+
M'!$UT%'N3"O<O1[T\D3+4\W.3P,I[5%/<KCIFTT5OH*JMC6I=-,ZFB<]&(QB
MHB.5$7&=_C[%-U4%#3VVEBI*6)E/!"Q&1Q1M1K6M1,(B(G<ACVK^)FG-#RQP
MWNO;1OD8LD;5C>]7-1<*J;6J=&.CL.#H^=+:^T3WS\VA.ORY]=&JK7>8[H^3
MDG1G!C66L[?*^CI74=OWYW5LBQ,>Y.F4;A57WX\LYR63W:NX*:I;&LLMMKF8
MEV-?NAG;G&<=SVK^5%SW*=I:4U5:]86:.YVB?TFB>YS6R;'-7+55%3:J(J=W
ML- ]K]\"UNFD;M6I:RH5V/E;<Q[57\>['XSSFLZ*QZ'1QJ=/EGBKMMSY3S>@
MT?2F36ZR<&HQQPVWWC;NY-W\--;0Z_TG1WB-B0OD39-$BYY<B+AS4\LIE%]B
MH96WJBFC^R5%*S05Q<_Y$EQD6//BB1QIE/R8_$;P1,9/;='9K9]+3)?OF.;R
M&MPUP:G)CIW1/)4 !TFB
M
M
M
M            $-J>PB            %)\3)HWL>UKV.145KDRBHO>BH50!!&
MHU,(F$(@ #GJP=C32]@[2%3QGAOEWDOT\\\[J!_*6F1TL+HG)T9NQM<N.IT*
M (;4]A$               $-J>PB      "'XB(
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MZLT[&R.1\CO6K*3Y,<W7JKDQL=YHURKZ^#.NV?Q8^*3@#J.XT\RQ76XL^Q=
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MG>FO[-?Y_P#;UOV;C\S:?E/_ 'AO, 'CGT@
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MO4CM3!%$[SUV.E<=(I6.4/*7M;):;VGG*( +6
M
M
M
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M]L$LS4RL+V2(CX9%1%PCE=G&.BX1>S0
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MT]L
M               DQ@$V$(@     $,$0
M
M
M
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M65M''43Z>HX8:*21N4AEJ'2(KFY^^1D3VY[_ %U]I]4-K=RNVIN5,*N.N/\
MJI\Z?@=_];.*_P#?;9_%JCZ- ?,+X,+^R?XI_M?4_P ]C.A_A0_[%6O_ &VH
M_P",XYX^#%7;VH.*35Z.^Q]3T7HO_?L9T/\ "A?V*M?^VU'_ !G 4?@QN'=L
MTQV:;;J2"D8V[ZDJJF>JJ59]T<R*>2&-BKWHU.6KD3NR]5\3)OA$=-T.H>R7
MK22K@;+-;EI:ZDD<W+HI6U$;=S?8JL?(WW/4O?@]O[$'AW_>:S^>SEQV]D3[
M4;B/T_\ V2#^<P@8/\%W7S5?97HHI7N>RENU9#$CERC6JYK\)[$W/<OO53D2
M[</*'BC\)U<=.72D;76R?4<D]53R(JLDCA@696N\EY>%3QR=;?!8_P!BXW]N
MZS^",T!PT_VVJ[_MA<OYA*!].&P1M:UJ,:C6_)3'1.F.GXCY?=JKI\)OPYQ^
MNVG?YS&?48^7/:J_VS;AS^VVG?YRP#L_MS_V)O$I?_1[?Y:,U=\%/_8R5?\
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MM.\.T77-KN;&TMPHJ)'T\=5"B2N<U_-W)RE:[<JM1$6-V,X QSX7S^MUP_\
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MEO1KXI=F&R1O143Y*(Y'.:K>F5^Q5!4NJJ."9T:Q.DC:]8W=[55,X N@
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M3C_4V^XJ+W*>(GO?;J>[ G<1()W$3"8
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M<QO'[0D%2NQ67VA1GF[TABHGY3[:,[D//=)?W*_P^B?9Z-L-_P"4P .0]8
M
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M11M1C(V-1K6M1,(B(G<A<80^=9\UL^2V2WQ?7-)IZZ7#7%7X(@ I;@
M
M
M
M
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M78^L>AKI5V^?B#&^EDN%35U2\F1T3G(YRR-8N7*F%Z)WG5X U#V4N&5XX-<
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M/0G%W6/$R_:EK-7ZJOKGTU+/4Q-C9;Z!7HYE/&UJX5<,9ER(GR>B)ERN#>(
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MQ/3H(4VX1<)YD9]V6]AF(M&[[-Q?(;[B9O<2Q?(;[B9O<>(?9Z>["( "0
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M;UG<I\3> %VGI>.?#>EJ(&X?J.VHCO?4QH?;%G=^(\]TE_<C^'T3[/3OAO\
MRG !R'K
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MKN)=WF2;B3<!5W$N[S)-Q#<!4W$,J294EW 3[B&XEW$N[S"2IE2&[WDFXAN
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MZ^KMX5CNA]&Z.Z-QZ*O+G:?BG 0'-=D
M
M
M
M
M
M
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M[TJH\'W&9WJ><Z2_N0^A?9W^S;^4X .4]<
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M^DP'M;5>,>C/]/:'PGU?-G]+?XG_ *\:5^F5/]'(?I;W$[]>-+_3*G^CGTG
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M_*>OFY5,O_$$[L#R.?-IM.]IW=6E*XXX:QM"8 &%@
M
M
M
M
M
M
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MEC^0WW$S>X\2^S4]V$0 $@
M      !(2N^0[W$Q*[Y#O<9A&WNR^(MLNTEN>K&L:F?:A95=4E;,_F8<]>[I
M@M723YYJXVE2HG:L7,:WUT0]I2?NOCF6V]K;O(K*56R;,97V'GU5+-2R>LU8
MF8^4>Y)'*FRI^4O>7M7)!?K>E,B(R;OSCP,QWM7AJP](7<M[UZEG)(Y,JU3T
MZZ&6WR+%MW-+9Z1+'['8+2(VEE_9ZD=)Q]X9Y3_[3VO^=Q'W0;W)[CX8=GAW
M_;]X:X^<]L_G<1]T&]R'G.DH_$K_  ^A_9W^S?\ E, #CO6
M
M
M                                                        "&"(
M
M
M
M
M
M
M                                      !*OR5]Q\7N/;GQ\:^(3V)N
M_P"R.XY^E2'V?7Y*GQ8X_NY?&_B(UKU7=J.XJJ9_\ZDZ'5Z-_N6>3^T/]FO\
ML*8YU5A4PC\_)+NJ@90T[4<J/<IYE.R*EQ.^5<^PGJ*I9I$5%W-\ST?%+YU:
MD;KF*H8VG1&Y>[^ OZ*N6H@<QS]IX4LCVN5-J(B^PN:-RL;WX'%).[U&2.YB
M.1RN8WHO4OHJY-O1/WSQMZQT[FMZ]<Y(TCED8J+T7S$Q]TQS:+1L^Z<?ZDSW
M$Z]RE./]29[BHO<IXB7VZGNPB #"8
M              D)7?J;O<3$KOD.]QF$;>[+X8R=:=(V95"#Z-(X-K<^MWY4
MNJ:DEC<J*Q25D$M;(L6W;Y^P]E7N?'KX_O6*"LI8X70U#5>J=$VGD2220UW.
MB3;'W(B%W76F6W.3+MQY]4V:/8L3MS\YVDE'5SN]*:TR7+:YSVQ+CO<>/<-*
MU$$BK'*VJ5_WL?@7%YN$U53LCBRCT3KMZ%'2U=/07B)KI%57KAR/4SNNX.3(
M^ -#+2\?>&K'T[V.34UM55<G_G<1]QF^)\=.'T=9%Q[X9RMI<0/U);$<_'_G
M463[%,[E//\ 2,_?K_#V_P!GO[5_Y5  <EZT
M
M
M
M
M
M
M
M
M
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M<IGR4//](Q]^'MOL]/X5X^:H #E/7
M
M
M
M
M
M
M
M
M
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M[WV^GNP)W$2"=Q$PF
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MWR;KA8F_8:I9GJB1(G*7\<2Q]?%<G'Z1QSM6[VGV?S1&2^*9YS#H@ '">Y
M
M
M
M
M
M
M
M
M
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MNKXC[T;OO%%^I-]Q47N4IQ?J3?<5%[E/"3WOM5/=@3N(D$[B)A,
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M. "ML@
M
M
M
M
M
M
M
M
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M6FW)C3:?/DO&\/IC%^IM]Q,WN(1IZB>XBWN/%/L]?=A$ !(
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M::AYEQU,E.S&47T&I<OY$C4CU=_!.V;'6-[6AMO/D,^1H1>W/P3;T76+D_\
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M:X,.3*:Q7'[5UGYDSU63RRSVK!YX;RZCJ:5H.V1PBNDW)I-5NFE_!;;*Q/\
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M=?B\T.E\#!S5^F/=G?O^,%<?M)<?Z.0_3(.SK^R$O[BW'^CC@MX'7XO-#I;
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M7UG:1X=T,O*GU"L<GL]"J5_@C,<%O!*N?%;NM#9V4&4-7Q]I;AS+\G4#E_\
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M[OZCJ/S9>Q\?="RM16WS*+_YI/\ FQP6\&>MIXMB9090UV_C]H2)<.O;D_\
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MN3^V,_T?HRW_ &/J'5")4UJL]1B]50\RV:1MW#RURPR.;,^*/:V2->CEQWF
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M]SIUB;1%GV[C_4T]Q,WN)8_U-/<3-[CQSZ;7W81  2
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M'I6H^QZP/JW(N%<B=#85EH4M\FY6+3QR]Z(G>9^RRVV&-TJQ-63VHB*>=+Z
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M?;(I)E=#&V1$[CSY7<B1=]/M<A='*.2O>=^:WU)P\MFIH^=&R.";VX0T)>^
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MD].CVN;A)7JJ,S[S-;-HC0.D;?4RT];1^CS*JO;#*CEQ["/$LZG>><M8:*X
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M@H8J>ED=&J\E>N#,::]0TKD:Q&L_$)O,**8*WG[S2]B[/%QFJ-U=,E(WV(;
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MD4WADU:^[ZILKYJVZ/;4TK.K&M-MZEAGHI';8D<SVX,$OEEDU L4"3+3T_\
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M%O<2Q_J:>XF;W'DWT6O="( "0
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M_1RO-\'%Q,F<KW7K2F]>]WI=3_1RZ-1BC]3FWZ/U>_*DN8Z2[4M'IUT:T_\
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M(1;W'EWT.GNPB  D
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M@4FQE1C2=C2=K>\"1C2LUO>08TG;W $3!.B8&WWDS?$"., $43($43"$0
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M^_QN14D5.F>YBF8\7M<WFRZIT7IG3U0RGN-YK52>1T39%CIVXW+AR>Q57/\
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MF^UJ[<IX87O7O,\TEKR\W;CSK#2]34-?9[;21S4T*1M16.<V+*J[Y2_+7O\
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MT"3:3;2=J$43 $&M(HF"*)DF EPI,  )R&$(@
M                                      '/UX_LR;%^TKOXDQ[/:(X:
MU>HK;2:KTXKH=5V!WI$$D*>O-&WUE9YJGRD3QZI]\9C5<+K?5<4:+7+JJI2X
MTM*M(VG]7E*U4>F>[.?77Q,VVI[ .3^#6OH^)':,COS8?1Y9[)LGB7N;*UK$
M>B>6454\E0R_0$S;-VI->45<[;57&ECFI'R-QS&(UB[6KXX;^78[V&::6X%6
M'2'$.X:PMTU3!4U:2-6A9M2G9O5%<K4VY3+DSC.$SCN0O>)/!VR\2)Z*KJ9*
MJW7FB5%IKK;Y.7/$B*JX1>Y4RJK[45<I@#Q^TW=*6W<&-0,J7M:^J2."&-W>
M^19&KT]N$17>YJF(<0Z"IM_8ZBIJI')41VVW;VN3#F?=X%POFB=/Q&0VSLW4
M$UWIKEJO4EXUFZC5'4U/=)E="Q4ZY5N5W=R>*(N.J*;(U?I>@UCINX6.YQR/
MHJQG+?RW;7)URBM7P5%1%3/3* ::XL4-1<.R;0>BHY_)MENFD8Q,JZ-J1[L^
M2=Z_W*EIP_X.5NJ=%V6Z6[BIJJ&CJ*6-S8*>M?LB5$PL:(CNFU45N$Q\GH;'
MX:\'Z7AW;KI;OLQ<+W;JV-D*4=R<CXX8VHY-K41,(BHY45$[T1#&%[-$-KFJ
MOT+ZQU!IB@JG*^2WT52JPIGIZO5%3WKE< >?PET98+#Q=OKZ;6MUU-J:EI'4
MU?'71/?ABK'\J945%5%:U,9SZJIC"*4+EPNT7QAU1>[UI'4-PL.HZ&;D5T]"
MQ\:<WJBJYCD:[.6KU:J(JM7O-G<-^%ECX86ZHIK3'+)-4NWU-;5/WSSN1/OE
MPG3.5PB8ZJ8UJKL^VZ[ZEJ=16*^7325YJEW5$UJDVLF<O57.:F.JKU7KA>N>
M]0,.TOJ377##BO9-$ZGOD>J+9>(W.IZIS?N\71^'+TS\IO5%54PO1>BH=#>/
M?_U\/WS76B>"5IT;?GZAJ[C<M1Z@<W8EQNTW-DB;A45(TPF,HJIXKC*)WE]J
MCA);M5:_L.K:BLJHJVSHU(H8]O+?M<KDW93/WR]P&<;30_:PL-:ZP:?U701.
MFFTY7I/(QOWL;E;E_MZ/C9W>"^1OPH5%-%5P20S1LFAD:K'QR-1S7-5,*BHO
M>BH!X>C-86S7=@I+S::AL]-,Q%5J*BOB=CUHW)X.15ZI_P#0PGM%<0J'1G#F
M[4CZACKI=:>2CI:5CTYCD>BM<_'X+6JJY]N/:>5=.R[9HKI-7:6OMXT=+,NY
M\-MJ%2//M1,Y3"KW9PF>B'HZ,[-^G-,W=MZN%37:EO,:H]E5=9$D2-R+T5K>
M[*+U17*N%Z@8I4Z0J-%=D2MMU8Q8ZY:):B>-W>UTDR/VK[,(K4_$;'X#0LCX
M/:31C=J+0L=T3Q5555_*JK^,R+7&DZ;7.E;E8JJ:6"FKH^6^2'&Y.J.RF>G@
M5-'Z9I]'Z8MEDIII)J>@A;"R27&Y6I[<= -,\')F4?:!XJ4;WM;--*R9C%7"
MJU'*JJF>_P"6W/O3VE'M-7"G_1EPQM[96K5?9=DRQM5%5K.9$FY4\$7KU7\%
M?89GK_@%:]::D;J2BNUQTYJ!C=CJZW2;5?A$1JN3ORB(B=%3*(F<GGQ=F6P)
M+05M5=KK<+Q35\=?)<ZV9)9YE8N6QN<J+AF<KTZ]>_HF QSM=T,EPI-$TL,[
MJ:::[<MDS5PL;E1$1Z+Y*J'BVVUR=EOB-1,=4S5>A]0,9#/53HBK!4(GRW8[
MNN5\VN7OV&[.(/#&AXC26-]=55%,MIK$K8O1]OKN3'1<IW=/ O\ 7VAK;Q$T
MQ662ZM<M--AR2,QOB>BY:]JKW*G[Z*J 8;Q\XHUW#?1]+46:..:Z7&I2EII)
M4W1QY:KE?[%PB?OY7N5#QV\%]57"C6IU=Q2O"1(Q9*F&UXI(F-1,JF[Q:G7J
MK4]R&4W'@Q:+WPYI=&WBMK+G2TFWT>LF5J5$2MRC%1R-QT1=J93JB8/!H.SF
MV5C*:_:UU'J"SQ81MLFJW1P/:G<U^%RY$\E0#&NQGRG:9U5Z.]TD/V4RQ[E]
M96[$1%7SP="[?<83PYX46SAE5WUUGJ)_1;I4)4>AOV\NG7UL)'A,[<*B=<_)
M3S,YV@:$X/-3[8/BJJIUWQ)G\:_Z"/:E_P"^N'>/U\C_ (6FR-+\,:'2VM-2
M:EIZJIFJKVK5FADV\N/'X.$S^4AQ"X84/$:2QNKJJHIOL36-K8O1]OKN3'1V
M4[NG@!A_'3B1?=.733.E=+K!3WJ_SK&E;4-1S:=NYK<HBHJ957]ZHN-N,*JH
M>!J_A%=J+1]YNFJN)M]N$%+2RRO@IG)2P/<C%5K5;EV45<)CIG/3O0V3Q/X4
M6CBC04<-P=44M912<RDKJ1R-E@<N,X5>F,HF4[^B8,<H.SS2U<['ZKU1?=90
M1.S'0W&J<E.F/DJYB+ZSD]JKA?% ,-X+773=I[,ZR:L7_4&6HFIZAJPO?G=)
MZJ88BJG54PO@N.I/3=G6YV:CBN?#;7]PMU-/&E13TM4Y702-=ZR+EN$QU3Y3
M%[S9.D>"]ETMH.OT;+)/>++5R/>^.NVJYJ.1N416HG<YNY%[T5<^"&*0]F=U
M!"ZWT.OM445A?E/L;%4X:UJ^"+W(G?GIX@>KV>>)-VXC:5KW7UL:W2V5:T<M
M1"U&LGPB+NZ=,]Z+MZ=RH;0JJB.CI9JB3/+B8Y[MJ95$1,JJ'AZ'T-:.']@B
ML]DIO1J2-=[U5<OE>J(BO<OBY41.ODB)C!DBLW-5%1%1>]% YOT'6Z^X_4U=
M?FZP72%@;5.IZ>AMT#7RNPB+U?E%1?6;URN5ST3H8[6Z3I]%]I/0UO\ T0W+
M4->K>955%TJ>=(QSD?L8GX*81%QU7KGN5#93>S5!:KC63::U;?=+6^LDYDUO
MMT^UF>O1BYZ8ST5<XP7U)V;]-6R\V&[T=7<(;K;*E:F2MEF26:M<JM5><KD7
M*8:J>KCHYP&/<6(T=VCN&#5ZILE[_P#&,[X]IC@[JS'_ ."=_"A?:BX8T&I=
M=:?U3/55$599D<D,,>WEOSGY64SX^!Z^L]*T^L]+7*QU4TD%/70\E\D6-Z)Y
M9Z9 Q_@2W_M0Z2_:^/\ @+CC%15-QX5ZLIZ7<ZH=;IMK6)ESL,57-3VJJ(J?
MC/:T?IF#1^F+;9*::2:GH(6PLDEQN5J>W'0]G:!K#LX72DN?!S3OHKVN6GB=
M3S,;WMD:]V47V*O1?QI[3"M:S,O/:OT534+D?/;:)[ZI[/\ <D5LRJU5\VN3
M_AH9#<>S=14]WK*_2VI;UHWTQR.GI;7.K87+URJ-RBIW^W"9Z&3<,^#=EX:/
MJJNDDJ:^[UG_ 'U=*^3?/+URJ9\&JO7V]$RJ@:\^R%'1=K][*AS&OJ;,D$"N
MZ9D5J.1$][6N3][Q,H[3MTI;9P:OS*A[4?5\J"!B][WK*UV$]JHC7.]S37VL
MM$V[7O:@K+5<W3QQ?89L[)Z:7ERPR,VJU[7>"HOXC.+5V<J%;_27/4VI+QK!
M:%R.I*:[3J^-BHJ>LY.N[N;[$7Q10/ XD6RHM78_91U37-J8K;;TDC7O:O.A
M7:ON[OQ'M:M_L5<__P!.TO\ )1Y_Z^1LK5VF*'6>F[A8[FQTM%6LY;T8[:Y.
MN6JB^"HJ(J9Z93!@>G>S_26'2&H--.U%=ZZV76&.!K:A[7>BM;G'+3&$5<]<
M)CHG0#4O$1DE/V>N%5R>UTMOHJFF?4L1,MV[78<OEE,?XR'5%/50UE-%4P2M
MFIY6(]DC5RUR*F45/+N_*8_;^'-I@T!3Z.JF.N5HBIFTCVU'1TC4[E56XPJ*
MB+E/%#7*=F%*>G?:Z/7>IJ/3SU5'6N.I]1&JO5J+W85%5,*U?:!YO9XD;>.*
MO%6\42[[3/7)''*U/4E=S)%547W=?\8K]D^-/1]=N\?LY(G[V?\ .IMG1.AK
M3H"Q16BR4WH](SUE];<Y[L85[E\7*B(GL3"'G<..&-#PVCO$=#55%5]DZMU;
M)Z1M]5R^"83N]X&N.*R?]T?PP_N)O^<;WV^XQ#47#&AU+KK3^J9ZJHBK+.CT
MAACV\M^[.=V4SX^!F6T#0G;);MX;V5?!M\A55]GW&;J>[VIJ&HKN"UY]&1SN
M3+!+(UC<JK$D;G/DF47W(9EQ&X=VOB?IN6RW9TS:?F-E9)3NVR12(BHCDZ*G
M<JIA4\5*.@^&L6CM+5EBJKK6:BI:E[U<MS7>O+<Q&\K^XPG=YJ!=\.[M27G0
MNGZVB>UU-)0P[=JY1N&(BM\E145N/:BH:BTG,V^=K?5%70KS*6BMB4]1,SY*
MR(D37-7S1>GO9Y'LKV9XK<ZHBTUK34.FK74/5[[=252K$F43.WJBIG")E<KC
MH9YPXX7V'A?:YJ&RPR;IE22HJIW(Z:=R9PKUZ=V5Z(B)U7V@99M]QH;46L-8
M\1>+UUT/I>\Q:6H+1"DE7<.0DD\CE1O1J+X9>B814^2JY[D-^;35NN>!%#JK
M5"ZFMEZN.E]0.CY<M9;78YK41$]9OBN$1%PO5$0#2O:,X;R:.T-#67?6]ZU%
M<ZBL9'!35L_W!4PJO<V/KA43"91<)NZ]Z&6<9'QVK6/!B]UBXM4,S(Y9G?J<
M2KRE:JK^5?\ $4RJN[,EAOEIK(KY=[S?;M4-:U+O<:KF2TZ(Y%Q$BIM:B[<+
ME%5$4SF[\.+1J31$&E[XQURH888XDF>J-EW,:C6R93N?[NG54QA< >U>;S2V
M&S5USJY>724<3ZB5_3*-:F5QX95.[VY.>>/VJJ77G"W2.M+?2U:6B&\-?)'4
MQ(U_+3>U7.1%5$3<S;G/7*>"F4IV8XJF*&W7/6VI+MIZ%6JVU3U6(\-[FJO=
MM3"=$1%3P-JU.C[/5:9=IN6WPK95A2G]#1,,2-,81.N4QA%SWY3(%[%<Z2>V
M,N3*F-:!\*5"5&Y-BQJW=NS[,=32?9)JH;A8=8U-/TIYK[-+&F/O58U4_A+^
ME[,=%3L=;UU=J.33&Y7+8UJU2%R;MVQ<?>K[$3/CG)YW8_IV4^F]60Q-1L<=
M[D8UJ+W(C&X D[)LS(Z77% Y[?2:>]/>^//K(BHB(JHO5.K%_(I1X@W"GJ>U
M7H"DBF;)-34KTE:U456;F2N1%QW+A,X]CL^*&4:E[.EMN>JJK45DU!=]*7.K
M<KZEULGVMD5RY<OM17+YX\BOI[LZZ>TYJ.R7NEK:^6Y6V265]142-D?622-V
MN=*[&5PG<B8QCS7(8WQ63_NC^&']Q-_SBWI8VR=L:M5Z95EG1S5_]6U/\Z_E
M-H:BX8T.I==:?U3/55$599T>D,,>WEOW9SNRF?'P)8>%M!#Q1GUPE94K<):7
MT1:?U>4C<(F>[.?5]H&LNV302RZ#LM4U9$I*>Z,](6%N5:BQO1'^6%Z?C0OJ
M'@3<[E1PU=+Q<U94TM1&DD4S*YZM<Q4RBHN_JB]/RFXM06"@U-9ZJUW.F;64
M%2W9- [.')E%3NZHJ*B+GR-/L[,?H5/);[9KS4EML,JJCK;%4>HC57JUO7"(
MJ*O>U<^(%3L]Z>TY9KMJV>Q:IKM2U,LS([A+60/:B2M=(J.YCDQ(KLO7**O>
MGM-U;?<8YH/0-GX=6**TV6G]'ID7>YSUW/E?TR][O%5Z)[$PF#)MH'(?#+AY
M6:FXD\0K4NLKUI>Z4UQDF=#;IG0^E1K(_P"Z*B*F<;FX7V/1?$][B9P?M%BM
M]##K3BEJ2HHZNH1E-#5+)5H^7:O5&)N7QQG'3=A.\VIQ!X%V?7-XAOL%;7V#
M4,2(B72V3+'(Y$:K41V._IA,IA<)WGGZ9[/=OMFHZ?4&H+[=-776E5JT\ETD
MW1PJG<Y&]>Y<KU7&>H&5\0]9V[A[HBMNMV5*BGCBY38),;JI[DPC,>*JO?Y9
M7N0YEX005/!36=COVI[3!0VG54#HX*E$55M[G/RQJY^2F-F<]<.3KZKD.C-=
M<([=Q#U%9[C>*VKGH[6])([6W;Z-*_.5<],95>Y,9[DQXJ>MQ"T':^(VEZJQ
MW5KO1I<.9+%A'PO;W/:J]$5.J>:*J :F[0CFVKB?PJO56[;:H*]T<LR_(B57
MQ*BN7S3K_B*;MO-YI;#9JZYU<O+I*.)]1*_IE&M3*X\,JG=[<F-R<*;5=.'T
M&D+Y+47RAA8C(ZBK5$G;MSL<CFHF%:G1%QW=%SE<X,G9CBJ8H;=<];:DNVGH
M5:K;5/58CPWN:J]VU,)T1$5/ #'NT)K2BU_V>J:_6Z&I@I*JX1\IM6U&/]57
MM7HCEZ91?'K@N>TA(VAI^%];(YK*>GND+I'NRB(F&+^+HW]XV?KKA):-;Z(I
M]*N?):K73OC="VA1J;$8BHUJ91>G4OM<<.;-Q TNZP7B.22D:C71R1N1LD;F
MHJ(]%]N%5.J8ZJ!-Q(N=/:^'VI*RIE9%!';YU5SG(B*JL5&I[U541/-<&M.S
MM<;=:.SI3UMX5&6J%*M:I71+(G+YKT=EJ(JJF%\$[B\M?9GM\3H(;SJB^ZBM
MM+GT6V5M3FGCPW#55G<JMZ*G<G@J*G0SO0?#:W:$T2S2\3Y+C;D25K_36M=S
M&R.<KFN1$1%3#E3& -.VW@%176WPZDX7ZUNE@I:[=/%%EZPKU5-O16N1$[L.
M1V,=3)N W$+4UZO6J-):JE@K[G8)49]D*=OJR(KG(J.5$1,HJ)A<(N,Y3**(
M^S1%:)YV:9UKJ+3EMF>KY+?1U*JQJKW[5RF%\UROF9UPYX8V7AG;9Z:T,EDF
MJG\RJK:IV^>H?UPKW83NW+A,(B97V@:T[**9I==?MY)_ 8A%JI> %^XI6%')
M#!-!]EK,W.$YDKD8C6^W#GL3_P!2IO?ASPQH>&T=XCH:JHJOLE5NK)/2-OJN
M7P3"=WO/,XD\$+'Q.O=FN=UDGCFMJXVPJU&U$>]';'Y3NZ+W?AN\@+'@=H*7
M27!RCH.L-SN$#ZR=_BV65OJJOFC=B?XII'L\\,ZS5VE[C'3:ZO\ IFKH:UT=
M3:;?4/B:U51N'JU')A5PJ97\#KW'8.TU1JWL_P!LOFI9]162\7+2=\GRL]3:
MI5:D[E5%W/;T\4RN%1'>.0,#O/"RRV#7ND:;4/$K4%SO/I;*FVT=8V2I57MD
M:O\ ;;$<K4ZKA,-7KT.D-ON-::#X$VK1U_=J"NN5?J34#D5K;A=)-[HT7IZB
M>"XZ9Z],XP;.V@:9[4=AFJ.'L-^HDQ<-/UL5QB=CJC4<B._?5KE_N#&=-4]+
MQUXF:YNK7I):HK#%:*1Z]4:M1&KW.3S:N_\ *;ZO]DI]162XVJL3=2UU.^FD
M1._:YJM54\^O3W&-<*.%-KX2V.JMELGJ*J.HJ/2'S56U7Y5J-QEJ(F$Q^^H'
M-.E+S+Q&L_#3AQ/ETE#=9W7.%R]T4"JYK5_Q'2-][4-G\>IDLW&#A9>:Y=MJ
MCJGPNE=TCC>KF855\.]%_P 13.-'\#[)HWB%>=74<U1)77'FYADV\J'F/1[M
MF$RG5,=?!3(]<:%M'$&QS6F]4WI-(]=[<.5KHW]41[5\%1%7R7/4#V*NL@M]
M%4553*V&F@8LLDKUPUK6IE55?!$POY#G3LZ4\KN"^OJ[8Z*DJYZQ\#7)A,)
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M:Q7HKL=<*N,=Z8PO4SR@[-"69):.T:\U-:;&]ZO6W4M5LVJO?AWAGW'N:;X
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M*OK;LMRN5^_7R-.Z?X<T7$'CGQ*CJ*NMMM=13Q2TEPMTRQ30.551<*GEW_O
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MF4QX+C/XSU:;LL6^VOJJ:WZOU';K!4.5\UIIJO;&_*]6YQU3'3JBKYF9\/\
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M.GL QFW^IVP+HCNG,L:;?[;]3[OQ(OY"''C#>,?"#V+<)/Y2 ROB/P&MFO\
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M?:-H$FWW#;[B?:-H$FWW#;[B?:-H$FWW#;[B?:-H$FWW$=I-M&T"3;[B.TJ
M"GM&TJ "0BB9)@!+M)@  (HF28"5$R3
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MGO=RW-1RXZ97)[FC.'6F^']+)3Z>M,%L9(J+(Z/+GR8[MSW*KE_&IDX D!.
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M?@X,\)P!("< 2 G $@)P!("< 2 G $@)P!)Y@G $@\B< 2 G $@)P!("< 2
MG $GGX@G $@)P!("< 2 G %-S4<BHJ(J+X*AK&Y=FWAM=:UU9-IF%LKW;E;3
MU$T,:JOL8QZ-1/<AM( >1I_35KTM;([?:*"&W4465;#3LVMRO>OFOFIZA. )
M 3@"0$X D!. ) 3@"0=/83@"0$X D!. ) 3@"08\B< 2 G $@)P!("< 2 G
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MP!("< 2 G $@)P!("< 2 G $@)P!("< 2 G $@)P!("< 2 G $@)P!("< 2
MG $@)P!("< 2 G $@)P!("< 2 G $@)P!("< 2 G $@)P!("< 2 G $@)P!(
M"< 2 G $@)P!("< 2 G $A%$R3 "7:-I, )=I,
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M;;7Z4D'*;NYF$Z[OE8\C YN)G$G5?$W5VB--U5+32T]5F"NJ8FHVBIF;D?\
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M&^D1-=(Y,^U5:_\ ',ADO9<L-3'HNX:IN29NNIZV2OE?W*K-RHS\65>J>3D
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M;54\<S-VV1J.1')A<*@%<
M
M
M
M
M
M
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M5QG&,E#6G >CU)JE^J+1?+EI:^RL2.>JMKT1)VX1/63IUZ)XX7"&UOQ#:GL
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M5[7(B(F/65# D[,L-JEJ8M-:TU#INV5#W/?;Z6I58TW)][U14]F5RN.F3=X
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MAM3V$0
M
M
M
M
M
M
M
M
M
M                           "&U/8-J>PB
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
:                               #_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" <G#+<# 2(  A$! Q$!_\0
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M /JF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;EL-Z1^SOI$V6JNNS_4M/?(:5S6U5/N/AJ*9SLXZR*1$>U%PN'8W5W5PJX7
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MD@
M
M
M
M
M
M
M
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M62%^$[%<R3"JGQ6]R'TFZ6/[5K;)P_\ K,O/_89CYK^X@Y_51VEX_P BT_\
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MQ5#F4]7:Z^CK8D7Q94C1)&Y3..#XT5%]/>?5GH4?M2-D'_5FA_HFGRA]R_\
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M[1::MDGDTM37.F][$D5RQLJ'1O6I1F>&,>#JJ)R5<]H!])P
M
M
M
M
M
M
M
M
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MH[&YMK=%M#M5/>-+7BAK*2NI*.Q5,5-14\M.D:1]7%U2X3,:*J9PJJ[O/60
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MGI[#8J%JMIZ*E:J-;E55555RKG*JJJN<JJJKE54VD
M
M
M
M
M
M
M
M
M
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MW"FNU#!6T53#64=1&V:&IIY$?%*QR9:]KD545JHJ*BIP5% +X
M
M
M
M
M
M
M
M
M
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MQ<J-ZW"+E7'N:AML^I?<B4I;>UU1+]P2R;L:95>J17/1./8D;O8 <6]PM_\
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MAZ=<?1.AL=E@V!+)]TU/6(RO=1K6OHGTO5OSE]2JYD1Z1X6/**CG97*'T?\
M<J+Q57?H7:0;52NE\"JJZDB<Y<JD;:F1R-SW)O*B=R<#Q'[I'2]&W0&S'2^A
M=CENTT_4SKJRX5EPL<K*V6&DC@F9U4U7O/>JO?*QVXKU^#RJ>3GV5[D;,R3H
M961K'[SH[K7M>GQ5ZY5Q[%1?6 >SP
M
M
M
M
M
M
M
M
M
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MWIN4WN\[9MCV367;?LWOFAM1/JH[+>(V0U*T,C8Y<-D;(FZY6NQQ8G9WF\@
MXAT9NB7HCHHVF^V_14MVE@O$\=14K=JEDSD=&U6INJUC<)AR]YS?;][F9L<Z
M0&L:K5=QBN^FK_6OZVNJ-/U,<3:R3EOR1RQR-1R]KFHF5XKE<JOK< 'C^R>Y
M9;!;-LZO.E&66X5<ET6-9=0U54R2YQHQ[7HV*3<W(T56X<C6)O(JYSPQU_HU
M]&/2?1:TG<M-:.K+O46JNK5N#H;K4LFW)58UCE8K6-PBHQN4X\CL(
M
M
M
M
M
M
M
M
M
M             (90;P!$$N\-X F!+E.X@<N=L3@D!T6)P2 "Q."0 6)P2 "Q
M."0 6)P2 "Q."0BWM!PF!+O#> )@2[PW@"8$-X;P!$$-X;P!$$-X;P!$$N\-
MX F!#>(;P!,"7>([P!$$N\-X F!( =L3@D %B<$@ L3@D %B<$N4[B&4.7%B
M<$A%O:=.$P(;PR@!$
M
M
M                     I3/W6J 3J]$).N3)AJ^[-IT7+L%C9]0MJ[O!3([
M.]O?,U5^H VCK?,0ZSS*5&\B(!2ZSS*.L\RE4 %+K/,HZSS*50 4NL\RCK/,
MI5 !2ZSS*.L\RE4 %+K/,HZSS*50 4NL\RCK/,I5 !2ZSS*.L\RE4 %+K/,H
MZSS*50 4NL\RCK/,I5 !2ZSS*.L\RE4 %+K/,HZSS*50 4NL\RCK/,I5 !2Z
MSS*.L\RE4 %+K/,HZSS*50 4NL\RCK/,I5 !2ZSS*.L\RE4 %+K/,HZSS*50
M 4NL\RCK/,I5 !2ZSS*.L\RE4 %+K/,HZSS*50 4NL\RCK/,I5 !2ZSS*.L\
MRE4 %+K/,HZSS*50 4NL\RCK/,I5 !2ZSS*.L\RE4 %+K/,HZSS*50 4NL\R
MCK/,I5 !223S*1ZSS%0 $N]YB8$%7 !$
M
M
M
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MSEB<$&]I$[<$6]I,2M[28F0
M
M
M                    (+R4LJYV[&Y?,7QC;G\&_P! !SG5UV=3M<N]@U79
MSJ)]7M'M=/O91W7=O=$]?J+_ %[(J)(:1LAE5VU^R)GMG_H) #U2WD1(<D(@
M
M                         DDY)Z2<DDY)Z0"<
M
M
M                                                 $,D0
M                  " 7DH!*"G/414\:OED;&Q.;G.1$,!4:ZMK).KIUDKI
M?BTK%?\ /R,TZ].GUI)$XPE+JHV-,]J8(M[35$U+>)_V/9'L3L=4S-:J^I#)
M:8O,M[M[IYH6PO;(Z-6M=E."X*X8JG4DHQOKW,ZZ<HJ[,V""$3:5@
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M&)M&HZ"\JYM+4-?(WBL:INN3THO$RS>TU4ZD*BO!W*G%QT9, "TX 0(@
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M95_AF_:74-7%,F8Y6/3\ER*%6IR>DEZC*UR+@$,D2\B
M                                           "23DGI)R23DGI )P
M
M
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M6UW[[38;[43!EZ;4EHJ6YCKJ?'G<B?2;*=.,WI*/IK\RER:W3?F8&*_6R/\
M8UGJG=RQT2I]1<MU'4.^!L=<Y/.QK38&W6AQE*N!4_A&_:'7B@;Y59 WTRM^
MTU+#I?\ 42\E^I5Q/_'XF!2\7F;X.PO3^$G:TBE1J27R;72Q>=]1GZ$,I+JJ
MT4Z+OW&G3T/1?H+-^O+2[A#)+4K^\PO=]"$7"C'1UOBOH23G+JP^90;3:GEY
MK;H/4YQ,EGU$_.]=:6-.YE/GZ2"ZRGDSX+9:V5.^1J1I\Z_46TVJKNN<4]NH
MD_\ IBK15]B%,IX5;R;]?R)6J]B7H7]HTH^DN:7"KK%K*I&JQKDC:QJ(OF0V
M-.TY_)J6O1R]9J&V0)W1QJ_!2=?$>N7ZOQ_!4Z(GSHI93QM"BLE./Q^K..A.
M;O)_!_0Z-ZR"^DYS[ZP?YWU&]_!MQ_-*D=X?^XZPC<O=-"W^HN_F<?P_%?4C
M[-+M^#^AT%$P1WD-)AOMY:GWNXVJM3SNW%7YR[;JJZ0-1:BS.>WM?33M>GL+
M8](T7UKKR*WAY\K&UD<>LUENO+>F?"(:JD7]^@<B>U"[I]7V>H7Q+A!^<]&_
M2:(XS#SVFB#I5%O$S:<>:$43!CTOMO=Q2NIL?PK?M*,NI;5 U5?74Z?ZU%^L
ML=>DM7)>I'))[(R@-<DUY:$7$<[ZAW=!&YWT%%-95$RKX)9JJ5/C2JV)/G*)
M8W#K12OX:_(FJ-1\C:25=Y#49;[?94=E+=0-[Y9]]4]A:/K*EZ*M7JN"'S4[
M&)].2E](P^[%OX?,L6'?-KY_(SNJ["^_6U(8Y4CDC<CVHY/%<J=B^8U.CHK/
MUR4U;2RVBO1?P9G-:]>]KLX4C)46ISL.OUQKWK^!#(Y<^IJ%:TV&:YW*-ZT=
M4EMW7)*ERDWEDX<,-7BG'M/(K2]IJJ5.*;]?EL:8ITX6D]/0RC+)<Z--Z@O4
MSD[(ZM$D:OKYE5FJ+A:U5MWMZ]5V55'E[/6G-!]QTU"G_)=TGI&]D,GWV/T)
MGD2.EU%09Z^@@N#$_#IG[CE_-4U6JT=4G'XKTW*KPGS3^!F:'45MKVHL%;%)
M^3O(B^Q>)D62M=R>BFA5E5:)U7WPL513O[7.IE^EI;,^Y+\&HF@7XO62,P6K
M'SCI*S\[?"QS@)[7^9TG*=Z!')VJASC_ -5>VY5#O342$/\ U0_"GE>G<KY%
M0E_,)=WK^@]G\?3]3HKIHV\WM3TJ2NK(&\YHT7SN0YYO:-3GQ].^I,V31B9\
M1B^EKU.>WS[O7]#OLZ[_ $_4W_PZG_'Q_I(3MJ(W<$D:J^E#G_6:,<GD0I^F
MA!$T8[AO1-\^\]![?/N]?T.>SKO]/U.B(]J=I'*=YSOJ=)-\BOZKNZN=Z$4]
MZF?L?4]3!W?KC?3YR7M[6Z7DU^AS@=E_0Z%E""8XY-!;=7P\(]7QN_A86N^P
MBM^KFMX:EH')^5"F?I)_S&/./Q7U.>SRY/Y_0WI<$F&YX&B.U-7\EOUL]/5J
M2.U)5\GZDH6I^3 JG/YE3['ZKZEBP\NWY_0WURIWDJR(G;CU'/7WI)/A-4.7
M^!I\%'PBW5"_?;E<Z[\EJ/1%]2(0?2*^ZO5_\EBPSYOX,W^HN=+1M59ZJ*/Y
M;D0Q,VN+8U=RF66MD[&T\:N^?D:W"VU0X6&PU=0[XSX%5?\ >,G!7W'=1M+8
MG1-[.LD:Q$]2%;QE6>SMX)OZ$UAXK?\ )%RMZO=P_8M RB8O[I5.RJ>?=0I+
M8*JNRMRNE1.B\XH/O3$\W#BH2/4,_914J?G/4BFG:ZIQX5>9E3M; Q(T*[3G
MK)-^+LOR.VC'9I%>&VVBSMWT@IX,?AR*F?:I1FU=1[RQT;9J^3XM/&KD]O(1
MZ=L5$[?GZN:3M=53*Y?G7!?-O5FHF[K*JFC:GX+'-3YD+%"2TS1BO4YH^398
ML^Z"Y9W8X;9%\:1>LDQYD3@GH+BGT=3K*V:OFDN$R<46=?%3\U.!.[65F;_A
M\6?-Q(?=M9_\>C]B_86PCAKWG--][_:(M5.4;>1GHF1Q-1K6X:G)$3"(3;[3
M MUG9W_X?#GSK@N6:CMLGD5M/_*(AO5>ELI+R90Z4]VF9;>:-Y.XL8[C!+Y$
M\;O0]/M*W6YSXR*61J1>SN14'S+C>3N&\G<4.M(]9YBRYW*5MY.X;R=Q1ZSS
M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS
M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS
M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS
M#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;R=Q1ZSS#K/,+C*5MY.X;S2CUGF(
M;WJ]HN<RE;?:$D;V<32]3U5QI:^.3PJ:FMKFHBR0,1RQN_*SV$:9MW=&V2DO
M$=3&J93K8D5/:AYTL:HS<%%Z>'U+U0NKW-SWD[QO-[$-4;?+S1)FJM\=4Q.;
MZ5_']%2]M^JZ"M=U?6]1/^)G:K'%T,53EHW9]ZL0=*25S/[R=PWD[BW21%XC
MK$-.?L(92XWD[AO(6_6^<=:G:HSC*7&\T;R=Q;]<UO:B>LIK7PMYRL3\XCQ(
MK=G,C+S?3N&\G<6#KK2MYU,2?GH0;=:5W#PF)?ST^TYQ(=IWAOL,AO-&\TM&
MUD3^#96.]#D4G29/C9)*2>S.9"XWD[AO)W%OUOG'6^<[G.Y2XWD[AO(4.L(=
M9YT&<92OO>8(YO:6DU?#3M59)HX_E/1/I,94:PM=.N'5D;G?%CRY?F*W6I0W
ME8*G*6R,[O)QP1RAJSM7OG7%%;:JHS^$YO5M^<IK)?KAY<U/;HU[(TZQ_M7@
M9Y8R'W=?!?FRQ4)<]#:9:V"G8Y\CVL8G-SE1$,'/K:WM>YE(R:X2IR;3L5R?
MI<C&_<[0Q*DUPG?62?'JY>'LY%1VH[/0HD4,K'JG!(Z9F\OS(99XJ;YJ/G=E
MD:$5M=E9;EJ"X)F&FI[;&OXYW6/]B<"3WBK*KC6WBKE5>;8<1-]B<2FEVNE;
MPH+4^-B\I:MVXGLYE1-/7"X86XW-V[VPTB(QOK5>*E"C*KVR\=$6Z0[%\66-
M90Z;MRKX1B>?XCWNE>OJR4&V%UZD8E+;6VJF:Y'>$R)B;@N?%3L-IMMBMUL3
M];P1M=\94WG+ZU,BCL<BZG@<SO4LO!?FROBO[M_,JL<C6(F<X3''F11R8*._
MD=9V8/86BLC+E*^\G<-Y.XH]9YAUGF.W.Y2MO(8^X.3JW^@N=]2QKW?>U%QE
M.4ZZ5'-D]!H.S^N?;=I-LJ8J9]5(SKL0L7"NS"]/K-\UP[+'^@TS9A_?0M'I
MF_H9"%2[BU%V8C%7U.Y_=Q6\?_5ZK7\[Y^0^[6XN\G3L^/E_U&;;VDZ+ZSQ[
M5[?:/T1H_I_A^+,']V=V[-.5&>S+_P"HBFLKU_FY-_*?U&;21J>4K6^E2F^O
MI8O+J86?*D09:BWK/X'+Q_!\S$IJV_.\G3LF/RI>/T#[JM0KRTZOKF_J+^34
MEIA3QJ^G3_6(OT%J_7-DC_PYKODM5?J*'-Q__J'\#F6^U/Y_4I?=/J5W!+"Q
M%_AB'W0:I=G=LU.WY4W]9*[:%9T5=UTLJ]S(E^LD^[VGDX0VZNF7\F+'VD76
MCSK/RM]#N1_V_P!^I52XZPDY45#%\IV?^\2N;K";.:RAIT_);GZE(?=;<9?@
M=.UKT[%=P^H)=]2S_!V!K/X6;'UD'.,OO2EX)_DCN5K[J7I]2":?OU1GPC4+
MV^:&/'V$$T&V9<U5UKJCOS*B$^=83<J.A@3\IRK]9,EIU?+Y5=1P)^2S/U!0
MA+>G*7C?\V<NU]Y+]]PBV>V9OEQRR_PDJ_5@N&Z'L;>'O>UWI<[[2@S2FHIE
M^_7]6)^]Q?\ D1^X&M?\-?ZZ3Y*X^LLC1?W*'K;ZG,_;4^95=HBQ;O&@8WT/
M<GUEE4:'LL>71SR43OC,GQCVJ7+=FM([C+7ULJ^>8JQ;,[*Q<NBDE^7(OU'7
MA*D_^BEY_1'%52^^S7*NX5VF8EDIM01UT353%/,J/<[S(N5.B6NI=5T,$SV=
M6^2-KU9\7*)P,=1:,L]!*DD-#&DC>3G*KE3VJ9MJ854/0P6'JT6\\M.S5_%F
M:M4C-+*OR*@(#*'K&<B"!$  $ "(           !(]VZU>&2<E<J;JD6P:7-
MKZH=754%%:):Q*=ZQO>C\<454Y8(MVBQQ82NME92>=8]Y"?4.EI6UBW2T2MI
MZ_\ #C5<,F\R^<HVK6%/42>"7*-;?6)P5DJ88[T+]OSGS+K5Z=1PJ5+/EHK,
M])0IRA>,;^>IF[;J^T71&I!6Q[Z\F/7==[%,RCD<F47*&L5VE;5=6JY]+'EW
M[I%XJ^G*<S%I8KWI_+[17K50-_P6JROJ1?\ R-T,57IZU(YEVKZ%'"A+JNS[
MS?./<1;VFG4>T.GC<D%TIIK=4)P5'M56^TSE)J*UU:9BKJ=W^L1%^DV4\71J
M;2U["F5*<=T9<%LVM@<G":-?0]"+JR%J<9F)^<AHXL.TKROL*V?./26BW.D;
MY53"GYZ%-]^MS.==3M_UK?M(\>FMY([EEV%_P\PX>8Q3M3VEO.XTW\JW[27[
MJ;5_E&F_E4'M%+\:]4=X<_PLR_#N(&*^Z>T_Y1IOY5/M*C-16QWDW"E5?X9O
MVG/:*7XUZC)+L,GR["#>TM(KM229W:J%WHD1?K+EDC7)EKD5/,61J0ELR.5K
M<J AE.\B67.  '0   0P%Y#*%*6HCA8KI'M8G>Y<(5N<4M6"=%["5W882MUI
M9[?E)*^%SOBQNWU^8IV/5]/J"M=!2T]0D36*_KY&;K55%1,)[?F*%B:+DH*2
MOW,LX4[9K:&R  UE8
M
M
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MG8WKT5/I)E9,W/\ ZYHB>=R?::UTEVP]&BGV;LE\&=((^LYA)4[J*C]9JO\
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M?65"TU)4PRRM3>5D3D7"<L\/2AMH473J1O.*[DOU*)S4XO1^IE@ >Z8P
M
M
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M\/9)'=ZP3-=])%NL8H^%1;Z^G[]Z!7?1D9(+5U9+Q_X"<N4$RR9>-4,3Q[1
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M9H.S;\M#:0 ?2GG@
M
M
M         $#!:MOCK%;XYVTSJESI48C&\TX*N?F,[WF+OETI+32)-5R]7&K]
MU%QG*X5<?,IEQ%^%*TLO?V$Z?76ES2?NWN]3^QK,_*_&:Y?L)DK=85_!E/'2
M-7M<B(J>W)?2;1+3&N(DGF7L2.-2E]W,]0[%+9JN;SJW!\I_3D[5*S?@OH>M
M:2V@EXEH[1-XNG&XW--WFK6Y<GLPB&5AT3!U38ZJMJZB-K4:C'/W6HB<.2%%
MM_U#-\%8T9_#284F2HU7)Q\&HH?E/5?K)PIX:.T)2\4]3CE5?WDO0O8=%V6%
MO"A:ORG*I7;I>TIRM\'K:JF+2/5CD3[_ $#/,C5(^#:JQPK*']!?L-472CM0
M?HBIY^<_BS(.TI:'\Z"#U-P6[]#663.:)J+WM>J?66JPZO;RGH7?FK]A!*K5
MU/G>I*.H3\E^Z1ST/O47Z'4I\IKU$VS>TORL:SQ+^2_/TE!F@)J/+J&\3P+V
M;R</F+ENJ;M3_LNP3HG:Z!V4)V:]MS>%3%4TB_OT."&3!-W:ROS1)2KK9W]&
M2Q4FIZ),-JJ2O;^^M5CE*J7N[TZ?KBQK)YZ>9'?,7E-JJT56.KKX47XKEPOS
MF2BGCF3,<C9.WQ7(IIITX-?TJC];_,IE*7WH_D8)-8QQ?#VZX4Z]N]#O)[4)
MX];V?@CJE85[I(U;]*&>3*IW$CH8W^4QKOS2[+66T[^*_4C>'-?$QL6I[1-Y
M-Q@S\M$+J.ZT<OD5<#D\TB$LMGH)?+I('_*B0M'Z8LLGE45,U?,B-^@YGKK=
MQ?JA:#[3*ME:]OBN:_Y*HI,:[)I2PMX(C85_>ZA4^LMYK-;*1JN;>ZFF1.ZK
MRB>K(]HG'=1]3O#C+9OT-J&%Y=AH<=;<7U+8+/=9J[CX\L\3>J:G>KC,/EOE
M(J[U=:Y4_?%6-?F*88V-1747\ Z67G\S8'4\4B8?&QZ?E-+*;3ELJ,[]!3N7
MOZM$^<P%1JZMI<I)+:,^:I=]&"S?K:Z2JJ4\5/-_ QR/^=<(0GC,-LX_ LC1
MJ[IF=FT-:GHFY"ZG7OAD<WZRS?HJKA7]97NKA[FR*KD^DL(KIJ^J^"HVQHOQ
MHD;\ZJ7M/3ZNFQUE530^E$<OS(9\]"KU:4EWI6)I3CO)!MHU33?!7:&5/WQ/
MZE*D;M61NP[P&9.WFA=MMNH=WQKQ B]W@V?K'O/>W)XU]1J=N[3-^TDJ36L5
M)>:_-C.N>7T_0ILK]1LSUELI7_)GP2U&I;G11NDJ+/N,1,JK:EA53359-^R+
MY6/3NCPSZ"RGV=TE0]7.JZES\^5(]'_22<<4E_3OYM?0XG3O[UOB5Z/5E974
MK)Z>RSRQ.\F1KV\2VJ]H#:*3<EMTK'?%=(W>+N33ER6E=3Q7MZ0N8K-Q\+%3
M"\,<,&+H='7BS9\"J:-^5_=(DSV=N%7L[RNI/&I))/OV^".QC1=[V^)<0ZZJ
MJG'@]CJ).Y>./H*S+WJ.JSU5FCA3OFD5%#7ZL@7"QT,R>G'V%9ESU&WA)9Z=
M_P"4RH1/I$957I4E+R7TN'&*ZJ7J193ZDJ,]964=&B]D<:O5"9-,UL_[*OE7
M)YH41B$??6__ .18_P#:6A+G?_\ (S$_^J6FA<+[V9^3(>_R:7H3,T7;-Y5F
M2>I=WSS.<7U+8+;1_!4-.Q>](TS[3'I7ZA<BHELI6^=:CA\Q%)]2._P6WL],
MCE^HMBZ$>K!W\"%IO>7Q,ZUB,X-1J)^2B$V\8#&I7=MNC3\Y1X/J5>=50-_U
M3E^LN5?LIOT(\/MDO4S^5(& \&U&G^&T'\@OVEO4U5\H45TUSML2)V/8J?61
M>*C%:Q:]"2I7V:^/T-G!J%OUTYL[XJV-DS6\?"*%'2,]?#)E(=9V:5$_7L;?
MEHK?I0[2QV'J*ZG;Q(RHU(\C-@P[]7V:-%7WPA7S-55^@Q=9M%H8VN;1QS5D
MG9N-W4)2QE""NY(Y&E.6BB;88.ZZNH;:]T3%=5U7XF#QG>M>PU9+]67M[VUJ
MUD%-RZFC@7QT\[UXF8MUYH;;%N4=EK6IWMITROI55RIB>-XVE-Y5VO5^A=P'
M#K:EC/-JF^+]ZIUH(%_!5=Q?6N,BGT)62<9Y:5K^USF.F=[7*9S[IZEWD66X
M.],:)]9#[H+F_P BP5/YTC6F?@4)/-5G*3\_R+.)-:127F6#- L5/OE<[./W
M.GC:GS(2/V:6Y_%T\[E[\HGU&22[WMWDV+=^74-)??'4"_\ NB!OF6H0DZ6$
M?W&_)G>)6_$O5&*79G0-\BJG9Z%0@W0DE/\  7NNB3N1W R3JW43N5LI6I^7
M.4EK=1IP6V4KE[VSJB%,J6&6T&O)ED:E7G)? M_>&]0IB*_.>B=DL".^<INH
M-1X5/?6F3S^#?UE=;I?H_*LD;_D5+2D_4=QCWNML%5COC>U_UE4E27.2]2V+
MEW/T,-5Z(N5?,^:LNL<[U:K$ZR!51J+W)GAZ2G'H&NC:C5OU0C41$1(\HG#\
MXS*ZTI(TQ4TU92^>6%V$]:*7=+J"VW''45L+U[MY$7V*9%A\(Y73U\6:%5K)
M;:>!@5T"DGP]WKIO-O\  C'L[M#?A&3S_P )*J_6;2OISZR!/V2@N5_C\SG%
MJ]IB*;2%GIL;E##^<F]]*F0AHZ:G;B.&.-/R&(B$9ZN*EC62:5L3$YN>Y$0P
M4NLH)Y'1VRFGN<G[PW#/TEX$GP*6BT\/H(\2?-FQ-\Y'YC6$J=45?P=+1T*?
MOKUD7YB'O-J&?X>^,A[VPP)]*G%6_!!OX?,[PE]Z21M RG>:RFCY7\9KW<)?
M,DFZGS$$T);W<99ZR9?RJEQWB57M#U?TN,D.<O@;(Z9C>;VI\I<$/"(OQL?Z
M2&!30ME[:=S_ )4KE^LF^XFR?XFG\H_[3N:O^%>K^AW+#M?I^IG/"8OQL?Z2
M$R3,=R>B^A44P*:(LG;1M_E'_:070]E[*9S?DRO^T[FK_A7K^@RP[7Z?J;"B
MXYJ-Y.\UK[AK>WR)JN+Y%2Y FD&Q_!7>XQ_Z_)'/5YQ^)S)#M^!LF4&\AKJ:
M;N+/@]05B=V^QCB/O+>V^3?\_*IV_4.)/G!^J"IQ_%\_H;"Y&O:J.:UR=SN1
MA:[1]JN"JLE(QCE_#BRQ?F+;WOU&SR;O2R?*IU3ZPE-J;_':!?\ 4+]I7)QD
MO?IM^C_,E&+CK&:^)A;QI9NGJ.6LCEAJ:>),K#70->J^;>YE2CTHZ\1,FJ8J
M>W1N1%2GI8T<Y,][L&1J;9J"NB?#/5T#HGIAS?!UX_.6MLT*RC14FKYG_DPN
M6-/I,+H7G[D'E_?B:5-Y+RE[Q>4VA;3#P=%)+\N1?ZB]9IFS4_%:2%ORU^U2
MW^Y6!V4=5UST[O"%#-'6MJYDA?-_"2.4T1H);4UZ_H5N;YS?[\R,\FFZ#>ZW
MWOC]*-52U75NFH<)$V.1R=D5.J_49:EL-MITS'0T[?S$52_9!&W"-B8WY+40
MM5&?+*O+_@AFCSN_,UAFN*#>5(+562>=E-A"LS5TTGD6&M7N7=1#9$54[,$K
MI&-\I6M]*G>%/G.W@CF:/X?B8'[J:_FM@K,+W*F?81^ZZ=B??+'<&^B-%^LS
M?A$7'[ZS])"9LC'>2Y%]:$\DN53X(Y=?A^9@4UQ2-X34E=!\NG7'S9*T&M[+
M*_"UL<2]TJ*WZ4,WQY9R4)Z."H;NRP1/3N<QHM57WU^_,C[CY?']"-/<:6K:
MBP5,4J<_$>BE?>3/E&"GT;9ILN=1LB7XT.6+\Q@+G#!8ZA(*"[U[JGLI8T2?
M'ISR(2K3HJ\XW\&2C3C/2+?H;YGSD4<G:II5LDU?4MS(M- SOJ6>,OJ3D9!;
M1?JM,5%[;"WNI8$3YU4E'$RJ+W8/X?4XZ2CHY+]^1L$M7#31N?)(V-J?A/<B
M(8B?6]GA=NLJO"'_ !8&J]?F0H0Z)MK9$DJNNN$OQJJ57?,9JGH::F;NPPQQ
MM^*QJ)]!+^M+LC\3EJ:WNS#)K)CT^]6NXR^?J<?2I%-6R_Y%N*?ZM/M,^W/-
M2.]YAPZO.?P.9H<H_$P":ME3_P!RW'^33[2+-8)R]Z;DB_P"?:9].)%/82X=
M3\7P.9H_A^)@6ZRCSX]LN+/3!]BE1NLJ?MH+@B?Z.XSY-'GOXEL:=;\7P(.4
M/P_$P;=;T7^+5R?_ %,XK-UM;^.^VJC^53N3ZC.,5W>5$\;GA?2:(TZWXEZ?
MJ9W*G^'X_H85NM[/A/O[F^9T3_L)UUI0O16TD5362+P1L4+D^=4X&;;"SXC<
M^A"JQB-Y(B>A$-$:=9[R^!0Y0_"_4YU<:6[7*YLKI[1,YT;V]7 B-5NXG8[S
M\C9&:IJV,Q[P5B+CCA$0V5,$3E+!2IR<HS=Y;Z(2K*22<=O$UZ/5TK^=EKVK
MYF(I5^Z]K?*M=Q9_J47ZS/<<<B/$U*C57W_@59H_A^)@4UI0IY<-9$OY5.[Z
MB*:UM7XR?UT[_L,[P[5^9"198F>4^-OI5!EJQ_ZB]/U.7@_NOU_0PGW:VY?@
MVU4R]S*=V?G0E^ZF:3X"S5\J?E-1OTF7=<*./BM1"W_6-0IK>;>F,UL&5_?$
M.>]]ZHEX?K<:<HLQRWV[*GB6"7\^9J$J7>^KQ2Q-1//.AD5U!:V+XUPIT7^$
M0E^Z6U?X_3?RB$';G6^1+7E#YE@V\7SCFQMQYIT'W1UT.?"+'6-\\;FO0O\
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M8^3:':FYW72R)^2S[2IT\+#256_F6J5:6T%Z&/=I&^NSF].7\]Q071UY1/\
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M]WX=7GT,S]*EW%<J]W*GIYD_>YT^LJ)=:IGPEMF3Y"M<6*E0W:;]3F:HMK?
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M<W3-],:D_P"J#9\?"R_R2D7+ /6Z^1U*NNTH?<3,W.Y?*]OFWU7ZR;[AW/\
MA;Q<)/-UJD%VCVIN<=<[_5X^DMY-IEO;Y%-4/7\U/K(.6 7WEZL9<0^1>0[/
MK4U4=*V:H=^^2KQ,Y:+-0VMZ^"4L<"JF,L:F53TFE2[3I9,]109^4]5^9$^L
MRFC=4W&]W>2*IA;% D*O3=8J<=YJ<U]*EN%KX3C1A26K[OS(U:=90;F]/$WT
M! ?4GE@
M
M
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ML?E6ZCF\\<ZI]*!.BNM3?H/?Y27J5?N&LO\ B35_UK_M)5T+:%Y4SF?)F?\
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MREFE5=9O(IXXT_+)5I+K-\)6-C3N:+4_NPO^^\Y:7.1DDM-%'_@\?YR?:/\
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M:!T51;[G'Q=1UC5:_'>B]IMO#ZRRCA\#6CFIP37@B,IUH2RR;]6:?^I!HO\
MS=HOT5^T?J/Z-_S=H_T7?:;AE.\Q[[Y0PWB&UNJ$2OF8Z1L.,NW4YJO]NTLE
M@\)%)RIK7N1%5JK^\_5FO_J0:,_S;H_T5^T?J/Z,_P W*/\ 17[3<!ZQ_+\+
MOPX^B^AWC5?Q/U9I_P"H_HW_ #=H_P!%WVC]1[1G^;M'^B[[3<./>/2O [[%
MA?[4?1?0<:K^)^K-._4>T9_F[0_HK]I%-D&C,+_ZNT?Z+OM,I>-6TEFO-KMD
MS)7S7%SFQ.C1JM14QG>]IG",<+@I.2C3BVM]%]!QJRLW)^K-0_4@T9_F[1_H
MN^T?J0:,_P W:/\ 1=]IM_K'K)>PX3^U'T7T''J_B?JS4/U(-&?YNT?Z+OM'
MZD&C/\W:/]%WVFW^L>L>P83^U'T7T'&J_B?JS3_U']&?YNT:?FN^T)L?T8O_
M -;M%^BOVFX>L>L>PX3^U'T1SC5?Q/U9I_ZC^C/\W:+]%?M'ZD&C/\W:/]%?
MM-PX]XX]YWV+"_VEZ+Z'>-5_$_5FG_J/:,_S=HOT%^T?J/:,_P W:+]!?M-P
MX]XX]X]BPO\ :7I^@XU7\3]6:?\ J/:,_P W:+]!?M'ZCVC/\W:+]!?M-PX]
MXX]X]BPO]I>B^ASC5?Q/U9I_ZCVC/\W:+]%?M(MV/:,_S=HOT5^TW!C5[R9$
M<O:26 PO]J/HOH./5_$_5FG?J/:,_P W:+]%WVD?U'=%_P";E'^B[[3<FM7O
M(HQ>\E_+L)_:7HOH1X]3\;]6:9^H]HS_ #<H_P!%?M(?J/:,_P W:/\ 17[3
M=>K7O)5:O>=_EN$_M1]%] L14_&_5FF+L?T9_F[1_HN^TA^I!HS_ #=H_P!%
MWVFY*U4)53FN2M]'83^U'T7T.\>M^-^K-._4?T9_F[1I^:[[0FQ_1B__ %NT
M7Z*_:;AZQZR/L.$_M1]$2XU7\3]6:?\ J/:,_P W:+]!?M'ZCVC/\W:+]!?M
M-PX]XX]X]BPO]I>B^@XU7\3]6:?^H]HS_-VB_07[1^H]HS_-VB_07[3<./>.
M/>=]BPO]I>B^ASC5?Q/U9I_ZCVC/\W:+]!?M'ZC^C$YZ=HOT7?:;AE?C#*]X
M]BPO]I>B^@XM7\3]6<MVB;,-*6K0U]K*2QTD%3#2/?'*QJY:J)S3)OFR_/ZG
M6FTS_P"[X>S\E#%;55QLXU)R_84G/D:9HJV5-=I*SK#1U3_UK']\EGPSDG),
M<CRH2A@.D6J4-X\O'N1HRRQ&&]^6TN>O([?XO>$>QO-R)ZSED6CKD_.9(XD[
MEE52NS0]4OE5K$]&\I[JQ]:6U'XF/V>FMZGP.D+4TS?*EC3Y2H6LM?:T:J2S
MTGYSFJ:&F@GNYUK5_P!6OVD?N [JQ/Y/^LB\7B'_ -+XH*A3_&;7/+IF;/6.
MM[E\ZM,!>Z'3,=/)-2UD=+4-3>9U#\IE.*<"S^X5Z<JQG\G_ %E6GT=4TLC7
MPUL+'MXH[P?*F2I*M55I4%^_,MC&G#539:V:JIJ6=]5?J*:26=&NCFDCRW&.
MXVBEU'IA<;BTT7RH-U?H+/JM1[N$O$3D7L= WZT+2:U7BH5>LDMTR]N_3M^P
M[2<Z$<L8-^*5WYW(-*H_>?Q?T-KAO=G<GB5E(G=X[4^PO[?7TU5*K(:B*1R)
MG=C>B\._@ISQ^FZ]><%M7T1JGT8,UHBRU-MN\DDT%)&U85;O09WL[S>'%>7
M]+"8FM*M&,J=DS/5HQ4&U*YT$ 'UIY0
M
M
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M;V\WM3S9-&%Q<I5HPE!J[\BJM3M3;4D=# 0'V!XP
M
M
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MDU[OSVHH2FN'^.L7TQH5J>YTM1Y$S<_%=E%+I'-7''/G)J$);/XOZG')K=?
MLDH:U?*KU3Y,:$S;3._RZ^H7Y.$+B6L@I_A)F-]992:FHX<HQSY%\R<"$N%#
MK2^+(^_+9? KI8XG>545+_3*I.W3U+S=UCO]8OVF-75:N^"I7/\ 2[[ W4%P
MD7[W0Y_-52GBX>^U_)C)4,JFGJ+XLB_ZQWVD6Z=I.Q9D]$KC'1W2\N\FB1/2
MU2YCK+X[_ X43SNQ]9)2I2VB_0K:FOO?$N4T]!V5%4U>]LJDS=/JU/O=PK&+
M_"9^HIMJ+QS\&I_Y14*C:J\-YT5._P!$J_83_I_A?Q*'?M)_>:K3R;M4)\I$
M4F;:[DW@V[.S^5$U23WQNC/*M:.3\F9"3[I*B'/76JJ9^4U$5#EZ*WNO4C[_
M '? N&VVZ<?^5O\ [0TM:VSWK=S3W-9/R53<7VD[-9T">6R>->YT9,S6E#(Y
M&Q1SR/[$:W^LKE+#M6S/U(VJ+9? QL4=*V1([LM?"]>".FE58U]:%>JI=-TT
M:JKJ15QSDDWE7VJ7TETKKA&K(K2KF.X*M2]$;ZT*%!IV*WT$B5,,,DSG*Y41
MN4;YDSV$*</?RTTI+M:9%RTO+3NN<QUA=K-&V1(Y:=$_(:BFF: JJ*\;1K;1
MMF7$BR^2U4Y1/7N\QT;6=+"QK]V&-O#L8AH6CHYUUY0)1HC:C,F[A$3]S=GY
MLF^<9*E*Z5NQ(RYDY*S?J=VATM;H<;T3I51<>.]>]3(06VD@3[W31,]#$4UY
MM)J-V4\(1/2]J?5Z"9EKU"[G6-;_ *S[$/"C.$>K2:\C8XM[S-I:N[R3'H1$
M)^)JS;+>W>5<]U/,]?L*C=.7-_E7A_JWB_C3Y4_D4.$><T;.W/'@1XISX&L?
M<E4N\N[3+Z-[[2+=&JY<.N=0OM^T<:MRI_$ADA^(UK;@[-OTS_'$'UG5&N\5
M?2<5VL:?2TTVG)4J99E==H6X?R]//S':VNPU/2>1@W*6-Q&=6>GR-59)4H6U
MW^9!\;96.:Y$5JIA4=R4T2JV.VIU7-46ZMN%F=*[>?';Y]UBKV\%^HWT<?,>
MO5PU.O;B13^9DA4G#J.QK&E-GEJTG/)4T[))ZV7@^KJ7]9*J+SX]A:Z_UQ:M
M/4%50U4F_73T[DBHT:Y5EWLM3'#EDW'Z"WDH:>>9DLM/')*SR9'QM5R>A2J6
M'M2=.A:-_3OT)*;<\\]36-EFF7:6T?2P3,W*F;[].WEASN35]"80NM5;/;1K
M">&>O9*D\+=ULM/*L;T3NX<S9?-])#B3IX:FJ4:.5-+M'%DYNHG9LU[4&@K)
MJ>GACKZ99'PMW8YV/5LC$Q\;FI1TULZL6E9W5-'3/?5N3"5%0]9'HGF539T\
M4<^P>R4,_$R*_;8<2IER9G;Q.6ZLME%>MK]LH:R%E132VV1KXGIP7B["^939
M=/[+M/Z?KTK:>GEEJFYW)*J5TBQ\/P<\$^DVGP6%TZ3K#&L[4PDKF(KD3S+W
M%1N?5V&:E@*4:DZDXIMN][;$Y5YN*C%M)*VYB+IIBBO%WMMQJ$D6HM[G/@W7
M*C?&3CE.TQVIMF]EU55-JJR![*MJ;JSP2+&]43@F53F;2G$&N>&I334HIW[B
MJ-2<6LKM8TN+9'IF&&*-E++%)%,V9*ALKEF5S>67+S3S&6U)HBS:NBC;<:99
M'Q>1-&]6/;GN<AGV<U)B$<%0C%P459]R.NK/-FS._B:GIO9C8=-5:5E-3R35
MC45&U%3(LKVHJ<<9^PRE/I2AIM33WUB2>'RPI [Q\LW$7*83OX&9:Q<\Q))'
M QJS2,A1W)9'(W/HR:*>#HQBHPA9)W\^TJE5DVVY7N8.X:1H;E?+?=IDD6JH
M$<D&Y)AG%,+O(3:ETI1:HIZ2*M27=IIVU,?5OW?'1%1,]Z<3/]6J(B^SSDN[
MYRR6'A:2DNMOWA5)73OL45;XO AQP3N;W@ZHVTV.7Y$A,C2(.6)7(HF29K0U
MO,J(TM42#9!K>"_4?/[W27:#5:^U_HK81;*A\-NJ&MU!J1T;N+H&N5(8E];7
M.5.]6'T&:WD?+3;8Y\?N@FU-EQ5/"Y+30> ]ZP)#%G=\_P#6?5?P_AH5L;"-
M38\W%3<:;L7U)2P4-+#34T38*>%C8XHV<$:U$PB)YN!5()Q]G+LXFLZ\VCV#
M9O:W5E[K6PN<W,-*Q4=/.O8C6\^?;R3M/W^4Z>'@W)VBCYC6;)]HFNZ#9SI.
MMO=>J+U*;L%.GE33+G<8GI5,KYD4]7^YW[!;ELFV15NI]41+'K;7%2EXN#9$
MP^"%458(5[E1'.>J=\F.PXIT3NB3J';-J^U[7-L%J?:].4#DJ=-:/JFKO2+E
M%;45+%_!X(J-5,OX*J;J(COHFKE>YRJN3\8_B7IJ.-GP:751]#@L-PUF9*O/
MSE,F7D2*?G<F>RB4 %98         :KM4X[-]2?Z#)]!;;-Z6!NAK"Y((]]U
M%$JNW$ROBEQM5_O<ZC[4\!DR8+0=KNRZ+LCX+IN1NHXU:QS.">+R/ E++TEU
M<WN_F;(_Z9ZV][\C?6KNIC&$[DP0WC =7J.'R9:6H3SMPOU$%NUYI\^$6KK4
M[5A=_6>RL1&.\&O(R<-\FC8-X;Q@&:PIHW*VIIZBE7\MF4,C2WNAK,=55QO5
M>Q7*BEL,11D]):D73E'=%]O#>( OT>Q61WAO$ =.$=XR%D7]=N^0OTH8F>KA
MI&N6::.)/WQR(I7TS>Z&X7-\%--UKVQ*Y<(N,91.?K)T*D%6C&ZN1G&7#;L;
MB #Z,\P
M
M
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M8ZTL\;,[TD;?E.0IMJH'KAL\2^;?0YXZQTCN+V.D7\MSE4-L5"G^#I[5-O\
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MA+'+ O<]BEU#74]1Y$S'?G(BE?M,ZF\W\B7!C':/YE5:F[.\J[RI\EC4)/\
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MF_#JB*:/WWAPD;<<?9Z3M#5\5/2>-@Y9\=B&U;;?P-596HPY[_,B #WC(
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MG<'XY4IN,FFM3Z*,KJZ)&M)FM]9'!@=?:\L.R[1=WU7J:O9;;':H'5%34/\
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M^0OTH;,+1IPJQR(SUIRE%W9L8 /ICRP
M
M
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MGT^<R)MBE47O(HZKT9CULL;5S#-- OY+EP4W4]SA^#J63IW2)Q,H"#HQY:>
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M2H9"R?LQ_P A?I0U87#QC6C*[]2JM)NF]$;& #ZD\<
M
M
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M:*JA>_KT5\;\-5G)<1JG'O+:.)I+I2=1R]TA.G/V%4U'4YK[J*R71G2'Z/\
MM"JXW-L%!5MIZB9>"1NCJF2NROG8Y5_-4]S5-"MXJH:VBE;4T=4UL\$T:Y9)
M&]$<US5[6JBIZCEO2KO&Q35^E:79UM@OT%EAU(_-KED:])(ZACD:V6*1&.:Q
MS5>GEKA4<J+P4X7;O<W]L-@H7:)MG21NM)LX<JQ^]S()FS-A7FQK>L5J)V<'
M(G#EV'TLZ,,;3BV[6>AX=.K/"S:2N<\Z..L;?KCW6[6MXM51'54#J:MIHZB-
M=YDG4TT4"N1>U-Z->/:9JCE9LM]V OSKY(E)2ZPMZLMT\R[C7K-31HQ,]ZR0
M/C3SX-4Z'VRBP[-?=,-::9T3+/4Z:TK:)X/":B3K7+(D%/',KW)PRLSI.&.S
M&.'#TETG-FVQ?I9Z[H]F%TUHW36V.SYDM<M+"_PJ)JLZ]6<4:R1FZF_A'HYJ
MHN%-SM?A=QGU?]0[EJRNI]"V.^:BO%1'16RUTDU545%0Y&-:UK57BJ\LX1$3
MSH>,_<7K@ROMFV.K1JQ)4W*DD1,\6HY)EQP[4R9^?W/':)J2C;2;9>D%==3[
M/+.WPN6U0+*Q9HHT5WWR21V&HB)Q<N^J8[\*:O[D#3MMNB-KMUHVR-MDUYIZ
M>E5?PFL9([FO<U[,^E#'1HPP%*<D^\T5*LL7**L<,Z'_ $5M";:]M^UK0FT:
MMOEKU/9ZR66DI;;6MIG3M9.]D^6N8[>5JJQ?6>IKQ[F#L(TS8[G>+SJ'65OM
M=MII*JKJ9KM&UD<;&[SG?!?-YS+](?H:46UO:'3;3=!ZLGV:[3:=S7/N=*UW
M4U3FM1J/>C%1S'[OBJY,HY.#D-,U5T4.D5MIMT6F]J>WFAET>DC5JJ6RTBI+
M5-:N</1(XVN7EC?541<+A2OVZC4M-5+'?9:L+Q<#L705TGL8T_L:UI7;%+K>
M[O8;A.]M9+>VN:]E1'3^2W,;>&Z],XSQ4\W>Y.1MFV6[4F.\E;U3\EXI]Y>>
MVMF>B],;)-G-'H/2=)[WV:CII((UD7>?(^1';TLKOPGN<[*KZNQ$.$]$[HO7
M3HNZ1U9:JO4U%?9KU71UC'TL#V-C1C'-W7;W-55W-.!Y^.Z0H5<+449:_,V8
M7"5:=:+:.HU%EJ$<O53M>G8DG,MTM5:U>,<:KW[YD'5]12O7PJF5S%YR1+E/
M875-5153=Z)Z2)YE/RUI-W/O$Y12,+[UUKOP(T_/*D=EJ79WIHV)VX154S?J
M+:HN5-3.W72)O?%;E5]AS*AGD4:>Q0,<CI7OG=V;QDFX:B-1,(8UE;5U*9IZ
M7JV_'F5$^8CX)5R?"UKF_DPLW22785RN^LS)\LH3&,2SL=Q=/._TOP5&V6G^
M--_**6*Y4TNTR;>TJLQQXHGI7!C&V6G[Y5_UBE>.RTG#,3G?*>JE\;E,LO:7
MDU1!U,C'5$;%<U6Y5R%"UWF.&G; ]COO:;J/C15143M+JFMM+&OB4[$\^[E3
M(1[L;>&ZU/4AJA%MWV,LVB2"Z4CU3%0U%_*X+\YD89&R<6O:Y/,J*62NI),]
M8L*K^4J$$M]M<Y%:L;%_(D1%-\,R[#%*QE6]I5;VF+BM>ZF8*V9J=V]O(5FP
M7"/R*F*5/RV?8;(2?./H9Y1[S($WX1CO"+A'Y5)'+YXY,?23>^KV?"4<[?.U
M-Y/F)\6//3R*\K+]._EZBQJK/!5/ZQ-Z*1>;H^WTAMZI,X<]\:]SV*A6BN5+
M)Y-0SUK@[FIU%JT$I1Y&.=8YT\FI:J?E,()8ZKMJ(L?)4S#)62>2]J^A44F3
MQN7$@J--[?,EQ)&';89'>75*GR6X+FFLM- Y'JCIG)VR*9#"H0RB<R2I4T[V
M.9Y %":X4T&>LG8B]V]E?8A;I=VR?L>GEJ/RD3">U2?$@M+D,K>I?D47!C\7
M&?MAI4[DR]2"6E).,\\TZ]N780YGD^K$[E7-EU)600^7-&WTN0H/O-&WE.CE
M[FY4J0VNDB3Q8&?G)E?G*[(V1^2UK?0B(+5'S2'NEE[\Q.X1PSR?)8I2J6UE
MRA=$E,V!BJBH^1WC)Y\&4X^HE69D>=Y[6^E2,HMJTI';KDBQ945M*BMFIUJ&
MIPZR)<*OI0C[[8\JDJ4_,R7"UU,WG41_I(&W"E=RJ(_TD.=713.Z\T6_OU W
M*.9,SY4:DS;U1NX+,C?E(J%U'*R3.X]KO0J*3.C:_P IK5]*9)K.]I+T_4CI
MS12CKJ>3R)HW+\I"LB>A?06\EMI9/*IXU]6/H*/O+ W*QNEA^0]1_46Z3'NE
M\8RKLK)9%DAD6!SN*MQEJE1**LB^"K5>GQ9FY^<>$5\/PE*R5OQHG(B^PA)J
M6DU8E%..S+%UIK&\G0O]:H0]ZJ[XD*?GF1CO-,KE;)OP/^+*U4+N*:.5N6/:
M].]JE<:5-\_B2SR6Z,,VRU;O*EB9Z,J7%/88FN1TTCIU^*O!OL,FKDXKG'I7
M!;R7*FASOSL3S(N?H)\*E'5_,YGD]BXX(U$3EV=R>@%A[\1N^!@GG\[683VJ
M$JJ^7/5TC8D[%D>GT%G$C]TCE>[+\.5&IE5PA8>"U\WPE8V-/BQ,3Z2+;- Y
M<S.EJ%_+<OT#-+E'\CF5<V35%UIH6O3K6J_&$;&F]Q]!86RJ@HV)X3&Z*=RY
M=)(U5WN[CV&7AI8J=,1Q-9\E$)W(CTPY$<G<I#)-O-=([F2T1+%41SIF.1LG
MR5R3EG)::25<]5N.[X\H2>]M1#\#6R-3L;(B/0DI-;JYRT7S+\%AUEQB\J*"
M=/R7;JA+E*S/6T,[?D>,GS'>)'GIY!1[&7KX8Y/+8U_I0I> TV?@(_T4+?WZ
MIVIXS9F+^5&H]_*/X[T_,4C>D]['<LN2+ME)"WR88T_-0J-\5,)P3S%A[]TS
MO(;+)\B-5"7"IF^"H7^F54:=4Z:V&5\R_!8=1<)O+J(X$[HVY4)9HW\9I9IE
M_*=A#N>3ZL3F5<V7JRL:O%[4]*DCJR!.<T?Z2%NRS42?X.Q?.[*J5$M=)V4T
M?L%ZG8A[I%;C2MYU$?Z:%%]WHT_=VJO<U,E9*6DCSF*)OI:GUDGA%''PZV%O
MH5J'+RV<DB2L8IU6Z.HDGHFROZSRV.B5?G+J.\HJ??X)8'=O!50N_?&E_'Q_
MI(&UD$G!LT;O-O(0C%Q=XR1;?38A%6P3^1,Q_K^HK-Y*6\]#2SIE\+%7XR83
MYRW2@ZGX"JDB\RKO-+TZBY)G4DR]_!((6*5%9!Y<;*A.^/Q7>PBR[0N=A^]"
M[XLJ84L51;/0EE9-<:YU'$US6(JN7'$QBU55+Q6?=_@^'SF7<YLS%14:]BEF
MZTP\XW/B\S5X%<X3<KQ>A?'3=%ANN=SED<ORB'5(O-7?I*7B6GNJ'>O!%MI1
M<YFD7T<"/#EV%ET6.[N\I')^<I>6R>25\B*Y9(TY.7O[BK%;((W+EKGK^4I/
M)-#2M1%<UF/P>TG&FXN[=CM[Z(K*0+3PN2;X"%RI\9_BI["/@4DO&>9SD^(S
M@AIS?AU(Y>TFFK(HG8WMYWQ6IQ*:2U$W%D:1-^,_BOL*\4,</!C&M]"%.IJD
MIV(N-YSO.'>UY,FK%-*)9.,LSG^O=3V%2*FBA\AB(I9OK*AW:R/Y*%)9)79W
MIG^A%(J4>2+;,RBY(+GM,6B+\=Z^LE7+?W1Z?G$^(^PEE)]1_P#1^Y_Z-)_-
M4\S]%IK7;0*U'(BI[UR<T_?8CTW$SWPIZFFG1989&K&[.4RBIA4RGF,%I/97
MIG1-PDN%GMW@E5)$L+I.OD?XBJCE3#GJG-J+ZBV+S(]"CB(T:%2D]Y;6-!Z4
MM/'%H.@<UN[FXLX9_>I3*='-DJ[,J18WICPB;Q7-X>6IO>JM'6G7%NCH;Q2^
M%T\<J3-;UCV8>B*U%RU47DY?:8UTNF]C^E6INNMUH9*C4W>LFW7/7M\IQW*C
MJKJ6&5!)N5SS1KBGKMD^U*X34"=1UC9)J?L;N2M<B_HJJIZ6(;UT8-,Q-ANE
M^JV.\=4I*=RIW8=(OHSN)ZE-+VUZ^H]I6J:!MF@?+! SP>.5(]V29[G<D3GC
M.$3..*N/3>S[3#='Z,M=IPU)((4ZW'%%D7QGKY_&5?5@25U8]?%UG3PD8R5I
MRM?P1R#I3-B;:+"L3U?^N)<\57L0QNQ?;#9-,Z9;9K_)+1^#N>^GF;&Y[9&N
M578PU%7*.5R&:Z5[4]Z;!P_PB7L_)0R>S#9OI[6VRO3[[Q;V54K(Y6MF1SHW
MHG7/X;S53AYN/H&72S*HSI1P,%56EWL<=UY>EVO[288[-3O2*1&TE-UB<5:B
MJJO<G8B*KE]!NW24T=/3TMFO5/"J4E/#X"_=3+FHF58OF_"]>$[3L^B=GFG=
M&]>MJMT=-.]=Q\CG.?(J)V;SE543EPY<#9JRBI[A3RTU3#'/!(FZ^.1J.:Y.
MY47F%8SRQZA4APXO+'Y'GC1NM]F2Z2@=>+5;X;K30(R6)UM8YTKFIC>:Y&*B
M[V,\5RB\S);&=36S6FI'0TN@[90-I6+*ZY0,8U8NQK?@^#G9Y;R+Y1NE1T?M
M"SSOF]YW1\=Y615,C&^=$1')CU&Z6#3-LTK;THK710T5,WBK(FXWE[U7\)>'
M-<\CJBBNMB:+A)4[YGVO8\L=(*-L>UBH:Q$1O508_1^T];PM:C&*U.[L-3U#
MLDTKJF[NN=SM?A5<Y$:LG7RMRC>"<$<B?,;<WAN_U_V_\Q9(HKXF%:G"*O[J
ML[GD/I&[WZJ-7PRO40\%SA?%Y+@ZQ9NDEIQNFHY;BM1%=HXL2T;8'*KY$3"[
MKD\7"JG:O:<LZ0O]]F?//JH/YJ'>-1[&M*ZCJO#ZFT-?5/7>EDAD?$K_ $HU
MR9]F3KT5SU*LJ/!HJLN7(X7L5M]3K':S+?I&)'!!-+7U#N:(Z3>W6HO?O.]C
M2CT@9&R;5JA[5RSJX>7R4/25BL-KTW0-HK;21T5,U5<D;$Y^=>_UF&U!LPTK
MJB[.N5SMR5-:J(BS=?*W@W@G!KL&=5"F..CQL[6B5D;M'71[F-URKCNX'E;;
M7::S2&TS[H((U6GJ)HZVGD>WQ4E8C5<UWG1S<^A4/3N^U.U/G4MKC:*:_4;Z
M.MHHZVED3#HIF(YJ^TZJFNYCPV(5"HY6T>ASY.DUIAU@6H5M3[X;G[ ZM<[V
M.6_Y*IGM]>.PY?L2T_7ZWVE/U!-#BFIZA];42M3Q5E<JN:QOGWESZ$X\\G9H
MNCUHE)EFEM3U>JYZM*F5&^CRC?K/9J"P445';J6.BI8_)AB8C6I[/K+UJKES
MQ-"C"4:$7>7:>6.DNF-I3L_XG%]+OZSL'2+B9^I=4NW41W70\?SS9M2[)M+Z
MPNB7"\6OPJL1C8^L\(D;XJ<N#7(GS&8U)I>V:NM+[9=J?PJB<K7.BWW,XIQ3
MBU47ASYG"/MD'PM_<W_0Y1T7%D^X2X+&K<^^3_%=V_>HCEZOQTA7.<F,7OBB
M?PAZBTIHZSZ+MTE!9J3P*GDD69[>L?)EZHB*N7JJ\FIV]A@)ME6DUU4EZ6VH
MRY.F\*6?PF7X7>RB[N_CFGH(R>4G#&PXM2;3]Y&F])BQ/O>E:.XTK'O?;)7.
MD9N\4C=A%=ZE1OJRO8:=LGU?L\ATTREU/;[?%<:;>3KJB@27KVY547>W5553
M.[A5[L9R>E6TU.YBLW&N8Y,.141<Y3^WF-&N.P31%TJWSOLS87N7+DIYGQLX
M\5\5'83(A=ZR(T,935%4*E[;W1SG0FN;'JW7;+;;=GMH=3=<YT=<RG9&Z&)J
MY21R=6N%QCM3BJ&*Z5:_^M5HS_BCLX^6IZ!TMHJRZ+I706:W143)%17N;E7O
M[MY[LN7'G4L=6[,]/:XJ(:J]4'A<T+.K8[KI8\-SG\!R)\Q,4\72IXA58QM%
M*VY:Z'=_ZE:?WU=^P*?'\FT\]](:2H=M#1E6CUH601]0UN<;GX>//O9/5U!;
M*>W4,%%!'U=+3QMAB9Y6ZUJ(B)Q557DG,Q&IM V'6-.R&\6^*J:S*L=E6N;G
MGNN:J*B>8IC!QE<JPV,A1K.I):._Q.*ZCUKL_LVA*VETY!2OKZZD=31QPP*V
M;QVJUSGO5,IA%5>*]ABNB],UM[OD:N\=U/&YJ(G'@]4S[50[9IO8_I+2]0M1
M0VF-M3C'73O?*YJ+W;RJC>[AQXE;2VRK2^D+FZX6>V.HJS<6-7)4RO\ %7BK
M<.<K>Q/0N"S+H:I8ZBJ4Z<4VWS9YKVKS):=M=35U$;VQ1U%+4*F,KN(R-5QZ
MD5#M^J==VC7>R?5-3:97S10T[X7.>Q69=NH[DO''C=O<IL^KMF&F]<2QSW>W
M,J*B-NXR=CG1OQW9:J91/.G?WD+/LOTW8[!766DM^[;ZQ,5,;II%67AQ\;>R
MG#NP26BL5SQE*I3IMIYHG(NB6BJ_56.'"E_^_&CZBI:W8[M>=<'T[GP1U+ZJ
M#*826%^\BM1>_#E:OG0]-Z2T%IW0*U?O+1MH_"MSKLS/?O[N]N^4Y<8WEY=Y
M>7^Q675%%X)=J:"NAY[LK<JB\4RB\T7BO%.\YF2.QQ\>/.IEO"6G><RU'TE=
M.LTY,ZTK45%SDC5L<+H5:D;E3&7.7@J(O=GZS3>C!HVJJ+[4:CFB<RAIXGT\
M#U1<22.PBJWO1$RBKWKVX.F4VPK9_2U#94M3I=U<I'+/*]OL5V%]?L.@4;J:
MAIV4U)3]3!&FXR.*/#6HGFPA'.NTC/$T:=*5+#Q?O;MGE&_8_NBF\$_Y\IL_
MRC#TKM(AC_4^U-XB?\V57)/WIQC*C97INLU&E^=9GNNG7MJ4J'5$K?OC5147
M=W\<T3FF#9;G027>WU-#4PLDI*J)T,L>]C+')A4SP7DN. S+<JKXF-5TVONZ
M'GSHJ1,EO&H$<F?O$?+Y3CT34(ZG;XE0J?DNYFLZ2V;6?1,M1+:;<ZE?.B-E
M5M1(_>1.*)XSEY9^<V2F:L.5=3O<J\G<U*9-2>UB&,K1KU7..S(MEJ'HW<WI
M._?:5FLJ%YQ0^M$)O#&IC>9(W\TEDND;?)1SU\Z8(VC'=GGN_)$[8ZCLZEJ^
M9I.E-.[RZAR>9J8+9E6Z?G,R'\G'$N&4+9$573/E3Y28.:2V5_,@^\D6GI87
M9E?O+^6[*^PF2YTT:;K=Y4_):5HZ6*+.[&U/3Q*K8VIR:U/4AW)+E9?$@VBT
M]]H?BO\ 85&76%WX$B_FEPUN.PJ',M3M^!6[=A;>^<?9',OYBA*Y[O(I9E]/
M N_P"#>TYEGVD-.PMNLK9.44</RERI%*.>3/6U;E_)C3=0KU$[:>-\CEX-+!
MUVF?GJX6M3L5ZE4G&.DFV+-[(NTM5/S7?<O>YZEI46ZFA8Y6PMSRXY4HK6U;
ML_?MU.YK2QKIJAT:YJ9.7+)5FA^$XXR[31]86V)N^L:OB\S'<#7=DM.Z/:K9
MW=;(Y$Z_@Y?WB0R>KI9D;)BHD]IA-CM3*[:Y9XW.ZQ/O_9^\2'HT)1NM#%5B
M^T]4IR=Z29?))6>2OI)E\D] QLFC)T7!)&3"Q64I:&FJ6KUM/')\IB*6,FE;
M7,[*TJ,ROX+E0RK>2DS>TI=&G/K104Y+9G)-KUAI+32Z<DIT>CGW>%,.>JIC
M^R'9FM;N^LY5MQ_YOTSR_P">(%X^A274/2(L-FN$M)34U3<EB>K9)H5:V/*+
MQPKO*Q[#Y58O"='8ROQI**=OD>FZ-;$4H<--[_,ZME$[";"&FZ?VLZ=O]@J[
MJRK6G@HTWJJ.H;B2'/+*)SSYC4/[IBQ^&+&EMKUI,X\(PW>]*-YX^<]&ITS@
M*48RE524MN\S0P>(J-J,'=;G8$P[@1X(:9?-K6G;%8*6[OJ_"H*M%6FC@3+Y
M<<T1.&,<E5>\UO3G2(L-YN3*2KIJBV+*[=9-,K71Y7EE47AZ4S@G/I? TZD:
M<JL;O8Y'"UYQ<U!V1U;@@PASW6^VNQZ-JUH59-<*]&HY\-.J8C1>6\Y>6>Y,
ME31.V>Q:Q?- CI+?61-=*Z&JPB.8U,N<UR<%1$X\>/ ?S; \7V=55F[+_F<]
MEKY.)E=C?TX\0BY.0W#I*6"CK7Q4U%65U.U<+4LW6(J=[4=Q5.[/>;+-MCTW
M!I1-0)4/DIE>L20-8O7++C/5JWO1/5YR%/IGH^HY1A53R[Z_NYUX/$1M>#UV
M-YP2HK5.,6[I-6V>N2.KL]31TJKCPALK9%;W*K<?0JX.BZCU_9=,6".[U56C
MJ69$6#J?&=/E-Y$9ZN)VATO@<3"52E434=WM;U$\+7I249P=WL;)PP.'(Y%9
M^DA8*ZO\'JJ.KM\#G(C:F3=<U/.J)R-BUQMBL6BTBBE62NJYF=:VGI<+XB\G
M.55X(O9GF<I],X"=)U5566._<=>#Q$9J#@[LWK@PG;QPIS?0^W"R:QKTH%CF
MM]<[/5QU"M5LF.QKD7&<=F.Q2SU)T@K#8[C+14]/47-\+MV62%6M8BIS1%=Y
M6/8=_G6 C25>5597S_>H]DQ#GP\CS'6&.Y]Q.BHYKFJB*UR*BH[BBIY_,:/I
MS:Q8-06:JN,=0M+'1IO5,=0FZ^)%Y*N.>?,:^SI"V5:S<905JTR+A)L-1<=^
M[SQV]YI_G&!I1A-U4E+;O*?8Z\VTH/0\Y;>_<\*ZFU5<->;![K2:6O%4Y9:_
M2M;XMLK'<UZOAB)5XKNJF[E?%5J<#RQM6UUM;V%6F-^OME,EBDEE=2P7"2L1
M])/*C5=XJL5V>"*N$7LYGU@N>U"Q6RT4U>M2M3'5(JP1PIE\F.?#LP> O=6M
MHU)K78_HJGAI)J:2*_/D^^.:J*G@TJ<%1?.A]OT5_%<J=6.#A65Y;+<\FMT=
M+(ZK@]#LGN:.Q]+)LOJ]K=VK6W/56T'%3)(UN&TE+&][60MRN>*M5R]G!J)R
MX^Q5540\B]#+:U0Z6Z)&RV@93R5U5';'=:C%1K6??Y>"JJ+Q]!Z+T7M,M^L)
M7T[&.IJUK5=U$CL[R)VM7M3BA\[B>F,/7QDZ4JB<[OQ-U/"5H45/+[IN3%W7
M(N,JBYQZ.)\8=I&HZ7HL])K:5H)*:HNVGJBZ>^-)X&W>GIUJ&I+N(U?*1$?N
M\./BY/K%J;:]:K!7R4;(Y:V:)=V1(L(QB]V5Y\SY:;4-1TU\]U/L5W:CJ>F=
MJ"TN7KE3Q4;#&BYQZ#V>@NFJ5'%35&:S15W^IEQ6%J.$93CHRO:MJFH]H%5[
MW;/-F6JM3W23Q6]90N@@C[,O>N41./:J'HW8%[GO=[WJ6BUUT@*VEO5PIE2:
MWZ-HG;]!2.3BBSKG=D5/BIEJ]KG)P/5E;MRL]-5NBIZ6JGID=QE8C6HOG1J\
MT,Y4;2K%#IQ;UX5FERK$1$\=7IQW$:O:G$MQG\;?S",J?&45'=(C3Z*G2M)Q
M>ILS49#&V.-C61L3=:UO!&HB<$1.[N0@KD7@<LH^D)8YJY(:FDJZ2!RX2H>C
M7(WSN1.*&9UIM>L>CHX4E>^MGJ(TDC@IL.7=7DYRJO!%[,\SXS^=8&<)58U4
MXQW/46"KQDJ;@[LW;>1I*N.9SK1NW*R:MKDH'Q36ZM?GJV5"HK9%[FO3AGU&
M-U#TB;#9J^2DI::HN?5.5KYX5:V/*<]U5YIG/F,LNF^CU25;C+*^?[U+8X/$
M.>10=SJY#@:1;-L>FKCIJKO253X(*3X>"5GWUCE\EN[V[WF-+CZ3MO6LW7V.
MK92*[=ZU)6N?W9W,=G<BD*G3?1]%1<ZJ2EMS)4\'B*C:C!Z':MY&\".ZG,U^
MHU]8J?2_W0OK6):G,WVS(BJKL\-U$Y[V>&$.?4_27L;JU8Y;=704V]CPC#7*
MGGW$X\$["^OTM@L,XQJ5$G+8C3PM>JFX0>FYV!%1Y-P::7JG:UI_2EKI:V2=
M:SPQG64T-)XSI6_&YX1/.OH,%I/I 6'4-SBH*B"HMD\SMR%U0K71N<O)%<U>
M"KYT#Z6P,*JHRJQS/D(X6O*#J*#RHZCPYD.!S?6FW6QZ3N$E R*>Y5D:XE93
M81L:]RN7M\W89#16UZQ:QAJ5B>ZBGIHUEEAJ<(J,3RG(J<%1/[(<CTM@95N
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ML_(SUIQX;2B;$G(B ?8'C
M
M
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MNGW'G8B$>')[&] )P!]P>
M
M
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M/H,;)8-W/55#D3N<W>^<SU*<U+35%L9+F8U8=[RGO?\ *<JD/!8OB\?2I?\
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MWW)"JJB(O+>:>I@IP]HA%-;F3$)\*3-_ !]X?.@
M
M
M                                $,\#!:IH*NX4,<=&Z-LB2HJNESA$
MPOS\4,[G@4I_@_645H*=.47LR=.3C)-&DT^A99N-=<99.]L*;B&3I-&6FF5%
M;21R.3\*5=]?G,V0X'CPPE"&T39*M4ENRWBME+"F(Z>)J?DL1"=U)%(W#HF+
MZ6H5O6$])H4*?)%>9]ICJC3UOJ<]914[O]6F?;@Q<V@;>]56#K:1W?#(N/9R
M-E!7+#49[P1*-2<=F:5/I"Z4V?!ZZ.I8G)M0S"^U"S?;[W#P?;$D_@947Z3H
M(X>8QRZ.I/9M>#+EBJBWU.;U#KC2POFEM-0R-B9<YVZN$]2ENRNK9)X(8:'?
MDG:DC&I(CLM[U[CIKFM<U4<B*B\,*:QHNBIZ.IO#8HT1&53HVOQQW43./0BJ
MIAJ8%JI&*D[2OV7T\B^.)O%MQU+"'3-ZJ?A)Z:D:J_@HKW?892BT)2QO;+63
M25TC5RG6<&?HIP-E&/.>E3P-&G9M7?>[F:6(J2YV+=:*!8UC?#&YB)A&N8F/
M88JJT9:JI=Y:1L3N^'+/H,ZG +DU2HTIJTHI^14IRB[IFIRZ%6/]BW*HB_)D
MQ(GSEC)IR]T^=Q]+5IZV*;T,H9)='T);)KP;_,M6(J+O.=/CN=/\/:I^'X42
MH]/M*"W:"-<3)- [NEC<TZ7XOF(.CC>F'-14\Z&:71WX)^J+EBGSB<W;=*-W
M^$QIZ55"*W.C;Q6IC]2F^OM%#)Q?20/7\J-%)6V6W-7+:*G1>]L;<_05_P O
MK<IKT)>U1[&<_P#?F!SVL@;)42/7=:V-%XJ96ATQ=+FN]5O2W0=L<:[TB^E>
MPK7BSP62^T-RA;NTSI]R6-O!K7.3".1#<691N".&P6:4E6=VGL*F(T7#T,9;
M-,4%J:G44[-_MD?XSE]:\3)M1"8'NPIQ@K15C Y.6K8 !,B   /46M5;*2M;
MBHIXIOELR70..*DK21U-K8UR?0=KDXPLDI7?O,CD3V<BTDT/41_L>ZRX[&S,
M1R&W<?,0XF.>#H2U<?30NC6J1YG-ZFBNU#<64D[Z=J3<(JAZ88]>[/8I>^\5
M^3/WBD=_K%3V]YMM[M<=WH9::5.#DX.[6N[%0L]*7&:LMSHJE<U5*]8)N]53
MM]:8/.6!A&IDDWKJM?5&CVF;CF5C!1Z:O<RIO/HZ=.U4RY2]I]!QO<CJZNGJ
ME^*U58WYN/SFUD%1>\W0Z/H+=7\64O$5'SL8NDTQ;*-/O5%"GG<U%7VJ9)D+
M&-PC&M3L1$P3\D-?U!?I:.5E%1,;)6S)E-[R8V_&<:)*E0A>R16L]1VN9U',
M3.<(A'?9WFE+8GU:*^X5M15/7BK=]6,3T(A!-,4<>5@?-3/['QRN3!D]JGO&
M&GC^A>J"_$;OP4B:A;+O66BO@I*Z;PJEG7=BJ'<',=V-=CGGO-OWO[?4;*-:
M-:.FC1GG!P=F  7E8-?UI(YUJ93-7#ZN9D'J5>/S(IL*<S6]2YDNMBC[/"%?
M[&F;$?9N/:6TNLC8((FP0,C8F&-;NHG=C@3A/)\V,H"^*RJW85 8!;UM;#;Z
M9]1,](XHTRYRG9-15WL=5V[(N!P-.6_7:[^/0QQT-(ODRU";SW)WHG82]1>>
M:7EV>Y8&F#VR+UC%OT^MS0L/+F[&Y;OG(*IJ4&I:^TO;[ZQQS4BKA:J!%3=[
MMY.XVQDC9&HYJ[S51%1?,IIHUX5KY?B52IR@]2'V$BE1>1(I>=11=S4U;7:+
M):X(E7'75,4?M<;3(:QK+RK0WXU=']9Y^*^SDC71ZZ,T[ER]!;/[2Z<G+V%O
M+VBVB+8%N[M*+^2\L^?D5W\BUJ9%BAE>B95K5<B=ZHAEF[*YKB:Y?=7,H*E:
M.C@=75V,]6U<-C[MYW889;EJ6H57>$4E+G]S9%OX]*KS*.F(T=;6U3EWIZIR
MS2/7FJJIDG'S=2O4JMN]D^2/9A3A!6RW99LO^H:%4=/%37*)OE)#F-_J3D;)
M8K_2WVE66G5Z*U=U\<B8>QW<IAD_"]!969? ]:JR/Q65E*KGM3DKFKS^DLP^
M(J1J*,G=,Y4I0E%M*S1O.\-XE3FH/:,%B<AGS$H L:WKQ=ZW447/K*R!O^]G
MZC94X<C6=;KO):&_&N$:?,J_4;(G9[5,]/[2?D6-?TX^9/GS#>7N)2"N1J*J
MKA.\T%=B=%QG)JUT=_RA/Z?J+:KUE4U\[X;-3LF8Q=UU5/E(T7\E$YF$J9KF
MZ=RS5<?6]N[%XIYU3%0E[L=T>AAJ$D\TC.(XG:[D:^RZ5=+QGC;/$G-T/E>P
MS$%0VHB;(QR/8[DY!"I&>QLE3<3.6!WWR7Y*&:WC!:?=F:;T(9OL-M+JGD55
M[Y-GS!?.A*"PJL:WK;$/O15IY<-<Q,_DNRB_,;*WL]AK&OO^:*?_ $N'^<;,
MG89X:59^18U[B\R<$@-!78BJY)D3!)WEI77:EM4"S54[((^]SD3U'')15V,K
M>B+["$[<&IKM"MKG8AAK*AOQXZ=RM+J@UQ::R5L*S+2S.7"1U#%8J^WM*EB:
M+=LRN2E0J)7:9L3?*<7$90B<CN7'N7)7C-BUU1ED56%S'R4MXN:EPSR?.:(H
MS,C++'2PR3RN1L<;5<YR\D1$-7MUC;J^O=>:Z'<IE3%/3XPKVIR<_P!)>:O<
MM1#1VN-<+6U#6.^0WQG?1\YL]+&R&-K&INM:F$;W)W%<H1Q%6TU>,?B_T*7)
MPCF6[^1A7Z"M$CLLA?3K^\R*TI_<#"U5ZNY5C.Y-Y'?2ALB(TJM3D7^Q4']Q
M%''J+[S-7302=MTJU]&ZGU$[- 4J^765DB>>7'T(;2WM(\R2P6'_  D./4[3
M76:"L^\F]#)+_"2JOUE5NBK(U,> QN^4JK]9G<(2^+V%BPM%;17HB'%F_O,P
MKM%61R8\!C;YT54^LM9M!6]<K32U%*[\B153V*;-A!A#CPE"6F4ZJM1?>9H]
M1I:[T6\L%1#71IR;(FX_VE@]]93<*FV5,:Y\IC>L3VH='])#"=B&.?1T'U96
M+HXF2ZRN<S==J=OE=8Q?RXW(0]^J/DV7>7S,55.C5$L<,$DDB;K&)O.5>Q$X
MFMZ/M,<TD]WDC:DE6]TD3<91C%7GZ\9,4\%4C4C3C-.^^FQHCB5E;<3 LJI:
MC/@]#55'G;&J)[5+R"U7RIPJ4<5,U>V>3*IZD-]1C6M3N(\#7'HU??G?PLBA
MXJ7W4:;!HRX396HN:1(O9!']:EY%H&@3"U$M15+WR2JB>Q#9O00X]YKA@J,>
M2?C<J=:H^9C*735LH_@J*!,=NXBK[5,DR-C$1&M1$[D3!,,><TQIPAU4EX(I
M<G+=@ %A$HU5%!70K%/$V6-W-KTRAK53H5L>\^VU4E&J\>J=X[/8O%#:QR,]
M3#TJO6B60J3I]5G.ZVAN]LC=+/2QU,+$\:2!W_=4LH+[!-E49*F/R,X^PZ56
MRLIZ665^-QC%<N>Y$,'H>WMAM'A+F(V:J<LSN'>JX3U)@\:I@7Q5"E+1W>NM
MOD;HXGW'*2-4]^Z/\8[/R5)F72*7X&*>=>Z.)5.E;J)^"GL([G#@U$]1:NC9
M\Y_#]3GM2Y1^)SZ&FNU7^Q[7(U/C3N1B>PO8=)7>HXSU<%,G=$Q7+\ZFY^,A
M,7QZ.I_?DW\/D52Q4WM8U./0:.XS7*KD7\E4:GT%7[@*3_&:S^6-G&2]8*@O
MNW\=?S*^/5?,U1=!M;\#<JMB]F\K7)]!:RZ2NU/E8*V&I3NE9N+\QNH(2P%"
M6RMX-G5B*BYG.JB.XT&?"[=,C>V2#QV_:4X+E2U&4;.W/Q79:ITA6[V<EA5V
M*WU^5J*2*5>]S4S[4,D^C9+[.7J7QQ2^\O0T_GRY SLF@K0KMYC9H%[HY51#
M :CT]3V>)L\-7421QN19X5F57*SS+V&*>%KTTY.*:7?^AHA5A4:2O<F*4M7!
M!GK)HV>EQ9V[3[:Q5GJ.L;%)QC@ZQ55J=F7=JX,O!8Z"GXMIH\][DROSDZ6%
MK5%=I)&JT8[F!JG)=9,4,#Y)VKPJ/)1/7VEP^EN\;<OB9.G[V]$5/4ILC&-;
MP:B(G<B(3-[>XVPZ/A'5O7N)<2VR-.=5I"N)XI8%_+8N/:5H:B*94W)&N^2I
MMJ,:YJHJ90L:C3]!4Y5],Q'?&8BM7YCCP<_NOU+%77-&%[^' MY**"1RJZ)J
MK[#*OTIN<:>LFB_)?AZ%NZQ76)5ZML-5Z%W%]G(S3H5(]:-_#4L56#YV,?[T
MTWQ%]JDWO33?B\^ERET^"X0*OA%LJ&)WQMWT^8D\.I8^$G61+VI)&K?F,DE"
M+]Y6.<9<G<D@HX&*N["Q%^3DNVPN=G"8*;+M0LY3-_-121;Y!A.J;+.N]NIU
M;5XJO)"OBPCL52G)EVE-GFXA+)!2IF5[8_EJ7=+IV[7%?ORLMD*\<<'R+W^@
MS]NT;:Z!4>L/A$WXVH\9?ZC73P]:MJE9=_T,4\1&.[OX&I1UKZG*4=)/5=RQ
MQKN^U>!=QV:^5&,4L-*B]LTF\OS&^,9&U,-1$1.Y.!!R]YOAT<OOR,KQ4GU4
M::S1]R=GKKE''_ QY^DEDT/4.:N+M-O>=B&XKC!3^,:/Y?A[6<6_-G%B*G::
M%)HNX6^5:B":.N<GX,F6N7T+DMUKO!Y.KJX9*.3ND3"+Z^TZ'CQ"C/3QU$:L
MD8U[5YM<B*AGET="/V4K&B.*E][4TACFO8BM5KD[VJ#-56C:"1RN@ZRD?^\N
M5$_1,=-IFYT_P-5#4M[IFJUWM0R2P]:'*_@:XU:<N=BT>ULC5:YJ.1>Q3'R6
M>/+NKD?%^3S3V&0?37.G^$M[GIWPO1R%I-<%I<=?35$/'";S%1/09917WUZI
MFF,OPLM?>B5O*=J^EI#WJF7]W:GYI<>^3'>3#,[T,4@E9,_/5TKO3(N$*;4W
ML:$YE%EHX^-4.7Y*8)TIZ2A7>>N7=[UROL)NIJIOA)FQ)\6/G[2>*AAAPJ,W
MG?&<N5+(P7W42OVLI)52U'P,7#X\G!/802C61<SR.D_);P:7;O[<"!:H?B8N
M2,C9%P8Q&IYD+6X3R0M:D:[K7<W8R7:D%PYKD7"H6-)JR=B2W,+U:/7*NZQ>
M]RY(HU&\D1#(26^%SL[N[\E<%/WNCSP<]/SBG)+Q-"DBT#E1O/EZ2[][XTSE
MSE]9%M'"W]SSZ>)-0EV'<R+!&]<[=8W>7OQR,I$W=C:F<JB852*(C4PB83T$
M2V,,HO< $%<C>*JB)YRPB1'8I1=61-7"/1SNYO%2=OA$V.KI9')\9WBH+WT%
M['G?I9_LK37HJ?IC-GLNHI-&]'F@O5/3PSU-/!&C639W5WID8N<<>3EY&M=+
M*&>&HTQUS6M56U'BM7SQ&1N]%N]%".=9'*O@\"HW/B_LIIW(Y<CZ*\986BF]
M'(QEIZ2-RK+,K*>T>%W^29614M*CW,2-&M7>7FJ\5<F$7L["C:.DY>[?=O!=
M26>"*-KMV9((GQRQ]ZJQZKGLX&2Z)VF::X4U^N+O$JF21P,D1,JC<*YR>A5P
MOJ->Z5%N\ U?;7JQB2OI/&DC3R\/=A5.9'%;%JAA9XJ6&4#(=(;:'<I>LT\R
MGIY+540P5/A;$<JKEV\G'.[A=U#4]C>T6[:8E@LU%0Q3TM;71]94.8Y7-WMU
MB\4X<$3YSI>U"1C^CQ:\+EZ4U#E/S6E?HIHU=$73*<??)W]%&<T9U5(4\%+W
M-G;]3EFU5N-NE4W*N_75(F7<5^#B/2>O]<T&SC33KE4Q+*JNZN"GC7#I7KE4
M3/9P1>/'ER7D>;]K./U>ZKN\*H_Z*(]";4+OI2RZ?;4:IHX*Z-JXIZ>2)LDK
MWX3A&B\47&,KP1#NBV,^)6>-"+3:MLCD*=(C75QIYJRV:9IGV]BJBRMIIYFM
MQWR-<C<IZ$^HVW9/MI37M?+;*VB;2W)K%F:Z!56.5$QG@O%J^;B8&T[:+S76
M]EMT+HAS:*%.KB>[>DB9SY[NZU.?:[M-&V&ODAVR4?7M;!)O5#9&HB(C52-^
M4]IR45)&AX>G*E4>11:U6MWYG2]I>VBX:&U@RTQ4=++2+&R1\LR.WTWE5%QA
MW8B=Q@+]TA[ZKY:JQV&/WFC=N)65D,CT>N>"Y;A&YX<%5<]YK723>U^TESHU
M16^!Q87](]!ZCLD=OV576BAM^Y2P6F6-J81$1&Q+A?K]1Q179<K<:%&G2E*%
MW+R.84G25AFT^BI:9);^K^J921*O5O[GHO-$SPW4RIB:3I&Z@M=XZC4%B@A@
M14WXHXI89F(O;A[ES[$R8[HP6IM?KFKJ5ITJ7TM(YT><>*YSFIO)Y]U7)ZS)
M=*NEZK4%BE?3K#(^F>U57&51KTQ[,J,JMJB_AX>.)]FR[J][G;M1W_WAT37Z
M@HE95K%2+4PK(B[KD5$5.6.SZCD5IZ3M?5VN=LEGCJ[R^1&4M+2-?NJF%WG.
MXN553AP0VZOJF/Z.C&N5R.]X8L;R?O;30^BG;*>HO=]K)(FNFIXHHXG*F=U'
MN=O8_1)1MR,5*C2C1J5)QNXLKVCI-7RWWQM+J>S004^^C94@BDBFB1?PE1[U
MSV<."ESJ3I(WN::IGTS8FS6:G=N.KJR&1Z.[G+NJB-3/)%557S<C7>E+"R/7
ME Y&HCGV]F\['E+UDB(J_P!NP[CIRR4M!LGI:&.!K(76OQVHGE*Z++U7SJJN
M7VG2VI'#0ITZV3K<KZ&#V/[68=ID-33U5*RAN]*ULCTA=XDK%7&^W*JJ<>"H
MN<93BO9+M8VRILTEIZ"GC;<+I,SK$CD7<;$Q>".<O:JJB\/,<GZ+BJFT.K3@
MF];9$5<?OD9T[;!JS0^FKG$Z[V6"\7M4:]&1QMZQJ)Y*R/SP3EA%SZ".5%-2
MA"GB\BCFC:]C0*GI!Z\HHHJNNL-/#0/5%:Y])/&U[5Y;KE=A?G]!TW3>U:#4
MNSF[W^@M[8[E;HGK)22N61-]K-Y,.3BK5[_3W'.-<;4-6ZXTA7LATBM#9'1H
MLM5.U[_$145%:Y4:G8G+/,R/1/=,L&I&QQK,F_3N5&]BJC^?L&57-%:A3>'=
M5P47%[)G'4U;6_=W]T7@L:5_AGA7@R([=W][.[SSS/5NSO:%)?M!RZAOD<-N
M;"Z7K$:CFM:QF%SXRKQ//V=SI#>,W")?.*8Y??#K'2<NLD.SZGAIWXCJZZ..
M7=Y*U&N<C?TFM7U$^XEC(PKRI4E&V;G?X&KWWI/W6MN+J?3%FBEB1RHU]4U\
MKY&]^ZQR;O#LROU$VE.DC-4W6.BU30QT:/?N+44Z.8D2KPRYCLKCEE<FQ]&"
MQ4<&BYKFV-CJNJJ'M?(J9<C&X1K<]B9ROK-=Z55CHZ=]FND4;65<KGP2.1,.
MD8B(K57OQQ3UD7'-N0A'#.L\*J?GWG2=I&K)M&:0J+Q1PPSRQNC:UDF=U4<Y
M&KR5./%?3P.2R=)FXK9(^KMM(Z[/E<BM\9(F1HB87GERJJJF=Y,;I?7>M==.
MC!2U4V\LS%CAWE7BJ,J-Q/F:A<=%C3U+4T-ZN4L._4)*RGCDQQ:B-57(WUN0
MJC!)'(4J%&A*=2-W%V*-7MQU10Z*MFH'VJ@ZFKJ)(%=B1$\5$1JHF]PRJ2)C
MCY'G.G;.-9)K?2E+=%C;#4/5T<T4><,<URIA,]BIA?0I<[2]#TVI=!W6W4\#
M4FZM9J=K4_=6KOICSJJ8]9QOHS:SBLS;_;*V3JX8X5KVJO!$W$Q*OI5-WU-4
MZH7*,M/$8>4J<;23^9L.O-N%UTOK=]AL]OI:R1K8HW>$;V\LKTRC>#L<E;ZU
M.XTW6=3'UV[UNZB/W$7=WL<<9_MR/*^Q6V3;0=K=1?:MN]'32/N#T5>&^KEZ
MMJ>A5RGR%/5G).*X1.]>PG%93/C80I.,(+5+7Q(@I>%-<[=C:Z5W<Q,E6*CK
M9N4;($_?'+GV(%>3T5SRKI;E.2%DGEMR4O!=SX.5S/,O%#(ML<CL]95/7S,:
MC2=EAIOPVOD7O<Y2Q4)RUL1XL5S,2ZHEASO+&]$^*["EQ#.E1'O(BIZ3(+I^
MB<GP:IZ'*476'JT_6\[H_P EW%!P*D?^2/$@R@3DCZ>LI\[\'6M^-$OU%-*R
M+>PY5C=W/3=4K?N[Z'='L5S'UT<GA"N<BOC_  >W'J+YLC7\6N1WH4JMYE4T
MIZ"]C"LD;V*B>;D3=8WXR>TRKH6.SO,:J^="#J>G:F5CC;PY\#/PVMF,YB^N
M:G-R>TBQZR+XC'O]#2_ZZF:Y&Q,ZU_8V)B*7D-LN=8S+6LI&+^,7QOZCBI2E
MI"[\"$JBCN8N*#J7)+4O;&C>+8\\2[2IGJ<I!'N-_&2)A/4A=Q:-JFR(]:QN
M_P!^[O$9:"Y4.5D@2JC^/"O'UH25"M!.Z=BAU82>C,?54R4L+IY%6HE3M?R;
MY\=Q9NDDJ.+YG.3XK783U&6CKH9';CG;CN2QR)NJ226FGDWG-18U5?P%X%$J
M;Y$E)&*ZEC47Q2VJV-ZIV&IR[C-.LR87%1(GJ0LZRS)U:YJ)/8A#AR[ Y*QR
MK5S4W9.">PU/9[C]46UHU^Z_[]A6_P "\WO5MI@:U^=]_I<:GH*G;'M MZ01
M9?F3"-3BOWIYK5.2IMM&1R69':TI][*J]SO60\$C[G>TG^_-X>#2^PBUM2[R
M:65?S3Q=.:^!MN4_!(_RD]9,CI:-JOCJ',QWKE"NR@KY.4*1^=REW36'><CJ
MF7K,<=QJ<!PW+J1L4RE%;LR5OJ'55'%*]-USDXHG(N2#&HUJ-:B(U."(A$]*
M*:25S(WKH<\VR2=5:[ _XMSC=[$5?J-6V/65NH-*[1D5N=^B;N_*^^/3YVH;
M!MX>Z/2]M>WRDK45/T'&/V0W:#3>R/75S>Y.L>J4[$[W+'NL3VR'P%=0ETW)
M5.JHM^B9[+S1P*R;YDOB:.RL\*V,N@=Q6"^,<Q>YKX'+CVHIFK<[WBVD:!N"
M>)X71T+W+\IO4N_FF%?;YJ+8W'4O14CK;UXF>UK(7-S^EE/4;'JJ)LFK=FE'
M3NWGQV^@;O-[W29^A/G/&IIQ<:KWBH6\V:923<HK9N7R,[J)7ZYZ2%#1L<JP
M6^2-B*B^2D3>L?[7+CUEOI:W-U9T@-1-D3K(FI5-=GCXJ-ZI/I^<N]E$C*;;
M]J9:M<3;U9N*[OZU%_FH5>C2U;GKK55VD3+]QV7>>257+_-0^@HIXVK34]YU
M).7@E8\V;X-.>7:,(V\6RVZ.=,RLJM8:6K$WX9X-U[/0KHW?2A-L#=+:=4ZJ
MT95KO1RQRM5OY<;NK7VM<GL)NCW4-9M*U=6S.2-K8IGO5R\&HLV57YE*>Q:9
M=1;7=3:DC8K:*)M1,BX_&/\ $1?S45?:68?*J>%<.MFG&W/+KN*VKKWVRQ?_
M +<BTV W);3;->T[EX04*S>MJ2-.>4\*P[,ZN5?W:ZPQ^E&0O<OSN0S.CKLV
MV:3U]<%<B.JX(Z.-%_"=,]^?8WCZBSOMOEMNRW3CG-W&U];5529[D:V-O\U3
MYZO-U</&FGI%2\KRT/2II0JRD_O./P5V;7M'KJNXV39_HVD5=]]%32R1I^%+
M(B-8GJXKZS-](JRT^E-%:0L=+PAIED1%7FNZS"N]:N5?665II&73I%6JE9QA
MHF0M;Z(J9%^DRG2KD6JU!IJD7*1*R3CV>,YB+\R'T"BJO1^)Q4MVXP7@K'FI
MY,31I+DG)^+N83;)0NTU>=!W)B;LK**!J_*A<U?^]\QC*ZW,KMJVLZ%$WDJ*
M6L5O#\+J^L3YT-CV^5'W1:_TSINC^^30,9&Y&]CI7-X?HM1?66&G9V,VU:PJ
M)U\2DIZURY[6L1&_0>9BZ<98J48]7,EYY=310FU04N>5^E]"OLPUB^Q[#]7[
MK]R:"7=@5%XHZ5K6ICUY,3::!;'T>+U7+EKKM7QQL:B^+NM<B93UH[V(:]9*
M>I_4DU%/&J]2MQI&OX=R/7Z7,-LUW<88^C_HBD@5-V29SG;OQF(]'?.Y3M.L
MY8>TF[0IO+WW=CLH*-2T5UIJ_DKF+U5ISP78YHVY)XKEGG:KO,]7.;_1_.;O
MMJM?O[L_TMJR-,538(F2N3XKVHY/8]/]XEVQ4BVO89HRD1O%'0;WIZAZK\ZE
MQM'O-/;-A>E;6CT?/60T^[W[K&H]R^W">L]25"&'6(I/1<*$O_;EYF2-2525
M*?\ YR7D6.UJX+J39WHR^N3[](UT<CORE;XR?I-4\N^ZZW-U?LAV2(Y?&DJG
MSN]*TZ(>F]?TDMDV/Z+MLK<3O5]0YJ\VY1SL>K?1#R%[JM6I/HK0% G_ +ME
MBIWK^6M,YRIZLH?3=!UI0Z5M/24E"_C;4\_%4U/#+*MG+TN==]SRJ&46RO0M
M=*J]31V2JGDQ\5)7Y^D[YL2M,NK-7W755>F^^%ZN8O9UKTXJGH;P]:'G'H35
M"4G1EMM1R?\ <Z^)O^LJGM/7W1_I/!=GTTN[A9ZF5_IQAO\ W3)AH<?I+A2U
MC&4Y/Q3T+*\LF'<UNU&/ENS2-FM&V][3M6(]-YDD=4UR^9TJ-^C)\L-IT:P]
M/6BC5.++Q0-5/1&Q/J/J9L0KX[=5:NNU2J-ZBFZQRKV9<]RI\R'RUVH2+-T^
M:216X62\T#]WSJQBX/0Z#4.!4=_>DJC\KE>+;XB[$XH^BUSW[90:*O#5PY.L
M3>_@JE5^AQMFVR=^LMI]@L$2JL;$B:J=SI'9<OJ8B&NZR:S[@=$4T?C2N;5/
M_2EQCVY-BID2#I'0>%IQRW<SV+X-AI\3!N%\.G:$I0OW'J-WM5>\5*WJ6U_A
M6]=).AID\9M,^%BY7/D1;Z_3\Y#8["VP[:=1V)S<TT[:B'JU3**C7[S<_FJI
M<[.&^_72*O=4Y=YM.ZI<U?0Y(T^927134?TFKQ(Y<=7)4JB=^&HGU_,;:-./
M%I8K9NJUY6L4SDU3G2?*"^9;;+XW[/-NMSTXBJE'5.DA8W/!6X62)?4W+?63
M;%U]X]M6J+>G")6U343Y$J.3V9^<CI^H^[?I*3W"E\>EHWO<Z1J<%;''U:+Z
MW*A@[!?66_:5K^_;Z-934]:YJ8\I[I48Q/6J(9>(J'#DG[L:DLK[K._Q-#C*
M:G&6\H1OXWT-3H'^%6#7%?SZU\+6^E]1O_\ =-DU)?9;;L4TG8(%\:XOEJ)F
MMYNC21VZGK<J+^:8&FMLM%L@KZY4PE9=X8&_E)%$]<_I+\QFZJE9<-8;-;6U
M=Z-E%0Y5.67R*]WT'BT7.+:3LYI+RE(WU$I6?X6__P"6)N>U+2K-"["K3:41
M$GDJXGSNY;TJM5SE^;'J0U/:39/ ]DFSZO:F'MA?&KOEIOI\Z*="Z6E0]NFK
M) B98ZJ<]?2D;D3^<IJ>W&X1-T3H/3M+]\G2DCGW4[NK1C?:JN]A])TM0A2K
M8FDE90A!+QOH>5@IRE"C)_>E)OPL8^XN]^-M%EF>G"Y4E.KN/XRG5J_29#H_
MZD73-GUPV5<+1TZ5+6_E-1[?IP4*>@\!V_V6WR<J**GBY?$I$7Z4-:T[UE9:
M]I-92I]Z\&SP^*ZHS_-:X\3#SGA\1QX]:\EY9?J;9*-6CPWU;1^9F=FU-+3;
M,]H6I)7.5\T'@B.5?+<O%ZKY\O0Q\&FNNV S7)6^-'=TDWOR<)$OSJGL,Q3W
M&&EZ,]1#$N))KEU$WRNL1W\U&F>KZ=;;T5J9J,RM0YCW>;>J,Y7U8-L:$:U/
MWG?+2<O-O<IXCA-N/.:2\$BGJFU?=CT=;#=U3?J[2Q/&[58CNK>GL1%_-,=J
MFZ+JOH[66LF7K*BVUC*=[EYKC+/YJM,O'>X;%T7(&O>BRU_64T;>URNF?G'Y
MJ.7U&O5=%+9>C;3MF3<=<[DDS6KP7=5W!?6C,^LU8C*U)I[T4Y>/(JI7NEV5
M';\RKM'O#JO8-H:-SLOD?NN_U;'-S]!8:=@SMFTM2N3]BTU*BHOY--OK]/S&
M,U6Z2XZ=V>::@\>H6EZU6M7/C3R8;GU)GUF:\(90[:=2U*IA+?1U3F93\73[
MJ?,>/5J.K7C5WRY%YI7-D%PZ4H=N9^KL8:Y-DVFZAUKJ*=7K24%)-/$G<B>+
M"WV(KO2=GT%_T+L?;^M(_P":AS;970=7L6VAUJIQEA=%O=OBQ97^<=(T%_T)
MLG^AQ_S4/H.B*/\ 5CB9:RJ1;;\]#'B)>ZZ2V@[+T,\ #Z\\T%A<:JCIV[L[
M6R/7DS=RJE^8.5C[7<9:J6#PB-_%'XRK3+6:BM/4G&S9:> S5DB24E(^E;\9
M9,?,7T-ONC6\:Y$\RHJE_27*GK&_>Y45?BKS+HA3HPW4B3D]K&*\ N,GE5^$
M_);Q^@)IYLG&>HFF7SK@RH+N!'FK^9',S',T_1,_<E=\IQLFBZ""ENCUBB:Q
M>I5,HGY33&&:TA_SD_\ @E^E#T,#3A&O&R6YFQ#?"EJ;L #[P^=
M
M
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M(%5)6+S\9O W8&;]HBI+F9\1'^E)IG1@ ??'S@
M
M
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M;-'D;(O-252;CVDJGIE**9*O/UDQ(O(%A@[]XU1:V=KJEKO8F3+\4,17_?\
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M9+@ ]2,<J2,K=V#.:/\ ^=)/X)?I0P9G-'_\Z2?P2_2ANP7V\?$S5_LI&[@
M^Y/GP
M
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MV71N::MB?^2YR([V+Q,[(F<\#!7'3%JN:JZHHHI'?&1NZ[VH9)0JPVEF7?\
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MCWE;P0O'L,6ETJTX^]LB)YE_J-BT)72U-XE;)220)U*KO/7AY3>'(L3.:/\
M^=)/X)?I0W8&$EB(MR>_89\1*/"E9&[@ ^_/G
M
M
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MJ^ID1))7KVN5,X^<Z%K*-9=*W5J<^H<IH-;,D\_6)R<QBI^BAYM>^=7[#U\
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MBETM>=<>ZFUM\N%KK4T_H[1J0VVNFI7I3.GEW=Y(Y%3=<[%5+E$7/BKW'M8
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MI)_!+]*'H8+[>/B9J_V4C=P ?<'SX
M
M
M                       *51Y'K*I2J/(]97/JLZMRV !@+PN%WLIDUW0S
MMVSRLY]742L3]+^LV)R<'<,FNZ-\6.Z,^)72_2ADJ?;0EXEL.I+R-B&.>"5S
M]QN>6#5JG5536S.BM,#96,7#JJ7*1Y[D3M+*E:%%>\_(Y"FY[&U\?,#34GU
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M'L3O5.XVVFG940LDC=OL>F\U4Y8-%'$1J[73['N5RIN&Y5 !H*@   .Q0.?
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M4R6OI&;>K) [=H)HJ"XK$W@B2KOHJHGYZGT8SQ/S+&4?9\1.DN1ZD'FBF3
MQDP07DI$ %-4X<>\^+_28EI^F9TD]0ZGTY%%IS3-@W;*R],:KYKK) ]R]:B9
M1$5%7#5[&HS/'@GUKVWWJ;3NQC7MUI5<E116&NJ(U;S1S:>1S53UHA\G>C=0
M14&QG3O5X5]0R2HD<B\7.=([.?/P1#ZC^'L%#%XAJILD9,1/)'0W7372'Z0O
M1XJ6W1FJI=KVE(5WJVS7IOZ\;$GX44J9=E$SR5R=[5QP^B_1]V^Z3Z1VSNBU
M=I*K=-2R*L%3238;/1SMQO12M3DY,HJ*G!45%3@I\_F.5JHJ<^PU+9EM%DZ'
M_2#M6L*61U/LZU=.RVZEHFK]ZIY'+XE4B=FZJJ[T=8GX2'L]-=!PIT^/AE9+
M=%&'Q#D\LSZ^@I0R-DC1[7(YKDWD<G:B\E*I^?'I                @O)2
M)!>2@&E;9/[UVJ.U? 9?YJG.=(7>FI-'V2/+I9O!(\1L3*\N1T?;+_>QU-_H
M,GT*8K9):*.ET)8JB.G8D\M#$]TBIERY;GF?"=(X>=?I6,8.WN?F>[A:JIX1
MMJ_O?D8ZEH+]=L+#2,H8EY/J%P[V&4I]G2SIO7"XS3KVLC\5OT&YHG,;QZ%+
MHZE'6=Y/O*)8F;TCH8*CT19J/&[11R*G;+E_T\#+TU%!3M5(H8XT_(8C4*Y
M]"%&E#JQ2\C.Y2>[(X)'PQRM5LD;7HO8Y$7Z2<@J9)Y(O='#6+GH&@K'NFI5
M=0S\]Z+@GL^PP%7:[Y9?A(6W*!/W2#.\GI3G])T=.!+NH>?5Z.I5'FC[K[OH
M:(8B<-'JCF4%ZI9G*USE@D[62HJ&U:.<CKE(J+E.J7BB^=#*W"QT%U9^N:6.
M7\I6^-[4+;3ND:6Q7*2II9)4:^-6=2YV6IE47*>PHP^#KT:\6VG&_F65:\)T
MY*UF;8 #Z\\8
M
M
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M1DIJ\6F2LUH]"F2DQ*2+42$OQB8E7FIS8FB3O-7O-,D.H;?4(F.L=N.]*?\
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M@\LMI]=$7LR_ !Z!D
M
M
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M8D1Q?VVPP6S><Q'/E?Y4LG%RE"IU:FCC9=[^5B;JQ6S*]- D$+(T3@UJ-]G
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M_@CJ/]&H_P#E4]A[J=R>P;J=R>PK5'"Q5E37JR=ND/\ N7Z+Z'CW^Z!V@?\
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MNYBI7GVY\%+S^Z2V@)_^(W4GJ\(_^53UMN)\5/8-QO<GL(15"+;5-!PQ[_\
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M</B=/C<8[\I(VQY3L553L/3F.9(SQ=XG[#XR<W4DYOF;TK:$0 1
M      !I6V7^]?J;_09/H*.R_P#O=Z=_T"+^:A6VR_WK]3?Z#)]!1V7_ -[S
M3G^@Q?S4/DJW^[+_  _,]6G_ *3_ -OR-H ![!G 7SA.1C+SJ&CL4*/J9=U5
M\AC>+G>HKE.--9INR"BY.R,DF.PC@TM=:W.LXT-G=U7X+YW8R0;JR^4R[U39
MVR,[5ADXF'V^C?=V[;,O5"H;K@ADP=DUC0WERQ1N=#4]M/,FZXSJ+GB;:=6%
M6.:#N4RC*+M) J0>64RI!Y9JI]=$'LR_ !Z!D
M
M
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MSM04UQUMJG44UTU'9::&2!;-.YSU;3.CD1'9RZ1=[&ZO)%7=55]N
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M$55X3*Y'X7GF.F>WV.7[0/H;A!A#Y[_^DXVD_P#T-]^_VBI_^5!_Z3C:3_\
M0WW[_:*G_P"5 =LSZ$8080^>_P#Z3C:3_P#0WW[_ &BI_P#E0?\ I.-I/_T-
M]^_VBI_^5 +,^A&$&Z?/?_TG&TG_ .AOOW^T5/\ \J#_ -)QM)_^AOOW^T5/
M_P J 69]!]T^?/NBO#I.]&K^-4_[73$J^Z<;2?\ Z&^__P O4_\ RH< Z0G2
M$VA[>-IFS?5\FQ74%D=HVJ\)2D;#4SI6??8I-W?\';N?!;O)>8.V9]B&\E(G
MSU3W3;:3_P#0W7_O^'J?_E0?^DVVD_\ T-]__P!HJ?\ Y4!RQ]"<(,(?/?\
M])QM)_\ H;[]_M%3_P#*@_\ 2<;2?_H;[]_M%3_\J 69]",(,(?/?_TG&TG_
M .AOOW^T5/\ \J#_ -)QM)_^AOOW^T5/_P J 69]",(1/GK_ .DVVD?_ $-]
M_P#]HJ?_ )4(+[IOM(1%5>C??D1./[(J5_\ P0"Q]"P>3^C9[H3HO;UJ=-(W
M&U5NA]9.WFPVVZ.1S*E[4RYD<F$7?3BNZYJ+A%QG!ZN;V@X3
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M=_(C5]ZG=\F;;O%2G7[X42K3_"KZ#Z.GUT><]F9$ 'H&0
M
M
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MB'R$]!Q?;]^P-*_QW3_]X[1#Y">@\KHW_<<3X1^1;B?L*7G\R< 'U1YH
M     (+R(@ ^>72<T14[;_=%MEVBM16VJKM%4-K\.6%8G+3RM3KI9-Y>6'/C
MAC=YD1.T^@-#1P4--'34D$=/30M1D<,3$8QC4X(UJ(F$3'<7@
M           !!>1$ 'SV]U4V916JQZ*VKZ9MTU/K"V7F*F?76Z!RRR-5%?"K
MU8G%6R1MW7+\=4[3WKI^IJ*^R4%351K#5S4T<DT:M5%8]6HJIA>*855X*90
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MI*RV7U,]:2RJ"!5I_A5]!2*M/\*OH/=I]=&)[,R( /0,@
M
M
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MN>?-<X5TF4SZ3!=$5C8^DSJ=K&M8SWC?A&I^^4IGM;?"/,%T2/VS>I_XC?\
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M*OH*15I_A5]!=3ZZ(O9F1 !Z!D
M
M
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M)'[9O4_\1O\ Z2E,[K;X1Y@NB1^V;U/_ !&_^DI3ZC"]6?@?+=(_:4/\CW$
M")ZH               )79X$Q*[R5 *#WI&U7/5&HGX7,\Y;2^G/H/0]TJK1
M:8ZW5]WIE<V6"T1;\<;DSE'2+PX8XXWL&T=,/5UQT7T>]67&UR/AK5A9 V:-
M<.C221L;G(O8N'+A>Q<'E[9GHVV:;T304U'#&JSP-?-,C4WIG/1%57=_/EW'
MBXW%5*4U3IZ:;GZ/_#'0&$Q]&6,QMW%2RJ*=K\VV][>!T'1>U!NUS45)J^2B
M2WK=;<O4TW6];U>Y(YBMWL)E?$5>7:=!3QOI/*VS:Z)LYOD^A;K5MM3HZM]=
MIFZ5+MVGD;(J;],]R\&Y7&%=PSE%5$>AZ BU[#0/\'OM+/::QO-)(U5C_P I
MJIS1?9YS^?>F\+7I8N=::TDV[VY]A]5C<$L%7=*E&T/N]\>5K[]C[S:M[VE/
M8_0T5QVG:H=4Q03TL5/$QW7,:YO6<.6?0IKD>JZO4LWO?I6WU%SKGKNI+U2M
MBB\[E7ACT\#HFF^C18V6J%;])45MT<F_430SN8Q7*N51$3L3O7GSX<C;_#O1
MN,Q.*CB*5).,=7?1-^-F?*=)8FC2I.E.5G+LU9TFIL>GVT[UCM]NW\</O+/L
M/,6C86.OMWEN+&LU$RH>DL3FHU(VY_ :U,8\_=CL.T_W-&B_Q-9_M;S#:HZ-
MUNIK<ZJTQ//17F!>L@DFE5['X_ 7/+/>?9?Q#T-TCTC3C.%&,<EW9.]_*RU/
M$Z-QF&PLVG-N_:OU,-P^;.<#AS,)IZ_ON4M105T#J"\4KE944DB85%3M3S?;
MYT59]1:EAL%.UO5NJ*R?Q*>FCRKI'+P3YS\@:DI.#W^/@?:Q>973,-M"\&@@
MHZF&26&_-D;X"ZE^&<[>3E_Y\\&QV[IR;/[/J.HTQJ:MGMUSH7,IJBNZGK*2
M29&-WT:]F=U$=EJ[R)Q:IYTU]KR[5]_J=*:6J6U6LJEJLNMYC=F"S0JF'11.
M3]UQE%>GD\6M7>RJ9G2VRRP::TS[S+1PUL,GC5#ZF-'.G>O!7+G^R<#]9_AC
M#8KHZG*HW9RMIR_Y/7CT!A,92XG2*>O5MH[/GJGIV)[[GO33^H+=JBUT]SM%
M=#<;?4,22*HIWH]CVKVHJ<%,FU,>D\0="VY5&A]M6K=GM/42R:?EHVW:E@>]
M7)3/WFHYJ9[T>F>_=1>\]OIQ53]7PU?CTU.VNQ^3=.=%_P HQLL,I9E9-/M3
MU5^_M*H" V'@@            @O(B07DH!*O:>18ZM]#TR=HDS%P]M@8C53F
MBJRD3ZSUUCGYCR=:Z%+ITUM?TCN"36!K/7U=+CY\"5W0JY=[,\K&6XM"_P")
M'=K)2,H;9!&Q..ZCG+WN7GDOC%:<K%J+<V&7Q:FF7JI6KS14RGU&5/CJ-LBM
ML?9.]V#"V!? ZV[T#?@F.29B?%WNSYC-&%LB>$7:]U3?@\LA1>]6IQ^DFOMH
M6W_(A+[-W-&U_P"1+Z#1]D?]]ZR^F?\ H)#>-?\ D2^@YSL_GJZ?:7;)*%K'
MU2==N))Y/&%Z+GCW9/=E+)%R:N>?%7:1ZS!HV_JAW%;C3QKG&ZV)%3Z/03-U
M#J"U9=64T=? WFZ#".1/1D\==(1VE%I>!L]GER:-W!C;)?:2]TO74S\XX.8[
M@YJ]RH9(]&G.-2.:.J,[3B[-  $SARO;]_S?I7^.X/K.S0^0AQC;]^P-*_QW
M3_\ >.SP^0AY/1O^XXGPC\BW$_84O/YE0 'U9YH                  (+R
M4B07DH!(>7-HJIJOI@:>H*CQZ33ME?7QQJO#KGN5$?C]']$]1Y/+FV14T'TH
M]&ZEG7J;5?K?)9YIG<&MF155F?:Q#5ANL^VS/#Z7^PB^2:N=8]6./UGDG:G_
M ,]=(7^+[3_3,/6W%'85,<>7=QY'DG:G_P ]=(7^+[3_ $S#;0W9\WTE]G%^
M/R-&H/V#3?P;?H0Q.LD?%975<+ECJJ.1E1"]/P7-7**9:@_8--_!M^A#&ZDI
M9[M#1V6B8LM?=:F*DIXV\U5SD1/G4]7EJ?G\+N:MN?331MV=?M*6>YN3#JRC
MAJ%3SO8COK,TG%3%Z;M;+#8+=;8_@Z2FC@;Z&M1J?093'$^5EN['[U1NJ<<V
M]D3  B7                   @O(B07DH!I6V7^]?J7_0I/H4H;+_[WNG/]
M!B_FH5]L?]Z_4W;^LI/YJFH;/KM?+5HBQ.6WMKZ):./JW0.\9K=U,93T'QN*
MK*CTLG).V3DK\^9Z]&.;":?B_(Z>#6J+7MLJ';DSY*.3M9.U4^=#/TU9#5L5
M\,T<S?C1N14^8]6GB*53J23*'"2W16 !>0 !+),R%BOD>V-J?A.5$0XY);G2
M8*F3 5VM[31.5JU399.QL"*_)8?=5=;BN+99I=U?W6H7">GF9)8NE%V4LS[%
MJ_@35.6^QMW)"I2X67&>..1IR6?4MRXU=UCHHUYQTK>/M,MIK2L5FK7U+JNH
MJZA\:L5TS\\%5%Y>I"RA7J5*D;0T[7I\"-2$5%WEKW&V@ ]XP
M
M
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MW6[N,&!M$:4FH;K'C"R;DJ>M,+\YG^"\2NG*53WY:O;T&51TCL1 !:
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MNAG?^K=*WXN\WV.5#.XRKC7]#+BT2Q_BZB5G^\OVF6?V\7W,M74?D;$ #45
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MVB'R$]!Y71O^XXGPC\BW$_84O/YDX /JCS0                    "7L-
MVT;)[;MCT-5V"O<M/*JI-25;$\>GG;G<>GM5%3M150W]$X<R"H2C)Q=T55:<
M*T'3FKIGD+2NV:X;.*Z/1FUF"2S7:G3JJ6^N:YU+7QIP:]7IR7'-?:B+DYEM
M$N-)=;CM_JZ*IAJZ26WVE8YX)$>QR=<SBBIP/>&IM)6;65M?;[[;*6[44G.&
MKB;(WTIGDOG0YM!T4=F]%;;];Z*SRT-'>XHH:R"GJY416QR=8W=RY=WQD[#T
M(8F"U:LSY/$=$8F7N0FI16U]UI\3PF_45%;:*G8Z7KJA8VM9!"JND<Y43"(B
M'I?HM]'BZQWR+:%K.E\#JXVJEIM,K/&IVJF%ED;V/5%7#5XIG/!>!W#0G1]T
M#LYJ6U5BTW24]8W_  N5%FF3SH]ZJK?4=&:GFP=K8S/'+!:%/1G\/+#5%6Q#
MNULEL1C3'#LP3?A!2+>1YA]N1                       !I6V7^]?J7_0
M9/H4M]E_][K3O^@1?S4+C;+QV7ZF_P!!D^@LMG=0E-LRL<SN4=NC>OJ9D^0Q
M#4>E;O\ !^9ZU+_26_\ +\BWKJ=NK-5/IG-3P*@3[XJ)C?<O9G^W(O*C9_0N
MDZRCEGH)>^!Z[I#9]3JVT/JW\9:N5TKE]>/[>DVGCYBW#X6G5INI-:R=SDIR
MA+)%[&J)8-1T?"GOC9VIV5$>5^L)#J],IX30+Y]W^HVL8\Q=[)!=637FSG%;
MW2?DC4ULNIJKX>]10-[4@C_J(Q[/Z>9Z/KZVIKW_ +X]43^WK-K]9#"]YV."
MI/K:^+9'BS6S2\BPMU@M]LPE-1Q1JGX6[E?:O$R !IC3C35H)+P*[MZL%6G^
M%7T%(JT_PJ^@U4^NB#V9D0 >@9
M
M
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M]]'O8;+L&TS<;-+KG5&O%K*Q:M*[5=:M5/#EC&=6QV.#/%SCO<H!U8
M           &D[9/[UNI_P#09/H,!I^?P?8M:G9QFVQ-]J(GUF?VQ_WK=3_Z
M#)_-4U6WOW=B]B3X]'3I\R+]1\3CY9>D9/\ _A_F>SAU?#)?^7Y&[:;@\%LE
M#&B8Q"WZ,_69(HTD?5TL3>YC4^;^HK[O,]JBLM.*[C,]9-D 1W1NEA @";"#
M"'; E!%51J*JJB)YUP0;(Q_DN:[Y*HI#-$Z"M2?"KZ"F5:?X1?07TE[Z(/JL
MR( /3,@
M
M
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M?V7TNKJ+0MG@UW7VVYZMCA5+C56B-S*623>7"QHY$7&[A.2<<FUM[28
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M*UOH7^LUX.4J594[WB]K\K&>M&,J;DC>0 ?5'D@
M
M
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M9V5YDS>2FY&Z$5%:$6MW3#5#EO%0K,KX)$N%_?'?87UWF=!1.5GPC_O;/2O
MFM="C6,B;P8Q.*_V]9DQ%3*LB)QM%9V7-OI.L5'8PQO#'>9V!FZA3IX4:U$1
M,(G87<;>9XK;FSS*M7,R>)I<L;P)8F\BLU.TNBCSYR)FH56]I*U.9.WDI<BA
MD<& K+9/:JE]PMS=]KN,]*G)_G;YS/A?)P)04EWE:DT6UNN,-QITF@?O-7@O
M>B]R^<N\& N%LFME4^X6UN7KQFI?P9/.GG,I;+E!<Z9L\+LM7@J+Y35[44C"
M;ZLM_F=:YHNE0BG!.)$M+E6)04,]0O'<;E$[UY(GM+6U%79S?0L[C?FTDJTT
M,+JJJYK&U?)^4[L+1*Z\.\;=HV?DY<JIZRC:Z1:>F1\B[T\OWR5Z]KE_M\Q>
MHF#R)5YR]Z]D;(TXI%#WSO#$7,5)*G<CG(5(]3K"Y&UU-)2=B2(J.C]I/DE<
MB.:K51%1>"HIR-:HMF=X4>PS4+VR,1S'(YKDRBHN44PVKG*ZV-@3RJB9D?M7
MB6MJ>MIN3*5%7P*ISU;5_<W\U1/,O$O+TG7W&U0KRZYTB_FM4W<3BTKK<RY<
MLC,1M1K41."8PB>9"/!J*6];6QV^EDGF=NQL3*K]"&NKX7><R54DE-!S92QJ
MK5QWN5.9.=94DES$(.1L2U]-&[=?40M=W.>F2I'4Q3)][E9(GY+D4UV.S44;
M<)21*G>YN5]JDK[)2*N]''X/)V/A56JAD]K?X?B6\%=IM'!.)$UJFN]3:7MC
MKG^$4BKAM3R<SY??Z38V.1S<HN4QG*<C=3JQJ+0HE!Q>I, "TX "C653*.EF
MGD7#(VJY?4<;LKL&)J/^4[]#3IQAHT2>3SO7@U/I,VB8,5IRE?'1+/,GZXJG
M+-)GLSR3U)@RO:0IIVN]V=>]B( +#@        !:UU,E51S0N\F1BM]I=Z6J
MO"[!0R/7Q^J1KO5P^HM+A51T5'+/*[=8QN?/YC6K+INKGIV+754\4.,MI8Y'
M(B(JJO'VG:>(="M>*S71&5-5(ZNQO%9>K?;6N6HJHXL?@J],^Q.)@*G7C9:>
M>2VT_7LB3QJB9W5L3U<RI#I^W0IA*.)?.YJ.7VKQ))]-6VI;^Q6,?V.C\54+
MZN,Q$^KH1A2I+K79945EN^J<3W>JDIJ-W%M/$FZKD^I#;;9:*.TPI%20,B;V
MX3BOI7M->BKKCI_X=9+G0)S5?AHD_P"\ALEON%/<:=)Z:5LT3N3F_0OG->"X
M+UNW/G<IJY_+NV+H 'L&<$,$0 2NC;(B[S4=Z4R6,UAMU1E9:&G>O>L29,@"
MKAQEO$)M;&'=I"RO7*T$*+^2BI]!371=D_Q)OZ;OM,V1(>STGO%>B)YY_B?J
M81NC;(W_  &-?3O+]9<1:<M4/&.WTZ+_  :*9,$E0IK:*(YYOF_4I04D4**D
M<<;$3L:U$*F")!%)J*6RL<5WN$+"\6N*[T3H)4PO-DB>4UR<E3SF0(?0=E&,
MUEEL$[.YB-,W&6MH'1U/[,IGK!-\I.2^M,&8-?MZ^#ZLN42>3-!'/CS\6_49
M]%X<2G#N3C:6Z=CLU9W*%74>#4DTJ)G<8YV._"*II^G*?]8^&2+OU-5]]DD7
MFN5X)Z$-SFB;-!(QR>*YJHOH4TRR.=2.J+7-PFI7KNI\:-?)4Q8S[2,GMKZF
MFA:TK&5'=S[N ')'+C..."C3F7%II[%#J:JI&>+#50I.C6\D<BX7!MK5RGSF
MIV+]=:KJIVKO1TD/4JY/CJN3;&\/H-N!OPGXNW@9*O7(@ WE1!J<#7;9^M]8
MW2+\=%',GJX*;&:Y5?K?6U$Y."3TTD>?0N3)B;^[+O1.F^LNXV,A_;F&\AG"
M=YJY7(&O7G4LL=4M!;X6SU:)E[G+B.)%Y9[U\QCO KG496IO$R.^+3M:Q$*.
MG/OE/4S.7>EDJ9%D<O-5SCZ#+'@YIUVYR;L^6R^!OC%05DC'L@NU'EU-=G2X
M_ JF(Y%]9F+#J%UT=+35$/@U;#QDBSE%1>3D7N+?.$R6+E\&U1:Y&^5)UD3_
M )*)E#L)RHRBXR=GNMT1E&,DW;4W!>2A$P@;_P"9$]Y=QA[B27R%- VC+C3]
MS_@'_0IO\OD*<]VF.W=,W7^ =]!55ZDB<>LC@=^3%MID_>F_08[HD?MF]4?Q
M&_\ I*4RFI&[M'$B\^K;]!B^B1^V;U1_$;_Z2E/2P'V3\#P>E/MZ/^1[B !,
M]$                  $KB8@O)0##ZBU!0:6LM;=;I4,I*"DB=-/.]<-8QJ
M*KG+Z$0\+;6>DOJ[I!::OM@T;HZ&+25<Q]+[YW6962SMRN7,;E$:N4RGE'<^
MGU<*B@Z-FH$IYG1+-+30O5O:Q9F;R>M#CNF**.@T];J:"-L4,5.QK&-Y-1&I
MP/GND:\G+@Q=E;7ON?KG\']%X58?^9589IJ5HW;LLMG>RM=W.<["[OMAV"VJ
MYT%@LUCJZ>OG;4/2OG<JHY&[O#=<WL1/8AZ0V)],"HU1K"'1>O; FE]252+X
M)-'+OTU7PY-5?)<N%PBJN<8SR0TA<*N'*<QVV(E%-HVYP?>Z^DOM*Z&=."LR
M[*\>[+47U'FT*T\,HQC)V7+3;T/M.E.C<'TY4JU,122J33>97332T>]GMJ?2
M9BYRO-.PT3:_M@T[L6TE/?\ 4=2Z*!%W(8(DWY:B1454C8WM5<+SX(B*JJB(
MINU([?@C7./%0\4=,55O?2+V=VBMS+;::AGK6TZ^2Z7CQ5/-U;3Z;%UY4:+G
M%:GXG_#_ $93Z4Z1CAJSM%)MVWM%7LN]F+VC=+?76TS0]]LEIV855%;[O1RT
ML5;/7(DK&O8K=]8U:G?GG[>9S'HU:\UCT:TO<TNSJKO4=Q=$Z>5M2UDD3(T=
MP1J([>XN4[-A%9P:03BBX3"IQ]A\K*=652-7/[RVT1^[T:. P^"J]'T\.E3F
MTY*\KMK;6YZ1V(;<M/;=-,+=[#+)%)$[JJNAJ$1L]-)\5Z<?4J*J+ZE.E-7@
MN3PET9G+IOI;WRWT3EAH[G84JZF!O!KIFRM1'8[^+OTG'NQGC*I]1@:TL12S
MRWNT_(_"_P"(^C*?16.=&B_=:4E?=)\N^Q5 !O/F                  "1
MW)QY0L_[>76G\2L_HZ4]7NY./)]E_;R:T_B5G]'2$9_85? \K%_;4/\ )?F>
MBNTB0[0O)3X='V2)9'I&Q7.5$:B955Y&K4&HJ.WVZJ=(]TLU34R3,@A;O/PJ
MX3/L+RXR2WVHEMU,_JZ6/A43ISS\1I5][*:V4JQTT+8TQQ5$XKZ5*J=2HIJ4
M.5QECE]XY'KN_5TZ2+%:G,:J<YY6M7V&I;&*^KEVRV)DU(V-KEGR]LJ+C];R
M&[:\Y2&F['/[\5D],_\ 02'M4JE25LTC-.,5LCUD!_4#T"@     X#E6W[]@
M:5_CNG_[QVB'R$]!Q?;]^P-*_P =T_\ WCM$/D)Z#R^C?]QQ/A'Y%N)^PI>?
MS)P ?5'F@                  $,H1              !#(!$$"(
M         (+R4B07DH!I6V/^]=J;_09/H-3MO]Z#2_\  4_\U3;-L?\ >NU-
M_H,GT&JVM/\ YD.FE^+3TZ_[I\3TA_N,O\/S/:PW^G7^7Y'26?!-]!$@U<QM
M\Z$3WH=1&,  F<+>OIO":&>'\8QS?:AJ&EIMZUI"[A) Y8WI\Z?2;OYC3+O
M[3UZDK4:JT%7\)N_@N[_ .W>>3BHN,HU;:;,TT9;P?,R8(12-EC1['(YKN*.
M;R]1$C=/5,MUV(_,4]GB=9[Y5./%FJ'*WT)_YF/O5PZB):6!.LJYO%8QO-,]
MIM.F+:EIM\-,G%S6Y<O>Y>?]O03PRXF)CEVC\V5UO=I6[38  ?5'D
M
M
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M<7&;H_+]7:I2*U)\*OH-]"G&DU&**9R<DVV9( 'J&(
M
M
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M,9DTS35S6WW*6">-::"L=UL+9%\A5[%]7T&YI_;)NPE15*:C>[6C*JD7&6H
M!N*@     =!6I/A5]!1*U)\*OH+:?71!]5F2 !Z!D
M
M
M                                   !0J/(7TE<H5'D+Z2$NJSL=RV
M(+R4Q&HH5E!3W")8ZB%DS%['IDP:Z+CI7JZVUU30*O'<C?O,]BFQM\4PNH;S
M+01QT]*W?K:A5;&U>343FY?,ACKPI*/$J)?F3@YWM%F%N5TO=@5K'UU+72O7
M#(>JQ*[U)]).E'<+VC7W5[61)Q2DB7Q<_E+VJ5[=:(Z)72N>ZHJI/A*A_%SO
M7V)YO,9!$PGG/ ;G-ZR>7LN;DDELK^!+'&D;4:U$:U."(G<3 #;1'?$
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M.9J(KX)$\B1OG1?K3M+J,\DKO8\S'X>6(HN,.LK->1@U16[R+Q7ED\E;6_\
MGOI#_P 66O\ I(C>K/M*U#L#GBTKM2HZF:UP_>;=JJEB=)%-$G!K9,<<HF/R
MD3FB\UYMKV_6[5,VWZY6BKCN-!4VJV=340.WFOQ+&F$5>/!45.*=AZE*+3;W
M7:?&XNNJB49:26Z[-#U=I#_HA8OXNIOZ)IR[I1W62JT;;M%T"]9>=4U\-'!
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M+<5$CB3D[*<>7=DMHUU*HDHLJJ4[1;;7J;. #VS"
M
M
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M7[;9?*:^+MDTQIK3D\3X4MJ:<JGSMF:J/ZWK-Y[\8Q'CEG*G89,[BX3*]Q.
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M(3T'%]OO[ TK_'D'UG:(?(3T&#HW_<<3X1^1+$_84O/YDX /JCS0
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M    #@  !T%:D^%7T%$K4GPJ^@MI]9$'U69( 'HF0
M
M
M                                   AVF-O34= S*(N'HJ93/'"F2[3
M'7GX!OR_J4R8G[&7@64NNC$8(@@J<#Y(]D9,/=K+X3(VLI%2"OCXLD_!?YG&
M71<$>SO*Y1C-683R[&+LUZ;<6NC>SJ:J/A)"O-%[_094P%^L<D\K:VA=U5='
MVI^'YBK8-0,NC70RIU%9'P?$OTIYOH*8U'%Y*F_;VDG&ZS1,T""=JD33<B
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M.2-1$3V%7M/4PV!C1EGF[R,E2LZFBT1, #U3.
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MIW)WKYR:V6I[95K:UR35COT8D^*W[3+(N$*8WF\TCM[:()GM(@%^AP  7
MN"':8G4[D]Z79X+UD>,]^^AEC7M5(M<ZBMT:JCIY-YRIV-3.5*JLLL';<[&U
MU<R#]05UT>YEK1D=/&NZZKF15WG=NZG;Z2'47AJ92\KG\JG9@O::G92P,BB;
MN1L3#6IW?V^DK%N><NM)^I7EBMD6#+C?Z?FVCK&]O.-5^94*K-6U$.4J[351
M_E1*DB?3]1<Y7N(>E2R-:M'JS_,YD@]XDL.LK5-XKZCP=W:V=BL5/J+B:FM%
M[:CGLI:SN=E'+[2V?#'*U4D8U_F<F4+&73MNF57+3-8[XT>6K[4+/:ZC5IQ4
MOWYD.%%:IM&8I-.6RADWX:*%CTY.W.)E$7'8:?[RS4O&CN57 ]/)2219&>A4
M7L,I8+U+5S2T=:QL5;"U'+N+XKV]CD-F'Q5.^3)E?E8JJ4Y6O>YG-X@JD%7"
M&O5FIGR3R4MKA\,J&+A\BNQ%&OG=VKYC;4KTZ4;S93&#EL9JO@;64DL$B99(
MU6*GF5,&$TG<VQT+Z"JD:VIHG=0_>7&\B>2[V%FMKJZ]V]<+C+(GXFG7JXT]
MG/UD6Z8MK>=)&_SR9<IX\\7.513A&UM->9KC22CEDS977.E9Q=41HGG<GVD&
MW6D>N$J8E7Y:&OLT];&\4H8$_-0B[3]M<F%HH<?(0L]NJ?A7K^AS@P[6;.R5
MKN+514[T4GWE])IRZ;IXU5U)+/0O['02*B)ZN159<[K:.-4WWQIDYR0INRM3
MSHG!2Z'2"VJ1M\2#H?A9M;G[K7+R\YIUN7WZKI+K,F\S*LI6*N4:Q%QO>E51
M3-U-SAN%AJ:BDD;*QT+\*WL7"\%3L4QM@:UMFH4;RZEGT%.+J9Y1BGIN2HQL
MFVB_]GL(@&+0T@ "X(8R:_64LUBG?643'24KES/2IV?E-_MVFPD%XIWE<H*6
MJ>HB\I9TE?#<:1LT#]]CO:GF7SFLZH^!?Z#(7*U3VZ9]=;$3?=QEI?P9/1YS
M!W6Z072BDDA7#F\'QN\IJ]RBG4URSTD''FCAVM/A92RZ'_[934O\1O\ Z2E+
MW6?PSRRZ'_[934O\1O\ Z2E/K>B]I^!\ITM]I0_R/<H /0-P
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M?042M2?"KZ"ZGUT1?59D@ >@9
M
M
M                    8V\_ -^7]2F2,;>?@&_+^I3'BOL)^!92ZZ,2 #Y
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MF1.#4]II2SM06[(72U?(W=,*U""1H[BK2*>,3GVR@K:GAW[""-1.2$0"=K
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M+R3':OF.-V5R48N;LC;UP03CR4YNM#<)O&JK]<)'<U2)S8VIZB*4%?%QBO\
M<D[MYZ*GT%?$B:?9)VN='(+Q0T"&]:BM:HO6P7F%.;'MZJ7'F<G!5-JT]J6D
MU#2ND@5T<T:[LU/(F'Q.[E3[":DF53I3I[HRFZ05I,"15<HJG_F:CJ3>U#=8
M=/0+B'"35[V_@Q_@Q^ER_09_45XCL5JEJW-ZQZ>)%$G.1Z\&M3U_-DM-*6.2
MTT+I*IW67&J=U]5)WN7L3S(G X6)F19"V.-K&-1K&M1&M3DB)RP06,NE:2*P
MC8G&1:+&4EA+YT9(L9RQ:IF/6$INA,BL9(L?F(92Y5#'+"8/5UN?4V.>2'Q*
MJEQ502)S:]GC(OS&U+#E#&7]S*6R7"61<,; _*^H92>?,K%U?]K5X=:[5!:[
M?"RY72G;-"Z61'HQBHF97-3@B<>&>9KMNTZE+435M7,^XW.9<RUL_C.7S)W-
M\R<BCL^LL]/98*^J<Z6MJ8F)O/YLB:F&,3N3'$VKJ5P0ROM,N'HT\.O=2NS'
M>#KZ5'@_F,CU*CJ!E/1XICT@1.PF2$ODA7T$6P^H93G$+%(?-DQUYL2W&-D]
M-*ZDN=,J24E6S@Z-Z<O2WO3M-@ZDBD.<'<I5*:DK,OW[3GU6R2YW7<2GO%,U
M:*:!/W.I548BIYE5V]_Y&LZ?LK+/:*>E9Q=&WQW=KGKQ<J^M5-<UC#-:+Q"R
M/_F^[SP)4M[.LB=EKO6GT&_LAW4W>:\_:6/WM#SL-0CA<V7[SOY%NV'S9)VP
M^;!<I%YB+F[K5(Y36YW*&[Z2.Z3HTCA#MA<E:WAW$[(]YR("Y@CPBKVJ2RE4
MI61B=1:7I-1T'@TZ+&]O&*9G!\:IR5##:<U+56>O;8M0/1*I/V/6+Y$[>SCW
MF[(U>TQ>H-.4FH[<^DJF<.<;VIX\;N]/.3RF?,GHS*;N>PBC,&DV+4=7I^X1
MV*_NRY>%)7_@3-[$7SF[I_;)T@[H$>/G( '"9,*B]_F.:VZ-;+<Z^SS8:]DK
MIH.Z2)RY14]"K@Z0U,(Y##ZATS2ZAA1LJN@J(N,-3%P?$J]WF\Q&<<R+J-3A
M3N]C"+@90L*BCOUD=NU5%[Z0)_A-$GCX\\??Z"U75%#&JI(E1"[ENR0.13*X
MR1[,:L)*Z9F>"F-U!6K26V1D:*^IG^\PQIS<]W!$^OU$C+I55^&6VU5=4Y>"
M22,6./TJY4,]I[2,M-7>^EUE94W%J8BCC14B@1>QN>:^<G&+935KQBK)ZF8M
M5"EGL5)0YWE@A9%E.U41,J-GT;J[:S52L3,=!:^K>Y.6]+(BX_W5*5\NU/:J
M*>LJ'[E- S*NQQ7S)YUY>LVC8[IRIM5AJ;K<8UBN5WE\+EC=SB8J8C8OG1O/
MTEL/>GIR/F<?55.@T]Y&^N7O]1/!620JF'>+\5Q2521>:FM2:V/C+)[F8I[C
M'-P7Q7=REVWM-;+BGKI(,(B[S?BJ7PK\I%4J?89X%G3W"*?*9W7?%<7;>1JC
M)2V*+-;D0 3.                            @O)2( ,#?=-Q7;=GCD=2
MUL:?>YV)G'F5.U/,8"&XS454VBN<:05*\&2)\'-YVKV+YC>DRA9W.UTUUI7T
M]5$V6-W8J<47O1>Q3R,5@56]^GI+YFJE6</=EJC1[C:YJ.J?64+>M23C-3\L
M^=OG[RWBO5,[*2R>#R=K)O%4R=33UNEG*LV_6VSLF:F9(4[E3M3SEVUM+<8F
M2HV*>-R91V-Y,>D^/K81QFUU7WGKTZVG:NTPWOE2[N?"8<?PB%%U[IE56QN=
M4O\ B0-5RJ9U+31-7*4D.?X-"O'!'$W#&-8G<U$0I]DEVHLXR[#7H;75W=WZ
M\;X+1\^ISE\GRL<D-BCC;&QK&MPU$PC6\D)MU/,GI,7=+LZ"1*2DCZ^ND\EF
M>#$^,_S&J,(4%IH4.3FR:Z79*+=@AC\(K9/@X6KCUJO<0M5I6E>ZIJ7^$5LG
ME2=C?R6]R$UKM+:'?E>]:BKEXR3N3BOF3N0R*KV$E%R>:8VT1'S  N.
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M_P!67?TS#W8WF?0]&?8R\6?DG\<?[C#_  C\B< 'KGYZ
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MI4^S5$*JVD3E:D^%7T%$K4GPJ^@]6GUD9GU69( &\R
M
M
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M9*/61EVINMQRQR(DOX),6K8B         0QP,!6.6GU?1.Y)+"YGLR9Y/PC
M:E^\5UJJ<8W*C<]I16]V-^QDHZNQL"<B((-Y%Z[")$ AV=P 3@A*YR(8F\72
M6*5M'2(U:J1,JYR9;&WO7SF,]YX95WJA\E7)VNE>JI[.PQU,2H/+%7+84W+4
MV:1S=U<*GM-4U/\  R>@J36.BW>$"-^2JH:IJ2WR4\3UI:N>'AP:YZO;Z,'*
M>*=_>7Q).CIN<HUKY<GH+'H@_ME=2_Q$_P#I*4I:FNDGA2P5C&LE7@V5GDO^
MQ2KT0?VRVIOXC?\ SZ0^SZ)FIJ;78?']+Q<:M"_XCW(G(B03D1/5-@
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M5#F%UVGZNT?23OU/LUU#0/IFYJ:AE.Y:9B)V]9C=QZU]):Z>VV7G6\4C=+:
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MU;7'M16ZJLJM7BBI3*J+Z/$)O>C:_P#YTV;_ &5?^ U_SEO58>?HOJ4>Q_\
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MI*9D+WLSA51,<,\?:8Z-2IBND'7=-QCEMK;>_<V:'&-+#JEF4GFOI?L[[&8
M![_B8C"ZH@=X+%4L3QZ>3>_-7!&GD9-"R1JY:],F7?&V5CF/3>:Y,*B\C65B
MFL$CV.8Z:B<N6N1.+/,IYU6+ISS\GN7PM*.4R6$&[YBA%<*6=J.;/&N?C.PJ
M%&INU/3IAK^M?R1D?%2'$A:]R>63TL4KS^N'4U&WBZ:1,^@V=J(G!#"6:VRR
MU#J^K;NRN3[W'GR$\YG/H[#1AHO6<MV5S?) K4GPJ^@HE:D^%7T'HT^NC.^J
MS)  ] R
M
M
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M &[S?5=TH1Y_(S1_%V&PP1M@B9&Q,,:FZU.Y$*B\@B;J8]03D:+94D1[R(
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M7\3*\13O;\BQ4Y&?!BJ+4=/4R)%(CJ:;L9(G!?695.WZE+X3C->ZR$HN.Z
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MH+J?71%]5F2 !Z!D
M
M
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MI]7@J#H4DGN]SRJL\\KK8CA"(!Z!2
M     01I$HRU#(6JKW80QU1<WNRD:;K>]>95.HH;DHQ<C(35,<#<O=CS&.GN
M;Y,I&FXGGYEDYRNXJN5[UYD#%*NY;&F%-+5D<JY7*N57SD #-KS+0
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M9[LH[AWF*V66F#2_2)J[13HJTD39X6(]=YR-W&NY_P!N&3ZN-5</-;D?@E3
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M]&8!A]Z]N_!IF_V](ZF]/\JHA8GF;D<;_P 7Z#+WHS ,-[V7*3.]<E3Y+/\
MR"Z>DD^'KYY/,CL?6.)4>T6,JYR+RY5E(RGDCGE8C7-5%3.5Y&-TU<6NB\#D
M?ES/@W.3RFE62UVVT0]=)&CU[.L7><J^9"BEKJ;MB>54I=U/O+&IQ;Z2ANIQ
M%*RN3CERV-@!A8+Q-0.2&XL5O8V=J9:OI,O%,R9B/C>CV+R<U<H:H58SYZE3
MBT3@ N(@         K4GPJ^@HE:D^%7T%M/KHB^JS)  ] R
M
M
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M^21<O>O>JF23S)P(X/>P^!IT'FW9BJ5I5-'HB< 'HE
M                !3DD;$U5<N$,?/=>R)/SG%<IJ.Y*,7+8OY)60MR]V#'U
M%U5W"),)\9Q8/D?([+W*Y?.2F*==O1&B-.VK)G/<]RN<[>7O4E ,VO,N  .
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MQ-UK&M1$:G<F.1,YQ*JDTE$^=JUZE:5YLB2 $6RH  X
M             "I%,^%R*QVZ9&GNJ.\65-U>].1B@6PG*',@X*1L37(],HN4
M[R=."&OPU$D*Y8[''EV&0IKHU_"1-Q?F-D*T9;F>5-Q,B"#7(Y,IQ0B:? J
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MHJNT6R4=6C4]%-ZZIN]4O%SY]U%]&3:#6]!M1+94KVNJ'*;(?.X9>Y<]&>[
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M)7QLF:K'M1[5[%0Q4ED?3N62@G=3JO%8U\E3+@[*G&>K1Q2<3$1WB6E=U=?
MZ)WXQG%JF3@J(ZAB.B>CV]Z*3NC;(U6O:CF]RH8V6PQ=8LE,]]+)^0O K_J4
M]O>1.\9&3!B$ENE#Y<;:QGQF+A2>/4$&<31RTZ]SFY.JM&]IZ#(^6IE 6;;Q
M1R)PJ&)Z55"?WSI?\9CQ\HMXD'M)>I'++L+D%FZ\T3?\(9])1?J"B;R<YZ_D
MM4CQ(+>2]1EEV&2*]'\,OH,'[^+(GWFCFD]*80O[)45DU4[KX&PQ;O#CQSE/
MZR5*K&4TEJ0E!J+;-A !ZQB
M
M
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MDSY5WGN5R_,2 &6[>K+DDM@ #AT
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M'EMV>62LS6G=76QCJVPKUSZF@E\&G<N7QN158]?.G8OG+-:RLIN%5;Y47M?
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M1Q^2QK?DHB$X+5"*V1S,^T%>C^&7T% KT?PR^@NI=9%<NJS*  ] R
M
M
M                                                  $,(,(1
M                               (+R4B "#>0'!N5+&>YQQ91GCN\W(A
M*2CJSJ3>Q?.<C4RJX0L)[HQG"/[XO>G(Q\]5)/Y;N'Q4Y%$QRKWZI?&GVE66
MHDJ%R]V?,G(I &1MMW9>DEL  <.@
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M494LN?-V?,GWAO$F5&5%Q8GWE"N4I@7%B97$,J0!&Y(  X
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M[@KT?PR^@H%>C^&7T%\.LBM]5F4 !O,@
M
M
M
M !+E,*13EQ")@M9[A'!E$7>=\5"$I*.YU*^B+G&$+2HN4<.4;X[NY#'3UTL^
M<KNM^*A;F26(Y1+XTNTKSUDLZ^,NZGQ4* !D;DW=EZ26P !$Z
M                                                       "AUF,
M%<M03CJ3]9YQUGG*>4&4!/*7$;LY0LKU4=31JW.72</475,OEY,'>ZCKJM6)
MY,:8]?:=;+J%/-4MV&/3R4 (=G<0/;Y$\;%DD:U.;EPAML$24\3(T3@U,>PP
M-CI^NJ^L7R8_I-A.H\G&3]Y0  .GG
M                                      %Y37*2'".\=OSF3@JHZA/$
M=Q[NTP!'*MPJ+A>\T0K..C*I4U+8V4E]1B:>YOBPDGCM[^TR4%1'.U58[>-L
M*D9&>47'<K  N(
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M
M
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MY;LFDH[  $3H
M                        ++_B+U.3C'J[GZ074B<$F]Z1O>D%UBXCD2*&
M5[N34RIJ\DBRR/>O-R[R^O\ LIE[E4;E&]B+E9%1/48?[2+-V&A:\V0 )X(5
MFF9&WFY< VMV5S8+)3]31M7'C/XK]1?D&-2-K6M3Q6IA")(^;J2SR<@  0
M
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M*'A-GS%E/K(B^JS*@ WF0
M
M
M               AVEA=_P!CL^7]2E_VEC>/V.SY?U*55>HR4.LC$  \NQN
M %@  +   6   L  !8  "P  %@  +   6   L  !8  "P  %@  +   6   L
M  !8  "P  %@  +   6   L  !8  "P  %@  +   6   L  !8  "P  %@
M+   6   L  !8  "P'8IC,\_291.STI])A>/#!$T42MO#>*65(*Y6HY5[.(9
MJL8^XS=95*WL8B(6Q(Q_623.^,[).1/5A'*E$&3L%/UE4^1>4:?.8PV.QP]5
M1(Y4XR+O R8F66GXE^ "=CPP #M@  +   6   L  !8  "P  %@  +   6
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M9T]^WAUG_$K/Z.E/4QY9T]^WAUG_ !*S^CI3O_3GX&/$?;4/\D>C@ ?.6/M
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M9U8KE%Y69L 'IF,
M
M
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M@I/0=1TX%K7X5YB^B-^V1U-_$C_Y]*936OPKS%]$;]LCJ;^)'_SZ4]?!??\
M ^8Z7Z]#_(]M* H-!P                     @YJ.:J*F47FA1I:2"D:Y(
M(8X4<N52-B-S["N     !D  +W  $D<;(LHQJ-SQ7=0G
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M?S.N,_MP+F@^%7T%JWM+J@^$]1^CT^NCY^759E0 >@9
M
M
M                                      6-U_8[?E_4I?%C=?V.WY?U
M*53ZK)0ZR,4 #S#6
M
M    #6T<;(:KO?019Z&$YE;>,-6R=94/7N\7V&3=)NM<[N3)@E=O2.7M55(,
M]O#Q]YLNJ/D[U%QYRUHOP_47297@G,$Y]9F<TW#NLFDQS7<3U?\ F9DM+1#U
M-OA3M5-Y?7Q+LL6Q\S6EGFY  '3.
M
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M=^2\TO8__??LGIG_ *"0W37?DO-+V/\ ]]^R>F?^@D+N1'F>K  0)
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MZ#X;U%%O,N*/X9/0>C3ZZ*'U694 'H&0
M
M
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M_B-_])2F6UK\+(8GHE?MD]2_Q&[^DI3U<#M/P/FNENM0\3VTH"@T'
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MM_$Q_I#K*SMIV>IQXT^Y23XB^P?<I)\1?8=X?_DQF[CV6E14MYTOL</")_\
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MT.AW/%P=9M4>Y$G#C@G&CE=[D7.ZM8R@ -!4
M
M
M                              2_A%I=/@&_*^I2[_"+2Z? -^5]2E=3
MJLE#K(Q@ /.-8
M
M!!?)4TK>])NCO)4T?CQ*YGK8!7N65>[>F1.Y"V)IW*Z5Z^?O*?$H9]1!6B7]
MK\I_YOUFS:;C^^3/[FHTUBU9Q)GN3ZS<=/Q[M&YW:YZK]!9$\7'RRQDNTR8
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M):UD5K&MCW51V^QO'/=GL/5!34:<M"R-TM0 "LD
M
M      22^0:?JGX%_H-PE\@T_5/P+_0=6X. ZV^%>8GHE_MD]2_Q(_\ I*4R
M^M?A)3#]$K]LIJ;^(U_GTIZV"ZL_ ^9Z6ZU'_(]M* H+CH
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M%&-5,%1L*-)TX< "(
M
M
M             )?PBVN/P+?E?4I<_A%M<?@6_*^I2NIU62AUD8P 'G&L
M
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MT7F@OU$VLME=37&C>JHVHI)6RQN5%POC-54Y\/4 7@
M
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M.W^W:I='HPZJ,;W  +#@
M
M
M                   !!.:EI<?@6_*^I2[3FI:7'X%/E?4I7/JLE'K(QH ,
M!K
M                                                  (.\AQS2J=B
M%?[=ATM_DJ<NJ5\5J>?ZBJH>[T5K)E#R1O$O'O&//VF<^IL9G3+>LJ]W\MOT
MJ="-$T7'O5[N/+"_,IO9II['R/2;_K6  +#QP1^8@ #YF^ZU;=+E?+SI;8+I
M61TU7=)(*R[0PKXTSWR;M)2JG/BY.L5%[XE[#LG2ZV6T&Q?W,_4.AK=NNI['
M:K=2NFC3"32I74[I9<=[Y%<Y?EJ>-=DE6NWKW6"6ZW#=EIH-2UU7'O87$=!%
M(E-P7_1X3Z >Z4?M)]IO\#1?]OI_::NK:)3O>1\D.BWT+=;]+2'4DND+I8+:
MVPNIV5*7RHGB5ZS)(K=SJX9,XZIV<X[.9TC:OT.^DET0[1]VU-J"62UV[==/
M==(WFH<E$F4:WK&/;&_<XXSNJW'/"'H7W$?_ )LVP_PUI_FU9]*=1Z?H=6:>
MNECN<#:FVW*EEHZF%R91\4C%8]OK15$JF65N0C%.-SQY[F]TUKATDM-W/2FL
MI8Y==V&%LZUC&(SWQI%5&=:YJ81)&N5K7XPB[[%[5QG/=$.F7/T7M!T%JTSU
M,FN]1)(VA?.U)&4,#,(^I<WDYV7;K$7@JHJJCD:K5^<GN7]XJ=/=-?1]&U^Y
M'717"BJ4:O!S4I)I,8[4WXF+ZC*>ZQZBJ;UTPKQ13O58[1::&AA1>"-:Z+KU
M3]*=WM&19SF9J)'9#T(=NO38HG;1+YJ*."VULCDAN^JJR:6:K1'*CE@C:UR[
MC53''<;\7*(N,!M"V7;=?<YM=6NX4U^DMM/7/ZRENEEJ'R6^O5B(KHIHW-1%
M5$7R)&^=,XRGV[V<:;I=&[/=,V&ABC@I+9;::CBCB:C6HUD36HB)V<L^LCK3
M9[I?:-04E%JO3MKU+1TM0VJAI[M2,J8XY4:YK7HUZ*F\B/<F?RE[R/$=[/8[
METN<MV!;5+%TS.C1%=KA11,I[]15%HOEL8N\D,VZL<S&]S514>W/%&O:O,\0
M>YO[3+MT>NDIK;HZ:GK-^W5-?51T#I%5K4KX,IO,1>39X6;R=ZMC1/*4^I%J
MM-#8Z&*BMU#3T%'$F['34L38XVIW-:B(B)Z#XY^Z1RR;$^GQ9M<VQC4K):>U
MZE:UKL;\D,CHL+\KP5/:<IV=XHE+2S9]E_M\Q!/;Z2E2U+*RFBJ(G;T4S$D8
M[.<M5,I]/T&O[3*K4]'H#4,VBZ*"X:L;12):J>JD;'$ZI5N(U>KN&ZCE151>
M:(J<,Y*>XGR,Q=+Y;['#U]QN%+;X>/WRJF2-O#FO'@5J"X4MRITFHZF&JAY=
M9!(U[>6>;5PO#'M/DGH/W,3;1M]U=J"_[;]456EJYLJ;M34NBNU16J[+EW%C
MF1D4;<IA,\,X1J(APJN=J?H"]*IEKTOKEM]AME53.J:BV2K'!<*=VZLD$\*/
M>B+A7-5JJ[=5$<BYPJ7\-/9E>9]A]Z4_M@L;E>[?9NJ\/KZ6B6559'X1,V+K
M')V-WE3/,\P^Z,])^Y]&S8E"[3<ZTVKM15*T%OK&L:Y*1J(CIIT:Y%151OBM
M[ED1>SCX.Z-WN<VM.EWH2;:?JG:"^Q>^]1*ZDFKJ.2Y55=N.<U\TCG2LW6J]
MKD1<N5=URX1,9C&"M=G92U/LU%(R:-CXW(^-R9:YBY14YYX<^&/:?/SW3CIG
M:_V"WJRZ&T-/2V62\VOP^IO:,ZRKC199(^KBWO%9P9G>PKN/#=5./,^A#HKI
M(]&CI"3Z)K=+W^\[,_#WVZX2K&]+8UJJNY74CY5:WFK7*K,JYN\BHKD3'F7W
M0?H\5&P';O6^$7R.])JIU3J%G5TZP^#MFJIL1+ESMY4W?*X9[D+(P6;5G')Y
M=C[:[#J^INFQ;9_6UM1-55M1I^WRSU$[]^221U/&KG.<O%7*JJJKQ7*\3PET
M%/<]]J/1SV^TFLM5U%A?:(K?4TSFV^M?++OO:B-PUT;<IE.\Z/[G#T-*SH_4
M<FNY]407N'5]AHY644=$Z%U-OHV9$5RO<CN#L<DY'A[W);*]+Z@3_P"PU=_,
M:<4;)V8OL?;T'Q.Z9.E:_H>].RFUO8H%9;JNX0ZKM[&)NLD1TBK4P+W(KTE:
MJ=C)$[SZ@]);I!4&S3HL:BVEV>M;(E5:&/L<[>*RS536MIGM3MPLC7KYFJO8
M5RA:UN9*,CN!;UUPI;93NFK*F&D@Y+)42)&WEWKP\_J/E%[C]L:J;A?];;6Y
MJ'P^2ST[[5:&2OW$FJY&(^54>ODN1FXW/+$[L\BE+[G[TC.E%MEO%TVUWE=*
MT.ZZ>*XNGAN,+45R(VGI8(YD2-J(B\]W&$54<JY)<-7U8S.VB/J]:KW;KY#U
M]NKZ6OA7BDE+,V1N%Y<6KCBASKI0;7:[83L&UCKNV4-/<KA9Z9DD%-5N<D3G
MOE9&BNW<+A-_*HBIG&,IG)\:.D3L=O\ T!-MMHCT9M*]\+EU"5L-?;?UK4TZ
MI(J+#41(]Z*BHC5PY5:]%7+<<%]D>Z+[)*SI ]&C1&W%;O#;&6+3D-RFM7@R
MO6I6M\%7#7[WB;JNY*B^H[PU=:D<S:>ANON7G2!UUTA7[6+_ *YODMUJ(JFW
MLI:=J)%34;%;4*K(8FX:Q%X97FNZF57&3!^Z%]!#:5TGMLUEU3HZ>QQ6NCL$
M-LD;<ZQ\,G6LJ:F1<-;&Y-W=E;CCSR>-^@+T-*SI,W>XZCI=406!FD[E0ROI
MYJ)9UJ=YSI,(J/;N_!8Y+Y1O?NS7#I.:7[/_ %/I?^VUQ/*E/0C?W=3Z\Z&L
M\^G]%Z?M52K%JJ&WT]-*L:Y:KV1M:["X153*+QP7]RO%OLM.Z>X5M/;Z?"KU
ME5,D;<(BJO%?,BGGW;+T@X>C/T.[7K1(8ZJZ-L]#16NEE54;-5R0,1B.QQ5K
M41SW(BHJM8Y$5%5#YJ; ^B[M5]T4O]]UOJS6\E-;*:I\&FO5RB=4N=,J(]8:
M:!JL8UK6N:JM16-;O-1$X\*5"ZNW8FY<C[9T==3U].D]+41U4#L[LL+VO:[T
M*U<+_P"96/A[K_1&U[W,/;!8ZRU:E\.M-R_7$,U,LC*&ZQQJU)8*B!RX1R(Y
M.URHCVN:Y%QCWETV-IMLVR>YJZEUM9FOBM]ZHK551Q3)X\2K<J5'1KWN:Y'-
M5>66\.\ZZ=FK,*7:CV>KD:URN5&MQQ5RX1"UMEXM]X9*Z@KJ:N2-VY(M/*V3
M==W+A>"GQ$Z$VQ+:;TIM)ZAV:636#M';-Z"L]];U4,C=(M3431LBCA<QKFK*
MF[ Y4:KD:W#E7BK36MOVQK6_N?.WBT,L.KI9:IU,RY6N^4+%IG2Q*]S7Q2Q[
MSD\IBHYF\K7-5JKSPDN$KVN,[[#[U@UO9EJYVO\ 9OI35#X$IG7NTTER6!.4
M:S0MD5OJWL>HV0HYV+  #@
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MK/Z.D/4B'ES3/[>+6?\ $K/Z.E)KJ3\##B/MJ'^2/28 /!/LP
M                                  :?M0_Y@I_]*;_,>;@:?M0_Y@I_
M]*;_ #'DH[G'L9#0'_12B_UG](XV U_0'_12B_UG](XV X]SO(  X
M                         #J!E*#]CM_MVJ71:T'[';_;M4NC=#8QO<
ML.
M
M
M   L[EQA;\KZE+PM+A\$SY7U*5SZK.QW,=NC=(@P&HANC=(@ ANC=(@ ANC=
M(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ A
MNC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(
M@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ AN
MC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ ANC=(@ E<WQ''
M**IWDG6'>0XY'.[[XGH0HJGT/0^LI$F]YPCN//M)<J05>7I,Q]8;5H%N]65"
MY\EB&\;J&E[/&YFK7=R-3YW&ZFRGU4?#=)2OB)>1#=&Z1!8>60W1ND0=0/BK
MT D=8/='WVVK5RU:UM\HUZS@[K&1SN=GSXC<?1#W2EO_ ,Y-M-YXZFB7C_I]
M,>%=OUHDZ+'NH=AUD_%-8KY>:>]I/C")!5JL%;E?C(YU0OH5%[3Z5=*_8[<]
MO?1_U=H"SUM);KG>&4[(:JN5_4LZNIBE7>W$5W*-4X(O%33+K)E4>JSPY[B,
MU/>S;%VIUMI_FUA[=Z2G21TAT>-G-\O-[OE#!>8Z25;;:G3M\)K:C=^]L9%G
M>W5<K,NQA$557@?-[_T+NU'_ #XTAZ-ZJ_\ !YF<TA[BKJN>Z,^ZG:+9:*W(
MJ*Y;1235,ST[43K$C:U?/XV.>%.O*Y7;"S+2QSSW(O9?7ZNZ3#M7) [WJTG;
MIYI:AR>*D]1&^"-F>658^9WHC4RWNPFRZNTWM_M6M6P.]Z-2VN.)*G=_PJGS
M&]B^?J^H5,\\K\4^I.P#H_:/Z-VS^#26C:*2"C1ZSU-74N1]363*B(Z65R(B
M*Y41$1$1$1&X1$+S;=L/TET@M UNC]96]:VUSJDD<D;]R:FF1%1DT3\+NO;E
M>.%14545%:JHL.(LV;D=RO+8TKH?=(O3?2&V.:?N=KND$VH*.A@@O-L61.OI
M:EK&M?O,Y[CG(JM?R<BIVHJ)Q#W0;I[2]'&2PZ;V?7&UW'7#JM*BYTM3&E3%
M2TC6.1(YFM<U622.<Q41%1R-8J\$<BKYNU[[C=M&L-[EJ= :VLEVH&O<L*W-
M\U!6,:O)/$8]KEPJHKLMSC.$SA-NV&^XU5E%J2GN&UC5EOK;73R->MHTXLKO
M"L.\F2>1C%8Q41$5&MRN51'-QE5H)YKB\K6/;?1 VS:FZ0&PRS:ZU3I^ET[6
M7*27J8**5SF30L=N),B/3+-YS7X;EW!K5RN4/FO[LM,VHZ3.E*:+$DT>E*='
M;G>ZLK,)Z>WUGV%LUJHK%:J.VVZCAH;?1Q,@IZ6F:C(X8V(B-8Q$1,(B(B)C
MAP/D+M)M#NEC[JJMCI/O]EL]UAI*ERIO-;36]B.JD7Y4K)6)YY&BGUFT'>R3
M/KCI6WR6O3%HHIE59J:DBA>J\]YL;47/K3YSE_2\VX5/1VZ/VJ=<T%+'6W6C
M9'!0PSHJQ^$32-B8YZ)S:W?WE3*9W<93)V7UY_M_;V&C[;-D5FVZ[*]1Z#OZ
MR,MEYITB=+"J;\,C7-?%*W/-62-8Y$7@N[A>"J4Q:O=D];:'RSZ-FQG:U[HO
M1ZBU'KK;/=J+3E!6)1RVZ)SI$FD5B/<UE,U[(86[KFX=NKE<ICAD\Z=+78MI
M;H_=(2JT+I.\55[HK9'2>$5-=)&^1*A[4>]J]6UJ-QO-\7&4Y*N3UOH[W,'I
M&;)=47*/0&URUZ>M5;XDMQM]QK:*>>-J^+UD,<:IOIE53QW8ROC)GC=[2O<;
M-0W&>U5.E]H-+7W*2F=)?*[42RHZIK7/<YTL6XQZHU45$PYSG9:JJOC<->:*
M>Y39V,][MC8:R?3&RN],21;?25MPHYN'BMDE9 ]F5[U2&3'H/1_N:^LK5J[H
M?:&AMU1%)46B.:W5U/&OC03-F>N')V*YKF/]#SJ6TK8G;]O&Q)VA-HS65,E=
M1P)75-K7=6*L8C7+/3N>G!4>BJF4XIP5%150^<]P]R5VU:)N]:S9YM,M/O36
M/6%\SZVLMTSXESCK61,>UW#**F\O%>7=4G&4<K))-.Y['F]T1V4Q;=ZG9,C;
MY4:ACND5GCJZ.C944D]2]S6JQCF2*_Q'JK798W"M=Q4\0>[0PN9MPT-+PW':
M<5J*GFJ9L_SD\W$],]"OW,V@Z.^JX=<:SO5+JC5U.QS:*GHXG)1T#W)ATC7/
MP^63=5415:U&[R^*JX5-EZ?_ $&*_I:T>G+KIN]4%EU39&2TZ)<T>E-5PR*U
M=USV-<YBL5JJF&+Y;D7DBB+C&6YUW:.^]'.H;5='[9E.WR9-,6QZ>NDB4^07
MN2O[;ZW_ ,35W\QI[<]S_P"AEM6Z-FL[I>->:JMERL\UG=;*.T4-=45*T[NN
MC>UR=8QK&-PQZ8;GB].1K70H]S@UQT9MN5+KB_ZET_=+?#0U%*ZGMRSK*KI&
MHB*F]&U,)CO.IQBFKC70VWW6?8?^J/T>6:OH:?K;QHNI6L56IESJ.3=94-3Y
M*I%(OFB<?-/:/TH;GM%Z+&R_9&Y9WR:;KZIU2O%?"(TPE$B8Y[C99V8_)8??
MG4%AH-46*YV2Z4[:NV7*FEHZJG?Q;+#(U6/8J=J*U7(OI/FIL1]R,OV@-N6G
M-3:BU19+OI*SW)*]M' V5U3.D:J^!KVJQ&<7MCWDRJ8RG:@IS5O>.2BSU/L@
MTK3]"OH31R5E%X3<-.6">]7.G1419ZUS'321Y\SU2-'=S$[CY^;!V[;_ '23
M7^IZ:^[7JW2U@MD3*FJHJ%7LIT;*]R1QQ4L;XVOQNN3?>Y53AE7*I]@-5Z7M
MVN-+7G3MZI_"K3=J.:AK(-Y4WX96*Q[<\T7"JF?8?+V+W*G;?LHVBSW/9)M2
MMMKH)%=#%<G5U305S87<V2MBC<UR<$3@[BJ(NZWLY!K7M.N]CS;T\>B_I'HL
M:XTWI;3>HZ[4%PJK:ZNN;Z]\6]$Y9%;&B,8B;B*C57#E5>WD?1;;W3NF]RGC
M:WFFAK([U-;2*OT'$]HON0FK=86.VWA=ID=_VBU=1)-?KI?I)G03-<UJ1MB=
MNOD<K-U4WGKXR*G!N,'L[3'1]N%VZ(E'L:US<*6:L33WW/S7"U(YT;&L9U=/
M*Q'HU5<QK8G*BIY37$G.-EJ<2U>AX\]Q(G1UAVN0?AMJK8]?0K:E/^ZIQSW9
MO]L]I?\ ZG4O_;:XV73GN2VW/1NJY4L>O].45I<YKGUT%=60NGC8]%:U\+8N
M+N&=U7*WN=GEZ"Z>?N?6LNE9M=M.KM/:BL5HHJ*Q16I\%S69)'2,J*F57)N,
M<F[B9J<\Y1>&#MTIWN-7$P7NE^FZ^\] K9[7T;'S4]GK+365F[R9$ZBDA1Z_
MZR:-OYQF?<>=>V2[='B[:5AJ88[_ &>\3U%52;R=8Z&5K%CFQVIE'-SWL1.T
M]B+LRM=]V2P:#U/207>UR6F*UUT"Y5DK4C:QRMY*G%,HO!45$5,*A\W-?>Y#
MZ]TAJN2\;&]H-+!2;[GT[+G4S4-=3M7&&-GA8Y)/E?>^7%,H135G&0LT[E_[
MM+KRR5#-G6CH:J*HO])+4W&JA:]'/I87-8QB/[E>J.7';N9Y8,OJ?3%QTG[B
MQX%<FS1U4M'1UO5S(J*V.>^Q31<%[%9(Q?66VP?W(>YQ:SIM3;:=54=]CCF;
M426:V233K6.3"XJ*B5&+C/-K6JKN6\A[5Z6FQ2X[>^CIJK9Y8:JAM5?=6T:4
M\U;OI!&D-7#.J+N-54\6)6IA.:IYCJDHVC>XL]SR#[BE"Q-FVTJ3'CNN]*U?
M0D*JGTJ<E]VF3&V/0'\02?\ :'GM'H ]$C4?1+TCJRT:CO%LO,]VKHZJ%]K6
M3=8UL>XJ.WV-7/'L[#2NGUT#-7]++7>F;YIO4%EM%/:[:ZBDCNBS(Y[EE>_+
M=QCN&%3SG,RXEQ9Y3TMT:6__ #N>RK_JI:O^QQ'1]TU79-I&IT%LLT;I>LFB
MJ:NRV6BMLTT&>KD?# R-SFY1%W55N4RB<#:S.^XL5[$-T;I$'#I#=&Z1 !#=
M&Z1 !#=&Z1 !#=&Z1 !#=&Z1 !#=&Z1 !#=&Z1 !#=&Z1 !#=&Z1 !#=&Z1
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MGV&7V[#?C1Z43!BM2Z9M>K;/46F\44-PMU0B)-3S)EKD145/G1#@']WKL_\
M\EZA_P!EA_\ &()T]MG_ &6O4'^RP_\ C'>%/L(O'89JSDCOVFM+6K2-KCMM
MGMU/;*&/*M@IV(UN5YKYU[U7F99KD7LP>;/[OC9__DK4'^S0?^,/[O?9_P#Y
M*U#_ ++!_P",.%/L.K'85*RFCTIP'#O/-?\ =[;/O\E:A_V:'_QA_=[;/O\
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MY%4\31K5Z,8.[S(];(TCNAO:1/GV?<<B&Z-TB#@(;HW2( (;HW2( (;HW2(
M(;HW2( (;HW2( (;HW2( (;HW2( (;HW2( (;HW2( (;HW2( (;HW2( (;HW
M2( (;HW2( (;HW2( (;IIVU%,:?I_P#2F_S'FY&G;4O^C]/_ *4W^8\DMSC,
MAH#CI&@_UG](XV#=-?V?_P#1*@_UG](XV$X]SI#=&Z1!P$-T;I$ $-T;I$ $
M-T;I$ $-T;I$ $-T;I$ $-T;I$ $-T;I$ $-T;I$ $-T;I$ $-T;I$ $-T;I
M$'4#)T'['3U_2I<%O0?L=/7]*EP;H;&5[@ %AP
M
M
M                                      %I</@F?*^I2[+2X?!,^5]2
ME<^JSL=S'@ P&H
M
M  E=Y#O0<@D=Q<GH.P.\E_H4XU)Y7J**I]-T+JY^1-O#>*8,Q]58W39SSK_D
MQ_\ >-T-*V;_ .'>AG_>-U-E/JH^!Z1_U4P "P\T#YO.  >7>GUT07]*O9G0
M0V-U'1ZVLE1UULJJUZLC?%(J-F@D>B*J(K41Z81<.C:G!%54[1L*MFL+)LBT
MK;->NI9=6T-"RDN$]'.LT<SX\L27?<UJJY[6M<[*)ASE3L-Z!)R;5CEK  $3
MH     !A]8R7N/2=Z=IF*EGU$E'+[VQUTBQP+4[B]7UCD151N]C.$SC)Y6]S
M_P"A;=^C='JO5.NZJBNNO]03K&ZJHY72MAI<I(J;[FM5722+O.X8\2/SGL$$
MLS2L<MS'%>8 (G0
M
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M>@_8Z>OZ5+@W0V,KW  +#@
M
M
M                      +2X?!,^5]2EV6EP^"9\KZE*Y]5G8[F/ !@-0
M
M                                             !*[X-_H.+O7BX[0
M_P"#?Z#BN]P**I]1T'O/R)]Y"&\2H[ WN"F8^LL;MLVYU_HC_P"\;L:/LV=X
MU?Z(_P#O&\&RGU$?GO2/^IF  6'F@
M
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M@7%BIO)WC>3O*8"8L9>A_8Z?V[5+DM;=^Q6^OZ5+H]"&QD>X !8<
M
M
M                                                    !:7#X)GR
MOJ4NRTN'P3/E?4I7/JL['<QX ,!J
M
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MFMM@
M
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M?L;:7_UCD^A3T<<Q;?&9EZ'LL)%)=OS  ,1[0 !VX  . ?@N*15_!<4CC.H
M X=                                                      !J.
MT_\ Y@@_TEO\UYMQJ.T__F"#_26_S7DH[G'L7V@O^BM#_K/Z1QL!K^@O^BM#
M_K/Z1QL!Q[G>0 !P                                ! RUN_8K?7]*
MET6MN_8K?7]*ET>C#JHQO<  L.
M
M
M                           M+A\$SY7U*79:7#X)GROJ4KGU6=CN8\ &
M U
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MO$C"1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\
M1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>
M&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1
M!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&
M\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!
M#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\
M 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ 1!#>&\ >=NG/(J;,+##C#9+_3(J^AK_
M +3TI SJX8V)R:U$3U<#S/TY5_\ F:Z<_CZG_FN/33?(3T'HR_T\/%G@T?\
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M-X;P!'\%Q2*F\4SC.H  X=
M                !J.T_P#Y@@_TEO\ ->;<:CM/_P"8(/\ 26_S7DH[G'L7
MV@O^BM#_ *S^D<; :_H+_HK0_P"L_I'&P''N=Y  '
M              $#+6[]BM]?TJ71:V[]BM]?TJ71Z,.JC&]P "PX
M
M
M                                                    "TN'P3/E
M?4I=EI</@F?*^I2N?59V.YCP 8#4
M                                     "528E4 @
M                       #&7;3M%>71OJ(T<Z-<HJ<,IW+YOL,E'$D,:,:
MB(C4PB(F,$0+)$Y5)RBHMW2  !
M
M
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M28E.,Z@ #AT
M     &H[3_\ F"#_ $EO\UYMQ*L;9$PYJ.3SIDZG9@P.@O\ HK0_ZS^D<; 2
MM:C4PU$1/,3''N<6@  .@                               ! RUN_8K
M?7]*ET6MN_8K?7]*ET>C#JHQO<  L.
M
M
M                               M+A\$SY7U*79:7#X)GROJ4KGU6=CN
M8\ & U
M                E4F)5 (
M
M
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MG?@]XIV]W89L;A?9:F52NFDUIVE^%K\>&9JSV]"( //-8
M  0,M;OV*WU_2I=%K;OV*WU_2I='HPZJ,;W  +#@
M
M
M                                        +2X?!,^5]2EV6EP^"9\K
MZE*Y]5G8[F/ !@-0
M                         )5)B50"
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M6*2>S+X$7-5J\4Q\Q B2
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M(YHZ@ %18
M         ><^G)_>UT[_ !]3_P UYZ9;R3T'F;IQ_P![?3G\?4_\UYZ:;Y*>
M@]&7^GAXL\'#_P"OK>"  [S,>P<GZ3^RBLVQ['+WIRW31PW)ZQSTRRKACWQN
M1R,5>Q%QC/9D\.Q:ZVD:8N]NT16:%W]2.@Q! E4U5E:U%1'IA=W'BKV]F>![
M+Z96OKQLZV$7ZYV*I=1W"5T5*VHC7#XFR/1KG-7L=A5PO9G)XPM?1XH;S;:6
MZ5=_N\UUGA;,^J\(3B]S<Y3*9QE>]/.?.=(ZU5EWMKX'[O\ P(Y1Z.G+$N/"
M<GE33;4K*[T:TVTYGI[HU]'F_P"E-BFL+=J1\='?M6.GEEAC5KTIDDC5C4=A
M517<55<9[$XGEJ*[ZWZ.E!#I;4NB:ARQU#H*>MAE7JIU<Y51K'HU4<Y>.,<>
M]$P>@^B5M8U&W8!KR2Z5[KQ4:5FJHJ.>J<KGO8R+?:QZKQ5$5%PJ\<+CDAYV
MT[H"[;<[,W5>JM6W6LK*RHDE2/K,QQ8<J)NM7*-QCDB(B(4XAPX-/A)WMIJM
MN9Z?0<<3'I3'/I&<73S+-9/5V]W+9Z*V][^IZ'Z&^S/5Z[1M3[1]3V=^G8+C
M3MI*6AG3[ZJ9:N\K5XHB(U$XXRJJI[#W3QAT+=8ZCLVU/5NSFZWNJOUIHZ9M
M72S5SU?+$N6Y1%7*X5'IPSC+<IC)[/XHO%3V<!DX*R7Y^O,_*?XPX_\ -Y\>
MVRRY4[9;:;W>V]R(3M 3M/3AUD?#U.I(\R]#/X#:7_UDE_[QZ,/.?0P^^6_:
M-.WC%+J.56.[^"_:AZ,.XO[9F#HG_1Q\_F  8SV0
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MOK^E2Z/1AU48WN  6'
M
M
M                   6EP^"9\KZE+LM+A\$SY7U*5SZK.QW,> # :@
M
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M-<99D3  K)@
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M5.61E+2QS)++)$F_E9%[T5<)RYJ=!VD<.F_LQ3G_ ,DRI\TQJ$^@=L=VV[Z
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M$/1Z+GT>?F>+C'&T*:=W%:M&_"I^]*UDWLP #S#<
M                                        ><^G+_>UTY_']/\ S7'I
MEG)#S-TY?[VNG/X_I_YKCTRSDAZ,O]/#Q9X.'_U];P1$ &8]@\V>Z"_M=+K_
M *73?TR',-,?]&+;_H\?\U#IWN@G[7.Z_P"ETW](TYCIG_HO;?\ 1H_YJ'SN
M-^W?@C]T_A7_ &2/^<ODC%]&&9:;HX[=Y43+HYJYR9\U,83H^,ZO979^/%>L
M<OKD<9;HT_M:MO?\)7_]F,7L _O5V;T/_I'&/[E+P?S/HJ?^JZ0__P"D/_[#
M:>BI^VUUK_%+/_O9[F[SPST5?VVNM?XI9_\ >SW-WGM]'?8^;/R?^-O]V_\
M2/R 0!#U8[H_/JG59YEZ$_\ T7UQ_P!89OH/1AYSZ$__ $7UQ_UAF^@]&$\7
M]LS!T1_I(^?S  ,1[
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MP+.S7J@U#;8+A:ZZGN5!.BNBJJ65)(Y$RJ<'(O'"HJ>DO TUN=T>P !PZ
M     #E@"/F^HQ=BU59M3MJEL]VHKKX+)U51X'4-EZI_'Q7;J^*O#DIVSDKV
M.76QDP 1)                 '4#*4'[';_ &[5+HM:#]CM_MVJ71NAL97N
M  6'
M
M
M     6EP^"9\KZE+LM+A\$SY7U*5SZK.QW,> # :@
M                                                  2J3$J@$
M                !Z0 G]L<S4-I6U.Q;+;/X;=YU=/(BI34,.%FG<GQ4[$[
MW+]>"AM9VJVS9/IIUQK,5%=+EE%0M7==,].WS-3M7U=IX\L%AU/T@M<5-PN%
M4YS-Y%JZYS?$IV=D<;5[<<F^957O732I9]653GE6AE-8;=-?;7;BZUVEM30T
M<OBLM=IWMYS?RY$PY?7A"_TKT6KU<-V>^7"&TL<N5AA^_P J^E4\7/K4] Z-
MT19]!VMM#9:1L#,)OS.1%EF7XSW=OT)V&=-\8QCHC&VWN<XTUT?=%:>W7OM[
MKM,G'K;@_?3/R4PWU8.ATM+#0P,@IX8Z>%B8;%$U&M3T(G+V%0$R(
M                 (IGLSZB  ./;;MB#-8Q37RQPLBOK&YFIV)NMJVIW)V/
MQR^,:;L#Z0TVSN9-.:G6>2PH_<CE<BK+0.SA4QS5G/*<V^C)Z4;S.6[6=A5!
MK[K+E;G,MM^1OPF,15&.R1._N=S[R,HQFK,G&64]!T%=3W.CAJZ.HBJJ6=B/
MCFA<CF/;V*BIS0K'@W2>T'7/1^O<EOEADCI=[>EM5=EU/*G>QW)%_*9ZT/5N
MRS;QIG:C&R"EF=;KRC<R6RJ<B2+W[CN3T]GH0\ZI1E#7D:XS3.B@?^8,Y:
M                                                      =.  '
M  =  !P[X &$U-KC3NC'4Z7Z^4%F6HWEA\-G2+K-W&]NY[$RGM,E:KK17RW4
M]?;JJ*MH:AG60U$#D<Q[5[6JG/DI/)-14VM""E%NR>I<@ @3  .@  X  #IP
M  '0 #@
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M:T'[';_;M4NC=#8RO<  L.
M
M
M                       M+A\$SY7U*79:7#X)GROJ4KGU6=CN8\ & U
M
M        E4F)5 (                  BWS<5-<U]KVT[-]-U%YN\V["SQ8
MH68ZR=Z^2QC?/\R(JKP0P&U3;=I[971N;5R^'WAS<PVNG<G6+YWK^ WSKQY8
M/(]57:RZ1FMDDE7K-SQ6HU%2EH8L^?Z^+E^;13HN;N52FH[$'RZEZ1>T9\TS
ME8KE\96[RQ4-.B\$3/S=KESW'JS2>E[?HVPTUIM<*14L*<7<W2.7F]R]JK_;
MD6.S_0-MV>6".VT#=^15WZBJ<B(^=Z]JXY)W-[/:;(>BO=5D8VV]6  2(@
M                              &+U)I>U:NMKJ&\4,5;3+Y+9/*9YVN3
MBB^@\V;2NCY==&NDN^G)IKA;X5ZW=C\6JIL<<\.+D3O3"_.>IR*+A47ZP#CN
MP3I.R7*HI--ZQJ$=42.2.CN[\)OKV,FQPRO)')S7F>F>U?H[O[?4>-^D3LA@
MMK'ZKLT"0TSGXKZ9C=UK'.7"2M3\%,XWO.J*=?Z+NU=^N])/M%RF62]V=K6.
MD?Y4\')CU[U3&ZJ]O!>TP5J2C[T373G?0[2 #&:
M                                          #QQ[H9A:K0>4SXE;],
M)W[HV?WB-#_Q:S^<XX%[H5^R-!_(K?IA._=&S^\-H?\ BUG\YQ]/B?\ :Z7B
MSQ</_K:G@=( !\P>T
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M/.2+#&Z1LJQ-65J;K7N:F\B=V>[S>8\[?W06UC_X.R_[2\?W06UC_P"#LO\
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M5%.]'-7O1>U%\RX]"'BUL+4H/WEH?7X#I3#8^-Z4M>SFC)  RGK@
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MO]NU2Z-T-C*]P "PX
M
M
M                 03FI:7'X%/E?4I=IS4M+C\"GROJ4KGU62CUD8[*C*D
M8#61RHRI  $<J,J0 !'*C*D  1RHRI  $<J,J0 !'*C*D  1RHRI  $<J,J0
M !'*C*D  1RHRI  $<J,J0 !'*C*D  1RHRI  $<J,J0 !'*C*D  1RHRI
M$<J,J0 !'*C*D  1RHRI  $<J,J0 !'*C*D  1RHRI  $<J,J0    8  (@
M         $6\5[U]@!*^1D4;GR/;'&U%<][EPC6IQ557L0\P[9NE>L+I[-HB
M1JN3+)KTY,HGFA1?YZ^HP/25VYU.IKG4Z,T[.Y+5"](*N:FSO5DV<+&F/P$5
M4X?A+YC,['-@%-8(8+UJ6G94W5V'PT+T18Z7N5R?A/\ F3U'H4:&F:9EJ5.1
MS[9SL(O>T&I2]:@FJ*&VSOZU\TZJZJJL]J;W%$_*7U'IK3>F;9I&U16VTT<=
M'21_@LXJY>USG?A+YU,G]'9_;[ ;>5D97J  #@
M                !0KZ"GNM#4457&DM+41NBE8O:UR85#R1HZY56PO;6QM0
M]W@]+4NI*E>22TS^&][%:[U'K]O,\]=*G1G6);-301\.%%5JB>N-R^;FWTX.
M-9E8[%V=SUXUS7M1S'(]CDWD<B\%1>U/3]@.4=&?: FM]F=)!/+OW.T8HJAJ
MKQ5J)][=Z%;\[5.KGBR]UM'IP>9  $3H
M                               !XX]T)_9.A/D5OTPG?^C7_>%T/_%K
M/YSC@'NA/[)T)\BM^F$[_P!&O^\+H?\ BUG\YQ]3B?\ :Z7BSQ,-_K:G@=(
M!\L>V
M           !A5RB<%\W,Q^H-06S2MGJ;K>*Z&VVZF;ORU%0Y&L:GUJO<G,\
M0[<>E[>M?2RZ?T4VIM-GE585JH]Y*VMSPPW'%C5^*B[V.WL-V&PM3$/1:=IX
MG2'2M#HZ%YZRY+FSO6VKI8Z;V7NGMEJ1FHM2,3"TU/(B04[OWV1.W\E./?@\
MESU&TSI0:B<Z5TURBC?R^!H*)%\WD_SG+VF_['NB)47)L-UUQOT=,Y4DCL\3
MMV:1%X_?7)Y">9./'BIZIM%GH=/VV"WVVDAH:&%-V."!B-:U/0G;Y^T]R$:.
M%5H:R[3XN:QG2TL^)>2GRBCC6S+HH:9T@D-9?=W4EV3QL3-_6L;D^+'S=CO=
M[$.WQ1LAC;'&QL<;$PQC4PB)W(G!,>A"(*)U)5'>3/7P^%I8:.6G&P ! U@
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M^-[4<US5RUR+VHO:B]Z<%)SPK/9GW$6II-   D
M                                #S7T]O[TUIXX_P"5V?T3STH>:^GO
M_>EM'\;L_HGGK=%?ZRGXF'&_Z>?@9CH/JOZA4//_ )SJNWSM.^' N@__ 'BH
M?XSJOI:=]*^D?]74\3N#^PCX  'FFT
M   RE!^QV_V[5+HM:#]CM_MVJ71Z,.JC&]P "PX
M
M
M                                       03FI:7'X%/E?4I=IS4M+C
M\"GROJ4KGU62CUD8T & U@
M                                !@ AO#>(@B"&\-X B"&\-X B"&\-
MX CZ3EW2-VE.V>;/*E:67J[O<U=24JIS9E%5\GJ;GUJAU%JYX(F5Y(F3Q%TD
M]63;0]KGO/;G=?3VYS;;3-;Q1TRN^^.3\["?FE]&#E/4KJ2RHR/1DV=,N-=+
MJRX1;T-*]8J-LOX4WX<B_)3EWJ>E$SQRG'M_K\YB=):<@TCIJVV>F3$=)"UB
MKCRG<W*OI7*^LRQZQY^X  .
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MO#> (@AO#> (@AO#> (@AO#> (@AO#> (@AO#> (@AO#> (@AO#> (@AO#>
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M[#JBKE1%FJ'I^$]?H1."?3M1ZLZR2X=)6B>!A, \_M.*>:;^ X=@ ,I[H
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M?HG_ %E/Q,.._P!-/P,QT'_[Q4/\9U7TM.^G NA!_>*@_C.J^EIWS>*ND?\
M5U/$E@_]/'P(@AO#>/--A$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X
M;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!$$-X;P!E:#]CM_MVJ71:V_P#8J>OZ
M5+H]&'51C>X !8<
M
M
M               ()S4M+C\"GROJ4NTYJ6EQ^!3Y7U*5SZK)1ZR,: # :P
M
M       04B04 @          054:U5541$3*JJX^?L](!J.UC7L6SC0=TO3G
M)X4UG54D:KY<[D5&)ZEXKYFJ>4NC3I&34.M*G4-8CI8+:BR)(Y/A*E^<+ZLJ
MY2&W[:9/M=UW3V>R(ZJM-'+X-11L_P *F<NZZ7U\D\R><] [-]$0;/\ 2-':
M(U:^=J+)4RHGPDR^4OH3DGF0].C#+&YAJRS.QLP -!0
M                               ./9S/+W2,V:_<Q>(]36IBPT-;+]^;
M%P2"HY[R+V([&<]Z*>H3":VTU#J[2=VM,S47PB!R,<J>3(G%CD]#D0 NM@6T
MI=I>@(*NI?F[43O!:U.2N>B)NOQ^4W"^G)T<\:=#_44MGVDUMFD7=BN5(]KH
M\\$EB7>3UX5Q[+/*JQR2L>E3EFB  4DP
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M.  \TV
M   $$Y?8:7M<VL6?9!I*>\W5W6S.^]T="QR))4S8X-:G<G:[L1%,YK#5UKT-
MINOO]YJ4I;?1Q]8]_-SE[&M3M<JX1$[U/GG?KUJKI4;6&I$Q8V29934[E58;
M?2HO%SO/VK\9<>8]/!83C2S2ZJ/F.F>E/8X*C0UJ2V780LUFU=TI-IU36UT[
MD1[D=55:)]XH(<^+&Q%Y>9O;Q5>U5]KZ*T7:- :?I[-9:5M-20IE7<%?*[M>
M]WX3E_J["AL^T#:MF^F:>RVF/$4?C2SN3[Y4283>D?YU^C!L9ZE2KF]V.R/
MP&"X*=:J\U26[_(  S'L@                                      #
MGE/IY>L\_=)G8$FL*.HU5I^F_P"7:=F]5TL:*JUD:)Q<F/W1$X_E(F.P] A%
MW..<8[>XLIU)4I71CQ.%IXJDZ<T>9>A[TB'6^HIM ZEJ5\%D7<M%9.[X)_\
MB[E^*JYW%[%X'LW&ZN.[@>#>E3L4^YRO=K6Q0=5;JF5%KX84QX-,J^+*U.QK
ME1/0Y?.=]Z*6W7]532CK5=I][5%IC:V9SN=5#R;-Z>37>?CVE6-P\9KC4EIS
M(]"=(5*-3^7XI^\NJ^U=AW4 'A'W8
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MWU_2I=%K;OV*WU_2I=&Z&QC>X !8<
M
M
M                             ()S4M+C\"GROJ4NTYJ6EQ^!3Y7U*5SZ
MK)1ZR,: # :P
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M#J5%\\[$7Z2,=QHY'8;6TKU[FSL5?I +@$6M5S<HF\G>G(@
M               ":/&^W/%,XP2C../8G$ \G;.'+8NDM01M\5$O4T'J>KT3
M^<>YSPM$[P#I0PNSN[FHVX<[L\=/M/=*\.'J//Q.YMH[  &.YH  %P  +@
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MP%&>(J2QV)ZTMNY!,)R !C/H
M         "VN5MI;S;ZJ@KH&U-'51NAFA=R<U4PJ?V[<'A34%LO?1BVQTU5;
MWO?%3/2HHI'<&U=*Y<.C=ZLM=W*F>X]Z>8YATAMEC=I^@9VTK/\ ENW(ZJH7
M(F'.7'C19[G)\^#50J*,G"6S/$Z2PLJL%6I/WX:IG9]&:OM^O-+6W4%JDZRB
MKXDE9GFU?PF.[G-7**G>GG,V>(NA'M;=8=25.A+E)U=#='K/0))^XU*)X\?Y
MZ(OYS4[SVZ>'BZ#H56N3/K^B<?''X:-3GLUV,  Q7/9  %P  +@  7   N
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M!EK=^Q6^OZ5+HM;=^Q6^OZ5+H]"&QC>X !8<
M
M
M                                    ()S4M+C\"GROJ4NTYJ6EQ^!3
MY7U*5SZK)1ZR,: # :P
M                            04B04,$  1    'T@ ' ^F/J!]MV>VVU
MQN5JW*N3?1%\ID;=['Z2M7U&+Z,FGV6S9VZXJU$J+E4OD5V.*L:NZSZ'+ZS%
M]-F9W7Z0BSXG5U$GKRQ/HR;[L<A;3[+=,L;R\$1WM<JK\ZJ>K05H&&L[R-Q
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MIMDVJ$UCLWT]=M[>DFI&LE7/[HSQ'_.TPXI;,UT&;8 # :@
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MN%'1P6^D@I*6)L%-!&V**)B>*QK4PB)YD1$*P!7KS/5C%1M%;(  Z3
M                                        ;P5%Y<>8'S 'B+I+Z&J-
MFFT^#4-HS1TURE2X4LL7!(:IKD=(U/SL.3S./<6R7:!!M/V?V?4<&ZU]5%NU
M$35^"G;XLC?1O)P\QS3I [/DVA[,;K1Q1[UQHVK74?#QNL8BJK4]+=Y/2J')
M>@CM'6BU!=]%U4F[#<&>'437<DF:F)&IW;S<+^:I=B8^T8?-SB>'@*CZ-Z2=
M%]2IKYGM,!.WZ_3_ .0/F3])\
M  ?.S:HU+YTOZR"I\=DFH:6%4[V-=&U$]:(?1,^=^N?VY-1_UFI_YT9]/T'U
MJG^+/&Z3ZM/Q/HE)PD<G<JIR\Y*32_".]*_22GS+ZQZ\=@ #A(
M     $8O+;Z2!&+RV^DE#K(2ZI\[MA7[;JB_CFX?S9SZ('SOV%?MNJ+^.;A_
M-G/H@?2=.?:4_P#%'B]&=2?BP #YD]H                    (&6MW[%;Z
M_I4NBUMW[%;Z_I4NCT8=5&-[@ %AP
M
M
M                             %I<?@6_*^I2[+2X_ M^5]2E<^JSL=S&
M  P&H
M              $%(D%#!  $20    !Q@\L=-EJ^':17"XZJH3/YS#H>R!R.
MV8:95%RG@3./K4T'ILR)UFD6JOC8J%QYO$-YV,-5FRO3**F/UHBI^DX]:A]F
MCSZO6-S !H*@      13NYD._GYL',MN.TF71]GAM-I?O:@NB+' C%XPQ\G2
M>E?);W<5[ #6]L.UBMN%RET=I*;%2N6W"XQK\$G:QCOI=ZC3]/Z>I-/TJ14[
M=Z1W&29W%SU\Z]W<G]9+IG3T6GK>D2*DE3)X\\V.+G<<IZ$_K,L19,  X
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MMAO(B.[^W]NT'DF\
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M9_,W6G^!C^2GT$Y)#\&SL7=3/L)SYB769^@TNHO!  $28
M                           #45RHB<U^;S@TC;7K'[A-E&J+VU^Y/#1O
MCIUSA>M>FXS'K<B^HLI1<YJ*YF?$551I2J2V2N>&MIMQGV]=(RII:1ZOIJFO
M;;*5>:,IHUW7.3S<'N]9[BHJ."VT=/1TS$BIJ>-L,3$3DQJ8:GL/(70MTG[Y
M:RO%_F9O16RF2&-SOQTBKE?4UKO:>Q/[?/\ ^1]3B+1RTH[)'YST1&515,5/
MK3?P  ,1]"
M 11<*B\U[$7D>#]H%+/L(Z0:W&@8K*>EK8[I2MY;T#URYGHQUC3W>>9^FOI!
MM19K#J6-BJZEE6@G=C\!_C,SZ'(J>LU862NX/F>%TO2;HJM#K0=SV'05\%VH
M::NI7I)2U43)HGHOE-<F47V*7!Q3H?:R75NQ*V02R=956>1]NE5>>ZWQH\_F
MN1/4=K/FZU-TJC@^1][@<0L3AX5%S5P "DV@
M       T74&W/9_I.\U-IO&JZ"W7*F5&S4LSG;[%5$5,X;W*A;3ISJNT(W(3
MG&'7E8WH^=^N?VY-1_UFI_YT9[&_NE=EO^?%K_2?_P )XCU?JRS5W2BFU'3W
M&*6Q+?X*I*YN>KZEKF*KN7),*I]3T+AJU-U<\6O=?)GA](5:4E#+);]I]*)?
MA'>E?I)3FSNDKLM5RK]W%KXKE?&?]A>67;WL\U#=:2V6O5]NK;C5R)%!3QJ]
M72/7DB<$/G)X7$1;O!V[;,]:%>EHLR]3?00]'(B9.XU:<@  <
M !&+RV^DYY<.D'LWM%PJ:&MUE;::LIY70S0/<[>C>U<*U?%[%RA09TE=EC5R
MNN;7CY3_ /A-D,)B':61M>#,T\122:S+U/'&PK]MU1?QS</YLY]$#YL[(=66
MBP])>DU!<;C#269EUK)G5TBKU;6/;-NNY<EWF]A[<_ND]EJ__7O:\?*=[/)/
MH>F,/6J3@X1;]U;(\KHZK3IQDI26[YG2@:5I?;5H76EZCM-BU/0W6YRL<]E+
M3JY7JUJ9<J91.294W7V>H^6G3G3=IJWB>Y"49ZQ:8 !62
M  "!EK=^Q6^OZ5+HM;=^Q6^OZ5+H]&'51C>X !8<
M
M
M                                        )?PBVN/P+?E?4I<_A%M<
M?@6_*^I2NIU62AUD8P 'G&L
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MKM!LLI[H]BIR^@#O]*@\<]+D  #@
M          ,7J6S^_P!8ZNC3"2/9F-5Y(Y.*&4!V,G%IHKJ052#A+9FG:*U
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M:R_1<_VY?VX@ \<^G6FBV
M      ">?D>8^GGJ9:#9_8K$QWCW*X=:].U61-SA?-O/:>G#PIT\;\M9M,LU
MKC7>2W6M';G:CY'JN/8UAZ?1L,U==USYG^(ZSHX"5OO:>IU#HCZ=2S;(H*US
M=V:ZU4M4JKS5J+N-^9IV@U_9Y9&Z;T'IVV-3'@UOAC7T[B*OSJOM-@/1J2S2
M;/,P=-4L/""Y)  %9L
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M_P"1=]@_5+T]_CK_ .1=]AZ?\VZ1[_1&+A='?B7J>4O_ $?%[_SVMG^P2_\
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M#?C7J;,"SMEXH;Q&KZ*JCJ6ISW'<4]1>%+3B[/0UQE&:S1=UW  '"0
M     0,M;OV*WU_2I=%K;OV*WU_2I='HPZJ,;W  +#@
M
M
M                                          !+^$6UQ^!;\KZE+G\(
MMKC\"WY7U*5U.JR4.LC&  \XU@
M                                   @I$@H!       BWRD3SD"+?*3
MTA \)T3O?[I+O<_QNLU!*_U,>Y4^9IZV7RG=^<*>2(?_ %;Z2TJ2Y:D=_D;Q
MYXD<Y&_ST/6Z^4I[4.JCS);D  3(@   (F]E 3,QO)O>3G*@'FG:%<%U+MMK
MUSO4]EIVP,^4J97YW.*YK>E*AUUO&IKM)Q?5W"1=[\Y5^M#9"+)@ '
M             "A74J5M#4T[N4L;F>U"N1;Q<B+P3/, WGHTW1U?LQAIWKX]
M#52T^.YN4<G\Y?8=3.)]%Z7J[?JRDSPCN2.1.[+53ZCMA,BP  <
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M&G'6.J/9PO2]"O[LGE9V<#GA47**F45.U.\&37F>XGS6H !TZ
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M2Z+6W?L5OK^E2Z/1AU48WN  6'
M
M
M                          ""<U+.Z? )\KZE+Q.:EG=/@$^5]2E<^JR4
M>LC&  P&L
M                    ,  $0      >,.EGI:?3>T^"^TZ=7%=(65#'MX;L
M\6$<GIX-7UG?]$ZGBUCI.UWB%4Q50HY[<^3(G![5]"HI-TBMGJ[0=FU<RGCW
M[G;LUM+\95:B[[$]+<^O!PCHLZX\'KJS2]3)]ZJ,U=)GEOHGWQB>E$1?4IZM
M&>:%C#5C9GH\$>[CGM(&@H   !1KGK'0U3TYMA>J?HJ5BC5QK+153$YNB>WV
MM4 \G;-/&TWUB\Y)WO7YC:C5=FOB:=DB7G#4/8OS&U$63  .
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M-*W<W]##Z(UE;=H.E;?J"T]<MMKFJ^'PB-8Y,(Y6KEO9Q13B7337.G-#*O\
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MV@WZ1G%C8FQJOG14X?,8Z\<BFN5CVL-6X_ D][ZKO6YNP /GS[(
M  (&6MW[%;Z_I4NBUMW[%;Z_I4NCT8=5&-[@ %AP
M
M
M                                        E_"+2Z? -^5]2EW^$6ET
M^ ;\KZE*ZG59*'61C  ><:P
M                                2KS4F)5 &\-X@ 3([PWB  ([PWB
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M*7N3['S\&>-B^B:N'CQ8//#M7+Q7(W;>&\01>[MX]P/K3Q+$=X;Q  $=X;Q
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M%=SDI\X8OYJ^+Z,=YDQ-/,LZ/INA<8X2>'F].7T.W@ \T^R
M     /(W3@J,ZFTK"F,MH9GKCGE9$3ZCUKL1IUH]C^BXESE+33NX^=B+]9XP
MZ:%>E1M-HJ=%RE-:X\IYWO>J_-@]UZ*M_O3HS3]#C'@UOIX?T8VH=Z0TP\(G
MF] K-TEB9=ED9G>&\0!\\?H1'>&\0 !'>&\0 !'>&\0 !'>&\0 !'>".7T$
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M1:6W]B,]?TJ79Z,.JC"]P "PB
M
M
M                         2_A%I=/@&_*^I2[_"+2Z? -^5]2E=3JLE#K
M(Q@ /.-8
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MI?>ZZZMK6*VJNTJQP;W9"U>*IYE=_,0'&=H<JN<JKWD "9$
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M[1T-TQ2Z4HWCI-=9=_=W'Q>/P$\%.Z>:#V?U[RX !]$>6
M                        ./8> ^FW;'6?;>EQ8W'AEOIZIOG<Q59]+#WX
MG-/KY'D+I^V'+-'7UK55$Z^A>[MX[KVY]CCU>C)6KI=MSY+^):7$P$IK[K3.
M_P!BN+;Q8[;7L=O,JJ6*='=ZN:BK\Y?'-NCC??N@V,Z:E5^_)30NHG^98G*U
M/]W!TDW5%EDT8L-/B482[4@ "!J     3O7LX@'FWI=WU]RKM)Z+@?AE5,M=
M58^(W+69\WEKZC2V-;&UK&)NM:B-1.Y$X(A':7<%U%TA=23JN_':J>.B9YE1
MJ(OSJX<?.>W3CE@HGYIC:O&Q$Y^2\@ "1B                  !C+)J)=F
MNU?3^IFKNT-4_P !K\>2Z-_!7+ZMU?S3)F"UM;??33-;$B9>QO6LQSRWB=23
M65\R4)2A)5([K4]Q>A=Y.QW?S!H^Q#5*ZQV4Z;N3W;\ZTJ03.S^Z1^(N?9GU
MF\'ARBXR:/T^A456G&HN:  (EX            '_ ) @LC(6.ED7$<:;SE7E
MA.82OH1;M&[/#&V]SM9=).JM\7C;UPH[<C?1N-7YU4^C"1MBPQJ8:Q-UJ>9.
M'U'SNV#4[MH72?MU>]-]BW*HNK_,UF\]N/7N^P^B/>OGQR_MWD.DY:QAW&;^
M%X9N-7?WI:>0 !X1]V
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M"]P "PB
M
M
M       2_A%I=/@&_*^I2[_"+2Z? -^5]2E=3JLE#K(Q@ /.-8
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ME1,)5M3M^7CG\;@<\TYJ6#4$+D1JP5<7BS4\G!S53@OJ_P#)3C)F7 !$
M         #V^HP-ZOT\E=#9;+"ZNOE4Y(XXX4WMQ5[5\Z( 2U%MJ=H.JZ+2-
MM<Y(]Y):Z=O*.-O%R+Z.SSJAZEM]NI[1;Z:AHXDAI::-L,3$Y(UJ81/I]?I-
M/V2[,(=G%CD;*YE3>:Q4EK*IO'+N/B-7XK?G557N-X)D6  #@
M  +"_P!XCT_8KC=)E1(Z.!\ZYY+NIG'K4 \R=(C54^KM?PZ>H-Z>"W/2FCBC
M7*R5$BHCO7E4;ZCUELMT!3[-M$V^R0HUTT;>LJIFI\),Y/&7T)R3S(AY1Z,>
MG)-:[8??>M19F6])+G,YW;*YRHS_ 'ESZCVR>?B)_<1MHQLK@ &(U7   N
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MF\N#=C^@<'6>)P\*K5KI,_/,135&K.FG>S  -A1<  "X  %P  +@  7   N
M !<  "X  %P  +@  7   N  !<?2<5Z86F%U'L+NTS&;\UIFBN#,<]UKMUV/
MS7N.U%AJ"RPZCL-SM-0B+!74TE,_*<,/:K?K+L/4X=6,NQF#'4?:,-4I/FF>
M2^A-J3PC3NH[ Y_C4E2VLB;^1(W==C\YG^\>D_,>'.C7=IMGVW)EFKLP^$NF
ML]0UR\I&JNXOZ3/G/<:9XY[CZ7$Q]_-VGP70U2^&X;WBVF  9#W0   31-WI
M&(G!55/I)2>G^&C^4GTB.Y&759X9M54MTUSKFXJN\L]UE\;T/<9XUC1?_.>J
MOXUF_GN-G/=?(_*IZR?BP  <                  !!T:3,=&J91Z*U4\R\
MR(;S"%KZ'1^AK<'.T-?[4]V5MUT<C4\SVHO_ '5]IWX\U]$.;J]2;1*1%PG7
M0S;OI5Z'I0\O$JU1GZ#T5//A(@ &8]<            &C[;M4II'93J6XH_<
MG6E=3PX7BLDGB)CS^-GU&\)VGF?IKZL\'L]ATU$_#ZF5:^9J?$9XK/:Y57U%
M]".:HD>=TA5X.&G+G8M>@+I3KM2:HU"]N8Z&ECH(W8X(YZ[SL>?=:GM/::>C
M^W]L'%>B#HQ=);$[7-+'U=5=Y'W&3>3QMUV$CS^:U%]9VD\?'5%4K2:/?Z!H
M>S8&":U>K\6  8#Z&X  %P  +@  7   N  !<  "X  %P  +@  7   N  !<
M  "X  %P  +@  7   N  !<  "X  %P3P?"L])(31_")Z4)1ZR(R>A\[]AG[
M;F@_CJX?S)SZ''SQV%?MN:'^.;A_,G/H<?1=.?:4_P#%'C=&=6?^3  /FSV[
M@  7   N  !<  "X  %P  +@ !"YF+;^Q&>OZ5+LM+;^Q&>OZ5+L]&'51B>X
M !81
M
M
M    )?PBTNGP#?E?4I=_A%I=/@&_*^I2NIU62AUD8P 'G&L
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MY:B^A7*X[V8O2VGJ?26G+;9:1,4U#3M@9PYXYN7SJN5]9E#QYRS2;/2BK1
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MU)2QT5+'!"Q(X8F(QC&IA$1.Q/,5@#]@@E!**1\*VY:OF  2.
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MNV?I<(*$5%  $28
M            )H_A$]*$I-'\(GI0E'K(B]CYW["OVW-#_'-P_F3GT./GCL*_
M;<T/\<W#^9.?0X^BZ<^TI_XH\?HSJ3_R8 !\V>T                    $
M#,6[]B,]?TJ79:6[]B,]?TJ79Z,.JC&]P "PX
M
M
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M^,Y.X]L]G+B9^D:RNJ,-EOXC^'L).6?'UNM/;N0 !XA]L
M                                             ":/X1/2A*31_")Z
M4)1ZR(O8^=^PK]MS0_QS</YDY]#CYX["OVW-#_'-P_F3GT./HNG/M*?^*/'Z
M,ZD_%@ 'S9[0                    0,Q;OV(SU_2I=EI;OV(SU_2I=GHP
MZJ,;W  +#@
M
M
M         !#M+*Z_L=OR_J4O>TLKK^QV_+^I2NIU62AUD8H 'G&X
M
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MV7:(UE*B^]MZW>-%,_._CFL;UX/3S<S:FFKIF5IQW.@@CW^U"!TX
M                      "2::.G@?--(R**-JO?)(N&M1$RJKYB?^W/!YWZ
M2&U='.?I&U3IN(N;C-&N$SP5(4\W)7>P U/:EM)N>UW5$%AL4<\MKZY(J2EC
M3QZJ3..L?YNY%X(G%3TAL/V#6_9?0LKJUL==J>5GWVHQEE/GFR)%Y>=R\5QW
M&!Z,6Q;[B[*S4MWI\7VOC^\1R-PZD@7Z'O3BO<F$[SNJ>C^W=]!YM:MF>6)N
MI4[*XX)P3T( #(7@
M       %I=KQ0V&WS5]RK:>WT4*9DJJJ1&1QIG&7*O!.*FL_JS[/_P#/?3__
M ,DH?J4NA1J5-8QN5NI"+U=C<0:=^K/L_P#\^-/_ /R2B_XA^K/L_P#\^-/_
M /R2B_XB?LU;\#]&1XU/\2]3<0:=^K/L^[=<:?3_ /*,7_$9^PZFM&J:1]79
M+I1W:E8]8W34,[96->G-N6KP5,IP\Y"5&I!7E%KR)QJ1EHI+U,D "DF
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MXM7*)QRBIE..4X\L8X8/OE0E02BXY4M-CYA554;EFNV  1)
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MAH(6PQ][\<WJO:JKE57O53,#L!\K*3DVWS/TNE3C3A&,=EI8  X6
M                                                     F8Y&N15
MY)Q7)* M ]K'AO8YLHUE9^D[1WFOTS<J2TMNU;*ZNEA5(VM<V9&N5W<N4/<B
M=Z?V\WTD45>_*$#?B\9+&24I*UE8S8?#QPZ:B]P # :0
M    @9BW?L1GK^E2[+2W?L1GK^E2[/1AU48WN  6'
M
M
M                                         "':65U_8[?E_4I>]I97
M7]CM^7]2E=3JLE#K(Q0 /,N;@ !<  "X  %P  +@  7   N  !<  "X  %P
M +@  7   N  !<  "X  %P  +@  7   N  !<  "X  %P  +@  7   N<8 !
M(B                  8^_:?MFJ+7-;KO10W"AF3#X9FY3TIVHJ=Z'D+;5T
M>*[9M([4.FY:BKL4;TD<J.7KZ!<\'*Y.;?RN:<,^?V:2R1LFC<R1K7L<BM<Q
MS=Y'(O!45%X8QGF64ZCILA."D>:-B6W1FK.HL5_E;%>D3=@JUPC:K'8O<_T<
M%XJ=GX]O!>U%/.^WSHY3:7FFU+I*G>ZT9ZVHH857?HUSG?9VJS/K;E.PK[(>
MD7#)#3VC5L^X]J(R"ZN\ER<D;+Y_RNW!ZL9*:NC!*#BST "6"9E1"R6*1LT+
MTWF2,7+7)WHJ<,$Q80                      !1KJZFMM.^>LJ8:2!J>-
M+-(C&IZU *Q%,KP1,G+]3=(O1VG]YE-4R7JI;^YT+/$S\M>'L./ZKZ0NJ]92
MK;;+"MIBF\1L-"BRU,N>S>1,^IJ>L#P.J;:=MM/HREFL]FF;4:AD;NN>SQFT
MB+S5V.;^YJ&F]&?8G+K*[1ZMOT3GV>GEWZ=DR*JULR+G?\[47FO:N$+[9%T5
M*^[54=VULQ]%0;W6-M>]]_G_ (545=Q%[4YK[3U;1TL-#2Q4U-"RGIH6)'%%
M&U&M8U."-1$Y(AAKUE:T373IO=E5';W'A_;^W]L  P=YJ
M                                       -,VR:%JMI.S.^Z9HJB&DJ
MKA&UD<U1G<:J/:[*X\S5/)Z= '5O#_UELO\ )R_8>XP>GA>D:V$ADILQ5L'3
MKRSR1\[]JG1+O^R?1=5J6X7JVUU-3RQQ+#3,>CU5[T:BIO)CAG/J,7L6Z--Y
MVV6&XW2UW6WVZ*CJO!7,JVO5SG;C7;R;O#DJ)ZCU=TU:Z*EV$7".1^[)4UU+
M'$WO<C]['L:IKG0%IY(]F6HY7-Q%)>,,=W[L$:+\Y]3'I'$/H]XAOWLUMN1X
M<L)3]K5)+W;7.:_W .K=UW_K+9>7XN7[#T?T<=D-PV+Z(K;'<JVEKYYJY]4V
M2D1R-1JM:B)XR9SP4ZH#YG$=)XC%4W"HU:_8CVZ.!I499X+X@ 'DFX
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M/=:UN4Y<$QV\?_(F!\IBL=5Q=N([V[CW:&%IT+Y%\0 #SC6
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M;(XV-CC8FXR-J(B-:B(B(GF0F/G,1B)5YW9]QT;T?3Z/HJE#Q?>P #,>J
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M4DY16B(RE&+2;U-U ! D     $#,6[]B,]?TJ79:6[]B,]?TJ79Z,.JC&]P
M"PX
M
M
M   2_A%G=?V.WY?U*7GX19W7]CM^7]2E=3JLE#K(Q0 /.-8
M
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M5GI;>OX4S6*Z5WG5ZY5?:;"#&ZLI;LT1A&( !"Y(  7   N  !<  "X  %P
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MM^C.BZ71U++'63W?-@ &2Y[(  N  !<  "X  %P  +@  7   N  !<  "X
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M\FJ(J5K^K@@A8YZ+)*_L3>7'-/3V+O?16CO\'28VI1ZHJJ6MO_@T'ATU"F[
MZ3?;P8F$X(BHGI,AT(Z6E;6[5JIK6^&K?G1O?CQNK1TBM3T9WO8:G"EAE52C
M=63YV_X*5*I5E"\K.[-ET!TE+P[7]+H?:5I%VB[]7)^L)HY>LIJEV5PU'<>*
MJF$5KE3..6<'>_[9/,G3C:R&W[-ZRGX7>+4+$I'?AX5&KCT;R-^8].+G>7/E
M=N3Q\3"#IQJPC;->Z\.P]"A*2E*$G>UOB0 !Y=S:  =3!F+=^Q&>OZ5+LM+=
M^Q&>OZ5+L]*'51C>X !8<
M
M
M                     )?PBSNO[';\OZE+S\(L[K^QV_+^I2NIU62AUD8H
M 'G&L
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M(X47^#;S_.53LM/3PT5.RGIX8Z>GC3#(8F(QC$[D1.'S%0%,IREJV6126R
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M2S3=S[S#82C@Z:IT8V0 !2:@
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M=^Q&>OZ5+LM+=^Q&>OZ5+L].GU48WN  6G
M
M
M                                  "7\(L[K^QV_+^I2\_"+.Z_L=OR
M_J4KJ=5DH=9&* !YMS6  +@  7   N  !<  "X  %P  +@  7   N  !<  "
MX  %P  +@  7   N  !<  "X  %P  +@  7   N  !<  "X  .7  !P
M
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M>?C</*O%1AR9TJ#X&/Y"?0A.$1&M1$RB-3"=O!. /+D[S;6QNC=*P ! Z
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M7=;CCV(JGM[1FP#9[H16/M>F*-:EJY\*K/UQ+GOWGYQZL'04X(C4X(U."?\
MEP,\NDJ=/2C#U-=/^'L5B/>QM5M=B/)^SKH'T%(Z*IUK>G5SDXK;[6BQ1)YG
M2+XR_FHT]+:2T78]#6U*#3]II;32)S931HBN\[G<W+YU53- \BKBJU9WE+R/
MJ<'T7A,"K4H:]OZ@ &0]8
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MS3CHT6II[  $3H     !F+=^Q&>OZ5+LM+=^Q&>OZ5+L].GU48WN  6G
M
M
M                                                         6-U
M_8[?E_4I?%C=?V.WY?U*53ZK)0ZR,4 #S#6
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MPWB4 6)MX;Q* +&:MG[#;Z_I4O"TMW[$9Z_I4NSTZ?51A>X !:<
M
M
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M^T[T-_I-@_I6EJIIM>!7F=CZY*U&.<U.Q<=O9_;U$"I+\(_Y2_24S)X&@
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M3"MPJINY^-P(G40!%S5:N%147SH'-PW>X(G>J@Z0!/U+USAKE1.Y,DJ^P @
M15JL1-[Q,\N/, @"*L5N-Y,9XIO#=5&[WDM[\X ( CNJF%QP[//ZSY^^Z>]*
M?:=T>=6:"H]G^I?>&FNE#4S5;? X)^M>R5J-7,K'*W@J\E0G".=V(MY3Z @\
MA]/W;WKG8ET9=*:LT7>_>>_UM=1P5%7X+#-OLDIGO>FY(QS4RY$7@AUCH<[0
M+_M3Z-&A-5ZHK_?._P!RI9)*NJZMD?6.29[47=8B(GBM3DB<@X-+,,ROE.R
M @2                                             !%%5N53GV$
M8*PZ"TWI:ONM=9K)1VZLN;E?734L:L?4KE557]Z\7>TCI+06G="0U,&G+-1V
M:*JD22?P.-&]:_&-YW>O'YS. LXDVK9F0R16MC ZCT#IO6-;;JR^6.ANE5;G
M=91SU$>\^G7*+ECNSBU%,A?+#;=36^2AN]OIKI1/7+J>LB;(Q5[\+Z>:<2^
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M$9Z_I4NRTMW[$9Z_I4NSTZ?51@>X !:<
M
M
M                                !87C]CL^7]2E^6%X_8[/E_4I5/JL
ME#K(Q  /,-P
M                                  !XW]UF_:?U_P#'E!],AIG0R_\
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M'*G6)(U$WL=W#(4U=> RNQ[$E^$?\I?I*9,KNL<YW>N?1G^WKP2F,T@
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M"OYEB=]0            4*[_ )OJ_P" D_F*5RA7?\WU?\!)_,4['<'R-]R
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MG[N]EJ*J._Y,K.*?PS#JMG3'W3KGNJO[3#0_\9V[_L;SN_N>W[3;9C_H,O\
MVB0X1[JI^TOT/_&=N_['(=W]SV_:;;,?]!E_[1(9Y=3S)PZQZ& !G+P
M
M                        #-V[]B,]?TJ79:6[]B,]?TJ79Z=/JHP/<  M
M.
M
M
M  L+Q^QV?+^I2_+"\?L=GR_J4JGU62AUD8@ 'F&X
M
M        $6MWG(G>N  C5W<HG#/,<.P\U='J^3;?=M.O]JLT\S],Z?JIM':3
MI$>J1;D:HM96*U%PKI7JUJ.5,HQN"_V@=./06B-97/2]LLNK=H%VM#E9=FZ-
MLSJ^*W.3FDS\M1%3CE$SC"HO'@3R.^A'-VGH4&F[(]K^E-MNC8=3Z.NB7*U2
M2.@?O,6.:"9N-^*5CO&8],IP5.2HO:9#:-M&T]LHT7=-6:KN<5GL-NCZRHJI
M<KC*HC6M:B9<YRJB(U.*JN"-GL=NK7-B!Y.K?=*]E]FL59=;UIS7&G:1L/A%
MM6[V+P9MX;O(GZU>Y^ZY<*CL.<WQ47N4]3V>Y17JTT-Q@1R4]93QU$:2(B.W
M7L1R91%7"X5,\_2=RN*U1S,BZ.>[>MA]AZ0^S2NT-J2KKZ*TUL\,[Y;;(QDR
M.B>CVX5S7)S3M0Z$31^6STH<6^A(YQT>NCY8NC=LXAT7I>:YUMICJ9:MLUT>
MV2;?D5%<F6,8F$PF.'K4Z.L;V>4U4]**A\[>C1T9]'](G5^WB[:UJ=05%;:]
MH5SM]-X!>ZBF8R'K%>C48Q<<%5>SEZ#8]J6D;KT -2:0UWHK5-_NFR^Y7>*S
MZDTI?J]U9%3MFSNU,#W95JIAWGRB)E45<72@K[ZE"DTMCW<W*\$YDRPR-3*L
M=CO5#R5TC=H6L=J/2%T_T>]GNI)]'PSVQU]U1J:@_94%%E49# [\%SLM\9,+
ME[,<$5%EU/T +5I[3]5=-F>N]<:;VB4D;IZ*\5-^DJ&U<[4RC:B-WBN8]>"X
M1.>5RB*A'(EN3S=AZT!I^QRX:TN>S'3U1M$M=/9];+3(VZTM)*R2+KFJK=]J
MM541'HB.W47#5<J=AN']N62K8F@#BNV'I>:!V':^I='ZI]]F7:LM?OE2)0T?
MA*569>J;3Q-:JO?,YV<-1N,(JJY,&H63W0S997PWR"Z4FJ-*:CM;HF)I2]V5
M\5VJW2KB-M/3M5SI5=E,IE%1/&7"<2:C+DCCDCTR#C.PKI8:-V\:@O>F[907
M[3&J[1$E15:?U10>!5C855$25&;SLMRK<\45-Y,HF>.F:@]T$V?4-UN=+IW3
M&NM?T%LG?3UMZTI87U=!3O:OC-ZY7-143BN414QQ1>1W+)\AF1Z9!S_1&W[0
M6T'9/)M+M.H*=NC88I9:FX5B=2E)U?PC96NXM<WXN..6XSDXY;/='=E5;6T$
ME1;=86G2MPJ4I:365SL4D-FFD5<(G7*N\B9[5:F,*JX.99=@S(]1@X7M>Z9.
MA-BVT!FB;S17ZYZAJ;5'=*"ELM"E6ZX=9(L;((6M=ETJJURX1$:C4SO%MJ;I
MLZ!T?H?35^O%MU/0W;4JR^]6CGVISK[/U;W,=FF1RHSQF+A7.PO#&1EEV#,N
MT[Z#BNQ7I<Z'VTZIJ=*4U+?-)ZRIXO"%TWJNW.H*Y\.?A&-551Z=N$=E$XXX
M&JWSI][.[+J/4NF:>S:LO^JK'=);7)8;':O#*RH6-$ZRHC8UWP*91-Y^ZJJJ
MX11ED]+#,NT]*\5X)Q4P.O-!V#:3I2YZ7U3:H+Q8[A'U=30U+?%>B+E%14XM
M5%1%1R<45$5#E5EZ1.C^D#L'VA7C1U=5-GMUJKJ>X6ZNB6FK;?.E/(J,EC[%
MRBX5,HJHJ9RG#SCT6.G'H_9IT7]$6VX6K66LJVU4DKK[<+#:)*VGMF]42O3P
MF=SD:BHQS78RJHF"2A+D1S(V2Z^Y!;#;A7NJ*:OU=;87<J2GN,+HV^A9(7.Q
MZU/16P7HS[/.C;9JN@T)9/ )*W=6LN%3(LU54[JKNH^1W'=3*X:B(B97AQ+I
M_2+V=Q[%F;69-2T[-".ITJ6W-S795-[=2/<QO++OY9N(F=[*')(?=$]GE+64
M+K]I/7^D=/UTK8J;4U_T])3VU^^N&KUF\J[KDXYW4PG%3K=22L/<6IZC!S3;
M=TB-%]'_ $_;KIJBLJ)I;I,E/:[9:X%J:RXR81=V&-J^,F%;XV<>,G:N%YMI
MSI^;.[]JS36DY[+JS3^K;Y<F6R.PWRT^"5=,KT563R,>[X)V%3>9E<IQ3B0R
MR["69'I0'%]M'2TT3L6U-3Z4J:.^ZNUA40I4-TYI*VK<*QD/9(]B*B-1>?%<
MJAFMB'2,T;M]I;HFG9:VCN]I>V.Z6&]TKJ6OH7.XIUL3EY+A?&3*+A4.97V#
M,CI[FJQRHJ*B^=.) \W;$;U/LFZ0>M=B%=4U%19*RE^Z[2#JAZO=%2RO5*NC
M1Z\51DN\YJ+R:Y4[CTDGX7%%[<IV^<-6.IW(  B=
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M--+1V*UQNCI()IG3/8U7*Y45[N*^,Y39@,SVN,J  (D@
M
M             #-V[]B,]?TJ79:6[]B,]?TJ79Z=/JHP/<  M.
M
M
M                                                   L+Q^QV?+^
MI2_+"\?L=GR_J4JGU62AUD8@ 'F&X
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MMB0 !63
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M1/I_0>F;75*JU5#:J2EFSQ^^,A8UWSHOL,X9GNRY;  '#H
M
M                  !F[=^Q&>OZ5+LM+=^Q&>OZ5+L].GU48'N  6G
M
M
M                                                        6%X_
M8[/E_4I?EA>/V.SY?U*53ZK)0ZR,0 #S#<
M
M    ,(O-,A%R  "*.5JY1<$  1SN9W4:S//"<5(
M      83N3/H        ([V[GN7@H3Q6HU,(WGNHF/F(  !//R[0 !P3"(B)
MCEA.
M                   'JSZCDNTGI0:&V9W=]EJ*BKO=_;P6V6>%9Y6.QE&N
M7.$7\GFG:AF]O6OY=F>R'4NH:5V[700=32N^+-(Y&,=ZE=O>HTCHC;)J#1^S
M>WZEJX&5>J-0,\/J;A.W?E:UZJYC$<O%."HY>]7>9#TZ%"E&D\16U5[)+FS#
M5J3=14J>CM=]QCZ#IM:3CK(8-1Z:U-I*&9V(ZJYT7WM>]5QQ1$Y\$[#OMJNE
M)>K;37"WU4-=0U,:2PU,#D<R1J\E14_J+356F+5K>Q5EFOE)'<+=5L6.2*=-
M[&>UJKR5%XHJ<N9SK89LVN^PC9I=K5<[O#?*:EEJ*ZB9"U6=3%NJ[JU<[FJJ
MW/+ADY)4*T,U-.,K[<F=C*K3E[^L3K(]1S_83M;3;5H&+4S+6ZSH^IDI_!5G
M2;&YCCO;K>>>XM+AMI90;>;;LS6SOD?6T"UWOFD_!N&O7=ZO=X^1CGV^HR^S
MU,TH6U6I?QJ>53;T9TL'$MIG2%NMEUV[0F@M)2:RU5# VHJVNEZJGIFJB*B.
M7AE<*F5RF-YO,Q&ENDSJ&UZ\M&D-I^AW:/KKP_JZ&MIZCK8'ORB(BYSVJB;R
M*N%5#1' UG!326U[75_&Q3[5#-EOW7MIZGH0'-=M6W.V;'J.WPOHI[WJ&Z2=
M7;K-1_"3NX)O+\5N<)R7.>')3FM7TD]I>B(8[QKS9+);-+.<B25=OJ>LEIVN
M7F]JYQS3@N[GTG*6#JU(YDM]KM? [+$TX.S>IW?7.M+;L\TG<]1W?K_>ZWQI
M+-X-'OR8WD;XK<IE<JG:8&_[:M-Z9V74NT&M\.^YZI9#(SJ:?>GW9%1&?>\\
M..>U35>DA?:'4W1@U3=K94LK+?6VZ*>GGCX->QTC%1<=GH7BBY.9;8OVAEB[
MO [=_.-5#"1E&+EI=V915Q$XMJ')7/4]FND%\L]!<J7?\&K((ZF/?3#MU[4<
MF>Y<*G NSDMZVPV/8QL3TQ=[R_KJF2UTT=%;XE3KJN7J6X:U,+A$X9<O+S\E
MOI=K=YL^QBZ:^OVDG6>HI*;PMEEDK=Z5\>6HBO=N>(JYSNX54PF>)CGA:B?N
MQT;LN\TPQ$+6;U239TP&M[-=9IM#T'8]2MHUH$N=.E0E*Z1)%CRJIC>PF>7<
MAK&C]M,>J]LFK] )9W4KM/Q-E6X+4(Y*C.[PZO=3'E=Y3'#U'F5M8[]Q9Q8V
M3[3I8//M\Z5LU-KS4NB;-HNLONI[?5I1T%-33Y2KPF9)'KN?>F-3&>/X7,Q=
M%TM[QHG4LECVLZ+=I*H?3.J:2:@E6H;-A%PQ$RN5<J;J*CL9YFN/1U=QO;7L
MNK^-C.\713WT\/S/2P/,FI>E%M&T5'!?]0[)IK7HN:5K4G=5YJXVN7Q5>U,H
MU5[G-1.Y5.UZJVKZ>TALW77%;4N6QNIHZF%8V_?)NL1%C8U%_"7>1/-Q4JG@
MZM.UU>^BLT]2<,3"5]=NTW E?*V&*61V=UC7/7'/"(JKCV'FVBZ0.V34UM9?
M=.[&VS:?F8DL+JJM_7$L?8YK$5JJBIR5&KYLG0]BVVZAVUZ.O-7%;IK-=+:K
MZ:OM]0[>6%^XJIA<)P7CS1%RBY+7@:L-9VM=7LUH0CBX2NEN]M&;#LMVKV+;
M!IZ:]:>\*\!AJ'4KO#(.J?OHB*O#*\.)N!X5Z+VV'4>FM!U>D]$:,FU?J1]P
MEK9NLDZFEI8E1J-5[LIQ547AE.7F.^[*.D;5:HUM)H;6^F)M%ZO2/K88)'[\
M-4B(JJC%7CG"*J8RBHB\2[$]'U*<Y9%HN]7MX$*&+C**4M_ [: GHQZ>?]N0
M/'\3T                  "*>W^W]O8</Z0VRZ_774N@]IVB*)+AK;1=<J+
M;>M;$MTMD^&55+ON5&[^%WV;RX1S53M.W@ L[I9[=J2WK1W6VTMRHY.+J2NI
MV3,5<9\9CLIE,]F>2^8A9;%;=.T+:&T6VCM5$U<MIJ&G9!&B]JHUB(U%4O0=
MN<L:W?M(*[3^IVZ4?1Z6U-=J:5([Y3T,2R-JE8J1SRINXE5KESAV>&3R?25?
M2?IJ!+3<]A.C-1:]9 ZECVH27.C9%E45$J'1)&DN4:O)JHBKR;C*'M0$E/*1
M<;G(^CMT>[=L4V V'9K<GTNI6TT<DEQDJ8$D@JJB5ZRR+N/145B.=A-[XJ+P
M4R^W/9)'M:V1W30-+X!;:*XLBI'234B2MI*='(DCH(^394CRC%X(U51>PZ*#
MF9MW.Y58DIJ>.EIX8(DW8HHVQL3/)K41$^;'(B^-DT3XI&-DCD:K',>W>:YJ
MIA45%YHJ<./>3 Y<D6MJM-!8Z&&AME#36VAB14CI:.%D,4?:J-:U$1//@DI+
M';**Y5MQIK;1T]QK$;X360T[&33HWDDCT3>>B=F5X<B]!P%DRQVV*\379EOI
M&W66-(9*]M.Q*A[$PJ,=(B;RM3AAN<)@7:QVW4-"ZANMOI+I1/<U[J6MIV3Q
MN<U<M7<<BHJHJ(J+V8R7H )5C;)&Z-S6JQR;JM<B*U4Y87S8\Q:VBR6_3]OC
MH+304MKH(L]72T<#(8H\KE<-:B(F555\Y>  YUM?V2MVKUVATGEHZ>AL%_I[
MY4220;U2[J/'CBA=^YM?(C%>OQ6X[3HRN5V5[^_&?7W=I '6[G-BVN=KHKU;
MYZ&XT=/<*&=N[+354398I$SG#F.16JF43GW(5J:".CACAIXFP0Q-1D<<348C
M&IR:B)P1/0B$X.'3#TFC-.T-Z?>:;3]IIKS)G?N,-%"RH=GGF5&H[YS,)PQA
M<8_MG_S  +.T66W6&&2&UVZDML4DKIWQT=.R%CY'+ESW(U$17+VN7F0=8K;)
M=H[JZWTK[K#$Z"*O=3L6H9&O-K953*(O'AG!>@ A(B.C>U6M>BM7Q7IXJ\.2
MIW=_I.?;!]E'ZCV@GV22>EGK:JY5MVK'4,'44S9ZF=TKHX8_P8V;R-:G<AT(
M';G+%C>+%;-0T?@MVMM'=:1'))X/74[)X]Y.2[KT5,IV+S0HW[2=BU7#%%?+
M+;;W%"N]%'<:.*H:QV,*K4>BHF4PG#N,H#ATU%FQ[9^U45-":71R<45++2IC
MS^0AMDD<=1')%+&V6)Z*UT;VM5CD7@J*G)4\V.TF!V[.61A+'H33.FJN2LLV
MF[/:*QZ8=46^WQ02N3Y3&HOM,U)&V6-\<D;7QO16.8]-YKF]RIVY(@X=,58-
M(V'2JS^\=CMMF6H^%6W44=.LB^?<:F>/><CVQ;+[_MGVQ[/K;<+>E/LQTK/]
MTE=4/E:OOI<F9;2TS8T7>1D>72.5R(U55$3.#N()9SEB9SE<KE7AQ_M_;["4
M YWG0 #@
M                                         ,W;OV(SU_2I=EI;OV(S
MU_2I=GIT^JC ]P "TX
M
M
M                  "PO'['9\OZE+\L+Q^QV?+^I2J?59*'61B  >8;@
M
M
M
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MMRHG%KF*B81>Q&]J$*F(IUYQK-I.+U7)J^Z.PHSI1E!)O,M^^VS,_P!&=?\
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M
M
M                                            &;MW[$9Z_I4NRTMW
M[$9Z_I4NSTZ?51@>X !:<
M
M
M                     !87C]CL^7]2E^6%X_8[/E_4I5/JLE#K(Q  /,-P
M
M
M
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M3NK-6ZATU:ZR2>\V)42OA= ]C8\KPP]4W7>I2,82DG**T1UR47:3W-H ! D
M"PU!?*+3%BN-WN4CH;?0P.J*B1K%>K8VIERHB<5X=QU1<G9'&TE=E^##:,UE
M:=H&F:+4%BG?56JM1SH)GQNC5R(Y6KXKD14XHJ&6GF93P32R+B*-CGO5,YW4
M3*\N/(DXR3RM:D4XVNGH3@UC9UM*T]M5L$EZTS6NK[<VH?3+*^%T2]8W&\F'
M(B]J<39SCBXO++D2C)2CF3  (G0          :M;MIVG;IM N.B*:LD=J2W0
M)4U%,L#VM:Q4:N=_&Z[@YO;GB3C"4KY5HB+DHNS>YM((_P!D]! @2
M
M
M                                         ,W;OV(SU_2I=EI;OV(S
MU_2I=GIT^JC ]P "TX
M
M
M                  "PO'['9\OZE+\L+Q^QV?+^I2J?59*'61B  >8;@
M
M
M
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MR*[FN&(B+ZTP>3B(4YT(UH1RZVL>C1G*-5TIN_8S<@ >6;P
M
M
M                               #-V[]B,]?TJ79:6[]B,]?TJ79Z=/J
MHP/<  M.
M
M
M         L+Q^QV?+^I2_+"\?L=GR_J4JGU62AUD8@ 'F&X
M
M
M
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MABC;R:QJ8:GJ1"L#+6Q,JL5&UDN2V-%*BJ;<F[M\V  8S0
M
M
M                               9NW?L1GK^E2[+2W?L1GK^E2[/3I]5
M&![@ %IP
M
M
M        %A>/V.SY?U*7Y87C]CL^7]2E4^JR4.LC$  \PW
M
M
M
M
M
M
M                                              &;MW[$9Z_I4NRT
MMG[$9Z_I4NSTZ?51@>X !:<
M
M
M                       ()P+.YMS2*O<J*7G:4JN/K:>1O>A7-7BT=CHT
M:^!W>?B#RS?W@
M
M
M
M
M
M
M           BU-Y43O7 6H,Y;F[M'$GF+A"2)O5Q-;W)@G0]6.R//>Y$ $P
M
M
M                                                           "
M"\B)!>2@& J8NIG>SLSE"B9:Z4ZNB21$RK.?H,2>74CDE8V0EF0 !66
M
M
M
M
M
M
M                                                  NK?#UU2B_@
MMXJ6IF[=3]3#E4\9W%2VE%RD5U'E5B[ !Z9C
M
M
M                                          )5:BM5%Y&$K:5:>1<)
M][=Q3S>8SF4P4Y8VS1N8],HI34AF7>3C+*S7@5JBE?3/P[QFKR=WE$\]IQT9
ML335T  1.@
M
M
M
M
M
M                                                           N
M:2C=.Y%7Q8^\ZHN3LCC=M2>WTO7.1[D\5OSF93N)&,;$U&M3")R)DXGI0BH*
MQCE+,R8 %I
M
M
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M+@V1BH[&>4G(F !81
M
M
M
M
M
M
M
M
M
M
M
M
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M1>U%!RZ95R@RAKNJ=?:9T- R?4FHK5I^&3.Y)=*Z*F:['/"O5,E]8=16K4U
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M=].7FWW^TS*YL==:ZN.I@>K5PY&R,56KA45%1%X*@.F<! B  2HY,XSQ)@
M     05.!$ $J>*-XPFJ]96'0UFDN^I;U;M/VJ-S6/KKK5QTT#7.7#461ZHU
M%5>"<>)I']U'L:[=K>A5XX_Z247H_&>= 1<DMSJ2*3&M:8VBZ5UG))'I_4MG
MOKXTWGMMM?%4JU.'%48Y<<T]ILF0+WV(@ $@07DI$U_5VN-.:#M27/4^H+7I
MNVK(V%*R[5L5+#UBHJHS?D5$WE1%X<^"@&P HP2)(U'-<US%1'-5O+"E7* $
M0      0(@$$3 7D0<O!36=8[1M*;.J2&KU7J:T:8I:B3JH9[S7Q4D<C\9W6
MND<U%7"+PY\%!&]M6;00PAS6BZ26R2Y2.92;4M&53VIE6PZ@I'JB=_"3SH;Y
M:;M0WJACK+=605U'*F]'44TK9(WIWHY%5%%F%),OP "0       ,;?;Y;=-6
M>KNMWN%+:[92,66HK:V9L,,+$YN>]RHC43O50#(X0AP[CF$/2<V/5$C(HMJV
MB997KNM8S4=&KG+GDB)*;IIG6>G]80236"^VV^0QKA\ENJXZAK5[E5BJB<CM
MF1S)\S.@Q.HM26G25GJKO?+I1V:U4J(Z>NN%0R""%%5$17R/5&M3*HG%>:H5
M;+=J'4%KI+G;:VGN5NJXFSTU923-EAGC<F6O8]JJCFN1<HJ*J*F#A(R(
M              (+R,#5ZRL5!JB@TW4W>E@O]?!)4TMNDE:D\\;/+>QG-R-[
M<<@#/@E;\Y,
M
M
M
M
M
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M;94VQ9JBEF159,R&2IG5CD[6KU6%1>"IDXHK02J25U'E8],[ ^ESL]Z1_O\
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M.CJ/HB[2(]+0TG@;;2M@D= L.ZJ*QS%AP[/;G*JJY7B<XZ-FPW5FTWHZ[?\
M9;>M%ZCTC8YJQ+IH^BU-034SH9'K+)%'&^1$SNN@@1^ZN$WU7\-<\RKF=566
MRU\CZ3QSLGC:^-R/8]J.:YKN"HJ<%14YH>..D9M^Z/\ MFV9ZJM>MYK]5Z8T
MMJ."W5U3;J=[&NKL5#6)&].$C<1R*JIPXL[T,5LDZ6BVCW.RMUK55&YJC2M
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MIE1/-O2O]JGL]O:1993EF@F3  X6@
M
M
M
M
M
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M1,%RT@R^,<JR]A, #A,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
*          __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9H#Z # 2(  A$! Q$!_\0
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M%!4C,D)24W*A%I'!-='A!Q<DDO#Q_]H # ,!  (1 Q$ /P#JF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                          6[
MDUT N!YJKS&PI0W3[F5.)[/3W)5T\BFKXF3:ZHFFQ7:]JHG9WGH8Y6RM1S'(
MYJIJCFKJB@9 #\\]7#30/GFD;#"QJN=)(Y&M:B=JJJ]P'Z >6M.9V#[[<$H+
M;BNRW"M5R-2FI;C#+(JJFY$VM<JZZ<_4>GZQOI N
M
M
M
M
M
M
M
M
M
M
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M-S:BJA@D;\;)')ZE4T/T*F$*6W</V,<1M;I7W;$3J5[M.V*GIXEC3XG3R_I
MUUF=T+$=JP957#+_ !]77'%%'"LT-#=::...K>W54C9(Q4ZIRZ(B*NY-W:J(
MNJ>@Z*WC)Q1C#$-QR6S&N-5<KO0P2366MN+E=5:0JB34<CEYO5J:O:KM51&/
M15T1J)TQZO7M.*U9 W*3IA616_\  LJ<9Q:I'V?[(1-5Z?\ Q3N0':P
M!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%
M-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U
M0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!
MJ@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J
M 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!
M4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%0
M4U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!3
M5!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4
M&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:
MH!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@
M%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5
M!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%
M-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U
M0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!
MJ@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J
M 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!
M4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%0
M4U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!3
M5!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4
M&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:
MH!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@
M%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5
M!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%
M-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U
M0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!
MJ@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J 5!35!J@%04U0:H!4%-4&J
M 5!35!J@%06[BX
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M'('@:I*[BGZ1C$&:RTTD5FMM56W^1)$TZMKT=!1PJJ:^>B/:OCU+P.S0
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MU?0XC90
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M#GYUTWT.M)M
M
M
M
M
M
M
M
M
M                                   (W=(O[S?,+][_ .4:8DB1NZ1?
MWF^87[W_ ,HTP&Q^&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4
M
M                           !"7I;?>XX<_.NF^AUI-HA+TMOO<<.?G73
M?0ZTFT
M
M
M
M
M
M
M
M
M                              C=TB_O-\POWO\ Y1IB2)&[I%_>;YA?
MO?\ RC3 ;'X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90
M
M                      $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;
M0
M
M
M
M
M
M
M
M
M                        "-W2+^\WS"_>_P#E&F)(D;ND7]YOF%^]_P#*
M-,!L?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E
M
M                 0EZ6WWN.'/SKIOH=:3:(2]+;[W'#GYUTWT.M)M
M
M
M
M
M                                       !:I0*2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2O!8 2
MO!8 2O!8 2O!8 2O!8 2O!8 2O(W=(O[S?,+][_Y1IB1Q&_I&/>;YA?O?_*-
M,"6R>&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4%0
M
M                 $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0
M
M
M
M
M                                       6J4#^XL"S/JO!8"XE>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P E>"P
ME>"P E>"P E>"P E>"P E>"P E>"P E>1OZ17WF^87[W_P HTQ(TCATBWO.<
MPOWO_E&F$&,^;9?#/[W'*K\U+5]#B-E&M>&?WN.57YJ6KZ'$;*+5X
M
M                            "$O2V^]QPY^==-]#K2;1"7I;?>XX<_.N
MF^AUI-H
M
M
M
M                                                  +']Q87O4Q[
MB['HQ;>JH*;AN*K%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!
M4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-
MPW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW
M5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3
M<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P
M%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04
MW#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<
M!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%
M-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW
M 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!
M3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-P%04W#<!4%-PW 5!3<-
MP%04W#<!4CATBWO.<POWO_E&F)';B.'2*.UX.LP?WO\ Y0I@KCU;,X9_>XY5
M?FI:OH<1LHUKPS^]QRJ_-2U?0XC918S@
M
M       (2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
M                             QR]QC,DO<8M4+]?1@VS\Y4%-4&J%RR5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"5
M04U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0
M:H"504U0:H"504U0:H"504U0:H"504U0:H"504U0:H"52.'2*>\ZS!_>_P#E
M"F)':H1PZ114]IWF#^]_\H4Q3*NN?/#9W#/[W'*K\U+5]#B-E&M>&?WN.57Y
MJ6KZ'$;*,:2
M                                               A+TMOO<<.?G73
M?0ZTFT0EZ6WWN.'/SKIOH=:3:
M
M
M
M
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M%,4SCR7:[?.PVGPS^]QRJ_-2U?0XC91K7AG][CE5^:EJ^AQ&RC"F@
M
M                            (2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ
M;Z'6DV@
M
M
M
M                                                  _)4KIHOK,&
MXRU:\VIZS\Q(UQ\UKN3,;Y9-PW&,&2&"63<-QC @EDW#<8P()9-PW&,""63<
M-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<
M8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,
M""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @
MEDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9
M-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<
M-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<
M8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,
M""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @
MEDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9
M-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<
M-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<
M8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,
M""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @
MEDW#<8P()9-PW&,""63<-QC @EDW#<8P()9-PW&,""63<-QC @EDW$<^D.77
M@\S _>_^4*8D01TZ0W7VGV8"?N?_ "A3%F<>663CS\[#:_#/[W'*K\U+5]#B
M-E&M>&?WN.57YJ6KZ'$;*(S:
M
M(2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
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M_5MOAG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E$-O
M
M                  $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0
M
M
M
M
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M?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V40'1
M
M             (2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M               HO8$Y($7ES,?6HB+W(#'V+_X1VIZ3SUDQS8L0W&MHK=<Z
M>KJJ-VV:*)^JL773XTUY:IW\CT'B8M.37DQ.F9^"[.NVF8VQ&5X ,JT   %-
MPU0"H!\^[7BDLU&^>JF;$QJ:IN5-5]0'Z65$3YGQ-D:LC$U<U%YIJ9S4V6N(
M)\18WNM7([6-T36IMY(NAMD
M
M
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M&/?'S<LW#M\_7XX;GX9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC91K'6@
M
M                                (2]+;[W'#GYUTWT.M)M$)>EM][CA
MS\ZZ;Z'6DV@
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MZ^Z74#: +=R%=?C J"W<BA'(O9S N
M
M
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MYMX<,_O<<JOS4M7T.(V4:UX9_>XY5?FI:OH<1LHTSN
M
M                  $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0
M
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M.TV7A2"X08>H675_67%L:=:[55YZ]^J]NFFI]G;W]XV@7
M
M
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M>?7XX_-O?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E&C>B
M
M       4U0"H+4>GHT&Y$ N +=R 7 MW)S_S#>@%P       (2]+;[W'#GYU
MTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
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MMCG]?3N;.QZMD71')HB]BHFOK-V[>P;0+@
M
M
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MG3V_^1I\<?FW]PS^]QRJ_-2U?0XC91K7AG][CE5^:EJ^AQ&RCGGJ.
M                                                   IN J"W<A7
M5 *@IJA1'HH%P+45%_PEP           "('2!\<4'"=A.BM5@CIKCF'>F+)0
M4U6BOAI($7:ZIE1%15YHK6-U3<J.5=4:J++\XV7>"+BNZ6UUHO;WUN'K->I:
M1(')NC;!;(I'+%IWL?/$[7^O.]('IL$\ /$-Q;VEN-LW\UZ["[+O'Y336VLB
MDK)FQO;JFM(V2**G:J*FC&KJFJZM:O)=H9,]&[F_P[9OX0ON$,Z$NN%*2XT[
M[S;IFU-!Y31HY.MB2!'S1R:M141'.;IR75%1"8V)N*3)W!]P?07G-+"-NKXU
M5LE+->:?K8U]#VH_5OQZ?&>VP?CW#68-L^Z6%L0VK$MNW;%K+16Q5<.[O;OC
M<J:@?6K[A3VNBJ*RKF934E-&Z6::1R-9&QJ*KG.7N1$34X_8VSZSJZ2'/&YX
M RIO%5A3+ND:]^K9Y*2-U(U4:M16R,\]ZO=IMAYHFJ)IJCGD_ND-Q;48+X,L
MU+A2R]5--;6VW=IKJVJGCIGI\;)G)X:D>>A1P;24&1.-<4)$U+A=,0>0OETY
MK#3T\3F)K_55$H&H,<]$[F[E?8*K%.7^:\U_Q-0,\J6CI(:BVU4KF-7E!*V9
M^Y^B-1NNS7FFJ:<]S=&!QR7_ #MEN>6>8M:M=BVUT_E5NN<R(V:MIV*C9(Y>
MS=*Q5:N[35R*Y5YM55Z%Z+WZ'%2UP-R1Z7ME)0:4E//C!8FPQIYJ,N,7N41.
M[^>M/#1/0@':T     !35!J@$)NEM][CAS\ZZ;Z'6DVB$G2V.1W#EAQ$[?OK
MIOH=:3;
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M:MMNK'Q7/%M\B>ZDC>W=#&LC97L5?VL43M=-=%4#<C>;4+BC>PJ
M
M
M                               !Y;&'NJ7U._[)YT]%C#W5+ZG?]D\Z
M;WJ?0X>;^+_6]_P_X  3FG
M           "V21L3'/>Y&L:FJN5>2)Z57N*$KOX#Y6(L4VK"="ZKNU=%10]
MW6+YSE]#6]KE\$0U-F7Q%4MIZVWX95E;6]CZYW.&/^I_9+Z%[$\2/-YOE?B&
MN?67*KFK:E_;),Y5^)$[D\$T^(D\?!MMY[>6&I['B&G'\W3SRWAB[BC5VZ##
MEN]577<]?2J1HNGQJOQ&H,18_P 18I5_W4N]351N[8=VR+Y#=&_P'GTYZZJO
MC_F!,TXM=?3#2\G9Y>7,[95^-5^/D4T\$_1_KX@&9%]?4  4!W*G_P!%]:
M9*>HEI)F2P2OAE8NK9(W;7-]2IS-A85S[Q9AM[&2UGW7I4Y+#7:O=ZT?KNU]
M:J:Y!;MKKMZX9M.7?C\]<PEG@KB"P[BA8Z>M<ZS5J\D;5.UB5?"3_O:&SV.1
M[4<U45J\T5%Y*GI.?I[G+[.&^X"D9%%+Y=;-?/H:ARJWUL5=58O@G+P(>_6_
ME;?K^(>=>7'XIE \G@+,RS9@T:R6^;JZMB:RT<JZ2Q^E?%OBAZPA>>/5O--M
M=\3KF<  *K@
M
M
M                              #T&@>/3WJ6.O[A^GTYOXT#QZ>]2QU_
M</T^G(_-]'M\,IG3^L:?''YM_P##/[W'*K\U+5]#B-E&M>&?WN.57YJ6KZ'$
M;*.<>J8
M   4U0T?G_Q@9<</$2P8BNCJV_.;NCL=K:DU6J+V*]-4;&WGVO<W7NU-F9A1
MW"3 F)&VA9DNKK;4I2>3.5LG7=4_9M5%31V[31=>TYD93=%OF'C^N6\9D7Z/
M"T,[^NFAW^77*9575=Z[MC57MW*YR\]%:!\W-;I4LS<654L6"Z*@P3;4UZN3
MJVUM6OBY\C>K3U)'JFO:I&_$?$;FIBVHEFNN8F)JM9-=8DNDS(D1>Y(V.1J)
MX(FAUERXZ.S)++Z%CI,-.Q56M_\ .\13>4Z_]$B-B_\ <U\3>-BRQP?AFF\G
ML^%;)::?_D:&W0PLY>#6H!P)H,S<96N=9J3%E\I)MRO62&XS,=N5-%=JCNW3
MOUU-G8*XX<\,"NC;19AW.OA8O.&[N97M<B?BJLR.<B>I44[AU%LI*N%D<]-#
M/&SW+)(T<C>6G+7L/$XKX?LL\<H]U^P%AVYRN[9YK;%UO/T2(W<GQ*!"G)[I
M:J6KEI:',O"BT2O5&ON^'U<^--5TU= ]5<B)R55:]R]NC2>6 \R,,9G8=@ON
M%+Y1WRU3<FU%))NVNTU5KF^Z8Y$[6N1%3O0BQF7T6>4^,&3U&&:BYX*KGZJQ
M*:7RNE15Y\XI55RIKS1&R-0U[PK\&&:/#1Q,VFNJ:N*ZX(J*>I@J;A:JET<3
M_P "]8VSP.5':[]%3DYJ+HN[4#H@          !P!P'DK?\ B&XX\<X&MN)G
MX2J[I>[UY=<8TD<O4-FE=,S8US5>CM--KG(B]ZG?XXL4-RCX8.ENKJV^.2W6
M:OQ)4R/FE<C8DI[G&]8WJ[L1C75#55>[JUU[% E=9^ADR1I++Y+7WK%]PKWL
M1'5[:Z")6N[W,8D*M1/!V[UJ0ES7P/BWHO.*JQ5V&;]677#U2V.O@5SNI^Z-
M"DBMEHZEK5VN<FU4W::><QZ(U>2=ST>B]G/OY?X3C?TP^-:/,'B%P9@;#Z?=
M2\V6A\GJ8J9$<[RJJE18X.7:_:V-=/\ UB=^N@3'Z4>XI?.!/$5RH)5\BJYK
M74:Z>ZB?4Q*W73Q<U3X70XS1R<)%2UFBNCQ+6M?S_&ZJ!R?P*AM?BPR<J<5<
M#F+\!T+9*NLH<-P^3QQHKGS24213-:WTJY:=$3T[B*70FYK4+L+X^RUJ*AD-
MRCK67^CA<J(Z>.2-D,RM3O1BQ0Z_UQ/$#J <7L\Z/[L=,A;HZ3S-F+L.S+IR
M7\%3T3W_ *=CO7J=DKI=:.QVVKN-PJ8Z*AI(7SU%1.Y&LBC8U7.>Y5Y(B(BJ
MJ^!QRX1UFXI.DXO&8U#%(ZP4%?77Y9=FFVF:UT%(CM>QRJZ'5.WS7Z<DU0.S
M@    #3?$9AC.3$5DM$636*[/A6YQ5#G5\UXB:]DL6WS6M1:>;1=W@AHGV*.
M.;X9<$_,XOLTFT .3?'#@GB.PWE-::K-_'N'<4X9?>XHX*.TP,9*RJ6"H5LB
MJE)#YNQ)45-W:Y/-]'60A+TMOO<<.?G73?0ZTFT
M
M                  'Y8Z.&"HFGCAC;--MZQ[6Z.=IR35>_1-3/M[R\ 6Z>
M/B-I< +=OZ!M+@!31"FTN %NWEIW%-J^DO %FB_ZJ7:(5 %J-5>TIL+P!:C3
M\TU!!-50U$D+'S0:]5(YNKF:IHNB]VJ<C]8
M
M
M                  #RV,/=4OJ=_P!D\Z>BQA[JE]3O^R>=-[U/H</.?%_K
M>WX?E@ !.:4                                              ##6
MUD%NI)ZJIE;!3PM5\DCUT1J(FJJI13TF6*Z76DLEOGK:Z=E-2P-WR22+HC4_
MU_3W$6LV,[JW&[Y+;;%DHK&BZ*FNCZGQ<J=C?#].O+3Y^;>;55F#<%IZ=SJ>
MQT[U2"!%TZW;_P 8_P ?0G8GZ577G;_]>WP)_#PU^=LYWM]S._S.//D(G^J
M F-.       !\        'Z[5=:RRUT-;0U,E+51+JR6-VBI_G\4[%_@)5Y.
MYOP8^HUHJYS(+Y"S61B<FSM3\=J?X4(DGZ[3=JNQW*FKZ&=U/5T[TDBE;VM5
M/\*>E._FG>8.3BQR8^],ZW8VX=L>?DGP#R>66/J?,'#,->Q&QU4:]750M_XN
M1.WXE3FAZPU><9US&76:;8WUQM@ !5>
M
M
M                                                !H'CT]ZECK^X
M?I].;^- \>GO4L=?W#]/IR/S?1[?#*7T_I]/CC\V_P#AG][CE5^:EJ^AQ&RC
M6O#/[W'*K\U+5]#B-E'./5<
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M?.TN         A+TMOO<<.?G73?0ZTFT0EZ6WWN.'/SKIOH=:3:
M
M
M
M
M                                  #RV,/=4OJ=_P!D\Z>BQA[JE]3O
M^R>=-[U/H</.?%_K>WX?E@ !.:4
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MNUWQFO[&O\6&^\-Y?+/'E[4 $5O0
M
M
M                                             - \>GO4L=?W#]/I
MS?QH'CT]ZECK^X?I].1^;Z/;X92^G]/I\<?FW_PS^]QRJ_-2U?0XC91K7AG]
M[CE5^:EJ^AQ&RCG'JN
M              'RL26"GQ/A^Y6>J=(REN%-)2RNB5$<C'M5KMNJ*B+HJ]QR
MQS>Z.+,_)2Z??5E5>JS$M-1NZZ%;<YU-=Z;Q:UB_A%T[XU1R\_,.L99KIRU
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M#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
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M6.NC,2J "J@         %T3O\  ":+W^
M
M
M                                   !H'CT]ZECK^X?I].;^- \>GO4
ML=?W#]/IR/S?1[?#*7T_I]/CC\V_^&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T
M.(V4<X]5P
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MYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
M            \MC#W5+ZG?\ 9/.GHL8>ZI?4[_LGG3>]3Z'#SGQ?ZWM^'Y8
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MC5D?^B-RI_#H>1/:Y..1,>T"+VJR73_JW&;;TRP\?[^$BP 16W
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M\N8[.TH  *@
M !H'CT]ZECK^X?I].;^- \>GO4L=?W#]/IR/S?1[?#*7T_I]/CC\V_\ AG][
MCE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E'./5<
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M^]QPY^==-]#K2;1"7I;?>XX<_.NF^AUI-H
M
M
M
M
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M7T.(V4:UX9_>XY5?FI:OH<1LHYQZK@
M                          ,#H62L='(UKV.14<UR:HJ+VZIV<S. (VYH
M]'WDMFE45%9-AMV&KE-JKJS#LODJZKW]5HZ+7TKLU7O(X7_H>V.J))+'F<YD
M"KYD%QLR/>U-.^1DR(OQ,0Z0@#E]2]$#BE\VE3F):8HM/=16^5[OT*Y$_A-F
M8$Z(W!5I<R7%F,[QB%[5UZFWP1T$3O!VO6N5/4YI/4 :XRKX?,O,E*/J<%X4
MM]FFV['UK6=952)WH^=^LCD[]%=IZC8FU=--? O
M         !"7I;?>XX<_.NF^AUI-HA+TMOO<<.?G73?0ZTFT
M
M
M
M
M                               'EL8>ZI?4[_LGG3T6,/=4OJ=_V3SI
MO>I]#AYSXO\ 6]OP_+  "<TH
M      !YO,B\OP_@.^5T3MDT=(](W)W/5-K5^)50](>*SGI'5V6&((X]55L"
M2+IZ&/:YW\"#7][$L7+G../:/L0Q3U?Z_P"NH -U[G%)H9-5"5666'W^BGVK
MI^U<YO\ D4U7G-#U6.JIVGZI%$[_ -U$_P A[GAQN"5N65+$BZK25$L*_&Y7
M_P"!YYW/RAZK$%NJT3E-3=6J^+7JO_:0U6OS>3.'58S;KZY^YJ\ $A$2(R=O
MR7C!\,+W[IZ)5IW)W[>UJ_H71/4>X(XY58J;AG$S$G?MHJS\#+KV-55\UWQ+
M_ Y21R<^?<0]M:Y;3@WOK  "C.            45R-[0:L<<4=.Q48UD3.;E
MVIHG-555_2NOQJO>>.OUV^Z54K6+^!CY-\?2I^N_WY*C=34R_@NQ[T_&_P#U
M'GR/OM[L)_!Q5^=D/J8;36[P^&[_ !5/EGV\)1[[DKNYK'+_  HA9K^]AGY,
M_-R]@ "6U(     TWQAV]URX;L<0M17*VFBG^*.>)Z_H1BJ<FSMCB[#D&+L*
MWJQU/*FN5'+1R<M=&R,<Q5]>CCC'B?#==@_$=TL=SBZBX6ZIDI:B/7DCV.VK
MIZ47N7O3F;7H;8C;5CWQ[W5SA3NT5ZX>L#3POWI';FTR^#HG.B5/TL4VN00Z
M/W/F@L\=3ES?*J.D2HJ%J;1-,]&L=(Y$1]/JO)%<J;FIWJKD[=$6=_\ FU-=
MS:9TY-L97Z^> U7Q3W>.Q\/F/:B9_5MDMLE,BI^RE5L34_3(B?&;4(*](%GQ
M0W*G@RWL=6VI=#4-J;O+"]%8QS-49!JG:J+YSD[E1B=NJ(X-,\G)KC!GRPA"
M=8^#FW.M?#9@F%S5:YT$T^CO1)42O1?4J.1?C.6&&L.5V*[_ &VRVV+K[A<*
MB.E@C]+WNVIKX)W^A.9V<P9AN#"&$K+8J9=:>V4<-'&NFFK8V(Q%]?+4V/>V
MQ&NK'IZRYG<=GOD;_P#V/2?1V'ALB\DKIGQBVLP_9ZZCM]3343Z]TM=NV*UK
MXV*B;6KSUE;W=B*>YXZ_?)7_ /L>D^CL/5]'!^OA>_S=G^DTIFOG3KXSK]BG
M\3S^/N!#,_ ]IJ+E%#;L1T\+5>^*T3O=4(Q.UW5O8Q7+X,W+X$=MJHJHJ:*B
MZ+KR.XZ?C)W+S7_7Q.>''7P[MP5?_O\ K!2]79+I+LN$,+?-I:IWX^B=C9%Y
MZ=B/3]LB&#K]K;;--U<Z^3TG!]E;D5F)$RH6EKKGBRA:DT]HOU0Q\;=.V2-D
M;6MDCUY>>BZ:\T35-9SPPLIJ>.*%C8XHVHUD;$1K4:B:(FG<FGH])Q4PGBNZ
MX(Q%;[[9*Q]#=*&1LT$T:]BIRT5.]%3DJ+R5%5%.M>0N<%OSLRZM^(Z1&PU;
MD6&NI&NU\GJ$TWM]78YOI1R+Z=,';XMM<VF<+],RV(<?>(_]?K'_ .[53_&*
M=@CC[Q'_ *_6/_W:J?XQ2[H_296;M>Q4\E1,R*)CI9)'(UC&(JN<JKHB(B<U
M55[B7]@X!;I)DC=;Q<WS1X\EB;5T%K8OFQ-:BN6!_P"RDD;JG[54:FO-3!T=
M& K)B;&6);[<Z)E9<+''3+0.E3<V)\JR[G[?V2=6B(O=JNG/F=#/\'^O^O\
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ME8KU^3J=FF*CF(J+JBIJGCZO28^]^_C.5=,H&=)BY/N]@-GXWDU8NG]M%_\
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MZ6!:AVZ38QJ-3<O>NB>A"G:YM.7&*^XUQ#ZX (3(
M                            &@>/3WJ6.O[A^GTYOXT#QZ>]2QU_</T^
MG(_-]'M\,I?3^GT^./S;_P"&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4<X
M]5P
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MM][CAS\ZZ;Z'6DV@
M
M
M
M                                                           \
MMC#W5+ZG?]D\Z>BQA[JE]3O^R>=-[U/H</.?%_K>WX?E@ !.:4
M                                 PUE)%<*.HI9V[X9F.C>U>]JIHJ?
M'S,Q@JJ^GHW0-GF9$L\B11;UTWO5%5&IXJC5T*&?/U0BQQA"KP1B6LM56B_@
MW;H9%33K8E7S'?HU^-%/@$R\TLL*+,:S]6Y6T]SIT5:6I]&O/:[TM<O?W+V>
M,1;]8*_#5SFMURIGTM7$NCF.3M3]DB]Z+W*G)>XV?!RXY,1GU<IVNMGAV\O3
M+>7"K?6[;[9W.\[5E7&GK\U_^"/])[G/2TNK,*P5C6ZNHYV[E]#7)HO\.TCS
MDWBAN%<P+74RNV4L[EI9E5=$1K^2*OJ7:OQ$OKW:V7RSUMODT1E3$YB.5/<J
MNJ:_$J)^@B\V,Z<DMKTMO:]>GOPB<#-64<MOK*BFG;LFA>L;VKW.1=%3])A,
MK&&_LH\<IB&UI;:N1%N5(S:FJ\Y8^YWBJ<D7U(IH$_3;+E4V>NAK*29T-1"[
M<Q[?X47P7O\ 3KH6;ZVPR\7)3*6X/,8$QW28QMR/9I%7QM;U]-KS1?2GI1?_
M *Z'IR)Z>K::YQMBV  %50      71K55>2>E>2'Q[AB>FI%5D7\\2]VU=&_
MI+,[8QZK]=,[_NOJS3,@C621Z,8WM<O8>2O6(G5R.AI_,@U\Y>Q7>!\^NN51
M<I-T[W.;^*WL:GQ'Y.?K\-#!MR3Z)W'PU\\J_P"NA0 QI0>HP=#^#JI53W2H
MU/BYK_D/+GN[!3>2VN%NFCG)O=ZU4R:8G,HW/F-8?0 !*:T     "('&GPIU
M6/7KCC!U$DU^CCVW*WQ<G5C&MY2,3\:1K41%3\9J)IS319?C_7P*Z;[<>UL*
M9Q+AZY):696N1\,T;M%3FUS51>SP77N-WX(XU,U<$6]E"R]PWJDB3;&R\0).
M]G_2:H]WQJI/O-7A>R]S@E?5WNS^375VJ+<[:Y(*A=?V2Z*C_6Y%7U=AH.[=
M&?:YII%MF/*RDA5WFLJ[:R=R-]"JV1B*OCHGJ-ICM</)C]IACKG#06-N-?-?
M&EODH77J&R4TK=DC;/3I ]R?U:JKV^M%0T<G6551^/-/([TJY[G*OZ=55?$G
M9:NC.ML,[%N6/:NK@W><REMC8'*WT(KI7HB^.B^HWYE1PM9>903,K+-:/*[J
MW3;=+FY)ZAFG>Q=$:Q?%B-^/L'Z5P\>/V>%<:YRTSP5\*E7@21N.L8T7D][?
M'I;+?*B*^C8YO.61.Z1S55$;VM:JZ\UT28 []>\&KVWVY-K97XQ#EMQU>^/Q
M!_8])]':>KZ-[]?&^?F[/W_^TTI)C-_@LPOG'CJNQ5<[Y=J*MJHXHW0TG5=6
MG5L1B*FYBKS1$[SZ617"1AW(;%M9B"T7FZ7"IJ:%] Z*N6-6(QTD;U5$:U.>
ML:)\9.SSZ9X/9^]97-F]#Y.*\+6W&N&[E8KO3-J[;7P.IYXG=[53N7N5%YHO
MI1/0?6!K_O9''3.S*:Y9,9@W'#-PW2QQ.ZVCJG)HE33JJ[)$\>Y4[E14/<\(
M>>SLF,R(XJ^=S<,7E6TMQ1RKMB77\'/I^T5RHO[5SN_0G]GOPZ8:S]MUN@O4
MM30U5OD5\%=0[4E1KD\Z-=R*BM54:O9R5J>*&F6]&S@C^F;$'Z8/]&;3'9X^
M3CKR,=<XSY)<12-EC:]CD<UR:HYJZHJ=RIZ3D!Q&\\^<P%3FB7JI5?\ K%.K
MN7>#UP#@VUX>2YU=XBMT20155<K5F6-.36JK41%VMT:BZ=B<_2:&QUP#X1Q[
MC*]8CK,0WNGJ[I525<D4*P[&.>Y7*C=6*NFOI4B];EUX=\YV5SBS6'1E?[NS
M$[_P=!V=W.H)V&G\@.&BQ\/TU\EL]TN%R6ZMA;(E?U:[$C5^FW:U.WK%[?0;
M@,?+OCDY,[87:^6'C<WLLK=FYE_=\,7)&L961ZPU&W5T$S><<B?U+N[O35.\
MX_XIPS<<&8AN5CNU.ZFN-OG?3SQ+W.:NG+THO:B]BHJ*=LC0V=G!SA'.W%K<
M1U]=<+1<5@9!,ZWK&B3HW7:YZ.:OG:+MU]")Z#-UN?'#.-O1;G$HL\"?$#['
M^,%P7>JGJ\/WR9/)Y)7:-IJS31OJ;)R:OBC>[4VWTC.9GW)P?9<$TLVE1=I?
M+*QK5YI3QJNQJ^#I%U3T]4?K;T;>"&N1R8GQ BIV:.@3_P#AGILP.""R9FWJ
M"[8@QEB"MKH:.&B;([J.;(VZ(J_@^U5W.<O>YRKRUT+]N3ASRXY/<I&8ASEP
M;A>LQKBNS6"A15J[E5Q4D7+5$5[D37U<]?4=F\,X?H\*X?MEFM\?54-OIHZ2
M!GH8QB-3L[]$_A4T5E%P380RCQS18IH[I=+I74;9$@BKEB6-KGL5BO\ -8BJ
MNBKISY:DAS'V>;'-GYOHKKB#0QR0LFCDCD:U\;T5KFN;JCD75%1?2BIRT4R
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MHUKPS^]QRJ_-2U?0XC91SCU7
M                    #SF.KY488P3B"\TK6.J+=;ZBLC9*BJQSHXG.1':*
MBJBJB=Z*<=),*\0W'3B5EWFH+E?*-'*D-34(E'::-JKYS8E=HSLTUV;GKHFN
M[M.TM131U4$L,K&20R-5CV.;JUS53145.]%3D?/NUYM&$;-)77.X45DM5*U$
M?45DK(((FIR1%<Y4:U/T <[\MNB'FDA;-CW';8G::.H<.P;M/^FE1/T=7\9O
M*Q]%[D;::;JZJ@O=ZD_Y>NNCF/\ T0I&W^ DG@?'V'<R+']VL+W>FOEJ=+)
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MUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
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MK2._3(J?X"W;BS[UV,[:^F6X),'4J^XEF9_5:+_D/RRX-D;KU52UW[5[=O\
M@/C63%^/JI$2YY?PT6FFJQWR&3M]#=G^4]K;ZR:K;^'H)J%VG-)GQN3XMKU,
M5,*XYM\/(55BK:/F^%7-_91^<G\!^!$TY+V^CO-E?LO0?BKK-27!J]9$C7_L
MV<G%F>/[&?3L9_BP\9:J-;A710]RJBN]2=I[]J(FFB<NP^79+(EI?,Y7I(KM
M$:[314;VK_#_ (#ZI=IK&/-BYN3&^?( !E1P
M
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MMU$_3R,'/V?::TTQ&%V-<XS.0 $-<
M                         &@>/3WJ6.O[A^GTYOXT#QZ>]2QU_</T^G(_
M-]'M\,I?3^GT^./S;_X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC91SCU7
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M37GH<U>C<Q[AS)_B%O-#C>6+#U;76^6TPU5RTA2GJ6S,5T,CG:)&KNK5O/\
M&:B=J@?DBZ+W/&6@\H=1V-DW+^=7W1O6\TU[4;M\/=&EFLS(X3LV8)98:O">
M,+2]LFQRHK98W<]%VJK98GHBHNBJU>:+S.]D]7!34DE3-/'%3,;UCIGN1K&M
MTUW*J\D3OU.0/24YTX4S;S?M,&$ZNGNU-8*!:*HNU*J.BGD<]9-C'IR>QB+R
M<G)5<_35$U ZG9)9G4F<>5.&<:4;$ACN]&V9\*+JD4J*K98]?VKVN;\1[LC3
MT=5LJK3PBX'95M<QU0M94Q,=W1/JY5:OJ5%1W]L26
M           (2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
M                                 \MC#W5+ZG?]D\Z>BQA[JE]3O^R>
M=-[U/H</.?%_K>WX?E@ !.:4
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M$[51.;E7M31$@\_!CA][)KM+;@ (RH
M
M
M                                               &@>/3WJ6.O[A^
MGTYOXT#QZ>]2QU_</T^G(_-]'M\,I?3^GT^./S;_ .&?WN.57YJ6KZ'$;*-:
M\,_O<<JOS4M7T.(V4<X]5P
M                  '/?CQX![KF!B&LS'RVI8ZJ\5"(^[6-JI&^I>U-.OA5
M=$5ZM]TU517*FJ*JJJ+T(+%:OI[]0/YX%7%>5]]DIG?=G"5ZB762'\+15+>?
M:K?-<G?VIZ3Y5XO5PQ%<IJ^ZU]3<Z^9466JK)G2S/733SG.557DB)S7LT0_H
M@Q!A.R8LI?)KY9K?>:;_ )&X4K)V?)>BH>$FX7<GII(WNRLP:BQKJU&V*F:U
M?6B,1%^/4#@FE3*Z%*=97NA1RJD6NK=53M1/3X$G^%S@*QQGA?:2OQ%;:W"F
M"(WHZHN%9$L,]4SD[93L=YRJNOZHJ;4YKS5-J];L-9/X#P;-U]@P3AVQS;M_
M66VU04[MWIU8Q%U/7[>?;R] 'SL/6&@PO8[?9K731T=MM].REIJ>)-&QQL:C
M6M3U(B(?3*:H5                              (2]+;[W'#GYUTWT.M
M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
M     \MC#W5+ZG?]D\Z>BQA[JE]3O^R>=-[U/H</.?%_K>WX?E@ !.:4
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M?:&W0IVQT;7U+T_:\T:B?$JDC,29\Y<81:Y;KC2R4[T37JF5D<LVG]0Q5?\
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M\5%TY*JH2M_^A7GXE#G]M]N3:VS-$>@ "BH
M
M
M                                                    &@>/3WJ6
M.O[A^GTYOXT#QZ>]2QU_</T^G(_-]'M\,I?3^GT^./S;_P"&?WN.57YJ6KZ'
M$;*-:\,_O<<JOS4M7T.(V4<X]5P
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M,7<US535%14[44#]
M
M
M
M                        /+8P]U2^IW_9/.GHL8>ZI?4[_LGG3>]3Z'#S
MGQ?ZWM^'Y8  3FE
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M@ *@
M
M
M                        :!X]/>I8Z_N'Z?3F_C0/'I[U+'7]P_3Z<C\W
MT>WPRE]/Z?3XX_-O_AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E'./5<
M                                                     !\?$F&K
M;C##URL=YHV7"UW&!]+54LR:MDC>FCFK\2_YC[  XJXOX9\X.'O/ZIJ,"81Q
M7>X;#<FU5HO5NM%14Q30ZH^-'/C8K7+L78]OI1R*G<O8O!>(),684M%YDMM9
M9IJ^DBJ)+?<8715%*Y[$<L<C'(BHYJKHOBBGVVLV]_\ KJ51FGK O
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MXHFAZG<BZ\E)7%RZ<VMN/:<?<B[\>_'FN^(S][* #.M
M
M                                  MW)R KJ@U0U7C/B LF';LEEMC?
MNW>%71\<,FV&'^KDYZ?$BGZ[-BW%MZC66CDPM6*B:K20U4RR)ZW:?]D#9.J%
M3R=HQLZ2X-ME[M\EDN+_ -225Z/AJ.>FD<B<E7]JNB^!ZO<!4
M
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M_P C3XX_-OOAG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E'//4,
M                                                   \)><Y,+X<
MS,LV [K<$M]_O-*ZJMS*C1L=5M?M6-CM?U3O1J]J=FJHJ)[G<!<"FJ&K\[.)
M# '#_9UKL8WN.DJ)&JZGME/I+65.G_)Q(NNG[9VC4[U0#9^Y"X\3D]F/3YNY
M:6#&5-1/M]/>*?RF.FE>CWQMW*B(Y4Y*NB:_&>V
M         (2]+;[W'#GYUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M  0\S.S@K,Q:*FHZB@@I&TLRR-?"]SE=JFGZ"89H+B<L]!;</6AU+0TU,YU0
M]'+#"UBJFWLY(!XS!/$%<<'8;H[-#:J:IBID<B222.1RZN5R_P *J24P;?9,
M2X5M=TEC9#)5P-E=&Q=415[413Q626';7799V:>HMM'/,YLFZ26G8YR_A7IV
MZ>@V#40/H[7+#;HHXY&1.;3Q<F,1R)YJ=G)-0-<9DY]VS!55);J*'[J71B?A
M&H_;'$OH<O>O@GZ36KN(K&E4Y)*>WTK(5YHD=,YR*GIUW'W\O>'ZY4F+/NGB
MKR6MIF[I4C9*K^LE5>2N143TJJ^.AOR*&.EA1D;6Q1-31&M1$:@&@<,\3TK:
MM*;$5K9%&KMJU%(CD5G/155BJJK\2Z^!ONBKH+A20U--(V:"9B21R-['-5-4
M5#1/$JW#2VRG5JP.Q#UJ?[G1%?U>B[ED1.[LTU^(]GP\5<E5E?;TD<Y_4RS1
MM5RZ^:CU5$^+73X@--YD?K\_W=3_ /8-Y9MYB5&75FHZRFI(JQ\TW5*R5RHB
M)M5>[U&C<R/U^?[NI_\ L$HZZUTESC1E730U3&KJC9XVO1%]/-% A?2X^GI<
MPG8I2EC=4>4/J/)=5VZKKJGI-XY:Y\5^.L74MGGME-313->JR1O<KDVL5W?X
MH:[M=!2R<0KZ1U-"M)]TI&]1U;>KT\[EMTT).TN'K90S-FIK=24\S?<R10-:
MY->2\T0#Q^;V9%3EO;;?4TM'#6.J9G1JV5RHB:-UY:&KTXJ;JG_[#HU_Z5Y(
M:NM-'=&-;64D%6UJZM;/&UZ-7TIJBGY?O5L?_,UO^:Q_Y@-!^VKNO_,='_UC
MSU.66?%=CO%D%IGMM/2Q2,>]9(GN545&ZHG,\KGQC6T4SY<,V2W4+)T5$JZJ
M*GC16KK^I-Y=O9JOCR/8Y$93-PK0QWVY1N^[%1'^#C<G^YXU3L_JE[_1V>G4
M/86S%U=77]*5]&D5(^5T3=45)&JC-WG<].2\E]9[,_*VB@94NJ4BC2=R;73;
M$WJG<FO:?J L5=$-19]YLOR]M#*&WJU;U7(O5*[14@8BHBR*G>NJZ)X\^[0V
MXKM-5(,YXWV2_P":%\ED=JV";R6-NO)K8TVJB>MR.7^V4YGQ[O;=/J?,]=LP
MW_@G3U[G:QKOB==?/+Q5975%QJYJJJG?45,SM\DTKE<YSNW55[>TP 'CNV^=
MLVVS.7KFFFNF(U\L,U'65%OJHZFFGDIZB)R/CFC<K7L<G/5%[4T4EYD'F[)F
M!:WVZY*W[M43$5[T1$2>/7D]$[E[$7QT7OY0]/;Y*7R6PYG6&:-VU*BH;2/;
MW.;)YFB_&J+ZT.@\%\0Y.IV==<9^;MGSPT'C'1X^UUMMX^=KB<93O!1G-J%3
MVAY&
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M>(FKYK:*D>J?ME?4(J^O1K?T(!]X
M
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MOH<1LHUKPS^]QRJ_-2U?0XC91HWH@
M                          ?-^^6T?\ZT7SAG^<#FQTN%!=*7'&7=\IH*
MJ*CBHYHF7")KD9'.DJ/:U'IR:_1$<G-%\W5.P]KP:](W;+U8_O6S>NT=LNU!
M KJ;$=5JD5=&QJJK)E1.4R-3D[LDTT]WIOF;CRS8*S*PM<,.8E=:[O:*YFR6
MEJ)F*G;JCFKKJUR+HJ.3FBHBIV'(+BZX/ZSA\O,EUL5>S$6!*J5&TU='(U\U
M&YW9%.UO?W(]$VNT_%7D!(+B.Z4VJKO++)E#1NHX5UC?B:XPZRNY]L$#D5&I
MZ'2(JZ+[AJ\R&F"LN\R>);'%2VST5TQA?ZEZ2UEPG>LB,U7]4FF>NUB+STW+
MKRT37L/1<)&#\K<<YMT5GS3NU7:[14;4I&PN;%!/.KO-BGFUUC8J<D<U$Y_C
M-.TV"K-@C+NP4UBPQ'9K'::=-(Z6C?&QNNG-R\]7.7O<JJJ]JKJ!\SAXR]N.
M5&2F#\(7:6GGN-HH&TU1)2N5T2O155=JN1%5.?>B&R#\\$\53$V2&1LD;TU:
M]BHJ+XHO>?H                              (2]+;[W'#GYUTWT.M)M
M$)>EM][CAS\ZZ;Z'6DV@              :.XJN>';-_9+_\5#>)J'B5L4MS
MP*RKB:YWD,Z2/V]S%315_3I^D#[V0SD]BNQ^J7^->>EQ7B:EP?AZMNU9JL%,
MS78WM<Y5T:U/%55$-39 YG6:'"4=CN-;#;ZNC>_8Z=Z,;(QSE?KN7EKJJIHJ
M^@]!G[&^\95U%102)40QRQ3JZ!=[7QH[M14UY(JHNO@!JIN/,P\V+C-361TU
M/3-TW1T;NK9&U>:;I-==?CU/J,R,S$N7X.OOZ)$[MZVNDD_@T/M\-^,K)2X>
MJ+-/4PT=QZ]94ZYR-ZYJHFFBKR54T[#=E7=:*W4[IJJL@IH4[9)I4:U/C50(
MQX]R-BP%@J:YU=P6MKUF9$QL;-(VHY5UUU[>SP^,VSPV_K84W]DS?XQK//[-
MB@Q3%#8[--Y320R=;45#47:]R(J(UOI3FO/TFS.&_P W+&F1?Z)F_P 8#4&9
M'Z_/]W4__8)8$3\R/U^-?_;J?_L$L (K6;WR+N__ &4E_P"T2I(G8_EGRZSO
MDNSXOP'E3:R/7L?&Y/.T\?=(20L&.[!B:.%UNNU+.^9-60]:U)?D*NO\ 'H-
M4-59V9K,P1;'6VWRM6]U3%VJU=5IV+_QB^/H3XSTN9.8-+E_AV2NETEJY%6.
MEI]?U23_ +J=ZD<LO[339AXOJKUBN[4L%&R3K)_*:AL2SN7L8B*O)OI\$T0#
MV.0>4[[A41XKO<:OB1ROHX9>:R/U_57:]NG=Z5YDB]IYV+&N%Z:%L45]M4<;
M$1K6-JHT1$3N3F?II,96&NGC@IKS0U,\BZ,CBJ6.<Y?0B(H'VP !CU(+9VV:
M2R9G7Z*1NC9YUJF+W.21-W+XU5/6A.KDB&GL_P#*&3'UJ9<K6Q%O-"QR-9R3
MKXU756:^E%U5/6J=_+F?'NEOV^K^SQ.VN9C[6_\  ^YKT^W/)F-=O*?L0]!E
MJ*:6CJ)8*B-\$\3E9)%(U6N8Y.U%1>:&(\<VUSIF-L>;UW3;7?$X#VN3%EDO
MV9M@@C35(:IM4]>Y&Q:OU_2U$]:H>.IZ>6LJ(H((W33RNV1Q1M5SW.]"(G-2
M7?#[E#)@.VRW6Z,1+U7-1JQKHOD\>NNS7TJO-?4GHY[_ ,%Z/)V^UIG&/FZ^
M><_#W?BT'C'>X^KUM]9^=MY8PW,SDU"H![5AY$
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MY=A[A&[>S1._DF@&0
M
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MY=?CC\VZ^&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4:AVX
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M-%J)5627Y3M=/BT/9:=W<51-.X*3.+AX^'6O'K&/N1=^3?EVMR9G*X &=8
M
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M6TFA54%-6[?*:>&HV]G6L1VGITU B][:/%O]"6SMT_4'_P#?'MI,6_T+:_\
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MY/!3Z\,#((VQQM1C&IHUK4T1$] &4
M
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ME&M>&?WN.57YJ6KZ'$;*-8ZP
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M1=6KXHIZ<C3T=$]14<(&!%J>>U:YD3N:JK$K9T37^%/4B$E@
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MR<FJNUJ-1>:J[EZ3T=Z:EQS,PW WSEM]+55LG[57HV*/].LGZ /9@
M
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M#BV&[U-QI:B%D3V+'"CMVJIHG:@&\
M
M                             ?,NJ<X_C_R'X-I]"YIYS/C_ ,A^+:3.
M//S<-%V<?M,K-HVE^T;3-*+59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE
M^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-
MHVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)
M*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOV
MC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&
MTOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)5
M9M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;
M1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE
M^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-
MHVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)
M*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOV
MC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&
MTOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)5
M9M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;
M1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE
M^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-
MHVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)
M*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOVC:)*K-HVE^T;1)59M&TOV
MC:)*K-HVE^T;1)59M&TOVC:)*K-I'?I!V_[4/'W/^@/Y0IB1>TCMTA2;>$+'
M_P#<'\H4Q9M^[EEXM?GX^.&WN&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4
M0'1
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MM@      IN*@0EZ6WWN.'/SKIOH=:3:(2]+8J.X<L.:?TUTWT.M)M
M        _/4TT=5!)#,QLD,C58]CDU1S53147XM3]  \Y@RW5MFLK+=7;I%H
M7+3P3N?N6:%O*-Z\^2[=$773FU>WDIZ!&?$GH&WL+P+$;SU[RR.!D:*C&-:F
MN[1J:<_29@!CV_Z_$5VK\9> +&,VJHVKZ>1> ,,<#8E=M:UNY=5VIIJOI4R;
M?T^DN %NTIM7^'TJ7@#"V!K)'/1K4>[M<B<U]:EZ,VZZ:%X PQ0-C5RM:UJN
M75=$TU7TKXGGL-V>I9>;Q>*^/JJJKD2"&+5%ZNGC5=B<N]SG/>O]4>G+=OZ
M*ZH5+? HCDYIWE/@*ZIH#Y=WQ';+!2K/=*ZGH($_XRIE:QOJU5>T\G[/.!>L
MZO[X:?=KI[E^GZ=NA%W[7#QYKOOC&?BSZ<'+R8G33.?P; 1W@.7>?*L^)+9B
M"F2HMM=3U\"_\;32MD;ZE5%[? ^GJG/F9]-]=\3KF6'.N=<QMB&0 &10
M
M             6[2NGH*@   *:>DIHI<    %NO,;D/AWFANE1>+)+05;8**
M">1]="O;-&L;D:U/[=47X@/O MWH-R 7%-4*;D])^"\U+J>SUTL;MDC()'-=
MZ%1JKK_ !]#<->T\EE7=JN^9=8<KZZ=U36U-%')+*Y$U<Y6\U73Q/I8?HKK2
M5UZ?<:MM33SU?643&]L,6QJ;%^-%7XP-2<0UHQ3BVJH;7:+/55=OIV]=)+&B
M;9)%Y(G;W)_A4]%P_8!J,&X7GGN-,M/=*Z572,>B;F,;R:U?X5^,VGRT7E_
M/$"X%J.3NYA7(@%Q3<-QY*]W:JIL?X8H8YU9254%8Z:+3D]6M8K?T:J!ZX%N
MY"NJ 5!:KT0KN J"W<$>BKH@%P*:H5
M
M                            /P7'W3?C_P A^,_;6^<]OQ_Y#\NG@2>/
M]W#3]C6>3*P%^WP&WP,LL%5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJL!?M\
M!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^ V^ DJ
ML!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^
MV^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256
M OV^ V^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;
M? 256 OV^ V^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K
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ML!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256 OV^
MV^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;? 256
M OV^ V^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K 7[? ;
M? 256 OV^ V^ DJL!?M\!M\!)58"_;X#;X"2JP%^WP&WP$E5@+]O@-O@)*K"
M.O2%^\_Q_P#O?_*%,2,1/ CKTA:?[3_'_P"]_P#*%,6Y],K^/7Y^/BVSPS^]
MQRJ_-2U?0XC91K7AG][CE5^:EJ^AQ&RB&W@
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M>UK7-U5J^*+JU?%%/3D:>CHGJ*CA P(M3SVK7,B=S558E;.B:_PIZD0DL
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MJJKV(GI.-/#E5>V;Z56XXTM2.GL5'=JV\^5-3<B4E/$L%.]?1O=Y/ZMP'9X
M   !IKB.Q-G)AJS6A^3F%;1BRYRU#VUT%WE;&R&'9YKFZU$.OG<NU317LK<<
M_P #6"?GD7VD38VKW\RNB <G..+&W$?B+*>TTN<& <.X5PTV]PR4];::ADDK
MZI*>H1K%1*N9=NQ97>Y3W*>=Z>LA"3I;$5.''#FO?BNFU^9UI-L
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M/L]?;ETU^?KB9^'JG("B%3V-Y.
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M_;.8U5_PGW3RV5[MV7&&'=O^QM.O_P";:>I
M
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MM3AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E$5M0
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M_.NF^AUI-HA+TMOO<<.?G73?0ZTFT
M       8^>CB".<EKDM.:&(X9$T62J=4)XH]-Z*GRB=R]AH7B0RFJ,24C,1V
MB+KJ^CCZNH@:FKIHD75%;XM75=.]%\$0Y7Y0]/?M=6>/$YU\X=%X#VM.KV\>
MTS&-O)%<%=%*'C^=8]7K>,SZ>8>ORAM4MWS+PW!"W<Z.MCG7P;&O6+_ Q3R"
M?H3TDI>&G*B?#M/)B:ZPK#75+.KI()$T=%$O-7*G<KN2(G<B>*H;SP;I[]KM
MZ8UQY:^><_=C_EI/&.WIU>KO;UV\L8^_*0#?<H5 /;L/'0
M
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M547:JIVIR,=5DM036O#M)%<Z^FDL+94H:F-S>LC<]4T<O+GM1-$3T*NNIL@
M>2P5@=^%YKG6UMTFO5WN+F.J:Z>-L>K6)HQC6MY-:B*O+Q/4R1]9&YNO)R:&
M0 >.ARWI:?+B3!T5=51TCZ:2E\K8K4F1KU555.6FO->X_#8,M+C9)J-JXRNU
M;0TR-9Y#-' D3V(FB,=M8BZ:>A>X]^ -0+P]4TE.RWOQ)=$L5)/Y3;;:S8UM
M%)O1^J.TU>B:*B([LW*?3Q%DM#?[U=)VWVNHK3>%8ZZ6F!&I'5.:U&[D=IJS
M5&IKIVZ&S !\C#-@CPU8*"U1325$='"V!DLVF]6M31-=$]!]<
M
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MUX9_>XY5?FI:OH<1LHPIH
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M.3XT0^\:7X.K5667ADR[HJ^DJ*"MAM;&RT]3$Z.2-=SET5JHBHO/O0W0
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M8W)JCFKJAFW 5!35!J@%04W%0            MW%=P%0
M
M
M                         !8_N,>TR/[BPNPP[>IH@T0 JQ&B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1  &B#1
M  &B#1  *:(1PZ11/]ISF%^]_P#*%,20(X=(K[SC,'][_P"4:8+\>K9?#/[W
M'*K\U+5]#B-E&M>&?WN.57YJ6KZ'$;*+$@
M                              ."./N*O-S,SKF8AQ_>JJGD]W24U1Y+
M3N]<4*-8OR3O<<@\PNBRS>PMUDN'YK1C*F1=6LI*GR:HT\63:,3XGJ!'7+'(
MC,+.>I?'@S"UPOVU=LE1$Q&P-7T.E>K6)\:DI<N^B;S%OZQRXMQ'9L*4[DYP
MT^ZNJF^"M:K8_P!$BD6L3Y89E9*7%*N\X>Q#A"JB<G5UTD$L":_M)D1&N_M5
M4V1E[Q^9X9>=7%%C.>_4<>FM+B"-M8CO1K(].M3XGH!/?+WHMLG\)I'+?GWC
M&-4WFYM=5K3P:IWHR':Y$\%>XDO@;*3!>6E/U.$\*VC#S=NUS[?11Q/>G[9Z
M)N<OBJJ0+R]Z7IWX.''. 4[NLK,/57^""7_2DF,O.D#R/S!ZJ./&,>'ZN3_S
M?$$+J/;ZY7?@O_? D3L_27GXK;<Z.[T,-;054-;1SM1\513R))'(U>]KD714
M]1^T                              A+TMOO<<.?G73?0ZTFT0EZ6WWN
M.'/SKIOH=:3:                                      ,4D\<,;GR/
M:QC>USET1/C/S?=RW?T?3?\ 7-_SGS\4X=MF-K%<+)<FI/1U4?53,:[1R(JH
MY-%[EY(OQ(0 SLR*O>45U>YR25N'Y7+Y-<&IR3]H_P#8N_PZ\M0.BE-7TU7O
MZBHCGV]O5O1VGZ#])RQP5CJ]8!OD%ULM;)35,2IJQ'+LD3]B]NO-/ Z!Y-YV
MV;-G#:UD,D='<:=O\_43W(BQ*G:Y->UGB!LK5.:ZGX_NU;OZ/IO^N;_G(><3
M7$-6W^6;#6%JB2"T1NVU=;$JM=4N_8M5.:,3^$C;;:&MO%=!1T$$]95SO2.*
M"%JN>]RKR1$0#JM#<Z.HD1D55#+(O-&MD15_1J?L(_<-O#HF6E.V_P!^5)<2
M31[4B:[5E(Q>UOH5WI7]!ON*>.9NK'->FJIJBZIRY*!F
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MN_N-$[T71475%[T-M9+7.2IM]=1/YMIW->QVO)-VJ::?$!XG[[,^OZ5;?_\
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MY+O9X:F7JUD<Y[-8EU:[:]S=R+X[=>7+T*J<S[(
M
M
M           %KN99M+NX%V&/./-;M&TN!5;"W:-I< 0MVC:7 $+=HVEP!"W:
M-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HV
MEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7
M $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I<
M0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"
MW:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=
MHVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC
M:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I
M< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP
M!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $
M+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0M
MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:
M-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HVEP!"W:-I< 0MVC:7 $+=HV
MEP!"W:-I< 0MVD<.D53_ &G.82_N?_*-,21(W](K[S?,+][_ .4:8HKCU;)X
M9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC91:R@
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M::V6^E8D<%)1PMBAB:GXK6-1$:G@G(^B
M  0EZ6WWN.'/SKIOH=:3:(2]+;[W'#GYUTWT.M)M
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M&<    !XJXYJ66V8G98I73.J%D9$Z5K$5C7/71J=NJ\^2JB*B+VZ >U
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MTQP=QM7#&(';41WEK45R=NFSL-S8^<B8%Q%^YM3_ !3C3G!RY/O6Q#_9S?\
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MD:FO9S_1N'(W]:G#7]B_]IP'M(H6PQI&Q$:QJ:(U$T1$]")Z#,
M
M
M                       !:I0JI0+<@ +E(  "   @  (  "   @  (  "
M   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "
M   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "
M   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "
M   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "
M   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "   @  (  "
M   @  (  "   @  (  " C?TBOO-\POWO_E&F)($<.D7]YQF%^]_\HTQ21LC
MAG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E%%X
M                                 #Y.)+[!AG#]SO-4V62FM]++5RLA
M1%>YD;%>Y&HJHBKHBZ<T]9$/AAP+P@XQAIOO%M5CNM[T1RT.)=T]=NTUU2"H
M56KI^RB;M]"DP+]9:;$5CN%IK$<M'74\E+,UB[56-[5:Y$7NY*IRCXA.C0QU
MEK6S7G+=]1C3#['+*RGBVMN=+IS35B:)-RTT='YW[1 .L-OME)::**DH:6&C
MI8V[8X*>-(XVIZ$:B:(?J]1PZP-QG9YY.5$EKAQ=<Y&4[NJDMF(8O*^K7]CI
M,BO9ZFJANFP=+=F51QI'=L*89N;NY\#)Z=WQIUCT_0B =7D=N[!JAR^DZ7[%
M#J>%L67=H;+^/(^X2N:_^I3:FGQJIX3%W2I9R7^&6&U08>PQK[B:BH'33MY>
MF9[V+S_: ==9*B.&)\DCVQL8W<YSU1$:G>JKZ/$U5:>*?+/$>:E#EY8L2P8@
MQ'5-F>K;7^'IX$CC<]V^9/,UT:J;6JY=>U$[3D-!?<^^*VZ26R&X8JQUO<B2
M4L<LGD42KV*]NJ0Q)XJB)_!I/S@NZ/V?(?$E%CO%M[2LQ9%#)'!;+?HM+3)(
MQ6NWO<FZ1^U>[1$7O=R4";0                            "$O2V^]QP
MY^==-]#K2;1"7I;?>XX<_.NF^AUI-H
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M6REM%''245/'2TL2;8X8FHUK4]"(G8?L
M
M
M        45-2TO %@+P%(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O
M(6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6 O (6$<.
MD7]YQF%^]_\ *-,22(W=(O[S?,+][_Y1I@JV/PS^]QRJ_-2U?0XC91K7AG][
MCE5^:EJ^AQ&R@
M         !;M+@!X3,'(W &:T*MQAA"T7Z3;L2HJJ5JSM;Z&RHB/;_:JA'?$
M'17Y*7JHFDI%Q'88Y%Y06^Y-<QB>A%FCD=^E5)A@"#=)T1^5S)I'5.*L731K
MV-CJ*5B]O>JP.U_0ALS W1UY%X)<V5V%'XBJ6KJDM\JGU">I8D5L2_&PDP /
MFV2P6W#5KAMMGM]+:;="W;%24,#(8HT]#6-1$3]!^_:I>
M               "$O2V^]QPY^==-]#K2;1"7I;?>XX<_.NF^AUI-H
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M!_%K@#$%JBEN-R=8[AII-2U4+UV.3MT<U%33UJANAS4<UR.[%[=?0>(O>1N
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M->Q3]]NMU/:J&&CI(FP4T+4;'&W71J)W ?L          %-$&B%0!31!HA4
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M3M/0X#;H
M
M
M
M
M
M
M                              $;ND7]YOF%^]_\HTQ)$C=TB_O-\POW
MO_E&F V/PS^]QRJ_-2U?0XC91K7AG][CE5^:EJ^AQ&R@
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M.HA9-"]LL4C4<Q['(K7(O-%1>]%])^@
M A+TMOO<<.?G73?0ZTFT0EZ6WWN.'/SKIOH=:3:
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MGNT1.U=>2(G).Q/0?6
M
M
M
M
M
M
M                                          "-W2+^\WS"_>_^4:8D
MB1NZ1?WF^87[W_RC3 ;'X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90
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MYT#41S/=?C+SU[O09\99-/Q4F-E2Y^3NQ!!3Q1:1+_.[H431RKKYVJM_A-I
M#2]#DIB2OKKW<\28I@N=SN=F=:'>3T:Q10HKT<CFMW=^BZIWJNO(]729;24N
M+\-WI:]KDL]K6W+#U2IUO)$WZZ\O5S/>@#1]/D-?</4&'9,/XEIJ6]6B:J_G
MJHHU?'+#.JJYJLW=J*NJ<^U$]!^:'ASO--2PQPXP7RBCO,EZHZI])K(V5S-%
M1^KE1R*Y&JJ>A%3O-\@#0>),N*BU8(J+'<ZUEXQ#C*\P^7U$,?5,5-S5=L9S
MT8QC%71>]3??@?F?212U$4[XF.EBUZN1R><W7DNB^*'Z@
M
M
M
M
M
M
M
M
M !&[I%_>;YA?O?\ RC3$D2-W2+^\WS"_>_\ E&F V/PS^]QRJ_-2U?0XC91K
M7AG][CE5^:EJ^AQ&R@
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MUTWT.M)M$)>EM][CAS\ZZ;Z'6DV@
M
M
M
M
M
M
M
M
M                                                   $;ND7]YOF
M%^]_\HTQ)$C=TB_O-\POWO\ Y1I@-C\,_O<<JOS4M7T.(V4:UX9_>XY5?FI:
MOH<1LH
M  #')(D<;GKKHU->2' C"-IN'$=G[0T-QN*4UPQ=?/YZK'^?U?7RJKW(BKST
M15T;X(G([]G"WBBR2Q%PSYXUU/"VIH;<M:ZX8>NT*N:CHM^Z/9)W21*K6JB+
MJBMUTT5%4.GF!^CRR-P=;8Z>7"28BJMNDE=>JF2:21?3M1R1I_:L0]RSA&R5
M:U$3*["ZHGIMD2_Y#G+@;I4\V<-V^"CO5OL.*DC1J+555.^"ID3L7<L;T:JZ
M=Z,/8_S7O&'=E_95_NN8"9E\X&<B,012,J<N;7!UBZ[J%\M(J+X+$]NAS,X[
M>&*R\->8MIH\-U]1562\TCJN&GK'H^:F<U^U[%<B><U>2HY4U[?1JNU+UTN6
M8=13.9:\'8;M\ZM5.MJ'3SZ+RYHF]G\.I%W&..<P^*3,ZCGNDM3BC%5R<RBH
MJ6GB1&M;JJMBC8U$:UB:N<O9IJKG+VJ!URZ/_%E=B_A0P-4W&1TU32Q3V])'
M\]8X9Y(XTU\&-8W^U)$FL^'7*A,E,EL*8*1[):FUTFE3+'[E]0]SI)53TIO>
M[371=-.PV8                              0EZ6WWN.'/SKIOH=:3:(
M2]+;[W'#GYUTWT.M)M
M
M
M
M
M
M
M
M
M                                          (W=(O[S?,+][_Y1IB2
M)&[I%_>;YA?O?_*-,!L?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E
M                                                    #S&.\N\-
MYFV">Q8KLM'?;3-HKJ:LCW(BIJB.:O:UR:\G-5%37M/3:H5 A'C7HG<KK[43
MSX?O=^PPLFNVE29E73Q^I'M21?CD4\)-T/%O=41+'FE4M@3W;'V)KG.]2]?H
MGQHIT7 $!L/=$-@FEEUO>.[]<8T7W%!!#2<O1JY)"4&2_"_EOD%$Y<&X<AH[
MA*S9-=*ERSUDB=Z+*[56HO:K6[6JJ)R-L@"FTJ4W%0
M           "$O2V^]QPY^==-]#K2;1"7I;?>XX<_.NF^AUI-H
M
M
M
M
M
M
M
M
M
M             !&[I%_>;YA?O?\ RC3$D2-W2+^\WS"_>_\ E&F V/PS^]QR
MJ_-2U?0XC91K7AG][CE5^:EJ^AQ&R@
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M;Z'6DVB$O2V^]QPY^==-]#K2;0
M
M
M
M
M
M
M
M
M                                                 "-W2+^\WS"_
M>_\ E&F)(D;ND7]YOF%^]_\ *-,!L?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5
M]#B-E
M  "W:7 ",&:?1Y94YNX]NV+[O]VJ6Z71[9:AEOK&10J]&(U7HU8W:*[:BKST
M555="0."\*P8)PK:;!2U=574UMI8Z2*HKI$?.YC&HUN]R(FY=$3GIW'W@
M                                $)>EM][CAS\ZZ;Z'6DVB$O2V^]QP
MY^==-]#K2;0
M
M
M
M
M
M
M
M
M                                  "-W2+^\WS"_>_^4:8DB1NZ1?WF
M^87[W_RC3 ;'X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90
M                                              Y*?S6W.#^EW!'S
M&L^M@=:P<E/YK;G!_2[@CYC6?6Q_-;<X/Z7<$?,:SZV!UK!R4_FMN<']+N"/
MF-9];'\UMS@_I=P1\QK/K8'6K<5-;</.8MRS9R6PCC"\0TM-<KQ1-J9XJ%KF
M0M<KG)HQ'.<[3DG:JFR0                             "$O2V^]QPY^
M==-]#K2;1"7I;?>XX<_.NF^AUI-H
M "FJ#5 *@
M
M
M
M
M
M
M
M                                                        $;ND
M7]YOF%^]_P#*-,21(W=(O[S?,+][_P"4:8#8_#/[W'*K\U+5]#B-E&M>&?WN
M.57YJ6KZ'$;*
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M"X       $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0
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M=B)R ]P
M                                              !15T J"FJ#5 *@
M
M
M
M
M
M
M
M!&[I%_>;YA?O?_*-,21(W=(O[S?,+][_ .4:8#8_#/[W'*K\U+5]#B-E&M>&
M?WN.57YJ6KZ'$;*
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M6IL<ES;!(ZF;*FK72HU5:B^&NAJ7+JSYQXI1*O&]\I<.4+F\K;:J:-:AW/\
M&D7<C.7HU W8FC4Y)HG=HA>?GI84I8&1(Y[T8W;ND75RZ=ZKWES*B.1SFMD:
MYS5T<UKD54]8'Y;I>;?8:1:FYU]/0T[>V:JE;&U/C71#Q4W$+EO%6)1KC*UN
MG<[8C8Y=Z;O1JB*A[VIHX:Z%T51#'/"[W4<K4<U?B5#QE7DE@*MK8JN7"%H2
MIC>DC98Z5C%1R*BHO)$[P/=-<CDU3FA4M;HW1$30KJ@%04UYZ#5 *@IJA3<@
M%P!37GH!4%-PU0"H*:H-4 J"FJ%-R 7
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M>*>)VZ.5J/:[THJ:H9P
M
M
M
M
M
M
M                  $;ND7]YOF%^]_\HTQ)$C=TB_O-\POWO_E&F V/PS^]
MQRJ_-2U?0XC91K7AG][CE5^:EJ^AQ&R@
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M*61L%0U(4ZREB3<J2.=R=KI&J:=NG60A)TM;=O#EAQ=?_2NF^AUI-L
M          #SV,<:V? MG?<[W6MH:)KFL65[55-R]B<D4\.O%%EKII]\L7_5
M2?\ =/.\92)[#\ZI_1<"_P#O$"^9S??\3Y.IRTTUQGR>P_)'Y%=3Y0='/:Y^
M7;7.-LXC$>[&/MPWSQ:9CX=S"O%@GP_<&7"*FAE;*K$<FU5<U4[43T&AF]_+
M0IZ=.Y-5_05TUT.1Y^QOV.7;EV\LY?0OA/A/%X3T->AQ;9SKK/GGU\\RZ X4
MXD\N[=ANVTU1B&)DT-/&Q[>IDY*C4U3W/@>BL7$1@'$5UIK;07Z.>MJ7]7%%
MU3T5SO1S:AS<VIS]/;IWGM\B/.S;PJBHFBUS#?\ 7\8Y=]]>.,>><8>2>*_^
MG/1Z_6Y^WKS;9SKC.T>7Q^QTW1=4U*ED?ZFWU%YV;YT  !:C57M'+T=Q<?DK
MF5#Z.=M*Z-M2K'=4LJ*K$?IR543M34#57$-GM1Y.X;V4RLJL2US5;04:><J=
MRR/:G/:G=Z5Y>DC+P89G5M-FY74%RGDJ&XC8_=(Y5T2H;K(U?C3<G+TH>OQ!
ME#=L#X+QSF5F)717/&%13S4M%&GGQTRR*L37M5/QD:[5O<WUEW#YDI)BG(*D
MN]OE9;L60W=]TM5>]JIM=&C8TC<J<U8[8[5/'4"9"N1#0F8/%K:,OLR)<'5%
MAK:NICEAC6ICE8C-9$14Y+SY;D-QX8N5;=[%25=PM\EJKI&?AZ.1458GIJBH
MBHJHJ:IJB^A4.?G%'5Q4'$S<ZF95;##/1R/7371J1QJH'0^Y5R6VVU58YJNC
MIXG3*UJ\U1K554_@-,Y+\4]JSGQ7-8J*QUEMECIG5/73RL<W1JM14T3^J0^=
M?>,?*ZML5QI8;Q5.EFII(V-\@EYN5BHB>Y- \!OZ\=9^Y4W^/&!(B/BRL\F;
MB8 2PUOEBW+[F^6=:SJ]V[;NT[=->XVUCC%,6",)7:_SP/J8;=3NJ'PQJB.>
MB=J(J]A ZF]^JW\Z/_XI-#B"_65QI^YDO^ #X.1G$/;L\I[Q%0VBJMBVYL;W
M+42-?O1ZN3EIV>Y4\GA3C0PUB''E/AFHM-9:EFJ74K:V>5BQ(]%5K=>]$5>7
MQH:XZ/;_ 'PQK_6:;_&D(SU&'[CB+&%[@M<#JBJADJ:GJX]=ZMC5SG*GI5$3
M^ #K)+-'!&]\CD8QJ;G.<NB(B=ZJ: PUQDX<Q7F/2X2MUGK9FU5:M'#<>L8D
M;^:IO1O;IR-"XGXKKKB[)*VX.I63.Q35N\@KJAC5UEA31&[=.U[T5&JG@OI/
M"9'V.LPUQ%X8M5PCZFNI+JR*>/77:].2H!,G.KBBM.2F**>R5UDK+E+-2MJ4
MEIY6-:C5<YJ-T7Q:I]_-?/2ARHP5:<25=LJ*^"Y/C:R"![6N9NCW\U7P0BMQ
M\?KMVS]R(OXV8V/QF?K"8)_KU/\ 1U S-Z0;#JZ:X4NB)_7XS<64>?F%\Y*:
M9+)-+!<:=NZ>WU;4;,Q%[')HJHY/4OKT-7<*^!,)8@X?J6IO]DM=8U\M3U]5
M54\;G;4>O-7JFJ:)V<^1HGA$;U/$;!':U>^A1M8W7GS@VNT5?3SV_'H!/C%V
M)Z+!F&;I?;D_JZ*@@=/(NO/DGN4\571$\5(Y6OCYPQ<+G2TLN';C1Q32MC?4
M/FC5L:.717*G?H9N/#'/W'P#;<-02:5%WJ.MD:BZ?@8DU_0KU9^A30>9>2L.
M$^'[ .*X87-KJQSUKWN_&27SH=?4QNGQ@=&HY6RM:YKD<UR;FJB\E3TF0U/P
MP8V3'63&'ZI\BR5=''Y!4*[MWQ+M1?C;M7XS;
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MT@5!15T&Y/7Z@*@     *:_&-4 J        "FJ%0
M
M
M
M
M
M
M                   1NZ1?WF^87[W_ ,HTQ)$C=TB_O-\POWO_ )1I@-C\
M,_O<<JOS4M7T.(V4:UX9_>XY5?FI:OH<1LH
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MW3U@7@       A+TMOO<<.?G73?0ZTFT0EZ6WWN.'/SKIOH=:3:
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MGJOQ@;1 ,,E1'!$Z21R,C:BN<]R\FHG:JJ!%WCJQ751X=P]A"B<U\MYJD?+
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M.%#PF5%)G=]_ZXBC=#]U7W'R'R9==%<KMN[=IKJO;H!I3CW_ %V[7^Y$2_\
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M4[B1H
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MMKGE6*-Z*NNB.C77DJ*B)R_0>UJ4CS!RUKX9D8_R^@F@D1$Y(]6N:JI\?/\
M0>CN]"VY6NKI7HBMFB<U?T<E/"Y<W%M!E_=:B9=L5*LTJZ]R)&CE_P H$<^
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M3Q153GKHBKIH>I
M
M
M
M
M
M                                                    !&[I%_>;
MYA?O?_*-,21(W=(O[S?,+][_ .4:8#8_#/[W'*K\U+5]#B-E&M>&?WN.57YJ
M6KZ'$;*
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M%EL=0M9+4W2G6!\LNFC8V-7GHGI\3<
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M9\S#6OWN6M%31?)8DY_U"'TP
M
M
M
M
M
M
M  1NZ1?WF^87[W_RC3$D2-W2+^\WS"_>_P#E&F V/PS^]QRJ_-2U?0XC91K7
MAG][CE5^:EJ^AQ&R@
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M])D %FU2J-]'87 "W:-I< +=J^DMZM?6ID %NWT%P
M                                                H!Y7&N7%AS#I
M(*6_T;JZGIWK+'&D\D2(Y4TU78Y-5T5>WLU7TGD/:MY;(G/#ZZ_V=4_Z0VLB
M]NI>B<C)KS<FF(UVSA"Y.GU^;:_)IC.?OPU/[5O+7_F!WSZI_P!(/:MY:_\
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MNLL-+%$_UHQ$_P BGU
M
M
M
M
M
M                                                         1NZ
M1?WF^87[W_RC3$D2-W2+^\WS"_>_^4:8#8_#/[W'*K\U+5]#B-E&M>&?WN.5
M7YJ6KZ'$;*
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M0ZTFT0EZ6WWN.'/SKIOH=:3:
M
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M-#V@ IHA4
M
M
M
M
M
M                                                $;ND7]YOF%^]
M_P#*-,21(W=(O[S?,+][_P"4:8#8_#/[W'*K\U+5]#B-E&M>&?WN.57YJ6KZ
M'$;*
M ' 3VM.<'/\ \56-^S3_ (.UG^CY\O2=^P!P$]K3G!\%6-__ ,G:S_1#VM&;
M_?E5C=>>O_!RL_T9W[ ' 1.&C-_X*L;?_D[6?Z/U#VM.<'P58W__ "=K/]$=
M^P!IOA#L=RPWPV9?6J\4%5:[G2VQL<]'6PNAFB=N=YKF.1%:NGI-R%NW73UZ
MEP                            "@$)NEM][CAS\ZZ;Z'6DVB$O2V^]QP
MY^==-]#K2;0                            "FJ 5!35!J@%0
M
M                        $?.,]53+6V-7L^ZT?+N_49B&G/P)E<:7ZVUJ
M]'W6C_B9B&IUGAFNN>#SQ[WC7RIY-].]&N<^F#GX#GX &WIK]CD/;\O\V?\
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M5\% ^\"FXJ
M
M
M
M
M
M
M          C=TB_O-\POWO\ Y1IB2)&[I%_>;YA?O?\ RC3 ;'X9_>XY5?FI
M:OH<1LHUKPS^]QRJ_-2U?0XC90
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M^JC:R-RM7L<JJJ(J]W:GZ5 W(
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M8/)V-:C9$ZWKMVG:]=8]53S?V/>;#
M
M
M
M
M
M
M     1NZ1?WF^87[W_RC3$D2-W2+^\WS"_>_^4:8#8_#/[W'*K\U+5]#B-E&
MM>&?WN.57YJ6KZ'$;*
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M5:->]&HG9O\ =?PGT<-8"H,.U#JEJNJJQVOX>;FO/MT_U[U/4
M
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M[5.U$_U0^AP)XWDA;B'!%<Y8YH'^74T3^U.:,F;\2[%T]*N EQMYHJ%X
M
M
M
M
M
M
M                                "-W2+^\WS"_>_P#E&F)(D;ND7]YO
MF%^]_P#*-,!L?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E
M
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M&R4-HM\=9&MOI(HG-JH%:K-K&>:Y>S<B*WUZZIKS ]R
M
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M:KI,VF23RC6:.1VJ-<K=NFQ533777FG(#WX
M
M
M
M
M
M
M            1NZ1?WF^87[W_P HTQ)$C=TB_O-\POWO_E&F V/PS^]QRJ_-
M2U?0XC91K7AG][CE5^:EJ^AQ&R@
M
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M!0X>N3*Z*IJJF>.G\E8ZJD1RMC\WER1-?<-TUUT[M-5U]4
M
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M@
M
M
M
M
M
M                                      C=TB_O-\POWO\ Y1IB2)&[
MI%_>;YA?O?\ RC3 ;'X9_>XY5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90
M
M                              $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^
M==-]#K2;0
M
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MMM<-)<6TFE/%'%&ZE<Y=R-;HJNW(FB\D/N@
M
M
M
M
M
M
M                   (W=(O[S?,+][_ .4:8DB1NZ1?WF^87[W_ ,HTP&Q^
M&?WN.57YJ6KZ'$;*-:\,_O<<JOS4M7T.(V4
M
M           !"7I;?>XX<_.NF^AUI-HA+TMOO<<.?G73?0ZTFT
M
M
M
M
M
M
M
M
M
M              C=TB_O-\POWO\ Y1IB2)&[I%_>;YA?O?\ RC3 ;'X9_>XY
M5?FI:OH<1LHUKPS^]QRJ_-2U?0XC90
M
M      $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0  MW(!<4W'X;G>:
M*RT;ZFNJ8Z:!/QY'::KZ$]*^"&I<69QSUK9*:SL=30N3;Y0_]4?Z=J=C4\>8
M&Y]R%QH[!V;U9:FLI;NUU92^Y2;_ (QJ?Y?C_2;>LU_H,04OE%!4LGC[]%T5
MJ^A4[4 ^F"FXJ
M
M
M
M
M
M
M
M
M                          (W=(O[S?,+][_Y1IB2)&[I%_>;YA?O?_*-
M,!L?AG][CE5^:EJ^AQ&RC6O#/[W'*K\U+5]#B-E
M
M                0EZ6WWN.'/SKIOH=:3:(2]+;[W'#GYUTWT.M)M #5F.,
M[Z"R22T-G:VY5K55CYE7\!$[LT5?QE\$_2;1<U'-5J]BH:-Q;P_PLKFUEMN#
M:6VM=NFAJ&J[J&:\]FGNO4OZ0/!W#$ERQ+6.JJVIDJ9.YS^2-3T-3L:G\/K/
MUTEGK*AJNBI*B?7OCC5^J?$FAY?']ZQ?9724V#Z&.QT4:;6ULD#9ZV7TN5[D
M5&(O[%B)IZ32%??,P:V]4L=WQ1>W0R3,CDF?6RZ,:KD15TW:=B_P 22NE'6V
MU$\HHIJ?=KIUS%;S3M[?0?'@Q1<[#4^4V^J=2SM['1\OBT[T\%Y>LV/FWA'[
MV+19HK?USK-2P>3M225TBH]%5=SG*NJJY%YKW[355':+AB2K;26VEDJYW+R1
MB?PJO<GB!N7+[B&I;K-%;L01I1UCW)&RKC3\%(OBGXJ^K5#=9H[+[AVAM\\5
MQQ%,E34,<DC:.!?P:*BHJ;U_&]2<O%3>&J 5!35!N J   !35 *@IJA4 "FO
M@-4 J
M
M
M
M
M
M
M
M
M   !&[I%_>;YA?O?_*-,21(W=(O[S?,+][_Y1I@-C\,_O<<JOS4M7T.(V4:U
MX9_>XY5?FI:OH<1LH
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M$2?\7$U&M3XD _2
M
M
M
M
M
M
M
M
M             !&[I%_>;YA?O?\ RC3$D2-W2+^\WS"_>_\ E&F V/PS^]QR
MJ_-2U?0XC91K7AG][CE5^:EJ^AQ&R@
M                                                      %-P%04
MU0IN\/ "X       $)>EM][CAS\ZZ;Z'6DVB$O2V^]QPY^==-]#K2;0
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M^_F>S
M
M
M
M
M
M
M
M
M     1NZ1?WF^87[W_RC3$D2-W2+^\WS"_>_^4:8#8_#/[W'*K\U+5]#B-E&
MM>&?WN.57YJ6KZ'$;*
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MKIM7\7N)1;?2I\B\X;H;]4VV:M8LOW/JFUD#=R[>M:UR-<Y._;N54U[%T7N
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MKPS^]QRJ_-2U?0XC90
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MZSZ@/;Z9O_DFXW^76?4";0 A+[?3-_\ )-QO\NL^H#V^F;_Y)N-_EUGU FT
M((XBZ1G,?"-HJ+O?>&3%-DM5-MZZNN-74T\$6YR,;N>^A1J:N<U$U7M5$[5T
M/T6OI!<T[U;:2X6[A9QA74%9$VHIJJGGJY(IHW(CFO8]*!4<US5145%T5%Y&
MT^D6;_M.,PM>S_8_E^^-,;(X9T_VN>5/YJ6KZ'$!'#V^F;_Y)N-_EUGU >WT
MS?\ R3<;_+K/J!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9
MO_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;
M_+K/J!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^7
M6?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H
M 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-
M_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H 0E]OIF_
M^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\
MNL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H 0E]OIF_^2;C?Y=9
M]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\NL^H$V@!
M"7V^F;_Y)N-_EUGU ^#?NDLQUA6Y6JWWOAMQ%9[A=YO)[;27"XSP2ULFYK=D
M+'T*+([=(Q-&HJZO;Z4)\$)>/-/]L;PG:<O_  K7L_LRV@/;Z9O_ ))N-_EU
MGU >WTS?_)-QO\NL^H$V@!"7V^F;_P"2;C?Y=9]0'M],W_R3<;_+K/J!-H 0
ME]OIF_\ DFXW^76?4![?3-_\DW&_RZSZ@3: $)?;Z9O_ ))N-_EUGU >WTS?
M_)-QO\NL^H$V@!"7V^F;_P"2;C?Y=9]0'M],W_R3<;_+K/J!-H 0E]OIF_\
MDFXW^76?4![?3-_\DW&_RZSZ@3: $)?;Z9O_ ))N-_EUGU >WTS?_)-QO\NL
M^H$V@!"7V^F;_P"2;C?Y=9]0'M],W_R3<;_+K/J!-H 0E]OIF_\ DFXW^76?
M4![?3-_\DW&_RZSZ@3: $)?;Z9O_ ))N-_EUGU >WTS?_)-QO\NL^H$V@!"7
MV^F;_P"2;C?Y=9]0'M],W_R3<;_+K/J!-H 0E]OIF_\ DFXW^76?4![?3-_\
MDW&_RZSZ@3: $)?;Z9O_ ))N-_EUGU >WTS?_)-QO\NL^H$V@!"7V^F;_P"2
M;C?Y=9]0'M],W_R3<;_+K/J!-H 0E]OIF_\ DFXW^76?4![?3-_\DW&_RZSZ
M@3: $)?;Z9O_ ))N-_EUGU >WTS?_)-QO\NL^H$V@! >P=)9CK%5RNUOLG#;
MB*\7"T3>3W*DM]QGGEHI-SF[)F,H56-VZ-Z:.1%U8[T*?>]OIF_^2;C?Y=9]
M0' 4G^V-XLM>?_A6G;_9ER)M 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3
M: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WT
MS?\ R3<;_+K/J!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9
MO_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;
M_+K/J!-H 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^7
M6?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H
M 0E]OIF_^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-
M_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H 0E]OIF_
M^2;C?Y=9]0'M],W_ ,DW&_RZSZ@3: $)?;Z9O_DFXW^76?4![?3-_P#)-QO\
MNL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\ R3<;_+K/J!-H 09N?2"YIV6VUEPN
M/"SC"AH*.)U14U53/5QQ0QM17.>]ZT"(UK6HJJJKHB)S/SX<Z1G,?%UH@N]B
MX9,4WNU5&[J:ZW5=3402[7*QVU[*%6KHYKD71>U%3M30E'Q+I_M<\UOS4NOT
M.4UOT=#?]IQE]IV?[(<OWQJ0-<>WTS?_ "3<;_+K/J ]OIF_^2;C?Y=9]0)M
M "$OM],W_P DW&_RZSZ@/;Z9O_DFXW^76?4";0 A+[?3-_\ )-QO\NL^H#V^
MF;_Y)N-_EUGU FT (2^WTS?_ "3<;_+K/J ]OIF_^2;C?Y=9]0)M "$OM],W
M_P DW&_RZSZ@/;Z9O_DFXW^76?4";0 A+[?3-_\ )-QO\NL^H#V^F;_Y)N-_
MEUGU FT (2^WTS?_ "3<;_+K/J ]OIF_^2;C?Y=9]0)M "$OM],W_P DW&_R
MZSZ@/;Z9O_DFXW^76?4";0 A+[?3-_\ )-QO\NL^H#V^F;_Y)N-_EUGU FT
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MKZ%)[D).EK;MX<L.+K_Z5TWT.M K[?3-_P#)-QO\NL^H#V^F;_Y)N-_EUGU
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M&J,5'R0I0[VMTDCYJB)Y[?2A]WV^F;_Y)N-_EUGU IE0W_[5+.7G_P"BE/\
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M?;Z9O_DFXW^76?4![?3-_P#)-QO\NL^H$V@!"7V^F;_Y)N-_EUGU >WTS?\
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MZ@3: $)?;Z9O_DFXW^76?4![?3-_\DW&_P NL^H$V@!"7V^F;_Y)N-_EUGU
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MOH<1LHUKPS^]QRJ_-2U?0XC90
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MPME:CD141='(J:Z*J:^)]("W11M+@
M       "$N:SD_FJ63:__NI/_%78FT?-FL=NJ+M#=);?2RW&%G5Q5CH6K,QJ
MZZHU^FJ)HYW)%[U]('T@
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M+:3:/FU]CMUUJ:6>MH*6LGI']932U$+7NA=JBZL54U:NK475/0GH ^D
M                                     (2\!:_[8[BS3O\ OK;],N1-
MH^;;[';K54U<]%04M'/5OZRIEIX6L=,[55U>J)JY=7*NJ^E?2?2
M                                UIQ+N3VN6:O=_P""EU^ARFN.CF]Y
MQE]^^'\H5)(BKI(JRFFIZB)DT$K5CDBD:CFO:J:*U47DJ*FJ:>)CMEKI+/21
MTE#2P4=-'KL@IHTC8W555=&IR3555?C4#]P
M              !"7I;7:\..'/SKIOH=:3:/FW:Q6Z_4S:>YV^EN4#7]8V*K
MA;*U'(BHBZ.14UT54U\0/I
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M /!2U?0XC99^6CI(J.FBIZ>)D,$34CCBC:C6L:B:(U$3DB(FB:>!^H
M                                  "$N:SD_FJ63:__ +J3_P 5=B;1
M\V:QVZHNT-TEM]++<86=7%6.A:LS&KKJC7Z:HFCG<D7O7TGT@
M                             !"7@+7_ &QW%FG?]];?IER)M'S;?8[=
M:JFKGHJ"EHYZM_65,M/"UCIG:JNKU1-7+JY5U7TKZ0/I
M                        $;>D8]YQF%^]_P#*%,22/PW*UTEXI)*2NI8*
MRFDTWP5,:2,=HJ*FK5Y+HJ(OQ(!X+AG<GM<LJ^__ ,%+5]#B-EGY:.DBHZ:*
MGIXF0P1-2..*-J-:QJ)HC41.2(B:)IX'Z@
M
M
M
M
M
M
M
M
M
M
M
M
M               !:CT<N@%P- YA<>&0>5]WGM>(<S+5'<('*R:GMT<UP=$Y
M%5%:_P F9)M<BHNK5T5-.9Z/*+BLRESTJ5I<"XZM=]KT9UOD*.=!5*Q$15<D
M$J,D5$1>:[>7>!ML%$<BIJ5
M  !X;-3.K ^2=A9><=XFH<-6Z63JHI:QZZRO1%56L8B*YZZ(JZ-10/<@UME!
MQ$Y;Y\PU\N ,646)4H-GE3*='LD@WJY&;F/:UR:['Z<OQ5-D@
M                           %-QK[-//K+S).FIYL<XOM>&6U.JP1UTZ)
M+,B=JLC35SD3THFG<!L($9K-TD7#;?;NEMILTJ".H<_8DE90UE+!KKI^K2PM
MC1/'=IWDB[=<Z6[4,%;0U,-925#$DAJ*>1)(Y&+V.:Y%T5%3L5.T#]P
M                              %NY--0+@?.N]ZH+!:ZJY7.NI[;;J6-
M9JBLJY6Q11,1-5<Y[E1&HB=Z\C7.4W%)E7GE?KE9L!XSHL1W*W1=?4T],R5J
MLCW(S>BO8B.3<J)JU53FGI0#:X!^.X7&EM5!/6UM3%1TD#%DEJ*AZ,CC:G-7
M.<O)$3TJ!^P$;\3=(IPY83N;J"NS3M<]0U^Q76R"HKXM?"6"-[%3QW:&T,JL
M^,OL[:&IJ\#8NMF)8J96I.RBG198=R>:KXUT>Q%YZ*Y$UT7T ; !35"H
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M=<J6[4-/7T53%64=3&V:"HIY$DCE8Y$5KVN1=%:J*BHJ<E144#]P
M                        !:KD3MY 7 U'FKQ890Y)5CJ+&N/K/9KBU$<^
MW]<L]6Q%35%=!$CI$14[%5O,^%ESQSY#YJW:EM6&LRK547*KD2*GI:UDU#),
M]5T1K6U#&*YRKR1$YKW ;Y!;N0N  QK(UK5<JZ-3FJKR0T/1<=V05QQ3%ARG
MS0LD]UFG2EC8QTBQ/D5VU&I-MZM=5Y(N[1=0-^
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MO6/RRV5#9F->B(JL=M7S7HCD56KHJ:IRYGJ0
M         !;N1/\  !<#05VX\<@;'B6>P5N:%DAN<,KH)6HZ1T4;VJJ.:Z9K
M5C3147\8WTR1KVHYJZM<FJ*@%X+'2-:W5RZ)X\B/6..D$X>LO;I-;KQF?:W5
MD+MLC+9#47%&.YZHKJ:.1J*FBHJ:\EY+HH$B :NRBXFLKL]NM9@+&UKQ%4Q,
M622CBD6*J8Q%1%>L$B-D1NJHF[;IJJ(;0U_0!4
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M+/$QG;^V DD#\U+615D$<\$C)H9&H]DD;D<US535'(J=J*G-#](
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M51-5;IJNG:;(U[N\"H
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M$?\ H-?.NF<O/_B;3_C5AU?.4/09_P"^V<O]9M/^-6'5X
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M<^&?"%UQ/C.*.''6(XXXWT4;T=]SZ1J[DA<Y%T5[G*CGZ:HFUB(O)=0FZ
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M^!4/J'R<,6&'#&&[39J=RNI[=214D;EY*K8V(Q%_0B'U@
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M 6>_0-ADJ%1-7)$]CWL>O)5V[D<J:KMY+I*+5 *@
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MG6LXJ3(N7_3$(E"BQ^48U:KM%_HV-.M_3Y0X#M6
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MR1.1-/.[6O5JZZ*J]P;;7QW.@IZR+<V*HC;*Q')H[:Y$5-4[EYG)+ N5&/\
MI/>(RFS3QI8IL+91VM8X:6&9':5-+%(KDI87*B+*Y[E<LDJ:-35R)S1K3KPU
MB-31.2 7                                $'N(KHZKEQ2\1]1B[&N.
MZBER]I:*GI[99+8JNJF*C$ZY$5[>KA1ST5VYJ/5VNB[=$)PGCLSLVL'Y.8>B
MON-L04>&[/)4-I65=<]6L=*YKG-8FB+JJHQRZ>AJ@1;Q%T27#Y=L+RVVVV>[
M6.Y]4K67F"ZSRS-?HFCG1R.6->SL1J:ZKX*D'^CXQ1B3AJX[JG*FLKDEMM?<
M:S#EVAC:JQ330)*L$[$7L7K&)HJ\T9(Y">&:_2F9#X L=7+8L128YOS6Z4]J
MLU+-I*]?<[IWM;&C==-='.<B=C5(P]';PNYBYA\2%=Q"YBV6HP[1^65ETI8J
MRG=3R5];5(_5T<3TW) ULSW(]>2JC$;JFY6AUC.;."NB,EQOC2^XQSRQ]6XA
MNEQK9:CR.RRKJ]%<NU9:B5BN7S=$V,8U&Z(B.5$.DQ31 .;O$GT1>7$.6%ZO
M&6<UTLF)K51OJH:2JJUJ::NZMBN=&Y')N:]R-Y.:[1%7W.G9\/H8,]KYB&WX
MNRONU8ZLM]F@CNEH25RN?!&Y_5S1-5?^+1RQN1.Y7.]/*<7%1FS;LE,@,<8L
MKYF1/IK;-#1QR+IU]5(Q601)ZY'-[.Y%7N4@1T)>5M;#[(F8E3$Z*AE;#8Z-
MRMY2N1>NG5%]#?P'9^R7T =5                                ##,V
M1T3TC<C'JU4:[371>XS #G-E%T05EJJZLQ)GGBZNQUBBX2OGJZ>VU4D5,Z1R
MZJY\[D2:5RKSU_!]O8IY[C>Z,#+/"&2F(\<Y9TM;AJZX<I77">W25LM52U5.
MSG*GX57/:]&ZN14=HNBHJ<]6SBS.XJ,ILFK[]QL:X[M6'KMY.VJ\BJ9'++U2
MJY$=M:BKS5KM$[5T["$7&ITAN&,XLNKME)D=37;'V(<31^15-9;[=.C(J=7+
MUK(F.:DDCW(FWDS8C7JNY530#[_0S9QWK&N4V+\#W>K6MAPC54S[:^;5SH:>
MI25>J1=>;6OA>J>C?IKHB(D],>XTM>76"K]BF]R]1:;-135]5)IJJ1QL5SM$
M[U5$T1.]51"*G1D<*5\X:LH[I68MA2BQ9BJHAJJFWH]%6CIXF*D,3].76:R2
MN<FJZ;T3M12SI;,82X:X.;S1Q+M6^W6AMCG(NBHU)%J%[^_R?3U*OI A3E-E
M[CSI5\_+YBO&5YJK+EW9)V*^EIYE<E)$_7JZ.D:[S>L<V-5?+M_;.155K2>$
M?17\-#;<VF7 $\DR1]7Y8Z^7#K5733?HDZ,W=_N=/ BYP3<:62O"3PG6*AO=
MQJ;CC"ZUM9<ZZS6*DZ^I:JS.BCZU[E;&Q5BAC5&J]':.:NW13:ECZ:3)VON4
M=/<<+XOM5-)R6K=34TS8_%S6S;M/4BKX 2@X9N%K"/"MA:]8?P;4W6HMMTN+
MKE(V[5#)GQ/6-D>QBMC9YB)&FF[5>:ZJIN4\EEMFCA;-_!]%BG!MZI[]8JS7
MJJNE<NFY.UCFKHYCD[VN1%3O0]:
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MGP.ATO$MSX1)J>155EOQ'6TT:?M5CAE5$^.5P$YP
M           "SK$0O-$<9'$E0\,&1E[Q:Z2*:_3-\AL=)+S\HK7H[8NWO8Q$
M61WI:Q4UU5 (3=([FI?.)C/G"G##EY-U^ROC?>I8E58UJE;N1KU3MCIXE=(_
M]LJIIK&AI/H_L(T^7_262X5I)I*BDLE=?K9#-*B(][(8ZB-KG:<M51J*I*[H
MH>&VNL>&;MGEC-DM7BW&2O=035G.5M&Y^Z2=57\:=Z;M5[6,:J<GJ1OX.?\
MRM>*?S@Q/_AJ@.SQ^.ON%-;:*IJZN>.FI8(W2S32N1K(V-15<YRKR1$1%YKZ
M#]>J'/?I7N).LPUA"V9)X.?)5XOQHK&5L-'JZ:.B<_8R%$3\>>3S$3O8UZ:>
M>B@1'SHO5\Z07-W-O'U)+44V6^7&&JZJH'*B[4CBAE=3MT7LDJ)6K([OV,5J
M^Y0D#T'2;L+9N<U_W9;4_P#S=0;FMO#11\+_ $<69&%E9&Z_U.$[G7WNJ9HO
M75CZ-Z.:B][6(C8VZ=J-U[7*IIKH-O\ @MFY_9MM_BZ@#I^
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M@>CV4D4:.ZFF1R<G.;O>KG)RW/T151J*LNP
M       -9\3:?[6_-A471?O3NRZI_8<IR$Z-+@XP#Q8^R.F-IKQ"F'_N;Y)]
MR:ID.[K_ "KK-^Z-VOZ@S3LTU7T\NO?$RBOX<<UF-15<["=V1&M355_G.7L.
M.G1U\:N$.$"FS&=BFSWR[SXB^YOD;+1%"YK?)UJ>LZQTDK%;JD[=-$=V+KIR
MU"=G\QLR#_HW&']](?\ 0$J\DLF</Y"99VC F%4J4L=J25(%K)4DF<LDKY7J
M]R(FJJZ1W<FG+1",&7'2[Y$XXO%-;;D[$&#'3N1B5E]HX_)$<O8BR0RR*B:Z
M(KG-1$UU54354F?:[Q0WRVTUPMM73W"WU,:2T]522MEBF8J:M<QS55'(J=BH
MH$:>._AAQMQ481PIA/#&*Z?#%D;<W3WSRATJI-#L_!JD;$TE5KD548YS6ZN1
M==41376$>AXR.LEE2FO4V(L1W%T>R2NFN'DZ([O=''&U$;W\G*_M7M[2=.T;
MTUTY@<(^*[(&]='9Q#82Q#@6_551;I];G8ZRK1.N8Z)Z-EIIMJ(DB:.9JJ(U
M'-DTT0[=9?XJBQU@/#>)8&HR"]6VFN,;6ZJB-FB;(B>K1QR9Z6O&RYS<2N \
MJ\+HETN=FB2B6*%=?Y_K9&)U/+O1C(-?0K].Y3K1@#"46!,"X<PS!)UT-FMM
M-;F2;=-[88FQHNG=JC0/1
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MY'560'#%A+#=S@\FOU3&ZZ72)R:.CJ9UW]6Y/V3&=7&OC&J]Y(<
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M*AQ$Z-3@^P)Q7U>846-YKO$RQ1T#Z3[DU3(=5F6H1^[<QVOZDW333O.TV7.
M+5E?@6PX1L4<D5GLM%'0TK99%>_JV(B(KG+VJNFJ^OD!Z@
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M;U;[_9ZG=U%PM=4RIIY=KE:[;(Q5:[1S51=%Y*BH?9
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M;&.>]_I7-HZ&>LJ6U.U5C?<JQ7;HV.7MV122*NG9OC_9(!U]
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M>L&+>)[C<J5M)-+=JQLVV)'H]6L1K&(FKD:JJNON4["10
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M\9WNFLV'LS,'WZ[U*JD%!;+]25-1*J(KE1L;)%<[1$5>2=B*!L4
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M5%14])^T^-A7"]!@[#-IL%IB=3VRUT<-#2QN<KE;#$Q&,:JKS71K435>9]D
M                             '@LZ\U+=DEE/BC'5UCDFH['1252P1KH
MZ9Z:(R-%[$5[U:W7L3<>]/%YNY5V3.K+B^X(Q*V=UEN\+8:A*63JY41KVO:K
M7:+HJ.:U>Q>SO Y3]'_C3 6)<\L9<0.=N8.&[9BJ:JD;:;?=:^.*1LTC?/G2
M-RZM8R-4AC3LT5W9M:I+3C5XK<F\:\*^95CL.9F&+O>*ZU.BIJ&DN4;Y9G[V
MKM:U%U5>2\CYO\QMR%Y_SYB_^^D//_\ ,&K.*3HN\F\G.'_'6-;#58F=>++;
MG55,VLN$;XE>CFHFYJ1(JIS[E0#X/1%Y]9<92Y58WM^-,;6/"U;5WMDU/3W6
MM9 ^6/J&)N1'*FJ:HJ:G1G.7.;#^2&56(,?WVH1]GM=+Y0UL+T5U2]VB111K
MV*Z1[FM3N\Y%[-5.3W1N\#67'%1E]BN^8UEO<=9:[JVCA2V5;(8W,6)KUW(L
M;M5U7TDS^E-P'<*O@HN%'AR"3R##]905%13Q:N5*.+6/L[51BOC>J]R,55Y(
MJ@1<P!A/.'I8,45U]QCB"3!635IK]L-LH&[F+*C=4CB141)9FL<FZ>37;UGF
MMT56)ZSB%Z*"ORWIVXZX?,2WBFOUGC\I2SU%2J5;W,:NKZ6H8C5214U\QR><
MJNT<G)I[;HFN); 'L#4F6MTO=OL&+;/65+VTMPF9 M=%-(Z5LD2N5$>J;E:K
M4YHC$733129V9&?F7F4^&JN^8KQ?:+9;Z=BO\ZK8Z654_$BC1=TC]4Y-:BK^
M@")71L<>=WX@?+LN,PGM7'-JIEJ*:Z-9U:W&!BHV1)6HB(V5FJ:JFFY%UT16
MJJS\.,W1EV"XYK\<^*,R[1;9J'"]%)=+C,Y&:1P^5ND;!3JJ<MVDCG(WGRB<
MO<=F0                                /S55)%5TTU//&R6"9JQR1R-
M1S7-5-%147M14Y:&O*+AHRAMT3XJ3*O!5-$Y=7,AP]2-15]*HD>A^K.K//"'
M#_@YF*L;5\ELL;JR&B6IC@?,K7R*NU5:Q%=HB-55T1>2%F$.(;+''=LCN%@Q
M_ARZ4KV=8CH;I#N:B-5R[F*Y',5$1=4<B*FBZ@13XZNCYRNQ'DMBK%V#L+6[
M!F*L.VV:YPK8:9M-3U44#'220/IX]K%5S6NT<B(Y':<U3D:\Z%+-.XWG!V/\
M!7"MDJ*&QS4UPMD$CE=U+)^M2=K/V+-\;';4Y;I'+VJIM'C_ ..;+G >26+\
M'X<Q-;\3XTQ#036B*CM-4V=*2.9CHY9II&:M8K&N=HU5W*Y6\M-53P'0QY)W
M;"67.+\P[M1RTD6*)J>EM:2M5JR4T'6*^9O+W+GR;4]/4KW*FH=(-R:Z$6^.
M?C7LG"?@9\%)+#<<P;M"]+1:_=-A[4\IG37E$U>Q.U[D5$Y(Y6_9XUN,*Q<(
M^7<5QGIVW7%=VZR&QVERJC99&(FZ654YI$S<S73FJN:B::JYO/'@UP9@/.W,
MZMSSXD<U<'RU\E7Y118?OF(J2*>IF:NC9*B%TB+'!'M:D<*HB*C4U38B(\-V
M]&3P<WM;Y/Q!YHQ3U&)[N^2JLM/<&KUVLRJLE?*BI[MZ.<C$_8N<[\9BITN-
M3MXKLCFZ(F<F7Z(G_P"]%#_I3W>$L:6#'EEBO&&;Y;<16B5SFQW"TU<=5 ]6
MKHY$DC56JJ*BHO/DJ ?=
M                                                   \[CC UBS(
MPK<L,XFM5->[#<HNIJJ&K9N9(W5%3Q145$<CDT5%1%145$4]$ .=.,.A4RUO
M%WFJL/XUQ#AZBD>CO(9HXJQL::\VL>J-=IIR3<KE3O5QMCAPZ,C*7A[Q#2XD
MV5V,L34C^LI:V]JQ8J5Z.U:^*%C4:CTT31SE<J+S3;W2^ %K6Z%P
M                               /A8QPM2XUPI>L.W!TK*&[44]!.^!4
M;(V.6-T;E:JHJ([1RZ+HOJ/N@".'"-P082X07XGDPS?+S>9<0)3MJ%NSHE;&
MD/6[-B1L;S7K7:JJKV)IISUD>
M    8GPI(W1Z(J=Z$+,Y>B9R3S0O4UWM$=SP#73.<^6*P2,\DD>NJ[NHD8Y&
M:+IYL:L;IW=Z38 '.&P="9EY2UN^]YA8DN=(CE7J:.GIZ5RMUU1%>YLGCJJ(
MFNO<33R-X?<"<.F$5P]@.QQVBBD?UM1,Y[I:BIDTTWRR.57.7T)V)KHB(;+
M                                   #X>+<,4N-,+7G#]=)*VANU%-0
MU#X'(UZ1RL5CMJJBHB[7+HJHI]P 0 _F*62']-68/]\:'ZF/YBIDC_33C_\
MOA0_4R?X CGPK<#> ^$:Y8BKL'73$-SGO<4,-1]W*F"5&-C5ZMV)%#'S57KK
MKKV)V<S#Q2\!F7W%K?K'>,773$-LK;13/I(EL=3!$V2-SMVCTEADU5%UT5-.
MU==>6DD@! '^8J9(_P!-./\ ^^-#]3+?YBCD?_33F!_?&A^IG0  :UX?LB\/
M\..5]KP#A>IN%;9[>^:2.>ZRLDJ'NED=([<YC&-[7Z)HU.2)V\U-E
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MP497\+D,\V$+5-57VHCZF>_7:5)ZR1FJ*K$5$:V-NJ=C&MUT3771#?@
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M<-9481H,+X1LU+8K%1-VP4=,S1$YZJYRKS<Y5YJ]RJY575553U0
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M4<-=ZAQ%1PUF*L5P_J-WOBL?Y*J]JP1-:C6+I^,NYR<]'(BJA*K;_P#0N
M                                 "+66/1]X&RNXD;IG-;;]?ZJ^UU7
M75WD%3)!Y+')5J_K$\V)'JU.L?M3=Z-573G*4   !Y7,O 5%F?E]B;!URJ)Z
M:WW^W5%KJ9J16MF9'-$Z-SF*Y%3<B.54U14Y=AJ?A*X-,*\(EIQ%0X:O-XO"
M7R>&:IDNSXEV]6UR-1J,8W3W;M===>79H2"
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M:KGR3RJB(Z65[E5SWJC4YJO8B(FB(B'O@
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M)HB)HU.SO7F;5
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M[U?**W7.\U#:2W44TJ=?5RN71&QL]T[Q731.]4 ],
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MV))#-&Y',D:J:HYJIVHJ:+KX@?K
M
M
M
M
M
M
M
M
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M7QHGBKHFI\9R9Z.#,5^7_%CA%KYG14-]ZVS5#=VB.ZYFL2>/X9L0'<L
M
M
M
M
M
M
M
M
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MJ(1_RYI> #,J[V^T4F&J^V7>XU#*6EH;A/>$?+*]4:UJ.CF>Q%5RHB:N37N
MG]GQ^L=F)^;MQ^C2'\^N7&'H\6YA88L51JL%SNE+12;5T\V25K%77U.4_H*S
MX_6.S$_-VX_1I#@KPZ-:_B RQ8Y$<U<3VM%1W--%JX^X#^A:UVNDL]NIJ"A@
M9245+$R""GB3:R.-K4:UK43L1$1$^(XQ=*A9J2U\6-QEIH&0R5UIHZFH5C43
M?)M<S<O+MT8T[5G&+I8O?6/_ '"H_P##(!-/HH7.DX4HD<JNVWNL:FJ]B:1K
M_A)E$->B<]ZDS]W*S_!&3* '%GI5O?:W']R*+_$<=ICBSTJWOM;C^Y%%_B.
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MCD7M14545%])_/5Q!9?4V56=^.<)4*O\@M-WJ*:DWOW/ZC<JQHY>]=BHBG]
M^-,:63+[#-QQ#B.YP6>S4$:RU%95/1C&)W)S[55=$1$YJJHB<U/Y[\YL=OS?
MS@Q=BNGIIF-OUVGJZ:E=YTC6/D7JX^7:Y&JUO+O3EJ!V?RD6NXC.!>UT5;5*
METQ)A&:TRUDKE55G6%]-UKU[U5S=R^M3BW+3XUX?<SVI)'685QIAVK1[-S$2
M6"1JZHY$5%1S53GV*U[5[T5#M[E<EKX4>$_#"XSGEH*/#=G@6Z20TTE0Z&9Z
MHLB;8VN<J)+(J;M-$3FNB:J:,N_%7PM\5^/;#@&_8:FQ!4W25U)17FYVYM+'
M"]6JK8TJ.L;/'O5-B(U/=*W73M CKEQTO>8]@9#!B_#%FQ;"WDZHIG/H*EZ>
ME5:CX_T1IVDD>'GC/X;LRL6*UF%;7E[C>Z53I73W2UT[/+*F1VJJE6Q/.>YR
M]LBL55Y)W'S,P.B#RSOJ3RX5Q-?<+5,FJLBJ%974S/4UR,DT]<BG,+.3+"MR
M6S/Q'@FOK:>OJK+5+3NJJ55ZN7S4<UR:]BJUR:IW*BIW =R.,G%U5@GA=S*N
M]&YT54RSRTT<B+HYCIE2'<GBG6:IXHAPPRDO6'L-9G85O&+:&HN>&[?<:>JK
MZ.FC:^2>)CT<L:-<YK5W(FW17(G:=>K)2W_/SHU6T]7'47/$5RPE(V-LJ[YJ
MN:#=U2Z\E5[^I8NO:JNU[>9R*R:DPE'FIA5<=TOEF#G7&*.[1[Y(T\F<J->N
MZ-R/3:BZ^:[7S0.I?\V!R:_I9QU\PH_K9S:XILQL)9M9YXGQC@FV5UILEXDC
MJ?)+A!'%*V=8VI.Y6L>]OGR(Y^NO:]>1ULI.CBX:J^FBJJ;+]D]/*U)(YHK]
M<7,>U4U1R*E3HJ+J1EO\/ #A3'U\PI>,+UU#56FJ=1SUS:RZU%*^1JZ/1CH:
MA[ET75/<IS:NFO:!(3A9IZK/OH\;9AZ:KV5MSP]<,.MJ)%UZO8Z:FA5=.Y&)
M&IR$EI\:\/N9[4DCK,*XTP[5H]FYB)+!(U=4<B*BHYJIS[%:]J]Z*AW%P-B'
M*3('AUIL1X6=+;,K*2%:^GF@AK*M>KFEUWHUZ/F5'/?KJO)$75=$YFA+OQ5\
M+?%?CVPX!OV&IL05-TE=245YN=N;2QPO5JJV-*CK&SQ[U38B-3W2MUT[0(ZY
M<=+WF/8&0P8OPQ9L6PMY.J*9SZ"I>GI56H^/]$:=I)'AYXS^&[,K%BM9A6UY
M>XWNE4Z5T]TM=.SRRID=JJI5L3SGN<O;(K%5>2=Q\S,#H@\L[ZD\N%<37W"U
M3)JK(JA65U,SU-<C)-/7(IS"SDRPK<ELS\1X)KZVGKZJRU2T[JJE5>KE\U'-
M<FO8JM<FJ=RHJ=P']%S$^+XM#(:5X.<673''#%ES>;S)-47.:U,CFGG=NDEZ
MMSHDD<O>KD8CE7OU[S=0 _G/SONRX@SGQ_<]=RUN(+A4JNNO-]2]R_X3^C _
MG7X@+"_#6>N8MJ<Q8_(\0U\+4=R\U*B1&K\::?I _H3PQ;6V;#MKH&L2-M+2
MQ0(Q$TV[6-;I_ 1ZZ1? "8^X2\:-9%UM99DBO,"Z:[>I?K(O_4NF3XU) X1N
MS;_A6SW1CNLCK:.&I1^NNY'QM=K_  EV*L.TV+L,7BQ5R;J*Z4<U%.W376.1
MBL<GZ'*!PZZ/C':8"XM<!U$DO5TERJ9+1,FNB.\HC=%&G_6K&OQ'@N(3'4^<
M_$#C3$=*KZW[L7B9*%K>;GP(_JX&I_T;6)\1XJZV^Y8$Q=6T,CWT5WLU<^!S
MXG;7PSQ2*U5:O:BHYO\  ;DX$<N?9-XJ,O[=)&LE'15WW7J51-6HRE19DW>#
MGLC9_; =<\7</]/4<'M;E-3L;+)!A9+= K4]W5Q0HK)/6LS&N7UKV''7@YS
M7+#B<R\OLDG4T[;K'153W<D;#4(L$BN3T-;*J_$=_P#:J=A_/YQ;9?.RDXE<
M?V"G:ZEA@NLE71[?-5L$^D\2(O@V1J:^ 'V..W'/W_\ %?F-7LD1]/27#[EP
MHB\D2F:V!=/6Z-R^M5.NW Y@%N6_"MEU:UCZNHJ+:VYU&J:.ZRI5:A4=XHDB
M-_M3B!@+#M?F]FS8+)-/)/<,2WF&EFJ'>Z5\\R))(ORE<J^L_HLH:.&W4L-)
M3Q-AIX&-CCC;R1K431$3P1$1 /YU\ZL75./<W<:XBK).LGN5YJJE=5541'2N
MVM3P:W1J>A$0Z*Y+])UDGE+E3A3!U/A;&<3;/;H:61::@I-DDR-_#2)K5(OG
MR;WJJHBJKE.?7$1@BKRZSTQ[ARLIW4TE#>:IL;'(GG0.D5\+_4Z)T;D\''3[
MAYX,.&+.G)O"F+Z+ \=:^NH8_+%CO5P:L=6UJ-F8YJ5":*C]W+3FFBIR5 (:
M<??%-ESQ25N$;K@^QWRUWJUQSTM;47BE@B\HIW*QT346.:15V.21>:)^J+Z2
M1G0U8NJ*K#>9F%Y9G.I:.JH[C!'KR1TS)8Y51/\ H(C]V>V5O!'P[8QMF&,8
MX(KH[C74_E2^0W*Y5#:>-7*UJRZ56YN[:[1$1>35\#?_  ;8>X>HK;B&_P"0
MU.K*:I=%27.9TEP<N]NYS&*E6JJBIO5?-_9)Z4 XQYU8NJ<>YNXUQ%62=9/<
MKS55*ZJJHB.E=M:G@UNC4]"(AT5R7Z3K)/*7*G"F#J?"V,XFV>W0TLBTU!2;
M))D;^&D36J1?/DWO551%57*<^N(C!%7EUGICW#E93NII*&\U38V.1/.@=(KX
M7^IT3HW)X..GW#SP8<,6=.3>%,7T6!XZU]=0Q^6+'>K@U8ZMK4;,QS4J$T5'
M[N6G--%3DJ 0TX^^*;+GBDK<(W7!]COEKO5KCGI:VHO%+!%Y13N5CHFHL<TB
MKL<DB\T3]47TDC.AJQ=456&\S,+RS.=2T=51W&"/7DCIF2QRJB?]!$?NSVRM
MX(^';&-LPQC'!%='<:ZG\J7R&Y7*H;3QJY6M672JW-W;7:(B+R:O@;_X-L/<
M/45MQ#?\AJ=64U2Z*DN<SI+@Y=[=SF,5*M55%3>J^;^R3TH!"GIC/U[\%?FZ
MGTF8AC'FCB.'*UV7D%<ZGPQ)=7WB>EC16^4U"Q1QM61=?.:U(T5&]FJJJZKM
MTF=TQGZ]^"OS=3Z3,?CZ-S@PPGGU:L0XVQLJW*TV^HDM%+9F*K$=,L+7NGD?
MW[4E38B?C:N7L1%#Q_1>T> ;AQ(T\&+Z5*B^I3+-AM:AR>3MK&+O559WRHQ%
M=&JKHBM=RW;%3M(C>:<S^?#-[+C$O"SGO7V)M5-27?#]>RJMESB\UTL:.22G
MJ&^M-JJG-$<CF]RG;CA>SXMW$5DU8\94:LBK96+37.C8O^YJR-$26/U:JCFK
MWM>U>\#F/TI>2=^PCQ 7#'RT4LN&,31T[HZYC%='!4QPLA?"]W<Y4B1Z:]J.
MY:Z+IXC(;I$<V<BL/6_#M'46[$>&Z!JLI[=>*?<L+-556LE8K7Z:JNFY7(G8
MB:<CHKG=T@>1&"[EB#!>*(;EB6HHY9**Y6=+&LD;G-7FQS:C8QZ:]B\VKVZZ
M*BGDJ7@+X<>)K MGQS@^@N>%*2]TZ54;[)6(S8Y?=,DA?UL;',=JUS6:(BM5
M-0-98?Z3?*'-2Y6E<W\IH8ZJB5[:6Y.IX+O%2[U;O>C)6-?&B[&Z[$<[S4.@
M&66+\)8YP90WG U=;[CARH;_ #O-;41L2>EJM1$V.3O:J(J+R5$..?&EP-/X
M4Z"RWJBQ4W$5ENU4^ECBFID@J87M9OYHCG(]JHB^<FWNY<T-W=#ABVZ,Q=F#
MACK9I+))00W%(G*JQQSMEZO5$TY.<UVBKW]6FO8@'3R^6YMULUPH7(CF5-/)
M"J*FNNYJI_E4_G9R=NJV'-O!%T1=%H[[0U"+Z-E0QR?X#^B'$]V;8<-7:YO<
MC64=)+4JY>Q-C%=K_ ?SS9&627$N=& K3%'ULE=?J&G1OI1U1&B_HY@?T7@
M
M
M
M
M
M
M
M
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MO8!,@
M
M
M
M
M
M
M
M
M
M                                  ,+XVRM<UZ(YKDT5')JBHO<J&8
M1FRWX ,L,I<UX,PL*RWVU7>GJ9IXJ2.M:M(ULJ.:Z'8L>JQZ/5$17<M$YZIJ
M29                               (SYE< &6.;N:U1F!BNHOUTN\T\,
MLE(^LC2D5L2-1L.SJ]4CT;HK=VJZJNNJZDDHH6PQHQC6L8U$1K6IHB(G8FAF
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                 6%=P%P+ !>"W<4 O
M
M
M                       %-Q4M3EXE-VJ<@+M4&J%.0Y 5U0J6\AR N*:H
M6[_$JGB4Q/O%P *@
M
M
M
M                  /DRXHL\,CXY+K0QO8Y6N:^H8U45.U%15'WVV/_ )YM
M_P Z9_G(_P"*T3[Z;S_9LWK_ %1Q\K_7L DK]]MC_P">;?\ .F?YQ]]MC_YY
MM_SIG^<C5_KV#_7L DK]]MC_ .>;?\Z9_G'WVV/_ )YM_P Z9_G(U?Z]@_U[
M )*PXHL\TC(X[K0R/>Y&M:RH8Y55>Q$1%/K$:<)HGWTV;^S8?7^J-)+
M**J(FJ@5!15T*@      %N[PT+@ !;N3L N!3<4W)V@7      *;AJ@%06[D
M^(KJ!4                        PRSL@;ND<C&JJ-W.71-571$,5?<::U
MT<M752MAIXTW/>[N3_7N-%8XQS/BBL5D:N@M\2_@H47157]D[3O7^#]*@;^W
M(7&L,N<R&UB1VN[2Z5'N(*AR_JGH:[]MX]YLW<@%P        +=R=G>7
M   %NY"NX"H!35 *@IJA3<BZ 7      *;@CD5-4YH!4%-R?$5  MW(7  4U
M0IJG^J 7 %NY +@6[D+@ *(Y%*@             %-4&J'X;W,ZEL]?-&[9)
M'!(]KO0J-5?\AHCV2<2_\[2?(9_F D+JA4T5AG'E_KL0VVFGN4DD,M3&Q[=C
M>;5=V=GB;U          M5R)Z2X       MW)\97<!4 MW)R N   %-Q17(@
M%P!;N0"X%NY"X  6HY'*J 7
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MW(G:I<     IJ@%04W%0 *:H->6H%04U0J !;N3XAN0"X MW)V=X%P!;N N
M        +=W@H%P+=R:Z%P
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MUO#^3M]#&=-N/&=HG.<9QCU]?N= P =B^=  MW)R N *:H!4 IN3U 5
M "W<GJ]8%P+-Z?ZH7@ "W<GJ]8%P+=R%P                         %N
MY/5ZRF]/]4 O         *;@*@M1R+Z?T%P    4U0J       "W5/\ (!<"
MW<A75 *@IJA4                       MW> W)\8%P
M
M
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M?/NIY3Y3I,L?N.I9L]SKVN[=#XO19>]"L7[HUW\<IH/HO/?*YY_])],>!TS
M  IN*GR,2U]5;,/72MH:?RRMIZ666GIT15ZV1K%<UNB<UU5$3D!YS.'-_#>1
M^7]TQABFN91VVB8NUFJ=94RZ+LAB3\9[E31$]:KHB*J>/X2\_P"?B5RAI\;5
M-ECL$DM;/2^11U"SHB1N1$=N5K>:Z^@@WFEPR9U9WX!QIFUG[?ON+'8;#6W"
MSX3H=J)"]D+WL16(KF1-U1NNKGRN1-'*W1%)&]%3[TJW?NO6_P".T#U'%_QI
M47"54X5CJ\*U&)ON\RJ<UT%:VGZGJ5B1==6.W*O6IZ--JD=_YLY9O@LKO[],
M_P!"='MJ]NIKW/C.2SY#95W_ !M>7-6"W0:P4V[:ZJJ'<HH6^+G*B>":KV(H
M$.L&]+G:L9XMLF'X,LJZ&:ZU\-"R3[KLDVNDD1B+M2'GIKKH="CG[T?.3MYS
M9Q7>.)3-!OW2Q%>:A[;"V9NC*>--6/F8U>QJ(U(HT[FL<O/5KB?SGM:U7.5$
M:G-55=-- (L<8G'50\*E_P /62#"CL8W>Z4DM;-2LN/DBTL#5T:]?P,BNW*V
M7N33JE])NO([-FWYWY48;QS:X_)J:\4J3OIEDZQ::9%5LL2N1$W;'M>W71-=
M$73F0)R$L=-QK\9F<&.+JQU7@JWVNIL5 [M3JIXWTD2MU[%=#Y3)X.D/1]%_
MC:X9>8SS)R"Q)+U=RL==-6T37<MRL>D52UNO<ND,C43M1SW)R Z)D?>(CB2N
M64^:.56 \/6:EO=YQK<5II4J)'-2CID?&UTVC>:\GO7U1.) ZH0;P:GLV])O
MBN]_J]FRSLC;93/3FUM7(U6N14[-=TU4G_1(![/B^XZ)>%C&N'<.0X#=B^:\
MT?E4;H[JM(YKNL6-&(Q()-RJJ>E.TU%_-4L:?DWWW^^LWU ^)TBNGMS>'[GI
M^&HOX;BG,Z4Z(!S]LG2@8QN]XH*%_#O>Z9M5/'"LSKI,J,1SD:KE_G)-=$77
M0Z!EB=GI_P !>           %-4*GR<3ULMMP_<*J!4;/# ^1CE37140TU[+
M&)/Z+C_ZAG^8#=6(?]X+HG_LLO\ B*1E/5U.9^(:RGE@EJXW12M5CDZAG8J*
MB]QY0#[&#/\ A7:/[+B_QT))D6Z*LEM]9!50.1LT#T>Q537145%0]3[+&)/Z
M+C_ZAG^8#?6J%31]GS/Q!676CIY:N-T4T\<;DZEB<E=HO<;P    4W%31G&C
MG(F1W#IB[$4$Z07>>G^YML771WE4R*QKF^+&J^3U1J!HZR=*#A^]<0<&7OWH
M.BP]47Q]E@Q;]U=T<CD<L;)>IZE$V.>K/^,Y-?N\"<6J>)R(OG"C4T/1KV#&
MD5,Z+$])='8K>K6JDJ44^R%41>W3JXZ>?7N1'>DZ*\)6<[,^<@\)XL?,V2YR
M4WDMS1JIYM9%YDJZ=VY4WHG[%Z ;BW(5U0T7Q;\3U+PJX#M>)ZO#\V(HZZY-
MMR4\-4D#FJL4LB.5RM=JGX-4TT[S3&->DICDO5?:\J,K+_FJMN32NN%NZQM)
M _35=JQPRJ]J:*FY4:BZ*J*J<P)M;DUT[S6N>?$'@KAUPBF(<9W%]'32O6&E
MIJ>)9:BLE1->KC9WKIWJJ(G>J&HN%CCXPSQ'XEK,)5=CK,$XTIVO>EGK)>N;
M,UB>>C)-C5WLT=JQS&KHFJ:Z+I%3I9<T;SB*ZVW!E5@>\6BSV.XK+2XGJ8WI
M17-7TS'.9$JL1JJU7*BZ.7W"]@'1O,?,9N ,H\1XZBH'7"*T6>:[I0NE2)9D
MCB63JU?H[:JHFFNBZ>A3Q_"AQ#^V<RH^_7[@?>WK6S47D/EOE?N-OG;^K9V[
MNS;W'@LKN*B^7[)K'^),49/XBP928,L;*R*FOS)(4O#$AF<]L2R0M31$A;JN
MCOU5NJ=FOON$_/>W\1>5*8NMF'OO8I5KIJ/R!96R\V(W5VK6M3GN[-.X#=!H
M;BOXDKOPX8>L5RM& :S'\ESJGTTE-15+X5IT:S<CE5L,NNJ\NQ#?);M YUW#
MI8L4VFBFJZ[AYN]'2PINDGJ+S+&QB>E7.H41#':NEIQ+?:)*NV</MTN-*Y5:
MV>DO4DK%5.U-S:%4Y$G./5/]J'F;ST_V.;V?UZ,\+T6GG<(=B[_]D:[77G_Q
MR@??X3.+6^<2-WQ#0W?+&OP"RU0131S5M6^9*A7N<FUJ.IXM-J(G-->T\)EQ
MTE5BQ9Q%5N5E]PG][$;;G4VBDOCKJD[)JB*58XVOCZEG5I(K51%W.T<K4YHN
MJ32VG#VEX=KGGWF7Q#S8>?,[$V&+E5W6AI(M?YZ1M;,DD3=.:/5NBMT7FK=O
M?J@=PMR<R/?&-Q7>U-PC8;]]ZWWU?=2O6BZC[H>1]7I&Y^[=U4FO9IIHAYKH
M_N*I.(;*IMMO=3NQUAQK*:YM>OGU479'5:?MD14=^V:J\MR(:FZ8]?\ Q0X#
M_=UZ_P#P[P)E8RS%^]/)F^X^2W^5_<RP3WS[G]?LZWJZ=T_5=9M737;MW;5T
MUUT[B#EFZ6_$.(J22IM.0%RNE.UZQNEHK[),Q'(B*K=6T*IKHJ+IXDL\X_>9
M8Y_,"N_DYYH#H?D_VM>)=?Z;JGQ_\RHO\P'F?YJEC3\F^^_WUF^H$G>%+B)N
MO$9@^\7R[8%K,!ST-?Y$RBK:ATSIF]6Q_6(KH8M/=*FFB^Y[3>.B%J=_<@%X
M
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M81JYECBDZBKH*QB1U-)+IJC9&HJIS1=4<U5:O<NJ+H&TP
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M-_\ !+[Z?OCEJ8O]\O(_)^JZGSOU*3=KUWAIM\22I&SC#XK;3PQK@S[JX/\
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M-KQ=F90Y?YAY?WS*K%-QD9#1P797/C?(]=(V/WQQ2,5ZZ(U=BM55[4 F.
M
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M1)W63AYRLPW=J6Z6C+3!]KN5)(DU/645AI89HI$['L>V-'-<GI1=2"'31_\
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M.,&YX#JZ7*/ UT;:<076*-;Q>>LZM:&GD549$U_XCW)YSG=K6*FG-VJ!];C
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MPH'6ZW8BJJFGHFN5=)))ZKRF?;RYM8K8V;N]=4[473HT
M   'A\S,*5>)+?'+1RO=+3ZN2EU\U_BG[9#1KVNC>YCT5CFKHK7)HJ+WDJC7
MN8>7+;W'+<;<UK;@U-9(T[)]/^T!I8%TD;H7O8]JL>U5:K7)HJ*G:A:  _U4
M^KAO#59B:O;2TC>S]4F<GFQM]*@4PYAVLQ-<F4=(W55]W(Y/-8WO5?\ (A(J
MTT"VNW4]*Z>2I="Q&++(NKG>*GX\,X:I,,6YM)2,Y]KY7>ZD7TK_ )NX^R
M %$4Y+\5V>6#\=<?N'H<8W1U/EY@&J935#HX'U#9)XM9I6[&(JKOF2.%W[6/
M4Z49\9J4N2^4&+<;5:M7[D4,DT$<G))9UT9#'_;2N8W^V(1]&5PX6#,'+O%.
M9.8N&K3B^LQ%<W,HWW^@BK?,C5W73-21JHBOED>U=/\ D@/5\0/'/PYYVY-8
MNP3/BNKWW:A?'3/DLU4J1U#?/@?^I_BR-8[Q1#Y?1&9U+B7+B_9:U]1K78?G
M6OM[7+S=1S.\]$\&3*KO^F:2W]J_DWIHN4N!E_\ ^;H_]$<\LTJ.DX&>D+L>
M)[52Q6; 6(VLDEIJ6-L=/%2S+U-5&UK41$2.1$F1B<DT8@'I^ETL[L09CY+V
MM';5KDJZ9'>C?-3-U_A.C6%<+6S!F';;8;)116ZTVV!E-2TL+=&QQM1$:GZ$
M[5YJO-3GQTHSFR9W\/KF*CD6KD5%;SY+4TNBH=(@.:>15JIL)=*]F':K3$VA
MM\U-5N?3PIL8O60P3N3:G+3>NNG^8^KT@OOS>&OE_P#M&C7_ /2,1^7*[_RO
M&/%[O))OH5.ACZ2RZT^$.)[A^Q)<G]1:J&JCJ)I51=&LAKH9)7<DYZ-<B\N?
M\ &]^D^]YYBO5>7EE!]*C+,B<YK!D'P%9?8TQ,RL?:*.V4\<C:&)))=9)E8W
M1JN:G:Y->9YWI <R,+9G\$N,;IA'$%OQ';H;G0TTE7;:ALT;)4J87*Q7-71'
M:/8NG[9#8W"+A&QXVX,LMK1B*S6^_P!IFM,2RT-SI8ZB!ZMD<K5<QZ*U=%1%
MYIW :Y_FMF1_]"XK_O;%_ICW'%WBVAQ]P(XNQ1;&S-MMZP]2W.E;.U&R)#,Z
M&1FY$5=';7)JB*O/TFS?:OY-?!)@7_\ )NC_ -$>!XW+51V/@RS"MENHH+?;
MZ2T104M)2Q-CBAC9)$UC&,:B(UK41$1$31$1/4!Y3HLO>A6+]T:[^.4T'T7G
MOE<\_P#I/ICS?G1:<N$2Q?NC7?QRD4. C.3!63W$/G+68TQ'1X=IJV2:*FDK
M%5$E<VK>Y4;HB]B =9CQ.<&;%DR3RYO&-L0MJG6:U-C=4)11))*J/E9$W:U5
M1%\Z1O?V:G@?;RY"?"A8O^L?_P!T];AC&N6W$?A&YQVJKLV/,-MF2FKJ>6!M
M33+(FV1&/9(W153S'<T[D CG_-;,C_Z%Q7_>V+_3$ILL<P[5FS@"R8PLB5#;
M3>*=*FF2J8C)$:JJB;D15T7EW*>>]J_DU\$F!?\ \FZ/_1'N[%A^VX:M5/:[
M/;Z2TVRE9U<%%0P-AAB;^Q:QJ(UJ>"(!KKBP;IPR9L+K_P"BUR^C/-+=%3[T
MJW?NO6_X[3=/%BY$X8\V?S7N7T:0TMT57+A+M_[KUO=^W:!,$YL](3?+EGYQ
M)Y:</-EJG1TOE,-9<WP\U9-*BJKW-_\ 4TR22)Z4E5#I,<T^!Z-,X>/?.C,:
ML3RB*VK51T+I.:QI)/U$*HOI2GA>SU.4#HKA;#%MP=ANUV"T4S:.UVREBHZ6
M!B<HXHVHUC?B1$-%\?&<OL,<-&*:ZFGZB\7AB62W+KH[K9T<CW)Z%;$DKD7T
MM0D6<R./"Y3\27&+EQD5;)G+;[;+&MRZIVBMDF:V6=VG>L=*QKD\7.0#%P'<
M6.1/#ED7#9K]B.I@Q5<ZR:ONC8K542HURKLCC1[6:.1(V-[.]SC5&>7$U@*U
M\:F%,ZLL+I/<*1W4/OD#J.6G>YS=8)VHCVMUZRG5J)I^,BJO:AU!CX6\FF,1
MJ938'5$33SL-T:JNB:<UZOF:-XT^#S 5_P"'3%DV#,!8=P]B2TP_=6EJ++:(
M*6:5(=72Q*Z-B*Y'1=8B-UT5VU>X"3][QS:;)@*X8Q?4LFL5);9+LM3$OFNI
MVQ+*KVKWHK4U3TZD5.B]PS6U64N+<RKNW?><>8@J:^294_5(HWN:G_YUU3^D
MC!;^+&2\=&C<L&NJWR8LIKA3X0B:U5662CE59HU1/V/4Q2P)_4)Z4UZ99%9>
M1Y4Y.X-P>Q&H^SVNGI9G-['S(Q%E?_;/5[O[8#GQTI-CJL1\3>3MGHJ]]KK;
MA30TD%='KNIWR5JM;(FBHNK5=KR5%Y=I[;^9MYR_E+WSY5;]:/A](JNG&;P_
M_P!>HOY13_.=*@(D\,O!WF)DEF5]\F)LYKGCFV^12TJVNK6H5F]RMVR?A)GI
MJFWT=Y+8            /A8T5%PG>-/Z%D_Q2.)*&NH8KC22TU0SK()6JQ[-
M535%]1YWV+,+_P#-?_Q$O_> T!_JH-YWC+;#E)9ZZ>&W;98H'O8[KY>2HU53
M\8T8 \-%5?!-?B!]+#='#7W^W4L[>L@FJ(XWLU5-S5=S3EZS=OL687_YK_\
MB)?^\!H_#G_""V?V5%K\M"3AY:GRUP[33130V_9+$Y'L<D\G)475/QCU(
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M]%4W.;=OJY(XVL=*[<JKJY6Z\U5>?:>K
M                                             %OI("<3?Z]V)O73
M_1HB??I("<3?Z]V)O73_ $:(W/A7TV?A_P X<-\KOJ./[L?\M7  ZQXZ
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M+KIX@3FZ*K*VIM&4N(,R;SUD]]QM<7S>42IY[Z:)[D1R^+Y73N7TIM)Q'G,
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MU*.;W G_ .4$XC_2M9>/Y60"7W%UAZ@Q'POYITURI(JN*##=?6QME:CD;-!
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MU'##FQA*>^XQN& KW;)(O.NTM73I4HFW7:V9CDE1^GXJ+N\ /M\*N ,H,'8
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M=->U&HY.3D \?T<*?[:CB/T_YQEU^?5'^O\ KJ:KXSLX<.4_2#V]V8M/77W
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ME!;,9T5/Y!4R/?27"W;M_DM5'IO9KIS14<UR+^Q>W7GJ0^Z&/_@SFI_9EO\
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M9K.__P!NJ".'3$NU]AKN_GNXKS_N0#8G2\^]AL_YT4OT:J-K?_T^O_\ 5_\
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MU$<J*[DNB:!UIW%3S^!8+I2X,L,%]DZZ]14%.RNDU1=U0D;4D7EZ7(J_&>@
M
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M..%O+3,=^$'XDPX^ZOPE$V"S/EN56CJ9K5C5-7-E19%_!,YR;E73FO-==M
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M79VGOP
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M\^-KO=2/3N54Y(B\^:ZHA)=.Q>1QWB/+KR\^<Z9F'LWR9ZO+U>E'+B,YS+(
M#6NM>-S2RDPKG/A&HPOC*U_=BQSR1S24OE$L&Y[';F+OB<UW)?$_=@' %CRQ
MPC;<+X:H?N;8K;%U-)2=;)+U;-RNTW/<YR\W+VJIZ0 #5V%>&K+K!>:5XS'L
MN'?(L9W?KO+;EY=4R=;UKVOD_!OD6-NKFM7S6IV<M#:( UGB_ASR^QYF?8LP
M[[A[R[%]B9#';KEY;41]2V*1\L:=6R1(W:/D>OG-7771>2(>-XO>)9>&#!%I
MQ%/A"3%MIKJ[[G5;8ZOJ/)]T;W-5=8WHY';5;HJM[>U>PW\?"Q=A"S8[P[7V
M'$-MI[Q9ZZ/JZFCJX]\<C==4U3THJ(J*G-%1%0",5EX<.$C-.GIL?V^P88J*
M:K8VK5\%SDIZ>/5NJM?3-F;'&Y$716JQ--%14Y<H[ODPSGKTDF75%EA3T<N#
M< VZ"G?56J)%H8XZ5\\RK&K4V[%EF9$CDU17+JBJBZF^KKT4F1-RN3ZF&FOU
ML@<[=Y%2W15A;SUT3K&O=IIR]UKIWD@,F.'K 60-DFM>!L/P6>*H5'5-0KG2
MU%0J=BR2O57.TYZ)KHFO)$ Q9O<.67N>]38JC'6'ON[-8GROMSO+:B#J'2+&
MKU_!2,W:K#'[K73;R[5UV: !K.'ASR\ASEGS7CP_MQ],SJY+MY;4><WJ&P:=
M3UG5?J36M]QW:]O,I1\.>7UOS@K,U::P)%CRJ9U<UV\LJ%W-ZIL6G5+)U:>8
MUJ<FIV>GF;- 'D\89J8+R^<UF*L667#CWQ+,QEUN$-,Y\:+HKFH]R*J(O+5"
M W"98[9Q)<=N9.=M!0-9A.R2K%;)4CV-J*IT24\<NU>USHF2RJG:UTK%7126
M?$7P@8#XG9K)48P2YQ5-H;*RGFM=4D+E;)M5S7;F.14U8WNU[?4>\RERAPKD
MI@JCPK@ZULM5HIW.D5B.5[YI'>ZDD>O-[ET3FO<B(FB(B('M@ !Y3,++/"^:
MV&9\/XOL='?[1,J.=2U<>J-<B*B/8J<V/35='-5%37M([0=%UP_17)E4N&[E
M)"U=5HGW>HZEWK\[?X^Z[26@ \[@O E@RZP[26##%HH[%9J1%2&BHHDCC;KV
MKHG:J\U5R\U7FNII_.'@6R=SMQ%-?\188ZJ]3I^'K[94R4KYUY>=(UB[7NT3
M3<J:\^_EI(( :4RHX.LH,F)9Y\+8+I*>NGB=#+75DDE7.K'-VO1KI7.V(Y%5
M%1FB*BKKVGH\F^'[ >05LN-NP#97V*AN$R5%3"M=4U+7R(FU')UTC]JZ:(NF
MFNB:ZZ&R !K'+_ASR^RNQQB/&.%L/_<O$6(I))+I6>6U$OE#I)>M>NR21S&Z
MO77S&MT[N7(]?BW!=CQ[AVLL.)+327NSU;-D]%6Q))&[QT7L5.U%314714T4
M^^ (H5/1?\/E1<?*6X5KH(/Z#CO%4L/K\YZN_P#>)$8"RZPWEEAN"P83LM)8
M+-!S91T42,;NY:N7O<Y=$U<JJJZ=IZ< 0PXL\M;/F3Q19)TMEPQ75>/Z&YT-
MUN6(&I.E)1V.EGEE=&Y57J=[Y7.V\E=JB(JZ.:BS/+-J^G3_ "EX UC@/ASR
M^RVQ_B3'&&[ EMQ/B)\TETKTK:B7RATLO72+L?(K&ZR>=YK4\-$Y&S@!\;%.
M%[;C3#EVP]>J?RRT76CFH:RGWN9UL,K%9(W<U4<W5KE35%14UY*>>RER7P=D
M=A:3#F![1]P[,ZI?5K3-JII_PKD:CG;I7O=V-;RUTY=A[H :ASFX4\K<_)H*
MG&^$Z>Z5].W9%<(9)*>I1OH62)S5>B=S7:HFJZ(>3RLX!,D\I+]#>[1A/R^[
MT[]\%7>*E]6L#D75',8Y=B.3EH[;JFG:2* %B-7ESUT/R7"W1W2BJ:2H1RP5
M$3H9$CE<QVUR*BZ.:J*BZ+VHJ*G<I^X :PR:X;\N^'ZGNT6 ,.,L"7-T;JMW
ME<]2Z7J]VQ%=,]RHB;W<D5$\Y39X 'FL>8"L>9N$;GAC$] VZV*Y1]354CWO
M8DC=R.]TQ4<U45$5%145%3M/&87X7LM<&987S+JS8>=2X+O*R.KK4ZXU4K9%
M>UK7Z/?*KV:HQON'-YZKVKJ;8 $8TZ-;AP3G['.B^E+Y<M?I!7^9J\./P=?_
M *<N7UDDV -.9.\(^4^0V):K$&!,*_<*[U-&Z@EJ/NC5U&Z%SXWJW;-*]J:N
MB8NJ)KR[>:Z_NSGX9,ML_P""G;CC"]-=:JF1&T]PC<Z"KB:BJNU)HU1VW557
M:JJFJJNFO,VJ (N8-Z-G(3!UXBN;<)27F>%=T4=XK9:B%J^,6J->B^AZ.3P)
M-P4T=+"R&)C8XHT1K&-31K43L1$3L1#]  _#=;<VZVVKHI))(HZF%\+GQ.VO
M:CD5-6KW*FO:>*R1R-PKP_X)^]7!]+-2VKRF2K5*B999'ROT1SG.7MY-:GJ:
MAL,   !X[,C*7!^;M@6RXSP[08BMJ.WLBK8MRQN_91N]TQVGXS512/%5T7'#
M_45R3LP_=*:%%U6ECN\ZQKX:N<KNSE[KL3XR7  UUE#D#@'(NVR4.!L+T5@C
MF1$FGB1TE1-IV)),]7/>G?HKM$773M/G6WADRUM.;U1FI38<5N/9W2/?>):Z
MID=J^/JW*D;I%C;^#\SDU-$Y)H;6  MVKS+@!J++'A5ROR;QA<\48+PQ]PKW
M<F/AJIHKA5/CD8^1)')U+Y71IYS45-&IIIRT0\7>.COX?;_>+A<Z_ 'E%=73
MOJ:B7[M7!F^1[E<Y=K:A$3555=$1$)(@",G\S5X<?@Z__3ER^LGT<+]'YD)@
MW$MIQ!9\!)27>TUD5?15'W8KW]3-$]'QOVNG5JZ.:BZ*BIRYHI(H >4S"RSP
MOFMAF?#^+['1W^T3*CG4M7'JC7(BHCV*G-CTU71S514U[2.T'1=</T5R95+A
MNY20M75:)]WJ.I=Z_.W^/NNTEH /.X+P)8,NL.TE@PQ:*.Q6:D14AHJ*)(XV
MZ]JZ)VJO-5<O-5YKJ>B  ^=>++0X@M=7;;I14]QMU5&L4])51)+%*Q>UKFJF
MCD7T*1DO/1D</UVN:5C,)U5 F]7OI:.Z5#87*JZKYKGNV^IJM3F2L 'C\MLJ
M,)90X<CL.#K!1X?M3%W=12,75[M--SW+JY[M/QG*JGPLUN'++S.ZYV&X8WP_
M]VZJQ/?);I/+:B#J'/<QSEVQ2-1VJQL]TB]GBILT   !K.'ASR\ASEGS7CP_
MMQ],SJY+MY;4><WJ&P:=3UG5?J36M]QW:]O,V8 !K+)GARR]X?Z:ZT^ ,/\
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M<U4T<U47312,E_Z,[A_OMT\M;A*HMBJ]7R04%SJ60O777W*O5&IW:,VHA*H
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ML-848^^1:]5<[G/)531:][$>NUBI^R:U'<]-3?8 LV]NA>
M
M
M
M
M
M                             6.:NG()'RT4O 'Y_)&?L&CR6+]@TRZ#
M0NMLP^RX_P"7#%Y-'^Q3] \FC_8M_09RI2V3V/']C!Y+%^P0IY(S]@W]!ET&
MA6VQ[+C_ )<*=6J)HG851JH7@M9@
M
M                                                           &
M/J^6B\_2876ZG=VPL5?ZD_44U0I&%<;9U]'Y?N93_P#(Q_)'W,IO^1C^2?JT
M7TC1?24KA=[3?[7Y?N92_P#(Q_)0?<RF_P"1C^2?JT7TC1?2(P>TW^U^1EMI
MVZ:0LY=GFF?JE1OF\E,I15*Q]BW.V=O54 %5
M
M
M
M                                           +-Z:[=?.TUT[P+P
M                                                           %
M-Q^*6]4$"Z2UM/$OH?*U/\H'[@?GIJRGJ6JL$\<R?^K<CO\  9MR 7
M
M
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ME)HD7:^-W)\3OV+F]R_ZH>D1/'M-WQ\FG+KC?CS.,^]IM]-N/;.F^(SCW+P
M9EH
M
M
M
M
M
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M>;V),!MRVK[_ %5FG2%:JFN+6];YC7JY&=4Y41-WI/+?S7/_ /LK??[X?_(
MZ%(Y%+B!."^E+^_'&-BL'L07JA^ZM?3T/E4E=N;#UDC6;U3J4Y(CM>U.PGL
M!3<-4 J   +=R=G:I75 *;D0(Y-->PUQGSGCA[A[RWN6,\1R2.I*7;%#2P<Y
M:J=VNR%B+WKS55[D157DA'CATX^<69\YC6&QIDE=K+AN[NE6/$KJV6:FAC9$
M]^]7>3-8[<K-J:/3F[1-0)H %J.3U 7 IJ@10*@MW(5U0"H+5>B&NHL_<$U&
M<*97TEX;78R92OK*FAIFJ]M)&U&K^%?[EKE1S51FJNT771$Y@;'!;N3M[@CD
M]0%P*;BH
M
M
M
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M]%Q_]0S_ ##V6,2?T7'_ -0S_,>/ 'L/98Q)_1<?_4,_S#V6,2?T7'_U#/\
M,>/ 'N[/F?B"LNM'3RU<;HIIXXW)U+$Y*[1>XW@1CPY_P@MG]E1:_+0DX
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MJV.*JI:*MJZ=M3(Z/5LBI"]J*J)RY\P.TQC14_U_A.>WM#.)C\I^^_WXN?\
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M#K3BG#=<VY6.Z0I/2U+$5-S=5145%YHJ*BM5%YHJ*AZ4UMD+EI@W*O+&V6/
M-0^IPHY75='.ZM6L8])5W*YDBJJ*URJJZ-Y<UT[39(&E^,/,GV*.&O,'$3)5
MAK&VU]'2.:[14GG5((W)XM=(CO[4^)P'9;>QEPJX"M[XNKK*^C^Z]3RT57U*
M]:U%3TM8Z-O]H:AZ2*IFS"OF3.2M%([K<6XACJ:U(E\Z.GB5(]RI^Q_#2/\
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MQ5E:VMLN&L6RLMMUM]53LIFR3SHL;V[&N<FBRI#+R7W:KV'78
M
M
M
M
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M/RRL.;^!;IA#%%*^NL5R;&VIIXY71.<C)&R-T<U45/.8U>WN(^_S,#A\Y_\
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MR4X3\NN'J\W6Y8$M=5:9KG$V&JCDN$\\4C6NW-\Q[E1%1571>[<[TFY
M            /RUU#%<:26FJ&=9!*U6/9JJ:HOJ/.^Q9A?\ YK_^(E_[QZP
M>3]BS"__ #7_ /$2_P#>'L687_YK_P#B)?\ O'K !Y/V+,+_ /-?_P 1+_WA
M[%F%_P#FO_XB7_O'K !Y:GRUP[33130V_9+$Y'L<D\G)475/QCU(    #F!Q
M$X>Q+P-\8#,\+!;:BX9?XFJ'+=HJ9G)KIE1:FG>O8CG/;U\:KHBNY<]JZ]/S
MYE\P_;L3VBKM5YH*:[6RK8L4]'60MEAE8OXKF.145/6!KG+?BGRHS4L<-TP_
MCJS/;(W>^DK*ME-50^E)(GJCFZ+RUTT73DJIS-#<8G2 X,R\P-=,/9?8CIL3
MX]N,3J2D=9)6U$5 KTTZYTK=6[VHJ[6-555VB*B'U\5]%UD1B>Z5%=!:[MAY
M9GJ]U/:;@K(D5>W:V1K]J+Z$Y<]$Y<CWF3/ WD]D;=8;OA_"[:R^0NW0W6\3
M.JYX51.3H]WFL=V^<UJ.YKSTY :[Z-GAHN61>4E9><2TKJ+%>+)(ZNHI9XU9
M+2TS&JD,,B+S1_G/>Y%T5-Z-7FU3571\^_-XE/&Y5B]O;_LC+S_A.BJ,TUYF
ML,MN&[ >4^.<58QPU:YJ._8FEDFN=1)5RRME<^597*C'.5K?/<J^:B >&X_[
M]B+#/"9CVOPU--35Z0T\4L],JI+'3OJ(V3*U4YIYCG(J]S55>[4T9T<^3&1M
MZR#M&(:NT8<Q)C%[YW7:6\QQ5,U%(DCD8QL<FO5-ZI&*CD1%<BZZ\]$G?=;5
M27RVU=OKZ:&MH*N)\%133L1\<T;D5',<U>2HJ*J*BD3[UT6&1%UO<MQBMUYM
M<4CE<M!0W)6P<^U$W-<]$[>2. C-TIV?&!\26S#&66#)J&O=9JUURKIK7L6D
MIG=6^-D+59YJO\]RNT]SHU.U51-^<;]4E=T<E+4M5%;+06.1'-75-%? J*B_
M&;BCX'\EX<LJS 5/@NGIK#5U$554NBGE2JFEC75CW3[NL735=$W:(CG(B)JI
MZK$?#M@G%F3E)E9=:&IK,&TD-/3PTKJR7K&QP.18F];NWKMVM3M[$T \UP-N
M3VI65_[D,_QW&]3S>7^ K-EE@VU86P_3NI;+:X$IZ6!\CI%8Q%5=%<Y55>WO
M4](!S?XY87X"X^L@\<5+>HM%4ZAHY*A>Q715SDF5?5'4QG1[<BD4^D>R*J,Y
M,@:NXVF*1^(\)2.O%$D*:R21-:J5$3=.>JL\]-.UT34-I\+><D.>V1>%<8ME
M8^NJJ5L-Q8W_ (NLC\R=%3\5%>U7(G[%S5[P(R]*1@>ML-NP!G9A^/9>\&W6
M&.>5B<^J=(V2!SE_8MF:C?7.IY7@UG7BIXU<P\\ZB"3[AV*)M'963IS8Z2-8
M8M.[5(&2N<B=CID7OYSYS!P!9,T,&77">)*)+A8[I#U%33;W,W-U145'-5%:
MJ*B*BHO)40^%DMD1@W('"LV'L$6QULM<U4^LD9).^9[Y7-:U7*]ZJ[L8U-->
MX"-72PW[$%CX:Z6.S2STUON%[AI+K)3N5%=3K%,Y(WZ?\6Z1K->[5&^E3[O"
M%DUD%;LB<)8AM=IPK>JV6V05%RO5TC@J:F.J5C5F1[Y-5AVO5R;$TTT3T:DG
M,98,LF8.&;AA[$=LI[S9*]G5U-%5MW,D;JBI\:*B*BIS141475"+/\RHR'2[
M.K/(K]Y.KMR6_P"ZKNI1/1NV]9IZW@1)X]^(#"&9_$5EU:\'34]?9\&U,<,M
MPI-ODLLLE1&Y[87-Y.C:D;4W)R55=IJB(JR*Z87WOF$OSHB3_P"$JC>V(^!_
M)?$^!;3@Z;!D-'8+74NJZ:&@J)8).M<S8Y[Y4=OD<K41%5[E7S4]"'K<X>'K
M!F>^$+9AC&M#47:U6^H950M\LEBDZQL;XT<Y[7(KEVO<BZ]NNH'ILKOUML)_
MN32:_P#4L(#<4B__ &I62O\ 8=M73^ZJLZ)6:U4UDM-%;J1FREHX&4\+5754
M8UJ-:FO?R1#76+>&C 6.,V[%F9=[9/48OLC(HZ*L;62L8Q(WO>S6-KD:[19'
M=J=X$,ND3MMVR;XELI\^J:@=66.A=3T-:D*^=UL4LDBL=Z%DA>YK5],2]G+6
M;^%\^LN\780AQ3;,:V62Q21),M9-71Q-B;IS21'N18U3FBH[145%U/38HPC:
M,:V&LLF(;;2WFTUC.KJ*.MA22*1OH5J^CM1>U%YD5KGT5&1%PN7E4%%?K9'O
MW>24MT<L7;KIJ]KGZ?VW^0#0-JQ$WC)Z2BQ8CPHQ];@S!4<+ONHUJI&Z*F62
M1K^:)IUE1*K6IVJWSM.2Z?1XZKW%D[Q]9/9CWB"1F'&T=+UM4QN[]2J9FU"H
MG>K(YHW:?MD)]959,8-R3PVVPX)P_2V&W;M[VP;G23/T]W)(Y5<]W=JY5T3D
MG+D?ESBR)P1GSAIEBQO8H;S112==3JYSHYJ>33171R-5'-54Y+HNB]^H'XL8
M\2F66!,%SXJNN-;*MH9#UT3Z6NBF?5<M4;"QKE61R]R)_@YD$.BHQ%)BWB!S
MEOLU.M))=(5KG4Z_\6LM6YZM^)7:$BL$=&/D7@S$L=X=9*^_NA?UD-%>:U9J
M5CM=><;6M1Z)V;9-R*G:G>;ER]X=<$97X^Q5C/#UMEH[_B>1TMSG=4R2-E<Z
M19%VL<JHWSE5=$Y :+P-QOT5ZXB<<909I6>SX-BH)7TUOJ*ZHW0UZM?HB/61
M$:G6QJR1B*B:HNG-=-? \>N27#E9LF<0XCBH\/X:QBV%'6EU@DCIY*J?=YK%
MIXU1LC7:JKG*WDFKM4T)+YZ\(>5_$3-!5XQL'7W:GC;%%=J*9U/5-C155&*]
MO)[=571'(J)JNFAK+!71>Y%8/O,5RFM-TQ&Z%4='37JO62G1R+R561M8C_4[
M5/ #[71QNQ$[A&P6N('3.>JU'D7E*JK_ "/KGI#V\]NGN=?Q-NG+0DZ?EHJ.
M*BIHJ>GC9#3PL2..*-J-8QJ)HC41.Q$1$33P/U <W\%_^6&Q9I_0;E]?^Q<)
M,CBQ<GM8\V?S6N7T:0R4/#1@*WYV5V;4%KG;C>L9U<M<M9*L:IU+8?U+=L]P
MU$[#V^,,(VW'>$[QAN\PNGM-VI):*KB9(YCGQ2,5KT1S514545>: 1;Z*I$]
MJ9;^_P#V7K5_]YIJCI-5_P!L'PZ+V?[(N7GR_P#.Z4F]E!DUA;(S!T>%<'T,
MEOLL<TE0V&:HDG=O>NKEW/55_A/CYJ\-V!,Z,289OV++9-7W/#<O76V6*LEA
M2)^]C]5:QR([SHV^ZU[ (K]+5EC=[[EY@W,&T0-G3"-;*VM\W<L<4ZQ;9%3L
M5J21,:O/EUB=VJIO3(G,W)+/3 -OQ#::#"<-3) U]=;)Z>F;/0S(B=8Q[7-1
M=&JO)^FCDT5%4WS6VZFN5%/25<$=52SL=%+!.U'QR,<FBM<U>2HJ<M.PBIC'
MHO<B<676>OBL]SP^^6197P6BO5D*N5=>3)&O1J:]S=$30#QF)>*K!U;Q.8:R
MIRMRZPICN.HECAN5ZIX(^KI7JY>L<QS(U:YL4:;W.1=%75J:*AY/I)+3<<L,
M]LG,]H*%]99[+54U%7) OG:PU#JAC%]'6,?,B+^U773D2\R+X7<N.'>EJ&8)
MP_'0UE4W94W*>1T]5,W=NVK(Y55&ZZ>:W1.2*NJ\S8.)L+6G&EAK;)?;=37>
MSUL:Q5-%61))%*U>Y6KX\_2BH@'E\-9^9=8LP:S%=LQG99; Z'RAU;+6QQ-B
M9IJO6(Y46-4[%:Y$5%3FA'CADXK,:\1_$ICRCL;*27)RRL5*:O=1.;-)*FUD
M;4DW?\8J2RZ.35&M1.6I^BX=%;D-6W;RR*W7RB@W:K0T]U>L*^M7HY__ +W\
M!)++7*O"N4&%Z?#F#K+2V.SP><V"F:NKWZ(BO>Y=7/>J(FKG*JKHGH @=T?G
MOW^(ST>67!/_ -)N)D<6+D]K'FS^:UR^C2&3+;AIP#E1C[$^-<-6N>CQ!B1\
MLERJ)*R65LKI)>M?HQSE:W5_/S40]OC#"-MQWA.\8;O,+I[3=J26BJXF2.8Y
M\4C%:]$<U45%5%7F@$$>!^ZWNQ='%CZY8<WMOU(V]3T3H]=[96TS7-<U.]R*
MFJ)WJB'C>C!RKR@S$P=B._XQH[/BO'_W4DZVEQ!LJ'Q4^QKVRMBE54=O>Z15
MD5%75.U--5Z 9.9+84R(P>F%\&44EOLWE$E3U,M0^9W6/TW+N>JKW)R-%X[Z
M,?(S'&(JB\?<>XV&6H?UDU-9JWJ:=[M==48YKD9ZF:)X ::Z2_._+O#F2[\I
ML)+:IKS<ZJ":HH[(R)(:"&&3?K)U?FM>YS41&KSTU543EKL/+ZK;6=%55/:Y
MKD3 ESCU1?V#)VK^C13:V$.!O)G!6"[[AFV8/A2EOE,M'<*R>>26KFB5456I
M,YRN8FK6KHS:FJ(NFJ'L,,</."\)9/UN5UMH:EF#*NFJ:22AEK99')%4;EE:
MV1SE<U%5[UY+VN4#0/1/\N%)O[N5G^",\STPR_[7S"?;_P *(N[_ -DJB6N3
MF2V%<B,(?>Q@VAEM]F\HDJNIFJ'SNZQ^FY=SU5?Q4[S\>=N06#.(7#5)8<;V
MZ6Y6VDJVUL4<-3) J2HQ[$57,5%5-LCN7B!'/C/_ /)K::<_N18?XZE,V3F9
MM]R=Z.#"V,\/V"/$M=:+3Y0^WRR.CW0^4O;+)JC5]PU5>O8FUJ\R1V.<D,(Y
MCY6>QW?J"2JPKU%/3>2LJ9(W]7 YCHTZQJH[DL;=>?/3F?5P!EM8LL\#6W!]
M@H_)[!;X5IX*6:1TVC%<YSD<YZJKM5<O;Z0-&Y+YT93\9.5%MK<5V["E?>>J
M6.Y8?NK89I*.;GJK&R^<C'>Z:]/TZHND*L[< X"RXXVLJK?P_521WN:X4[[C
M06>K=4P4LBSHBINW.VHZ+K5D9KM:U.:(BJA+W&W1AY$XQO$UPALUQPXZ9V^2
MGLE;U4"KSUTC>UZ-3GV-T1-.2=ILC(C@[RNX=I7UF$</_P"S4C.JDO-PE6HJ
MU8O:UKG<HT7O1B-1=$UUT0")?2Q*B9EY!?V96)VZ?\=1G2$U7G!PU8"SUNF'
M;CC.V3W"KP^^22WOAK)8.K5[F.=JC')NYQ,[=>PVH!SHZ/A43C-XE.7;<JS^
M493=/2?+_M/,5=W\^4';R_\ .HS;F6W#=@/*?'.*L8X:M<U'?L32R37.HDJY
M96RN?*LKE1CG*UOGN5?-1#[V;.4N&\Z\$UN$L6T<E?8ZQ\<DT$4[X7*L;T>W
MSF*B]K4[P(\Y?9FWW)SH[L(8TP]88\2UMHP[2U#[=)(YFZ+5&ROU:U?<-57J
MFG8U>9]W)?.C*?C)RHMM;BNW84K[SU2QW+#]U;#-)1S<]58V7SD8[W37I^G5
M%TWQ@G -FP!@NUX3L]+U5BMM,E'3TTKUETB1--KE=JKN7I(WXVZ,/(G&-XFN
M$-FN.''3.WR4]DK>J@5>>ND;VO1J<^QNB)IR3M B%G;@' 67'&UE5;^'ZJ2.
M]S7"G?<:"SU;JF"ED6=$5-VYVU'1=:LC-=K6IS1$54.N.[M\#2>1'!WE=P[2
MOK,(X?\ ]FI&=5)>;A*M15JQ>UK7.Y1HO>C$:BZ)KKHAZ3B%S;H\CLF\5XVJ
MGL1UMHG.I8Y%Y2U+DV01_P!M(YB+X:KW 0HX685S#Z2[.C%E*G7VVT1UE-Y1
MIJU9$EBIF(B^+8I=%]#=3I 1 Z-/(ZJRRR0FQ5?6R)B?'$[;M4]<B[VT_/R=
M'>*H]\B_U[1>PE^                !8G<A"/B(_7AQ%ZZ?^(C)N$).(EJI
MG!B!7)HCNH5OBG41_P"9?T'&?*GZEK\<?EEUGR9^N9_MS^>&MP >3O40
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M0QU$;=-51TZ*V6)R=Z*Y%31=4(8\"-IMF'^/3']LRIN-1<<L*>BJ&R5'6K+
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MB=B:KHB&QP
M
M
M
M                               #6&-,O+[BN]/JTJ:%E.U$9#&^1^K6
MIZ?,[54^%["=\_HJW_\ 62?]PW8 -)^PG?/Z*M__ %DG_<'L)WS^BK?_ -9)
M_P!PW8 -)^PG?/Z*M_\ UDG_ '!["=\_HJW_ /62?]PW8 -88*R\ON%+TRK6
MIH7T[D5DT;)'ZN:OH\SM139X
M                   ,4D3)XWL>QKV.31S7)JB^"H90!X"^Y06JYR.EHY'V
MV1?Q8TW1_$U>SU(NG@>6ER1NZ._!5U$]OI>KVK_BJ;H &H*'(^K=)K6W*&-G
MHIV*Y?5JNA[K#> [5AKSZ>#K:G33RF9=TGQ+W?$B'I0!31"H
M
M              !8L>[DNFGJ-1Y*<-UBR'Q!C2KPK7UT-FQ+6I<'6&56>24,
M^BHYT"(U'-145$VJJIHUB)IM-O@
M                             &H\].'.Q\0,^%8<4W&O6QV*XI<I+)3N
M8E-<9&Z;$J-6JY6M3>FB*FJ/=X:;< &&*%L#$8Q$:QJ(C6M1$1$3N1#,
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MB:&4                       QNC1VFJ(NG/GS+D:7
M
M
M
M
M
M
M
M
M
M                                !31"H IS\!S\"H IS\!S\"H IS\!
MS\"H IHA4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
4                        _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3[KQ=JC-':6DY6WTRW+;F/3A(T[GT'K7NG_!5W]IO]KK]FO]KV\\&?#WQ?\
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MI^TKJFCP?#CX5V-RUOIFI12Z[J"*Q F97\N)'"]0.6QT.: .9_:D_P"#LKQ
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M8T\$-'#'$S>(B"R*%/\ JO85X[_P:*6L=YJGQ@\Z)9-L=IC< <<GH.U>T?\
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MC_@H]KC>#=;T>/P=\0K>W^T16:S^9:ZHBXWM"2 0R\_*<Y]:^7_ _P#P<N?
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M(Q^9B..?R% 'YD-_P<\_%0_M=1?#W_A7OP__ +-?Q8GA_P"TYO//$9NQ!O\
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M]4\?:UIEY?Z-X?$,)M;(*LFUOE4#/'&.E? :_P#!VI\&U!_XH'QQNSR T/\
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M/Q"U#]GVTL? *J)VB?3)L10Y'+$2&9<@_>( [].!XA_P0=_9:T']H+_@K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS<X]*X_]EW_@H/\ !G]M#6M4T_X8>.].\77NA1+=7L5K;3QFV1F*ALRQKG+
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M?_!J:@_X;_UMF ^3PQ/C/8Y6OU*_X.'V!_X)5>/B,?ZVU_\ 1HKYM_X(=?\
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ML$FES ?+EAC+<@C&XCW-?K\W_!(K]F(%4_X4/\,S@CG^PH,'/?'^'/%?(/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%(74'[P_.ESF@ HHSBC=0 48S1N%% !THHSBB@ HHSFB@ QFC%%% !BC%%%
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M#B_PKMO@?^PU\(?V9/$EUJWP]^&_A'P=J5[ +>>ZTG3DMY)8\YVDJ.1['UH
M]7@;<GXD?D<4^HH(_+'XYQZ9J6@ QFC%%% !THQFC-&X4 '2BC/-%  <T8SU
MHHH ,48HSB@'- !THQFBB@ Q1BBB@ Q1BBB@ Z4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:"\1>$/C5\3_ (%ZEJ,VH:#HOF7>FH6W);2QS-%,4[*K  X'?)[U^V,9RO\
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MH7%W=?!OP?+<74C2R.UIR[,<D_F30!XJ/^#G3]EHG_D+>,/_  3#_P".TO\
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MA(_6@#WJBN;^&?Q=\*_&'0/[4\)^)-%\2:>3S<:=>QW,:GT)0G!]CS6AXO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_NV_P#Z.DH _;8&HYQ\OZ'\:DKS_P#:F^*TWP/_ &=O&WBZW56N?#NBW5]
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M'_ J_-/_ ((F_MU+\(?^"/'QLT_5[IK?4OA$MX;=';,T:W"E4VCKA9FV^V*
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MRF,9Y-><_P#!OO\ \$C_ (9?%CX$^ ?CYJ4VO+XTTG6[J2*.*ZVVA,,FU?D
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MC;RNZ]0#[5_3P>%]_IUK\'/A+I\-[_P=4>(_-B63R?$-Y*F1]U_(X;\.?SH
M^D;C_@U7^$.I_"^:WU#Q=XTO/&TT6^37C<C:]P5.<Q%<>66/(.3@=?3Q#_@V
MH^,?BSX+_MB_$K]GW6-4EOM(L%N+BU@D8[8;BVD*,R*3\BLNW('&>>]?N"W
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M5 /.3S7](TC[@O\ #R,?R_J*_#?2+.QL?^#JN9;)E82:D\DP QME-N=X_/\
MG0!^A'_!;3XW?%;X._L<7UO\'?#GB#6_%WB.;[!]HTFT:XFTVW()DD 7D,1@
M CH:^-/^"=O_  ;>>$?C#\#-*\>?M WGB[6/&?BJ/[=+ICWLEFVGAB<+(1^\
M,G<Y/X5^@O\ P4M_X*.^$O\ @FQ\##XL\0Q3:IJ=\YM](TB!PDNHS 9(W'A4
M48+$]J_-GP/_ ,%&_P#@H=^WU:KKWPA\ :5X5\'Z@Y%K>-80^2R'N)+K+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1G%&::[8;MGO]* '9YHS7
MG'C_ /:R^&_PK^*.D>"_$7C3P_H_BS7MO]G:5=7:I=7>XD#8G4Y((%>AP@T
M29HJ.4<]_J.]> ^+?^"I_P"SK\//$M]HNN?&7P'I>J:9.UO=6MQJ2K);R+U1
MAG@CTH ^@J,XKYM/_!7[]F$=?CE\._\ P:)73_![_@HA\#_VA?'$/AKP/\4/
M!_BC7YXVFBL=/OEEF94^\V!S@9';B@#VO.:"V*AB.SY?4Y KDOB_\>_!/P%T
M1=4\;>+O#?A.P;[D^K:C%9I*1V7>1O/LN30!V>X49KQ'X8_\%$O@3\9?$4>D
M>%?BUX"UC5IGV16<&LQ+-,QYPB,P+'V ->U1,">M $E% .:* "BBB@ HHHH
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M#DGM0!Y;\7/@WI_[._\ P3 \3>!=,V_8_"_@>XT^,@;=^RV(+8]SD_C7P/\
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M^$O@7Q%KVHL&N;^_TJ.:><X &YCG- 'Q9_Q%>_L^1_+_ ,([\0CP.?L4//\
MY$I?^(K[]GP_\R[\0/\ P#A_^.5]:?\ #H7]F$?\T)^&?_@DB_PH_P"'0W[,
M/_1"?AI_X)8O\* .1_X)X_\ !8WX:_\ !2WQOX@T/P/I?B2QNO#=G'>W#:E
MD:E79E 4JQ.>#7UU&<[OKS7E?P)_8G^$W[+VO7VH?#OX=^%?!MYJ4*PW4^DZ
M>EO)<(I)",5Z@$YQCO7JD:>6NT# H )/N_B/YU^$O_!.<8_X.;OB3_UVUO\
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MJL)#R, GIZT >)?\%WO >H?$C_@EW\3K/2K274+JULX[P0PJ7D*I(N2H&22
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MR03LW<#/TKT+1=+M]$TJWL[2".UM;6-8H88T"K"@ "J .  ../2@"U7YG_\
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M6LFE74 DM7B7 5"G3:,#CT% 'PI_P:['_C5W8?\ 8Q:E_P"C:^E_^"J#!?\
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M  =F? /Q1XO^'GP\\>:7:W-]X=\-R36>I^4NY;-I"#'*P[*>5ST%>S?L*_\
M!>_]F"#]E[PAI>O>+K3X>ZIH>EP6%QI-Y8SL%>.,*2C0QLI#$$Y..2:_1#7_
M  W8^)]&N-/U2SMM0L;I/+FM[A!)',N,;6# @CZU\QZM_P $3?V7];\4+JDO
MP=\)B;S#*Z1VY2%R22=R?=;K0!^8?_!:O_@I]=_\%-/A'JGA#X)^&?$FM?#/
MP3(-:\3^(FLS'#+Y?RQ[<GA07!&<,<GCBON3_@VB\9V?B3_@EQX?M+>:-[K2
M=6OK>YC5B6B)DRIYR?F'-?9&C?LQ?#WPO\*KCP-IW@OPW9>#[R'[//I$5DB6
MLT7=60#YOQST%-^!/[,/P_\ V8]#N]-^'O@_0O!^GZA-Y]S;Z5:K;QS/@+O*
MK_%M R>O% 'X*_#[]J/2?^"6?_!>WXF>*OB+IFM6^AS7>H6KBUAW3&.X*&.9
M Q4.A]=P'OS7V-_P6]\4Q_\ !3+_ ()*Z'\3_A-#K&J^'])U;^T;JV:'R[HP
MH3&[-$K-DHPS@$\$U^@7[0G[!?P>_:JUBWO_ (A?#WPWXHU&T4+#=WMH&F1!
MT7?C./:NN^$'[/W@OX#_  WB\(^#O"^C>'?"\#.R:996RQVWS\OE.0<GKF@#
M\O?^",'_  6Q_9Y^$/[$'A/P#XV\10_#_P 1>$8#:W0N+.5H=08.?WRM"C;F
M;/(;IBN?_P""L/\ P5\L_P!O+X-^(O@G^S;H^N^/#JEN\OB+6[:S:.VM[*/]
MXZIY@!^;9RSXQC K[T^(/_!&?]FCXJ>*)M:U?X0^%_[0N)C--)#;"$7#'J65
M3M.?<5Z]\(/V5/AS\ ?!L_A_P;X*\.^&]'N8S#-;6-DD2W",NU@^!\V1P: /
MS1_X-(_%UI=_LP?$K1FGC_M"Q\0Q3M"S'S CP ;L'G&<CTS7ZY(V1^.*\Q^!
M_P"Q]\+_ -FW5M4O_ /@'PQX0O-9"K?3:78) UVH)*[RHRV,]Z].BSMYSU[]
M: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4<S8J2F./FSS^% '\S'[5GPF\57G_!U%;ZW#X9\03:
M/_PG5I(;]-.F:VVA.6\P+MQ[YK^F@#YJIG0K-[P7#6-J;@'=YIB4N#V.[&:N
M1)L7'O0!X;_P46_85\*?\%&?V5O$/PO\6+Y=KJT8ELKQ5S)IMVF?*G4=,J2<
M^Q-?S@V'P#_;P_X-[/C=K(\!:/XDU#PS>S9-WI.FOJ^BZQ$"=KR1*K>6V.[
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M *6Q5_=I7\)?['G_ "=U\+?^QOTG_P!+8J_NTH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "OCG_@X&_P"4,_[07_8LG_THAK[&KXY_
MX.!O^4,_[07_ &+)_P#2B&@#^1']CS_D[KX6_P#8WZ3_ .EL5?W:5_"7^QY_
MR=U\+?\ L;])_P#2V*O[M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ***1@2: %+8HS4-P&'][VQU'^?
M>OGCXN?\%5_V?_@#\1-1\*>+OB1I>B^(=+8+=64MK<N\!/0$K&R_D<5=.G.<
MN6"N_(QK8BG27-4:2\SZ-S1NKY,_X?>?LML^W_A;FC>O%G=__&:Z#X>_\%;/
MV=/BAK<.GZ+\5O#=Q=S/L1+@RVH)[?-*BC]:U>#Q*5W3?W'*LUP;=HU(W]3Z
M3!S1FJ>F:G#J<,<T$D<T,RAXWC8,KJ>000>01WJR#\U<[OL=RDFKH?FBFD\]
M*4-04+G%&::[J#535=7M]+LY)[B>&W@A4O))(X144=22> ![T:MV1,I):R>A
M=S1FJ.C:O:ZS8PW5C<P7EK<H'BFAD$D<@]58<$>XJX#EA0.,KJZ'44A;YJ7-
M PHHSQ2*V10 M%&<4A;YL4 +FD+@&HK@[.X45G6/BK3=1UNXT^WOK2XU"Q"M
M<6Z3*TD ;.-Z@Y7.#C/7%"U3:1+E%?$S7+ =Z0,"<9''6N&^//[0G@[]FGP!
M<>*O'&N6_A_P_;R+#+>3([HC-P!B-68D_2N,_9K_ &^OA#^U_KVHZ9\.?&MA
MXGOM)A6YN8K:WF1K=&.T-F2-0<D8XR:TC2J2ASJ+MW,I8FE&:I2DN9].I[;F
MC=44;$_7VIYQ69N.S2%P#U%-5N>]<]\4/B9H?P@\#ZEXD\27R:7H>CPFXO+N
M16:.&,=6(4$X'TH6KLB9248\TM#H]X!ZBC>/6OGSX%?\%-?@7^T]X^B\*^ _
M'^F^(O$$T+W,=E!;7$;/&F-QS)&  ,^M>^0JS!LYYQBJE3E"7+--,RHXBG53
ME3::18!S12*N*6I-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^.?\ @X&_Y0S_ +07_8LG_P!*(:^Q
MJ^.?^#@;_E#/^T%_V+)_]*(: /Y$?V//^3NOA;_V-^D_^EL5?W:5_"7^QY_R
M=U\+?^QOTG_TMBK^[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGP0E]3;?=BJ<BEH'6BOF#[0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_!,?XNEXU?RM&WH&7.PB:/!%?D;_ ,&U@Q_P45&W_H7KWGU^Y7Z[?\%F"O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KXY_X.!O\ E#/^T%_V+)_]*(:^QJ^.?^#@;_E#/^T%_P!B
MR?\ THAH _D1_8\_Y.Z^%O\ V-^D_P#I;%7]VE?PE_L>?\G=?"W_ +&_2?\
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MU#59[BV3'0%"V&^C5]R8HQ6E+'8BE%PIS:1G5RS"U*GM)P39\T_'_P#X)3_
M[]I?4]&NO%7@FUFFT.T%A9?97:U2"'.=NV,A>,>YYKN/#?[&7@#PQ^S5+\);
M329D\#S6[6C6$ES))MB8Y*AR2<>F#BO7L48J98NM*RE)Z;%4\OPT&W&"UW/F
M;]G#_@E+\%/V3OBC#XP\"^%6TG7[>"2VCN6O)I0J28W##-CD 5])PICH,#T]
M*FQ1TK.K5G5=ZCN:4,+2HQY:2L@HHHK,Z HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;(:1N_<<5G@\#6Q5;V-)79KCLTH82A[>L[(_4 L!W%+FOR%_X)-?MC_MA?\
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MCZ7)0<T4V+[OXTZ@$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5\<_\' W_*&?]H+_ +%D_P#I1#7V-7QS_P ' W_*&?\ :"_[%D_^E$-
M'\B/['G_ "=U\+?^QOTG_P!+8J_NTK^$O]CS_D[KX6_]C?I/_I;%7]VE !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]H]U#J&DZI;+=6L\3;HYHW4%6!^A].N:_F@_X*K_ !(^"?Q2_:4;5O@;IO\
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M^B>&?$>@Z=+>:3J&G6JV\D3PHS["4^\A . ?4>M;XS"Y;A:JPE6+<G;7U.;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHS03BFNRA>:+VW =37&67ZU5EU5(A\NYJK2ZA)+QNV@UG[1%JFR[<SI$_P Q
M7/I7YZ?\'%7[+M]^T%^QO;^)-#MVN=2^'EX=2DB13O:W<!9&'KMP#BOOACDU
M7U33(-9TV>TNK>&ZM[F-HY89 "LBD8((/!'7BM<#CIX;$1KKHSES#+UBL/.@
M^J/YY/\ @AS_ ,%!K']B/]HR\L?%%T;7P5XRC6UO)\$BRF4CRY2/0Y.2.@K^
M@SPQXYT?Q[H,.K:+JVGZMIEQ%YL=U97(DB<=00P)]?K7Y*_\%"_^#<C4-;\7
M7_BGX(7EC':ZA*TT_AR^?RUA+$LWDR<C!)X5AQSS7Q?>_P#!*;]K'P9=?V;'
M\/\ QHD8R%%IJ<7E..@/RR[<?7%?;X["X'-9K$4ZJB^J9^?9?C,PR6+P]6DY
MJ^EC]'/^"]O_  4P\)>#/V?=6^$OA76]/UKQ1XJ46^I-93++'IML&!?>RD_.
MQ& O7\Z^0_\ @W+_ &7[[XL?MDR>/)[.3^P_ =K)*)RA*M=R?+&BGID DD=0
M#5?]F3_@W;^-_P 9?%%O=>/OLW@/2)&#7,EU.+J^89!PD:,4R>0"6X.3CI7[
M5_LH_LH^#OV-OA#IW@SP7I_V73;,AYI9!F:]E_BEE;&2Q/KG@#M7/C,=A,OP
M+PM!WE+JCHR_+\;F>8+&8J/+&.R9^=G_  =0-N^%_P )_P#L+7GZPK5C_@UF
M7/P7^*0VY;^W;=2!U/[@?C7IW_!?K]B;XD?ME^ _A[9_#G0&URXT._N9KM1<
M)%Y:-&%!^8C.2.E3_P#! ?\ 8K^(O[%_PO\ 'VF_$/0?["N]:U:"YM(S.DJR
MHL0!.4)P,YZUE+&4UDGL7+WK]#98*H^(?:J#Y+6U,K_@NS_P3#T_]HKX27'Q
M*\&Z3;P^-O"\)FO8K6':VKVHY<8'5USN'<C-?FY_P2!_X*2:Q^PG\?+.QU:\
MN)OA]XBN%MM8LW.8[1BVT7"+GY64@9QU K^CF>%;B%HV59(I%V,I7(*XQR#V
M[8[YK\3/^"GO_!"'XA7G[2VH:_\ !GP]'K'A?Q*6O9;1)XX3ILY.70!R 58C
M<".G2GD>:4:U"6"Q;TMI<.(LIK4*\,PP"U3U2/VLTC6K;Q)H<&H6<\=U:7D(
MGAF0Y65&&Y6!]""*_E.\5^'X/%7[6^I:7<^9Y.I>+I;638=K;)+PJ<$\ X8\
M]J_?;_@CAX;^-?PI_9X;P'\9/#<VES>&G5-&OY;N.X^T6YZ1':Q(*<@$\$5^
M7A_X(N?M&2_M1?\ "0#P%(-);Q4=1\X:A#_J/MGF;C\V?NG..M:9!6IX2K64
MI;K1F7$=*MF%+#R5-Z.[3/W"^!/[-O@WX,? 2Q\">'=%L;/PU]B\B6W"?\?*
MR+B1I./F9LD9/N>E?SS?\%6_V)K[]@G]KG4=/LUGA\-:M(VK:!=*,8BR?D#?
MWD.5X] :_I6TN!K72[:-N&CB5&'H0 #W/I7R[_P5U_8$C_;U_9BNM-TR"$>-
M?#[?;M!E)V[Y!]Z(G( ##U[UYN2YS+#8V7M'>,MSUL^R%8C KV,;2@DUW]#B
M_P#@B'_P40C_ &S?V>(?#^O74;>.O!,*6FH;V&Z]@  CG'.>1@'T(KQO_@Y@
M_:M7P-\#?#?PMT^Y,=_XMN/M^HHC?,MK"2 #[%\Y!]*^6_V(/^"<7[7'[%'[
M1VA>.-#\ 7!6QF\N^M1J5N%O;5C^\C;Y\$XY&[H173?\%-O^">'[3G[<7[7.
MN>-+7X=W<>B,D=GI,,VI0*T-NB#J ^%8GDXZ_6O6^J8*GF?MXR3AO\SQ98[,
M:N6?5)0?M-MNA\D_LG?\$Q_C3^V!X*G\3_#_ $..?2K6X:T%S+>BW9I% W!3
MU(!/.#7J\G_!"#]JAHV5M$MW7:5.[658'/48SSU[U^V?_!//]F ?L??LA>#_
M  ,T<2:AI]FLFI%/^6ER_P TASDY^8XS[5[9GCG[V,$^G0_TKGQG&%55G[-*
MVR.G+^"*+P\956U+>WF?RD_%GX1>.?V&_P!H.+1_$5DVB^*O#,]O>1I%+N&[
M(>-E8 9!QU'45_27\"?BE;_MU_L+V>LZ9<0I)XV\.36<SD96WG>%HI P'/RN
M>E?&/_!>3_@EOXT_:X\;>$_&WPST*/6-<C@?3M7A65(2T8PT<A+$;L<K[5Z!
M_P $(?@!\9OV5/A1XF\"_%#PS)H^E6]XNH:-*US%,B&3B6-0K$]0&S[UIG..
MI8W PQ/,E4B[G/DF6U<OS&>%E%NG+0^1%_X-:OB X_Y*AX8]LZ=+S^&^OI;_
M ()K_P#!$[Q+^P[XK\;:AKGC#1O$%OXJT";1T@M;5X60N&&XDMT^:OT>W$]:
M"JG.[=C&#COW_I^M>'5XDQE2FH2?NGTT>$\%2J.K37O'\NO[/FKK^RE_P4.\
M.W6L1M;1^#_%ODW7F J8465HV)SV 8'GM7]"'_!1;XZZ'\,/V#/'GB:34+<V
M=_H4EO8RAQ_I;W$91-O/S$AB0!U%?$__  6!_P""&6N?M"_$J^^)WPG%A)KF
MI[9-7T28B$7<H&/.B?H&/&5/!Q[U\*V__!*O]KKXDBS\+W_@WQ8VGV;A8DU+
M5(Q8VQSUYE.5/J.@["OJ)_5<P5/$.HH\B5T?&T?KN6>VPWLG+VFS1<_X(&?"
M.Z^)O_!1_P )WL=NTMOX4AGU6:0C"Q80JN?<EB!7U[_P=+?"N:[T?X:^-H8W
MFMX))])FD'\&[]ZN?3)R*^K?^"1'_!+J#_@GE\,;Z;6;BVU3QUXFV'4;F%?W
M=K&.1;QDY.T$Y)[\^E>X_MG_ +)7AW]M+]G[6/ ?B+=';ZB@>WND&9+*X7)2
M5>_!X([BO-Q>>4WFD:L7>*T/6P?#M=9-/#R7[R6MCXB_X-D_C!IGB']EGQ-X
M+6XC75O#^L/=M;[QO:&495Q_LYX^HKX]_P"#DCXNZ?\ $']N73]%T^ZCN6\(
M:.EC<M&P*QS2-YA0^X[^F:Y;XF_\$9?VH/V5?B-<-X*T?6-:ME8QV^K^';Y8
MVFC/3<K.C*<=1R,FO0?V'/\ @@-\6/C!\7]/\0?&*SE\+^&;>X6\O8[J=+C4
M-3(8,8\!F"[L %B<]:]BG+ T<5/,E5336W4\*I]?Q&$CE7L6K/?H?I;_ ,$3
M?A/<_!__ ()P^ +&\MS:W&IQ2:JT1ZIY[[Z^L-V%_+^8JGHNBVOAS2;33[&"
M.UL[&%8((HQA(D4851VX&!QZ5;9<IGJ5R1]<<5^=XBO[;$NKW9^H8/#_ %?!
MQHO>UC^7_P#;%./^"E?C'_L<^O\ VW6OZ;/ 4C)X)T7#$?Z#!_Z+6OPO_:8_
MX(\?M!>/_P!N/Q)XNTOP/)<:#>>)_P"T(;H7D W1>:K;L;@>@Z8K]U/"=A+I
M?A;3;>8;9H+6*.0<<,$ /0D=J^JXDQ5.I1I*FTW%:GR'".#K4L16=6-E)Z&U
M%J;*XW#(J<7D<F/FP2>!ZUG4CKE?Z>N/6OCX2:9]U4@M?0_F8_X+#-M_X*7_
M !;/'_(;D(SW^5:_I(_9W@6S^ '@F- #LT&RQ['R$/\ 6OQ+_P""D7_!('X_
M?'3]N#XC>+O"_@EM1\/ZYJCW%I<_;88Q*F!@[2V1T/UXK]O_ (-:?/X:^%7A
MG3+Y?)O+#2;6WGC)!VND**PSWPP-?89YBZ=7#4(P=^5:GP/"^#J4\;B*DX-)
MGY9_\'+/[;7B[X:ZCX7^%OAG4K[1]-UJS?4M5FMG,4UT Y1(@_9!@Y(]:\V_
MX)*?\$.?!'[9'P)L?BA\0_$FL:A%JES*D6EV<_EK&J/M/FR<N6./X2#TK[*_
MX+;?\$G]0_X*"^$=&\0>$;FU@\;>%X9(8(;AML-_;DEC$6_A;<>#WSS7YR_L
M]?LB_M\?LU?:O"/@?1?&GA?3=2DW3"'48%M(V;'[U6\PA3UY49/<5W8&K2GE
MZIX::A/JWN>9F5&K3S3VF)INI3>R1QO_  7%_9K^&'[)W[2FA^"/AG81Z;:Z
M?HR-J48N&GE\YV)4L[$DMM&.237[$?\ !#H1G_@F3\.O+V_-;2%L?WBQS7YD
M_M&?\&^?QY'@S1?%"ZC)\0?'GB"XE?Q#"MVH^R C*-YDA!D;/!-?IG_P1C^#
M?Q$_9\_8OL_ _P 2- ;P_JVAWL\=LGGI(L\#G<I&PG&.1S4YSB*4\#"G"IS-
M-7-,AP=>GF52I*DXQ:=ET/P?^,XW?\%)]6]#X^7C'7_317]2.@X/ANS V\P(
M !_NBOP/^)O_  1K_:(U_P#;@U'Q9;^!?,T.X\6KJ27(O85WPBY5]^-V?NCH
M>>*_>[2;::VTFVCF4^8L*A@/4*,@_C7'Q#B:=2E1C3:=EJ=G"N#JT:U?VL6D
MWH?S'_\ !8!<?\%,?BVOKKDF/?@5^O7_  5]^%=Y\4O^",5K]@@DN)M!TS2=
M7*Q_>V10J#CU^]G\*^'_ /@I1_P1[_:"^._[<OQ&\7>%_!,NH:!KFJ/<6=R+
MR&,2QX'.-V1TZ=Z_:+P_X*L;3]F[2_#OBQ;>.S_L*#3-32YD58P/(6-U+,<=
M<C/XUT9CF5+DPU2$KN-KHYLIRNNZV+IU$XJ:=F?AO_P;C_M.^'_@'^U[K>C>
M(+Z#38?'6FI96]U<NL<*SQ2%U5F) !;.!ZU^QO\ P4,_:J\+?LO?LH>+=?UW
M5+6&:ZTR>VT^T\Q?-O9I(V1%C7.6Y.?3%?D]^U__ ,&YWQ"\/_$*YU;X,W>E
M^)/"EU.9;.WEO1!>6&<D(I^ZZKT!S[U/\#?^#?WXJ>)-*U3Q)\;=:.FZ#X?T
MVXNX=+BU%[JZN'2)F4;@2D:Y&3C)/2NS'4\%BJ\<9[2RTNNMSCR^OF&$P\\$
MJ3EO9]%YGRE_P2;NC?\ _!3;X2S-_K)?$6]N0<$QR^G'Y<5^C'_!U'\.[BX^
M&GPQ\410S2VMC?7%E<NH.V#=&&0D]!D@CGK7YV_\$G;+9_P5$^$T,'W%\1;5
M./X1'+C]*_HP_:\_9>\/_MA_ 76O GB.-FL=8APDT9Q+:RKRDJ'CY@?4XY-/
M.L9##YC1J]$B>'\#+%Y97H=6S\0_^"-W_!,+X1_\%$? WB;_ (2KQ)X@TWQ5
MH-ZH:TL+B-/,MW3*R892<;L@GITKWW]J3_@C%^R+^QE'HT_Q#^)GC/P^NO3/
M#9EY$E+% -Q8)$6"C/7&*^>OB%_P1@_:J_8E^*DFJ?#!=1UN&%V%IK'AV]6V
MN/+))_>1LZ'(Z8!//(I-(_X)'?MA_MU_$NUN_B='K5E&JA&U;Q/J:S>1'N!(
MC16<YZG&!SWK>M6C4JNO'$<M-].ISX>C.E36%EAN:IM?I8_3G_@CW^R[\#O@
M?X<\4:Q\$O'&H>-])UIXH;V6=]RV[J,@?<4[B"#TK[<CVYKQC]A']C+P[^PK
M\ -,\#>'3)<+;DS7M[,/WM_<-RTC>F>P[# KV=8]O';M7PN.J*I7E+F<O-GZ
M7EM#V.'C!QY=-AZ]*6D3I2URG>%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !11F@M@X[GH* "BC.:,T %%!.*"V/YT %%)O&>HYZ>]+0 4444 9/C+Q7
M8^!O#NH:UJEPMGI>D6LE[>3L"5AAC4L[D*"<*H).!VK\(_\ @IY_P='ZE\>+
MR3X/_LBZ-KFJ:KKTATX^)%LV^U3%L ?881\PSG_6/@C).  "?W0^+'@&#XJ?
M#;Q!X9NYI[>S\1:7<Z7-+!CS(DGB:-G7/&0&)&0>:^=?^"?7_!'3X&?\$VM"
MC'P^\(P2>('01W7B#4@+K5+OIG,AX1<Y(5< 9/')H _F&_8N^"7C;]GG_@MI
M\+O"_P 1HGA\9VGBZTFU1))_.D6:7,AWMW?+<^^:_LEK^7/]K9=O_!V1;^_C
MZSS_ -\?Y]:_J,H _,W_ (.HOVXM8_8]_P""<KZ5X9U&?2?$?Q,U :'#<PN5
MDCM0N^YV$='*E0#Z%J^)_P#@W+_X-Z?A[^T+^S]8_';XWZ6OC%/$\C-H.@SD
M_9(X%8@SS\YE+G. <@#'O7[R?$WX1^%_C#H_]G^+/#VC^(M/ .(-0M$N$7((
M. P/4'M4GPP^&GA_X.^#++P[X7T;3_#VAZ:GEVMA90B&"!>N$4< <_K0!\9_
MM*_\&Z7[)WQ^^&EWH=K\*?#/@6^DC(MM6\.VRV-U;28PKY3AP.,J1@\ U^+'
M_!&;Q1XT_P""2?\ P7MD^!L^H2WFE:QKLOA#6(P66&[7!:"YVGC<, \?WB.@
M%?TC?M>_M7^"_P!BKX"Z]\1/'FK6^DZ#X?MS*Q=QYEQ)CY(HU/WY&. %&3SF
MOYT/^",/@OQ3_P %;/\ @OAJWQZO+&>Q\/\ AO69_%=](J$Q0D[DM[7<1@E@
M>G7@F@#^CO\ :G^)B_![]F?Q]XJD?R_[ \/WUZA;@[T@<I],MM_,5_.W_P &
MK_["'@G]OG]HCXS>-?BQX'\/^-O#]C"C06^KVJW4"WUQ.97PK=]A'/O7ZY_\
M')?QR3X'?\$@/BA(;AK6X\310:!;/&2#OGD!XQR!M1A]*_G_ /\ @DM^V_\
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M\<_\' [;?^",_P"T%_V+)_\ 2B&OFO\ XC&/V1?^?3XM_P#A.0?_ "37S_\
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MY*F&7(9#D$$?, ,]LFO6":CD'S=_\:TIU'"2DC&K24XN+/Y>U\0_'W_@E_\
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M2T4P$7I2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#3P_.&$()_LKPY$?^6LK=);AQC@9/3C&*_H<_P"";W_!.OP+_P $TOV;],\
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M_P"%?#=O]JU'4)KZR:.TCR%W,(YF8C+ <"O[1Z^.?^#@;_E#/^T%_P!BR?\
MTHAH _D3_9%;=^UO\+?FW'_A+M*&?7_38J_NRK^$O]CS_D[KX6_]C?I/_I;%
M7]VE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !G%&<T8S0#0 4V1@H^;I4=Q>+ .OS>E9UQ>/<'DX'M4
MRDD5&+9;N=15/N\G%4IIFG89)IE%<\I-G1&-@/6BBBI*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "G1RM"^Y33:*+@:5KJ*S_*WR
MM5D-D5B<@_+P:M6E^495;\ZVC4Z,QE3[&EC)HSBD5PU#+NK;<Q$89.<9H_ T
M)P*=2Y0!:***8!1110 4444 %%%% !1110 4444 %%%% !11FFF4#N.>E #L
MT5#%.LDK*K*S+]X \BIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 9*-W][\#_D4L0VIC&WV]*=4<XSM^
MH% '#_M$?M)>!_V5?AQ>>+_B!XFTGPKX=L1^]N[V<1AF[(B]78YX49/M4?[.
MG[1/A/\ :H^"^A?$#P5J#:IX7\16XNK&[\HQF5,XSM(W#D<Y[8K^:/\ X.NO
MVS?$G[0O_!2&X^%EK?7DWA7X=PQ6-IIL)8K-?2C,K^7_ !29(5>^ *_2S]B+
MXB_$?_@E#_P;=ZMX@^)6GR>'_%GAW3KV70;25T\^..Y;%F"HX5P&#;22?E-
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M_P"%M[X.C\(^%+:XN+VWUK5)+.1KZ1MH90L3AE\L 9)X.>/7\UM%_P"#2O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445#<7B0#J"WIFE>P$
MCNL?+'%4;S4F+;8^!ZU!<737#?-^51$YK"51[&\::W8K,6//-)1169KH%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1F@KE?[HSR:\^^,'[0%C\+G^QQ1_;M2;DQ;MHB
M'8M^72KITY3=HF=2K&"O(]!(P:*\M^$G[3-GX]U,:?J$*:?>2<1$-^[G/8<_
M=/\ .O4B-OOCJ<<D^].I1E!VD*C6C45T%%%%9FH4444 %%%% !1110 4444
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M-\57.DR.?+OH]\8)Z.O7\Q_*M,=1YH7ZD9?7<*G*]F?1E%!ZT5\^?2!1110
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M0 4444 %%%% !0>G/2BJ/BC5%T7PW?7;-M6W@=^?IQ^M5"_,B92M%GRK\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'['?PW_:Q_9P\5>&O'/A71=6T^72[AH97ME\ZTD6-BDD38RC*0I&#S7\T/\
MP0>_8V^*&@?\%D?A?JUGX)\:6OA;PUXAN)+S5KG2;F"S-HBRIEIF0(=^5X)Y
M- ']9T9RWTXJ2FK][^M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOCG_ (.!O^4,_P"T%_V+)_\ 2B&OL:OCG_@X&_Y0S_M!?]BR?_2B&@#^1']C
MS_D[KX6_]C?I/_I;%7]VE?PE_L>?\G=?"W_L;])_]+8J_NTH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^D_^EL5?W:5_"7^QY_R=U\+?^QOTG_TMBK^[2@ HHHH **** "BBB@ HHHH
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M_P 3/<SW^+#_  Q&T445]#'8\,/X?\^HKY>^(_\ RD5\*_\ 8.?^5?4/\/\
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M5HB>&\/06&JT*$HJLI:-G5^/O@1\4OV7O%UC-8W.J74EQGR;C3&DE!.1N5E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA;_V-^D_^EL5?W:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4V(Y3/K3JZSE"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUM0 4444 %&X T$XKE?C+\7_  U\"/AWJGBWQ?K5CX?\.Z'"UQ>WUY*(X84
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M_P#@BK_P63\+_P#!6SX+W5_%8P>'?'WAW8FO:()/,";N%GB8_,8FQQGH<C-
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MO[M*_A+_ &//^3NOA;_V-^D_^EL5?W:4 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /./VQ& _9(^*7_8H:L?_).6OX7?"/BS4? ^OVNJ:1?76FZE8R>;
M;W5M*8Y86P0"K#D'D\CUK^]/QC?Z?I'A[4+O5I+>/2[>TEEO&GP8EA5&,C,#
M_"%SGV->8_"_X7_ KXS^&(=<\):'\-?$VD3@>7>:;:VMU"?;<H(S['F@#^+E
MOVT_BXIX^)?C4_36)A[?WJ;_ ,-I_%P_\U+\;_\ @XF_^*K^VS_AE7X8D_\
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M_@#4O#7B32[;5]%UBV>VNK.X0,DD;*5(.>AP>".0:_F6_P"";<EU_P $F?\
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MCMG+O%CRW89ZLI)_"O@3XK_\&1237F_P/\<WM[=6.(];T,3R,.PW0R1C/X4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48S110 8H
MZ4%L4 YH *,9H+;:;YJ_WE_.@!W2BC-% !1110 5#<+\XP.H_P ?\:FHQF@#
MXO\ &W_!"OX!_$#]MI?V@-2TK7Y/B&NJ1ZN+A=6F6#SD& ?*!"_I7V9#&$/'
M<Y)QUJ3%'2@".4$G_/%?,_[:O_!(/]GW_@H)-]K^)WP[TS5-8V"(:M:EK/4
MN20//C*O@$DX/')KZ<HH _.SX/\ _!KS^Q]\'O&]MKT/P]U#7KFS<O%!K.K7
M%[:@@\%HG8JY'49%??\ X1\):9X'T&UTO1]/M-+TRQB$-M:VT(BBA0#A54
M"M2B@".5=Q7^G45\S_MJ_P#!(3]GW_@H+-]K^)WP[TO5-8V"(:M:EK/4-N20
M//C*O@$DX/')KZ<HH _.SX/_ /!KS^Q]\'O&]MKT/P]U#7KFS<O%!K.K7%[:
M@@\%HG8JY'49%??_ (1\):9X'T&UTO1]/M-+TRQB$-M:VT(BBA0#A54  "M2
MB@ '2BBB@ KXY_X.!O\ E#/^T%_V+)_]*(:^QJ^.?^#@;_E#/^T%_P!BR?\
MTHAH _D1_8\_Y.Z^%O\ V-^D_P#I;%7]VE?PE_L>?\G=?"W_ +&_2?\ TMBK
M^[2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBC- !WK+U*Y\Z7:O1>#5Z\G\B+-93MN=CZF
MLZDBX1NQ****YSIV"BBB@ HHHH #7R[^RM_R>S\7O^NJ?^AFOJ(U\N_LK?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M17TAXP444'@4KV#?8**._O1TI<UG9H6[T"BBBJ&%%%% !1110 4444 %%%%
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MXRN=8\7:?/Y^FZ+8SM]AL3T 8\ @9/ %?HI\!I/+^+^A_P!YI\$_@:XVNN^
MW_)7]!_Z^?\ V4UE5^%HTH_Q%ZGU\W#$>E%(O5OK2U\PY>]8^OV=@HHHH&%%
M%% !2K]Y?K_44E*OWE^O]12EM]X'R[\)?^4A'C+_ *\(_P"0KZCD^]_GUKY<
M^$O_ "D(\9?]>$?\A7U')][_ #ZU\_PY_#G_ (I'N9[_ !8?X8C:***^A/#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #.
M*CFPVWOD\<<5G^+_ !/I_@KP_>:OJEU%8Z;IL#W5S=3'$=O&@RS,>P S^5<S
M\%_VC/ 7[0FC_;_ WC3PSXNLMH8OI6I179CS_?"L2I]FQ0!_+7_P<L?L[^)/
MV0_^"P?B+QQ#:W-O8^-+V#Q9I%_(I:&6X!!< ]/ED3&WKBOT;^$__!UC\$?C
MU^P?XE\,_$B/6/!_Q&NO"5[I4T4=H;C3[ZX>T>)6C=22NXD?*5X/?G _2O\
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M (-&M'^ /CS2?'7QZ\067C+6-)E2ZL_#>F*5TNWF7E6FE;YIMK#( 51R,J:
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MM9_X*7?#IO$(L_,U7R_,V&Y%D!"/]K[P./?&:]T\'^---\?:+#J.DWL%_9W
MRDL3[@?ZCZ'FOQW)8,=N>YZ<<5]3?\$P/B=J%A\4+KPKYKRZ;?V[W2(S$B-D
M R1]<C\J^"X9X^Q&)QD</BH_%L?;<0<#4<'A)8C#R^%7=S[VHH!8CYNO\J*_
M6[WU/S$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_L;])_]+8J_NTK^$O\ 8\_Y.Z^%O_8WZ3_Z6Q5_=I0 4444 %%%% !1110
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M_9L^'#:]X@\<(Z7'BJX*FS\.!6VY96(4/@[@6R/;(%=]_P $K/V/OB9^Q[\
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M;Q'QC@Z&84H:OD=V?H7#_".-Q&"J5E9*:LC]<F^__GTHSFO&?V-_VG8_VBO
MLS72QV^N::0E[$F-K ]''L?Z5[)&<C\:_1L!CJ>+HQKTWI(^&QF$J8:K*C55
MI1=F.HHHKL.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ H)P/UHZG'KTKR7]N/]IV[_8\_9B\3^/[#
MPAKWCG4-#A#6VC:1"\ES>2L=JC"*S!0>20K'':@#UIE9E''&0<9//UK\Z/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "B@\+N_A]:-W7_9Z^U  !N..] )+*.V=W4_,!7S;_P %0?\
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MB@ HHHH ****(Z2Y@$*9.:6BBC2][#YGU"BBB@04444 %%%% !1110 4444
M%%%% !6AI4>(V/;-9_0_I6M8ILM5%:4U=F=1Z$R]****Z#G"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,'XF^!;;XG_#[7O#=ZTT=GX@TVXTRX>(XD2*>-HW*
MD\;@&XS7Y1I_P9G?LUD<^*OB1^%Y$/\ V2OUZHH _(;_ (@S/V:_^AJ^)7_@
M=%_\12?\09O[-6?^1J^)7_@=%_\ $5^O5?(W_!>#Q1J7@G_@D7\=M6T>^N],
MU*Q\.&2WN;60QS1/Y\0!5AR.IY]Z /CX_P#!F;^S3G_D:OB3_P"!T/\ \12'
M_@S._9K5QCQ5\2<>]Y"?3_8K\A/^"$7[4WQ(\;?\%>/@/I>L>._%6IZ=?>(Q
M%<6USJ4LD4R>1+D,I.#T'Y5_7HF<F@#SG]D;]FS1OV//V<?!_P ,/#MQ>W6@
M^"=-33+*:[8--)&A."Y  SS7I% HH **** "BBB@ I&&?6EH(S0!POQC_:3^
M'_[/$-G)X[\:>&_!\.HLRVLFKZA'9BX9>6";R V!C..F:X,?\%.?V=2/^2V_
M"\_]S%:__%UX-_P6Y_X(NK_P6%\->!=./CAO!?\ PAEU<7/F"P^U?:?-0+C&
MX8QCK7YYO_P9"QDY;X\-V'.A?_9T ?L/_P /./V=O^BV?"__ ,**V_\ BZL:
M#_P49^ OBW7+/3=*^,7PYU#4+^00VUM;Z_;O).Y. JJ'^8D\8'-?A/\ M9?\
M&FO@G]BKX ^(OB-XY_:*33?#WAVW:65CH@WW$G(2&,>9EI&8;0 ">3Z5\V_\
M&[?_  2N\2_MS_MOZ5XRM9+K2?AS\,=5BU&_U5DVR7,B/NBM8^V]L L?X1QU
M- ']: 9BWW>WH/\ ]=>0>*_^"A'P-^'_ (FOM%UWXN?#S2=8TV4P75G>:];P
MSV[CJKHS94CT/->F^(O$%OX6\*ZAJEP1]ETVUDO),#&$1"Y_0=/2OY*/V%/^
M"<VJ_P#!=3_@HY\6K67Q9_PB]K#>7FNWFIFT-T2'G98EV;@.<8_"@#^GH_\
M!3G]G93AOC9\+P?3_A(K;_XNMSX<?MR_!OXS>+;?0?"/Q0\">)-:N@3%8Z=K
M,-Q/*!R=J(Q)QWXK\76_X,BHY3_R7AUP=H']A=/;_65]"_\ !+S_ (-=1_P3
M<_;"T#XK+\5F\4'1(IHCIYTH0>=YB@#YMQZ=: /URCY:I*CC!#>O/7'6I* "
MOCG_ (.!O^4,_P"T%_V+)_\ 2B&OL:OCG_@X&_Y0S_M!?]BR?_2B&@#^1']C
MS_D[KX6_]C?I/_I;%7]VE?PE_L>?\G=?"W_L;])_]+8J_NTH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO-!OOA)X3\.W$]HUO:ZMHEBEE?6!/"LDB 9P<':1CJ.<U_/[^SEJ?CC_ ((
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M72VUZ.$6ZZB;5#<)'V428+8&>@K8QCIC\*"=QS^GI104%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% !111F@"KJW_'N/K6<Q_E6EJ@S;UF5SU8ZW-Z(4445F:A1110
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M$T[Q%X@;.HZI!:+'=7WO(^"Q_&NFL-/MM(LH;:T@AMK>%!'%'$@1(U P %'
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MY$?V//\ D[KX6_\ 8WZ3_P"EL5?W:5_"7^QY_P G=?"W_L;])_\ 2V*O[M*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "FM]X4ZFM]X4 1:B,VQ^M93?>-;%W_J&K'-8U#:D%%%%8FP4444
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MSZ7+X<M*X4445QGH,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4$9HS4MG!Y\Z^B\FJC&[L3*5B[IL!BBS5EONT*,"EKHC&RL<\I7=PHHHJB0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *CG&?\]:DI V_I@B@#^4K_@Z
M(_9=\1?LG_\ !5K4?B-8V,UEH_C]H/$.EZI&A\M[U-OG DC&]9%!VYSMP:_8
M+_@EY^U#XL_X+=?\$=_&]GX^T'2['4]4LKOPO'/; ^5J;QP@),58G#;PN<=,
M"ON;]JW]D+X=_MJ?"^Z\&_$KPOI_B?0+@;A%<)B2WDZ"2)Q\R..H9<$&L/\
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MX]Z_0JL_PWH%GX6T>WTW3[:WL[&QB6"W@@0)'$BC"JJ@   #''I6A0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7QS_P<#?\ *&?]H+_L63_Z
M40U]C5\<_P#!P-_RAG_:"_[%D_\ I1#0!_(C^QY_R=U\+?\ L;])_P#2V*O[
MM*_A+_8\_P"3NOA;_P!C?I/_ *6Q5_=I0 4444 %%%% !1110 4444 %%%%
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M/ B^'?AKX1T?PGI()=H[*W6-I2>26;&XD^Y["O1TB6%%5555QP!CC\N*6BX
M1MXXQVQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5D^.]'&O^#M2LV&?M%NZ#/\ >QD?RK6HQNX]>/K50ERR
M4B:D;Q:/A6>)H)FC889#M(]QP?UIM=-\8/#9\*_$?5+3&%\XR)[JW/\ 6N9K
MZ>G*\4SY*K&TFF%!;9D^@HJ[X9TE]?\ $=C91\M=3I'CU!/_ -:G*5HN1$(W
ME8^K?@#H'_".?"C28V'[R9//;ZMS79=ZATVQ33-.M[:,86WC6, >PJ:OF:SO
M)L^NHQY8*(4445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
MK0TVW\N/=_>&:JV<'GSJ.PY-:JC:*UA'6YC4ET%'2BC-%;F(4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_ G@_3SI?A?PO9K8Z;:>8TGV>%<X7<22<9-=C0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7QS_P<#?\ *&?]H+_L63_Z40U]C5\<_P#!P-_R
MAG_:"_[%D_\ I1#0!_(C^QY_R=U\+?\ L;])_P#2V*O[M*_A+_8\_P"3NOA;
M_P!C?I/_ *6Q5_=I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\(Z$1+?2N<X$G!$63TW MZ*<UZWK_P .?"__  4C_8RL=-^(W@_5=-\/^/\
M38+O4/#]],T-Y:;L/Y+LNUE8''/?N!T&%X/_ ."5WP-\&?M8^(OC9#X)M+WX
MC>))_M,^J7TKW7V=\ %HD?*QD@ ?*,\5]#A BA5'09X'^11N3S?><'^SK^S+
MX&_9.^'5KX3^'OAG2_"^@Z>H2.WLHA'YF.['&YCQDDDY//>N\Q@\4#_Z]!X-
M*Y7D%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH */XE^O_UJ** ZGS[^V-X1,&KV.L1KB.X7R)<#N.A_
M$5XJ?O-]37V)\8?! \?^ ;ZQ5=UPJF6#_?'/ZU\?7-N]G<212*RR1L5=3_"P
MZU[V7U$X69\YF5!PGS=&,QFO3OV5_";:Y\1!?.FZ#2X_.Y'5N@KS'&"N5/)%
M?5/[-G@!O!?@*&:= MYJ'[R0D=%/0?I58NHJ=.SW9& H^TJVZ(]#(P?\\T4&
MBOG_ %/IM.@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !01GZT9
MJQIUMYLN[^$548W)E*Q:TZW\J/+?>JU0**Z8JRL<TI7=Q%_K2T44Q!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV@O^Q9/_ *40T ?R(_L>?\G=?"W_ +&_2?\ TMBK^[2OX2_V//\ D[KX6_\
M8WZ3_P"EL5?W:4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% #3]^H=0C\V$^W-6*:R[@1ZBE*-QQ=G<Q
M>E%/N%\N9E]Z97-)6=CJC*ZN%%%%2,**** "BBB@ HHHH **** "BBB@ HHH
MH *#P*,\_3K7$?M"?M)>!_V4OAK?>+OB%XETWPKX?T]2\MU>3"/>1T1%^\['
MG"J"?PH [5S@J?KSZ9]N]?'/[</_  7'^"?[$WQ.T;P+<WFH>.O'FL7\5D-
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MWZ5>KHA'2YSU)7=@HHHK0S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX6_]C?I/_I;%7]VE?PE_L>?\G=?"W_L;])_]+8J_NTH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &N,_\"&*R;J+
MR)B/7D5L'FJ>JV^Y=_I6=2-U<TIRL[&?THH)S17.= 4444 %%%% !110 3^/
M2@ H[4=#7DO[7G[<GPM_82^'<GBCXG^+-/\ #>GX(@B=MUU>$=HHE.^3'' &
M!F@#UB>5;=&:1E5$!9MQ&!CKUZ?7VKYQ\)?\%9/@=\0OVR%^!7ASQ<GB+Q\(
M);B1-.A:YL[7RN6C:=3MW#GIP,\UM?%WP;H?_!3C]AJZL?#?B[Q!X;\/?$K2
M8WL];TL?9[V&%R&+!6'&<$8[9-<Y_P $[?\ @D_\(?\ @FKX/^R^!=$%QX@N
M%(U'Q'J&9M3OR3EBTF. 3_"H _6@#E?VO/\ @BI\+OV[/VN/#_Q4^)FI>)_$
M5IX?LX[:#PI/>?\ $D=EY$K1_>))(+*3M;N#7UCX0\'Z5X!\.6FCZ)I]II6E
MZ?&(;>UMHECBA0# "JO X[<_TK2"[?QYQC^=% !1110 4444 %%%% !1110
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M#_;[^(?QA\:?%SP?HOC71=/%O;VMOJ-N)HX[V5C+(^#ZJ1^M 'U<?^#V/X2
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M]*(:^QMU?'/_  <#'/\ P1G_ &@O^Q9/_I1#0!_(C^QY_P G=?"W_L;])_\
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M4ZNF,;'/*5V%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBQ)_ 5\;?\'L7AZZU']E7X,WT:EK73?$MX+AB<8WVZ!?U!K[=_X-W=1AO/\
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M_@MQJ#:DG]J>"K-H=XW_ &6Z=&V=R-V03['% 'Z(9HS7FW[-_P"T[X9_:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5'<#@=.QY&:DH
M)YH _ O_ (.E/^")'CSXQ_&$_M!?"G1+SQ0M[:16WB;1[*/S+N%HAA+F./\
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M^E 'R[^P!^P&/V5OM6N:]=0ZAXHU"+R=T0/EVD?=0>Y)[]Z^H(N<&I,9HZ4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &<4;L4R4X=?K
M6!IWQ+\-^(?&FH>';+Q#HMYX@TE4>]TRWOHI+RS5NADA5BZ!N,%@ : )_B!X
M^T/X9>%[G6_$6KZ7H>D6(W3WVH7"6]O /5G<@#\37F?[4%MXQ^/W[).O+\$/
M&FCZ/XI\1:>O]@>(\BZM8]Y'[U2A(/R9VL"1SGCK7Q5^VE_P1@^+_P#P4Q_;
M:U"\^,'Q<DMOV<]+E6;1?!VAR20RW.",K<'A<G!R_+8P!MQD_HE\%/@_X?\
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M%L>14O[1QEH_,**.E%;:+1D?,**#TJGIVN6.J3S16MY:W,ENVV5(Y5=HCZ,
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MS2Q+]7% $V:,XJC+X@LHF^:YC_ Y_E4;>*=/S_Q\+^34 :6Z@'-9H\4V&?\
MCY7\FJ6'7K.;[MS&?^!8_G0!=SFBHXKN*7[LL;?1A4F: "BBC- !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%&::W7K0
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MN]CTJ,<&L#7^K-WLM['U8&W?AQS10PPQ]Z*^R5^I\KIT"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH4X- :!3HX6G;:M36^GO
M.03PM:$%NL"X4?C5QC?<SE4ML0V=EY'S,,M_*K0HHK>,;&#=]0HHHJA!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !3)6P1[$9I]1W SM]0>!Z_P"10!_.Q_P=K?\ !5M?&WQ
MD_9IT'1]#O+'PZT5[KFJ7=LD]S%=[<K% S9\K:.688)S@]./Q@^'GQY\:?!Z
M]6?PKXL\0>')<[\V%_);\]<D*W6OO'_@X)_93OOA+_P6[\1-XN\VW\,_%#7K
M76H;V3]W']BGDC23:_0>6 P)!XYZ8K^C_P#9N_X)9?LX_"7X7:/:>&?A-X#:
MQ>RB9+MM,BN)+Q613YC2L#O+9SN'K0!_(?+_ ,%*/C^APOQD^(C=\G6Y^?\
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MG'2+L@Q@GZT445IN2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4449YH ,T9S1GC'>K-MISSCY_E6J46R922($5GX45=M-+V?-)R?2K$-NL'RJ
M/QJ6MHPL82G<%&T4445H0%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"OVL^'O!FGIIMA]ID\R;RDSC<W<\FO0* "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 J,R.&5MK+T-=7X5\3B\1()VQ*O0D]:Y.ECE:"59%X93D4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*G"CUK-;K0 'K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^T1\-/B7H?P5_9N^$^M>(/''C"S\UO%MY:DZ1HL;MM/[S'E"0 $Y=N,<*2*
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MX/U#0/$6F6FKZ+JT#VUW:748>.>-QM96'N">GH*_E]_X)]>$8OV.?^#HJS\
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M>#?@'X5T?XB:[;>*O&ECIT<.LZG'%Y4-_/C+L%YP/J.3D]Z /BG_ ()8>/\
M]LS]MK]K*W^+7Q$F_P"%1_!>"*06'@=X=MQJJL,1M*K#<" 0=[8;C & *_52
M&/(SCV__ %5Q?A:86FMP>A^3&>GIVKNL8>@ C&,YZ_SIP-%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !.*3=[&E
MHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH 3=[&C=[&EHH  <T444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!YQ^U_<R6O[*7Q.>)GCFC\):JZ,G
M#*19RD'/7CJ,=Q7\.4OQH\9*W_(V>)?7C5)^?_'Z_O.OK1+V%HY462&53&Z,
M,A@>",>A[Y[5SL/P8\'E/^12\-^V=+@X_P#'* /X4O\ A<WB]T(;Q7XD8'@@
MZG-S_P"/5AVVKW-EJ"7<%Q-!=1MO6:-MDBM_>##!!_6O[R_^%+^#O^A2\-?^
M"N#_ .)H_P"%+^#O^A2\-?\ @K@_^)H _A1E^-7C'=_R-GB4<=!JD^!_X_1%
M\9O&#2#/BSQ)]3J<_3_OJO[KO^%+^#O^A2\-?^"N#_XFFO\ !CP?N_Y%+PW^
M&EP?_$XH ^=O^"%FJ7&M_P#!(?X 7=W=7%Y<W'A*W>2:>0R22-ELDL>3SZU]
M8U6TC2[71--AM;.WAL[6%0L4$,8CCB7LJJ. !Z#BK- !1110 4444 %%%% #
M7^]_2F/\H"J<<XP*2XR&!'\LY]OQK\BO^"Y/_!RMH/[%[ZA\+_@O)9>*OBA(
M&M[S4T;SK/PZYX"]Q+,<Y"CY5P,Y/% 'N'_!<[_@M]X2_P""8'P=O]#T/4+/
M6/C%KMJR:3I4<H=M,5A_Q]7 !^50.54X+'D<5\ ?\&H__!-?Q9\3/C=J_P"U
ME\1H;DQ737,7AY[M3YFIW4K?O[OG^$8*JW0G..#7*_\ !'K_ (-[?''_  4%
M^)0_:!_:JEUR;0=<N1J=MI.J,PU#Q(2VX/<!L-'">H0@%AZ#%?T/>#/"6E^
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M]:_G1^+O_!YI\;_AK\5_$_A^U^%7PIN+70]6N["*60W^^1(IGC#-B?&2%R<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME>B YH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?'/
M_!P-_P H9_V@O^Q9/_I1#7V-7QS_ ,' W_*&?]H+_L63_P"E$- '\A?[)/\
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M"C9_C4>G;% 'V1FBHXCD^W;Z5)0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?'/_!P-_RAG_:"_P"Q
M9/\ Z40U]C5\<_\ !P-_RAG_ &@O^Q9/_I1#0!_(7^R3_P G7?#+_L;-*_\
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MIGFW+7++\L?"_6L&"%IYE11EI#M%>@:/8+IMC'$!RHY/J: ))QCH6& >G?\
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M YHJ&"42!6Z;AG''%3!LT %%&:,T %%&:-U !11F@L%ZG% !11GF@'- !G%
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M<GBOS_\ '?\ P7Z\)^*/VPO#_P '?@EX-USXS:Q-J2VNNZII+>58Z3%Y@5Y
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M,.V,=,5X3_P2>\6:M\._VAO%OPYFN9+C3H5D94).V-X7(W =MPQG'I0!O?\
M!;PYT'P(?6>XQ_WRM?25E^TKX#^!_P *O"\?BKQ-IVCRR:7;?NW8M*!Y:XRJ
M M^E?-?_  6[./#O@?&[YKBXQ[?**T_V0O\ @G%HOQ"\"6/C+XG?;M=UG6H4
MF@MI9W1;2+&%!VD'.".G& />@#ZG^&/[1?@?XSLR^%_$VEZQ(B[C%&Y$F!WV
MMAOQQBNZB8,.#D=J_-W]NO\ 8RB_8XETGXC_  SN=0TNVL[M$N8!(TGV:3JK
M!B<E&P00<X_&ON+]E[XQ1_'KX(:#XH4;9=0@_P!(7^Y*O# _C_.@#T*BC-%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?'/_  <#?\H9_P!H+_L63_Z40U]C5\<_
M\' W_*&?]H+_ +%D_P#I1#0!_(C^QV<?M=_"W_L;])_]+8J_N0\=Z7O2.Z4?
M<X?W%?PW_L>?\G=?"W_L;])_]+8J_NPN[=;J!HW&588H \WS15C5=/;3+Z2%
MOX3UJOF@ HHHH **** "BCM1T8_[(R1Z4 &><?C5+Q'XDT_PCH=WJ6JWMII^
MFZ?&9KFYNI D,"#EF8G"@ =R?I7SA_P4-_X*V_"+_@FYX:SXQU9M4\4W6S[#
MX9TQ_-U*Z+?=^0'$8/9FZ]@:[+PK_P ([_P4F_8AMV\8>$];T7P[\3-'']H:
M#J#-:7L$3X.QBA5D;(!R-I]>M 'A/P>_X+H?#_\ :@_;HL_@S\+?#'B+QUI:
M^:FJ>,++C2M,(!Y.5)=&P!NW#.<#I7O'QC_X)\_"']H+X^:#\3/&G@O3?$7B
M_P -0_9]/NK]/.CA7.1F%B8SC/!QD<5M_LL?L<?#7]B_X<V_A7X<>%=-\-Z5
M"/F,*;KBX)ZM)*<N[' Y+'@ =J]- PH_SB@!L%O%9PK%!&L,48"JBC 4=@.G
M3IP!Z4ZBB@!'^[^(KY>\=#'C'4O^N[?SKZB'>H3I]NY+&WB);DDH,G]* /DT
MUZ[^R\/EU3_>2O5/[-M_^?>'_O@?X4^&VCMPWEQ1IN_NJ : )">:*#U_SQ10
M 4444 %%%% !1110 49HSBE48=?5N![T +'"T\J*H)9CP .M=MX;T-=(MOFP
MTS<L?2J?A/PT;-%N)ES(P^52/NUOKT]^] "BBBB@ HHHH R?'W_(B:U_UX3_
M /HMJ_./_@DCX#T7QW\;/'4.M:79:G'#9HT:W,0D$9\X\C-?HYX^/_%"ZU_U
MX3_^BVK\^?\ @C,?^+Z^/O\ KR0?^1S_ (&@#[*^(?['/PW^(_A^;3K[PGI4
M<<@^6:VA$4T!_O(PZ'_)KX/M?%?BS_@EA^T?_9$\DFI^"=2E\Y%901<0%L%U
M..)$SR >:_4 ?='MUKQ']N_]ENU_:>^#5S8QQJNO::&NM,E ^8N!DI[[@.GK
M0!ZMX%\9Z=\1/!^GZWI%Q'=:=J47G02QXVLI_KV(]0:^!/\ @JC_ ,GG?#;_
M ';?_P!*EH_X)5_M17'P\\77?PL\42-:I)._]GF7Y1;S@_/%SVST'O2?\%41
M_P 9E_#7_=M\_P#@4M 'W5\5/A7I'QH^'5YX<UVV%UINHPA'7NAQPP]QVKX5
M\;?\$FOB!\,-;DU+X9^,=ZQ,9(8WF>SN$QT&]<ACT';ZU],_\%!?A3XE^*O[
M/<T7A*ZO+?6M-(N4CMYC&UT@4[X^.22.@]:\$_92_P""I>A_#GX?V?A7XD6>
MM6.L:'']F^TK;;VE Z"16(*L.A[<?6@#AK?]L7]H#]C77+.W^(6GW6J:2SX_
MXF,8D\T#KLG7G=[$FON6R_:8\.7/[/:_$J2:2WT%K+[8X;_6*1_!]<Y'Y5\4
M?MQ_MLZ;^VAH.F> /A[H>J:I<7%]',\\EN!)D9 "!<D+R"S'C'TKWGQI^RGK
M5I_P3=;X?VN+C7K/3UG>)7XFF!WLG],=Z /'](_;"_: _;$\0Z@OPNTNUT/0
M;64H;AHD7&>FZ5P3N]E%:NN_L5?'SQWX=U"Z\=?%::WL;>VDN)+2WN)9T8!"
M2H&5 Z'DBN6_X)]?MV>%_P!F3P%?^!_&]GJ&DW5IJ$DR7 M]Q)8_,LB9#*5Q
MP<=,5Z)\<_\ @H=_PT!H5UX&^#NCZQKFM:Y&;66]: K%:1MP6'/]W/)H X[_
M ((HPK;>+/'T:MN6.*%0WKAF&3]:H?&ZW2[_ ."Q'A]&QM-W: Y&?^61/]*/
M^"-=X?"?QH\=>'M09K?4C:JH@<C=NCD;=W.['7(]:/C(?^-Q?A_T%W:_^BF_
MK0!^C&W _&OSH_X*1#'_  4"^'_^]9?^CUK]&&8#^=?G/_P4D;;_ ,% ?A^>
MV;+])UH ^I?^"D61^QOXR.<*+=#Q_OC_ .M7Y[_LZ_L,^,OVE?@EJWB*UU#R
MM+T6.4Z9:.V[[9,/FD51_"3TSZ\5^A'_  4D/_&&?C/_ *]T_P#0UKB?^"1#
M?\8=VIZ_\32[/'^]Q_.@#F?^"5W[5C>+?#K_  W\12>3X@\.JT=IYGRM<0J<
M%,''S(<BOIK]HC_DA/C+_L$W/_HIJ^'O^"B_P(U3]F;XUZ7\8/!4;VD,UTLE
MX(<A;:?U('\,G0Y]*^G]*^/VF_M'_L4Z]XET^1!)<:+<)=P!@6MY_*.Y2/<\
MC/K0!XC_ ,$0_P#DF_C;_L)0_P#HFOJ;]HWX_P"A_LX?#6Z\1:U,H6,%+:W4
MCS;N7LB_CU/85\G_ /!%J^73OA#X_N6#/'!>I(P7T$&3C\J^;/C]^U'#^T_^
MT=#?>-Y-0M?!NEW1BCL+)0[Q0J>0 2!N?')]Q0![/^R]\$O$7_!03XXW'Q0^
M( D/A>SG/V2U.?+N2I^2-%/&U>,D=3FOT2L+&/3[:.&&..&&) B(B[50#L![
M5\6^&_\ @KE\+OAYH5GH^A^%_$$.EV,0B@C55C"*.V,G\?>NJ^&7_!6KP;\4
MOB'H_AVT\/ZY!=:O<"WCDD*%5)]>] 'B_P#P5 _<?MO_  YD/W1]D/\ Y,KF
MOT6297&[<,8SUKX1_P""PGP@UI]9\)_$+2;6XNX]$'V:Y$:;_(PXD5V]!D8R
M/2NB\ ?\%C/ '_"!6K:Y8Z[;ZY#"L<L%O"LD<C@ $JY8<'Z9'Y4 <-_P67E5
MOB[\-X\X?RRWX><!7V)\71G]EK7/^Q>?_P!$5^9O[8/Q,\6?M"_$+P[\0-6T
M>71?#EY>+9:'!-_K&1'5F;H-V2>M?IC\7"H_97US!Z^'9,>_[B@#Y9_X(B6R
MMX&\;W"K^\_M"*//J-F?ZFOI#]O!=_[('C[_ +!A_P#0UKYU_P""(9_XMOXW
M_P"PG%_Z*KZ*_;L/_&(/C[_L&-_Z$M 'B?\ P1;A5?V?M=9456DU7YCZ_(*]
M$_X*?G/[&WB7ZQ?^A5Y[_P $73C]GC6?^PJ?_0*]"_X*@'_C#;Q-_O1?^AT
M<_\ \$OM9M_#G[#UCJ%Y+Y-I8W-[/.Y'RJBMDYKR+6OV]_B]^U#\2;W1/@SH
M\-KIEC(=UZ\*/(Z= [L_RKGMCG&/6N__ &$/!LWQ&_X)K7>AVLC)=:I]OAA(
M;;ER?E!/N<"OG_\ 8'_:BTW]AOQ3XF\)_$#2=0T^2\N%)GCAW/ Z#:RD$@[#
M@$$=: /6(?V/?VDOBH53Q=\5/['L9@6E@MKEY,X[;5" >G6O-_\ @E[X>_X1
M']NOQ%I;74E\UA:7<+3O]Z4AADG///U->W?%;_@J9H?B+2VT3X6Z=K'BGQ5J
M:^1;!+4K%$6&-W7)P>YX'>OGW_@G'9ZE\*OV^[C2?%2?8=:N+6ZMYD/\4[A7
MP.3UR3Q[T >J?\%N&4:+X#9C\OVJ;)]L#-?:7PI\G_A6?A\0[?+_ +-M]N/3
MREKXK_X+<#S-!\!Q_>W7-PO^\2H'X=>OO4W[-?\ P4?M/@!X(L_!'Q5TO6M-
MU;0X4CMKJ&#S5NX=N4)R1V/4<$8H ]J_X*?26R?L;^)OM 5O]4(\]GWC!_G^
M=8?_  2,^TG]C^Q^T;@O]HW7E _W=XQ7SG^U-^U1J_\ P4/\3Z5\/_AQI&H#
M1?M*2W%Q<1[6E;H'D SMC7)/J3^%?>G[.GP?M?@/\(-%\*VA#QZ5;B.20=)I
M.KMZ\MGK0!W XHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXY_P"#@;_E#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ."CEWXP/PWC\0W6G>#[U;)]3O;#R;2_<@$&%NI'7LI'![BN>^ W_!&_X(_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'H>I[TZF+P1Z>XQ3P<T %?'/_!P-_P H9_V@O^Q9/_I1#7V-7QS_ ,' O/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !106VT4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#BJ_LV_P"'(W[(O_1N?PE_\)Z#_"C_ (<C?LB_]&Y_"7_PGH/\* /XR?\
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M_P#\57]EZ?\ !$K]D64G/[.?PF7G_H7X/\/Y4_\ X<C?LB_]&Y_"7_PGH/\
M"@#^,W_A=7C+_H;/$W_@TG_^*H_X75XR_P"AL\3?^#2?_P"*K^S+_AR-^R+_
M -&Y_"7_ ,)Z#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W_@TG
M_P#BJ/\ A=7C+_H;/$W_ (-)_P#XJO[,O^'(W[(O_1N?PE_\)Z#_  H_X<C?
MLB_]&Y_"7_PGH/\ "@#^,W_A=7C+_H;/$W_@TG_^*H_X75XR_P"AL\3?^#2?
M_P"*K^S+_AR-^R+_ -&Y_"7_ ,)Z#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@#^,W
M_A=7C+_H;/$W_@TG_P#BJ/\ A=7C+_H;/$W_ (-)_P#XJO[,O^'(W[(O_1N?
MPE_\)Z#_  H_X<C?LB_]&Y_"7_PGH/\ "@#^,W_A=7C+_H;/$W_@TG_^*H_X
M75XR_P"AL\3?^#2?_P"*K^S+_AR-^R+_ -&Y_"7_ ,)Z#_"C_AR-^R+_ -&Y
M_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W_@TG_P#BJ/\ A=7C+_H;/$W_ (-)_P#X
MJO[,O^'(W[(O_1N?PE_\)Z#_  H_X<C?LB_]&Y_"7_PGH/\ "@#^,W_A=7C+
M_H;/$W_@TG_^*H_X75XR_P"AL\3?^#2?_P"*K^S+_AR-^R+_ -&Y_"7_ ,)Z
M#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W_@TG_P#BJ/\ A=7C
M+_H;/$W_ (-)_P#XJO[,O^'(W[(O_1N?PE_\)Z#_  H_X<C?LB_]&Y_"7_PG
MH/\ "@#^,W_A=7C+_H;/$W_@TG_^*H_X75XR_P"AL\3?^#2?_P"*K^S+_AR-
M^R+_ -&Y_"7_ ,)Z#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W
M_@TG_P#BJ/\ A=7C+_H;/$W_ (-)_P#XJO[,O^'(W[(O_1N?PE_\)Z#_  H_
MX<C?LB_]&Y_"7_PGH/\ "@#^,W_A=7C+_H;/$W_@TG_^*H_X75XR_P"AL\3?
M^#2?_P"*K^S+_AR-^R+_ -&Y_"7_ ,)Z#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@
M#^,W_A=7C+_H;/$W_@TG_P#BJ/\ A=7C+_H;/$W_ (-)_P#XJO[,O^'(W[(O
M_1N?PE_\)Z#_  H_X<C?LB_]&Y_"7_PGH/\ "@#^,W_A=7C+_H;/$W_@TG_^
M*H_X75XR_P"AL\3?^#2?_P"*K^S+_AR-^R+_ -&Y_"7_ ,)Z#_"C_AR-^R+_
M -&Y_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W_@TG_P#BJ/\ A=7C+_H;/$W_ (-)
M_P#XJO[,O^'(W[(O_1N?PE_\)Z#_  H_X<C?LB_]&Y_"7_PGH/\ "@#^,W_A
M=7C+_H;/$W_@TG_^*H_X75XR_P"AL\3?^#2?_P"*K^S+_AR-^R+_ -&Y_"7_
M ,)Z#_"C_AR-^R+_ -&Y_"7_ ,)Z#_"@#^,W_A=7C+_H;/$W_@TG_P#BJ/\
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M\&D__P 57]F7_#D;]D7_ *-S^$O_ (3T'^%'_#D;]D7_ *-S^$O_ (3T'^%
M'\9O_"ZO&7_0V>)O_!I/_P#%4?\ "ZO&7_0V>)O_  :3_P#Q5?V9?\.1OV1?
M^C<_A+_X3T'^%'_#D;]D7_HW/X2_^$]!_A0!_&;_ ,+J\9?]#9XF_P#!I/\
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M_P#BJ_LR_P"'(W[(O_1N?PE_\)Z#_"C_ (<C?LB_]&Y_"7_PGH/\* /XS?\
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M[$ GCI7]$:U_.5_P9$?\G,?'7!R/^$9T[_TJ>OZ-ATH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:"%Q)'HEK][R58<%V).XCV':OU LM&L]/9FM[6WMV;J8X@I_0581-HYYH ;
MN$^ZHYR<"I.E'2B@ KXY_P"#@;_E#/\ M!?]BT?_ $HAK[&KY)_X+L^$=6\?
M?\$C_CIHN@Z7J.M:QJ/A[RK2PL+9[FYNG^T0G:D: LQP"< $X!H _D!_8[_Y
M.Z^%O_8WZ3_Z615_=IFOXG_V2?V&?C9I'[5'PSN[SX._%*UM;7Q3I<TT\OA2
M_2.&-;N)F9F,6%4 $DG@ 9K^UY6W/QSCB@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J-UR^>3QC _SBI,XHS0!&8\GV^@Y^M.C7:O?\:<#F@L!0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%&X XSS2;U]1^= #)8M[9ZX' ]^U!0D\_3-2!LT$X
MH ;&-H[]>].HS0&!- !12%P!U%*#F@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC/-)O7'4<=>:
M%J.6+>V>N!P/?M3V8(.2!]:"P'<4 ,*$GGZ9IT8VCOU[T[=FD#ANA!H 6BC-
M ;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%&: "B@-N''-&: &2)N<<'Z^GYTC(2>GH..P]N]
M24$XH ;%D+SZTZC=Q1NH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FNN6_KZ?2G;AG
MK1F@",I\^?[WO_\ 6_G3T&!2DXHW#'6@ HI-PW8R,^E+0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA8<]@GN: /ZGH"2OS<'T[#@=*DJ&SF6YB62-@\<@W(P[@\U-0 4444 %%%%
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M_P $DO W[(W[%GA/QQK7AB"\^)WCRS34M5O=2M-UQIH).VT17&8P@&.@.2:
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MZS<I*R@]"ZXX[E:_HWA;<O(VG- #J*** "BBB@ HHHH **** "BBB@ HHHH
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M+O\ (FC<QW2*.R\;SCC+>] '] F:*8G+?_6I] !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y6_\ !X'JTUC_ ,$F
M?L\;^7'>>+-.$O7Y@OF,%..Q-:/_  :+:9#9_P#!'C1;E8U2:Z\3:MYKXY<K
M/@?E3/\ @[L\&W/B;_@DA>WEK'-*='\3Z=<3"/\ AB)D5F/L./SJO_P:&>*;
M;5/^"1MAIT<B-<:5XHU-;A<\J9)=XS^&* /U(*[1CZ?C_G%?S4_\'<^@?\(O
M_P %4OA3K-MY,=W?Z-9S!PN'W0W05=Q]L5_2JQSM]<8(]3Z5_-#_ ,'8_BA/
MB+_P5_\ AKX5LYQ->:9I>FVOE_\ /)[BY5T_/=G\: /Z/_@U<R7OPB\+32,6
MDFTBTD8GN3"A/ZUTE<_\*-/;1_AEX=LY&W2V>F6T#_[RQ*#704 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 55UG38M8T^:UN(_.M[E##*AZ.C#:P_$$U:HH X'X%?LU> _P!FOPU_
M97@7PGHOA>P:1G=+"T6)I6;[S.V-S$GN3Z5_-/\ \%[QC_@Y.T/_ +#/A?\
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M%%% !1110 4444 %%%% !1110 4444 %-E^[3JAN3DA?IW(Z_P"/Z4 ?)_\
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M]/P.XJ?:G4@(Z>E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X?_P %(?V58?VV?V(OB/\ #%MOVCQ1H\L%F20-
MMPOSQ8)^[EU49[9K^>'_ (("?\%95_X(U?M#>.?@Y\:+6^T?PKK&IF'4+CRV
M:30-0ARAD:/&6C90,XZ=>]?U$7:;B& SVZ9Q_GIQSTKX=_X*5_\ !O\ _ ?_
M (*;:U-XC\1Z??>$_'4R!'\0Z&5BN9P.%\U&!CEP.,LN>.M %KXX_P#!P9^R
ME\%?A'-XH'Q8T/Q(6@,EEIVD>9<7MZW4($*_(3_TTV]\=*_$3_@G7X&\7?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4V0X'7%.ID@^8?>_#_ #_G% 'Y[_\ !PS_ ,%;C_P3 _906'PS+$WQ
M.\=B2QT)6 /V",#$EVP_V-V%'=C[5^-W_!#K]DOX$?'7XF77QR_:K^,'A,RK
M?O/8^&]9U4-<ZI=!N;J\R?N _=3^+OP!7Z^?\%?O^#?33?\ @KA\<=!\9:U\
M2M:\*KX?TP:;;V%M9QSQH-Q=FRW<L?TKY&;_ (,B_!Y_YK9XFQ[Z9#_A0!^G
M>@_\%9/V5?#.D6VGV'QG^&MC8V<:PV]O#J2)'"BC"JJC   '05TWPY_X*:?
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M;Z<"G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!WQ7I_CSX@>*;.72TGT\NUGHT<J%'F:3 #,%)P%SR:\P_P"#.?\ 8(UGX?\
MPW\:?'KQ+83VK>.0FEZ!YZ8:>U1]\LX'7#R':#T(7->D_LK?\&=_P%^"WC:U
MUKQWXE\4?$K[,XD72[P):V#D'(\Q8QN=?568JU?K3X,\(:7X \,V.BZ+I]GI
M>DZ7"MO:6EK$L4-M&HPJ*J\ #TH T8EV@?YQ4E%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !C-&*** #KVHZ44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !03110  8HHHH ,9HQ110 =**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HSS110  8HHHH *,9HHH ,48HHH ,4=*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M#&:,444 '2C&:** #%'2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQFBB@ Q1THHH **
M** #&:.E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M11FC- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+,>23L7G/J?\]: -+5-9M=&L9;J[NK>UMH1NDFFD$<<8]2QX'4=:YG0/V@/
MGB?5/L.F^-?">HWQ.T6]MJ]O-*3Z;5<GL>W:OY;_ /@Y$_X*=?$S]H'_ (*
M^._AS'XDU;1? 'PZU)M)L-'L[IHK>XDC'SW$FPC<[%CU^Z, 5R'[)'_!OI^U
MM^U?\%M%^)7A&PL]+\-^(0L]B;W76M;JXA)P)EC7/R]2-S D=10!_7<CAQQ2
MUQW[/_@*;X6_!'PCX;N&9KC0]'M;*=F;<6D2)5<Y[_,#78T &:0.".HKSO\
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M\%A-8\(^.-+_ &??AKXBO-(N-*":EXJO=/N#%*)"/W5H&7D8^\W?/!K])O\
M@@E^S5XG_9T_X)P>"?\ A-M8UC6O&7BZ(>(-2EU&X::6'S@K1PAF/W50KCUS
M0!]K45_)#_P<#?M/_$CP'_P5N^+VDZ+XZ\5:9IUKJ:K!;6NHRQ11C8O"J#@?
MA7S3X6\<?M2>.M#@U30[KXV:UIMT,PW=C#J%Q!+V^5T4J?P- ']NE&X9ZU_$
M???M+?M1?L]W::A?^*_C)X.D9PBS7LU]8[FY(&7"Y[FOOK_@D]_P=5_%/X"^
M/M'\+_'C5KGXB?#^[E6WEUB[_>:QI(9L>=YO691W5N<=* /Z=LT5B?#_ ,=:
M3\2O!VF^(-#OH-2T;6;6.]L[J%]\=Q%(H9&!]P1].G:ML'G% !111GF@ HH+
M8IOF+NQN7/IG_/H?RH =10&S06Q0 44@8'N*"X'<4 +10&W49YH "V"/?I[T
M;O\ "HY/G9=O^/0U_/W_ ,';'@;XG?LL?M$^!?C5X$\8>+-$T'Q3&EA>P6=_
M+';6]];8:-B@;:H=0,YZD$4 ?T$!LT YKXY_X(D?\%*+/_@IO^P_H?BZXDC'
MB[1<:3XEMP>8[M !YN,D@2+A^?4U]B(,?CS0 ZBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OYYO\ @]T_Y*;\$?\ L&7G_HZOZ&:_GE_X
M/=/^2F_!'_L%WG_HV@#\)[2*0+N"-C. W/WAS@'L>M?U"?\ !K#_ ,%6_P#A
MK_\ 9D'PA\8:H;CX@?#6W6.T>:0^=J>F9 1_=H^$/? ![BOS%_X(U_\ !,.P
M_P""FW_!+7]H/1[6UA_X3SPGK<&J^&;HQ@OYRVN6M\_W90-OUP?6OB7]BO\
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MM>\$Z-\/] \5VVM:I_:;7-[=2Q2(=@7 "D#&.1QWK^H'X6?M3Z7X@_8W\/\
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MN&3Y<A&G98PV>Q 4XK^HY#G\Z /XZO\ @XS;'_!8WXS_ /837_T!>M?T2_\
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MC\$/^P7>?^CA7]#6:_GE_P"#W'YOBE\$0.?^)7>?^CA0!Z-_P9+QE_@+\;2
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M*\_"73M6L+/5+"XNYA+;740EB<>2W5""#V_*OW^_X.KF_P"-.?C0=_[4T_\
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M G_!57XO6>O6UU#'KFLR:OIUQ-G%Y;2X,<@;'..0<=Q0!ZQ^PQ_P;V_M.?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&T3X/_ G2?A[IG]HS^']%TP:1;BZN6GN# %*8,K?,2 >I.:[S%'2@#\UX?\
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M?^"8OCO7/$7PLTS7+'4O$5FEC>->ZI->*T:OO7"R$@<YYKBOVPO^#=K]F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 UEW'_Z]&,?6G44  HHHH **** "BBB@ HHHH :XYZ?_7J*:RCN
M!B6..5<Y&]0<?I4]% $2P+'\JHJKC: %X'M4BTM% !1110 4444 (PS3=F6]
M?PI]% "*,#M^%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :L#Z # 2(  A$! Q$!_\0
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M<='A%B(R4H&QP09B\",S-#5"8W+Q)$,E@C9%_]H # ,!  (1 Q$ /P#:F
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MC<N>Q.)'+Z#(5KN+O1?B.17:N6IW;E.DN_9OVK].];JB8?0 &M8
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M-5[&R,7SF._>N1%]1Q[N+>L?[E.G[._CYV/D_P"W7$SW=J[0 5EX
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MJIP<J<&34'0[G0)@  9.H  '0[G0   .%.IV4ZA,!PIR<*3!VN  0R=  !T
M  +V* O8H3V.H "  $RR=5.#E3@R ZJ=CJIC X !D.H  X7L.IV7L.H9=@=#
MN= 0  )<*<'*G    =  3(ZJ<'*G!D!U7M4['5>U0GL  $.%[#J=E[#J8RS
M 3 ZJ<'*G!': 7L4!>Q3(=0 !PO8=3LO8=0F Z'<Z @  2X4X.5.    Z  ,
MNQU4X.5. D.IV.H X7L.3A>P#J "9'"G4[*=1   B4P'5>U3L=5[5)A,@ (2
M'0[G0   .@ )D<*<'*G @#JIV.JCM'  )'53@Y4X   2F'4  @.JG8ZJ$N
M!T   X4Y.%#+L<  $!T.YT"0  =   7L4ZG9>Q3J .%[#DX7L Z@ ,I=5.#E
M3@)  90.H (@#A>PY.%[#(=0 $RZ  )#A3DX4#@  #JIV.J@<  #H "9 ZG8
MZDP!PO8<G"]A$CJ !#*7"G4[*=2"  !+JO:H"]J@F .%[#DX7L,AU  3+H
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MA3J=E.H(#JO:IV.J]JA(  .@ ,N('0[G0B   D#A3DX4AE+@  @.JG8ZJ$N
M !T !/8!U.QU$ <+V')PO8.T=0 2.%.IV4Z@  $PX4X.5. =H  ET  '53@Y
M4X !>Q0%[%#+L=0 " ZJ=CJH2X  '53@Y4X '4['4   .@ #-PIU.RG4(@ !
M,)<*<'*G [0 !D.@ "9=5.#E3@) O8H"]B@=0  .JG8ZJ3 X ! ZJ<'*G!EV
M =5[5.QU7M4B   D=  0S<*=3LIU)E$  $)<*<'*G!   RD=  2REU4X.5.
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MA>PZG9>PZAEV!T.YT!   EPIP<J<   !T !,CJIP<J<&0'5>U3L=5[5">P
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M144\#M##]EN:Q^&>7R?3=DYWM=G2K\5//Q\530 '+=T
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M+V*=0!T.YT   #A3J=E.H)  &4!U7M4['5>U0   Z   =#N=  7L4!>Q0.H
M"9=5.#E3@)@.JG8ZJ$N     '4  #A>PY.%[ .H #*'"G4[*=0Q#A3DX4)AP
M  R  9#*_H-]+"?:34<&C=3UJNT3<YN&.69W*V3N7D]%7LB<ONT[$SQ<O.XM
MJK7(YN47**?GX-HO@[ND0NXFA)-#7NI6;4.G8D\7?([+ZFARC6+ZUC548O[U
M8^U<GDMK841'3VX^/S>WV'M"=?9KL_#Y,Q@ >7>V
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ML7G\GR_^4C?ICA,LJ;%RN-::9G]%M@[OC?#)(Q[7,>U5:YKDPJ*G:BH=#)I
MO8I6K?HC45TI(ZJBL-SK*63*LFIZ.1['87"X<C<+S1?8>&[6:X6.H2GN5#4V
M^=S4>D55"Z)RM551%PY$7')>?J(WHGA$M\V;E-.]-,Z/" "6@ !,LG53@Y4J
M5ITQ>+ZQ[[;::ZXM;R<ZEIGRHGQ\**3O1$:RV46ZZYTIC53#JIZ[A;:RTU+J
M>NI)Z*H;VQ5$;HWI\BID\BD1Q15151.E3@ J=ITQ>;\Q[[;::ZXL;R<ZEIGR
MHGQ\**3-44QK*:+==<Z4QJI0/3<+;66FI?3UU)/15#>V*HC=&]/D5,GF$3O(
MJHJHG2IPO8=3LO8=24=@="X*K06IJ&EDJJG3MVIZ:-O&^:6AE:QK4[555;A$
M]9;Y$515RELFW5;X51H  E@X4X*I:-,7F_LE=:K377)L2HDBT=,^5&9[,\*+
MC.%]A\[OIZZZ?DC9=+966U\B*K&UE.^)7(G:J<2)DQWHUTUXMO0U[N]IP[U/
M !DU.@/I34\M941001/FGE<C(XXVJYSW*N$1$3M55[BMU6WVJ:*GEJ*C35W@
M@A8LDDLM!*UK&HF5<JJW"(B=Y%541SEMHM5U1K3&JWE.#E3@V-0=5[5.QU7M
M4)[  !#A>PZG9>P^E%1U%PJHZ:E@DJ:F5R,CAA8KWO<O8B(G-5,99Q][A#X@
MKU9H'4]MI9JJKTY=J6FB;Q2334,K&,3TJJMPB%!%%451PEG515;X51HZJ<'*
MG [6 %[% 7L4R'4  <+V'4[+V'4)@.AW.@(  $N%.#E3@   .@ #+L=5.#E3
M@)#J=CJ .%[#DX7L Z@ F1PIU.RE;M6A-37JB966[3UUKZ23/!44M%+)&["X
M7#FM5%PJ*GR$;T4QK,LZ*:KDZ4QJH0/5<;76V6NEH[A23T%9'CCIZF)T<C<H
MBIEKD14RBHOQ*>4<T:33.DAU7M4['5>U28)  0D.AW*K9=&7_45/)46FQW*Z
M0,?U;I:.DDF:UV$7A56HJ(N%3EZR)F(C665%-54Z4QJHX/?>+#<].U3::[6Z
MKME0YB2-AK('0O5JJJ(Y$<B+C**F?4IX!$Z\81,33.DN@!]Z.BJ+E514M)!+
M55,SD9'#"Q7O>Y>Q$:G-5]2&4HC[W"'G4X+BKMNM66VCEJJS3%YI*6%O')-/
M;Y6,8U.]7*W")\9;I%-451PELJMU4<*HT#JIV.JD]K6X !(ZJ<'*G   "4PZ
M@ $!U4J%FL-SU%5/I;3;JNYU+6+(L-' Z9Z-14178:BKC*IS]:'JOFBM0Z;I
M65-VL-SM=,Y_5MFK:.2%BN5%5&HKFHF<(JX]2F.]&NFK=%JN8WHC@H@ ,FIT
M   X4Y.%#+L<  $!T/9;+76WJNBHK?23U]9+E(Z>FB=)(_"*JX:U%5>2*OR%
M3N>WVJ;'0RUMQTU=[?1Q8ZRHJJ"6.-F51$RYS41,JJ)\:H8S5$3I,MT6JZHW
MHC@H  ,FIT  !>Q3J=E[%.H X7L.3A>P#J  REU4X.5*]:=OM4WVACK;;IJ[
MW&CDRC*BEH)98W8547#FM5%PJ*GR$35%/&9;**:J^%,:J #UW2TUUCKI:&Y4
M=1;ZV+'64]5$Z*1F414RUR(J9147XE0\AE3Q83$Q.DNH $ <+V')PO89#J
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M@V>AL1';/%\'V]FSF9M<Z_=IX1\(^<NH +[S@  .%[#J=E[#J .JG8ZJ$PX
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ME89F0W.WU5NE>WC;'5P.B<YN<91'(F4RAX%$3KQAA53-$Z3#J #)BX4X.5.
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M$SC*>TI)CK$\8*J9IG2J-)  90APIU.RG4CM  &0Z@  =#N= F ZJ=CJH(<
M )#J=CJ   '53@Y4X#+L<*=3LIU! =5[5.QU7M4)  !T !EQ Z'<Z$0  $@<
M*<G"D,I<  $!U4['50EP  .@ )[ .IV.H@#A>PY.%[!VCJ "1PIU*M9-*7K4
MO7^1[/7W7J.'K?$:5\W5\6>'BX47&<+C/H4XO>E+UIGJ?+%GK[5U_%U7CU*^
M'K.''%P\2)G&4SCTH8[T:Z:\6WHJ]W>TX*4 #)KAPIP?2&&2JGCAAC=++(Y&
M,C8U5<YRKA$1$[552X9=L-8TT,DTVD[Y%%&U7OD?;9D:UJ)E555;R1$,9JBG
MG+;1:JJXTQJMH &36Z  #JIP<J<  O8H"]BAEV.H ! =5.QU4)<  #JIP<J<
M #J=CJ   '0 !FX4ZG93J$0  F$N%.#E3@=H  R'0 !,NJG!RIP$@7L4!>Q0
M.H "0ZJ=CJI,(<  @=5.#E3@R[ .J]JG8ZKVJ1   2.@*I8-*WK5,DL=EL]?
M=Y(41TC:"E?.K$7L54:BX^4^E^T;J#2T<4EZL5RM$<RJV-U?1R0(]4[417(F
M?D,=ZG737BW=%7IO:<%&4ZG93J92UP  0EPIP<J<$  #*1T !+*753@Y4X"1
M>Q3J=E[%+K;M!KQS45-$ZB5%YHJ6J?\ \AC-44\Y9T6ZZOPQJM(Z'<Z&3  +
MLBVCUU-&V2/1>H7QN1'-<VU3JBHO8J+P&,U13SELHMU5?AC5:2G4^DL;X9'Q
MR,='(QRM<UR85%3M14])\S)A(  F ZKVJ=CJO:H   =   .AW.@ +V* O8H'
M4 !,NJG!RIP$P'53L5"Q:9N^JJQ])9;577>J9&LKH*"G?.]K$5$5RM:BJB9<
MB9]:$3,1QEE1$U3I"F KU^T#JC2M&RKO6G+M:*5\B1-GKZ&6!CGJBJC4<YJ(
MJX:JX]2E!,::HJXPFJF:9TF-  &;%U   X7L.3A>P#J  RAPIU.RG4,0X4Y.
M%"8<  ,@ &0Z%^[&[HU6S>Z=@U;2J]64-2GC4+/^FIG>;-'\:L5V,]BX7N+"
M!JKMQ<IFBKE+;:N56ZXKIYPW]6>YTUZM=)<**9M11U4+)X9F>Y>QS4<UR>I4
M5%/=CFIC)X/7<B37O1\M]%52=96:=G?:'JY>:Q-1KX5^)&/:Q/\ )J9-YYGS
M2]:FS<JHGLE]?QKL7[--R.V'< &I9
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MRB=3HOH2*:2-$^1&(GR$VH?,KM.[<JI[IE]BQJM^S15/;$?L^@ -2R
M       /FJ<BEZGNS;%IRZW*3"LI*62H7B[/,8KO]Q52/=_*Y]!M#JF1B\*N
MI%BSZGKP*GL<9VZ=ZNFGOE4RJ^BL5U]T3/HU]5%1)53R32O6261RO>]W:YRK
ME54^8!]"I_"_.5<[U54NH #   '"]AU.R]AU '53L=5"8<  )EU7M4!>U0$A
MU4['50."LZ0TI<-;:BHK):XNMK*I_ W/)K4QESG+W-1$55^(HQE9T(M),='J
M#4LK&J[C;00.[TPB/D]N8O84\J][/:FOM=C9.'[?ET69Y3S^$<TQ;5;(Z>VL
MM\7B=-'5W5S<3W*=J+*]>]&^\;ZD]"9RO,XU#T@]OM+5LE'7:BIUJFKPN931
MR3\*YPJ*L;51%3T*N2Q^EUN76:1TG1V6V3NIJR\.D;+-&N',@8B<:(O<KE<U
M,^A'(83G#QL.K+CI;M4\7O-I[9HV15&)AVX^[SUY1Y=K91I'<C1VY,4K++=:
M6Y+PKUE.[+9.%>2YC>B.Q\F"%-_^C!0UEMJ=0Z/HFTE= U9)[73MQ'4-3FJQ
MM^U>B?:IR7'),]N*5AOU?IJ[TMTME3)1UU*])(IHUPJ*G\Z+V*G8J*J&R3;O
M53-<:'LU[8U&K6TS9'QMYHQ^,/;\CD5/D,;UFYL^N*Z*N$MV#E6/ZALUV,BB
M(KB-=8_>.UK)-D>R$;5VBTBJM3^YD']!#!W?W2#-%[L7ZWP1]7222I50-[D9
M(U'X3U(Y7-_T3.38_GM%I%/_ ),@_H(6-I5Q<LT5QV_)S_Z9Q^@S;UFOG3&G
ME+RZAWTT+I6[U-JN=^AI*^G5&RPNBD56*J(J<T:J=BH?"BZ0.W-<K4CU5;VJ
MY<)USEB]O$B83UJ8:=)5.'>_52?^VC_J8R,Q:V;:KMQ5O3K,09/]29-G(KM1
M;B8IF8[>R=&S;5.BM-[DV;Q:Z4-+=*.5G%%+A%5J*G)\;TYIV]K5-?&[FW<V
MV&N:^Q/D=/3Q\,M+.]$1987)EJKZTYM7UM4S1Z*UMNMKV?M<5V9-"YTDDE/%
M,BHYD3G9;R7FB*O$J>IR&/?34K()MTZ*&+A66"V1ME<B\T59)7(WV*B_Z1KV
M?55;R*K43K3Q]%G;]JUD;/IRYHW:YT^/'L7!T%DXM0ZKRF?[&@_I/+PZ<343
M05CPF/\ THW^JD+/Z"O]\.J?\V@_I.+XZ:=#47'1VFZ2D@DJ:J>[MBBAC:KG
M/<L4B(U$3M55)NSIGQ^G[&)1->P)B.?']V&EBL=?J6[TMKME+)65]5(D<,$:
M95SE_F3O55Y(B*JFP#8C8ZW[1V!JRHRKO]4Q%K*Q$[._JF>AB+^$J97N1*1T
M=-@J?:ZU)<[G''4:FJV?79$\Y*9J\^J8OI]\[O7EV(6UTF.D:FD65&EM-3_^
MG')PU=9'_P# VJGN6K\(J+V_:IZ^R,B_7F7.AL\D;-P+.Q\?V[,_'V1W>$>,
MO%TF>D@RP-J=)Z4G1;FY%CKKA$[^U4[%C8OPGI7[7L]U[G#I%SS7FIR][I'.
M<YRN<Y<JYRY55])P=W&QZ<:C=C]7A]H[0N;0O3<KY=D=D0]%LMM1>+C2T%)&
MLU552L@BC;VN>YR-:GRJJ&SG06DJ;16C;18J=&NBH:=D*N1,<;D3+G_&YRJ[
MY3#/H?Z#^BC<SRM/'QT5DBZ_FG)9W9;$GR>>[XV(9)=)#=B;:O2-#4T2HMQJ
MZ^%L4:]\;'))+\BM;P+_ )0X>T:ZKUZ+-#V_]-V;>)BUYM[E/#](^<K0Z:&@
M/+NA*?4=-%FJLTN)>%.:T\BHUWQX=P+ZDXC"-3:5/#;M>Z.>QR^,VN[46,^_
MBE9R5/D<:RM6Z<JM):EN=EK$_LBAJ'T[UQA'<*X1R>I4PJ>I2QLJ]K$VJN<.
M?_4^'%-VC*M\JXX_&/G"D  ] \&X4F;HP;-0;I:KJ*N[1N?8;4C7SQYQUTCL
M\$7IQR55QW(B=Y#*F>_0YL#;5LQ2UC41LMRJIZAZ]Z\+^J3\T?YSF;0O39L3
M-/.>#TW]/X=&7F1%R-::8UF._3ZK\U9KS1FSEJH8[O54UDHW9CI:>&G<N4;C
M*,CC:JX3*=V$RAQ5VW2&^.BD54I+Y9JMJ]5.U,.C7L5S55.)CT7XE[E,/NF3
M>I;CO)/1R/58[=1PP,9W)Q)UBK\:\?YD]!)O0,O4\UIU;:G/S3T\U/51M]#I
M&O:_^J:<*K$FWCQD15.]PGS>XL[4IO[0KV?51&YQCRYZL;-V=NZK:_7-PL$[
MUFCA5)*:=4QUT+N;'?'CDOK12^.B_LO#NKJV>KNT:OL%J1KYX^SKI'9X8L^C
MDJNQW(B<LDC]/&PLBN&E+RQB=9-'/22O[\-5KV)_M2$F]#;3S+5LM1UK41LU
MSJIZEZ]Z\+^J3\T?YSHW<NKV**XG[T\/\\GG\79-OKFNQ,:T4_>T\.&D+ZU9
MKS1>SEJH8KM5TUCHW(L=+3PT[ERC<91D<;57"93GC"905=MT?OEHAJ\-->[+
M5M=U4[4PZ-W-.)JJG$QZ+\2^DP\Z9=ZFN6\T]&]ZK%;J.&!C.Y.)JR*OQKQ_
MF3T$G] N]3RVG5UJ<_,%--3U4;5[G2->U_\ 5-.=5B3;QXR(JG>X3YO06=J4
MW]H5[/JHC<XQY1QU8U;M[=U6UNN+C8)GK+%"J24U0Y,=="[FQWQXY+ZT4LXR
MQZ>EA9'7Z5O4<:=9+'/22O[\-5CV)_M2%F=#33MHONX%U?>**EK8Z.A6>+QN
M-'MC>DC$X\.Y91%7GW'<M94^RQ>JX\/H\3D[+B-ISB4SI$SP\(GB]/1NZ,]?
MK2YTFI-14KZ33D#FS0P3-PZN5%RB(U>R/TJONDY)VJJ9;[S1M3:'6B(U/[BU
MF/\ J'EC:MZ4&GK1JZRZ8L#H;Y<*^X4])-/"_BIZ9CY&L=YR>[?A5PB<D[UY
M86_-Y5_]R#6J_P#R+6?U#SSM^Y>NW::[D:1/*'T#"Q<3&Q;MK'JWIB)UGQT:
MO%.#E3@]M3^!\<J_%+A3J=E))V-V.NN\][FAIY?$+51\+JRN<WBX.+.&,;]L
M]<+ZDQE>Y%QKN4VJ9KKG2(;<:Q<R;D6K,:U3V(T.%,_[/T+]M[=3)'605URD
M[YJBL<Q<]^$CX4P>>_="G;VZT[V6Y*^T2HGFR052R(B^E4D1V4]2*G9VH<KK
M:SKIQ\GJ?LQFQ&NM/PU^C <RIZ K4?J/5N4S_8L']-Q!N[VTMVV>U3):;FK:
MB"1O6TE;&F&5$><<6/M53L5O<OI1459SZ G]\FK?\U@_IN-N;<IN8E5=$ZQ.
MG[J^Q;-=C:E-J[&E43.L?I*N=/M$2V:.QV]=4Y_!88;&PKI(;,77>:MTC04,
MT=)14LE0^KK9$XDA:J1HF&Y17.547">I<JA\+/T+MMJ"C9%54U;=)T3G/45C
MF*J_%'PHB?(<W%SK=BQ335/'CR^+O;4V+DYV=75:B(IX<9X:\.QK\!DWT@>B
M5!H'3U5J72]5/4V^EPZJHJE4>]C%7'&QR(F43*914RB97*F,AW;%^C(HW[<\
M'B\W!O8-SH[L:3^[A3J37L7T8;SN]"EUJ:GR+IU'*U*QS..2H<BX5L;,IR1>
M2N7DB]F5143)RU]"[;2A@2&IIJ^XRHB(LU16N:Y5].&<*?F[BI>VA9LU;NNL
M^#J8FP<O+MQ<B(BF>4S.FO\ +7P#-K</H+6*OHYJC1]QGM=<B992UK^NIW?O
M>+'&WXU5WQ&'=_TY<-&Z@J+1?*&2DKJ.7@J*9ZX7T\E3**BIS1R9145%0WX^
M9:OQ]R>/<J9FRLK F.EIX3VQQA1P9RT'0RVYU!IF"YVJLNKDK:5M12S/J6.;
MY[.)CE1&<TYH8/U=)-;ZR>EJ&+%/"]T<C'=K7-7"I[4)Q\NWD:Q'8QS=F9&#
M%$W--*N6DZOD=#-#:;H:Z4U/MY8;O?IKDRY5]*VJE;3SM8Q$?ES$1JL54\Q6
MYY]N3'GI"[84VTVY=78J!9G6YT$532.J'(Z16.;AV51$SY[7IV=QA9S;5ZY-
MJCG#=D[(R<3'IR*XC=JT^/&->*-3JID/T6>CO9]XK??KCJ!U;#0T<L=/3+1R
M)&KI%17/RJM7L16?A%'Z4&TVE=I]0V2R:9=75-?4P.J*EM1*DB\+G<,2-1K4
MYJK7_F)C,MS>Z&.;#JK(IQ8R^&[/CQYZ<D'@S(VHZ#%%):8*_7%;5>-S-23R
M;0O:QL64]S(]457.]/#A$7O4DYW0VVJ>CD;9YVJJ8XFW";*>OFXK5[4LT5;O
M&?@Z=G^G,R[1%<Z4Z]DSQ:Z3J99[V]"F/3EAK+YHFKJJUM*U99[75JU[UC1,
MN=$]$3*HGVJHJJF<+G"+B87L;(MY%.];EQ<S OX%S=NTZ=W=( "TH.JG!,NP
MG1LN^]4TM=)4+:-.T[^KDKG1\;Y7IS5D3<IE41>;EY)GO7D95VKH4;84%(V"
MII*ZX3-[:BHKGM>OR1\+?S',O;0LV:MR9UGP>BQ-AY69;Z2(B*9Y3/#5KN4Z
MF<>X'0-T_<+;)-I"Z5-LKV-564]:_KH)%QR;G".9S^V\[XC"R_Z?N&EKS6VB
MZTLE%<*.18IX)$YM<G\Z=Z*G)45%0VXV9:R>%$J>;LR_@3$7J>$\ICC"GG5>
MU25=CNCUJ#>ROF=1N;;[)2O1E3<IF\2-=C/ QN4XWX5%QE$1%YJF4SEI8>@Y
MMQ:Z1C;@RX7F=4\^6:K6)%7ES1(^'">K*]O>87L^Q8JW9G6?!:P]B9691TE,
M:4]\\-6O8&>NN.@?HV[T3G::K:RPUJ-^MMDD\8IW+^^:[SOE1W+T*88;A[=W
MS:_4]18[_2^+5D:<;'L7BCFC7.)&.[VKA?6F%14145"<?,LY'"F>/<UYNR<C
M!TJN4_=GMCC"U@35T6-G['O)K&[6N_/JV4U-0^,L6DE2-W%QL;S56KRPY28M
M?]!:CEONGJ/2-35TU#,L[KG77"1LR0,;U? C&HUJJYW$_">KM3!%S/LVKG15
M\)98^Q\G*Q^GM1K&NGCST89G0V*6?H0[96^WI!4TM?=:C'.IGK7,<J^I&<+4
M3Y/:0]O#T&:^U5U#4:!FFNE)53M@FI*YS>.EXO\ I%>B)F-._EQ)R]UW:K>U
M+-56[KI\5J[_ $[FVK?2:15X1.LL3 9]Z$Z".BK3;6?1-45=_N#F^>L<SJ>%
MB^AC6X=\KG+GT)V%!WAZ#%D\A55PT--54=RIXUD;;:F59HJC"*O UR^<UZ]V
M55%7"<LY$;3QZJ]W6?CV,I_IW,BUTND?#7BPB.%.[F.C>YCVJUS5PK7)A47T
M&<&V70OT%J_;W3=[K:B[-K+C;:>KF2&J8C.-\;7.X45BX3*^DLY&5;QHBJKM
M<[!V=?SJJJ+>FL=[!L&9>V703I:VKK+CJ^JJJ>WNJ96T-K@>C95A1ZHQ\SU3
MDJM1%X6HB\TRJ<T21M0=!C;6[6]\-MAK[-4=K:B"K=+A>[+9.)%3U)A?6A4G
M:EBF=-9ETK?].YM=&]I$>$SQ:[CJI(&\NS-[V5U/Y)NR-GIYFK+1U\+52.HC
M1<91/M7)RRU>S*=J*BK\=G=G[UO-JZ.RVA&P1,;UM972IF.GBSA7*G>J]B-3
MM7T)E4Z,7[?1]+K]WO<3V.]TWL^[._KIHL0&P_3/03VYM-#$RZ^4+S5(GUR:
M:I6%KE]368PGJROQJ>J[=!?;"Y4JQTE-<;7)CE+2USGJB_%(CD_,<SK:SKIQ
M\GHH_IK,W=?N_#7Z-<8)3W_V%N>Q>I*>DJ:A+C:Z]KI*&N:S@XT:J<3'-RN'
MMXFY[E1R*G>B7IT1MA=-[W/U4FH)*YB6SQ7J/$YFQ_MG7<7%EJY_:VX^4OUY
M=NFST^NM+B6]G9%>5[)II5X_#7]F/!U,WKIT#;14;CT%+;JFX4VE(J3KJVHF
ME:^:657N1L4:\*(G),JJHN$^-"J;S=$G:O1VVM]OL$-=:IK;2OF9+%6N?UDB
M)AC%23*><Y4;RQ[HJT[4Q]::8UF9=/[/Y=-%==6D13WSST[F!IPO82ML#T?+
MOOG>YHZ>;R99*3'C=R>SCX57W,;&Y3B>OQX1.:]R+F-:.@OM=;::..MIKA<Y
M4;A9JBM<Q7+Z<1\*(;,C/LV:MV9UGP:,/8N3FT=)3$13WSPU:X0;$]1] S;B
M[4;VVMUQLM1CS)8:I9F\7I<V3.4]2*GQF$.\&T]VV;UG4:>NKF3JC&STU5$F
M&3PN54:]$7FG-'(J+V*U>U,*N>-G6LB=RB>/BPSMCY.#3%=<1-/?#)OP;\:/
MEW"RF<);_P#B3CPD34:_;["8Y7#_ (8[>#=7$FX7Q6__ (DE7I,='VX;[ZDT
M53Q5C+=:;:E:^NJU:CWIQK3\#&,RF7.X'\UY)PJJ]R+PKER+6T9KKG2(^3U]
MC'JR=AQ;M1K5/S:U@;):#H.;44E%'3SV^OK9FMPM5-7R)(Y?2J,5K<_$TQ\Z
M1/0QFVVLT^I=)5E1=K)3IQU='5(CJBF9\(CFHB/8G?R16ISYIE4ZUO:6/=JW
M(F8GQ>:O;!R\>W-W2)B.>D\88^[=?NA:7_C2E_KFFV3<9J?L>:EY)_<RH_JG
M&IO;K]T+2_\ &E+_ %S3;)N-^YYJ7^+*G^J<<[:G^Y;_ ,[G<_IR/_SW_P!/
MVEIY ,P=C^@@[4%HIKQKVJJ;>VH:DD-HI%1DS6KS19GJB\*JGVB)E.]47*)W
M+V3;QZ8JKEY/&P;^;=FBS3KW]T,.P;*ZSH.;35%++!':ZVED<F&SPW"7C9ZT
MXE5OM13%?I&]$>Y[,TKK]:*N2]Z7XT;)+(U$GHU541O6HG)S5543C1$YKA43
M*9K6=I6;U6YKI/BOY.PLK&MS=TB8CGIV,>E.#E3@ZKSH%[%!L*K>@1MU'8IZ
MF"6^2538'21L2K8O$_@RB8ZOGS[BED95O&W=_M=;!V;>SXJZ'3[O/7Q:\P9R
M[-] 2U-M%/<=PJF>>OF:V3R51S=7'"BIGAD>B<3G>GA5$3GS=VEXZSZ .WMZ
MMCF6"6NT[<&M7JYDG=4Q*[]^QZY5/X+FE2K:F/35NZS\>QTK?]/YM5O>TB/"
M9XM=)U4NK<K;:];4:NK=.WZ!L-93X<V2-<QS1K[F1B][5]J*BHN%14.NV^VU
M^W5U33:?T[2>-5TR*]SGNX8X8TQQ2/=W-3*>M<HB(JJB'3Z:CH^DUX=[A>SW
M.DZ'=G>UTT[=5K V$:$\'OHRT4<;M47*OOU:J(KVP2>+4[5Y*J(B9>O>F5=S
M3N0KU^Z!&UUTH716^"XV>?M2HIZUTBY[LMDXD5/8OK.7UMCQ.G'R>AI_IS,J
MHWITB>[7C\FM=2N:#TG+KO6=ET[!.VEFN=7'2MFD:JMC5[D3B5$[<9) W]Z-
M>H]B:^*2K>VZ6&J?P4MV@8K6J[&>KD;E>!^$5<95%1%PJX5$F?H,;$Z<UQ;$
MUQ<9*UMWLE[X:9D,S6PKP1Q2-XFJU57SG+WIR+-[+MTV)NT3K'8H8VS;M69&
M/7&DQSB>[M25?^BOHO9K8C6U;2TOE?4#;+4JZ[U[4=(U>J7/5M[(T[>SSL+A
M7*:[S=!K+2M'KC2MTL%P61M#<:9]-,L+D:_@<F%PJHN%^0UX],'H\Z7V-@TJ
M[3LE=(ZZ/JFS^.SMDQU:1\/#AK<>[=^8Y6S<S>JFBY,S55/\/1[=V7T=%-RQ
M$133''S]6-H)@Z//1KON_-TG?#-Y)T_1O1E5=)&<?G8SU<;<IQ/QS[<-145>
MU$7,^S] S:BW4+8*RBN%TF[ZFJKWM>[Y(^%N/D.ID;0LX]6Y5.L^#S^'L7)S
M*.DIB(I[Y[6LT&=^[?@][/46RHKM 7"II+C&BO;:Z^5)()L)R8R141S%];E<
MGIQVF#5TM=79+C5VZX4\E)74DKH)Z>5O"^-[55'-5/2BHILQLNUD_@E6S=GW
M\*J*;D<^4]DO(IU,S>C)T1M#[N[3T6H[Y-=6W":HGB>VDJ6,9ACU:F$5B]WK
M/38O!_0W?<W4+:RMKK1HBAG;%1)Q-=65GUMJN<CE;PM8CE5.)6KG"HB=YHJV
ME9IJJHJX32NT;$RJ[=%RB(F*N7']>/<PI!LXDZ!VT<M"^G;;:^*=6<*53+A)
MUB+[Y$55;G_1QZC#GI/=&6IV#NU%44=;)=-.7%SFTU1,Q$EAD;S6*3')5PN4
M<F,X=R3!./M&S?KW(X3XF5L7*Q+?2U1$T]ND\D&*<'OL]EKM1W>DM=LII*VX
M5DK8*>GA3+I'N7"(AG5M7X/"PT5OIJS7ESJKC<78<^WV^1(:>/TL<_'&]?6U
M6_+VF_(S+6+/WY5,+9V1G53%F.$<YGDP&!LWN70)VDKX%CAH+A;Y,?MM-7O5
MR?A\2?F,0^DCT3;QL9&R[T54^^:8EDZOQSJN"6E>J^:R5$54PO8CTY*O)4:N
M$718VC9OU;D3I/BNY.Q<K%HZ28B:8YZ=B 090]#_ & T!OM9[[#?Y;E#>[7.
MQW#1U+(V/IWM\U>%6*N4<UZ+S[VGAZ8?1GM&Q?T.7#3;ZV>U7#K8)UK)&R.C
MF;AS>:-;R<U5Y?O%-T9MOI_9Y_%_DJU6S+_LWM4:31\>//1C4IP=V,=)(UC&
MJ][EPC6IE57T(;#],^#WT$FF+;+?:J[I=O%(W5KH*QC8DFX$63A18UPU'9QE
M>PRR<RWBQ&]VL<'9][.WIM:<.>K7:%[%*OJ^*T0ZJN\>G^N6R1U<C*)TST?(
MZ%'*C'.5$3FJ(B]G>4A>Q2Y1.]&KG54[DS"NZ!TC-KS6MDTW#4,I)KI5Q4C9
MY&JYL:O<B<2HG;C)GSJ'HFZ(V5V"UQ6TE*MYU"VR5*ON]P:CI&KU2YZIGN8D
M[>SSL+A7*1GT#M@]-:YM2:YN4E<EZL=\X:5D,S6PKU<<4C>)JM55\YZ]Z<C.
M+66DZ/7&E;MI^XK*R@N5,^EG6%R-?P/3"X547"X]1Y3:&9/3Q13,Q$<WOMC[
M+IJQ:KE<1-543I/=P^;2B=5,F>F3T=-*[#P:4=IJ6OE=='U+9_'IVR8ZM(^'
MAPUN/=NS\A8W1]Z,NI=_KC.^BD;;+!22)'5W:9O$UCL9ZN-F4XWX5%QE$1%3
M*IE$7T%O+M39Z;72GQ>2N;/O4Y/LT1K5X?#5#P-F&F_!];66FCCCN:7*^U'#
MY\U15K$BKRYHD:-PGH157M[5*5K_ ,'7H:]4$C]*U]=INX-;];;)*M53N7]\
MUWG\_2CN7H4HQM:Q-6G'XZ.I/]/YD4;W"9[M>/R:XE."[=S]L-0;2:KJ=/:C
MH_%JV)$>Q[%XHIXU5>&2-WVS5POK145%1%14+2.S17%=,54SK$O.7+=5NJ:*
MXTF ZKVJ=B;.B)LS8M\=R[E8=0.JV4<%IEK6+12I&_K&S0,3*JUW+$CN6/0:
M[EVFS1-RKE#9C6:\F[39HYRA$&>^O?!WV1^HM-46E*NXTUNJ)I'W>MK)62]3
M Q&\*1HC&^>Y55$SGO7L12^-2]!#9RUZ2JYI8KE;THZ9TTUT;<'+(QK&JYSU
M1R*SL157S43EW',ZVL:1IK.O@[L?T_EZU:Z1IX\_@Q_\'WN'IC;_ %'K";4U
M]H+'%4TM.R%]?.V))'(]ZJB97GC*%Q^$#W0TCK[3ND8=-:BMM\DIZJ=\R4%2
MR58VJQJ(JX7EE4(WZ'NP.E=^=1:II+Y)<(Z2W0Q2TOBLS8W^<]R>?EKD7DB=
MA6>F3T9])[#6/3=5IN2XRS7"IFBF\>G:].%K6JF,,;CFJE>8L^W1,S.]W=G)
M=I]HC9<T[L;O?KQY_-BPIU)@Z.?1OO72!U%4TU+4-MEDH>!U=<I&<7!Q*O"Q
MC>7$]<+RRB(B95>Q%S?L/@^=IK11]77TUSO$N$_LBJKW1NSWX2)&(B>TO7]H
M6<>K<JG6?!RL/9&1ET=)3$13WRU@ V;ZE\'EM=>*-\=J;<['/CS)J>L69%=Z
M7-E1V4]2*G9VH8&[Z[&WS8?6;[%>%;4T\K5FH;A$W$=3#G'$B9\UR+R5J]B^
ME%15SQLZSDU;M$\>Z6.7LG(PZ=^N-:>^$<J<$A[';(W_ 'VUG'8K*C888V]=
M6W"9,QTD.<*Y4^V5>Q&IS5?0B*J9Y:5\'AMA9[?''>5N=^JT3Z[435:P-<O[
MUD>.%/4JJOK4C(SK.-.[7/'N@P]DY&93OT1I3WRUE VA7OP>VT5UHUCHZ:Z6
MB3'*>DN#GN3Y)4>GYC!KI(='.[='O5%-15-2VYVBX-?)07!K.!7HU41['MRO
M"]O$W.%5%1R*G>B,?:%G)JW*9TGQ;,K9&1AT;]41-/?"'P3+T3=H[)O3NM]#
MFH'U3*#Q":IS1RI')Q,5N.:M7ES7N,C-X/!Z6VG;I^CV]=<75M=<.JK:NYU#
M9(*:F2.1SI'<+$7/$C41.]51/6F=W/LV;O15SI/HU6-F7\FQ-VU&L:Z>+ Q3
M@V=Z2\'?M=9K8V*\K<=1U_"G65$U4ZG;Q8Y\#(\<*>I5<OK(YZ0/@]K+:]+7
M+4&WE36PUE%"^I?9:I_7LG8U,N;$_'&C\(JHCE=Q+A.15HVMCU5[G'X]B[7L
M++HM]),1.G9$\6!2]BF]>C8GDZ'E_P!$G\QHH7L4WLT7]SH?\DG\R%';/_\
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M5O*IWK<O)96'>PZ]VY&G[2Z@ N*(<+V')PO8!U  90X4ZG93J&(<*<G"A,.
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M3;*=U36U4B1QQM3T]JJO<B)S5>Y$53TTUQ33O2^66[==RY%NF-9EGIT9>/\
M82TUUF<\$V,^CKY,?FP8O=+=&)O-6HWM\5@XOCX%_P!V#-316G8M':/M-EC=
MQLH*6.#C]\K6HBN^5<K\IK\WNU9'K+='45TIY$EI73]3"]O8YD;4C:Y/4O#G
MY3S6!_J9%=<<N/K+ZEMZ?9]FV;%?XONQY1Q9X;/M1-JM'_Q/2?U+#X5VB] W
MJ[U2U=CT_6W1[LSNFI8'RN<O>[**Y5^,^VSZ+^Q1I#BYIY(H_P"I88([XN5N
M[VK%1<*EP>J*GQE7'QYOWJJ8JTT^;J;0SZ=GX=JY51%43I&D_!GS;MNM*VM6
M246G+33/C7B8^&BB8K5]*8;R4B[='I4Z>T3X];K5#/<[Y"Y8EIY87P1Q/]+U
M>B*J)Z&IS]*=I;G13WPJ-11_0C?ZMT]PA:KZ"JF=E\\:)YT;E7M<U.:+VJF?
M>\[UZ0FQU-N;IZ2MH(&1ZDHXU=3S-3"SM3GU+U[T7N5>Q?4JD1;BU?W,C689
M59->5@>T;-TB>V-./C$>+!B_7VMU->ZVZW"59JRLF=-*_P!+E7.$]")V(G<B
M(9,]!/\ MO6?\"C_ )YC%J:%]/+)%*QT<C'*US'IA6JG)45.Y3*3H)_VWK/^
M!2?SS'H,V(C%JB/!\]V!555M:BJYSG7^64M3;J:JK::IEACDJ*?BZF1[45T?
M$F'*U>Y53E\62E6?7%DO6HKM8J&X0U5RMB,6I@C7*Q\6>6>]4QSQV*J(O,C7
MI3;FW;;K1=+'9G)!5W.9U-XWGSX&HU556?OE[$7N^/"IA]M;N-6;;:XH[_$Z
M29C7\%7%GG/"Y?/:N>_O3/>B*<#'PJK]J;FOP>_VAMVU@Y5./N]L;T]T3^\I
MZZ86SO"[Z.K5#E%X8KI'&G9W,F_F:[_17TJ8J&T>-UKUIIMJYBK[3<J;*=[)
MH9&_S*BFO+>;:^JVKUK56J1'NH)/KU#4.3]LA5>2*OOF^Y7UIGL5#K[-R=ZG
MH*^<<OA]'E?ZEV9%%49MF/N5<_CW_JL(V$=&;0GT#;5VUL[."MN*>/U&>W,B
M)P-7XF(Q,>G)A9LWH==P]R++9G,5]-),DM5Z$@9YS_BRB<*>MR&R*>HI[51N
MEGFCIH(T1%?(Y&,;SPG->2=R&K:M[E9CXK7])X?X\JOE'"/WE@;TK=<?1;NO
M6TL,G'16=B4,>%Y+(BYE7X^-5;_H(9(=$O7"ZKVHIJ*:57UEF?XD_*\UC3G$
MOQ<*HW_04OY[]$32/DD?8WO<JN<YRPJJJO:JJ>RSW'3%'*L5MJ;7#).J)U=+
M)&USU[DPU>:\U]ISKM^+EBFS%$QIVO18>#-C-KRYO1._KK'[=O8Q$Z9V@O(6
MO*74=/'PTMXBX97(G)*B-$:OQ99P?&J.(&L=GJM0W>CM="Q)*NKG9! USD:C
MGN5&M3*\DYKWFP7I&Z ^C_:J[TT3.LKJ)OCU)A,KUD:*JM3UN8KV_&XP/VXO
M-+IW7NG;I6O6*DH[A#43/:U7*UC9$5RX3FO)#L8-^:\?2.=/#Y/$[>P:;.T8
MF>%%<Q/KQ^:_TZ)>YCNRS0?CL7_F*;J/HVZ]TK8JV[W*UPPT-''ULTC:N)ZM
M;Z<([*F5Z=+K;7"?^F)_Q&;_ ,I9V[O25T%JW;;4-GMETEFKJNF=%#&ZDE8C
MG93EE6X0KTY6;55$54</@ZMW9FQZ+555%[6J(G3C'/3AV)4Z/B-39G2?!V>(
ML]O//YS"CI,?NX:K_P K'_4QF7_15N[;KLC841462EZVFD:GVJME=A/P5:OR
MF*/2PM<MNWPOLCV*V.L93U$2JGNFK"UBK^$QR?(88$[N77$^/[K&VXZ39%FJ
MGEP_9*G0)SQZX3*X_L+'_P!//1T\N#Q#1Z+[OK:G'Q<,>?\ <>OH)6N6'3NJ
M;DYJI%4545.UWI6-CG+_ %J%M=.V\,FO^EK4UR=93TT]0YO?B1S6M_JG"G[V
MT=8_S@F?]/\ IZ(J[?YG5D'T>N%-E])<'-/$6^WGG\YA/TF/W<=5_P"7C_J8
MS+_HIW=MUV0L&'(LE-UU-(B=RME?A/P5:ORF*/2QM<MMWOOLKV*R.K9!/$JI
M[IJPM:J_A,<GR#!^[EUQ/C^[';G^ILBQ73R^[^R5.@-GK-<)E<?V%C_Z>>CI
MZ<'B&CT7W?6U6/BX69_W'JZ!UJDATYJJYN:J15%5% UW<JQL<Y?ZU"W.GA>&
M37_2UJ:Y.LIZ>>I>WOQ(YK6_U3A3][:.L?YP35_I_P!.Q%7;_,ZL7XZR>"GG
MACGDCAFPDL;7JC7X7*<2=^%])>&Q_P"Z[H_^-(/Z:%E+V%[;'_NO:/\ XT@_
MIH=^_P#[57PEX/!JGVBU']T?NS]WS_<<UC_%51_5N-8YLXWS_<=UC_%51_5J
M:QSD;(_VZOB];_5G^_;^'\@ .^\(S#Z!/*UZQ5?AJ;^C(75TOMUKKM]I6VVV
MRU4E%<+Q)(BU42X?'#&C>-&KVM<JO:G$G-$1<<^9:O0'YVK6*?\ MZ;^C(>?
MI\VB=\&D+FQCEIHWU-/))W->Y(W,3Y48_P#!/)U4TU[0TKY?1]2MW+EG8$5V
MITG3]YXL=M$[P:IT-J2GNU'>*V=6RH^>GJ*ASXZEOVS7HJJBY3EGM3M3FALG
MIY*+5^EXI71I/;[G2(]8Y$]U'(S/"OQM=@U2M:KW(UJ*YRKA$1,JIM.V\M4U
MBT#IRVU*.944EMIX)&N[4<V)K51?E0W;5HHHFBJGA*M_2]Z[>IO47)UIX>?U
M:Z]*65=.;\VBT\2N6@U-#2<2]OUNJ1O^XV"[RIG:'6_\25G]0\P+AKH[CTFH
MZJ%R20S:O1['-[%:M;E%]AGKO-RV@UM_$M9_4/->=,S7:F5C8=---C*IIY1,
M_P M7*FW=BXIT7T--1"FW5/[5_T/]QNVM_\ Q_K_  K_ -*<LC]/Y:U-WM[-
M2;@ZSKZM;K5TUNCJ'-HJ.GE<R.*-KO-7"+A781%5W;GU(B)E?T-=?7;6NW5=
M!>:N6OJ;96K!'43O5\CHE8US4<Y>:JBJY,KW83N,!G.57.55RJ\U53-+H#?W
MJ:I_SZ/^K+.?9MT8D;L<M'/V%E7KNTIWZIG7758/3PI8X]Q;#4(GUR2U\"KZ
M4;,]4_I*3WT1M*0Z=V5M%0UC6U%R=)6S.3[97/5K/8QK/ER07T]/[_-._P 7
MN_K5,D>C5<(KGL=I*6)R.:VCZE53WS'.8[\[5.=>JGV&B/%W<"BF=M7YGG$<
M/1C)TOMZ+[6:_K-*6RXU%OM%L:QDS::18UJ)G,1SE<J<U:B.1O"O+**IY>B/
MO1?K7N%0Z7N-QJ:^S73BA9%42+)XO*C55CF*[FB+P\*HG+SL]J%D=**U3VG?
M+5+9F.:DLK*B-R_;-?&U45/ERGR'EZ-EGGN^]NE(X&O7JJKQB1S4]RR-JO55
M]"<L?*=3H;7L?+AIK^NG-YN<O)ZW_%.N]IIX:Z:?!GATA5QLKK+^+I?YC%KH
M(5U%!N%?8)U:VLFM_P#8[G=O"V1O&U/7[E<?O5]!E)TA4QLGK%/_ )-E_F-:
M^FKS=;!?:.XV.HGI;I3R<<$M/E7H['<G>BIE%3L5%5%Y%# M=+BW+>NFLN[M
MK(]EVC9NS&ND<FPCI';)W7>>QT%-:K[Y*DHW2.=2S*_J*GB1N./A[%;P\EPO
MNE,;=,[2;S; :A;?+1:'W6FB54GAMM1UT-4W"IPNB14>OI1>'**7MISIIW[3
M,-+3:^T=51)*W+*ZFC=3NE:G)7)%(F'?&CD3U$Q:&Z46WNO:^EM]%=WT5QJG
MI'#25\+HG/<JX1J.YL557DB<657L*]/M.-;FB:-ZGS_9=N1L_:%V+M-V:+G#
MMTG7LX3P\F(&['25USN#:ZW3=\I**V4CWMZZDCI',D:K7(YN5D5SFKE$[,=_
M<I#2]BFQOI+;2VC7VW%XKW4D;;S;*62JI*N-B=;YC5<L2KVJUR(J87L547N-
M<B]BG<V?>M7;4]'3NZ<X>,V[BW\:_$WJ]_6.$^'<ZE:T3JNIT-JFW7ZCI:6K
MJZ"3K88:YCGQ*]$5$541R+R5<IA4YHA120]@MKV[M;D4%DG>Z.WL8ZJK'1KY
MW4LQE$];E5K<]W%GN.A<JIIMS-?+3BX>)1<N7Z*+7XIF-/BD_4/3'UIK_2M1
MIRU6/Q&\U>&^/6>21TJ,SYS6,PKD5>SB1V415QSYI2=HMKMZX=5VV[4%#>K;
M%'4LEGEN-0M.U[.)%<CV2.17HJ9RG"N<F7&KKYHWHW: =716J*WT$;V4\-+0
M0M22HD5%X6JJ^Z7".57.7.$5>:]N/57TZM0Z@OE#06/3M%;(9ZB.%7U4CZF1
M4<Y$RW' B+S[T4\U;KJN451CVXBGOE]"OV:+%VBK.R:IKC32(X,M-?TL==H+
M45/,WCCFMU1&]OI18G(J&I8VWZSYZ,O?^8S?U;C4@6-C_P#?^BM_5?XK7PG^
M N[9W]UK1'\>4/Z0PM$N[9W]UK1'\>4/Z0P[=_\ VJOA+Q6'_P FW\8_=M'U
M->H],Z;N=WF17Q4%++5.:B\U:QBN5/S&KG5>\&L-8ZDFO5;?JZ*J617PLIJA
M\<=.G/#8VHOFHB+W<_3E5539+O4]6[.:W5%PJ6.M5%_^</-5)P-D6Z:M^9CB
M]S_5%^Y;FW;HJTC35LRZ+^MJ_7FS=DN-VG=57*+K:66H<N72=6]6M<[TNX>'
M*]ZY7O,.NF52QT^_5[>QN%F@II'^MW4M;_,U#*+H0?N'TW^?5/\ 20QCZ:?[
MO-T_S2G_ *M###IBG-KICEQ_=MVK5-S9%JNN=9^[^S+WHKZ+I]';*:>1C&I4
M7&!+G._O<Z9$<W/Q,X&_Z)C'TF=1;FZUW'NM!06S44>G+=,M-2PT-+.D,O#R
M=*JM;AZN=G"\\)C'KR_V0KFW/9_1M3'AV;33(J-[$<D36N3VHI!6ONG!4:$U
MG>]/3:%Z]]MJY*=)ENJLZUK5\U_#U"XXFX7&5[>U2K8JN>T5U4T;U7'GV.EF
M4V*<"W17<FW3I'*)G7ARX/OT,]6ZZ?)=M,ZNHKQXG!"E305EUIY6JS#D:^+C
M>GG)YS51,\L.QR[+.Z?VC*>DN6F]3T\:-EJFR452Y$QQ<&'1JOI7#GI\2)Z"
MJT?3ZKJYDSZ7;:6I9"B+(Z&Z.>C$7LXL4_+L7M(EW\Z3[M\=-4%I=IM+,M)5
MLJTF2OZ_B\Q[>'AZIF/=9SGN["Y8LWO:HN33NQV\8<K*R\.K9LX]-R:YCE,Q
M,=OC'Z/ELYTK[YM#IR"PTECM=;;8I7S.<[K(ZB1SERJN>CE:JXPB>;V(G:?#
M6FHMT^D-J>:\VZSWYUL<J)1TE&V5U+3-1,(B/1$:KEYJKEPJY]&$3(GHG='B
MQ6C1%LU=>K=3W.]W.-*J!:F-)&4L2\X^!JY3B5,.5V,IQ83&%RW>Z;%KT!J.
MY:>L5C?>:VAD=3SU$LW4P,E;R<UJ(BN?PKR7W/-%QDRF[35?JC'M[U7;+51C
M7*,.B<V_--$Z:1$<>7!=_11TOK_26CJZBUXZ;C\81]#%553:B6.-6^<U7(YV
M$RB*C<\LKR0@7P@U)''KO3%0C<2R6Y\;G>E&RJJ)_M+[2=>BWO;J#>NVZBK[
MU34=*RCJ(H:>.CC<UJ(K55V5<Y55>S]1"'A"/[\-*?YC+_6(5\7?C.^_$1/A
MRY.EM&;=6QM;<S-/#29Y\TL= WGLM4_QM/\ T(RWNFEOS?\ 0%39],::KGVN
MLJH'5E750HBR]5Q*QC&JON<JUZJJ<_-3"]I<'0-_<7J?XUG_ *$9 73QE5^]
M-*U5RD=GA:G_ %DR_P"\FU:IN9]<51K$:L<C(N8^Q:*K<Z3,1&J(=:[MZMW#
MM5NM^H[Q-=8+>^1\*S(WCR]$1>)R)EV.'DKLJF5])G[T,/L=],_PZO\ 2936
MFILKZ&/V.VF?X=7^DRE[:E%-&/$41I&KC_TU<KO9U55RJ9G=GG\88;],'[(K
M5_QTGZ) 9K=%3<']D39NSU,TG65]O;Y.J\KE5?$B(UR^MS%8Y?6JF%/3 ^R*
MU?\ '2?HD!??0+W!\B:_N.E)Y.&FO4'6T[57DE1$BNPGHS&K_P !IAD68N8-
M%4<Z8B?FV;/R_9]KW:)Y5U3'ZZ\$?]*_0GT"[V7R../@I+FJ7.GY<L2Y5^/4
MDB2)\2(9H=$30_T$;'V=96=7577BN<W_ ,]QU?\ ]+2/Y<EN=+;92;<^NT+4
MT43GSLN;;?5OB3FVEE5%=(OJ8K%_#)+WCUI!M3M)>[Q3HV!U#1]11QHG))78
MCB1$]".5OR(I0NY$W[%NS3SGG^G"'<QL&,+,OY57"F(UC]>,_)@'TK=P/H_W
MHODL4G'0VU4MM-A<IPQ*J/5/4LBR+GT*A$)RY[I'O>]RN<Y<JYRY55])P>JL
M6HLVXHCL?-,J]5D7:KM7.J=0SZ\'K^Y1?OX[D_1X# 4SZ\'K^Y1?OX[D_1X"
MAM3_ (T_&'H/Z:_YL?"4->$ _=FM7\10_I%09*]#/2<.FMBK-.V-C:FZ.DKY
MW-^V5SU:SV1L9\N3&KP@*8WHM/\ $4/Z14&6G1>N$5RV#T;+"N6LHNI7'OHW
M.8Y/:U3CY$S[%;B/\YO2X%-,[7O3/.(8J=,_?/4%9N/6Z/M5RJ;99K2V-DT=
M+*L:U,SF(]RN5O-6HCD:C5Y9:J]YYNAMOGJ&U;D6_2ERN=5<K'=N*".&IE63
MQ>9&JYCV*[FB+P\*M3EYV<90L'I86F>S[_:M9.US4J)HZF-R]CF/C:J*GJSE
M/D4\W1<LM1>]^-(14['NZBL\9D<Q/<LC:KU5?0G+'RG5Z"U['RX::_KIS>=]
MJR>MOQ3^+33PUTT^#8-TD?W"M<?Q7-_,8D>#]T1#>MP;WJ*>-LGD6D9'!Q)[
MB6=7)Q)ZT9'(G^D9:])%<;%ZW3TVN;^93'/P<EQC;/KJ@7"2.;1SM]*HBS-7
MV9;[3CV*IIPKDQW_ ">IS:::]K6(K[I\XUF$J],+6.L]/:)HK;HJCN3[A=)G
MLJ*RUP22200L;E416(JL5RN:G%R7"+CU8F[2W_=W;?6]ONC+3JJ>A=4-2OI*
MBDJ7QU$2JB/XD5J^=C.'=J+[#,OI&=(";8:CLE4FFTOT%PDEB>_QWQ?J7,1J
MM3]K?Q<2*[T8X>_NA.#PBLU1-'%%MSULLCD:R..\JKG.5<(B(E/S4SP^DZ":
M:;451.O'6&G:56/&9O7<B::HTTB(F=/+O9&[_:+I]?[0ZGM4L222^)25%.N.
M;9XVJ^-47N\YJ(OJ54[S6ALK^[#H/^/J#])C,HKQX0BKA;445;MM+1R/C<QS
M)KNK'(BHJ9PM.8N[+?NP:$_CV@_28RYA6KMJQ<IN1I'9R[G)VKDX^3EV;EF=
M9B=)X3';&G.&V#5%\BTOIFZWB9JOBM])+5/:U<*K6,5RI[$-46K]Z-9:TU+-
M>Z_4%PBJED5\+*:I?%'3)SPV)J+YJ(B]W/TY554V=;XO5-E-=JBX5+#7*B__
M $.\U'&O9%NFK?F8XK/]37[ENJW115I&DRVE]%+7ERW"V2L=RO$[JNYQK+2S
MU#^;I>K>K6N=Z7*WARO>N5[S#'ID23Z?Z2%UKK?434=:D5+4,J*>18Y(Y$A8
MB.:YN%1?-3FAE-T$/W!J7_/ZG^DABQTX4QO_ ';_ #2F_JT,,.F*<VNF.7']
MV[:==5S9-JNJ>/#C^C+GH;:@NFI-C[;7W:XUEVKG5-0UU173OFD5$D5$17.5
M5PB&,_3'W*U=IS?"Y4%IU3>[71-I:=6TM%<)88T58T55X&N1.??R,B^@J]'=
M'^W(BYX:RJ1?^L5?]YBGTY47Z8"Z*J*B+1TRIZ_K:$8M-%6;73,<./[FT+E=
M.R+5453KP_:5<\'O^[;<_P"(Y_Z^ FWPB?[CMD_CZ']'J2$O![_NVW/^(Y_Z
M^ F[PB7[CUD_CZ']'J3/(_ZA3^C7A?\ 0[GZ_P (Y\';H>GK;UJ;5<\;7S43
M(Z&D5>?"LF72.3T+AK$SZ'.0D?IS[SWK;O3-FL6GZN:VU]Y=*Z:MIW<,D<$:
M-16M=VM5SGIYR<T1J^DH/@Y+A%)I+6% CDZ^&OAG<WOX7QJU%]L;O86WX1NT
MSI<]%75&N=3.BJ:97=S7HYCD1?6J.7\%?0851%S:.[<Y?1MIJJQ]A[]F=)GG
M,>,Z2@/:7I!:KVWUQ;KQ+?+I<+;U[?*%#-4OE;40JOGIPO=CCPJJU>Y<<^TG
M#>SIOZ<W)T-=]+TNCJV>EN,*Q)45]4R%T3D5',D1C$?E6N1KL<2=G:8D6NW5
M%XN5+04D:S555,R"&-.USW.1K4^550EG4O1&W4TK2S5=3IKQBBA8Z22HI*N&
M1J-1,JO"CN+")S[#LW<?%Z6FJO2*NSCH\QCY>?[/7;M:U43SX:Z:K/VEW3N.
MT&KX]16FAH*^NCA= Q+A&][&(_".<WA<U4=C*9SV.7ES)FU_TMMP-\-,P:9T
M[8*RV5BR\=7)8'S2RU#,<HT:UO$QN>:\USA$[,HMN=$/8ZAWFU[5>66NDL-H
MA;/50M<K5G>YRI'$JHJ*C5PY55.>&X[\IFONWNYH_HQ:2MZ-LS6>-/='06FU
MQ,A:Y6HG&Y>2(UJ9;E<*N7)R7NHY=ZU[1%--&]6ZVS<7(G$JN5W=RW//AS[_
M (,:>BUM3O5IS<BRW6IH[K:=.))BOBN55U;9(E145%@<[B5>]%X>2HG-#*#I
M7TD=9T?-;1R-XD;1I(B?OFR-<U?:U"!- ].+5&YNZ^FM/45@M]GM5PK60S(Y
M[ZF?@[5P_P UJ<D[> R"Z4?V/^M_XO=_20YE_I?:J)NTQ3/#E\7HL3V?V"[1
MCUS53$3QGX=C 7H<?9(Z._RE3^BS&;W36^QHU?\ '1_ID!A#T.?LD-'?Y2I_
M19C-[IK?8T:O^.C_ $R$MYO_ #+?Z?NY>R/^EW_U_9JX !ZE\^95^#PT-3WS
M<2^ZCJ8VR>0Z1D<'$GN)IU<G$GK1D<B?Z1D-TR]:ZUTYH6@MFB*.YR7"ZSOC
MGK+53R22T\+&HJHBL158KE<U.+DN$=CTI$7@V+DQLVO;>J(DSFT4K/2J(LS7
M>S+?:3QTE.D34='ZCL=6W3+=04UQDFB>_P =\6ZAS$:K4_:W\7$BN]&.#OSR
M\?ES75G:13O:::1^CZ=LZ+5&R-ZJK=B==9CC,<?#P84;/ZBWAVRUS076.T:L
MJ:%U0Q+A1U%'4OBGB5R(_B16KYV,X=VHOL,]^D/HFGW!V<U1:IXDDD\2DJ*9
M<95L\35DC5/1YS41?4JIWF-D'A(YJB:.*+;7K99'(QD;+TJN<Y5PB(B4W-<G
M6\>$5K(8ZF@K=LI:.61CF.9->%8]$5%3.%IC.[9R+ERFOH]V8\85\7(PK%BY
M:F]-=-7?$\/3M8P;!_NW:!_CNC_KF&V?5NH8-):7N]\JFJ^GMM'-62HWM5L;
M'/5$]>&FI?8+]V[07\>4?]<PVG;PV&HU/M1K"TTD;I:NML]7!!&SW3I'0N1B
M)\;L#:D1-ZB)Y?5']/3-.+>FGGK_  U;ZXZ06O=<:HJ;W5:FNE$]TBO@IJ&L
MDAAIF_:MC:U41,)RSVKVJJJ9W]"O>NY[M[>5E)?IUJ[U8YFT\M6Y$XIXGHJQ
MN=CM=YKVJO?PHJY55-9BM5KG(J85.2HIG5X-:S54%FUU=7QO2CJIZ6GBD=[E
MSXVRN>B>M$E9[2]M"S;IQMZ(TTTT<S8F5?JSMVJJ9B==?\^*R?",Z-I[/N%I
M[44$;8WWBBDAGX?MY('-3B7U\$K&_$U#)+H.<^C3I7_*5GZ5*0AX2ZY1.JM
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M2LIYDH:AS4PKXGHYS%7^"YJHG\,C_H)V&JK-S[G=6QO\2HK:^.25/<]9(]G
MQ?C1KU_T2:^F[=H*'9Y*21S5GK*^&.)._P U'/5?D1O;Z_68U4Q9SXBUPUT]
M>:Q9KJR=B559$ZZ:Z3/AR>[H;:T^BK9VFH)9..JLT[Z%_$O/J_=QK\7"Y&I_
M ,8]^=KY8^DM46"G8L<>H*Z"H@<B=U0Y$>[XDDZSV%Q=!?6?D7<FX6"63A@O
M5*KHVY[9H<N;_L++[$,J-6[5Q:BW@T7K%&M3R-!5,FXOM\M1(4_T5?(XPKK]
MBRJ^ZJ)G_/U38M=<;-M?FHJB)^$3I/HO9)Z#3]/;J%7LI62.;24T?8BN1BJU
MB?Z+%]AB?T_M)IP:7U+''V.EM\[\>GZY$GYI?:5[IC;G2:.U-M]34SU<^AKT
MO,\35[4C<C6)\2HLR$M[U[>Q;Q[;I;(7M59JBEJ:>=%Y-;UC>-Z?_.G2>TJV
M=[&KHOU<JM?DZV7N[0LWL.B.-&FG^>BG=%C1R:-V1L$3XT94UT:W"9<855E\
MYN?6C.!/D,0=2[@4>J^E=37ZLE:ZU0WZGAC>J_6VPPR-8U_\'S>-?C4S7WJU
M9%MIM#?;E3*E.^EH_%Z1&_:R/Q'%CXE<B_$BFKE3I;/M3?F[>J[>'F\_MR]&
M)18Q:/\ MTGRY?RVP[@:7JM9:)NEEH[K/9*FLAZN.OIL\<2Y1<\E1<+C"X5.
M2KS,([WT0-TM#W!+E8IH+I/"_K(JFV5BPU#?7A_"N?4U5*EM9TJ=P- Z<B9?
M-/U6H].TJ-C;7S1R121-SPM:L_"K7)GDG$F5[,DX:4Z;>W5\X6W"6OL,SN2^
M.4RO9G^%&KN7K5$*M%O)Q-8HIWH\_JZ5R_L_:>Y-ZN:*XCAK.FG\(1UCTL]W
M-+016FZ62GL-6V%L;ZBLH).NE<C41TB<2\"HJ\^3<<S&:>9:B>25R-:Z1RN5
M&-1K4RN>2)R1/4AMBO-ET]N?I/J:R"DO=EN$221NPCV/:Y/->QW<O/*.3FAJ
M_P!RM(_0%KV_:?:]TC+?5R11OD1.)T><L<N.]6JBG2V;?MU[U,4;M7:\WM["
MOV-RY5<FNB>6O9_]6T=HXW32-C8G$]RHUK4[U4ZGIM54VBN5)4.3B;#,R145
M,Y1'(IW*OPR\E:_'&K:YM[I&ET#H:T6"D1J0T%,V)5;]N_&7O^-SE<[Y37+N
MSOQJC<75]?7)>JZCM:3.;1T--4.CCCB15X.351%=CM<O-<^C")LW8Z.MH..)
MZ.CDCRU[>?)4Y*GM-0=TML]GN57053%BJJ69\$K%[6O:Y6N3VHIY?9=%-RY7
M57QGY\WT7^H[ERQCVJ+4Z4^'AIHR=V8Z:*Z*T9+:]70W34-=#-_8E2Q['.6)
M4]Q)(]W$JHN<+A>2]O)"'M\MTJ3>76S+Y26%;)4/A;3RL\8299U:JHUZ^8W#
ML*C>_DU#R;;[):MW7HKE4Z:M[*UE YC)4?,R-7.<BJB-5ZHBKAO/GRRGI/'J
M?;_4VT]\MJZFL\MNF61)HF2.8])48Y%7"M545.:=_>=:BSCV[DU4:;_=K_#S
M5S*SK^/11>B>CCMT_ELQVOT+2;::"LVGJ1K42C@:DTC$_;953,CU^-RJOL0P
M%WLZ3>K->ZNKO)-\KK/8()71T=-03N@XXT7"/D5JHKG+C/-51.XV.,DCN=I1
MT,G'#40Y9+&O:UR<G(OQ+DU#7JT5=@O-=;*V%T%91S/IYHWIA6O:JHJ>U#D;
M,MT7KM=5SC/^:O4?U#>N8N-:MV)W:9[O#32&6'0[Z16H;OJ^/1>I;C47B*NC
MD?0U54Y9)HY&-5ZL<]>;FJUKNW*HJ(B=I*/38V\I]4;2SWQL3?*-AD;41R(G
MG+"YR,D9GT85'?Z!BOT/[#4WK?K3TD$;W0T"35=1(SLC8D3FHJ^I7N8W_2,U
M.E+=Z:S[$:N?.YJ==3MIF(O>Z21K41/7SS\F2,FBFSFT]%PUT_=ELZY7E;(N
M>TSK$:Z3/A&L>4L9?!^?NF:A_BK_ /S1F0G2ZW)N.VFU$E19IW4EQN56R@BJ
M8UP^)'->]SFKW+PL<B+W9RG-$,>_!]_NEZA_BI?ZZ,D[P@SE_8TT^F>7E=O]
M3,3?IBYGQ35RX?LC"N56=B55T3I/']V-'1]W,U%9]ZM-3.O%94I<KA#15;9Y
MW2).R5Z1KQY7FJ<645>Q40V3ZHO4>G--W6[RMXXJ"DEJG-SC*,8KE3\QJMV9
MY;O:'_CZA_2(S9;OH_AV8URJ=OD.M3VP/0C:5NGIZ(B.?S/Z?O5^QWJJIUTG
M7T:T]0;Q:RU'JE^H:K4-P9<NMZR)8:A[&P<\HV-J+AK4Y<D^7)M VWOU1J?;
MW35YJ4:E3<+935<J(F$XI(FN7E\:J:C#;%L=G]A?0OI\A4*?_L[#;M6W3;IH
MW8T:/Z;O7+MZ]OU3.L:_KJUD[MT[*3=76D$349%%>ZUC&IV(U)WHB>Q#9IL1
M^XMH?^)*/^I::T-Y/W7M=?Q[7?I$ILNV(_<7T/\ Q)1_U+2-H_\ 'M_YV,]@
M<,V_'^<V&O2WZ0&I+GN+<],6>[5=JL=I=XLZ.CF6)U1,B?7'/5JY5$55:C57
M'FYQE2L]"_?K4<NO8=%WNZ55WMMRCD\4=62K*^GF8Q7X1[ESP*UCDX>S.,8Y
MYAKI*V&HT_OCK""HC<Q9ZY]7&YWVS)?KC53TIYWYE3N*MT0[3477I :7ZAKU
M93.FJ)I&)R8QL+^:^A%56M_TD+LV;7L?*--W7]=.;D49F5UK$35/XM-/#733
MX:,O>FMH^#4FR-QN"L1]79IHJN%R)S1%>D<B9]'"]5QZ6IZ##;9'I%7G8UMP
MBM5KMM=%<)&/J'U3)$F5&(J-:U[7(B(G$Y>:+S53.KI7U[+9T?M8/D5/KE/'
M"U%]\^5C4_G_ #&/70MZ/=DU;:ZC6NI**.ZQLJ74]!15#4=#YJ(KI7M['\UX
M41>285<+RQ0Q+M%&)5TL:TZ\O)V]I8]V[M2B,:=VJ:=9GNXZ:^2/=R]X-Q^D
M=7TJ6.R7BFM=/$D?D^S]=/$^7*JZ1[FM3*]B)Q<FHGK7,]]#S0FZFC;I=?HO
M95T^G:BE3J*6NK$E>V9'IPJV/B<K$X.-%SC.&\EQRN??+I46'8NZ0:>HK*^[
M79L#9%IH7MIX(&+GA17<*\\)GA1O9CFA;_1KZ3VI=[]R[E:[A;J&W6FGMDE2
MR.E:]TG6)+$UO$]SN?)S^2(AKN55W,>9HMQ31ZMUBBQ:S:8NWYKN:Z<(TC]>
MQXO"'T[';=Z9G5OUQEU5C7>A'0R*J?[*>PMSP<7[;N#\5O\ ^)+I\(=^YIIS
M^.&_U,I:W@X?VS<+XK?_ ,2;*?\ IL_'^8:J_P#K]/P_A+/2\WDN>TFW].ZQ
MS)37JZU/BT-0K4<L$:-5TCT145.+W+4RGVV>XP1U!OOKO5>EZK3MZU'572U5
M$K)9(ZGA>[B:O$B<>.+&<+C..2>@R8\(U,K8M 0?:N=7/7GZ$@3_ .J,*B]L
MNQ;Z"*YIC6?FXNW\R_[979IKF*8B(TUX<8UE.&R?2MOFRM@2QT-BM=?;75#J
MF1TG61U$CW(B*JO1RM[&M1/-[$&O]8;I=(_4[[K:[)?O):HUE+06]LTE+3HB
M(BKQHU&JJKE5<N%YX[$1"?\ H=='/3\>B*'6U_M\%UN]QXI:2.K8DD5+$CE1
MJHQ>2O=CBXEYHBHB8YYK.]/34M&UVHZ[3=HL<E\N5$O5U,LDR001OPB\*8:Y
M7*F<+R1,]Y6JNT59%48]O>J[97K6-=HPJ:LV_NVYTTB(X^"M=$/2&Y6C-.7F
MCU\M0V!\L4ENAJZUM3+&BH[K4RCG<+?<*C<]O%R3OAOPB]-&W4.BIVLQ))35
M+'.]*-?&J)_M+[27^BAO[J/?2HU=->Z2BHZ:W+2MI&44;T1./KN/B<YRJY?,
M9Z/B(E\(W_=K0_\ F]7_ $HBOC[\9_WXB)\.7)T\Z;=6QIFU,S3PTF>?-Z_!
MN\G[AKZK?_Q))?31WANFUN@J*DL50^CN][F?"VKCQQPPL;F16+W.7B:B+W95
M4PN",_!O<W[AIZK?_P 45+PC%BJ*G3VC+NR-SJ:CJ:FFE>G8UTK&.;GX^I<+
ME-->T=VOEP_9KL7+EK8._:G2=)_?BQ2T7O1K'0VI8+Y0:@N#ZEDJ231U%2^2
M.I3L5LC7*J.14Y<^:=J85$4VJZ=N])KG1UMNC(>*BNM#'4I#,B.S'+&CN%W<
MO)V%-.1MUV;M-38]H]'6^K8^&JIK/2Q31R<G,>D+>)J_$N4^0W[6MT43153'
M%4_IJ]=N]+;KG6G2)_7ZM9\NFV:.Z0C+%%GJ;?J5M/%E<JL;:E$:OX*(;0-Q
MDSMWJ;^+*G^I<:U]:W".Z=*JOJ(G(^)=5-8US>Q>&I1N?S&RC<9?_<ZU-_%E
M3_5.-.?,U3:F>>GR7-BTTTTY--/*)^;6YT1M#P:YWSL4%5&DM';^.XS1N^VZ
MI,QY]*=8L>4[TR9]](;5U_T7M5>*[2M%4UE_<C*:D;2P.F>QSW(BR(U$7/"W
MB7FF,HF3"OH%7-E!OMU$F.*MME1 SXT<R3^:-3-O?/=2HV=V^J=41V;RZRFF
MBCEI_&.HX6O=P\?%P/['*U,8[^TQSYJJRJ*=->6D=[+8U-%&!=KWMW69UGMC
M_P"-=]GJ]Z[)J-M^I*?6271)$D=-)354G6<\X>CD5'-YKR7*<S93;$9N7MI2
MI>K:ZE;>[8SQR@F8K71=;$G61JCDRBM5RIS3N,4?JD?/GMVU?]=__:YZKAX0
MZXVQL:5>U\]'UC4<SK[LYG$U>Q4S3<T,\FSD7II_TXIF.Z8^;7@9.%BTUQT\
MUQ5V3$_)AEJJQR:9U+>+-,O%-;ZR:D>Y4QET;U8O+XT*65O7.I?HQUE?K_XK
MXEY5KIJWQ?CZSJ^L>K^'BPG%CB[<)GT%$/4V]>CC>YOGE_=Z2=SEKP#=50_W
M/A7_ -FW^9#2J;JJ-,V^)/\ V3?YD/.[8Y6_U>Z_I;\-[]/Y:P>D%TCM5Z^W
M NS*&^5]LL%'4OIZ*CHZAT+%8QV$D?PJG$YRIQ97.,X3D3[T$M^+_K*X7/1>
MHZ^>[R4M)X]0UE2Y7RM8U[621N>O-W.1BMSS1$<G9A$PPUQ8:G2^L[Y:*R)\
M,]#6S0/8_M\UZIGUY3GGOR9 ^#WL]16;RW&N8Q_BM':9>LD1/-1SY(T:U5]*
MX<J?P5]!9R;%J,.9B.$1P<[ R\FK:6E54\9TF/\ .Y+GA%-&T]=H?3^IF1?V
M;05WB;Y$3MAE8]W/TX?&W'HXU])7^@/MY2Z=VE74KHVK<;]/(]9.'SFPQ/=&
MQGQ<37N]?$GH._A [E'2;'T].Y4XZJZP1L]/)DCU7V-_.7;T-;M'=NCOI16.
M:CZ=L]-(UJ]CFSR)S]:IAW^DAQZJZ_8(CLUT_3G^[U5-JWUQ55IQW=?UX1^R
M"NFMTE-16'5[]":6N-1964<<<M?64KUCGDD>U'MC:]%RUJ,<U5QA55V.Q.<+
M[)]*K66W&L*&>ZWVXWS3\DK65U'<*A]1B)5\Y\?&JJUZ<U3"HBXPI]^FO8*R
MS=(74-14QR-@N3*>JII']DC.I8QV%]"/8]OR$*V>TU=]NU%;*"!U375DS*>"
M%B9<^1SD:UJ?&JH=S'Q[,XL3,1I,<7D,S-RXVA5I5,3%6D1X1/#AXMP&YFA+
M?N;H.\:=KVM?!7T[F,D5,]5)C+)$];78<GQ&M/HYZFU+IC>73&G8+S<K?027
MR&.LMM-621T\KN-&/XXVNX791J(N47*(AM(I(FVBS1,EE^MTT#6NED7')K<*
MY5^3)JLV?N4=XZ36G*^%,0U6I&SLY8\UT_$G+NY*<G XVKU,\8T>DVQI3D8]
MR.%4SI^G!LBWZN=7:-F-:5M#534=;3VJHEAJ:>18Y(W(Q51S7(J*BIZ4-3VH
M];ZDU>D+;_J"YWIL"N6%+E6RSI%Q8XN'C<N,X3..W"&UWI&+G8?7G\35/]6I
MJ(+&R::>CJJTXZJ']1UU1>MT1/"8_EMYV(T+!MQM'IFQPQ-9+#1QRU.%SQ3R
M)QRNSW^>YV/5A.XP.W]U%N[N-N+>IXK5JN&RTM6^*W4E+25+(6Q,=ACT1K41
M7.PCE<O/*]N$0V.:2NT=[TQ:;E$J=75TD50U$[,/8CD_G,1=1>$2GTU?[K:*
MG;E/&*"JEI9,WK'G,>K5Y>+\N:%#$FYTM=5%&]5XSR=G:5-B,:W17<FBGLTB
M9UTCP7UT(]8ZXO.DKS8M;T5V9/:I(G459=Z>1DLL+T<BQ\3T17\"L[555P]$
M[$0@'PAFA*?3^YUHU#2QI&E]HUZ_A1$1TT*HU7?&K'1)\GK+]I_"+7"KHIZN
MGVKGFIH5Q+/'=W.C8J]SG)383Y2!^DGTF'=(5M@1=-^076E9U1WCWC/6=;U?
M+]J9PXZOUYSZB_BV;].5TF[NQ//C#E9^5BU[/Z&FO?JC329B8[?&.YF9T#?L
M=K5_GE5_6J0GT]-]=0V[6%+HBQW*IM-#!2,J:U]'*L<D\CU56L5S>?"UJ(N,
MX57<^Q":^@;]CQ:O\\JOZU3$/ITR+)TB[VW'N*6E:G_4M7_>:L:W3<SZ]Z-=
M-9]5C-O5VMD6YHG36(CT7CT"]V-11[J)I.LN=5<+-<:61S:>IE=(D$L;5>CF
M97S<HCD7')<IGL0R&Z>E#'6='NYS/:BNI:VEF8J]RK(C,I\CU]IB+T%N72.L
M'^;U7]2\S'Z=?V.-_P#\XI/Z]A.31%.=1NQST_=AL^NJYLB[%<ZZ:_M$L=_!
MS:'I[MKK46IZF-)'V>FCIJ7C^UDG5_$Y/6C(U;\3U)JZ=.]-YVMT/:K9IZJ?
M;KG?YI8UK8E1)(H(VIUG O:URK(Q.).:)G&%PJ1]X-.YPK2:[H%5J3MDHYT3
MO5JI*U?D143\(Y\);:*B2BT'<VL5:2"6LII),<FO>D3F)\J1O_!)KB+NT8IN
M<OIK^[*S5-G8DUV9TF>[XZ3Z,8]L>D#K';O6U!>VZ@NE;3-G:ZNHZBJ?*RJB
MXO/:YKG85515PO:BKG)D-N_T\]+:\T7>=,TFBKA74EQIGT[IKA51P+'E/-D1
MK4DRYKD1R<^UJ<S#&EII:RHBIX(W2SRO2..-J95SE7"(GK529M1=#7=K3D$L
M\FF/'::-O$Z:AK(9$1$[?-X^+E\1V+V/BS<IJN:1/9QT>9Q<O/BS71:UJI[>
M&NFO[.G0^W(_8WWRLDL\O!;KLJVJJRN$X951&.7T8D2-57T9,\NEYMZFX>Q.
MHX(HNMKK=&EUI>65XX<N<B)Z5C61J?PC5)&]T;FN:Y6N:N4<U<*B^DV^[";A
M1;N[/:>OTJMEJ*JEZBM:Y$5.O9F.5%3T*Y%7'H<AS-IVYLW:,BGL_P AW=A7
M(R+%W"N<IC6/UX2UO=$S;]=Q-^--T4D76T5#+Y3JE5,IU</G(BIZ'/ZMO^D9
M_P#2_P!QDVVV*O\ /#)U=?<V>2J3"X7CF14<J+W*V-)')ZVH65T1]A';4:XW
M-KJBG<QK;EY,MCI$\[Q1$29')Z4<V2'Y8U(.\(KN/Y<W!M.D*>7BIK'3^,5+
M6K_\(F1%1%_@QHQ4_P HIIKJ]NS*8CC33&O\_18HHG96S;DU<*JIF/X_;BQ&
M"]B@+V*>NA\_YI=Z+^L]0V;=_1EGH+]=**TUEZ@6IH*:LDCIYN)S6NXXVN1K
MLHB(N4[$1#93T@+G66C9+6U=054U%6T]IJ)8:FGD=')&]&*J.:YJHJ*GI0U>
M='#]WC0/\<4W]8AL^Z27[@FO_P"):K^K<>3VC33[51P[OW?0=B5U>P7>/+7]
MFIG4&MM3ZX=317W4%VOZPN5(&W&MEJ>K5V$7@XW+C.&YQVX0V\[/;=4>U>W-
MDTW2MC_L&F:V>1C<=;,J9ED7^$]7+\6$[C3G:JSR;=*.KX>/Q>9DO#Z>%R+C
M\QNS1\=XM".@FXH:J',<L2]K7-Y.:OQ+DRVM]VFW1'".+5_3WWZ[UVKC5P_E
MJYWZZ66L]Q];7%UFU!<+%INGF=%0T=OJ'T_'&BX2256*BO<[".PJJB9PGKF'
MH/=)W4U[US#H+5=SJ;Y!<(Y'V^LK'K+/%*QBR*QTBKES58U_NE545$1.2F&=
M^L=9IJ]W"T7"!U-7T,[Z:>%Z85CV.5KD]J$S]"/3M7?>D9IF6GCD6"VI/6U,
MC.R.-L+VHJ^I7O8W_2.A?Q[$8E6D1I$<'&Q<W*JVA$S5.LU1$Q^O&-&8'3XV
MRI=7[,5>H&Q-\J:=D;4Q2(GG.A>YK)69]&%1_P ;$-8QMKZ7UZI['T=M:OJ'
M-3KZ1M,QKN?$Z21K$1$]///R*O<:E#7L>JJJQ,3RB5G^HZ**<FFJGG,<?,,J
M_!M?N[7K^3\_Z33&*AE7X-K]W2]?R>G_ $FF+FT/^+6Y>Q_^;;^+,[I.[KU6
MS>S]YU!0<*W5>"DH>L:CFMFD=A'JB\EX6\3L+R56HB]IK3KNDYN==;'>K1<=
M6UMPMUXB=#5P5*-<BL=C*,Y98BHF,-PF%5,<S-;PD-3U.R-HC3MEOT#%Y_\
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M/S'E\)DB?L4:85/_ ([3^HF*5OI/;Z9NQ$3X?!U;G13LJN+54U4QVSSYL?\
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MD_I'[OHW]/TS&+,]\R[@ X;TX
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M#9*N9TKFMSG"*Y5PF3F8N'5CW)JBKA/9^ST^T]LV]I8U%NJC2NGMU\./F\0
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MFNK*YK'5MPKG-8Q&1\2HC6IR8U.)RKE57UX1#"GIV[_6K=S6]NLVG:AE=8[
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M>^Q[D7;5-4=K\[YV/.+DW+579,Q\O1U !O<\  '"]AU.R]AU '53L=5"8<
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MJ:K6KN]RK+I58QUU9.^9^/1ERJN"FEW#PXQM:JIUJER=J[7G/BFW13NT4\H
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M[YEMKZ;=@J-2]&/6U-2Q];/!!#6<*<_,AGCDD7Y&->OR&&_@Q'(S?Z^9Y?\
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M%=<<OD^M;-LS8Q:*)YZ:^;Z@ I.F
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M<J<" .JG8ZJ.T<  D=5.#E3@  !*8=0 " ZJ=CJH2X  '0  #A3DX4,NQP
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M  /2/EX  .%[#J=E[#J .JG8ZJ$PX  3+JO:H"]J@)#JIV.J@<   =#N= F
M  [74 $RR=5.#E3@0.%.IV4ZD   F'4 !  #*63A>PZG9>PZB .%.3A1VCJ
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ML ZKVJ=CJO:I$  !(Z  AFX4ZG93J3*(  (2X4X.5."  !E(Z  EDZJ<'*G
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M3QGY,@6-1K$:B81.28.X!X)]0@  2
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M"]@'4 $R.%.IV4ZB  !$I@.J]JG8ZKVJ3"9  0D.AW.@   =  3(X4X.5.!
M'53L=5':.  2.JG!RIP   E,.H ! =5.QU4)<  #H  !PIR<*&78X  (#H=S
MH$@  Z   O8IU.R]BG4 <+V')PO8!U  92ZJ<'*G 2  R@=0 1 '"]AR<+V&
M0Z@ )ET  2'"G)PH'   '53L=5 X  '0 $R!U.QU)@#A>PY.%[")'4 "&4N%
M.IV4ZD$  "75>U0%[5!, <+V')PO89#J  F70 !DX4X.5. .%[#J=E[#J
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MG4WHW:N%7[OC6V]@W,&N;MJ-:)]/"?FL@ '6>.<+V'4[+V'4 =5.QU4)AP
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M8Z@ $!U4['50EP  .JG!RIP .IV.H   =  &;A3J=E.H1  "82X4X.5.!V@
M#(=  $RZJ<'*G 2!>Q0%[% Z@  =5.QU4F!P "!U4X.5.#+L ZKVJ=CJO:I$
M  !(Z  AFX4ZG93J3*(  (2X4X.5."  !E(Z  EE+JIP<J<!(O8IU.R]BG4
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M8<H> R,BO(N3<K_^/IN'B6\2W%%'Z^,OH "NO@
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MNJO*46G0E7Z5[<S[UW?CM-\Z=?I7]SOO7?\ CU-\Z/:;'YX\X.JL[W57E*+
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M-&,;Z5]:JO-57FJ\U*_R0)R0<L>HX,S-4ZR]/33%,:0Y  9@
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MDMWF^\Q?RG1_/#VS']Y'G!U=F^ZJ\I^2$%.";?I+-Y_O-7\IT?SQS])9O/\
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M\>V8_P">GS@]@R_=U>4_) 8)[^D2WS^\9?RK0_/CZ1+?/[QE_*M#\^/;,?\
M/3YP>P9?NZO*?D@0Z$^_2([Y?>,OY5H?GSCZ1'?3[QU_*U%\^/;,?\]/G![!
ME^[J\I^2 PO8I/GTB.^GWCK^5J+Y\X7H(;Z<_P#U'=^5J'Y\>V8_YZ?.#V#+
M]W5Y3\D! GSZ1'?3[QG?E:A^?'TB.^GWC._*U#\^/;<?WE/G![!E^[J\I^2
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MNYJBNQR,@\*@[AV'F[ERN]5OW)UEZ^S9MX]&Y;C2'8 &M8
M                                            !Q@Y  XP,'( XP,'
M( XP,'( XP,'( XP,'( XP,'( XP,'( XP,'( XP<@ <8&#D <8.0
M          .,#!R
M
M
M
M                                                .,#!R .,#!R
M.,#!R .,#!R .,#!R .,#!R .,#!R .,#!R .,#!R .,#!R
M    .,#!R .,#!R              #C P<@                   .,'(
M
M                                                    XP<@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                           %
M%U1JBT:*T_77R_7"GM5HH8EFJ:VKD1D<3$[555_^Y0*T#7IN-X2N_P"I;E/1
M;2Z8IX[4U5:FH=2-?F;G[J&F:J+P^A7KSSV(651=+CI$13+4KJNPU2*J+XI-
M8V-B^)%:Y'<_C V@ PTV5\()#>;[0Z9W3L4.C[G62)!27RCF62UU$JKAL;E=
MYT+G+R3BRU5Y<2&9+51R91<H!V
M
M
M
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MDJ-5Z^IJ*!+0
M
M
M
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M-IBI2J17*BN:V>%6<N_#E[_2H&S
M
M
M
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M#<H:=%2)[^%',E8BJJHUS5[%7DK7=V#(,
M
M
M
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M<CVHYJY:J914[SN
M
M
M
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M44;DP^DBX&MBA?\ OT3B<J=ROX>U,F4X
M
M
M
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M;"^H_MAU!3K)GMXNK;G\Y73Y11MCC:QC4:QJ<*-3L1$[CZ@
M
M
M
M
M
M
M
M
M
M
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M#J"U3>YJJ&9)&HOH7'N5]2X4"YP
M
M
M
M
M
M
M
M
M
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M-<_@[M=)I7?/6.AI9UCH-24+;Q1P*OF^-P*C)^%/2Z-S%7_)FQ@
M
M
M
M
M
M
M
M
M
M
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MH5J]@&;P
M
M
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MU<KWF4(
M
M
M
M
M
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ML;A([CD=8J:!Z_OHF=4OYV$P@
M
M
M                                               !U<B.145,H=@
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MZFIB5J+'%&G#PPLY8SE5Y]B)ECX"W_#;_J3_ (\#:H
M
M
M
M
M
M
M           &(7A,]WZS;?82.P6FI=2W;65:EH2:-</CIN%7U#F^M6)P9_\
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M[O?-9'%&J_%Q-<GR&8P
M
M
M                                            !JZ\%GM!K[;[I'[H
M7/5&B=1::ME9;YF4]9>+344D,[EK&.1&/D8B.7A15PB]G,V:W2L=;;=65C8)
M:MU/"^5*>!JNDD5K57A:B=JKC")Z5*@ -!\=GZ1<O2*K-Y;OL%J;5>HYK@^X
MQT6H=)W.HHXI.R'S&)&JI"U&(Q%7"<#>7)#)SZ?SIP?_ *./_P"8U\^?-J@
MUJ[3=-CI@ZJW1T;9-3["^1].W&]4=%=+C]!UX@\5I9)V,FEZR296,X6.<[B<
MBM3&53"&<V_&S=CW^VFU#H/4'&R@NT/ VHC1%DIIFJCXIF?OF/:UV._"HO)5
M)$ &GW0]AZ9O0"J+EIC2>CY-Q-%R5#I:1M+;IKM1O5V,RQQP/;/ J_;,=PIQ
M(JX7W2^M.CSTG_"#[BV2OWFH:G0&@[>[C\7EI?$DIV+CC;34DBK*Z9^,=9-E
M&IVJN$8NW< 472NF+;HO3-IT_9J9M#:+72QT='3,SB*&-B,8U,^A$3M*T
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MR%TL:/5J*O-43.,E^$,="[[$W9_^2UO_ *AA,X
M
M
M
M
M
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M:J<N]V5 F/9G:VV;+[7Z=T7:/.H[12-@69R8=-)VR2N];WJYR_&7R
M
M
M
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M]CUHG^5+/T2I RIZ%WV)NS_\EK?_ %#"9R&.A=]B;L__ "6M_P#4,)G
M
M
M
M
M
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M7IR5/7E"7P
M
M
M                                                   #2MX:W[*7
M2W\C*7].KR5? 6_X;?\ 4G_'D5>&M^RETM_(RE_3J\E7P%O^&W_4G_'@;5
M         *)J?35MU=8ZZTWBBAN-LK(EAJ*6=O$R1J]R_P Z*G-%1%3F5L")
MF)UAC,15&DM9NLO!GZA_9DI;=I^M:F@JUSJA]TF<U9:"-%3BB<S**]_/#53D
M[M7APN,_]K]K]/[1:/H],Z:H6T-NI6\U[9)GKCBDD=]L]V.:_$B81$1+P1.\
M(F"W>R[U^FFFY/"%#'P+&-757;IXSZ?!W !4=$     ",ND-L3ISI&[57C0^
MIX_[#K422GJXTS+15#<]5/'^^:J]G8Y%<U>3E)- &FW2U_Z2/@N+]<;77:=D
MUMM.^H=-UK&O?;Y$7'UZ.=J.6CE7"(K)$PJH[S7X1Y+55X;_ $RVSI-3;675
MUVX?[6ENL38$=A>76I&KE3L^T0V;.1'(J*F4*)#HK3U)6>.P6&V0UG%Q>,1T
M<;9,^GB1N<@:CV[9](CPG6XUJN^MK=/H3:ZBD5\#I('P4M/"N%5::.3SJF9S
M>76XX.2\VIAIM@VQVYL&TN@['H[3%$E!8K/3MIJ:'.783FKG+]L]SE5SG=ZN
M5>\NT :CO"J:#U-J/IB[>W"T:>NUUH8;!;F255%0RS1,<EQK'*CG-:J(J(J+
MA>Y4-N( '5R(Y%14RAICZ6W1NUQT.>EC9MS=H;'75ECK*MUVML-LHI)HZ*9.
M5312)&BXB>CW(B>;F.56)[A5-SP QMW@UM^S;T%M=:AM%IN--4WO2%:J6>HI
MWMK()U@>UT#H\<2O1Z*WDGG<E3**A 7@:-)WO26TVX,%\LUPL\\M[B?''<*5
M\#GMZAJ91'HF4SWFP\ #49X3'H8W[0&YE%O5M5;:YT5RKV3W"DLM.]T]ON37
M<;:MB,151LCF\2KCS9$SGZXB)MS &MO=+IBZSW,\'Y>HUTA?J#=.YNCTO<J"
M&U5"*K9&JLU8QO BI%) R1O[R1_#S1$5TD>":V%JMH>CM/?[S;9;;J/5U<ZK
MGAJH5BGCI85=%3QO:J(J<^ND3/=,9N  13TGMG:??O8?6>A96L\8NE _Q*1W
M9'5QXDIW_$DC&9]64[R5@!JV\#QJO66AKUK';'5.F[W:+56M\M6Z>X6Z:"*.
MI9PQ3Q<3VIYSV=6Y$_\ 8O[U-I(  P"\(YT(-5[PZ@L>[&U*MCU_8F,944<4
MJ035;(G=9!- ]51$GB=E,+CB:K<.16(UV?H U.6_PC/2NLVG4TS<-D*JOUE&
MSJ&W.;3]>R1[DY<;Z9B(CG\E7S5:W/VN.1?_ $!.A9N _=RNZ0.^JU2:PG?)
M46VWW!R>-+-*Q6.J9V-Y1HV-RLCAPG#GW+.!B&R0 6ON-H.S[HZ$OVD=00>,
MV:]4<E#5,:N'<#VJG$U>YR<G(O<J(O<:FM)Z>Z3W@S]7WFUZ?TM+N+MW<:A9
MNLHZ":IHZC'FMG^M9?2S*Q&HYKLM7&/KB-:XW&@#3MN5J_I4^$7K+;HN'057
MH/0GC#):I9:2>EHG.:O*2IJ)D19N!<N2*-.W"\+G-:J;/^C_ +*V7H];1Z=T
M!8G/FH[3"J254J8?4SO<KYIG)E<<3W.7ASAJ*C4Y(A)0 & 7ACM+7K5>PNC:
M>R6FON]3'J9DCX;?3/G>UOBM0G$J,151,JB9]:&?H AWH@T%5:^BYM11U=--
M1U=/IJ@CE@G8K)(W) U%:YJ\T5%[E)B
M
M                                  XRGI..-OOD]H8ZPYR@RAUXV^^3
MVG/6-]\GM)T-Z.]V!UXD])V(9
M
M
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MF4YH:4MTJUM1;4@:G')+40,8U.:N<LS$1$]>3=+0-5M' BIA4C:BI\@'I
M
M
M
M                                      :5O#6_92Z6_D92_IU>2KX"
MW_#;_J3_ (\BKPUOV4NEOY&4OZ=7DJ^ M_PV_P"I/^/ VJ
M
M
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M6I.UK6NXD5J(U,+DF-.1QZ3E.>3GU555SO53K+K6[=-NG=IC2'( (;
M
M
M
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MU8Q&<2KZ5X<@3"
M
M
M                                     !AITU_"+Z1Z-]EN.G],5E'J
M?<QS5BBM\+NL@MKE3]LJG-7"*G:D2+Q+RSPHO$!ES37RVU=RGM\%PI9JZG3,
MU+',UTL:<N;FHN4[4[4[RI&HCP/>H[OK#I,[J7R_5E1<+S<+*ZIK*FI7ZY+,
MZKC5SG>A<YY=W8;=P!1FZNL+KFMK;>K>MRXN#Q1*J/KN+T<&<Y^0UL>$"Z2&
MX6[._P#:^C1M!<9[?53/B@NU51SN@DJ*A[.M6)TK>;((HL/D5J\\O147@POD
MJ/ A4;=$JVGW1G?JY(^)))+4UM K^W@X4>LB)W<>57OX?M0-I8-97@[.DEN!
MH#>N\]&C>&MJ:NZT2RQV>JKYW3S0S1-ZQ:;K55>.%\*+)&JKR1O"F4<U&YC=
M,+I%4W1>V+ONM7QQ5-VRVAL])-[FHK9$7JVJF4RUJ-?(Y$5%5L;L<P)>NU^M
MMB@;-<[A2VZ%RX22KF;$U5]&7*A]:&X4EUI655%50UE._FV6GD1['?$J+A34
M!T>.@5K[ISVAV[V\6X%TIJ2[.>E!Q1)-5U,;7*WC:CE1D$*.14:QK<*B*J(U
M.%5I^[FQF['@M=:V;<'0&JYM1Z!K:IL%4R1JQ1R/PJI35D".5KD<Q'<$S>:*
MB^X7AX@W-@L[:7<JU;P;:Z<UK9'.6V7RACK8FN5%='Q)YT;L?;,=Q-7UM4O$
M   -*WAK?LI=+?R,I?TZO)5\!;_AM_U)_P >15X:W[*72W\C*7].KR5? 6_X
M;?\ 4G_'@;5
M
M
M                   (7WGZ1UIVMD=;*2%+OJ%6Y6F1_#'3HJ919')WKR7A
M3GCM5,ID([Z7G/>WHX_RF?\ TH#*E.XU/[_=*J_:HW'T1<:RLIF5&FKAX_%%
M1T[>"F<JL]]E7+YF<.5>PRGVJZ:TE>^DCU33T]1;IT;PW2WM5KFHOVSV95')
MZ>'"IA>2J7[]JNFU;F8X:3^\N3BW:*K]VFF=9UC]M&7@/';KA37*A@K*2=E1
M2U#$DBFC7+7M5,HJ+Z,'L*#K
M
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M>=V@M74EZJ8&\<]O<U]/5Q-SCB=#(C7\.>7$B*WFG,EP
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MM$7M1ON&KZ5<J=ALO
M
M
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MB1W=CS>/X^_N)*V\WJTIN8UT=EK\5S6\3J&J;U<[4].,X<GI5JKCO D
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M^XSCMY]G:!MG
M
MX Z@\-PNM):*:2JKJJ&CIF8XI9WHQK<KA,N5<=I!^XW3EV=V[Z^*;545]KHV
MY2CL+%K'.]76-^M(OJ<]#.W:N7)THIF5>Y?M68UKJB/U2QN)JM-$Z)O5]PU7
MT=,Z2)KT56ND[&(N.Y7*U/E-2V[V[TU+65D4-4ZKOM6]TE35.7B6-SERJJO>
MY<_(2[O)X0N?>*SUNBM/Z733]ONDK8$NU=5=;481[71N2-K4;&O$U$7SG\EY
M=AAG?;776BYU%+<6.;5-<JN5RYXL_;9[\^D]#@;._P!36_PTXQ'>\UM':O\
MI:8W&)X3/=X0\#WOFD=)(Y7O<N7.<N55?27IMWN)/I"J2GJ5=-:Y'>?'VK&O
MOF_J[RR >HNV:+E$T5QK$O&V+]RS<BY1/&&VKH0;C^7;1<].+5)54L#$KZ!R
M*JXC<[AD:B]R<2L7'I<XRG^0UX^# T5?Z'4&HK[5R.CM'D]*>.ED3SD?)*QS
M7^I%2)W+O[?1G8:SED^=Y%JFU=JHIG6(?5,6]5?LTW*Z=V9['< %=;
M
M
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M-3W+4543#, 8WZ3_ +ZK1_GL/]8T_4B?EWL<;8=<V^-B88RY1M:GH1)4/U$
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M#:Z6VV^FBHJ"DB;#3TT#$9'$QJ8:UJ)V(B(5
M
M
M
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ME"VTM4K>#KXF2\.<XXFHN/SGL
M
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MS<+-*J)E?4B81$3N1/3E2^ #SCUP
M
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ME%#40R4[Y'?O6)+QKZF\N9^BJFJ8JJGCG@D9+#(U'LDC<CFN:J9145.U%3O
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MIL1\$?M_/HGHAT%QJH>JDU+=:J[M1R8<L?F4[%7U*E/Q)ZG9[P,TP
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MSL^:]$Y(Y47L<AE,
M
M
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M"+A$;Z^%$R!\-A]L5VMT#36VH5'W.H>M56N:N421R(G B^AK41/6J*O>20
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MU<KG*R?2>!2NW#%;ZS>Z1]CCDXO%H["],IG/)BU7"U5RO/GA5SS,V.BYT0-
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MKT5OG2/SGC1>6.PLSI;>#(T/TFM456L+?>*C1.LJI&)5UM/3I54M9PHC4=+
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M\V*/*(JHWFY6MXE=PMP&0T$3*:-L4;49&QJ-:UJ81$3DB(?<
M
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M&5+>Q/B,5NE]^[=T<OY3/_I0&5+?<_(6;G^U1\/YES\?_>N_&/VAV !6=
M
M
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MEJ*N7+W+OFTII>V:,TS:M/66DCH;3:Z6.CI*6/W,44;4:QJ?$B(5@
M          "-.D)LC9ND'M/?-$WI>JCKHT=35;4R^EJ&\XIF^MKO:BJG>26
M/S^[@:%U9L!KFMT5K2B=0W.G55BF:B]16Q?:S0N^V:OM1>2\SKM1J2'3>O5I
M'^9;+VJ-8C?<QU7Q=W$GYT-UO2'Z.>DNDEH.?3>J:3$B(KZ&Z0-1*F@F[I(G
M+^=J\G)R4TPZXV.U1L)TD;1H34+$J9Z2M2JI:Z)BI#6TO"[@G;Z.]%;W.14]
M"@2-NBQUITC?*J),/CHY%3\''^\C':6-E+:**-O8V-J?F)7W48VY:3O%&QV'
M34LC&_'P\B$]K*YS[;1O5,(YB9^-.2_G R/T_,U(TP7)#<(>)C'R-8YZX8CE
MPKE]"%E:2J.N:K7?(>Z^YAX9&\U8O$W*9POI0"XKI5-9$Y,\S&G4U[=N'KC$
M<G666S/=% Y/<RSKR>]/2C?<I\I<.[6YTUMTG704\BQUM0B4L+D7FU7KA7?(
MF2U-N+,]U'3QP,ZN!C41/WWK D_2U*V"2*-GRDKVZ-&PI\18^G+$^%C57FO:
M7E2K)&U.+L0"HYP4:\5K8FYR>FJN"-C=S+1O=:L[EPN&(![H=0R0M7JTXE7E
MC!;ZZ2MBU$U:VP6YM1)S>^.E8USO8A5+# V9Z9+QBH6(Q.0$57:QKXFZ&"GC
MI(557K'"Q&HJKWKCO(>UGIR2D<Z5N?2927:VM6-W(BC6=G;,CVHW($5Z,O$D
M$CF*N%:O-";],5BU,;7-7B3O(1\F^3;]"B<D=VDNZ(D=#(C<^:H$I6J%9(TS
MV%0?2L=&K<=QX;5YLBX7DJ=A5@+,KJ7Q5R(J8[<%FT,<4FI)HG)EKDRI)]YH
M4J(783GVHI$CZ_R3N926^>/#:ZG>^*;/)7,5,LQZ<+D"4+=INF6)KT3F5F"C
MCA:B(A\[8YJPMP>P#X2TK)&JF"UKE:74]1UT3?C3TEWJ?):=LGNDR@%FK%'4
M-6&9C7QN[62-S_.6IJ392RWF.2HH8EL]QQYE90?6W(OK1.3D]2DGU5I8YJJB
M'DII.K<Z-W8@$-Z JJRTZAJ=.:@;"ESA3K::HC1495P][D1>QR+VH3'20I,U
M$8W"8(TWNHUI;53:@I$X:^SSMJHW-3*JS*)(SXE:J^PDW2=PBKK?#-$J*R5B
M/:OJ5,@>V.TM1N7<W':"F2*3L/>>6J=U;L@>EO>?*I:CHER?.&L;P\SXUE:U
ML:\P*-HS6$NU6_.WVLJ9RL93W2.W5S6_])25+DAD:OIPKFN3UM0V^&CS>":I
MKM/U,-#(D5?Q-?3O5<<,C7(YJ^U$-KO1%WGEWVV'TYJBN:V.]=6ZBNL;4PC:
MR%>"7'J541W^D!,P
M
M
M                                                      TK>&M^
MRETM_(RE_3J\E7P%O^&W_4G_ !Y%7AK?LI=+?R,I?TZO)5\!;_AM_P!2?\>!
MM4
M
M                                             \TU/'5PR0RQMEBD
M:K'QO:BM<U4PJ*B]J*AZ3QUTLL%'4RT\7C$[(W.CBSCC<B*J-SW97D!:B;*[
M?=JZ&TY\7DFG_P#(8S]/C;?2>F]HK+56C3-GM50_45%$Z2CH(87N8J29:JM:
MBX7"<O43'^RCNOC]RC_O:/\ 48<=-WI35VJ+?3:"K=.4]LNUMN<%QJ>KKDJ.
MJ=&UZ)$[A3".57\^>4QCM[+^'%VY>B*9F='(S^AM8\S5$1KR^+/MFR^WZ8_]
M1M.+ZUM-/_Y#U6K;O1VD:M]SMFF[+9JB-CLU=)0PP/8S'G>>UJ*B8[>9BO0^
M$6I)M)TU_FL-MI*6:18>IDN[5G21$17)U2-XU1,IYW#CFG,QPZ1W26U/TCHZ
M>PV:\*^CJ*AD5-I>QTLO%5O5R\/6.YNE<F4\U$1O)%X<\S.C%O5U[M>L1VSQ
M87,K'MVXJMZ53SB(TU9)](WPBVG= R5%CV\92ZLO;4<R6XN>OB%*Y.7)4_;U
M_@JC>SSEYH88:8T%NYTSM?RW&62HN\KEX:F]W!%CH*)J)G@RUO"SEV1L3*YS
MCM4GS:#H VC1UFI]9[WWAEOHHW,D;8:5RKE5YI'.]J*KE[<QQ<^7N^U"[MP]
M\*K4M*W2.B+:S3>CX_[&IK9;8&QOJ&YY(K6)R1?>-]//B+TY./A1N8T;U7YI
M<^G$RMH3%S*G=H[*86'IW;/;?8")&4L5-N'KZ%<NO59'Q6RA?E>4$*KB1S<)
MA[\IGFF/<EU:(VJUMOK=ZBY\4DL4DF:B\7%SDCXL\T:N/.5/>M3"<NPE+9CH
MDOK(X;QKJ-\4+DXXK,UZL>N>^9R<V_P47/I5.:&55LMU+:**&BHJ>.EI(&)'
M%#"U&L8U.Q$1#C7;UR].]<G67H;&/:L4[ENG2%A;7;$Z9VOIXI:.E2MO#6JD
METJ$S*N>WA3L8G=A.[M522@#0L@       +9UY6:CM^D+I4:3H*:Z:BCA5U%
M1UDG5PRR93#7.RF$QGO0QY_9#Z6?^*[2'Y33_F#*I$.#;;N11'&F)^.OS5KE
MF;DZQ5,?#1@EN7I3I.[GZLT1?Z_;S3=)4Z3N"W&EBI[HS@E>JL7A?F95QYB=
MF.U21&[@=+-&X3;#2'Y33Y\RH3">KXPB853=.3O1$;E.D?'YJU.%NU35%=6L
M\^,?)#VR.I-Y;Y<[E'N;I2RZ>H8XFNHYK55=:Z23B\YKDZQ^$Q\1,/:WLR<+
MZE.S4\WMYE6J=Z==-/@NVZ)HIW9F9\9=P 0V@
M
M
M                   %A[U;.Z<WYVYN>B-61U$UAN+H73LI9EAD58Y6RLPY
M.SSF-+\ &+^S'@Z]G=A=Q;;KC25%=X;[;FS-@?5W%TT:))$Z)^6JG/S7N,H
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MZG2O1UAOE="Z"MU9<)KSP.145(789#E%[,L8CO\ 2 RM
M
M
M
M                      &E;PUOV4NEOY&4OZ=7DJ^ M_PV_P"I/^/(J\-;
M]E+I;^1E+^G5Y*O@+?\ #;_J3_CP-J@
M
M
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MWFW=EVVT_%:[/2MC:U$ZVH>B++.[O<]W>OJ[$[$+N/#OHX
M    .,'(
M
M
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M-N&QL:B(UJ)W(B(B'6V6RDL]O@H:&FAHJ.G8D<5/3QHR.-J=B-:G)$/<
M
M
M
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M*7].KR5? 6_X;?\ 4G_'D5>&M^RETM_(RE_3J\E7P%O^&W_4G_'@;5
M
M
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M7_\ '1PL2WB6XIMQ\9[V1  *:^
M
M
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M:21%RV21RI]>>F,HF.%/7@SY
M
M
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MQ<4S^><81.7:JYW^ M_PV_ZD_P"/ VJ
M
M
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M_&.U#35>BN)^[$>?S;;>--$Q]^9^.GR2< @*ZZ
M
M
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M.Y[&X3**^E@5>?R(!FJ
M
M
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M\E7P%O\ AM_U)_QX&U0
M
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MN-<)R]!D7GU'5J)A<<OB.4]R4ZZJ:I^Y&GZZNC:IKB/OU:S\-'< &+<  #C
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MY4M+%0TT4$,388(FHR..-J-:QJ)A$1$[$1#U$-@
M
M
M
M    $"](#IE;?='V9;9<ZF:^ZKD8CX=.V=J2U6%SATBYX8F\NUZIZD4H/3FZ
M34O1ZVTAI;!(UVN=1O=1VAK\.2G1$3K:ER=Z,:J83O<YOK-:FC--/GJ:FX5T
M\UPNE;(L]77U3E?-42.7+GO<O-550/#N]K+='I!;GW#6][@H*9[W=5;:">5T
MC+=2HJ\,3&IR1R]KG]JK\A28=#:UN,:05=VI+= [W:T,*K*J>A'.7E["=;=9
M(VQIYI48K3#&N5;D"(M(;.TEGXUIX'*^3G+43.5\DB^MR\U+OJ+*VWM8V-O)
MI?3(VQMPU,(4B]1L1BJJX BO<:L\?TK=[=Q8=/3/C;\>.7YR--J-1-DMM*CE
MPY&HBIZ%3DJ>TOW7DT;6288K_3PD I7/TC>)9VHY+?-)Q+R_:7+V_P"BH&7-
MBOC>K;YQ<L=Z;U?NC'73>OHW1,S(G9Z2[(M;(Z/S79 D:]WQJ1.\Y#S:>NK6
MKQ*N$])&E1?*JY2(R-KEYES6:9U+!]?:Y$ E&"[1R-3FAYZ^YM2-W/!9K+XU
MJ?6LX]92[OJ98XW94"X*6XMDKERO+)=ENKHW-1J*A$5BJ*BOF5[>Q5+[MG64
M[4XD7(%WNJ&MSS.S9&N;DI,$BS(BY*@QBMCPG,#N]['<E7)0KQ3M=&_&#TU+
MIHW\DY'S5OC#51P$2:\D926>Y.5F>&!ZKA/WJD2[+4OCE%#4*BX5$:GR<C(#
M<#3Z3V&YQHGG/II$143*\VJ0;LU(R&STC$[FIW 9$:8I6MC:F"]J6%K(TY%D
MZ;JV\#>?<7I23I(Q /24*^<#95G3BZUK.!/.Y(G:N$]/K*Z6KJR9:>!S@([U
M-6^,3*Q55ZY]RA&>JKK5U5SAL%MD2"JF;QU$S$YT\7J_?+W>TO\ B1:VI<Y%
M\YR]OH0C3;K_ -+7NZW.3SI*JJ>J*O/#&KPM3XL(!)VWVAJ.ST<4-- UC>U7
M=KG+Z7+WJ2K;+(UD:(UJ(GQ%!TQ&W@87U1HB1\@.*6B93MPB<ST .7':!PY.
M)N"V;U')0U"U",7@S[HN5TC6MSGD6GJRY6NQTE?=KA4)!!'%]=EF?YK&IW-3
MNROH[5 CS?O5$+="QVFF>WQ^]2I3(UJ\TB3G*[XL)CY2/4HV6[3:-5$8W'9Z
MCQ0U#=4W^?4M<KJ2@1%CH(*A<+'#G/$[/8KEY^P]E96LU$V/Q5>MH$7S7,3]
MM5.Y/4!8]90NN%UI8$1%DG\Y(^_A3O+E99JBTN21J*F.9?V@MN9*JN?<ZMC5
MDQPM;CW/JR7)J#3;.I>U68Y 1]9M9>+<+)'85"Y8]=1I'RD1/E+$OFE9^N=U
M;41V>10TTG7N<K'SOROVK +NU9NDVEC2"GXJJMF\V&GCYN>O^Y/6?+1E/6TK
MI*VY.:M5+YSFM]RSU(O>>G2VAX+6WKY(^*=W+C=S4]VM:B.PV^GIXL^-5<G5
M-QVYQE5]@%'O&J([Y='4$4S59"Y%GPO9Z$)0TE<F4]$B(N&HF$(^T;MU'2TW
M6NCQQ*KW9YY5>]5[U*M?+M'8+;43*[@IZ=BN<[XO0!X-UKWY:NEDLL+N*6JK
M62O1.Z.->)57Y41":].-DEI85RO%@@C;#3%9?+A)J2YL<VKJDQ%"[_H(L\F_
M&O:ID9IZEZB%J8[$ JD3G-:B./KQ(?*=Z1M52G)<4\Y%4#M>&M6&5%3DJ84F
M[P8]V;1ZIW;T^YWG/DH+G&W*=CF21.7'QL:0!>;DWQ=_/N)F\&A32W#>7<^Y
MQMS24]JH:1[_ /VCI9'HGL:H&Q,
M
M
M                                                MK46X^D](RMB
MOVIK/9)785([E7Q4[ESG')[D]"^P"Y06'^SWMG_C$TG^7*;_ ,X_9[VS_P 8
MFD_RY3?^<"_                     &E;PUOV4NEOY&4OZ=7DJ^ M_PV_Z
MD_X\BKPUOV4NEOY&4OZ=7DJ^ M_PV_ZD_P"/ VJ
M
M
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M^1W>]Z][E]/R=B(A<9BV
M
M
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MT_4SJOH2-^'+\B 2L
M
M
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M?LI=+?R,I?TZO)5\!;_AM_U)_P >!M4
M
M                                                      ! _3C^
MQ8U__FL/Z1$2%LK^X[H;^(J']'81[TX_L6-?_P":P_I$1(6RO[CNAOXBH?T=
MA9G_ &(^,_M"A1_RJO\ UC]Y7L "LO@!YYIV01ODD>V.-B*YSG+A$1.U57T
M4_46HK;I*RUMXN]7#;[90Q.GJ*J9W"R-B)E55345TA=[-3=+[>&CME@I*J>U
M]?XG8;/'GB<BJN9I&YPCW)S<O8UJ(F<-55NOIQ=)ZHWSULS1FE)W5>D;;4HR
M'Q5%<MRJ^;>L3'NFHJJUB)VY5W/B3&6'0FZ'\6R%H;JO4K(ZK6]RIVIU3F(J
M6N-R9=$U<KF1<IQN3T<*<LJ[T-FW1@6NGN_CGE#R=^[<VG?]GL\**?Q3WKUZ
M)W1>MW1QT:^*5\-QU7<,/N5SC:O"N,\,4>>:,;GU*Y<JO<B3-J+4%#I:Q5UW
MN4[8*&CC66615[$3N3TJJ\D3O540J4DC8V*][D:QJ957+A$3TF#W22WP;N9=
M8;+8I)'6"B?GBQCQJ;*IQX]ZB<F_&J]Z8X5RY5=KFNN=9EZ6Q9HL6XMVXTB%
MO[CZ]O?2"W$IJ:@IYE@DD\6MEMXL]6U<9>[N15QQ.7L1$[<-R9B[0;46W:O3
M$-#2QL?<IF-=7UR-\ZHD3/>OVJ95$3T<^U54M;HY;)P[;:?2YW.%':EKV(Z5
M7,YTL:IE(4]?OE[UY=Q-1K;P
M
M
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MRUE3G*ROIW<+7KZW1K&Y?6J@9%@
M
M
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MM4
M
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ME[<*GOD4SFIJ>.DA9##&V*&-J,9&Q$1K6HF$1$3L1$*Z\]0
M
M
M
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MV-25C&Q/YE0KKS$V)R\2$)[F;@3^4F6*R(VHO,[>-5=S93Q^_?\ [D[P+>W
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MB&7J++>JB*QWZ+GP202OX8I53WT<BM5%]"N3O-M(
M
M
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ME7P%O^&W_4G_ !Y%7AK?LI=+?R,I?TZO)5\!;_AM_P!2?\>!M4
M
M
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M)A,+ESW+S<]R][E7FOZN1<(
M
M
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MW(ANA:U&M1$3")R1 .X
M
M
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MKV+PYSAR+WH3IX"W_#;_ *D_X\#:H
M
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M-C:C6M1K6IA$:F$1/0?4
M
M
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M]32PW+<2]1M;6U$7G14,*+E*6%>]$7"N=]LJ>A$,HP
M
M
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M_P!2?\>15X:W[*72W\C*7].KR5? 6_X;?]2?\>!M4
M
M
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MW8A'_1MV@7;327CE?3XU#=&MDJ>-/.@9VLA]6.UWK7'/A0F4UK
M
M
M
M            6WKO75CVTTI==3ZCN$5MLMMA=/45$JX1K4[D]+E7DB)S551
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M1$[$1#[
M
M
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MZ=7DJ^ M_P -O^I/^/ VJ
M
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MJ=R(J]C3/>W4%-;:&"CI((Z:E@8D<4,;>%K&HF$1$[DP<]UWL
M
M
M
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MW6^FME%!245-%24D+$9%! Q&,8U.Q&M3DB?$>T
M
M
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M4NEOY&4OZ=7DJ^ M_P -O^I/^/ VJ
M
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M@
M
M
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M*^TKZ.\:TJ6U\=/,W#X:)K>&G:O>BN15?C]^AEZ
M
M
M
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M2)))2>6Y9'1PSO\ =5"HU45\B(KL*Y<(KE7"NX50/TG
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MJBMEEME':+;#GJJ.AIV00LRJJO"QB(B9557DG>58
M
M
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M0/E%$V-B,8U&M:F$:U,(B>@^H
M
M
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M&?D6#_RFA[]BC?W[T-Q_R97_ /E'[%&_OWH;C_DRO_\ *!^D@
M         !I6\-;]E+I;^1E+^G5Y*O@+?\-O^I/^/(J\-;]E+I;^1E+^G5Y*
MO@+?\-O^I/\ CP-J@
M
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M#GQ_RZO_ %C]Y7S%"RGC:QC6L8U$:UK4PB(G8B(?8 J.@
M
M
M
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M&.@U5;)$HKY;8URD-0B91[._JWIYS57UIW$Y
M
M
M
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MV4NEOY&4OZ=7DJ^ M_PV_P"I/^/ VJ
M
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M.O\ "]:BY$?ZLQ,^$:?RY !@W@
M
M
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MR^U4-S(
M
M
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MH
M
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M;[U7=:N/82T
M
M
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ME_$ORE\@
M
M
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MR5? 6_X;?]2?\>!M4
M
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M>MJ:I6<+IY5[7*G<G)$1.Y$3XR]0
M
M
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M#C5JXDY_&=9-63W)ZQQ<2HO+):U1#;&RY;PMPO;DJ5+J&UVFG\^:-B)WN5$
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MO%=K:]>%ZMRV6!_?'+&OG,>GO7(!?(
M
M
M
M@_IF:5T+J_HVZTMFXUZCT[I>6"+CO$C'/\2J%F8E-+AJ*Y<3+&F$[4547DJF
ML+H2>$,INB%07W;C65"_6&C8:Z6HM]UTT]LDD;W*B/ZMLJQI)#)A'IQ*Q[55
MV47BPS:=TJ=CIND=L+J?;J"\,L,MZ\5Q<)*=9VQ=350S\V(YN<]5P]J8XL]V
M#7S]0UNW^-^B_(#_ /F )]C\,7L&Z-KG0ZM:JIS:ZU1Y3U+B;!]/JQNP/P>K
M/R4SYTQ^^H:W;_&_1?D!_P#S ^H:W;_&_1?D!_\ S &V4
M     !I6\-;]E+I;^1E+^G5Y*O@+?\-O^I/^/(J\-;]E+I;^1E+^G5Y*O@+?
M\-O^I/\ CP-J@
M
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MI>&H>U'6NEE3FQJI^W.3TJGN<]B97T&4@
M
M
M
M       /E)$V2-S'M1S7)A6KV*GH/J -,/3 Z.%SZ*VZ==<[=22+MM?:IT]M
MJXVJL=#(]>)])(OVN%5>!5Y*W"=J$$ZXM5)N#9XU9(QM=3KUE/(Y>6>]J^I3
M?YJ?2MHUG8JRRWVVTMWM-8Q8ZBBK(DEBD:O<K5Y&$NXG@EM#WJX35FAM67;1
M#97<7D]\:5U*SMY,1[FO:GJXEP!J@MU5-23/HYII*.M8OG03K_17O0KM-XW4
M.X9:A49WJCC8=;O W4ERD@756Z5570-7,D%NM+(7+S[&R/D=CE^])1N7@F]D
M9=,SVZ@^B2@KW0\$5T2[/DD8_N>K%\Q?BPB?%V@:NJ*GHJ=4:V3C>O;SRI).
MD*5W5MX&)@B[>W9[4_1EWENVA[O4^/34KFS4E5,Q6QU],[FR5B]RXRBISPK5
M0OO;O4'CC?K;N!Z<E:X"7[-;VR8XFX+JIJ&.-B<N91K!4MJHT=P\,B=J%QQN
MXFH!YJBG;U+TQS+?K)%CJ(G+R<U<*72J<379+7OS4CXG>L"X:&3K(6\\J4NZ
M:NM=&VHA;5Q5%9&UR^+1O17<2(J\*^]SV<RT[[N)3:7M;JB:1L;8DRYSEPF#
M'?5>^+M1W"5\,4TD&5YPQNPJ?&B<P);U9N112,8KT9$YT:.=!QHKF.]ZJ]BE
MC4>KZ?RAQQNX6N7.%+$H-24]Y<YL;(VO[VO145/CR?>JL\TCD>R+@=]J^/L
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MLT3K):>EW L\+9>MB7ACN]-V>,QM[G(O)[$SA51>Q0,K0
M
M
M
M          PU\(;TVM3=#U= KIVPVJ^?1%Y0Z_RHLJ=5XOXMP\' Y.WKW9SZ
M$,RB'=_NBGMMTFEL/[(EBFO'D3K_ !'J:Z:FZOKNKZS/5O;Q9ZF/MSC'+M4#
M6G]6XW,_Q?Z3_#J?G!]6XW,_Q?Z3_#J?G#-/ZE#T:?O*K?RY6_.CZE#T:?O*
MK?RY6_.@86?5N-S/\7^D_P .I^<'U;C<S_%_I/\ #J?G#-/ZE#T:?O*K?RY6
M_.CZE#T:?O*K?RY6_.@9=@                    -*WAK?LI=+?R,I?TZO
M)5\!;_AM_P!2?\>15X:W[*72W\C*7].KR5? 6_X;?]2?\>!M4
M
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MOK3.=EJM=+9K=34-%"RFI*:-L4,,:8:QC4PB)\@9O6U$:F$3"'8
M
M
M
M                                  QUZ8G0[TYTL-$Q4E5*VSZKMJ.=
M:+XQG$Z!R\UC>B>ZC=A,IW=J&H5FC[_LYN7>M&ZF9'%?+-4K2U75*JQR<D<R
M1BJB9:YJHY%]9^@0UI>%1V'K+7J"T;TV>E?+1]2RUZ@2-JKU2-5?%ZAV/M>:
ML<O=Y@$+::NB>:Y%Y*B%ZT5:US5YD":1U8R2&/#T[/22%0:E;P)YX%_R5;&M
M7F6?J:Y-;$]<GFJ=3L;'[M"--P=?QVVAD<BK+,Y>"*%O-TCUY(U$]:@65JRQ
MW'<^Y7>.FJ$BH;1PHUCDS'/4+SX'>I$_.I:EKN$%!6+1W");;71\E@FY(OK:
MO8J?$3YMUIGR'H^"EJ5ZROJ'.J:MWIE?S5/B3DGR'>][=4-\8K*NCAJ6=W6,
M10(,O,=)41J]B,1WOFJB*4NW;APV6=*>J57QI_TB><B?'@FA=CM+4D;I);:U
MW[UTCL<O5DCS7-ML-#406JV66DGKZA>&*%L:(B>ESE[D3T@<2:[L-P@19*F%
M$_A(46IU?0M1[+-0ON$_9QM8O WUJOZC[+LA?:>-*VTU5LDJ^U]$QJHUWJ17
M<L^P]&FJJ.JF5M72K;[A Y8JBE=R5CD]0%U;74;W5'C,_"ZJ?[KE^9/49&V"
M1D=.W'F\B']-,IZ65LL?>G82#17R-L?ND0"\*B;K'(B<SB"AX9DE1"F6R\4\
MSDRY%^4N6)S7-16\T M_7FE/HQTS444,GBUPB<VIH:E.V&H8N6.^+/)?4JE,
MTAKCZ)=*TU9)&Z"K9Q05<+URL<[%X9&Y[_.12[:JH2GPJK@Q]T)J)TEKN$<*
M(Q]1<ZJ9RHN>V5< 7IJ2[25TBP0IQ/<N/B*MIFP,HH4>_F[',I5DLLL\O6O5
M7+G)>D%'(V%&=B 4V:7JY'*B^:A:M?<GU5>D;5RB+S+JN5*L,+T;VJA9$\C*
M.J17KYRJ!>5EH>NX5=S+G@M;.%.2% TM*M5P*WW)>#4X6H@%$N%I:UO$U.9Q
M:*I8\QN=WE;DC21JHO86Q79HI9.7+M14 NAB\29/G41MDC7*%&M-^CFCPYR9
M0]E5=HVQKAR 6MJ"G:DC\<C'+>A&]=;X.WKJMC53XES_ +B>M0WJ-O6.5R(B
M>LQ@W2NDU\OT#HFN2FI96HV3X21SD3"?$F0)LT#41QM8Q>UJ)R0F"V3HQC,=
MY#&@Z5[N&1>URY)BL].YS6*H%R-D3A13EKD=V'R;"N.:G223Q=KE MK<S5Z:
M1TO7UC(EGJ&MX(8OA)'*C6-^5RH?#;C;J+25"^NKG>.ZDKVI)7USURJN7GU;
M/>L;V(B>C):NZ%1Y2U#HZCD<B037F#C1W8O#ER(ORM0F!?=*!3ZSBI6J]B_(
M>!UR29F']JE4KX^.%Q9M3(Z&KPJ\L@7+0TS97<6"H^*LX<8*?:*AJL3F57B3
M&<@6]?;8BPR*WD0W9K&EPW9N;I&\4E/:FI&Y?M4=*[BQ\>$)QO,[6PNYD7:2
M:R;>.N1O-765V4].)DQGVJ!0-':8@U9N)=KE/&V:BL\OB5&QR93K41%DDQZ>
M:-0FQFG:=\;?-X7)WH1ILI,R&34E%(N*BGO%1UF>WSE1R+[%_,3&Q45J8 LG
M5FA:&^6N:EK*:.I@>F%:]N4^/U*6-8-)U5OB;04U1/+!!YC6RR*YV/C7M)KJ
M8^MC5I9J4[Z&YOD:GVV%0!8M*OC<JR1]6[O5W-5+KI;='3MY(ATH[BR9$1>2
MGKDF8UJKD#J^=D+%7."V+UJ)M*KG*["(?._7QM*JIQ80B_<37U':K9+/(].S
M#6M[7N[D1.]0/7J[>>"QN9!%')77";E#20\WO]:^A/6I1Z&;<'5.)9KK!8XG
M<TAHH$D>GQO=W_$A:^V&FYZZMEN]Q8JW"K7C<CNV)GVK$]&$,A-.6EJ-1O#V
M 1L_3^OK;&LE)J1MRQS6GN5,W#O5QMPJ?&6E<MRI].7FAK/&ZW0^M[;+U]#5
MQ(Y_"_WT3VIYS5YHK5[4Y*AD[Y.CX<8+$U]HVCN$<=0^FCDJ*9W'#(YJ*K%]
M0%ZZ8\(%TB*ZRNHWU&F*BJ^UN3[4]'\..U6(]&Y[.XN33_3DW_T_4=?<7:9U
M73M7+Z6:A=1O<G+DDD;L(O;C**1)I2G;-"S+4SWEZP6V)T:\D SCZ-O3&TKT
M@I9[,ZGFTIK2F9UDNG[C(U7R,3MD@>F$E9Z<<T[T0R#--VJ[)6V^IH[Y8*IU
MLU):9FUEMKXN3H9F\T^-J]BIWHJFT3HY[OP;Y;.Z;UE'&VGJ:Z#@K*9JY2"J
M8JLF9\CVN^3 $F@
M
M
M                                        *=<[Y;K) D]RKZ6WPJN$
MDJIFQ-]KE3TBUWRW7N!9[;7TMPA1<+)2S-E;[6JOH J(
M    #2MX:W[*72W\C*7].KR5? 6_X;?]2?\ 'D5>&M^RETM_(RE_3J\E7P%O
M^&W_ %)_QX&U0
M
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M*B(KW>Q.7<B(A#8]^C=)6W0NG*2R6J)(:*E;PM[W/=VN>Y>]RKE5*^
M
M
M
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M(F )-M%];PIYQ7&WYG5KYQCW;MQZ?CPDS<^A'(5&JW2I*.G5\M6R-J)]LY$
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M&4_@R=P*>VZKW#T!4R<,]<^/4-!Q+[MO"V&=J?P7-C7_ $P-@@
M
M
M
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MXD3U8)#+:V_T9;-N-#Z?TG9F.CM5CH(+=2MD=Q.ZN*-&-5R]ZX;S7O7)<H
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M@+?\-O\ J3_CP-J@
M                                                   !%>L]FKIJ
MO4=9=:?<+4EDAJ.#AH*"J>R&+A8UJ\*(Y,95O$OK525 !!E7T?[Y2T<\R;L:
MP<L<;GHBUTG/"9]^6=LUMOJ/<O0=%J"JW,U7135$DK%AAKY7-3@>K4YJ_P!1
MDQ=O[F5O^1?_ $5(KZ)_[B5G_P M4?US@/']+Q??\;.L/QV3_P Y-@
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MOI3OM9M;9MJ=/K;;4UTDDJI)55DW.2H>B8ROH1.YJ<DRO:JJJWL
M
M
M
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MW)8VHQE;"[/553&]R.PJ.3N<U>Y4 R6
M
M
M                                                #SSS,I8Y)97M
MCC8U7.>Y<(U$YJJKW(>@UQ^&?W:O^D-KM$:-M%344-OU555<ESD@<K.NBIFP
M\,#E3M:YTZ.5._JD[@,E-RNDYT:=14-=I36>O]"WV@D7@J;?65<-9#Q(N/.Q
MQ-1R+\J*G<8@;J^"OVNWKL<^JNCGKNV1(JJGDWRBEQMCW^\;.Q7R0N]*.X_1
MAIZ='>!0TE6::H:F[;IW&XUE1$V;QFST4+:1R.:BIU?$YZO;SY.RG$F%PG81
M5M-MU>^@;X1716WMBUE]%%JU&E/!<8X8_%^."H65C(ZB)'/1)(E:V5%SS16K
MR1ZH!Y=.]*[I4] >[4NF]T+'6:FTSQI'!%J*19V/:F5Q2W%BNYXQYKUD1C41
M.!IGST=?")[.=(5*2WTM\^A35,_F^0M0*D$CW]F(I<]7+E>Q&NXU3M:AD;J3
M3-GUA9:NSWZU4=ZM-6SJZBAN$#9X96^AS'(J*GQH:_\ I'>!VT5K9M5=]I[D
MNA[TY%?Y(KG/J+9*[FN$<N98,JJ<TXVHB81B ;%P1;T:=$Z@VXV'T/IC5,J3
MZAM%LCHZR1LZSM<]F4RCUYN3&,9[O02D      8F=&[H V;H[[[:JW+I]4U6
MIZN]TT\4<-QI&MEI))ITEEDZQKL/5W"C?<-5$XN:\2H99@P.Z?7A#Z/9>EJ]
MN=M9FWK=&N3Q9\]*B31V;CRWFB9XZE5]Q%CS55'/[$8\,=-RJFVZO\,II]-'
MMZ^HI;Q0QW*6D?R?/3TR+5+R]Y&Q6/3TQOSWD_>&<UM56'HV6+3]+(Z-E^O\
M3*K'8^&&*27A7_YXD+O]$^_@T^A#<ME*:LW1W%BF=N/?H7MBHZQROEMT$CD<
M]TBJJYGE5$5RKS:GFYRYZ%@>&_AD=H7:R9&.6)ERKF.?CDCEBB5$^5&N]B@9
M==!;;VDVWZ)FV%KIJ;Q:2JLL%TJFN14>L]4U*B3BRF<HLG#A>Q&HG8B'EZ?>
M@Z/<7HA;GT=7$U[K?:9;S _"<4<E(BU".:J]BXC<U?4YR=Y).P;D=L9MTYJY
M1=.6Y4QW_P!BQE&Z67V+6\O\C+S^@S 8R>!OUS4:DZ+5=8ZF3B^AR_5-+3M1
M<\,$K(ZA.7=]<EF_^[)GB:W? AI_[CVXRX__  ]%S_\ H=I<7AK?L6M+?RSI
M?T&O V  _*N ,_\ PUOV4NEOY&4OZ=7DJ^ M_P -O^I/^/-59M4\!;_AM_U)
M_P >!M4                                                   L7
M<C1FI-7K;O(.L*C2?B_6==U%*DWC'%P\.<O;CAX7>GW1?0 A3]A3<3_''</R
M8GSQ9&EM/;B:DW!U;IG]E&X4WD'J?[*\21W7]8WB]QQIPX^-<F41"FUGV0.[
M'_T%_5J _84W$_QQW#\F)\\27HFSW'3^FJ.WW6\R7^OAX^MN,L?5NER]SDRW
M*XPBHWM^U+@                                         'CNW]S*W
M_(O_ **D5]$_]Q*S_P"6J/ZYQ*EV_N96_P"1?_14BOHG_N)6?_+5']<X"8
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M
M
M
M
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M23-ZF%OQKQ/7'H:H&TH
M
M
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MM_U)_P >15X:W[*72W\C*7].KR5? 6_X;?\ 4G_'@;5
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MFS33-4:Z1VPR_ [0472
M
M
M
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M[GP=_5,]#4_.I$FH:E+_ +DTM9[NDI*ZEHU7N<]7+(Y/DPTR-HIG7"CXF+S
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MK#;K!0<O['MM*R!BX3"*J-1,KZUYEP@
M
M
M
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M[-VZ?T6_0Q^Q_;_+GBOCGBOE%G[3GAXN/CX>WNSGU%=^CW>O_%E;_P K0_.
M36"T=O+OJ>\6:>;5EBAT_<FU#F1TL-0V='1<+51_$URHBJY7)C/VI=P
M            A3:S[('=C_Z"_JU)K(4VL^R!W8_^@OZM0)K
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MU=YT=/<  Q;0
M
M
M
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M;)%+&Y'->U4RCD5.U%1>T#V
M
M
M
M                    -*WAK?LI=+?R,I?TZO)5\!;_ (;?]2?\>15X:W[*
M72W\C*7].KR5? 6_X;?]2?\ '@;5        =?28L=('[,CH\_ZU_J4,I_28
ML=('[,CH\_ZU_J4+6+_N3\)_90S/]N/C'[LJ$[#DX3L.2JO@
M   .O:=>?H(\WGU'K_3>EZ:IV[TG3ZQO3JQL4U%4UL=*UE.K'JZ1'O>U%5')
M&W&<^<JXY$-_LN]*=/\  7:?^T-+\^;K=F;D:Q,1\9B/W5+F13:G28F?A$RO
M].?2U_\ U8__ ,Q-.<FOO]G'?+Z97Q;]BJV_1KY"QY%\KP\/BW69ZWK>MX,Y
MY</%GU$MKNYTI5;^X7:?^T-+\^;IQ:Z>=4><?-HISJ*M=VF9T\)94)R"JN>[
M!'FRVI-?:DTM556XNDZ?1]Z;6.BAHJ:MCJFOIT8Q6R*]CW(BJY9&XSGS47',
MD-4YKCFI5TW9T7Z:MZF*HCGWOH #%F          #H@3D.SU(1ONWT@]![&K
M:OHVOJV;RIUOB?\ 8=1/UO5<'6?M4;\8ZQG;C.>6<*3%,U3I3&LL)JIHIFJJ
M=(21@A?:S]W_ '7_ /H+^K4H/U0'83[^_P#NBN^8(PT'TSMG;+N]N#?*W5ZP
MVRZ^*^)S>3*QW6\#%1WFI"KFX7THAN]GO?EGRE7]KQ_SQYPS4[/B&>(QZ3P@
M6PGW]?\ =%?\P2_M]N#8-T=(T.J-+UZW*RUO6>+U7521<?!(Z-_F2-:Y,/8Y
M.:)V>@UU6JZ(^_$Q\8;+=^W<G2BJ)GPE=0 ,&\             ?+C:SM4(]
MJ]BH0KO/T1MO]]M3TU_U73U\UQIZ-M!&ZEK%A;U37O>B*B)V\4CN?Q%B+X-C
M9AK'?V%>/RD[]1OIHM51$U53$_#ZJ5=R_3,[M,3'QT_AE-UC<<G-]HXFXQQ)
M[371T7NAKMQNNNX_EZFN$GD+5-7::3Q>M='B"/'"CN7->?:3C]38V7^XKQ^4
MG_J-U=BU;JFF:YUCP^K19R+]ZB*XHC2?'Z,J6NR<E%TCIJBT;I>SZ?MK7QVZ
MTT<-!3-D=Q.2*)B,8BKWKPM3F5HH\->#I4ZZ<0 $L@          #7OTEFS)
MO7J=)O=]9&J?P>J9P_FP;"#&#I<;/U=[C9K2T4SYY::)([A!&F7=6W/#,B8R
MO"BJCO0B(O8BJ!B%5_VE/_DW?S%H;.?WAT?^4E_IJ7?5_P!I3_Y-W\Q:&SG]
MX='_ )27^FI=I_X]7QASKG_*I^$_O"]VYXDQVY-H5B;-'8[>VISXPVGC23B[
M>+A3/YS5S;]R=(;>:EM];JQ:FKI8'>,>3:%C7S5'#S:Q>)4:UJNPBJJIRXL9
M7D>7=+PCVYVL:RJBTTZFT7:'M<QD=*QL]3PK]LZ9[>3O6QK<9]/,SQ\&_?C6
MF-([Y:\G:5C&G=F=:NZ.;9%NAOCH?9ZVK5ZNU!2VO+5='3.?QU$W^3B;E[OC
M1,)WJA@QO5X3Z[79D]NVULZV6%V6^6+LUDE1\<<**K&+ZW*_XD(EVNZ%^[N_
M]<Z_W2.:T4=8])9;UJ:23KJA%[7M8N9)%QV*N&K[XSEV7Z FV.UOBU;<:)VL
M;]#YWCMX:CH6O]+*?W"=F4XN-4[G%^+>'A_CG?J[NQRNFS\__;IW*.^>; _:
MGHO[L=*6^2:CK7U$-!5OXY]27]SU2;/P2+YTO+LX?-3&.)IGQT?^@WH/8^L9
M=GL?JG4:(G#<;I&Q64[DQYT$6%2-<I[I5<Y.Q'853(]C&QMPU$:B)A$1.P[=
MI3O[0NWHW:?NT]T.AB[+LV)WZOO5=\NR-1.Q#YR2-AC<][D8UJ9<YRX1$]*D
M2[E=);2>W\,]/3U++]>6+PI0T;\M:O[^1$5K<=Z)E?48N:UWLUWO+4)9V]9X
MK4.PRT6F%V).>41V,N?W=JXRF<(<QVF1VZ72HTWHV-]+9'Q:FNG-%;3R_P!C
MQ>MTB(J._@MSV<U0QGN%VUYTB]5MB1DUSE:Y5CIX6\%+1,<O:O<U.SSG+E<)
MS524=M.AI55T=+<-85ZT<3L/=:Z3G+CWKY.QJ^E&HOQHIE!IW2EHTC0^)V6V
M4MNIN664T2,XE1,9<J<W+ZURH$-[/]%.TZ+F9<M2=3?;PQW$R/'%20^A4:Y$
M5[O6Y,)RPF4R3ZG+DG)#L    B75'1TM.J;_ %UVGU+J>DEJY.L=!1U[&1,7
MT-:L:X3Y2E/Z*5AFC?')JS5TC'(K7-=<8U147M14ZHF\ 0;3=$O3M' V&GU1
MJR"%G)L<=PC:U/B1(CUT71@LU#605+-5ZL>^&1LB,DN+%:Y45%PJ=5S3D3.
M
M
M
M
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MO17L5/2J*!M,
M
M
M
M         :5O#6_92Z6_D92_IU>2KX"W_#;_ *D_X\BKPUOV4NEOY&4OZ=7D
MJ^ M_P -O^I/^/ VJ        Z^DQ8Z0/V9'1X_UI_4H93^DQ8Z0/V9'1Y_U
MI_4H6L7\<_"?VE0S/]N/C'[PRH3L.3A.PY*J_                   ,1E_
M]\H7^1W_ -69;^GY#$A?_?*%_D=_]69;^DMY'_;_ .L.?B?]_P 9<X.0"HZ
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M[XW<V,_VOB0RBT5H"Q: MB4-CMT-%$C41\C6HLLJI]L]_:Y?C+E
M
M
M
M
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M&HC43T(A]0
M
M
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MG+]OW-<O;V+SPJY](O$F44Y&1CW,>N:*X^KMXN5;RK<5VY=P :%T
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ME^)$9A&(GR9]9*T4+*>-K&-:QC41K6M3"(B=B(A]@5ET
M
M
M
M                                                       QCZ8W
M3"INCE::*RV6ECO>X%Z8]U!0R.^LTL:<EJ9\+G@1>2-3FY45.Y5,EY)&PQN>
M]4:QJ9<YRX1$3O-(>I=<5>]F]>L]=7&1TSKC<9(J-KERD-'$Y601M]"(UJ+\
M:JO>!Z]2.U?O;='7;<34MPU15O7B;3SRJRDA_>Q0-PQJ?)GTJ>^S;;6^RM1*
M2@IZ?_)L1I>.G[>QL+>7<5Y::-6XX0(YNEF>UBIA&-[,-/G9=+1/DXE9Q+Z5
M+SNE#'PY5,(@L\;&KR \?T*Q=5^UI[!3:5@1RJC&H[NRA=!\E<C9 *6S3Z<F
M\6&^A$*A3T,=.U$:G8>CB3':>"6OZEZHKD7Y0*@42[M2-R.3TGM\J,X<Y*%=
M+DV:7@SGF!5+,KI,N5<H5<I5FD8UO"BE5 M3<[5*:-T5=;MP\;J>%7,:JXXG
MKR:GRJJ$'[3:9ZFE\8J%ZVMJGK45$B]KI'+E5+_Z3<CDVTF:B98ZMID?SQAO
M6)[>XHNWTS/%H>?<!*EDM+&QMY%8\18B<DYGEM$S5C[2I\2>D#Q),L#N$^\-
M0V8I-YJTCSPKS/M97+)&BJO,#[W!BRQO:U.TM:[6=.%$QESEPI>ZM3A<A1JM
MK9:AK?0H'EMFGV-A3S>[T'L99^J=EO(JL#>&-$/H!1UA<U%1R%LWJEXIO<\B
M_'1M=W%+K[:V1CEQS L&>E8YO"J'D2UJ[DR3A0J%\CDA<YL:%H55ZJ:=RM;G
M(%XVS3<2KE5XG^LN2AX*5O JYP1%'JVKIW(CYD:GQE6IM;-ZOSI45?C DNON
MS(XEPJ>TA;<NH?JNX6S3=+]<GN54U'HG/AA8J.D<OJPF/E.-2;FPTK6Q,<^>
MJE7@AIH$XY97+V(UJ<U4OG:3;2MM+ZK4NHVHE^KH^KBILY2B@[>#/>Y>UR_(
M!0[IH2)RJUD7J3!:M=H-T+_ME^4R(\CL=E51,E#N^GVNXL- A.+1-8UJ+%*]
M$*C;M(U$LB1SN5WI]9,%LL<<E*WB:F4Y'H9I]L<B/1J9 MFQ:191PHC&8Y%T
MVZP,;&F6\RLTU.V)C>7,^W)H%NW*QM;&KFH6Y3VOQFL=&K<E^UTB-A7);MHB
M26[/>B\D ^+-.-:UV8_BY'EGTFQS7+U?,OGA;V<@Z-KFXP!&T6CV2<2K&B_(
M>"Z:>BH&\FHUQ*+:=L,;E5.SF69<&^-5$LTB>:BX:T"Q9[E-0MX6HY5[CP,M
M]?J!WUWB9%Z/270RTS7*K<_@PQ.SD7?8[&SJ^%S41X%"T=9FT^(>'"-Y8+_A
MM\;8U3!2F4"VZJ5Z)YJ]I7(*ADC<HH%&N=''31OD7Y"Q[M?O$G*N>%"Z-::@
MI;5;:FLJYFP4E,Q7R2.7DB(7AT4.AU-TJ=.KKW65SN%AT3/.Z.UVNW8BJ;A&
MU<.FDD5%5C%7*(C4SRSD#'JX:_?5UU/;:"*>XW6J>D5-04<:RSS/7DC6L3FJ
MFP_H)=$2X;4,FW"UW"U-=W2GZFFM^>)+12NYK'GL65_)7JG9A&^DF_:'HN;7
M[&HY^C-)45MKG-1DEQD19JMZ)Z97JKN_N5"6
M
M
M
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M?BM1\V/IY-COO_I/Q6H^;-,'[(^TGWP:S_[+TG_UQ'[(^TGWP:S_ .S%)_\
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MK6['?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_\X/JUNQWWJ[@?DZA_P"< V
MU_\ U:W8[[U=P/R=0_\ .#ZM;L=]ZNX'Y.H?^< V  U__5K=COO5W _)U#_S
M@^K6['?>KN!^3J'_ )P#8 #7_P#5K=COO5W _)U#_P X/JUNQWWJ[@?DZA_Y
MP#8 #7_]6MV.^]7<#\G4/_.#ZM;L=]ZNX'Y.H?\ G -@ -?_ -6MV.^]7<#\
MG4/_ #@^K6['?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_\X/JUNQWWJ[@?DZA
M_P"< V  U_\ U:W8[[U=P/R=0_\ .#ZM;L=]ZNX'Y.H?^< V  U__5K=COO5
MW _)U#_S@^K6['?>KN!^3J'_ )P#8 #7_P#5K=COO5W _)U#_P X/JUNQWWJ
M[@?DZA_YP#8 #7_]6MV.^]7<#\G4/_.#ZM;L=]ZNX'Y.H?\ G -@ -?_ -6M
MV.^]7<#\G4/_ #@^K6['?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_\X/JUNQW
MWJ[@?DZA_P"< V  U_\ U:W8[[U=P/R=0_\ .#ZM;L=]ZNX'Y.H?^< V  U_
M_5K=COO5W _)U#_S@^K6['?>KN!^3J'_ )P#8 #7_P#5K=COO5W _)U#_P X
M/JUNQWWJ[@?DZA_YP#8 #7_]6MV.^]7<#\G4/_.#ZM;L=]ZNX'Y.H?\ G -@
M -?_ -6MV.^]7<#\G4/_ #@^K6['?>KN!^3J'_G -@ -?_U:W8[[U=P/R=0_
M\X/JUNQWWJ[@?DZA_P"< V  U_\ U:W8[[U=P/R=0_\ .#ZM;L=]ZNX'Y.H?
M^< V  U__5K=COO5W _)U#_S@^K6['?>KN!^3J'_ )P#8 #7_P#5K=COO5W
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M?_U:W8[[U=P/R=0_\X/JUNQWWJ[@?DZA_P"< V  U_\ U:W8[[U=P/R=0_\
M.#ZM;L=]ZNX'Y.H?^< V  U__5K=COO5W _)U#_S@^K6['?>KN!^3J'_ )P#
M8 #7_P#5K=COO5W _)U#_P X/JUNQWWJ[@?DZA_YP#8 "&>C#TG]+=*W0-PU
M;I&W7BWVVBN<EKDBO<,44RRLBBE5R)'+(G#PS,YYSE%Y=BK,P
M
M
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M\Z&5?0"U5-HKI,U^FF28M>K;/)*Z)5Y)54JHK7(GI6-[T7^"GH V9@
M  'RDD;$QSWN1K6IE7.7"(GI4#Z@PPWF\)=H_1]YJ]/Z!M3]P+O3O=%/71U"
M4]L@>G=UV%6547M1B*G[XBZ'PD&Z<7'4SZ:T.VD8BN= ZIJHW-:B?"JJI_L@
M;( 8?[*>$KVUU_=&6+5TT.@;\YJNC=6UT<UOJ,)SX*E,(U?WKT;ZLF4VF]8V
M+5]&M58KS;[U3(N%FM]4R=J?*U5 K0
M
M
M
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MS.C=%8_H\VJ=IV2]+-XCUU^I:I)DAZOK?[75_#CK8_=8SQ<LX4W3FJOPZ/\
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M=DI?';S>*V&W4--UC8^NGED;'&SB>J-;ESD3+E1$SS5$-\7A2/L%=S?]6?\
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M!1^Q:U5_+.J_0:$V
M
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MJB<G8K7L1R?F4"J
M
M
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MMWVKU'+;;C&Z2F<JNI:UK52.H9Z4]"IE,MSR]BD(ZN_=(T?_ //_ .B7</\
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MT4_I0MK+KHWZ*/HL\=O,MW\=\G^)<''!!%U?!ULF<=1GBXD]UC'+*Y!@
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MC'+*Y!@
M
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M<
M
M
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M'2QTAM1N]M_ME5]9<]5:NK64T='1O;FBB>O"V>;*\FN=E&IVKPN7N G$
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MUS7(J*U4RBH7@
M
M           #6'T^.DK<MT=?UVT6EZ^6DTG99.JU!44SU8ZX57?2\2?]%'RX
MD3W3N2\D-BVY6KHM!;?:EU).YK(K3;JBM57KA/K<;G(GRJB)\II(VPCJKM&Z
MZW!SIKA<9GUM3+)S<^61RO<JKZ<N4"^-*Z-IZ.EBCCA;&QJ81K4PB%V,TU&L
M:)P)[#WV2FX8F\BK@1EJ71T,T+OK:*O;V%I0:)H;M ^FJZ2*=O8K9&(Y"9+X
MUK87*J<E+4H*=(ZI[T3S7*!5]G^D1NKT<5;;]/U[-4Z48O+3E]D<Y(4]$$_-
MT:?O5RWEV&3VGO"BZ=>L3=3;<ZHLC?\ I9Z-(JV-O+M1&N1RHJ^HQ<K;7UV)
M&IS.*:22G:B.I^+UH@&0.YWA'=1:CHYJ#:_1<]I63+4U!JA&M2-%['1TS557
M._A*B&$6H*:J?>*Z[7:OFN]^N4[JFNN54N9:B5R\U7T(G8B)R1$1$)2N-5-)
M&Y(J=V?B(;W(N%7;IJ>DAX9+S7*K*:+NC3[:1WJ3^<"AZFKGZSO,&GJ=56W4
MN'W![5]V[[6+_>I,FBM.LBI8D;&C6-1$1$0M3;C;AEIH8HU59'JO'+*[W4CE
MYJY?C4FJSV^.FIV1M9C"8 [4=I8V-,H?.NLK)(W>;DK#&HU,(%3BY*!8]194
M@XE?"CD[EQD\4ES2U-5&4_ O[UI(+N"-,.1%0H-ZCIY(W*C$S\0$/:VUI4^*
MSN9&YJ-1?.=R+!VTH7TM)6W6K1'5M9*Z:1W;CT)\B%[;E4Z/HI6,;CD6-!=D
MLNEWN5.;6+R ^UXNEPUM<$LU#*Z"@_\ A=1&OG*GP;?1GO4E+16@*2V4<<,$
M#61M3"(1YLE:^&TQ5$J*L]0Y9I%=VY<N3(JQ4[(XF\@/%%I2/J\=6GL*!J30
MT-91RQJQ4:Y,+PKA?:A)S>%&E*NRMZMR]P$$:8U%66/5\^G;CB+K&=90U':D
MC4Y*BY^V:O=Z"==*.ECM-/%55+:NI:S$D[6(Q'KZ>%.PA3=:T121LN+6R>,6
MYWC<3H?=^;VHGIRF>1?VW5\9?+325<,R20S,1[51>U% D5[T1CN\M/4%*^H1
M5Q@NN-K>!.\I=\D8V%WQ 4C3DR91BKS["[F^Y0C.U71D%Q<WC^V)%HJID\35
M1V5P!Z"D7R-%A>JIDJCIFM[5*'?KA&R%WG)V 6?!"BW!G#R57DC4D*)&U53"
MX(UL-2E3>LKS:U21(:]O$J)S0#T35'BZ<RFU5R1[,)S4XNDSYFJC$/!;Z5RS
M)Q\P.5H7567.3M/!=+4D,:JB%Y0T[6L1,'@N%.QR*K_D H.G&]4WA=R7)<\%
M*QS<X+2?6-IZCDN$R5NANR/8F% ]%?;F/Y)V'QH[2U6N\W![8IDD5.(]K<)V
M 4ZW4386N:J'PJ+/PS]?"O"[O3TE85OH[3S<4K7+A,H!\Z=TO"B.4],CVPPR
M/[<)GM/))'(]<HG"?"J<YE)*QW/B3 %%@2-K7RHU&HY>34[D/FRTNN"JY4\T
MIM/6\50RF<N%1<*7W;86MITP@%I3Z62/FQN%+7U#IR*:%[7,Y_$2\Z-KDYH6
MEJBE:V)Z@8O:BMK['=%6+*)G*8+KT!=/'ID>]?.SA3MJJB2NN"(C<]7E5+4L
M%3)8;JY%Y1.=E% RAT\K'1IS+HB8S@])$VE]4,?"Q4>7G3:B:]G)P%0NR1L8
MY2SJ^DGK&O<F6QHF2X)9O&FN?(Y&QM3B<YRX1$]9'^L-S*6*GDH+0B3R*G"Z
MI7W"?P?3\?9\9;Q\:[D5;M$:J.1EV<:C6Y5I^\K0N6G_ *,+EXG-Q/H4=Y[$
M541^%[%]1)UAT/!3PM:R)J-:F$1$Y%I[55D]SO4L$D4;HVLXW28PN<HB)Z/_
M .A.5)2LAC3"&-_'KQ[DT5\V>+D49-J+EOEXK*K-*-C;Q-9A4/9:.LBAZMW/
M'(NB1T-5&_JWLDX55KN%R+A4[47UEO.1*:M=Z%4KZ+,3O<E3\GI-#S0HUXLZ
M20]6QF/2I<M%,UT?:AUKG1]6N50ADQTW6H64%5IWCX60^4F\2N[,\*\*>W!(
M.GKQ24--'&DC>-$Y\RR=^\W*CMMMIG*E357")L:M7"IA>)5]B'GM6F+CPHDD
MJI\2 2K5:NACB7$J+R])$NJKQ5Z]OK[#;)G04\;>.X5K/^AC7L8U??N_,G,^
M^K:>JTYI>LK5XI'QMQ&UN55[U7#4^550MJS5+K+IMEMI\I+,O75M2ONYI5[?
MB1.SXD+N+B7,FO=IY=L]SG9F=:PZ-ZN>/9';*9>A77Z1T%O#=V544= MQIF6
MZVU3\8XT=Q.XGKS17JJ(B]ZM]:$_],FZ6^Z;2S4T-9!-/35L$Z1QR(YR<U9V
M)V>[,$T<O:G)3(?0DM3KK0[Z/4%)(^G56QMJ'.5JU#6JBH[MSE%1.??[3TU.
MR[=BY3735/#U>"S-OWIM54U4Q,5</A'\L>>0PKNXR:@VLTK3>YM$;E_]I(]_
M\[E*M1Z,L\*IXO9*-'>EE*U7>W&3LS>ICB\I3E[\Z44S,L4HXY'JC6,5SE[$
M:F5*A2Z8O-;^T6JLF_R<#W?S(9DV705SKDX:.@;#'Z5X6)[/_L%X4>R%TGB5
MTU;!$[&4:QKG^U>14JVA9M\ZH_?]G1M8V?>XV[$_KP_=CS8]"4FH=$V>&\44
MU'<Z-BI#51JL-72N:Y4:YCTYM7L7T+WHHWDU5JEVV%/8;M6Q76G;4LS7MBX:
MBHX4<K72HGFHJ(F%5O)R\\-[%EO46B;OIE[O'*95ASRGB\YB_+W?+@H1HHMV
M+U<7:8B9B==84>L-H8._8NZQ3/.)_C5AYYOQ'7D9;5=AMUPFZVHHH)9?A'1H
MKOE7O^4JMFL&CY')'<]-6F;_ -JZBCRO=S5$R6KN57:XQ1K'A/\ "[A7,;*G
M<JKW:O'EYL-.T8,\9ME-KKI2)(_2U*F4RCJ>>6-/]AZ$::EZ/FD^L<MNM]5#
M'^]JG+_2R49VQ9Y54S#TU.PLB8WJ*HF/BNO:2X-L&A]-QJN.*BBD_";Q?[SK
MTI=8+-L^V".16NGN$#45JX7DCW\OP2G06^9*&GHXE6'Q2%L4;7=O"U$1,^GD
MAY[MH";=^U0:=FNR6B:GG\9:]\'6I(J-<U$]TW'NNWF>9LW*/:HN5SI&NKU]
M^S<]CFW;C6K31C)0:XU':\>)7^Z4F.SJ*R1F.>>YWI*S#O+KB-BHNK+M,G_Y
M15.F_IJI-TG0&U-41J^@U-:9NW"5$<L6?1V(XH5PZ"NY=%Q=4ZS5V/N>M<F>
M7[]C3UT9.#<YS'ZO#>R;0M<HJCX2CFFWVUO3NSY7;*GHDI85_/P9/-J/=S4N
MJ+?+1U=3'%'(J=8ZE8L;W-SS9Q(O)%[%5,+SY*A<&J.B]N7I"UU=SN6G49;J
M5BR2U,5;3R-:U$RJX1_%A.?<27T<^@QJ/=VY,EU0ZY:/LSJ>.KIIG6V21:Z)
MZ<2=7+RC9R5%\Y57GR:O/&%SV#=FN8C3PT_AG:ZRWXHB:HF>_7^67O@\MX++
MK_;*OT[;=/6O2<^G9VL6W6E'I&^&1N6S+QN<YSW/;(CE557DG/F9993F1)L9
MT8M"[ 0SNTM03I<:F)(:FY5E0Z6>=J*BX7L8U,HG)K6]A+?#VGB[]5NJ[,VH
MTI>_Q:;M-FF+TZU=KN@ -"V
M
M
M
M #2MX:W[*72W\C*7].KR5? 6_P"&W_4G_'D5>&M^RETM_(RE_3J\E7P%O^&W
M_4G_ !X&U0          >.MK*>WTL]553QTU/"Q7R33/1C&-1,JYRKR1$3O4
MU9^$*\)?;[[8KEMAL[<_*$59&^GO6J*3*QK#A4?!2N^V1R91TJ<N'*-5<\29
MT]+?H]5'2>V:J] 07U-.LK*ZEGGKG0+/PQQ2<;D1B.;Q*N$QE43/,QKW]Z'&
MVW19Z"NZ\.DK6^IO51;(65E^N"I+6U']DPY3BPB,9E,\#$1/3E>8%?\  Y?8
MB2_RCK?Z$)FU4U<-#2S5-1(V&"%BR22/7#6M1,JJKZ$0PE\#E]B)+_*.M_H0
MDX=-K4TNDNB=NS<Z>9]/-]#]32LE;GB:Z9JPHJ*G-%^N<E[NWEV@:X+G==S?
M"O;_ .H;!8]22Z6VCL+N-C7->ZGBI^-6PRR0(K>NJ)58KT:]41B(Y$<G#YUV
M;Q>".U#M%I:76VS^O[M<-46*-U8E&YGBE7)PIESJ6>)R*V1$XL-5,N[$<B\E
MF#P+^DX;9T;=47Q(X_'+MJ26-96)YRPPT\*,:Y<=SWS*B<T\[UJ;!P,//!K=
M+FOZ3NTU=1ZGG9-K?2\L=+<)F)P^.0O:O45*HG)'.X)&N1.7$SBY<:(F89J-
M\'8]-OO".[QZ,H/K=G5][M[*>-,,3Q:X-ZI<9Y<+6O1.WW2_&FQ7I,?LQ?0+
M0?L)^0_HK\HQ^->7_P!H\3ZJ7CX?W_6=3CU<0$ND&[ =%G3VPFJ-?:FIKE4:
M@U%K&ZR7.MNEPBC2>-'N<_J6.:F>#B<Y<=_+T(1YL7].)^RG9/V5/H'^@3Z_
MY2\C_P!M?M$G5<'_ ,]ZK/JR<]*KID7+0NL(-H=H;([7&]%TB3AI(6H^FLS'
M(BMFJERB(O"Y'HURHC6X>]4:K4>$2].BGM.J>FYT9K)I2*)=RZ>\,K+C4T>$
MFBML<T<J),Y.:M1D=4]&KV-X^Y_/8<8R=$3HA?L%I=-::VNKM:[Q:D^N7O4<
M[EDZM'85::G5R(J1IPM15PG%PMY-:UK6Y-@  !86ZVF[)JC3U/27[4%3IRDC
MJFRLJJ:M92N>]&/1&*]Z*BHJ.<N.WS47N(N_8<VW_P :MW_[0TW_ )"5-TMG
M-([TV&"R:SM*WBUT]6VMBA\:F@X9FL>Q'<43VN7S9'IA5QS[.2$8?4_MA/O%
M7\L5WSYNMQ:T^_,Q/A$?.%6NJ_$_Z<1,>,S'\2Q\_8YT=].?Y)^CBX>1_H5\
M8\K^5H>MZ[K\=7UW#PXQSX<9)]39[;C_ !JWC_M#3?\ D/M]3]V%^\5?RO7?
M/CZG[L+]XJ_E>N^?+5RNQ<W>,\(TY1\U*S;RK6]PB=9F><]OZ)-VGTY9=,:=
MJ:2PW^JU'2253I7U556LJG,>K&(K$>Q$1$1&M7';YRKWE\\62R=K-G-);+V&
M>R:-M*V>UU%6ZMEA\9FGXIG,8Q7<4KW.3S8V)A%QR[.:EZKGGS*$Z:\.3J4[
MV[&]''P?0 $,P       'PDE93QO>]S61M17.<Y<(B)VJJFM3I_>$SMENL=U
MVWV:NR7>^5<4E/<]46UZNAHH5:O&RED:OGR\.<RM7A8G-JJ[FS-7I2[+UG2&
MV*U1MY07M-.SWOQ6-;DZ)TJ0QQU44LGF(YJNXF1N;C*(O%S7!C=JCH/;9]%7
MHC;O3Z?H9+OJF725QCJ=271&OJG-6!^61HB<,+%]ZQ,JB)Q*[&0+=\"5]CUK
M?^5+_P!$IS8@:[_ E?8]:W_E2_\ 1*<S'Z2&JI]$='S<W4%++U-9;=-W&JIW
M\^4S::18_P#:X0-8>YFN]Q_";=)F[[:Z"U$ZR[3697*^9JN\4?!$_@6LF:U4
MZ]\CU3JHU5$X>'DW$CBN;A>#XU15V.OTOMIJN:?5&V36U5O<^/Q2>Y/E;UCD
MCE:_ZS(BHO!E5155$5S?=%]>!&TE34VW&Y6I^!JUM;=J>VJ_M<D<$/6(B>A%
M6H7L[<)GL0S$VL^R!W8_^@OZM0((\&)TOKUT@-%7K1NN*E]1KG2G!QU<[>&:
MNI'*K6OD3OEC>W@>N$SQ,5<N5RF<1J-Z-RLVO\,!K;3MORRDOE;>*=S6-Y-;
M)"ZOX>WDB.B1$[>Q.7>FR;I!_LH?L;5/[$/DGZ-/&(>I\M?VMU7%]<SZ\=@$
MF&,/2?Z-.O\ I+:VMUBGW"DTGLNVWQ^5[1:$Q<+I5=;*KV.>K<-BZOJ<95R9
MXLL7DJ6SM#].E^R18?V0OH&^@SQC_P!*>3,>,]5PK[CUYX?SF8@&O?P5&G:#
M2&K.DA8;3$Z"V6O5J4-+$YZO5D,4E2QC5<JJJX:U$RO-3808%>#(_=1Z5/\
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MRUM_U!=)%5]7,R6G1O"Q57A:G&[&5<Y<\UPB(FV8P*Z<_P!FYT0OXYJ?ZZE
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M_P ZN/Z;,0_TS.BIMYT8N@%KFV:(LW55=1/:TK;S6N26NK%2MAPLDF$PF>?
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M7/>N?X
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MA^K9B #SCUP                      ' '(
M
M
M                                                   TK>&M^RET
MM_(RE_3J\E7P%O\ AM_U)_QY%7AK?LI=+?R,I?TZO)5\!;_AM_U)_P >!M4
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M70-=+5U%'-"Y[ZI'OA=ACD7#53JE[?29%
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M22K4UURK%1U16U"HB+(]41$1$1$1K43"(G>JJJR\
M
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M5O+M4T4T551,Q'".:S5=HIJBFJ=)GDF$ &+<
M
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M9;+;Z>U6BWPMIZ6BI8TCBAC:F&M:U.2(B%5
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M75;22)+!2WI\:437HN6N="QB<:IRY/<YJ][3-QJ(U,(F$.P
M                 (:Z5/1LM72GVP;HB\7>LLE(E?#7^-4+&.DXHVO1&X=R
MPO&OL+CV%VDHMB-I-.:"MU=47*BLD#H(JNJ:ULDB.D<_+D;RSEZIR]!(0 &)
M_21\&SM)TCM156I:V&OTKJ>I7BJ;G89&,2K<B*B.FB>US'.Y\W(C7+A,N4RP
M &!^UG@?=F]!ZBI[K?JZ^:W6F>DD=ON;XHJ)RHJ*BR,C8CG\T]RK^%4RCFJB
MF<]-31T<,<,4;8H8VHQD;&HUK6HF$1$3L1$/2
M       "+.DKL/;NDCM#=] 76Y55HH;C)!(^KHFM=*SJI6RHB([ES5B)\HZ-
M.P]NZ-VT-IT!:KE57>AMTD\C*NM:ULK^ME=*J*C>7)7JGR$I@ 8O])CP>6T_
M2:N[K_>:2LT]JN1&I->['(R*6I1K4:U)V.:YDF$1$XL(["(G%A$0R@ & VW7
M@;]GM)WV&XW^\:@UA%"Y'MMM7+'3TTF.Z1(VH]R>I'HGIR9TVJU4MFMM+;Z"
MEAHJ&DB;!3TU/&D<<4;41&L:U.36HB(B(G9@J
M
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M,ZJ/FG9Z24**N9)"GG(8F;?;B130QJDJ=B=Y+=LU]'U*9D3V@2G<[A'%3O\
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MCH@
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MUW4^.=;^T2OX<=;'[K&>+EG"X#8
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M-/&C&-RJJN&HF$RJJOR@>X
M
M
M
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M7517O1.G9I^[Z@ X;TH
M
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M6Z@IK30P4=)3QTM)3QMBA@A8C61L:B(UK6IR1$1$1$3T'M
M
M                &$72*\*3H_HZ[QZAV\NNC+Y=J^S^+]964<T+8I.NIXIT
MX4<N>22HG/O13-TT ^%'^SIW-_U9_P"%TH&QK8'PJNCM_P#=W3FW]LT5?+77
M7J22.*KJIX711\$3Y55R-7/9&J<O29R&&O10Z FT.@*+;?<^SVZYQZMCM5-<
M$GDN$CHNNGI$21>K7EA4D?R[LF9#E1J*JKA ,5>EQX0;1_1(U99=-WBQ7+45
MUN5$MP=%;I8V>+Q<:L8KN-?ME9)C'O/66!L=X670.]>ZVF]#1Z4O.GZB^5'B
MD%?7SPNA;,K7+&Q4:N<O<C6)CO>AK(Z3^X%PZ5?2^U!5661E:EZO<=CL36R*
MZ-\+7MIJ947GA),->N,\Y'=I1.D3M/=>B7TDKUIBW5]4E1IVO@KK1='M1LCH
MU1D]/*BXX5<W+4543'$QW),80/T>D>[\[MT6Q&TFI->W&AJ+E162!L\M)2N:
MV21'2-9AJNY9R]%Y^@]6RFYM#O-M/I/7-NX6TU]MT-:L37([J9'-3K(E7TL>
MCF+ZVJ1/X1G["O=7^+XOTF$"T.BEX1S2W2KW+J=%V725XL=7#;I;DM37S1.C
M5L;XV*W#5SE5D3V*9?FCOP05YH=/])N^W*YU<%OMU)I*NFJ*NIE;'%#&V:F5
MSWN<J(UJ(F55383=O"G='&T7R2V_1G4UK8I%C?6T=IJ9*=%1<*J.X,N3/VS4
M5%[454 R[,&]_?"JZ.V W=U)M_<]%7RZ5UEDCCEJZ6>%L4G'$R5%:CESV2(G
M/T&6FV>Z>DMXM+4^H]%:@HM1V:9>%*NBDXN!V$56/:N'1O1%3+'HCDRF4,=.
MD7X/39S<^Y:UW&OULNDVJ*NCDJY9H;E)''UD5.C6*C$Y(F(V\@+=Z.GA2=']
M(K>/3^WEJT9?+37WCQCJZRLFA=%'U-/+.O$C5SS2)4Y=ZH9NF@'P6_V=.V?^
ML_\ PNK-_P  ///,RECDEE>V.-C5<Y[EPC43FJJO<AZ#!_PL72 FVAZ/*Z7M
ME6ZGO^MI76YKHU1'LH6)Q53D_A(YD2^J953"H!=&PWA$M*](K?:NVWT;I:\5
M<%(E5._4$DL3:5::%W#XPC<\?"][HVM3&?KC<HG/&7!KL\#-LY'I?974&XE7
M3M;7ZJKUI:25>:I1TRJSEZ.*99D7';U;?1RS,W.Z0>W&S%;0TFN=8VO2]371
MNEIH[A+P+*QJX<K>7-$54 D<$3WWI2;4::VPH]Q+EKJTP:.K72,H[FV57I5O
MC<YCV0L:BOE<CF/3A8U5\U>1$NE/"C='35E[;:V:VDM,LKN".INUOGIZ=R^N
M56\+$];U:GK RR,"MW_"WZ)V@W/U3HFOT+?JZKL-?+02U-// D<KF.PKFHJY
MPOK,Z:.I@KZ6&HII8ZBFF8V2*:-R.8]JIE'-5.2HJ+E%0_.ITX?LNMWOY1U?
M]-0-QG1$\('I'I<ZKOFG;-8;EIZYVNA;<$CN$L;^OBZQ(WJW@7[5SX\Y]^AE
M6:$>@1J2MZ/O3JTS9[M,E,VJK9M-5O<V5)VJR%45>Y9D@<GJP;HNDAN4FT.P
MVO=8MD:RHM-GJ)Z;C=PHM0K%; W/=F1S$^4##_6/AE]O=*ZMO=ECT/?[G';J
MZ>C;74]3 D=0D<CF)(U%7/"[ARF>Y2>.AUTW-/=,/Z+O(6G+E8?H=\3Z[RA)
M&_K?&.OX>'@5<8ZAV<^^0T"4VFZJJTG<=0,X?$:&MI:"7T]9/'4/9^:FD_,;
M._ 6_P"&W_4G_'@9/7[PBND=&=)YVRVJ=-W6P7!:]E!'>ZB2-U&Y96(ZGD7"
M\2,DXV)G'FJ[GR153+8U3>&LV89%+H?=2B@PZ7BT]<Y$SA51'S4JX]./&45?
M4Q.Y#+[P>O2%EZ171KL5VN52ZHU)9GK9KQ))[J2>)K5;*O),]9$^-ZJG+B5Z
M=R@9-@
M
M
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M$QW'"<EYG..TYUV]7>KW[DZRZMC'MX]$46XTAV!PAR:E@
M
M
M
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MN;'I2L>]?0GC%*F?:J)\H&[<
M
M
M                                          (1Z672/H.C7M?/?70I
M<=0U\GB5DMBNQXS5*BJBN]$;$\YR^A,=JH!0NG9== 2='K56G=<:HH]..NE*
M[R:Z9W%.^JC5)(NKB1%<_P ]K47"+R533U8;3J'7U+0TURB=06J-S7K2?;U#
MT['/]#47FC?:28^"_;G:KJM7ZTN4M_U-6KQ2U4WN8V]T<3>R.-.Q&I\O,ONT
M:?CH>%R,Y@>2W:?ALMA2%K<>;S+)HVHS44BL3"JF"2[JR:HA<QB83!8Z6Y:&
MY)([M<O:!)U@DS2QIZN95BA6"H;U3>97.),9R!YZR7A9P^D\:S14\?+FI\KU
M6-A8JHI:272:MJ%CA<J>EP'NO%1'(UW$N"*]:VB@NE//%*WB21JM7UY)6BL/
M71YD59%]91KUI=CHW?6_S 8L6RCDH:B6T3JL=53_ +4YW_2Q9\UR?S*7/HS6
ME3IFO;0W9OB[W*O4S?\ 1RIGEA>Y?47EKC;^.Z4+7.:Z.:%>**>/D^-WJ7_<
M17)<)J?_ -&W^GCJJ5SN!M5P^;GNXD^U7U@9*Z>UM3R\".G:U,9RJ\B1=,W6
MGO5O;54TG6PNRC7X5.+'>GJ,/J#25THY&I;+M/31.YLBJ&I+'\65YX+WT=N;
MJ7;F[4E)?Z1%M\S^K2:++HI%7DF%^T=ZE[0,@KY3-9(UR)WY/O:'-5W+D>#4
M%R;/0QU,2HZ/A1>7;S*127YD?#(UWF]_,"_SSU50V.-W,MOZ+(NJ]VGM*+5:
MF=62+'$O%ZP*K(U*RK5>U$/5;J5KJIW<B'CM7%U:JJ<U*O1T\B.<J)CU@>#4
M'#3^>WDK3Q55S=-1L5G-RH?:^1OJ)',53K:*%%PUR=@%-AH7/;UDB^<J]A=-
MCC:UJ)@\U;0JU$5J81#K;JM8787D@%T'FKFHL*Y/G%<6.;VG@N=T:V-?. CO
M<!R4\+Y6\G-YY/KH>J9XG"YSD153*JJEG;O:L;;[8Y&(LU1,Y(H86]LCU7DA
MYM,V>^5%+ L\R0OX458XNQJX[,@3]254+VXZUN<=F3YU4C8U54<BD:45'=*9
MV%G=GTJ?=*JYT:JCWNF9V\^T"2J.L3J\(I]4N"L=A4Y$>0:BDB;E<HIZ&ZO:
M[#7.3($C03I(U5R=*N9K(EYEGT6J&<'N_P YY[IJV..%WUS\X%C[Y5S&Z1NC
M<\WQK&U/2JKA$_.2=I&X,I[51TZHC%BA8SA]&&HF"%H(W;KZYI[=$[BLUKE2
MIN$WVKGISCA3TKGFOJ0E"NI9;4[B5JN9[YH%[37!G5KPKE2TK]B2-[GKR/"S
M5U+%&[BD3B3TE%J]1I=JA(XEXDSW ?2BMJUU=$QB<\Y^0OY]GZNG:W')$//H
MZTLIX>ND3,J_F+BJ9&0PN<_L1 +/GZNESQ<D*)=+Q30Q.\Y$+>W4W)H=,-:V
M7CFK*AW#!1P)Q22+ZD_WD924>J]8.5MP5=/4,G_0L7BJ'IZ%7L;_ #@5>\:Z
MKKM=)*#3U)Y0GB7$LJNX88?X3O3ZDYE/N,>OF-6;RG19QR@9 [A3Y<Y+]T%;
M:.PT:6YE.V"-O8C4]TOI5>]?67DEGI*AN<(!CW#K36-I<OCUK\:C;_TE*[G^
M"I7:+<._7).JI-/72:943"=5PIS]:KA"5;A8:2//FM^,H[KU16.9TCY&L:G)
MK<@4W3^U%ZU?415FL)8J6W,<CVV>G?QK*J=G6O[,?O4[?23#36^GCA2)K6L8
MU,-:U,(B>@C^BW7ML;4:]5SGFJ%>H-=VBY,S#4HU_O57 'LO-AH:R-]-6TL-
M91R\GPS,1S5^12V8>CIHNJD62G;<;:B]L5)6O:SY$[BM5EZ21$3BSGFBEQZ?
ME=+&BJH$=73HOVF9O':]17BWU")R665)V+\:.3^93Y:.V,U/I[4MNJZK45#7
M4%-.V5[&TSV2/1O/'NE1.9-IRQ<97U%G%IW[U,>,.5M2[T.%<J\)]8TAC=NQ
M<?']=W)47+(7-@;ZN%J(OY\G?9ZW>5-Q;+$J9;'*LR_Z**J?GP474=)<4N=7
M5U]%44DE1,^5>OB<SFYRKWIZR6>B7I)]^UG75^/K=%"UF53[9[N7YF*>[S*^
MBQJI\-/-\YV5:BY?MTQV3'HS3T9120Q1\NXD2E?];1J\E*?IZVMI:-BKVX*I
MU+<Y/G;ZVXF=B)ZIZ#R4,SG.5.X]J-1&X[CQTG##4RL7DO<!]:Z/K(512)-P
M(70PS*SD3#,Y&QJJ]F"+]?\ #41OCC3B<[DB(!C]8I%DU!,LW<[DJDH4L+::
M%9X\><G,IB;>OIX4J>%6O5.+L[3RSW*JM=,]LC%5C4 J>G-40)?EI^/A<]>'
MA/IJK6OD.2;Z[YKNSGR0@K6VIFT=2VYT#U;+ _B>SLRG>61NINX^Y6Z"EH'J
M^IJ<,9CNSW@5G=;>&JO%5Y+LRK4UDRX\WFC$]*EO;/;7K1WJ6NN$CJZZS+F:
MHDY]_)K?0B>@N3:S;5M%;4JI6]=62-XGR.3FJDPZ)TGXI"^58\.XLYQV@2'H
M33,<<4?F=R=Q)])9X884RU"VM'<,<+47DJ%R72Y)2PH[/F]X'FKG1T:\;53"
M=I1Z[545%B1LN$[T+/UQK;Q='I3JWA:F7.5QBIJSI,UEVNDMHTG;IKU7\;HE
MD<BLIXW(N%5SE]'J S)K]>4E33.7K41<>DBC5>J)KE,M/33Y1>UV>2(0?8MI
M=9ZU_LC4>J[@B2<_$[4[Q:%F>Y%3SE^52Z6=$^@DA3BN%\QVN1+G-YWJ7SNP
M"S]SMT+;I=ODJAJ$KKQ4.X$IZ=>LERO>J)V)ZU/IH+;Z\7Y()ZQSDC:N6L;[
MG_[*DL:"Z,VEM/5"/I;;&R;.5<_+E=_"5>:_*3O9-N(J5C%7APB8:QK41$ C
M'3&D+A;*=$B<Y,(7*ETOUGCSXI)41][H^:I\A+%!IF.-J)PHAZ9=*Q3-5.+@
M^(#'+4VY%R6-\;*"I=)[WA5"%M:;<:AW-:Z.ZI+16MR\;H8UPZ1$7/"Y?0O>
M9SQ[=6U9G2S,ZU>Y%0H.LK324],YL<3&(U,)A -<.MM(NT360/B;U;(\(F$Q
MR]!-6F)GR:5HJUZ?6IFIYQ;?2.CCBI)53&<\BY-$2/J-LK=3/3+XXVHB@5>Z
M66.G;1U343W2<_4I=\U*MGCHK@QJHYN%RG:4>L;UMMI:=_:F%4N"_7%)=-M1
M<<4;,90#(;0%\2XV>'CF21^.1='6MXE3)CMMMK!E)9XEZS,B(BJGH)"K]<10
MM;(V1,X](%XWQ52%ZM?CD6));WUU1[M7+D\%1KE;BO51<3E=R+PTE;TDC21Z
M*KU]('ML%ODI$;GL+E;V*=8XT8W"())FPMRY<(!V<Y&M55[$*747AD>4R4?4
M.LHZ',,:<<CDPC4+9AK*JIF1\C%1KN8%QW*5:Z-R]J'ULMK<UK9FM[.U#UVV
MU=="QRKYN,X*W3T[:=O"WL YA:G"BXPI]#X5%0E.W)X$N76/>_.&IR0#UUE8
ME/WX/"^_1M8N51"A:@O:-C?A_/!B]TAM[-1Z6CAMME8VFCJFJC[DB\3F+WL:
MGVJXY\2Y[>7-,EC'L5WZXHHYRJ9631BVYKKY0OGI'[VV+35M?;I)TK+NKFOC
MH879<GK>OVB87OYKW(I@]>[O+?[M65LK6LDJ)%D<UF<)GN0\E352U51+/42O
MGGD<KGR2.5SG.7M557M4NG;':O4V[FHZ>QZ8MLEPK)785R<HXF][GN[&HA[O
M%L48-K=FKQF7S',O3G9/2Q3I,Z1'\,A?!DT'CG2.J)<9\5L53-\69(6?_5FU
MLQYZ*G1'L71SMLE8Z7ROK&MAZFLNG-K&1JK7+!$W/)G$QJY7SG*F5PF$3(?O
MY<CQNT,BG(OS73RY/H&RL:O&QHHKX3/%W !SG9#C!R
M                                    "VUV[TM(]SWZ<M#WJN5<Z@B5
M57T^Y*^QB1M1K4X6HF$1#O\ *$R3-4SS84TTT\H=@ 0S   .,'(      .,8
M*-=M*V:^O9+<K30W&2-O"Q]73,E5J=N$5R+A"LHN1W#68Y,9B*N$J9:;!;;#
M#)#;:"EMT;W<;HZ6%L37.QC*HU$RN$*FG8&]@51SYIB-(TAR  D
M
M
M
M                        #0#X4?[.G<W_ %9_X72F_P"- /A1_LZ=S?\
M5G_A=*!NWV8N5-:>C]H6X5DS:>CI=+T$\TS^36,;2,<YR^I$15/S\;HZQO/2
MGZ2-YO-+$^2Z:ROS8+=3SX1S&RR-AI87<.?<LZIF4S[GO-H_1!\)+H_=:[;=
M;,QZ+NT5?4VV.T/K*J2%],Y8*-5>JMSE6N2)R8QWIDSDI- :7H:B.II=.6FF
MJ(G(^.:&AB8]CD[%14;E% MO06Q.BM!Z,L&FZ735JJ*>T4,%#'//0Q/DD2.-
MK.-SE:JJY>'*JJY554N/]C32'WJV3\G0_P#E+D 'YV>G3LXW8GI2ZXL%%3K1
M6F:K\K6IL:(UK:>H^NM:S'8V-ROC3_)_*;,MVMY%WX\%'?-9R3-FN-58((+B
MK45,5D-3%%/R7FF7L<Y/4Y.WM,U[MHZPWZI2HN=DM]QJ$:C$FJZ6.5Z-155$
MRY%7&57EZSZP:5LU/;)K9%:*&*VRKQ24;*9B0O7ES5F,+V)W=R ?G.Z.>C=S
M[MJ6OU?M-'53:ET1%'>^KMR*^KZM)&QJL<2(O6IY^'Q\^)BN14<F4,E-T_"X
M;N:WVXK]'-L%GTE=ZN&2AN-VH$G94-:J*R1(6/<O4/QE.++E;SQPKA4W-V;2
M5DL$TDUKL]!;9I&\#I*.E9$YS<YPJM1,ID[56E;+6W)MPJ;10U%>S'#52TK'
M2MQV8>J93V@:D?!;]!S4EWW%M&\&M+346;3=E5:FS4M="K)+E4JU49*C')E(
MH\\:/Y<3D9PY1'&V'<O]SO57\557]2\N4P)Z5'A/-);0ZUUWM97:-O5?<Z*F
M=1.KJ>>%(7.FIFO:Y$5>+")*F?B4#7OX+?[.G;/_ %G_ .%U9O\ C0#X+?[.
MG;/_ %G_ .%U9O\ @!I<\,WMW-8.D+I_5K86LH-161L?6<\OJ:9ZLD1>7=')
M3]_?\6=T9B9X2OH]5&_W1IN:VBE6JU/IF7RU;XF9XYFL:Y)X4PBJJNB5RHU.
MU[&(!(G0IUK%K_HH[6WB.9*A_D&FHYI$QSFIV^+RYQW\<3LFO;PX?[HNUW\5
M5G]<PE+P+V]<5\VVU3M?63HM?8JKRM0,<Y,NI)U1LC6IGL9*F5_SAIL/N^E+
M+?GLDN=GH+E)&F&.K*9DJM3T(KD7 &(_@C/L,K'_ !K</ZXA7PXO]Y6U'\85
M_P#5PFRFUV:AL=*E+;J*GH*9%5R0TL38V(J]J\+41#XW?3=JOZ,;=;71W-L>
M5C2LIV2HQ5[<<2+CL0# 7P)7V/6M_P"5+_T2G-;'3A^RZW>_E'5_TU/T1V>P
M6S3\,L-KM]+;87NXW1T<#8FN=C&51J)E<(AX*K0&EZZHEJ:K3EIJ:B5RODFF
MH8GO>Y>U556Y50,=_"';8NUOT(]:V_@26OL5%!=X7HF4:M*YKY53XX4F3/[[
MY#2CT8]NOV6.D#M[I)\"U-+=+U2Q5<>,YIDD1\ZX[\1-D7Y#])U720U=/-3U
M$3)Z>9JLDAD:CFO:J85JHO)45.6%*30Z$TW;*R.KH=/6NCJHURR>GHXF/;RQ
MR<C<IR50,*O#-4$E;T4[+,QS6-I-64D\G$JY5JTM9'A.7;F1/D12(? 6_P"&
MW_4G_'FT.[62WWVF\6N5#3W"FRC^IJH6RLXD[%PY%3/-3XV;35HT\D_DJU45
MLZ['6>)T[(N/&<<7"B9QE>WTJ!C!X476[=&=#/6L39^JJ;W+2VF#+L<2OG:^
M1J>G,4<O+_<8M^!"VXE6KW,U[-#B%L=-8Z2;WSE59IV_(B4R_P"D>/PSN[[]
M1:NT)M'9VR5E11_^F*ZG@17N?439BI8D:G/C1O6KC&529F#//H8; -Z.'1XT
MOHZ:.-+UU2U]XDCQY];-ATB93W2,3AB1>]L30)S
M
M
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MN[.]7Z1\'< '*>C                              '!R
M                                        '!R
M
M
M
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M$OFIU:(S@]ZK&*G-$4R#
M
M
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MM1J-3"(B81$]!W1,\N\\+DY-S)JUJY=SZ1LW9=G9UO2CC5/.9YR^@ *CM@
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M?%UW%P\2KC.$SCT(7?9*N@Z?7A]='G^N+?M_5^[.]W]G+5DR#A 4GH'(
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M.%G%R;>7:B[;_#/+].#Z X0Y-:V
M
M
M
M
M
M
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M)4][!_7QE>[CTV,JF*.4S'[NCA;2KVCLJ]7<_%3$Q/CPYL5.C1^[9IG^%/\
MH\AF?N+N);-MM-37>ZO7"+P0P,5.LF>O8UJ?SKW(BJ8-[):DHM);F6B\W*;J
M**C2>25^,K^T2(B(G>JJJ(B>E4.VYNY%XWBU@V9[)%C5_B]NML?G=6CE1$1$
M[WN7&5[UPG8B(=/*Q9R+\35^&(X^;R^RMKT[.V?531QN553I'Z1QED/:.E_0
M7ZY4]OH-*W.JK*AR1Q0QR,XE<O\ ]W;W$YW&Z+;;!4W"II^<%.Z:6!KD=[EB
MN5J+CGV8R15L!L1!MM;4N5TCCJ-1U3<N=R<E,U?M&KZ??.3M[$Y)SDW6[?\
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MX7\Q-FV6\6GMTZ-[K54.CK(4S-0U"(V:-.S.,JCD]:*J<TSA>1:%RZ)^@IK
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MNSI!PG-#DXKWX
M
M
M
M
M
M
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M4J)+25#NW,D#O-5?6F%/?1;I[ZZ7F2HK:;36K(VKY\/B\E!*]/4YJJU%^-,
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MZC5OY%-FJJJ*:8^"S3;V;=S*+5NJNY/#28F)B)_7L[V63/<(=@#SCZE   D
M
M
M
M
M
M
M
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M7[4.,X3M,Z[UR[^.K5JQ\#&Q9F;-$4S/='%]  :70
M                                                  $:;W[XZ=V"
MTC%J/4K*V2@GJV43&T$+9).L<Q[TRBN;RQ&[GGT$'_5.]HON74?XA'\Z>;PH
MOV/EI_E%3_H]2:LDQA3T6SMGV<JSOUZZZO'[3VI?Q+_1V]--(;5_JGNT7W)J
M/\0C^=.?JGNT7W+J/\0C^=-4H.IU-C^/FY'7N5X>3:U]4]VB^Y=1_B$?SH^J
M>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/Y
MTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7
MN5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB
M^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J
M>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/Y
MTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7
MN5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB
M^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J
M>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/Y
MTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7
MN5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB
M^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J
M>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/Y
MTU2@=38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7
MN5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:U]4]VB
M^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@=38_CYG7N5X>3:RGA/-HON34?XA'\Z<_
M5/-HON74?XA'\Z:I0.I\?Q\V5.W<KP\F[37G25TEMYM)8MQKFRXNL%Z92R4K
M:>!KIT2HB66/B:KT1/-3GS7"^DB/ZIYM%]R:D_$(_G2.^E9_[WGM2O\ ^36/
M]!<:[<>8IS\'9MG(HFJO7A,PZ6?M;(QZZ::--)B)Y=[:O]4\VB^Y=1_B$?SI
MS]4]VB^Y=1_B$?SIJE!T.IL?Q\W+Z]RO#R;6OJGNT7W+J/\ $(_G1]4]VB^Y
M=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_ !"/YT?5/=HON74?XA'\Z:I0
M.IL?Q\SKW*\/)M:^J>[1?<NH_P 0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z]RO
M#R;6OJGNT7W+J/\ $(_G1]4]VB^Y=1_B$?SIJE!/4V/X^9U[E>'DVM?5/=HO
MN74?XA'\Z/JGNT7W+J/\0C^=-4H'4V/X^9U[E>'DVM?5/=HON74?XA'\Z/JG
MNT7W+J/\0C^=-4H(ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?S
MIJE!/4V/X^9U[E>'DVM?5/=HON74?XA'\Z/JGNT7W+J/\0C^=-4H(ZFQ_'S.
MO<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M
M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]
M4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?
MSIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.
MO<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZGQ_'S.O<KP\FUKZI[M
M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]
M4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?
MSIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$?SIJE!/4V/X^9
MU[E>'DVM?5/=HON74?XA'\Z/JGNT7W+J/\0C^=-4H(ZFQ_'S.O<KP\FUKZI[
MM%]RZC_$(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1
M]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_$(_G1]4]VB^Y=1_B$
M?SIJE ZFQ_'S3U[E>'DW![5=.O;G>'7MJTA8H+TRZ7'K>H=64;(XOK<3Y7<2
MI(JIYL;N[MP?;=OIR;>;+:XK-):@@O,ESI&1R2/HZ5DD6)&(]N'+(B]CD[C7
MQT ^72TT'W\Z[] J"H^$.Y]*G4W=_8U'^C1E#JVU[7T''3=U_771TXVK?]CF
M_P -[>TY=FFK,?ZI[M%]RZC_ !"/YT?5/=HON74?XA'\Z:I07^IL?Q\W+Z]R
MO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_.FJ4$]38_CYG7N5X>3:U]4]VB^
MY=1_B$?SH^J>[1?<NH_Q"/YTU2@CJ;'\?,Z]RO#R;6OJGNT7W+J/\0C^='U3
MW:+[EU'^(1_.FJ4#J;'\?-/7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/Y
MTU2@=38_CYHZ]RO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z
M]RO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z]RO#R;6OJGNT
M7W+J/\0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z]RO#R;6OJGNT7W+J/\0C^='U
M3W:+[EU'^(1_.FJ4#J;'\?,Z]RO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_
M.FJ4#J;'\?,Z]RO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z
M]RO#R;6OJGNT7W+J/\0C^='U3W:+[EU'^(1_.FJ4#J;'\?-/7N5X>3:U]4]V
MB^Y=1_B$?SH^J>[1?<NH_P 0C^=-4H'4V/X^:.O<KP\FUKZI[M%]RZC_ !"/
MYT?5/=HON74?XA'\Z:I0.IL?Q\SKW*\/)M:^J>[1?<NH_P 0C^='U3W:+[EU
M'^(1_.FJ4#J;'\?,Z]RO#R;6OJGNT7W+J/\ $(_G1]4]VB^Y=1_B$?SIJE Z
MFQ_'S.O<KP\FUKZI[M%]RZC_ !"/YT?5/=HON74?XA'\Z:I0.IL?Q\SKW*\/
M)M:^J>[1?<NH_P 0C^='U3W:+[EU'^(1_.FJ4#J;'\?,Z]RO#R;6OJGNT7W+
MJ/\ $(_G1]4]VB^Y=1_B$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_ !"/YT?5
M/=HON74?XA'\Z:I0.IL?Q\SKW*\/)M:^J>[1?<NH_P 0C^='U3W:+[EU'^(1
M_.FJ4$]38_CYG7N5X>3:U]4]VB^Y=1_B$?SH^J>[1?<NH_Q"/YTU2@CJ;'\?
M,Z]RO#R;6OJGNT7W+J/\0C^='U3S:+[EU'^(1_.FJ4#J;'\?-/7N5X>3:Q]4
M[VB^Y-2?B$?SI+FV'24TENSMMJ#7=ECN+;+97SQU3:J!K)E6&%DS^%J/5%\U
MZ8YISR:3,8P;$^@Y]A'NXN/_ (5=?_#8#GYNS;./:BNG776(=+9^ULC(N317
MIII,\NY(OU3S:+[EU'^(1_.A/">;1?<NH_Q"/YTU3 OQL?'F.WS<Z=NY6O9Y
M-K7U3W:+[EU'^(1_.CZI[M%]RZC_ !"/YTU2@GJ;'\?-CU[E>'DVM?5/=HON
M74?XA'\Z/JGNT7W+J/\ $(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI
M[M%]RZC_ !"/YTU2@GJ;'\?,Z]RO#R;6OJGNT7W+J/\ $(_G1]4]VB^Y=1_B
M$?SIJE ZFQ_'S.O<KP\FUKZI[M%]RZC_ !"/YT?5/=HON74?XA'\Z:I01U-C
M^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7
MU3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1
M_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC
M_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C
M^/FGKW*\/)M:^J>[1?<NH_Q"/YT?5/=HON74?XA'\Z:I0.IL?Q\T=>Y7AY-K
M7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(
M1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZ
MC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-
MC^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K
M7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(
M1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZ
MC_$(_G35*!U-C^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-
MC^/F=>Y7AY-K7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/F=>Y7AY-K
M7U3W:+[EU'^(1_.CZI[M%]RZC_$(_G35*!U-C^/FGKW*\/)M:^J>[1?<NH_Q
M"/YT?5/-HON74?XA'\Z:I40$3L?'B->/FFG;N5-6G#R?H18N6Y.6]AUB_:V_
M$=F]AXI]#IXPY  9
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MC!R              #C!R
M                                          !AYX47['RT_P H:?\
M1ZDU7FU#PHOV/EI_E#3_ */4FJ\]OL7_ (_ZOG.W?^5^D  .\\T
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MJN)T%732NAFB?VL>U51S5]:*BH::+M-R9IB>,-]5JNB(JJB8B7E !N:
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M>Z\V:NTY>:VTW.FDH[A13OIJBGD3SHI&*K7-7UHJ*AX39$Z\8:YB:9TD !+
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MK70\7"M8Z+K(&KRPBR,56IG/+*\R/N9LHNTW(UIG6&%=JNU.[7&D^+@ &QH
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M8
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MU-N-M].;3:/H-+Z5M4-GLM$WABIX$[57FY[E[7.5>:N7FI=8
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M  >3>X
M
M
M    !AYX47['RT_RAI_T>I-5YM0\*+]CY:?Y0T_Z/4FJ\]OL7_C_ *OG.W?^
M5^D  .\\T
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M.:S^O>;@.B#J*Z:MZ.VC[S>Z^HN=SK89Y:BJJGJZ21RU,O-5_,B=B(B(G(U
M;K>;NAK)?_EFL_KWE/8]-5-Z[%4ZS'SET-M335CVJJ(TB>4>2U@ >K>+
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M(9@
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ML
M
M                                                           !
MAYX47['RT_RAI_T>I-5YM0\*+]CY:?Y0T_Z/4FJ\]OL7_C_J^<[=_P"5^D
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MX3L.2&8
M                                                ^4R*Z&1$[5:J
M)[#0;I;3U'J&UUMHN4'$U*F:*6)W)S')(Y%^)45#?N:A^FOLM7='G?>Y:DIJ
M9S="ZPJG5U-5-;];I*U_.:G<O8WB=E[?2CE3N QTLTE=H+4SK!=)72MQUE%5
M/_\ A$.>7/WS>Q2;-/7R-T+5XBS-26VV[AV&.FGF6FK(5ZVDK(_=PR8[?6B]
MZ=Y84>JKUH&9::_TCUB:N&7"E:LD$B=R\N;5]2@9,Q7B/@Y.*9=-0,B:Y>,A
M6FWGM<T:)'71N<J<FM7+O87[MQLYNYTA*F*+1FDZJ&UR+A]^O+'4E#&G>J.<
MG%)\3$4#BLUPU)'HZ9K4[$RIS1:N6I<B1UK?]QF)MIX*70]MHVU&XVH;OK2[
M.1%DAI)W4%%&[O1C8UXU3UN=\B%2UQX*?:VZT<SM'W;4&B[DB*L4D=<ZL@XL
M<N..9554^)R+ZP,*;E>*F.)7(J283TE,MU[BJ'>>N$5>>>X[[P;4:]Z,FI&V
M77M(C[;.Y6T&H:1'.HJU/0CE_:Y,=K'<_1E.9'53>XZ>IZZGE;+$_P!TW/8!
M+%TML=92QHQ$=E4+NL%CBAAC16YY<LD?Z-O#;A30HK^)$["6+54,="G,#E]I
MC]UCGC!86X%F966R>%Z9:]CF+\J8)(EJ&,8JY(\UY=(J>CF>]R(UK5<JY[D
MV,] G6$FL^BEH*HGE6:IH:5]KF>Y<JKJ>1T7/UX8AD&8T^#KTO4Z9Z)VD%JV
MJR2Z/J;LUCDPK63SOD8GX*HORF2P
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M#7P8])"W:_<&OADZU:[6%6][F.XF9;%"WS5[^SVF91QG>
M
M
M                                                 8>>%%^Q\M/\
MH:?]'J35>;4/"B_8^6G^4-/^CU)JO/;[%_X\_%\YV[_ROT@ !WGF@
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MM\DC6JUJHLB+P^;RPF$PB)W(6OJO>S56M-R:/7UTJX)=4TLU/.RKBI8XVK)
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M73S?9*/PP)V')PG8<D,P
M
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MN54"JVBTTEAM=);*"!M-0T<+(((8TPUC&HC6M3XD1"H
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MU+101TTDWPDB)F1_RO5R_*7R
M
M
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M '&>BC@
M
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M>[3ERHFZ5W @A69;8Z3CIZYC4\]],]>:JU.;HW><B+E%<B.5 S
M
M
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MW>Q!Y8K/AW>Q#Q #V^6*SX=WL0>6*SX=WL0\0 ]OEBL^'=[$'EBL^'=[$/$
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MN]B'B %]@ P9@
M
M
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MPX]#D5"Q3M2S/_=^[#JS:E'XK6OPF/FQKV"M[DOERJG-5.KIDBYIV*YR+_\
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MIT0]I9I7N>YNGZ:!%=V\,:=6U/B1&HA/
M
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MC=S54[4:K>\#<(     K]Q_N#3_$S^B4 K]Q_N#3_$S^B4 B  !(
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M(;Z(^[-UWAV1L]ZOT+X;[3O?05SG1K'ULD>,285/MFJQRXY95V/03(
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MMFHJF2OOFFYHZ=]=*O%)402-<L3I%[WHK)&JO>C6JN555 RE
M           !?8 ,&8
M
M
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MX6HB(B81$[@.X               !X[M_<RM_P B_P#HJ>P\=V_N96_Y%_\
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M=';*&%M/14<+*>"%O8R-C4:UJ>I$1$/<
M
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MI?T5.U^_NE+\3?YCK8_[J0?Z7]%3M?O[I2_$W^8CM3V*< "4
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MBY^E\:L3\[C'[P6%$^/9_5M6J.1DU]6-%[EX:>)5_IDI[&:8 "
M            *_9?[C57QN_HH4 K]E_N-5?&[^BA"84  $H
M       /G45$=)3RSRKPQ1,5[W8SA$3*@13TF]_;=T>]L:V_3]747BHS36JA
M<O[?4*G)53MX&)YSE]"(F<N0QXZ-&PEQL^T>O]W-<]96:VU39ZZHA=5)]<IZ
M>2%[E>OH?+R7U,1J)C+D(.J=]]#](7I-,U;NK?/(>WUCYVFSS4D]1XPUKO,8
M]L3'HG&J<<BKVHB,3*<TRQU]TZ-CKUH/4EMH=;=;5U=MJ:>"+R37-XGNB<UK
M<K B)E53M7 $6>"B_O?W'_SJA_H3&>AK&\'QTAMOMD;/K6#6M_\ (LMQGI7T
MK?$ZB?K$8V5'+]:C=C'$WMQVFS&VW""[6^EKJ63K:6IB;-%)A4XF.1%:N%YI
ME%3M"9>@@KIE[#5V_P!L[+9[.^-M^MU4RY4$<KD8V=[6/8Z)7+V<37NPJ\N)
M&Y5$RI.IA+X2K?6^:(L=AT+IZLFM\E]CEJ+A44[N&5U.U48V)JIS1'N5W%C&
M4;CL54"%L='/IS6O9C1\.V^Z-GN=LNVFU6ACJ:2%LR+&U5PR1O$BM<U,-16\
M2*B(O+OM/>[=*^=/[6MCT-MM8YZ>P6N1:N>NN;FQJCG(C%FD1%5&L8BNPU%<
MYV5Y=B&2>Q/01VYV_P!%T#-3Z?H]4ZFGB9)7U-R;UT<<BMYQQ,7S48U55,XR
MO:J]B)#_ $T^BA8]JM*MW5VQ;+I*XV6>%:NFM\SV,X'O2-LT7/+'H]S$5$5&
MJU57DJ+D,V] Z.I=!:%L&F*1[IJ2T4$- R21.<B1L1G$J>E<97XS[5*670UE
MN]U2EIK90P1R5U;)30(S*,8KGO<C4\Y>%OQ\B..B7O%5;W['V/4=RX?+#%?1
M7!S41&OGB7"O1$Y)Q-X78PF%<J)R)4O5GH]0V>OM5Q@;56^N@DI:F!^422)[
M5:]JXYX5%5/E P=Z1?A#=*ZBT+=M);<TU=>+K>Z=]O6OJ*=T$4#)6JQRL:JH
M]TF'*B<D1%5%RN,+*G0+Z/%TV,VUN%7J%K8-0ZBECJ9Z5CD=XO"QJI$QRIR5
MWGO<N%PG$B=RE:W&Z#.TFN=,5%NHM,4FF;AU7#2W.TLZJ2%Z(O"YS47$B9[4
M<F53O1<*F.7@]-T=1Z.W7U'LSJ"KDJZ*F\9;2Q/D5S:2JIY%;*R//-&.1'+C
ML16(J(F7 ;#0                       7V #!F
M
M
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M6:T44=OMM# RGIZ6)5X8XVIA$3/-?C7FO>5H \3,S,ZR^PQ$4QI  "60
M      !0M6:-LFN]/U=BU%:*6]6>L9U<]%6QI)'(GK1?Y^TKH PEU-X,:P4]
M;+4;?Z[OFCX'<VVVH:VOIF<_M>/#T3U<2GITUX->W5$L:ZWW(U!J:D3]LMU"
MUEO@E3T.5F7JGQ.0S1 %NZ*T-8MNM-T>G]-6FELMFHV\$-'1QHQC4]/K5>]5
MYJ7$                  /-5T_C5+-#Q</6,<SBQG&4QD]( U5_4+?_ )MO
M_P":?_VZ;1K-0^2[514:OZSQ>%D/'C'%PM1,X[NP]P U=ZB\"5Y>O]SN7[,O
MB_CM5+4]7]"W%P<;U=PY\=3.,]N"G_4+?_FV_P#YI_\ VZ;5 !JK^H6__-M_
M_-/_ .W28^B3X+OZ6#>>WZ__ &2_HF\4I:BF\G>0?%.+K8U9Q=9XS)C&<XX>
M?J,\0!KYZ2W@IJKI&;V:GW#J]V?([[Q)$K+?]#OC"4\<<+(F,1_C;>+E&BYX
M4YJO(C'ZA;_\VW_\T_\ [=-J@ U5_4+?_FV__FG_ /;I.G0V\&G]*=NW-K;]
MD;Z*NLMDUN\0\A>)XZQ\;N/K/&9.SJ\8X>>>WD9P "S]S=K=,;R:+N&E-7VF
M&]V&O:C9J6;*<T7+7M<BHYCVKS1S5144UO[B^!&CGNLD^A-R?%;:]RJVAU!0
M+)+"G^6B<B/_ .K;\:FU  :O-JO GVVAN[*O</<"2[4,;^=LL-(M.LJ)W.GD
M<Y41>]&LSCL<AL?T+H6P;;:4MVF-+6FFL=AMT754M!2,X61MRJJOI5RJJJKE
M55<JJJJJJJER #5#X<O^ZVS?^1NW]*D([\&3T9-$])_;3>336LZ!S^IJ+3+0
M7.E5&5=#*K*Q%?$]47DO++516NPF4Y(J3+X9S;O56N[CM,[36F+SJ+Q6*Z).
MMIH):I(N)U)P\?5M7ASPNQGMPOH*CX&';[56A+=NRW4NF[OIU:J:UK EVH):
M59>%M7Q<'6-3BQQ-SCLRGI CZY^!#U$V[21V_=*UR6KB1&35-JD9.C>_+&R*
MU53^%SQW=V9_1$Z V@NB;%-<;?)+J;651'U4^H;A$UCV,7MC@C152%J]_-SE
M[W*F$3)X   !A)TSO!M_3;[JT.M?V1/H5\6M,-K\0\A^.\75RS2=9Q^,1XSU
MN.'A^U[>?*8NAOT8/I3-IYM#_1+]%2R7.:X^/>(>)XZQD;>#J^MD[.KSGBYY
M[.1/( &#_2P\%IHGI$:IKM8:?O4VAM65TG6UTD=,E31UC\85[H>)BLD7"9>U
MV%7*JU555,X !J2L?@0+^ZZ,2\[IVV"VHN7OH;3)),Y,]B-=(U$54[\KCT*9
M_=&/HCZ Z*>FIK=H^CEFN58C?*-\KU22KK%;V(YR(B-8F5PQJ(B=JY7*K-X
M
M
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MQ(!Y_!W;2U^VNQ:7&ZPOIKAJ6I\I)!(F'1T_ UL.4]+D17_$].Q<F40
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M_7FG<CZ>LO<S9EIWHN>*-C&-8CLXPY6JJ83"ISSD$
M      *_9?[C57QN_HH4 K]E_N-5?&[^BA"84  $H
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MJH%1                       !?8 ,&8
M
M
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MBO5
M
M
M                                       *5J/^T&_Y1/YE+9+FU'_:
M#?\ *)_,I;)E#&0 $H
M              5^X_W!I_B9_1* 5^X_W!I_B9_1* 1   D
M                                             ![['_=2#_2_HJ=K
M]_=*7XF_S'6Q_P!U(/\ 2_HJ=K]_=*7XF_S$=J>Q3@ 2@
M                                            K]E_N-5?&[^BA0"O
MV7^XU5\;OZ*$)A0  2@
M                    7V #!F
M
M
M                              XP<@
M
M
M
M                'QJ*6.JC5DK>-N<X//Y'I/N=OM4]P \/D>D^YV^U1Y'I
M/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D
M^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM
M4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U
M1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \
M/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/
MN=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^
MYV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4
M]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1Y'I/N=OM4]P \/D>D^YV^U1
MY'I/N=OM4]P \\E'#- V%[$=&W&&_%V'Q\CTGW.WVJ>X >'R/2?<[?:H\CTG
MW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?
M<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ
M>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H
M\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'
MR/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW
M.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<
M[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>
MX >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >'R/2?<[?:H\
MCTGW.WVJ>X >'R/2?<[?:H\CTGW.WVJ>X >.&VTT$B21Q(U[>Q<J<RVVFGD6
M22)'/7ORIZP!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?
M(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<
M[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]S
MM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[
M@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR
M/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(
M])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[
M?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM
M]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@!X?(])]SM]JCR/2?<[?:I[@
M!X?(])]SM]JGUBI8:>%T3&(V-W:WTYY'I 'A\CTGW.WVJ/(])]SM]JGN 'A\
MCTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]S
MM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.
MWVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN
M 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(
M])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\C
MTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM
M]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.W
MVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN
M'A\CTGW.WVJ/(])]SM]JGN 'A\CTGW.WVJ/(])]SM]JGN
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9.FI555P$7)3Z:MDFE:QR-1%SV(OH*@B8R8S&G-MIJBJ-8<@ AD
M                               %&KO[:D^3^9"LE&KO[:D^3^9#.CFK
MWOPO@ "PI
M
M
M
M
M     *K;O[6;\:_SJ>L\EN_M9OQK_.IZRI5SET:/PP  -@             '
MDN']K/\ C3^=#UGDN']K/^-/YT)HYPPK_#*E  M.:
M
M
M
M
M                                     ^U!_;4?R_S*5HHM!_;4?R_S
M*5HT5\UZS^$ !K;P                                        HU=_
M;4GR?S(5DHU=_;4GR?S(9T<U>]^%\  6%(
M
M
M
M
M                             !5;=_:S?C7^=3UGDMW]K-^-?YU/65*N
M<NC1^&  !L              \EP_M9_QI_.AZSR7#^UG_&G\Z$T<X85_AE2@
M 6G-
M
M
M
M
M?:@_MJ/Y?YE*T46@_MJ/Y?YE*T:*^:]9_"  UMX
M                   4:N_MJ3Y/YD*R4:N_MJ3Y/YD,Z.:O>_"^  +"D
M
M
M          @  2  (  $@                    (  $@
M           "  !(
M                                                         JMN
M_M9OQK_.IZSR6[^UF_&O\ZGK*E7.71H_#   V              >2X?VL_XT
M_G0]9Y+A_:S_ (T_G0FCG#"O\,J4 "TYH                  @  2  (
M$@
M
M
M
M                              #[4']M1_+_ #*5HHM!_;4?R_S*5HT5
M\UZS^$ !K;P                                        HU=_;4GR?
MS(5DHU=_;4GR?S(9T<U>]^%\  6%(
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M'1
M      56W?VLWXU_G4]9Y+=_:S?C7^=3UE2KG+HT?A@  ;
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MRK==)WREO5$U4;(L#E1\3E3*-D8Y$<Q<=SD0NLT33-,Z51I*W15%4;U,ZP
MAD L/=#?70FSE*V;5VHJ6UR2)F*E\Z6HE3TMB8BN5,\N+&$[U0@N;PEVU$=9
MU+;?J:6-<_V0RAAX$[>Y9D=^;O-]O'O5QK11,PJUY5BW.[77$2RP!%VTG27V
M[WID6FTQJ"*>Y-;QNMM4QT%2B)S548Y$XT3O5F43O4E$UU456YW:XTEMMW*;
MD;U$ZPQ_Z:^]M[V.VFI;IIRJCI+Y77**C@DDA;*C6\#WO7A<BIV,Q_I(0ET+
MNDUNIO=N^^SZAO-/5V.CMTU;4Q1T$,2NPK&,3B:U%3SI$7M[B@^%'U7UVHM#
MZ98_'BU+/<96>GK'I&Q5^+JI/:I1>@+KG1FS6F]<:WUG>:>U1U,L%MHF.17S
M3*Q'22I'&U%<[W<.51,)RRO,[EO'IC"W]W6J>7#CST>>NY%56=N;VE-//CPX
M-DH,5Z?PDFT<UU2D?'J""G5<>/R4#%A3GVX217_[!DAI#65DUWI^EO>GKE3W
M:U53>**JIG<35]*+WHJ+R5%PJ+R5#C7+-RU&MRF8=VUD6;LS%NJ)5@ @S<KI
MI;4;872>V5]_=<[I Y634=HA6I=$Y%PK7/3#$<BYRWBRF.:&-NW77.E$:RSN
M7:+4;URK2$Y@Q2MWA*]IJRH='-2ZDH&(N$EJ*"-6KZ_,E<N/D[S(+;K=/2>Z
M]E\JZ3OE+>J)JHV18'*CXG*F4;(QR(YBX[G(AG7CW;<:UTS$,+>39NSI17$R
MNL B;=;I3[;[-54E#J/4,:79J(Y;;11NJ*A,]G$UJ89RY^>J<C7115<G=HC6
M6VNY1;C>KG2$L@Q2HO"5;35-?XM)2ZDI(>7]ES4$:Q=W<V57_P"SW&1NAM?Z
M<W)T_#>]+W>GO-KE7"3TSL\+D[6N:N',<F4RUR(J9[#9<L7+4:W*9AJM9-F]
M.ENJ)E< *5JC4EOT;INZ7V[3^+6RVTTE74S<*N5L;&JYRHB<U7"=B<U["(=%
M=-/:G7^JK;IVQWJKJ[K<94AIX5MT[$<["KS<K41$PBKE?0:Z;==<3533,Q#.
MN];MU1375$3*<P0!NITX]K=J+]/9:ROK;W=*9_5U-/9:=LW4.1<*USW.8S*<
M\HCE5,*B\^1YG=/C:&GHZ&HK;G=+=X[ E1#'4VJ='+&KG-XO-:J*F6N3**J<
MC9&+>F(JBF=)\&F<NQ$S3-<:QXLB 6GMANGIW=_2L>HM+UCZZU/E? DDD+HG
M<;%PY%:Y$5.U"ZU5&HY57"&F:9B=V8TE9IJB8BJF=8ER#'JX=/C9>W5]322:
MFGD?!*Z)SX;?.]CE:JHJM<C,.3ER5.TG'2VHZ35VG;=>J!)DH:^!M1!XQ"Z)
MZQN3+55CD14RF%YIWF55JNW&M=,PUV[]NY,Q35$Z=RJ A+<[IE;5;67">VW'
M4'E&[0.5DM#:85J7QN3M1SDPQJIV*BNRGH+&L7A(=H[K<O%:EM_L\2OX4K*Z
M@8L7;[KZU(]V/]$VTXUZJG>BB=/@U59EBBK=JJC7XLI@4W3VH[7JNS4UVLU?
M3W2V53.."JI9$DCD3U*GKY>I4P5(K\N$K<3$QK "&=W.EUMGLQ<7VR^7I]7>
M68ZRV6N)9YH\^_YHUBXYX<Y%PJ+@L_1/A"MH]7W2&AGJ[GIN29R,9->J5K(N
M)5PB.?&]Z-3UNPB=ZH;Z<>]53OQ1.BK.58IJW*JXU^*H]-S?&][';76^XZ:J
MHZ2^5]SCI8I)(62HV-&/>]>%R*GVK4_TB&^A/TE]T=\=VJNUZCO-/5V.AMLM
M9/''0PQ*YW&QC$XFM1>U^?\ 14M+PGNLXKEJS0VGZ>9LL--;Y;DJQN16NZ]Z
M,8N4[>4+L?PO67=X+;2?4Z?UUJ9S,^,U4%NB?Z.K8LCT3X^MC]B'6ILV[>#-
MRJF-Z?FXLWKEW/BW35.['EPC5G0 #A/2@+6W"W1TGM39_*FK+Y262C<JI&M0
M_P ^543*MC8F7/7U-15,>KGX2S:>WRJR"CU+<FYQUE+0Q-3X_KDS%_,;[=BY
M7&M%,S"M7DV;4Z5UQ$LK@0YM#TM-M]YZUM!8KUXM>'>XM=S9XO42<L^8BJK7
MKV\FJJIA5["8S77;KMSNUQI+;;N47:=ZB=8 4K4VJ[/HVSS76_72DL]MA_;*
MJMF;%&GH3+E[5[D[5,=-0^$:VBL=9)!337J^(Q_!UUOH$1B^M%E>Q53Y.XRM
MV;ES_;IF6N[D6K7XZHAE "%-I^F#M?N_=&6JSWQU%=Y,=5072):>295[F*JJ
MU[OWJ.5>79@FLQJMUVYW:XTEG;N478WK<ZP B7=;I3[<[,:CAL6J[Q-17.6F
M;5MAAHY9D2-SG-155C51%RQW+M[%[T/O2=)[;FHVS=KZ2_)2:7Z]U-'554$D
M;YI6]K(XU;QO7M[$7L7T*919NZ15NSI/@P]HM;TT[T:QSXI3!C]M5TWMOMW]
M>4^D[%2WUMRJ>/J)*FB:V%Z-8KW+EKW*U$1%YN1/YB9=8:WL.@+)-=]1W>DL
MMMB]U45DJ,;GN:F>;G+W-3*KW(15:N4U11-.DIMWK=5,UTU1,0K@,6;]X2+:
M*SU4D5(V_P!\8UV$FH*!K6.]:==)&N/C1.TNO;KIP;2;BW*&W4]^DLMPF=P1
M07J'Q=)%[$1),K'E>Y%<BKGD;:L6]3&]-$Z?!IIR[%56[%<:_%/8!Y;E<Z.R
MV^IK[A50T-#3,66:IJ)$CCC8B95SG+R1$3O4K+FO:]0,:=6>$,V>TS634U/7
MW/4#HE5%?::+B8JIW-=(YB.^-.7K/CICPBFS^H*F&"IJKO8>L5&]9<Z'S&JN
M?=+$Y^/C[.?QEGV6]IO;D^2G[78UW=^/-DX#Q62]V_4=JI;G:JVGN5NJF))!
M54LB212-7O:Y%PJ'>Y7.CLMNJ:^X54-#14S%EFJ:B1(XXV(F5<YR\D1$[U*V
MDZZ+>]3N[SU QIU9X0S9[3-9-34]?<]0.B545]IHN)BJG<UTCF([XTY>L^.F
M/"*;/Z@J88*FJN]AZQ4;UESH?,:JY]TL3GX^/LY_&6?9;VF]N3Y*OMEC7=WX
M\V3@/%9+U;]1VJEN=JK:>Y6ZJ8DD%52R))%(U>]KD7"H>TK?A6OQ<8  $@(%
MW$Z<&TNW5RDMU1?WWJNB54EALL/C*1JBX5%DRC,]O)'93"Y+0L7A)-I;M<&T
MU33ZALT3G(GC5=0QK$F5QE>JE>['^B6:<:]5&]%$Z*=679IJW9JC7XLJ04C2
M^K+/K2RT]WL-SI;O;*A,Q55'*DD;O2F4[T7DJ=J+R4JY6F)B=)7*9BJ-8 "V
M-QMQ[%M5I&MU-J2K=16BC6-LLK8W2.R][6-1&M157SG)V)Z5[B::9JG2.:*J
MHIB:JITB%S@AW;/I;;:[M:G;I_3-WJ:VYNA?4<$M#-$UL;$RYRN<U$3N]I9F
MM/""[2:-O<EKCK;E?WQ/ZN6IL]*V2!B\\^>][.)$]+.).?+)NC'NS5NQ3.OP
M5IRK,4[\UQI\62H*/8-5V_4&DZ'4<+WTMKK*1M<R2L;U*LA<SC1ST=[GS>:Y
M[""M:=/[9_1]PFHH[M6:AEBY.=9:;KHL\^22.<UKOC:JIS[3"BS<N3--%,SH
MV5W[5N(JJJB(ED:#%_2'A%=I-47*.CJGWC3G6.X&SW:C8D65[,NBDDX4]:X1
M._ES,EK9=*.]6^GK[?50UU#4,22&III$DCD:O-'-<BX5%]*$UVKEKA<IT+5^
MU>XVZHEZ@6EN?NKIS9_2[M0ZIK74-K;,R#K&1.E<KW9X41K455[%]A9NV72P
MVUW;OE5:=-WF:IJZ6DDKYUJ*.6".*!BM1SW/>U&HB*]O?WBFW753O13.G>FJ
M];IKBBJJ->Y+X,;=<>$%VBT9<9:*&NN&IIH5X7OL=*V2)%SV))(]C7?&U53U
ME[[,=*+;[?*HFI--W22.Z0M61UMKXNIJ%8F,O:F51R)GGPJN._'(RJQ[M-._
M51,0UTY5BJO<IJB9^*6P"Q-T][]%;-6QM;JV^T]L61%6"EYR5$^/>1-RY4SR
MSC"9YJAJIIJJG=IC66^JJFB-ZJ=(7V#%ZS>$<VANEU2BGDO=K@5R-2NK*!.I
MY]_UM[GHGQM)@USOUH?;[0M#K&[7N-VG*Z6.&EKJ-KJALSGM<YO#P(N>3'?%
MA3958NT3$54SK+11E6;D3537&D<T@@BK:3I.[?[V7RKM.D;G4U];2TRU4S9*
M*6%K8T<UN>)[43.7)R[>WT$FU]QIK715%96U,-'20,626HJ'HR.-J)E7.<O)
M$1.]37-%=$[M4:2W47**Z=ZB=8>@&-NKO"#;/:7JY::"YW#4,D>>)UHHU>S*
M=R/D5C7?&BJG/M/3MUT]MI-P;I#;EN59INKG=PQ-OL#86.=G")UC'O8W_2<A
MO]EO;N]NSI\%?VNSO;N_&OQ9$@X:J.1%1<H<E9; #ASD:URJN$3FJJ!R"!=Q
M.G!M)MW<);?-?WWNOB=P2P66%:E(U[\R92/*=Z(Y53'-"TK%X2+:.[5+8JN/
M4%E8KL+-74#7,3UKU,DBX^3N+5.+>JC>BB=/@IU9>/35NS7&OQ93@HND-:V'
M7UBAO.G;K2WFUS<F55)(CVY3M:OH<G>U<*G>A;V[6]^D=D+30W'5UQ?04U;.
MM/ L<#YG.>C5<OFL15PB)V^M#1%%556Y$<>Y9FY133OS/#O0?TU>EO<=C%MV
MF=*L@=JBX0>-25=0Q)&4<'$K6JC%Y.>Y6NQQ<D1O8N4,*(.F9O@LTU6S7-<_
MAX5>OBM.Z-O/EEO5\*95?1S*1TIMTJ3>'>_4.I+3.^HM$G4P4+I&.8O51Q-;
MGA=S3+D<[G[XRWZ$^_\ M5H/;;3&A9+C,NK[M6JVI@CMTKDEJ9IE9&U7HWA5
M$:L;<YPF%/34V:,7&IJZ/>JGGP_SD\G-ZO+R*J8N;M,<N*<.AON1K#=G9JGU
M+K*6GGK*JLFCI9J>G2'K(&89Q.1.2KUC9.Q$3DG(F:\5#Z.TUT\2XDB@>]JX
MSA4:JH?2@M]+:Z5E-1TT-)3L55;# Q&,3*JJX1.7-55?C47!T+*&I=4IFG2-
MRRIC/FX7/YCS=4Q5<FJ(TB>QZFBBJW;W:IUF(YM6.G.GOO/<M06NDGU#2.@G
MJHHI&I;*=,M<]$5,\'H4VJIV&$-FW&Z'4EUHF45BI&UKIV) Y+35)B3B3AYJ
MGIP9L5M9%;Z"HJYW<,$$;I9'(F<-:F57'Q(7,R::IIW*)H_335S\#?IBK?KB
MKEVZZ/N"!-.=.3:#56H+79+9?JJ:XW.KBHJ:-UNG:CI9'HQB*JLPF7.3FI5M
MW.EUMGLS<'6R]WI]5>6X5]MMD2U$T:+[_"HUB]_"YR+A47!5Z"[O11NSK\%W
MVJSNS5OQI'BF4&-^AO" ;1:TND5!+<J[3LTSN&-][IDBB55[ED8Y[6_&Y43U
MF1S'MD8U['(YKDRCFKE%3TF%RU<M3I<IT9VKUN]&MNJ)=@ :VX!CQ6=/C9JW
MUD]+4WZN@J()'12Q/M50CF.:N%14X.U%0GNS7:DU!:*&Z4$S:F@K8&5-/,WL
MDC>U'-<GJ5%13;7:KMQ$UTS&K3;O6[DS%%43IW/8"BZTUG:=O]*W+45]JO$[
M5;HEFJ)N%7<+<HG)$YJJJJ(B)VJJ$1Z0Z;&T^N=36S3]EO-;676XSMIZ>%+;
M.WB>Y>]5;A$3M55Y(B*IC3:KKB:HIF8A-5ZW15%-541,HVZ>/2)USL==M'P:
M0N4-!'<8*E]2DM)'-Q*QT:-QQM7'NE["N=!'?;6&^.G]6U>K[A%7SV^J@BIW
M14T</"US'*J*C$3/-$[2YND[J;9'3]=8&[N6^&MJ)8YEMRRT<T_"U%9UF.K3
MES5G:5/HQZAV@O\ :;\_:2ABHJ*.>-*]L5)+!Q2*UW!E'ISY9[#HS-'LD1T<
MZ_FT\>]S(IK]KF>DC3NU\.Y?^XVZ>E-IK"Z\:LO-/:*/FD:2NS),Y/M8V)YS
MW>IJ+["-^C=THJ/I'7[6K+59Y;99['XHVFFJGHL]3UJS\3G-3DQ$ZIN$15[5
MRO<F'/A =]M';QU^CJ32UPEK9K')<(JYLE-)#U;GK3HU$5R)Q<XG]GH]9\.@
M3T@-%;%_1U]&-QFMZ73Q'Q7JJ62;CZKQCCSP(N,=8SM[<FVG _\ RS<F)FN>
MS]?DT5;1_P#U1:BJ(HCM[^'>V@ LB3>?2D>U:;BNK9$TIXLE7XUXN_CZM7<*
M+U>.+M7LP6=MYTPMKMS]40Z?L%\FGN4L<DS6ST4L+$9&Q7O57O:C41&M5>:]
MQRHLW)B9BF=(YNS-^U3,4S5&L\N/-- ,9+YX1':&RZ@EMC*N[7**-ZQNN-#1
M(^FRBX545ST<Y.WFUJHN.6>6<@]':PM&O-,T&H+'5>.VFX1==35'5OCXVY5,
M\+D1R<T7M07+5RU$373,1);R+5V9IHJB9A6 1ONITB]O=F&\&JM14]'7*SC9
M;H46:J>B]B]6Q%5$7N<[">LAN+PDVTKZSJ%I]11Q91/&74#.KYJJ9PDO%R[?
M<]YLHQKUR-ZBB9AKKRK%NK=KKB)96 L[;3>'1N[MK=7Z1O\ 2WF&/'6QQJK)
MH<]G'$Y$>S/=E$SW%XFF:9IG=JC25FFJFN-ZF=8  8L@'5SVQL<][D:UJ95S
MEPB)Z3'W773PVAT-<I*#RY-?JF/D_P B0>,1M7/9UBJC'?Z+E-ENW<N3I13J
MTW+UNS&MRJ(9" Q@TUX1C:*_54,-7->K%UCD;UERH4X&9SS<L3Y,)R3GZT]>
M,C[%J"VZGM,%SM%?3W.VU3>."KI)6R12-SC+7(N%YHJ?(97+-RU_N4S#&UD6
MKW^W5$J@#XU59!04LU34S1T]/"Q9))I7(UC&HF5<Y5Y(B)WJ8[:R\(%L]I*N
MEI(KM6ZAEB56N=9J19(\HG=(]6-=\;55/686[5R[.ENF93<O6[,:W*HAD>#%
MW3OA&]HKW41154E[L:2.X5DN% BM9S7FO5/DY?K^,R.TSJ:TZPLM/=['<*:Z
MVNI;Q0U5'*DD;\+A<*G>BHJ*G<J*BF5RS<M?[E,PBUD6KW^W5$JH 0#N!TYM
MI-OKE/;YK])>ZZ%W#)%98%J&L7.%3K,I&JIWHCE5#&W;KN3I1&K*Y>MV8UN5
M1"?@8JVCPDVTERF1E1!J*U-XN'K*N@8YN.7/ZU(]<<_1GDID1H7<336Y=C9>
M-+WFEO=M<[@ZZE?G@=A%X7M7FQV%3S7(B\TY&==BY:XUTS#"UDV;TZ6ZHE<0
M!!VYO3.VKVLN4UKN-]6YW2%RLFH[/$M2Z)R=K7N148UV>7"KLHO:B&-NW77.
ME$:RV7+M%J-ZY5I"<08L6CPDFT=QJ%CJ6:@M;./AZZKH&N;C*)Q?6Y'KCGGL
MSR7EV&1>C-<6#<&QPWG3=VI;U;)5PVII)$>U'(B*K7=[7)E,M7"IGFAE<LW+
M7&NF8:[619O<+=42K@(PW<Z26@]D+C04.L+E44%171.F@2*CEF1S6KA>;&JB
M+GN]94=HM\]';W6^XUFD+C)7P4$K8:CK:=\*M<Y,IR>B*J*F>?J,.AN;G2;L
MZ=_8SZ:W-?1Q5&]W=J_@""-5=-[:#1VH[C8[CJ*;RA;YW4]0VGH9I6-D:N'-
M1S6JBX7*<E[44FW;KNSI13,_!-=VW:C6NJ(^*=P6_H+7=JW'TG0:DLDD\EIK
MFJ^GEJ('PN>U'*G%PO1%PJHN%QS3FG)2(MP.G+M%M]<I[?-?I+W70NX9(K+
MM0UBYPJ=9E(U5.]$<JH*;-RNJ:::9F88UW[5NF*ZZHB)3Z#%6T>$FVDN,R,J
M(-16IO%P]95T#'-QRY_6I'KCGZ,\E,B-"[B::W+L;+QI>\TM[MKG<'74K\\#
ML(O"]J\V.PJ>:Y$7FG(RKL7+7&NF88VLFS>G2W5$KB !I60            !
M]J#^VH_E_F4K11:#^VH_E_F4K1HKYKUG\( #6W@
M                  !1J[^VI/D_F0K)1J[^VI/D_F0SHYJ][\+X  L*0
M
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M"I2*^7[-MMZM=YS4>WZ[*G\&/.%[G.8:Z.EG2^)](W<2/&.*ZR2=F/=(CO\
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M?KJFJN:I[7I[-,6Z(HCLC0 !@V
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M3B8Y$547U*G<:LKVFQ:FBY,54SV]K;AQB7KL56XFFJ.SL2Z #S[TX
M      ^U!_;4?R_S*5HHM!_;4?R_S*5HT5\UZS^$ !K;P
M                         HU=_;4GR?S(5DHU=_;4GR?S(9T<U>]^%\
M6%(
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MIT9&  X[O  "0
M                %5MW]K-^-?YU/6>2W?VLWXU_G4]94JYRZ-'X8  &P
M          #R7#^UG_&G\Z'K/)</[6?\:?SH31SAA7^&5* !:<T
M    #5YX1;:ZOTOO2_5J02/L^HX(G)4(GF,J(HTB?$OH7A8Q_/MXEQV+C:&4
M'6^A-/[D:=J;%J6U4]WM51[NGJ&YPO<YJIS:Y,KAS514[E+>)D>S7=_36.U1
MR\7VFSNZZ3SAKGZ)'3@HMDM(?0?JJTUEPLL,[YJ.LMW Z6G1Z\3F.C<K4<WB
M5791V4XEY+RQ.]^\)OMO16Z:2UV34%TKN%>J@DABIXU=Z'/ZQRM3UHUWQ%NZ
MT\%Y8ZZL?/I3659:(7+GQ2Y4K:M$SW->US%1$]:*OK[RUK;X+.[R52I<-P*.
M&G1WNJ>VOD>K?B=(U$7L[U.M5.!>JFY5.DS\7#IC:-FF+5,:Q'+DQ(W UC>M
MYMRKGJ"HI>OO5\JT5E'1L<[FN&1Q,;S5<(C6IWK@VY=&?:Z?9[9/3.F*S'E*
M"!T]9PKE$GE>LCVY[^%7<.>_A+9V(Z&^@]BJIETHHIKYJ)K<)=KGPN=#E,+U
M+$1&QY153/-V%5.+"DV7*GEK+?5P03K2SRQ.9'4(WB6-RHJ(['?A>>/45,S+
MHO13;MQI3"]@X5=G>NW9UKEI0WTU9]'.\>MKZU_60UEVJ'0NSGZTCU;'S_@-
M:;=>CSI--#;&Z(LSF=5+36F!\[<8Q*]B22?[;W&+M)X+:SPUD,L^O:RHB;(U
MSXO)C6\;47*MSUO+*<LF:E^M4ETT_<;;35*T$M52R4\=0QG$L*N8K4>C<IGA
MSG'J,\S)MW:*+=N>$,,#%NVJ[ERY'&6DG=C5JZYW-U;J'CXV7*Z5-3&N<XC=
M(Y6(GJ1N$^0W)[*Z2^@3:71]@5G5RV^U4\,S<8^NI&BR+CUO5R_*8J6;P7]G
MMUWH:R;7-5604\\<LE,ZVM:DK6N158J];RRB8SZS-].1CFY-J[311:G6(3L[
M%N6JZ[ER-)G_ "6J;PANJ_HDZ1]PH6OXXK)04U F%Y95JS.^7,V%^+U&7'@Y
MM)_0]T=XKDYF)+Y<JBMXE3GP-5(&I\687+_I%L;C^#HI=Q]?:AU36:]JH*B[
M5LM6L+;8UR1(YRJUB+UB91J8;GU&4&U^@Z7;+;VP:4HYEJ8+31LIDG<WA65R
M)YSU;E<*YV78SRR99&5:JQJ+-N=9C37_ #XHQ<2Y3E5WKD:1.NGG\F'7A2=6
M+'9M#:88_/7U%1<IF>C@:V.-?EZR7V%O>"XTGXQJC6^IGLPE'1P6Z)ZIV]:]
M9'HGQ=2S\)">^DCT,8>D3KBCU#5:OJ+,VEH64,5'%0ME:B(][U=Q*].:J_T=
MR%\=&KH]4/1ST;<;%2762]25M<ZMDK)8$A=S8QB,X4<O).!5[?ME(]JM4X?0
MTS]Z?F1BW:\WIJX^['+]D-^$TU9Y)V;LEBC?PS7B[-<]N?=10L<YW+^&Z(@+
MP:>D?+&^%SO4C,Q6:TR.8[&>&65S8V_%EG6^PR_Z3O10BZ25?89ZO5,]C@M$
M4S(Z>*C;,CG2*U7.RKVXY,:F/4>SHP]%JW]&RFU"VEO<M]J+P^%7SS4R0K&V
M)'\+41'.SSD<I-&5:MXDVHG[T_Y^Q<Q;MW-B[5'W8_B/FB[PFVK/)>T%AL,;
M^&6[W5)'MS[J*&-RN3\-\2_(01X,_2?E?>N[WN1G%%9[2_@=CW,LKVL;_L)*
M9<])OHFQ])*Z6*IJ]4SV."TPRQQT\5&DR.=(YJN=E7MQR8Q,8[BH]&'HNV_H
MVT>H(J6]2WV>\20NDGEIDA5C8D>C6HB.=GG(Y?E%&5:MX<VJ9^]/^?LBK%NW
M,V+M4?=C^(^:+_"=0ULFRE@?!E:%E^C6H1J<\K!,C%7U9RGQJAC-T$-W-#[2
M;D7>KUE(RA6MHD@HKK)"LC:9W%E[5X456\:8\Y$QYN%[39SKG1%FW'TG<M-W
M^D;76JX1=5-"JJB]J*CFJG-'(J(J*G8J(80Z@\%K,Z\/=8]>LCM;WJK8[A;U
M=-$SN17->B2+V<\,^(G$R+,V)L79T8YF+>C(IOVHWO!4>EYTW])7[;NZ:+T!
M6OO59=X_%JRY,B?'!! N.-K5>B*]SD\WDF$15YYY&,?0QT^S4W29T+32HBQP
M5<E:O%Z8(7RM_P!IC3-K37@[="V#;R^V.6X3W+4%U@;"M_JH&JM+A[7Y@ASA
MF5:F<N5RIE.+"X/ALMT :79K<ZR:QI-;U5PFMCY')2OMS8TE:^)\;FJY)%QR
M>O<;[>5C6;%=JU,ZSKS[>#17BY5Z_1<NQ&D:<NR-59\(GJSZ'NCG5T#7\,E[
MN%-0(B=O"URSN^3ZSCY<=YA]X/32::CZ2-LJWQ]9%9:*IN#LIR1>%(6K\CID
M5/B,[^D[T9V])"WV&BGU)-8*:URS3*R&D2?KGO1J(JY>W'"C7>GW12^C'T1+
M=T<+O?;E#J":_P!3<H(Z='2TC8.I8URN<B8<[/$O#Z/<E>SE6[6)5;B?O3KZ
M\/V6KN)=NYE-R8^Y&GIQ_=D$ #C.^&$OA0]6>*:&T9IMC\.N%PEKWM3WL$?
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M <-Z(             ?:@_MJ/Y?YE*T46@_MJ/Y?YE*T:*^:]9_"  UMX
M                                     4:N_MJ3Y/YD*R4:N_MJ3Y/Y
MD,Z.:O>_"^  +"D
M                                        !KZ\)%:]5:TW"TK:K+IR
M\7>WVRVOG=-0T,LT:332*CFY:U4RC86+_I(;!3C!OQ[WL]R+D1KHJ9./[1:F
MW,Z:L-O!K[9W;2&DM97N]6FLM-;<*Z&DCAKZ=\,BQPQJ[B1KD1>%5F5,]BJW
MU&90[ 1=O3>N3<GM98]F,>U%NGL  :5D
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M-&-BT8]&E/&>V>\ !67
M
M!5;=_:S?C7^=3UGDMW]K-^-?YU/65*N<NC1^&  !L              \EP_M
M9_QI_.AZSR7#^UG_ !I_.A-'.&%?X94H %IS0
M
M
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MZJ[;Z*BF*:?!./LZFU<Z2Y5-57B  YCL
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M?S(5DHU=_;4GR?S(9T<U>]^%\  6%(
M
M
M
M
M                         !5;=_:S?C7^=3UGDMW]K-^-?YU/65*N<NC1
M^&  !L              \EP_M9_QI_.AZSR7#^UG_&G\Z$T<X85_AE2@ 6G-
M
M
M
M
M                                                        ?:@_
MMJ/Y?YE*T46@_MJ/Y?YE*T:*^:]9_"  UMX
M               4:N_MJ3Y/YD*R4:N_MJ3Y/YD,Z.:O>_"^  +"D
M
M
M
M
M                                                 JMN_M9OQK_.
MIZSR6[^UF_&O\ZGK*E7.71H_#   V              >2X?VL_XT_G0]9Y+A
M_:S_ (T_G0FCG#"O\,J4 "TYH
M
M
M
M
M                    #[4']M1_+_,I6BBT']M1_+_,I6C17S7K/X0 &MO
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M'R\6C^";^"AQXO#\$W\%#[9090:R:0X:U&MPU,)ZCL $@
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M1#Z@!(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
F                                               __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :6#Z # 2(  A$! Q$!_\0
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;Q_'3ZRB[E3_ &1!RI_LB$>A)\?D>L\?+\UZ/;Q_'3ZQV\?QT^LHQ^E?J_\
MF/I7ZO\ YCT)/C\CUGCY?FO.[>/XZ?6.WC^.GUE&6?\ ;_93;Z?W1Z$GQ^1Z
MSQ\OS7E]O'\=/K';Q_'3ZRC3Z?W1]/[H]"3X_(]9X^7YKR^WC^.GUCMX_CI]
M91JW_;J9'H2?'Y'K/'R_->3V\?QT^L=O'\=/K*-@/0D^/R/6>/E^:\GMX_CI
M]8[>/XZ?64<@>A)\?DCUHCY?FO&[>/XZ?6.WC^.GUE';<F>OM'H2?'Y'K1'R
M_->'V\?QT^L=O'\=/K*/.OM,\P]"3X_(]:(^7YKPNWC^.GUCMX_CI]91\!Z$
MGQ^1ZT1\OS7@^<1_'3ZQYQ'\=/K*/C9F3'T+/S/)CZTQ\OS7?^<1?'3ZQYQ%
M\=/K*0NOM'7VD^A)^9Y'K3'R_-=[YQ%\=/K'G$7QT^LI#8IDGT)/C\CUICY?
MFNZ\YC^.GUCSF/XZ?64BFW7_ &4>A)\?DCUJCY?FNX\YC^.GUCSF/XZ?64C]
M?]E'7_91Z$GQ^1ZU1\OS7<><Q_'3ZQYS'\=/K*2L^P9]@]"3X_(]:H^7YKM?
M.8_CI]8\YC^.GUE);.]>AL/0D^/R/6J/E^:[+SF/XZ?69\YC^.GUE)@'H2?'
MY'K5'R_-=EYS'\=/K'G,?QT^LI.;XF1Z$GQ^1ZU1\OS78^<Q?'3ZQYS%\=/K
M*3@/0D^/R1ZU1\OS78^<Q?'3ZQYS%\=/K*4?H0?0@]"3X_(]:X^7YKKO.HOC
MM^L>=1?';]92FWN[U'7UF/H:?'Y'K7'R_-=7YS%XO3ZQYS&OW;?K*5.OK,MS
MGO'H:?'Y(]:XW_=^:ZKSF+XZ?69\ZB^.GUE*P'H:?'Y'K5'R_-=3YQ'\=/K'
MG$?QT^LI6,M\1Z&GQ^2?6NGY?FNH\XC^.GUCSB/XZ?64L@GT)/C\CUKI^7YK
MIO.(_CI]8\XC^.GUE+?T&?H,?0T^/R/6NGY?FNC\XC^.GUCSB/XZ?64N?0;?
M[=Q/H:?'Y'K73\OS70^<1_'3ZQYQ'\=/K*7O]NXRG>O0>A9\?D>M=/R_-=!Y
MQ'\=/K'G$?QT^LIA_P!NX?[=Q'H:?'Y'K73\OS7/><1_'3ZQYQ'\=/K*8V?[
M=#/U_6/0T_,\CUKI^7YKFO.8OCI]8\ZB^.WZRF7Z_K'U_63Z&GQ^2/6N/E^:
MYOSB/XZ?6/.(_CI]93*W./\ YF>O^RD>AI^9Y)]:Z?E^:YCSF+XZ?6/.8OCI
M]93/U_V4=?\ 92?0T^/R8>MD?+\US'G,7QT^L><Q?'3ZRF?K_LIOE1Z&GQ^1
MZV1\OS7*^<Q?';]8\YB^.WZRFK*F6^)/H:?'Y'K9'R_-<IYS%\=/K'G,7QT^
MLIM^D?21Z&GQ^1ZV1\OS7)>=1?'3ZQYS%\=/K*;F^)D>AI\?D>MD?+\UR'G,
M7QT^LSYS%\=/K*;C<>AI\?D>MD?+\UQWG,7QT^L><Q?'3ZRG$V3N7H/0T^/R
M/6R/E^:XSSF+XZ?6/.8OCI]93H!Z&GQ^2/6V/E^:XOSF+XZ?6/.8OCI]93HG
M?W&^5'H:?'Y'K;'R_-<1YS%\=/K'G,7QT^LIWRHRH]#3X_(];8^7YKA_.HOC
MI]9GSF+XZ?64\-[C(]#3X_)'K;'R_-<+YU%\=/K'G,7QT^LI[;XFP]#3X_)/
MK;'R_-<%YS%\=OUCSF+X[?K*?3+?$CT//C1ZW1\OS7 ^<1?'3ZQYQ%\=/K*?
MP/0\^/R/6ZGY?FN \XB^.GUCSB+XZ?64_FW*/0\^/R/6ZGY?FM^\ZB^.WZQY
MU%\=OUE0/*.4>A__ '\CUNI^7YK??.8OCM^L><Q?';]94*WN4R3Z'GQ^2/6Z
M/E^:WKSJ+X[?K'G47QV_65"@>AI\?D>MT?+\UO7G47QV_6/.HOCM^LJ' ]#3
MX_)'K?'RO-;QYS%\=!YS%\="HAO>9^@Q]#SXSUOCY?FMV\YB^.@\YA^.A43]
M!_0GT//C/6^/E^:W+SJ+XZ#SJ+XZ%1O3V?N#I[/W!Z(_]_(];X^7YK<O.HOC
MH/.HOCH5'-_VZ&?]NX>B/_?R/6^/E^:W#SJ+XZ#SJ+XZ%1_^W</]NX>B/_?R
M/6^/E^:W#SJ+X[?K'G47QT^LJ2Y5]G[@Y5]G[A'HC_W\CUOI^7YK;O.HO[8W
MZQYU%_;&_65)M\?]"&?I_<0>B/\ W\D>N$?*\UM7G47QV_6/.HOCM^LJ5^G]
MQ#?Z2/1$^/R/7"/E>:V?SJ+X[?K'G47QV_65,?2&=_?^Z/1'_OY)]<(^5YK9
MO.HOCM^L><Q?';]94V"?1'_OY'K?'RO-;+YU%\=OUCSJ+X[?K*G&?[=3)'HB
M?'Y(]<(^5YK8O.(OCH/.8OCM^LJ= ]$3XSUPI^7YK8O.H_CM^L>=1_';]94Z
M;]/]E'HB?&CUPI^5YK7_ #J+X[?K'G47QV_65/\ T?NCZ/W1Z(GQGKA'RO-;
M!YU%\=OUCSJ+X[?K*H&?-^Z;#T1/C/7"/E>:UWSJ+X[?K'G47QV_651&X]$3
MXSUPCY7FM:\ZB^.WZQYU%_;&_652F4[O >B)\:/7&/E>:UGSJ+X[?K'G4?QV
M_654?0@^A!Z(GQGKC3\KS6K>=1?';]8\YB^.WZRJO'Y[_;ZAC\]_M]0]$3XD
M^N-/R_-:IYS%\=OUCSF+X[?K*J\?GO\ ;ZC+/G'HB?$>N-/R_-:GYS%\=OUC
MSJ+X[?K*KLI[1E/:/1$^(]<:?E^:U+SN'^V(/.HO[8WZRJUO>;?0/1$^-AZY
M4_*\UJ'G47QV_6/.HOCM^LJO^@RQ!Z(GQI]<J?E>:T_SJ+^V-^L>=1?VQOUE
M66?8,^P>B)\9ZYT_*\UI:5,2I^2-^LW9(QZ9:Y%]I5FG<O0[YPAZ^]P=9U&G
MJF3EI+JS,.5Z).Q%5/FYF\R?.C?6>%[3*[5N:XG?9NX/[56\O(IL54<._+?=
M-3*&35.OJ'S%*[YC*87K])_/SB+^V-^L_A7T,-QHIZ6HC26&>-T4C'=SFN3"
MHOSH5P[A:0FT+K*[V.7*I23*V)SL>G&JHK'?2BM7]PWL7&_$S-.^TN=U?5*M
M*HIN<'%$\NJR;SJ+^V-^L>=1?VQOUE6_^W=_\C7Z"S]$3XW+>N=/RO-:5YU%
M_;&_6/.HO[8WZRK7Z!] ]$3XSUSI^5YK2O.HO[8WZQYU%_;&_65:_08^@>B)
M\9ZYT_*\UI?G47]L;]8\ZB_MC?K*LL^P9]@]$3XSUSI^5YK3?.HOCM^L>=1?
M';]95BN,&OT#T1/C3ZY4_*\UJ'G</]L;]8\[A_MC?K*K_H,*/1$^-CZY4_*\
MUJ'G47QV_6/.8OCM^LJNRGM&4]H]$3XF?KC3\OS6H^<Q?';]8\ZB^.WZRJU>
MY37'Y[_;ZAZ(GQ'KC3\OS6J^=1?';]8\ZC^.WZRJK'Y[_;ZAC\]_M]0]$3XT
M>N-/RO-:MYU%_;&_68\ZC^.WZRJA>_N0?0@]$3XSUQI^5YK5_.XO[8WZQYU%
M_;&_654?0AHO>I/HB?'Y'KC'RO-:UYU%\=OUCSJ+X[?K*I3"]Q'HB?&GUPCY
M7FM;\ZB_MC?K'G47]L;]95$"?1'_ +^1ZX1\KS6N^=1?';]8\ZB^.WZRI_Z/
MW1]'[I'HB?&>N$?*\UL'G4?]L;]8\ZC_ +8WZRI_Z/W3"CT1/C/7"GY7FMA\
MZB^.WZQYS%\=OUE3H'HB?'Y)]<*?E>:V+SF+^V-^L><Q?VQOUE3H'HB?&GUP
MCY7FMB\ZB^.WZQYU%\=OUE3:]ZF#+T1_[^1ZWQ\OS6R^=1?';]8\ZB^.WZRI
MHU^DCT1_[^1ZWQ\OS6S^=1?';]8\ZB^.WZRICZ3'TD>B)\?DCUPCY7FMI\ZB
M_MC?K,>=1?VQOUE2OT_N(/I_<0GT1_[^1ZX1\KS6U><Q?'3ZQYU$GW;?K*E%
MQZD_<->5?9^X/1'_ +^2?6^G;]WYK;?.HOCM^LSYU%\=/K*D>5?9^X:?[=P]
M$?\ OY'K?3\OS6X>=1?'0>=1?'0J/_V[A_MW$^B/_?R/6^/E^:W#SJ+XZ#SJ
M+XZ%1R_[=#'3V?N#T1_[^1ZWQ\OS6Y>=1?'0>=1?'0J-Z>S]P=/9^X/1'_OY
M'K?'R_-;EYS%\=!YS%\="HGZ!] ]#SXSUOCY?FMV\YA^.@\YA^.A40O>I@>A
MY\?D>M\?+\UN_G,7QV_6/.8OCM^LJ(-5[_ >AY\:?6Z/E^:WKSF'XZ#SF'XZ
M%0H'H>?'Y(];X^7YK>O.8OCM^L><Q?';]94)U]GU&G*/0\^-EZW4_+\UOWG,
M7QV_6/.8OCM^LJ!Y1RCT//C/6Z/E^:WWSF+X[?K'G,7QV_65!*:CT/.^W&>M
MT?+\UP'G,7QT^L><Q?'3ZRG\$^AI\?D>MU/R_-<!YS%\=/K'G,7QT^LI] ]#
M3X_(];J?E^:X+SJ+XZ?69\YB^.GUE/>$-1Z&GQ^1ZVQ\OS7"^=1?'3ZS/G,7
MQT^LIY-5[U'H:?'Y'K;'R_-<1YS%\=/K'G,7QT^LIWRHRH]#3X_)/K;'R_-<
M1YS%\=/K'G,7QT^LIV7.#4>AI\?D>ML?+\UQ?G,7QT^L><Q?'3ZRG0#T-/C\
MCUMCY?FN*\YB^.GUCSF+XZ?64YKWJ8(]#3X_)/K9&W[OS7'>=1?'3ZS'G,7Q
MT^LIQ4U)]#3X_(];(^7YKD/.8OCI]8\YB^.WZRF\U'H:?'Y'K9'R_-<EYS%\
M=OUCSF+XZ?64V_2/I'H:?'Y'K9'R_-<EYU%\=/K'G47QT^LIJRHRH]#3X_(]
M;(^7YKE?.HOCI]8\YB^.GUE-65-.O^RCT-/C\CULCY?FN8\YB^.GUCSF+XZ?
M64S]?]E'7_91Z&GQ^1ZV1\OS7,><Q?'3ZQYU%\=OUE,_7_93"_[=1Z&GQ^2?
M6N/E^:YGSJ+X[?K'G,7QT^LIE^OZQ]?UCT-/C\D^M<?+\US?G$?QT^L><1_'
M3ZRF3Z_K-7?[=!Z&GQ^2?6NGY?FN=\XC^.GUCSB/XZ?64P_[=P_V[B/0T_,\
MCUKI^7YKGO.(_CI]8\XC^.GUE+_CW&/]NXGT+/C\CUKI^7YKH?.(_CI]8\XC
M^.GUE+W^W<:_01Z&GQ^1ZUT_+\UT?G$?QT^L><1_'3ZRESZ#'T$^AI\?D>M=
M/R_-=)YQ'\=/K'G$?QT^LI9!/H2?'Y'K73\OS73><1_'3ZQYQ'\=/K*6%[E-
M2/0T^/R/6NGY?FNH2IC^.GUF>WC^.GUE*P)]"3X_)$?M73\OS74^<1?'3ZQY
MQ%\=/K*55->OK(]#3X_)/K73\OS76><Q?'3ZQYS%\=/K*4^OK'7UCT-/C\CU
MKCY?FNL\YB^.GUCSF+XZ?64HCZ$'H:?'Y'K7'R_-==YS%\=/K'G,7QT^LI07
MQZ&I/H2?F>1ZU1\OS78^<Q_'3ZS'G,?QT^LI/!/H2?'Y)]:H^7YKL?.8_CI]
M9CSF/XZ?64F@>A)\?D>M<?+\UV7G,?QT^L><Q_'3ZRDTPO<H]"3X_(]:H^7Y
MKL_.8_CI]8\YC^.GUE)6?8,^P>A)\?D>M4?+\UVOG,?QT^L><Q_'3ZRDA<F.
MO^RCT)/C\CUJCY?FNX\YC^.GUCSF/XZ?64C]?]E,*/0D^/R/6J/E^:[GSF/X
MZ?6/.8_CI]92*!Z$GQ^2?6J/E^:[OSB+XZ?6/.(OCI]92$N<]XZ^T>A)\?D>
MM,?+\UWOG$?QT^L><1?'3ZRD+K[3^8]"3X_(]:8^7YKP?.(_CI]8[>/XZ?64
M? >A)\?DR]:(^7YKP>WC^.GUCMX_CI]91\:]?:/0D^/R/6B/E^:\/MX_CI]8
M[>/XZ?64>=?:.OM'H2?'Y'K1'R_->'V\?QT^L=O'\=/K*.E,#T)/C\CUHCY?
MFO&[>/XZ?6.WC^.GUE'*JN#0>A)\?D>M$?+\UY/;Q_'3ZQV\?QT^LHV ]"3X
M_)/K/'R_->3V\?QT^L=O'\=/K*-5_P!NICZ?W1Z$GQ^1ZSQ\OS7E]O'\=/K'
M;Q_'3ZRC3Z?W1]/[H]"3X_(]9X^7YKR^WC^.GUCMX_CI]91EG_;_ &4Q]*_5
M_P#,>A)\?D>L\?+\UYW;Q_'3ZQV\?QT^LHQ^E?J_^9IRI_LB$^A)\?D>L\?+
M\UZ/;Q_'3ZQV\?QT^LHNY4_V1#"IT_\ DA'H2?'Y'K/'R_->EV\?QT^L=O'\
M=/K*+.GL_<'3V?N$^A)\?D>L\?+\UZ?;Q_'3ZS/;Q_'3ZRBI?]NB&O\ MW(1
MZ$GQ^1ZSQ\OS7K=O&B?#3ZPD\:I\-/K**?\ ;N0U7YAZ%GQ^2/6B-_W?FO8[
M>/XZ?69[>/XZ?642_0/H'H2?'Y,O6>/E^:]KMX_CI]8[>/XZ?642_0:KW]P]
M"3X_(]9X^7YKW.WC^.GUCMX_CI]91'T]0Z>HGT)/C\CUGCY?FO<[>/XZ?6.W
MC^.GUE$2]W_T-1Z$GQ^1ZSQ\OS7O]O'\=/K';Q_'3ZRB T^@GT'/S/)'K/'R
M_-?#V\7QD';Q?&0H>^@PY._N'H.?F>3/UFCY?FOB[>+XR#MXOC(4.&,(/0<_
M,\CUFCY?FOD[>+XR#MXOC(4,Y]@S[!Z#GYGD>LT?+\U\W;QK]T@[>-/ND*&<
M^PPH]!S\SR1ZRQM^[\U\_;Q?&0=O'\9"A;KZQU]8]!S\SR/66/E^:^GMX_C(
M.WC^,A0MU]8Z^L>@ZOF>2?66/E^:^GMX_C(.WC^,A0I](^D>@ZOF>1ZRQ\OS
M7U]O'\9!V\?QD*%/I-!Z#J^9Y'K+'R_-?=V\?QD';Q_&0H1,+W*/0=7S/(]9
M8^7YK[^WC^,@[>/XR%!V$&$'H.KYGD>LL?+\U^/;Q_&0=O'\9"@U3 ]!U?,\
MCUECY?FOS[>/XR#MX_C(4&&'?[=1Z#J^9Y'K+'R_-?IV\?QD';Q_&0H)_P!N
M\?[=X]!U?,\D^LD?+\U^W;Q_&0=O'\9"@A34>@ZOF>1ZR1\OS7\]O'\9!V\?
MQD*!@/0=7S/(]9(^7YK^>WC^,@[>/XR% QK_ +=X]!U?,\CUDCY?FO[[>/XR
M#MX_C(4"?[=X_P!N\>@ZOF>1ZR1\OS7]]O'\9!V\?QD* USC_P"9KCVJ/0=7
MS/)/K)'R_-?_ -O'\=#'G#/C)]90#CVJ8=_MT0>@ZOF>1ZR1\OS7_P#;Q_&0
M=O'\9#\__P!/\ ^G^ >@ZOF>1ZR1\OS?H [>/XR#MX_C(?G]7YD,#T'5\SR/
M62/E^;] B2M=W.0VRWUH4(4.N-1V*&**VZANMOAAZQ1TM;+$V/KGT4:Y,=_J
M0^TTYQ5[O:8Y?,=Q+ZYK5]%M95+5M;T[D2;F3'LP>56B7(]VO=L4?M#;GWJ)
MA=VBHB#.2J+1'E+MV=.O8R]LM.JZ?/INJJ5*:9?TKH>5J?2Q21NW7E0=!:AE
MCI]5V.Y:2F?C-2Q4K:9OSN8B2?5&I7W=,R;7.8W^RSLZQB7N7%M/U3011T/E
M-#[EZ6W'MRUVE[_07RF3X;Z&H:]8U]3VHN6K['84^K3N[RMFF:9VJC9;T5TU
MQO3.[8 $/0
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MA,!LWN4U-F]RA#(  &QJ;    ,M\3!EOB!L  -F]RF3#>Y3(8!L:FP   ;@
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M>S  )@C< !#+FU4P94P9G,-#<T(@Y@ ).;4 $[G-JI@RI@;IY[!H;F@W(W
M-TL*8,J8&X  ;C0 $R-5,&5,$@:KWJ;&J]ZAE   Q#0W-")9@ $#53!E3 [P
M !(U   T-S0)@-5-C500P  D7N4U-E[E-0   U4P94P&7<PIJ;*:@@-5[U-C
M5>]0D  &@ )D#0W-!   2!A3)A2&;  "(#538U4;I8  &JF#*F#+N U-C4B
M !(T  &%-3934   F&%,&5,"#O  $M  !A34V4U   ,H:@ $!A>XR87N"6H
M PIJ;*:@#"F3"@8  &JF#*F S#0W- B  !(:FQJ92  )YC53!E3 3W,*:FRF
MH(  $L*8,J8   #0  #0W-#* "]R@+W*8\QJ #,87N-39>XU,&4!A3)A0=[4
M !(:KWJ;&J]Z@  9C"]QJ;+W&H90&AN:!$!A3)A0R8  &@  &JFQJH3W,  $
M  "6H  &AN: #"F3"@:@ #"F#*F GN#538U4(8  9M5,&5,    -38U   #"
M]QJ;+W&H PIDPH92U  8L*8,J8#+=JYO,U4/'4\H\=[>5SB890T,_.8!*7L;
M#J"YZ7ND-SLUQJK5<(7<T5713.AE8OL<U45/H4F-LEY3#4^F.PMVX=O;JBW(
MJ-6Z436PUK&^MS.D<N/V"KE5YE4A3\YCYC2OXEG(C:NG_*PQ\R_C3O;JV_1>
MUM?N_I3=_3[;SI.]4]VI.B2-C]&6!R]4;)&OI,=CP5.O@?;Y3V%"&A=P-1[:
MZB@OFEKO56:Z0]T],_O3.>5[5Z/;X*U45%]I9EPL<>MCW<\STWK)8=/:P=B.
M*15Y:2O=W>@J_ D7XB]%^Y557"<EEZ7<L>W1SI\W<8&KV\CV+O*I+[*&31%3
MH,]Y2.C;@                                                  #
M&$,<R>L#57-:G52O;C)X]7<];H7;&OQCFAN.HZ=W=X.BIG>OUR?M?C'F<>O&
M*ZV^Z&V&B*U6UKD=#?+I3KA8D7X5+&Y/NU3X;D[D]'OYN6NY/%.__;KDZ?3=
M-XHB]>CEW0XO5=5VF;-B?O+955RJJN55SU55557V]?::\V>\P#KHY.*WWZ@
M#$  &T7PS^Q_&+X9_8(D-S0W(A  !(&6^)@RWQ(1+( #%LWQ,F&^)D)@-F]R
MFILWN4$L@ (#8U-@   &6^)@RWQ V  &S>Y3)AO<ID,9#8U-@@  &X  RWQ-
MC5OB; #+?$P9;X@9    !BW  9!EOB8,M\0Q;  #8  ;-\3)AOB9#'O9;XFQ
MJWQ-B.\D !$H;  =P&6^)@RWQ(&P "(9;XFQJWQ-@B0V;W&ILWN,I0  B!N
M" -S0W   #+?$R8;XF0   W  1#9O<IDPWN4R$2  CO&P $@9;XF#+?$Q1+8
M  ALWN4R8;W*9")#8U-@@  &X  RWQ-C5OB;   $2RWQ,F&^)D'<  ,6X  V
M;W*9,-[E,@ WO ;WA'>V  )#9OB:FS?$(9  &X (@#8U-A(&6^)@RWQ'<-@
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M)U:9F+%^?M/^5@X-4<GQ@F3EG:-@
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MZM:U/W#4MYENY=FU3UA:9&DY&-C4Y5<1P5;;<^?/Z.>&%,F%4W5/W,  F.I
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M#4EPJIK=2OJ6POAC1KU3P7!J1J6/75%,3Y+.O]G\ZW1-=5/*(WZPB&84S_\
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M0W-#<B$  $@9;XF#+?$A$L@ ,6S?$R8;XF0F V;W*:FS>Y02R  @-C4V
M9;XF#+?$#8  ;-[E,F&]RF0QD-C4V"   ;@ #+?$V-6^)L ,M\3!EOB!D
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M]2PVXVG3V[FA'T]5'#>-.7NC:Y.GHRQ/:CFO;ZEZHY%[T7"IA4*3BU7@,O\
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MD-C4V,2  !#+?$V-6^)L -S0W &S>XU-F]Q/<B0 $'<W  8AEOB8,M\0-@
M;WFQJWO-@CO#9OB:FS?$$L@ ,6S>Y3)AO<ID   .T\*.OOQ)[A-M=1*C:&\H
ME/Z2]&S)E8U^=<N;^R0G$U4R5<4E5-0U4-13RNBGA>V1DC>BM<BIA4^E"QO:
MW6L>OM#6J]LY4?41(D[&_<2M]&1O[9%Q[,',:I9X:HNQW\I^[ZM^R6?QVJL6
MN>=/./MWOKEZGK[O:Z>\VNKM]5&DM/4Q.AE8O<YKDPJ?2A[%%Q\QGIWE%$[3
MN^A54Q73-,])5EZVTK4:*U7=;'59[2BG=&CG)CG;T5K\?GFJCOI/2$F^,S0G
M8U=MU;31X;*GF56YJ=SDRZ-R_0CD7YFH1D.XQ+O;6HJ?G_5L*<',KM=W=]@
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MJZJIN,[4]<36,CS[%[:3ZC<P;?:Y%%/=NK=0N]EC5U1UV5SY]'!@ ^DODX
M@       !M%\,_L?QB^&?V")#<T-R(0  2!EOB8,M\2$2R  Q;-\3)AOB9"8
M#9O<IJ;-[E!+( " V-38   !EOB8,M\0-@ !LWN4R8;W*9#&0V-38(  !N
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MM\;*UOK1D$Z+_'3ZS[/@/KF57#E9(FN15I:FKB=[%6=[T_<>A'7RBFXE/?\
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MY^7/+G]LIN46JKN%331.T[0J[V1:QM6KN7J>*F)GDL27AOVTPN-'V[Y^1?\
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MTREYI5[:N;4][Y]^UN#VEFG*ICG3RG[.+  ZA\H:  #"FILIJ&4!A3)A0=[
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M6:K^6<3HX._R@-.^'IU7\YD/3/Y8='Y?HU]"_P#*WOS_ %A$'BY7/$%JS_\
M1?YK"2+X!Z:%FU][J$1%G?>'L>['7#88<)]"J[ZU(Y\7"?\ =!:L1/72_P U
MA.N\ VM:>GDU'I6>1L<\JLKZ=JKCM,)R2(GM1$C7Z5]1GDTU58%.WPAXZ=<I
MMZW<XN^9_KN[?N]L1H[=:\T=9J2NK(*FEA[&**GJF1MY5<JY5%:O55\?8?*Z
M:X4]M]):BM][M]VKTKJ"H94P\]=&K>=JY3F3DZHN.OSJ>BXR-C;UKUEMU+IV
ME?<:ZAA=35-)$B+*^+*N:YB=.9457^BG5>;H<$V5X7]1[A:N93Z@M-UT_8(4
M<M74SP+3R*J(J-9&CV]55<9Z81,^.#0LT[X^_:[1WPN\NY-.;P1C155,\JO^
M4S=_IK;=ME]94[JJ"14MDTK6]HU55T;5>WQ[\M0K%));_<*MCV?TC+?Z?553
M*G;1P4]!4TS7/G>Y5]%'M<U$PQ'N^#]R1M+C3***;<S3.\3+E?V@OW;M^FF]
M1%,Q'=._]1>Y2:WD^Z.!NF-6U286H?6Q1NZ=4:V-53K\[G$*5[E),\"^XM/I
MS6MTTW731PQ7F.-],YZX19HU7#$]KFN7Z6HAZZE3-6-5%+6T"Y1:SZ:J^G3\
MYA]#Y0:Z5'NCHZ@1SFTG9U,RHCL-<]58WJGBJ)W?IE(A_P#T+'>*+8RHWETI
M1OM<D<=^M;WR4B3/5K)F/1$?&J^"KRM5%];<+A%52(&GN$_<V^7MMOET[);(
MT<C9:NMD8D,:?&RBKS)[&(XT]/R;-&/PU5;3"TUS3\JYG37;IFJ*MMMDT.$V
MY5%TV"TI+4N<^1D<T+7.7.6,GD8S'LY6HGT$-^,.AAH]_=0+%C$T=/*]J=,.
M6%B+]*X1?I)\Z0T]:]I]O:*V-J&PVRSTB]K53JC4PU%=)*[U97F<OJRI6=O!
MKK\<?<O4&HVHYL-;4?:$<F%[%J(R/*>"\C4S[5-/3HX\BY<I]WFMM=F+6!9L
M7)]OEY1S61[&_E,:)_42C_D6E;&\GY;NN?U<KOYQ(64;&?E,Z(3_ /(M'_(-
M*U]Y/RW-<_JY7?SB0]-,_B*_^][SU_\ @+.WT_1\>:KWJ;&J]ZG3OG:0M@XM
M;GM]M#I[2.E:6)ERIHIDJKC5LYTC5\TCVMC9W*N'-7F=E/#'B>'ICC7W-LM8
MV2OKZ2_09RZ&LHHX\I['1(Q47Y\X\<G!@:'X&QSF:=YGJMXU;-CAX:YB(B(C
M[0GKH[CTT9=Z-J:@H+A8:Q,(_LV><P]>F6N;AWUM^L]!N9QZ6J&V3TFB;=4U
M=?(WE;7U\:1PPY3X36957JGJ7"9]:="$P/"-*L4U<2QJ_:+.KM\$S'WVYO::
M;U-=M(W2.YV2X3VRNCRC)Z=ZHY$5,+X>.<?,I]-JW??7VN;$MEOFI:JMMO-S
M.@5K&(_V/5C45R>I'+C/7VGTO"Q0:3O>ZM-:-6V^EKZ*X0NAIO.E5&MJ45'1
M]<IGF1'MPN<JY$)5[\\*5DU1M\ZGT18;99[Y22MJ(G00-B6I:C5:L+G^U%14
MRN.9J9QE5(OY-BU>IHN4?FG"P,O(Q:[MBYR[Z?B@5H[55QT1J6WWZTU#Z>NH
MIFRL>UV$=A4RQV.]JHJHJ+WHJH6Y3107JSOBFC;-2U,.'1R)T<QS>J*GS*5R
M[9\)>N]5ZOI:2\6*ILMICF:M;65>&8C145S6955>JIT3'3/52?.Z.NZ+;+;Z
M\:AK%:K:.#,42K^22KZ,;$_3.5$^92KU*NW=N41:G>?HZ+]G[5['Q[U61RI[
MM_IU1)X$DCM&[6L[2DG.YE(Y&=<JK8YT9G/[)#HGE!J=9-K+%,B*J1WEB+],
M$R_YB-'"KK^+0N]EHK*V=(Z.X]I05$LB]$23JU57U=HV-57U9)T\16UTV[6U
M5UL=$D:W1',JJ)9%PWM6+E$SX<S>9N?!79&1_H9E%=73DRP/]WI5VS;YS&_+
MSC^JNC9&%U1O#H=K>O\ NY1.^A)VK_F+.]UZIENVOU;4O5&MBM-4]57V0N(>
M<+O#)K"U;J46H-46>2T6ZSJZ9K:A[>::96JUJ-1%7*(JHY7+T]$[GQG:]@TC
MLW<;:V1K;A?')0P1Y])691TSL>I&(J9];T]8S:HR,JF+<[L=(M58.G7:[T;;
M[]>7=_E7 :J;&JG51T?.>]*_R>E+&_7&J:I<=M'0,C;^E=(BN_B-.A^4(K9X
MMN-/4K%5()KKS2=5PJMADPB^M/27I[,^!PG@GUU!I#>>"DK)4BIKW3/H$>YV
M&I-S-?%GYU8K$]:O)D<2>T4F\NVE3::%T;+M2S-K:%TBX:LC45.15\$<USD]
MBJB^!RN3/99T5U]'T33Z9R='KM6O>Y\O/SA5PI:;PO5DU;L)HR2H55E2B[),
MY7T6/<UO?[$0@9I_A6W-OVH66I^F*JW9DY)*VN3LZ>-OBY7Y7F1.O1G-GI@L
MHT-I2FT/I&SZ?HW*^GMM+'2L<[O=RM1%<OM7O^D]-5OV[E-%-,[O/]FL2_9N
M7+ERF8C;;\U:_%A^:#UE_?XOY",^CV-X/M0[NVN*^U]<FG[%,N899(EDGJ$S
MU<QF4PU>J<RKW]414/G>+'\T)K+^_P 7\A&64Z,BH(=(6>.U,:RW-HH6TS6]
MR1<B<B)]&#UR<FY8QK<4=\-?3\"UEY]Z;D[Q3,\OS1XIN#_9K;NF2JU5=7U#
M<9<^\W-M+$OS<G)T^=5.U;1S:&DTQ)'M^E ECIZAT+O<YF(EF1&J[KCTEPK?
M2Z_.5S;E;9;E5^Y=VIKO9+U=KU453U;/'32RMF;S*C71NQCDQW87HGJPI//A
M=VON&U&T]#:;NC4NE1+)6544;N9(G/5,,SXJC6MSCIG.,IU*_+M\-J*ZKG%,
MKO3+T5Y%5NW8X*:>L]Z'7'.F-^JS_ *?^*IV7R>^XR5]@OFBZJ;FEH'^?TC7
M+U[%ZHV1J>QKT1?_ !IQ_CN@=#OM*]45$EMM.Y.GZ=N?\D^ X=MQ%VRW=T_>
M7R=E1.F\VK,KAO8R^B]5]C>C_P!@A;S9[? C;K$1Y.9IRIQ-8JKW]GBF)^TN
MX\?NW,T>N-.ZBH:=7NO$?F$K(V_"GC7[7GUJYKT1/[V2XT59:#:+:>WT%1(V
M&BL5L1U3/C">@Q72R?2J.=])[+5NA[5K=EH]TXEE2VW"&YTV%[IHU56JOLZK
MT]IQ7CEW#72&T#K-!)V==J"=*1N%PJ0M]*5?F5$:Q?9(45-RK)BWC1W?]_1V
M55BC JOYWQCE_P!^LH :ZU94ZZUG>M05>?.+E5OJ%:JYY$<J\K4]C4PB?,3F
MX7N*S3%YT=:=,ZFN<-EOMNA92,DK'\D-7&Q$:QS9%Z(_'*BM<J97JF<]*_X.
MS=,QLKG-A5R<ZM:CE1N>N$7HOTDZ=)\!.A;O8*:Y+JF[76*K@;/33TW91Q/:
M]N6NPK7.5.J.^$A?ZA38IM4T7.7PV<5HMS,G(N7;$1,]\3*2FI- :1U_ CKW
M8K7>F.9Z$M33,E<C53O:]4RGT*<-W X#-":CIYI=.256EZY4]'L7K/3JOYZ-
MZJN/TKD^8B=/HG>39B_S6RVP:EMZQRJULEG2=U-4=5PYO)Z+D7&41<KZTR3E
MX6[UN+?=OWU6XU/+%7^<JE(^KA2"HD@Y6X62-$3'I*Y$RB*N,KX*M+71<Q*8
MKMW-X=78O6-2KFS?QYBKX[?W5Q;D[<WG:S6%=IR^1(RMIE16RQJJQSQJB\LC
M%7JK5]?>G5.]#Y@D]Y02Y4%9N[;(*=[7UU+:61U2M7/+F21S&KZEPO-\SD(P
MG58MRJ[8IKJZR^=9^/1C9-RW;G>(GDT+;]@J.*CV4T+'#RHU;+2/56^+G0M<
MY?I<JJ5(%G?!MKJEUCL;9:6.5JUEG:MNJ8L]6*Q?M:X]2QJQ?GRG@56L4U=G
M35'2)=+^R]RF+]=$]9CD]/K;A#VSUIJVZWVZW>Y-N-=4NGJ&QU\;6H]5[D16
M*J(F,8SX'O\ :#8+0.RM^JKSI^[53ZBJIO-9&5M;'(Q6\S7(J(C4ZY:G7/BI
M%KBOX:=5V[<>[:EL%EJ[W9;Q,ZK=[GPNFDIY7=9$>QJ91%=EW-C&%Z]3R=@^
M"*MU[8KE<M;,NVE^9S66^G:UL4[\9YI)6/;S(U,IA%PJ]5[L9T)HI_#Q-=[E
M\%O3<JIRYIMXT<<3//\ ONZ5Y0U:&X[=Z9JX:B&>HI[JL2=F]'.1KXI%=W>&
M8T_<(*VRYU5GN%-74-1)25E+*R:">)<.C>U45KD^943K\QUGB3V)MNQ-^MMJ
MI=1R7NIK(G5#Z:2D2)U-'GE8Y7(]>97*C\=$QR'UW!GP_+N=JW\4MYIN?3-F
ME1R,D;Z-74Y1S8_SS6]'._8MZHJEICU6<;$WF=X<]E47\_4N&*>&OE]=MD\-
MHM07K5.V^G;MJ.@]R[S5TC9:FF]O@_'W/,F'<J]6\V%ZH<.X^=2:HLNU])1V
M>)S;%<*A8+K6PN7G8W&8XEQW->[.7?G4:OPNO2^('?NU[#Z8HZZI@\_N%7.V
M*EM['HUTK4<G:.SX(UJ_ME:GB?4K^)[>7;I>D5UT]?*3N7[ICD_R7M7Z6N;Z
MT.:MSV5RF]53[.[OKW#?LUX=%?\ J13S^/\ V5/18IY/%?\ M*W3]6Y_Y& A
M/O9M)<=FM?5VGZ[FGI\]M15BMZ5,"KZ#_G3"HY/!S51.F";/D\/RE;G^K<W\
MC =%J==-S%BNF=XF8<3H-JNSJ$VZXVF(EP[RB5742;O6.F>KO-XK(Q\;<KCF
M=/,CE]75&MS\R$7Z&LEMU9!50/6.>&1LL;VKC#FJBM5/4J*A8CQF\.5VW<H;
M=J+3,+*F_6N-T,E(Y_*ZI@5>9$8J].=KLJB+C*.7KE$18V;*<(&M]5:YH/Q2
MV"HL>GZ2H9+72W!G(LT;7(JQ,;GF5785.9/11.OL5AY5FG%VJJZ1T-2P,FO4
M9JIIF=YC:5E&&ST7IM16O8G,UW=A4ZHOUE>O );Z9N_]Z1>5_FEIJE@\<?V1
M"W*+^E54^DF]N[KVEVSVVOVH:F1L?F=*]8FKT[2545(V)[5<J)].2N7@^UU3
M:&WWLM37R)#1W!LENEF>O1G:)Z"JOJ61K47U)U\"JP[=55B],+_4[UNWEXU-
M76)_798IO!ME8-U-(^X.I*NHI+<M0R?FIJAL+G/:CL(JJBHJ=<XQX)ZCB2<"
MNT&.MYNF>[_A*+_4.F<3>TE1O-M37V2WR,;=8I&UE$DBHC7RLYO05?#F:YR9
M\%5%*[+/PV;EWG5,%A71]UHZA\G9/J:JD?'31-SA7NEQRJQ$3O15RB=,D8=/
M%;G:[P[=S/4ZXIOT[X_'O'*5I>GW6C36GZ"ST]TBFIZ&FCI8GS3L5[FL:C45
MRIC+L(G@A SABLE'3\9EVIV(QT5!5W3S;EPJ='2,3'A\%RGW^N/)]:4L&GZZ
MZPZWN%II:*F=/435]-'4,8UK<O=AJQ].B]/X2-'#CN!3[9;U:;OE5,L=K94+
M3U,CO11L,K71J]V/B\R.7]*;>-:H[&[-JJ9F8VZ*[.RKE.38IR*(IB)^._)/
M/CAK)J;ATU*R%%5)I:6.1R*J*C?.(W+_  (F/%%4J]_TX+A-XMOX=W=K[[IA
M9TB]TJ=/-Y^]K)6N;)$Y?6U'M:JIXHBE<%1P?[LT^H/<K\2<TJN>L;:R.6-:
M96HN$?SJN$3QPJ9QX9/32K]JU;JHKG:7GK^)?OWZ+EN)FF8[G)JJ[U]=2P4U
M36U-130-1L,,DJN9&B=,-15Z)X(B8/.T)_QYT\OC[HT_\JW/_P!2RO3/"3MQ
M9]NK59]1:=M=TKZ*E1M9<TC6&263JY[ED:K78157&5RC40KMNM78H=X):C34
M'F&GH+PGF+.T=)RPLE3E<KGJY5RB<W>OPC>Q\RWD<46Z>G>I\K3KV%-J;U>^
M\QR^"VS7*9T)?L?\WU'\FXI=+K=1VY]VTU<Z&)S4DJJ22!JN\%<Q43^$J.UQ
ML3KO;:R^ZVI=/36FW^=-HFS321JBRN:]41$:Y55,-=Z7P?;U0K-'N4T\=,SS
MF5[^T=FY7V==-.\1'/R6A\/U+#1;'Z"BA1$C]Q*.1>7Q<Z%KG+]+E53E^N.#
MO:_6VK[O?KM=[DVY7"I=/4-9<(FM:]5QA$5BJB)C")GP/=<%FO:76>Q-BIHY
M6K765JVVJCSU8K%^UKCU.C5B_/E/ BWQ<<,>KK;N9>-3Z>LE;?;)>)G5KEM\
M+IY*>9RYD:]C454179=S8QA>O4TK-%49%=$U\,K7(N4S@V[D6^..7+X<DJ]F
MN'O;_9#4%7>-.W>J?45=,M+(RMKHY&*WF:[*(C4ZHK43.?%3E/E&5H;CMUIB
MLAJ89ZFGNRQ)V<B.<C7PR*[N\,QM_<.9\/W Q6[@V*YW37;+MI3TFLMU.UC(
MIWJF>=\K)&*Y&]41$7"KU7NQGFG$QL+:]@[_ &VU4>IGWRJK(75+Z62D2)U-
M$B\K'.<CU1W,J/1.B8Y/:;UBU;JR8GM.*J/I_=5961>IP)I[&***OK_98)PI
M4D-'P\Z'9%CD?0]HOM<][G._=52O7B^KJBNXC-:OJ,HL=3'$U%7*(QD,;6]/
M4J>'K55\2:/ 7K^FU3LI365946X6">2EEC5R<W9O>Z2)V/5ASFI_>U.3\:/"
MYJ;4.NY-;Z0M4EXBN$;&UU'2HBSQ3,;R(]&YRYKFHU%Y<JBHJ^)CB7(L9M?:
M<IG?]=WKJ%NO+TNW-F-]MN7Y;2CMPN5T]MW_ -#2TRNYW7*.)>153+'HK'_Y
M+G=%\,EE7$A^4+K[K_\ >:J_DW$4>#GA5U3:-PJ36>L+;+9*.U\ZTE)5=)IY
ME:K4<K>]&MYE7*X5781$QDE?Q(_E"Z_]7N-4_P FXQS;M%W+HX)WVV_5ZZ3C
MW<?3[O:QMOO.WY*?P =?'1\Z_F>\T%_QZT[^J--_*M+CM>=-"Z@Z_P#WNJ/Y
M)Q35I*H2CU99JA7<G8UL+^;XO*]JES^H[<^\::N=#&J-DJJ26%BKW(YS%:G\
M)R^KSM7;W^KN_P!G(WLWJ8Z\O[J22Z7;6AI[5MUINEI,+30VRF9%RIA%:D34
M12I;76P^O-M;-[K:FT[46F@\[;1-GFDC7,KFO<B(C7*JIAKO2^#T[^J%D?"/
MN=2;F;*V%4FC=<[33MMM="U?28Z-.1KE3U/:UKOI5/!1JD]K:HJHG>(GFQT#
M>SD7+5R-JICDK.WENU5?-VM:5M:KUJ9;O5JYKURK425R(WYFHB-1/8>QX>+I
M56??+0-12/>R9UZI(5Y%5%5DDK8W)\RM>Y%3V^KJ2#XI^#+5C]?W75.BK>M\
MM5UG=65%'!(B3TT[LK(O(N.=CG*JIRY5,XQTROG\)/!UJJV:^H=8ZXMWN116
MI_;TE!-(CIYYD1.S<J-7T6-7TO27/,U$QC)O59EC\+RGNVV_X5=.FY7X_P!V
M=^+??\^NZ8F]%#!=-H-9TU2B+%)9JM'*Y,X^TOZ_.G?]!3(6G\:VZ]+MSLM=
MK<V9J7;4$3[;2P(J<RL<F)GX[^5K%5,^"N;ZT*L#RT6FJFBJJ>D]&W^TERBJ
M]1;IGG$<PL;\FQ1P1[/ZAJ6HBSRWR2-SO'E;!!RHOTN=]97(3B\FMKZD@EU3
MHZHF;'5U#F7*E8Y<=HB)R2HGK5$2-?K]1L:K3-6-.S0T&N*,VGB[]X2$WQX<
M-#;TWZ@N&K+E74M71TWF\,=-61Q-Y%<KE7#FJN55<9]B'QVD>#+:G0^JK5J"
MVWJY^?VRJCJX.UN43F<S'<R([T,JU<85,]RGS?'?PZZ@W,9:M6Z6HGW6X6Z!
MU)54$*(LTD/,KV.C3[I6N5R*WOP[IW+F-NP'"!JS<[6D=+J>R7K3.F:=KEK:
MRHIUI97*C5Y8XDE8N7*_&5PJ(F?'!26*=\;>;VT=\.IR;G#E[1C<56_*I/3B
M9J+7>]@]>TRUM-*J6F>9C$E:JJZ-JO;A,]_,U"O7@IZ<3FB/[[4_S28Z#Q+<
M&>GMCM#SZEI]954J+.RFI;=5T;7OJ)'*OH]HU[43#$<Y?1^Y7UG/N"C\TYHG
MP^VU/\TF-_&MT48=R:*MXY_3N5&7>KNZC9B[1PU1,=^_>GYQHUCZ'AGUN^.1
M8U=#!$JHN,M?4Q,<WZ4<J?25**6P<<V5X8-9X15ZT7\]@*GU,]%C_0KF/BP_
M:2=\JB/I_>5OW">]S^';0BN=S+[FL;U7P151$^I$*U^*W\T3KW]47?Q&ED_"
M;^9UT'^IS?X7%?&\[*"?C)NL=U:U]K=J2G2J:[N6'GC[1/VN34P)X<J[,=V_
MZK'5*>+!L4[[;[?H^ZV1\G]J#<&RTE\U5=?Q+VZJ8V6&C;!VM7)&J=%<BJC8
MLHJ+UYEZ]40[FSA%X?-I(XYM6W2.:1J91^H;PV#F^9C%C1WS87Z23.JH+G5:
M1O$%EE;37:2BF912NZ(R98U2-5^9V/J*@W;*[GZEUG4VN;2=_K+]+,J3OJJ:
M3*N5<*Y\SDQC/7G<["IW*8V;MS-JJFY<X(A-^Q9TVBB+=KCJGOE;9MI6:7KM
M$6J31B4K=,*QS:)*&'LH>1'N:JM:J)TYD7KCJN5ZYR53\5Z8XB=>?JB[^*TM
M&V/V^FVNVHTSI>HF9/56^D:RH?&JJUTKE5\G*J]<<[EPJ^'J*O>+>G=2\1VO
M6.RBK7\_7U.C8Y/X2-+VC(KVG>/C^;/7.*<2U-4;3O'Y+4-GNNTVC%7_ )FH
MD_ZAA49OU65%;O=N!-5*YT_N[6M7F=E6M;4/:C?F:B(U/8B%NFS_ *.TVB\_
M\RT?\@P@MQ@<(>KW;DW/5VC;/+?+3>)?.9Z>A;S3TU0Y/MF69RYKG9=S-3O<
MJ+C"*N&F7J+>17%4[;O36,>[>P[?9QOMSG^CG7 ;7U%'Q-::AA5S8JN&K@F1
MJKA6I322(BIZN9C%^<G%QSTT53PP:R67#5B\TD8YR?!<E7$F4]JHJI])QC@6
MX6=1Z'U54:XUC;WVB>*!U-;;?,Y$F17HB/F<U/@IR^BC5ZY<Y51.A];Y1G<*
MFL6T--I9LS5K[]61JL**BJD$+DD<]4_3I&GTKZCUR:XR,^GLYWVV\GEAT5XF
MDW)O1MOOY\D?_)L?E]73]0*C^7IR0?E+/RA[7^KU/_(5!'SR;*XWYN?Z@5'\
MO3D@_*4I_P!HBUI_^7J?^0J#/*_\C1^3SP__ !%S\W@^3,I(8]F]15343MYK
M](R1_CRMIX.5/K<[ZU.H[[<-NA-[+_;KCJRY5U+545-YO#%3UD<+>17*Y55'
M-5<JO3/L]A'7R96X-'2R:LT942MCJZAT=RHV.7':(B=G,B>M4^UK\RKZC['C
MXX<-0;FQVC5VE**2ZW&VP.HZRWP(BS20\RO8Z-/NE:Y7(K4ZX<F.Y<ZEZF8S
MZHFKAWZ2W<:Y35I=,Q1Q[=8_-]+H_@KVET1JRSZBM=\NC:ZUU<=7!VURA<Q7
ML=E$7[7GE7&%1%3HIT'B>J+5?-@-?4JUU-*J6>HF8UDK557QM61F$SW\S$(
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M8Z;OJ^FW>UQ:*IZ[-P ::S
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M3_19&S*10QY7$;$ST;U\>O557*JJK\R;D6,.SCSO3',S=6RL^(INU<OA'*
M&ZIV6^)DPWQ,@  !N  QALWN4R8;W*9!(;&IL$!EOB8,M\0-@ 1 RWQ-C5OB
M;$2  )[D2&QJ;&)   AEOB;&K?$V &YH;@#9O<:FS>XGN1( "#N;@ ,0RWQ,
M&6^(&P  -[S8U;WFP1WALWQ-39OB"60 &+9O<IDPWN4R    V-38"7G!YK[W
M3TW7:6J)<U%N>L].BKU6%[LJB?I7JN?T[4)'XQGH5R[1:X=M]KZUWA7*VE8_
MLJIO5<P.]%_3QPGI)\R%BM/,VH@9(QR.:],M<U<HJ+XH<=J-GLKTU1TE]J_9
MC._%8G953[5'+\NY_1?@J<HXDM"?BXVSKUACYZ^V_P!FT^$RJ\J+SM^EBNZ>
MO!UK&$4_F]K7-<BIG/>G[A7VZYMUQ7'<Z;*QZ<FS79KZ51LJT!]SO5H9=OMQ
MKM;&,Y*-[_.J3U+"]5<W'Z5<L_8GPQWEJN+E,5QT?GC(LU8]VJU5UIF8:  ]
M6LPIJ;*:AE 84R84'>P  EA>XU-E[C4   -5,&5,!E :KWJ;&J]ZDPB E!H+
MB_M6CM&V:R2V*LJ'V^DCIW21R,1'*UJ)E$(OF%[C5OX]&1$17W+3!U"_@535
M9G;=]+N;JZ+7>NKQ?J>"2EAK94D;#(J*YOH-;U]?5I\P >]%$4TQ$=S1NW*K
MU<W*^LSND;L[Q56O;3;ZVZ=GLM9634BRJZ:*1C6NYY7O\>[X1RS>W<BFW2US
M+?J6CFHHWP1P]C,K7.RU%3.4/@@:U&+:MW)N1'.5G>U3(R,>G&KGV*=N6WP?
M9[4[JW?:;4:72V<D\4C>SJJ.95[.9F<X]CO%')W*JYRBX63]#QO:2?0HM99+
MS#5<OIQPLBD;GU->LC55/:J(0M,*>=["LWYXJHYO;!UK+P+<V[57L_">:1&L
M^,&YZCOEI2@H'VNPT==!55#&R\U15LCE:]6*["(U%Y>K?W51<'LMT.+>U:]T
M+=[!!8JRFFK8DC;+)(Q6M])%ZI]!&0","Q$Q,4\X>DZ]G54UTU5;\77D^AV\
MU-%HS6UEODT+ZB*@J6SOBC7#G(B^"J2!W$XO[3K31-ZL45AK:>2OIGP-EDE8
MJ-54[U0BZ#UNXMN]7%=4<X:V-J>1BV:[-N=J:NO+Z;-5)8:6XT+-I_3-LM;M
M/5TKZ.DBIU>V5B(Y6,1N4^HB>I@SOXUO(VBN.C'"U'(P)JFS.V_T>SU/=F7[
M4UWN;(W11UM9-4-8Y<N8CWN=A5\>\[3L+Q)VW:+1]59JNSU=?)-6OJ4D@>UK
M41S&-QA?TJG S07,>B]1P5]&.+GW\2]-^W/M3OYND;\[JTV[NLJ:]4M%-0Q1
M43*58IW-<N6OD=S93].>_P!B^)*Y;2PNM552^ZM@?*LJ0M?RRP.7X2QJOAXJ
MU>F>Y4RN>, B<:W5:BS,<H94:EDV\F<JFK:N>J:U3QRZ/2A<^&RWF2JY>D,D
M<+6Y]2N[1>GMPOS'/;-QK7C\6T]QNMNS8/-W0PVJC<F6/5S7)(Y[D])V$<WP
M3KE$3QC2#6HTW'IB8VWW6=?[1YU<Q/%MM\(=PXA-^[)O-9[;#3V:KH*^@G5\
M<\TC'-[-[</;A/:C%_8GD</O$A;=G=*U]IK+15W&2IK752/@D:C418XV\O7]
M(IP53![_ (.UV?8[>RTZ=6R8R)RHGVOLZ=Q [MT>\6JZ.[T=#/01T]&VE6.H
M<U554D>[F]'V./DMN=4Q:*UQ9K[-"^IAM]2V=T4:X<Y$\$/GC0]:;%%-OLHZ
M-.YF7;M_\35/M[[I4[B\8]HUKH:]6&&P5U/+7TKX&S22,5K5<B]50BL 1CX]
M&/$Q;[WKF9][/JBN].\Q&S"GM=(WIFF]6V6\2QNFCM]=!5/C:N'/2.1KU:GJ
MS@]4I@]ZHXHF):-%<VZHJCK"6NL>-2S:ETC>;.S3U?#)7T4U*V19(U1JOC<U
M'+]9$H U[&/;QXF+?>L,S4;^?-,WIWV2'V(XHK9M)H9+#5V:LN$WG4DZRP2,
M1N'8Z87YCG&^^YU+NYKE;]1T<M#%YK'3]C4.:YV6\W7*?ICG@%.+:HNS=B.<
ML[NIY-['IQJI]B-N[X)![(<6U;MQ:(+#?J&2[6BF;RTTT#D2>%O>C/2Z.;ZN
MY6ITRO<G6+KQWZ2BH7NMU@N]758]"*H;%"S/M>CW*GT-4A$I@\+FG8]=7',<
MV[8U_-L6NRIJY?6-TH-$\;UUHKW>JO4UO=74E5V?F5'0JV-M*C>;*(JY5W-E
MN55>]/!.B<[XB=Y;-O-=+3<[?::JV5U)$^GF=4.:[M&91S,<OQ563]L<C-5[
MU/6C"LV[G:41M+7NZOEY%B;%VK>F?ZI+[(\6-JVLV\M^G*NQUE=+323/66&5
MC6KS2.>G\)Q[>;7]-N=N)<]1TM)+1P5:1(D,RM<YO)&UGA^E/B09V\6W:NS>
MICG+RO:ED9&/3C5S[-/3E]-D@.'CB6MNS.DJ^SUMGJKC)4UKJI)*>1K6HBQQ
MMY>OZ1?K/C>(;=^CWEU;0WFBH)[?'3T;:58ZAS7.54D>[F]'V..8FA$8MJF[
M-Z(]J4UZEDW,:,29]B/H  W(W5?T:J2UT!QJV;1^B[%8IM.U]1+;J&&D?*R5
MB->K&(U7(GMP1*4P:M_&MY'*XL<+4+^#,U69VF7O==ZBCU;K.^WR&)\$5RKI
MJID4BHKF(]ZN1JK]))K0/&M9M'Z)L5CFT[7U$MNH(:1TK)6(UZQL1JN1/;@B
M0#&YB6KU,4U1RAGC:ED8EVJ]:G:JKKR>[UYJ*/5NM;[>X8GP17*NFJF12*BN
M8CWJY&JJ?.2 V3XN;3M;MO;-,U-BK:R:C6972Q2,:UW/*]__ +Q&(&5S&MWJ
M(MU1RACC:A?Q;U5^B?:G?SG=]IO)KRGW.W(O.IJ6FEHZ>N6%6PS.1SF\D+(U
MSCOZLR?,:>O]PTM>*.[6JJ?17"DD26*:->K7>/S^I4\4Z+E%5#PC0]:;5--$
M6XZ0UIOUUW:KTS[4SNF+H7CVIF4+(=7Z>J'5+&X6JM"M<V5?[W(YO+^V7V(G
M<>^O7'OI&GII/<NP7BMJ>7+&U*10QJ[HJ(KD>Y4[URN/ @X:J5TZ9CS.Z_H_
M://IHX-XGZ[<WW6[>\E_WAOK:^\R,A@A16TM#3Y2&!%QS*B*JY5WB[O7IX(B
M)\( 6=NW3;IX:(VAS]V]<OUS<N3O,B]RFU/42T=3%44\CH)XGMDCDC=AS'(N
M45%3Q_@-5[E-3/E/*7G3/#,3WI4;8\=-SL=#!0:PM3KTV-O+[HTDB,G5$[N=
MBIRN=[45OT]YTFIX^="QTZN@LM_EF5%5L;X86(BIX*O:KCZ$4@<"JKTW'KJW
MVV='9_:'/LT<$51/WAV7>[BDU'N_3NM;(6V+3_,CG4-/(KW3JBY197X3F1%3
M*-1$3.,HJHBIQ<RI@W[5BBS3PT1M"GR,J]E5]K=JWE+W0'&]9-&Z&L-AFTY7
MU$MMH(*-\T<K$:]8XVL5R)[<$6M;WZ/5.L]07J&)T$-RN%16,BD5%<Q))7/1
MJJGBF>\],IJ>5G$M6:IKHCG+8R-2OY=NFU=G>*>G(-5[U-C5>]3<5H  -  3
M(VAE?3RLEB>L<D:HYKV*J*U47O3'<N26FUO'K4VBVPV_6EHFN3H6HWW2M[F]
MM(GASQNPU7>MR.3YO$B2:&K>Q;61&UR-UAAY^1@U359JVW_HGO<_* :'AHU=
M0V*^5-3R<S(Y8H8F<WQ7.[1RI\Z(I%?>WB!U%O;<8W7'EH+13N<ZEMM.]5C8
MJHJ<SE[WOPJIS+A,*N$3*YY@#7LZ?9QZN*(YMS*UK+S*.SKJY?".0F<]^/'*
M+CQRA*G9OCDK]*VFGL^LK=-?*6G:C(KC2N3SE&IW(]KEQ(J>#LM7IURO4BL8
M4][V/;R*>&N-VIB9U_"KX[-6W]T\KSY071M/1.=:[!>JVLY<LBJ6Q01I^F>C
MWJGT-4B#NSNY?=XM3NO-\D8WD;V=-1PY2*GC3KRM1<]?%79RJ^S")\4#QQ\&
MSCSQ4QS;67J^5G4\%VKV?A'(-5-C52P4Y'(^*1KV.5CVKS(]JJBM5.Y>GBBI
MWH2YVEX\9K):(;;KBV5%U6!B,;=*!6K/*B)T21CE1%7UNYD]J>*Q%!J7\6WD
M1M<A88>??PJIJLU;;IP:W\H-9H[7)%I33]=47%S5:V:Z(R*&-?!W*Q[G/_2Y
M;\Y\GM;QS-TII=U+J6V7&_7>:JFJ)JQDS&M7G?E&HB]R(BHF.Y,=.A$E3!K1
MIF/%/#LLJM?S:KG'Q=VW3D^SWCUY!N9N3?-3TM-)1T]PDC>R"9R.<SEC8Q<X
M[_@G8]@^,^NVQL5/IS45NDO5EI6JRDGIGHE33MS\#TEY7M3/3JBM3IE43I&D
MU-FK$M7+?951RA7V=0R+%^;]NK:J>OP3WO/E"M'04#W6O3UZK:WERV*J;#!'
MGU.>CW*GT-4YUH'CWN]OO=]K-5VU]QI:M8UH:2WN;&RD1O-S-3FRKLY;E57*
MJWIT5$2)H-:G3,:*=MEA5^T&=77%45;;?1V3B8WNL>^5[LUWMMGJ[574<#Z6
M=]3(QW:Q\W,Q$Y4Z*U5?^V.,(O?U^8%C^UW"YM/7Z?TYJ9FFVS3U-'3UK8ZB
MKFEAYGQM?E8W/5KDZ]RHJ>PF[>M8%N*(B48V->UB_5<XHB>_N=+V*KKO7;0Z
M2J;Y$L5S=;H>U1V>9R(WT7.SW.<WE<J>"JJ$$^-O<+\66\M1;()>>@L,24+$
M:OH]JOI3.^?F5&+_ 'LFIO?OII_9G2M745-5!/=UC5M#:T>BR3/5%Y55J=48
MBIU=X(G3*JB+5G<KA4WBY55?63.GJZJ5T\TSN^1[E55<OTJ5FEV)JNU7YC:'
M0_M!F1;QZ,.BK>>6_P"3QCNFQ/%GJ79FD2TRTS-0:>YU>VCJ)%CE@RO7LG]<
M(O>K514SW8RN>%@Z&[8HOT\-R-W#XV3>Q:XN6:MIA8%0>4*T%+$JU5CO]/)R
MYPR&&1JKC.$7M47/?WICIWGR.X'E#8)*"6#1FGJB.ID3E;5W=6HD:JG?V;%=
ME?5EV/6B]Q"I3!7T:7CQ.\\UY5^T&=7'#Q1'VAYU[OE?J6[U=UNE7)77&JD=
M-/43+ESWKX_Z$[DPB'@@%M$11&T='.U5S75-54\VA]QM'O)J/9G4;KMI^=B=
MHWLZFBJ&JZ"I8BY1'-14ZHO5'(J*F5ZX547X<&%5%-RF::XWAZ6KU=FN*[<[
M3'1/G3GE$M)5-'&E]TW>+?5N7#FT?95$+?;S*]COJ:>GUKY12VLMTC-(::K)
M:YW1DUZ<V../IW\D;G*[KGIS-^?P(.J:E9&EX\3NOJOV@SJJ.#?\]N;W.I]6
M737.HZJ]W^NEKJ^LDYYZA^%7O[D;T1$1,<K4PB(B(F"7.@N.+1&W6D;=IVRZ
M+ND-!0Q)&Q5GBYGKXO=ZW.7*JOK4A:#<O8EJ]3%%4<H5^+J%_%KJN43SJZS/
M-]]OCO!<-ZM>U5^K&OIZ1$["AHE?E*>%%7">I5=GF<J>*^I$.D<,_%I-LE9:
M^Q7:@J+W99']M210R-8^FD7X;4RF.1W?CP5%]:D=P*L6U7:[&8]EC:S\BW?_
M !%-7M)-\17%!H[??2+:!VF+E07>CD66@KGRQN2-5PCFN1.JL<B)E/6C5ZXP
M=Y\GBG_:5NB+W>[4W\C 5UEB/D]9(V;*W-'+C_=N=?\ J8"GS[%%C&X+?3=T
MVBY=>3G]K?F.+:?H]7Q#<3>H-B-]J2EB@;=]/55GIY:BV2OY.5_;3IVD;NO*
M[")X*BHW"IE$5/(?Y1+0+:!9&6'4+JM&](5A@1O-A%QS=KW>W&>G<<2\H4]'
M[VVYR=WN'!_+U!&0SQM/LWK%-=<<V&9K.5BY-RW;JWIWY;\W7-_^)346^U='
M'6,;:[#2R<]+:X'JYJ.[NTD=C[8_JJ=R(B+T1,KS<@\47U?Z?]/B;*:EW;M4
M6J(HHC:'*WLB[D7)N79WE*[9GCUO.C+52675]M?J&BIVMBBN$$B-JV,3HG,C
MO1E5/6JM7IE<YR=>E\HGM['3\\=EU(^957[6M/ WQ\5[9?#U>KP*\S"E=<TO
M'KJXMES9U[-L41135OM\8W=YW_XN]1;U4C[-34K=/Z:[3G=20RJ^6IPN6]J_
MHBHB]4:B(F>_FPF."@%A9LT6*>&W&RHR,J[DUS<NSO,I+;$\;U^VPM--8-04
M*ZDL=,U&4TB2]G54[$3HQ%5%1[43HC785.[.$1$[R_RBVWB4SGMLFI'39QV3
MJ>G3U=<]MC'7YRNY3!H7--L7:IJF%OCZYF6*.SIJWCZPDGOQQLZ@W6M%5I^R
M4":<L%2B,G5)5?55#>]6N>F$:Q>F6HF5ZHJJBJBQJ7O]:)]?SFQH;MG'MV*>
M"B-H5F1F7LNOCNU;RG'M9Y0VV46G;?;=;62X2U]/&V&2Y6US)4GPF$D>Q[FJ
MUR]%7"KURO3N/C>*#B^TQO1H%NF['8[K3N\YCJ?/+BL<7(K<HJ(UCGYRCE\4
M(G U*=-QZ+G:TQS6->M9==F;%<Q,3RZ<WW>S^]&I=D]2+=]/5#,2M[*JHJAJ
MN@J6)U1'-14ZHO5'(J*F5ZX5468^F?*/Z0JJ./W=TW>;=5YPY*+LJF%/;S.<
MQW^25^FIZ9&!9OSQ51S>6)JN5AT\-NKE]4[=<^4@M;+;(S1VF*R6O=T9->U9
M'%'T[^2-[E=USTYF_/X$*M8:NN^N]0UU]OM;)<;G62=I-/(O>O<C43P:B81&
MIT1$3&$/3@],?"LX_P"[CF\\O4LG-Y7JMX^'<^OVIW8U#LYJN&_Z=J&QU#6K
M'/3RHKH:F-5RL;VHJ93U85%SUZ=Y-;3_ )2#1T]J:Z]:<O='<$9E\=$V&>)5
M]37.D8OUHGSE?"F",C!LY,Q57'/XO3#U3)PJ>&W5R^J6V[/'W<]85M#0Z<MM
M19-/QU<4M9(^5%K*R)LC7+'Z/HQM<B*CD15RBXSA51?>[H<?=@U[MWJ/3D&E
M[E33W6AEI&322QJUBO8K4<J$*U-3SC3L>-MJ>CV]-9D\6]7O=0 %FI6'?"]>
M/]LDYMJ?*)VVAT[06W7%DN$UPIXVP27&W*R5*CE3"2/8YS>5R]%7"KURO3N2
M#*F#3R,6UE1$7(Z-_#SK^!5-5F>J6G%)QA:6WLT"W35DL-TIW>=157GER[*/
MLU9S(J(UCGYZ.7Q3O(_[3[P:FV:U$V\::K>P>]$;44LK>:GJ6)E>21OBG?A4
MPJ>"H?%@6L2U:M=C$>RF]GW[]Z,B9VJCX<D_](^4HTU4T3$U-I:Z4%9G#G6M
M\=3$O=Z7INC<GCTZ]W>IIK/RE&GX+=(W2FE[E5U[D5K7W9T<$35\'8C>]7)[
M,M^="  -/T5C<6ZR]/YO!P<4??;F^KW,W/U%NQJ>HO\ J2N=65KTY8V-3$<$
M:*N(XV_<M3*]/'*JN5557Y$W-"WMT4T4\-,;0H+E=5VJ:ZYWF0]GIO4UTT=?
M:*]66LEM]THI4F@J85PK7)[/%%3HJ+T5%5%RBX/6!>Y1-,51,5<XEC17-%7%
M3RF$Z]N_*44K+>R#7&F*IU7&W"UED5CDE7UK%(YO+[</7YD[CZ2^>4HT32T4
MJV?35]N%6C,QMJ^QIXE<N%1%>DCW)WKUY5[BNX%55I.-,[[.AIU[-IIX>+R=
M&WPWYU-OMJ%MROTL<-- G)1VVFRD%.U>_"*JY<[IS.7JO3N1$1/"V'W(IMI-
MUK%JZKHY:ZGMKI7/IH%:U[^>%\?15Z=[\GPJ]QJ;_86XM=C$;0J/Q-VJ[V]4
M[U;Q._V3#X@..2Q[Q[27W2%'IJX6^IN/8<M1/-&]C>SGCE7*)W](U3Z2':F3
M"F&/C48U,TV^C/*S+N9<BY=G>8C9-/9SCZL.VFV>GM+U.E[E63VRE;3OJ(IH
MVM>J97*(OSD6]X==0;E;F:BU12TLE'!<ZI:AE/,J*]J81$153IWH?' PM8=F
MS7-RF.<O:]J%^_;IM5SRIZ)H;(>4/FTGIZELNN[157GS.-L,%TM[FK4/C:B(
MG:L>Y$<['W2.3.$RF<N7[G5_E+=*TM!,FF-,76OKU;ACKIV=/"U<=^6/>YW7
MO3#>[OZY*]C5>]37JTO'JKX]F[1KF91;X(J\N::6U?E&:ZR6NYLUQ:JF_7"H
MKGU$$U"Z.*.&%S6HD*-7P:J+A5RO7JJKU7@'$ENK9MY]RI=5V:U55H6JIHF5
M<54]KE?,Q%8CT5O<BL2-,?G3E@-FUA6;-R;EN-I:M[4LG(M1:N5;PG=HGRC&
MG=*Z/LEFETE=)Y+=004CI63Q(CUCC:U51/G0^/V-\H)<M#4WN/K*W5&H+-$]
M4I:VF>GGD$:JJHQR.7ED1$PB=6JF,95.Z("]QJ>'HS'VG>.K8C6LR.':KW5B
M.J_*7:1I[7)^)O3-XKKBYOH-N*14\#55,Y<K7O<N%\$3KX*08W1W0U!N]J^K
MU'J2K\ZKI_1;&Q,101I\&*-OW+4RO3/5555RJJJ_*FA[8^!9Q9WHCF\<K4LC
M,CANU<OA#L/"SOA1; [B5FI+A;:BZ036V6A2&F>UKD5TL;^;+O#[6O3VG2.*
M?C'LV_VWE)IRWZ?KK3/#<8JY9JF5CFJC8Y&JWT?'[8GU$5C"F56'9KNQ>F/:
MAA;U"]:L3C4S[,O9Z6U1=-&Z@H;W9:V6WW2BE2:"IB7"M<GL\45.BHO14RBY
M1<$X=N/*9TL5N9!KC2U4M7&W#JRQJUR2KZUBD<WE]N'N^9.X@4!D8=G)C_4A
M&)GY&'^ZJY+&K_Y3/0M+13>XNF;]<:M&9C96)#31*Y<*B*])'N3O7KR],$*]
M\M_M4;^:C9<[_+'!24Z*VCME+E(*9J]^$55RYV$YG+U7">"(B<V!YX^GV,>>
M*F.?Q>V5JF3ET\%=7L_" U4V-5+)5=S!W'87B\UML3&RW4LC+YISG5ZVFN<J
MMCZ^EV3^^-5[_%,Y7EZY.' \;MBW>IX;D;O?'OW<>KCM5;2L@L'E.-#5=(SW
M8TM?K=4NQS-H^PJ8VY_/.>Q5_:G\]0^4\T92T3_<+2=\N-4G1K:]8:6)?;S-
M?(N/V)7&"J]$XV^^T_U7OI_-VVWC^BTC8#CKTANW,VT:A;'I#4+E5(XZJ=%I
M:COPC)5QAV$^"[&>Y%<<#\HEIW;G3%ULL=ALU+1ZRN+G5E9/0N6-GFZ(K6J^
M-%Y.9[\JCD3.(W9SDABG>O\ MCU?_4_I+4S53F=M+)+R,[-O:.SAJ=R>/1/5
M_I,K6FTV;_:VYVCX,;^L5Y./V5RF)J^+W&B-<7O;S4M%J#3]?);[I1/YXIHU
M^MJI]TU4RBM7HJ+UR3LT!Y3BQRVR&+6>E[A27%J(U]1959-#([Q=R2/:YB>S
M+E]I7N:&UD85G*YUPT,34,C$W[.KDL*U]Y3JR1VV6/1>EKA57!R*UL][5D,,
M:_&Y8WN<]/9EI!#6NM+SN%J6OU#J&N?<;M72=I-/(B)GIA&HB(F&HF$1J=$1
M.F$/2&%&/AV<7G;CF9>H9&9RN5<DIN$_C%L_#QH2Z6"X6"NN\U5<WUR34TS&
MM:CHHV<N'>/VM>OM.=\5.^E#Q [CTFI;?;*BU00VR*@6&J>U[E5LDK^;+?#[
M8G3V'&P33AVJ;LWHCVI8U9UZNQ&/,^S"7?#%QS4.QNV,>E+O8*Z\>;U<TM-+
M2S,:UD3U1W(J.\>=9%S^>0^%XN>*&GXC;AIQ;=:JJSV^SQS)V-5(USGR2.9S
M.]'P1(VHGTD?5,&-.#9HN]M$>T]*]2R*\?L)J]G_  E#PD<7EHX==*WNTW*P
MUMWDN%:E4V2EE8U&(C&MY5YOF/C>+3B#H>(C6=HO=NM55:8J&@\S6*JD:YSG
M=HYW,BM[NCCB!JIE3AVHO3?B/:8SGWJL>,>9]F&  ;S0:J8,J8    :FQJ
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M+?$V-6^)L  _V^KO"?[?23*-I9;XF3#?$R0=P  CJW  0V;W*9,-[E,@ WO
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M)(YSM#53!E3'^C(WC?=.T]  $H:@  :&YH$P&JFQJH(8  2+W*:FR]RFH2
M@VEJI@RY?2QXF GN84U-G?P&H3$2&J]ZFWL\35>]20  &@ )D#0W_P#H:?\
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M_4F "]RCV^ 7N4BGGTE/T:@ F3;?DPO<:FR]QJ0F.084S_M_F,*1O"=IZM0
M2?4-5[U-C4G>$[2  R0PO<:FR]QJ&4!H;FOU>L;_ !1$;=6#"F3"ADP  -
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ML?QB^&?V")#<T-R(0  2!EOB8,M\2$2R  Q;-\3)AOB9"8#9O<IJ;-[E!+(
M" V-38   !EOB8,M\0-@ !LWN4R8;W*9#&0V-38(  !N  ,M\38U;XFP RWQ
M,&6^(&0    8MP &09;XF#+?$,6P  V  &S?$R8;XF0Q[V6^)L:M\38CO)
M1*&P '<!EOB8,M\2!L  B&6^)L:M\38(#+?$P?9[.[:U6[VX5GTC25L5OJ+E
MVO)43M5[&]G$^5<HG?E(U3Z2*ZHMTS75W<V=JBJY7%NF.<SM_5VKATX);WN[
M;Z/45_KDL>EJA.>/L%:^JJVH['HIU1B=%])V5RB>BJ*<FX@-&6S;[>#4^GK-
M$^"V6^=L4+9'N>["1,<JJY5ZKE57Z<=.XM7V5T!/M=MC8-+555'75%M@6)]1
M$Q6L>O,YV41>[O(F\2O!?>=0ZDUSN,S4=##1]C-<O,U@>LG+%#E6\V<97D[_
M &G,8VH\>35-VKV9Z.VS-&[+"IBS3[?67RWD\]"Z;UO=M;,U%8;7?FT\%&Z%
MMSHXZE(\NE1>7G:N%7"=V/ ]OY0G;W3&B+/HQ^G=.6FQ+43U23.ME#'3+)AL
M:HCN1J9QE>_/>I_;R9"XOFO<_P#>U'_&E.A<=NVFHMU*W;NPZ9MSJ^ODJ*R1
MV%1K(6(V'FD>Y>C6IGO7JJJB)U4PN7>#4?:G:/+H];6/%S1_8IWJ\^JN4V_^
MI-JR^3/K)+:C[MKN&GKG-ZQ4=M66)COT[I&JY/H:<6W[X2M6;%TWNK/-%?M.
MJ]K'7*D8K%B<JHC>UC55Y,KT1454RK6YRJ%U;U#'N5<%-7-R]W2LNS;[2NCD
MX> =YV-X-]9[SVV.\I)3Z?L$BKV=;7(Y7SXZ9CC3X2*N/2543HN,FU=O6[-/
M%7.S2Q\:[E5\%FG>7!V^)DG,SR93$I51=PW]OG+9$M&&I]';Y_=.3[Q<#>L]
MKK-5WJ@JZ?5%HI6NDG?2QNBJ(XT155[HE545J(F5Y7*J97IA#3MZEC7)X8J6
M%S1\RS3QUT<D<0"6TOD[=116&6Z?BNMJL;3+4\OFTF>5&<W+G)LWLBW8V[2=
MMVECX=_*XNRIWV1,"?[?02,V4X(=8[JVB"\W*LBTK9JAB/IYJF%TL\[%ZM>V
M)'-PU>G5SD]:(J'1=4>38N5);Y9K!K."OJT;E*:OH5A:]4\.T:]V/8G+])KU
M:CC45<$U-NWH^971QQ1R0P;W*9/9ZHTO=-%W^X6.]4<E!=*&58IZ>7'HNPBH
MO3HJ*BHY')T5%R>L+&B8JB*HZ*BNF:*IIF-I@ .P</'#?<^();\ENO%-:76G
MS?M/.(G/Y^U[3&,+TQV:_MCQNW*;-,W*^CTL6:[]<6[4;S+D([^XDI7\"VKZ
M7<>W:4I+G2UL=12+755R;$]D-'&CU;Z77+GJJ>BU.]<]R(Y4^GW*\G]+HG15
MTOU/KBGJ4MM*^IGCK:!T+'-8U5=AR2/5%7'1.5>OB:?I#&WB.+JL?1&9%-54
MT<H=;X-]K-$ZGV&LEQO6D[%=;A)-4I)4UUMAFE<B3O1,O<U57"8[R*W&+IZU
M:9WYO=NLMMH[3;XJ>F6.EH:=D,3<PM7*-:B(BJN3ZG9+A"U1NSM[0:EM>KH;
M5154DK&TDB2Y8K)%:J^BN,JK<_2<DWIVVN&TVX5?INYW%EVK::.)[JIB.P[G
M8UR)Z2YZ(N/H-+%IH_%U3VF\\^2SS:[DX%%,VN&.7M<N?)\.#H.S>Q6JM[KO
M/1:<IHD@I^7SNNJG\D$"+G".5$555<+Z*(JY15[B3EK\FLO8(MQUWB5415CI
M;9Z*+ZN99>OU(;]W-L6)X:JN:HQ=+RLJGCMT\OBA(WN4R2ZUIY.?45IHI:C3
MFIJ.]RM17)2U5.M)(J)W-1W,]JK\_*A$^Z6FLL5SJK=<::6CKJ65T,U/,U6R
M1O;WHJ*>EC*M9'[N7AE8.1B3':T[/%-CZS;#:O4F[FHVV73=!YU4\O:2RR+R
MQ0,^-(_P3/3Q5W@2FL?DVJN2GB?=]<1Q2\OVR"BMRO:CL?<O=(F4SZV_487L
MRSCSPUU<V>-IN5EQO:HWCX]R%H]9,74WDX+U14<DEBUC1W*?KB"NHW4R*B=R
M<[7OROMPA%'5FDKOH74%98[[0R6ZZ4;N66GDPJIT145%3HK5145%3HN2;.79
MR.5%3'*T_)Q-NVHV^O<]6#N&PO"K==^-.U]WH+W1VR.CJ_-5CJ8G/<Y>1KN9
M.5>GPSR;CP<:T3<]^C+4^GNKH*:*JJKIRNBI:9KU<C4>KLKS+RKT:BKW^H3F
M6*:IHFKG#*C3,JNW3=IHF:9Z.#M\38FG2>3;D6A3M]=HVL5&K]KM>8VKXI^2
MHJ_/T^8C_O?PZ:GV,JX%NR15UJJGJRGN=)GLW.1%7E<B]6/QUPN<HBX5>53"
MUFV+U7!35S>F1I67C4=K<HVA\QM%0TUSW8T51U5/%54M1?*&&:">-'LD8ZH9
MS-<U4PK53*85%+%]Y-F-!VK:'6U;1Z)T]25=/9*Z6&H@M,#)(WI3R*CVN1F4
M5%ZHJ+DKOV3_ "Y- _J_0?SF,M&WW_*1U]^M^N_FTA3:G5--^CAETN@VZ*\2
M[-4;S'^%0[/]!D][H70]XW$U-1:?L=*M7<*Q_*UO5&M;C+G.7P:B=Y)>J\GG
M>Z&CFJZG6EJ@IX6+))-) ]K&-1,JY55<(B)UR7M>5:LS%-RK:9<I9T_)R:9K
MMT[Q"-^V='!<-QM*TM5#'44TUUI(Y89FHYCV+,U%:Y%145%15Z*GB65;D[.;
M?6_;K4U52:(TY!50VRJDBFBM4#7M>D+E1S51F45%QU*U*/3,%?KVCL%INS:R
M*HN$5%3W)(G1M>KGHU)$:O5$RN4SU5,=R]"2.I^!O6.G],W6[3ZX@J(**DFJ
M9(FLES(UC%<K>JXZHBH5F=%%==$S<X5UI$W+5F[3%KC^O+DB<#H.R&T%9O9K
M&33U#<(;9.RD?5=M.USFJC7,;RX3VN_<.\^]S:DSC\5UL^?S:3_26-S,L6?8
MKJYJ:QIN7E4]K9HWC?9$=O<HRA+GWN?4?=^*VV9_P>3_ $GR>ZO!9>MJ]"77
M5-7J2BKH*!L:O@AIWM>[FD:SHJKT^$>=&H8]544Q5SEZW-'S;=,UUT3$1S1S
M##K.P/#O<=_)+XRWW:FM:VI(5?YQ&YW/VO/W8[L=FOUG]M^^'*Y;",LKKA=Z
M:Z>ZCIFL2GB<WD[/D[\KUSVB?4;'XFUVO8\7M-+\#D=A^)X?8^/DY$#S++;7
M7B[4-O8]L;ZJ=D#7.ZM:KU1N<?.I*"\>3]U!:+367!^J[?(RF@?.YK:>1%=R
MHKL=_J07<FU9F(KJZIQ\&_E4U56:=XIZHIF6>)_:BI5K*R"F:[D661L:+\ZX
M),ZLX$-0:2TG>K])J:@JH[=135KH(J>1'/2.-7\J=>BKRB[DVK$Q%R=M^B,?
M!R,J*JK-._#U1B!)K:_@1U7K&UQW'4-QCTI#,G/'2OIUGJN7\\SF:UF?4JJO
MK0\[<;@%U#IJT5-PTU>FZD=!F1U!)2]A.K4\(UYG(]WCCT<IT3J:_I#'XN'B
MYMST-FS;[3@Y>:+0_P#H=JV5X4=6[OT_N@YS-/V+G<Q*ZLC<YTN%5'=E'E.;
M"IA5543OZ]#KEX\G36Q4#W6K6<,]8UF&PU= L4;W?IFR.5J?L5(JS\>W5P34
MBSH^;>HXZ:.2')L>XU?HV[Z"U'6V*^4;J*Y4;T9)&Y47PRCFJG>BHN47Q-M&
MZ-O&O=04EDL-#)7W&H7ECC9C#4\5<J_!:GBJ]#=FY3P\>_+XJKLJ^T[+;VM]
MMN_=Z4RWQ)>:<\G?=JBDBDO>KZ6@J'85\%#1NF1/8DBO9U]O*>1>O)UU\-/,
M^TZTAJ)ON(*RA=$Q>GB]LCOXI7SJ6-$[<2[] Y\T\7 AZ2PX"]$:>UC)KE+_
M &*VWOS9*'L4N%)'/V7-YQS<O.U<9Y4[L9QU[D([;B[;7_:S4<UDU%1^:5:)
MSL>UW-'.Q55&O8[N5%POM3&%ZDI_)QI]NW!^:W__ !)AJ%<5XDUT3\'IHEF:
M-2IM78Y\]XG[/G^._1.G='56BDL-CMME2I96+,EOHXZ?M>58<<W(B9QE>_/>
MI%0GIQD[5ZBW8U5H*TZ=H^WD2.M=/42*K(*=BK G/(_P3V(BJO@?)T/D[9'6
M_-5K=L=8Y$RV&W*Z)J^*=945WS]/F-7$S+5FQ3%RKFL-3TK)R<VN;%'LQM](
M0W!U?>?AMU5LORU5>V.Y6:1_9LN5&CN1J^#9$7JQ5\.]/:<H+JU<INT\=$[P
MY*_C7<:KL[L;3#9O< WN!Z_RO*CWEJ=LV8V\DM-,Y^B--J_L&95;33YSRIW^
M@5;W=K8[M7-8UK$;/(U&MZ(B<RHA*VDX&=8U-'%4-US ULD;7HWDFZ)C*)W^
MHB;5T[J6LG@>[G6.1S%=ZU1<*OUE+I]---5<Q<XG4ZU5773:XK7#_3GT?Q-_
M_H2AEX"[_#8WW+\5% K&T_G'+V$F>C>;&<GS>T7!OJO<RUP7:XU,>FK14,1]
M/+41++/,UR91S8\IZ*]$RYR91<HAN?C\?:9XNBJC1\WBIIX)WG]' C+?'V]Q
M+C47D^+E2T4DMDU=!6U36IBGK:-845?T[7NQ[$Y?I(LZATU<M(7ZOLUWI'T-
MRHY%BG@>B91>GBG>U45'(OBBY/:QEVLC>+<\WCEZ=DX.TWJ=HEZ\ &RK$R.!
M[0&F=7Z,U#/?-/6J\S0W%K(WW"BCG<UO9M7"*]JXZJ?9<3?#79+UM[)<M(Z>
MH;3>;4CJA(+921P>=1=%D8J,1.94PCD[^J*B?"/6^3X;G0NI_P!4V_R325*\
MKLM[UQW?.<5DWJ[67553/1]=T_#LY.F4T54Q[4=5.'J]O<22X(=)635VM-04
M]\L]!>8(:%KXX[A2LG:URR)U1'HN.B^!Z+BUV67;+7;[G;J?DT]>G.EAY$]&
M&;O?%[$ZY3V*J)\%3[3R?_\ Q_U)^IS?Y1I?9%Z+N%5<HGJXG Q*L;5*;%V.
MD[/:<<6A-.:1L.EY+%8+99GSU4R2.M]'' YZ(UN$=RM3*9]9S;@YTY:M4[O+
M0WBUT=VH_<Z=_F]=3LFCYD5F%Y7(J9ZKX':/*$?\7](?X5/_ !&G*>!O\N]O
MZG5'\+#5L53.GU3,\^:RR[5$:W11$<MX=TXL=LM(:;V3O5PM.E[-;*]LU,C:
MJDM\44B(LS$7TFMSU3) LL;XS?R@[YUZ]O2]/_'L*Y#UTFN9LSQ?%I_M-;IH
MRZ8HIVC;_+I7#99Z&^[UZ7M]RHJ>X4,\LJ2TM5$V2)Z=C(J<S%RB]<>'@3/W
MRVET59=HM75M!I"Q4=93VZ5\513VR!DD;D3HK7(W**0[X5_R_-(?X1+_ "$A
M/+B(Z;)ZT]MNE7]PU,ZJ8RJ(IGER_5::':MU:;=JF.<;[?T5=%H>G=F=!SV&
MW2S:*T[*]U/&Y7.M,"JJJU.OP"KPMUTPBIIBV=?_ +EC_B(9ZO,Q%'#.SR_9
M>W155=XJ=]MGSSME]NV]^BM.)_Y+@_U3QZK8G;FNB6-VB[$UJHJ<T-!%&[ZV
M(BE;6YGY9&K/U7J_'_PSOK]7J/I]B]TM1Z%U_8V6ZOJ7T5360T]1;E>KHIHW
M.:U4Y,X1R(O1V.G3YCQG3KU-OM*;C:HUS$JR.QKL1$;[;\O\.N\2/";1Z,LM
M3JK1S9FVZG3GK+;*Y7]E'T3GC=\+E3[I'*JHF51<)@BT6ZW:W17>TUE'4M1T
M%1"Z*1J]45KFJBI^Z5&+$O;NB:G:.YN5O)UYOF-W2\FJ[353<G?93_M%I]O'
MNT7+-.T5;\OLU,M\21^@^!S56I*!M7?;G!IQDK>9M.L2U$Z9^.U'-:WYN953
MQ/M:GR?D?8JE/K1Z2_\ A;<CFK]':&U5J&-3/#Q*RWH6?<HXZ:/ZH> Z;N_P
M]ZHV=6&HN;(:ZU3/[..XT>71H[P:]')ECE_=PN%.9&]:NT7:>*B=X5%_'NXM
M<V[U/#,?$-S0W/2&L  B1LWN4R8;W*9,D2  (AL  AEOB;&K?$V,9 W-#<2
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M:=,U$\$*Q30)W<[HU5WH=R91RJG>O0CZ;=F];OT\5N5?D8UW%KX+T;2U7O\
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MCY)3!E3!MM+N#538U4$,  ,FJF#*F    &IL:@  !A>XU-E[C4 84R84)EJ
M AA3!E3 90  F$AJIL:J)&BNY6G\3=[LK[#0ED      ,M\3 $]?)2:;6;46
MOM0.9AE/2TM#'(J=ZR/>]Z(OL[)GUH6-HG4BSY./0B:3X<J*YRQ\M5?ZV>X/
MYD]+D1W9,3YL1<W[(E.G0^=9]R+N175'V?5=*M=CBT4SUZ_U;  KUL
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MB;&,@;FAN)  $#+?$R8;XF0   W  8PV;W*9,-[E,@D-C4V" RWQ,&6^(&P
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M6.H5R/=%-(WF3"\CIWN8OS<JH9:ECV[5%-5$;3OL\OV:S\C)O5V[M4U1MO\
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MN5%]KG?Y"'.^.W6KKQN+;M.12?V/9J5'O;X=M,J.7*>QB1_ME*J[_NLV+?\
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M]\H[^5]I;]5'?R+R A/ORCOY7VEOU4=_(O("&WI7\-3^;1_:'^/J^T?H$O\
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MC3Z&(U/H(W>4L3&\^G_U!C_G%0=D\F7^55JC]6U_D(CC?E*USO/I_P#4*/\
MG,Y9XU,4:APQW?X4N;7-S2>.>L_Y1( !U[Y["SCR?FV=)I39>'4CH&^ZVH9I
M)Y)7-P]L#'N9'&B^*>BY_P#XSV(?#<8_&1J+;K6C]$Z'EAM]71QLDN%TDA;*
M]LCV\S8F,>BMQRJU5<J*N78Z87,A.$^6*;AVT$L..7W,8U<?&151W[J*5M\8
M$%13\26NFU'-VCJQCDRGW*Q,5G^2J''XMJG*S:^UY[;_ *OHF;=KPM-MQ8G;
M?;>8^VZ3/!UQEZCU]KJ'1>NJB&X5%P8]:"YLA9#)VK&<W9/1B(U45J.5'814
M5,=<])'\4Z_]SQN G_Y(F_@*SN$Z"HJ>(K03:5<2MN37+CXB,<K_ /)1?K+,
M>*=N.'?<#Q_W(F_@,,VQ;LY=$6XVWV_5Z:9DW<G N3<G?;?G^2J_8C;23=O=
M?3FEO3;35E1FJDC7#F4[$5\JHO@O(U41?6J%MFK=1Z>V+VMK+I) R@L5AHFM
MBIH$PF&HC(XF>USE8Q,^*IDKL\GE/!%Q%TC9D19);;4LA]CN5KE7]JUQ+[R@
M-/53<-=[?3NQ%'5TCZA/7'VS4_C*Q?H/;4=[N51:JGER:^D4]A@W<BB/:Y^2
M)]Y\HSNA5Z@DK+;#:+=;4>O9VU],LR<N<HCY%5'*N.]6JU/4B$X>'#?FAX@-
MO67R&!E!<Z>1::X4'/SI#*B(J*U>F6.:J.3/K5,Y:I3P3\\EY%4):MPY7N_L
M5TU$V-/!'HV;G7ZG,-C4<.S:L=I;IVF-FKH^HY%_*[*[5O$_'N<,XZ-E:/:3
M=MM7:*=M+8]01.KH(&)AL4S5Q,QJ>K*M>GJY\)A$0LDV@LM!I_:G2E!9HXTH
MH;53]@K>B.18FKSKCO5RKE5\555(B^5'G@[#;J/*+4\]>]/6C,4Z+^[CZE/C
M.&3CS=MEIRBTGK6W5-TLU$U(:*XT*HL]/&G1(WL<J(YK4[E145$1$POAJ7+=
M[+PZ*J8WF/-NV;MC!U&[17RBK;:?AR:[HZFXMM'WVIJ[E->4IXWY;-8:..>B
M1B+E%1(V+RMQ_;$1<=^3['1WE*H;1HFDIM5:;K[MJ^!71U4E-V5/3S87#7+E
M55K\=Z(W&47'141)-Z)XJ-J=>M:ELUI;(YG]$I[A)YI*J^I&RHU7+\V3W>X.
MR^A=WK<L>H]/4-WYV(D=:C$;4-3P5DS<.1/'HN%]2FM-ZCE3?M;;?#DW:<:Y
M/%<Q;^^_=/-3_NKK2BW$W"ONIJ"S-T_3W2H6I6@CG[9(Y'(BO5'\K<\SN9V,
M=%=@M#X#V_\ <KZ+7VUW\^J"NGB;V/=L'NC5:<BJGUMLJ(&5U!/+CM5IWN<U
M&R81$5S7,<BJB=<(J(F<)8MP'K_W*^BOGKOY[4%EJ55%>'1-OIO'Z2J-%HKH
MS[M-V/:VG]80*XZ?S4VN?_T+^8TY+;R9'Y1FH/UR3_S:E(E<=/YJ?7/ST7\Q
M@);>3'_*,O\ ^N.?^;4I&9'_ ,?;GZ1^AI__ ):[]Y_5['C6XHKCL/26RR:4
MAIVZDO#75,E7/&CTIH6X8CD;W.>Y4PG-E$1B]%Z8Y'P?\9FN=8[LT&DM;5[;
M]17CM&4]4ZFB@DIIFL61OY&UJ.:J-5N%3**J*BX147X_RF;W?CZ6*+/VMNG8
M7(GM6IJ47^!#DG".JIQ(:!PN%]T4_B.S^XI-G$LU8/'-/.8F=T7\^_3J444U
M;1$Q&W<L2XYM.4FHN&S5;ZB)KIK>D-;32.3K'(V5J*J>U6.>WYGJ0<X"=KZ3
M<7?6GJ+E VHM]AIG71T4C>9CYD<UD353V.?SI_>\$^^,9/\ N:]>>KS)O\JP
MB5Y+RL@CW!UG2NQV\MMBD9GOY6RHB_NO::N)751@79I^/^&_G6Z;FIVHJCN_
M1+SB=WQ9L'M?4ZB;3,K+I+,RBM]-+E(Y)W95%=CKRM:U[E3QY<(J*J*0#TUY
M07=RT:CAN%TNM)?+8DB++:9:*&&-S/%&O8Q'M7'<JN5,XRBIE%D=Y3RBJ9MK
M-+53.9:6&\<DJ(G1'.ADY57]J[ZRMQ3;TS%LW<>:ZZ=YEHZOG9%G*X+=6T1M
M^:]'1>J+=K?2MJU!:W=K;[I31U<+E3"\KVHJ(J>M.Y4\%14*D.,;\TMK[_#6
M_P DPLLX0:&JM_#;H**KYNU6W)*WF3"\CW.>S_)<TK3XQOS2VOO\-;_),-?2
M:8IRJXI[M_U;6N537@VZJN^8_1QI3!E3!U[@NX-5-C500P  R:J8,J8    :
MFQJ   &%[C4V7N-0!A3)A0F6H "&%,&5,!E  "82&CEQE3<_C*[K@D?R  9
M    #/M/<Z.TO6ZWU99M/6YG/772LBHX$QE$>]Z-15]B*O7V(>G1%^#]9,_R
M9FR[M5[CW#7U?$ON=IMJP4?,GHR5DK%15]2\D:JJIWHLC%-/+OQCV:JY6.#8
MG)OTVX_["R+1>EJ+1.D[/8+;&L=!:Z2*C@:O?R1L1J9]N$Z^M3WJ(O4V0(O4
M^;S,U3O+ZO33%,13'<(9 (9@
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M3*R14]CI'R*WYV]?:<!JJJ>NJ9:BHFDGJ)GK)))(Y7/>Y557.<J]ZKGO7O\
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M>S?P>%7,3[57*'%0 =N^$  "&@  PIJ;*:AE 84R84'>P  EA>XU-E[C4
M-5,&5,!E :KWJ;&J]ZDPB PO<9,+W$,FH )[AH2^X,-RZ6:R5&C*V9L593R/
MJ*)KUQVD3L*]B>MS7*JJGJ=[%(@G]Z*MJ+960U=)424U5"]'QS0N5CV.1<HJ
M.3N5%ZY-/)L1D6N!:Z7J$Z=D1>CG\4Z=_>&^'=FKIKO;JYENO<3$A<Z5JK%/
M&BY1'8ZHY,KAW7OQZL>HV;X<:+9NX2ZIU+=Z>JK8&*R%S4Y88.;#5=S.ZN>N
M>5.[O7O54QQFP\8VOK1;V4T[;9='M;A*BK@?VBK[>1[47ZOI/C-;[[ZPU]<*
M6IN=P1D%+.VIAH:9O9T['M5%:O+WN7*?=*JIUPJ9*BG$R^'L9GV797=5TCM?
MQE-$S<_I'W3OWH_*EUEU_P#O15?R3R >S.X+MLMP+=?'+(ZC:JQ5<<?>^%R8
M=T];5P]$\58A]/?^*776I+)76FNGH74== ^FE:RF1KN1[5:Y$7/J4Y&;F'AU
M6[5=%WI*KU?6+65D6LC'W]G_ #NLWO=HL&[.B):&61MPLUSA14FIWIW=%:]J
M^"HJ(OL5.J$<%X%*M;QA-4P^YG-S<_FB]OC/=CFQG\]GZ#@V@MW-5[;R.6PW
M5]/3N=S/I)$22%Z^.6JG1?:W"^TZBWC:UUV'(MOL:RY_)%IYN['J[7OS]'L-
M+\'E8\S%J>4K:O5M*U"FFYF43%4)9V:UZ>V?T(RD9.RW6:UPJKYZAZ97KE7N
M7'5SE7U=57HG<5_;O[AR;F;@7&^N8Y*5SDBI89.BM@;T:BX]?PE3/>Y?4::_
MW=U5N3*WW=NLDU,QW,RCB1(X6+X+RHG5>J]5RO54S@^--[#PILS-RY.]4J75
M]:IS*:,?'IX:*?\ L)_;/Z+VQUIHVBO-HTS9WK,SEF9) V:2GEPG/&JORJ*B
M_6F%3HJ'$-5\$NIZ>]5/XG:^AK+2]^8?.I71RL;GHUZ<JHN$^Z3O]2'$=%[@
MZAT!6OJ]/W6HMLKN59&QKF.3"KCG8N6NPBKC*=,],9.NT7&SKNGCY9:*S52X
MQSNIY&JJXQE<2HG?[.OA@U_P^58KFJU.\3\6_1J.EYEBFC+HFFJGOI_X2,X=
M=IKKL_I"KH+Q<F5L]14=ND%,KEAI_11.5JJB=5QU7")W?.1LXQ=<4.J=QH:"
MWR-GCM$"TTTT:HJ+,YV7,1?'"<J>Q5<AZ36/%7N!K&BDHW5U/9Z=[>5[;5$L
M3G>SG<YSD3]*J'('=7*OBOCXK_LOK/3$PKE-WMKO5X:KK%B[C1A8M,\$;<Y^
MB?G!U^4E;_\ ":C^44C+Q<?EXWK^\T_\DT]3H/B+UCMSIZ*RV::CCHHWND:V
M:G1[LN=E4SD^/USK>Y[AZCGO=W?$^MF:UKW0LY&^BU&IT^@FQBW;>37=GI+S
MSM5Q\C3;>+1OQ4[;_P!$YN$%,[&V?^_5/\LXBYQ===\[W_>:;^28>MT/Q'ZS
MV]TY3V.SST;*&!SG,;-3H]WI.5R]<^T^,USKBZ;B:CGOEW=$^NF:UKEA9R-]
M%J-3I] Q\2Y;RJKM724Y^JV,G3K>+1OQ4[;_ )0Z-PB+C?2R_P!ZJ/Y)Y*+C
M!_*+O?\ ?Z;^6807T+K>Z;=ZC@O=H?$E="US&NF9SM])JM7I])]AKKB2UIN'
MIRIL=YFHWT,[FN>V&G1CO1<CDZY]A.1B7+F53=CI#+3]5L8^FW,6O?BJWV_.
M'I]D]Q7[8[B6R^*KDH4=V%:UJ9YH']'KCO56]'(GBK$+$+[9;'NEHJ6AJECN
M-FN<#7(^%^4<BJCF/:Y/%%1%1?6A7!MEM]4[FZNI[!1UD-%55$;W1RU"*K<M
M8K^7IU[D._6O:7>W9"RUU38;[0U5LIHWU#Z&G>LV6HBJO+%)'\)43.&X55Z=
M3PU"W15<B8KB*VWH&5?M6*Z:K<UVIZS'=\>3Z6T\"MBHKZE5<-1UE?:6.YO,
M4A2)[T^*Z1'=R^/*UJ^I4)&:7KK37V2F?99(9+8SF@@=3)B/$;EC5&^&$5BH
MF.F$Z="O/6'$AN%KBAEMU9>E@HIDY)(*&)L/:(J=45S4YE3ORF<+GN)L\.VG
M:[2NS>FK?<X'4M9'"Z22%R8<SGD>]$7VX<F4]>2MRZ+U-,3=KWET>D9&+7>K
MHQ+7#3MO,S]T+>*G\OK5?Z>G_F\1R@Z-Q&76.[[V:NJ(G98VK[%?GC8V-?W6
M*<Y.KQ8VLT1/P?,-0JB<N[,=]4_JT)&\#^LO<7<6OL$K^6"\4RNC;X=M%ER?
M6Q9/VJ$<CVFE]25VD+_07JV2)%74,R30O<WF;S=45%3U*G3Z2,FUVUJJVG3L
MK\%DT7I[IYK6:NHCHJ>>HD<C(F,61[E[D1$[U^C^ K*L^Y,T&]$&M97/8KKQ
MY_*B+U2-TJJYGS<BN:?57[BSW U#9:^TU=31)2UD#Z>7LZ9&OY7M5KL+GHN%
M[_ XT5N#@56::^U[W2:SK=O,KM3C[[43O^:W6-Z/C:]%RBIG*$!N-36GXH=T
MV6F*3GI;+3-A5JKEO:R8>]4^A8T_8J>KM/%UN':+72T$-50NAIH6PL62E17J
MUK41,KGO5$0Y)?;U5ZCO=?=JYZ2UM;.^HFD1$;ESUYEPGJROT8P886GUV+LU
MW.C8U?7;6;BQ9L_F]KMI^6+I7]5J1?\ KF%F&Y?Y6VIT3K_N54_R3RK:S72>
MQW:AN-,K4JJ.>.HB5R91'L<CFK^X==N_%WN%>[166VJJ+>ZEJH7P2(VD1%5K
MFJUR=_M/;.Q+F1<HJHZ0TM%U2Q@V+MN[OO5T<7)[<#739VHST_W3G_B1D"3I
M.W/$/K#:ZPNL]BFHXZ-TSI^6:G1[N9R(BKG/YU#8S[%>1:X*.K3T;.M8.7-Z
M[TVV?<<<7Y<L/ZE0?QYB1'!>J?C&V[K_ /=51_**0<W%W(O.Z-_;>;Z^%]:V
M!M-S01\C>1JN7&/V2GU.W_$GK3;;3D5CLL]&RAB>Z1J34R/=ESLJF<FM>P[M
MS$HM1UA8X>K8]C4KF57OPU;[?F]MQB?E\WS^]4W\BPE'P7*GXQ=NZ_\ W54_
MRBD$]>ZZNNXVI:B^WE\3Z^H:QKW0LY&^BU&MZ?0?8[?\2>M-MM.16*RS4;*&
M-[GM;-3(]W,YV5ZY%[$N7,6BU'6&&#JEBQJ-W*KWX:M]OSE[?C$_+YOG]ZIO
MY%A*WA9W2H=PMM;=0NG8EYL\+*.KIU<G/RM3E9)CQ1S43KZ^9/ @1KS75TW&
MU+47V\OB=7SM8Q[H6<C?1:C6]/H/#TUJB[:0NT-SLEPGME?#\&:G=R+WYPJ=
MRM7IEJ]%QU13.Y@S=QZ;4^]2\L76(Q<^YD4T[T5S.\?3XI8[S\%=RU+J^MO>
MD:^@IH+A*L]115[GL2.1R^DK'-:[**JJN,)C*X]1T#:;A/TSH[1[Z'5-OMVI
M;K42=M/52P92+HB)'&Y4YD:F%7/155<JG=B/MIXY=P[?3,@JJ>S7-S45%GGI
MI&2.7'3/)(C>_P!2(?,:]XJ=P=?V]]#/<(;31RHK98;3&L/:(O3#G*YSL8\.
M;"IT5%-*,;.KIBU,[1"XC4-&M5U9%NB9KGNF.7^'J^(6#1E#N%56[0]'%3VN
MC8D4LL$[Y633=5>K5<YWHHBM:B-PF453F1LGW7K^?ZU]JFIT%FCLZ(HWWV<-
M>N]O=JNQ&V\[[!JIL:J>S7A@ #[LOJ+W*:FR]RFI"(^JSCAALC;!L7I*!$1K
MI:7SIW3&5E<Z3/U.3ZB V_UZDO\ O/K.KERKDN<U.W*][8G=DU/J8A]3ISBY
MW!TQI^W6:@FM[**@IHZ2%KZ1%<D<;$:U%7/J1#D-WNE1?+M77&J5KJJLG?42
MN:U&\SW.55_=4IL/$N6;U=VOO=9J>J6<G#M8]G?V=M_RC9X:DB."K=2BT1KN
MKLUTG["BOC8XHI7_  &5+%7D:JKW91SFY]:(GS1W4PWT514[T\?5_LI9WK47
M[<VYZ2HL/*G$OTWJ>L+,^('8.@WQT_2PK4K;KO0.<^CK$;SM])$YF/;GJU5:
MWKWHJ(J>*+S?8K@T=MUJVGU)J*Z4]UJZ)5=24M+&Y(FOPJ)(Y7=ZHB]$1$PO
M7)'W0_%[N-HBWLHDKJ6^4D;>2)EXB65S&^KG:YKW?LE7_,>\OW'1N->*66"C
MBM%G5WP9Z6F<^5GTR/<U?VIST8F913-FF?9EW$ZII-VY&3<IGM([MG=N,_>&
MFTCH:32M#41R7N],6*6-JY=#2KGG<OJYL<J9[TYE^Y*_U[U/.NUXKK_<9[A<
MZR:OKIW*Z6IJ)%?(YWK55[_8G<>"O>I=86+&-;X>]R6IZA.HWYKVVB.@=4X9
M]SX-K-U:&XUS^SM=6QU!6/5,\D;U:J/^9'M8J_G44Y6#9N6XNT315TEHXUZK
M'NTW:.L+6]T-N[5O)H2KL5;+FFJFLFIZJG5'+&]%RR1O@J?PHJH1>TUY/NO9
M?F.OFIJ5]GCDYGMH8GI/*SQ3TNC%7IU]+'@<9VOXG]=[4V]+;;*V"X6MGY'0
MW2-TL<73N8K7-<U/8CL(O7'?GZ#6O&AN+K&W24,,]%I^&1%:^2U1/9,YOJYW
M/<J?.WE7VG/V\/,LS-NW5[,_]Z.XOZIIF9%-^_1/''=_RL(T]-;'6V.FM+X7
MT=(JT;6TZHK(UC]!6)^EQRK[4P5U[S7B+3W%C<;K4M1T%!>Z6JD:Y,^BSLG+
M\_1J]#U^@>*+7>V^FH+#9JFB;00OD>SMZ9'OR]ZN=Z6>O55[^ISO6.K;AKK4
MMPOUU=&ZOKGI),L3.1JN1J-Z)\R'OAX%RQ=KX^DQLT]2UJQEV;=-J-JJ9WGX
M+8+W;:/7VBJ^@BK/["NU ^%M53.1?M<L:M1[5^9V44@_;^ ;74M_6EJ[I:::
MU(_K<(Y'O<K,][8\)Z7L543VG/MK^*#7FU5O;;K96P7"VL_(J2Z1K-'%UZ\B
MHYKFIC[GF1/4F553Z;57&YN1J.WOHZ62W6%KVX=-;:=R3*B]^'2/=A>_JF%Z
M]_B>-K#R\:J:;6VTMN_JFFYUNFYD1/%3W0GUH73-NT9I2VV"UO[2DMD#:5'.
M<CGY1$RKE3[I<Y7YRM7B>M[[=OMK&*1BMYZOMDRG>CV,>G[BG]=N^)?76V=J
MJ[?:+A#-!4U3ZR1U=#VSUE>B(]>95SUY47YU5?%3Y3<O<F\[J:A;>KXE,MP9
M"VF62EA2-'-:YRHJIXKZ6/F1/4>^'AW<:_-5?.):>JZIC9V)3;MQM,=SZWA=
MW"_&ZWDLU7-)R6^N>MNK.N&I'*J(UR^I&OY'+[$4LZ=0TT]3!5OA8^>%')%*
MY,N8CL<V%\,X3/S%0^B](7?76HZ"R62DDJZ^JD1C&QHJHQ,IE[E3N:WHJN7H
MB%MM,]M@TZQU?5\Z4=,BU%7+TYN1GI/=ZNY5-#5J:>UBJF><KG]F*[D8]=%R
M/9B=X0O\H#N#Y[J2Q:.IY.:&@C6X536KT[5^6QHOM1J.7YI")5/*V&JBD?$V
M=C'(YT4F>5Z(N5:N%1<8]I]+N;K6;<77]]U)-S(ZX53I8VN7*LC1>6-J_I6-
M:GT'RRG08EGLK$6^]Q6HY4Y.77=[M]H^T++-J-N]H-=Z&I+OI[2EEE@K(4;)
MS4[99J=ZM1'QJYZ*YKFY]F>].]%(Y:KX!-9T5\G9I^XVRXVES_M$M5,Z&9K.
MN$>U&JG1,)EO?GHB9PG"= [HZJVSN#JO35YJ+:]ZIVL+'(Z&7&?AQN16NZ*N
M,IE,],':Z'C[W$IH7,FMU@JUQRMD=3RM7FZ=5Q*B*G?TPGSE5.-EV*YFU.\3
M\70QJ&FY=JFC*HFF8\/_  E7PT[07+9;04MEO5U9<JJ:J?4JR!7+#3Y:U.1B
MN1%5%Y>9>B)E>[Q6''&IN);M=[N=E:IF5%):*1*%T[%1622\[G287Q1.9&_.
MBGJ]?\7>X^X%OEH)KE!9J*1%;+!:(EA[1%[\O<YST3V(N%\4.,?N?1X__7Q/
M;#P;ENYV][JU]4U:S?QZ</%B>&-NO7DP:FQJ7D.16.<&N\=#KO;2AT[//&V_
MV*!M-)3N7#GT[?1BD:GBB-Y6KCN5/:F?0[Z\%$&Y6JJO4FG[RRSUM:O/5TM5
M"LD,DF$17M5%RQ53.>_*KE,$$+!J"YZ7NE/<[17U%MN$#N:*HII58]JXQWIZ
MT5<IXHJHN4Z'?K#QZ;DVFC;!506:[N:F%J*FE>R1>GCV<C6]_J:<Y=P;]F[-
MW&GJ[G'UC$R<:G'SZ=]N^$K.'/ASHMA[/<.TKDNEZN#F+55?9]FQK6YY6,;E
M>F55555RN4SW8(O<<^[%!K/6E!IJTSLJ*2QH_P ZEB7T5J7*B.:B^/(C43*?
M=.5/ ^1USQB;EZZH'T3[G!9*:3*2)9XW0.<GJ[17.>B?,J>TXGG.5[U7.<_[
M=<YR>^)@W:;O;7YWEJ:AJV/7CQB8E&U/FL1X+=ZJ'6FWU'I2NJ6,O]CB2G;%
M(Y$=/3)E(WL1>J\K<,=ZN5%7O/Y;_<&5%NOJ.?4ECNR6*\U*)YW%-&KX)W(U
M&H[HJ*QV$ZJF47'<BY5:^[;=*RSUL-=;ZJ:AK8'))%44[UCDC<G<YKDZHOMR
MAWG2G'1N;IVE93U4ELO[4_Y2X4RI)R^KFC<S/SJBK\YY7L"_:NS=QIVW;6-K
M&+D8U.-GT[[=_P!DF.'KA!M^S-\74%RNONY?4C=' YD/9PTR.3"\J*JN5V,I
MG*=%7H?*<<N^=':-,R:!M56R:[7'D6X=FY%\V@3TD8Y4[G/PG3OY<KW.0X7K
M'C>W+U7;Y*."IH+!&Y%:Z6U0.9*K5_/O>]6K[6X7VG!JFJFK*B>IJ)I)ZB9Z
MOEED<KGO<J\SG*J]ZJN5SXJI-C O7+T7<F=YACE:QC6L><; IVBKO=#X<-74
MNA][M)7>NE;%1Q53H999%PV-LL;XE>J^")SY7U(A9IN=H*DW0V_O6F*N1T,%
MR@[-)FM1RQO14<Q^%[^5S6KA?45!.\/GST\#M^V_&/N+MS:XK9'4T=\H(6HR
M&.[Q.D?"Q.YK9&O:Y4QT3F5V.Y,)T/3/PKEZJF[9ZPU]'U:SB6[F/DQ[,_#[
M;='1]-^3QU)^*!B:AU#:X["U^9'6YTCJB1B+T;ROC1K55/'+D3U*38TA):4T
MW1PV.2&2U4S%I*=:=W-&U(56)6HOBC58K?V)7!N%QC[C[A6V6W/KJ6QT4S59
M+':8G1.D;ZE>YSGI[<*B+ZE3H>'H/BSW VXTG0Z<LU10,ME$CDB;-2(]_I/<
M]V5SU7+E-2]AYF13$W)YQW+3%U73<*Y,6*9X9CK]?L^9X@OR[M<_JM4_RBEF
M>Q7Y26@_U H?YO&5/ZHU'6:OU)<[Y<%8M=<*AU3.L;4:U7N55541#K^F^,O<
MC2VGK99*"IMS*"W4L5) UU&USDCC8C6HJY[^5OUFUE8=V]:MT4]85FF:I8Q,
MF]<N;[5='/MZU5N\FNW)\)+_ %ZI]%1(J+DLNX?-W*'=_;BW71LT:W..-L%Q
M@:N%CJ$1$<N/!KE3F;[%]BE5NHKY5:FOUSO-;R+6W&JEJYUC:C6K)(]7.5$3
MPYG?4>TT!N1J/;&]MNVFKG+;*O'+)R86.5OBV1BHK7HOAE.G?T7J>V1@3?LT
MTQRJAX8&KQAY5=<\Z*DN]TO)_P!1?]8UMTTI?*2@MU=,Z>2BKHW?:'.7+D8K
M47F;E5PBXQW95#N&P6SMBV!L<>G([E'6Z@NBNJZB9[4:^H[/E1>1B=4C9SHB
M95>K\][L$27>4%W)6WK E!I]DW+CSE*695[L<V.VQG/LQ[#F-EXC-=VC7U1K
M-UW]T+]-3/I%FK8T?&V-SFNY6,3#6HBMZ(B(G5>BY-"</-O6YMW*N4+JC4M+
MQKT7K-$\4^7V2L\HUUV^TMCK_NHO\C(0%.F;J\1&L=Y;71V_4DU'+34DW;QK
M3TR1JCE:K?7ZE.9EO@V*\>S%%?5S.JYEO,RJKMOH$IN S=^ET9K*OTI=JIE/
M;[YRNI7RNPUM6SHC,^'.W*=?%C4\2+(1RHN4547IW?[=,*>]^S&1;FW5WM;"
MRJ\.]3>CN6><3_#7!OQ:J*HH:V*V:BMR.;3U$S%6*6-W58Y.7JB93*.Z\N5Z
M>D<HV&X$*K2VK/=G7\MHNU)2HY(+5 U:B*9ZHK4=+VC&IA$7*)A<JJ*N,*B\
M,T#QI[G:#M[:+W1I=04D;>6-EZA=*]B?WQCFO=^R<I[^_P#'[N9=Z26GHXK+
M9U>WE2HI*1[Y&=V519)'-]?W/C[,E#3BYMNF;%$QM+L*M0TJ]<C(N4SQ_#9]
MUQHZ(VGVVTPRFM.GJ*CUE<'M6G91RR1^;PHY5?,Z-KD9A>56MRG>JJF>53Y'
MR=6?Q[KQC_F&?^<TQ&[4&H+GJJZ3W.\5]1<KC4.YI:JJD5[WJB(G55]2)A$\
M$3IA$/?[5;L7_9W4-1>]-R01UTU*ZC<ZIA21J1N>QV,>OF8TL)PZXQ9L[[U2
MI(U&U.?3DQ3PT4_#X)O^47_*;LF._P!WH?YO4E=RG5-UN)36N\M@IK/J2:BE
MHZ>J;6,2GIDC=VC6/:BYSW<KW'*U/3 QZ\>S-%?5XZMFVLS*B[;Z+FM#?\1K
M#ZO<^#^2:5+VN]0Z;WCI+Q4M1]-;[^VKE:J9RUE0CE^?HU>ATRV\<.Y]KML%
M#!4VQ*>GB9#&CJ)%5&M1&^OV'!JZLDN-;45<RYFGD=(]>[TG.5?\YK86%<LS
M7VG>W]4U2SE4VHM=:/\ A<I?;71[@Z&N%NBK%\PO5OD@;5TKD7[7-&K4>Q?F
M=E%^8@3;?)X:^GU$M-67:STMI;)UN,<CY'+'GO;%A,N]CE1/:<YVIXKMP=HK
M:VV6JX4]QM3/R*ANL2S1P]>J,5'-<U/SJ.QWJB97)]5J[CRW.U1;9**E?:]/
MI(WE=/;*=Z385.N'2/=RKW]4PJ9[^F35M8>7C533:VVE97]2T[,HIN9%,\5/
M<L0V_P!+VW0^D+9IVU/66DM4#*1'.>CGY:B95^/NESS+\Y5SQ6VZ2U<0FMX9
M&*WGK>W3*=Z21LD1?J<?WVUXIMP-K;15VZS7&&:"JJGULCJ^+MWK*_E1Z\SE
MSUY47VJJKXJI\ANCNE>]WM2LOFH/-77!L#:99*6!(FN:USE153Q7TN_U80]\
M/"O8]ZJJOG$M/4M5QLS&HHMQM,3T6R[1)C:W2"?_ )'H_P"081UWWX0K?OU>
M(]<Z)U#1TM5<HV/G[5%?2U*(U&I(US<JUV$1%3"HN.N%SF.-BXW=SM/V6AM5
M%4VQM)14\=-$CZ)%5&,:C&IW^I#Y3:CB4UWM ]\=BN;)K;)(LK[77L66F5RJ
MJJJ)E',SGKR.3/CDU;>GY=FJJY;G:5A=UG"OVZ+%VB9I[_HG=PO\*]+L&RX7
M.MN#+OJ*NC2!\\4?)#!"BHO9LSU7*HBJJ_%:F$PJKR#RAN[]#-1V_;ZW539Z
MQL[:ZY]D[/8HC5[*-WYY>978[T1&+XH<NU9Q\;G:DM<E%3>Y5BYV\KJFW4S^
MU7*87"R2/Y>N>J(CD\%\2.=765%PK)ZNKGDJJJ9ZR2SS/5SY'*JN<YSEZJJJ
MJKGQ4V<?!O57NWR9YM+.U;'IQOPN'3M3/?T3;\F3^2;C_P#D[_XH>4U_)-N?
M_*/_ ,,1CV@WZU7LC[K+I>6DB=<^Q\X\Z@[7/9\_+RY7I^2.^L;O;]:KWN]R
MEU1+22NMG;>;^:P=ECM.3FYL+U_(V_4>OX*Y^.[?^7_AK>D['HK\)SXO^=TG
M_)Z;QTT=%<-O;I5,AJFRNK;6V1R(LK53[;$W/BF$>B=ZHYR]R*=!XIN$&3>V
M[4^HM/7"EMFH8XDIYV5O,D%2QJKRN5S&JK7)G&<+E,)TY4*W:6LJ+?515---
M)35$+TDBFA<K7QN1<M<U4[E14SG_ $D@]&\>6Z6E+>E)4U-MU"QJ-:V6[4KG
M2HU$^/$]BN7VN15]IC?PK]%^;^-.TO?#U3&KQOPV9$S3'24@>'/@;I="55PN
MFXD=IU)4SQ=A!;TB\XIH45459'+(Q.:3HC4PG3TNJ\W3CO&[I?:S0-9;[#HZ
MQTM'J=TG;W"2CGE5M-"C5Y(W1\_(CG\W-W91&HN,.0]'J_CWW1U/;YZ.FEM>
MGV2=.VME,[MD;U[G2/=A>[JF%Z=,$=Z^NJ;I6SUE942UE9.]9)JBH>LDDCE7
M+G.<O5555SE555]?0SQL7)[;MK]7Y0\\S/PZ<:+&)1RGOGJ_@ "]<J^LVIW(
MN6TVOK3JBV(DD]$_[9 Y<-GC<BMDC7V*WI[%PI;+M]N)I;>S127*T5$%TME9
M&L-523M171JYN'PS1KW+A>J+T5%Z9144IM4]]HK7^HMN[NVYZ9O%59JQO3GI
MI,->F>Y[?@O3\ZY,=$*C.P(R8BJCE5#H=*U:<#>W7&]%2?\ =.!6#3VM8M5;
M:ZOJ]%7")[GQ0RTK:R.+F3"M8KG(J-5%7+7<^>[N)):;MMTI+!#27^OI[U<&
MMY9JN"C\V9-X96-7O1%QWX7'J1.XKLL?E#MT;73LBJZ>PWA4QF:JHWLD<GC^
M1R-:B_L3^&H?*"[J7JE?#1^XMD<[IV]!1*Z1$Z_VU[T\4\/J*:O3\VYM%>T[
M=[I;.KZ98B9MQ,;]VW)9%J"HK;?8+A46JB]T+C% ]U+1]HD:32(U58Q7+T:B
MKA,^&2G'=6+52Z_O55K2BJJ#4594NJ*F*JB5CLN5?@HO3DQE&\O141,$G-AO
M*!72Q2MM6Y#9+Q0+T9>*:-J5,7LD8F$>WVIAR>IQZ'CBXB+%NU)IZQZ4JX[C
M9J9JU\]:V-6JZ9R.:UB<[4<WE;E53'57I\4]\&Q>Q<C@KIY3WM35<K&U#%BY
M17SI_E14)<>34_+5U*O_ .1U_EXR(Y]MM)O+J39:]5EUTS+315=53^:R.J84
ME:K.9'=R^.6H7V79JOV*K='5RNG9%&-DTW;G2$VO*6?E6::_5I/Y"8KL=W*=
M5W;XEM;;U66DM>IIZ.6DI:GSJ-*:F2)R/Y7,SE%]3E.8456Z@K*>J8UCWP2-
ME:V1,M5S514SZT53QP;%>-8[.OJVM4RK>7E=I1[JV[A@V9@V8VIM5K=3L9>:
MMC:NZ2HGI.G<F5:J^*,3T$^;/BIYN]VPUJWULU':KW>KU;[=32K.M+:IHHF3
MOQAJR<\;E7EZX3*)Z2^S$#4\H#NVU.5*RU8_P!O^D)Y0/=Q$QY[:_O>W_24%
M6F9<W)N;QO+JZ-:TZFQ%B:9X8C;HDC[VIMKCK?M5?XU3?T<B=Q<;$6'836EH
ML]@K+C6TU90>=2/N4D;WH_M7,PBLC8F,-3O15]I[]/*![NI_]V6K_$&_Z3DN
M[>\VI=ZKU1W74TE-+64M/YK&ZEA2)J,YE=W)XY<I98EC-HNQ-ZK>E39V5IMV
MQ-.-1M5]DZO)J*GXR5__ %PS?S6E(]^49_+^IL?\RTR?]9,<YVDXG]<;*Z>J
M;)IF>ACHZFK=6R)44J2.[1S&,SE5[N6-I\ONONQ?]Y-2LOVI)();@RF;2(M-
M"D;.S:YRHF/7Z;B;&%<HRZKT^[S8Y&I6;F!1BT^]&WDM2X7=9?B[V%T9='O[
M2=*!M+,Y5ZK)"JPO5?:JQJOTG#/*6:R]R]NM-Z:C?RONM>ZIE1%[XH&+T7YW
MR,7]B1,VHXK=?[.:96P:=JZ-EN\X?4(RJIDE<CG(U%PN>[*9^E3YS=W>[5&]
MUVH+CJBH@FFHH%@A;30I$QK5<JKT3Q5?W$0UK.FW*,GM9]W?=NW];M7,'L(W
MXYB(3;\F8O\ VJ=4?JTJ_P#41'&_*6?ESV#]0H_YS.<AVAXF=;;)66MM6F)Z
M.&EJZGSJ5*FF25RR<K69RJ]V&H?/[M[QZCWIU!2WG4TE-+74U,VDC=30I$U(
MT>YV,)XY>[Z#;MX=RG-F_/NM*[J5BO3HQ8]Z'PX +YRZQ'R=F\U!>-#3[>UU
M0R*ZVJ22HH8WKCMZ:1ZN<C<]ZM>K\IZG)ZEQ]1Q2\&+-];Y#J:QW2&S:A2)M
M/4-JF*Z"I8U5Y556]6N1%QG"Y1$3IC)6A:KO76&Y4UQMM7/07"F>DL-33RJR
M2-R=SFN3JB_2A)73WE%=TK+:VTE73V&]2L;A*RNI'ME5>GPDBD:U?'N:GSG,
MWL&_1?F]C3U=EBZKC7<:,;-CE3_V$CN''A(M?#A=)=7ZMU!25]YY6TE,]K.2
MGI>U<UF&J[TG/>YR,3N^&J857'6>*K\SSK_]29OX"L[<'B@W!W+U):[Q>KLU
MS;75QUU%;J>/LZ2&5CD<QW(B^DJ*G>]7+A53QP>_UIQL[FZ[TM=-/76IMK[=
M<8'4TZ142,>K'>"+D\JM.RKEVF[<G>>]LT:OAVK-=BU3,1W.9[2[A5.UFX]@
MU52M=*^V522R1M=RK+$N6R,3U<S%<W/M+?+?<M*;\;:/?3S0W?3=\I'12(UV
M5Y7-PYKD^X>W.%3O:J>PI5/M-M-Y]:;05TM5I*_5%K[54=-3IB2"94Z)SQO1
M6N7&4SA%1%[T++.P)R.&NW.U4*G3-4C$XK5V.*BI+.\>3!J9-02):=;PPV)[
MU5OGE$KZF-N<HU<.1KUQ]UZ/S(2SVKVQTQP[;<)9Z&H2FME&CZNLN-=(UJR/
MPBOED=T1.C4]B(U/404IO*5[GPTRQR6?3$\J(B)*ZEJ$5?7E$F1/JP<@W;XF
M=PMZ(W4^HKTY+6KN;W+H6)#2]^4YFHN7X5$5.=57IT4K9PL[(F*+U7LK6C4=
M-PHFYC4SQ2]UQ5[[P[U;Q27:B9YSIVUHVEMT,R*U)HF.5SY'85')SNRJ=4=C
ME3I@GILOM;LCN'MS07W36C+!/2UT'9R<U,R:HII%9B2)TCT5[7MSC.4ST=W*
MBE3A]GMIO'K+:*Y.K=)WZJM3Y%19H&JCX)L>#XG(K7=%7"JF4ST5"RR,"JJS
M318JVX53AZI11D57,FGBX_)(G67DV-=T.H*EFFKI:KI97R*M//6SNAG:Q<X2
M1J,5%5$PF6]%ST1,X27O"=LA>=AMMI;!?;S'<ZR>L?6=G3*Y8*;F8QJQQJY$
M54RQ7+T1,N7IXK#:W^4JW0IJ=[*BU:;JW\F&ROI)VKS=.J\LZ(J=_1$1?:?#
M[E<;NZFY5OEMT]UI[#03-5DM/9(5A[1J]%:LCG.D1,>IV%\4*ZYBYV1$6KNV
MRVM9VFXDS=L[[_![?CWW0M>XV]BPV>>.KHK'1-MSZB)V623<[WR85.]$5[6_
M.U?63;X#L?8L:+^>N_GU05)>/M]?KZ_Z3N&VO&1N/M3HN@TM8*FW1VFA[3L6
MST:/>G/(Z1V79^,]QMY>!77C46;7<K\#5+=K,N9%[^:'D<="I]E/KCYZ+^8P
M$N/)C]=C+^G_ .<<W\UI2O3<?<&\;J:SN.J;Z^%]UK^S[=8(^1B\D;8VX;^E
M8T^XV?XIM=[(Z<JK'I>>AAH:JK=6R)4TJ2O61S&,SE5[N6-OU&>1B7+F)18I
M]Z-O)&)GVK6=7DU>[._FZOY3/\OJS?K<I_YU5')>$G\T;H']46_Q7'S6[N\>
MH][=34]^U-)3RW"GI&T4;J6!(FI&USWHBHGCS2.^L])H;65RV^U7:]1VAT;+
MG;9>V@=,SG8CD14^#])LVL>NC$[&>NVS2O95%S.[>/=XMUM?&-^9IUY_@3?Y
M5A6?PL;PMV2WDLU^JI'1VB?FH;DK45?['D5.9W1%5>5S628[UY,)WGT.O.-;
M<O<?2-STW>JJVOMEPC[*=L-$C'*U%1W1V?8?#;%[,UV^>MUTO;;E2VNM=2R5
M,<E8CNS?R8RST>N<+G]B:6+B3CXM=&1TGFLLW.C+R[=>-$[Q'+[K>-;Z+TYO
M;MW562Z<ESL-WA9(R>DE3JBX?'+$].F47E<B]47'<J+@B[I?R96EK/J5M??-
M6UE[LL,B2>YB4R4RO:GW,DJ/55;Z^5&KCQ1>I\3;=F.);AATC<ZW3^I[;76&
M@B?52V^EE=5,:QN7/<R*:)%1<)E49U5?I.!;A\6VZVZELELUSU"^.W57VN2A
MMD#8$E1<>BJL1'.1?BJN%SU0J\?'O<Z;%V.%<Y678]FO*LSQPMOTI>;3J#3]
M'6V&>&IM+D6.FFID3LG-8Y6>ACIRY:J(J=,=4*C.,;\TMK_'_?S?Y)A9WPQ:
M7N6B=AM&6>\4[J.Y4U BS4STPZ)SG*_E=ZE1'(BIZ\E5O$U>XM0;_;@5L+T=
M$Z\3PM<BY1W9N6/*+XIZ&?I/72:>')KVG>(_R\]=KX\.WO&TS,3M^3F*F#*F
M#KW!=P:J;&J@A@ !DU4P94P    U-C4   ,+W&ILO<:@#"F3"A,M0 $,*8,J
M8#*  $PD/%<[F7)_:5V&JGK/X$L@      ,^WP ]CIZP7#55]M]FM5*^MN5?
M4,IJ:GC1,OD>[E:F5]J]_L+M.'O:"CV.VHLFDJ9S99Z:/M*RI8W';U+_ $I'
M_-E<-SW-:U/ B1Y-[AGFH4_'7U'2]F^:-T-AIY6X<C'='U./#F3+6^M%<N,*
MU2P#/?[#B=5RXO5]E1TC]7T+1,*;-OMJXYST^S^@ *!U(
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MWQ V  &S>Y3)AO<ID,9#8U-@@  &X  RWQ-C5OB; #+?$P9;X@9    !BW
M9!EOB8,M\0Q;  #8  ;-\3)AOB9#'O9;XFQJWQ-B.\D !$H;  =P&6^)@RWQ
M(&P "(9;XFQJWQ-@B0V;W&ILWN,I0  B!N "/J!N:&X  $;'V9;XF3#?$R2
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M*9!(;&IL$!EOB8,M\0-@ 1 RWQ-C5OB;$2  )[D2&QJ;&)   AEOB;&K?$V
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MF2?J  C;O.;53!E3!++ZL*:FRFH1'Q  $L*8,J8">H  CFT   T-S0S +W*
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M/ RGIX6)''%$U&M8Q$PC41.Y,>!Y9LB>TR<;]W?Q$1T  $@
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MLWQ,F&^)D([V6^)L:M\38(D,M\3!EOB!D  #<T-R(  $2-F]RF3#>Y3)DB0
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M  PIJ;*:@  &4-0 $0&%[C)A>X,FH  PIJ;*:@#"F3"@8  &JF#*F S#0W-
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MH4?R276J^TT<7KS*OPE3XK4<[\Z>-=VBU&]<[0][5FN[5PT1O+FBI@F#PL<
M=ZW06DU+KUE38-*NQ+#0=8ZNO3O1>O6.-?C+Z2IW(F4<DIN'?@&T9M M-=K^
MV/6&J68>E35Q)YK3.[\Q1+E%<B]SWY7*91&=Q*5C$1%3"G+9FK\7L6.7U=C@
M:)PS%S(_H]5IG35LTA8Z*S66@AMELHXTB@I8(T:R-J>")Z^_KXJJKU/<&R&3
MF-YF=Y=A3$4QM   R
M          &B=WB#< >#6T,%?2RT]5#'/3RL6-\4S4<U[53"M5%3JBIX>)&'
M=7R=.UVOWU-99J>HT7=),N[2TKFF5R^NG=Z*-_.QJPE88Y4/6U>N69WMU;-6
M]C6;\;7*=U3NXGDV]UM(S2R:?2WZQH4ZM=2RI3SX];HY51,^QKG$=M8[9:MV
M_E=%J73%UL+LX1U?1OB:[VM<J(CD^8OH1,(?RGIHYXWLD8V1KDPK7)E%^="[
MM:S>HY5Q$J"]H%FN=[=4P_/O#U>W'CW']B[S6W#?MEN%2ST]^T-9JKME:KJB
M*E;!4914<F)H^61O5J9PY,HF%RBX/A_L =A_D0OWWKOPY84ZY;F/:IE4U_L[
M>W]FN%/9N7 >]_[#_(A?OO7_ (<?8!;$?(AWWWKOPYEZ:L^&7GZNY'BA3^"X
M#[ +8CY$.^^]=^''V 6Q'R(=]]Z[\./35GPRGU=R/%"G\RWQ+?\ [ +8CY$.
M^^]=^''V 6Q'R(=]]Z[\./35KPR>KN1XH5 @N ^P#V*^13OOO7?AQ]@'L5\B
MG??>N_#CTW9\,L/5W(\4*@6^)DM]^P#V*^1*_?>N_#F?L ]BOD1_ZUKOPP]-
MV?#)ZNY'BA4";-[E+>_L!-BOD2OWUKOPP^P$V*^1*_?6N_##TW9\,GJ[D>*%
M0H+>OL!=B_D2[[[5WX<?8"[%_(EWWVKOPX]-V?#)ZNY'BA4*;%O'V NQ?R)=
M]]J[\.9^P&V,^1+OOM7?AQZ;L^&3U=R/%"H8%O/V VQGR)=]]J[\./L!MC/D
M2[[[5WX<>F[/AD]7<CQ0J&-F^);O]@-L9\B7??:N_#C[ ;8SY$N^^U=^''IN
MSX9/5W(\4*B06[?8#;&?(EWWVKOPX^P&V,^1+OOM7?AQZ;L^&3U=R/%"HMO<
MIDMU^P)V-^1;OOM7?AA]@3L;\BW??:N_##TW9\,H]7,CQ0J*-BW/[ G8WY%N
M^^U=^&'V!6QOR+=]]:[\,/3=GPR>KF1XH5& MR^P*V-^1;OOM7?AQ]@5L;\B
MW??:N_#CTU:\,GJWD>*%2 +;_L#-C?D4[[[5OX<?8&;&_(IWWVK?PX]-6O#)
MZMY'BA4BWQ-BVW[ W8_Y%.^^U;^',_8&['?(QWWUK?PP]-6O#)ZMY'BA4B9;
MXEMOV!NQWR,=]]:W\,/L#]C_ )%N^^M;^&'IJUX9/5O(\4*DP6V_8'['_(QW
MWUK?PP^P/V/^1COOK6_AAZ;M>&3U;R/%"I(%MOV!VQ_R,7[ZUWX8?8';'_(Q
M?OK7?AB/35GPRQ]6\GQ0J5!;5]@ALA\C7??6N_##[!#9#Y&N^^M=^&'IJSX9
M3ZN9/BA4J9;XEM/V"&Q_R-=]]:[\,/L$-C_D:[[ZUWX8>FK/AE'JWD^*%3 +
M:/L$=D/D:[[ZUWX8?8([(?(UWWUKOPP]-6?#)ZMY/BA4R"V?[!/9'Y'.^^M=
M^&'V">R/R.=]]:[\,/35GPR>K>3XH5--\3);)]@ELG\C5^^M;^&,_8)[)_(U
M?OK6_AAZ:L^&3U;R/%"IMOB;%L?V">R?R-7[ZUOX8?8)[)_(U?OK6_AB/35G
M?W9/5O(\4*G 6Q_8)[)_(U?OK6_AA]@GLG\C5^^M;^&)]-6?#+'U:R/%"IX%
ML7V"NRGR/=]]:W\,/L%=E/D<OWUK?PQ'IJUX9/5K(\4*G3+?$M@^P5V4^1SO
MOK6_AA]@KLI\CG??6M_#$>F;/AD]6LCQ0JA!:_\ 8+[*?(YWWTK?PP^P7V4^
M1SOOI6_AAZ9L^&3U:R/%"J%OB;%K?V#&RGR.7[Z5OX8S]@QLK\CE^^M;^&'I
MFSX91ZM9/BA5&9;W*6M_8,;*?(]?OI6_AA]@SLI\CW??2M_#&7IJSX91ZLY/
MBA5*"UO[!O9;Y(.^^M;^&'V#>RWR0=]]:W\,/35GPR>K.3XH53@M9^P<V6^1
MZ_?2M_##[!S9;Y'K]]*W\,1Z:L^&3U9R?%"J8W+5OL&]EOD>OWUK?PQC[!S9
M7Y'+]\ZS\,/35GPR>K.3XH55 M5^P<V5^1R_?.L_##[!S97Y'+]\ZS\,1Z9M
M>&3U9R?%"JMOB9+5/L'-EOD>OWSK/PP^P>V7^1[OOI6?AAZ9L^&3U9R?%"JL
M%JGV#VR_R/=]]*S\,/L'ME_D>[[Z5GX8>F;/AD]6<GQ0JN!:E]@_LQ\CU^^=
M9^&'V#^S'R/7[YUGX8>F;7AD]6<GQ0JO;W*9+3_L']F/D@OWSK/PQG["#9GY
M(K]\ZS\,/3-GPRCU9R?%"J\%J'V$&S/R17[YUGX8?80;,_)%?OG6?AAZ9M>&
M3U9R?%"K$%IWV$.S/R1=]\ZS\,/L(=F?DB[[YUGX8>F;7AD]6<GQ0JQ,M\2T
M[["#9KY(K]\ZS\,/L(-FODBOWSK/PQ'IBSX9/5G)\4*LP6F_81;-?)%?OG6?
MAA]A%LU\D5^^=9^&'IBSX9/5G)\4*M&]RF2TG["/9KY(K]\ZS\,/L)-FODBO
MWSK/PP],6?#*/5C)\4*MC8M(^PCV;^2#OOG6?AA]A)LW\D7??.L_##TQ9\,G
MJQD^*%6X+2/L)-F_DB[[YUGX8?82;-_)%WWSK/PP],6?#)ZL9/BA5T"T;[";
M9SY).^^=9^&'V$VSGR2=]\ZS\,/3%GPR>K&3XH5=-\38M#^PFV<^23OOG6?A
MC/V$VSOR2=]\ZS\,/3%GPR>K&3XH5=@M$^PHV<^2;OOG6?AA]A1LY\DW??.L
M_##TQ9\,H]6,GQ0J\;XF2T'["C9SY).^^=9^&,_84[._)-WWSK/PP],6?#)Z
MKY/BA5Z"T+["G9WY)N^^=9^&'V%.SOR3=]\ZS\,/3%GPR>J^3XH5@ M ^PJV
M=^2;OOG6?AA]A5L[\DW??.L_##TQ9\,GJOD^*%8#?$V+/?L+-GODF[[Y5GX4
M?86;/?)1WWRK/PH],6?#)ZKY/BA6$&]Y9]]A7L]\E'??.L_"C["O9[Y*.^^=
M9^%'IBSX98^J^5XH5A@L\^PLV?\ DJ[[YUGX4?86;/\ R5=]\ZS\*3Z8L^&4
M^J^5XH5AFS?$LZ^PMV?^2KOOG6?A1]A;L_\ )5WWSK/PH],6?#+'U6RO%"L8
M%G7V%NS_ ,E7??.L_"C["W9_Y*N^^=9^%(],6?#)ZK97BA60"S;["[:#Y*O^
M^=9^&'V%VT'R5?\ ?.L_##TQ9\,GJME>*%9)L6:?87;0?)5_WSK/PQG[#':+
MY+/^^59^%'IBSX9/5;*\4*RC+?$LT^PQVB^2S_OE6?A1]ACM%\EG_?*L_"CT
MQ9\,GJME>*%9H+,_L,=HODL[[Y5GX4?88[1?)9WWRK/PH]+V?#)ZK97BA6:W
MQ-BS'[#3:+Y*K]\:O\*9^PTVB^2J_?&K_"CTO9\,GJME>*%9H+,OL--HODM_
MZQJ_PH^PTVB^2W_K&K_"CTO9\,GJME>*%9[>X%F'V&FT7R57[XU?X4?8:;1?
M)5?OC5_A1Z7L^&3U6RO%"L\%F'V&FT7R5_\ 6-7^%'V&FT7R5_\ 6-7^%'IB
MSX91ZK97BA6>;EEOV&FT7R5_]8U?X4S]AMM'\EE^^%7^%'IBSX9/5;*\4*T3
M+?$LM^PVVC^2R_?"K_"C[#?:/Y++]\:O\*/3%GPR>JV5XH5J LJ^PWVC^2R_
M?&K_  IG[#?:/Y++]\:O\*/2]GPR>JV5XH5JM\3)93]AOM'\EU^^-7^%,_8<
M;2?)=?OA5_A1Z8L^&4>JN5XH5JFY9/\ 8<;2?)9?OA5_A1]AQM+\EU^^-7^%
M'I>SX91ZJY7BA6P;-[E+)?L.-I?DNOWQJ_PIG[#G:7Y+K]\:O\*/2]GPR>JN
M5XH5M LE^P[VE^2Z_?"K_"C[#O:7Y+K]\*O\*/2]GPR>JN5XH5MM\3)9)]AW
MM-\EU^^%7^%'V'NTWR87[X5?X4>E[/AE/JKE>*%;8+)/L/=IODPOWPJ_PH^P
M]VF^3"_?"K_"CTO9\,GJKE>*%;K?$R61?8>[3_)=?OA5?A1]A[M/\EW??&J_
M"CTO9\,H]5,KQPK>;XFQ8_\ 8>[3_)=WWQJOPH^P_P!J/DPOWPJOPH]+V?#*
M/53*\<*X#+?$L>^P_P!J/DPOWPJOPH^P_P!J/DPOWPJOPH]+V?#*/5/*\<*X
M@6/?8@[4_)AWWPJOPH^Q!VI^3#OOA5?A1Z7L^&3U3RO'"N$W+&_L0=J?DP[[
MX57X4S]B!M1\F'??&J_"D>E[7AD]4\KQPKC!8Y]B!M1\F'??&J_"C[$#:CY,
M.^^-5^%'I>UX9/5/*\<*Y&^)G*%C7V(6U/R9=]\*K\*9^Q#VJ^3+OOA5?A2?
M2]GPR>J>5XX5R9090L:^Q"VJ^33OOA5?A1]B%M5\FG??"J_"CTO9\,GJGE>*
M%= +&/L1-JODT[[X57X4?8B;5?)IWWPJOPH]+V?#)ZIY7CA70WQ-BQ7[$3:K
MY-.^^%5^%,_8B[5_)IWWPJOPI'I>UX91ZIY7CA72;EB7V(FU?R;=]\*K\*;?
M8C[6?)MWWPJOPH]+VO#)ZIY7CA76"Q/[$;:WY-N^^%5^%'V(VUOR;=]\*K\*
M1Z6M>&4>J>5XH5VM\3)8E]B/M9\FW??"J_"C[$?:SY-N^^%5^%'I:SX93ZIY
M7CA7:"Q+[$?:SY-N^^%5^%'V(^UGR;=]\*K\*/2UGPR>J>5XX5X L/\ L2-K
M/DV[[X57X4?8D;6?)MWWPJOPH]+6?#*/5+*\<*\6JGK,Y0L.^Q)VM^3COOA5
M?A3/V)>UWR<=]\*K\*/2UGPRGU3RO'"O#*&Y89]B7M=\G'??"J_"C[$O:[Y.
M._Q^J_"CTM:^$H]4\KQPKS,M\2PO[$O:[Y.._P ?JOPH^Q+VN^3CO\?JOPH]
M+6OA)ZIY7CA7L"PG[$S:_P"3;O\ 'ZG\*/L3-K_DV[_'ZG\*1Z6M?"3U2RO'
M"O=OB;%@_P!B9M=\F_\ TZI_"#[$W;#Y.+_CU3^$(]+6?#)ZIY7CA7P"P;[$
MW:_Y.?\ IU3^$'V)NU_R<_\ 3JG\(3Z6M>&6'JEE^*%?)L6"?8F[7_)Q?\>J
M?PAG[$_;'Y.+_CU3^$(]*VOA)ZI9?BA7T"P3[$_;'Y.K_CU3^$'V)^V/R=7_
M !ZI_"$^E;7PD]4LOQ0K];XF2P+[$_;#Y.K_ (]4_A#/V*&V'R=7_'JG\(1Z
M5M?"3U2R_%"OPW+ /L4-L/DZO^/5/X0?8H[8_)U?\>J?PA/I:U\)/5++\4*_
MS9O<3^^Q1VR^3J_X]4_A!]BCME\GO_3JG\(/2UG;;AD]4<OQ0@""?_V*>V?R
M>7_'JG\(8^Q3VR^3J_X]4_A"/2MKX2>J.7MMQ0@("?OV*NV7R>7_ !ZI_"#[
M%7;+Y/+_ (]4_A!Z5M>&4>J&7XX0",M\2?GV*NV7R>7_ !ZI_"&?L5=L_D\O
M^/5/X0>E;7AD]4,OQP@("??V*NV?R>7_ !ZI_"#[%7;/Y/+_ (]4_A!Z5M>&
M3U0R_'" C>\V)\_8K;9?)UW^/5/X0S]BOMG\GG?X]4_A!Z5M>&4>J&7XX0%-
MF^)/C[%?;/Y/._QZI_"#[%C;/Y/._P >J?P@]*VO#)ZH9?CA @$^/L6-M/D^
M[_'JG\(/L6-M/D^[_'JG\(3Z6M>&4>J&7XX0(;XG5N&S0GXM]S*%T\?-06O%
M;.G@JM5%C1?G?A<>IKB3_P!BWMKXZ?=_CU3^$/K-#;8:<VXBJH]/6_S%M2YK
MIOMLDBN5,HG5[E]:_6IKWM3HN6YIHCG+?T_]E;UG)INWJHFF)W?7M;A$,XZ!
M#)SCZAT?R=AC55>XKYW[US^+W<JZ5D4G:4-,Y*2EZY18V*J<R>M'.5SD^="?
MU;1LK*6:"1'+'*U6.Y'JQ>5>BX5%147'BBH<Q7A:VURJ_B?=C.?]_5/X0W\*
M_;QZYKKCFYC7=/R=1LTV;%41&^\[H&&I/;[%O;7Y/O\ \>J?PAC[%K;7Y/._
MQZI_"%WZ5M>&7#^I^7XX0*!/7[%K;7Y/N_QZI_"#[%G;7_F!W^/5/X0>E;7A
MD]3\OQP@4">OV+.VO_,#O\>J?P@^Q:VU^3[O\>J?P@]*VO#)ZGY?CA <$^/L
M6=M/D\[_ !ZI_"#[%G;3Y/._QZI_"#TK:\,GJ?E^.$!E-2?7V+&V?R>=_CU3
M^$'V*^V?R>=_CU3^$'I6UX93ZH9?CA 4PI/O[%?;/Y/._P >J?P@^Q7VS^3S
MO\>J?P@]*VO#)ZH9?CA ,$^OL5ML_D\[_'JG\(9^Q5VS^3R_X]4_A!Z5M>&4
M^J&7XX0#7N-2?WV*NV?R>7_'JG\(8^Q5VR^3R_X]4_A!Z5M>&3U0R_'" 0)^
M_8J[9?)Y?\>J?P@^Q5VR^3R_X]4_A!Z5M>&3U0R_'" "F"?WV*>V?R=7_'JG
M\(/L4]L_DZO^/5/X0GTM:^$GJCE^*$ 3"E@/V*>V/R<7_'JG\(9^Q2VQ^3B_
MX]4_A!Z6M>&4^J.7XZ5?AJI8%]BCME\G5_QZI_"&/L4-LODZO^/5/X0>EK7P
MD]4\OQ0K]!8']BAMA\G5_P >J?P@^Q0VP^3J_P"/5/X0>EK6VVTGJCE^*%?(
M+!/L3]L?DZO^/5/X0?8G[8_)U?\ 'JG\(/2UKX2>J67XH5]F%+!OL3]L?DY_
MZ=4_A#'V)VV'R<7_ !ZI_"#TM:^$GJEE^*%?(+!OL3=K_DY_Z=4_A!]B;M?\
MG/\ TZI_"#TM:^$GJEE^*%?(+!_L3=L/DXO^/5/X0?8F[8?)Q?\ 'JG\(1Z6
ML^&6?JGE>.%>RF"PG[$S:_Y-N_Q^I_"C[$S:_P"3;O\ 'ZG\*9>EK/AD]4LK
MQPKV-"PS[$S:_P"3;O\ 'ZG\*/L2]K_DV[_'ZK\*1Z6M?"3U3RO'"O,%AGV)
M>UWR<=_C]5^%'V)>UWR<=_C]5^%)]+6OA)ZIY7CA7AE!E"P_[$O:[Y..^^%5
M^%'V)>UWR<=]\*K\*/2UGPR>J65XX5WJ8+$/L2=K?DX[[X57X4Q]B1M;\G'?
M?"J_"CTM9\,I]4\KQPKP-"Q+[$C:WY..^^%5^%'V(^UGR;=]\*K\*/2UGPR>
MJ>5XX5V@L2^Q'VL^3;OOA5?A1]B/M9\FW??"J_"CTM9\,GJGE>.%=BF"Q/[$
M;:WY-N^^%5^%'V(VUOR;=]\*K\*/2UKPRCU3RO%"NP%B?V(VUOR;=]\*K\*/
ML1MK?DV[[X57X4>EK7AD]4\KQ0KI!8M]B+M7\FG??"J_"C[$7:OY-.^^%5^%
M)]+VO#*?5/*\<*YU,%C'V(FU7R:=]\*K\*/L1-JODT[[X57X4GTO9\,GJGE>
M.%<YJO>I8U]B)M5\FG??"J_"C[$/:KY,N^^%5^%'I>SX93ZIY7CA7)E!E"QO
M[$/:KY,N^^%5^%'V(>U7R9=]\*K\*/2]GPRCU3RO'"N3*&I8[]B'M5\F7??"
MJ_"F/L0-J/DP[[XU7X4CTO:\,I]4\KQPKC!8Y]B!M1\F'??&J_"C[$#:CY,.
M^^-5^%'I>UX9/5/*\<*X5,%CWV(.U/R8=]\*K\*/L0=J?DP[[X57X4>E[.^_
M#)ZIY7CA7""Q[[$':GY,.^^%5^%'V(.U/R8=]\*K\*3Z7L^&3U3RO'"M\%C_
M -A_M1\F%^^%5^%'V'^U'R87[X57X4>E[/AD]4\KQPK@-"R+[#_:CY,+]\*K
M\*/L/=I_DN[[XU7X4>E[/AE/JIE>.%;IJI9)]A[M/\EW??&J_"C[#W:?Y+K]
M\*K\*/2]GPR>JF5XX5M LD^P]VF^3"_?"K_"C[#W:;Y,+]\*O\*/2]GPRR]5
M<KQ0K;7N4U+)OL.]IODNOWPJ_P *8^P[VE^2Z_?"K_"CTO9\,GJKE>*%;0+)
M?L.]I?DNOWPJ_P */L.]I?DNOWPJ_P */2]GPRCU5RO%"MA3!91]ASM+\F%^
M^-7^%,?8<;2?)9?OC5_A1Z7L^&4^JN5XH5KJ:EE7V'&TOR67[X57X4?8<;2_
M)9?OA5?A1Z7L^&4>JN5XH5JF%+*_L.-I/DLOWPJ_PIC[#C:3Y+N^^-7^%'I>
MSX99>JV5XH5J LK^PWVC^2R_?&K_  H^PWVC^2R_?&K_  H]+V?#)ZK97BA6
MB"R[[#;:/Y++]\*O\*/L-MH_DLOWPJ_PH],6?#)ZK97BA6B:%F/V&VT?R67[
MX5?X4Q]AIM%\E?\ UC5_A1Z8L^&3U6RO%"L\%F'V&FT7R5_]8U?X4?8:;1?)
M7_UC5_A1Z8L^&3U6RO%"L\PI9C]AIM%\EO\ UC5_A1]AIM%\EO\ UC5_A1Z7
ML^&4^JV5XH5F@LR^PTVB^2W_ *QJ_P */L--HODM_P"L:O\ "CTO9\,GJME>
M*%9IJI9I]AIM%\E5^^-7^%,?89[1_)5?OC5_A1Z7L^&3U7RO%"LL%F?V&.T7
MR6=]\JS\*/L,=HODL[[Y5GX4>E[/AD]5LKQ0K*4P6:_88[1?)9_WRK/PH^PQ
MVB^2S_OE6?A1Z8L^&3U6RO%"LHU+-_L,=HODL_[Y5GX4Q]A=M!\E7_?.L_##
MTQ9\,GJME>*%9(+-OL+MH/DJ_P"^=9^&'V%VT'R5?]\ZS\,/3%GPR>JV5XH5
MC LZ^PMV?^2KOOG6?A1]A;L_\E7??.L_"CTQ9\,GJME>*%8BFI9Y]A;L_P#)
M5WWSK/PH^PMV?^2KOOG6?A2?3%GPR>JV5XH5A@L\^PLV?^2KOOG6?A1]A9L_
M\E7??.L_"CTQ9\,LO5?*\4*PE,%GWV%FS_R5=]\ZS\,/L*]GODH[[YUGX4CT
MQ9\,H]6,KQ0K!!9[]A9L]\E'??*L_"C["S9[Y*.^^59^%'IBSX99>J^3XH5?
M@M ^PJV>^2;OOG6?AA]A5L[\DW??.L_##TQ9\,GJOD^*%7RFI:%]A3L[\DW?
M?.L_##["G9WY)N^^=9^&'IBSX9/5?)\4*O06A?84[._)-WWSK/PP^PIV=^2;
MOOG6?AAZ8L^&3U8R?%"KL%HGV%&SGR3=]\ZS\,/L*-G/DF[[YUGX8>F+/AD]
M5\GQ0J[,+W%HOV%&SGR3=]\ZS\,8^PGV<^23OOG6?AAZ8L^&3U8R?%"KD%HW
MV$VSGR2=]\ZS\,/L)MG/DD[[YUGX8>F+/AE/JQD^*%7"FI:3]A)LY\DE^^=9
M^&,?82;-_)%WWSK/PP],6?#)ZL9/BA5N84M)^PDV;^2+OOG6?AA]A)LW\D7?
M?.L_##TQ9\,GJQD^*%6H+2OL(]F_D@[[YUGX8?81[-_)!WWSK/PP],6?#)ZL
M9/BA5FI@M,^PCV:^2*_?.L_##["/9KY(K]\ZS\,3Z8L^&4^K.3XH59FA:?\
M81[-?)%?OG6?AA]A%LS\D5^^=9^&'IBSX91ZL9/BA5@"T[["'9GY(N^^=9^&
M'V$.S/R1=]\ZS\,1Z8L^&4^K.3XH58FI:A]A#LS\D7??.L_##["#9GY(K]\Z
MS\,3Z9M>&3U9R?%"J\%J'V$&S/R17[YUGX8?80;,_)%?OG6?AAZ9L^&3U9R?
M%"JU3!:E]@_LQ\CU^^=9^&'V#^S'R/7[YUGX8>F;7AE/JSD^*%5BFI:K]@]L
MO\CU^^=9^&,?8/;+_(]WWTK/PP],VO#*?5G)\4*JP6J?8/;+_(]WWTK/PP^P
M>V7^1[OOI6?AAZ9L^&4>K.3XH55*8+5OL'-EOD>OWSK/PQC[!S97Y'+]\ZS\
M,/3-KPR>K.3XH55 M5^P<V5^1R_?.L_##[!S97Y'+]\ZS\,/3-KPR>K.3XH5
M3@M9^P<V6^1Z_?2M_##[!S9;Y'K]]*W\,/3-GPR>K.3XH53&A:Y]@WLM\CU^
M^M;^&,?8-[+?)!WWUK?PQEZ:L^&3U9R?%"J0PO<6M_8-[*_(]WWTK?PP^P9V
M5^1SOOI6_AC'TS9\,GJSD^*%48+7/L&-E/D<OWTK?PP^P8V4^1R_?2M_#&7I
MJSX93ZLY/BA5$O<:EK_V"^ROR-7[Z5OX8?8+[*?(YWWTK?PQCZ9L^&4^K61X
MH50&%+8/L%ME/D>[[Z5OX8?8*[*?(]WWUK?PQ/IJSX9/5K(\4*G06P_8*[*?
M(YWWUK?PP^P5V4^1SOOK6_AB/3-GPR>K61XH5/&J]ZELGV"NRGR/=]]:W\,8
M^P4V3^1R_?6M_#$^FK7AD]6LCQ0J<!;']@GLG\C5^^M;^&'V">R?R-7[ZUOX
M8GTU9\,GJUD>*%32F"V7[!+9+Y&K]]:W\,/L$MDOD:OWUK?PP]-6?#*?5O)\
M4*FC0MH^P3V3^1J_?6M_#&/L$MDOD:[[ZUWX8>FK/AE/JWD>*%3!A2VC[!/9
M'Y'.^^M=^&,?8([(?(UWWUKOPP]-6?#)ZMY/BA4N"VC[!'9#Y&N^^M=^&'V"
M.R'R-=]]:[\,/35GPR>K>3XH5* MJ^P0V/\ D:[[ZUWX8?8(;'_(UWWUKOPP
M]-6?#)ZMY/BA4J:J6V?8(;'_ "-=]]:[\,/L#]C_ )&N^^M=^&'IJSX9/5O)
M\4*D@6V_8';'_(Q?OK7?AA]@=L?\C%^^M=^&'IJSX9/5O)\4*D@6V_8'['_(
MQWWUK?PP^P/V/^1COOK6_AB?35GPRR]6\CQ0J0!;=]@;L=\C'??6M_##[ W8
M[Y&.^^M;^&'INSX9/5O(\4*D30MQ^P-V.^1COOK6_AC7[ S8WY%.^^U;^''I
MJUX9/5O(\4*D#"EN'V!FQOR*=]]JW\.9^P-V.^1+OOM6_AQZ:M>&3U;R/%"H
MP%N7V!6QOR+=]]J[\./L"MC?D6[[[5WX<>FK7AD]6\CQ0J,4P6Z_8$[&_(MW
MWVKOPP^P)V-^1;OOM7?AAZ;L^&3U<R-MN*%11JI;O]@3L;\BW??:N_#&OV V
MQGR)=]]J[\./3=GPR>KF1XH5$@MV^P&V,^1+OOM7?AQ]@-L9\B7??:N_#CTW
M9\,I]7<CQ0J(4U+>?L!MC/D2[[[5WX<?8#;&?(EWWVKOPX]-V?#)ZNY'BA4,
M"WG[ ;8SY$N^^U=^''V VQGR)=]]J[\./3=GPR>KN1XH5#&I;W]@-L9\B7??
M:N_#F/L!=B_D2[[[5WX<>F[/AD]7<CQ0J%!;U]@+L7\B7??:N_#C[ 78OY$N
M^^U=^''INSX9/5W(\4*A%[C4M]^P$V*^1*_?6N_##[ 38KY$K]]:[\,/3=GP
MR>KN1XH5!&%+?_L ]BOD1_ZUKOPQC[ /8KY$K]]Z[\./3=GPR>KN1XH4_@N
M^P#V*^13OOO7?AQ]@'L5\BG??>N_#CTW9\,I]7<CQ0I^4P7 _8 [$?(A?OO7
M?AQ]@%L1\B'??>N_#CTW:\,I]7<CQ0IYD=T1#^)<S1\#6R%#V?)H.ED[-<IV
M]74RYZ^//*N?IR?:Z=X?=M-*(U;3H/3U%(SNFCML2R]WQU;S+]9A.MVX]VB7
MK3^SMWOKA2MH[;C5>OJCL=-::NE^DSA?<^C?,UOM<Y$5&I\Y(C;KR;VZ^L)8
MWWZ.AT?0NPKI*Z9L\_*O?RQQJ[*^QSF%KL%-'!&C(XVQM:F$:U,(GU']L(O@
M5][6;U?*B-EI9T"S1SN53**FU'DY]K] N@K+W#4:UN<:HY7714;2HY/53MZ*
MW\[(KR3]#;Z>VTL-+201TU-$Q(XX88T8QC4Z(U$1,(B>"'G I;EZY>G>Y5NZ
M"SC6K$;6Z=F.4QX+WFX/)M
M                          -#/S&P UYC!N
M
M                                  U^@?0; #7Z!]!L -?H'T&P U^@
M?0; #7Z!]!L -?H'T&P U^@?0; #7Z!]!L -?H'T&P U^L?6;
M                                 -?K'UFP U^L?6; #7ZQ]9L -?K'
MUFP U^L?6;
M                       #7ZQ]9L -?K'UFP U^L?6; #7ZQ]9L -?K'UF
MP U^L?6; #0&X   #7Z#!N -?K'UFP U^L?6; #7ZQ]9L -?K'UFP U^L?6;
M #7ZQ]9L -?K'UFP U^L?6; #7ZQ]9L    U^L?6;
M                                                    U^L?6; #
M7ZQ]9L -?K'UFP
M   U^L?6; #7ZS!N -?H'T&P U^@?0; #7Z!]!L -?H'T&P U^@?0; #7Z!]
M!L -?H'T&P U^@?0;
M
M          #7F,]3( UY3+>XR
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME<9PN%15:O*O*Y<*=6
M
M
M
M
M
M                   &.9/69.-<3?$WI;A1T'0:NU?17BX6ZLN<=JCBLL,4
MLR2OBFE:JI)+&WEQ"],HN<JU,8S@.R@K_P#?K-C_ )*[@?>ZA_I@]^LV/^2N
MX'WNH?Z8!/\ RAD^7V\UK1;CZ#TUJZV0U$%MO]LIKK2Q53&ME9%/"V5B2(U7
M(CD:Y$5$54SG"JA]0
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MA-*\-.@6ZPUBVO6T+5QT/^Y\"32]H]'JWT5<G3T%ZY(U^_%[!?VO5GWJ9^&
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MW/CQ(WLYJ>5BX?%*S[EZ+CIURCD5%5KD50Z$
M
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ML54QK9613PME8DB-5R(Y&N1%1%5,YPJH?4
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MPC6SL7E3*_'Y$ EH#5%14RBY3O/Y5%1%20R332,BCC:KWR2.1K6M3JJJJ]R
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M&O?EC6.5V6],+S]P'6P
M
M     (?>4\V&UUQ";"V'3NWUA74%YI=2T]PEI?/(*;E@;2U<;G\TTC&KZ4K$
MPBYZY[D4F" * ?>MN)_^YE_Z_M?])(JGZJ#\JX'Z4N$S\RULW^LRS?S&$ZL<
MIX3/S+6S?ZS+-_,83JP
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M<HJ9>QW>WI:85&:BY-2^6OIHJQCI(J>YTW91N=S(U8;.Q[%3/=Z;.?'K5?G
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M-H$F] ZRMVX>BK#JFT2=K:[U0P7"F?GKV<L:/;GVHBHBIZT4^AYD]9 KR/\
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MK*9&MJKW9J6MJ&L^"V9\35E:GL1_,GT'00
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MU#>JBPZ8CJ'4E,VCB:ZHJY&HG.Y%>BM:Q,\N<*JKE.G+U"3_ )0K<O2NZG"
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M=:5['/NNKY8Y4E?\)U/#5QQLSGKE9.W<OKRA(GR4_P"9DJOUP5?\E !,<
M
M                                             !KE,'Y6L9[S]3-P
MN%-::&HK*RIBI:.GC=+-/,]&QQL:BJYSG+T1$1%557U'YMK=M8V2R.=42*RX
M2)S,ZY;'^=7UY\?5X>W9Q\:[D;]G&^S3OY=G&B.UJVW?H!X3?S+.S?ZS+-_,
M83JB+@X]PC7"DK^&':IE+5152T>F+;0SK"]')'-#31QRQKCQ:YKFJG?T.OJN
M37F)IF8F.C9IJIJB*HGE+^@ (9@
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M?):NR<])(GQIF5)E3*<^57DZX\"8:(GJR;!!=NUWJN.N=Y38L48]/#;C:&0
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MM,+Y9Y9*.)SWO<K<JYRJJJN>JJ1X\N)UT5M3CK_NA7_R<)./A,7_ +EG9O\
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MYSHP
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M3JQRGA,_,M;-_K,LW\QA.K
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M&?!4:J]$P!VC1]937#2=EJ:1J-I9J&&2%J=R,=&U6I]2H<(\H=4TU/P@:_\
M.FHY)&T<<;<][UK8.5?H5,_01-V3X]=6<,-BI]L]V="W.:2QM;34<[?M%5%
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MWKF%TJ8\5P0I\G=8;QOCQ"VC4VH975UMV]L45+1\Z<S(\-6&EB^A'2R)XYC
MF-Q;Z.H=ON!'5&E[:G+;[/9Z*A@Z856QSP,1R^U<95?%553YCR4_YF2J_7!5
M_P E ='X]?S(VX_^"0?SF$YOY*?\S)5_K@J_Y* "9
M
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M-[V<>K&KX*)]C]$J0 ::P
M                           !X[X6R8YF(JM=S-54SA>O^WTG]N4V
M        ?+Z[VXTON;8I;+JW3UMU):I%1RTESI63L1W@Y$<BX<G@Y.J$=*SR
M6W#75U[JI=OY(4<_G=!#>JYL:KG*X3MLHB^I%1$\,$LP!SG:KA]VYV0I)(-"
M:-M.F^U8V.:>CIT\XF:BY:DDSLR/1%55])R]ZG1@ /B]PMG]$;M044.M=)VC
M545$YSZ:.[4;*AL*NQS*U'(N%5$3ZCZ"QV&@TY9J*TVJC@M]LH((Z6DI*9B,
MB@BC:C61L:B81K41$1,=,'M  /F=;[>Z:W+L3[+JZP6_4EH=(V;S*Z4S9XN=
MN>5W*Y%3*97"]_4^F 'Q^WVUFD-JK?4V[1FF;;I:AJIO.)J:TTK*>)\F$;SJ
MUJ(G-A$3.,JB)ZNGKMO]A-N=J;C4W#1FA[%I>NJ8NPFJ+301T[Y(^;FY7*U$
MRF43H=!  ]1J/35LU;8ZZRWNVTMWM-=$L-50UD3989XU[VN:Y%14]F#VX Y!
M0\)6RUMI[A3TFU6DZ:GKX&TU7%%:86MJ(DDCE2-Z<N'-22*-^%Z<S&KWH?9Z
M VRTIM99IK3H[3=LTO;)JAU5)26FD93Q/F5K6K(K6HB<RM8Q,^IJ)X(?6
M .</X>=LI-<IK1V@=/NU;YRE;[MI;XDJTG14Q)VF.;FZ=^? Z.  /YJWV']
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M'-=5T5/4N;U:Z:)KU1?6F4Z'G@#^3(FQ,1D;48U$PC6IA$_T']0
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MFB](4\J444CJBIJZE4=45L[D3FEE<B(BN5$:WHB(B-:B=$ ZD
M
M                              'Y5S]5!^5<#]*7"9^9:V;_ %F6;^8P
MG5CE/"9^9:V;_699OYC"=6
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M*AYH ^,L>S>@=,W/W3L^A].6FX\W/YY0VBGAFYOC<[6(N?;D^P:WE[DQ]!N
M!\E?]K=':NK6UM]TE8[U7-5.6IN%MAGD3"83TGM5>B*J'UH ]>RTT;+>VA;1
MP)1-:C&TR1(D36IW(C.['=T,T=LI*!7K34D%,]Z>DL,:-SCJB+C&<9//
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M6GBIXU555L+$8F5\>B>S^ \P
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M%SS)C&%S&$DAP1UE0W5VHZ5%5*:2A9*]/#G;(B-_<<X"88
M
M
M
M
M                                               ?E7/U4'Y5P/TI
M<)GYEG9S]9EF_F,)U4Y3PF_F6MF_7^(RS?S&$ZK]R1S&N4[_ !-O YC==^--
M6C6Z:9F=4><I(V!U4C6K DCL8:KD=GHJX7IA.OJ.F(J=37M9%J]-46ZM]NOT
M>MRS<M1$W*=M^<?5_0 &R\@
M
M
M
M
M                                               !6[M_Y)&FU1NC
MJ'7&\FHWWJ&X76IK8M/VN:1.UC?*Y6)452X?\%416QHBICI)X$5O*X::M6C^
M)+3]DL=NI;1:*'25%#2T-'"V*&%B3U6&M:G1/H+RRD7RS7YK.V_K6H_Y>J N
MZ(A>55U9+I?@PU7!#*L,UXJZ*VHYJX7E=.V1[?F5D3FK[%4EZ0<\L1&Y_"(U
M6M54;J*B5RHG<G+,F5^E4^L#T_D:=$0V/AGO&H5CC6LOU^F5TK6IS+!#''&Q
MBJG5</[9>OQ_KGV0P\D8O_<9V3]5;A_+$SP*3_*K0/VHXX[+K"SHV"Z5%LMF
MH$>Q51?.(9I(F.7U+BD9W>HL3\HCKAVF.";<FZ4;O2N%O@H(^;*9955$4+_I
M[.5ZX7U8(">6RK('\0.B*1O^^8M,-E?Z/W#JNI1O7QZL?T\/I)F>4V17< 6H
MU:G,C4M*JJ>">=0)G]U/K Y%Y$G1-+2[3[A:N2-%K;A?([4KUZXCIZ=LJ(G7
MIE:I<].N$[\=+*2O_P BC^9:U5^O.J_F-"6  4T^6;TQ^)SB$T9JJAE\UJ[E
M8FL<^%5;(DU//)B7*=47EDC1%SE.1"</&]N?/!Y/;5FJH,)47VP4,*)\'+:U
M\$<GAT]"9ZX]A$CRX51$_5>TU.WK/'17%[O1\'20(G7YVNZ>'TG=^.!%?Y+*
MB5$SBS:=553P].E_T@?%^1)T32TNT^X6KDC1:VX7R.U*]>N(Z>G;*B)UZ96J
M7/3KA._'2RDK_P#(H_F6M5?KSJOYC0E@ %-/EF],?B<XA-&:JH9?-:NY6)K'
M/A56R)-3SR8ERG5%Y9(T1<Y3D0MUT!J%=6Z&T[?53K=+=35O=C\DB:__ -XJ
MT\N%41/U7M-3MZSQT5Q>[T?!TD")U^=KNGA])9CL-^4=MW^MVW?S:,#[K*'S
MFNM/T>JM&7JTUSDCIJJE>QTG*KUC5$54?RIWJUR([">*%$_E1<?9S[F^"?[F
M_P#LRD(OVRADN=PI:.%/MU3*R%GZ9SD1/X0+0J"OIKI3LJJ.9M33/54CE;GK
MCO7KU14]1_<];IRQTVF;#;[52,Y:>C@9 S/551J8157Q7IE5\<GLB9VWY,:=
M]MIZAW3@QW9L=JW)O.A:RCJZ>^72&.HH:M6<\-0R-KG/CZ? 5$RN5Z+A4Z*B
M<W"SLW"5?DL^[E-3+$Q_NG2S4G:.1%<S"=KT=WHBK&B83IUSX=)IFF-]XW8U
MTU3MPSMS\D[0 8O0
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MRG,WP?&],X1['(YCF^#FJG@?9@
M
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M2*LCV:JYY[_'N76IUU:AE51C^U33'+;X=[JX-45')E%,Y0ZMSK(
M                                                       !CF3U
M@9!ZN[:EM%@Y5NEUHK:CO@^>5#(L_-S*GJ7ZC:TZBM5_C>^UW.CN3&+ASJ2H
M9*C5]2JU5P![(&,H9     8R@&08YD]8R@&08YD]9D #',GK&4 R#',GK,@
M   ,90#(/XNFCC?&CGM:LCN5B*N.9<*N$]?1%7Z#^N4 R#&4&4 R#^,,S)FJ
MYCFN1'*W+5RF47"I\Z*BI]!_8 #',GK/&JZ^FH(TDJJB*F8J\J.F>C45<*N,
MK\R_4!Y0/'I:N"MB[2GGCGCSCGB>CDRGAE#R  !C* 9!\W?MPM*Z7N+*"]:F
MM%HK9&-DCIJ^OB@E>U55J.1KG(JHJHJ(OK13Z0  8R@&08YD]8R@&0#&4 R
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M /[@  #^4DS((GR2/:R-B*YSG+A$1.]54_IE ,@     ,9090#(
M
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M]+T=^XM>-?=>RKHRELNI*:HJ6^;U$]FTL^FK)FJG*J.E;']J[\JYG9X]:)T
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MO6J)U4\C[DA+(
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MB3O)ZE2FP-4FR_E?]:Z7HO0M^I*JXT\C$7T6MG@2XL3'J1[&M3U(H%M8
M   !C*&3X[=77OXVFB+AJ)*)+CYHZ)/-NV[+GYY&Q_"Y78ZN3P ^Q,90BO\
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M'_.[9KRD6T^OJ%?-//66NKK)8^CI>SJGT\[7>M'4[6-^953P+:P
M
M                           !^5<_50?E7 _2EPF?F6MG/UFV;^8PG4NB
M*OK.6<)OYEO9S]9MF_F,)\EQ$[M7[1-^MMKLE4RBYH/.99.R;(YV7JU&^DG1
M/17N-#,R[>%:F[=Z-O%QKF7<BU;ZRD"U$ZD,^)2QK9=T:BH8U4970QU35;TP
M['(N%]>69^DE=H6\SZBTA9[I4L;'/5TD4[VL^"BN8B]/9U.;<1>UUSU_;[;6
M66%M17T3WM6%SVL61CL=RNZ=%:G?ZU*G6+$YN#Q6HWF-IA9Z1?C#S-KL[1.\
M2Z3HF^IJ32MIN:83SJFCE5$\'*U%<GT+E#WW=GU'PNS6E;CH[;ZW6NYJU:N'
MM'*UB\R,1SW.Y<^/?WGW/3J7.+-=5BCM(VJVA47Z::;M<43O&\[/Z  W'@
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M4*R/1_I<U8R&)_5/',RD%/)?V"&\\4U'5S,;(ZU6JKK(E<F</5K8L_5,O7P
M^ UULWO1P;W:S7ZN2LTK-6+BFN=IKVO8Y[41ZPO=&[&43[E_1V%PCD12TC@G
MXE7<26TZ7*Y-9%JJTRI17:.%J-:]_+ED[4ST;(F5QX.:Y,(B(?->4QL--=N$
M[4-9-'VDEKKJ*K@=CX#W3LA5?I;,Y/I(J^2+U--1[NZTL"/5*>OL:5KFJ[HK
MX*B-C>GBN*A^,>T"S36>MK%M]IVKONI+M2V6TTJ9EJZR1&,;GN1,]55>Y&IU
M5>XIZXY^+C[)36=-061DU+HFQO>E"V;+7U<CL(ZH>WPRB(C&KU:F5Z*YR$D>
M.3AAW4XBN)*@@TM;9WZ=IK/3M=<KA.L-OIY%EEY\97TG8Y55(T<[NRB$:>,_
MA<M'"]%H"T45PGN]VN5%4U%RKI/0CDD:^-J-C8GP&-15QWN7KE>Y$">ODO$_
M[E:@5$_^^M9_&0EN1)\EY^95H?U6K/XS26P ])JW4]OT5I:[Z@N\_FULM=-)
M65,W?RQL:KG*B>O"+A/7@]V0R\J9N,[2?#W!IZGG6.JU+<HZ9[6KA5IHLRR?
MY21(OK1RH!%+ANBNW&CQN?BQU+%VENM\JWR>E<O-'3P0N:VEID\%3G6)%3[I
M&O<O55)+>4ST3N9J]=M_QNK;J*X>;^Z7GWN"DJ\G-YKV?:=GZ\28SZG'J?)&
MZ$AMVVFL]8/C_LNZ71MN8]4Z]E!&C\I\[IW9_2(3Z HZ_&2XF?DUN'^UJO\
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MUPIKA74?FE6C6<Z*V5G*UKVJCO1>U$[ERKLY3MWD>?\ C'N?_@E!_'G LT
M%$'&/^:CW.Z?_?N;.?GZ%Y>F<_B=M7K\UBS^T0HTXQ_S4>Y_ZMS_ ,)(G5_%
M)Q([_4,LVT>F]0V70UNC2GCFLM LE1.K&HU5=/RKE_>O9Q*G*BI\)41P%JQC
MF3UE-^S?E"-W=I];04NL[M6:HLD-1YO<K7>8T\ZA1'(UZMD5J2-D;A?1<JHJ
MHN4\4MPN.M++:-&U>K*JNC;8::A=<Y*UO5OFZ,[3G3QQRIG 'T',GK&4*A=Q
M./W>W?37SK1MHE=8Z":96VZT62D2>NF:F51TKT:YRNPBJJ,PU$SG*)E?F]5;
MR<6>Q;Z:OU/>]8V6&6;EBGO,?;TTCU3/(CI&O8JX15Y?8O0"Y\JO\KJW_MKZ
M'SA?]Q'K_P!>_P#^A*K@2XLJ[B6T7=X-0TT%/JNP211U;J1G)%512([LYD9E
M>5RJQZ.1.B+A4PBX2*WE>/RV-#?J(_\ EW@2I\FJG_<D:7SW>=5^?'_[ID(A
M^5,WBO\ =MX(M 17&:FTW::&">2AB?B.>IE17]I(B+Z2HUS&HBY1/25,<RY[
M7PY7S5&G?)GU-ST6M6FJ*9*UUO6AI^WF[1:U47DCPO,O*KNF"N;=[4VM]6ZY
MKKGN&ZO=JJ2.)*CW2I?-I^5&(D>8^1B(G+RXZ=P$G-A?)MZXU[8=%:ZJ+W8J
M*RW&2EN#J&:2;SE:19&N545L:HCUCRYK<]ZMRJ=<6Z%5W _NMO[6;G[:Z=N3
M]1+MHV+S=K9K0C:/S1M,_L?MW9?!Z1X=S]>GK+40!4#Y5?\ --4O3*_B>I?Y
M6H_A0M^*A/*L?FFZ;];U)_*S@6&<%&?L5=M/U);]'I.*\+]P7[TU/$3<=10Z
M%K'V:354E?'5I54^%@6L5Z/PLF<<GI=V?9DL/X)_S*FVGZDM_CN*\+]QH[TT
MG$3<=.PZ[JF66+54M VE2EI^5M.E8L:,SV?-\%,=^?:!;A=;E':+76U\W6*F
MA?.]$[^5K5<O[B%#4MPUQQ9;WT<%9<4N&I=1U_F\#JR5R4],CNO*U,+R1,:G
MP6IW)W*O?8CY2#7V[FD?Q,TNW3[RVSUU#6MO'N7;O.8^7[6B=H[LW\J<JR=>
MG3/J*P]N+YJ?3NM[1<M%K5MU13R\U M#3]O,DG*O1D?*J.7ESX 6D\$_ WJ7
MAGW#OFI-07JTW=E5:UM],RVNERUSI6/>KVO8U,8C1$PJKU7H35(B\!FY.Y^I
M-!:UNN\55=(9;?5,?!/?*!*+LZ=(E<]V.S9EJ*F57P(L;_>4EW!W$UA-8-IG
MS6&PNJ/-Z2:EI4FN-Q57(UKDRBJQ'*J*UC&\W7#E7.$"V#F3UC*%-ERWYXL]
M@G4%XU/<=56^AJ9?034E'V]-,[',L:K*U>551/@HK53KA4+#N#KBOM_$_H>I
MJI:6*U:JM;F172W1N56=<\D\6555C=AW1556JU455Z*H0EX\=-W?AIXL;'NG
MI1WF?NRY+M"Y$7L_.XL1U4:IGJU[7,5W7TNW<A9=M-N-;MV]M].ZRM**VAO%
M&VI;&KD<L+EZ/C54[W,>CFK[6J1G\J=H2'4G#@S4'9_V7IRZ05"2^*13*L#V
M_,KGQ+^Q0^)\DCN1+=M ZQT153J_W'K([A1L>N52*=%:]K?8U\>?8LH%@ (H
M^4;W;U=LULG8KWHR]2V*ZU&HH*.2HBCCD5T3J6J>K,/:Y,<T;%[ON3X[R9^_
M&O=[:+<*36^HIK^ZVRT"4G;0QQ]DDB5"O^ UO?R-[\_! F^  (!\=O$YKA^Y
MEHV-VJJ:B@U#7+"RX5M&]&5#GSHG94[']\2(U4>YZ*BX<WJB(O-Z.#R2M366
M9*VY[HU3M7JWM5J&42R0)-C*)S.>CW(BX3GZ*N,\J=Q-5^PNW\NY$&X#]*T#
M=8PO65MXC:YLJN5BQJYV%1'+R+RY<B],>I,>OW*XF=L-H)*VGU7K2U6ZXTC4
M?+:VSI-6-RU'-S SF>F6JBITZHN0(><'G$-N!MAOY6[ [JW*:]2-G?26^NJI
MG32P3-9SL1)5])\4L?5G-U;EJ=$7"3SUYK2U[=:-O>J+S/YO:[32OJZA_CRM
M;GE:GBY5PB)XJJ(5M\/]KO7%QQSUN\5%::JUZ-M=<RK6JJ&X1>Q@;#3PY[G2
M.5C'N:BKR)GJN4S)+RGNII]/\*URI(7<K;Q<Z2@EZX7D17SJB?.L")\RJ!%S
M0^C]UO*4ZROM^O>IIM)[=V^H6&&EAYI:>)^$5((H>9J22<BHKY7+]TG3"HU/
M[[Q<)NY7!!1)N1M=KRNN%FHY6K<8VQ=B^%JN1K'31<SHZB/F7"Y:G+E/1QE4
ME_Y._34&G.$S1;HF-;/<4J:^=[4ZO<^HD1JK[>1K$^@Z_N]IB'6&UFL;%/&V
M2*XVBKI58['W<+VHOL5%5%1?!>H'S'#%OC1\0NSMEUC!%'35DO-37&C8Y7)3
MU3.CV)G[E<M>W\Z]I$[C.XC==[@;S4.P.T%9-27&:1(+G7T4_9RR3.8KWP]H
MG6.../TGN:N<Y;T1JH[P/(_ZFFDMNY6GI'.6"":BKX6Y]%'/26.1<>&4CB^K
MV(?*^3J_[8W&-N3K2X(V6J2FKJYF>O++45;$YFKX88LC?F<!]'7>29NM#I_W
M2M.YTS];P-[>-\E$Z*G?,C<HQLJ2+(STDQVG7U\B'UW /Q/:QN.M[ULINI43
MSZJM7:I0U=<_FJ7.A7$U-(_KVBHB*]KU555$?Z2IC$\RK?B-<NV7E-]'7NB9
MYNMSK;3/,D2X5S9E2EF^MK79]:J!:0  ,9090@7QU\3VLMA^(3;JEM=_JZ#2
M3Z6GKKO;Z6&)ZU,25;TE1%>W.71M5O1R?1WGSC).+[BGH'ZOTW<Z;;72%;]M
MM5O6K\TEFA7"MD1[(W2OYD1/2>K&JBY:G*J 6,&.9/65=;8<>6YG#OK_ %'H
M??2*JU![GPR(C>6+SR"H2/M(D21J(DD4B*U.9W-A'M5%PBM7ZVLL'&EOM0?B
MOH;Y2Z$ML[?.;?I^&L2CD[)>K$PUCG.54_MSTSUZ)W 6,<R>L90K\X(>+_<&
MZ;PUFS>[2R5-[^WQT=740-CJHJF)JR/@E5N$<U8VO<U^,^BB95')B6G$-OG9
M^'G;&Y:QO+'578/;!26]CT8^LJ'Y1D;57..YSE7P:URX7&%#I_,GK,E8FA+S
MQ><8,-1J;3^I8="Z6D>YM)(V1UOI7X<J.;$Z-CYI,.145ZY3.4ST5$\7<SB1
MXF>&"PW;1^X\WGT]TIO]PM74K(I%BE:]CG<LG(C94Y>=KF2,1Z<S7)TPBA:)
ME#)'7@.W)U-NOP[6G46K;K)>;S-6U<;ZJ1C&.<UDJHU,,:UO1$]1(H"!'E;-
MO?=;:_2.L88N>:S7)]%.YJ=T-0S/,OL1\+43U*_VJ24X1=<_CB\-FWM[<_M9
MUM4=).[F55=-3JL#U7/BKHU7KZS^G%CMY^.CPZ:]T_'%VU3);)*FE8G>Z>'$
MT2)ZLNC1/V1'?R2^NO=K9?4NF)9>>:Q7;M6-S\&"HCYFI_TD<R_2!(#C!W&_
M&NX;]>7R.7LJQUO?0TKFNPY)JA4A:YOM:LG-^Q*I>&2LNVPF^NSNK[FBTUHU
M"_F9([/*M+-/-12*[VM5KI._NY%\4)>^5DUQ43:>T#MS;>::LN]>ZX2PQKAR
MMC1(H6KZT<^9^/;'[#T7E&=A8=%<-^U-5;HT631K8['/+$F.:.2%N9%_\;"G
MTRJ!9"5J^5KU=/==2;<:!H$=-4N9-<7T[%]*1\KTA@1/I9,G7U^PG+P\[BIN
MMLEHK5CI$DJ+G;(GU+D[O.&IR3I]$K7H0%N,7V0OE2DI_P#?-HTO6M1Z?"2-
ME!'S*BIXHM4BI^S]B@3SL\=DX<MA:)EQF9!9](62-M1*Q$17]C$B.5$\7O<B
MX3O57(GB5YZ'T?NMY2G65]OU[U--I/;NWU"PPTL/-+3Q/PBI!%#S-223D5%?
M*Y?NDZ85&I*/RGNIJBP<*]PI(5Y4O%TI+?)UPO(BNG5$^=8$3YE4^C\G?IJ#
M3G"9HMT3&MGN*5-?.]J=7N?42(U5]O(UB?0!$#>+A-W*X(*)-R-KM>5UPLU'
M*U;C&V+L7PM5R-8Z:+F='41\RX7+4Y<IZ.,JD]^&+?&CXA=G;+K&"*.FK)>:
MFN-&QRN2GJF='L3/W*Y:]OYU[3Z?=[3$.L-K-8V*>-LD5QM%72JQV/NX7M1?
M8J*J*B^"]2#'D?\ 4TTEMW*T](YRP0345?"W/HHYZ2QR+CPRD<7U>Q +&@
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MHYE#1*[TD8LE9#/.U,^#&^;M3V90EWY*?\S)5?K@J_Y* "8X
M
M!C* 9!C*#F3U@9 ,<R>L#(     ?S1O7H?T    8PAKRKU3P-P    TS[#<
M   -,^PW    "O\ \M1C[%O2Z+\LZ7/7_P#$:\L .-<3^MMG-!:"H*_>^GL]
M3I.6YQT]*V]V5UUA2M6*9S%;$V*7E=V;9O3Y41$54SUPH4E<+.^5'HU\NEK]
M4>;VJJE[6EJY7893R+WM=ZF+WY\%SZ\DQF.1R91<IWY0ZHG$MY///2T: _\
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M1--R-JJ>KV  *U=
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MO;'Y,_\ I]5^%/9:6V&T/HR]T]XLMC\RN5.CDCF\[GDY>9JM7H]ZIW*O@=#
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M;;\/<CO7_9TJ1JGJ7YRUT
M                                                          ?E
M7/U4'Y5P/TH\)OYEK9Q/_P S+-_,83AO%'5^<[H/8G=3T<,?[KW?^\=QX3?S
M+>SJ_P#YF6;^8PG\M?\ #]:]>:KBOE365%,YR,;40Q(BI*C>B85?@KC">/\
MG*#6,2[F8\6[77>%SI.5;Q,CM+G3:7W^BJ)+?I*S4O+CL:.&/'S,1/\ ,>[-
M(XTCC:Q$PC4PB)ZL8-W.PUR^PN;=/9VXI^"HJGBKF6$7TN_J90BYI/?'4S]X
M?<V[U;5MLU?)0NI$B:C85YE:Q$<B<V4=RHJJJ^/L)1-7N-3#SK69%79_RSLW
M,G"NX=5,7/YHW?T !8M$
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MK8.QJ-4U_;0<R8<ZEA18V.7YWK-CUIA?$":H/@M0;X[?Z2U1'IJ]:RLUKO\
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M"E/*EZJT_H75&G]8Z,6W;F4<;J6CJ*9BQ4[9E]%73Q/<KF.:F7IRY:]41,,
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MC\>OYD;<=/\ \4@1/\9A.;^2G7_N9*K]<%7_ "4 $R
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M*XYK7'R+>3;BY;GE+^@ /)L@
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M&+L*2^34K'U<$>'IRLD5,M3$C^Y?NW>L^O
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MER]K7)F/)-,T1N$[NXW
M                                                        'Y5S
M]5!^5<#]*7"8J?8M;.?K,LW\QA.G)4Q/E6-KVK(G56YZ_4<MX45QPK[.K_\
MF99_YC"<%V[O5=<]^Z:L;4R++47&57.YE571KS*K5]F$QCN3HI49N?&'7;HF
MG?CG99X>#5ET7*XG;@C=-0P$[C);JQ"??NT/TGNY6U-,O9^<.CN$*IX*O>O[
M=CE)AZ=NK+Y8K?<8^D=53QSM3V.:CO\ .?';C[+V3<NOI*NXRU-// WL^TI7
M-:KV9SRNRU>Y<X^=3[>TVN"S6REH*1B14U+$V&)GQ6-1$1/J0YW3\"YB9-ZN
M?=JG>%WFYM&5CV:(]ZB-I>> #HE(
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MG&>A]8  (D\4/ #;^);<>+5]7K*IL,D=!%0^:PV]LZ*C'/=S<RO3XZ^'@2V
M'Q&S6VT>T6V&G=&15SKE%9J5*5M6^)(UEPJKS*U%7'?ZR)]R\ES;+ANE5:T7
M<&L9+/>77CS-+6U6M5TZRK'S=KW=<<V,DYP!ZG4EG34&G;I:G2+"E=2RTRRH
MF59SL5O-CV9(=;*>3,M>S6Z>G=:PZ^K+M+9ZA9VT<EL;$V3+'-QS)(N/A9Z)
MX$VP!A/4I#WB'\FWH?>>_5VI;#<ZC16HJQ[I:E::!L])42KU61T*JU6N=XJU
MR(N5545555F& *V[!Y'U6W&)U[W-[2@1R=I#06?EED;E<M1[YE1B]>_E=X]"
M<&RVQVDM@]&1::TA;O-*/G[2>>9W//52*F%DE?A.9V/8B(G1$1$P=$ $#O*U
M[@1VC:C2VD(Y$2JO-S6MDC:O7L*=BHN?G?+'C]*OJ/LO)C;3NT#P]1WZKC6.
MXZLJEN*H[HK:9GVN!/:BHCW_ /C3DG$%PR;H\47%Y2U%\T[5V;;.AECM\5RD
MJ(L>91<SY7M:U_,CY7J_E7ERB.9S?!+"K1:Z6RVNCMU#3LI:&CA93T]/&W#(
MXVHC6M1/!$1$1/8!R3BJX;H.)W;VWZ5JK[-IYE'=([HE5!3).KG,AFCY.57-
MZ?;LYSGT3T7"5PATG"M!JB"DU+-J-+XZF<]9Z-L'9=DDJ=,/=G/:KW^HD0
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M[D]?B=B
M                         !6EQ>^5$USP[\0VKMN[/I+3]SMUG\T[*JKW
M3]M)VU)#.[FY7HWHZ54[NY">VRVLZK<C:#0VKZV"&FK-06*@NT\$&5CC?/3L
ME<QN55>5%>J)E5*./*C_ )NG<W_R9_[+I2ZCA,_,M;-_K,LW\QA ZL
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M8956ZK<Q%4;,+=VB[&]$[MP8R9,7J
M
M
M
M
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M5*/,U"<3(M69CE7.VZUQ,'\38NW8GG1&^R:  +Q5
M
M
M
M
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M:Z:9B)GG+[\&/I'14(>C(
M
M
M
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MD1>]$7U%-J&!&=%'/::9B5G@9TX<U^SO%43#S(_@)\QL: MXZ*QN #(
M                                                       ,90#(
M!C* 9!CF3UF0    QS)ZQE ,@QS)ZQE ,@QE!S)ZP,@QS)ZS( &,H,H!D
M  !CF3UC* 9    QE ,@&.9/6!D     !C*&0    QE#(      !CF3UF0
M  &,H!D        &,H,H!D   #&4 R#&4&4 R 8YD]8&08RAD
M ,90<R>L#(   QE!E ,@&,H!D&,H.9/6!D                 QE ,@&.9/
M6!D&.9/69  QE!E ,@&,H!D QE ,@&,H!D QS)ZP,@QE#(
M
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M>NG^)2?ZI^C7A5AEI>&/:&&:-T,L>C[0UT;TPYJI10Y145$PJ+T ZN
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M=VX "0   #7/U ;&,H8RGK, ;@
M
M
M
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M9$RO'VE5HV;7FXW%<]Z)F)6FJX=.'D<%'NS$3#< %\IP
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MHYBX7#T[^545$5%0ZS5T-/7TLU/401U%-+&Z.2"1B.8]KDPK7-7HJ*G144K
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MH+(BE_0FUS]G>-#:+2]1&L=P@J+)45K7='-J)F1RR,7]*Y[F_L4+H
M
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MP[=JS-FB-HE3-)MWQ"\.DLDU-;]6:;IXW<\DUID?-1JOK>L+G1K^R.P<.?E
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M H&P     #7O,<R=4SU W
M
M
M
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MVL_%7Y/O9S6%-#SUVE;/;5E<U.OFL]/%&_NZ])$@7V(CC[7RO'Y4^A_U;?\
MR$AWW9_1-%N1P7Z-TK<.E%>-%TM%([&58DE(UJ/3VM5<I[40#V?"-NE^/#P\
MZ,U')+VUP\S2CKW*N7+4P_:I%7U<ZMY_F>A%#?7'$QY0S1FWZ)YWIS1;&U%>
MQ.L:N:B5%0CE]3E2G@5$\4^KT_DY-WOQF[?O)H/5SUI':79/?GP*[JQ:=%BK
M&IGQ16083QZGVGDP-)UVJJO<G>:^LY[OJ2Y24D,RIA53G[>H5OYU9'QM]G9*
M@',=]?\ [532WZJV7'_11%HQ5UOK_P#:J:7_ %5LO\E$6B@
M
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MYOG,'NW
M
M                  &O,8 W!H91< ; &.GL R  ,9090QCZC &X-,>U3.?:
M!L#55[C/K R#7ICU#[D#8&AE0,Y0<R>LUQ[1].% W      : #<&OCWA5Z]X
M&P!K].0-@:+Z/>IGU]0-@
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M>&7]Y8&B]^!D6*L>[-NHP\FG*LQ<I[VX -=N@
M                   Q@R     @CQM>3YFW<O57KW;I:>GU3.G-<+/,Y(HJ
M]R(J=K&]>C)5Z(Y'>B[O56KE73N %%%HAX@.&JLK:2WTVL]%(Y>::**"9E-*
MO1.=.BQOQW([KZLF;G;>(#B6N-)!<*/66M',5'0-J(9G4T&<IS)E$CCRG>_T
M<^LO31OJ0<OL A+P1< ?XR5RAUOKMU/7:Q:QS:&W0*DD%M1R85ZN[GRJF6Y3
MT4RY4RJY22_$10U-SV W,H:.GFJZRITQ<X8*>!BR22R.I)6M8UJ=7.551$1.
MJJIT8TY?#'0"G#@/VHUOIWBMT'<;MHZ_VNWP25:RU=9:YX8HT6CF:G,]S41,
MJJ(F5[U0N2-/H4W K]\I5PCUFM*:#<_1EJGN%^IT92WB@HH7235<71L4[6-1
M5<]G1KL)\#E[D8ISKR<.L-P]G=?3:+U)H_4U)H_44C>6>HM-0R*@K,89(JJS
M#6O:B,<O=E&*N$15+1<+[?K'+G(%7'E2MN-6ZOW_ +!6V'2]ZO=''IFGA?46
MZWS5$;7I55CE:KF-5$<B.:N._"IZR67D[]/W33'"QINWWFVUEIKXZJM<^EKH
M'PRM1U3(K55CD14145%3IU122G)[#+?$#Y;<K;VT;JZ%OFDK[3]O:[M3/II>
MB<S,_!D:O@]KD1S5\%:BE)6I>'C=G:#<NLH[?I?44UQL-PYJ2[VJV3R1O6-W
M-'/$]K5145$:Y.O3QZHJ%\!HB8\ *V.+'>W7N^/##HRP4&@]44VHKK4<^I:.
M.RU*)$ZFQA,<GP)7N;(W'<D?+G**>=Y++A_O.F+_ *NUWJBQ5UEJ8H66FW17
M*E? ]W.J23/1KT1>G+$U%\>9R%CA_/"_/_G_ -N@']"/''7LW)O3PZ:AH*&E
M=5WRTXN]MCC8KWOEB1>:-J(F5<^)9&M1.]SFDAS7'@!4#P"P;A[,<0UHEN.B
M]34=@OK'6FOEFM-0V*-LBHL<CE5F$1LC69<OP6J]>XN -43)L (J\>/"75<2
M.B;?<-.I"S6MB61:1DSD8RL@?CM(%>O1JY:US57IE%1<<RJDJ@!1MI?6W$/P
MXTUQT?:?Q5:1AJY'=I;W6Y517KRHKH5?&[E54:GIQJG1$ZG7^"K@>UCN#N+;
M=;;@VBNLVEK=4MKUCNT;HZFZ3M=SL:C'>EV?/ASG.3#DRB9555ML_+GP'+X8
M _A6TD-?25%+41-FIYF.BDCD3+7M5,*U4\45,H4[<1'!?N1PY;D/U%H6@NMT
MTS#5^>6F\6=CY:BWHCN9K)D9ES',Z)VBIRN1,]%RU+DS16]X%'&H+AQ!<65W
MM-KNE/J/64]([LJ:-:%(:>G<J(U7O<UC(V+A.KWX]J]5+3^#CALBX:=IHK'5
M2QU>H[A-Y]=ZJ'/(LRHB-C9GO:QJ(F?%>9W3.$[RC>XV %;WE6M :GUCJ_0$
MNG].7:^104-4R5]MH9:AL;EDC5$<K&KA51%[_460FOQ@(M>3<T[=M*\,]%;[
MU:ZVSUS;G5/6EKZ=\$J-5S<+RO1%POK)3FN%-@!"3RKNW[]2;$6?4U/3K-/I
MVZM65Z)^1T\[5C>O_2) GTDVSYC<?0MOW+T'J#2MT;S4%XHI*.5<95O.U41Z
M>UJJCD]K4 ASY)'6D5UV>U9I=RHM39KPE4B9_P"2J(D1O^5#+]9.TJ7X%+W<
MN&GC O&VVJVI2/NR/LDW-GD\Y:O/32)ZVO1%:WU]LBEM %*N_FU&NMQ.*W65
M9^(G44]JKM3RT[*I+54+"^!L_9->C^3'*K&HN<XP72LC2-J-:U$:U,(U$PB)
MX(;<O3NZ&X'\7QI-&YCVHYCD5%:Y,HJ+ZT*A.*/@)UULYK6KU%M[:KA?M(NJ
MDJJ&6T\TM;;G*[F1CF,7G]!WP9&HO1$RJ*7 FN/5T I/U1OMQ,[P:?=H"X3Z
MFO%+(C8)[?2V;DJ:A,>BR9\422/3"+E%7#D157F7J2_\GYP/WG:&[.W$U]3,
MI-0R4[H+;:,M>^B:]$YYI')T216Y9RIW-<[FZKA)W\O7HF#^@$=>-7A>3B8V
MSCH[?)'2:KLLCJJTSRKB-ZN1$D@>O@UZ-;U\%:U>[*%7FC+MOYPF:LKJ2RT.
MH-*7&I<V&HI)+=V]/5\JX:J->Q\<G>J->SP5>5>O6\TTQZ@*<=?[&<06^V@;
M]NSN+%>JJIMT4$%JM4] K:JI[2:-CNQI(VM[*-&O<]7<J95J+A?25.\>2@T%
MJ;1M_P!R'Z@T[=K$RHIJ)L+KE0RTZ2*U\W,C5>U,JF4SCNRA8JC>F/\ -W&W
MU@;  "DWBSV@UY>>)+<>OM^BM15]#47B9\-32VJ>2.1JKT<US6*BI[4+G].L
M=%8+;&]JL>VFC:YKDPJ*C$RBIZSV*93P,_0!3[Y03:S6NIN*S5]QL^D+]=K?
M-'1)'5T-LFFB?RT<+7<KVM5%PJ*BX7HJ*3NK=CJG>+@5TUM[4\UIN\VDK2R)
M*N)6NIZN""%[&/:O5GIQ\CO%$5WB22Q\+H.7PQT H]T7#OEP:[E3U])IBYVB
MZ-8ZCGBJ:!]31UL2N1>3G;Z$B*J-5%C=X8RG4ZSN%IGB<XR](W346J;-+9M*
MV"DFN-):?,WT<=9*QBKB"!V99I%:JHUSE5,91JY<J.MI5%]61U]N *NO)?V/
M5>W6]EZH=0:0OUIH;W:711UE;;)H8FS1O;(UKGN:B(BL[3Z>5/$]OY5/;_5.
ML=S]&5%@TU=[Y!#9GQRRVV@EJ&L=VSUY7*QJHBX7.%++E3/@9Y0(U>3OT_=-
M,<+&F[?>;;66FOCJJUSZ6N@?#*U'5,BM56.1%1%145.G5%(.>4.VNUIJ?BEU
M)<;-I&^W>WR4M&UE50VV::)RMIXT<B/:U47"HJ+UZ*A;PWQ, <TX:*"JM/#W
MMK15U/-1UE/IV@BGIZB-8Y(GM@8CFN:O5%145%1>XZ<:8QC"8\.XW %4WE-=
MM-7:MXBZ:NL.E+U>:)+#2Q+4V^W33QH]))U5O,QJIE$5.GM0M9- ..<'EJK;
M'PS;>4%RHZBWUU/:VLFI:J)T4L;N9W1S7(BHOL4JJU%M!KV;B?NM>S1.HGT+
MM8R3MJFVJ=8EC6M5R/1W)CEQUSW8ZEW.%]OUF.7I@#YW<2GEJM :G@@B?/+)
M;*IC(XVJYSW+$]$1$3O557&"H'@LVDUU8N*#;VON>B]06Z@@KG.FJJNUSQ11
MIV4B9<YS$1$RJ)U]9=#RF /7:AL-#JBQ7*S76F;6VRX4\E)4T\B>C+$]JM>U
M?G153Z2G?=OA$WAX6-Q&ZBT=37:Z6NAJ'3VK4=CB=-)$WKA)V,15C7E7#LIR
M.RJ(JHN"YPT5O>!2_KW?WB/XE=/-T36VV[72@DF:E126BQNC=42-<BM[56-[
MD<B*J=&YZJG1%2:'D_.#.Y["4E?K'6L4<6L+I"E-!;V.23W/I^9'.1SFJK5D
M>J-SCX+6XRN7(DT,>S!N!$;RG^L$TYPN5ML:_EEO]TI*!$1>JM:]:AWT?:$1
M?TQR_P D5MW+;](ZXUM40\K+E50VRD>Y.O+"U7RJGL5TK$^=B^HY_P"4XUY6
M[J;X:0VFTU&ZXU-M1C74L"HJRU]4K$9&J+TRV-(U1?#M7%@>P&T]-LEM!IC1
M5,]LRVRE1M1.QN$FG>JOFD^99'.5/9@#@?E.['J74&PU@I]+T%UN->W4U/))
M%:(9994C2EJT57)'UY>96HJ]V5:?$^2KTWJ_3M#N6W55IO5L?++;UIO=BGFA
M5Z(E1S\G:)UQEN<>M">F%^;_ #?[=3;E]G4#8  0HX[>#J_[K76V;E[<.6+7
M-H9&DU(R7LI*ML3N:&2)ZJB)-&JKWXYFX3**U$7G5E\H]NOHJSQ6'6>REQKM
M6PM6-:E>WH>W<U$]-U/YN[KWJO*Y$7P1J%CAIRYZXZ^WP K;V&X<=S>)O?N'
M>;>FV2V6TT<L511VNJA=3OG6-4=!#'"[+F0,5$<JNZO7/>KW.2PG66D[;KK2
M=ZTW>:?SFU76EDHJJ%.]T<C5:["^"]5PO@N%/=M;R]R8^@W JMTM!OAY.K7-
M[M]'I>JUWMY<)>U:^GBD=3385$9-SL:[S>;E]%S7)AV/NL-4_ONEO7OIQUTM
M/H71^W-9I72M3*Q];)*YZQ3(US7(LU4]C&HQCD1W(U.953N?A$+2<*$Z\R <
MTX>MD[;L'M/9=&6V3SA:1BR557R<JU-0_P!*214]2KT1%SAK6IX$3N-?A=U[
M9MUZ+?79V&HJ-0T[HY;A06]G:5*2L;R=M%'_ ,JUT:(Q\:(JKUZ.1[N6?QA/
M4H%;U7Y23=NZV&2PVS9>KI];/C6/SJ-E3,UC\81[:58>;.>N'/5.B9SG!T+@
M,X2M3Z&U%>=U]T8Y/Q;WGM.PHZE6OF@25W--/*K>B2R=W*GP6\R+A7*U)N]?
M4;@  !6_Y1W0.I]3\1^VM=9=.7>[T5/0T[9JF@H99XXE2LD<J.<UJHBHBHO7
MP4L@-#<"M[BBV_U1>/*([:WJATY=Z^S4]=8737&FH97T\2,K$<]72(U6HC4Z
MKE>B=Y9":>'5,^/K-P*WM4Z U//Y52#44>F[L^P)74;ENK:&5:7E;:HV.7M>
M7EPCD5J]>BI@F)Q,; 6OB-VMK])5\OF-7SMJ[=<.7F\TJFHJ-?C/5JHYS7)X
MHY>Y<*=;Q_I(S\>UQW,TUL]3ZGVQN5PH;I9JYL]P9;VI(YU$K'M>Y8U1>=&O
M[-R].C>9>Y% BMMSK3BJX/*-^AY-N*G7.FJ:1WF;H*">MAA1791(9X.K6N<[
M/+(F<KT:WJA\CQ/VG?[?#;"[;F[IVZ+1.E].I"ELTZM.ZG?-+--%$Y_9/<LC
M51K\N=(J+Z.&M1%=B2NQ/E--M+OH&UP[B7>KT[JNEIF0UT\M!+/!5RM1$6:/
MS=CN5'XYE:K6X551,X15XQQE\85'Q06VU[3;2VJZ7Y+A6Q2U-4E*YCZIS.K(
MHHE]+E1WIN<]&XY$QTRH$E_)DQOCX3+"KDPCZ^N<U?!4[=R=/I14^@E8<OX:
MMJ9=DMC](Z+J'LEJ[;2KYT^%5<Q9Y)'2R\JKU5.>1V%7P1#J &G+S=Z?65X\
M1_ 7K+1VX[MT]@JN2CNGG+ZV:RT\K():>5V5>ZG5RHUT;LNS"[UJB<S7<J6(
M@"L2MX]=XK7I^HTMNCLC#?DJ(EHZB.NMU32-JL]/MD;F.8[.%Z-1J*J=$3!'
MJU\.6ZF]^J;K==";3U>CK5-&[-+&^:EI$:J>E&DM5(BOYN[E:O*F43E1"[W'
MCC( K!X$M_M#\,];>-O-PM+W#1FM*NM1M7>:FG?*Z9<XBADC1O/$U.;T51'-
M<KU<JHBEH)\?JW:C2&N[G:;CJ+3EONUQM-3'54-940(LU/(QR/:K9/A81R(O
M+G"XZHI]@ *WO);Z"U-I+<_<2HONG+M9:>HH8VPRW&AEIV2+VRKAJO:B*N.O
M0LA-?N0/#N57[G6^JJU8^9((G2=G$U5<_E15PB)WJO=@I)GGWCN6]LNZ-\VN
MN^J+VZN6O2BO-BK9:1'HOVIO(SD56QX9RMYN7T4RBHF"\+E-@*RF\?7%,F?^
MTW1?^:]U_#GT.W/&]Q*:GW!TQ9KUM11T%GK[I2TE;5MTY<HUA@DE:V1Z.=,K
M6\K5<N7(J)CJBEBAKRYR!"+RJ6CK]K#:_1L%@LEQOD\-X?))%;:22H<QO8O3
MF<C$543*HF5)(\-%!56GA[VUHJZGFHZRGT[013T]1&L<D3VP,1S7-7JBHJ*B
MHO<=,5IC&,83'AW 5-<?6PNM=-<15\O>B;%>KA:M6T#9ZE]GHI9F->]49/"]
M6-5,O=$DBY_MGL+'>'7:YFS>RFC]'<C6U%NH(TJE;U1U2_,DZHO]\<_'LP=)
M^Y-@*U]ZMO\ 5-P\IEIN_4NF[O4V..YVA[[G#02OIFM;'$CE65&\J(BHN5ST
MPI90:\OTFP
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MEKJ)4]G/(B,7Z'*?'ZV\G!L_JE));;0W+2]2[JCK76*YF?TDR/1$]C>5/F.
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M7P5PV,?(MY-N+EN>4MP80R>3:
M
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MKT1K_P!F=D3J4URB;=4T3UAT-JY%VW3<IZ2W !@]@
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M8
M                                  #EVM.&O;;<76=)J[46E:>OU+2I
M$D5R2:6*5JQNYHURQS<JU>Y<>">I,=1
M                  .6VCAHVULFX\FOZ32=,S6$E1+5.NKYYI']K(CD>]&N
M>K454<OATST[D.I                             /Y\JKT5.A_0 <AU9
MPH;1:VN$]PO.W=BJ:^=_:2U$=,D,DCLIESG1JWF5<)W]_CWJ?2Z!V7T+M<R1
M-(Z1M&GGR)B2:AI&,E>BJBX=)CF<G3N5<'W(
M
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M9_0 $/4
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M7K/_ (=6?RJD<_*KL_[8.AD__)DW\J2,\G"J?8OV?_#JS^54][W_ (VW]_\
M+6QO_*W-_A_A7?QA?FF-Q/U3=_%:6NWC9O1^\.@-,T>K[)#>Z:CI89H(Y9)&
M(QZQ-153E5O@50\8?YIG</\ 5-W\5I<IHU<:-LG^ 0_R;3+4*IILV9IY3M_:
M&.F4TUWLBFKG&_\ >5(NWFGZ"\[XZ9L=93MGM55J.EH9J9SG(CX7536.8JYS
MA6JK>\MGJ-O-!\*^W&N=6Z/TW3V>>"URU4S8Y)7]NL+'NC8O,Y?NE\,?"*J-
MJ/S26C_UVT?\\86\<26G9M5[!:_ME+')-5366J6&&),NDD;&YS6HB=ZJK43'
MM/74ZI[2U3,\IZ_U>6DT1V5ZN(YQT5$[,6:S;J;W6J+<+4,-NL]PJY*R[W6Y
M538$EPUTCFNE>K419'(C<]Z*_IW8)\;K;<\+6L-M[C9K-?-O+%=8J9_N?<;;
M=*.*=DR-7DYWMDS*W/16O5>B^"X5(!</&W^G]T-WK#I/4URJ;3;;J^2G;54K
MV->DW(Y8VY<UR>D]$9W=[D)P7_R9>U^E[)7W>Y:UU'26Z@IWU534/=3\L43&
M\SG+B+.$:U>X]\VJW3=HXKDQMTB(Y-3!HN5V:^&BFJ)ZS,HX^3UW&J]$\15J
MM23NCMFI(Y*"JC5R\KGHQTD+L=RNYVHU/4DCO6N;=4]9 'A^X>.'UVX^F[WH
MW=JKO5[H:MM526RIG@BDJ',RJM[)T3'JF$<JHU,X1?43^14[O44FIW*+E[BH
MC;[QLZ+2+=RS8FFN8GGRVG<5?14I7W1D=N#Q>7^"M59XKAK%U!UQZ4*578L3
M]HC4^@NG>B<BE*-Z5='<6]<^3*>YNN'O7F]3*_.>OK1,_2;6D>]<VZ[-76__
M *XGIOS76L;RL]28*:.-O7U5KSB0UB^:9[Z:TU'N12Q.5<1,A]%Z(GJ63M'+
M[7*7,IU9]!21Q6Z=J--<1NXU)4L5CY;S45C<^+)W=LU?VLK2-'B.WJGOV1K<
MSV%$=VZR78C@OVXT5MI:Z2^Z2M6HKY54K)+C772E;4.65S4<YL?.B\C6KT3E
MQW9[U52 ?&SL;;-B=Y)+;88UAL%UI&7&CIU<KEIT<YS)(N9>JHCV93JJHCD1
M54MDVTUM0;AZ#L.I+;41U-)<J..=KXW(J(Y4])BX[E:[+53P5%1>J%:OE,M<
MT&IM\J&ST$S9W6*V,IZIS<*C9GO=(K,^QJQK\ZJAZ:==O5YDQ7,SUW>.IV<>
MG"IFB([MI^*7_D[/S*^FO\*K?YS(?'>5%LK*W8BS5_)F:AOD6'XZHQ\,S53Z
M5Y/J/L/)U+_W+&FD_P#QFM_G,A\[Y3JM92\.U+$Y41:F^4T;<KXI',_^!BFM
M3O&H<O$W:XB=+Y^&'Q_DJ+_+4Z"US9729BH[E#5,8JYY>VB5JK\R]@GU*3H[
MO:0(\D_:70Z=W$N2L5(ZBKHZ9KO!5C9*Y4_ZU%^DGS@U]1VC*KV^+;TK><.C
M=L#"=QDKEN
M           !^5<_50?E7 _0YLYMC;MSN$C96CKIIJ9]/I*SRPU$&.9J^8Q(
MJ=4[ESW>Q#M&B='T.AM/4UEMZ/6GI\X=(J*YZJJN5RKCORJGPG"S64]'PK[-
MNJ)F0M_$;9DYGN1$SYC#TZG66/1Z9145/!R&G%BS%Z;L1''W_'9[S>N]E%J9
MG@[H[MW]@ ;CP  !JG4]7J2S17^QW"W39[*KIY('_,YJM7^$]L8QW^T\ZZ8K
MIFF4TU33,3"$VQUXET5NY24M4O8K)));IVY[E5<(G[=K?J)K(B*G0BEO'LYJ
M%-RI;CIVWRU,%PD;4,D@7I#-E%=S+GT?23FRO3JOJ)2T39F4D23*UTR,1'N;
MT178ZX^DYC0[5W&F[CW(Y1/)T6L7+61V=^B><T\WEYP$7)J>AUEJJDT3H^^:
MAK4>M%::*:NG2-,O6.*-7N1,]ZX:J?.=93&\[0YFJJ*8WE[W">KJ;8Z>TBIP
ME\;#N(_65]TY5Z:;8ZNDIG7"F?%5+.U\+9&,5K\M;AZ+(SJG1<KT3'656>JF
M=RW7:JX*^KRL7J+]'';Z/G=?ZG=HS0NH=01TDE>^TVZHKDI(EPZ;LHW/Y$]J
M\N/I(J<&_&[>M^-=772>K;?;+?7.IW5EMEMK9&->UJISQ.1[W9<C5YD5%3HU
MQ,6I@CJH9896(^)[5:YCFY147HJ*GBBE-U@DEX7N+^%DCG0TFGM0K3O>Y>^A
MD<K%=^R@ES\ZH66%8HR+=RB8WJVY*C4,BYC7K=<3M1,[2N<!HQR.:BHO>AN5
M*_@
M
M                   !C*#* 9 ,90#(,9090#(     #&4,@    ,90#(
M
M     QE#(
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M>LR
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MAK&-1$:B>Q$1#S6^)67KDW;DUSWRN<>U%FU3;CNAL #R;(
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M;/%%*USHE7N1R(N6KT7O]1YZ(B'G._>]:9B8Y2V !#,
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M,N54GA8[S1:ALU!=;=4,JZ"N@CJ::HC7+9(GM1S'I[%147Z0/9
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MZ]M4]CO-RI/<^TV>K9R5$-.YS'RS2L7JQSU8QJ-=AR(U^4])"R$QA#(
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M?82Z5_Y]O'UQ?Z@$.8FHYR(KVQI\947'U(?V\UCS_ON'Z$?_ *I,#["72O\
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M#7F,]/8!D        &/#UF/F V!H -LH9,-[C"_.!L
M                                                ,8,@
M                 #^2MRU45,HO@?U 'S6GM ::TI425-DT[:K/42MY))J"
MAB@>YO1>55:U%5,HG3V(?1(9[D]9E,8&\S.\L::8IC:.C( #)_&2-)&JQS>9
MKNBHJ93Z3T.G] :;TG435%DT]:[//*U&226^BC@<]N<\JJU$RF3Z)%P$Z(I.
M\[;,)IB9B9AG&3(!#,
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M7M'1-5RX]JJJI\Y=:APW+=N_3WQM+G=+X[5V[CU]T[Q]GW( *5T8
M                     BM]G+_^9*??;_\ 8#[.7_\ ,E/OM_\ L#JGV+>V
M/R9_]/JOPH^Q;VQ^3/\ Z?5?A0.5_9R__F2GWV__ & ^SE__ #)3[[?_ + Z
MI]BWMC\F?_3ZK\*/L6]L?DS_ .GU7X4#E?V<O_YDI]]O_P!@/LY?_P R4^^W
M_P"P.J?8M[8_)G_T^J_"C[%O;'Y,_P#I]5^% Y7]G+_^9*??;_\ 8#[.7_\
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MJ-])JKCP52V'F3UE7VR5KI+-Y5/4M-1\J4_NA=9.6-,(CI*>1[DPG=ASE3Z
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MMDB.Z81RI5(J?4B?4!8^
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MTG:NHZ6*G61$PCE8Q&YQ]!49-NQ1MV-6Z^PKN3<W_$4[/;@ TEH
M
M      8R@7N4T7YP-\H,H/I-0-LH,H8^A3 &X->8V              ,8,@
M
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MV5U[>]8:9IJ^*]7B*6&J=4U;I8U;)*V5W*U4Z>DQIV.:%LT,L;O@R(K5^E,
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M]E=G]+Z+IU;(ZUTC65$S,XEJ'*KYGIGP61SU3V*@'1
M                                                  ,<R>L#)5+Q
MM>4>WAV$XG-::$TM-9&6&U>9>;MK+=VLOVVB@F?E_.F?3D<6M$8=XO)V;,;Y
M;BW?6^K+7=*F_P!U['SF2GN4D,;NRA9"S#$[O0C:G3U 5H>_!\0?_?&FOO3_
M /QG@7KRMO$5=:5T5-?K/9WJB_;J&SPN>G_2H]/W"P[WH[AT_P"8[U]^9O\
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M#,\WU64&4-$Q\YDAZ-LH,H:HN !N
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M]W/$[#V_2B%+>Q+]CWZ>7Q[E_CYV/D_NZN?P[WW>4',GK->;N"?==QJ+%N
M
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MO5L #R;8
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MG&S5-55.;-<+I58[>KD1,(JXZ-8G7E8G1,KWJJJO70
M $8-"\+>HKEQ0ZAWCW+KK5<YH42GTO:[=-+-'00IS-:Y_:1LP]K554Y<ISRR
M.Z+@D^
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M%;#74T=2UJKE6HYJ.Y5]J9Q] 'N
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M1C?1:]57+GIW(6->'0I\FU;LU\-NKBC9?XEZY?M\5RGAG=_0 &LW@
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MX<4C?N7M7HJ=W<J9144^U;XYZ'(33-,S35UAW5%=-=,54SO$MP 0]
M
M   /RKGZJ#\JX%O6GG*[;G;5/!NB]/I_ZMIE_P Y9';TY*.!J>#&I^XA#+:7
MAZN^N-H=G[O1UM+%;ZK1MB2=95<DD7+;X&KRHB>ET:BIU3Q1>A-&-$9'R)T1
MJ(B*<OI>+=L9>1<N4[15/+Z\Y=#J63:O8V/;HJWFFGG].C^X .H<\
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M@ :2S
M
M
M
M
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MZY\%7'J Z^
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M.C7*J'U*+GQ*&::J>54;.FIKIJYTSNW,8,=#/TD/1J#9,^)A0'T&,9SGJAN
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MWJ?S=QH.555Q6*I^SO@ .8=F
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MF7KX>&.\GK&O,Q%]:%9BYUO*N7+='6B=I;^3A7<6BBNY_/&\/Z@ LV@
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M<OL[-=F8WB?)6W\*+N11?IG::7TJ UYD-C16H
M
M
M
M
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MG><2X*HTBX7]OD1,(M KOKE>O^<[:P\,C][7/UG]6>)^XH^T?HV !X-P
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M*B^I44F=L-Q T6Z%&RV7-8Z+4\3?2B1<,JVHG5\?M3O5O>G>G3N#M0,90R
M
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MU++HB,3TEA1',G3YD8_M%_O9NX-<6\BBJKXJO4J)N8M=-/P5) SU,'TA\H
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MV?NFM5K%_2G.ZU5$6(IGK,NH_9^W-61-<=T.W  XQ]#
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MH)FU-#6P,J8)F+EKXWM1S7)[%14^LLL['HM33<M^[5"ETS*KO<=N[[U,O9@
MK%X
M
M
M
M                                                   %&?'#L<S8
M3C@CU1JFW/J]NM3:BAU$M1)"L\51$^H;+70.1<HKFN67[7URQS/C82\PH]\J
M;OAKBMXD]P-M:G4,]1H>CEML]-9Y(XW14\BT%/*KF*K>9KE>]ZY1WW;D[E5
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M!D
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M*."JI9XJFFG8V6*:%Z.9(QR9:YKDZ*BHN45#R5Z],X4Y#:8ZN\B8F.3< !(
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MYRY57+U5555ZJ?2IW'SW,RYR[G%W1T?3=/PHP[7#WSU;  TEJ
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MRBFR=4]1X-MD
M
M
M
M
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M:@
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M/0E-)Z+.K)+I(U>L;%[TC14PY_C\%.O,K.PKR[5%J+V_)PUO"O7+W8Q'/O\
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M$PC6M3HB(G3"'GIUR8Y3EK^1<R*N*Y+L<7#M8M/#;C9GO0R :[=
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M&@M@
M
M
M
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MNNX/-JJG9;AFV[T?6PNI[C0VMLM;"Y$18JF9SIYF+CO5LDKV^W ':
M                    ,90R0=\K?N'JG;GAQTY<]):EO&EKC-JRFIY*RS5\
MM),^):.M<L:OC<U5:KF,7&<9:U>]$ G#E#\RNT'_  W6?X.O\=A[G[++?#^[
M)N!_YT5WX4]-M!_PW6?X.O\ '8;V!_$4_=7Y_P#"U_9^A7A61/L<MN/U"I%_
MZM%.J-\3E?"K^9RVX_4*D_DT.JIWJ:]_][5]Y_5[X_[FC[1^C( /%L@
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M5)8%5.9,>M.]J^M$ L?!_-CVR,1S7(YKDRBHN45/6?T
M
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M7E'MX=A.)S6FA-+361EAM7F7F[:RW=K+]MHH)GY?SIGTY' 6M HR]^#X@_\
MOC37WI__ (Q[\'Q!_P#?&FOO3_\ Q@7FE?\ Y:W\RUI;]>=+_,:\AE[\'Q!_
M]\::^]/_ /&<QXA^._='B=T71Z6UM-:7VJDN$=SB2WT/8O29D<L;<NYEZ<LS
M^GKP!,?R%O\ ^&W_ ,B?_'EJA57Y"W_\-O\ Y$_^/+5
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M,]Z&NWNK(
M
M
M
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MXVT_6Y0?S=ATIGPE-:]^]J^\O?&_<T?:/T;@ \FR
M              "O+B(I9Z7>?53*A<O=4(]%7XKHVN:G[56I]!SDEYQ9[-56
MHF,UA98'5%92Q)%74\29<^)JJK9$1.JJW*Y]F/41# #_ #]1ZCV%+1W"WT]+
M>644J4;:A&Q54D"NA=*W#N7*^BY>[+57N LJTA1ST.E;-35>?.H:*&.7/?SI
M&U'?NHI[DX/M%Q26/6D#*'44T&G[VU,*^63DII\>+7.Z-<OQ7?0JG<::IBJX
M6302LFBD3F9)&Y'-<GK14[T _N#&4,@
M
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MN5K$1%=A$3*^I#Z ^?WZZ;ER:Z8VB>Y].Q;=5JS315.\QWMP >+;
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M'4[.7[,3M5\'5P8SGN4PJ%:N6P
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M\<;4WXHO<7W+\P_L"EI>Q[;SSM/R")G-GLH_A9QR],97-@(
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M1.9SO8B81$1$[UQU55Z*G3YSSO54U7)JMQRE[8U%=NS31<GG#^@ /%M@
M
M          USDRG>IKW'".,?>74NQ^SD^I-*T$-9<//8:5\U3&LD5'&]'9F<
MU%3/5&M3*XS(F<]QG;HFY5%%/67C=NTVJ*JZND.\<Z&4Z="+7!/Q9S\0=FN5
MIU$E-3:PM:))(RG16,JZ95PDS697"HY4:Y$Z)EJ_=824G3N)NVJ[-<T5]88V
M+]&1;BY;Z2V !YM@
M
M
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M9T5O>IJW)WN53]9;&/RM4_:/T;@ \VP
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MQCVH2[
M
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MHKC0S-J:.LA94031KZ+XW-1S7)[%14^LX'4,/\+<]GW9?2=*SOQ=K:OWH>R
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MGCF^S-_%MC1/XD/Q-^9?_?;S[SGSCSC_ ,!'R<O8>W//X8ZRM
M        #53\K;$RY$]I^J1.\_+%0,YZR%N,Y>U,>OJ1,[1NRHC>J(7\<*&Z
MU51:<T)MK<*&)K[78:2U1U<,BNYWTU*UKE5%3N<D;E3U=W4E%U[B%'#FU';N
MV55^Y[947_Q3T_SDV4[CG=#RKN98JN7IWGBE=:SBV\:_31:C:)IAN #HU&
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MD
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M$N8E5=,S[,\X>: "N7(
M
M
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MJH[I;*R"XVVMA94TM922MEAGB>U',D8]JJCFN:J*CD545%14 ]@
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MI*ZG=S0SQHO,Q>J=.OMP?;@
M
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M-=J_B UU=ZBI>Z1EYG@IWHY<LBAD6.''S-8WZ<EK7"!R?8S;?<B<K?<J/O\
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M^M1'81,_%T^@53&3,1\$P0 <4^B
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MI&R1/:CFO8J*UR+U147Q0\JN*KVI>U'#3[$3T>2 "'H
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ML+"U7%RF*Z>DM@ 0]0
M
M
M                                   *I_*8>4#UKH[<RKVKVSO,VFF6
MF./W:O%&B)533R,1Z0QO5,QL8QS55S<.5RJF41J\UK!^>;=NSQ;B>4 U;9+W
M(^:CNFY-1:JA6KRN\W=<E@PBHG149A$7OZ>L#G=1Q+;O5<SII]U-:S2.^$^3
M458JK\Z]H?Q^R-W:_NH:S^_]7^$+6/*<<*N@[+PDU%XT9HRT:<J=(UM-5,?:
M+=%#(^GDD2"5CG-;S.;F5DCE5>^/*KWCR6%DV[WFX666[4&B--7J[Z?N-1:J
MR:XVBFGEJ(GXGC<]7,57-Y95C3F_M2^H"IFX:SW!W:KJ6T5M\U+K.MF>B4]#
M/5U%=)(Y$Z(R-5<JJB(O<G@?HBX8[376+AOVIMESI*BW7*BTG:::JHZN)T4T
M$K*.)KXWL<B*US7(J*U4RBHJ*5<>4MX=;-PF;DZ#W.VHD?H^6YU,TC:&B=RL
MH:R#LWME@3JC6N1Z\S%]%%;A$P["6D<-F[D6^VQ>BM>1MC9+>;>R6ICA7T(Z
MEBK'4,;[&RLD:GS =.                           @!Y:AF>%S2R)E57
M6=+A$3UT5>3_ #C?%39[/<MF+Q+>++;;XM')%/1MN=)'4MIZASTB2>-'HO)(
MULK^5R=4STP!45L5PP6VPVRFO.KJ-EQO,J)(VAG3FBI47N16]SGX[\Y1%QCN
MROW>^<,5/HVBCB8R-C:V-&M:W"=(Y.Y,'2_F[CF^_'_$^C_PYG\G(;V!_$4_
M=6ZE_"U_9W#8K>O4^V5CL3J"NDJ;;YI#VEMJ7J^%Z<B=R*J\B_GF_N]Q8#M_
MKNW;B:7I+Y;'JL,R<LD+ERZ&1$])CO:G[J85.\K#TLWDTS:6]^*.%/\ (0E?
MP1Z@F;>-2617.=3R4\=8QJKT8YKN1V/GYT_:FM>_>5?=M8_[JG[0EN #R;
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M5T[#7V;3^[NE9X78[6NCHW]>BME7LE3YD1_UX4L6
M
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M]B*[_,2@V\\H;P^;D-8R@W(MEKJG8S3WY'VYS7>KFF:UBK^E<H%27O6W$_\
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MAJZII%%O4XSK<[<4<X[I>NCZO7=TO\#<C?AGE\8?WR@RAKTSWH9Y?:9MAL
M(7>4YVRNNJ]J[)JBW2224VF:F1];2-SA89N1O;81>JL<QJ>Q)'+X'JO)K\0+
M=2:4J=M+S5YNME:L]J65V5FHU=Z4:>M8G+W=_*]$3HQ2:EYM%%J"TUULN-.R
MLH*R%\$]/*F6R1N16N:J>I454*H=4\..YW#WQ*VYF@[-=+HR.X-J;%<88'R0
MR0N=CLYI$3E3E:JLDYE;Z**O<Y%+O%JMW\>K'KY3'.)<UF4W,7*IR;?.)Y3"
MW &K/@H9*1TD,@ )
M                      !HA\QN9J-^D-N]47V-S6R6RUU5<Q7]41T<3WHJ
M^ST3Z<XYQ@79;/PT[B3HJHK[5)3=/_"JD2_QSTM4\5RFGXS#7OU<-JJJ.Z$,
M?)R;GZTU;OQ?**ZZCN5XH*JTSUM5%75+YF]HV6%$E1'*N'9?C/J=CYK,/7CO
M*T/)4VGMMS-:7-6K_8UICI>;U=I,UV/^J_<++T3OZF_J,4TY$TTQM"KT?><:
M*JIYRSCIW$7^/K82Z;T;5T<^G*!;AJ2Q57G-/3LPCYH'IRS1MSWJN(W8\>SP
MG54)1(%^8T;-VJS7%RGK"TO6:;]N;=7246O)[[?ZUV[V8KK9K&W3VE9+I)44
M%'5=)HX7,CYLM[V(KT>J(O7JJ^*$I,J:KA/$<R$7;DW:YKF-MT8]J+%N+5,[
M[/Z (#S;(
M
M
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MFF],5%&VMH+7YLM.ZGCG^W<KHUZL=S2*JM\%54.:[_<#>T'$?=?=G5^F'-U
MD:1+=[5.ZEJ7M1$1$D5OHR\J(B(KVN5$3"=.@%''$!Q.;A<4VK:*[:XN+:Z2
MF1T%NME##V5-2M>J<S8F)E<N5K<JY7.7#<JJ(B%Z/!'M7<]F.%C;S2%YADI[
MM24#ZBKIY43G@EJ)I*E\2XZ98LRL7]+XGS&R?DZMD-BM24VH+)IJ>ZW^E7FI
M;A?*IU4M.[.4<QF$C:].F'\G,F.BIGK)WN\ ,@
M    ?%[NZ2EUSMM?[) U7U-13YA;S8YI&.21B9_3,1#[0QE *L)HGTTKX9F.
MCE8JM<UR85JIWHJ>!S3?C_B?1_X<S^3D+&M[.&"FU]<)[YI^6*V7N7TIX945
M(*AWQ\IU8[OST5'+]*K5WKS=#3>Y>B6R:>K_ #U*6NA6=JPOC='S1S<N4<W\
MZ[N]1O8'\13]U9J'\+7]G8-,_P#%VU?X+$G^0A,;@LT3445MO6IZF%8XJSEI
M*1RIA7M:JK([YN;E3YVKZCG7#QPJUVL-)Z8OVH*ME'8ZJ@IJF*GIW<T]1$^)
MKFY7N8U6JB^*IW80FK:K92V6WT]!0P,IJ.G8D44,:8:UJ)T1#7N^_5]VY8_=
M4_:'G@ \7N                                                %8
M.K-/SZ5U+=+14HK9J&ID@=E,91KE1')[%Z+\Q9\1^XB^'B;<*7\46G6QMOT;
M.6>G<J,\[:B(C51R]$<B(B=>BICNQU"%H/.N]DN&GZY]%=**HM]7&OI0U,:L
M=]2H>5I?1]YUC7LH;);:BXSN5&\L+,M;GQ<J^BU$]:J![+:>JH*'<O3-5=*Q
MM!0TU?%/+.]%5K.1R.3..Y%5$15\,Y+(::IBJX(YH)630R-1[)&.1S7-5,HJ
M*G>BIXD"=P^&W5NWUF@ND\4=RH^1'5+J+F<M*[Q1Z?%_/)T[_9GVW#CO?4Z
MO]/:;S<G,TK4<S7-G17MI7JF4>WQ1%=A%\.JN5$[P)T \:DK*>OI8ZBGFCJ*
M>5J/9+$]',>U>Y45.BHIY(    #&4 R
M
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MX'FM3H;M[AT4YCKSEV$1$1M#( )9
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M:7.G9_R54Q$Y\)\5R*CT_.N0VZL:NFS%[^65=:S;=R_5C]*H\W7  :BQ
M
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M9W_)SUZ]<QL^F9GV*HV_-;$#&3)3.A
M
M
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M&VU=FX;MJ*"NI)J&MI=)VF&HIJB-8Y89&T<2/8]JIEKD<BHJ+U147('40
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MC5N3O7,MNQRMTQ]']  >;V
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M.&.'1#=S%73]7J":X>93>C<J6".+D56\W5DCESW8Z 2\
M
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MF.&W3M#4Q]RO>?T!YM@
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M\;W;CUDB-7D;;Y$5V.B9DCP2\QT]ISG[/35.)[4]\KK7=HRYX?A#8 '3N>
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MJ?(PINWZ+]NK::>OV?;(J&31<)XCYBO7#<
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M5PUR^DUN<=,],]]1R+DFJW7;G:N-D6[M%V)FB=]FX ,'N
M
M
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M="<&VV%IND#H*Q:&:N6-[>5S65-5-4L14\%Y)F=/K D@
M          !'SC1X4UXN]K;7HS\4_P")+S&]17?SU+?YYS\D$\79\G:QXRL_
M-S9^YQCKE)!@"JOWB[]&W]Z7]=*Z-H/^&ZO_  9?X[3]-9^93:'_ (;J_P#!
ME_CM-W"_?TM'-_AJ_L_1!PU?F=MK?UK6O^:1'24.;\-7YG;:[]:]J_FD1TEI
MJU^]+9M?NZ60 8/4
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MY&N1>5>=W1?4ITGF3U@9
M
M                                   !H;@ : W    :_69Z^PR
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M%?/ GL5.:1/4J/[\H7%6/;O8L7;,<Z?><];RKMC-JL7YWIJYTRL7 !3NA
M
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MMT\OR<]B6+N+EUTTQ[%7/\TC0 4[H0
M
M
M                                            1XXDN!G;'BEO]HO>
MM*:X176VT[J1E5:JEL#Y85=SM9(JL=S(URNY>['.[UE4O%#Y/;7^BM\]3V3;
M#;S5=_T/2^:^Y]P\W=4]KS4L3Y?MC6HCL2ND;W)C&"^$B5QD>4+T=PFU=+I]
MMLEU9K.HA2H]R*:H;!'31+GE?/+RNY5=C+6HU55$RN$5,ASO3'D?MD*S3=JG
MN::LAN,M)"^IC6Z,;RRJQ%>F.QZ8<JH>U]YRV!_MFJ_OJS\$1:K/+;;AR5+W
M4NWFF8:?[ADT]1(].GBY'-S]"(?R]^YW,^0&E/VU3^$ F?H+R5W#UHBZT]QD
MTO7:CFIW]I&R^U[YX<Y[G1-Y6/1/4Y%1?4I+B*-D$:1L:C&-1&HUJ=$3P1$\
M"GCW[G<SY :4_;5/X0M6V7UK5;D[0:&U?600TU9J"QT-VF@@RL<;YZ=DKV-R
MJKA%>J)E5 ^X                           &$3 R@&J83Q/S,;0_\-U2
M_P#XN[^,T_2)KS7MDVVTM7Z@U#7QVZUT;%?)-*O?WX:U/NG*O1&IU4_/MI+2
MD&FZ-6IB2JD3[;+Z^Y<)[$7Z\%MIN/<NW>.(Y0I-3R[5FS5;JGG*^3AHZ\.N
MUOZU;5_,XCI*=,D9>!O?[3FY^T=ATM12^9ZBTO:Z:VU5NG?Z<D<,;(FU#%^Z
M8Y&IG'5JKA?N5=)K)77J*K=R:*XVE8XUVB]:IKHG>&P /)M
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MJ:>GE;UZM;&LJ+CUHL:)]*@3N        !C*&0    QE#(
M
M
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M21KW.8K414<F47*$G53U?64F@VZ[>%$5QM.\K/6KE-S,JFB=XY/Z  Z-2
M     (*^59E<W;W0\:+Z+KK*Y6^O$+D_SK]9X_DH85;H_7TN$PZX4S,_-&]?
M_>/MO*:VJBK.'J"KJ(N>JH[Q3NII/%CG->UWT*U5_</E?)30HW;76LOQKO&W
MZH6K_G.@IJWTR8^O]W*31MJ\3]/[)S  Y]U8          (:^4QVD75VT=#K
M"CAYZ_3%1F96IZ2TLRM8_P!J\KTB=[$YU]9\]Y+S=OW9T9?=OJV?FJK-*M?0
M->[*K32NQ(U$]39<JOMF0FCJO35%K#35TL-RB[>WW*FDI*B/XT;VJUWTX4J
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M
M ?S\/85/^4OJO.N)+L\HOF]EI8L?.Z5W_O%L*%>_&KPA[D[L[[07_2MMAN-H
MN-+!3/J'U4<24;F(K7=HCG95N,.16HOBF,XS::9<HMW^*N=N2CU:W7=QXIMQ
MO.\)J[20QVG:32$<BI%'3V2C8Y7=$:C:=B=?5C!\!H3C-VGU_JRNTW;M3PT]
MQIZAU/"M<G815F%QS02+Z+T5>B)E%7O1,=3A7E$]T+KM=M9I#;VQURTONS!)
M#<)H>DCJ6!D;>SSWM;(Y_7'>C%3N546#.H-C=3Z=V?TYN15PQNT[?*J6F@Y%
M57QJQ51CI$QA$>K)$;U7*,S]TALX^!1?I[2NK;BG:&EDZE<QZXM6Z=^&-ZEY
MS7)ZS8C1P);[NWFV<AH[C/VVH].I'05RN7+I687L)E]KF-PJ_&8Y22K?$IKM
MNJS<FW5UAT./>IOVXN4]);  \VP_DJ]R=357)&BJY41$ZJN3?N14.4\3^A+W
MN5L1J_3FG:AU->*RE18$:[D656/:]8<YZ=HUJL]7I]>F3*B(JJB)G:)>5RJ:
M*)JB.<0ZE2U4-7"DD$K9HW=SV.147Z4/Z\W12JCR?O$+5;3;E_B&OTTL.GM0
M5"4S(YLM2CK\\K'8^YYU^UN3'?R*J^BI:JQ<IT-C)QZL:OAGHT\++IRZ.*.L
M=8?T0R :JQ
M
M
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MYJ95&M[FIGO55<M)K%5B8B/YU_H5&1Q35'N.J  Y1W(
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M-[M^["5[(F(WS3L.SY%<OQW9^%[.XZ\
M
M
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MWDQ@8R@^DJ%^R
M            !CP4#'3J8Z>LPBD M[>.76^AN*)^D;13T":7MM=3T,]+-#F2
MJ1Z1]HY9,Y8J*]R-Y>B8151W<>^/CUY%4TT=8:>3E6\6F*KG29V<:\I1J_\
M%%Q%OM4;^:.Q6RGHU;WIVC^:9R_.J2L1?TJ$^7; 46H.%JAVMKVI!_N%!1K*
MK<]E5,C:Y)<>R5.94\>J>)6QJEJ;F<<57357]DP5VN$HWYZHZ!E6D:?1V;$^
MHN/8F6IU\"YSJIL6K-NGE,1O^:ATZF,B[?N51OO.WY*?>#_<BX</?$E36N]-
MDH:6MJG6"[TS\?:GK)RM<[/=R2HU57XO/ZRX5KD5I4]Y2';1VB=^VZAIF+%1
M:FI&UC7-3E1*F+$<J)CQPD;U7UR*6,<.^Y*;K[+Z3U2KTDJ:ZA:E4J=,5#,Q
MS)_TC'X]F#SU&F+U%&3$>]'-Z:55-F[<Q*OY><?9TL %&Z9CO,<O>; "K/RA
MO#O6:(W)77FG[?,ZQZ@?VE6ZFB5S:6N3X?-A.B281Z*O>[G]A8!PZWW46I=E
M-'W/5E++1ZAFH&>=QU#5;(YR9:DCD7JBO:C7JGYXZ*YB/Z+U-DPU/9\YNW<J
MJ]:IM51SI[U7CX5./>KO4SRJ[G]0:\R>M,FQI+0
M
M
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MFFF-HAL@ ,&P
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MZ/9&C%Q2.[T1$]8'= ?![<[Q:<W3EKX[#)4O=1M8Z7MX5CQS*J)CKU^"I]X
M
M
M
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M "L70
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M@
M
M
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MCIQS'A<_,U[3_K2M/\SB.G&E5[TMFU[D  (>H
M                                      'CU%1%202S3/;%#$U7O>Y<
M(UJ)E55?!$/(/5ZAMS[O8;G01N:V2JII86J_N17-5N5]G4#YW\>S07RPL_\
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M;E7G;U\$=A4]KU),@
M
M
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M]0 0]
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M5QSA&/?MY-N+EN>4MP >39
M
M
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MWI;-KW(  0]0
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M .M_UB0NQFXU;NCHCW;N%/3TDZU,D'9TW-RX;CXRKZP.B@
M
M
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MI+FLBQ=QLFG)L1O%7O0LR!AOP4,E*Z6
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MK/T4^'A5XE^NJFKV*N[ZOHP81R+W*9*U=
M
M
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M?4LJM7"HY$L6\FO::ZS<$VV%/<$<E0^EJJEJ.5558I:VHEB7KZXWL DV
M                      !!_P KEM]JG<CAQTY;=(Z:O&J[E#JVFJ9**R4$
MM9,R)*.M:LBLC:Y4:CG-3F5,9<B>*$X"/7&EQ6.X1-K;7K)=+)JWSZ\Q6CS+
MW0\RY.>">7M.?LI,](,<N/NLYZ84*,?L3M\/[C6X'_FO7?@CT^T/_#E7_@R_
MQVEBWOZ'?_VDOWV_U(KIVA_X<J_\&7^.TWL+]]2T<W^&K^S]#G"Y^9KVG_6E
M:?YG$=/.7\+WYFK:?]:=I_F<1T]>XTJO>EM6_=AD $/0
M
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M'(J?N ?V
M
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MBX3]"M3Q;6.^NMG7_.7U_P!G3K<?7_+EL2>+5+L_3_"0@ *%U(
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M6)NVYWJCK'T4]S/[#)BU<C:F>D_59V#5KD5.BF4:5RX9
M                                     ?R54:BJJ]$*RO*0;W:0W271
MEKTE?Z6^+:YZY:[S17*R-ZI"UB\RHC7HN),*U51<>TL1W)F\UV^U/.CW,[*U
MU3^9O>F(G+E/;T*%D[E\5SGJ=!H^/%RY-V9YTN4US)JMVXLQ'*K^RX3R?- E
M#PIZ/>J8?4OK9G?35S(G[C4)&>)QG@WMON7PR[>P\O+S6QL__2.=)_[QV9"H
MR)XKU<_65]AQPX]$?2&4[C)A.XR:S=1F\H'MA^.'P\W>LIXEDN.G9&W>#E3T
ME8Q%;,F?!.S<]WSL0X%Y*_<[L;AJS;^IFPR9K;S1,5?NDY8ID3/BJ=BN$^*Y
M2P>Z6VGO%NJZ&KB;/2U43H9HGIEKV.3#FK[%15^LINTG657"CQ9P,JWR,I].
MWMU)4O=G,E#)EBOQX\T,B/1/7@OL+_<8US'[XYPY;/\ ]MEV\F.D\I70 \>G
MF94Q,EB<V2-[4<U[5RBHOBBG]O:4/1U$<VP "0  :]3Y7<S6"[?[?:EU,E))
M7K:+?/7)2Q='2K'&YW+GP1>7&?#O/JNB'CST\57!)%,Q)(Y&JU['MRCFJF%1
M47P7U"GE,;]&%6\TS%/5#OA-X]OQZ-7SZ4UE0VZP7>H57VJ6C<]L-3UZP*CW
M+B3'5%SAV')A%1$692*B^)4YQK\+$VP&K:?5NE>U@TC<JKFI^Q56NME3U>D:
M.3N;T5S'=Z<JHO5$5TVN"?B$EW[VI:^ZKS:FLCFT5RD1N$G7&8YOG>B+E/C-
M=T1,%QEXUOLZ<BQ[L]WPE1X.7<B[5C9'O1T^J1H,)W&2G7X
M
M
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M
M                 #3E7]PW $ .*"-L6^&HT8QK.E.OHICOIXE7Y_7]).;2
MD+(=,VAD3&QL;218:U,(GH)W(0;XI_R\M1_I:;^;1$Z=,?\ %RT_X)#_ !$
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M68M+515=/'/!*R:&5J/9)&Y'->U4RBHJ=Z*GB!Y
M
M
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MV5W/)#-'&BOQSJYR.:COAJBHB(@%@%-P!</5+1>:,VHL+HD:K>:1DDDG7O\
M3<Y79]N<D-^/;R8^A-%[47[<?:NEJK#4V*/SNOL3JE]1334R+]M?&LBJ]CV(
MJO5.=6JUBHB(N"9'V?W#QYEYW^.Q8.SY<\O._M/VG)S9]F"$/'SY3O2&Y&V5
MVVWVHDJ;K!?&)#<]15%,^FB93\R*Z*".1&O5ST;RN<]J(C7*B95<M#YSR)>K
MKM3[O:^TLQ9'V.KL27.5.JL94PU$4<>/!%<R>3Y^1/BEPI GR3VT^@]O-N]1
M55EUA9]8ZZN/FLM_]R)TFCMD2I)YO2\W<JY29SG-Z.<F.J,1RSV
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MV,>F/156JN%PJ+A?!47Q/">*K>K;DV*>&B(HWY^;Z8&J.-C%Z@
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MZO*QDVLCBBW/2=I>2#"=QD\6V
M
M
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MT,L>C[0UT;TPYJI10Y145$PJ+T.K?[=Q_-&JUJ_6!_4
M         "'WE/-AM=<0FPMAT[M]85U!>:74M/<):7SR"FY8&TM7&Y_--(QJ
M^E*Q,(N>N>Y%)@F,H!0%[UOQ/?W,O_7]K_I)Q':#_ARL_P '7^.P_38?F3V@
M_P"'*S_!U_CL-W"_?TM'-_AZ_L_0YPM?F9]H_P!:-H_F41U Y?PM?F9]H_UH
MVC^91'4#3J]Z6U1[L  (>@
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M8[>LCJ*C8L<?;*BNQE5ZJB(GCZCW@
M
M
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M31.\0L\:NNY:BJY3M,MP >39
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M[2-%15\71L3Q+^J/Q>'%7\U'Z.5H_P!AJ$TS[E?ZK0 :\WUCVH4#JFP
M  ($^4%X2)]1Q5>Z.D*19+C!%F]VZ%N5GC:F/.6(G>]J(G,GBU$7O:N?6>3H
MXHKA=:V#:;4<TE:UL#Y+'6.57/8QC5<ZG<J][4:CG-5>Y&JWNY42P)6)(U4<
MWIC&%.5:!X7-L]M-<UNKM.::BM][JN=.V261S(4>OI]DQSE;'GN]%$PG1,)T
M+.G+BK'FS=C?;HI*L"JC*IOV9VB?>CXNMIW#*&.9#".[^XK%VW
M
M
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M90G4T-*KWI;='NPR  S
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M67^(H$(^$?\ +GM_^"U'\12=Q!'A'_+GM_\ @M1_$4G<
M
M
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M>UK9%3_PAV=.B*O>5D^3)WG=IW7ERVZK7JM!?T=6467=(ZN)BJ]$3\_&WO\
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M:W*?GF^MQ9@BHIXY=B<>[-'=W-C3\F,JQ35WQU^[=.@ --9     #5/ >)L
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M &0
M
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M[/T,<*?YF+:#]9]G_F4)U-#EG"G^9BV@_6?9_P"90G4T-*KWI;='NPR  S
M
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MJJXZ>L^M/F-OJZUW+1=FJK)2QT-KGIFRPTL2(C8LIE683HF%547'BBGTX
M    ,90#(
M
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MMZ*B^']C1EUG?PMG[.>TS^.O[_'^[[Y#)A#)0.K
M'\E3+7)A5*CN./96JV*WM;J"QH^BL]]E6ZVZ:!5;YM4M<CI8T5/@\KU:]N.Y
MKFHG<I;FN<'*.)/8ZAW\VMN6F:CDAK_]\VVL<BKYO5-1>1WZ5<JUWYUZXZX-
M_!R/P]WVO=GJJ-1Q/Q-GV?>CH_APP;X4F_6TUJU$U\:72-J4MTIX^G8U3$3G
MZ>".RCV^QZ)WHIUXJ X0]Y+GPT[[2V;4*OM]FKJE;3?:6;NII6N5K9EQTS&_
M**O7T7/]A;\U[7MZ+G).;C]A=]GW9Z&F9?XFUM5[U/*7]  5ZW85!U]AD >%
M65L-!2RU%1(V*")JO?(]41K6HF555\$1#YW1VYNG->25,=EN3:F6G7[9&K',
M=CUHCD153VH>[OMGAOMGK;;4M5U/5PN@D1JX7E<BHO7Z2%E_L=^V*UXQ]/,K
M71N22FJ$;]KJ8E7"M<GMQA6^'U*<]J6==P*J*XIWHF>?T7.GX5O.IKHXMJXZ
M?5.5%3V&<'Q6V>XEOW&T\RX4B=G,U>2II7*BNAD\4]J+WHOBB^O*'VGT%W9O
M47Z(N6YWB537;JM5S17&TP<J'H]6Z0M6N-.W&PWRABN5HKX705%+.W+7M7^!
M47"HJ=45$5,*F3WH4]HG:=XZO&:8JCAGH@9M#Y/34FUG$/;=54NIJ1^D+35N
MJ:54?)Y_,Q6N1(7M1B,3OPYW-U3P])4;/#IU7P,X3OP<NWXX@])</>G:.[:I
MEJG-K)NQIJ6BB22>9R-5SL(JHB(B8RJJB=43Q-FN[=RZXXN<]&I:LV<*B>'E
M3UEU+F"K]1\9M9NCI[>#1]'J?2]>VNM=2G+U3EDB>GPHY&_<N3U>U%3**BK]
MC]*&M,33,TSUAM4U17$54\XE_0 !Z
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M7N[1B85?%T<:)WG05_[W#BK^:C]'*V__ (_.FB>5%?3[K0@:I[!U.?=4V
M    !JWO4^#U]LEH7<^X6ZNU5IB@O=9;W*M--5Q<SF(JY5JK]TW\X[*>P^]Q
MTP83N[Q35-,[TSM+SJHIKCAJC>'CQ0QPQ-CC:UC&(B-:U,-1$[L(G@A_=')U
MZGQ&\MRU-9]K-4UVD(5J-34]OFDM\2,[15F1J\O*U>CG>*-7**J(F%R04X/.
M/"\Q:O=IC=2^^>VZY/Q1WFL:UBT<RKCLY7(B?:W+GTESRKC.&Y5-NUC7+U%5
MRCGLTKV9:Q[E-NOEQ+)$7)D_FQ[7(BM5%1>[!LJ^!J+".?1L  D
M
M
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M&>%3\S#L_P#K.L_\RA.IG*^%+\R_L^OKT=9U_P#0H3JAIU=6Y3T  0R
M
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M,Y]N3V8
M
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M -'(%<1F\\G$!O1J;<.:U,L<MZEBD=01SK,V+DA9%T?RM5<HS/<G>!^EH
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M<N$3N3'?WEEEY%G)HIN4QM7WJG Q[^)75;JG>CN= !KS)ZS.4*M>,@
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M6HN7(AC>N1=N3733MNSQ[4X]F+==6^W>_J#7*>LSA#Q;;(
M
M
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MJM<G5/!S7(BHJ'Z!>'7=/\>K8_1.N5B;!->K9#4U$3/@1SXY9FM]B2->B>S
M'20                          /FM:[A:6VWM<5SU=J:T:5MLLR4T=9>Z
M^*CA?*K7.2-'R.:BN5K'+RYSAJKX*?2E?_EK.O"UI;'7_LSI?YC7@2K^RRV/
M_NR[?_\ G30_A3\]&T'_  Y6?X.O\=A\&GB?>;0?\.5G^#K_ !V&[A?OZ6CF
M_P /7]GZ&.%#\R[L]^LZS_S*$ZH<KX4/S+NSWZSK/_,H3JAISUEN4]  $,@
M
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ME.:M_P "7^,AP#@A_P"-6I?\"C_E )@ QE#(
M
M                                                          ((
M\2?DL+-Q&[U:DW&J]?W"QSWGS?FM\-MCE;'V--% F'K(F>;LD=U3Q)W "L;W
MCK3?]UBZ_>:/\*/>.M-_W6+K]YH_PI9R *QO>.M-_P!UBZ_>:/\ "CWCK3?]
MUBZ_>:/\*6<@"L;WCK3?]UBZ_>:/\*/>.M-_W6+K]YH_PI9R    'QVZFX]G
MV@V[U#K34,RP6BR4;ZN9S?AOY?@QM];G.5K&HO>YR'V)PWC!X>[CQ-;(W+0-
MNU%'IA]954]1+52TBU#)&Q/YTB5$>U417(Q>;KCE[O4%4=SWGXEO*,[EU]FT
M?-7VZR1+VGN+:ZYU);K=3*Y4:M3-EO:NQXNRYRH[D8B>BGO+EY)_B0VVHIM1
MZ?O%CN-VA8LG8:<O-1#7.[E5&NDBB15SUPC^N.G7!9#P+\*U3PG[05FEKE54
M%SO59=)J^JN-OYU;,U6L9$GIM14Y6,3T>Y%5RHOI*20R@%4GD]?*#ZTAW.HM
MF=XZRJN,E94^YEMNMV3DKZ&M;Z#:2J5^'2<SV\B*_,B2.1JJY%]"U6:>.EAD
MFFD;%%&U7/D>Y$:U$3*JJKW(A2=QDP6R\>5$H*?2#.TN+[]8X:I:9>CJ]%@1
MW+CN5$[-'+\='YZY+(O*)ZZJ-ON#C<ROHW\E95T,=JC7./1JIHZ>5$5$[TCD
M>OT(!7GQ \86\7&SO/4;<;(2W2FTNV:2.AI+-,ZEFN$3.CJJJFYF\D2]Z-<K
M6HCFHY%<>MN_DJ^)7;JWU.K;%=K1<+Y"U9G4VG;U4,N3NO,Y6N?'&USLHBX1
M^55.B*N$)#>10VSI*/;?76OY8.:X7"Z-LT4KV]6001,E=R+ZG/G3*^N%$\"R
MX"L?R;W'WJG5VN&[,[M5=167U_/%9[M<(U;5]M$CEDI*E5QE_*QRM>Y$=S-5
MKE<JM+."E#RF]E?L)QR637FG86TE7704&IVK'E&.K(9WL<JIZU\W8YW@JO5?
M%2Z&U5\-TMU-6TZ\U/4Q-FC=TZL<U%1>GL5 /.!CF3UF0/YIU0_//P8[?V+6
MNM+O+?*"&YPT-&DD5-4,1\?,YZ)S*U>BX3*85%3KGP/T,^!09P!1H[4FK)/%
M*2%J?2]?]!4:M<JLX-VNB=IB%OI%%-S,HHKC>'UG$ U(=?\ 8L1K(*>WT=)!
M%&U&MBA@A9#%&U$1.C61M1/FR7@44*4]+#$G5&,:U%^9,%(F^C5J-TW1=^8Z
M=J8]J?\ S+P(O@-^8Z"BNJYIN+57.\S3_ARE%%-O4\NFF.E7]Y?T0R :RT
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M_P"<M?T?$M/I6SQNZNCHX6JOS,:>>=_"V?L]--_C+_W_ +R]X "C=,
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M:O*O>U41/@JG+<W<6U>L1>L<N'K#GK&7=L9$X^3W])^*QT %,Z,
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M6))E:Z;E1'JU,)S8ZX^DV,VBS%47+,\JN[X-73KEZ::K5^GG3W_%Y@ *Y<@
M
M
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M<K/\'7^.P_38?F3V@_X<K/\ !U_CL-S"_?TM'-_AZ_L_0QPH?F7=GOUG6?\
MF4)U0Y7PH?F7=GOUG6?^90G5#4GK+<IZ  (9
M
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M#W(
M
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M=MT8ERY:F[1SB&C<S[=J_%BOE,]_<GME!E#5%16ICJ9^,::S;
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MVLCNEKYO2@D7*(]N>^-V%5J_.B]44L<G"[*B+UJ>*F51AZAVM<V+L<-4.W
MK5V
M
M                                                     #P:^UT=
MUIWTU=205M.[OBJ(T>Q>F.Y4P>%:='6*Q3.FMMEM]OF5,+)2TL<2KW^+6IZU
M^M3W8 T1,(G0W,9090#(                             ?F3V@_X<K/\
M'7^.P_38?F3V@_X<K/\ !U_CL-S"_?TM'-_AZ_L_0QPH?F7=GOUG6?\ F4)U
M0Y7PH?F7=GOUG6?^90G5#4GK+<IZ  (9
M
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M<(W(^FF1S42/F<G,N45WHJO3"8QA<R@
M
M
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MJF/:>5H/7UGW$T_!=;)4+/3/7E>UWHOB>G>QZ)\%4Z>Q47*90\6T^J
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MXC'M4TUU=.^7W&4&4-47/BAGU]#R;38
M     09\JO/R[:Z*A17>G>)'<J?!Z0/3K^V.,^2UA<[?O4$N4Y6Z;F;CYZJF
M_P!!V[RIEAN%PVNTK<*6CEJ**@NC_.IHV*Y($?$J,5V.YJN1$RO3*HGBAQWR
M5T/-O'JJ;EZML*MYO5FHB7'[G[AT]F?_ (RK;_O-Q=^)]+4[_3]%H  .8=H
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MPHU7Z6JN%[T5V7X>[V?;;>RP_%V8O=A,^T[Z#7Z3!KMUN
M
M
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M  0R
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M=5YL=R(JHOBJ94"9 !C* 9 ,90#(
M
M
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M>$K</\5V@/<:IDYKC9%;#E5RKX%SV:_1AS?9RIZSNP
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M*HGL-&O:JN:J(VB6];B;=$1<JWE[ &O,;&+W
M
M
M                   /SU[LMI+-Y0G4[]5)%!:6;DRU%<M<J+$E(ZY*_F?G
M*<G8NSCU'Z%"J/RGW 1J[46X-;N_MU::C44-SCC]W+10L62J@FC8C$J(HTZR
M,<UK$<UJ*Y'(KL*CEY0E'Y4+;N'<;@UU750Q-JZJP24U]I'([HB1O1LKD7^\
M2S+[3F7D;=VX=5; 7C0D]6QURTI<GR0TV<.;1U"]JUR)XIVWG&<>MN<90^X\
MG5ME57O@/H=.:Q?<*FFU$RYTL]!<G2<]-2NDDI>Q:U_P&\L:N1J)CTU]943N
M9MWN7P>;O7*S35EYTE?J&22.BO=JGEI//J95]&:"5CDS&].5<(O1<M=AS5:@
M35\M?H_2-JU5M]J"BCIJ765UAJXKCV2(DE33Q)$D,DJ(G>U7.8UR]51,=S.D
M_>"?=&OWFX6]NM7765]3=*NWNIZNHE^%/-3ROII)'>U[H5>OM52@6TVO7W$+
MN%34%,MZU[K*[2-C:Z>:2KJI5Z)S/DD551K4[WN5&M1%551.I^ASAJVA;L5L
M9HO02213S66@;%4S4[>6.2H<YTD[VIZEE>]>O5<Y7J!U
M              /S*;0)S7VJ1/\ O=?X[#]-9^9;9S_C#4_WA?X[#;P_W]/W
M:.;_  ]?V?H5X4/S+NSWZSK/_,H3JARKA1_,O;/?K.L_\QA.JFK/5N4]  $,
M@
M                                               <(XB=ZJ[:NYV6
MGH[1;KFE9#(]RUS'*K.5R)A,+[?W#C57Q<WJLHYZ=VF+"Q)8W,5S87Y3*8RG
MI=Y+O4>A=/ZND@DO=FH[J^!JMC=5PMDY47"KC/=W'JOQDM _)"S_ .*,_P!
M$"-N]=5&W>IX;W2T=-731QO8D58U7,7F3ERN%1>G?WG6?LP[W\E=/_\ 0O\
M]8D]^,EH'Y(6?_%&?Z!^,EH'Y(6?_%&?Z /[;5:FFUGH"S7NHIX:6:LA5[H8
M$5&,])6X3*JJ=Q]@>!:;11V.WPT-OI8Z2C@;RQP0MY6-3OPB?.>>      ""
M7%M=YJ_>2NII%Q'04T$$?AZ*Q]JOSKF1>OS(3M(@<9F@:BEO]!JRGB5]'5Q-
MI:IS45>25F>57?IFKA/5R+ZP(U@ #+7*UV4[\YSW^.47YRS+0=VFOFAM/7*I
M7-166ZGJ)%[O3?$UR_NJ5FL:KNY%7QZ$H-I>+BBMMMH++JBW+2P4T+*:&XV]
M%<U&-1$3GCSGN3O:J^QJ 2R!Z?3VIK5JJVLK[1<*>XTC^B34\B.1%]2^I4]2
M]3W    "'_$UIK7]GU]4ZLH)[B^RL;&M+44,KT\RY6)S-<C5RQ%<BKG'*O-U
M7.28!HJ<S514SE/H B/MEQC5U!V=!K2E6O@Z(ERI&HV9/:]G1KD]K<?,I*33
M>HK=JJS4UVM-4VMM]0WFBF9G#NJHO?U145%147NP<PW#X7=(ZZD?5TT3M/W)
MRY?/0L:D<B^MT?=]*85?%5/O-N=#4>W.DZ.P4,DLT--S.6:5<ND<YRN<J_2O
MU8 ^J!Z#5.L;+HFVI7WVX0V^F5Z1MDF7JYR^#41,JO1>Y/ \C3^H;9JBV,K[
M17P7&C>N&S4TB/;GQ3V*GJ7N ]N        #^,[^S@E<G>UJJGU$)OLR->_V
MFT?XJ_\ UP)O@A!]F1KS^TV?_%7?ZX^S)U]_:+/_ (H__7 F]E#)%G9'B2U9
MN#N/:[%=(K<E#4MF5ZT\#FO]")STPJO7Q:G@2F
M
M
M-"A_R?.>RU[ZO[!_^(+X.O@A0%P/Z]T]I&MU;1WJZTMKEK4I7TRU4B1MD6/M
MN9$<JHF?3;T\<]"EUFW7<P+E%$;SR_6%SHURFWF4U5SM$;_I*5W"[2I/Q[6]
M_P#:$J9._P 5H'M_]XM.1,%7G!!5T^K.-"ONM$]):2.WU4S'KE.9$9'%S(GA
ME7?46B8[SH*J9HL6**HVF**8<O8JBY>OW*9WB:YGS;@ \6^        $=.->
M\>:Z#LML:[E?67#M53/>R.-R+_E2,)%D/^-ZZK)JC35MSZ,%')4*GZ>1&_\
MZH#^?#M;O-=#U%0Y,+55<CT7\ZU&M3]U%^L^_P!262/4-AK[;-A&5,+HT54S
MRN7X+D^9<'I=IJ%+?MW8HT3"O@2;Y^=5?_ I]8!';APU5+M]O%14U8Y8H:V1
MUKJFN7N<YV&Y^:1K?HR3[RA7GOI87Z?UXM=3YBCKFI4QO9T5'IT=CVYP[]D3
MAVMU>W76@;)?4<U9*NF:LW*F$25/1D3]LB@?6
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MN-XE4IP2\1E;P_[F3Z2U/))1Z6NM7YK70U66^YU8B]FDRHOP>K48_NPB(J_
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MGG3W_%YX-6JAL5ZX
M
M                                                        #U&I
M-3V;1]GJ+MJ"[4%CM-.F9JZY5+*>")/SSWJC43YU/;E"_E,N(J_;O\1^IM-/
MN$B:4TA726JWVUCE2-L\68YYG)G#I%E21.;P:C4\%R%M\_'+P_TTSXY-V],.
M>U<9CKFO;U]3FY3Q\%/0ZKXMN%K7=J]SM3:[T1J*W*O,M'=4CJ8LXQGD>Q4[
ME]13#I7@EWWUC:8;G:=K-22T,S&R133TBT_:-5,HYJ2<JN:J=45.G5#VGO>W
M$7_<HO?UP_ZX%OVBN)[A-VYIYH-):OV_TO#-\..RP0T;7=<]4C8F>J^)(W3U
M_M^J;%;;U::J.X6FXTT=725<*\S)H9&(^-[5\4<U47Z3\^GO>W$7_<HO?UP_
MZY>QPYZ=N.D^'[;"QWBBDH+K:]+VNBJZ63'/#-'21LD8N.F4<U47 '20
M                      /@MY]>5FVN@*Z_T-/#55%/)$U(ZCFY%1\C6KW*
MGK]9]W\8];>[!;=16Z2@NE%!7T;U1705#$<Q5145.B^U$(YB)/V;.J?^8K/_
M -;_ *Q6[?>'JS;3T<-UMURKJN:HF;2+'5<G*C7(KL^BU.N6I]9=I^,IH'Y(
M6?\ Q1G^@H2VQUG?M7Z4ORWN\5MU2GN-O2'SN9TG9\S*K.,]V>5/J-["_?0T
M,[^'J^RSC;CBAO\ MOM]IG2%%:[;5T=BM=+:J>:H23M)(X(FQ-<_#T3*HQ,X
M1.J]Q(OAYWCN>[U'>I[G14E$M!)$QB4O/A>='*N>9R_%3ZST'#;MAI'47#OM
M?=KKIVVW"Y7#2UJJZNJJ*=KY)YGT<3GR/<O>Y5555?:=CTWHVQZ2;4,LEJI+
M4V=465M+"V-'*B83..\U*NLMVGW7O@ 8L@
M
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M3*87#D1%[OX3WH
M
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M%ZMRB+GHJR&3/JZ&C<MUV:IHKC:5A9O47Z(N6YWAL #!L
M         (S>40G[+A8U,Q%1.TJ*)GS_ -DQN7^ XUY)Z!$LNX\N%]*IH6^S
MHV9?\YGRHNZ%SMEKTUH*E9"RV75KJ^ME<U'2/[)Z)$QOQ4YLJOKZ)TZHOF^2
MBCY=%Z]DS\*XT[<?-$O^DOZ:9HTV=^^=_P!'*57(KU:(CNA.].XR80R4#JP
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M
M
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M %S]$G"Y6U%QX:=I:NKGDJJJHTE:99JB9ZO?(]U'"KG.<O55555<@=3
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M%R;DU?26X *Q=
M
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MUD%?1R? GIY$>U<=Z91>\]D /%JJ6&NIYJ>HB;+!,Q621O;E'-7**B_.BGE
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MZSR0
M
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M5-3K_G.DFN*M,C;NG^[D+=N:=6F9[_\ ":P,)W&3FW7@
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MU;MFNQ7-%<;2W,?(MY%$5VYWB6X /)M
M
M
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M'[#:ON&X&R&WNJ;LL:W6^:>MUSJUA9R1]M-31R/Y6^"<SUZ ??
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M<KWX5KT]B<J)W%=5[VZUH]V$@$[C)A.XR8L@
M
M                                     QE .?[_ 'Y3FK?\"7^,AP#@
M@_XU:E_P*/\ E#O^_P!^4YJW_ E_C(< X(?^-6I?\"C_ )0"8
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M+E6KZ\]V4^9?'JGK+0KW#+4V6XPTZJD\E/(V-4\'*U43]TJ]D:Y)'HO5<@8
M '6>%9BNWNL6%;TCJ<Y5$5?['?W=<KWIT3Y_ GT5^\,D$U1O7ISL<HK'3/<Y
M/!J1/5<_1T^DL"
M
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MA(CR8421\/%<YO\ RE]J7+_T4*?YB_KM\&G4_67*6KG::K5](V2^!A#)0.K
M                     QT[C( A+QX<'GXX=OJ]PM'4.=54D?-<;? WK<86
MI\-J>,S6IW?=(F.]&YXYP'\8K-O9X-O-;UW9:;G?BUW.=WHT$CE_(GJOP8G+
ME47N:Y5SZ*^C9RK>;O0KRXZN"MM.RY[F:#I%Y,NJ;U9X6Y1.N7U,2)]*O:GM
M<GBA>8F1;O4?A<COZ3\'-9N+<L7/Q>-UCK'Q6&,D;(Q'-<US5ZHJ+E%-T7&2
MO'R?_%]RNH=K=:5RXZ16&YU#O'_O1[E_ZM5_2?%0L+3&%Z]Y69./5C7)HK_J
MM\3*HRK<5T_G'P?U 0&LW@ ]'J[4=+I#35RO5<CEIJ&%TST;CF=CN:W/BJX1
M/:J >[R@RA7/J;=;5VM-85VHZ>NKZ&H8Q7,;;Y7M2EIT5<-RU?@IGJY4ZJJJ
MO>2'X8=_:G6#WZ6U-5NJ+QZ4E'5R8S4,PJNC=^>1$RB^*9^+U"20,90R
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M=-E<)SQY[L_=-56^TV<C"N6(XNM/QAJ8NH6LF9H]VJ.Z74P :*U
M
M
M                     C!O#Y.W9C?/<:[ZYU7:[I4W^Z]CYS+37*2&-W90
MLA9AB=WH1M[O5DD^13XU>/;3/"+1T=L2WNU/K:XP^<TUF9/V+(8>96]M/)A5
M:U51R-1$57*U4]%$R!\[[T?PZ?\ ,EZ^_,W^D>]'\.G_ #)>OOS-_I.\;#[Q
MQ;I</ND]R;NZDMK;C9F7&X=BY6T].]K%[?E5RKAC7-?WJJHB855*L.(#RO6Z
M.I]77&GVNJ:32&EH)5CHZB2@AJ:VI8B])).V:]C>;&>5&)RHN%55Z@37]Z.X
M=/\ F.]??F;_ $DK]$Z0MV@-'6+3%GC?':K+04]MHV2/5[FP0QMCC17+WJC6
MIU4JLX5?*^ZGBU7;M/;U-H;E9*M[8%U-24[::HHWJN.TFC9B-\><9Y&L5J97
MTNXMMBF9/&V2-[7QN3+7-7**GK10/Z@                    !4/Y</\L7
M:[]2JS^686\%1'EPORQ=KOU*J_Y9@%GFPWY1VW?ZW;=_-HS[L^%V&_*.V[_6
M[;OYM&?= 5 \>/ ;OKO-Q6ZZUGH[0WNSIRY>8^:5ONO0P=KV=#3Q/]"6=KTP
M^-[>K4SC*=%13G^RW OOQLMK%VJM6:!=;=/T])+'55C;K05"PHN,+R13N>O5
M$3HWIG*]$52[ON((^6%\^^QWT4^V/>RX1:WHI8'Q?"8]M%7*CD]6%3/T$Q$U
M3M")F*8WGHXG<[G36>AGJZR9L%/"W+G.[N_"(B>*JO<1TW UQ-K:YMEY.QH:
M?+:>)W5<.[W._/+A/F/&U)KJ\:SIZ)ER='&D$;5=!3Y[-TG*G,_"^M<]/!/W
M?G4Z':Z=I\6:>.Y[TOGNJ:I.15V=J?9CS2FTEJRBU=;6U=&[#^B30K\.-R]Z
M+[%\%)D<$-JJ&4>J[D]JMII'P4\;OCN:CW/^E$<S]L54:8U-7:5N<=9128<G
M1\:KZ,C?%'>O_,7%<)&X.C->;/VUVCY59YFUK+A13.1:BGJ5ZO[3UHY47E<G
M143IU142BU#!G&JXZ?=GR=)I>I1ET1:KGVH\W<@ 4R_
M
M                                           ")W$9KC<&Q;DS4FG*
MR[06SS6)S6T<+G,YL+S=<$L37E KVO&NMTK]:ZBW7&KOE715#>26&2G=RO;G
M.%]#V'I]*56N-%5%3/8H;O;)9V\DCJ>F>G,W/1/@^LLBROJ&5]0$ ?QTMW_^
M=-0?] [_ %"=>GIII[%;I*E7.J'TT;I%=W\RM3FRGSY/9Y7U&$Z> &P
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M<\KF][%PU>[HOJ0"10
M
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MY35FF:9F*HVF&Y35%4;T\W] 8,AF
M
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M:UN.B97O5RK(#'>4.H9]655-%/*F'0:7IM.)3QU\ZI\FP *AT
M
M
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M^Q2=U!4)6TD%2C'QI*QK^21,.;E,X5/!4S@#RP8R@R@&0
M
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M5>J_.WO^95/L>#;<?W0M-;HZMFS446:JB1R]5B<OIL3YGKS?LUQT0"38
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MG+_C<J?YCHLFW%O3[<1W_P#+D<.Y-W5+D_")C^DPDD #G77
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MOV/M/.X,MR.22OT56R)RNYJRA5R_=?\ *QI]&'(GL>H$L 8RAD
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MT\BQFV,B9IHJYQW/LP :K?
M
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M"VSU#>JM:Z[7;3-LKJVJ5K6K-42TL3Y'\K41$5SW*O1$1,]R =)
M                  BYY07B?U3PI;,V75VD*"SW*Y5NH(;5)%>H9984B?35
M,JN1(Y8UYLPLZJY4PJ].Y4E&1\XT>%1W%WM;:]&?BH_$EYC>HKOY\EO\\Y^2
M">+L^3M8\96?FYL_<XQUR@5L^_5[X?);0'WOKOZ811V4^'<OT\'\+RP/WC']
M&W]Z?]=*_-E?R2Y?IX?X7%CI_P#$1^?Z*O4_X6O\OUA^@+A._,N;/?K.LW\Q
MA.JG*^$_\R[L]^LZS_S*$ZH5\]5G'0 !"0
M
M
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M4>I]N*"X:GA='<'/>ULDD?9OFC1<-D<WP5>[N3HF?$Z/S)ZP,@QE#(
M!SK?#<NIVJT;'>J2BBKY754=-V,SE:W#FN7/3]*<$^S>OGR:M_\ TSP)@ A_
M]F]?/DU;_P#IGC[-Z^?)JW_],\"8 .8[#;K5>[>EZ^[5E!#;Y*>M=2I'"Y7(
MJ)&QW-E?TRG3@
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MN6Z[57#7&TO:U=HO4\5N=X?T !B]@
M
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M0G5"OGJLJ>@ "&0
M
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M6-O==:#J[U'J""6@LSF(R*CEE:]'3([\D8B.7"<N45?NLIC..@2-   &,H9
M]+J32=IUA;_,+U;XKA1H])$AF3T>9$5$7I\ZGS/XP.W?R3H/VKO])T  5XZ@
MT_;J7?NHLL5)&RUMO[:9*5N>3LUF1.3YL*3._&!V[^2=!^U=_I(@ZH_-,U/Z
MYF_SA"?P'HM+:-LNC*&:CL5NAME++(LKXH&X17JB)S=?8B'O0
M         QS)ZQS)ZSY#<K<JU;8:;ENUU>YR9[."GC7[9/)C*-;]'>O@16O7
M&5K.LKG/M]);;92<WH1.B65_+ZG/5>OT(@$V01HVBXN&:ENU-9M6TM/;IZA[
M8X;A2*Y(5>OP6R-<JJW/QLXSWHB=22X  QE &4,D:]V^+>'2]TJ+/I2EAN=5
M3N[.:X52JZ!'^+6M:J*[]-E$1?!4.=6;C,UG15C7U]%:[C2J_+X^Q=$_E]37
M([HOSHX";(/D=MMP[7N7I>"]6M7-8YW9S4\BIVD$B(F6.]O5%SXHJ*?7
M
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M)*>)O_01K_"JDAJ:%*>GBB;W1M:U/H3!&_>QWNAO[?F]_-<F1?4C&_YB2@
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MN5%]1_8CGPC;LNU'89-)W*;GN-KCYJ21Z]9:?IZ/SL543]*K?4I(PYEV
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MD,@
M
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MY)I85ITKGJY51$?S8RJ^PKYZRLZ>CO0 (9
M
M
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MR;?;OZ6W*8[W#N+7U+6H^2CF;V<[4]?*O>B=.J*J ?=
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M=?F0Z@<"X5MWJ_<"S5EEO4[JFZVMK7,J9/A3PN7&7>MS51$SZG)G*Y5>^@
M
M    !_-&JA2UY:W\U+I;]9E+_/J\NI*5O+6_FI=+?K,I?Y]7@7,:;_XNVO\
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MLO1(9D7#'^SJJM7V.7U'?B/N_F@%M=P34=&S%-5.1M2C>G9RKW.Z>#D_=^=
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M#9O$FY6E?,[C,CM0VQK65'-WSQKT;,GS]R^U,_=(!V4
M         5Y:S?[H<0MT;W\VI'1?54<O^8DT1?A=[I;\S2]_::@DE_Z]7$H
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M='8[A-V;NVZ>:3YY4?U^"U<(UWJZ+X+GFW7)R
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M_(WM5'<B>UJ]?F5#AN_'"5J':2KFU#I9U3=M-PR=NR:'*U=!A<HK\=51J_\
M*-QW>ECHI[K;3BO75=D71VYDS9H7M1M#J3D^V4\J=&=NB?":N<*].J955YLY
M3:R,&F]3-_%YQ\&IBZC59JC'S(VGNE9;LUN;2;IZ,I[G$C8JV/$-=3M7\CF1
M$SC\ZO14]BX\%/OTZ(5\[";G/VHUXR6IEY[+68IZ[LG\\?)GT96JG1W(O5%3
MO:KL9RA/^">.IB;)$Y)(W-1S7M7*.1>J*B^*%#M,<IY.CB8F-XZ/(  9
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MQ[2K7C<&/I,@
M
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M6NEM-/-4\JR/C@B;$US\(B<RHQ,X1$SW(A].
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M "J7@
M
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MZJJJO=A$Z8
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MS,KMR;-%GHVT,=C'KFE3_,= V_C[/0VGTQC^P(5^MB+_ )P/?@
M  /"O5GI;_::FWUL?:TU0Q6/;XIZL>U%ZY]?7N(S1S7[8C<6&KI)%[>F<KXG
M.SV57"Y?2:J>I4Z+ZE3UHBDICYG<#0U)KFQ2TDR-95LR^FJ%3\B?CI\[?!?9
M\R8#MFVVX5JW*TO37JUR>@_[7- Y?3@E1,NC=[4SG/BF%/K,H5[[2[F778W7
M,[*R"3S*1Z4]RH5[W-1>CV^"N;E5:O<J+CHBY)ZV.]46I+52W.WU#*JAJ6))
M#-&N4<U?X%[T5 /:                      !X]5/YO3SS+W1L<Y?H3(%=
MVWSO=#>"CE[^TKI9?W'N)3$6-D(UFW+M3EZJU)GK_P!$]/X5)3@        ?
M ;O[>MUG85GI8O\ =>C:KX5:G65OW4?T]Z>U/:I\IPN[S)H:^KIN\S=E9+A)
M]KDD7"4L^43*Y[FNPB+ZE1%[LG:C@V^&U[J::?4EJBS"[+ZR%B? 7QE1$\%^
MZQW=_<J@3I]77((U<*F^+K["S1M]J.>X0,Q;ZEZ]9HVHOVI57O<U.J>M,^KK
M)?* 1WXF>#C2W$+2/N#42PZOB9RPWBGC1>V1.YD[?NV^I<\S>F%QEJUT3TF[
MG!'N7VC>UM%6[HV5N9K==(47./!'M]G1[<I\%2Y[&?$^8UWMYI_<O3E78=36
MN"[VJI3#X*AN41>N'-7O:Y,]'-5%3P+3&SJK41;NQQ4?!1Y>FTW:NULSPUN)
M<,'&CIC?VECME;V.G=8L1$?:YI4Y*GUNIW+\-/%6?";[4](DGS=/654<1'D_
M=7[3S5>H=$RSZITW [M6QPM7W1HFHN45S43[8C>B\S.O155J)U/I.%CRAETT
M?/!IO=&JJ+Q8L)'!?'-66KI%]4N/2E9[<*]/SW<FQ=P:+U,W<6=X^'>UL?4:
M\>J+.9&T_'N6:*J!,=YZ'2FL+-KBR4UWL-TI;O;*A,Q55',DD;O9E%Z*B]%3
MO1>BGO$7UE),33.TNBIJBN.*)Y/Z  AF          #'AW#"&0!_/&<Y3HIJ
MD>,X3'S']@1M ^7W#N5TM&C;K666!:JZ10JZ"-K>9<Y3JB>*HF5QXX(#ZTN%
MQUO>9+I=ZQ]1<GHUCI7,:U%1J83T41$3Z$+&_AM5%ZD!-]JU[M\M10PJB1OJ
MXHNS\,]FQJ_,N>OUG/ZCB9=ZJF[BW-ICN[I7>G9.+:IJMY-&\3W]\.U:0UC:
M-04<$%%4XFCC1%IY/0?A$QE$\?H/HSEMBV<J;+J>EKDN,<E)3R)*G*U6RNQX
M*G=A5]N3J1MZ=<RKEJ?Q=/#,2U\^WC47/]K5O$P>OI_\O#ZSANZG![H+<?SB
MKI:5=,WF15=Y[;6HC'N7Q?"OHN]JIRJOQCK53K"RT=T2W3W*&&LZ9C<N,9[D
M5?@HI[A.[/AC);X^;%%4S:KYQR5.1A1<HCMJ.6W>JAWMV<N6R.KHK!<ZZDN+
MZBE;6Q3TG,B+&KWL;S(Y.CLQNZ)E.O?U4LFV*C=#LMH-KN_W#HG?0L#%(7^4
M#FY]Z+8U>G)8X&_]?4+_ )R;&S478[0:&C1<HVQ4+<_-3L.DS[DW<6W75U<I
MI=JFSF7:*>D='V!P+?W;[S&J_%)0QXIYG(VK8U/@/[FR=/!W1%]OSJ=]/'KJ
M"GN5%/25439Z>=JLDC=W.14PJ+]>?9@YIUS3A:WD;K73[--76?-\ML2)"]Z]
M:F!.B._3-Z-7UIA>O4[[GP*Y]46*[;-:YIJZVSOA[*7SB@J\=51.]KO!5ZJU
M4\<^W!-_:7<RAW4TA3W>E1D50GVJLI47*P3(F5;\R]'(OJ5/'. ^Z
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M%RB::HZON0:\R#/0KULV!KT'W0&P
M
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M&<Z-LW\RA.JHSN.6\)B?]RULW^LRS?S&$ZKA#!'##( #(
M
M
M              ?QG<K*>5R=Z-54^H@W]EWN)_WS;_\ $V_Z2=*IE,*F3U/X
MDK'_ ,R6_P#Q6/\ T 5[;C[MZ@W3=;W7Z6GD6A21(>PA1F.?EYL_M6GO-'<1
MVLM#Z;I+':YJ-E!2(Y(FR4R.<G,YS^_/K<I.W\25C_YDM_\ BL?^@?B2L?\
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M[<-VPT'1655:^K55J*N1BKATSL<V/8B(UJ>QI]V
M
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MTC9&+]S0P)_U;3D'&!,DF\,B>#*&!J=?8Y?\YV?3S.RL-M9W<M-$G^0@'G@
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M%]I[JR/';4Z*K*B!5\)(G8<WV+C"XZ*I69&'=QY]J.7Q7.)J%G*C:)VGX.A
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MY?%Y:5R\W14Z'$]X.#S;+>B::NO=A2BO$BJJW2TO\VJ'*OW3\(K7K[7M<O\
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MY:]^F83:RK-[W*XE[< 'BVP
M
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MW_U!=/Z,4! ?I2X3/S+6S?ZS+-_,83JQRGA,_,M;-_K,LW\QA.K
M
M
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M F"#QZ:IBJJ>.:&5DT,C4>R1CD<US53**BIWHJ>)Y
M
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M+=71>EG,4C?@2M\'-]B^*>!,:-O9M1J?<I@#(                7N[O8H
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M*:)OU,0X+Q5S=IOCJ!O]K93,_P#1V+_G)"TT?8T\4?Q6M;]2 ?T
M  ^-W*VZIM=V=8TY(;E BK33JG1/'D=ZVJOU+U^?[( Y(S[:;DWS8_5-32U=
M,^6WR/2.X6J9?1D;W<S>JIS8[E[E^94/JMR^ [;W?FW.UCMI=6Z6JJQJR+31
MQ<U"^3&5:Z-%1T#L]'(WHG>C/%?N-RMLZ37EN5[$;3W:%OVBIQ\+'W#OSJ^O
MP7N]O']L=SM0;$ZMJ*>:&1U&K^2OM<BX1Z9PCF+X.QW.[E^8][-^Y9JXK<[2
MU;^-:R:>&Y3NC-3U>[_!-N(K%2HL54]>L4F9;=<XFK^UD3"]Z8>SF^Y7*$X-
M@?*+Z0W*JX+-K*GCT5>I,)'433H^AG=ZNT5$[)5\$?T\.;/0[_ NB-_=$(M3
M14.I+)4+AU+70->L4F.YS5RK'HB]Z=>N47JA#+?_ ,F;*L]7>=JJMG9NS(NG
M;A(J<J]_+!.[/T-DQCKZ?@7$7\;-]G(CAJ^+GIQLO3IXL>>*CX+"8*B*HB9+
M$]LC'HCFN8N45%[E1?4?UYD]:%-VV?$7NYPGWV73M2RJAI*=^9]-:@B?V;4S
MWQ]4=&B]51S%Y5[U1Q8+L7QR;<[QTM+25%RCTMJ63#'VFZ2HSF?W8BF7#),K
MW)T=ZVH:=_3[EF.*GVJ?C"QQM4M7YX*_9J^$I&Y0R:-5%3O!6+IN
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MA.->JO6HKJIX9GNEN #Q;0
M
M                                              0>\KEM]JG<GAQT
MY;=(Z9O.JKC%JRFJ9*.RT$M9,R)*.M:LBLC:Y4:CGM3FQC+D3Q0G" /S6?8F
M[X?W&MP/_-:N_!'*C]5!^5<#]*7"9^9:V;_699OYC"=6.4\)GYEK9O\ 699O
MYC"=6
M
M
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MJH8I9IG(F7N5J*JKA$/K@
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MQ43"^"DWM%:ZLFO[.RYV.NCKJ9?1>B='Q.QGE>U>K5^<#Z0
M.6<3TRP[&ZH7UMIV_741)_G.IG'^+";L]D;TU5QVDU,W_KF+_F CQPRQYEU&
M_P"*E.WZUD_T'=#BG#+'BCU _KZ4D*?4C_\ 2=K              !Z;5FDJ
M#65GFM]PCYF.ZLD:GIQO3N<U?#_.>Y $69Z75.QFL(JZBJ'TTS5^T5<:?:JA
MF>K53N5.F%8OJSZE)A[*;[6C=F@6%4;;[_ Q'5-"KNCDZ?;(U^Z;W>UO<O@J
M_)WZP4&I;9-07*G;4TTF<M<G5%^,B^"^I2-NK=#W[:;4$5TMD]0VFBDYZ2YP
M+Z4:I]R_U+UZ^"Y^= +% 1ZV)XG*36JP634[HK=?G89#4?!AJW=R)^=>OJ[G
M+W87H2% U4-\3.4,@:'J[]IVV:IM-3;+O04]SMU2SDFI:N))(WM7P5JIA4/;
MF%$3,3O#":8JC:4!=Z_)@T-RGJ+IMG>4M<CE5Z62[*Y\"+G.(YTR]J>I'M?U
M[W(1=M.J-Z>##6#:65MPTZKG]HZVUF9K=7-3O5$158_IA.9BHY.[**7-M[E0
M^:UMM]I[<>Q36;4]GI+U;9%1RT]7$CT1R=SFKWM<G@YN%0M[.HUTQP7XXJ94
M5_2:*I[3'G@JCX=$8ME_*1Z#UY)3V_6,#]$W5W3MIG=K0O7'5>U1,Q^OTT1$
M3[I26UNN%+=:.&KHZF&KIIF(^*>!Z/8]J]SFN3HJ+ZT(%[W^3#I:KSBY[7W5
MU%+U?[AW:1SHE[UY8I^KF^Q'\W7O<A&&Q:ZWNX/M1+;56Z:93G<KK7<HNVH*
MG"Y<K$7+'9^/&N?SQL3AX^5'%C5;3\):]&?E8<\.71O'BA<ZKD3J$=GNZD)]
ME?*9:3U.R.@W"H7:2N6,>Z%,U\]#(OM1$62-?8J.3UN);Z-USI[7MI2Y::OE
M!?:!5Y?.+?4-F:CO%%PJX7V+U*B[C7;$[7*=EWCYEG)C>W5$_3O?2&,H8:[I
MWH/J-=NM@ !X]3+YO2S29QR,5V?F0KMV,CYMRK4OQ6S+_P!2]/\ .6#:CF['
M3]TD^)2RN^IBJ0!V#C1^XE(N/@PRKW_G%3_.!)\    !6AQIR+)Q$:C:O<R*
MD:G^+QK_ )RR:UQI%;:6-JY:V)K?J:A6CQDN5_$=JY._'F:)_BD*_P"<LV:U
M&M1J)AJ)A#H,_ECV?M_9R^D\\G(^_P#>60 <^Z@  1]0 !+X'<;;5NIW)<;<
MV*&YM;B1'=.W:G5$5?!R>"^W'<B8X[;=27?1MTFBHKA5V>OADY98XY5C7**O
M16]SD]G5%R2@/B=QMKJ#7=*LJ<M)=HVXBJD;\+'<Q^.]O[J>'J7G,[1;>77-
MZFJ::Y[XE?X6KUXUOL:J8JH^$OJ.'7=S4.MKE6VF\-;7,AI^W;7M8C'(O,UJ
M-?RHC5SE514Z^BO?X=^RA7?I/6NK-A]72JUKF*JM2IH9U5T-5'GHJ=?5G#D]
M:^U%FOMENK9-UK&M9:9NSJ6(GG5#,J=K Y?!4\6KX.3HJ>W*)9XEFYCV(HN5
M<4PK,N[;O79KM4\,3W/N.T9\9IE"%>K+7N5M[?Z^Y5-1=8U?(Y[[C3O<^"5J
M+T553*(GJ:Y$^8]OISBGU5:W-;<8:6[PIW\S.QD^AS<M_P DI:?V@M4US;OT
M54S]87'H.]<HBY8KBJ/I*7R.3UF45#T^EK[%J;3]ONL,;F15E.R=K7][4<U%
MPOUGM<G34U17$54])<Y53-,S3/6']#&4,>'>8/1#<            !7WQ%.\
M\WYU$G?S5$$?K[H8V_YB2)&K>!WGF_\ ?4[^:ZLC^I6M_P Q)4
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M :+DRWQ-@
M
M                                       #\JY^J@_*N!^E+A,_,M;-
M_K,LW\QA.K'*>$S\RULW^LRS?S&$ZL
M
M
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MI=(_J9!_$0^U/BMD_P J32'ZF0?Q$/M0
M                                                    -,%#WD_&
MHZ+7J.3F3^P$PO7_ +XR7P+@H?\ )_O;%!KYSW(QC4H7*YRX1$1*GK\Q3:OO
M^"KB/I__ -0N-)X?Q5/%TY_I*PCA'I?-MI85QT=-EOZ7L8\)^Z=I.1<*<:-V
M7LCT_P"4:CO^K8G^8ZZ7%,?%3Q]  $@
M     /C]P-L+9KZG1TW]BW*-O+%61IE4QW->B_";^ZGAC*YX5:[IJW876*34
MSUI9TPBM5%=3UD6<X5/%J_6F<]%3)*4]9J+3=MU5;W45TI6U4&<IE516KZVK
M]ROM0#ZW:7B%T[NEV=$Q7VN^\N76^H5/3PG58W=SD\<=%Z=QUDKUU_M#=-"U
M7NG9Y*BJM\+DD9/&N)Z9R+E%7'MZ\Z8QCPZ'5=FN+9\#H;1KESI(O@QWAC?3
M;_?FIWI^>;U]:+E5 EJ#Q+?<*6Z44551U$572S-YHYH7H]CV^M%3HJ?,>5E
M,@       '$>,";L]G)V_P!LKH&?NN7_ #';C@?&?-V>T]&WI]LNT+?^JF7_
M # <FX:8^6PWE_QJIK?J;_\ ,[$<FX;8\:0N3^OI5[D^J-G^DZR
M        /YU5/#64\D$\3)H)&\KXY$16O;ZE3Q^8_H (];E;'5%G?)<M/1OJ
M:!?2?2-ZR0^M6^+FY\.]/:?6[(\559IQT5FUE--7VI,-BN2Y?/3IZGXZR-]O
M>GAGN3K'^?ZL',-QMDJ+5+YKA:E9;[H[+G,Q]IF=ZU3[E?SR=_BB]X$L[1=Z
M&^VZ&OMU5%6T4S>:.>!R.8Y%]2H>=S)ZRO'16X^LMB+]-2QH^&+FYJBUU>5A
ME3/>W'1%7X[?9WIT)F[5;RZ?W3MK'VV=M/<6MYJBVS.1)HU]:?';^>3Z<+T
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MN6IX;D;2O+5^U?IXK=6\/ZY0R:],=X^?J>38;
M
M
M                         &,H9(.^5OW#U3MSPXZ<N>DM2WC2UQFU934\
ME99J^6DF?$M'6N6-7QN:JM5S&+C.,M:O>B 3ARA^5@ZM]EEO?_=EW _\Z:[\
M*<I _2EPF?F6MF_UF6;^8PG5CE/"9^9:V;_699OYC"=6
M
M
M                                               .6<1&X-WVVT%'
M=[*^*.L=6QP<T\?.WE<UZKT_8H1H^R[W$_[YM_\ B;?]('S>K/S0=U_7-)_.
ME+#BL&MU-77#5,VH)G1^Z$U8M>Y4:G)VJOY\\O=CF.J?9=[B?]\V_P#Q-O\
MI G3E#)R'AKW(O6YVCKE<KX^%]5#<'4S%@CY$Y$C8[^%RG7@
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M*F4[_G/J@
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MJB7]P:.7VX&>B=3![-P
M
M                                                          #G
M.].PFA>(32U+IS<&Q.U!9J6N;<(:;SJ>F5L[621H_FA>QR^C)(F,X]+..B*G
M1@!%3WK?AA_N8_\ K^Z?TDH"/U4'Y5P/TI<)GYEK9O\ 699OYC"=6.4\)GYE
MK9O]9EF_F,)U8
M
M
M               \.LM]-<(NSJX(JF/FYD9,Q'-SC"+A?]NIXGXDK'_S);_\
M5C_T'MP!7YJ6E@CXC:FF;"QM.FI&L[)&IR<O;HF,>KV$[/Q)6/\ YDM_^*Q_
MZ"#&J/S3-3^N9O\ .$)_ >%16ZEML;HZ2EBI6.=E60QHU%7UX3V'F@
M
M                                               ?S1/#!1!Y/I,,
MUY\]#_!4E\"9^DH%X)=:VG1]MU[/=*MD"N91NBC7X<O+YQEK4^E/K*G5+5=[
M$KMVXWF=N7YPL],O6[&3%=VK:(WY_E*TCAZC[+971S?_ ,GQK]:JIT(^,V6I
MUI-I])PNZ*VVP_Q44^S+>(V54<XD !#(
M            &.F/_I\WM  ^&UIL]8M7MDF2%+=<'=4JJ9J)S+ZW-[E^?O\
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M+\9\SO\ K7)_F/OSXK9:/L]L[(G5,MD=]<SU/M0
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M3$[3&RQIJIJC>F=VX,=/88]'UD,VP
M
M
M!^5<_50?E7 _2EPF?F6MF_UF6;^8PG5CE/"9^9:V;_699OYC"=6
M
M
M                                                        @#JC
M\TS4_KF;_.$)_$ =4?FF:G]<S?YPA/X #',GK,@
M
M                               :)WX/S4;,X[.[],_D7_OGZ5U1>].\
M_/3PF;<4FO;1KE\T\M/5T,=*ZE<Q4Y>9R3_"3&5ZL3N5#ULY=O!J[>[[L=?S
MY?W:U_$NYUJJQ:]Z>GY<_P"RX+;2/LMN],-RBI[FTZY3VQ-4^D/E]JI.VVQT
MA)G//9Z-WUPL/J#SFKBF:OB]Z*>"F(D 'L(9            >P
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MZW.7_.?6GJ-(V>33NF;7;9WMDEIH&QN<Q55JN1.JHJ]<'MP    >P=_=U
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M]4S4PY:%TM'*OM5RK(WZFH=PTMY47;2ZNCBO%EU!9'N^%+V$=1"WKZVOY_\
M(.RZQX/]G=<P*RX:"M%-)G/;6N+S&3F]:K K,K\^3B6K?):;>W.*5VG]17RQ
M5"IZ*3NCJX6_L5:UW^63%W3[WO4S3]F/8ZGC^[7%?W22VOWUT+O%%.[1VHZ6
M]N@8V2:*-'LEB:Y<(KF/1'-[E[T.@=Z$:>#SA-K>&B;5KJ^]TU]=>'4R0S00
M.B=&R+M<HJ*J]ZR)W+X$EF]$*F]3;IN3%N=X7N-5=KM15=C:IL #Q;0
M
M
M         QE#(    #',GK R#&4,@   /RKGZJ#\JX'Z4N$S\RULW^LRS?S&
M$ZL<IX3/S+6S?ZS+-_,83JP
M
M
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M']HZ*EC1C5<J(F>GCA$/<@
M
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MML-)3325*W"TI0QVRI:]C60-<V-%RJ.5.S<KEPWFST573^_&VN7]OI/V[O\
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MO5+4JQ7)CF>JO1Z(Q6X5/A(MD7TF&^/3YLFX
M
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M8
M
M
M                         !C* 9
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M-LW\QA.JDLN@
M
M
M                  ,8-3<
M
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MUW]# ZK[^C^@E^^W^I#W]']!+]]O]2.5>\I;X_*K;_[XUW]#'O*6^/RJV_\
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M
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M^]+^NEJ@
M
M                   #X/?':^EWGVBU=H>L>D45\MTM&R9S>9(9%3[7)CUM
M>C7?L3[P 4;<&/%+>. 3>75>@]QK/6,T[55:4MXIHFJL]OJHLHRJB:JX>QS7
M>ECJ]BL>U5Y4:^PK6?E4.'K3&E9+K;M73:HKG1N?3VBVVZI;/*Y$Z-<LL;&Q
M]<=7JGCA%P=)XB.##:KB;2*IUGI]6WJ)G8Q7RVR>;UK&)E4:KT14>U%551'H
MY$RN,94CM9_(O;,6^ZQU59J+6-TI6/1WF4U931LD3/P7N9 CE3'?RJU?4J 1
M*X1=(ZGX[>.2JW5U#;V16:U7*&_71\:*L,:Q(UM%1M5?A+]JC3KWLC>J^"%V
MA\9MCM/I+9G2%)I;1-BI=/V.FZLI:9%7F<N$5[W.572/7"9<]5<N$Z]#[,#B
MNE>,/9S6>X4>AK)KJBK]62U$M(RV1PSI(LL2.5[<JSERB,<O?UY3M1#[;/R:
M&@=KM^Z?=FW:EU'57N"X55Q2DJGTZTW/.V1KFX2)'83M78]+P3.28( J:\N1
M_P 8=H%\/-;I_'IBV4C=Q9\#ND.+VLTU5:HOEZM#[#'/% EI="WM$E6-7<_:
M1N_M:8QCO ^[X3%_[EK9O]9EF_F,)U8^8VXT12;;[?:9TA05$U506"UTMIIY
MJGE61\<$38FN?A$3F5&)G"(F>Y$/IP   'Y5S]5!^5<#]*7"9^9:V;_699OY
MC"=6.4\)GYEG9S]9EF_F,)U8
M  _*N?I2X3/S+6S?ZS+-_,83\UI^E+A,_,L[.?K,LW\QA ZL
M                         'Y5S]5!^5<#]*7"9^9:V;_699OYC"=6.4\)
MGYEG9S]9EF_F,)U8                                      _*N?JH
M/RKGZJ                                      #E/%E^9:WE_69>?Y
MC,?FM/TI<6/YEG>3]9EY_F,Q^:T#]5
M          /RKGZ4N$S\RULW^LRS?S&$_-:?I2X3/S+.SGZS+-_,80.K
M
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M:>VXT[2:?TM9*&P66C14@H;?3MAB9E555Y6HB*JJJJKEZJJJJJJJI]&
M              'Y5S]*7"9^9:V;_699OYC"?FM/TI<)GYEG9S]9EF_F,('5
M@                                       "@'RH_YNG<W_ ,F?^RZ4
MO^* O*D?FZ=S?_)G_LND G[Y%'\RUJK]>=5_,:$L *__ "*/YEK57Z\ZK^8T
M)8                                         !57Y='_\  G_Y;_\
M@#E7D4?S4NJOUF57\^H3JOET?_P)_P#EO_X Y5Y%'\U+JK]9E5_/J$"ZD
M                                     K_\M;^9:TM^O.E_F->6 %?_
M ):W\RUI;]>=+_,:\" /DM_S=.V?_E/_ -EU9?\ % 7DMOS=.V?_ )3_ /9=
M67^@                                        <IXLOS+6\OZS+S_,
M9C\UI^E+BQ_,L[R?K,O/\QF/S6@?JH
M
M
M               " 'O*6Q_RJU_]\*'^AD_P!\SM]HFBVWT'IO2-KFJ)[=8+
M936JEDJW-=,^*")L3'/5K6M5RHQ,JC43/<B)T/I@
M                 QE#($ />4MC_E5K_P"^%#_0R;.WVB:+;?0>F](VN:HG
MMU@ME-:J62K<UTSXH(FQ,<]6M:U7*C$RJ-1,]R(G0^F  &,H9
M                         0 ]Y2V/^56O_OA0_P!#)_@#YG;[1-%MOH/3
M>D;7-43VZP6RFM5+)5N:Z9\4$38F.>K6M:KE1B95&HF>Y$3H?3
M                             $ />4MC_E5K_P"^%#_0R?X  &,H9
M                                #YG<#1-%N/H/4ND;I-406Z_VRIM5
M5)2.:V9D4\3XGN8KFN:CD1ZX56JF>]%3H0F]Y2V/^56O_OA0_P!#)_@  8R@
M&0                                8YD]8R@&0 ! #WE+8_Y5:_^^%#
M_0R;.WVB:+;?0>F](VN:HGMU@ME-:J62K<UTSXH(FQ,<]6M:U7*C$RJ-1,]R
M(G0^ERAD    ,90R
M
M   $ />4MC_E5K_[X4/]#)L[?:)HMM]!Z;TC:YJB>W6"V4UJI9*MS73/B@B;
M$QSU:UK5<J,3*HU$SW(B=#Z55P,^'B!D
M          ,<R>L#)#W?KR86U?$-NM?-P=27_6%%>;QV"3P6NLI8Z9O901P-
MY&OIGN3T8FJN7+U5>Y.B3" '&^&'A@TMPHZ!N&D=(UUWN-MK+G)=9);U-%+,
MDKXHHE1%CBC3EY86].55RJ]<81.R
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M]Y2V/^56O_OA0_T,G]E#( &,H,H!D&,H9
M
M
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MI+&J.5$7TFN8YF5:[+@O0!XU)4Q5U-%402-F@E8DD<C5RCFJF45%\45%0\D
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M1X<O=G,;X\X7)>)'(V5B/8Y',<F4<U<HJ>M /Z
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MV70&MJY&:0KJJ*"[Q-D<M%+3RX;%<8>;&%9T578SRM>Q>J= O !C*&0
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MIY<-BN,/-C"LZ*KL9Y6O8O5.@7@ QE#(
M
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MWH*B.JA9-$]'QO:CFN3N5%[E _L
M
M
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MO]4??X]YW@C?Y.EG)P6;5H[HON=*O7U><RJ20
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M3U#U3'-*M-&KW=Z]%=DZ><9X,45O"=M BIA?Q+6[O_P=AV8
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M6MW?_@[#LP
M                                                    (5>4EXT$
MX>- +I#2M:GXY.I(%93=DO-);:5RJUU2J)U1ZX<V/\\BN^X5%[_Q(<0&G>&O
M:B[:XU',BQTWVFAHN?EDKJMS7=E3LZ=[N5RJOW+6N<O1JE<? /MM]D5O3=N(
M_>G4%IE?%7+):+;75$;.UJVJG)*V-S_1A@1$;&W"Y<B+G[7Z0=+V(X,UX=>!
MO>75VJZ%OXY.I-#WB2J69N9;;2K12N;2Y7JCUPU\GYY$:N>1%7X#R&W_ !BW
M@_P6U_QZDG?Q3[@:6K.&3=ZFI]26B>HETA>(XX8J^)SGN6BE1&HB.RJKE,)[
M2 /D4-1VC3]_W:6Z76BMJ34UL2-:RH9%SJCZG*)S*F<93N]8%NH/"MUSI+Q1
M,JZ&JAK:63/)/3R-D8["JBX<BX7"HJ?.AYH
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MO3/)&;NW3<;AEEL5WJ'54^D;DZU4LKU57+2+&R2%JK^<YGL1/!K&IX 3A
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ME?:KQ5R*^>IIFN:R2*9Z]7O:KV*CU57.:YV<\N5L=
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M@U$J53/BG=ZBZWF3UE+NMYO=/RQ].^&-ZJW6%O:K43*_:X(4<OS8:J@71@
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M.151TSDQS.3*-3+6KA7*Z=H
M
M
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MNMNM+:3IW<]/8K52VN-V57+(861(N5[^C.]?6?4@
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MU4MKC=E5RR&%D2+E>_HSO7UGU(
M
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M"7LE6<.?#_I7;JON<-YJ[,M7SUU/$L<<G;5<TZ8:JJJ825&_.AV(
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M-'1TE+$GHQQL3E:GM7IW]ZJJJH'OP
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M<M=*U%1J<J*O)&S+N1F5QS.555SG*O>
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M#OA%T[PE;</L=MF]U;_<'MGO-[=%V;ZN5J*C&M3*JV)B*Y&M55^$Y>]R@=_
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M6R^Z?/[I^90^==I\+MNS;SY]N<@>Y
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M       &,H9(E<<7'A]AK7Z0IET1^*_\4$=5)S>ZWF/8=BZ)/[1)S9[7V8Y?
M$C![^C^@E^^W^I 6J JK]_1_02_?;_4A[^A^@C^^S^I 6IY09[R&W!-Y0S[,
M/6^H-.IH#\2/N3;DN'G/NSY]VOVUC.3E\WCY?A9SE>[N./[K^60_&QW1UEHU
M=H?=)=.WJLM'GOXINR\X\WG?%VG)YH[EYN3/+E<9[U[P+*<H9/C]IM<?CG[7
MZ.UEYC[FIJ*S4=W\R[7M>P\X@9+V?/RMYN5'\O-A,X[D[C[  #&4&4 R
M          &,H!D             ,<R>L^5W"W(TQM-I2LU)K"^4>G['2JB2
MU==)RMRO<QJ=5<Y>N&M157'1#X3ACXF-.\4^D]0:FTK1UU+9;9>Y;-#-7-:Q
M]5V<,$JS(Q,\C7=OT15YL-15PJX0.S   8RADKVXD_*P_8];VZIV]_&L2_\
MN)+%'[I?BB\W[?G@CESV7FK^7'/R_"7N^@"PCF3UF3F?#GO"N_>RVE]P5M'N
M#[N4[JCW/\Y\X['ED>SE[3D9S? S\%.\Z8    QS)ZS)'OC3XK%X0]K;7K)V
MEDU;Y]>8K1YE[H>9<G/!/+VG/V4F?R#'+C[K.>F%"0?,GK,D*."SRCZ\7NZ-
MUT:FWB:3\QL\MW\^]VO/>?DG@B[/D\WCQGM^;FS]SC'7*37       !C* 9
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M7Y6%.(3>W2^WOXUB6'W;EEC]TOQ1><=AR022Y[+S5G-GDY?A)W_06$  #&4
MR          !CF3UF2/_ !E<3-TX4MM*/6U)HE-:6[S]E%6L;=/,G4C7HO)(
MJ]C)S-5S48O=A7-[\] [_E#)P'@[XM+%Q<[;SZEMM![AWBAJ74MTL;JE*E](
MY558E23D9SL>SJCN5$RCV][54[\
M
M
M
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M=SJHJ*DI_<2XL26:1Z,8SF=3HU,N<B9541/$"3H
M
M
M
M
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M_P $&L.#&[V6XRWEE_T]7S*VWZ@H8'4SXZAB<R,D9S.[*3'I-P]<HU51<M7
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M45MPM$+:R5%^'51)V,Z_]+&_H!UX
M
M
M
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MNY=_JM2Z>OU0RAMUUN3W35=#5/5&Q-=*OI21/<J,]-55BJU<HU%10N$
M
M
M
M
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MJKU^D_2)MCN5IW=_0EGUAI6XQ72QW6!L]//$Y%5/C,>GW+V+EKFKU:YJHO5
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M:O>K7U4J1N^EC6*GL5 )9
M
M
M
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MM&6&^K#YNZYV^GK5A5%16=I&U_+U]7,>_
M
M
M
M
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M72JN<H[LNB\W2ZX
M
M
M
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M
M
M
M
M
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M3RR3,I6222JKY'*Y[G22.<]RY7O<Y>B(U,(B(GVX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
+          !__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 8]#Z # 2(  A$! Q$!_\0
M'@ !  $$ P$!              @! @8'! 4) PK_Q !X$  ! P," @4$!PP3
M" X( @L  0(#! 41!@<2(0@3,4%1"10B8149,G&!D=,8(SA"4E56DI2AL=06
M%U=B9W)U=H*%DY:FLK.TM>3P)#,W<Z+!T=(E)R@T-39#14938W3"X29498.5
MHZ3#\41DQ#EFA.)'I>,IE__$ !P! 0 " P$! 0             ! @,$!08'
M"/_$ #T1 0 ! P$&! 0$!04  @,  P ! @,$$042%2$Q01,44E-187&!(C*1
MH0:QP='P(S,T0N$D\4-B<A9C@O_:  P# 0 "$0,1 #\ ]4P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRX]L>VY^L6I_N6G^7'DLCT2CBV%[D)7 BC[8]MS]8M3_ '+3_+E4\H[MRO\
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MLFHON>G^7'DK_IDXO@^Y"3@(R?-]:$^LVHON>#Y<?-]:$^LVHON>#Y<>2O\
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MF[-$?6>__N$'RP\G?],G&,'W820^$?"1O^;KT3]9K_\ <\'RQ3YNO1'UGO\
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MC!\L/)W_ $R<9P/=A(8$>?FV-&_6F]_N4'RQ3YMG1OUHOG[C!\L/)W_3)QG
M]V$AP1Y^;8T=]:+Y^XP?+#YMC1OUIO?[C!\L/)W_ $R<:P/=A(5%]\J:'I^F
M1H6;"/BND&4RO'3-7A]_A>OWCO[5TH=NKIPM]G?-)%^EJ::5F/V7#P_?*3BW
MJ>M,LM&UL&N=*;M/ZMLIS0IV'2V+6%FU+"LMIN=)<8T[74L[9,>_A>1W"29;
MG'+WS6FF:9TF-'1HN47(UHG6'T!;Q#B#*N
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M'/HN!3*%0D
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M&3/.K2/A'1<WQ[RO_P"'J*-[ =+2'&UUYR>KN+RPO)5  %EX "H&]H#>T"X
M   !<WO*_P!NTHWO*@/[=I<WL4M+F]BA$J@ (A<  @+RPO %6=J\RA5O>!<
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M<L:Y1?5CM147DJ+S14.X1>TX,Q-,Z2^BT54UTQ53.L2N !#(
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M(7-[%*E&]BE0@#>T!O:5[BX $R!<WO+2YO>51*H !"YO8I4HWL4J$2%Q:7!
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M=:9_;_Q.UO>55,GSCE21B.;S14RBY[3Z<2'E7UZ)UC6%0 %@
M !15P6ND1B9=R Z#6>M+/H'3%QU!J"MBMUJH8EFGJ)EPC43L1/%RKA$:G-55
M$3*GD3TH.E'?ND/J=ZN=+;=)T<KO8ZU<6$\$EEQ[J54^T1<)WJN8=.3I0OWI
MUD[35@JG+HRQS*D;F.]&NJ$RUTR^+47+6>K+OIL)%]$1.X]GLO BU3XUR/Q3
M^W_KY[M?:<WJYL6I_#'[G_G]\ 'H9^#RGS"K>\H5;WD(E4 !5<WO*E&]Y4)@
M+F]BEI<WL4$J@ ("XM+@   %6]Y0JWO N  %6]Y<6M[RX*R%6]Y0JWO!V5
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M( N+2X2!5O>4*M[QV%P (%6]Y<6M[RX   B5S>P!O8 D !,*!>6%XD  (%X
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MQZM8Z2^U; VQ&T;7AW/ST]?G\W?@ YKU@
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M  *KP !5O>7%K>\N([@ "42N !$'8 !*%X  JWO+BUO>7$=P*M[RA5O>3(J
M"(%S>\J4;WXYE14!>6%Y    7%I<61  "J)"K>\H5;WEI0N !$)T5;WEQ:WO
M+A* N;V%I<WL([   +P %87-[%*E&]BE0@#>T!O:!<  !<WO+2YO>$2J5;WE
M"K>\)7  *JM[RI1O>5   K(O !8"K>\H5;WE!< "ZLA<WL+2YO81W.P "4+F
M]Y4HWO*E>XJWO+BUO>7"0 ! N   JWO*%6]X1*X  A>  JJWO*E&]Y4 7-[R
MTN;WD2*@ 0+F]BE2C>Q2I4  6E$A<6EQ$$  (0N;WE2C>\J +RPO %S>PM+F
M]A/9$@ (.R\ !4*M[RA5O>!<  !<6EP JWO*%6]X%P "BK>\N+6]Y<    N;
M[E/5W=Q:7-[!\I3')-7HI[F.U=H^2RUTW'<[1PQY<OI20+[AR^*IA6^\C?$W
MJS"9P>=^R>MGZ#W&M-QZSJZ265*6JRJX6%[D157WEP[WVH>A\;N)$7)XS/L>
M#=UCI+[=_#>T)S</=KG\5/*?Z/J #FO6             "S!%3R@6_<FU.UJ
M:=M-3U6HM3]93,<Q</@I43Y](G@JHY&(OYYRIS:2J=R0\8.E[NN_=[??4=SC
MFZVU4,OL7;\+EO40N<WB3U.?QOS^?.MLS'C(OQ-72GFX.V,N<;'F*>M7)IA%
MP7%A>>^CET?,=?@  2@*M[RA5O>0B50 %5S>\J4;WE0F N;V*6ES>Q02J  @
M+BTN    5;WE"K>\"X  5;WEQ:WO+@K(5;WE"K>\'94 !"YO>5*-[RH O+"\
M   +@    1*K>\N+6]Y<#L  (7-[%*E&]BE0*M[RI1O>5 %Y87A60N;V*6ES
M>Q0GLJ ")5"XM+B(  $"K>\N+6]Y<%>X5;WE"K>\)E< "ZJYO8 WL!0"\L+R
M9  "!> " #>T!O:!<  !<WO+2YO>$2J5;WE"K>\'9<  @+BTN*P  $@7EA>0
M!5O>4*M[P+@ %%6]Y4HWO*@"YO>6ES>\"H  N;V*5*-[%*@  $2N  )"YO>6
MES>\*J@ "\ " *M[RA5O>)1W5  1(7-[RTN;W@5  %X (@"XM+A(%6]Y0JWO
M'87  @5;WEQ:W'/GS\/A+@  ")7-[ &]@"0 $PH%Y87B0  @7@ @&]I<6M[2
MX: 7-[RTN;WA$_)4JWO*%6]X.RX !4+BTN   "K>\N+6]Y<$=PO+"\$@ (E"
MX $@7-[RTN;WE>XJ "9 O+"\B  !915O>5*-[RO=GN\2(3(5;WE"K>\2A< !
M O !4"K>\H5;W@5   O+"\(D+F]BEI<WL4'94 !5<  *M[RXM;WEQ'<"K>\H
M5;WB1< "(  "595;WE2C>\J.R>P "$+P !<WL4J4;V*5 JWO*E&]Y4F5>X7-
M[RTN;WD$J@ ("\L+P   N;V -[ $=PO+"\$@ "J\    !5O>2%Z(^YKK+J&7
M2M=-_<-R7K*57+RCJ$;S;ZN)J?&U,=I'IO><FW5U1:Z^GK:65T-53R-EBE;V
ML>BHJ*GPH:V19B_;JHET]G9E6%DT7J.W7Z?!ZAE6I@QO;S546M=&VB]Q<.*R
MG9(Y&_2OQAZ? Y%3X#),H>%FF:9FF7Z#M7*;M$5T])YK@ 590
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MNFCQ9U18I-+ZFN]FEE;/+;JR6C?*Q,->L;W-5R>KE]\ZQO>99NXO^VMK5?\
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MO8I4HWL4J5  %I1(7%I<1!  "$+F]Y4HWO*@"\L+P!<WL+2YO83V1( "#LO
M 5"K>\H5;W@7   7%I< *M[RA5O>!<  HJWO+BUO>7    +F]A:7-[ !Z([)
M:H75NV&G;B^5TTRTK89I'+E721_.WJOK5S57X3SN)D]#*Z^=[?72A>[B=27!
MW"WZECF,5/OHY3B[5M[UJ*X[/<_PC?FWF3:UY51_+FD*@ /*/L0
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MG1CG&L.'-,T3I*X "%5X *@5;WE"K>\"H  %Y87A$A<WL4M+F]B@[*@ *K@
M!5O>7%K>\N([@5;WE"K>\2+@ 1   2K*K>\J4;WE1V3V  0A>  +F]BE2C>Q
M2H%6]Y4HWO*DRKW"YO>6ES>\@E4 ! 7EA>   %S>P!O8 CN%Y87@D  57@
M  *M[RI1O>5 E]T,-3K6Z1N]CD?QOH*ELT:*O9'*WL3]DQZ_LB1K2%70[NZT
M6Y=91J[ACJZ"3#?%[7L<GWN,FHG+)XK/M[F1.G27W/\ AR_-_9]&LZS3R?0
M'/>H                                        6N[4/(?RAM7YQTI-
M21]OF]+11>]_<['?^(]=W>Z0\B?*&TOF_2EU+)V=?2T4OOXIV-_\/WCN;%_Y
M,_2?Z/,?Q!_Q(_\ ZC^J-I5O>4*M[SW'=\Y7  F0 !47-[ &]@"@7EA>   3
M*\ ! &]H#>T"X    !<WO*E&]Y4 7-[%+2YO8H1*H "(7  ("\L+P!5O>4*M
M[P+@ !5O>5*-[RH   D+F]Y:7-[PB%0 $!>6%X N+2X 5;WE"K>\(E<  0O
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MC9&*O)414S\:$ZNDW$UNPFNL(G*US=WJ/-SHS?X>M"=Z^RD7->WM/2?I-_X
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MCH\G5&[.BX &1CD+F]A:7-[".YV  2A<WO*E&]Y4KW%6]Y<6M[RX2  (%P
M%6]Y0JWO")7  $+P %56]Y4HWO*@"YO>6ES>\B14 "!<WL4J4;V*5*@ "THD
M+BTN(@@ !"%S>\J4;WE0!>6%X N;V%I<WL)[(D !!V7@ *A5O>4*M[P+@  +
MBTN %6]Y0JWO N  45;WEQ:WO+@   %S>PM+F]@ E-T()E<W6$6>35I'?&DR
M?YB+)*CH0P\,6KYOJW4K?B25?_$<W:'_ !ZOM_-ZG^&M>)T??^4I3  \8^Y
M            " _E7*SAL&W=+W2U5;+]JR)/_&>=AZ)^5;I..P[=U..4=36Q
MY_3,B7_P*>=A[[9/_%I^_P#-\PVWKYRO[?T"\L+SK0X( !(%6]Y0JWO(1*H
M"JYO>5*-[RH3 7-[%+2YO8H)5  0%Q:7    *M[RA5O>!<  *M[RXM;WEP5D
M*M[RA5O>#LJ  A<WO*E&]Y4 7EA>   %P    (E5O>7%K>\N!V  $+F]BE2C
M>Q2H%6]Y4HWO*@"\L+PK(7-[%+2YO8H3V5 !$JA<6EQ$ >P'1KWDMN\FUUJN
M4%0U]VIH64USIE5..&H:G"Y53ZEV%<U>]%\45$\?S)- ;A:FVWOC;KI:[5-H
MN#4PYU,Y%;(U,*K7L7+7HF,X<B]G8<G/Q8R;<<])AW-D9\X-R9F-:9ZO1S=?
MH%Z"W%N=;=[;/5Z6NM4]TTRT6'T[Y%7+GK$[L55^H<U/AYD=]4^3WW+T34>R
M6D+W1WN6G=QPOI9G4-6CD3DK45>%%_9G:Z!\I3J*WQ14^K-,T=Y1$PZJMTRT
MTOZ96*CFN7U)PH23VHZ:&V^ZUSIK335U19+S4N2.&BNT21]8_P"I:]JN8JYY
M(BJBJJHB)GD<37/Q*?Q1K3^L/4TT;)SYUIG=JG[<_P"3S<UU>MR=/W&HL6KK
MMJ2DJVM5LE#=*N?*L7ER1SN;7<^:91>Y5-U= S=K2.U>H-65.K+U%:(*RFIV
M0/EC>]'N:YZKC@:N.2IVDUNDEL7;-Z]NJ^WRTL:WRFB?-:ZQ$1LD4Z-54:KO
MJ'JB(Y.Q>2XRB*GD,SW2]N>]?C_T'1L7:,^Q51,:3\G$RK-W96737KO1VU_J
M]TT<BLSG+<=Q![IG](3;O<O9QUETSJ2GNER]D:>;S>.&5B\"<>5RYB)WIWDX
M$1&T^$]SPGA?ZN[P.3LS'B[<JKF?RZ2]#MS+KLVJ;<1'XXF)_;I^J:'0DZ*-
MLUE;&:^UC2-N%N=(YMMM4[46&;A7A=+*U4])J.1S4:O)>%57/+,I-Q^DCMGL
ME5PV2\W2.FKFL16VZWT[I7PL7&.)&)AF45%1%PJIS1%,RVHL$&F=M-*VJF3A
MCH[930HJ]JXB:BJOK5>:^M2(VXW0"U7K_7NH=23:SMR/NM?+5)')!*Y8V.<J
MLCSGFC6\+4]340I-VG*OU57Z]*62+%S Q*(Q+<55SU2*K['MCTJ] )5)'1ZB
MMDB.BBK8F\-31R(G-$=CCC>F47A7MRF45%/,K?#::NV7W$N6F*V19XX<2TE5
MPXZ^G>OH/7U\G(O@K7)ZST(Z*/1OOW1\DU%%<M0TUWH;FD+V0T['L2*2/B17
M8=RYM<B+^E;X)C3?E,;!"R?0UZ8Q$F>VJI)7X[6IU;V(J^^Y_P :FW@WO!R9
MM6ZM:)Z.?M7&C(PHR+E&[73U_DQ?H-=&BT;COK-9ZJI$KK30S^;45MJ&(L-1
M(C4<]\C5]TU.)OH]BNSG*)@EMN5TC]M=CJJFL=YKDI*Q(D?';K?2K(L<:KA%
M5&IPL3U*J+WXQS/,O:#2VX.K-0)1;?,NWLBQ..22VU#J9L*97TG2<36L1<+V
MJF5Y=O(DK;?)\Z]UK<GW;7.NJ5E?.C5FG;UMPJ'\+4:B.>]6<^%J-SE<83M,
MV7:MS>WK]WE\.\?S:NSLB]3C11BV=:N\ST2XV_W0T+O]IZMDL<T%[H8W)#5T
ME73JUT;E3*(^-Z=BX7FB*BX7"KA<0'Z;>QMHV@U_;JO3].E%9;Y ^9E(WFR&
M:-S4D:Q%[&X<Q<=W$J)A,(DV^CUT;;!T?XKLEJNM=<ZNYMB2IDK',1N(^/AX
M&-:F$]-W:JD>O*<I\\VX7/=<O_U4T\&Y%O+BBW,[L_V=/:EGQ=FS=OTQOQ\/
MJUGT+>C92;QWJMU!J.)TNF;3*V-*555$K)\<7 Y?J6MX5<B+SXFIV9)YZVW&
MT-L-IBE=>JRCT];.<-'24T/-^/I8XHVYY93L3"93.,F ]!6T0VSHVZ=F8WAE
MK9JJHE];NO>Q/\EC4(?]/;4M3>ND+<;?+*Y8+31TU-"Q>36H^-)G*GCE9>W\
MZB=R&2JFK/S*K=4Z4Q_1@MS1LG9U-ZBG6JK3]TO;5J+9WI55M'/;JF&?4=EG
MAKJ>185IZ^#JY$<F%<F7QJJ(CD15:G$F<+PJ;5W<_P %>LT3L2S5G\@\\I>C
MWJ*ITOO=HBMI9W4ZK=J:GE<WZ:*1[8Y&KXY8YR8/5K=Q<[4:RQ]9JS^0>:N;
MC^6O4T1.M/;5O;,S?.X]RN:8BJ.NG?DA?Y.3<=*345_T/5RYAKHTN-$URX1)
M68;*U/6YO"[WHE,_\HOM_P"R^@+)JVGBS/9:I:>=R)_R,V$157U2-8B?IU(/
M;5ZYJ-M-P]/ZFIN+CMM6R:1C%YOBSPR,_9,5R+^F4]:MPM-4.[6U-XM$,L4]
M)>K<[S:?M8JN9Q12)ZD=P.^ W<N)Q<JB]'2?_IS-GS3FX%W%GK'_ -Q^[QZL
MUIJ;]=Z&V44?75E;.RGAC3Z9[W<+4^-4^,]CK#:;5M7MQ1T;Y&PVNP6QK))W
M)CYW#'Z3U]>&JJGG=T)-LYM1](*G?7TSF0Z:9+65,<K?<S,7JXVKX.21W%_[
MM2573TW(_(7LQ)9Z>7JZ_44Z434:OI) WTI5]Y41K%_QA?:%<Y%^BQ3_ )JI
ML>W&'B7LJO[?;_UYW[@:OJ=?ZUOFHZOBZZY5<E2K7<^!JN7@9[S6\+4]2(8_
MR\3-]D=#T&Y.ZFG=,W*:HIZ&Y3+%))2.:V5C>![D5KG-<GTO@I.!/)P[<JG_
M  [JC/\ WJF_%SK7LVSAZ6JH>=Q=FY.T8JO6_CSU>="=R]QZ.]#WHU6#2V@K
M/K&]6^"XZDNL#*V*6I8DC:2)R(Z-&(O)'*SA57=J*JHF$3GJ_I"]"W16T^T-
M^U99[K?JJXT"TZ1Q5D\#XG=941Q.XD;"UW8]>],*F>XW[T0]X[-N+M18[5%5
M11WRR4<=#64+WXDQ&U&-E1%YJUS41<]RJJ=QR,W+G(L159Z:Z2[VRMGQAYDV
M\G3>TUI_SXNKU'T[=KM.WJJMO67.XOIGNB?/1T68U<BJBHU7N:KN:=J)A>[)
ML*BJ-ONDGH!*A(J/45BJD<SY]%PR028PY.:<4<C?%,+S147"H8ON'T-=L-P:
MRJKYK3+:+C4N626KM,W4J]RKE7*Q46/*JJJJ\.5[\FB-=^3]U+:[/4P:+UF^
MOH7/=-[$7'B@:YV$3/&Q58YRHB)Z34SCFOAS:(QZM-VN::G;N59]N:O$M4UT
M3\/_ %H75&C*'97I&V^VNN;*NR6V[TE5'7\:2+YOUK'*K^#Z9B(YJX1.;5Y8
M/3O;[</3NY=C?==-7&.Z4$<SJ=\T;'-1)$:U5;AR(O8YOQGCUJ33=STE?:RS
M7JAEM]SI'K'/33HG$UV$\.2HJ8PO>BYYIS7T*\G8G%LG=$[$]FY_Y& Z>TK/
M^A1<FK68<385_=R[EF*=(G6=/@V_N!OOH';>[MM&J-006NOD@;4,@DAE>JQJ
MKFH[+6JG:UWQ'F/M=MS+O'N]2:=I)714];522SU4;><5.U5>]_9A%X4PGBJI
MXFWO*()_MX6W]0J?^7J"--L;5.N%.R@ZYU:]_# VGSUCGJN$1B-YYSX=Z^LV
M<#'\.Q-RFK2:H_1I;7S9NY<6JZ8W:)[=9Z<GK326[;OHU:#?4=51Z<LM.C&2
MU",XIJAW8WB5J*^5Z_"N,]R'0Z Z7&V>XFH8+#;;O+#<ZEW!3QUM(^))G8SA
MKE3&5[D545>Q,J17TYT2=[-SK'24^J+]+;;.US)X:*^5\M2^-4141S845R-7
MA54PY6KSQRYFX=K>@+8=#:CM%]O&J:RZU]MJXJR".EA930I*Q[7-1457JJ<2
M)V*BKZDY'(KM8]--7B7)JK^3T5C(S;E5$6;,4T?-V?3)V!T]J;;J\ZOHJ"&@
MU):(5JW5-.Q&+41-RLC9$3D[T<N153/HX[%5#770)W4TII/3=;IN[7>*CO5T
MO+4HJ1T;U6971Q,3A5&X3+N7-4)2=(!/]H_7_P"H5;_(//,'8/EO9H-?_;E'
M[_\ ?V]YL8E,Y&)<HJGIS:6T-W"VC:N6J8UJY3^O5ZUWV]4.G;-776Y3MIK?
M10.J*B=R*J1QM17.<J)SY(BD#>G#O'HW=&V:3CTK>X;J^CFJ'5#8HY&<".;'
MPYXFI]2O83&W^RFQNOOU"K?Y!YY.Z.M++]JNRVR3BX*RMAIGX7"\+Y&M7'AV
MJ5V98BK6_KSIG^C+M_*JIBG%B(TKCG\>J<G1"Z*EHM6FJ#6FKK?#<;O7L;44
M5)5,1\=)"J(YCE8J861W)V5[/1PB+DVOK7I7[8;>Z@DL5RO:/K:=W5U#**G?
M.VG7FBM>YB*B.14PK4RJ=Z(;:F@>ENDBIE;'+U2MBRGHM7'+..[)!:I\G7JB
MLJ)9Y]:VZ>HD>KWR202N<YRJJJJJJYSE<]IKT5T95RJO(KT;MRS=P+%%O"MQ
M,]]?\[I)[A[/Z!Z1^CHZ]GFM0^JAXZ#4%"C5E8O/"\28XFHO)6.]:<EYIYCZ
MSTA<-!ZKNFGKK&D=?;YU@E1ON7>#F^+53"HO@J'IUT:MF[OLCH>KT]=+Q#=V
M/KGU4#X6N:D37-:BL1'+R3B:KN7>Y>]<D0?* 66&W;U4E9$QK5N%IAEE<WDK
MI&R2QY7UHUK$^ W=FWIIOS9BK6GLY.V\2+F)3DS3NU]T:0 >I?/7IQT((VOZ
M.]B54S_=%7_.'G-OVD=M-H-5:@W+U?5TD5SNE2WJ:FLC61T#4C8Q(X(T1RN=
MZ'$KFM5>:]R'#Z#J_P"YVL7_ 'BK_EWD6>GKJBJN^]2VJ65WF=IH8HXH5]PC
MI$ZQ[D]:Y8B_I$/&46JK^97;BK2)F=7U"[?MX>S+5Z:(JJB(TU^.B;6W>^&@
MMW_.:33=Y@N%1$S,U%+"^*5&JN%7@>U%<WQ5,IS[2,O3,Z,EIL=DEUYI*BCM
M[89$]E*"G:C8>%R\*31M3W*HY4XD3DN<\E1>*,>RFI:K2&[.DKK1RNA?%<86
M.X4SQ1O>C)&JG@YCG)\*GJEN=:(M0;<:HH)4S'56NHB7]E$Y,F2[;JV=D4[L
MZQ+#CWJ-MX5R+M$173_D3" '017&_E)_W"I_ A//=?;VQ;CZ62VZDD5EEAJ(
MZVJ3K.K:]L678<_Z5O+TE\$5,IG) WH(?X?:7_N%3^!"6736O51:.C]?VT\B
MQNK):>D<YJ\^!TK5<GPHBM7U*HSZ:J\RFFF=-=/YHV-53:V9<JKC6(F>7V?#
M3/2FV6L]PIM+V>ZT]OI&.2"!\-"^*C1V<81W"B(F?IE]'OSCF9OO)LQ8-XM*
M5=!<*2G6MZE_F5PX$ZRGD5/1<CNWASC+>Q4/)G^W]OPGKYM#/)5;4:/GE>KY
M9+/1O<YRJJJJP,55*YF-Y.:+E%4ZRR;*SHVI1<LWJ(TCX?!Y(5%GK*:\2VIT
M#EN+*A:5:=B<3EE1RM5B(G:N4[CTSV&Z/^F-DM)PUM7#1SW]L'75]XJ&M5T3
MN'+VL>ON(V\_#*)E3SNWA1&;LZW1$1K?9NN1,<N7G#^PVCM+LKO3N/IV1EJN
M5PL^F*V)6*ZY7&:&FJ(W-PN(DXE>U47MX,+XG6S*9NVJ9FYNQW^;S6RJXQLF
MY33:FNJ.B62]-;:=EU6B6]U' DG!YVE#*L.<X[>'BQGU?>,XW*VGTGO5I9U/
M<:2GJDGAXZ2YPM198E5OH21O3M3FBXSA>\C=I?R=<+'QOU'K"21JIA]/:Z9&
M8]Z217?Q/]!+K2NGJ72>EK79:!\CZ*WTD5) Z14<Y8V,1K<JB)E<(G/"'G[W
M@VIIG'JG5[;$\SDTUT9MN(AX_7RSS6&^7&U3^E44=3)2OX>]S'*U<?"AZ5;$
M[!:9V1T7#<*ZE@EO[:?SBXW2=J/6%4:JO9&JYX6-YIRYJB97)Y[;O/=%N]K9
M[%X7MOM:Y')VHOG+U/379[=:Q[R:(I;G0RQ22R1-CKZ%5174\N,/8YJ\\9SA
M>Q4YG6VE<N56J)C\O=YC8%K'\S=B=)JCE&OW:VGZ=NUT5>M.UUUFCX^!*AM#
MZ#D^J1%<CL?L<^HS_56CM ](+03)ZEM+=+764ZR4ETA1&RPHOTS'JF6JBIS1
M>]%1R=J&':TZ$>V6J9)9J2AJM/5$F55UJGX6?N;T<U$]340T=N3T&=96BSJS
M3.I5U-;Z9'.CM-4JP/:BJKE1B*Y8W+E57Z7M\5.=1&-5,3;KFFKYN[>JS[=-
M47[--=/R1EUCII^D-4W6S/FCJEH:A\"5$+D5DS47T7IA5Y.;AR>^35Z)?1:M
M%JTW0ZRU9;XKA>*YK9Z.DJ8T='2Q*B.8Y6+R61W)V5[/1PB+DA9I[3\E;K:V
M6.MADIYIKA%1SPR)PO8JR(Q47P7.4QXIX'K[-%(EODBI5;%,D:MC54]%'8Y9
M1.[)TMI7Z[=%%JF>O6?BX/\ #^%:O7KE^NG\O2/AJU3K3I3;9Z U ^QW*](Z
MN@=U<[*.G?,V!W-%:YS4QE,85$RJ=Z(?7<#:70?2(T@RO8M-4/JH>LH+_0HW
MK6>"HY,<347DK'>M.2\TCE/Y/;4]342SSZQH)II'*]\LD,JN>Y55555SE5RN
M21O1PV?NNS.C*JP7.\Q7=CJQU3 ^%'-;$US6HK415Y)Q-5W+O<OBJKR[D6;-
M,5V;DS5#T6/.3DW*[659B*)Z/-/6.D;AH75%SL%TC2.OM\RPR(WW+O!S?%%3
M"IZE0Z=O>21Z>UFAMN\])50L:U:^U0RRN3DKI&ODCXE_8M8GP$;F]YZW$N3>
MM4W)?,<^Q&-DW+4=(E<3MZ$.GH-';-ZAUI5Q-:ZLEED23LS3T[53M_3];\1!
M(]"=.1^P707E1B\*OTY4NRWQE215_CJ:&TJI\.FW\9=G8%,>-<NS_P!:9F$!
M+Q=JB_WBON=6[CJZV>2IE=XO>Y7.7XU4^5#1SW*K@I*2%]155$C8HH8TR][E
M7"-1/%5[$..WO)A]#39>GM-NGW2U+#BEIXI)+9"YBO5K6HJ/J.%,JJX16L3M
M]TN,JTW+]^G%LZS\.3FXF)7GY.Y$\IYS/R^+**>"W=#+8ITLC8:G7=[1$PG-
M'5'#R3UQPHN5^J7/9Q\OIT"+C57;36M:ZMJ)*JLJ+FV:6:5<ND>YF5<J^*JN
M2->^.IM8;RZ\JKW4V&[0T+/G%!1NI),00(O)%PGNG<W*O?V=B(B27Z MGN%G
MT?JIE?15%$]]=&K6U$3HU<G5]J(J<SA7J(IQIKJG6NK35Z_#O3<SZ;5NG2W1
M$Q'Z=?JACN%_Q^U/^J=5_*N)&>3UM<<VN]45[FJLE/;HX6NSR1'R97X56-/B
M-"[DZ9O%+K+5%7-::Z&D2Y5+EJ)*9[8\+*["\2IC'9S]9(CR=\R,O^LX5]V^
MEIG^OD^1/_$=++JUPYF)[.'LVW-.U*8KCO,_S:AZ65Q=<ND#J^15RD<L4#>?
M8C((V_A3[ZFI.7AS-F])J%T._&M&O:K5\^XDSZV-5/C-8F]B1'@TQ\H<3:$S
M.9<F>N]/\WH%H=ZZKZ#,Z5*J]8[%7,;GM18'2HSXNK:0 )_;.R+;^@]422(J
M*VSW:1$=WIUE0Y/O8(Q[%]&NX[X6JYUM#>:6UI13-A<RHB<]7*K>+/)>1R<.
MY39JNU53I$5/2[3Q[F53CTVXUKFF&G02Q3R>FH5_Z5V[[FD_TFD=[=FJO934
MM)9JZXP7*6II$JTD@8K$1%>]N,+^D53I6LRS>JW**M9<&_LK*Q:?$O4Z4IN[
M>;>W"KZ*%KTO;9XJ.MNMG_OM0B\,:5*J^151.>4;*[EXIW&N[5T.]J;5,RW7
MO6L]3>,8DA2O@I_2\6Q*BN3X54TC=NEUK^Z:,_(U'+0VRFZID"5=OADBJ4C;
MA.!KN-43*)CL1?6:5<YSW<3G*YRKE7*N54YEK"R:9JG?W=9[._D;6PIIMQ%K
M?FF(CG\DK=W.@U46"VSW70]PJ+NR%JR/M=7P^<.:G:L;FHB/7\[A,]RJN$(J
MHCHI%]TQ[5\,*B^HF)T$]VKI<J^YZ'N=5)6TL-+YY0.GD5RPHUS6/B3/TOI(
MJ)]+PN[<FH.EWHVFT=O9=64D:14URCCN+8VIA&NDRDBI[[V.7X?49\2]=IO3
MC7IUGXM7:.)CW,6G/Q8W8F><?"6K[EK"_7JWQT-QO=RKZ*-Z2LIZJKDDC:]$
M5$<C57&<*O/U^^=4Q.SU_P#G_H+>W\">LE?T;.B4^Z>;:LUY3K2VIJ)/2VB?
MT73]_',GTK.2+PKS=CGZ/)V]>O6\6B9EQ<7#O[1N[M//IK,]H^K-^A#MC4Z1
MTQ=-9WAGF?LI&UE*V;T5;3,57+*JKV(Y<8SW-1>Q4(J[VZU@W#W7U+J"EYTM
M34\,#N]T<:)$QWPM8BF\>E#THX+_ $U3HG1<W#9VHL%;<8O12HPO]YB_.<L*
MOTR(J(BMYNBLW^W^8TL*S7575DW.4U=/E#J[6R;5NQ1@8\ZTT3SGXRN,EVSU
M<[0FO;!?VN<C*&K9+*B)[J-5X9$3WV*Y/A,:">.?#[QU:Z8JHFF7F[-?A7(K
MCK":G3STG'7Z2TSJBF:UZTM0ZDD>Q$7,<K.)JY\$='C]FI%;:S2BZYW#TY8>
M%7QUU;%'*C>WJD5'2+\#$<OP$PK%+^77T,ZBD7Y_<**WNIW-[7==2JCH^?BY
MK&?;FH^@OI-;QN=7WN1F8;-1.5KOJ9I55C?\CK3@X]Z;6/<HJGG3K_X]IF8M
M.3GV;E,?AKB)_3JE3TA]),UALOJJWP,:^H@IO.6-9[KCB5)4:GK5&X_9'F.>
MA&P^Z#==;I;L6B:1LM.VN;+2LSEKHV-\V>J>K$4:_LE(FZ.VH?5=(RFT5+&K
MX*6\/9*COIJ>)ZO<J^IS&<OTR%,"Y-F*[=SMS_9DVU9IS*K-VQ'69I_24EM9
M,39#H>T]LQU%SJZ)E%PKR5)JA5?,F?%K72X7\ZAH#HP[$-WCU+53W-TD>G+9
MPK5<"JUT[W<VQ(O<B\*\2ISQA$QQ93873TUGYU?]/:5A?Z%%"ZOJ&HN45\BJ
MR-%]:-:_X'FWNA?98[=L/25,&&S7&JJ:A[G<TXD>L2+V]F(D,<7*[.+-R.M<
MLWE[6;M2FQ,:TVZ>GQF/_6/;A])S1^QE4[26D=-PU]11+U<\5,YM/34[\>Y5
M4:JO?V(O+MY<6<H6;?=*'2&]M6S2.L--P4+ZY4BIVU#DJ*:>15PC<JU%8Y57
MEV\^647"+B55T";E654]1/KF"2>9[GR/=;W*KG.7*KGK,]O]O%3= BXTL[)8
M=<01RL5'-<V@<BM5.Q47K,^'Q%=W$W/S?B^/-EWMJ^-^2/#Z;O+31J_I-;%,
MV=U3!+;.LDT[<D<^DZQ>)T#F\W0JO>B<2<*KSQR7/#E;NC%L2W>'4M3/<UDC
MT[;.%:I(UX73O=S;$B]R+PKQ*G/&$3'%E)+]-6TMK]D7U$O"^:WUM/.CF\D1
MRYC54_=/[8.3T+[+';MBZ6I@PV:XU-34/5>:<2/6)%][$2&7SE?D]?\ MKIJ
MU8V19G:VYI^'3>T_I^K']P>DSI#8RJ=I'26FXJ^HHEZNHBIG-IZ:!^/<JY&N
M5[^Q%Y=O+BSE#Y;?=*#2.]E6S2.L--T]#)7*D4#:AR5%-/(O)&>DU%8Y57"=
MO/EE%PBXI5= NY5=3-//KBGDGF>Y\CW4#E5SG+E5_OF>TI3= JXTT[)H=<4\
M<T:HYKFT#D5%3L5%ZS/A\1BW<3<_/^+X\VSO[6\;_;CP^F[RZ-8=)G8ENSVJ
M();;QR:=N7$^EXUXG0.;S=$J]Z)Q)PJO/')<\.5S7H%)G<:__J5_]UAN+II6
MEMPV0=43*U\]OK:>9'-Y8<N8U5/W3^V#3O0)7&XU_P"[_8K_ .[&98N3=P*I
MJZPTHQ:,7;=%-OE35ST^TL)Z2]KK+WTCM1T%!325==4STT<,$2<3I'+31<D3
MQ)!;;[<Z8Z+>@YM6ZQEC?J&9B,<K</<URIE*>!.]RXYKWX7GPH;5MFVNFM/[
MG775M1+%-J.^2-93+4.1'1L9"UKHXD5>:JV-7*J<\>"(I$/IF4>JJ/=#COE2
M^JLLT?':>!%;%''A$>S&?=H['$O:Y%:O+*-3%;O3E[F/$Z4Q'ZMS(Q:=F1=S
MZJ=^N9F(^$:]Y:^W>WAO.[VHG5UP?YO0PJK:.WQKF*!OQ>DY>67+S7U)A$E+
MMEI'2O1VV7@UY>K?Y_>JBGBJ))E8CI&++CJX8^+DQ$XDXE3M5%5<X1$@\3NV
M9W.T9O9M51Z'U)-"VY1TT=%44%1*L;JCJ\<$D;L\U]%'81<HJ+W85=S.MS;M
MT4TQ^'7GI\''V)=B_?NW+LQXDQ^&9Z:L&CZ?%0M8G6:+A;2\6'-2O7K$15\5
MCQGX#,]V=":2WXV?GUS8:2.FN[*62MAJ6,2.618\J^&5$]TOHN;GN<B*B\/;
MT.J^@9;YTDETUJ6>E7"JVGN$396JN>SC9PJB>^U30^Y>PFOMLK;QW>D=5V.)
MV?.Z&99J:-?%6\E9[ZM1%5>U36HHQKE5,V*MV8;]^O:-FW73G6]^B8[:<OGK
M$-8M[S?'0QU(ZR[S4]#G$-UI9J5S<\N)K>M:OO\ SM4^$T.S'I>)GVPM8M#O
M)H^1KL*ZY11\E^K=PK_&.WDT178KB?@\CLVY-O-MU4]IAF/3!T>S2V\=9501
MI'37:%E<G#R;QKZ$GPJYG$OZ8TDWO):=/RE1M7HJI3W;XZQB_L>J5/XRD2V]
MYBP*IKQHF6?;=F+6?<IIZ:Z_KS7  Z$.&O !4"K>\H5;W@5   O+"\(D+F]B
MEI<WL4'94 !5<  *M[RXM;WEQ'<"K>\H5;WB1< "(  "595;WE2C>\J.R>P
M"$+P !<WL4J4;V*5 JWO*E&]Y4F5>X7-[RTN;WD$J@ ("\L+P   N;V -[ $
M=PO+"\$@ "J\    !5O>5*-[RH&U.B].L6]FGVY_OB5#/_D2+_F)\8($]%V%
M9=Z["[_JVU#E_<'I_G)[(>1VI_OQ]'V/^$-8P:HGU3_1< #D/<
M                              +5[%/+ORG^G?,-[;%=VMX8KC9F-5WU
M4D4LB*OVKHT/4//<0M\J!H+V9VHL&J88E?/9+CU,KT3W-/.W#E_=(X43],=/
M9ESP\FG7OR<3;%KQ<2K3MS>9)5O>4*M[SZ!W?+5P +2  *BYO8 WL 4"\L+P
M  "97@ ( WM ;V@7     +F]Y4HWO*@"YO8I:7-[%")5  1"X ! 7EA> *M[
MRA5O>!<  *M[RI1O>5   $A<WO+2YO>$0J  @+RPO %Q:7 "K>\H5;WA$K@
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MO:[B92Q?4HN$RY5YJ["97N1$1$V\:YE9.1OS^&CX.;G6=GXF+X5,Q7<^,?\
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MV*5*-[%*E0 !:42%Q:7$00  A"YO>5*-[RH O+"\ 7-["TN;V$]D2  @[+P
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M8 )ZP'/X/#N]\N;V*6ES>\JB>FDJ@ GZ$+F+R\/>*^^G?GU%&]BE2"0N3/\
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M3I^T.H7F7,Y<6/'^WPX+2YO>=EY;\2H 'U0O':JK\  CX:GS&X1,?"A5GWO
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MH.RH "JX  5;WEQ:WO+B.X%6]Y0JWO$BX $0  $JRJWO*E&]Y4=D]@ $(7@
M"YO8I4HWL4J!5O>5*-[RI,J]PN;WEI<WO()5  0%Y87@  !<WL ;V ([A>6%
MX)  %5X    "K>\Y%!13W.NIZ.EC=-4U$C8HHVIS>YRX:B>^JI\9QV]Y('HD
M[9NOVIGZIK(>*WVQ>&GXNR2H5.U/%&M7/ON;CL4U\B[%BW57+I;.PZ\W)ILT
M=YY_*$I]N]*Q:)T;:;)%A4I*=L;W)],_&7N^%RJOPF2)R4=B!O,\)5.].]+]
M"6K<6J(HIZ1R7@("K*
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MD(E4 !*\ $PH%Q:7"0*M[RA5O>.PN ! JWO+BUO>7   !5O>5*-[RH   7@
M(A<WL4J4;V*5" -[0&]I7N+@ 3(%S>\M+F]Y5$J@ $+F]BE2C>Q2H1(7%I<$
M   O   O+"\   B56]Y4HWO*@[  "J\  5;WEQ:WO+B.X  E$K@ 1!V  2A>
M  *M[RXM;WEQ'<"K>\H5;WDR*@ B!<WO*E&]Y4B0+RPO    7%I<61  "J)"
MK>\H5;WEI0N !$"K>\N+6]Y<1(%S>PM+F]@[   +P %87-[%*E&]BE0@#>T!
MO:!<  !<WO+2YO>$2J5;WE"K>\'9<  A5O>5*-[RH  %9%X + 5;WE"K>\H+
M@ 75D+F]A:7-[".YV  2A<WO*E&]Y4KW%6]Y<6M[RX2  (%P  %6]Y0JWO")
M7  $+P %56]Y4HWO*@"YO>6ES>\B14 "!<WL4J4;V*5*@ "THD+BTN(@@ !"
M%S>\J4;WE0!>6%X N;V%I<WL)[(D !!V7@ *A5O>4*M[P+@  +BTN %6]Y0J
MWO N  45;WEQ:WO+@   )_IY^\;=Z/&STFY6HTK:^)4T];WHZH<O+KW]J0I[
M^$XO5R^F13&]I=IKMNG?6TM(UU/;H7)YY7JB\,3?J4\7+W)\*X3F3WT?I*VZ
M)L5+:+5 VGHZ9O"UJ)S<O>YR][E7*JIQ<[-BU3-NB><_L]Q_#VQ*LNY&1?C\
M%/[_ /CN8HVQ,1C41&HF$:B<D0^B)R4JB9[QPKXGE'V&/PQI"X !8
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M+2YO>!4  7-[%*E&]BE0  ")7  $A<WO+2YO>%50 !> ! %6]Y0JWO$H[J@
M(D+F]Y:7-[P*@ "\ $0!<6EPD"K>\H5;WCL+@ 0*M[RXM;WEP  !$KF]@#>P
M!( "84"\L+Q(  0+P 0#>TN+6]I< +F]Y:7-[PB52K>\H5;W@[+@ %0N+2X
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M7O-D(F/6>.SLOS%>[3^6'VG8&QXV=:\2Y'^I5U^7R7@ YCUH
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M/@4? H%6]Y<6L]XN^!0K(5;WE/@4JWO!V5  0N;WE2C>\J +RPO   "X
M$2JWO+BUO>7 [  "%S>Q2I1B<E_\ROP@5;WE2C>\K\( O+/A+_[=@1(7-[%+
M?[=A<S^W('94#^W8/[=A$JA<6_V["_A][XA H"O#[WQ#A][XBH-[RXHSO_T%
MV/[8".ZA5O>,?VP59_;D"50/[=@_MV%H57-[ &]@*@7EA?\ V[RT@!_;L']N
MPB!>!_;L']NP@ WM']NPJWO J!S\!S\ !<WO+>?@7-SCL")5*M[RG/P*M[P=
MEP']NP?V[ @+BW^W87<_ K  KP^]\0X?>^(2*%Y;P^]\1<0!5O>4*L[5Y 7
M **M[RI1O]N1=A0*%S>\IA0S^W,"X%.+^V1Q?VR!>WL4J6L[%_TE?B^- *@I
M\7QH/B^- K,KP "9"YO>6ES/[=@0J!_;N']NX"\#^W:/[=H@"K>\I_;M*M_M
MS02KKS5  )"YO>6ES.S_ ,P*@?V[1_;M O Y>K[PY>K[Q$ 7%O+U?>/I_;N$
MBTJWO*_V[BC>\=A< "!5O>7%K>\N   (E<WL ;V )  3"@7EA>)  <O$0+P
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M6O7WW8ROPJ9 C43L1/B/IC)1$QZC7FJ:N=4ZNG;M46HTHIB(7@ JS
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MM;0_V37_ ..#Y,JGDU]$)_TFO_VT'R9+WA'".(9/KDX/A>W"(?M;.B/LFO\
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M:K]VO\U4MNSLW#LSK1:IC[1JM;&U$PF$]Y,%RH7(B%.$P?-T8B(Z+@ %@
M
M
M
M
M
M                                   "F"H
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                             %O%Z@+@4R5  MXO
M44X_5RS@"\%K'<29+@ *90HCO'D!<"WBY=A<
M
M
M
M
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M
M
M
M
M
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MZU5LKURY\D#N!KW+WJZ/JW*OBY0)"
M
M
M
M
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M/1U=)<X(_I4=,R1DB_\ R8@/2$
M
M
M
M
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MKM],SNXE2KBDQ\4:K\!A/DAK1)1=&N^U<D:L\^U/4R1N5/=1MIJ9G\9'@3D
M  X%SNU)9;?5W&X5<%#04<3IZFJJI6QQ0QM:KG/>]RHC6HB*JJO)$3)SS']<
M:0H]?:+U!I>Y2SPT%ZM]1;:B2D5&RLBFC=&Y6*J*B.1KEPJHJ9[E[ ,6^:7V
M@_-6T3^^.C^4*?-,;0?FJZ)_?'1_*$;O:D=H/LCUM]W4?XH:EZ5WD[]N=C-@
M]4:XL-[U167:U>:]3#<JJF? [K*J&%W$C*=CEPU[E3#DPJ(H'IDDF>[F7D?.
M@7J2[ZOZ*>AKQ?KO77N[5/GW75URJ7U$\O#7U#6\4CU5SL-:UJ97DB(A(,
M
M
M
M
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M?S.C)M
M
M
M
M
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M]POVO_I&F >3G^@WV^_;#^D:DDB1N\G/]!OM]^V'](U))$
M
M
M
M
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M#Z''4GZZZG^9T9-HA+Y)#Z''4GZZZG^9T9-H
M
M
M
M
M
M     6\/K+@    MX?67          1N\HO]!ON%^U_](TQ)$C=Y1?Z#?<+]
MK_Z1I@'DY_H-]OOVP_I&I)(D;O)S_0;[??MA_2-221
M
M
M
M
M                                                       &M>DO
M]#CNM^M2Z_S.4V4:UZ2_T..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3:(2^20^A
MQU)^NNI_F=&3:
M
M
M
M
M                                                          $;
MO*+_ $&^X7[7_P!(TQ)$C=Y1?Z#?<+]K_P"D:8!Y.?Z#?;[]L/Z1J22)&[R<
M_P!!OM]^V'](U))$
M
M
M
M
M                             :UZ2_T..ZWZU+K_ #.4V4:UZ2_T..ZW
MZU+K_,Y0(W^20^AQU)^NNI_F=&3:(2^20^AQU)^NNI_F=&3:
M
M
M                                       "GN2G$45Q3B)B%9E=Q#B+
M>(<1.B-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBW
MB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXA
MQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0
MT-5W$.(MXAQ#0U7<0XBWB'$-#5=Q#B+>(<0T-5W$.(MXAQ#0U7<0XBWB'$-#
M5=Q#B+>(<0T-5W$.(MXAQ#0U7M["I:Q<M+BJX
M
M                       !&[RB_P!!ON%^U_\ 2-,21(W>47^@WW"_:_\
MI&F >3G^@WV^_;#^D:DDB1N\G/\ 0;[??MA_2-221
M
M
M
M
M                                                      &M>DO]
M#CNM^M2Z_P SE-E&M>DO]#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG1DVB$ODD/H
M<=2?KKJ?YG1DV@
M
M
M     ^;_ '2EN4*O]TOO%A:&"J>:[*#*%H+:*ZKLH,H6@:&J[*#*%H&AJNR@
MRA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!
MH:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KL
MH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6@:&J[*#*%H&AJNR@RA:!H:KLH,H6
M@:&KZQ^Y^$N;V*61+Z*^^7M["C8CHJ "$@
M
M                 !&[RB_T&^X7[7_TC3$D2-WE%_H-]POVO_I&F >3G^@W
MV^_;#^D:DDB1N\G/]!OM]^V'](U))$
M
M
M
M
M                                           :UZ2_T..ZWZU+K_,Y
M391K7I+_ $..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3:(2^20^AQU)^NNI_F=&
M3:
M
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M^6%0 0N
M                                                   $;O*+_0;[
MA?M?_2-,21(W>47^@WW"_:_^D:8!Y.?Z#?;[]L/Z1J22)&[R<_T&^WW[8?TC
M4DD0
M
M
M
M
M                !K7I+_0X[K?K4NO\SE-E&M>DO]#CNM^M2Z_S.4"-_DD/
MH<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@
M
M
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M<*WNRQZ^O_,AR_I33J_-+MVOR0N !5E
M
M               "-WE%_H-]POVO_I&F)(D;O*+_ $&^X7[7_P!(TP#R<_T&
M^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
M
M
M
M
M                                           #6O27^AQW6_6I=?YG
M*;*-:])?Z''=;]:EU_F<H$;_ "2'T..I/UUU/\SHR;1"7R2'T..I/UUU/\SH
MR;0
M
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M_FF'J,>=;5,J@ HV0
M
M C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-, \G/]!OM]^V'](U))$C=Y
M.?Z#?;[]L/Z1J22(
M
M
M
M
M                             UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6
MI=?YG*!&_P DA]#CJ3]==3_,Z,FT0E\DA]#CJ3]==3_,Z,FT
M
M
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ME[S"G7'IGY+P 8FZ
M                                             %.("H*<7QE0 !3*
M 5!3B*@      C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-, \G/]!OM]
M^V'](U))$C=Y.?Z#?;[]L/Z1J22(
M
M
M
M
M                         %O$@XO4!<"SK$+P *<0R@%06\7/&"X
M &M>DO\ 0X[K?K4NO\SE-E&M>DO]#CNM^M2Z_P SE C?Y)#Z''4GZZZG^9T9
M-HA+Y)#Z''4GZZZG^9T9-H
M                         %O$!<   +>(N
M
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MH='_ .\YO\9_X4.^3_,><O?[M3Z;L_\ XM'T7  PNB
M
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MF)(D;O*+_0;[A?M?_2-, \G/]!OM]^V'](U))$C=Y.?Z#?;[]L/Z1J22(
M
M
M
M
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M<H$;_)(?0XZD_774_P SHR;1"7R2'T..I/UUU/\ ,Z,FT
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MUWJRJ<NWLSMG* 5
M                        89JK_A/]@GX5.F;V'<ZJ_P"$_P!@GX5.F;V'
MH<;_ &H?,MH_\FY]50 ;3F
M                     RO1_P#O.H_QG_A:=\G<=#H__>4_^,_\*'>IGER/
M-7O]VI]/V=_QJ/HO !A=$
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M0?WSSE_#CK,^Y7.,<NU FWY.?Z#?;[]L/Z1J22)&[R<_T&^WW[8?TC4DD0
M
M
M                                                          IE
M!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *
M@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!E *@IE!
ME *@IE!E *@IE!E *@IE!E *@IE!E *@IE"H
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MO8](\M<BHBHJ=BID#6'DD/H<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@
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M':!S
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MSRG-43NP9E@XMV?]2=7N\&G=QZ8B=>2\ &)O
M
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M<_T&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
M
M
M                               "B]A4M<N&J!0%@+L>J\%@!JO!8 :K
MP6 &J\%@!JO!8 :KP6 &J\%@!JO!8 :KP6 &J\%@!JO!8 :KP6 &J\%@!JO!
M8 :KP6 &J\%@!JO!8 :KP6 &J\%@!JO!8 :KP6 &J\JWO/F71^Z*)B7T  7
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MG0OVHZ/]>MRTMIU)+UC#;Q<Y/.:IB</"O5N5,1Y15RK$:JY5%RF$3>?"!<
M   &M>DO]#CNM^M2Z_S.4V4:UZ2_T..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3
M:(2^20^AQU)^NNI_F=&3:
M                       !IO=79^\ZYU.RY4%30PP)3MAX:F1Z.RBN5?<L
M5,<_$W(6JS($;/F:M3]J5]I3WI94_P#MCYFK4_\ Z]:?W67Y,DJ -&;<[)7W
M2.LK==ZRKM\U-3]9Q-@E>Y_I1O8F$5B=[D[R[<':75VO=0S5\E;:XZ5/G=+
MZ:7,<:+W_._=*O-?_(W?P^L<(&+[=Z+@T/IN"WQ<+ZAWSRIF:G]\D5.>/4G)
M$]2&K=9='FON.H:NKL=30T]#.[K$@J'.:L;EYN1.%B\L\_A]1OKA"L1P&&6.
MWWNSZ"J:*^S4]354]-(QM13O<[C8C%QQ<36\^XC1MY9J;4.LK7;:QKG4U3(Z
M-Z-7"XX%YY\>1+R\Q.EL]>R-.*1\$B-1O:JJU<$;=L-!ZBM6O+-5U=EK::FC
MF5SY9(51K4X7=J@<Z\='"_4]:YMMJJ6LI%=Z+I7K&YJ*O>W"IE/4IG&UVR$>
MDJYEUN\T5;<(_P"\QQHJQ0K]5E?=.\%PF/?-M\(P@%KHT<U6N1'-5,*BIG)I
M/6?1TAN-5-5Z?JHZ/C7B6CJ47JT=GZ5R9PGJ5%Q]XW>4X0(RTO1SU/).YDTU
MOIH47G(LKE3'J1&\_A-Q;=[56W0-.]T4CZJX2MX9:MZ87&<\+4RO"G).]5]?
M9C-^$N Q#7VW-NU_;605*NIZJ'B6GJHTRZ-5[45%[47O0T[+T?=66F>1UNN%
M+(UW))(IGQ/5,]Z</+XU)(EJMXNT"/MAZ-]RJ:])K_<X6P9RYM*YTDKO4KG-
M1&^_S]XWS;;;3VFAAHJ2)L%-"Q&1QM3DB(<E6Y+@--;G;&R:FNLMVLU1#3U-
M0J.GIZA5:Q[N7I-5$7"KCFF.:\\F*V+HY7RIG:V[5U/14?%Q.9"]9'KXX3"-
M1<=_WB1W".$"/FH^CI<ZN\U,EGGM]-;<-;#'-+(DB88B9=ABIE53*^^;RNE'
M)4V2KI&*U)):=\37.7T<JU43/J.QQZRG"!HO0&QM^TKK"W76KJ[=)3TSW.>V
M&217KEBIR16(G?XF]BF/65 P/<C:V@W!IV/65:.Y0MX(JEK<Y;G*L<G>F<KZ
ME7X#4,G1[U933/C@GHGQ.]%9&U#FM5/6BMS\',DSA"G#ZP-/;=;!Q:>N$%TO
M=3%7U<*HZ*GB;F)CD['*Y>;E3NY(;C*80J
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M@M%NFGI#%5D7:_S53/W5Y>LH 7T8M^K3341>SF$5.7B -$?<[L?YRG"G/_\
M J"5?HRK2*YHYO'K/_"AWZ=QT.D/]YS_ .,_\+3OD[CS=_\ W*GT_9W_ !:/
MHN !A=$
M                                  !;P#A]9< +>%"X "WA7Q'#ZRX
M6\/87        C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-, \G/]!OM]
M^V'](U))$C=Y.?Z#?;[]L/Z1J22(
M
M
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MHRI3B3Q'$GB-#57*C*E.)/$<2>(T-5<J?2/M7WCY<2>)?$OI? 5F.2U,\WV
M!1L
M             :UZ2_T..ZWZU+K_ #.4V4:UZ2_T..ZWZU+K_,Y0(W^20^AQ
MU)^NNI_F=&3:(2^20^AQU)^NNI_F=&3:
M                                           !K"?I :>I[Q);745R
M=/'4+3*YL<:MXD=PY_OF<9[\ ;.P@X?A*@       '2:KU/3:/L53=JR*::G
M@5J.; B*_P!)R-3"*J)VJG>!W8,'T/NS:->W"HH[=35L,D,77.6JC8U.'*)R
MPY>>5/OKO<ZV;>NHDN-/5S>=H]6>:M8N.'ASGB<WZI ,Q!CNB]:46N;.ZY4$
M-1% DKH>&H1J.RB(J^Y<J8Y^)D0
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M[D1TABJOW*_S5:@ ,C#O5*(G9W_ 5Y^( 1]5$7QYE0"3Z
M              $,KT=_O.?_ !G_ (6G?=R'0Z._WG/_ (S_ ,+3ONY#S5[_
M ':GT_9__%H^BX &%T0
M
M   C=Y1?Z#?<+]K_ .D:8DB1N\HO]!ON%^U_](TP#R<_T&^WW[8?TC4DD2-W
MDY_H-]OOVP_I&I)(@
M
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MR6ZM:H<T &!T0
M                      -:])?Z''=;]:EU_F<ILHUKTE_H<=UOUJ77^9R@
M1O\ )(?0XZD_774_S.C)M$)?)(?0XZD_774_S.C)M
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M5R\T7Q]2\NS.\]#Q7F#35)%?T:MTC3@D>QZ.XT1?1<JIWXPB^]D#)
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MJ8\.)T?-]HW:_,UTZSU^P41$Y<BI3"&XX_7JKV]H )1]0 !(
M                                        !#*]'?[SG_QG_A:=]W(=
M#H[_ 'G/_C/_  M.^[D/-7O]VI]/V?\ \6CZ+@ 871
M
M                          "-WE%_H-]POVO_ *1IB2)&[RB_T&^X7[7_
M -(TP#R<_P!!OM]^V'](U))$C=Y.?Z#?;[]L/Z1J22(
M
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M\Z'"ZPY5M=Q5"_I?\Z&.N/PRS6*M;D.V !INX
M                                              !K7I+_ $..ZWZU
M+K_,Y391K7I+_0X[K?K4NO\ ,Y0(W^20^AQU)^NNI_F=&3:(2^20^AQU)^NN
MI_F=&3:
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M817)SROQ 2";>*!U;)2>>T_G<:^E#UK>L;E$5,MSE.2H8?OIZ6U]WQ]5 O\
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MJ81,(G)/PFW]C-'56E=)O?71K!5UTO7+"[DL;,(C6JGCVK\(&R@
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M2>_:EZV=>W#'U*K^R<J?@.WH^C/8VHGG=SN%1C_J^"-/OM5?'O[S</OH55<
M:[HM@]'4J)UE%/5JG?/4O_\ "J'=T6U^E*!46*PT2JG-.LCZSQ^JSXF4Y]14
M#X4]+%2Q)%#&V*-$PC&-1$0^O"7 "F$&$*@              PS5/_"?_NT_
M"ITYW&J?^$__ ':?A4Z<]!C?[4/F6T?^57]0 &VY@
M                                       0RO1W^\Y_\9_X6G?=R'0Z
M._WG/_C/_"T[U#S5[_=J?3]G_P#%H^B\ &%T0
M
M                     C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-,
M\G/]!OM]^V'](U))$C=Y.?Z#?;[]L/Z1J22(
M
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M/%<KC.9:79J%_2_YT.IZTY]D?Q5B_I%_"AAN4Z42V\2YO7J60@ YKU8
M
M    &M>DO]#CNM^M2Z_S.4V4:UZ2_P!#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG
M1DVB$ODD/H<=2?KKJ?YG1DV@
M               IGU&J]R-[Z32%5);;= RX71G*7C<O50KW(['NE\4RF/$S
M775]=IK2%VN4:HDL$"K&J]G&OHM^^J$-)IGSR222/=)(]5<YSERJJO:H&Q)-
M_P#6#YE>E531MSGJVTS>'[^5^^9[M]T@(KM51T&H((J*61>".K@RD65[G(ON
M??ROKP1[ $[.+EGN+C -D=0R:AT#1OJ'K)44CG4CWKVKPHBMSZ^%6_$9^
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MMC/WSO !TEIT78K&]LEOL]%22MY-EC@:CT_98R=UCUE0
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MICQ-6R;_ .L'S*]*JFC;G/5MIF\/W\K]\UW-,^>2221[I)'JKG.<N555[5+
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MDN !A=
M                                                   (W>47^@WW
M"_:_^D:8DB1N\HO]!ON%^U_](TP#R<_T&^WW[8?TC4DD2-WDY_H-]OOVP_I&
MI)(@
M
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M[F]D4Q\V6 HG85.*]\
M                           !K7I+_0X[K?K4NO\ ,Y391K7I+_0X[K?K
M4NO\SE C?Y)#Z''4GZZZG^9T9-HA+Y)#Z''4GZZZG^9T9-H
M                                      ,5W+L\E]T)>J*%JOF? KV-
M;VN<Q4>B)[ZM(=X[4[^28[^9.SA-%;F;#U-=6SW33B1KUJ\<M YW#Z2]JQJO
M+GX+@#1 \.\R)^W6J(IEB=IZYJ[.,MI7JW[9$P9YH'8&XW"KCJ]1Q^8T+%RM
M*KD667U+CDUOO\_4!L;8&SR6K;V&25JM6MG?5-1>]JHC47WE1F4]2H;*/A3T
M[*:&.&)K8XXVHUK&IA&HG)$1/#!]P
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M%EE]2XY-;[_/U$B:>G930QPQ-;''&U&M8U,(U$Y(B)X8 ^X
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M-O#3RI^?S]Y#LDYG'N?GE[7$C2S3'R7@ QML
M                                                 *<0%06\155P
M!4%O&F,CB]0%P                       !&[RB_T&^X7[7_TC3$D2-WE%
M_H-]POVO_I&F >3G^@WV^_;#^D:DDB1N\G/]!OM]^V'](U))$
M       4X@*@  "WB+@
M
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M_9K^%#ICN-*_\)K_ (M?PH:U_P#VJG2V9_R:/JS, 'GGTT
M                        6\2'&K*^GM])+4U<\=+31-XI)IGHQC&^*JO)
M$]\#E@T9JKIN;%Z-K):2Y;F6-\\?NTM\KJWAQW*L#7IGNQVYY8.BMGE$NCO=
MI."#<FE8N43-3;JV!O/UR0M3_0!) &(:)W:T3N.QSM*ZNLNHL-XG-MEPBG>U
M/SS6N56_"B&6\7J N                        -:])?Z''=;]:EU_F<IL
MHUKTE_H<=UOUJ77^9R@1O\DA]#CJ3]==3_,Z,FT0E\DA]#CJ3]==3_,Z,FT
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M67 "F/$J                                 !;P^LKCUE0!;PEP
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M;R?#ASK2WAB?^F_S(=@GB<*U)ADB?GO\R',^E.=7^:7HK'*W"X %6<
M
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MF)V\E F@UR/:BIS1>Q>Y2\X-GHW6ZUTE(YW6/@A9$KD[U:U$S\.#G
M                C=Y1?Z#?<+]K_P"D:8DB1N\HO]!ON%^U_P#2-, \G/\
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M&YLC'M1S7-7**B]Z+X ?8
M
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M4_Q%B8F%7CVJXJKKC3ESTUZS+*@ ?>GYI  2
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M77^9R@1O\DA]#CJ3]==3_,Z,FT0E\DA]#CJ3]==3_,Z,FT
M
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MHTS"Z.V6^"C1_NEC;Z3O4KEYK\)W( MX2X
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ME
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M_>5 ,@
M
M     !:WO.AUA_O2'_&?^%QWR=YT.L/]Z0_XS_PN,UC_ '*7/VA_QJ_HQ/"?
MYBOK[P#T.[$QI/-\QIJJIYPIV]^5'->WL\"H)IIW>A-4SU  75
M                                  '/P  ? H_MV$  "0[E.XTK_P )
MK_BU_"AT_C_^!V^E>5S55_ZI?PH:F1_MRZFS(_\ DT?5F@ //OI@
M                             P_\M?2+=>RZ(DU!0PZN9 RI2SS2\$\D
M;LJCHVKCK.35SPYQCG@R[B[L9(5=-CR?U;TB=5,UYI34_L1JVGI8J9M'7MQ3
M2I&KW,5LK$XXGY=VX<G).PC9I/ID](?H:WV#2V[^GJW4UD8Y&1K>'KU[F)RS
M35S>)LR)X.X_#+0)K^4'U[>=NNBEK6Y6.::EKZI(+?YY![J"*:9K)%SW98KF
MHY.:*]%3"\R%O1C\F3IW?#9ZR:VN&XL\<UU8Z1:2T4L;VTJH]S5B>]SE5S^2
M*Y.%N,JG/&5F%IK?W97IV;:WK0L5Y6GJ+S2+#46*XJE/7PN3#F21)E6R+&]K
M7HK%<F6IGP(0:N\E7O5H^[5D6C[U:[]:G/Q#-#7.H9I&IV*^)_HHJ97DCW=O
M>!B_2LZ,;N@IK/0VI=':^=<+G-4OJ::&:%D-72/@X%214:Y4?&JN5O-$3Z5>
M+*GLW9ZYURM5'5NC= Z>%DJQ.]TSB:B\*^M,GF3T?_)2:H?KJAU!N]=K?)::
M.:.=]HHYWU4U<K>R.6141&,Y(BX5RJW+4X<Y3U#X0+@        "WB N!;Q%
MP  L63'<!>"WB+@      :UZ2_T..ZWZU+K_ #.4V4:UZ2_T..ZWZU+K_,Y0
M(W^20^AQU)^NNI_F=&3:(2^20^AQU)^NNI_F=&3:
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MEB:OH2M3Z9F?P<^7,#9(
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M4\!PIX#>-V%:?^]K[Y]/JBD2>B51.2F.>K:IY1$+@ 0L
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MY1?Z#?<+]K_Z1I@'DY_H-]OOVP_I&I)(D;O)S_0;[??MA_2-221
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M53U)A#<,<21HB)R1$1$1O).7J/KPE0
M
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MU3]=&,_ESV3_ -4N'[FS_7/A5;TVUL>:6WU<S_"7A8GQHKC+_P BED^L]O\
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MUEO86=-V_31NQ$:]H9H #C/=
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MZ,FT
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M?4C44":@
M                      L5O,IPERE"T,<QS4X1PE02C13A'"5 -%.$<)4
MT4X1PE0#13A'"5 -%.$<)4 T4X1PE0#13A'"5 -%.$<)4 T4X1PE0#13A'"5
M -%.$<)4 T4X1PE0#13A'"5 -%.$<)4 T4X1PE0#13A'"5 -%.$<)4 T4X1P
ME0#13A'"5 -%.$<)4 T4X1PE0#13A'"5 -%6)AN"K>Q0WL4J490
M
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MO@!DX,!VUW3BW$GN$<5N?0^:-8Y5=*C^+B5WJ3'9]\SX
M
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M\*'3G<:4_P"$U_2+^%#5R/\ :J=+9O\ RJ/JS, 'GGTX
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MSHR;0
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M*Y3>&V^V%!H"E>YCUK+C,F)JMS<<LYX6ISPG),\^:_ B9QPE0
M
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M4X1PEP*KZ+>$<)< :+>$<)< :+>$<)< :*(F$*@!(
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MM?\ TC3 /)S_ $&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
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M0O<[J45/2;ER)RRB+CQSX@;
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M^C%  >E?+P
M      [C2G_":_I%_"ATYW&E/^$U_2+^%#5R/]JITMF_\JCZLS !YY].
M                                 &.:WT'IW<G3M78=4V:COMGJ$Q)2
M5L22-SA41R9YM<F5PY,*G:BH0-WF\D%IZ]5,M?MIJF73BNRJ6B\M=4T[5SR1
MDR+QL:GYY)%7Q/14IP@>(FJO)B]('3E7*RETM1:A@CROG5JNU/PN1/!LSHWK
M\+<F/4/D]^D+<9GQQ[;5C'-5R*ZHKJ2%OK5'/E1%3X3W;X?7@<//('D9MQY(
M7<J^RP3:QU)9=*4:XXX:57UU4U.].%$;'GPQ(J)X$Y^C]T#MJ.CY4Q7.UVJ2
M^ZDCPJ7R^.;--&[DN8FHB,C7/8YK>).SB4D9PEP%O#\'O%P      !Y!>4$T
M%>NCKTN;/NW9:9SK==:VGO5+*O\ >DKH%9UT+U[D=PH]?%)78[%QZ<;);Z:1
MWZT10ZETG<X:V":-JU%)QIU]'*J>E%*SM:Y%RG/DN,HJHJ*O8[K[2Z7WIT77
M:5U?:X[M:*K"]6]5:^*1,\,D;TYL>F5PY/%47**J$!=3^2!N-KO4U5H'=*2W
MT4BJC(KE2N;41L^I66%R(_W^!H&S?*<=)>P:'V?NVV]OKH*W6&HFL@FHXG<3
MJ*D5Z.?))CW*N1O C5PJHY7=C>?U\E-L[7[>[#U^IKK32TM9J^M;64[)$PJT
M<;.&%^.U.)SI7)XM<U>Q3%]D_)):7TG?X+UN)J:36;X)$F;::6E\WI)')SQ,
MY7.?*W.%X4X,XPN4RA/JDI8:2GB@IXVPP1,2...-J-:QJ)A&HB=B(B8QW >3
MWE'M&WC8OI8:8WBM%*Y:2Y34=QCFY]7Y_1JQ'1.QG'%''"["^ZR_&<*>EVS>
M]&EM\]#4&JM)W&.NHJEB=;"CTZZDEQZ4,S,Y8]J\L+V]J9145?MNYL]I7>_1
M%9I/6%M9<[34JCTY\,D$C<\,L3TYL>W*X5.Y51<HJHOG_>_)#7^T7JK?HG=1
M*.VS-5K65U+)%.UO9P/=$_#TQE,\+4PON0,B\JWTE+)3Z"BVDLMSAK[Y7U<=
M1>8Z>1')20Q+QLBDQV/=)U;N'M1&95$1S<[^\GMLW5;,]&>P45RA=3WB\R.O
M=;"]JHZ)TS6I&Q47L<D3(LIW+E#6G1T\EMH[:;4]-J?5]]EUW=Z.9)Z.F=2)
M3T43T7+7/9Q.65R.YIER-\6KVDX>$"H     :UZ2_P!#CNM^M2Z_S.4V4:UZ
M2_T..ZWZU+K_ #.4"-_DD/H<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@
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M&.=GX54#+0
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MA8Z7XCU53D5VM7K?BCX0OL*B? JN3_VE> #B/2@
M
M    4XC6V^._^B>CSI%=0:UNOF-/(]8J6FA;UE35R(F>"*-.U>S*KAJ93B5,
MD M=>60N\E3/'HS;VBIJ=$7JZB_5CYGN_/.BBX$3WD>OO@>HV4*<7P'D![<'
MO+C_ (MZ%\<>85N?YV9QH3RR-YAJ86:RV\H:NF=A)*BQ5;X'-\7)'+QH[WE>
MGO@>I(-8[%=(?1'2)TK[/:*NGGD43DCJZ.H9U552/5,HV6/GCEV.15:O/#EP
MILX        "WAYYR5PA4 6\)< !:C?%<CA7Q+@!;PIV%P       (W>47^@
MWW"_:_\ I&F)(D;O*+_0;[A?M?\ TC3 /)S_ $&^WW[8?TC4DD2-WDY_H-]O
MOVP_I&I)(@                     %CFJK51%PN,(I##1CV4.M+(^H]!D-
MP@63BY(B)(W*K[W^8FD1>WFVVJ].7RKO%) Z6T5<CI5DC3E ]5RK7>#<Y7/9
MW 2?_LA$_?":.;<R[=6J+P]4URIWN2)N?A3L^ [&T[]:MBMT=MBCIZ^K5.JB
MJ'Q/?.J_ [TE]:I[^3#=7V*ZV2Z-2\\7LC61I5RM<N7HKU=[OU]OO<@)"U\+
MY]@&MCRBI98W_ UC7+]Y%- :$M%WO>HHZ6R5BT%Q<Q[F3I,^)<(BJJ<2<_'[
MY*/0U+%7;=6.FG8V6"6VPQR,=S1S5C1%1?OD<]4:1O>U.IV5M.V5D,4O64=>
MUJ*U4YX:[UX545J^/@!FKML-SW-5JZFD<G)%;[*3JGO+R&A=DM2::U9;+I42
M4*P4\O&](IG*[A5%1<)P^"G0ZCW\OFHK#46SS2EI5J&]5+-#Q*Y6K[I$RN$R
MG+OY*IEFP^B[[35*W>YS5E)0-8K:>CDE>U)'+RXW,SC"(J_#A>X# -\F/;N=
M>%>WDY(5:JIVIU+$3[Z?A)%;<U$=1H+3SHU1R)0PM7A5%YM8B.[/6BH8+OKM
MG5:D9%>[5"L];3Q]5-3L3TI(T7**WQ<F7?'ZC56D-V=0Z#I)+=3M@FIV/5R4
M];&YW5.5<KC"HJ=_("3%VUE9-/UT=)<KI3T-1*SK&-G?P(K<JF<KR[47M7N*
MWJNIKEI2YSTM3'4T[J2;$L+T>U<,<BX5,H1?;3:DW>U0^H2):BHD5K'RL:J0
MT[.Y57GPM1/%55>>$4DHS3\.F=O)[53KQLIJ"2-'8QQ+P.55QZU55QZP(W[,
M?X2[%_C'_P FXW7TB/\ !Z[_ +W%_P"(TILS_A,L7JD?_)N-U](9.+;MV/\
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MWL4Z'6'^](?\9_X7'>G1:O\ ]YQ?XS_PN,V/_N4N=M#_ (U?T8H #TKY@
M                                                     )V'<:4_
MX37](OX4.G3L.XTG_P )N_Q:_A0U<C_:J=/9O_*H^K,P >>?30
M                          !3B*<7+*<S1G2TZ4UCZ+.WL=ZN-*ZZWFX2
M.IK5:&2(QU3(B9<YSL+PQL14XG87FYJ?39/)[<KRA>^>X]=4/_)G4:9H7JY8
MZ'3J)1MB:JYPDK?GJ_LG@>ZO$4ROA]\_.N_?S<Z1[GOW&U8YSERKEOE5G^4,
MGTITR=[]&5,4UNW/U)(L;O0AN-<ZMB3&.75S\;<<NS&/4!^@'B]1<0$Z$/E'
M9=YM3T>@=PZ6DH=452*EOO%)\[@K7HBKU4D:KB.543DK5P]>6&KA'3[
M    %,(5 %J-\>9<  +>$N %O"7        UKTE_H<=UOUJ77^9RFRC6O27^
MAQW6_6I=?YG*!&_R2'T..I/UUU/\SHR;1"7R2'T..I/UUU/\SHR;0
M                                                *90"I3*'PJ:J
M&C@?-/*R"%B9=)(Y&M:GBJKV&JM8=(*UVY74=AA]F:UR\+9<*D"._"_X.7K
MVC<+G26FE?55M3%24[$RZ69Z-:GPJ:CU3TA(4E\PTK1/NE6Y>!E1)&[@5?SC
M$])WPX^$Z:V[9:MW.JVW/5M=-046<LIW(G&C?SD?8SWUY^HV]I305DT;#PVR
MC;%(J8=4.]*5_ON7G\"83U :EL^T&HM<U:776=?/$UW-M-Q(LV/#">C&GJ1%
M7U&Y-/:3M.E:18+30Q4C%3TG-3+W^MSEYN^%3MLYQA2O$ X2X    !%KIV;.
MUNN]%4.I[13OJ;C8.L\XAC;ETE*_"O=COZM6HN/!SU)2EBQ\645>[ 'B>&\_
M[<CTFW3Z#FA=P;A/<[9+4:5N4SE?+YBQKZ:1R]KEB7&%_2.:GJ-?VCR;=M@K
M&ONFNJJLI?IHZ.VMIY%]Y[I)$3[4"*.S&U5RWAU];]/4$;^I>])*VJ;V4U.C
MDXY%7NY*B)XJJ)WGKA;[?#;**GI*9B14]/&V*)C>QK6IA$^(Q?;/:73&TED]
MBM,6YE#"]4=-*JJ^:=R)CB>]>:^]V)GDB&9@
M
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M'NNOD=(U?M',3X#?2>Z.1F7/%OUU?-WMGV_"QJ*?DN !IND
M
M            /%7RD6JKQN/TQ+GIB2HX:2TI16BW1S/5D4?6Q1R/>OAQ/E7+
MNW"-[D0F?MUY)W9_3MDBCU3->-7796)U]0ZL=2PH_OZN.+"M;ZG.<:-\J1T4
MM1U&NI-WM,VRHN]JKJ:..]LHV+)+1RPQHQD[FMY]6L;&(KDY-6/FOI(:-V^\
MI;OKH"STUK2^T.H:6GC2*%U\H4FE:U$PB+*U6O=[[U5?6!Z.^UI]'3S7JOR
MR=9PXZ[V;N'%G&.+'7\.?@P83KWR3VS>HK14LTY)>M)W/@7J:F.L=51(_N62
M.;*N;ZFN;[Y%#VWG>CS7JO8+176</#U_L?5\><8XL><\.?@QZC"M>^4SWUUU
M9YK8R]T&FX:B/JY9+%0I#.YB^$CU>YGOL5%]8'+\G%J>[;==,BSZ>CJ.*GNG
MGEGN,<,O%'*C(I'M<B]BXDB8Y%\%7&,J>V)Y6>2SZ*VH)=<Q[OZCH);;9Z&G
MDCLC:IBMDJYI6*QT[6K_ ,FUCGIQ8PKG)C/"IZI@
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MM R//Q(AV&$*@"G"4X<HJ%P IPE0
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M^EH^&Y*O_9K^%#@]6=KIMG#7N7\XJ??0UK]7^G+H[/M;N33/S94 #A/HH
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M:^]=VL>YWY7-15/J+%>HIIJ:FD<JI35,<;I7.9X(YC7Y3U-7NYAZ>
M
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M1#LOPE$3P"&IUG66]$:1I"\ !8
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M;[??MA_2-221
M          IE!E *@MXBX :+WHW;JK;5RZ?LDW4RQIBKJF>Z:J]K&KW>M>TW
MH0>O%9+<+M7U4RJLTT\DKW+V\2N55^^!Q99'S2.DD>Z21W-SGKE5]\[#3VI;
MGI>X-K+95R4LS5Y\*^B]/!R?3)[YU@ EYMGKR'7NGFUB-2&LA=U55"G8QZ)V
MIZE_T^!F1''HSU<L>J;I2HJI#)1=8Y.[B;(U&_QW?&2.       !1% J"QTC
M6M55<B(G:JKV&+7C=+2MARE7>J7C3M9"_K7)[Z-S@#+"F4-0WCI*6*C1R6^W
MUEP>G>_AA8OPKE?O'0IN?N-J[E8K%YG"[W,S:=7(G[.3T/O ;].-55]/0P+-
M4SQTT2=KYGHQJ?"IHUUDWEOG]SU5:Z@C_P"N;-!%]^'TCZTO1UN-RF2:_:D=
M,[O2)KI5^W>J?@ SR\[U:0LRN:MT;6RI_P G1,67/[)/1^^8/<>DDM5)YO8[
M!-42.]PZH?S^T:BY^!3+K+L1I&TX62BEN4B=CJR57)]JF&_&AFUMLU#9XNJH
M:.GHX^]M/$C$^\!I*._[Q:@3SBCH%M\7_5]1#%]Z954H[1.ZVK'*R[7?V.AS
MA6K4-8COV,*87X3?>$&$ TM9NC3;6N;)=KO45K\\2L@8V-,_IEXE^+!ED.QF
MBH4;_L0LCF_3/J95S[Z<6/O&? #IK1I&RV%46W6NDHWHGNXH6H]??=C*_&=Q
MPE0!3A3.>\<)4
M                               %AU>H6YIF)^?3\"G:(==>DXH&?IT7
M[RF2U^>):N5&MFJ/DQWJU\!U:^!RNK'5G8WGC/"<7JU\!U:^!RNK'5C>/"<7
MJU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\
M!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:
M^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!R
MNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'
M5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>
M/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<7JU\!U:^!RNK'5C>/"<
M7JU\!U:^!RNK'5C>/"<7JU\#LK$W%:OZ1?PH<?JSG6:/AK%_2+^%#!=JUHEN
MXEO2]3+O@ <I[                                      <:::.GC?)
M*]K(V(KG/>J(C43M55[D0C%N3Y2/8O;BKJ*'\D<^J*Z%7-DAT[2K4M147L25
MRMB=\#U-">5UWTO.GJ'3.V-HJY:*DN].^YW=8W<+JB%']7#"J_4*YDCG)WJU
MGASTAL!Y+77&[^C;5JJ^:DM^C+3=H&U5'$ZG?5U;H7X<Q[HT5C&HYJHY$XU7
M"IG $EI/+$[8\;T;HS5BL1>2N;2HJIXXZY3*-*^5BV/U#4107&/4FFN)6HZ:
MY6YLD35Y97YQ)(Y43/U.>78:>]I<\-X_X+_UPZ;4GD:;]2T,K[!N?;KG5HU5
M9#<+.^C8YW@KV2RJG=SX5 ](]!;B:9W/T]%?=)7NBU!:9EX6U5%*CVHY.UKN
M]KDY9:N%3/892>&G1JUMK3H=]+&BT[=TEMZNND-FU!:TDXHIH9'(U),-Y.5J
M2)*QR<_7ARHON6                         -:])?Z''=;]:EU_F<ILHU
MKTE_H<=UOUJ77^9R@1O\DA]#CJ3]==3_ #.C)M$)?)(?0XZD_774_P SHR;0
M                                               +>+M N/A/41T\
M3I)7-CC:G$Y[UPC4\57N,;UON-:-"476ULG654B9AHXU3K)/7CN3UJ:AIJ#6
MF^$_7U4_L38$?Z+>:1_L6IA9%]:JF/4!DNN]](X9/8K2:>R=QD=U?G#&<3&.
M[D8GT[E^+WSC:'V-EK:A;SK*5];6S.ZSS-S^).+QD=WKZD7!GFB=L;'H>-'T
M4'75JMPZMGPZ1<]N.YJ+X)]\R_A]8'PI*."AIV04T+((6)AL<;4:UJ>I$Y'(
MPA4    (B;P6>2S[A7AKVJUE1*M5&Y>Q[7\UQ\*JGP$NS!MR]M:77UK1JO\
M-KC3Y6"H1.6/J'^+5^]\>0B4#+[SM-JNRU#HWV:HJVHN$DHF+.U?M<JGPHA]
M]/;.ZKOTR-]BY;?"J^E-7(L2-3QX5])?@10.UZ/MIDN&OXJQK5ZFAA?(YZ)R
MRYJQM3X>)5]Y/BE&8MH+0=!H.S>94BK+-(O'/4/3#I7?YD3N3N,I
M    >$VXSFQ[NZI>JX:V^52K[WG#_P#0>[)X1[FPK4;JZMB3DK[W5M^.H?\
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M*G@N /9T
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M9F]%BF=:DH0 :S?
M                                        'B/Y12UU.D.FOJ6ZW.C\
M\HJUUNN5/%4>YJH&T\3%9V>YXH9&>\U3TEVXZ?\ L3KBQTL[-;T&FJCJF];;
M+UFDDIEQ[A5<G Y$\6.5/6=YTI.B'H_I3:>I:6^236J]V]'>Q][HVHLL&>UC
MVKRDC5415:N%RG)S<KGSCUWY)O>;3E1+[ 36/5]&WG&M-6)2S+ZE9-PM:OO/
M7WP/3SYJG9CS;SC\MK17!P\6/R04O'C&<</6<6?5C)A6X/3ZV)T+8ZBL?KNW
MW^5K'+'06/-9+.[ZCT$5K<^+W-3UGE_[6QTC_P SK_\ OEN\/^\F9:'\E#O9
MJ2JA]FVV/25*N%EDK:]M1(U/SK8$>CG)ZW(GK QSR=]IJM8=-;3%QM=$VCI*
M.2ON<\,'-E+3]1(Q&IWXXI8V)GZH]O30G13Z(.E.BMIJJI+1-+>=07!&^R-[
MJF(Q\R-]S&QB*O5QHJJJ-RJY7FY>6-]@                        "-WE
M%_H-]POVO_I&F)(D;O*+_0;[A?M?_2-, \G/]!OM]^V'](U))$C=Y.?Z#?;[
M]L/Z1J22(
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M)4#H+-H73]APZ@L]'3O3LD2)%?\ ;+E?OG?<)4 4X1A"H
M
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M;CX\/J.5:^52JXQZ/^=#Y\!R+>W%0OZ7_.ACKG\,MC'HTN4R[4 &B]
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M9R@1O\DA]#CJ3]==3_,Z,FT0E\DA]#CJ3]==3_,Z,FT
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ML;T>D5?<)7QY3.,M141R97L7*<O#* 8QT&-Z=WM[6W:Z:T=1S:5I(^HIZYM
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MSE[7.5$3+G*JKA,JH&2
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MS6S*(RKEW*O1K/2'B-N.D>SO2,U$NG%6DBT[J.9U"D;E3JFQ5&6,SZD1&\_
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MY:\VCL:Q$95RJ)UBGEK_ )]&5 HG85/+O:@
M                                                           "
MWB[>XHC>SF>+_E#ORS-#])75ETDJ-26;3-TGB?:ZJ*IGCHYVI!&UR1N:[@54
M<UV6IS3.<<R/^E[INSK9:E-.UFL[_P";</7^Q<M74]5Q9X>+@5>%5X5QGP7P
M _1 .%.+/?V'Y_/R+[__ %IW(^YZ_P#T#\B^_P#]:=R/N>O_ - 'Z T<G]N\
MO/)'R=5DW9H>DY9I=6T&LH+*E!6(^2\PU;:='=4[ARLJ<.<XP>MP
M                 C=Y1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-, \G/]
M!OM]^V'](U))$C=Y.?Z#?;[]L/Z1J22(
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M##]+[4:;TK"UM/0-JIT__,UB)+)\&4PW]BB&7(Q&MPG),8QW%X MX4YEP
M  4RA1'H!<"F?45
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MDP]X-!;PZ%U/=*K3+[;9;]0W*I;3W"5[^JAJ(Y'HUJQ)EW"U>2\L^!ZQ@
M                     #6O27^AQW6_6I=?YG*;*-:])?Z''=;]:EU_F<H$
M;_)(?0XZD_774_S.C)M$)?)(?0XZD_774_S.C)M
M                    "WB]63@7>]T5AM\U;<*F.DI8DR^65<(GJ]:^I"/V
MX._5=?.NH+#QV^@['5"\IY$Y]GU*<N[GZ^X#,]V-YXM.I-:;)(V>Z\VR3IA6
M4_BB>+_P>_R,1VMTCIO4EQ]D-17ZGNEVF<CTMSYL*KO%ZKA7KZF\O?-/)[I5
M7M5<^^OBO]OB*IRQCN7($YH((Z>)L<;$CC:G"UC4PB)X(G<?<T7L/N?4W"J3
M3EUF6>7A5U)42+ERHU,K&J]Z(F<+ZE-Z
M
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MTJ1/6=/:EZFY=BFB=8B'*V)9JM6JJJXYS*]  <9Z(
M
M      8;N?M7IK>/1-RTGJNW-N=FKF<+XW<GQNY\,D;NUKVKS1R??3D>-FGK
MUJKR>72YJZ&2IDJZ"@J6T]<Q$5([I:Y51Z.X>SCX%:Y$3W,C<<T147W%.OJ[
M';KA+UM50TU3+A&\<T+7KA.:)E4 K:KK2WJV4MQHI6U-%50LG@F:OHR1O:CF
MN3/<J*ASSX0P,IXFQ1,;'&Q$:UC$PC43DB(B=B8/N!;P_"7
M             "-WE%_H-]POVO\ Z1IB2)&[RB_T&^X7[7_TC3 /)S_0;[??
MMA_2-221(W>3G^@WV^_;#^D:DDB
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MT#%]"LAEA>G<J(U7I]]GWR5
M                                                         !1$
MQD^,J<3/A/N6/3T1'56KG#C=6O@.K7P0^P,N\U=U\>K7P0=6O@A]@-XW7QZM
M?!!U:^"'V WC=?'JU\$'5KX(?8#>-U\>K7P0=6O@A]@-XW7QZM?!!U:^"'V
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M''=;]:EU_F<H$;_)(?0XZD_774_S.C)M$)?)(?0XZD_774_S.C)M
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M4>HZJ%64-+Q)3\?+KI514XFIWM1%7GXX\%Q(\
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M\!L0
M                  ?/JT=D=4A?A!PA&BU&IC&<%?OE43 P@2LX.[N*HG/F
M5X2N$ IPEN.?=D^A;P@6HQ.2JO,KP</9V>!=PCA J?/A3Q^\7IV>)4"QL>$[
M1U9> C0  2^:-1>PHC?==Y].$HUN +@ !\^K[?64ZOES7XCZ@(T68QZQP>HO
M*-[ E9U:8*\*%Y3"!&AA"S@1/_P+T]_)4)?-L:)ZB_!:5XN81]%P "0
M
M                    !&G=;R@VT6S6X%VT;J6LNT5[M;HVU+*>W.E8BOC;
M(W#D7GZ+V_&8K[:OL+]<+[_\)?\ Z0)@ A_[:OL+]<+[_P#"7_Z1[:OL+]<+
M[_\ "7_Z0)@ CMLST\=JM]]=T^C])U=TEO-1%+,QE70NA8K8V\3O25? D2
M                       (W>47^@WW"_:_^D:8DB1N\HO]!ON%^U_](TP#
MR<_T&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
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MG#"G['*\7PJJ>HVC!314\+88HV11,3A:QC41J)X(B=Q]L(5 MX2X
M          17WVTM-8M:U-;U:I1W+Y_')CEQ\N-/?SS_ &2$J#I=2Z7M^K;3
M+;[E#U]._FGU3'=SFKW+S^)53L50(5^]S'=_YFZ;ST:+@R=RVF[4TT"KR;6H
MYCT3P56M=GXD/OI[HSU'G"/O=UB2%%RZ*A1RJ[]FY$Q\2@=;T=-+SU>H9[Y)
M&J4M'&Z-CU1?2E<F%1/>:J_;)XDD#K[39*.QVZ"AH(&4M)"WA9&Q.2>OW_6=
M@
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M9I:.^7RAM<\]/YQUD<<T[(G.;F7'$B.54RBIG'(]0P
M      !K7I+_ $..ZWZU+K_,Y391K7I+_0X[K?K4NO\ ,Y0(W^20^AQU)^NN
MI_F=&3:(2^20^AQU)^NNI_F=&3:
M %O%Z@*Y0U9NCO!%IE76BS(VLO;_ $%X4XVTZKV)R[7Y5,-^,Z_='=B=M<NF
MM+<53=9'+%+40IQ+&[O8S\]XKW>O"X[3:W:&#2:)<[KBLOC_ $N)R\38,]O#
MGM555?27F!U.V>SSVU7Y(-5YJ[G*])64TR\7"Y5RCY,]KO5V)Z^6-R<'+M'"
M7 "SJT1%3/;XEX U]J'8[2NH)W3K2RVZ9WNGT+T8B_L516I\"'&L_1_TI:JA
MLTC*JXN:N4;62HK4^!J-S\.390 XT%,RG@9%$QL4;$1K6,;AJ(G+")X8.2
M                             <>6-TD;F->^)SD5$>Q$RWUIE%3/OD)Z
MOR?.VNA-;T6K-6Z_=-IZ.J=4U=%J5T$25K\*N'U'$Q,<2HJIPKE$5.6<DM=S
M=7?D VZU1J;J?.7VBVU%>V%<XD=%$YZ-Y=RJW[YY%;=V;4G3 W[H+9J?4\WG
MUV?+)/6U&9.IB8QTCF11Y1$3#>%K$PB9S@"4?2=U_P!%RKVNOUEL5'IZ?4JT
MSDMDVG+.UCH9FY6->O8QK.#B7GZ2IAR\C3'DVKC+1])2G@C>YK*RUU<,J(JH
MCT1&R)E._FQ"0.ZG0@V?V7V,UIJ"2.NN=VHK5.M'<+K7+Z%4K5;$K61HQJKU
MBM1$5%[2.GDY?HG[1_W"L_DE D'Y4':?V4TKI_<*C@S46N3V-KW-3GU$CN*%
MR^IDG$G_ +XYODO]T_9S0%]T+5SYJ;'/Y[1-<O/S:955R-]39$<J_P"-0EEN
M=H*CW-V^U#I2X82ENM')3<>,]6]4RR1$\6.1KD];4/(38S<VZ=%W>FX5U;3/
M2KH(:ZUUU&G/BE1CT:Q?4D[(E_8@9=T]-S7[H=(BYT%$]U10V!$LM)''SXI&
MJO7*B>*RJYOK1C29VL*&;HE]!BIH;<_S>_4MM93OGC7#FUM4]&R2(J=['2.5
MJ_\ 9M(7]!?;&;=WI$V^X7%KZN@LCG7NOEDY]9*UZ=4CE[U65S7>M&/)[=/3
M3D^HNB]K!*:-TTU%YO7<#$RO!'.Q9%]Y&<;E_2@><W1&TOM]JC=E)=S+O;[=
MINWTLE6L5RJ&Q1ULR.:UD2JJIE/2<]43FJ,PO)5)6]*6S=&W6>TE[ETI==$V
MK55MIW5-N=8GT\,D[F<U@5D>$D1[45J(J+A514["*_1"V@T;OCN?-I/6-TN5
ML;/0R34#K;/%&^:H8YJK'\\C?GYVLCN2(OH+[Q+/7?D]MC=M=*U^H]2ZOU?;
M+-1HU:BI=54[^'B>UK?192JKEXG-PB(J@:M\F#N)5VC=&^:/DF<ZV7B@=5QQ
M*JJC:F%6JCD[DXHW/1<=O SP+O*G_P"%_2?ZA)_.)C<O16V4Z/\ :=R:34>V
M>XEUU)?Z.FF>E!5U<.5B<WJWN=%YO&_"<:=Z87!IKRI_^%_2?ZA)_.)@.^Z!
MG1)T9N9MW<-9:XM7LVE55R4=!2/GDCCCCCQQ2^@Y%5RO5S>:X3@SVJ2RGZ+N
MDZ;92[;7V.>XZ=T_<IGS32T4R/J%5TB/5JOD1V6X:UBYYJU$3)BWD]H6Q]%;
M2CD5<R3UKESX^=2I_F'3LWEO.S6R3ZO3T[Z.\WBNCM<5:SW=,US)'O>U>YW#
M&K47N5V4YID#6NANB;LET:]07.[;A:OL=^6:)K:&AU.R&/J.:JYW4O>[KG+Z
M.%X.6'8[>6@>FYK;8G5M':$VOI*&+4%/5.6MJ;1:W45-+ K7*[B7A8CW\:,P
MY&KR<OI'4=#_ *+E+THKSJ6ZZFU%64M#;7Q><^;.:^LJI9N-<K(_B1/<.RY4
M<JJOJR9_TY>CEMGL%MAIJ+2M#+#J*NNB(^JJZN2:>6G9%(KLMSPHG6.CYM:G
M-4 V9Y*RXRS;=ZXH>-RP0W6*9K<\D<^%&N7WU2-O/U(10Z;VO*S772/U<E1,
MY]+9Y_8BEB7FV-D/HN1$]<G6.7UJ2F\E,O\ Z'[@)_\ I]+_ ";R(W3#TS4Z
M6Z2FOZ>H@DA\ZN3Z^+B3D]DR=:CD\4]->SO14[@/1K8?H?;=:*VQL]'>=)6C
M4%ZJJ2.:XUMUHV5+W3/8BN1G&B\#6\D3AQ[G/:JJ0*Z<VQ-IV/W>C@T[$M/8
M+S2)74](KG.2F=Q.;)&BKS5,M1R95<(Y$[$/3[8W<RU[L[86#45JJXZE)J6-
ME5&UR*^GJ$8U)(GHGN7(N>2]RHO8J'G/Y1S=6T;@[Q6^V62KBN%+IZB\UFJ8
M7H^):A[U<]K7)R5&HC$7GVHY.[F$G.B/K+\KSH'R:G1K7OM--=*R-CNQ[V2R
MJUJ^^["?">?^R]ML6Y&]MI3<2^MH;)6U<M9=[E6U'5=9AKI'-<_*861Z(S*<
MTXE5"=/1UT_/JOR<][M5)$^:LJ;=>4@ACYN?*CYE8U/6KD1/A()]'30^E]R=
MW]/:7U?7UELLMTE?3+4T,K(Y&S+&[J6Y>QZ>D]&LQCZ9.SM GUNC8.BIK7;R
MX6*WW70-EKFTSDM]PMSZ>&HAF:F6.61N'/\ 21,HY5XLKGGS(F^3]W$JM$=(
MVRV]LSFVW4+7VVJBXO1>JL<Z)V.SB21K4SVHCG)WDH[[Y-79S3-DN-WN>I]7
MTMNH*>2JJ)W5=*J1QL;Q.=RI>Y$5>1CVP6Q?1HJ=Q].7;0VYU[NNH:&K;5T5
MOK*F*%9WQIUG"L;Z6-[DPU55$5%PB\P)[@
M                                           !3B J6\13K/46]:SG
MS^,*S,1U?3*#*%G'GL3(5[4[>03R?0'SZSU??*]9RRG8#5=E!E"Q),KA.?PC
MK$3M_"$;T+T7(5<%BR(U/])3K<HN$R#>C71]04RA:LF LNR@RA;UB)WI\8ZQ
M KO1*\%BO5.XHLG#VKCWPMT?0'SZY,^KQ*(_FJ8YIZ_4$:ZOIE!E"U9$3WPD
MGJ^(&L+E[ WL+.L3^RE6O1R*J!&L=%V4&4+$E1>64S[Y59$0&]"[*#*%G&N,
MX^^4ZY.SL7PR$ZP^H+$D3GA"\)"G<,H /@^5L<:N=AK6Y555<8-47+I8;/VF
MY^Q]3N)8O.>+A5(ZM)&-5%PJ*]N6ICORI%[RGV\MWLK=/[>6JKDHZ.XTSKA<
MUB<J.GCXU9'$J_4*K9%5.]4;X&LM#]";2UVZ*53NA?-55ENO#[=47&GCB=$E
M%$C%>D4;T5JN>YZM3*HY%R_"(JISZ]G#M^%3<OU3&]TT>=R-HW*;M5FQ3$S3
M&LS+TXL&HK9JBTT]TL]PIKG;JAO'#54<K98I&^+7-7"G:90\QO)<ZRO<&Z&H
M-+1S2S:>J+6^X2P*N8X9V21,21,]BJDBM5$QGDJY1J'IPW///8:658\M=FWK
MJZ>%D^;LQ<TT7  U6^
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MX7[7_P!(TP#R<_T&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
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M)V%P
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M.3/<6FFJ(WICDQTW**IFF)YP[;A'"7 JR:+>$<)< :+>$<)< :+>$JB8*@)
M                                       :&WXZ%^VO2,U11:@UI2W*
M>Y4=$E!$ZBK70-ZI)'R(BHB<UXI'<S6WM56PO9['7W/ZK/\ ]!F?36Z6=+T6
M=NJ>MI:6*YZLO#WPVF@G54C]!$ZR:1$5%5C.)G)%15<]J<N:I#?H']+3='>C
MI7V^BUIK"LN-LK*&L<ELCX8*1KFQJYN(F(C55,83.7>M0)*IY*O8/E_L=?>?
M_M9_^@>U5;"\_P#8Z^__ !9_^@P/RDO34OFSE11[<Z"KO8_4E=3I5W.[1<Y:
M.!ZN2..+N;(_A<JN[6MX<<W93S(35&X%X6JU)[+ZDKO-Y$=47A*FHDZIZ][I
M<^BY>[*]X'L5H[R:VRNAM76/4MJH+RVZ6>OAN-*Z6YN>Q)HI&R,5R8YIQ-1<
M$JSS$\G3T[]3ZBUO1;6;C762^,N+7MLUYK'*ZJ9.U.)()7_\HUR-=PN7TD=A
MN51R</IV                         -:])?Z''=;]:EU_F<ILHUKTE_H<
M=UOUJ77^9R@1O\DA]#CJ3]==3_,Z,FT0E\DA]#CJ3]==3_,Z,FT
M                      #YNE:U%5>34RJNSR3 %W'ZE-+[G;M35E4NF=)J
MZJN$SUAEJJ?FK5[%9&OC^>[$.#K[<RY:VNRZ5T=Q2MD58YZN)?[XGTR-7N8B
M=KN_WNW.MM=K:'05&DJ\-5=I&HDM7CW**N58SP;]]0./M3M53Z&I4K*M&U%\
MF;B23M2)%^E;_G=WFQBF$*@
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MJM55-/<-72Q.@@BI7*^&AB=CBPY4172+C"KV(BJB*[*J2UPA1&^O(%P
M
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M $;$_EAFX --TP
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MF)(D;O*+_0;[A?M?_2-, \G/]!OM]^V'](U))$C=Y.?Z#?;[]L/Z1J22(
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M=<US)&*KH*B/W<3E3&4]7BAH2]='[55OJ'-HHH+I#GT9(I6QKCUH]4POJ15
MCWN!LWIS<7Y]7P24MQ:WA;74BHV3'<CLIAR>^F?!4.CVP\GQ^6%=ZIGY,YJ*
MVT[4=)(VVH]RJJX:W/6HF51%7..[LYH2GT]T=]1W"H;[)K!::?.7\4B2O^!K
M%POPJAO_ $OI.@T?9XK;;8N"%KE<YSN;I'+VN<O>O^9, :JV(Z(.@-@Y$KK/
M2S734"M5BWFZ.22=J+VMC1$1L:=WHIQ*G)7*AN_A+CA72XMM5LK*V1KGQTT+
MYG-;VJC6JJHGKY <T$*O;3]OOL3U)X]E/\KZA[:AM]]B>I%^"G^4 FJ",^V7
ME!=IMQ[Q#:G5EPTQ73.;'"E]@9'%*]5QA)(WO:G/O>K4)*MDRB+CM O!$>F\
MH]HBHUTS2R:9U E8^Y);4FQ!U?&LJ1<7]\SC//LS@EP
M   &G=[>E;MYL*YE-J6YRS7>1B2,M%MC2:J5J]CE:JHUB+W<;FY[LFF[)Y4'
M;&ON+*>NLFHK73OY+5O@AE8SUN1DBNQCP15]0$Q@=%H_65FUWIZCONGKC!=K
M16MXX*NE=Q,>G>GBBHN45%1%145%1%.]
M
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M<=95\29XV,>L\OQM8X]NF-X4PAFVK_ITV[/PABV)K=JN7Y[R^@ //O5@
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M)#Z''4GZZZG^9T9-HA+Y)#Z''4GZZZG^9T9-H
M     !8LF,Y3DG:!1TK6HJKR:F55V>28-$[A[AW#7UV_(EI)'30R/ZNHJ8UQ
MUN.U,]T:=Z]_O=M=QMP+AKB\_D/THCIHY'*RHJ8UPDN/=(CNYB=Z]^,=G;L;
M;C;FAT%:>JAX9J^1$\XJ\)ERYSPIX-3P IMQMS0Z"M751<,]PE1/.*OA3+US
MGA3P:G@9GPE.$N
M                   %O#\9< .CK=%Z?N<[JBLL=MJZAWNIIZ.-[U]]5;D[
M"@ME+:Z5E-14\5)31^YA@C:QB>\B(B)\!S !;P^LN
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M;C:/,*BW+&R:&W<,$-; QO"R&5J)[E.2(K<+A.'.,8W?0V^"VT<-+2Q1T]+
MQ(HH8FHUC&HF&M:B=B(G+"&IGYM&533NQ.L?HWME[/NX556_,3$_JYH ..]$
M
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M-Z2'2KM%HO\ 5T=KTNZCK)6V2UTZ,B5S8G*USWNXI'JG;[I$Y9X4/2T
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MNE=''*U[D:BJB*N$[U3WT/1*H\J3M>V%ZPZ=U;)*B>BV2FI6-5?!7)4+CXE
MA5TJNCA4=&[7M-:&W%;M9[A3^=4%7(U&2</$K7L>B<D<WES;R5%3DG8GH;T
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M&XW;3>I*;5&IZUT3;O)'$Z)]%A,L@2-Z(Y&YXEX\8>J93W*8E^
M
M                                   *=Q4 <.X5L-MH*FKJ'I%!#&Z6
M1[NQK6IE5^)#PGZNX[P[K.;!PI==4WM>!9%7"35,_)7*F>69.>#U_P"EWK!-
M%=&_7]R1_#(^V/HXU1>:/G5(&JGO+)GX#S7Z!&COR6=)O2BR,XZ:U-GN<O\
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M%QBH&.7MX8(^-<?#/_D^HG7E<Y.;M.YXF3/RY.KL:UX>)3/QYKD*@',=P
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MKM4(GG-0B?#P-]2??7G[V<\)7"%0
M
M
M    % (6]*+H/:HZ06Z]3JFFU9;[;0I204=-2U$$CWL8Q%5V53ES>Z1?A)*;
M&[;LVAVHTUH])F5+[52I%+/&U6MDD55?(]$7GA7N<OPF=X3':.#NSR-BN_<N
M6Z;54\H:=O%M6KE5ZF/Q3U?0 &NW
M
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M#M;T<JN.YZ;ME37:B;&Z);Y=:A9JCA<F'(UJ<,;$5,IZ+$7':JD@"U7>HN
M    !H[IF;6:DWEZ.FJM&Z26+V<N;J5(FSS]2QS65,4CT5W<G QW(WB6\/K
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ML
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M'T..I/UUU/\ ,Z,FT0E\DA]#CJ3]==3_ #.C)M
M   #7^Z&Y]+H.@6./AJ+O,WYQ39SPIG^^/\ !$[O'XSN]=ZQI-$6&>XU.'R>
MX@ASSED7L1/\Z]R&K=I-"3:QN<^LM29J'32]9312)Z,COJU3ZE/<M3U+X(!R
M-K=M*R[7/\ENJ5?/72N2:G@F[47ND<G=W<+>SDG@;MX1P^LN
M
M
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MCBU5[D5QJE4"QLF>[D5XE\#3=)<
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M*+_0;[A?M?\ TC3 /)S_ $&^WW[8?TC4DD2-WDY_H-]OOVP_I&I)(@
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MKJ,\76SV6F>[.<YRK,]O/WS);'IJTZ9I5IK/;**U4RKQ=30TS(69\<-1$.U
M%O AT6I]"Z;UK3-IM1V"V7^F:Y'-ANE%'4L:J=BHCVJB'?@#$]-;4Z+T=5><
MV#2-AL=3A4ZZVVR&G?SQGFQJ=N#*N'M+@   ' NEGH;Y0RT-RHZ>X44R<,E/
M51-EC>G@YKD5%^$Q*W;$[;6:X^R%#H'3-)6H[C;40VBG:]KO%JHS*+[QG@ M
MX>[N\"X
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M5V(TB&I7FV:+U-G76JK]D^4 !J.B
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M8X(FHQC&IA&M1,(B>K!UNFM+T6E+/3VVVQ]5!$G-RIZ4CN]SE[U7_1W)@[H
M
M
M                                     L5<'C+TWM8?DQZ3>MIV2<=/
M05#+;$F57@ZAC6/3U?/$>OPGL;>+I!9[565U4_JZ>EA?/*_ZEC4557XD4\0-
M!6>?>[?FST=8CGRZEOS9:M47*\,LW'*OP-5Z_ >@V13%-5=ZKI3#RNW*YJIH
ML4]:I3 Z-'D_Z#7^D+;K#=*MN%1-<:6)U%:*>98NJID8C8NM?CB]PUO"QJIP
MM1J97L;TG3KU+;=C=!:8V(T,M1;K0L+[E<E215?-$^5ZLB>],<2.>DCG9^I9
MW'H_!3MIX611M1C&-1K6M3"(B<L(G=R/)?RCL-7#TF[FZI14ADMM(^FS_P!7
MP.1<?LT?\2DX5VO+RO\ 5GE'.([*9]BC"P_]*/Q3RF>_S;=Z"O17T'J#0,>N
M]?0T=VJ+A+(VWVZOE3J88F/5BO>S*<3G.:[D[EPHBXYF&^4)V&T-MS)IS4>A
MZ:EMD-QEEI:VWT<J.A1[6\3)&,RO!E.)%1,-7"<D7.>PVL\FS!NAM[IW5E-N
M;'317>@AJU@;8^MZESFHKH^/SE.+@=EN<)[E>2%]\\G5I+2]\99KOOW9;1=I
M8TGCHJZV10S/8JJB/:QU8BJBJUR91.Y3;IO6J<F;GBS.G;2>C1\"Y.+%$68C
M7_MK'5)7R=^NJW6O1NH(JZI=55%DK)K2V21<N2-B,?$W/>C62-:GJ1#S6U]?
M'U72"OERU[355R9'J)ZWBD;(K99(F3\,D+'*J8]!O WFB(F,8QE/4GH_;?:5
MZ)^TC;3==<VNIH*JMDK4O5:Z.@AF<]K41&\4KD7#6)S1W,P3<CHZ;*=,2Y7:
M_:6U)#'J6FX8JRZV&9DL;W*WYVLT:^B_DU<.:K57APKE1,&GC9-NU?N5S$[E
M7>.SH9.+=OXUNWK&_3VUZNMTO#T2-^=.ML=LH=-VFKGC5D<+J9MKN,;U[VO5
M&K(Y%PO)7IXY0Y>Q/D\[9LYKZT:N_)W=+E<[9*Z2-E-214L<C7-5JL>BK(JM
M5KE1<*BKXH0WZ0W0DUKL#:)[_4U=#J#3,<K6/N%*JQR0\;N%BRQ.YMRJHGHJ
M[FO:2!\F5O?J*^W6^;=W>NFN5MH:#V1M\E0Y7NID;)'&^)'+](O6-5&]RH['
M:7OVJJ;%5RQ<UH[ZL.->HG)IM9-J*:XZ3"SRK&L4;)H'2L;TQ_=-RGCS^ECB
M7'[L8ET!.B-8=U[77ZZUM2+<;5!4NI+=;)%5L4SVHU7S/PN7(BJB(F<*J.SV
M8-?>4/UA^2CI-7BF;)UD-EHZ>VL5%Y<F=<Y$]:.F=GWB=?0#K*"JZ*^D(Z)[
M'.@6JCJ&(J*YDWG4KE1W@N'-5,]RM,EVJO&P*(HG29_KS4LTV\O:=<UQK$1_
M+DT3T_\ HLZ(T7MA'KC2-DI]/UM#6105<%"W@AGADRU%ZOL1R/5G-N,HKLYY
M8X_DI]754K-?:9FJ'R44/FMPI8%7T8WNZR.5S?#B1(L^\95Y4#=*CM.WMDT'
M3RM=<[O5-KJB-.:QTL64153NXI%;A?"-YCWDK-$U=/;=<ZMFB<VDJG06VED5
M.4BLXI)53U>G%]_P*Q555LV9O3K.O):::*-J1%F-.7/3Z2T-T[]]*[=3>:ZV
M:&I>FG-,U#[=24Z.PUT[%5LTJ]RJKVJU%^I:WQ4E;T9.@'HJQ: MMUW!LJ7[
M4U?"D\M+6.<D-$UR(J1)&BHBO1,<2KGTLXP>?%TZJV;YUBWYF(*?4;_/VR)]
M*VJ^>HJ>I$7M/<JDGCJ::.6)[9(7M1S9&JBHY%YHJ*,^Y5C6+=JS.D?(V;:H
MR\B[=OQK/PEY5]/[HW:9V,U'IRZ:1B=06J_,G9);72.>V"6)8\N8YRJ[A<DB
M+A5Y*WER7"2X\G/N+<->='V*DN<SJFHT_726J.61W$]T",9)&BKX-23@3U,0
MBWY3'=6@UINM9]+6V9M1%I>GF953,<BM2IF5BR1IZVMCCSS[55.7"I)[R<6A
MJK1?1S9<*UBPR7^X372-'HB*D/ R)B^\J1*]/4]",G6=GT3=YU3_ )_).)$4
M;2KBSRIB.>G^?%#/RA^KOR4=)F\TK9..&RTE/;H\+RY,ZUR>^CYGI\!(WH<]
M!G2TF@K5K3<"V-OUVN\#:JFMU7E:>E@<F8^)F?3>YJHJ\7),XQE,K"&]S2[X
M=(*K="]SGZJU(K(7=[6SU&&>]PHY/B/;ZBI8J"BBIH&-C@A8V-C&IA&M1,(B
M? 6SKU>-CVK%,Z3\E=G6:,O(NY%R-8UY/'CIP:!TKMMO[<['I*A9;;>RDIYI
MJ.%56.*9[.)R-157"*U6.QV>EW'I3T.:2JH^C+MY'6Y65;8V5O%V]6]SG1I]
MHK?@/+#I):BFW*Z2&MJRES525=ZDHJ3AY]8V-R018]]&-P>P=)<M-;.Z%L=O
MO%ZMUCM=OI(:"&HN-2RGC=U<:-1$5[D3.&E=H35&/9HJYU3_ &6V7%/FKU=/
M*F/[O&[7U\=5=(*^7+7M-57)D>HWK>*1LBMEDB9/PR0L<JICT&\#>:(B8QC&
M4GYI:#HD;]:=;8K90Z;M-7/&K(X%IFVNXQO7O:]4:LCD7"\E>GCE#LMR>CIL
MKTQ;G=K]I?4D$>I:;AAK+K89FRQN<K5ZM9HU]%_)JX<U6JO#A7*B8(7](7H2
M:UV!M$]_J*NAO^F8Y6L?<*15CDAXG<+%EB?S;E51/15_-4YFS3<LY<46]^:*
MX[-6;=["FNYNQ71,]4Q]B?)YVS9K7MIU?^3JZ7*XVR5TD;*6DBIHY$<U6JQZ
M*LBJU6N5%PJ*OBAH+REF^-9J7<6+;J@GEBLUA8R6NB:Y4;4U<C4>W*=CD8QS
M<9[WO\#-_)D[WZBOUTOFW=VKIKE;:&@]D;?)4.5[J9&R1QOB1R_2+UC51O<J
M.QVD5NES!5P=)7<5E=ELBW61Z<7->K5$5BX\.!68,>-:KG-F+\ZS3')DR;U'
MD*9QXW8JGFFET1NB+MM;ML;1J+6]';K_ *BO-.RL=!<I&NBHXI&YCB2)5QQ<
M*HKN)%7B7'+'.,G3OV7TMM#N=;)-&LCI++=Z-:A:.&99&4\[7JCT8JJJHU45
MJX7L55QRPB;DMWDK(;G;J:MH]UV5%+4Q,FBE9I_+7L<F45,57/**B\C'JGR>
M.C+??JBPU/2 L=->J;"36Z6W0LG9Q(CDRQ:SB3*.1?A0FS?M4WIN579J^6DH
MNV+U5B+468ITTYZPFYT4=<5FXO1[T3?[C4.JZ^>AZFHG<OI2R1/="YSO6JQJ
MJ^M5-M-1.9@.QFV,.S^U.G]'P5_LI';(7,\];#U23J][I'/X.)V,J]>]3/T1
M#S-Z:9N531TUG]'K\>*J;-,5]=(U^JX &-L@
M
M#Q@\JKN%<=3]*"KTY/4*ZVZ9H::FI:=/<L?-$R>1_P"F=UC$5?!C? V'M=Y(
MR[:QVWM]^U#KINGK]<:5M5%:XK;U[*='-16-ED65JJ["IQ(B>BN43B-$^4?F
M\XZ9VX[N'AP^A9]K;Z9N3W,BA9#&V-B<+&IAK6\D1/ #\^MCDU5T3ND91.K<
MV[46DKNQ*ED+O1EC:J(]J*F.*.6)SD[LM?W'Z#6O1[4<U45%3*+XGAWY2R!D
M/3,UZK$YRLMSU]:^8TZ+CXN9[=6O/L=1]WSIG+]B!R^'M[BXMXD1.9<
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MV>XN  M1V>?<5X@*@MXBN>60*@MX@C\]P%P
M
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M:;W\FE@8U-.T9IB=8I[_ #29!1.PJ>3>Z
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MO]#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@
M              %,H5,"W6W$CT'8G)"J+=:I'-IH^WAQVR*G@GWU5/7@,.WL
MUQ4W&K9HRQ\4]74/:RJZKQ7'#%GU]J^KEXFPMN]#4VA;!%11XDJ78DJ9^^23
M&/B1.2&&[([>26NG=J6[HZ2[5J*Z+K>;XV.7*N7\\[/P(OK4VYP@7
M
M
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MNO:-543%%$4S/68:5O95,3'B5S5%/2%(HFQ1M8Q$:QJ(C6HF$1$[CZ@'(=\
M
M                          !XB^4%T!J>\=+S<2LH-.7:NI)9J-8ZBGH9
M9(W8HH$7#D;A<*BI\!HW\B^YOUHU9]S57^@_15P^OGVE<(!^<6IVXUU63/FJ
M-+ZAGE=C,DEOG<Y<(B)S5OJ.>FE]S$Y):-6(G_=:G_0?HKP@P@'CQY-6Q:WH
M>E19)KW07ZFM_L?6\3Z^&=D7$L3L95Z8SGL/8@MX2X
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M.9GHF'/XE5S<_L5:@'<Z-T9;]%6=E!0,_/33N3TYG?5.7_-W&1
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MR)^R4]50
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M\*M94-8CG4\J+F.5J>+787M3.%3L536O9M$Y-%5/Y:6[C;.KIQ+E-?YZT/\
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MK$.+LBS7OW;URG2:I?8 '#>F
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M\55>8'8-9P]Y<
M
M
M     %$[.1P[A;*6[4DE+6T\-72R8XX9XT>QV%RF47DO-$7X#FEJH%=->KI;
M5I"QV*H6HMMHH+?.K.K66EIF1N5N454RU$Y<D^([K/J*(F>\8]9.LSU(IBGE
M$+P 0L
M
M                           !&[RB_P!!ON%^U_\ 2-,21(W>47^@WW"_
M:_\ I&F >3G^@WV^_;#^D:DDB1N\G/\ 0;[??MA_2-221
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MTBZR6"-\]3.Y):^YU#4Z^KD1.2N5.QK<JC6IR1%7M57*NT0
M
M                                  L1N/\ \!P]^"\IA +%;E,%W9W#
MA*X0"SA[^Q1P*7X0<(%/?0MX?67X0IP^L"WA7Q*\/K+L(,(!4MX>WN+@!9P>
MH<//D7<(X0+<*[O+P /GP\\Y#6)AR=I?PCA(^8J "1\^'WRJ)X%W",(!3A+@
M /GU??DKP\NTN1.13&$4(7%O#ZRX!*Q&_#\(  O +>)? "X
M
M       UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6I=?YG*!&_R2'T..I/UUU/\
MSHR;1"7R2'T..I/UUU/\SHR;0                 U?O9N)^1:SK:Z"1?9>
MN:K4X.:PQ]BN]]>:)\*]W/-M4ZFI=)6&KNE:N(H&\F(O-[EY(U/6JFG=I=,U
M6O\ 5-3K2^M62%DO]S,<GHND3LPGU+$Y)Z_>4#-=F=O4T98.OJX\7:M1'S93
MG$WM;'\&<KZU]2&QRU&^LN
M
M
M
M
M                                              1N\HO]!ON%^U_]
M(TQ)$C=Y1?Z#?<+]K_Z1I@'DY_H-]OOVP_I&I)(D;O)S_0;[??MA_2-221
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MB;##"Q,-8QJ(UK4]2(B(<KA]?WBX"G"4:W!<
M
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M>JX[N+"'LFBNQS[<<S!EXT8U<13.L2V,#,JRZ)FJ-)CK\'V 0&BZH
M
M          &M>DO]#CNM^M2Z_P SE-E&M>DO]#CNM^M2Z_S.4"-_DD/H<=2?
MKKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@              6J['<7&NMY=?MT=I
MQ\%-(GLI7(L4"-7G&WL=)\&<)ZU]2@8%N)=*G=77])I2UO7V.I)%ZV5/<JY/
M[Y(OJ:G)/%57Q0WE:+/366VTM#1QI%34\:1QM\$3_.O>8#L?H'\BNGUKZN/A
MNMP1'R<7;''G+6>_SROK5/ V<
M
M
M
M
M                                                   "-WE%_H-]
MPOVO_I&F)(D;O*+_ $&^X7[7_P!(TP#R<_T&^WW[8?TC4DD2-WDY_H-]OOVP
M_I&I)(@              Z;5&IZ+2ECJ;I7/5(86\FI[I[NYJ>M5Y':2RMCC
M<]RHUK4RJN7"(GBOJ(^ZHNE5O9KNGL5KD<VQ4;E5\[4Y*B<G2_\ A;[_ *U
M^NWVF:W=O551JO4+>*VQ28AIU]P]6]C$_.M[_%5];C?[8T:B(G)$[$\#B6JU
MTUFMM/0T<;8J:G8D<;&IV(G^<YP
M
M
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M:LB>\DCI#U$Z.ND/R"[&:&LBQ=5-2VBG6=G9B9[$?+_EN<5RHBUA6J=.<_\
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MY*N$;ES53+>)O-<Y/.9EG)F:KMV.^FO]GJ<#(Q:::;5F>L:Z?YW;\ !S'<
M
M                UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6I=?YG*!&_R2'T
M..I/UUU/\SHR;1"7R2'T..I/UUU/\SHR;0             !P+M=::RVVIN%
M7(D5-3L621W@B?Y^[X31.AK95;O[@5.I;G$[V*HG_.XG>YRG..)/%$3F[UKZ
MSL=]=1U-]N]MT7:EZR::1KJAK?IGJOH,7P1/=+W<T\#;&D-+TVD=/TEKI4]&
M%OIR8YR/7FYR^M5 [KA+@
M
M
M
M
M                                                1N\HO]!ON%^U
M_P#2-,21(W>47^@WW"_:_P#I&F >3G^@WV^_;#^D:DDB1N\G/]!OM]^V'](U
M))$           !3B*F,Z\U=!HO355<Y_3>U.""+_K)%]RW\.?4B@8!OIKB?
MYUI&T<4MPK>%*A(O=(URIPQIZW?@]\S/;705/H/3\=*U$?7S8DJYT[7OQV9^
MI;V)\/BI@FQ^CI[I75&M+UF:KJ7N=2]9VY7*.D_\*?#ZC=?"!<
M
M
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M2>*JO:KE7*JY>:JJJO-3#F[0HR[44:3$Q/V;.S]F7,.]OS5$Q,,E !PWI@
M
M               -:])?Z''=;]:EU_F<ILHUKTE_H<=UOUJ77^9R@1O\DA]#
MCJ3]==3_ #.C)M$)?)(?0XZD_774_P SHR;0           #I-5ZDI]*:>KK
MK4JG!3LRUN?=N7DUJ>M55$.ZRAH+=2\5.XVNJ+1UI?FFIY?[HD;S:DB)Z3E]
M3&JJ>^J@<O8?3M1>[M<M9W7YY/-(]D#G)VO5?3>GJ3/"GPF\SK;'9J>PVJDM
MU(W@IJ:-L;$]2)VKZU7F=D
M
M
M
M
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MF$:U$PB?$<H
M
M
M           (Z=+GHP7/I+V_3E!2:FAT_2VJ::>5LM&Z?KWO1J,5%1[<<*([
MQSQ=V.?9]$SHTKT:M'7>T2WB*^UEPKO.WUD=.L#48D;6M9PJYW8J.7.?INSE
MSWHC,>\5X<_ 9_'N>%X6OX?@THQ+47IOZ?B^*\ &!N@      4 J
M   !0"H
M                                     &M>DO\ 0X[K?K4NO\SE-E&M
M>DO]#CNM^M2Z_P SE C?Y)#Z''4GZZZG^9T9-HA+Y)#Z''4GZZZG^9T9-H
M        4X@,(W6URW0^EIIXW(EPJ56&E1>YV.;U]34^_A._)CVQ.AUL5D=?
M*UB^R-R3+>/W4<*KE.WO=[I?5@Q2ZYW<WDCH6_/;+:U5KU3FU6M7+U_9.7A]
M['@2!:U&M1$Y(G8B?@ O   'QFG9!$^1[FL8Q.)SG+A$3Q5? U?J'I$6"TU#
MX*""HNSVKA9(\,B^!R\U^+'K VL#3]FZ25EJZAL5PMU5;F.7'6HJ2M;ZW(F%
M1/>13:ENN=+=J.*KHYXZFEF;Q,EC=EKD Y@
M
M
M
M
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M_P!!ON%^U_\ 2-,21(W>47^@WW"_:_\ I&F >3G^@WV^_;#^D:DDB1N\G/\
M0;[??MA_2-221         '3ZHU%3:5L59=*M?G5.SBX>Q7N7DUJ>M5PGPG;
M\1H/=F\5.X.MZ'1EJ>JPP2?/W-3*=9],J^IC<I[ZN\$ Y.R&G:G5-_N&MKNG
M62/E<E-Q=BO5,.<GJ:GHI[Z^"&\N'UG L=GIK#::6W4;.KIZ:-(F-]2=_OKV
M_"=B
M
M
M!1.P%$=DTOTGNDG0]&O25LO-5:9+Y+<*WS2.DBJ$A<B=6][GY5KN2<*)V?3(
M7MVZKE<441K,L-R[1:HFNN=(ANCFB]A3B144B3IGRB>DKAM;=-;7VQU5DB@K
MO8Z@MD=2VHJ;A,D;7R<"8:B-8DC.)RKA$<G>J(O,Z+?37K>D?KFY6)FA766D
MHZ5U7)<&W+SAL;45K6L<G4LRYSG93GV<7U.5V*L.]335553RCJU*,_'KJBFF
MK69Z)5IWY*9(J;Y>4-T#M-=JRR6FEJ-97RE<K)XZ&1(J6&1%PL;IU1<N3OX&
MNQS1514P:LTYY5NAGN2,OFW=114#Y.<U!<TJ)(V=_H.B8CE3],G@7HP,FNF*
MJ:)T4KVGB6ZMRJOFG^G>.XQ3;K<BP;I:5HM1:9KVW*U5:+P3-16N:Y%PYCVJ
MB*UR+VHJ?A0QO?'I#:/V T[%=-4U<C9:A7-I+=2L22JJG-QQ(QF43"93+G*C
M4RF5RJ(NI%NNJO<B.;=F];IM^)-7X?BV>BE/A//6Y^5@_NY?8[;;K*)KO=U5
MXX9'M]YL*HQ>WO=VFV-B?*(Z+W9U!2Z>O%LJ='WFL<D5-YS.V>EED7LC27#5
M1RKR3B8B+RYY7!N58&113O31R:-&T\6Y5N17S_1+3.$&3&=QM:TNWF@]0ZGK
M(UFI[/0S5KX6N1JR=6Q7(Q%[E<J(B>M4(DZ'\J!I74=Z?3WS3-1IJV1T\D\E
M;)7).[+6Y:QD;8T5[W.PU$1>]57DBXP6\:[=IFJW3K$-B]F6+%44W*M)E-OB
M08( WORKUNCN:LM&WE55VQKU3KJVZ-@F>WN]!L;T:O?[I>SX23?1VZ3VE>D;
M8:BJLB34-THN%*ZU56.M@XL\+D5.3V+A<.3X40O<Q+UJC?KIY*6L_'O5^'15
MS;D3 RAUUWO%%8+;57"Y54-#0TL;IIJBH>C(XV-3*N<Y>2(B$,=Q_*C:2T_<
MIZ/2&FJS5D<3E:M?/4>90/5.^-%8]ZI^F:WXN9CLX]R_.EN-66_EV<:-;M6B
M;W:$YY("Z/\ *KVRKN<4&IM"5-MHW.1KJJUUZ5+F(O>L3F,RGO.5?!%7DLUM
M!:]L6Y&EZ'4.F[C%=;16LXX:F%>7;A6JB\VN145%1>:*BY+7L:[8_P!RG13'
MS+&3K%JK5DJ*,FI>DEO]1='7;^/4];;)+MUM9'10TD4R1*][FO=[I47L:QR]
MG<::T%Y2+1>H-,:AONI;3-I>GMCH8J6E\[;55-QE>CU5D4:-;CAX$RYRHU.-
MN53(HQKURCQ**=8+F98M5^'75I*7N2Y.:Y//FL\J_3MN;DI=MY9+7Q8ZV6\(
MR9R>/"D*HBIX(Y??3L)B[*[T:?WST/3ZITW+*M+(]T,U-4-1LU-,W'%'(U%7
M"HBHO)5145%3M)NXEZS3%5=.D(L9MC(JFBW5K,-@HI3.>Q,FL=\ND+H_H_Z=
MBN>J:N1):A7-I+?2M22IJG-QQ(QJJB83*9<Y4:F4RN51%B%<_*P?W<OL=MMU
ME$UWNZJ\<,KV^\V%48O;WN[19Q+]Z-ZW3R1>S\>Q5NW*M)>AG:")FQ/E$M%;
MLZ@I-/7>V5.C[U6/2.F\YG;/2RR+V,27#51RKR3B8B+RYY7!*J6KCIH7RRN;
M%$QJN<]ZX1J(F555[$0QW+%RS5NW*=)9K.3:OT[]NK6')0HJD-MV/*:Z&T7<
MZBVZ5M%5K::!_ ^KCJ&TE(Y<X5&2*USGX7O1G"O<JIS,8T+Y5*QW&ZT]-JK1
M=38Z.1ZM?7T%<E6D>5]TL2QL=A._"JO+DB]ALTX&353OQ1.C5G:>+35N37&J
M>/8,=OK.GTWJ>W:ML5#>;/617&V5T+9Z:J@7+)&.3**B_P!L=YVW%VFA/+E+
MI4S%41,=UX*(5"P
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M<C\)Z-]%K>J#I ;'Z8UFC&Q5U7!U-PA8F$BJHU5DJ(G<U7-5S?SKF@;:
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MF/6G@:L,FVTI9*O7]@CBRKVUL4BHG;AKD<[_ "44"9
M
M
M
M
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M921N\HO]!ON%^U_](TQ&[VXW]"+^$W]4-:](ORDWY?NSFH=!?E=>P/LMYO\
M[(>SGG/5=5413_WOS9G%GJL>Z3&<\^Q0FWY.?Z#?;[]L/Z1J22)&[R<_T&^W
MW[8?TC4DD0       6\0&-:_U8S1FE:ZY.5.N:WJZ=GU4KDPU/CY^\A@'1[T
MF^&WU>IZU%?5W!SF1/?S7@XEXG?LG?Q?6=#KFOFW:W)I--V^1WL71/5)9&+R
M7']\DSZL<*?^9OJ@HH;;1PTM,QL4$+$C8QJ<D:G) .4
M
M
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M-:Z-514YKW]YOM$R>>RZJ+E^JJCH]7@6Z[>/337UT7@ U70
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M$D:L@IG=L+'=JN_/+V>I,FT+;IRTV9SG6^V4="YW:ZFIV1JOOJB(=GA *@
M
M
M
M
M
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M)GMC9]*SW^?$OK7U&RRWA+@
M
M
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MJJ]YD:)D<(PAR)F9YR[U,13&D*@ +
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M**[FVNY:RL]1I'1-!(L399J1]+1T$*JG6=1'*O'/,[A1%=S3*(BJUJ(AZM:
MT1:MN-&672UB@6FM-HI(Z.FC<N7(QC<(KE[W+VJO>JJO>!D(     :UZ2R?[
MG+=;]:=U_F<QLHUKTE_H<=UOUJ77^9R@1O\ )(?0XZD_774_S.C)M$)?)(?0
MXZD_774_S.C)M       Q#=#5?Y#]'5U:QW#5/;U%.G_ &CN2+\"97X#+L^H
MT%NI52;B[EVO2E&]74M*_AG<WFB.7G([]BU,>_E.\#)>CYI-;1I>6[S,5*NY
MNXD54YI$WDWXU5SO6BM-LG&I*.*AIHJ>!B1P0L;''&U.36HF$1/@.2
M
M
M
M
M
M          X-PME+=:&IHJVFAK*.IC=#/35$:21RL<F'-<U>2HJ<E1>2G. &
M"?E#[:?F=Z5_^"4W^H/RA]M/S.]*_P#P2F_U#.P!@GY0^VGYG>E?_@E-_J&2
MV'3-ITM;66^R6RBM%O8Y7-I:&G9#$U57*JC6HB(N?4=L /A-3QU$3XI6MDC>
MU6/:Y,HYJIA45/6:FN/1%V6NUV]DZK;#2\E6KU>YS;;&QCU7M5S&HC7>/-%Y
M\S<  ZC36E;-HZTPVK3]IH;';(?[W16VE93P,\>%C$1J9]2';@       C=Y
M1?Z#?<+]K_Z1IB2)&[RB_P!!ON%^U_\ 2-, \G/]!OM]^V'](U))$C=Y.?Z#
M?;[]L/Z1J22(    "WB P#>;67Y$M'3I$_@KZ[-/!A>;45/2?\"<O4KD.+L7
MHS\C6D6U<[.&MN2MG?E.;8\?.V_$JK^R5#!]0?[:V\\-L9\\M-K=PR</9PL7
M,BK^F=AGO84D UJ-3A3DU.Q$3D!>
M
M
M                                     %,%0 **W*8*@#K(K#;8'M?'
M04S'M7B:YL+45%\4Y'8(A7&!A/$G69ZJ13%/2%P (7           *8*@
M
M               %O"7 "U69[^_(:W!< +>'UEP       -:])?Z''=;]:EU
M_F<ILHUKTE_H<=UOUJ77^9R@1O\ )(?0XZD_774_S.C)M$)?)(?0XZD_774_
MS.C)M      &/ZVU+'I'3-?=9,*L+/G;'?3R*N&-^-4-<='K3,CJ>XZHKE5]
M57O='$YW;P\7$]W[)W\4ZW>BYU&L]9VG1MN=Q<$K73\/-$D<F>?J:S*K^F7P
M-U6FTP6:W4M!2MZNGIHVQ1M\&M1$3\'WU YX
M
M
M
M
M
M           !&[RB_P!!ON%^U_\ 2-,21(W>47^@WW"_:_\ I&F >3G^@WV^
M_;#^D:DDB1N\G/\ 0;[??MA_2-221    8ON'J=NDM'7*Y(O#.V-609[>L=R
M;\2KGX%,H-#;XW*?5>KK-HZWNR_K&OEQV)(_DF?TK<N]YV0.\Z.VFEH--U5Z
MG;_=%QD5&.=S=U35QGX7<7Q(;=.#:+9#9[92T%,G#3TT386)^=:F$^'D<X
M
M
M
M
M
M   :UZ2_T..ZWZU+K_,Y391K7I+_ $..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&
M3:(2^20^AQU)^NNI_F=&3:    <"\7:&R6NLKZE>&"EB=,_UHB*N$]?(YYI_
MI%:F=16"DL=.N:BXR(Y[6\W=6Q47'PN5OVJ@=5L-:Y]1:COFKZY.*5\CHHW=
MW6/7B?CU-3A1/4Y4-ZF,[?Z9326D;;;>%&S1Q\4V.^1WI.]_FN/@0R8
M
M
M
M
M
M                                1N\HO]!ON%^U_P#2-,21(W>47^@W
MW"_:_P#I&F >3G^@WV^_;#^D:DDB1N\G/]!OM]^V'](U))$   .ON]V@L=JK
M+A4KPP4L3I7^\B9Q[ZFF-B;3-J;4UYUC7MXI5E='#E.2/?S>J?I6JC?>=@[3
MI$:H6CL--8J=V:BX2(^1K>:]6UR*B>^KL?$J&>[?:9326D;=;>%&S1Q\4WKD
M=Z3N?OKCX$ R8
M
M
M
M
M                   #6O27^AQW6_6I=?YG*;*-:])?Z''=;]:EU_F<H$;_
M "2'T..I/UUU/\SHR;1"7R2'T..I/UUU/\SHR;0   6JXC_:?]M'>^:M7Y[;
M+6O$Q>UO!&[#/MGKQ>]DV9NUJC\BFA[A4QOX:J=/-H%SS1[DPJI[R(Y?@.DZ
M/^EO831ZUTK.&IN;^NYI_P DF48GWW+[SD V?PEP
M
M
M
M
M
M                  C=Y1?Z#?<+]K_Z1IB2)&[RB_T&^X7[7_TC3 /)S_0;
M[??MA_2-221(W>3G^@WV^_;#^D:DDB /F^1(VN<Y4:UJ95RKR0^AKW>W4OY'
MM!5K(W\-37*E)'CMP[W:_:H[XT U[I)%W4WAJ[W(BOM5N<DD:.[.%N4B3'K5
M%>J>I20?":[V-TS^1[0M++(S@J;@OG4B]_"ON$^U1%_9*;%
M
M
M
M
M                                                       :UZ2_
MT..ZWZU+K_,Y391K7I+_ $..ZWZU+K_,Y0(W^20^AQU)^NNI_F=&3:(2^20^
MAQU)^NNI_F=&3:  '"NUQBM%LJZ^=<14T3IG\^YJ*H&C=VZJ77VY=HTG2N7J
M*9[4E<WN<Y.)[OV+$^/*&]J6CBHZ:*GA:C(8FM8QJ=B-:B(B?>0TCT?K;->[
M]?M55C>*6218V/[N-Z\;U3PPBM3]D;W
M
M
M
M
M
M           1N\HO]!ON%^U_](TQ)$C=Y1?Z#?<+]K_Z1I@'DY_H-]OOVP_I
M&I)(D;O)S_0;[??MA_2-221 &@-W)GZZW0LVEJ=RK#3N:V7A[G/]*1?@8B??
M-YW.XPVFW55;4+PP4\3IGK^=:F5-)["6^;46J+[JRL;Q2.>Z.-R]B/D7B=CW
MFX3]D!O*&!E/"R*-J,C8U&M:G8B)V(?8
M
M
M
M
M                                        !K7I+_0X[K?K4NO\SE-E
M&M>DO]#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG1DVB$ODD/H<=2?KKJ?YG1DV@!
MJCI#:C]BM',MT;^&>XRHU>?_ ";,.=]_A3X5-K90T!JO_;%WRHK2B];0VUS6
M2-^EPQ>.3/OKZ/P ;2VOTU^1?1%KHW,X*AT?7SIC'SQ_I*GP91/V*&7%,(5
M
M
M
M
M
M                                       1N\HO]!ON%^U_](TQ)$C=
MY1?Z#?<+]K_Z1I@'DY_H-]OOVP_I&I)(D;O)S_0;[??MA_2-221 U;T@M0^Q
M.B/,6/X9KE,D6,\^K;Z3U^\U/V1D&T^GOR-Z$M5,YO#/+&E1,F.?$_GA?6B8
M3]B:SW$_]/=YK5I]B\=)1JQDR)S3LZR3_)1$]]#?B,QCU 7
M
M
M
M
M                                                        !K7I
M+_0X[K?K4NO\SE-E&M>DO]#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG1DVB$ODD/
MH<=2?KKJ?YG1DV@.GU/>XM-Z>K[I-CAIH72(CN]V.2?"N$^$U3T=+'+.R\ZE
MJ^*2>JE6"-[NU>?%([WE<J?:J??I&:@>VVVW3],JOJ*Z5)7L;VJU%X6I\+ES
M^P-DZ-T_'I73%MM;$YT\36O<G>]<N<OPN5?C [X
M
M
M
M
M
M                    (W>47^@WW"_:_P#I&F)(D;O*+_0;[A?M?_2-, \G
M/]!OM]^V'](U)(6Y7"*U6VKK9UQ#3Q.F?^E:BJOWD(]>3G^@WV^_;#^D:DV+
MO[?_ &(T'+3,=B:X2M@:B=O#[IWWDQ\(&*]'^WS7R_Z@U35IQ2R2.C8Y>:<;
MW<;\>\G"GO*IO8PK9^P?D?T!:X7-1LTS/.9/'B?S3/O-X4^ S4
M
M
M
M
M
M&M>DO]#CNM^M2Z_S.4V4:UZ2_P!#CNM^M2Z_S.4"-_DD/H<=2?KKJ?YG1DV<
MH0F\DA]#CJ3]==3_ #.C)9[AW[\C6C+Q7H[AE9"K8E_/N]%J_ KD^(#4MA3\
MLG?*JN']^MMK7BC=]+PQKPQX]]^7>]DD!A#4O1RT_P"Q^D*BYO;B6OG]%?\
MLV>BG^5Q_>-M@
M
M
M
M
M                                                       C=Y1?
MZ#?<+]K_ .D:8DB1N\HO]!ON%^U_](TP#R<_T&^WW[8?TC4G9[M/=KG=2S:8
MA<KH*=6LEX>Y7^E(OP,:WXE.B\GQ7Q6SH4:'K*AW!!3QW*61W@UMPJE7[R&2
M;#4$NH]5W[5E8STU>YD??Z<B\3L>\W"?L@-YQQMC:C6HB-:F$1$[$\#Z
M
M
M
M
M
M        UKTE_H<=UOUJ77^9RFRC6O27^AQW6_6I=?YG*!&_R2'T..I/UUU/
M\SHS=_21O,CJ.S6&#+IJJ99WL;VJC?18GPJY?B-(>20^AQU)^NNI_F=&;<;_
M .GG2"7_ )2CM+_?1.I_TR_A W1IBS,T]IZWVV-$Q2P,BY=BJB<U^%<K\)VQ
M3"%0
M
M
M
M
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MY)>'M3K+E4*Y?@8U%^%3T'CC;&Q&M1&M:F$1.Y/ #Z
M
M
M
M
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MVU6\$D,#5E_QCO2?_E*H&1
M
M
M
M
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M5W$YE0]?<QNQAJ\U3.$RJ!*<
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M$W]4'MQOZ$7\)OZH!Z1 \W?;C?T(OX3?U0>W&_H1?PF_J@'I$
M
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MMUEIJ>>/B:K7<,C&(Y,M<Y%PO-%5.\SL
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M]SCJ7O\ _2NI_F=&3;
M                         #6G27;_ +G+=;]:EU_F<Q'#R229Z..I.[_T
MKJ?YG1DC^DN[_<X[K?K4NO\ ,Y2-_DD7?[G'4O?_ .E=3_,Z,";8
M
M#S=\CGS_ "W/VH__ %T](CS=\CFJ)^6[^U'_ .NGI$
M                                                  \W?(Y\_P M
MS]J/_P!=/2(\W?(YJB?EN_M1_P#KH'I$
M
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M7"<U55.W
M              '4:DTO9]96>IM%_M5%>[34\/74%RIF5$$O"Y'-XHWHK78<
MU')E.2HBG;@#J--:7L^C;/3VBP6JBLEIIN+J:"VTS*>"+B<KG<,;$1K<N<KE
MPG-553MP
M             !CVJ]"Z;UY;HK=J:P6S4=!%,E0RENU%'51-D1'-1Z-D:J<2
M(YR9[<.7Q,A ' M=IH[);J:@M]+%0T%+$VGIZ6FC;'%#&U$:QC&M1$:UJ(B(
MB<D1#G@
M            #%M9;9:1W#\T_)7I6RZG2CX_-O9BW0U?4<?#Q\'6-7ASPMSC
MMX4\$,I
M                                            %O AK/6O1GVJW%ND
MESU)M]I^[7*1W%)6S4$:3R+G/IO1$<[X54V< ,3T-M;H_;2DFIM(Z7L^F8)E
M1TK+30QTW6JB817JQ$XE]:\S*N'UEP      !;P%P MX$Q@N
M                                                        "W@'
M F,%P
M               *<)4
M                           !3A*@
M
M                                               MXN6<&G]SNEMM
M#LY='VS5VNK;;+G&F9*&+K*JHC]3XX6O<U>_"HF4Y@;B!IS:WI>;/;R71MLT
MAKJW7.YO56QT4S9*2>54SE&1S-8YZHB*OHHO(W#QH!<
M                                             %O%ZN8%P-3[<=)[
M;O=G<'4.BM*7QUVOUA21U<R.GD;$U&2)$Y6R*B->B/5$]%5SVIE.9M@ "WC]
M7(TCN%TU-DMKKQ46K4FX-MIKG3OZN:EHXYJU\3^66O2!C^%R93*+S0#> -6[
M3])S:[?&1\&B=9V^]5C$5RT/IP5/"G:Y(96MD5J?5(W'K-GMD1R(J<T4"\
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M,B-D1N51,JW&5P;&X_! +P
M                    !PZZX4UKHJBKK)XJ2EIV+)+/,]&,C8B95SG+R1$3
M/-? T!>O*$='S3]P=156Y=%+,U51745#5U4?+OZR*)S,>O.%[@)%@PC;7>;1
M&[]M?7:+U/;=14\?"LJ44Z.DASV=9'[MBKCEQ(F3-LH!4'PFG93QODE<D<;$
M5SGN5$1J(F5557N-!ZHZ?FP&C[E+07#<FWR5$;U8[V/IJFM8CD[4XX(GM^^!
M(,& [7;XZ#WGM\U9HC5-NU$R%,S1TLN)H<KR5\3L/9GNXD3)GO$!4
M
M                                  !;Q8]9&S?;I_[1[ WF:Q76XUFH
M+_3NX*BV:?A94/IG?4RO<]D;'?G.+B3'N>S(25!"/17E:=GM27B.ANUNU%I>
M*541M?6TL<L#.>,NZI[GHG/M1J]_83*LM]M^HK327.U5M/<K;5Q-FIZREE;)
M%*QR9:YKFKA45.] .R
M                       *90"H(;7?RK.REDO%?;I8=32RTD[Z=SX;?&YC
MU8Y6JK5ZWFBJG)5QG*'$]MMV0_\ 5-6?_#(OE@)J CCL%T[MMND9KF32>DZ>
M^1W1E')6JZXT;(HN!CFHJ<22.]++TY8\21P
M                                      +./XO'(%X(UZXZ<VD-(](Z
MQ;.4UMJ[W>[A4T]'4UU+*Q(**:9R<,;L\W.1JM<N.2<2)G.422@ %KG8[LD:
M=\_*#[1[#7N>Q7*XUNHK_3N5E1;=/Q,J'T[D[6R/<]C&N1<HK>)7)CF@$F 0
MET/Y6G9O4UWBH+O0ZATK'*Y&MKKA31RT[?TRQ2/<GVJ]Y,FT7FAOMLI;C;*R
M"X6^JC;-!54TK9(I8U3+7M<U5145.Q4Y =B
M                                     LX_5WX(W:XZ<VD-(=(VP[.4
MUNJ[W>[A4T]'4UU+*Q(*&:9R<,;\\W.1JM<N.2<2)G.40)* %,H!4$,;AY5[
M9.VU]71N@U-,ZGE=$Z2&WQ.8[#E3B:O7<T7'+D?'VVW9#_U35G_PR+Y8":@(
MZ='_ *=6W'20UM4Z5TE#>X[G!125[UN-(R*/JV/8Q414D=Z69&\L=RDBP
M
M
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MY(;4,]IZ0VJ+#(Y6P7"P2.?%GEUT,\2L7X&NE^,#U[
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MQIGDQS73,>J>^CH^?YU /3X
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MK6\.>YTC# _) Z&K[!LOJG4M7%)#37Z[-91HY%3K8X(^%9$SVHKY'MY=\;O
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MT/
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M89$3[=95^$"<@
M                                                     "._3KW[
MGZ/_ $>KU>K9*Z'4%RD;:+5*WMBGE:Y5E]]C&2.3\\UJ=Y$;R<70MTSN?I.H
MW8W'H/R3^?5<T-KM]>JR0/1C^&6IESSD<LB/:C7<DX7+A55.'M_+-7Z:&V;5
MV5DG]S3S7&MFC\7L;3LC7XI928/0QL,>G^BMM;2QMX&R6&FJU1$QETS>N5?A
M615^$# ^D5T ]L=WM"5]+8=*6?1^J885=;KE9J..C;UJ)Z,<S(T:U[%PC<JB
MJU%]%4QSC+Y)_?*ZV?5FH-EM132) UDM=:H:AWI4T\;\5%.U.Y'(JR</8BQR
M+],IZ>\*^)XXZ.5=NO*KRQT:MC;)K.LB1J81.KJ^L1S<8[DG5$]Y /9
M
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MD^-V%P].7+"HB\C=P
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M85LB]YZ;\)XX[69V\\JG4T](K(X7:ON=,V/L:D52DZ</O(DJ8_2H!['@
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MJ)&JK[E&\:KE3/?;4]\=#WUJ:UV[LL%*Y^7T,UOK+=-P\_18^21R)V=JM=S
MGALMT,]K-@-5U&I-$V6IMMVGHW4+Y9J^:=O4N<QSD1KW*B+F-G/'<;R-*]&;
MI5:.Z3^DY;MIN62DN='PLN-FJU3SBD<N<+RY/8N%P].2XY\*HK4W4
M
M
M !XW^4Q:]G35HU>OH.HK8YN57W/$Y/PHI[')S]9Y.^6&T1-;-V-$ZPCC<RFN
M=I=;W2-_ZVGF>]57P7AJ&8_2^I3TVVOUM3;C[<:8U312-DI[O;8*Y',<BHBO
MC1RM7'>BJJ*G:BH!E9XY^3 C6JZ95?-3KB%ELN$BMPGN%>Q$3[Z?$>K6[VNZ
M?;7:S5^JZB5L4=GME16M<YR)Q/;&Y6-3/>YW"U$[U<GB>:GD=M%2UVZ&NM7N
MC>ZFMMI9;62*B\*R5$S7KA?%&TRY\./GC('K
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M?3NX^L9F.ZFKJJ6U4[U3"?.F.EE_EHO>Q\0>D@
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MU]O/50JJ<GPT\;6HY%\.LDF3]BH$]
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M3]-\($R0
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M[[YN'+2N=;Z.IN6HIN-/1CDG>]D+%]:+-E$\(U\ /8(
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M[;GBI9:GYI_RD4%VT]UE=:JK5,-P94-9A%H:-6*LB^"+' F,]JN3O5#VK
M
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MI+C?ZASFJK&35+GLC8J_59G>Y$_[-? #V"
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MU2ZK;=V5'!A/,:1Z/1[OJ4<R%B<^]Z)VK@]J@
M
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MURMSSX&M:UC<]J-SR55-S1P,BC:R-J,8U$:UK4PB(G<G@?3A]8%P
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M&P5C\%X?>+P
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MWEP
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M"U$QZU:1TK;=$:7M&GK/!YM:K52145+#]3%&U&-15[^2)]]3N>#\.2X
M
M                                     Z#6NCK3N!I2[:;OM*VNM%TI
MGTE53O3W4;T5%QX+WHO:BHBIS0\M:OHL]([H5;CU]^V;\ZU9IRI5&<5!&VH6
MHAXE5D552<E5S45</8BHG$JM<WB5IZTEO#ZP/)C6L_3/Z7MOI])W;2-9I73M
M2]J544MN=9Z63A7*.G=-\]<UJ_2-RBJB*C55$4G7T/>BM:>BSMRZT0SLN6I+
MBYE1>+HQ,-ED1%1L<:+S2-F51N>:JKEY9PF_.'U\O>",]8%P
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M7
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M#>_#ZQP^L"X
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M(N%5R\WJB*O)&M23A:C<9QR+@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MDC>G$U[5RCD[E1>\^P
M
M
M
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M$7&I^C!9]6V?8S2::[N]9>=6U=*E;<)ZY462.25>-(5PB8ZMKFLQXM4VP
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M;^8'H:#7FQ6\5HWXVLL.M[+Z%-<H<RTZNRZEG:JMEB=ZVO14SA,IA<84V&
M
M
M
M
M
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M57:6N$'LG:75+^*1C7+P21NQR5[5C1,HB9;P*>D/DJ?H2K?CL]EZU/\ +0#
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M<-55%+N=N#IE)/[FKK1%<E9GZ:"9L:*GP5*I\"'JZ
M
M
M
M
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MG;]-L.COM[IM8NIGI+1!)4LQC%1*WK9O_F2/ BI2^5AI/RYXM#W#;N*UV_\
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M]6RJJIJ*1O<YLL$C,+^R5N/6A[N@
M
M
M
M
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MH
M
M
M
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M0>])Y'>2%VNFO^\>H]<31YM^G[<M)$]4[:JH7"87U1,ES^G;XGKB
M
M
M
M
M                                                      "W@]:E
MP MX5SVA6Y+@!;PIX>LB!Y1CI5ZGZ-N@]/4FCV1T]_U)-41QW2:%)6T<<*1J
M]6L<BM615E;CBRB(CEPN.4P34W2(Z->D.DOHQNGM61U$:4\OG%%<*%Z1U%))
MC"JQ5145%3DYKD5%1$[%1%0(";N]'J_UW14K=VMT=_;YJB6NM4-?;+)#5*E
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MLCG8SV)A#91;P<\Y+@
M
M
M
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MG[;::>KVUL>O]MKS#U5?[+PR/;#5M?EK7/:Y6MRW@<U5;G+'8=V8BUJGI/\
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MQGKX57EG!OHM1N%S_F+@
M
M
M
M
M                                   UMNUT=MN=\Z>&+76DZ&_OITX8
M:B1'15$;<YX6S1JV1&YY\*.QE#7^B^@!L+H.^17>V;?4LU;!)UD+KE5U%;'&
MJ>YQ'-(YBX[45S55%YYY(2) %G5IC'=X8+P
M
M
M
M
M                                             #BU='#74TM/4Q1U
M%/*U6OBE:CFN:O:BHO)4,6I-F]!6ZO974>B-.4M=&_K&5,-IIV2-=]4CD9E%
MYKS,S %O G%GO+@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                        %O$!<"F4*<7/ %P   MX
MBC9.),XY 7@     !:CO4!<"SC\$R5:N?P 7 %O&@%P+>+U#B]0%P
M            %.("H+>+U%P  MXO4!<      %O$!<   !3B J"WB+@ +>+U
M%&NXDRG8O9S O         +.-._DO<!>"WB\.?PA'9[ +@6=9^=4KQ>H"X M
MXN>, 7 L61&]O(KQ 7 MXO47  6\7@F1Q 7 M1W+*I@KQ 5    MXO5W9 N!
M3B*@ 6\7/!< !:CO4$=ZL 7 L147^WWRO%SP!<"G$.("H     "WB]17B J"
MG$4XL@7                    6\0%P+>(<7J N!;Q>H<7@F0+@6\7>7
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M\61Q\\8 N!;Q=@X@+@6=8A7B N!;Q(N>\<7JP!<"WB]7(([QY 7 IE"H
M      IE *@     *<14 "WB\2O$!4%O'ZE"NQW 7 MXBX "WB*(_P!6 +P6
M\0XL@7 %G&G@!>"WB]119.%,XY9P!>"WC0KQ 5!:CL\^[Q'%Z@+@"SC3P O!
M;Q%P         %O%ZAQ<\ 7 ^?&G/XNTKQ]G("\%O%RSW#B]2@7 MXO4.+U
M7 MXO44ZQ,X[P+P"WB]0%P*<13B\$R!<"G$5            "WB]0X@+@"WB
M]0%P+>//8F2X "WB]0X@+@6\7-4"/SS3F@%P+>+U!78[@+@6\7J#79 N
M               %O'ZE''ZE N   %O&A7B J      MSX^^&NXNX"X
M            IE *@  "WC]2CC]2@7                         %O%Z@
M+@4RA4    *90J                 !3B*@ 6\7B5X@*@MX_4I7B J"WB]1
M< !;Q%$?ZL 7@MXO$KQ 5 +.-/ "\%O%ZBBR<*9QRS@"\%O&A7B J"WB["G6
M(O9S O      "WB N           %,E.+U<@+@6\0X@+@"WB[@+@
M     %O%ZBX
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M!]Z^Y4MLHIZNMJ8J2DA:KI)YWHR-B)VJYR\D3WS16]F/R_\ :C..4S_X[?\
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MJD6=@MH*;=/0LEYNVI]2T]4VLDI^"CN"-CX6M8J+AS'+GTEYY)2ZB_X N?\
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M[_;;344<%=7TM'-6/ZJFCJ)VL=._EZ+$5?27FG)/%#IUW0T>EU]C%U-:?/\
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MCK+/J.UZ@;.MLN5)<FP/ZJ9U).R5(W][7<*KA?4IK6][QQQ]'U=:Q2-965-
MUD:-[6U;_G:HGZ5_$OO-4Q:VP5.QO19J*Z#YQ>JB%M2][DPYDU0]K47],QCF
M_"P#;UZW+TIIRN2BNFHK905B]L$]4QKV^MR*N6ICO7!WM!<::Z4<-725$552
MS)Q1S02(]CT[E:Y.2H1,VUU9LG8=(TT>H(XKQ?ZJ-);C55]NDJ']:[FK6N<U
M<(B^CEN,XSVG?]'35]HI-V]1:9TO735.CZRG\]H8JCCXH)6\'$QJ/Y\.'/\
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M7)\,#LL@C5W$K55.6>34Y91$:G-3#^E7JRWU=\TGHNNKFT-NGJ65UTF7*]7
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MC:QTCURYW"JL157O7#4,]
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M;+3U=MIN%J+3<5#4/TI=7K=;;510N=%32KA)8'N1%1B\D5J*J<F^*X-O</K
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M[NB;+=ZG5NM'W.^ZRJI%=UWFS'Q4K>:(D>7]N._"<*8:B)SS-3@'"!K/;?I
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M)JDB>$<($:K/N99=7]&F^66@?,EPLNGXX:J.:/AYHS@RU>],L7GZT-J='_\
MP.:3S_ZFB?Y3C/8Z>.-SW,8UCGKQ.5J85R^*^)]>$#0FV:_[J#<S_NT/\6(^
M6U2_[IO<WO3J6?\ VS?_  \L=Q7A T)M,O\ ND=T?TD/_A'2O=_<NA?U=C_
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MRN>>/6JK\(&A]V8Y(M^=I&2RK-(U9$?+PX5RY3GA.S)LO>MW^U'K#E_S9/\
MQ%,UX?PA&^/,#771WY;+Z41>7]RK_'<;'+>%$+@
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M'2.1.:JC<Y5$\4.XN=ZH+)035URK:>@HHL=9454K8HV95&IESE1$RJHG/O7
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MH)YV,?.[ER8U5RY?23L\4\2V^:GM.F*-*J[W*DM=.JX;)63-B15\$XE3*^I
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M>=1VK3=(VIN]RI+53.?U;9JV=D+%=A5X45RHF<(O+U*!VH./'5Q2T[9VR,=
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M:2.ZS,66*A=.Q)Y&)GTFQYXE3T7<T3Z5? #M
M
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M<*G,.GTKKK2-CWZL3]O:E\5EOG]R7*W]4^*-LCG>@YK78QZ2M7EV>DG8[";
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M'113,;UCECPU4PUSHF91/JG*F,F9=%]?]GMT._\ V=D7_+D%]^C$TW^H;_\
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M/[FT45-9)I..U5L="^2GFARO)Z8<KG85N<)R5%S@#Z;7:;V_NFX;M6:!U!#
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MQM=#;ZN\[@3-O>K;C.^2I=7T+JEL3<JC6M]%6]B9Y=F43L:AW&W>N-+VC?\
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M>["\.X=+'2=1IQ[[,M;6:CGC5E+9_-).MZY4PB*N.%41W;A57P10.'NMMW[
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MB+P\+D7&3K.D-N12:_TI01Z4M%1)I>UUK)Y[MYLZ"%9<*UD<:*B*O)57L^I
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MGJ:@&;@
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M8(X72+E[HV(BN]_Q.1P?![Q< .(VWTS:CKVP1)/_ -8C$XO7S[3D\/K[L%P
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M5<G+';C/8<M&=N5SDN %.$MX.WGA2\ :8WCU9K:IJ*_1^F-'U-5[)4W4MO\
MUJI!"V1.%ZKZ.$<B*J(O%R[>?89]MSHV#0&BK38*=6O2CB1KY43'62*JJ]WP
MN55^'!DZ-]>2N$ <)1&^/,N %O#ZPK?7@N %O#\(X40N %.$XTM%!-.V=\$;
MYF<FR.8BN3WE7L[5.4 +>#M3N+'Q-D:K7(CFJF%1>>47M/J .-24,%''P01,
MA9V\,;$:GWCD<)4 4X2G"7 "U&_V5"X #C5-'#61\$\4<S,YX9&(Y/?PI>R%
ML;6M8B,:U,(C4QCU>\?8 ?-T37M<UR<37)A47O0^=-1PTD?5PQ-A9G/!&U&I
M\2'( %K6HU$1.2#ASV]A< +>'M[APEP M5B*N3CTUOIZ-'=1!%!Q<W=6Q&Y7
MQY'* %O#ZQPH7 "WA'"G(N  MX?67  6JW/?]XN %O".$N 'RE@9,Q62-:]B
M]K7)E%^ MIZ:.EB2.%C8HFX1K&-1$3XC[@"WA/DVGC;(LB,:DBHB*Y$3.$[L
MGW %O"5X2H Q&HTA/7[AT6H:JM8ZDMM*^"AHV1X5LDN.M>YRJN5PUJ(B(G)5
M,N+>$N MX0C?%<EP XKZ"GEG;-)!&^9B8;(YB*Y.>>2]IR.#UJ7 "WA+@ +>
M$<)< *<)3A+@!Q9:*":=L[X(WS,Y-D<Q%<GO*O9VJ<C@[4[BX ?":FCJ(W1R
ML;-&[DK)&HY%]]%*LA;&U&M1&M;A$:B<D1.Q$3N/L +<+X_>/@VA@;.^=(6)
M,Y$1TB-3B7'9E>\Y( M1GK^(^4=/'&KU8QK%>N7*U$])?%?$^X MX4SDX\EO
MIYIVS20QOEC]S(YB*YO//)>TY0 MX?6.$N %O"7  :8Z2NDKOJVRZ8BM%OFK
MY*:\1SS-AQED:-=ER\^SF;>6B@=4).L,:S-3A216)Q(G@BGWX2X"Q6HO_P"!
M7A+@!3A.-4T4-7$Z*>*.>->UDK$<G9CL7E_^)R@!\HX6Q,1C$1C$3"-:F$0N
M1N,KG)> .)3VVFI72/@IXH7N3#G,C1%7WU[SD\..2<D+@!Q)K?35$[9Y8(I)
MF)ALCF(KF]_)3D<'9S+P -4[VZ1K[A#9=5V&G?4ZATW4I5101HO%50+_ 'V%
M,<U543DGOIVJ;6+.#L7/-.SD!PK96MN=!2UB0S4Z31MEZJH8L<L?$B+PO:O-
MJIGFB]Z'(\RI_.%J.ICZ_&.MX$X\>&>T^W#SR7 6HWUY+@ !3"%0!:C/7D^$
ME#!/,R66&.21GN7N8BJWWE[CD@"W@]:EP %O#ZPK>+M+@!:C,9/F^%LL;F.1
M',<BHK7)E%1?4?8 <:FHH*./@IXF0,SGAC:C4SC&>7O(?;@]?WB\ <1MNIFU
M*U"01I48PLW G&J>&>T^Z,3"\^WX#Z "WA'!ZRX <.6W4M1,R66FBDE8O$V1
MS$5R+XHO:G:<I6%P T_8=.5VMMY:_5]UHJBCMEB8MNLT%7"Z-TKU3YY4<+D1
M>%5<Y&KCFF%[C,=>:/GUK#;*%U8E-:HJR.JK8>KXGU+8W(]D:+GT45R)E<9Y
M&6)&G(NP@%2WA+@!;PCA+@!;C^V"R2)LC'->B/:[DK7)E%^ ^H X]-1PT<75
MP11P,[>"-B-;\2'VX%^J4N '&AHH('ROBACB?(N7N8Q$5WO^)R,(5 '%J+?3
MU:L=4013JQ<M62-'*U?4??JT5<KS+P!;PEP %O"?".AIXYG3,AC9*Y,.D:Q$
M<OOJ<D 6\*\^9QGVZF?.V=]/$Z9JY;(YB*Y%]2]IRP!9P>OX#YMIHTF=*C&]
M8J85_"F<>&3[@"WA'#V]Q< +>$KPE0!\9(&RM<R1$>UW)6N3*+[Y;34<-)$D
M4$4<,:+E&1L1K4^!#D "SJ_66,IXXWO>UJ-<Y<N5$[3[ #CU%)%5PK%/$R:-
M>UDC4<U?@4OBA;$Q&L1&-3L1J81/@/J /FZ)KFJU4RB\E3Q/E34D-)%U<$3(
M&9XN&-J-3/>N$.2 +>$QK<B@J+MMYJFAHHG3U=5:JJ&&)O:][H7HU$]:JJ&3
MEO"!KC8O2]59-H-/VF]6_P WK*=)5DIJEB*K%ZY[FJJ=F<*BFQHXTC;A.2>"
M%R-P5 MX1PEP XT=%3QU#YVP1-F=[J1K$1R^^O:??A]9< .-44<-8Q63Q,F;
ME%X9&HY,HN47"^"GWX>><EP XE3;Z>L:C:B&.=&KE$E8CD[<]_O'W2-J-1J(
MB-1,(B)R0^@ MX3X^:0NG;,L3%F:G"V16IQ(G@B]N#D "W@3QY#A3.2X 4QR
MQW%.'UX+@!\8Z>.%'<#&L15XEX4QE?'WSZ<'K4N '%FM]/421R30QROC7+'/
M8BJU?%%[C[\'@N.>2\ <6HM]/5,X9X8YTY\I&([M/K'$V-B-:B-:G)$1.2(G
M<?4 "WA+@!:K.+M./-;Z>HDCDFACE?&N6.>Q%5J^*+W'* %G!X+CGDKPEP M
MX4Y%DD#)F*R1K7L7M:Y,HI]0!QJ:CAI8^J@BCAC;V,C:C43WD3L/OPEP XT=
M%#"]\C(8VR/YN>UB(KE[>:^^?7@[EYI[Q] !\H:>.!J,C8V-GU+6HB%_#ZRX
M <5MOIVU#JA((DG=R65&)QX]\Y'#ZRX 6\*<APEP &F-*:1N]%TF=:7^>WS1
M6>LML,5/6*B<$KT93HJ(OCECOB-SEO"!\*:A@I6JD$,<+57B5(V(U%7QY'U6
M-'MPO-.].X^@ XM-14]$UR4\,<"/7B<D;$:BKWJN#D<'KY%P ^#::-)G2HQO
M6*F%?PIG'AD^O"7 #CU%)%5PK%/$R:->UDC4<U?@4OBA;$Q&L1&-3L1J81/@
M/J +>$*W)< +59E%3.$/DVGC:YSVM:CG*BN<C4R['9E>_!]P!Q'VZF?.V=]/
M$Z9JY;(YB*Y%]2]IR.K\%PG@7@#$=):/ELM]U+>JRL;5W"\U#%=U<? R*&)J
MLA8B97*HU<JO>KEY(9<6\)<!Q*FWT]8U&U$,<Z-7*)*Q')VY[_>/ND;4:C41
M$:B81$3DA] !;P>M2X "WA0X]30P5O"D\,<W"J*WK&(["Y1<IGWD.4 +.#'8
MN$+P +.K[>9\*:A@I5D6&&.'K%R_JV(WB7Q7':IR@!;P)A4\3CU%#!6</7PQ
MS<"Y;UC$=A?%,_VY'* %J-1O9R0N  MX0K<EP L='Q=Y\)J"GGD9)+!'+(SW
M+Y&(Y6^\J]AR@!9U?YY3YK31K*V16-61N</X4RF?6?< "WA^,N '%AM]-3.E
M=#!'"Z1<O=&Q$5WO^)R. N %O#\(5N>_[Q< .-/1057 LT,<O N6\;47A7Q3
M)]^#UJ7 "W@0^+J2%\K9G11NE8F&R*U.)OO+W'( %K6<.$3DG@?"HHX:N/JY
MXF3,SGAD:CD^)?[<SD@#Y,A:QB-:U&M;R1&\D3N_ 7\)< .-'0T\<SIF0QLE
M<F'2-8B.7WU/OA?'[Q< +5:OB41G;S+P!3"%.'UEP XC[=3/G;.^GB=,U<MD
M<Q%<B^I>TY*-[>>4+@!9P>*GP;;Z=M0ZH2"))W<EE1B<>/?.4 +>'UCA+@!;
MPEP %G5^L^"T%,ZJ2H6GB6H:F$EX$XD3W^TY0 LZOUGS6FC65LBL:LC<X?PI
ME,^L^X MX4Y#A3.>\N %O".'GVEP MX4SD<')4R7 #BNH:>29LSX8WS,]S(Y
MJ*YO//)5YH??J_2SDO %B1IS3N./)&E/'-+#$UTV%=PIZ/&['),G+*80".]/
M3:NWUUQIZ>_Z3J-)Z8L$_GDE/7N5SZJ=J^BB(K6Y3*)]+CA5W/FB$B.$MQV\
M\^_V%X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
4                       !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  5 +@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#OM:U/4_$G
MBQO#NEW3VMM!G[1,G!..O3L"<8]:34_!-_I%F;[0]5OY+N+!,;-G>.^,?R.:
MC\+2+9_$G6[:?Y99C(4SW^8-_+FM7Q+9>(8&OM2MM?6VLHT+K#LY&!TSCN?Y
MU]&YRHU84*;48VB]5?F;[Z-]3S4E.,IR3;N_E;YD'B;4-3/P\2ZN4ELK_>@D
M"MM.<XSP>AZXK*\37]Y#\/=!GBNYTF?9OD60AF^0]3WJ*^U&[U/X5O<WL[33
M&Z WMC. 1Z4WQ5_R3;P]_P  _P#0#6^'HJ$J<9)?Q)>FWGT(J3NI-/[*_,T[
MOPC?6VBOJ$'B74!+'#YP$DAV\#.,YIMEXMU,_#FZU%SNO()! LQ'7.WYC[C/
M\J=<^!;RYT4D>(KV3,0<13,2AXS@\T>%]=TJZ\%SVNL1VUM:Q-Y#!1@29&00
M!SNX)X],UDY1J4N9_O+26RLTNVVMRDG&=OANGUO_ ,,,T7P>-=T:'4[C7;Y[
MJ==^Y),A#Z<\\?45>TZ]USPQH6J2ZX?M$5J=MK([Y:0YP/?!XZ\]:K-\.Y+<
M>?H6N7%N&^9 2<$=OF4C^58-SJ^JZKX5UC3-0;SKC3I48R#J0'VL#ZX/.:JR
MQ3:4U*%U=-6<5?I^0OX2U33L^MT]/Z9J:+X>U+Q=:G5M8U:ZC29CY,4+8 &<
M9QT _"@W.I>!/$-K:W%[+>:3=' ,IR4YP?H1D'CJ*ZKP7<17/A'3C$P.R/RV
M [,.#7,?%"19YM)L8_FN&=F"CK@X _,_RK.E6G6Q<L-42Y-5:RTM?5:=+%S@
MH455B_>TU[E'QO?:K;^,B-/N9U\F!9O+20A<*"2<=#TKM8]936/!=SJ-NQ1V
MM)-P4X,;A3D?@?Z5STR#_A;5K&^&'V3:V>_R-6?+N\':MJND.2--U&WD:W)Z
M*VTX'_LOY4YTH5J=*G%>]&,9+S5]5^OWB4I0E*3V;:].QTWP]N)KGPLLD\TD
MK^<XW2,6/;N:D\?3S6WA"ZE@E>*0/'AT8J1\X[BJ_P -O^113_KN_P#2I/B)
M_P B7=_[\?\ Z&*XVE_:=K:<_P"ILF_JM_(Q='\)W^IZ':WZ^)-0BFFC#A2[
M$ _]]5;\+>(-2M]?F\-ZX_FW"9\F8]6P,X)[Y'(-;_A#_D4=+_ZX"N/FD75/
MB]";0AUM@!(Z]/E4Y_4XKH4WB)UJ55)J*DT[)6L]-4EZ&;BJ:A*.[M\[EOX>
M7ES<ZIK2SW,TJHZ[1(Y8+RW3/2IOB;=W-II5DUM<2PLTY!,;E21M/I5+X;D+
MK6NQDX?>.._#-FIOBLP_LK3TR-QG) [D;?\ ZXK1Q7]JQ5M-/_22;OZHWZ_F
M4_'EQJ/VK18+&YN$DF@QMCD*[FX]#UKK?!^O#7M#260_Z7#^[G'?<._X_P"-
M<WXH!7Q5X4!X(*?^A+2Z@I\&>-8]2C!72]2.V<#HC=S^?/YU,Z<*V&A12]ZS
M:\[-W7S6WH.,G"K*?2Z3^Y:D?A>]NIO#?B622ZF=XP^QFD)*_*W0]JS_  -X
MCO;/4XK?4YYI+2_^6&25RVUP<<$_E^56?"9!\+^*2"""'P1_NM3=*T'^W?AJ
M@A'^F6\TDD!'4G/*_C_/%=514E[:-1:.45?M>._R9E'G?(X[I-^NIK^,KJY@
M\5>'8X;B6..27#JCD!OG7J!UHKFIM=_MW4?"TDK?Z7!.(IP>NX.N#^(_7-%>
M;C*+HTZ4)+5)_P#I3.FC-3E*2VT_(Z_Q=X5AU!QK%O<R6=]  ?,C&=V.G<8/
MO6)I&FZAXI+0ZMK4\UI#\QA"!=Y[9(HHHH8BHL+)WUCL[*Z]'8*E./M4N^Y?
M'A;_ (H1M)^V?\O&_P WRO?IC/\ 6I=:\,_;O"6E:;]LV?9MO[SR\[L*1TSQ
M^=%%9K%5N=._VF_G8KV4+-6Z6*#:#K=S"+23Q/<&%QL*B''R^GWJW8? ^EQ^
M&WT9B[AV\QI^C;^S#T],445.(QE9647;6^B2U^2'3HPU;5SD)(M;T6?^R+;7
MYQ IVK^Z'RCVR21^!KL_#GA2ST?39XY&-W)>+^_DD7&\$=,>G)HHKHQU>?LH
M6TYM79)7?R,Z%./._+8Y74]$O/"-R3HVL3P07!SY10,!^9P?KBM?POX766[3
M7]2O9;Z\/*>8,!#Z]3GV]***=;$U7A%._O2T;LKM>MKA"E'VKCT1H2Z)O\>P
MZO\ :,;8=OE;.ORD=<^_I4_BW0(-?T<Q2/Y4L3;XY0N=OJ,>A']***\_V]15
M*<D]8I6-_9Q<9)K<7PCI7]C:$MIYWG8D9MVW;U]LFI/%>F?VOX?GL_.\K>R'
M?MW8PP/3(HHJ75G]9]I?6]Q\B]GR]+')6_AS6$MX[*/Q-<QVX&P(D1&!Z#YJ
MZOPYX6L?#D+^06EN)/\ 63OU;V'H***Z,7BJLER-Z/>R2OZV6I%*E!.]M4<Y
MXH\-'3;]]=TJ_ELIY"?,5%R"3U/7OZ<U7T#P[)XAOTU/6=2FO/L[#;$RX![^
MO3V HHKJCBJOU/GO[RTO97MVO:YBZ4/;6MIN=!X@T3^T?$6D7GVCR_LSAMFS
M.[# ]<\5JZ_I,&MZ-<64_ 8;E?&2C#H:**\UUII4VG\.WWG4H1][3?\ R.<\
M.>&O[-\/:M9?:_,^TH1O\O&WY2.F>>M;'A+2_P"Q]!2T\[SL2,V[;MZGTR:*
M*UQ&(J34U)[M-_<13IQBU;HC O\ P7 /&,.I6]SY*M,D[0^7D;MV3@YXSCT[
4T445%?$5*D8<[O96'"G&+=D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>orka-20240930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" targetNamespace="http://www.orukatx.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:orka="http://www.orukatx.com/20240930" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="orka-20240930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet" id="orka_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" id="orka_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedIncomeStatement" id="orka_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3" id="orka_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" id="orka_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow" id="orka_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" id="orka_r_NatureoftheBusinessandBasisofPresentation">
        <link:definition>007 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" id="orka_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommonStock" id="orka_r_CommonStock">
        <link:definition>009 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactions" id="orka_r_RelatedPartyTransactions">
        <link:definition>010 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentsandContingencies" id="orka_r_CommitmentsandContingencies">
        <link:definition>011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensation" id="orka_r_StockBasedCompensation">
        <link:definition>012 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEvents" id="orka_r_SubsequentEvents">
        <link:definition>013 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited" id="orka_r_Eventssubsequenttothereissuanceofthefinancialstatementunaudited">
        <link:definition>014 - Disclosure - Events subsequent to the reissuance of the financial statement (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" id="orka_r_ReverseRecapitalizationandPreClosingFinancing">
        <link:definition>015 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurements" id="orka_r_FairValueMeasurements">
        <link:definition>016 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" id="orka_r_AccruedExpensesandOtherCurrentLiabilities">
        <link:definition>017 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty" id="orka_r_NotePayablewithRelatedParty">
        <link:definition>018 - Disclosure - Note Payable with Related Party</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" id="orka_r_ConvertiblePreferredStockandStockholdersEquity">
        <link:definition>019 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxes" id="orka_r_IncomeTaxes">
        <link:definition>020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreements" id="orka_r_OptionAgreements">
        <link:definition>021 - Disclosure - Option Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShare" id="orka_r_NetLossPerShare">
        <link:definition>022 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy" id="orka_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" id="orka_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables" id="orka_r_RelatedPartyTransactionsTables">
        <link:definition>996002 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables" id="orka_r_CommitmentandContingenciesTables">
        <link:definition>996003 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationTables" id="orka_r_StockBasedCompensationTables">
        <link:definition>996004 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" id="orka_r_ReverseRecapitalizationandPreClosingFinancingTables">
        <link:definition>996005 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables" id="orka_r_FairValueMeasurementsTables">
        <link:definition>996006 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" id="orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables">
        <link:definition>996007 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" id="orka_r_ConvertiblePreferredStockandStockholdersEquityTables">
        <link:definition>996008 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareTables" id="orka_r_NetLossPerShareTables">
        <link:definition>996009 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" id="orka_r_NatureoftheBusinessandBasisofPresentationDetails">
        <link:definition>996010 - Disclosure - Nature of the Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" id="orka_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996011 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommonStockDetails" id="orka_r_CommonStockDetails">
        <link:definition>996012 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" id="orka_r_RelatedPartyTransactionsDetails">
        <link:definition>996013 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/CommitmentsandContingenciesDetails" id="orka_r_CommitmentsandContingenciesDetails">
        <link:definition>996014 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails" id="orka_r_StockBasedCompensationDetails">
        <link:definition>996015 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/SubsequentEventsDetails" id="orka_r_SubsequentEventsDetails">
        <link:definition>996016 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" id="orka_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" id="orka_r_ScheduleoftheAssetsandLiabilitiesTable">
        <link:definition>996018 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" id="orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable">
        <link:definition>996019 - Disclosure - Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable">
        <link:definition>996020 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" id="orka_r_NotePayablewithRelatedPartyDetails">
        <link:definition>996021 - Disclosure - Note Payable with Related Party (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9IwYN8Ri93cM9asw4nvQuGEy6hg3+HhbXc=] CSR-->
      <link:roleType roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" id="orka_r_ConvertiblePreferredStockandStockholdersEquityDetails">
        <link:definition>996022 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" id="orka_r_ScheduleofConvertiblePreferredStockTable">
        <link:definition>996023 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - Schedule of Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" id="orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable">
        <link:definition>996024 - Disclosure - Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - Schedule of Common Stock Reserved for Future Issuance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" id="orka_r_ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable">
        <link:definition>996025 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" id="orka_r_ScheduleofStockOptionActivityTable">
        <link:definition>996026 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock Option Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRSAsactivityTable" id="orka_r_ScheduleofRSAsactivityTable">
        <link:definition>996027 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSAs activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" id="orka_r_ScheduleofEmployeeWarrantActivityTable">
        <link:definition>996028 - Disclosure - Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable" id="orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable">
        <link:definition>996029 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Company&#8217;s Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" id="orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable">
        <link:definition>996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/IncomeTaxesDetails" id="orka_r_IncomeTaxesDetails">
        <link:definition>996032 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/OptionAgreementsDetails" id="orka_r_OptionAgreementsDetails">
        <link:definition>996033 - Disclosure - Option Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" id="orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable">
        <link:definition>996034 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" id="orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable">
        <link:definition>996035 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/NetLossPerShareDetails" id="orka_r_NetLossPerShareDetails">
        <link:definition>996036 - Disclosure - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" id="orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable">
        <link:definition>996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" id="orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable">
        <link:definition>996038 - Disclosure - Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" id="orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable">
        <link:definition>996039 - Disclosure - Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.orukatx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd"/>
  <xs:element name="CommonStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfTheAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfTheAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
  <xs:element name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfConvertiblePreferredStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfConvertiblePreferredStockAbstract"/>
  <xs:element name="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfRsasActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRsasActivityAbstract"/>
  <xs:element name="ScheduleOfEmployeeWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
  <xs:element name="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract"/>
  <xs:element name="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
  <xs:element name="AssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_AssetsAbstract0"/>
  <xs:element name="CurrentAssetsAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CurrentAssetsAbstract0"/>
  <xs:element name="LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract"/>
  <xs:element name="StockholdersEquityAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockholdersEquityAbstract0"/>
  <xs:element name="FinancialAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FinancialAssetsAbstract"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
  <xs:element name="SubscriptionReceivables" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivables"/>
  <xs:element name="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt"/>
  <xs:element name="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
  <xs:element name="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
  <xs:element name="IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization"/>
  <xs:element name="AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger"/>
  <xs:element name="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
  <xs:element name="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
  <xs:element name="IssuanceCostOfPIPEFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceCostOfPIPEFinancing"/>
  <xs:element name="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
  <xs:element name="ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid"/>
  <xs:element name="CashAssumedInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_CashAssumedInConnectionWithTheReverseRecapitalization"/>
  <xs:element name="UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable"/>
  <xs:element name="UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable"/>
  <xs:element name="UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties"/>
  <xs:element name="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
  <xs:element name="CommonStockTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockTextBlock"/>
  <xs:element name="OptionAgreementsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsTextBlock"/>
  <xs:element name="SubscriptionReceivablePolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SubscriptionReceivablePolicyTextBlock"/>
  <xs:element name="ClassificationOfConvertiblePreferredStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
  <xs:element name="NotePayableToRelatedPartyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NotePayableToRelatedPartyPolicyTextBlock"/>
  <xs:element name="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
  <xs:element name="ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock"/>
  <xs:element name="ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock"/>
  <xs:element name="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable"/>
  <xs:element name="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <xs:element name="AccruedResearchAndDevelopment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_AccruedResearchAndDevelopment"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems"/>
  <xs:element name="SharesIssuableUponExerciseOfPrefundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_SharesIssuableUponExerciseOfPrefundedWarrants"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofRSAsactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue"/>
  <xs:element name="ParukaWarrantObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantObligation"/>
  <xs:element name="EmployeeWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeWarrants"/>
  <xs:element name="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
  <xs:element name="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems"/>
  <xs:element name="CommonStockLossAllocation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockLossAllocation"/>
  <xs:element name="NatureoftheBusinessandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
  <xs:element name="TerminationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_TerminationFee"/>
  <xs:element name="AdditionalPaidInCapitalTransacationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_AdditionalPaidInCapitalTransacationCost"/>
  <xs:element name="ExchangeRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ExchangeRatio"/>
  <xs:element name="CommomStockExchange" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_CommomStockExchange"/>
  <xs:element name="PreFundedWarrantsOfCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsOfCommonStockShares"/>
  <xs:element name="NumberOfSharesPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="orka_NumberOfSharesPurchased"/>
  <xs:element name="CommonStockDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CommonStockDetailsTable"/>
  <xs:element name="CommonStockDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommonStockDetailsLineItems"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="StockBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_StockBasedCompensationDetailsTable"/>
  <xs:element name="SharesOutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SharesOutstandingPercentage"/>
  <xs:element name="EstimatedFairValueOfWarrantsToBeGranted" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="orka_EstimatedFairValueOfWarrantsToBeGranted"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SubsequentEventsDetailsLineItems"/>
  <xs:element name="ResearchInitiationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ResearchInitiationFee"/>
  <xs:element name="DevelopmentCostsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DevelopmentCostsPercentage"/>
  <xs:element name="ReimburseOfDevelopmentCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_ReimburseOfDevelopmentCosts"/>
  <xs:element name="NonRefundableMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_NonRefundableMilestonePayments"/>
  <xs:element name="PercentageOfWarrantPurchare" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PercentageOfWarrantPurchare"/>
  <xs:element name="NotePayablewithRelatedPartyDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NotePayablewithRelatedPartyDetailsTable"/>
  <xs:element name="ConvertiblePreferredStockandStockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
  <xs:element name="OptionAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_OptionAgreementsDetailsTable"/>
  <xs:element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_MilestonePayment"/>
  <xs:element name="OtherDevelopmentCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="orka_OtherDevelopmentCost"/>
  <xs:element name="NetLossPerShareDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="orka_NetLossPerShareDetailsTable"/>
  <xs:element name="NetLossPerShareDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NetLossPerShareDetailsLineItems"/>
  <xs:element name="ARCABIOPHARMAINCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ARCABIOPHARMAINCMember"/>
  <xs:element name="ARCACommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ARCACommonStockMember"/>
  <xs:element name="CertainRegulatoryMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_CertainRegulatoryMilestonesMember"/>
  <xs:element name="ClinicalDevelopmentMilestonesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ClinicalDevelopmentMilestonesMember"/>
  <xs:element name="ComputerAndOfficeEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ComputerAndOfficeEquipmentMember"/>
  <xs:element name="ConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertibleNoteMember"/>
  <xs:element name="ConvertibleNotePurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertibleNotePurchaseAgreementMember"/>
  <xs:element name="ConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertibleNotesMember"/>
  <xs:element name="EmployeeWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_EmployeeWarrantsMember"/>
  <xs:element name="FairmountHealthcareFundIILPMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_FairmountHealthcareFundIILPMember"/>
  <xs:element name="ORKAZeroZeroOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroOneMember"/>
  <xs:element name="ORKAZeroZeroTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ORKAZeroZeroTwoMember"/>
  <xs:element name="OrukaAdvisorsLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaAdvisorsLLCMember"/>
  <xs:element name="OrukaCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaCommonStockMember"/>
  <xs:element name="OrukaPrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaPrefundedWarrantsMember"/>
  <xs:element name="OrukaRestrictedStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OrukaRestrictedStockMember"/>
  <xs:element name="OutstandingAndIssuedCommonStockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OutstandingAndIssuedCommonStockOptionsMember"/>
  <xs:element name="OutstandingEmployeeWarrantsToPurchaseCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember"/>
  <xs:element name="OutstandingUnvestedRestrictedStockAwardsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OutstandingUnvestedRestrictedStockAwardsMember"/>
  <xs:element name="ParagonAndParukaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonAndParukaMember"/>
  <xs:element name="ParagonMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonMember"/>
  <xs:element name="ParagonReimbursableOptionAgreementsFeesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOptionAgreementsFeesMember"/>
  <xs:element name="ParagonReimbursableOtherResearchExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursableOtherResearchExpensesMember"/>
  <xs:element name="ParagonReimbursablePatentExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParagonReimbursablePatentExpensesMember"/>
  <xs:element name="ParukaHoldingLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaHoldingLLCMember"/>
  <xs:element name="ParukaWarrantObligationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ParukaWarrantObligationMember"/>
  <xs:element name="PreFundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PreFundedWarrantsMember"/>
  <xs:element name="PrefundedWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_PrefundedWarrantsMember"/>
  <xs:element name="RestrictedStockActivityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_RestrictedStockActivityMember"/>
  <xs:element name="ReverseStockSplitMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ReverseStockSplitMember"/>
  <xs:element name="SeriesAConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesAConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockMember"/>
  <xs:element name="SeriesANonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockAmountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBNonVotingConvertiblePreferredStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
  <xs:element name="SeriesBNonVotingPreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_SeriesBNonVotingPreferredStockMember"/>
  <xs:element name="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
  <xs:element name="TwoThousandTwentyFourEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
  <xs:element name="TwoThousandTwentyFourStockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
  <xs:element name="UnvestedStockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_UnvestedStockOptionsMember"/>
  <xs:element name="ConvertiblePreferredStockAndStockholdersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems"/>
  <xs:element name="NatureOfTheBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems"/>
  <xs:element name="OptionAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_OptionAgreementsAbstract"/>
  <xs:element name="ReverseRecapitalizationAndPreClosingFinancingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="orka_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>orka-20240930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedIncomeStatement" roleURI="http://www.orukatx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="orka_SubscriptionReceivables" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="orka_SubscriptionReceivables" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9LEKvLE+mShiS6bldHSFOqLEfHDYy3VH8o=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:href="orka-20240930.xsd#orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_CashAssumedInConnectionWithTheReverseRecapitalization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="orka_CashAssumedInConnectionWithTheReverseRecapitalization" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="orka-20240930.xsd#orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" order="3" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20240930.xsd#orka_AccruedResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="orka_AccruedResearchAndDevelopment" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligation" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="orka_ParukaWarrantObligation" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrants" xlink:href="orka-20240930.xsd#orka_EmployeeWarrants"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="orka_EmployeeWarrants" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>orka-20240930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedIncomeStatement" roleURI="http://www.orukatx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommonStock" roleURI="http://www.orukatx.com/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentsandContingencies" roleURI="http://www.orukatx.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_Eventssubsequenttothereissuanceofthefinancialstatementunaudited" roleURI="http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_OptionAgreements" roleURI="http://www.orukatx.com/role/OptionAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofRSAsactivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAsactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommonStockDetails" roleURI="http://www.orukatx.com/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentsandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_OptionAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="orka_SubscriptionReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:href="orka-20240930.xsd#orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20240930.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_IssuanceCostOfPIPEFinancing" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20240930.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:href="orka-20240930.xsd#orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_CashAssumedInConnectionWithTheReverseRecapitalization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="orka_CashAssumedInConnectionWithTheReverseRecapitalization" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20240930.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommonStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CommonStockAbstract" xlink:href="orka-20240930.xsd#orka_CommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockTextBlock" xlink:href="orka-20240930.xsd#orka_CommonStockTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommonStockAbstract" xlink:to="orka_CommonStockTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAbstract" xlink:href="orka-20240930.xsd#orka_OptionAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsTextBlock" xlink:href="orka-20240930.xsd#orka_OptionAgreementsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_OptionAgreementsAbstract" xlink:to="orka_OptionAgreementsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_SubscriptionReceivablePolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ComputerAndOfficeEquipmentMember" xlink:href="orka-20240930.xsd#orka_ComputerAndOfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="orka_ComputerAndOfficeEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="orka-20240930.xsd#orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:href="orka-20240930.xsd#orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FinancialAssetsAbstract" xlink:href="orka-20240930.xsd#orka_FinancialAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="orka_FinancialAssetsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_FinancialAssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20240930.xsd#orka_AccruedResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="orka_AccruedResearchAndDevelopment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharesIssuableUponExerciseOfPrefundedWarrants" xlink:href="orka-20240930.xsd#orka_SharesIssuableUponExerciseOfPrefundedWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="orka_SharesIssuableUponExerciseOfPrefundedWarrants" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAsactivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockActivityMember" xlink:href="orka-20240930.xsd#orka_RestrictedStockActivityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="orka_RestrictedStockActivityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9JSzLCyYcvKN5v4boEuJeN6/dI1tCl7oXI=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligation" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ParukaWarrantObligation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrants" xlink:href="orka-20240930.xsd#orka_EmployeeWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_EmployeeWarrants" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockLossAllocation" xlink:href="orka-20240930.xsd#orka_CommonStockLossAllocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="orka_CommonStockLossAllocation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_NetIncomeLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember" xlink:href="orka-20240930.xsd#orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingUnvestedRestrictedStockAwardsMember" xlink:href="orka-20240930.xsd#orka_OutstandingUnvestedRestrictedStockAwardsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_OutstandingUnvestedRestrictedStockAwardsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingAndIssuedCommonStockOptionsMember" xlink:href="orka-20240930.xsd#orka_OutstandingAndIssuedCommonStockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="orka_OutstandingAndIssuedCommonStockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_ParagonReimbursablePatentExpensesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:href="orka-20240930.xsd#orka_NatureOfTheBusinessAndBasisOfPresentationLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20240930.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="dei_LegalEntityAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseStockSplitMember" xlink:href="orka-20240930.xsd#orka_ReverseStockSplitMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_ReverseStockSplitMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20240930.xsd#orka_OrukaCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaPrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_OrukaPrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaPrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20240930.xsd#orka_ARCACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_ARCACommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaRestrictedStockMember" xlink:href="orka-20240930.xsd#orka_OrukaRestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_OrukaRestrictedStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PrefundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_PrefundedWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ARCABIOPHARMAINCMember" xlink:href="orka-20240930.xsd#orka_ARCABIOPHARMAINCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="orka_ARCABIOPHARMAINCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TerminationFee" xlink:href="orka-20240930.xsd#orka_TerminationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_TerminationFee" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20240930.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_AdditionalPaidInCapitalTransacationCost" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20240930.xsd#orka_ExchangeRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_ExchangeRatio" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockValue" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CommomStockExchange" xlink:href="orka-20240930.xsd#orka_CommomStockExchange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_CommomStockExchange" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_PreFundedWarrantsOfCommonStockShares" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20240930.xsd#orka_NumberOfSharesPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_NumberOfSharesPurchased" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_Cash" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="27" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommonStockDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CommonStockDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockDetailsTable" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="orka_CommonStockDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CommonStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_RelatedPartyTransactionsDetailsLineItems" xlink:to="orka_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20240930.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaHoldingLLCMember" xlink:href="orka-20240930.xsd#orka_ParukaHoldingLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="orka_ParukaHoldingLLCMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaAdvisorsLLCMember" xlink:href="orka-20240930.xsd#orka_OrukaAdvisorsLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="orka_OrukaAdvisorsLLCMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonAndParukaMember" xlink:href="orka-20240930.xsd#orka_ParagonAndParukaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_ParagonAndParukaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20240930.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_CommitmentsandContingenciesDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentsandContingenciesDetailsTable" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="orka_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_CommitmentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_StockBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20240930.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_UnvestedStockOptionsMember" xlink:href="orka-20240930.xsd#orka_UnvestedStockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="orka_UnvestedStockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_ParukaWarrantObligationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SharesOutstandingPercentage" xlink:href="orka-20240930.xsd#orka_SharesOutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_SharesOutstandingPercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20240930.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="orka_TwoThousandTwentyFourEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNotePurchaseAgreementMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotePurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ConvertibleNotePurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20240930.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_ClinicalDevelopmentMilestonesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CertainRegulatoryMilestonesMember" xlink:href="orka-20240930.xsd#orka_CertainRegulatoryMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_CertainRegulatoryMilestonesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesAConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20240930.xsd#orka_ParagonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="orka_ParagonMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNotesMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="orka_ConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitiationFee" xlink:href="orka-20240930.xsd#orka_ResearchInitiationFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_ResearchInitiationFee" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20240930.xsd#orka_DevelopmentCostsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_DevelopmentCostsPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ReimburseOfDevelopmentCosts" xlink:href="orka-20240930.xsd#orka_ReimburseOfDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_ReimburseOfDevelopmentCosts" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20240930.xsd#orka_NonRefundableMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_NonRefundableMilestonePayments" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PercentageOfWarrantPurchare" xlink:href="orka-20240930.xsd#orka_PercentageOfWarrantPurchare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_PercentageOfWarrantPurchare" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20240930.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20240930.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="orka_FairmountHealthcareFundIILPMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="orka_ConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockAndStockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingPreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="orka_SeriesBNonVotingPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="orka_PreFundedWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20240930.xsd#orka_EmployeeWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="orka_EmployeeWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/OptionAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsDetailsTable" xlink:href="orka-20240930.xsd#orka_OptionAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OptionAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20240930.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_ClinicalDevelopmentMilestonesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_CertainRegulatoryMilestonesMember" xlink:href="orka-20240930.xsd#orka_CertainRegulatoryMilestonesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="orka_CertainRegulatoryMilestonesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="orka_ORKAZeroZeroTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20240930.xsd#orka_NonRefundableMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_NonRefundableMilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20240930.xsd#orka_DevelopmentCostsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_DevelopmentCostsPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_MilestonePayment" xlink:href="orka-20240930.xsd#orka_MilestonePayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_MilestonePayment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20240930.xsd#orka_OtherDevelopmentCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_OtherDevelopmentCost" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="orka_PercentageOfWarrantPurchare" xlink:href="orka-20240930.xsd#orka_PercentageOfWarrantPurchare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="orka_PercentageOfWarrantPurchare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="orka_NetLossPerShareDetailsLineItems" xlink:to="orka_NetLossPerShareDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="orka_NetLossPerShareDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="1" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>orka-20240930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balances (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock Issued and Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockAbstract" xlink:href="orka-20240930.xsd#orka_CommonStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockAbstract_lbl" xml:lang="en-US">Common Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockAbstract" xlink:to="orka_CommonStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl" xml:lang="en-US">Events subsequent to the reissuance of the financial statement (unaudited) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:to="orka_ReverseRecapitalizationAndPreClosingFinancingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Note Payable with Related Party [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of Stock Option Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfStockOptionActivityAbstract" xlink:to="orka_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Stock Options, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Outstanding and issued stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Beginning Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Ending Balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of RSAs, Unvested Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0" xml:lang="en-US">Number of RSAs, Unvested Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Grant Date Fair Value, Unvested Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule of Summarizes the Employee Warrant Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="orka_ScheduleOfEmployeeWarrantActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Number of Warrants, Endning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Outstanding and issued employee warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Endning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsAbstract" xlink:href="orka-20240930.xsd#orka_OptionAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsAbstract_lbl" xml:lang="en-US">Option Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsAbstract" xlink:to="orka_OptionAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total discounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivables" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivables_lbl" xml:lang="en-US">Subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Shares issuable on conversion of Company preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AssetsAbstract0" xlink:href="orka-20240930.xsd#orka_AssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AssetsAbstract0_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AssetsAbstract0" xlink:to="orka_AssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CurrentAssetsAbstract0" xlink:href="orka-20240930.xsd#orka_CurrentAssetsAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CurrentAssetsAbstract0_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CurrentAssetsAbstract0" xlink:to="orka_CurrentAssetsAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:href="orka-20240930.xsd#orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities, Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:to="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Related party common stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl0" xml:lang="en-US">Warrant gross proceeds amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current portion of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Convertible preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Convertible preferred stock, liquidation preference (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockholdersEquityAbstract0" xlink:href="orka-20240930.xsd#orka_StockholdersEquityAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_StockholdersEquityAbstract0_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockholdersEquityAbstract0" xlink:to="orka_StockholdersEquityAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Loss Allocation, Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Loss Per Share &#8211; Basic and Diluted, Stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share attributable, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable, basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Shares Outstanding, Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20240930.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl" xml:lang="en-US">Issuance costs of Pre-Closing Financing and reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:to="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:href="orka-20240930.xsd#orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:to="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_IssuanceCostOfPIPEFinancing" xlink:href="orka-20240930.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl" xml:lang="en-US">Issuance cost of PIPE Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:href="orka-20240930.xsd#orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl" xml:lang="en-US">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:to="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xml:lang="en-US">Proceeds from the Pre-Closing Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from the PIPE Financing, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_CashAssumedInConnectionWithTheReverseRecapitalization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash operating and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability arising from obtaining operating right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl" xml:lang="en-US">Assets acquired in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">PIPE Financing issuance costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl" xml:lang="en-US">PIPE Financing issuance costs included in accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20240930.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl" xml:lang="en-US">Non-cash accrued interest on convertible note converted to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Converted into shares value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Other non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl" xml:lang="en-US">Other liabilities assumed in connection with the reverse recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series A Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series B Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series A Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl" xml:lang="en-US">Series B Non-Voting Convertible Preferred Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Shares issuable on conversion of Company Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Series B Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl" xml:lang="en-US">Series B Non-Voting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockTextBlock" xlink:href="orka-20240930.xsd#orka_CommonStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStockTextBlock_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockTextBlock" xlink:to="orka_CommonStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl" xml:lang="en-US">Events subsequent to the reissuance of the financial statement (unaudited)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl" xml:lang="en-US">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FinancialAssetsAbstract" xlink:href="orka-20240930.xsd#orka_FinancialAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FinancialAssetsAbstract_lbl" xml:lang="en-US">Financial assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FinancialAssetsAbstract" xlink:to="orka_FinancialAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total financial assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee compensation and benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional and consulting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AccruedResearchAndDevelopment" xlink:href="orka-20240930.xsd#orka_AccruedResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Note Payable with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" xlink:to="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US">Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharesIssuableUponExerciseOfPrefundedWarrants" xlink:href="orka-20240930.xsd#orka_SharesIssuableUponExerciseOfPrefundedWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl" xml:lang="en-US">Shares issuable upon exercise of pre-funded warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesIssuableUponExerciseOfPrefundedWarrants" xlink:to="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Number of shares of common stock available for issuance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Total shares of common stock reserved</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common stock reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:to="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Stock Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Number of RSAs, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Number of shares granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Stock Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Stock Options, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Stock Options, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Stock Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Exercisable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term (in Years), Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Term, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of RSAs activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted average grant-date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" xlink:to="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Endning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl" xml:lang="en-US">Number of Warrants, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligation" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantObligation_lbl" xml:lang="en-US">Paruka warrant obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligation" xlink:to="orka_ParukaWarrantObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrants" xlink:href="orka-20240930.xsd#orka_EmployeeWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeWarrants_lbl" xml:lang="en-US">Employee warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrants" xlink:to="orka_EmployeeWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsTextBlock" xlink:href="orka-20240930.xsd#orka_OptionAgreementsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OptionAgreementsTextBlock_lbl" xml:lang="en-US">Option Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsTextBlock" xlink:to="orka_OptionAgreementsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flow from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Lease payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2024 (remainder)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockLossAllocation" xlink:href="orka-20240930.xsd#orka_CommonStockLossAllocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommonStockLossAllocation_lbl" xml:lang="en-US">Loss Allocation, Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockLossAllocation" xlink:to="orka_CommonStockLossAllocation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total anti-dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Related party accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="orka-20240930.xsd#orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ComputerAndOfficeEquipmentMember" xlink:href="orka-20240930.xsd#orka_ComputerAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ComputerAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computer and office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComputerAndOfficeEquipmentMember" xlink:to="orka_ComputerAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Shares issuable on conversion of Company Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl" xml:lang="en-US">2024 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option Valuation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_RestrictedStockActivityMember" xlink:href="orka-20240930.xsd#orka_RestrictedStockActivityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_RestrictedStockActivityMember_lbl" xml:lang="en-US">Restricted Stock Activity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockActivityMember" xlink:to="orka_RestrictedStockActivityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember" xlink:href="orka-20240930.xsd#orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Outstanding Employee Warrants to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember" xlink:to="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingUnvestedRestrictedStockAwardsMember" xlink:href="orka-20240930.xsd#orka_OutstandingUnvestedRestrictedStockAwardsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OutstandingUnvestedRestrictedStockAwardsMember_lbl" xml:lang="en-US">Outstanding Unvested Restricted Stock Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingUnvestedRestrictedStockAwardsMember" xlink:to="orka_OutstandingUnvestedRestrictedStockAwardsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OutstandingAndIssuedCommonStockOptionsMember" xlink:href="orka-20240930.xsd#orka_OutstandingAndIssuedCommonStockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OutstandingAndIssuedCommonStockOptionsMember_lbl" xml:lang="en-US">Outstanding and Issued Common Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingAndIssuedCommonStockOptionsMember" xlink:to="orka_OutstandingAndIssuedCommonStockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl" xml:lang="en-US">Paragon reimbursable Option Agreements&#8217; fees [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable other research expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonReimbursablePatentExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl" xml:lang="en-US">Paragon reimbursable patent expenses	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Issuance preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Purchase price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TerminationFee" xlink:href="orka-20240930.xsd#orka_TerminationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TerminationFee_lbl" xml:lang="en-US">Termination fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TerminationFee" xlink:to="orka_TerminationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Aggregate net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Purchased shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20240930.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl" xml:lang="en-US">Additional paid-in capital transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ExchangeRatio" xlink:href="orka-20240930.xsd#orka_ExchangeRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ExchangeRatio_lbl" xml:lang="en-US">Exchange ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommomStockExchange" xlink:href="orka-20240930.xsd#orka_CommomStockExchange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CommomStockExchange_lbl" xml:lang="en-US">Common Stock exchange (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommomStockExchange" xlink:to="orka_CommomStockExchange_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Common stock conversion of convertible note (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl" xml:lang="en-US">Pre-funded warrants of common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl" xml:lang="en-US">Warrants exchange (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NumberOfSharesPurchased" xlink:href="orka-20240930.xsd#orka_NumberOfSharesPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NumberOfSharesPurchased_lbl" xml:lang="en-US">Number of shares purchased (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0" xml:lang="en-US">Converted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl" xml:lang="en-US">Purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued to purchase (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Number of Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Net cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0" xml:lang="en-US">Leases term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Income tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity holding percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Own capital percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lease discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl" xml:lang="en-US">Variable lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xml:lang="en-US">Percentage of diluted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Shares were reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SharesOutstandingPercentage" xlink:href="orka-20240930.xsd#orka_SharesOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SharesOutstandingPercentage_lbl" xml:lang="en-US">Share outstanding percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesOutstandingPercentage" xlink:to="orka_SharesOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20240930.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl" xml:lang="en-US">Estimated fair value of warrants to be granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Employee warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Warrants outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Restricted stock awards authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchInitiationFee" xlink:href="orka-20240930.xsd#orka_ResearchInitiationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchInitiationFee_lbl" xml:lang="en-US">Research initiation fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitiationFee" xlink:to="orka_ResearchInitiationFee_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_DevelopmentCostsPercentage" xlink:href="orka-20240930.xsd#orka_DevelopmentCostsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_DevelopmentCostsPercentage_lbl" xml:lang="en-US">Percentage of development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_DevelopmentCostsPercentage_lbl0" xml:lang="en-US">Development costs, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReimburseOfDevelopmentCosts" xlink:href="orka-20240930.xsd#orka_ReimburseOfDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ReimburseOfDevelopmentCosts_lbl" xml:lang="en-US">Reimburse of development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReimburseOfDevelopmentCosts" xlink:to="orka_ReimburseOfDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payment to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NonRefundableMilestonePayments" xlink:href="orka-20240930.xsd#orka_NonRefundableMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NonRefundableMilestonePayments_lbl" xml:lang="en-US">Non-refundable milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PercentageOfWarrantPurchare" xlink:href="orka-20240930.xsd#orka_PercentageOfWarrantPurchare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PercentageOfWarrantPurchare_lbl" xml:lang="en-US">Percentage of warrant purchase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PercentageOfWarrantPurchare" xlink:to="orka_PercentageOfWarrantPurchare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Initial principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Interest rate, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Aggregate proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Debt issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Unpaid accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Employee warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Employee warrants vest over a period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US">Common stock ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Initiation fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_MilestonePayment" xlink:href="orka-20240930.xsd#orka_MilestonePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestonePayment" xlink:to="orka_MilestonePayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OtherDevelopmentCost" xlink:href="orka-20240930.xsd#orka_OtherDevelopmentCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OtherDevelopmentCost_lbl" xml:lang="en-US">Development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Research initiation fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9J7/dJKAxAU0BteBkOoGwjmNuwpQzgXkQw=] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl" xml:lang="en-US">Weighted-average number of shares of as-converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl" xml:lang="en-US">Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Classification of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl" xml:lang="en-US">Note Payable to Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl" xml:lang="en-US">Research and Development Contract Costs Accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xml:lang="en-US">General and Administrative Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share Attributable to Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ARCABIOPHARMAINCMember" xlink:href="orka-20240930.xsd#orka_ARCABIOPHARMAINCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ARCABIOPHARMAINCMember_lbl" xml:lang="en-US">ARCA BIOPHARMA INC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCABIOPHARMAINCMember" xlink:to="orka_ARCABIOPHARMAINCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaCommonStockMember" xlink:href="orka-20240930.xsd#orka_OrukaCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaCommonStockMember_lbl" xml:lang="en-US">Oruka Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_OrukaCommonStockMember_lbl0" xml:lang="en-US">Oruka common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaPrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_OrukaPrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaPrefundedWarrantsMember_lbl" xml:lang="en-US">Oruka pre-funded warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaPrefundedWarrantsMember" xlink:to="orka_OrukaPrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ARCACommonStockMember" xlink:href="orka-20240930.xsd#orka_ARCACommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ARCACommonStockMember_lbl" xml:lang="en-US">ARCA common stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaRestrictedStockMember" xlink:href="orka-20240930.xsd#orka_OrukaRestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaRestrictedStockMember_lbl" xml:lang="en-US">Oruka restricted stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaRestrictedStockMember" xlink:to="orka_OrukaRestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseStockSplitMember" xlink:href="orka-20240930.xsd#orka_ReverseStockSplitMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ReverseStockSplitMember_lbl" xml:lang="en-US">Reverse Stock Split [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReverseStockSplitMember" xlink:to="orka_ReverseStockSplitMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PrefundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PrefundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonMember" xlink:href="orka-20240930.xsd#orka_ParagonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonMember_lbl" xml:lang="en-US">Paragon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaHoldingLLCMember" xlink:href="orka-20240930.xsd#orka_ParukaHoldingLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaHoldingLLCMember_lbl" xml:lang="en-US">Paruka Holding, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaHoldingLLCMember" xlink:to="orka_ParukaHoldingLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OrukaAdvisorsLLCMember" xlink:href="orka-20240930.xsd#orka_OrukaAdvisorsLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_OrukaAdvisorsLLCMember_lbl" xml:lang="en-US">Oruka Advisors LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaAdvisorsLLCMember" xlink:to="orka_OrukaAdvisorsLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParagonAndParukaMember" xlink:href="orka-20240930.xsd#orka_ParagonAndParukaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParagonAndParukaMember_lbl" xml:lang="en-US">Paragon and Paruka [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonAndParukaMember" xlink:to="orka_ParagonAndParukaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairmountHealthcareFundIILPMember" xlink:href="orka-20240930.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl" xml:lang="en-US">Fairmount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl0" xml:lang="en-US">Fairmount Healthcare Fund II, L.P. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsMember_lbl" xml:lang="en-US">Commitments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsMember" xlink:to="us-gaap_CommitmentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl" xml:lang="en-US">2024 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl0" xml:lang="en-US">2024 Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock Awards [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ParukaWarrantObligationMember" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ParukaWarrantObligationMember_lbl" xml:lang="en-US">Paruka Warrant Obligation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_EmployeeWarrantsMember" xlink:href="orka-20240930.xsd#orka_EmployeeWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_EmployeeWarrantsMember_lbl" xml:lang="en-US">Employee Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_UnvestedStockOptionsMember" xlink:href="orka-20240930.xsd#orka_UnvestedStockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_UnvestedStockOptionsMember_lbl" xml:lang="en-US">Unvested Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnvestedStockOptionsMember" xlink:to="orka_UnvestedStockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ClinicalDevelopmentMilestonesMember" xlink:href="orka-20240930.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl" xml:lang="en-US">Clinical Development Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CertainRegulatoryMilestonesMember" xlink:href="orka-20240930.xsd#orka_CertainRegulatoryMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_CertainRegulatoryMilestonesMember_lbl" xml:lang="en-US">Certain Regulatory Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CertainRegulatoryMilestonesMember" xlink:to="orka_CertainRegulatoryMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNotesMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNotesMember" xlink:to="orka_ConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNotePurchaseAgreementMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotePurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ConvertibleNotePurchaseAgreementMember_lbl" xml:lang="en-US">Convertible Note Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNotePurchaseAgreementMember" xlink:to="orka_ConvertibleNotePurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertibleNoteMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ConvertibleNoteMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_PreFundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-Funded Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SeriesBNonVotingPreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_SeriesBNonVotingPreferredStockMember_lbl" xml:lang="en-US">Series B Non-Voting Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingPreferredStockMember" xlink:to="orka_SeriesBNonVotingPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroOneMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroOneMember_lbl" xml:lang="en-US">ORKA-001 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ORKAZeroZeroTwoMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="orka_ORKAZeroZeroTwoMember_lbl" xml:lang="en-US">ORKA-002 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable_lbl" xml:lang="en-US">Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:to="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems_lbl" xml:lang="en-US">Schedule of the Assets and Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:href="orka-20240930.xsd#orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_lbl" xml:lang="en-US">Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - Schedule of Common Stock Reserved for Future Issuance [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:to="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems_lbl" xml:lang="en-US">Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) - Schedule of RSAs activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:to="orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems_lbl" xml:lang="en-US">Schedule of RSAs activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:to="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems_lbl" xml:lang="en-US">Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable_lbl" xml:lang="en-US">Condensed Financial Statements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20240930.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="orka_NatureoftheBusinessandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:href="orka-20240930.xsd#orka_NatureOfTheBusinessAndBasisOfPresentationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems_lbl" xml:lang="en-US">Nature of the Business and Basis of Presentation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="orka_NatureOfTheBusinessAndBasisOfPresentationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockDetailsTable" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockDetailsTable_lbl" xml:lang="en-US">Common Stock (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockDetailsTable" xlink:to="orka_CommonStockDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommonStockDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockDetailsLineItems_lbl" xml:lang="en-US">Common Stock (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockDetailsLineItems" xlink:to="orka_CommonStockDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsTable" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsDetailsTable" xlink:to="orka_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_RelatedPartyTransactionsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RelatedPartyTransactionsDetailsLineItems" xlink:to="orka_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentsandContingenciesDetailsTable" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommitmentsandContingenciesDetailsTable" xlink:to="orka_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_CommitmentsandContingenciesDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommitmentsandContingenciesDetailsLineItems" xlink:to="orka_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_StockBasedCompensationDetailsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockBasedCompensationDetailsTable_lbl" xml:lang="en-US">Stock-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockBasedCompensationDetailsTable" xlink:to="orka_StockBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Stock-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsTable" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubsequentEventsDetailsTable" xlink:to="orka_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_SubsequentEventsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubsequentEventsDetailsLineItems" xlink:to="orka_SubsequentEventsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20240930.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayablewithRelatedPartyDetailsTable_lbl" xml:lang="en-US">Note Payable with Related Party (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayablewithRelatedPartyDetailsTable" xlink:to="orka_NotePayablewithRelatedPartyDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Note Payable with Related Party [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockAndStockholdersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems_lbl" xml:lang="en-US">Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="orka_ConvertiblePreferredStockAndStockholdersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_OptionAgreementsDetailsTable" xlink:href="orka-20240930.xsd#orka_OptionAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsDetailsTable_lbl" xml:lang="en-US">Option Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsDetailsTable" xlink:to="orka_OptionAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Option Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsTable_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsTable" xlink:to="orka_NetLossPerShareDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_NetLossPerShareDetailsLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NetLossPerShareDetailsLineItems_lbl" xml:lang="en-US">Net Loss Per Share (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NetLossPerShareDetailsLineItems" xlink:to="orka_NetLossPerShareDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AccruedResearchAndDevelopment_lbl0" xml:lang="en-US">Accrued research and development.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl0" xml:lang="en-US">The amount of additional paid-in capital transacation cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl0" xml:lang="en-US">Adjustment for change in common stock par value in connection with the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:to="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl0" xml:lang="en-US">Amount of accrued liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl0" xml:lang="en-US">Cash assumed in connection with the reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0" xml:lang="en-US">Classification of Convertible Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommomStockExchange_lbl0" xml:lang="en-US">The number of shares in common stock exchange.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommomStockExchange" xlink:to="orka_CommomStockExchange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_CommonStockLossAllocation_lbl0" xml:lang="en-US">Loss allocation, stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockLossAllocation" xlink:to="orka_CommonStockLossAllocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_DevelopmentCostsPercentage_lbl1" xml:lang="en-US">Percentage of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EmployeeWarrants_lbl0" xml:lang="en-US">The amount of employee warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrants" xlink:to="orka_EmployeeWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0" xml:lang="en-US">Estimated fair value of warrants to be granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl0" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl0" xml:lang="en-US">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ExchangeRatio_lbl0" xml:lang="en-US">Exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl0" xml:lang="en-US">Issuance cost of PIPE financing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl0" xml:lang="en-US">Issuance costs of pre-closing financing and reverse recapitalization.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:to="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0" xml:lang="en-US">Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0" xml:lang="en-US">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0" xml:lang="en-US">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance of Series A convertible preferred stock, net of issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_MilestonePayment_lbl0" xml:lang="en-US">The amount of milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestonePayment" xlink:to="orka_MilestonePayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NonRefundableMilestonePayments_lbl0" xml:lang="en-US">Non-refundable milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0" xml:lang="en-US">Represent the amount of non-cash accrued interest on convertible note converted to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0" xml:lang="en-US">Note Payable to Related Party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_NumberOfSharesPurchased_lbl0" xml:lang="en-US">Number of shares purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OptionAgreementsTextBlock_lbl0" xml:lang="en-US">Option agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsTextBlock" xlink:to="orka_OptionAgreementsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_OtherDevelopmentCost_lbl0" xml:lang="en-US">Represent the amount of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ParukaWarrantObligation_lbl0" xml:lang="en-US">Paruka warrant obligation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligation" xlink:to="orka_ParukaWarrantObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PercentageOfWarrantPurchare_lbl0" xml:lang="en-US">Percentage of warrant purchase.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PercentageOfWarrantPurchare" xlink:to="orka_PercentageOfWarrantPurchare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl0" xml:lang="en-US">Pre-funded warrants of common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl0" xml:lang="en-US">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:to="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ReimburseOfDevelopmentCosts_lbl0" xml:lang="en-US">The amount of reimburse of development costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReimburseOfDevelopmentCosts" xlink:to="orka_ReimburseOfDevelopmentCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0" xml:lang="en-US">Research and development contract costs accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ResearchInitiationFee_lbl0" xml:lang="en-US">Represents the amount of research initiation fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitiationFee" xlink:to="orka_ResearchInitiationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of fair value of the employee warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:to="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0" xml:lang="en-US">Number of Warrants, Exercised (in Shares).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Number of exercised of weighted average exercise price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl0" xml:lang="en-US">Number of Warrants, Vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Exercise Price Per Share, Vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted Average Remaining Contractual Term, Vested and exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Vested and expected to vest, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl0" xml:lang="en-US">Shares issuable upon exercise of pre-funded warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesIssuableUponExerciseOfPrefundedWarrants" xlink:to="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SharesOutstandingPercentage_lbl0" xml:lang="en-US">Shares outstanding percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesOutstandingPercentage" xlink:to="orka_SharesOutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl0" xml:lang="en-US">Subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_SubscriptionReceivables_lbl0" xml:lang="en-US">Amount of subscription receivable from investors who have been allocated common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_TerminationFee_lbl0" xml:lang="en-US">Represents the amount of termination fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TerminationFee" xlink:to="orka_TerminationFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl0" xml:lang="en-US">Unpaid PIPE Financing issuance costs included in accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl0" xml:lang="en-US">Unpaid PIPE Financing issuance costs included in accrued expenses and other current liabilties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl0" xml:lang="en-US">Unpaid pre-closing financing and reverse recapitalization issuance costs included in accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl1" xml:lang="en-US">Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred St</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesAConvertiblePreferredStockMember_lbl2" xml:lang="en-US">Series AConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesAConvertiblePreferredStockMember" xlink:to="orka_SeriesAConvertiblePreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl1" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl2" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl1" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl1" xml:lang="en-US">Unpaid PIPEFinancing Issuance Costs Included In Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl0" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1" xml:lang="en-US">Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:to="orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsMember_lbl0" xml:lang="en-US">Commitments [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsMember" xlink:to="us-gaap_CommitmentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1" xml:lang="en-US">Note Payable To Related Party Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NotePayableToRelatedPartyPolicyTextBlock" xlink:to="orka_NotePayableToRelatedPartyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="orka_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Option Agreements Fees Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOptionAgreementsFeesMember" xlink:to="orka_ParagonReimbursableOptionAgreementsFeesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US">Warrants and Rights Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReimburseOfDevelopmentCosts_lbl1" xml:lang="en-US">Reimburse Of Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReimburseOfDevelopmentCosts" xlink:to="orka_ReimburseOfDevelopmentCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl2" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2" xml:lang="en-US">Series ANon Voting Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1" xml:lang="en-US">Research And Development Contract Costs Accruals Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:to="orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl1" xml:lang="en-US">Shares Issuable Upon Exercise Of Prefunded Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesIssuableUponExerciseOfPrefundedWarrants" xlink:to="orka_SharesIssuableUponExerciseOfPrefundedWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0" xml:lang="en-US">Condensed Financial Statements [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Company SStock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1" xml:lang="en-US">Series BNon Voting Convertible Preferred Stock Amount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockAmountMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl1" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockTextBlock_lbl0" xml:lang="en-US">Common Stock Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockTextBlock" xlink:to="orka_CommonStockTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ARCABIOPHARMAINCMember_lbl0" xml:lang="en-US">ARCABIOPHARMAINCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCABIOPHARMAINCMember" xlink:to="orka_ARCABIOPHARMAINCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeWarrants_lbl1" xml:lang="en-US">Employee Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrants" xlink:to="orka_EmployeeWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0" xml:lang="en-US">Operating Lease, Variable Lease Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl2" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaRestrictedStockMember_lbl0" xml:lang="en-US">Oruka Restricted Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaRestrictedStockMember" xlink:to="orka_OrukaRestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl1" xml:lang="en-US">Proceeds From Issuance Of Pre Merger Oruka Series APreferred Stock Net Of Issuance Costs Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:to="orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TerminationFee_lbl1" xml:lang="en-US">Termination Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TerminationFee" xlink:to="orka_TerminationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OutstandingAndIssuedCommonStockOptionsMember_lbl0" xml:lang="en-US">Outstanding And Issued Common Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingAndIssuedCommonStockOptionsMember" xlink:to="orka_OutstandingAndIssuedCommonStockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued_lbl0" xml:lang="en-US">Class of Warrant or Right, Unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Schedule Of Convertible Preferred Stock Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfConvertiblePreferredStockAbstract" xlink:to="orka_ScheduleOfConvertiblePreferredStockAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OtherDevelopmentCost_lbl1" xml:lang="en-US">Other Development Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OtherDevelopmentCost" xlink:to="orka_OtherDevelopmentCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember_lbl0" xml:lang="en-US">Outstanding Employee Warrants To Purchase Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember" xlink:to="orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroTwoMember_lbl0" xml:lang="en-US">ORKAZero Zero Two Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroTwoMember" xlink:to="orka_ORKAZeroZeroTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl1" xml:lang="en-US">Issuance Costs Of Preclosing Financing And Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:to="orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock_lbl0" xml:lang="en-US">Schedule of Auction Market Preferred Securities by Stock Series [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" xlink:to="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series ANon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesANonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl1" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl0" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Expected To Vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Employee Stock Purchase Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:to="orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl1" xml:lang="en-US">Adjustment For Change In Common Stock Par Value In Connection With The Reverse Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:to="orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl1" xml:lang="en-US">Unpaid PIPEFinancing Issuance Costs Included In Accrued Expenses And Other Current Liabilties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:to="orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl1" xml:lang="en-US">Unpaid Preclosing Financing And Reverse Recapitalization Issuance Costs Included In Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:to="orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AccruedResearchAndDevelopment_lbl1" xml:lang="en-US">Accrued Research And Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AccruedResearchAndDevelopment" xlink:to="orka_AccruedResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AdditionalPaidInCapitalTransacationCost_lbl1" xml:lang="en-US">Additional Paid In Capital Transacation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AdditionalPaidInCapitalTransacationCost" xlink:to="orka_AdditionalPaidInCapitalTransacationCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0" xml:lang="en-US">Series BNon Voting Convertible Preferred Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl0" xml:lang="en-US">Preferred Stock [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract_lbl" xml:lang="en-US">Schedule Of Weighted Average Assumptions Or Range Of Assumptions Used In Calculating The Fair Value Of The Employee Warrants Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_DevelopmentCostsPercentage_lbl2" xml:lang="en-US">Development Costs Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_DevelopmentCostsPercentage" xlink:to="orka_DevelopmentCostsPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities Convertible Preferred Stock And Stockholders Equity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract" xlink:to="orka_LiabilitiesConvertiblePreferredStockAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0" xml:lang="en-US">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EmployeeWarrantsMember_lbl0" xml:lang="en-US">Employee Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EmployeeWarrantsMember" xlink:to="orka_EmployeeWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0" xml:lang="en-US">Two Thousand Twenty Four Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourStockIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourStockIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl0" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split, Conversion Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaCommonStockMember_lbl1" xml:lang="en-US">Oruka Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaCommonStockMember" xlink:to="orka_OrukaCommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonMember_lbl0" xml:lang="en-US">Paragon Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonMember" xlink:to="orka_ParagonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1" xml:lang="en-US">Noncash Accrued Interest On Convertible Note Converted To Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:to="orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfTheAssetsAndLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfTheAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfTheAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of The Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfTheAssetsAndLiabilitiesAbstract" xlink:to="orka_ScheduleOfTheAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Summarizes The Employee Warrant Activity Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" xlink:to="orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivablePolicyTextBlock_lbl1" xml:lang="en-US">Subscription Receivable Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivablePolicyTextBlock" xlink:to="orka_SubscriptionReceivablePolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClinicalDevelopmentMilestonesMember_lbl0" xml:lang="en-US">Clinical Development Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClinicalDevelopmentMilestonesMember" xlink:to="orka_ClinicalDevelopmentMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1" xml:lang="en-US">Classification Of Convertible Preferred Stock Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:to="orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl2" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl1" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingPreferredStockMember_lbl0" xml:lang="en-US">Series BNon Voting Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingPreferredStockMember" xlink:to="orka_SeriesBNonVotingPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:to="orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FairmountHealthcareFundIILPMember_lbl1" xml:lang="en-US">Fairmount Healthcare Fund IILPMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FairmountHealthcareFundIILPMember" xlink:to="orka_FairmountHealthcareFundIILPMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_MilestonePayment_lbl1" xml:lang="en-US">Milestone Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_MilestonePayment" xlink:to="orka_MilestonePayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl1" xml:lang="en-US">Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaAdvisorsLLCMember_lbl0" xml:lang="en-US">Oruka Advisors LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaAdvisorsLLCMember" xlink:to="orka_OrukaAdvisorsLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRsasActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfRsasActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRsasActivityAbstract_lbl" xml:lang="en-US">Schedule Of Rsas Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRsasActivityAbstract" xlink:to="orka_ScheduleOfRsasActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursablePatentExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Patent Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursablePatentExpensesMember" xlink:to="orka_ParagonReimbursablePatentExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable In Period Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_UnvestedStockOptionsMember_lbl0" xml:lang="en-US">Unvested Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_UnvestedStockOptionsMember" xlink:to="orka_UnvestedStockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl2" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl2" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OutstandingUnvestedRestrictedStockAwardsMember_lbl0" xml:lang="en-US">Outstanding Unvested Restricted Stock Awards Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OutstandingUnvestedRestrictedStockAwardsMember" xlink:to="orka_OutstandingUnvestedRestrictedStockAwardsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaHoldingLLCMember_lbl0" xml:lang="en-US">Paruka Holding LLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaHoldingLLCMember" xlink:to="orka_ParukaHoldingLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl1" xml:lang="en-US">Two Thousand Twenty Four Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_TwoThousandTwentyFourEquityIncentivePlanMember" xlink:to="orka_TwoThousandTwentyFourEquityIncentivePlanMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NonRefundableMilestonePayments_lbl1" xml:lang="en-US">Non Refundable Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NonRefundableMilestonePayments" xlink:to="orka_NonRefundableMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OptionAgreementsTextBlock_lbl1" xml:lang="en-US">Option Agreements Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OptionAgreementsTextBlock" xlink:to="orka_OptionAgreementsTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertibleNotesMember_lbl0" xml:lang="en-US">Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNotesMember" xlink:to="orka_ConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_RestrictedStockActivityMember_lbl0" xml:lang="en-US">Restricted Stock Activity Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_RestrictedStockActivityMember" xlink:to="orka_RestrictedStockActivityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1" xml:lang="en-US">Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:to="orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommomStockExchange_lbl1" xml:lang="en-US">Commom Stock Exchange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommomStockExchange" xlink:to="orka_CommomStockExchange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SharesOutstandingPercentage_lbl1" xml:lang="en-US">Shares Outstanding Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SharesOutstandingPercentage" xlink:to="orka_SharesOutstandingPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonAndParukaMember_lbl0" xml:lang="en-US">Paragon And Paruka Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonAndParukaMember" xlink:to="orka_ParagonAndParukaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0" xml:lang="en-US">Paragon Reimbursable Other Research Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParagonReimbursableOtherResearchExpensesMember" xlink:to="orka_ParagonReimbursableOtherResearchExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0" xml:lang="en-US">Accrued Liabilities and Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl0" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Fair Value Of The Employee Warrants Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:to="orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ExchangeRatio_lbl1" xml:lang="en-US">Exchange Ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ExchangeRatio" xlink:to="orka_ExchangeRatio_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ORKAZeroZeroOneMember_lbl0" xml:lang="en-US">ORKAZero Zero One Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ORKAZeroZeroOneMember" xlink:to="orka_ORKAZeroZeroOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantObligation_lbl1" xml:lang="en-US">Paruka Warrant Obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligation" xlink:to="orka_ParukaWarrantObligation_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CommonStockLossAllocation_lbl1" xml:lang="en-US">Common Stock Loss Allocation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CommonStockLossAllocation" xlink:to="orka_CommonStockLossAllocation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ComputerAndOfficeEquipmentMember_lbl0" xml:lang="en-US">Computer And Office Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ComputerAndOfficeEquipmentMember" xlink:to="orka_ComputerAndOfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl0" xml:lang="en-US">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1" xml:lang="en-US">Estimated Fair Value Of Warrants To Be Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_EstimatedFairValueOfWarrantsToBeGranted" xlink:to="orka_EstimatedFairValueOfWarrantsToBeGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Assets Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Period Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalDeferredPurchasePrice_lbl0" xml:lang="en-US">Supplemental Deferred Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalDeferredPurchasePrice" xlink:to="us-gaap_SupplementalDeferredPurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0" xml:lang="en-US">Payments of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_FinancialAssetsAbstract_lbl0" xml:lang="en-US">Financial Assets Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_FinancialAssetsAbstract" xlink:to="orka_FinancialAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ReverseStockSplitMember_lbl0" xml:lang="en-US">Reverse Stock Split Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ReverseStockSplitMember" xlink:to="orka_ReverseStockSplitMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl2" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0" xml:lang="en-US">Weighted Average Number of Shares, Contingently Issuable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PercentageOfWarrantPurchare_lbl1" xml:lang="en-US">Percentage Of Warrant Purchare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PercentageOfWarrantPurchare" xlink:to="orka_PercentageOfWarrantPurchare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_AssetsAbstract0_lbl0" xml:lang="en-US">Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_AssetsAbstract0" xlink:to="orka_AssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PrefundedWarrantsMember_lbl0" xml:lang="en-US">Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PrefundedWarrantsMember" xlink:to="orka_PrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsMember_lbl0" xml:lang="en-US">Pre Funded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsMember" xlink:to="orka_PreFundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CurrentAssetsAbstract0_lbl0" xml:lang="en-US">Current Assets Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CurrentAssetsAbstract0" xlink:to="orka_CurrentAssetsAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1" xml:lang="en-US">Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_NumberOfSharesPurchased_lbl1" xml:lang="en-US">Number Of Shares Purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_NumberOfSharesPurchased" xlink:to="orka_NumberOfSharesPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ARCACommonStockMember_lbl0" xml:lang="en-US">ARCACommon Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ARCACommonStockMember" xlink:to="orka_ARCACommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl1" xml:lang="en-US">Cash Assumed In Connection With The Reverse Recapitalization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CashAssumedInConnectionWithTheReverseRecapitalization" xlink:to="orka_CashAssumedInConnectionWithTheReverseRecapitalization_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceCostOfPIPEFinancing_lbl1" xml:lang="en-US">Issuance Cost Of PIPEFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceCostOfPIPEFinancing" xlink:to="orka_IssuanceCostOfPIPEFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl0" xml:lang="en-US">Operating Lease, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_OrukaPrefundedWarrantsMember_lbl0" xml:lang="en-US">Oruka Prefunded Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_OrukaPrefundedWarrantsMember" xlink:to="orka_OrukaPrefundedWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ParukaWarrantObligationMember_lbl0" xml:lang="en-US">Paruka Warrant Obligation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ParukaWarrantObligationMember" xlink:to="orka_ParukaWarrantObligationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1" xml:lang="en-US">Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:to="orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertibleNotePurchaseAgreementMember_lbl0" xml:lang="en-US">Convertible Note Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNotePurchaseAgreementMember" xlink:to="orka_ConvertibleNotePurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SubscriptionReceivables_lbl1" xml:lang="en-US">Subscription Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SubscriptionReceivables" xlink:to="orka_SubscriptionReceivables_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_StockholdersEquityAbstract0_lbl0" xml:lang="en-US">Stockholders Equity Abstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_StockholdersEquityAbstract0" xlink:to="orka_StockholdersEquityAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_PreFundedWarrantsOfCommonStockShares_lbl1" xml:lang="en-US">Pre Funded Warrants Of Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_PreFundedWarrantsOfCommonStockShares" xlink:to="orka_PreFundedWarrantsOfCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ResearchInitiationFee_lbl1" xml:lang="en-US">Research Initiation Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ResearchInitiationFee" xlink:to="orka_ResearchInitiationFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ConvertibleNoteMember_lbl0" xml:lang="en-US">Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ConvertibleNoteMember" xlink:to="orka_ConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_lbl" xml:lang="en-US">Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:to="orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_CertainRegulatoryMilestonesMember_lbl0" xml:lang="en-US">Certain Regulatory Milestones Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_CertainRegulatoryMilestonesMember" xlink:to="orka_CertainRegulatoryMilestonesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:to="orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl1" xml:lang="en-US">Series BNon Voting Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_SeriesBNonVotingConvertiblePreferredStockMember" xlink:to="orka_SeriesBNonVotingConvertiblePreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl1" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>orka-20240930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Nov 14 02:19:07 UTC 2024 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedBalanceSheet" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedIncomeStatement" roleURI="http://www.orukatx.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ShareholdersEquityType2or3" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConsolidatedCashFlow" roleURI="http://www.orukatx.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NatureoftheBusinessandBasisofPresentation" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommonStock" roleURI="http://www.orukatx.com/role/CommonStock"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactions" roleURI="http://www.orukatx.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentsandContingencies" roleURI="http://www.orukatx.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensation" roleURI="http://www.orukatx.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SubsequentEvents" roleURI="http://www.orukatx.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_Eventssubsequenttothereissuanceofthefinancialstatementunaudited" roleURI="http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancing" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_FairValueMeasurements" roleURI="http://www.orukatx.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilities" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NotePayablewithRelatedParty" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquity" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_IncomeTaxes" roleURI="http://www.orukatx.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_OptionAgreements" roleURI="http://www.orukatx.com/role/OptionAgreements"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShare" roleURI="http://www.orukatx.com/role/NetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccountingPoliciesByPolicy" roleURI="http://www.orukatx.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactionsTables" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentandContingenciesTables" roleURI="http://www.orukatx.com/role/CommitmentandContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensationTables" roleURI="http://www.orukatx.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ReverseRecapitalizationandPreClosingFinancingTables" roleURI="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_FairValueMeasurementsTables" roleURI="http://www.orukatx.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_AccruedExpensesandOtherCurrentLiabilitiesTables" roleURI="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityTables" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShareTables" roleURI="http://www.orukatx.com/role/NetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleoftheAssetsandLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" roleURI="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofConvertiblePreferredStockTable" roleURI="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCommonStockReservedforFutureIssuanceTable" roleURI="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofStockOptionActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofRSAsactivityTable" roleURI="http://www.orukatx.com/role/ScheduleofRSAsactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofEmployeeWarrantActivityTable" roleURI="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable" roleURI="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" roleURI="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" roleURI="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" roleURI="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" roleURI="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" roleURI="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NatureoftheBusinessandBasisofPresentationDetails" roleURI="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommonStockDetails" roleURI="http://www.orukatx.com/role/CommonStockDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_RelatedPartyTransactionsDetails" roleURI="http://www.orukatx.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_CommitmentsandContingenciesDetails" roleURI="http://www.orukatx.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_StockBasedCompensationDetails" roleURI="http://www.orukatx.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_SubsequentEventsDetails" roleURI="http://www.orukatx.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NotePayablewithRelatedPartyDetails" roleURI="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_ConvertiblePreferredStockandStockholdersEquityDetails" roleURI="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_IncomeTaxesDetails" roleURI="http://www.orukatx.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_OptionAgreementsDetails" roleURI="http://www.orukatx.com/role/OptionAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#orka_r_NetLossPerShareDetails" roleURI="http://www.orukatx.com/role/NetLossPerShareDetails"/>
  <roleRef xlink:type="simple" xlink:href="orka-20240930.xsd#DocumentAndEntityInformation" roleURI="http://www.orukatx.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivables" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="SubscriptionReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockholdersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockholdersMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockholdersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockAmountMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockAmountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockAmountMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="3.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:href="orka-20240930.xsd#orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" xlink:href="orka-20240930.xsd#orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" xlink:href="orka-20240930.xsd#orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostOfPIPEFinancing" xlink:href="orka-20240930.xsd#orka_IssuanceCostOfPIPEFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock" xlink:to="IssuanceCostOfPIPEFinancing" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="orka-20240930.xsd#orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" xlink:href="orka-20240930.xsd#orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashAssumedInConnectionWithTheReverseRecapitalization" xlink:href="orka-20240930.xsd#orka_CashAssumedInConnectionWithTheReverseRecapitalization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashAssumedInConnectionWithTheReverseRecapitalization" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashAssumedInConnectionWithTheReverseRecapitalization" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" xlink:href="orka-20240930.xsd#orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" xlink:href="orka-20240930.xsd#orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommonStock" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CommonStockAbstract" xlink:href="orka-20240930.xsd#orka_CommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockTextBlock" xlink:href="orka-20240930.xsd#orka_CommonStockTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockAbstract" xlink:to="CommonStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactions" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedParty" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAbstract" xlink:href="orka-20240930.xsd#orka_OptionAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsTextBlock" xlink:href="orka-20240930.xsd#orka_OptionAgreementsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAbstract" xlink:to="OptionAgreementsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShare" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SubscriptionReceivablePolicyTextBlock" xlink:href="orka-20240930.xsd#orka_SubscriptionReceivablePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SubscriptionReceivablePolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassificationOfConvertiblePreferredStockPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClassificationOfConvertiblePreferredStockPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NotePayableToRelatedPartyPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_NotePayableToRelatedPartyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NotePayableToRelatedPartyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" xlink:href="orka-20240930.xsd#orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" xlink:href="orka-20240930.xsd#orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationAndPreClosingFinancingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationAndPreClosingFinancingAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputerAndOfficeEquipmentMember" xlink:href="orka-20240930.xsd#orka_ComputerAndOfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputerAndOfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfTheAssetsAndLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfTheAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable"/>
    <loc xlink:type="locator" xlink:label="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:href="orka-20240930.xsd#orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfTheAssetsAndLiabilitiesAbstract" xlink:to="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable" xlink:to="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="orka-20240930.xsd#orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:href="orka-20240930.xsd#orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract" xlink:to="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable" xlink:to="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FinancialAssetsAbstract" xlink:href="orka-20240930.xsd#orka_FinancialAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems" xlink:to="FinancialAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialAssetsAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedResearchAndDevelopment" xlink:href="orka-20240930.xsd#orka_AccruedResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="AccruedResearchAndDevelopment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertiblePreferredStockAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockReservedForFutureIssuanceAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable" xlink:to="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuableUponExerciseOfPrefundedWarrants" xlink:href="orka-20240930.xsd#orka_SharesIssuableUponExerciseOfPrefundedWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="SharesIssuableUponExerciseOfPrefundedWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:to="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRSAsactivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRsasActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfRsasActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRsasActivityAbstract" xlink:to="StockBasedCompensationDetailsScheduleofRSAsactivityTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RestrictedStockActivityMember" xlink:href="orka-20240930.xsd#orka_RestrictedStockActivityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="RestrictedStockActivityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityTable" xlink:to="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofRSAsactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEmployeeWarrantActivityAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfEmployeeWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
<!-- [WMV6][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra9a2jfwGt44jro+lUyqzQL6/x1O9iJrf+dH3ymvrZRNb86/I06x7A9ljBSSeLHwUVO8zSU2wTDcbvo9VMwGaa9lLVYPe10sq6eTaiosvU//WQmETUn2YQF1MB+8Rrhxi9ypA8OCouD7AN9fcOhYxcJN+bW1vx4tZgDrEkxHw7OREH1QcuYc/HlxByK/E6Vd+/J9AmhwyCDseHEsE8kIbktayf3C+Snf9LkFBkgOmLr31sNl9Dz9mzIYn3WIFzpDOo=] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" xlink:href="orka-20240930.xsd#orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:href="orka-20240930.xsd#orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeWarrantActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligation" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="ParukaWarrantObligation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrants" xlink:href="orka-20240930.xsd#orka_EmployeeWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="EmployeeWarrants" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract" xlink:to="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable" xlink:to="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="CommonStockLossAllocation" xlink:href="orka-20240930.xsd#orka_CommonStockLossAllocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="CommonStockLossAllocation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems" xlink:to="us-gaap_NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OutstandingEmployeeWarrantsToPurchaseCommonStockMember" xlink:href="orka-20240930.xsd#orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="OutstandingEmployeeWarrantsToPurchaseCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingUnvestedRestrictedStockAwardsMember" xlink:href="orka-20240930.xsd#orka_OutstandingUnvestedRestrictedStockAwardsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="OutstandingUnvestedRestrictedStockAwardsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingAndIssuedCommonStockOptionsMember" xlink:href="orka-20240930.xsd#orka_OutstandingAndIssuedCommonStockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="OutstandingAndIssuedCommonStockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:href="orka-20240930.xsd#orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract" xlink:to="srt_ScheduleOfCondensedFinancialStatementsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOptionAgreementsFeesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOptionAgreementsFeesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ParagonReimbursableOptionAgreementsFeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursableOtherResearchExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursableOtherResearchExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ParagonReimbursableOtherResearchExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParagonReimbursablePatentExpensesMember" xlink:href="orka-20240930.xsd#orka_ParagonReimbursablePatentExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ParagonReimbursablePatentExpensesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsPayableOtherCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:href="orka-20240930.xsd#orka_NatureoftheBusinessandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:href="orka-20240930.xsd#orka_NatureOfTheBusinessAndBasisOfPresentationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NatureoftheBusinessandBasisofPresentationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OrukaCommonStockMember" xlink:href="orka-20240930.xsd#orka_OrukaCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaCommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaPrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_OrukaPrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaPrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ARCACommonStockMember" xlink:href="orka-20240930.xsd#orka_ARCACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="ARCACommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaRestrictedStockMember" xlink:href="orka-20240930.xsd#orka_OrukaRestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OrukaRestrictedStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitMember" xlink:href="orka-20240930.xsd#orka_ReverseStockSplitMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ReverseStockSplitMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="dei_LegalEntityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ARCABIOPHARMAINCMember" xlink:href="orka-20240930.xsd#orka_ARCABIOPHARMAINCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="ARCABIOPHARMAINCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrefundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PrefundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrefundedWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureoftheBusinessandBasisofPresentationDetailsTable" xlink:to="NatureOfTheBusinessAndBasisOfPresentationLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SharePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="TerminationFee" xlink:href="orka-20240930.xsd#orka_TerminationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="TerminationFee" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPaidInCapitalTransacationCost" xlink:href="orka-20240930.xsd#orka_AdditionalPaidInCapitalTransacationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="AdditionalPaidInCapitalTransacationCost" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRatio" xlink:href="orka-20240930.xsd#orka_ExchangeRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="ExchangeRatio" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockValue" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommomStockExchange" xlink:href="orka-20240930.xsd#orka_CommomStockExchange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="CommomStockExchange" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsOfCommonStockShares" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsOfCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="PreFundedWarrantsOfCommonStockShares" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightUnissued" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesPurchased" xlink:href="orka-20240930.xsd#orka_NumberOfSharesPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="NumberOfSharesPurchased" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalDeferredPurchasePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalDeferredPurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SupplementalDeferredPurchasePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_NetIncomeLoss" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_Cash" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NatureOfTheBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommonStockDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="CommonStockAbstract" xlink:href="orka-20240930.xsd#orka_CommonStockAbstract"/>
    <loc xlink:type="locator" xlink:label="CommonStockDetailsTable" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommonStockDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommonStockDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockAbstract" xlink:to="CommonStockDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsTable" xlink:to="CommonStockDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20240930.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ParagonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ParukaHoldingLLCMember" xlink:href="orka-20240930.xsd#orka_ParukaHoldingLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="ParukaHoldingLLCMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrukaAdvisorsLLCMember" xlink:href="orka-20240930.xsd#orka_OrukaAdvisorsLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="OrukaAdvisorsLLCMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="srt_OwnershipAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonAndParukaMember" xlink:href="orka-20240930.xsd#orka_ParagonAndParukaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="ParagonAndParukaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20240930.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="FairmountHealthcareFundIILPMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="orka-20240930.xsd#orka_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_CommitmentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OperatingLeaseVariableLeaseIncome" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsTable" xlink:href="orka-20240930.xsd#orka_StockBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="StockBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnvestedStockOptionsMember" xlink:href="orka-20240930.xsd#orka_UnvestedStockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="UnvestedStockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParukaWarrantObligationMember" xlink:href="orka-20240930.xsd#orka_ParukaWarrantObligationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ParukaWarrantObligationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEquityIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourStockIncentivePlanMember_0" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourStockIncentivePlanMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEmployeeStockPurchasePlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20240930.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOutstandingPercentage" xlink:href="orka-20240930.xsd#orka_SharesOutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharesOutstandingPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFairValueOfWarrantsToBeGranted" xlink:href="orka-20240930.xsd#orka_EstimatedFairValueOfWarrantsToBeGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EstimatedFairValueOfWarrantsToBeGranted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="orka-20240930.xsd#orka_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesAConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesAConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ParagonMember" xlink:href="orka-20240930.xsd#orka_ParagonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ParagonMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandTwentyFourEquityIncentivePlanMember" xlink:href="orka-20240930.xsd#orka_TwoThousandTwentyFourEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandTwentyFourEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotePurchaseAgreementMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNotePurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ConvertibleNotePurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentMilestonesMember" xlink:href="orka-20240930.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="ClinicalDevelopmentMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CertainRegulatoryMilestonesMember" xlink:href="orka-20240930.xsd#orka_CertainRegulatoryMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="CertainRegulatoryMilestonesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchInitiationFee" xlink:href="orka-20240930.xsd#orka_ResearchInitiationFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ResearchInitiationFee" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentCostsPercentage" xlink:href="orka-20240930.xsd#orka_DevelopmentCostsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="DevelopmentCostsPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReimburseOfDevelopmentCosts" xlink:href="orka-20240930.xsd#orka_ReimburseOfDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ReimburseOfDevelopmentCosts" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableMilestonePayments" xlink:href="orka-20240930.xsd#orka_NonRefundableMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NonRefundableMilestonePayments" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfWarrantPurchare" xlink:href="orka-20240930.xsd#orka_PercentageOfWarrantPurchare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PercentageOfWarrantPurchare" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="20.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="NotePayablewithRelatedPartyDetailsTable" xlink:href="orka-20240930.xsd#orka_NotePayablewithRelatedPartyDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="NotePayablewithRelatedPartyDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteMember" xlink:href="orka-20240930.xsd#orka_ConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FairmountHealthcareFundIILPMember" xlink:href="orka-20240930.xsd#orka_FairmountHealthcareFundIILPMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="FairmountHealthcareFundIILPMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotePayablewithRelatedPartyDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:href="orka-20240930.xsd#orka_ConvertiblePreferredStockAndStockholdersEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="ConvertiblePreferredStockandStockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PreFundedWarrantsMember" xlink:href="orka-20240930.xsd#orka_PreFundedWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="PreFundedWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesANonVotingConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesANonVotingConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBNonVotingPreferredStockMember" xlink:href="orka-20240930.xsd#orka_SeriesBNonVotingPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBNonVotingPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EmployeeWarrantsMember" xlink:href="orka-20240930.xsd#orka_EmployeeWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="EmployeeWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockandStockholdersEquityDetailsTable" xlink:to="ConvertiblePreferredStockAndStockholdersEquityLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertiblePreferredStockAndStockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/OptionAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="OptionAgreementsAbstract" xlink:href="orka-20240930.xsd#orka_OptionAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OptionAgreementsDetailsTable" xlink:href="orka-20240930.xsd#orka_OptionAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsAbstract" xlink:to="OptionAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroOneMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ORKAZeroZeroTwoMember" xlink:href="orka-20240930.xsd#orka_ORKAZeroZeroTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ORKAZeroZeroTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentMilestonesMember" xlink:href="orka-20240930.xsd#orka_ClinicalDevelopmentMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="ClinicalDevelopmentMilestonesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CertainRegulatoryMilestonesMember" xlink:href="orka-20240930.xsd#orka_CertainRegulatoryMilestonesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="CertainRegulatoryMilestonesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OptionAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="NonRefundableMilestonePayments" xlink:href="orka-20240930.xsd#orka_NonRefundableMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundableMilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForFees" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentCostsPercentage" xlink:href="orka-20240930.xsd#orka_DevelopmentCostsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="DevelopmentCostsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayment" xlink:href="orka-20240930.xsd#orka_MilestonePayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherDevelopmentCost" xlink:href="orka-20240930.xsd#orka_OtherDevelopmentCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="OtherDevelopmentCost" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfWarrantPurchare" xlink:href="orka-20240930.xsd#orka_PercentageOfWarrantPurchare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfWarrantPurchare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherExpenses" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/NetLossPerShareDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsTable" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsTable"/>
    <loc xlink:type="locator" xlink:label="NetLossPerShareDetailsLineItems" xlink:href="orka-20240930.xsd#orka_NetLossPerShareDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="NetLossPerShareDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsTable" xlink:to="NetLossPerShareDetailsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetLossPerShareDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.orukatx.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="orka-20240930.xsd#orka_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503182288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oruka
Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000907654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998502180096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 410,875<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivables', window );">Subscription receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">412,949<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">160<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">938<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">414,090<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,145<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">146<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,357<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,039<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, non-current</a></td>
<td class="nump">842<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,881<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="nump">35<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">397,345<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(57,943)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">342,368<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">414,090<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Related party common stock warrant liability</a></td>
<td class="nump">7,681<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivables', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="nump">52,841<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivable from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503145392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">545,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">34,998,550<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">34,998,550<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference (in Dollars)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">2,439<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember', window );">Series B Non-Voting Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">251,504<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported | Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505795360">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 25,691<span></span>
</td>
<td class="nump">$ 49,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">3,758<span></span>
</td>
<td class="nump">8,248<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">29,449<span></span>
</td>
<td class="nump">57,805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,449)<span></span>
</td>
<td class="num">(57,805)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,330<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(504)<span></span>
</td>
<td class="num">(1,468)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">826<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (28,623)<span></span>
</td>
<td class="num">$ (57,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable, basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable, diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,013,655<span></span>
</td>
<td class="nump">7,765,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,013,655<span></span>
</td>
<td class="nump">7,765,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember', window );">Series A Non-Voting Convertible Preferred Stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable, basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,461.1)<span></span>
</td>
<td class="num">$ (6,077.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable, diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (1,461.1)<span></span>
</td>
<td class="num">$ (6,077.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">477<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">477<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember', window );">Series B Non-Voting Convertible Preferred Stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable, basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (121.76)<span></span>
</td>
<td class="num">$ (506.44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable, diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (121.76)<span></span>
</td>
<td class="num">$ (506.44)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,191<span></span>
</td>
<td class="nump">19,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,191<span></span>
</td>
<td class="nump">19,015<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998501207376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Series B Non-Voting </div>
<div>Series A</div>
</th>
<th class="th">
<div>Series B Non-Voting </div>
<div>Series A Non-Voting</div>
</th>
<th class="th">
<div>Series B Non-Voting </div>
<div>Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Feb. 05, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,077)<span></span>
</td>
<td class="num">(7,077)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2024</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(7,077)<span></span>
</td>
<td class="num">(7,059)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,405,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Feb. 05, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Feb. 05, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,943)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52,841<span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">397,345<span></span>
</td>
<td class="num">(57,943)<span></span>
</td>
<td class="nump">342,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="nump">34,998,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2024</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(7,077)<span></span>
</td>
<td class="num">(7,059)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Mar. 31, 2024</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,405,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(22,243)<span></span>
</td>
<td class="num">(22,243)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2024</a></td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">334<span></span>
</td>
<td class="num">(29,320)<span></span>
</td>
<td class="num">(28,981)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Jun. 30, 2024</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,405,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization</a></td>
<td class="num">$ (2,931)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock', window );">Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares)</a></td>
<td class="num">(20,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">26,445<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing,</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">248,437<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">248,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost', window );">Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,061,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization', window );">Issuance costs of Pre-Closing Financing and reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,480)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(20,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger', window );">Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">144,433<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">144,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant', window );">Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceCostOfPIPEFinancing', window );">Issuance cost of PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(28,623)<span></span>
</td>
<td class="num">(28,623)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Sep. 30, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 52,841<span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 397,345<span></span>
</td>
<td class="num">$ (57,943)<span></span>
</td>
<td class="nump">$ 342,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances (in Shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="nump">137,138<span></span>
</td>
<td class="nump">34,998,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for change in common stock par value in connection with the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceCostOfPIPEFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance cost of PIPE financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceCostOfPIPEFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs of pre-closing financing and reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998506044064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts', window );">Issuance of Series A convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503143632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows (Unaudited)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">9,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,357<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid', window );">Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid</a></td>
<td class="nump">2,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable to related parties, net of issuance costs paid</a></td>
<td class="nump">24,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Proceeds from the Pre-Closing Financing, net</a></td>
<td class="nump">228,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the PIPE Financing, net</a></td>
<td class="nump">189,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashAssumedInConnectionWithTheReverseRecapitalization', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">4,940<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">450,065<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">410,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash at beginning of period</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">410,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liability arising from obtaining operating right-of-use asset</a></td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1', window );">Assets acquired in connection with the reverse recapitalization</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Other liabilities assumed in connection with the reverse recapitalization</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable', window );">Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable</a></td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable', window );">PIPE Financing issuance costs included in accounts payable</a></td>
<td class="nump">374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties', window );">PIPE Financing issuance costs included in accrued expenses and other current liabilities</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock', window );">Non-cash accrued interest on convertible note converted to common stock</a></td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock</a></td>
<td class="nump">$ 2,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashAssumedInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash assumed in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashAssumedInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of non-cash accrued interest on convertible note converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid PIPE Financing issuance costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid PIPE Financing issuance costs included in accrued expenses and other current liabilties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid pre-closing financing and reverse recapitalization issuance costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, classified as other, acquired in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504610672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. Nature of the Business and Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Background and Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Oruka Therapeutics, Inc. (&#8220;Oruka&#8221; or
the &#8220;Company&#8221;) was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded
by Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;). The Company currently operates as a virtual company, and thus, does not maintain
a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory
skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company&#8217;s potential products will require
approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There
can be no assurance that the Company&#8217;s potential products will receive all the required approvals. In addition, there can be no
assurance that the Company&#8217;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February 6, 2024, the Company had no cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#8217;s development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company received $3.0 million
in proceeds from the sale of Series A convertible preferred stock and $25.0 million in proceeds from the sale of an unsecured convertible
promissory note, both of which were related party transactions (see Note 7 <i>Subsequent Events</i>).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">ARCA biopharma, Inc., a Delaware corporation (&#8220;ARCA&#8221;),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) on April 3, 2024,
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation (&#8220;First Merger Sub&#8221;), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#8220;First Merger&#8221;), and Oruka will merge
with and into Atlas Merger Sub II, LLC, a Delaware limited liability company (&#8220;Second Merger Sub&#8221; and together with First
Merger Sub, &#8220;Merger Subs&#8221;), with Second Merger Sub being the surviving entity of the merger (the &#8220;Second Merger&#8221;
and, together with the First Merger, the &#8220;Merger&#8221;). In connection with the Merger, Second Merger Sub will change its corporate
name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA will change its name to &#8220;Oruka Therapeutics, Inc.&#8221;
ARCA following the Merger is referred to herein as the &#8220;combined company.&#8221; The combined company will be led by Oruka&#8217;s
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Concurrent with the execution of the Merger Agreement,
the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in
a private placement financing (the &#8220;Private Placement&#8221;) shares and pre-funded warrants of the Company&#8217;s common stock
at an estimated purchase price of $9.71 ($5.55 prior to impact of reverse stock split and reverse merger exchange ratio) per share of
common stock and estimated purchase price of $9.70 ($5.54 prior to the impact of the reverse stock split and reverse merger exchange ratio)
per warrant for gross proceeds of approximately $275.0 million, which will precede the closing of the Merger Agreement. Shares of the
Company&#8217;s common stock and pre-funded warrants to purchase shares of the Company&#8217;s common stock issued pursuant to the Private
Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock,
respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private
Placement are expected to advance the Company&#8217;s pipeline, business development activities, working capital, and other general corporate
purposes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $0.4 million or Oruka could be required to pay ARCA a termination fee of $0.4 million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company&#8217;s financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve months from the date the financial statement is available to be issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the Merger Agreement discussed
above, the Company effected a one-for-twelve reverse stock split of the Company&#8217;s issued and outstanding shares of common stock
on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Company&#8217;s
common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively
adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of 6.8569 as calculated in accordance
with the Merger Agreement for all periods presented.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>1.
Nature of the Business and Basis of Presentation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Background
and Basis of Presentation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#8220;Company&#8221;), formerly known as ARCA biopharma, Inc.
(&#8220;ARCA&#8221;), is an early-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#8220;Pre-Merger Oruka&#8221;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing biologics to optimize the treatment of inflammatory
skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">These
condensed consolidated financial statements reflect, in the opinion of management, all adjustments of a normal and recurring nature that
are necessary for a fair statement of the Company&#8217;s financial position as of September 30, 2024, and its results of operations
for the three months ended September 30, 2024 and from February 6, 2024 (inception) to September 30, 2024, and cash flows for the period
from February 6, 2024 (inception) to September 30, 2024. The condensed balance sheet as of February 6, 2024, included in the condensed
consolidated balance sheets was derived from the Company&#8217;s audited financial statements. The condensed consolidated financial statements
and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;)
for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;)
and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
results for the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024 are not
necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The condensed consolidated financial
statements include the financial statements of its wholly-owned subsidiaries. All significant intercompany balances and transactions
have been eliminated in consolidation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Recapitalization and Pre-Closing&#160;Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2024, the Company consummated the previously announced business combination (&#8220;Closing&#8221;) pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the &#8220;Merger Agreement&#8221;), by and among ARCA, Atlas Merger
Sub Corp, a wholly owned subsidiary of ARCA (&#8220;First Merger Sub&#8221;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of
ARCA (&#8220;Second Merger Sub&#8221;) and Pre-Merger Oruka, pursuant to which, among other matters, Pre-Merger Oruka merged with and
into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger
(&#8220;First Merger&#8221;) and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub
being the surviving entity of the second merger (the &#8220;Second Merger&#8221; and together with the First Merger, the &#8220;Merger&#8221;).
Following consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#8220;Reverse Stock Split&#8221;) of
the common stock, par value $0.001 per share, of the Company (&#8220;Company Common Stock&#8221;), which became effective on September
3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September
3, 2024. Second Merger Sub changed its corporate name to &#8220;Oruka Therapeutics Operating Company, LLC&#8221; and ARCA changed its
name to &#8220;Oruka Therapeutics, Inc.&#8221; The Company is led by the Pre-Merger Oruka management team and remains focused on developing
biologics to optimize the treatment of inflammatory skin diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#8220;Subscription Agreement&#8221;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#8220;Pre-Merger Oruka Common Stock&#8221;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 6)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#8220;Pre-Closing Financing&#8221;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the unaudited
condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded
warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of
Company Common Stock in accordance with the Exchange Ratio (defined below).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#8220;First Effective Time&#8221;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company Common Stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock,
par value $0.0001 (&#8220;Pre-Merger Oruka Series A Preferred Stock&#8221;), outstanding immediately prior to the First Effective Time
was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $0.001 per
share (&#8220;Company Series B Preferred Stock&#8221;), which are convertible into shares of Company Common Stock, at a conversion ratio
of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase
shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a
warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective
Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock
shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Net loss per share for periods prior to
the close of the reverse recapitalization has been revised to reflect the exchange ratio. After applying the exchange ratio and the reverse
stock split, net loss per share for the periods from February 6, 2024 (inception) to March 31, 2024 and for three months ended June 30,
2024 and from February 6, 2024 (inception) to June 30, 2024 are $(2.21), $(6.96), and $(9.17), respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Pre-Closing Financing and the Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka&#8217;s largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka&#8217;s executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger
Oruka. Additional information regarding the Merger is included in Note 3.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Reverse
Stock Split</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect
the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>PIPE
Financing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On September 11, 2024, the Company entered into
a Securities Purchase Agreement for a private placement (the &#8220;PIPE Financing&#8221;) with certain institutional and accredited investors.
The closing of the PIPE Financing occurred on September 13, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Securities Purchase Agreement, the
investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate of
2,439 shares of the Company&#8217;s Series A non-voting convertible preferred stock, par value $0.001 per share (&#8220;Company Series
A Preferred Stock&#8221;), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Liquidity
and Going Concern</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. The Company has incurred a net loss of $28.6 million for the three months ended September
30, 2024 and $57.9&#160;million during the period from February&#160;6, 2024 (inception) to September 30, 2024. For the period from February
6, 2024 (inception) to September 30, 2024, the Company used net cash of $39.0 million for its operating activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had cash and cash equivalents of $410.9 million. The Company&#8217;s management expects that the existing
cash and cash equivalents will be sufficient to fund the Company&#8217;s operating plans for at least twelve months from the date these
condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative
costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials
and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general
and administrative support for its operations, including the costs associated with operating as a public company. The Company&#8217;s
ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed,
the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the
commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company&#8217;s business
opportunities, as desired, which could materially harm the Company&#8217;s business, financial condition and results of operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505755008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. Summary of Significant Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Subscription receivable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>2.
Summary of Significant Accounting Policies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;1
&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful&#160;Life</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217; equity (deficit) on the Company&#8217;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#8217; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#8217;
equity (deficit) on the Company&#8217;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Note&#160;Payable to Related Party</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Contract Costs Accruals</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development
expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;),
and the Company&#8217;s related-party Paragon (see Note&#160;10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments
are classified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss per Share Attributable to Stockholders</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November&#160;2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting</i> (<i>Topic&#160;280</i>)<i>:
Improvements to Reportable Segment Disclosures</i> (&#8220;ASU&#160;2023-07&#8221;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In December&#160;2023, the FASB issued ASU&#160;2023-09,
<i>Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</i>. This ASU expands disclosures in an entity&#8217;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November 2024, the FASB issued ASU 2024-03, <i>Income
Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504273408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of February 6, 2024, the Company has the authority
to issue a total of 65,000,000 shares of common stock at a par value of $0.001. As of February 6, 2024, 3,197,975 shares of common stock
were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is
available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such
holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends,
if any, as declared by the Company&#8217;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders
of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive
the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504120832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"><b>4. Related Party Transactions</b></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company issued 3,197,975 shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC (&#8220;Oruka Advisors&#8221;), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common
stock holdings.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>13.
Related Party Transactions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
and Paruka each beneficially own less than 5% of the Company&#8217;s capital stock through their respective holdings of Company Common
Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Fairmount beneficially owns more than 5% of the
Company&#8217;s capital, currently has one representative appointed to the Board, and beneficially owns more than 5% of Paragon. Fairmount
appointed Paragon&#8217;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable Option Agreements&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,140</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable other research expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">146</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable patent expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,357</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503983920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. Commitments and Contingencies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party,
nor did the Company have knowledge of any proceedings threatened against it.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>11.
Commitment and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b>Leases</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
April 2024, the Company entered into an operating lease agreement for the Company&#8217;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.1
million, and operating lease liability, noncurrent of $0.8 million on its condensed consolidated balance sheets. As of September 30,
2024, the operating lease arrangement had a remaining lease term of 36.0 months and a discount rate of 17.95%. For the three months ended
September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable
lease expense of $0.1 and $0.2 million, respectively, in general and administrative expenses in its condensed consolidated statements
of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September
    30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for amounts included in the measurement of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    cash flow from operating leases</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    year ending December 31,</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%"><span style="font-family: Times New Roman, Times, Serif">2024
    (remainder)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">380</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    undiscounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(318</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    discounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(146</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">842</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On February 6, 2024, the Company&#8217;s Board of
Directors approved the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), under which the Company may grant stock options, restricted
stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The
Company reserved 213,085 shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued
under the plan.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>8.
Stock-Based Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Equity Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Equity Incentive Plan (&#8220;2024 Plan&#8221;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#8217;s continued service, and expire after ten&#160;years, although stock options
have been granted with vesting terms less than four&#160;years. As of September 30, 2024, there are no shares of common stock available
for issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Stock Incentive Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">On
August 22, 2024, the 2024 Stock Incentive Plan (&#8220;2024 Stock Plan&#8221;) was approved by the Company&#8217;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#8220;Board&#8221;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock and as of September 30, 2024, there are 4,526,324 shares available in the pool. The shares that may be issued
under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase
on January 1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded
warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective
employees, officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible
to participate in the 2024 Stock Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>2024
Employee Stock Purchase Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
2024 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) was approved by the board of directors of ARCA on July 20, 2024, and by ARCA&#8217;s
stockholders on August 22, 2024. The ESPP became effective on August 29, 2024, at which time 463,489 shares were reserved for issuance.
The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee.
As of September 30, 2024, no shares have been issued out of the ESPP.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Option Valuation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three<br/> Months Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from <br/> February&#160;6,<br/> 2024 <br/> (Inception)<br/> to <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">97.3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">101.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.5</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock
Options</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Stock Options</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,507</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,507</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
September 30, 2024 was $6.44 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Restricted
Stock Awards</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#8217;s service
with the Company voluntarily or involuntarily terminates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of<br/> RSAs</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
                                            Average<br/> Grant Date<br/> Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested balance
    as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested
    balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Option
Agreements and Paruka Warrant Obligation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, the Company entered into antibody
discovery and option agreements with Paragon and Paruka (the &#8220;Option Agreements&#8221;). Under the terms of Option Agreements, Paragon
identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company,
and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license
to all of Paragon&#8217;s right, title, and interest in and to the intellectual property resulting from the applicable research program
to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants
of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#8217;s stock, on a fully diluted
basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board (the &#8220;Paruka Warrant
Obligation&#8221;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for
the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after
the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As
of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $11.0 million. For the three months
ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $7.3 million and $7.7 million were recognized
as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As stated above, on July 3, 2024, the Subscription
Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Oruka&#8217;s employees,
directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months
ended September 30, 2024, the Company issued 3,054,358 employee warrants at an exercise price of $7.80 per warrant, which are accounted
as equity in the condensed consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Warrants</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.8</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,038</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.8</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,038</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
weighted average grant-date fair value per share of employee warrants granted during the period from February&#160;6, 2024 (inception)
to September 30, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the
underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from<br/> February&#160;6,<br/> 2024<br/> (Inception) <br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#8239;Months
                                            Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,772</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,310</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,229</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,001</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $7.5 million, which is expected
to be recognized over a weighted average period of approximately 3.4 years. As of September 30, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.4
years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $17.8 million, which is expected
to be recognized over a weighted average period of 3.6 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months
                                            Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka
    warrant obligation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,251</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,681</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee
    warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,314</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,314</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">765</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee
    stock purchase plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,001</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998589861968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. Subsequent Events</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company evaluated all events subsequent to February
6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Stock-Based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In February 2024, the Company&#8217;s Board of Directors
authorized and granted 1,184,749 restricted stock awards at a price of $0.0001 per share to employees of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March 2024, the Company&#8217;s Board of Directors
authorized and granted 1,022,804 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 5, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
213,085 to 498,789.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 22, 2024, the Company granted options for
the purchase of an aggregate 399,222 shares of common stock, at an exercise price of $5.16 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company&#8217;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
498,789 to 1,179,193.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On May 7, 2024, the Company granted options for
the purchase of an aggregate 779,971 shares of common stock, at an exercise price of $6.84 per share.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Antibody Discovery and Option Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into an Antibody
Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company
was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right, title and
interest in and to the intellectual property (&#8220;ORKA-001&#8221;) resulting from the applicable research program to develop, manufacture
and commercialize products directed at the selected target (&#8220;IL-23&#8221;), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research
initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development expense during the period
ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for 50% of the development costs incurred prior
to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement
is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $5.9 million
of development costs incurred prior to March 31, 2024. The Company will be responsible for 50% of the ORKA-001 development costs incurred
from and after March 31, 2024, through the completion of the IL-23 selection process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company also entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby
the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#8217;s right,
title and interest in and to the intellectual property (&#8220;ORKA-002&#8221;) resulting from the applicable research program to develop,
manufacture and commercialize products directed at the selected target (&#8220;IL-17&#8221;). The Company was also required to reimburse
Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and
development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company
paid $3.3 million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January
1, 2024 to March 31, 2024 of $0.9 million, which was recognized as a research and development expense in the period from February 6 (inception)
to March 31, 2024. The Company will be required to pay Paragon $0.8 million for the research initiation fee related to ORKA-002 within
30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of the date of issuance of the Company&#8217;s
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0 million upon
the achievement of certain clinical development milestones, up to $10.0 million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number
of shares equal to 1.00% of the then outstanding shares of the Company&#8217;s common stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Series A Preferred Stock</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company issued 20,000,000
shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. (&#8220;Fairmount&#8221;), a related party of the
Company, at a purchase price of $0.15 per share for gross proceeds of $3.0 million. The Company incurred less than $0.1 million of issuance
costs in connection with this transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The holders of Series A convertible preferred stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding
shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which
the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote
on such matter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Each share of Series A convertible preferred stock
is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition,
each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion
ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Company&#8217;s common stock
at a price of at least $12.00 per share resulting in at least $50.0 million of gross proceeds to the Company, or (ii) the vote or written
consent of the holders of a majority of the Preferred Stock, voting as a single class.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The conversion ratio of Series A convertible preferred
stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue
Price is $0.15 per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any
stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#8217;s certificate
of incorporation, as amended and restated). The Conversion Price is approximately $0.26 per share for Series A convertible preferred stock
and each outstanding share of Series A Preferred Stock was convertible into common stock at a 0.5712 conversion ratio.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)
in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series
A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred
stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred
stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series
A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will
share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would
otherwise be payable if it were paid in full.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Unless the holders of a majority in voting power
of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger
or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the
surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
Company&#8217;s assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Series A convertible preferred stock does not have
redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On March 6, 2024, the Company entered into a Series
A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with Fairmount, whereby the Company issued
a convertible note (the &#8220;Convertible Note&#8221;), with an initial principal amount of $25.0 million, that can be converted into
Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its
next equity financing) or shares of the Company&#8217;s common stock in exchange for proceeds of $25.0 million. The Convertible Note will
automatically convert into shares of the Company&#8217;s common stock upon the closing of a corporate transaction, including the reverse
recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues
interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not
permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue
additional convertible notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million of initial principal
amount of the Convertible Note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Oak Grove Lease</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">On April 12, 2024, the Company entered into a lease
agreement with Oak Grove LP (&#8220;Oak Grove Lease&#8221;) for office space located in Menlo Park, California. The lease commencement
date is June 15, 2024 with an initial term of 39.5 months. The total lease payment is expected to be $1.4 million over the initial lease
term.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998606653472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Events subsequent to the reissuance of the financial statement (unaudited)<br></strong></div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Events subsequent to the reissuance of the financial statement (unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Events subsequent to the reissuance of the financial statement (unaudited)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Events subsequent to the reissuance of the financial statement
(unaudited)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be
reissued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504360208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReverseRecapitalizationAndPreClosingFinancingAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Reverse Recapitalization and Pre-Closing Financing</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. Reverse
Recapitalization and Pre-Closing Financing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
described within the <i>Reverse Recapitalization and Pre-Closing Financing </i>section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReverseRecapitalizationAndPreClosingFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReverseRecapitalizationAndPreClosingFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504251552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>4.
Fair Value Measurements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value Measurements as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Financial assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Money market funds</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total financial assets</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">There
were no transfers between Level&#160;1, Level&#160;2, or Level&#160;3 during the period from February 6, 2024 (inception) to September
30, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503964512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. Accrued
Expenses and Other Current Liabilities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    employee compensation and benefits</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">933</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional and consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">204</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">573</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,710</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505706432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Note Payable with Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Note Payable with Related Party</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>6.
Note&#160;Payable with Related Party</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#8220;Purchase Agreement&#8221;)
with Fairmount Healthcare Fund&#160;II, L.P. (&#8220;Fairmount&#8221;), whereby the Company issued a convertible note (the &#8220;Convertible
Note&#8221;), with an initial principal amount of $25.0 million that, at the time of issuance, could be converted into Pre-Merger Oruka
Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued
in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $25.0&#160;million. The
Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note required all unpaid interest and principal
to mature on December&#160;31, 2025 (the &#8220;Maturity Date&#8221;) and prepayment was not permitted without prior written consent
of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity
Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, <i>Derivatives and Hedging</i>, and as a result,
did not require separate accounting as a derivative liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the condensed consolidated balance sheet and were being amortized as interest
expense over the term of the Convertible Note using the effective interest method. For the three months ended September 30, 2024 and
the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized interest expenses related to the Convertible
Note of $0.5 million and $1.5 million, respectively, which includes non-cash interest expense related to the amortization of debt issuance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Immediately prior to the completion of the Merger
(see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount
of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which was determined based upon the Company&#8217;s
fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued
upon the conversion of the Convertible Note (including accrued interest) automatically converted into 2,722,207 shares of Company Common
Stock. As of September 30, 2024, the Convertible Note is not outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998594222576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Convertible Preferred Stock and Stockholders&#8217; Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>7.
Convertible Preferred Stock and Stockholders&#8217; Equity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Pre-Funded
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
pre-funded warrants were recorded as a component of stockholders&#8217; equity within additional paid-in-capital and have <span style="-sec-ix-hidden: hidden-fact-110">no</span> expiration
date. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-111">none</span> of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Employee
Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#8217;s employees, directors, and service providers immediately prior to the closing of the Merger. During
the three months ended September 30, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These employee
warrants vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#8217;s employee
warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the
exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued
or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry
custodian. The Company recognizes compensation cost related to employee warrants on a straight-line basis over the requisite service
period, which is the period in which the related services are received. As of September 30, 2024, <span style="-sec-ix-hidden: hidden-fact-112">none</span> of the employee warrants have
been exercised and 3,054,358 employee warrants remain outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b><i>Convertible
Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In March&#160;2024, Pre-Merger Oruka issued and
sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock to Fairmount (see Note 13), at a purchase price
of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million. Pre-Merger Oruka incurred less than $0.1&#160;million
of issuance costs in connection with this transaction. Upon the issuance of the Pre-Merger Oruka Series&#160;A Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not
require the Company to separately account for these features.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Issued and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&#160;Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series A Non-Voting Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series B Non-Voting Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,428,149</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Certificate of Designation of Preferences,
Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#8220;Series A Certificate of Designation&#8221;)
filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock are entitled to receive dividends on shares of
Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis, and in the same form as, dividends actually
paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law,
the Company Series A Preferred Stock does not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company
Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Subject to the terms
and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing
will not become convertible until the Company&#8217;s stockholders approve the conversion of the Company Series A Preferred Stock into
shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the &#8220;Stockholder Approval&#8221;),
which resulted in the Company Series A Preferred Stock being classified outside of stockholders&#8217; equity (deficit) on the Company&#8217;s
condensed consolidated balance sheet.. Following the Stockholder Approval, each share of Company Series A Preferred Stock will automatically
convert into 1,000 shares of Company Common Stock, subject to certain limitations, including that shares of Company Series A Preferred
Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than
9.99% of the Company&#8217;s outstanding shares of Company Common Stock as of the applicable conversion date, which may be increased at
the holders&#8217; option (not to exceed 19.99%), effective in accordance with the terms of the Series A Certificate of Designation. If,
at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series A non-voting preferred stock,
the Company fails to deliver to a holder such certificate or certificates, the Company shall, at the request of the holder, pay an amount
equal to the closing price of Company&#8217;s common stock on the trading day immediately prior to the date on which notice to conversion
is received by the Company (the &#8220;Fair Value&#8221;) of such undelivered shares, with such payment to be made within two business
days from the date of request by the holder, whereupon the Company&#8217;s obligations to deliver such shares underlying the notice of
conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request
shall be presumed to have been made by such holder if Stockholder Approval shall not have been obtained prior to the date on which the
notice of conversion is delivered to the Company.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#8220;Series B Certificate of Designation&#8221;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of September
30, 2024, 34,988,550 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,439,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series B Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon
    exercise of pre-funded warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,202,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued stock options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued employee warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Stock Incentive Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,526,324</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Employee Stock Purchase Plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">463,489</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,401,287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505706432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>9.
Income Taxes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of February&#160;6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as
the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated
to date.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503951472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Option Agreements<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsAbstract', window );"><strong>Option Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OptionAgreementsTextBlock', window );">Option Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif"><b>10.
Option Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">In
March&#160;2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon
identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company.
The Option Agreements include two selected targets, IL-23 (&#8220;ORKA-001&#8221;) and IL-17 A/F (&#8220;ORKA-002&#8221;). Under the
Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon&#8217;s right, title and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#8220;Option&#8221;),
with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will
be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the
achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement
of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial
sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s exclusive Option with respect to each research program for a particular target initiated by the parties (&#8220;Research
Program&#8221;) is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the
associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than
ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect
to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the &#8220;Option Period&#8221;). There
is no payment due upon exercise of an Option pursuant to the Option Agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the
expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed
extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration
of the applicable research term (the &#8220;Term&#8221;). Upon the expiration of the Term for all then-existing Research Programs, under
the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements
or any Research Program at any time for any or no reason upon 30&#160;days&#8217; prior written notice to Paragon, provided that the
Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a
Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its
affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise
delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program
upon (i)&#160;30&#160;days&#8217; prior written notice of the other party&#8217;s material breach that remains uncured for the 30-day
period and (ii)&#160;the other party&#8217;s bankruptcy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In
June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for
IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred through the completion of the
IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months
ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement
of development candidate as research and development expense in the Company&#8217;s condensed consolidated statements of operations and
comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September
30, 2024. The Company&#8217;s share of development costs incurred during the three months ended September 30, 3024 and for the period
from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research
and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other
current liabilities as of September 30, 2024.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company was also required to reimburse Paragon
$3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development
costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. The Company
is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection
process. The Company recognized an amount of $0.8&#160;million payable to Paragon for the research initiation fee related to ORKA-002
following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from
February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $3.8 million and $6.6 million during
the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as
research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable
and other current liabilities as of September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number
of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the
fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition,
the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note&#160;8) as stock-based compensation expenses under research and development
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized
$13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OptionAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OptionAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504098080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b>12.
Net Loss per Share</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Shares<br/>
 Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Shares Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(21,936</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">15,013,655</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(1.46</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(47,192</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">7,765,381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(6.08</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series A Preferred Stock<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(697</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,460.62</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,121</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,077.13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series B Preferred Stock<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,990</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">49,191</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(121.77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,630</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19,015</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(506.44</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(28,623</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(57,943</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was 477,196 and 184,462 for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,099,227 and 1,584,575 for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">For the computation of basic net loss per share
attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock
as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding
includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,287,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,287,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,549,671</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,549,671</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998497760144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubscriptionReceivablePolicyTextBlock', window );">Subscription Receivable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Subscription receivable</b></p><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Subscription
Receivable</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Use
of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
preparation of the Company&#8217;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Concentrations
of Credit Risk and Other Risks and Uncertainties</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#8217;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#8217;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#8220;Paragon&#8221;) (see Note&#160;10).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Cash
and Cash Equivalents</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Debt
Issuance Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#8217;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Fair
Value Measurements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;1
&#8212;&#160;Quoted prices in active markets that are identical assets or liabilities.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;2&#160;&#8212;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 24pt"></td><td style="width: 24pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level&#160;3&#160;&#8212;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company&#8217;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#8217;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Property
and Equipment</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful&#160;Life</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock', window );">Classification of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Classification
of Convertible Preferred Stock</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#8217; equity (deficit) on the Company&#8217;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#8217; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#8217;
equity (deficit) on the Company&#8217;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NotePayableToRelatedPartyPolicyTextBlock', window );">Note Payable to Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Note&#160;Payable to Related Party</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock', window );">Research and Development Contract Costs Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Contract Costs Accruals</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#8217;s research and development
expenses, with a substantial portion of the Company&#8217;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;),
and the Company&#8217;s related-party Paragon (see Note&#160;10).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#8220;Option Agreements&#8221;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#8220;Paruka&#8221;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Leases</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#8220;ROU&#8221;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Segment
Reporting</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#8217;s chief executive officer, who is the chief operating decision maker (the &#8220;CODM&#8221;), reviews the Company&#8217;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Research
and Development Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Commitments
and Contingencies</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Stock-Based
Compensation</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#8220;RSAs&#8221;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#8217;s common stock at the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#8220;ESPP&#8221;),
based on the fair value of the common stock estimated using the closing price of the Company&#8217;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments
are classified.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Net Loss per Share Attributable to Stockholders</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#8212; Convertible Preferred Stock and Stockholders&#8217; Equity.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Income
Taxes</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#8217;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b><i>Recently
Issued Accounting Pronouncements</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November&#160;2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i>Segment Reporting</i> (<i>Topic&#160;280</i>)<i>:
Improvements to Reportable Segment Disclosures</i> (&#8220;ASU&#160;2023-07&#8221;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#8217;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#8217;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In December&#160;2023, the FASB issued ASU&#160;2023-09,
<i>Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures</i>. This ASU expands disclosures in an entity&#8217;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#8217;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">In November 2024, the FASB issued ASU 2024-03, <i>Income
Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Classification of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NotePayableToRelatedPartyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Note Payable to Related Party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NotePayableToRelatedPartyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development contract costs accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubscriptionReceivablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubscriptionReceivablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998594041776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful&#160;Life</b></span></td>
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font-family: Times New Roman, Times, Serif; width: 83%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixtures</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    and office equipment</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3-5 years</span></td>
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504628192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock', window );">Schedule of Related Party Accounts Payable and Other Current Liabilities</a></td>
<td class="text">The
following is a summary of related party accounts payable and other current liabilities (in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable Option Agreements&#8217; fees</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,140</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable other research expenses</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">146</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Paragon
    reimbursable patent expenses</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">71</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,357</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedFinancialStatementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedFinancialStatementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503951472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table presents the Company&#8217;s supplemental cash flow information related to leases (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif">September
    30, <br/> 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Cash
    paid for amounts included in the measurement of lease liabilities</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating
    cash flow from operating leases</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">74</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments</a></td>
<td class="text">The
following table summarizes a maturity analysis of the Company&#8217;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Amount</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Fiscal
    year ending December 31,</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%"><span style="font-family: Times New Roman, Times, Serif">2024
    (remainder)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">63</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">369</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">494</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">380</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    undiscounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,306</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    imputed interest</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(318</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    discounted lease payments</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">988</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less:
    current portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(146</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Non-current
    portion of lease liability</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">842</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505965936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock', window );">Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three<br/> Months Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from <br/> February&#160;6,<br/> 2024 <br/> (Inception)<br/> to <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">97.3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">101.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.5</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.3</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Stock Options</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per<br/> Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,507</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.97</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.6</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">21,507</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSAs activity</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number
                                            of<br/> RSAs</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/>
                                            Average<br/> Grant Date<br/> Fair Value</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Unvested balance
    as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Unvested
    balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,207,553</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock', window );">Schedule of Employee Warrant Activity</a></td>
<td class="text">The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/> Warrants</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Exercise<br/> Price Per Share</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term (in&#160;Years)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate<br/> Intrinsic<br/> Value (in&#160;Thousands)</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Balance as of February&#160;6, 2024 (inception)</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Balance as of September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.8</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,038</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and expected to vest, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.80</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9.8</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif">51,038</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Vested and exercisable, September 30, 2024</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period from<br/> February&#160;6,<br/> 2024<br/> (Inception) <br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected term (in&#160;years)</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6.1</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">99.0</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4.2</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected dividend yield</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td> <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif">&#8212;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following table summarizes the classification of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#8239;Months
                                            Ended<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research
    and development</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,772</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,310</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">General
    and administrative</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,229</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,459</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,001</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense</a></td>
<td class="text">The
following table summarizes the award types of the Company&#8217;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three&#160;Months
                                            Ended <br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Period
                                            from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Paruka
    warrant obligation</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,251</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,681</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Employee
    warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,314</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,314</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Stock
    options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">427</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">765</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Employee
    stock purchase plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,001</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,769</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of the employee warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504385056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReverseRecapitalizationAndPreClosingFinancingAbstract', window );"><strong>Reverse Recapitalization and Pre-Closing Financing [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of the Assets and Liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4,940</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">114</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accrued liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(54</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Net assets acquired</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReverseRecapitalizationAndPreClosingFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReverseRecapitalizationAndPreClosingFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504609808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Hierarchy for Financial Assets Measured</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">The
following tables present the Company&#8217;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Fair Value Measurements as of September 30, 2024</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Financial assets:</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"><span style="font-size: 10pt">Money market funds</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt">&#8212;</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total financial assets</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt">&#8212;</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">403,322</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505675104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following (in thousands):</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    employee compensation and benefits</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">933</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued
    professional and consulting</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">204</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accrued
    research and development</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">573</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,710</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503728544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock', window );">Schedule of Convertible Preferred Stock</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif">As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):</span><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Authorized</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Preferred&#160;Stock<br/> Issued and<br/> Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Carrying<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common&#160;Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Series A Non-Voting Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">52,841</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,439,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Series B Non-Voting Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">251,504</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137,138</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,428,149</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span>&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text">As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September&#160;30,<br/>
                                            2024</b></span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series A Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,439,000</span></td><td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    issuable on conversion of Company Series B Preferred Stock</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">11,428,149</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Shares issuable upon
    exercise of pre-funded warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,202,207</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued stock options</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,287,760</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Outstanding
    and issued employee warrants</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,054,358</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Stock Incentive Plan</span></td><td style="font-family: Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,526,324</span></td><td style="font-family: Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Shares
    available for grant under 2024 Employee Stock Purchase Plan</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">463,489</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent">
    <td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif">Total
    shares of common stock reserved</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td><td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">29,401,287</span></td><td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to auction market preferred securities, including liquidation preference, liquidation value, par value, rate setting interval, redemption requirements, dividend distributions, roll forward of shares outstanding, shares authorized, aggregate value of auction market preferred securities, variable interest rate earned, and other information necessary to a fair presentation. If redeemable, the auction market preferred securities are redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504383456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
 Average<br/>
 Shares<br/>
 Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss<br/>
 Allocation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Shares Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Loss Per<br/>
 Share &#8211;<br/>
 Basic and<br/>
 Diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Common Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(21,936</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">15,013,655</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(1.46</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(47,192</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">7,765,381</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 7%; text-align: right">(6.08</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series A Preferred Stock<sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(697</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">477</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1,460.62</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,121</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(6,077.13</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="font-size: 10pt">Company Series B Preferred Stock<sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,990</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">49,191</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(121.77</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,630</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">19,015</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">(506.44</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(28,623</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(57,943</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was 477,196 and 184,462 for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,099,227 and 1,584,575 for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.</span></td>
</tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</a></td>
<td class="text">The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three&#160;Months Ended<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Period from<br/> February&#160;6,<br/> 2024<br/> (Inception)<br/> to<br/> September&#160;30,<br/> 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Outstanding employee warrants to purchase common stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,054,358</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Outstanding unvested restricted stock awards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,207,553</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and issued common stock options</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,287,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,287,760</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,549,671</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,549,671</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998495925888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 03, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 29, 2024 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Issuance preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TerminationFee', window );">Termination fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AdditionalPaidInCapitalTransacationCost', window );">Additional paid-in capital transaction costs | $</a></td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommomStockExchange', window );">Common Stock exchange (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="nump">39,873,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock conversion of convertible note (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PreFundedWarrantsOfCommonStockShares', window );">Pre-funded warrants of common stock shares (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants exchange (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,664,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,077,000)<span></span>
</td>
<td class="num">$ (28,623,000)<span></span>
</td>
<td class="num">$ (22,243,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,943,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Net cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant gross proceeds amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=orka_ARCABIOPHARMAINCMember', window );">ARCA BIOPHARMA INC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_TerminationFee', window );">Termination fee | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Purchase price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.96)<span></span>
</td>
<td class="num">$ (9.17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,784,139<span></span>
</td>
<td class="nump">$ 22,784,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommomStockExchange', window );">Common Stock exchange (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,764,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,764,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued to purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalDeferredPurchasePrice', window );">Purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued to purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,460.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,077.13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock conversion of convertible note (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued to purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember', window );">Oruka common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Aggregate net proceeds | $</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaPrefundedWarrantsMember', window );">Oruka pre-funded warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Purchased shares of common stock | $</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember', window );">ARCA common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.8569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaRestrictedStockMember', window );">Oruka restricted stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued to purchase (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NumberOfSharesPurchased', window );">Number of shares purchased (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature of the Business and Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred Stock, Convertible, Shares Issuable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AdditionalPaidInCapitalTransacationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional paid-in capital transacation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AdditionalPaidInCapitalTransacationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommomStockExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares in common stock exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommomStockExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NatureOfTheBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NatureOfTheBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PreFundedWarrantsOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre-funded warrants of common stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PreFundedWarrantsOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_TerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of termination fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_TerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalDeferredPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalDeferredPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=orka_ARCABIOPHARMAINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=orka_ARCABIOPHARMAINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaPrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaPrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_ARCACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_OrukaRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505750064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 15, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503837200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details) - Common Stock [Member]<br></strong></div></th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockDetailsLineItems', window );"><strong>Common Stock (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498232864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="nump">34,998,550<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=orka_ParagonAndParukaMember', window );">Paragon and Paruka [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Own capital percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember', window );">Fairmount [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Own capital percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParagonMember', window );">Paragon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParukaHoldingLLCMember', window );">Paruka Holding, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_OrukaAdvisorsLLCMember', window );">Oruka Advisors LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity holding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Paragon and Paruka [Member] | Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Own capital percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_ParagonAndParukaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_ParagonAndParukaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParukaHoldingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_ParukaHoldingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_OrukaAdvisorsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=orka_OrukaAdvisorsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998497573536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 15, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Leases term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 938<span></span>
</td>
<td class="nump">$ 938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">$ 842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Lease term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="nump">17.95%<span></span>
</td>
<td class="nump">17.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseVariableLeaseIncome', window );">Variable lease expense</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember', window );">Commitments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseVariableLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseVariableLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_CommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498698144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,998,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Percentage of diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharesOutstandingPercentage', window );">Share outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Employee warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,988,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,085<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,634,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,401,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares were reserved for issuance</a></td>
<td class="nump">463,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_ParukaWarrantObligationMember', window );">Paruka Warrant Obligation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Percentage of diluted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,526,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=orka_UnvestedStockOptionsMember', window );">Unvested Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EstimatedFairValueOfWarrantsToBeGranted', window );">Estimated fair value of warrants to be granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EstimatedFairValueOfWarrantsToBeGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of warrants to be granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EstimatedFairValueOfWarrantsToBeGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares outstanding percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_ParukaWarrantObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_ParukaWarrantObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orka_UnvestedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orka_UnvestedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998496154672">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 12, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
<th class="th"><div>Mar. 07, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 15, 2024</div></th>
<th class="th"><div>Mar. 05, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,287,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DevelopmentCostsPercentage', window );">Percentage of development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReimburseOfDevelopmentCosts', window );">Reimburse of development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,691<span></span>
</td>
<td class="nump">$ 49,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted into shares value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember', window );">Clinical Development Milestones [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember', window );">Certain Regulatory Milestones [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PercentageOfWarrantPurchare', window );">Percentage of warrant purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchInitiationFee', window );">Research initiation fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DevelopmentCostsPercentage', window );">Percentage of development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,222<span></span>
</td>
<td class="nump">779,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Restricted stock awards authorized (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,022,804<span></span>
</td>
<td class="nump">1,022,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNotesMember', window );">Convertible Notes [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted into shares value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNotesMember', window );">Convertible Notes [Member] | Subsequent Event [Member] | Convertible Note Purchase Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember', window );">2024 Plan [Member] | Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for issuance (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember', window );">2024 Plan [Member] | Maximum [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for issuance (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMember', window );">Paragon [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ResearchInitiationFee', window );">Research initiation fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMember', window );">Paragon [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment to related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Convertible Notes [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="16"></td></tr>
<tr><td colspan="16"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PercentageOfWarrantPurchare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PercentageOfWarrantPurchare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReimburseOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reimburse of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReimburseOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ResearchInitiationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of research initiation fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ResearchInitiationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=orka_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ConvertibleNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ConvertibleNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=orka_ParagonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998496321408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computer and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=orka_ComputerAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=orka_ComputerAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998496247344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems', window );"><strong>Schedule of the Assets and Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505973616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">$ 403,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">403,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">403,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">403,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_FinancialAssetsAbstract', window );"><strong>Financial assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998497171104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract', window );"><strong>Schedule of Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee compensation and benefits</a></td>
<td class="nump">$ 933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and consulting</a></td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 1,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998506011952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note Payable with Related Party (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,722,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember', window );">Fairmount Healthcare Fund II, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Initial principal amount</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember', window );">Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Unpaid accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Note Payable with Related Party [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Aggregate proceeds</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_FairmountHealthcareFundIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=orka_ConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998502070048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable shares</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Issuance costs (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,998,550<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,998,550<span></span>
</td>
<td class="nump">3,197,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember', window );">Employee Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Employee warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Employee warrants vest over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Common stock ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Common stock ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="nump">137,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingPreferredStockMember', window );">Series B Non-Voting Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,988,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Pre-funded warrants</a></td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable shares</a></td>
<td class="nump">5,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Converted shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems', window );"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ConvertiblePreferredStockAndStockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ConvertiblePreferredStockAndStockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=orka_EmployeeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=orka_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=orka_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498243616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - Schedule of Convertible Preferred Stock - Preferred Stock [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series A Non-Voting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems', window );"><strong>Auction Market Preferred Securities, Stock Series [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized | shares</a></td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Preferred Stock Issued and Outstanding | shares</a></td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying Value | $</a></td>
<td class="nump">$ 52,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Preference | $</a></td>
<td class="nump">$ 2,439,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Series B Non-Voting</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems', window );"><strong>Auction Market Preferred Securities, Stock Series [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock Authorized | shares</a></td>
<td class="nump">251,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Preferred Stock Issued and Outstanding | shares</a></td>
<td class="nump">137,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Carrying Value | $</a></td>
<td class="nump">$ 2,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Preference | $</a></td>
<td class="nump">$ 11,428,149<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=orka_SeriesBNonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504609424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Preferred Stock and Stockholders&#8217; Equity (Details) - Schedule of Common Stock Reserved for Future Issuance - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharesIssuableUponExerciseOfPrefundedWarrants', window );">Shares issuable upon exercise of pre-funded warrants</a></td>
<td class="nump">6,202,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding and issued stock options</a></td>
<td class="nump">1,287,760<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and issued employee warrants</a></td>
<td class="nump">3,054,358<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Shares issuable on conversion of Company Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issuable on conversion of Company preferred stock</a></td>
<td class="nump">2,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Shares issuable on conversion of Company Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issuable on conversion of Company preferred stock</a></td>
<td class="nump">11,428,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember', window );">2024 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">4,526,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems', window );"><strong>Schedule of Common Stock Reserved for Future Issuance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="nump">463,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved</a></td>
<td class="nump">29,401,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharesIssuableUponExerciseOfPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable upon exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharesIssuableUponExerciseOfPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504360736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants - Stock Option Valuation [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems', window );"><strong>Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">97.30%<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498570496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Stock Option Activity - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule of Stock Option Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Beginning Balance (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual Term (in Years), Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Beginning Balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options, Ending Balance</a></td>
<td class="nump">1,287,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Ending Balance (in Dollars per share)</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in Years), Ending Balance</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">$ 21,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Stock Options, Vested and expected to vest</a></td>
<td class="nump">1,287,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 21,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Stock Options, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in Years), Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Stock Options, Granted</a></td>
<td class="nump">1,287,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">$ 7.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Stock Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Stock Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998601533584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of RSAs activity - Restricted Stock Activity [Member]<br></strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems', window );"><strong>Schedule of RSAs activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of RSAs, Unvested Beginning Balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested Beginning Balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of RSAs, Granted | shares</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of RSAs, Unvested Ending | shares</a></td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Unvested Ending | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=orka_RestrictedStockActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=orka_RestrictedStockActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498228336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfEmployeeWarrantActivityAbstract', window );"><strong>Schedule of Summarizes the Employee Warrant Activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning balance | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Beginning balance | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Beginning balance | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Endning balance | shares</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Ending Balance | $ / shares</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted Average Remaining Contractual Term, Endning balance</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate Intrinsic Value, Endning balance | $</a></td>
<td class="nump">$ 51,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Warrants, Vested and expected to vest | shares</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">$ 51,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable', window );">Number of Warrants, Vested and exercisable | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Vested and exercisable | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Remaining Contractual Term, Vested and exercisable</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate Intrinsic Value, Vested and exercisable | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted | shares</a></td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised', window );">Number of Warrants, Exercised | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Exercised | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price Per Share, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfEmployeeWarrantActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfEmployeeWarrantActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants, Exercised (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of exercised of weighted average exercise price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants, Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Per Share, Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Contractual Term, Vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998502118816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract', window );"><strong>Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998601254096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Company&#8217;s Stock-Based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,001<span></span>
</td>
<td class="nump">$ 9,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,772<span></span>
</td>
<td class="nump">8,310<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="nump">$ 1,459<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504117552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract', window );"><strong>Schedule of Award Types of Company&#8217;s Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ParukaWarrantObligation', window );">Paruka warrant obligation</a></td>
<td class="nump">$ 7,251<span></span>
</td>
<td class="nump">$ 7,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_EmployeeWarrants', window );">Employee warrants</a></td>
<td class="nump">1,314<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee stock purchase plan</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 9,001<span></span>
</td>
<td class="nump">$ 9,769<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_EmployeeWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_EmployeeWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ParukaWarrantObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Paruka warrant obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ParukaWarrantObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505742752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998497799952">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Option Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Initiation fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_DevelopmentCostsPercentage', window );">Development costs, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,691<span></span>
</td>
<td class="nump">$ 49,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_OtherDevelopmentCost', window );">Development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Research initiation fee</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember', window );">Clinical Development Milestones [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember', window );">Certain Regulatory Milestones [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NonRefundableMilestonePayments', window );">Non-refundable milestone payments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | ORKA-001 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_MilestonePayment', window );">Milestone payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 13,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PercentageOfWarrantPurchare', window );">Percentage of warrant purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | ORKA-002 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Option Agreements [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_PercentageOfWarrantPurchare', window );">Percentage of warrant purchase</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_DevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_DevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NonRefundableMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NonRefundableMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_OtherDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_OtherDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_PercentageOfWarrantPurchare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_PercentageOfWarrantPurchare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_ClinicalDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=orka_CertainRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=orka_ORKAZeroZeroTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498100720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - Schedule of Company&#8217;s Supplemental Cash Flow Information Related to Leases<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flow from operating leases</a></td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998505973072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies (Details) - Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract', window );"><strong>Schedule of Company&#8217;s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remainder)</a></td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">1,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(318)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total discounted lease payments</a></td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion of lease liability</a></td>
<td class="num">(146)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liability</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998503725312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NetLossPerShareDetailsLineItems', window );"><strong>Net Loss Per Share (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">477,196<span></span>
</td>
<td class="nump">184,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NetLossPerShareDetailsLineItems', window );"><strong>Net Loss Per Share (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Weighted-average number of shares of as-converted</a></td>
<td class="nump">4,099,227<span></span>
</td>
<td class="nump">1,584,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NetLossPerShareDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NetLossPerShareDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998504340208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems', window );"><strong>Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockLossAllocation', window );">Loss Allocation, Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,936)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (47,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,013,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,765,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss Per Share &#8211; Basic and Diluted, Stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss Allocation, Net loss</a></td>
<td class="num">$ (7,077)<span></span>
</td>
<td class="num">$ (28,623)<span></span>
</td>
<td class="num">$ (22,243)<span></span>
</td>
<td class="num">$ (57,943)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems', window );"><strong>Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockLossAllocation', window );">Loss Allocation, Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (697)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss Per Share &#8211; Basic and Diluted, Stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,460.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,077.13)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems', window );"><strong>Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_orka_CommonStockLossAllocation', window );">Loss Allocation, Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss Per Share &#8211; Basic and Diluted, Stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (121.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (506.44)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_CommonStockLossAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss allocation, stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_CommonStockLossAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>orka_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998502793520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">6,549,671<span></span>
</td>
<td class="nump">6,549,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember', window );">Outstanding Employee Warrants to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">3,054,358<span></span>
</td>
<td class="nump">3,054,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingUnvestedRestrictedStockAwardsMember', window );">Outstanding Unvested Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">2,207,553<span></span>
</td>
<td class="nump">2,207,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingAndIssuedCommonStockOptionsMember', window );">Outstanding and Issued Common Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total anti-dilutive securities</a></td>
<td class="nump">1,287,760<span></span>
</td>
<td class="nump">1,287,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingUnvestedRestrictedStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingUnvestedRestrictedStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingAndIssuedCommonStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=orka_OutstandingAndIssuedCommonStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45998498586160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 6,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOptionAgreementsFeesMember', window );">Paragon reimbursable Option Agreements&#8217; fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">6,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOtherResearchExpensesMember', window );">Paragon reimbursable other research expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursablePatentExpensesMember', window );">Paragon reimbursable patent expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Related party accounts payable and other current liabilities</a></td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOptionAgreementsFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOptionAgreementsFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOtherResearchExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursableOtherResearchExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursablePatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=orka_ParagonReimbursablePatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>83
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M]4^Y>"'FGJ3TFH5_!S[?7 QF ^33-<E"?L.>/M.=H+&TY[$PS?^BIZ+L=#Q
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M9*TN6F$+AK&E]^X&MM=;O>$S$ZSX!X\-;G'P$6<=@&I#UNK2%1UAF(X.W.+
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M*2XF%R^<Q?G=WGO&.=OFCQM*1&R6!<3W:\;XRXN\+EQ>#U_\!U!+ P04
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MVT-Z6)/N0LOH2I8:I^^.25[NT_,/<U=&P[EX"[O8Z';.0MG($>,.$(X/A!,
MX81 .-'WXW189A]89O\/638T\-GBB*#O_W&L4S9Z[* &">9#@@608"$D6 0$
MUN&D<^"DH^1DO5Z=,L%IR:;5+<G*N-:QR#=V3&3,4B*.2+. <#P@'!\()W"$
M.\^PN60,*%2D#-4AA'L@A*LDQ&]TR%GGI50)4GJ.Z'@@' \(QP?""8!P0E?,
MYFW=YC@4#5EUNM_06PU2/UFQ^34N+C5L]"_A&ZR!O$8=<42'0P'YDG;SR_'&
MI'-O<=ET*+&1]93<S')[NNI(+C;.4EZ&N\TX-3E0MV!L=@"*YDNNPC)URT(.
MWY6084-0M @*K4NA5IXU /59-=:("0 *R(,"\HUAC;8Q48HL4.V)),%Z9%JC
MU6F-_Y)0J\8=*Z* HGF@:+YQJE@+&C8$18N@T+HT:P5;0ZW8JC)(M>MH)D&B
M>:!H/BA: (H6@J)%AD1\MFS7Q#WC5:OX&FK)]WAN>B1;FM+HBC'J#/U0/C=9
M8FJ(')/+:3V)F9CY^A(K+ PEHG:+71N;%C^WB';<[]STAP3/1'CN]/1'*Y(:
M:I6T;_X8[ILS!#?%73\7DU<3NWS_B%8&M@WL\#TDVF'3=1W+TOE^@KR*$!0M
M@D+K,J,5-@VULCENS6B?M&8\0Q63IXA 0+ZDW<*M+(JNXII1M)&N&:5FO6O&
M5N\SU(+?^6M&46OJ6S.>H6XIIF5(-%]R%3UK1LBP(2A:!(76I5"K$!IJB? <
MS5@-.69ZAA(/H8!\**# $!4]C Q^^ "*%@U$ZU9[M>HA4JN'JN1?[3JFO@M*
M3X0"\J&  BB@$$DT1X20D"T.VW69T(J3Z$1QDDXN_]IEZ@RQP1K("=01Q_0[
M$) O:3>?$R!1I<38Y(O[1*,I_0&0SO>6S,YQG;[[]JA,\T0=D$L+AGM.%*IZ
MT@)U"\:F!:!HON0JY&D!:-@0%"V"0NM2J)47D5I>/"<M4$..71F"HGF@:#XH
M6H!$G=*P^15K"!HS&HK9I4TK%R*U7.A_2U9Q]G)R58SVG!?OAG=:EF?3UWTY
MO\IGMZ4\K%9$2VARPHQI,'9:$.I2LK_)OMP^_:?FK)2K8AGF5#9)056/2N))
M%":H< $44 @%%"%16.S\ %W"M;(B4LN*/R3AAJJYD$3\ZYMG0:M4)8&E.AIH
MU  4+01%BZ#0NO1M55BD5F'W3RW5CRO6I= M![.\VB=PR7JW9)R+DZ3844JF
M645H4ZI/["COED^#C(Q A9D+*" /"LA'8N&N\.R.1(^>FX)\#]6DJ"=>C[R/
M6A$7J47<_S.Q!D= R)K+!2B:!XKF(TGIKHU8/3_//-":5E"T" JM2^96YD9J
MF;OW<1'VB"R-.'W>94O*X+>X*&+V9&VZ)^L#_6K1$#9(,PI!CRZD?(0J@X4"
M\J" _ :HDWGRNV%(LAU@.B;F*UVA&A7U!+1Z"AY1*V<CM9P-2Y7!8>P,_58Q
MC$&B>:!H/A(%9O82!\/%_--KH'%#4+0("JW[:&VKIV.UGGXO//HAI5W-U3$I
MFSKLB-$+"LB# O*A@ (LD\9UT^%E%JB T7# +HM:+1ZKM?C>(8XF;>R5*Z38
MGS>OC6!FMU\6M]I3FF_I4+:)+[3[++ED(Q_-"[/F52=O:;7ZWJ6#NN%C> BU
M-P %Y&-Q;X 3;P(LROFFZ[H\OX!:%$G"6<?Z09==[=X!5N\=_!CL&IIXU1<Q
M=N(%1?- T7PLJ1U&NN,X_,H5-&P(BA9!H74Y??1."_5F1A^G+UK)\#0E\$*5
M1LKH_G#_X+<3NY3)9\CZ\C$3B[N7<]WE4G@/*IXOB3?G*2G99#!-$_-55%!M
MBOH"]A1:X79? ZOW-7X4!@V.BZ EV5BBV8O%F: Q?4E,2F-1&0] PX:@:!$4
M6I>M[:8(/O'U&FR=42\SAH<AT%=K8+%2>HJ1->>9 _K6#%"T $OV:!S+%H8N
MT-V(P:!=0K3;#%B]S: JY%*[CIF H/1^*" ?"BB  @JQ*/=/D3-'?"'7L%V7
M">V^ #Z]N'NPU%^--88:DFIKR6,8$C/))KG$2G@,0V8C>PQ#8B=]#$.&IW@,
M [?2-CZO@GNX;R"+D!=8IL>*,[WD#06R[6.)7<]C&*!7$8*B15!H>V;,CMXD
MRMY=^VM<O*19J:W),X77+VW*K6+_.MC]295OZY>+/N55E6_JPQ6)Z9J;&=#O
MG_.\>C]A[RL]O)3WYC]02P,$%     @ AS1N6=+-X,1Z @  0P4  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6Q]5-]/VS 0_E>L@!A(B*1I^3%(([7
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M1W13L"ZPA08[Q28=.0A B+I--P,JP_GP;0K.<-7F8,D9,40=Z= @]5D<5Z:
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M4 D<1)B]CV*'@3[<FWCGG?$<#%* RI#[Z8KU /C&YA33/.OXA];.>:,DB!_
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M"%.$X?HW%)+EH)!\51:V4MYQ5'\%1Q"JX=C03)M<TO6T,CMN<'KS2[N[',N
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M( W9<-#22\'[$VO1H;=@H->^@&H*?#&<NZ($-=Y!@9:P+-A^\:N:61 ,N>A
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M7!]U'YIR1Y>B+\NF*;?T)[XLI"M\ 'Y?E1!YV@]X@+]6_^W_ U!+ P04
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MC7-=%PUFJB7WOF_VR^-FGVN5$W43XS3ASOQX4T ZJCL-6BWA5Y9XF*QD77^
MM&--!N;*17M5TJU:2&/7P7C23;NN;MA/=($^/C'Q]'ROC<6D["ZG&87R<$:A
M>%!"X:L%T1<B@_FZ,ZE:9/[ 4GD=[GH1:'FXL)($T3XPQ):X/0W Q6AIF(+Q
M:1E6DPNHOI!ZCD.H>"9(FLLB!5\R.-!O>ZT8-A8? _A+Q4@H&,-^[C&D\R[(
M.C)W$@&Q,E?(RB$6V/96A19N:QVXY-M.1!>9]C,[\B!ZC8)#8GA4_'H 2=5K
MK9;DM^J1TSMR0$.@I&?,0=+!S^Q/R<#99/'GY8>WO\08T0!(J5M[L+LL[<.4
M^UJ,T[D!HUK!J:]<[I8$:,DI\'A^U^K)47289TH*@,B^EH=@[?K1,/#W*9YB
M/\5#4I']G**ZF'E)87/,SWP\!@=#4Q;##PL9-MZS+_IN9%=PK+M[5BAXRWX'
MO[=0G5KJV,[L@B*9'22Y 93IC0TR#GS,S2FJ6T'.&M<'R0V9#TC7,"0+<;@0
M$AJX'D'>0$U9?)8QD(O95.;>^5^YVEC5[#].O<J$D3[10[AP)KW-B@WQG@+F
M)=6_]YU1U!C'?0%[<14)S*KGF#X)WWUG>NSE8E_'V(B'C)*#?6CG8QIJN4 K
MY--\C8)\!TN^2V?=6Z 03Q#B-A]MF_UXS1-3#DI/-*K%R;AAQF0!;Q[',:Q*
M\"W<7]MWE+0- ##@6YG<AXQA@8#,DDQ&Q\E^#G2[N]ECE,>+%?GD4TXJ<R6=
MN- O!@<^]UCHLY2==%\Q\9QB..ZRU/RNPBV/BN,!:E)T*!';S")G(D"@K 8Z
M;S37&>;E7S"S06A/4G#1$':VW.@/,_G.<]D](P8G?R9(@G,YT>.0._U*0U >
M, 0>LDS7YGP-ZQ=1R,5?I%@M00J*7;>^L\$_9_HE.10NT"S5,?TO_VWZ7]RE
M_P?4GW+X6A"G- 7[:TKUY%(%<=>.BW]R)L&W@J\FW22S!(JNA#QTHP$/.GO:
M5IK:SET3D18K03+$'3;48PV : 2G1V<>C$7F>K.T,..F.ML\ZZ6[!+%07 ;"
M?A:Q4<:H-""5! Q^9+T3LQ!NWOCLC(L?"EY.<QS/'9D.^[H^\*3$)#_SDPLU
M4'CMIQ+=\8%DWD$>1N4YJ&DO<'' WH6PLE?6-:<1E5R/;62:T"448$GO?;)N
M-FD:G%Y$VI7 #U9S6$DWN&@53]E7Y;J_I>:4&9E$W]]HDU,)2)S.Y#9T5PQ"
MQC6)Z/-"(XY7')"!)%E/92DN59V^(:O <NVM0GYI1?I)I?,]M2/NAM@*YW"!
MB;<EW*Q&D51OG*)22!-^#0ZREVA"JN,Q@1*;WZ7(5KA+*6E/]"SFD(?#[76R
M._>[OU#(FTV2!F_:"N>YKM=]JWQFY31KO,O$J C$H#@7CXG-25NU9=F0P;J^
MB*62N*Q<"E-LCO2RY,R:3PDZ3"X$D-9FV%0AA=<W7B64./8/O]_ D&YQV"=)
M'I?R5S;GRRP]<GI683#^E$%)#V6PCC[#3&@[@FDG1G0_P6,8+0G77!C3U(DC
M;RIKKG/8B9OX<;?@T14>UB17)$URS@+^-B)"&9*<.?M^?_L*LZ[$;[?2/^-7
M=A#!FS-%UQ_9E_-YV.W<=5[JELXUZ(^<TM_FJ394&^@ZQ4T..N\:H1XY!HC<
M'3JYE5!$X)9CI_W3!YH=)H$[]_O>+)6.O1I[+1AX%G/5"(:\*:0B2')9=__^
M7UHY\"Y.O 2+IKMYJIHLKJN-YB1] *0;EVP.?B,0,K\FZYE%=[Y;!WN#6PU@
M]P%2'U:N*"R^<:7Y+'/CVAPF:NDU3PK,9' .28>[U7B_[F6&($G12SKGB)@R
M9)$2<6J^,[,3;^N^\Y#3=7+ZQZ_@O8/E?'=]=15KY_<8^VRAM)75Z[5O'!1[
M^B K:>,M<@<OO,7LR7ACMIFDOC*#'=+((#:E&JM54MGE%*6S\#AK3NM833F*
MUM-^GCN:!./EG0>EUV1'16H7\%6\/"'.AD#R5F/2V)E=[4S?^E0!8Z38GM<_
M<))@2%T(5^3S(""'(OY,VR0G>,U.\&* 'P+2\CUHUTEK7PDTHVOG$]J1R-$I
MP7=P?/FXM"6PB#Z6-9BC2.7ONF7O5:#C#+?]*>_2-U)G:>APBX>5RZJ:VL(9
M?SV@'[7@XP"=R4D09'8<,&0;K*6GFKLC&D0#G.N@@_JW'*17MKAN++LEM"6-
M2Z[#\Y9?V:.:TPH&FX0U7%A-NJ]RQ2!+<NR 21]A\G*%I"%>G5+TKA+ P,#5
MI;&2NUVNX,4*2]?6.K5J]4HG-W6HEN8G(;(L1W(\[H:R)+-X$@EB[NT5E7#O
MGDY>84!PH]!Y+FPC=*.;I[3[K M,^E9O*!L=^Y]N?%NEXB#;"67H>. 4]BQ>
MLVB!#7F.A9)RKK^[Y/MA0Q=:TA#7!7L-<?>="D$1HBA1.M0TK;O'+A5!B55)
MY$7[0G 7PG4.>!.1\-:Y<->S7<,&W?JYA3FQ:[WU&5A[&OOH. >;K\$16KK.
M44GSX, UW3"%J% ;^IX(-)&LA5#JUSO%/33T)1(\%7WWJ@^;O!HB/:&'/+[M
M)UB1>7'MXZX7_O[177<;2&RN]_N5^0H)%<O>3BW;O;9!;M(^Q!"ZHEOP5I-^
MT1G/0K)2?9FE12D.LMV^(IMFQ^Q,L4_X0W:FISR3M&WPY*0\1\Q-J&<X6_-^
MDML?UD2;JJWI*@VGOGB=XE#<F4>:(446@YRCS]*N1_^:! 9CD^1!.%(\D,S@
M[&T.^P10LT&+[,M/FLH9OW[(6PT"3<=<828PP9RE+>QLD=/>V?MXX:_><A+U
MU#]!E5T2H>)7JGX=KWXZ0>,:68+;8M='3/:(Q_511WBWD416C%>]P6N\6F':
M(U=4"T_,D*%V:7L:0FS#](K?2,+EH?@RI&B2]T.L@R_YB=AOBCNQ%"(:K-KQ
M;?Q[]^Q2\J'M+0/',;5@LY3"H;O=4@1C=XK%^%-Q_$5.PA7522<7C3"^>4W:
MN(-@RGVN#/^EV_(UASJ\WXAO;X4NL(+;X1Y&AI#Q"E>U@;7E$L!$JB8]M%SI
M=&+3ZL^JU6L$ML);>96(@V/)!GR(1HMRM4+:I:+$N-O1_D53,]^UP!U!-&]X
MFY'/7XW^:I,82"["!NRF*&R@)%'AMD7:NNF-V_%.>I/(_4G6I>5KMM6TO?H0
M+?DH-%(RF5S:H [!^'(H<L.WTGJ8=886H<N2X<]*R2L5/*%]C.+*3<':$3L<
MW7;'=),6<B_;8>_E(KEPAS:C,S5V<WTFB%(HPS<<GD$6QL:7*9:JDL0J+4?!
M%]>!N*ZAZ.KL'8T98WBQ$G<99Y;JP2T/!TT"-4O3JU6XRX)C"KB-;>%?=I-<
M(Q:;G&3%25^E8!.KCVXG="_?V$&R(GQ<Q+[,4GX/ #5H!B+O+1%5(<B<EWJ+
MT?)^*!;:4"I67RIN<N/7&>S\JGRF$99:W$.H(F0;XI<Z\+W$PU+-[SX)ZQXX
MD7BOSJOS@0-%FB7TBLF<!W*MB%P3P<X+%&%J(EEH3(JBX<P,:8L-K\=Q;H0J
M&5FOX3=G_Y%:)-ZYE+)%30LF/S7[<PD&FC.TO#5?X3UF <O0"\8VB6VVM'UP
MJL??'V#++F^YE%OY8Y><)9$\Z^S2!.'P%6K$;;2YI-J75I8E4G7=8I*:@B0-
M>FJE*1OI6V1#/<D#!C>\-T48G0+2H+:9Q'#@<+"B0JT6E+%I=_PR'$R2OLO1
M]%T_NOY*2]UJ?X<EX_$8^TPD,[X.(XY$-(_S<=+Z34\I$)_?>G]Q_294!O3>
M@G'8IRWGG?RXB^O8$TM+GYZ]F/G^H#+I#^JWP'[GWYV5+XN?-B03*O31R5/L
M8?S M^'EC'RXMZ#$]'#8;]CG]2>W]O>S0O!=*?CND:S[XOG9XY?E=-WXY'2]
ME)C/CZ[W_/3LV<SCR6NOD"Z@BD>_S%)<\KA[R)77:7G?"T2*DN[FT?6X&(1X
MYV>G?([)TY >=Y*PA\+7[0^]#O9)\J+A#>5^Z/W+W)?>#?+.X?!M>,7S!;_9
M^$E\7-X/_0LLB.ZHG+S$T+/YBV].I'/:?\#.^;7%BWX8^@W_N585])(>P._+
M'@[9?: %PHNO7_\O4$L#!!0    ( (<T;EE3Q@!8B@,  .H'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;(U537/;-A"]ZU?L,)V<."1%^2N.I!G;
M::8]=,83-^FATP-(KD34(,  H!C]^^Z"I"*GDMN#+0#<]_;M%[#LC7UV-:*'
M;XW2;A75WK>W:>K*&AOA$M.BIB\;8QOA:6NWJ6LMBBJ &I7F67:5-D+J:+T,
M9X]VO32=5U+CHP77-8VP^WM4IE]%\V@Z^"2WM>>#=+ULQ1:?T']N'RWMT@-+
M)1O43AH-%C>KZ&Y^>[]@^V#P16+OCM; D13&///FUVH592P(%9:>&03][/ !
ME6(BDO%UY(P.+AEXO)[8/X;8*99".'PPZ@]9^7H5W410X49TRG\R_2\XQG/)
M?*51+OR'?K#-+R(H.^=-,X))02/U\"N^C7DX MQD9P#Y",B#[L%14/E!>+%>
M6M.#96MBXT4(-:!)G-1<E"=OZ:LDG%\_F*:AY#QY4SXO4T^,?)Z6(_I^0.=G
MT!^Q2""[BB'/\HN7\)2$'-3D!S5YX%O\#S7PYUWAO*6R_75*V$!T<9J(6_G6
MM:+$542]ZM#N,%J_?3._RMZ_(G-QD+EXC?T_D_8Z>I' BSCO')@-4"IM1V,!
M8S9C\#6R82OT'FKAPEYTOC96^OW,&Y#.=70$WGBAF./J,LZRC/_ U8+BYL-R
M\.6"+^')OA46=D(1EC[_E"59-D_.JEC$\W?7\;OKRS.4LQXM#E(J$+H"FGSG
M:2'U%NC2('_:4..2PM+0+%=H!<]C#'TMRQIZBLQBB32;%4@-OPE+IX/OUDHB
MH$@Y]$IX#(L-D>E2$B'Y\4@WA"?_,[$34HE"(0.*25("/POB"]K_E0U"2J]P
M2&UM%&ECL-$(.T/>6#Z>A]>H*CXD^<964.SI:BOKV4C$5XY2-*O>HW6\'0(.
MV,'&P18UY4.I/;"#44_%(EA  K\?A)VHY0^(,8M0R1UE65<NGLD-E60? ^6X
MPE(1(L@\ZJRW;V[R^?5[!_=&V!#-!TE$WEB7P.>6G%642*.ZH69*?NUD%0H(
ME)Q>#G7N6D8>T<9'*74S^G:Z>6+*6/$WN9N*;/D2=1/94>0\!,>=12,M!SZ:
M[PU:CFRBK#GOQ<GDS,(0.8??G4PC]KU_N.P4M;>R"&$S7A+@1>6HB\EXSRW;
M6M,:.UDRI^Z:@EO@$#>W2G+JYDF/KFY^!:G]MU([4+BARR-+KB^C(2G3QILV
MW.:%\?0VA&5-CS%:-J#O&T.-,V[X@3@\[^M_ %!+ P04    " "'-&Y9,T=$
M/FP$   Z"P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6RM5DUOVS@0
MO>M7#-1MT0*")7\D3A/;@.-MT 5:-$BZNX?%'BAI;!&11)6DXOC?[PPE*W:@
MNBVP%ULD9]Z\>1P..=LJ_6 R1 M/15Z:N9]96UV&H4DR+(09J I+6EDK70A+
M0[T)3:51I,ZIR,-1%)V'A9"EOYBYN5N]F*G:YK+$6PVF+@JA=]>8J^W<'_K[
MB3NYR2Q/A(M9)39XC_;/ZE;3*.Q04EE@::0J0>-Z[B^'EZL)VSN#OR1NS<$W
M<":Q4@\\^".=^Q$3PAP3RPB"_AYQA7G.0$3C6XOI=R'9\?![CW[C<J=<8F%P
MI?*_96JSN7_A0XIK4>?V3FT_8IO/&>,E*C?N%[:-[9B,D]I85;3.Q*"09?,O
MGEH=#APNHN\XC%J'T<\ZC%N'L4NT8>;2^EU8L9AIM07-UH3&'TX;YTW9R))W
M\=YJ6I7D9Q=WF N+*=P*;7?P58O2"">PF866\-DJ3%JL58,U^@[6!7Q6I<T,
M?"A33(_]0^+5D1OMR5V/3@+>8#R Z#R 432:]/$Y[7Z/U0#&49_[$9UQI]78
MX8U_62OX9QD;JVGT;P_-ZP9VT@_+Y_325"+!N4\'T:!^1'_QYM7P/+KJR_E_
M CM28-(I,#F%_FO5<GT::S* $X)^S1!6JJA$N0-I3$U6XV#X?AJ\GYZ!R03E
M!FH-B2H*:@9T3)*'P+.95O4F P&4N-Q;E%;+N&Z:QD8C4@^R)@"K.*[8J#+@
MC_I!P$>5I[+<!/#ITPK>OGEU,1I%5\V:&PROW@4@2B  282YAQ*O>+<' F%
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M93\^P^Q3BN8^;'9=LC2J7YO%ZY)*SSE!83_G][J+L6HM408H0 ^B&KH;6N&
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MS"[\*/7*ON$^TV6I,_MU*05R/2W _;G69?A!!]3_1^+E?P%02P,$%     @
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MA 5#LW&*JC,@*3E1F:H$$U#> 3F)E+2 8KD(*SRX.5_LS\?7B*1HDY.OJ5[
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M1HT)^4+YXX0N5F8$@;(<!S18&+>.PW/G+,:YG\<-R.9"X1;&IDCM$$X;6:K
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M[N>FZ/0:F>:6UA\&)O.GR+M=E$T>YXVR48X1$!!EN*XVKM%WI]BY?\$B'B5
M%MF(G)/<_.3:./$,WRGUKSQY><K+/STFCGDZT?NQ;/$I#.7ZD^'G)-S/^@Z_
MCL>@/-**L\"C[_SXR60F!X:N:=UTD;%2HY=99.U/9^AP%A&OMS*"&(T'YU=]
MZYZ["E)(.BD<@7X6W7[06/)([7/L%9+O75P'@DBUC$<G@D?[\5#DY(3+7?,#
M6CRCK<EJ]94+-:66/YRI5RXA'C_"UGR,CJQ>.8@<#$Q3BZ1=8^)WAN>CLZ#Q
M).A!56*(#P8\(=E5.EO-/6*%P4.KJ!>D[!KUUH-G^.C>],#(;_ZXEW#\D:KU
MTG[KZ'1_,'A)!W$G;.%>+S']FV'<K[;^:( &2']FBB+KNMM,Q#L C*<W_1-U
MF08G2@K]14'95>$,BX_\L;&#4Y()Y6E"&I$=V98&-3S\#4-#1TO"?"R9,,4$
MG% JTZP[!N1A[AZ>^['9",^81O")%!N;!C;#R>0@?8T_"QN\%'F0G)&,/KN<
MIBFJ^U%FT'40LCRW'V=\UF>\/>+$B?@HOXB_T0NHXD=^M_1C."B?'7V]=H2:
M7(4R.7P])A'YJ7\?9+A.Q,,EO[>\)!;-K^"+JBFDPQ[QDZHK/I\$7_X.48Y[
M:RU=./+*[M@.Q8%?B>#I-F+A'QTJ]LR_\WP AC3.(W-<WDZN!-+1KOV4T#8T
MZ'!RD\BB$_?"QF[HV6SRLK?XG7^7-@AW]J E)L?^<N B^2,,^GL6E"<T$P:/
M+>V;L^GD^NK,Q57X8)LM_UW&HK' '/YUK= ?M70#OE\V<*+_0'_J$?]0Y^U_
M U!+ P04    " "'-&Y9B!&NE$4"  "\!0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-2YX;6RU5$U/W# 0O?,K+%>J6@EMLEG8(KH;"6A1.;1"H+:'J@<G
MF6PL_!'LR0;^/6,G1%L):*6*2^SQS+QY;YSQJK?NQC< R.ZT,G[-&\3V.$E\
MV8 6?F9;,.2IK=,"R72;Q+<.1!63M$JR-%TF6DC#\U4\NW3YRG:HI(%+QWRG
MM7#WIZ!LO^9S_GAP)3<-AH,D7[5B ]> W]M+1U8RH512@_'2&N:@7O.3^?'I
M(L3'@!\2>K^S9T%)8>U-,"ZJ-4\#(5!08D 0M&SA#)0*0$3C=L3D4\F0N+M_
M1#^/VDE+(3R<6?535MBL^1%G%=2B4WAE^R\PZCD,>*55/GY9/\:FG)6=1ZO'
M9&*@I1E6<3?VX5\2LC$AB[R'0I'E)X$B7SG;,Q>B"2ULHM283>2D"9=RC8Z\
MDO(P_[P%@Y[NI/!PV]&>H678 #5<>M\)4P*S=3RII2%3"L4\"@0=@M]U1G25
M1*C>KQ(D/@$U*<?:IT/M[)G:YU#,6+K<9UF:'?R9GI",24LV:<DBWN+5M;!?
M)X5'1[_,[Z=D#30.GJ81QNC8MZ*$-:<Y\>"VP/.W;^;+].,+(A>3R,5+Z*]\
M82_7/IJQ_RN_M]OC"\-*:\PXGKW$YF] >Q/0?G2<6=T*<\\:X1ELA>K(6^UR
M@X$M-LYVFX9]LUO0!3@V7PP_W0!34=JS#>L)6VR%5*)0$,06L#=0A&KVU'TF
M.\,8WK6OPFVD\4Q!34U-9Q\..7/#6S$8:-LXGX5%FO:X;>AY!1<"R%];BX]&
M&/GIP<X? %!+ P04    " "'-&Y9S2V,0Z8"  !K!@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970Q-BYX;6RM55%OTS 0?L^OL,*$F%2:-$W'*&VDMC#!PZ#J
M!#P@'ISDVEAS[,QVVHU?S]E)0X>Z2J"]).?S?=]W=XXODYU4M[H ,.2^Y$)/
M_<*8:AP$.BN@I+HO*Q"XLY:JI :7:A/H2@'-':CD012&%T%)F?"3B?,M53*1
MM>%,P%(179<E50]SX'(W]0?^WK%BF\)81Y!,*KJ!&S!?JZ7"5="QY*P$H9D4
M1,%ZZL\&XWELXUW -P8[?6 36TDJY:U=?,JG?F@3 @Z9L0P47UM8 .>6"-.X
M:SG]3M("#^T]^Y6K'6M)J8:%Y-]9;HJI?^F3'-:TYF8E=Q^AK6=D^3+)M7N2
M71-[$?DDJ[6190O&#$HFFC>];_MP +@,GP!$+2!R>3="+LOWU-!DHN2.*!N-
M;-9PI3HT)L>$/90;HW"7(<XD*]B"TD!6D-&*&<K9+]JT2^1DJ>#U@DO-Q(9<
M,4%%AM8D,*AKT4'6:LP;C>@)C4MR+84I-/D@<L@?XP/,MTLZVB<]CTX2WD#5
M)\.P1Z(PBD_P#;LF#!W?\-F:0'[,4FT4?E,_C_6CD8N/R]E[-M85S6#JXT72
MH+;@)R]?#"["=R>*B;MBXE/LSW2B)S6.5S#LDU;;^X=&SK27@\X42R'';]\4
M3!!3 /F/,T&JBBI#Y-HQJ+^0/>==R+*BX@''P5W-%&I:)]4:C';4G-&4<688
M:+2UP8C4CB[RRB4F:XU1^GSLS4I9"^,MJ"X<,+,&(.F6<A#(=D;BWMLX]+Z@
M@L*[K!2Z]U*#0>S-LDS5\%CRU2@FY]YGZ *[/,_(J!>&(3GVB00' Z $M7%C
M3I/,9MC,@L[;3=)9,T#^A#=C^)JJ#1-8.ZP1&O;?C'RBFM'6+(RLW#A)I<'A
MY,P"_P:@; #NKZ4T^X45Z/XOR6]02P,$%     @ AS1N60XC@/W; @  J 8
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M1J&WBV@4[19N^:9R?B%>SFNVP3MTW^H;0[.X5RFX1&6Y5F"P7$2KT6P]\?@
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M*=O#0%"J*OZ5#RT/:P?.)@<.S-H#LX [*@HH/THO+\^M60K+NR&-'X*IX33
MJ8J=<NLM5A7.^<M?C2=Q(U=RK@FJ?2&^DI:>,GRT?G4^]E#"6\=I*_!]%#@[
M(/!,?#&5+YSXN<HHVSP_!K@>X:Q#^'[VI,!;JD?B>#(4L\GLY EYQ[W%QT'>
M\8]9+/Z^FCMO$2W_[#,^RC[9+YLSZ*VK94H7 Z2((WM/@\L7SZ:O)^^>0'[2
M(S]Y2OJ/^.II@:]'R??8N*Z2+]*F16!_*'Q!XH,I:UFM!%6>+#:JRALAQ2U9
M14Y<B1OD%5E>N?4FO1.RRG"FNB?K%6N)*AL(13:)JX4E0I9[<<3"7SP[F\TF
M[W:7P\+TW<LD@/PDE2U-@U.?26I?I-*2^-1 T_7U4/PRNAF)HU94O[63,!3+
M L#GJPUKE',-($N1KD&M&.HZKC4[ G5K,AF6K,"&\DIJ45M5I:K&DXQ 32Z>
MSTY'$V2QUER0?"']4$@?8'A4.M[",&25TA X&IV).76 .J9![ZLO9!=DQ6^V
MN9/)0>*/C(4]+BY#=MVONP)\N8  &H7*0+!*@55QI74U2J: *@;6;MUW/%*6
MX(SR3E3TX 5]:Q2B)E<5C%#5XJ4 AD<1V]B9_1)41+P01 ]P>[4@D3/V!9R_
M0#!"M4F),K=#XDC\7E"R$UTR36T3"8.GG6>6I; L"A*FL]'D)U$#A*RJIAR)
M*[_&>PR*+8&6#6/3I=:BJ6JIUH4C['IW)^ -S:)!/,*PCY12.8>FXVDH8*<;
MT?2%]S%?*-U]*+7BJ):KD!9+Z3@.&6^I/(<!AQKZ*^L$2TO+7RL.$X?]"0SL
M0WZ/:8]QV2F0VE2+&+^\88>[$*I[.&%@64/LMKP!+>V^SJB$C>K\$W-,.D?X
MB2Q">NF"L3D%OH)W]VJ"!F,SL AN8ZSF$ :!-5:KD&[,<H:&\R@L!/<R)%'K
MO62N<M05Z4/@7#DP8'U4JAB)U"NGW&:1ZR'S1P+'IE2I0)!RAT!F.>1-M +/
M=[T).W "$9W4)".V'M4XBS#[1$.V>J^)(6=4UF%P:44$OE--TNI54)AJ@^EF
MA:VQ8+<)F]'<B\*T<9DA4#EZ6@H@'T;+F"(<(<C14;(&3>R#%BM0F,-,P'38
M54O$3%"X#RG(-*F270PC)7NPH^2S61)D!?I1^'L_=A:4/*)& _-09!E-'F18
M=2]YN$-F<I1<W7X09]/3(;*O6XDN^DS9 @9OQ&1(Y0"CRQ.8ZWRP4,/US$(E
MGD]&T[YPAR*I0QAUI&_S$-V]3VP@")64QU(43_A4LK.;M#,H$"ZM73'2>ZF;
M4+-VB&ZS#:Y!0G" <OX;K;) [USJH#,.]FQ[T#LG%HJ&!$G_<AZZ/LT3>JA9
MD##WG&C<DA '!_W<.)840CW/*8S6CQ6C)!2H;"0P-T=)!9JX*.-<2#P78EJH
M?5L9V]&.42:A0L%K!IEC32D^T=PVN"R(U^VF(U0O"C'XDKG?%;.9OA8INZB"
MK3VZUE"WG3C;O3TTF\GHM/<[T_A\^OAAV/5*&*]7/%8H#$H J)N,N&A7KU+I
MBAW-VXI;?\@N C;"9B2NRY(RSAID4"SY[;D41FI:CYO86Y,C1ZV;IB\/-+10
M3#8'B__;IOD2E'7QM]ZC-P>>9+M7#T6M&]=US]TVDV^0B[R_5QPI[9RV5H.@
M":$=V0Y-Z+%D16Q-W?>L$ ;<6J=OWKF$^]3J5:9TPU:GLE9>ZHYY=8CG2$7H
MI9L!WPUMCYLBV]\9<^+8U(-<KZX'LNTH!E5(WBW>,"\TN"3*,+\!^9939\,W
ML]EP-GFSYMXN.2*J)* *_1!KAQ-JNR?'J01SB/-(#.XC^ZXXX[6K:<F4\ 6<
M0P\1$F^I_=?^CG\5K[:/V^,_"' /0?5VJ,HYCDY&;TX':+KATAU?O*G#17=N
M/!@)CP5)= 3>@/7< 'C[P@KZ_WQ<_@=02P,$%     @ AS1N66B=#>F4#
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MVGHN!'A#^&%FB8P\00?%@P'_5'<O@DZ'A=#(1#5L/*OL$3!$Z3004P ?EI.
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M MN?$CZ>HF>'7E"V17I"2PJ-?Z\C-1JSGQ_15F HE/E5B4-3=F^.Z'P$%OO
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M$XX5;74T/H#\I=9N8_@$_?_$_"]02P,$%     @ AS1N684^CR:]#0  I2D
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M*]!<#WXQ*:VJ989.'B)3)1UVK&63'1SX;Z'F2,^"JO>>'@C;ME;1<'3%5[$
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M!]6U5%0TX6BSJ/5*>F+LSX#+.^+RO04#*)!!<0,B*Z9I N!QZ).5#^H)6VC
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M]^3$XW[\TIF67\1;F*XS&_ZX5A+ZT@+\OC0HV.$+;9#>S'S]7U!+ P04
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M.D!;V[,[++(N@(H_4FND! :'3J<#9!?)(H&71MPZM1=B2GN('P1J X00_3F
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M'T=SX&P)0,DZC\D?O( Y[@4^OP#S&6R]>GKL'*[8FK?[4K(NN99DWIA/R-U
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M&=/H@X.<%\[QU@@!NL$__0-02P,$%     @ AS1N6>G:VFFN @  " 8  !D
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MT.AB?!F ;N9.$UA5^5Y/E*7)X9<%C6K4+H&^YTK97> *=,-_\0]02P,$%
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M9@#V+X30VXHQ4+V/3OX%4$L#!!0    ( (<T;EFX$ AYH (  .<%   9
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MWDWF"EO<6%2)@C&+E(KCK&!R0TZ9Q!W5&$0P9[,!OKD%D2$0/OR@YQ$U5R\
MB"0<(VW['4DSD% R:\@)N4J2OJ#6J@3CY@KE/L])P#9VE'$T[O.<(ZKSRN<4
M\(0CK!9._N0R&9R0T?GE*"*'7BS<:T@!>N/'CG/:2-OV9K_;3[9EV]!_TMNQ
M>$?UADE#.)18&@TO)P'1[:AI ZMJW]Z9LC@L_++"Z0S:)>!YJ93=!8Z@G_?I
M;U!+ P04    " "'-&Y9L::U"L(#  "!"0  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6RM5DUOVS@0O?M7#-1%T0)J].FOU#9@>U,TAVZ-N-L]+/9
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M'$D5L$979Q!C8<IV[FP?M*C-K+<2&B='L\QP5 =)!OA^+; D=P\4H!O^9_\
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MU02J252+4$VAFD:UF-+,-#9ECJ&]S,%5>NT#=8XAVN- M1#5!*K)6C-*N.[
M[YW[NS?5T'$5JNFVM?![H]&YV]\]?/P9-8UA4],8=JAIW*ZO]>?5/JO<A]UN
M7?E?+(L.YVEHGP/5 E0+44V@FD2U"-44JNE:VSY/<U]?"*'&-(/6]#V&)YFN
MQ3Y*YVP-7_TSU3MW=YXB%:!CAD>-*8YZE43?681J"M4TJL649F:AJ7(,3U?E
ML _5.1"O;]1[O;9)80-TW!#5!*I)5(M03:&:1K68TLR0-66.H;W,\==L]4=2
M'L1M'=]9+PFB?0U4"U M1#6!:A+5(E13J*91+:8T,VM-7V-XXK[&$.UKH%J
M:B&J"523J!:AFD(UC6HQI9EI;/H:0WM? _Y\EWVTSEE$BQVH%J*:0#59:^[
M."-\]5&V"!U5H9JNM0.?QHL/OLS(A=]T,7Q[%Z/;S,M^R]WOT;#M7.C:/F[7
M;1K50E03J"91+4(UA6H:U6)*,W/45"Y\>^5B<V95TF_N5XN[],[YMGD =FX]
MP;*C77<CJ!:@6HAJ M4DJD6HIE!-HUI,:6;DFLZ%?^+.A8]V+E M0+40U02J
M252+4$VAFD:UF-+,-#:="__ U"KU1?J[Y^OWZ[O%6Q<:]QU2;EBCLKSGB!)M
M3Z!:B&H"U22J1:BF4$VC6DQI9J":%H9O;V&L9U,_^E*]'>N\[T+[%:@6HII
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M#18T:W=1[(*VCFVB$NF1=)S\^Y&2HLBNS%FNL!M;E,[[\O A19&<[!G_+C8
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M;9B$\3;>[SFQOUBOG2FH.8+2?"B-0VD"1=/35I;)G%]H9PJJG* T'TKC4)I
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MO:'\_V.:%J]/J@KV=_I=_!]02P,$%     @ AS1N60RA>?9=%0  F'0! !D
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MNUN&:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFER;EGM+GW=@V( =J
M0#43U2Q4LU'-0347U3Q4\U$M0+40U2)4BU$M0;64TN3X:QL0 W4#HMW;VQ0>
MWCT5(9JJP^N7AU;C9P<@6G1 -0O5;%1S4,U%-0_5?%0+4"T<''8$C%YW?'!^
MP>C4!\;H\TM0+:4T.;;:ID-]\X=6J^<>3Z*>[^PD(S43U2Q4LU'-0347U3Q4
M\U$M0+40U2)4BU$M0;64TN1,;&L1@[>K10S06@2JF:AFH9J-:@ZJN:CFH9J/
M:@&JA:@6H5J,:@FJI90FQU];BQBH:Q%),9L(;26*QR7L9NEZD\_G65&V]QY?
MQ:(M"50S4<U"-1O5G*TVWED6==[K>^<1<]$Y/53S42U M1#5(E2+42U!M932
MY%!K:Q*#URXN\4-OSZ$E"50S4<U"-1O5G*TFO=_3>?QG/]S0 @2J^:@6H%J(
M:A&JQ:B6H%I*:7*XM06(@?K*$W:1E_6^69%/A)@>/>Q7#9P=8&C- =4L5+-1
MS=EJ^]?-V0\OM+Z :CZJ!:@6HEJ$:C&J):B64IH<7FU]8:"N+SQ^W/!\1KBF
MN7 TP=#B JJ9J&:AFHUJSN"PN* ?!AC:6T U']4"5 M1+4*U&-425$LI30JP
M8=M;&*I["X]7KBZ;LX>LOONM,_4<Y\8;JIFH9J&:C6K.5AM);YWUA[JQEW#H
MK!ZJ^:@6H%J(:A&JQ:B6H%I*:7+"M96&X0]6&K3_:(\I6,V:4_Q&>54__'N/
M(%$_F;.C$.U"H)J%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B64IH<F$8;F&_7
MA1BB70A4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42RE-CK^V"S%\K0LQ
M6TYFJVRN98M\O3SZ?IZ:.#OFT,8#JEFH9J.:L]5VW\\S^H<?2:"3>JCFHUJ
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M)NQ/61J%NPSS3+: +2@-9 $YK9FAG/VB;;E$0>8*+F9<:B8VY)8)*G(;G=^
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M2AIL#BXLL1N#L@=P?RVEV4]LA^C[>_8;4$L#!!0    ( (<T;ED2CZA<4@,
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M5L\ZM8D9I?FF:&V/7N/1^]27M\*;4FN2YINBM=4V$P=7FT$WF9M GQ<D Q%
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M7-M'#BH78+\OI31/$[=!\VQ*?P%02P,$%     @ AS1N6:FNU1[(!   IAL
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M77=EHBP_%,H;@B[UN<J,"D%3?;D $@)3'>3O<TK%>T,-4![-#?\'4$L#!!0
M   ( (<T;EDZR(H(U@(  , (   9    >&PO=V]R:W-H965T<R]S:&5E=#4Q
M+GAM;*U6;4_;,!#^*Z=LFC8)2$A?86VD%L:&-";4"OB ]L%-KJU%8F>VTX*T
M'[^SDX9.:C-UXDOBE[OGGN?.SF6PENI)+Q$-/&>IT$-O:4Q^[OLZ7F+&](G,
M4=#.7*J,&9JJA:]SA2QQ3EGJAT'0]3/&A1<-W-JMB@:R,"D7>*M %UG&U,L8
M4[D>>J?>9F'"%TMC%_QHD+,%3M'<Y;>*9GZ-DO ,A>92@,+YT!N=GH_/K+TS
MN.>XUEMCL$IF4C[9R74R] )+"%.,C45@]%KA!::I!2(:ORI,KPYI';?'&_0K
MIYVTS)C&"YD^\,0LAU[?@P3GK$C-1*Z_8:6G8_%BF6KWA'5E&W@0%]K(K'(F
M!AD7Y9L]5WG8<FB%>QS"RB%TO,M CN4E,RP:*+D&9:T)S0Z<5.=-Y+BP19D:
M1;N<_$PT-3)^.AZ3K@0N9$:UULREZ^,E&L93_0F.84I'(2E2!#F'R72DRUQR
M\T)[$]1&\=B0O\."T6;O\0:S&:J? ]\041O.CRM2XY)4N(=4'VZD,$L-7T2"
MR=_^/@FL588;E>.P$7"*^0FT@B,(@[ -[\$'O60*=?5JB-"J\]AR$5K[(NQ-
MT>-W,H5K@YG>F8H2M[T;U][)<YVS&(<>73J-:H5>].'=:3?XW,"Z7;-N-Z%'
M/PI;H0WG([@3*RHGE7*,"RX$%PL8LY2)&.'WSER5$AJ#[)8 #>P[-?M.(_L'
M=^6([6B%BKX@\%4Q88#N <(5XPKN65K@/U2]'H9=RAH)'*ZL6ROK'E07)XP$
M-!6A1.PZ1/LI7D5A&/0ZG=; 7^V@TJNI]-XDR:\4FS/:&.WPC/9K&?W_.^GT
MB;$'HBFS_<,R>U93.GO;XUM3;<YP8]0#,NQO=94,U<+U3@VQ+(0I&TR]6K?G
M4=F57LW+WG[#%-T\#2G.R34XZ=&]4F6_+"=&YJY'S:2ACN>&2_K%0&4-:'\N
MI=E,;(#ZIR7Z U!+ P04    " "'-&Y9ULD3FE0$  "R%   &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,BYX;6RM6%UOXC@4_2M7V=%J1III$O-1V@4D:#N[
M\S C5*;MPVH?3'(!JTG,V@;*:G_\V$E(,KO!$,1+$YOXWG.NCWUJ][=<O,HE
MHH*W.$KDP%DJM;IU71DL,:;RBJ\PT;_,N8BITDVQ<.5*( W307'D$L_KNC%E
MB3/LIWT3,>SSM8I8@A,!<AW'5.S&&/'MP/&=?<<C6RR5Z7"'_15=X!35TVHB
M=,LMHH0LQD0RGH# ^< 9^;=CTC$#TB^>&6YEY1T,E1GGKZ;Q)1PXGD&$$0;*
MA*#ZL<$[C"(32>/X.P_J%#G-P.K[/OKGE+PF,Z,2[WCTPD*U'#@]!T*<TW6D
M'OGV#\P)I0 #'LGT+VSS;ST'@K54/,X':P0Q2[(G?<L+41G0/C2 Y -(BCM+
ME**\IXH.^X)O09BO=33SDE)-1VMP+#&S,E5"_\KT.#6<*AZ\?AIK7B'<\5A/
MMJ1IN=[?HZ(LDA_@$TRU%L)UA,#G\!"O(KY#A!<J!$T4C$Q=F=K!.W!!+JE
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M%$TGU>0H47-M0U/-O)^G=.KO=90,U=(U6@VQ7.6F;"[U:MW+QZZ%^;_#RXO
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M<1K4RQ '=N J -\O&)/;C3J@_!? ^PM02P,$%     @ AS1N62#8N)GR @
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M"KV91J-HN_#,5[7S"W&>-6R%"W0OS9.A63R@E%RBLEPK,%A-HYO1U6SBXT/
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M52.6MXDJXX'K :I_P9A\;NA"L?EC$/X&4$L#!!0    ( (<T;EF>S;1%O (
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M5ARM+JRJ%T[VY8W,BG!.TO)QAY'(#$4'\7U#"']Z*0PTUX:SOP!02P,$%
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M965T<R]S:&5E=#8S+GAM;,U7;4_;,!#^*U9 "*2-O+5I@382+YJ&!**BL'U
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M4VJ&B?H- *XWJ.=3QN1RHCO3^L<B_ -02P,$%     @ AS1N62ZAS3Q@ P
ME1<   T   !X;"]S='EL97,N>&ULW5A=;]HP%/TK4;I.K30UA*R!K("T(56:
MM$V5VH>]588X8,FQ,\=TT%\_WSB$0'T9Z\,& Y78]^2<>VQ?YZ.#4J\XO9]3
MJKUESD4Y].=:%Q^"H)S.:4[**UE089!,JIQHTU6SH"P4)6D)I)P'W4XG#G+"
MA#\:B$5^F^O2F\J%T$,_[#0QSQX^IR8:O_<]JS>6*1WZCQ=O?RRDOGGCV>/9
MN[.SSN/ES6[\H@(N_< I>GV Z%6G@PL#B(G'!XKO5T?E>X?)[Q/'I/L'2>]1
MQH23;>&M*?C]D'L=)[W%Q8@ADG<K+4;N.LCG#?,<HT7NG.?MG)8<U%M@-,BD
MV.R$R+<!HTYRZCT1/O3'A+.)8L#*2,[XRH:[$)A*+I6GS18TZ4*(E,\6#FT/
M=F>MDS,A597;9K"_D_KT'6#= X.,\\9@U[>!T: @6E,E;DVG.KD*OH"\NOVP
M*HS#F2*KL'OM;PC5P2292)52M;DB^.O0:,!I!G84F\WAJ&41 *BUS$TC960F
M!:D\K!EUP\A.*>?W<.GZGFUI+[/6NE4E)IJF,50WK8SM@'Y;S6JW97NOTO4*
M]B3UIX49CJCZL*GHG:(96U;]9=88P-1#7)T4!5]]Y&PF<FH'?W#"T8"L>=Y<
M*O9LLD&I3$V *M][HDJS:3OR4Y'B@2[UNIR6&>ZY>X*>_^X\SZB@BO"V:5/[
MQSS+KW9<W^K_A>?JLK+KV&DRZAV_Q_KQYMA-QJ=@\B26NW\*)I/C-QF=@,?Z
M8?C838:G8+)["B:CHS09U ^^K:?KK6?K)NK!.\S0_P9O1'R3U)LL&-=,U+TY
M2U,J7CQB&WE-)IQNZYOS4YJ1!=</#3CT-^VO-&6+/&G.NH.)J,_:M+_ \,*X
M>8$RN9A(Z9*FX[JK9I.JZ9F&R5I_@+"+W%8?-X)Q+.9& ,/R8 XPCF5A>?ZG
M\?31\5@,\]9W(GV4TT<YEN5"QM47R^/F).;C'FF21%$<8S,Z'CL=C+%YBV/X
M<ZMAWH"!Y8%,?S;7^&KC%;*_#K UW5<AV$CQ2L1&BL\U(.YY T:2N%<;RP,,
M;!6PVH'\[CQ04VY.%,&J8MZP'8PC28(A4(ON&HUC9'9B^+K7!]LE490D;@0P
MMX,HPA#8C3B".0 /&!)%U7UPYWX4K.]3P>8?\:-?4$L#!!0    ( (<T;EF7
MBKL<P    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E
M\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!
M2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/
M06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3
MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M_SNI'L_WENOC+\NODY-7Y8)SNJVHSW\!4$L#!!0    ( (<T;EGNU>T8Y@$
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M9VN7?QP_///6U-TAGPW_=IJ] 5!+ 0(4 Q0    ( (<T;ED'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ AS1N64(^AX;N    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ AS1N69E<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "'-&Y9
M:&KV>>8"  #,"   &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ AS1N62=/7Z8.!P  *BX  !@
M     ("!*0L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M (<T;EG,.,GHUP0  .H=   8              " @6T2  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " "'-&Y9IT>TF/(%  "0'0  &
M            @(%Z%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ AS1N61A0HROP"0  H%<  !@              ("!HAT  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (<T;EG2S>#$>@(  $,%
M   8              " @<@G  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " "'-&Y9*OEZPW(&   ^&P  &               @(%X*@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ AS1N6:@*5+]S
M&P  8E\  !@              ("!(#$  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( (<T;EF#YU-&.1T   1;   8              "
M@<E,  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "'-&Y9
M4\8 6(H#  #J!P  &0              @($X:@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( (<T;EDS1T0^; 0  #H+   9
M      " @?EM  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ AS1N648KM(3W!0  _0X  !D              ("!G'(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "'-&Y9XK4'UZD.   O,0
M&0              @('*>   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( (<T;EFATU!"+1   +0S   9              " @:J'  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ AS1N68@1KI1%
M @  O 4  !D              ("!#I@  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " "'-&Y9S2V,0Z8"  !K!@  &0
M@(&*F@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (<T
M;ED.(X#]VP(  *@&   9              " @6>=  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ AS1N69=QU;*0 @  & 8  !D
M         ("!>:   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " "'-&Y9A^HDW<@&   %$0  &0              @(% HP  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( (<T;EEHG0WIE P  $TG
M   9              " @3^J  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ AS1N6=W0T%'- @  ,P8  !D              ("!"K<
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "'-&Y9A3Z/
M)KT-  "E*0  &0              @($.N@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( (<T;ED CQCV&@4  +8,   9
M  " @0+(  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MAS1N68$#S'W_'@  L&H  !D              ("!4\T  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " "'-&Y9)3AAQ[L"   $!@  &0
M            @(&)[   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( (<T;EGIVMIIK@(   @&   9              " @7OO  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ AS1N6>Y^-"Z: P
MLP@  !D              ("!8/(  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " "'-&Y9JQ.$#[D%   K%0  &0              @($Q
M]@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (<T;EFX
M$ AYH (  .<%   9              " @2'\  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ AS1N6<\T5+RQ @  2P8  !D
M     ("!^/X  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (<T;EE1[D&$< (  )(&   9              "
M@;(? 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ AS1N
M6<"[TH-5 @  UP4  !D              ("!62(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " "'-&Y9+SQO'BT$  !S'   &0
M        @('E) $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( (<T;EF_9/2[X ,  $L4   9              " @4DI 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ AS1N69P&2*-0"@  ]7<
M !D              ("!8"T! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " "'-&Y9#*%Y]ET5  "8= $ &0              @('G-P$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (<T;EF#&K"C
MQ0(  'D+   9              " @7M- 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ AS1N6>UUG[!_ @  ZP4  !D
M ("!=U ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "'
M-&Y9$H^H7%(#  "U$0  &0              @($M4P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( (<T;EGX<M=.@0(  "T&   9
M          " @;96 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#
M%     @ AS1N61%9IGM:!   51D  !D              ("!;ED! 'AL+W=O
M<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "'-&Y9P]*:@?,)  #B
M<0  &0              @('_70$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;%!+ 0(4 Q0    ( (<T;ED!^_VA*P,  )L*   9              " @2EH
M 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ AS1N66@1
M';@<!   QA0  !D              ("!BVL! 'AL+W=O<FMS:&5E=',O<VAE
M970T."YX;6Q02P$"% ,4    " "'-&Y9I+$6HA(#  !""0  &0
M    @('>;P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M (<T;EFIKM4>R 0  *8;   9              " @2=S 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ AS1N63K(B@C6 @  P @  !D
M             ("!)G@! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " "'-&Y9ULD3FE0$  "R%   &0              @($S>P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( (<T;EFN 4&(\@(
M .T(   9              " @;Y_ 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ AS1N65'NI0LU P  #@P  !D              ("!
MYX(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "'-&Y9
M(-BXF?("  #&"   &0              @(%3A@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( (<T;EDX2,DF%0(  (T$   9
M      " @7R) 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ AS1N6?+,QAGU!P  !54  !D              ("!R(L! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "'-&Y9F(Q8#(4"   ^!0
M&0              @('TDP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( (<T;EDIK46^2@,  "0,   9              " @;"6 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ AS1N69[-M$6\
M @  K D  !D              ("!,9H! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " "'-&Y9NQYELLT$  !"'   &0
M@($DG0$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( (<T
M;EE8E!HZAP,  ,</   9              " @2BB 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ AS1N6=ICL8\$ P  9 P  !D
M         ("!YJ4! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
M    " "'-&Y9+J'-/& #  "5%P  #0              @ $AJ0$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (<T;EF7BKL<P    !,"   +
M  "  :RL 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (<T;EG0!F0OXP0  !@J
M   /              "  96M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "'-&Y9)V75I0P"  "$)0  &@              @ &EL@$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "'-&Y9[M7M&.8!  #U)
M$P              @ 'IM $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..1P!' &@3    MP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>208</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders??? Equity (Deficit) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Events subsequent to the reissuance of the financial statement (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited</Role>
      <ShortName>Events subsequent to the reissuance of the financial statement (unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Reverse Recapitalization and Pre-Closing Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note Payable with Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedParty</Role>
      <ShortName>Note Payable with Related Party</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Option Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreements</Role>
      <ShortName>Option Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactions</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Nature of the Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommonStock</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentsandContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SubsequentEvents</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable</Role>
      <ShortName>Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996020 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Note Payable with Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails</Role>
      <ShortName>Note Payable with Related Party (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NotePayablewithRelatedParty</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Details) - Schedule of Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Details) - Schedule of Convertible Preferred Stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Convertible Preferred Stock and Stockholders??? Equity (Details) - Schedule of Common Stock Reserved for Future Issuance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable</Role>
      <ShortName>Convertible Preferred Stock and Stockholders??? Equity (Details) - Schedule of Common Stock Reserved for Future Issuance</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock Option Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofStockOptionActivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Stock Option Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSAs activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRSAsactivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of RSAs activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Company???s Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Company???s Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Award Types of Company???s Stock-Based Compensation Expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable</Role>
      <ShortName>Stock-Based Compensation (Details) - Schedule of Award Types of Company???s Stock-Based Compensation Expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/StockBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/IncomeTaxes</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Option Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/OptionAgreementsDetails</Role>
      <ShortName>Option Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/OptionAgreements</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company???s Supplemental Cash Flow Information Related to Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable</Role>
      <ShortName>Commitment and Contingencies (Details) - Schedule of Company???s Supplemental Cash Flow Information Related to Leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingenciesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable</Role>
      <ShortName>Commitment and Contingencies (Details) - Schedule of Company???s Operating Lease Liabilities Showing the Aggregate Lease Payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/CommitmentandContingenciesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShareTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable</Role>
      <ShortName>Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/NetLossPerShareTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea0220567-s1_orukatherap.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable</Role>
      <ShortName>Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.orukatx.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" isDefinitelyFs="true" isUsgaap="true" original="ea0220567-s1_orukatherap.htm">ea0220567-s1_orukatherap.htm</File>
    <File>orka-20240930.xsd</File>
    <File>orka-20240930_cal.xml</File>
    <File>orka-20240930_def.xml</File>
    <File>orka-20240930_lab.xml</File>
    <File>orka-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="602">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>89
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0220567-s1_orukatherap.htm": {
   "nsprefix": "orka",
   "nsuri": "http://www.orukatx.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "ea0220567-s1_orukatherap.htm"
     ]
    },
    "schema": {
     "local": [
      "orka-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "orka-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "orka-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "orka-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "orka-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 249,
   "keyCustom": 55,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 41,
   "hidden": {
    "total": 147,
    "http://fasb.org/us-gaap/2024": 118,
    "http://www.orukatx.com/20240930": 27,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 208,
   "entityCount": 1,
   "segmentCount": 72,
   "elementCount": 520,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 602,
    "http://xbrl.sec.gov/dei/2024": 8,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.orukatx.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c4",
      "name": "orka:SubscriptionReceivables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c7",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c21",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c28",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c31",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c31",
      "name": "orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.orukatx.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statement of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation",
     "longName": "007 - Disclosure - Nature of the Business and Basis of Presentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.orukatx.com/role/CommonStock",
     "longName": "009 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "orka:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "orka:CommonStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactions",
     "longName": "010 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.orukatx.com/role/CommitmentsandContingencies",
     "longName": "011 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.orukatx.com/role/StockBasedCompensation",
     "longName": "012 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.orukatx.com/role/SubsequentEvents",
     "longName": "013 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited",
     "longName": "014 - Disclosure - Events subsequent to the reissuance of the financial statement (unaudited)",
     "shortName": "Events subsequent to the reissuance of the financial statement (unaudited)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing",
     "longName": "015 - Disclosure - Reverse Recapitalization and Pre-Closing Financing",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.orukatx.com/role/FairValueMeasurements",
     "longName": "016 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities",
     "longName": "017 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedParty",
     "longName": "018 - Disclosure - Note Payable with Related Party",
     "shortName": "Note Payable with Related Party",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity",
     "longName": "019 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.orukatx.com/role/IncomeTaxes",
     "longName": "020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.orukatx.com/role/OptionAgreements",
     "longName": "021 - Disclosure - Option Agreements",
     "shortName": "Option Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:OptionAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.orukatx.com/role/NetLossPerShare",
     "longName": "022 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.orukatx.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c65",
      "name": "orka:SubscriptionReceivablePolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c65",
      "name": "orka:SubscriptionReceivablePolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsTables",
     "longName": "996002 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.orukatx.com/role/CommitmentandContingenciesTables",
     "longName": "996003 - Disclosure - Commitment and Contingencies (Tables)",
     "shortName": "Commitment and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationTables",
     "longName": "996004 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables",
     "longName": "996005 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.orukatx.com/role/FairValueMeasurementsTables",
     "longName": "996006 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables",
     "longName": "996007 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables",
     "longName": "996008 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.orukatx.com/role/NetLossPerShareTables",
     "longName": "996009 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
     "longName": "996010 - Disclosure - Nature of the Business and Basis of Presentation (Details)",
     "shortName": "Nature of the Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.orukatx.com/role/CommonStockDetails",
     "longName": "996012 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c71",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "orka:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c71",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "orka:CommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
     "longName": "996013 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c6",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.orukatx.com/role/CommitmentsandContingenciesDetails",
     "longName": "996014 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:OperatingLeaseVariableLeaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.orukatx.com/role/StockBasedCompensationDetails",
     "longName": "996015 - Disclosure - Stock-Based Compensation (Details)",
     "shortName": "Stock-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.orukatx.com/role/SubsequentEventsDetails",
     "longName": "996016 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c87",
      "name": "orka:ReimburseOfDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996017 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c124",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c124",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable",
     "longName": "996018 - Disclosure - Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities",
     "shortName": "Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
     "longName": "996019 - Disclosure - Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured",
     "shortName": "Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable",
     "longName": "996020 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
     "longName": "996021 - Disclosure - Note Payable with Related Party (Details)",
     "shortName": "Note Payable with Related Party (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c66",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
     "longName": "996022 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c141",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
     "longName": "996023 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Details) - Schedule of Convertible Preferred Stock",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) - Schedule of Convertible Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c60",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
     "longName": "996024 - Disclosure - Convertible Preferred Stock and Stockholders\u2019 Equity (Details) - Schedule of Common Stock Reserved for Future Issuance",
     "shortName": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) - Schedule of Common Stock Reserved for Future Issuance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "orka:SharesIssuableUponExerciseOfPrefundedWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "orka:SharesIssuableUponExerciseOfPrefundedWarrants",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
     "longName": "996025 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c176",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable",
     "longName": "996026 - Disclosure - Stock-Based Compensation (Details) - Schedule of Stock Option Activity",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Stock Option Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.orukatx.com/role/ScheduleofRSAsactivityTable",
     "longName": "996027 - Disclosure - Stock-Based Compensation (Details) - Schedule of RSAs activity",
     "shortName": "Stock-Based Compensation (Details) - Schedule of RSAs activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c179",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c179",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
     "longName": "996028 - Disclosure - Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Employee Warrant Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
     "longName": "996029 - Disclosure - Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable",
     "longName": "996030 - Disclosure - Stock-Based Compensation (Details) - Schedule of Company\u2019s Stock-Based Compensation Expense",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Company\u2019s Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable",
     "longName": "996031 - Disclosure - Stock-Based Compensation (Details) - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense",
     "shortName": "Stock-Based Compensation (Details) - Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "orka:ParukaWarrantObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "orka:ParukaWarrantObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.orukatx.com/role/IncomeTaxesDetails",
     "longName": "996032 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c185",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.orukatx.com/role/OptionAgreementsDetails",
     "longName": "996033 - Disclosure - Option Agreements (Details)",
     "shortName": "Option Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "orka:OptionAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:PaymentsForFees",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "orka:OptionAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable",
     "longName": "996034 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases",
     "shortName": "Commitment and Contingencies (Details) - Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable",
     "longName": "996035 - Disclosure - Commitment and Contingencies (Details) - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments",
     "shortName": "Commitment and Contingencies (Details) - Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.orukatx.com/role/NetLossPerShareDetails",
     "longName": "996036 - Disclosure - Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c193",
      "name": "us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
     "longName": "996037 - Disclosure - Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
     "shortName": "Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "orka:CommonStockLossAllocation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "orka:CommonStockLossAllocation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable",
     "longName": "996038 - Disclosure - Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share",
     "shortName": "Net Loss Per Share (Details) - Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c13",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
     "longName": "996039 - Disclosure - Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities",
     "shortName": "Related Party Transactions (Details) - Schedule of Related Party Accounts Payable and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c5",
      "name": "us-gaap:AccountsPayableOtherCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0220567-s1_orukatherap.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "orka_ARCABIOPHARMAINCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ARCABIOPHARMAINCMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA BIOPHARMA INC [Member]",
        "label": "ARCABIOPHARMAINCMember"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ARCACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ARCACommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARCA common stock [Member]",
        "label": "ARCACommon Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r506"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r616"
     ]
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableOtherCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "label": "Accounts Payable, Other, Current",
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedEmployeeBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued employee compensation and benefits",
        "label": "Accrued Employee Benefits, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional and consulting",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "orka_AccruedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "AccruedResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development",
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8",
      "r15",
      "r368",
      "r371",
      "r424",
      "r466",
      "r467",
      "r650",
      "r651",
      "r652",
      "r662",
      "r663",
      "r664",
      "r667"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r616",
      "r761"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r662",
      "r663",
      "r664",
      "r667",
      "r724",
      "r762"
     ]
    },
    "orka_AdditionalPaidInCapitalTransacationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "AdditionalPaidInCapitalTransacationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital transaction costs",
        "documentation": "The amount of additional paid-in capital transacation cost.",
        "label": "Additional Paid In Capital Transacation Cost"
       }
      }
     },
     "auth_ref": []
    },
    "orka_AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization",
        "documentation": "Adjustment for change in common stock par value in connection with the Reverse Merger.",
        "label": "Adjustment For Change In Common Stock Par Value In Connection With The Reverse Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r287"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r329"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total anti-dilutive securities",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r101",
      "r130",
      "r148",
      "r183",
      "r188",
      "r199",
      "r200",
      "r207",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r363",
      "r365",
      "r399",
      "r446",
      "r527",
      "r590",
      "r591",
      "r616",
      "r628",
      "r686",
      "r687",
      "r749"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r135",
      "r148",
      "r207",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r363",
      "r365",
      "r399",
      "r616",
      "r686",
      "r687",
      "r749"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r379",
      "r607"
     ]
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auction Market Preferred Securities, Stock Series [Table]",
        "documentation": "Disclosure of information about auction market preferred security. Includes, but is not limited to, liquidation preference, liquidation value, par value, rate setting interval, redemption requirement, dividend distribution, shares authorized and outstanding, aggregate value of auction market preferred security, and variable interest rate earned."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r61"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "orka_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued liabilities",
        "documentation": "Amount of accrued liabilities.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of the Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r78",
      "r79"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r449",
      "r500",
      "r522",
      "r616",
      "r628",
      "r646"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r128",
      "r583"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "orka_CashAssumedInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CashAssumedInConnectionWithTheReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "Cash assumed in connection with the reverse recapitalization.",
        "label": "Cash Assumed In Connection With The Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r75",
      "r144"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75"
     ]
    },
    "orka_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CertainRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CertainRegulatoryMilestonesMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certain Regulatory Milestones [Member]",
        "label": "Certain Regulatory Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r132",
      "r133",
      "r134",
      "r148",
      "r172",
      "r173",
      "r175",
      "r177",
      "r186",
      "r187",
      "r207",
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r399",
      "r480",
      "r481",
      "r482",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r514",
      "r536",
      "r558",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r630",
      "r658",
      "r668"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (in Dollars per share)",
        "verboseLabel": "Exercise price",
        "netLabel": "Exercise price per warrant (in Dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants issued",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants issued",
        "verboseLabel": "Warrants outstanding",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightUnissued",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exchange (in Shares)",
        "label": "Class of Warrant or Right, Unissued",
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClassificationOfConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ClassificationOfConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classification of Convertible Preferred Stock",
        "documentation": "Classification of Convertible Preferred Stock.",
        "label": "Classification Of Convertible Preferred Stock Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ClinicalDevelopmentMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ClinicalDevelopmentMilestonesMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Development Milestones [Member]",
        "label": "Clinical Development Milestones Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r97",
      "r448",
      "r513"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r221",
      "r222",
      "r578",
      "r680",
      "r685"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r579"
     ]
    },
    "us-gaap_CommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsMember",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments [Member]",
        "label": "Commitments [Member]",
        "documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r97"
     ]
    },
    "orka_CommitmentsandContingenciesDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommitmentsandContingenciesDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CommomStockExchange": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommomStockExchange",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock exchange (in Shares)",
        "documentation": "The number of shares in common stock exchange.",
        "label": "Commom Stock Exchange"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CommonStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommonStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares of common stock reserved",
        "verboseLabel": "Common stock reserved for issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "orka_CommonStockDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommonStockDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CommonStockDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommonStockDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_CommonStockLossAllocation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommonStockLossAllocation",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Allocation, Stock",
        "documentation": "Loss allocation, stock.",
        "label": "Common Stock Loss Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r620",
      "r622",
      "r623",
      "r624",
      "r625",
      "r662",
      "r663",
      "r667",
      "r724",
      "r760",
      "r762"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r514"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock issued",
        "netLabel": "Common stock, shares issued (in Shares)",
        "label": "Common stock shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r514",
      "r533",
      "r762",
      "r763"
     ]
    },
    "orka_CommonStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "CommonStockTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "verboseLabel": "Common stock issued",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r451",
      "r616"
     ]
    },
    "orka_ComputerAndOfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ComputerAndOfficeEquipmentMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer and office equipment [Member]",
        "label": "Computer And Office Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r106"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Events subsequent to the reissuance of the financial statement (unaudited) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/Eventssubsequenttothereissuanceofthefinancialstatementunaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Events subsequent to the reissuance of the financial statement (unaudited)",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r635"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted shares (in Shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock conversion of convertible note (in Shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "orka_ConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertibleNoteMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "label": "Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertibleNotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertibleNotePurchaseAgreementMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note Purchase Agreement [Member]",
        "label": "Convertible Note Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes [Member]",
        "label": "Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes payable",
        "label": "Convertible Notes Payable",
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r758"
     ]
    },
    "orka_ConvertiblePreferredStockAndStockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertiblePreferredStockAndStockholdersEquityLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Reserved for Future Issuance [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertiblePreferredStockandStockholdersEquityDetailsScheduleofCommonStockReservedforFutureIssuanceTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) - Schedule of Common Stock Reserved for Future Issuance [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ConvertiblePreferredStockandStockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ConvertiblePreferredStockandStockholdersEquityDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash exchange of Pre-Merger Oruka Series A Preferred Stock for Company Series B Convertible Preferred Stock",
        "verboseLabel": "Converted into shares value",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r23"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedParty"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable with Related Party",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r146",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r227",
      "r228",
      "r238",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r254",
      "r261",
      "r262",
      "r264",
      "r407"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r94",
      "r96",
      "r152",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r613",
      "r659",
      "r681",
      "r682",
      "r683",
      "r740",
      "r741"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "verboseLabel": "Initial principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r407",
      "r408",
      "r595",
      "r596",
      "r613"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate, percentage",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r257",
      "r740"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r613",
      "r659",
      "r740",
      "r741"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r594",
      "r729",
      "r730"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r152",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r245",
      "r250",
      "r251",
      "r252",
      "r253",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r613",
      "r659",
      "r681",
      "r682",
      "r683",
      "r740",
      "r741"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Issuance Costs",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r30"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r504",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r568",
      "r569",
      "r570",
      "r571",
      "r618",
      "r620",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r92",
      "r502",
      "r504",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r553",
      "r554",
      "r555",
      "r568",
      "r569",
      "r570",
      "r571",
      "r584",
      "r618",
      "r620",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ]
    },
    "orka_DevelopmentCostsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "DevelopmentCostsPercentage",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of development costs",
        "verboseLabel": "Development costs, percentage",
        "documentation": "Percentage of development costs.",
        "label": "Development Costs Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r289",
      "r320",
      "r321",
      "r323",
      "r604"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable, basic (in Dollars per share)",
        "verboseLabel": "Loss Per Share \u2013 Basic and Diluted, Stock (in Dollars per share)",
        "netLabel": "Net loss per share (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r165",
      "r171",
      "r172",
      "r175",
      "r176",
      "r177",
      "r182",
      "r358",
      "r361",
      "r375",
      "r376",
      "r444",
      "r460",
      "r585"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable, diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r165",
      "r172",
      "r175",
      "r176",
      "r177",
      "r182",
      "r358",
      "r361",
      "r375",
      "r376",
      "r444",
      "r460",
      "r585"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share Attributable to Stockholders",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r179"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178",
      "r180",
      "r181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax percentage",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r606"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of diluted stock",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r718",
      "r719"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable": {
       "parentTag": "us-gaap_ShareBasedCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option [Member]",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "EmployeeWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable": {
       "parentTag": "us-gaap_ShareBasedCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants",
        "documentation": "The amount of employee warrants.",
        "label": "Employee Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "orka_EmployeeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "EmployeeWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Warrants [Member]",
        "label": "Employee Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.orukatx.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r123",
      "r139",
      "r140",
      "r141",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r166",
      "r168",
      "r185",
      "r208",
      "r211",
      "r212",
      "r274",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r410",
      "r412",
      "r424",
      "r459",
      "r466",
      "r467",
      "r468",
      "r489",
      "r558"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r354",
      "r632",
      "r633",
      "r634",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity holding percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "orka_EstimatedFairValueOfWarrantsToBeGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "EstimatedFairValueOfWarrantsToBeGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value of warrants to be granted",
        "documentation": "Estimated fair value of warrants to be granted.",
        "label": "Estimated Fair Value Of Warrants To Be Granted"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization",
        "documentation": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock.",
        "label": "Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred St"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse recapitalization (in Shares)",
        "documentation": "Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the Reverse Merger.",
        "label": "Exchange Of Series AConvertible Preferred Stock For Series BNonvoting Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ExchangeRatio",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Hierarchy for Financial Assets Measured",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r727"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r391",
      "r392",
      "r394",
      "r436",
      "r437",
      "r438",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r607",
      "r609"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393"
     ]
    },
    "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Hierarchy for Financial Assets Measured [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r387",
      "r389",
      "r390",
      "r391",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r443",
      "r607",
      "r610"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r276",
      "r281",
      "r379",
      "r392",
      "r436",
      "r600",
      "r601",
      "r602",
      "r607"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r276",
      "r281",
      "r379",
      "r380",
      "r392",
      "r437",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r607"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r379",
      "r380",
      "r381",
      "r382",
      "r392",
      "r438",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r607",
      "r609"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r393"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "FairValueMeasurementsDetailsScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of Fair Value Hierarchy for Financial Assets Measured [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r377",
      "r379",
      "r380",
      "r381",
      "r382",
      "r391",
      "r392",
      "r394",
      "r436",
      "r437",
      "r438",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r607",
      "r609"
     ]
    },
    "orka_FairmountHealthcareFundIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "FairmountHealthcareFundIILPMember",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fairmount [Member]",
        "verboseLabel": "Fairmount Healthcare Fund II, L.P. [Member]",
        "label": "Fairmount Healthcare Fund IILPMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock and Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_FinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "FinancialAssetsAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets:",
        "label": "Financial Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r538"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense [Member]",
        "verboseLabel": "Research and Development Expenses [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r219",
      "r220",
      "r384",
      "r388",
      "r393",
      "r463",
      "r465",
      "r543",
      "r582",
      "r608",
      "r759"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r384",
      "r388",
      "r393",
      "r463",
      "r465",
      "r543",
      "r582",
      "r608",
      "r759"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r349",
      "r351",
      "r352",
      "r353",
      "r485",
      "r606"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r111",
      "r167",
      "r168",
      "r183",
      "r191",
      "r200",
      "r337",
      "r338",
      "r350",
      "r461",
      "r606"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r335",
      "r336",
      "r342",
      "r343",
      "r344",
      "r346",
      "r479"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r657"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other non-current assets",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r258",
      "r265",
      "r597",
      "r598"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r654"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r189",
      "r200",
      "r590",
      "r653"
     ]
    },
    "orka_IssuanceCostOfPIPEFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceCostOfPIPEFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost of PIPE Financing",
        "documentation": "Issuance cost of PIPE financing.",
        "label": "Issuance Cost Of PIPEFinancing"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs of Pre-Closing Financing and reverse recapitalization",
        "documentation": "Issuance costs of pre-closing financing and reverse recapitalization.",
        "label": "Issuance Costs Of Preclosing Financing And Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing,",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cos"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and pre-funded warrants in the Pre-Closing Financing, (in Shares)",
        "documentation": "Issuance of common stock and pre-funded warrants in the preclosing financing, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock And Prefunded Warrants In The Preclosing Financing Net Of Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warr"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing (in Shares)",
        "documentation": "Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the Private Placement, net of offering costs of $[x] million.",
        "label": "Issuance Of Common Stock Series ANonvoting Convertible Preferred Stock And Prefunded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization (in Shares)",
        "documentation": "Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the Reverse Merger.",
        "label": "Issuance Of Common Stock To Former Stockholders Of ARCABiopharma Inc In Connection With The Closing Ofthe Reverse Merger"
       }
      }
     },
     "auth_ref": []
    },
    "orka_IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs",
        "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs.",
        "label": "Issuance Of Series AConvertible Preferred Stock Net Of Issuance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease discount rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total undiscounted lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remainder)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails",
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease terms",
        "verboseLabel": "Leases term",
        "netLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r53",
      "r54",
      "r56",
      "r57",
      "r58",
      "r59",
      "r148",
      "r207",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r364",
      "r365",
      "r366",
      "r399",
      "r512",
      "r586",
      "r628",
      "r686",
      "r749",
      "r750"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities, convertible preferred stock and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r98",
      "r454",
      "r616",
      "r660",
      "r677",
      "r739"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r127",
      "r148",
      "r207",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r364",
      "r365",
      "r366",
      "r399",
      "r616",
      "r686",
      "r749",
      "r750"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Category of Item Purchased [Axis]",
        "documentation": "Information by category of items purchased under a long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r223",
      "r224",
      "r225",
      "r226",
      "r283",
      "r330",
      "r382",
      "r441",
      "r462",
      "r464",
      "r476",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r572",
      "r580",
      "r581",
      "r593",
      "r599",
      "r603",
      "r609",
      "r610",
      "r611",
      "r612",
      "r617",
      "r688",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Recapitalization and Pre-Closing Financing",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r90"
     ]
    },
    "orka_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "MilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r223",
      "r224",
      "r225",
      "r226",
      "r283",
      "r330",
      "r382",
      "r441",
      "r462",
      "r464",
      "r476",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r572",
      "r580",
      "r581",
      "r593",
      "r599",
      "r603",
      "r609",
      "r610",
      "r611",
      "r617",
      "r688",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Own capital percentage",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds [Member]",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "orka_NatureOfTheBusinessAndBasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NatureOfTheBusinessAndBasisOfPresentationLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NatureoftheBusinessandBasisofPresentationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NatureoftheBusinessandBasisofPresentationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Loss Allocation, Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r77",
      "r99",
      "r125",
      "r136",
      "r137",
      "r141",
      "r148",
      "r156",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r167",
      "r168",
      "r174",
      "r207",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r358",
      "r361",
      "r376",
      "r399",
      "r458",
      "r535",
      "r556",
      "r557",
      "r626",
      "r686"
     ]
    },
    "orka_NetLossPerShareDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NetLossPerShareDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NetLossPerShareDetailsScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NetLossPerShareDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NetLossPerShareDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "orka_NonRefundableMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NonRefundableMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable milestone payments",
        "documentation": "Non-refundable milestone payments.",
        "label": "Non Refundable Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash accrued interest on convertible note converted to common stock",
        "documentation": "Represent the amount of non-cash accrued interest on convertible note converted to common stock.",
        "label": "Noncash Accrued Interest On Convertible Note Converted To Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash operating and financing activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets acquired in connection with the reverse recapitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Assets Acquired",
        "documentation": "Amount of assets, classified as other, acquired in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other liabilities assumed in connection with the reverse recapitalization",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "orka_NotePayableToRelatedPartyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NotePayableToRelatedPartyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable to Related Party",
        "documentation": "Note Payable to Related Party.",
        "label": "Note Payable To Related Party Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NotePayablewithRelatedPartyDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NotePayablewithRelatedPartyDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Note Payable with Related Party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_NumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "NumberOfSharesPurchased",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares purchased (in Shares)",
        "documentation": "Number of shares purchased.",
        "label": "Number Of Shares Purchased"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ORKAZeroZeroOneMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-001 [Member]",
        "label": "ORKAZero Zero One Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ORKAZeroZeroTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ORKAZeroZeroTwoMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORKA-002 [Member]",
        "label": "ORKAZero Zero Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r587",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total discounted lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "negatedLabel": "Less: current portion of lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofCompanysOperatingLeaseLiabilitiesShowingtheAggregateLeasePaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, non-current",
        "verboseLabel": "Non-current portion of lease liability",
        "netLabel": "Operating lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r414"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysSupplementalCashFlowInformationRelatedtoLeasesTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flow from operating leases",
        "verboseLabel": "Lease payment",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r417"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_OperatingLeaseVariableLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseVariableLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease expense",
        "label": "Operating Lease, Variable Lease Income",
        "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r422"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r615"
     ]
    },
    "orka_OptionAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OptionAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OptionAgreementsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OptionAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OptionAgreementsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Agreements",
        "documentation": "Option agreements.",
        "label": "Option Agreements Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaAdvisorsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OrukaAdvisorsLLCMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Advisors LLC [Member]",
        "label": "Oruka Advisors LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OrukaCommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka Common Stock [Member]",
        "verboseLabel": "Oruka common stock [Member]",
        "label": "Oruka Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaPrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OrukaPrefundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka pre-funded warrants [Member]",
        "label": "Oruka Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OrukaRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OrukaRestrictedStockMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oruka restricted stock [Member]",
        "label": "Oruka Restricted Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued development costs",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "orka_OtherDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OtherDevelopmentCost",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development costs",
        "documentation": "Represent the amount of development costs.",
        "label": "Other Development Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70"
     ]
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIncomeAndExpensesAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party accounts payable and other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r616"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income (expense), net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OtherNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research initiation fee",
        "label": "Other Notes Payable",
        "documentation": "Amount of long-term notes payable classified as other."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r96",
      "r758"
     ]
    },
    "orka_OutstandingAndIssuedCommonStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OutstandingAndIssuedCommonStockOptionsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding and Issued Common Stock Options [Member]",
        "label": "Outstanding And Issued Common Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OutstandingEmployeeWarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OutstandingEmployeeWarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Employee Warrants to Purchase Common Stock [Member]",
        "label": "Outstanding Employee Warrants To Purchase Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_OutstandingUnvestedRestrictedStockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "OutstandingUnvestedRestrictedStockAwardsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Unvested Restricted Stock Awards [Member]",
        "label": "Outstanding Unvested Restricted Stock Awards Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonAndParukaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParagonAndParukaMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon and Paruka [Member]",
        "label": "Paragon And Paruka Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParagonMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon [Member]",
        "label": "Paragon Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOptionAgreementsFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParagonReimbursableOptionAgreementsFeesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable Option Agreements\u2019 fees [Member]",
        "label": "Paragon Reimbursable Option Agreements Fees Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursableOtherResearchExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParagonReimbursableOtherResearchExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable other research expenses [Member]",
        "label": "Paragon Reimbursable Other Research Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParagonReimbursablePatentExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParagonReimbursablePatentExpensesMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paragon reimbursable patent expenses\t[Member]",
        "label": "Paragon Reimbursable Patent Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaHoldingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParukaHoldingLLCMember",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Holding, LLC [Member]",
        "label": "Paruka Holding LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParukaWarrantObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable": {
       "parentTag": "us-gaap_ShareBasedCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka warrant obligation",
        "documentation": "Paruka warrant obligation.",
        "label": "Paruka Warrant Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ParukaWarrantObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ParukaWarrantObligationMember",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paruka Warrant Obligation [Member]",
        "label": "Paruka Warrant Obligation Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net of issuance costs",
        "label": "Payment of Financing and Stock Issuance Costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initiation fee",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance cost",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "orka_PercentageOfWarrantPurchare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "PercentageOfWarrantPurchare",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of warrant purchase",
        "documentation": "Percentage of warrant purchase.",
        "label": "Percentage Of Warrant Purchare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "orka_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants [Member]",
        "label": "Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_PreFundedWarrantsOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "PreFundedWarrantsOfCommonStockShares",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded warrants of common stock shares (in Shares)",
        "documentation": "Pre-funded warrants of common stock shares.",
        "label": "Pre Funded Warrants Of Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share (in Dollars per share)",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Convertible, Shares Issuable (in Shares)",
        "verboseLabel": "Converted shares",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation Preference",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r269",
      "r273"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Series B Non-Voting",
        "netLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r622",
      "r623",
      "r624",
      "r625",
      "r760",
      "r762"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r266"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred Stock Authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r514"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Shares issuable on conversion of Company preferred stock",
        "netLabel": "Preferred stock, shares issued (in Shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r266"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r514",
      "r533",
      "r762",
      "r763"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock and Stockholders\u2019 Equity",
        "label": "Preferred Stock [Text Block]",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, value",
        "verboseLabel": "Carrying Value",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r450",
      "r616"
     ]
    },
    "orka_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate proceeds",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Gross proceeds (in Dollars)",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased shares of common stock",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "orka_ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid",
        "documentation": "Proceeds from issuance of Pre-Merger Oruka Series A Preferred Stock, net of issuance costs paid.",
        "label": "Proceeds From Issuance Of Pre Merger Oruka Series APreferred Stock Net Of Issuance Costs Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance preferred stock",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the PIPE Financing, net",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs (in Dollars)",
        "label": "Proceeds from Issuance or Sale of Equity",
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r480"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of notes payable to related parties, net of issuance costs paid",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the Pre-Closing Financing, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r655"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r421"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r421",
      "r445",
      "r457",
      "r616"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r107",
      "r110",
      "r456"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r223",
      "r224",
      "r225",
      "r226",
      "r275",
      "r283",
      "r315",
      "r316",
      "r317",
      "r330",
      "r382",
      "r439",
      "r440",
      "r441",
      "r462",
      "r464",
      "r476",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r572",
      "r580",
      "r581",
      "r593",
      "r599",
      "r603",
      "r609",
      "r610",
      "r611",
      "r612",
      "r617",
      "r620",
      "r684",
      "r688",
      "r729",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r223",
      "r224",
      "r225",
      "r226",
      "r275",
      "r283",
      "r315",
      "r316",
      "r317",
      "r330",
      "r382",
      "r439",
      "r440",
      "r441",
      "r462",
      "r464",
      "r476",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r572",
      "r580",
      "r581",
      "r593",
      "r599",
      "r603",
      "r609",
      "r610",
      "r611",
      "r612",
      "r617",
      "r620",
      "r684",
      "r688",
      "r729",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756"
     ]
    },
    "orka_ReimburseOfDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ReimburseOfDevelopmentCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimburse of development costs",
        "documentation": "The amount of reimburse of development costs.",
        "label": "Reimburse Of Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r282",
      "r428",
      "r429",
      "r447",
      "r455",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r532",
      "r534",
      "r563"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r428",
      "r429",
      "r430",
      "r431",
      "r447",
      "r455",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r532",
      "r534",
      "r563"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429",
      "r748"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Accounts Payable and Other Current Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r539",
      "r540",
      "r543"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r282",
      "r428",
      "r429",
      "r447",
      "r455",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r532",
      "r534",
      "r563",
      "r748"
     ]
    },
    "orka_RelatedPartyTransactionsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "RelatedPartyTransactionsDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_RelatedPartyTransactionsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "RelatedPartyTransactionsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r426",
      "r427",
      "r429",
      "r432",
      "r486",
      "r487",
      "r488",
      "r541",
      "r542",
      "r543",
      "r561",
      "r562"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "orka_ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Contract Costs Accruals",
        "documentation": "Research and development contract costs accruals.",
        "label": "Research And Development Contract Costs Accruals Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "netLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r582",
      "r590",
      "r757"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "orka_ResearchInitiationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ResearchInitiationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research initiation fee",
        "documentation": "Represents the amount of research initiation fee.",
        "label": "Research Initiation Fee"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r182",
      "r209",
      "r210",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r373",
      "r374",
      "r375",
      "r376",
      "r409",
      "r411",
      "r423",
      "r424",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r675"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r124",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r182",
      "r209",
      "r210",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r373",
      "r374",
      "r375",
      "r376",
      "r409",
      "r411",
      "r423",
      "r424",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r675"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofFairValueHierarchyforFinancialAssetsMeasuredTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "orka_RestrictedStockActivityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "RestrictedStockActivityMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Activity [Member]",
        "label": "Restricted Stock Activity Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r84",
      "r453",
      "r470",
      "r475",
      "r484",
      "r515",
      "r616"
     ]
    },
    "orka_ReverseRecapitalizationAndPreClosingFinancingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ReverseRecapitalizationAndPreClosingFinancingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization and Pre-Closing Financing [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Assets and Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ReverseRecapitalizationandPreClosingFinancingDetailsScheduleoftheAssetsandLiabilitiesTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization and Pre-Closing Financing (Details) - Schedule of the Assets and Liabilities [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split [Member]",
        "label": "Reverse Stock Split Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability arising from obtaining operating right-of-use asset",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r615"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued to purchase (in Shares)",
        "verboseLabel": "Number of Shares issued",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Purchase price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r644",
      "r666"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r168",
      "r182",
      "r356",
      "r358",
      "r359",
      "r360",
      "r361",
      "r373",
      "r374",
      "r375",
      "r409",
      "r411",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r639",
      "r641",
      "r642",
      "r643",
      "r665",
      "r675",
      "r678",
      "r679",
      "r725",
      "r745",
      "r746"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r169",
      "r284",
      "r631",
      "r666"
     ]
    },
    "orka_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfAntiDilutiveEffectExcludedFromPotentialComputationOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Anti Dilutive Effect Excluded From Potential Computation Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAntiDilutiveEffectExcludedfromPotentialComputationofDilutedNetLossPerShareTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Anti-Dilutive Effect Excluded from Potential Computation of Diluted Net Loss Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Convertible Preferred Stock",
        "label": "Schedule of Auction Market Preferred Securities by Stock Series [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to auction market preferred securities, including liquidation preference, liquidation value, par value, rate setting interval, redemption requirements, dividend distributions, roll forward of shares outstanding, shares authorized, aggregate value of auction market preferred securities, variable interest rate earned, and other information necessary to a fair presentation. If redeemable, the auction market preferred securities are redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r36",
      "r61"
     ]
    },
    "orka_ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfAwardTypesOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/CommitmentandContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCommonStockReservedForFutureIssuanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Reserved For Future Issuance Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfCompanySOperatingLeaseLiabilitiesShowingTheAggregateLeasePaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Operating Lease Liabilities Showing the Aggregate Lease Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCompanySStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfCompanySStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SStock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfCompanySSupplementalCashFlowInformationRelatedToLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Supplemental Cash Flow Information Related to Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Award Types of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRelatedPartyAccountsPayableandOtherCurrentLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r119",
      "r152",
      "r635"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Accounts Payable and Other Current Liabilities",
        "label": "Condensed Financial Statements [Table Text Block]",
        "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r661"
     ]
    },
    "orka_ScheduleOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfConvertiblePreferredStockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Convertible Preferred Stock Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "orka_ScheduleOfEmployeeWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfEmployeeWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Summarizes the Employee Warrant Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r354",
      "r632",
      "r633",
      "r634",
      "r720",
      "r721",
      "r722",
      "r723"
     ]
    },
    "orka_ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfFairValueHierarchyForFinancialAssetsMeasuredAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Hierarchy For Financial Assets Measured Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants",
        "documentation": "Tabular disclosure of fair value of the employee warrants.",
        "label": "Schedule Of Fair Value Of The Employee Warrants Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSAs activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "orka_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r421"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/ReverseRecapitalizationandPreClosingFinancingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Assets and Liabilities",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "orka_ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfRelatedPartyAccountsPayableAndOtherCurrentLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Related Party Accounts Payable And Other Current Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfRsasActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfRsasActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Rsas Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r86"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "orka_ScheduleOfStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Warrant Activity",
        "label": "Schedule Of Summarizes The Employee Warrant Activity Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfTheAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfTheAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of The Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfWeightedAverageAssumptionsOrRangeOfAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Weighted Average Assumptions Or Range Of Assumptions Used In Calculating The Fair Value Of The Employee Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ScheduleOfWeightedAverageAssumptionsUsedInCalculatingTheFairValueOfTheEmployeeWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Assumptions Used in Calculating the Fair Value of the Employee Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r588",
      "r589",
      "r592"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "orka_SeriesAConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesAConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Convertible Preferred Stock",
        "verboseLabel": "Series A convertible preferred stock",
        "netLabel": "Series A Convertible Preferred Stock [Member]",
        "label": "Series AConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stockholders",
        "verboseLabel": "Series A Non-Voting",
        "netLabel": "Series A Non-Voting Convertible Preferred Stock [Member]",
        "label": "Series ANon Voting Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesANonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesANonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stockholders",
        "label": "Series ANon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A",
        "verboseLabel": "Shares issuable on conversion of Company Series A Preferred Stock [Member]",
        "netLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r689"
     ]
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesBNonVotingConvertiblePreferredStockAmountMember",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting",
        "verboseLabel": "Convertible Preferred Stock",
        "label": "Series BNon Voting Convertible Preferred Stock Amount Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesBNonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stock",
        "verboseLabel": "Series B Non-Voting",
        "label": "Series BNon Voting Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingConvertiblePreferredStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesBNonVotingConvertiblePreferredStockholdersMember",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Convertible Preferred Stockholders",
        "label": "Series BNon Voting Convertible Preferred Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SeriesBNonVotingPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SeriesBNonVotingPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Non-Voting Preferred Stock [Member]",
        "label": "Series BNon Voting Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable on conversion of Company Series B Preferred Stock [Member]",
        "verboseLabel": "Series B Preferred Stock [Member]",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r647",
      "r648",
      "r689"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow",
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "documentation": "Number of Warrants, Exercised (in Shares).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "documentation": "Number of exercised of weighted average exercise price per share.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "verboseLabel": "Shares issued",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Beginning balance",
        "periodEndLabel": "Number of Warrants, Endning balance",
        "terseLabel": "Outstanding and issued employee warrants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303"
     ]
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Vested and exercisable",
        "documentation": "Number of Warrants, Vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and exercisable",
        "documentation": "Weighted Average Exercise Price Per Share, Vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable In Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "orka_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and exercisable",
        "documentation": "Weighted Average Remaining Contractual Term, Vested and exercisable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Exercisable Period Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock awards authorized (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for grant",
        "verboseLabel": "Number of shares of common stock available for issuance (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options, Exercisable",
        "verboseLabel": "Exercisable shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options, Granted",
        "verboseLabel": "Number of RSAs, Granted",
        "netLabel": "Number of shares granted (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Weighted average grant-date fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning Balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Stock Options, Beginning Balance",
        "periodEndLabel": "Number of Stock Options, Ending Balance",
        "terseLabel": "Outstanding and issued stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Beginning Balance (in Dollars per share)",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r293",
      "r312",
      "r313",
      "r314",
      "r315",
      "r318",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable shares",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Endning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsUsedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Beginning Balance",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable",
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Exercisable",
        "verboseLabel": "Weighted Average Remaining Contractual Term, Beginning balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of RSAs, Unvested Beginning Balance",
        "periodEndLabel": "Number of RSAs, Unvested Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Unvested Beginning Balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Unvested Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Ending Balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Endning balance",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofEmployeeWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for option awards Vested and expected to vest, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Expected To Vest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee warrants vest over a period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (in Years), Vested and expected to vest, September 30, 2024",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "orka_SharesIssuableUponExerciseOfPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SharesIssuableUponExerciseOfPrefundedWarrants",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issuable upon exercise of pre-funded warrants",
        "documentation": "Shares issuable upon exercise of pre-funded warrants.",
        "label": "Shares Issuable Upon Exercise Of Prefunded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balances (in Shares)",
        "periodEndLabel": "Balances (in Shares)",
        "terseLabel": "Preferred Stock Issued and Outstanding",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "orka_SharesOutstandingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SharesOutstandingPercentage",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share outstanding percentage",
        "documentation": "Shares outstanding percentage.",
        "label": "Shares Outstanding Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r145"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/CommonStockDetails",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/NetLossPerShareDetails",
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails",
      "http://www.orukatx.com/role/RelatedPartyTransactionsDetails",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable",
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r132",
      "r133",
      "r134",
      "r148",
      "r172",
      "r173",
      "r175",
      "r177",
      "r186",
      "r187",
      "r207",
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r266",
      "r267",
      "r269",
      "r270",
      "r271",
      "r399",
      "r480",
      "r481",
      "r482",
      "r483",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r501",
      "r514",
      "r536",
      "r558",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r630",
      "r658",
      "r668"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ScheduleofConvertiblePreferredStockTable",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r123",
      "r139",
      "r140",
      "r141",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r166",
      "r168",
      "r185",
      "r208",
      "r211",
      "r212",
      "r274",
      "r347",
      "r348",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r410",
      "r412",
      "r424",
      "r459",
      "r466",
      "r467",
      "r468",
      "r489",
      "r558"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r185",
      "r412",
      "r442",
      "r478",
      "r501",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r537",
      "r538",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r621"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/ScheduleoftheAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r169",
      "r284",
      "r631",
      "r636",
      "r666"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r185",
      "r203",
      "r412",
      "r442",
      "r478",
      "r501",
      "r505",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r534",
      "r537",
      "r538",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r558",
      "r621"
     ]
    },
    "orka_StockBasedCompensationDetailsScheduleofRSAsactivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "StockBasedCompensationDetailsScheduleofRSAsactivityLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of RSAs activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationDetailsScheduleofRSAsactivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "StockBasedCompensationDetailsScheduleofRSAsactivityTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofRSAsactivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of RSAs activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "StockBasedCompensationDetailsScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) - Schedule of Weighted-Average Assumptions or Range of Assumptions used in Calculating the Fair Value of the Employee Warrants [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_StockBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "StockBasedCompensationDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r34",
      "r61",
      "r62",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares were reserved for issuance",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in Shares)",
        "verboseLabel": "Pre-funded warrants",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r84",
      "r480",
      "r558",
      "r574"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69 (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofStockOptionActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Stock Options, Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r84",
      "r299"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/NotePayablewithRelatedPartyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal amount",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r84"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r61",
      "r62",
      "r84",
      "r489",
      "r558",
      "r574",
      "r627"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A convertible preferred stock, net of issuance costs of $69",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable": {
       "parentTag": "us-gaap_ShareBasedCompensation",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofAwardTypesofCompanysStockBasedCompensationExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r62",
      "r65",
      "r66",
      "r84"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofWeightedAverageAssumptionsorRangeofAssumptionsusedinCalculatingtheFairValueoftheEmployeeWarrantsTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Valuation [Member]",
        "verboseLabel": "Stock Options [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r66",
      "r80",
      "r516",
      "r533",
      "r559",
      "r560",
      "r616",
      "r628",
      "r660",
      "r677",
      "r739",
      "r762"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "orka_SubscriptionReceivablePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SubscriptionReceivablePolicyTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription Receivable",
        "documentation": "Subscription receivable.",
        "label": "Subscription Receivable Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubscriptionReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SubscriptionReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subscription receivable",
        "documentation": "Amount of subscription receivable from investors who have been allocated common stock.",
        "label": "Subscription Receivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r434"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r434"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r434"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubsequentEventsDetailsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SubsequentEventsDetailsLineItems",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "orka_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r435"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.orukatx.com/role/ConvertiblePreferredStockandStockholdersEquityDetails",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalDeferredPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalDeferredPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price",
        "label": "Supplemental Deferred Purchase Price",
        "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r23"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, value",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r233",
      "r236",
      "r237",
      "r328",
      "r452"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, liquidation preference (in Dollars)",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, par value (in Dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r32"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "orka_TerminationFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "TerminationFee",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination fee",
        "documentation": "Represents the amount of termination fee.",
        "label": "Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r747"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "orka_TwoThousandTwentyFourEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "TwoThousandTwentyFourEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand Twenty Four Employee Stock Purchase Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TwoThousandTwentyFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "TwoThousandTwentyFourEquityIncentivePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Equity Incentive Plan [Member]",
        "verboseLabel": "2024 Plan [Member]",
        "label": "Two Thousand Twenty Four Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "orka_TwoThousandTwentyFourStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "TwoThousandTwentyFourStockIncentivePlanMember",
     "presentation": [
      "http://www.orukatx.com/role/ScheduleofCommonStockReservedforFutureIssuanceTable",
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Stock Incentive Plan [Member]",
        "label": "Two Thousand Twenty Four Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.orukatx.com/role/OptionAgreementsDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing issuance costs included in accounts payable",
        "documentation": "Unpaid PIPE Financing issuance costs included in accounts payable.",
        "label": "Unpaid PIPEFinancing Issuance Costs Included In Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "orka_UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing issuance costs included in accrued expenses and other current liabilities",
        "documentation": "Unpaid PIPE Financing issuance costs included in accrued expenses and other current liabilties.",
        "label": "Unpaid PIPEFinancing Issuance Costs Included In Accrued Expenses And Other Current Liabilties"
       }
      }
     },
     "auth_ref": []
    },
    "orka_UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Closing Financing and reverse recapitalization issuance costs included in accounts payable",
        "documentation": "Unpaid pre-closing financing and reverse recapitalization issuance costs included in accounts payable.",
        "label": "Unpaid Preclosing Financing And Reverse Recapitalization Issuance Costs Included In Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "orka_UnvestedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.orukatx.com/20240930",
     "localname": "UnvestedStockOptionsMember",
     "presentation": [
      "http://www.orukatx.com/role/StockBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Stock Options [Member]",
        "label": "Unvested Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.orukatx.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r104",
      "r105",
      "r108",
      "r109"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails",
      "http://www.orukatx.com/role/StockBasedCompensationDetails",
      "http://www.orukatx.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r619",
      "r622",
      "r623",
      "r624",
      "r625"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedBalanceSheet",
      "http://www.orukatx.com/role/NatureoftheBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related party common stock warrant liability",
        "verboseLabel": "Warrant gross proceeds amount",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesContingentlyIssuable",
     "presentation": [
      "http://www.orukatx.com/role/NetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of shares of as-converted",
        "label": "Weighted Average Number of Shares, Contingently Issuable",
        "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.orukatx.com/role/ConsolidatedIncomeStatement",
      "http://www.orukatx.com/role/ScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable, basic (in Shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable, diluted (in Shares)",
        "netLabel": "Weighted Average Shares Outstanding, Stock (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-6A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>90
<FILENAME>0001213900-24-097737-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-24-097737-xbrl.zip
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M.;^@Q$YY;L$EYA[R08IZ=SICLP_E_VJ2$V7N,;*+OCWI/"2:P="ZA7#]%2Y
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MFYS<\OINV2"!E5+NNJSG\)BEU^?[M:O"5W9:R*0,MC*E:MPJOT;5N8SD4&*
MN$K9(+@'G@W3?\-8@.?$ OQ&+* 1].09ID[=KPU/NV:<B?)SA@WVFNKW\3W1
MQ+ADO%3@R?Y*+TOH@N8[G2RW3W.WPQ,K.@MO87U?6#O#E>/>\3D6"<.%=R94
MMFX7M/3^29,_%#F6H3].@*ZC69:G^71I8.XE-8K$F^7PGW@97)!$I:2RV*G
MX:TA16'1DH_!(-5>NU^!W*C,],99D6=)Y)? #A@Y1)>"NT0\#>B><"DKE6Z
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MMJ[4.'&:7!"H31Y'::!4_QC<8]B,G."B7;G1 $N#4PU]SN97("O*NB3\;3%
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MG]:%^*-1+ZI!"NGY[W%\%*]UH^VL(5H8E;LO_?,\K4%-R%C4YCLFF<=V(,:
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M@(?_!<:V5 AA&$=;M((;\*<$'S@Z-E,2GL+X31*!\L6E2$N<,H7I^NY(HV2
M3U)*-%.=D/0>(666N% ]%IY+COD<357S!5P!CT--P+09A\NU*E^#?^GI.<
M'F]"C7""SGZ()*26-OLI;9+SI[D&!UI0W0G^&]T7JBE9A6IYSX7*PQ*!?RA$
M&S()8SV 1 ,S4L4\)>PLK%:O28YJDD(+^!\\2865=!-G4&O31G."A:G 2U9C
M#)CHJF2_>SOX'>/8><BF ]?YOCQN%L*G A;9R+=X3M3 ..*]6)7MD=O.("H-
M'^:$81RA$:R$!-/U\IZ!E_R##(K..34;+AA (/!?O=U;A?,I+;<ZX65P2 OI
M7" K7L,/N&$7:P%RF;\!8 S0],DO>O#B. HPI;*M;HV8,9M</:4D0B3));X-
MW2,0V"LRU,(B*64'N$*,J_M76*Q$$CVS&DDF=Y0F!JDJT6#4ER+ 6DXU!:+0
M\<MHN(D\ZS;[=)%B*2ST4Q--RW0#.PASCM;#>CP#&JP+'D7$)+\FF7>>G.?6
M$<G=[_SS! 2[_9)8T>$/3F(T7X *&<,5K_"R9^HT"FI@$;#:Z])K#V%R3P%M
M9K)R!5&6@8]3"AN9![I-^^V'.D5]Z+(;_Z7[/&E M$"ORDX'[7N#FPW)QBG7
M/48(CV5BKY=_">]#&MT3;>Q$(:R?DZEIKD] 9RQ( ;<@#JA$PB9O+EV$^Y8Z
M2HUNNP=T5=1)I1/@X$KQ%NJ(L[U;<[24<S]WWR6[=GCRRJFHK!CEI&==^C8>
MF6.-/F.QG#'^EH(-0_\I!1D2'D:0[ +_>(H99/HOEV5*7O]?&)Q,6JFWML&)
ME@N("UQ&S_! Y@H7:R?W;0LWR48J(7AIJ'',V(YX)(%%?BQB%O:*[LK*(HRI
MGL"!K/6:H\+*EV[AJEC&JZIX07 +8B=/@\V6J^%UE^9*W:']6Y['!J;4>X\9
M,JQV;V"/ZX; W_8=@)"\<.%WG6=-:[0927UU47=?^E@6,F5QW&5S9P>L#_RE
MDX#U$YO%OXTW1#; =8>9[@:2K[T0+HB%^!CFG=;@SF1SCZVD><-MN0FW6 "Q
M:'VB\P7P.X)PB7T:G1DSM1(8BI'%VK_RJ)-2Q_U1AK]D>)8)(Q$UX2XL6')%
MH+5(Q42"%,QF/R T$_!:/\Z+*;AOT@NHSW[_G6D&]9QR:4<::_I_=^R0^CS\
MR'F@3.&"J ?%$@"IWMZ5OY0<N<L_/+6XSM!XP=X1?(B)-VJ\[^KJV7Z##W%[
MM=O/?YS:[<VA=OO[)/@O<9K)[:!V(2 &5'+<"4A6TJ03O> D%/D@JNF%D$1.
MJD!/A>#I]!,Q0\ JJFH#9,_QH8;;XCEI(A:3)GIM;OD:[?Y3#I:_RS.$^L8+
M7^5A$=NLJAERU%HY?.P.K.AS%+U5>/ZG%/5J35#I]<4Z&Q;7)-U#!P^\!R7=
M,9;<OK$NUE_;?KID4FS>R0Y8/8_/9D=@E;_BI(V]O'"LWRMW<97C9)6_..PT
M+R;12W!V;I8C KFM8I(,B2> T6A42$Z<XG^<&,=,N-U%-\<2 D5E:I)4=L*M
MA8)T;*LI^NX9^7&I?@E=TA#&<, )5ZIBBMX6.Y!\Q_7'L/\T1K=F>\O%U^[N
M+\5B!//=;8GMB</T&/=DE'KNZ+]^%T$0&73GG[2DFAI!7)\"YY4R78E9CV.4
M]';0]0"SKDK1)J:B7Z>B&R$1G15F0N 2-8KB8]WB/(_)V,,21N=[OJ7,UY#<
MF1YFR-"?!JVAE05W*B$Z@T88;4]@#W11DI(Y"_&?F +$M8WAZU8%!@4#2_=W
ME)#VW*J9=G)ZL.#N'$#*46<ZU8!2B$.9W GIY#VDL:BWYD$"G/U@9K:>CE6I
M!1?Q-)]>,.I&F]*&:H&O7P3N%H2X5$&UP5).YV1VG'$G0B!M6<P#&1U0/<'"
MX=RI1%=M/-7KC:?V144XG<?:6MJXR_ZI'%U4Y=73/OS6M _O8H:)0.R+,1!J
MI.F!<Q(J**/Y2=CY@N_C[$=[; C\6IC'W9F>2=(]<V.\%7-C^L?#."-?VFP*
MTGVF<6RXN+S3;Q&("G&'DF RD2KO5@R,\6][8 SG%5O[5U8JC.7M/-UVWQO6
M=U2U5M37/W+3O]#9O:2RJ#"&.Y:>VS35)S,[2UPU?<9MH+_.0B^<IGG:D-Y9
M&[:<JUMSQKUNJSKM-=!'$R3)J/B>T@GCI:15/J5>I4&1WVT1)?:K96&Q##P)
MXU7Y D.S$LHC9D8EG\Q;&=J^.7=LZU/Y HVB="0]_7BLJ'K2:8>C A%;QX"I
MF!#D$^?\SW&M.B%)8;\8BQ8&O?XU2Y]Z$1D;.'S8KY#FA+5OR(F1/8B2VIG]
MZ]6SND4NU)_A$;JN^P@.?"?:Z<G6#%GI0I0J-/,,C)O"+@L#*4T2\B1E 487
MERY)DL_(=#W))8']_]E[MRVWC61;]#V_@B]G#'L,J-J6>ZWNWGZ2Y<O2ZO:1
MAV2?/J\@"5;!(@DN *PR^^MWQHQ+1N+"*MDJ]:XM/EDNDD BD1D9EQES!F&'
M)]/85C=2H1/F'F4FB7?G'@K*_7"6.Y$'%DKXQ_\3GWMET?!H,)WPO&]$P2/E
M^SG6PP237T-U#<;M4^7KN)?C@:-+1NVTTO&KB""GTH0!O_#,?((^G'JI,IU!
M8]ZV0JD8760H/O(;%Y<E#T_Y^/;*MJ[9S#TX%YHI!>&C2J"A-B<^OE4=,X F
M9RBO.V;,82Q1-@-K*=QTR->ROL Z>_T/L4A/8S<_K4.*V/C.V93N1B-"VGC5
M6N@H2FZ:80^[%W$VAV T,S'#,IH(GM2RA>DC\(&FC#""[N<#VP+;5'?OV.WU
M3M$@;1BT^0#C<P29Z=2=":TT2R:MCF>.9M^HW@ZNV'$OT=39;VDX"9RT89QX
M7!DZ*_7N+ +Q:<QK4MFE5Z](5H978!0YJLP;T>!84[T)+89F1&VF>J2&4Z4_
MW%7U]8TE3-M>6<$P+V:9MB<]DC@/P<*Y]+. /B-]71[H.$:[NUXT<=\'8G@9
MPN7<M:PWC\&T)W+@&2.T'8!2N4)   &!=GG2O/$IGIJ7RWP 8Q3ZN'@1K)?R
M3EIJ^M-!B#,2EL6-A@_H4W.TK&M",[LW?R?'S+KB4@"X%JR+*T\$T?0>6J*T
M"_ZQF<$5!,P26,DC1PON.NB21VS&9N@##\X\?]Y)13F)-E,L',ZO?8^8BT-R
M3XWM[U8RD$B@[IW4@AX+.4W(-LW3K#/1;K[*35\TM<-)DA</(4]I+6^H]H_;
MY2[GXX>KI__UTZFG?W6II__?N>#_.!?:5/:!\+>HH?JRD+3VWFK1EG**7<WU
M5%_<Y-Y)8=4XY]SQG31E5FJ!3%EJ'-;XIMSV,Q)%]?ZF7M8S;9DMDPC-Z%"U
MUDW/ -2X(\)]G9R7C,E''/L;B8RU:V;D*W/2%6LUAJCD>W*3L4,4=T2E(+3+
M ):3MA][I7E%?FJ!&\%\# P(XA:OU!$MVE7X)TBZIE9V7,HD[N9:&H?L %F-
M0=JH>@K![O;<W(9L>GY'  6TRU-_$TX0AP"<O&*VEXF*C1';;.[9T!QR9%L9
M!>ZD;>?WQJ#^&"S95$VEYA<.!SWLXF)>#OEY]B%R(-$%59BI%7W8'[PS)F6%
M)027%4]?5HB)3ZL[$24?*2;:H)0W7_Q3P@W!D? \30-RO0L:F''CU9MOB@R%
M,_6>4E<OW3[K7Z4BB,JO2,G.^[\E]_MMK#OE5W4?E3_7*C0CX!*8P1@XD&T:
M;O)A]OPY#,O5XBV%N<F>&F6&3#.O&##+U4TB)J(NGV/7MR=E[JBE(8@V #<M
M&FE4O.2N!IW(N'%S@A^ J2O0F(E4U:8Y[M=)B<*/GK-MTFABK9(;#K']0G$\
M>L(@.'Y@W)?W;[9[\F[*E*834%G\:M"O"M/Z@5!$>\3"NZX"X<($9-YMZN]2
M]TY^[W3!I)0SCGPY :/]!<&5O:;;U(OY4Y^3 7P8C\Y5$QD:U#@5<\;3WS?;
MJI5@+-"*BRM>"\A*OY@'Y&=4,OET$-@WYY&/K>4$YAXCC]DH=15F'^IJ\;.F
M9YY5T;^XCO^0%KK<MCKDHBAE^J216$:5+\(T:49C(\FG:-EL9SO"A\EC$6F0
MG,-[M&:C7Z3W6&W+FCB*?K+OY"= US4K/E_H'#L7^'IQ LX:;&'WFWCH_$O%
M"O;E-0,PV3P+T]*..JVQ1>($H=L-/5A#-)[F"\/Y$>PI4X$\B0)KDBV2Q,X$
M)1$L21R8CB4&Y]'6[JOMU>*%UQ-$(WI+3D079D/[W\MTD_<@7:+]QZ<]JQ)*
M(8,0"MGL'%Q1("/B!4U\H;]I2<)B1FE,X(A F !!J FUTGA/9Z &8-.5KWB+
M9BR?R<,<==AG):D[[6\-2RZH =8)Q$A&XW2O9J?LNN,>7&MD*(A?I!RTTVV)
M(ZR=?:H6NC'JC4R?5N6FKUHGXFP9\2F/*F/E-OP&\+::^ 1Q*AOD$NJ:@.ZB
MMY(3)'AT1N?,+0-PXK%V[;-3=%*D8QH]1I?M^SC;=Q.FN@,MD@%1B$"GQD6@
M#\_>IER8#V=O6\RPMS%A&R>EZ3 FRR)D\0FSJ:#,>^C8+E1L3VE-<YK&03^E
M)*66/KX9: VE154-BTH2.0H?$H<]T,PC>D@NLCM4H*H#-LH+W6NM,FZHP"NK
M5RKN<G%-GEK5LKI??4.-K,S[)%Q)3RNQ])238M]4B&:#VB==(6E#"SE0=+25
M!H^7#H[\3;,Z,L+3#.%0VL!2(WMC>.966X[;A-/T>Y#6E12(%$$@GBF8QVVX
M?$GWVC5=OS#Z_H0MG6<>&3LKM&+CP*X;9@7= CC54A\]VRL%ZA#+&=>X>V'\
M=\N>LP-F<S&#NK:GLL0,$=4I!.^&8%;6U:KN#$K#&8:C] !C^X5\^PD_K+^)
MY@\8LJM;4.+,[(%X&$@?P1G96T\YHW 4&C3Y0H-- 1K.E O<@W[563I1Q64A
MQ%*),321](])F[QH:DE'+\=]AHKJ;_Q#ARS_+OJV\L0,4#]?]9=U0+7E?3R)
MNQM0DW(6S@Y=R>T,W4?SR(WOE@X]D=F0MG/IYF].)24MR[8E0 @?U)2(@8ZL
MM07&P3C.5*2<8$^QT"E312F[C?5G$YD7Q->V(XG8, 8NI,>997!\&@;K*1[$
MA)<:ZQ^,$Q&V#6V+C>)"G,H)B\,:\=:!-\Z4<=\$1S-U2= <S>,6DI<EZ.'"
M:=3%+7.BO@!3.3&->4UET.IB#&.B!MAD<!FCMAMH&BE73G /A:3IL4HMBLQ+
MV2[<3LHY(2\>PL<<.^6$0[V9+(DZ!4:UMR,[.5SF^\1;)ZL]<8>GHYSD"=*R
M2?Q_8;2V#S>G3M;V8G)MRWJ69.AH$9N$IE^@##WM1';0+5!:G(KP'::=E9Y/
MJ0*=JHN?%^00&CH8>S!Y<"L.*%/AU^S7]LNZYYQ( E%1Q(89J-9!MR4F1J5N
M@&*$/-)V0G/%20/YO -$(,AI044$$=M4=T\2G(E?^*E[?<4K6DL:(2M%.JVE
MQ<.EEN@V$Z(SA!;3Q"J*6[@,6&FLE+GGLRW8/6Z(!YZ.49L'U\%]SS/]R)8T
M;\LA-] 7/8V=41(WOD 1B&<F 2Z3!'&RQ8DHQ:N#\G)U@,MUG!RJRXGBA5'4
MFY+5O) (!5_T4DRZ/-,@&AAGIT(0@_C;6O1-)\S^F7%S5@,0413/2>F V-8<
MNV9YV[12Z*QWR^AS5[K(BEQB)%7^EB3NK777^S0/*,$^6\<A/01@_JD$0]Z5
M%96YUTT,B&LN2.]06Q8TBCW$PZZ27 [3I<Z\!DZVQ/ F!D!+4,6Y8EW!=%O*
M-<8@YT'/[!!7Z QB5D'Z<:I2=B[9RNV(0=H1IPD:V*AE @M"\>G(1R_^XX=#
M$O[MTT$2_OF")/R_<\'_WM&^5?_*ZJ;FNJ#QP]JGZ602.K&]D&B[DQ7G3=6M
MVGI9Y<>\9V(52FYSMUR8Y/XMQ'O!DZN1A]ET2,@89:!W.?FL(TN:N%6LF8(S
M-/4MD]I3I:PU<YR*266?66[B'Z)L?G"(%JY*)X46^(^9ZA6HM.,9&U\.5-K)
M_U!Y/M6(/3 HPS>'O+H'MTA"C,FI.O9)S,U"TGV*2DFMDU4MTKFT%&":,,05
M4U$B9^9:>A17<_/N>)C)S7AQ2&F@:5IM]T_)L<NA]8C1[DM.]CJ.'/;JD-_$
MJG/-0WER-8?-["OB +P%6R_W]DQ0W<0%4'D@H:R22Z;@(X[]GU4@XR=N^XPX
M[0Q31$&Q5V$;-Y>-4U&T;!UM<C+E"975J_!=J71KFCHS#3G7VFJ"MTDMV.'T
MW..@+G]P^K*2]* DU=8_C9 HZ;H-4^NVMAP"7RK;$QP2,%[4ET;H5^-1E*UI
MGDRR07 W'&:<>RF171'B;;FMOI=YII,!6&XPDI$(<>OP>?ZE!__2+<WCAR&!
M37<3KY&; L;?3V[SI[%%GJ(AES*R\K.=I8@AS# X?U6B@M[Z+WLJ*?*CO^VY
M*U2[_RD5,V@M3;V\J8N5L>\&/=:RV243_&^@DDH]JKHD!KB8>3ZQ>Y;%U>+%
MEL@2KF^RM3%<%Z,FH]0<<>^R&V"(HQ^+R^82<X9AZ9BJ,<L<2H(P6N5@5GF"
M11+:63'X((WU).,N%!*J3K5?._&<I5(HU$C4.?KV*::L&+%(?%3'H"*.(AYW
M/QN+E<.A8B",%A:''#A:APU?_'+U5IXJ_2YM44R0/H[K4Q ,TM2/P3.=/DBQ
MG'"44\V36(PRJ9)U12J^.HU$]U"5!!S?'(>-TZQIS_C9*;D]1UHC,'$=,QF.
M[6);WL6U0/<<8\J%LR-1=1T/$FUJ<%:FC)]K"L$, TE=:VQ5;K?NWB'-!]U?
M_%;CVLPD2EPXA:5O ^->9NKEP&LV8DO=B/<L_[H/=W*0ON-EX'5$P/H(CV8H
MA9*#PY9<J1#J$O(HGA'*\1CGYCJE[/F[C*R@(R+.7;FO1*%[VX=A"TW"].O+
MF@((^ Z%] ))>HK.!6:6J;71+^>WVC5KHB?Q*C9#>BN4U5DF=[6MRI9)Y1OK
MBLH:7V36QO/,?!B)?,'_"'0HUF1U\5L>4Q:N"&><8J>AI59,^V4ZOP&X:\E
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M,0^_]*C;1)4#V+EO+_=2OP.M:%6)%J(E^S!P^E&X)R=A^^<RE]6VJ^XHFLD
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M3W=N&IC1>;07.R7>RW>:A\=3\*#""/U-KD'L?HRVK3F':/$:YJ-4,<&-/PV
M>L_HBY($)W\GFS]P8W3"H4$((>"]P-,E16[T;C4;Q*)[$I= 'QR 8S_&&+/1
ME\4D3XYDVYOJ@EMM=/D4EB@"(*GNC[TV.P%O,YI7"AH#';Z]Z&6Z S::$BM[
M(R%5K])EY43D);=O]L_2D2K+T&[!F4.274*WD13<7>\9>1DAU3+86!^VY,>Z
M]C&*8D<T36S>4VQZL62/%:,H02*RWIP]F92/FT>"WE5^=6H7:I)EC7:E&: E
MF^56-H7IDJ/9;!VRU :$SW-U/,:FY1TSJ#=UU0 /6[@MG7Z;JW[9/F!HJ1[,
M"E%RCQ,_COXZ-,TP5T8K3I'_Z6Q:!K 4 SL1!BW9)AIL]'"5>/__$)V]3S:B
M(ZK;R5J")OQX,?$VF:\O\'Y0E.88_,0*O]*P.95N1+VQ.[:W5;R0MG%&-[#N
MC8H"\#(!$\;EO)J'@Q="4;%GQF6W 5 "DVW8ID:B(^2:TQX+CBJ;7)EKH@EO
MC@?:^V5+#C&=V&TE$NFBND3PGQ%A([.C<*W)$3NAPJ6SG23-4'&",\,4[B#P
MSM-W&;V(;[LWC"Q?0"BX-?+=V:F\8-?Z^F3![IOO?GRKL2X*3II=UMK:M.A2
MSO5!%?EZD"KD2)/;R7'KZV-TFHK$ ;O E*4T'Q@KY;O4]"OZ<P;ZK;9R9;*W
MH.)BC"EX*Y6Q4]\D>7J44JR7?,KOJKC<UHEVEI8B/M?2%9PFGOTXJ)V6]/JF
MV0[85$+].T%9;D8GCY8SE35+9\N53)HK*%"XSCNT<^B9/,V@WZ)N!5U<((V-
MZIY+U!<6?.FF*Z#IU:[?5=4!W];B:1&Z^+1QS1:NB@UBS![%8:A;[QH> _5:
M%-G;*40T7OL>Z)\3ARS-=%O=R$&;8'(NC@_N7;J7H&1NYWMKEJ>'OTQK&LZR
MX[S70[)_\+^=^5(AP7&).^N4@+\(JUGH0I47F( GDL#:/X._H<IWQ&E@I9.@
MK,TO?_CQ)W[&'U[^U)DK/=E XB@*4O8FM1=D^9<<$BD(GIS!&.LLN)8-1_K@
M.N\!C3$/B*._>E7 ?]@W1^"F4T_(J+0U?N4#&'>:&=XQF)&+GWUFL.^%9/SR
MTT$R_N<%R?B4E_NC(+G@ZDPBY*F-"H3C)#A+[2,Q?#KNW^TY?^JCH3*%<NK,
M#(6:-X-PRA2NFVAA6UZ)IT)$9=REF<O"+/ =DU,X[[GVY7-*P,P\C22,FH'+
MO!".G6!/,$;:R_WAY!ZSCDH^0OE?5,YA(%)_LV[+.X[%_5 M*:\PR%;4E37<
MR&Y;A.$X9[@QQEVO"0MWY#&A9\<W3]PTVS5?4V+^)K'5Z&6RR*+93TR,5?@E
MNN"F052WUHMMU?>@IEU%UT\:"EKBNH!*J03I--A?XQ&I9!LR4UU5_RN^36+'
MJ)!?Y& EB*^U!'7N;;.--Q.X6QS8FE_YX;BDAH0!?H 1&O3^Z]Z"N\'T&HK4
M3Z% ^XAF/WOX, 1T>(U55<;&ZF=:HCVT>=9"%DS=T.1/>_WAT>MU$+<Y@EQZ
MJA%6C1WH,3.1*+3YP)(("L1G4ZDVSMM0S<1?R6ZB=)-IGB^NR"/CWP H, $!
MN(5D21P1])8<[2V_EY:.YQVQFE&<><E)?;1W]IT(1OC$E#5',:,A%<HYO^)2
MFHZZV_5/:3M<-!RK7C5N51X<=J50RB05EIM(B(79=/ 403E Q::56"SV):/>
M6BV!Q*M-CC815Y4MR<=@?4H7@:U-;AD<$#9Q^2K&Z37"H+,M@TP@X2%978SQ
M^-!18%:Y+@]]DM6 .3,E#V^R@_8+KD4G-3X;&?EA0EC?H"*=I\!@HC[O7T *
MV@SPM6TZ!K^/6]^#3UNB6I6H*G+U%"4^=\)!!R$:Q\EQ,<:/B1$S5N6!T.R$
MKF&FP@=7-N/:+ 8\_ALMZ'9 GU(5I 1:<"R99MIJBTPJ0 9"'&M&])\GH5QK
MK+NY6[1,6.E]G_TF_H+]=V!]X@,LVN,6C$$^B0H1;'$SS+F['#T?K2GMW[XV
M,U&I!RU0T0Q.ZP;6?7O*.KC;\K@6\J"C^*,C%8QIFE/D. ,^DZI*AZ0]C'Z:
MJ]9+T/IIX0O*Y6[J Z48F?+&=TX;.>%T\$ 0]#MB<V"-TT),?T'2M!P262YY
M/K=N)$:$D/B)>7C17>^I>[7&-<4]06R,58A!>8>>:.BHQOB\[D2OSKU3KBII
MCQ+K=@/AJ&2S245!.!Z]"$EZ\)=O7N,JQ-+M:T(#<1.L243%%(<0Y('^ZVMW
MJ[(3]9!]5RJE2QSP7C"<+)9&20?EG%2&6P3Z_OUA&0&%@0):R*Z:"L]HTZP)
M"D0N![,O3AI"3A70_UVW=6)Y&M!""@K'+>K\%05,46.NCV<^9H9G?A'H<XLC
MY7']6C4'8BSXUP45_BBN/-7H&/\HC0IXZ>2M#ZRK6-0D$S(RK3"2*D"3P1"F
MS^,I<\:L>$(6EG$=47J"EWQNA>"D;IHC(]:78$^XK1NO;:@KMI-[2F6%=W=R
M\X7(&H*_/CY)+O^!GHCHBY/D=>YX^(Q#EOHQ1X-21$7*#W&$E 4*Z7=A7>Y(
M/K(@TTW_$=@7 :+(EJ2A/]L0@$_BB/Q,$]HSMWN!1[V^Z5T)"RDMAX !#*##
M.R#LMOPY*!*;4%C.[^<_1@-_':U>Q0WAB1*'DE$Q5FKV_(&R<!P!2)7GBZ,X
M<MF?4G9ENQNRQ8+.1DI55#&C4O9.4DY(;QTU5=<,%XAC%EM7&Y'H+DGQKV.L
M)&=R)3TF>J+W\W$'7]+/WWO;D=EVTNZB)4K5A *I,A=?Y6TQ#QBA+<<XS"4.
MZC[HEX]2H;9=*M^[='!^1-!:UFV7Y39%C7/D^ C>];A/6IYQRZP<1$W-,!/S
MI$ )=0LJ%_%>=OJ?(<7STYJD#7%:SZB70WC$*^G2<%"5<+P%3+4UQ5EPB8<^
M(O9[KEWK/A:*>X 6!,RJE(I+8!:_1A/;K:62H.DI3N"D)AO")SG]DLG?/J@3
M/C]:$8P/W05^!HJL\J&%UWF)84A#<N^>S.!U*I?ED<3D/\<=J&#/(7(ZWXH"
MH>^FA9TT_D)%RK1Q=0K*VWC428R8G?GB2F7N ^%2?(NPJB+R5X.)(Z;P,HM3
MKCQC=X:*LN_/RBMK/32_Y2*[I0P#:<1JSRHA>9PD])."DZT\#T9UXCDY2 ,7
M<$C40[N-7D(^X<P[>/9QPMG'$2!]WU>[0V\,;6AQA1]*T!;DI#EYY&PP(IL=
M<<USY6V@R"RD@D<"OKO'@]0,%9&IIFA9='2S4<Z:==40N6,=IVP[ _C44KO>
M'ZOR)M^SC.Y"B8:_^".!V?_)=;KI3P)JX5F3.H'W]SH?[!U"() !:IB2'-QL
M\H&.6LTU2EPM7EA98'OBR'_4M1+FU,\D4YPY_GAAY&F2XR><)PT4C#:;9X#
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M"$;GDA+V<<$F8(>DFXE_)"TY^/#L%= HB\)(O">S_E&H'[]!1#;K^2>9?HK
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MH<B"7D;HM]"(+*J%@>@KUR>-K<1C 0.W8M?7#[R5M4+L*X[^TWZ:M05F8L+
M]N!-# F35(V[&+X?!]5/T6^WV#:KLA^&'R6U_5,\"IT\2*%P;7H#!.BL#=3=
ME5HA6B826IZL)T2W9&.]/&E,',...-):Q;MNV:?$[P+_;H TC9[ %H$33GE
M6BLZC[/$Y<06SP#TTZL$SJDWMSR#@3FG.?U8 :MD3._C>\R^927#0)!9ZKZ<
M"*:I9Z!EPAY_^2#Y W7YF7&E1"[CY7F:H=1;X#Q5ZYE)7K'D/P39A;T@4+O-
M< 7;:"A,*NOML:UFH(XSR6D9R208WEO$M.[U5+SX4Q_<G_I'V7&GF#L<45MP
MC8W[<B=)#HY[K[6=$1S%;$B9,*%'ZA-NQWYFC2^/]7:-2T)FZ'KO3[V@V29/
MHJJYM2$EU03:\K) /A @XL^?#B#B;Q= Q%->[H^I)F!*Z)Y@+V4RW%G'/2!Z
MKFHI9% AM0!E]3_'NJNM]*328"H!_^A4 X\R9T^QXOX-Z3MV%=)) V2DI/>X
M$X4<O\9B"0D6Q#WWDIBBV#I1X$5_[CAG2C^Z;IL[M!*'T2DWI@H;5)ZQE%HE
MT$Q+2/X %9Y*TJ7CUI'1,"F&T>X:)Q3 -UFHA'*ZC?80G7RQ,CY65L2MBA21
M)NSK:#23I3-U-D4/*&LNEVP#._0;RG.[+>A@Y)([_AFH;AJV)OG=/K34R-R(
MPJB8USG:+*3]XCD@]"4+)Q!-^5PC&:O6CBN YOEP;+MCI7J=4GM*B6>;^O<;
MFT]EFHQYV2-&K%D1P69*P^[Y,7+C]G2*$URPE ]='Y'PX4I%%\/F&)66Z&9W
M>CDT.=?@)'/9XGOU+.E"O.2!B,YBPC12/+,24H>CZK-[:K.%K6PJ>""H1<Q%
MM5BT&?&T)^M]Y!9[) E'N^(/OR7*.,9X2U\7!T4DQ2@0K1U%N)2K<'CT&$D=
MV[T: N8UU^(XR8QOMU[S(PW6TQ<&"=72<Z9&N@=M2GL '^NA7BKB(6=_Q95/
M'D,1O) 'O8UE7 +4)>L[.C92W]Y6MV4RSKDVK2Q2;<A*HFH26^X?T/H5)EN_
MM-%3FK\>*\;XP"?;4_*Y_DF)'5H))*OF<@EXZ^"9=NR)!MI@9=+$ PD"#@\7
MV63E'2:XYSWO#P;M8.;]'7H,]8[B5YSQ@(K8"I ;>P(-IF1,<,RIDO'<O;%)
M\_P7DB#L= 17B&9C8R($FOU#YX)D!;'Q'0?BA)C% ZYB(O#ZN%41;).[*=8D
MU/D'1^?)CK3RF+V"$@?[/LD5+BF^UT#?R$C2+DWIQ^4I"(<-VF (AN>T+ZK!
MBQC6:J<H&J4CLQ&(2+*&\]!'J@0360J3J-^2#X9'(1$X8:J2)DQ<K!AZ:TH#
M.SSFJOGVLME<1RASM:,,J\5Y;%^S@ ,53Q0 GX[F A$]CRO$[Y.L[^"@!8;'
MH"MLKF^J,-Z>5GNUS9*06K/K1"\I9ZJ Y]83;I^E3N-)(_2V.C5!IX:+.M6O
M<>6L>%<I9P_(?.Q_>+7)/2MY7:.MHNDG2J''VPB(HFG>+=#>2LEOIB3J6=$B
M.A^$W[6Z-<$O=G"J>(98)W0T39=SY5% /:/7R0Q!4O ]5]ELALQ<%%$0"P*!
M1"?B$8:)J0C&\+Y!TZ=(K3=;.:_$DE2$.!!Q;7]HW57#B$L;XS8^C+(QL!X:
M+G53'P9Y"![2\()KI1'HM4B9\#-#5S>S^7+5#'^4]DJR/!ZW,6%G<MPXPI&Z
M"^_CU$U548OSKEXWT^9_\?4>';_1A[I+G2<^4LVB*W$!-2.&X :L6HW6X[M>
M=J3[*^(I9E*28.B[7"LCOWPH]08%=8+S()) B>U.Q7G0\4=D-O'H'U3P<5!P
MLX*<!!U5.#+4J#_<CIWP^Y1]$(7*- N>U^1A0K3,IUUQ))O!7@KGZ HMG"9G
M-D/L!>W]W8(/,W55?%S,? [PP?P-(.:\<317XHYLXGO!2T8W"WZ!@+_).+V7
M\4N="UI#6@,Q3.R:8G)YN.$-':G*7*1ISR\+&@<<K\Y8A/LH00:V(N>TR"5#
M%7;@L)C:$3"F<V'KRC#G@)!:IQ:^%G1.X8*OK2#LW7W_9G)DC;SWP8J0@\HR
M=HZID1^;%@8I@S( J=P[&6ICP-3MX.3%W;6[<LMHGF+D+KNC4KY5[IV.D)IX
MFB#@B>CP;D[,U:=LD'P04KT]-;&I5ADV8^X^NO>_S A"+M;^@X_UV[H['$E\
M.^G="AL58RC7TRYW6UV38MML)LD+=9IY,MR0"QO_5X9DT&2R8(4%+=I;7MA=
M8]!$ O97K*AGTOXF;A2AA[NO*3"2W;'VG0,FYI';Y)"!M QQO4 9?#+NW+A1
MPHI'TU$SF8*;BS[/<.NS?)WB6TX%+N5QP[B-U$?!;ML,+M''">PVH"/5_*F;
MQ:\E@J9CK6%'%#<PMQ3%?:&* !(L1U7R_YGQ45^[6OS:U!354@)9V!2DWC(]
M:Y)-F0SHW.K3S,?70=\>(CJ1*;2!IC"VROS5"^3@ T$._N.3@1P\_^(".7C*
MR_TQ(0>Y9)6DB?2$P,FTVI;USG1G%6R*EE7YZ"'MFKDC-$F9'%BHB/L@O)Z"
MYA>/,UT]L*K*99<2BD\+&O#T00WS>>QM?(O=JCQ83^FR;AR&/ [DV!'?8W0Q
MB-22^.XKTE/5K#%<(D+"UH=MC)?:$\+GNLL;KF( )?$SY69!A\T'<O1+B%O0
M-<ZC,'PLX9>EI !ULKU7:_T@EE),0XPMI<_8-=>-1-0<(U5\7O41)[N5E%C^
M++2CWF2BLMP+YBHH%,H6P0(1J*3R7FXK9:QZ ,]5FA N +EAG'+5NB5]#Z@%
M,A,+I_@9IG,/%&UY"G436UVBAWDE>7HIV2*\G8V\-5@3>C9UN,VWXRD-3 8\
MJ#V@3V]R(8O!^ZRZNKXJ)JUEDR.U&>C^N<J>^DDP)[YI SO6.G<% REH4TEI
M/@88QS:7\T)G.S>$6X?P+:&YD9'H^^1%2J L.M_XZKOJY%1?,2E,,&MH(-I,
M59LX_R7'HOWSC'[0KO4[D;ZVC-.26J&S-D_7@+@\:<- HGMMV;%.\/&K\-:U
M50U;MEVNN(NFH[0+254/7,K5;W/F*('4&2[CVCW0_WZG!--FV 0QX%8G]BQ#
M2YQJ[F@=)<Y5RB!,!!DU 9)3[XCP.)?Z\N@::;SOE:=VA<"VI% 8I81+UN&#
MC_5E6IW2P:$!MB2+[FCV^>"H/)]2SJVS:@ZGA'09,TK8 @8'MO;$#JT/[^-,
M8VK2V#H'SLM0C5@F\BX/;A3DSA*VA;PBZ:1JWBGR3\ZDD%I,9+3R&V\%G=*X
M?$@'$Y^O KC3Z62PEUF=LW-D $/7P%DP/F#*;",[4K&X39GZH\>-T2?!22:&
MQL&QF9?3]/EK:J>>;L\N6"VH8>YI@5YRXUO?'BMW02.2E)GB%G!6X6FK#9"7
MGO^HTM90G,UD<0)7XD$$Z7KX>FY+5Z+N:[3?=ZFXF">)%]*0E%WD:O&613E%
M'#,]NBWQ;,:#+KT'S7;J$Q)" 6X9T3(^WPG$ =5\&[PFLGA"6[0B8AT&[4C-
M+S8]<+#\=$<TCP]1'#RJ^ IC@-UQC]XKZ<,JT8GE@"#.]S/WAC;,"I3 DFC"
M3W%5/EIF'1.OZ3(KU\XG4GE7MFN&BNX9BRM^5K(>TJ1X5SFB82NSI.AK>X*4
M$TWNY53YX&-5%H0Y9WF"GD\!_XD(5R1YV7'N>\I(T4+%#I&,HQE$V1H@8Y"R
M_XN]^A9!-V&I[5.E'@31*=I%^R$ITF1)+=97X=W$IF_;DCV49L/$^D;W4;C'
M,G 3#JGPP&:^U-DNX2D_ZK:Y(R;P6^G*9*&Y_9IV1'PD/+I[@BZC)>:&7?ME
MR'YI^G.;BO1(MFS5NKSY,3U@FG78P6(01\FAZOCYM:C' UA5?)1AP,%-N:-X
M454N?B@2'&YHXB0:4RL)8T&A+M-6<QG9;F(\%B2*;5?.GP2.-UV3>OHV==OU
M8,SGQ#5&R5HAJUXL/>.A+A;C,;DJ< :/H)^6'_ NU7GT])#"H?#-'88#0KE-
M/)WQ(9_5C;/R2%5EG*)3+!$XDRTL961K=(UNZ@/_=-HZTI3N]M2E :1C,!K(
M!GJ$=N0AM*.E3<6T#I /9"8;Y?S)/60&<S'X7B-SA&\5L\\0GQLL,W4^B.[W
MBCNF71!'3>Q5C(<W'/+.3P37)<'0)IYE/'EK?BO.!_=(7#]J/OJI/S9-DN51
M"-Z:3GX_(L&&IM[ZB?D=PF74V%@M'Q,;S>YEFS^68T !1Q&6Z72#^7;I,Y:L
M,46?6Y)5M7<(CH;]7OF*P()Z7[+$(BY./KES,@P1Y^=LBB+@T=$$0@BXY5V6
M[YDA3K#T)1W,T"GEA%+B4@C"XQ0-5%R%I\,@KY0>P@W_LD@_9I%)JT82WL/
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MJF9<FW1R&X8NJ$F_DT1=!0;B:(CJ]9&(VV@U%&>60S&Q'E *TSKG])J8F?.
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M0(DFA*@5R .&6AJ=-[WX9K:FP?=!$8)*YV6BF/?[8;E4G2ISS.46C0+HXV4
M/WE?QLF!F]JP;1P'Y_41(!-/1J-!2(+M*4';_;:C>E<BX?KM4+=6Q"XG+EP$
MKP1S+B(:J@V*_-:E\^'?T55H0=" XMI1$"B(IZ+2$_=HE?MR>^KRY@8TJ_,*
M5.L9+Y"4<8W&= (-Q] 6[5[+%]OX"J4>[E4O#> -8K\B[H(69]==-0KJE#U$
MAQA-,/):@ > [V9&[XBS"-K]E9T-YRK898Q'2\56=6Y+-IG$M4$))X&-;D^$
MC%<;[R<[%N$VV;SFE'&@/U=B3!:=W$_TLPBR@U_175L3,;1CRUE E"SY;^X(
ML5*TKRS?U!TAKJ\6KX]3W3.9J5']K_$#T&J;FGZELS [-JBY2_K"F[D!-Z@W
M.':V*_J.YFAN14R8T"# EB&26W^LTS.QC) ]8$Y51IV)AH);^9@5GL><6E&F
M,6V8 )H]22BE9/#,.J6Y=<OTCKE(H,AN]QY/,PW#N2-)XQ[H"YV0=*8,-[!H
M0U"_)&BTIP%6]Y\03\&^/B5_(JNP*%<8F+9F "$SJTI6C'J:#.I$X_.*.,Y[
M<D2]\PEZ+P893B4JSYM91$\:&^;%";IP?SH0\FC+#M*!^I:[&P ":!A?_I6O
MMXNS=!-_@"X6 <FPV4>C<SX0U\@<URI5PJ$HMR%CN2VOB1P/T$YF;%$Z-94'
MGDDY"AT+X\8;('4,+Y-/!\Z+Q,;C[-6XA4)Y<B;,3E<8,19!'!3D/-5JXB"-
MX?4$P3X&C0&GC'C.Y4,?%N<C##/$^>-IX,W]^1THQ8.K4F26U!$@J4@692'F
MFE*:#.KJ!6<\::-41E*/>]Y[F)Y@1!=P,5&/S10W0T^D50/S2KW<6]/F:F^>
M$SD7UAMSZ3\MW_Y)1R7GJ0!S6@RF\QO*8?<S$M3J^E9H[<O>_Z1,0#!*2L+H
M[6TU+32=OFJ>Z=\D.46NN/.0]I#;913JH6K3>F3UV0E+EN??XD_-W)#UD77=
M5J!BY7*3(Z^_DD9Q6?!KT;E<))U+4<;:;[9T5L;?4P.LE[:T FF]/%HUE 24
MJI9QB E52 ^WIJFQI^+X@:$.G?"EX7A&F94;:O1/BBCLE(Z_V=ZF+A#?_)5(
M2[$@N!DC9%G((GNFI-0Z9B;.[B1W&>:Y6$ RH_E5JGXW5;8$S*AH[BXDF3$6
MATSPO:O%/YRL#*_TC/R;5&+B\+@@X\S2A($;:EG^R1NXJ_!B&Z=I+ZYVL<AZ
M)P3?2 .H1!^$FEF49ZV37=<R-;(+SASIBX(&9L1'()T<D'S,651R99 1#="A
M1+/)F/E'"9"(=E@%!>YAD!5NA3 4M.<# '-BZJ%'(H<[?]VKQ5M<D$Q'CQ/H
M/8# (0&!'Y]O9C'/-Q,ROAFWPLRD7KR7#S[6Z#R'D>(KTX039&<_SC<,2&K'
MA]R>A9H4 I*1KSM.$=?JD^IG!3O2E@M)8\H0S]CYC0!$AGLH3S40:&3(V"&W
M?;69/9%#VHY#2:/D=<<!GJ4<X5/G-%3\4F!0!FP2LB\7QQ0,)A\$-[RU)/D@
M'_A0!3FP<;_7P[L"IHHH13@+Q.X>IOA^ 5Q_*,#U7S\=P/57%\#U4U[NCQ(^
M,JPZ,)&OY8++=5P<9:_EZ%XICR:KPO/ZH*RPL;"K)14"JHY?PNV/A3WB<U')
M513>0,@=NB1ZUJ93L-POO=TNAJ@E3K[&NU#S5UFO.2;<4ZZ4I4BS:G("C MA
MWO84GG_!-SH!9P__AJAKXO]M:PK=I_HI#46A,)URJ]1!0&72JKN*YIP117$*
M2;M0^Q?):U F#F-J"#0)?I!%JGPEX%T-WJ]HUVE".IW Y.*/<H5G='ZU@[O@
MANX4W?)0J*D-TY=+M41'8"_(:.74-OWKM"/%<?%56TPX,:<TX'F7?&L,3WZH
M;X7$(=^5P61!M'+IHO3XFBE"%BEFIT\L'%OQ&OOXG_&C%S9'.JV:49V8)D ,
M L_"@H\;L)+>-&T/Q '%LG,_EN)QPH^OP9RD87Z1\\\EF5ICJVG[33RFFX6@
M+H)2M1V%-<*)7R7W%7[SNM(\_Z0TN?F5FO2FID 4UU;&4'L)RQX-$QR#,U=X
ML/>.5Z4@Q+&259ZCI/HV*EZB*/JTSH&G>X*=B:R934EJ;;(A$SK?:M,NZX5=
MG,O-&N62Y(B$>V!-,+R,:OH$#04&4\KF7I0KT@8EWF/81,;1<*:)W">N2>K)
MY\N+FWK//5A8@_9+1P20E^?D;&+:G+ Z=M'#AFRAHUXFI.#JI@$1EL-V()KT
M_-->I&E0!%R\PE%-Z6!BKF&BGF8/L1W3*??YA,!$!$R!XP2HW'8S;O!CIQCW
MNZ0+ D%SE]<R*?,!$4N6+DA;V+T=22QS[S9Q^M3=17CLD6S)F[I[UX4W:;52
M\3C^+T.,XQK[&=;T)[:F3\?8Q$?3-_&$ALQUT]0AJ#E'WB5PV=JVE!Y6,8+Q
MU93736H0I:WS^@#[\,+LI23YX5@=]YIX,YQQREEJT=WN&/P=6=55)=UF?Y./
M4E%;7LT@:QZTEI@1W@B0Y*=TQCW=TWERW24+_0?6'F<0LK,!)!HIZY#D#%?E
M@>%EPF@Z3"=?7.M'(%;/-G*8W\@*1')U2"<CGLN2K[5Z2'_3WER".%%/_FVM
MI10DVQLE,$N,,L$$48?5%'-8O$@J[!&O7K"VL)<Y_ULX)T0VLZ+(>$L<9]3X
M4;7PK9@/B6P=BJ(L<<*?<>#IBM;FI1)QH"[YY)W&E8V_RGYI9D&V)L+%!2&[
M$I!6C"6M0#0\?1]VD\7WM.+XD*A.!#H$9$V_:0Y:S"U7#*B:$PWE$@T[;Y!F
MB''N4;#2T]N>N;H3. "9)@+VKLYTH,@YI9TP0) +XU[2X_-O(/ ;.'<B52YP
MR)G^N7N+YQ[#C:;G&JL"?RL&EQTM(P6SA2SVL!<V>)E<0>>7H'Q5J5!^5K59
M(7L#@B.9WH+*Q,<-H1E)0E:1N"V8BS0/QFF+ 131152"E]Z _ GQ0=RNY19!
M=)KCTKD4KT>3DY(Q%%$8X9B^36N*,L<C;[:?G@)=KWFT'[^_0V;34EW#1\*J
M"?P] ITCSZ<ZV<>#RNF<QR5LJW+M(JP$%S'!='>.35\JFA')/B3%I%R_MFR7
M=<_+MM!E[L5TEIRF?89*\RX1<*'62U%6?5L)LIOKFF*HYM@8PG1J<\![EK]:
M#?-,@158?5E^>(T,!9?FQJS([42D2RW25H$Y4EGUCX)H^3\SE$GIW#%$T!OG
M(H8?W#(:ENI66@9&-0[?/@"M!F6:11-M.K?2$W%;-@&\EL-$I%I\V P3J6()
MB/A^FIU F<N>81P\JOTE+_AH,K*TS'0'BA868Z8.VQ)'6P6L$)6N$B-M<R ?
M]+BOE;*GVM_PP4]&S7FA@J@X:$>_/]$.]8%/M+C%-<.<P>':B8ZA[.*V(;9R
MW!]%;56-?5MQ]R@MZF6UKS:96GQVX!5)_VO>B0,X.\G:<@:I 7F@)N,\L!II
MG52SB5LT>EF9 1+,6[0YU])JQL2?A*/:5V!,)K:9_?4SVC+*NPVP.S3:"FFK
MH8ZDUDU*/(J//;^.ZK>:ZQ5=WZS>W33;M>BY1N^J/1X8&#, 2AF$ZVDLXZ>T
MY03X"T<A4^EQ92U""HH!Y)8&L"_3'LS5Y]BQ@?$DUEEI_$CTF.9"1#L,CY.7
M 0O>L4:8T0JUYL..(%IG?:M16U4RW28HE U(2K#NC"$:Y#@%!&Y -\.Q4Y8&
M]MB[N(4]4HB@H\=610.NP3%-P-%ZCS+2_7H*WHCDQW9(8\6#Q4==570*\89>
M^I&+R[>DG!"%:.+HD$[V]=[[SREG>P1= N>/[\ P3AXNDZCS<6O^5^"X/S-2
M623(/EBY:ZC8JK@SB /!>>EBN-]Y6+%?.M:MET\EXKH>ZL$658DRBF*SC!0!
M9.58;7Z KG(\_-C=58X4*XXGTHH-:](316D65J=^V-_X'A,.'<'0J^NFIXWB
M6&KXP:!$-7+1]H CR= QDUNRQ$/U;YA$KQ#NE@E5JY6,!@" 1,!AWNY41)V=
M4RXHL4?(&. 'L1EAZAEZ$)9E5],[!T=&=6#><8F':3/2L3:,"UT*8G!EA'',
MM(9]ZBJ]C,+D1GE>)5C1Y,_U5(S!PQO"^_Y-F-(55N4?3,7FV&)=&RW9-*2
MROI*5+)CU"]%<!=\X(?"!_[MT\$'_OF"#WS*R_WCU)0$B"SQ$;+] ]Y(!;I[
M5E,Z0X^B4-8=$4")1:O,=>GZX]I8_O6//<&KNZOP2L.._-)BKBT[Q-=W4?DJ
M1C G\.ZQ.X6N)^W=/?:B^KRKJAZF'<(KZZI<4VPVM,U!;;/VC";\$]S4VQ)Z
M9H/0K9HQW9?RU,<+.G"<Q[?-:1B_@&D]U'MVN.4+DGTV/]-GKM".U2$!ITG+
M052B71D[XHM LB]^O><NNR*\?/,:S8R\" U-%R\0__SRQ]=\R23+3>N<FB<
M):&-0QOP#VXF27N/$3'PRN!E8UOGU9;1UC,&N!6DZ1,,^$&#X/[[.^-IC7>A
MW2HXGE((Y]G?IKJ%^4L#-)^J/7&:EPI&G U,UTW#Q*P5Y#LJ@E%89H1GF9_R
M@0_@!$0L>T!-E&5?NE2@5C<?^FJ0[TN96QHV942XC0Q=_*K35$$I*\X9EJB
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MJ2'F/?MYU*'PP+:SP5M(#1"%\R)NZFM&BG:,W4LS*'6B^W24+R"YCTW[^IW
MH!<_0K,M?OE':HDBB_-#V]SUK,']&N$6?KP8<,9^(UONZ>1SGBQ%[*M]0"6!
MVPD=Z+3V/$(HJ>:MB(+_80B\!%;7K:"(.@!5>1LV[76Y-YJ#E%WUM(G./:+R
MY$Z72T\"2]=8,Y?4Y,=+3:;$O'M)'J?#KT3#[$3R,6J"X-7@902]@A52ZO&]
M@YM<+E;2\46(-7_.9.<+!4%##8K5C61$W=53FM3]T4?1F^C2M-*KX>!KT0F/
MGBC^'JROZVKQLPKH+89GMAS//"F<;4""U:'5TF["(;WSG6-T33HRBS10>60[
MY(/E8'@/GKKH-G:%YQ)SN13AJ'%XX%5[K'OIWBR=\F*\SV2>YUO^(5/V,D0Y
MC25GR0%H4+[C5HN\;=<+VU?E#CE$KG=?,Z+1[_;28 6I <;/LY_@\A0&.6)#
M@8(3$B\*]7.:HLZY!0ZBP'F ]YN;I[&)GY@+P25"*GR1NX>H)N5Z\=;>5:=%
MO@G2RH@_0CA#2C/9]SQ3>=X1,R050^Z$8B%"J<H8)M[^'#?/F9/3P@>E$[P<
M9!_O(*,77PXB%C(,TV F3FZ:-4NIO^B%T(F1JE[+JMJG%@QO:Y?C)2Q-ZXE3
MN<S)C-U)53JVP:Q2DUBF])0%AQ=T.<EWXL:\U&U ]].FMQ@2QFVR#3L@S+NQ
M:2Z&@B$IE(LVVU@>I^RY7I/V1*(JYA8S=@0\MW3<<LC34Y"+R90:J!4I!*R=
M-K&"LNN]UB8&14";!]?G]^B2MD\*T/%!\$M??CKXI?^\X)>>\G+_T#WAYB2$
MS$F8\@[X-+".Y+;V0F[J(_C"UY!3'S('1O7C^JF-5Y3\7G33,)THL;T;":4U
M9<T>$<E$DH5-@9I 0W>':LU.L^30/4A 3Z\B XI.DQDVS%!^*R%"5T%,#2",
M,9OX>_E..1R:>X[IW4P\*]TY?TPE'#$=*\49$&,C.O"DTU?*[ZJ 2$U6I9.Q
M4@<AQ;W4L'U;KX_$V"-L)]8486PX9!C6/9*OW;MZNW4LHQPS&?O\<%:L%"Q!
M'IVQ,[W#PQ>".L@(9?#2T>O&F]U065L5Q4W.,L;$S5:;P?9$@^JR-TN/4:/?
M%QP^%:K !@AZ?"/B#W15R%WX*8K.:Y.@]/R_7&>(DUVU),EW'QNIZ_S8.':"
M%!2@ D&;U$U])J,IF6N)*NAUS;A'Z6DP><=]C3Y4"\+-X_.<7Y<(\M$[M170
M!DK<;6_MMN7ZMNY0 TLV>.[=IN\*BW%'7;D4-Q+_PU'$\C+%(5A#D@*<3EO=
MRP&;K!RK84P/WF@)V*ZA1B7_)@M/UI%9PXX#%@[77*?D/'P+/$BK-S@-NIC5
MJ=8RL*$2O<B?= Z:43\R0^,(S>I#)8F_7?"-T,GP2"[J'AP9? +BKY*)U*GC
M(WAI-OJRV1Y1/37+>V))<,P+:1K*[183C54<55>RD0 9XR0KT%8$H"18EU9G
M75NMR\NYLV]YC''$GEF4!,"'BA+]?^IGJR_LFA]MY+][92BQ]<B%F8.=C)>0
M$ 0QLB5X#/^0.7XH+,-<@)(G9$B!%"23 A*1TA"_TMDRMA(3X!@"6WZ81.YI
MUYH#TYV#4"90[)[P''KM,2N<AP:.!YK1!_ULQ+5=13#.&:^24_0GHVPZQM/!
M>,JYT)&P@>:FT7!OR_;$T+GIIKND/2+7I&^6+9_+Y:82($E%_KJ2H'%')AHQ
MI]C^IT@Y'48>E1T2$:I7DO<-\?B.WUT>ST,'DD0M\V]).[&ITM5*3/GK,1J@
MM> $STF0Y?1T(0-%$?9K+_A46#Q=WWQ6\JMW*R>C'U0()  J1.#?ZQK6PU$9
M^K5VE#9A\!HQ%'SH3Q,897[EZ^7)07=7MRA./Y^"4"4N/L*>!.Z$D=69<2/-
M(-#(W$=/AJ V0\:D[N'V@TO:<O@$=_C@94T?+$-F!SZ1N#.6WK8%^EZQ 5W<
M0C\RV//1X2Q_*\"G2DPFDG@ :^H8.:=ODIBOA$@2X>@9B1+:[D1CHG>VS7?Q
ME1[15R)>YQW#>#=VI)AN%)LV>B.KLNO]=]P1*LCY1C" 8%3K)2IG0;J-0.C9
M5M0.Y*DZ:9+8X>TMMW.5U1$/)IDZH#JBSZ^1=,OV,.EI/"W_Y&E[5A-+)RTM
MG(^\8-):(J?&63(/X\@('RC$C%]=EH+1IW:0W2'!W=-ML*J"+@^_+'51<@2;
M#RR-R$O-=\JO;C2#\@!BZ_,#;'X;7(7O'K8%&%.,A"S=^OSDO>^."*HP\SJ%
MIL2%DJ9_)QU^_2 -X3+$./TU#ZJ?C5*ACH1M</DP'P$]A57^E.P[[4A%Y:IW
M8W5?%^R [-D#XP:+M&=]J99H3C5Q:0OW>J;[IY!4/251JW4@G[:RY*6X.T76
M&Y:4*I"PHE(1.Q'U;DF4_9:;NDNJ7-25*AE9=:+%D>!;E;V-_*2J' -$6(S<
M6^H&0'="W/GLXDI#6)=9))2P;5,6TFNU%O2XM3%1SFNFWZ[NPKYLX]9#4$#D
M^94VFLO4]"21QBPKS4&ZES <_ADN[O+!,5JX.74Q7HC76MTT-,G QNM%$I>[
M1X<$I3_/'D_7"J(_1IEI#)1ZQ_4LMYZM2Q7[ U6QGW\Z5>R_7*K83WFY/UX<
MHM70(E.Q<6(7A:\\%-[N#X1M#%F4:^ 4"]:TX=;1Q&>$A%"\G:IY5_MK>LN4
M7:(""BO86($:$-E#U68$W<E=HBK+H+';G0>F("+'6PJ:+['*QP7?41]6QWE4
M3:&PSY AQ1]O+89[U^)"(*#22IUSNO^N=9I@@N6Z@6M&P&9F_?)*3='% M?:
M\MA3S4,=HNT=T7+%:>.NP2'A G0^_%"X;8ITBH2@1E'9!'LLN>9,V7" ')!F
MITR1=#MJHU?=Z0.</+XU,>O"9^3N1"C/[YG-&8VG# I<2X*,I%X;TEMETC9+
M34&O?LCJF;TPQ63SS*J2 %VOO*/&1 I^JMW.2-_*\SHB]"M'!'^IO3_RT2(9
M:WJCD$A@=$G"95C7 OSPAO$TO@T46S4C+2JLZ)"TF)HV-PJ>\4@@4"J@WO+-
MSDO/%@M6H*Y9N.48EWR;I%:H\90D"E2'90F58H\V/>XE_/B7B!^(10@E1_/$
M[LW@H8+;6&,$?UP-J@WQ\E4OS.OQZ3:\Y44?H3!+R6-I%,UBGWNR@=0ZF2JF
M0:@H%"XF<4B1!2>DOF3$%T!J"7)MV3+>/G6R>EJ;45O%Y8S]>+ 7X+RI8%8"
MM^%U]U*S^UV2U,JIS)"6L#Q#RY43% X*K3+%)=(#:R?\/(7I>F%5%XQ2W! 5
M N%@X@*K:$.]X\0$GV&%G@&%T*H68"YH9%/@"KNZ%WK:&_(;/I-QH)W';OZY
MWRI%ME'DQ\0, A%UWA?)81QLF,D*B9)OQT&V* 8E4(%=F'?@8'CI4V?Z/K\<
M-A]\K-]6W:'N65W;4J2EFB$SVKNJ[$#T0D9P3UX,D0$P<1^<'SF*V!7% A?,
MIKV](H$1ZS9EJ:6&)Q6;(%1 U+*(XNN.:FD=E^#2&:CM#9Q75Z*$!QR5LFV;
MM*E'A ,X-,/XE/S,(=Q $2C"13-25I\7XTO+8;JPPY2WF"<H,:@E]DH8G,OD
MA-F3M+E$P.UQ2V9$/%QD&];B4/+#K,L=>BUELO2TX<R9C,Q_0OX][A6#R^U&
MB(2*Q9Z8-?C HE(7\'SQ-_&X[G;1,I8MSW&U)1V%W7%OF49RT&F+MY@E<33S
M)AM;;^848'2.GR/(\/?:U"D^[?(T#(#F@Q[+_!NM61S;GVR>!@IA1-1!@UB=
MEE7[K.S[<O6NX_>Y/-'4U"O"8@]_QH< .4))?(EK$IA36J=MR8Z+T'&HFE4O
M*/3">S8%TVN52M<19[^KT!S$RJKL"?$;)O\(,,IH6"\F\X./]6VSH[(OC$(,
MV32<U7*?E=T&X,P4]68K:=B]0()B@%KRJ^87_ SJAT*9R'>.IB=D]-4BO"6<
M)71K)?_B$&X'G#N#43=QT0K>85UM0.OEH^UOA?@&\T#,6[*I>7_LRE_%I\95
MBG G)?.'N$.%@FUS<U4NXJEP?1/WM42]B5!E8IX(VTI*2H#69I,9IDEBQ+EV
M^T^H&5T?NS?#_#P>'\O\M.28;!F%;" G0<TVS=IZ,] T<A5>[5T_?L&T07$6
MHF_6[.[02,FCYBHQF4N60-+3;WM"/J'<&L Y+EBU$C[.R*RVBL.Z9POYD]R"
M,-VQZWK]HQ32##PTX<*)BQ]M(L=>D504V!0R)TXUBMC]B1WGMY[(F:*1.I0G
MAMDP,=&VNJVEE2%1;*I2 9&SCR:*$SN^78(JA(*U3HAH^,I< =([,G$3U Z3
M](9#>TTD-DRRRACL]6H7D_K!Q_IS$YA9H.?DF<CM^IBX'3H'K-7-M&\2GD^<
MFG%9."#]V5.40J<P?8H"FN-DB O5/&3IB25M7\ADKWD5$90$TN1)-YB-6;,"
MR^7:*3V!^-)2!>P%9_M+QJ,6]OZNAWE0GW%TB>ZB=7\IVYCV!*L@3/"M^<IW
M*KG!:!X@#I:H1E-:2/*5F:($>O%H(V4,OCR5RI$Y?LMX*<YL-Q,NNWXF:'<7
M 3!_6<G<=QGJ(R>M<'EP/[]0W8FQS*7KX;%0[?%T?M96! +GL1.=">3;V74F
M3$"5-2H@(ZZZ- \(]K!]K=TP8],!_3+?7$A$CWT-K.Z^ZO'ABKIEC$ UKODC
M!SS"-X#>4"5@B5O]!H<CTSL3!H5.,&%"H;0]RPEM&R7N6[RPYR+'R)CT,MG?
MSU3]9R@2S-2 ?*G/96=S<4AI&QUO+CE)MK,2FDF=,$M2"A^Z3&#B]!N)]S*H
M8_#[A<CP(4NPDM9+-U0BM)&F)U% RN-R?8./"*UZ4C7K#P+1^.K3@6C\]0+1
M>,K+_4,7S,D.!Z5YM^1FM9Y(:T:?,:[1:NU3FB7!!+L^?9L*XC0T3L6UE=+'
M[AO']-Z+8FA7I:M3F!)\\=<8_%/3=Z[5DJK*0Q-KS?!G3SX]\$3RGHY1IE]C
M8K>X,3K1O8N^&?9)3T=0"9[RZ,3%G7P@CAYR>%GD%VF_RC5-L5/(HZS6K!$;
M#X<><K.C.8LOH3/O]RJ8VSE!7:@J6NJ)*9W4NJ*#F^/_7;6&0,?4^Q-P9/(W
MG7SI8#:OPHL4!&9528[DM63I1-RY!8YYZ_F<C3-!4(*VBA$M>9H=X0)NFNU:
MJ('&Z^=J\5;\8"KOT , VD$EQ>TIY5+2YT,N^4%U7EK67"<+']R:*U!M/LJ"
MBE&\1+&/@M#)!([N3_U[C\>W\AK320*I:WVE,5V/R1I9_'<HJ4VPKGH5$Z2'
M%+9F+__8[ EB++8JR]NI<^:O:ZOX /:6%8#!VA1N:W9X)8L?!;TC$>3DA7V-
MB5A(*O3Z3=9HQK/I#,B$]0D)7>1292X(]S^?VBR+?ZIFBW(%D!^[98/# 7I'
M".-SHTT8"NM>C %TW6U.4A-3V^.BX&<M\_CRA;P=(A13S]H(Y5W9FKP+Q?">
M\!VX=$ED8)C(<4QQCK05?Y<##KKF@(>=,Z3/D"&57+0D,/F$-3E):@/D4\4L
M:;RP]=Q:SV>X/I:D35W9L3F]"'VA1,Z_K&@FT>"8.USJ.Q9LN!]UIK84P#V7
MJC278/\1@!4;<L0^HS2:>\LG+1 T.ZT/?'[/3D8FCBJ?50LT!38@RX;:[]93
M/S22TWNV>K'0@-LIU59[Y"0XYZ:!^0:L^)),SC%WA2JP.+D5U1WB;  8JA"Z
M?QTR'@:1,A@UIJ(^B?3Z]4U\.YEV2K/WPF33Y\)G,\B-S[]>D"_$ P_N6ZMM
M2>)ZV[+>Q4$"3[K;F^R ]XF^3OE[SG'$>?]Z7"/XFHX<QF11;2!5"[JO\PI&
M&%4P_.@S8I1XP,E#)/I^RCU^[7D54:KAU_:UN)=?>R2*])S1&,DUDY43S%WC
M8E!/3%8LJ9Y6"V>IV-7V;I\;+Z^,1D[\E")='>-?=_'+G^,DB $F[).\?J$(
M[^D%%H$AJL3&:K_BG&KJ<0%3SGV2S]QF9X6O*DN)7LS>H^0X$_>/EVRC8RN5
M>1$G6 G -2!S1CLN4U+\NC?LG+L@.85>W4U;6+V?H%'O4596AEU4UP&I<EB$
M19L$!JQ*<E_P!*(PH7L %4U;)>QZ*CY8*UVB-Q"_4>"D\Z-N0+N_8X-6^8>P
M6D1S[(-52";&:_YM(6 FYM/P0QK0TXI%VE9,BZ*5! BS4DW>\;%9BS=Z6^>N
M?R#XK !K,=N7K?FX'-F^F[LG[(,5UY15@BK$158?QJ+1MIC"*.)I]1 $TOOJ
MOCU;UERA.T99)HI@U0I=BDQ(J==KG<]S+@_@;YRG >YS:+@+W:J2\?RJ1#6.
MMKUILZE+\[EX.3P3I0G-X0FQ^=2M4/]%_2WS$F36Z(:C"D-P+@"+Q4&(K72$
MSA=<]$?L/4* [\$]T6TW$5,F^N9$%0>6!!3Q^\IHC-;Q THL&H4!4::,ME>1
M[R_;0N'<%EJ,ME"1RV58@[_NZ\(/D6A,JU8X?ZS6+PY[M-\'PATIHF;O(F[R
M"*./B<T$!B5'Z>2@4I[\KSUN'476[*Q)&_NNTU3.A'D)[BB>FYKQS' ^:)C9
M!(NG)(99] N^;Y?7SLF-[ ;6*8RMT_)$YW(S0%1ZSX$3J",3-FULQX9M(,VE
MW8LA@W8EV="L.NJ;&U?M,:XM\KM6/GQCASU%< EH,H%_LERKXJ>"N>K^E[E1
M'/I\6!MWA!3EF*),_2%J.Y,(\;WZ>X5@22X*EA_/NG.B8XJ=S&E'4G/%3167
MU8V<G2!F PB-VVN=&;04Y=@X\"*%8R!KE(OM*T0=Q OCT) B9GUF/<%2"F'*
MH./E<M!^W";?J7/S=ZX?3Z5&UL_8_A;6L'?B[-$:R7=)Y(=X!JRW."'1E$09
MC!B?%(ZF0U"PT:8RD=Q-^:]X5--0D\HFTKW4)B#U!Y?2H>.FWM\V6R'/$CKP
M=!4R7IMMN=L)(9]<TS_2ZJ;:49U$W,(:I13E"6[+==V4*]&CEE\/4MJ2!V<,
M7IQU<C@X.X/]@]SRFNA_\[W,4M5(1DJ<]KO>#HY0,O:CRTU]&[44RNO4[3Q_
M? YF4T0@]^O$^WU_;WOOX*;L$7#1D\X1RLWY>1KF.5.[B44$%RC/AX+R_/G3
M@?+\[0+E><K+_;&2-1)R9236[,=LJ^NZVW(5(B'YZ7#KR]\DI,D<HNED^80;
M?7%^/E870'0[$!?' ZW<&LOK+U=OK_AQ-M6:A+?)&P$LF *H9H6F3_C&\4U+
M:-6*"'P)16_FYF^KVSK>>JD\^)VZ'VL%7[DU%!1E <>"=91?:8_I&R$=>RLP
M! 7LI)'^W +,<%I\2SS0\)>N%B]U$398DSAN/TM]@O#0VZIOU6EQ68C/)2TW
M)/KE6GC?K-X9X*@EJ0!*+&3*  3'[U326UIL""6"SL4XF)8L)>I)\.=$Z*!9
M)YUQXC*N?B-,&/F2\2?P! 625FZW.4^S5"X4?9>C[1,$6W!NU$5;#5H(I@-=
M>(4 /3@R37AQU""_I.XY;&.!T<4%P> Z6A\\*SG;M/+R 2PFNNIN%K0"$=V;
M%7 NEI )0K6A5'/R ] ,1AO#HR_ .D>9A<'7[E),-GQ )MP\67M+NGMTWWS)
MF;ST7_:UH4/>]NCQD"_+BMT(&]\;HC7&OUZL>D&3;/B_S[]X_MRX+Q4EV>5D
MX&(_XQ\77_X_<0@KRE'0(J"*!Q-B!BS#^!RG)6%"!H[V,FZM_9[KH0N^(PWP
MYWB)ET=.Z_)H_KM9=FF,U;9F!3PCX+D5X2-7=.%6$BPE,++/R0*R9GL<D04Z
M4F3'%CB4D/N@S;*C(BQ3=N^$G8&J.4#';.+.Y+&=XDVX%2'=T)HH@Y ))>,R
M\:J0\J&+?OD?#[CD(ETR+O.N%F6I\74Y,Y>,T<OX'@D1&6I<@WZ)+*>9.Y/#
M4KH3].^#HU(B$Y[9.E7='S3'7R]NFKL*'.1<N00C4QB#9>T^@$AUW+.JS.J'
M>!AP'T%*C[%EHBT!)&5:GFG-"@W-I,4T(&Z [0/WQE2>C"EL>0&D'>H]@Z=P
MKCY93T]Z2&SF)=MEF =NPMLMDL);W*=( 2-+X #5.6[94_(OX]O=U'VB#?5]
M-A?7[^/EO?P+=XBHN7<__^)1K$3?V*]-'6T*$;()#'^H46(J@-*^&:2\GS3S
MHF=PO#;Y//-_+#&J>LCCE8J[,:20?J'<Q%0.<:C?*?WC@/+$:(FB*QKWL99D
M=[MZ0ALJ%P+4)BP^UK@6Y9_)^6A,/<(:OJ3K%Z?/6A9B'$[5+<(C64E/]?_$
M&TS ?<\^ICA^)ZVQ/P'4--&IZMZU5# <2=WXM>-%I8W+[Q50+[X2L_(I2H0G
M5^0EZC91-B1C0/)<-Q0)#MC"K\+/Z20;X&]H46ZWS9T^VM"<L!8&%"V=:$!W
MBL<+ . V#$T[TCO\]=BAO8!YEJTQL @S#&4/K1@)76$#(.*E'O2H)YEH,:-*
M678W! %*>0:O9%A(]TW\\K+<PI[Q4HX>=T6550Z MZ=G0$M5:X9\B<=G7=2;
MF<N?"R(]141YRO&7%(V16R=&&+&6:&$G3H2G=-P\W8,2B$):0S<5"N#\#/MF
M_PP0A>BZ/UM&QSR:($'H*WAA_ G+X72RMC@Y\#TO,$I;--2Z_,I >2^;]J!B
M7Y^)JOCWW[YZ*7KBGX>$W],U^4H\JF6Y?\>17UJ*%M[2HG553J*[0S8!4/$#
M4X<P?P(^$3XP>7J,O4N^FXTA."CD.&Q>T,#CS9MW2L%*5W@;-T#\7TJQ;V/\
M_4T<-1G-'RG,X2G[\HN"8M>O>+OI7+VIJ,$#2<E.6^D6E&4@K8@U@_QDLA>:
MI3$YOAW1X]W%/TMV@N,@$O9MML"Q[V@RW#PD(P)"F/@/BF&9)(;DX*<>XRK\
MEXO#^.G5Y^#$"<ZDP1!I4.I%\_D)5A<D5NB5&H77(-0WMOW!!:-O$IRB5'KR
ML6KSU&V*X06UJ\-8054Y4Q<V0U>ZRJT7?"/8-U(Z60M:T 86;HP7^U,Z38'J
M<*+1OD\A[]U$#5[-*43CTE7BTU>BA4Q>G@S]_#OU]?O]S*G^QZQW[DQ,'@\7
MD/AC'D8_<(HAO"'FJ^^9X>OIG$GQ 72^G]"0AS)BFA25^$3^-ZE"I?/4Q(PF
M?Y+TQ:0)C21'^)\CI3&[9IB0&^,/)P27]/Q&#"%7SM3'_$!RP27^Q,8V(;W$
M'[#^4K@HDET4R2Z*9!=%LD_Y>+XHDET4R2Z*9$\&(_<?GPQ&[JLO+ABYI[S<
M'Q<C!T"4$XMB<B'I ]J5W-1H#<+<9AKM4LUGP@T1]5=<%RK']1D]SXSSG@.%
M_ P)70_$.% .CH_4MR5KRC"U1A,<@M)12JK"9A1%?FV%?4K^_-.-1,9Z8PF;
M-7Z54DW:$ =%PSH,X(LPNDE.@X+ A0IH3!()!;,I&/N@;E@$*QKR>I)F@0/U
M7I6KZLAL27J^.KH>EU!ENI=$>HT1X:\@@#&_8Y/SP=(17KC\7I![SVR+@0Q$
M8O.BZZ@^D]W+!C- *TB",;6K#;<JZI"=]H=K(A,Y50(XJ@>&9SQV5>XO<G?"
M"CPJ2==I,)E.B4*A-QWHSQ,A-E_O*E"B5 :BI'E';N KV_56$O2<G-T1#U#A
MB(BU="RMP#!2@')M*I%(&K&Y(XP=)BD)#2<1I++#>GISFG6K=@Y>\31O,O&S
M;HF/_QH>.D0GULZ]/F/.@H[ FO@':X+%Z9(BG?)$>[X"):9"X6^&($&]\SP!
M+40W#E' 8:.4(2>N0[?W9 7T'O#6EW._X$SXD)_!45KYQSEQ$00(CV@-F-BK
M=/"$B<G$>A)B^II]:%EB<>:6+;V6WJTVO-+C/I5%TT2R:!Y7B@*$9$;?X1R
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M$72,H&,$FV,$'":BR7"Q,G72J&5\J5%,J,@S%<&?4]6:[FGCS$L)HMP"UFE
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M,AF4J0A//LI&%;MX39=E8*^!7Z4)7NQKI9TN%,3!$@M.2R.USGB D6>#ZI4
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M&6(-Q-Y:4S21S-3T,AXOW,T@W[@6N(Y<;1.@&D*1:K$3S)PH/.YY@@"/E$I
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M#OL=P-:.7NL-M4EH!Y3V'PW,NRNEO+F4\A90R:Y^LJN?_&IN<'JVJY_\<@8
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MR B>B;&;&<WYS=N]_8,[>,(Z/M7QJ8Y/K8M/G?4.FTSA]M(@>&XT53/L.;#
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M5/C788%.AH,:PL0JMZ=_9X]GKSO431ZJ!@Z0TSM:\^FQND<5S1D-]S)+2:-
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M-FV0K-B:NF8VUN//)3%L7A3*P2FROD<V4.QF#_&CN-,8 RX%]8^*G0JJ19H
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MBD]Q&HC;@H:&QZC-RW3I481,R'*):M@7<C5.R#FMJX9=/S &\75(7R6Q@!3
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M:L[(RB5U>LZDI2*3+C5:]%/@]F8O/4V0>)$3W K#AKEX44B!(:BI=T"*."3
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M\*+1@A/5[JX )2(C8)(E?%UTM=0^X2)_7;G#:PWDN.[;"6XA0S?8XHR@#XD
M'<1RG21S#2OG,A?B^CY"N/^\\U8/([<DY]@+$ =UZ&G-=\*'*8.IEHR)*2[*
MALNCKC,<6MLP;>4,<609RO.QMW3VEL[>TKF^I?,:D*AKWL==G'>_[EHI.='&
M7'1GMX 2""NFY3>9.C#Z9@R'5% .=-BU1C'CDKQ(N[H3UR7)N%@/ B@(U,^K
MTZ4R. A]"ZVG#F*S KSH]P[C@Z))(9?:E^7;WD?DTQE<:Q LYKU3R.4%T&L%
M&P<\2BL("DPX7F#[%+0Z^$S_>9U1#&,DM@1?'3TXTI58)'8+?HH<I"?_,#,+
MT9T!G<[U8@<XDJC&JKWM$'01PX"5CG_=SHO8#',X@\/\6$Y07RQ+YK.X=A!#
MR3R- P?%(GS(9$ND@(RVK%AK48=FG.#DKX$#3",8XTMZ72]%EW^03)1L$YNY
MG#W#&FC\:! 3RL^KPNJ'8Q!(393KF<,XN*A@XX*U$,7:I3 "L7&HE.4"YRF&
MO.8C[;Y\8.FN:XUBIPYX;TWLK8F]-7%]:^(;0!>NF?A? 8)-]@!SP+V')7Z,
M'3TF0I+*N=^;%?D@) 1R\7U?+J>UP!,,8EV^ VQ9H,&KLEU=,P_!Q!=EO5*W
M;ZE*7"#24,[.PN&<24U:'ZU9^U;)J30+;C'S*0M64A$7I-6N-91+C;8[GLG^
MS "2OY990M?'%0Z!0W) _@V;HN8:D6+:&C<_SIO1>Z/R2"K:N'!3>Q4 !;BC
MH\F<J8R_!#G);,"E'HM1&9"Y2W-JC0U*-= ^N(W!YP<^_,S1R6]"=M;X534P
MBSU_PTT.?MC4:S0=3&N/7T6IN$<UWR1KTZ;+@JN6A.M]@E?=L) *3Z."6JP5
M&4''R\8C>=^JZ->29)^7LV(.\%J@;4ZBN$57CC:#N&@9'&S4RE:[5".C&0IP
MC%EYJ0<JQ1M$RF9V@^"7+V/X&\AF$"L;H?(NK[-T[DQ9F:7E160F_4TR&2(U
MU.55*:;9"!F%%&/N4$*[T&(6!Q,H?KCQAJ^.X@X=A<$"^U(_S_%2<JC6"F$(
M]- SSM)?-#IYQI]5IZ?HCVX3-1YJ"=R:E1,I3=RPM*8X=!*)Z)!O3V@!05@U
MT=@K&5(JF?5H,/QC:QN(RJEJ1AO1@45$>;QL4>BQF2(=!#0RKPHF$N!:0SHM
MJVH6>*Z8VKJU;B5@3E'<2J0= &ORNP*^)?YT1H]P<^)</YD;R,QX$X\^EC$;
M54A'P7M4@ C;.F7QUOKJQ2,SV\[JX&A7\*SUH7=4D5RK7NO+NU.O=;2OU[I=
M!_DC3(97.R(J4Q$5.O.VM5'>>8OIIJV,_Y6F'9_&8/I?F,IEC5@>CC5B^?+^
M?=^(Y>'31]R(Y78OP>UR5F%&* (#A6KHC!:Y*P1S 4M( 0",3!'F?K(&^M"*
M2BB'&$@R*U#?;B:8]E)OQO2_\8"_K:0!>@;<0&^$>+$-+\"4=4&RO_>^K%HA
M*?T>+"&&J;2@ZR!3B-:M=ZB :=EU;,<GPQ/R_6;.=F>6]FM[_JR/7 4)U1,)
MJI# B>:/ZUP6C/*Z>BLFYW_\^]-'3[X6M/(#VHD?7Q[@5X^_G@1Q=J3U*UG\
M.FWU1E(_2:,P'7QBG4<;6,> G]!RGOYH_"K!2N=6] ]\_Y2T?8ILBDR0QO_R
M1XSU2\GLQ:'+C\DSCX[<0X^.1IZ:AZ?22AR9^6\]8>#2N'8PV7#6?!23'72F
MZJZ5[U8%PXF?VQT$/46U#<@\TFW,=!_><M.5IJ4_E/D9S;=+V]6XO@]R;-U1
MEDNT*,NYQO_2>V&0"@6R2&</=G1P[Y#.88+%M@&'OA]'/[&^.<ZU0AIH6<VZ
M=LI<I B"SHVTK"DWZZY=G54UZ&ZZ326Y6%CC')W<=#QY[_\<YK\JT*-Q'B?[
M(/&8"4%]-=VL [/EB-<QB?#UO^BJO\.UE?UO F?OFH\![Z"V!0F.I%'R)+U7
M,M^;!BXM/?4NNA0W'=!D\+Y;=$2@AQ40[\TL"[7J\70'P1A=QN3;\!^E@PRW
M,2Q[85]D=4'7>],U>LOH<\4*V6/.F3:X;#72QNMR$M0$"O\T!3\#SI,[2YRC
M/@S)=1(OW$N%B8_INAJW#^;JM022G!/K$H-H1!%QY/B("CWQM@V!+HU #1:A
MTD^UITAWNG/@DH[CZXQ;*^2YR<<V#?=BV*TFDV?&5J3H,6HQA)'^6DPCBS$=
MRB<9_]Z!OBC0'OMP1E1H47S/N0+3%E?%M! :TWMG5A7)9(KR5^G/*:U1)6(S
M":/1M'L)M"%BU%6O/;_P3X$D,#$W%Q+,>VMV<9C_@A+0(FZRV"J33.0W3PZG
MJ%!\8!#X]-^!/:+2;,+F"]=.ZC/C?IB6HK/&73U$OF]WY=4P9.6[U?*IQ\ F
MTK3(B(%4J,U+Y/9-J6'\\3"^E[&6R;BYU&2'Q'>22:@+6TU:I"[T;&%9F7 \
M)/7;:5]VYY<R%L?AX._SKK@0]@>]'&I_L16 ,A!P:2.HUQ45X+"JHY2/"P<I
M%$GL=%L2#,Q.OZ7\]_5;NHM:X+J!I:_N3F#IX3ZP=(L.\DT3V)"N<KQKQ@97
M6?JD4](^Y&5&$SR71],9D:_-'"Z*\]*9ITJ#HPFD28YDS)*YR3,GN=Z'??N&
MCQR/XL'3K^[W$^EH2"(6@K]D$LLS$)RS65:H-1W,$9.BTKB!_ >&BX5>=O25
MQ+N9;\G4:[0,PX\R,'P&KW)UUJ[;8"(M2QH%?>H=&V%B#."IU;RW9(51\*DF
MXMF(QXD9B>&GI2?:F-.-QM:8<W#"NSCMVF*N<X6S $^ID*PX>=^(.)#>:;L*
M;3)>XJD/GCZ]CV<<W;__%?<HO.!>'YRXGXM-16:06CT79>@ABBQXU11*)2"$
M&Q9$L-45;3LRR$@@$FQ@YTK;8KYH2,#4V;T2W0\[P%>D&\JWFV75%?F]8DZ2
M<LGM0] ,M$$\PNHAS[4(0<XRUA*]0)!EX9*5!GW3$+Z8;KV5)^LM":MUVHLP
MT\EI]U17B<1 !CZQ-F/?$-87&[%5$-&,S'\DEVST@IFNA^G0%%W77JCQL%/R
MR^=C;.O!?TEB$@?@GBVK/P1?Y,85$3IKR@/(Y)#4)WW1;4VT@;[(.'10,N&G
M;>AH?=9:N9M\*"?F!6V2+$?8I+DWQ *XEZK_Q-@C@'^<4,FX4(9M+'OK%"4Z
MC;9AD+(37SUT%ZVA&U8B1K"9N<(<+D42RE#XN1-.!3?M!7L#='2W,6?MG><B
M9X[62+9S&=O\:&LF+;!_$V,@H4U):,(K5#FN[@>=):QT>LA:HY7V4JXNF1=N
M41$Y8RT,,!&%PU%CX;CFTH*BV;KNAUFQX-8[K&J"_#M4&2>LW>PX.K*#3N06
M*%SO/U)WAT1P^18K&RN6;.@]R+4W3!!+.MMW7@0 HINHW,PN4DH%>8LY4Z@N
MW1[P, _PJOS>/XY^_6+W%2>DL@L(X4V_+NE62Q.GY-$"CY>7&WNVE,VYID4/
MI=,0R1(9G:ADG>LHI]1\.!A&-[(275^4)%;DP1=<Q'#O'P]H^#1<;7 ][S:G
M?9@T;_&T+)LL#)J>3"M*"_Y47?QRV3:"4IL;L-QW>U$P1W7>KCG<LN$Z/X_C
MUY5R$V-Y.]V05]#TX-,=S*>?9/&(OR'G;;&E=3XE-5._Y64V-2,XD4M7@]-)
MZ6)\]>L78H<\:U'FN7U'6H$\^[!_',0NZO5O^;WJ7>C-96ZS%%H.!AO?MPBG
MSE[W"$LOX=)Q'HNZMK9B4NL+F>&":QK(E;!N-KA^Z4>QL296L+4D]-X"&@2U
M#-5_\G;;5;]5^3U?1QE64A,WO6U6,#UQ?(93EG[E>AK%_*L:5Y)*NV(ES$HE
MK^<F-H&ELU%(TW54M$(8TTZ\/CYY]06]I>7./SE^S)]*YW+^]X/[]V,KM- O
MG*N!A]V$M,5:GK18F\2KJ7$6$*P(0_3#"9\F[6AGH35LK9UUB5.\ PJS%X&G
M2SI14SO32\M]Q!W3%!VZ7?%Q7,N7)(P>[4%AGX'?JS+7[66*%P/H2^%B$S8%
MK)I=FJ6<%0DEW8C8%H$=R5&N5A.[I&9LSK?M4@-\"6]FU61L=&"?-1>#5MX8
M9K#=+N/0N8M6R<>A!@++MVR]1-F\ 7@%38Z(97+J\$7L)D?KX]W^/X!%^+0X
MU"N'/3;?3P&K>#0&JWCR.(%5'#WY\L9A%6.F]4U-]G8Y H@F64S:TJ?./(<*
MYNRS.KIM&UQFPS7M7% H)",6@M7G:A$'9,:DF:HU7K%I$.:HMV+]%]J))2:G
MA.EXB7XY^C4N]85OZ#U#(4P<^K##1"V'<#J.1 VH'?'@AM[-$8@,K@\I5@3R
MIZ4O&7(<E2YM/2B"!7RTE"H'L2<C990FHN'6T\#;CJ<S+25OTTDN;]UR?GU>
MT"9F;2>MM&@=15V)8QVSQ.B+R+DZ*ZEA@;IE0XJ.SUHJ?EQG^X7W989[4H"\
M8^W\':$]+2S?,JAM'*F5=L+8$='Q+BI3"1KU<!>O-1.W(-XQ7,>=[H)W5,->
M*POR].YD01[MLR"WZR!_7!/(G\B-0'-<P=6:1W:/E-47^PZ6GPY=R6W@K4BV
MV*Q;36=8O2R+!]4;#$216HQ>TD-SNC&/9?+TQIJ)I[B(U75W4KH/Y&=2T@!@
M7(H:EWJ2Q0=J@YX.'9.T.YX#[SQ0^,W#/ULT?M6NE%8K%RP$]U8O9NB2%NDE
M\U\Q'G>PGA?<\I)^7E>;)?GIT-(<Q6?Z,ZBEM!6<>KN8#=."A<Z9$PO2-:"/
MZ L-OK!3_TZ3:/F?;)FFNDSBWQ]9I(-&%): >R)U9)W0?__T\"C]WG2+[WTE
M>:H0>J$_<(MX3?0)6@W@OA#;&':1MBT??DY,"]B$!W-RH#L&@-#^=%N4%].4
M-WW NTK#3KJW3/4YH9$47<\T$36'*WM:-^EO.CMSU.?Z;9A0[8SQ3LWV B:;
M^81@A[#P!4>I0X?GC!MI!=^1?K>::"MW=%EBMU[/Q=NF5$AN64_;"T46GM8;
M.HDUF"D6:T1G0N_I<)Z*&IW%2/F5;'?E#=EHO?&KD<X#CJ=J:!TR?E_*;<L1
MLVI=U S6::39M<UR;F9C4CH%_"A^6(?<)1*IPJ[6-N6!M8=GJ!/];#W9N3Y*
M]U0\;.L,'C-]UN&MX'W%$.GBT&L>W _WAZDX^DVW8& 4 F"&COWFY#B 8RTU
M)!VZI>OX\"U9?,M2TL T6[R)'N2[?,O9M0.8%+$I1RZ;_WT[JV)W\E >2,>]
M[:;5G+F$TJS#,8UN6O;5>CO)EN6ZF)(!,\O[;3/OVB6-D^&P."L<C)M7!=G!
M!CGE9'/;T[GH6FX\1N9Y1:Y"S]MTERO ;ECI'/<H4"1G"]Z64EY.PJXK@<P[
MS:H?:%G?/.0C8ZZ8!EGM9(K-5XE)S9%LK_1E[("/@[61EA0PAU^)<\P^%S/T
MTMV0SA60(%)CT(M35VL:*A9E(E0H.V(ETGG- ^& ? !',EXXEBQDF'?;*'=E
MDJU/Q8L@X%P./=4SC^1BCS9L9X=?6U;+9N7D8#+$4&1!YHLG&4HR5QA*@)F&
M:]AO>B:NT.X--5W6B8*OV\"TQ_B34.FK$]/J75?=8";'EJR$);(L^"+=V .V
M'TP2X N:R+F+U_"CXG/_]4Q,(T:OO(GX&&ST][%MI!BPG^4$O(5].P2=X-+3
MF[BL:FF*'BR:G#GEN#'E2EL.PS8@PXX4404X<2?!GYBC8\C03^ORMQI@FQ5@
MI'71K[^8:#9/@27M@E2=\KMG6DC-:/0YB,[69:3(W&UY9I8$><H'JNVC7#ON
MN7P?D!R!]1PO:<8P;8Z1]UFR.'D>#>2#'PLAN,FB^?T2=IS<:30T7BX9 1\3
M3I9W/ZBY<$L9O"1D=,70/L?#>[O4LV;D!;4C6FL$110R]+N(A30=>'3? 1XF
M>FJ46MF"R()^9Y,QTL<)=T'60<,N#O,7+K>OMD*\0DM26AN$8<$RQ]E)Y&61
ML>7L)JL5T?N"Y7#'; =OP4BZS1)V?SDC@Q!&24VN8!9JQ@+JRAG' 8&>8N1R
MCY&;C 'D)MI"=EGAZN3W8 U7T.8Q"1ZP+D7V]/Z?93E=)HQ7Q.8;NQAKFCJ,
MD2R%!T\\# "-?+V3_7C$RWX\L";84,Y XI9_X CHLVZ9Y*GRVGSLA4?I"R_!
ML^C*:#V54 *M'MT'UP<X1F,5MN42^C-&?5C1P .XW1X2T] -TKH]7>L82F_@
MK<E79?\.=^!OV3AL8S*&V9 ^]V0T_2N_-^U:.@D"\9#2!>Z1X89A(KKWR(/!
MSGV9KEF6 !,&:SYJ'C+8Q3I16!-R9IPL->)CIYH5D;"@:U#A!T0@0+LN89?0
MZ&;D2KRBF0(QLR8=V!5Q0<:A-+Q,H^"0 0+LDB7RT\Z^O#]RUKX:.=QNW72-
M\X=CWQU>#%Y'P$E0>=N2#\D%'IKIZ",*-K/&,V,R8Q0=(K.U%0Y($)*\BEZ)
M_-Z,06&G>U@8XT!.?8VT*\.Z^WYLK'L5^M$Y5[.O,S1-GUE+=M5< J51H&VJ
M K42O.I#[X.Y2U@>YL?YEX^ODKP7G)D-A8,*M<\THNHLOSGIHS//DB[W33&,
MD587#T1,7B)(Q0QZ3'K=_QK@ODRPA-S,VAI#J&<71SZQBR+EN 4(X&$E),N3
M=%!"=S[.0E\B I"V)@%%@XW#6RNW/Q<&\U(/#)<MH[$2D&/:O(&V\-'#/_-2
M//YJ(!Q,W 0)P0I5/GOD].HHYS^MZ @P5,&1Z(>E(73:];/^,!L(U<ODPN_%
MA<E<A(;RR:,_IRBV'4,![KA?L]R0;=^2NCI'[$8(E*3SY#PA3;88\0>AST3S
M->Y1 YV4>9TTD> W^38%RNMV-9-DX=478I?)SA+>8VO:E8M:ROVX'J_HWK(T
MU',8[A@\-KO57,#9E0%?YN%LFV99TJ!*G.#C)#!C4=MQ]^72?EQ,X:E<R@50
MB7I3V;<L.7Z,]PNOE^;>0[7]LI*ZCL!&P?6*L1_I-LQAT]#L:C"A#1"+A1-%
MH'CK+&_?^8:<F=%PK^PNAZ(.OSH<=4-J!721@BI5EFMN>67@A@3>T6N)L?8Y
M\>=NX!9#@&278R)<CPM#(%P-DQCO6"*5GUUI. >\@\U'LD]7F)@],8OR+V#:
M M5'"J4P3?X>$NV)+/MN^:@1MG5ORWGTI(:;8VTW[J*&OR;,@H9R9V 6C_<P
MB]MUD&\:9H%LUW%'9@B)? 9<'.\!%Y\,<'&< BY2G@<C+$[A%HQ8#U14D/3_
M;$F3JM27*.^LY5;C,=]CH5KQ88O<DL@@)(&+T<VS'?_U$M.$4]ALG<=Z+K90
M/3>(]5)GLUNJ@ WQ6)PV;6_1%T[2JDW(N;TF.RU64'J]E >WOCY&RJ2LU=A:
M:42;5FN:TP6)&3-%#E2@C,43'XXGQ6@D\D4C2LV$/,,F@$QWA817T93B48D'
M_989-%)BK]?#9P<@)/]"WK,B6VM"YZ9:+!HN4&.;!%@+[<%>,B>J$%'0B5F=
M<7%4V.YW7";QMB3; +89.#7H;*!8#882KN\DGQ<S.I?R;R 7E)H&1"4TQ-.-
MNGJMI+53!EDR-06J()"2>GL(CFX&+<"Q8FAJAQK>3DBW==D+H+U]GG+:@H-_
MPU3@!8*H./+RX7ODQ&UK;. 7$I'=K5-G4++@A04,E*$NMI14B4\DNB:I?&$8
MPTP&G#O_W\/N#Y1.Y3OT$!0*.'U5-(#?-N1+2:!DG&/.EW_1NDG_/TF5=@7Y
M9!.?'@XI8V,[;NL["1ZXJ:SE\3YK^<>HJ!<BA<B5&A1 X:[\:T,.H* T&%W'
MM]&ZDK)ND2[60BK05$"620U?B J-,R-**$D%--Q'"_'/)"! URX1B1PJ8'%8
MF.4R0:79J!AD*6NJ@F5B D;Z :"%W31M9'',3#\(PIW&W*E8;U"#RGE:'M.Z
M2KG'I:K5\B$_GAR_>M['A(P4L($ZJ_:4%6X50^V_#62H=5P(!FR/L8HU(,%V
MT%KV7@9RS%OEP(HH.)ZBST[/2B8KB'ZMQ0Y&.2*,+(VUDP9]1)<@M,,>^]^+
M9M/GM!\8C2W.WX^_VTVG'>;/%.P5;2/&#69LDV"MQ5F)1S4T9I6.I\H9/ADA
MG<HOK/2#-/6B[#K- A;A&&IM=(Q?\"%RBS7)C--J-X/^ZIOGG+H7/6LG",<:
MFU'D8^0-(T/:Q7F6S7S%JE3Y+3+-?NY4@(SLBL\Z<$R"=>WQLY]=(%C+'^E.
M Z$T;!?O8X=Z/!'&1HJ3Y/0@-!UP <_:NBY/6>G^?%9N#!@0=I]&$':?0]F6
M^]2Y]3OF4 #D29@-D=DXW\QG/J+2'DF_2M%UM?RMHM\CS$B^>$C4A;RKL,9-
MVX-B_D_D(>=8LL?W8^H%<%^7D1M-&3U\_.>,C)2C1SX)RT?E'Z&6V<UFN%]^
M(M>K$O<3B=D?DAS==><UFB.&<3V<U["HW@=^'X7)9N.!;=EYI!Y"UBLD:K62
M_)>FHM'*"T_6A= B=GR>K[EK/D:;T1;MYLEEBQZY+4IDPH++FP:W)#@!9.N3
M.!W$=&D;Z(.]6(B15E7=HG-24(CO>>H.1C&?JPNDPB"L:&BGJ_HYYS2"S^/L
M#<^/#)18/!QL@KZ5Z3Y.\FF,T%>DX><6"VD]?G5B(C$V:/$4K9QX\-0@GA.D
MR$E03L'VXG<TI;-QS6><Q,V^/5&3\V1U?!=OTPWO[[<G5X3!DDY].UUZ-)QA
MU;SB&<S+<G70E[SC32O\)[Q?TQZ4$GCSO%-,,M>CBDS-%M54T/[]C#E3\4R)
M@#B+BXN6!J4?N99^&'0#<KGHEJM*O=-34+@>YL\W@6?:U3-H& AU".QH!?9<
M'25'4]IYVZGK0F/KN+[&H %Z,V!9*9P[*2AIRM-"*F[[[8P<@Y;I-<@V0_0#
M(0LC%'8!O$,<\0&B?:H=I&((C]/W;*/:>T,)EY*8<Y>X!W^.Y5^'T7$7#BE<
MT%6IA&I-9%O1\IC,]M3PL+P$#.'CMG! G&/+:+'.VF[91G3HQ'#DD2--%W!#
MC@KXA,<,P O=/=[GE\^/#\S6R#@A*7[K*"?(2+B4UE H =<&+L/"H]+KP6-:
M2S(&Y"S8G^@IE]AR]*6?R#R86HM*<,'0'IF_Q[1=!L4?D%=Y2_$RPIG.4MR2
M9>TX7NI8]:1]$O,*)=*TH=WOBE.(1.:'<HPW 4)A=5OO-Y/&K:,A/'F?L/R
MA.6#NY.P?+)/6-ZB@WS#E@-;8%<8#X%L78CLK4C,<FF<1ENAI$#@(#/2TW55
MS#3'HMP>[7+%A/,LJY.D2Z"'Y7 <9Q)Z"["-9G>2I$M4V-&?".)S$!!EQ-+F
MO-P-;?HP: A^:K,]RWNDZ2A>-&97MS2=== @P;Z9K3=,P<=IG,B=Q\L4B-A<
M"@BKHLD=$N;HHEU.H57QA:+.8H(GY<-;%D)[&JR3:) L6ZDBH[F=;7M>C4CL
MBXF10N J,WH?6IG(+K1<J%![&P2&O1V0\8IRV":7!A&\K6*/DG"O+F08GL5
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M^^6E43.,"OAKZB,3DQK%]J4WLH-8NX=#-?#D\$GXQ0<JJ?RCE-2XB3K00)]
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M !#;$E;:J$+;K!@(5^07:W7#6]")6F_DIF=HV&AWQ"*)EA)^]<TS2PB#.5[
MS\G7W9>4$10&HTAC5!GU(,0-M<CTI9JY][ER:SD%^!F$OEG/C3'15:/9S.H2
MW35FU3Q?MN2*;6IQ/OGY[N4J5KYYIC-4@*].9LB$Q'U-0B\:OG+L^#$<FZ3Q
M6WBM*P&QGPF(74NSR^:\ZMK8>YO%@1K&N$CQ$O60CLP':Y=UP%X_N+AW\29=
ML^SIR_MWI^SI\;[LZ18=Y!M6"<\2'=M;T8)$K5V!10S:76*R!;O<ZC4\W?5
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M%@=W!=IH/:X<G:&S4A>K3[=S^VSA/EOX";*%KW&.LP<2E+G,-6&>TMAR=VV
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MX&XW3I\,EL34=J?&;4V2D9$ JJT9"+XH#T#80:-G-,!HS7# *KNZ#"G<"18
M<RO/.TQ\TP!B+[H7G,JEU:Y  8VQ&>0OQ^>A.!X#_BB;YD@P.+-DT4A Q5E;
MDC@2&B01?QH8MZ0^VX;IYO/Y0 REY5C&II&XU<)TQJ)30C$L=*?^?Q8RF7H
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MH".33'S? &1_@V[9#5H L3C)+@KIPBAEJJQMSMIZSB K5G3!7!GJM_T%V%^
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MKS;3NIIQ7<L@3#WQ)MW.1L;T)^XD<SV,7,K\M3$[25F3\6Z"LO&4JXEC!Z*
MCP.&ARFYPN8A$V]5)X$M<\CD8Z=.>2?HJV37+LK.\DPX2=+U5%%V$:Z5'(O#
M_&3#V'^_^@KA6BZA>F=="P)WY=+@PI#=^692K%%7Y7GI"D]&'KMF2C"N%[5R
M:>VFNXUT7#3I\Z(#KFM6=;/-4NA6'3M5X-^U:\G@X&EY5IQ7PJ*QBGLA2UAU
M: Y:B67C2Y'\,R?Y67L!6,$D),<3C(XC9T\,FC;0&O^3BX(&YUFO515R?I]G
M<?/GV4KQT=VILGBZK[*XE>?Y(P;X344F'WVXZ'KMHTA2G'==Z^3R%Q*E.X>V
M_UPG<OMLN^-GQ[YO%$GN=;6&<U5PD2ASX+Q^]NHX%-9Q)3,S8A33:<=8T*1*
MKUB?H:[2MS2/'.).O9]5IV=,+,*;SL7%VJUL&H["1)N6P?IA8A22.P* 9>-!
M('/<N/D@Z/0N')S=UT<EQUS<H+U6^!Q]QNA ,L,#]TK?+^:/3!&PZ]BZ)B%7
M$./6#O%GJ=ANU_&,(@&6:B;G+^VE)D034QB+GJT&O VT:V@7*N:@X/1\]["1
M1E\6X(PG*+(6Y:BZ9^[6M G-Q#L>$V:QM>)LE"A=X&76TKJHMVN/\\!WJV7Z
M\]R7UTO[-*2\E2$R?^5O !>99^F")(2Z\3@:0'-W:C;IP$T&%'5*+B>]JK2Z
M'Z#JF1*DR'?$YNQ)A\>1NP:@EZXH+-U3L"<$AE9&P2\B(LQ)"VLZ5Z(F88D.
M%:M:ZL8$+2#]V<ZK^::H)YG?X)%MG<:""&DNI\7Y@O?M2:R 94QAOBB4"RVN
M'( W&9'1XY,D!7<!%U)+^(YAJ9R?E7\ D,I?/"NC%ZM>[KG"UD7/E<YB'AF\
MIV31D\:$6&[3=T5F=FV1J9!?H6V2KK7-#B.*+<N G<*%3H=T&9F1Q^T>C91N
M1[5.T43ODZ,0=O#( ^GU%--A2.I6I%W]>SKJ'F;26>"=-G,9,":+$]^=PA.*
M'5J$'4N^-T%!QX;=HMX'.)S22XBIUI&8LF0699YAYOFGQ4-<IFVUX,EZCIRS
M33>OY?2'^H["%TQ=J9[#Q>K70J_-,>B65F>>X2![S_A50Q)YM2Z9Y//H_M&#
M6!ZJ*G1]T48VK:@^/3^1A+$Q0ZGN.7<=&9*N1<58A>LB$BD[':NQG-0H<']/
MU[U-.2S\^>5GT"&."ZBE0ADJC38C90/S>0P?L'VTU_<?K>^9 "1S%N>@(5;@
MZC+YYD64E06/$7AM2&R FV/3Y=L2YR9VD PL'J$6.0BDP%EX0:='R"%I*&73
M#P)'0YZ+ <']U>-=%O,R2D8?IY1!/SC*=,B&FQ;.D<:5#.Z*T-T1'^;/!;#-
M'2 ?'!W@J59RS<"YX%QAW4.VBL.S(+X6.:'RL^ _"22<&5^BU!E1]1&0I!H'
MC@8:VS'39^@)')X8J!=C=DS$E<D+N[>9%-#$IN72WMPH<J6M]E44.,..[2PC
M$E[=*WH.8L;5NL\2WX)/KM34F:=D58=NB77A>_.2HD +J,=^1["%D%E^O)9M
MY,0)J0?T&P-)._U88UNMMV-0)^@S2@]5_VKP8/.QW-E#H3TJD""3UQ-I#EK,
M*]BT('JLUE:VO#HKNF4A]9VBQZ!33E'PU,@GI%13/P<N@8N]I+P!/M418S9V
MT"!]7-8D341RI+<["A*VE^B/7E!LNA&+,SG@\FE[:9"14>[&WN3O-T"J:#&*
MQ)Z6XT[^N&2!6>ZFEA6G=,]H="*]0J;I^H,SF80&C$)L?J_Z@CT!%IN^$ZVT
MP]IM13;)[E7TG0=?I6UF?8WBVE@20:&!S B*>TDN<7TO?7ODZ[(.?5MOE"#5
M%$XJ&.G>GG/X/RLX!;6IUN'9IO7"\NB7,'FQVA9#Q1O<'\</38^_5YU_D3\Z
MVAWAX+N9= <VT<:D)#8JD#@VIRU;G]KQEQ[PZ.B 'ZIR<B\Q;D!BC+AV\*I8
M5:FG%!NWJY[W<D.WYI>&B<=.UL+1_SI\);$@:(]#-Q\RCGI'?"D<S K3'].)
MK&+Y+$K0!7*GXB?HH4C>I%&A3>-,I)(=-14#R2LZ4MTSJ0SM_$L"]ZI)T*2!
MQSG=-S)%NM -/+"-#EO=CR26U=E63TE5\*\=KE'#K"MEOS85S)T(F:A"GN=M
MBJHWC]/3?H@#:&(3+DPYMUI\J_D?6JM_WY B/[K_X*O@QV61?0%'8A;Z\$@/
MHQE9SL7I.+DQAS"TOX[1'"<N6*QCYJWQY!&RA@U_B9XBT0F3::<QE<^\/PMR
M*RW!V!6KDB3@S,EXC,6'7_.?FOQY.3.G=0+'E?[W&4D;!F<52W5-Z5VOOST!
MZ8:&-X3:\=E/__WJ^<&#IXA]5"7F5->^TTR/!38:/&?C#QI^<Y<DX9BD1Z^L
M*5_+(1N9G2-+0FFWT#"QKYO16@3X)?=EV@E"F5"]-)QB-V33!PU;>%_6(1U,
M9J<N32;6W%)[ -/ 8"GS:'H$-M<2#P_Q&/,M=M7U[F6WNFK'F.#<O[X5 T4,
M2VY4&5C\]%(,+K>B-R8R/*6(+Y.<M+ R((69H_'IJ<Z8>3@E:BFWPIK@ZCLG
M@R#+)--+5LS6R;"UC8(QG/B(#2X8NP+K[5ZC?;Q&Z\$B1#*!_7&221>R<:]^
M/M;&:6[I(6/J0B^<A*58<"Y:)K;AF+V&BMU=5I<T$KR"ZNQ"N??MPV('(PKY
M>>9\/D\PP^,[ V;X\OX>S' KS_-'#)"U6N8@XM\;#O!9Y*79,^[=N$YX+6$F
MM@V+6DCTFZK<8=!S_9%=D9>CSV/+5G"<;/BH!6V58<XD8BVPM<;DG$-2"Y8C
M7P)FP=4E:9/_<]-5_=R89BH7Q-UZ<N:JRZ=DU31,Y,FX1,:1!IH9RS;&_J9_
M389W3*[!P7?5[.T40O"$4QAE=D]]C^/O3M3?^.+KY&LOR6 BPU=PMZ#9MF^\
M?':<?D-.-IF)/3D&C-$!P;>RGF/"Q\*E;K]2SNX'3Y\^"</X]M7KX_!8X6%2
MM:NK-0D#4Y*F-7I\%1NXE%-NF@V53._OT2FAD>#BYZF#;]<M8EC0=R<!I]R/
M@XG)A.^MZ2X2L]*-#3XXF*V8HDV"[N0Y(=J_944\J]9*)JFDYQ/I(ZCL,JMB
M*\1QRPU@%&)J<_H0#L9$VR.1F[OI."$TR<M*1Z7.3Z>)EP018%U75QN$%J4M
M2.@5'Y)^^,ZZ7#((H.S.@9$-+>LR&AE?^- ;>%X:5U2SO:)F5'QX!!F26<6@
MFO?<IUU;S*7=@77.I:?SBF. YS"9]B?\QD[XZ!X(^81L0D''J3E5'6WPH56B
M90;<A=I"ZXRQ+%+]H%EGS5?;$>3/<JB!KY4<$Z=8!&F !C/6-D=+8B13V>;G
MY'M8EHHF,Y'B";S\_V?O;9O;-K)UT>_]*U!3-:>L*DB6Y)<DDWUVE2PKCB>1
MK6W9DS/WRRV(!"F,08 ' *5P?OU9K]VK 5"V8SDCV;QUSVQ')(%&HWOU>GG6
M\\ M""[@,_EFV:$()*Y?OZ?\KFE3EPMI-&>F,Z\U5N;S0L)AN79K,@[AZI[_
M%/^?D04-570(V/-E$.LV1'.D[ PS>X$4I)JH0QP-9@$\"+_#6-\;&K%2;3X1
M)MD+;H]CP4TDH(('AG=87XLM6I+^UT314B*\%9L;+XZ$3>68!D#XGVD=9\E0
M10[!U$2EBX!WH,G5M\]4N/SJQ=1Y^X/_/11Y@)_!0U5KIQJB0A@NHJE<#:_"
MA)+5"G.XE[Q>->9YM>:,&<JR3";4F$C"I_B?2BXJVJ<*PI)D*=LYU&@:OD=^
MDK&W&/6N].\4H2DXE1HDW247A=6?D3NZC7<,[1#43-0)$SEZ54M,V<$;*KG0
M$NI L(0PW]5V>2;ZGO0-TBJ1S%BP 5Z+'H5@5M1(S8(X,)N[%^M=_+^JMJD)
M9/ATM5@)O"OD2&4N4(00C0=OAUZ7QY&<L<11@"?L.CPA[6.1:W=H?>"I\-PM
M\^G<[WR>/3KMC!YK)Z)U:D *6A44/QL!^(64S#+Y'F[O[<GSN2?/\;!Q:D9N
MM[2[H0O;SYF#^YW*\L!.2&2RI6($=URMY3<!*(?KDV.7J4>?\D_A.VU7YA>4
MQ7+$S%_ $;.0E#]U+K//-^[R!8^J]6MRQ.M#HX>?D7/7P)A6K7"!7N3Z(5:&
M^)D)"JC>%=:CAT'6#/9K&RLFWL32D09X&T\N$:-"Y+ J46<RB</$T,SGS+5"
M[&@3[WS4V$)R*TU^1,I=S;.Y#"_CSBTV(PI"[H*07PCW8*02$N%$Y5.)B9PD
MK8VT;K12,'NY>0JLG!(Y!S2^WY&#'7E*^2*2\,81,U8F;'6Q(.0E%1Y HO6#
MD5F5*]*[5!=!J8B.M^BXS[<<%"\[WWX1,ABZ"KQ!$:LO/L[-.SK_G7PG4K-$
M;>5%SB H>K$4V9C%)=).3A:9W9#+IKAB9S20>L.>KAM!M4L1C!<.Q?)#O0%S
M)W U.V)5O^$(=/8(3#8=@>:B_$QZ)MH"*>]FFN$/G)7V5-5#TVT/S3^C!_WX
M2'7M\PT9":Y/MY0["GSNMC7=MUJG,8^M"(CGK<I;D+IRVJLO2_,O0I.+B?9K
M^"R)Q V3T/90(-!06>5)8Y#B3$YE"6B(]>/ AG:B=X9-P$5[ 3XG1A)>Y5GN
MR6$B%JP=E3?#W3_IAJO*0UGY?C1%^70,O;Y=P+>R@-_M0:"AMMIWC"=G[/BT
MR?FJ:F$=YY0L]4T]"A[M)1G\ O5+<72E,JFF2F3$>2RLD?HV?#: I_0KQ)/R
MOXJIYLV.+XL2ME[E 6;##+">"01Z\18TQ/LI]^F@F@D)5Q(%H8"TCZD(QZ/T
MM_Y?X*S\Z,>$4TF/ZK/2QZ<^CVW)I_A(D08EG=P@I(SYXAG/H:-T&EGWC/5:
M8T=JEI/GA<ZN.>A\/WT:_HUM(P4)H,-?JQ51+%#DC0-B5@5%&O.G0A\ OVE3
MA^^8U5OXPZP".W29=_1ITOMT=U%,KR&4;-5D91/*#E[6[;+H2 '1-#W4UWC[
MRV(IK1*H[B&JRMBX!#> 9RZQ@N$,44!0ABD6"T(XH2.-*QT6%N9TP P]\YKI
M,.5_A]6)$<D!P6P>I<DQYBCJIBJRY CL]0*57)]A['QP^-WW876;KX7;4W0$
MRVJ>B[( G/68\/"L"'*ROX;X)VP?1'QCS!T01A'<\R,WWK=HZSZU=/_TVRG=
M'VQ+]_=H(=_RH?U;3LT,Y&:-UXZU8$E'NVA2F6HO H[0TI%H--LMDNWR_7E(
MAZV&R21QJ/."T]Z8I4V=I;3A*]!91GKR >-TG:U]L,6Y7@I*N(EEH5U&Z"6O
M!$I*>#^4.@N@!!9'PD[C&0E>U4M)B[,LV*Q>52';':<+,%BL13*84B(UE\9X
ML"&;0^W!@0W)M_8@F#<?281[8J%(R6Y8 T\YR96&0)AUY;A-M^$$K+G8-%O
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M7I+6G,(3@DDDH9>4EO\^9[=8?\M7@*B/@_U%6,.K)?FO]<)=YT0&?R?/L?L
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MG""L+Q D_J?\HN%;/+;%9UBQG +*A+X(K7:IJ$<XJASY\O4T+V63B^J#\A+
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MI516:/%/ARP $J4,=.NX12KU_5&I#R'$$8_D[\#ZD4(IHLAK*MH[E*%NIL0
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ME[IL&Y+3B@SK)70R*F/IJ^E/-S@+.#6"+)_BL5KZG]EIFX#KX5- (^0BX>W
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M9+9,)9RFPD/[?#75A530.*.)0:\PFF"$?$1V_DV7Z?6I/AEF!-V084,?@UR
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MZ,;^YM;/+52W?Z(ONS=Z;"')\5UO\;RG17ET5W+D$4FJ.N'?)$TT[Y@9Q;"
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MD<7E=QQZ;A8&6!VN3PP56S7A!W-WJ ])[E?<# K,"M2;MMS:<FO+K>OP!50
MJKMA;D2>U#G3S-B+@&=Q<<5JI;"BCV:-O+OE6BYAN83E$MOA$F?Q7UFXF<UV
M)>(;$=S&)"[9#?0O'!Z>,PQ/Z7A<CO05!Z)E<8E7; 1&23G*>85E%9956%:Q
M'5;Q:R1"L1&-_A*%<(G7,KF-6; .\5%29<E=&D1!Z1L!8MF"90N6+6R'+5R(
M+-B(&/\[\\- W&IE_,)1/_?<*#<^SW.2+N40BY/C>9E+; 3$]],=ZCS[71@S
M3L':HEVTF9#Z&,%VS6V[_0<E3FXYB6?9=[N%+,H\^.JR($@FV.!:MS3@\#GO
MDV/H6$PT<M_*H9I-@M_TV!_*L?7*K[K>0A4HUN]1G-IS9\(?.?B/B$:&J]$6
MB"$Y-\C;$2YG.>?E#^E-Q"TC)_[51!52T?ODJ"HWFA6()6!Q!FP/@0T"YB'8
M5IFZ:B#&AF):N=KV M>UIK@H9G$M8E\@-,E4!,'!4,R2Q^(:C[F=RVR*5<WE
M0OJOB.2[L\5U[V5+HPY5%A]2 YPJ2!C]K](4Q!>8K5:3]L8:X0N5_W8_W8:>
MO9%88(T+!J.UTA'O7: "/(&@149TD3.J"U6[58.N5K$?=<M%@B%NI3Y)!K#F
M%P!7CI_^XT7WQ7V O^OD*[=7*P7]#PB5&FZA\L@KH*_U%IXCQJR%#ULDZ6J5
M^E($*$QHCX/XU1MW[^7^3TDV>[/7V8=3R&;E,G2+9Q;/[H5G/T=AEE2A6=>B
MF46S>^V-TGP-E#KCYBD%?EELLMCT(*9U%B@?P6?,"3=0K61[+3"TGF5H%@7O
MY[>*4A$LR,A=12#T*==M/L/APV%?Q5$6CM!XC^(?W?AJL-=M][UN[\3K'A[N
M/\S$5M9_]^2'.YV4!QV*^.C3Q2=RSG'?<_SH#R=",@I\:?&I_HRS>:.;&A!!
MNS9^V [Y/02BFDWCVAB: O"T;@#1&UOGC=:8#EW_Z34?X1IV8(OH%B.3?@!\
MO?ZAUVZW+<)9A'L<A*, 5[?6&VWT^5F$LPAG$:[)!U8WPG5ZWHF5J!;?'DV%
M.SS9-83;30_ LM5?HX5?X67$-AO*M5@J-R(/D+.JZ(@]C?W<T_A K&@,<3^>
M%Z BO5;=SO< %5/)FE0371M#;"1F;?-H:L6KYAC^%K.^^]$T"K/J,[@L9GWW
MH[&893'K&6!6;3:[1:SO?C2-0JSZC/-=M,CKMK>W'F4W6LB=J2 []8=[FE38
MG&!Z$R/HEI7OT-'4;1RWK7%LD>BAHM_BD,4A:_%:)/K.2-0]!!/$QA L#CT
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M]1T0MKJ"9B>SV1J6Z?@Y=,JYBQT>UM)6DXC,2IG".[8PD"8M)S?2-[<7W?"
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M2 !+S?6^^,FW9*O /F?V2 4T QGX\AJ1/57L",M\ ;&O(B1KF2*#\_0_B)$
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M(-P#&$M3N PPJ=,X"@)\+UTM 4)G!EN8*4]+"2$,^:T^)[G;/P0A.YTB.J0
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MC5=ML% B]"9AO18I* A#'DI*5H4B"8SJLS*O8U7@: )T=U?@Z'9=91&C""#
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MQA7A3X0;H*:LOZ'C85T8, ?XNQ][@S%P!Y\#Z..@)&MU.:]<-^S/88(*=IP
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M&^H%)ND;6>*Y#O/K=+@N[Z&W'$\&! 44J>2$JBG/2S(9;MUHF&O6D4>DKG'
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M'M7+WM*?F9\IA2XUQBWJ^0T/4DTVY[MZL<3./ T)47I"I$9$D<(L$NV=2[V
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MW]&"%#*3$1GAR^1G:LL@)_!2(47!G,_>]W!74Z !7H8)H49 SWKHIQDL8;.
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M%C<^\$8'K,8D8@@L>#"@.^^ ]"6K[\:><K,%LJW"1+9X=F,S #A(9JX.S6>
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MG7R^J'SC[01WM_P+1M"E/(2_P*^@VC!(TZ*L#UV^+QKW8DU[2,$MH5)5M!E
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MH"NL+P0.R8EQ1 UUHT8MC#TV'[Q^C,K-NUD0V/_7G4Q?VV?1+!F@@^;CQRN
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M0(=('[;T;L0W=T)3R1V>PTL-J?MX.SFVP':U 8V:,^>BN1,4>FJR7#P !8<
MD*1;LBN6ZXQ'TB)T<PMQY_HSUI.4.5BT3V:QX"GJIH(%<'H3X@XJDL)6V_H>
M<5#ON1>@06(KB.P26 B&UI:TPDCT68L/A.Z)OO ]4 S3J:F\%3ULR#49JJ^O
M=L,:? $JRQG>"0/ S2EM_A-KAKNIM^B]\$$:6J[Q;^J+G"JDI.2C^4X).99Q
M:Y0+2BF0([QN)I-90$VMASR'-G/W9[Z6]SV_';_!T;LB+<G;]UY)WP6)'.87
MFFUGLJ*NR],B>K%91._>]^"]7G 7^G?R5A1R;BQ<3G#_^[Z@&86.*H '*X8J
M=*G)M/AF_V<VO"6=OF$!P]"0/Y K[.6)A!P/9@]*\;YC=\+/\<]+FMKLUE[>
MAC%W\H7+RQV,82L)Q@LWO] G=VZW.LH7)[ZANJ-[EXO1"/U=:0$I*M-J:E,,
M6FN2FOK6:J:^2U<RV\XT;M[E>O T1:ZG@)$]X%< B(<YX,/<@Y=L]LI>B$6@
M?8:KB2!3>#+X8@=(2;EW8Q'=D6NGO-44,C[.D"4W1VZ7&[VR2FN;5@I0'M:Q
MR))89+N.158@M(6QQ/;SQ!*I[M4NJ7O%5F;6V]./IY_/SNWKW\_/;_BC_0M4
MW^$R W$8:PG-?>2EQO_J.8L'%@FJ2LG_"[/X<]G^JT)>M2PQDRJ=R[118UBP
MO4"E8D78 T:N?]MK[RUY89ET>%@.F4$DHHLTB[RDXB<#;&ZZ#$+Q4*IXI7SY
M[(M/KZ_/L9J% 5L53R92*--G+W="CP3XS9DT$DY!'T!%:AO 6R\!3O+'\?%/
MQ;2G!>2:+_$ZF1I/RNJPXT:;"!N#9F -3.7XOX'P[I"Q\Y2FN'2M<E[CQP]7
M]A93N_YG 3 GE=\GS_)7[]LO01B\C^3H'9K_]2WY@AF @]8>6$T#;^+Z\6][
M!YT]FYO'_+;G?4M^"6:3@V&8',@G]JCK\V][8?35_<7$Y!>-R!B("B@!'H)7
M@77)J\SBX1Y=1MZWNX-V^[!WLO>F!29\!JXW50^A#'GK$>H*K+\*-797HL7V
MD:3%FS!!DS3#LA5$=7>=JG+X$07P?%$B-U>BQL>^]JF(<A8?W+KN]!<6@2N1
MX6%S%3(L/>65</=\4O-!HCN1-+=8KI>^<N%VRI\KO3Q6>^%CF+7(F2OC@X)+
M,BJ,!CE'L&_!Q, XUCZ9U;U73XPOTUPYB,7@P/MV,/:& /TO-O__P0B(\\"P
MHTDG?2($KTV ZQW!BR3)E>Z/E5%T?7-Y]L?OEQ_?G7^YUE4W_]^?%S?_VFFT
M/1.AI<H?V%("IYL-C"JGJ4Z[BWD$VO\LO9K:YM54[6;2]524:7KE1I<1!5J'
MY/6Y$M$U6KWZYFIF;ZXK.5TMSEYAK;TWS4:S6;S&L#>>C3$H 2;5RCNZ^/S^
M$7NB#<2G>AYNZ5[*=M'>>]-NJN&^Q:W(2;KIH%W8DIF,O4QHYEN.+'NVL_<F
M"+,-U]7:<J8OM;XU1G^7YT"NQY4%5>L15T4+>9)2>)_VKEA#%='L*"</KL1V
MK?79CI?9),]U'LUSK<?PG+&AM1FNN_?FL%>-X9YO/Q?$:ROOI5?%FG@T<)<I
M]Z\,X>'>FX[3.CER3HYZ)?9&'OO/(&M6UTV?RDXS$$N\N)K%=@28?-!BVR[]
MY-$^*V.ZU]3UA@>88.].O<3U5W*0/K+UW*JTLY9K:O_IW  ::5> LXO@C#%F
M4AFF]<![EY';,>@EE1T$"YU3KW;)+Q675/H+JO2O?56;(E*SY(R[**PF!5=R
MGV[6;Y4K@7Z&&-SS=CHK5))PA1:%(;&/>B)N(Q+ JC][><[N$V05K!BG7"G%
MX*A.,2A),>C4*0854G:*N06=;<@M^'QY<WZ-?0H7-GU^OG0?N0 +Z,\SRJ'/
MWAI@M.AJJ>$IW!;_?CN+O4#$\3NAPVJGP9 *=BY'5T;6\ V\Y"U.B#N M_P;
M7_)ON(/@5^X4]<\(5>GL-5/]U>EUT^JUNNWUN+B(K%8#>"^914)EN"G(R-;A
MXB0:W9>"I# +2'VZS.4-OORMMAF6[6FC2^=TNW8W*T*>:H5%]?'VOII&CP_(
M.F4[C*PEQ=/WF# ?HXK!8W>XEL68C)-.O*?:(C5F&:]=JN07/@\:P2$M.0.Y
M(>NY<8T1'HP86OTYB/_(O87'EVQ /I*66M\8)5$R+]N?RRI*5!8P)?_.BY*9
MZ]M2E7!D#O4,7J[K$M50+ OGB\@]VF/A#N4<+K/JTZ@]&+D#K$WS1)S=4S3A
M#.ZAN!-^.+7['EBKM[ ?*KT!?I]X?PM"6 (W5:)J0;Q@Y+N3"4WMM.*O8%8.
MO1CGMG!F].Y2IGE,7JQ2QQ$97""#)Y+6=6+!V8!=D5CXXD;^_  (ZU;((_32
M&A- ['3L@GH_('J!4X:%9W$2S8TZ?\?NSQ(Z9A\0G\@A4IRP+DM,Q,#W DY(
MQYBC_,-*:+:5(ZNE\%%9)H=C5=TIUGW 3S!96)4(#] UA(F\2%U\^EQX.*<%
M83UJ;P&''0 Z$S$8!TP:!'H [Z,2//PQEP$.! XY_2KF6&\0AT$@?*Y?-JI\
MW83'YW ='Q5V =WZ0*58V /;#.<" <J.C_6BX0%JS\ OT2U@]6^U-.PEX5X\
M""?\-8T\>"O0I(9W+O'GI65MMUA0$TSD^%952^AHS,"S#+%CEO!R;53T%?N%
M4^D;PS=2/S.J%O5^+:J!MMW4"R.]+S1%#P5]6D;]<A@GK=&&T^'";XTC*I*7
MU2162I>J8H6J0M^'(8OQ=]'LUCX=8K67GITD"SA O&($#M5FD')ZK"XR'-
MYL2'<F#39(*DJ007_1VQX84U\B28 13@!BQL"4*CNE!/GEI]7YC+)*@U!B?A
MRZH9M=&86FXH<G!DI8E>VUIK;9 ?([D".ML)DKXHU&<R[4[!RA(.K!71L@Q
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M<&,&A7&V\)XRZ"I?047;M(RX=R8B=_AVI%?#?7'Z&2_KQ@I*VDXQ7:'E:=1
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M1B8R;!;O2%?Z%0HX9W0Q='9G\A4L4'[(2^4H'8/[XN96\3ACI>.F@'-N$B!
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MBT);AQZ_%-5KD_6>1'4;:+I9TG))RSG3\C;AEDUIN0.TW&U;]49)T"5!YQU
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MK@TE3\JC,3G3*$0= \[2D)5:)I5JG:S#D>3,\A,MFE2AXTD4]*FLXP6=/^:
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M'0E\4>0"RT1JMK22!VD'"T8S%:/1OC-BP,1^)X;E;LA#GZQ-T#($F(#HDL,
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M[;Z$EFP"XK("C>H5-5ZP Y0^LX#CI)$/4>G1,8]?K#"#0B4#?9=99<6_.Y@
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MF&X*X1>TS&](3FC3T]!F;PI&5G^FP,\?-,3J@\#][O'RSWJ<TLV6_?AW),-
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MKS9\ZUQ^X_23E&](:#S:?VUHD2YZ/F:*=@N!(\!3-1X1?.(G21%9>;K20,U
M!D7VKL7@8\0]2" CFB<W0L2+4F?93)5Q06&MRA(Y\F!+*V$H%2AXK0+ITMZ%
MJ'Y2LJE2.%$?B(_@K2(R_D2-OZ."T)$=,Q\$C0  ]/8QRAN<]$3#4$;@P*B(
MG?QE]9Q%[9^"\8ZYRZ-TCS"6YI$R)X%D0#8H#$:_&0+*(654/A7'8V1J?"*0
M8-S<R4;>$DSRU,8\[G'4YR8K' ="O1'M2!6TM4$8W]GV0B412W<[NN"Y+5*"
MM.(IUHQ9(6AG[/[IC-UGWQ?5D&BUR D8V@1D)!4'I=I(QI.,R(:4/NF\H.I#
M7U 8U02YV,9MC$'84"86S62C1U;B"$Y#>3T<C"9@]HXAIH7WYXL?B!F_,W@C
M6CN<' &S8RBV>%.-M+VDI>"3G!Q.A90(>RZ@+- X ZOKC?'48W#WAH*.)\?!
M$VFYT49+K[@H;E4:&1Z'V+?W10R* _$$6,,6 1XI$>+[C.T\J!I4D9(",QI2
MU 9H83:4I5@CQ^9<=1P.8S)4=4JU6\Z3>S)0'/,*9H8KY6ANBIDGP.ZXB47L
MXL@,X94JH;$7QV0B@&/)+PI&QL2@&IB0;!(E=/ERBDH^4'QR>6!4=2YF H:2
M&X133B,APO-#OJ%>P PD_']%[G-#1$))<;^4/R$\;9/\)_&A<!N<OVS"0,41
MA&T(H]*:9G!QLNJL2F1B$W)#V?(X7;[XACYNRHI8L_>D8$U94+1GVGY%V2\9
M3\V(3HU%3+SZ1KT:MTRA'D:D(00^RJUP*I\5MSJ6Z:3!XGY%[ZA4UG35'*&'
M7NQQ^+_/:C&0W$]@@)\/_>FY^,)<6$AV?U/,>0^#<IW9#([K5D4)STS0Y9%_
MSF&$&:@W-#;8QTX<1[=U=MFL2(U8SO?R%_UFHWUG5 P6]P81#W;"H>HHD,#3
M,6VLQ"58=)-*/[=P<M-B& B*,@ED<QU2$QP,*2)O$_MJ)Z'Q32CNMX0U#PP9
M^), :_3URE@=#X%C!0)(DQ-:@ ^8RN.Y,D/5/T*5>DGM4SSN!X9Z6G>^**$3
MHW?R-Z86.Q6E2&GNACBVLJ1&69:44I94JY1E2;MEDZ6%2)L4$C77+"2"N6JO
M#7S/GPFPZG K0,EUWZO[A+JU5A%\0O<.LMCXW;CAS,=H/69\03^)PVAC4I&.
MI"UH;7=-W[^#E8AW*N\'7*IU5CB_*M4]FK/Q@$$*2M[_W<>L)IE7^+7W\+NJ
MB7'GR"5Z[,>$\OWD<[V'J"L##GU>:5MF!&MJQF!-S0_PR:,_<0=BKAW4PBX_
MPE\_&3<OJ$,Y"I*;GR3+7K[L"Q=98YXZOTZ?A%P\S"!"L627BN,]V^1+86 F
M?ME0O4RZQCB)B_$JP7P?<+] BNYP]-7S9@)(A?0@]T7&8'^()$Y7Q&]#>VS-
MO23RAT1-IV79>*R9FYAA!)FE]+W >9J!-H[5Y,FF?K=?_A S$UD5HC1?Z^V&
MY@J72G%'/]X'=@R8 EG@PNP)K'0,)EBRNX8AUAYM&JAT?7^&0%5!=%#BG5&:
M7>S=C$60= Z)S> M3NSK=6SOP';PC44;J$.\\,SDMD3N0W<J,DF4'9;H:6$C
MW)>$TD)7R=CV5"K%L_^FWFG,5*E_8FO#Q7LKC#8W$&:?3'-4WTZ H*(]1 %%
M&ME7D7T-$M5 )J>#2O) Y.^E$L$YHI? K'$:C3RVOH<=[22@[?P92W/2\8;,
M-["XN3F0[U(U[QY11P$TT73'9]\!$4?^)7N$MN07N+0B<59MDIU0MV)L)Z-K
M@L;G7FID>FD#"(R8R1Z*+&V7HF\O[G0J6OPJRL"(+;," FA$$+93;@^!G6UE
M38U\F3\R2"+ KFC Y,M=*WN,N:Z;F[#QW5??]O+<F<\-+L\X86B7)]R'ZAZ,
MDW77,E2\S:1XF_E!N]3:C<K'3V;R-HN^GKS%D,X$E8#  2H/8USJ>E'G6B7)
MV+]@R- "^6P\!+#B@YLJY!?]39SW)7P-3LCU96"S/$MGTH^+APM> _F P>*!
M2\G\URQPPZ$[$"TK:;(S5@+0 RVY6V,YE3&9C-_ _C4%LS+ZH+A5YEN/;L=Z
MADRR* ;K9<ELV(*[=J]9:JU)$GQ!GYQ7ZJ3SB1#T@]Q2D:NE5$ ZT2B!G[\N
MOB3@\9 Y)((X[HW&*^:'AUE_BGQF@LYW3ER6^#8<N^ S-0=#!Q_46$W=CN3
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MLN!"L85V.KA Q$,/U([)?25LY"?@0M8D)+'%T.,PW^#FZN93-!@Y'BV0*65
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M]9$&Z(BT6=$@SYY1ZN[*:'KZ?4!IA@4O:E#*+_R?US3GS3 ? :BGF5D)2MG
MO!C$Y&D.'M T249X1T-9#T]BMY8:]2A45Y=98]K2/_'XCN%%)2[B$SE.@!+
M/5X(\V1Z2K_^R5*WC*>&E@[D9H!EYC O2FU_Y(C"T]KC*=8KW\"SXUW#_H%[
M7ABNK%F,)0S%JVMIELKZ] >>5H)W*&E$"&X/N'T@(?!DDD;;#!:)T'4+2XK^
MK4S1H!(!C:<E1=2"U&U0CE%^R#<R0N09<!&I ^*]<5+0GDQ143!A4^>!Q0*&
M/&\_JS1!+1+E28R/;&4SQ4W+LWU'VU %C56G4RQ9I;2Q\$PM[!>/:!)84<K
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M A/DF6@?+?<4CA+B1QW!: ULWH5J+&KZ- 9%R=P6&];"CV/Y8/# E?NH*I#
M"$"A9P3.FBLH*5&72<\[$Z'/K<$6+*L, :.R3=/3HTV%LP^X/EEHKGC,X7 4
MF8"[KE :N-K6!JZ>R\!]OXV!J\4-W/<Y#%Q]K8$K4]Q7&[9INP9(1<MOV&Y^
MWWZ&K;:%8:L79M@F(:]M8]AFF09IL&QKV+Y?H>IN,&Q3>IGD.& CN>8DD)B-
M!3. S!N-VD;<JM625NVG=>9$&@JF%U/2A2 7NEY"CBOJ#/=WR/%V2#E2,.!6
MHD9$E,L*#_.#B\FR=>7-9!.EU-T\&]*461K<[+!)Z"M:A)S9:#KI_J/GO5:O
MU^N^[12<WUU-%E[DO&(J[HU&$-35O$6L<'4">8:HO++!;EDX@M8$8_4V-^\;
M[M,^EHY\K^ [-AH;] >K"W^-\)4;Y4J"HV@Y>^84"@&>G9I[]YVSBUZ_,3X_
M;PP&V[<AC#7&L6<JSU2=.,^W^QVR"+#$@KJC 01ZZR!P^^W26['9NAQGKQ7N
M6,>CG+YR[K>.97UV7&S^\QW]3GL4\&SY@3A:]3;R3T%1]\8LKB%@WQKWD3<4
M S.7QI*&7A?#$P4YWMMDQ+WZ![U#R<WNA[QEK4U^ .6KRDG6VN2'TSL]?U(W
ME=*#[@^GDT['V^:3*U+KBSKJC-3^G O+7P90X%KW@>2F1)#,+:53A X/^;TW
MLJ?_2+S? ]V+$R9I^B$[%?/3VPTJM: 3R_L?KPM3S(/=@92WCJ/L(TZG[9;#
M<#97D6SS7<$OS\\STY)WA@]7!FEAIBS*X7JG$H;>%.LL #F4!/:*,*>U:>"'
M9SD;$O/W5#!7A0G/B\X!W]((ZZ]/Y"\.#4^%"16F]1R8YZ3\AWL?=F48316Y
MRS.RE/&!6<I@0X)ZH; \7D92I#:S-^^(^ :&86@A:G?=C%[]-;LX"7;1VX59
M..X/XVV\ QC6G<N^X-=SY"*$+K(W>&[F,5PW,Z+F'1560A07&:V(HN?<92UR
MF'@_])IQO%S&4=3@*P77MAE\!?P%J^<:W?-18S0LQ=XY#?Y2K*?E>9A,JMEY
MS6AJ1K,SH^$MBJ]LSW<#O.A=8]+5]WO#%BSHJT.CDMEL2P9TOJYC?\V *JS@
M*%X6X]$PK7! Y!U-':'T8G+OBPR%*QN#$)B_B+-S:VYT$MRH4T [H5WX4;S1
M[:7$O\^.^Q?$OMSL9WQVT6\,NL-&KYO5\:-F/\^@_Q0?1<[/FL()4)Q'W<@^
MQ86PJ.,/CU>1MVVWZI*Y7^>8N5^W#=QOV&OTSTOQ2Z^(QY\&2RQ-(TO#K;]0
M+N(M;_7Q?I.''=^P:,U12F5FVEL)2%!HUEH9_ \6J,^< ,CIB-C?JD57F?LI
MZ80?^'1JSLYN!?(!-_M,&9=R7$YNMH:M)L>-?IL\6\_!V?K/Q]=D:ZKLID_Q
M*T?=>B=W%O)'T\/B84 42E$-Y>@M'ZGX ><?I<3H]L,$]OR,.DM@T!T4T"4H
M/:,O7L53QN"^\Q8OZFG2)G45#L77^.Q=AB21K(P"I+T7A^:'QMUJ*==(73&U
M_PJ_WS.-FWA9,-9?B0)?N@6OA&6\6#=HS)R%'S4#F#B@=*.6%,[\SIP^" +R
M,YNX@>$N.7R&O,B@I6$5:?BEV)CR]%M\1YBIL3!A Y4R'[BA'P80#30%LOZ
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MLH7C$I>3*<$$&> 78+%YR"B5Y_&CH O/-)'V"V3G$XBH< 1>8/#D8\'SX,B
M/DD86([GX<:) D76\E0Q$0F0L'N/5ZY$[%41;/0A>5]+OR0^EW9P--86QZA\
M43DPA?#UD$#R5#"=Q_H<#?*SQD]R@6&)T?5<, 'ON_.>B0A.R":':UH2]0?
M)(%+IM/.0?^RX(>6_EGP#/\>Q+W^ )NX]S1 !-A[1NV6E.Y9:;)Z=@E8YDEL
M@MYX!^A)7\,G48WPC5-L=J A="CP&IOOCF]8ZM^Q^.^KX_\/@R410?TG+\B'
MV" QHWQ"0)Q N&'[H_;Q;I_Z0Z8[8(7;)[[GAB_5<M&^RRLRI?*STJAI(']
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M'J&B7[SGN)@FO>^/O_'W,704/L&FW[UJ9MHDFH'G3K7IE9QJ4S<!+UCF%@W
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MXF,G*NQVIW#%.%#(&% XLN%B;T%BMO#&.9PN:>[$\WZR:>##SZ$!$I)Q@VX
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M+K?^:[O<_&Z=FY^5FW]>Y^8?O-PP-4XH=[Y]U?9ZZ6G(Q]8D66/:BG!)2:-
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M/63-_L9LBP+ /QKZ![0D'-<V#:&^:U0)#/)SAOHU)5AV!C*/3#BPI,N(*GZ
MHZ]C0IUQ)R9TFAZ;OIT%+DG[)$OZ KHY8]=RAX1=6!R$,^C1#)GZ<7$S '$S
MCO(>9=@FK&)0P[T$+52,Y^AN@(.:LE!N4$F8S>M<>)E+',A:".263HN*AZQ
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M+KWVV<6PU<[*Z]H>Z?-K4VE=*9U$$/-"-L>+O"F3GOD?QMUKI&,M<&X#^M-
MQ[[4;UPV9S2=E.M=7K"X>-7!+(Q@D8S%KD.4O&BWO=@9'UK5PIC+<#S:B!%K
M>%])D-L&<)7@:KTN"I5=0!F'R7;P3/&I?9'P@.P)IYPV^L-V:[A9+C\_0FZ
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M^W#173@\T+"NV!Z>NL.6N W=Y.?H+_%:O!H_K*.GF)X&/_H&!A5-=QH\8!/
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MVL(%F5U200S'5+#E_G.(D<J,@CY*>W[E_]DSU/D5_6QHC[2K_P%02P,$%
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M+A$9+9@QC%<4A+6FPWZ;;;N;<$19*AB'4-Z4BH&K:UVA<_7P%5!+ P04
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MS:WM'SN[Q%]'OX]/3DE__OZ'ZQ* YG]"___$Q7&!ZS(M+0TM_7^X+EV.^F\
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M\,M +W:2S *%]]0:=?8:I0J-F87>)I@'NF];3$-]B:*'CB :-W?_A5_#=3]
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MS9=,E52W*"F@3AVY_'&:P[I:]_C4LM]=WTQW.HE-_' H.)8^K&N=V:HS4W?
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MAJ9%WD616LO6%;I/V+DR1_!Y@GF5[OW:?N3[,[9U?1'?*S]E;QP*'6EYB\I
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MQ4T). ?$?;[(>YM#-%@I38=V^4*47*$8$18PDZF%(49A5!["Y\1UH_;@!#'
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MIO2A&%E3%B*_-X-YT^Y0Z;96LWWOPD_?_72"Y@CBOSKXNK;,9T3<2H_%37)
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M;5M<]<T+1+Q"M5SU_'4<4SQ:'>M51G$X=<U[_,6+)JCIHWS05[%GP [-X7-
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M-BJ6YLY-J-VO)FA>L.UEDB_Y2< YH!65C6.-P:QJDBIJ=V'7$?OE,H2?9?A
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MC4*)K^Z/-?*T<8$+8>*"&(J KMY49:1@H1,#RP[DG 8KO*E02[(K_O1\!?\
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MCS<WXS?\$6O^"'WBKQCXC\'?M<_MF>#I/#OA#0I--\4_!CX$>);=8-8\;ZA
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M %%%% !1110 4444 ?_94$L#!!0    ( (<T;EFAH%)MWP % -NQ!0 -
M:6UA9V5?,# R+FIP9^R[9UA36]<VRM[V@HJ(*$6V(B"$LA%#1YXM(-*%$"(U
MC](TH4A)Z/!N"U($I L(2 U)()$2 H3 HS0! 2DA @$DH24A8.B=L]CO.><Z
M/[_S\[N^=U[\65EKKC'FF&..^[[G7!S\./@I<,'TOLE]@=^ IOB;HH# P9B
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M.6T2F^X;9PZ-*U#7_V:2!+^@C=H$W<J1-"%]0W#P_L,56(WOY3%N^%.DU8'
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M!3<3GF0?[7;=$[)3GEF/+--1:GR4F%+<R[B]0Z[SN2MHU$;X[MT 4=W]%WT
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M!NL!TAG1Z,/4_AHS'H%[5$8-",':[FNN>^]^_Q!1T*9?"/]WT!^,\-02YH&
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M#1YA?1QDC5'GA[50#^=S=S4OBQ*YIF^U3JQ]DZ\9B/;V^*D&C%<ZGD #J,5
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MD]]=W)^QRIOV>$[UT8)8R'PQ*'?Z1N&,806X<,)1<2F4:1?YJ#_YG/[* [S
MHSAU=4&F-W6?-&+Q'"\GB!,N@?V=W]K.M]2[N5+=RIPAG-[2Z$5 7><F("*(
MRYJ/_87)'8>["* ]>'SB9GETEN)*\&*1WKOP4R$ +W4U9*L"-EJ+<E01Q')E
MR2FW0ST&IJ8YE&JR]& NA?9\^48_7)@64*_[HPL<[IS0,EO.LY^@FI#XB.O%
MO]PH-D\Z(']4O(%#;88_=_S\??+2\($=] F8=<+\Q& QFO61;,,WX,@L )-2
MF&MLIK%FW^NN-17.A93I6XZDC:_2#>*J*F@5[O)L^_HCYI19C?W93T2=N<!T
MK=T-.[#-_WHM,HKD^PO@?3"8?18W>%EW<),N?>S5>:AO5++]OS4YLP4?N+/S
M\#]O>@RQ C$Y?WJ-GPJ;P1U8]%Z&UZ]I5!%8SBI+B#-"?ZP 9!@>IA=.MXGM
MJC9+<:(ZT/Q<'. U12/?BI=SZR8#N+QQU(N!GVK7;021TBS3$1E_'\.HLHM=
MX(X4ZI Q=;*)AES^5%KXC\]H4_&)I:H6<T)3;]9#T^8%4;XY%NIB02S-NK6;
M7:%\/I#JD:0%D2*O/=N]L5A)FG>:L"V\)2;NZ!>^ZT%GA9(]S!0),'22?F)5
M[B\UN,#R&;7D^+O-=T;G='I0Q.N1'W<A$O1O J#^N$G]B6_E&X0IJ0;HG]_*
MK$J?,=Q/7#>&[5#6I'A=9E'B5\:G\\Z17)LO1B=9+.IX>[#2YT/+;1:A\:P1
MARGY9]%-P8(;]3RYVSWW1'-Q_S-9SW'^,4BEC7X+3BPJKC&94@B+&%#14QPL
M0PKC3]D$0OAVE$*<V6MK2%"\_W_?O^JA*SUNN'>N^-5_J6TC>R-E&QAGK/9E
MC)]6P7IB<#KB- ONZ\6JYGANNF3[N^8!Y#$G4%TM%L0\_I)E.CA)NBAKIZGD
M%+KHV;7+9=&F*G^J*VA7UW1F3#"O&4V:\3M:2!:#@W!3Z8.;7,NSZ5[2#\+5
M4P.B<QJBDZ)(Y^*$3^@J?5WC=S]GQN)G!3 RDBCVIO7? E#:HGM_3H0]$*24
MM;+DB4[;I;Z(F,_:E8YAZ)QN_]B:YM,9WA >7P8_68(Q4ARWIFHN:+M8+VW=
M3RDG;=LI3C7%2^GU"+ZK5;ZO;69H Y&"3KUL((KSCWL EF_VH@E=5N&*\?&Q
M:,^!S3"$W_$>)XPHJ<O3<0.*KV)1!RIY$\C] I\_UF <5'\'S&DCS\72213O
M2+3F]R9B$3UPY8"LN:HWC:4EQ5O=M')0=!E.!8 ?;DB'AW;H,%XG*&_^$1H[
M2 <M\?13SU=4#HW%YXVI\HI@:VR=H>K5)MSIHSY%[QJSCLAHV9I&>)O+1!.W
M0M"[.?5/D&;,MO]\(D-5,!H!L]K_C=8"@PJT77IZ/)/HC "R8F<U 93EN=A;
ME3@^+96*BYLITT*)KL]7Y@: \(M.[!LLC]0[NF'T1C$)Q(PW@OODB+?+X.!R
MAHV*=LF+J,?%0S:,J "4OK2S>_6G*[>^+D8W]VS5L$;OG,O-V)2(3DS_.$MB
M54DFBP(Z"U6AUQ>Q*SSHWWONY>'0:1\?L#,E89;;R_^^H^@RR='ZJDMM-+5_
MUE#J[">1@:.7A?NXO?=CV@J:9>*-J=1CAR/[=*7[DYS+'T.#+Q5^JM_@$$\S
M9K1-$MGP/>@'7*XX%I#XIGO)'[<1M0P9'3!\D)UK<Q;*YXMPAELV>F/0;I*N
MT;;0V.-Q?7HXYUQH<^"1783@?C3Z<B/:;'CVLTL]%4X6?]C,]Y?: F/^Q@,J
MCRQ0P5BNP$DHW#5"!]#Q5)29DA$/;/[R>(ZEQ');K.8A_VFT4W11]6X_="!U
MGB NO"J'-=R;*O6'>XYOZW%NUL^C:2LSM"3)>%;!0BA=5/@RB^?"B5?-1G_F
M]61,YFXZ\I8?;-P$RH@:W(3JR1:P_V_VM XC-D\A;!#<GW7,\MM6-&CN\S:5
M>G=^N;LD!EFYO.0.TE)6!6B#E3F,?]I4=\O'!VB1?3=[M^(9(A!_=,E9;<>:
MU"G8?2B7>'Q1;N,9J4.PV?,PM#(I"W>C%N ?79/1]KL'9JIRZUQG1T))LC[4
M]+$<?U;6YN[5UH#M/X(P/\-VK-*$2X-^2U>^]M^U"4$7_?O#J&QQT7\T'(4=
M7L>/K:UM<'831'X%XC6 08YS%+@POSQHO=J.5BD+P/LQB(R@K74RZ 97EEHU
M3A[5M^?QE0W!A'0+KPHTWJ+^#(V82R#FQG'BJ$<5@4:;H'T-^]0;NH1-,//Y
M%Y_0JJ!O 5,;'E<P3 9>W;F)"2!9Z\)ES.U4.'0: <F]@&T%H:JJI7B.*"60
MDEIM=[K\799^T5=H>\8&*0(M)-@I5Q#C'U]B^R]8V^6ZKH4&Q'#<?53X']S&
MVI1'$W\O*4WQHU-7P"KA.V_G/0[N5^Z-=$^IP:T;XM^41BZ<.D5F0:%*]R9V
M( 1K3:MT?(\C"$]BKSQ K]/SC\^< WYA+9#%?1^V?K[%^1TXJ[EBXM%PVW*T
M"<UD%<U[ ?Y?0M[\G0V$>^.>[S/M+%0[:JNU4VLEEEI";>U3Q!Y*1(AM:JU$
MHF)/:-\NM*B8(%0T,=9((E%+$!J>+O:M2.RA=H(HM;1,.^^\?\'['YSK7-?G
MON_SPWVJR'-'W[J8'ZD15VKKY(P@&O*D <F2<=J]]P*!AU;U2^XL/?*@K==B
M."ZQ)=:4<Z%U3I/$&K(:1_EVXN"-_KJA8SL,8I*WQ;V)3EY'>'O(P?7 ,UC&
M^N3"MED+MOF4B6LYL;;F! Z[KVIR/ <T2]9CYHKJ@I8H>:#V":<L;BC\ES#/
M'HVXG_@^.:-L$,>X <"&XBK:<R/ZE(8"OE#?3_&^6K>U>5?4S&47 >Y<<)_9
MO%(VMW):0=GO0ZC? >SZ86ZHQ)[/$YR;F&GR@ IHAB ?1JG3PDY1$B<L9_BT
M\CX?ZC@^84;XZ@PU"^C5<FR?P\RKCSCBQF1)>W>"6ZYF4.K?<1]KOC<+9WP[
MNS3?SW253R@V=^*?+F@('GW<=8@W>L/9*)Y;V3.-C,RY8]/6T3:1%_[YVVA)
MT9L;AR8[ENKD3=6^^AZH6W]40+&;MC$RC,FB]<G[;?9S$>LX+Q!]#<IN-78A
MO<M'WI<H*@(&@@ADEQ*2VSW[E0%_KA0ZN"O-"$7<PT$UL-\^\WTR5P80C0,.
M?5MR<HRJ^3H^7\DLZ]?(S%CUQ2F[0*_8QQZS&U4,PK(,0]IX(I('D>Y2,PQ*
M3O=7MW2$>G9W,!Q'F6N1S+4/0XP<KO5]$/)L.W(ZLC E34KXQU,&]=M;PF38
MXFLI'XM)I>Z*<5V!,0H)/!7M\D=:;:<W_P@FZ<1VBEA'K 14E0-'=U1C,";D
M6#FA>AAB'(M(BAJ0ZE^L$D6M5<,'@.W+P?\YA>(<7M6B[3;D/I?C:I&&'L@\
M5.ZML3@<2&_<6Q"I/!KW6*D).<LC[&S&<D>0VD,=^_Y&^"_ 6W?(Z</1F-18
M8$,MDNW9M:X_\4RD7NCHX:EM!A*N K)7W4B0U,Y8O\N#<8USN(XB#RVP?BH[
M3)R)9>]Y^=O;76JAHCO?0!S3T!EMU([JY'(4MK?TI30'!;#$G4S>X W' ^K<
MF8*T])8+!G+F(G()<P6EOXWA9[<#Q4;Z">5B+TNX?P5!GL\6A^+'>RL>Z>M_
M;YA%GVM;[[H?YZ?:X.CMS8-AF7/5OZ8MK57D-?@NG/_J=[SY$7EB.4#XD]_?
MWUI)-3O$A^X:,S#JFZ)=YYIHK%<G=YMB-:"ABBCLRT\X>L4_MG%TZ7?6R6DO
M!\/5CU.4!/OZ]GE>FB,U\ZVS%$H/[<@6T-;35ACAT)" [)SB]:8HH('8EO9Q
MZ:$XA;JY@C9=*2!D-2]*"#1KJ*!7/2UUUM)Q:,<NVO1#BY[ 9P//"9@($5WQ
MI3K/^Z#)4&:)LS$S@^O6O-AC=M&CPUNW/>?/0&9']]OW&0H@I0;#W.+B2MO!
ME X)\H^!WH@P@L#/9"V5/=->=%T4H=3P#<EI=@(LK>UBL"MB&U63,KWM!%"T
MGDMM]2%Q7B((J:\(H=^AA.;4H7 V\U?'F/:6<M2K?UCB':).NU!(C5K"C9C3
MPG]^^*RLX_JI>Y:VD@ V]0>H\"XO/H8)KQO&9>V<.P*0<EZ\0ZP>*=*D&" ;
M_;<ND%N YJ+KT0.+*^DRQNTJ/CF=497EC^S#QK27YA=!Y^2&<\(&%#ZE2BH5
M@0?[#]S"U;(_>M-H64C%R[+6TPJ,7OAK\?R\]NLB5P_,BL&D&'E<T48UC8^7
M;3&MK7ADBC&SBKO-+L!J 4Z&(O,,O02Z>6;5<KWS^P'\3_:U2/H51DT-,_6W
MBBF>C;U>P*3STS;M[9X^9)*"OA-W-SK?1FEU2^!";+Z>TJ<D=DRF6\Z&,EF^
MYM)Z=>V;$MUVRDBUFO90]\\OM*L0YEBU+M2LB(&7.]_#B);'.0.0:E.SZ;O0
M$H[^LCN,#[.\5$FN>,$<S&Z=KGW]SP].(0O<[/'_?4%0Y,R3J94DK_'NWM48
M8^O46@6S_@'S<A[PLDEES]PHK[?COOW50YF[9:3+Y^1^+86II9]R!;2K0K.G
M9;7L#F!4E#PB*97&B+>W88'C6Z+PC^D[L6)&?B4AF*?788RJV2A6[: J716*
M>!_,SQOAWR=TAA5&CKD"W(KCED65R7F+GW![@5_UZ'GQ\(K\59VFWM9P#W!\
M*T1MNSVD'7GJYC!>O:M0R-+2MR:D"V$J%$@I<C2S'*U6]*.J%K[D*<BJ+];V
M[X2F5[.KF_KPS);NXN%N=>7)IS/]1<_(^EL:>58\):R9>KG!^SV+7!_'V/"X
MJMI'#L;P&-1\=N'7BWX@_2 J.QQL$]#4*\YU>-"&[X^HUPU=KG9W?U??8^S4
M/; @W/UL(YJ:2!_RQFK$SB&%E]]K\9O;D,5*&UJY%23Z_I]3HX%T[72 CE #
M7F[4W=1SCB=_LU-EPE20Q\*/Q?M=ZM2ZAI-FO;T..W A=A-$A"/9CVR7KYYT
MR3N9-[[)M'8?'LM>/?AF>7L,78A9Q>.('Y<=M5V6GKQ$U/K5[OAPO0)2"Z"P
MVY9RM+"\GH8P,=A]?ZS%GR\T0!.J]F_VP<M$OM$MJO#8E7&C$FD<QH"5'$!H
MP+KO)CDCF6O9C.C!AT/E<2T6[#V[![Z<G4[?'BG8&8AC1:+W?WG7J( H2I3+
MJ<V9:W#OEE3T6X[LGJE/I:O)6DU+;9[+RBQ0*8L;)3F>'!TZ9$JA6 5MA=L
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M35E5C[6EX6E<^IP_4_$0]JO7L9]"?-0<__>A6&AH+=K&8RY0Z?#-RXT.P_%
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MNU<Y22OMV1ES)1*(@C(4Y3ETF0UQ95__*]\9=%9RGS+P* B 0HH4[&Y!>'0
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M#)ZPAZ7%"$)TOB@M^#Q*$$WJ;@'%'<'FM3.)GI]V16#+%)GFFWXN<X6]VU<
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M//^ZR'VL(M3G3A@6-V4K$E9\C"?$P<P9TB7OKUQ*BMTRA$OJO_ES'@V\8*$
MDOZ[\'0$F?\L$>>;I@:OBG;ZYP<_!,__"^&QX&^]ZC8_D:*F\_/#_@2+'Y^_
MUJ2/*EP5%VKWBN[:I,P(X/?W ",*<<%:D<I(I,0EY*SJ?'K_5)7#CJ-A[")_
MO.]<_@WZ)E!']&SA/Y/NP0R0?.Y?:*OE0D>&QB)VL>_+\^*CA7IWA\'AFCGL
M'._<Y-J38\P^VOW18VD>P?Y!T]CKY%?0F4VD"#''LEVE7C<'^ZS6Q-%0%;F*
M^Q8CN4IM+J)G&[H"-@'DC2U?:1Y7T;?R+Y6$--O,"G 'NN9AD(%\K8%07WH
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MZJ%Y;;D(D'#P[(0[=*QZ87K6#G$X)&:0EQ$%!WH/X2\/W[7@)8P]?JRJK(Q
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M1-8*B6_B"//B#UQ)E+DQ/CT&-?$(6$.+&FX@=9Q4BNWWK^#&]S[-DTA_SI5
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M(M5W>(6GB8%#W"=R(1%3((,?3OV1HU*#%)YU2/4:-.JWGQ<^'<-@J[9-!(U
M?K)Q;MYA6W1AQ[*&VG/FH_[WY4"TT\R"\,\+'T,2*ODYOVA!GY/7BG!X'Q/]
MM*4V9>!IVX>Q#L_BG%9/C:MI+/8D5+:F/-VOZ. 0/EA-_GDA/WEXW[[?(D4L
MJ74=JJ&FWWA_[0YP-;*T#O%2>919:4F5LS7O_@>.=O1;UM"RERIF\,IN$A22
M7*MQ=3[9BLD AIVIN=X2V@]@U_)RU=JL>,2JG3#>W)DV925X.?R/9'Y8DT)W
M5V"(807 WTXMT3=JZW9]58@&RX9(R@9ZIF3UEF ]O"9O@.@%YO:E!9[EW=_?
M'=:E;IWKJI$V\\P9'W,[E4OAD7M >L?/"Y?1T2\'R$3I"=E<^WN3'L\ZCZ/?
MJFAR&R16CHWLSUXY(-VH18R=I/]FL+"-.:&Y/KN)+JKJZVNKR$Y (>/'1PI@
MP&UA;G.H\I]Q<:AF7>?@C+S7\%KX,*4K9$76[?D2(5W<Y8LS\NI,N<6YJ["W
MWGK/S8(QU#>29HQFP7?&1=/TI1\X3,JRH@C:8E7@2^BU1\OT :,A"F>!Y("&
M92QM_V9]Q)T>A,3,'&&!4DAN/,*[097CT_1==OC66BQ&0!G[74_^:K8-%28!
ML.]X;:G%A1PH[:\ZG4S7RH;K.9D%98C0V0@>^ECV5HO#,,ZDDH#LQ[_+FU(I
M&^'AEVRRB^H"UB?4>>);\2+)%7P??UZX=&4;?7I'?FUG'F:H8Z_]\X)G_R9/
M+]9WN+.84"PI6CS?\&!U[VRGN$8Q$^<UP14$B%D>'Y8#'9>DK8)[:,+O_5S
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M1;A@K]=E2MTC'"PV:S2H.9E($8+D24$V@'7B 8EZ/9S_X8DMJC3'A@+OHA2
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M+ 231@EU(N=BE,.OW.[W-U"W3&.D.(1,TD 7=50O6^6N@7/==M\X7LARP>G
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M'8W&8M%,=@O30]*M\8+F/@8-(3'VLE5Z_B;"@EFOEB:NO4OV+/F.&P)VKRU
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MYSN'?^E?#C,(Q-XNW5(",I<DHZJ0*D5.8,8A+[DG)-XC42@.#.SVMTT#*[8
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MH,TOJ/"XM4?T=P)FQ&\BLA553!8C@^ZM9CD-IEN/\=9_,990)"B+W>V_:]R
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MMWM:3>^U<S?_7_O6'_V3EB.A]87X;@N%\UEB)!4:5TS#W!\K/(#L2W/QRR<
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M<_JTH)GFK[U6N_+-6D$:IQ[3T+/;_-Y[0[WW;'W>EZ5XI$&05>ETO)'AZFK
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M?$O/(4Q.:LRYU9&9KKS(X;EW(*E+T--^[%=O?0RPJ40C-?@N7WVKY(@T'JR
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M3V5AV1'5L4)A@^*OOJ^"6Y1C^OI$[>@Z.AEE+<J5V[]@'ED^&12/PV!MI91
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M$)F-8Q0)8?*"-%J4#Z/$_SH&3!X#COR+5/&_<--/(-4C%D'7TEOO)3V-WLN
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MKKVK'!@M>Y/G7?C^:47M[?;YEM"^97I/LJ.0\&PM0"W50_&R[:-A[I*CZFR
MI]+K&)+5/;FI)CFBJ]:L8I]XUL6Q.?7B#P(YQP >_?.WVSXCO8G5-82A;2!2
M\&$EAL62=?X;1Y9C&TNCLZA?DTN:J@0#*+A&(;F!WYW%C1E0';4!K2C8!..B
M>NAE]%4?O_)1.M1)F=(=/?P3<^IG<TT0RWRPD;(E<NYZ=M78*N=WFK6Z7G-@
MLCW(OC[BM]]006O65!T(L*A"6_Q )K%[[H'$%:*<D:Z^58R\ I(>'CV*LB/%
MG_W29'AOX^\EW-%5?[CC9O[#VB'4;J759^VW]"!7DQ2[J-K1,B=*T_+KQ1F'
M&:FE^%>7=".-SK,:M6%+%#PJ:,N8P1^0K",&5!':7TDZSPX0DQ$F&P2(O[,F
MN@KK#]@<O?*6*H/J&[KO\6N,5KUNEFC,KNYEY46$+^#T*T) ?0C*[WG2C5,8
MU52YHP]3W\)*=F"*6]7B(0,50[1[IAVV?Q!'G0WSC@&P!UF=X0:'OS'U[4HB
M7O=O2=T\NB2ULOO^&.!Y^8#ES'I\*2F%:1(Q5U#X*@,S/_%N,&U[1B %^;_E
MY>-)/-T179'L%-3)4^^[!P6?PL^Q9=K//1;Y'&=1FCUB#+L'J7QU61!62;]?
MTFE7D@5KF,"MAK/D/S4^;U"ZQ]3:#C]A1A>IZ;@$'V6OBY0L!F\3/M$66VO8
MVVO@BR'/K?F(!!TH:M@N-^@O=U^?6.BP+9E9F*5V=H=&R< /O$E'\C4-I\:O
M5'.-9U;^1&EDF>G>8[0A]M(0Q*;5V<U3C>R4>@7%7]34]^Y?]R P7[]*3[_6
M(>YM'AV'MA 4U(WV/$\[3-B*]&A40(RQMVIZ_QZE#XOL.!F:CEGH&GZ=,^VZ
M0!:THT+!,)^+TP7_]KL,J;..HN7U)@[3.T+$S 5%599+;:OJC[T'=0B"E6D.
MDR@S_6+-9JIQS<H]3+$S!XW/7#X&,.M]%X**M5?,ZK5G;(NVSLI8(LWN4BL"
M5V 0 5#D?#9IIR]ZQSZRHL,\LNG?K[[WF^93UFJM6"B;Z;_XMU=R>H#5PY_3
MX@XDX'("JQOGKHRY3T<[3&R!;2;9]U:Y<2/!69&%9:&X-AOFOF[?6>C0<'NC
M>,>UT'UA[601JH5%:%YN=YCR-UU2M<9G3EY@5H>WKC-[+7L<L4 LD[5W377)
MF2##R)!+5 NM;T../!V22@<7OB,9_^P=(GWQ=KM_OG^0&IA?#N;,@-?F>UY3
MK/*H%E8ZG]1#6I8/70-]]V<@"[0LJ3&9_V\>\%ZFWG^4W"VM=?Y[U^B6]>U&
MHX/$4S];S>P4$4$[)J S#=%D/'%:^,?,+^I[% -\KKQ&9?H9\WE4C3JPEKH#
M7:G;^^Q;,V3G\2@_M_ 5+O&LC'1Q<=QE,=&L7K3%S9BY*$%NU^HI_^_99:G1
MF>IU8&_ZNK6QK6^ZZ]/D6RI"7H,/<@@]K%K-5N3K>5+FDB$WB?UDK.G:9Q(;
M+I95F:;2.QS<;/*\^!G]2TFY(RCY#HL\K?MV:8?>6A]WM[!Z"R9N\#Y%[JZL
MV.6+]$T%9D>'3.JYPS(D&ZYL]@YLUNV.C"H-73<.CJA:[KMB+T>9*OW98P21
M,*WHW+:4SL]%5/292FO:9&'?1>ELQ,YXT!A$9JCDE67;P&V53@:RS%+1E-]1
M1$_6 &M_V-W99!3B.0GVHM=H*=!//#:96*/>;V9KNA6(J>@:[&R.G^(A_Y?!
M_E^F6U:+.1[\IV$6)(HB\N)!=>*\E0Q-%U-)A>1.A_I/"UUQ8:8^;.<J;%L/
M/XZ<%P]44Q5\,MD[PL!]F.LV+D^!8N7= LF^D3"HLCW))>5EN(K*P^DSZY;<
M>9N:6(J9FG\Y>57Z[QZO3%FSNU=!0=[,81^_QO,';,&&SXO393.O[KTGJ]5G
M/.@!6XA),JXQ@'FB>YQ6OF2)L &K^UNUNI@,>&XZRTQ**8VV7SI4IOV.N"S<
M=$TEOR[- L&IA7574B6>D95?:XGUZ2"T5; A #(L]94QR,0ZCI15M/*^]J&-
M1U[><]3]+^U^SVJFH:R+X8TK0MS%<ZA>\!?C4BNM[-P,UJ!_74?SN>7J:2R^
MG_C_K-<Y&Y8D/37;H\O!)@!^^>>_Y4P7 ")SY8?A>6<+S,P,WBC,H50ZTO<Y
M]5[U(=)72CA&?["MM33:H&7H7B,D\RPO<8'V:7Z^D]U0,1'E*ZDLDC2,OKU<
MHQ[0T:1'6[Y=4#O*9$"DO6&^H>(?>Y\0KU!EO4(T?HJS#SX>;58$R?$1*5'J
M/Y)MW;L-K.RL;8&>*,GAY$K-6(K8A"]- IMM3:V<;;[8D[?CVO&.@U0++KM[
MP:([ZX*[\A/*)#K]W/=TC8"ER1%-(<(7Q0K&O=]@;TQ$=4F9OMHRS^!=G&NX
M.:@F":0@]$<PE 2ZK9W=8.33E#&69,N2NE1&J] 5UH#_WRMU2B[_..]32=MS
M(%8T]K;FDI_O&F9)]T47"UBHJL=-ALL^=K("\+O?^5_648/X1*Z:?8>SL9$I
MKZ?:D]@)3O4H_->/=ZK'RCAP=!:,S_:,Q&_GTSWAZ6VM-L,P6(LR1ME/?&;#
M<EE,^!CP-#0;6Y@RC<FJ3[16?]!M,X_1&/1DG".#$:[P'P0FH=7L3SK83,$%
M;$Z(#=2'SI<_VS= F4MM0"S'.7HY]<O=NT&_58'-0G)34N =2\-LHWP7-,P^
M"=JGDN10['K*\+KS,_4V,7MQ;Q2H%"4M+1UH8,#]HUFDN4ROYK"@[.CN L))
MQ[* 4#Y35%98B'N0CHL%(U3N\<'ZL9.G!T5'\OY=/O+H]_/_VI%(T.O<M"_>
M3Z[=H1L-HH^R:U@9NMY%F_<@_C76!A^&+>F&\7AKY2DJ,<O\MQU@G6MIW1/D
MEUI6EAR6IDC$3R6M/*XUN_^69)T?W.=L%:RA<;M/XTGNEI3D;19/9X22)])V
M(Y"++QK6TGI2,+CM?F.XPI1C@UI.L,H WRH'!]QZ%Q(AC#>GWF-!^!XGNWZ?
M>EJ%8NM;]%,F_S3.G_R1'Q+P/?3Q";D&63%Q3EE%=8+>;/X6$W)2Z7RK V'Y
M4OUB[1&'A-)..0:LP8$,K-U\!T(<O1%B[>_X3&MML;7WT7L0[%I"O?D\KMY>
M]\'0@+5JT5:J6Q^T9!@<"JS%&!(&$>^=FW_U>4O=:*AVPWWOK10QYH?DFX[=
M;+"U-Y)!Q,',V5_GG77W'5>7M[!16D?];1)";G2[" (EA52HC;J2($(*^/%N
M;B, )DR,G2@I>7S@_6TM:[;V_%JHOM6=[0&Z=Z)F;HL)1#6TTH:.S<RR*@>#
M,<I@J\6XVBAD40//M +-<* 9Z1'#$I_#I2=PDFCNYQ+ULC4"_G[[!]B:+.R'
M6\P[Q=%9T'\A\CI07&%UN>2Z(W1DBF)PR[9$WJ(S'NL"]EKOB!CY0N[>44C/
MTA"?/6'![;$?,?:K'T51#ND9<#5*LAC,ZOK' L-RC-*M=;TYJ_X3->U\7IE;
M^/TWN\7X9$Z*_5\RL&I5!6=2RE68@\'#VD*U\-V)Z'4)(I%\9T+_C.-OP,"H
MTVOI>34:K4HEY0MW&!0KM0'I]HX@;J,;E%MT<3%BM%IX,J,AV/;VVXL7C%%U
M=,MI&6N*WY;;*'$&O!DL.O_#.#W<HMKN^FIPO8EK?;86D/=V&@0"X;.H:!,3
M%"Q%R6&DI:^4-1ARG] F"VY'*J4-\^[9RKP=NJX4N&ID9J1U3; KFTL$YF=\
MS[Y>@GN:XQD.\1[1BI@,KQSI\*<@'GF;@4P54KK$3AQ]?B&6+E*<,(^:$EQ"
M1OKA&J!+C?H$A=R8/_'$==0SHK4ACFPH4^!$U%#"S&BYPIEAC&H/,CTK"HTB
MJ+7]PJPR+&5Q6XU,:X&7X9J37:B" >"\:AS54<19KM9B(]F?6:DQOE1G>U=B
MW!=AKU 8$/ "?']P=W,Y>1/2+H:>^>U;K4 @Q,V^C0;QT 4Y43N0]T=&QA4O
M;M% Y&0-D&2[S%MYVN24^S'@;"I7>CERHWY]T5+\K8"[.2V\<CTI><*43*2)
M!LL+KIH,.[SN% Q5EG[Y#M,HU+8TL?-Q3^53GP#SMD"KO36N @*#W?6=6@MW
M3AAZL-WHL*TD*'AK44E02_IO@2R=$RWIG4@ZW$ < ]+ZPN',[-:%5U$S>K4%
M.V:H(-,]C8?WBI!A=0]2"8H!-7$V+.-TQL_DC)O$DFAJ"S''%+";O_&<ZY3S
M,J3;7&.CM])FDM_>I;[#"QP_P!+NJB3K-LN*K\6W"V'RR"':$F:CM=6'^IYZ
M(I65-?>_C5Q*]@9]3XN.,]+FJ\PMVW")QM69SQO)/9/_R#GS;)IX(X0/-)*B
MM>(:)E!,*$J^-283$$PE9GL4]_#+M_C<X +9,-W@I,'Z?%N/]I[N1*QN9>B[
ME;)*H%*'YHEN'MQ"*.D^'HQXP#G_<<?H<>/FH['V99_"-*<&5II>*RT?/G(_
M$\>*<A[K,5*=EC$W6EW>>+*"E_:K["_U>)R@%.O*B7W(/.<Y#[]Q?U%=XT0Q
M42>&)[*_A&*AW0U^'DTRP:ELF4(U=H81RF/+E4^^)/=CKQL!GZ@!)4E9/%RD
MGO!HNP706/LE8?#*P)Y1\2HT%-7A4S4^\R"4+UPG,&F@EII@.(P6VTDHX3FE
M_#GV2XATWN9WBM5^&V3K^5\;E7S%CR3'+ZKSS;=1+J5)2335-+ZVR2O))Z"%
MJQ[!8!<T5D.+'2HTA>1&\Y]%7-3K8Y!EQK>RJX;4@?N'W)=K%.LA.X*4U<.]
M$)\4N54G(-MY"/+C4]"ZN$0V'_H@Z!A0L?+L&+ Q)&ZQH1M9T2=W#'@Y$'DA
M(')C:)]TTNK$7*(H93;:!_U?[+UW6%-;MS>:+=N&(B(@2E6*" BH$*H!MS2I
M,28A=)1.8NA-0K'1#4B'(* @"4DH4A*:@()T 2FAA"8=0E=ZO;C?LO<]YWSG
M?<\?]_G.<Y^]_IIKS376'&/\QAQSC#7G7"O.UZV<!G4N_:K/ M?K^+C9+V2-
M@;0;0ZW+11&*C<DPV8U/IK6YQK4M7&R7:286/_ V)%*&I[+S^2WB>1N4G9;$
M8ZS3A 9LL=WWE_S2SY_GRY9?.2X\:&>8*Y*%(S.(F$S-;KLTHEDUO2EL;U'M
MTIB;?Y'JR3,IG:X_UT_D,O&(2W#3AKBK.+6SFA]_F;GL%HC:\@+7//Q8D7Y>
M0<N^TK$"9+MT;Y:Q:@@9F!T"J<=U"=Y41UT(GQ97O.RM-YKKEF] '-_E]N.D
M<=^/L$#M^2/+33W-]\O$< ,TV5?P<KF]'F-XOKJ9MG#J_JTWDE5_#LT#&@3Z
MRFH%Z'=5GW1:,DL]ZZ;OO#"Y'Z$[.T=]1P[>CFD".[Q-(&G*=$SI+]ZE3ZHW
M9]CS,8+7YC/M2V<7V\R4J>8.XNA$<=-;-V"0GCLS=D$SJ293BC=IW^_)??M/
M(=8OW]._A>]7FK3O+>7_2 *3C]=&-H (8A52<YBA?3*X-9O'M>3GM]-U;N=8
MH 3*S'+=_,?V[ZF,IYW/I<ERB^H. UGH@9I4DUG;G.SX@'4YH-D\!G&R T0*
M=0%JU1Y'WS4KWI4B)3@?:\*@N*L&2;>K+BX#$6<K;KMVE9"M.\K5M+21G45?
M&F!JMZ/\I.D3,!-<@Z",-?PF5MT)SGYU4O,;*/#95*UY'D9S#N0)/163%O/L
ML4@T.2%+ ]9J6**"?M2R,-L]I'HJ?RVNHWHI2#5%SX/+5JHM8;_U]35\URMM
M/MNQ#+!NA9DU<@S_UB2TPKTWH5L=!8$HQ[N$3RK.C7I8[NC,+#G/'%(:I-=&
M-1\[ ,R#]\)?R^X1G5<&K7<%%TJR%"KK!]I/S^24Z&KTT.,=B@83KE =+\5?
MF.GKJ6PF8Y<V;N@]+S (H#EQ!W27;+9]5]BA1MF!,#61LM*\/OI'8?,QA'FL
MC5=?C';NFM%.3H0 W.]^1IGE"YA^^U PZ9=5O*\/XZT?5+W)"N-5%@/D[17<
MR,C8>-LVZ#8O63-\PX@\ ,;/>% SHR,])<?:CT 58\8EC8T^:]X='%>.]9()
MTE!LO[TKU9U3HG&L]*NGF M6K@5N14(6:EWQ?7=SU#A>?<V[HF'0QTQ_\YZG
M]+D%3VYH$)V;.O2X7#13S6PK@90KC^>\_$S.(QH3[2VEO/[4>UD'55$I1>I]
MK4K"::.CN^2F.70F#:%?FNZ+R?GX[@RD.TMRWM)3IGZ^Z:):TI8^QC$_Y)23
MUHMI!KI2.6UDM-)K8$\1NQY*S[_]F"=Z?#OSLHS!@F"&,H;4HS-G?B1"H/+B
MC8/9I<.3;F7#7VXH=^B-4$-L9S!Z+L/BW!<?9-(2$LOQ7:9*#TFDT*BGC%1(
MC* H3*,65[>HH<&RHV9ZM#F2N=S8&'1M_E&!+O=D%"KVZH0E!PPFU1[/>W$A
M_W-:X[W:VD@)AY8@3]+0!K<L$4X@9X55LD6#F@I]8ODS,L;YVNBAP3VTD5/X
MJ/!VB>*JL"I#<T/I,NJ2L.SR38-],L_P-% F_?1X[0>647H1-3ZQ<&A<=X"<
MX\XXN70:YYB917QT_WY-'<ID+P^Y.#CI)FBKHE8>CS&>I>?)>RG13OWF1'J3
M0RK^A'D67(!=#=W2Y=/Y/$6!L^U<F'K(Z9NO]]JS?ZZH[<-"5#W"U3W"X\?]
M6<-F>IQ-A](51";7C:[?>!(E"<XCRGE0L3*S:<5J*"U[BB0NF('GY 1\6WIF
M'>;A;<'),#^WE320E3%!Z?A,#O*_]04I2%'N9<7V6TQH%=&]DW](1 W%E4;T
MQT: QZ:9'F;G%)=[MTOB1XXTB9RR*(OANI-L[)@:M*A'X60_69 O V);+IT-
M*I&31+]=,IS+<:0&OH\,SQ!55%*$%*D K>R7X A^&M,,:QHX]I9;CD'' >#$
M K[!!H.<E>P55S;%V\,F[^?+Y?IZ+[@9I&'\;LE(B?L)<W=AXSIGVDXYM%!8
MZK_1PF@+&MFE0EPG%F&0C'>ZWPIMFP<GY?(XAD'/=\[#O +?DFB^3<5KW(Q)
M+K%7GU>CJ7U<Y*2H18\\,V=WWRO7:;#F;*_+/]1&A3L]/_"/E[!N#CV(2!0N
MJJ$G"CXD(W2R9S:D]^]+0T^-GDO7;14:$'JAR@=*6S,//O&XU^&2*9:2G>S6
M71.^3JER=MH\ #0P0=?W%I@T'.?CP1 KTA?<_@7'[->TM<HS=SL=TZ.LZAC2
M&]TRTL\/ ,]G:Z1:UW\E/H_UKCX D.%E>HKG;0QTN?I#8VX1GL</TU2<7:QT
MIY&MWI^<.,UPL]>XS8LTQ!>]32S<2:)N^>Z(N,91YQ2>!94^#9Y+V(+ZGD(Y
M? ^%^$(=_.MM\72Q*F:!>6S/R))OX'3<-"UV=-IFL7-U+W$S*]M3!!Z,OMW,
M.(EN G/JW,Y%@'E3-B3,NQ8#VL^JC#Z?#IRMZ3^,E+F7AH(#; )>2Z:OW\C;
MZ[.?NKU]R>_=-W-\^-IR.G);-T@$Y"F1GSCIP7E#3E.< (+ \S0,(KJ7TEKV
MWCKNZ+@,ZYOKVR9\8I>8?+-J3#IG"[<VJB@1,DGUWK#^.,K?+K"0A:P>(!\
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M?MM S4F?+\[RHG0CD*EB8$O>1 6[;M>VAH\1<X(%PG#OLK/%FP\/ #UM' <
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MX:WFY$45<U<>C<-(YGE%L:0%I=-PNM?!9(N_CW\*M%H(O;O0HJ'<M:;(0ZE
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ME%N\@>A@M$F4ZG8UO"EV,RH* QG@39J9@-=L93S]@1A]N%^-8UV/_EL*+!7
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MHSO; =((BIN#7X%&=>JG9S29X98D*YLS95 0?S N]-E^DCJ/&([5:&24;7"
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M%Q2>=/[23\"KF;;#4ED"[]<RI;(#_7NJ0ETSDS6O>798D_3R\W<0[/&^/>O
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MG527VP]41FGGCY"@5J50>C^% UOL%_KG0274ZDZY_E_M]C!.2<-2F,\NA9<
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M2-X8/R?7Q)EY81):$5E441F%Q"4EH94,@"!04N'K^'@03+G;_ D[.[=4+X?
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MYRPF\EYB7.V7MU!]O'@Q3:ZW.>"THQ*][>UNQA#[9WOV>YO^[\;4\Y-$FD\
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M-HN,7-^]4&P>V9#(7ZN7PRNL(QKFCO!)AT#GX[;+RW3D^*FCL>D@XYD-#?V
MV"&SD%_I?U<1LAB%J/+!$3\IW4.BS<\M,PU&?1#]G" .=OD!GYD.7'2ZS\V=
M;%3*FWOO^MNR;>ZXN?= FV[]<NE_JVM]K79&VOYB&\ZS0O(@.\NT_P1@,86'
MX?C#2U8[#Q0;W^,7JQF/<S8)2GZ)E,)/"Q=HB9+>YAHI#8EG B5E%+%>^T*6
M5^4<OF*2.>V&\GF+!YC8H 7C2$TK+7/L ,/K>:ZHOQY?8O$T;&_FJB)I50\Z
MO!.7DI3C6P!M?E.IFV,IE3F&75/8T.YOCQIW@2,6%7@/"E]5*SU^/Z2:5Q;T
MMJ5.OQ!>PQ=B<*E%C1@]>S=S%RC.3_NR5LMZ&!Q=4_LJ_*;Z1^O1(,P7J?_S
MBNG_O/V5:O+7"2#P0"]&]-B(-05<TV:MY%PMQ+@+BH;$PS_5:D_0U)1)-K;\
MD,<#RL6X+%[*/*++$FN-A:,_K904.-H]OXEH;'="7\2YYG3K^#D\9@9)[ 9I
MZ!4,&,G>75*A*1JYHLY)V9O-[L!W[LYOE[S9TL@#P:% G\$@KB,-:DQ M@1\
M!I(F8)T]I1R2JB>C=X\J\7FU%<D;K-K/GB3<UU14DE_7/E_#DYK"MZ<N;VLM
M,[BH\C'?T56*9]-Q35ZE2ZZ(0&UO>*8]%ZAL$^W ;2L@G3I_ GB(PZ3RJ"@-
M@2 *+D_)!D^\QB((D[?065C!\8HW>%3Z,103]%Q(_?X3'?6K['Y)G8_GI @#
MV3A9EF74E\8S<26[C(4Z&6&Y$<_K[\\\H/WXJ0SZ!6;%/A($+)]C\E;1#H_[
MJ@G#]H)M1"^4 YG&E%%1QD5/V\.#+Y-_(IOZ)EJB/QO>A+=,(CSF6NTTF>I#
M-A?JS(W$&O+V"]'DOQM-'Q(2GN[ZHF/Q',EM@3C\*,ZA3IPHSKE]MD@5&F=K
M*^'>FR?/Z\I)O!R/W2W1XUW!3H\*>0PJXKVP.4&1=K42S72=QP=Q#1']@99C
MY"QI][QL9^50'.$I#CN.T6_!<_882V?;'5^ C[ECVH$Q(9;4(_VA3)=ZL.()
M $E>Q.VJ6QOHSWT+V4>S>K4&FIR_#AY>:5UV_RJ_Q,F,LO&6'Y^_:ZI>:5UU
M_%"X_4X,M6) ?(R(IXK8X;!+PL)/Z$N8>^?>]K$A+>[M$#I06H@DNHZ AJEJ
M8@!0A>>?0';5:.<% [LL<\GUIA6E1S!!XQKUVD*9 :TF\3\W+A&%3P!TSH]^
M"ZP&:N )( 2\<@*HVG)Z9^V<TJ?WP$ADE.2;=0D*]<VFL*ESX2OLW*L/:^H>
M/1IQM5JK[AM0CST!E$=%T9'(2^4LZ+<Q4$D@M"%[X1%8!V8B8"2MY1%KX?14
M.4FN/0*1B)24](.836:C)5W,;CNX>=>07L.%Q2<ERY!H6"/G[,9&VB,NF;+K
M3[.#M7OBZ 15M0%FR&0HB$U5-.PM:157!5&5VE4[^()C78<7IV^ $'6."]_"
M-UB5?:%99U/&C#T]5X=J49A"MQ?J2,WB#+$B9P\P/=?A-\<Y VCZS'RX:UXQ
M G8[J5P@XLA),IBM.A62RLO[O-"XF/EP '+T7(6$?%3V@>I(V)J<9,QC^Q=5
MELUI#5>N[\'J+)[[3C:D6!_I&G)/X *>YY1LO Z-=K8_]@W_'"I94FT&(V*A
M1IS:HRNSY0*O=Z=$)=PAD"N^"]B;?ZX:2N7%\^)R8B[B2QG] >YIUOFUQ$3<
MY D@86_8?^V^ N/.\D$-0EWI>DG5<&E-OJO,<CS%$0/]Z"NC^8].(@RWXAN<
M&(64O*D/?XX3#O%I'1;Q>=+EX\2I'AM9E*->M>\@9DTK!?I;.',VR,;8HI^O
MV+Z7D1C9X?]YW]U'-H]^>X2U9CBSD\BQ3BM&F2@><AK'[>G?7P"5S/2BC3_8
M"_AC>C-"LUT$4O47K&/# T1@9?87K$(%CMFLPJU=U7.*:XY_LL5(F[2Z5^%?
M-3WC.@'\O3!BC]I?RG;MYG\=RITFF$U[WDA/Z_9\,171Z$1$%0X1O68O023<
M\WR3,1H0'=UI^[-N+@.[AJ&W:;%O/VC'OD"/\[:9_.0%A$E^?1MO>.@5T19F
M'( W5<FL3 KR6)RO(O8]?>U%Q!?$5J/A09-N7_2I#E/!IE;3D*:\O-VBJY%'
M08S,>J')55R?CW"!XD$;4BJ3!.NG7-.US?&4[NK)-JF[_[ ;U_G 6EPQ#W5A
MNE6IG<.F=A?'/4],+JCJ'OE(K'N4/V5MU7IH> _VA'7G"!$07FYBJJFRY&Q2
M#AQ)DX%]C.GTV</5B<5W-$@2E [\H!NW^ZP77&Y,8S"Q6?PD2'ST:-FD3.67
MOG87RBPU/L_V\OTY096^_OHF<TQ43/LQ1?7NT$:C[A?[;:HJ'&@;43:BCVK&
MNZ;A\SR9*Q =I;'I15R41;Z7(N9=-W_UA^?MQGL.IB_0KWU1QWU[04UC2AM7
M*REC2^<RRM M8)4"*/. ]HR"8TJ5URES4'V<P/=!2Q$V7%T)T0*8^]EEVH-P
M"LPWV+0/&!WOP/%S+-F4Y[H[:*T)J)+C"E2ZM.U!3!0=L#+K#$W$O@KMIK,]
MS N69V)#BZJ<7NJ8EHJ]:/>L,"-P)WH4HK*R5"GFPC?IV2D%GLBI0Y:LDL"%
MI(#"34_=O;O9W9E\!1.PBR4'QNDKZ*)S)52B]+=Y"HN<U<$P23O@-H1U-NG>
M"<#3^+/_D4??/9671K^E\%8T)8P8?NN[1!:U5^DP ">2L>;C#WU4<O=/=KE1
M;]?L[:XAK2WD9;1AT%U_#B'_]:V(>L])(>=@RB";DCTPMLA?%[^R4]45#%V&
M.?CYB..F.XJ\XH8NUDJCNW\-R)Q$-G*BRZ"C8P.^M(_:Y3&O0+;%KV,5\W89
MO%DF5>B<2%Y5JT])<&D)IT;UT[Z/?^N[>*0=5;9J\/4[ET5@P3M+:::^7>P[
M:ZP#QMEX#1H='8 I=.W>:2,>V86I<(BN&$R/):X_$<AZKJ3SOOOZ\':APHBZ
M(9LE'H?.$L>&6PKFT.:H)@*E<%F;#!V2]L"%H=&@0RM/5PIY9E%NBJ "DJ*S
M>=.4N5?")GV^C:Q?NWKV2Z+:5KM0)X"ZJY'8J0/A7)9MSJS&I,%EWX][TP[V
M?,D(]'2'I.R+7 >N[.J'S ;54 7!(6%B5T1Q,9;*J1)T\TO?DJJ&:K_[7F;I
MLQ?^EMBT. _NHO&D5[\I$P;^>R1Q-PQX K!<\3[4LSYZ%=5!;Z,*?IMK++O\
M3W?0YSJRVC#SX0%KZ<<E"2VG%@C-W[V,G/.C_H#09X/OH9=,OPS;.Q<-<.L'
M&Z#WQA^PN97^V140*-R*HA63;(I49DS.>XT^17#-R-71K*ASEL/>>I9 3D/H
M]<WVLUJR>B*IXE)V;<(S_+%9IJ:FW+>=-/FM]C4//8M/ /YP#5+D*7%(^^O&
MR%A\?Y%;+:73T)-QIW\JP3YD?R"\CBID\ZY^@P^ZJ,]M2M\!3B[H$G2DU?U#
M*K5Q69W$;DC'C<%39R*'*[??OBT15\EDHOCLGFFF0T<-:@O)GSUD$!5X3TY@
M5G:LI J;;6A>0019^$7VS#WOUH%5;:+ *Q-O^ZDT^Y"]@9RZ'2&;YL!KJQ*+
MWI[U@WS @;EHFJQ:@T]7F#+QD+S3FG\\5'PP*PZS5@^UV8&"V\%@4Y%"=%!V
M64B"STRW;]HIM0!7%F9@V^PMZ5 HCOSX4%G!J?.X\UON*[_KUUW3.-^!E;P#
MPQVJ]0F+QNF8S=?D!8HD<@^:!*W9[\V4$4$_O8$96?H6YR,E]:ZJ6PSE[1(_
MC:$\D][RROH\_V4T4IQ+U>3ZH))Q72:U[+)=P/H8>'4AX4R-G]D)8/2L7?H)
M@*DR< *8++@?[EVQ0LGU!U5&R*\?W';1>-_.7XZGGR&-V.WJKEF':8#3WE.I
MC :7$C/5(K$O\W0[=>"FM>CNH /+:=9B;[CLWDRI=.J*I5]AGH-IXGM:FI0#
M/%#$EQJS*J=:.EEW:"_MWUV=Q["4G]6/Q=J*)NR2.G"%J+7+VS=K1XHDS0.C
MXT>7G#N3[KL'O?U!;:NM>=;0$U9CLZ@:GRJE[L2:@[I&E+CY<0Q^.@@0 ;-I
MMQ)HT3'T5_//@W_82HE8??0I<:L8),X%?TOCSQ<^:["YMQ,LM0+=,:=]W:K(
M2W(&B?B\M5'&Q4;:>D^-LWN\D0*!2\JN8'RA"0[PS!8?R2>F'6,$0_&$JJ%#
MRC1I=?ZA5U]_]TU_?Q[O-C9I.:$.PC%]$??HN_FC-7O-K4;D?\R]?F@MG@(]
MST!&'W\X15Y>_K>VH2+D.Q<.4^MQ[K^"5#\@HA]F%X\"WQHX_5! #/KKU&+B
M7Q0Y^7_A3Z?VC:/RA?^%I/?=]U'RU/5K1OTC^0=&]!W.>NED^Z\6B)57A)[R
MZM+9QAP<4[Y#8A*K8J.*SD[?'C:#T\8:G>X]A9&4@D_QK1_^CY%0I>_>(*<T
MP/K(R51&[<6,^D].%[_SS$_!,K/OO$/R*69WLU:LXH?AQZDVX[^M.3X+8VO3
MO&\Q:KO;W?XM&<F6#OEN CIIV_P$]IT+^%$I/OV'@N6W+HK\JTV=*Q=.,;U3
M!<A_?M=Y]>J(## AA6)L0WC>++* BQ<.<#J_)ZGM(:G7E_9#[<>4SP?6K\F^
MF#,B' <7B\:8Y@Q4W6V?P._JB9I,-TIT+D@P^L;"&2/S5MY+KNSK]/$_SKS7
MJ/B?\J;$X$;V&7@C$^AW CB;O(=#=DX&J90=Q]/#/Q2PA-\XLZB-$6\I!R<
M&7Z&SDY'?SBC-YSG"M.S74O#SXJBNARO^75<=_MX93M<B]Y%S[S51?%=5<@Y
M1&!Z9#O-0SISZTS>]6V_!KO/31P(&6P'NK4;[!#+9!8\6$,"?FSEX=L9FHEO
M6U4%Q'?L<*S)M#VG>ZM86W>FAFRO\#CE/#I#HZ/DJ.'9D -_=WKKFL:6=X#*
M":"!"-N]WM@L$<9F[[: =IQ ;Z[F3$*<^IC&4>W&]VLT]EA/&$Q<'\*5NIU6
M.QPM8^J>&+Y9SE#8HY6> %X4?5JNQ'.MY=VJTC_J<DNW&K!C@3=G63J>)KZ/
M=P\?+ "I:DJU=]S&H0^.K;DX<,O=VT=N,#_FQ-Q8%PV_K?X1B705JD#/\/8K
M<^>)L,#<XV\@)P#^T?I@I:*GO1WIFELL6NUI?=K-7@[+W?(3P':H@$2KNUF=
M050@<E;=TFR>](L4#*>^1,1E+Z^> *[/K/8<F&Q#/^(#F!Y%?W>Y433/\(5+
M42GJZ8KBB/C'PY)W:&%*3C?BK.6#"!8]8[-A$'F-#A63Y6=))91.P5LDH^A1
M+&M&T%13*N4$D'@]&[-U+&=HNU/@>P)H9"7VF_P^G^%T;*FL<]RX0@X&UFI]
M$)P6OAK\RX:'PHI*([,_*WQ+M_'/UOF)[#_[E<)N#$LNE7!U=)">^C2X+H@$
MTW=UQ&%2/I36M!7U8[^Y$\!/<7O\U@N"O;P9VJZ+!NJ<8A565A!S;>(OG\IL
M<&1<0<QDPX6)$/*5,I."!<-A('O',P=R>-S\?E5=O+WV1%%.@[!XH^=+#^_Q
M5RK/V-B\R2,K58,XFJ)H?.@]5PZ[C$1.W, "E;N1!ZCT+#@+=/7Z_,*D;V+*
M7YW78R:FM?&]L-$2K2/GN++[_=C:E]HTJ==?/H#>^&)=\BV^[CK?)G1FXJ(I
MP>ON&I]'I<MJ1AVI2OJ!?3H=%L5Y*62[E:_T6VH< ASJAVGMYOX4?[J4(5K%
MT%QQ+&"$9(L-/:_MV%92980)S0]E"1T&JQ.^Q1V%R4=*K/BYJ&%YAHE;S>(!
M#FO]T]WJ;)UV80;O@!X4&DHW\26.'W)5B+.0C>VULTAKNK]8$6'DI]78I-*-
M!I?T_K<EW0/VG%IT^DK;NQ[=Q3E0WU:&.S/AR,TO+-4_BV-@K7KK!)!SK'B5
M=Z_-]","D_M8BE$._E2?Z@\J]O&;5=;\4XW=QUWF'UX2=[#G"@;NAN,D,["W
MISV/5[,.1W.BEDTHN[N^!=M*[IS/"Y.*LJW]FP2A-D8IT;$QFV]G0 MC69W+
M$+N91S7/G<HD[D<42A#^<G?\JKMX$SZ7(AE2=%AO&AH;:_FEGI?NO@F?6VOS
MTV](RW"I\FLN2&C.WM_[]O16,&LP-HZ9+XITE3X>@-\#U_C\B$L6\S&EBAI6
M R9W0@:2C&(ZX:N0'@HOPOC<.E=%&[*,0$U]:]_AP*<[+-C^=DX21_D*LI%\
M4MM##.<&,4SO!L'(QUQHXL"HA[]T4<&?L7/M4N^B<^:@S&#DS8\#?F$YMYY3
MG^4$]O;W+_G?6._.X/:G6,D291(K1K:I9P?1J&P48\']98A</I>Y%/\,HGP\
MOIAD'QCC_I6%R[7$+M0H#Y3X71,)X=T9B]NC\HY_0FC<\58DQUG%_KSP=TH5
MNVH:2'MP5@=?'B7YG-01TRL?0Z?"R@R\5*-D&+,H-^#M.!^\CPDT8G[H"3M/
MCH.IIB1V]IXW;W=JYL'S$0&'QK;DWL5G?EF<-Q2Z=ZMVG_OZ]/!J$E(+H6O;
MA:R?5#4?A+_+N.C\[>'YG66$N>&-.9A?-%E/8?TD<SM,(0EU/?^8JU16NIY@
M4KC)?**XTF;H\-6W2H757-JC;C,2M!<N/X_P4Z_4>;DA3-9IVXNR\]8+7_'&
M@37WY#'[XOPIP_NPJ6"3)QHLSVE1:<+_P=Y[AS6U-8WB\5A1$0$1Z4<0D-!$
M!*2K-)$2(40Z$>F]UU"L5 &E%X%#)Z%)KP&5)ET@]  2>J^AEYL=U'/>[_?=
MW_O>\SSO?>Z]W[?^25FS9V;-FKUFS=I[9CCK,K11U5]%8;MD'/M'H$<;N>J\
MYDNCY7QO381G=#:]#BL'O6O[XG9(2,R+#RIU,V)2^\S\!KTC[\3R-"9AY.BU
M7;>]*6:4OVE1JUC,<Y?X?.U/#1".%UL,E7Z&2K%M12"&]QJ#/@63\,0DYV9A
M-C,9'$.M=<3J#=L,'V)TVQI4J'2R1K]C-O$C0>9@)[YAD^R<"HHF@?9I(? 9
MGEX!9-17_)(%M%[] %PF#1-/MSH36SZM'8E(&1\F8PK417X@3ZX?YE]93MQQ
M:#3WY#;)5Q\P7]SXUHGI$31N_WKMK5P*+"!$#<*DZ;X]_;5]CUVM0Y(L:SQB
MR?%6W]>OA5LY3_B:_;>Q6=MMI[.<9.;?[HX(-2K.FK/#Y5)2_.W?%X(S8_91
MT[P0>W;EFK%J?]][9N?II"'RAD&5Z1'(H#5A^VE$0<W[R^MH:H:,U#7SCPW]
M.,%#D\J#R@-6_O29!7>=WI'UCD9K:^M%J+/6$G.M;+",$17+->0"(D*GIBJ;
M7Y<F91NFD,9U!$JF652LE%>@#RMQ'\Z3$\Y<$"9O>FO"H"+ZECU0AZ\W-LQO
MR^+U$[!_$BKSX?>(8(O8;&D+VJPW.LS)S/@&,5N]E@'1QP6M<Y'8F8E<V:5'
M=^0,*D55%5VF6U8_;*>C!&(*G>@]IM&55[N50RXQUKQTLRETG:VF,#4'HQ3J
MDX>49UE<1,Y'LSIT2V!TFP,L+Q[R^Y5)U@6&7!+04>N69^%V:._G-#/4>PO3
MK>P4H^_1R2N^O-B_LCE=PYX[XZG'H,?Q02U T:7.M:KFT2R_V>TZHYHK$,?]
M"-#9)+OG_^)9\__N=JW]XUAN*(XIN11F9L&3;L0VF:%07T%;Y.LL9#DEX#QM
MX1"\S_YQTZIWUT*\.M;')Y961$0C[M25C=54NWHZ%?)L Y5;O<G,S,R.T@\V
M0* 3++$#M#GV++'(-S**R;$^6P,LK[1>YCY"'=*9-:J)-T\WD9Z\CLUZBUKK
M+(?I5>/A9F7WKK4'C"U%C?44]QYP9^2X.P?-EZ\,<="<U*ONLY+&HA%]>5 V
MT,63>BN<OA]4$KL$K ,+1K-HA_UAZK*-:BS>IUF_2#)J?H;>6Q'UW>>)63?C
M9C#^V"->"8?)2#<H3NU=5;166VN*?WZ&7>G+,(U4EF&/VJYL_9E,Q(<M/5S)
M@\$^X;8GY4\,K?$P<Q2O7B;*1P-T+6+HC3OX #E;S-HBUV]-&Q"SVG1Z!#5P
MJMA.1$ FJ"VF3;U8*S.@1V8&^:WEWA5LP]<^@38Y@29@S$F92^*A=_F<RW*<
M(!<W!C&<$4L:,S1T.I-SJ"D!\JSM;U@0V6\#R44'8<KR&8N]G$:G_5<KV+4Y
M3,>#(UKM]=LT8C'FR<DHL 'JRAT7THTHLABU-LZT[ ICD30+%)UQ:>W#,$[[
M(/54*Z7F&!V32K#AIXL0[97:AZO@6%HKS70KD>!KNA57L3/CF9.\ ?DZ 3D=
M+HK7@C\LI'T^8+=7>)/E2^M^OE<4P1;J7U AY$7IDE*2%TMG8HXX]X(4N< G
MHD<U4Z&K59%+RJ3OJ\8YS#PR8/FB&#4MH#'MT%FYE@,SSW5/1KG0F/XF)U @
MH#4A)P ]'Q C(T"Z7"!WIOBT3@1L7[ [.!,1T1%*>T:J7)T&-IEBCT)[SE5W
MVS[GBZ>J'>:MS;+(V=6&:&TLTO4YC)6HWCZ#]LP=]"]WW\K32__7WUR@V.:H
MKUAMN5J,"5'DW4T!GLIHC1>%E2NS]N%5NN:#9&=OY^RQ0H'',D5>^V6>G*(&
M>6OKOV<^2B@0-8]"/@YZQLRS 3$;3Y/A5N-DE8 U?7]CSLY9$--8M6"Y+@:!
M=].Q:#0^&*[QR'R<K?;JPL-IJ]6;W3"1\V\LAJ*Q:(7!IIC".S,8\_U4V/52
M@=6EI?6=%C:Z"YXF'AF\;BR%%PJFW>MS!G=.7Q#VJS>F/*^M8>-8BNRY 9->
M9Q5OKFBGDWC>N$:)E4'7L>R0+#&/C+>)XQ'O0:>>__-Q4\COQAW4381ZI1^!
M[&*W4KR=X21SAJ'RF W+L#7C9C9#Y<7AQM@@!_78K$@O<EK.,-4D%62W^+;X
ML&=C'=*J4,%E92]T+EVA-4@W43.G*6Q^4<6BM)B&5-0MFK!/W;H&(1$0X$Z>
M"$*F&4DQUG#2?%ZV$SGE9 [[3&F8ZNX165JNUI7H-IL^]&SDFJYL2EEO4XL#
M-@"MM9 G-92/4>#'R:>[B+"V+S9GNI8TPPLN.3'S# ROZ50SO=W,WO3/Y!0G
M69AJGIQ9""MZ@!9//UC,_[+GL\1JNF19V=,7()B,F'[&)!=6MK/Z9>3JU]AE
M>1VVQ,@Y1 [!+9@6-38_ D7ODM/J9\3W(58VT72::6RLMT#3E7][]0-=I L:
M[770]>I2]Q9R6PNSP]L$,_7:Z!YV]@&_O>UF=YF&*Z<2"80K0[;#?[[6.=ZU
ML/+HN,;W1>0+J-U%). D_ZB'34S70_!A@1+=#<Z_2GG>^.6)&^C_?&'4DATK
MY+H=7NH65&LLG/&S(@*-$;%X N#-$W#_F5F'>!9@8D3,S-., %+B *ZTE*T1
M]%?U!OYC)QPH;0[46A@QC'GP#S6TB04@PK<N#R\#1;0#M(&W5]4!$G6_2C*(
M HA_5OH65 ,R"-7%^>"T;Q#PU<55-;F0OE$BUE4X/@BH.\8W!518.&;U1<&/
M@SS]B%^L@H'JHZI8H1/_\=R">!!PG$;H/ST)&"'_4;_"Q+#D5U5PG];C:J9H
M$@(SQ&JFV@#& :!Z^0SQ<"%,%+Q$+/$.-S7Z>0C!7_#C/."5X5[4X(^B&'\I
M8$X@1JP_2N!>P19[ZKA\N2OP%O#XO*]^-4.-+SIA@4.%&ERQEEO9CM7WF@_6
M\]A1"@'2/5ELVH[1[UOB%@.5;MB+8&?%V<9ON-4Y9NMVN8_0A5V4V6=/VO0*
M#:45,47B@O*E*%7>!OGY]193GO-+('G5XMCN.EC&LA-5NB><%K^8&;TC=ZC^
M]&0S^OM_HK"_P<TFYO(VA9R/0&>BM@/<MY?%T/(7(Z[2A:L(P%EF)RRT$L Y
M:M(W6^BZAES9@[T.O*,NKB1)+D:D$Q9(":"@1 6SD<CU^JH[8R6HDOF]TTJP
ME]4)YRP,/,+D3[[/D;8'H_)>,J3V?&'FF#AL>U;-)<S"ZKS7H;3Y2H#?.'4\
M_G!>SKE$-OU%\5@9O.#]$8B%[^WF7TX2XISCNDO%Y9-S,)LHCOEIH\^APN&K
M6=B@R:\!9=*;*"\HTT)AJHV(>8JJR+PELO1&3L9#-+. \0)73 ,T]W9BN(^.
M)G>W8U/MUC/10X:N!/JR\:0U@YB];LGU4=*].XH)[ V;Q00KJ=(4KJ:W_M(I
M*#+#M^*P.H#*455[;B>\8UG-G&>[[_!2C^@ZC0PT;D]QI7G:$SUD(ZCMV-/5
M1-&-*8@5;U?*BA1VYRW^6H--*MSTE;.2/3]9S^0>5I'PHJ</DM"_UH&MLN+F
MSN;%ZSSNZX;54H::[Z2\C*7FM=>_UGNXQCL.+7,L#F;@S^#NK7#<"Z+G>H-"
MS[^6AL$%EO=-;MN2O2[-=-JGINM)3_<)?2FD6(_RUPH)*_>+:72&#6P6S5^*
M'V&5-'$<X-"><VCH*]I_XKB4096C)$$R$A[R$@4B,U[+Y5\4B\9%0+:YX)_2
MQ[]GD&Z@YWTBM0;W3E?GHC1&"I0$1'6F/3N'YY"8/MTDQZLI-:N,YBU6D045
M,6;)-B+G8&U8OX5TI;'/HE9&<3Z1C\!S)EVP>KKW*\W#N>996&3XRHPK3TC7
MJF,ZPBAC>+IDM06]@!^,#GY;JZB^UUFR!Y&8+K0:.XPM>ABFHL$=7E!L'^(3
M+"@J@4VQ-[QHH!5/F20YSI+(/]3-P+>6+2WFF6>QUUUY;[/J"/2L!++2<ZC4
M0#G@(J4MP+HT[IP7DLB=\TR#V>6K7#E]9=0@LG05G/>Q_R"C:+A/=;9%^DF6
MQQ8-2Y8ZNJB3H"7]$^WDXAGQ Q;R(W<P[D$\O7-QW@)/-8@:XL#_-D/'2)(#
M=WO6A%WYR58N?M<^Y #MQ0VSV[@SGE92<@1:;]<K-3VD8T-VU1C-)+6U]_=)
MDBH7U(YL[J ,[!%1@Z8)9^SX]L5Z'D;<YK3$#SU#652FP-%1^WJ3:[!-AD(6
M"NDG*"-4-#2X+.?3?%N<!NS@99':D\$YB67JY+I<2TV8NERGB#ZBZJ-"^AW-
M.[L!%D7Y'5X(EF^[V9HK<"E4 IQTV/^*/Y<50B>@CQD,YH$R$BRT"J*"-K!P
ML46E4+FZ(S,G F/_.%DP-AW%:BY/_<IAT<:EDK%>$.>*;YK?**^4!4\,61TR
MDG%GUF,FBX5&;=YR+96*6 A4)U<4/(%V=>=WR;/TG>M--H)Y7V^@?X)+ZP@H
MW82JIK86%RB%JRDJ9@>WDR\IXATJ],5N^\7H3'LY!V?4##MZBN<VV:!RM6)?
M;X3(!,']AGK([0Y*1K?!#M(ZG+UV:,8V80>#]_;!EF0RD!$Q^""#<O)FD""X
M@ZS1=-G]\/GGC#1VE<C.QI41@["4,I9/NTID%UTL:GB2#UAN^W=J/@I,"-JL
MS%-'=(H8J=OGMZK54E$W7:)29I@_ O5JMXM)3%^O1/#-MDGIY]:(;-W7?=C$
MXALQ&^2@ A.R;O F+^S4&J')C8QFBTA\>P0BU0OKM+F*@:M0E[[V)FSIY((X
M@CD(?C]P(B!U[PCT,8YL^R)34]&D!-?*J-JP:Y!75LI'=;7N%FB%<,J+YCXA
MDA[JNKD#:H@ 6VC!9S'K -.9,8-Q%X3.6VDUE6]E-B&:F7&]S]C<W N[=NPF
MNLQP891\] ?7#>JOP ,]H<.')3#O&^NA"(GT)=Y9S.&(S<0-D66_\ AJAM.9
MLV;/'/'\VBB6 $$VG2T1(185L1Y;!_93K@CD A:2W]NG,8_DT'=$[:2_:#,W
MIDXV0E3V2-Z<]1"J>6BV^*BU#B()32XT2 ]4T6Z5;K7?B%(U1ZM(I7+!HBS>
M8BNTG)?L,V#V6P2D.EFOI3>1];N5ZO"RENSK-MQ=(F[":FI<L %*Q,%  ZP=
M;O*276ETT'DH$T]G=;5%)K>@Y$W G/\PA#)A^("V3@=!Z3TI)?7YR[#5R9Z5
MV994FWVV>QMZU:["!Z*9&*.V:QSR'^Q&BUQ**RC/)%ZEZ4#4Z2%*$Z:AMJ]>
M"R[1:>]T.("7^?,IS(N7S!UUWVX*28C/O\U[R=82+%M.[S?A4C8&#T1[[[:X
M'8%>7.\4C^5RR6*,*J]'I&6EQ/0$; KFYUI$5-+U\(]]B/?R[VM=3$\G2?.R
M5I<W38Z(EUFO7Y0\!U$9=%!0'3ELD C%#6@_#N]2N&%I:<=S@,J%>;D[Z8U;
M.T1O4^TH13>U[=LL[,'MT4_,&024!T,>MA:K<>O(M\+#-UUY5-0Y1A.M;6/7
M8^KA^=Y)1R!9C()<,)R],W6'8<C%JGVTL?2T\ZRX7ACWZAR?4LI&ZX/F#>LP
M6$!4]V1 QYQ_PA1WEJ'1$<B/.DI[E=,BE]]>$"^7,JF+2CA,#%]N?M@KXBP
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MAK=%]ZMA@4>734)N06^ YX&$GOE%.J#&WK*;G"W6\+BD'<&/N 6V@9L>>R1
MY%RKS_?VIN-B<SA=H'C=#X0^L./GF\MTZ+'X,&MBV!W!M3K.4YTP5D;WT[$Y
M R5X*P BX DG4&J.X)5\^AG[]TKT)]A)(#(0!_@P53^>E_[PK(Y3F_YPK6P>
MZ-8:.__Y2%@I[$=A/,+EQ-2K5;7@GW&#GXA1@P3_\)</>%R7#TB*^L,Y(Q8/
M//:!Z-B!PH!;P)/<,\W'N5W?+C1[_GQN+$CU\[FQ97LST;\EN*8CJ_D%Z6-E
M:57 8 A<21$\X(N9_YE;M:/Z*U4K4/'/[961(I(@BOE%5BP-#$C,>AG(U$J
M5@!2M8*76(G)8D^5' <@KJ7^>@I-K"1(<-[,V-2B;(TD<*;:K-(Y 6PB\GJ5
M6@W)J*RH:]+2R["9Z >RS.6VF&;4&-]XQ.QR,W)#+I_)@.3.1)'.@[X-.IZ<
MNMY <2F1+I,LDXAJ"A>K9WCCV]6E39T]<[-IC?4\P:_DPC2C7KYO&9<@S>N/
M*XPKHZN=[M/[W<+):I%&W'P1CTR1QG.L+RJB*AF68,J5*LIAC:IT*I379I0^
M,$FTA [D"7./\F:9K:A# OB@%>0@JI)[_ZEF7XGV'PU.K>M_\+O\]DMF@V3*
M=X,)GUC/8^"W[:_=^[TWF=WN]!;E<Q#HQI,=KP=W;3Y&^UQN^,8,NGW#F5)<
MTC607"3LQ,=W+XNIRRD'(:_A)XK%GS_JW?X>/+)V]\'O#Z5(%L GZ>Z%D22,
MO5YE/VE*X;CYFQ5RX9H4LX[URO7BLH;SSTF<V7$LKS?)SPB^8"/WN.Q#*5[_
MX-K]C^$^=<N?'Y/^\2CG=^6+S__^C?M_?"/QPBO3XZB'!492#1"'33!O\'C9
M(5Z9$7>1UQJ-*2AN"BF B4OB<X4V]/;+Q'F!@\(5U?<Y02X\5]8YOUNI)O/H
M^+E;)L:_=E _+?"FL]6_]&:UG-'4U2*!65*QHI7Z*(/3"E +MSC#9RDP3]\,
M:R=Q;@-##S!R9.'Z@D[N8^6IZE#Q(',G;/Q#B+M3MB+RMC#=ZZ'O"A#& <8^
MGG/=NDS0QT&R*=!K35PKU>"@#GLKN'Y0N9#=,L62,9#H'W=QYZ8,NC$.(;+%
M#"+YY\.]<2,,+[3GW_3C]>T'AXN)9UDC-N:Y;'QMX!3).B7EF2$SO5N7T3 E
M6R0B(K-.#WVY-"GCI>'[#IB\5K0%Q"5DV$,0L4BQT;F("LI5MX(:VUH;:^$9
M"!NB]D?.Z>(ZR&RSL< E\TFL?X^MH^]OIE9"*,?@Y#?O.;T4L.BI=.O'&VA*
MG[O);9,"BS:;B7,R,-G27 BX37^P40TFBU'3B_. &"L\:+I7M+DQ@<J0D?ZL
M3T5J51W/,:7.UK.CO 2-:^2%1K+@-C=DZ(5(K3(FC.F:R[K+*8<YU19\''7H
MK9+&/=G*NEMHERRC:!U=])8KBA9>+S>U]BBNRBZ%R-7)6!7\ >IV>OZW%>8:
M$X-D=G7505+NH<WU-:@=OO0M!J8N06FA)2+B9HXRYRI^+Z5TDFKMX=:]#0LM
MS!R*L&.7;H=$,U%@'^SX(KWMYB229MU96#FH<?&)HGL07S:=\-@G)L9,A(7N
M]A'(WYK9HQ8S6H9G>NSQ:)5LBC']H!&YZYLTO^J6A$.P>:]VI'X\J*M\VXB#
M^\%O%4LN"<AAKJ]RUD&BM>*V&%/F+M60Q5YJ2MQWF.62M"-M,"!VN:< 713[
MCU8IIQ@S#AJ0NS[N^Q*F)@7F8F$$.. P4O\81^(6;<8<F;\>L\<7S!&HK$?R
ML=.VQS=G);E03U;?I>N5K:T2K*Z^ZQ>@ASC,P0,FBBJ9G3<H23MSKS_F5W;^
M6(@- ?A;K+6+]I GT+J:"=!Z3;C$?_TL\9+[?6/K]P<$F,83Y?6'?,9O;8?A
MA%H9('N!4/RY??E5ZJE+1/9>Y=5.O:YD2VF2"*UU 2P2/Z\_#_/^9X"G8LG'
M43B(W^@M <DE;@B&P8OI#D.8RL1/A*$$A*0J>T%0_-FZ*/+JI^;>6*W$3%%9
MICO\/^A6$LPC =\E%H]//4S $*-P4@ ZR)(  5T*(+_,(Q#]K@)9<^@2OZ0_
MXPVOQMW$K:L9<Y>WWQUC)[![%N[;=M:PXU!X(Y(.L.4Q^P]7F38E>B2/&93R
M9\H_S#RH)XA:!!!U_C01Y27@:+?5ZX9KR![37"+ F03+-O ]!/AN0ACVJP*3
M-4CJQS:"*8S>E[-CVI0D,$E &5+G32%I< #]"VU@S 1#39-8YTM^!#)8A!Z/
MVO<7W,7-M\ L3Q,1$@QY3$:="Z&3 .A/D+>'["K+IO@QP\X$0%&V%$!M> D&
M>/S.=@@.LH! >=N!O9+(_ YO'#8.9@$BN+9XS>-;E"'&C;U+PYA@D(W-5FGJ
M$OOWU YQ:@?W__)=2OQ8D@#MG%IWFHPZ$PIO@T783]*<FV($TA$_%$SQ" 1,
MC39 .1"G3J!<0U J N5V5B^ ,D7&W*5.W[:+FSK'@,3WQ6+RZN $G&T_<,K8
M<1*'$P$_'@X/\6;)J;6+V9>QXR5TP8&N$,(U!&&U0?=\87@2I^VJSOFS1L1I
MI"3LW,8%B.3=".3!U7\0OL.![[9SU4G!A!M+7+F%>&=QVO$0^/0_[B0 _N S
M-F^+(FO=&$'0-88HR>WI'Q*R6J6JJ^E?AWGA8%Z6OG7J 'DTC$!^IP"0T2^D
MQW+WPYDLN&5)VH%K!*5P+/XU^2-9!W6H_7Y [AW'<G^RS%?6YL7L&K7',%>#
M%<EK>W=\%>H(9#M7(TC0=;$?=X0V03M*Z^0H)0W0Z@#!_%7RNH[^9=CA6(^7
M98=N8!OCQXYC':8D;'SY!8EX7+(D 302S'=C]AC,B01B",M/2D_",:,L *-"
MV[XXFY^@"JMD=:/]RT^.T<():#-^<'H\?J!W_HD7T.LAM2JT*=*36.8$CV/P
MXKWC'G_,*1T@^K^@E,+1^1^!\MNS#FI1^P,)-=2QXOH\+8F$!>$+4#2 W]O/
MB]VK4:MTZU+6N@&.TG\TOS<; .T'..V]U$+4.\*>G:YU"$<-].80>[=?XUP6
MG(Y)B.SKF>)?%1)O-V"?^L'C@9WHIG!/#< ;T^4/R@?!3C9+#.I3C? ?@B(P
M^G1 5;?!896D;KE_^GA$(76\E#4&09I[;PCR[<.MRV43)I^P7+XD[)^GB9RU
M$VD/D/GIL1\VTI9NG2>PG%<_%:)!4-$;NPIG@'<7 >)2FT(_B>L\/@@6^"MQ
MHS: ^!YAYQS344=]1=+ 4Y>H0;] 27^!&A/YW .J.7SPN$_ >K=GM SV VM0
M\5] G2T/Y3<B+Y19\X?X2=P\;!@LW3H#B/-"@&1^0^[!YU_B; ,$_]F%L.%?
M%]Y^@?-=L,FJL34'9NDD ;0DYT]0FH7R?8)-H;/C6>87W7Z."UFPRO+^"VCN
MP9<_)^D8ZV6LB?=E>I6#(+S+$I7Z5)/7[W=3]NC,E[&T-6W!Q(E/:(D#((5(
M&UPV:U:E-@5["'9  !YWG?!+@?"K!OA!U*;/ X6 WK&-1?#7%!^! ICR2_(
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M@0F&28Z \((UZ_ R8S-QX,31.'FB=ZD)Y X8@<%XW.']@?VNNBW6X'A^, <
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M2DNM&  $-W-8T[W4)H8K S'(*Y;$C-!_S2KE[T+3#\-* 3:#X.9\1);9/$@
M3FWT)7! 550"BAN$I1VHMTJP0.3] Q++?,12JH:AD C :EC_]LNX$$NJ!FC[
M?/^3WK%5 ,*H:7YEWS[.J64D#@1@BQ*6<?1Y!'HBKJH6_#.#U7F W)72RP!"
M0Z&\HC"P A ?70NDLJ9C(^;?-K!C,1PB!G&_M0PE1DX#)FGUX\_A&>@3DW\E
MX#=#@7JLQX@K6[\B 5M!&!XQWANP1D#<]7&L.!"O3LP71HP+_V'+"/;ZIQB
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M;</,6$=%!P51ZD@1#4V4@/29@8#4&),0Z2-%(*%W"&4LM&#"  +2E4Y"@I0
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MWZX^5/G-V +MZK.6S7A[?>&NU/6]/;.WA6D:JP$7X,^;VQ@080#Y&M+^<LP
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M5Q $E/+Z(F+X9*.>(H( =F+.XI<;^!F0UA0X14%1./B2I'BX+A-I>75XE3L
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M/N8PE)/A?334$XJ996_"XBL(I<]T)$#&M.XW/3OY[[9_X:_6">16O5>QD+]
MYAD]]*?6R,\9]]+OI]_6:'H6;3VA48T(><=(_;E/X-&2W="HNA $Y,<(5*7J
M\][7"U"RB_S+8,;)&\ 4*5=LN0U968&A/A5O?,[$H=+(<$4)<Z]C#I+&YS-_
M_!<N=%4I2 <=_9<Y:J+)KB%J^+="K$B,+9WW7+'@&#,75+>Y.79K=&IR51!X
MICL.IZKY")\A &'K8X 4JPM)]WR4'XQ5K*T?<SA0GI&.I*Y/Y+F4;X3D:<60
M";2NW^-?;HOCV*4$Q>:9^J3-/*@.05JVPAAT:%(,C[;B,9HZK??TJ]KI,7<"
MJB1B94;M<L\/SKE*BFG)#"23+\A"X)+N<)+ETCO+W%ZI7N^/Q@T4,>MMFP]6
M+S_WBZ];SQUS0"MNNJ"[N@C.\OU5/Q6,&&!37/%+?,Q/3>5>7E7(Z=QE*W"3
M2HZ:I%FI%R8=GYZ;,BF0J&3>47HTMP2U@@^L< -7L?/;<H0W9(J:?G RR9,2
M=2T^:H3V.+7)V1(I&?C.LPDED&'_+VV%I[50U\HD:LN;(%SZTO],<9;CO !_
MME2QOB8/DE%2I1-86 W0,8?I6NBH"9Y* XOHL"G45J2,('1T!_T;T(Y9E'A6
MS=1?<%'()7MJ1-X=_HQD(O1.!PC6C>+^9/5H4<XZN@$5%0KOT48B,<G5;^)@
M<PP=)?B5'V<*)66WWQ%<'BCQ1!N@[_G['H)N9Y(2<LVIU(5E55 2\I;/G(B(
MK):O/^V-7/WZ)M.NW$CV%=&K1<"+7--G")9?F0-R/1BW'PJ)Y$;D 9X@Y&Q.
MKJVVN)=W\3&DA@%&B_L\!*E<K;H<>R%<SI-&A+,=65>:YKT.[SKN%P_O26:N
MO.U%$94C<#$K55"@0-3;Q0?*:?C&^4#2TDRCH:;;I%%4=BR6P5UJD<\2VT=P
MNBI%$':OX U7'@943I1I]GL%?]4M.X!P\!GE?U^W'V\L_*GGN-)W$)BSM%O/
M[OIU)XM0U;F170YI/2P :L; %6U.T)=DHB#B?!I/J][;<GV0Y!C PY8$,%P>
MN12-$7"CJ0J\QY4BV #]^WJ88DT1PER*(+OU'69;! VYE\3V;.J9^'T"SJD_
MF5>&1+\R71);H_W=K/3@3>YN\LHJ"MISKEL_OO^I>T.$.3N/B<0B M)N-%<P
M TF+9*+1++E@F-Y@&CD>D6<R/_:R%F;A[ Y#&CIJ_D&(B9C)RL[T1C83MDD>
M;7SVK% />PI<.3WJHZ,7 ]?G^NE+3*_RB$6N5]D^*8IF=;[_'-!.TY&]N!+P
M;-4<V(]1E4.HRX;V @MF\9&S7MCTS=]"*GYS(R.@P\Z;G+JW\#E))4VBB":2
M"P3:Q;VKV1+\M^G75PE\A$U."X6BC[U9&5 @MQ$F\ZS$6 W/"#LO@&"^] SN
MEF: +K%"HEOL1VS 8#@4^#RB*.WJC$L[101>[SD)6D$'V%V;$76CMA)#]U2N
MFWO&Z3MO[4@W]5+6;-^8MCO7-FW]ACA?TY *S',-YIZW,/'IJS"M3G$Q;D_L
MA2GPG:-&BO) 6G&@^DW-#PZ$6Q0("&XH:9^;KM F$$.:I>*3=$1V,C,_K$N2
MA;= [OQ;6X1=D'R5BKZ%D3Y4HH[:F[RX(,?<J9'-$LXUK,LXYA#T/>SRW=-]
MO_-H1TZ,)>Q>]3?#7"JZO)9S>TIROT5\+6Y\A6YN-C$2AZ"Q%^W. 'N%T'=G
M<V)ZL%SMPX#,J56#Y-KQ0B;M"95NVMX"498H$/C<=<UBU4.T>/?RZX4]Y5)@
M2H_$_:J:.+(UHZ7=HKA!B'X@,SE3E[ L1RC KX!/3F/8?3W'M&$\UHF(I$(U
MT!FMSJ7CY94TT_#70T/E#8%YL7W!Y,Z188HRN35B5BW:-0 @:8X#G]%<#+&N
MN=_O3GCA4TT>0L!&Y^UC!ZT>YV?X)*CA8[T6XK'K)S#8N9+.G)?,R[9K4F%:
M7,8MJ"!='WKTHS0!4^$.:8*#1^D,""&/$*:2,HU+<W1,NS]S@L'<1[XD^Z=>
M6X9_>+CM7VFZD0-R8L#D%Z#W8;U5W-J2,120Y1'>$US?<%2\-G<@4KT3<T.Q
M#GKH14[7,!D\J#;H ^D[Y$%.CFFTJ'.PWL9KQUKP7M"#-6 (G\KO\S4_LAS8
MF\XT>C<I,=%0WZ@IP?]>$D+T&HF^[K'!CAS-?^VWVX)5^YOS(C1?UN.KO7F+
MI@MV/I9IB'OC@DY.6_'UA/:<KQ6L3&HDPEMPM\!!GVK,XD<G1/_(R<I%4HJ!
M%A$+$_;!]RNU<^%P. * SS$5O,2VQQT0+@;H9]OH"EJJ^R;VH:SJ;]6;=34G
MC[G&[IN9P46?O4Q([Q.=CM4!B,@1C?!X?.2K7$>D(!0L@(M<4UK6D7)MGIUY
M$%J/MQ_&>]A;IS>_/>"OJ".0G54 P"Z89;8,#"WM3I$KKAGDX66&A/E4G/ P
M"_*UGUXAH.; MH;P*OXJ?J1L=!1D[ [@2#/=+XJ5%YIZGYFH)NM7B:B:<XXI
MIHM+\^=\T^EA^8I,W:TN*H8\9GUZW \+?#"Q]9Z!. /6+J.U/2%V*^&T]PK!
MBBJ<8*#FA-W*NALC<3%ME+)"H"#HAB90D=OP'L_X+RK;WYQD3V![,\E9<?M9
MSX+E7^5Q896'"T$?QQ,=I&^U+%JT5^L:&ZI(?U6X$(%_]M36FE*=7&EUAAU1
M.U10VD<"QUB=J[BN+O-P4]<1GQ&/9'#EE,,\)@K4X?25%LSJ?K)]=7)>OSP;
MN>A%R^FH$^P=GA^Q9:^MLVJN_<EY#GXIX2M84.J)KFARZP!F3FGQM=8J'+[V
M>]6'>N&?\@0EO3;3&0TH$+0@^]/O;%9V# 72G:.C%-/0MVHY2[68;C2:@=H8
MOAQZ4XQ3EU8SSJQR@B:,G1UC4FLK@9DKT,?!$;>I]-_Q@^H-O55^-$B@F+E<
MVRP#]O5^\%4?RD3X39(NLF\ODEA=#>CP#C3*3=8"_SU"6WP-;X##N7C@U\YU
MC78$85?3LA=<*A0L;?J,^7ZB\O=EYYJ&=RF3!8@VBD >/LPPGJ+^1,2>= ^G
MO(9XO.4V:;JPM]?< >5V[S=;>8N<WRTF)#H1UVUBECP ]ID5F44@R^W2LO*R
M<>(<3LA:&6%BVHQ^HDP):@!)SZ:]I:GK"C&U&Q%*/>8B$@'XHI=\&L5%_!)3
MB:>7*\S>I'8LU^B8N1BMQSZE\8C!UD9;Y#IF\>EGPW<,*N<L\I:OI_,- 2P,
MQ2<EC$>L^!D";)AGDH":^N8*BC%JH+4"?UBY0;EOSU:7U4PTT7.LUFEP9H68
M;AV-,Z,HAK]6O42-: &(<4MJDGE8'MYZ4(- NC,<_$!B0@*5?L,]>3J!JI&?
MS*HN*:Q -+(=L[4..$>$*D'F0#B$"PZY%SBR5#$PNCNDE[#H:3>K!GSV/H5&
M5=:SRP_L(T#:F0\\(9!\8CLA;D;D=L#4^:F*,]Y7["^+DS**B$[Q<CJ"WC4+
MVJ3H%#Z*3_O8=26A%I'< ,D P 9\&:VACS*Z,.HW,9>5XQU?:$\5)20.RYO[
M36?N7KU-Z?$ \B7!X?7^1Z+:/O)37@<>X\3R9?< W:"*UD7GME'9!'F0+H^J
M8G&GQS&'T\E2O=PQK)QS^_AX<,?9GA D,O*+Z7YAC)+IPMUM2DS#V_U^I1+)
MN!9K"8^"II8<ZM=-#=X/'<1<-47''<5FRG)''?646_J("<'$H^B%NY@"WA^0
M'#69RE1,?+MN. CFUNRD99R_<A88Y 63S,\MIG?FO]F7>[0CVKYO:U!<,#LG
MXI^AH7)OZU>Z8#;+G91':<A;XKZ:HYIX=]RK.]9."XY3$"$+Y#-T9,PS[M;T
M3I5MVSAK#E:%C?D$C7+JY!%N;]B2,&=>/LJ%><841<MH@5!P2.L,:(C28K!5
M?38Z.G]1(G+N,*<HV7O]T7C0B^Q"3/E9\&GB"0.*MHVI]C1G&&1F;@, ?HF.
MDX%K._<?SO@0*",/[;P*@N U?#KFSD;Q[82S_63Q4'QMP*?&  D/9]\)8<W:
MF_7TA3G#!/>.7H=-(&/B#=F  YCR]W]"E)<DWHPQHTV/>IDAOWR=O3RUL,VG
M010J/\PI//IMKJ-KU#YW/N1D^3M.F KJF(,2O1-OV/C=:G*JUVGW0&+8Y5!B
ML)M3MXYO)+""\D=">@+^PYT4(TR_%.#@]N&H"K2AD8;&]4_HUZX J,',$8TP
MFR1BFY-786\(]+.70LKUS%U4K&)$8<]!Y;[^$/0Q$F5([).Z:X'@?)"CU5XL
MM%7AHW&S!/WKFHS03S6-,2/9E,-8I_9/K4^D4\G/Y<)E@JU6;_!R"I[L#PO)
M?93N0>GEV.6])9A#R*IW;<,/ DFR%L;*6E_BDYUE)+V" \NCJ1;EQQR)XO]D
M]*8*OZ9(?/?B]']B41=JT6Q2W\UO\9! 6'#R::9PK>C Z%F^]Y/%=L&^:R)>
MBZ_797<$ZV?7?<W*6\0;ENQ4[H[!I>8;T>5R72#MS**0PC3$^O3BJ,"B"__:
M&&*PTCDS2;"]JERGG#1Q&AL@FG1MK$H7G1U"P&+GAXO:FB\;%\$?9CKB%"M"
MUJ_HTRQX+>"$.&#FW9HQI<1?UBO"#"9D*N/ +>;[<29@[M$8,5V^F4&+RO:\
MU72-2QNP5"WF%O%A>_GGFO%M($"@:WZDT'._)&GWX<'SKN7<8XY]7X;LD<VY
M=7.'(;W!>22_FGPOM'LL3@QL3%%K#]WSKS%4-3J8Y4L>]BO;6WPBNF*,KC$J
MVO\-5>/?%SRG\O7UM8^" =LH/>]CCI&5@XG.D"P+S;U#CSW;C 7E4R7&KZGK
MUQ[KYZ\BT%%ERQ\6(J8)P>U)Z]76F\W,S*S4="6D;&1/EX71!</EQ/D51VG:
M4&<Q)ME_-#BH,^3-2 )@1R-;,#@#HN/EFGW_](LRE'![C_FJY;2FEHNBA&.-
M"K@):R;.R?/[49AS;)7RH\&T4NK]*!4JI7YY2\(779JS+>MQ&U'=TZ;:'197
MR,X<M$^M#!(WU$ F.P8-G.Q3Z9'!U=+43TY9U?U@SZ#,L,BE,*6D'_6[8DQ)
MGL%/ M\:'W/4:UZ="KD \%,ACEG'YC#*>E[$<S/TA9KB2?,4%\0-#R65_1BU
M/#T43T9IORW+HNJGZ]$0<[MP3Q9M.5WG:W:[WS(*GA%Y(2C?6?[ 8MPH;5*Z
MY';AAGN)?TQ4O-/]B9+2+A,1Q9%P@4\!G]*R,$%M:>E1BJ!Q+/=4=K TZGK&
M9,C&Y.&WW/C9YSK.+N9S,EQ$ Q(\0 0=D!X^NP[131JLDC*_2FX;G%UL1%.=
M;7FDDVAF"Q^,Q3SVEB,I'7#$"N9@J@Z#%LQ WX.Z%SWJM\RC7S.U )OOR6.4
M;6-XG=QK?>!M.Z@^H;/0H4SMM?U7GY0GAI',SM98?+&H50WV'=Q*0E<L:M4Q
MW8???.T![&B('J+PY]=!X,VLT]-1OJS$M:T]Y\L)WN2^H90FQ^T:S_)5X66.
MBH/-_+V+P90K93^.?&5FS4OOS?%^RVH[-V? *[:#L1=15<KEK-(@,W#9N7/C
MX^6$K-(Z[]BE=HP8P20[4F2((,JJ.$_84>I)*OPGWZW\$(4TEG0<-;^TU1(G
M3L1] F:\#/K'3:IC67:0]+V<5M]M^(]_7M>X5=WYSQLM_*]4_GN1[TN]?TIX
MQ4>^ERC_EQK?DQ/KF^'3E^]&M??_*27H#!N7&%;\5U+^/[+M@)63#W2_^59]
MLZ?]5B_]3Z$ =&16T^V;)?"7[]94E_#_]$OT???_M-=]\"][W4;%4W8G0W]S
M@1K6M_FWHU1S&\#EZZU_AON7^=/WPN.VDG\/^,W6Z7MUP5GXOUVB+OQ[<K-G
M#%L8Z0U1Z9W*BFH!S&,.U=1=S<J]Z@'[(KM#_E7B$5II;@^USW,4LK5YS/$\
MA$T\ !].U/QY+CKHWO\VNO##)6]I&1Y)'4W(XTB*-;:'M5P/&/^DRCKFV&NS
M.)P$3Q; YY &.=%IF0+3U(^2B&..4DB0W-CCESZUA>"C+M!&2Y"FH=L7EJ%?
M_W5EOM;8 %-,ZU0"L%N  9O'I[5827"4\0%YG'X^YHB/6Q16_SRS8/17E)G0
M4VR>?56_S7S7&8+YNUQ?[*X^-*@2^.Z8P\8]2"[X Y7<7!@<2V/TSR_TYM!I
M8I$7,\B"\5JK6E:.XQ5_)E^43#FMON*4\938HD#^=)M^)Y+VBT%(@^;GB=P*
MP[R.(-#VNTB6:\+*6?UY\LUU*%BWT*!Y_\!W,'R-4":HPP5T\G%THGTFT]0M
M;9#&H$V(L@WRIL[-2H+B1>F$O7SB4J4TC,!'_NJQ-7$"6%)W!T/V%NJ.+LJN
MW2I!6X44+U[9@64T*ID&Q]!MYU.3H\Q6=;SVE/WW-,XH&R<C^U? #8QD-ZLH
M3W>]] 6Q\EG6(><Z6:&SQ&484].X%;Q;:N2YY,^,@OH=,J],5LZ7?O8R"DQ.
M$[P_D[:LL>]6!>:4WZN>S';F.N;(C9C4<>3#GB.2?!XNO2ET%FF.E,3#,<LT
M\B$+L5:\@ZW-6L71JTP9/E[FX<:]+8^+5[I'ND#-(3=;TC*5W:,@SP+_.'+E
M8GP2,U_K-]@U*^@[,LR3S0)2-OF6=CS (Z3]@"J+6UD-X:!PA8=S#MC#F_Z_
MZZ9P@P,Q6!0$WNTQP:7:W_#!!/U&,>JZ9$WVYWY)B]A'4R0\4J<*L61DBG<U
MF$"S$HX>],U^FFI",17?A:<W/:4NFAG1'HR-]_-5DT,S^^#BP-@1\;&$9<*3
MW2<WXD/(Y@"*QE5N^3P4*B@(]0=U2*SB]VUGO?SGNJ9CBHKG\].7BF*FUJ)+
M0T%JH^59)F8#\\]09H97E(IP=N8KGN5X$A?7O:@W*U;/L#YQGWW4;@:0=>U?
ME 6G"!"DY9'59F2S<)&@%5\ 6LT*J'K; J%OW:#,Z@39;"QM^7F-\*9(.:PW
M=O:P1YAE# @"JJ.FBCU!6SB;H:6LY(*QV(;';%1P/+G'O8JAHZ-_P:XG9NQ3
MY&1-HQ$>%=S)RU<U>E,N7F];QQ J=D]I]]"0"Q^1_HCD(5'9*_AA\V"OR)S.
MLHX);C;-?BJ*I78 O&(6ERT&D>A/W;-Y.?OJ8<GIPM3@^=W*/1=,>9#=!NL+
M:;^GG?\B9*L:PY>#:;'UUCI?J;LH/D#ZJBT"F%J?:UV?5[$82=[88/%(T>:*
MLCIW1J*;<6JDRSX^Y"Z;W$_( %\FC"%7TJ0])VG"S\-E1KV&IZ 9O)GV%](N
M+3[>\J8E5BDV<1:7M[FSP8]F4,DU,W#DD;S2PW4O9H#W@3O_4:+V8( P9]ZY
MT]UC!2$-I =/_=XP,#A$[_"-E P=2%A;-(_18=O*RGK=1X@;X^'E?<=JMVHS
M?8.X+S+7!V/6Z#HTH8R[)(,= ,".M^MR9Y]RLR&BP:^(_K,G>S8+S3)BK";E
MYQ>"UX?RO?8D<EP+INK2%=K I*[+<?/MCI4/GJ4M^  ;73[[</X$VSNKH)]#
MPT3L^?%P%<_5]5A&U.C&;V7>X-1PDJBRFUWP<K(:,L93-*;WCM;_=#3B9#O_
M1IH?I_L00J6E82NQ)<1U"B0(CHZQ&DXIK@!05PZT%R<U?MQX8\JW .0IEPRR
M$)2*:X+PIV(PS?B]02L3WAOF^YZCGLI'\0QM _J['-3(-:'+;\;GB?)]EPU7
M'7<:O\QV>_%>E3K0+%<NZ5-)ZX Y?7Z48AO:GJ3E$9+& W$?HX%]'UM:]VV9
MA7;;CO (7$GK K'SF81X#;^IT:YMTY00'J+7FE(;IZ==F!\M0.U3A89&9"?H
M0']96;0,.+4$OK *Z)_4>XM+BEP>WM"1.! <^XOM4/5D*.W,)N\)9)TZLA;H
MLM=N3C&S4$,3*[(_\BR_,OSJXIJCR(ZN.)LR.SRFY\H ]OSH9X.<E(9/N%[M
MX9'FMQF8M]4.Z$;XXO-@#2&!PVY;YK0'%5[>ON?R7J4\:3KF2';;H.Q9(1ZU
MX3:'0L)1T/!,^8I41$Y%]$RIO$*!H7T.L3_A5_9SIIQEC!(KG@J7>VO@=_-'
M6?^I!4-%P^Q";A^,XB,VTM@):VO1W0P/(*GV/'N\7>DW)6@C02US/?AD9'3S
MTV;PRD%MZ*^_J40DOO^?5E+]_]5V.]8:CCF(J7>/]CV/I.^RU-)K"R4X0T:[
M2G<+[3\4/01G5;X?NLT^E$/1L9D(X@,76&'2K3'LMU".BEFJ[X1:F":R_(F)
MM%?"8I"JEQ>W6TEZ>OKU+!N,@@BP$"GA(7+2_'X1^I/C\HT=G2)5DXG"*H25
M Q;D]Z%WP]66%PFXD-AR\;93ZTZ&I!G#Y+8Q<+&"@91MKY_[I+'S:$<"O\%0
M"YJ#:.B-^#N0C:OVE$;GQZ+-;*9L4D0]4P$R;FFFC'GO,Q:":MY2=,:]%@A8
M\KK2K?B(637\.V,*;V9FWLMD]<T!U M>=C^<X38Y*$"*2RJ/U2TP2<4?1*0S
MI]1OM&B=>JD"6UP,<2%]'M(T7"MAJ:$=)TPE1F_G>04RE;4\9SSA7%TO;\\,
M^O#*^G IVY?N^_EX%4V%_#"9U?>9^#RG+[:\_*7 WJ842D'_0HC3[$1KNHP-
MM''DT\/Q(\R$=(VI&G^N<U7P38@2 ?2C@F[Q2&<<(;T@?E>/.HL\UQW<7'O^
M>B*-[\=7X:GP?$)?O^2/ 6>D>Y&.XC:3U@232T0;^'J-O):]\13J&@ 3VN]T
MY;6$/O*$U']6E2@HI/-&?;W^$IW*W:O5:AVP'.@.7-9I$Z7!(\.F+L-!\+I^
MU4=+#?7=TOWJM?#Y%+O>"9%GFUTV[_-#PHE2>OTJ/XW$/W$1\+&=</V)<-,B
M1QZ4R[!L;)#TUP=JAE 20)XI&>*G$('"@NDRJF?&"2/Y=ZE78$B^UY7&4"4Y
M<7F'1J=[M?O/<^< ?E*8L5-)E8Y'+/C85OW,03UT89:^=<-0^)R\VN6*.),^
M1Q4#OA(=RLJG%NU&/!S-@X/'W6PGPWG;X!Q=/8G_+;?[:K3RP0=OH8\YC$0+
M"8<B>EDL2(H7B=%6SY30HD1V!>1"3/,QF+2!4S'JUYW/^=-597I-8UFGR0JL
M,X%M;H_6"J[9.SGC$#:4_%E1SV..MYJB2U16RBMY\RN]QOKE67F]OF;B^ M\
M!&_SJYF2F=A"KQA*(2Q #>KQ#-Y.,L\U:L'GA)6G(P,B3-14B<:ZW%@=X#*L
M/C-S P8S_X.6*%1_<+YJ.*$F*VRKN7-."M/N+_%2JBAD>%#4)%KZO8>&LPMS
M;>L-S=?B7+V9<\?CIW=,MLP>CYD8[(P[RZND8[4\1+*XNG0D1W"%2" /;*CV
M;&,T_? O6::^,U/?NRL1L*<-_W5)7U<L1H[6FMXI26NE#H*46XS6:A\YJDE#
M<PN'K!FHCW#M';PTO:S0]@%Y>6@C)C^]9GH>3VGWQ?Y43[U5OP.8Z%7V&,E[
M5NAII>HSY%,_:$Z'@6 &=F[X<SW!74%E0%[[(Q$4Y[FAJW-!":YZSV6\NV.+
M'<10;@7D^S-AVEF647P OTR930]72X7 6ZE7LR:H>\E] 2YE% 1-WY S-QWS
MO$3G40OP*J*U$676C_?V44G.^VU=XL7>Q:BN/)>2W@36U_$.ZW3\Z3GMJ%1R
MR6VAR/Z'H&8([]_U\OW6,F<7S.)DN%4?DM4+< C%OC1I,ZZ@_+;TK3Q?HS2.
MN9"7Z-<5(W>S@"YE5;T=.IKY&89GJNZ:$KUHFIT(HXC*39Y>4=/:(156G)G;
M_F$%H):%RCCF2)%0?]]T[1:VT ;R!BEJRLSEXE*)^;GAKM^##_GD/C)1/;:L
M@7!=I[4B 5(,B.^Q;IZ9M5$RQF>2T/&/+S_^O^1L6JCE!@ZK"DX8'G/ U''Z
MV0K\:+QQDOC 0DQ$.FE)AB<('VHIX!8"<DL8DQ;"]BF,:%S*3V5DON 7&UB9
MU67TP-H/<BR_U%XC>"W7AB?'%B&>B >_R_N0@,:J+*0]'OP%!>\!8;G@;:]7
MCCGN\567N"+W7.A,9TWW[+Y21^800.1%9S)18G85E?:VP2PZ;M+UZU_!EZDW
M(2Z] =LFTB^&+'L*@:<K+DI_6!?3Y_S191HOIY(23H!2>&Z^;0< -M=.32GR
M>G>_G\BK/X7?#$[^D#SC46(Y0_265A&824C[>#(KH%M46*$JW;-FDP=!N1^4
MI/['VF#^:FCZ"LZP;>OW&5K(W^*GLI=J?T*<DMQ(<=D,P)2P+#I&Q!/,O%8+
M;-;CK94*GXX,UY0OH>&7GTY0:Q]O'7,LOP W\K$,0;7A0SX.@IBP%<S#7WSO
M*UN,B7_1%R&D1]00+&?67- !JP/1+RI84RN;@0_) ;8X!.4N\^DMA&S(<!;:
M9NU V+6,->1I8"H?FLL/Q_3KV)?__0Z#>WFVX9I:%U+D%X&FM<@GZS+AK[VJ
M4L*V][NREN1[E=<YDS]\;MW3*2UL)\)\AX?I[-'\:,_J&+BJT8\'8JGWZ%4_
M,BY7U^CF>L.!*K\0G2VD>IN@HM#+"4JBJ+C+]0 RRQR#?P<S*'HN"6G-S\=$
MC3JJF0Q4OPQ@3JDYL\)]\N P)2NILL!V$#KQ)GR:DH80/#KF<!"09764&2<L
MPSUH =="Z3RFI#FP^=S]*4'1*1,K44C!:<, 409A= :F98BUS,<4#*0^6JJ#
M$ZOY'J^E]37(O"</YD_E%""L@:0\&YY[A.%^2?/.'>!L]T0>QT/ONKD.&5SO
M]6H>+>S 7K[UR./9.15C>WRMZQ:E[N-6WL<KB2-1:+LG6Z@/E6N)4?0*?AZU
MDA+$$T:'T:[@KW,J7G_I7X,&-P50ECTA(Y94N5!%88?HU]7A>V@M\WP_5Y^4
M)^RJ5HLS0 -820-8BX2<M%<V5D2GI&:98I(,E* 7O.:N5IYK(,E*N3)-U0>#
M\['5-^&J*O:HD#/BSX6P7[HOA?R^I3D^Q[DB9^ZU?84HO_F9-(]'FNY11'TG
M@'U*;,97H_>>JW5Q@[W;#<[20?U#>(PI?W<V2B0SCX L]UO@FT%G!\CP*)&,
M\2*Y[OR(52RX ;PU1#KF*.>5G;V: 380B7Z5+!1NUE:X4):6RVDB.KQM:9-E
M#0=0,2V MC<SIOBH:?R?S^?^:XGNL\T;=:OF-S]713]]PNX@Q94AV*:Z(@D7
MR2!18<BU3//&62KT#A$& ADM_=":<5'AU2>V$*^CM*[S2],4YY<UMI5B?K#(
MTG*%%LGB8;HGU[>7<&[%;%DN=]4ERYQ;D!1G0?H65(BQC#.<\"K23Q >FC93
M^=$P$Z F5$"YAY]!R$ E;!A/&LS 0#4MJ?1T8X(81CLK>0O_# ()  !D[CET
M1#\+/FWAHF\%:4#;//=, -FIQM5=1]2N.,44MB1\5A(NKT#YH;4=JDFO)J3+
M9_*EN*7VI?-="W,#W122!7NT,Y6X(!&S6?$K+<9 /@S>I?9ER?(9U^?^"S9)
MPD#!+P6Q+>F%PZWIH^E-.O9?]B^G]'V2[>4#Z\,6" KOR*9+/) :0)2WM.3-
M2\MH'ZH84J*(H@P@>:1-_;96^LBM_D*K?%AJ^4(K2J"_1[ \[6,Y G@/D_^N
M?0+]]RZ997VX#F)]U5VL)@H:E =XE9LSGB$!'=S@01$Y. 0_/5,$@JT:X 6K
M<U2TYH]HJOS]B<["$#A0^@P/7&JY,.^I93]1F:(L^S*KUM\PLE'FZOR1E-FM
M]TQEC['\@O<>-=?[?X]^:EX0:JR2E8R/2*K/=3-9VWXQ="W4QRP^2\\Q61)8
M-4UWMOV9;!Y_'FL\P9Z!^^+Q:4&$Y5-A1^=DC[9#MG6..7+3=5R"^=FXGI'L
M98&0WK>Q\"'[@I>YQ$[D4A[>QHQ_,@8ZW?* ZYKOA-+"&)EW7OWEQ.TW$ZZ#
M5SX')Y(7:HUF]A #[<8-W8/5SY=L'HX>H!7OQB%8!2YE0&[OLL^,7J,FG*G_
ME$Z+*/P>T1/Q[?)YT6D*GK@][KQM>'_&@T[F"R"+HG+)3#.V6+*B_05FH3NE
M:'&2 5^'.7;X=.2,51QS."UJ9Y6:$:0/-'H73]GFYX.>WQ6)Z54J,B9=-1F>
M4T3*:N_[X-/R++[=:1?S\CH:4&82([6V5PTO*2T<3;9DR=&4G>O*-W!OBAU4
MN*\[*SEDE9B.'QKAPLXV\</1_><CXZUX5A^KK?T7@G*U=EIE./#1U'34^DRC
M%Z@]-X<2HOS7OM,W3X:UL>BO-9?5W*7G*6 :L$WNF(/<[KUWWX=:&X[;U[&4
M D:GM)4-"X.AW 2V I"=5UM@ET5WQI$B4ZL:P;'IMZ_I6W3EA,A!N )5P;\S
M_)PO.<4II46]5;N]FKY<W[5!KL\S4+Y0$#P# +@B2??#CDJ0K=[BU%AR2ORU
MBZ_2[(H,]37%V 7=*+<WK@%)5SC)\"!L5]Y@)\A<"I#FAIQ>':%D=<4F*>!F
M-PO(C[LZ@E2%2/>/.1"-U 3ELU#@=<5,LL:9\[_YY7I7W4SC9_2L.H4$U#P7
M;I36V3J;KM@DFEKB9U\]BFKT",! !5BXU0*Y?Y1-SA_]CHZHJ/S2@[:<_O6'
M7_ZW'._T:]+NY>UK5ZM/5O(Y5T6U;,1>%L;7T-/B$'Z_X<IXGN9E8C)W/"MU
MKCCMT#/.ATWJ;AVZ2\AG4PRP/$$N8>EEC@'+H  S"Q[ESJU:>[D"]CY]"TCU
MLQ*IN93D86@W"V54>!1")DA;;Y'Q42(BM[E9"%R/(MH"B\SQ$6H\-.)N*W+^
MI$Y'))/SPEC*:@3LJO5XYRS$7.GVB,6SB8X255$N\VT_">@?:RF_RN17*YC.
M"PS<JL]4H@K8)VN6RM/76]QKX&)2KG LWEXY)6+/ZK>!F[]I&C06P&"Z5;8M
M)B;AT+, Q[EULZP_]ZS[G>D)7K:0!C'OSY+7<N%/M,>7-XPP@>_'9?D6495-
M60L2BSR&;-SIQ1UH<>V<>A%PE!24[]_E6GO%FY94/-NB9E7WD..SSS\KQ_V5
M!D[*N.!2DD^<#([KG9\V57$F,M@1U"\]DLGY-;-_=X9XU?0MD/JFY^HM]*74
MLKE6$9+/2Y_4J.:-KB01HIL9!WDVF9+7&=K''.?]CU+*^G7EA&\Z];QL":.3
M*P2M2/@/3F1N@B I<D7+TI2"WXU7BR);&^2]I*B",]LCW'GK$!:G/P&8W'=F
MB5J*96G+^].H<2P?8>;=2+1'6E5&(*17(059U%B;B>+IA;IBL" 5P"^Q=_GZ
MB^>)GN9)(- :3/V63]S$AH#,5"ZY3SXF6UX^OCM(WG#%]CZYI+EQ^[[VD>;*
MU8+UV@IL(*\,(V#ED5!_"__"+W#[J"3=BQ89\AZ 8-&0#])RZ8P=I]G#]\0
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M9VTH1FU$G27OMM W!7\!6^NDNT[/!+35)YK7H1[C/HPV]XH63()%2D,[+VW
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MOR(2\]QMS\<Y@9,X"D#U"@Z/F[K'2?<V]4#IKZOD^Y&7;NL'FR2>(3SIC-.
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M(=CW5_3P[!"=F7J,.Z<;2T1_A5I,K$/.D&5P7Z#ZN5$%Y%:-AS?">M]1/W6
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M*$F.@;+-\9('1N5C?>3SD+ T8;,$2SO7""J"5D_U_^ =.>)5!Z/=$'4NW$W
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M) \64LJ*4Q3/%R^>[_!J)4W6=U)OY$2M+5/^#!-/[EWU$1$UH3?G:6BB^]H
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MWXZ"Z(*=F@V.A7GPC K@,,74269,[Y4#M"!!VV5R2RM_&]9J%YCNE8VNH<^
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M67I7T1[^11'JX:?6K[OE&@*^5?KX"\[EU/$3-,>/4(0:@8<.5J</N7,J?IR
M1M.$:+Y='?APYC\J6G1H%O28$CB IBFJK&U-T\74>-U'N;\WYRD+UP@0/QD4
M91K@NL$#8S37Q--<XVDU,+H0MC$2_]-/KO_RT^D::1,J93(.B3G!IWY*0%]7
MMO3..S5)^T',3]<C3ET?MN[DH4'<T(*)T9 D9$FS"/S3HL2Y9U S8-W#"%2:
MG\1/0-K@"*L24P.:;IAUAQT-XM;I>[*$YC/G8$4 X-5AKS(!1;M.0 -#"S$;
M(W&'%J>:]B\D;LQ\_*EIPM^:0L^H ;!+0N1DM8B,=M^EN6:14"Z3 VA-PS_+
MH1T0;C27<GWK]P<TM5JWVP$3MS0I-)"(K+_TT#Z='G4H2AAC.5TF5M*Y2$!1
M,;BV.$U/\'J%57]X<(+==6#-" B:]=RZWTX12O_,OA[P$@^A3";O<#]'*05"
M80E;M]W1)FYH4J1H(A?/_(P.Q3>G!KD-="SD;8Q\.'0Q)KQ0SDEL41XMXB=,
ME*QA!M]?_HEETE7:Y*)P;<$(=$GRZ>1AZS8[!H!(V*G(C?\L$CR  43._!3)
MG1/;8C5:Q/M39-=_$GD?<#PW3:;VWP9),\&M)!(''=%9W&#WOY/7F)P( +LF
MRCU7@>!&!Y'<8;CZS<.G4Q!*T("R+I+Z'J;T=[3_'/B-<D]/D-JX_L^!01 *
M].^!?W[[VT?/:3[:/2)\J2XY/,INI/DH.(&>"6Y)B#F=^_&_YC:EB6RDW.,2
MH#:L<_\M4L$8$,E]*O+A?Q:Y1_@B4W)XD!W\4R0=TPG(2N)OF?]<G[6? TO(
M1?\<&+9NN6-&W'MTNCY$QE-G<F=L"G$#D>DXUGA)T?HQB9(TXNOD)>=J>C$
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M'S#)%6QWD@6=BJQFESYAM^82[9M70C=5'_)]RL3!FR+?IS@0);[6C4U"W%;
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M7I/\^+S!W1_<5)I<-?3Y5;LP/H/P2S$39F$$+Z#!DP/*HG?N?66&;H?M*-\
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M6P^ZS#%\:#V==D2];\Q=3HL@99TW926;;P%?G^;X4X$)@$#E7)7Q2=)#JRD
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M\)")?3=1R&0G(&5^\B [X)YC(J(Q]<W-/&V;"#]2%\AV/-2=RVO5\5HQ8?>
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M+ R D*$LE]#)6+\O5Y^#,>/C&P4W54"B/ZLR2VLZ)XWWM<(BPN48B7-/+G>
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M&5S3EBN6:;QHUV%1-AZY6'[<%HQP;_N9&J9O_-/>VV?/7]D.M4TT:G[[F&<
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M2GI^29:SZ:2"]F[J:N:'2(E">/R:SS7EN!J#*R,9SS^5ICF2PWW=(<_ *!Z
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M!)G)S^5AR=+VWWKX_<J?RP<1WTZ%>#Q/>O!9%EE2W@>IKL?:/2<G9B=S1;/
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MXY0,ZMP'4T5R_7*,^E5KNL)-<DFTV>R=SHS_L%SNPANAP[,"#S  .K!O&]S
M2/_[A]]:M\MN4\?C[O#GIC?4:*]M#X<XS#'VN6N,H"QA3*&4J+@V))5.$Y=I
M-MYP3ZXEM.R#3#IFT-=181/.],[[VF!:[YRXOQ!M*4Z Q/^AK'2 :[P8^<T_
MJT*3W+*=8/TY%-?(* H#7WE^0/2CY.1LPL:\]%3@%I6M_Z$SZ@F1R,M,],GR
M827#F.V/0K0]:H;XVQ< 7JC&?>.IY]S$GD>OW(V</-AQ2V?'.]G<%H&SB^*=
M7B0_'5B?!:F&K0P+1K?>JX5WN8*KZJN^-6CKMGB,W_DKVS!^]3J575'%:-U
MG#PA=A8O>VD,K]'RFVYN2/( <*W]70_1WS_8H-M]T+1GT#Q@7DID^Y> T[W
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MZHY;C<2]($F5XQQ*HY5O!.5@FND,+=K^27!F?<USM,DQ[<F[\=$I3W.2X'#
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MVXFJL6WTS_GZ3 7-3'#.KD;N&8Y?^W6T%/:1\DKSU*3'MA(K458LI9<ITY#
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MVO[6I(3\F!*?KPEG?/\L2+10<^-/2=$Y9M%CNGGZB>XAZ3B#1G')+6KIC9R
MK>*2Y6XV:YL91;:X^W3JKTS5F.ZZ/YP;^2B%=HFLA]3E<@ZOXO%[Z83)JHQ"
MXDU3<^UGC>K0]7+72S )<.<I5^C9&^M4G4]O-*_2/';6C<1X-,ZO8W3K ;L@
M6>-1*#'C DP-:WX]3X_:%OB?$QDA@AY9EL>Y,I]5IX/4_0U.D8A][>)\%*$+
MG?8[U&>/9^Y:"/:9K9/@WW30B(KFN;40X#M8]W9.<X:9Y3W0@N+O[2YU-'_5
MWTDE^?C/J>>NK0]O-G/E3Z?5KU)?PF!^>H;].MN#FDRAJW5%A36T6:<8W:%Q
MJ3VK6[MYIH7/Y+6\[9D;X4C[+T>E*2:W^V".R/^/D?=^:VI;NX9YSMFZMP7=
M2%/JD2(2VJ8$I,E1*5(" BD0VI8J"0$IH020=ZL@+4%*Z&73$I*0("5 P,"A
M-P&!A%ZD0^B]P^MYG^\/^'Y=URQCSC7N,>Y[K6O.X%7^-=,,R60?B)-D]X_+
M5'*#.KE8 BD[:^^/M^3&7AN/FO%#BP!?=4&'3['- -VPBV+\A+<;4INQ>5"J
MI'$*CY:#&K\VDJLN"!* BNK:!=MX;NQJR6AV)LW_-'R[]KSJP4FIU,S?9NQ4
M+7<Q)?&(L]]WD$3"W]7L*?M.DCN6C/5Z@^U.S&SU][9Z=SNJS2W_^W! P#HQ
M*J-<,D>G,W:Y<12I&]%>#9+\42&Q,1$9:IU/H65VKP4'9',RQ$%,6"H-8M$9
M@F!C+>_/P)VNX[=NN8@-?:4H/<V/4US,V&M4]!:4]GS#%'!%IA]@9+KL]ZT?
MSM:9WBDI-)9EI&SX^<.7+K9JIMV$JB\0WE^CH!,70F,6BD["66NZN@USRC:X
M@\#&IN4+/&O($R/LI7[8[U7LZ*Q);4GK(*>W;2[5:-4BH/<E%O8#> BJ"9Z-
M:(&2"@-BCE\-2 2<;$CU G48'(E,.$GY]9VX)"\VZK827@OI5X3+0EZ4 "/O
MCDG;K(IRO'S\,0_<^B.UO&.W+"0%0F2)R?684) ._2XQZP^]NP8K)0[AV0Q-
MZA+4)'HF>>TH-/:8/%8*UVPA(9+>#ST#@0R/-S:("$GX9G1#.#>:4DOW*:#"
M,3Z<8JR6+K/[BHL7!K/?@@SWA0T]M0E-0G4'I^#,::&:V#[(=(N(QR^HKY7:
M"?=H00H3K@&(1FG=3TD]A0">+:K#7EEH=@A/7^RTM>\G10CL/V7VQZN .9N<
M7D."PUR&0(WBR^T*$Y2/@WME[[-_/EA!W\ ><Z(>6$?/0_<T3L?&<Z79S50Z
MR-$$L_OZGMJF1:NC?0#5,"]<BHXR+.V=Q()W'^>,#$IH3[L9\.W[=JAM++;(
ME$X&Y?H9?8,=],%DDTX7;3A=/%EX&U;S(\S#/[&@*8CUI#5J IB3U'&DR<];
MN^_2^\(W(2ED,]1NED7EF["/;G,DC9">/#^8R5Q,JGD\HEI+'N/IUW?F?Y,E
M9-5-&;90P:M(6O9W^*+!9F60\FH=[4+\7?5 .F6N!!;6\VIQ6[:.I+[++J%L
M-#UX7K]9$#O<P1#<X<N1J&]]7Y.ZV ]NDD!! ?G7AR?:5\B4YZ'&\$D@WX?0
MLZ:*31E43QK).G!QVDXJ=K)&]$;Z,B! 6@#R1X-+S>S+QMK\?QXR_)@WXR2\
MG?@4XAZG&_D=XR43K8E^O_NI&#T23?#T74&LL#N7YA](\O;>>"_S"%SK&IW3
M5GK7XAZ9*<R^50#NA8$"%U9,#N=O%OTK<)WT8(I1$NV!U@88[1K'2 3^GM'7
M.65&&"]:VWU%& G""^]"C)M5N^0PR_DK++LU!:PSVYHBF<@#7S3?MPH%WB4X
M>'KRJ/;ZN8'H9?LHMTTA+8SZXFLL]3RRO$Z[ZD(U>T3WZ4%')5'M/(VS\/Z7
M*8%P-ZON64]R.4N>WW*V[3([=_[YB71-=Z),AK2>P&S-FU#@M9LM*^OZX+.B
MV$_);P<PT)N>Q'",<M>4&"CH:<E7L$JP1TFW'M.&B)=/^E;^[PXM8RFP@0''
M7(>WXG 68J'61R1\"I /,N;1(CVW>6 M,+PL.[NN@@SG@ZO,\M68O LS3_"7
M[)@)_2,D>;*$L57Z/J9S5:Q^[/@QLQ5O^L!%I&-#OUV09.L:."GYUA1>3Q8K
MKW'V&(=D!2X]TKEY4E$H/%:CZ./T-BG "5+:S).\Z0VVRA!SED_VM$WRWI)M
M'3Y832*P#N^\,:%7K^D2-JXUBUL.,'@+CD7EO!AM8=56["&EZ9_UU+'13P9I
M1C.[<[@/FMI>[B?#WBVZ5#!41CL";4;\<Q<P%'O/.]I&\AA<6E#GXKX&O:%'
MH;LBJ*BD<SRK1O/MFW? R7LUEL^'.\<>W.)O("_X.WDBCW6=0X2G<$6?%4?<
M0F.*8$%$WQC$NV+=OV8D\[4=<68H^R1&'%TYM3,'IMMJ_3$F.Z((_Y9EOC=L
MIP>8Q.^:C,C52:&L.Y<\-)_?2[JK;WCTV?9&8GU]M'5[&\G0O/8U-CG:RK_&
MM;!JGP;>?K[%\?"QN-?4\$B@U2O9\XZMND; PQQ&I[& &@[\P5'E+VQDH(A&
M2))NZ.GOSHKL&UX9CBR$4HPCH%3C@7R1WY_ZFT5![LBN-3EK!'I;)H97=Q&K
MZZQ,3H=(NP6*#E#>C^)5L6L8\OJ/8ND7085A.G%09M\JFZ^D:C72/F/*[*=?
M?O-YGS*]&)3Q+,&P?%0ZRH/>-9>AW-:52Q5THZRKB_^3^F7RX$7VT=S+43(+
MN,"I>!F3\F+FNU#AON [^+)&$ 67TXZ4H_#L!$25F@=FUDK1+!AM'R?]__&2
M%="9TTGYH#*<#26QE-4S!4K-LAIO?7"J-C)<5N;$,K9D/!?P:XYB+]L7$^TS
MFHS'7+[$ULKV U0I,)(J(*=<)<,^.&4S'I94S2\4E]!JJ"E&<X*UC%H32_PA
M01)_9@ TOL6;8_N[A0N;&093/OK01T%\"\A"+ ]IP&3DMPGST=&.95]$0J:%
M)3E6PR4*7(3,X="S4MX;2?,.6*Z.,&^6&C_$4-):QE_!?/QSIC4<;!8RV/(X
M=UTFC-D9RL)4O%??@^(? !YI2 2GUQDT^A%XOY%^X=F=PG=C!\<%#P0_=?&.
MGFO[UTA^3:DP.9(/Y>\N/73]>X5-BC^Y5\WO8Z5=V0)I-3?2])TT/TRQ9V$9
M!D=)*J"3;O+]*2SQ1RX$F]&<4F.X5%:5N-VX]3D9">O2IY&SL1R#\D*M9-2>
M+.JGZ?.5S=7/5LR)>)M_RN=#'4!X?\V[[8.L_[XO"0L_O$699G?6^C/!+P:K
MS5=L%G56+KQ^,/^:$/YH7GS@[Q?DM>]2F)J?D"@4:]=V<W-M)K<$H][@6H+E
M8'4!:]H2L9JR::'3>0$6K]&OB]NV0_;]#*=C,?=:3"%BA\ N2:W%NXI"(>%@
M+,Z?$1M;NQ*JWIU.W=6M1!L%6)G44WD51WZ$C^?NM6!^<^ON'-W.L81=<>4#
MEW( B'L"$MX6(D?9,46U:0'?=]GJ.$]1OHWQ=DH:=W_B]S#Y89]A 0((PF$_
M3_??F[9&A#FL"T5/N+\69?9FQ&. \>;DY?LS_"2D=RH_CG4\J&^&(4>3,6G\
M)<22J6\PJ;B!L96HLKD#A4O&=Q B<:#0#K_(L.1K]5$9[7IGG^N._0X3U?0I
M^PJQ.G6SSOKH?-!E\>\U)/W(MH?;?^K%;<^/Q8[1F.S'=0A +"::!KRA+6DO
MJ8%^,<-.)=AOH'F_OQ#1>#*DT_^9<72<!O^:S7%$NEN6;/*VN9!3L=@<%ZS]
M%TKR)1DA)N8KL!S<H, <V"WPOPA.*[@/UJI_);U['=HCSV/XE5@C%[FWI^%
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M.'\?XK0O@.=398']^5U<PK']I[_UWR8B^K8>U>4:%_:(SK-O^RVZ&$'*3Y8
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MN6,\K)4Y*ZXU>4(DQKJ.L]Q#+QH,*=3860=565<2.29)L0V?8_TKE-/W/]-
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M4-'RWWY<$X1\.-#Q?E';-Y^E(?ZQQCRE3WH=8C(]7.H*_?G),%;A4YE0V',
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M,;XA46%!QG9"<V5Z^;;*F/*@P-CF_%-9.KV#*QPAG7IY[V1:N:F7;O'*S"W
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M.QF?RF%">HUK&N5MC@ZQ!%AE(^JUU/=>P\F,NTZ7U@T)-8 6X>'=JX<;IV#
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M8E:L'E@_M*6%^;&%R;H*5N_]Y2-<X)E?43'D,/ZAIC8Y_4Z/QSQ@6K-V6KG
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MG POQXR48-Y0-#HB#2X4+_5OFL$ZD0[M>#)(:3CG6-I _"%YBZ]GR#$(B9W
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MIJ\_G(KIS&*^A"@/:(AT2F7!+9?(9')BGJQ5>?F%?&2;;Z57APGN+1M,KOR
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M!  /1:\TO)BQ['SYM>[QSDZ="[&02BA=T6Q[VG@K"_6URWQ;,5VO_#CV3<*
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MKPV23VNI$B]3MK0+"_Z<%RX5NP1KT%#I.:/;>Z$FIMYIU(;OAIW4*RIVH;_
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M:HBC0;EY*%W&[5 Q67'[4T[&YTQ%!B@O_)S>BH8V=H2"&LO$*R/PHF65]&\
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MH*->Y_QEPE 30A^%3F8+;J9H&T^(Q41C>PP#/'K@UM0%](+A4I9@NQ(_CE"
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M/J$75EE*S1^FHUC^/K4)N/L?,&>8K</PHHF G>+ H>*ML(54T1A:9$GX'.5
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M(0UJ:4Y#_"2X#C=1A-VX>U\2%V,ZN^\-5.!ABG&I2HG0?GN A'%&9_M,I?H
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M>F..H0LN!FP(EO;T<=,*/O+)P]4)" EY_EV_:2\<6<DG)MP^E<'59P42)]
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M4P6%GV'-\LB=C6"YZB?(BU'78YW54 =+)HNYF&D%%QX6_0=_(7,]9#@]/XF
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MUI^(;+(L5:]O<K6RA_*N;VC!Z?> Z:+@48:!XI2&#4@^HYVJMG_)P=JY9/O
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MXL[M8VZ[2E/>VN[#YSYEL*UG=G_Z)I#U5,B_4U(6M"HKZ[18.W-')XZ0C3?
MZ7-M.(D8AB_>B]V/K@HF\.U^V'#?[M,WZ4JQKEIO:H>B1R6-T5XAY.Q:,4+-
M1\,HIX/&R:$WNR#0C3?_&P*LUC]$@(W-?X\^.JJPMMM5D/-S?997 #5@^=&8
MLX*"EPOK9G4RTB7Q\:;C_GCY2;68*%;T?<J((S/;@G2WWE*A9\,VN,^P.3^U
MVY7]?8)91E#\%#4MT+3^&*^M1,SP.)%NZ]8*DUH1!@]?UEY'^GT3D'Y]JS7G
M(EASN3F>S%#$-A73K3Y[3 ']S*=?G%' O<L"7/-GE+ECN[8[#\I'4 ;9MB0-
MA+5"LR:8<O9UD4NU65]336_JEU+;E[Y0EB2.6&INCRG W%PEJCI[B QIM;3V
M6WR%F%^.;;0W+C;9$IM_'AJC-<YN)TB5WT(@U!QIJPR4.IHR,Z3[6?7MUJ?4
MKG[K&XV^K8+$44$\C7%US,[5Z,X?'2S,1I9+D18PUCR>P%YFF,K0W&_,/Y&M
MS.+WO7GA6W K;&6WGY^7/R;G;00/,9$&.3:^F3SCQU&AC-W54[4RO?Y91,C"
M$X[1B$!ZM4ME<(ZA;94D])U],QR0&)",%[8<D=TT76_S\$TJ8\ K?VJ6/'9%
M@DD@J*QM_8X86G7O;XA:/!XC1L>KN(Q%$ZLO%^2VW:FH:+MS.]JS:=BYT14
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MT,>9"_I3B9GN>2OO;@F<TDTUG^2W"YTG<I'V=";NA.\SAP4+JS0*.L=3!""
M^&9?S TGVFT'RS]Y']-Y,?A#"!*!@/<@N'7!;MN+E,G''128^%:!'2;JIP>7
M4H0[)66$R6#D4CI O+=]S II)ST9WKT0BN^\E-=]R_V;P,USC4<%_U9WVUU-
MM2+OR_%,3/G1#?]3W2W#,K#M=TL_8VNR"@#X &W&YW4<UB<D"<!>H\VG3WF,
M[]%_:L[BU,5".QH$$H%W;"M:53#VUJ;;01=M0+1Q]R]*$!MUD?'X,^=OCV^H
MG)+,<,486V+BUJ/4V$A,FDD PF(;&1P9VE'PXD@*1D84PW(Q)]DB_JP=43.
M?_0=R^GS"VKPJ<-*I9XNLA.,,U)*C:O?9O%W^XI&TT-3Y!ZUF47YYO>/7Q\2
M.5'$#5HSO;%N=X-3_%+.T\ B'F%@X83Q-[5%P8R1.^:]1H<;EQ5E%@3F[2]N
M:M\X+MH)E9C\Y T))3:P66S=64?>A%BY:S;C=>)C3N)(B>#NJ0J-+]=>\"8
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M*D<\],RKQTXZ_5)<K.S"N.MO+K<?F*LR9@_G*F.4>;/>D(MK3HOQ9GWNKVQ
MH$A"2;C T-K:GY9F>_F&[C6L\")C^_<&KL9J+F48O,WEBK97T"\$8-^F/;Y%
MJO9#VV(44-<6WA.Z*#=RO:(RKI(;WT!$+5*1MH^^UUOVWNI#L13/"E>R,A4E
MHU<!:T8'TVQJVLPF:<*]ZV8K(^>@R>DSD ^G)VZPAGBJ[.E%BL9;_B/J.JCU
M5\265\QA"4/"&"ML+?\_CC?/61SW-S('2ANMD<Z^K4.*'+_R-ML,32T@@8*O
M2#I<Y*Q5MMT_?J\K$K4=P#<C>=9+-2XJES/Y8RIL7PYY"A@ %C>V.N8!J:>'
M1?%(G-^&Q-N@DW5V+$<V"]XTZ,09OW=RZOJ"(U4F<V,;WIB]W\$[Y"/"E;AN
M#)"[6J5I($&>:,CFHP_0F8,SU1$UI]X=P?OU_VI;'5K4W8G2J>>SW_AY7)"8
MS@TV).)B>+(**_YN*K/:LY12<LN$/R)HQ!::5FNI\$2Y!T1CIG@@D4AQ&6&;
M3R5@HS#[WK,U=*<RB-_X#H'6C^@@$'8)SZ6WO-YM"@6$GVWE;*,Y8T2*!$V$
M,Q%V%[%F(:>:)X\"Y4*3DA8WH&UCWCA)@Q2[+E5V<9:OSAH[:,0U T.3D1)=
M?3SHD5[I$5 U1BYDA?O,TI A )?HY5>X&)4GBEA+!56T2HP1Y"+X9CW(Y;N&
M:OE/["9+GM.'32&0D_YXR7!Y)]:N4M+#0UIU.65=.Y1UUI:2UNXEK+J4;?RB
M1[M 1"X)C+#MJRD8.]GZ:64*2Y#Z7MW%DZ)5&H)<QB#7@BN!,CR^G&8;)D>3
MIII3_AZ :+/\-R+Y8>['DU5?S)I\F_8XS/Q[%\.N9 G>F*1;8+U>K)$BID::
M.<3P0P_ZZ2$EK$> O],RIF.0WX;)Y?DR5!1T0*RD<GD<0V]1J]5 79SQ,\<D
MP=_.\V<=.F.HLB7\X9 X3I=MZVH!7:SL-"'/EF.L:YAKT0V6<@WG!J2X<]CT
M\PD)$AYG]7U-7Z%U^M2ZB<3TXP,<_&&9F\S'F]DYBVJNJF0/O\SD;_W&[O/"
M:(I//O[3[4A<X$C\66DM0A/<E<?#%'@X\GK_SIPPD1,T$9*I!-OXF5J.K06\
MXBZ*0DUK86VX)%:%J#IK9P530_Y#H44CD?Y-X.<O5_V$CKULAB:U]<>2&]W
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M/M^CSGME2E!<^IA16<7N K78OYC)W5IB"9MTL^B/7;_%"(M62T?ZJ:'Y^"$
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M9;3/$?<X,,(TU1-:77MVQW1P3^W,LIIJ TO/?^XDH03=\\F%HTO,--3[EB'
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M@)R?0I32P;9FU:A3K(E:$1H# ($K&Y TJ[NYH7:RN(U</GT\T,D?T)P[0=&
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M7ZD44?2XP2"+U/K*^-L\A_U#+8I>38Z:H;MXZ=DV0\,\=R0O#*U@ IDV->4
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M"^P9S\/=VN&15ZQ8?CX-"_+DA,']ZA8DRJ,P#3[*.3M^QQK\(!V8=$0U"Z+
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MV.%E6LX+MCB">[ZK[KF36L:AM&J'Z-Y*JA'^V=KMA#(7&LK\]I]Q4WN+/@!
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M$MF".V!K>Z85TN0;UWJ>LAYPC4JYGQM_@2X^?:,$5^R_%6&:OPZV%UL< 4J
M_%EJ:A5F5<[7;ID!B<N+/JF2S-G,;4N$$ZT_YY+UFDP_'CBR,[;TS\T?N9L<
M0.9K_'G$N&/9K".^8EGTNQWP&I6AN>D[9:@7AH]E[&^W#;H78($CG_VBX%)^
M_/D%:4.+)40G[DR'FCQI::?:*2.8!=_B3[>792L;MJ2,4?J8'>EVR#>@&]5-
MALZ@D=*6&#*?<7Y4?>]LEL#O<>' :C@G76RAU6TN4@8<5/[+;HV''9&O39['
MZT2X[_8[^P7:@B6LQYM$\YK@)H.*5LZA(=[O"*$H>]S8]SUV2X.X4XMF3':$
M>V4F>R5;@KN6P_.YU&;"-(?$U_=*V\CP\G7B==?^J*/[OS](R6>RZPJ9)53#
M#1L?=Y!UICR1Q'GT?=?9)7$S0'15=LG,H'?&^H?EW6"OS7C[%S]NNAX+C2&M
M4=;#QC7/I_RT,$WY67X\K7C'$,7AYKHYRW,Y6X!T5,F+^MQ4Z/FA^)=*$P\X
MLTT#L:B$KSAX%DJ=8Q=A5$S[W;O5M/!@,!31"WH[O!' Z"]4"(#U2-_M'E<3
MS?!\01F >3LQDR05]UIBS>,NG88P)@X5]?-3Q@@+A@&M8UB##!TRBJ.TVV,6
M;<D4!C(9-)/N(H?F\:TH5;\UY:>X0!OI5\^+"I=;>P"$:]RNV!*UBZ4*-44R
MDQ+.KC+SHZ/5<&:3NK>KNGPJ0L=_F0%/EDWX,;T]3WB_Z/#<S/SEAY'3]%6D
MV5S(6N_A@B;VJM&30[4CBWJMC,G8(]+[5UVX='AETQA<777"J2*9X_]W,RXB
M5>8_'QV@* A^>F/I:GBF??][S\B5N+A,3?7A_]1;MQX+U9"WYRAUFY0W=^P:
M'$Q.\EHROAL'_W=+J)Z:0"/ML,*D?B$YK\;AH*3QL>HH@U;&KDL/?VFOQ*Z2
M4*;"K'#]+XV_J[(EL? V_VM.I:X1X3M\K5\(M\W/K,*2@R4>!M@9]C+XW<BQ
M 9EVQRKE)4XZ*D'AX$W]KCZ6.(.^H'B04C+'Y[09Y+07F/#.83J0O^T<&,O@
M=5F4?T,VZA@?CX7.W-\JBQWK4=2"2R%&@$ZT.\%[,C9')D]WHJV3['V3E&OS
MF/V\Q1[G;*4,-\\LW[W<W^-70\L1@'2V,F3UIB5J]!T/)F9!]2X1G'ZT-!S9
M^X0PS1(Y.JQN6;[[:7N$&4;WE_0,@[RP3T]SSSWK]89XO=6CS;B,<<6:P-[H
M'H0%M #%?/<_9'LOG5Z\\^H ?OHQJRY&:=;2)]MTHY?\]=59'-0RIA%27T(0
M"]1L&J;KY,*DL];2Z)[?Z<VO8T0R<@'YFQGIC\$.T)XUK?P]3WI<SD*D2\5-
MTF-RG%<7J_Y#YLO()TI%NAE5-70;=\GA-&[0@?7[X+SJ@5[F#3?! HO?]\H-
M:!!-'?AWYH"F #L<ED&-B46]5!7?@^/?VL0AT_KJ2A$K8B\AOHS53@&%M&V
M;-PMSHHLI785"HR7$(GO2@1^KA=B!2;0+VM=,L47</^= 0=T2%NIKZO;#[=8
M8>HS<HD\" %INL8\>3_Q\\R/(^BZ2]S%I#79;%V/ ,_-O042_Z>9:K&38J3A
M69=CH5,,OMC2U=65PUM1KX^%?AXIG$V!J2*LKW%WW\Q!/]>,]VP#+O_>Y+1:
M.^6@_XJ%7RY-K_)1>)+4Q.Z\'5E<H^7 =)DFJ=Z3FJE+PJ_=+8MM 1/1EZ._
MN[-E'00WK6]Y$2K(!QM_M+&;UP[6-<Y13K4H@_WC<@:/A:I/*S:UPA#"35>2
M#Z93W2LF9NG9CH@DOON(*?\!-:FYR/. 80JV'1C'T5WPT,RQ^L(O8L4R32MA
M8.M.'&%P7K,3DVE+YTV7Z:?8V"TTD[>]4C!VK5K&68JJ#^]/T8/[EZZJ?DB1
M6(_=4V_7A"]MYORFU/]>;N_&T_C?[$;XGD0TV['U7?M>YD, 8@HECRQ!9+B5
MI[*D'1B"9T'NF@, W(CQ'&"+5AFXO&B)!5?.6-D/21L&(<A/G@2+AZ$O_?N3
MO=7:X7.2L7MNF:!K>O3;R&EX;2C!7GC4J>BZQO2P(2LLA]?MO3!6=Z:5:6;C
MAA^@K_9!1A:^>1 BL^K66<XHUQZI66'8KJQR4DC[9[A.JXFI^W7M^D1[@*K7
MOQ37GHC&%%70["*DS<AI!E^_]M-43KYTOEN5_ZTRTZ#)S@5_.*+&R'ON_NPC
M 4':X.A)9J'F%S;YTN$<Y(^N6:ZF<CA#>%!0A68KHDPL;6WNX&^8 R8FYL&)
MBC!4V+65=7+F"]7[:8.5(#X4NY%-":O)2@DNT1'@O-Z,LD)W^ 50"L.<CC>F
M-M\E>V;]";%->C-1;KYAHI(F?OZ%/Q=Y3S?_I+0*?*X*9HPZ=4-USVK9WKJM
MIJ:M_[ZFCE$ZI2B\ZQI:)'7A>FQ>0+][YJQ=DW%HA6W]5A;IQY%[KM(5))T:
MGXLZ<" 2]ITK+U)BRGQI/[/7)P413HM56\L2&#&XP.O$07GPNQQUG6,A*'7F
M?UR)F'V@,XV31[O[4V2VCW3&1"="N:JRI.T\Y7J"DZFIUY@O[5EBBGN0IJN@
MTZ[-SI\ 6*&-*(7B:M.K]HT).7EC2OS]S*,?UM=+\@T$L;@-],3N>G&XSPF2
M)'B/XS"KN %X,_TCT.$@(,3:YKR)@JCQ2,NZ]M=#^4WSK3)3;>APE![: 8K;
MZ3/,0'1\B3-(GW0$?/#Y^4!I/-,TP($IMNJP/'HPJO.:$^=B[-I>:&(D\4-U
MW'G2\4BR"Y$%X[^%&NA\N%_)$!=1#UJ_NG,#>>%93=<GOT+UOG1HO59GGV]'
M-'KA,VG*<YUY$DV;57?/%,W*S;]7XQ7O8GV8G/PFO+!$1O;Y-90]0."UZJ""
M\/O^8!17HJT->GQ]*VG+R_[;%OB;HSEY-;5K!0OF!MUM#DB6LH-_-ID.24]Z
M7F2B6"2_HR'*4<L5E7II1A']^FKB%HA2@#2!&#8B,KF"\V?7_M4[C>1M[)@N
MW#3QW2WW";TZ[ZYUR1BMHU2/UFW^DF#LL#%F!W=R7M!/-^RM-+@Y=ACBYHZ7
M^OR3!G$-&LY7/^WWV*>H)#SXZTMV!#KL6&A#Q4@6T6!1'@&H'!",I1@%7I=Y
MW"LX2C0*O)&-FZFDNLNE*=W4<B$UZ^B#BEPM%1[7OGR56)D2S8\[N]OM:OF
M6;$C@'F9?[.!0<<!,:.- Q;9DEFLV =&TNS&AYJ?3]C"*&[R9;9^DA:3<KN
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M Y>V$G*BK"1M%FBO]--/%%72$;UF:^R'M%4Q6CPRN7L+8V:.3LVO<N]Y;BX
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M2B@0?_5Y!1L?FG#-OAR%@][A$MRLO-5J[$\'^D(;M'7T,+&2N-XP?U1V$YA
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M=/YW+%C7OOS<)[60HY[ N"GF1SH%/OF</WXGL%EE:C;G1)&)VE5O:!P2]*Z
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MLTE7K-F.D'JH/)$"_E T4 H061%OK_WT0^I< Y^ 0AB(AS;>RV)FT:/]JJ:
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M_#EI"E(FS!>Q?$LE3=83P-76E(A+KGG0X+JQ'UU+!Q'D@[38]6I[:D/QW':
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M\7M]?\DEEU6B9X,WIIB=!:N*:H]#+?PG-*L,"U=X OH2.VFIWM\V15ZM0I8
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M E^8+&W>I1IEE\Z)H] M>#,-4?!^E+"P//_3<7P)]@$KVG@>-:OR,TT)A!I
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M94)Z&[F]SF8-@-VCFV,JGGE)%A2XA XZ@A%$/6NUYE,+I'0.]V'N4UR*RV"
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MK6.<C-M2C(*SH;.Y19V6TJ^%R;UE50V/0PHK9/-:_1<I? _.2Y\ MCC_I1P
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M)"KL>I%Z<#IWT9H5)LFWF&-V^3-^E%:<Q__L117!:62B=E>Z0O4S_J3'=2T
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M4J$WW4K)XSE52)3]M'[77TYK)D/2/KUN@0^ /#M;\U.\P(18:XO1=RX>@AP
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MNK],_B)Y*@]XKHR,3#%UXY"B&P;X'E\>>GN+_)H.5(!YP]&#R8P+SA0O_\H
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M*P9 H)M*$]PK'[]L2*VR@IN.-Y4XL/8LY!E'+@MF^MUSY:LK678K0;=#R2Y
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M/,+T\#-4LG9;&CB26,O7_=!>=%@C>BE7UN;<$!NUE]+GL"=J1<+[GI.5^E.
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M%(VE_:PHI4J=*<63$2*Q*G/Q.)/%@[]2'B<A)K![0;J$OD.((N]-;H'R"#A
M(L%/H15DF8I\0_.(KNZD+D42@G]2DZOO%I30Q,>:ZQ$!JUD_*HW150L+GDLS
MJT:7PII?YO=!Z/@8N3&]I.S,U-;@PN.$?6H9>>V4@$^Y:6PJUVL"A"OZ,2XC
M%FS&7:@ +@OR:ZVI_EO9HE<,'MV_4*ND[7R)7^4/Q[N*T3Q!SA#?%DI>&"GU
M-)ESNRRTP-!\,N[G=TDL5J>ENC4K3 :20 G(GMV"// JD&/2R81^:/A >I?7
M!SU)FU3K BG]%ZL@](WL>4#3/($+PT="[/8=<Q7T'7R/.@F+)]3>CYVS]D[S
M0=P:QXD+/__81]3+A @4F$\)&)Q/Z 9TJ_=_:##AW513C]K/R;X9D))R6/WA
MY^Z&Y!6#3ZG$"1UD:N%O' X+=$DVCDR5M^86L?0!P7C*D%3</S<K^*GI9D'P
M!K6C!)OF(X-C]UD#[ J8QCOM3&9-JYL:;#+9LCB"L%#HXM/2Q<F6EN<XR9YE
M)VV7-36B\''IU]Z;=<=?0M<XQ9M;YG226^B"4*2=N_M6])/N1]=S<8G=A2%3
M*8(C<)0I2V9RWB?%[SG3EVIS9M%F__HLLHGK SO&Q\@%0NDO5$EU52=A+.@6
M(:CM(SOPXOK9_D&5X\;I'>^3(8F7M%.-:>[G@WJM=)\QFH%LYJ8SUR/TF17<
M%=U6IF\6N\@1@$*Z&W$ZDR'2!O4E_OVJ AJ=&YJZ::J_*(*9ICPY2%4^1?=*
MS(/%/B>S1L)YR6& C4MYC!#M8R:DT4_QC5A"-#8Z0.L.RO-:AOG[4,69U8'
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M+&3-LNF'#1V,:?XQKZ,QO_K&N99H*1ZI/DS)KLRL OOYZ+W)_A(\OZ'H._U
M,Z1[ >_SU3O1Z,ZE+TN!(_@\[5^S$-)H!7G^ *#S.>3FB&/_LMH#7XYPHPNS
M.4U!'\\AR8FLV(/<!"+,N+XK&Q9G*OVZXSY107,B./;;RXQW!$+40E?2R0_W
M95;#)#_-(TKKIFM9@,B;]I(>%4.:VH\8\^C6'PEG-..IV^Z)3Y):]92K:/7=
M-5TGQ<I_39[^.F'K@.9;\I>?3=""X !3\/M:+JI:KB_\8V*5,'A>;>ME>E>&
M,P%4=KN$3;&Q#B*\,(FV]EU4T3%2[="$FI1#>2W\PVLF5+?1OG?MK?'Q? U0
MH2EIAT^-=.=XI'"@TD1^+#Y4\4,-PE<:, W+IO,Z7XLIRK)ZPQFC#8F#%?[O
MS'$V"-\F.?56?K_8]O.1SNY7?;U\[[H)USSWA@T5)>D/GQJ$2#@=N:#;D8[T
MH!]?TVG9W])$]P@NU7U6VR]TPN [Y\QW!]9?"K\GKE=W_:;K97?O>$@]'0&7
M_!#,LZJ!ZLW4BWM74J>Q*C[,KQ&HY:BLU%$G>Z._FN-]?@B0H]H^<$\4 (!M
MZO?IN+G,1=H-;42LK#E>@"J'L@@K72D>Z3]L3.3="/6$BZDIP^\ I2L&$)SV
M?7X^+)J:-V3PJV:80\/4LV#-@>RQHW)W8X=OJKM]?]<D/+.H1BX^QU.%8LFI
ME +,][C-E77;_+_2SXK[D\(;:'+Y9E-]MK5L-B^1((S//#"#B<7 H51IC;-B
M,S7REFV).W,4+]HJ L'\ROKA0O>A[:-VEF]KN$J?V)FR@;Q',!+G#]/,0OE5
M81Q:4N%C%9T#F%3S^DVCU[YCM^<#'H%32ZR+Q2D ^6WP$$(X].I]/B:O W'&
MU0YN!5SF#G6E>!$(N5N\7+5:FSMFK?K=CQ._H8HY++H N=/UW$U\!N4WNT_B
M.0@$?*IP*A?R0X')(6^%'\F*#"+SZ;@MHC3YRBJ$)ZBFU/[TZV[1WGIF!=27
MWV;EY/4'M5?S2]RYL]%GHA7#.\8;OO?&*GO 6=W'J[DQV\JT;HVE?$Q(.Q@>
MF6,YV'?S-6&]UR,NWI^Y)XU=>#NJ)>QW@NS(\4C)I'!PQ%,/A3%VA@<[$R,3
MR\U<U5GKM:X=V!2.GC?V\@%()L1FO[S#MKAK'(0_SK.V7T &[#[BJHJ-,TR6
M\["?0R#8<I/K>WJSQGPOKA=RSXH+'-2E>1N?\P2L%J;5:?&;*E#T.&A9&@]7
M9XT]$(B?F,7-Y;#DAJR\(;;1MY6HU16[%> CJ [+NT@)-($< QW:02#,;H]/
M6'@Z)96OC=F\]OM65QN-,)Q8+UOOEY,!<%%-W/K?"0%] H9+TQ)O1\Y8<!L1
M.\QZZ*ZF\.(J2ZO124^!U-C;3@AJ+"[VV5/]9.DQ$E)]T>D]#V$6&?MRS.*4
M3XE)^VMSBWA&W/;[J2'R.*$HSIQ\K[?@4*=@/T9/?]RC?<, \, WP@ IR1[&
MM*B/G@^%,[;B"Z10A96(R6%AT<R42/)/P^15(^$!8T(DR:"6/M6Z/E/S*H\3
M=ZFSXI@BA<W1BW;VP7C1+FW3J[JCOVT,UOF&=LW\H@[V$<())19BDEYRYUQ9
M>57T&-3;83\^FN>0S#*6XSU?Q&8\US2G)W?7^_DX9[=T[8K1WC"S7FZ5+6T2
M5,MQPEH9_MQY<CG$H%8L(DLS:U!3H6__,(M".]2 @L&.M-7(+^<\:L]K9]O&
M1W7T<EKSO ,:'CV:?ZJ7*5R(Y:;_7#"];S=N>&$0ZSY2E$2<*Y$Y:$\NXIU<
M_:OS:/**08$BL%N"4#ANH1B#(/:DK&.+T>=DM@/B!"39*@&ZT;LQ+=(3[5R?
MZF,KT+LOXE1TEE-4)2-Z>7^LJ9'R,V*(#(.-UY\UO,AX^>%"*J5NC__Q9XU&
MXUC100.42?.8M8@^^!6-<1;#*[^&_QT&Y_"^FP,6UPDD&NL%'!>)-E#=MXPO
MF42XN1Q8'0!^<'KE5-%0].3$083RL4W,DY@E&4")TWN@2[?+BSJ0#0?F[WZX
M9.14I9N^)*=P X^1=SP P=+AMHLPMP]B@A27SKW+B9[YE2FD9O18:P#9W1N\
M(6ONO[)@H!R+*[)$A2D( D7/Q+_#V]"%:?IT/^-5[K<-=MWCB ][B"%DZS?U
MD[\\'")B9]:W+"/)B%<"S.]/_;0)OV3]4)1\=J('H*C5C+2I@AG-LAN6A.E2
MA;QN5JQ=UT"0<F6XG[!5X;R[)PZM8]UR3SNMDW@&?;W3Y2L8C6$DXS_E A[U
MU8%6K^543&ZQ2QW 3"PT?.TFOKCG:A&G\!/$NFQLX[+T+^./CN&.&M9U2KSS
M$7SY>'J\V\ID"&8\ZV>>29:U/ 8JGN<?EQ]&[)[])L5%9F:YW9-:U(Z.878:
MUFT?'\H.)5G,<L6ZM1_ZQ'<6K3_*@XU#'4<B.K@R-6()#;9UM=U5V8.A[+_T
M6O* ?-:6!9A%/#9;1-4R2MHLK9M0F,<XY2F?:BII4##@@63<I7Q'(M(X^O#&
MI#@%T5UK.#"B<4V)Z=T(&[8"*5:"[="J>.G6@= XP4[W^B435\T$: 0R6$(R
MTPD9]<G^V<!&A#DW./]'Z34M28 K730:=X -XN7W>3<6\_RYYX9?ENX8/U-@
MIQ?)->&#*;OAJ #.S]_\@4TM,?@\%5BX]'3 5V#E_1*NGJY1$P_K3G(1+L]@
MN>=[Q?!27L.]MVJMVQ%'K[LQ.JC1.1,C-)\VX 21B//FT[9+^R'@VJ9_H-#G
M<8U#1W6,I"<\^?R^H#$U*&H(W![(L@@\_:;ZTLU7!#RZ-D_L3KGW(BLQN70F
MUG6P*?3A/E/M_LY+V?I$Z2.9S6(]]SVWPQ1YSL/,MSD4@PTAN4&I+4GE<9)A
MJB?,[7S+K9U9=V/8E-NV&66;4UJMA- 4<VJ2@2'8^Y?V"UD,OCG\J;Q:7RS-
M 8:GP1FK\Y#4[OW?,C&RYRJA^D#O9[$/ZTZ2&?,L86IUTG#OCZ*B0R/RR=OF
M\=R:L;>99SN]C%8.G^79W53S:D298? ^FE(!IK'(H8[R6GM#IF#=N[OK<>1Q
MMH.#EB78.]E26^Y;1(9K?W8U/>#+*LF<T:+!.(<PN6MENM38%,:SQ>/+?J/6
M>67YZP896A3YJUR=UN-[,LT+WS-95#F(U\6S'DKT<(<6YP%'*_@=I6PT+9-=
M3"6"D1P!+Z$%Z8:+\4+V6"J$(^.!2@OGHB69/91=#KIVF_YR8/04-P?$S\U^
M+]I\_$^E)WX!Z>Q?L[?/9H.=4N1MR3+J[0*#Q'GN>HG"EKF5LZAZ2:G 8_9[
M.5/:A_6"W,K56J6"EF(3 _"T=_Q9(HL>.@F9/?U$+V9-_69]0=E'\D9G=P:F
MF?WKC.:U:9-=]_B%[*X8Q(P$'WCD$&T3S;;ZT<\T,&'':^P4#@!^TX/\6+FW
MO\T+IIGOCN1R7Q;(N>UP":*[=I&&_RG7X*#M$FD*6G9:XUI;NVMT]H59Q@C,
M7X7'D"_31M8"N+RP9QT**GN"_WTPJT0"1?%N]5AO"Q?$"OH@ *#][OP-"K5A
M<@A\87&!D_0TKI_!_]NNK.F?R=<N\8%'2MF]"*&YV2WR^9<NW6Y<5NYQ.>BT
M(R ?56@/9K/:UYCGYA[<W1*(8!FDB5H6-X'/[['J@,L.$O0*1'(O[HQASZ8?
M+$KL<R<#H&:'W?F]%#KU;/)'6=2Y0&!N.AK$=<Z1?:+R)@]=RK2LHGW%H$P\
M9+G,G@UZ$!8X&.1#H'35ZPMV*^O9C&U"9\8K*DY@DA#YG3KQ;G)>XJ[-&YTZ
MC7#W86-"V@E465_&5]BO5$_ABL'[GQK'JM6.2X,KA@TF$8S#$6F",C&DTZ4_
M86X/ELS\KX]#EN2FA]7/H20Q&4Y6]\[+5DQ0<8E>"]FAGQI#$$G]I[V-6]A*
M?;/'G''XHZP]PM+<&$#'>TS^UF^ZBHE[ G31')TZ:"I<PDSDJ21^V;Q#!BD[
MD^ZP<G@)!UR+@-\5TUH63F:N53U)E \6:IGN@0J)#J6QBX!$P+_+F7=>%:JC
M#V3L!Q2?%N'2O@*+2CE5JP:JK%NC0 DT;9B\7T.'ZI#'M[+2R5"I[74+#K;8
M6,_AI-NJX6/17?7!RA>]HR?ESAE6>(U55!FOJ-5"\31^,F=P:,6UD:5 W^3]
MEMF!V'V4_5\ZC13E?B5FJ$\E-F94YY;R?B/^P/=V&H8JNFPX=,50?'9_.^^5
M&A%2RFL9Y?=SS+B^(?%QL++@'+JW?&IRT>0(_O/@[$X,)57Z!!EV6AUU3%G4
M6="=?>RNVC>Q,Z,6Z3Z#>>*&$-W=I(#R_#9X)CE*3&27=9NF*UV);H4[3Q.>
MA ]5S:R/[_?OM#XQHG%L 0($ 6/MV9I0J8QDH'6:J5=(31!(1_'EV-BZI+Q@
M_">W%&GF3*/574D#B%X(>7KI]4Z5@4R)L@'A'6PB:0!8!49[FM#8Z.,A:8/U
M/COCRY,6I<[73V/V7?<>-YI(RA[.J2BF)0 $[^65%=M#LXPK,W;U*>60->N9
MT[K4@P0"2$$^I*1YF(TD_QJAA!"X\-C?5"\:*$&D^HEHN2PFNIXR^CRS7TY+
MZ-'A2JCHBM\AFV2% %,>4S-EV6(NP/M\N(F]?KCAJ$V:5\K _C>MWNZTI@NP
MS[N^!=J^P/TZ&DJ^$G-[-JLQ(7^[VK.<TEW6R%(?)FZ]%\#W*K$P%(=7C=4?
MW. RDJF+&*TPHW+<Z<*OSL8VI5GYBTS&>LFC>%F><&*3/(;ZBHT-O/4'*/('
M3EK\*DI#:KD^R=!,.5C_-S_^N^=:D1=57!II;C9>.S).Q54PLZIFAYSBD&36
MP7$KS)ROBYGHCY.D48_+GLK+[%*-,5\?:X*3-Q\A>?"YO^)-.995J>SK(93\
MM;L8,/RV\)?(!1VQ(P!G-O(=-N6_26CM_+ETIZ.JUD4S)^!+1SY2;7B=?:1P
MV]2X:Q&$+7=J68%I&"C=KBVC3>'&5SE;TQ!00O&'=2+:J7A;O:P1]DH (9.N
MX7JC=A8/E7Q6&#A71,TP[MZPU(RR\K5Y:!&35-[&!Y>R*G(H,4KN74P%2>P]
M<H3D/A^K>S;NBC-ZPAXOX6P@7[OI]NC07<^"^;MNM DK(MM-EMXOY=!W*5"(
M.[1\1T'8&T%U^&@Q*JI4_<[RQB)\QZ.SNP4*23DX*F7:,.&]_[?\>SN[O:TF
M.);F#VD8=KG6!+4_."K4.V$3*6J\[BM=N5GWHBWR;AD)!BD,XA&)CK5F2_=F
M\^V<D#T!8U;QZ"+FKAL+7VQ9?VP]E2H83#+.S4H 4E.]L%[4#EJS=X>ROM91
M(8LBC< #JNC3K%]^GO*8+2%AS7D* #$%K\,,CAMNN7X'IT_=*QJ'QIK'/Q63
M")>Q0/)$)-A42C9TAP_2'C!]QKP'4?TOCR!>GQ"EY,O($97RG.UQ L?D:SPW
M9TW=C5J]AZE#PS+P1L. &QB?)R)2(\L=FQ\=H:D '<8$RNL9^;7_*K%Y^U\Q
M# 4@MR\Y &7?8J!QT@!I#J>V _[GK!+?*'#E$:%92\M(*1=5,LNMB*49Q%\9
M 1GUK[!]#6/RGVP.JPW,UE",&1,M&FUJ.K*'O*C^;&>^#<6@I-79F8G,W+@O
M0P[9=MC-3[:RVE5'9D6-&D[?M;/T*:+>#[.2M4K36 ^":J>_H5*ZJE10^ -E
MS<=5PP"A]S52RBTS(3"#6\A:&-<RP;LKMB720WLEL<BKE[CA9S)^'7_8*//W
M IYBK( G-O(L LB Y^;?9R)C]'N.@3@Z#W@%6VNV#"S1:5>,\$6_&MVV]X3M
MOWHNS61C1>SO@PN8*4<&>@OX/4MB,/C_ARK]A[ !C^T]$#R]F_W:L<+7D#.G
M6%2==]J35:-D0JLTTL01>39!5Z!N/Q)[6\E=LEXGVGDLFAY?%RN)X>J[/;<K
M=UL3!/%T]VM.*U=<S:HZ:N8-0&_B7@9O:MV?>L%MEA?6E9*2([?QXT*9;<.G
ML#_8N(ZZ86AZ85M>QAR[C>GL:O''2C'--KQ]5"R4YU;U6Q&3@T32E'@U_7**
M.Q!(3IH?H#L2=5?ED3P_GET;-LD^WO+^?Z"!=0.U]\[W;VHS3XFQJ5QX;7UN
MUGB81I_-QZ38YT4H^KOQ)._W;H;.NONS4CQ+'306?XB^3-(.+/< OC:(=BI1
M=4UEJN<,9S@5__G_UMWR[_KOPRYGPP4'QRE];7GBQ]F&&&<3O0ZD0T@"#B:@
MH@W,\#:=L"F%40J$2E22YK%H <TS[P2(A O9 &+8NN7^S;W4;RY&T8KZLK$'
M'*^0R G7@4ALJV@OZVLV1&XL;U5[5P,)_I5UL#8,((AE.)9)L7%;EMN@I'+0
MQ=/!V;LMJL/\2WM/";?@'6$/BK>"M>K3"*L7\,+PSGFM0QXWH:9%S3O'E/:H
MR<;LK_UR ?;"M<^F*PZ>QW)@%T;]^"]/=!OX</G:2V5F3;09E*QFQH1UO<Y*
M'-,;FG-2Q+&3=Q<:_V>0W9F5>X (G+-D<2@]T+H;&SMP#!A,L9ZKOM-F/OL1
M3I4&IP*I^YH)S!-XF_:%G=(TDR(317D4+3QRW653-Q];%_3 8&' :LTAZP'9
M[%B?7UN!TX_QBB$>M9FRJ#E'FLK2"A230)S$N"$;=V6$N7D@6=J[\%^/J()L
MQ)=+<"[7!W&PQ3WKB8==SZ=YY2[,S06OU[>W7FQFQ_6AZO97F]@.#+?$K)O?
M/*S$"EQR!A1QBH&#'3VB)H86Y%34&BZ? U^8--TP3JNDC4Z4%"5?,;2 ^:TJ
MVSH>Z&31()F'*09K#GUX1^7B;:^*2,GWP%/_MH54.^Q%IS$](O"Y?9*.D8/@
MYI0O<Q)20'O<MVW;,]EA7ZO9"!'E%A)XY%FD([Z]<-*C?]2>MZ./GV@2#R\H
M-U)X\.^=/8&'3:AG<WI!"7C6=HJ<JG;=*KQW64#  >?=Z@K@/%EKPA:^UN8Q
MU'T78;^^Z1UL\OD5 _U>N1HOX(F\4F*M>791]**QINJ%T4@[(PKTQE#$(Z'V
M\8G<RVD.-6+4H7(G_*ZE89;5RPW*?HSR)(0Y4$SQCE9*+6\_ @66ZVN)58$$
M4,\?#=M6B#%\4R^!G8BUB 6B$*SQF+6<8PV1*P8Y9P$"_Q"4N?M$G ]E@%13
MXC30(F8ND!L+<M'/++WX0^U2JWWN> *&UJ(X1OG=N:;Y1WY\3C9</#++3S(]
M4$XP!UJ9-_[=F7C49I)D,/N[1)X<FQ8W#%'?T$D&O"5%&ESJN0H<82NJU.%4
M'*(UY<BZ:=8I&:#95Z*\__8] A7T8S*N6RM5I(P*!M-$E,]3A%R90F_4LJDI
M."?5*!$RU<9"[0".@ 2#0>*"\I0:T%G0.:.1*>;AY% NCR"?<OLMF5[GI**L
MY.]-TA"!GV>-MY:OR]B_*YKE@P85Y!-1VM/ ]^,GG7J>8S$-=$MS0[<P*:_!
M!55AMT&P!%F2-6HDOM$[("-J!31,4+B7<&<I\#@]]C GYH@>5^YPGD+X?$2_
M>UR<><4@("G#,2&]"2V]\9K2.Q33&YIM^I(0@5*"Z9Q H8<7.)N/5PQ.-=LX
M8J0::&:9<1V>W1M$WXN$)"L*O0C)T%-[3]0F[\")R-"Y=WWG\UJ^!@72*2<-
MB,B"3Y^&+4G/=RK @ZK320M"582;)9QRFDO32EFR'>J;(,M\\Q[W9"4'?:'+
M>UDTJ=\D1/1;-"LPZWG2MBVKNN>S10Z2N?4\&NWJ!U/0>]JGUZ_9Q;&_)Z5R
MID[*BO=I7_8O)%P =4Z2=?YI#'JC\.^N"^@NII$)"$+]WVXZH6(!SO9AGX!L
M!1<1C(!IF6(53%Y45V&,'#U-E&-(>1I LO!/$DI1J!CEW^'[]FW9RXIOB.QN
M^]TQ5OF8]J?J>5=KM5=N4^W$RMP>[^_MT=@]R!_)LI,'Y\%3(I-%#YM4Y$KW
M=N5.Y@4%M_3W+YA>MK0D:8[1:B:F.F@(<FR(=R[=,**..)YPFJUG9F\<D\+A
MVZK->=;#F4J9>MMXF;AM+U_RYO%O[!K77/?1<I7A6WY$=G,*V7=5[9ZT->^?
MPIT67N9Z82)0674T/=J&@0S76SO1@2'U,B+WW8PCTS%S;_^E$8NU1DO%CZ>L
M=:PGK;W?2TC.;GQ$2;$CZ(.<Q(+Z\37X0:.)V EV_Y1)I5?-15]%1]:J"CL,
M$5O\)>Y7UOG%',UA&5?ZF)S]#WX6WYBN]@8QEW_/#_!\O\'>": ;J'VYZ[_X
MT]MO43'1B$EMN^Q=H.6;U6?CTS$-DL*'1@%#3FMC>G"],T*C=#<N+SZ(O\^9
M"@\D-LBP>R6D90/50%3(?C(C)DB)R 2O&>=>/F7D&*/[/AN"+,4*%#K$?L_O
M"FJ<( A$H/,*K#!UBR$-[I/)SX=H+/EK DB:YLZR6ZV.:*F&0'/>$[BCG/#9
M>A]M;4R F ZY>]"W%5,4<XB/R#8R$SCF +[G/-NC]>RQ9J3C@[4$W9XZ75):
M2+&MFENH?_;QOPH>(_\Z.[ATW!JNW!;<TLV] !KU(#R3 T_>%^VKAD]_+=D<
M3.P7+? =G'*F3C]\[0A8,5:(V;,M(16G_CR)5-B#D4<]P#U3R\#207,VV@$I
MI]"(:W+SE>H1/@&>N 9.;7-3[JT>;,_X*T9>_?40'0D6UN$H[5)BY)\K1^P@
M/E?7L@AO/)/%Y>H <W7T9OHS>34*!'^.HC3OFCQB0:V@ 3*"_$IZILON*2KF
M*?ER7KLIRN8IA>)Y#>R]Z>Y^/I_=85UA/#)R2_>Z$#!^^$BYK)UQ!F+"=4W<
MR,QHSI LE.260C%:!;(+WUMK$D?>,?V%G'Q>HX'.9@Q1=,'/-16R>^QK>0A+
M[+5 &7VZY,+;!0L0NH3/XVXUC2AY1A0;?+C!][V_@O"&D, [O%FD#UKL,,Z.
MM8'3]!I5S-]6TJ1M7^;N!?=89&,]E0;3BMIY'(G&7">OAC2,T10I%N9G[<#Y
MMU4_.YI""5A<SJM<7>K+M543X/R@'XP8D\=)*_2PZ DMVG@TLIJF!0*\0#8:
M:=J>4=A_$$T77C]8=%\V:\G6&Q<>#U\B8:5V#>>3$<CA$9L51P]]!XLNF([Z
MJG]RE@UYT%<Z,UDH@->@NE:5(U5.1-:7FI)UO>"-OFGA=E12E'!MU8T3YI,&
MNFE[T5">CR28<R3X("DNSW38_1FYJR[\?12XZ#@]?=X6D&HQ<*2MZ&OC)YWT
MM?I.6""']*_!.4UWKD4/9T.:3P[$L<(V.)[@\RN]F6=E<<F01M.7*6Y3CMD7
M9=1NRCNW<!X40QCXY&-<)1P/A" IUQ!GBYK)8.R7%_K1%>SMNBKY2& 1%Q62
M8E(B6RW@YD!:B,1WW"(8#:+P*\,^T3V7XJE DRV0ST-<-3!=;Y1EF^NV=&J#
M,\A'C,@B0XI_L937T)TF8E4Y",WX034[Q#'&+&[Q)A__LXF3KWJ8FQAX&_?A
M(A:-3\ROG5J!,T]PZE+/.<*/4L="!+7:!:,/R7)TE,(6Y#',%EV:AM!\9U @
MN*G1P7_WC)@VXIDY]"3TZ\<@.3=BH 5A _!-X !:GBMP6%N"P:(3T ]]JV5?
M3?-(8[??*&-GW2WR>!TE1+6L)Q P*&R52SEP!_Z=XI?G;U.?;SC^/(G\JQV?
MY$LA5#].$E8I+4X0\)?$[V(73F,$A#TRE5UU4/#GKM6>90>10V3Y6_JQXYKL
MB=K]VN)[^/H3LG6Y3F??MD=OE^=D3,,:%G_RW.U")?],J[(]\G.5;\AQ$579
M'(T]=U'.R+4(1 -0=X.B;%>^!@B:H8Q\,PZ--?W2:L@AU@/,0N9.7S&ULB4%
M@.G<$,X $V.G)C2V S[)6^2U.T29[;>LA\'EHMV?X2?[;ETQJ-PJX+YF8@X
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MZLO__G]--(S^\?N^F<Z^61'K@]^"YC\TV;QQ5.6@3^][V$ WU;GZ3$SX%VM
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M!KN,(,1-%WO9(K5!^$-Q.FC-0N:<XW>BFK+NBE6&[51V!MU8UGJ>&&#39]D
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MG+7.P(9_CQZ%.1*5;Y+;F^.$ >[RHX@C'X^JN^D#LL:__##,O*X(F5T\5<D
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MG'(WZ>8X"_#"Y_[TUA.J9L+1)4V" CPUBOG\>?-Q7FN'&[%X__%:1,*<CBY
MYH&^,931:4T<#K$&U;+O+%7Q1R@]&AL;2@ UN@O"Q[[-7KEVS/*O#%!W5I_)
M>T4RS-K^G4%UO1I>,V.3K_V]9:LL^SI(;Z)2\S_SQ)PTFVLQHHA<:%P\NBF<
M6:._ARWPHIL_6S(QCL;'/:*(G4]QJ'FL_&7!.I<N^>]QS-U%";Z?+ S==!,G
M-/6#7VI)0DAARU3TY916K&*CE,#X5Y%,75GD=;?-Q)A%F= ?CBF7_*S<MKG6
M],,,<>.0D];K9D7Z^Z=9ED>8.F"'AL/*!%-B\RBV3LFV(GA6,\*AO%MC ;3[
MY#&Z:5D>1L#6<$?B\]#M'# (X?GT$=3[XSSH:>Q\@+,74&U\WT'=8)Y/L^U4
MGM>+D"4K^!VN7 PT$3WU,M9TK0=0202K&8 6.Z#&E02#G3Y1-4ZT4.;EIA.;
M/WYK28#GR!>AVCQ#&X2&EL]G%_V;GT5<Z6"LB^F[06H%OPZ;"A\S155<_A;.
M\++8E:>#G??C6Y8:M+K%FO-S\\\P>P2)Q;U_(/C>D^-CM/QQW4\6PRY!7#D\
MRJ7C2KNOC"@JNUA'R3H#!YA\BH0*C!N'<S3Z''D/ODV,-))7**\S3MX8YT3H
MT;6>7:>F%HGQ0J7.I%Y-+HGV>_+C;DF,#-<M7EPSCN%Y>:C$'-A'NC^?"<K>
MC,XRIU3\9,GX]TI92T*(V[Z:K9@)[_MZ1.^$Q9;GV67OG_<]J"PW6%AX_V_B
M )MB*N:QV7]EJO0+[_R]+?;RZ[:F>T2F[NSG=(NFJ,.'RGUY@\< @2L)6V6U
M]7=4WCB8K?=X?^N?8W>LD<9%1)<ZV&A?^TQRQ [E01@QO#2R:A[Y)U#MV>A%
M$6FULZQ@YGBXS,XFJ+[C YQH)$Z= ),?J F$*%.2M75#%TF(;_B3IYUVSS\K
M)>IO"/1VCRR]6E^+54GP\!)EX,J2A7!9*)3E;"X/'0@$'CW.XRWWL=XU&;47
MIXN"]64"C$[WFG@L#T$@D.6Q_Q*EZ,2#RN&)%PD>SO;$.9=$9G+12ON-:TFH
MB8$-#8:OJ#]YMY*]J S6#QE Z32-BNZ0O^U*'R *V$K]0(-NZ0FM][;YAEGG
M&"WC6I3\C^>ZPR.3,6K!<X^_]D#?1IH0._JHV=YQLIVU9S6C;1YIVZ-^XU<H
MTZ'=ACG^R9WL1$(@F0Q#^3K'!@QR3<@_X$QM^<G"?@Z:\*VP2 W04-L"-1J#
M@Z<5*DD(FZ!69D2?&WK6XFX$T29?X1R;_[W[WN-FIX'&$J5I5)[ZO1QV\&AW
M;\%_UTH4/>XF<R7#_;6U09:@81FVM9LM<Y3?GIK#^\WCJ_[)Z1S&Q45_R;:<
M@A#.UOEO&3OGU=$;HJ_2_23X4[+U^[)#YZ7HP1$&ZLKNR4?6F5#0#+ Q55(*
MO:_,1<".^97T(H&3O@/?)L=[#J/?_]4GTIPQB7=%-Q=G<M-4QX\BSH>Y@EG7
M#Q#3?#4IQ;^U%2#OJEI6K6\*;B_?$4O_7L]_3 #LG##L^H//?V6L,37O_!#:
M **^N,95Q1]^!*@IS1W\NT*4L)*P+Z3!971$^S5GBJ6"\2>+__]#6OD?59:Z
MTI\L+]/6!:>&KZY]CBD 7M*0A/]A+KUY]N=7F"(5R>EBN?$)_Z9=8*YC<7+.
MR#W^&Q7'6EPQ,<=8\DX*<LP_B]8YOW-C3L+HR7>BL79TV"GN*VC0T1=QH_QS
M9="R>DEB24WHWNBJTZ)AJNR?W;*0&<&?+'>2-<PA3+&N\$]H2&@%QT\6J]==
M]NEUJ4=:[R0]"NQ*MT]N$!?NK20.Z4V$(%US@NG&BK<-:_=$G.VS3(J'971Z
M9ZL& Q%DL!Y&1<YM)Z/U;?IJ[0N-:S$I;R1?:#)JSM^]84I.$Z"7PTS9O]>J
M>]+SB:I?D(E?_RYY]"DTR &TD/K/@;4.BF$2%+DIE@/F^E*&)C=T,)3V#R\,
MXE[U74C_9'D6G2[OZ+^7[$'='2/4YI0>ZG2S:!3O_?U_A%[T_S&,*O*W&Q8_
M60;W8F[GO\I:/<Z>I\0>6"]Z"0<#TOAWY36%9N\H37BK+02$W"?'EX[;/"L/
MO4 /IJ4J$U'77T^ZF@CC.31%\ZV"/\SR#S&T(2)!4[''GTXZ"$_C"@-QW;'@
MWNCH,;YJHW-@5HB5UR[/%5G\ZF&HI8;Z__SVE.2.*$'<T*NJ[$(W$4";+=PQ
M'8\#=#+]ONS 7V-'#8VV5WN:?[(D_0#8Q_A)IQAV"BZ:_%I3N4(&JQ<(4HQ7
M>N[*QDC,4*V>O%+1^@8L/9'A*\PE/]#JUN=:,/A6;>@]&J7NDG*@DU,&?3VB
M_Y#!K]NTK-E]-H;U;,$T@ZR"7"I:7JYT3(Q)[?I0(_5Y%^F#D8^$(=HKR^.2
M!U6KDB[EI<5[#N(!/PQBP+Z-KS,U1*Q$^IPP"G6Y\9678'&YD+$ \N<Q!3?Y
M!P^JR6!]6B-!ZI\[_X!*ZC[3]]NRAXY*#6@MK(""JR,P-]?>1E17S59'%C9)
M02ESD7FW3_2Z/ ,X7-5:M4>:!IMC<Q%4S]RD#,5N8G\Y_ \*LB[5R.WFA'K9
M1Y%;!G;F63?8ZX%#)X&%Y^PI'.*/>@RPK_2&4X]>\>U7*9N8+APEV&3C%NW;
M"OIU:WL%+&K1^]5R_=AQ' /P+ 4[D,AZ(I)3WI/8(O)+['7U.RCFZIM ?/.4
M3.53%8X]X3S2GA#&)G#?L$N,MW%*92+*$@U% S;=3P'0^#8NA"0R=LNTFKWS
M\;A(D,WK0"MWB;GFF^5$]!_I&)JK@W72@?:7\U?6F'D[.\/,@2WD]3,?__+O
M7.[Z3<V4#AZ,$M#>(MH=XC/%;M9_8U'#/0K/GI4!?W[60;<_J8A.8S^?;DP!
M1),TQ/53\FL_K7/MB@XA\F#0P2_OYI+[H0X*WN(^@CRICR)O7<KD(][NG6/C
MR-^V3M_KMB^?EB$2A4JAB'?1;E^8$=;I2Y.,@V7-ER^]:S>ZA5+O?S@ZOW/?
M?+SM=[^0L[V(5C?Z;>4JG92.-@1*M5_40-Z^ZIG@8HUX\Z.ZIZ^)WJ2=+(J#
MQ_?&R>A':$&39-:T=:EVQ+TY\Q%[7UI7)@&YHL_Q7;51A\#6B$V@(.J=,-&R
MACCY"B/E!Q"*H97W86I%1+%STU2ZF:2,5YIJ6&H)*G'/OJ?,-2.>B"T@[F.@
M&(GJCORP<@Q^S^&=2*V?;>&E]GH>Q1S/^C+DD\%N>F*#Y^*[;\M>&@8<RN=W
MX';"*%>4-=#K!)%Y7]L(L2=:8_:?K2NF@QG_U6V0O*>N<?-[1MJNS-\]=?M3
M:MG6L3]9S'47=)O>>, YD(^%OKR97+68='C=+B;FL&)*C-K7W.*N%Y5=?GF?
M# U093M\8A6M+SCRA;X0:;.?7F/C7;U60<KZR9+:-?LJ;.LP8,\2O7,Z3$T:
MC90"NPYFT-FL2V +S-F?+,D/):.=ACOS# ZM%<>,^<)ZQ#@@8Z41SYU3WCP>
MOTQO5X:4B)!H^T)9 @\W#]&+#D !1.8MK-4.%3-R\J3YX^)?+0D,"]%(<7&L
MO$N2+CF\L,!U5]<B_P8^^]<M7P3ZVMO1^:6-?;YC0\7.<8,?QS5=)H[F8L:"
MRN9_H^Q/&- 2^FPA0UP6QU ,T8T=[V&,^.&B_/Y3+5E]V=V<%=5=!+F90SIX
M(/YPO]L_ ULHA>'"JTI!?1<GBBPHO676N'LT91?[H*67LPW[SV4:LTV$PR8.
MJ"1TJ@":CWZHS,I>>)9;(XTP+/\,%?]=ONS0>$V];]ZI.+4P9 #S4*IO#S+I
M+9_^^X2\RKAK7SL/O>/"R&M+$GZU@Y^\K%LY8+XJ0JQXXIX7W152Y<3:MJ43
M2C@A/2G/2AW'56+7P$_7V<<[I19ACII"<<H09%SO6(KG7TBUF >M'<D:%UX"
M/H"F& T9^2C;T)7)Z+5O5S1]P5T@5!N@:\@A!JN2?KP@\R3OB?VNE@&)V[+X
MQ^TR4WM@YX4A@D/_X5] ??940AV70RR&Y)"86_FYVO#MD:VH9R[)84[0;NQ'
MC5PR.%&J/WS3<^.D<<IZH0]&K2RKM59>H=+'?>N7=)?JI_E]JE/Z@E7G*H+0
M0\?IU72.:4N((7L(C$T#,_J%036DK)RG]]-@9@,+S<K_1!]7:T=.)7ORXN)=
M$P5V<K87S 9CNS[RD^4)!7C\;='9F)14M[\/XYX/>G)7+)=N;7 B%IE;=BBB
M:^LT9'5G8YX^!VG\0$V*.\G_*V[B(6@;L\TK#'..7I.$CVU!O^N'9=X*#;85
M*<J6HL(%/K15H.XZ%(9(O,96JX3OC#<2(X6SE+0W"H(]CD!CP- P!%^^KK'N
M@R?Z4[;M26_S;@E6A+/-EO><R#%WSWMW+^1THS9NY>] I]<0L]L67^/$"A$Z
M!%12#J#%TX:TGV8ZZ$\AM==\_7*:PR5NY,8L:ECK&B;=^ZOV[J^#!5OOK-:G
M#>ILX'[C4QX"Q#R>8^TUW V "(?VP5-C^Q9%&KPPXQT:E#M^?;0.E]\R=!;1
M^BX;^6#R)PO&ZR=+B59>9'&@ -G^[\Q(S?WRV:"+(^D-+(J;-:UHIUMBFH\1
M5-(&I9E#H217<3]GCFIEGN0Y! ].RJHB.'>]QHHFLUN3O1GR8^&/% -Z:Z$'
MH2#R_-"B^U+>JB^ "\>W/ZV4;5@B NZ?>Z82=,QAK O)OB@KS]0)?K?^DZ46
MT# [<_VZC2=3V/X6=Q'!I8)Z-LEP&(3,TN7$P@AQ=0GF8R-T^9IV.:\,?>X1
MG@GY2.LR/%/9SZ"INTL^&E,R-3XI]=7*<2QEL,**ZS!5)4Z9:\H)_7BU:M "
ME]$ #2S\#HF=:1F\^CSYW*[0)T_0MS9'*; \^D3F5HZLH[VW5T077,3]!K\_
M8Q(IOM[)#9)HLEH/"V8.LRJD4H95E#:YHQM.;,BD)3J8%W8-3_0L*DM&9(E
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M(22P--M_Q'99M ==2&Y,>_[&@&I]K-M *)_5F"AG?2,,GE(P(%US4<6L8Z^
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M^4R_^Z*+>O)D=ZGAM]SFMP3%K]=OJ]PY3_ZRV*B?5E6W]F>:],C8=4_RR0E
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M5Q#T?UF8]R-J2?> OS%G*+S0SH)TTK;(O&.11I -J^8#4JH[_5GQ9T'V3\)
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M%PY6'0R% \GKUN2##C<>08SPV-X:8LZ?D3*9LJ5>.(?HU@F(X9DT:: FAOB
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MECR-5?[>%U4%M6%1WHMC@;:"2=7P6&J N^+]WCD2K)*W588A]0TYZ%&*5@:
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M$Q52+:3'O9'3I"G:;<-)7\/^I<77B1N'UHRRJZ"0P(G(+-<HHBNTK?/2"NT
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MEC]O'ZGH[5#+W5]Q=7E/8M>03CS9OAI('2N=OR<#V=J#I.]9K,#'DGJ2QZI
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MR],MYX=5=<)E]0Y<GAD>/ KJU1PR-."'%ZWNZ"MSD9M=?EP),$Y?M*3Q?35
M;RZ6?)&L43S3D>M<]/K)TLLPSS+*(+5\6NB^%Q_T_-@NI2_TNW.O'V/8,MW&
ML4O97ZOJ%9EQ_N-/*C/S5O-TO2),,*0\B.>+@CAT\K3*MJ'O7I 8ET)1^HQ
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MG9+G_+%K0M37I0RUQ/&YQ"\9.A#L(U<]M\'7[\*J#JF/?N1Y0BF)T)4$52\
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M@&=G]&'-=$ _A/)F^>M7W::+HR@E7VKC[J 6*%S(W*?N,5]*-#3Z'9KU]K)
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MF2OXC.KU,87!M:.K_$JE :[#0H;#EJL-W)JWX=";!J.YN5S\P=4FF_0CF["
MJ9M//&P04MQ ZNJN:]*0X-Q Z'E_\_)J$OA@F2RO]TIO_9[LA,KW.I<I&QBL
M?!)?XE"%>(%03C,FB4B7X+TAR_0MUHY4<2BDJF'C[B>V"3,VMOOG;[>8L@L"
MAY+_2 'K[3PSFX=,3XSVLVU[TB;9?O&_VW<@U.V;91Z"N#\<#+]AICN!<^%]
MKV/\*!1^ S;:>W<?_;S+S)B,<4Y[4WE*9'Q+[[7\=J#I=D@M[A6DL_YX.J0+
MLEMIM^V$Q3GQ/9Q;+8_CZ43MYWMGI;,>'TO,5/:;+;<-'*'%T<$/8J,X<+'_
MZ*KFI''J&D(>@A2YY0/XO,]7YE;$-69[1B*OIXFX> LJE"V?,FY_^U1@GE]2
M'7\@5.O6;!O!>][4 M'1?]>:'N^@O :<89'J1Z5"9U+4W36TKLRN/JJ[-N*L
M>CK+^4V$!%G5&DJ8<$U_:>&UU0M>M907Q>SU[M@-LJ+NYV/M.(*8&%*?R7B%
MB_42 "LA@6^TU%/?4[VAGQF:&(T5;N09>,;$-[+[!IT3MR:?[SGK5BB:B.H>
M6%B*79^>"N>PK%(?^X;EZZDB[W,U^PGU5?=H%WLO\1G]9,N5+FA3^U926$P4
M@)!*15 A,W/5[#OGTYA6KZS=3><?9SNKV5'9/]E*TATWM0I#XR,-"UIT%L;B
M&/;!I)![G7R<PQU8F:"+/7QI\2G;:6._:6C^5/P6X'S#(:^R8C6M>+M*"W!_
MKB"UWN+MUQ.NE5(,:7&K OT[.O5\8%7GVX/IH#' FD8..<FR!)XDF_MNJS"%
M6WTC[;H;#LO0Y &&U>*<,+#%EH G\Y(:NGTR%F];7+/[#A79B5 P7^#H))_-
M2N._\<LZ8(T'/)_KOH3.(^<OE40G_:'!S?//_%-F])UB?DOQ_F6G#=FJXK4#
M]<A1/^^P4?=&U_4U#]KX60*HS@)I>JGQ*9]P ')ATRO-OV^5S'DG["4QWVSC
M=2V[5_5V:B1?S6H>G?M>F4QQ<TO&CAZ7=P!*V( PPKMB2<1?4^&\D; DB3\O
M=*R]A@NY\'7<(%PS=9P.&>'[46EP 9(\$7\5_I^;_5L.\$U<>FK'(.^]M]""
MWX=Q:DN:"7Q&*)!>2>\&CEF"S/D)]=W!2^^OF8<5VF)A.B8 8KVFW^'$B?Y:
M<=78!BF601\WU;:]K$SR YNDFG_QT^I\)=Y,[&YF,L#HDFV.GIF*>^<HUYSH
MR=5Y+YFJ=6E3"&&#M9VD.@ZMTCTR$E*QBD]&(>)!,XW)$N<EX5JC:J!UMRMI
MAE:>BD=D#0,_M(7M!V_C.80^<447SR,;MF=VQ\MQ72;[]=,9"1+"P[J">VRM
MTRC(55*(-G#*>*"T2!:@KNCY5J@_WX?,%RH; $6)M4N.M&.DX8TG!>;F4"4L
MWM5?MP.ALNU0_4I(B%CA?L?#1FLU6^NK]7>ZNM]V"LJHY2-E7>"U%Q(/G3_.
M"?(1L*L\B)WERZY6B1:%FR.:*WOR/MS7"D@P]\E!*F,0I*.H$>!1U,!2Q%CC
MS3+6B(7FBK"([Y&M"Q)0B=%M>)?3CPU/VX6M1G)[A1D$DD=Y\>8CATED6N!Q
M__)QQHB:Z2B#N U*UO-;>;\@)/:XK#WKT,5CBG>D&L+I2LO@M1R9W#I,&1E]
MEH=!N@#GB$WP<#C<-%/@%TJFOH_6AZ!FS=[@Z)(@MY@S'.$(E)F3^=IX*L;5
M<U4X;.RTL;03W TRN]U::\MC=#L^3+#:R\R'G(Q40JEV@\;Z@RK!1MF1AZC<
M3B21* 9]$H"X0<SZO-%?8$B2<UFOO#VSN9C*)S+FZ9N(F]/!'NAC=*&X_3EK
MNY2U\=X[=Y ^Y8>O-SZ29#4$@HS#C%P49"W/.P6T2W:9S$"':JZ>"K3Q#(@,
M<RXY>+GCNR-P<U;E2TVXQ+H"KL8^1<2]H'I.NO:D/"%356(ACV/8@1&0G>3X
MY*J+>[CL!@]M&F+!NF;C$[93!>1>B(.[TZ8T97!6!#MBI:9U7?8* F3^@K6%
MHT0XBDK24+-5AX#I8 RM\2GC*,=FTJ2R=/>&VHJ]/'7%A[!G?A?L:W>XR+ K
MJYI=,0;">6;.G/.S,TVF%G"ZQ?R!*?)<?JF)ND+*@M[/>[0"HC18LUNG#6NY
MLK*6?XJA&O)OGL"47D,#*)[2B5-, 6[=3^3=QNSNP9K' !F>@;6]GVRP\!&-
MM_T.6,1UD"SU3FB2!Q W&F:3G9^7A[&&EJ/Q^WUA>=Q@9[E_7K, 95*?O&MQ
M.'SMR&<] SZG8CRF$LP7"L(8"X7?^!SEN_\;R8\' ")TVJVT"8GS$X\?G6,+
M3>[9"J_M!#RH J(H6J:09#/PT+B>;4">[2F[?I'.<!:<0\-C3.Q%[T'.S,#(
MOL\EE*WQM.*>VER7<.!LJEX=WQ:2,MK<6LBS4>%_Z*1FVD%UIE8DYJ;LC"19
MB;P\F;6IIMM1']D3/V)H\N,A'TA9O%GG4T;U9:R4.TJV90]>U-$8NHTC]&>]
M-EMK$JNX CVEE6J;R$KO!"O/[&+=JA.?[)3DD*_Z)#CF)UOV(:I9KT_@;T<
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M?GOP'B!<BE25O*M[@L/><AVSK 5GQ&U"9%T"%@G"?G=IQ*K:O %TU'I'/VR
M^,3+W&HTXP(J=2NZ]="V83-SA-H@J7JZD1=O8RWFT*WR^$T]_9M:8F)?NC@9
M7WQJ\'Y8Z67&=6U'ZZZ2CW\X_UCC<. 3$'G8<$0^I?FK9*.9%= ,HV!H\(>2
MN0[O#+?O&;M_9&;-+MNNHD-/'RA1RHU!)&1HVF5=F^10V\\WNS]U%M-(3\ZG
MA<2SHDLG:D0#*<IQMJ(B_XA;E#4=+:PHOQ7J^/^EX<%7[UJ]JQ-O=2K@D-@M
M=O7]>FEG./?_7?[]_]6O B6 LZD3"^6YDX[>E/6R<1"<[,OS-B?I%E[J_V;D
M8*O5UXA*"37#U=+IBZGD&)^/.R:3DJYZ^$]YU*D9!BR+HM@_*W+;M'3B\1O^
MKL9LH3.H>%I[F6#Y!>++^,OFD=?GM=7BIX@*_WDGP"8JO/[//F+Q!?-:9,P%
M<Y[;IZKD6F5]./<3D$*NVTT?436BXA$G@S-26+>1%D\XXG+\G>F*MB$/TPL.
M]U>KCRYN^E%O4A WC$1()MUPC?)O#<F7Z=@& Y17Z?O6UY=1PFEC2TZ0;9I:
M\8^AE?&<_8O?W(U<,4&*K@$R1Y$^</2)@1"EI6M7?FQ3@YM47U*2=/E[^A)+
M-O2V1N<_'TWX9!62T!E;E50;R6UZ%92N$)K0R9.*.\$=2\9BQOMO6S.*YU*:
M^(0 2NYX-'Z!3U7H^)\0K]Z10:F]X$SDDV(?P9+6VY0/<[H,J9J['KU$C/5!
M%M*6)&KC?J/4;;@SC+OX;RR[94]73]Z0#DPNB/?9**PAB L2TH51YED%_F@*
MKFEY:.&P-*_]>.A+[K=LYGKV/?&Y5>+;00'MM$TYQ7O6OCS9I1\:QCKU#!N3
MTLCP@&66SH'0[]BP3T@9WI8N@V?2RCE?_=1_#6</WS:Q_*:<\TIVQ3#AX/?S
M]%)6\_A27?>S")O6UXOOW)(7E?A#VQIXLQ!"XKGCH_J ;R&HA-%&\N?+7PYO
M$*L-H.;?I;:A388SA7MJ&?PKN[)E%-&J^?3L*I'H3O!<2.4MU!%[)$-9&G;'
MQ?X'IV4.R515N:;OBY7T\?P$_5-7ZP,^[''6'>[;KB3-FO+&5O.7).P@>,I]
MX:G9-!;D&#/C?])%%X\3#L_9,YJR=S+I+E*^OUQ+C[ >[71,W1YU,I;U-PS3
M1Q9:0CC=G ]0HQ)@IUD-S\80#=T@F:K?&6 UCCV-*DJH"C$^QL4Q$_S%KVS#
M LES,"@5WW',11N.++K !/EH1XG"],O.##H*[I6K[K;&MO[YD:>&M.@=]2D_
MS<$HXT,QV(#TF/X#KKZ>=;PG =ODI8IUCULQA:T%4^K"=!?LFK..<U]2_1WV
M4;UY"P;KY=]':M;>AM["(YW80WU57Q'\V:ORLQ0P&ZO# V_BG!L148.-5*7C
M;@-!9IA\2-(*_77TG:R!A)S*G+)ZVHAR6.A2G%9$U"VU(Y(P=@ 7BUO\H9^^
MUV#3FM=#TBLD!5;,6ZF+.42Z/2M/8$'E!-1<?#=M$DTZD$+\E- #\]/6GO"$
MIO'OXN9V]7JFIMZ8Z-L>0<G'XK^Z>Z["9*W]RTKK&Q=[+L;$/Q+:I[PE$C:$
MN^M3VSLO"M$79U>4J%0N+\\/17'"KR06G='>/CJF[\OEY3I&N+'6GN]0 VRW
M4_ZC 1AXK><.9D;Y"^]VHD[2S?3K?8!)#L[1F+/!=^.!XW/;)^NM9TX5IK;_
M$5UBO5^U4?>J+328[2H.=R=,EX$F"HF#'/11%%5:EF@@S&SP14J3 %W(%[\F
MJ6UI?-9'!$(%UQ=SY(U)=H#*IA0>FBD$(J H'2^FI*3\"D1H/QN6(84V4%\$
MUVZ-FZ3;#,H_#,*R]O+<<D+V15&9$XY301"!,7@,.1!T?>AZBM6.D[>+']W
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MJKDU/6_=<?OLIC (%!BTOF5^Q6?^\>SA717TG*$[3.&N[KAX0)IHF3<=@P9
MJ]6_/1#HYI@]^/U% J.P(7LRG;?#Y05]UF3YF>C_MAUPKGSL3W]J&S*@'/$O
MJT\T;PC+X)K$:)[SI; ./Z;JNGQ*]5"ZS]A!RY$6R0YM\H;F7C% C9N&@!+X
M:*VE+'90+;.1;G<?Z4H(3+.TT'MGMU4$; ]5@ZNO&L:OL!O5*3",<Y>BKYB:
MPU6SL,6%W_)0V<#W&C[%"V,VEFON>7UC\+;UD8U3F57&$4 HYRI34BZTI_<S
M02_P9:8^<]9@9 F.L)B1MG<11XK4C*I8]9H3&ZOTA,34$/%B3Y9BG]@Y@FK)
MT[44G)&H*+BZU _!)^D>5LN%QE$-1'1TNB\O-K_+5;O(A#Z]@N+O>R><#UJ=
MY(U_(^GY!\Y]!:3^0JXIA\^<</#(\#5S7GLF$FC0(EQ4GT'9P7_$4*PS<DR@
M-D2WU&9AO(]Z*IW8?+!0FA2 10#*NE74'Y'*L6&<<$?OZU*),55'R/@FT3C^
M9(P]<];14+!^VF32;?+9U(GWW#>E!M&])G$"DY'3)%>_M1:N/IJR%LF!WSX/
MF$HC4^A]9^(PD2.:D"RL9SKQ6=)R U+87(4(J,C%V!J.Z+:\35]_5AQ6:X9:
MF@DS=5)5V];RN$?T$K9B$A\L!%U/4MM9HA+F,+/(L]L0FI];)F]9-<B-G&]8
M>E;D$_ (V3!2!KTN).3?Q7DS<7O[Q/5P26A&!QD2_#R^4L4E66CM\I)+1R$F
MCU^;3/'>5Z BYF:+'_K8&@,# H%W[7+D<;*W_(+"RY:B@A6Z!6)9(Z_UD397
MX7-^<.[=+[T/H09@*'!$H)/;S5+V\DHLF>,%^0!PPAL/A*L/$;.S4])^@ 9\
M?[+59?G8!D8<5KV4\O.67#$AO-%A=1GO(V_OAX 8G:.YHC<4]U?G;<\$=4>-
M\E/W@2]7+^")T=?%IP+)Z7RRY!9JIL44H:@LX[<F0>+]T=!9&T!#A<YJ/3S8
M?X*T!89^@<$^:5]&W17;9@(13?7,DV_X#U6*.WS!N9D&1@DW4C!592_SS6H.
MR16U&SIU_9X&%8\_TZL(;NW</>_UFAN;1@NNM)%?XCV>K1_85U N!_%(&R&
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M\HG<7(%VL<;""*OMQ%,L[4+"E7#\)3/.6S5U7^E1TDO1@!.^?"L0,@\.M57
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MDIXINN>EO;K=0464WQ<?&KL ^%%,4?7409BM+K?%]]"V*:W$T6HD3#))BLV
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MN\@>4,^COOT>"S<4/#%#4YOK/7[5EQ>#?Y_G"M0FZ_FJ[]I[^="YIC#)1+E
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MPK[OZ>_^'80!)-\"XL_YA?Q75$;*5*"#'!=#:;A).K2]ZN^!%)Z=#TT6P*M
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M?]>!+7$\!"$=79%K+-3!WG6H_A)+]-Z. !KF,:7Q(,:6HAH:AR\A6?!M/"U
M@RO8%HD+'<M*]Q,LM^0XD4GO&0\TZ-D!Q[3QC :3_!HJ'!!Y5BAT7.\E<2F@
M!N'WA4#QV U]X0\)Z/P^K.$S2-X*2Q*O[)5^6DKFL03X)Y3(<YO*CYG+%91/
M8JH(LXW0%D]5"D>Q=5:Y"(UH.@*8^,'PV3*,PWF[)JQ\)5& XJAJIMY&@F\L
M:[[/K)K+@L8ZH>AKP5]B-1BE@>4#Z"&TH8E >NMN8BZA8VZ/8]>18;7-91DU
M);C35SR7?3)O05Y8>T*)J888G%$B='_6_#IH)"<7((L1;!<J3?-;>MUL@]+
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M[L]SY"HDNO&_-IOKQ43JL#H&DERFO1UF7\A,9&J8VE:.H5YK03H7TB";GI2
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MEH]%+=.VD,U-KK .WX$^3I?!.P5Y;H= -01ANIK0T?MZ5C.JJ75G;/(\(M7
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M4$_VXT6EC-%%$\?.:A8:](!ZA1!'[_"Y':#P U'^J/['[_IUQ^(2]AX44R\
M[/GY&_8/+ G0_'7*>5Y*CE!)Q?LO^K,0X*[2;B*30>P(*+.JY"%9X6I1V\D?
MI6 &F],7EG[^R(X#WCZ+]4$_5J?!IOB!XK=#<)\Q] R!,HG0(?HH[YL^[5FU
MN+:&\ZHJ5V]V'G,B2=A7Y[EYNI[ $P0.(FI/9TU&]8R[,J,_'#.U-XRPH">F
M?XC4AW*8T][JG*B94ERF<&S+GHB(VU:QX?U/U@3N1LM-'$)V?V7_9XP OTZ1
MX+^([+?&7+P 5Z+^<-?NA.MF8S-NJSD]@)UR<PF9[*%O_X.,%9NX#\YYN,9O
M&_>1N$M//RR^R:RJ3Q$L:S\*,;P!>JGR7L.;:2EJ,<E!Q'79 2ZG[X*%[MF:
M*FK<E3%_D?*TU?ZY7LB#=+O^*!SWG+L8JN35CN5@4?')E#\)6?%!=3XO 36Z
MP;LH"7_),L@=6R^'WIYVMW99P OWQN*W_"4'5W0\C@?%EAM%;\%C<W>W5-,S
M&]S\^KEUEM1>8<K]O@P+<TND[>?DJY,J#!^-\(M0N:*W.4#S6=(E1;$8-#;P
M\"2^:U:,GAG=_?IV\,L9.M@JDKTT$+3+D>=UQ*#!#8)&ZWL04D&GA@<L[P5H
M'A%410]<V'*SEPW_V(JBT!VY1QO$$V>'FL0Y%3#]I@-OZH<JR7K3^QR%B['[
M1;SBPR@W.Z:(G\<AO5J3OWL4ADUZP*6\MN7O<*M!1"-)KE['CU9 RDBC?P#C
M-B)^J<XYT'%+B-/[*>5;@R^.TR38]&:&]2)6!?9B9S7&@SXV=X6H3Z:5:?.Z
M&^X^1AZ'3A\E!O7O"-V0>.O3IC2@>].;>AG5HY/Z+7ZK2HWM?\ 6'R&H^ZH9
M:G#:_"#5/\JIY(/Z0L6!C2PA>H":N[]F%$<K#Z]*&9"X[_]D)Z8C*.5!4[%'
M6EO>9I"8RC4O*OH3,D6MBZ-P)W'=[7"B<6W_?J1+I7N$=V7*NN#D#*93.RRZ
M9L!''E,"7VC)K!5-ICY]"LM;0Y]-XVO*N@>A!0OTLD;:2/.*-Y;T$FKE@K#)
MMA%0FOJZ,[=AV++[_.GR45*AM^B'(B+J9N9J_,0<3M(@,43H+)]/0/S,23/\
M\_I="W\;*BKFKM5H^8E1.%W#43Q&^(%!!9[L3Q_<%GRR$2!AU94=]/2?\>%G
M]MLN=PA4H&7WM7(>MS1M+Q6B>B0G4XIQ8JW':'A24VIX%#&#^$%%9+)@4RSQ
M+DPM8(73_'5FH7 P-D7*9(HDMV2!3 I*KC>&_>/L10DVXG92_,L];C-YO@Z[
MO\Z?%XX#T]<CC%G<==4[EGS6.-XDUUE4AJUORU&^0+D&]S]= $#X!/]X#]0D
M>K>UQ.L1V DZS:*ST#699Y19(#P 0QJX@>(S,%F^R:$_#8.GJY+W@^;@ @6E
MAPA,E,G(,PLJ\>UNNF>XY9/8[P+"2*\16TM\[&-,U&LA5<,D#N^DEN1G<RK9
M.3%,A&ZYJ)46?E.$AVWOVH?&2 %/N2"_\])D>T.:?-^9/A(2K6KMQN_=?[N5
ML7I,,JR45%%EF($7'FR?!5^&_;P \-6X2%E#W**M&?FZD^Y]W=IB IIR=9<M
MC3YRK+:_.[$>44Z3BA;-<7B4#I,6&./P$@O]FC^2-CK^/'RQ;(9RM_]/^S;6
MJV +N@Y"C=->RI4\1]A/&T!!26!.BW @MF5/F42, !+67DV(Z=H]9A.80@UY
M$AW<\-1FLYXJ[D155GW]T"'I5QQ;JC$H>?E%; A.QX0^?!08FQ/Z<4;]*(O3
M.1Q2)8XP)QFE3+BY0M4?181$EAKEZ?-F1Q--W%0294=#[%@I^PSRS(]:46V+
M';A7E,;AGN=]DM@5/MN,RW.YX0DE!6YM!X?K;ELSU!:G 9G $6=['XD[?VR>
M/N0)P' S<8P^D>7^VEQ\ 1AT'']I_0UR6R)VO%<W=Z)PLD6"\9;29?UT!A=A
MD4LK_[P"QT.N,+141W+WZXT2[WO"!DC]YSQ<4T%[#V^6H?PX"#B'X>Y(NM4/
MC2)U&775=-N!V*H(J6N%VWRRVK+:#^I'2-PU^S0#]41UXD+'=.LR:,9*^]5<
MS?W(A%E<IK:KEQ]3VA5(E[GYL<&G!A&5)]YZ [L<#]=<#:0>YC=DJR45 ]V%
M6,YOZ14W(L&T>LX3%IJI.0MC6Z%EO*9SE+<IS*_ A)_;,#EBP9SC>=G;]6LY
MI7L7 %J;+[(M92,FP!EFAS[_\:DO(QS8/&E;[5 "B8B=B *2FH:3Y^]_DQ&Z
M94OF4"5FXUUO!;-4MV"S_GY>#.XI48*CM"?C0=#T9B3Q*IO]$=\WMR(N>BJ^
M5D1WV=WJBCZ4184WO&%M-S4/!*-C]+G<R%,B1CE/;"="Z]L*2X9CORW+A>^%
MO^HO)IJ;,78&/Z=06OX&EAAR3H2WQ2I+IFU4^$Y6Z_!P,O95(Y=$U>H5I*-+
M [9(8H&B-L*T/59P=E,I4$/&N31-?VI9&F0='97+CT +%;_MMPIPB-EH-SN<
M*-SUC:35+8*P.(-E)DX7'N6&-DI/!D99DLNQCH?N]1Q3RLRN\2[3<FH3F<L@
M,>[MPX$_/F1H@"<\RKL[F22G(O4YS6V$66@@R:^Z*G&"C6%'!2&OW989//=Z
MR<7C7'S@#TC#PA=URF3!CE!MQ3,S$K+0.XC?/VP^=)I_K'" )?'Q<W\3V5=J
M8*V&21<<2OYJR?*57%1NN2[8Q=N"A=)['KXM0CK\1C%TR-FRU(^]R;Z5NGYS
MCY7PJH(*%G_@^CA^B/HDD,<7"SZAB!FK9X#^K(Q-S9R9BKY]7(%B_AO\QLO[
MFI[-Y"G9(&Q-4OQY<X?I/ZF]X"+H-Q.?G7 )6ISVX'94[&3C*:^TI5O &_%<
MDJ_!"1&!W' M@C?LB0]7?FF;C;ZTVGNR(94U]V!T3%&EQFZ4!Z$]2MP492$;
M#U99;N>@R3/4T\Z27AM,:;^G^*HR5DIA,YU*IV(X-2OJUY,,XRHW-'YN'25W
M==NG"3NK?Q^P*U^Q4J.6S=5@;:0]#2_WMUSV57,R=L)6UA7#W[;FF#1C-&^7
M37@6"9<.DHMW-M7SILR/8GS+1@Z/0G.S/2SDG8H:2D0=+(RPM)K;'&^\,;%3
MP$*99I]>>?^NU;V40]ZH;'%_%X=>7VE"O*G9S>44!&L*EU-,1&>A$AQVF2?.
M0/JA(<@Q_AYB]E[2_7,7,X.9O@M JW]@:$"KMYAY<W(4LG+HOB!XKF#@9G3]
MA'>/RJ1L(W25,#L<T5FVQ0D;?;5]\MW[[""CA=SJ#WYO,HA!:.,6!8 N^\=R
M>WO?2:B*P],FB5&A,&UCF#S"QGYO!X_]_D^?757 &U?4TC<G]BJVIE*Q\"[R
M;.0VA*T-.%1T)><&@4HZ4Q#5"GY"7++!# UBJ)R?=A!JK:QW[,E\K9XUXZG$
M;Q6'+,)\!+;/N*-\:\%$=5E-8V.!NVA9X^C' ?R=&MOV"?8QYP7$G\0]SE2&
M0'IM6$YSZ3%YA#=D/&8]YF3=G1.\9QI?#5L2O8.I&7Z4H7%VD.OR4ZW.&IOB
MRU>:@Y!5G0WU'?ZYW#_(#"6Q>V(%N:VK[X"*8%KC-'.+06#P3[IOO^M23?3W
M=LZ8 )[7R]BE];4S]ULR2MN6+N'[QP\:]I!$A4WA@\D8!?<8;VM[WZ2*0:B\
MN@$<:4S848);"!4N=#=P;(D\)()!'HBP(CU[QH^X!7 K8V?4E':2B@O+<QT)
MB8AG_5%HP"719[_][K7!]A,03OWLD!J]ES#3:]PF'C.P+>PF_S)+6G>-N)9(
M7"B8\">>==T1)OFR9!C/S!*2#U-4Q.S$9IIO60#3M1$K/^15$L(:==IC[XE3
MT'#;KJ/4$AF83S8?1RHM2[M=D:8U:?B3]B+9LM"4VK[0[5OBPIE*TP0*"_'0
M$0D@U,I(IS>3E:O?%YW8;7[A^ZQY/W,'CYOD&HU[JVZ.YT6_;$XF5$G]2=9X
M8A8M@O1P?N^6*%?_Q+QP6=TW.P_=U\EI@:XV6I2]$<JJ9AP1:?&]T<0EQI!E
M>+0QGQ#W<WFDL>L\N\_I#<S;_6LIJ"8]PU#,E57^YJ&ZI<"H'ZM]#9)*DXCU
MYU:*2!).D8WKL')/,/5*2COVBNUC:6GJ75:FZ72MI'*1/"%3J-1*^CE0 O52
M?2I@]350:LI>?(X\D1%V ? 9Z<5GY'JS8'591$Q62HV.CO8S9E[[Y5P%X5\
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MURN,2U\.RN:ACM#E3KUV:^_LK("+_;XV5'$ZVL2S,1,_MPG^BS8:]6!%^,X
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M@+&2CADOSA7/ET0!-06E/@);*[Z-"NY\:=/YU5)*U-^Y '>*,6["M0J0X\U
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MI0=4*<D45_16R2C3<,U#["I/34]H??>(QF.5[_S MOW+VE(S9B(R4<I:.A9
M#L"2G_;Y4S>W>._2+P5)QO-!&DW+<J#V/*L)IG (OLVVSU<X:2I^ 62;%USF
M1*62HX^NDH=!I1]:/2[L)>/KK''XESP[/$?=Y0V6E+DI,CV)/1[E; 11ZUX3
M3XK[6$ +KWK8(L>M^J'2?D&/I(*K$!I%8T7*;>"#;9 [SBB+Y8.B/EO5:+2
M5Z .\C:B \A]V9RPF.N\+L001"5RH3(,*%LVTX#]BO2!:0DP1T3?EV>L-^0)
M2/4OC\R37OH(1=_*CL=I'DV*EL%.N/P*(]XX%X[<:B]9 ;?G5E2(GG@]6I0X
M-N;NW=C=^KWHBU WG!Q' I@_-46JA\BJ]^1E-&.;C?C&[ BPM?H'095H5_H
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MN*]6-U<2:P,SS^'*C2W3N<UE53H#+:B!U&4^1P,&6"YMEMI6V\ZZZC_UD5J
MZ1U@EF9%.%KN1B5NQ"I]6FAAT7U4%MR041"8%#??&X.1W>^Q_$NLI6)L#,5N
MOL;7&2*D#+9%M0K,G+<9M)D#O"E<D:<5/8C#<D%&_"+S(^3&^U5HWK0Z>S2:
MZC!18/MV%@?7D(S0V*HA^G.&NRD#VYCE5[G!H<_"2Y>3 +92>1AF/K(QK*5J
MXJ#N]PB)CC1\SCB\?VV.E]K*3]&921#8'M<QSH.8=.9R\Y<G5]U<9%G8"7/'
M7W?*GKDT%]R#;)WT"5 I'/_A34-:&!G>70*3,L9*%QFU#N,4IRP6*,&)NR1)
MH\2PQVQMP621@_8(:</J)&(M+$#FGJ/LO H6 _=FP?0UV$1# G@3+/BE>S9N
MUK)ECZM+7?8(CH ^RWOD4\TO3<"],H"*?4C?<_? ;3Z F5@8\E@OCLU.@(,%
M-B9^(- +Y5H1M2L7B@-4RJT]WDOQ^84%PD2=-V'BKEO] M\-9I)[' 035J9>
M=:,71SVXL"U8HQUXWX%IS5=.UC?"TMV)WAS>2[F6GT3\XY6X^?,R'3Q)N:/Z
M ]S\,'(EU<A][_MRM&A&KPAG)_>=M)3 *UV5A4KLF4)X[ WXW?&('NG<FBO)
MN^#LJ^[L ,5/-30I%]&>6Z-\=D_AY'+]"EQ=2LU]"EQ(F3ODWHV]0'G3C;?\
MUQ40:[&EWW]>(00^1*,F(IVF%_XR7?()T/C:*1.OERE)L$T \'PYBDLXJHDL
MY(07>A#CW7@,L;S><$%UW%ZS<;6^G!>7H93K;*?+LN"OTY.#[0PGW(^\1@AJ
M(H)C7WUXP.PEVC8/QZ"KNG4/;%(!U;I%?@K 6Q42(H9-&P:-]N$+F2?#K3Z(
M!?THQOSVZ6T0B]G\SUZ^5.--:^J^I/$9FXN6MZ&N?%R:G%)PQ7;KAT$36"4B
MJOBGK;[U<ES.!#I0W7]<6U14CH^$BBN;;AM9N]7[NX)#D*E<M?KOX_OJK)/Q
M^5=K[A8E;J8J(>EK2<B,N3<*(85KXHW'%7WM@&K!WP1ZO)*\T983\&<\ZUO<
MRRT-E)L>7VI",P:0WS"*$WO 9Q2OKQDPL8('08L(.J<YXPE O?DI2C@ %8!/
M2N\@VEM[AUMV%%0%\+%F" HQ@XA1R5'^@<8YD%I:T/+W#<5+=<CO'2%JBW0=
M/]5+W^V$DX=T>_S0GQ8WM?T)0WKMP]B?M[,[QM5U*GI($WXG+*6/Z-P%#?]Y
MQ5'Q@=1Q.7QB"RE0.[#[4H532_A=UVB'A,@#TF&'1V^2<LOS2KW8+U,%O%K!
M7GLR=4D# (]QP;4<Q9+A/7R^:6M "2F%_([V3<)H<?*20N1!J]/%!;]6N2+(
MLF1C7T0W=*V(SDVB.$@CKR#Q'10^9IV-(%?EG%ZAD)O@V]PDY;!:7ABPTG[]
M-TJ4X2^C5=O[$9U+M8,UKFO(*-&[ 0T,[@DW;*AR=>C,F/GI =7\5*SD-,_D
MC<E$5IC;<*8)@11'XYO',TJF\34MG>$!:3TZ7LDZY:8+>J1IDM_VZJ/3Z<S]
M;R-1F^HR)P5F@+68J-6+#5&8D:;"U]0<<>CMW/VG=T=&B9S&[MDZ0]_<<?R!
ML02S!&A2M&D=/B[/1QK;OAGB.Y/:?;K X#$89B0-J]OM'*M[%V!,==[5H3@C
MKQ+!AD"'#4T>QO?]I+KW<\':,$C^5DG348#RU=JC=I?%DRJ#:3OUP1VX3)Z'
MDQ86)"HF>;,E$1['4]$#'>CT''W JLY1'-$@XYO<WY,O- S0P!:@BDH+LQ50
M!\D9$7PN'- AXXAN9T'+1_M[G_*-6HU>YU/]#E2,8T@ZPM<8)K-.=Z)-I)<D
M\UHU %S?-98RND2\LKG@ ;XJRGAA*/> 'DE@Y*WLXFW"1-FDR;X>[0_:>HD.
MU'/HWM>5- 7U"!>73Y/Q,[Q"RN&/4!NNY*'I^/KAR;J&1'A6B/RFM *B L?$
M1??J+7PXZ6G (" ^V3YV<&+1$F6]^I*^KF<-J-WTG/B4Y'Z[L[X^/RRCQI<K
M4>-@AG&DR++L6*(J.)-*PZ4,GV9-@&; +8(3N,]]1PHK9.K5Q;G"@+"9I>51
MO?3]&U_GX-CCF?[PU4Z;0\SD7[O>53;6^;_KE)ZQ&>=]/EPQ]9QFFMYLI05$
M\(9)=A.0.>DPJVE)/HK?]H/@,.UZ-Y?05*64G.0Z3J MIV>PB8)VQJ9Y6<>!
MB''TR>;DLXC@K#Z@LLU&TO&HNN3G[$$ME).0S_E'C\OW=K,><<N6O<U%<.=E
M*AZ950"'OO%_$YP/.N]=8(:^X0GD?!@[!&N9<(L;S5'K(/O+AF3;5=3_X>@C
M] E457=_>T'(M0#<4$PT<UZ=+6DK2/[R=UDU (Z+^#HVOD=-V,&UGP8==ATX
MB/UJ;@&;@YO>9"XG*/$%9%]85PB10<KX'7;6WV*/KO1T :W=9,XMM\ =OJ3V
MH/W%O2A/_#%>&U0I^TOQ<PIA0(.O/@2I4S?;^?@2+?$OCY.EI,&Q3[35M3;'
MO(&J@REB560R=Y!_!+LJZK JA2C_L Y/R&YA;$6"J.PZI'K5EO$BM]FY#MSR
M_1'63736':%U@,RD*'*/$E7395_X=$O4WF^_W-D+];C8?+]GX[M=LZ%$L'!N
MM,&NRM=91*!\6EZLD(2*IH>&H=W;>0*8$Q@B(=[&+*UV"P&NR)DW5#X2:!7.
MGNV0D ::*)+\ZH:&N#I*LY*/(;&><.2(MTF)KL.ON%XKQDGW3P975[UQYT#@
M/K^E9"<I(/Z0" KFBC=:]I>VJY3C)//1=7Z\_RJ6=7$#+NX#A0HV9AC.!ZUX
MF>!/+GH2IH)SV\$B:7W^+@_@1+M@"BA+F6F98O?]SUDO8P=3_AH'(#ML; %C
ME$QOEHU8LS+(3YD%P1*[=?F?IR5+!%,H#O"4QG8#0H- Y%4QIRDPO"!U9'+J
M(&,#XE'UW$S$%)Z]#O((<R)%O;:0F"*KY?9F3K(4%94%Q@KG'N5BA0-5*DJK
M[J<)V!=__I7V]Z\H%]!]EBM:]YLPG!*ASU])/7^OZ!34I&V6^ZQ(!PU0'7P%
M8LFYOW]DZY>^V?]@6VPY#OM@P.V36BK]O6Q#L3C6LV%XL.'MW^Q7_B?(83L(
M$@4+]%';D^,F/8)+\/727[2%!UN7DDF[SX_BC:,M RS]>B5KK%L6>N<5"-(Y
M!'1>/ RL9CXC59*H+R0D@=_<R\.^#9"TEU3HYP6!A0D5]5;VQ#TF!2Y1%'_G
M9;G),5?LW[A!5 8Z5*KJ)$P(P%?H%N@%@,@6JT2.7WIV?]I!-3O1 ;XIDF\*
MA4./N1.BG(HVP>Q+,X^XEA;U;N"DR<,NNB[4I5Q ,#XE&S4&!5SW)J0N:2.J
M;>^O/BRV?"=[;V_J<7E)F"E28CDQ_R P9>&O7$8DG\@96WU,NT\M:,QC .D!
ME3>;G3]A7U#X42L#K=$(%B?D=U(=%]G"SC_7/O?7.1*J4FA=09!EDB%GC6#P
MVKA[3#0L7W=N^Y4DX%*OA?!Z-E[\H-R.>.Y^4TI<_A/3 %CJ3\,FS'I5=_+=
ME1WTIOU;=.BIV-(S_B(OU+^4OR)4.W<S.3TZ+=6<:FB%9VSGXYR_B&IEC]Q/
M#&WTH9?\+F)>6.S;\MVLA7P-]U*$T["TI+*B.;A6Z^NF9]RZSJ*HB8RB 1ID
MEYNN-O_7F[X@8 +3QHOK$^4M38G7TUU0$+#2X5;&%5X\VUCUY;W",?) HXRB
M@S;IT]=0^PG=Y=VQ%S!ZOF:FF,$:6F'D=7 'WN8PE"_-&G/*2_PIA,.R.J*8
M&KQ"ZW1&Q)XA3_9<B%@!1X][COSU1^W3%'S\(LBD4IF>6$KN_@J'D);"W0?;
M03?E5H7%JALQV3>KREST@S76V/STI>42']^G9?EZ8"NT<7@<[_0W\"4SE(^(
MGS3/^1%&1_@\UO$D$+^$A:_K&UZU( $2":E>/E<_C+YH^N. &L(KL=OV-\><
M#E\N1]#PT:3UN-#/ & 7FG3)RY4"/IJ$ I4?B^P,Z.=KS;;'-E&E=\QREJ5G
MG.Z>4&*V>+\&9U/L7I3;!SZH8$C]WGBSURHVD]+Y=EIW#KV[?6O]5PK=!>[#
M)=PHI6K[72LQ]WA.W:0'QG+&)3O[;8-[-%X]"%'&PBCM5 VHS(O&1^96!JV5
M[.3;,-.@@-J?ES#"R1&NCM]*80$!58QK!PI>:L[QRKJZL[/VTY./33*D'<XS
M;E+XYPR9.F=L*;%IJG]T)!3.B+G5C7.F.8F,DY5^GRW@NLA_QI;%-0%KN3UM
M&!XMSU$D+7_2>W#AY)+/UN$E_W&,:K#)>-3?P7U@"$[(=UGXQ63JS1'G$U;3
MD\3%Y&/77?W-?[XO+I'-3J96^0IM+XWNW&K\EV*(9=2_!4,&/D>D;JC=3CM&
M:LZ&O64S^=^:MM=KW[_<,K^L44B_P6?;"0VLLY1->9DB9JJV;J>0 )>@="[J
MJ$F1T2E'U.*;V8U#\MZ),5*B=JT#QPN!638/5COFNKR!?!03;%JP1C[D4MP5
M5/8+\?D 8_FJO@;H2'-63ONR=B(K[OZB_&Y=]L71&X] %65.H0J<N,^':\GE
M8M*78>GD=<K1PD:4[I35G<-T:]?L]**@E<KAB8[!8.6>KVO'SX:D\ M/GGZR
M7F(M+R"T!QJ#)8J2J?5*=A/? 8ZWWPWEFUQ" <ON]B/W/F<[6("%#D3Z.YM,
M(=]2P>&9TCP7\906N7:.N\\);\2[@H9B=151E"_[=4?&JY(%>8\E95?*;Z^0
M>>BA59* RT6WVH?]:#[:JRJ@HN<1RA9$$UT1O*E2%DQ^H'_=K1H[X"KM5T_[
MV*_85,VA6H$053]C ]+K[G,&WWTI,IE1J*MKB4*M@K]N_W@;AR]]BUDU6#T0
MMIMIUFX6? 3VB1#:"W8G=E6/P'F7H6:-QB4SS:!N1M61%RP46+C C3O(WSAC
MTP.QS)(3^3Y562!&PW3M.QO>-Q0%U Q"3?KV1T6QKMR65L<- E455KUVL9)\
M>Y+!3 5X\$)^35874L&SVZF?*.-O_ E/I0?SZ+#F$,8V(B8HP2]\;U?7I$&?
MGG'G\CUY7#CU$-<Z%%Z&M0(+0S3KJ_OO4/N+_O[V [\3H:9B.4]+J2>-C$+1
MR4,Q8U5[X_)?QU=DVV\DJ^()!:4Z7CL#X1#L'8M"O S.+(WQ@Z(FVI_5B3F"
M3DKMF%F[KP7=(.!>U/.Q<B2!@HFGTB=BMU?<$O 1>N>K*FY\Z@RK^IGT]8SM
M[9%LOJY3'I_,N(>A0T"^]#'W7^>WY_\31T\>RPW5ZCT.#<1N2OY+%=O^_]6.
M!?]'.U9(NTI&5$/PCG.L,U*OV3^=LS0+;*]'?%):NKJWA#78-U8P-4F5O0BM
M_RDQ);<B(RUK'%&:,6YR2LK0X.;"JOW42X]8P51;E 7T5<NW<NM,-Z9+8"T*
ML].4[5P2'4)FD6LG,!6#"MO<%KP_VHH<$5-2$7=$">IT=*:C4"2;K;V.^"3F
M%G]U_=Q=S(K_\::-NMP9VY.[JQ8X"ZMN8?D9[DIUYPN[O_7=_]?<?BA;338]
M]7"8J8LZ;G5_TP9XTKSWOY-0794IBAKSU> \O#D=^34SORN7+0(X__=_+-$Y
MV=?_+8ROM9U[\I\*Q_]3_\(#ZG2Z.Y)S<A[P@;[:-/'JGZ+Q%\!/AF)WQ1D;
M<O7?"L?PZJHSMGEM3.8TC59^C/V^\^8XH>G;MGJ9TE'@J4/R@,V&Z0[GGXPN
MQ'8!U\0;X*W/;%E?)QISOKJ[O=E,\(\HA?/9(I9MM=:N_S6'8FUC![Q/G4RH
MGU?5D2ED/L(3R$9.T\NU,[;5B=#'I;4="@A,%TT/^F5;]NEK"T7K_A4_9=)T
MHH\,\+H2P+(S<"BI"S0\'8@^M)QISB[HF-2*FG=:AUPI%"UYH=)!J;=Z5$]3
MQ] P4CB/FF\FN7;,N<Z)N863AG,;G;&QB;"B;9? AA&K546V7W;U_R^@03KW
MZ'N117[8;OJG5[^524B4$C<8%F1GV] 40V$S']?E9-""[B[OLJE63NJLT:4M
M@Z8_Z^,]$>%*$M9+'I-,72$7P5V9#W6R+4;&LO(K*U^PXT3:L/3UP8&OK,5Y
MV%)<"$VB-3P(ZVU:_[20S&TKKN0:JV5V9;[ &%F 1UFIO#\U3N?#[=T0:Y35
MM0U#AB"<:A4J7( \#3TKBDB"8&/%\7;_$\E&N2)=B^F,EVA43MJ&_F]A17"A
M6PT9555^AD';\KZ%%+@UBZHR<E^EAEI6&I9A6'S0:Q\>W@(.%;^&-,?R =LY
MDM-KQ((N^HIDN&KSYPLG)\!=[.:^WB5UXMW*D[NJ:,5=\"DXIM/QY\1676U<
M '(E35C<"Y46O)",+^;)2I6%,14./FK1 ;E1G6FU 8&;C)E]E;<U_LMF>IH^
MJ-UXJ1^-=(!]@W>YZ?J8^]:D<5[TT;5&L\@ROCG1@4(LF"(I7L^Y!=I%>(.!
MOJTOC[J3LM%*G):YQ513N+(%[/OG7__ZEQTN"CVMH(X.S.@M?J((2?_T$U.D
M*(N'XWE2<M,LT]\WD!_MP7?+B\')U/1'I-G^/7)[+V,$G2KTE.1>G;TW]CX_
M-%(8#_=K%8DJ[=:;]0?:4N#8W]>U;LP>58Y!L^1"Q5\VT=N!\HJ+]A5EN 9Y
MU#S3[RL2;-ZS%XKRC6)Q1(86^Q8B'Z<YBLRP!V6 (,GV:+2*=<X-$[U']9S7
M<*^%KMX?T@YH!5NT^Z1[EJ8&.<\\,/TQ#*IY$YIR=WB">Z:BA>1<BA^&&;5/
MV[4*N30]0Y69%9F/S@'&;40T>C2! )-RL.C7++7WF F?@O84E417&AWJBISB
M!T4[&#W=]5\HQLO=AAI+R#F\U-(O]E7O;,>E:+ZT(*"<B_)06[G-.KL%."KF
M"=]<+)6YUU$_[U_B8#O;MI9AI5^T&E [FZ"S]UPFZ9?;+^_6*1F\\T]&^>>6
MHG0Z\%N Q[^C//UA"+V?,J^?[SSSWW9N@]OP3#2_0,.T1]DC/%OGI1[XJLS9
M+;\LW.4LK#RWONZ7R1U%(G/<>+SY%$7#APZ^C)#P+LSUH&Z[>E![/W?J\FES
M.>E\LWY+W[VKXOM7?=JK7!2<TAE3Z.+?M@-.H7]P"Q85+7M!^H9!$1:0?,OS
M&:?[Z@,:?.? GK>:OW8>&C5\[Z[H6YOYXF2Y78A[:4U0U;6C6-11%14M=<7.
MM[7*S%)NY#)A3@66K:_(3:)@C9=6-":4AHS#K<$CIU36%<+;&E[>*O_>*/QJ
MJ+M(X ]C2=WA3(.)',*-3>F5C]0<R(H,X[%XW;^4@J'N73=+\WJP<3&_?]]-
M7*)U33!DZ99=126)%VF74:5TP)/H?Y)J1V8V(>Z@3Z=!Y\Y^YH@7?^U<9S)8
M,X)R)(A\4'P)/N&B=2E+YN*'^8580UN[M31&B>E-C*V&[*L9&?1 _)!;FO&,
M,#?8H'TFW.^1B%/J%<_4^XUI#X&*GXS480:#S%'ENG2(K$[>RCK@$5DYFCJS
M@-;U5%#*EFXI[5@:$*NQPY7?0)66I%?J-8SUAZ6K=I0G#<%KV,/WZC+'I7!4
M\TD^9*1)7D.]ZF9GG]?>R(%WFCGC+TJ<U;J2VL_%Q@#U+L6[$*N,%%V+1%.K
M%CD(*R2P,:[) ^?-G5&Z1O>S^.<1H@LT6[C'+^(-+RS*KG4 ;O]FL(C.@/U>
M782L&PXX">HO8Q"7W,I0*6,>DE.>6ZVDY;HVYX7>.!^)D+8(:^L-/#_H0:0Q
MH_$5L^CM%.%VA)=$V5K65IBGBF;Q&5O=':+\M,.>7[9BMZ>-4 P>C]H)J"(F
MVS ;MHP((O'3"D"B[K:80+X!,>QJQ0A2GO3]65D84=-_8(C9J%=(<1#QULT"
M902/E7^I&=^];#5TTVBD1>O[3Z?#(Y0*-+K35O7+(K\41PGD.K/M?3AQ54]H
M4\=^2P&IQ02.I=].J//VT9Z3[@H*'O O,&.L<=L:ZUB-+^!0>_N=IMX1+>.^
M\:'< H/ZPQE%J?%@[H>X;HZDXAI]^S3^L&K;ZG1262 $I@N2:=C)-NO5(V4,
M&Z#\CUJ_,^QQ KL_$L%^"Q+UG%?+=BXNPVX$5'4L3J&HI6.;.O?MQ&T"'*O#
M"501.%Z],<!2:F\AXS!0XA1&_.3^'(%>D3TI0_["0F2.>9+"-!FH*G)97E(*
MNC 1EZJ^XE7*F!CS>R8P0??;0RL/<\R4M#XAE!SU=:,'/55%OQ;<2W:.@4;+
MIQ1Z%_?U7L<7XIWN-[2GZ6HO=FO!356%VDU5R]/$6TNS?%6YMF#M$:X.@.4Z
MS\H'#^EU:%PC[,&$"&I;(NC("+?SD@JRDLG75<.;!VLXVM>I[[QF'5;CI2!5
M@O?KSC?? -(,84"CJHHO1H/*'4-90H1Y)"&O-0.2>&UOTA"1[$%Z!^6-;,=D
MR9^XE+QK_ *VBJ><ZVMEM*:WWE3.Z0YZ/#4\'_R&::H2,B!QF&[,-QJA\(6:
M+K_919]C*O"<@T_C3;'&QN&&?9]!+^&DFH,[8M6>#@.C!3K!,)EG X'![ HF
MRY)\U9/AB\@N)]*+S?(X_-NLCKU[T%3XXG ?%D[U'RU2Q%8?\1$01'(9A:FX
MRJ</]D^/8R3>^_I^+.D5$ SD"J3BNHX\=1'%-852:ASQ7;D-T3OI5U)SMN<?
M),K:!,:9O-DZF%]63/HSK'"<?2U/9*IF.8]=X/JR*DREGPY%[SB.B2?;S7LK
MAP0F@(,XP9S L:VWH4V[_JR*\SUW*H,7"3,,NB=BOYLI#O,UX*92&Y#22Z3U
MN*06WU&T&'UHU@J_1KK4_KQ49WP9EKB2$O-H= (BK(&R"(ZOF//QQQ;N48>X
M,<LXQ60D"3HW< Y31/.IU0@I?0;6EYPUG7.SG=,QNVTD5%B>4(KFV-<G$B)9
M<WCB:OI'*:^])>?T]OH$".WK^)S9F)M&T4IXYHB*2H84S/F1[YP(JGWK& /1
M1V&73[.#83#,#O?1+J:84&,L.)(8N_YBU=E\G2*0^S N[I^:7_>R5NGH(\>'
MN=S<(VX*\Q1610514K%58V&IG+E8 (4U6=JN^A!*T9G\1(,EOMJ>I<*0[DD?
MT9EHE4P*M0]S\C'N.&9@[Y71J"NVK"10L+)K7WBN.'HI7N23TRO[U7$ZW%<'
MW"-;BMS-,7TA7=D'MBR^3@824\/6_9ZOKS@\REEF.D],3.B:%"YDI<_,R#/D
M E1D@7 P[X_>0.TB#<H(8]30D\CEB*=_'%U=KQDK7>1G]EY920P3,:#%9Y<N
M".&%9@(YRL>.1L0,NO6#@K)&]- 4Z(Y@CJFQKK8ZK$0<O'O9>IA=4#A98-_;
MI]")&KO2)B'R)OXV<8?[YI1*.:]=(UGLLDMZ\5M T2?3VD]S^Y3]?BH<JLAR
M,RXE6[UH''I@:&K?"H$ ZQXGVS?K8;:V.K:4' (!3U7U1O88.X&MNHL$)O9#
M266(VN[-#HA)V^PR>I5A.5OKD'>UP*PLO=L2@C]JJZZTJOE#Z$>88W?VMT/_
M]M1'VWK9Y9@[6GE2^W]@RLR8?$^@S!'O_A&8W9(T62FW90U?9N:9/NS\MC2Q
M1S:^Y8SM0Y268-B]H6>C&D,>$E(6_?1VW\("BD0((M"? 19+SQUJH72L\U^!
M"#U[^&;@_)B;F[A=_+Q%6OK5S/A<?./SS4RK!#/MHD";B3?1$4S!.,1O")Z(
M]W3WO+M!#$[S 4@ECED',:4K;VD1]9TR@#R\:Z RVZJ;Q9C%FR>7CP7] _VK
M0T4OU!.N'T!>>S>H$'M1S0_1_@,)Q!3%J4H)L?>,<NYMFF>G_+A3C=M+=PCM
M=? ($,3OKCOJ&L\*\/?+H&)"OHWE#5GU[6F2%%^!B3N(&6.:U0AK"I.Q8+0(
ME1M5!!-[%5JYMP4&,>MZ1+QG8PY/!!@;%!51[S$L0>QUZ4A!]?[CN$#AP5!5
M3MM9AR>[G)ZN_B$-$<7A*A%CPH/GD[P@#0G+13#B^SE!>45M_]%!?9A+T0J'
MUV#[3;X.OF#U6^G7OPEI$CJVP#IV;C&^J?/KNBPD>.7\.KBP"O.ZR7R4%'Q?
MC*(-=%Q64@(3P[(D1^O&/KTD@1_&OEHN$M@)VMN:K7M9%]S&+$NT[ C!UU\$
M-7LD%P8^U-@+Z71ZL_-UZ"L"\'14YY->BX1*[" \,#D8F8UWMN%;V1/.'E2(
M!&Y!/C2V-UE%IM1I]%LS,GJ]<R8]8[8.<(!?=^,8V\K'Q)\S0^-R>YT#D2?X
M76;[#C.6F*\'H1-%10=ZG;,8"FG>GA""8>4\7C4>W/86GZ6-/<X3O+(&N[.C
M?L9FX=EQW@(^KL<$58XL".?KZC$FOC&XG^]3+^&&$GQ$V_&2KPQ'LZ(;U5VP
MOHO=VGAQU]JVH5FC[#?*P(_:;V2*^E[O&0>D-2!T#C:RHR>08HY!=R,$JV,2
M]4L$'\BS-@L=A:@]#7/L)?/9W2:5=%5>NT<H70@E+%FU-Z_D":XN-=AM#+1T
M_PG/<?$B8QQDE&II+Y%+>HE&QTDC#+?VRTNXDM7X,K8!+=8XR5NY(UTMC64D
M=0R]/^P;F+SB%6S M(T/A]<+:M(QK88F0TZ>H,%5Y;$PG:J)/%V @/^ '0M_
MW0:W9%.[X^C"[=\.2GI&*_3>]LO-C)UR1,-)&A<R83WB>D;?-UN[:E'O15'O
MVY\STUK$<L0Y/4/3K0<XM AAIIQZ'K)2JT*_/ .="Y\*Q5U['G'^RA0\^V7!
M/KM_Y$D//+(]=54NI^UQZ%LC"8-[T[:V:^;CXA;ND#=B"N&8<KBX"S[GC$VX
MJ^'MO,21TKN4!:_LC))]]JA+^>//?O*FKDJ[PUGK5;+/?\Q:&7/]Q,CXI2N)
MBYDA-;/N+V[?7-&QU#4SRGUH6N>4(Y*AKYA!Y'ZZY5BZ8KGF^\YI0*^0#.RV
M-\KU7U9[LW9<-I+'Z!<<X&_T<XPV-;%\1YA#ZM%7'5:;S;P"JLO=;* ^GB$4
M.&?[4D?6I5Q#G'OJYG.#G5V\4,3O#2D9MB.,VI[F1'G3D9#Q;BYR!]JODM(4
MZ#ZVB;AS53/!N^3"Q7N'5:ZYGU2#A%#[W,$2*@HS7$#7L+"-6A^FE4['#1]-
MXKJE?_EY@U;MY1[0LO3EW?+OR2X:.([^.IT;&6FST:EZ\^K4;K]G0 ,/G ,?
MW;QMSH\FX:T<6N;93#GL*&GX=)H".$T8.TW)?#;+T)V J#MV_\T6IB?[Q[>!
M9S)1Y01Q!''+V;[.1XZ/HK.7A:7<8OAG<IA)8/@!9/@LKK;A,5TU2//'Z!>-
MRFST;F$BB28_%O1<ZT\>2;_'_U6*__*[2?*?N6&R3NN0WVOZE;M-#R>HR7(-
MG9VKNYQI:> A\LX#/'2]>[QJC.7.N",S9W@@M<O+W +X_-K2[V,<(:1#FDP&
M.PB?R@UF9\[>O=FP0+WZD8W]R15W1[R4+,ULJ=,99VI1[\#W4Z!)7/7G/!AR
M3LMV7/6AL2L]&=)6Q;ALJ\(\-#>H_[G84.H:?H(A.WB^G.%3M"(=AU3KA93#
M]PO3<#(,*Z5B)5T;7*@L!==)N9V'3NTO2/#=AQ]EN>GGFA)^X3I78=1>I%_1
M'6:7I:\4QW6[*W 4I$CE/+H,'C4?L,UE&BUH!!\^_#>G0WO#\XGSZ8Z BPC3
M +2"R18UHK.;D^?BI-;3YK?$^[8/!\[8DA'WQ>%=+^'0-(HU0A5U<F0)/^J_
M6 .V FWBJSJ808UYBV=L.5F/=5MW;WT"3ZHVO5GT:+_R3<J3.C#^8=G#Q9 W
M5\+I$F/-TEYWJK0?^P*.U->=+K'T<2::&==EZ>Z<8";0^:NI?=^L IV"R+:\
M;I=3^M@XG-G6SG&&LCW%U2-<P$E?"E$\.V-N_.TFW-'A$H>A>#.I9:@9XU"\
M=0&DDO_:^9OJEUYRI?_$>%N<[\/]<951?&5(L:WM8N.5H(A+>:6NH;\>TE#6
M<QG?+7-A_1B*3$ L19TLD;F9MOY5)E_PA;A,L(CUL-FHL]F"?)*^.E=7WOQ,
M:Y=.\XJQV[U!UWRM,S;WB+>MP\2'-J4#%SG!:ECU"5!N [X![_!WS,'7AXG6
M6>L1-M=^^?-)/2K, @OVKZ"+_8X 6#6^43I"Q3X.1<%/A*PF5RT?3%>HPTL
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MR94M:V;PC=,2:3!GMY^$BRK*]9.II3E8H[I=TF-LG<\((NV8VC^&?4O?6-N
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M_ 2W!+(3+4G3^-U*S? 2U,:;$"6P%)O*LLQ^6F=F_OTP6 %IE2F%YO"#D?O
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M#![#"B430?;%X_FX*E&U\=W4.\!6KI9HZ2K_C3981Z642X--R6/'-&FGW:J
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MM.9(#,CI#P WQ@_7S1O*_[0XNG-H['44_#-J/.#C.6 D\;!S-FS[B\/DF?V
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MN=J":7_9:-NM ;,I< A[";J+D;<8%(J6\97<3RD6\]4T_3H0EQPY=J2>Z[S
M1$F7==R 2,GF^K4O=N6N^U[+?F(K+J "1Z_3#!>L=R8&<@7\U)QH,I.J1N^U
M]]]:I)E9>/A7@V5#UOYAI)UCA'VY]+'LL-T(7^Z'*M742B7("_RMSZ0&J9MR
MF0-/JX+NV6,7@>PSU)K&;'<+O%*ZE%VZPO)(4^ -BVL5#UXT9$6>6GJNP>AK
M/_,<:-WU/MANG5P4@$-?MF!CN!0%YZHY;RF)5+2S=B$:U)>2TF]8>%Q&]!M9
M6KXIP&1L/&E)'=MW5CPZ50RO@L&G$D9A)KJ)[]4X[DN> N<40.C2\%+RQ)&)
ME956,^93=@0=^]_T197SM:XN859B=BW ]F5K 2BO39'.RP7DJ\!H*QD8C4BV
M35]5M9V83I$HR^6"?-_8A)UB]IE3,J^9(&D/R[L"9*O4NBB";Z7;YDE#^G1G
M6U2YYI)?8ZK&+/3Q<*2?H/YX#S?07%PHC:FWW^BVCX^KG T;3/?KP(3RT=S&
M+FV] 2?PBU?8IK$.C-,48:=C9S'#GSYOGC[#/$;?[.6:Z+ F5CR=7J7ZY%-U
M]P'6[,9)#@SH'^1]WWW_&KK#QF.2KGD4R9C-)1#*/SC[[%+/?^EUWV_I/+QX
MT7_ Q:3<)E)%9[ EPS<M)!49+Z/;]>I11;<2E,*7:GM9_9=ER"\W)(48-B^1
MTW'?2\9$;#!^9U=;7']\&--,3Z0O@G#0_0TC'OEHS"-0!HWC"7E]Z^*5><L9
M!B\F")PS8O+\AZ,+&P+31%T97O[TVSQVW)O0=M+ X)(-L+O.R'XU"9/T"#P'
M)FTG.C@(M'"K1X1ZCR6I6""%E^3DRFA:'#S,D"L#.#1B[<G$H<[Z0L/KUE^?
MM#W6DV!&3&DZYX"0B[".7 ^!IUK&*$ZI,^H;F_7,6HT,@SQNVG?0(UR4,,G.
MPJ%, GE\_&BSEDJE%]-CQM/1RBG^>,;>WHYQ3(SVVN#6"P?2-D].\[A@SWO%
MG)RH GQLN[6WL)SH24M>P[W[R?>DI(KM4"./RU\%R5_#Q?Z<0LP,YH^](-L:
MPJMR46<T1CSQ/!8!7,0V+;O2LN"W<"(".#?#N0[FFP?/B@")'^.,TVTC2A7]
MOE^8>?='[M=H '? UUX+K/U:4S" S:F 2>_EX[N;=Z<K!<H.T?/SY3?!^T*7
M7FA0W_AA9&%1T;'!JN)5Z8T]!SA.)_F2[ZY*EVKM)=WYR^7[G\FN<"]O7,*7
MZ95_2))6G-NP.Q#J#=Q]8'$]/V>9O[@MW8AU2&*.?4[.5=03;!)L'I>6Y.&#
M3U@R/+;B&V1XT(+U%&(6XI;H(:+(+/S0E^(,'*HS3MSEQVX"_% [-2>$?'B_
M_QY<2,RM A.]?;<7.(0!C5R*TX,J_J.?9X#C,\ K_#VGLDX!#PXWYD\8&#@U
M!Y%+-Q$'M 7FD@QL?U4N;_6:_SH,KXZFD\S5+1U:I4%5;;M\A7PPAK ET6?T
M6\?/2!)**KFPUDU767_8LO_AZ++4V^M@+_RW'KAT56 [M3E/>&J24-++Q1CD
ME4SLV\MG?\=K6KL,;Y=E58D3MPC=^@B+*4[!^0R20M;MM81_5,[Z/V+),M+!
MVW)'C"OIRH:\16W?DV:J,I!602BE5<<<M[)+U:W8>F=H]4G5Y:&&_<HU4$U?
MAZ9!@^\NDL7_?8L\K/GTOT##?@1#]Y^? _[+?SIFZDCRE]XNG?"<==7UF'&:
MI38ZG@.VK9/.0*@CZ-+"D]&ZDY%_]D"6/;3W?\NT1I_1GJ'Z.Z\LS#R\YIV"
M"E[+^Y'1+'HJ!"IQ.@V\W:;0-,XO[Z#\\8PW8PFYD_;H+*.;+?P<<.4<4%VW
MF='VK9?S$_C9X83-ZA6A?\>_KJ_>WIN#G /T3$Y%;WM*).V 'NR)_(<V "<A
M_QD/ P NA=3[V\0XE)()( D"]@<Q(B^RFZFO&"D$QL?388FIAX=11CR7=#LI
M$GM[*T[3X@$BGXN?D@W=/LQ'<;#P,,8QGJBNDH;:6#@P6$HI['K]#R@W*.Q
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MEZ-JD<Q^/,,\SPWO;2R_RK;8B%A"]L5:DABOD OS699C8I#+3 8P#,: (\&
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MCYC8YB2E%64!O8#.T%T@'<DF^X/Z:BW@GO[N-SE+8=B60/*""C*LR<W27DP
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MC^#0]NXZ\__L62[1QT0_K(F[H&0.PD9JHE/)?#O?]@[38-9Z)4@W+J8#Y7.
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MOUS*;7V6R,5*FMV5->2*T]KX=7[UJJQQ7+)X9>E>8!M<(%R\+HRA7Y!ZN'B
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M]NYQ[P1V5T$P!5> "9:C]&Z,87)9;E6J!/M1-G3[/+V5*W&\L=M85OTMFS2
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M7_E@B=/L8E'T-1VB*[Q8ZH_4N)GZ_-S^2]'/G@!L&NB!0,ZQ>CR8E ZY56%
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MIOV=O\XCD+YMVB2UH@=.:O(B/^]A-597HBLW)X5$D(T,5\,D=&8;D*)KWO]
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M]*' 9%V$#4^7HW:<KX5Q>TCX1AOV$DUT0#K&T]&"T*UE <MRPM134K/54["
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M,GI5C\H2_6A;>WIV0"SJX"0:_:5.M/[%ZJN,3(+GGS7(,9G4%9/BC528XRK
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M&*;QH.YG,DRS16>\&C?GC[A996! UH69>UQ?MI7\AGDO#C8-1K%^P^7U>^'
M3L&!9(B-'>O1@M#!IA,-DGM?Y_G&YW.S[GICLN+BEWYQ<'0Z^R3%X2\&J,EX
MT8 !W<.J\8I%DV)9)'CUJ0X>U;MG7[ZJQ%JE=*T"I"(/(;G*LRXT")J(OAO4
M.$@CO#=,N:&+_>ZQC_?U/@[ )O*JWLG"5?I402_$SHORUW13_V(P<C78ZHKK
MV0\> @IVFVRZFLR.5^?/]CD[Q;\V8WM5JC&#JEWL;9@M5%A"53Q]N;'E3"9
MO-,H@4F6%RS6JVS]RUT&9?9 8\KAFRI.&GC[0Z'V2)!4'==>75#84L_J [4O
M*&]S[()A8N4H*HQ9U4]DOW^FP:KGI\QF$NOLFHD#,90JU+C2::766"*>XB*
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M"ME!B3-V+"J-W.ET!?Q[S3E?P2&EH.H)B(K>=&27,#!F"ZK0.Y^'H%'EXBH
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M$9[(G4="O5C*KS C&7ZS<?Y@9]$3O@#-U/X#,7+?<./NC*&__NFU/\3"KWD
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MBF3XNY CXS),/I2!,<(#&/!YAH^A0M".)>YR[Q**^2SPH&6'ZVFZ=J!=RVA
MOGKP+-[UI^;PD@G[V-KPUSTOE4!>6HL,*>>?2>EL53_?[\_YA-'OLOP9QK"
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M.^59*2^]\G^Q6[UQ8@^>LP(5]-HRQ[1?@ZK'0&9YUW\2%#1S/DCY\J.?TGV
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MT1!3,D<]&TNPEKV[LX 7)EHN^Y?WPH/O QR-0J9X'(]U^Y:6C<!_ 9O79F>
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M(VG,6MWHWLD%%U<#TUT-]6ZR@<Z=IL]K3PS7C:CV/HPNXHKS*WS-5&5-!&N
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M )# $(@.=RU>,V5^ &?#O!I]65Q=[,Q'XRV)_WS(\3I53_F1S_<1_NG@CE\
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M&3*_@-37).A4LI^B91TE6$!<*]<%4_-SJW^5FOF;WJ\=F8K>DW,0R -+Q8[
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M6)\$]A6%Q$=/"&59/&%D+AD]4L[;29\03X$XC:]Z6MQ;_67B]D2&[4P"P=Y
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M7)U]^Q0>P9W&$Z/\,T#EZ.W.Y>8S0+GN[K'1T^_7H-NR^PX<9X!,=SVLU!D
M-]S@OD&='8<_/ /L.5DU1JRJ[G7Q=CO_*$SO-5L3/0.@>?)"N<%G@-\*!G(7
M5:N+3E;]XHX]C4XN9VEV(7U3[>76OK^MP3:H_UTR%498E_0Q5[3J7_O<%R7?
M.A\6?+%>4O!:!(QD,0GMK4LI7V]TP>:?\H7N)&(MS(_%7@GEP!@)PXTM;J?Q
MB;L>BD8?OQ&35XPWE2O>WY/A_D<J]T-;X!.HSNVN^*08T\J:&0,#WH)6F+OD
MMN'G=./Y# &?U</7=OL:^6XG!O6;DS>'#44IM1)G )3_^/-$VX@7R:-J<3VV
M$1_4.W+5D3>';<&E+"SWO>!XEUEPK;DQDL ,-DRA![J?*\PN@DSBHF(%K&ZM
M0J"&.NT/%8(C5WC6^C3@/Y5UYB /)&^@$('>S<->/!9$8BT_=6>4YQ$4#GY?
M<H-A=UTN4)NPS2L89/5Y!O9:QO.0_98!)$!.9^G;_B])Q279OZ_%P6AB$485
MS%DP"^&L?9S(,LCZ<LYWE.@'OIPN5=]IV)PK*H;B>? (ADW3GQ#KF7Y6$9?G
M67!;N";B%=$[<5U#IAY:Q<CXA*531NF*0XX1GUUKTJ1UI/$>-N6W)6"-<7JY
M*BG5RZ[)@\W>SW;**</=9CQB$:_5N"AR(##W@S _I>4I"W,I'V_[KO4J(;KF
M]8#BC,_LM#-  [%#]4W6\4',%Z(+NA<=]P8A0N[N9)''-5=N[%4ACNYJ0*;V
MNPR9MG)D)>(Y>ZAJ#M!-<".'8GG\N/9(R1MBP@N*TA&Y/>N"XU5^IU;EH6\O
M&:D8OPXZ0>$(AF38!Q)R8S +B^;WLG&%MI:)X9.*%Q<=(]T**CI][.L)#6D@
M)X7(9(A1P<KMBC*II;UNPT4)-C;Y' E5_<8A^,T*-HGT2@V_H0W8Y+@!)Q2B
M(U98DG"IKNYV1IVR9@I!AE:2.S)<$9)79G(TCEVAC% /0&O>G(LB]E[ST+G"
MQG>(Q,(1[WSVO<&5\L_$7MD4OMR=).M3&X6"@X>AV#=46=>3M8IV5'WB&6"@
M@A*H)T\8"\%!O5&HN[.9-U>^)YA^::8];!R."G!P2GWB@54HN6)[_C1.\CBK
M@RRSZ#MFY_;V:$+/DSS! )G2#L,F[9Q&=(P+,\7<0A[:>_8]:Q(N@2E6TGP8
M#@.$WL%>;/3 &(ZWI6)(]Q0]E//-$GPIQG]^HAPACJ/Y/27I+NUZSQ^%EX0I
M,P@%V*F89/4V\UWU*>A"5'I)?#6PQ[>HL/(;3H:8-? 9,Z/E7MWN2:Q3N"!]
MV9\:\8F[,!6J?[B!:#9)5%BA(4-:'IN8+ 3>J5?T7-%W/$+K5,HI$FI#JS_=
MN;@F&U*F*22^H%QM;?B <3=C<9'IS19C)UBC7:N& \%3A A6;YG*J3(I&[T2
M,5>C ?$N7=(\7O*_F9S,690\<@9XOMBQ$PXX^/W?S^:/?[S_J5L!M;?YKPTV
M@>^V1M).ZLS[#I*R!@;CK1TE?[K-QR@,C5>^/:6KGOKGM-V(2N_<*X79#83=
MMVQ[^.UM*,OY&,M9S')M3P!V->P==3[AU<.^DW.O=4;86U.)3=PQFUB[>!AQ
M3<^TY1K\12LRW^X@:O7NOK!0B_7O71)HR&V1H\2$KY(?@KMT-CG&I-^TDQY]
M+2'KJ/ >79C,RV()?G'O,]I@2U9P71F$6Q2;EDGZ/K:&L95*RI7T^\^NF1B%
M-WSZ2]G3"P959+'V\I/UU_A)VE;H)?E#7:MKX&N?#!JRV-65D'];_-N61W]O
MGWV^AGX(7#;T!6C]^99Y0/F6$>??+JC,\W_W4+XY*.^!7^ZXLYEH'<9,.>A'
M ]-UP0S<5KK_T#^,_C[3X'4KY>EJ0UG5IM3IVQ511>=QNN>LT3_\?^T?^DTJ
MK7K/' *IRI L;6X2.@.P^86 _H/0BU=G@%]Z)M&232)HX7HB%R5FGMME!_<?
M95Z? 1)NU<;:'XCK9\(UUU/##=@:!&LECF9KY\!MUE[Q01I[U_Z2O[HQ^WG!
M 6WQPE^01:G%ZW7DWR'=^4N$7:"3A;Q*+CWOS7]\B=4W6&,DN""RX1\"O[QQ
MT>G82QS2TKN2H#L7<X]*]$Z)Y_4&O[8N\4*(DC2\!\S;B:N@DB^:Z0E#U ;O
M1 L9Q/!(2R=7+;O7[G'F=/F(CS]UC/H&X98+]N6:C.A4#BO=U^Y,958.#DFM
M?^2!P#=G$K-Q!_K0V=7%977%1"]IIU1^=ZVVG6[+*=V,J%6E;3,]'E^QX6VY
M0'FNFH7#T*K/WHAH'C%6%2"BUA>%*NWC:?C,DU6GJ8! J__'[@--S+0='S)I
MEY[O?(W*-OK(F56CR#/^'QO_10$';K+G=G^,8-LD\+Y^G1'[R3_:G3\GN5F*
M<4/?\VH?:^OT/V[JSZ!W>W\H6?]3T]IWEEUI45KR-YW62SEQ @[;1C?_J8LW
MV\U6B@'P;_QG-Q7+_<^LW[L>W.[*!'J#>K8PC^5VH_LJ-JO^;O&_A)JX55"*
M[_:,O>-EY_UO _\9[L/@6:E5O ,>:(5KG30N_H^&!+B\Y;^[;"@4=?J/UN7I
M\I9:7<Z%M2T4*%WD&6FC[ K/<2H+";VH:K%VS-"=]C(),GI'-A[<_Y6^5;K2
MHO]3QYM!+W?)B.U;>J;)<>5 %,<8ZMF4=\1D8'9]?L^=9LGW<U21_B64DB6/
M ^7VG$YSS*6V&!@ZSKN&].8]H!_R/WWFZ/]&YQI?FL-5?F@4I9NL;T3I%7R4
MFP_6A8'_W'W[YG? =O3O_^4&.3K!NE,[:;EU23(A2KH+@6/GT<G0M:E45C*3
MC?,D,6EE<5UX\Y[C\"-S@9.2KM"%$X<>[.S17-\:0F9$W*PE=<VH>-+G&%WA
MAD)F%NVPJV]Z;G7?DA@2!$BJN #47KO_>BWLX'O:^3U-/8:> 4Y2]Z_O!E4N
M=_N,,I&:DD<?71;-QQ-2/[2TZ!,M]T5X>6U5<A=N3]1W$G)<%5W,9V']B!,I
M/8W@>NAD]JM\1."(M%GF'FDL GPO*JRIA-7@]:05%='5DF*Y+*N)#U^4:TH"
M/:!1!(,;G?%F0LBR=U.BZE[$+$5H[K+1X,A%&<ZC,X#>E1L8! 4H;2^:MV(U
M/SG3RFXV-6QUKS <]\EX%U634HZHY^A?L1L)U&H(9)8T4T-F%6F8^B=*1LIS
MD%7V<)G[.7X9L3E:Y/K<P ?3N1044W%-MYEZJSW09WCYO#+[EJCEDLV4USI>
MI"JXU^I6DYQHEHZKK0,[<[G+WK><7: (Q<RM?_<!'T_$S<(Y[]NMJVCN$;+2
MTFL>#9\4/KQ$>]?55QD7W#+X9.78\SXPJ/-Y&>?MAI-,+XO<$G3EC_8SK^TI
MBNU&8LX =Y7ROU9WAL+ZC1PV&,^H?MN#;=."-54C:E<24RRXTJ1[DL4\^>--
M9];@"SE (E1CYLT\JUW1ONC>2EF/AE>*72TT/[O25-)D.;?&U!P_]UJ$X-+)
MQ#W*!]ZJWI.+N=H\P#3YR2 6>>B:[2H*,J'W@+6DAP>,^WUCL*_R8<+&W_+4
M?<IXYT%L$6&;=?9M8EX6DPNP,6]KO]GD-F4Y8NC)HP7EZ'Y!V>:!G^RC;9X6
M.6D%4M:AWWH#UI[[W!\^D0CYTK!0XH>6=CX#7-L(J_'%C?B>,M<4T\?6X&KE
MZ=Y&\K3#ARY-C;86UP:HO,M0 [BU?;:KV.Z-R#7<FI:\UV2.Q,,"&>'$9/4(
M384L7M*=4TIAZ,G<8$!C4Z[(4:YG9ZX"FB:9M-DM?J.W@L:+3)MOZKAK&T=>
M2.OOR$S_UF<&5^X5]_183KT]?@OG<_AD"/JID#VL6V&X6"PU7O1^Z=JZB-RE
M6=N(R1IG'^'2'=*0C[1X\Q2SM:/MX(3OY JOJ3P(?H5A*!$-K6/C$(="]>=[
M+/SC:G[-87C7:1!=KCNU4'IJ!Q7U"1P-5H>5ZD_8L[Q#BZ>,/M%FLW0VA=X'
M+V09H]\?ZB[KW8'JP7UKAEL^V_K&YN&]P<-1+^J=K+W0+E!6.7TD,P[4[[*9
MP+>073Y*&?;MT=#R3]R2B@-.H1Q]_6?&%/P^G7P^T2HU3-KATLII&!O2F)"
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M:($\*\Q21@XLX6)I6R1HTR;PMK LJS7#5\[!@58P5:4*572WN='=<T^>%%2
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M[XPKV'O4C/0HYA\;;K[GWZ/%&XZP_8;KUL-L?E)[70B+7"\Z&*)VMC6J))X
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MV CSWG+/"30;SCYSR\ES/*N.XI[KJ*^\FJ@YR:TA[.#G1V8'SS)6\A\XYY\
MFKZON*SVNI\ ,N()56(PZ9P9,RC6IJ,7F#K4(0VB]@2I#E07P%?=/"-A-\>$
MR2$+$0/1^1YW=R2 K4J.E3K+$<<Y SMJ :) ^@)4^;UEOBJE3'8DQ5&=6[H'
M=1-9 /Q,"AP*?'N<>\1FB%VTWR>U1*"-FO60)DN2XH9/!O?XHA_7/4L)&"#*
MJS*G]?G=<ZBW=C*<Y$XNQ'BJ;IA?A-^/??Q^H6+4SE:>Z^UDZD.+#X0;_*DQ
M9$UBM4U'DI$4QGO#H:B-8#5R:IX(;D+9>^CBVVX/CCZ(S:& 8IF$&VIU,:5C
M,;5E+F+ZNCW1F+KSM9@F.T:\[&P'\D%J+F^W\83DW=+!@SO]94>7]^F4N6P8
M7X^)SKWT)_2D,M#:Y;NSBD8O=&T][AOOTIQ9F&\@X4\ 'N_,E_Q@:\-8#]S+
M43H^:&XN9 6EU+'#Z=JLQCP#VZB:G?2/ X= .E CU/HYJ\09-3./U:7T3_GB
M4,E<V)T)W<D0/7ZVL4W0)XS=2$!MQ!B:%-0A%B';:YVL@R<N<NHK,+03"*(,
MW6_&1ODMX=UN+HI?UOA"J_-79IF&RY9KH\0H&XOUV7[W8'#QG+*)K()!QLM8
M&+; N3# N$_26J\EM(7=B3T+XC('69T-O$$:ET;N\,[ ?)$A)=*#0_U\1Q?H
MB$*5E[">;Q D'U.D<C!1P%3QG7E! IG;@P[8#54:2:W:8\D;UYWPVVU#-U0T
MK*P*]VU/>2V&*1?GN[OD)!6+[HP=#E/I2/85Y]GI:_'3+A+TA?/#.L+3P"8J
M/6)&*6KZ&3.]KNP>GF]AOP4Q0_.CS!_A<^37T*VRH_4DV9P3P)*GT!&^8M1C
MH5*@7)89,Z?&5C\0JY<@61#HP4#XK<IGA**'^XH7%)Q*);B55X[.+0JF!2T,
ME9 -<23-@@%B>/.SS,QB$#2 $9C(Z1&9B_X1!SUMBY*98PRA&>>=F-&G.[>6
M0*XZZ/TU/VVXKW@3/+HL (Q+KDFDR\U^PU:_S VO3[$-;$WUMZ[V\*FV-X!:
M($X =C5:VA"5FE2KC+@\@_E6J W+V$XQ7=DV^TK'<.#H/::KX/Z'WKAV^_!A
MTY_G#/EUQ(H[)E13P'=K&!AHP9??=G<'KBDLC_^"F:UQ<'XF6J3C7$E9J1SL
M5C#5)+3<')VRBM&*VZDS =\% >UN48FNF1^457UK?]*=^FP1FIE;WZ\&=L6\
M*526BV<$1EK*5YKESK4ZS?L^[5P*%';M#YIN?6&2+.JIT]<WM.7.GHF77"_6
M8#RWHO>X>2N>=&'GES57F)2C!CX5HAR(D$S6YDH:Y1S(MWI'%1X>IAT1N0DS
MPJP9M_GKYR";!:7]%\D8O*\%)@.G/VZL%+NIMYY-FPUTZ<FMAD.T;G!!+20Q
MO@CT7:)X1>G8MZL5.51TMB35=VS2!91\\T>/,.FJ*0GC2'7'J%^#KZF< )[Y
MKK(]E[T.O*U8RX$58$)L.-3T>A4@,(S$(8TA8/$:GW0@W&1C946T(-WT##!8
M3< ;Z9SD_,30D7Z[&I:;C5@LY4B;BUOO]+ZY=E-W,Z6K(N&&KY::A[WS"4 Z
MK:-^*0=[W$K;MZ.A;TU40CUT*%4B^[5GHK$EITY8J<9YO\K;5Z[ >YRT&3TA
ME>J9+F*ETFOW](N_NZ$L4@H>3M& :^/,V;^>%5<B7_OI^UO _[:7FK:[R'0,
M>%U(_%9 G.@1. VCSOKKYC%N5T5=7+&>Q(^N#QW>HR"=C7!^[8$\@J-F0P+2
MMTB!^SL!J+RT>'_G%\5EVKCU2;>/%(BR)#I2V-\_"GPVI91K)*!77?7^EQ[-
M=I%%[Y\^;IKO^*\<',;E!H]:G !:;H^OEJY_T\LX =B^/0'<)#2D6R20BB;A
M;+'J-_/5D(Y^^%YM^QIM!9=R77;.P4UNHUD02"OUVI?;X\NE)X!O9J<%;;X7
M?.FQ/7J:+'P27-)X HCT?B/W28@U!-KS>)T(4S,J@Q=(.Z:-:SED1/&-\([
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MQ(O+IRV QB1K+75"AM"CXR_3<FXH6Z4QU>@/^K[**E>$7R@[^FT4R+7$7UH
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M$;)A8LYSAV,] E[@Y%H+N[P2*Z!DGN;#8Y [_XH%/C:G4U \/@P^ ER"'@&
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MW<-W7O/8/=^0ZC4SW;W1%;_U=]H"L;X$XJ&,QQ$@2KMW/"I:;%/'9[]XFWG
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M^3Z0?3H""U=-?)J:0E[M(>QFSEY?)!!G=B;"L=6!H-J,XH#6(?20Y)-,ULB
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M6,JB#]@Z%9:YBLCL^AIM@+XE=A&):?,5@O:;\6]Y^I^'0+LE(3;?^6NLC*W
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M869^*#+>CB0;53-[UH=-"R\.2=5!;U[BX8=Y)RRF=,_.3H!Y@+FV2XZ%_4[
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M;OFO#4%7JC*H<A7(>^X+KR@I<CLQ-$ 3I[BZI\#4%\!^-.F?:+UPTQ&^;'1
MC14+,?TS$*'. ;;R>WGJZ9=_WUS_6]S/S?9Z$;+A\HG<0Q< )62YDTN*1IL!
ME\]]_@^P_5Q3>'0&<$;KYX?;FPZ.>R9U')E0NG!LNN1^ISQG*WOX\/L$L!GZ
ME61$GM[Y[,Z@ 7MF[-Y0CIE/S2.?H49(DDB_("9BX /F0%_)@<LF0KG@R>B7
M<Z__1,L94'7"%6J $WN'BX)6O,;P9"G)LC9'[$/1EU"+.RUM?;[0-E<XTS)@
M8*<1'SSRKMV<(S.[27NVG"[4<5V+U*RP",_IIU!3,_LI&"8%>";\)C^<1<E_
M:6PT;4 GVX-BXCL>R9T9>]=[JRM<#,Z.3E?)[6!X_@7PXZ^EXXV[0>;V<%<?
M?@9[V@FS9E(Z=V40Y#MLW3;H+,>#+I=SASK&0CK=0=4K^D(+;6D7JFO\7C5[
MU5[,S_.[7U0\ZQ1=[N4 QWI^5)FJ5'ZW<G"/IUW(P+($<3\QM7'=>*P@ _@F
M47D479#V;-+OJIZ]L]8C7*X4W-$IQ9I/1R9:9%IB-+D%+BP&FN=7;?_':J=L
M DY_HH3UU]$ 3@/Y6:$:8%-KYV<OCKCX%I?-#D)<WAV@&R@KN_KMQ_,&NJ0*
M6 V<5U?A> Y=NEANZB<V4$6^"?*5_\1%%]TYAT78)E0)C/(6K224[8JQ0?0,
M-"EK[HP^REY":A#O>^9:)(TRMM8/J]2)D5).K9I_WR7L#R$T0$;],8CK>_8/
M!S80\!C:\PRBCMM*?#'A$*' 14T,./<5N'YYG\]H7],P&VQB!TW[,/$9.R%T
M%>(9(7H<O*[8^]V6&NP(G"XX#/:X$JLR?AY* YSB*EC+E:,!'J0=".6IA->O
M"GV7/Y$*O#DLC\X@^PJ)XMNLG*)<.^4_NI4P.U8O"H8L>KP"L\HGB54.(Y</
MOZ/##$[#L$1]HBN3ZHIC\ON1TK'LQ\ZV&9#=QP8NQ<;<P<)57OF^02,B,DD+
MTS%;PAP*O]O3 )U0M1T:H,WMA<6X;:R\FEUU>&.^27!B>^="BC47J[]W#/&R
MK]*3\5G=%T?QP@$7G>]A@2)C2C?G!]\65@3<AE8*9O$-K: .4II=2>!/TS0
M5H_ZC'WM:;49Z4K2L&?4\/-A/1M4V?WA:VR9TGZA*<Q0+):?O D!;W-< Y+
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MH9C_Q7-G=6F%2,;S)7HF%[:RCZ=N_=+P<_-)2?&EZ*K,)3^].FQ5OGYV7**
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M+NUVG8 /.;C4@,RS_,2REX K "N7Q.!A&W,2:2@=:<4$6WMV(XTH<D)7];X
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MJ+K6B-<+)T(D%>.%I'ZB @]:R/&VJSF6V\B!NW5?/9SO$^K!(\ I,C(:6!J
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M"@7V3J_??_>8*T01+D5*<)RUN%M83;98TTH!?L(L5HI$ @!74\:XK;UR%Q_
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M6PM_=%1$O-_9#(85$*:VQZYN-F[+U>QDRE*ODS_;6 G+V9*MO=:RJ:"#P+\
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MI>K:QQS+E<8/R4(C3J^*]DWS-XE*3USG.4K*XV'(YXI;90K.%KF+$L4=)GU
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M=?$CA#YQN+^3+1<;% QIN&$%7*R-A"9I$8MKHP!L&G]_8NGG3NL(!X6A+6R
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MMV1)=;D.@9=OMT)L2R:PCZ.A3V=J:FZM&N4N"GR1@<O'N%ZIL+%)3I:K_66
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ME*ENG/R"H>_C0)"^[^*EQ>G34+'PQJYZ]#810BP@%J!*,L='A$Q;?6,:]0Z
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MLP_>#2JQ%U$^"06+JG,</!,\Q10T$->Y*8:G/C_U$P 0]#+=0\N)0/'P'QU
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MY@HGRDT2MP*O3[^G(D=YNED]FA5M"T'J"1JO;;>FEX &.W<?C+>0OEOC_G^
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M!]L3O*4S93IV-[(P3L"+ R/5W1L!CQ</GHWXWL7DPF\[Z):M&S1P>*4&.4!
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M-"Z\J[I" RU-(LI5HH2=E-!EFMF, Y:TSW92-;(R ?Y>;$=.92< ,=EA1*Q
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M*LF#!^E\WE6$M-?RC3>$"CY9:XC=9(C3^)S$3%1LE,TT#BPU! 1RTXD6Q?N
M4YM5P&< ];]=V7,93+<5<I[E4SA0W^.U$_&#ZEK:75$;NH6@%TYLKH:]8Z&M
M:$N5QNH9V0%ZK\3O[@?^>6U?M,S%LWE'U9<B0?P1 H6-;^JTV"^G* E0W=)0
M;@FF5JNW:XSLP20V(8_/.48I$G3\9$_F)3>%9$MWZ&7Z,,I6X@,P2-3B&^QS
M#8*M\/>9(H<[QRW1 3;9CAKNQCQ)\ ,=SL#.[5&,S*=SW2&2"Y.5=C?K347Q
M.:\S;IRFV9E] ;5"]7+%<@RSJ1BO$\!LR)]+:KC/&_*IV&K-A5N_(/_K@.:;
MEXOQ=&K5VOI?.,K_!/#I)MY\JK&9]/U9>VOH!'!^<4,B>R(>.[7P[/#JEN:;
MT_])]@A![-$P,_X_ROU3K<\80\*?2*"PD^J@_99EE)VFE]FMN!- @&;>?H;6
MC_5L.5^_33ZG47'NV\6%@UQTQ 2/>H ^-L\@I.A(?Z8F=%AG,V<EC+U$*OW^
M0-)0EY9-^W(H[6.7\9!<6Q?*ZVN-NBF8>=AIIS?TR<W4=33N7:B3!%.'[O+S
MN53?I__$[7NJXSD2VZ3*?!:LE9^BG3R9:8'SDY:TM*I)+NM@,25DUW_#"(>L
M=ZBJEU_$%)]S"+/I@LAQ?.[0L$M8F&5JQC\PFZ;:LI5FG1WVTD_K8A.V\GWD
MOWWWZ02E!3('+<KY-.L/3G^7$20;.PE,!?[J7M-O2]C:WN*4,S?M_N('_GW.
M5R!S";L5$!S'Z\7/M3)F@70C8?M&2.9K*Y%5:TKPC'0),?@WXZW9R6 MDV5@
M6%\VU/@I,3_Q?& 5AF0N0=!@]-P0# G<46UHF%V:EGA4O1"9N*)Y%L31NSD]
MXZ46FE\CL'$VNIRUPK4>UX>I]]=D\W$S=:Z$J/)JA+^:V]K$$,_N+K5$G%;,
MG5GI6^TG7%P'%ZX^!T1[]]S-^5"O0'HPH10J\[Y.28Z_/XZ]#!.PX1,26J+!
MIDDW3O*XZ8Q"),<IA:4I03V,+YL[*V^DS@L>@+L1U[P\U[M9%=<Y(N,=FYO\
M8)<LZJDIWM,&_#F6=#MJCW R,[*$G]-0&<H]L)-^!N@!! >^SQ(?K2].N+9M
M7C@R^&Y0&E(__%1&IEEMQ!ZNSW1]K5HPEG/\O,2G(5HFX,T)8(MD5H-=TLLE
M=KNC1#.J>O>9F2Q1;TP+&\3$='$8$;N'XW;(AL^(MSDD%GYDF$=(7&:/(VPS
M]WU\3KU09C2I?GJ%H=L<U:B&E5&2_?+DV"*V$3R#BE!<!Y-@4L71V-'=//#B
MG4#^X">5W_P=7=Z6)AVKX79=$L8],B_[*:F/,IFU32.T/7J2@RS&GX.F)OIN
M> ?91V\9K: V7+!N=VD:;*--AD-BOH"M86FN6S*B,.?<8$?0H^WC?D["0%J(
MP<5S)<#-ZEP='K$0+]]MP<P4E_IK*Y5JA3 EI^]=F.8.XY60,&MNO!74N%FZ
MI)XHL6';#9OZ6<&00]R5GWUUFBP0QVL0OGFT\=-@Y5VE6+='S84\@[F"@F+"
MVJN__'1]>P'1)F/UI\JV'\,[SYPJ]/ =+Z%^&%NZ9=20&RADE?5D#;JZP#D9
M%9N/+>YQ.. =9U/S6,L_5/,F647H4>1SUYK0RG>G'0O6'ASPG0"TA#=++H=5
MAB<I2_O0I'ATT%P'VMWTS(<4"*ZXAY6B/=-<XDU.]9D'GCWJ6\X9;:;#](BT
M!"0RL7_8KJ.>W_0$$)F=N3"2?/WINL2^T"(FFMBO!,S^H6)1YL$ 4V7+@3 *
M>V)%M"A[ZC?3-J1WB5[OT372CL.M/]CLZF@:_U_4O7=4T]G7+\QO9AP+HC]$
M1"DZ4B4T!0-2'970"4(20D<Z) 000@O%L: 4$X82D!:&4 ()"5*2T!VI M("
MA!("HE(2"$V:(/C./,_SWO4\][WWKEO>N][[GK_.=WW/=ZV]ON><O?=GK[T_
M.^,Y=-=:P> F>@,RTM8;)8O0O.6% %8B%$7+DWK$^K\+Y6]45W>Q;U"]+B:.
M(B$G$@L2"Y(65E84C2+%4@BR;CO3J<RE@932X=&:;D?#66VAGRT)[_['PI6J
MP:_'QAQH(4/ZH8T6CH[@59YX,M8]2/C3V4H@[.<7K%W]PV%?R_!6<4+1 ZPW
MYH:X9OGH0K.ELKM>+^W=P*3KC@%EB(/85_'#>"Z6A@-=]-SAC#E9MF5H,'Q\
MTQB$CW'NO+X2N5/0C<J3K]U*'MJP'>$&/" _C[ QCR8A$5GBWQ2)])[,T B_
M^CK:9%G?OCFO401FF(:OK.^@/?G<$:[F1 0PS]AO] +B+T1+6P9P+ZE+"56/
M(_MSEH7Q;V:R2HW9^]D^,A<V9><@)X[B+3-2XT/B3N'UML-,@H#ZDJS#%VEK
M(R^:,XNY$YA<VK9E;<'/3!%3-+*">EYUO>]I;@5[%2C5C!T4#]U$^(26Y]SR
M.6XF("]C_&:VW-X5N)8.PSS+ZV%!UG8=WQ2!XEKMU:)1M%L5CWD:58CM[T+W
M#O7+G<]!8C9@)OQWKRCUKV9G;#):.]P]\E]#T:]*JIV+&%-H%=3&B$FO=R"N
M&]:85YC W?J]^/G+@ V _&>.4Y/"AXCPZ=(L"7.%ZC%M94:?VV3@=OI;<UN_
M9H[/>@R>2(T_L%3R/(+ 4R\+9T)=),&-/.7P@V;JL+X.2Q/I?'CV%/^%Y9C=
M2%,Z'29QJKQ9'.:4\R&G[17VV<JR/[N@@1_G5:F\@F[=OR\/_'V2/_79,?>E
MO>YP&4S<MM6N2OIKG]L3:QQ*HTK%S]BY>?>K@1J?<#LC<Y#JUII^KNAN2H%Q
MK7Q6/NW@X$P7U2+Y>I/UK/N/#R;'S9WI;D,!6XK#Z-RE?G,G+E^I6\?1YCXE
M'RC=C ^IA\*LUN<R@EG. 4$5'&WJY+XC.WLU_D+?6NJS8/FO)B'\74ADWV*&
M[^BHI&'XL63F_4Y_R_?!86J0:5@2P! F;B>]LQ@.EUD\-:DD8$WQ?6Q=S25)
MF&\2Y_"2P"*]Y$LHF::#%!>R7?Z#>?3LZJ(M9V:24RUR(ZBY<8CYK++*YZQ=
MQK9^7G_H6G!04U/VF=@!1U;#H>^HMO0W+\Q:R\O=GK-G;V_C&V/>L5>ZK>GP
M4\M;@*0C:I=P666V&?#R.^\:D\E@:S)F^ 8OJS&PLSYE8>9MU8\F)R%X>N2U
MCM&,08G>;E>.AIFD3*Z[&B9H+"#/?EDJ$QNH;:$;*<W6F'NWHKX:(R:3XW:B
MU+I:4$;Q:I3LB6T,F* @*>2/Q;E/ %V4!S%3Y/J,L*YN=7,\;&6QJ]%P9#20
M$CPNT*]S\*A@[^[EP8-'TV\_:HO,T$C N9W$@\ 7-R.C'TQBHKX+80[UO\4=
M_R)MO[XUYW:^AFL4.?MG/A(,G8?,3:!%F*B%5$_WT)II-1JEJ!G:>(DL9;3X
MI(M-'X@7E7AT8DWIA1S!;=],8#&+BB\OFSQ-';[!K%JF "*1,F?%EV6DX*I6
M'E'TAWB875]9@0$,S_GE283\[STQ)BTI/?UNI&ND8GJQY*%2>7&8K>,'\6O4
ME3V=[T+S?+GLLR;7^T\/6%.#.>\$?&B88V6QE_T(QX/.;TD=K!.&GK.VECF]
M'52,?S=>\CL=MJ';D]FK M,L>&77VKF3E><ZR67"M*<8F95H[#K<FKT:9.@\
M/Z>5[\<.<<,":$LP,J1P1KW^R+*6_49W:/_"T3A*=ZI"#?P(#P-4/7^FW%]*
M3F<^]I$<R?RCM-]E(H#!GL*VC 5V!O+'2,R]1ZT$T7F?\J8"M\4SL;M8B N:
M9"U7U\=.>&IN[U8%W7B[%@L-\]FN-6,W/71N^@BDPD*;#'*1]B3ZX6WUI;%>
MQ4*$1MZ:;86(LK4TUS <7>6I9Q98OC0&Z8'ASL-L[*KJ1DX#+S*5U<X'+T
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M#=VP&S')B1UIN-A%PI#)LN>OF3?)LEG3Y-.N>=!)H&3/&FAA-MSA2VLF[.$
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M>+LT<CN?\J0LDR1!3$8.INE%)3$RJ11FT2S0=^CFZO/ULXW"+8:DV9/?)-,
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MC]>.4@H%9#LQ[R-1EL.K@^@A5!@=Q<(E;+3H:'9@@ H1[A_+^,'J\+2YP];
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M-7/?_&3Q'G2K:*RAJ\Z@=EBFEULMJ( 4MKH?[MMEU1;E$0D3SC2U$ M!/C\
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MCGG?KT2L?*M4*N?0W]S!L/D(2MD@W0LM4/N_6'O/H";7KFV8>V][W6Q$I*J
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M]#.A U>5-=U&9RW!&)^PN'"2=7F@SB#I7D:>5_/+]^WDX=8H]\>Y 4RH W2
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M\M U\BO>,K\"7E#U"!Z("E*-@,T+_YV)T+-1KB1BS^?1) :&:8[;_X\4E*%
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M<I*=Q-EQ1I6O)335 20J0UF5]@X(.&[H4%-D!)KX)<MR_+:$2IT\YI<V\,Y
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M\K5 C-C0CS]D%(?;#*<*G%CWZ_+T:_(LEI>JFKBNYW;B=%)K:''A]%CJA68
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M5-"+V>2X^??6S5 $RS2J0V6C_]"-F DMS*]E#2R"(H54U)>%O?R.@IX?31G
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M,).)#I?)2E&IY(%?7)?!9/>&(>424G6$;J;MZ#1(C6IX/#"QSJIGTBJG<B&
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M^J8FO>,X7WA&02IKEF7J#2.6*HL:9B,D?**LI&V;Q6 ]#2(!H<EWZYR"K@W
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MAW#B _AQ/\A,H5S#:4%QV%GAE:HVOG1YD7OS$/1C9LNC$+6NX-#"7)VY/NM
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M!?;>[RK?X:.F*X@A.8<^5I03(%GCEPB#FC@2C/1"(E%[;U--,[Q>6K5/XU3
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M]5S?S2R\],\P>XWD!-X=I?4*I# ;9KYE.5'V4 /OH=2:[-5$DYD:"9T8>66
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MB@$69+SS_K/X'$I+^LN)90>AY3: FN"^$6H>KO9/X278B7=EXY9F?+?O3Y3
MPWPMFJ'JJ>-UA!#W6<@&^8EQ&*U'N&;FKH3TTU+/EZ6QIY*.SS9U&N%&C5;W
MDA2_)WHW=_U8<)^.&=<'%L6=Z78&&J(LEEFL#D1*]JV(EI")U$-PW#Q40GDD
MQ%E$K?.O3?V*<WL@5JF'-8QI7ZNS^XB(>\(<!*A87UTL$<^J3M6D./XH\,?*
M\Y$(_/:FAVC5STH26$Q..AG:#^:\$!=L@'+-G[W;U\Y9G;V#?ST="D:,2P8-
M$N_-,1;C]_Z81)]5SC5_PYK21-\,B?V(IDI6_VQRN5QM>?Z:CP\6JO7+Y[#4
MM[&H*Y,&OM+375^X,0OO;\G57S'27AV?UFP5E,WF\RZ ]5QF,R,HY5/@C+VZ
M_/BUG4W?\]?^RL'TT\'7=ZK.E0YZMIDA_>Y#GX<#4\,K=QUG*?B\NVTBH$Q_
MN]D *ZW;?F)YY&'1ALX^^]G@$/P&:Q'Z5O0@K[-?G3*U&B;B5(1VJ<Q(+CB%
M5U%DL$M4RL,5T"GYX%)L=#!U+<DBTA1H;[+![TX@B;\[YXT?2P<'_X4!ZQ$;
M,E$6RB6LE]W#Q N8#*:?.MFAW>$CY TSS[IM/#K,UU&,]OGY2L0Y#',+.K:<
M.:'BZ,@(RE&UQ5^;B.+;XA\R)&C&1)MQ3\BV1HS(UQ-I W4!0VU?T^DIZ=JY
MCHM8+X$S.Q]U5U,S%&D/HN,C<CHBA[5Q<3/_3!%T>R^\YD44X87/QZ.IG((#
M1<3LS5]Z53NUL^7$C1:#=YGK0[^WPJ'3A8Z#OG_M@K$[#^+8!$\6M]$)W+6
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M*M__F6L-4G=4FA0UAZ\>Q^WB<L>'$?PN<;03Q=;UCL>)% ]]H ,5M+OZZ88
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M<9 F'@VRNBJ&V0[^7JHG+#TM$'TI&?FLU8A1U_N.%<$Z/[-K0<Y>%=II CF
M*02&!E).($]"*=]QA^7SDVJV(KM"1I/9U0@4Z.R_]//R2)+5O1+MTI\F[?MH
M+QI$D_5ENR6:\8]LW[1:E;H\O,[U6<VBJ*D=7.6?Q 5C3B3494GK*L3;T-%)
M5767JM4"GH-WU[;= )^JF[#)6,)4MK1: ,X4U3WUB=_FR2K7V1&3ZH4S^D28
M,T85-2(INNTW6S+4:$%G44WU2,+W\5S5UA[5H@\MA9+HX^]0"X>I-J;M9]Y(
ML.4F/#)Q4A0P:R(LE)5[C2-0HN8#L,OS[K>'C^4+("Y6.B&.C*<WH3>C;65>
M^S?SQ;R!9-&*JV/2K=<X-0-!J>%H(_(9G!$M:J1$S*Q.M<^BC=J4M%^,GOGV
M2SF1-V:B$+*2@,IE>O/6LE#L3_6]/5,][-J+I9.;+##$1<=(5E/"3_,=3S-W
M$XYO.+0,KED5_YNL%U8ZVM1+N6RJQ-B^ !M4QTUWYSAU^F>TNW^+E-]<) 4%
MI[33E,C_@*%>_Z"!+,U=-9V)T7C)B]%P^-2V:4;[.G\;9?S, 98<DJ9-^/=V
M;+<960W=8/$%R-DX 0M^LGW$K"-+6ZO42>6Z</C(^G#5+5'\;[15O 9_RI0C
M3&@_<SB:UA%Q[20KDV\^6I<6DIWAV=3=X]>=&(,QW%17H_%RQ1ITYH1H('(;
M+E[=-JZ-'SS^F=]7)QA:Z9CAK.4S)BJ1[O!>E"8H7UG@U_%LTO!E#'P2%;<R
MU%<C:OFCM.;QB,?ZL+O,*6R;L(F:XHC\?V Q[IR][^G<0Y._M]N(CJ)9:-2A
M:.]S'2/J&F5:=.KK'7:MB<X+%TGY_W#HU94OJGV1QA[(1A,641.<,Z!-DLU%
M=+U\>V_5,5@;7C0X$Y?"JZJ3:WY5T"Z[N^GQX[W>@R.F,2P33S'1&;VQH[H/
M_>&CIR5K&NG]765H" CNLWC3L0L>HZ5R_L.CS,SI(7KEKB-XJ('Z['JZHU!B
M+OFUP_*0CDFNIONR26Y.^\O;QV^>V)9HC'G7,V&'O0U[XX9F38GF,Y;02):J
M@9672#$PB),I"V/DN/3HOX9"R4//Y?^]">'38!126<^H4I++8]\JSARXOBJN
M!<;?[1LK?7Y>,L>[H;M)%%+J7GAWE(K;>E0&>C.2O(([SL<>I[;E7KH!W[*?
M).I54*=#.L8<;HMZ1D)35V(>\\PX2>A\@^S?7%Y7SJ5K#\=R$V*7;/O-0.L:
M9$^KU++5W28L="(3F]S_P'4$CAA#&'EK&QM3R/@HS'\WZ:&OQLV>0"_>5YQ9
MCSC77ME[:>7DX+;G4*3:U0=PR7[*7<<#-P.D=L)/ZK\,_M*@I#%#/_E^^=ZV
MJ=!)7I@\?3 \<VGQR_)-E7E.Q=S1B>W$F?FE,L[O2:? KFU^,RN*WK GA:E2
M8KO;OY.JP:4HH6?IC_\9L31SG]N2/;,V_JK@'9SVN<2$R&VF!('[9MX.Q;O?
M_NYNC7MRCSW4RBJW+*[W_!O%,GR>*.P5GO#4*<(UE9\S&OXX;/'JG[&%/?YJ
MPW$=1PV3VM$=J"SE=AN') EYE.TY19A(Y4PG$Z9U'I/F8_+'7RE7SN0<*5<U
MWQ3DJ[;VJ@^%TY3,FOY.$\\CKIB(O'WYUNI-N$[<BTK>4(0ICKFCS.16;[@]
M+Q"[K+G8[J4GARC13 $Y=@T)2FK\8D0_+0:+5"?OT^QZP05]6YRQ^.KZN@'O
MYLY@DQ9B._BXQFHPN?&2JF?42F\<5?X3^[Z7>)!>FWV]#)5F=L*J"$B4;@0O
M[@R ?YS&#TUOGQ1N#]O)4,TN$7ZFVSQ:C7=$1=.+7J5GOXP[I-CZ">)CR=#G
MB4,H8F5XYP7>4S:A,[/WQNH@8TO(ZN)8$MF#T.>H7J@:)26_KQG7#S:OSRAK
MJUC+NMI;9*'7EQ'A:&7_F3Q6L8\0N3E\8D=;*0E]]L-47<-M(L??:^=M%1[V
M?28TAFAF:TQ:F=LZ@U0%PRI:?)F>"XX["H>Z';)U<3NF9'3Z3,S,(E;U89$=
M34?E>^= B'^PN$@KZ_=8OE+5.WE58#-E@G-0@U,!KN%Y)%&_.4:OY;5L9:QO
M1XNB7'@X'\/B)NJ=6$QU32RVOD!>AS7TU<7YO7*_0<O/;3FEE??NCZ?YQ1\+
M7:^16_'_(^27Y/YYS=NTH3&I.YAS8LOD^.W4L<L_S0KMP!LPN987NW6G30OS
MB<5**Y[LU.;;;/UGO%#],(U_.6#+9/>AN@/JIF VQ/W9]V3/@;:);F6S%G1K
M_,=\\[=M/9"O"EE>=KO*@S/PY_']U ?Y4J+2R*L19OOQS,5>=%#-^X?R(4P5
M-F;-,WG;&;B-V?:,1<[X?[PRO>M0UQP9<&5TE8P;_2973*=#,!W75;)!#R(@
M 4E:MB&QESR-^EZWG$[(8'<CE6+3Y.[WBM.N;W?@K0T:Y)FEMHQFV3AV']H"
M<VEV(035M8Q$[%G;[SD24MRS@;3Z3#GGQ\I85II:0D<HPK5-GKPZL/.?U;K*
M=9^"8>_@CG$'=-/52=O5I2QB8S@8+70]C2UA+L-'&1TWWAR;M%!U-##9L4ZI
MC(]CG>L<2XZK#7^"ZJ[&;'VKF-T'X^W/JHI_R3+BN3IN*/US6<?%070(<Z#(
M&ZW;_G%HR[K4>;JFD>&;[T)-K=:JXPE#^]O;H"A-/BQ8,=[GF^I:#'?AN4!Z
MAGP?()YX$=]6!_;O ^GS7SA)^0\F!1&=;BCMJ I&7+D6/P4&)F,Z-VQ?Y-XK
MR83.SFE7Q[;9 #UEUI_';L-EV BUZ"G 1[\(<][MH%(D?&QJ:S$_#>[=E6\R
M8& KQVCJ[@1C?1BD6>';WAOS\%%SJM68^AD>ERMKE9!K9&-=W39.53.22%4W
M5XM-*. *ZX(?:)YJ$:S^#,VJC<XA/]]78HOL<-<<,]#HTF5U4>*#QU6@1EDG
M_MZT07#!:6:TRU/?8&+@1X_7[(7/HZ?V(A<6J+/HX +DSU:X%T%\<OSTXYT7
M35(O-EBG^LN6ORS'N>^7!4PVZO;Q6!HAFYT_V%^3>!,!A6[JF<BKVLY\I'->
M<\,Z10]@K%DS.D>%965*([CT8( )COWV_#TSK<7>G"+R/_NJ-3;TXT,$NQ91
M LQG%A)8WP'W)H00$LZOOL%G5#VHKT;>)%&=KO<:HAI81%D7/.U +^X,/J]^
M+L:P>,]?5DO\7?;C0"!/,"L7YBEF4E-SP#G>?A,-2%7!._9]Y+;*@3)>-NZP
MA9L6EGR$0G@R:-A=U1++ I!VJJVK01S2.%UB^57A^&]6Q\/&7FZ"9MY?AOKE
M8%T,&C5R3ZB0+^!Y$_- S@4>7.#193:A)5G&GM1&?&CD8'2M$+)+*W.DKM7C
M).*5;B8.4  :M.8.0!3QH!.C&Y[..^R2CD8AAEY\=2LV1#/$U,XDSR?Y0::E
M_OH\0A)5I/X;X8=W+P)P#7.88 +_K;OKL@V"@ITTZH0?7YE>5M<QQ;&X%UQ<
M[F)\7>Z^O?Y$9#E_TQ"Q);]YHHW((F2Y*BXG:?UDE8J+2DAM7++6&OO.7G8Q
ML//WB!T)S<3EULBZ"M8*EY >R@0(W>4T,T(MQF*&EK:ZB*&QT<)>$MU4DF(Z
M:^FWWG](' ^[.6;I/^@+<-+?_L!WJANK[OLT*OD7^*3YN^#R?'_,UDJ6BH2C
M!"^ :;&@KF1Y?:5UPKA3F(CM@SM:20A-?7:]'3Y-L :CSC//SVI=>^? 1 8
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MGS*-8QE^6?7L >,4[W;5.XOUA5=1?A4IGM1B>6:#ZN33'"![^MDM8XVNX:+
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MK*OLL2\-P5R&&0/\S#_XM#+'C*PB9J[NG*?SQ)3R5;G%(2E!I(;F@<B$DD\
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M#P&52Q)"QEK9Z/?P5/+L6Z?0"H5E-EFW&;/K<EJD$X(%Y B\J\3P"U\QGQ;
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ML#>BBE2\IQMU2P2E4T9-VV.]U5J52Y9"AOH].8@Z/H<NNH\+K&H<&_#X-6G
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M4I#H@NW>,1(8C__2'9,VP=4ECR<Q1WC<!D-(>*@?ZVFHP^2C!DY=J1C:0$'
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M>(0N0$]B"5'8)13&UE]-K^+#UE9I,MCLN8NYKY=B&EEO3><G34I>WS[@TCZ
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M]A,HN3I7(N7EUT%=T,&L"Q,>C5,6/ODYA#(P"&JA5-IB9,!?I4TZT*<0\,0
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M@<*2"U15=49Z8[?EX'+DB>/FWE; &.L,X MJ31Z:9$1QE]%<:HSM%@"/G0
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M ["M\JFCPFATFZFZ(I2.9AKKKP2)%\',*R'K(GNJ2LT^A9I<R%<<]<<YK$D
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MIN\G/]V.0G<%@^#.D;_':4*M?]6G!G/O4B:^O+$?;RQ'S:O,#&LURIO #\\
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MUD9\X-IQ^0__^#<9OJ6A2G^FV="16>?[%M9TDF_1N/IQL_;OF9&\#<F#Q#.
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M7 (?FW7",V(^DK09_+8O),PVSKN /W:Q[Y)WK*>O>Z9<W\/!**$7\2?AY6>
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MGUS_N?#_L<KG?]S!_?M_8Q#_CVD:Y'_?J%WX]VK@X#7SA>=;.5R'XQ-1S)<
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MTB4">_)ALQKTZ$FGF2)D%>X%EWM=^2/\>\$D_!=GVC>^@C8Z=P7K6L)&W>0
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M11_*JIS8P=*](/[^Y07OU]=F9TS6+)+RJM];*[]4>1Q XAUTP6.?#Q[U& ^
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M"_6$ #]-YLR*SQ_4S[>W[9S(\3:M-GKY3N74>+-JJCW8O?K>XN?9^?&4MF7
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M7;P05F*5%1HN'/A'1+L?)M5SM;PQ=@D;_J&RL]KM>:F@"T!81?/1L#]T/SD
M>" P_'@_;8NAXKDZJ"K=E40>^ 3$Y<<@I'Y7IE=I$F4SQA@YMQ$O6'EY";'9
M-Z_&4_5%P$7Q,=]3MP4#?;T'0C\,?[;G*<!#TGVLLQ\+2<P"EG7(2NWMFL^=
M@36(A_F8EJH2 &RE2O=:$Z[:0HSO#)?X(2NPHT*,/M<;?,OKD$?$\2M@J/:
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MW1>4&\(/BJK;LZ6IC::>:W"SAY&$$%.;QUGS$FJP?4N/[&KK. :HC:(DX-#
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M01$_+*'*249YN.-N1O407C:?'\[T#8M(T#*68=*RRLUVDN?97%3W%$)[$);
MGR]S>[7*?@];]/Q)=(,"A0_DQ_ 9&ZM?CJ,2-Y\1%3CK/ ,1<\/8M+AK8RA%
MR3B. 1%-,L9"MZ@#)A&5@(61V+HK?8>F+$)EU+J8+]/?BI6X&T5+P0T>L?06
MC0]X9\6JT#+6C, (0LI@VPA/SQK,&)M/\@Y? 2%T#)2P,0)E/:*>XJ +0ZDF
M"[EDFW!NRD&/IQ>W'MNP>#FB">Y5\"Y6$\2^_"K*+VK1BGN$X(+E$\[6IWO:
MWQ,/EV3'CO$X5,(=M_::#_$@O ]-O51FQ<J *^TV;B2@%19A3S0.UW.H-/M4
M-BBF('K]NFKI+M0JQE")I;*PK/T(TW88NB\U(E0Z/G39 AB4H]""WY2)=U75
MFE%YX5JD:9NZ0(PZ!/CS+':Y4*Z@M]Q!1U+O6W3@2C9>G4V*H'B[5\NFYY6
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MKRZOXE*^50?3):;UI7L--];?1<^P!*)YJ8K.QX#[1D?.<GO\R#U/B]V5J6.
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MD'NDC@%%/6SW1(B8=EN22%EO"HV)DK*K^JJ5O&#6XUZR@<^*TI 7UA3!D@S
M()8O&]>TWB"*]L_[-^/2N)(>;#='OV/CSBR9ZJ =W+2MNK&NLVPRFR":,C\(
MM=IXUV&NKUV9SI*HMCE;%0MER/#*CN7HC A@RP<D9#98B9>TV-,TY#V4_'M1
MGLCAB8S2S^JH):N:D@T.U"P!J"]4BXG$ADT+D^CF&QMO/NVD?<67CMHYK=RS
M!\[1.HCR[I&Z.JM$E6V0CENM.QWG3PC*,2^Z8*\;G$KVX*/ E7R. 6^RB!U&
M#L76>"HC;J_$D?Z0<43D:%,[NA$21;K^ELIA-7]_.CH_,_/()QDRE>G6Q=&[
M!(CM5WH[^/:N8%5,VR#TGA\Z8\ 51DE+OVJ;SIQ77G@,",B_T;<6&/%KW  B
M8J9I/]C&3)S(^H-1&!WNCY.I/.3YO(J2AW=J;BPX'?9+[C(E^1T#O"54?E0)
MRTUH-KL 3>R#,4!P-:#TYG)B_CLV%G6J[LB1)KZ<2BX:A>K2U-P*Y4-P<Q#(
M20[KLPOI[ZN+!K3MNUH19I2:(JB*EF@.[4/)(65TSN+T,C#MW%CSZKM5>-$2
ML#?*"R.L!>?F.H2R=(W['$PW^QPTN1?:+MR9>Q8O,!+'1U@:\+!-.W_:H>:#
M]+2$5.^26U1B,V\QU!"BQ() =JB9;S+TUJ\V-X5\]N E4@?SG-C[[# #$5:F
M^J/=%;O8[3V04,KM4969L,MZI$"GW,\%1(W]8X"2_M'[8\!'IHZ/V^=-TV"6
M7&$/0N;MAC6%^BU]Y'%H'_VH SFLT,ON8X!18O56SE[Q5)UUV1WLW<SY#'>S
MWUJXGO9X&H9MB^1*C*PW33FJ#M^])!Z\#';.SGL7HQ3.<WMI &N;FG?FG_@=
M_AO@Q+H$IETE^N#]]P'_"RCOUIUC0&. >%:[XL&0##PE@"HJ&YF]KT&50=-L
MNDJJ;0<$L&V9=@%=)5K09(WNPTS;6-P?"%V"A@[<.EN1:.W\ =G$)6ZU>.,2
M!\D!V5"18ML!BQ*'J]"_J_]=_?^9ZG;_6*1V[)W:??PQQO?)4C=KLM?CAF/
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MJ)\9-BS7/ %GV7^!.-!,FG4V.LRC<;-HY@CD+RC":8]R5QR4"EA)=N&K,,T
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MI:?IAC%W<H&P4/##LU'OQ>?LUL:?7F=SA[A%Y\0F-O?AM6(*H%#(5$X%O?Q
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MD-#R>-+==^+@);^G$GRNJR)&2>3)1<$/G#H_#5IEEAK;#D182E';+KQ( +&
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M-8G;8O&5QJ[<9S>CLX@U3&S^YTG02FT^C?!<&SK?>A>+I@2C4X!=MI7[C/E
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M)95.$>-QC,HY\KC#AMN@0$A_IWF7<1_ZE/+RUW;Z^CG;87&P>#G55V!/Z*,
M],QZ4-8F(4F$X?D+3L;L1#^=V338#EF7^R'W5;JPQ)[$H-:>!) .9Q6<]A^H
M*/'F.'ZYSB?2<%8S[B&MG1MU&'QO#ZHKML*T9Y0 -G[*AT"8_ *:R,) -75W
M^C<>I?V:UNOKWID!%35W)@KSS&NY)N[9N'[IJG6:5LR\=>IK)TEU9:2?^1?
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M$#_-5XT^)ZT<1-8$NXV>S<W*Y:?AC*"U%M;KH:P.Y&95[+B%)J79L@6WN0N
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M/(:D@-&[MA 5)\_[J3TBAU#LO*< PA&.0QWPC$RHZ 0_(/B]D1R@#0H7:(=
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ML:)FT,TQK4H)U3]FC^B=@ TN;9S=4OA8;=@[YY8#M?8@,2V;06?20-QR_HZ
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M=_%GO6/I2[H\L\KNW5PS H AD.V$SW%XL1?Z?1OMM&OV0<CZ>'M?_ZS+,F$
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ML3@A$)&FW<L"RZ:-M!8.#?8Z4$UG\YXMPJ7NI>=6NF['VE.)-]:3V6^<Q_O
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M<GFHO^-J^O")+]4'W=>7C++V\U<NN-87@F_M+,PM?^-I_<G<]AO/Z_<?D%\
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M6^2F"B: U)H9CW!P-HT/SF:CO1OX)H_@BD3#P?+)E>#Z&[-776>RT90;0[V
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M>,U[HB-Z_M$S"I#,]GM3T=-%2=0UN=-TB7<N+SVBBCYK$2?8+X^T(:%$1\*
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MB74?/H< [0MY.4&VZMOC@1BA!K6@<?BJ5F\!44,/@D*^ZQ/6,'F_-/=,1A+
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MT9][Q)Y*O<WX0VBMV%=G%QR>2RR9.BL:>J,$..*EJS89E*@TC"E(PU:SEWA
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M*0IO=D>15*V%HIC6,%#N0TXG>H8T0W G,:K7OK%//-9:ZEC@K$_H Y\%TW_
M=L$"5VH= 08%A6GD'&=B6*]X\[$@F_C/Q$AB/TM57*+>;\-YU3?(=NK@WDP,
MI-\QJ&J*5-+'$:[Q*P44)?T@%%0%@EH:?D9GK#0Y%AC%FHS)E8"8XF[2#H3K
MO[AJ^.[,F_J_H>6]OFSM6/TD?;J"QT;*-UWL<Y^E&/2\!16GFP"T^%VO">M3
MQ).C_[H@^;\!K67UCP/R+9\KY&]%4:#LJK-MBOFD<$IZF@0&;,H'A>I+)(+!
MNK\S,EC[PM%,]?KW$ 5OP0#2AT-@@WH@5C^G.OSI1)&'>[$J;2'6#X\R;ILV
MV?0I5W\VU])F?WGMK*+D$#R&!I38:[,9&:8YY@5J6M3*6/4CM%6,1:=1A'7C
MFMZ=(TC;]__:D_X_<3XLYAE=$?@YI4CS&;KHM[8TO:?Y#>H1B[,:%4DB$8FX
MGG;"7&W.\E\2$7]R+CQ1O. 0-56OUMXY8W?W[1+1MI1@T?3W9I6JI(<W<!%.
M(A4[NA=H.S__;U_I&"PK@0X4+PB\4 H*E$:9JBA!X$L\G-6SZ"[?:>PG":T$
M?2JYBAB/TWO*#*"110K\ XW_.JGN(78J+<#(MG8[U2IAU@ '6W@Z/S]O1V%#
MP4'IUW&D2/PBQU@K=GS[CV?S;RS//]84]</*7AGH?SC+M,&FJ?0%EX!@70[W
M_:29XM=*/OZ[=4?')SC*1K$WZ+/GV89R3[WZ(8_Z;Y^4L(]O:W0J_^T?BFQ%
M++& PW7W_(RL<\0&*_7.5^$KA7$S .>XC;ZXWV*![P[D^LX?H%7*Q[&CX\+3
MD>0/F+X+G-F:1F[@%7_ XR2A0=;":!2?\CHL<)%:$S744=^H="0MI)&RU_R\
MD?U0QX-2!KF=($7K_\3K'-LUFM-KY<PRP_1 3%AL>QO#J\>.'#KF&_SB,E;_
MQ;4_J;-Y\^N,S%3H1E_JE7_LR.3B0MI?*5$ZOSJ9M%5]-&S!B[\\*&@F ;1<
M4O(@@FDM)E$!BG$*<B \[9^*&NDT?ONO/ @CHY8%5@OX!X6_OED+P4R\^JKC
MX](E6T3G:52S&<R-Y;$PF$)4>% /X)@^O._ S5]<RJ:2H?G5'P]W'OU\F/WM
MSR,'C?)QAWB?7US;GR,6G*M;@I-IJS^35+7JZC% 5K*MQL.WZW93SDGG%ET3
MW.0X34#RK,&2"@+U9?#Q69<LCO9C+XEGJ/$B?U?/KI=QBX6NL8O\8$DF !-O
M,.8)%RQ-MS0%\8,N9%6\%SER>[(V3IG&QZ>U&1YH$^"RW*=/ &K?B1[+Q/O.
MRQR]M\KZI&>YRN!>?W(&RK(<CMQ+6V&[FP>V7B(!:/P\E%AF@9/P*-H8TW-V
MYU_I^(/;Z7(D=UI39>U^)(EV0C6'5,4V=0!JBV%$GL3^:)EE%.F;,UKZ+0'B
M<DGH%7/?OZZ>7.<KN;/GWOR+Z^OI*X79.F<W0,ZU(@T"5=5"<:+=VK4D0#E8
M^W,<.2AU P4<<1=>(E%F"80]?DW#,:Y2QSV#[(9FO2;HVK408D,2-_7S<U*(
M &'6Q5=XN$ Z8R:JTX*!9G=YL0'S)"K^8L>1+@_9+SG)6^U%0,'OOI'%;Y5K
M[,J@J_6& ]),.O5%'%QEBOF47"SEKOEC7>'9 /2),+?2&X_^<CE^7K]/^@\[
M>4 +5%2Q&L@27]-&A<%A,%/HOU)Q^8IZ";X[D^$6>4/Q:C))3GLANW5!ZGV0
MM28O"B3:#*(B ""*O2=T>C#HKV-<)F$/_YZE IJ__L/"VT-'G/YOWP6]_+GV
M?B_M"]<QJ_'L'++"<YOF3?7ZTZ-KP*YYX+'DI102,T#<PSM(=%JO\1BR:O5I
M!@L"MM<MX#HBX#N2,WMT=LM_V%=U]T7=([CG]SRW^"^WC[W2?04. G[ES< O
M$M:7I]_+_O7O,<ZSCJT]_4%-T#V\]H JV.ZTNM<?(/<=<Z%A5O*G_4:H-3>^
MX)MM/OXI<VOAZ9T9V:FX#5;<QL^>WQ;?^2CZB^M_'81,I?MX\9G5TI2$QQP)
M2W11>;N#5)/A"F^)]:C<<%.QJG*L[HB(&8\(IX:YX/GM1/K$E3><\@F_GN/2
M&K1=F(N<:)L<791\W$5Z>33.Y$'FOCW.JWIK06<D^_[M8R%(,:\.#["1 98T
M1W*_B@=/M^O3A:*Z31LWMOPRI;ET[:_L*?_POZ8L=DXR_$RX? /:7+*?7K%K
M+2&;"V9)X@24B_3%"0"Y^#;6##::D%N)1"O^*RM_4AKNZ!V:^O!'RBF+]8:/
M1_B ;9:)55:(B]>A(!X>,7EOY"3JQ\P4 A3$+C4TYYJAJ-U7/.7BMY?17M>I
M/W-X0D/FTO47M8&D@MLV =75AK[U*2=!3I^7Q.X_3I<86(()@V'!C-9I_KY2
MN)_<AJX31A?FX8F$F?&;P2Z,73W_Z7G9I^ R2UM$>FURR<F^ME$T*PY!AVS(
M'F6_ATC",/OSS:-UZV&"_:V'7+._N-;Y4+^CJ^/\2NSY_FZ7Q$Q^:\,$Z_2(
MM<Z$_1CD<OF#L,+\5]/P!PO^=Q!TM5QT!XK@Q4Y,Q$LS\XD/O_TK![O;06"I
M+;8MLM)<Q\&3$K;!4DE2SHWOY!VF!(FRIBA0&!@\161>N7ODC]+K[]NE:9@F
M1 ?0M^Y;7OQ^,B[!CV5>\8F21-I8^<45 S4.THS3?AW(CQKH<^#;B1.>D-?A
M1I)Z>YO/\DK.4G'PRTNDC!3$/R%_+II+"V?C8B_0QGW-,&S5)2']_. \<*'0
M/3[(TK@K*(,TRT ;VTW#X)JF%A28,>C:\S\$W;Z"+<QF[66+&OIOV7TPGBC7
M-[;>OM2! >I2X7 )0I E,@G#=J3SPV 0>[>H]A?A6J1ZRZ=R-'NI.B>A]U!8
MQ>Y;Z(_?2]U]8")X [CDP*]QCFM7",D]O)KTZE6[2T6?#47E0OEI&X!Z@LS[
M6%Y=I,V8 3[P//7?PXJ+QQ=+C3O@;<Q7+G'4,GY1-[3@^=;!MU?DX=_TA,8!
MINE."X>X9#_%+BU-443Y_2EB>N:W.E,F]F]>2STR52HAM]KD_7@QG*]) (%<
M"F<P30T?83-Z,,CA&1(H#CR#0_P69^#[?SKBPD09E?#<K.8X'_ZLL!5]*;&'
M%UAR(F,#=7J*6;%F:)/1(!,<EW@V]Z@HR*P>OB *UC_K"FA\=ICC7RMW98I4
M0SYFC !&%TPJSE[7%HTDO2&-_.+Z4OG?#$Q\P&HCY)L'=4)O/F-@9/.0M ^W
MA,.G^&_>FZ*U6A0O\G9&7::8T/8A_CDP.*CM$1?7R:2.ZN/@M-V0J ^8-D(@
M,N1PU Q9B(^W&4H3[=%0 V&GH)S(:2B+'^0GG/V&>O9&\9_)&6"=\&*UZ,\.
MU\,1:8K=47Z;GBB@<(P3>MN+#<=,#[V_^M_DM*,-LP(6MJ79\CZ73U:Q8&8C
MWF]QN?C Z\!2/2RQ"D]%)L+--,U,/;AZ[*ZO)H4_?_!9+?W<I2JXXAI<SKP\
M@$J^6",:3X\<V/1 B#\=#5@<]B(-RWCQ^?9"&]JP[JEST^$6$FD2HE@L6_P'
M% I7N6/UQVG74)VMAT[1G?#>>MO@3Q>A(/LR549.<A3.GN6!4K;K9SL +\<:
MHW5UM;*$Y\S:-0#YK<'-5H0E$7@QS* M$(I"+MN16@6-54QL_+?\T79'OJ%\
M)3]XW7]<>8-ZHJ3>I4QO,VD)P?AA"B!(Y"4MPWS'B/TSY,'(*(+XM95_Y>+H
MI]ES#Y_(;W_$I-X1'DY8<2[T=;9B-C?L3'FK&C33S3I1BM6;*U"X&>Q/S2@-
M7M1R>;[EH,^A)%UW&NR,^?+)LB);A46)@R[U[6!6YE;_..?\5=?+V"5O2Z1Q
MSS;_#NFE/U@_P&KD/C83.V?5OZ@MK-V%6.S,9;\GO!HU/*N@(E^0%Q:+DWGB
MJ!Q/*\RQZ?_G0$%Q\<#S@UQQHI!5\%^5E=GGH$XBL8<CVE&E)6E;@%3'L2$8
M=BK0B#N2*>^>'QG=B6$GXZ]I\-_4%CSDFUQ9"3O?WWKP?TQZK9;U*>>%D.$/
MRZ.//7E0E>E) A0B-1:K.Y+];X/!?J0F9:9T9%0.I+0F(/W?B_E_\!_\!__!
M_S]P[';GN;?R16TQ'^N^[=>\%H+:?6=YYQ#Q6&S2%\;2DH4<R8:4509>U>I>
M?UR"W+-NMB^^FL.>?VSR[-Z;^=>MQ?-NH@7;QP4+3.=H!X-:^,-D'W:'3&WY
ML=D3;TK6XE\5!ZMS?*EG7/:TY.[/JMJ KKZ42[*]]00NE"BGW9=(GV_?N,Q[
MG6E4TJRQ#FA^)>\G:FN$KFK9>8<?-WS0(DR)78%WN1AE#C9^1VP?4?CKOQHN
M47>QVON;O:"R6'Y[M()Z^#C,-\^FQ<$U_Y4%,'+3%6<M'6N& 7\';[X4/W+B
M3OKQ1/>1<)]>__6*GI\>/U7$E"[)6=<5E4X"M&LR,<PT?[\M#Z)_3MU=Z57Q
M0_A&_)3>8\[\4F<C[Y/AM@@)1\_#I'X:HYU3LAY;-P(ZI=YJ*V'6"?_G9*M,
M;-;?-_^QYP_\^QF:HN-XAABZU&;%LDT.T[7^:-@(P]=;X& IEZ+KX;%ML@97
M,=F\JWWC_W(BX-V'?Q<QQ[MOS'Q*36Z-6O2*AX"A\Q1H6:].N2X,(=[ZJ!G9
MGHT_1C@F9)*JA>\[Y)ZD:-9ER!R6APB?2^;$DSV00 'Y=QSFG3:%#\66W6OE
M)BO?V&6GBLY"$H,?N;P(+M?]I,[$SMN*P'[8YHX>MQ7.I"XXZ]789)?H6JPO
MJ5*G^NR_ ?[/AAW91<I=J^@UAD%4T!M?:+U&\E0]6JPNRV[:_G<9)A7_=:7
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M+@F_C\6G2,:9XJ0_'A.<P2M&CQ0\&3+!BG[<_SX>[V'>@B/6JUG/]6"9Q1!
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MCEZDJDO&.R<(@7?,6<'0N3I=I9KP]=T>V 8"DE4=^ U;=+XQ_,DGLX<+SZG
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M^?6?=3YP/):0*J0^/\C[%):14T**T0BHF[\W]'ZZ,C(/':0]/Y7\*EP^H]
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M")F!;$59^#'#E[4--B%_Y6WWUAYLF*6)Y[ ]#V9QLXCI21P$)A_Q1NU?U?Y
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M^H:9[9)X/^$NZOD&QH>TK&D,R@Z$P8!*">Q7]?N$*2Q-VFF"\E4EJQ/OI4\
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MBWHW " ,&$,1C@I\F#%2?>.)G-V0-B+REMFU)I;BZO)[XB;Z!6VS%.7#Z%=
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MW,OQUPD;8W _Y.B![8_E/-T>SVTL?4JN,FR32ADXFKXA?#I2\)S_U_BP(Z7
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M#J-;*#&0'[8*5M4VEIBV?G4I+T+DW?<]AD[:F,:K^%$[EQ5NXO[^O)-A9)7
M12%J^7=_CW@0:&RPSQL%> !#3EL!^^?8&\H'M"V>O$2#$2:&K9W\0$3WV X4
M!I&BN(Y0@EZ:. M?]?-+3,UX\V./8Q)]8Q-\<'/R/E3H:DF)49WO?>XB#((V
MI*.B4B2G7TN>9,,.OUP]X]%<*W;0B:TRA9BE!"\%%F6[A5,@IA77"N)$?-!#
M=<:F5(3*^\'LM(G? &7NSQFM?D9RS)SC'[9>WF_R%80O'N1!L3D1]!NW)H/<
MW!/S9]T^WSNP]\>,T +X\VL+WE_=%VY-5@?T=:?<?9'D<N 4/AS^&&%=_R+
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MX%;+*2,3=(B,[GR)M\>>R'%^&A*"!6GO;FPVTRV]]!+AW:W>O&9I'*0Z:;)
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M3=2N. QP3M[6.NL?O!^_.$#)Q/RG">],WDKP3'[S\R9\$)=Z5B(\!FX$G32
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M[R>O]R&@(/'7-S& V"'@/Q9L\]2&0VP. 8M2AX"JTX].U_VG JUGJUE=%H>
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MBU\&+87_&"@9.V?]O5$DYR##J>+62S.SK:(4BB.0EI8Y[;>]0\E\!M <U?K
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M$W%JIG<)IL-EX2+-VQ(K>8K_8T5=U?8-J02W^=!LJ^V:E>&M,=GT%?0$[B]
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MIYQ'P"?WA3,X^Z:CA!)S+XO&)P>[^'O![?)PTYB*=00J"L\$DTLU2U'[_H<
MF:#CEM^TCP!!GOY+JDG ZT/RL$E4EDJ*T68A.:555*[&/X:^+BM<D!E([/W>
M!1:^<6R-;LQ?,7D7C*UG4\+ERI!N,V\+\D9G HI;/SO'#;/TU2P8YC 8C)V0
MB9/QLS_MC.5+Y+J/TQ_64*;86Y2U4XCAGQA"\=AYNQTLZ'UY3XK#RB.A2'"5
M>>OP#^*Y=.]G\RM)F\L#O)\$I?+R]?;Y#-)9(5<P2(HT-5O,1/;&B1;-=W6W
M<64..HK5/76AO('X%%8!%X0ET@C&2B8FQP]1W <-WIR,8DUW(B^T^%3J^V?G
MOR/KR_%RJPM>!-LV>?H!%>)1V=ES-61R_G#>RI'((!Z)C-V'>=601]<FY<YB
M_+VH@4F=9O,A-4/<2.5A<G3-,,%4<UHU"!!<$/RH(#CMF5>0$\]7U45'AGXO
MRTQKU=%@I'G5_[,^R-24][=IF @^W[5KLQ5,YO_"+'68-?M6W=J\L&A. YE5
M0'#6[+F=UB)7<N-!I%HF=9"9=O^80$^.3>2)V25,]K[9GA][_F3X?Q2F4OW'
MC9U7S^R9O.Q/IOYY_Z[LSKE5<[V%LRCM.5:OU_/.N(614J-M$BTZAB+]OCJ8
M5E<-WG5N\S@$/,FHFN3H0:+R"<(F/G$=3VC2V91EPQP8=@2.0%%(%"KI?3L%
M$/-:+>?!W]<")F33?%ZEI(XCN_2#"I.S^8IBK7/L8N9"P)IGU4ZJ^!>7"+SN
MGXCC+G RUROGH7/ST/_\";A0'U"INNA)S4XPE(@G\7^:;5@N0AWA"&H'B!X,
M*B T#\O6_SI[P/JX66HV^)YD5&X4G6PE+KNI#^ZP&X6B0H@1]4=4(&BIN=56
M/*WB9,FDIL8_487DY25\A7R;<)V+<$V/:-XDR-1@#=[E6_\3XF?\1<>?])P?
MGAN_JMY8*\1H7>FP6Z1K7[<%@/KN37$=:Z[V>'5#F*/+4C*56SI3RC^)Q[T_
MX>X69C1C7[8,PC;NF;4)<FZS,?:&N>:JBEA,#HQ(C@4E,TGZJ-W]2J#>/)_J
MKPM?IGJ[P-(1?0 .;-'U;Z>RV\1X_>JDUYYW7KK_7FGGW(Z?TSB%*/O<?)+P
M@B#E%Z"8U)67W@OKRB>EE]W^/*JNL1M6-ZK K_[CV#0OJZ>6E&U?C3CE35A!
M@+$5;[E!<'@7]Y\)?YUI^=%N)_*0J^XGV&^_9=.G3G_FUOWA.^X-?*$G7J7@
MH,[P3;@X5G:LMYVG:ZT.G6=!BT<=<?YT1G;"U6/3RAQRWVO1#JG??RG2N\:6
M>8#@WG+?A3@_B6PM?'K_)LO_-^-=EBP3Y;?5@?BYF(U7OWI9'F!]961!/27D
MQ_(O[<6RY$<7-)Y\O_Q4H7CY\M/SUE>7+%"ZL @\7BI>=7&0>055!$(H@NS0
M^7./CL_:R97=>,)&>#)-S8<]6:8%YMUPW83/LOSE-!0I'K(I(ZBH)2BB@Z2Y
M6WZY K^9QEK-S6'"5/F!-.H,8V5H 54.3B@^-KD^!+R6?&^\>>F&^D?]R.6[
MR!&()#^B&JJFU4;-7-81;*6$RO6-MRDJ,V<=JIQ"=7:\* T[+5Z)OQ.NR(Y2
M!Y)NT(NE"FMU*S[ IZD  /_5A#OPZ%A!R8-(N9KQ7\1%DT?7#@'#9[Q>Q!LU
M!GM"3*QG) DQN^[BE=".I1YD<&KIT\CANLXTCTL"B^?-QIQ(V(7@X=EZTS]V
MEH@@]&#,:-0ROR[K4O^W,_5/F#?\A$_8"V,CSZBO:IHL_HU?M9*_RTUC9@<8
M5=M&'_C[7AY_7*S7/XFV$C85Z@.IH"2N2.FN*#]2$4/[@!/!;3'3#;MI9]ZQ
M\S?7B43U@?GW>;I=?'J-F^B,//E!KYZZ!&&SG10!S,5O30["GS.)RY'(XS+)
M3QA4#3[5;,D !(7"4&%CJ\MG:>\[[P'PO%K\/[1AMJ&Y51;,,SIO)M_#Y;3K
MP NK/R=T[\LQZX-=(KX5.VC(7W[2?EK5M$LWUFO%FH$;GNX"^5$H\X,A/O\#
MNI[G>^_WJA='$LXQ$@B4'/FCTNY(I0;U_+A*(A^A*7KP+DVV1&(ZAI(:<VU+
MF4)UBJ%0W[FF33D%6-1$[[82*<! $A&==R-02VHSZ6*]ILF3(+:^OB2<YEW(
M7[Q1Q+VX[MX_YN$$3F];$B>,*O<L!^E?$*N>%/9=C,-$;S3Z1AT"M NL=^-"
M]6+FA8*(10_J^E=T[BP> LS%5Y_:<U-"]#(E(9LOCHH?IK)_D73&SGGU8"-8
MXPXZ:VO/RZ#^H?L_1LT1'TWD;=?J3QAG(FAQ\:K4]%6SOQ6#3)IM,@4+;>VC
M9++T87/)ZD*&_)UQM&7"_# EG<"?!6+?=A\?>0C=VQQDK'^IRDKZI=2SL*NO
M(S8TJ>&'SO"-WNC '+7NK/7S6\>[LL1.5788BQ7SA=O(]_T(<[)9%JU]8 (5
M3^XU]\"EE2,LG1V+%(WR2P#<B7O$83!Z?R1\WV]ZZVGW]"'@A)5X,B)HY76X
MPG*7K21VER*;F\GHTDB.?_#*X">%B,(3@8'"_<><K/,[D5!THB;89?7")MLZ
M]%CDKV^W_4/]+)3;4, 0MI)(K'V]P4^F5Z K<?'+P!O.X^F:7,[;06.Y=8YW
ME5CVTE#I*AN@^!VIQ;8.@L"_K*D#@M0X4-FW,OS8>,\YUS:IROR4F?GPN[BO
MS'$;N:0 85L6FD!+ZAB@(B#]<2RP3#5 B"V]&_P!?.PV)N>#ZA7+? 6SBA!R
M*).46T0@D^.-F?K+2%[S]AX[Z\5L<1WPKDV;R"$@0*Y_DL-\!.W^FEYO+Y)@
MWDNG[M8X>Z'31U%D-C ;2)EOAY8!7C @'Y+O3'W>SOSI\ F:7VM.FU/@MXX&
M3CT?7(AWLJL6FIK.Z2)/;:;QJUV_<VJ6Q!?)Y435&6G3!$$+G<7@6NKOVM'$
M^!&._E6_'1)QOK,T06SSV/JU;>$WGY(Y/.-[3*:2JSWE8+!B;\Q^E9.C4ARK
ME<($D8D4"BU]"\1J>AY:S)@9!K]5X%^@]RI?QX[D>_'"%F;+J[F1(GX5:JA1
MHWA4#@$N2J-X?@!\MZI.N*&FY=-P R=J]6ME8(+BB99)I@2I?NECD)>[M.)W
M%$/<:>D'%T( \>"<#UQ&,Y^[.9*&SAM"?./YS&M);,1EC3PGH3AOFVR*5G-4
M=(UYH!0+&I>HJ?U-[@F]S?U#WQF/->.I,*C>SAU3LZG5! 2%,5KH#T7HWG8&
M:(=U=$'"*F!#-'__K4U>I0+E[MZ&!(@L?T)Y.ZS+-.S<,Y=:?Y?O/P,9>^AK
M2?!JA.Q4WELF[+H,+P*I2F6CKAS)XNA\X",Q9?GKB6><M\4\8T[V7RW^21>M
MZ3*C!QK]5!F39",,EE6@'7![GB_65<@V654OV,PS@0<%3<KM4JO5+ 0+IH$;
MHMOV3Q&^N,9NF*--A4:A1R31[=B>[-6W56;M4%,>H,R,4TZ"H%"\TR"9/$-1
M1 $5\!&E+:,"ZV-_4VE)0<<OM$1.,T&%!4X*(///0%!KX0^1$@:Y$([%1^'3
MDC1X[PU^._9]S?5BN5.H\A'G;%4=EN<W<K^Z*),Y"Y**7K9@5!/)^2W!0"!0
M405F]V 8@"[(:)8[^Q*+.K X5GR]_C;2=!JNE MC<25#R;WPT"(,045W*B8/
MA 3!V=.NAP .*X=,-M5E2'3<<I7-X8SFE.LL(#]UXAVJH$ D3>>K,^,AR_:&
M%8_XZ-7FNKIZ>8Y_O]F(?/PELU-XLW+),$*=.M7RCLWA<GO>.2,XN%N2'SV2
M[<YHIN:%NZ;M'GNWGO@T]DV+$4/6AW3^71[#4/AMP*<**^""*H/"ED3*9I1:
MT&+HPA0_\R[GL0LW3O]UU<L_Z%3#(N_E5HM.^(446&_Y.HB7NX5M\).:30EF
MHMN0_K== "":R??EE+WS;:77+C]=X5'HOH[J71_$9S*61NCAG)+;\XP1(C;S
MZ;7UL0LSM><9XW?A_^R8??354R4E%B6+SK4(2X;N#K-)+YP0B8FEQO4L@"8-
M.5TKWAHKZ/GIM<73%>23X1>>H"OV<D/<Z^KZP>O@3J3=CJ*:HE=&9&:'@LCZ
MCO:(Z\'/^D- H%G'GM1;>WDR:2%#NGUQ5U"PVJXP<Q&I,CU(:@,$R8VTB AG
M5CF*:,47'%7V6(.KEK]J@VL*NZ)M>[%SF4VXE!H5MG%8)'M;J_A /&QR[X^P
MQ; O!S%36AY9*\9Y^0N5*V/[66G5V%71X,S7Q[Z51$KY>.F.1W_?/EGZ\U-I
M&VR!W7,9MK&2VHZ&#^7B1E8L&WJ08.SY_^IU:P#N[Y>^"%19-LOXGHP\UQ)6
MYA!T=5[0#4_O8@)U_7TD$_2OZRM:L%"T*98IA3(U0TKZL.?]J8E_6^C\YX)/
M%6>*DF(7:2I*PV.&6B"]_)K2IO.$'#9LQ\L[,Z9Z+?JI3V7/"!EX%?4MGA1/
M4KNM<K%<I$5@JJL=@TC(SJ8 @PBW>3=MIHRO5$.1)NAJAZFDUEFS@95SS=P(
M*+9"KPX5PDV)RF@^X3BQ_10PH^TW13-P9ETNL;9!?GK0E_L\7UY%(3^!BVX[
ML\BP$KD0BJ>L&$753INJE[BGX\<5Y:JP_AO?AK7[%9(X%V:J+5H7B SA(H8^
M([1AB240!^D"0;HXOYQ^WJ&95?P@\X_"C_U9K7TM5E)^)J(BBQQCK!JQ7H3;
M^TH0->_Q_+4.T;>?++%LQ_+ZJ>TV%RD8[&OV8LG5_EBGAU(H<4N O,7B$5T^
MX=I4(RK(_5H-'U-H_&= )C/0B]!GS9"1/*(9E"VH72&%N=%%QH4FCBO+5H43
MK0L$GX]G,UJ/N%LN[$4^!1/ ,A67H#78;;KV(GE@4UY_G2K[K[I;7L+$8C3X
MAL,'OA_FTMR)?$.HE;/>5"?9BUDMQ-W1F9K!QDT+2ND#K7QJ8I9RJ#@/KX.&
MGDH]:UMVJS9SV8WV@D+.ICIJ@VV&LK-WLQ6?D-Y %B]P#4O-_#RI</^KPY*R
M"HA04;CR9/ZR"K=L(B9-7EG:P\,/2)&U[3!*[R&(%ET<]_@^+]"ZJ&#18ZIS
MYCY0'6MHZA[-%QV7FV"=PL"/J;G.2T:+]Q<A31$P\W#DODR)]+1? B4S^2?J
M>0?<2%V#6" /0<+S^Y16>@X\0Z$[">_5OW&)%VP,^:B*170//M>'L< K1%*N
M>6E!T@(-9HR*8Z. M"@BF?=_(B(YW9<Q;9VN]B[A-8> ']H#K)]]ZX,O,+T!
M0@%:#^#[*6DKFKC@9"<OD?6#:QO"%R:';T?^J.-SV(I<\?PHBY)<?TB!)^M\
M+-&-&]3JL->BTM[O^:GZ'/_@NJWWK6"G7J4?)SJ0?.">2_4,O2=ONWGP "W6
M\'#.K@F7*G9$_[0[ZEG]<BI!KBW>I4-_KZ,#:C/5C=Q 1YDXYR@3#_\[E0N%
MPQ'=83=/E;5T''7JKY'@@T]'G?))^+X[13OJ5/XB4NSGOXS=F/YK%AHPVQ\1
M.MJL>3RS[[5\U2JGN?W\?%9MIJ'(;M[CMD%ZNS!Q>S$;%37UWUT]"A"[>R$G
M3\+GY+;L9[$+![DVYVL\S@91DRD"*=7?C;%-[B,,_ENW['V62R]94>5V\.=P
M&33:Y8CL>)I4@HQE32$&K@+3?O/'U9:NF/K-RCQ$]=D^*6,X_*W+8&XQQJ\(
MLY/G190DJ-QVMM_5;EFZDU+Q@]/FL9OP\SG@>V9F1+QA/OQ*_TQ ?,*5"GV&
M]3*O[31;ETU7&?[ Z?TZ7?N^)ON#ZC!/C%S\>P<J>CPA.=YHX?5P$T3HLU!!
MP9'4S!&9VDAG+E(6WG>Z1%Z;YKI8;".'I81+E]O(.&:_>XK+8MT6YH[UF@4R
M_-&F1T+3;DN[^+CEY/_,4&II:[<-:Z7V6]1Q3E3#^*GR&-/2KEZ).:8"N=""
M J9!9G[?.R&1R2$^IU);N"ZN]T2FE;=./RY(')+U^C,7I-MC>X4\(J3AIX8>
M):?W(/W9U<7#'XY]PSA)%NL%65H]:!((2?BI?Y'Q56XH%:214M[5RM*G(W39
MJ-]?W9QS&S+1D[XYN-)B(RU *W+BQ[@MK"0R3R"#_?0EB@(OPTV,WQ4#0JM%
M(T8BY#:Q5,A)>=J0OM!M$WU]#D<\GX0?6JA75]?DUM_B&/Z<-LE2V8N]]K0;
MT%Y^H53UP3QKU%1N_ ,4A4(OQV97VZ%Z(?!9&G/Q\B,A^^/? Q/WPIY[5X4T
M/9YS]]QI-;RJ8))@Z)*?_W@^YW5IS:*D:;!"G)\;^8B#2V<%GO'9>N0CC1CQ
MFVER"N#B9.J;<R+I+):R5&P&OH68H TA'!&=@Q1I(H44\V7@_@6.5PS%IR4:
M'(:1U[1R5D1368I4:U<65&?<-D[_]U12M="H]7Q;\<_@%TF6)FK7>G=Q I;Y
MBMO1*7X]+%" 4YUSDT3.ZY4Q,"6F/3CS_;%+[B%*0>&DZD*4@W6+Q.@+S_,I
MJ)2;>'S,@59K>AG2EIF .#^.,^:BFUEY6 S:0$AQ&4@0YR5YO( -[8AH07G@
M</@F)7_[II"3^BZDM>,OFG^*)CK"QMX_]P%<-$!+MZQ'SIT6B\GQ\T(!*23F
M?"<4A'PXPIQ,3K\Q+JS-\_#OTON+\B>OY_*"9E;Z=/+U%2CQF= .:,<R"^<_
MW3P0\7)"^9GMZ8;U_K'8A*F6@I]^YG<\\@T0'M5JY<TS#%Y07,W@XXLW'$L&
MJ](G#ZYAB$-ZO1]W ^:&PO01]/( Y!WWG!1][$+S=$JI!:6)AO=__7W@=J*E
MB60Q4I7W8T7%8.&UFFX&>3HTT6@U0.J%G;??7#1E6T)".BHJ>N6F /*<05/Y
M'!O4DIV3"(/UT.]^.-,4NW^CY(+@V&7FG:<9: H1GNPZB,XC14#@+',JND))
M4R!.==O,V>M4\]#Y9 _.2'>/2WY@4>6W"&U4I#13KJ0&O@Y$,;W\YF*RW=)?
MA +85C4O;QS76KXW1!\5?%=7;[S\]8Y$K<PX?'E SNO?VP3_ @Y(FG-NK/DN
M?]B=,LM_=JQR'NZ^J;9H,S<1US)5ST72=)=T0S0V$QX=VWM+<M&$QJN""/1J
MRT;2ORLAEG2G(FK^RQ#8!@BVK6\+U2'N7I]]K@0_/7+GY&>!0:)QK65@CI1'
MW,8DQHZH%6=G;-RNP5$RJ7#M%^S^$/;2)W]QOP*^S1"S[H!N*"MGRC]^8PJ3
MSF2LV*%J\L@ M^');TU7-_J6#FKE/OE"<1CN&/^WF496(WF.=50_58BNKBXB
M)T57=TEYJNATJLG+P-.VWQ_RXC._SP2@_0N)1I177D2@4C?P7<@&VU'-;B/@
MD<[)5I9A<&7O5UL9A\(W^7%=T#OFPLYX"Z#;;V3%P/FAEV)3?L6NB*]6FLA[
M7217 &OLI2[QJR??VF+;^Q7!4(%N[>1GE"-:26K^P4W8/FU5K"?VKKBKN="_
MXSEO#PS,;2HJ1X.'XHFTM"1_=G+D1*.FYK?S8:F6./&Q C%DC(=\=,70B^1>
M_5XI/W6]AYP)4EY=JWY[[5CFW/NX5P"AIA,^LRD#P:_[(\7&EW2F!$K_E*OS
MIW'8F%YY%5#RKN0AY[J<)VL9M1<'59EN(Y0^$K_"/=XJ8G6?:;E2]LL<Q>AN
M@2!.[2@71NC)BHVTP_Q0;" *C\]H#8[-;I$3)E@Z>F@\]C@:RH(-N'KY9@M<
M2Z\47(C.8"(8H].Q4%!/BL/J3>X=U1L76V)GZF!C2J<N>FHMY,*W>+<IT3)2
M&8N[ZY*\ CN_!JRI$P]::L^4X"2+_APM[KODM$I LVQ7,"UP%>L=NEBU9?Z!
M=+EH)Q2Z#2CU]GK^[7]YFO;_)W;,B<CT.RLN?^G]L;T?A*QBMW7+NOL]"D]O
M+7K4+U4= E+.VT'%E\PW+TB_V);_><HO5SZQ?^UGK-@=_J4_\Q*4MSE_GD*>
M>NY)_[?NN0!4=#:65X_"_Z3O_O_VKIS2+DJ.Z>QV"&!FC!33$?N)6Y=8Y_1X
M&P?877L/9\P/ <U-Z_K#K=Y[ K\,]\OL#;K"+LL^'^T)+S_::_;OWGMA7TB'
M ,*+J2PJ9#..OUOR=-G8\D,]&_<ATLO2E ?$!PM)PC/KYC(0,_JV?,? $.O>
M,?C_]F[^WV4<:J3J@(TRMO%WQ?^Y T^JB>-M6"<XWI67K2F^72_7:3V]<GJ6
M5)"7CRK@:;H>OC <?P@XEN9W[']TZ_3_>>, S?:#IM[C@12%O,Q&@=&NQX47
MJD8H"6=,L>4:=CN8#>OHP?=U3U-C$A/MY#&U>[$.2-!0HH<[Z8JB?E4V^,RT
M3>,)[M;"G'JS3CYJSBS58"0O4,HI<?>NV+"53J[J(2 T?$_OA;;6UT;'Y0Y-
M_IITDY+.74-DO:]0355)N)'GK]U#P'ID)9_)/+1N3/R7J0G[E_B/0P"Q+E_C
M$-!]5!4ZR#N<60+"^3K_>C7T<^T0,"TX5_7AB:%_0;W9;;%\ZML"0]&\\,M.
MX9\08EI?.QQG0OEK8L/XPC_I9>_RCC1O6,J*6JV-Y)9O$U\1I9!%<<-9/'6.
M,SN*^V_GN35QT#%QZ73FY$/-#N55]\H>+ZU2TF[LY/![@*OU_]LC\_\]H]O&
M01$)6$J1+ZF&$+X6,_WSP8%@4<+\" N]4HM(QXET-X3[?#^8G_!3I51:#F5O
MH,,%Q][Z;U5UA8V*UOTJOGS;-AYJ3L1FYP4'3UPOY?XY5+^<E]2\0)&7Q%+;
MVW\@'C[KZ>L9>O3[6O*CSQO?3 1&X1#G&4AM)::I]L(J,"(^8>A2/@_%)82R
MK ]4("H5!3H>O/A3=65B4M<GXS,\!Q\JBJVQ63;KERT,&-5'H,EDPW=QO.2Y
M*9;0J/$&@<>X3Z//VP=0Z<?+ I#EAXGHD7G0J&AG.D],J<56BL6=:J^@Y+:[
M"]17_NT(R-&A<4ZA&1FNLQLH- D?WQ5\C*[VMZ^8\F(,2C.^_0?S@_EXZLJ&
MT[G7;^)KU2L:!B$);U\N%%@H+*NM+!NWG^4"D";>H2<Y8ID*%_G/%+KRD1O&
M0K41Y7\5>NJ8]P:H+U)%JP/M,N-4=Q]+5;X9C6!,7%";:/9XTW!C/;O_H,$"
M>VOG7A-0=SZD93(F,8F7!T+@I^,NM-<_#/BG0=K$BCX-HMR14E/K!95=[TA4
MUZ8%-C 90E%,*FAI];C;T9]HPP#0R+#X82O?U.=!%N5#M7,]"G\U\//_^J,)
M:M:?:V".[*EIC>_OA0VFE_MMH[/G_\IW7<>[Y?9X6S9@Q_3RR8+E-_'N-(E=
MZ@?;ZP/NBTH!SNL(BYSW$3W>,844RA")$DTYD@SF"*UVXRE6,'=[#="?KS=^
M,JQEV,6M_CI#6'3D"P3"XJ&+]-$1"&FB#A%X3#,F\.W$>II:,0W[K=46_I1&
M&"G8XK+<*:>P/TOZCXC$PEA%7OD4Q2/] ('8@MFI90.@)($B87C#X.N"LHNP
MDHSN '<5IKN(31FR.K/0BZF05GWI@O\+B"Q%Z,Z)-1E/8V&/O9K7OO\\<9-U
MOUAAY$_8$I8,Q;_,47%4US?H*&R.&@E=O872WPN!>;+U>_L</-XT6D9>N#FK
M:D-UT@.18[(5XM"#6<*)QM:/-0+_-M?W&?L\ Y@(>9+O4^@"D9^)JW%!)D\+
MZ<,YU#P7N;GA1:Z43 S<G\7M#[_-FL6&?EL1OV;[.DO(UB(B)MS<Y,3=,5.X
M CY?Y"Z[ QM%'8R*PE/(Z1_ZJ_$OY6MD5;A[FH+S6Y8<N,[CNNH"RU"E$"18
MHEP2OM)3N'QYYMXLWZ5.$?X[^.\!795W[B[0&5BJU!.8+@(BR9]FEY:8L/-[
M#0#^[<K_$9_F,,T*Y:9704:<,;D03(_E?%?X\]%GVLE7ZB"1<N6@;C>JD+LP
M_UIF_LQ;42_^<S&YSJR ZW*E7Y8[,74?,I\9K]X4M_@9MRJ UR^$VDP^QQV)
M%F?W\;SP1DKHGX!:P7=YB:$F_B8FC7'8HGGC!U6?!DK]RFI>VB:QST']$1I;
M%GE/?JDU[9N< 21NMY7+3^#5F89F;E)0ZYFLXJ\,SYBL2._S>42H_);QD"0\
M6&DD:O,0H!C9X/WFJ.GB\=-^N:5#E,5%5T^0J)Q)9O [I+"()P233AV.BJ*<
M7AA]WG!CO/)=..<:1YK2?:R#]7LU>6=>GGL6<(L*>QG_A]CVJ,9E>%R)!A(!
MQ6=*-1[%MTP5ZA'LDKX$<?'ZQNH)%_DQ+JLUT?&RG0)]&\Z3)0,<%D;X:*DD
MNF1%'L,1W$(=)J>70>!=EU0E&'_2R"C:9>4.+M$2_'S\@OQU>XDWR6>2\3+=
M_%K.2?2\]$*DRDC1 ]_M=1-ER8Z[U/J@0:'3-A(UW9?-W<8DC.@2%!++3P(]
M,'=\)'GEUN2'!YENGQ,8)M%*[[=GD6]+>MZM9,?#HKNS:PJ[1,CDS,6O;W#+
M];[Y54Z=43<(K7@Y#/1!PF=>J.[7RR(][SI0C5LHVA0:%Z8?,9X5R]265.87
M&@=ZR&K%WU6F[>>C;911*JE.4[U.V TH#G96^HC20L?>G7O%NB!,',B+]$/_
M,>+K>K7(DY/T!(1+@O.NUT&&1#Q_/&"8ZYI\EP#F)8T_U?DV@9#]JW&SPEWN
M6CL"!#1MOY?(X /ICC"$1D=P*L>]4$]ADK.7AEW&,R^AKO5:1K1@JYG[@Y'_
M["A)=&OG.NE[C6YO;Q7V0'&7NL[V\">''@*^*_)>R8&19O-^7N59A '_"97O
M[DD)*N(96/+OU[D$,<<41.!EQ ;#"OU?Z($0A@$]F!K1MD'C1S)%^W/F(=PQ
M,;0;!>E Y/>?V:%:IGB%%%0P*@L*M>CG(_(QA-@,>#Q++%_BBN)NGG"*M/*M
MH0Q!AXBUFK<BK;*?)5$7^77\/DH *PR2S,LM-W&\.-8;W)O_G,O,8<!_MT<$
M^7>^^1[\,:-*3?+:L_Y$(3O)LB'K:DD(Q+_\HJ*SKQ*XIFV\A8=(N7)-:[0F
M5PV[D[Z1EHN=Q7LEUJ<$2X9]ABGIF%P-N+//\M:^<^E::ZQ=9Y.]Z?+UE%S9
M/QR7]+YHO;BVW"9'6S=H)AX\W=^W #?CH^72!';+66"F"DIB@793^JN.%@@&
M_U-?Q4S5\AT*G  *0!/S*4#%$/?1![\=F<)Y[UPRE7!N(8(R8:,Y/LZ^NA*T
MDMUU>1TH>#_:+3OC;\Q^BXV0PC1JGK2, PPRWYI_FLITU4\/1D2LE5GL6$_4
MF/WV3*#1' %^I$2Y04N;8G/'O*8V7P-1V3FDY. ICVNZK-"$9G(?/;\=#L=Q
M\]@]/)4X7AI%J9585,H8''#P/'6R?)AOY,'[EGNTY(69C03=..LT 6*I,7IE
M<QF5?6KK).A6VE>.Q]![OX..=8I\T@CUU%=463%F4+-RXL%IYZ4J5]1"NB&O
M2D&U*IU>PE5AY=3EU$]95L^U#^CTN7CM#^(;WI.@?ZK./3*'_?&&-,X ?3T:
MF3]&FG,#C]TSAPD_(I]4^_T#"+@T#+HIP^"(FGV9;M<U^]#?E<_NG^>S92;/
M7,EXHSU985F4!3#I,5P@%LJ<KRX/.Q$S?/*F#.7WL3(,#=RCJDO#:L>@<VI_
M4W<)'>0@7"M'GR:YK 47T;^/9>)E$BZ'6VGZ7LDL])..D:[):.IN?M\3H[Z>
MQ>44)=]1]C$DSSJBRQ!X%.-:[5UV45&ULU]/?3AJ]]'Y;1B@GO<T\LE_O*:$
M$^M>\A_YV!^YU5]I9'<NZ:HGM/%&5@1=U$+L@/X4J.#QIG98(K4%1 /SJAH3
M<N!2WDP(!#9;#H+["'\0QX]@<JOOF;--8?H(?3C/E2=!F?'.! :W]0P%^_OC
MR3L+#[_^1V=6PDK73&E,!/[9BU260&.F A-M')U]]8N(\3BA'8V^:F+6X-Q=
MKVYN7^[][Q.*MN+Z49.U,.^*#$V$=K63>!IY[T@(!6(RZ/.QL^OHE\>FBN"
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M_E\Z%-VO3T87B":6C*=2%WQ%8#W7EUH;G/Y:=$G6XM/"TWHH\!U#VC>I^P"
M3!49<.XH9DA3,VI")G@OF6NS'#<NRF[-$&URPYQ'[WB6F3<3:BFZ4"25Q2O0
MF)U-+4."=+O@IH 1W,LJ?*B<;W3,;F0C9E!1$!SPD2^+L6[K4 N'M4E=S-96
M+5%=R8L3H1F"6*+M0M3*6_"5HU;6S';4.G)X"9:RD316L4WAJVO,$"(S)4<R
M0I5$PR3AN/^\\.X"YZO@N@A,Z=F?&P[ ?'1!/(68#&1(6"8\T)U&I_=5=^@M
MQ)"F('8C%[P9@"J^%5W9WX'KPWNRFH$>1AQM0:M'@<HZ-?7'FZ-! APA6$-
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MX_=78+@ J_.&LQ"L\Y;(_ ZR'XDIR(-7;NE>^>[A5C4S?JNE]%W,WF'FN+%
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M*%_(TGR78\"\X)F #)@JL(U=Q)"AXMMY3Y?0'=Q4#>6R2^#&*G8]>$/@?.4
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M=E!%\LNHG.Q#GKJ?OY&[[ H;F;<B%]?GSI8/C*RL!_<\32\L_$B5J%M#V^T
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M/%$[> _+33O!=$Z^2-P/;@RPB4.;K*5BP",#]8&-NRXXJ V)N<19*)A;B&5
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M[3_QG_A/_"?^#^-P]+\ 4$L#!!0    ( (<T;EE<#W:.]&T"  (I P -
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M&,VVX3W"^R)EN<=8<M\[?/,\C-*/=U<Q9!\?=TO;N-%$SY$ (G,#>R4#-K)
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M[%2,Z*#*&W==H';YW>5$I;[]3JZ]*!>#,3]/YIJ?83.W@+P,.AH27=P"P!0
MRA,+FK<+1?=L 5R90O8(CX3;@Z-N 1*KZ"33F38G$@+MKV7A;&QA.6UV!OG/
M%A#]XJ 0HSYCW'UI5?M71P%@FF)RJIK_X8J5H%PV1<WV $W* ]#)-QI,/U.D
MT]G4.7>3;T VQ?!L&..TFH)S=7UM^I6*BN1_<\Z;G3\RL..:JTM<S($$1/5:
M03?> %5)Y"JXTWM24?YH52\,<LH^B6M&6QN83CU16E:CJ^JF(7_).RWD94X-
MZ0<!-(%]V$O"C5'+;C3D@_1+V9=90_>#.ZMK:J+[+X\YK=C-Y,3\CC;0X5_U
M/)IOU$S5QU63VF&?CT:Q0;"!HP'UHB3*B0F0Z9"Y;N&\NGK.W/)$NW-1B$[-
MO@_1K(Y)*^2G>Z\;#\&I+H[%L_ ,?;BLYYE+J>9A)#2&T.H>^73AC->$8Z/[
MV0QA$;8\.^0*ZA4@=ZK:^RB]Y.9/.!R^62)M@)R;Y,W<;7$AMO:W3Y3\_N:>
M8\9Q$XB-7;(*'%HIA),W'+[^.UPO>AN9]AHI4Z\[B4I1U_I>C\KWWZWKJ1+U
MI/18M8".^AJ'Q3$+6,_1!"5H/YW<JI_,;7)LRZMKLNS&^QR8[VYHCV=8J17(
MW<JM1*G#D)3Q]0S79B4?TW[GT#Q<V\#THP'@E/45U%.EW&TIABF&67]7*+O=
M- 7PT$'L3G]UYAT_O$XW\XU\4P"=W,/X5X(Q%C=A9 M,%+.2U$NQ:EJ77U[B
MRHU!HB]H>%#+O255XDSK8&1::5' Q/5(EU?^N6*9IYY<[FQ^2W\INUH2  EW
MPJX!+%>N7 !-/]D\;"I* N5T,VPV<"&P6.Y!5;R=E>83QS7-M5RI3X:VNW/(
M!7IPY&S_USRM*_3'>D;U]'2,J(ZX5"2_D*IJ+Y_#!?W3>_<$Y?<UBL!!Z]\"
M*#YZ>-J+'-6^5;34;"5N)Y@X=<0KP"G@7Y3OQP?7[_6]?^RIJ7K +GP]5ZJ1
MKUNEAC2M-02)1G#"< .9"CA-)BFI40OMQRXSA*T5_D8TN-!Z!W?R>)W+H?7(
MH2H\Q7(+H/U&IZ!%H7T705]Z-K[YS&17T=.*FH:L8<\Y#W>SB\^OW *6*1NY
M4G]V'K[Y 2Z:@,&<O;T?*LQ$GDUWN,4>")I&U^V_E?<TL50@K%@4T-&6NU$T
M9Q(R8K7<N;M%==_U"&W1%+X]V<-AN6)*K\FOEL#]B5P%SREM MG?J4>*NX-%
M33)'TJ@B9A>RB]77&-D7JL^W/CET3,0*HPC-D@;UP5V9[?IRV% X'+=!P]8)
M(Y90P91S)-LI/03_UN5&SI5/VTT.S<3.6R'1TRDF5]P\M\'Q'+>XV0U'&9V%
M8MZA,D)9&FP[4)HY<P8,F>KV;(ZH+:FR:/@U*!-X+_^"C:!VOU8,RJD*,/U>
M)T3>!@<D&<F\C$I2(%8\)<5!QIA13JL'XM&VD>&).8-%Z&N]]KIW"(30]EN0
MM A8KU#SO&4Y2T^C<XE],=H_NP6FR$2X  ]D<N6H=/+"&)PC\BR3>*P42[NU
M49VY]JK@S<>+'JZ_V^-?=TD3SLRCRZFEJ(=AZ"3R)Y.6GZ$7ZXEN/RH>28Y.
M+\[9<#K?W!5\3KP$KZU'-U\9^BLI"4\C(<OC"QGDT$FP<3_FW5TTZ&Q'9%N'
M)'$)E0O#]JI!4^2"'JDO*W\&[SA<?#%I=^VGXSX)P*M[5YA:QZ4PTA,RK0JO
M@G7GF.,IYN8^4SV"\Q$3ZBRAG%ZQJ/GSNIJ>1 32@SN[!=S'H&BOMP 5E#]I
M+&V^!;_=<A?F?IOR_DB)[KZ1B4O!UKN?4G@W^=<-S;^CGQ.9H0J,6)8NVP8T
M85:Y@<%_H^Q>VUX5$11EG,KP2[]R['UTK/8*J9,D!*>T.RIP*:ETW'%R*0DM
M6S',&-Y?Z)(64/ @O2DH)7Q&B9(K-1<7-TSZ343#B_X)-TH4FTF8]V#-M#;L
M"5W&^X]VR;FXGMQ(4ECY%JV[RO^?0D1(8%+IU'8UW<G@]G2?T'>8V/A*PI3B
M+J=0S=80N;G<O3_3%/D&8U W^&^DI,FT2GQQG_/[%L*-!\R.Y(=AG\*KY #?
MJPRC#XD\HC58SGCTATE$M=9R[ZAI.%>IG(ZNW_'D)/>]5*[V["D\11ENQ7)X
MRC&RS]A2DM>^LOX%_5O&=44.>H$9@>>9&D"*@6.@^._DSERIDK*LO;*Q3C!0
MGOH_IF#EVN;W4U\-YT'\(\ QB^\SJ8,,[K)G#+$"V(]A"^YS+S'):>8A'S 9
M5KWG9S]\*"GX>O[WK9]R;]N/N"$FT1\/FG2FT4LB>_G_Y(??A&$#1KG;"))7
MSFIL[.+1V248">'X'8:![5&+T:TIN!1ZC&[!@"C&1R6=,+02%*"=JB6;PSE.
M#Q[-[J!^(BQD3'9'35)3C/7%_*L\ID:[PGRTVC$C4E]<_[V7*]7[];N7%-P3
M.L'$$JP'+Q:2 [-;L^*_%9?,1PJ8N%=%( Q<-7SW=PP,U;OQV<K][SW1(GA*
M!WDYA:2T!0PQB-!#4EW I#YX9!TZ=8Z.VN25;0'?_^';"-D"A$HOCXSB)D;I
M:.<@<13ST4E^E[GMKUH(S^G&/''\+?#N6OUW#&IE5)]%^J7//L9[BM/"#2&W
M+YJ;,:N<ZWX8ST<=KGVF&U50>75[$\KP8$__:..+8'!7,".W \5,G"<FD+?W
M_-X#X$_6^K1GXK7F34I?Y,]=N7[C)(=T<@C%JJ+;)VP!OL$)HX4/S='OQF;5
MU7LG U+KWCGRAOEC$'N>KP+7R*9PDL L?]B=[K[@&\52@@[<K!KUF#_E69)S
M*TRPEEK^:GBT0YZ.9X87,G3?WV1BCX#NWG<&-V\4R-4NYJ:TBKQ =R6KZKL=
M#;Q[-%?2E_T&QI1/]583!O5EH#WM\NZQXU5WTN<\YLO[QTF^%WIC8EB4GYM#
M>DP52+(3S'Z-R9('DVEXB?E170?!EMGXX@-Y2AU?''6BUM!?&MPAB2RX6'PQ
MB X\WR)DA.DZ5LK2*GWG;S#L)SVW/=F[-$6V@AIP^_(8.5#JQ#H1U _FRHI-
M]K12A\EMR.U&* D_4\3#>K$ 7H'$-#'PH_&O$U88]$W*9W,9,V6 8\^VXI5R
M)3@A7,6/K)Z8->.!\JZ,RIN7@JH_9JNV[<.+2>&$*:1O,,SKXKD**U/:7-D.
M]K<!G#(83+$4&[I;9V'0MW&K8D>M@N0-YU;<G.VEVV:^\LL(KO((Q\F?*$$.
MFE]*++Y-';8\TK\G/5?[M^?SVW^:[@J\VYE#<X>3!W$T*!C<-UW]DSR)[",@
M2G:U =%[.5=@Y!S(T?E^H-S99/)6[&1GB8)K7+3WJ=H4Q]T!_[KUR-<&<U)<
MQI\XSHR2[5 T K&R(PT53!W9/=8!F3#93_,NC4]T^?D'FB21O!\R#":3=;]%
MAJ /P%<50=$RX+NNP:LMU=)HP!J*P:+H4MO!N;WZ$_/GRCP)6C^3152C/@'M
M+E9+:'@A!1NW8R)H^BV/])MQ<GUZJQ;\=@];_'RV":;)=QY1I"WC"_V!.6^D
MOO$*BBN/9_/UX6EYU$^WRB:5\E-0TA?RT7],'D@,#CD8Y%N$DW]JC+OWGU/]
M[+G([(BQOU7.Q\W#4\SP 4@88G51P6(6-F>K:DOONS8&R;8I>R>X7?E9NMR
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M/OD5+D+SL2>B!$[9?7#*NN)I9&77A5B6&21/:$%*V+,TIHZ1,\TUL,\J#;:
MGMT:9K\R>4_;+2*'>D9[N/(S[$W0.K_J8?U%#FK4Y/X/W'>#PUESWVV(]=@:
M\:+8G$LA$XVG8$LU<2-H0=PV7'_.$;"8-7:V.E@.?<CT.,E_/4CU2<V]Z^RK
M33.Y\INE>)AN*D"=M?'_/':>:CAV4^OT$[M-LT^F56[6M'<4Y",@TI4KLP5
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M1J"W9J5C3RCZ&8H9MK30DOL3J\KT;?/T5 Q:XZ%.F=K^8K4K, XZO"E9&4]
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MWP,_AP\]W-EW"//.L.SG=Q<++(43N+@,JN+8>UW^@:1^QW ]J?[XV^*4!HW
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M4R"4G+@&\5OW^GG5[+HK@38G8_0=IOE;234/S$.\(M]!O+2=^)$;]][S\FA
MWA'W9-,\P1U_V/RVA\)7+(Z7("AQ..#4"&[P$S,DJSGO2$4:\F$>HD8\P,MO
M_&:0['7M!Q&*1I?75#.&O[[;3NO7Y?XZUEH0'!8*H$A_1SU/]GY?]&__I)BU
MD66E? A!F7$:\L-O"*.W%_ZA1UKO%JSY#.[CX!;L64T* G#8@HT$KI"YHEZ<
M%$M9;!M7"_05:\+Q_QF72+]<]3F3<?CJ+AVA!GYJW""-Z(3PQ8$JR(5V&B&Z
M87=_%3R.*U9+[#_J[I"<Z-9]*]LNWO49Q_XHSQ_D!S);*H2JP99T:*YC9@'#
M*QZ?ZX&Q2I<PXJT*UK'W=TQMAL.,[/<QRV68V5 ?5K!=6["/OJVI@=\LC_2;
M.PH\O"NS=\PN\(V@]SDK<^-G!N3>KVW,VYPX[E[N]V.=13A@XEN=QOVEM8?G
MA'_<W/]W^.ZEPV^=\C76"$W+P\E4;!P#SQ5U3VCD:O8%5:7RNC).2Y,'SJ?V
M=,G%).[TR?B6+]:# A.[F.X"W!,-^G!/A2U8=3>.,H,8"N3&CNM!(Z2Y!:,_
M6;"'A':6DWU##G) NI2>M"/:_ (;ZP5$"F14/C96BY'P_)"F[.N A2(_$-F2
M"50\U&,[<JC8@W6WJ@YB@F_:\,KB -[W>IC" _XSZ'4"-K5&%]?L74]DHCAI
MEG+<[SG8(G]@I%'>Z?[BFO\E]^8/#_<][[\BL9R&.+2VZX',&X-.O=YH)=M@
MQZ=5=^HT6O$"8&ZK3 .\#^-*+;/VZ@N+>N=8W4_-^3N"$FE0\YY/V^"5Y!F0
M@-P:NBL%0<E'[JSGH3&[J]*3\@0__"[$Z5R&7WQ8&91Y9%)\STP%B>#<@W%_
M S$[1D#.K<+B"?^G@M--87R-/V[-DF^';IQLPW3S5Y@4&M+($X S/F83E=P9
M%\SP^?9HCO3KALS 56?9V\>#1NS,K[P@E_\9?ME0X2/RNZC9^%*-\+3-87U!
ME0RGT*LD95JT-F+GC89P*.:DO-F"">$H+V<+\ ^'LPN"=!_6=U4T^00R$T^>
MOO[LEH?.&8-YY(F30^OKO.8N%,+BP2*[_^: +WB"@CKR*R1+@0]?^OH3.#^U
MZV_*@92EET]BX"M=2G]XF7%,!\Y[M@PK "-?P9B)7A-$U2-*3@$%>8A#U^Z:
M')K->J#\9+8X YF( (+2VW*7A]J81>!+EB'XRG]_IME0>>7W:8T#:(5K;WEF
MZRS*8I:1U;?%+UP+2?/CG8% 4LP5.@^T<06'?*@LPD.R6TN]EVKVR9LMJ?AA
M87V8NWE*J.+TUYIO7.U/C)G[E5]13OH*2FX#9E_NS%>EW-&\_GV-I#3/H'-%
M5V4!%]+ @J'P+SRX@SPK$$WT3T\@?FI;: >6G!3!KJ8\J16VJ;>/XRFFR;6L
M/1J:]Y=O1NYV%B#>2"$+ B@(3 *+?%?6E0493Q,P9Q5Q\_POHQ3_VG W>3_C
M]GIV&N=]U>09:I$CF()$UB6V'@=?/$1W@J-=FESX0IB1G%.:Q2K]=B_!F3[)
MB?N(*F*36'H-PA= I==KT;3>\#5T^)3:J+4*A&S/R*5I\O8:V-@)W]J"6?@]
M?W@@6O55[19,CAT*N#2]C" [,&12ZK7RY\(&C08BTLKXREJ^:?@-9IK<: _^
M9L[P//?CL^0#CR/?3>>M)&XDT=@76<=!L6_CA]./D\U15"6X1^Z5]#-?![07
MER9PH\UGJ)U+@XK,\@\UIC]&K,3/4(+GCOG6;+1@R) =/D1LQ/%@AW+"OD6=
M6'9'/I1__6%DI#G;K"SY5#Q9_Y;28Z9%X+"A6)J78!\[2BR^''.5&HF3/#67
M,2L>T&V'G8S]MDL8I1KSPB>_ ]/#D&#*<5Y@(&;.MZ>'>W ^3[7O*MCA8U$_
M$.&#?KZ_UO?D=RMM\V^_3KU(?ZH:*03;7&+^-=/R5\_(UJ1[+BR1Q(\<RQR/
M,T6<:@%1$)LA2J\*&B*%YZ6/,7-%F@<>S'5>/6I[.3>PY,I);P4++=HR:&),
M?Y-(F0 UTM/-$;YT$8W3C"":^T;$3;?*VW/G;3LR+^UKM#UG\<$N@HZ@C!#3
M+05[()*,W0O\7D^IUPVD198%L-6?!+\E2;'?_YT*YK7\>_G.$4BJ\%/8 01P
M$1X/K\"U$G:# JWK.?W*^QA^R2P3-]?PGB.9%Q/#C*@UTY8OM6:%7:6O7?)*
M,][-(E-]V8IH!#V ",OE/A_$YL2Z+#BU$(?GJ;B%%:GWEB:,Y7BV@7E&J7OD
MV F3&15>O*X98SG%6:#DK >"U#6L\HT(OZE:"R"3ZQ&TAU>GD0LC?V;\0OHB
M2M5P%"N7VR;Y.^HCF;\YU1AA%C_[4$(K;L^-_H+NR?JT%K>?(UV/3FZTM6>T
M"7R-%,'ZX4C]'I"Q-;T9Q7:Z 6OS4HZVW."\Q%J@<<Q<4#L?O=+X=]2!N@63
M<$]NUZA-;\]XE&EY?;&;')0#/N4*'F=TD8@[$)1,/-^:KARZT!KXF@QB+3[.
MN52,))KZ_%U"&)_]-H./V#2FS"R& 37,!W6!.#[T>F.#>NWII>J/_2KAK?Q.
M2RO$U198Q"V_SD,FN8@E%O,]7H%MU<U5^),9D+=OX&Z9F.-]ZM*:<.WB%>NE
M)2NV@96">PE! EAF2R(HODGL<\,VZ2WI/*,!0B,[<<.,??=FX[U'+G.T!O._
M.#S,O#SIJO+HUJ5SNZY;D)3LOL)<&'8/#V,.OAH+<'LR50Z!L_EZ[>?:QS:2
MATP/+YR$";VC."G-(B0P&CX$/V/F<'7Z6[OIX;&1!K#\//ZYDV.QDAT_40='
MF46ERVMAO]<AXU>1LOZ^7IY1,F=[#Z]=Y@YFW.]42T1&$,HI?%';[BL4G*6\
M#&3R@L;42(0<VFVY>8"K$*/6N__WE4C0]?AH&2SDP).N?1#6WS#P;"D7*B*:
M>',10;$L#"O#->+>=DC5[RG*GK_AOZ=NVK%)\> BTKXY1$ML%AD/KSKW!**/
M)>9[^V?.]VW!5K-/<6+ &E8(1@E4H/&\!K_0[.)6+1QN7ZJJ[3_?E9*7FV%_
MG1ULI5R3=,S% &BB"\1C]?W@PWD2#/5$FJ=YM4AK;J34KX HP1.WH](-^VY$
M"P'+([G,+1@8"75D$SB311-[^%2^J@'_?LSPY;O+(U$%]=^^I-E.T977E@RW
MMSL(!*VPU-G& F"]C8Y%>J8F[ZHU$\&IJ!=FH=CJ":T-L/Y<YYXW3\K&;J3_
MK*W)B'B?F'GQLU+@;P=O8DXZJ*JQF$OK E5K%NU?^5N:/Z"U4<DMPB=UEGBV
M8.<5S]%_UJ>#=S[S5"SG/>&H^T<4-52\&1D;[E!J*>L]_.%GBMRU2W+GQ#!)
M,&!BA, 5L@#(7$%J(1IW#DP-?3OBCLX,UW[?\:1X6+;RBL&U6[*4-&[5/%X4
MNV]V"R:%@<25==+ _DW@0&ED0*\.6:]NREXI3:\U\"\"\AD(AK^ER!9LT(OU
M;X&&7&ZC"O<(F8KG) _@-K7]>#LL^7$D#ZX8MP=?I;U.VH+M'@_L0Y,= C/,
M0RZ'WZ.08M3A. LTK>%5_#WFU85(EQ4.)%'L%NQ)0OWU+9BGX01'4&N3K]-O
M1T,1^BC+WC=HW&-O97I,'DR5 ;K\FOCHQ);*I8HM?F(4NP$:,2C#+_@]:*RI
MUZ+. J;D:?N=^^]NF4ZZ]'H=1# < WB)0Z_IW!V!@ M7!$_?+L[BPJTGX%9+
M2WB9,LP)R)?'L,VAYTC0^!1#H-D]]1SY]$!Y3N_0^S)L=ZL5KV)J$R]_ ]2L
MAR^(UY^U(JHPUXP8Z0M>^ WQ^ERNZ* L)\M2 ;\$/O!&=[$KO&*_3(!J"6SQ
M2&;8O[FU?T$[6KH$6PLHKZ(I!5H]F-YDTD://M7/'/+&"<'^W"12IO%#-YA_
M3=S=&->40X)6U'H^)*\U9<UW1Y!_0[1N>;$&(#)_ :,Y^":<G+^E^H.]=7[Y
M=YY*<RS9C@E>M3]DN^C_EDW;1UXHICV\D<J5]!M ^%G+1<I$ABBCOQ^*8*T1
MVI;3<0)K>'"_,5NJJQ$'W)\W[D.[G_M275_E.GG8MP(*:!\Y9*TL[@XW?R%V
M"L;-Z)_.+@$C+Z9[]KQ?OCHV.=:8]6;IBZNUV(Q+LG<T_Y6O9RPK?:7LO,B'
MV:97M9D%X8%7?6]^F<ZC794\2WAG<(5GR1&-?PC1*_QV^;2U!Q5$\"OE<GE&
M]1/'LVJ0B:V_GSX0;3&7-,V58WL"A%8E7M;Y1JQJ#\:^.*NC]66DTO_"KH"V
M!9.=M>3MOF48%'*AK])3IYO78FKMI_M(H^"WT:43! W%'%A_I^9A@0BZ+[A&
MR47QI$O5I)A#I'E7NZ_\M]_[ U72\D\+GHB**=?]!@><Q6)Q4FS;.J<$[D&T
MQKG^Y^S:Q;X+J=<RTH$2591EDVF^V(U./PTI1;,[P1N; \A43$@AV[Q;XW?5
MF,N9GLHO9Y^7+]^Z-"Y+'+^Q3PC6_[)B%>($;W"DBUCQ.7AUR@3/U;J!+1CU
M2M/MH!3U-NDOC0]4?HVEY8V]JP)QK'"V'$B@X1=T1=EG *^R]R=/%;V6?X^]
M5O8G3B6<*4?X[L3W 0&$>A5MP:X.;<'@JQ$PSO!]GPI>$QCSU<VXVMT4B7.^
M1Y4?\ZPX+5Z%"(,S>)XEPPX$)J(Q06%EUC0QZ0WD4.- >V?J_<SWUB&W9#?2
MBT]MGABP>2[UM#"UR7(-1$)&:1_NYR5+R(9\OH+[&Z7%5*!-+(9"*H9.&H K
M0MZ(*U>;:3B"BBRQ4YR\$C(U@[5@),'6A S^KWC;B^5S3"@:4&]HJ*OY^+'*
M^O"ZC/@N6KR VO-<'JLU<V>^A1Z/B29B\K@D6!,4$DQ%2J+#F@>8MP[D>6J<
M?;"V_XZ^5,I-DKTB925IM)^@\N%3)LW?YX&L\P_5--(E0UZU1'.8@&H.K,+F
M#DZLP1 TIO5Y%,=CW*D$"8L\D6^]H2=U3\O-$MMOC. C7+$&H"5<F1"/;,$J
M.DE\V.DW<_Y^P.Y=WP^(C/NJX+_T1A^KIZ60,]@7.'66HFQQAM"LY2'P"55)
M[(+VAV&/N;,;/5F<U9V02XGQ_D*$8>R +5B+F)CU.S3*HW=M48?.\1S'ARHU
MBZQ>4\4*Y,#^A$ L%\X@+TX!2"HA^>D)LJ4F6O?T[^1GP\-!EW3UU17WL*F[
M+,)\I&8A#^/UG.XH/G&^9TU+R=VISK-[;&A4%?AE<9$\A6J,-M2<\\_\+A52
MJV,Z[W6<H<7< +6!](N!<'&,,V";%0D70ZF729RZCPMWSD:V2?(L>&JV!G9P
M1;$#2!&$G^TU )%NKDOS?ZI&^4!,L_^F9)]NUM:?M&SHZ$T^T:>CJZNS_].G
MJI3VHRO?5=(D>=6>/XO.%[6'!J?SL:]Z+>>_DUD.VY-9"?%KVOS?GM3U!X6Z
MAR]J?Y],R/!X11\E\[S"D6PM><'D%MQ@-E*Z7L"R:#H\<._O5\X=?]YW5!%Y
MK90G<@Y]_3^?QY+R.0IS/J.IL:."[4\O4Z NQ5B6E0<,WTLO&DZ?\!P?+:O7
MP]7_NHV0_[\+7A<[819O3_=Y?G%YRG;E5&(EV,+U@4@9C"V C;O[3"0H].T_
M&J=7?X6/(P[!U@[WN7[S>E5?3-58K *2Z:T$#IXJ]G!\+[E*C%I5U>_#LE[?
M./OP1ML'PS%PIFT8WA0D6(7:&QAQ)JZHE69<WX\2'^#SOLT3OLL#L%./UD2R
M/8 .8G,R<I?1US=B4EY6ZWK^WA3#D1/X<";OD[/X^B:I?M+//+T.K ".I(/P
MT^8G<X6G&%K-#>J,ZE34JPY1@DAY<6E CYW?7&>L89I+U(N8UKYYY)=Q:<:]
M)_27_!.7>D(=$9=ZEV6BODZE]HZ.='Y]KGKN8D*MJC-_=;!M8%>##K:?*(K=
M83DAAYYO')=[5$X5+2BUV?W+XI]K2PAGK6?@=IH*/ZC"0'FF.P+++4Y\<V[W
M1VUNU;U5S83;[+:E+T!&TZ]#2E)?RV=W6>L=L_[\Z?_'5Q#_W_8X\-FS&9>G
M;X!,VX(!M[=KF[4-I[<11;F_B+O6M#H0E\GU]P>6#LMETL)J39)&]=D_8^Y<
MCLL3#496G!=I3Q\@[E@^,8<$0BWJYCW>@D7QV0M/3&I0AWV(<OEB)43?9= 0
M3^&^!'HGN-(WRF@H";!Q4VF]QAEI\=YHQ5C#NW2C.F_Q10[(8KX%!1DJ7)$.
MSOMZ+;IN0H/Z@.'R \O]M6IEM^[X9%Q@,S_%_%T>=M"*/L9R6=7\:KJVUH'U
MQI$&]OK/< 4YKRR^(6MT$_>Y(PLNK>B!WM&6-> B(] 19$!4IX_ADGHT:]H_
M3Q5P;&'#6YI&]%2*?3+P 6R5[?J4V._*VR?'9?O+XQMQX&E#,4'V/F"1,@"I
MUP?VIP"#D_=>6ZWZ5$48PT*0[^ 50EZZ;(5V;_)S'XUHE)LZH@7^5'UB"FFY
MO=5\X"P^%B&C8\3=J&KW2\9]8F*V)X*K6-=Q) )Q]UWX4)?;[P:9@/$#O>RK
MU!$YU"OC]1MH0[BVPY.K*:4F-X.^_9B=A\@9J0Q?17C(U69+,(J;<!)(KX#S
M:-%%M0_9T^=5,]S;:V4355]HQ:4'<$S KBV8*JKE16A/.1196)/I"6SY\"V8
MVE-Z&ZMZ"[9Y[!2,4\U?^ )#+& 'G%K9@@WGTBHG>+>/UU! UXU=+,>8O1I#
M6HE9'[ ]Y5MM[!V-V(NCO,'*)G!WC4'HDMF"Q?< "6UY,ED7&'SM[:5H'7^Y
MI0+7SSG&-O2?/I4I'S_,=TE5L$Y";>Z>$#=' J?H#MU8J29*E(]7-<N8N;B0
M^6/W_M96-,_Q+L1!LXKE,U H=&<+=EU)ACD%SC-4Z,4MPFBVZUN_G$R[0)'-
MC0JUT:'GKP\U<TCQ7D>,R(LR+6)#?=^(<N;"X52\.-K%NG_5\93$3N9?MP.E
MMG18#&FU[;8F[PJ+*]+.B</H N[46P2&&T+A3X,Y(R%-TB;,\CDB5SKGN8Z/
M:9.@O6K%OM#MTPY:R);U6: +!<66:*!O%^'=SK0.KT+%;"H7!2-BV6=+VXN$
M3?%Z=4>#U+X\$N7=M].7N(.(H4:U@ZL6?CQ@1[C88AM+!1W&'./DLFV ]>9'
MI36_RP:'1X/:ASPTU4TO,/=7K,E)S??_< DCF ?/6L&[!-@2"<PUA@![3SLS
M!7P))-#*RE9S=GK[!^5;_4J,B(8H,F[FQ3?8Y8B9JHBG[+V13#.&#%N2S&PB
M$P,(R=6?//_<RRD<]:M^ZE!GUO[H3LQQ^L_[5\0B"B'JA +AIWJQ^A@=<M#[
M*PF7^BOG'^J4[]U1/Y>)^=+%\%F9)"_8+=A3/%6HY(6GP+I]=R5X=.R8R(Z.
M7LTLO_9_WC=O9C9G1OWA[2](;X?=\Q+H??W:S0W&-MVN5(:8O <>WX)YN2 W
M]8G>B.L9^*'B;W"F[N4MV)_[A#8<:-;%M</%;<'69B#$%.1P$CG9B,EA#,3D
MO-<2N%E%L+"@%IP19%Z<\<,Z[<SMM93[ADX/Z[+Q1J4^5"6LT@GWRQZJ6?'W
MR[M/JH#$4]Q,96+>Q#!O8PXRE4B9>:>DY5I1U5\Y9MURI"4X*$0V\V#?=]-+
MYW:MYHN]26 K=0$TE4K,088+?$WROL\6;'\O%,\+A&*,N;KQEH<5K^Q]V[0%
M:W:9E>7$-X@\-061E+1HW/<#<*YZKO&"+H RQQP!3JYS?R2,XNY%Z^,H>1/5
MU4\AW>?AY![=@B6Z6::'%PP&R(1))_J&:F:?_*7[(?,;3Y?;NE CB /F3X"N
M^3I9U Z-,]VKS\;RS!PTI66?/)M*ZX;],*P3M8$96:\1IA-:Y9'-N(<XP"T]
M&2>*E9W71T=>!K-H"F6BR\[I9HOOA^).#PD<VI'VRR"'^_0UB_B0&PJ:099K
MM8].A,25RST@<Q%U8-[UB;[!"H^RY4LGRU6>U;#D+1CE=_I]8R+?LG80QH$N
MG*X4E3&LY!WYX9S[R\\;K_:5G!M4KEW.8<] &AX\AU>VM 2)%SCI; .Z0X=,
MDWQUJ7G=8J_91K5T=?/[60EI/A]OF2DEIYLNJT-LE?1O9,HR6X'ZIBD8$D8R
MV&%@^\#A6G^C<>C8/0I]/L9*>8IE"Z&F'"%828!8BWL]4/R0[2F6<C3(*' 0
M1;BULP?IH'B=V:X,X_E@]R/M3$0.BBU?P7)$9[5"@3=W'T:7P5^@4PB/6?+Y
MW'=_Z5KF\$%!N_3@&;_;M_6#YY%OD5*VR_%8]>_S16-0"V[F$65QE-\\-<QG
MG'R3#<PSJS9.E,-_SSAQV((%N.,&1YCJC)FT:UG7I[)?,.L"LBH[P@X]3A&[
M;6^R!;M&GEEFRW]AZ7J*)8R;@=3R-M7AXA1"&MXG1/?7LKS2BLFJ]GX5BV]2
MK3A2WQ:LLF,]K1X%+%,$'K@Y?+6=.[FFQ7*XMS&5=TDP2,8CI'TWT["+VU$W
MPY9L9[J">OF@&(G(OW@3@Z"R@OG>&N9E=S:5^OH8.2B_SO/C%> *)U ZG+B"
M7=LIN "\K4NT2:T\E^9*_:VAI_,[G&IVRQF_?$PQIJ\(.X/1 !.+,>X@J@ L
MM'^NT1?*DB64C;G?UCKP8+Y/Q<1D202[ ^JR'5N%A>,.PG<F8;S!D^^H7;N>
M&_J$!J&N2E8G28A;>C_^[/G52IGS;K$+-.)E_D*EP2LXZTTOSZV5&W8]J%'7
ME+[T*]/5/DNF0:I&'3>D7,DSB0#"BMF)2($S)S)P45WY@_ABMW>0"DY"NB-"
M6"0!R?9@!<L>G=PB/[;^<-&;^[/GTF*^NYF:9P7JZLKN$@]->C%F ,+CSXP?
M5%3L.'8J@75FP93WB6>)@C+8R8?]A.VZ=&\3]PW/9QWP-IOQYY*#K&RK96?>
M8Q[0$Y*+/O0[?F 6=U<&G2#,O@G*T%![FJCHM5V+2T%OGGVZC#BKF-I8K\]3
M(])Y?)KHB-6$A&"/JX$@D);3MLA'Y;O^&T&58UTXZ3/&=.B]I+[SWO!D1MHS
MWC+())!:N@='<:1#[%!FH[&=Q;N1S8T"KD?D&L$8 A<6*S?([88#-E, +OE]
M!S>N?$Z^_*6JV,!)^>,IOFG'X@:[!;Y/ +8H4'4+UM0%'G)I0NUANX%=M,60
M%NZ!N@&-)$]])><6PP^[[<-=G9ZO5'SG%4Z!'2/[_,>!QH4;(H9>M5DSR O%
M&BD*S9>,>]ITDJ4+&_Q(/R3L#J?4[S#=/=@"^409(F5L8EB%>0*,#Z>AAMIH
M1Y]*.QW,W.5#C-(]GWCGU!N7R2<)O)E\5V?QP.7E$1Q7L*G,=9!]"[B^]+7@
M?:RNL4=?XZ>_QT?"Q7;/[$Q="(&<3N5$Q:4:^L0>["]ED5JPX'5[ <ABF:H,
ME*G>O><>OW%YZ<2%&=BD\MK<N1T1H8LMZ(D%.=8-,)"YPGEQ%/EP7,:U;&'M
M!,/)W\A\Q)2^X674YK&7S-8:BOF>+_8=!QXC,R-KZT$;@$5;>B*L7D 5<6!9
M3E-$SQT4!1.5>_E-UPG=RX,"]-?PRO0%7V"Y]=$/1?R(O-J7CJ[1)\Y:.\P4
M8T^NOX4#YY%#X_!A/%,6S*"04[UH++L<VJ\GHY=H4OJV=@TN<. 0&X)DK#IW
MS & B F#\<GI]U+.Q#GPGYH'8TJ?C@;>+CKO-Q__O)H%\;Z=T)4%;'_R%LS/
M"=1,;]Z")<L?:@]]!<*;C0:RU^.6W-_K2];(K6G+;42N('N?+G0P&IKH3@L$
MRH2R=J-A6D6!^]RY7TX_80_E!-G6OA\(K?!!)Z94+3@"@>$ N$AK;T=50C8L
M(F5S+?GC%.FC=T?7N>*["8;CV&8XX#S(5<*1/G./93IT@7C0L!@H>N8[:4B6
MGI]#W.O$"<&V,[E/^H5@)W" !S*)**]+]Z],%QCU:+_F,;5W+.4(G_GJ1>UT
MVZZ('YRWY#"VDAGET9FP +<[+Z)Q4P-G"@$" 4$97!YZY12'_R"$KMN4D[@
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M&'?*X)2^=@J;FKG7I7\'[,+XRA'&\))L=:"&K0+9:X8C.BH8M?][7P%]"K%
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M)]K'N-6K79M?3^&7H-38:5S*,M)VVB:&?8BF&U?V1+VEH-A[7KOC@N9?RLO
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MXBXY$]<%98(?02+1=R!/X0+&)YP1J^TXX6:E7.#[Y@_-1?%L9."DQ>R;;Z]
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M$B%LS@ #BJ1.B]PT]W@_?64SOF>BWU_>7GH />VZ06NBZP,PAKE-(33%& +
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M'AUU[#@:LZ_?IR,2] %$!IV=BH3F8("CJUS5(6ZA!F8@D$;%38MC2KT:[[(
M6&-R;TTF3 2UI'FD7308KU#DR%"@<U#TDTV$[G1]&\N& E^B^58@&%-\R7[Y
M?>1L&?'XT>\JHF7I<B1=?J?Z*[ZKD%$H>S^-ZDNO?>O?'$'=;&\Y.J @:35?
M#ENV6$\5FB!@'6U&NMG[%ZD!=&NG& !-76OG^%5S8J?V#YUWXY9%'VJ>^K<2
MBM^!NS& %L;R=?ND*C!2-/$!'^RF5-N\</KOU^3O[6>E9FR@%&?<LBV!*6="
M#AQ?T/?G1*A?BM@1C2A(%;H]8*3_^N"JX7XR6ABP7.T S_K8>6=:^6]BTT/U
MY!XISADM9'YB2"-5:!)=#/@SZ=AV$O\D@CYT,5,.Y6*LBWN69EFZ_W3:X[1.
M4-BK%S8T#3?B$&X?6Q#]?="5$X\_SFRRX\08Q=/*,RMA<[C+Z]JSC? E-VJ1
M.3 ![0B'Q[:(Q>*S[ S7?.=OY6Y?NKUVZ*1FQI<YN>.\ _F&*(4M(D6"*;*$
MQIM Q!"N=HZ+ \SY_C7L1(CKJ?&P6[>"MMBUL\9[6(DMHDPUH#IB&BO$\:BZ
MA&FAZ]_HGST(-C=63QJVO](]Z[R&GSD'X5Y8#,*VI1S@U@(REF8Z-_6M! ?L
MSA?O[4[)GM13GX4A9*JVXO7K>'HB9JA-;&$!UO.-U>AM5%XP;1>I7<+*YW6-
M[UO]Z67Q'Q*LJR)==E&I^Q0B-1_#W9DFP-UW3!?JB]G8J20)&^+#\,$1H[=+
M1[WR(2L?\=.=2(HO9]E9LK+N(:]DIS/EJ$5O8A^TT1GO^/0H^]7P&^_ >#B@
M/K>\ YK2 %1^IA4ALEJ-#]#V8#F@-A;V9-_&ZZ^"WH_"=;_+OB'?A?%<?^.F
M7(XJ1'5/GJBF93$/"%@W5N?H#:)DQ]N/]7\W_]APUS#G_#JVE&G/.,TTHN':
M4H#SM0%[@! ._!D^]Q!695/Y%A>ZB0Y-!LNS:U9![!X4+P"G9@;L M!M^L)I
M9$9TNM[#<"?3Y)_V&<]X$N^;A'/"))Y;I9?*-[5:'Z=>O<Q.@I>2I(8A3^55
MG9FDX4TD>DR\#!*)J\*U8T;"K5LJ@2 R1A@XTW\M[6YC@D6EE?O;+Z-2D>0W
M@2Y#!85C"]D/A^IME3K+^[2"3 ]__YJ4>CWE@O!Q7IH-6\CP/DZRQ2#]G(SZ
M%G1CU)+5P*<]"^=%N\-CH-6N!1]<.7,,B6$>"2KWD_@['Z)V;_.I+',&M6GX
M5ZW_P&V$3$3Q+K5%Q K9*]\>\5O&Q2FOA!RU122#$S*Z(-0 3Z:8C0/M3:/P
M^U*D$NUW58K^/II<3TV9<\7*$Z^7Z8<2HS:P?PY)57A.8=O @LQ[U+)MB00M
M.8T.1Z.^Y<P^]H3',]Q>OO5WX&AC%73K=U(U_&G+08L*!/K& -,,:PU^%9!K
MYJ9H]ZRA[?O<C&Q:;[TEDWN"WQ6QRN%<8FAR<XL,+2#YWLD:W$%$%7O:(7,H
M>)2:_S$]BH^/)V2#=QY>"P>CR<FDZH"V5;GV*74(13G:;5!]W&)W^NA6B?_6
M5_=+WTLV)?^H]??3=0"8+RV/+:Z%!B-/M.C+:0_V][HF_RM 7S%^SK.5P&&/
M'DA>FED"6QYI2)O-\@V*H)"$OFGG%,V<G*GVWG?Z>WM5#LQH3[CNDAJW* WK
MY6%65O.1@L7)DS5 ^ >O,&=Q"6GKF<0EL>E$E>.]7=]-#ERYHG<,=U%[!R0T
M#& N-?1O6!GX7>B:-_Q4OG+ 0K8[T>_6ER?&M6ORY1R/MV9E;>!$3Y9HM)+V
M/VMN5\L/F3GRP$+Y0<30XCG(2S35$<?ASR2F:#]%OH0"?H*2HAVKI1):SPCY
M=K"/^FK*GME"GPA_@+CJ+/+F]+?I>$8&6RB7]A;S#$K.DH?4U&?K-O8%^RZ&
MOQQ\YO4L0_71MZU8;?JE),9II!$5UU::PNL]*4"=R(I:/<(PW+[H8)Y9;3IQ
M$[2%DUT7)3V&5H/;=T C*29-_=Q4?8&*PA1;SXV/S3N4!L@2(IN^8VE^O,I8
M41Y C<,.\OK0Y$PTU97T+$<52"CT==B6)89%ER;<"+WLUG#<[16OF' L\;X\
MDSA,HCJ11/'_[7Z2Y1\.Y#ED4N;3 ND+#EB6*?6([6X\]?YTDY9E3WJB9J3-
M;N(?B>7]C#U,>=:'V@1.<HZ#@Y&Z4TF7?EUH#PWWDG8__RMT^BR]HHG"M\0B
MXSB@7&B*FA+5K)&'"&VC:E9Y9SITR]43NF?T^)0KO'C_;K+W<5+MGDI6#NH
MNT/^$!6<U&S*[:@(XA*O[\.3)V:\@O<*HY'E_#JS]_[*%*IQ)> X>;H5?F('
M%* 1A3H**#-T_FROI@B7^/\%$ISJJKV6RY?R6-,?'D5"7GN> +I.J:W:Q$&I
ME] C>5-%\<>&:M%/C278O0TO>[12Q_:9MLL7O+C2CPET_4R-HE\'@JA\K=4
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MY_" >W_%1,7HN/?*@3/NT5!TJN:$[P"4_ ).O?I9@LWOR3CL!3^T/N84H;I
MF^RW[3^(UIHGGGY;>"9LK75W\OEW@I#1)O:^2H8.>X@DM&H(Q2)/4BM>&_;6
M.#069KEGAHZ&IY[Z]352)'&7V?W3<(+-TB,LT,W>=YY;-[R6*C14;C24(-^<
M QFPMTA6O]:VW-9^^G*J5&BIYS"W?/:C,^TRYDL*R:=NO@Z9^*"G;'06/Y/-
MOHX.P!X:X_3)'$?^76H0$,O05@NA^6<5M ?N4Q===%_P>"[RZWY21O_12.-!
MSCB-'ZAO(SQ^<)N39'SA2<-;Z('WB^NS.$LT.<H9W2JW _)\%[8#:COBAY\:
MI*TRY248!MTT"?;^?@I:X@9>JXA"B'-+ZW +C!>(8Q:&T%W>_=X!A7UV8@OY
ML(K6,2E0JB5F'Q V-*59AM1+MQ9F#[2X/[Z^DO3Y_O>1=^ ^*;ES"U!]]AT<
MN2)+9Q-'?9@2T]*S]BB,_EBVP1E%%2/,#>$*RV%VL195F0NS7LO+Y=.:5EKI
M?N;/!3/]AT%H?;8KF\\7S^:_S4']5LIQ#^' *R",U*7IHZ9S9:!_Z7D%+7GL
M26H8<H"'=>E'V^63JY^WMU.^XV("1MVF-1(HK#QDA"Q*C784#XG;V'.U\0WC
MG,2U6^#7[^C8%9?^WXM-]_'*>DRH]%8>5WO\-/N[O/+@2JVZ"1T)W'P4$:%)
M,%SS.J658=Y1K2GKGFZAI\7#W5MN6Z!EL81RCG%F(7\'Q+2'4!N1[NC9>S1=
MMI RA^^6,DY#J!<#1B38202*!OL0%1V-Y/[:7\4MVLON@?)RW/$%3L801MX!
M<="?L*'NE+7$N;4E;77HI7B!!#U#(&;]_IFBW8F]?&O!# CR%BUX==F-VB+5
M;#^EG!P@/F];U5)BW"?]]_#YK4:15H(/>SI7SX9=IP;8L%)CF7>);2VAGIVC
M-C;;K 3F&GSBQ7\XMOLO^X\Q,=F>^/27T[,$:#0(K0FI]6P+$'-%MPXX;(\;
M2]%VCT*9R@[I,NO]A;Y^[_4"3IT<#Y_%%48:^Q0^5--MEA!R\_'GF9A]^;S!
M*'G)H^+B:PGY=1X*CFH;, QKPU!M,2-.'5 !YHT6EXIRR<SO--@9[WIOC&JP
MW)G\-XQ#\)]"L5^@8^ULH25@HBR%QXNM.&"H&:YC/9E1V(+-7139%=*<IEJ?
M.;SR1:3?$+9Q-W$@:,SL?I.[:?"*I#ND+1*:A4Y$4V_ @>-PIJA3^P.D(74'
M]-30-F_4UX)N54,EQ1RK3I^Y<:MTO"I*.F<K6+YVFT,7]BYQEB5N.VMI?[$%
M+6AJ860<>65@F5D.O6)#.OGXT ZH;)(9^Y;@( L";4++A_2-*MXX+='KZ$OC
MAT1O!P&1JGV%))07[V-6 <Z3),P>A.Y"VE)7.S,#%^0A- ^,4M+O>[SW)R1Y
M)YP$]_VY#EO3I G0A5BU4#()/>KI0--MLX*+^+I*9%^*)][\=>]*B6>)XXJ2
M^,JPFM]]S?3NQ#=1/>CKP\4KZGT4G<83\1/7(\\SA4!H=;0\E%S.W28#5# Q
M4(K3O+$P[5*66]G[VL]UG&['%%7Z?D$<=8KAO9/Z2&;09AY>0J+ZQS(/3"ZR
M][\F&YG@,0<R)P/B)T_5F1<^D3AHENO(6E6Z<=_EF4$<7:YT8U?WI>K^D>S)
MH<F)UR7)AXO6Q6X?\IK+!MT3>,KXH/?M2XD^!QV!U*8QP%D9]E4"XSQZN J]
MGBO-D&[AZA\]QLT(<A"T!"N!$]\LC[P#_S:C&^Z ,AH!IQV0&RIC!U10"=OT
MAK?!EQ[M@)2#J?7L+A;G4:L[V)6^_WAD\E_VG\^ .;;PWAW0<TUV+YQ^ L,Z
M'M/2A4U&D\D!6R;0Y3T[H#O?=D!]<5Z\6R*L%.COE1;Q'= PB9-OY^_9LT9A
MU"R&//K;!%*= R9Q%IPGATL9-?]+9O*?WU0D#WKQ6-U)'-#EB=W\7#F QH1M
M34_-,<7@=#3 2SMD2RU*:%'T#M.(>U@G$'Q7O;R[>??Z[K)[N+1.%_V@-Y]N
M53 3?>^H]#D/2EO]V-;5\L=F0"F;F*HQ8Q+@E*V+%0]%,ST:P;$XJ@-AI'\J
MIEX8D\MTH$YTCA,J#Y*[??8OKUG&0QT'R305EWYTX/=J9YF0)'/2P/9EV5_9
M184^]Q?NX[4.FFEI'D=,Z@A6%*6>YTLU"ZL"]SBO,.2^6Y2^W\K-MC%2,;EZ
M]5.G5&%3L;:=_>#R>I.><D..#.+(M;\6"D^OVPZD(T#AOTI#+GZW\%5^'ZKE
M4?QG]'-%M9O08-(/B<SZX_(J[U,M9*,&;]PW:RB-G(GF3:RHB+4U=YHMZ.'E
M/TX0C1\1!=78OKDFOE5Y3B#[ EDZGKRT(NH0G!)?,V'FU-"_O%I^4EO@0'F@
M?X::!>C>=%C4BY_"FD11=3OO@S-B-$WGCW+SO+L"T_".E!9#=F^.,"L;R1,X
MA97US61#J*SF!,'Z#(5&!5W0'6T/199:(BM[!Q2 ?0JM97\NGL<((WUO3X4O
M'Q/[]"E^=-+=]Z%;C8Y[TOEODM/':I)4TV/U$^J#5.YX7_)YGO\)<Z6H;C9I
M4/2>#7$T)_#FZ^2>(_?!MM8.<Y^#2*+&Q[S0^PS!)8B,CJQO!7_"#(]-_5TQ
M]4B6Q#L<.7\68BE>\?65Q27#OMX_FY%A\;HICEMK9!A3E$B&+QM-_VE6(T,A
M\RU':;M[/_\(N>KD?(D@[1;X(RT21"@/_ZWZ0T9O3O+#"[T+SM76FJIGXX/M
M7NADFT8&F1ZM4/&Q;OL/=_3_I/9_ENJPE:7_AZ0(8E]$NQ&V#+#1.+KN/'3;
M20P=\H*IQ,9C_H;"!=!+ 7WH]3I5]O*__Q[P_T8K_-1:9 <O!YVY9HG&^+ ]
M<.3ZJ%"F:/T4C!_=EWH[]H,@I'\#.Y]I\PG^@T/AUV;_J95MOIKP]>=9-IF.
M+>.PF\U/+@]#C"62RZB5+<2!;04ZBC/"WDP3VAJ9%,.\&T"#F_7?IBD]#9WW
M.Q:MF.0OZZYR^]3NE+]JK5!R+H1J!HG#4*^P=N$[' OSBA"OVV&'$MR*AR_U
MUM84&5R,&^DBGYVKB%#;L*$?YKR\A?T3*HAVWP&!@%!7H"#?>_MG1MYYOU#_
M(>)EZE>)%XH7P\*EM\+9 L_^.;!YEV&.W!40 Q5:5:1IPETZ@QY]B',T"'=/
M?+-[#>3A\5,S6:WORZS4ZZY&?^.9C<8^_+/$[@=QMU[X/&#-U%0OA$"H?C;+
M^"D-2%(X!?),6R#IRMB%6FL3TVS/$U33M^7"-DKGYVA'<2Z\I\Y!F_!#. $H
M>5@C:K3B,^,RHKJ+Y)%I)&':%YU J'F:[GT#&55YY+KG(MP,W?H(32[?WESJ
M*3:E%E$^;])#XVL%;(VQ)<<$&Q]>$RP+S/DYK&<4H_:MYTQ]7(]1C/BDY^>T
M61+L.ZHR(<#,'96!>#V%CT$>TN\L0R28].7[)X2C17>S!=MJM30.>4\J5UJ5
MZVS_9(^>?Y$Y>3=31_Y'?M00[C5NY#5[OR_WE]*+AJ<#I_V, X!,5_,0'^,C
M@XHIRW,5;C(W7BR_N?-QAI:US,'0NQ^P<M67L-I"3N<'WJL=K_7-,'Y5VIY^
M5G)T?C/KS8$'/KC!!MWC=F5OTL<(E6\0=677?6&Y XK+:(5MCY;,L[D>+P85
M;#.5/N;EL)I@9 Q3@D1?!A(JV(/RAP$WMZG7"5!>[]3VF>%A:);<V!GWK<2B
M.?S[P_PL?<";<5&7*09F[R\H7V@1^GNOV6Q*_:C?&=]+#<?K8%_VN)_0LTU+
M#>PEKG4SKK$)\B=9+U&:"SE"M([4^F=:OVUJM&#'9DZUJZU]G$MQVZA(EN[V
M;KXX'0?DEKL)G^CY$"Z-A@%WRW= )MO<PYHH1/SW3;HQ$'!P8NS;?2V9J[^>
MB388WUC0S*:7,UR2$=@N*'!4F7G(:AK6!AV5:=T!B1F>5TI 2*^9OEH>,K+-
M3]UOBZR<N<73+X<HA5#A4$#-\UDSA":\1L:U)]WQ$Y?3$=D![1?.\SXV]DSQ
M]@Y(_OOT\ZO@GN0KOC]+,AC. 8/4OSC8S$)8 Y(Q3%: '^*3J'(A#/783(=&
MK1L%,(PW.UUEJELF/HY9E[3+CGW6$?\94>FB_GD=EG;BXS?9M/J)N_>B .):
M)]6&O<^4<0'52]KGQWPD__YV?G>)T^M2 ?5+V_;-GRZ<*7CI7DCFD5+0FRNW
MYLSN.*?O+YC<@F&/4 .I3#T@.N*#,V#','U8[F0YH'3&^/E,W5:EN)ZS[$%]
M$4)Y@%VL76(+UOZ*[81"3HJXM:6&F&G;F07"']>UJS%MX#./<F-.W7>\Q)]'
MT]X3\\GS@SA#?:+V2TKFWP*'L8U6;.P.B(P;'?^%;M72[NXQ_FN.'%O4L3C\
M_/U=#[?4]IQ+0BAC=*LQZBSS(7%E8S4:RK>"E>F B@AZ!Z*(PDK5]2FK8JF8
MB0KPCV%"P8.9+=G*&Z'P5Z:F(^/+/QJRSSI?]GK@8N61,J]@!Q H<LIP:1=B
MO*&!7XF[QHC2P'N+;T9[V\:J =@%)8M='V^%/C@51ER+8MQ'M\H;GT5UDH1Q
ME%N(E!NUM+V9%<:DT*+)'L6ADW.E_E)WQQ\A-[0WL$R98 8">-W5<F*H11C(
M<F@>4O?C4-":AV:?4K\IO;N\7V%\Q"!,)(-YJ;Z#RG2+120:V6O++07=1KQJ
M]AP,U'KC-+Q=RA;XQ'!#--%M6.EY X:\Y:8%OJ.%!7)/L_:5*E(O?LE4!4\H
M#[7<X01/=[;2)%#M!#25(EX[<Z#)]0'_\OSL!?;BPXS34C]O;&R'PV(X!+@5
M6HGK"-B+ZD4=!DI+C+#,PXXS2^)UEAI2O]=T0A,D7<__#B-VXS[.,0\QIO#+
MU:P&DN#OJD2ONWO(&%O?"U:"A:>*0M>Q<(%,RJ3#3 _.;JYRI$M5;S ]!.ZY
M 7T7 *C,+64%,P)0WT:S'C^<"+6A,NN)5YV5ED>SHB^ZO[EOYKQ-))"H9C:
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MS9,L_JCJ?2__!3P_7UJ'78*QL^M4W\*#)!#9^:O"C+UCI<F15^^6/.5\S@G
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MVZ-R7,_.J)WE- NS0I[5$80A,'M1UYHUL1%"IGAB;'Y!.N21VYF8,WSE7 8
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M:5_UH+XIK:J 'XI#IQ%:P MP#;K<;="/'#RU_'")NCB1G!0VYDSCVVNR3WH
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MF<2IWZM%,8XQNF]N 148M2LA4RR%JT!5!*%,>L(W-?5ZB:&)W#6:\W07"(C
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M*#5HD_=8X1;$11*V]$0<*M)FF9#<J4MCH??%+$$;1N+-0*]X<]CKTNWPP(1
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MV]1W6LQX5)N.W(B6M7R\/&ZZAGEL+[?1(<PN76%WIDLZ6/+GTW/,]WZA,>M
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MAU\?/4!<^!4<*IN8,FY!NE7X6A8WTR7V/(&3^4HO7(:PLM5)-X=0"K=![PG
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M_Z8_G/0H:>KKQW$-/7:#)@/)^]N0$M>JE*1L,-_9G+,CU7M1,SA,8PT&M?7
M5XA!WJ0W[)OMI.J)EBU^_L9&4 63\MJGE3:.EPR8WN"Q? 3< X2Y5V(#TX!8
M5'R"M1K?38W3<Q7RU.6-F2DQ#'LN11]P&UD.=?A][<66BP'3%M8='9L/9>&B
MB_>2@+.WN.2O?*FP%OZ41V^'\#:(+Y[Q23:I>G#)A:N3[!?15'IYN1)TBB-C
MGKN;H;#+Q<-PCKA04Z>:^-\_D^1&M'K\'3SFJ-%>"3:T01N/!90Z[5*X4C1W
ME&LE$Z^0_#X(C_T)'HVX6=ZW#W+"GM&'E8G&R@3=?2C]M8.&2G5W'+Z]X6 H
M%/1EMRBN=FPT9%/B3W<V,Z>1VW#58C&Y?96Q$ R)L*GWKXKBBM?+8V.&K_H/
ML*:O[ZB>HS"P\QC]$#!#KJ@:*'<@\>Q5*QO*_N[DXXMF5XZ6_][JKS^#><,#
M+<.LA$R/WLR^[PFSON]8[CUG>*31?/MP@U(]$=J"&<8]B-6&89^YM6D[K48H
MU1[J_\/$2U9TY7YAWFI>:'7%P\8B-$V@N??^\S*)6U(E"5&I4'3#$809+;'.
MUEXIJCO7\V(;(CE*_O-[SICJ!]=$:<?;E7;@*[]G"MT)/$W) NMGG!+Y+8H#
M!?L,A9OF?%B9JUH1FE/&@$0.6D/2G7\IU@I&+O:T_M#4H-K!BE.&K:X/3Y+?
M_$(]@Q]NSW?*(V_H3=AVE87(,6TWJ@J%MKY*$0AOE+F=&?*%P9)$>@@_M93Z
M(EK-H#/1[9\<DR1M'G5=1*86[^Z#E+:U&5@-0F4AH"0Y$_IO$AWK6NO]T8-*
M8X=D^<?DV]#0AM7)=-_KZ[LG ?2]*HI=KKL<=2L^>5,4GY_0;M'#HQAGQ;V0
M$;[=PW4 W(G&512Q3+B<SZP%-91AKDW^NJ2%S[)BT#K-3P80)>8]?#.D?8N;
M'-*TJD^QG/Z#=DV=<,ASW^*EQ\_]>?79[\'M^GG.5PSK39 <\*^SWACXQH5V
MUZ3+0)I/EYGJ^I_I$^9UG-L':64T0(%HR,SC_[PXV?,?DA#<UO#;D)Y#1[Y:
M10?AIM*%A0:4I&O]M=IZ#'QSJJIB[*.Y3-Q^KC:]&8L+WYTX#TBBHH0'=>60
MF?09K3SD?;]+*"LB=A1./ZE+#*2?F)\:&&R0\"G!ZU$,[E5\?;N+W_D(V>@^
MY::O-M8L')Q(MF9HQ"@$F%;>< YH;L:Q4JUAA$*=QDOYN4IULN27]^-9T:_Y
MW(Y?-%BTX\A"-1YNX 0"R9,D\7:YT*0T'$G'ZC=6]\_';)]@78QQ7\TCL\O'
MIN3;"-=F(O\TA)*,76AY$,=59OK),,I95),*C-##Y0-M;E"OJ&Q F__BM9KX
M<'SR:\@1YY<O?S0S"]7T49A1C2I(+E2C.E(@)Z1! '";:#(XG+QJ]NC/$G_<
M:RTG!Q>#F=<Y3#FW=B(,CWO4WBQ<G8GF?70M3-!^3E<0I,X* C$XC)D):$Q^
MJUL?$@5ZYU^LRW7(W:A::N(!50I0"B\R'<":P.Q.'%G@M2#&])@I/WEOFB1M
M?OG??>7YKV[BW((_F=4$7Z+VZ.\36>JP$TRJWS6B)^>7H=TA5$$&+#,?\BEM
M ?,JK;_&,7N.1C$W:PD_+2&=+7TDE^B:WQ.I6><F)WG&OQ_=H$U.YQC",DP1
M%AV*//U[35F-=Q12SL<.;QZ5I%Q2'%/.$CILP%KP]=C0MX#++8)D+,;E((9J
M<FBM;;>0895(D.[^$( GGWW;IK!V9;=].HGNAGH" 2Z*KS(8U]'#!DK&(2B.
M[?533H62#SR3NRK(3V8/WRBI7#_><]4]$&JFOP\Z]HX^Q&/!HN"D=33:"+>$
ML1/3):M&1M)4TSDF< $'-=DQ0^ODOFKT]1+@X[1 ?L=7O52" *IXK4=0(.CT
M[-:W%_C?R$, ?!IR=-0_L[E&+#!;Y^6G06N6^QD/N%\WLJ9J\\ZK+D+;X:N6
M#"R]0LO9!SV..NP,;P.S;COVKGSW]30ZGVA2&8+].7KE!V1$"K0&6^P!5/9!
M=);Y&=30_ PFF,Y+U</#$;K$N!9+IYSS#1\Z5$*RW+C%PCK$.]F:Q6\+AH/H
M.:>]T%:>%OU%@V3N!+%QUE!A%;#GP,9Q\H6"WO_1GODG(3;XH=__&(P#0EV
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MV'368#5%DBI.NG%*863![D)59>T[V@#GM2,H@ B)]\]GR&Z)JE<,,*C,$1]
M:E!!YW*?!WHEC RN5;STXX=_8]&!CP$3Y63[/N@H%RV "B,.*@?+/E\Z.J#X
M(,OFLV7O&9)C/^3*?/ID%_(08]'P0J8JA"\P=-5YGWU0*^08\HJ/L5T5\?G2
MI1WEF$OC.M=J>=G[/G]@C\+SV6PS)X'H6=FKHV.1^ T*Y<&2-.4>JA%_5MWE
M?;\164Y@V.E1<_"?+FW1TVV3[^CE.^*K6,9B"4(($?&-^0O($XMV8B1P5+G
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M&DZ^O,Q\ 5HAO3XVL+& >G8K,T1VQ/7F)&2&O"%R0T3\T>00SHI9 "5]@I9
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MZ$\(PD]6"?*@97TZ"I%GD&W$LAV,'<R2&DV*PUIYCZ4^A8\Z_G&U7(6HK9X
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MEA)FXNHOX3 \(8:##L$ZGD9@IX:H8R?C#MEU/-;3>H#=]PRL_:4;P4G&7U<
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M[!DW] C]GP&K#)D8?I?UF^\=IRX>WVS_^:W[1M%X)F;*CJ+CFB):Z7,W(;'
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MP</%YZ/;LJ0S%YH[;AQAO8$L@OMM5U-$W&:UP <0S6(T7FJ4ZG.WH]ZN/KA
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M9H28LRYO)5&O!B<ON$P#8^Z_&J\DO?$2S&S6.7!CN13#HH'^#)G]7.O[!$:
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MR?XDS>&MF;%%DC"A-Q>?T3ZX!:SI#GF=&RAGN_IL3D8@ZW4V3P]DS'..)8[
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MJCSOD]V?YMD-%8%?IN;2TNJ,*-[HQAM8MW$Q7$W+"&ZYCR3;I/4!S_/4(FM
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MYXV]8'XS=%DS_"\YUAXF&9B:QP^U=>V/T9.:/'F$Y?S\!@#,"+-6FC750I_
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M)\NFVIZ4AUR\1>4)[FC>;C("3I^ E7;FK9PA]?WHF[%&6F07)%ZM0B3EC3*
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MFL,N+U&XP([M)/!884 4P7R]K%Y0\^H;EY7:E41HJL$UJLPFOD1@CSD9]\O
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MQ'LV6$\5$EQW30&?38O"^J.+G:7'Z@I7#=<&"SWPCOH'#13;-N%)8F+=])O
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MU2XS$+&C%DJG=6I\J; ;/='GVY8JH.<I=L7E8(ACENZ>$(SN>C<*OF"X%RN
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MRQW*OG&@JR8L)'/I(4N8YXM]2EK (K+%6-XMNBI]RK,.E1))=Q5Z"/^E(I"
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M_[^^W_;;?MMO^VV_[;?]MO^)AET>^ ]02P,$%     @ AS1N65Z0L:@BUP8
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M?=:,3^/#O8J[Y*>2ONT?8*?A$V"71N4' &#GHOG#L/J[V'R\<EY1/P(:0N<
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M.53>XB.PZ:)>I'NP8CJ_CO8_?I)L^3MP6%<'/(Y<C@QTZ6OXGOLTX9D;C(A
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MHA:J1)K2ZTJFW2AR+B2B?EB;Q9C4'"NYQV=U]F)R TQI\6GTHEO>"\M T>6
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MYY"2\+2+@^T*,G""$/>9\NY[U%?BU6G,<2&US*DT:G9@@/UK4](%NHCT_$]
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M:/F%[3OIHT&%Q* <Z35Y,&0B(#2PEME;AM"%Q-$UGZU^:5>569D12K]K4,<
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MCI5E$&IGXPOKGE]H^<HF+E8HR+J&9!II/ZK9_02N<8TA_29QJ$(9)OF2A'R
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M+8#/.X'[DU'75+YM&Q[1YP+K)MV&L_DK\MJ<<U3,5K2?X_9S]=H$+!$S[5Y
M+)'HOI'L>T@%2CS4D@<;MG.%8Y7AT@JN)*0U)WG)R[Z_:% R+>G6=EKF6S.(
MHSYEX5;!GG]O6DY 75ZWPQ7'-PNM1^:&G?X?<U<"KCC>:X:I0N[!^'K\KS@2
MQ)TSA41@ KLX9; 6.+G)W@]GS]X@0;69O0WGM]R>Y 4UBXR$2W+BCT7WB(Y)
M#H8^Q.#X4^VHY(@ZA* #B9^JJT)Z76=_YVT!T-A 2.N(S9[)GY4#4;\_2G4Q
M*>.I'OM,$='0/U0L\*NB;#B)VP$1==98(2<A*S&\5-Y>_&JIV'31>;I]X2D&
MK#%UE*U-;Q+UE.Q9K?$5;$,&A3[/38VP?."V,Q>];N]R,I'#7BUPG_7$;H7C
MPB6/GY2QL?P%C)JYFZ97'/Q65QR.%-^"E#,TU.7;8/%&85 C]BS[BF-T+8@-
MUST_ON*PI-N'<PP+I:W_:_OI*TR;#QU?@(3R9^B]*@>YCT /#/(VDKKQQ:\2
MLG9_=,JA"NZ,/HPTT=E2X/JEWTSIB,;QL=Z=KKJ6T;<%YD!362[ZIK<[_&7]
MIX"<%'3#-[ _B;LG.KV=:P>I9++)*B6:SN<L&0[(INBC4\! @:E2>! 8?#^%
M2YW(<U\J?PJ!*J#"?,I/:I:W9*M\_KM.A"+S[\'PC;9UOMJG'_'SKP5"A!(C
M<L4[C$'30H]\31H5[I\\24BM*=;YEOT#@?SF+FD.OWC.CR6V".GL:D?:'UR'
M;RW\V]3:C_M8J!N'CCC-G]%"&:E"!!_CT ^%$SZO182!N=0/0KW#-G7^5Q,9
MT:B>?<.G8;NKVIGH7D15E.F,[B."==^LHJ3IN8?4UJISI)!,#.64Y# _(=;M
ME>0D"9:O'F3X3$U"-^8THU]_G+)>',D # <9=JP:*B A],3$I%@#/2)CFW06
M$F*N4DQI0 .<GLC,KK6^5W,S"WQ^' IX@B8-BHKB2X5T\E/3RFEQR-BM8PV+
M.$0HB6(Q9_-1A:M$2YC]9-Q(@&0PV'%A7YEXU"699$T*ERX5]=B<SX,$62S+
MT'9>"S@%EP3;G,BKA)]9E:))$_+_Q<[ICOJ<J>E]C1]0Q/^C@Y$NBPA.V*&E
M#52'R.3?-1XBLHIR++HTO3W)U#Z3F7(HP0U"OI\ U S,^/?"?$I$FJO/MXSJ
M[19;:'&7*>)UXA2A%DTT7 D3>0?N!?-P!1!B]?/8MWPM"FF\GVE\#V4<0NN<
M3[SS;HWXRG0)6JDFX*G@@\)V9G\]4GY.16+[?A7BL9LO@^1IJ!U8WJ>&WIE$
MQ:S7E![YN )(?G(**-8U7Y+T9CL2. &(J!BSF>^G--6/=B\Z8EI'OOC(R1@1
ME:LGN@+L!/0",5'*0S?3:[["7P;@DV)/;X<==JT?5!RIW);>UA0/3FW1P=6?
M;&UG"MD;??KTODEX>R%WQ7=V9 .3E*D$MC[7%IZ;B1+BGJWEXJ8(1E[8TF^\
M+1LS;-TYGY.,5 J7M!QO?P@.3B^,1BA1>V>Q]_?'FFX;&#A/_BCXNO\>J6SZ
MHY%S4"9V L;.QQ^3=D[%%F$Z>KCT!MDE*AFTJ7-7-ZX6'O28*16?B%PC57WQ
MBMX^T=YB\0XF;O\C %?>W)MX1-]<,?Y7P8V!Y'2@8 ^+[(@N1.0"@DG4&7D
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M!.K)_8].](& *CGX!MWDA%?ME3SOJ>*9'P!)'3B)-#Y-UF.*C:OLUZ;7[1J
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M"7#TIH_'7$[SMZC([81'<.V-RCSGL$$^D7=W@Y53.R@MAD* RNJF :D-;.3
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M9A/NF&TR'WYEQEE,$T)XZ=0IFPHQ(>4C?JJQ>Q 7#_A%Q(\MEJ2K\T#00H6
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M@PLB>%HA^:JQ-6*1BF"0?KZ]P> .D<T.AP%N6M#J$WCZCYXO0THQ\$*9PKQ
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MN+EV<9(>%MTWG!,B'DUKF$>939HZEE"@3/T0T\>68+BL_X":0K/$(Y:1EW1
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MAA WQ)J?P)TH 3P6ZWUIA>X-HPV3@A"@D)"0;O)O_7K'HSJ*;&8 &'SYCZ'
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MG'4PQ+:IX0A2@NI/"[[5O)Q!O4I2Y]KP"5\D%/MQ<5AH=\JT$OP0&[-!2R=
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M\K3("@^*F/%I0AQ=Z9MOT#:GND7'B-5FE$$N5=EWM@S?(83=/Z6D=1\9>&Z
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MS7&_/[,\#T6'4F]WH36LO4U\G<:LBE?&5FRFUM]N=UW\4!;HZ&TZ;%(RWZ4
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M&-\ /NJHHA(Z.I+BF#GH7CM7Q%=)\@[[:U6R=GA(M'KE<K&/FCN*7+("R%,
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M78FK/5\Y)/%XF7WUW%JKI&^<9!K5B3HS*5K?N[%_Z42,7S[48U16W5NH51R
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M&"*1^B$_D>A#?J>ZFN@HJ-#4*/NX&5*S>%C]J%U#4UQ<*FJB=N6(C6XX-*"
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MQZK9_V^AE%+V!3M5>*+F9>G0->="[3*:RJRADJ%)%\:JR.2W:),6J6X<4E+
MT,.3=>?*0D/72HEOK\5S&^*0''2=N'3._/E M<G)!LE: ]_!].:T7WGE&"I7
M<I=A2H?NX%Q=3#L- %R*?!*U@P%>ZV6SL93JZT-/\>/^+@J3-K^-S,M8(449
MQU6&L3GO/$9&B>C1]+<-<'#$O+/AFYZ,8O-+!04-9>"YG@*:K]&B)3X C#\
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M)%QQ ;UZ<$QN<0=E(&7YO+R/IWD/5$]12E=]1O 4>!(O281R!U8JY]3O:+7
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MO-R:7]/^4!.\ZG9N4?[2E \K"<YZ'G5IUUXQ+\V39]AH"#\]-'2D\V=_+UO
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M_7>?N $Z*/@ =#!E $C1D>,H>2&* *.;Z/TYYPBZ'/$>=!IH&Q@V('%)]0]
M=T "ALSZN7B \63638 P_YD<3I8SU!P%JHR-,>+L[\B,1+_^0RX/F1A"Z$M1
M> FZ_$OZ9M2?H!CF,'1TCCGF"+VC V/0K%QB] =@$/K?X\SOIB&,@66_$3F2
M_01/]!P!&B.3;*D@D'+FW]U(6^#.@6- 1WL/D ITJ(%)USL\^K,H:)\,Z-Q^
M]8..:<N]/,",X9@CZ""PD3%ZH67/=V!, ,Y49_P(<(@R"S#['V,@2S&F!W^
MF@#+9__GQLC\^@XWXW,ULZ@',D#O!FG_!7@JP.CR$(X/ 3QW?KNHQ9SQ[H)
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ME8O_#WOW'=5DMC>*GQG;6-"#B"A%1I 6!(8N(*#2NY"$2%>*2""@0  #@;&
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M>GDA.NL43CE\>!]1%LW(VB[]0D<ZU3L8GQ(7CCDAZWG^WE?O=Y\"J7FU=K6
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MMLGA-KE$C*?)=9RHN#+T\/C #D-D]M8IUQO>PM76(0G;X Z?5R;'C[D9]"@
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M@]HZW-3)YZZ AL/9'GV%$EG:"2# 9P28(Z#ZO. SGU-E"%R9GCZOG"B0Q9]
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MY:U1;>H6XLJ6Q2W#Z++<>M8%C]><4'03H8B*:IKCD%_'M1F/IQ5V$A@;V=Q
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MQAH0E0>FN[;T@("N00/+AZ55D33)5Z5KS4'2B)"K9B-]>L=+EG>N/_C!E<*
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MJ&DS,[6!QR*(K]K1:]*ZNXYBCK">,+&Q:%HD-EEYA['!6%8PJ@)5:IA<\ZK
M"'>YP@R>D(K#,J[R!UOOO4'.,>:IL65@_G2I=TSN5 9^&R(EUIQT=@P,BS(,
M?3TNZ65VGPF%&DDG% RQQS%\Q 0/U7 %HY#"CR-N%EO[YEK/GDWQ])RI%ZY"
M#&*YYRFLK3 ?3^P0$-@=?PP9</84'M)9L.^OTC(\LD?P4K+K %>YK_1,,P)J
M'7T\6# 46H:<@ZVN%:0=H?ANZ\^&BOLZ5D]-*;Z'8Y0P(E?_<Y_"^:3FSH(D
ML/"H1*B<]; T%!H&A7T\51"JN*<KIW''PU]#^G-!!D5F=3W3*$ ']!VX(YFD
MH:=LW/9=<B8L5?0U'-(F\/+ %"O6,:4Y5Q< :L5;01@'P_V6/B(9)^[]?I8F
MKJ?$QQ3T5 3-+H#W5N FW2UO1>S,?#W:M&L&?*POS89A1AV+#-"SL[$)2YMQ
MF^D>XR;HDH^M@(%1/5^\U =W&LF)[C!S6<=7D:OY>ZQ:[?'21EAKX59N 740
M37S&3H%:RV#FB$\ "M0 '0^_&5M)QU$YX;4I,UN;MDN+/-N3O2_'AVU0%(XB
M8AB$VPJ2LWV3BY*RM@[YXD2E[?1T.WOQ*:*8 +^:0]U<YLBU-#F;RJ1Q4?S,
M$W]O->F:D3:$<$SJNSFVL(K9LJ$%A\D3.QE.PB$^1,T9B#T0IKY&Z(0"Q3_Q
MV'@M_+59%ZS6O%V@4'LB]WUWZYTX!!(Q4>]C)4SUD737?QV]9IU-K5YM\[:[
MPKT67YO43<6JPZ#CI(KQ<9T#.1-M)T4\)MV@F9%#7@'JQD,PBEIKH/::A9PA
MD]AQ&W7X&,UTV@UK\P A.DHNKOC8 - $ (HA?:"=]$7APXU,?V3]<OM#S\!7
MS&Z_DGSB5R,V0 [Q[;8@PR$GWM3S<W?FBM_GS];V5$I"N(B6!+K$7E5+6&..
MY+8=GODR1D:CJ]V<!0,A$(ZH#6W1][YSO.C8F)3>&S'5S]M8(M>JT&5?#B._
MW74+ZPD[9B.:>TRT&'L3.\"2"AZ]0<_&_2WF= VMPKGMJTN=M9BH?%2KC;:"
M5&T.Y2]+2<?Z(8(SHKNGB_975X%)RV.3.X@B58^D/KL :B,*:J[' ^EB+G&H
M1;HD43QB(5U3;JGW C)[(-!$XGX%4D2[L5.7\04=%B G._-EI8^;EU_*Z9?_
M9_\SX>006R^T(%SJ7ZEE +CUB8(KNSEB343/PJV!XD=_8L;? 0Z9V#NS!]^3
MS_@&VT<T:K_]P:5:\CW[5)O[F&[[HXQ!=/'.H7^?UZ^%!47XZ^":7@ Z)J7K
MVM37HI6QF*^URV[Y-;62\(1VV0Q@N7;U%TB;=^[?-UW?.>XHJN^ME>\7R"=P
MMZ^9Y?_@PD\?ZT3YHMTK#WF48L<?NZUN'1FN$=,$WW\HP7PFQR0O! U6]MSC
M%Z^U(J]!==>DE<M.&0XQ;J;HB7^^^^X'UV_J:V:,"/SH\8-SV[+(<$WWP:\&
M ,:DGD>LGH]VBK>R=(U//!7$#T3<%1:::"KK_DG9"M0?7&8AC<_'D[TJWJ<J
M4I--QIRH?D,HXZ5+J4O;UK34"7!OR"SWJ_X$TX2R=M^F>)%C8Y=O<:'E]]QH
M.=:IB-K 011"?-Z ]--9AAX@NB;(@I/C>M*?5@"V:?XQ9VTK!NF3#L>$;J._
M\?N T7T>:;>L^<I%4H/_," _O #I-D:23 GH+_D-!T<VX$VMH0UX^!?(/!Z"
MV9%MDBEPYRVXQ,*B7_]KY[O.VOU)]KAK ?/@W1:T2#XT]=%QD9?@(N:@Z=,V
MSCIP]Q=ZCM$@+/# &>T\MOH[@;*24'?_9]5P6WARI-K]5Z+U-D;R)M!9+,67
MJG16$<7]VW_V/J%$?^<7$*NT:5(Q<ISG! .9-FH@IFJYM5'*>^?FU_R/H9[#
MEF(VYW.9_6S=&J>M+>C-E3F\J>X<&/@L_JG =*G/#ZYV_XB>:[_M7?D9'7T_
MH^/-]^SYCK5*J_"=5#=/N.KNV:>203 $M[,+K-1[%MZY4>X6II;SA,%$/_;
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M_M=#,'#5TZ; -7 :NJPYL^=1B=%C=0PQQ,0)]HE5N[V^3,JRK[ G8PC]XDG
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M&THIJD9I)^Y/R+WH#JU&0/OU&3D.7TPQ.:V:9N"T)8/KJ1TEMABJ5:HZ!A=
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MZPUW4WTR8#S<NVL@D9['&]8/;7$GZ" )P#]$3F]@EE[::H!@HT5S:MEUR'%
M=?OKLH /=N^ROEU&V_>].)6&6JFDU,K=<O,4SJ5LK>WV./GHTK[Z@#HW+\?_
MTQSS7^,4HUXP[%Y)Y6'ATT7K;=T8%AHS:NF5D;*='F<"D52IP5Z:U;VM*PX.
MAJ).-V3W9$[*B7E4(9%J9S"39MQSAL'"C"0(%A&,CAFCQ8N'PLE<JE?%\@I_
MVBN:>MKZ6W068@G,N%#=#B'[Y_02\+*:U[Y=2J06*NA*\*+._#UE_:JSC_2-
M]/L/KH*$'UROA_ORU,A<0XQ!_Q'."VJ5GNXHZ';S_E73"2^X/\HHX6/ EPN
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M\MF&#1GZ@/K^KC_]IY6XZZ'+)_O' 04Y)9[AF,'6@.)8MVN41/ZRS$QY(^7
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M&?P_N1R.=U02N$YQU4IEG /:K2_R7EM&&](UPQP<KX+U! I/L]VC1IWX'^Y
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M2<A%GR^LTB\#1B*8V=F<&0T(3:,]GA1W:BRW9NE"HD;ABT^64!LE55YY,@J
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MV8<)YSK66,SW_8Q([8UY]_XV,-]W4I@NHW(/Q&Q0*&_1E7S6II,'8B4K0)D
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MB)&TO\CTOM8_H26D0*X#<E")VU2(S6VQNNG+Y2=NSX>[ZP#/6]-Z3BA B1:
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M;\V[,82K@>]&I=+82U.'NQCJ%A0*72BI)!OQCU4.\OUSLQ$NSU>']2)5]4A
M1TQ[+Y"8IPO>#^Y(,(9_'"L^:3'7\>/8PI]CH!+Z7^R%CJHCP=@N)N+;$UU]
M]0&X*F0 6D?#(J5"DLW-Z7 [F-QY\\5+:(90+D[,A'UAV[)A&UR-8$NTLB*8
MX<N$ O^Y6.V9S3!LN5EPONQ6@0[<>56U-VOJ+/;\ !("1?+'?BHR70$4>T*'
M!@>)4#4_/EG0P#NZY^8&0Z*YC5D%2+VC%1FJ9V,3>/2B=CG6*YKX9M1_-G2.
M3,7(-(!$0#AFC07]ZA!0I!=NF8S0_H=8"@N)N8+)A;(5;ZQLZ]$(K?.=5>4Y
M\DWEQ&O=3\9>G0AZ5;D,X$^=71>(8]?<V2@6=44 B^)[@KVD9;IDV8U]P#RI
M@J7LW=#7X)KGQ!K"E($'R$*>.C=62]F>!Y;=M[:<=]K0K)1+?ND)%#K=[)!X
M6OI]RN$\RF(S_M'.@YS#-].U$9,_CBFBIHO,;WD8L,6@8<U5 2JQNF5/;=22
M"83P-,1)Z@I[J*+6U.K2^]3S=P->Y$:72!'"%/(&*SE$MS+1,<1),O+:!6BR
M0ELSMG/62+\55BT WT=?;U1[_>,8D/W(_N48/?=H#_5HH>+1S;-@WO@'ZZH2
MX[@75.+0U0#(X";4=*$G.!SF,6P@W^EI_F"6NK.HX#RV5/\*123"0G8$M=15
MO8S43/L63H O7SQ?F>W_*.7*H?[<S$PA1R_7P4+ $%689JFFYW%;4D_,O-8*
M]*)+%60XD+P;,CMX02/DT?;_";7!,I'I?M6-WU$[P^9(_D?/1]4%[.60M?()
MYG07U:!O,$84X7MR<C*Y,.GH7&^J!'_H$J^88?S6CG?H0P'P!FQ:6E?L1,+-
M@(BCT5]TS<L=G^TI8<WGR:G0R NLN*D+<2_&8ZL]I!CV$W<@XV).R];>A,?O
M@SY:@)OW2"Y&/7YK*/.BVM">WB89@&SFE8.?.B9O=_S[CH%#U'*9TU<1UU:.
M2R97%0L5BQ^P,+Q@W_TMBR0W9^7F\S%B#"M!6O^P;-/2Y3*]HN1;]+B1H%-"
M(J193C07 ")8Z-W-$$7G/8(*""0(_B,FAB_5@1@*91H=/:-F@M]^,W^ZHYSL
M-ETOG,L_XU./K/M;6KZ&^[#$NK=,I!=E-+3T.K,]::S,FPZQ_WYOY.[-H$2Q
M@J?L4(@S+3S3I+1F<OD3_:\WX_G6RU&@Y X1J/>C"_H4L2))_O$")U_"1LB=
M%9.7>K&?. ;)J9]+Z*7DA"IKNR"T*JX+%7Z!66X5!5"I[0>1*4]:Q5Y>"B8!
MB2E.O%J@0-;GVV%O..]G?Y^@^ 6^,#'R\6A->:9H='"5!90>?.0!"EOD9;^.
M>!],C6'X,-YVI$WZU[JWF5@)[E2U'K69"8.8O:M0[/XGLR ?8[>/3D1*';2M
MF(E@MY6HR%FPAQ\P'@[.FKH35$9U4-E2HP@-N86&$MBVW9(>LT'(?YFJ*MB'
MX8I4% ,QR7-8E\G+H5Q3SI;G<Z5D\E20$S/)HVGBU.V;0LI%@2#&)0EQ+-+U
MI:GI7.+3B?^LJ+^L$A\CVBF.[TRZ $ \G-2I! "*G#E0])=M&:7+A6E\!U&Z
M>I^/GF^Z/L^5=KC<>OCC&.A(!;3EN_YX;_Z5,G27)EU@-&- ^ +_>//ZS_OE
MUXN6K[<@3 )K:[X5KX\&916B4FR6J=&,T4VVTT#;V6ZH%UC=G968UZ@%J$*_
M'*+ZRG[$H]6@FG9 T^Y]HO="<KBA'RY@Y;!ST-#K/GZ+6@ZI0<:@H"L N?<%
MY)P9+^/!R6]#!.J! &00:(\3[PJ'@DV#H0:WEJ%W;TJM+WQ;*GM>_7"7WM!R
MHY+1Y6#)=0$@H(:.UP;Q6Q#;+P@?+?*]H<-]VZ"]]<;!&AU'9W(F-+5AN**<
MBC,T88CIMA8P0PSQ:$3A<QU#[5K#M*$5 9BQCT@-:ZG1]6WG(L=)$5$JV(#I
M8$4 [N<TJ8R/1:JN3HYA;/',@)VH;^-."!JAF82A'S7O-<0)H>PH%]SB)L>%
M;.[4J;D1,5J881*Q=%'RT5HY!G"Q^=NIFLGH.68*%QJ.@IJ+NF5^@K%Z[3FF
ML%#(8H=0&B:IH*L&[]L'^E74T(B;&66N2V5@#G+@M7MJIN;:>+0Y,TGP 3TR
M(,,-UG^!%[U,%__GBRMJ'6%<_3OU87<!:5Y$U@&F%WG_[')O!5:BMCI@5@T2
M./$L9[J;5;[;II$NI#M8I T4&%()%SAI3F2_[36/&Y80-'2O[Q<T#G*_5%:=
MS[^V:_GI%8Q]Z>70UZQH#$W&;V-J O#=KLFOP39I &_212@+9+JHO7&CN"8F
MOZ@Z%R<DZ1")S%^!0E7R&]ID=LW&!\O";>NR0@)G6[-XB>#2+)6(@M>I"<-F
M#C<MI%F/"W2\P,-//N_L9=[@6_GSIRV>A?!BOS'#T/]ZUISC5//^,Z=_=V4Z
M](MHT".&Q?NOV=>E#U?>7CPL'#GF%/:?Y<#_,YPPAU^PRQT^()7$??)094L[
MPM6XE^V7:4IJ0*'WB@(UF?29Z(ME[OK4E/@Y,F4B6.=XXA0_5C-Z0$JP-*)K
MIX3=$>+3RNHMKATT.8/GYD!%G+?-3"&K<_=>Q3L$ %LK>3XAM2,Z\->-;I/^
M!$_H."J48THW-U1N;07X&%_2LS[VG0,*K/DR7N@<H'.979P$2W(1*&!@^TBG
M>Z<LQG<5IL_73[[[GNWQX]B+0Z4_K^MCA!#,$BDDJ?B5Q4KKC7&L87%85B<'
M 90/@D+=GMT;%4L0)WDLVPD45JNG#C+KU@2:Z-&97)0HCPIJL-9\H[DB 3M-
MS[*X'SV+V).X<"S.YRB[C//CF"CF_1<!6,]SXDKX]9:"-]__AF[Y\5X?_]H]
MVO!D8LQXO%\$*!%)4_Z8\.VV7)6=%Q5YD4/VI.71+@L*"@&HP<RX&IA#V-]C
M=>L)G'X6:EAIHS-Q<"6C"A@JV7VX)9G8&&_[+].F[_VV^!QS<"GXNMD:Y" Y
M5VH 8:!\,"8 );FH9JPTL;R3Y.+"-':NQ[=3NI2[J]7Q?T<?F'-!+D$B![,A
MBT2<FT-PSD[D.:KIECNYY9-Y78'(2!_18<#YA%O!N>>GUH;]@5+JB^OQ1G<0
MF C##O'8\L!&&;H9HD\;3^5FQT/%.5#S>2@LY?0HLXFR>V[EQ[$O0].#O.X:
M3<7_>?UN4,R\!TOC2=>)KAT/JKV-9$WPD/)$,AG!5J\1#U#PDD[U'U;UYZ)]
MP"G7W.][>X!C> []-:FQ#;63.PN9C%LIO^ID[$#YK2M*'C%\/6D81N<19S5T
ML;ML'Q#7*W#BR'S^X.3-MU>OFTQ>-#@1]-3*V.[6XFB0N)\%VS0VJ)@]:*!T
M4#\_>?MN?/Y*O.E,I\QLDFO"?LW*C5'=NMO.VPGYQ$T5M8+,C+ WU/GV(1(R
MNZ&3A2['4"FA/UEW77>H[,_)4TB,E0=3G%$AWY+J(MH";<*N@$(+RM\<ROUY
MZK=]:X-3[AC+.Q]6L&>$U8=K\(]$"J9E<\4] G#0'H0Q5#RM CIAY&PAFRD"
M%@!:(1N"@RU<NS(3'I>[H>;-/'?"(_:EH#>J]$$@$><\?7>9F8X^J>2XM'?B
MQY<8'X1"V;;+!]9U1 */I!.85KPG917V5W]I*;0K+5^NJ4>6];4CBT!W;^AJ
M1"D3U_#:MF/5.UEI!A)V]"P# VOGPVZ0.0<I_NJ"C,B?_XZF6(-;@=C<XLN#
MTSIV/ QYI<@"#&5H';@F;"7['HQ]1@!(4?)_7K]>]U=AN.\[)'Y2I$PI_W8H
M">I<@M  N8F-]? WCM+6S.;J>^M E"N#F)T Z04W#0364V^B#;H9&:*X>#N\
MX<J!/D\]S?5<K!XU0%-&IC&!=P($\%=83U/46$1\0:/!M@:S7@SSIC!<M;_=
MK69*01H#0$$2/(N!U?7J'_,;4[>=]O1%C/E^Q;)5PTF6TP""K8F!OLCUWZ0_
MRTH1L1DUR4KC(R-CKUYF[H&PK ##%@FIIW8VLA*;&U^N&)?20]>J@R%-^DFO
ML/H:BR=DM[_W6 Z>[!!HNJR@^068BIE)G&]BQ9YV<;4NHB,8TU?6&Q<N7Y+H
M<:ZWZ_3CY]U05R&"7832C;H#.,/,H,NUS>CP+#?M2>%S#J&J*QV?':SU)DB=
M[H8,UJ!;6'Z8\!?5<,;IC#<LL5SH2GQD>XZ:76V5,2=L\UTO_110\'KLRB\.
M YRRQY9%?IW6NTO];TC-S@?HYGUG+APY!H?0Y%#VZLV_%.4)(UN0GD%H#()^
M>F2RNSHXG&:8S9_PQ^6E\+,O&)CJ3]#Y9Z('/!5/CIWK^$D6XT)H]"S1R_VS
MIXC-68$<7MIF<GQB\]ROT(B*\B3V1>79XG@HO**I&0$HQ\S6/V44Y*7A>C-9
MVSE6$34,KT@9I:&(B.[G"+T_S#!:FW(7])-KG<IU% XUG1F:C!ZXW.<KT@I?
M=0_Y%.4B ]27DJ3.)DY\I?Y*1,1[8[5'(-+6;>9E;2$SC*A*=;$TTGVG7[KI
MQ$V8#,"+>3+WMJ0CPHJ ]J';4A2G_!T)8O?U=PDXV97OZ:R,K*^S[Y&4J?V2
M/OE0$:UNS /6+W>8 6R?I'+3!:=[1:FB!!EI0R_\&^9O;\X_J2[%45^J(3.)
MG!VI,+O]P0&/Y9BL_,KHXL[COJ4@#O!^#C8F:,T;V[>555(\:J.VH ]0\G0S
M;KOLX_/;T$3*BNG<W(ZR(M?5>8%*N&P=8, TT(OXX_>I/ZFEU<OB^?ID"3[W
M&?L:/$$'XN-NO&X*_QF9"S4';J4#!;%-][!Z;&P "C+V&'<-N;I50]4#:E&[
M"99]2:ZT5;E)Q0?)[.FS_0 5>4]CVC*D_?+(FIKY_,1$Q.,<F?0W>P6NI/"@
M]LM9>Z\ 644$]U?7D!+ON_>'G!@5Y5>5QK2=;1AN6\RQSIS.5O"D+!,&?+N=
MD:ENZ8TX>$!'I@]Q=/?]MQXJ4.B#.U<_M.-@F\#MS]"VLUBT/FW-5+>N7RQJ
M?AKU=!!/8)6E[G#9R2L2X--C[;#'[IA,D-31"Z&K_[5A_S^$_U^=GW>B!V@4
M_J#C;$6-<S&B8K.!7!8*O4HF-Y#)& >IL,I_+,!J1G!-0]G0HI1KLV@9JI[Q
M*/R&:U)E7>P86\(^!FY%^G&LW>NZ Y8Y@ GV+V4X8;7]&)#K() I3VGI2ORZ
M9W$.@N::$M^$WA&27BUB[Q]V7O_L_S.A>"JEAP'#$"FQNH_+!C-VNQ@UBR=;
M232Z=2JEG[&$,XR_F@I]9!)EZ\6L/)+T8&%D<G+ZV_N64%[=7$'Q+_M5:[D:
M3-[S0_/!E!4WN^M'M[F(\0:I8L1T:$U G1J>H&L(#,NX^FY7^W)DP1"!X,7,
M2=XV$4185><#CY "-6E9 :*72VSJG,)P@B(=7-F'7"'EQ0>S^%#-]\615BB'
M 0.#: '\1GD1F>P-&8.WV6B(N'&[W@\9YA+1/D8<TV YN.26=I'H3OCZ<*E%
MX.;]4)7+D[74J4R':XF#3E;;V(V4@,D3\F;/@R_9T#10%EIN*06-5ZSGYCO
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MHT)'^'0NH[_\"[O"8]TLE+.ZZ#3$+4!@_^"DFBVW5-DN."96EZRIP#47AT^
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MR/^TV%2E,_M/B^X]NL_6_15J6D > >;_S^+(-&*"N:\46/E%(W5SX0OB/SU
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MH!=EYED"8/YB?7%XZJO1*HMJI'Y2]9FG-2:!<0F6'^SS-=GS5\:-"A&LDF*
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M1WZ YU91_5QW$+UJ>=D+ZT"?77]%?%DE_V!1NEUJIMA+ R"C(!)Y_(4-/[\
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M'W=S3BDS7; <(A+P77(E9#I#!KX]FH!,(J;Z37"=R*U@0@U9!FA'VX%QDPL
MT1^ZUQH _FSU0%Y"B]\*R6;<U.+=P,# \.PNH-]**"!DXJZ02A#NB>''C4<M
M7V<S<\3B&$%J7#[3QM91-1FD3B0^1> ;E]VLYV8)I <Z//8J/4P"M*?W(CP=
MZ[=GC6\U^>9F^ 5+@%3:<5'CI^T\F/XJIV9V>PC[1:6XT^>^(0+\9*#RH>TK
M@R-U9?VXVKH$J#6A<16)&G4I?HJ'6O$GOGCG3:_+U::1;XH$NXJT\%Q91[0&
M<C88#P)L7H+R^LR55',^Y"+"(2\5S*TX5:.X3BT.$Z?[J*AT\RX!W_5Z=LX%
MJG3U.4UM.<2&F7890K&WFS)B^T&_QS8?#;23?O!VE!+,S;I=MBLGK4 >)_!@
M+NJ,=K0_F6&D)5ZR:!7R50[=/(IU(A"1:=HW0TOTEM7VW,9(X386,JP8Q3M^
MSUF$+OZL5T8/ C'A1"A@-%J[,:,>AT].O2=IUOIA1><YAKIOJ,U'ZVK;.U*(
MX+"<2E@<T Y$1Y=+"F%Y0E.7[^%=JK9?/!&=V&W3#H[UX@POL)A1,>&@-/5S
M!LB"$<H0=*#8,PM*9P*Q8<AN"+&T@*=GA-YA02K/H,:Q(FEBD\'*2>M*F>52
M0W7HNXZ3=FD-D*].>!?+JOKJ<\8O2TR\-*J2;X>U9:A-G_7O'XB%;C4]TUMH
MME!,BDT,>Y^P-.F?&KY14/H@+S!%\J6\NFS_S=@^^P234R62RP\C-9TYT9@3
M*C^//(.)0SYM3X26MIC+#H/MK82@-EY  -2]Z[/=I:'WM1HBU[$HLL].D3')
M(@=%#G4\XG# TP/S*9$%&'HWH>I& !U BHE9OR*B:M1*"B83J%&UOBZT(0^@
M0Y/ ]0D&W[5ON ?Y.L.[)H_VO.UYV6[T.D%%Y09L:S81E?%-*W@'0-<+S$^)
M-N^0"I#BAX^<-!8M T4"$$&7QFOX@OJ1(WQ2J8;29MJV1E_MRH" "UK^R#J@
M05YR7Q\)+3HW8@4R=W8'&7FC7W<#89)$0]67+)@^7(M%UX$+Z$<WT"2ELIES
M[&/\K%U#@<&"@@2;[*2.Z#NFL$H+.RF^4I26D/B0XSM:<-?#P&!P1]"!&M$=
M-'0ZE^CQ_GZCGO77_53>9;NXH<;9>+:1LWR/'R8)A]MR)(\<-WJ"H=XV[6V?
M>^0:LPN[$]=EJD 4E#: *?N_P%Q;SISP*DQ@M-\RY>^ =DX;1_RQ)SL*,D"T
M1_Q8!,N<8PTM\*OVW;H)GXF[M$0]91KN.*DY%>6BRER>OIST969^8S1W4%)-
M(P3C$=9L(61#=$IZ8_ODI-@#;-NF)O(&(?=;FW/&.HK'O(EUD^3(%\NBX)]I
M&GW25/_PWVW"_\_%$3C; \:1 #O$5 4H=6%>I A?F%%CVL$]1 H7R)DG0<'&
M5J8WI;#/C4!U,>_O_I JN-87I9FKUMAOPY..6X_B;;K)_[6*OKWE^/S]GP[B
M.N^/;5G_X44QP@TOWPOO"PYSSP^LU&_V1,XD*TM:-KI:]L^T"WC[IXZH[E&F
MHY-ZD!\U<,%11F.+E3R$ RIP*]#S21J*P$!;O^[+UA>2&AO3J:&%G1VO"-@O
MI@4(U&X]L[W\>Z#%'I51^+1-UN(.\%VO;^"HG?FK&KNIZBOEE^I*H,/?34PC
M[:.^5_&Z,D&];Z8<V-^NW,D1(3U?T_:LZT966Q37+$A1RTLJ.H<((! N'UN@
M^[K&('Q@3/Q.M"F .XY;H@.@?-ZXKZTZ"L4AU[[Z\TCZ59CD\H_KU]_+O?]A
MPUGVU]_[]BS,,$"G6TURJU&MU+*G'1#!RTW:)88G@^A*RLKY-CC<K"RWM)^D
M+%>HI%#1>=TOAB5.I7E%8WC'=ZU*U@NNEC8EV\YX2(+_NP0C:7$7GYR8WKN7
M?A[I@>>AQP(,*Z#-A5\R)Z)*'+3MHVB2($(09CW0LU[8,8'W3#US+H:8VA9;
ML*XJC4]8UVMJY1\B^0MD@,'3./S8\[>_E1PLK8'F1UV)8DS^8"(B:,4*N_[<
MFA7?Q!:*-(TDQPD_NAZ?JMF>I,)?_UISS\/U\138S=/*&!?,#6%ZJ1EP?VV7
M*<'H64N(@,'@', &R*D+B"!:+TVT3+?)-AP1O,1,P+&P9TQOQ,:UGOOR/_S>
MU&/3)5J54JV<I@&S;)WE#1;7_++L-U%&&@I[\RK'>J@1GO=IL:812URQO%)5
M;V5+L_7.J3NZ\]1=G:[*/3_:>S#L=974FV/?]_B4Q!6@QG[?N'SBAA)@<M(4
M"[DU[RU7.,5UB8C#W\9+V,U[W##Z7)!<9+V7+>?/*^.]6I6>3+FX,F&-Y6/.
MC"4>/)R]50I+#;NQ9/RC=V1[E'[S'EGP.+"Q<U%O/!_9(2.0?EJP@TDF.9US
MOA4AH)HZL!P<EF_M0OWH-[!<^\,8_O.(UHO$L) #%-_N]U0YMD_NLAPM:+EX
MOO'M*F#<-G4H<AP@>BO<-</=DN2-5W:&T;AK?>+UMH=*X6RIW%N0']WSCH/Y
M5WX> 6OZH!QW4U4*S^W<TK;",M(R8.WIIR+?*R /B,=H<NIS-/FX>7"7+/AY
M#[?K([P-?6CQA+N[73&U:6M&!-_*^&ZX9#SN'&ZM'>Z(*:G^1ML&\.J*9.9L
M?)UAX94?9DPW[0'&9O CL<2!7K5EYD76T*7K[#_1F6DG1'PU^$/^/I>1FW;#
M?S3X?VI-.<)*CSX9*!FH..,>@2O(Z:B XX?#J^_W-;AFK%CTDL=>(8!=S84=
M=E,.?$3H4(51+LV^M/*2IT7\(UD<H9@0?-97B]E&*-VOAH9>*_CQ<N@',7SO
M_J+:A]Y>;<=>F/*?*'39TF>#KWG12?D,);E,] 1,2 [[[@S6T!QL;#3R@'9A
M^6(D(K3MF:BNAF4"\MI(L/3*$M+V* 764P]A!YX@,,RBV'JG F4X2G<Z:LTN
M]ZAYV /'A=Y>2  /.K>)()_$B4(J*&>DI8:'&J=#W)52=$ *>JE5\()F1>CP
M#+@K7P9\/REHM%;9_,IUG-?VAAS-0T'.>R[H_)F]ON)\[PS);>]5;4 54,1<
MJ<-/\KL3IQBA%DJSOY)(C%#RZS#G%]GQ_^&?#^R+X,. "U=:Y65!E&2@]X3K
MP0<G>9NJP6?+YCW<IM?\JFM/@9[Z '.TS^ K2*J'S-]HZX/N #EJ5!I"*5/S
MSW4AV@:Y*T7]((APQ"..V-4'%SQ,\^>@1@U=X0AMHYI]E&T\W"H04"M% O:P
MS EKU<]37J^&S98JEN*->3!UZ_=GP/6_G?;6$PT4QO<-PFK?=]K 0WUT)!P<
M-OQ-SQ? K)W[T@OJI=Y&#_JGDR';^CI44(%6"?]+<2G1'O1C GI)Z@^ZU@#4
M/_H:40QG'=(G\(,IY5&G#^68BC]BHQ1/4>W192G?R(E/5JM"ZD?_89DVY"[K
M#:[7ZA?VWR@5'H1JF >D/R;Y@<>(8S9[2+W&BYY&O^_\=A7T\PAQ%2#9NNP[
MC$NG:ALVBW_!RG7J@$XSTZKZBH-<PV96H^A0V?=Y VFJ4N>IJYF!;IO .Z]W
M-J>/=_G4-?(I)P39OL +(-0BSOKI'E<1A"HYY*MP3YF-,/F*@B:3$BT7G/PH
MMF,)J^:4W,^#PAX^E;)V7F$[N"L2%%+$+7JS.06_ZO\99Q7L]9A1 $RP=MV?
M69)LSV/H;.RLRQ53*&+CG^9S\5<NGI9/VS6T$O#35KIH5+^NM22'I9PIT?]^
MRTP$-ZT9_#".R9=9JF&3GY^S8@UZONTYN82LCA][:F$Q.LHT6U<CS32._*57
M-IZE;\:VKM%]HQ)M[#2T$X-^HD?(Q+'94][<TTD#6I@PG2)V'D$.\II0C$_P
M;\P,Y0&"OW:C2[,\.<LDKIK;V@9$\5Y0+''VYSZXTOCM+FT1>#&KDI#&EN.S
MO)X3'WBKQ_3*RK?LW-25+@=>@*>K^1^0QF;?^SV&GD!:39+R51=FR,S@I?@T
MX-VJBMF,=7QR:$I"^V#NY(^W98%&B*GD*X82_()''ZJ<&4O.*8GFXGXMZ&FX
M,!3WI.#1@\?"<T^GK"#O,)O3)Y^:^-!YQ;V%NDN'LRP(19I5)AJ68ROD6,)X
M7+@)8:24,Z"ES]>:#!&WR/E.^\VQVV.[J/_H1V-!#8?)R8EDC/;W[+[0L$0G
M:]DT7B'Y$Q3\Z!.M-D?)4"A9>>3EJ4TK3W-@73J1DI]E*(G1-9;'+OM59MFN
MNR;OI1H@K1>CT6%$-0:OJ0V;]TE8\ XVKY6-V,%D?.0V)6G>;QHU+*CPLJT$
M7AV Q?(?Q/O%O;=)W"W9_;PMUW+B]CP1Q;( )@9? !H\91@AM!IXI9F5MF>*
M%SWZ!Q[9E8AJD\U'=#H[Q>3"Y+S;C/?T]OHUNU2J3J.36N9[3PX.3-BD=="W
MQBYN)AJ"V;7PFB\28>CRQMMC?;.F,CUU\]/^9=-JO%3ZA(;)[+<!@U0U?KUF
M,ZVJE6.K@LGJI2.1#HG!9"UR==KIWZXAE"Y)*&4J2AO-C/S.^:CRF^R$0,^W
MNF#?7C^D+!]JPKG,7,W*,-8>.KLS QWL6O.)=K73>K7>*N0_,?<D6L,RE6]'
M0A0*3AO6E^*K1<5]ZI=\I/^7J-K-PBE4:NP+38,PCA$63^OLVH;:COBMQH&X
M%P1 FA9S#OW DJ*H9#;S>=J7,SA^(VSS_AP=:EJFW..$H*L;(X(EL0Y)/,6L
M )YO.0>OFDKS_]3!A\45=YJ+BI5;-AH*S9VZ'RSS)2^Z%HX(8_.F.#R7\T_O
MCGT>MROC&.D*UW5:=Q-<L;>5.Y:JIBK1H6XBIDRI\5>IV.I=:!*.&)^[AK+E
MK-K^EL:G=[I7-;.M$)D^]+Q,C8N&8WJ_='RZN\FZR9?[&7=![&W_2U-&ATB*
MXNT!5,FO\QE<*I^:.Y8HAALN!E%$+[X*YM3FEO!@]A:)H,;Z)A>AQ(&R:HZ<
M[S+&NL>^JH%NLG,&69FY,S3Y4*_E0H3[=.$[8-0[NT&^$J<-<8_7_C;94K,S
M7#Y%+*'H5^N4%TC+)@R0A#CT5S+7D3RDYW%L,,]'4T?F#HC_ )-W4T;P$6>:
M4MA:;?RBD8L$PO[XB=:QDG-X2@=>X;.7'\W=LU(D0")WMJ X#/-(S^6O8Q>H
MFQ_CR7MB$YP1GB4SQ8B'?LIO-*%$U>LX&GCA=8+C>P98'C/J740UO:<+-@2(
MBDAK@7\_JW4SP>@3TCQ9_%/XW?]N(_^/UE$.-K![T7L/=L!Y(*"^-)[W\\CE
M]3NB?8I_#.^5E"=*!T6YNZC<[&(8O3T;F3=O6 D1Y"^!\W.O7KT'[2W4+ F$
M/_*.DQ3&S8B?X+H]Y3VTXWQ*?>I+W#S;.3\"VC:!ORZ1L8(EU(+Y^==I/4*7
M11G82#9(T2.RH#^EETHOBDZ(B8EK?X8G)+6TO":NAJ3'#<S5]SMF8%0ZAL-
MR!5#,#RO;N5*GA]=LS _;N/>/?Y45=9-]4IC7A%C"A@R2R"F<J9:?;\\RK4-
M0+K+6$^6S%FLM%S?-I3NLM^R;C1;WD/#CZUEEF\0U=U85_+6(@)B>WDRO*##
ML) (:=U/6WD!0+\I1I*&<.Y[8=WW'Z=ZART]7:8'J%,VMH15$,\RI-U)US?\
M#3 SN/J)DM9N:"LO'Z4T <8)GO0"  3XR?]N,__G)G\?OR/S(Q.GH@K&?AZ!
MT]4\<SPW@AO49@.LPPU_1V\2Q"'3A)R:LUW<Z=VO.VV>)>&W =6Z[HO1"ZLP
M00#UR4D(!*)7Y>&!<(;]/$(>'W#_><1_NP[/SF=<..49L"&7:/1*,8RW-$-;
MKP\Z%:FB[*NSZ[_:+*()LKS4$X8OJ;MHWC4]Y2G0VE1Y$3YE:R,\N[OE/7"@
MP5@-D5K)C*$68?HNML(CZ;6^(MEZ-3?(OL_"UW Y'4AH>!*O9\!%"]MCA1+S
M$WKAP)A^@P%'!$'^NI"#L'6&W;2FYMR0]3YW&4OM^?""H(PC,K>ESX58G(1+
MAC*5N=$PQ]YGFD:S&'%5IZ8KKU0HL.+ :+LWAQ&6;.T2H :'FHIEU.3NAOG0
M$&$I$BNO7GS&MY3JA9@*Y*5U-KRP!A+_?N%IA9W%,-9;Y$SLV[-K:VL;1%@=
M%?5K2OHXR]3\7@2+B^A4IJCHH!>K4O=^'M&?#T>F-,Y+[R! '(A@G6Q5SQC%
M.FW)"2X;DG$<EQI"JSKO8&+TYY'6RCU/*3[O_5%*5&;CP>_ KN\A7[N6.==_
M'I$M?1:Y_,J#-0*G3FF:F/2 ^%!Q^1[;T&Z"LJ23GVN<X!BSDW_A*_/]9[7Y
MN.K 5\&L>6*T1F%E'V7U[2*OFB8.->,@YV\3.]-<I]E,-[^!,OKK_Y\!^Q?7
ML58HE!.@0 %<H)X2^G64H!^P&"$&A<*2A<1#2Y9_K$4OV#X,+^D-O_'5,T@O
M5/#WH7K,Q4R]=*&)1V9*H;C//X\PU'C56L>@-:*C8E,Q(,^7O="2C<)!$IYY
MR[SV#GF>1C G8!4"B"]^;'[5DG.+%X!LO2._0/(Q-;4P?IK'NO **_DC]% K
M$A!=T'<VH^6;4)6M6(#>M UFVVW:X6$X%W?2U0791*XR35(ERW#JIMAESC"2
M@61NM+:_YM=7+7L@,6T^/Q5(=YE._\M+U0_RR186H$9<Q8$H?26N-<<LT!];
ME_!U;CTH#T;S/&@WJ*=8VU'!T?AT:T(![*-0&!^Q(W[=3\ZSX=TMHE[,S=H
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M^L9WZPB&<GFHH<VNL*K[X=<5V/GI-GQ<X5:U^>8AG:>BQ?X&5 %R%P?-(7C
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M>\,PA[4['AHWHU^W']KJG8\^"6E-M5,&)!@I_=.Y.T(7$D\KEO?6*CL.XK;
M9^GP]@H6K]KGK+;$ $+3UW;;YKXUY_DM1'D6MZIN+OSL=;F>S$A#DPYM4=30
M@89 A+YL9T$"8NBSI(](C:K;B.1&IS(.,'7B^[5156"49L2]?$\^<X-A6:\:
M\W8K<]LP]"'>CCTYD$.6;_8J0Z$037]E68/IZZ!$+?>#A\>E8?N<U'V 0DX
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M1#TSRH7NLSKX0?^$G/N<]Q^*<EE=:8\N<JIAMGXD9];!!5'#+FET(WJ)?H2
M#ZC(@+#>4HSPK?Z'AW]!=D%"="FY.>SV*QW:F.O.C#';HG>T%:<Q2'BAA5*3
M]6'9>BJGG0_-'LB8--@X3..1+WHW$#$(96F+_H5+4PM608$B2 O60_/'HA-3
M6A.P--\.O;5+2A/GV!/$/>$%3GXW1J;+H'_@9*YU6^8BTU\=X'CEQ0)&9]HU
M-Z.-0, (9[3Z.1?]E^",UO]/U3_UTTRK\I_GE0PC7_;;O0@_&=ROJ"\2W%X
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M]_]NA?_WX32"+5V!.N:OXVM!D,H1]PJ0=C&%W$Z?A"$-#:W\D)0"(+D;#!3
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M0RU[5_)2(F'4*AT/:PZL@_@@F)Y")W49*.I5VWGIP#+7%=F7*&?)S1L@=]B
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M%T]TJY<1S7CF_\AS0&V$I!\GISAVX03$L%;?[/+1/%7XHUO"Z3QA;Y$: I%
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M)T"4G?>8&+!=*NV2AH;ZEK5G3>O0YNP]FH"C==K*L1R@>[PI^[9-D7>W(^7
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MH*W4M1\YV#GH'\)"^[XJDF*82T?I+%>?9_H&D*FPAO@8,V5<EE7OS?#@JY<
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M;8@$T;,:2L(!(AOB@W5L^X8_?P^7:E]- EG@[8S;MSLCLAD\Z2!\7=5:?&!
MW<BP>O=RM4&9:)/T ?'\ND)O<9W]M6-W*XWLI &"L=$#_H<_,?>BQRT,U%+@
M(/;^9T77<I)CM8%21V/!U:O:JJ]BJR2"C#9_G)[L;Z]&6)9@$-?*(OB5!^YJ
MZZA6JMQ)]#$2F.1^2*+Z?K!5(H^:Z8^RU'*1M^$I^I7$[CZ:RV2_N:=>RA@)
M.:IZ\F:CV+NK8 W]1(;=")8629';WPK2A?-W$4IDZ15!)6SWNB'=B"(_M6Z_
M7FED>*CP=&2BT[&D_8=UK!4+"DFO0EP&+RXK1=@G]0NSWH8#RT&I?=66)G\U
MI2QI@02SNT5;.T4MAQEWI-4IR0"[#+G][1>7N?L_7'6Z&\A4^\(V*5A#A;DF
M4,4U[8*+__S'5>F'R:(IWWF,=-;O:E>N3TS.Z!V>:M_)U ZG*X%[?KBUZBL8
MIQ2?M3D J2@1+29/0T;O?<V\8-L?['<F\J.29;\]D2VWE+@Z([ALR0T)IJGM
M_J@XC>S:V@\&3DAYW\77#W>MW4P1*K..)S65 ].+\U)ZBI:$<:9.,Q=R2, *
M9I!P @KY !??F%H%&'#RO>"!HC[/]F%4F\&5Q&$!"BH#Z"7X#L.:U$2=&^PY
M>V2G=M$D]J[H/@*A4:^]@CI@)A8DI[JMYY^V!42/0=H2E]7^G V0^/V"ZE"4
M'V]8>P!].0BU<NW0=RH\6NM._V"A6*P^&4.476-_9E>K%D75I/)D[)\K=O7O
M:O#,:Y2B5]75.U*E2:G151JT6;VE$\\%.(*A;;S?V:7_NC]B6MT"]TR=X/TJ
M6+K.D(TJ\8MP!J\,S@8#<L4=5CRQ&PK>]V%KRXT#;RFQI'UGX HI7"8\1"D4
M,&U?O=71&%R6($9#I=%$T^V^\^@MVBO[)3&B'[M635^=XP-4&E1! 6))W98L
M ]@A.9I81BC.,B1A*^:P !A<#[:)#A>D;2+6*W!U"N+M;J1A"\T3(8;R(31F
M<W'[XYYF_;N+?\J-F<2\K')]=0$H4XNW V6>74Y-?\)^CQ!-E_WB:B"SK"-\
MZ4DO1C%*+SE.>M?F#EHRBG06R%Q=%R9I"\F)KLFR3U(!@DH;LW\EFY(S_>-Q
M:=ULNS)XN?P=VIJ0@:8M]SIEF)YX[51.)*J^6?E&A&/GR(QMFB.2[%NCK<5E
M>H"2=D!U>H\4? *:]MCIS"Q6145NE>M"F]?F\M+^;<,1_OZPBJ @N+C;0&/"
M&SSA'\YE26Q11/,8QRPX.>V=C7WGB-VMV"W[XB_*BT>P!EF5?"V?.1=^J/8C
M@W +(HU69C\6VGHZS*C3^Y+@9P)7-ASJ^4HZO"&2?ULPM7)T1'LJ4>LRKM6J
M0QM!@K?(7K4QKM==D%U6>KI75*=:) 14-#>W2MO]L<_G8I9M2A5CW;ZAIQTT
MD9==;AKI9EN4?"?9=GGGMM^H5Y.BU"N%+W]L!=55>TXEVW]6GGV?Y' WUZA\
M%1Y31=@'&S^><HF]*68><@*!'YF*,D/9N.!R1B1O'7SONOG'[BG>"%_RE/8/
MEC(7]P=?/?D0H%3OQ_<TG_A56!7TG<?TTK-_=@KQ[T,0N67@09_QO,L.,39&
M572G=8-U5;9<V69)?U98CY.SBS4Z IX*BWGAAJN?#C[7+<23URP]A[(5A&.*
M:];%)8Z[O8BHN@4?BX':C:R!OG)SCZ2C)F01.7W 7?F<BY#0%]^?)BUKPA=L
M1BQH-'RK.YFA:RY!4K:12!A$V1/'V6CI@.ET./9^F9.1;^Q8CYE\(]9]CGB7
M&*<_N3Y/M)Z2J-".>)"KH_DE"Q)9A_70G]AK&.?FBDCL%]UNTIAPB*8/^I:/
M9(>HIC%<LM3NG1HOV0#GX%"7P,Q?$PE_H-)=CX7\KCSGG71B,G.=AJM%$KN]
M7,H;=(RQ"?9]\L,/WL1W%8%#>$$ PAM[D !OQ<:J28,V3P5,DXBGGJI\L&"W
MFBOX9-G((6\'YF<%I3[LSY(*A)+8"(DE_CXKTOQJ06&GJ6-B"+FT'LD=,Z%A
M"3GN;E:YE<FO68K\A"/9I6@;&5Z0\"6T-#__>D+ZBK NY<VIO)]JO>_ZM&]P
M!<A<TRW(JK1.?]7KQ'9-LB2AIS+S&J7#EF4_Y\@*?L19,3CMB=[>Q,>/5O_5
M8YN[A<?10B4'?T(S$D9!C)665_-Z^[^_[D7Y[;G5^*KH% P'NVMHPE.>\07)
MNX8(,.N*]4'VC1MQNX[[W>@__L74YVJ9OX<^IE\E1WA,W'B5<;&"E<HZTL#O
M7+Q()D0YN[D]RT\!)R<G\UL8W0&W4+_-76^C47W_"GVLH'*9Y<_5)?LJ>-C3
MK/U>1C(Z5>_X)<NQHPPWPWDX[T"''P1:! CT0 ?VUCGN$]79.DPC!D-=@V0,
MD+,N[N_MON^6)"#O<7>A(H3.,CX L3,W(KM.R(ST(7O+B; >">GV*(UR@-7U
M?**J@X@S*XHB"3.DA)FSPY?TQD-V2\?,HVPB"9SPYO&_8Z?=\GKNG?NJV)\=
MNOM3C"EGLVSJ0N']R;_&$[.H8CE;Z+7KPX-OK6@UTI_ZML(*R<OK65XE;J:!
M!_+'B24HUQ177__N,$6Q!B .?6[Z!Y^M;[1:7_V75>N-#RVH67;]8G!6NO\G
M<G$J87$>O#PF[5_AZ$D@-,9V_5-[8/T V-#&,I&-!C9!95,*1JYQQ7_&/7M&
MW(Q3% *16^(7.^ -)AMPJ4<_74<,?3LR,=#JKA=YWROF&RXQ9C1XH2#:9A)$
M.WZ%WA,7>DN:ZD> 07II54_CFA"@!S<J(,CO/-!T83^NF]^1\'<>L&%E40Q7
MRN,[CP+T-/"/G5,EX=F=FO*'XNG?>=15_XU.Y^U)>8>R$'W0'FTM!KFZ[VGB
M4W6K'H7L^D+TV89;65;%K)6U%!5'7>J1S_X03_*F(NO9[8+Z-<##[<DJO2F&
MAMZ]%RWBP[IP!+)GJZJTN'R$$YT=NP])[T];P_E$0V.\>L((2?V6BLOQHW,_
MAANM( ]B C3<?1U&-^!VDL=CY6/:NK;MUK?LPZJH C^37TJZ^/Z:,!6OGUM*
MY21Y!B4'8UDL2'&=I69ZO0L6=*BLOTU#'BIUU<%@VLOBJN66U_;Z_/0"(L=4
M_1;9Z@ ]KNF:@#P8(6V*D5F[35;-=1SRPHJ(])N4;0==2D&)J^7+W[&7<?@1
M.'<C@9-(&)-X"O\UQ5=[+?\^9E1M75XA*Q&5/%P-B^,-M6M;8<2<U$<DYWEW
M]*Y!8NVBM\R(6:*TIKJV<KUD*)Q$S'P&<.PH4U37/(UG!N/ N<'N2:GE@[+6
M$P_H7,?$K8%- _5O#ZT,?7U7.32ZF5$P4[XT,)\]8J%/'#67OM^">PYAPS?-
M'?G]\=4UEGNOIP[\:T @XV17GYY674@2ASS%&H!'L*. \8K""E[#!DZ/!ZZ(
MD$)RQ>X5T;")=W?A6W-^I0@@^?ERG:[* 1VE( HO>TJ?G$_>AR 5'$+.W2'$
MA),.00#$I4V]_25$2U/&-C77SIV3KT.;M'2XDT8R@MNHJ0-O)+RL+!1@$+N5
M&TDD<L1_DJ?_7\.?Q[_M/9J,3ONU4Y58R\0=\3V0VZ:-[0-2I84O(8K"ME:X
M]HG//_*,4B??7PF+J^IVGF[SN:(C-+79?8>0/Q%X!ZGTKHE6__ZWPDV$K*_(
MML44=;ACN5&AJZVX"%U4=+2%).-PI<& B]L\EMY6HM$Y-<.V%;!?[7QJ4TM4
M]C*J2@+:VC;_+LM2>5__K8QG/?Y&)O;]<&^0)Q"[W!11EO$T,'W:0,L[%:!M
M S=_G53JNL>J2%YMT!Y0?3BGNSIB0U2HU6S%$QV@Z"K+T(K/64+ IG!!>*"[
M:7"Y,65PV[[I3Z>LM;<-G$\SPDL,T[_CG&N2+M$7DUA@FP++3-Z33']PD*9S
M^/Z2X^P(6_&JK6V=FTOC]1#>LBK#%2.UMOW]]RF0F^7MGP^R=;B.5ZM;?:@=
MFTP\4]#JVSZYK;GO)R,' %B_V,[8<+&,H!=)Q'70U<VS4_T]Y4M&/:R@19KD
MLDQHP5^.GI$>I58;V45JV!'TD<-WGG%%,W4WS!BRLV- -F=92?'K#S;E4_JM
M/JG## &22QX9-R5SN]8JVPRR?ER@44T]C1QPG*ITCC1\\UB'I7KH !)0^%6"
M?&TQJU(\&1FH_Q5I*G)&L,\UM(,G1V6?ST+ULV(=<7Q4XG=:.4!A#N+6PXGS
M7X)= 3D(N/KRWTOO/9N?TU.V#.1[TKEP&:SSCB$V\PBZ47ZO6^2(4 (B8DHX
M!E;@F%KUVKZ<4/FUG673F94%QMK:GL#>FX_V63>JBXV[G&[<?ZTY7CF,>-Q7
MA@24%!M-9M_V]-(: :5J:ZI?%1=4P'@V_F5[*']?C+T;FE%#H64QO=4%/N0E
M.--^GKP1=OOIC&TW^4W'\2/ZK1$M95"?*>"8SWL()(#C/67.O/IHZO$S;+TX
M;O)']:_:J,_CQ2%2J>,#O_ ]9GX\B=!:NEMA1IG0-9><^M8&G_,#.27P4BB4
M-$<J=]>_3L]\6=)X7;4;QB8$NZ)77N@L\9RL)H9M(.6#P$.-#F ]9$^HT^1/
MLHR5C1#DUQ=F-RDYWD-#>BGSD;O]FBY^R.)%=%'$KQ@VPH@DZU4NU!3"E\Z,
M^W1:?&^E>='7N#_=1[+*LJ.J,UN?A8)/_55#&4%6(*R.-8R?%_DIJB#=KB4V
M;LQLA@!,]#O!DM8;+]EJ<O<FM9):-S>E\@$E-D+V!VY<>\;X,LF0W^M 567W
M40>YH]O.3H2IH=JQ"!E=>O@&[W/ &M:TVZ?"MM)X525SQ'#AV@,#@,#5EL_*
MOFLN+D4AN5,V+*N5)^OZVE7 3A5%)$.@JL]1,9H"<,K@&V"[)-?NS!'B68OQ
M;]Y;83O-;8RK3$0=VR'MNDEP2['1(B4O*S_"SW9VWGL",(TUSYQ1,LMKG]1E
M2;^)W-L,C#+&O)LID+KO61EPOT.$Y4U!178JJL]I_]3J'UO]>+,L0,R*<UUJ
MB(N*4?,4FFY%J40Y,XNR9.S6\Q@;LM(8^0*(2)U<Y422PZCIZ* _HW.RU09V
M6/0U1RI)/Z<XLR)<CQ42YM_I\4RU2"+Z=XE<J[0R:F/J;Y"NVW[25<DMM^_8
M*&QZFRU&4C+NOAA NO"&*P"24?S*9^W:%PX)Z''K031+-X6!^[+0(7'8=7ZH
MWT :P&<)'ZIB<>T#(9[V%)*+75X6GL0 U7X.A/REI8'^6 T'Q3=4]37?.E27
M%+\BZ9[IBOX,O\/Q$ED=B7URA=A"%>?\F: M<\M.HVB8TV-CTYI7Z.P5D?F=
MQX^:G&ZWIH$KL[!V6TC$P6%Q>%"/R<4W*ZV2D>P]M"-+BIF(R2'O",&'NUEL
M]1VT@=+OHK=6=X;K]3"QU))@TN"=]3<N!HBU^F<E01D#)V[ZE5LO!UTF,SKN
MI[3XJM!M2@M ;@K#<:0(L^-_K($ HPD;XF"5A'ZQ,9D5\"*QV^P%1G9- =%X
MK+_@S%9,QIZ8J;^>RE(MOF['5\.&WVOLV@2J:^:QN; S4G_\LRGDW\$5K5WE
M+'6IS*T459#]"L,_66^91)YZ\7;L9EQ,<.6Q+JI6/[D6QGHRN0^'VV>KWT+7
M4!)SWGWZ:PDRRA@ISM0\+N&>D5*3+UG1SP?K.I2"<,T?Z)P+PL_PLS:(2ZY:
MAG6[56TLM%)/8G['+=_*9\TH.J53A[2Z0ME*E2"5I4<698NZS&Z+:@(^/]XV
MUGPU%(?+%__X9!B.1<;AMY@AHLEN>F:Y'=Y[3VBI7<M%98BV%?+D8'IUGE%L
M2S"_U8@/>_NMWW,$V&<KR29*T)8J8OD^(.7:5Z<4WMC,ERE%=P*'[B383D #
M^P'D[AN$\]F0/<J:Y8<;6R;XP\>=-L3:01&#GVP3P?FOD&X!)@'.];A[RXVN
M^B#^!R(>@P9./^,&,+'&)E$*NZN6L,'E([XGP-\D9R?B2P<1BH@J$2X(,EJ8
MRDPWG=B/S:(,1E.A,Q4@[_5U6=]?5$/=_ K[T$!@I"?J.T])R#\FP2AWML,!
M;I%Y8V\1<23!&"30C+FHY^AE:V52WD@R(>&Y\P]5_N!&$0SD[63RBP_'+K">
M]'51<+6&1K>HQL"8=HYI\5AN^K6.B,:?2O[%<N>D,;ZK9]Q7MYLX9/3:OIE5
M&;EQQ%S0?\I+9,+K#A:39:/147\%X5\<U0H72,+N *^[7[R\MC]WI7@BW+:1
M,6F3&SXMLKCC,6B<H!+LJT7'2H>NPZ/:K'?AT,%-?:U[(VB2#[.Y5:YLQ(!>
M22AM>-*)SDK]6J"MK:Q@\?DPM<IZ;Z_CZV'Z85R@'=PZ7-6Z]O1N2G+VQE=3
M4J?+7)R<U)S3M]#7]:<"VQ]'5G71$\;(_J$I:WSPPFQAA'-Q.;K)#G-57>S0
MD$3.68*!T96J9;EYC%7K&Z)?7(-C.=VI*=8Y:(I+08KA4J*4WA&4<B![/>B#
MG9^7ZFR1^[CM&K'!UIA\5]@8SP#<J&&#@'?F>SQDJ_WG(O@)^?$OLLMF_BR>
M<HRW*S! "#AN1.'M^JZT!!A(22@\5B<U)L5/L??5NV>,-,\M!G?XC& 9X)&L
M)=.0[SS.'5"F35227>_7EPW?_OSU6O='OS&02'H1.R@%#U$J[-TW4]"$!K;^
M5)Y2J!X2A;9I/JGV2*B8_5$DAJM=U_OJ.\\5\.!WGD*.O:/(;!7*).;N6LQO
ME6=^Y_E*_N/^=YY6NP.+-;]%-Z4U]B+YH\)WGDO-Z^9?=N'N;*U_/8T\Q_Y?
MV[=\PF@5]Q+VAN_GR^\(P]%*HT'38*#9@IB]EGKO9,H-X?"HH2B>V^;CE@$/
M.\5;/SM'[KAZ^6C78=/]@WQS3C-\!6=^6X^I;C 2']M/GC\4\VI]E8QVX^?U
M\9@X4W_S].RI[1^GL6H"7P.F'DK+#%YU3*B9PGS#%M.G_92=-N86-GR5.]E,
M^\8!4[K\2XGBB&A6W?^'OC<TZ8?*]*])WWF*2A!##P^OUGSGR2)\8[01@[\M
M6WWG28W9@R4>RWR;MXKYS+XY]N#"'_\Z]/S@0,M9>Y!QT,&I[XA0>'T%IUHT
MBIDB8P:U?++G&G!/TW[)L0U$'4YJ$0T<[:_S\J';*(A$33WIC[*G4:K>M.Q[
M$I+XA L>!A-?!?3S68]GHY'#\7.3BM%6/N7&($KH@8$W_G*V@W9%N/1LP+!F
MH)-X*YRQ74IFZK&M%<87N>>!SD81Z==1<&'YC/=)VF+'DBC?- 0!),5%DL1E
M0(\KW#Y7@Z/ 3E>8AM C! /1O^ $$M8FS5P%KZ9^.!?55E+&KG\%<,.WK:@:
MR]^/IFJCH(&=0));JI*SQ-,!,!R,?(IPL\J%BZ=-F_WFAX]+3,2JME[2UN1/
M;>O BXQ2U24DI']]8;L,+A>1'GTH4N_65I,4XSDF7%T'G3#FFVH,<U[M?+ME
M^]# SHN(LK@LHF'OEC'D!G4/#V[DA@B##B'S<'B'\#FU'*IFKE\E8YUW@BML
M*!%9!>_;#\QYCO O*VQNA!A-&9^<1F&_\]0?X\.R#Q([A^]IIE9%^=S[HOZ%
M;4B'?N>)H#OMVL2\74AU7L),X^MP&O6'6] /<%^7N+RLIG9;2U/;5:IX4Q$2
MU=>UHDP1)M_DE<S\M1WB-=%OU#&%+8X&;3'C:&L+8\8EAC;:+D/EB:H2#/^$
ME#8#17YE,F[_]A;EVZ>MFXO3IVK",[E-YGCJ6=J6:1TNKD@C+M('K?CP'@X>
MA @GDH(6[O[J,^)WXTV1RIS \G@<9XM:@*J=]+'"!S#&@\SL4C5Z$NYQ\]?W
M9)QE>LCA/)9._WO,^,]'F+S<T[KA?A.H@'M93DJ*X:(I=0O60K5L! @..QGU
M)Q!6Z4UP)OI.X%[^A+C_NP'N*F &P]MTK(;^QDN-Z)]]?=/T1A)+7(;V?O1Y
MCBP(5,4MK[;/RRLDS,$^QH1W[.W:%UP]>"MBQ@:D3E =:,MC3S-E:X=E*H05
MG 8(4?NU%6DF@/>4/C.R?C.+@BP2/&6-T/M%_2M&.+A9J3*H]88-P$VLL=Q^
M(8%\T(]6A'9W0Y]\FA:]CRD9TA[(3=Y*U EUK$+T.7W;?@1(TE-LV.![_HF>
M\$Z?8U5/!<RL]7YV^R5'Y2 _L16_[I')0(.&&0A6CFP$M*B(.GDKN7O4B%N2
M.EV)WH4[932!YO?#(4L_><932E.)7X _W:1;'3K(K7/3CMAJ%\3OYZ<L.1I]
MEKYP=<(G2*RJ2%K;+;<6$,#LU<N?MK/<%5"X]%.0%K!N\PP5N_INB=3PH6XB
MT@_1'Y&$CC!NE<<-[/;.[U8*B<?^N.!SE.\\%[ FKR(<QR"N\$N-,NTB4\))
M>$V(+*C-I]7*5.GMA3C\I]&.I@"]CT$MA<)4/N5T6.AB_-22LM,QZIDG9_&)
M#MI:7'C,V=SVXXDN&IM<%PBWG%=T1?HOB+W2VC/-I"S&GRW%L)+8]3\S%#B\
M+^"(( K8,3(I91_EITIMJ+Y[(+T$L.OC[<^!VLX:;32I2](;OT"DRZ0Z5;ZD
ML$:_%?+;Y@V>/1I6N/-R)1;Y]A?'1>0X9DG%@BD#8_4##<ZJ1*\;5*YO*40$
MX18<)-=)U6D/L2M5VF#'Y7%4B&)^IM$;GSWSG K' 36&2-(F6&,]V8'-U/0A
M71%AL([>6=8<0_9 FJS+JJ113GYW X+1>U=%Q1L/#E$QNM%@G/!90N"E:L=H
ML$SN#O\,QRO$:])2SOY;=<6VS;KT%QMQ;O8\U]SBZG06R' R;G?SB<[H),K+
M\0T$_/MJUQ=(S_FX^8,27_#>#?F?[H:\E,2F&(0 T9K3V#SC^+*9$=Y[C$=:
M:O*!JXLVQ.P+,R/42[M89;W6Q,74DF08K-M]W3K28*-OL<+^\X_T0*;J@TS&
M;OYXK 0NTT'-EM@=)F<^DF847E"9BIYI>WS@(R JQ*_Y1RFG9-T]$%&CE<B-
MG,HZ#11*<>].,>*$5F(YV$&_M+ RUWOZ[$#<X=-_^8)[5O<)7/<BJEW2;H?H
MA2].O/[K6%E7R=/P*;L9TD+4LT%+N&%C9J:3=6R4SR#HZ)<J5"6G(\7@;JT*
M5\_12^P[3P5/MQ1[Z--N=/23:>M.=.>52FGE;A(U-[<3T'2.?M-'%1Y]]Y9[
M4^-(%1G4Y):[A1U[>UT!2KXV?M2%&]8:Q2[+..=7EUE_LQ[4"C?$TNW7-8Y#
MRF%#DT_U=DG $O#<$>]9YJDWK5L!#H:QJ4HK4K8=%/"^1Y7 _!E)3"Q;@\ 9
M>UJWEV9V=OW!O)_ B'@^'FA#=Q[3'R7!_:D]A)14$LL)<D$8@N+8[=J. ^?3
MM?O#9:]?,8-?C'^#=HOR*!3+[P%G]=9F?.7KJ/O2VS(9:L0/L#_;9:GT"YT\
MWWF?Q5F6#TQ+C610W]7C>';U#QA0 >QA=J7>9.TQ"G\Y+0A( D>\K:#!.]B=
MHA8ZC,0FG+#!$2O))UM_QW@_Y*G,GG0U;*,I:[1G]5JUW1ZU&L^D0):-[H>_
ML=NI%!B[$4<0-?YG1]U_#[<<LT\%O;45@AM5VGN8)MH#B3%B5(>BI');KSHX
M*<7=,D4-Y%_1$PR"HN/-'UU2IK_W&4[2#["M7:ZA'=VN#,Q9G-:U-+D"VK)F
M)[=41O-'@Y0-WG[G^5.([APB(MXU%?4;.(8-\Y+<VA.B&TEI7>T: XWTWDU&
ME<3P3<7GR<:3*+V9_)9/;_TW=<X_VUCP0I7O_.0\5J*T@\F="LJ3;VU?'U ^
MUW0<O;?!&C6S[T^8D&99<2]%3)@$,.W&T\P,US3EO-(+QM@ P'#,$#4L[ @3
MXO%;S'E _=."RPU3:KK$$)VRC4WO-UC<AY5 Q_.*X=V[.+GZFKB0QB]4YT_.
M&.*(QD&9'0>$RZ6M]^24$;)V3$)Q&B^,E$D]W#MEBY3YX( UB\?'%LS(F)3C
MF!,3^"Z/C^S[9K[1\5$4)>F&';UM;668[JD82$TE3]4.HCZF7UN.3[KK!]_4
MK^IIRGBG2BZ^8H8ZM[IZ@B?-R/J&.\?M&%@&%YK]9@ED0:N#-4*_" D:!.BG
MF *+% /2GQYNB#=;V"@*H:ABH /F<9@<<G7=^E5BJ",;-7Y0*86DP@':O.<>
M?'D0@AVK;Q2LM5?)O,=<PWLZO[/W'.KN/$,<3VTCX5ZTC:H+UV#+4+"R+R:'
M%'9MOA#(K2F\+NV0M#;M0OM ;CA*<U(M_ +Q''U<#62$!<B+9B *D\,WWILQ
M1-TJ@509 Y_^X!P\,9ST9'0*Z(GT6D!([,MI*80XB2AAXF<,XQM0_=&<,^\-
M*NFBCL/K*:D1&5N6E[3B5SY $:Q1<[B(IAP?24K_[CW2$J"JB"+<;P5<^A'U
MR<0GUFH68UQ8-];V!0F"#Q3MC2^:RC^UJOZ9$2XV_F!D."U2'X'R:1H^2?9*
MF2!C^HMADT]S@"[%34_ -GQ2^@RBA+(^@[]KK/%!59ZZ9:-Q>_6LB1O=\LF0
M9;L1V$3@]V<XH6(;01\]E/5HV1V]OV'^V_:/P&/+X(=?S7R^\YQF%1X5[N$W
M8[Y@)[_SG"CH[NJ1>(::8YO]]FB3>RDCP=-2^/)CJVG5=#PQ+:7W-X"88B9*
MWK9:7A(%M:]P$4BZW@K5?)VO]9]XR_)'0<Y@]?G@A\=\QU3IZG\C_(CZGX[[
MH2720S?S4%K'UW?>;S_)=FH5XSXR&22=FT3>,2DY)-R*/$I.B7;!5,#FPAL;
MANZWXG;E@Y<9P]*2"QK16VJ*[:00O'0T/RF4^9DZ&O.O=8JJWW^M4Q)])UN'
MPW&3""E(I^W3,F\E3%K4+Y9*?*$(^><%N%]2F*K;5J<('S"#(^]5P8QKFUCQ
MAN\ZWBX+G!X%-CZX*6__!@[;5(B0"O?SLRSKT$%&3_M%A 0'?3'123&U,IM9
M@R2=Q-K&;%U2&LR!)&6 X>\=ZP/]S-QE'-<23K.V').8:P(B(1VOWO*,SO#X
MG[]UPYA$\%Q;(A RW_TF -_.,I"T[2ARLR<UI/)K_G52G/VSOMW$\!5];X4$
M10W\ KL?J)0XZ?7NF$F%+-^7ZQU> 8(TQ[#7)H8-6D"N(X)H&QK3$W1V6?]3
M=UB:FH*XC%\=6&_#:2:)*Y#-7!X15,TN_K:":1X%(=:9I!?0?D74/G@VP67
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MGP;3HC6TWL3Z(!<HZ+VMM1'"]E+ZK:T]=WO("VM5,<4]GI5<.H0=9L*^=4R
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MX&@JTLT7,S66>=CL-*?]M-:WVD0UD][=B/8,FT):!KD66Z37F/'-\>OGV-J
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M],,*LJ<@&D43XW-=)*98,9.7CS6)YI+,42E@Z_E(FE^E\-FJ"4M#$O3[3SE
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M)T6J-ECKA<,D>M'["]:-&Y\2N/A41E_XR]<7$1)N5:"0A VXN"*;J84"[5Y
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MPD&/X0%IM@@?$8&4@V-66<JP:S5-;^7AM']K+6.1[E&L:WV LM*/GX.IF0O
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M]H..:VS*>#C4,XO!?E_),@U:*N(+$<]#!:%&T@Z_;!\'[S8>U@\+O':^ ."
MOWK.#]QZ'NN=2C>B=21AM_I)&4P$#!AP.Z:\\+*M>Y%B,@R?K;\\3=F<C5PO
M:S11R**9XH^K.BN"J,QV*Z3P99-;_EYO5QVVT,$E'@M9?I_#?V[#% K#:YD"
M16#W*323O+M= V4EKNP?1ZYX3@P\DI-9.?N]=5-[#N]6'N804GW4/8C2E^62
MX Y>O5_]S5(HUQ8^!T7/C2B,K:%SA4X/L[21(1R=!6^32W[FW)T *A#636M1
M3S'#,$3JXJF-Y2SB-)2.VD*X!JE+!=F=Z/6K/G5VP?EQ!*'"W;,S._T4T,9[
MKLS=Z,Y3OR+FKGIOR:J=H'6FG.CSW2CM@3*$'R7(-G/(1B=7YO&ZFI4E7-#/
M22#/19&=$^??RVS3_[2%7#WC^L L&9+SY]/WR /'H\ -=V]IJJ=UY6)*V^8-
M GD?D'KO(@1GA=+),-LX",2]J+"7Z8]D'MT+>%$^FAL7P%_:N1:8]2)<^;<G
M+;6O@\CT7<XQ($_6\SUJA?=R\M,EGT RDCBS.A41O;^_I"S!2H#!=GWPV6)H
MV>2VPDD^*27TDL 7F:T$[YM_[ EH2;JPQK1RP72Y\Y,.Q+A)K+SF!P:[-+^9
M>F)#,=&\QE(7QB3%1GT*SW'(4E;/3&,/ C9N/,* 75'>&,-GCN7(P]T]@5OU
MDU;.GJL0T8"I(D);([][JD%S3H5LZ-/=#4@;;1=3:?V%)$6)7V*Q'6ZZN_KA
M6'3=^TWY^/)L?Z5EEIT$:^@!3VC#7:(H6E (MR1/Z@ZRSKRE3#)8Z1:^]D?5
MN$NRX\<ZF8%FWE]ZJZX.J9E6326:TN)S>0H7*TGK!3&Z3=V9F#5-*?B0V;!*
M8JT?C[G$6!J=TLLB)+88]SFKX:!\#R="H@XK#$.[ECFWU\>Q#PKO546%+3F>
MZ-B7F)A_-9#B5:A46NJ/3NYNSJ>,CUN*<A:$^<BXD_%AYH^W@7+7UD$<<GI!
MC?BDSW%3#K9P7NAN=%>]8VQ<8_;/#6\+#?KJ2\DO5QVMLI4_FBW/JQL:DS&8
M-37+8"QNLN;5L@4'QDELHTH8W*0 ]"XEK7Z;B#J*,E@?#$NCF([M%I=5*67#
M3:-A>@$,JM\2XX_NC,(0C4XO],2*G$YMMLC@N&2?B/*U]*J2I>=,JN?!<I*+
M1G$-.]I5"DG<AK5J]PX5=3(*57Y/UD#4.*XJ%!<(5_:J9Q[M&6MMPE';EPOA
M\_F7D0XJ#]R2HMK#O+R/[65,E,,CV[;M@I62L25-2?TO>X9TK(AT5J@;BX*N
M<(VF[:$!"2958WC]O,6H:<2I(JP.'UH?U^K\ 64RK_,WZYC5&(-8!AV33B*N
M^0V;)T72+DOPH/RUF-Z^::MA6I2Y9-E(.W#;BWI-:'Q'AAB5'?WA[)\ U5LF
M8\UGBO(UV"#G I!YY<5@_57R[DY^2K<VQ*SG\,$?6B'CZ-JCO^**L[CV%_L8
MBZUS.W(""')1/!CA;YGHMBAC^S\)$#"MLFW8\_E^Q^OFZ=>[X_:#C&Y5G<X
MJYKDR>_966.2.=O"LV_=,_G?H](Y1O94T,%I6PASPG;Z;>R:3=EE:F*$(/(E
MO;?:U]H^4$W'5G;;:NS SM*%V($^B!!;+Y+* 0/2/9(VP$(QV*E;5N7+_53.
M,S;"F@6E8=WPR9Y4>K^F[GV6T?MP$-L 5&:TW2W=,N\?0VOG4/$+0()A4XBO
MRS/%&_HA_[YO@-*5 -;_S??O_P#\8[CSG[&L"MFU/8BY\?,_ .??LO_%_5_<
M_\7]7]S_$NZK#GDWM<\D!ZI^GP"YQE592^Z/B6<FTP3KFV^;2!1'BL$^QW4)
MNF]]Z?'K@?AY [_\_7_V)]_O7)GK?P]R7WG;[J624^ET#%Y+7X+S*<)GX<17
ML2Y9#_<UUDUFA\8+"K+D,#88;'C==@>B*/('LC<^R*JP\FJ_0L>+ .[(ZD4R
M5$TMPTEHO1QF-%3Z@EA 3/XEST?8=NP ]+D1R),YQ"?F':"[Y6>(\:0^JIVH
MZOQ8WX4[!756/UD?4+1Q3*O18V8PINA0AI/X@B&VDFC&^<#*; .3+[^X/+$I
MSP%1A/-^_*#/R;V_I_V%0C;AGB#^U9#!B.NX!B]^ON#],8JT)!CXP<I'MT))
M"DG0JYQ,XTV=G=<<)KL8+)A6 1MRI_$35PE,CI(D2$A@ZO>_\7@[P#-S-&G,
MGTR(M>%1EV _W;L95U_=GE\NS9-;Y52 KR(QK>G-D]S O& CX?$PFC_-K(,K
MY4.>-N7CJ0JXMSC&!6,*EV?KB:-83TF!O9QC49!!S=:3K])(*Z/CMCRSM:0,
M.][!S_%:M%W.L.P<YE%5C_2J#_L?>M^9%83^1>6 IQF]L?,G070DH&C]%-+0
M6BG,Q*[;&P(XW-# 'H/ZN:(4$=&XPA^9UO410O"(J$.M,&67RJ) #S+(Q)2E
MFO=C][4C<7YZ<URPB8AC29QBF#S\C4'/JV=U/$95XN5[G%GI0/'FA!/!N_)@
M>$PKS!!]&E05XLN5E0(!]5?UB*.1G/=12_>BC5PE@]-\(/X?B%4Z4SIE,HC6
M]IR.1).1R7F[UCK.9>3&(\72BC[:],85YQJDUJ3LXQ;3-7B^LR,QJ_"Q/LV'
M)Q";7$DW=POMZD16\[>=FD,_!8S(V25!U[IF#;^J/FCX*$HKT=>BHXV,M^)-
M*7R98AQ3<M:1D1SF),&H.?_;M:8KQ9FPVY6UY$"Q;GM\;MS:_M?KX7DT^>[%
MS%A;U,B&;H<6W, -E+ZW5XTR2V*UYOHD8BX$9] 7K8;2"Q+D.?@CHU:O@&WC
M.A*54L1D6'*E6"1%/KRD*LTU>P]!*KGL1JZ\)4D;6:PLQ,-!14,P.'#NZCL7
M^X*A<?S]"+S3BZJQC XWKA_0,JO+6$+W!4#@A7%AA79MS8P+"\7RQ]JP@(RQ
MNGS8P:\.PV,-^7L)T9SO\E!">(-"$=%KMB]?D"^AZ>^"5Q6>=,MR+I"!N,U*
M%V$A(4-K#IB!_?*</1[M58/;/SP?)=QW@1U!\C\)BX_1T1U?<J FW3 YEMH'
M/\H]6]]/Z/?2!5&FAHK;^"R-%Y+M+@#:D]DBUU90<^B9V[DF9A,,8NZ,H;(=
M*TPA+P^&\/G.F_IY<>%F9E^EQK?GTY4V'%&?5%/G-TRFA?>E[NL=O-[$%SA+
M-GD+8&8X$&@0!V]04D=SYNL![8R;-?.^0$KXE-ZZDAR2/C>#/(A4 "?5&:Q?
MR;;Q3G>3(=N8=^?2*F([3PK6E>F[>MA,FMA6U1AD P:]0N(8QQ+GE2%P60/M
M,3^EY-)2]R QL0&5J3[E)-Z9D!9S$Z"">9YAT)MO1#<&UZR$#D')8C=M<;B(
M"Q3/:!NDNL/R\,Y2728_=XXTCBP5_T-[TQFC? 3W\8,)\MHGB\[;7?-DE\?E
MR]_S'_C7Z#L%5CF)B,?'AJ(V6*;V<V=E RE+.SR:6^ZKZ9+Z_0&&YB^A=NTZ
M#;K"SJK.[1H+&-X&O$RW3V=AJ;,'V(IVG.8>H_6U$ OO:_"?^Y:3% 2@0L?$
M\[N#TU^E4IGC2O$UPM;:,)TB,EJTP#:@/^0-[D]9^_\[&^[$:[2T*V]H4 E)
MF)2K$2M&*A^:61>W4AS/!/Q(@\<_#9W]73M8WV]HQ??<9/PW?Q^O$5@2)  2
M3CB9E7K?]*S&PV.HM[!"T>E.Y-+OS/2B"49N()"(/_G-^<\[(66X6_74X0,-
M,ZIGWS+/MW0*ED[M[W8K:L)\)>@)P0]*-([+[&0S&+*2-AI44_'NACV]J-#T
M:6C'6+8X['?R_]FZ\!\G[I:MZ9459(7]T'1<F82GW+50%IIRI\1VTRYX8?PL
MNGIIHKY^7%'F ']3,TU!=]>_<47A=NSRFZPUVF@6,%>N75!SJUQ\PW=D16AV
M8_7QR)]:XW=#\'1%F0\ET%0+5&C8&Z(*;TGZL;<\>[K@3J^_:$MHQ&#RMK[M
M\OO:) XWYFPPCE" 2H(H'670953@]82=5/:^\B95W?Y&+4J?FUW\GDMP9K(.
M$KA,2/HVJ-E"K* _I$%6_B;62;D&TE&^$.[("NNT27EQ?Y0PR<[;T&!*ZHF<
MSO(D['X?-6%BHMU#D\<\B3F#*A7"[;D^98._)GNKW3N]QE#("-&PTK11%."%
MLT*,#A]EXMI,3&2LH[*#8]V.66P:V.O?#0?=\[[57+A_W+K[S*]@:.C@%T*=
M*XOK'1Y=.$]VZY-HY,Q 6RJX-VOT'4*__LZ^049>6ZN3<N,;#:@NLN#\"R%6
MZ3%=:R'>I]!OJSC6^_'(A*B'^'<?I EN P&G9A> Z?W&H[@]R6/#D"B!D_/+
M=N21V^YW1YE306'#0?Q>^E*9$SQ<?6>SQ(B4JTZ7Z^(>\!X)H0YSXM;U:L38
M66C? AX2TG&MNXB)C7CM@#/L;F^_0)Q_K,!Y;T$!TW^CG'C68.KA0$R86.)5
MVD[L,3G\=^[X$0_2#4Z8GFT_OP!0+P!?$KOA7Q=7V',]R:N0J?V]!\65_F(4
M#KJ*194V_=EMUWC-K;(<Q!J(6(T$4N0%"<>_"N*2;5XR=BX 0M*J'[[\O%C1
MV?C/%B9PW*3_+I#ILKKL4J?,OTN5S9N0Y$\/[H99C >"5$SR"+-9_1U"YLW7
M>]%VI5HT:'O&>)+>N)7 DS8R0['QC_)E*U5- A5F&.V;1:1ME]T]=)H/S-2]
M'XUT;QNF/9I?'%JWUJ5NLKJ-4 L:DST;/PRGSVT%, \]I75=V$.*D,J)#ZWN
M.R.K->M=DO1M,9,IXB8+5QR&%*T&V,$(@AC(=-C12HFJ17%.8C<Q(".#RLI8
M"/SA]>%U3V'@7;&Y:D>'=O+N+E>LB!:U<R&91Y]GY<4WGLP7 ZKRUKLS"Y.X
M5Q<  E6R'3Z-DCJP> ^#PU1CM/F.XMAI; _#LSZ':W#7'FCU7P!.+P#'HFH_
MU111[-,&WYWW6 ?5N%IBEX>C@U<C7>3P12OSZ2A8V54A)&U'VY#'@I&+@<$,
MM$)O)>BL;\Q.$B0]D]=5BRBN<]M(H*R:4D^S;W93FUU76"G,/3..6-^Z3-8$
M04P>U"7=CCV6= F2G3K4V&\H'+WV1X75J"?N@5FJL['L*#1>AC"!PR!P,<+J
M\Z$_&^!N-_BL4\<FQ;UQ]( RIUKEGNSWE-R2F <BL1%%B]LRAV@["E@/_P1J
M_:U?MZ+6PZH0N2>LDO:Q%U^TH 5T[7_&0[@7!RN*#B0L@D;C,I,P2U4#[T1G
M-$\4?.3.S"\ H0/QE.Z03;G-QIV>C.-5L5^"UL>X'"G#+$AN'OLD,H68]/&9
MON&0]OTR>0C9ECLJ11X&86-/)^)"<H)23E(T+P ,D_-RCAJ1H,1:N=/R\N"L
M7SB^*[?TT1!G94SK6ZE5_L7HHZN/?B7@*XKCNGCB>(=+/T_($R,C(S.3;N\&
M 3E[MV$7 '3C!>!>J75$]DO&9:,@)#']H4GG;Z3)BE%E2&3)2=(%X.CG@1SG
M"P"'S8'X!6"'!P7X?_^1Y2?2J-6/'T[ARQE:YKN;6 _?QB3"7=UA][FHM\7J
ML^WLF)B>^[L9D2#X/R[VN1*RVG@($$P:G10J65G*&1^W2J^Y .CU\F@Y][4K
M35K"V&"^CQ8+$4.S:YVYTDYLB'50I6(HN&%.&\3JI<B0)S"%3+5YXMS)&'@Z
M\-8%X#4$OI)#5_T\5C)8I/]ZMWG9QVVZ5KWJ3/6V[)F7)K]0FOOGC>M(="1L
M RTJ4A^@W+G35%5;CIGC]U?,#@L(P*%0:\PRVX*JP[SR!B4EBSAE[W$7.^:,
MH=HS79"+B]K  Z>5D9)X3> ,-P,/@EG/*V_V^RPBJ8/7G(J/?]LNN;7C9KS1
M2)F=81[*X"1V/E6<AYW=>. -'.3,&_( 6U*8<]^R.K;'4^>7;J-&2J (^955
ME)^=U<JC;^0YRZFEQYV*Y['";\LW%JPF8]AXEVJ9PZ<!BOF[MV6,-H3+NM5"
MB [88KEPVS>OL)UDL(&2?$<R[6GMH\B($82"KMT3_EJ=QIPL(8<A:_'F.7[M
M?#NX22N.7X7,]5Y)JBW %]YGI 02N\Q V@4A_WU>!/]GJ[S;RY!+O[7C6!8Z
M:A'#</D@67IUN6NZ4**[A^WRQT9$V"0UI!'M=W-^W50@8$EC] D]><:[9KU"
M]L2N :=34],9I7B7]]<V.F8^("E5@UI$)$V$N\C+LQGJ2I>B_$+B4K+[[$&5
M5/@NI.P"X.5X&?,U(4/Z-CK8P5/H!6""? 'XC$2<0;\C!'T:4Q09-']1NZK,
MYS+(22/R://9#8SSLC78H3+C\C(GQ).*_>?ZZ))!7)J5X^\)#W;W4W,&?587
M' 2BQM=W/W8]J;N.F6X:<H5?1V4V%!+B^?_IGS ?_OS);=]S/?NX]P)PC?2]
MA'06SZM!4\O0L=7*OO'UY&,_(',5*+'VREV-!]8;MV'Z@IN12RQ!W[LELNK"
MF>7P Y<EJZ) MR7X>\1_8^Z]PYK,VG[1.)91$1V&IA09J1*:(*$7"[V7A$!H
M0Q-)""7T)J,C2#'!4*5+@) "04KH903I @))**%([RC2! 0.\[[G^\X[[[?W
M_O9<USG[.L]UY:\\9:W[OM?O][OOM9[UQ&_N(!W[D*:%:2/4AN;.GOZENP(9
M'Q68M;R:06/&W+[TNF937;>AJN/2=G*AIZFGO2LZ-ET'6(O:*VM(:HBI;%]%
M3I;1 C//9\P_M ^NH[<^U#;HAH(>Y4#SA9R!96R<=G,F\-@/?5.7=4<D:IM7
M^K];O!ILUNHO3WMT D@-]![*.ZND&%IMNJ91@'^+8 PN,]N,A1"XPIRK9?9G
M<W9!^VB^UU"=[?7^C'!YK_(A'K(AW%Z_:-7C4=GRWD#YNEV[I%$A+-T*^$1#
M6-M!$4>5S0J:9GGXKWLM0 =FUSB6 TX *R^.Q6_?,(E/[O:[YZRI7?*%EL;Z
M;D UR%XRB#?@ZV?=1]&D/"BE0'_156\NB$EM")EV"'^+T1(SWI^\':A!(J4B
M/-/@,91A%L/06@M1Y>V4JU']$#!$"T6%*$O+G<M_5,%88<E6KYLP.JA;22OP
M?<CCYY=6?P(H+YR&#DP%>3SZE(#<@"#;0SN] M][MRU"J)&RBL%JXLB,CGQ&
MQGAZB<_0"N\JV<*&#7($]K4R/7N]S>']IU@2*9M$GGAN1#YK>P)X>^'+"2"N
MIV/>UO3[\B#R^:32;%@Z53&6+S89;H^\E+(=Z94I!$!([+)-.6Y*!']O/+5R
MEHJFF^)H6:/+J&U%04?&,)Q%U1Q:RQGNZ[NFX .@EZ[='7SX_0$X<FP5VL_&
M=0)87?^P-,&9L+0%SRYR;92<%!IV),(375^05R.I].]*JRY[UOW<DM/&0QGD
M+TNG&*6Y,_4=\)-#]V>%N>TH.B?,SSMP+-?,P>-QKD]&6L^=(9\_1H70_3.9
M3\DO#'F<N#6"'K'Y2M+6<HVX/\SC1WGMS/84[!_>VQ/K3D$>.[=]N7V47$?>
MOP$Y"+A4]PKTHTV9_=V%*%[3"D:H^R+P!"!EIIF6SP*SG%_:'PK4HY<P><'2
MC@<Z]E*UIDCGH@7%ZX"/#H<0_]=+DTPY+Q ?CX>WAV:,A+TWR28TI[3XJ'#0
MY\M.V6&Q>WRJ3TV5@L/JX+4"!2)Y*#,,:DZ0D:>9UA@;,@8L_^\VIUO36PO1
M=^)S52LNUGR(O)KPC?T$8'\"^.-49.JN%=(=.[M/D?E>I5?$U3KG(0DB>4F"
MZ"B$*DZS9CJCJ%"J9OF ;Y<!S[;@LKD$)-$6GZB(\K,O62?%Y429\BGZE02Z
MZ&[P#Z1)W7>WC?(T*U05WB3BIM%\BX)."5KK?K6S:MTL=5+(9Z"I@XK1$\#\
MCJ.*L1J;6N'^[G!J9EN+A.4O^25$%X_7B55*.=OZJM_>YJS.+NC!PMXH[*]D
M\E.VO :V$YD;\F56EAI(;<^HC3@=H1$*>D<JC#O*4@HEE%1FSHTUH:OV%_M#
MXT-X-F<<--LL+8_BKV2AI.4^J\<GQ-Z)GC]07Y/^G<%DK1K#[+ML,NFSQK;2
MG'0'9;4(SZ^#'<()TZXQC/D^2*LYV]TN-I:0R(W^Y4-Q)]\R]LVC,=_QIF>\
MLY6JD3Z,L7IMN>%" B\+2?I*_4>PD(7-#0XX.BY(N;,4&[N VUVL #Y4,36<
M #4557K4B\A@)KTYWS()'G7M'<.FDFB,@J^Z>4E/5FP:4- ] \=+_Y(*6RZV
M/Q-T@:DM8*ZMRXK/N5B3,LY6/J_#P$,@T(NQO5#1=)5_T17&(;=6FG]4U,MF
M+_2&8?:JB=IN%0/&/A3B5WJ=">EBOG^B9E3*Y46GDM.N0'R[.(W<-0WL)9O:
M2N:/=1PB[[_^SGCZ*BS_HT2$@OO#\1U,V<=)W:' 27+[JEKI?4THPZ S?4%;
M-:<V_*6)L9V[1!>GGJ/^<AB^FK:+5G0MW&3VSE3Q!K J6H\<+,]CR]K[Q$B@
M6C^LW+R6T1;X8;@#1\);J%\D/?=;X:W")[&Y;M*G0D9R;:KHP7G-D%U>^^T0
MNGR=GX^GX\.].)*HW2W\9@TP^(W?'+IT)EJ7*K=48 1<[%UKP0<ST='#F=3"
M@)S\P509X*@_DCM9ANJ@>$Y#_,=SY;Y?NH3LQ3+/D6,&>A9VW2R5@_YEL]#-
M3U.'7*$>D4*\!ZRT*P")T%+#"7F=H@:/^@F96 ?/G0I;,K&NO8O6SX'!Z/C*
M0BBM&<14$FXVD<3Q ++LMFOQ6>9KW]:!_Q_V3-M3*REF/F0&8# ?)ZV'@J2K
MVR1.K?2C#;W[6^Z"H:K#ZW!O$Z31K'B7N6'^BNUVS@F 2W/OJ/38=2SM&7.-
MDRFSDWLL;N5FS?/#0>J16'-;PM$) '$"2)?AO?8L/A!>8F88CB.7V_.W#9MI
M&[*Z.&^E\,;F$SX%VK9LV*>W;&DKO@Z8T?I\5J\L6*+Z0E^3QD'\[YF&.SOP
M,38Y]%993G.:D\'@T9F=Z&./ V/'QQGE*CS/_:_H(;ON^O&.TQVDJ8W+2XHA
MA,FIO,,B^6-&T@'09?CWDJ5LKDH&] 3PG'&<= N5\&TGW&7?CTQ2)^4^/UY'
M'NEGOS\D3>_S:RY<04YIQ&=F#U EF\MUT@_XO@X[S@B,;E/M@RSI.\V5!L=\
M ?\!0$=BFXJ#T60U%<U/ID=!)P" I3\(T>KVI\>CZ:!3)"UVU.*.@XF-BYYZ
M7+SF5\3L*2AEZ(!\EEV,!!?[UEJD1;W_-1-+!/\5/E-_:RILUO^\Z7("B!P[
M 2SHTJJ7U8\E(S\?.G[O:O[XXT)S^(&T5Y .K?RXB\=]R:_'/C(FTGV0'C!A
M"F4<#TA\\V5T;)3E2-NTS*27'[)2#A[",TJ4JQDR.)8V*?8-=LO@<8[Q.Z#-
M]L5-8R&>&O\R/)O?8J 3-^^U_V2&,YS!'*=9*>3[2]*1RO.+I7_Q]U_STLPC
MP!/(A]>#3ZYZ8568!J-4_B1OBZJ>8%ST]$/+>;)_A.?/[:-"D2PK;+T]=O$O
M!('N&8*O^YXDGZ8/\;:*WU]6//G](L^=B9M/;9<K5&XN%@=@HK]J9%;M."C:
MS(=>.F@JM]+JEQ,?W^F9<T;!9Y4=]$@/#O[W(6?F2T'$L_K,X^(30)LXJ\2V
MT:%XH/>^^Z,CE9^$U?]60OUR<=GPKWI+[II_Z'EO_(>EL)PRA@IOYX$7DQX\
MX9ZR)+9RT&7#KM99Y#<L@XWM(K^<#Q$DLBRKR_@S#G(&\&O)3:HA#5:M7GGX
M55X!>[5R!:71]SLZU=(H43M"; X\QCN^!;M[></[H.($P%$@7SIP=ZUPM'D^
M.W-[Z5[19XU61%.""C[-Q(LU?NG))D2KY[G\I.)Y4XZKX5CJ=[/.7;P]1VR4
MW7[C:W _K^_;L:W 2DH%+=2B;=Y6&HW[&K5+;O_THNV73ZDF&C>$$05;OZ;X
M\BB'3WX@N4M__Y<7O-5X3P#._<8R<RZ1]^N>_G;>&W**C#&T/;1B6.&F1&].
M%2(@0-%Z5"5]!CO0V2<*I([X0>3H8#L4Y$&,0:-D4[?]_+'-9*3):Y9ZQ)]F
MVGH<YE4V,,;;P^,US_A6>&JF7U95:AW9OW>Y(X:NH9=[B5ENRD!Q_W^++HLO
MMJ<.=#L^-44;\ /Y[#U'BZF"O6]E)X#F]<@MH;\$YM32W_M;Y$5C!&OUB_S)
M5#PM+"I_R'241+;UCB[J]@]0LZQ3%D8H.:5O&%6)<P-?;X6AB+D#7:4G@'^I
M:#PE("EC1X8-8RNC^97(TAZ>N'E&< GW2^U3T'R_[[C8O5!VIW.R83R]G3T#
MQ[[XK\.XX]G4VC)3\Q0RN:V\O[&>^6NO$_Y2J(E\<ZWWR?Z?]20TT>TH4;[_
MXV+J:8+ZTW%_(6FU+J>TY @'_3);DC#AHF97$=5V]^\@D8+ ?V; /P#_!88N
MLCG^2W,[_XKHB@> [^1TV8+O?!." 54I%7!5T<E"9.JF-FM+=%&/U=+!B BZ
M7.>8FR:4F5K+?54+W"^O+9MU).YO=,A5Y;U_X]'1A9_DG>K4?Z@>>N2OWF^]
MRL\Z%Z&(7&GPJNC>9M^)<"V.S7&UK%U-ZWP_1V]'-6#!4=LY:76("-/'0X$&
MCOP-DQ).U69# >@$2HX-+Y_G3&B^;9HRNS18JQ^DI=@VK7=X_I^5CC@+'NA2
M^J[%VM37OMX#_U\,IO[5_:)  =+O7RD7[AW="EL_Y'[2.77O-#-,G_/&71/?
M=_C]\"%A]6"#7+JJ"=^J"0ZN+\O1T>0]M< >+/)[^@G@Z,:;7T306TNUM1.\
M%CV'PAZY>?U2 <>WCG(-(<,!ZHZVAUJETQVV G7MP;7N+/'0>\A'A/$3 $YK
MB&M*/.*:#0ET?NA0\':#0W3N"TKF*L:;^QIO.&.^)T</W]7PG]3B7'I/HP][
M C@!/ H0^*YTG61_F$<]2'L40._714@X8G<XJ\F;))GK<4]*BV,3*_IC^YSG
M$V5#E'VS9.3!4F>!#;=/ .XF"R< LN:7.C-)XZ0_JWVWY*DF^<R)FQG/>@UA
MJ^%T#<M\_'1V68=0>JO\!]1T>7NM5D<V,]G.,?<OYGKRC>-)6PGD>P7IZ,+S
M$<"_\[S 7TX^ =S[VR=(JO^M8N0QQCCR&^*T25+?*PJ/+C2P/D0&#J_8+PQ;
M]?+G(Y]8TZ#2%6V/&YQOJ_11Q+I/ !I04&RTSL["7-^=+/I/N1I_(5D3-:X_
M+74JV$^IXDM=1>0?CUG^&];SK2[-J_JR'39(&TOPJ0SU. 1!$,@OM'T33%%<
MD*XPVOW*7?6NU#;!><N;WEZ0NP+K?Z-US/[HZC78X%2/BN-'Q(<S7VR/LE7=
M_P3!EI4_%O^;=ME1'=+J'J--@X>"ZAQ_;AA=?50-M0Q )Q%SQ/GY7LXXD^U?
M@"RE(-H=(F!1=,D29U-F;]YZ78?N8V])C_HTVYF4'.B;WXM7YL--MT2R2XTT
M%(L4\+[)<X3"_,&>M<))Q_GLQ>UE-"U8JNF=??D)X'2<S:3\"D= OBG7:2UE
M2X32@AH;#22D<N(040&FJ26# 6;:O 78[Y($J"HKG,(31\;HD5R4#RQ.]:>4
MM\Q7N:V#*QT+E5?(?PT&6;,CL$"*C]R/RRQ3WB/UNSH'/YX :/U"$3^%F'9O
M"XSQZSH.!]A'VAQ"LUM;VR9>?I7]-O7Y!% W= *8ZS\!+/6>.2/IG:O=V[<T
MENHX*F1T=#4$4;IY;>T 1JDGKAQ,C8E$7E49.6+<;>M1LK-4<'2B3NDA+2%%
M"G_.*@07XB):X-Z\SS*C+S0IC1^+%[A KZ;*MTB';WP0G'4ZYA?X(G9<?P+X
M3;#TAX110U(S-L6QR.R4)1$6R[8YV)JV^T&%FP9$ E'Z2D(Q8NN\L5K '4TI
MB*G*C?Q 5<OXRS$$0K*%U;+,(0X6B?US&?C^J@^OQ2G^QL/(^^Z0 ]9+;\\Z
M'I\7*$- (B57FN_G*?R?G7MJ:\I4E^$?6&B[7[3]WLRN^NJW#BF.N_L#9BWQ
M+R!&M'4M!V-OIBHMSNU60>/0<$]#HW#0C]"F(+"%QMQA0&/?&E)$I=@7%\H&
MH02USY]]OZ[H/VZ[5A</LP?NV!\$S$0$]!XY5VLB>*&]:.(X W?+ES)NZQK+
M*\6JAFY7<D5S7M[(LJYK$%6^R42_*T9D],'/QT-Q)0H,4JMW01'X,T:T^NB]
M;,.K%J:1;\M[FU2\: O:!+XA_3E)N)7H51HKT-;_<5"JN%*?"-)N;A_X66EN
M%B[CHAE^7J.7T6%R8#V=0OT)Y]8'S^?DKF"9#!4L;**K1@DL'-PQ@+D8=/A'
M&\SYY7)J859XB,\]C>U OLMVP.^%O=N_=,+B&$Z6M',R^D4;G *VZ=T=3W:N
MU>\R8$41(1N1/<^<#WC=K8<%G4S#D.(MZ.GNIQ>'D%>\4&Z4L,AP$L'1BK6Z
MJ"#J>B</3>L0_$Z(6;SN%[ZP]2VNDH.M)?LW'4B&U-LB]ALM<VMS$03BJ*3$
MN5ZM4-2:<&B&J %]SJ8N^D5;<(&[V"\<J_S5;>0:-KDVBX."RG8&;I<K.IML
M\$(B;4+,(V)0+U'GM9FJMLG(T,47<NW#LI8_/A'>SH&-%42+V#U]M(+_5LWQ
MTH'36T.;;%X<'IKB#)X)19T UG)ZD>%;(BZ6$ACMS,+;_.9WQX_AE,Z;JO/9
M7C;Z ZZ>6774->F22X5.A=$*Y:(ZL2,,*MM/Q!"11EMZ[T+V/,+(1V=.:ZV3
M6T0ANXA0Z&_9TN6,<OJ )2R4ML?!N->?#00,JN1Y<GSIW!BVK!T0_(X&/] O
M1*EHZ&*EWEHPK!C404FZWGLLOR"9/8J3/:H1O;Z(^2A;-5VY/:8(*8S(F3JO
M];.@[/:.1'LQV#&P+3#D(/X@WLPN_;+.F&('QBXID=/8!L*O[N*PYH/;ZC*J
M7?&0#MS5UBHMT&E,T']-FX$@L"'A'LG[]S"*0JZKH"C#G?.G:DYW<D IJ\:J
MW#.(M*<ZO"YI>'7:OO(#!M\P0&M?@CZELY4YLJ>H#G3UC!B#.$!!E\&NR3T2
MMB,KL8Z"I26H!EK>%+RT<IO(R^1(WL3S\KKHX,3R^7\S7]ZC3-!PWX;5 @6!
MI5N<$@^I#@O],[MP\9+*:_,B8],\92^]/_,T3'[^8+'=A(M6F;ST)C9!^S.Z
MH5GV[@A5U9Y=[=CQ.K=5U(#5>O/0)FS]NZF)2&)H>J0G 1LQ--F4\KVKL\8O
M<>A )"%*;MLT^?,%4FS3_!+A?*L58\<+8D0T+HC"I(3<5$$;=8B)&/%+[8DV
M&2TVL&2C=:AW7N@3F8)\EA^20'>*1BYS]K5WS4(#50>CJE)5HC^0ANMICH.Z
M#-%K6?XOO0/O58I_#TS50J3X6/T:8*\5_"#?1J?C[NVLCPM/>SWA<83?0L37
M<KWE-O5"K1FM/6\/]6VN("'^Z);0;E#W^C5/% A*>Q-48X1)NES4-,+8<<L$
M+0O(L"13QJ31TR:_VKEIE+M&:RT$VL8'0U"V0<PA)Z-YN?.AH;O?ZDBEOGPK
MAH/W[>AP7+-:5(^-W$5'AM$XSBWD*_RG(UOO^GQ'M:J#6*G=BUL\X#*-6HNU
M+2L9O["*R7/]^C65-*2.O@UO@2D5/D<>1-0 ,]^/#OA-) EP(Q<KJ$2.+9G+
M+K%]$-1WN'\TZ;-+&@LOWANU]S3IIQ4KY=I9*;0;11R9.A87%\OD,R^S6P3N
M"OYTX,4:9OM'\J#$T8\D9J$$E>ZF5OT\[#$N5"^Y=LN!.-JVK+5]!CK6K5(7
M9QBU01+3-0],AYM3UCV#WR,=M\W5\3K; @4$6H3,]NJTKF2@K78$TA"K#+K)
M:'GOJ -979.$AX&M#B,O@]@O:N^RF,R/@Q;*GHROD+(E1W%%>35=^G?SPP>^
MD =JX>XW@IR!9ZJ.UI:?5AW>@,SUE P:MN-1(:DL$FJ/*IKYD-KO/59#\ZZU
M3K/5#NLE6:SU[F_S'[EUIU>4OO\P.[#;+H1<U%U%1W/XETNF)(;L@$QZ"K*/
M-ORR2//[X+3U0 E,-B(X(U$GFT"X %W;,^H]4\_=6;DU95] M2/NU(OFO6B;
M3P\;Y)ZW 1YDU.ZPCY;TZN/]=V=&&7'3)F@L*2'.>OC98V$3Y)_U(I0T)Z?Z
M!6U_A<F>OHHW38^EW"QGQUH-=H)K:N]4J]R0>T4#AFU/6VGRK_<SSR3]TJZ!
M/5+VQ_?T2N<,%<?;(CK<U!)TS6)9!3ZO%!H5>!Q.^3<]7[_CXNA?,M6+O#N7
MY/-HB"SVL_9#O(>-*9_-QBQ*8B+!@,#K1H?UM>$DOTY0.2>CNY!1G/VDTNRW
M9;*KJ")-<PHF;>).Z2EY<V0&5<A!+):!+SM"Z-FV>; J-_-?\7W\?Q#'CFWZ
MV%/]?GI<DDEA5',Y@$H65HNE2\&H_E!RQ -0A#'J"^Y[M*X'FOILR*@/GTYL
M>6UB]^HB[SU/[9NORBP?TB0I<?+>MD _NU#30J_HZ$/KRG@>%<XMNW$4^+.V
MW.7](@3PEI5$)H?#3C;)PC-#OS( [9<^UKATOBA?1<F#! O\8KT$HY@J6V1G
MG0!D+8E+T_I%JYFA@R#.#.E3Y<?/V=<*'%+G5"[BM>S%-J4V<G)TLH(\T6\K
MTGSM,Z+%A:R^O.%H>IDM(J.2;Z;II2CR]B%%_ TLCB5;-;1&!KQNI[SN/68T
M:>=I8FU7)#DKUANXC:VB>809*U K'O'N)A/=9N(>[ZNN&J8+]3>&AR-/&WWW
MT'AR>4<TM\I^V0Z#+\7'D<3$G*EKNF(+9L#?_L^*D[]]"#5V+!U6U=>J052&
M'HP$2+D:?W*S;XE6[&,<TI+X]'**/VTCVSN0QP.Z$OY6\>4>0499=PT]\S W
M1+36=!O98[LV26F?_KS168-)GJGR-,-((?%(DU(1QS/>WY G (O(#BST5*X7
M#DYU=CL.D;N@?]@>\T;2<C<_(<WP$R7@H$,W^_+%AZ:^58R6 SA)I293\N[[
M7;(C[\@<V,^.#K8B.9E#.(@ P=)"Q3_?[V-,G0!&X0(9(F: *E#5E$=$>V6'
M)[WNT0 )^?9#BNS U&W!XJC$?#L:]H:07<P<8C++NH^/.%G WIS-O]NOO1[5
MMU\8.*6WO$H5FK$:EU+@@<%C1A;S^=")2@.=<9B6Z1 <,:E0PLQZ&01*K:([
M]%5ARKGO2\!J'+A%N5G&FZ+.0MMBR<W^:($3P*F4QADS"ZG5$60:BNDE6V?@
M#JQ+I9: ,7DYR=M -[GQK[OB%U<^3PCIG@"V3G5WFL\)@.^[V*Y?A>:Y<)>]
MJ%U7TX>L0LAZ.+-QMWSHH8WMXZC8A_;F1AW]NL*$775GK&4<R$]IK &8K@UV
MT/KQ4044SI*BWC1A*.6&?%@C&,VUJ=SM>=8YL*S>$B=8_6&A*X 4]-*J>[*O
MS#*)+6R V,.H=?B:E,>7:VPY\!D1T'A V2/L#NO!67HMJDMKQM?DJ2!V'^KU
M264!GMH1!(S6_54'%WAK&3<J55?]>#7Z5<%'%>=<_6&C%%#@=<_M#WG$%,ZX
M1/T?[C[=T([35#:'KB+W"(Z_B7##0N^NGX]>U_:CKBO$5-L1%MR,I=Q$L_/C
M'HNX8#]@$SP?E_C9Q1#F[' XH$#&[SMF\-*5TY1RZS1 MDX%?O6]_HV_K'5H
MRZ/R< :V(N0#T093XD=71PGK-U7I 0ZR,U_DI"M^CQU7L[LQ/6/G?L-A\/,_
MHMCF8!7N;[+X+6$@]>700?7[X._0GM0:B7#'A!<)Y%7KC9O2%]RO][/XC41]
M KS=MNI<GV3:B]0N\Y_!RU.['UOE&/1(961@W-]3$*F@<$\X&?+!^<OB#;@,
MBOL3P&F%*0YM@3)*Y-7A'AJ-PBM#\<5'I0D:A[_W]GLI!]YX>O!2[P2PERSS
M5?4$0):;VN&6TUS[<\?!-:43@-\)P,.ZKM\U\#/*R]=N)_"W(1[\[!5Q8WZW
MA5YCF[N"NLI=/!HZRN:$Q<9@OY>UT$;31\_'LMFK;JIO\^;+'R=N;ESC^<I/
MN2QS_=/,IU45O&+\"_2W/M_W:X'$X!\R<1Q,*@ES O D5]DM>6PHC(TX&D-T
MH>QNT<$Y=,1L&%\<!I%!BJ,; 8&XE%_.0;;Q:Y'?,I@G@$.IAUM:) !7>Q5S
M7::&\7H]H]IH#&1<=2,1KZ(Z?P[RJAR,R$@4$D9@^=!A0_$W6E-4:6^6'1+"
M;'$RM.I&Y:JZAZ:3'I )[?91IT(\X44LJ<-'KW.@M\=N@<*=H6Q9IL]QQK@>
M1OB\VUWOUA>=,XLLB=JF@P-\%:S=8]>MFA3+.@D+M21"";@%1Q*_&2%>+W L
M6G4"..XQ^SX _.UV1J[^**@QFM1%E-P]/$HEV@XS*97%Q*+,J,[=S?9MJ_JK
M"+MT$P.: TTRTU0GXLW;"0(EL!$_P+6:PO>!6%A<,%3I:WRN&*6<*+N.YJ0@
ML)Q\\<E@[0?F .O0?SH#._Y/9\S_+YT!:LYG,&#%BO$B%T:7+_."9HE?4^IR
M6@WYU;W!\^'V_AX"5[*N0OR"L:<:[;6%-D";D?/R\+Y3O;G=>I@Q3FH8J)QN
M:6BC7_1X)N.2]9R?L N31\)N6!"HS'V;$!>=_OV7R"DI[Z_]EI$SEKS+('+]
MS6O]>$?_G>RDI;TE[\YA4D_SRQ"!]KK/ MD[_([7'/INEL:_B)=H>SG=^)OI
M,8OW6ZAG,R/R6Z%-BJOI@+>+1NIZ_)"MWWPI3D;PV_!I\)ARKM:M$-V/R.CO
M2JO!$8.++]0JGO]SDQBN)W6G<59[++3M=AIG)9LW-3F_SE,N3W'/3L^N'#!4
M7\0_36^_VS*^>RL8(*G.7:X:5#6L[Q6J>\\#+87*X,0GEO<\PN>G;TIDS*,=
M>7E(=+_K#<KML/CQJ&]_Z^ZS V%"U6$(_]3% O\+KP>'Q?-@'A*257"X<N[/
MM11K^F89J00J&]^:Y49H['3\C<729V>]U,N_T7AE6>R*;.DY7]!(^"!0Y@IR
MA\(]HP79N!/I4W=_E372_FZV?\Z0%U0&<O\^L+V]NI:/&!5Z,#$U$@,)#84@
M)*KF1M<#(_3YFWIUD:[QVB*J-W/N[ O/)@'I#IYZ29=K3#C;Y6K;37]!]#>1
MO-_/G@ Z;:L?I<>0$#%^&ZY0D\HV=@W9HEY3YKJJ1U,;8:9VC.!E+K<J<R6@
M\D,Z<71\#KSQ4"-4WC\ZVGH=)KAGJG^?3U97&YZ!X;)L:0<11I8/J@1!A)@8
MQA><F+!1T.MK'A]5ZKIF-42(XGF;Z58AD649&V*E\"WX[!Q0=H3ZW0*T1D]>
M#X/>GLM_9!YYKN+)1'U*+WB8QZ *M)I:TL9IF^TR/;6)[ =[J(I6OZ7;@$0R
MGIT W$A6.[NK)1) CX5IE'J#;R,GI35C6-0RD<I-90$.#>0^EE2$2V27>E1J
MU\WKW@5Z(,3EU_DL[TOP85Q?AKEH(S+FM'4%YSG9S$K6YE?JCJAU%M/^I,W5
M+$9W0#%I6F=G*)]-..EB3.S[;=0T&YN<0X=TL GFO4D9*3.0:CZUGA+8D\VJ
MWLZT95DF$59F/-_VLX^5A'N[8,U[_2#F,&*4-MA"[< R4/.[\2D5'*7F[>,@
M9X"B18.!QMY.I'*XH7K3?],)T;_3B>1[7#<K1OGKQS,+@M3MW\BW$VL?7K;4
MM0FIL+0RZL3VH702L!@P7/FS ]^L-.2S9;9BN6U _GI:O?WO]SS"^*MVKL7;
MWUX_C<U@Q,QT6&CM2+N@P>0-81-N0?S-N<\6AP!M1P.OCA- ;$GS":"<IBG_
M^,?"M%'#AN8>U?[E(8'"N[#ZLD]>1TE!IC:K,J-!75V$4DA:Y,\'/*OACNUB
MX8V. NCJ^!<)?';B6>Z71LZ= #Y5'9X/[#ER/P'$0=*MM(ZX=N\N>XTT@JHU
M8 >"7V70D<LR')L.]112:N18S50KIOK%A'2P7X^2_J]7KX1-7'W!Q3_(V%.W
MA);L-)+PS>39_$I[E^A4C8OI/#ZR3BB\>0RY%T4BN0KZW8N)<],.,%<94C&$
M!"[5FZS[%LM")J\92^Y*V-?ROEHX%6'>/M.1!_?GJX*5*NUS4L0?@W8_?1P"
M06Q9U2<OCJ3;47B2OZW+]<P)W*H?\W[BYNU<UA]XO71'?;LITA_=V;$YYWC'
M5&46+F^R\"T.(76C:,<[9O-;:9J4C]6W9H%K E!&V2FI7^F3S>%:+&-I8P?0
M[;LW/!I5EJ;@O5S4<33(.D/F%+>1E,3Q;<PI;L/FY26,1=Q2>XUU[\Y 03T\
M30H@"&E!]A2WJ=RU+%_.7O@".)]+J2K2VHB,.;KQN%>3'*Z;T!9>BWA6W?;M
M6_!!$Q4S/?/ID>_++]7J,<';#O\N"3+^5Y( \ /PKU'[L!)&6./JMG4KC\Z9
M0.*BDFF5_EB%V[_&HG7*%60),0PJ(0:MU2(H>,L"8 [22"I'A+%"DBQLUO<.
MI4ZE6+6]AXVEJ2(+=GT6O502R,>HE<M*(302;!3^!IT\QP'^]P5U@D;R1,()
M@-TV\G2 $9X\3KG'86Q:L)8QV0IQI:6&11SW@$M6UX=A5N"AWI:YL.#94 G[
M%R"*49$(7 ;.95R4K_'1VHL&5748>AP?T(UY!!YD6'B,*>&?62GS=5W?;8\;
M!IVJ:>UNH&#>[=\DU=U/^:-646\CM/Z4/RQ1T1QX3/G6(WQQ.E8H:PXM(,1'
MH/E-GO*''7FR2,7;M6I5ERD36'_AM\%=5>2* %>=.=.31OLRW-:RN^-7]E(K
MI4%.+TM:VTB]:[)P%Q#7]->^?+QF*%.>%A*9&I0[A-<T>$0-<OECXE!T(Z>"
MX5C^.2G)W($L?2RR#6)\:WYILA_:I,GKS7WMIE*-I5(?^]M+)X!WR-W+ZVE_
MKD3D(,L5QQY(K;D/3I2%(KS"J=O:<XX\)X!!!_&9QB![B.0)@.K;_(+?^UJ=
MW9?%5)_$/_ZDUA]&&,R(PCV>(?X*J^5,'6)5JQRX0S?\35PYEP':ST++%8T2
MPI:&^KHHH8I"TY1^4!ELO+E;K>5(] [U0_I'YS8,DNOBT>6MAL;FU]@AF$]8
M;'YF:FVOG8P\JL@Y\?;?D;LO$K37,!/KU$';'.Q''A=#.WR41T%Q^2B1L!!N
ML%#K FUO)U'MVF6N^J;B]FX].;WUO^=9PJK:),P[S\(JV]L>ZXRQVS;&AKKZ
M[,[1%U_3$$(N/#%H!"PFAF8D*"C(^<MY=LOE_Z"?G*G(<KI$Z&$ (R5%?LNG
M]N:DTF3<L%,O(DF\"Q8_%I7DL=1?R<5+Y>P;KAP3G$#EIZ?(4Y,S C'B;U(P
MNG(ZZF4X:B]*,!^+BHLA&/QRAO._:,3F!X&F>:9YN4)F$:S?<I,:$F:*-S4Y
M5PZ:N5=\W]%]0K*N3T_/O^02&\PL.P',(+Q/ &O4:[T_$W[H'[:UQ 5IOG_R
MLO)1+KU)J&.FR8[ZSG;F>[A:A".LPV?3YZY2>[!MSGMQJYL)]=!"KH4J8^K
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MT4I=P8I#3+J,=(E2&(N+N1EU/?)GU ^#@^@DC);#3I<PT\GJ_?,PEQ3!8JM
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M_2C@ <NL1Q4II\N@8\<X )SC/^224=_(%G'Q_%U39..>C7(Y7"6U5;?+WJL
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M]\U'N;VICZ=*/!0$PUJM0TAL6(<*PV8$*)X1I]W/.YW=L!6V\<O^ Q/OB.T
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MI?]3,$5.7;!?^/&?Y)N4HCY^%$[<\*[(H6H'_Z''+P5D8-1IPHPVU&1@Z(,
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M+.>6[YE%%VC#>37&EZ929X]5)V@S,;N[:W1A><4?JO.0R_9[C_8=,=#V)\C
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M1L.UCP8J@'M(K71TJ]FSE(<\N@A J!JL5H[S@@O*W;0-*X3ME1PB&:^\LBV
ML=26$,=[ N,F;W]*1$B%GO-V,(*1-F"YT90QTAQ6W'6_1\Z1XL\7HJ+G#^_B
M4WXYAZ1(@0'G;NA_%]J);PN._[^(>].@IM*N79BG;;MM:;01$&701T8) B($
M!,0)PCP(29B'EIF$@"2,8>JV!1E,:&8)DP0(22#!  '"V*(R&A R "& S(11
MD!G!XW/JJV^H>M^JK^J<JK/^[5WW7;77M?>UUK7JKKU6[1&1KD,H3^%[V,32
M[-]J;/B$!:UH?OT9&.?WYKXX1:\2@39Y^\"W=ERPYI 6JU99@:_ R*=>XKV$
MN[#GDI.A]_]+ZC@?U336CU,:<)4F#E!K(_.$1EM$+KE(U">EEN9$A6G<P&M$
M1PG].SYY0CQHXH*VX935Z$;X" ^>\S[8%C<M?6E7SPM[5_R3E;<H_BO95NA?
MZ<=*S1*(/ MT0 5GER'0J!\JA_">#N^^=94)().D&"X+/1_(-<*\U5"-<Q)0
M*Y^A]G.RS5Q]:F7(C@CO*/1U@"Z034D*^!07XKG(J-.[5/6LZ\Z Q$XIK5;\
M__4?KL60OE)WHXO'!&&;0R[N]VXT_GMXR%XKZ3:O\ 0(_6YNY/]II"=__)=>
M"_VD']:Q%.@E^"N0!9%D/@A]?:O[SI=W*[&A;3[.4EUD XQ!DUC=L'6SJM5[
M_'9XFNT#K>5_UW]\\$!F6$Z^>+0,+MJ7T@_ ]'H(_:HZ=>^TTL#&%0*9K7VN
M.2"&XH;%D7)-36>R#/M2%ZO/P\HDHD^X%"LR&4_"_?'KK5'/TWZ#JX2J,C;G
MPD0X93W)A&DZWRN_Z1(MQ0C").D 9>8\ KNHQA"0,<@J'_??1+S?[EEB4W6"
M<P^OL @A><TK$L"&F3PEZQ!,>@P_P_SJV4V"9HI$O+$"IG*<AR"-6ZN575\F
M4,M?N[YJ> ]]E)QI,?KRA:F>6"Y4K*E5Z-1Y_0?[&A$)\>% FPI,GH@D454A
MC)-S4;)K%#"'G!\V%^8M;'Y'DU%XQX),[:-:O15Z?*Y_7V$7#J<#U0[7#*?<
M'8;-,M]8HF,#C4?P\]2P&UZA9.3<GE[5)$M7*IG=J?3;ZG_C2%(S9#N('E8Y
M_M-2VOO)VEZSG,\C^QSA2X+;9? AZ>?(SLV:UTV[DH'7&^0#M1>>-CI"W(C5
M?^N?(2_CN+UR^J;WU$VV!CQ(_1_-[O\KY5@A5MK ?-C #@IS&85O4RM)'H""
MHB0330 _F8C%*=,_H!A?D/)N358,J]="O\=SHZY&A#Q8!L10#IL/*-Q\@4+$
M4<%,:DI?:FJ:O+R7WE<6OVH?>@L+P^</6EO+RFB^%4=\9]0+GR 8D )3$A45
MHXF>-_NO'?OAAD#U]>YZIH%1Y$=)UQPH/FE6X<)=:@HEK'JY(HB8C)UG.J5L
M83$&YX.7)NIUBOX%8T#=EQ##MO* %1=NWTF#HP61..F6LUQR3>6/GS2V7WZ.
M1MPSKVJIV<-9, W)<R;E(RTR+U)=LN%V%//1!4;F8U&QM#.K<LH717_K$_KI
M%&+DSP[_^J)=:<S))A'X[!'CRCC"C<9BF6,%%W3*^,7E:.5*I3 >!=( 1ZBU
M/\V5 DB9%9PV!-X)E DU81O#I=AS7+R<G%S$[\3_YM7]K]G-O<Y(^D[SR.^O
MV U-LF#/,OAX1*P5R%'M%GUH@)C"(X[(MRN1* 4Z9.RLM=BE;0@$! *M?<_/
MXD,.+.:/0PT!BK!:LTDVRNT_4RHU8  I"X$OS6II?/A*HZW+?I8U?W:KK8@Z
MR'T<PT__R_#8=<CN'IKR0YL?IG:X,1>R$/#5I PC-G$%<4V.XSJ;T3H$5F0"
M::K75A?^0)D3[2_5%4X+@UU#I,/6Z%"5"^B#=KJY32^R]D-;,@EK;;Q 557U
M#[.&(*EGT)MF_;GK_1<.AEP$3EU*=R=M]?I7C>\#T/[WV3# =NNR>>Y*>-;
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M]N=+426O)'9%[T7L22/LH'WX5'GGG)@1(BTXF%\D=[%ATL'N_OAZ75,C%8$
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M":A!F<]YI0CQR'/9TG'"66J(F(I%@<\MPWL&CR:D,R2HMG8"G:*CEWL!>+9
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M+DY%VBRS)OAWQJ'RV,FIE8:<N7V/D(8U/41Q^XJG->+5G[<KR-7Y-)!4A.\
M\C]S\D#V86_'DF'<G,BS'P3@NR@?9'=OZ/K0[81[_G??.KDKHDUAZIE2)Y'E
M.58L&N2& _Q&]#0<U3G"(*U7),#(\^"T1+UKJLZQEPJR4,,O&%#W:FY_]=\[
ME/H/!S(+U%LO8C$PNNQFJ%+,P';0BL-2:JUZ\(?=.VVN#L?C.>"T$+0\O:[(
MD$31;QZ7Z.H-*VMQG3^F4I^69AEOI#"A($#^6F^%2-4$ C5D% ZX](Y8AGM*
M":S1N5RR@\NEC\;(I&3/=#,RM+ 6J41R&L-:A42DY^;2EX5]BL+;YRUE?0TV
M$YWF8'J,;75)'-K".0J%T=349]VI&.X<K%174M(F%S^AYY5?&6F@!+HW'=K1
MKY]0'KO.ZTK=NSW=[5RXF'MVH)D_H=K 77!8QA@%OV;U]NDZ0AH4,\#T2QPW
M1IQ9:L &&-K\W&."[,1&33/ZY8 3J21 S;W'?Q\:E-W=#.LE4_B6E"YL9F:#
MJ8)$8[0/W >F!WZ*TP'V96@BV:LV? #5)C'FUD21*@-E$1./M6ZC1:QR@B?:
M8*NLO=SN>ENSXWJ^:Q:"%^G""Y;\><M7'B::=:^1K[GO&!$IEVEOH"+03FAK
MNQI>:8HQM7Q $LSXOY#K-T(U]M54$J>[+]"6,4@],J4/($>P"TT$:1V]V1AV
MF6W!><R6AP.]R3N*J3KF(CX#'^C9Y-;KBX?NTDTNU W3.CTW\DCOV/8XG356
MA<YI5:N$CK>=/HR$F;>IZK0@&N]9.0?LJ3JJ_]UHS]5W<2E18=F%UU9)2!2"
MZ3T;0.B3PH.+(\;'.6/'%+;N<EO]2(>)! =2G4J]>L/>,5RS;&ODR3]=5<C6
MVM;DV<Z:HY=+@[//$^RN24>I<!)\9,._.I_?*6?Y,3H+"KY41OKK2-Y2Z_I(
MX,[!I\9[Y?<M(TW>/N'IN^OY<G*7T_@N29?6=7#"V2'$(.NG92EUQB.A\G;'
M'G:]SR+/QY\1?M-!J5]_-FGXP)6DT3!QSU0-:^9-;'8PM9:><TF6N(3-Z$E=
M!3K*-H&VKW@4%$GO^$VNB)@VC9BK45][UFR9FO5%%PJ&?,U]0Z2AR2D+7:M?
M/**N'6-&,>8=A\6U;PD*I=CFS Q.C>NS@90B%\,7;@ @_XM\M/=P^.8J;_<R
MYD1L(*;0JC#M9$HB>!-K-SF!?<F)0'C#L(N55+9NBP\6)>T<3/(U!LRY >1'
MR:G$MM9!1%Q7[I@YT-K7"I(]I)ORQ6;;^]*4!2-:+M9'=2@FF&HHTWSO%JL:
MMO0JEWO8MTQ.#70P\WZ>,JS:E$-L+<CQ<.^J1UMN%[+;K@'#+<NKB!7#?P^0
M@NJ 3[HT]8!;<C$,MT*.X^T9B(VI\-6?D,$<D$3<Z!K:K:CL4D,@N3G^V*ZW
M7C7=DEE(YT95'Z7XH/9S&$_C&?E6QRVBKA.";;3EALGZW3R^*XPKB'L0TL[2
ME;%]1?)IO;QJ*J?NTE[1B6L=.CDGPN?@D-*MF-I13VWWH#!)EWQGZ"!-AFL\
MYT5&O<V1N)5,+-P\[S@4?-[$FNGD=LA4(5.HI@UFG@L][SUL0 MC7A$&6YR%
MU"*B!Z; :[W>N87R:,&&VTNOB*0$&C?F%O;;.JP7O_B8\P@,<W?U87&TM*I3
MI2E]4HX]_-D4DGP&5*O_NI.L>/-#\';B^!D-;*J^Y9I,L7)XN==!=9%46M<[
MZ."I(;O>XD$]AH?,RY!IR#%;VW_3Z)M03>B'[G<%#-G3L<II=5E%%VEQ>*SF
M6PY-^%P'2Q_WWG!YB(B(=+US#N7;9.?0#;P#8X.0^B8,E]1D8E7.?.:;@HJN
M@3?A6S&-%[I'RIHDF*0/SGW*:\3"2XOC[_]R<+4+YA>MUWU$G/O;\2Y+%M)H
M\=(>E/IK2Q6,:7^RJY78JI*XT)H!?=2V!W]SQ(BQ*UL.5\CDU>P>7L^%<5U\
M,H99-%'HL*JG=-1+]AJD#^\+%16%+'4QZX+;^D>T\^?/F;KZN#<..S=6F^H=
M;R/PG,BRMD=&KB%52>VI$6731$)&K:F\(\UE@8ROI)R/C]:0MRWZ5=_&/<+T
M"6(7MRQ0&))$)[&XPQ;?A"@LO66,1:X_O\I1QFG/>B"Z#*H3,BP=K1*A :O1
M;R?HL&VMV*FI&0/=+R"&4=[^[W-FW%#3<&R\B<B'F"%X\9ZRHUC >$\==&RZ
M9? -$A[7/WP4>I\W84=4XP(B_?_D<&ZD^$#63.2H;NT$/,G'6=\U:.>$<5V@
M>^Y#SOD$!RX;$B[BB!8=EK=#30R6A)*:;T?^7.&PUGVJLL .5E#'B5I$W[HN
M#P.0CT9GO/PSE4FBT"=UZO-1NGO"]P/ZF _,D?1EQ=(4%N>173@F7Q[F.Y".
M(:9WRE'U +.9@"U]S;H@E^&T$6URPN"7K!QI1Z7UG7Z=';RT P&G_[) (20H
M@R'*C)&\3FP=LHOYN"WG:PW9%A:81HVO)01];&P^ &PG+OL-@[L?G6B(DM S
MNB95H]T&(JB8.W.1-]0CB",$"1L;!S6G1EW K&SFVK3?4#X<+6^.#>4?_G$6
MF_R_\Y#5'GBEO"'@^%YHNT?5XP8>XN-= K6V-%1&4_/6(B,F0U3"@A$,GS@/
MXV/$XH8C>^9R!]%EN4]K;_LX32Z5P^@]6)N )NC"C^#M@["8;T+2:/AFQ\F;
M:,1S,\.F233OT%JD&H'&$Y)T^L&R[1[ %*P;T+T_$X!_N;DCC]9/V%3<V/KP
MKFYHJI3 "WO<XA&L?^YI.Q:_(JRRW(ID[)RI]LYA=AK4X8ABI#^/[]VY!FE1
M,7)NE(8;A+B6N16K*FR31FXQNQ?F[;2Z[1DV9PX^D\M*=JOC&*S9ROCR.OB/
MHVT96'AN>Y-A?:1T11OI1GUZQLWL^IZ2[7VW9M QQ>#.:G6DYP//G]4ZO#S/
M=?#]34FZ)I5'US#Y]@%JYR)UG^A!T7TOR)O6A4I/!O9:[\2+7'G6J);=X! <
M\:G;(%+:[N%"+;9.'3=NL[?94@V%>K1#31AC"VP;B86:A_*?Y\ ]2Q%>/IA^
M85FT=_FTASBRXBP>< B56HVU7-)Y]?O5)$L$.=S15/HNL2S1+\MRTEG-0>R.
M.(LVI#>UT_8PUJ+]#RW/H&]"J#:UKU#+8\LS>X3GHP6M]WKASW?.JYW\V?(V
M:-(CC7=NULBI+_4(VB ,'!!WV'P+M97V1AJ2UJ.&*!GW8N1C#(25.U-:=29J
MEDI(E%O<;MD]*+TA)AQ04Z+JMDLQ>EVX[WKVGOKJ#$HT;ECNF?,GBZ,K](ZM
MBF]">'!>0F+'DW";\>U05J2:(BE$RF%6IYI B//-;7?1*[DPQ&5X.W8MD.EN
M71KG0G/Q>]?</D,0%283VP]H$ =P.ZX*[ CQ+)))R_F4]?2Z^WBOK+BHH:&-
MS==\0TK#D>4ZD&#@1V'I8,"()!\2%GOP0,+G1H[40GERK]2<J;S']DS7DWF;
MG5-?*K?'0I[OS_//'X'=OY0):J?.;_8W7=TEM"Q:?Q.*4VFY>J+4\$WHI/_1
MUX^'X(A[7ZT1WX2.<TL/7MW3=QGW7"[J:@&A.,VYF^3@1YW90UR/E?GJ_ SY
MPCG,5?E"(ALUV:K7Y58U2>AO_;_[KT1]O7;EO"RJ)C*7^61,I*K>7A"P^AN+
M8^J;.0%+A-L3*@:A*</&U$B'I=@3B3XYI5B^PIM/%4L,QK%TA^_YL:M6Q^<H
M*[WQUXY++*$CX7?UN"=#JONAW.YU6K&Z<^<GG?^?['1I[D=J<Z?TTY>25F3K
MNF\?8FGID5=_/B_) *W.A(24-Z="QVUX-1.>V6O9D5>J##TQ__1&:;V839&\
MW!GSF["R(&O<LYV<<)C2L25J,[6AA*G;4)J9A&MD/ AB[->D0O15)!0_>96]
M3N83)(>??1,ZDA78MJ7=FQ%-F+]*F\P^&JT[N29Y\D@MA&"+B#\D?1-:5OHF
MU..!AMN[AH?CA.EX$KUA&:M.CJ"[8*>1='Z.:+0>N>3:_#%VNW+R?<GFF8ZM
M'$M$<R['I,\"$$ 4> _^J+U9=HE/)D\37UJ1R5]?Q?SQOS.:_1\RD:A]U[ P
M=Q,N_*+)QN7*)HB+ C(B'-G-U;TG !TPGTNM?J[?4,I.-QD+NP&\P >&BPP(
MOV-OOT1=#\R@PMK#CSP4$G"3G+754Y<;-MO<VRC0!3-N3Y0W9 TD9_U+M$_V
MD!X5!#*V!S>XO5Q0OFD(C>#VL:X"M54K]PAKXJ1_>'TNZ.2\838(=A+V=<'X
M;EOAG>3&F#"@![D4WS;FM:+1D(/*OZ!^QTMB+_1K; :8^X=;,WIN2M+*H(G(
M#/5)Z^5_3-1VF'[@;I&<>0-)B_+!"#KW^4449*1*.!4/+\0&];07_VZ1VYQ;
M!<ZWG[7R5XCV9UM/AQ0GHI;^;+VR=#9GDD3!?#U*<P T,B$4T%L[VZ*!KUG1
M&+>Y[5'*>OY%T-JIT>P:RCSOF5V[U!5\>]\!,<,968Z$@,TF;4QUBT7C GN*
MUK*+P-&EG]@-2=RWQ3)_IO).>9B2E^5*&9S]1,X)W!O].),<\;FFDMW:>Z[V
MK:?MV6J)X$CU;I31FRH=_+BKG;Q/N9>.:=4^C@_0BQ^3T,-_!>G\Y:5Q?0YQ
ML;H%/-QR@E%V?&SHO'IJUFOBDC;S!.9NU:N&P#!2_>GN,DUKTY"-G2OD,76#
M&E*@!KT^!%_[$>B,J,B_N3/8G'.2Z*8DUM127VDJ#&J@-9[=@[BON#)K^0K.
M48[#R:UI XM^V"2,LW2,&$WL]9FM6N/$%Y5>T0-S'NB'79,4K,,7^^XFNE=S
M)W;^0W9]=O6RT^E^RT ,C?!HRSV(UBO<RK9OE,Y@6OU,4X!GW.]:<S?&2;JY
M G]4X0QS+'B [54X;O[ME?:&EHZ/Y9N_DX.RUXQM+!)+FW@/11[ *8T0NCT@
M"0 4\#CKD!W\%S7K5G[@C7!1 <5</C#DIO*/8+-63:ZFGOQH57_:\"3_S]O-
M%_6T.E.VQ%M>6$U#5CUFY_K[F!=F:3%]UKRY-A>\P< IEL0N():V#_^[=-G0
MU];44B$]GT8CDJF.CW^CATM86XT91Y[*HXW),ZT)XY%AVCM0+4>+/=]Z2L2E
MJJ,Y&_;^/_L.D^K2-6&YN4F!*M6:+4D6Q)'S)(]=6DS!RH;"A$J#]D7>]=*G
M^;0N=J?2+52I=JIKX Q&WN1SY1VE7SPX#T=G;>X[08]"0<YG&V!.\\&:SVF2
M!_V/;UP(3.TJ_^7-3T\PQIW7])M_4@U]RF5SM8N+EKE?UD"G>G\/RA&E.^+R
MW"[N5NI^N9%V>NJ=6X;U CG"IU6EQH[9F4SZ</:O_W1>12FD2"-+:^G,F=[[
M;,GDI5+47(94$?\?3VI0D/J7EC0=3E10^(6.M-SHBQY-$_KH&^!W-:2JG%")
M&R*SF: =N4AT#^& 1&<:%&@%C!O]0'4 0F*))1=#_[[5+,SQM023.[5^'E*7
ML/FB;&,YZ;V0S^41L#E9;YUX2[P2-\R':7LCEFN%R(QV4FG:::-H/>KVGW)#
M)NTW7WH"+58"[9AJ,:!A/<:F#T.^R913>5,E;UEAV8VT],:*)7;K*N50?'M9
M^NWE4P>ELKKN8!>8HO/5//\L,/T^;LS C;6PW$6/WI)#NX]C00[E-CL ZGGO
M\$,(*J;)+NYW\PM\^65^H5N_O)U[9C$(;5#'?40.9XMN^ODM#A7[EI*!NB]T
M?XU'O^]$_? IJ1V_XY3ZWD/<?K_6>0XC-;_07LO^F$U9=B+G0Q5CPM2"W/^(
M"RC@=&(\6*O%3U#1R-L8,O?+J>K/.T.,Y$+V0NI3P'4''>"=]1"WF(J=[#5P
MO+4F824X]A?Y5S!5I_E./6@/VQ:6*]&20-F2B]JAXDN&EQ2"4@[V;3WKGAP:
MA$9$?3@TFHM)"/ 8;(.F:>ZI%"EW>>\GZH8V) 4LMR;8LO0#YCVIC[I?T"88
M?E QX:7U_19UM5:N;EL+K7T<P5LIY" ?#W,L7871BX?0Z&DQAD%;++NH8<!2
MO6(X;*09&/N1K9HAJQTKG$NF@X7YJ:F.,,^0B@PW&EUR1L_52*>%;DV%=->\
M7XTXQ]R-$9]LTQ^!1!OOQCDMZG"#[Q[Q,PT?_*H/MR9O6AJ9 GJU>TM0"B^M
M=(<QRA-:]5RFF/?3<2.;GGPQ42)7]]+#Q7I8@'X[^<K%0YP;).P$N$CVF6ES
M[26H!9?"HUR?EA$UA(VLY@:U'U)LI8PNNKU\J,-/8P4*%E".-*&T2&GW!S9C
MGG>*2N"9]UX[5=&98#_B##;]KH_*TC8I<-E"$&[2D)3?UV8I^XZRG:_6X!)_
M6S!M(VYC]K,4*E!%6CC^=5I_F_"?$9QZ\^Y3M^\J**9)%.MT<J;7 2Q7K\R[
M5WZ3<_45%KB0;H4"#17IC*-0PIZD-<>%6L\DEQ>UHUQ:U6&5VBA'AEWT7,XZ
MSL54;R"%KS*9F!Y;._QP9*>V7;FR]$GJ3S?'*09E]5MW4YEQI9R(2XP'(A,#
M262E2*"O51EMY6$&>D)DE U-"4D2!F%D>SDW,CBV(>]2DXN'?^?FP8&9N<:Q
MR7NQT?;_<A]K:(182HC;N\%F04C[84V?Z1T&.%.C5*BUNNC*.+G"UX'4RM^1
M\#X>YD#U:%_-I:%2R6Y 0^%M>J=D%)[#4T8B<4D$$XTOQ89Z3;K["ROS]5:C
MF[T8FP#/AKB59<_CG!__KFQ#25X__>=YH[5(1*J#5KA/ZE^W4W4^TEG ]N>&
MCKC#0868?U4V+)@'T^ET=,$C(#GE2?.]]+]8_PQT?7V6'R70)+1:D)C-8(9*
MCNLMX)@3/R4'9&O^$PR!($>VFZOQ[)^2G[( GVW1Y!0O&XDU,Y=6_KS-R;L?
M=%F%Z/1P]<B%:'98S>9U!9MN@+H':6OZKI%:?;I]PWY6VQ/3882A^M/AL.RP
M386@2HRF +H!]=B!&KI8VM\M-OL$W7DE5J_] G=I-&6P/F\[*PJQ2>\=9=OX
M6)8Y+9]0^D>M+YJAF_T(!G^4+4L:8B-_5KBVUI7!+,NPFXP7+Z)F5X>%H)*E
MPW%<%C.Q2_3^R&YQ!:(_(KS6JA79W)((C0E]^GL+8N2%'4M-/WHI?^[9A?&5
M((/-A(4-27*1-#>NQ@D#ZN[F^9[\P;"?('G-.K3\+<ILM)Q<0WB3AM8\MM?5
MT5+,1]PR=*.>0>_,6"41)A]\:>JQ6[JYG>G5ZSSJ#Z<: _H;B 6ZRN8BJM%5
M6NLG]^S^O=90DEIBUU&5GG1I4UI,ML<C3PH-1PBSF*;>35\" )#-^7P]H./?
M8AA<T>MAFMW-RASM(CQ68!>1]/3VRCS(7!%>F+RZ6W,N"K729=M6&ZGS$UX)
M_#./2BMR(43_Z3]98".0* *[YJP;<1[3N]]G/WP>6_W>2XZ@EW<%1[2AO'++
M>-3%Q?^.AZG> +,ZF"#0PQGO#";(J#LL1,(@2\A[7J*EI[G303-*+A^%7<T[
MCLBJ: <_8;-J/3S@)V-W%=?4*(B'A]+;(<8+"YN5]9EAY4-05V\W?,TOM3A"
M/C=_V"78&;^C!>I)25G-%B5M@ZRQOF%JL1_]<\$XT7.MO$-W?UV,#MG"\J]+
M&?B6 8S=+6+JY/KDAJU7?K^=-X'Q<,&"2\Y(>CU^QL'4\M>HR(JV2O^K@2,A
MB0/W6KK\O@E9\LAH-_U&P/KB59,.NDYBJ\!<=C8,NZSUC)@VD!+OL9'RI**5
MV+3@KWWX0T/ /*8Z: W2V;4]-[>-/I/@%F0H:S6L7ZP\!L\K<:@^[.\86M\?
M[V>C@V)7G$4[/2QV"JL!C<B X7O:H2FNKLK#;T-UE +PKR=E7?U@![OP/'%V
M:OYB9SX($Q<$V9D;O?)^_X'.4?C%XI'XC##$B:/\!>%GR<O.Q:TTF7UCJQK4
M4%N3%:Z9[2*U4:'P/DZ^N7":+GHP9'"L_OTIRRL^LLP_+HOL#7,B86'$AD<C
M[^8Q)_.L*MI9C0K1_0B#_=!)*+.SFSKAJ#TK^WHEZ)@4P8&P)%:L/IA>T>P*
M"XXS.&=S>?W1W.=!HA%9^?'CD/>9B >UN,,QJ_>9A._:\4<KFQ%#]H9)9>/I
MDS"4'1,"F;.6".9(1 )';([%;&/N2R$WY@R.:V??=L^$VT&>5":<&AK]VO65
MX@B(H3?G-F<Z#%J"Q?R2'-1==O5$7>8\'^+Q.#^![VMZBTB+K@$JT/U*49/%
M88OA0Y3W)T?_JL%VC&,BN#%3P_OOGBO/BPPIN%,60P%Q72[)%+:(&:*QQSML
M F(X9-4USU?[KO72^G_!.AOZ?:S3BPAH\\>6U'\M5O:= _\5/U_ !Q[/+HS)
MH?9?1 DV2(';&Z U=YD:N%_3?MMI QEB84CL!ZCQ3IG47@(>$MRF$V'/"<FD
M'^XF16@RS *]<YW=VGI>P+5*TC,C/XT\MSS)A1;)U[#K<Y<#*3A][MY=;&Z9
M;+@Q^:7SO#'4V,U7B@V=!GG$(PM?R*@V:K" 8$U1_<W/$;O8.)SF,B$5#R-K
M8VY_<3J6O &&G<LP"#7_%:XU'EM!0MEI+1C)6>SL9U1##T32]LVCP_RK;4_
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M88E[>A64.WF<P9CTYE2L:I&H12ET^P*FJ4B,&WAE6%X5(.ZB]?74U,KJK.G
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MXDS51LAOG5V"60>)A<A0 TT+?F4*P20\]\][4#3 IZ8[P5J=IXG]S<E7!5O
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M:74IOFZO@F#-*Y!UZT01%<NSS@  @:_[38NTWQ9FZH9V_R.?['86*&:0H2&
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M.(^:S"Z/#D<J',:>F?!JO\:[8C]NST^:3!R6:/S87*%:!M/\:&&QKUI6&/O
MW,KXMF?#"+1DWVX8R.Z!#RO<(B9"^%SBJ/W9A>[K<0@9:8(UREGP85[!)/$_
MN,K;Q[;<.E[!>L,QMQA3V'T"7<M,WDPX++&SI\1PH-%YN/$0:7R))8@*I81]
M55?2Q:I^S-&FE,-,_;-5Y@=2#2?*4D5U^((CV'@Q#:FM7K*W$B,]9$2J%/.-
MZ89+Z"._^I!A,LKL@94+U&?AB.??  ' /@L_1PHG"-6$ZNO-]IE("D:]E!'M
M^/T]\Z6C;!W7A#9V'T+9BXO6";)EJ_ YZAMZST&2MW&3LG3,^O2"L41YNA\$
M45NB_==?D05E)L)^5;W\$#WW3&G)Z/J=VK [G_?WA?VW;ELZ=ICU#30C\9UX
M%]U)\PD9(4X0HK6U/^A4G4&XY@VB2EK8CQZF];2HV4F% O<EQ)$G4[^[5P+'
MMYH7?7Y2F4>>G(;8_6QD2$KLXCD?HUMO2?=_\Y6QD93%YX_ PWQ<X&TU&A,8
MH0O#L3.8GUS?3V+713R^[89K>OM5W'LZ(31NLDJ]Y59IMV7#Q)NGDZCLGK@>
M"&RR67 +]=6P1?3?M;$/@^?$O=;]#TN=/SU@;5ZF?%FMT5IN/HC@SGSI+TTM
M#P5X?<'Z.C^Y>BYTV=DOH,8& M]C_!,%-/"1$*L/Q^W&2Y2?7!<V-P^YL;YB
M@UZ;Z0,:V<X6@S3]LP9.AY).<D@IYQ!%[#9J5M\DX5\0M\7>A;VVLEY64U=Q
MVV'JZ1:LE?^AZ&+16SNO7]F+^:%9I[/FAXM4>^_%@H36R>?$1%%*0H;M75VS
MRYFUR [A$8#3WOV!%=,!&;N]H"&=E$7REA9\5%DCD-4R =XU60AR;J5L54B+
M2^M?)#A?)M/5_&P]?(QG?:@7AV#SXK&\$@:OA56!3<>/0P<UTY4+X/0;9*K0
MM!01G]3:L;.HAB>1I[%.;4O>*9N?1Z?-+NX12^)[@HD0!(0U>>V5X5:WR7!]
M/IEW0J=J?DYKWF.ZG>!5T]-&5/&TZZ$H,.GED\\B;VQD%(^"2E)!2&2V$.50
M66U85>FK@<D<9@-S#;VLR40!Z) 6UWPIF\Y5U4\\5OZ0.:K-ZMJW55_KAULZ
M1$5S*277\JV\5C!4/\)]LR]BD4)-5;3]519/H*CYL5!^+!V(TM!C>SK;GJZ9
ML, NZ7A?T[ '23RCP1_U H$P4+=">=MCG4+%,*$&%E\WI&BI.X^&VD*?+S(S
ML^UE"U'Z/AEAC3W:L9<KY;7C]&5;(6 GRP<NLM.(%H)MY6XF<CQ+6VYJ6.)S
MD;^KRP0URC3_0MY5;L*0J5N-[<.'MD#3!^8\CY[_2\\FD/'',(.G_-HUGG/5
M#?(S=?&O3F1B.5M:3_(6ACWC'/8?_M\-W-8-\D\N#DM]_EC"AT40M;:*?KKN
M7/B3RS#)RE3I%3LD<$0I!^)0IHQ.^;Q$G8_V/F.Y5N(1TW^=4I2: X$Q +S[
MX5HU69G.O&;F"JN[R6*^;3IYDYX7I^\XU_XP,@V7_\F%XH;%M41$Q!J_Z'7W
M V2@M##' NN$K&'-3>NVL5"UP!5Z[1N\KJY=_<"# B5JT=XZ206"<^;DXDI!
M) QZ5'9TX4/.1=ULRC=%=$+M0D(68J&M_7G>YCUK8XB5*$3*T _]1-H%D*+:
M25IB4KNLK2%\ H-1MK7+O_)OKF=25Q7P[BNE\Q/E_H6%&O%U^Y7OXYREQ@G+
MU6&1X,*LOM3.FC  ]J4\]3UOY]"_?'XGED!*[.TVK-X^M[0'A>K<>*+(5BV<
ME9=7!D%5:-<2EI_Z[?IB+#Q?0XG%*]8,E!*KOM2J[6.9JRL,^BU5[)J>8/V
MPUM.\B.J(\EOJ'P-!%\*,(:Q=QX8HM'))M80"()$21*?#>RZQ@Q%87A$.RYT
M1>3.5RT[-CJN[6]95JR-=M0D&UK[:;Q\%/!2NN3/_VGI]?^,3U?C;FZL3LYP
M/$\$S/P/_E^[YW:^_9O+?&<'<6GOZ7L\/Z-DZV(<L7Y2[CO&)\BQ98], KH
MJ*NN.EUW#L=D_IWY?';S#LO?;#IDZ_6$D!!6WD%*G;XO.$JBP;.^CL*W]H+$
MO7/QN13=X^<*.V:;OVXD#69G_.2RO53,6%F34RX+Y7F&%,%#= 5&,IL,.1\V
M\QHTCV\/$UY,R<M>XX,</9V7L,W^&LSN;NI.@SA/%[R($:YS]_L5B!9>U'KA
MFR?5:,J;GHJ0M8FX.52$PQ@'2@OE^B,B$24C36+7N"=6S]9H<_.5\G_0SZ@P
M<8\<G(@DOSE8\!Y?NI,8#E-J^;J!(H;?&/KL,IW.GK"F: U7P'2*+(:E8DX[
MOK#B)<,4WDQS/F>5H2C?=9]:O-IY]2,NBOK=66#UC^S8G5!_E0VIP7IC!%)J
MS5>;#'T?Z+1%*($/ V!ZV6,I I0C0<)G/8D[CYW6?G()M!U9_.ZE7AC?YA1I
MO*U9X^\+,_7ES329K(&/?J6AT5(^93!UN8YE-0/^,F6#LPA7N4HE]HZV;[K'
M)-1V13A];:IT52YW3:>^Q-7C>;6;'[P[ONB:$!;<P?MD6DQQA\D3%ZC[]S**
M4+3JK\?S<72QE)7^[NZ("D LY9XX0U_AO?#('#*GY?3N3Z[/6S-)[>_WWK+2
MO*0,H2"0_97\AHG)16\8#2>!AJE"KMWDI1N[V\H.X<A;([H3D\V3VY!8/DBL
MS>[N^T>X;&+)(F.86%VMBZW#L%,,F3Y=4N]O\U&GD](ZVI^^W%?9UQUR;H,X
MLQNX><*53OKPE3^Y[']RS89X_.3"<!W\;R-_"MW?^;!^J*EBEE"UZSE7S(+"
MD7X%(FA,MI_\2Z8ML[OKEE4B1CORB4 +=D2=J+4(Z 4;2Y7#*7CR0C>X.YK4
M]+>V[H"Z,?"MCOIF7").4H7(8EOA2Y&%(8.&8U((>?%=W+:35UYT+RH\X"=7
ML"/]1+[TA!G/UFHWZJH^LN[])W54#<H#J&G@-?N/0[$OK^X#Q[?G*/WK;\[6
M?SY>,;<:7#8$DL.4?W*%I#Y8M5^LL"L-OBZI9PD[8*^50>D2\V3GH&5 -[DU
MH17XKD$2?TGC)Q=0R;ID2T>'T@12)4N0O+V\IX:;L.'\!M+%M1:,WG0*.PR_
M=">;Z/&^X1K-.U+(/IUF"'.D#G4GCC?ZJ36+R[R+^WZ[>1K*CA6$_>2"G;]>
M]OQ2P);.1&%Q1CW>(OT*2[LNR5$A;S$HQZ*\35<X?<N;@"/A>[UM*\\C*XE7
MQT+J9[IUFE?)%;&G8*,<VD^N=)4?UW.'.RQO5JR'-:>%Q+(>2LZ<MTPN&SM)
MA<?:/ P<@$PI:D7]T*T-MQ%**/"YTE%66C(/=HJ(I5WNVR%L<Y2."YZ^^*HW
M^8>?XA[L3.)D[IK6_73SGAHY"7+EBN+VY;X_S3#OQD7]A<.A6%/%RGJ1J9&[
M8X5 9UA2SX&9]PAJOVF;61_%&#=B;L5()S+8#K-1QTZKR.+41-5)G)2&5\\=
M^';G]:VBB8C@CK]LS=>R)'HX6G,&H1\3QRYKA/RF2FG*JY"/.[0@_&O3+6)O
MYX7OVJ;S7\9NP:6X$$WH>B.-86'8+B_J1X^>^:':;_#TWVQN%/6DA?0U8Q^(
MMKJHBNI7RWOGRM?N0H42)CG+/[DJUWD6MS?^(/Z-*W,KFHQI'_!6R%# 4"XU
M!#)[6D9L>X< <'P")1W4'UG$,]#S6%_+[;ERHFXMX[;=2?RZ4"YHSE(38YVO
M<KTF/\R+FG]:TBJU)&;J(Y)9OFK6T1AS89Z7G(\LC'[K]]]L$?7_#:>NK;H/
M&OQ5Y#32'Q,L%\C6_!J>GC)*[W@U)"]?6#\@S-.'.N(1I?SYL"[4,?@,7HP!
MQ8\(%29;ZJR:;4O7>09:'I&&)).HB=<0/[GT:< 6%2E;*ZBP9<$(NTIC1!9_
M#XGIC1R,:7S *N_?TQ3(UAXW37[^@SE.I\+6S=-J?H#@#39#H"U7_^! [8K;
MK'*A?!6UXRJO@Y5PQ*NE7U.FB+,5HS;\-6+^:EU%2'5KDU(+><(%Y;4NRJT@
MP3<6_#H.&?$+*;J,GO$S^$>I&N5$:A94%GHQG@-:@MU.O=$I%MD5;O]A5<];
M _SEZQ*QFV,W:D=!PTV#LZL+7..Z\S)_V6H &TLXMM:*-WH_>5MGV\]+FS,5
MHCD[F<(5KCJ*N4%P,>Y"G)+1E2E.\\=SB@ZR"P6DC &=TA#P3RX&8&:OW+,7
M%:N6:?!J.%W'H[%*V^.@?I+*[OW)92SOF2' C $NTK5.=$LN(9;J  5.LL3D
MU/DP<NPD$(60_A?'A9JC\#4R8NO<4, A<VO.BN%L=T.!R&#H-9Q?'6>WHZB=
MN.#>X3R.OR]$ ^^CW*UY )[KB(Q\9?!V$&8&$,KHJ=H;T,T1)R'-;[:E+S_?
M'YC((8<N;9J:QA8#:SZ>T*23E-% )].X8^/(S*K+SYML-5,T._&'!M]>:CKV
MX#ZS!:3['XA:F&&3XP0R_=5PID_=HM4TI_UC_U#9[8<\')T/4YLX4DRB['MM
MRC+@64,IBH$J J472S%FW0PG]H,AOQ)O"GXR(7P3X0BG$#7E]X*_2N22WG">
M?6:+:)Q$12A8\4%Z6=;E]KW=+\</A=<D@_@LJ]&\",VNT;-:0@+ZC6Y)R_+?
M!$!8+0;IC=Y0E3P;B'S\V[H?U<XQ;N%/QU^SF:1W=*M<&#^@D?A\.=C;U?GV
M^>T D;2=)NC7H(B%HY5(0GBN<A".SU:>4H*O'R^O/G;%)52"+1;0@@X3$D,1
MMY986E&+0,5+>EV7#JRAM^N%:C<Z>3A28!4_G>%ET2R#$!LM38BQ.*Z$3W0P
M:]1^*M\L/YC"'* 43:]F3?1779#'ENLTB.>#:Q5$XRP-(\X5ID@OHM"1PM3Q
M#<T^BV<2]W1,AA!X^25O<2?W?"#EQONMGUR Y3KDZ'S<#.+[9[OC143[JG!1
M4.^74E\K,\HLSVY***Y6+6_(V)+TRJ[ ]7:,(%+Z//S\5-W14MX43VWI,-.&
M,*L]SESMNVT[R%QJ*I:ZN&;O:SD'I69M9Y_=U'R/A^_0P55EHRG:S/7.G4J8
M39MP;;&EY%X:O-$H$_D"*S5GL?_+7F$U+238PB6H[^G]DYA\*M$[L.NWW95U
M<[G9]6*+[N8WM10WMS^8_1N&I_KSJ27] I*RF>9M&JJZ?89*F^S);-$_AJN=
M %1YT0]G12ZT22:M6>WCTM(BR^P #@$0%ELM]E-Y.$4L+\ZI_2?7;;ZH]CIZ
MO:/D6Q8[[V&>5&L%M?;QRP/+O:/4+*O:CK(W0SG=P?8=LC=.U]HN]IGOWW-X
MLJ'AY>>N^PC3F,#>-U^%;#O;1TCEI10P6WY)#E@'N7JA#CAE[47^/Z04F"<7
MT\>5/C0C4BG%K!%3 MA"!M*2^P-9>Q]2:^<ET9\]\ZJHC@-TS1HT,"HG=]$Z
M>:?N, 1HSM9\'N\RY!V"1))]\_#?O>6)GO"3CT\YNC&2'T#^1"QO(LU;D/T!
MSFX1CSQ_DA2R6<X0XB"6LPN<WHZ$)J6J<YMIGG!@7%$J6D)"G3,@!W-N=Y&&
M_,L?C36? I7>1.H\J2/SFX5.^I(:RVV@C:6'/+4TJ%.*H>%<7T1AIEA^^F [
MFG(F)'BEV2NK(;01&%[#%D?9NYN.-@L![F1996!'>ZV(#*4Z.M7ZX<A#6\LQ
MIW:6?HJ^<+_8JC4@U:M'X(:SM2<__IC=\0K@8+/]( Y5=H&#N869* _\\B,,
M!494"&B=.ZJ%)S3GR\3DU438!OJ4R[N7=U>J',E2\O//"E@/(FR683!GH+6I
ME&%_>N1!;I\?JBPRLLNST"DEYMA^!#:_'OR0D04^]JS/7'+)VU9K2A(B[[!Z
M=_'I2&7G&HM0BTAU*R-KT\O67[<DS6 _?(4:THBKZ]Y>3T:I$\_)[!J 0>C1
M1"(^(8^\HI>F#N@#;^F3V$;SM5\& S[8*@BD[/_"H2>7QEF;I ;<"O[C8^F"
MA3I 6(CR[5$2YR<7MZ$_5F,NB"G^N^ /%YP;FT=QJF^!8L;[KCJ;+T\OHNLC
M07JZ*8^7/ MMM$VJK/K:CZ(P6/H5JA#,7?G((/#=S$7B_&S0R,L71TB:]P)
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MRMSA8>BV%7A$X6S[G-/-2_ \*Y)QM^D"'T.9UY>U\6O.NN\NW0FJN3]1,K%
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M_-/H^T3Z;>/#][L?)U]M$E-!=9[V&PD_%K'"4@,\-EMT"OR&A)WLK52>OIF
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M:73.U5B\AK' 55!:05EA+#CN$6]#1^V7(F&-J9_$F)WZ0;.NU,;.Q;Y^!]2
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M7/LO?^'+GO^'/Z_GRDB\U>75;H74PBE7K3DAI&U:I(W=4XH36;VGK"QH5DP
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M:L@"D(KIC'U,"38&-G6M3R*S/W;A7LO1TI@+R' F;6*H-(8ESK#N#:F&67(
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MP%OVU-SZ5TIG.P?<;#HC4^5JG[&YZ;3H()O< M#TUYW]F72'I5JY%S&&]!W
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MK:K<:[G4'BKHGED92_/0S@OJN0(L,@A4"T<L^KL<_Q</]2HO<Z&I?R,&28K
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M"C4VTO*/E>Q<ULR70_&;F_3;(I@:C@<[-->]DL:A,1O54X6X8;]0['1,UFT
M"^PX=YUO]5XLXAN+QM!ERI910U[$3Z\+G\OEY.U32C>/$SK!8KXU-,%^?DP[
M"94_MG@"%]^%.GT1$+$HO%8]8L('7] 7PDZ0SI*;H,ZALU8VWJ;$AI#,^]8E
M9B966U.]OS:SG!%/0=&"G&UR=@Y SKN.78$AK7R>W[4RW=O7)%8"?S"XS,7N
M;=;M[/E/W<P>0-J+5CK=5M*]S4*ZLC=D^H#:!3Z5S&,9[^#RZ(2<O='(@5]%
M MR.(F^HAZ13OG1+4V]B-J%.NY.CNG?SZ);UG0WL$V!7KYF LR.)@Q00BI&
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M FW=RB09R/X Q8ZSKYF2\YU%52UC$PL'M=H<<^;5()_)687[E_5T8"<[S[B
MF<2XR;H.<AW9P[U[=4R]]_9=^,TACO(0><[/92%8LYQG:(@,QSZ;Y[H(9PO9
M3+J4DR@&*(<>G!H.N#TMH2X=B'=8!XY$[]R(A@Q([LM9'<G6N]W6=]Z.![@D
M^?B@!&JS \5K;Q&^CJQ+S+WY1B(TN6O@YRL'VD;C3RJ4,,Z57C<GM_I+4K3;
MQDDQ"_'LK8\$M7?UV]C2AWU6XEO)(W=$U"?/CM:A%Z>S,K/69KNQ$4^D04L(
M8][KKI-^1!BAN,Z^<@\3ZDF<4BHOOVDP=MGI!XW9^V)//2:OO$;1JL9W%"ZS
M4%&*]Z202(!#G&3EM;=GC&D"(A>A'?-:+EFWEYJJM^%-3O<FBN+:D95MHW$R
M:'1@>X^ZY'YHV?R69/B'H03?$LOPY=HFVU52FA_*8X2>H#,:_,4C^?7M&6[V
MD56.K;S3@065QSGD.RD-#5FP31?F>'Y]-[@EU._)XK&0=L4HI)B%/]P51G83
M F-4.]^V]:2-^>F7]I4AJ!]9$9C<M6B8*(#YD2E88FB];61<.V-R<;E"K!-:
M%4)^P3IN.TK!<@8'Z*!2(]]0QZY/'6YARDCE$!EU%Q@TE&4?BRVL@ <G 34/
MG")D2?@)AZ"DR*I#/MXGXNB9#6)QJCPM1)XT;^2:HK]#0V%),49&K_CC<UNS
M[VSY#G$4'[JP(/"9)&Q2?1[.1)T&=!0V'=)ZE+38?H$58E%<?'G3PLJGOVH7
M . 5&>M7^%[,/160]KNM'BRA5K<\!Y<;KH92?,]AE9>0ZJ$0KU$U&)N%DS7
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M):,P8114' X=6WXX+P.T$(G7H#]66^0:W=L?\>E[%5A=\8X(N)CBX.I"HJD
M;R22XSK:7UU)DH;NW:HKKBJVS[V>:7W(%]NB" VTX.!J;($!XJEDDR]'YJ:Z
M8EUMYYQ2VPO6@*=#3E>T#AIQ9Z*5G,Z[/;XCTFM6X?.(O/)%0OE;62>'K((+
M\\\?%:GN\_(,,J:@D+AE3Z[+_2)4K7@=QF@/9B#Y&M&S--GI2":QX3?G8<5
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M(Z1S*D&<>7!;5C#E^5?X.JJUSN4-HV_+OKRVTTK3\PDJ7-23'*=90'M[CV%
M;]7U]54=632F['4LO%YB% 26K)#@V@GO#5'-K0[%9@*4+\<*X0T ^1L/?I_0
M@I$QLJ2 I1%-==X4?A#U,<@9F&AHV!@LC&>-V1^;&>M//;@]^MH]G(1]>].0
MDD@1SQDHUPI6TL)E.$O.YJLF>GPH#D>2LR;Q@1G&\UBE/O4UL*#ECOG1%P6T
M^*1*6E#4I%U*P* V3@VY,R]T3\TA.&0QPRL2MA*,J>'*>E55W4P='K'7N9?;
M,:+=@L/I(;H=:J"6Y%(9:: ECE T#<_<WK?:=IV@F)&9OQ?ZN4V/Q<4K&J(:
M0X.EJ#^6:[OXE-Y$>'>1DT@;VL>#*BFC"P <&>#2/^CT<LOW2@>7VET#MG6<
M(48.;ERWY'G8#<3 = =FE=>:5Q?$>JN:\*71$?>'ZAJ&RV>&?F&*Y8X^@HN%
M5 LC*AALT/ L5A,ILYSWRKS4\;HD&KI]%=%PWXLNE,X:@B<%R;B>(Z1=7!-Y
MI$5.B%ESD+]GV'JC+O/ Y1*93)[,FIDPR@Y>W8(,"-@HZ@@HY2^UXJK8O.>K
MOYQQ01+GO?O\!RG9S>P.-YW.71A7[#%C@%YM7R@== ;&;YK2$#.)2FF/65L8
M5""M10$$,P[:R:M!;"$HI*L)6J(C3"1/L"3E*3F&CU[;%X5K>7X5(%Y;MVU#
MCB%,:7;L;?ZY32S5 :_U"9V:KOO>\IRUL4YY9S^ "0V@@DLJRS$>5[)P;!7+
MT*MC&491QX-K!CGM)E#QM/,LF#H@!B7@P(0@0^3T&XT87&WM,]>[]8>L]X^!
MJ9+7*Q2*>&SRN']XRJ/\\T)LZ,J[%LV F([X4@>:)(#L85RK:;?C3J;V":CV
MFBZ\H-8);2G29BWLCPC%Z>E2L<"@>V1_( @LOU$0XGME<)BA+WJM]&7/#HBY
MED!*<UF8,W38C^H0P8<%K&@Z!W]ZIP?L(,?C29R+X"<)1D+V^-AXY*+HH_SX
MB_N@P.._P1ZK3V_AELX]H7WQ:>X_4\^.WNRT@3PX($>F',W&K;THGR#2(&6V
M,E;B*\0XQ#URCC=:BVD98(D[GPN5%MI*'8 8=L2'B99$W@.*MP+!_/$)[2 ;
M9PW.HS4122R B9YK'K)E*?XA(Y8#R%B\7-[+7Y7K?MHRXM#9:I_&?2S#-PF%
M693S 8O/(L1)JXWAIVK]U"5,5YL3]%@Q;. 7706$W5J%0SA3ROY;_%7)G2,=
M>"NZ*X*<VTX.M&54?%P=Z@?[2M*^_K05);1U/42::JH0SND<DOS</YN@M?*Y
M7?O '3]H:WX A6MY*?P<I4M%U2!^6R KB3 ?%8-$3G8! H#=8VE=5E 4[GV)
M;H0 5)T8&\_DBO==R5]JQZEU\YYS3;X3;>D?B*;2E9Z2YUPUK[(SGL0=-H(I
MT(+(01XNHCUZJE9DY\R\I;ZS$_O*GA';DZQY\%%GMFVOC"&Y(\UP-B*MI]$E
MU0WRRELXWL? #4?O!W87%3S5]DQ9_IO\\J?*_O#)VBD'&LR:D21QKF)*[-4!
MV%7P7ZB0K/&C2U7+/.(!<Q)'BK*\6W3:SOW[-!1?# Y'SP,.HAC"B,JJ0?N5
ME.[+:@/4._U>PD:SMO2Z^D3@J?(LR()@?IB>8H#U7._9F1R+"^/9@WT"#CO<
M]U[+N=5EOGIT>>4J13)ODVV9YUT.F 6T$M16K!$)29Y%3N?N^(A<=K;D+;\M
MPRT2 S<*88QKY!3<;&6#;JW9+E:N:/JFAY_D:LT$CA3K55=9CE;@*HW%41H,
MPQ#E+/7IHON$\Q]&[5W<O%>]S]HVE" !4NPO[,X82 ?Y$WCQ3;6"Q6K=]*Z]
M J"0'&G]9,*[8X<93R3'9V[11>:DW:Q_T61F;@UIN.=R^^^WG 4"!]#7,+PP
MZYQTVUD?Q5\#[SUAM"VF7$M;%@$#6M<^AU8F3:%?)%NO^*8.P!_/N^(95&A]
MW1(75Q("CR=F&EGN %Q2"6J.KL^:&X_VWI2O1:BM&8%QR,96VMP$.19+8%CK
MM0F7%M0GD$LB^Z 3Q%GTO/QT'M ERI2&021C(*E;5X:])FH* H5U(KPFE+1'
M)LE[;JT>@AEY>HBX)>6SS9KJL)1@5@B2["Y:LC)N&;YO$3P#6._;TES3.AIB
M]:%L>ZV+Z_,^Q#ZTFL[&6 MS!IC.68(?:#:!<>-)'5<?![1Z-3V:VR+E MF^
M(:1<&<?M[/L7K$2\XG$1,LD? V_T=;U29CH6V81S"RR_A,;I&1875#=9K;)%
MW[M4FUA)I9R'OPC;M/@B5PJTW T._ZD6'CN^*[Z3C6JK#58CDS(AK2,UF6P_
M.$- ;U_;XL#^U2"^;.UO3S7U(@+$RL<2+THX]5'02!3/S3T;9KSGL%":#-XT
M@D*^%UC:$>KSZKN[Y-CY[OEHLHJ?:W=>?!;%*JA?-J(VRXBZ<\K,U^0H-$JZ
MBL[C%%*(>8EI;7'/9CH4$)UU($@A]W$<2\(&=I/F#IW,%=U0UWE&#30E<5W@
M@R'-*P1BEOP A8"AM,,'C78D#*%:E:_"I8(!N5?2<S/B(.\[5IO94X5%_NK7
M^C"&*/MV <&3R;\\7/MN3;E=I?B2.B.0]-9&R7=KLI7CIX416DS%/\.RAH:]
M\"S2']5(H)(=/3PI:5Y%;=>\?XQ:7N&3QL(GM8KW-8&4$9)6@+:W=H9S%-Z=
ML1(U! %Q'T]W)&;?-Y,L3"F%HC+G5@(<<OK "MUZ@-QXA\NDI \YKTZ.< 41
M ;9?>J]L@9.1V8C38+&W50-/C[PJH"7 B]/H0\];FQ,&@S8^?KEOMYF<H5_A
MT@^'_VKLM6\/I&D8W3&/'\[<I:3=G$?/P_*1I/L[X@0/K]P0&@*C0+%-]#[M
M#<=3U(Q4]3HU'%:5,L?ML!FUKD&"*F^ODYQ+ E3T3NQ,^_,<",2$N26WPG1'
M->9D]I6H1BN1S6U$_M>1FT>UQ)5S#_F&;S)>!8][&8%_&HIP=W:%-@2/6^XN
M550)]WEA6,B]\Z-M/,=)$8XY1;K'QN3\CIR'="-Z1=EM/O_6VMS*]SK28!*)
M)=-"R+ENP>SLX&OC=$M#$]='#S+,\R>PZ]^,S_&P5A$*U?O1_L'"3691!3Y@
M.UYQO"O4M1S0\X7B^-?Z1O!:<4;#F 1U.V_!P9># @S=M1(W;<\&'XD<;<%]
MBNB+ $7$M3ZHH@Z8^+CE]87A-W023]ULYZ^K>+1AN2N7PX8XFN?&!Z]/XE4\
MXP$'?03YV?;?@X//=%17&\%6>TULW\X^V]BX'QAUI@JA:.^>6K$,/:\4Z>A5
M:%Q*@I87UL4_:R<$3E1:CN(8HTNX@J(8 ;'3BDW@H67H.G2A;OZ^OE0U^/B5
MVB&ECS2JXX"$Q\Q,5W>VOV5O &4X&8G#@S\4693LJWKFNH 57986Z!SSM_>L
M?%.D9AVW;0%:68[;QO-F/KKC.;OH&[CYX$6XG/'RY^J;7A-UAM K-Y[XU)U3
MLSISQXU(9(U?3.H%Z]T1?6^YH_RC:/U[FY>953NYU5XH%\4=[$6?K92#3*]A
MC&\$.PI0G[90[$0_J_IL596VW=F01(67?U0I=W?O%K#L#?2/XCN6<>O_XC'1
MGT3]'G_F3CSM5T'JF7>,7).CN F*_7+*]55)P)6M#H7L3H':O*@C$MO6.PEK
M")//SZ*UP]Y>:W"9)^P9V>SKF5&D6RYLV>MXC'14-CBR>!L'-DBGYH:^L0&K
MJ_1H<D25$QIIT"RU-Y#_ES[O+WW(&UZ0ND%R=LH0T_&*%34*/($[R !]NRK1
MD_P?4'^ LOX'\S^8_Z<P)81GFY[U<X/1L2:;! /(]_[\7_IXTBU>9+2$.F1U
MO/2<["IPT0PAP\@V<QY'92LIE3EF6<@H>/V.(A@2X]R2X\A;AIO@?&#COFDR
M+\]'9!S[:N/$M\"D?=OH];!5\T.^/6#REHCH:FLFP>"X^T@;#EGJ*'B#Z['J
MG1C.Q6/4,N/F)T<;V+JCRLP@B1F!+]Q>MM[?^N2[@=K9$JW=G<M_#(133UKK
MB^HD'O+]E+QH\A]@?Z"Z_OM -F"7SWNY$6G3<Z-#?P\L[1-JC7:5"K_<-L@%
MFA__)S G>-[1$JJEZ+>ZV?!_"$A =O^>BE_TK))G%X+68"]>H9S^'BCDY:V*
MC+.2_[C9[&M2I/(OD3UU'1\_^:#^(? /', 6__C_)&;C7VH\1[;_B0F6A&_=
MV-3>56AJIY?^/="W;1/\[[Z$?'WVOQ)CXS@?&J9QG([0WED,#5JEF-J]J;O)
M]5\.?V$+JM"L9PC.AYPOBB<MM*RMC4OXC'';&=F*- 6U]#=/-V5Z4E+:I9:X
M]Z7M4F)WICLEE5U>U0RUWM)'**I)1&NO?P#P)S_3R3?/M9KXBC'95W,[2Z6O
M1AV_K!'T-:AO $.)'EXXY#NSNJH5[$51^?:_G#!.?Q!=0_F_D^D#_X0,8O\[
ML_2OAOD+:]3I_Q#0_X?\6=U[,CC\3=_S7TQY_Q5!_XP;_"^5_C^8[G>,VO9?
M^"\!6?_#F?._!XJ8U9=EU-)75JO?# 7;K2E6C#CI!EF1GY1DV5Z\K_H9G@QQ
M G*3O'IE7ZDDB@DN:>T(K,W,'O+%(*(_#I]][-M=F8Q4("""8@.K'W/:VIAJ
M,#S6\M.::</?O[I 5R[[;T.U/+51OK&@$SG.'6/"=_YW!'D:_H<W)_\S-/+X
M/X#^<JG_FFR8_!=Y\W\[AO"_5\>_LN/_H(Z7_PD%_1_,?Q$F[S]QH>Z_NY#A
M$>O6UMBA9*S7&!-LFZ.;7R"L9/\J?>>R\U=J@\!(W8OXJ+-Y-^;X+OU7O49Y
M[+7&XP'U)*Y9K7 \GID:]9,-O$>MD:6=:-D::9[\I66YB^_CZRU/UL1"\:2/
ME#&O8]E*+GYJ]:/&S5Y3-M1UQ:8Z, P"6;4M7;_UOJ/SJ7IR'&4\9$#H##%%
MO#X5B.-4,12\T3?=F:4VP*6WKVO4TO92.DIF%E_*AGJX.*^J/#6/R79<-A-?
MUQN2HR.6D$!BW(JA; ?UER;SMTKODM7W=\>E!X>,'MN2ZWV/AZ>$"N[]>7=5
MIBX#%</A'?)IL:%*J,M)+<!0>'[V9M919'ES&5T37/;G:J7R\E'[4QG++SL^
MC^=5H;/$7$FH-]8/_.][N5P;'Y>3%!X*KGZG]DJC.T!K+A=)D3(=;Z7=-+1/
M$Y,NSJ<XZ? ?M?%>/\<#B3---%+DQRHU<BBCOT3X.$P)8U2[M>2!(RC1I>PN
M_C$X9D5+.ZB[!1VT\7P_[$_;NAG2)K<)(6R@Z)S)0__VJ*-7<K>M&.^/(N P
M*)"<"E%7PUQA.D;*CW1>^>TJ=:;_;*TS%^4!(U[K0QS!S%4"M4JLMW"[X1>6
MJ[&-.G6GA<XX7I'>S*RC.FXYQ9D=JY[DDO/FK7T6GETM5>Q?92]8S-/KW"HJ
MK %D]4^!]P#3CLWK1HZ#6T]2TVN;+I]CW6$#1S0?Y;3]\*YV9Z_05A'LG/4V
M]T+";SNE!:"P D??1;#9,]>-AL%DHQ]@22LYYED+4"(V5;*!;HKMHQ304FJ"
M1?13#_GHCIGEA-SQH^^E0%UH@/#9LB(/VUV7O LLLO)U;U170L@=.'C$FYZ&
M;G]N^-[!@Q[Q:OZN5()S.Q2W'OC:,]7!=RC,ZV?GX'H39HI*?3W2[Y25S^54
M=N6%B.#]$U<KBK.J2=R'&-'WR/>_;;>Z0Z$P_5>(R3-Y<8PZ1'#9FF\EP\IO
M0#U$N[K7#/+>90U8"G6Z: OP('N(8"EKN3'6ICZF9WZ:"D1,/=A5VF.,QB0G
M50QH5^=Y":9! >1M56!$7W>KAS..X!]8]'H7 #%JG#^3LX5?2L9KW_7*E"I-
MXUB!?4T42^^"C9/2CSH.3^9OI0!VZ#!.?#PJQ"'09@J30TWEIUZ"4GP2H:9K
M+#==KU0-IJWT_JS(Y7% 'OT'N4%[D G(;G\L<-->X0HSL(K6J!<=.?E>OK=/
M8U\3ZLZ.<K@V3DE/TVPH?FJ,^Y!-#R0FI;]" E_3;RI='+D^8#B5UFN(C"2[
M.C:':@2E,VOO3>PF>6[MY&"Z4P+?G[EM 85-O=.E;KIX%)= H5MO+NI%#)]:
MKN[I8P5M;[?CETM)[HQ.U<C]--/)Q4$-9LF,QX]A 1"H<O?1ZG1^?5JY_,1]
MIR0H,/F^XU2"[JNY.]X3UUC:_7X:)A;54\-<KD_0A;+W>IB4\DM">H;\23'$
MN#4X,;X'$3L/O(H#"EG1R#AV$#YU(OA-UB#[=0#A],N.]TW8N6W GZ*@\+E"
M=*>$M/X@"^/5!UI.O%)#&]R^NPFY-S(H>$?,D1B7MO*;$&_"2]R_=.@$K[."
M]:+(G4EBK&*>AE/FD F(0$+*SX7X7N=!TWK?*-/X>6G]Q#I1/ST%^JK/*139
M>U_T VD^XKT..,E,9+R_D=*) 6-K\_G#V6>8J^D<+TQ>WQ;<PPS^<^6HO-CS
MIE.1B[5UZR&H24JWP]O!TS]]R#L949KB.63GRP;[\H\/#HSXK/#ZHLZD&W5\
M6O_]#J!:K*!Z9"N2%-5J/2I#&U3V^W%]*"[2O3(F D2#&+?DX27#/UF_^4>I
M/!,>"H*U B>[^TS;.-<F_$DFC_;&[6)J>@OY[=1^JM;3L&K,]\[O*J)/6_8#
M!;@3=4,O57KP%0YS;VAH95FC>X/&6N /R1A2_M35<TL*11J4<Z#FA)8>Q^*U
M>SV*;8QP+.&UE@[X2DF)0CII4:5IMOO.D%J]5J&?BHO"3(6>(&=PQF9!Y6%4
M?]8+L.7()47=KAE4BDN$2)V.T&G?<<Q1]9>U46ZT](F[ZRMA.E"1266J@78D
MX0,5=B[A=_8%RQ$*%K3$)A,G3(#Q89J $2E\7-)*A)"@YC9N47[Y<SO#UFL4
M7FL_T1A/G@Q3,;EMEXU?V]*P3_UH(9:R<7MHVJZN8R5:@_'!-?=833'3OJ_"
M?%+(>CQ/PM.*U "U742$?7%R'U$)SPGWJK7&HC^'EK=L%TV9A%.Q<:$2YS<^
M$B3=1U!5&79C5KI9P3?9Z]>[FXO,^5L=/-U1PV_S&^LZHJK1GU]._IPB(-"5
MT>,7+!1QUJ6L*^I/@7;0K:!3<?>'R75%S]-4/FZBK_([T$C>Q.+2Y&X3.;7/
M'2O[?6*6[:%?^\-OI?1SSTF<.W]U>V,X:E_ 4#2K'^@X7@<;OG.PV:\^^\;^
M6&Z9NC;F8: SZUA#C]L%1()NW%?A7>*EHS79E875DQ=YV\8%!165]$1BFG:[
MP=/FS8RYVSK6.6/VS23!;2&(67+I.Y?<KL^;OUZN'G./I#]*W7N<'O5+%-%1
M:RU#:%DF((/)W)7G65[5'U6OR"K#7[7NO75>*89[G!&!X\JK+1"+2#6X  ;$
M/8]DL#?6)_38\K5B,PUN-X?6P0I4URYMN U6+?$H$9'.P)EXL@2U5[ VIUUL
M$?A8YOI7+7+IJ-/=_B6K ">9'M&N5M>&WO9-!;"^HO9N>S)ZO=IPZTF ':^H
MSB'-M9=?_FIW0'SWG>'8FNLHR/6J\9RX=N*:1V\X\'0PXEQ@C;KU44)ANJ'#
M;J&(1#Z?R^2;0:C8+FO[O.7V8VQ9#R]<-'(^M2LA3A:ROMA>_\SF_BNQ:)QS
M4IZ::9]6^ D#G.P(!^II$;00#C,YO;)\W@2OF19&/H!T?%5A]\\3<\8Z^0(?
MOR!XHQ1F3![J'7E8 W?6)H<,4&ZTXA@Q>J?:VN+&4^\J9([/G_@5#@!;[[E"
M;#=_/+TC63R*9%6W0Q<@8\CYX@A8;4QG<O>OP$ A;IVEH_]3;>P,+VJ5'13(
MGVLBI%.$TA>D6"MGG'CVM7KLY8@DAO98/">-K_N4WD@R1@!"O:/JOBLM44PO
M05.$^L/JOK0[]D%&"ET34\23+'>>W$\5;A]]8:U&\--O6GD_XVM=@;ONU_N&
M__+,@?B-VK.6/ZESD<3"XESH4D[<*4?CE^]4"U/LUL9=FS ;#>Q6&Y HA (^
ME=8F(*XJRYSD)W/V!H.KMZW0.]>3'&HESC\\W3<J*A1T_50BVO)B8:6PLI@O
M?-QX=[YG':J*0E%!_:VG+N;4/;#4#CY+NS _'./]&73[Y0!=D"'>6]3S.Z9S
MI.V4"4)!U]QAMBQV7VY074S_]_[*7'%M&H4XW]GC(KYE$]=1O%HSY''GCF1*
MJ6%U2;:5%90CV1W '()9SNWVY+8GIX@^D7@1_W'*Y]8KUH@79M+;DWY3,AS6
M[;<PLY-BI:M,Q&H6^EU(U;K(V8?"3L3 8!-OZ20%,G;M&L?ZQ- N9A.\*?OX
M7D$UA\Y$QDI/=P42*VMGK:V^\!(^7>GO,E97JAP1_5;ZW UFRQX=$.A ]NL+
MC+:M OWB^]P*"^) ]C:"+KW%(*W2CK<=!=[V2M9Q;4/S/]44$+TQ1D:Z/F"@
M=<5!%"5PC'$!+"[UZRS43/ 3S5E+9/">^\"'KI5J79$3*CYW<_$/ Y$YUVXA
M9'9NOW+PY-7TYP%K[BEC0&USNS<96,G95<0:5*</TH[3FDQX&ZPG&%FCD"*<
MGN3U:A8E!-XLR*W!DF.3."Q>O-=W895=2PC)!1+5)4P06]2D9&OXLJ>]%/7U
M3]*@=]J :O='A'#3(3P,^WO:0&55W^1$8,IX-Z7 _+)BB:]PQ[$VKKWQVLG?
M43GD18")E,-@!YG\:8%,QK?O'U]W9TSI_1CU=ED4"V^X4"-S1FUPJ_U4#C6N
M]%7"BVZGL4O#<9.!%=5!X^':YGA9<6\]B@=@T<A*57"IXZ>?Q F!?SRA:CE[
MB\__UY?_27$^>_QGOG]#B#^8^][3?/?'ML;^3[ZC_RWV[_$_/G],%/_SWT_^
M*_;_OCU<C!%9^>/?==>\#OE,2$!'GSN-"3OZ\.C7:H=\A8/84KWZ]X=\R?OU
M 8SH^<<O^<YN=O_3U_X!\.4Z:?%,?&#)(=_D]FCI)DIB20DXG!OO;5/L\6V7
MQH[.MCOD^\6?UKP"QE0TC%(.^;Q"U!L.OH]F^2S?<:]W?[U,P*<C .'+!D&#
MNYH^U:@@M\GIFS/:YA<OJY5^SAR$.CV\.1I^QB]M)E>.\ %HZ8Q#DZG%A!"#
MR78%V*;0<AO=;X,ML)%&"=WU_<8O^UC@YM-ZJ71<S4O@M]]\U8? 5&M2'\,"
M>OZA</F'[=>KT!6CM!Q+(Z?;---#OAYU4'!V"E6PY :-'4P(KNF/M*R9G5.R
M.LF 9P3XW80'4G'X/?^DXQ 6-DO (84.9X< K4UIR,CB;Y,O:GM[=4)"OQP[
MY%L LA]/,/O).+F9GL0(AE0XUMVE\:=%OT<KLI>TK_JI@>K6QFH["D'04!=4
M1D:! +KAO+ Z;73BX1OX$,]'.:RL5:KFOF+C<[N+VRV/AK2(27L7P"E(9C\6
M%PUA8X)C.2Q9J6D%N\64QO/T5SC.,L]>\<SH4(%O4/7HTB6P%5C,ONFZGV&
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M5$\'I64ZN4B53Q8VTR:*';3<&V=(_A+&/3%D/U?4MQN+)Q?B*D>+M15=5X+
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M<:$2,4N,IJ7K.OKYFCM3U0>DA:U3P,(=:X)&%9R6\(75*EEE</C1>GQ2M&.
MQ[=L-C.>,AD[I9!7;N]M%-"O]?!H%&@;][!UVUC.^4?:5][>%__"6QUTYBXK
MR*E3([,J#QO;/X#X AS;)8M>__+O\)#CG)H?X QQI8?DG1T0\K&&$J7$JL&,
M'@;5R)\H:C-:FE?XXA2D<4F[*'3=8UGBVXT9#FAQ+C.*T-$$M@4/[BAT#*6\
MQR\?#[7MVJTUD/I3W?8&;@[E.RU8.LS6[FT3 B.&QM;6%;X^&&:7P*Q+YSTJ
MQ=@X MV8,T#[M;50^',/$RGI,+[+QT#X+530(.W0'\K?'<Q[9G2E[LZT=P@S
M2VT(-ZU0[C6,PGLE-5(]V.2=&EG;L-CLH7[*'<J;\67<ER^5_%,,)'/GVL*N
MD49O"]@NWA)_"N@*"U5&+,WLDI)2&*> @[6EI4?AC#H/'[+FXU/ .ERG^*U?
ME$XP[6Q6A=%60+E8]A0\;VV*M&2&K:6++.[2^(3@%P6#WS3#-D9O.V#G0DB9
MF7CAR"H3+:>E[RDI0<YOH\PMV=]770S-R>L>9"8[!=\T;"KPN[EL2<B;1@4C
M*]HGI!PNJDX/?_O O#9W109)VK6^I2LT#?X9M@MW+Z<DBW2#.?".4X 3O8.;
M!W$<76^G3Q[1@IQN]W06*X[>/L[+,AX4=L>7O-@<7/^X!.QI=JS@VI\"%.^+
M [5E@D##&]8CMO[6RHN]GR#A6U7%/< P]XH,_NZV6]00M=UKNGV<J;,XB8 F
M"Q3(/+7)]"2L#3F%<B81W>Y%LC0HY0)HL37X^O,1$W)J-B2@@)1MQQ$UD,#L
M+VU\,OJZL!VV/N%(<\;<KN;7#AO61&JXD.4:&96C\)20BH,E+,:,U1+2:45^
M<_#5KUES6@V%0D'U>E !X+\A^*]3PO?YQNMX_7\]]//":%'9(I%.BE>IG5>
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M"8BYX;@;'NW+UX+73<;=]\T7RH^RW(;/MZEY4M^0N\T77G@\["A)!CAN2#+
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M8QEA"OH<W7N7F;3,P3+73$F]YVFV&6(&MM/[W\95X4\[?(TJ0.G/(80;*^N
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MZ7S4$+15I0_PZE6C&B5DU[MSY=M26QW.?-?H*]O0F@*OLDXALH)(>W[^#%A
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M%DI]2) ,A'-H>J(@<359K+7VSO)LYN3&FI38QV6? MT,7FU-$U0\9?X&/N8
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MM9CKF6"TVB>-JY^X,-5&#W/QAO 5: +A)4A^F%*IGT,!Q[E6-1NC4!M$3*X
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M0Q\2?BB<A]AZ\_Q1N.[=O-JA-H;7,^,LGR+*LO+GIC9:MGHK"W,/HUA0=@-
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MW\EN9F%X(SC"TZ,I[,&FI^]G?<QWIP*#<HGERFPXCY9O53EUJSMS%BF:7HC
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MJ$BQ97I1O#+BW;\V];G_K1__OUW$:6IYN0TU[5S'>RFZPZ.P:TS+2=D]IPT
MO&US.>],GMD?G,M$\']K+/E_1D3D3V>^_>E_+C'^C7&]64PT]/!LI'M:W?]'
MW'M'-;5U?:,Y1<^QH <140*BH"!!X% " J)'Z9V0A- "1SH)-?1^CDHW($A
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M2"H/,_3NE9W#;#<I,S.EKYE HAH>;Y?A8P1]$R[S$ZG8[IE*;\4ULB)9M7.
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MK*_=WY(QIX1;472WW^J_#K?[ (/KP+M=(-"KYF.^-UOB#VH"IT13:Z8H RU
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M68QWS$^;?NT9F#9.X9:_M??(?!H>.*(*[0>^HEL=RO>,>?]&I<:.N1_]@Q:
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M:S?"!ZKT'P'"[M@)H.%E=,F1H(9#:X/%H<FQ$^D_RIRHFHF^@/3_>>G/_JW
MVY[3DT*G,YL03%MN%U+0N;](=YNB*]'449$*H<]RVW:"+OW^TY4P7<\1['A^
M7,XSU.".ONSO#S).95LN;,+40.*;Q:GC_IDTJF_6?'Q<_[N2'175;[,5>T7R
MR3FMCB.MWSEPW-;K)+'_.G%FS<4<<//9=<%P1NT^\!'+YO 1W*^<&*[$6L:C
M;5K%C=<]<$BQM2]C0:H^RQ(^/VH]*=235,B\>QXAIPE:@.\9&VR0S5M,-&CP
M>.;*#)$4T\?3";\),SO.:'G_>Y ]E2:;/T#UA/F[59EW)T[UJ^<E'7_5T*D8
M6AP672TRG8-V]ZE4#\H:2BHMZ21\'ZY*:/ZFV"GJK$WO*T;0GF@[2V-U4FS=
MYINX780U.G/!(H1C9L.ZD&S[2@;'+^I(3"HH^5(AL%G?N7XJ1F!N_,C6LGS>
M>92)%:*'>,S"C[.DUUQ? V[\SS?]7Y5,?_Q7]TP,X#^2RA?S=+0#TK_V@S8^
M" BN!RD]U^[^^_)6SC0[6*^YBM1JQF38@Y1,4(68XVES0A=<(^1JOG_F0'Q6
MS\O.9"SPC%\-]WKK9*__B"7:"^I&+H]A&FQWAX7>#,>M+D<T93+:49**\S=6
M\G8'CFZ&F2A9\DB;'\,CG98\:GH--/5>@,F;5W?:._%^1+^/%:SX%\9ERCVB
MD<-%3A2;BQ:V[H$T6P3"BU#V5/[6J&H"+Z$7C7DK+@F'4GU_MOZ,/][=%3M<
MB=L7N+:,!K[[,@3TJ=/M)_TY0CL!B/?XY>.V2%_4$_;;G5STY$>*@A3:IR:"
M<A3J)FXTVG+0!.=5#Y2CYZ!!C*FD&K]-O;U'.HQ[)O/-TP:7-7#0"<!SK2Y<
M8\YK?Q+6@_L90[\Z/C6BF9Q@UYQK$OZVHB<!B-/N?D5XWG*)M-WBGB0:]YBS
MTD7ZZN"4@9^!F/*N(4V9NBJ21'_M<-R$50>D?@W^1TS58'\9F.*J'*'ATZ 2
MGE?-+66Z.Q&*8VK$.YAVBKI?Q*F]QF#!)OWR^*9&KB9O4F;)C(MV&F![.>7G
MOT.GHI;(='H54>WC"^MB;;AN53SY/<1NR24TZ&9:N," GO?W.>L,*$$Y^YI0
M0EE"&H(QD3.J)Y(XY=?^81."A</Z%)N)S?$O3P F#Q*O:!*'2)/(*L\&PSF7
M?,&*4MJG':6_U_79RG9?.XLFVF$ZNA5P1!I^7LGGC^45Y*E"3V''5%YVVN C
MOI]NI:I]3*VZUD[@V+E$*7$M,I!\+HV3%AG9XUH_8Q"6728_*MWID,G?E8#V
MV5\YC(B?P]M_@?M$=8YMB_;$]9Q'#-J),+312PF^%&U3@_8I(:<S,1@\YK81
M,S_%?'R5B[@*A/N0GQK:O!9+-Q /AU-0<_F"@M"%GWX)T_FF%4#&#]"\;M.4
MF:-))%[>SC:EO"R _X\NFTI,%;%\UR .)'5+&Z[3/7<.%'!N^4O 6"^U'KYR
MI8Y/J[PDN33,4DUT=J.*F*K0G8N;"I^HMY.Z)(7!D3J6E6JSEXQAMN6U'R2S
MZ@/ME&D:1NJ$FV'B&_1>G?:$? ;&!=HL=/;UPN>M25&](IH#9*WO344:.3&G
MP]9(8!ZADD;,U_&L3+D_F*R-F:L2C"]/R/SA[<!_(*?0&.#=Z_]OJS'_F]M/
M2_G(YS)#:+00<GF!#FFKMO?2YSCJ2N7=C:2DC-2;WMHN%9@4L&G-OU#1MD,.
MQ>=X3A![_9#W9_24A%_T"%I1TCOW9%76L0GHK37!-<<&&[40Y/.E?PZEMNHC
MB[U*@UY9K(2^'G-O,I6*'AZ5ATVGG,TU^BJ>M3"$0!W_!<Y9+9_Y7(.TXQ3J
MEN5<;J[66S&F7 K+%&U_$-Z#V$<KP 5ZOQ@2Z37R)DFUJXWW0SB5(;>6:6=G
M"E42#5 H:9Y0N&;AM-UFAEI)\NT9^&)B.3$AOX]YPS JSZ:PUR>9TV-\E+4B
M>M=!#)T;'GQ:/6L+.2)L55*>KQ\"O"R+4!N'Z;1)^=R&"J\H'_6EMMJ_(<0Q
M;\GY;!9"Q=S&XRM*#H:5-L*B:X4PXEDUN^+W/,@-U9CI8;Q^WA&N.'/XM??U
MUL>=R]NXL)8<=4>.:67YV\DW\&[7!T13!YGL)RL=BT1JK[]=7CGAT]R9J=C]
M.ON[7\O,F'5YU$PS=>K1307OV%F.Z#L:W$(15(XO=Z1RRV/X0\O6X4;RSKMG
MD?)V/7S= =:%QZ-9")RV?KV>%$E#\*&U^\[2KX;""%>2\ E "VKDFX'/+Z*$
MX_/S;%)2SKV@^J7;V[_*PU5[#>O6!8YV(-9. .:]#=3N(>F-9/7J<$-O3>7+
M,O>9"N]_]IJ+2%,3'J$*@(@58S&KGI,'LC /QM0=5WL>N23YV$5!_,N;"N6@
MN 8W<\:$8[*@VXZVB9X:L7P"A,<'[WQ^OB=8M:.#D,ZB:]0L-OKO)S.A BG
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M00^2GFV5&1MF34KI[$D=5Q/KGXL^@,<_&JHI/6FZO!9FFU/_>L$7 ]3/+/>
MXFQ T 2G;$E2<G+[7AK$8/"IVY)/?UU>9$"+:?2 3ZI5&!:;_*!@16(EG_-B
M<I&H]3(Y>0IHWT5J&A#IW3RGYC\[RG]W8V7DO?:[=<_)O//CFH+/0CI2H[J^
MZV"<ZW7F-EUFL;-V4^ #[&LPWXU34U_M>)@!'EVKW40GV1S^-""=5@V[]\1?
M-/C3_F\-&/X^V[0RR'!6LV2IL3:-=RY>:\6V_%C.;%@S,*_F<ATEY+,0?04X
M.OA9J.3,ZL("",17C WS+F@"5=A(ZH<T1PRQJ$E79Q9HQN]AR4UO#U1"<+S
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M=Y\/J3C[NI4>I15@B^,**]$.Z=0:*&WSHE8D;KFS(NG3DS/<4)\4MD6WH3N
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MG^AKDQ@OK5]/*EZYHGQKJ,BGMFUOWJ>2#52FU;,[+6Z/"(989)E 1X;PJ]<
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MUYH47YCE^6)T!R6G%&.]$9CT7]UE\%=X39G^]"?0N#58ML"3Q>$9D_%2SAY
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M>/6,DW E^EH 32'AP':0\:M5SCACL6H H#P:A;/3GL: 8M%7NVN$H9S\!PK
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MX@2T 7V&66]ODR2'-2:PI:GDTI45]W&]?<C@2L@D][X+V8(%V_-+R0GRAS]
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M=X5W(N:=Q)YGP[B].<UPZ:H'BFXDL*'V_N:E,T<*<Q'+#1.S7L(.&*L]J:3
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MA'+!,^F4]$Y-__Y^&-[PAN@7OL>?+&"9=LL&]J04?6,?V5IJ5T=*=X6EB-
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M"/'#G"'Z^SH_R+"KDW_C+8,/^?Q$N, CB'B#TR!<,;=G4+O>I'3:[5;G@F[
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MM4;U%:\@DFT0".]@/L'55*[.@H"B,ZYZG8\6@XN99EM^'P83I*$J0+$TN<Y
M"*XW6R2J'P.:O06G:Q>R#VJ*'&K)[JA;"R&RZV]TM[U^L@)0^*7R8T;_VFV]
M+EL:UQCS585**W_9D3Q8GJ0@UW!P_9!=E5:I_B(3!T2LBEY.#*95=HE;CI2-
M\)0]&B0C^^^Y+S#L1'0/@&7CZ- 'C04#ZD,?W'!NLK_;BE7WVUF,;&+G+HF4
ML3TNS)?E/]]4B3A>?S0<"@)#EB+T,2'I#0X,I@.S,;>BI"P9XQJ;B&B;@Q%F
MXD0PR2CB Y[7$XWVNPTW'[(/D@\2K\*2K.!G^&WY6?K%:#IL_B!98F-7ZG#D
M EV+">G(REIYEEN-S<3"_RIG5JAUO%(O\0?\ZR>*E2E?J]= MBIUS"&4"X7+
MRIJNF56*CQU@&X)<F=T#1Y="#F+D3,R=/A)0.I/=$_1)GD7QB8H;XB%2+B1_
ML7H5N$I*1N.K;<%1'_)SQ_+^KOR31P&Z,CLH8\4:^>>YQCQ&YNW6P&!P;<.#
MD$7*V6AQ(JOMN0<K&SP;FU<]!NWIK$:/"[ODPQ,<+]!(8Y2&Y#X:HS3R10YM
M<1*SW<.59IO:A>!>-^AV6Z/:I0_/^-3Z8?5L%Z7OUEPI=&)U21$NEMQ7?W>M
MG/V^(&;W0NNYQP.LF3,IOF_)N#SO!5H'UA3ME>-%GBNPS'O1\O[RO0#J10E!
M\:]&,#9N..8BW8$RBA^GLV4_QV",SL\1J?\H6MYQU)VR8.6KE=2897IL4B&!
M8Y[N:NXF+=CX)FG8%S[WC,S',Y9[[&HV)WUESM18H%%'*;1'AC&\EW+R6/!%
MA%R]^+L!!:<[7Z.\"-,,/271?G-S$?[[_@J,I>,KZ$!7+9L^ZJW-Q;Y^]K.B
MC%3Z2+E?E>M<!=F9KGREU *>2"8AK]OUSN:IPA9X:1@(X=<#<:\UVYZD*GB%
MSBN"X8JL[:GY&#++Y=R)SL?9"+G78T64LJGY>291#KMJLO:N0+RB4!!:]W8U
M;G2O-RDW9W3<5XN:H;<4C*\S_5[F_3"K!V71XCH$Z+%QLL83T )IJPN6N,I1
M*;-Z(SBTP^)@Z<=\,ZN;5X W7EA4N%/'!$("_YP%@U?4\U,+13^LD8$1"\C0
MLPBK!X$R8+NJ;$2V#66A>0* Y9F:P *4F[0%]C++2UHX[TO<LWD#0=.LS/N$
MM=9N-!Z1&$!"O@WWZWN:8,K9(JU\L&--; N8W!Z6([P*TMJB@'?M ^["RD>;
M!YMGJ +^8#!D0M6^3W.61"%FN^[2(7T9Y@U*1"X$\GG^T2K4!%>_V%5YT !F
M]6F7#":8+(F?3D@!5+;>^,+GC)R*U@V@7JHP_>K\/U%\?J_U;(+>E=$G31P9
M)FO[A?;'SLZG[:J$<Q4&8H-EO=);+YKB/KA0X5WJ>N8/=A;GY[9V5?M-1[!>
M5?J CZ.-V'XP)]3W0;V-F6RY-_G.J!PBHMKEO-F:GQC'I]21ZS+1OOH*7D(!
MQ/!^K].VN(>!2"C\T+]Q.S^#+DBQM<]ER A\7FPHJK_YH9E6Y_GR#5/S<<Z&
M<?/(\ 3RSQ5\T4AZW^D=SX?EZ=>SP@/<ZVG[D)Z)[N;<'>[8%.1&QG$L]UU-
M?8$E<YRX#3 L("TELQPX.PSYZ+U/.6, =$N?.TW7&F4ZFS5$OW1^W/CD1TC$
M#\X\JKB]\ .[*]/YICF%=M!X-P#/06;A%*M74!"B08A;(JP[CMM/O0/6@1,+
M(6X4JP<83Y/53_:FICN%.BO0W\B"-5"$RUPOP=<MZE6HI!#[UG!Y(3K$X 6^
MH==F+A 7/9\%[O#XPM?J[SQ]O^*$X_/E>CMU86XOR*8?(65.V-GL"F>%9%T+
MK5\\'^Z[M1J8(MJ0*QA&+ZI[2&"M0,"K:K^<50&1NEN\MX1-F-8FO84EQQFY
M=UUJ)=8(WDN7,5<I(BC8HGS@PY&[V4M;4UOK=%CK=B7PO>#.IQ6S%Y.^-T8=
MRE\ZP<\Z9#3B[-+!%)BG1Z38Q69/0CRKV5/LE&MSYW-D3I_B_,*"NPV$H9BO
MWH&5NJ 7NN@2,C)2,]%0D?(VI&I (R[=IB3#6PF/?:-.%]6F.Q^?Q"OI"HJ
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M&HP0U;'<'!^BJTIVI9]*]_)+/BV5?_W_+H;=]J&*%@W4Z]@,/\BTZD8Y -U
MLP>6"A9L;5G9Z8^(&8,'67T,D.;-^IZ)F%D8$RY2,<+E09!P '+W+:TFL^LL
M@U4??^1>Y\3.&9<2,4KSD?Y)O$M!(CW/.[OY5FS=RO1V[O=\G4?<]W0=>2V/
MA*0+M?A8W&_?P1_\-?YEUW0#F46TH?=%Y0N5@TO(QWH20/[,&[;MNJ[Y&]FF
M;K<).AFHU#N:-(@62PB,E.J!*A((\CE>EFM(KT);L_BC:=:F7W[]@_00;Z(4
MZ <$4SF(- /5,Y?9:1ORA-)[YX83C>]UO/\A^'#;C8@.,[\7JN7AWI]DEK:1
M/[+&=\+SS_^L OP[G'#XMRK265H44F?&;0'$!A/SZK4B+_!]]_J_$/^MBA3=
M=^7=H=,7/O$H/2'SZW?=IM*O\CD'_O8_4:;_+"Y$,)GXN</01ZDD+:Q.FG](
MIV<1@2:;7&5KDPBM[)^S$^D)+)C?(>AG:C5_G'\Q=%C8W[CM6)NMRM&K*HI.
MUZ(.PE0RGUV?CK^O# &I-L\HIC=_TK$(>$+TT/,=7226*+UJ:ZKV:0A\18,Q
M0< #HI._CF5NM(!*AUH.HU]-"G!%ZJ<S9SK5"MX*B;?,%1B KO=I7D?_LF5-
M'G%&,"!$"8E@S\YS8HEQ\4FW3XG8]2+H&@FRZ1)Y*!,_#3KHVG?8STN4T<6R
M$L72M]</]7*A>E;I0$C8WW_(6OD?FXX3Y'J:TJC9\-+2LH?2%3J(@YA[Y2D+
MX^(T;LUA+V 76BAMZA/POWU]/^,\P/XF[RQSF $Z:O P1BIX@BHR20P5=ECB
M7@F!92^P*I"I!0#KPHR(DP>7X(O4*Y>FD;E(\H<!!1<?*J321?/5:KZ94GC9
M!&+0%5$7(BBH63 FL'5Y> G&$8'X^8Z6AD+%V=TEN<DA<R#PGWRZ-L/_'U%_
MX-T\HDIW?>YTB%?Y9Z-X+6@/NF^*[V3M^G_\F$70*%_+S2@-D91_-HKW,@=@
M)J/7^42%__X_-G/_A^!_>DWX_XV(*#.J+=J/RK[=;_KRF),T=^RI;!:_7^'T
M^6]\[(G_^*O"B#5>N:'M_*TJ.V)3;?&^4?:9Q?D*S'HCW_?-+_[72/^_"=\3
M_8[9_FU-O:6D39<F:NY&Q:?R925(+US<Z P?W[_3WDM6SW:JC[6.@[Z^@E-'
MI"]\6"/<ST5YOU:L=Z;QJ>B^_-_V!/\K\)^XU.*'V==M<UU%R,R!LF>#WZUO
MA$7^W/3XF:&*]%N=]3L'<R?O(*\.2*N))GW,W;MZP]GHL?_'PNW.,R_9P,N;
M&]['7[E/6HOVY(]/2\->=@K<^T;]1OU&_4;]1OU&_4;]1OU&_3=JP/3Z9Z&H
M$^=J[WB>K/(Y*SZ(?#C8C$[\\\>__SMO["<(0K<.Y6G@]?M/[UJG_OH5R;V:
MJ!\GWQHOIUV\22JR>/3F7T9\^8^1G@U=U7CBI/6LZQ\CGOO'2!&H)U<!J=^H
MWZC?J-^HWZC?J-^HWZC?J/^D%K8GO%L'?A8V'+F9)MY1;.@;HTUQD7!N3#,Q
M?/G_\L:^X1N^X1N^X?].&'T9^7\ 4$L#!!0    ( (<T;EE4_J]ZIT\' 'L>
M"  -    :6UA9V5?,# W+FIP9^RZ>3B4__<_?DMI$25)$0HE>Y8AA,HN2QI#
M]E>$&ON>&5L+64+('C*RC2UDWY*R9HNQ#X6Q+]FW\+WO&977^W/]KL_W^^_O
M>M\7=76?YSG/<Q[/\SS;W6[/[G?@I+*\DCQ !CX\9#P L-L/R #D!PY /^!S
M$/PY=.30H8,'#QT[?)CBR/%CQX]3'J.DI*(^=9**FH::DO+DF9,TM*?IZ.B.
MGZ _>^;TV5.GZ4Y#0LC(09Z#AXX>.G3T-!4EU>G_YV?W(T!SA"+BQ%MR,E;@
M  T9.0W9[F> &2 ##I #Y&1DP._GR%&R X</'J(X1@[2W4X"9.3DH.Z@UJ<I
MCYP@HP'(#H VT% </G+J(JW S:.G637NTYT3O*ME]R3D+-NM\(XS]$*BUXS-
M[9V<GX8FIN3FY7_H'&6':SLXOL94MW_[>4D8)B*#"$NZS'%%T^29=\2[Y()/
MGW\LB,G**3PP-7M>,\(Y+.]SSR5R#-S]/!FD'=D^Y0"R0P<.4I ?/@)296C(
M0.5 ;8Z0'SX(&@$<WM/MU$4!VIMW$^G.L IJP._;G7Z22R$D?"NDNIV-_<=/
MF/$EF07[RR)R)J%YNWW <7)P"QIR&D :*+@*_/?Y[_/?Y[_/?Y__/O]]_O_Z
MD!N:G&^N%72KS1^PXB\Z4Z<]A=ZNK+N-NZL[Y?.E-9@"DZU?^;G1_U%,*M+$
MF0ZA*E !SY\2>M(2GW=VCB.<_,:CADNIWPHMXK/B*CI*[OI'#PG%^^\"V<)L
M$06+4=:5B8XO<[\\_/;>O29]LGS,<0,O*D0_87S&^<- ;/FZ\U;Z/'(]PM7.
M9E7W6P5#-*(:J_9E*NA6L-,037]TR>ID5E^2SH!U1)\WLDGF:\_;$-U1!]<D
M8S9M:@O]:+5E.;4TAZ^I:7FI,B6%*]HGL3FK_KX9/1@SEK?6?=(OGQ4&CUS<
M6!<56F8R$FH@3)]WJQ*=H 5?7IA-6J_W\/@(O:]?"9(RBET^W%^W\,IYX=<#
M:6D?O:4+1 [F/(6F)0^OLL<[@M2#TB]?C.\"DSMDR[L L)\L 9+=38K K6X<
M7]@%;IVK*U!X.[41K[02*F44LPO\9O<&1OI2FEND-X)OXI:N!^NP$39REHH@
M94;6Z^]P;+D$K\XS/\L8<V7K4MSPL-B"7D.R3Q_=P8_5M#FYM9((&W\(QP]#
M^RADABS^ZE[ZK?^5L[V5;']7K_U93;N#']DNJ_O+,ON'A;=$4/*P]M=%A<Q<
M\/WXG_=7^X\0WTN:!D>.53&#1CR#[+S9<_,Y45/FO+JF):-@&Y;:FQ!/XLF_
MJROG?J^^I3HOLJE VA82W_U'/'Q2L/4-BCHG>A35Q,+?[&Y0[GGN,"CLEG?I
M9IW1/=+I1( @;J(?5X(8\K_TIG1:":K,G1"#A+6#PCKZOT#"W!Y<,9>J3OAG
M^?RO5G:B,#=\N1$HC+[VEH_#C. 0#<2BM!(#"MOX(XR:[*^@NC^"T!,L-R Y
M;%T/0?Q^@/A-KD03_WPM-4@ @9(6:@C.7 !Y*O[P^%5>QDO*2SV/6QU9E#0'
MS:^H')0.2M"))_XIZRXIDYJ6<$L]N'XE'M1@=0O2H _4@-:=?(*M+>PW4_Q^
MIJJ;K^?G=L@FE!8VV+H>@ZKT$I4((E+E6&8'GFV7O4*=<O-0("J3!<+:,<U4
M[LDDE>??&[PJ*]31N_7LKVPIB.\>R0X=D.2C&R>]<5'J>0)+R/1UMRK8)'@D
MCIMU-BQUZIF8.<U=X,'-QH097X5$CKI15"N(*$H2DIU+W.9*W:11QBX0M:D]
MM0N,21Z5DB:IV+)/17F=7<!F%6Z3NO97AJO[/AD=D]OMRSL3R^SKOX)U1L#;
MP ^Z2VH7Z*SB[J8,1=NET<Q_M!M=_:M=TC]_-VS8MZ'"!0@-Q14,"/%"&23%
MA"A0H]_>/.<#$:DL&A"I%_N0"A;?4EDZ03P9B.WG?K:?I.UEP>V_;WR&]!ZG
M 95HE!(Q4W&GA+P@2P 4YSE.XP:J]D8.%,I)F?/!:35L0@ET*R(1O9](Y?^
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M_+&,''*=Q_LH6[\I!SR+'D.[D+9G![??7OV]/;G^R"X0G2V))<Z3U8G3ZET
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M"$L1)JWJBGB=(ZO:C#C#?E3Z).;<Z^Y<Q1 R9IQ/;WZ8F^<VBTYQQHKHM1O
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MG,HY.-EK:X8<5"SX&W;$Z]/:N:L5GP7'.@%UN^:WP+.H^RI1=^+15X'+1P:
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M>/_F8"<H@02N%W#N);]=>MX:@\\=!L:8@S<@9!M G0%0[5SL\[6K &A3Q%N
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M5G14KH='QXX6-95&P\+3!X2XI'_^+U(&@P,K:TAL8#9']/L8.JM"UZA94[?
MA;8"\2P>]]9T>P^7:TA^=.F*? GU=D:!:I'<H]CDG=D[?;=-"^-68+02)9E(
MKIR6RG<+B%NA1=TNV7H_2HKB#.S' L/51]\E.^2][FQNE*//P/!I,\TY1'XN
MZA"0IG7Q3UN]WSJU,>1=4"V[A? (?IX6KUOR+L:527A1(FY1D> 03YA'(* ?
MZ4C;PZXJMLMN?>8>;X$&7RC'/01S2O (?8TT6+"/^8S> H"]SN#6I5> \5Y1
MKP*E#[C9VA7PW8W_CW[)A!C. ');8"\C>(%_/^-=( >[&N!+,2!(ZH5\>+T
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MGW9Z4_P@G/OXPC:/O(#VA#T-N;-ST"Z07QJ^:C%J92]9D0Q[P)5!)^M:)X1
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M_%FK79=B[TZ63EN)"HJVO.F,H#:=4\/YCYFZZTCQ%%L8."4X?K@$,^XH+&Q
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MMG>F"Q1<5T%["++5?"CR;MP+CB0OMWUJS[=L"&\;"M&N*:KNMCT3^CZ*:\B
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M_A9VJXI4EJ]HROQ,_E">LJ6J&V HYQLF>VN[QSG=?"+G.S='E 7&%UYH")2
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MH#B 9FH I]HZEOV\\L[Q1&1"6,PY$?F'RN:F3%PG_Z>:D65).^=0JG5-O\)
M"I)=5W!_ !-BJ.L6*NA7PT.K,%M*-GE%]>.56P,.14_/^N$&W[%A)BGGX7&.
MR9PS-/C2BFIMT#1M4F^=4S^XO!6#M(R@,%-"L'H\]Z_V$9*W">(.\?$I>S_U
MN;MQ=JQMT9XM_4'D)H0YWA,H8X-;21.^AR!^7C$,DHPG7'*(?PX^?.Z1]VF_
M-F!+[Y^E:)23/(I"5*2S2MVO&'K"W1.DA. MQ_*4-.QJ=B;NYFX=W-JH[^.<
MPIF\R;MK$B,7V^!&_?.I=3*R@9/^OBJ?G7ISTSS6*!4\RFJG[ZM]V]SA6Z!
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M=]?!ERS] B@A!@F>?05SS;'U(^HUV =JPYE6HZAU]5+[$@$I$()=G9& 0ZO
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M/RHL) MH<I<H+/NPXMQ4;^9:$<KW)&)]8R8SA^@&2"&*F<V*D5HO;SB@LXW
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M,_O 8?[@RSQEP .5QX:NK*U7!'&JG25%3@'$Z]M[IX"OT$'70JNS80V%*0C
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M"S$=1YR_?9&=E.B0\:)P)ESK9CXKE91J+$;=@#^ Z+TBK 97:JW[ES<O(YW
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M)36Z_<I&YS526G..41\+3/O<K1>V;H-[1MCBCY\PNO$>NPNA[B+ \W-(A^^
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M>X!U>7SU&U/^AT\T0#-NIM9!,LL]TI.M/Q%JF:14]A<#C\+4FDQ0(Y6T?[>
M'J8G<+OZ2EZD"*C@>1[Z+37F":;8EDICW_O]M#7-93RL-0TU5(0R?T(E1:?X
MHB!T=/M[<ZENZU'"^UCE+[VIAUSZA3(U9&:KAJTJ&9>R8N#86>N&(+=<N:;L
MGFJ=%I<T(QO9Q+'KAZ7RG=8E(8ZQ12B]+Q]W]F,W(C#E((VJW=8Q>,&E;HA9
M:D4Z9_ZY 97Z#*<9[*1G(AF )2FGF"X\8#61G^8I\[*G:0Z@P@^3P\4!#EK%
MK3:OW5=PX3);'5/54W.[?%6OD9]!*-4T>=MM19&W L41SQW]@W1O>_.*:7WX
MQ.).&GG+6ER _[I8Z)F\?U>"*AN%PE&I]4"W$,=/EHW9"W$^9XN,I52N_ A2
MG'S7T+D#]SPY98XU?E)!Y/S6/^1F)N;*H.O[E]1G*G[>L]KB94L1PI671_8K
MDS-P$^2E(M5WO@2F"R4E#IOGF$"=,&Q>B>;R6S2DHYZZU)3@'8<CA;G'^PM-
M0:K+;4,<+[A_=W5$Y+9S4>J$/S%%)H)TH8'1LKRN;TJ(Z4;(,?7?7@F<;G4U
M%F(^]XA50#)\*T\6EM PB<5%#@D=L[S)U2])50^O.=D/M<1S_SZ3_N7,_6I:
M8E/Q-P3DN+&^1E6UR[XOS<!%W5Q:K5L^[5A4L=&YF37;6M;E&ZR-B15X?49L
M&OAKR5LC4\(PV%G1[)A+<3@_"C=OKYG%0O_Q*2JZX^%\/'FP.0?HF-NXDD)U
MFNU]:V/;U7 (I0XR:T&-OAT-%(GI\"I1+ATSEE+*\,NVK<B8!U;HU*4Y?=MA
MAWQ%:-K:,J_<U?8>K,3GB"?43)S;'\57K:#*"R/>SE[YR/9_MNUH;%?$5FQ6
M==L[]F(DMTMS&;5/^<H]E;QI8-9]=51!-K2*+6M0P;+/CPZK[0B-B1],:3I6
MK#?M4]>[CZ[+[1CQFMY5D+IS9:E'O%+52^Q)"8?OQBPR3HO2[8X%?WZ6XOO4
M7N=X2<X,^NRIU@ODP'D3&\^20<^^<GSKU+RY.>S&;&R.=U01MD[-UM2U'ABG
MURD5Z)=XAHS_#JB V.W#. HF;%-7KTN)&ZIE/F[+DY0#D2S _I8D;^6E[L.K
MF'?;4:XO1"?%#V%(,L4QHVZQOB$C'<;Z!6K[H:E[^0)?IC) N\.4;2BR51Y-
M)');P&J_)T\U*Y2>8>2D59EAK*(&^BQ12;I2M38M4L-SLF6*=NZV<Y']!D)9
M](!WN@*W/[R?**,E-C"VDQ=;)"HLMFQ3JU"8LX3^KA!SW1,>ZTS'D*PMGO/K
M/_NK>S:KK%+K;R^*S8]ZLWL"DV"2DJXD_H*HZ$BB/3^EFU_+_M1->P,=B2S;
MP.GTM (G%QP3+4V:O/K,^NHIL=.<.U46\O1-%&8"DX0P:6(4+.2Y*DI,\QA+
M*YH30F".[ON3TSU8Z[!2(OLW]0\%PF)DQBK*,[$^4^'SGH,_[ZRG@*D$U;MC
M(1YKP<[&U_#'JRXWV'QN; :=;%IYAC=;NT.O#69A>GJ-C57%^O6XAC@@N#G;
M"?,M^-23J7F"6+B4MYBO5S^5!JGK.MLRR+XYH+EQ<\X/W/U9+[8@U^@\\FWL
M%76WFA&]$-@M[B7"^MX?M*'O@#]T&PQ%4N,D_(M6>W%O^L=FJLSS$4[Y*;$&
MDLI%L[8^+W;&%:X\>C4E93FL%+B$0I& 8J=4+:BO/;+F ^."5.1#JJ],':$Z
MFTH4L#2F("357'SAO>9TGOV#7VH__O]K(AM)]<02#<"]OW]&SB+V<CL-=A)?
MW+\,N D  'ZU_7+99\ECZM=);[^T,N;@G ,(S!R2ANGO4Z\N*9B0OP-DLWTR
MUF'Y1/WO@-"WUL(Z6,OSWP%5F&-!=R9!]Z):QL%3YPT_8C-* G=,*@""].?_
M=UO8XH>W=6X/ZY.F\A ?J%4%)&*"CH]Z;&Y#ST3WL9<;&59V/E,J8OGZ,_12
MA$G,9/>F(7?W?/63\5BPTS>S.>[@A,CF8Q. 1._\_P#D(^ZX\JX^LSOQ[>UI
M\0SQA*. 7Z_]3+8ZFGKMEYC_\N OBVLPH=#,T9<'YWXIH;P! /ZW//4AE^V+
M27RKB+^?13:1WOXH9 WXGZ#MS]#NB0/\'A+^!/CP,V__3 7@ES< OLQ_ \*1
MD.7*]X/L.IGW08F H\GJ@).??MYU;1# ?^+GI8-Y:53U#;&:S!Z<0I>'Z/TY
M"G"L#N3KX&L _$CE3^);5P'\:#L;Y3D^J_(CRU3RVB\2TW=^[A-H7U/6:Y:Y
M!OB?F/,-:760^E$ P/O'"_Q;01MP=61Q[8]O$T8JL?FI_[ZMM,0_ "G:78#N
M?V_VUZ$?"8"&(7< TNH^T92RT!NB/^+848<<$?;_-<L-XGOPF_^BW\)_(>QK
M!SSKL@T8_W0:\$>D^)%OQ2>" G;K''5QIO&N7GT#(:KPBCU&P'&K59=\B.YT
M QFW9?L=X%:UZ,'BT(UC^ZM9S#DDI2 TNIVUQ,87EW,CK:>" Y'<H;61L9&G
MA,"]BN\ 4_S.@Q/C!T.W1.ZD?P<LZ+7[F_8<$/ QCO-W64CRP($]6!,:?C>6
MZ0GX57W0)[B$%LY?SUZ47?52[7[P>UGS%8FCT3FQ/ZF04"N%K?Q!M,(UY+KZ
MA:C_I=L/A@  ) W^0YY)PE\ 27' K_]MH'CF=$"$]P\ #W^B[:\?6#UA_S\%
MQG]$\/_\;XO%G5_^_*\I,/]? %GF:7&QS#//_Q?.@X-A'JC[^%+*0J)7]1[\
M>G+N$^#]?\V#_P'PK1V0*?B-X3W/"0&$RTZ$)>"(0N;!7#28)@>,=4#-0R/N
M"IHH&N-":9M!KD]1=@G(-\=D$C5QPQD]^"1Q<.7VX/)6X +_V)-+)R)TG-N8
M5GU8YU#TT<>6GT:N?QGKGZ4NBK[@)'5<1+5D?9@QO#GS);,UM\P.KE#VA)>5
M2@XIKWE[OG5/9)ETRCY&8S$NX-OS5G_3S;,M'*6"IOL/=CI&^MM']@_?JZ5E
M)#6*2//95:>/QPB<@Z"$PJ+RH8(= ?K\_38I2^5##-1PM9YW% :V9([=[RZ,
M.(DVLTJ?N^07OK*"\B?4JY:.AOL-XU2#91*)[A<25D/C<<PUW"RJ+:=NG-G5
MZ194X=5(\]4+NJKMZM1IJX]V+3+[" A1>X% .(-.O+Q,,I$##P)^>_/?GB'
M$>J=UA<G7H)LN>H'APS_+T]65>Q#HISZ +"['P'7?F0(Y*STCOYS?O_:7)O7
M T#RCQ+H;Y^+B6><^0=P(O+E+UN/5\;9)J*(7R!O7S%?_G4 ^J>D_/&]_4<V
M@>A_U=(+G & QWHF6WQ\'0<"X]"^J'2<7_D/8,V[*AJQVZ:]'P&G(U\"CD3.
M/;PL=O! Q!G ;S&CI(-9DE[]!7CD?B" F6&7[KWX8]4>"LW^>N25\ND?:0HA
MVE TRP@ $ /\\5Q-XX"_W;\#^FX$YGP"7/@AGF\Z_0/X\P>XQV]^)C<(C!Z(
M<"( </,CKT^L;L_KX9T\%L;]KV8E5S[D,Q\E"IR:K24+.SG=%R'S@E:H2JPN
MF#=9'G>?*4C8N+5M))5&&U^F[H7B[@LX@V1R79/]'55!?L\!1^T/,/#KR<^
M"PJ 7\#>#1F9X'_Z_@+<WSKQJD#Y8$(M@L_/! 45%Q/"URHA329*=X=ED\M(
M+NGCLIF8XH[>=SN0G/IO+W]UD-2\(>/B&KSX;_WY:_8F+VY?_B\GP_X N8X
M@,H@2!VD\AP@P"S[<?JW[<LD4BOV*."72Q<? >\ SHE^/@)NVE.9I'GM90!.
MO(B,G,O=-WIP?#1OY),(\R8YUPC670!(5Y](.CZ*]60UO9;1/"+8M7?_14-"
MK:S[8A_ B,N'9D%CC<8%RA\<DOYO9YGH-3=O#RZ^Z3M 4,^+_>B84T.D"0#P
M$0!@0V.1LLP'!T(% &AS>?FK^L&-;C=_\ S?-8#]3Z:@9HH5_/T X/2#1WZH
M$6CL-0"@X<#W4O(M.'0 ZG';;8#NL7^9$"#P!Q]RD*WW3.PFZ[+W?9%BU6@3
M$."W'PW(I=%)JRG8*T7=I9);#U-ZE':R.KX#QA5%68W08#4O)::OO(2N@$+E
M,'#1+M>,YWO_1(&URM\-2P+GH[^^VO(ZDO[,,O=9VYU?;G*N_9]:\WQ7%7T"
M.)[I'P1AU9?$M$FC_%6-XF:Q33N]5TL3[CM8Y#X\$TH4$UBW?Q<P7*HNO^@I
M=-M&:M:TMF V#O9**F5UGR"^&];9)D,@DV&+U+Z5P"I&KP1*#*#S[,MMP-&?
M@WB)O+M:\M7A0)T>?3[Z<33J&N#TD7\[,=S4*P6<L-;X5U+_\6"(U8H]T%2_
ME0*.\L5"'_RKP_Z5D8 #'6ORP@>7?L+I_ZNC_E.V3@>CG*D$'+G^L_EZXX$:
M?0#P_-E!0GGM/ZTK5?L<H/?J#2#H9XOVTP<B-.J_2T=_;''CA8 K&-:L*O,P
M*2-KH3KB[/ &TI0=(C[T_@M:+OO+#R]8GJK0"V*/=613@4R,-4FS?67?AO;4
M] ^?D!J?O#[T[DP)!_MX/OZ->1VUJ& 9?Y%])END)Q MET,@9F5&\8EZCJQ\
MZMO%=PA\JK">][Q=8<A<;=!K!M)2\'04FM-L.L7FH:_!&"..=WK8*/@ TOJ.
M12Y<0*@0OZDYI&>[NB&S+O\V;/[V(M2OJKW/_W(W3Q53VW$'W](FJ&F^Z2IJ
M:_H=X-[NB-4.!D&'6>D+*V5JWFW'7I3!*OOM%&8V/U;[6(\QRD!"D0/A7MJ"
MWD\JM:XLFFE7(VUM ^E"=[,'/T/JDV5]_)NBRA::.6.:[B4*>EPCU:)DY=Y+
M+SRQ4:L&)-^4M2Y\[DC+\ZHZC]$#ANR[WY2\@ E<(1'';HW5O.%D^M&69@H*
M$P:1'G\[J)]S/S>[T$\*&:!2B;*HR\R@1W >V6UC@<N(%U&[[Y"]N+E(1_A\
M>SU<^D5U2;HB;W5X50P_KU&(#&2GRH"W5A.H,[L'9O'>I+RYIXU&=5F'T)XI
M;;@90SE3:)%%C1KO!Z%F6K?T]9&M#&;KJP"?V\U,]&&0'V[;O[!&?>_6PLSD
M)XEYQWL:_2%=7G$;B0C.WF\$5K873M-.1\OE2N^D)!UR 6D:\RP3[6-=!A/R
M*S,^+[:*"A5V'\=(U,D8M7?)($ZGP(/X]NMP0Z>[(\G=(_/;IK!:#-\2A%Z&
M&B\ <KCZQ!1Z8E!/TP)5*I8?9;N0@A(JB$Z9Q5&=\?9\8'PJJ&62D"JB%MJF
MMCY@*.T+2.WY @X0-!?USB4L84O*VQ!M<SVN*:(=;5F9&J4*@R/EV97NCI,3
MK5/+E DGDP/KZ[J4.B)"PK&Z(DI) _BAO"CC5=1N,-7>OZRS<7&@0MKO+IO#
M[H192;[J#C!,<I@U\DGU.%(645<DGDPJ?F5AQ86=["X.A$2W;65PL5?Z4&]!
MZBL+7U*ZFP5QND<.K+BAQ5@E_^Z@O2=Q7,,+AWLB401\L.]"S=$"EA80"-0\
MFRTD(EMXR>T%5;)@H8">3J20'-T?''IS=_U=6%?4A?H+U>M0]P!RQQ[L2G37
M_$J(B>/Q7HF,;X/K-;A,M8[67<@E2_J^KW>?C\J,5'U58LK7X]A=F^9*]UO&
MV0J> 8(Q-BB<)\Q)S3>/79>&82Y2%AC@ <B'..1N6.O&?6.B/ZIG'T:_N&@V
M<FLW?;KHI?\E/PLVVKY%BBWDVZV)+HXF<TYX35VI+@SC3Q=D([M;)7P>A15V
M:^7:%Z:)]R>5V'B?AIHE(@>L[3/0DJ9;)JP.%$8&_*&H23&'X9[]A3526#$,
MAM8!\<YQJ9'9S]^/-K!;0051!%K28J#Q8P5X#3CD.L4+7RV.$D(FEI0G2C,=
M2O6QQ<2J5IK?5E82/G!XLGSDB1UI-4C8AN:>%[U*=0"?G'?$1',4\9+3"VHE
M[GGK 3#WVLV9L@[ZS">XR?!DG.V 8FCNR9./RD*$J)75:Q#A+%+T7^39S>I%
M\L;U7Q7OQB'U4:B&73D"4]]VRM3J:T;;H.1HP/@%I+X%QRN'H$1+=U[B_ET?
MI-X8/4FE8Y_9*,D#<\#^&SNOI X,3$4&.2D7;N667]";D1&W+0_')#.02T:2
MQ""01#N/^O5K@=Y>/JFTT8]:B7'/SZ/GIWSL@*FB2@UXVT1B3JI*D5/XJJVH
MA>:9)(DBL#;"<4G]'98KLXI5'_(?^ST;N<%+;)/<:#RDHQ;_V61K'7WO=$;S
MS# M,4=VC/O>U[B-]T&NJ)675[*MY!^=W%54#W^RW'9E\YT-9FC:G6GIRZ)J
MQ,?CA.,ME0,TDB*X^H;2J0J.AKA<^E_TO  5H"S.C['6NG?W,9R=<6OM5<!A
MY[@]W0O5'(-52_>9!JJ_OKZ^*8']XS\FT7-VZ,.LO@FN_&L6M :KOKL-L0!'
M-GRF!4S$@NV"7K*Z1Z3R:)NH.)(LI-/6H"9=$TU^IYT9_[M8MP9D5Z5O-X3V
MDD2@4CFM"Q3W#"X.=([>NJD$W,("MW<?SUF0*$3L_(F"7A5:)738+9V$OP(.
MA4:3C69&$MP0E0-NPXT&Q<,KP;&TJ=Q$8G%7[YS4M^W/' I/A7ZX1AK53R73
M+J[ZIR^/SNC;HB6YCNL#Q[.(BD+!R(9^KQCV701:@V20DA9KZ(&+?;4IKJ\+
M]1N+%3)$P810"OH;D:(O<]1"I!VIHNT#(,0QM@E)2+ D;&8H]G?LL(27M2'1
MGWO!!I)8;8']J_R?%BD\XD,!CRF:C+0M*&#*USM]!RA"#^W67_\ZI])=.;&1
M,#!1M+LVUR,XG(V [EYQ[EE07R@^O<P6;[__1+=L_P@LY)4_9-H7!!+.+>DI
MLFDH^5KD@_2P?L;LM#M"#$JTI;7,A[S*RZ"3K:Q>DI_$2"<9'1IN @D 9U$8
M2<F EA!;%$U5<)3FGG;1%=;20O*H-%T_.E'A?Q>C(7ZKAZTKH:\V8'5S-M(E
M[P7O4H>^1P+\X(<FDJ.=K9/*,L-\1HJ@*".BVHS0[1'@:X);T6W0"O[&K"$(
MGJZOWVS&D-MJ%]KEQ;UUKU$O!<8\1B*WI:.[&8OS>69Z6*Y>ZZPJ&R'1]C%1
M*_<ARY&\U=&_HE,503P&-*(Z11>FJ8">H>7Q="TB4"B]6S^@6]7O2<!K:)NY
M=Z]PU;=:IN1=K9,?O Z[\#Q$U;A\#>).RZ_#T%Y@S!P5U.ZC*#"\-@KN8G50
M5.,; \KF-]VO]EB,MI>X#M+I6 \Q;UL4I"A#(Y:G%[@MUWIZ?GR^+VR",.)R
M_^W,=X#11@CMK?,2=NO" )*]> NX("<N5G?4?7R@)L.@C$C=VC',%HN$H/25
MT9KXT>Y-KU[0@-Y[0S6_$UJ=_WQ>\YUH47I6.48I\L#>1'WS%<_N&M[<=JR1
MR-AWY4W4G:5;'VV3IXO@/<C5<>F%M^YEC9MV)=7+#T"(80;-4UZ!K'B1\IZO
M)PWM=W+..T[/S%S;O%0Q8*O8I\Z#E-11 Z\-@&E6Q4AOWTV*G-(YV-AUM_)^
MS'GJRH9*QN^=<Q4Y>F@<L4;BVVL1G)?E"\+B8E:H^!<D&Y411, 3TU/OY0X3
M4CSD_R)Y,(4MQ<64.JND.PL_Z=YV5Y#%UQM1"H!YE7"HU8(D.>'L5ASH/C!@
M@=:J.#-<HBPBZ[4K=?YW*2"0V@'^S#7XRZBH^),A:DD<$R2AZQM_2U?%K_G6
M;D .+6VS?<[#,M>,6EQT"NQ;=;A/"]N-N-N+)BT:7D^7N'Y!R5Z+H2UEZRHU
M-AUO>+%;*^/;\^:IR:FYT2WU ^/JBF8P\>.!3Q18E#)I:+ZZ?[7ZI)_:?DQV
M^ZW%#Z/SQD^00<[G$)G'7J!0>FM+'Y?2XF6AGLA3 33+=Q!'R\AWZ&LE!MOA
MZ:6:5KDE9L"NYDKT;WTQ6CI>BU<X>8EG,\]-HQ=&ZB+Z BKD9\4+Z$@? R/Q
M%)%W<G/4(")Q5N3]B,'"2!.K3S#5F.]$RK;8D]DX=4<^F!"N^"WV'G5+PV56
M6SMD8X=: ]PS;?/Q"*M8&^.85+Y/R_!KF0@L>$TP'B_.?UD0*/3Y=G>U$\SA
M9K&KG<_%&=O:[(#/O>U[IN611)^JB-(GW<KX>ZQ2\$Y^Z*)%-]A7<?]0KMKZ
MW;\YEZX<[Q8+L6BAFWT'.%2,?QV2"Q&L,C.\ZMPQ?W:T=@7CF@(NR0I8O?'_
MF'O/L":S+6PX9QQU+.@P-*7(#"A($!A*8.@S P&19DQ"* %&$('0$XJ$=L89
M$(+ T*4D:*A)2) 2>F 4 >F&))30I(02"""]\S'GG/?[^?Y^G]_/]3Q[K[VO
M=:][[W6OI>^O.N:Z4PWI>\*&17O;)?1WTL>9_>UP,T;R*@RI1E>/Y3^(492,
M:@J,]HDY!7SWN PA-F,=;/MNB>B0"P+Z.2='[B8<&L4D'XN4!H?8X2R%DL<\
M'F39W>L**$PNH//L@_H^)N1[1&Q.%L$42V_J(\KJW.%>RC;X0L'<_65G0U-<
M^7,\[JVB0<JZK9L<>4]6T61.D#ITQ/$)[;2?LZJ50C<J5.!",L6FC&U?<3[T
MTI^VJZ-I/D*V#[JZ^FB^D)6.J?LF@2%1"]-U<-]6%7B$>X-#4<S3GDQ)_53*
MYU%A;"6BC6%8>E>5BBP1& 3;K,]5S#IW4*J;I*RT P*%5B]6;#27[6:5^HXF
M-:>QK!86D[0K5FYF.ED;8;KQ)[_;[8;6ZM,Q]D.54@9)9G5$.0SP!V7OGVX.
M@;2"8#K(OX>ZI%R2YO*([G?Q)T0%#JLQJ^K9K=609'-UYV48$GCLH5I@K<5!
MMO<K0JEPYV#N#+WM6'<K1B3FY,\WV?]N.M+6&6\5$[W<P=KO5'NL@-7)N]FU
M&0%^UT(9[T%*^"1985',AQ^B#.C"]ZI[AQ4@?2E*BQ6F/?DYX.X?&O:.HDJ>
M-0(+S?MF2@B7)F/,O]*8D@T(4@5)I,_P+,&W:ZV=S_M!'5^54@OM(8@M043E
MBHUK4:+>"VMD3>Q!2U]84910=S(8]^Q60H8+06F2 S:7VR/.[51F^\@_JS.8
MU,6&VEQC8?%$EV: +T5$_G?!OTI"HE^R-:>TMLF;6CKB53KC=POQ?0%/.>^5
MN?7\TM$@G3;GM.VZ*F1-,N%-S:3???Z?ST<MI&^%2(!3<2]-YV'O=?4/B,1(
M^:%](RG\%=(I #9VE&[QJ)G6$S$L,Z7;_F22-N0,AQK*.K/65^:6,IAP=8$Y
M_"<L@_$A[?,+"P=0: U;=+?'\/S\-UZ.>[/UCZI"Z3UR(:9853VUWQ?KZ:,>
M8RJAA_C&@G1;E_REQW.V9C>;IB0J]7B&N+*"\[8U&V=;N//8XB!_BB?I^L0E
ML1Z.)&+K\Z\^J*0_\'5.3J_F!K6_T9I/?;L4?L_NBD?.)L<J36_*7/H:5M[I
MSS!EJ%*!0U^]+BN+"FWJ,7E&9TZ4'??C3P*<;;H*Y\%/)3(_D@B4SZ$I=\V/
M7 =EIZ&G .%2I<\!&VL!_!#S];><2EA_ :QW<[ZJAV[J$PP1[GD69G,OM.>^
M-R.=@531<^GSK?!E?^22+2,A]^.KU24&?3 <C9^K.O;ZCEZOX;$[6PSC+RO*
M?VT/^N14&[B*%PA C5X])7=+O<:.&A%"65BIU>VEB*AN'&':Q*"JJ(8.T;Y/
MP+_$Y?<BB=N=+W[7W.WQ#H9G>]%#_"[\50D9@HX51\)%=S[>O.UONDA%Z]PM
MTI]VW3@Z&_EWIX ??C"HCU^JPK+&_#-C MG]9'=@?$DX^M@N5X82XEV'>K4@
M)3@6"W:\A1_%7S2,F[C'5;;IWH5V\##4'X%D"K3B;^!ZG?./N%RWT>%30(/[
MB=Q-_J:Z:&#_@-IH1# </@D,&_,<T/?8$3 .E&T43RS_.(9VDD?P#;0$]]#$
M2A 9E__I$UBJI59.R<DI9_\):H"#;94]TFQI190=1"5.J)B_"3E.RN(?9#-A
M0R:V$'\$A9BKHTN%S?4+?TQDCBRQY@T\;1C6+8-Y26<0_J!*7W+%U.PPH.=(
M;^T[ P7F8H^*#9G9EU/+#UXHK^WFQ7C(FBXD35W)-%J2)I?EP) *W]0X4;D3
M8I,L!_-'[&"Q;QN5)!D0QWDR,'H)DOC=SFH"B:N?E]F,#V]Q#[/L(@M 4'38
MJ.TAN'2LLPG<HR40"^A98?=$6LB^WI/F.*;]3@\;RY<,2JO+J5G^CFV3LR<P
M!U'W&S*A'PX="Q3GHG#%1C58RU- ;)U\;JNYEQ^\S!UJ8/"@!RL>U7V&. =O
M/NOYKZWODK5#'I<U5$DNPP969NN9/&9AL^06VB/9=>+]M,V3 ,<F,/=9&7X:
M$G-K507COVV@*?OM^*?QK;BW_T^?3QO@'CA0R*]+2I,&!S0'?YKUC"!0_C3=
MYME*"YJ5O-3:;3X?5D D0.=S$M2*QY<RX7*VA=?#JC,UGCU!)FK/-]C_YL;)
M2P?G1BR< MA58S)BXK\SM9ONW1_6(]P6/$%%ZCHO&4Y99D:_E'7B:/B^0KFS
MA?64WG%@'(1HZZ^C=.N\X+$271,K.4S$_80.F^;-0U[3 U;7#EEA?^*1W)8
M^<H=P7T)=SUR^XY\C"UE#>G'#E*/\7>DU0CFV%PVW+7TC9-CZ4,V?\(<S8!7
M[%@'K^5TY6\0R=.D%=/W4>=;LCUKFCH-^Y5W*O0K.UYB/?$Q188/ <NRLEZ
M<Y=1OB5O,BZ(=L5>C   LB3JV:,1_QP2_N=4.>,"9;*D@S)9]/[['QD=5FI!
M5W/_?6E5$A#AIU1$XW)WSQ/[S.]X^$Y DCHD":KH"@QTJ$0,+FK:9VL9RF^
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M.BT'9 P[=H_@C=VMI?)&*F6ZDT,1%1J;LYR/)5ISW#Q\!EQ@"/R[JZ1S1J'
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MR;H/(_^5L7S[3R7?JT[_/O?]?ZO^NHT +OP-T/ZO_//&;M7_LC<F[P/D'HX
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MYZ^Y&DD2I[[6Z]/6GB52)HIVCWZPD=Q@BOWAQ%?VT$.W@=&DTB3]8_$'\Z>
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M]:./5($#0YT6G)C)E1.@V/F(4T#<&8]X?_M$(^O8XQ3P;Y+QN]$C&/#"[BE
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MH0DAE-"D0VC2.QSFV<__G//B?,Z+O,@J6?>ZUUKW]?UE7??OFOQ!Y=:<0:O
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MGW-T#&KLN#_4[Q472(Q#TT[L[>:@3E=K">M9)R)>9K>A%YV^U;V!J8.>/@8
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M"RY_M;]DXB@B7-Y2U;70B&&WMFW8WO6%'GFB<7?I%Q9(_E96IL_8)*HVRKR
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MI'#/:7'7*>#\5BY(WMK</&R4>LF(=WR5]QX]EN6RP*&61@++0\.V)MWB_VM
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M W^5.O&Y&VG3#C@5_][:93(B ]B_U/P_!R1]1?5,T6JK1_ D_[FRC]E21EM
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MO<L@]$6]Y:<(/ FK:,'*(I!*SQ]#A! SI[#C4V\,'<3['K=GN/J8RFBU<W5
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M<L;1(K@0=Y8;>191"JL79%]S7!#V_LN8A[Q9^$@;-NAI^$!M-2\B*8;@K!^
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MQ8;.2P)'?MX55G// O+X.7#R&R V1&^ANQX/')P(03UYXTCP4\#RX&"',X8
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MOCW<_OSAF1N/CYP_S!W=98"/2/T1.?,_O_0\!\T\EW1Z!OH7N*#X_.C9B6]
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M05G[.-CX0\ 0,U%>>>03=IA%DS^1R_X/R$7Y!_M[47H$$4-NEO\(@/XV_P)
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MVS"=/0W6L"_LP-N:NZGW"SIRAJ-NWX%X?S7_Q[K<_=A%N3,7=O7L1T2\$,U
M>_10DDM)K]C))@_T0ZN!C.N"S#E37G1_V.Y4G7V;LFR#B6M+N=()">2P';<W
MF&Q=:E!\APWF!:.D9%A29CC)D&N^.KX?KH"^OY#& K2^_58R!-!X[%.:2+&E
MY#9IZCME:T[00Z^W;?"22Z&B PG?VO/U^3SN8#N3@(5L%SJ[V2@J-^+*91&[
MG\PZ5CJ*TY._B:D&;$6P"X^LU23W$,&J)TBHB:99KQ%4\>S@A;*-I_@W=/O2
MK@:PIHG>HOUDZ,*D]4"E< YF+;7O/[QF#E\L#">NWY,Z/CC!U30GY;'XS\U7
MG172TVQS%YX,K!6)F7O=70PX)TW)Z)@=53-/43HU%RVS\\W_U![1.'#6;NQY
M\H??+'>?_G[ X$A+@R5L6A.=B#?\A:I\&W--K2"DN*VJGTD6(IF9B;;5!-XI
M5:?(:L!R/G6>=_4GE?C#+<WC$Q.14C&B.]6M8)'=_\PE.W]K-&6+SF>=O=^0
MD-=$785AMUUTO!9_NO_\*$1KX:-_&B&WN.ZJ%S.VX4K@Z#*!E+UI?CC9T,RI
MH(GEAXU%J;:7>:S-=)VE@4&.8 /Y2T?;;BNPO&=U)R8]MPS[YN68$ZK<2):0
MFCK#J&(0I8!CG=>0D+CE-J$S=5%GS.,MSUAA9$3QER3#X9NF B6QA.*.K=4Y
MCPRG"_-; VWP=SX0\7O\Z@9-'+YA[R*(?</#O[F0_"5\=FKG=')SM03E(ZQ3
M@)P2#NVQUI $K@JRFG691'BL!N^&,">#I^[F:*!(#7($-&=AK?C--#T58!,9
M%<J_\G#C,=X:;)0 E$NF!#&95S)XY;F+,=>I(WMW3KF/,(EE&-!F3&7;>:MC
M=5;(XR^&"IJX O9C3',.&*Y:D<K/#:?A^L7F.@/N.Z^=)G64G(&80(<VO_'Y
MRV'H3\:^:;638>+RWE0Y5E;3"?#%5_];GZ,?FD>D\&WD#9YU3I.Y?HY^NZ(.
M0$?M.K98"\,5=:^7-Y!*7;?K3K Z@7O/V7P[9U:,2\S$^3W%=+ 8C7[CU:"A
MV@@0:&AO:^R=-N!UC1G\+:V0TQ0:\6E8"SY7G((NE7!IT,H-G*0<,#@A>'@!
M<M=J/<%#6#B.#\CZ2U8B].(9'Q;@#";7FU,[R\'!YEU,28D9;Q;.E03@4V\,
M6YC<ID[U7Q(6*'F]?UEV1]5>04P9,]2<3"*!W[=$>LNPI%DH\&IR<F30$?,V
M6E&HD@Y/L 4MI_+E 4/#&2X.S47:[4'P=GLVQV)_A[F7PJ\E?))#!94I/,WC
MJ;W*GY30'5]7RA4YW1?NM8IE>@=E?,JW0!6W!F86=FMK&T&QQI[R)M81UN!0
MHF-*N) BC^>88])4V=5!B<+M!G.P>E/_DV)=$ZXK"@A!!+[6';OI27DTVL_\
MVXN[(J=PH=L'#+5/<TLZ'2(^.KD@4P&0\E;Q"&N_S$? 68)-A*HG4L:3<A7"
M%W=1?8<H>JI3._B4?-GI['0+,Y?L8*N3V$C]L0B&%P$,;G7K+DL7"X<N=.;@
M*"9B*\7HS[2H#GQ;L;=GM(P_F#6?A/<@YQIC>>M#7YFS^>'N7.MS?IPUE0]:
M,$XL^7USBQ-B7Z*F!N'85"JL[:D2IL"PJ'&LA/O'@/!U..PB*X&6OY9:;D13
MA@"\]1Z)]$7HV^GL-VG.GKIASV:IF+QO '"6$V@S*<I2LY&6 5\!R""0B5FN
M_ 6\0M6A8*[2ABRF*"56\Q$V _0!@YAW:)'_0KJK6.@U4IEO:_)J SH?U+*$
MOV(SMZ /=)'G&)/I57_DB.5N!1K=/[DL!X:(>SE[;& WB;F7@F.E[@]_7"Z9
MWQ^<&];.%$_T--/WR+, .(.E.@TZRMA;3[:%SM9Y&P)(YC006-7<6A@.XPDJ
MM-[76CPS,LLS\_P1P_\)1=Z)ZRI"M8N1BS/<<5U79B_8^K]L=78D<\Q(S0@$
MW6KBY$AN]V$A,X,ND:C719? ?A:K6:S6_=FR^PO/WDBO"I;VUJD2S,?O.#X%
MZ6>+SBJVLM(].B"FC6/=VX+?LC\'<9"DP9*]DF%?"'J/>GFD #L,J5OW8Y4A
MKK=%=5P("6\.&#)=I7L'5:FYSFI21-1$_:-U+%_\!-66H IJ=]\K88&H?9"^
MB*;)7-8$GXKL-_*(/AMW,2JO=@N<4\F8,V0W<*;S)</.4J+*Q*FE70^>U4N!
M*P\#GA\^N9$J^\^%EJ1@+>]Q&G[&/M%[%A<$OO3G%'4^S DS,=+EZOXVQ7/.
M&E;%<TOQW(MLTJE"<+\P81TVZX\H*!!LU3?1YE46>82)]03+"]_H9O8,'9'/
M-9=TG.46\^IBYQQ6LRA02(**"$7*DHC(1V2W):YJW Y?KML&1=KL@(%4O.#L
M6MQMZH"S393.Q/A;\2G(<=512U!3L1<1L5(!^X4];,[_R%I,A!\PN,%I3TL>
M%';36DH=.5*O+8$M0T)2P&!F><PYFV6R?;]HVBG!%U5@29N)UP%?V"@SR3)^
ML#%(-_R#_F'Y."F[ [20>1I=8BF^'92AW6.L,2B&+E:OA/D0/VK*&9V=?PRF
M++2Q8P%"72_"/U O:QMNF4BKO05:.,<FRB]XHU%89*K\)@#EY'W>&H$1!0;1
M^Z@!$\7]E Z2JVQ_GTQ6 L'VU$@:Z:&-A]Q7"E=N]&V +\ZR5R;H5^7/# R'
ME?&TMP^Q<)I;SJUJ=/$7T]PBYILT5N^+=!MG-=5M,!C(S(+%HG@!.3<VA&U>
MEKVC=I6P-=?,Y&Y;&8P(QZ\YXI*CC#*^5IW+A8@B6!7(9$C/VZ"QN3#=JB_J
MB5F)QF4PLSI1!:TP&:HT'"MKRY+"S&JZ;H<VQ86C_3R>^_QNG:!D _O"'D$I
M&>OY@@RK7?.-T*#V\]@5J?<+O":HTKT(GHD]MK_DP+'S  EQUJOGSI_52*_
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M)*R@ ^**(M=7S\;+:5Q*ON\P\G.1D82/G'%JL?BC15F,>9C,56K:*1A,UQQ
MVFM3M0S)F2Q!&QMW#<X\Q6!3Y6'VCV8$$B$9C^I)4E-R$!0O+P!+=&\ JX'
MTC2NX>'R(G.4*,HWU,^^DL28S=G!9;)@/.ZHY2R 7C/WU9Z?$[+59^5^(+D;
M[CF"$<U0!_#*-'\M^SP?V A 886@XT^-%X$>MU&^+@R2L#.GQXU"&C=M^D07
MB6\+HG< Q<-/7[K@HPM EFK&>UV/N@/@J2(<V:$C6GG+8U! #D86^7L#63@K
ML+[LJ5W&Q!.C IFM#AZ)A>Y+&A-[GUW20D\;NZ+7Y7$@(PM' >2H"RYA=#$V
M I:) %]44S/VB? TNP%DC_*+B3D[]Z#(.?)]7O^@??&,H]BIK(CYP?O:KF^$
MF4L; ))X]?%LGTNI8U5:=:AB)I?<7U3[DNYG3S_V-^*V>7B]C=X (U.G -LT
MO=A3/M]V)OH[$VL>6,HL]O1A5B>)12H"MKJIO8P:VMZO,2WKQ8*K-M,A!&@^
M2XH'30TBT[I-%'!ENRVV-3"P]S-._(HY*3)JO@]!NSB)+'N]]3 3MM?5AW\T
MM+BFUVJ.G9(S]I#+61\S$C8*9@!%#.J+H,F=LHV#K&2 Q+IJ1 I'W^,<S[Z0
M^,7]!CN]%(:Y('.K302)!WOX>#15/W3AN*/3'ZA6@^ZQ()1;9"ZR*[Q!D,!@
M<+?IXX#"9@$N/?\1N@NX#0+ 3F$Q-P)*J[Z)0N^"1 \88EYMF+'0C?NYR_O%
M*COCGJWQ#CO!8*-.N!5_1QX>YU/2[E4(?U6JIZ1;Z4^/:&[ /-)[3:;UL(<R
MT4)@>-=5EX;\5B@@D/&UF?M:#5WBI\&%=)G*[AY07P[!%5DY^K"@3"T=@_8*
MQ'&L@3V_>#Y]:KIF&>D/!N->VI@'%/@S:^ALB2QL5Y:!%M^(.HF!K5*Z4)=Q
M[B3C+UO&=T(*@0YX)9DP;5/KE4<3,;<^0M'^6UG8G)@+:HCIB%I[BA]'#QUH
MGNXUP&/8D+OJ_-9 C:.&M>=E*B6*[)&K:>W8<9<*N-OXKBN =, PYU[5]D1L
M2;]O1GH8/FS_(<(ZO:1+0_/$K:_6ULQX?<SE#*)@VN4RC3<4(!E6 ^GE-]#(
MO@+0NH9@0U=Z8R+,SHM9;DC B)Y&XC[,#"5M_,^B.[E^<:99YM+ <N 6GQUS
M<?T[I?HC4?6C$'/R7 >&%L#LJ&WM<]M-$;W3(#OGDHM@:RU*3WB<G97MF6'3
M8ET&-(3%AVWQ#\^255<+<M\EIH4 7 "E65T<:0%3N273'&5],SUO!M:<?+9/
M^2?VY+<U?'BG7]PXJ@OD-QX#XK6_=2+-9%.ZC)LM4S.STO,ZC1I869583/OX
M7G,DA]2ZZIG_>FD&O4HOU'QD?Q.I=5;,)RQ +#L+E17!![\V$.]HVKVH^G$*
M1%/1T+^YTMB7'H'=XO>/XNA!V8+!_E$LM<L/P^B*([3^?5:94V(W9R[,@;$.
MV^KCX@_ICLBLOJ^UY_C\8LCMKGF,>YWEP59TME%+7E(N4-M(7\,F)R</#2;8
MJECV##ZNWKWQ##,QN8ZC0+6M^)!;XJ1^T;;A(8""-O(];D&$@S*G8D#P-^O%
M(:(S&W%#(9N?=M($])JJH)MFQ2.XGQ\1Y:FVE-:6[DEGJ6P!46:C16/9]9Q4
M)OG=VKM(USP5ZOLM]JORMT#@PZAS(XKG?MLF>O!9O\RJNBMV-X2=Z[SM:8/S
M"#NZ[=">6JE_5LFNPHR<>619DR[$A,42?SA&M9GUIJ'UXO7741[P!'_ND1%D
M/.@I:J*[TG3;'G=MAC>;W.4#) \UTMZT->0;*8TDR7V; V_]GFCV>&*R+Z*\
M0[J8D7+.D0;&,4H5+/F_$,+DQ%SS',!M70%L\/T2VM6 ^6ECQ96E*:K^XIM>
M#C84OHQQJYUOH1W1J21BQL=IIDH MT2H*]^NG\)BY1[A$':W"""\E5CKU4L#
MK22<Y]T":PI(M4F*[,A]VCQ-*[_*@*7&QU?VK>-Z&,BQ'TB*-3;3Z965C%35
MBGQ(:WDB,=6+P&P_(52D!DAT?(O*);6MN7(*T*ZVE=TTZ-0536"U=8SB1UB&
MOI[/L!YS?!36_-9C_+RJ"5.=#QJ?NZPU0+BE-65LOEJ9X+4L,PO'\4VG'C!P
M$6 HM']R]H"?(/ZKP5=(UE1H2).HZ")+RX3^JPE,@#UNY]I VKT;9UB#="WP
M0ZT%Y9KIJX@J]3DHHXD@J=ODR<HSJ(TCV/ <RA4U20%RMD<^);"R7W>LU&[<
MJ[W@0W>JF[IG"9C E4Z3G]B>+R@7-PMH7*0J8NG^MQOX_/-ZY 6SW7]5VIH&
M^483TIVY7)<$X.\DS91:R)I]= C3A;;3&N.?^[E2E?8^/QJ]O*ON</%:\=9V
MC6D[B'H.8 A'IKY,>)J(S6J)5J\>F22!\Y7\4O%0CS$+Q(.43>*HTN=Q(]T1
MWRN.I_32^O$B-YTRT0M<L3C%@DPQ#PI0<3)[(<7/B+E0Y,T*MLE+H;! 7B)@
M@0VG1\YOR!'S:0[WM1>>\A^\TBTEQP>E<$Q,N=XDKG(C#Q,6-4A][8#*_RJ&
M<UZ?U?(//"7=TX?*RHK@A<L*V A'6'/$0X7T0N)/M"P#@YZ(L>ZSNN_[2XHW
MADZ@=FM-17<!X[OK3RR>*S)EM2%;G7-+(2 IY)MH=GTEU3;U N$^^)0<E=(8
M L?B/K]-5=4'6$ZV%N_RS#[""'G+N&1B7GZ\&F$NP5_1GE!UZP/\*3&?>N;L
M9ZI\JNR=WWL"[L_*^_%D><4D.74BMY'9-R]9NC2YP3&M7- 9KK"T8A"IU>K^
M.?>&X$G%X:KNZU4M 9 8=I?Q3UQ<]B4^NI$%VX6C //:ZL:93%!$\YQEW7LT
MY,OV.])XU<H-E]'9\Z.3/TEO7:FZU5.RYU6UE27'$Y #DY^J&;TFK_%L=4(7
MO?'883&O":&.KXYH<<*#U#;%[9*P&YZBHPO@]Y:JQ)8U_ &#A<2^@Y[W78!@
M,WK!+3T'ATE?$-_67.B^2DU1[F4! X 0[N'?,GT4C65?"*Y>+"AQN0'/FTU2
M3<$3UE1.52=LS?4W<RB1UU$ WFS\U>T;-FOO11L/&"IFB'=\<CO WDI9[>J]
M-V]J4,S7,G(@FDQEVVF#^2P?KXW&1^]"EA3]S]1,DGIV%VR=3S%EE)":6EM-
M>#,-!!6!_/[@P!#<YU,.+BO<#9#8+^\>JAXP*'0,/,44]_<RYF^EL""U:):E
M+84^^3+3\9;/XK _.YGNN,Z7)Z2[PN3W5 >2!+Y$:P$2O6:FY5BE:#MQ0AHR
M1E@ [^;E$XVM!89FTNJYPX.YE[R;#;K+>ETP*5(;AK437LM\Y33^M OFFUV!
M K$OS%-U=5LJ%L0GYQ;9UK*,LHA=8&]668[07[J1;.52]=V3[:(=\SG6,*S,
M,AWVL[6MKM^#;$ONW0_^X/*B.QDO*^6UPEZ%Z\A;5H.S,6J@I<DL+Z>US\4&
M?Y7G4F_T-;!K%D351U,5EE#CZ&$]O*;0_,B^I1V?64<.E@*^?.G91:-U0^>W
M5.\#ALO87>;)J@#ING$U*--D2EF-9R V:J6,U7K<5Y;U6J1C!X$.$;SU7-DQ
MX,[[],%SR ZG-PJ$]&K1+_YQ!6@U'513)!8+AT>HZ4.S=>J;W[&81;AC32BC
MWJ)^!7V8SZ&YKE/NX=B V6R9TB& "XTF0XJ11Z%1&MHW"P"XU"EQ,&00<<#@
M=./.E4NN=ZJZV>"EGVG @C47#Y2R?5_?+)_.!OJ77NMN#.*;N[@3Q\M1K--J
MK[:S-F :\"A:[:;C2-HDZ+!9TA_D-2E\-"[(<6Y;R<KR'-6:#M@_:3FI1'"\
M$;IMXPE95\X3R+O[:HVY4X6_\_@SN='$%X5W!$IAL8</88!L\JC8)9SW>5D%
MM352KQSKT/N"5!M'LBG!(X,6,A("IWSV.LKM9=?FZUM1?'ON'<%7K'O\Y#?M
M!YQ__[SDNK0=YR+=NKYAMO@29.["UO@TU=+LM8[SI'\2HH:C9[<QQ/_N3;M)
MU7=K#6J[FI'<'_5CX^Q]+KW1Y?Q 4I'Y:51,V6]*V=K5YOU><8%?$I4>=6OZ
MX>C%KT+FR>SSTE'DM(C3$=5H>9//T#W[(02%KOBY7=-M7"VK1,4I(TFK$VS!
MZ9I3W*6WYJQD9<??H7^"1IWN79!04S7G)6%'+,FQK#<>#;]Z>8Z'6YR0LJ"3
M*3F FO38CDFTT=F=5=$3NH/H"3),J>GB]"V&R9<E-J@8S(:(8+G>)9J8A]1A
ML9Y DQ-\4')."%UUT@,7)Z;^&N^60B:5U]6DCLYQ)DY.>175SC8L9QAJO7DJ
M9QF2TCAU6.),A=MS\Q4@\0WE0T6V%\-_LVB=NC'=^M34U8N[E??F'I%W95^S
MN36MK%[?.V\0?+'):?'=ISP]1.K8("H3F14^X;2,>FK"3)F.C+*<4 ,WW 9;
M+A<&I,X=,"S)CH@G@'8-@A>$?R_FOH]QEM=J!_M46@CG]B0:^R!8-QC?W#\I
MMMD>-1L!]0?K<0KQ["IJ>)N><:&$VDU.3#F.3/L7;@%NQ=P8>7+&#[26\K3J
M2[.K+/J (<<"O7I2Q#4:G;ZD7G,"FQW@:?P0GM/KXR[(;%X*Y=O.5@B]KS81
M/T8MU&[0/U6P!.;OGHX:R: TSJ3$SH@"E;NQE .&$W%$MRMS#^<4+E(*[OMU
M07"!^UW*AO)SMMJ GX,4.F[4@:@!4Q545LI']C.<O=5$ENW0?WJ!S>X;%AKJ
M0@Z7T<**0\9*7\%A8 J@U;"<#VX<B8QAS,&DDNBRY,7502%-]'J<WJ@XL:*=
M3\(;>0UI\CG#^E8_WR-*]B"XZ2L'V<D5.I[$R.UOYIZ4O^/KEOK6P,4G-9/P
M>BBZ\Z,Q0JIVR6CPBIQI99WB7M$7G'W)R\_-/N^&% 06Z0! @ZNMH0:85PA6
M++1,<0]?U;_"Y]8_\7Y0WB*_P+Q$/7(FB%;"\7 6)]Q9H/50V'P]H_QTL8PC
MHD6-[D%NCN,=8Y;G$J(*_7XC<BQ-=:#DEK/C(O*-[!PKUSH6GJWSGMP:]:WU
M)#9YP;A,FBK7MD0%>*PQA4[JF\1$NKTN10P2:]2'9I,R%[%E$%/>%6HH2V?B
MLY6KT1*D]H@V*VA*^'E/H=Q<BRZRQ(T@ U'E7LDY,*D<6F \\K-C)<U,40^J
M&SL;J:&5;X22 -D=?I$F#0-=%\?N.JSK6\P) PG8 A,LSF'@@.'E3 (+4I"8
M;T5-TSP= $\4.9(9K6B4-=:-L!8?6J(M1,GP;+1=>0*,> M;1H3G*]TS.>DN
M>ZU35N9:/8I7!M/!4GXV]92B'_,!@X18\/:0ZTI\6*1(0^.[+3_' X:>\>#D
MVC-FRYWSQ+)MB8>+B M2\M@NJ7X7PP+I25,'A-6)Y,5]8ZUH&99>HY7HAA>Z
M4Q:K8\$JL_*)1/D*HT[_."__9/@!@WSVCMEAR6:4Z6@BT<KKR^-=*]AEY/J&
M.B?&9!Q>-SO*?UE9G9[7+91]LBH/D>L['Q1=$A"A0(1DEC!9.2TL%!AJ@GHM
M'!RR0= :$[T)./JF[PHYC(.($>EF@@)<J8.E[&*#(WNE?8&2?% <'U($*S*
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MQ$Y?:UT5?O]_L/;>04UNW[\PYW@\*GPMB(A2]$B5T!0(2%<A]!9(")  2I5
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MEL_'#S:)W%:L): Q,46ZE+''S&(^LT%/+TWUT*J5ZT-C-QK'>S[C"C*Z([L
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M3SQ^RDWS2F4JK5L8A022]#@:B;SG.6WN4=,E\,4EL^"FPT?2*$Q(KM<J23/
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M6IR('[/#/TVZ7H*^/T"QS[/*_ZR9SU"F'__A=<JECE031PD_K]5:LQ]1@RU
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MBIF9J8*+B8GZ='U*Z6["BFC 0?1HQ+3[\HOI";F99..0I@%L .-VS,GX#QN
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MDUYBO$_-I=E=I8B[)':4 IIBZR!]PJWF,32JE= H.7.WP7Q90YY9"^NMM59
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MXHO6XU/!I[J\+)!W]@SW2$$KGR=SBAR;>JWT* T-H>7P U.>(ZO&B>A&:@C
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M;R>5I#=<%^%:94)U@@[YAP"G&:_L5H;C)I1/#D]8!.:G79-1=E/.TOHJR(!
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ME8^6A4H-TBU#F*RNB)A'B>#@'JY11'7?R*K&LX&1Q8(@]1ZN83)$P\]<T6G
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MPN2FN.HE&;['OR0J/IHG*OZCR:T;L?(2U<B(M(BL\5Z"8V(.EHK001])9;A
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M&?'T7FX-GAL,%FR8,#V@#0\A*Z/E"SPUDG6!K^@&$*>=IO#7>X"2,=>9O\;
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MCHA2QCE[^65-3OS3)-*DV_)48'=,0PU04HYI'?M-<M^ZRID/>:#\.U69\/&
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M4D]C.G<\=BKIE;DQJ) [([$9VU^]87/0T5C5IE<:+8Q,&8U#;AKV T-#-AM
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MQB^]3Z\N *U8@NIFS0:CJZM[,YPUE4PU[ZKE+&61 "'+2?_<6?@USS#@EY%
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MS3[ #OK[<K[O=JSJ"6?Z/GK4#]5<LP;5J;NHP[W*^Q3-4Y[,Q=/3XC8_XEF
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MVK.YX">L_!CT.]&W7&2W;8=AODE0J7*%M04W3/A:1,7485SK<K 3G84P.O>
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MB6$9L2&JL<WL/U'345>&M>_$'@Z?B*6)=_J*7[%0@=:(.CJU BE>8_6Z():
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MQYS<+PQ96''(W>?XM7QWF8FR#[Y'@<!J"A<5KP<\S;;L?D=)P0 /L[YK@R4
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M%Y/V[@%)W%H;$.\_CR#3ABH,ES^OJ(P+6(Q(.37O&&&25PY?>6_96?VSJ82
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MW!^B7/(7-WE5=;9/*9K'!J5*!Z^W@0I9H[ B)%9M 1GS<]H[4Z-!J )Z$96
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MSYP?S ]Y" RT'-_<\U.TSRVZ2KF"+4N81):Z:P=<1U/"[&96D"G-P@3!X8&
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M#_XDZ2'FNQCR::KAE:M?*;\6)V!KJ=+(BUK@LYI4AL)0(H#:Y+9!QN&/-W?
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MDJ='21'4I<!^F.AZ]82.B:DSP;W9R/IO#=@11XJ-=M[BX*P50.YW1WFP*=1
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M<+"'6^T+^6E@RF1E?\6 <6P>6Q7SHB_ >4..LQ!T=/O@R<W-0%GIZI" CQ-
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M<:NO**M">:[/*35-VP,% 6]) ?<CU2$0F%M^='KB#QDVY7'7LXF%>_*N14!
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MD[RNYO?ZE*NVKL%@_VZK)I\_JCXY.9FW,<24M>!;B/%^KY7NS=8+1P"!RL,
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MMWJYDCW@HA]6UV?7RZU$99V\Y(6_<K==CC('I,51$A('WUG^K*/W?54U:?0
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M=JA(25IN&E(=$L>:%<V@UHK!^F!Q3BM>2ZQ$X<>JO=N?>YS"1[L:^[<E+C$
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M13TL2WSL'(#!YVUNI*@X@*XSDO$[.0D4<G8N\61@]>>&]PJ=,$L7WS?"D^9
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M;7<\_H6B(O9ERAB(4>I_(;X:Z6MNL[,<$L?'O-_$VPL&E;*V] US$O+TL
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MOKK[0H8JF<8H=52O]QW2)<4KQY M3S$[RP?[<8F2<WZ&AV+!9 TC.?RG3@1
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M_ZECH(4?O#XI5S(-W0!WV7Q]RY%8#(_"7X<.KT(G:LO>#K=_R,)9%..7ZP:
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MQ;PVOC/X ?S@?X8.SHQPGW$J!2Y>%G3V!0*9Q:N@GC7%6!0EP$K\9I,PK7H
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M,_F"R\JGFX2B")][$\'6YE"4HTC\EO[^.N"L*61+*<M,HFGM*CK1T5(C;G#
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M/*\*'4U"*RJ2_U#U5^A&G1=0_0Q")]2MI$_(WFO_&?%W5QH\2"/JLH5^&<>
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MRBIK0#6"#C[*VHQ9]TU/?4QNO#^5=H7[P$]\'H#;SQP(]MUG1:*= DG+AZP
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M1MP<(&1N9SNI3Y#<?OT]N%\P,"_ 45N!F$M<_XJ[F:'G#DK>\!12-,&OHJ:
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MIVQ_UXU0S& Y*4"@!ML8#FXR6.4Z2GOR!NL$/M@Y[E ,JH4=LB&[/$IVI]Z
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M<[.R]Y>C?@RP #R],JXOY<,<Z5DAUX7]N%5RLT$KQVFG'8 KMY>3[:"3YHP
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M\TQU?$^_<&YZ90*MUF/YM'3MP>-&0;Y9&5)+5SF^H'N<Z:"  /)^+#C3!%;
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MDD@$W7@16=LS(>1FEN1%MS\;=#8L4W+R&T#-8/WFG<Z%%TC-8MV5@!I*'J&
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M%;.FG.65YWP&.XAQPL0!TCP]&6812ZHW, / CP7$[:8B07S5_$:_D[FD=I_
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M@?JJX%/4!72%K^+E@Y_".6M6WF]&"IH=W4BD7.SY@!5.W^Z'>1K=+M" 05*
M!S 39,UY\K6SCRH:>(6.RS?]2^FP09-[4]>)A#6KQ.P<]%E?;J=ZN+([6("V
M@>E1&<P]],#1!WHY5C:W&*_EN39;'3M;(/]FJ ILL?G^CNTM=8%_E7U]]NK+
MUF8F1Y,V8 ]_@J=SUN(L5J>9 ]>K+26/<OIR-/;6'WDG^:D9F&F25#K0P8V,
M5$@ '>1)\%K?AI_-A;P7R_R]"I2N7QPVE<G;1C#M_[$;=TLV%4F>RW;PIY47
MYRHT4!BI$TOR-ER7<#^+<+5:;>.ILE$3"U=^_OGD)*AI23U\7&?9U9#L*&@_
MX[7;O-4UFBI\T[5\"X3X^YS17-$P2'OB6>,8T&U-RJ6I6T8#O2>MWM&M$^D;
ME!E9^&@TA//27.Z#?MV0=N\CJ"-(*/GT(S=2YF$Z$,XSBJ@RV$XE,@JD&"WC
M@7]8IMVT8-KO^"&<KCRNDHI> L0A>&E7;;,5J]6!D>TFXR?1>]":Z,*[J\/L
M,<U#2E:O9PF]K\N#,.T34*DGNF'!YY-VJ7 &7Z'UO'.& ONH%EG8ZP(XG[FU
MV< Y%F!Y'@NDWG'^O_N8@/MH'/)UNE:M/>A)0>TR\.<Y$_SSI7O=H]W"8CKL
M9(N$:!CCD3^I@!$&!I>ML6VZ(4^J!^[ZU5H9C%XC7N/T2%O1?D\RX/^V9MS?
MWBF)0<>40\DU1+%=1]@':G'UUOXO(&@Q2[# CKENB-NZ^?[TTJ_ANQE^42IY
MCRI'P(HR9BBO"-L3A(<EWLU7B0[UN2&*+^#T)+!OE!G>,>E;KA34N79<M]TY
M))K)RLVEC3RY*^<_#RV_)'VC>P6E40!.T^Y4%)I^\1*,^*!0[[NUCE\H+ZT(
M\R)4\,ES$:BH[@;#$".+N V7@U9KC6E;:1]C=NPP#B1R.N7'?[VM3<[^\N<F
MUCEPY\;P6!2I_%GL9**QU^P]PH.X<4*:O-D.$"BBE#31\0WYQ^,1[8O<U7(E
MCV&6>?3[QGO1QIE0]K .[S!.I*E4/*=V*%(+'^SQV_O9<&3F%UQ0;G(PH\_/
M.P]0UBM[WIM[?\1ZF82D<GI.#%*\)XP:)O)N<L46_[)V&>6F^;'?7#9_5WC>
MK,5?@J@"$ETSC6F*KRW5-GZ-ADM60H%4HLP%X\(RL'.:I?]E*SRHY7DY.L?*
MDYH\>Q9%+4[,;,Y/,M@P;!%UQEIZ:N\<& TBCV*&]IU>D:]@GPO^G'UQWL?'
M$*U&"\C<(3HV0@4W#KCZ3,DP?:0G<PC6*:M[W18N"?_ M'0EC ZQXW^B;5*7
MO<@04FT/$IF3556R3@W20VR:7$G]M6P?-3:TI,A[/JC9\--=ST.004Y)]2<H
M9\;!125>\[%:7_T^DQI8YG@LL%EV\]J">)*4HD93F"8N21C\>JON:,GMX7D(
MF0;1BA_8G8#8'FW5?.IWUG; "!LN4+]88@)4-5>NX*:=T:[18@XK!JE Q00G
MLDMK-^J9R+=,74R$6T7(W4"J99#C/,EFX,K=_>\<:V1YOSF"> YL"U,4W^$E
MG?N(="H9KCL5S-R)A^>\W4+M#)+P@!1]Z4&=I/Z%V/:YUV7)LM+KFR"K31,2
M,)2E-R3*)"3MBU 'BYM8B![#UT-U2N0=DJ 46/0\EH(C=X\924%5$1&G)V:W
MGMGF&=$X0YW[COSD\G',A$:Q7$40&*P"!#\*CWNE]&NI]RC36[C7SX./ &[#
M4?B,3>V4[@/JT]"!.G!$W4&1?[UNC\@*:6G&)T/L>MNX<E7'SKTY# [0W-74
M+%D/=_CMDYHL=,4,8;1T6,(F'1J=<>!U[]GYN@/Y:,^BI&4RW(&/AJ/BB9GZ
M80$A_0G@$0X9(5+;D&[H>85FH\NULK_S56%+O_VP*LJUFP7/,9A[@CF\#:@7
MF+FPWGJ@IKR?'*7+K+U'JQN&;^+#ITG,<!10^_1'<@AP6J1<+-PXNU-\:]FQ
M:-8N=\NM@I"C4B.:_AZ9AC,H23,RW+9XRB9^S&>, $,HNL"0 LONDWN.ON>7
M:RYW$?N_YM5 I\)+]\_%DRLB-#.#W5MTA,6HW%3II'^LY0[ L%O[>3^E3Z&U
M.T:^DB>:F0WV-/-W+0$RM+_(=^Z3J!I64TAO^\0CB"1 X__@[+W#FDJ_?U&F
MV$<=!A&E.4,1"&V0)B"H(U6:(0F!D,!()X%00D 2P+'0!08T("U("R&!("6$
M@($1I0L()/0B2H"$7A*:P'6^OW/O/>?>^]QS[UE_O7L_^WGVWN]>^[/6YWG?
M]5E,Z<B,^"GUOD\64<O[>&;X+EWO4;U!D@S"-#6K"M0A0"'_Q! 05^0*-UL)
M=DE/(8[UM9KNXC/<AW6@FS;+]+<1D1N&71U2@Y2V.=/YJ)/E]N6G;-O,6@HG
MWYW[ NEG6]D"9<JZI3\:PX2:VC@ZJ+'Y#:U)4F%J2D7G@Y%+*=W+.W? ,>N*
M<U2S8:%%CY(_=^D+GIFV:J/[#>8[..\XW2EP6^,Q)L3U1BX&.J2:YPPI(%_-
M@C-#.G9^Q=0L=Y5M'-X]8VM\_IP^K$TW">A,!LBH]HOEG(T]7@2)LN( ;QAD
M#IVX,BG[ ^-*'$+3N5*O&;.R#5BT09=7%*$0UMHOARB=\N+5!M7WKU&EG@.R
M^-R%ZO!'-.6KG^W]*9YO]"[1L8GF(/C \9!KH2& ]GO)*X$W5?N!AO(ON::F
M8-.TU83GYG.6;+QT+LU"#F @P=+B.U1&9MICBQ(F.ZJ + 0J@%02PMF"OQYJ
MZ<C;W& =B32<Z%Q)V4&?FUHO8-;B#$DSP4UPOG<-3+G1QTI:K&=4WK6#$ %9
M-@W3'M0PX\>365#D&^)^7S'#VFKQ3._G/[C6SR#AI??@_#?K'F;S:7E%V7FE
MAG)5D]'+^'[#KRDI-:VXC2I',^#0=4T( 5Z_3UXHQIN4ZE+S[_O]<VOJ^DX'
MI\'%#>@O9&.T'8<,3ZJJSJ#<C!3S90@Z)U>2\=ES3%<6**^^A0OBJD=;]V"H
M:NN3V(QU1VT(*Z_0]+4UK$.6"4'V\L;F?0")Y(28KCW7FQ*O_VZGOBDSK*;,
M563 SDPN?_S&$.:<\$X>+9JM@6!!2"F9_C-@\8_ N<6UFRR=QHA&J)_@:A+%
M,00"MME+Z<I;<:RF$"TT#75I9G,)^#1*?'R]PQ\1=T.CIO9?_\T_T,54%%$'
ML>H4@I"?V9;>W]W5:?)]Z34YH4;?8]WN"<Q#52XI R'&8)BA;@B-DFVU$4_G
MG*;%X&7YCA[( P7*:,X-HX064CR=?]R0EBTH6BBCPE9HA.K^JDKX'D<<:C+Q
M:#/W)_071ESL@78PE0RCME90?>I9*U!CKR<GAXV[.?"%(7W*WE0I=>-QX$\Y
M%N]B!&R(70G+#9Z!5#(7H,;'Y#.@5PU)<OXOPY\0BGTV@J<7A1[Q4>]'C;;>
M5&98(6Q25[ 0U=S$<GOPWTRW_"0Q^YEVXRBHZ,2?OL99=)MYH(M"BB3CSG!-
M1K0S4H$WW6G7IG%#G/:]6=#Y4H!P,69'U[NR@=,-C+ *).CJJTPKY?33ZY.H
MA*"IGKS20RU+YM7/@4HO[F #+ZI+1)+[\1A_.*N'L*[UMRJA//0@>]-6)SX%
MG*K,YKHNJ69XKI,3BAX8#-<./<BQLK='QD[_]'NIY:?0JC_*[7WD":>_?CH2
M"6?,H^H.><>'E@EZM!HH'*%KUHN"0$"-WFUM0OBZ35NA+CDIQN:@"E<9<L*+
M3;2-ZAA7!>_%!81[SP2Q:\N=TY.KK-#I);P8L&=%'H_0(J?;&=,F/K*R!/]^
M'8.9=D$,6Z),S5&-9T17<VHL\Q G].6)<W)R>N8&L%134WM;ZK/9N2M>[9>O
M3&C$'8GHTZX,V,?/_(!F1*<FG\1.D<?':9F%3=V8;-XU%^[C%"7;GZHW"ED0
M(/6:]DF:*R7O%E\Z+-BM/*#QB?^H+34;A@"Z\A]0%WDRW?=&?<!+?H71H)H0
M^@=,<==]V0D U@0Y/-LT3&-<.X"\$8!Q7P@U\@6)X=4&6FN1\W56$@/[M>X>
M;\__/<)&4S=*^=F-B9NV=\+?"%7T(>&>G7\FB\WY_,?+:\M?7<ABXO*#-6_<
M6U"]RM--X8S!*.,>V04L!$0,D.$[AV\DTOQY/+FK( *> T%_+,]7]BHD9CZ;
M+*HW';J&[*CHR4D3%8<05DTQ+%2<APE)[L%%?Y%'AX[&9MC!<?RK63I\43W=
M"ILERS>,:Z'9M1<"Z"#CR%.?;IU7G>=B&4<BE,$C$;F_0G(<VP)39?6V)DYA
MS^J]'/RY$#CBJR&N701)D]//2_:0^!8#!RJA1CFRB7(*3X=<JO"?K)]&&:#9
M$DK(O ZJLXK?C0W*W9<#D!!6[QRN*..2!T8R/F^Q(\^@(7Q%0NWCR/60<<GK
MAOKK1G>T&\*;+*7DAWF8B>(?-NJACHZKYV)J=:\HB(XZ.GFL.2N2TV@MN'6Q
MFT'G;_H_T)F<4E?[';7<-S$>0XI=FKY>6)2AS^Y60*VY_KW9?N&GD/NP9+.N
M^Q$@I9C*4/3.KA$MC&7K,P1"1?V@L_RX\/2+M-J)1<(2MQ0S/:KZ^DUU51?3
M!B P#1^[MPYL.]N0>/IN0/RK6.+)\0M ACT\:$CNOJA$+^Z^J$G1+",S;*=B
M^BRS<:'B3K7H.R13(:JX5N_T7)]DM6/'L):;49J$FIVPTNR>FK4?0Z^_<1_C
M,90!=1\/(UGU5X*A?\Q"_-,,\,R70B8U)0M)F*D,+PW=69J6BIU:#N C# K4
M^8+T:F+X/YU^(ULHB@\>(GOH!9Y-,,2B046YV!0)-<DO_@].31J>-?-N\-N?
MK#O#KMM#CB!^ZI3\6&=N'$].2NGW!+<GJFP>6DIYR8=&?X'#GFWR5'E_XC;V
MK*0\\-E9 E7BD0CYO MV(VR%UN,B0ZEK#J/2#$DQK$:RE!W_IA&87X$L[T-Q
M@A)&.W)I[9#%)WE!]UF&C6$[GQF(0('@]Z:98Q[\@/X^>;\<>>6)5L?W%/*T
M%:5^#:(>EV7LY>9/H*7W<$'L6G9DF?U*S)"=T^#)E'2B!?/WO!$,P>0OPTQ"
M*A 1*IQ:,%"'&G9[IB.\+1I2"M:HSZL6$BO ?6[?_[',BK*9D.$E=@(4TZO&
MSF7X@ WXU89F##J$O_J,.GS32O)K93YA:/J0:O\U\9<[_@^U' E'(E^CK(Y$
M:F#'_-?**K9KL'YHO/TKW6.(!GSYX<*DKB+$DZHNHQ" $DU^"&U+G%?Z9RN7
MDI#!R((6!&:*C#]Y#=.88<+"L:J5VU*&>K0J]UC8:9)Y4DQ:>ETXE1E!@(B[
M+&P"-'":G A9]:"&TM 5.P_$#?^ZP;:O.%M41DF??1;DV0%%#)08:C93$[H9
M8SJH?VSQ\/Q5B<7O3P:$[:SV21E&#];MX;8F565(F?D@Y YQ@5OFSG)0V(?)
MT7N1]V$<.ZP%A0K#J>]^:@_>L1L(G&!I->@R,L9]8C@UH';ULZ;2J_[^T4;0
MXN0Y1]T05O=$V?/JW=^4/WN/H?BU]@RK\%@EHZ'D.)7]RN"I':']?KK^%=+#
MJE_;=]C7W<K/HUJ.;PRM-K7XL2 AYB5?"%O0<SVB%9'K!DX\45%1L3S1RF\)
M";+Q5/])5..;V^BX2U*+SG0IW;#T]I*%?'DE)LAFX<9,&D7O;A;)&SX2P;JH
ME7]6>J*0,L.2>H0JL4W]2R8@I!BJ1TO0A/S,9"WC5=)ZV@>>_O&I.T0_SK^$
M ]FW9ZRAG%6E[(]%#H[SD5]'I<8,*@*]5$7??.UJRL!TY$W]IK 8F9'=]1:-
M';=950?1_?V=)6FD[+3TSI3XY]7AQGDAN2.NA[,K)HV/>M7H,<-N"#UHV)#9
MD-[4D"& 3P,3H7>( T2(7;J!9.)<1_ZIBA!*I9E;[KYZ?<?A3.C-W>:@P_00
MA&*Q_C0B.*E8W]IA.6K0CFV/9U2TP<Z UP9:SSA<5\ W6A@#C11<O>;:<5L_
MO-EU$H@/VP>L/$GG8,KKK!2'//%D_I733"/9> K'1K!F\H-9P+F=X$&2KZ[,
M*MR*,?Y@),<:6?=VK)=^-L' R,=TN"T=P*3M>Z;T8KK8?D)9:%_78N"1"*3T
MT.R4SSOC!E6W<_OW;<_ AABV+KEORIY"#;-2,$V9@,J!8[[HJ8'5$\_'=MW9
MV>%P>^P@ 2+S!/F;1;NM0GSB2DLAH0\#S4N&V "V4*\KP&;JVDBZ0&-AN2V'
MLV6S5+8*_GDHS)KC@1G+_>"&0F14\BQ;N;"8]* >4UJ@=A:Y#,X1 %KOY?]#
MP=H=#\E5"FBNG-A6.@B-_^OA.<.Z0YEW,^$(D'$N1Z]!]\V@L1B@?7#.#+P[
MDJX_%Y)[)-(9QWR.BI;.\J;F#0SYX7;5.WN9X3G,7YRBG\YCQ$8O*S!<+_'#
M&,YW](Q4U#C/HO%,QQ/SVR>E9A]0".SQ"IMRR*/*.LL4WM.0$@= E&7^O8LF
M_S\W</S'@!8O:OSI,4<BR8C62KJ?-;?K<2"FT3#;*'3@_5>7LK2@.3HP:!;L
MAE3!S6^BHL1Y?]_4RG_6]NEK#+LY@G^3?4.U=YP_:6!)AP9HXNB#2I&<C-T"
MG^5<]AW!R8>**#@'28*5Q=CGGN]&4'K<(BL3IP,*R?50F_J4[ PE:_FU1&K7
M4"%ER\R5>#(ZK1Y>0*Y;X]2RZ4'65I!SZ;5F.F)5S@J! 1<LYYC_;G654&9A
M<@G67.18CTQ-SBZI,ONR^^#P.%>>EBEYQF-?MN7!W'N(/RIXM,',0H 6RY8P
MFE$E^']Y'(4O8VC'Y#6P]UJK-0IH# K8]AH.>]:S,D5E<M'9W3,$L+,Y7W^.
M_]^4!/\O9HQ^5=>T_"?S7M5$-7C0Z@R"#]5RR9\T3OLZ+>_N0=R6A[&[*)6F
MMP #N/!!6S4'W0_I^B$LFLV_E0P%'_Z[3=FG MZCLP>PPTR!^7.V8S:;^M#8
MJTFR?M^\:V77B:C,XB<,&T?B3/-VCD02MA[.?#BT^^.=W:%<:D,EZ/!<<TW7
MZ-6-A5A-6J'9X?<V095^Q/DW0C\YCSP9U:ODK&6WO]XG]YCM$GJ140J!(SN.
MMF)64A&P:GLE*%,R\<U(%V7[MS\C?Q\))3Y[A;T!BQT.XPSK%<W'IA>D&U[5
MUU@:3?F*A0)"(:9KIJ"?1J?EFAN-36Z.]0N?QHI(6O_\OT_%\(N1[Z2O9XRH
M1FT,!PU=C+OMW^#0QJ-ZI'5*0VR16/BV[L[Z/HV[R)XU.O%>W'&48^'7: AC
M::GNT8V5!@R@U-'/%6X7#U2&FWQ1MIJV%:'TKE:G7?E26HQ[:%HH7H(E362#
MS?9.[TT<5+Q91AQ:1PV8#)P21]BZ2&KZW'OONB4 A';C-Z=?M#QRSZ#2%5>F
MCV&/F6)#L3]9R65+R&<+*Q,!LNA[?XV+-^ON0T/N GH'&FT_+/58$^8>07"=
MLOC,H>D&^T"'D)% MF%&GQ6FCEU-2RS+*W9H6RHLW25(%)8^WOIA[/_!"?X'
MNP1>\/SNJ^M4/R4%#<3=O[OQN:]SVPU"D6<W0M#)'^$46->B--K?EI2V\C7[
M7Y4M&GRZ_E^5+7_KXT;)N9%)+P7!+AD9=HKE#=?1=V*"F"W<U#AU]='W:?]-
M'FO\/_)82<;?7GN DN7V8V#HVVKLB>1P529\&+YZ34CW3M(Q:Y#WC2MD-VB\
M+5_(,R.KA>U/RAV)=$ 'JL.B[,W^,$'U*87UH30X6X[9/>J.@KX ;XHCX^;4
M[+R[4A4YWR)"J?^G3UV3^QFL+M(E>%L-?ON%*17DNJLJ,&96VQ8)L$WKDEX]
M)0W_\*V,XU,"C>!-'/-<1ZKW3LS,5)D [%@!=(^AS4=!'H?WV,W:-Z3]B<E)
M]1BL3)0 Y-D:1#]56^8SRI)III K$-L>R?>]0I)O?B%I2_-%4KC.\QQ[7!3#
M$505X9H)<&T+*PPO--$ ]]%[0M*-;D4 MW2_I,M 2S4:T#X:%W%0O;H?A91"
MK2,1T(7GV8N>.A>Y[9J?<RQA@6(&!I%S./.PA?P\PN];>])/0X>C;=3I;)GR
M,?1\V "F\9/YZ"^TO.:JYX-N>W?&&6^;]\>N1_>=;&-7[8XQQ2TXTSH2HN,^
MS.2$!HSSMQ1 <>=""MD2"3T2$5-2/1()VMQ&A=5.=2\T+-N7H5RL+4Z'M$H%
M5;/ODM]4F4\WA'R9,S6#M,B5.>.G9P^']O5)Z.RL3&MTP>M[^D0_E1P%K'K@
M-?TL=T>*!\4+N-@53V']G!(N8QO^QJ5,&47C<-A@Y*H>J8P<F7:[)P5M3GT]
M,2-6B&W!-?@[#ZI-O:3T]/!6=^B:R.WR]_VX*4ZX_3;V+/?S<QAZ;@Z$W(9V
M>V]K0**R4U*@\KY2Q"VW!MR,0?Y44[&I>=W[ZR:?A>/-8>:C@1J)TQ4+7_:C
M](#EY>[A/;_@OL*GSVWQ^@':!'R?1RE=O-O:39DF3!RMV#94^06)(U_I6IA(
MZ@<^Q+#AGCSAREBB2C+)4/FU0.KE-HD+>F,/.:!K$>PGKIEJR+QYA=-V\;N+
MM,6'E0R,%>9GJ!27(:N)E4<BIX?E0FI,U"$V/BJ#A59YVDR<M;,<_E'9TG9N
MJ3UF\7/^3@HHOC$UK =D&]J]X!BR-$4"%)+G]D#702=G!8>\%^$##_2V8X\;
M_]4W8#'YW,;K]S*.W9WWT^>W(N\$L!NB<:,!G*V-",XQ:_A*Y_,BB%BMNV8Q
MQPPL((5\@]$GQNT]BP&M@T;8V^)A94T?G93GGE<GXI/OW/>8CG$%_UM@GE@O
ME,W@T[(_^RZ>Q;.!"#$)P[LIC#/HRGT7*JIVJK@@?1I3'"W=7FK!,)9MW2=1
MP@&AH+D@2@DY6!_Z.M?,3W\0O*+WDL$'F /&:9U!25J40HKY5\T2R4I<>*'
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MET'>!%M *=0\.19M<#$_EI_WSP3N@=]*>67V-+JD$/F>$:[U#!P: )\1=:W
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MSGHP(S\E[AQ,^%8ZB@Y:KJ26(*]"?)Z(F2?PNXO,#SN6;MXNRDY!?HL*FCA
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M>(3<2@ASQ,R41P#?>;*K4H?F>@XVY& T?S91XA\+D*$/R!45/TJ%VFKR$$H
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ML*Q@,+0&4*Q.AIKX<4PD?,Z(>CZ_;+-!#W[^:/P&%7Y]0L/*_ #A9B&5WT&
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M(.6AQ/R7,X>8LB#!NZ'BSU+.=3V>R('Q5]ST+V&$Q-?][<3$>O <_C5YZ($
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M_V\XNZYH,)\HYMVY* B5$20+Z$7B)Y:O>,@8WLY65(\Z+LM%)(U3JTXG-LP
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M!P.YZ,+.8ES"G*\8N^S I/AKX5=C@9<AH&PYLK3YE84&M8[$YPN#.);9+](
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M!5QSLI<^%9)AM334Z,V\,1P>1>(=A*!O3F5-?A3"W?Z?D)LS+D+-B$NZ"-\
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M&8SHBZ)TJRWL;"$M%7+D#.5+^F.^"XW__5VHM_;P>(Y'_:B2FA;HY$S<PD2
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MS@^SVI_^[>0W19V^L:*6'MDK['V)YS/P&+NKBR@5>;NQ4>*J8R20N-DW&E$
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M3F8O4?@<$J$8?QQQGI!D2"'FD M>)GM'.3XK>".87)(\<[U&<OG&L&RD=Z_
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MP"294R-2&'3U.5HM817YV;@N3WM] 8._T08?V"DK.?1)AT<_8DE#'1)>=;E
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M0-_8G'0\LIVCC"1X,H0!I>YP56XZA:10G-GP7'0=J /M<',>O3WX= S?#_3
M3OF>))LIKH#*0_L%#7LE"LY<F'3#.Y-6EZ<@%4BS!Y,>%J($L0P3=H"J&=A
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MSF' ^6?_V5@II"O^/BT3/</*I\RT63IL9Y36>WF_&:_*09EVJ416O]65*";
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M]>ZHO&5]8NO59W\MO8>3=_Q6\W!CCJ4#7A QQ\*!T)PPQ4=YPZ'E10DB/>Z
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M[?PJ/S_=']E>K^)V0V0YIUN?53)#=ZX/PE0N$*H$%&K74FO22H#88>4S0%+
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MOQ4U5_%H;^^$=()[2A3FUK0_^@+.DQ.R9JM%0W^@]Q]Z-E@@-6QB!KX='.?
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M,)N.(?8" WZAKHT4!_VE0]1W)[.:H;))FGWS)BT:<[6>*P[L[42\?-)XA6O
M1ZP8)4HEIXX5K,DXIEW$^Q<B]S1NMSG ]'31FPPTB125#8;_4+ R:)'K"=<D
MF-^!)R"LJP3GWR7 U+^=<IQNB)BH<!+"KSL/7#_$Y\\]2SM<H)K<(Q>:W^G'
M !=%?JAER(_[<*2.<_@]:O3GR2HM,=9.P\]5H5U..+C1)6N!-(WR!9AY.XXT
MB)#EYN:&W])C6@W!FA5YN+56*#4R*[XF/O**0O:\'WXZ ^S\9J<V'.Y]:%,_
M+GTZS";+&!(]S:QE*W"=3O&,M6Y$:Q5C-0!-#S[:Z+N"7_\MZ@F,&YU!I 4S
M76D4#"]$PU@VZ66]N/NQGJOS^"_NONH1T0*7AEFXE9_2$5H9[-+:BU2[RR0F
MV)0U9$H&CUP^&D)_"NVK1,;P/3A4J7U;W4?W3E&B01?M"ZGJ:I3/"X58QUIK
MF<G$$[?<ZMZ/++QZFR7XN[Z2W/WQ00R"T*P'*O[L]Y-.X_ANZ&BHY,/N8QLJ
M9>_-ZM/S5E_^ [+ZQD(8P1^<5T$8,.%3K2ZF5K>:-6#&BKW]U78W*_-$#+=.
M34LD(X;755KZ.!*?!X:1#RE4Q,8?'DZ(BK_,6G^BQ5XL52O!9"TP.NH^-=*Y
MN<$P%TD!=55/Y9++6%JL+\WGDV^SIIMY9V,5_B$_D9ROH#O(/N#MGM>7A.>-
M3]5(3;T,TU;N^5%XV6+[R'7'-J:(XG>/Q?GH^Q#7*N?&A9^WR-K6QR@'C2WM
MN0#/%P</'_]V!L"(G(3[GB9JK83="&?$GS;4A!N*9@DCVJ^*&_K;Q"<))V60
M4T@-"D'XV175O>WP/^2FO'9^D5QH\:ZJU%0]8NR/N^5\6*^UB<\Y [@,P?PG
MXMU&3T'2!SZL]B\^!$]&HT,QM]$S@EK]QZGF2B70S/T-U06[D]VM=;6M^+MG
M@'<&[9V?@C$]T[BR?_CFZ!+TF%JJ, =R.\PWW=IL_KT;VV;]:G[-&'N8H%CA
MV1$U27IY[/VF9@AJA;GG06V,D*@?>9)/-X#_%,,)&#"CTV!ZIHOBGM"= +];
M?+8SU[P7!OTYH["PQ4JHW3%DX'ANU'0VNW>3MF!!GE^>#"SP*YX9:VDPN9[G
MBG]2#5@:?/PO%W$9W"S4B )=T8B#?9=X7]H]Q00U"S,0K5'V!$/( ?N\ >^H
M_.8;EJ_SYGON["@$^)E:6>;D4+E49S:EB-,E/@*F(]H@M).M>2YYLQ NU]69
M6*5)V+B3!5N6%'42BZ!/&> ?YBS>SQ_8?24],-6SC58G;&4[:S#"*!&FL[\(
MCM&> KY7['6XS5  T+JVRB58/K?"ROUM4B@PQ8FCX+JK 9(R$&V_8"')\DS6
MB\SI8+M@.I'XUMRDQ]*CL3$>P>C5J!6NAW7(%?$6RF\FN[*C=VN::&M1Q0PW
M5*9@N6C(#0FH_>(H2USG7M'F\67D[0"XA4E@Y>!!;/%;9<]K:"?AG8QX%)AP
MV=F*3&9VQ"T/OND8V)1Q[LN),]T>6AW:/J3**VYP[!$#FT@6.92LNA[_0M(;
M4 ]["M!6]:T"=E6H7]V@T,_-.Y''^+6AA?$$."5K6#[.F(A85"-E0$V9,&Y>
M$&YZ/=I&^H-3XJQUH0,EKZBJ[1-Y;>1[Y7*#CS'% ;F+HO1QFBYBCPX&_Q8:
MMNK!K/7WWSS)]RPZB?0E^@*WC8O1OKYH27H\"I%3  RPWSE9?&$J+@(*<UA>
M+@+:N-8/T'FMWDHG*2AK+PM$/!C:,':8OA[X:=#1JL0K3%U*89-C/Y6+W),L
MF4"W7+F>2@:R71>?FYO\1#4H>S".0^&_ZGGHNM[]=N0^;Z;'$(:GSNO2TV_^
M^J^D,M_$ T1%^(_MIP*#&MQ6OD^KLD;)^B5S:.34N1%F<6Q.PBN4U2X-00V#
MP1E,]1W3Q?P55]4M1QE86BW<Y0^R>U\[Y _1>?[17#VT<O!(@TQ .'I;6C%^
M[0^5LAG\P1_&L>ICN?GT=\,G_;L>V*K31)<W*):D:5.^4BBN&71POBSBHH3#
M3*N 14[URTH3O+L%'29/A_0$:$5C%\Q-V,CL)9RUU*ZDW5WEF="/AHX)[JK?
MT[N1#CVNXKJVG'532<EE1+;V13XQ9/7 !+5B:+!,!6F5GJED]I6[,6"KN8.^
M1W/678VV$^N$PLHINMYY(QH4G"_K)_2P,45>C)&HYC,$5N!0S6LOVS(_K5Y3
M\AY;_C6?&/UVH+&E5=!85Y].2M?5W1%]O-G9GB>!1T;MYE$<SEU=N 4;4%SM
MN1OT^EL&^K]B]/]NB+1O5+J.MU9EX/3T0.=U2-^^W-_H'8MK/#T<7QW$]T E
MDFH6YNVS1Y I7IF,SG3>#DY)]"B2" LR5Y5K$HV;V?$>Y/N1QO?P,#;%=YQ9
M '.DI<*GN8O2&##XA:CLD[;(Y=,-H@?_,P?K C)NKM2E?*O#V:@]RR4M@^]F
M8ZA>D(_!W)LZ+^(!T@/S9%C%1A%9<T#^PVWOJ])Q72VR?SGU#9AI(Y#=I[TR
M?!YN4,>_>]=2T&H$;,##DU+LQ/+5IW/_%I5UPLW]\\C&XKA(&C9MG6EPN+BT
M9^SQ?6J96R>L)E3-J8B 2P0&2>RIRU6J%>M3:JJ:P?!EK:I9MWSMAZ/:>_=/
M22)X+K]RB">N&)<:(T @#Z;=Y*8Z"-R"P>[7B&+'.>EL9ANA:?M^HWX/=%7G
M,I;GWH@:Q9O>BS'/$_HX/-@EMIA!M;N>G\CD#@'SY 8(B::..O1M*RM"S*R+
MDWWHCO@'>3B""IT'N/A5FXMB!S>+]ZRD3\BX9??BY[,>U)<I2O3DQ$H+E^@U
M P5]+3)I@4&.P>E!O^+<IW_FLQL+(,NDSU4E8(1OZH@=;1>?HU1M]J'UOJJ8
M70=%C(?11F+RA@".!K:D_E5@OZP\20[.WLP\ _Q><,S-577%>3MLTN)UM=N*
M#F,G<5#EA_9%Q8>T.*OY%N$]21@R,%#@D\@'R!X<R=,4:S?J/:YZZM)5=N(^
MIH-O\77>*T)H^'TPG78[^8;H4<$?^?9U'GT \EXD U*;J*([3%<H)=.X-6&8
MYT;>U!I\H<\*_9H5;ID3*V7_K+<PLUE$E&$;.Q1GO"<99H(J;4*3#CM=1/:@
M)V]$W_V0]/C?#-5OKE1-V7*TTOR\*LSY5SZHD(XNOT]^2\DS?L]?R]6YD=)Z
M9XA_RV==!5BCL>,W@X)F9=<"WYBWK*J1QTOD6O03(WT"B15KPV75;JQ,(1O$
M=FB.4M_#8?KX!GWY!;0'L[$M6.Z_3Z1[RDY.^*XIX\H2L=V=J4&W4/A)0XN=
M;AXM<$S. T',/7;<$V+=&6!#&N)=N,;07/SH '<1',_ZI-<:W$,^]MT+/_4=
M%-F^? 9XM+D?.LD6RMH+[I&A\XGXUEXV?;_F)>G"6E3;V2)J.ZGOC3(=#I2]
MSP"%CZ]: '[H0MG\X#0NH%O9.<^%^B7 7 UKR%.O*#0Y=-+,013>N\'9N[QW
M4DQ %= ';.[(V#K27LK+J ><T'G(#C1$-A_19QRDN-\NX.R0_O=.W_9DJ-WY
MWW\A]&Y(A8U5-=_W\4WK_!X[\/&XZ[*F/78O+ 7K^Z6C2*%"MJ',DS>[2EH(
M@YQ>2E2L>9#%#+*=W"WAR#W[4)7V@FTTE66KA/ 96QD92!RL=KQ:$LX:J5$-
MUKZR;'JE4N!9X"</#$S9I'1%M*H+1=W1[&M(RQ!*_F+@:PQ<9&+]OFUZD!8X
MJ[WE7C,"5C7M95;L7+T7;YF3,H\FAGO_%1S,,!?Z6!&T@Z-+F.>*;_?[XG^0
M^W-T>IP)R=V7^MQ3:O4].4@RQ^A1^QT<G,D>\4/38,$GC^^O?9X:BU@?\QCT
M2R6C@ET7?+M\KZIU'%?=8 ?+4&>LYNF'YAI",OC$&HF.@T2W HQ-&E!6703<
M7/GG #\PWK2R"550"7IT,.P_<"RIS)T.T[-=?Q$JPF7MEJ^<.@$UMW6O@ /W
M5^;B'-,TEP8=>$FDV 'FNR !I^:78XB53+V(X$M"2K"R74^\&F%17@T6$F9O
MDL/M/-K%6\B![@EX$O+R:84!2HHML1^;V=GJ1]ZAU?]=!/[_4,+[?WVDM_IP
M'9.P'=:R7:-*Q[(8K?$:9>>5OM[&(2P]? ,7'6H;K3AT@7O>MJI3-GNL9IB\
M^_/0\#U.MEJ.H*<71W\V'$0$MN<"]\E^#XE91DDBY]%/K^2N?0DI\08\%'E2
M<92&80D%H8:&L5;\M=ETV[<&WG$]D7(.Z60J"L]H&N$BQ+Y4IYWZA!??S1BH
ME%&U<REXLV5%)X5<3TGI*DZP[A1A#<&P3OO&Y$/;[[ ;ZA+O42LJG]:_3Q\*
M8%F1QYR(+H.&YP7XEQ';T2<$[FZ4=[RY+ R=WH,0Y8<7CTU534^2EDI;&Q &
M#LUT93_3>(F(_A63'[V&5>,,W&FEUIXHD- MWF"1:XE:L9)*S*0D&6,U;J$7
M"RN?([_93$9QF9)F+@*M'5\5X;N0,<\KG=5X!73<[F03(,U%8A@V#!W( W<*
M+.U#F+4&]>^FV?I.3+L)ST<87KWX\J7W4.J/#NCI+KAJ,R\O9NCGIYKV7VKA
M3?6T0@*^/K@^DUEC*26-/)$:%95UC(&+^@7DXPR>J)517LQ#LC^0D5WDVG$R
M8=$HTU@_Q^2Z9$PZ 4TX!87>NIPV'0^"*H@[F4PB,^/N)Y4HIL+UF\\ >3@%
M^MV486560]0EOP!247"^TT*@U"0.47;;T6*Z]>.PZG(["O$+.O356&A;%G4/
MJ'T&X'-"-SR<*UP;/J[P2P0>VJX.2]JMKVOY[L=FJ)(IIUM/BCZR/I2;2*>,
M\>]ZB5RNP5JS@GIF_@09"(4K2(X)B0N6R_63UXOS*7'U*%A+6<0;-<F"C-ZV
MJ1[E<<H1J6#0.[EA3VEMBJVDTRS5ZC,A.!9-SKDR)ULSQ$A';%L2B@:S)4>9
M_E'+M9=<6*7.<SMCQ]H^ID=-#3?5*9%&YV&)G4YEXVMTF"<U&^60(HD9>F6?
MJU6BJ]O$<Q.Y?]C]'?7]GWD,Y]CM+XBXZ8^63!O\3"VFHB:"2AD^-N7$[8%[
MW8Y2V,MHDIX5*N0J5"4C7;]51$$R=YC.K5!M&E-0N12=73:N92E$76&U*^W$
M7&- #45U+N/$#90%*<NRD!1MA=EA>,_W639NP@+;3NR)P#);V32C[&9)W^2?
M(LL=+\51D4[]HI1REJP\KFBDQ#"N1@!#K)X;S?3H;R++^E[#* _T[IH!(0=-
M,+ US)0I2$6K,9>H;!(3NXE_ >,=\*P)]/BPF>9 ]&ZNX8#AO!UY64!1HKD)
M3#.A)4%^':ZBLB?/BX[>$?FPIUYEA/!5(=6ZK=1QG>\>A=P2W]@K5!0DD0D5
MMMMVUZ!:\B-@*,S8^"YYQKXH^BG >=,%^))YH.675=,0$2P(NV(I60[2HO;
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MX;=A056>/==G@GY7]DC<$UO(J_$TT2._L:JC;04@4G\2S?6%.G/S-1067PX
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MB'-;SF*%#LOW,G:N=:4G(YO'7F1=D4F'?)3X>YDG['[TL!V3%#F47ZS&R!_
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M?_.59R(C\VJL7?W'73T6VUF$KHU*=T]X9= .2O^L1S3SK$.E(XZ2&8!D""W
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MU4E5<8V4M)C7:Z8(Q^ND>RW_H?S1SS=\XQH;XD<O45O="\H,J"#1-E%MUNT
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M_-)3X'I=KE(WE?B@Q%1(,V77^9V%N8,B.?T08-7-DL+63)EB\O)Q@H*,%QG
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M^FKV"EP%+C1Y=7=U9B0^?3ZM%B!B^?K_/YK^[X'<(WLN=:DIEB!(%0P_HSC
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M9?LMJC5DJ>$.%FIKLJHR,G>MUH9F, -,9:BN0?/0[IFZ7B+>(8<+7?R1\>$
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M$-0WAZL%VQ@?H,'A%-7L:?RHM"N$K0F9Q1G+8IIEI@OB*/ "H8HN-5O,V\G
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M=D*BTZ#<->&T\ZZX%-+ZO8\LU6T['=?KZ'V?(T#]5N1O@(+@_[@.SX7^^A)
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MH/0/D2-&+U(UW^9JP#W;>\I]1>5\D#.;]_F509 RM3IN3RD4RA#\ J.()*W
M\4\O0?=/%K+5;3G%Q0*]QNQSJAJNWE[GUMD\DRZ)CHXDBH" .A8+#!6^S<%^
M;J8X/_9P'>\PS<%*>>HOGGO<4#!J9Z<\@DU5EPN]?QX>-]T4D%@46ZZ/;E[?
MPT7*=$&%9848&DS2D.^I*G.$:FZ\3UD!F388L4!52?BLF6A@4:+Z'@V-%/!#
MTL 9[4U)MK90(:,!ZU17+QQ7%T6]^:IO+OEM7SNV#2IXHQ-84\=CK\Z=P9%@
M,U/FT9\G 6>X_R^FD/\<4:CJ/S-"$I+)CT+J+5K ICZ<DKIVHT:0/4B#=)%,
MU@W%$J<Q(X<);9B3TY#?'2P5I!::8FU>#\G](&+&44YO,;;W2ID1LO_%+1SD
MS.'Q;N]4*.QJAYC@@2[7,T=]Y7.&?10,BBHR%N,/7(N=M(',*RD+R^OP6)H7
MBV8[KT:,CX\MBKQF"E%^::B\6G;9V<R]12*%C$"Q8=7[3 =OU))K\(T*&%!C
M,[;.8/I&X"V$S,IXS#H47((*@D]L5$7Z$(,#)=[21RE;E6M.M[UDKZ'5LFIX
M K-*VGZJ72U9VDP=(:^6=WGL[MJQZTWMT'H6H06AFN >;9C6?.),U[R3Q,T)
MJ%Y@?E)<1KF"U/D<<O<K 1\?@7 UJ<QX+(.AN$G,I1'%'0M32Z-22ZO55CWF
MAA=[-O<ZZ&4<CX5Z?$9J3QV7CS"[J(CE/GH*^C209)8@CA47Y]8RLQ7.L+W?
MEMG)R*W?-##4,^;[!?_T^EB*?H\^M0AS*C;V][#7_T0;)]<^;E_7"3K\_8>=
M?U-/>+TORF7S?Y1P&OIX<" G,CHVMZ=S7T0ZRG48<^!N\_?AZ?L9RV]VLD+"
M-]!_G:UF\QC.R3%1@!__J]77_U.<I-#[%K:*; 0:GV:."8NV]4+O]5L(UD@G
MZ<W%@/M^UPY?J>VNOTX6^\8;3=01;I==170=_BJXB__R[X?"95TQSUI-)S=G
MI:6_KZ_AQ!NFB3D.&UR$N,O:^W^\2>1Y[# ^+3#(S4/"JR2D21V;(G"S3!PK
M,=Y);HY+]K+02'^RH<QZV--B"N9_"='G.H^G$#F@YFH(Q*&(MBQWFQO^J=P6
M;-U'V;+=0QH$/<VTL;,S(8DD695"U5:Z#IHQJ?)\V-]. <(JYZY]G#L.68>
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M<%OU SSDD^WAA-<>>OQY<,CPY2QYV[R*P%B/H<XJQ+YU27IG-#+<]<1#MH
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M;U"OO'OQ2.8;0QF76(GV$5(?$0$H>^ZDND",00R6;ZSK1/#O44/^<+ TLQK
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M$0EH_3$H&1019H>P/+M2*/M#:B$G"BH;*LQ6>OM=SL?_SFP7$;DN@Z>G+)H
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M'__S6/B&CY.!)>I 1)!ET#$[W48-_Z+U]I7(%/AD-3>DLF!V@9O\T^ DD18
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M,08'2,F-BA='^&BJ6><$Q> =KZ XG,^Y[0V5J1:0,)=\JO73!3U@D?W(N]?
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M?*0R],&!B&L\33HT_/A@\58\5],])J-=EB)<,[6!-/QFW2V&VU1($*/.&X=
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M;;BMXV]:Q^&UY^9BY^\344,"[]J0=C?\#+]2,GVQ]6$,\M[=W=$S[B[!DZ,
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M+A.QOK$Q7(JIA229T-OJC:G6#63"-F??LD)3S@X4>?DU-]2PSUA'_-7'W-#
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MN#^?1JU*$*=7HOSUX<OH()5*\=;TR8H1H\">2B,LM@H^,#^>E&HYF>*(Q):
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MUDJG<X&0JU?B=248ZX<"A"!)( (-/GN\F2-<69"7MC?0-_V$.+]!A38)M^A
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M /RP%WX<.Q2VRMP!(BL&LF1LJX'LQ.ZG'/-N"57BNL..=EW,Z(][QV\.*1T
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MN-3=D7<"^TF!0"5IFA,A#B?.S;QX ,CX93XDC%C$K-"P )L/!CNF. 2Z]I3
M].V<U@,G9X!/_6,N4P/\OC39!J1VV26%G(WK)43A<+*]+ZP*/06TK)!]!@R$
M9A=22BJ0N-OR%>H=GH%/L!PJN#2%]#423<_3A5^W1K9]='%09EU86K$8:*G!
M7/7JN?%Q[M[W;_9DEJ*,3&-F(6+1,84"VTY>B[=6[D%K8/%I*19SV !*QN\
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MP8>U9>>_T]'9,;/VMZ5X."\.& 54?LTN>]37.% 0T<62PB9DH6]G#4&+1Y1
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M8(O@'^WQ._3IA>J?6G#SNZO/8\KP+=+(,LUAFGZ[AGS=LUW9;Q>#+K!M/E;
M5N \A LKUG9DQ=$-,[AG@J(R972<FS,S Z\&NZ2(5-FQD1L2<)G&5%HM@WF=
MH<&Z\&9JKTFSKVH05;.W6C0-LA&\DG5RAJB6C@:*]K1EX\"20M!)^8HD**0F
M5\L"_&IFQL5G:[E0?,]0JW.P8'F'+M@G\RP>]WB4*CC$A;7H_\X/BM_'M7J]
MREUR^=!V;,"V:Q;><W]6LT_]B:#$%SAH)J>%P>R4T1'7+_WRT4C,.\017(.^
M"M']B&VIT_ $S<UFAB<Q[P5\A6"\(!8' +MIOLY/1=]2=6Q%Z^CY<5;/7N)]
M"A0B7'+"XY:>M$,Q_J=]=<3:@?I(OD_4T[R<3=M1^M!0Y:!?0I0-RC$KEX++
ML";PE'W7D\O#OSUA(HY!;W;W"</=-/WH+:*F83(S0,FS\'*"8H4QWT)5FT"$
M2"?U9[?-$'=G7G>[YWQC[6C .;_ &;WWF?,^):[N)R<GL!M2NR[R\MMM-TQ@
M[>V6*"GX8: N094T^:)?O\ 3E2[TL>KYR5W8;OE"*(1KMY^.9&-4T$'B/XX4
M9=Z:R\F_=W&.2#GI&(S1.=6<(P,C'^JQ>%7.['0?V[<_AAL+1T:M:78L:/<E
M#=MJ4*00_26P-)EFBVOOOY#!-NGX.)_>ER"&M: /4#H/6+9V)K6 %NP[H+(@
MV;%OC/L:JN3=;^_96U'1 1=B)VQ[XLL[.Q7#1P\5GGW6'4VVS]7.ML'H"==%
M'DED7: .]C7<1)0#MFS_1=MXQ;!*2W/>Q ;6\16BHO!GC3XEH>$CR'":USY9
M-C-Z@\>FIRKI>1%*VR9ORU-_P5&?ON%MT6 #V]3>&[.JZWG PLISIAZ6M(7
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M?)GPT7+P5L!MM0#'IT$BS3;% 'UMF)X1B7U)XU,9=IZ&Y5.OWTC"?]0Z@_S
M<I<..$+3DFZKL#1A^YQF!OV,S)/GV3(HHD:&.<9%,DX!O-,:H+C;S6L%DJ*6
M\X[\X[HRKO,L,,4"T[5,%Q)3H V5@DXM\7?5*G0R[A>;O*X( 7G'WRZ[[N"
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M?_QYAW&9.:,P"N\V#]AD7#19I5YL[%YV6))0<\^+6=QW6>TU\O"YH-A]0EJ
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M2M)_?Y)22I/BTP1_FR3\>D2U[O!0_.I[-3-?E$^I\"+RTLX":?>9A]9A29S
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MX?O_$TV8KU+#[4K%M@5AQ;AFEE-V;1!T-!L-:7W4=BM#3,>&MP+?P-;1>G\
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MJ+\91MC<%ZG=A9]3L?6XSJ+(6OE2TD?V"[FB_JP>XRIH;64!DD>0\B0G")I
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MWLDSRA+$T]2>QS:#L;[-*$TU:GG<S^EBRZ >-68*M*22U9GZ$N6&H@*B?+(
M:L4F<UY@MOQ4OWSQ5IUE5VU?GRVUY7J]( ME*H,,S0!,\EI$"FF?/IZM]BV+
MZ@\4GKI)Z-FJ&L[Q'R%L2&7!]<TU(*Y$0:Z,3#^1$9YZAD[#FQ^6"C\.@]PO
M[0 >P7+.-NHQ#=#"L;&;I\EU<^YPEZ/^*K/:Y[H79R)M2*OB5IKIJ3!CW\H,
M)>6"0*PZP@[*0HDB\D9[F9$K 1+IK=MUT3VW9/*/7KXBETV%4_*:/.UKB@S(
MIGP*S3!I^7!1Y!ST(!*3.C?%'NULJ9I*T7?IHN;<)&I^5;_;T)@P'EU]1%7$
MB^4GLCJOU?RBW*5F\NFAB$:4>D0$F3<N_R1#5@-X,L0^J8:8]+:<;5QAQ>-Y
MX#%7&0$2GV2&[J>KYUHHF^K5KF4DCL]#K5F'MO\S2N9?WP0C(C#&*KB1IY[S
M*QWEJ80DXQXQ;J41/9GG6%%W3^M)-;XI]>G7&[-A2Q_O56!L>?6P]Z[-B=B[
MAN%M7G#!IPYR;AY?>7RRQ[DJ-T9"/?LT::W15R$>%&61B:]6)/ZX4_"2\J;0
M/\3$95356R"V+:V_Y\SLIF!-R@' VE)(YJ1<Y\S5]LB4H2EDMK<ZK?I.C%95
MC4409OEITT,A0PAQPX9)I"-39*%;[F'%AI)OHN<>%=)FJDIE@,"T8Z/\F\Y$
M6^<>-DG2FHFL,2*]\639G6/L])3N/(GS_U:D^ $["SQ5]>$5/8#V2FCJ[XS_
M<,LL^[O; W2!NQWE]Q,8<884I:E9J3ZE40L1]YLM>@J0AA5IP>&0LUQK>QR/
M&KP4I]3]9JX7+.0$0$%XH7*E0GVNT#II#ULVSE*MM=;/5B:UU_;<-P8WEZCS
MCZKOWGW<41&0.8:9F<[YT8OJE67BH&]C+A-4B*"W>JC9FJ2T89ET1*Y/X,7*
MG!7^LZFLTB1M5]QD'H-\?RQOFB%LZM(*:<YQ]XP)_$3GQB?L2^2,BS82DT]G
M9K/DE;%MY2M/E<SH5H!]88_'^:X"/R\B04\.:P^VAFD0>7Q30D9.<XNZ91/Z
MK$]X"21)JU<;3H6-V>5/X1*/\* !+1^*^GY:OM0!Q9?/>H&4QM!$6>J,@+^9
M/("6%L,OU+66Y)]7>EPVK'I$X%6W@G5>EK/<6W/-DRDSQ!41N_MG?]Z-H.?2
MM3^ ZS8V> FPPW'K!E=4\/V<1F%-YJ9("^= +79,D9I :IK[RPJA0#;VT_E/
MY"!9O/F90G[>! "K#Y*_DZ(NHA)G9S/H'E1TX-R%,UV=J"$N:O;(M<DJ6._S
M3(_AH?FW/SE4,X2#HGR'OAT>GW:0_#H)AINJFC2@!UA[2,=<^H\GE'>T(DSC
M^%'L98]N/GM[X'50(8FW)E 8"1NWUL7R/X-K#G&BULE</U_T-=ZH37)8B<5:
MI4NF8FH8U]9,X^YY@,JC9QOBEK:L2F@PW3 &=T(?>'R"9>[J<?QHJC&]G5QE
M5NAS%(*8GJRX.J=V)V'R!/$<<QPP4E)S3Q]I V9RNY-\538<JUS.5I4MJE9(
MR79,6B&VB%]Y)5AW.Q%A!='P;^L7^]X,32S9<W%%YYW_E'$T]:@J7'C9WZ;U
MYD$5WQ/54CNU.]81FQ7ZD374["0]UX9R'S]'*U/ .'LVYKN$CQGX]YK1-'5Y
MC^2(E1.3]8\V3>=59U9L6I@&K>KI_@,_./\_[+UG5)-KMR[,6DN7KV)9B &E
MZ)(J06 )!*1;Z-5 "B7 4GI",Z%(];6  @)2 A(@* @D3TB0$B"A*4AO @F1
MT*2$3I"N%/U<>Y\]QGZ_\;[?.=\99X_S9U__GG_/<\\YKWG-,9[[FB-N=SI7
M \&2CRUI0JH_@@4^$+A>>O%;RD/'%0[[M&$;K!G4,&PCISI;MJ2>6CT+=S>@
M;XO4(%2>+_3L&_.;L5D;>^'3>O>E7U2\!%.Z'A7>,>)&F8E=J:@=$PSJ;4-J
MKIPVX7RDJ*PT8,,"'Y'1D/N">_!0"JX0R+.&:OBX?['5>UZEJ8<<XJ%+!R='
M;[HJL7W]N ?TUTLC%O?(^!KKG)(8L4;FCW(J/]WWX! B,*J25"\Z>E:TM/KJ
M+_7_O$@3OMDF^FC$?6J[6UP4;F(7^%#0*>Q-EI_A6@LX ED>E/O><-V//S[Z
MF=+D7S*:&^P*.N&\<:O+Q.*PXFGSQ2\+Y*F96+D@)+;!!PZ'BXT'P;'N*0W(
M,_!/O;ND+$/FR,9W <MKR7)]1\Y(P":4=_2"H<YV+]4IV1(($I KCEXLVLQ0
MQRK;O\<(]<WPL)2"I?YK*:(VRJ!8<6Z+/Q>#=\Z[N@%0!G_/D[P_XR0XLOA=
M(%U&N6/5Y,1^&*SATX%X<:E8;RQ>7*\4^7%!GG'=F@-(E?5BODZ:-&JYX<7*
MY54ASH]>#P5"W]"Y4=L^(0FFJHG]VU&O15[DDUMU]B<3S:!1=5^W\=(M+KVC
M=40)A,_(]H,:F&QU?_U''A"J5A"@,TU(A5N7^JNR7;*28$:=O&M5-,B6XN;]
MHTZE=XLC7F6N&<#-Q/.[X EJ$8=@;=AB[]S(*Y]N-$J=3([)<!YDVV"<H4I6
MH'+YJ,&S0QTR3XFOL0T&W(L*5Q<:;I9\.<JIID3(1$$ZFRU<A:&J9&%>K"'\
M*X'A>D?A0MU3:YO61W?3]*+&XNY^%YA?^;GC6-KZQ$*\MM7MRMVX%(@B_XRH
M8.2 &]!F(W/:.&')T)$LNF [<JQV?7+4+>E=91 XV4$>8%JS;1YTMMK2<9Q&
M53GM>RH#PIQ8/RB<>C5L1''%;<A\)#:[VN;6EB7.O+*?,C9>#QK6#FN]=\4H
MX.C(M?@7KN_IM8W[DD\\_VGV1/+K!M0)WP4,T9)74 !7G,W,']'.]Q+J$2\(
MGPQ7,5$)VS11FQ(/I];I^\Z21@5+3@+%%8,%4X48!B(_M+ZL622PKFY CXJ\
M'0:%=_4+D$]*:,K;A?WQ)8Z%.-$SL-4[R'DZD)I/2U7I*$CLG,?XH'C&EMUZ
M[503J6+M_,ENQ.5-UGG$>8D5[?"(F)- :0.B2A:GI)Z!+K*1FOZ$LQ"7-NJ+
M;SQT=C@1&+\/-JYF+BJ%4M'4\),<1&Y!?F+DP#DXJ,/*Q#+)>.-U0%,[#PFA
MH1DNE)C4W4?MN?3UCT5);;1@OQ,\-U@2\&G1D1#2* FZXWZ%\6-&S(_\9.)_
M1F,:M49M;0HHY-A8> R<T:QR+2YISOY9/^\\QN)X#GFDGA8O$YXO)]8&7J<0
MV&7W+YT'0A(_30<O<2D7_'QV=++4QN"*"LC:H32W+^&@P2J)F_X3:??O^X34
M8OELT9[:Q+6"A1G<HEM2S%)G)U-49\#-J9,1IP="M(_#0B32!CNQ'.1G14:"
M=0*TN\N75":O89\)1BHR[TE#D?JOVX6FV^,*R#Y5&U@Z4M'9P2&HN I7&N$6
M>YYS=-'(,:FA ;8EXHX,35'HV-;'/.YS;;G)N? MSMK^*>@G'GT@G:635\7%
M/T.P1ZD@]=.T<$6?'Z(Z^OYR<?!JJ]IH3+ZO)SD;M=SP@,4^M[*J'3UQ-P7U
M AY4V=_.6&P4'RH,#,,"'W=[LHHLMY\E?=X)QTM4FN8Q6RX+/V[LIE?D_9MK
MW[7%M_\DKPZ=8!$M+$XNKUTLJ5;#0@ZQMRVH[\ ^ZBNE!.5[W%;(Z?S@YC1=
M("<E'RQW1?Z![M]!AWFI R)6OYSO^*C.^Q$U]U?Y3!.KZT:"=^+5YXI<$FU
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ML'.=#FJ/)_%<W VOO7!L<SO=^'@I8^"6%LU^\_Y4>)+)K@_7Q#3E!J\O7)K
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M\=-P(T=I]"=+I^R9"+:X1Q6WVA[F+UO$/&& IM2:64@V()B>[P1Y""D*$UP
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MS'CIG.\E\6&6!2/C;+O&_WHZ^3^(OPI57GV\]V+0J5,B8/&A2==,FQ$,.G*
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M%(^<Y>2^KAK1J#!"N=,G2M,I3L&,@?99&S-C&N[<&7]++-/(-PL&0]#C#LI
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MO.5/*")2:? -W__;@H-Z46G58M=AN1=Q=4.8].#TYS!M&MG=LI7GYH[0.!D
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ME#DX87*Y:$RY'RX088&.='W.RRK&2G8P!/-PN*>3],S?VI-1!A%*_J2BKG
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M?<4"EY^/!TS+O-"P@J^5G44%K'I7YT0V[1(93%>5H@$I#=)Q24UU]M=?9N^
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M/=3X9S_<$[U!V#GU?2U##XI%E*%G+"R&!VK'UD]L= =8*_JHJ>5838WRKTZ
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MU]PV(O8,W)-(G\MY:>, U-Q0- 0A;Z;XX&J$:VD,'\_ 5UNW2(?6Q$5,K>;
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MH'XK]MFSMN$?^730O$E1U>AB[W\/#B[>#MIX^>!9>:]KC7"SZBM6[Z"6NPD
M!?!U&6'#<Y>&.[K1ENRVW)%6W9D+T*(_3)5\MQ_=6 Y]7M2/E&J7CWGKJ)FJ
MFYYB#6#,XMBKP2G@'MQ<^/C<PK/!)D7%R-K__Y_"?_-O_LV_^3?_YO]XHK^/
M_#=02P,$%     @ AS1N61M<B&NRP 0 2[0%  T   !I;6%G95\P,#@N:G!G
M['IU6%1=U_<!05$L6D%$:0<!"Y V"&D1A@X!%>G.H0R4$)"65I0:&JFA14)
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M9[C'?;M/=,T-SQ[ <]"Q!P *4]X%F'SQ"!@N10"A>I]F75E.\<CW?,NY"T7
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M\'Q>7U'E2_-&^.RS$*5&]H(L-9[:BN]:F<7URBS)H?U\5:MASV8X-XV,X+L
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M"PH:BL885+_ XJH9J[T^F/.$&[=$OLY<%ANV2Y6UB)MN:008)QH^+1W0'KO
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M4<*$.F?ZR,47).,L]@NAC&95T#7?\GPJS.WNSF3G)QK-XD%]^::'N/=A@ET
M K'?-_G(^D]GWP8N\_J%H*=!07>!4^.B@I[)W3=RAZ.E7D?)=@OG"=]KOWL7
M^_=25T"O74=I%5T[QW$N0Z:LIOQN)T+GR:B,]8(2Z\F>- UZ)^%%AZ;"+WY0
MXFY&ZLFW96]65;@I\"?M7R<B"EVR-'36T)ZTC>T.>>VVCNMOQBYY_ ( +LM1
MBSDS"[%[;8OJD>>!M$\W?%C6P".O5MP R!DX.]'3PM"X'>^;E'9%KO/?,[EY
MG*V.Y*-J!5/^-4Y$@Y-3ER8D+].B*J\@R8KYJ25!9FS#EME@<%3 ;BC $;96
M7-1((\=&EF9'^TR]\7TE,=J&K'_[<GIKW3FH%BV<^A!]9#<4MF 351J=_\?J
MIJ0;Y&C1/F"^4UL'KDA>+K2Q??*EFKZ0/L,UD(]0-]Q]26%*76ZCDE?A3A$%
MM&#&A,@41C/CZ[55Q96R:W^:]5!]21[(_*NI&YWB:*PNPLP9&AD">LP5'-\K
M#?Q$/+8M:P-?2LG^<?+2Y?W@<!T3+GQM44_X^$P@--T5^@@^J'O=+H XJB3&
M^-3UX$S =%)&(<^O-A]_<.NEYT.X9- +@-QP6MN\K%.R R\%_@"?^CU7M%PD
M&2UOB'6+C2UZNX4SGA\6(QJ#'7A^'O"GHJ56"I-NL2-CMS:IW(*W"QX&B7JK
MQ_CG11/TS(B#H?3-FF@&?75S-24Q!3&-H)1"^$VZ.$A4?_.N!XF0OHU46G[$
M4XZEOH(_D]\$!%.E"_*T.Q;)<(U#Y9H'X0V3-CL9-6DH#E5ZWLFJ127<^Z'G
MG NU5;<%?AO_,#RB5+Y7K'.83%D>A8,:75E_FLV;@)Z08VO7%_<3>;6@[\O"
M(PK]C^(+;>]SC?RCO9ZJ_[7'>O]Z+IZ6M'4O!^OR)5*U:I3JU 16W%%MC[/F
MNSP@K/OOHTY&*8B5"X5%1;ZUQ!J8 APBVM#B9AX>H:!$6)4W^;R]Y'SU3&"-
M9QNU_:/^,>CKJ?PW%5<&>8BM/R5*ZQ1K7/"/$F40Q%'$NFMEFDLGR3OD<\-G
MA?9?G+'VD"RVJT1<.ZC91V+.^JE06XOQ0=_4S7_U&-==JM/9D[Z7T6 VMI+)
MELC- F3W_$7RH^G5G@DX_G8J1@)\($0*%YKPO8TB?F%A&8-'U4NKWP#_[K)[
M[WQ+TFH\,DML'BH#[@Z;#QR+]3IZWO'9AUQC -&F4K-A[S*UIL7EXL'K8(<^
MZJ#;-?!^HF(_!K?AG%C&V!LLQ4OJ^5,C@"H7 UH"/L(]BG$*=9@,"4KNM.CW
M,[5)O?XGVX^88)4V'L+P]6ZI4Q?.<#%(W;L?C)J_&Y>KQ[SK3II\R-N49BLP
M\!IAB3G@Y4HXY?6P.<T5LSWP<1E8'<WVFRRDEKM1)$W=K"E+U/EDU.* ^YZ2
MRZO%XR4RUOC3<D?1[:#K7-XN\F( P7DQ.:;P^ZQ?U%1%W"[+)<+>Y<>=XQPK
MQS7Y1C+&<UUH+^?0\A,:=)#'NO P$=Z9C\&!)C0SL-D1MW*=93?01DIP3LAA
M@/')3U_%R?5:.H:?K\NPO_G0CM301W.:NDGL&FGR&3KVDBPPV8VCZK:LC(R$
M$%_5$LGSB.G\)N-0%J^D<IRZ!,CF<FT[E^2\!]E4,F6S8$GT5[^?KN>-QJIJ
MJ-/)#5QS6^I<\R?BKI5->"_<9B %4VSR///OIBR4Q3W1F%W9H,'2 -\);86G
MZ,+3NV8;I(J7'MCN@1'%$H?IXMK^TI6>$A+)UUE:K;$,=?QMIF='$VKB6A M
MAUE1"GN9@9N?ZC)5&X+F%/NG'L=N9!(3RW>Q^^>K9P5/;"VF(%%8<^&/6HB?
M(Z[SDMXVK9AGMUZJRZYZ2TO+<@3,PT&/A@#A/7IEM[_-^(!WAK7>(BYT^.?9
MG#XT/Z:D\Z6T;(@BD44AW:K P:WQ&PS^JJ==?,['=KLFP0S&,3<:+#04=OW)
M<LV7',@N4C"((E93O0^O%]\(]2NGV:W$[_%NNZ/F)5[9Q=7NZD!=\GNN$GL*
M]\X$B/+/G^V'1]?H'3>HTV'NY@IX3RO:3^#]B]:^><@T/)7ZD_B1A.-,0P"=
M:)XSI)4D%E]DBNE*B1^$[V<L43Y=S2DR-16/V9_R@P>N.- U@X]"3#J]^TNI
M%3JCF.VVUYW N-&=XKLT$I[<3L629/(Y65ZCU/D<UA EGF&U-7Q\R$R\E2Y4
M,2$V1A?^VQ\]C<.?ZN#S;B>(R61QT_>[-T*#/<P#,B=4FWI_ $MRI8,LM#((
MSKY"U(9 -J&?),G1H6XAB422.O_IL,>IGNU!U-]=R?.7MONVO6C!,,@X741[
M9./.X.#AX-,?2EV<:$(,*R5"[B?B?O -U>%D7\O77!]U7DZ 6+>__2ZAP+KJ
M@XV!4\O>@&G.GC/(Y91O^K@@SKNT-/M/(^%PY+Y>M/"L@DN.*?],P#CB^V_6
M]P6195M/RKF0.-D\GXR[I=&B$O]MMNE+:F^/+#((J@P[\^N**B+[WTLG2Z3<
M6"R/;]P7AH/FM/?-_).T+ZTW.E&S*>Y5?;VP.BV8N44%]?WB?$^/F,?M(86_
M'L_/@;O2G:ATQ==#3N)*W])N# ?P2  &H!]XZN=M.?^5[WKL&$'DB]4^E<'<
M6C5@K4(>QNC3$,4-PN2GM>[4*94ZEX@W/\7K48U7TOV4=*N'9."AL^%ZQ59Z
M> Q\C@4&6SW0SX>/N)UHD5S7PB5J3^]/GMP*1M5X8B<Z>V 12=N7P#8$\-^"
MK5QJN=A<,VNT1U MY$%9<$.X$[*-9IXT?EBS6;HP'^ XIND+ANH?^@KS(%*H
MM'<E7YT)5+46JY\)Z/YR_*I%<[P+:0]IX]H?!0<]L9U $1/9KSV\T-H?IT'2
MXP0&<YV45\$+L&57K^C6TDB)#74[#P,"[!E'=G"<)RQ/"*J>2YH,6HJGNV2I
MN<]"NAP==GH,H,>]VX6&)G$UJE05,+DP-<?BUUU[$Y8O;3QAA,LWZX-=#HG2
M*L&1'/L116QMJ,'+WN2D"UCE;10M6EZLU1<6_>"E1$K<.KR#-Y++RGE9%"$W
M6>F^<NN-TH_QH]<@3_MXM8% 0>W+CZT#9%'R(H&OF-3L=KGM5CV]J//Z:GN[
MP@DV!)8VP^;V\JUO50K5*QZWR>O[ #'X1L/;A]KYQAQ\P82+AR,BU+JNQ^LQ
MNLN*G=:Y&W).=+OQ>4;$G/4VVO^65;C7Q-2J9MOK_CZ[=[XI.ZD6AU>_RY&1
MH&,<VIAA,BDP'6N?T5> Y>XXYQZ_,8+SDV*V6=5>>$-@NQQ"D/5C)C#D'"'I
M*2 9#2B)5W-7E G: $^<:X!KK%B".P9%,D93N)DL1Z#^ANLP+8Q(+0NXD*;/
M#:-27DK[O*+DOB9T<S@YD*"U@RV@,7(HI-'0#PFB346H](-\-:L+![ [7((M
M1U+%*#64A JF2=#!O@,&-_EVKDBB_[%?@YX+*T1/3F9"KOX2N0C!0%!QGF*-
M6X4Y^?;AG!R:KH@O6WX9L#/?AC]H(\YR)JN8JF"P*4[550*@*B)T:&LPH<(<
MBC^*5TK4W GJ;8IQ #@L@)*M?5NXQG:N8=UZUW@MQ$$DOA1QX%V9PE2=X[KG
MA 57,12VGWI,=Z4EM2O!1?1@>>$G#Q>FQ&0G(N/W^!;TQS6"3A:^)"="TK1)
M=_:ZL:GY7M$-!5)'^7#CRTHHNW.QD8<IZ6JRN:O0$O^"?^7OZ?&D<J6U&YN4
MIF2$.2G*8?FX5_D_'("AI&0%.__NA-^_-='YOP_Y\"],^ 7+G!&!](GOY!':
M#N \B)/I4Y^[4:\39,E+1E<N.C4&T(*4(F4SHC8E)@K.!*3*:K9Q^=/T4,*M
MJ'E%*P%]C_7_U>1]=V4>63K]UF]"#<N$5YS0I&V.O0DOB9'P.FN]RQ.#L^E!
MP/+%G0]Q49\4%Q]L5-L<.T6>"7"V+]64Y9;Q3[[::MZF7_Y.X.I_!G;?&U,%
M!!G_:0 )_S<DZ?M_^C__AB3]OQ7:_Z@JOWGXGSN7.W__ZK];2__N.OU;ZAWW
M7QK6\[_]KXY:Y'\UK$H__=?YPJ/W_W65_,]4[[_6SINPYZHWY(>=&/?M@/NH
M1XX0# EN?0\EEJL*MZ$$BW!<=]RNV=G<^I#VL_]U$B]\UK_.B0][5 N\LPC3
M$:D WJ$.EZ.'B1[WT&K>#SIZ6E_E!/:8O\0\].Z^U)&=Z)-79JKM]L;UV;@S
MP6^2!W+-K.."!JRJ'"+TYN!=>>5ZY?#( H[-RVS)79NT*?0.Q+3"Z==]T_!,
MPOB3QDSO^]S"%!TE*"):=,_;]\W38MWXJ6MV1Y56?9-0X<O4&JNJ_M-L!_("
M*\*\^47:6!)>/*!N6-<7 @P"IV[;SB6)*569WW(X$Z#XCC'<&6'2 "*5*BT?
M)@'!;"H>0^F&I2"(YN/<PZ'L"6KD^)>2F,,)PHT3# /)Y:C5ZJ(BFB^\XOX$
M8+&S/ QMJI?CTH/W%&793;B<T_8UX[N^X6;H5NR*$ 4[4<$_'WJ$]ZW[YM&2
MOF7H (+3G(LR6WG:9?XT_E9_6TWGHWP@HUQ(7!96"(=2-\@XHDQ:>9CJW5C*
MG :H?V^1'6FX(RDN^JBG'"XL9M/1TED9XNDYX%K?QW-;V8=(Q']85&D//%_G
MO?."Q^X:;7?$=A>5U"'9*24YG-D8>[6O N?1"](A)6'WA(2J#FPPS:%N*^N?
M=/0TI%3'J:S\KB+VY?$N!H?JUV(Z&Q=W4A=)*>A-(R96.CK?+&,FROA?7S1;
MX/G!F-=OUB*B^SNY-N;D.0R4UA$*1^A7*FK?*DH:7<M :EER^G51"^4BU:L1
M>L5/E9'_= F\H%"HJ""%(V35A5+^P8=0U5]-?3B=E#0*$03L,:11@#(Z G\T
M&,M+[+T 7ST))P?)CG6/)]<-=]FE='S-<!A9!%3H+^*!#2HV,*@@9 Q=QH4?
M[12G*B/_:B&JJ[3">^SBR\KYR19L@0QS22EBM5E2/& DYQW,5%I!T]0C29L$
M#474**;;P3[0/XVA^%GCEIFOZ2G>21*6YO!W28V$U250Q-/<A(]T-*[G5]W;
M.P%-V*=I4#!Z4',8)X[_=<_(NKU<.M5 %O%@G,5\GW!D?R"O.97>]O<%A=YA
MDOI5[VIJ*F*62>&R8VD;K#,!L9Q0[0:);*8__5%>4B2W[=6KV^]9)GSL[JF5
MVYMADP23V<9*QQ6J,:.JMV=AT'XL1OH=5!HHL?^>NP^QEC\"Q:\MWGXM5SV/
M3>:Y)%%)Y9.^J:GETJ;M_C7]I0D2J%JP'>I).<B"S#YHU_C ?M//>TX#?@7U
MVU:=?%]^;RZ5=W_%JSG;S;P_$%@*;MZC>H8%;\G2:SJVRX+H'?M^& ;%T4T7
MZ$5@^S47'*N8$'4V[#'3*&T=Y ,]J]%@.H>_NA_V5*]]&[6VEC X"[Y1'41K
MZ#&NY9WT]M:?E- >EG.^68_1E@5B,[ KPR;S5D0#[1+WZ3 B0%54L!;Y<V1.
MN/BCL4M1_K2!G66P9^//A]EFDX]C'HT/II2"U_PE6MM#KA(?W(G3.@)A_=YB
MH^+7,FGTH&[&PD@JR:)=73SVX"#TQA!)>" $19%J*%'<YM0B]Y%-)W8#?[.N
M;\TD8/0J3P@@BG?K:&7PB7K3K2LTQQV5I5'SAA#JQ"_D&6R=UX"2AP4<;ER:
M+X&\[$;Q#86_3^B)HXRFAJWZM?7R+I$477"EA0-#W4_Z^F%&G(,CAYE$UGSZ
MFI4\[%['[SLB54:/EW@E7AZAGG0\E>CF7+=?;MCA<?_E"8BI EDM4FF;4F8X
MJ&AB!WO+PX#D@WYO0.B\)_]X10%]$T J/>ZD<W5AM_J>C?=5! =IDTN<J /[
MECQ[XNAD!KP*PZ,^R(>.>L?4Y8&C?58_KLR9RHMT9+518Y.,X:A ^2<- #^7
M+T'F&QQ'N%R9F_]>?RNK<))(Z?\\053R\0[2I8_A\Q#:R\04?I))69+#HOP5
M^YI #%.LZY8CS?#/,%I.\GP9S-BZ:H_+KM1XN@[J7'@=7\@@'/X4E986V)\&
M==L!(5DQ=9JU?<"N%^:.,9V#NZP&U7TBS' KX4OJ77'T50?-9^;#GE-Q">%]
M_I;& R%XA"TP-K_$]HJ?*XO,@[P;.,+G)"3Q[#N*/$1S9GHNOCI)$WG?1((-
MT9L'[/283.T$X[NM(+F5\0VM?&8\P_N:K0)%\J^-WR>ZXEH[B3O8_--<3K[F
MPD>7UKSR,X'QR VITB%\SNYDS"CXEHNCLY[B=*)!]D;(!=BLW4&/1ZE6CCV7
MWRHI/O=8J_Z;\M+4$'F#D(N1:</#,53*8LBOD,H<Z,ZSDH@(C>S+^(?,#/7.
M*8R&*"V1]G$N9=SM,U,.80-Y?QR]UI*)"\/5G8!UH4"QQM2?IRR^E%A"I6Z;
MT7O1F)3(A&MG GA*.;]-2FZ->CH5<!(V52O66.*VZKQ02)M99<#1=C27GC^H
M\Q^]&X8^,4%F,89=+9P]4Z->?^L5GPD--)Z8%S-_MU4V/<G7TR-4:LZ>Q4%'
MJ#U+^T,_5P]-.1.XO/+J3&"2TB2J.USY>'H910X;=\E)JW*G#9WJ[X;U$KK&
M<7J]^X7PYY:/E S*V<X?:U<L2R_2XYTR91.+XMXG)=Y(Z) HG8:'H !4>2&=
ME=,_V1>P]@/\2Y_M'==K5FB)7PT4!=K;G)L)<81*6,^8- \'@\('!+/7M3>,
M0;.5_JJ##GPH'"RYU6$J><GSPE2<NC@T,4,HC(8<!/>@J26![SE=N0E"\#S\
MLNI>Y^CFRVRM+>SD@%-43P)M,$(ON-YZDDIG>W;/''G7*?28@E]SWU/C$Q$L
MZKK/6%ST>L=;,E7K<U'>[Q8OXI.A#M24#X<[R+N_R-^96\B%OI^ZUKP-!C<7
M)*S?,G)Y.R[623VDWQU3!:HZRM&J.(.T<5H&NASJT4FE4C_-AV\]2@R9.QFL
MK@=9B:DY-C9&]V G6Y"A;WP)+ZPVR^%):*(T#F(UBS_ /'J%JYI@^%!X+/L(
M%JV%"<':O#L3<!*U>]0IF;$L'E!=M]!9+U>]80Z7C!(S:PP8*N\L^WCD):U#
M>V'MY^H TN/QWPW49WE$#$.0'G7W334H4YJ/,5!9$R:\%BV]I]-T<W:H:" $
M)!=16NE*]JP97Y8J[X'H*@B[O/@T1Z:\4L.IAI4 =Y0Z1G*=%;#6+7O^47._
MZ89;]!Q=0^*9KP.U1$[&ZS/="=)!!(-+3;7B&V^")]=Y)N3!'YQ6Y_Y@7GQF
MYHDK13%0>BJH$E^732D/?O!X5T,XV[S$1PYKM\NTM039^2V*Z,%=]_<>B$;?
MR0-09OPV;C^+JHFNV17,/\0]T^2)VZU&Z]W67;1G']_1R@=YY-%>F,B$+1I(
MKJYJ/5$_UA-&XZOPA3L^?D]'Z[.NTTC:C_(FO$L4Z)J9_/HE[ILI*!>ZW*6B
MJYXZ*'./1 [Q",T@EV6L?F)HC+\T>J.+],N;0=U0UN(UO!U?<?G;1M)/9L:<
M\&J:8=>&8(E $>5WBQ #A*LAE9A2;/H1\42ENGOX;NBCLHRMP4:@L9VIUC6$
M#"(:?F<>M=VNZC4]-OE[M>0E,E^4UT8IK1OFH69*G^DZ.$($+=J9'# 802VY
MJN!.+*/H2,3S/08@KG(=U*:T/H?W'!9<R.L#S)0SNM,Q(@FB5*]LTY;(/[T9
MS(RUIW,UUTQ4C"&=[T>%=/3ZNE+@&DNSY?!+0;T*09JDM(&@.G]^2'S2+K:!
M>9LB*<[U0I@*"T=#:ZWJLX"_VF)_M]E+'C[[4ALTO=??/O_;88#7<[<3ENG&
MF4!40%AYG-6<.Y)(6>845VD_J4ZD95(24?.&90AZ"(][F5")</&'5>.GP.>H
M  4TH"B0*=*-)F+F8HLN+;]KP&EC_?#6(*7PF)4C':KD_9'"E-SO%MK?Y<F7
M#)8]4*_YK%A>]WE7L.;P?)[UTJJEVABCZW%:PK.*:C'OZ2<-:BET9&@PQ27;
M'3!TVK"<O]15LT4E*;;&)BHE14E1.OHN$(N)7!(92&+4O NL'RYG7K/+L#)M
M-Q<DZB39 QX\#%'P# =)2*M"RN@X!#]F<N5[9832F$$U8<+%Z#9E2L]G&*_D
MNB!-U!&Y0[>BAA#%48^D,I>E2?;M:G;T!,4E9F#7O?6.;ZA/"3AB!=%Q<:AZ
M>446Q]XR_YJ!R?WBJ51:[CQFS+?/Y28"4";-%J]1GOBK'-R@%*@QY;9=9[XN
MU;,DE7*DJ[L71C=:*9A],WCM-C<CH>="R^L9E)J<!]NG(ZSD]5&/&5)3BE;G
MLUKJ(QG1&/3,+H 5\CQGAFL%4'M6L#QL0L^I7TMZ21L8MFS1#C9@[=XWN,ZB
M"".'B.5"71WW\(SYR?D-9,KYSG]YQDRP[3)2U.G.T:2;GI@PI:+'J>T9NX5.
M+0>7)G)P/DU:[G2?M3E^@QDKSMIJH-X-ZR,@5;P]7"+YG8SOD=Y(!LQP0B2J
M6PH3,&;JI_4<CKK4Q=W%IB#7,U164+XRCI+G;+7499YIFBH1E@*5\%Q7W_&7
M5]ZLG FPQEK/!$)IIRYSCLNK5 #C\V UQ3,D>^R1>])MQ+A,D77YNHW3?&Q3
MD5$;%$4[S.#%5\5E<W<OU/"GU[H0I%@J.7; +2F.61,^_:8FJMM'<V+A0K2Q
MU8=!V^:#8A/J-.(//ACS%'XW][-9UX!&H1RI_6&6JP_@-I\?8[QG^XQ '@E%
M-BAJ^MF@R?/6LM:6N5MVKK?;*_"9-#/_[M2ZOLXE-Y&VZWK1&JWBDZ]2J'F7
M/7+S!?,H_D%$E5]JQ(C/[#X$V=?%9NU!=>X^K/>G$U*LUU:OODO&)=9$HU7[
MA%P,YZQ^//^+2-NI;=0X(.HKX9Z@O;W6VB-'E;I4L&>F6.PJ*JUT96RO->M!
MSY']UD[6WR)WLSO.X;Z+>CGF]CG:YN.OCM@AMIV3KJ$;ST:Z;:7#9UEBH<S@
MO 47_?1V/'<7\.H(5787[T, #AP6>L A]&PT==8A+L_-^YW5#FG4%]2<8SFZ
M7K5W9*+SXQ^?>AL!FL&!+T($I>4CLR.DCF>S<S;D/SAH)UC >Y&*BD,UE*AL
MY#WATI(46!]:K^;EO:YPD2OR435[QPIE.4;Z&<[0PL6,E<.'E7WL;O27;_BO
M5KA2=N+<0D(Z7+=+OK,[D0+NTB8GRDQ_"OL)ZEU*:K!$82\[)P"N9_B,Y%H[
M0CNY[M+!#%CM3L^#.L/EQ-3^)T/<=Z:@D[=!W/WX&*:+<"UZKWQU72; \"+1
MTT:O)EHHIY+>)R0VY;6:HMZ5E6OX=DS/LJ)^H/8HV,2)@;A@\)H>Y\!@(;UB
M\$1M[0NQ:7&N7##_8_,!X7&G%Y_JY>_?'I7#>4R=%9>?UQS#KR3%/60#JPE9
M<*+SA.E7YG\O^A@!WN7.UKQ,N+D;,7MOG%[2'\XM)M@$%I50S:=GBUC-@X[N
M\( "V0#KP86$5]/A[R>*CPE/RC>;H*O?RZ)(MVQ\228>DZG@D$W#7DNZ4@D%
MFY?)''UT2V:)OI-B^_.RB,1\XBN3&D!L-E(:TRP5N?\<Y9.+*T%4MVSK: Z;
M^-7&AIX\K>0\:$3ZP8[@UX+NVC:]9'] ,P,_%2S;MZQ=SQZ5%+W47)?Y?0"_
M9#LAL3^X<$C$A,I.H2Y&)R[DLJCR"(4\7L,^N'YL=,U5M/JSTQPZF'C8-;@S
M[%WCU-Z E\Y<-%*VM92%)#5&PT4&MV:O>. ;-G.GPT5T"'[%Z'E[\NMC]J3'
M;T[MV]KN6'QANN^^K\]1,!\+7[4>=O%*3OX#(&ZTI&- $4(FM:]A5C1.X(55
M5\Q4ONY8<;;$,H=@I>E99E!QY=M-5NU43VI\;E]X'[1C+$:2KBO$SZ2D.E)N
MHZIVC;/A0=3(ZY$+.Q@H"&*L&3RW<W/(/D&WTFH%/CAT]!!36,4%_+5'I+*@
ML0R'<1;<K9B_"2,8>\#5M5;QJ,/Z&FI/#00:R0$.;)FX>)#RBX"0H0^'A50G
ML9=_9?S $DD#BO;A'B#2<EXJ-$)<XR*NTZ_3M8U*F9Z-2M$S+'I>4BI)$XLM
M!\B\GG??<I3L&'7M,?TN(?6Z#]]0SK^ZVF'U06J>#T,(VG,QKGD/\/Z5G=LW
MW3 IQ8^XSYJV<HUF%'BY50K- VX#EDQR-%[OZ!]#K-: KU/RV-XS'\\$KDP[
ML7'S1\O';)EIFMVJ=3K/^PWPW%J(4K]NW?D@3$4285OK/ ;LFSO8!KMA]\_/
MXI;+7V,NY_MES.ZR$R#WC\BXS@LG@MIT[V>%:1(0\%QI"%U'33,)=@AB?C%7
M94_I(WF\J=*4\I^=C/ ,.!R.R4 RS,7[WGFOUVL4 DI%]3X@@G7+N7<,KF&<
M_PGN3"%$:B#0I8O=-4-MJ$_QXJA_29:!1GT>W=:03KZG8RP1IS\PI&LR71 $
M[OX;FRA35O/A[?O$?=5/F*=0F&!>L5%)0)@L+MRQH'H#)&>G[&O?R+U8P=)1
M*O*=2XZ+<A]2^,MD83^OYNH_VL:.I^T&+1X/QYF2T@CAFH++><]-'T\6#&4$
M AFEF8Y7K3\,##!A-3LG 2V_R/02=&Z]=?EFWD1-L,G:KEYE,T,6?JJ+%[>@
M?%JNV<SR_@TF!>RJ_)*#>CWXEYHH*N%DIG'1?EVW;G2.DC&I%I[1[99H=WB_
MKP=->Y::*CH(MS,;(<9H=DW.(V6@^O#P'V9K&EY'7-)RS1OPS\<RE>\5E\2;
MJ_S)BM_U=8I/)D];41E"3BW\?<M7-$C7_G)K9>FQCD[MZXS%N77CK3R,H5K"
M[9)G$[U=[@3EQ)@2E\D^X>\YDM!W':# YH2,H^(>[UMJ)3\G),)Y$%^GE;$X
M  V@ZH=W+$;6F;*R$8 #*L-LN%$WQR% M8'*'ASQ[^VM7+QVS;\H[8>?$SI$
MOU\G<#K9)X38V%2W-RIYT]Y]1Y2,'?@UFP@L:FC0>(G;P=TC C#W$.3X0%)=
MB=/* *+L'5M;8YGI3U#I$Q8Z"CHJ2)J.:N?;')7 CVEQ-^=VF>U:]5R1=51I
M^M[2M&]EA]"69Z2(P\",INK<<DZK:@57!./D6U!DF6&92;3PKM979C1O CPD
M<T\>QFZ%?'C5M'H/,=&8F7W::)-BN"FI7,=\EQVW-KW&PU@/DI22M@TY9)PC
MT@6]?(XV!^\T5;ZOG>]^]SO> 6R#0M$)Q6@%F)-=+A_[FK"IW.UUV1YZHMT!
MQSW W3A4L[U3 E*@H9,EC]NPV<9]4S!95_;FP[(M=3>I%=FVR+Q^WN+505WU
MGP+Y/#UIWM$5.W-I@-+C?1\AR4F"IU':QF^OPD7[&+.-UVD$OTL+F4/I,"W1
MNT0%$)(ZJ;SE:JIP>5X+50^'%8%M+*LVUSUAR9#:(19)#'NU53\/'QVU[%*_
M[F/8[R/)'Z6RTP>K,E&KKT0543Y7Z;)_Q+<8(]BUS:<I=LM.'RIQ]$[ $%+\
MLY+2]?RKN[JV.?5A-36"C?'7V6I^>0!='CW_,_]7M8L^MM1#$:C.O+@2*[0D
MD,%WN;Q'XFJH#+-]09#9&ZG7RI[E]V\^MHB?.X!#9(*7@\K6\1I;0(DJK4Y_
MRI]R+HTWI2EFO!<??6NYPK=?KX%W\?!NS$3+HE+NE\*- ;?V+%7&>U&F)H;"
M]0[%G05]:H1\(WUBDZ)DZ1/=S^'7+SS>=[GRA%Q?<;TTF<G]=/@.3Z")XV.3
MW;JG-<:IM;\"B+J*HA/J?+>+ #7R:\+7^ZAE=!EK*9Q@EU'UMO]P_EQ)"O)M
M(7+(0+:G_\B,G&_9O#Z.?UX\F4CJXXT&><KZB  [[ZVK)%)>^!9UFE$VV$EN
M+P>]6]C!.0.)N*#\!,2C&8_QUA+#Z]KNWKE/Y6CK3LTGN)IVHT#V.&VI$&?1
MB:.R9!/+OI0K,O# 7,#V[N=%NY:UW3.!Q=-GDU-_Y54@=AXOI7\NR4%QPJRK
MJDE$&\M'^7W8DV.,0G]EJIK@=K#.D3Z!C=MM<)+W;&U]UU3EOS[00ZH$%:YP
MCG[@)UJG#(A"O$.]LS\KBCM:C+)%_#1$D!74,G>=P%?[0-'R^_'U//IOXZ#A
MP;IG6005B,W%RQO80*)Q^U,5=\4&W/V=PF=G A 8$8L<UPHF_NT<F-!G\4IM
M_W633I=@DU4L.9:^L%0ZQ3_UL!3D!"'L(=TPA$VZ;KVS/+?^VF\>W55]^HNS
M2J^R'N]BJN39;]W&%F5NHT:5R7'KA?#I%.$I=Y:!L-CWL_E7&H)\20"B3U9.
MI5LT6BGI+9Z@OY,;=&1IM1+OQ5RUO+]B+M4"_H"NC*/E?XT-/<&G./MJ$E<)
M[P8RI42>!G'+30':-52PJ5G3.:&N3\*"K6KSP[W=Q)3(J"?$FCH"AQ_B8D%>
M.CQ@E7KS\,EO&M.<VQ81DW->#RJA.DX;%#S<7OLXJ>KC[&2.P_YM:MA V2F(
MY*6BH[/G#[L54QMWHEML8Q8ARWE0<42=.B=V%*O8,)_H73<;9VN'PG'%DT>E
M//)>/#98TG;QSUQSDD^I&*AF5?17ZO@6>CP=7<DK!8N==ICE%%87[+K(*%;9
ME=,^%C> 4@L;\7D*M'':"N9FU\Y[V%=SH_'\<7[/WD.>O<\'*H<G-.25WV_K
M[*BN953 !U5*@KL9<>E(I0Y;5#3B0_:FKXNJZ#;YT>57>C],S XR8>,3LCCT
M:#,3*4C';H1HM22,)S0W6.1NOK *]-02M8%X+R).0,4/H@K %V@K8@GIB/?4
M]WT1CX::/H;5U(F.>M0\!LE9W7@\+$;%OV2-#\1)E4OO[;G+JK=VKLUPWJ\B
M*\/"'>MM<X3%!OSS\F\FGWCP7O9C3-<\8569*0-/A@>A:@A]NVX_$%!O<QT.
MI99%N:NI3B(=.Z_[[5M(_L1F/N[7?0?Y^]>C>3,*[_X<F90'1LJ@Z6"/#$16
M@($CN%E5#MXK/^\(!QD?+7ROD+W^-#F(W<G 9 %8JQJ\DP:[B:]4-2LK'():
MA#I;38&<-V@EN)Z(:&G/RQ9$B#!F.U(M6<N%3YN--/MTY+\U8%*V#"RW&IV
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M+6),3\)R;,Z^3+D0)E(_D,5*%BY6OT7#R%PG9(MB5DHB6=FQ!R;L^;*:\-
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MRU0-F##CZ*6/%D@:<I;.JGJ!T3OEG\1@X;KA#BK!=3G^4X&3_OW:?ZC"?EV
MP;RSK@*7DL+3ZE.U];EP'57ZZJA.^77W1/&1VA%G>6H%JE[$QHNX]?OJB@ND
M;D<+8"ZNI&Q'L.NV#L7#35F4#:!,#QVN%R<\=XI\K,8OMOGX8&$W(@(R5$>J
MJ @#4%=D';WPB$ #TW_ZA>S5#/DR8ZE4O1 FSX(G3VKZ+(G>/EQ8L8TG!OPR
M?L_U]BPF;#J<4_HAK.8EA.KA(M<]ZCCH,@:?JK>#L86']U"G>0EY?XJX?A]
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M NJ-\DV3>S,&D'=)#L.T%R7L-%5W8ECD0_< N&/0X$,&V4KL-0]O]>\,FW&
M8E6"VM4*Z)>9,T(EOL71.FBU9!%)^VN].Y76F#O,NI8*U2GC4* QZ)V)28/>
MG,^<_IYG/OUNL:V#PU"DNQTS3P>!EM_6D=[TW?1U7H[/>J_^UA?S)37>M"_+
MA4 VNGW',3[.YY;0=F8F81P5/VJ7'DCBZ$(6%6[5TRPG0A?G3"-YWKQQKHH5
M7,$^\[D5T1\>T517<6^]L-AJ/6I=8>1^26ER_30%V'S!F)N>Y<FX7Z^79?4.
M#-682FA434TNL&K#20QA[6TJ*N[XEY9"?1RMJ?J6A<H:D(K6/]D+_^27+](F
MS(9 &>=T%^-@AATDL+=++ZC^E4FC*-;OVMUVV\JKC9,-60);9NIZ/<W[-1WG
MJ\S*9#CDZF9;T]HTW7:=B+ED>U3ZFBOZ7K>*YX9^*KG+E\'9:\GN+VS_A3 &
M5\L;22KD6DJ=+"EO!U>X-21H:'45(#=:Z:1!W+.Q&?YOQ*#ZC\]P@S4)S]>6
MWZD4U^QR&GL[1#VT](#DUN2<JP9FKRD-S#9L0V<;9KJJ8LDV3/^I^.0T?:@5
M)=L[^<, %VFPL2F2'=Z+L;V+%>#T:-[(_RO-@.TF+?R.\#*G[/=W4],SS-["
M[0WY-O<0R"OAV];4X3.E _!!R7M.L?EY.*B6EB"H40[^SML#LDD,,@-#7.(]
M;C?&.+E$D]U;V]Y($-VAO)7[(]6;,\3VDQ7*T708)U8C/R[03^7 B(MJS=,5
MHD/(M #Y?HCLEP!68+8>/"G]Q$YE#PP9G)5<0B5RJ$VRVE$<2IN<\."I@?.Q
M5X@/*?EZ12./]10[>;<S3Q? ;W]X!X87=%.-U1:D"^$V,3PGBJWSH25]XD44
M>X>$[B/$'H * Q6<44$AA[<('?C;4U>^*96I' ***::MC=20-N/ C/9GJH<
M+4?Z[5G][-+S?T.$4U*+ N%WAC#PIEA^%JKY4\]^W,6+_:@)&I?:'*/5.S^J
M;<9E\..7+_)LPMF %F(!*CTWQ4K,3@QI;\-3KB#:G@&:4QTF%21K.NDQ/%;K
M7 1N+:WSXY/!"![)75[J)KN)Z&]1-=Q+!;9O)=X>?35S)F6D573!I-ZD7;;;
M"@5M)\Z2,87ML[_.N@5Q[_DHY)ET4T2QV;DH%D8]P-[>(IQKO<K59#^5(PJW
MF*^[N*8^P+,]5FP$UB%U2A4V]RH]NWDU:M?8:UY+]]PYN\&TDP7&HWQ@_[)_
MI@LB;A!%P.A(4H1_"D]\&D?&Y.T^BY3=3@M;CS@0<5A<)%?#KYO2"86CFMX9
M/%_K5T"LX,2C31IB=VD=_6V%IL+Z$>BY>$YEWVX5_#FWE^ZQ?)>]OYD0XT:Z
M2G+[J"C1,(TP9^GYP/IM/1A>Z@..SLVC/8- ;CQJFDS\4AC<=I%RM8'H#ZI4
M_^9TMXLG&Y(T% ST+F2WYI&:^9S3C4*\]&\KQ=AYBG7TSS]N[U1%%3]:3QYN
MT:>/6.R12C_ 79<_ R7/1MNGU/,82]EP"4I7>F<0^DWK([_U3C:.X9Q"H$5K
M\Y".R!FBJ@[V)B9H1XG&Z2/';1]4LIYHH'G/HN@1=6#7A7O2+DA:4ZS6C9PQ
M:#?GT7-%#:HET5[:;C#-6<%%S6U.9:E%SDO3Y5MCNE%UVB^=/PLC&[:T)-RU
M%#3)O QP"T@:B=V*%W<-M'8)ML_AU%L,%3=<C+@>1UE6A@?BL&.\FUCQ=]\F
M4@5QQDH>=F[3EL01-O(&>I%^WJFUB8*Z4L5#6=3K*&GY Z7X=&%M-]U_HV-E
MJ[V+HL:[43TWL^,#/+E0RGY&7?XTN).CD<*-B>^RB/[L7\3LZ+']Q:/F3V^[
M#REEPE5=%5<*N(T4YL2'-L.)&UN)D"C4KM6@2'?WS#[U1<]Z=%2[0WFV]EG/
MSV^>_EE?BS-.OH1]+/NJ RAN"O;#W2S4J-M*<2C[V_E2*MG))A(KE*#1J83@
M?Z,<*<G7_>N71'E/DW\,Y7I9III37B)>7>WVJ<1P8G3LM<'PJKUS6?1B?>LG
M'IMJ,+!P6YG^=[E=X^UQ:/?"U/L"U>A6Y?MB51KE4T&RM\V8,U-V66E"L/.(
M6&1DU,3<5D1L:;!42>G';A*=)U.O5ZU+^+9I]<DD3$YNN99:;N3TW3O3X82$
M#LO^V$1X)<RE"2N_73@_GV9^M>^6.X.:/Z?7V<@./X4J]R4%:ZH&LD*R1WB,
MN^B6BPWHY$=?F$/N>//,R^?(J29SY<;=2''#ITR)LCL+X&6%O?4+FCHWNR>3
M(\7N1]4E$+P39S?#J^"8W8SS6^ME)=HY4]T\/F<(N2,"J<V>#^.N3H1R\EZ4
MC?L?N0$=8"@="4,9M6ESR:\#=9'DZ7_%!C;N,#2M%E L9]RGR/0NZTSOM('(
M#OVP0'VH!A2\H(<%;7.R<)H?J/T*D!1)1E&7I)NK2>+YT&&I($BDEE+*,A3A
M%=W3X@OZP%IU[F:E;\?1<Q3VGJ";AWB"LR#,JH.Q<T&RZM+R& D9P5@@<E->
MQ8IYL";J2$TKQ0J9A96V-F&94J84%UE>ZL9<E]]]&GO-?.2]-.>W<4?O4JJP
MS<.-ULP+581D0?\5,3B6>RY'O9G<.Z=E)=G#'E'T13;KH:<' XQ'/K/UR)9L
MJV!0JMW+"NR0M8&YKNPLFS#I6JC//=;F!9,TL;UL M[ZDB(_<EVAS]_71R)U
M?&X>//U$YK9"6$!%:AA2^UV^'0X8,*$6;;K;6_8D[]*Z31DW'6;F4%_C_&0,
M(J5O".SJ2$FA+[1_\#7(8@P%NK@#%5HIU=&@FY=N9F78S*;5I2!B27I/"W)"
MQQ=M-/GFP[*&K+5L'V@CR<7#-X@"!K>[.K:3T613HB/P=HI!=9A!$<]G6)'%
M8"#;3X'EG,D"=FD2(U2?3)DVU2,%LV)ADBVBR-SR#FV1H)KU8.: 4 4S[W&9
MC0A<. ["ZNILOA6^87"/'?X.W/HQO<AF82YIL3,"LL%)3ZJ0L1N?F)QH?.&%
M7%">RY\5<+K0-9?#7U:)J%1(J88,;0!K/13GA"/R<U_?3$ JY89/ZH$*+DE+
MK$G-SMF]_\!0MF']<K5E=]!E@C &<7>%=YRT!>Y,Q&>^]+^>.D!QUMH/GW,W
MY7ZWF.Q;:!AG1-N(!X&\$/Q+&<4WOY(6!#?7W&G/EA%*!3ZQ(I(J9F^[C2@M
MA+,WB.70)2@,1-PB;@L*PB>ZQAW 0][N=('*$(5#P(MB//=^$Q7IG!1/CMUX
M?&)EZ'6EGK=4DCF,$-]OL?-N:BHQEJY\-R:BAONB71>"0!N>65CWS&= XV__
M;I:IMZ7$W;,-?93*)[%T<6&QP4P.*D'HA69??L*LM_#G9B#WBS0R3Z>9'P+8
M4/<>OPP+E?-!/+!5^ (DDWCIQ^!4Y4XQ-1C@3-[U'VVY6EX? 2(_F6T3%W]V
MNIX"'#O^%?!_O)\Z3?S)M/J#)U(C\OF)_PR@300<<_G.&%QW#P!X];]H6W\V
M_AHX/ 3\,5\%^/F"ZSO/ZG]??GVU IS^+U<QX%_2)!2 4^P#FN#BNSEE,3W&
M@/VV7%F/MN=0/P1PG(O1\-75(\<-G5/S"'*/].TN-7\W69L=%[0R4UWBE7A>
MJJ? M\=P)9EZP%&H* NJQ$^%^8?^J9HU_[_ZA_VF5.EY7OUIUNUO6A?\<JU8
M^.[&HZ!!6*;:JY:K46<5W_<A2P4L^J]=ZH3*5V@3[.&.UH9<G78:6\P&?*U_
M#'O;P*70W<.<&//J$*#8J;"?,1R)V*X-G0IEO7^="#C^Y_\+U.PO8A<ZLO'=
MRGN04="XFSY?]=B)#0ZE\/4XT:;(S<?&&,N$;0,'$7J2I'$6R.T+G:[<[H?U
M/J_C)']-^+:,98+)5"B"BF)%1 QE+K!%\&!F^H7!(5YN8[/NGA'7RS/H+'+.
M6-#Z&]L=17GHG7[,@>5 ^ZV(VD%_RD@X%9'O&XA^G>94QX ? K07Z6G%79V6
M"U<^Y'\H'Q '+>3',MU\<7COMR::4<W##R/?(/'RB$3@>:?&]8#>O8Q\M]@O
M W.Y;K$F6B+@7JP8^)SJDUSB)!*?_4U,M Q$)/2G=VJY9D@HO'YDK!P8[ </
M)4'<R('=M+OV(/EGPA(UWB6#?"J0'7QO+SL&#.3Q&"=Z57%<DO.[^\_HWUJ=
MD^T%Y]W6MM=\A!R^UO=7<F7YV:1^?F*[Y)WJ7F_K7:XW&,C-[==C\G"Q0;,A
M+SUO^?HX$'J?P>A4IEPM:IH%DN;UB&3."1$!'??48O>I(C?Q[%FX9"!<ZQ#@
MS>B1/@=&"F*S_(V'M1(Z@%#K5^ Q/6R]TU8:2OI*Y14VL9QEG%%:&EH556))
MZ;BYM-&U&&VD$R0F9[IJ^WR9C>LSUY(W,>XV.)M0P&8A)DS,,NI(GXO[J6#(
ML].!L,(,>=]#@.%,'E@TA]:(IP#E5?X@1M/(#D9J),U\=#SOC>A:E=.YA'2O
M!KT'.,B>6U+! *(#4PR'BY,V V9Q^+ 7 N)6TWKUR'PTO/!6A[0WK>GUW5_J
MZVG0BMR42*IN 45(0(4_JF<X/-7.^1!P22"KHPC7IR*3+;5.]VG9<Y6!T!8P
M"ME(2C"+TCRW\(? 0^N0*A[#2NZ778;Y\N?X?F%/Y98I4>*RC8QH[)EM+M7E
M2+25\WDXWK-A!M]=G64' DELP5W<4TV+(-2N3X2^[N97X#C55:2X\6F&R3P8
M# E(XUB/Z1]I*FTHX]/ZBQA1G6P8%"%D*BV!/]L.":JL?&KJVA?ZC)"&ZFGI
M<; 8-$N@<_F)XUE8T#PY:?94M;)IQ;[SL&YB1=RU[M_YO,I[-%L2-5JW@23D
M6%4\Z!VTQ>]F?H6FF>(#K6$W7[>F'J1-MA^?OK [55)'OLH*M [?U0<OMGC5
M3MPQ<D,\2^,Q+E-0^/R8Y/X^-S3]\N:<JI6,#(?:97,@QQMGJ?F"W+4:[RWU
MC<K!CDJC40=[(OMIPP-ND-8)ET4A.W]!YS(E*-0&[OW4;F.HV MY$Z=N-1R<
M<V=3 DR4:O?IM G\W,7\V\)H +][UPQQ8P(-7^Q()9,_Y*8;!.IL"H(.?+C1
MC4CL=FP63NQA1E/I8ON:]I>1.;F1I-=Y#AR/I(TE%KRX%PN[\=E4F+2PB3L'
MY[6.9R/G=VV&%&I;4J7-JI_DDU*Z'UD)HAUTW!7%,<W<F.3C-*BA150H<A,'
M%.[(8_+'6-3&G<%E5;JHK!I3 G,*<-%$_\&\1,W"-J\NM8>OE5T*!$!YR9)+
MB+Q"<*NY_V6+8M\;[^@VH[:+/4R(I=HF4<V%Z-Y!Q*327 @$-C&=;#["W50$
M FUF^;]+6>E\T1< ,9O2IP:*O8_R!-M:[)3>/99L$1@\\SME7SX.$]N;P7E2
M&+UIOMX)-C>T9&0_U61XV=<J*94IF4PR!73-U_N8[11F,-#)6H:@>K"!R(>5
M9O0 #3T_"SW]IK0B3QUW11Q!35USW/RT,3+/B^/N$/BVE!G>"687%6O2V%F@
M9EG0O)]W<RGM@H$+>F$M3<01+!>[?ULX3J)I:D/:;-*@FR#P[?V0N7?)(D(^
M^W*\@6,%'<R[(0'/>YR+OG.'E]:4CP#*#E;9_)HQLU;C9QW:^ZS%2+93$NKF
MJL@3PDT10_.6>P7QMQ&Q!P'-3/R'"LL<<O=<GK*!%/Y#F<\;C:3(E;77LFHD
MI$J77S7#9".ITGWSB@D3FV%G5KADOZ#*[4GNJS0)>O90I.N,RV)E3)7OZ?Z;
M.;IJ<47B:#?GXQMZ9AD-#<Z%5EOR')Q*#3#JH_4R/PL"); 910O+/[@WZ3U2
MG:XLKCE("QMB1,\^#<Q^YF< R<_"P@L4L>+&Z*:,\!Z33CCY#NR/8?44%?"S
M+]QQ0V!B+[REU4=?@H-45)B[(\ 92VJI"T^!0N#E\JOV0H)3BB"LG0K2_>N.
MJKBBA#%2E%RLO)'![^SWU_K<^^A)7/F #LI:H\J/3TVL<%4HN=O,L_[TWC H
MWV %'A U-B?<^">?)Q3O1RE5R(XS')UU>&G6'YD[((C(<8B*;A.R&869MRTN
M\*AL#VY%>X@7(IT:W..[R;8%&C-#DNGOAV@N!4L]5:H62>,M'5?P=P9CL=2\
M.7-;%:J?4O:%V8'R0T"\&QO#,)#FJS1X,"U1NRNNO&NL,@HVL3L$1*E=&B:Y
MZ):E7MHC@#[.D!**##Y--?)T<;V(F/-*)!G0^16L%A,5\W+<&DIA!N;FLBP,
MS)>VA*2V5.\2"VJ1F_H$&M(#UJDO]&U/Y1!0QT5H+(;(5UO2\P\!F3#/LHKI
M&K>-Q&)CBW%\:O6(8.M9'WTO+-0T+U@8\9T!9=Y$&!2@J2C)R?]Y-H8*"KDJ
MV*1V;EA7$1\XI=Q:;\]R&*=3X;3KU5LJ.-^R$1K'TVZ_*)_(U!%;QD91%[VC
MV9+1TLQ32TYI7GR7TB)E+.K\H>*D^^5F<$ 4U$)BP%X,3WQ/2-4V!-Z.!B,L
M,MY-1R_9C-_P6K2ZM)4EK9^[?C(L60?A#P<M>.?&/AHFF,7$8>3TA#V<$>\R
M6M*[E!X;7V5-FE-C$$=RT@L:Z_NGF9(28L7&XV_.?GL'+LXAKRZ V>1FWXJ<
M!E00^:6%^)2R#@DII42[X^"+HMUV7K<8W5WX1N=2GD.C2U/S?!ZXC$J<A]U3
MIE;9A 5@\2AD>2M,M4/2=W$=-:Q52E[RZDXV3VV3WR(^V6THRQ2>>Q>]9/R"
M6/&7VY6!?EM=1_++6>'?)_&4_K&Z@)95+:RPFSMJ#;,.OI-<TX>[B>M(#++)
MNV1_GDJN>D>,"2.=G.(K^4)'+$C:7C =W"6>NO:H%\=+<HA@4(-@],!GC3UN
MHV(:PRA)?[A8>75;RDK;Y;G,ZGNDD1%$]<I<8+NNOVF1-H<@'H>&FNN?@4(+
MRXZ0*Y%(8T_9?..A?W#65N'O4EC"R^MU&UH@\&Y60%)$M\+-CV]0-KW8RO.:
MQ:EB(AZJ@I.S#G;#^-.I@6UW[@24.L,9@0'&QK-3YTL9*H'SW:486*.A0]@=
MJUY0=K3KVHJ\JE6Z_F3ZOO#*G0,#FHA'U>)&1\4$IR.QY$M^PA>=] %Q3*_X
MRG@/3*SZVV[WXS[OS,$GDDP_J;*2:F&(L*L'K'5I65"\>H7%?,[L=3N_;TUQ
M0ZL>U!M:0WG&Q\QZ<9':B<W1PNO6886SZ5YPP;';4:_Y\_H*B865,C)G=[SM
M[9V[DN7K#4W6HJWB[7&^<^R,W*&H8-,DF%&GM44"W<I(+M8E[=.4A@82))3Q
MQM'0,W3)Q"2,1\:GC^=S-?=]4"NM[Y$Z9M; UI"5>$FGZ7&D9K768ZA%G8:>
MF+.\QM)]Y&#%HWGFI!G?R89#@*NCB%Z0[%!!5[;+G/V0X%.5K] 'E@CUI#3#
MXM+4%K62XL%%17-JGJ2<&RX+49DI/MB[LLH*8ZFE>+B08A1OE"E@>RE!UKS]
MQ8'[2IRQ'!HNK;9_/_.8  X)%*1&M4M 6U?^W%"MZ*<&9LQ\@308#["O$/UP
M\*LI>Y.;M/7J@0S'+/*5BGT#$9!5KJV^\>DA^'"A3VR>S7"V&10B M$):'6J
MU,_QD3_7\=)47ZV4E"BWNDR]NJ6Y[F4=JF'#B_5=4]CTR8N%3P&-93:]?'O!
MJ442(V564([E#)M2CT3AC3U9\DT"UIO>ZI#OX-D0248E<8WE1@P2 T0<B(2B
MOB_6*;QH-WECX6@]D"(Z6LL^JE@UOFI]Z+YWPQ"?LPLN*>L1W2R/O\X\UQUB
MEL&YD@B1AW")O<2N;4@+_>D]/K+P6[DRI-F##AM$D;JCOQ8_'#15LW>%H&=8
M/N_&MJS4(O/:/A>S*^T(A7*01!^WA517AR$\*"J6)-.B?K/0 '8^MWL^MY1!
M+=DZK1&'(8K49CDX66SN[F Q-G-\@TS)4P1W!?'>CSV7_4 WK7ECJXLT.KCB
MTQ*G&7H@)240"'2SN$)JO=%IP'RL.[46%)EV63=2Y=6I1A$A*-2?E]DG*YY@
M,LUT"=43U &AE_M'$ 9\/K7[N+QNN58^;W2$D'&FO2-<225(I4W.LN#TE*$U
M;<:9&MC+* 2;V P3E=>Z>'V7W"ON+T)>81F7>5Z;:P'MJ%^,AMUEZX5CL6,%
M>O+&YVW:)FZ&@FL_?%"LCK<TI\23E#<71'HWM,[PU(LXI_NX(L6[J)T2K#LV
M_D:(13S$^D+6@JSQK':-<-]K35)HH4Q;3L0(VIQW'H1_=BU]&^_"8N)ZDOEL
M<\67_.#)T.$\G/=:6U5Y>E[G[^FQ*K<BFF]%##2Q77?=82;#Q'!<Y@AKLZJ_
MS#W-E-SNL\7*5_YT;"1 #*_V6X"WST?6(< L[\!Z.GQVKR3YX8:^:.6'[#@L
MW5"OQ8)55^^7UE1O@LC\VB<4FTM+\5#O46R\-_JA^_./OF76!=/UHB(WYJK-
MN@T9[R-)5OASUS*=0UG#F5??*T6<$T2HRWLMSU5V.H,5A:M,6ITC]R!D9'?5
M"4A&U-YM1N6&>UV=R]U37:=W;R^@Z4@_I[H6'9<K0V[YD:5CL$\T*YG"X2 I
MFSJO;7]#%21U'FS<-;+6L_QD_SVC3]O!%7&NR E</RK>GX^N.3/<LZWW#!*G
MHH5W<\]]#3.?P$\?X")&'%)L1C,:(N>_G9">?= =K3^7&];N&(9XEI03*Z*1
MED!!BHG29J*:"8EC'NH,Y):@<ZJ'\R@.CG\8AI8?GW?5F2E#@H@%K^D& R'W
M!)9WM \!3PG??M?AQPA\O92W<3]MN^5!1\3>B\=#:L,O=W+GJFK[6[2QWJ0P
M[6 Q^3O&80K4$>:OV[./N[4\%%5<X*Z!R(.R,_'$KXD?24 -<X3UK/3E6$H5
M;<U>E-'<CLW%>:-5Y#:?Z:?Z0@=!9$6\C<7:?:\^=&KGU ,L=77S4M3.K_P/
M,%$+F;K!N?0]'YRDS^Z'OTC84F.C3H'"#8AF4U-JG^)-;NR880#V:S/%K0^9
MJBCHK)U4MCRU9PJG*H(B [3,NRZ-T1,LRG(2?3#C:(O3-,M'S8-36VYK>"(E
M1#]:X-6ZI=<2HT+(U>=D;[-&2V2KVXDXNG'6[3I3BF<2'F&H-*;R=G4(QIYR
M7[*5!X<1#(UV#+W>$S3%8?Q/9X5"SL0".0N?YD8:J)%G<][[)":=J!Z^AENZ
MT5N*32T$7H=-I*4<H4$6.Y&K!\$:H,JXET>\"Y]F]@^8K;?/^< N,TPZXOZV
MB/?W^PV)2.))RJJTFB3&"CE>OD2-56NICC*Z\IB8UQ\>'AA"N<*=(5/*;=II
MQB07A?7I&Z@8HH0=]+7$&B)=:/>J+4]1&)Q,U_5>G:&YV!8&?9U#&0N%ML:3
M$8:DELVIYN5,R<K9QO<%RCX493*MPGVQ6+?^ 9^D_GT%=7DS!G\3 PB-'-XF
M@L94S@5E7MJ_O.V+NQD3CW+N4.<;_.8:3B16AS!.^]VF2XX&RSL6*5T/"R1I
MP2!]'0>_RG<0 @6IJ+3$A65%=-0'_FD7D$7>U*\X;.G(S?=Q9M><,>[5,$%'
MH7'-0LX(8[[IN-%*'(:VV(&M=$'$%/FBT 88+3&C[8Q>-8YN>4LAB^JE*+[^
MQMMZ\](0RV"UU+C&<H]<1Y,[T2H]GAOHQ(P1A&4[;T2K)+@3OC9-LUR+O;JN
MGSO%Y$?\F@XJ6J3'FL;G+[892-5<A0=+TXU]Y%Y%X\CY>%HV*-];$:ZG]FX!
M['6'+^';IG;-1YX"A=6%*04LIF=.+TY7^'RH58$](S*\P#Z14])JHC@.B_>,
M9"P*:"W8FR;KHMUC"D@M*AU2WLL;.Y#Z-M+XI#?J!5W7?5T_<7T0Z<06?^7*
MGIV9L??VGC>!6!F8CG%GIH_;6+\6W%"W?UCF[(LGUI%O.1&7'.I-?-&&C3CQ
MFW)E#Z?*AU+K,HG9Y)1\#3T(YLZ2:6%DWL[$%XO 7'G--#=P!<'R9+ TGYJ)
M>*AF4QME86,-K(KN5:Y@D2EJ1X':/[-#2KX[OZBRD)/*'3'<2^'(S6AZ%3'3
MVKV?YN'R6A?>/TTHK)LW[/N4;I #GPHL4Z3,MTP!E?!.P%L1M.37R#R%K8#V
M6^.N-((=TWHF;YENQ>ZMJ/%1#'G 5IX#3L!&9Z7DD/E&FNQFSJ@SS>TM:W <
MD*\_-Y>JL#BZP'IXKN[+ND7J: %[!IL'4^9&A-;Z9P<]*4?0SYE\3BZ^T_+8
M$ H\Q:F^X8HIP4=75._A$>6<DI;I^MK<Z7L\XH;-@[21:8$*-44YTSA*YZ])
MR:O:?M[P?J,K2C>Q?O:F6E) XYJS'4'&);TK4M8XR2Z$]O;,R!M7%"=T:,!8
M;K,[X! @)\.LT'=QZ96BS%66).NV\TK *W0Z[[#[)V%9_L6M2AU<&.#94S26
M?>X&\#-T-*\ 9O&? +*HPP*MU8H)0]H$D7J"ODCEZ2T,IET67&%7,+#V+7)\
M:I"(<[)SKK&MF/CB5N9%,;C7$F[&K/ NM/K#GC-U17,VM><0((+/%!Z>.4E^
M7T!/C0)#J>2D4ZJ[&,6UB8B9-[&YF'-(Q;L3Y]V[<4%WR'?GE"LKCU?8"^;)
M&TSC'I\R'^T\01X\2"M!!;R72/79-0KLLYSM!N:Z(<QB:@M4GTJI!!WIA[)F
M\&]DZ8IG'\A:7Z#-O_A7IX3/%S)7R\YOZX74B(ZT*A21Z#7<G].<00?M-)/!
M#+%L7$VID#OX$!"^=@A8^?5;2J7R78\J%99S1=\_SG$=";*EP&CM;AO5LB@E
M3=P%Z5.&7UA!<C8,EXP'VD1I]083**/HH5E"O&Y=CQ/0BX<WHUI,2/;X2*5E
M+R'#)MG1K7(+J8@41S-#?O<J6\N9XO](#RS0D-5OUQ?"^0A@E$EDN(27F#H_
M_\'YMJUW!O<EK:^D,<M=Q$+.PB*5GJ02R^$/TV_+JA\"3$D&EF_IRBUC!KZ,
MOD&V>>"@#G$'%ZD'\I3I5K(HMW%):/2(Z!M:!"JDA<K[\"[A\G")Q0_D$*\U
M-RLC>*/&H_[.@O#)Q"@0IJK&^RA2'6Y*P([*XCW%0P!$C<O8CGE3.NI,7.2.
M_F52&G^,68,PQ"G(D+M^/U; Y:8CF1B9BE'4-Y3MOC..OI/^G4>80P59_H^B
M=Y^V=<DH'P_P;^^;A 7&@F9>DD/@/>'PS-''B=4)NF^F@(:&0&,IO4Q+[G6W
M@<!#@/.,5$^9;O:Y<=Q8;K!7_^+H/5*K(;M&KXI>?T[%'":SL"UOF4)4"LI0
M16?:W_XV.5BI9PA3Z@WXMJ-"FD:Z-FJ8R4T6E?(D]-RRB.6FSHG&GS&,,2HC
M&UU[8CW6R^.B:ZR/\T!:_$4(U!87BE3,2H]X9:N=-^Q NUZV6(:BJ!H+&SWJ
MS_5/>Z#YS1-+OI,=SYNX: +13M#0, !:&[F-C;=?P4G5Z3$ZK$;P)8+38'4+
MIYLX0<% R-LA6WG?N?UW/?NMOS6_"\L9/M,P!5?Q\2VL:']JUI6PE,N>0 Q<
MX":.<??H[>K0PFYP4E'TCR.X^HJ +@[.U=>@_*&MN^<&IW-W.H7S1S'AFY)5
M0UQL-VESKTI= V$C$TF]V*9.11,3&.5JPZ:2&975*FPJXJ=5G>P[]^N[J(>(
M_NQ<2CU7&GW84L"J]Y\W/L::$8EP,6'3K.2K8,C:K<P_UQ]7F"@OSM%*?W>$
M)KK85VB?X5)K%KBD5)/C+C,<CI2<9-:GYM+T&,O).;07Z$Q]+D\$#FV?KC>;
M_;'Z>:I448$YT\=XW*34R$@Y-*Y V'O)BS<7<\?.R[83'_%RO8Z1L(M'+:*/
MLJ+(@;.^BPH%(B@DBZ+&HK5O?1G:B^\>U9X)OKES=3#5K%=3HU#+G/<,4%X(
M!6Q'Q/()K3$);]:@-O41@SJZ/C9%):VY;*ND%/&LX%H7CDYHJ TC,?@R#)3G
M7RD[F,4?.5=I:NV9[1LJZVY&06MV4*P,U)Q0(LY@F^@K>]:I?'6]75JU_=_8
M+^-('$)X-&=4AT.GQ-CM'IN'[_S<[SQ5C\T (12Y+:)^34FRX).(^D=X>$#2
M3WZZ?$MF*PL%5:K\1]B:GG.^V6:>;N'.U41<*"K,CTNRU#=JF 2#-4S8A:]J
MD1M74]T%P&U2-^9;:D@[!QI?L%,^-FEE"^W&0_%EONVIGH2&^AI]&;Q27WK+
MF1"/ZLP9*0_W4U_27G=YA8:4YP\L?XOI7!4V9LXE)56Y0WOS-!4P:BI"C]><
MNND5OR(CPK_)6$1BXE3*%^VGV@?+1(<;&1-K"CY72[?&%^3G!D5>/C__]ZMD
MOF/R<5K6A/7T5<?XAB&T*F(@:5SI&5 +O(FK'T+_D<&O\-G+XY)&OT-T:1%<
M/H3^F5O<)39X"[1?>*%4UJ:Q=(_PN+J'UO7H\UV8V2*7]-D+D-^H%A&)M2I1
MOZ=,ID< NZ.R,3%]/+:2KW68UIYY><0(D/V:^8>Q4&HL[+9,;G6\V;L-C+-H
MO5=\I=XS[I*^^=U?.SJ*(9VC5!./H5Y!>99RR2% @V:S(%UMZI@$?2CE(E+M
M#&)%Y>L5<O7URF=>D\FOU$E:C V,L5:^NPB/,CD;VC_51X7&V?>^>9%941#!
M.I<ZIQ:]\ "9XW<2RCN?&SIJM*G$R]CN.D4OSY"6$X$,,;'T+:IC34^7,@@>
M(IMKGR9$?ZVJ4P<7]T]$/4M."N#J++:-TAN*:>?62>.4Y9> <;'#1S)F>E&S
M Q?+\BR>F?$0"-+H^'P\AC"/MUG,>1<MOVW14%";_6G&'I7%4!&"X1T#?1*
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MPI43"QUJR\<VH+2#HN\52!S#.YE#%*TQ0"+,/DGE$4#H*Z:1I.0?^%;,KQH
M^UKE)_A8_<2G8Z!B2L#:RI+XJ\6IT:8L5&OXXH]RGN98OP-;_U0U?A\^_F_S
M?%MP<J*D(SLLL?GA3I^JH5#L<DTC1_,GAL:\QV\19R L+<29TI<]<LF5?):Y
M9)-H&%C((C*='FIH00@%@TT:7Q)R8NT\NK(A\;P3;+;KMZ8ZZO:$A9-<9OH=
M/TM]ZTB6N7M!:,]&2;PZYDG&8".EI4_L4VX-1_U2\PA"TM&K;S"2O.<?='N8
MZ!\X^SBT4&BY!R[%'9Y2*U;S=X["3>8(^J!&3'UZ\=MVL+SJ,WGIQ8;@X'()
M:8D&P*GCX]WC3<^? 4[O ]_^4$L7+NF[WQJ=ZV.JCIGMI#,\0OYI94I)>@0\
M/3Z]>259\:/OB8.1N:6]J2"5EF,;7(< !WYUROSB(6 %$&H_2:5%P@X!C6,W
MF/4@I?3*>ZV?>WE&1L:B_U0LR8PM8)>';']3_X.C7> O&BVBM;B8-^K(M R:
M9>\2<]J65K:C=,JJ@C[8M$:&N([=-KF0"G0>%=^O*=L]?724?"7G-VP. ?\T
MA4P>$[A^O8+7K<76)T>37)XE5.PR+4'S)H8WFHC#7BOMAJTHP:C^>IPA9=I#
MA>4;?6;I2_9_&,B_AV_=9VS9[*63;5_S+OO(\502%BI^#>;1MFJQ!-ZG.D=>
M-1L0&??C+,]NO,2*D[Z+#&=^/B='ZL]K2&-TMJ@_FF>V9373HYS-EF =(24_
MM*"]\=I30$41E^+'$BKME9\*X/BC'W,B"#;CI*5_I?86<%$*\'\X  #Q/^5<
MBE5'_S;Y,!?PYT\."<(CP)6$A]_I(BX>N?;_51OV<X5-C>?'S[=^.O;HOR,G
M_L>[G/P$P/Y<$P#X>58BZ:[DU\^JAU%0BOW<3:%8$'$U12,B&FQB>W;5HWI2
MC2/FG+.0AK?!D):+OHCD;BG_F<0![FFA^.[H#+7:P'):7Q5I6;%6],*US) &
M6K;WZZ&0L.4C^P/EK4$[0K)F $H%%O_CV7>4@ LFJI:SB))5UX-=N*[J4Y\K
M%=2D";?:QWD&LHE-Z V98=?]EQBZ?57$LT>DT&<LMWAY*#:3U,/]N A"LD?N
M1LKKM=6MF([Q8W TSK1H<EO3ZM:$^934K_UU:W=VZ;T8#U!KJ]JB(ZOF=5O)
MD:Q_\(]<OY0+ /T<SZ%WLGW>J'MZ\\:1B_[S2(X P/^>SM$:9<FT^JGG_BI'
M_ODG9\JQ@,?^1Z+\/F9$Y">3"=]SP/TC5VB$GC=Z#_TY^F.U=CD_].?S#1S_
M/*'SP=/%\^+)9_);/>^%)L.W=:9#/!:&88UJAX"AB>_GH*X5K>3_HQ!30&CB
M3-H,V9BQ]?SD6RKP:?K!(>#)\L:S\^M;?Z..F6B/K02OKM:N.J@== :AONWM
M/!?ZFHD]! B8+75N+@!>G30N.P0(OJ!E36:F+BW,'8S."D!7 .H/$-YN Z#@
MW3[@H#NJ-3\Z<E32 7H.KUV.&1#R.%T609W\MKE_4SU0U5O[HZND(Y21?*J@
M;';"S*CHB26G(/HI65,SLAQJHD>DHFZ]TV.UZ]<,NX$I6TM.Z[1Z-S^-B"\!
MM0]XJ_].3O-W0*0-9XPTM%6N=S//C/#,9N;Q:?.^,55[,O,U8FY.*^M.:G4I
MD5>BS2IOP[W+!"S :IXM=7(_+\(!'11%1,P=Z-S?N>^7FG0&>(5I21P0<30A
M$:FEBM@-3\7N:#&O2;+?F>6JY;K=[#^\4)TTGUH<RUS-VE&#XF.LY)"$#0"N
MJK6V0SN@+43"LD? E\^-;RP-W7E)']*4^G#SC?29<H [];%?7GE)>3ZBBV--
MS7JD'(0AV^[X7OY%8TZM]MMNU)G&+LXVR-(;(BH?+WAD+?>?1>*=-[=U<+!K
MM@MO  8,?8VCR+8MED^5Z3P5$W#KR#X? ENVR"AJHK-4)]#V_*C_D0%.8"IJ
M?6#+VT<Q\/S7C%S:P?(Q ?DCC<@YBHWWU9\#+JVSW@\-9O"Y6AT"OM7;W/4+
MN+#K3I1^&'6@A$_KWIM="[MZ/G&4+P";_V70U0)3.N06:C5M7#NI2;&:\BI,
M6((:\S&4R4LD#T[K LJ:%=F(0@K6Z(<I<8>C.Z4F->[T;_L,-!,WC%M\ M^,
M$!!"O[Z!N[ @F27*H=-6'59F*P>CY\_HIC%];2Q70  !$VD^8MXR0&B,L,;S
M2B_H!C03]>DH68F&YQV\\8TY!%S\3:[IYZ :4"977GF(^Z??NI17N_P/F#6/
M3FC50G<)HW&' %2LR]/$G?7Y'];&EVCEN*==#N6Q+#=UT_WM,CH[C;5,"6C_
MI6C ?)-(Q)P)9?U]D0^3=<X;[-W.V6WN9DVL][3FLS,JQN$BLVMNUU<$!FJ:
MFKM_ 9_4^[*V_C'O<M18$OXXJ] LG)9M*JMBN@)/LQGM?9([-Y$,@8HG]OA<
MO TYB<Q*?M&2XI$=/EF+XVN_A;N*&!\BM_,D=E2$B&X&[P4H!B$\LSO-=K:^
M\)._GNM''N3%+SUG?OI=-=C_8/0BX)UF,6%;A4,EJO5,\Y\ P9-SG67U,(J.
MF$@+TM8(>"+H!8TP-M+ZD:J>UDN5]'!Y>MWVQ>EBYH_,3.??#"_.UPIP.ITZ
ML8>L3?:SIZH+=H]M&/0<I5HA[I. H*[UGWQ OR_B"VK*[JAC5O_Z6/6J;;4+
MTGD(N&#XZ#='6,CVYHE&9(C'>N#S7XOI'S$Q!]K1X]-X^%%&614=N*H4!#R%
MT4Z<FMM^+B$PVXSTNY*<^/?8A^5#@.N%0\#EJ?W*3V*I%=^@<!"9 PAC;M><
MYA2U6)_YW%5Z6B0D;8YG5UFS+C)\>SJ6I*7"UWPYZ/<:3&/$15<_[7P87"51
MUMXB53M-U=KUR>8*Q= 0FM<<@/7-Z*T:UCV8LA[PZI'/LX3R:I^YU5"8;P=:
MU<0^EDWLE'(* Z<6,#0,IJ+)'5<<K_HNPO0@WQIBEV/>[)M-H_;VD#S_QL"#
MP0=1Y"I6Q5? "W] [D].J/> H^QX[-(1-M'53>M_/W_DHO]; #VN\L)T*P'$
M7!'\>NPBX!BHY4<\U'+8!)RX[@_X3Z7YBQ]L5=DMM-KIK>]2>@G]D7,# %;,
M3SS]QU5"C_YX"P#:?'?<I"6ERY>-A^<(,[/VW@SY2PHWLN!>J/1RN%@U,?-:
MHT? 'X'""VD%@RF[N")^\>!"?Y?M2N%<DP6#RPB8^EY:=+W\JE1]E ],*JGC
M<X&B:)J<'R;DADYP97?ADPP>ER)PJ(Z.;\.6&/WN-50U%ZB@UB&B6<ONUS55
M$6.:2O?^*?BP!?8&/AMI<_QX_O\=  $ 9V'(TDUZ!;?H4D[!6XG-H80S9\,9
MGU-I)!2,VHZ4;ZJ^\3K*DE&\18H9%H].I!5+AP:VP'$4BY9R8/ I<\S4O$G+
MF*$QU<#+<TZN41L3K0!YNWN]=Y#B>&XUYO:05/HU[TL@5+)?OOMDM(&1-/QZ
M[\! M2EML$:BG ?F'-"*ZGGVQ/_3V>2GI4N/W-R)^?34U%&14I9>5?\AP$O(
M:X86/>]E'5J+0W$5&AK*9#&-K:S0[$!U%RC0(F,P2QMPXO^%*5E'><^I'U^>
M^%@.^/-G;/\OKGT...8/$/P/,OYW@RXVXU__"[A,=-[_-[Y_N'3TL!, P!'L
M^Q?[_?X37__]$7"Z '#L9T(0_14@<K0M#;[GQV[8?%>W[YF6)]^G'TGS;="1
M5_G1 ?#P[;]/ 1QE'^87 :>Q]__=Y53.F><G_K--C1<_FB54CJ#EIV-F_^%@
M^^/<PC':>ZOOZOVO7'1R?O8)/ 5<_\G<!CCI8 .0^)%\MIQY?I+QEDH+S6F?
M%Z+V RZ%_MB SM;1ACP1J-97SP'?^R_^M;7E""O "6G 2>C/CHVC@\II7Q($
M_WG\Y,_XI?,<4(*]?P0'_CA*??XWX]F/%<2*A $7?6T IT/_T\X . JW/Q\N
M!3CY<\WG (#8;L!>P\C,2G&WNVF6SN!VHMP&;8;]6EJ*MD\XC=J&2,.D<6 9
M6LX@HG1VU%+W89_QT =DP%0@=KENE&# )8T,$G\U;1 LD$VJ$*W7?4+Y<S!0
MV6F9DIL^3%M$;E%A(**G5[$=0]8]@G6W>#CD@JM.T:(F>/O;Y:.4:GO1#ETH
M<[5' R[*D9L>>P$K)@**P*S45HLE!(?=/>MRYOFQO_YKAR=#R>@BH=1%-QN=
MR/2$W>>JT;.TKC!]=-^%:G.7C)W3M#867=P06N)%MF+[+.LYFH\/X[M!L5G#
MFU(F6U$V,SRB4RXJT6D]<GKE%GGC9E,1^P1F-'Q?//9I+J$_]_5;/A%E.39_
MC'*ICD[_)(F>:$0<DC[G\4$691C32$TD#$8-#:9 G$L& E9\WU&0(9>]=ZK]
M*)L._60/BYC/:L_T[_QV"'A=>^&>M,3_$XDNX/A_&EBBQWX<N\[78T^@7BB
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M/-=ZQ=7QM2>J$+!$]0-O O ^=-2 D"8/0OCW768LWJ_ PJ ?"-Z:'JBN@CY
MO'E^UY?[]V6T9A$(N++G+P'N@4 4_, /N)C9$AF+ /RC'"I'X*XPHQJ+DR95
M;(2.)/AFU><[-D_WV8]SQ=>J"8A6;K=F3R=M.=VGZ%?,S0@1=?@Q-V!U=T;
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M4^&JF9S^_&S<:4FT2:)GW2I=C_IV"/_",^_&BQNDNQ 7\X5O*M+T)D!G1;T
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M1SX=BW@V#0DHWDT2QD)(-,2Z/[T]WM>Q^?FR71*)8/K<M+49]^45=GZN)Q)
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M;H$17OX9H<HQ( ]D'CG9%['R'G\C)$NTEP620J($C*,IWIP4X!.F*6'?I_O
MR9& 7\@>1=*[$/-"&8]0 ^!  W)@^?+GQ)PFK1+; =?+,TP5FYM>M^!L* Z_
MJDKSK;J8P35Q57,AB'1B2=S6VIW.DO2&6-RF@.347L^\^2<97,B 9S==&+,5
MT=#>Y'W$#ITKSR6FPLH"3GLJLH;5R+#B&"O C-_J/V"-W4U?1' V" ><.Z^Q
M9?96731;X+%XYZ U);%X;< :S1IF"%Q/\4%;3( B299;%: BV3U%'&[Z,:*@
MVPO;@*(5IR[R94S2QE6-P7LNL\%:8/10+_,668\0 PG 4=J.M* MA@J/?$#+
MRU,DXB$S^!QF8]Q,Y_.H)O Y7&VJ-!)L+/ =K=7TOK :+!D"G)J/2"Q)U7_W
MU*!G$)Y?K1(L2&I#<VG?!=_%S\8UPD*B3(SKY,">)F/UVGF$^LZK = P\QV@
M ,#/QUMQT*,1&1S0T0]Z]"5PB[[" XS+\VP9(W[/%='V,I2X2.2[>C5SXE5Y
MY&;38*7<MYP]%<.W&?=V+\7A'F]-;$6^4Q<Q/N2*CO$@4!,8F[OK%W%#O*I.
M0%4->@-1L>=NL/FR+&XO%\P2,G++71+OGPZZ60?H=\R]VG=#/+>/_J>M6%_Z
MB3P/4\"A5H8)]"XD1>)KKI<5J&87(N<1HK\#1,!,*VY(^PX0,SGZ 9M$(9Z+
MH\="W<#AN=\.@0,2@ &A ?@T[9E3#4BX<@PP5P[.IN;XH68Z(*V%0,*AP7=K
MLEQF$[0^6HMG0 =>$\IY[&6)[LKIG^[=NHR/S6BSX>03S$T>]P_:4K//U\#I
M5W[L>D-RZN@\N%Q41]K5#SBU<T^<$7O##5R2[A]<96>?KF%_;$>S62-.B&%5
ML@9? TG:<B68.K\+:3XY ";<\YX'X^H.7HIUX;<4(^$WDA3/ROX=('_LRP13
M)+EKE>!*N>%S00TT=N0#=NB"Y[W _;&O-Y[R!W=L@1J-XJM>LN'CO^=F_5+R
MBDP( .KQ#K%>#V1(6,;-@'.H<E^&,+YV-98,F%O#C:?V41U;'>"B'#_>;& P
M;P"N-R>@+@*B;_J ]4(3?5X^,L63NY8+^%#G_E%$8?;I*M[EM\^(\"Z[27:#
M>E9^Z3G1++FOQVY/3P/A>UR&C.1K/GD/KW)WZ^UH@]>"\AZO],$(F=H)B4"7
MGP#P$TX:(7)LBG\7DH ?'K'Q+#]A3ZE1#% 4 6+YUN()F)M7MS]VJ\S@H^%=
M)C23W'.N5L#[P@TP08>[=EH9!;_1I>Q4]E=T@Q/K&08DPA5,1!A0J-&ZL;;C
M]?"Y?]S<UW/5[X>4?/HVSF4=F%BE^\?. "M$VYFV$9MTT?.^..OJ#A#S+B1#
MXL!K^5C6%U7.81-YXGB+GKN0/DJ)^WI __+BIYW$#1][P/G&&I)-[Z@JYY>L
M+Y:[:/>BE/2:"SS^0U,^'7>I;!N?#9U;'E[ 2U#I(U!I,'AH ,81:SN3+<LG
MIU1RUQ*"Z%8)["\T W6B9+^GD%<K4P%9]7TQN3]H-;C2$ Y$"@;!NWQJ?U@8
M4PXH*1O_=366Q&1+;6L78F^^\1Q([0S@76WP:T-YG%<9."W,5^(9CP^+S<F"
MD]KC#0CQ R'4_ LA(0]#WW9@YK.I 6VJ@5Y7OH#9=083-__:ZI:'9YF[C5>&
M/#?=W:'58-']0+:W$%;?!%,E*O4EA"I;Z:[TAV_BG->'=R&JH;H2[S[-T#HQ
MXN=$=F--IG52.%5]QZO,(]]@FN2UW2W<WLNS"K[M@.V&45?\>MJ%2$SV+9^>
M,LCM""X(P-U8)@'B[4@ 7MZ4 ]!>A1-CZT^%NY#77K=PGF4>9:!"X*5[*0Y4
M*$6;Y+/ -6$K;C;H)MKM;;7Q@C^WHZ>R!PK,WJ^724Q7*@Z?'-S+"B!EL_$B
M'^RJH=CTD7@@SK.Z.;_X>2>)<1V?%E!*1[([N(_Z=U^BU4WQRPG+F($1P#?9
MA<T:DBR7WF"M#P5>:+H2H>WJ$IV9O;Y*7N[(S2WG+=/*5B;@MN,$/),#MU?P
M\ER0P>\^SN6S9@:YA<&%P! 9H,9WGY/-^"GFQ<L2 8HY5[:R+Y.96>5&@<FY
M*0-D1&S\EUBPZ@I[,['T2)E^?''=\%WM@ 4'&2FSR83"R%%H3!_,QI5;;57
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MRI0 4#DG1GN2#L#+("[E!W!I4A@((@)\AEWI3XJC] [O@W=N%>8*8 SPT U
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MD9D;QF32*L\#9$:B[VSPK5S]Z?D5 +G@-P\HY8$Q!:5N $A0JKOIQX#1YC,
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M8^?5%@.>$CA (83CXP<A,<7A;F]=;.4*8 "/\"M!"H'A[U "W-L?1*1 MQ<
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MLK;T1H>R:B;4%S(_S)SV07J=$OL"^\X-.ZU"D67CVB!X5^33M1G-:EOG<L.
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MWM[ ^J/(OJIDA+M&89'_6&O-($U&22$;?@5[82GS#JB^OIGNMKN&>9P3<D,
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M+'!?Y8:6W-S2TE8EQKK!K*H&OV83B?DPUSOKU@DP-B\RU@7KVBLL;KN\$%*
M+ZJ#0_K 6]Z*?U+M@_9G'F$TV\*F!%&79LZI(=2P*4IUW?K)@8R=H0G@^S:Y
M4L&H"'Z'$=L\&$1\([V3KBUD@"N.CQ[$F:.:AQ71O&08NUIV25LA\1*WU"]N
M[D>ZJU?\AHJ+)X5492>6*F\+PHM-"SHX(O&GPGNB<6;/'JFVCXVQ?B3:#<&R
M:WZ=ND0RGUBHZ2SIF$KM/$P*/?^LHV_#!**__Y40M:7<9\;S;+$",A0]<<S;
M(?N'Z*?5\T;N0Q];B,4_6TGY2<-I3?G+!;,>MG8))9T+BPN&ZT\]9-[\^O9_
MCAO_A9[7?K?NC;9<]J'TA/?K0)MCT3- K5$3T1#_=]8]^?#%>9>_,@G^H*3_
MXASP%\#2.!9$U $P+%%G ,\?]I_2OI=7?)/GW'JZ6$)=66CB\],BEO4O%=6"
M2T(X_9=F.PR6P^D52$J7?E?9125&\T"13[Q'B=/@L-17C07Y17JU>725<.-@
M^]3&A_ 0<[6'4\;'9X#^,!W[KQ]7%"):KH$Q)'QPM0#H5.;=$-3373FLWCPG
M2;FV(SYST9B@6KW>;=C;0<Y5[RNMKE=,8IP!-H%(C]"LHMY4E]VPTQ4=]8L_
ME?&\]NZ%:"R> 8Z2JPXT1>?:G!TQ>*2Z*MAHLCQTWW ;GOO:2SPC1N)3=R.S
MVVB6/U/;N1M9!+72N/L1+G68)?7Y##!D)( @5#TO8V_,;&O?A\(AX#- 6'[$
MW3NE(,\9(,G=_QVYC6"S7^\M6#K'>(^F[QFF-F[$%/:? 6*B;I_Z"4M:9AX2
M.^? /773.7J/\H<JQ:PEE2O$YE8$M4^O9GAV<1DBSP . D?:9X"W*_3*T$_7
M'@^1PNXH@M6C(WTL*@Y=N",KUZ5" ]6'!$Y<&)<F/Q*+(.H&G% /0L9+ONBV
MSXU[7HW'RZ\MU+;'!#HU],S$3@.+$*&\)W-UKSWD%M2K*Z7#C 0F]RW]H8>.
M?=HGBZ/:W/N5%[.. T3\UYA_;/PVT)^:23X7NMVMG)28#%>=G("(4<:R=5NJ
M:TGO.&P'L,'*U2X+_JRI/#P\X$*$= .KOLB4I-&UC0N+KS[5K*@,R85:2#-3
M$<Q5M.NS]4N^AQ\:H2MF[!LUNH+I\5X(LL5B'X7$23P8'%,Y2OE!M5\J\,[5
M7O.<[1W(@3N$N4CKR 9244>+!X-9)V*T]I@M?B[M<M@W(H?A6Z3Z=DG-]/Z?
MHP?[]8#8H.#50W+S1MCPTT,0$+=6CGM^%QT\/D5P'S\UZR2.!MM)#P_#=*DG
M-E=DF8DCOU6EO+,62E#?.WGW>L!=B_!Z\B-0>[\C([/E(_.X4*YWJ/EDRF8W
M-H=KTQG[^0Z*/VQ#,B+]"7W%S<N\8'B',7>LJ*SD:L!Z1V4JFG UC-8\= 9X
ML_![GT=:D :'&9?K,4W_A+:P^N ']*VJE0$#D'7/<P[%@!=RVA/K;0>=7D3U
M,\"YMTFAL>2GQ<Z+6ZOJF^^FB=Y?Z->9&6> .?7-\HV$ZNWO3#11L'."/P-P
MQF5]_2&\[Q]AY']+%A\>HQT^7 EX5@V0F+%A^[0J";#X]*_AF/]K&^4=JAV!
MV_%>TW^\,2F.(T ==+U%(K_[V<(8-*PSML!0<(M79U8."!>3R7V<T/R][@O-
M,K\S<=:(K9D@H %#9HM!HE2T;P1@6/_/:8X68-@$''B+1(7HT4,N."I*Z&^C
M7US@^4>&]S\=LOQ#H0C]!V+!Q@T+*TVD[]:@A$Q-26O1K+;7TM&B-^'XA[+W
MKU[/_&NB%=\T"F3 ^8C#8*Q4-(_XTASK=BGZ#*#3/M@DEN5/0KV<?/73EZ,R
MY^$JEFAE/Z";C :7Y0()@S'DS4)^2B% CU:I/97NJ_FX.2.X CZ;1D ,23X.
M\"&(**S\>;7YUGK,4*+Y8L]JTH] ME]PM7>X_T H/X@DKUL68$.%_U'4^KG4
M7\18^.?_=LKW$.?X:TOPQ) LM<?RWMU??)."AHV^./5X^B][3QSF\1^;*8EU
M+_>5!VI;I_+O:US%H?<J?CE"-.[KJ+>(S$#RCB]*%U15&4)-<A*G4,\R>$4_
MW5 @P%<R(H 0*AMIL]\\-_[@4Q"=3>T;_RE[A2WCYEAD:L#5-7$FTK7XS0+9
MT5LD;OK.%EE=B/O;3DU656"V6E('B\)&>[58FH^7Y.W5XE#W,\ 6KWI'5BK_
M&2 O-;G<C3'-E 2AQW54U*_?PT=3VQ&+[IKK97B',X#:=D["?N?K@6^IJ1WA
MC>T%TR<]C:L)L]\5' '.3:AJ='%3BLGENWLT6WQ)O547HS2&\?XM]_3 /\^F
M7SUNT[Z9OF<<5;VZ#NF:H[4.A?+B\?)]IO?;V!%.)RHCIV+WN:<(B<UW.%E5
M75,/-1C@VK2@JYM0 _7]:M[,5I!2#3-O9$HR*X*DN;[*$=L[#;F?-SZIK'>R
M3F,Y \3"U3<+QB C[N75*^X[[[_KWI=%QY<,4XCU3[@>.=/U>X?,=U$1I44]
M[JQQ&)\.2Z9.YLNB7P>'E!8;U3SM5B K.!S(!@,=DT  V;@C!S<-FQI??0@
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M>-C*^F'T^&_$U778SHZT Y@/S"\;PU?=Z_D!7<PT+:RL[3SX[N+W-QUD8B>
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MHC^L+]W0+B4;O&^GU!,[L0L;/UT8GS[9(CKUOSK:RSB1T)Z)O9J=3<RM^N8
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M0SP[!1P-&SHPL3U-WH*V/2K1%]M;KU4$>:]09]"9.<*E1+^9:ET"BU?C,%R
M2\G9W#7^MM:S_67+^K<!:+Q-']D7\U@P^ YV#F2CV5DP'<M_-'I>\#\@ _+^
M=@VL^<(36^HMFD\2]R #-N_G%U39X=D)LW[P&Y2A(V9*VR_]R>.J9%E N1]G
M4-?\];83/1NI+7.BMD6_@$Y_Q:3Q$(V"U&01AJ=(Z4":60GD/SJ3Y$"3]S92
M"H8DE/,X42*T2MW78@&;)>QW;VLANJ?JPJAKITZ9W"9MQZ27U--S>9$&$O5<
M<4S:Y .?\9,O[6> ^"<'6HBC/'0BK4LXC)&7>=<M_^)8O:LK9Z9V;M.&CH%
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M/I0=&8M:0BF':ZFO[ L8-=!L[IQN>QTMP^  UUJ)5WV#^7B'F[L(_/9@XQF
MY=UDGWMHXENH::&<;D&W4OMA[UU2;U3BTB#T>KCJ0VB)X+/6D6Q0DS0&!%*K
M%_K \OSBSW^'0SU_E::^F7G*4&?!*TX@,O>-OIML?T6;VKDUS=!8M- ^A84]
M [C7_$>5S5_T<^<.ZJ@G[&_0]\EV7R7EDZ6_H.\2RH,JM TF JWN= 9HR5ZN
M!SS_A\YN_GWZW_0"S+GAX"1)"52-<84O[D[HNLC^+X/?5U&239=*[3@1R/G5
MP+]&X^HP5W]SV>"@*K(^045TMMK0P.B:90R*Y_C^2MS?MJ4,\*PY$FEZ^N!Q
M1CG]*BNF&!5$[8PL]DFAPL\ @DUW13Z.)I274B P<PC[X39>77N@="_N>G.9
MW$ 1#.3R;8'[-+^D[\AG^%>$8Y])5XQJ2S?64&CA)AZ3L,E_F*+:W(4YL>5G
MAM[@V)B:"'T"?+60&Q,QX TC9%[N5' :P*@N6!(+.KYZ-&#JWAV(E01?L)&I
M7?6P%;BS[BJGBD$5671P#199[RK7L8O5Z]'<5K?[G?R:QV\-.I@1G4WIZNG'
MIYZ9>HEG@"]7G.)*O<\  M+%E9 G3ZHM4&0)G)B\_^<.T7F; U$PMNFH:QW>
M(N-FG=QQ.KSW5[XEMU,M"&DY)+5L16IK*XSC:4>% :."DXR%&.TDVEF2>MI(
MM2(9L)/GN;[7R)0QC/]8U"R.@Q@_2!N<7.66Y)U&<[!!IHS0R#LXA5N2XZ]8
M'1X6$0A9DS_&M[=T*I(H4)O('B4P R?=31O:#U2.$%LL43ZZS7^R2#I-C).E
MZ1FWXURL!)[;:M[EZB\3JU?G29E3&4)A7G*L'1X,%.H;== ?\0_Y09? G47"
M(BOI/$@Z3ZD_49-0(A'HV?BAFO_:5*V\Z^1CNNHG#V@G-7.WZ&CRC\^C0\ C
M"Z)I?=^.](+JSOV>ZH&DH/.6\"]!8"7L._N\A!H[V"RF8]-N1M-PKJJ"3HJY
M574$(>YX5X(&K-8*T8$]C32U<;I"RDNHQKDQ!JW2XT($P71% +O8/M"33_/:
M4U04RPZ&15-C-OV_R?!!"HN4U$:%T/V58L[FT?E85,ZNX6)51=>*QL1X5QDL
MDU,,,ZE4;Q7 =*Z;,9"E#H @=+7X/#I40#H3^#J.K]XZY>"]&^-6Z7&GWQNF
MM9UEU*%UJ>7)6ORV&8*[J'68(^76VV!BM>$(G3[>/3(_,M[5>,LH)'7,1Z/%
M<US774J=I>PS9[(# @E7C(Z#,FFP4/9/;K5.4K+")XU=TM)W4>5C?EJ2=X#1
M9P Y??V3=S?VN,(57(VVC@B5-L%' _L^FU\S7#*DHI9VQ<F5TY;-![,M[J0*
MCJVE2Z<_Y7DUL.!/KQ#LO_8K3=$*BZ0M)?ST"5Q9WD"NZU'>Z]93@S:,T<^3
MI]Q4@UI)N^'.?+PO(HS-G%3+F(?TI&*+SP!1[%4X#G_>C)IW>4&_KB=R6QAT
M.U<.*Z9TU@,YTRQUC.Z >X)(DN:DC(3'/6@MQ;XR&\2)73 YKP:>ZY>'Y6TP
MF]-,P<"_>'(_A^,4 Y?*AH(NCU4*2#Z:PT,V&;M>!:-51$[D4I+T*=*[UI;2
M*Y="_^ZV'X'"LG$S2.P55;'N9QUBCV=S8C)O%H-LQ42"YBZO['?\,, GK99P
M(O&=MYT;LQP3JZ!]EI[]'W 3S_.WG7/"U(KJ+Y$_?6U(EIWIHOK,RKY?4G"C
M.::5TRD#3X,?/LQO&MF9>C-,62TL1[M?6'4#NH$[IV7JP$J*J4TUABZ)K<KF
M-4US0W\,CV/<=2CEN7Q3*9<HAI=G>DQN0R:!H7=Z;T*MMZU]4\;#.N33]!B\
MEG >"YB]%C'WH6JQT<A1SJYW0)K%\RK%\3"2,4MJ@!N32]#OMC6XCFZ_+Y/?
M0 ED_:Q+?.[4H]KM.(D6.:Q NF"J7MV^"=+L5&H[.!*ZN*U*K^2.OY5QW+W<
MF M=8I9J>L0A952GWC_,2"M.99]>L8YB=B3D2T@C5%6]JO2P>96$I[!@-%<%
M&+[QYZ_)KLE3KL+MR_N2G*1&'>P:'#@QL$/Z:PULRT\/#5G%%AR72!\9%O)<
MUZNNVK+;-FRL=][A4#[W31K#5LV)\7/"5HZ:=,#,:<D7D'Y_UH0FT2<: X/C
ML/43P9(ORO3@7@48QZ^PB"2*8:432@#R2?4D,EBQJ^SK_GA?75YM?:R=U9:*
MQ.@4/>ONAA'\P 5A2.95\]NAIL[HGQSC;$%AGR?RC\G?!9Q+9DUDMJ:F]X2[
M*PU$,S\JLLA8$P;7>\)\4@:G==#SPHLY ]TIGAXFYH[/BZMT]-AYQK%%YI$!
M[A@#.%%X5WH?,6PT#"\=Y]!,\RZ$J4?C@2?Q[+^I-RT23E2FVY\:WKPG.8(P
ME8N@EEDA4B((:6&9BHJ;TNV%R.-+:\<LAJM^8SBZ)I^5D#[LYC>%*%SSCH\E
M(5<C>-^6<7-NV,,I0__;=T88)R$?4 S-!9;T-0^FDG>5LC>U_/$_A_VU 7*8
MV5'>K 1;Z;Q"6^]SS<(G='NZ%>>O#$=Q+VW.9.9]"E9U=E*]P>@?< XZ3+U5
MZ&[@D]%BD^=JVKHTIRWR(8^:EK4^12*)F$:>ILE.Y+FOB;D4RZ5FKI*#4*(_
M'YJ%_9$F-=A^!DA*3$G59[N>F[+_-.M$/^[ S)"R=??X]N&GE/?J2Y"=Y+5E
MVNE/:XW$_%.KQ5Z(J>]WWOF1TW-@,$QRVZE@9+1QDQ%VW/;-1_8,L#!Y!CC,
M7"3Y\Z%I$X_:#CVW14?XL^[3;. 1^,P\T%&G'^,TP+M41 ^F1YGC=>(JXG,9
MG Q4Y^C\EQ?G216X>*QWAG6Y7[;OEF6Q=*MW4-\09J %6=UVNV55VUS!Z+]N
MTT5SJ[3P$ZF#+RM! YGV81RVI_%A++<\(+DWQIMKJ$')OP(4*2;_B&GSOSXI
MB&@FF,04"*;+A4.3QWVO5EO=[K16D(*Q, 5*UE-:9-YLR5KYH?W3^KE<$Q%1
M#W\6:R6/MC;$A!Z^8Q5.W>X0Q*GV/]V%*_98DDA[^3PW#,X 0]=3K9.@?56*
M*^/Z4W<;DXX6@ZLF[_'7P;2?Y-^+CC;C^EVI6B;>(3@C9AU]3*'\& PP[)$T
M6Y=\Q!H_*(/@.Z]U^+HPZ2;63V"*2FZ*+.JEA%MLW=[_E\Z>I]28+DM!3S2;
ML"PC/HG8++D@_OV\9VL /KYTS9&=XQBA2IJ>MAB1I8M7IRWNFN0$1[K6" *1
M"0'B)H$:^%9Z3@ZF%^ZD"!=S4E1^?X%#QB_%2L&UH80'634 SX9<7F(#KF1R
M\[T]?Z?"64+1*4DHN[3OB3+Z<\$5&(.9A,Q''0M]N/Y'XEJ:0HN ^9XB1[%K
M/ =OS%@TH>QM@KMO>06?3R'G+NIDLGJ_3FTK ? XT7_, BWK0A>=S25ZUD3?
M&FM5F +I<PZ/BWHD4G+)>1'%^)'9B("^-4M)B(2U7O<UY_.D2GJZ9M(Z;MHU
MZUU\1]-2_T I$+H)0XCPKQ+P%5-),=Y5QO#"P*_;^3PBU[PSO/GG2M0$R@!>
M[D-IRII* U^,/VI<A$U:R1E@:JQI3<*R[4=ZVASZDM&.\LX9;TR>9CPMV!!M
M!]A=J0P"T_@0]-4PKM?/INY6K!VUH76T+[#*BM+?80F7!L+C0<VNYH1+41W7
MGIZ;XFB596*35[,*%6KP0'1:! DES.DB.E:*KI1E]FS^T&_N:Q7=NM?A6=9G
MK#MED/R8.\YHU$[$+\[LV?]CM=WL_/&9V)6 6/_MZC17HZ5>BER)HK*=W6';
M"1FY47_Q*2O8JE]='Z+*^)TP X\CVAO8<<WXQ(=N?:'MX))+3*YHX4,JKC%5
M?4D;W[BGPF[Q##P 6V(\X+B@;I84B2G:@:D+WHF(0FJ-A:!KR:<'P?[GP=,P
M^\85K((_B;\#<NS@S/-[(WR$X>Y#6M^!'JO0!/,14BT)U^HV3A,JLW&75R2-
M1?K[FZKW)_]0"@[3BKDIJ6UBN4HJZ0W/8,LZ6;!I<*C$9_;+QSXT,14)0JN:
M.,+V[Y R UB#I9Z*+ZS 7AO2D_#T71?!=>C6C*W"W=L@6CH5U9L^>MREFCE1
M%'< 4\  '\IYY3P#M=L9MFH-(D0^O![^@_7Z@;$KPSQUD#O\7OCD^UHGG;@1
MA:M'2_)QV1SGPZ91G5''0?G<O4W%NR%::S-B%^M+U[3B*[QJ=HPG[#WM5H7A
M8;@)A8W;#L*XTF<B3&#6[YG',%F>4[LJ0,@HCQT"F(]!^/.+\!_??_9]R4._
M3\,%V14QN\.50P8P1W+X >V&Z3T8!EZ&07.>[/[RJ*A]ZM#@/DRH<O*\))<6
M,@731?N5VKX6G+NEGZ=B8"%\!EC]Z3-%E^0\GK'KGN=Y?;KS9-NJ6W8)IR,8
MG!._4NR340.#,8P_" I/^[Z(9L#X+K[]74S4WOK2RM?.[RL;*57#_-90SY,=
MDQP<*:Q[\N]S_0^9+_[-XOGDIRLV<09@_H6YVK^YL2L@:QES,'@LYF=ED[]A
M1SO-4/,NE_@\/ZRNP!6NS9)13!E4:@27U2\%&,]NYL] DFB'K^$K/&WADE(L
M6 [%[Q_YA;ZK__\K_X>5^J^?YCU8V&UO?'EM-[@G18_(*MA(M/GPVF\J<'5Z
M'7JHU8N1SH_#??TA_)^<H/Q_RZC +%(UQF\O>1?Y"UA9^24=5B8WET%@EF+"
M$49*+Q^_H5L668KW07!$C\L^'I@O?4]XHU[+R%>$"FHD?&I)6K,!6W-84@+;
M/XU6OG<M7BC (PA!M8IF3"2CSV->*U$K/OOR)+HQQFLGW*H$7%2(\!LLE9*\
M#%;TV;1VMX$D8@[A3BCUIPAN<>J%<#.(@0BGRK?,<,::":57F4,Q1+!5ZP\,
MA\_4\ZY1>9D-2&C!FV+"5M>AS*R[WGXEHD0?-*!*S-Q%\!WVF[_R\A4B$881
MP:OC<#Y0.25-OE9P)4?;H7,>,6,9U0&=V_'\HG#RDT=]"_KM]FTQ(;LLPTJ%
M+7X@LB$FI:U^HKWGSL=/&=LRK3T5BM(ILLI;7?.?;C/MN+WY!9!.-IG;7AZ5
MU5+^8R3N:@N@W%:M2.MZ&Q#"\L>3055>()YCO93'JL"5P4@R)F3W/'>ZB:C1
MSR;$)*ZM"=ORSY43X=,MS,C>47_Y6,CL+G:SXU4Y9>UDXTJ&4=MQA%2E2737
MQ5<EX^39%7$7%[.;)=[ "4G08JHFU.:E8:;O7M!PC<GB;K&Y<L;E[>@A81@[
MM5B?R(XVTT?]-J)R862]H\I$B)PL<&?>U3#-!P%.\(^94F7/-5_M8/$XX?.C
M1>1V&7GH[H^1HY:)GG*&/;KY\_M8(&?SZM$@PRW9+/L0ABMV!')GLBS-"G_C
MWU["14Z;+8GL.W$%FY**U.[.JUX-8W-PZ4ES#%62F_JR@\[YDO2PUDH$.Q<
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M;"P85AC-6>5-;K<LRGU%#_#! HU(T#/ +SRMY!SY>&*J:8>XF'GFM_@G$6>
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M\5M$BH8[L,JM_O,O.DC2/ZK]?U$ P\[?,'[WUE9)\&76VK\J_$+<&W',&U4
MDE+6=3YI.=Z1AC<2ITD.RI@W8H?)R\'?[O],#!F0JV&JO,O.[EC]Q(^PH\F7
M2K3VEE 5B%I8-\WO/*[=51UH.$T*H0*6?";L[']4QPQIBO;TE]T/M#![;D3,
MB_:?MKI5[S2\?,]%RK,7TCJ$F;=NXW'1TX-O0PX^J- L]R1*:MR$11=KLGU
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M?4BF>CW+.8A/8Y>EKSKJBU+A4GSYDSQ\PZRGGP*NX\E)[>F^4=?+E5VT%,,
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MA59T,FUW0[:?P<-6L.R/:@80@4DH^9R,O0CY":BT1T6QO"U$S4:>Z[Q+Q7>
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M^Q.9#86!P6)O^Z0;0G6]#Y^&K!%/D\]IY2$!@FH4*\4JB/X4N:B(.#'-NA\
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M8__,GBCHZF.%AR7:H/X-8X+"_5BC+7TS"\D7$5+4*E)XIS_RVS[VW#^T'H!
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M*'AZ<<3DB? 2]FVKP$/>&?D9Y")-XP&%S.(,J/D?W_"DMD:J1TXLTU@5(Y,
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MQM +66"]T^DUVSG5!H2%*]I9&;MD,VY,E&QASYGY(X)O)W4XL$G;HJ<#$)V
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MVHS=+)&K.J?=*6(TI9M\KT'!=E>GSU=F9@9! ><)?=  5#@S;ONT6.&<EKI
M-8WI9N;<Y9*@Y:.'<KBU"CPK5Y8F<RD5F](M?G?4?3$5/CRZ>PAT39%,"7PX
MEN!=/FQ^W:LDG@KIO2\<B:)V\P159)*AX1N4:<L>*J'K3$[#0X?ZLOY<Z;(0
M8T+N!=+#<FV.?.IX.T'\<:8JSU@*0 S5(DV:W&9L)7EWX[QN2W;?G>NVO/]
M0HU=(P]%?W%QUHA/\7=6[\S<3A=6'69\N4,>"K_,NNMB^T7A!7KBY1C-U2)U
MC&=R.ZA25#D @ >H.V953RV^-18SX^Q96Y"O8Q6EMIHV<+XO%"7(KRR])NH&
M!P9&N,%'0 ^<(5,[[UEFVD8%K3?ZI(" 2 ;T29CW6^U??!L.?%.7*Z/PM?8W
MZV&*#6YB[(+8$3-B',7&*('I(O:2(A@?+AC?CKXY<*>VPFP[<(@EM-4%LS_U
MC)#G%UNXER&B/D!4%\ 3TM'3 EK!XJ2:(446B,A9&?NT.MQ5'96P;E]HKM,;
MDCSJG.>]NGS*U^W!%4,.QFA$;L:L[#Q/W!*ZF[48<18=-KAB UE:>RF:>0L7
MI&[>T6=OM;GE^(.,!;7A<R%JM*$8W(U-T/YLP8T]],)8DJXKWD6%XP(67$VE
M6G?O2U^=1P9 #+5T!.4*CWZZQ3U2W <X*JC)E$\4)MM4L7?!'8)$UY+T[G!X
M&TWBU1.3UGE! #XXX)CO(BAW:>#UD79-N(8)U==<E1Q0QEK &7IS$A]I7*BE
M!QYJ)Y2(VOV$BT7&/+T1OI'KK/-T?"]T;#B/&ZF?5??%>DTDT<&[-K*FP)8X
M'7%IIHX1*2)5_::'$=E*6=(:N-/?O^(TZ<6#@.\_8OS:CD0ZQ_=&*E*U.MOH
M\<L*5M>E %)N6H]$&B#KO6D>!LL.ZDQO,E2/R$P%XH<@UA\[38(+"NBNG2J.
MQ)QDLB.KLTQ1"5'6EBPP[1LX$(1ZU/LB275VK0WH-2!K)=9QM'A=W?U/6XG/
ME6Z^#MB=L*+Q5SN(>Q?YT9$H+5Z(,=EBJ'UQ8%3L0GDZL6&Z%".^;7FT,N?T
M_$WNQ>HI!]^=UW0GGD%6U0CY(>.=%?MA*>9SAR#0F984P#B]9:&DA$I;C/E)
MQ!(H:%>X;\K)BB?D"@M/N]"M39,,;&KO%B7D;9.3A8&.Y2KKH2,5C0*" CB'
M<')RTJ=/8+H-3]6&H88.ZQ_R\;I;[1:(S2M,?/HH'XM\Y<)_4S^>;3*_.[D8
MWO%\]5?)+[#9_,_D*@@*F&(#*TP7T,Q0'-PHK-MLR8EJ']$QGQ<9D[_+'OFB
M6 .UX]V64/B)\-9-J.)+\TND5(.<"G%<Y]J'=&(F9/'EGY9%.T>LP)AQ#MF@
M<NOAJ->,]\TJ+,*OQ8(%[=KLPG0N:OF-I)E1[B!_FW7Z'(2@B_JL[/IPS]='
MW[Q"[JE=QG7I?]R"+@L7](GV6C->!S7-2O"+KTU>E9Z9YWP\Y@MG6J0MQ#Y?
MTBJZ=V/BZC;D$D8,&*2S9JTCN5*6/* >U?_1\O<IXS6L@5OOE:.@B GN&]^F
MUH(W*9].E"S_[RI2NM"M9"2I=7:[F;X<#]#TNBT/\JPV5&4E&[);Q)/0>WYZ
MT*ZZ)Y@U?=FHB3"YX&B+$:DD2'<H:\C-.8AWL31(\=;7KQ3-=V1?0H]?801!
M0H@F85";&E+975ZPCJ248'7&;@V7FQHJJA1>T\F:C(2WMDK1M=1=%AI21#5\
MZXOK5MXJ;K,K&_HXHO#0@5L.$?G&Q2BKG^/*:?#=\'6HDZTD]@ >*:$[1#S\
MO8/]9):RXS/=DN.2*!%],>K\50O&EN7CR8)*2(6%,7H@1.\4!^E2&@0Q^CJ?
MHE5.\250?!M E[P7T=^J[_"#@G)T@=%47D18JR9U4?=OZ;]_)H?/JTXY!'ED
M#7=-G,Z.+="CV"E"Y,^O.>\9\<(SUZE6D;_Y'^; \[C5#G<4]]':6$ X+L]N
M3>6#LI!_H50RUU_9><;H]9S3*80+(-PYS&ZN8HF,OSFDLO:U\&W&F$<^+D5'
M&OF:G$+QLBT-Y'XS2CMH6+2?R[E%6=4F'/&W_WDXSOYSZL2_L>K^*_ONR7\^
MG&TT\<_LNS_]7YOAUZZTF0[#32OS/?%ZS!3RKX6C :&R(3=3-+.&E!OP+U2?
MUYSP_<$E_W$R/4D_7/RU#?U.0MX9YHFAP6'OM(J@=V/+SJ^J2[&G:5.B-WJF
MN=],O0*-,]]1.GQKM,J(^26$\+#"DA@*Q$G2,YCOTDNAS<&VOP3%! 6II4@I
MN>9(8?I<?=_?'N!X^2U_J.$ELNGO$I'F"6,.&O96OL5Y3OL=OZ%R-XGBK[UF
M<1AJ<VN;6)@ZYEO-]Y'OA:;U5 <>0'I^*'#]N)\IBK6,MZPY^8>IV]O\$&%U
M8:!.7<!Y<]]/#S*;WBPJ_6MW;QN&;GWW*8CW:L6;MM19NP^'U67=]<IJ<0H'
M^,LK_$:.*1_LEM"W6$V1DQYM/'>B_>])KO\9W^S*MR61($W&+XB+!>M$\MW3
MQ'$?2"5J[(,B'NL4QB"Z7%[/2XBY_O6C(M9WH#P+VEM?KWGPR:-%E:/&FBTB
M4\2KAKR(Y!!GO1 9\X-QT\T"B0=!:TL<&K1BA)$4#Y.7]DK&-U9DAL)F?M%8
M%+!0_KVOJR0DW/IP83H@J%;QD<.B0'/B.D\^A;S4;07^S.DV27RX'DPP*H].
M*P,=O/=&M<YXD4Y;5WTV%ANLNGNO-'JT6NF@50(ZH&,*_K@TBZ-#:/?FI9[&
ML0X\"HYFYUV7IG!X*XDG!!*]D4$D"(I\\KVW];(GR5NM^/L?A-#H\1V<AX/%
MB,,F7?@7-C12FHA:L%6L]?M,C^PJ03-@.^<M/[\1'B</TN7 EB4VZ6NKF;<'
M-:[SCY,U8H0;LJ;.0$TMA16CK?@%XC=O=#2=R,_,KW8_YCOJAT4'T8[Y>"C$
M4F-'#'%PV;1_=#$X$Z!^I1 >'Y5--/PXOYO' UG&3=;P7OXDFB6)J776*,RU
M"T1+S</+6^,:A3P;+V="<5Z!Z?D)PZ6!%67AQ+$AXE&#V?L30_:!1^4?$Q>N
M<$S$=[Y4GD^Z=_G&\*-SO\LW@5_<PB/^'E[X7P%-IR?1IEK-+_JEY7M<^.1Z
MZ#)/)Y0@?<QW]<U3LRHM1'%^KNCLT'59:1:V=([G0@)>_+PHR8_Y[U=B;<]F
M@UQ(6D!;3NOFIYH)6TZ/I8TVM3Y42<-&NR+U6RG?_P\4-@G>A^N)I93]C7Q9
M$V@WNESU9(@>K4G8[6,WPO;]EU8/[.EJO=WI?!<%E][^![*^=+.>&C"DM+ED
MZP8[N-K%_^8D;#RH!Y]\LS4<=B$Q)50.GYG[O9K!X,#CNW_6>9J( =TZ32,N
MUHX7)F@,W432K@2;\2SN$HU;8G>DI)YL-96Y#>H4F)\Q89PT!TFXW(83^W:[
MO6K:68'&K?'L!TJ"0/L]^VZM AJI^PYKR]X^T&;*X66]"4W[@945"6K[RI3?
M%?],?S'&^&W/G<RY5275-(O02Q$UY2[[=>;+V;P\(A",HB&XQI=YW+K!%D5Y
MT0!'):IF*)@=%3T4M.L^LK!-88MVIL:C:Q[9%]L#%VB:=9&SV>:XD,+0>6^A
M0.TI6]+$!U:'A(.]?VZ.R1S$#'W ]U&]6"GSW?90@@0NLV)8GN=VSF["$-#>
M4T%.O!W?D2<K0UR@@;5\5-(<H[;R?+?YMX(==X[Y;!_ZZ"V!'X#\J@]W^G][
MC$G?-.\5M"!W6<%SAINA$"@(H? $_<N_(_#_UZFE3PD_<=&N>[*:)9OKX$]J
M7O,5E'?>+D&'%H:GLFM^N8,H>TH.8N_9;5<4%14<\[E1O!V%$T0BUC2BPB;U
MBCJ>L9%<KWIP!^A1463Y1\IT"@1-JUF??=6X3=ZS,G_Z=L>YMQ#>F3D\EMNO
M]:6Y>]O%Z;1&W=3"V]^$:A_8^QR9HI19%I6CJBWB2DB:RI?VNL'/O4YAD-'1
M!ZC*KQA?86%14^C+VVX&UP$'7<-OOKN1L;'K6L,/I:MPW<C>HU(#M.HS%$3]
MC^][?-.'5_4/%<9=72TFNT&W=QUAS670DK=.ZO&Y'1_6OFHH-)R7>R+!F"VR
M*:;@H=5MIMZXW@*F!WPU5"&W(^K[!RNX?0,G3R)\C P$MF;KI;3V4""60I#Y
MC=^8+>'4B4_?LP;A67] 1_-KQMQ7"'/SG\B..W2=](N?,!(204*5V@WVU@R;
MK 8YY3,AMLTS(,OAPM29#9E_H0H_:8Q NZ]VY\W"[MM3O+Q6Y-T"!?4YR!@;
M()'LKR3==A.DX34MN?!@:(U"BA=Y@=VU'9^M4+]XS&<D67DX=G#]RUNKHR[P
MEKMEH;:Q=^PT0KIZF>OM559C?+2&<>>41!-*T=+ID4:9-](F3>R[G-$M-6G*
MJ9*)#JAP*]@'(')V1AIFI(2!EQ5BMF)3OE;RTH3;%_L1>.B$6;WFC&]1'!GM
M)T6"M:7@)=E^:,P#8BW<6RF!"=T1FZPH?EOWL(/)'-3^87QI"MMBTTK8E*?H
MOLF>#9C@XDJK..<R%=;1/L'6#>5NH(CM=62M"#!\,D<968;<4(="H9#/QWPE
M%Z.\(EO,COEZDKY*_[(3A2T'C!HA\]'&WW\TOKJ]:D-T$YG1.@TL)DX7]@<;
M>V3^V3QZ554&:U 0P640<5Z^] '$\AA0V$S]3YUR>)C JF//]OPP_HS:R;EE
MZ[ND'#P;AR1._W@)KTWT-O8B$8)T14RTB )6I/-!YP/Z8=2?$U,K9G@GGMR>
M??"' _HMK?8NVV9PH#0!XVRI:DN!SL5E.B*)9WZ[]!PJP#1(T=_I$$L6ICC/
M"XLTWHHL_QUR_9J<JT"#L?CP+-*MQW]:0!=JH7YJX=DR.PSC!G16>3*/2R^;
M=ORH)/*G^(9MTFKG;_4G!CCF]A[]502?5V-DB;P)T6_*:$/^G\T)C/CF>?W.
M73ED;O_<)5.)%I;.T8 LR?)]YXL!\#@CA@J?R%#O8O.,947$YZ.+FQF=S%7]
MD_T O<PQ!2BBT\#G K6</GYV64Q!:G>_344TOHL&DZSPM5=*>X4^AQX]AT?A
M%YV-+YCK#!C-(7>T*!8FB3,Y26K5RAU4=)\]-)#U(W(_G,QF&>QSQE">&9H3
MXH]A[<DFY0 Z/&[53T63X;"]A5IW&&VC3Z5W@\ <11B^)"LKRQ!0K&[F5PO3
MRCN[H/[%$@RK>XT._2_LS_^,DV:^;:#<ZP-2Y;U61 ZEU!Y\$YNG?2ZCN3=/
M =J)+T40-S1F=,B887.5_@-SF^'M)K9>"H7,*N]P IA*M9>ZJ#1C+&R=_3>A
MFW>M(]SN5:O*)3JN+=1G?75D'_,EUHE-B?1=*:PW?>D=6S*%Q6K;%ZF?*DF"
M]/ICLT84%F(R]F.;L0')@LI=,$W]^74";S@O2=N^<!X[BQKH@N\I<*Q+O!06
MC%UATE;X\4)PO[Y%K["3H&?!>8#(IH]/*/KK]3^<ND8W=1V&)_<(?UP9OU Q
MJ%.,PU$Y=2#@PHB<'C&?E*%#%6\K$6^3BE2%BF1]OE-IT3^<8).9Y2Z;Z49\
M3=% 8AY=4,HSQ5!)E AF"-?4%Q=>L5"*?\IUCC1%+-50IYLI=S-Z N^,'J52
ML"LH6D=@_5_+H""&T<C"BQ;;.#8U<6Q9'=]0$;$AE7NQDL:>W([9FO AN-UL
MI20@T<AXU;^$RC#P-HK6M#B^OOX"H9/AKP&@!'H.QB3Y;O;KHR0$HDM@)MYG
M)YXVCE8VO*N8\M58RO:-S1NRES =$V-I+P*O$DLM2!B@8H#_#3'=UZ,"HW]$
MH'B"LS"PUP%J?$2EH^(C PR>]G#8%#&<JYL U? NUB_'#@#VH>;$W,DDO0B@
M!722TFNGC;X3^*1RVZ]OP&Z)F!M 9QN-K&G(53SU2!:\8%"MT-2*<W8+AS6O
M# 6WWKUM0X8RU#6#5^?FYP?1/+'*@?$<K5[=Y,6PVO/<O,\.B_6L :BM<FJ9
M$&O'2^SRQW5BN/B0"JREG>F_2[C1B=,;_,.'VP5FZ"\KFP:WU&VOC>-L]2.O
MS?6,8K0"$ZH6@>O61:BTPAH(-8U#[P04F:%>3<(>A?>EWZV#2J0\RXI]EB&J
MK1TZ)J2VO5DH_7??-](?*24K\./B9_EN8WH4=X0]#R_H42<)%!.=K^IQ5EN3
M)W,U5Y0H-$/_$E3-IU1 !V'JI5_K]@+KVTZ%)[1C>K?@WN$KM:V<"U )C:^4
M=+65J1P_Q6MM4[Q4><$7U.]D'S+JLZL*30"O8Y2FAQMUAF[%9]!')9[WZTAX
M!EU)K@#]4DXC6-GP[ !(%9Z_3E8)%/8B%:SP_(%6K;U7V15.ENBP"[&(@.GK
M_IYL>,= Z^<%HC(2 , U!5@!77YX>15)(>+0A(5>4.TMG/_K@1\7'X8I5S4L
M!F80)T*9-O P2<KG6P#G%,W/XRT1R,.HS!Z9UB$NH\RK4KC0:.2ZU<VJH<LM
MY]--ADQ6Z0@B#P5/(%*@"*EK_@&W,MOB,Q9 8Y4MZBS5'S^@+G<GE) "F\T*
M>SX'7AN[O5!G&48J+!W<[1A*0!^H8>+=0UA +.HUD;%F4/B*8:9C\$6UJM "
M,4.A6X8S)^#S\DK"BF[:%/\$@J#H_&[-.\:2:9J94)L4<WZJ)'>8$NA".B-)
M/#0N4']R.SC+]/8IH/ I135(8'_5+:_E60-#0='7*#ASCJD_%Y?S\GK8CJ"A
M+^-I!L/^L0DE'\ID_5GWK""SZV6I[UJ/X&T$[4DFJ$E,PN2WH9): BDJ<V&4
MR!(>I$/\]?G/I/(CO6%J!'(-1^'C!;36+2)GQM5'?\V_35"<L9P&F2LQ+#W,
MRP:3@\[O>A76P5F;'_AO<=,%/ICS2V.HM%(/FYJY9F@G!0H-[P ^OPW9,R=T
M-4)6U+NL?U8I4$NX,>0U)BR;^6Z,+'3>%H^7+RQ^RB .#S-1X!E]'>4F*\'W
M-PCLH(QM@^0B9;Y3O_\O+J__ ]?U)J/#3_\Q*9ET)+Z68NY4HQU@.(K+I*=4
M$4.Y*>UY2LE)F,X&&F*_?6)>9IF!#R[?[RX?X^S"?2\6>X,F/U^\XBDF!2@_
MFQ[Y@?4Z/"^G7_PC(. G;-I28X/8F$4M=J2 =^JK:)'QY14$ PXIP,G=M1N?
MI-[332"LG.Q/RIQZ^TT)Y?]F1IYV:C/_JU)"O/;NPP; Q*D2M2".K<!U"8CP
M^3KM>V?4M_1 H,,MI4B/C*@A$:->]95C/H5,[09)O>MNW,/05K^_AC8]6"]?
M4_!+U 9[K4MSL;,%ZL(IVD(K&<N_)$J!I2)UBI[V</KU"%"^W6FR08E@2G!H
M>!OS\YL.^F"TM8][H4/9N-@?ZQJ&@PWAZIQ"23^ P:3<8.<Z+N0[K27>-D/$
M#98!O/KOR._?!. U)TN'I#DM:8PKCQ[S+8O^)OG/ 7@&ZW+W^GRKIZJN#ZC+
M)/\7AN@?,3.34I].)TYBQHA5K"[<:FK0G=;7)*)'+;(,)<J8I'$U\L^4":>,
M*[%X8$#IH*5,F?_.ID(Z;/UI2X9AMW11\EJ*84! 'AVZV_/!$FF?]ZKF;OD(
M[*9BMV.$PA)#5_R-6=X7-M_-A9&5]J"U/&]G]1NE,1-0B/QP6T$PCA ]^,E=
MWV^I%Z:(+EDV22"<3W-P2:V++U<7.PR)<,7^_2U/Z#\$\$M(PUE0?RDY)''G
M*FTVL)+\0AZ&+IZU8/_ZE=:Q7ACP^YVFS </)[5-;/']';[5;(1D[OIT3.(&
M!;8N<<XG:A:Y9J,@DMFT'J#JQ6I_4Y':=_#>=Q #=;)\\%TW6#>P7PZU@%8A
M;! *'5PG[1=W@5 4_IOU3GG<!]J=WDXB*QO:8SI=LXX($JIU [*UT(,08A2?
M:E</SXO_#IT4Z/V8<,PGI]_RZEZYI>'Z:V!;40K+>&%'YWO699UQ[?S#K_UX
M^IY05VF=0)&WIMVM8KI1+K8T'?$&^=JW-=;;N^+AR P'[[F\-+ONK6O4?/#>
MZ];Z00M>L.?6TI4ID2,GJ_-.:#?H+:Y@[2BULXLV-;P4$(-DJL>M#S>]=GH^
M%7K_^4E3NUJU,?A"1W =TZ91UZ3]ZO#@O1+'FWOOW/Y<=4^($?O:K(CU'=0K
M@?8VY-@>M$;P+9-%#;H>0>R#*"F8I;RU6_ DI\CASD,/OR;("0NAGO"V_Z('
MY-_@U L8WC[+76YQ<$-^],:08VK"Z:A<D77YE*'%>.2\014R*56",_0^"/7)
MOY;*RL4LOMS(<21'G+%I.*- DK"=U)43(3F=8)4][>2TV6@D_=#RKX4QLTU^
M:-J&!'Q/G%(:Y!+Z_].*)\NI&L*DOYU*]=NOR'5/BJ5&&S7&G!=!LN-]9NP'
M>'?6?S\CO_H?C9&X5PDV3Z-#8;1].&$1R(G#Z'.ACG._JOA8IB4Y[\Q0"EYL
M&>KA*3&(D1N#E21K)L2Q.;US.'<#:/[#?-"4:4]>_J".BR<I(R%EW>(@=\(E
MA)]XPY#WI(G$.[=@M"B'IN6);\>^#[L=U+J^-&9#;$":1KVLG'CK#16WP$4Z
MV.='B;?5JMFHX!>(6H(8V+G,]Y?AEHH6PYL,L4)U9ZI("KT23\S37$GK5"M+
M3W3A7=!_B'!A9J'BX=BL>9_'R>IA;E%^,EB(V9%%6+!H^"AB8_+>IT;>AQ)F
MGD$V[_;YLG<^D;6+-ABHJP:_SM+P8JC"B"(Q=WP/<LEH^\J,5V[O8+]38/I:
MXD.XN^,5EI5)$E)+![ZV0]=R(\68[5PSGL89D+W)VA+;U(+!ZL",24KM W?F
ME<K4!/G\Y'9FZH6Y>:11"K6C=^@%0)G^V_\LW@O_G(^\I//?A#,]%3M,N?X
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M IV4C @SF94#Z2+<D (RO:UWSBM^=@D/02+M@NOA^A9]I9[B;)F5G$=_&D/
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MUY2@- O>24VY5HB 5L?T$FT0I7+*I0L3T4>\4S%Z.O:"C26DDB6QX>*J4VM
M>&BH4 LA?U%LCOLD7:8M?J+K#XW8><-W-FM; TLGXA8XW&Q SBHZR FC+U8T
MJUAU<]>Z,A%-8"O2-.:AV;#GWMN^636T5%,?JH)0I,>(_NN-SFO!>R^7?KW'
M(K <M!K5Y1/!GA@*Q Z&_M2&^I)Q2[ N$*&R;)_(FDI(R :!['VCCO0\M9/#
M$;(9Q1DV*X#<A:?C2P,B%N"Y#@@OA%<PVX0:)N7?!^'5@?D+B(9TSML1[6H=
M*.!EKZ\+;0WXOM;\*7G"I;JUCU7 _?3WQL^4^K,:/?,T.::K>+ R*0&98$'W
M296O_(RT5%--8;VPZ.[EGL-3=2]F<;L/3(0)1.Z1)BHRZ*N"P\::46Z+VOZM
MS)ZE[<X/GQ9CM>>YO0<?E,G_.6J<FW'38YZI7J0$QU(&^T>+R^A*7M5XC=<]
M"0DH/:H?CO &^\1P,^)<9_X-7P -6GUQ%3NE6R/O"-</<B2C6B+!ST+"MZV/
MO\5G5D\LEZI,&!^KE1)$[OI3Q?'%Y;ININ(C5=4/9-_,^.'PB4E&C1M"?_L/
MQLS_,WZB$_1=@PR<7@G_(BBGAU7,Y3^>M[AW[Z6LJD9#0E'  O05Z6^7_#)F
M"X+-"WTOW"CF2\5ORWYL'1O[XM"B^JA\>\;\=J-C7K[DHZJJ&0U]:\<?E;A^
M4,  !=X5J;!""LRNH7RXZO[^$<YN.OLPP"GNZ#?4#1?1JH]LA3M3']!YMK]6
M7A)(;SGK\?RR*N_#;Y>'IKN?9O95%84G;MA"$[/T!_RX)/Z3FOU/G/5D^=Y1
M'O :_N)0XU-:T0!"DNN5&=7YD\O/$@XFQ/WF'*,2)S:S*FLKWS7;*S1_D_R+
M/__XZX^WCV''EW=;CD^Y6IR^IW (JPHCE]=/N2Y&'SW*XDJ:>##4":-,.PPM
MG4A# S.V+:Z_5T0'RK].&)UH6S>$?DCY^=\+\M^TSN8'DT+4VE5JK7=M @V6
MV);0ZXW/WKV_<5PV.UE5/K4H+Q@_17JD(?2]M&;9V'Y$@]F?-. 3>SSO$,B)
MD4*N(8I^$0B)QC;]CA9R&;+M07/2T*:!<FFQMSK/.+4F1:Z!#IYN3T12CL'K
M"Y7YV]'XB, WB%)NO(Q WU(Q78JLP4H:J00Z68I;V>[]+!HW(;\#K==C?K9^
M[& T[WBK?-X+!>ET5B-,L.GB.=>38_2:5.I5R*$I??8 A21DP,K/VB\GA9JF
M'+.=O/,F+]7EH_L=2<'N.?8%BYPG?LO>(&-"X.ZYK_%C6 )*0M=Q6&$(&.E!
M!>V^%1IO'12=\1TJUX?HKY:R2%]BBO2?5_HB:'P8JO:5W!YO66I./*8!U6,L
M)W[\<ZK^HUSMBWQJ)\T/;>*\H +SF7!=7S[[L3HJPCR/:K5>=(T2.]+%;56B
MKCWF1=].K"'1&(N)!'3NO;)51*/3)7PXJOB<$GBC]F:QJX6BJFT'D!>7?R%^
M,O+=ZT>45W7_IC;.0J>]Y8")MHSA75AZB$)!IY2:_]:L>;3F*9?K*YRZ@W$I
MYZAV2*YIGL?)[+OGKDE( (;62_\*,6M_^HL3[5-(]()/#ETO\0]IQ+@/8^@1
MH9N,6]#B^P@A!D=):!\AB[7T<\770YZE7K>O!UQ'$)I?S)E$&/UD-S!D3(?B
MW)L,!4OEA'U0R6 G(Z@4/]\4K')".E[B:M.0:W'5Q-O"MR_3:_ZDO$ZI4I.N
MG-[-^^V_VK;^!ZX[MB294,ZU"[P3L_9+NO:V033A[P=!F195H]\\RB[, 'XH
MRA5_A3O__T4Q!'7.*E7&QD0?^.''6_],ZAN; G\+*5,PXS@,^ 9XU;]H_;6:
MM2Q;L5K7!,>8=HS4>Q;/F/U$5HQ+:Z 9+'/:?=Q'K=./;0O09X8_ATG^JVO1
M2>N%R->>YN3RPZ=:\%D3MS !44?OG]!V?B%\03MF:.*@^HN,I,.(0C)=ZV%N
M4$JGTFI\OX];YS5QM-6=\ER$ELX_$.Z_9YMZNW;VCU0=:Y^D#1 6,IQX7[EZ
M[Y3K<:@5JH9-B^\E'X);HQY4LD1&\\B]V!H*O^FP_EU+QI-<8Z&&43H]M#*D
M\G+2$#PXAELJ/J#^:_7!*9=Q?&_;Z(.)UGPF!+*3F25B-K:Z/0$Y_)D91J#V
M[*#3AQ0$+J,1R6E:I-U@Z<H,%>F?Y =:[+G>$W1!)GL'F;\!]PI'.;(XZ< 5
M8[EZ=V399]K-Q&-^$"SB@G_%R>V=4GSA>X,>0B*&JC=LE, X$$316]/<N%0_
M6]W//P_B$[K^]Z&1CAE<?.^%_)MJ/_]CI7_HS% Q%,H::9)6X^==U>V-]$P'
MTYN>A#=+]X\OF?J""$"?YL#Q</4R,', !GU\S;KY4EVD/A^?L%%">0M5%SR?
MFSH2$!0R=\:'K(=E1\SO)7J#D,_MO^J#^/)1\Y/XZ:8P?DJPM^'0F:@E.4R!
M5=_BB'NOQ"[Y5EIY_)O )%>+>5X^[ADXWX7L?J[T2.F@4RY0#XW4;.,%#@^/
M-*KI-W8=1_0/J]_*0:/"]Q0KOGQUC$K%"C>B%.?&ZWKU!RWS+TPM5%>/0*_@
M$G#)NGI=V6;?O9X\6BM[PETP%OEF&/.[P0HI!"8+7M'WJQ]1* 03K=N(KAX=
M^-T$AB[8<5 ]3"TJ_EC_I.7]H>2/CP^?!A>,F<J6[5]*NL*PG=M3IO691>HF
M?7W=RW;--3SE:E)K,CX9V@MXY!0H9W]87D5?K#%%;&][HB%=TU:N^H!3+M03
M&Y_@WXLG64T,=<N95Z7U ]VFG6]V?<&]$KJ;+BDD<[NG6WPN*LK+ R'A/OS,
M&KI1_04X,8CA24\ NPQ4.%F:=67N_>S&TE(!'A<.BBT^UMT'/QWEO5N3TDE/
MT,/O]L1_K2;DK.@I98^WQ/C$1YX'>'C3MY&[<N3T]7Q@:XX=>,<K5:P,*2*.
M)IQRO1@4V!&8N$4)*3%MFO&'LY?N)@6M-=FH[::2EYGBF31K*'"JQJ6;,S1D
M9HZK5X"?Q:*&3$$+NY-73"K/!E2Y.H7=ZI@_N2,:$*@W>!R)5W&3G.RE-;&P
MG)UJ2 44$-,NXM6U0$X!X+%6@P%,/DSQO4:TH=U@1M\ Q88CN>8@$S2@3(1X
MEP694H>EAUHEUMR!+VU$K^DB+6SC<'40D%F+[,Z3<6ZA)HT"Y;1A%6-TU?O/
MW< SQ/?M0@LX%PSA-ET\*BJX6B-5[.CR^C6ZPZ%6K8IW(#'J+^[?#)VXR_!@
MXLJ#(!H'H?G#E $W "$SOJ]%#/"2$)&E$0_U8 DM)*>ZJX^%O@VR]P?@BV'/
MK?%J&FD)*EH"(HU7-N2WRDZY7I]('[TJZ)=240!YIR^=<GE.8DSU:Y'Q08S,
M(W7/_'3^(+]YYX!P"G4@K-&WQ;\L_+F?9R4@^L!I,!IG^.WKKQIK+_.N!;Y8
M\&:UVL 3H>\](5!)D7/BBZFJLTF:_L9+:OSVE5 5S(SJ@_&2ZH*BM33LF''M
MR.ABW3+K(2)[VU3N>M?1:ZA!LC5A3M^M#OZ,ND#4-<FBI(W?Z!RP,U+C#Y#8
M)=D?'#+*OS\?>A_FJP&L-B<,#34E;8>2DD;XX5JL!_;=HOMD9%ZK(%F ZI"^
MD'W&=LDGOD%RH/*I_=K$:\)JR#Q&JC8FUJKZYE$2C!1BN=] 0ARI.EY]%JP1
MYB&:@YEP#O(6*51N2HV1>VP.GB>6U]BR0*9W+XW(UF6^CMO?++XW!]M"'.E;
M?#[E*II7,)+M+ZUG>X-LC'6\(QP#%OKA*X#2'!2B^F$\WZ2&/!B!KR1(10]E
M%F>,K=X8]<35$*^\8P-6BL39>/8<)LQS['K"*D7S3IY+\<)P&?"1LGMJ]>S=
MB1#2G=#)=SI!"2\HFBGTUX+S^TQQWX>6O#K8O<:*$0?Q70389'%P;'%/+$-R
M872,IVA.=[=[6"T29N0K>?^4:RGJB_0I5]G@*9?4EGA@ZQ!0W:X$VUR&^]T@
M@CUW=%"7EC9V/P@WMVENBM08L*KCT:N]7;C'\B!6O1^8"D07/W7$EXMC9NV"
MBMV,60]&$^;<!17.V'7SQ8HN:N'QCTBY$WR>HR=32=P:UX9&%93B'<P-2 &I
MV9-F7BE%E4 3LG VI$6-KXK'O%8E0 [YOO8&-PA&2"J5*D6A+<A=E64X/:!$
M_%+^?!=UCM:3.(H+H\\+L^STOJSS-XVY$A)FC,MPC<.P+,?D>)CH;L#XB+2D
M7I&B0 %,38/Z*G<IN:)9MO_E%BP0[GAL"ARL5M:H6G>M)M@V';\KN+CXO7?"
MRRZ%5IL^:;SBX84F(X8=UB!D$:A-3+T^D-[SW#5<_'[N4#SDXM# B#D=_RUW
MOP$B88ZIQK+"#'Y)SBD :+NY6 V3=,U?_1XIHJ2=.9DW/33N!!T9MKM+,70R
M(2O=KU83NM^Q5DI%BN:G#51T:&=K:#PJL"O^=:F<&+PUXTQA!7)G4/]RU)$M
MDT>AL%^RRS/47'V$3[D,^>[,.]XEA6V+^:;M^P-J] TFY&COU6I93T8F8$5?
M=QSQG>K2+N_C)>!66K@D1$AJTO$<<ZSO@6L=:RV\ #HX@9.9P^/RF('XE(Z.
M3;7)<F0*?]C-O8]>3GH)>9U#F=[<U)$&4F'A_T;;>T:UD75MHNYV=SM@<&.0
ML0EV-QF1FB"R<+N-R%D2(@AX348B2N3DUVX;$XQHLLFVB)*0,$$"B=0VF"!,
M1B2!, 8!(@B3#4[7[\S<N^:;^=;]YIL[]_EQUJI5M:IJ[5UG[^>IL\\YI&!W
M0&=CM:)3=&^I_\7>4V?.2C<<+NP0EO[F O]_F:7]]RG1]A>@6P^T[O#J8=W:
MR/+%-SV1B9I_*KKTE?7T(ZB&L3_L)7ZWOPGV3*AW&52:$43X_F3?(,M<TO\D
M4V>R_>E7B=$.L5\1/Z9+@VZ-0\E,-9%?.!D1B;>MGZ,&_MFX]8QY]3"EE+>+
M:_B^;4SYI5<'M!4_T#W7>OQJX>;O":<K(Z0>_*VB:OV:^DEA2GVUO:^ DXE=
M@FQ9?8KX*^Z6X);*ILA'):<.R;1:X;H(]]SK?_3DB>5#C4_@63]+C+8I:CXJ
M03]9WLG=S&EJ2- 4J3-^UB!K&_/'^[]JPIAGC"_G-?12HL2GN'!X^)\P),,Y
MZ'/UVE:B[3OG]K7T1XX&S5D9,"10F9U?;;A7Z;%7'JK*82[<:LDGTA77^=K#
MK<@I!:!!S =65@_I\"(Y"V[(DGB+5KT\6FSESE""\1_MPYW<ZB^WP)"!RZEC
M<J+FK^,@$F.NE/@RLC517TS]E301NSG;W;($Q7R&2BQHQ\YG5&"*J2X-UM83
MXF\&)])_PM-0Z3;@\9&P:CJ;*-$G")<DYRM)O)L&A=4$YAKU[B$WE><EGM=J
M-V.M=,IJJ9U+*A?IN.NSLM86(N T@C350:/,DF[ZG->-'0$GY\,S5:."-TDU
MCW)6MUX/:2//@-S>_N]\$/\/+NL;.,9J'PZ?AO:2IITR'&JVCS:;_S(01[%*
MY?P1=I)6KU^*UP2A.CJ>@OR;>?1[?D6(9>*)S"@N>T$QPM]450&P"+4"P5\U
M#/LRAB"O-HKZJC5KT_G.A2C]S0'-U"&X<.3C/W#%@,\JAS=H5<0)449(T1!
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M^(N.LCY/[&G=US,'U\MM0O(C.JY&;931\O.5R^K:P>_G A3@YI]_L&T,% 8
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M74D$[LVU@UAX(D^$0/DX&-9I1Z**&H3@/YVVC(W-UWB[F5,EW:'7,DV.);/
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MMZZ'G:T@C\4EK1D2E56BYAB/XPDU%1D[GHEPNN%% 5]52E[N)&S7$6K&O_M
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MIUFBG$"(E\@\@<S4WQ^Y QEZL(B0Z>:IY'FG;?]6Z GK1V2&J45W#SG^1NJ
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MU/)S\NU&X\^C& LV8&GFRA:J;'%N['6RRHM6,B%VQ.YW9:J"P(TD?GHFR5D
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MG^KAO+BS2&L_.Y]<,U;=?G[7KCGZ$/#30R.QR.WP6M708'%.82-W!"BO4PJ
M Y37!]Q@RR8$<4Z^EY@8&+N)-LJKFL"(O=\/V9>Z';CQ*K<BJK1I.8)!-'-T
M@DV'HDHGGIH"O='4N73.Y5[X[QORC=@AR:@BCT(*VWG=J<M/X/I\7-U''J\%
M8V; >206):<9,#=40K^X^W"NY+;%+67;%U!U"22D:*6H3E#L(I'&NEP)ZN-<
MKEXU/9P:'&%H3)GEW[_#2) D?14J^S 51R-3*$/:DXZU5G'U*E#>6QRU,E\T
MEYC((S$;CG^DRI:+_V:CRX_FL1TZ5Q5?C;MB&&5D6Y)KW\VX[VC]6CDJ[&R
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M7W"E<?)I%IX>O;8EQ<T?-?_.HR:F+"\TDGKXO&M+:[+[ [<>L1EVNO''JUT
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M_4!04B(=3' 1A,9##:$WVAOFZM4\ N$,T(NGD\N=+:U4<PQWV)V\!Z0N'MJ
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M@.$T)GG..VC+4<]CV3L0WW: []Y)X0'M.5VX]@#,'I7<"E6#\7"'K^8\2,@
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MFQO MI!U1&W?',\2-:P,XV6PL9=/@7KH88X5/4HYNFG"88\*63NVG"S'^N+
MT4DT*0+BN7=*B^ GEK0%J@+BPW*:$8Z4%H9AS5;F^MJ?[R8[AI"@8[%[D<D)
MG /'),-^8MX#5V:_Z4:?A&B,&DJZ3,,A',X?K\H+&WQWTZ_ C Y*;1Y7Z7M
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M'O90Q.>W& JZ&6$'L3,LG?7^8[&TZ;,<L'==GY6]C"HC9^'IK4NZD^<*'*/
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M !&:>#F=J$SO+<)/Q0$Y5@Z$3/N#I0-TD)WXM(35SU",.LB\JF-3^-HS[=V
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ME]L.L(*&3KQE\2"_]XEI%3WUJ9$+2B$HJ,4Y/7KK)$],I^8[[)E'FM5$K=A
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M+Z=8%FM-@;0 DSUQ3!&HU46VIYA 1^H;&7WR="9&D1 C.XB3HUY_,2O2FP&
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MXN.%K0*ZSF7==SK="KA]3<BEYR6GU_GE;F1#'Q38WXT[#146%I80U3C<=5H
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M$K@IABVP!W?D9E(_)'$E>R5I&F M)L6-E10DSIP8[849FW2K]*S#(?"TZ30
MRLY&IU [-#[S_+J?M5/<ZTHC$I1<)B3?H1*!E[?:\1PQ*\LZV<_J?T'&3-5T
M">3T$K&%3%W/LMMU.FSO'FB\F&K06@+ ?R20*O5;+X7'JV[,QIG@TC[DV#1L
MSO@8(,_T5ZQ6&[S1MX'Q'28$C!2*%[.LGW95PDJBRA)-T'Z.R6@=F/6=J$:+
M:0MBT@K GQ#O-:,!E1!5[T#U3G%6"( *K(-8.?@>WG+ .5B(8T6N</E=G];
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M1D;_&A>?Z2/\LBQ'\]J T)YA.HR?2BU@F#6 "5A%C< *S?[\!=.TE\2*:J9
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MJ.G+.\WI76"1%]FE,PJVB_JY\/P]DE)0!G6WCF/ENE]-0F;7B,';"1-!HZ4
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MQZVF8?,JDY[L-,,1&BPPAN-]@74>SI9*P<7$P0-%F' ,8\/*=-G@]*C$L[&
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M7X+P#T-$<T-7:1_-<B;'W"+)#722Q1,ATXE!J-/MJHF+NY(+$, =3JP%NRL
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M\"Z@N;V+*^\3LPZ@N@ZG(TH7BYJE&*YU8]+@I:6!<GM_1)D'DI@ZN$-I%1I
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M]::B\9_QNKY5=]*N ,8RS_1_TYY$E/ ?Y)PGAXMIZH4R[;%3!8K""A/L@N3
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MHO=1]HCGUDVYWO@&+U:)GX;LQ,J!&T>&5&5'5AE%A08XW[$3>;4LL64EW4?
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MT0MSB !(!'M'-B K=SFC@' ED!6A^)FRS J&[!#3Q]#"#WN<^^NK%C&P1DE
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MK\H&;#L:?/0/G+A57-?_OCY1&F>8.9->1M0)T[V[*_U!_'K--3MMZ\5?D "
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M5D(! (".#AT,-K9I-W;X\:>&)JD*_B1 *<(O+&)[ERI'9QBY^5<9.5#^X.7
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M2_VE6D1\UP]L;]TIYQD\KNF*HF;T4Z,T+M,493W/*C4(Q5>K4U?V+J?TJ3]
M[SI&,,&NM7:]Q%78>,#:KG-$'.O24XKG5V.A3J!RBJ,.A 5C"(DR %.G4D[:
MQ/2]BX$U3N,/UGU6(=X-\&&"+M+;/>SRNE9.@K0.Y&#M'&NM.]@ 7I;QB  )
M.VF^JC!0[5>K16AGZ.)!A&H64G&1L*A/@6@Z5'9*L_*M/2X(1^;W7Z>TT1XO
M/KHL%;>KD_VU(R_D0+YZEW]=UOJ7MQ%F$YK:8(.Z&@1WVAR1M0@U_$G'($%_
MT(:-CM"+<YP7K8P2?W_& *R/"?MD=$5<V0[DM&V@,0*R%TPL6"I]G#G\W4O;
MC/+;-P?+*F!&=BM$V1J.TNRL&R!!@O7ERRF> 1%$6@V+&._=R)J4KQ_<JK]O
M&>H9H)QA:#8I9@"G6W5L4XL^ELKUTRX@XHB?LKM'=<\O1X @;\)J^:8@",2^
M_RFB-.'7QA2WF0A7!>_]$^VV]1<VI/(GM7HLI\.,L8;+GB4-OD]FX@IJ>=OE
MQGX2%IP$R0XJ?<:1 8%"T3FZ7X]4'L:*# ZT_IJI<PT':15CM>ER>?14\2U(
M)+(U(;-;^E[^Q\W^R!E5@:C8>4E.WF2E2UNO2PF&0&0LX59^K3TW.-RT%<:!
M=#R.1MKCG<58Y]/#I740_ 7R2MBXY'P BVMPML?Q@^_8ZLVH>Y^4@L(8ZG]P
MQQ:5<KMDS ;(Y7U7<QL'A+/0-)[*A_9 MM;H*A,NYE=0_ZQ1V,[QS]&BM.8S
M'FD0^VG-\O&G@2^F:))02.VY<(LF-DU%SW!0F]$2^8MLO5U8.CM&(\)QU,6V
M=!(LHBY7/^!!A%+S!L,1U#F4TA0?,2/>)20L@8>]DXK'&4$K"Z3";J?6,<H;
M[(::L5NHHH]L:QE26HZ-96M5L)?.S7A/'&Y@,V";%.'@>UK8J](1J.18E9Z<
M<(/<1!FFALQRVOS/53_*BD'>A9Z/9ZU+PB,V505<6A\\K#N"8AK,/IKY?G35
M\JZ @,B,?O$GTMKQ6\M!A)0QR2OB=$Q6\[DNRY.@]&:*,Z?SX;J_K]C\G67D
M>VP=B@8#?Z57K_DW/+(NIM@[=T%47.B#UIKIF"IIXE1R*(=,37%MFR<X'<L>
MF/7AAJMY:]8^(J5E-(]8)%/([C<5R%C:0IK>QRJ==_WN-T]GNKSL_W]W/<=_
MI1SM*[]6!9CA?SHT[:L/Q3CN;+UNAH_N%50YN$0N/8O?;FLNZ>^3R#/IN>+$
MA8BV"):#UV#2.V?/\_@G\FM1#2H8PJ;1\3Z.B_ S"I&:?%'D#?HF?*%"[@_]
MS*699WL@E$$19:)I?224IW)KE"KI\E>=*Z+[4;#.)%Q#GJ50X#HE&K(1//]N
MOI7*$DVKO\4,W1&4<S"M[Q<DXD:$Y>\(1GOV#T[9QCP8U,W2FS]W]SZ<7&+^
M++&^GD0E*"A@P;(I[CMH-%!>^(0WLP"P_0J%61UQ\3507U$M8=4Z0CE&;@YE
M^"JS=(,FRQ*G >H6V(0($?[I\9&?]6DN04@BQO7NU*I^DJV;D;WD<<0;VQ!]
M6V>NY_R>LQ 4]Z3MHZZ;PJU".O>GP=3@G?$;0T"M%.>+)IU 5B7480-4YH?7
M*7986@BU,=M67&J>#[B=,[DJZ5("BJEDYIU&57H7AU6!V\IPKNVF'0LL:HH?
M3,5AA9\O63P:<*&R_N9>J)'S!?=JPQ).4*G_IS?TG-?L4,XG5A_TE5C^2+KT
M7[]<_4*!AV\P)V5J]\.>%F&@I;U<>)?H1-2DBE&)$S[DH2GHC<,ZXMJ/=?;^
M6_F?XE9-:I?&*?YCAHO0*'9][HC<J0!##Z6+)J,77NF10O->)(@##F:0>.-.
M999&Q>5;^RCKPMHQ7][V<&?%]MCF+U"WE48-@^<<QJX?8IL%GV#>ZX4&HCMO
M3CY)@I<6?Q,P2;[V?*]HLG;?U_[FR!AA0*[V]M7(+[V#15J>%CFRH?6U\Q.7
MVXP1VI>GWD]/F=JX7"IG+7X3,,O>K9'=O]22/H0*POD.]!71OPF8@NII$&0)
M:VBPC^.93.+-)H)"8;E*6=HL_4/B1&D(2-E%V6N)S3#'"WVFRJ^F)N8NZJN/
M6)ZZ,Y7]H\MF#BQ;%N=A<P<J]M5.JKP@9K#'*)J(D>M.),Q8S(/#0! M1V"I
M.PV16/#4URG"(B-:5VP*4U IQ(T:A/:G_\@JP_QDK227H ^M8JSR9PT6LZ1L
MQ4_W)9'D)WL@@=32V S'$'-E57>0?O<S82"EAWF2J=6@<CP]63&@)FQ+I!>*
M-K(4]G ';E><@@@KZ#@EI=XX<_%A,';_$T+@P90]X;%N-E8SJX"S!TQWP>];
MEKTAC%MPX+FYOH"D]K,*VH;:ZM#S^1RIE5!C\#WQ(T-^8?6J["F5X"KQ=A6C
M,?RY)HLN0LV@.D#X'F0US"^VE8%.3!@E>-=/Z%=.8"*2%3W9JLF!M8FG\HAS
M[64DS^YI7(*H0&1HTZ2"MC>I?;O7@S#83>9ZA66*W;&&=,^%T>+X*4'"4SO$
MJ!#@C!#R82#,L#!,8&DR=&FFBN!!SGW-L.:5!VK_Z+2%M<=>?OW^@XU%.<HK
M)/,#KI(P: HO"U^6O)8W[N-+_NV; *TDMI+Y 24M,771TJ#@!>R!06//W:-3
M4E%=P0+?A\0%V(\.1U#:DK.'H[75;ZT  7BR\<I<U,MYS.2.X7AQ>-;;Q7XW
M-[U SL<_\FT=B^IU?3X6--HZ2[[Z)G!K6L3@DBZP5_QFW<0XFE8USJ.KTZ",
M##N377CYSE4L4S_[_&*/ $HU-N:B/9'0[KRU:FD_RAM1Z?[X97&?:L)4!G_T
M@'=@/T.CO$_LJ9C,A!ZXO_^O'EG_3PJH=C4L?+Q@LS1.!5.\%+1>:G,>)6L*
MAHB'$L[UBM4:!T9])%9F@@Z2EHX\KS^S"Y@:9;*K'5\J.)^B0S& R@[*6HC$
MH$Y2"AL&@HH2HBY)_W$.X_LX(O*O_T=+@/\_+5<98<$C]I:V]B(8D4\,^.<2
ME X=M5U4],E!'66=]]:1MPV#+"7K6"+%]SH<7OF6>B9'<&32<L +C6_>' DZ
M&N+=6/=?#>&_Y;_EO^7_?W)NXTBP8J9B>[\ XI\E;UHVLGTZ1_[9,><X>?V&
MZ-&^:S]T.=+O"(@*N'3<19R*;#)*8O_O^\*(?#CZE)G$1@@<G5*[\:^=4%S:
MOI_T3T5\G8#*![Z(7UV&XKNF_!?_,2T<[=-<GVMZX7HJLE'GRR5)P@O5XP7>
MBPX5HN13=U4^+#X^$JSL+-34F'BHW^'5H@+'&UU_2CN\*4.R!_A$J>WX']]W
M<N%'>)ZZ9R/]]$B0J+[H/PJ;8I\??U$)$-V/^=2(^'C\1>FOARI\;^]0/UB\
MX/U\\-6J_UW]<_^T(>'Z5/6PD6?M[W..OG=I_^>3"4>GKMG=.ZQ;G?N?"[)%
MN@$"IZY^^;7B5]&C;"SN5?RINX?_'@$CSOP&//P]<L,^OO2P:NI2.^_[77@2
M?R".!-ZI_:/N'&-45>"(S>%9@;!7Z]_7LA\VB?S\STG_P#G$\.+JW;I_*71H
M1&:"\*&AF?$A1_Z][EVQS?X:]_L5#_MTSAA&'GW_+TLC_HT#^P#YM^IQC0>'
M0'/^_ Y;Y<,_#0BNPZ;_*2@.8^\VG@O9RVP\-.@?A^YLZ!3M./ZB.JFZQ;"J
M/!SW_#]:5/F@./R;Z-W#*VY\-TI1XQ\.YS8\0S8[!.K.;82?^>W06>Z [_=N
M2R)LM/->'")6@_V6LC%W_ 7I!OD_]/F^X<:_U'8X5&3C$.7UH(N4/QLD7QPV
MG'08_TG'?Q-P%&@\MW%&^5[P\7S?]\??'[H)XCEC-9L5?%A.%MPX<@.>TF^X
M+O3=G*>N#KTX]3)(Z'_:X[MYO_MX=Z/T6E)-Q47OW]2.-R*J)ZXV61S"2&)?
M;?J.L FLV]:G]Z+Q'VX>/?1_H_!O",$0P+_=_YW3\=])QS_$/=OO[OD/7[]C
M;$1PCE[3'\K]AX+'P_7NUOV'B?]7_AQOO%TB<;ODNSM<.F(C[_X#6J4_M5EL
M3?7]_WHNZ8;@W7]8E?*=6/_7[GAHZT,6:L0>LOOHOSSX;SGR+YXGN/X&_+[^
M\CN9I]0@A_%S&^3BH0,.#\X>>NFP6WT\^O'0,I>K@DDA/5</R_^HI/)A17%8
M>COTZ,=_0;[[[XA#I,OFT'6'8/]EA+5_L>K?%O[//ZTPZ7LB['J6]N? *(KJ
MNXSB><=I#5DL<=:AL>>38C?<FLTU#+>>+%;4/GHU2N__RM<H?7],\UT,V[IW
M\,>]E@*WU>[,';$(!4'B;M$UJ3.M^]TI-I'JR0MT:LE4+_6^6 [Q/BKGK-EL
M&GQD9F"_V&;Z(5<;->1<E9=JR<JZ*BE'8'%M8XA)7'PW@:"/'"^D&>^5&.[3
M(HEL\99J4;WH54H1%;]II"2:\631-';_O9D@]9V/;PF9@L]\:YRXV*.45N9G
MWP3%_=H9($XL5F.*/&7R<%"D1^&+U^YE[O7@C^[>@Y\U4$ANBG7[5( DT[YO
M:<4F-A ST$;E9$NZ$Z&0:)E.U;YJPQ.0NKQCQ#4LL%X\("5E*+BD-+H&GPF1
M1=>:,*"--E9* U"=#>#G[<UC6B-CI#PSKE)!-XH'OT LS>XM@,HXI>:<7U1/
MP&_E4Z?1^2,GA =&@L?+M@!-JA%[N)1B+-O:WJ:ZTMN$OV8,3=9AD!/;;,P?
M.FP820QH.S'MB6"DS;/2N&580#'5V_E&'VCY9O)71/Z^5#(:BV1U[^3?3F6'
M)\L]]RN;K1VLW; %(V7Q,7:R5:!T@]>=.CK4Z-66LY%'6(PS[WU[9;=-L<WC
MJ^D&&N]X5*=.EIY&,K2;A.MK[;W#1 F>&X8O<^F:*5!C0OJM[G:'51MYNH:Q
M=>F(.!)07[59L1"P[(A R6:5<+;4*/[6W42G:;#+NYSYT4R;CB+)YFF_&'7O
MZ>4 P[O4M'K4_ME7SD&\J0ZPK@Q>HJ.A4F-X.]RKZUW=45O4::CW8-AC2A-2
M4>6&P81*#*(W6:+Y)P*'?ZES*'?1%K70Y,^DBN=67B5TP^.:5FSF0R'H0D&A
M_0B>SQ9I]SJ9T9M8])58_"S 0)!OG27F&R.E*@_\2%U,3=\Q %QY4#=8&U,Q
MHGO03M8$K9TZ/AS+VSW,U@\"&=;S6?Q DT\S'\ SX&X]@XE6XP(M2IT#7+-W
MJCE+EDPM*<Z-+.J K'NBRH-:R1'RQQMPI6 &UF]4,%[2Q06BD#?PMJ,N[!/0
M>R2N%#N#LV\72-7U X_SUP9<F><V:/0DJN\X1*,/'S]L9RE&[133EJAK.M.^
MYVFR'3H]?HP2F%OANZ*MU]ILL2N#D]1,>&0U_'J!<=#($#JLG@+WFM?"RELH
M3%03\E;RF.NBVZ*HDF2M=ZTN@DJ#;X'G'Z(_[EFFAF9V7?;'O2P!,J"%9J..
M%@FH)6>8U9[96,W&J]9Y$^JBBH.?GGI/@C#S;W$)CH&,]HF60*TIEU@*MB$9
M:G1Y)N]1$@4FDU_1>0M2AI:/DJ:*.[7SIQ[4!JH64*N0'T(IMUH9&WJ_)'#7
M7#EK#OM?!B W3IL'+E&,L$Q[#@_I0E9E^HJ-RI(3&4TNKA3\^P]^>(B>4&C_
MRU]JQX>6):LFP0-XOK:D98F2[]Z>9?Z&P0%JSA0(6E](6 -0)V;S $(L!]VZ
M\(;(VJD3KXH97@8'G+/NNN(/('034G";N1!$R, VJ-%3/+1Y)+?<]TSR2&Z,
M)G\OG$8I289>*L %QU.;ZA Z$G-0*_0-;4 ?W\B3F$Z?=;:];GZQ@4!U[.C8
M[ 2ABRZQG2)D+'FY^)+JZ=41L>)NO@A?.>R)#6>F+V19L^,9H[,1*4O5G)]9
M-LP?T@P@6\BS(!G="QVT]GZ"HY4:53^"CE/9'BTW"'P+K7]@,ZZX]977/<P9
M8H_+F(G&TL%HO0<7YO'@5; Q8KLHCM?HIC)V.X&3;;'G%R .%>( 0K4N#\#2
MI5G=\6A?G@<E3N<9SBO1A/AD&PC4H?4"1%_]$#ZE8J]:O51NA"M\U.=W%K^I
M)/QCE<QGU[JO5V!IC5M7[FS)OT@878DQ%/XF$/96)SP9[-<2U>T2&!9QG)1!
M+5!$75!S^"9 B1"L$-S+SN'  K7PM7;]]O;D\I"A5[I#YM+#)N2NC-R..K?P
MA/Y'#*'3L(&;0BBF..'.Z.BU4X\5O,+K>^JPWP2">2#)*W01K?WBWM+B=)AL
MC&>Z>0??V*&;Z.$>&>J*R#@B+^HXZN(1L#P*O^8N,24_HF*DB[>:O?QE!B?:
M4C?C.]DY)%9%V1K&?6V>O<%&EVGR54(Y0L'4Y#ZH04Q^KY!A,F,Y9O_!=?.C
MG<2M9 9#:&QL1]G.;,Y]OIN&ASIG &GX]WQ*X?)4JI;E2OA8DXJD:FKS#0<-
M)[J("+D??"73D0%/9+7.1WWJC!2'DZJ 5^4(41=^5@>Y[LJB0>7&5E1JA3OV
M3?A0O>Z?NR$6IVZ7U@P[ZDS\'"?V;H(K^C*AT/)]%Q%KR=O3 0VG#V+CFN$J
MJI6US;R:%;3R04;N\$T6 MA!?M)W=9-@1AE<;G*NA/5>A(%]XL21PY<1/#&J
MGO_?KT?A.=[":60ZV,'85<Y-BOWZ+$>2$*G^TTZ$\>#$1; AK?J57;LCJZ(\
M68CZI!M(G1'E9,"Y?@?%$VM)_+,W^G8Q,A19HKG3BJ%7\F?7J)V@9/7\;;K5
ML2!^X)L&LT%NN7VI=.74S83?RLCESUPKAX)G^LW3 "O]@9(I$K-U/WG_L$+0
M:M9F;+"NYF[3(5T39$K/23=?SKFD39ZS7_T PLUJSG^UF.)).TN/THN%Q<:(
MAG]6NY?D3\\L&M@[FWM_] [2W#\L)2NW6L61*'K! TJE/$3KQ%A0'_D6;?>]
M? H,'!I5=+.6&W3(I?3A^V>Q2MGZ(]GU$=[Q%VXFK:E6I/[IX\?9=I48&*+-
MFH8;0K><IF-Y[,]63Y-CE/C(T]9#%C[4[H6W;SD.5?5<C<7%8!E\^4IWQ1=B
MY8?A>ZDK!1]VF;D[EJ;D0! T3&SX788ZQX[5FX+!X>-S7"UCW>^LFWNW@6W^
MWD]Z!@I\Q&RQY@EBFIUX[N2G_A"S3AG[TZ%P*MO&R:]EQ\=,I7GX;S_D213;
MRI&(HJ2;PZ<ZS!(>,=^C@=$":,:YAJ'ZZS+;@7PCO[#\=V.4L4X=?0@ 3?9=
M;6=O3&K34 LUR#Q8 "5L-$;25D)CYG52+ZUU1147?::4.)7*#'QU.$VBNJ\&
M03GX]?L$P6'9-/L.MM_SX0HUDLFFC5D_/%_2K39K\MB@VA_6MQ[U!C 5)Z4A
M#*A'HB-)J@SL!@8 DAZN_R%;,K4?,+1%P(15E##MO1_1:3F55Y0FLX&7!D<C
M;,U08FQB+<\%Z>4RV=H=27U797!'=V)^^LC=M>'40;[N&(>"Z2LNN?_*]&C[
M\93R?.4LJWFWM:H#=@^DQ2)'<W@?%4-IY-:$)Q3'B?/EC -3J$-!&.4 &SFP
MJ=HI""XT<S'3YB_+Y:9/TW\5Q00,UN=.FK0;8\ .Y8E:\\$YH7CA&JZ:>&%Q
M&>!Q<1W/$@FP' !<(I0GAP,T$BF'?6"J69[!%7)6Z23Z41<C1#A"-WID&A&+
M'=0(<4PEW$[RN'%/>V[6!KIN2 O+&UL:-)^630:'2S5GA.0K");>PD7=J_Z*
M)P8<HV5119[Z^VEPE)-Y _$YL!#O\YWZVW\-YL$:0]R81@@[) 8D^%:#*N:B
M;$-)3NOF1"=LTN_HAS:=\<4CGK6^^W&XE[)S*L!/UB66,*U1GRZ6.6M\'XPV
M2,K? Z;<LJ\&SG<6ESI78L5M'=9/+)BJY"::P /558XACT$5\;)X^P?9<F#C
ME8]_R,JMV\&W)L4XDVN:M=W^'XL9H5KRU-FK8#0)QLPF?^#VAI8R(IQ7Y-;B
MEI:&U+SDC#Q#A=M[P=W1E\'+A.:!L0?1&%#@!Z@A#IH%NS&V2OLYPZBM4PFQ
M R)3\AFP0E3#)AG34%@GCC&">K/S F14L.G3#B.&8G"%H5?Z^I]SYUJU&4(Z
M'I?IMC__T)U+TO5Q4Z[2NIJ;;XN;B!\N"O_^GO+ONQ%Z%FZ40 >M<O. <KI%
M%.3Y$*>R'TV4:$Z4WG/J#+?V'M3:L:? _O 5T\T>&$0EUNJ2G"8?89R3A0Q\
M-]L1:NQ+F;RI5*QNA3'G!KRL9G@\5O\,1K+U1#!;PY&I$EJ\8[.0D%^!W3[2
MME2 M \9 T91J7(4O)^"C0ZA(ERHJP<84#_V3H5=S8%:=:-\G+AR!&^9\QU%
M0%H^K4M(2,]A:/+7:R\FM;]NWVF-FZZH'4(L42\O7THAI3]+$GENP0YU;0>#
M4=\_,[9]1.16MLVZR1;*!)7LWFT):'(&4&IVSM],";+\B<."0B8&$-0)*K54
M'RW;)DH[\21.29F9J M[.P#Z"H:ZG'4<JKR*[92F1P9/!;J:/!A=/5*JM/,*
M?1GEGWEE8'S1??"ZK(KC=6X%RV:M[7-2A+;IT')*9JV+9!"\MCO)1=)9(LB1
M7UGIE7$/"A 57&"(2NQO_BTKGS_LJ(*TU1RV9$@.7T6^DAY\D_H>NF+J46U8
M3:=/)E\(J#.\3W,84^2]HZ8F\Q^#W4M1>H5%S24@K=VQU08U!J,&JY5<FYAL
MA)24H,>NA3XOPS;$(FBOLJH?9:M9!\?3,K2'FB1K5(B61MZ4YQ"$%R^M>L3V
MK/*G:U(9 P?<'"CT%53];RTC5%'T3U<\_9XZ;A3'4UK+.T();_[JY.TH6+P=
M([+Z*2K6S.Y%+=VL89,%L_(=LW;P%E['2QB8H[G6 87Z(L%UN B0%3[L7(IN
M$O8-"R<=#H'39AZ9U-GPT3L%)\'6E$I4^05['%LD9$JJNW30[CJ\P/-WD_B4
MB&.B6=!^U_426\!KL^[37AZL4<]&N\DE;X8I07?8H9IR2P_2UR=DGQ4ZFC%;
MRCC(XV18GL[=OQZ:JPF-=F"<Q@T(!=,>(F8-OCX,&VCP0)5Q3Y=IYN6IS5DD
ME+%42JI8OZ6[GL?'+Q1MFI3U.=CV%:G:IXVOW4ZI7AWF!WB%YS]+[)7K9K$Y
MZ@-,6O**:>MA'I0&E4.KZD4=D>NU;\$2[9QJ)ING2XH*@D2QM79:]*OY<R1W
MJA>/G/2J%SY1@:9N/V.D9D$,OLQF;W\\!K8=R(7C/*ADQG"QM=UP2%4SO)TW
M"520=9R]_.93YUFJ-\/FFP!Q>Q'JUU29M8K#R@54.2M2><')YD+)?GMOI&^*
MQKY.2MFF<-;/?'2HIXP)&W4L$Y[3P7&FUWLSE1U>Y2\JR&*E]WL7J(UIHH76
MS+]7W4P+P+=*T=8./0;^_"L*GAGU)T/T"B-D4=C<NW_MB5HBL29:,U2^W,%J
M0)4AY>VXBB-E+ZNRO#6$#D&3FS[WP6GYTI?^#BB8VF'B2NUKF<LU(U2Q1&AY
MM2,'6!_X ]2UO(<0:7)MZOW\0X1"S(!7\JT.WV8IBWD*#'<0"CP_/"^O:Q?0
M4#2OEFN1LC'3UK+PX=A?:Z35\=JJ24LYJ(IUQPQB!PR^;C%M$4'2R.F4W<K[
MT+@KG9OJP3]!;@G:+@VG);,CU-S%UM5-L9HKH3.X\_%)8\G8T-4%UDN9PNO6
M<@X #?MV.:L?YQ*]U0$;Q,JV9(37E8=]>L$YFN&)0?L5S)-\^9\_K>Y._G:!
M]&5->=^#B8F &U[TE$NKR6STS:HUE<E.DOSLAZA;F;MY3BI%^U1)EGC!C@OO
M,M]_@[\,L76D2&JF;*61)[P@HLPS@2$]#WNPQJO\6[.K#.OC34U>W5FW'.W!
M7;HC# E.( X/7_0P^&RS*?(\C%024"_N-6X]]4U 7KV:ECYR7)K:"T1#@_2+
M@*58='_D!?D7R_MT4E&+[U?C[5YRV+S[@ /[2M6M^5Z_KU\J1S^+-HX;>RYU
MC#/G*^H&D;/^@$TE!5J<ME?EFUT)_JT[>GC4?EO>T6M<EV3/ C4,7IBW@)$-
M)T^\DY0N\W>E9^=J5XKF;G9B"^@;08" VD6IA('?FQ?+EF, O(R$&A6'?N&&
MM G] =$,^T'7%5ZR7R1[N#E3K+[0S$Z+M(\FQB4J5'P3R#:U'Z*5N,[-F$30
MA746WX7O&PS[.ZXA-#O*/<]RIG,[!Z=9U&Z^6VC;6F0H'G+'D-V'3CPQ.6[P
M_/:$+Y!#9[&GU!@W6'Q,QIL=(DRP4:BH0KZH K2*WG2=LU(CNM8_K5R95>*K
M;(L9NSQ\XWF8\X!O"]%:.>@]9-/4;I-JXRJF\(/;9Y''!2+AA)>4L!CHP5<C
MR0^>M/3<7$+E6;-+[B#J(BBI1Q5-#^4K+D-_4KC)WBZ F#&T<'BYP1\02EQY
M_WC.1X2:7">ZT*5I>[R4J\_CNED&DOI_0<*NN-^"-:@Z&/W!;;IFSBP (KV?
M7WFCHFUIQ[8U$JMP2#$._WW:KEIQIFW.2OI]%]//E(LM"$"QZQ?M[%[>)-YS
MO]_IV'?.4AY=L>-\!^5%GBZQNE?H_'\3*0VL9S4@3S*S+7B6>)737 ];=?.I
M/NV&9/*\!W(-+[86"5Z5Z?C/Q$FWIJ<M8^2+EKZJ\&9-3T.[Q:.%7T%DA-Q.
MS84A4)P]Q-[='BV:VUB%2PBJC,+6!&$RP\>B M/KZ=JZ!<MB(<KOW*ZC4U8[
MW0O:;RUR@3]1+E'8PT\\R]S-3P(\[^B[;^N(7FW=47-_S]G"N@YX+C6Y.5\/
M+"72ZGSCS*&:ZD0WO?2?YY=3S='SG_NJB0>=OKCMR5'&\;VIY8(IRF2H5ZZO
MNK!'FHNX6/R<C82ZJ&#^9[R>SI&J,'KAT^)) TC8(VCMO M46%PE6=XO*U;H
M0B\\%6HUHP<O(+5K2HTJ[),CKA@T^_UR[;[,[2,TYB(2RK6^8HFJ;A%+^29P
M8SS@I*$_C H:C)8PBV_J"[6-HS>/Z^JM_F!5=$\!(R-N;BZ^B]EL -)OZ^$C
M)UH$T>H!-V4J"E1J,#\\B5&IFI2S4,<5.UHUNHF9;D@8/DG30!D(2_[YX=X(
MR)]W&#- */WO/WR^N^<[>;\^$%PKOC"+LF2 ,1[8CK&E>;-G)1X9^H)3 &.$
MQ^7X_%U5F^/?!,QXA%1M''+68B)P+,_*]L88MD?%QCN-93-,M/^I"R#T.IY,
M9KO*VEEH,T(^6X3(A+:1\[\)?#IF%$9J<!@:#?-D8P":!9@Q330(*9S/"6*A
MT6[WK!8CP[Z>>/:LJAU)$R\>%-OND:C(J=SMJ8,MNF:,YR]67AE]]Q=2-;BV
MX'Q=Y[Y&.Q^7L3HXKUZZ]8@WY]86+$ZE?Q,(>%I1\HQ:9S<TS-F(8FA6,=*M
M7XV_X" :I(BD6UP?+MTWX!:E1I>%>&QVMM9000?V(WNQ-W0BOU=M\-;;_6WN
M:G(E7MBNQ'-PJ!D5$=Q4AIOUXXBR(J&=,8TX\:+R?4A,[J1["1/J0I&TM[6W
M>6/9UM9?O#;B)7RJC39.F/HK2*LAONY%N.JB?=28M0H,ID0B8\2=N!(L6#"5
M 8B&G38R/"JY8LAI"2^+2$KNA+J1BTOHF"L>)=0M:*-*.%22$'VP@5]NRFA>
MC<NAL\?LD6Y9]'&Q?I"!YQ?_7,T=!$L[W2OX,*E\_DK7P*_7K:1,E!JC4U3,
MWJH:J3=E:]S^P:,.GG^U=3%=>G'8&TZ=;\25^Q!>GDDA#0Z/S?&H?D JG&XV
M<L%F8B:D_[0KXFX/CS^Q-TT$]]L5[99[@8N(R7^AF?<=0]2[.:NVYM22\*3@
MLMQ0G[ \ON1!5B*I"(^8OD9%6:KU2^2TTJ%7'O9[W^SFP WSKH>AF]XI$K@W
MBZIMVO%=L3@\/70R984%#5E6ETII )$"];S]&Z=6@Z=H:S_C\",G9,OCM)K>
M>,B@/J&"2='HYNUCN+$*!^UN>4<7/]]EKNR.\&#WZ/GUJ%ZHT3TRIH\PF&_8
MZW99)1#M54:E> :B(XE0=,N1$BW@6*]X4T-22?F@N62ZB)>5)AU-\PBM$\UN
M3)GI#Q3+@;Z$]UZK'?O%F:?4\9ZG=.M9$\)KV<7:Q7*X7-82[Z>;Z:R'%P+8
MYX)^)URJ#]NN&]HKO[BBPHM;JF0FK):0/2;:OGR2GC<4T<'4IXSXEY42RU@#
M QP'8I8@-C%.PQS2S(4?TDOR\XITK&')0/76PP',/NX4F0OT@J/:[^>P/UJV
M9[J> \H; %H_&<\5?'G34,Q/&WL4&CXX.%IR#_^IQU+V;[K4NZG/N5_4(HKH
MQ\+'M97,IR[ ]U3,_2@I"4ERQFF<CO*$A#$^8O918?V*8MA$KX)720F%SL[J
MCD3EII;BJ*.;"U1JR)537.W+C4.*75:G7%8-,\>_/A_FP&\/2-9'K0Q=ETW.
M,J4]28:V;NC@]J.CO*^J'Z2ZZ) J]&X&-+J55[JIBIZ?2-R_CTGX605=F=:1
MM 818Z\L]N)81^KGAQV!?A(1E" 1H3%98T>884ER[&B_!R>X*6EZPM[63T^J
M_+ZY?S9*CR;C8%JNW)MQ#U8I&3M?Z"Q>?VVUX+!3TC",VK51U7 5'73Z*4QM
M.>_S^1US&03?VR,[3KY4?YNZO:G7': 3-+Z6I65YN[ TH/[^JG<Z*M<GRH3>
M]B6MJ>N)4]W&Z[-'UV-JN7NVNO6PP7%*]:L1Z)MW.?BU'ORO7/^&TF+0:11D
M'*-"KRI?F_'2A_H[2[44!*+7[[Z(^$_,8;E^,0Q#]E38F)[QH-'IO?0B;5.H
M+[,^2ZOT;!$Q.Y;<Q.H.[5;X7=YHP1/2M(Y6?VS%ZD-(*R12$E\U8%5QV94;
MO#Q+WN>ZLYHT;VTO^UC1J]#N<&_Y9],Q8'03MZEN<(#38_,5J7FZC)STX^*5
M7XEI]B^1VJ(1=9TW"Y%[NDNH53E0>M9+4Y,#BO/IZ!"%_,HE0M*P;=@\>..&
M5H10PDA@Q^/:B8O7H=0 $;X_U+1CKT.ZTIXAV3_@9I>;&L%3&[=^?FY5;Z5[
M8HUA7\O&]R8['91 UEJQEN^&B5?>-^4L>,,CB+6Q-;X^_GPM0:7'379:6.X'
M,,%T=A![;?(*D%J'(FF<>!U'THUWEE4S]\!!>G$  !UL=9@EJEJ+#]R?@;F%
M33A0J+DETHU*'N:>L.!2D?P,@_CH>KUACB\RJ'S[$YR"6E*Y$M7>= O->I.
M[&7M%(C-Z'%ZIEP&; ]$)BHX)0>:=X,L"P01JXPP/YD9B_C"LZ_;7^6U)>:
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M#>I SV+-\Y0 ]HRKN75=0EJ%B( P1UY/7TL.L]PYA)P.SX:];2ZIU 8F>\0
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M$>TV['#8]Q$@@Z3G_>41-Y.$(Y*W;Q;8C]4YMM R8NTE$Y.FO)AG4O;$#"[
M ETT-1RB&C[3;<'P4O-8UTI/:%\D:_;J6H?.D9H/:54,J7934%=F*.PR98+L
M,3+9/B3FVI0)PWVMGW38.MBTM^LP$&9! >CX9J6>-+*6J#-TK!X$F_2*R+>\
ME5C=.ZY0TI4,JVRNZ:E<E[YDDZH'<6?K G)+[5VX?,#:KG)UKT&'_)NR(*>%
M(I!H.G V :JS:?O#L1S)-8L^?-AC4D7T]FB9HG* Y\2-%GTG'$3T% $Q5#=M
M_-= [IF\(%U'E=JI%*]:/P3>X;E.]UI)2I]3CFL;SBW5KK39_*-FH;ED$'9H
MJS[(ULGOW$@P&Y-DQI@LL!1RXCA$#%++'F\U0(1"8J]>TS!()YWKA1YF_]:C
MXH6&FR1<67B1$@!RI5_"F9]SP%VUIF'"]@.8HH:YD6[#@\.M"<-_''R)9-BG
MERJ3=(J*% \CTXCQH+R77FQ-;.OTQ;K[#9*HTG+/UB]VER^<Z((M&URC84[$
MLY>1D<^8(/FG+0[&!Q?$L[ZL>H9'XN%;#E;4(@87;^61R@3P[;?P$RA?X*WT
M7%T?QZL(OJ/V0++HZ16CVC&5C^1A9OVD&GEE;:B>FES@P<VG<;K9JXZ+N6J:
M""\T(1WXC,PXP:U&[?2'*LT6QV Z(J7CTL\5T2('KTY4W#;$DQ-IZ]&7SZ8S
M'9T#F&8J^&RLF O>1#=7AT?T')P/SE>&=F_VNT=<A!N8^]5- ,F7U\+PF*VD
MQ$0G;X_YV&@I-H(Y8V2W%3'@ !KN6-Y/;J]/M9^">*6S8(K6$\\K#?&].ZHK
M'5?M!U9YC,=W\(7FU@;D)P7("JC12H![$7HY#3Y,W5$P+ GE18IW;\0PG2X7
M.(?124P[$(1.+LNI-$ELBJ>CBT(-K_!P8#FPB/#DY6<$5F-89=>-COIGY!RH
M.W#^=4*_XH1OP0%TI"&V2&M!5.DIF;QM,S=<X:G<)VPP:M+S\6.!FGF/H-N.
M0H#RQNL]'UI)5KKIBT95?]MHJ]O7_J(?\Y]B!.)'ZCUNN 3L-4\+1A4G$VIS
MRY,6RATZ70BR5O(QPR'+AKDV,^YOL4=[ 8%E1;2G?KI/*@#XD$J\:@_^=WXX
M($K-O<+]"8$Y%J/(W+]93JWY6J07MCE*NF\NKIP*4Q>CQ7Y [VQ__M07C-;R
ML!SEW^KP%;/DU&8M6DLH*<E0$Z2&65);IC=Q'VD;][(/7+ R*YVVWP0VS'0V
M.PQ& _86O8;'SFUG8K-2Q*/_MOR!B=7-,M2%SG2S7%-FP"B@&LAF:M9D;:%P
M2#0 ?&9RR5K1&VD*336L,S7K$X_6KZ+6S:VH@5:-7<WH:/%?( '\A@!= Y2E
M9*5$9;M_P:>^N:T%O#/7K)G1^2(^8>)$4.WP'LXPH6; ;DKXQM KT5.J 5@#
M!1NYK;HTJ.BK](J;MW@6>S%5G$WC'5/E<&PG8P6A0_W[FF#2!$O7,*7EO8O%
MG4G8YS6]WO%O L>Q_?QSS-V3]R[6^GE<J!N/"&@90:T:F=O;<=/>#D%GDF?P
MO59> )S8(YD;;U%2R7NOK#@05%+LO@T2V#A<-!V";7+IO9(2V2>9B996M3^5
M.1<<;M+3P,'Y^F5;H$X!3B<CM2&VSF+UCA]@Q,UXY-8$<E'4KL%QJ0E7BE$]
M[!??!+Q*<RZ8@VI-2@R41\&FRCYM']Q,DR2J7XW5M<;QN""HP9DNGCF7E$ZX
M%<7\N5('/M=K95;GP+\@-= C9S+"U?%*^]2]#[V2OT.EY=.$T53:&$EN$%6D
MV_N '=JZE7[!V6Q;IW&@%_X$"C \;J0RVO_1EMABIW@GW>?"O;+ZZ\O>/LCR
M!HX1L-/-B>!AV=KX>0X,=N SXG=P2_Z#:NNW:RLG(Z8M1M4B?ES:.BATH)?C
M!OK !1"I82!(5#]==J<8?>2=OQQF.BA":ODIZ+0_'^T(>1E,S"*!T64%+HZ.
MVDJ$G=MSQ7]+VWQ9H^/+6[B2'L7KP2-397RSKK\\9-U[3D0^IRZ4%B6F! 5]
M*4HOZL64-H^1US2#EGV!,YX;U]KI*&#,_+'\ZU,IV.:-OT9T;\^@65"'T74H
MZ)R7^4+HV*A0F@ZM%P<=-"%\8IFW_6EPNJ2D)0S1,C(8(M?1=><PZS+!D3X:
M';TF10>$MKC?M2Z.4*;>_-'#<S@B #:H-80+P%@J9RO5_#W0.IJ?UO6SV6/P
MS$IKD7Q,M,G:R#AU9"LFG$0,5U+=@@P-55T+R^C./X/"CC7>09'JZKCGEI#]
MH^+B\.3T]!P[+YM=Q'P8[6.3PT\JSN1RQ^58N=->W2E9]>4AUI::*Y[5:@_$
M:-G1)Z>:YRW]BPCT6A+0P@Q.3X^:>IP<7T!=5).UC1YP&4WM^2: NI)B?^WS
MZC>!-^_RE@]^!*&I=WH__791<J()[%P-SYKUJ_!\6S^Q^QN-F*?BZLJM0&U^
M/AUA7K?I,Y64U9,9$>G+^*%&:<$/JH14[C=_/H_2B0&9-!@LJF8LZ4=$[/]P
MT!]CA5KU>,H*TWM*IQ+CBJKN/TK,\CV?^!G*.6VJ!&NX_ 3Q_;D/L=9O%6_A
MS/!2\LOJ$0Z$]M(\YHEI&UC;[,$MV.7YQ91VC:^US*'1+6M28M;'W#C"^3KG
M4+\!KFZ(6DE;(KE9 H\[[6):LGK.)HG#SSS'P^HVQ#WQQ-L;B8$V6;_UN=9M
M9:NZ/5[5*D6,AG\3^*NF9/";@,N"B)*H_0C&-F,(UO)3' A62>NO_EL\?XE_
MKKK2]W*."F_=U,]C]TH?R0^PO,MV]?MXOC9[NO>GLJ#,81QHLY\.!<XEBA07
MY,R@6#$*ZD(Z(!RLX439Z"0H<"H&4X9)(9,"9C(YS5Y!1%J0\P]"3"#A_AZ0
M/"5E\:2;%8*?D\S:\@/Z]=6.B26=YN(==]>;$.GC/,A&5P)EP&GM^.+XNV;Y
MEQ.KUX*:7,,>\^'E]6BX[E:N8(35,.ZWN3 _CKSKE!HZX6%__8KFPGI +,UX
M_<S8Q$KF*G-@0LUAHQ?\"U'8RW\ :%"^8B.+ $K'2%_P-C?N8(RY7?1VZ?_I
M$+^ .&&74@Z_E<#)QB6K5.%%']&I.95,@RZ\ZS3DQ5!>+(D1EI+2$\.<6##9
M^/X"1%C\Q&R"2WZ1=\N)Q]/\E/8&W5 (CR8'_B9@-#2H?$K$:EDF#A/ZB>Y>
M(5A1-U?7K; 8'!.@M4J9*("5KN5J;-J65+ !DEB[P:&H:JJ>Z#T/!Y.&#)B^
M3C>P:.\^V-H>H&F;Y2LNXH]B]>/2Q-@V'*CKJ_/,M8[D!D3ZM"E5!01(B3AV
M,Z4RL0)-%Q+O'T3LR%N[#:H6E=HO2YYB;CA86@<V.I1QOMKCSYF-D>.GD*\3
MI&>K+W/6- I@ R/@:<U8,&':\QG#H=BII").=IEXVT#4X(#+S?>2H&4>>SXQ
M:6"$;?:]0 .YA,UE0KG*FGTY%U8>U!%=*4*N4ZIM-F;-R\_?+*]OCUN#)0"<
MK9I0QVM44DI1>.502W91&W0K.Q=M*R(S]=%YN0S0(!? FHC)IA<W5"DJU3<?
MSS[[9WP=#+AX'HS8=.A7?94SV#IJL+!>N[WG.VT.@85A]#%"Z&@;7!%*1Y0%
M@0I,G*H7,U!M[E EU>Q^$[CH^#QJ)=KLR^PCYJ1WEI[-@V(08BL/1"DE95E$
MY?V,ZI)!,[HVA\.!V*J0=:24)OAV<FZ[M0>Q.)OL>#W8WWQ1.4,J:=@MK/$C
M-;'.]=6-41 FD+ITAY(3C-^$PN>VKY6GH1?5*V)7P*Y?0$O3[^[5JFRIHZ12
MME%^L5_]0]BC7-WQFO2/9:Y)H@FN=!L4Y?&&@B]^5%4KYN*SE>1RMD/Z^ =2
M'$&)@;2\(&E'%(Y=.HP&$ F9K16M?J?_REF*^H4'^&4FOCTB!]HDHFET.('>
MG_XR^2)HO'G!U^!:\.8I0C'CK:.7T%]D6G)J8%3I6>#>M3,_WT^G ^LN:)[5
M\/$T#I5-_KZ3HD9B8@'+2JW5[]1%TUYQ^;24Q$6?Q)E@:JQL&<L!"[6S6IC_
MA$G*EMX 4N5#UI\<,I/7G1/^81%L8+28,AV>2RA,Y3JW=MXT0-B@O_P6$&!4
MIQMD_KIR*JAVWW-"W_RTM:6X3-Z'Q_UGO_P84[-0587J]I6O0OJL578^Q Y:
MC5X%X(1>)RU54()]ZEWD1P)*%KY"*C"G2Z$HX%@)P7L84K862]LJL%#.!R:U
M+\]T*I^O36&+.=[.T,667F_=$S? *#_GF(QAXA0+7BKAG3A[B"K07$+O4PO@
MI*TO8T0CL7;1U-SI<X&>[P+90S8L  PS$*,11(P1%>X>-3R5<0HQD",T!$'E
M&8"MJF357W0O?9[#TH7$)N9'H39MB%S3VUL]F#MFUK]X99E[D,J+>%3=[&#6
M0$AWE;9A+3%C"JJS/_U\[X[EZGS NAE\W+=^C!374AZ[CN.DS4L0TNE"0A.6
M*5._RKH)#3OS ;0;+Y6W:062?>>+G0KE $;R?E+Q.2@:-+AQ*#M($]3,G/Q,
MV3X^UIS&E;1NC4T;(HKF 65M ,;\RLCL;<&(O M%UW[#>7@RNB["')<:%RCJ
M_>49@Z&P*;#)0=O/K5_F4]I#0A'ECD-F9,IX%Q5<<'],,&#H;95KX%BAW1!'
MJ\KBMJ#>?2W#<XS$I$?J/87F47.9]4D' JQO I->!S+Q>0.?2C$WWVJ0DDJJ
MV/#H3^!>7';Y\E67-@)7!_?WE8"@@84*,]^]_;7L$;%$PO]@[CVCFLS:]U'>
MT2GBX PBH!2=H4H?A  !P7$D]&)(0B2TD4Y"#9V(OCJ"$-I0 M*"A)+D"0E2
M B00&%% 0,! $B TD9K05)J"Y3B__SIKG0]GK?/[>+X\G_:79]WWWM=U[?N^
MK[T8<9>OI1P7J1B 46#$))9F]T$Y'UPOG)D\DF*@$[X/UTM(_GSARM K"@XF
MA9O<.G\Y0:= LGV9 +-%BC<'9RSM36;09;7-$$=X^I1"X;8MOV]CN9$E.YQL
M8.7E_/H C!A49+?FY/J;^+P:,J?ECT-4%_)O8]1&1I2V4[9<__G.D6(J[RA"
M59IV^FX*Q 1K'Q*IEEYP<K(3/&*9:('Q7DG;LQD<2@FTC%,COB:5N@\HLA8+
M2H',%^E'KO6M^ FR-[)^9GH.:+?<03K'/$IQ:T0,I@MHI=3)]&7X"D ;_2&]
M0C""\;8(FV?I*6@P;$6.>Q9+<4KU.(]O'5$'AS]LC3CYWGV_];M:+\T-U=#$
M[PUG06?4:^\@8<IZU]1C]0?))[E ITZAC^,KT@YE,QE+8")QV>J,DE&[:5#8
M9BI^&0*/E"'(7"XNICKK_'B'4&S_0?'3%I>NA=C<0B.,M+LE 8.GALXCN>^&
MYNGJU06K@FE%N;?1D9A$EL[9I?=GB6:$WT?V3E4^HLW20?'%[B9I3:5$&\C-
M]=+,&_A\3073;-GH9YQLWQBQD>/_Z?+Q'F.73CO,J))I)8V&1K//EON<M=I_
MJ 3=GDT\NG#E\FWLHW_V5EAC!\.?VWL;M)>\07_F4JH?V2WE:Z%_*T$RTSE;
MV)V^1%1%^O'"\8[4NKBPT;2AVVTSJ[G:[T.!&Q\4TML'V\!]N#?QLJB<"4@T
MN0T^0_VE'5[W9TU^?*L';*<>,=1UW$TMHJ]-.+79TI;]S?Y47&!KXG(M2N'[
M\4ON;S5EO,HOCHS<>D/+BM<NV3J:L/<D[6_'4%70O.G@NOH\U0UQ'<:'6GE*
M@]G==-UT^?47B;!Q7B8RH=U-*$K,JT@)V$RS4G<B18.A1@.W5?.D8F7<FFKS
M^PX3&M7"AK$Z"*#$-OBI\LI=T2_Y$9:C-FME3A\=L0$'2'#F4.K?'#_?)&3N
M:S.YV1&43WI$_7KQU _4"G]T\)BM#KMU49"G;?'JFVL>VX+-JS:$(EJJWDC>
M(#T<HC1<!/JW!QJH<PG(-SD[<\!2Z*OS6M67EK9 .-F&[.8N:4:$R248W4L,
M+?W Q26O'F+O%*YJ_O/@Y.V(=QXF?[DCK+?.R66_5.TT[Q5_2/[TFZ%S547"
MM1N^II)TI<.+=2E OTQ!8>PF?)$@(R;2AF^9%90J'*8HZJ_&Y@E:'6B?A%.V
MCL?0U0Z21"5M$[G%DX7]=9R^M;6O9#2<'&Q<<W%&MS"\(EK(\2]R^B)1&#+Q
MM'Y)!&:,6P]?E1H=GIHP?TU\@'CZ?9!,V^5?PGXJ^>/!QCP\13"_Y[+J%3[,
MSD5O"K%MJ&&R*$2LL#)'(V,"\K![-F#Q"@EX:W!GK&H\J=+.X!/.\:/+%XGK
M9*>6/N[30_)/;]6.)339/'7!KVH>\R3@BD_<WS8<E.*.R2LV-!:RB7RH#^-5
MN(7.649,<X[<SF[QY<<E,(_8LF[WWMI804D5-4ZI-*?5W+[.;W'UAG4,#B<[
M$I2T8PW?OD1-M@@Q%47>5&F$_4[/32W^KO'R9FZ_EOE\7/G7U,0UYOP>7%1Q
M-:S[4H)GQ)DVN2<JO494S3"JXCB3L8#H.2S<2-][N5**\E:GOJ(D#UQ&4A4.
MP#'%:F$0Q&@R(RG_S'^J]CA6P*R>L,SVJF_,>++-K$,!7P!E<MFLD06$?T"?
M? %7VL)2'JAFJ43^]<##TS6BNA0 @F"P/R:L[.NPH"QT# +A8T=\K)JV&#)=
M:5L6KL$88Q>M(^REG*+=A0SF"6-8X]#L6ITLPG"JTO$B-4M_<,Z9?SM#.!J\
M.3R<D@R1.A80<3M)-3$/8>EL:]#U$$3_O. QEHF 386]*"J(I(.T],*'A]WU
MO*@#"J.3P()%7F+Q>;QRO\.:AW+WU7%F>N% <C; 6^)96UL[X::^>1P;T<&;
M+(NE3*#N64:\'XL#PE$U/Q)@EKZGC'J(JY=]O[.4N31IV4>;L93[H$\1^(:/
ML_$<A?*+#9'^;V<+^Z*',I2SXA6-7Z:<P\Z&=CA'G#[#:?A&,_A@8.?SGQ:6
MAE[##7/H6:7E5X_1)NQ5#/I=F*PD;<)Z'D:0C9X=L!BFQ?+V,Y5V__9BM+B+
MT+-/796]'55BQ?ATRC,LB85=V0]F7G;6&NL=::K[BQ>-+9U.BCQY-&YVVW*[
M0A%Y([RN<B).@!\:UA$'MPR*J$I37L_\"3< ()V2L]*WO_KXQY9Q2UT=('P:
M @/I6;>,U0:<Z#_)S^EA)05*O0BU*OXB\2J"_/GH^X7K1A<&AINO;:8V?<#1
MQ*&D1W<1(UY=R'K[-*95R2!G_J>;M%C+OV"1=;6Y'N@D=#W;35ZSL?5&8.SM
MJ)EW,?S?OE(]A&_=AI.Q (4?:&#693'7IRN.&SR^,?:34>.+'/<!IV<NX/*1
MW03)0*0D_6L.9)3XMB7/3;0KN*3MA"Z$7\Y>B%7*"UV*U+19VG+_M-M#5C_F
MMOL,:*@;.XS0"7?B-;MB;Q10\OR10:8W96$=&E#N=BP:-%)!Y">]?@"?4EYA
MOG4=M'W3(&E'75P#+'8&9@L-&<49GWM#NOEUM[^U\EPFZRM&TM;:?)W_8,3J
MA\F7V@0J&CO>7_1UJU.@Y3AD)6#O#HNTHFA5O",_83+U4=A$S@G%,W@>-OKI
M0+2P@M.E$=RE2)H%N+GMUV30$00W==#Q4Q!W-L360";/ BHMFX*YOUQ>^C2%
MJ?X= YA:'V[RZ4IK$D_Y)R0'V6'Q%8-X_+\?K+G3XKMAH0V/A+NP41K-3&+>
MON/:6WD7MOC-D8$-\"G&7GD""P()%F,IUGDAH63,33+$-3H570?CG,V.N(5S
MZ4"&AD.YO8UH9R,<HTL44H/!T.7MS4?H *7<CCH W@=+R\H_N&Q7\_! ?S0T
M+?+2[YMU BWHITV]N+.#V-?BB;\^,GZV^&E@K\KXF_53C7//DG(KW_J/O7KU
M>J&?GZ)_.4G!PB94V7;LCQ,@D_JNB:G=F7Q6ZY$>PX6J)&#!L@=9H\9]"%GD
MR9PSFZ)I==3N!<2ASV75YE':SN?YK'E%55<IJ_'0[\89_IX!IWS'=:2]/[NU
M2]G6QUN)6@09(/U9\<DV[]\KPO9+J<EKJ]F_,9Y"I>7S Z%0;'H[?'LX;H3&
MX%DJ1TQ,P! >^C*>B'=757U__'N@T-;_8F86:0''A3JWK*JBEI&J4 ND6?^=
M5[\I'ZXVES;WOYAH;IO]1?GV"-H<9],[:2 /? :("J:.EMXP?I+J[# "AVR\
MC&R?*!*!-.U37(3[P][D^*UY[1JMDX)SM/+,5"_2_B+8)X2W5!(/%\A5Z#4<
M^(;^$BA[I2R4?N6;#\SS7IE8@A)P +(J@<K.U;]SM?>B:NRK1M%17R2N<@<B
MR6GWT'*M1<"\9%1KQ=I#%[D#T,"PU1F?D$<>G66YWPVO:;A><YK"U,));6[=
M^I$7) $=UC*4DCD_'%7BM/1/&$>!MC>LEN#]G#?AF3U6=1I255=!3ZN0M>R3
M!4I<=OU K+>;NB*CW"'34$6WC(T[3:%]_!7^AT]7Y&Y_ZYJ5Y[,\M?F-D7A3
M#S W:]6SKXN,FYC5.Y,='D<2:7KPF0B9#%FPIE6_B@KIS6K&&:$%@5K5'0;9
M^H0FVCQ!A*)*DQ2 ?A*80IWL+"X1_K\FC<SUM:ZNZJJ*R//>>,FM;T>MCI=^
M5>.7%N=^-PFV16?03#!.KE!C@HS5.=DQN^68BIT),@BV/&95AU8NXHV/.ZI?
M?A%P^9+U'J9LY_UX/CGX5VZ3=?Q :(3LZ$B-*SYXZ<-N*=;4?\\E*?EGS2\2
MT+-*)_7_<AZ?4I:W]4AF>?H,.B07(ZX//]7-L2.TQQ2#71VM#G^M.Y@(G66Z
M#ZD[=R#$DFT3[A^:Q^H:"CQ[:(4+UBMVF_E>X>?S!F]:9OWU/AUSZJM$>WO'
M[C--\ZW2]QA;KA\^!S@WCD('UT=BWGO#9RQ.EAM43T;^++&N\_^AN\WC9J7.
M%_OZR\-0M[Y(Y-)N7-ZW4KL=_71ZJWE(N:Y2=#.,N),PC4LQWJZAT-CF1/-T
MEI6F)1>DE#E# =)BDM?>DG1VPP3:&&5E-<X?32?_\G,%!SS<]6DZJEU-A2-Z
M]O_38O9)Z57?]G1>[2[3M<PG<G\]T&$A&8^O,W$R\*/%% [4[E?&,6(Y"I%M
M^ QOT,B3">@UX\_YK.<"72\?,P^%^21*_/1/S>;8MM^YO@W[;,PG\7YO/15H
M?U9@4 =0TG,&51:@"!P"@;1,O\L.+\;K\!5U]/BQ>[M8'![OX:D6L9KC@@:T
M^KO$F38EU3NTWI'\"2?&@CU&,\P9L3H@.UCBXS@ +M5TF9YNYJC],K;_H$L9
M1*7,N@DUM>NC' 3/NQY8>2WV=WY,T+ REW?A;D>\7;?8K\UHLPC'UX8+Q%J7
M'I-4YWC8MNX"L\>=S2H-V/]PC%?:QP\Y#7$Y.Y X,5=I?PP.VO+3WF=16*ZI
M4K"QG"Y@WI$D5P2@ _,/%'UYS^M?1U@.+C)/9=;(_=6V29!J]ET[--,U]0P/
M""LR-U&+&E4D)($S[F_V8*T'P="8^_T6-<NQ"8X:LP+()S'I[?'A@W(>_.,O
MD6Q\>XBHEDBRN7H\'&GEH92-054  ">=V'R^92OM[ZZ)#ZG=,"%&>V;KNZM2
M 1&QF:^>C=:^">"FJ.^ELLG1NUT%W8)AVQK_;'UY$-D6& 16J_VQID2KA!SO
MBB!<@;)^%[_LW&WN7FQ\"(GI_3IUM JH:K/_D4Z0T;6UI$.PVB25M\']S$O'
M6U^[7H!FSIA>LQ,R&*WN8@Q"'8<\=0_]7+C2<&\YR8#J?$5N>U:9ZWQ(0!,B
MLQ],?I$PPW"LK-H >Z/*A">BX&?/31IN&M_WC YSK,TO$GE'UP0Z>R.\0D2)
M2V@PE+$99)3%A"8%MSU4CN?. .C#W[>\?J*5HA.YF6<B\KSZR*=CT,'**T>J
MMK;.O\TJ<W / @/&7*74G )<2V9<Q/P/?MH'  A5HM8N79"\L:?049-&&/<9
MFM$K1 @*/>32 K.?T^,<FRJF=J%&KP+<8N%DC)<X)8ZZ0'$)R^-?[-3?\K'#
M=Y_#;Z>\7KTI M?HU.^3?;:N"Z7]'F'>NWNQJ;34GL4?@.[_$"SBVK <.7.]
M>K&F3S_?G?P-=H\&:U-^=6M?!H5V\$Z@QN_ )@82:2U,M-;6): ^-ULV&XYM
M0&O;]6M@J825SL;BW8R)4R^G/6.)1%M;WZ]'%B*2O5AP<=D597B>NFYMGI(G
M[-@JX_C&I340SX'TU@L6[DX%2-/:"0!UZ')I>5-ZM@OZS[)1AFY"^*=Q$]QL
MG[FE)3G:P_V .8(1RTIO1BAD$NU/WS(XUCII/LV8WU)>CV1^&\LO@,.N19.*
M2) $F</6>CJ:<=O@2/.TUE /WTU]NVX]%$5WK@$1"SC7HCI1:#/-NUEY-#WS
MY4F$.^FFI<G16#Z1'T?N1(DBSF!K>(3KK8D!KG7^!1GRK^'?&*V=_+:_YL7!
M)H0"4A^;]4NC\UJ*<&&BTX:4]"5DH&S7\K#3HC9KY2$XN3_$X&L,S]=,=_!?
M<PK?]0G+]!SHUX*RO9\.T*UM50)ES@YJ(&1_2TC.K1[>[Z7HR\^V\?7'FP7@
M@*+92P9EK \(KYM*#P??0?P6D/DDK#GU(":NE4RK]!:Q,;W9Y[/RER/=JPLN
M-Q<92,9LQ7A6_FQBLS%'KI\<FATQ$^L19#P]K\ _7URYZY6=($E6M]6(ZFHN
MX'XFH8<KQF7@#A]64B[1:O(&5RW&$] -H1,1R_N9L#"IS^N1! U2?6O-F^ZS
M" Q!]A(1?+06P[:X<]?[*Q[$^2XK?==O/+>V#8DK/=+/X;:69@KHL2$-\-S5
M,]DQ4-2!]CLO%=(!R&@8E_T\;NSZ>(]PJOJ>AO/U.:T:C+2R2G4BU(M#NV_M
MDC+SW_%/TA@QH\,7B?"X3 "=G@V.62(,KH(1C0  O&?<-LKK-A\\D)IV7LLV
M\MA(F8>ZU!<QJ2+8/YDB<!?3.N'*=_J&PBCVN2\2]\!?). KG]6"99"!GWYK
M@04<Z#;;K8WW)FKOO/DB426QL&Y9R@[W*:/P2VW=YU;9PJE51)07^O0-='4D
MV*SL_D9$DGX2R.*3ZB6^XN10?&\O(^1A+U!/SFYY:Z$MX%DFRM)>9V,MYA>V
M!LHB+H&F[P#2D^Y'\HCR_3M)T:=!,C4)UN%G^_5_23FT>1L=;PHRZW]:F2Y%
M"UH[B..AT(K+BY[B'YC9<#VJ0SJ:D >S?([/>F4](I.OKT1<-OQ+?U+J'Q9&
M^4IL*_I[4)QR&CU$QXO7TWW.AG/G,C!! E)<G"F"-R05+!KKFOX2)XF?%<T=
M]_NX/2H$,J:(38'O=WH/_IEGY*GZER_;,*F$K[0>8OF4,VGJB3L7T(%!)3O+
MVOZ>WX3VO*][SR-)FWP#H".U&[K29S0L[#W4PO-R_+E*$QJR\HVP?[**-CO&
M3\?6L"9G;SZ*(UE8!(6?_F>.VN1WQ5YQ<3CI\)\Y\]#8E8QFC[ S$^EFRM^P
M,YB(, _TC9)D3N=X]F\ R^4&F)W@+9I%0*'?%AU<C2L]A;6UOSZEQ!LQNN_S
MXH"L>G4W9SR\<RM'.!DZ<VB.JDF1Z9Q*]'KNM=^X5GG4I79I\]DX^\Y-DPFW
M^=A4MH7S6,BOU6'#>=OP%^E?)0 XBI(;TSQ'*7FN>/J Q79TF;G<MTK9C)4M
M>4I=H?G[S'E L,%Z3@D,B^O;:_K&$^9FP-HJGE$$?YT3HF;;N,996UJBH)UK
M)\/5(8_"\[W#6A(R*U(LT&(Q;<&>V)!'6;:A-3_-(F'?C**7^EN;*J:]NY'#
MWT*@*B*AV#7@(G4YF?/G'75W)@+9D6VYTO:/U+1^T^,GZD_RY^C<KIET)CW%
M*Z3E.2=3)?CEZ.KC6\8KG'$V:\<V@,/U5GM0GC<V,L'**(_65ED]M[VA*JA\
M&6M^5#/'(G=4B_7.H ?)+]]J0RY3!$U6QI"5;%M+V(08 6E.WI^;)IMZ_@$+
MK;-P,;INN7\X[S=!M;5NR&[HT=0/R[NM]LWOXUL1!?4=ZH"4(Z;TU6J4^N6X
M,*0.ZU K=:6S0Z:D,/"']3&=X):T<J'V405QP!G3P&17O(2[M=V#O"[) RQG
M&Y:VZQ KZ1&<[[U!$]=$8N$#FEB;SMNQ6XVG5<@@D(O7K<QWKO-#4Q3C.ZYS
M[:/KR:G>W^HZ(>OS]15X/2I '4*^.)IL[/[<J^TGES&Q92@M[K1/Q(\[15=M
MW?Z^1& <7,QR9\@K\:6E9<R>_ J]C',Z%F]ZC\\4U+&K01.EA>XOA:]7U49\
M[(",846B0]=GZ=^?QL/<?.L[4JG[<U\D8O,_KCLYTZK;7P!->XY/UCA([<Y:
MOQTO<DT)O,_<,5!YM":"R8N@=7GIH?2'KK? >?$#R;5 <K!^\LZH?DI%KK53
M#$QGLH+%\5#GK"N[;>DA[O@T.=RZJ;4X@AIU:R#A*Y[WD:/'8O6M/](8V.",
M=SX:,;.O./#+W6WI%Q3/M&7GS-),BF@<@4\+D61[">]86!' :R:/J7;*#C[S
MNBE?#^G1CME.:-T$&.Q,E[7A2^(.>$(PC=8 ?P-.3F<=7OQX$Z!,:"] DT"7
M2F!DD7'OQX>;5[YY'1GT22E^.>"OYH4GW=@*SL-O+J][XZDO%=P7J+&M3;R?
M??2BV*T0.LU>A8I1?+;K_H8,0M^4QF;>A[@DF7Q7-(,AUDS= (6K,_EM&1=]
M]J_W\.%%\3HE Q:)B.'12+^'<N*(;R,VO%:GL[_KBA,T?#OW9J;^9TBE??K2
MIHM#9LX\M@3A%9&M7*L5ZU/4>F.-[_WMCWH92I3T!I\)< IZ&8D3?U<\AI-)
MG(B_V""<AHNUPZ^A,HU"J:OB<Q""C]P;G21M3;2&87GRR%'U7 MG5IL95-@M
MP.EXUNF<SBO6-"!;R(Z!S C(L@*:3TJ[#QK !QS5^DTD3%(7N,6'.C*GP8K7
MQ0_;*U4)GD][MKZ/(FG*&Z\2KOUGC1M;.\X_V/PIBFF/X;=$H@!QAJ:'>[=V
M27$&SK"/WV_E.H(%CO]756Y[*EB0HFZ\4AHWUS5UU1/]&D<)<M?6<:M:HPI+
MAF1>J8GDVO*+ODAXC&4Z06K%U)#(D9:&,K@[TULF2DB\O, X=%';V(0?TZQ?
M>[SV2ZR CJ.((J1VJTK11(WJCN:G/13BNZJ9V-")@_#H6AU1Y)B>LV 4L9(+
M;*Y[9C$1N)F'<-\QTCX#J<!3B*Q1I3.EC:!3:+-%>&^WM%-7'8MK>G(=XI18
MT0TIF\UC^RS4A= )<KA-1IQGK:7G^Z5\! (]T'M_._B4X=J"3"4ZU=P0R4?R
M(B3AO.'K>?-J&/,IV8]Z0RP-W,]"X5_>H9LZN4&1\4?^Y25A<0A=_YF2?@U@
M.>F]0BZIX6@UNAL9\%'?#*1P)SS^BP12K-/Z"JWH4]TU YAOU345TU$W^)<F
M#PL]Y)M_P%,GLZVM!Y=,?2H$K5*H"?9 4A5[+[3D=$Y5/KADX[6U5UU*"/:+
MA)I[2R?NYS8%:W9]"OKZWL;Z>RL:;53.,E&EXA2)NZ?\:TO<[?GQ+CR>.DJF
MB445KL<!RI+/=Q9GESK'?R#B%4\%?9'H./43[\J.F=1$0K=GRR=%8(N_VSIH
M X#0.AIA4%*#7S08>NF63AR"*!0?KV>_'--+K@X]G5QD-"(;?3]71]100URU
MI+Y&=Q5WOXH@3WA^<Z>0/(IK"2NE^6FAJ8GYB\%U9!:,0UQ_F6WVIKL6:= E
M>/^?CO<Y3:.4S>2[S?2F97MLV$_BNCBU#8+J'9QW#RUU3XL>B>M72KF 1/6J
M>GC ?A?89&^&>WZ.IU36WCE]- R3:WT":^3(H74>?>@5D^1XG"TG< '\JTKX
M9'1VY:/NL4B?-@.'T,$E$ANM$_BMW_X32YC"_N$,GH7VYT0EM,@K8&J50+$$
M:83;BW+H\/'T?4L+ L/%X;[3M+='4[RRJO/Y1SDZO9\!XZ)%A&]$?M4G#(N&
M6@5%I7?E>&8M6I+O<,>10BW32&AHA8$WR"6WGKPC/ N8O7]$Z%1R0E^I/*7T
M18(9<DYC9F[>M1OWB,G?#F3G7%SRZ0JTJT*KZ)2SO$#2EUB*]IU./,]*ADC_
ML"AUU[D^+7_@)*#JKQ'LH0/]=76GW^+E2@EB,+&J?SKYK'[*+P=^^0P-N!OO
MJI+1-57H<%Z.M2T(BH-"H_^JF]23^9,RNSD<UHH'6Z:S;5IW8_5\0<^:;_HO
MKP%1ILWBZR?,_\3UMSM/AQ_S3?0#[0U272&G=Q8K/MB\V[9>V4@T'OWA:$QZ
MB[W%X(?N[5(#VC_PN W&R6IY^Q]_^"*1_7M_@J_U3.MX<,OL2BD0U_72:]HW
MCA*&S[S<K&T.R8/-)H=G=QYEJ$WOJ;:\\VE_>W6E*TEP9^I-].IK<TO^^(4"
M*1;/_7YN?1$IWZ6V>Y_N8O9%8@CC+ ]CG?J0&S*KA&?N2=>F4BIH#VBRW3_J
M^F;]Z(N.LSR<99G#W&<QP 6T ,1LV;QG[U4?%/ 4*F/F2@13IR;Q:9]%TD#
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M"W\W<?F(60U1YK 17"]1^,&$X>4>,+$W'[)^=J(^+*$#CGG767SN6D6SL*<
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ML5^]\.FGHWKX7R0(-H#NG0C\.&LF -/Z10*N^IB^KT\#;WQ^]]H,9A6T>QZ
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M7[CZ)/K)C_N$F+[^@A94 ST=_/,[=IOHMQ&XLL_WN=%WD\]EJ7 X P4QMES
M.[,1^1M<RC2W]Q;L8@@3J(1FX ,&(3G:)5-.+N\. */_4V0]IKPCR5[(<J1%
M4)2#\],-POLJTV9Z6.T]PJ,H,6VOH6FNA4OWZ@)4,A(UIU:KLBU$ON?>,O^0
M*A]E.0*;1PH>E+&2U5TQNS90_XHA@V%HCUEZ L$* );*K>K7,0M_9HGIO*Y$
M#5Q44T6OM:XIG74.2T%R)#E*?K'LYUQMWWE!.%9SZ2G"TB-')J(O%C:M(MO)
M&9E?,F/5J.8TPZW Q4ZD("XD.[Z29+C?%<PQJ<-0<7*S#097=<XD_U !_Y0X
M['W9Q <UJLO2L%38[@PN@N?-J+[EEYV? AZ"OL0G;@D>\O&]$HKXQX6.HA/V
M(S/K7'.?D(MI&>:.L8$&W3K?VAB(,N9$K5MCL.T98D_U%\OY7RS5G+^)5S&*
M]=28<?[OJ;,D*Z-5SN:36*FR50\5K\*<,8]6;(3ANZR$)$HO]'PQ+F%Y-+"2
M+4>U=#$&AB@H3P+J&G*B3<'LUH:HX((\T(9C"43LN2K/VU\L\1P.$4$J-'+@
M:G7_!P\YL_&5N]V),=VLX.BL7'3H[SN @>$(H+2S,-C6-=T@MY102!/@G>YQ
M]RH)']5U%<)P(91_BO.E<W!2O&D*>][5HK\+L4/P7P5[/^I&W)]"S[.GUA0^
M+L^$EP]J>#FZ3_@($C':1Z;BMVJDK'?U:[8^5![_/N&+"(F\&9#=?&W_7#%&
M),6\@V)+]:6H(MK#8<?;V#\^!/;.;'Z8ZC\I>=P>/Q/3H%8^97WIY=@ .7L%
M\D':5XQ=8#15+[2^ Z;#P3F?*J0\?4JQ&1C@KH[/&9T2\H4-:A@:Z&3G")9%
M8XFAE7G!?+3W8F-U*MJE6ZM>&3^L;-PSE26<G>7UCX!.ZC^EU?[YLF=P7&"R
M$A;01YXQ19;D"5LLKV+#3<""OJ'>5 Z?-]8/E7%<[*""4'T3U^QP!?66FBEW
MQ=4'0^(B$7)YW4F^\XOI8&NG$* T4EI-X'K]&,_=U'28I1'8>-3TVQWC<4\>
MXKOT\IJX;.BCQH1)#,U7,570R9$&9U=W#^>^"5%557*T5];XL8>ZW=;F $ [
MA A9QL<GS%X(7C'R0M%P>Q>Y6!L-0*,/'.8"$3$E#/VRT-EU%1OIDS\*?R>)
M9^M/1/;6J^(K )ZPL=-&A;?WCD?R.Y.^U7_;.B@8Y6]>ZOI]YSBW%HXFM4]C
M-@(_W)O>@!=/NYL[?<I[@J%L_TD68/O%,F=;V+U[8$/_Q7( 3>5YY7W<\Y\6
MQ=*9#9T2SGN[CK_9T;1L>:O':8\H?49LG,GW*8<VJ76R_@G@].! %)XM$1_R
M]#YK.3B5U&H8W] K"#QF$ B'"BD?D7MEX60B%:I1Y.@5=6Z[GI4,*>-Y*.P7
M0KX:T=HCT'G7$A":8"'\$2+TC>J6UP9''F$/ U]P!6 :;9P:)OTB8FFFGD.O
M$0JIL4T5#TN! AW3BH+ 4$E#4:QS#6MC=T*>EU_SY+"K.EQVU\BJ0''L<MEK
MQGG6Z<XHRMV/B[]8%(Q^@E7.,#^K[73%G ^!AY$1'>U:1[O\#_[C8HBVV^D/
M1/P.7_T/B^;O$B2!LW4;GN,8L5F2XMB-J&#&N8=NQ]F&V2MBH$GOY7Q3G"C6
M0<H/]F1E!1L*RBUI85Y?"WD&YUY>=V#-4=^?6C.C3A(G-6*J>JV<"\. #WD>
MB-]F10:"EM%N4"@WW!K?F)/"'8*#BZ@;<(%\5,3G,,%CE-1R_MQWZ[9V9V*C
M2E:<'$F:#AR/T,AG-Z_L4D.1BX3J'D]*;$[Q@6Z]8:>!C8"P:UM%YV>^W-9I
M8B)?Q-V9 $;,QMJQ^0H0K7(X<;NZ$FH$J,CJF]!1F:::LH.MO8E"]=[$IBNX
MG=GUI7 ^\'GG@+_! $-"3%J,TML9NXW_R-^F3#9ZU K<6YYKZJ-D=61\J%$P
MW8>6'QD*:WN/:,[-^I8YU[4(H/.+\E(Q+9AF*8\:X^'*:.+8DI?%;_?E"_)I
M2<@GPCHCV5=^8^IWJY6EW$J=:UX9C_V$WJ&6=OM%-L[K_-8SB-">L](I-AI7
M1A?E0M>2O^_BW2\<W?_%A-)1K.1'>!\58%1+=OIQ57/'ZYF?&N4M%SNDJ7V_
M6-PBK([3$#\3D]Y3+"^]7\X]N^ ^,T]\G.&]\NSL@M?C><(OE@S7FL':+7[E
MK?.% YN_6 ;J+Q.C\Q]3JP;KV9V>%SS_;ND4=0%^J()"/(Y+C+DW6J.TLU>A
M/>*IJGJ9]0_>ZF+?TC"06V3\E J/Q9K44'<59<A$Q9PHZ#>U #.CP$.(6*#H
M(WPNX:7T0%BV]U1C)WSX-BJX2H0?F3:UBJ>5Y<' G;!U' ]P6B]=$TF<?Q#+
M)!3$5FA<G<,\=U:3E>'/.^,ZEA7M&'&# D9Q_ZK*T/\,\HC89=\:/GZUL/Z+
M!>!5%,BZ_>Z@MHGFFBON1X4:P^@2'Q+"IS&I/+H_A&WU#6]CR;*$]$W]%X3J
M8]!(Q /0_J;P?$&U"<1CSG8%SIN8'"O.R5 <+U/0>V+T7MY-L%:5W&0M$A#0
M[4GSWUHBY%_0%VM.7\SANW8ET[UNI9&S"3!7X/_@:(F87UHU:C:D@KW=VK;N
MC07-Z-&P0,'M;6"HQ!O;^LC#AVG6DU6GAKE5L!KM"4^..CT2(8,W'\B\AB9F
MMH#(UO.-RH'/K?N]<"6::[,83^Z>T ZA\O'Q-XO?\CF^N"EQ7AV?O?1RQ4E"
M;#@+M.ZKCFGZ>XE*>F/WUS>88NYXU+>Z/KOOTF? '#)7IX93\)-D]3ON4&1D
M,D)/C6P&\<ZHR+3._7(@%-ST8VQ#=&OR /EIXT89%E^!F"A*%U]5B>OAUC<,
MRT&U(X%E(%]GW@[E[]8ZMIP,*/BBZ;N*5O[N]I[@;XFM6\ZC"3M_W-G3(!/&
M;!X0RDR,1XR-818+>GY(B\_";[Z0-5-,=_L@5'5SD:M>-TIJV;F;C_U,K+8F
M_&Q=WSG7]CN&5I/I@'K9IWDB,&0@COO+NM]2(D;7 C+,IJFCRS0;IKL YXT,
M,W0=PVKK!XF8%D:XSYG#[[06_"D&L#+@WRW\/M0J^87Z;QN_JT>@MO\?CD-W
M0>HF>;^7*FOI7&DN3KB=FD"[VBIB)()4'7WGEPZ735C&(5@)79,G$5)!NNQ=
MEJA@HI*KH%MHAR"#_\O@E\P=0[WMD[97LS^5^7]3X@6/89"L?S"=X-]N.ITE
M!NT:LWH>>BQ?65;00II*Z"*MFM/GW*^G3( F6MT>ZAF.275\(_@4^:D/J:B1
M4F2F2^8[RRX-M1R=SAMXW2:/[AK9%<KW)>.)'AV9@AXGI;!HT48ENWPP!UFS
M?]AW8_.3P&6M,?CF;=S(9)I_<G1H1KM'D9<O*,F^F[ *=U,^>[?X/Z&Q F9B
M&1]XHFGI?I,JO*L-%4XA8"K <#_ZED2ZS^P[V;R;CTK7@TZ@:]?M_HMA=/7J
M_3R<M7KO5A\=D0\?",=F(<+BE6P;3(!!1*&T*PT5U,V6[@M>R3*M_7^"U?/H
MIY43/?+TB(XZ9A39MIKA9ZE([#ZCN5EOAC\@-HQ1X(CFJQ44A67SPZ=. ;T>
M*)V%Z*Q8%T<+K)DT#R)/9Z;+H+VUO\K[YY]NY/_!$(+?SQ9_ZY'-&M>9#43)
M2=HWRYF%NT[A#U[&Y;MPJ#JJZ+I*-4VZP6-7N+OVJ_K3[9:V0>M[BV&3,0@Q
MO]<GGL^7#8: =)U">3"*H29+@XC8=%<(NQMC'RJ3X-\T$4[6Q#SFE<14^/9Q
MYXU@@%>A 5&"!\)'J1:3P!9$Q^:B&HE)^!=XTO;]N(U?++H;W+@JA;PJLZ<!
MED0 KVN1^4K6$BD3(,@(_H$S3LUY0'C1NHT'E&GOI0ZI#*GV+)M4W[;$Y]L9
MK^*SVK0GD^:OVX9_%2LP2\:-!IY"R $B=1GS\(A:]0$1:\G,$C1Q?7M'D,'=
MYQ>Q/)!BK5'>.IF^<(F#6)VLORJ@[%?=:4\9,D 8'A404!@%#3%@Z$.P%O-!
MK=U_QNB<(,?]4"U&(=G":=API(X;?;8BZ/?V[;IMLA=!R6 WV<+PGCD/Q^2'
M4DG0"20<EZ?0=6$L!)M"7O<SR[L .X+"K]ZR:LGL#[ZYZ^Y>8Q4[/Q$XU$A.
M'2S8I"$@U%\LWY.\;ICV5/)[(D*'X-L*=[<=EM 36^._6.YX:U^_88FY%W_E
M%\N0)6#R4O% W1S@*@DO&6"XN]22Z<=+=DA!?.:)Z4I?2$SF?%FG>OA\2J"A
M:;S*'_0V= 5O)V65D3O8"38<F4O_KCS5V T4E4NW=E9+$&C=SF=%/A 7-/N+
M\[X]D6K%!R6D;UB+!0-DTZ.F K=&Q,ZXE:K,ZA+'GF:8F/PE GY:BCIHYX/W
M!5WK7M34W+ &Z;"UF+[,D+W@/AR6^WQ4@&\K0T6L=QV=;2@,AW;=8W42-%LD
MY;EFG.[)T5\/'_0^+3\VR=CP**0."PO8/[4P'+=H[_BI>AVLST!D5MG_[[0P
MQO* J3M.LB]]/VR& GR#FZF@D%<*4C+!X-84JJ$NH<N HPC$'\$?<%9<A=0&
MBN^U+Q'</ [-G_FG4! :B;50Q ,4&J;9+<&9BEU(B[N+3074YG+MR+K0)[H
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M>4=(RC6.()#/]\N_=#[TSM'-]'*C HG.K D3OH=BA>PU?E7TP.1!L\28LY4
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M8V\T9?A'*Y[Q(K1P+Z4/73IWZ-)G0WHK5C(VY-4QNB8@QPGJO> :CGE(QL[
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M D\=WW\[C!MC^WR?QW#@DKB3+\@,*0:T[]1ZV1WNC4NV-X3FSEU)M"1F'QR
M1H5.>WPYKR.7E?>XL4H(V%\)GA95&5K+]7G&2-)@_%4[E8BH;P0/ANR9JV&[
MJ'%O@=M< [<IX%=)_5!8T \G&3577/9Q-2(4<MK^E]M"9 #*OWYH<CFJWF0/
M,G'9.(-K3&'D+CQ3^&;L(9,C=&ZTQRLKXSO(Q/*J+^Z7P++51OWKUBT=C/G>
M92.R9HR2S9>@"E8HZKI;'&^H[]>.9@:$,1?P-J"JA8-CHU/:)GWK+AR);</@
MXGIR[-?O$HNS<[!#+JS-29=W?(18CT4V3UT6@C;K*"7U5?E[%^H1$$% *J1<
MHF@?]<)-&R$0>'JP*DGR?#YRUCPT/203.4"\H/PI2":Y?&WI7HWIU95_#GC_
M],\!EZ5(@@@GIIB(:P+.A+4?7/&@QR\JVZ)[GG3\93$2PE4B66IE2/$M%I\J
M_JQL_Q&!-A 9A$[KU#K3O.X=5&/3O;1#FV0P-&)S26U >A_,P:_I#_:/%=]C
MGG)'0K=2B0N\%5(9=Q"EV1 ?PP/WS3^SU5KZL/G'V1LF%'=+/Q;?9.*0F$B=
M'25'#K;?Z+1+9__\]W>8]QS9Z#GIS$UCT=X;1_0".Y'W&5]&24B-0X8"'2-_
MC'@F8$48KGQR_4#@C1-_*:NG.8]QU06[TD _>>;7=N=F:J$//Q5IQX# HT&:
M5W0)!9<:>XL]*O%:V^&YZD G:%1$:\J0>H=1^;AY$'P$%2PT[(7Q=>3VX57A
MT$P[8+=&4I]=W<J"0W:C\NM!GLP*4M2YL>(LVHY5IPJW#]D# D50/_SYQ[N'
MS,=PM"10=)H6B"1,71P3VYMWC]:8BSJ4%GR3Z<M&E(J8J(*BTYL1NR15B[#8
M>I$X\-R&)1QEL/DRUKFM6PVEAE]AR";0!,G=$,T'.6OLPJ(:7$$ W)(Q0?-A
M<59\BV_WQ4RXBVT$3E13H&F2GF"^JWS_]F^>^NN&68E#.9826QLWS'8RUYZ5
MZADZS&41H%*"_(S<ON$]=A]C^2;"IP$^]9,'U70K@V?NP3&PO!6M2[^V_LM+
M3L,0VF^>R:$G$K-/S9)C<D\:ZET!^ELT__:U]Y@LT*:O9!.':?@ZJ7Y<YM:V
M71C)W.YK(;"++#IK;*9O-^H9.OW.4X'(#LV2D9%]H:%Y8F,IF7FGFU+=+R&I
MX8P&/%OS&;146+\<H2#IL)>TS!*-F#\8G7/_\$5$@XD9\<VA.^.%0YD9 D]B
MA+ACP>I=YTDP/'KNXK-CY0ZS]K_@XX=72[.VJMR,3]XT)4>H@=K-D9'GHH+Y
M#M$;!VL.Z_U?[[!XW'UC9^WJJ=#)]5.\)>_T_WAEA?(T&F ])3(8>@Y(9<;4
MYHC/,><9_IZ-*-S-.[",.S3"C7+_CAO"?869.P'#VDJP/M:G^K(-8N64.E6T
M,*(>D*[/@<\'3]&GE,_#@N*;\8[^-M;35>W0 ,]0-8)GL@*M:3-S(!&A&:)1
MQ'OIO^-DL^?"RO]>M[ ;>E+.@PJ"IETQQE1<V7TP]O!,5:!#MG"[%^8O-)Q(
M\ 7;Q,24FUBJ: !P?D\Y]'675^[SCD5!5P=8#K,(4E'1O'OM\\'CCR.WS$7-
M7GVNON&6)\&*BU4S_0#2@KHHQ7=HT_^[YH7T?=W#FJ%3ILK>]2:)+Q#C?I+1
M=?E6L!?>9>3EY!>YW?=>OP,PU'>A+U4U$BU*<M4"+<'_G<,/NH[\HE$W_'QX
MQ%Y]9[S+SUL">A?NY3<>K4__8WN NDHMER^\49X_@K[G?*G;6_#:7?FDCX63
M4&_=P_>L,W5>5EP42=>P[5,<D@V;'Y)#^XP%-"->"Y$8*K[#L*>_P>0.E["^
M XZ>[TZ[,VD8.]]X U[FS6B@S%O,.Y?!E/JRP4@,2'6_9EZ#_AB\HE54YV0/
M  9APN=57MG1A4^\\.8]_'ZL55)N#WT0$ZEK/7[!GPG:5F>#T.6;+T&B*B>?
M126[ECWK3*Q_[^]GK4S,Q:>O_C81X];^K>MDKNU#ALNHWMBZ*&2BM[;&827V
M,/LVT[MQ<,JD,CS9%HI=\*U)EB'<CVQ25YA6^M@MGN8>KW& FU2O!)?QAL A
M(X#=Z,2S8WS$,V;3VV5!7 4XM+!7_4/\\B7_MC_I.(5=+K\#H/'-M]\>2RJ_
M\<G$IU.Q<#X +>SA]SXRWP3T</C^H4AB-[Y6(7L$"$:&NCD>=U/:942"9>+4
MMS5_UI]6F;/<^I7#J%]#?@2$?8 ^ICS(U8"XW:)OYHKPPRE'5X01J^H:YP^Q
M-APT]!G%58*^30O&/$)\^!J:-- <SK.'W1:&6;O^VX&4FBZ:*O5EY;Z?Q3%\
M12L&.Z1ZH'>HU7W(C.'K!,,EO'HP!.H0N2Q'E\3*1',ZBH)N_)!19J'"?"ZN
M  ,8%<VD\S=NK4ZQSJJWOO(4142*0H+_M8KS5;K ;V%'>T(&5'7FMB_('Y1M
M6"]/J\(H_Q(L%#>8B!L3WML[=_!3/KT;*'G_=DU-Y.Q7V?S*9.77"4NIJV-'
MD%47_P2"4\2^C\\B':;?0QVXT)"NQI3"X\J#G>%3K(M!\#><+:X\GUW-(R</
M=XR=/MS6;DY4PS 1/V"HD9 [=HTVRWM2]L,B>:MPMT" "]>K'AWRX?O!9?)%
MM&UDORR7/GZX_?!5.'MK'BP'>-5]#KAXT0?MOQCN=4?&)CDKM;>]^\\]8%&B
M,[PW_9+AA]/2EB="4PV4%LC[_4%EOQ5)HE4X/T/?>NRD]@PUQ+];":^Y,1&P
MDF%<4<'PG%[5 -!)S=FFKOI2Q*?TG^X,6XU2/;R'3+O$W"L BOQ-E_;LSQN]
M*;_R6!=S4*YYNKXFHW_&K5^:V\@7Q#+I8=DDOKM7O1-<<+$4;8WS#G!5FW++
M[RA'#0$S[Y+'#]N,&6<8O\/B'$AYCZ9\B_Q.SL=5\'$H;7,1<N5*P WQ]KHY
MD"JOC5.IDB5KR%VQ^^< /$!+@_R /,T61O"N7CD7?MF%TXD#RQ'F=^]O?#/L
M G;/ YR:R_O"2AJNM9O'+FO>3FK'1D7(D^?X#OB6>7O_DFQV-15DXY)!M%Y,
M/].A2>1'JWS3,ZMD09M,[1K>RP@ AX;]3:6R6/%OM/Z\P$CW]C'+.]ID55C3
M.)H\SQS7UC7XT!SM58+C?X!@YC$<',?O['NSP/_?QWS57(_1USL4\1D3>7$;
M7)8I"WE%O&>:ZJJ:U]V'H^[9$.F9=HQO,A\RJG!0;%F)3:]]1_:\#;,EP^G5
MF.*S8Q4>>R3UP(9AGGC2F?T%7^%V3PK@V=2/UTHV"&EV>R#!V-K!GXX@/(1B
MEG6@6P)CSC:XN(?K6Y'%\02@^]I.#CH8>R+;=&+0:?)*.X7=OU>H%O2M<V=?
M3[WY?A\*G<K_>$W_KZ)98Y0E$Y_%2'FLIMMQU<:/G1JS-^$QML0$@_>D'*J;
M(SJU6^@R RV7,Z)RM)[L:/I<^_TWR>T&XAAMB5P]'%S&'P*]W]XB\RR\H8@+
M OK,U'1<X,@$/CX+Q\Z1<L,;[M>-5Z.YS^)ZDHYXN+R#Z05H+/L?M\2,:_F4
M<<5BT^">*,9H]=4M5K_[V.2MJ8M:H N&N WPI0\(FS'ZIIJN,^3R97ATD6*
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M.++43H6Z'/EX%0V]^&O.@:3?ZP:'@ $Z2V](#.FKR-7R#%6?P4#0M'6_E&X
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M]GY?"5M_MXQ'(25N9D5UDZ#TR\+K-T3I<'E*26B6(UKC0'?ZFT_R"IIE:W%
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MB5._ &^^$VE;UFUU%][\_N6D5I]IX+"$F5I=;9+D[EM)5F! X&OS!T5*(V
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M/=T3YNG>FM6BTE%8"EM\U1<CS_F,$/\9J[V_RDDSZP(Y[-C&H7-SL?+J<XZ
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M[8U>H^5<S'%Y02(\AH 5+CTM#UV@ FYFSL3B=J2WRJA+]A-U&=FE]>Z>)Y_
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M;Q,5!N6S.4E>?J;?PWT-O-&?V#1H&A;=:H$^M&%WWK>X-.]ZT<XQ4FB6&8.
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MIQT0D:3>'$U" FH^SABIT5K48#;GE2BEN\FEZ!A529?D:VW>O46X[M6@Y0X
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MCO .28K#S_[O*3>#>(Q0XP2^>KNF<$^YR)U_+'8R;F#[$GWOU","$X2^5,)
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MC;/J>. L^FGR>V,W&Y(A2)F%-^2MZ!Z CV9\\1)9(E$QG'&C^73O>GV-]-K
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M5KH;J<E.O0QM>G_(/"JS6J5((BMDVA?'FR.?5\#8/ILVRH!C8 M)<#+7\F2
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M]R%#_9(9QU[]L>6@C^U/@ 8MW]3V!AHO315C8 B4S/0ZTDL)S6[U"2VY1V)
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M2O!LWM8HAQZ5Y1BSY<S_ U!+ P04    " "'-&Y9.!=KH@8,  "%A0  %0
M &]R:V$M,C R-# Y,S!?8V%L+GAM;.U=;5/;N!;^OK_"-_?+O<.D28 %PI2[
M$Y)0: .A>:%+=W8ZBBTG*K:52G9>^/57<FRP$\MQ'!DGW7[H0(VM<_0\1^<<
M'<GR^S]FIJ%,(*$(6Q>%RKMR08&6BC5D#2\*_6ZQUJW?W!3^^)^B_/;^7\6B
M\@%:D  ;:LI@KM2Q.>ZJ2.D18%$=$U/YCVW^5RDJ(]L>GY=*T^GTG<KNH2HB
MD&*'J)#R"TJQR!KTFZP3R!L\5WHC1[G#$Z5RK)0/SRO5\_*ITN_5E</RX?'B
MD=_>&\AZ&@ *%::W12\* 4FS 3'>83(L'9;+1R7_QL+BSO,9OQ"Z?WKDWEVI
M5JLE]Z\OMU(4=2-KME+Z\[;554?0!$5D41M8*A= T3EU+[:P"FP7R;5Z*<([
M^/^*_FU%?JE8.2P>5=[-J%98X*8H[PDV8 ?JBJOYN3T?PXL"1>;8X JYUT8$
MZA<%3)Y D2-8KAZ5>1/_YE>^D6]U;%%L((UC?PD,WI7N"$*[H/"F^YV;4"<P
M<9Z />/LE?C?2\+'2]FH>,.LTH1=F_UN0BN-ELLM+!25KVD=T-&5@:<I5'QY
ME.DF12]NJYIC0*S;(UBC%-H46%H+@0$RD(T@[8$!;RR1I@D;X[A*5KZFJL2!
M6G,VAA:%7&J;J4#J#B&,R:V[LV'SKN'([N$4$*W'6J!8YVX56'/:M;'Z=,F<
M@,:O,-5<W^)IF;*GZ<1('-.ONOCRVV,>45C :4&F1 #M[@A/V65N;,,A@4,V
M0MQ;[L&<#^"49$L2ZXU0%1BJ8[B(M5CO/0RXR)3N,X0LG-G0TN#"[?_&.7AO
M8#5TB\%##B;^<P880..BX-#B$(#QM\4H#5/#U:),+S?JZ( .W-#C/5'BG)6@
M85/_BLNBR^!2HPL$$JOD\M]U!E0E:,SQZD 5H@D'DR:R'=&SKWX\S$>-A-4"
M1/7EL%]7* H'8>^.$G5,TVVMB%C8\)_7"39%(-MX75\QT2!AR59!F4(T'-G\
M5\]IIB38\U29\.RWO8,P"T#P\#U<QC?E&+HGF+D*>W[/1JE=L[3F#P>-N2>X
M@[(1CQ6UPP3$0^3Q<22)C[#C[O 6VWJ?+C(2R83$RWH=M+M%QQJ$/#Z.E_A(
MQ07/DQ:*W&%+S<0-1<MX47C'H(\&Q(/\]Y4AD 9T-V$;88,U2?E(L^>2$8\0
ML,5X90F7B6PW=6*N@24^W#*AI:+EN+^UWG&2 FCG83%BSH+6$PN5(&U(2PFV
M7)T>@.' #'@(-9_K8$T.?1@2R6E$3=,0UQ08]P!I-U8=C)$-#-DYFT!*[LE#
M,A:$((ERB'0)'=0A<\Q:9@,@2D*^R4(R^".1$:0+Z;#O0!L@"VI-0"SFVVA-
M51V3@P&U!M21BF1G#PD$[@,S27"3FF3P4B3_QU6: (.'I ZD-D&J5Z=D 2I\
M(7"G['BRE2X[D"DNS<]#<6<[G$6UA!V8*$9T.E%=)"+@IO3R8Q9#O#IFS:OI
M9EDO22(QV)^=HF8CV,0S^C1,!6JOV1 3(6";1$Y5L<,&WSV8<\/-J/86+23G
M68R8J5 2)P!(X@1F2<2+F2X6<C(WJ(W%Y^Z24S&7 %:1S]Z^L.=+FV=#X1IA
M>?OI9'RM0TRNG_X"" &+TH1;4Z1MQ^9[(/AF$<GLQ(K:D\$4#Y=H5I6Z"INY
MTQ-)V1,ZA"")IDU;IC+9Y3#YSF@BNAB$.09A\21%2IS(;@%BK;Q=&@(;Q(F(
M%0I9U<Z 0LS_9;YBL5;<[B3.L7 (1E+<$$K#3@^:8TP F2^DUUFDFC/KJ)D\
M^ZO9-D$#Q^898 _?@PQ&U.;R\ZW1I:$O!<;QR?2^=#SJ+D$BRG=0E9:V4,G;
M5[6R930(66!KU58QR-\TF%7,>6E_BY([A8QS7DALP DTL+LSPVM7>K4]3E:^
MMBRD+%QGCP5+YM:MQ59Z@TFJ:2:R$+6Y>A.8#3/KI.6:4R:B9BU><NO'+SHM
MW$@+T\S&>$#"C@R1U3Y'II.O=*T.C.(6BT_N7(UEISBL3S8C8XVP]!9T8TT@
M=7=S+%J\L6Q(V!7)^@O%Y&Q+B3@,FI48+\D32+]A3Y>@DM*Y$4O*>4J2AI\8
MV%:=;W$;[WL'[<S\;KCMW.?ND5V-=+?!VX1#8I<[LL;D8@-XAA.%US>V!#.$
M]$;,F[XG>()80Y?S/N6SDA<^:RK+7[(H%FX@.'6,_F>-T UY#%K]$E 25T$;
M<$R@BESU)3,0:CI_O[(%_&&0XLJ<[MO(?WVY?3CY^Z\_U;$S>[1^KVK/IY/A
MX]SJ-YSIAU-2/?UT^+W?FU/C=*(^EXV/=LGNPH_/IT=/LXK:LLM?KZX.NY]*
MD]EE_;$\T;H$5,'A=WWZP3X^_D[P@=&?_WC^W#HIS2KM*OI(] /M^FAN3LC7
MSMW@[*1T4SZ9G=:JQO?+;A>VKJ?]A_;9<[=_..TUU,$$5Q]NIQ\ J!JMA\=[
M6"G3'R>P!Q"FDWZI].6SV>SUK</'SU>5V\N#LPX9S5!U/JZ=M>O8:9S6[JJZ
MVAX]SM2/=P>#+Y7)[-C^.FR0YM/L>GK:[C2O*Y]5YU$M71NSR_FG4O/D03LH
M?:S6S-%T7F]0>-VDS;.GF\&3#>;Z4?V@:^G55O/3I-4\,+LCU#T9&-IU]ZK]
MH]74KQN/\Z.'ZS-\\;=2[W86KWRGVNX^ @2NO)\HV=X%0O;:\D7 R7X?QXOJ
M*M^;END,+2@AW\G-=L1$(B9U03BTWI,1*9$R<BTC;<E*-&C"7;4IIYXJX<TW
MX.+GC;6TYZ9'@":;JH1"]SS/2@JM1^B)A 0L4N325BE_$]6K>66V1V!K=?;9
MJ6[/A6<8IS(\\*HV@C7XS$U )'>//?4&X'J<GKV1]^Y ]Y6,>T#>:GC'2-_K
MY'5CJ#VFJ])JQ,ORPSOCJ>M(,F<X4NA/%ZBCH?4K)64YBTH17L//PQ>;H#(Y
M+"6IU)\K] J0]1F-6":466!=+"3E4&"-$IS:7E_.&\(U]8>#"!2>LB&Y<QL(
MWLT0$\-_Z%6G#0 6K6]+M-HK9 %+S<%JHP1O;+7NJWVL915"C5XQEFXH=?BQ
M5FV=>?=;2(8L[>:+,%U(>"8>?M68:=;6_2?JF/(HC[1P]P7'0LF6N9...,8V
M7MZKE Z^W#VG0?7NL W]/$ZV\Q*)V4=>UV,G\_VKH!3?-UYAXL;R[)W3IM)W
M,_2D(#01U))K]B)?@29L3L7"GPJSR"N2"=W5V4T*:N.@E7 *E^OVW3,"F!R3
MZUC'E@55WK\OR![U1FR6S ]W9C_4Q4DJZ#EB]4P06=.UO*?T;8/E[AR\<<_B
M.]:6YV/-F6HXFKM?4QT!:P@[S!2;NLYZ)WF(O['R>;^EFP]72YM+$D_<=W#+
MV,X"&#F%%&X>^05@,G<KS&+D[^]+>O)YD*7@CK\TKOO2H<B"E-:Q.6#=]PZX
MP4,+/3-(- 8YTI%[L(*KCU=UT&HAO;SX(_]P6=G:I9UFR-3#L_#LCI[*6-E\
M)Z49V6O0.V1-MMP:A51M@Z7O+!:+,E;VEVEN2;:<U]'<>8E,55=W122:#&:L
MPD]K;6_"WVI>57PI V:65VWZ4191II725XMW]V2WP2J9S-13?Q]1<VS@.827
MT((ZRNSK#O'"\IY:;T3OTAEFL2"NF06G8HQ-?G0VO-V#BZ]@AJ?.Q0G;=\:$
M(*Z9=F\01SU)T2_Y)PJ#\2WD_$&(30E(@DGL$7+9Q9:4G\,2QI@]?O%DD_5W
MP"'U#IYK#PPT3%[M%SV;>ST_GH;7Y6]1WZ4X?%>$'U/\D_T2X;KR4+X?0T@&
MYFI/!4XXS;A:#LW\9*&W&&K)Y>XX12F E'L2J.N*^>(FU!H.0=9P44EV/QC@
M_JWMGNY-FS-(5,24D>TT-Y:?\QG_B2E-@>SJ0G+Q#:KJLK[>*)X5ICIVD"60
M$ K>!O E-Z1_[R.QV"T.24\BH@--@!B"I*U?(<I(?F0Y71Y]C58D]U1B4_,(
M'<>X!0%RJ]1)>W''QE-O"HT)O,66/9)^(FU:-?(]OC9K$X@$7N8VO:1:<-/K
M37%.K/O2\SYX]0WH?@$Z;GD[6YH9N7G%M%?Y.1]5^E9,+[ 6?A5+ZIG6DCF-
M>1=4LN+_R(\VK"$QQ9<;)&4,OTY,SX"K)*>G"V9@[TM<R("UQN_Y/U!+ P04
M    " "'-&Y9K[Q-O#Y4  #NLP4 %0   &]R:V$M,C R-# Y,S!?9&5F+GAM
M;.U]:7/C1K+@]_<K>GN_[,9$3Q\^VS'>%]1E:T8M:B1U^WE>O'! 8%'$& 1D
M')3H7[]5.$A<=2(3!4C\,.-NM5"9E9F5E97GW_[S:>V_VI H]L+@Q]?O__KN
M]2L2N.'""^Y_?/WYYLWLYOC\_/5__K]7K_[C;__KS9M7/Y& 1$Y"%J_NMJ^.
MP_7#C>N]NHV<(%Z&T?K5_TG6__?5FU>K)'GXX>W;Q\?'O[KT=V+7BT@<II%+
M8O:#5V_>T 7+)8\CPA;\X=7M*GUU&6Y>O?_ZU;L//[S_^,.[[UY]OCU^]>'=
MAZ_S3_[C;[X7_'[GQ.05Q3N(?WQ=@?1T%_E_#:/[MQ_>O?OJ;?F+K_/?_.&)
M_:#V^X]?9;_]_N/'CV^S?]W]:NQU_2)=]OW;__IT<>.NR-IYXP5QX@0N Q![
M/\39#R]"UTDR2DKQ>L7]#?:W-^6OO6$_>O/^PYNOWO_U*5[L4*2_LTAV8*H+
M?/,V_\?7C%ZO7OTM"GUR39:OLBW^D&P?R(^O8V_]X#/,LY^M(K+\\748_>Z\
M8:1^]_&K=PS6_V8_^2WZ[3@,XM#W%HQ)1X[/]GRS(B1Y_8HM_?GZO+;;,$I_
M=Y(GQN:W[-_?<C]_F\L )HJ_73D1"9(523S7\>.>&#=70]K .3U_:W*3T#^O
M*3@#I)LKY(C"8'JSHD18A?Z"ZHS3/U(OV=[213Z$T5>*B H6R/!$QM),)-37
M@]M#E:/'3KPZ\\-' V'8?4HQ \'KTDG2B(1+NN>C-/8"$L=.0 ]*[,7A\HHJ
M>DJ.3 LJ(JN^'J!\I.NU$VW#Y8UW'WA+RKH@F;ENF 8)O?FN*.U<CR@+A]IB
M;^$4\GH=!C=)Z/ZN+ _[+^"(>$U\)F#T -#CP$P QV5L4B4;]W-0O;I>>PE3
M@DRFZ+%@'*$&CCIS12N ZE7&'"KT],!2BXE0:F@<(<['H/BE=S'Y(Z5T.-TP
M8BB?C<9G<.*7+QCO "0AU2 1\>B/V)6=*92E%] _>U0QEY=A&CCIPJ-RI[B!
MOE# 3OTU868Z7<-U'KS$\;T_,R93H:0Z\M@/J>:\/\L1">Z5CZ#.FE 7R)GC
M15\</R6?B!-3U;_6D*?N;^&$BNKM*"6+TR=VB@@[\G/&[^,T8K?\A>?<>;Z7
MJ*L/]?7@]G 9)N3*V3IW/GGTDE55SZI>R8(5()4*5:=4 !./PJ$"MR24*(M,
MEU$Z9?^MF5SJQH_.HG!TS\WN6^=)63JJ7\#A,7]@AWAV'Q&MH]7Z#% B27(1
MQO$5B3)#6E4*&U]!Z9^V;7:TS?ZD*F&"!88V46_9&84U5(LE :TPGJ6GA;QD
M$2CAV-M[37-/"UOI,OBVHYYHB):P8\-H2H?^RG!GM=,JT<)?M *DJ"C;(UK8
MZZYJSX;0/,0&2T/NK7$#:B'?_2W@_>2NR"+U"?/1A ^43%M*%4:)!R:[&3A5
MW:.P$I1ZW\.B CJ+8Y(]ZYL2JHVX<#$P];F'MU,7/WLD<B)WM5V&T5GY#,U1
M*33)PFQ'^A  #88]&GJ:17N7FLMCG!ZNDC';D60Y^'-4\2U>DYA$&[)@DI(R
MI^YYX24QW8KJRAA\^85X]RMJ<,XH.9U[=KS3=?9"BL/HVJ'6')6>_<]2:CEY
MP;'CNRDU4ZF-0<5H=X0R_7!*L0BWA/SB1-1Z30P%=ABL,.B9\;%X8U++?5/>
MF-HDX"Z$HH"N;V;92\,<W_8*H+;_#DZ#E?V(+%P,X4+CR_5GZR?+% .<VV+]
MX 3;N/N]5MQCQNI6=6D< 9X].M&"Q55CU'T:@D'1+COXZ0/]/',7^&7 ]CQ@
M*349(H7O(PDOJ,5E:NOT@86Z^?D#2RFBYRJ#6#&Z;E;A8W[<9O?W$;FG>&6_
M<N5L]^]C8SKT! MO2;&0MTM-T!//3RD'&@^X69)$WEV:,.!)6+&-BD>H&3$@
M8")I@R#Q,JR\#3E=+HF;G#ZY?KJ@1F 4KJ_"A+*"OD08-],\/R!<=N_"4$T
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M,9T1'=VQI\CA\TO>^$W;\7CZY*Z<X)[,E[)^ZF=AM'>Z;01.-R6W) ;<,=\
M>,26]IH;@TS0W[4E%@ST6%4'*KE5FMA!FWXY.BR6.5]^IH0>\O'5AFW%03[
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M5$M2! 1MZEPS48'CC;5LN6(OX;*L0W"J)0A,UH'S_+GU#A1O<IZ0-7132P6
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MK)(K K>&MFK*H*PS*.4Y55)07=]-^'KH)$-);X$;PMP)SUYEA=67SS[-YRF
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MB_-@0^*$X=K^*2&LC1[0Z+!>X-$>H3BZKS^Y@?NZ,X1X -5UI(3#$@"6AG]
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M#.<'V*&RLU(R4"4V'79U?Y:*0$W,O!.3K6073$]5F=3L4J0'.H)[>%-CFIR
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MH+X$8U;((;?<(RT]NT5?O>#'33TS0E8#+P+#4O!0LC48,ZAI[,K?!WB[7[(
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MM,ZK-!27:2=_'0[#J'Z$T6W627HGM:#F47":L'$6JU.I&X:%E4"6CBHQU;]
MGPUJ+ODL7F$$(\T"F#_)V@^C3^!=V19H:BB<IT69[["W<+7!VY?I8[@T60_!
MR+*\3:$;=DI<2D=DDCJ7N+YQD+ZT]2X[0!@V\.F84@5//X&2PBR;/GLB6G>9
M.10<L.(8&K5%BL45) <L>,35 7R'TK@2V\&<? U4!U8[/5I3C7/6L"8243)G
MI;ZCN$OA/8Y0%>%.P \OYZL@49:?9[J3LNL_R14/V%BN&:0XL9U9&X_$<C0.
M)BFB)@.T5) EPQS?/X8_%1U7:%*D924Y$,E<_"Z<.S<&<] TR>+H#%(GM'5(
MLJD:VV+G )+)&N]ZCX"/W%VS >A-_2F)>2+/!G="Y@3^5['9MUEUX7&58Y5;
MOERA"2[1H1J'?6QM!%#+$_:Q]<JSQU.2B*F' &M'9/)OJ\9$4\*ZI><K-771
M]R*IU29(]\VLQ'U=-SD2#9CU<5',XL+@@54>N9K,"C5KQ_N(-2MN,.?^>*D7
MR (DJ5XB\V98Z]5M]0*16S3C ]S<219ID^S*^;,!.;YX\6RU V5AOA$-X35^
M0(4)<>@1462-Y0QIA"6HM./3G6M=7@<V#)K2@+0.-9<6^)'V\<]/6FR'^J>]
M3B*Q%Y:NGA_=.2;@X^7AF(V)M'/D2Z_AE%S)]*(DV>,R?G$MX8IFL\+2L[TY
M9BW15S;=![I!/VWML>_%M<?4S2CI/AW'."BR-V56X6LLVI%H&ZAJH'JL]:PI
MZ>%FH#1M%O2LI/VEPJ;0$&O%Z]M(=BFY V/!$_)&F I_0FM,;D4NR3!S*=I#
M57=3A]"1A7U"OD\O^X0T>^)]XD@2E9Z5C+* !TA4FRUOVX,2FX+MX6@YVX-3
MR1VHZI B+_]U$\(TR.,,=?H89[LB>;F&VPP'1<@?^U _G2,?^JD][DF1</8V
M0X8;_@UR]3FHO_<2U:HB,PPFZ2'K)8^1WNHJ4]O&@:7?M=N'/GI,VCJ]+-A4
M8LI?W6(:3^.L([:$?M4%KG+7/H"KRJ09<VHYP-65O_HV;0*XM;>)F=[3BI=6
M1,E]2D,!-Q,:U?=5KH3$NN[$J8$:?D,AX<2=X(AIC=.88?*(""N!YG4$#KW%
M(2:#./%Q,+EG7X =X1U8B%5C>G$D^1$Z;7X5$CG4SO/C0 ,+8AT<I^B45KHR
MCA0_.3CEX+*$J(4I7E3='Z]QOMU%'4QQPM*1$JKQ%<ZY1LB FAU,']C8.$WU
M>O84#:;(IOQQRO]UB*9LU4]*HPGR$RRFP:G@(9UX,_SU"77&X[K.XV$K%M>X
M?_<GW1$/7%.+/"@?P<E'@E">6'HY/)GC<G^<9?+!7K[M!(^W^%<US0?:QYQ5
M%)$P\2#!%6/.TV,:)F]E]8EI.<_K*&2'E[:N:0-PH_TX!54SWVXH*4%V@30]
M_!D/N59AN-OL2. <S8.2;;8Y?(!I$3_"\S3,-M .Q*3INDZ=*,T9OQY]W1Z<
MP'4<QMX+7R@+N0<_I?G0=Z@?[8HXA45Q HLPC[<8\:LT.@J*N""EM0J<=QC_
M]A8^ET?)*%'.;$AJ,.#!!Z3.)2_)2%!6R9OQ^ZNZ6_+4D/16Y1QI^O-[IM9'
M1Q?+FI.GNV??Q/=IC#0 ?ME(<[@A\_PJ2Y!.@(4M&$L2]1'H+\<:-_OX9A/D
M+QB6G7Y VQ&H>_*M;M7$WG.2RT^09IVAUBCEX(]71HC5T*'ZXS*QW$/9Y(2W
M17MXX])\_MQ]"7&;!VD1D->VQ4F3L]^6\E&A[/NIT01_,F^00+</SV=_#:'S
M7L_(S,PLUU%<DB0 :.\]SHB.@RG6</;QJ4C<]=E#C3V!ZJLZ(=9<KQO?>Z.>
M](=^%<4YTC^4M#U>KO'!!YUZB'U8K1:26Y3$6" ;$B^>*KF%)?3.Y<:'QIW)
M,\\8Q'OE/FD"NKUZO6LU!)9>KCP#LZ>MJ6]V=P7\>8=Z/'VT"6L^'0_G:RXS
MW&-)_3V@#;Q"<%)DO=.&<*BZAUZDD2.<[ZPNC10DY^DZRS<$M^B4'> L5%78
MV66:O+C8].=SY./Z:3;7',A2:8.B16Z954EXNL71\6_6-6U0E$CA8.T"/M^E
MP2Z*D?KYPN\EC#&<]<T+,].N7Y6:G0[+UN*0(.C\PF>:)YXR#A]@M$NJ?,F=
MY&FGC.1I7B*#9*4[J#XM,QUSTOGQ*'PLX'J7O(_7T!7L.A2]1%A.LL53JD49
M;XAG8$<^!0GZUJ=^5)"I%-@&,Z!K'M 4YD4G\1D^QB$MNLVJ'UN-:LWBU&3"
MN2+4XY/KN:(I]H;UDXB"9!:O\NS1F@>5+JAGS.,,K5KO1I=K-.79?1K_ J-S
M9%R4\3J&4;]>'&)GG/OO%K_9L';J,LR=\\5A>  2)@6VB.MZB&C-O/=<7,<R
MSGI'10MS/6-EU?>XR Z_0\J*>D2&?&&*$IQ55:L[=:HMQ1588M;YNK,['IY3
M>[(>N]^X!+M(9,4P6)S^I:S,;L9R&[46+#/[NE?F:#S"5,_\!/JO?5%R06AM
M4;)G?L:B/ OB_'M<-LC!T4I,R_F2$++#031N T@C\ $&N,G&NV-?2H1=1$X/
MW 2@*$BK68HN,>@1>M'1D<346<>8+'D?%Y^J3$J</SK _"Z&.8+/PPNI]M;X
MJNOC24W-]W6_+E"82%:92+WPN&8>*S5]5Y1Y$ YJF' BY'AMG;^"Y##"4W8-
M=.C6_8V_.K$3L]^$RXD&J/V\AG3%4)J&51>?C@=O-Y<9#E9NLQ+A9#U C-=]
M<5)NO:<,PO%J0Z=?GKLJP=JUZZH:PYU?M:0K:\_65FF8.1\;J=DA\%_MD#K"
MI]WB=/1H4_7 =O?Y>L]C 7&#1S^FYUP_#*GQ/8[9<.0AGR3L(0^7-',2AJ4^
M^OWZNV4!P79E2TV<9AQ'769^LTVR%PB/8 K7<5E4LVE>R8N(^; LA!Q-Z&!8
MM<*EVIN(1P+)NZH?OR:'E&@'VG1J-F88'[CKJSQ;PZ(@KX3/(+2+,QXQ?SCC
M<#2!LVVG%;U;R-)BEPQ3O7C$V(18&1@3S816$;FJWVM80.QOP-?F\!$F&:.X
M)^=@+.[!;<95(2\3<,FK1@0J4=O,8^42*>$TY^;IP<]X* 'O2ON1O#PJ7AXV
ML'GAO;;.2@@J:YI6O607L_*C;B:DUWN1(!BVMHG?SU-D+]253<4'>CB\J&=S
M)-JHF]WX/W[WI[>'7_^9A+SZK9(V(55^*CSS!\<=><SX(<A_@F5+"_N/B=U_
M]$+HTDQ:#HZ3>NQXC+#2XUCBY"F7FLWO(7,6>#A'3_WYG!7FW5UE[V.D(2)R
MN*)_@&A2B&/4JMX5D/6>4I?/&P?*G0:@;;&@C*_30N:KX8G9T,Z*TJR"3MZ#
MRUU9E&@K0V>OZRQ)SK+\*<A=!<"J\N'3VZ?(JY0*[J37PX>#_!&I8'*MO",I
M@LZK1V&^#\6S@</6Q3HSJE4HCN3B/Z]2\7_<9NGI,\S#N( D]]!ZET8P^B'(
M\V 4@\I+RZO4H^ML+4K<\7 ZJ%^P0[T 6'6#P;O-X3[M"3Q577E-TZLCXS:3
MJ_*,:7JGVR?CW4?E*]SQ/0EV0O;'\%7Y"B^%BQW.]':YIIRN'H,XP:RBA?(M
M9LJTAK;%II?D5Y8&(UXY0?TY4>CWN('ONA&6L==3\C;GW$<=;YL#8J7>I<VP
MHBTHGM"_0FHO%-3[T,-7\WS\\Q@9%*3%%YZ/<9\(VG3*F-=\=0R<*G<L)53;
M>H@.M?1J0\^P&E>G[]S3H<RB,$**LU;RJK.%I*Y6PP(GM;7";+FM:3N+5T$6
M\KXH>UKOURE7Y8JWU-1MCE]-.-[E^O8!UG?DM94K\@#P3D5Z73LN_:C%I,1I
M_@<8WS^4,-I?H<41W),'J[L-276+-%(.KO%F1&)^.K_?X3Q:)$5Z$N)4S_@5
M.'[LV@DXKYZ_UOR!'QBG+??'K5DH:L]=^L*844 2+ZV[:6OA;F@M=./A:PGB
MP*T02?T6YIM#&Z<P.XSZR.]E;32\Q"#5-P"QMB&&\0L,\IY=[,TPM@J_D6EL
M;]:U7=&Z%KN(K>\SK$&3N'RY#DK3MK0+CMW?,]H?U-3B?&R^?J7G575$&CFZ
M*DI@3C85DRQ>Q\5/9SF$YRD")RS*I:]4)K\>KJ%LCXF7N@A]NK]&WR(CE7X,
M<O2U]PLI5Y"TME2Y,G!]L2#2(R?Q8QS!-%KZ(F7R^\H7*6M,4WMI5'T+7F*8
M>'^"[ R2UO?3D0QT%VESW&6S2:_"*>U56"*JY8NC2 QMAEQGZI_/LH0OAX9D
MT%Y W8OO<Z,Q\+"C,69-I[HWIKUWUSF=7M8+E-S28WYJ]UOE?;N&FR!.:5%6
M\DA]%R3XV"H?WN&6+<=.4.<#Y"RZNC6HG:9->]#I -S6'IQ_$ _.'CB"]W%*
M/CL*DF&(E)?8$R\H[@>PN!?H3">LSCY=,4SN9XOS] KF<19]FV>%Z>R!-CA\
M5>$O_''PGMHT,0O=_;/8 Z0+_SEQ+&+.B DZ,>&O*NQ%/!9QQ,OUS8H-FM\P
MHSS/!B]ZWE'4I+#T@)A#F1BI>PJ93R (:A'H.;2YOQ=*/ V,DCHZ]RJ/C0=-
MN>1\@3XJ<Z.3-?GK1H"T JACNG@96\ 2E[!Y("LM;</RTO5L88,/!R?!Z&2'
M,P-2<E0)=WT(-<7(]*I59\!'#(0REZJF=M/0M]VD#8@>^O7FRUI4PM1BJ]EX
ME?N6&O.^(HB<C7#^]L58BZ]Q ],"M=$]3%UNSN.2*D[/LGP-8QRIBQ/UG3YO
MXYSTT'"^,"?5-+\+-%'GCDEU3ZTZ]/M^P!DR31XLY43A.N1!EKDE;=Y6Q[+$
MO=SF@.=O[6.5\$GJ!.,[O76ISMKX9UR@=1(82%Z@O5W*:X$9(WA-SPCTAVGX
M[OJ4$&==7+^JYPCS@6_DG<),L?HZ*'P/BY*4(6K>5&3X5YUA4'-T87:&--NO
MYRF#XLA4#P^T7Y(L$#8/DC+PB'[]FH\3JO@U:24HB<K'PP=I/E_1"6/F8)R'
MB7H=[OP#AD!M[($;M+@AT3=?'>P!+.I/6Y6X/H88$+Z'Y\FZS/,,I,4\9S8_
M,&]Q>(L8ON'SS&M358N0@8TSD&&$Z*=_MJ-^.S'*J_O['-X')7X^E\=I$8<V
MTN?Z&\<G8BU-CY17^:'^&C2?TVPH<N>I5QHK.AOW#FP@29'Z>QC087"1'I0Q
M?Z]ML8]&H!FCA#MXU=<G7*B97(?LV3;O>'?P&( Y%-93@,Z'56CW;SC1G%R/
M[B_^F[(E^[EDN7Z-3[DDQV8L\NU3TO"N?5 JLIIW4IMQXE1_-KHTIY+."%[A
MK;?&,$W?>B]))?B!O$E?CZY 3=_+RIJ-[H?*,BP5P-O-,7#W:81JO&[H'BQB
MF^O[.A:\FPT9?=V;UF TZFY#YO;SRA<Q!XN6UBI+!/,KD5W@,H38TWB-_A\9
MM&55 NUC&I>N<V#I\.(O_94&MQ*9KW#N!1 ,,UYY37<U R+L3%>Z,[>4;#>#
M79/\\01IO2:%W<)<*JK<OS:'N.+X9 ]6I"7 33OE %AY45ZA8T43T/:27LA)
M[56ZW34&*CP[!14^2;:5_0CC<XWQ^8A;^S_;_^I0J>7D'Y3?N-EM-D$>_P*+
M<?4-&2MLLB*,!@'G93-G,"MA60T+N/C.*VH, 8QJ+IH3Z/HAZ.G/.\3(>8JL
MP!W^97%9/L#\]B%(F:MQ*6:5*MNOYRV&XL@F P_J^D%CJ^DU[4Z:,#6R+>E(
MQ$^].9=#9-E'I'-:,?D5I[I\95A3KH'GFLE7<U8W/JY7E#C$]-A_)9GO7"\1
M'TI&VB^@E_O>R@@X.?9$R>XM\^$AN[W=$2E8GLR,?'YRU+M!6S\IO0,YS"D^
M89<]32O WTI5W-X_K47M<'_WG:9S<5/J0WE8W>/M&RI-#JI7YY\:<_XI'19&
MHU,P%EYWJD%]R+HQ[=F26>K"QEG0/AWW@=*@/B&/M<JX;>0E_!3UA]+*<*I:
MY,6L?6<[,Z)//1O 5_*'$\=\>3F#N!WC_%<8).$@.XS]M17*FX%=8Y7R=&6X
M."N#/O!_=6>' =N?D*70'YG"H>%32S&H"5TW&SU#2C[>6"OR^>F<(U3']2EY
M%A3';C4+X2=Z-:FY;'SH'LM7DTYMI'Z2H84>. 9,NLP L8@1FSB++$VC+&)B
M%W!(84C:>6IT1?UWFY5!\MH-F,$@7E56F5E#M93Y[Q,V1MAX]V%Y,"2I_#;?
M\B5O)WUA\X+9<Y %DZ5/)XR"-3Q=)P;KK?XG%!XA J>#  BNI)85QLAB\[4$
M5,WCW=4#Z"5/@F'GA>?L'TN>:<^:1^,%]L*5U.M542I.U4]50QG63]+.D%^?
MAGH=^DD[/X2;%&638^*D::=#M>$U\3 */[? [@<ZTVGRVE.@F<&ZD?QH!N0X
MY]JXS;3 5'0DG56MTQ!9.JJBV&WH[QPE5#/"G!>7J-$A2"0'J;>7_=ILZ'0&
M/B+J($[!<9"$NP310L8$0ELG*Q3N O]FF&.D\+S0K<"4G=3-F*#TLXPVO-1B
MN('Y(SJ4<NR5A'2'_G6YOH9A=I_&OR#FB;5QG!5E87]]FN;3_39L:R@22Q9W
M'*0O__&[/[T]_/K/!2URLD]H@BY1@*_6TL*7*],9.MG+TH9<C&R<7?J8QEF6
MCU5(:P<471[9HR"<'KU<(<0XVE]=CL%#')6/<4HL?+*Q@%LT\&*>'O"J!3S@
MGZTA7 M7YY+C*LAW/P65475YE\3WA)"4!X_7UGGX$(<1#N+IU^"I2E:7-=][
M36,P(8C&120:JVI<"^EPD,2ND!+]J)'3BYTA=8Z@FS/#T_C,X%[ O'EN),L<
ME;;-7O=V!%.XQMF?TXBM4PSOX?)T72=#EN9L"DX%*?JW10P^H*9@B[[R; (K
M"[N[8:G-B[XC^#P-LPV\#9Y/XB),LF*76S,DA:1\N%U$#''@1IL U 9Z4UPJ
MHNM":G*X>I>=U-VQNL\A-9C44O;R6[L.5>)RPH$"_1ZT#7P&#TT*H=G0Q,/4
M?3;8FM=!\7"69$\WN^TV(12"I,6;*T^P&A<^:M7HL:KC)^KT"S Q@*F!\W2=
MY1MZ4KR&25!%M[Z':'_QKMEFPHES\%.>:"W+'9.Y"N((G2M7FVQ'<ON%R2["
MX:RW#_ #FF!$#I._7)/9?A\'=W$2ES$L5G<%N;*7TIQ&"#D_%9K@FK,*"+BW
MJ&^ H T"VCN(J^[QC0:^L]BT%/!R23 -D+1$O!Y'3(*GT?C&IESWA<;E%N;D
M&HGT7OE8"L/*GT/$O1^1S0C7B*@^!B%&[QJK9HP'D#5_2(8JV8-"%DNPJV\%
MHS=\M)3(T<UGAI51FWR$% CYZO7/]X'V>GT/BP+"?L^U3GCY$)2[W':1-!T.
M7'LN-'C4,-]:!4'AV='-X.8A>ZHOY]N8'/I=C02_.)Z!I"[(=:=:WRTBI%C/
M+8VUC&!^N3Y#AF20X.+#+E>"F!$?+A5]=CEK T\(^#RO6WSAV:<W'Q?2N)Z>
M+6TWM!3=DQV\0*OI]@DFC_!#EI8/IDTV;386I>H%C/(Q_9^^C]AS(: ,8][T
M6-;1B"Q>+[=/F2?PUM3='T04.>2#]8\^TSII2ED'G]V)T'2$*I%"2#2=1T"=
MOO,@.F46^<#\>L'6K4C8VN!LIF-&3-IID./W0<45I($OMLYP?#H>_.U<9GA/
MQF$)WF=% ;;U T^_4)L46N_N6#C8^474A_T?!44<KM+H)$YV.*>+FSL>-2Z\
MWO$HL2KA)"#MR2.;J@?0X+5YD Q699G'=[L2=XZO=HZSS29+:;S@0Y:@ X6O
M&TM#B.)$ "O/M=XU#YE-,IEXWMLH0;F[&VYKU[?>7$XX,"0@:[_:HWCR>?4]
M*8GV(D0XUME7WZNTC".,LO@1WL 0.Z5B6)P^T[N6,\0Q=NZA!4F#25WMPQ88
M]!F<;6H0,I'7B-3^244+G*[7,"Q!38E>TUQE);+/8GRUWE+%;?F*V??)WQY@
MV0K9J, T%^E,'NBUJ>%U:88GY\<W(VQS%A])](7L&K3L:A*@:&AXME:,8JB[
M5,S-J,:IL,C+WN.(-,*/1J*S. W2$.FU&T2V"A13-NM1WYV%@'YJ%X$V66=X
MU^508E^IXZVN@KQ\ :LPI)$JZ+!/;'5LUY/GW>!XE^<X3N6]__"4N3C!@)\U
MI=J7'?7\5M-+9K::6-,:74#)O<DDX(:#T1J76X++H,;EMH/+C. RK'#)#)OR
MH9JG1=Q3N!,SH_-DZVA7Q"DL"J2J[Q">L:INGY:>1]A(7,>8VJHH8%FLPI]W
M<4YROW2CK?!+<?3+,,QWL/L'J4.E91:,:=YW%, I"5>(N"=3N\/AI3:A'WI'
MMD-,-<=C!Q,^(V$1/K6?H\YA=((LI/2>/M<FZ2BZ61<XQ:CGGZ*5Z3M<+]I,
M\HP5\I8JHQ_[=A+J"KYW&M6:F!F7+,);G8]I%!=D"X(1,O/1IU8.F'H\F(P:
MDD>N%J\\%R7ZX!L0XR,3"?M&EI+OG-VSX"!]6RB<)VW[^6R'SINXTB!2]&?Q
M,ZDY^ 'BC,J&\2H@Y#K@A\\*!W-- V(EKZLFX$?:Z)]>P3<MP"[")H:NOH/7
MKG>\''/4Z>5Z'8<0)S3;XK,>"TK\6Q-Q)^X.65+\\-ZI5,WH@8HT!+!NZ1<R
M2K+JWJM,SX.F;^I#G,:;W49>X4PXG?K].;QM&Q'GH*/ZAH$#]PX?YN37GISQ
M8'1%'#R;%7&O/]<B[A+GB9A^LPP1LR:_$?%H,#-,X@]9"E\^!/E/L#S;I9$=
M&X)#Q+WWC<T(#Q#X8[ A7X,U_IR)#0^V@UAH7;M!,&#-2[LFU_%YBK:7XCU\
MA,FA'<M30,D]= 3<<$\\Z!-PR *-#WMS6FX]@W-BN ;1\]89>MXN"CUO)=#S
M=L'H>:N&GK=VT/.5,_1\M2CT?"6!GJ\6C)ZOU-#SU7STW, \AL71%4((S'-(
MTP);08^(DH<H+3XW/$\SCF H0%P4.W+'F*4 2?D1$:KBJ*KWL(!V#8Y TSF-
M/!SCSH>/>EK>/6_TQ#2Y?R@_P1'KM;R\0/Q<&Q@5B?I;>N(8N7W*;A^R71&D
MT>T33,N7,R0\>A>!!I#B@!^<-53!!:;6H^M@8B7N1 ]^*9*:1@"W\KK2]<79
M>,G4)T<G#H%)I<F*C:E=52D232!OJF/'#ED='D4P;))+4CS6C9<,1TE1BU$I
M,V5SLJ*W-ZYVC*)1_QY,H2$/PJOV*I=@4S)B*9LH3U"CN_712#W8,"P^F)9+
M9\H7<D6G/]&:ELDU+,H\QC6M2:^K$&T_.)>*_'X@[L%MQ3XA+]Q@Q[I-I=WK
M5M[=\O(":K3X] 3H1UZAOB'B^@&_H</GXXS<[%75!:SH;QF*'MYS2K#%QQII
M29]LMFWK&@V+.,0JR+FKE61G1??9\;<PA7F0H.Y7T29.8YR/$-O*-@$H1].]
M42'%%P>#55L"P7YK/@H]73HIB;R+1?GY<6^>2//&,EFF%,A"S!C[@M,T=RYW
M95&BN8O3^V%!A]NL/N!TG@<KV$&:7;LUD/28Y.4L;3L;5P#$F0::<W(WY8#O
M&VT#.&ASJ.M/IV;\7(?BQ_21%/4<VGRX3!0SJ&(:N#)=.JTEH\:;!$[K7L#8
M["<=^??FZ$F8!4G9&=,L]] 20NJ:QM1WH%X=J_5P.-VA-[4YR9H$"/'F33OI
M:T:^*\(G"J6ER\*@W'1I*L.K( _N\>.D>'.WRTF%Z6%5BS/(#E+G%TU3Z-'U
MM8H2=_SZ:K@/D'<Z :,2)E7:8;"&+)/2-1BUY-RMR:8X:YJE^D94\'O2VF*O
M#?298!1TZ71C5N--!8OT97%>'W0@]V"S!!1.2U@(PXD9T]N8&82N@K+UQ<R$
M(+,OM]NQ)%<JJ-N2]@W:_K\EHDTD11',N'.C[PL^3H*BN%S7A2[S:UQ&?O4<
MF\X,S:=C?N]-&'";Y(/WM =_C\.6?JCKF.: M $_XE9^O3.3PNMZ9,0C5W7"
M1##^UWMX'R2G:1F7+Q.(*6#XY7WV^ :UHF!!_V@QPNK+M!YB88)!EQL2B;X"
M]+.1X-T:]8*)Q]+FC6G&._W=71%'<9"_W 0XRPL]>IK7$'PZ;C4$EP_>?7]
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M0=4O?C;I_?Y,>SI& IXYL:[UI1*[^#D@MG/3 N*R=L0A>TQ]?;36A*C4APY
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MD@P*E_5H5F$9/U)C>NI*N:5+[AA)YG%">H]FG:ZH T2^D3GFX O\9\P$J+G
MI_'/,2,@3K\ #2^@968Q-]>6)YNI"9P(V*4WSV%)%)91T.S_EVM &:B.5+<9
MH#R +A/XLQX;&,W86&@Y 9@5@','5LP PLV@_,VRRC-]6J5O'%\J-&ZL#S#
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MKI#&2XILXO+/>:) O:?'2#5A-Q<9KKDXM$]5#4B5T4U<5%"K&YGZM/;SA5[
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MJN=]J(^8 X6]\] H.HXF](M 8G?Q[,BMF"0QLK#ENC[\D=USA:LNH-1OX,!
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MPG?%OP[%5F0CR3_D7!+>.,2H.8U%@G4T5@N(1,2RBAN\4\2T'._>QW*KH!P
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MF:DGKP[X>/HBC$_H1/N .A)+SN9/%.D'UK3^&^5;S5B,<^1;S=X3]& E<[R
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M-+!B:D#BX#?*!.I6][!+*?;;O 5PBKNZ@DX[VS<O'[FR<U-."!QR"A+M0],
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MWYO>:3I,*.7PVWVZMP :_ON]C4JX_OE:A88ET[$9"*[?O5MR*V=-0"<P%PP
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M2<F!'Z &4]GH)BQ/KVL\%**4M(;OE!/F2K."FD6Y&SCZ+=!"0)[&UKA'R,Z
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M&V[O>^/L^P/D[/L:9\W["<-Q]D-OG/UP@)S]4.,LQ(SB%V&KF'B/0/)P%5V
MU7TJN2M%WPZP89>N)X^[H$0DPNPCDN'2L%-@?2>&@W6FVP6V?"9;:#3T 6D[
M[:36>DT8[-"+=-2 3X3 -<,<ZNOK/N4+2'G?YQ,2D(67%(W"H ]-.S"DDP/
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M+_<J"NTT'1+"ZO;)0-!72UL:'-+(31[Z5C+<;S(,'B 7#I^1^V3W"K$09VX
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M7=L_16$,WNW< H8O[N)O9%,A>^:!-2N2%ROM:4CF*2#FAY:8 \G40GXU(G$
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M:QVRBJJT(^$ 4WET9.\RH"J0W%(F<#5_E>-J8:Y2&R2<:[87G546G59B#TL
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M N\KAT /5!SZWCQC=S O0V>-'?=.6;-7U;S3! A.RO7IBHQ0J,;76EE#CV2
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M\Q'<K!&(2[Q',J=8ENIRH!6"&G"\G MC5:!(Y5PB?D!*@V]ZY)^1>^C*XA9
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M+UJQK*:?B>,G#ZZ3U1]?7E[=*!"_>Q5,ZTG("8G-XPPHZG(2GFS*_V+!TZ8
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MQ5;(R2[ZZ;ON&+B3D*7=+\Z\B+CT-^+3!\>+5LW/:"WN= # 47O2W.@B#^I
MAQ<ZA%0U,M\Q?M2H81\0VX[31X_31T?!@&'T>&((3Q>E?$D+:J\9QI#]C1W4
M06Q45YYP.0GFUV'@['Y2#KI9.7^JT'%?8JVR71DUJTI4(X59>P(6C2(FRXAP
M@/H/8-%2V('A3D;(D@1PAH[>Z3O\6<V*&K)Y2K-)8S<[)?''(<WPQWJ$0YKW
M"CPL=\<7PT%^.'3RKH5"N"_U%SXV23>9OG5@DDZYIFE&_7%BTG%BTJ I/[R)
M22^WU;RBUNMN,J]36FS\>#]VF1]*E_D"P+'%N4*+<QR#[RH,EG<D6A5. ::6
MO20K[3ZE*GT91IOI@A6G%K\QMZ 2=;$8B<+4)K)!Y;JQ.A4C+4#9BJK5Q0+Y
M 6AXK.2$IX,/^D;L*?V+YSK^&7DD?KCF/D+/)W%"33JE#"*)=<;/*"EJ860@
MG9*(ZJ5@1I:IS_YYH\?$SE6P+U\('G:3"G!&^6 OK.XF%X4<FU0JZ8; =9O1
M7*>,@]-%UNIQDB8/862A4QX\?@,*XEY9::,JYHS^4!*0=G?EL1F\D=8-B?C/
M;,A,(YQA:8IN]C<3"S?] DHN'RD)F*J\""/>.W2@BF,/S8&%.7O1(?N\TK^X
MD7OE"YI,AS%X),8"AB]"]MHXI%'2;=X+AHWYHC1ZN&3-[_@N+HA<O[3F+X=N
M@0CVJU_"JO_:*CW_6&_"6+'?>LOG0V="V\[U"\[,&T[P.1,3UXVH77+E.?>>
M3X6$Q*=IQ':=I:*YV5^ %:H*Y#$I2B6*8DP]F!%O=9_2KZ>+NE1*:D'Q]X/J
M*R+0ABV[!YMEH-?\:)U=F_%T46GK0^ZASUXKJ#$=MG::8<XN*&Y=>N!+<G;^
MS$PGZ!=R.ZPA90EU,+.59/J9G?MO%"664H4](XLTF+,WT];IF=NX<CJS8XD1
M.#*ZB #6=E^I7]G6BMK&E3/W==T))>I>UO+]\*^RUMT;9)E N)6J?20M3BUN
M 33T-X$,K72BVXU/9#TFABXA\_B";JV8A3U="+N%@G-6#?KP#ZPV70TB2@ ]
M";<6UG;V+$.XX<%@SO(V4&.R2]MI5K#3V/<">JJWN:8]G>,=O%%QMIMZ!7N-
M'3H -V])J61_C"E9>0#*ZCW< G8$MJXZ*0N6&SMR-&_J:LN?"\<EDU68@OOL
MA&!&\\84$ZI@(< @2UT.[L0JES4R+_5QXGA"SVJ2!CNB8RM/RH+G&AXBB"E?
M56&\#*@<T6?US$G(61IE8U;AYWM+ AW3G2Q+QX+=Y@,BM9*%21P3,EV3B-(Q
M6%X1)R8L)8];_C8&34D '(W>EB%>D<2@XH)J>"MKA=$JB#6[!LTC9LU QO/N
M%5&I8!Q$51L?- <^@([WA' VS/?Y5+1PVX8:NF;1:4D4[\V8@[0TB*X1A(Y[
MO(LV\A/I9->"Z;&Z)ZQ6KMBKZN0ZQ"3P-IG*?/R2G(29@F96??_2AM@I'K->
MY]F9U*(>!]H=!]H-G1/#&VC7?-4<=G-W PW8TN?=K&[TV.A]O(W>]=O<#:#M
MIU*3]Z%TKQ/,9^MO>B/B\#,#[=5*-H"Q:)"\M#ZV<1\6JCZ3$&D)5@+,5+M@
MS<R97_MGXOC)@TLQOTB#^>7EU8V"HNM>!=N$EB2X!#D >RF-2IT(G2 @4\V.
MX4NCF]PL>JF1?0E3P%=.BR@9'Q9RU]L@#6GN3BLC6\D%:*4=HY(#.:N=04F(
MTEMS;G]R$HH<O4(HFE8Y7 $TG'>4 D>KI-*WPD&RK;?IAAS'7C(T]R&-1_NV
MD0NJ+E:3E86BR,M>+%R@31#&8@ U4@>S?G:;WDOF9;7^Q?'34I9@);G[EKA,
M<7@$/F1E@LM(E+ AP:$*;F%,*S=BB1!YL7 AVY8MJV:8H]'=DB0$J^35C&V6
M)+%4U;/-181.X^R&-R++68)X4)6].4G@$X:$Q3Q.D/WW(?3I%N*L%7AW#I&.
M$%X09J*2N*6TR%)FD0IDC7""%G'EDY ,EH?<S*0)VM[!T=M)Q]K(#4<U!+<6
M]%(6"X@\&-V9A=[<<Z+-K<,FF%I+9Q+"0>*U^1FN3S84D!$FPTF+MSM46 1[
MNK =)I, B/K0ZQ3V"DLEJ+>7#:76/2 +"9%Y7CROTO%7]"VVF25%8N'&D3W/
M-Y'WZ"3DQG=<X1Q"@/A!(Q#D;#25DR$B$U3WY>-0+.S;3&ID5O^):\>!6<>!
M68.F_/ &9KW8<@5+&E%8P8#0;/]8P' L8!@))X9;P)!A=M(;*YLAC8Z5 H)A
M]7'/Y>LZ#+Z$K,!7J/T5GMBJ:XZ A\ID@FF0KL[)DRV*ANSK6&@0=GTWQ[K(
M 98SHL*I.$I^F['N^[+F)/V@I"?IWW8ZLKH6!E=@[,4:34 2FO68(G^%R; %
MV;O8*&H5>M=.@E9Y%EOLDQ=XJW0%1KWJ>DAOH5;RU7:,,PV((^(\PY*^LMX@
M25_=,=ST.H/7Y,L;K0WK*>@>O*V1)PCD*3B.W48?NWV^6OOAAA"-D)_@TQ%0
M5;1IZ+MF=$I#._=&/XW4UWF4=22_9OEQU^2)_U-/:<5UH%BVJ6'^E$1N\1YY
MX8KMM(3 <!+;^3.)7"]F9R&;"P@M+^#X#>H]JB%6\ R#+%V&LVBF:1(G5 '3
MD].'65,&-[!;2%U(N@D*Z=N%G-)9'TS\.:!X\MUG\GOC.UL9)KQ?-G^0%3-)
M2]*=RWLO^@@>ZT.X /MB,%RY))SVJNQ@^X]Q_J\Q>,F&%@X'(&2:Q-?PY39%
M*4T3>2N3E#-;\3(HI:9:3.GM!#VLU#<-]:-$9WUW#DQFSP[9VD!W6P)0!7-
MS*[13_]Q#<-877/]_'GM1?R7+;1/@,+JI;ZEZLQ!'?6JO8OK,,ALJ(Q4NX+*
MK?T%W9C%*JJC?[79921<E2N8D;R]E[<U]:>.[Y/YR:9NLO5A+BM@<ZB&LPI#
M]"?H@KRZ^$FX[SXL]P(_V!<2)V1.Z<:Z?[CTCW?A%]X+9/N^_(6PG=+?H21W
MEF1&6, HR[/BU:*IX[.A(=!/N0%M[ #$?$#4A)MJK'MFCB-8>Y4][<FL )YX
M,/&(LJ=5MMT^)*(*<.P/4QF:ZHQEAAO(6]E@N='1UEFRW^L"@/-R4,?/?DGJ
M&@QEANJYVCF>=,:(WY<@U,$.+9\,4!;V*(P[TKE4]U@/UD _PUH@C?[V;R4C
MW%1G(!YG3G';_,VA',"[0DA R.'-,*RUF$C1!NH0F=R40@$QX]E2W[C+@/Z1
MW#G/)+;3%&X+X,R+73^,T\C6>,DV2-HVSW;1O /L"0G(PK.&>@T*=O6U!/.J
MW7(%Q-)/8&RZRN!/0>;)F2PCPAT^P$>AOGJS_ NRP(4?J]IN@CW*MREL7<#H
M-O+I3T(6+'LD);=;3+7Q=4A%JOF?2['Y_2G 8+<7(&H8D= NT6.GMUTP$ 9V
MLE*I;;'LK4L")_)"H*+3YG6Q]*S,F2R*QP04 >"/,F]R!#X'\9JXWL(C<_G:
MHB[^"-?&>>UURN*6/6*B&+4@*:]]$4;$=6*%/G62U*XMC.)24Z9TG1K(S00S
MXV>[@ROVR[4Y8:#68C,DG%,BJ\>D: 70;@Z0?U:J)MMAH?9,E1!C"4X"S!<L
M(,PH"2CZ#]3D.B./Q _7O$-;]L*PTKA'!B)RQVI%+DG1$$I_ZC#Y)_I2C!R?
MXC>9K[S 8U8J,ZIMLED.)FZYK2*?)<F(7]ES1W]GNB@]F2Q<D\TPAO *Z[H>
M!=2!Z3RHQ:_]MZ_3_-RU<E)5H>.>V5;9+K-9F:A&#XGI[!^3_R91R/XW#52&
MD3=_B=E*JY/$@LWB-+LI(W/W%&I2?O?E:"A?VBQNKQO!#.?X9%/^E_[&PC<!
M'L?+3862 -W03)EM?3K\0-KDJ@NXB*EPW</+JUIZI^T!.!P^P/<3U^'A51@L
M66KR34I?CTY,6+C;2[*DZ%.*ZS*,-M,%BV\4OS&WH$5UL4!ZI*OJ5&TBXS48
M$Z,L0-B*(M;% MEY8WBHY$2G@P_ZZOV4_L5S';_D2/KD^21.PH"HM#>366?\
MC)*B%H;G[91$5"L%,[),??;/&STF=JZ"?2-#\+";5'#/F^%?5[#Y&@"=[50O
M,8KDC"S28,YVN.5E,:1=2NX[ED#66S8R:I@$=!$.+,U+JSHA1^,BC"X(>%/"
M^NH'RF$A,0&#ZTK<+=V;IV&<Q#<D<AFMEW(Y:RV?8WK1;+&OC5IX09^ZII#B
MW-Y'A\BO?<K -2H#C[7W&67'S8&PK5T[R(S8>6SBNF%*-TKED=WQ%,%I\D B
M^N,HI3AXSKWG\Z8/T!$^:;B'J 8TJ*_O^M%_,G)D:E>,7!BKZ<,#M:":B:3_
MR@&PC#E*UV%""L$"/KS[ZR/WJ+=\3!OHB=+=:V?=;9OT9#Z,>E- T4SQEN\/
MDX.M%(/K?J5_2G,; /IZK:Z-[9+KY7SN* G7A<I*[=DUM=G"."[:47:6GNG(
MUKD3L7Y#6R"6*C"%8%0U6S--Y$O5VKY7?APU+[8G@1H(7:'6ALD*!_?\M3$$
MHD1,;SK)"YUU+7$\U(99FU7W:?'N.%$9?J*RBN/].%$9F97M$Y5!)JT,53%U
MWJA()6"U/HW5GO"L62.])NG._8VEEF?J\%'<I)(&45GD-2@+%4RT8K2?A2[O
MGLRZ?E+D64/E11BMG/)$!L.N$6T@E#I(2"VD>&+FQ-NN6UJNP4*O'(J8N']>
MAH]OZ.?9>:!_V!V#UD4UXDZ"]026NSFB%7,>X5RJ2 P[G.U,+%U$2&:NC)"U
M[&/_/MGM15F.,H+.R)+7U 7)M;,R$_3&!5'4N>PQ*4C=3 K8%C]:9YS5IH"<
M:;X0QI-<E175G6.D$3(L)A2%.4/CPG?:^L=U,Z"Z$HX65>5!;?=@F8!Z&NJ4
ML);B_B4U.9[_0=JZ,<NJJ/J*P[H,.K34'CD !\%I<NC"\TE49)X"\*>Z'I9O
M7X\]-5KH%XR9)+_LT+E=.;Y_DL84Z=C,.FQ:;URLJ=$"*M] ES7G*Q(MZ2/Q
MIRA\2A[8H 8G@#@]S>N.X>YOI0M4OH$>LUC7BF@=9N.ON&OLE.6U1)O3< YA
M-;>O/R(CNH-08%D%+:'+O[YA>+'9)NQO_Q]02P$"% ,4    " "'-&Y9Q5KP
MW]@\! #;4R0 '               @ $     96$P,C(P-38W+7,Q7V]R=6MA
M=&AE<F%P+FAT;5!+ 0(4 Q0    ( (<T;EE,^\S!M D  /?M   ;
M      "  1(]! !E83 R,C U-C<P,65X+69E95]O<G5K82YH=&U02P$"% ,4
M    " "'-&Y9416W#U0"   6!P  &P              @ '_1@0 96$P,C(P
M-38W,#%E>#(S+3%?;W)U:V$N:'1M4$L! A0#%     @ AS1N63S8T7[C"
M,"$  !H              ( !C$D$ &5A,#(R,#4V-S Q97@U+3%?;W)U:V$N
M:'1M4$L! A0#%     @ AS1N6?U28MU]2@  RTL   T              ( !
MIU($ &EM86=E7S P,2YJ<&=02P$"% ,4    " "'-&Y9H:!2;=\ !0#;L04
M#0              @ %/G00 :6UA9V5?,# R+FIP9U!+ 0(4 Q0    ( (<T
M;EF8@C'5?]\& 'B*!P -              "  5F>"0!I;6%G95\P,#,N:G!G
M4$L! A0#%     @ AS1N63]T&\'!0@, <6($  T              ( ! WX0
M &EM86=E7S P-"YJ<&=02P$"% ,4    " "'-&Y97 ]VCO1M @ "*0, #0
M            @ 'OP!, :6UA9V5?,# U+FIP9U!+ 0(4 Q0    ( (<T;EE>
MD+&H(M<& &'J!P -              "  0XO%@!I;6%G95\P,#8N:G!G4$L!
M A0#%     @ AS1N653^KWJG3P< >QX(  T              ( !6P8= &EM
M86=E7S P-RYJ<&=02P$"% ,4    " "'-&Y9&UR(:[+ ! !+M 4 #0
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2     !$ $0!'!   WI@J

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>ea0220567-s1_orukatherap_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:orka="http://www.orukatx.com/20240930"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="orka-20240930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">orka:ARCABIOPHARMAINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParagonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:ParukaHoldingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">orka:OrukaAdvisorsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-05</instant>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-07</instant>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-07</startDate>
            <endDate>2024-03-07</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-06</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-30</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">orka:ParagonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-06</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-06</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ConvertibleNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-12</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-12</startDate>
            <endDate>2024-04-12</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaPrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:ARCACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:OrukaCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">orka:ComputerAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">orka:ConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-31</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">orka:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">orka:EmployeeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-03-31</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">orka:SeriesBNonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:TwoThousandTwentyFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">orka:TwoThousandTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-29</startDate>
            <endDate>2024-08-29</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParukaWarrantObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:UnvestedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-05</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">orka:RestrictedStockActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <startDate>2024-07-30</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:ClinicalDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">orka:CertainRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">orka:ORKAZeroZeroTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
        </entity>
        <period>
            <instant>2024-06-15</instant>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:CommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingEmployeeWarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingUnvestedRestrictedStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">orka:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-06</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:FairmountHealthcareFundIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">orka:ParagonAndParukaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOptionAgreementsFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursableOtherResearchExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000907654</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">orka:ParagonReimbursablePatentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0" id="ixv-22658">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-80">Oruka Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-102">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-299">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-312">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-328">false</dei:EntityEmergingGrowthCompany>
    <orka:SubscriptionReceivables contextRef="c1" decimals="-3" id="ixv-22659" unitRef="usd">1000</orka:SubscriptionReceivables>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-22660" unitRef="usd">1000</us-gaap:Assets>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="3"
      id="ixv-22661"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-22662"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="3"
      id="ixv-22663"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-22664"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-22665"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-22666"
      unitRef="shares">3197975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="-3" id="ixv-22667" unitRef="usd">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="-3" id="ixv-22668" unitRef="usd">-2000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-22669" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c65" id="ixv-15142">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. Nature of the Business and Basis of Presentation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Background and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Oruka Therapeutics, Inc. (&#x201c;Oruka&#x201d; or
the &#x201c;Company&#x201d;) was established and incorporated under the laws of the state of Delaware on February 6, 2024. Oruka was founded
by Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;). The Company currently operates as a virtual company, and thus, does not maintain
a corporate headquarters or other significant facilities. Oruka was formed to develop biologics to optimize the treatment of inflammatory
skin diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company is subject to risks and uncertainties
common to early-stage companies in the biopharmaceutical industry, including, but not limited to, completing preclinical and clinical
trials, obtaining regulatory approval for product candidates, development by competitors of new technological innovations, dependence
on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary
technology, compliance with government regulations, product liability, uncertainty of market acceptance of products and the ability to
raise additional capital to fund operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company&#x2019;s potential products will require
approval from the U.S. Food and Drug Administration or comparable foreign authorities prior to the commencement of commercial sales. There
can be no assurance that the Company&#x2019;s potential products will receive all the required approvals. In addition, there can be no
assurance that the Company&#x2019;s potential products, if approved, will be accepted in the marketplace, nor can there be any assurance
that any future products can be developed or manufactured at an acceptable cost and with appropriate performance characteristics, or that
such products will be successfully marketed, if at all.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The financial statement and accompanying notes have
been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Liquidity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The accompanying financial statement has been prepared
on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of
liabilities in the normal course of business. As of February 6, 2024, the Company had no cash.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company will devote substantially all of its
resources to advancing the development of its portfolio of programs, organizing and staffing the Company, business planning, raising capital,
and providing general and administrative support for these operations. Current and future programs will require significant research and
development efforts, including preclinical and clinical trials and regulatory approvals to commercialization. These efforts require significant
amounts of additional capital, adequate personnel, and infrastructure. Even if the Company&#x2019;s development efforts are successful,
it is uncertain when, if ever, the Company will realize significant revenue from product sales. If the Company obtains regulatory approval
for any of its product candidates and starts to generate revenue, it expects to incur significant expenses related to developing its internal
commercialization capability to support product sales, marketing, and distribution.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;As a result, the Company will need substantial additional
funding to support its operating activities as it advances its potential product candidates through development, seeks regulatory approval
and prepares for and, if any of its product candidates are approved, proceeds to commercialization. Until such time as the Company can
generate significant revenue from product sales, if ever, the Company expects to finance its operating activities through a combination
of equity offerings and debt financings. Adequate funding may not be available to the Company on acceptable terms, or at all.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;If the Company is unable to obtain additional funding,
the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its planned
operations, which may have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and ability
to operate as a going concern. The financial statement does not include any adjustments that may result if the Company is not able to
continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company has not generated any revenue from product
sales or other sources and has incurred significant operating losses and negative cash flows from operations since inception.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In March 2024, the Company received $3.0 million
in proceeds from the sale of Series A convertible preferred stock and $25.0 million in proceeds from the sale of an unsecured convertible
promissory note, both of which were related party transactions (see Note 7 &lt;i&gt;Subsequent Events&lt;/i&gt;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;ARCA biopharma, Inc., a Delaware corporation (&#x201c;ARCA&#x201d;),
and the Company entered into an Agreement and Plan of Merger and Reorganization (the &#x201c;Merger Agreement&#x201d;) on April 3, 2024,
pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement,
Atlas Merger Sub Corp, a Delaware corporation (&#x201c;First Merger Sub&#x201d;), will merge with and into Oruka, with Oruka continuing
as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the &#x201c;First Merger&#x201d;), and Oruka will merge
with and into Atlas Merger Sub II, LLC, a Delaware limited liability company (&#x201c;Second Merger Sub&#x201d; and together with First
Merger Sub, &#x201c;Merger Subs&#x201d;), with Second Merger Sub being the surviving entity of the merger (the &#x201c;Second Merger&#x201d;
and, together with the First Merger, the &#x201c;Merger&#x201d;). In connection with the Merger, Second Merger Sub will change its corporate
name to &#x201c;Oruka Therapeutics Operating Company, LLC&#x201d; and ARCA will change its name to &#x201c;Oruka Therapeutics, Inc.&#x201d;
ARCA following the Merger is referred to herein as the &#x201c;combined company.&#x201d; The combined company will be led by Oruka&#x2019;s
management team and will remain focused on developing biologics to optimize the treatment of inflammatory skin diseases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Concurrent with the execution of the Merger Agreement,
the Company entered into a subscription agreement with certain investors to which the Company agreed to issue and sell to investors in
a private placement financing (the &#x201c;Private Placement&#x201d;) shares and pre-funded warrants of the Company&#x2019;s common stock
at an estimated purchase price of $9.71 ($5.55 prior to impact of reverse stock split and reverse merger exchange ratio) per share of
common stock and estimated purchase price of $9.70 ($5.54 prior to the impact of the reverse stock split and reverse merger exchange ratio)
per warrant for gross proceeds of approximately $275.0 million, which will precede the closing of the Merger Agreement. Shares of the
Company&#x2019;s common stock and pre-funded warrants to purchase shares of the Company&#x2019;s common stock issued pursuant to the Private
Placement will be converted into the right to receive shares of ARCA common stock and pre-funded warrants to purchase ARCA common stock,
respectively, in accordance with the exchange ratio at the effective time of the close of the transaction. The proceeds from the Private
Placement are expected to advance the Company&#x2019;s pipeline, business development activities, working capital, and other general corporate
purposes.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;However, the agreements are subject to the satisfaction
of customary closing conditions, and there are no assurances that such conditions will be achieved nor that such financing or other strategic
transactions will be available on acceptable terms, or at all. If the Merger Agreement is terminated under certain circumstances, ARCA
could be required to pay Oruka a termination fee of $0.4 million or Oruka could be required to pay ARCA a termination fee of $0.4 million.
Based on its expectation of continuing operating losses for the foreseeable future, as of May 13, 2024, the date the Company&#x2019;s financial
statement is available to be issued, the Company has concluded there is substantial doubt about its ability to continue as a going concern
for at least twelve months from the date the financial statement is available to be issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In connection with the Merger Agreement discussed
above, the Company effected a one-for-twelve reverse stock split of the Company&#x2019;s issued and outstanding shares of common stock
on September 3, 2024 without any change in the par value per share. Unless otherwise stated, all information related to the Company&#x2019;s
common stock, common stock warrants, restricted stock awards, and stock options, as well as the per share amounts, have been retroactively
adjusted to give effect for the one-for-twelve reverse stock split and reverse merger exchange ratio of 6.8569 as calculated in accordance
with the Merger Agreement for all periods presented.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="c66" decimals="-5" id="ixv-22670" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ConvertibleNotesPayable contextRef="c38" decimals="-5" id="ixv-22671" unitRef="usd">25000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c67"
      decimals="2"
      id="ixv-22672"
      unitRef="usdPershares">9.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c67"
      decimals="2"
      id="ixv-22673"
      unitRef="usdPershares">5.55</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c68"
      decimals="2"
      id="ixv-22674"
      unitRef="usdPershares">9.7</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharePrice
      contextRef="c68"
      decimals="2"
      id="ixv-22675"
      unitRef="usdPershares">5.54</us-gaap:SharePrice>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c69" decimals="-5" id="ixv-22676" unitRef="usd">275000000</us-gaap:WarrantsAndRightsOutstanding>
    <orka:TerminationFee contextRef="c70" decimals="-5" id="ixv-22677" unitRef="usd">400000</orka:TerminationFee>
    <orka:TerminationFee contextRef="c65" decimals="-5" id="ixv-22678" unitRef="usd">400000</orka:TerminationFee>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c65" decimals="4" id="ixv-22679" unitRef="pure">6.8569</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c65" id="ixv-15216">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Subscription receivable&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <orka:SubscriptionReceivablePolicyTextBlock contextRef="c65" id="ixv-15221">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;Subscription receivable&lt;/b&gt;&lt;/p&gt;&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accounts for any notes received in exchange
for common stock as a subscription receivable, provided the note underlying the receivable is paid prior to the date the financial statement
is available to be issued.&lt;/p&gt;</orka:SubscriptionReceivablePolicyTextBlock>
    <orka:CommonStockTextBlock contextRef="c65" id="ixv-15231">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;3. Common Stock&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;As of February 6, 2024, the Company has the authority
to issue a total of 65,000,000 shares of common stock at a par value of $0.001. As of February 6, 2024, 3,197,975 shares of common stock
were issued and outstanding for a nominal consideration, which was received in March 2024, prior to the date the financial statement is
available to be issued. Each share of common stock entitles the holder to one vote for each share of common stock held of record by such
holder on all matters on which stockholders generally are entitled to vote. The holders of common stock are entitled to receive dividends,
if any, as declared by the Company&#x2019;s Board of Directors. Upon dissolution, liquidation or winding up of the Company, the holders
of shares of common stock, subject to the rights of the holders of any outstanding series of preferred stock, shall be entitled to receive
the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares held.&lt;/p&gt;</orka:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c71"
      decimals="0"
      id="ixv-22680"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c71"
      decimals="3"
      id="ixv-22681"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c71"
      decimals="0"
      id="ixv-22682"
      unitRef="shares">3197975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c71"
      decimals="0"
      id="ixv-22683"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c65" id="ixv-15239">&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. Related Party Transactions&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company issued 3,197,975 shares of common stock,
through a series of contribution agreements, to Paragon, Paruka Holding, LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a
vehicle to hold equity in the Company, and Oruka Advisors LLC (&#x201c;Oruka Advisors&#x201d;), an entity formed by Paragon as a vehicle
to hold equity in the Company, as part of its common stock subscription agreement with such entities. As of February 6, 2024, Paragon,
Paruka and Oruka Advisors each beneficially own approximately 44.7%, 44.7% and 10.6%, respectively, of the Company through their common
stock holdings.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="c6"
      decimals="0"
      id="ixv-22684"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c72" decimals="3" id="ixv-22685" unitRef="pure">0.447</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c73" decimals="3" id="ixv-22686" unitRef="pure">0.447</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c74" decimals="3" id="ixv-22687" unitRef="pure">0.106</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c65" id="ixv-15248">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company may be subject to legal proceedings
that arise in the ordinary course of business. As of February 6, 2024, there were no material proceedings to which the Company was a party,
nor did the Company have knowledge of any proceedings threatened against it.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c65" id="ixv-15257">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;6. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On February 6, 2024, the Company&#x2019;s Board of
Directors approved the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;), under which the Company may grant stock options, restricted
stock awards, restricted stock units, or other stock-based awards to its employees, officers, directors, consultants, and advisors. The
Company reserved 213,085 shares of its common stock for issuance under the 2024 Plan. As of February 6, 2024, no awards had been issued
under the plan.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c75"
      decimals="0"
      id="ixv-22688"
      unitRef="shares">213085</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SubsequentEventsTextBlock contextRef="c65" id="ixv-15266">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;7. Subsequent Events&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company evaluated all events subsequent to February
6, 2024, through May 13, 2024, the date on which the financial statement was available to be issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In February 2024, the Company&#x2019;s Board of Directors
authorized and granted 1,184,749 restricted stock awards at a price of $0.0001 per share to employees of the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In March 2024, the Company&#x2019;s Board of Directors
authorized and granted 1,022,804 restricted stock awards at a price of $0.0001 per share to consultants and a director of the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 5, 2024, the Company&#x2019;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
213,085 to 498,789.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 22, 2024, the Company granted options for
the purchase of an aggregate 399,222 shares of common stock, at an exercise price of $5.16 per share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On May 7, 2024, the Company&#x2019;s Board of Directors
approved an amendment to the 2024 Plan to increase the number of shares of common stock available for issuance under the 2024 Plan from
498,789 to 1,179,193.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On May 7, 2024, the Company granted options for
the purchase of an aggregate 779,971 shares of common stock, at an exercise price of $6.84 per share.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Antibody Discovery and Option Agreements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 6, 2024, the Company entered into an Antibody
Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby the Company
was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#x2019;s right, title and
interest in and to the intellectual property (&#x201c;ORKA-001&#x201d;) resulting from the applicable research program to develop, manufacture
and commercialize products directed at the selected target (&#x201c;IL-23&#x201d;), with the exception of pursuing ORKA-001 for the treatment
of inflammatory bowel disease. Upon signing of the Antibody Discovery and Option Agreement for ORKA-001, a one-time, non-refundable research
initiation fee of $0.8 million was due to Paragon. This amount was recognized as a research and development expense during the period
ended March 31, 2024, and paid to Paragon in April 2024. The Company is also responsible for 50% of the development costs incurred prior
to March 31, 2024, provided that the Company receives rights to at least one selected IL-23 antibody. As of the date this financial statement
is available to be issued, the Company has not received rights to a selected IL-23 antibody and has not paid or accrued the $5.9 million
of development costs incurred prior to March 31, 2024. The Company will be responsible for 50% of the ORKA-001 development costs incurred
from and after March 31, 2024, through the completion of the IL-23 selection process.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 6, 2024, the Company also entered into
an Antibody Discovery and Option Agreement with Paragon and Paruka, which was subsequently amended and restated on March 28, 2024, whereby
the Company was granted an exclusive, worldwide option, on a research program-by-research program basis, to all of Paragon&#x2019;s right,
title and interest in and to the intellectual property (&#x201c;ORKA-002&#x201d;) resulting from the applicable research program to develop,
manufacture and commercialize products directed at the selected target (&#x201c;IL-17&#x201d;). The Company was also required to reimburse
Paragon $3.3 million for development costs related to ORKA-002 incurred by Paragon through December 31, 2023 and certain other development
costs related to ORKA-002 incurred by Paragon between January 1, 2024 and March 6, 2024. This amount was recognized as a research and
development expenses during the period from February 6 (inception) to March 31, 2024 and accounts payable as of March 31, 2024. The Company
paid $3.3 million to Paragon in April 2024. The Company is also responsible for the development costs incurred by Paragon from January
1, 2024 to March 31, 2024 of $0.9 million, which was recognized as a research and development expense in the period from February 6 (inception)
to March 31, 2024. The Company will be required to pay Paragon $0.8 million for the research initiation fee related to ORKA-002 within
30 days following finalization of the ORKA-002 research plan as well as for subsequent development costs related to ORKA-002.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;As of the date of issuance of the Company&#x2019;s
financial statement, the Company has not exercised its options with respect to ORKA-001 or ORKA-002. For each of these agreements, if
the Company exercises its options, it will be required to make non-refundable milestone payments to Paragon of up to $12.0 million upon
the achievement of certain clinical development milestones, up to $10.0 million upon the achievement of certain regulatory milestones,
as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial sale.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Additionally, as part of the Antibody Discovery
and Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant Paruka warrants to purchase a number
of shares equal to 1.00% of the then outstanding shares of the Company&#x2019;s common stock as of the date of the grant on a fully-diluted
basis, with an exercise price equal to the fair market value of the underlying shares on the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Series A Preferred Stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 6, 2024, the Company issued 20,000,000
shares of Series A convertible preferred stock to Fairmount Healthcare Fund II, L.P. (&#x201c;Fairmount&#x201d;), a related party of the
Company, at a purchase price of $0.15 per share for gross proceeds of $3.0 million. The Company incurred less than $0.1 million of issuance
costs in connection with this transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The holders of Series A convertible preferred stock
are entitled to vote, together with the holders of common stock, on all matters submitted to stockholders for a vote. Each holder of outstanding
shares of Series A convertible preferred stock is entitled to the number of votes equal to the number of shares of common stock into which
the shares of preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote
on such matter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Each share of Series A convertible preferred stock
is convertible at the option of the holder, at any time, and without the payment of additional consideration by the holder. In addition,
each share of Series A convertible preferred stock will be automatically converted into shares of common stock at the applicable conversion
ratio then in effect upon either (i) the closing of a firm-commitment underwritten public offering of the Company&#x2019;s common stock
at a price of at least $12.00 per share resulting in at least $50.0 million of gross proceeds to the Company, or (ii) the vote or written
consent of the holders of a majority of the Preferred Stock, voting as a single class.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The conversion ratio of Series A convertible preferred
stock is determined by dividing the Original Issue Price by the Conversion Price in effect at the time of conversion. The Original Issue
Price is $0.15 per share for Series A convertible preferred stock (in each case subject to appropriate adjustment in the event of any
stock split, stock dividend, combination or other similar recapitalization and other adjustments as set forth in the Company&#x2019;s certificate
of incorporation, as amended and restated). The Conversion Price is approximately $0.26 per share for Series A convertible preferred stock
and each outstanding share of Series A Preferred Stock was convertible into common stock at a 0.5712 conversion ratio.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company may not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Company (other than dividends on shares of common stock) unless
the holders of the Series A convertible preferred stock then outstanding first receive, or simultaneously receive, a dividend on each
outstanding share of Series A convertible preferred stock in an amount at least equal to (i) in the case of a dividend being distributed
to common stock or any class or series that is convertible into common stock, the equivalent dividend on an as-converted basis or (ii)
in the case of a dividend on any class or series that is not convertible into common stock, a dividend equal to a dividend rate on Series
A convertible preferred stock calculated based on the respective Original Issue Price of Series A convertible preferred stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares
of Series A convertible preferred stock then outstanding are entitled to be paid out of the assets or funds of the Company available for
distribution to stockholders before any payment is made to the holders of common stock. The holders of Series A convertible preferred
stock are entitled to an amount equal to the greater of (i) the applicable Original Issue Price per share of Series A convertible preferred
stock, plus any declared but unpaid dividends thereon, or (ii) the amount per share that would have been payable had all shares of Series
A convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed
Liquidation Event. If upon any such liquidation event, the assets or funds of the Company available for distribution to stockholders are
insufficient to pay the full amount to which they are entitled, then the holders of shares of Series A convertible preferred stock will
share ratably in any distribution of the assets or funds available for distribution in proportion to the respective amounts which would
otherwise be payable if it were paid in full.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Unless the holders of a majority in voting power
of the then outstanding shares of Series A convertible preferred stock elect otherwise, a Deemed Liquidation Event shall include a merger
or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the
surviving or acquiring corporation) or sale, lease, transfer, exclusive license or other disposition of all or substantially all of the
Company&#x2019;s assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Series A convertible preferred stock does not have
redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On March 6, 2024, the Company entered into a Series
A Preferred Stock and Convertible Note Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with Fairmount, whereby the Company issued
a convertible note (the &#x201c;Convertible Note&#x201d;), with an initial principal amount of $25.0 million, that can be converted into
Series A preferred stock (or a Series of preferred shares that is identical in respect to the shares of preferred shares issued in its
next equity financing) or shares of the Company&#x2019;s common stock in exchange for proceeds of $25.0 million. The Convertible Note will
automatically convert into shares of the Company&#x2019;s common stock upon the closing of a corporate transaction, including the reverse
recapitalization transaction, and is otherwise due and payable at the request of the holder at any time. The Convertible Note accrues
interest at a rate of 12.0% per annum. All unpaid interest and principal are scheduled to mature on December 31, 2025. Prepayment is not
permitted without prior written consent of Fairmount. Pursuant to the Purchase Agreement, the Company has the right to sell and issue
additional convertible notes up to an aggregate principal amount equal to $30.0 million, in addition to the $25.0 million of initial principal
amount of the Convertible Note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Oak Grove Lease&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On April 12, 2024, the Company entered into a lease
agreement with Oak Grove LP (&#x201c;Oak Grove Lease&#x201d;) for office space located in Menlo Park, California. The lease commencement
date is June 15, 2024 with an initial term of 39.5 months. The total lease payment is expected to be $1.4 million over the initial lease
term.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c76"
      decimals="0"
      id="ixv-22689"
      unitRef="shares">1184749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c76"
      decimals="4"
      id="ixv-22690"
      unitRef="usdPershares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c77"
      decimals="0"
      id="ixv-22691"
      unitRef="shares">1022804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c77"
      decimals="4"
      id="ixv-22692"
      unitRef="usdPershares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c78"
      decimals="0"
      id="ixv-22693"
      unitRef="shares">213085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c79"
      decimals="0"
      id="ixv-22694"
      unitRef="shares">498789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c80"
      decimals="0"
      id="ixv-22695"
      unitRef="shares">399222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c81"
      decimals="0"
      id="ixv-22696"
      unitRef="shares">498789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c82"
      decimals="0"
      id="ixv-22697"
      unitRef="shares">1179193</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c83"
      decimals="0"
      id="ixv-22698"
      unitRef="shares">779971</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <orka:ResearchInitiationFee contextRef="c84" decimals="-5" id="ixv-22699" unitRef="usd">800000</orka:ResearchInitiationFee>
    <orka:DevelopmentCostsPercentage contextRef="c84" decimals="2" id="ixv-22700" unitRef="pure">0.50</orka:DevelopmentCostsPercentage>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c85" decimals="-5" id="ixv-22701" unitRef="usd">5900000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <orka:DevelopmentCostsPercentage contextRef="c86" decimals="2" id="ixv-22702" unitRef="pure">0.50</orka:DevelopmentCostsPercentage>
    <orka:ReimburseOfDevelopmentCosts contextRef="c87" decimals="-5" id="ixv-22703" unitRef="usd">3300000</orka:ReimburseOfDevelopmentCosts>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c88" decimals="-5" id="ixv-22704" unitRef="usd">3300000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c89" decimals="-5" id="ixv-22705" unitRef="usd">900000</us-gaap:ResearchAndDevelopmentExpense>
    <orka:ResearchInitiationFee contextRef="c90" decimals="-5" id="ixv-22706" unitRef="usd">800000</orka:ResearchInitiationFee>
    <orka:NonRefundableMilestonePayments contextRef="c91" decimals="-5" id="ixv-22707" unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments contextRef="c92" decimals="-5" id="ixv-22708" unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <orka:PercentageOfWarrantPurchare contextRef="c93" decimals="4" id="ixv-22709" unitRef="pure">0.01</orka:PercentageOfWarrantPurchare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c94"
      decimals="0"
      id="ixv-22710"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c94"
      decimals="2"
      id="ixv-22711"
      unitRef="usdPershares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c95" decimals="-5" id="ixv-22712" unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c95" decimals="-5" id="ixv-22713" unitRef="usd">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c96"
      decimals="2"
      id="ixv-22714"
      unitRef="usdPershares">12</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c84" decimals="-5" id="ixv-22715" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c97"
      decimals="2"
      id="ixv-22716"
      unitRef="usdPershares">0.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c98"
      decimals="2"
      id="ixv-22717"
      unitRef="usdPershares">0.26</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c94"
      decimals="4"
      id="ixv-22718"
      unitRef="usdPershares">0.5712</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c99" decimals="-5" id="ixv-22719" unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="c100"
      decimals="-5"
      id="ixv-22720"
      unitRef="usd">25000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c100"
      decimals="3"
      id="ixv-22721"
      unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c101"
      decimals="-5"
      id="ixv-22722"
      unitRef="usd">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c102"
      decimals="-5"
      id="ixv-22723"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c103" id="ixv-22724">P39M15D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasePayments
      contextRef="c104"
      decimals="-5"
      id="ixv-22725"
      unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c65" id="ixv-15380">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;8. Events subsequent to the reissuance of the financial statement
(unaudited)&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In connection with the reissuance of the financial
statement, the Company has evaluated subsequent events through November 13, 2024, the date the financial statement was available to be
reissued.&lt;/p&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-22726" unitRef="usd">410875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <orka:SubscriptionReceivables contextRef="c4" decimals="-3" id="ixv-22727" unitRef="usd">1000</orka:SubscriptionReceivables>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" id="ixv-22728" unitRef="usd">2074000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" id="ixv-22729" unitRef="usd">412949000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c4" decimals="-3" id="ixv-22730" unitRef="usd">1000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" id="ixv-22731" unitRef="usd">160000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" id="ixv-22732" unitRef="usd">938000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" id="ixv-22733" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c3" decimals="-3" id="ixv-22734" unitRef="usd">414090000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c4" decimals="-3" id="ixv-22735" unitRef="usd">1000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" id="ixv-22736" unitRef="usd">2145000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-22737" unitRef="usd">1710000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-22738" unitRef="usd">146000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="c5" decimals="-3" id="ixv-22739" unitRef="usd">7681000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-22740" unitRef="usd">6357000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" id="ixv-22741" unitRef="usd">18039000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-22742" unitRef="usd">842000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c3" decimals="-3" id="ixv-22743" unitRef="usd">18881000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c7"
      decimals="4"
      id="ixv-22744"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c8"
      decimals="4"
      id="ixv-22745"
      unitRef="usdPershares">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c7"
      decimals="INF"
      id="ixv-22746"
      unitRef="shares">20000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c8"
      decimals="INF"
      id="ixv-22747"
      unitRef="shares">20000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c7" decimals="-3" id="ixv-22748" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c8" decimals="-3" id="ixv-22749" unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c9"
      decimals="3"
      id="ixv-22750"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c10"
      decimals="3"
      id="ixv-22751"
      unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c9"
      decimals="INF"
      id="ixv-22752"
      unitRef="shares">2439</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c9"
      decimals="INF"
      id="ixv-22753"
      unitRef="shares">2439</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-22754"
      unitRef="shares">2439</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c9" decimals="-3" id="ixv-22755" unitRef="usd">52841000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c11"
      decimals="3"
      id="ixv-22756"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c12"
      decimals="3"
      id="ixv-22757"
      unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c11"
      decimals="INF"
      id="ixv-22758"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c11"
      decimals="INF"
      id="ixv-22759"
      unitRef="shares">137138</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c11"
      decimals="INF"
      id="ixv-22760"
      unitRef="shares">137138</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c11" decimals="-3" id="ixv-22761" unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c3"
      decimals="3"
      id="ixv-22762"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c4"
      decimals="3"
      id="ixv-22763"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c3"
      decimals="INF"
      id="ixv-22764"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c4"
      decimals="INF"
      id="ixv-22765"
      unitRef="shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c3"
      decimals="INF"
      id="ixv-22766"
      unitRef="shares">34998550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c3"
      decimals="INF"
      id="ixv-22767"
      unitRef="shares">34998550</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c4"
      decimals="INF"
      id="ixv-22768"
      unitRef="shares">3197975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c4"
      decimals="INF"
      id="ixv-22769"
      unitRef="shares">3197975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" id="ixv-22770" unitRef="usd">35000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" id="ixv-22771" unitRef="usd">397345000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c4" decimals="-3" id="ixv-22772" unitRef="usd">1000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" id="ixv-22773" unitRef="usd">-57943000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-22774" unitRef="usd">342368000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c4" decimals="-3" id="ixv-22775" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" id="ixv-22776" unitRef="usd">414090000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c4" decimals="-3" id="ixv-22777" unitRef="usd">1000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c13" decimals="-3" id="ix_0_fact" unitRef="usd">25691000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ix_1_fact" unitRef="usd">49557000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c13" decimals="-3" id="ix_2_fact" unitRef="usd">3758000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ix_3_fact" unitRef="usd">8248000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c13" decimals="-3" id="ixv-22782" unitRef="usd">29449000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-22783" unitRef="usd">57805000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c13" decimals="-3" id="ixv-22784" unitRef="usd">-29449000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-22785" unitRef="usd">-57805000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c13" decimals="-3" id="ixv-22786" unitRef="usd">1330000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-22787" unitRef="usd">1330000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c13" decimals="-3" id="ix_4_fact" unitRef="usd">504000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="-3" id="ix_5_fact" unitRef="usd">1468000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c13" decimals="-3" id="ixv-22790" unitRef="usd">826000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-22791" unitRef="usd">-138000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-22792" unitRef="usd">-28623000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-22793" unitRef="usd">-57943000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c13"
      decimals="2"
      id="ixv-22794"
      unitRef="usdPershares">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ixv-22795"
      unitRef="usdPershares">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-22796"
      unitRef="usdPershares">-6.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-22797"
      unitRef="usdPershares">-6.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c14"
      decimals="2"
      id="ixv-22798"
      unitRef="usdPershares">-1461.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c14"
      decimals="2"
      id="ixv-22799"
      unitRef="usdPershares">-1461.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c15"
      decimals="2"
      id="ixv-22800"
      unitRef="usdPershares">-6077.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c15"
      decimals="2"
      id="ixv-22801"
      unitRef="usdPershares">-6077.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c16"
      decimals="2"
      id="ixv-22802"
      unitRef="usdPershares">-121.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c16"
      decimals="2"
      id="ixv-22803"
      unitRef="usdPershares">-121.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c17"
      decimals="2"
      id="ixv-22804"
      unitRef="usdPershares">-506.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c17"
      decimals="2"
      id="ixv-22805"
      unitRef="usdPershares">-506.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="INF"
      id="ixv-22806"
      unitRef="shares">15013655</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="INF"
      id="ixv-22807"
      unitRef="shares">15013655</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-22808"
      unitRef="shares">7765381</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-22809"
      unitRef="shares">7765381</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="INF"
      id="ixv-22810"
      unitRef="shares">477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c14"
      decimals="INF"
      id="ixv-22811"
      unitRef="shares">477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c15"
      decimals="INF"
      id="ixv-22812"
      unitRef="shares">184</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c15"
      decimals="INF"
      id="ixv-22813"
      unitRef="shares">184</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c16"
      decimals="INF"
      id="ixv-22814"
      unitRef="shares">49191</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c16"
      decimals="INF"
      id="ixv-22815"
      unitRef="shares">49191</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c17"
      decimals="INF"
      id="ixv-22816"
      unitRef="shares">19015</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c17"
      decimals="INF"
      id="ixv-22817"
      unitRef="shares">19015</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c21"
      decimals="INF"
      id="ixv-22818"
      unitRef="shares">3197975</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c21" decimals="-3" id="ixv-22819" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c22" decimals="-3" id="ixv-22820" unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" id="ixv-22821" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c28"
      decimals="INF"
      id="ixv-22822"
      unitRef="shares">2207553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c28" decimals="-3" id="ixv-22823" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c29" decimals="-3" id="ixv-22824" unitRef="usd">-2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts contextRef="c31" decimals="-3" id="ixv-22825" unitRef="usd">69000</orka:IssuanceOfSeriesAConvertiblePreferredStockNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c25"
      decimals="INF"
      id="ixv-22826"
      unitRef="shares">20000000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c25" decimals="-3" id="ixv-22827" unitRef="usd">2931000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c29" decimals="-3" id="ixv-22828" unitRef="usd">17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c31" decimals="-3" id="ixv-22829" unitRef="usd">17000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c30" decimals="-3" id="ixv-22830" unitRef="usd">-7077000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" id="ixv-22831" unitRef="usd">-7077000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c32"
      decimals="INF"
      id="ixv-22832"
      unitRef="shares">20000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" id="ixv-22833" unitRef="usd">2931000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c35"
      decimals="INF"
      id="ixv-22834"
      unitRef="shares">5405528</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" id="ixv-22835" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c36" decimals="-3" id="ixv-22836" unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c37" decimals="-3" id="ixv-22837" unitRef="usd">-7077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c38" decimals="-3" id="ixv-22838" unitRef="usd">-7059000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c43" decimals="-3" id="ixv-22839" unitRef="usd">321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c45" decimals="-3" id="ixv-22840" unitRef="usd">321000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c44" decimals="-3" id="ixv-22841" unitRef="usd">-22243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c45" decimals="-3" id="ixv-22842" unitRef="usd">-22243000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c46"
      decimals="INF"
      id="ixv-22843"
      unitRef="shares">20000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c46" decimals="-3" id="ixv-22844" unitRef="usd">2931000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c49"
      decimals="INF"
      id="ixv-22845"
      unitRef="shares">5405528</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c49" decimals="-3" id="ixv-22846" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c50" decimals="-3" id="ixv-22847" unitRef="usd">334000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c51" decimals="-3" id="ixv-22848" unitRef="usd">-29320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c52" decimals="-3" id="ixv-22849" unitRef="usd">-28981000</us-gaap:StockholdersEquity>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock
      contextRef="c53"
      decimals="INF"
      id="ixv-22850"
      unitRef="shares">-20000000</orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt contextRef="c53" decimals="-3" id="ixv-22851" unitRef="usd">-2931000</orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock
      contextRef="c55"
      decimals="INF"
      id="ixv-22852"
      unitRef="shares">137138</orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredStock>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt contextRef="c55" decimals="-3" id="ixv-22853" unitRef="usd">2931000</orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt contextRef="c13" decimals="-3" id="ixv-22854" unitRef="usd">2931000</orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c56"
      decimals="INF"
      id="ixv-22855"
      unitRef="shares">2722207</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c56" decimals="-3" id="ixv-22856" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c57" decimals="-3" id="ixv-22857" unitRef="usd">26445000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c13" decimals="-3" id="ixv-22858" unitRef="usd">26448000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost
      contextRef="c56"
      decimals="INF"
      id="ixv-22859"
      unitRef="shares">20061932</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCost>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c56" decimals="-3" id="ixv-22860" unitRef="usd">20000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c57" decimals="-3" id="ixv-22861" unitRef="usd">248437000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos contextRef="c13" decimals="-3" id="ixv-22862" unitRef="usd">248457000</orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization contextRef="c57" decimals="-3" id="ixv-22863" unitRef="usd">-20480000</orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization contextRef="c13" decimals="-3" id="ixv-22864" unitRef="usd">-20480000</orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization>
    <orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger
      contextRef="c56"
      decimals="INF"
      id="ixv-22865"
      unitRef="shares">1208883</orka:IssuanceOfCommonStockToFormerStockholdersOfARCABiopharmaIncInConnectionWithTheClosingOftheReverseMerger>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger contextRef="c56" decimals="-3" id="ixv-22866" unitRef="usd">1000</orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger contextRef="c57" decimals="-3" id="ixv-22867" unitRef="usd">4999000</orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger contextRef="c13" decimals="-3" id="ixv-22868" unitRef="usd">5000000</orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c54"
      decimals="INF"
      id="ixv-22869"
      unitRef="shares">2439</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c54" decimals="-3" id="ixv-22870" unitRef="usd">56097000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant
      contextRef="c56"
      decimals="INF"
      id="ixv-22871"
      unitRef="shares">5600000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarrant>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c56" decimals="-3" id="ixv-22872" unitRef="usd">6000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c57" decimals="-3" id="ixv-22873" unitRef="usd">144433000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr contextRef="c13" decimals="-3" id="ixv-22874" unitRef="usd">144439000</orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c54" decimals="-3" id="ixv-22875" unitRef="usd">-3256000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c57" decimals="-3" id="ixv-22876" unitRef="usd">-8573000</orka:IssuanceCostOfPIPEFinancing>
    <orka:IssuanceCostOfPIPEFinancing contextRef="c13" decimals="-3" id="ixv-22877" unitRef="usd">-8573000</orka:IssuanceCostOfPIPEFinancing>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c57" decimals="-3" id="ixv-22878" unitRef="usd">1750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c13" decimals="-3" id="ixv-22879" unitRef="usd">1750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c58" decimals="-3" id="ixv-22880" unitRef="usd">-28623000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-22881" unitRef="usd">-28623000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c60"
      decimals="INF"
      id="ixv-22882"
      unitRef="shares">2439</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c60" decimals="-3" id="ixv-22883" unitRef="usd">52841000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c61"
      decimals="INF"
      id="ixv-22884"
      unitRef="shares">137138</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c61" decimals="-3" id="ixv-22885" unitRef="usd">2931000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c62"
      decimals="INF"
      id="ixv-22886"
      unitRef="shares">34998550</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c62" decimals="-3" id="ixv-22887" unitRef="usd">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c63" decimals="-3" id="ixv-22888" unitRef="usd">397345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c64" decimals="-3" id="ixv-22889" unitRef="usd">-57943000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" id="ixv-22890" unitRef="usd">342368000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-22891" unitRef="usd">-57943000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" id="ixv-22892" unitRef="usd">11000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-22893" unitRef="usd">9769000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" id="ixv-22894" unitRef="usd">1468000</us-gaap:OtherNoncashExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c0" decimals="-3" id="ixv-22895" unitRef="usd">65000</us-gaap:OperatingLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c0" decimals="-3" id="ixv-22896" unitRef="usd">1980000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="c0" decimals="-3" id="ixv-22897" unitRef="usd">43000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" id="ixv-22898" unitRef="usd">1621000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="-3" id="ixv-22899" unitRef="usd">1650000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-22900" unitRef="usd">6000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="c0" decimals="-3" id="ixv-22901" unitRef="usd">6357000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-22902" unitRef="usd">-39019000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-22903" unitRef="usd">171000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-22904" unitRef="usd">-171000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <orka:ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid contextRef="c0" decimals="-3" id="ixv-22905" unitRef="usd">2931000</orka:ProceedsFromIssuanceOfPreMergerOrukaSeriesAPreferredStockNetOfIssuanceCostsPaid>
    <us-gaap:ProceedsFromNotesPayable contextRef="c0" decimals="-3" id="ixv-22906" unitRef="usd">24980000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c0" decimals="-3" id="ixv-22907" unitRef="usd">228127000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c0" decimals="-3" id="ixv-22908" unitRef="usd">189087000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <orka:CashAssumedInConnectionWithTheReverseRecapitalization contextRef="c0" decimals="-3" id="ixv-22909" unitRef="usd">4940000</orka:CashAssumedInConnectionWithTheReverseRecapitalization>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-22910" unitRef="usd">450065000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-22911" unitRef="usd">410875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="-3" id="ixv-22912" unitRef="usd">410875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-22913" unitRef="usd">982000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1 contextRef="c0" decimals="-3" id="ixv-22914" unitRef="usd">114000</us-gaap:NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c0" decimals="-3" id="ixv-22915" unitRef="usd">54000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <orka:UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable contextRef="c0" decimals="-3" id="ixv-22916" unitRef="usd">150000</orka:UnpaidPreclosingFinancingAndReverseRecapitalizationIssuanceCostsIncludedInAccountsPayable>
    <orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable contextRef="c0" decimals="-3" id="ixv-22917" unitRef="usd">374000</orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccountsPayable>
    <orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties contextRef="c0" decimals="-3" id="ixv-22918" unitRef="usd">6000</orka:UnpaidPIPEFinancingIssuanceCostsIncludedInAccruedExpensesAndOtherCurrentLiabilties>
    <orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock contextRef="c0" decimals="-3" id="ixv-22919" unitRef="usd">1468000</orka:NoncashAccruedInterestOnConvertibleNoteConvertedToCommonStock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c0" decimals="-3" id="ixv-22920" unitRef="usd">2931000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0" id="ixv-18338">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;1.
Nature of the Business and Basis of Presentation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Background
and Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Oruka
Therapeutics, Inc., together with its subsidiaries (collectively, the &#x201c;Company&#x201d;), formerly known as ARCA biopharma, Inc.
(&#x201c;ARCA&#x201d;), is an early-stage biotechnology company that is the result of the reverse recapitalization discussed below. Prior
to the reverse recapitalization, the private company Oruka Therapeutics, Inc. (&#x201c;Pre-Merger Oruka&#x201d;) was established and incorporated
under the laws of the state of Delaware on February&#160;6, 2024 (referred to in the Notes as the inception of the Company). The Company
is headquartered in Menlo Park, California. The Company is focused on developing biologics to optimize the treatment of inflammatory
skin diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;These
condensed consolidated financial statements reflect, in the opinion of management, all adjustments of a normal and recurring nature that
are necessary for a fair statement of the Company&#x2019;s financial position as of September 30, 2024, and its results of operations
for the three months ended September 30, 2024 and from February 6, 2024 (inception) to September 30, 2024, and cash flows for the period
from February 6, 2024 (inception) to September 30, 2024. The condensed balance sheet as of February 6, 2024, included in the condensed
consolidated balance sheets was derived from the Company&#x2019;s audited financial statements. The condensed consolidated financial statements
and accompanying notes are prepared in accordance with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;GAAP&#x201d;)
for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;)
and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
results for the three months ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024 are not
necessarily indicative of results expected for the full fiscal year or any subsequent interim period. The condensed consolidated financial
statements include the financial statements of its wholly-owned subsidiaries. All significant intercompany balances and transactions
have been eliminated in consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Reverse
Recapitalization and Pre-Closing&#160;Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 29, 2024, the Company consummated the previously announced business combination (&#x201c;Closing&#x201d;) pursuant to that certain
Agreement and Plan of Merger and Reorganization, dated April 3, 2024 (the &#x201c;Merger Agreement&#x201d;), by and among ARCA, Atlas Merger
Sub Corp, a wholly owned subsidiary of ARCA (&#x201c;First Merger Sub&#x201d;), Atlas Merger Sub II, LLC, a wholly owned subsidiary of
ARCA (&#x201c;Second Merger Sub&#x201d;) and Pre-Merger Oruka, pursuant to which, among other matters, Pre-Merger Oruka merged with and
into First Merger Sub, with Pre-Merger Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger
(&#x201c;First Merger&#x201d;) and following that, Pre-Merger Oruka then merged with and into Second Merger Sub, with Second Merger Sub
being the surviving entity of the second merger (the &#x201c;Second Merger&#x201d; and together with the First Merger, the &#x201c;Merger&#x201d;).
Following consummation of the Merger, the Company effected a 1-for-12 reverse stock split (the &#x201c;Reverse Stock Split&#x201d;) of
the common stock, par value $0.001 per share, of the Company (&#x201c;Company Common Stock&#x201d;), which became effective on September
3, 2024. The Company Common Stock commenced trading on a post-Reverse Stock Split, post-Merger basis at the opening of trading on September
3, 2024. Second Merger Sub changed its corporate name to &#x201c;Oruka Therapeutics Operating Company, LLC&#x201d; and ARCA changed its
name to &#x201c;Oruka Therapeutics, Inc.&#x201d; The Company is led by the Pre-Merger Oruka management team and remains focused on developing
biologics to optimize the treatment of inflammatory skin diseases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Immediately
prior to the execution and delivery of the Merger Agreement on April 3, 2024, certain new and existing investors of Pre-Merger Oruka
entered into a subscription agreement with Pre-Merger Oruka (the &#x201c;Subscription Agreement&#x201d;), pursuant to which, and on the
terms and subject to the conditions of which, immediately prior to the Closing, those investors purchased shares of common stock of Pre-Merger
Oruka (&#x201c;Pre-Merger Oruka Common Stock&#x201d;) and Pre-Merger Oruka pre-funded warrants for gross proceeds of approximately $275.0
million (which includes $25.0 million of proceeds previously received from the issuance of the Convertible Note (as defined in Note 6)
and accrued interest on such note which converted to shares of Pre-Merger Oruka Common Stock) (the &#x201c;Pre-Closing Financing&#x201d;).
The Company incurred transaction costs of $20.5 million which was recorded as a reduction to additional paid-in capital in the unaudited
condensed consolidated financial statements. At the Closing, the shares of Pre-Merger Oruka Common Stock and Pre-Merger Oruka pre-funded
warrants issued pursuant to the Subscription Agreement were converted into shares of Company Common Stock and pre-funded warrants of
Company Common Stock in accordance with the Exchange Ratio (defined below).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In accordance with an Exchange Ratio determined
by terms of the Merger Agreement and upon the effective time of the First Merger (the &#x201c;First Effective Time&#x201d;), (i) each then-issued
and outstanding share of Pre-Merger Oruka Common Stock including outstanding and unvested Pre-Merger Oruka restricted stock and shares
of Pre-Merger Oruka Common Stock issued in connection with the Subscription Agreement, were converted into the right to receive a number
of shares of Company Common Stock, equal to the Exchange Ratio of 6.8569 shares of Company Common Stock, which were subject to the same
vesting provisions as those immediately prior to the Merger, (ii) each share of Pre-Merger Oruka Series A convertible preferred stock,
par value $0.0001 (&#x201c;Pre-Merger Oruka Series A Preferred Stock&#x201d;), outstanding immediately prior to the First Effective Time
was converted into the right to receive a number of shares of ARCA Series B non-voting convertible preferred stock, par value $0.001 per
share (&#x201c;Company Series B Preferred Stock&#x201d;), which are convertible into shares of Company Common Stock, at a conversion ratio
of approximately 83:3332:1 (iii) each outstanding option to purchase Pre-Merger Oruka Common Stock was converted into an option to purchase
shares of Company Common Stock, (iv) each outstanding warrant to purchase shares of Pre-Merger Oruka Common Stock was converted into a
warrant to purchase shares of Company Common Stock, and (v) each share of Company Common Stock issued and outstanding at the First Effective
Time remain issued and outstanding in accordance with its terms and such shares. Subsequent to the close of the merger, the common stock
shares were then, subject to the reverse stock split of 1-for-12 effected on September 3, 2024. Net loss per share for periods prior to
the close of the reverse recapitalization has been revised to reflect the exchange ratio. After applying the exchange ratio and the reverse
stock split, net loss per share for the periods from February 6, 2024 (inception) to March 31, 2024 and for three months ended June 30,
2024 and from February 6, 2024 (inception) to June 30, 2024 are $(2.21), $(6.96), and $(9.17), respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the Pre-Closing Financing and the Closing, investors in the Pre-Closing Financing received 22,784,139 shares of Company Common
Stock in exchange for 39,873,706 shares of Pre-Merger Oruka Common Stock (which includes the issuance of 2,722,207 shares of Company
Common Stock in exchange for 4,764,032 shares of Pre-Merger Oruka Common Stock on the conversion of Convertible Note along with the accrued
interest through the conversion date) and 5,522,207 Company pre-funded warrants in exchange for 9,664,208 Pre-Merger pre-funded warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Merger was accounted for as a reverse recapitalization
in accordance with U.S. GAAP. Under this method of accounting, Pre-Merger Oruka was deemed to be the accounting acquirer for financial
reporting purposes. This determination was primarily based on the fact that, immediately following the Merger: (i) Pre-Merger Oruka stockholders
own a substantial majority of the voting rights in the combined company; (ii) Pre-Merger Oruka&#x2019;s largest stockholders retain the
largest interest in the combined company; (iii) Pre-Merger Oruka designated a majority of the initial members of the board of directors
of the combined company; and (iv) Pre-Merger Oruka&#x2019;s executive management team became the management team of the combined company.
Accordingly, for accounting purposes: (i) the Merger was treated as the equivalent of Pre-Merger Oruka issuing stock to acquire the net
assets of ARCA, and (ii) the reported historical operating results of the combined company prior to the Merger are those of Pre-Merger
Oruka. Additional information regarding the Merger is included in Note 3.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Reverse
Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
September 3, 2024, the Company effected the Reverse Stock Split, a 1-for-12 reverse stock split of Company Common Stock. The par value
per share and the number of authorized shares were not adjusted as a result of the Reverse Stock Split. The shares of Company Common
Stock underlying outstanding stock options, common stock warrants and other equity instruments were proportionately reduced and the respective
exercise prices, if applicable, were proportionately increased in accordance with the terms of the agreements governing such securities.
All references to common stock, options to purchase common stock, outstanding common stock warrants, common stock share data, per share
data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect
the effect of the Reverse Stock Split for all periods presented, unless otherwise specifically indicated or the context otherwise requires.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;PIPE
Financing&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;On September 11, 2024, the Company entered into
a Securities Purchase Agreement for a private placement (the &#x201c;PIPE Financing&#x201d;) with certain institutional and accredited investors.
The closing of the PIPE Financing occurred on September 13, 2024.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Pursuant to the Securities Purchase Agreement, the
investors purchased an aggregate of 5,600,000 shares of Company Common Stock at a purchase price of $23.00 per share, an aggregate of
2,439 shares of the Company&#x2019;s Series A non-voting convertible preferred stock, par value $0.001 per share (&#x201c;Company Series
A Preferred Stock&#x201d;), at a purchase price of $23,000.00 per share (each Company Series A Preferred Stock is convertible into 1,000
shares of Company Common Stock), and pre-funded warrants to purchase an aggregate of 680,000 shares of Company Common Stock at a purchase
price of $22.999 per pre-funded warrant, for aggregate net proceeds of approximately $188.7 million (net of issuance costs of $11.8 million).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Liquidity
and Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Since
its inception, the Company has devoted substantially all of its resources to advancing the development of its portfolio of programs,
organizing and staffing the Company, business planning, raising capital, and providing general and administrative support for these operations.
Current and future programs will require significant research and development efforts, including preclinical and clinical trials, and
regulatory approvals to commercialization. Until such time as the Company can generate significant revenue from product sales, if ever,
the Company expects to finance its operating activities through a combination of equity offerings and debt financings.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company has not generated any revenue from product sales or other sources and has incurred significant operating losses and negative
cash flows from operations since inception. The Company has incurred a net loss of $28.6 million for the three months ended September
30, 2024 and $57.9&#160;million during the period from February&#160;6, 2024 (inception) to September 30, 2024. For the period from February
6, 2024 (inception) to September 30, 2024, the Company used net cash of $39.0 million for its operating activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, the Company had cash and cash equivalents of $410.9 million. The Company&#x2019;s management expects that the existing
cash and cash equivalents will be sufficient to fund the Company&#x2019;s operating plans for at least twelve months from the date these
condensed consolidated financial statements were issued. The Company expects that its research and development and general and administrative
costs will continue to increase significantly, including in connection with conducting future pre-clinical activities and clinical trials
and manufacturing for its existing product candidates and any future product candidates to support commercialization and providing general
and administrative support for its operations, including the costs associated with operating as a public company. The Company&#x2019;s
ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts needed,
the Company may be required to significantly curtail, delay or discontinue one or more of its research or development programs or the
commercialization of any product candidate, or be unable to expand its operations or otherwise capitalize on the Company&#x2019;s business
opportunities, as desired, which could materially harm the Company&#x2019;s business, financial condition and results of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c105"
      decimals="3"
      id="ixv-22921"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="c106"
      decimals="-5"
      id="ixv-22922"
      unitRef="usd">275000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c107"
      decimals="-5"
      id="ixv-22923"
      unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <orka:AdditionalPaidInCapitalTransacationCost
      contextRef="c108"
      decimals="-5"
      id="ixv-22924"
      unitRef="usd">20500000</orka:AdditionalPaidInCapitalTransacationCost>
    <orka:ExchangeRatio
      contextRef="c109"
      decimals="4"
      id="ixv-22925"
      unitRef="pure">6.8569</orka:ExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c110"
      decimals="4"
      id="ixv-22926"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c111"
      decimals="3"
      id="ixv-22927"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c112"
      decimals="2"
      id="ixv-22928"
      unitRef="usdPershares">-2.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c113"
      decimals="2"
      id="ixv-22929"
      unitRef="usdPershares">-6.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c114"
      decimals="2"
      id="ixv-22930"
      unitRef="usdPershares">-9.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:CommonStockValue contextRef="c115" decimals="0" id="ixv-22931" unitRef="usd">22784139</us-gaap:CommonStockValue>
    <orka:CommomStockExchange
      contextRef="c52"
      decimals="0"
      id="ixv-22932"
      unitRef="shares">39873706</orka:CommomStockExchange>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c0"
      decimals="0"
      id="ixv-22933"
      unitRef="shares">2722207</us-gaap:ConversionOfStockSharesIssued1>
    <orka:CommomStockExchange
      contextRef="c116"
      decimals="0"
      id="ixv-22934"
      unitRef="shares">4764032</orka:CommomStockExchange>
    <orka:PreFundedWarrantsOfCommonStockShares
      contextRef="c0"
      decimals="0"
      id="ixv-22935"
      unitRef="shares">5522207</orka:PreFundedWarrantsOfCommonStockShares>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="c3"
      decimals="0"
      id="ixv-22936"
      unitRef="shares">9664208</us-gaap:ClassOfWarrantOrRightUnissued>
    <orka:NumberOfSharesPurchased
      contextRef="c117"
      decimals="0"
      id="ixv-22937"
      unitRef="shares">5600000</orka:NumberOfSharesPurchased>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c117"
      decimals="2"
      id="ixv-22938"
      unitRef="usdPershares">23</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c118"
      decimals="0"
      id="ixv-22939"
      unitRef="shares">2439</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c117"
      decimals="3"
      id="ixv-22940"
      unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SupplementalDeferredPurchasePrice contextRef="c119" decimals="2" id="ixv-22941" unitRef="usd">23000</us-gaap:SupplementalDeferredPurchasePrice>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c120"
      decimals="0"
      id="ixv-22942"
      unitRef="shares">1000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c121"
      decimals="0"
      id="ixv-22943"
      unitRef="shares">680000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c122"
      decimals="3"
      id="ixv-22944"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="c123"
      decimals="-5"
      id="ixv-22945"
      unitRef="usd">188700000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="c123"
      decimals="-5"
      id="ixv-22946"
      unitRef="usd">11800000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-5" id="ixv-22947" unitRef="usd">-28600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-5" id="ixv-22948" unitRef="usd">-57900000</us-gaap:NetIncomeLoss>
    <us-gaap:Cash contextRef="c3" decimals="-5" id="ixv-22949" unitRef="usd">39000000</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-5" id="ixv-22950" unitRef="usd">410900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-18468">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;2.
Summary of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;1
&#x2014;&#160;Quoted prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful&#160;Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 83%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019; equity (deficit) on the Company&#x2019;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#x2019; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#x2019;
equity (deficit) on the Company&#x2019;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and development
expenses, with a substantial portion of the Company&#x2019;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;),
and the Company&#x2019;s related-party Paragon (see Note&#160;10).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#x2019;s chief executive officer, who is the chief operating decision maker (the &#x201c;CODM&#x201d;), reviews the Company&#x2019;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments
are classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In November&#160;2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt; (&lt;i&gt;Topic&#160;280&lt;/i&gt;)&lt;i&gt;:
Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU&#160;2023-07&#x201d;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#x2019;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#x2019;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In December&#160;2023, the FASB issued ASU&#160;2023-09,
&lt;i&gt;Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures&lt;/i&gt;. This ASU expands disclosures in an entity&#x2019;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income
Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses&lt;/i&gt;. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-18476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Use
of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
preparation of the Company&#x2019;s condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management
to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent
liabilities at the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the
reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include but
are not limited to research and development expenses and related prepaid or accrued costs and the valuation of stock-based compensation
awards and related expenses. The Company bases its estimates on known trends and other market-specific or other relevant factors that
it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in
circumstances, facts, and experience. Actual results could differ materially from those estimates or assumptions.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0" id="ixv-18490">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Concentrations
of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America. Cash balances
are held at financial institutions and account balances may exceed federally insured limits. To date, the Company has not experienced
any losses on its cash and cash equivalents and periodically evaluates the creditworthiness of its financial institutions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company manages credit risk associated with its investment portfolio through its investment policy, which limits investments to high-quality
issuers and limits the amount of its portfolio that can be invested in a single issuer.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is dependent on third-party organizations to research, develop, manufacture, and process its product candidates for its development
programs, including its two most advanced programs, ORKA-001 and ORKA-002. The Company expects to continue to be dependent on a small
number of manufacturers to supply it with its requirements for all products. The Company&#x2019;s research and development programs could
be adversely affected by a significant interruption in the supply of the necessary materials. A significant amount of the Company&#x2019;s
research and development activities are performed under its agreements with Paragon Therapeutics, Inc. (&#x201c;Paragon&#x201d;) (see Note&#160;10).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0" id="ixv-18528">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Cash
and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to
be cash equivalents. The cash equivalents were comprised of investments in money market funds.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0" id="ixv-18542">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Debt
Issuance Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Debt
issuance costs incurred in connection with the Convertible Note (see Note&#160;6) are recorded as a reduction of the carrying value of
the notes payable liability on the Company&#x2019;s balance sheet and are amortized to interest expense over the term of the loan using
the effective interest method.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <orka:SubscriptionReceivablePolicyTextBlock contextRef="c0" id="ixv-18555">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Subscription
Receivable&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for any notes received in exchange for common stock as a subscription receivable, provided the note underlying the receivable
is paid prior to the date the financial statement is available to be issued.&lt;/span&gt;&lt;/p&gt;</orka:SubscriptionReceivablePolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0" id="ixv-18569">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Fair
Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Certain
assets and liabilities are carried at fair value under U.S.&#160;GAAP.&#160;Fair value is defined as the exchange price that would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are
to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered
observable and the last is considered unobservable:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;1
&#x2014;&#160;Quoted prices in active markets that are identical assets or liabilities.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable
inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in
markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated
by observable market data.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 24pt"&gt;&lt;/td&gt;&lt;td style="width: 24pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable
inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities,
including pricing models, discounted cash flow methodologies, and similar techniques.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s cash equivalents are carried at fair value, determined according to the fair value hierarchy described above (see Note
4). The carrying values of the Company&#x2019;s prepaid expenses and other current assets, accounts payable and accrued expenses and other
current liabilities approximate their fair values due to their relatively short maturity period.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0" id="ixv-18616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Property
and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful&#160;Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 83%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0" id="ixv-18625">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost less accumulated depreciation. Depreciation expense is recognized using the straight-line method over
the estimated useful life of each asset as follows:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful&#160;Life&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 83%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture
    and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; "&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer
    and office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3-5 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c124" id="ixv-22951">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c125" id="ixv-22952">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c126" id="ixv-22953">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c127" id="ixv-22954">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock contextRef="c0" id="ixv-18679">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Classification
of Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Prior to the reverse recapitalization, the Company
had classified its Pre-Merger Oruka Series A Preferred Stock outside of stockholders&#x2019; equity (deficit) on the Company&#x2019;s condensed
consolidated balance sheet because the holders of such stock have certain liquidation rights in the event of a deemed liquidation event
that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Upon the closing of the Merger, the Company converted
its Pre-Merger Oruka Series A Preferred Stock to Company Series B Preferred Stock and has classified the Company Series B Preferred Stock
within stockholders&#x2019; equity (deficit) on its condensed consolidated balance sheet because the Company Series B Preferred Stock is
not redeemable or puttable to the Company by the holder under any circumstances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In connection with the PIPE Financing (see Note
1) the Company issued Company Series A Preferred Stock, and has classified the Company Series A Preferred Stock outside of stockholders&#x2019;
equity (deficit) on the Company&#x2019;s condensed consolidated balance sheet because the holders of such stock have certain rights (see
Note 7) that, in certain situations, is not solely within the control of the Company and would require the redemption of the then-outstanding
convertible preferred stock.&lt;/p&gt;</orka:ClassificationOfConvertiblePreferredStockPolicyTextBlock>
    <orka:NotePayableToRelatedPartyPolicyTextBlock contextRef="c0" id="ixv-18697">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Note&#160;Payable to Related Party&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accounted for the Convertible Note (as
defined in Note 6) at amortized cost. The Company considered if optional conversion features are required to be bifurcated and separately
accounted for as a derivative. Costs related to the issuance of the Convertible Note were recorded as a debt discount, amortized over
the term of the Convertible Note (see&#160;Note&#160;6) and were accounted as interest expense in other income (expenses) within the condensed
consolidated statements of operations and comprehensive loss using the effective interest method. At the effective time of the Merger,
shares of Pre-Merger Oruka Common Stock issued pursuant to the conversion of the Convertible Note (including accrued interest) automatically
converted into shares of Company Common Stock (see Note 1).&lt;/p&gt;</orka:NotePayableToRelatedPartyPolicyTextBlock>
    <orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock contextRef="c0" id="ixv-18707">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Research and Development Contract Costs Accruals&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company records the costs associated with research
studies and manufacturing development as incurred. These costs are a significant component of the Company&#x2019;s research and development
expenses, with a substantial portion of the Company&#x2019;s ongoing research and development activities conducted by third-party service
providers, including contract research organizations (&#x201c;CROs&#x201d;) and contract manufacturing organizations (&#x201c;CMOs&#x201d;),
and the Company&#x2019;s related-party Paragon (see Note&#160;10).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company accrues for expenses resulting from
obligations under its two antibody discovery and option agreements (the &#x201c;Option Agreements&#x201d;) (see Note 10), by and among Paragon,
Paruka Holding LLC (&#x201c;Paruka&#x201d;), an entity formed by Paragon as a vehicle to hold equity in the Company, and the Company as
well as agreements with CROs, CMOs, and other outside service providers for which payment flows do not match the periods over which materials
or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to
agreements established with Paragon, CROs, CMOs, and other outside service providers. These estimates are typically based on contracted
amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers
as to the progress or stage of completion of the services. The Company makes significant judgments and estimates in determining the accrual
balance in each reporting period. If advance payments are made to Paragon, a CRO, CMO, or outside service provider, the payments will
be recorded as a prepaid asset which will be expensed as the contracted services are performed. Changes in these estimates that result
in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations. As of September
30, 2024, the Company has not experienced any material deviations between accrued and actual research and development expenses.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;/p&gt;</orka:ResearchAndDevelopmentContractCostsAccrualsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c0" id="ixv-18741">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies
a lease as either an operating or finance lease and recognizes a right-of-use (&#x201c;ROU&#x201d;) asset and a current and non-current
lease liability, as applicable, in the balance sheet if the lease has a term greater than one year. Lease terms may include options to
extend or terminate the lease when it is reasonably certain that the Company will exercise its option.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;At
the lease commencement date, operating lease liabilities and their corresponding ROU assets are recorded at the present value of future
minimum lease payments over the expected remaining lease term. The Company determines the present value of lease payments using the implicit
rate, if it is readily determinable, or the risk-free discount rate for a period comparable with that of the lease term. For operating
leases, lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, lease expense
includes amortization expense of the ROU asset recognized on a straight-line basis over the lease term and interest expense recognized
on the finance lease liability. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments,
incentives received or initial direct costs. As of September 30, 2024, the Company has one operating lease and no finance leases.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for lease and non-lease components related to operating leases as a single lease component. The Company has elected
that costs associated with leases having an initial term of 12 months or less are recognized in the condensed consolidated statement
of operations and comprehensive loss on a straight-line basis over the lease term and are not recorded on its condensed consolidated
balance sheets. Variable lease expense is recognized as incurred and consists primarily of real estate taxes, utilities, and other office
space related expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c3" id="ixv-22955">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-18763">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Segment
Reporting&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions.
The Company&#x2019;s chief executive officer, who is the chief operating decision maker (the &#x201c;CODM&#x201d;), reviews the Company&#x2019;s
financial information on an aggregated basis for purposes of evaluating financial performance and allocating resources.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0" id="ixv-18775">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Research
and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
and development costs are expensed as incurred. Research and development costs include salaries and bonuses, stock-based compensation,
employee benefits, and external costs of vendors and consultants engaged to conduct research and development activities, as well as allocated
human resource costs, information technology costs, and facility-related costs, including rent, maintenance, utilities, and depreciation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid
expenses on the accompanying condensed consolidated balance sheet. The prepaid amounts are expensed as the related goods are delivered
or the services are performed, or when it is no longer expected that the goods will be delivered, or the services rendered. If nonrefundable
advance payments represent a one-time cost for obtaining goods or services, with anticipated benefits to be utilized within a year of
period end, the payment is expensed immediately.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c0" id="ixv-18794">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;General
and Administrative Expenses&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;General and administrative expenses consist primarily
of salaries and bonuses, stock-based compensation, employee benefits, finance and administration costs, patent and intellectual property
costs, professional fees, as well as allocated human resource costs, information technology costs, and facility-related costs, including
rent, maintenance, utilities and depreciation.&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0" id="ixv-18807">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Commitments
and Contingencies&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities.
The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the
loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the
balance sheet. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but
not probable; however, it discloses the range of reasonably possible losses. As of September 30, 2024, no liabilities were recorded for
loss contingencies (see Note&#160;11).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0" id="ixv-18839">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company measures all stock-based awards granted to employees, directors, and non-employees in the form of stock options to purchase shares
of its common stock, based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. The Company
measures restricted common stock awards (&#x201c;RSAs&#x201d;) using the difference, if any, between the purchase price per share of the
award and the fair value of the Company&#x2019;s common stock at the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company grants stock options, restricted stock awards, and warrants that are subject to service or performance-based vesting conditions.
Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line
method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards
to non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for
the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. As of each
reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation
expense until it is probable that the performance-based vesting condition will be achieved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company has issued stock options, warrants,
and RSAs with service-based and performance-based vesting conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company recognizes the compensation expense for the option to purchase common stock under the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;),
based on the fair value of the common stock estimated using the closing price of the Company&#x2019;s common stock as reported on the
date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company classifies stock-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the
same manner in which the award recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments
are classified.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-18872">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share Attributable to Stockholders&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Basic and diluted net loss attributable to stockholders
per share is presented in conformity with the two-class method required for participating securities (Pre-Merger Oruka Series A Preferred
Stock). Basic earnings per share is computed by dividing net income available to each class of shares by the weighted-average number of
shares of common stock and participating securities outstanding during the period. Pre-funded warrants were included as the exercise price
is negligible and these warrants are fully vested and exercisable. Company Series A Preferred Stock and Company Series B Preferred Stock
share the same characteristics as Common Stock and have no substantive preference attributed to them and, accordingly, have been considered
as classes of Common Stock in the computation of net loss per share regardless of their legal form.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Net loss is allocated to common stock based on
its proportional ownership on an as-converted basis. Net loss is not allocated to participating securities as they do not have an obligation
to fund losses. The weighted-average number of shares outstanding of common stock reflects changes in ownership over the periods presented.
See Note 7&#x2014; Convertible Preferred Stock and Stockholders&#x2019; Equity.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Diluted net loss per share is computed by dividing
the net loss attributable to stockholders adjusted for income (expenses), net of tax, related to any diluted securities, by the weighted-average
number of shares of common stock and potentially dilutive securities outstanding for the period. For purposes of this calculation, stock
options to purchase common stock, employee warrants to purchase common stock, and unvested RSAs are considered potential dilutive common
shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company generated a net loss for the periods presented. Accordingly,
basic and diluted net loss per share is the same because the inclusion of the potentially dilutive securities would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0" id="ixv-18893">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Income
Taxes&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities
for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#x2019;s tax
returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis
of assets and liabilities using enacted tax rates in effect for the&#160;years in which the differences are expected to reverse. Changes
in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred
tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence,
that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established
through a charge to income tax expense. The potential for recovery of deferred tax assets is evaluated by estimating the future taxable
profits expected and considering prudent and feasible tax planning strategies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company accounts for uncertainty in income taxes recognized in the condensed consolidated financial statements by applying a two-step
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to
be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the condensed consolidated financial
statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized
upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits,
that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or
penalties related to uncertain tax positions as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c0" decimals="2" id="ixv-22956" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-18926">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Recently
Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In November&#160;2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i&gt;Segment Reporting&lt;/i&gt; (&lt;i&gt;Topic&#160;280&lt;/i&gt;)&lt;i&gt;:
Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU&#160;2023-07&#x201d;), which enhances the segment disclosure requirements
for public entities on an annual and interim basis. Under this proposal, public entities will be required to disclose significant segment
expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss. Additionally, current
annual disclosures about a reportable segment&#x2019;s profit or loss and assets will be required on an interim basis. Entities will also
be required to disclose information about the CODM&#x2019;s title and position at the Company along with an explanation of how the CODM
uses the reported measures of segment profit or loss in their assessment of segment performance and deciding how to allocate resources.
Finally, ASU&#160;2023-07 requires all segment disclosures for public entities that have only a single reportable segment. The amendments
in ASU&#160;2023-07 are effective for fiscal&#160;years beginning after December&#160;15, 2023, and interim periods within fiscal&#160;years
beginning after December&#160;15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of
this ASU on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In December&#160;2023, the FASB issued ASU&#160;2023-09,
&lt;i&gt;Income Taxes (Topic&#160;740): Improvements to Income Tax Disclosures&lt;/i&gt;. This ASU expands disclosures in an entity&#x2019;s income
tax rate reconciliation table and disclosures regarding taxes paid both in the U.S.&#160;and foreign jurisdictions. This update is effective
beginning with the Company&#x2019;s 2025 fiscal year annual reporting period. The Company is currently evaluating the impact of the adoption
of this ASU on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income
Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement
Expenses&lt;/i&gt;. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including
employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement.
This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December
15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating
the impact of the adoption of this ASU on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c0" id="ixv-18952">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;3. Reverse
Recapitalization and Pre-Closing Financing&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
described within the &lt;i&gt;Reverse Recapitalization and Pre-Closing Financing &lt;/i&gt;section in Note 1, on August 29, 2024, the reverse recapitalization
between Pre-Merger Oruka and ARCA was consummated. The Merger was accounted for as a reverse recapitalization in accordance with U.S.
GAAP. At the effective time of the Merger, substantially all of the assets of ARCA consisted of cash and cash equivalents and other nominal
non-operating assets and liabilities. No goodwill or intangible assets were recognized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0" id="ixv-18965">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the recapitalization, the Company acquired the assets and liabilities listed below (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,940&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;114&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;Net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c3" decimals="-3" id="ixv-22957" unitRef="usd">4940000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther contextRef="c3" decimals="-3" id="ixv-22958" unitRef="usd">114000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <orka:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="c3" decimals="-3" id="ixv-22959" unitRef="usd">54000</orka:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c3" decimals="-3" id="ixv-22960" unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-19017">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;4.
Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;There
were no transfers between Level&#160;1, Level&#160;2, or Level&#160;3 during the period from February 6, 2024 (inception) to September
30, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c0" id="ixv-19025">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following tables present the Company&#x2019;s fair value hierarchy for financial assets measured as of September 30, 2024 (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of September 30, 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-size: 10pt"&gt;Financial assets:&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 52%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-106; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-107; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: black 1.5pt solid"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="font-size: 10pt"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-108; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-109; font-size: 10pt"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;403,322&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c128"
      decimals="-3"
      id="ixv-22961"
      unitRef="usd">403322000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c131"
      decimals="-3"
      id="ixv-22962"
      unitRef="usd">403322000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c132"
      decimals="-3"
      id="ixv-22963"
      unitRef="usd">403322000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c3" decimals="-3" id="ixv-22964" unitRef="usd">403322000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c0" id="ixv-19141">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;5. Accrued
Expenses and Other Current Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;933&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    professional and consulting&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;573&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,710&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-19148">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;933&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    professional and consulting&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;204&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Accrued
    research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;573&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,710&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c3" decimals="-3" id="ixv-22965" unitRef="usd">933000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c3" decimals="-3" id="ixv-22966" unitRef="usd">204000</us-gaap:AccruedProfessionalFeesCurrent>
    <orka:AccruedResearchAndDevelopment contextRef="c3" decimals="-3" id="ixv-22967" unitRef="usd">573000</orka:AccruedResearchAndDevelopment>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="c3" decimals="-3" id="ixv-22968" unitRef="usd">1710000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-19215">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;6.
Note&#160;Payable with Related Party&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
March&#160;2024, the Company entered into a Series A Preferred Stock and Convertible Note Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;)
with Fairmount Healthcare Fund&#160;II, L.P. (&#x201c;Fairmount&#x201d;), whereby the Company issued a convertible note (the &#x201c;Convertible
Note&#x201d;), with an initial principal amount of $25.0 million that, at the time of issuance, could be converted into Pre-Merger Oruka
Series&#160;A Preferred Stock (or a series&#160;of preferred shares that is identical in respect to the shares of preferred shares issued
in its next equity financing) or shares of Pre-Merger Oruka Common Stock in exchange for aggregate proceeds of $25.0&#160;million. The
Convertible Note accrued interest at a rate of 12.0% per annum. At issuance, the Convertible Note required all unpaid interest and principal
to mature on December&#160;31, 2025 (the &#x201c;Maturity Date&#x201d;) and prepayment was not permitted without prior written consent
of Fairmount. At issuance, the principal payment along with the accrued interest on the Convertible Note was due in full on the Maturity
Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company assessed all terms and features of the Convertible Note in order to identify any potential embedded features that would require
bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the embedded features. The Company
determined that the share settled redemption feature was clearly and closely related to the debt host and did not require separate accounting.
The Company determined that the conversion options of the Convertible Note were not clearly and closely associated with a debt host.
However, these features did not meet the definition of a derivative under ASC&#160;815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, and as a result,
did not require separate accounting as a derivative liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company paid debt issuance costs of less than $0.1&#160;million in relation to the Convertible Note. The debt issuance costs were reflected
as a reduction of the carrying value of Convertible Note on the condensed consolidated balance sheet and were being amortized as interest
expense over the term of the Convertible Note using the effective interest method. For the three months ended September 30, 2024 and
the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized interest expenses related to the Convertible
Note of $0.5 million and $1.5 million, respectively, which includes non-cash interest expense related to the amortization of debt issuance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Immediately prior to the completion of the Merger
(see Note 1), the Convertible Note was converted into shares of Pre-Merger Oruka Common Stock based on the aggregate principal amount
of $25.0 million, plus unpaid accrued interest of $1.5 million divided by the conversion price which was determined based upon the Company&#x2019;s
fully-diluted capitalization immediately prior to the Merger. At the effective time of the Merger, the Pre-Merger Oruka Common Stock issued
upon the conversion of the Convertible Note (including accrued interest) automatically converted into 2,722,207 shares of Company Common
Stock. As of September 30, 2024, the Convertible Note is not outstanding.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c135"
      decimals="-5"
      id="ixv-22969"
      unitRef="usd">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c136"
      decimals="-5"
      id="ixv-22970"
      unitRef="usd">25000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c137"
      decimals="3"
      id="ixv-22971"
      unitRef="pure">0.12</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c66" id="ixv-22972">2025-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c138"
      decimals="-5"
      id="ixv-22973"
      unitRef="usd">100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="c138"
      decimals="-5"
      id="ixv-22974"
      unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c0" decimals="-5" id="ixv-22975" unitRef="usd">1500000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c0" decimals="-5" id="ixv-22976" unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="c139"
      decimals="-5"
      id="ixv-22977"
      unitRef="usd">1500000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c0"
      decimals="0"
      id="ixv-22978"
      unitRef="shares">2722207</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockTextBlock contextRef="c0" id="ixv-19252">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;7.
Convertible Preferred Stock and Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Pre-Funded
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
August 2024, pursuant to the Subscription Agreement and immediately prior to the Closing, certain new and current investors purchased
pre-funded&#160;warrants, which, at the effective time of the Merger, were exercisable for 5,522,207 shares of Company Common Stock at
a purchase price of approximately $9.70 per warrant. After the Merger, there are 5,522,207 pre-funded warrants outstanding and are exercisable
for 5,522,207 shares of the Company Common Stock at an exercise price of $0.01 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold 680,000 pre-funded warrants, at a purchase price of
$22.999 per warrant, exercisable for 680,000 shares of Company Common Stock at an exercise price of $0.001 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
pre-funded warrants were recorded as a component of stockholders&#x2019; equity within additional paid-in-capital and have &lt;span style="-sec-ix-hidden: hidden-fact-110"&gt;no&lt;/span&gt; expiration
date. As of September 30, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-111"&gt;none&lt;/span&gt; of the pre-funded warrants have been exercised and 6,202,207 pre-funded warrants remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
July 2024, Pre-Merger Oruka entered into a Subscription Agreement that provided for, among other things, the issuance of warrants to
certain of Pre-Merger Oruka&#x2019;s employees, directors, and service providers immediately prior to the closing of the Merger. During
the three months ended September 30, 2024, 3,054,358 employee warrants were issued at an exercise price of $7.80 per warrant. These employee
warrants vest over a period of four years. Per the terms of the Employee Warrant Agreement, the holders of the Company&#x2019;s employee
warrants shall not have any of the rights or privileges of a stockholder of the Company in respect of any shares purchasable upon the
exercise of the warrant or any portion thereof unless and until a certificate or certificates representing such shares have been issued
or a book entry representing such shares has been made and such shares have been deposited with the appropriate registered book-entry
custodian. The Company recognizes compensation cost related to employee warrants on a straight-line basis over the requisite service
period, which is the period in which the related services are received. As of September 30, 2024, &lt;span style="-sec-ix-hidden: hidden-fact-112"&gt;none&lt;/span&gt; of the employee warrants have
been exercised and 3,054,358 employee warrants remain outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Convertible
Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In March&#160;2024, Pre-Merger Oruka issued and
sold an aggregate of 20,000,000 shares of Pre-Merger Oruka Series&#160;A Preferred Stock to Fairmount (see Note 13), at a purchase price
of approximately $0.15 per share, for aggregate gross proceeds of $3.0&#160;million. Pre-Merger Oruka incurred less than $0.1&#160;million
of issuance costs in connection with this transaction. Upon the issuance of the Pre-Merger Oruka Series&#160;A Preferred Stock, the Company
assessed the embedded conversion and liquidation features of the securities as described below and determined that such features did not
require the Company to separately account for these features.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
August 2024, upon the closing of the Merger, the Company converted the Pre-Merger Oruka Series A Preferred Stock to 137,138 shares of
Company Series B Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
September 2024, in connection with the PIPE Financing, the Company issued and sold an aggregate of 2,439 shares of the Company Series
A Preferred Stock at a purchase price of $23,000.00 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&#160;Stock&lt;br/&gt; Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&#160;Stock&lt;br/&gt; Issued and&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Carrying&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Common&#160;Stock&lt;br/&gt; Issuable Upon&lt;br/&gt; Conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series A Non-Voting Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series B Non-Voting Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Pursuant to the Certificate of Designation of Preferences,
Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock (the &#x201c;Series A Certificate of Designation&#x201d;)
filed in connection with the PIPE Financing, holders of Company Series A Preferred Stock are entitled to receive dividends on shares of
Company Series A Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis, and in the same form as, dividends actually
paid on shares of Company Common Stock. Except as provided in the Series A Certificate of Designation or as otherwise required by law,
the Company Series A Preferred Stock does not have voting rights. The Company Series A Preferred Stock shall rank on parity with the Company
Common Stock and Company Series B Preferred Stock upon any liquidation, dissolution or winding-up of the Company. Subject to the terms
and limitations contained in the Series A Certificate of Designation, the Company Series A Preferred Stock issued in the PIPE Financing
will not become convertible until the Company&#x2019;s stockholders approve the conversion of the Company Series A Preferred Stock into
shares of Company Common Stock in accordance with the listing rules of the Nasdaq Stock Market (the &#x201c;Stockholder Approval&#x201d;),
which resulted in the Company Series A Preferred Stock being classified outside of stockholders&#x2019; equity (deficit) on the Company&#x2019;s
condensed consolidated balance sheet.. Following the Stockholder Approval, each share of Company Series A Preferred Stock will automatically
convert into 1,000 shares of Company Common Stock, subject to certain limitations, including that shares of Company Series A Preferred
Stock shall not be convertible if the conversion would result in a holder, together with its affiliates, beneficially owning more than
9.99% of the Company&#x2019;s outstanding shares of Company Common Stock as of the applicable conversion date, which may be increased at
the holders&#x2019; option (not to exceed 19.99%), effective in accordance with the terms of the Series A Certificate of Designation. If,
at any time after the earlier of Stockholder Approval or six months after the initial issuance of the Series A non-voting preferred stock,
the Company fails to deliver to a holder such certificate or certificates, the Company shall, at the request of the holder, pay an amount
equal to the closing price of Company&#x2019;s common stock on the trading day immediately prior to the date on which notice to conversion
is received by the Company (the &#x201c;Fair Value&#x201d;) of such undelivered shares, with such payment to be made within two business
days from the date of request by the holder, whereupon the Company&#x2019;s obligations to deliver such shares underlying the notice of
conversion shall be extinguished upon payment in full of the Fair Value of such undelivered shares; provided, however that such request
shall be presumed to have been made by such holder if Stockholder Approval shall not have been obtained prior to the date on which the
notice of conversion is delivered to the Company.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Pursuant
to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock (the
&#x201c;Series B Certificate of Designation&#x201d;) filed in connection with the Merger, holders of Company Series B Preferred Stock are
entitled to receive dividends on shares of Company Series B Preferred Stock equal to, on an as-if-converted-to-Company Common Stock basis,
and in the same form as, dividends actually paid on shares of Company Common Stock. Except as provided in the Series B Certificate of
Designation or as otherwise required by law, the Company Series B Preferred Stock does not have voting rights. The Company Series B Preferred
Stock shall rank on parity with the Company Common Stock as to the distribution of assets upon any liquidation, dissolution, or winding-up
of the Company. Each share of Company Series B Preferred Stock is convertible at the option of the holder, at any time, and without the
payment of additional consideration by the holder. As of September 30, 2024, each outstanding share of Company Series B Preferred Stock
was convertible into common stock at a ratio of approximately 83.3332:1.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, the Certificate of Incorporation provides for 545,000,000 authorized shares of Company Common Stock. As of September
30, 2024, 34,988,550 shares of Company Common Stock were issued and outstanding, including 2,207,553 shares of RSAs issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issuable on conversion of Company Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,439,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issuable on conversion of Company Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon
    exercise of pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,202,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    and issued stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    and issued employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    available for grant under 2024 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,526,324&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    available for grant under 2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;463,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,401,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c140"
      decimals="0"
      id="ixv-22979"
      unitRef="shares">5522207</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c141"
      decimals="2"
      id="ixv-22980"
      unitRef="shares">9.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c142"
      decimals="0"
      id="ixv-22981"
      unitRef="shares">5522207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c142"
      decimals="0"
      id="ixv-22982"
      unitRef="shares">5522207</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c143"
      decimals="2"
      id="ixv-22983"
      unitRef="usdPershares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c144"
      decimals="0"
      id="ixv-22984"
      unitRef="shares">680000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c145"
      decimals="3"
      id="ixv-22985"
      unitRef="usdPershares">22.999</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c145"
      decimals="0"
      id="ixv-22986"
      unitRef="shares">680000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c146"
      decimals="3"
      id="ixv-22987"
      unitRef="usdPershares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c147"
      decimals="0"
      id="ixv-22988"
      unitRef="shares">6202207</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c148"
      decimals="0"
      id="ixv-22989"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c148"
      decimals="2"
      id="ixv-22990"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c149" id="ixv-22991">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c148"
      decimals="0"
      id="ixv-22992"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c150"
      decimals="0"
      id="ixv-22993"
      unitRef="shares">20000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c151"
      decimals="2"
      id="ixv-22994"
      unitRef="usdPershares">0.15</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="c152"
      decimals="-5"
      id="ixv-22995"
      unitRef="usd">3000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="c0" decimals="-5" id="ixv-22996" unitRef="usd">100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c153"
      decimals="0"
      id="ixv-22997"
      unitRef="shares">137138</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c119"
      decimals="0"
      id="ixv-22998"
      unitRef="shares">2439</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c154"
      decimals="2"
      id="ixv-22999"
      unitRef="usdPershares">23000</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock contextRef="c0" id="ixv-19312">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, convertible preferred stock consisted of the following (in thousands, except share data):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&#160;Stock&lt;br/&gt; Authorized&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Preferred&#160;Stock&lt;br/&gt; Issued and&lt;br/&gt; Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Carrying&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Common&#160;Stock&lt;br/&gt; Issuable Upon&lt;br/&gt; Conversion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Series A Non-Voting Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;52,841&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,439,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Series B Non-Voting Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;251,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;137,138&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,428,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAuctionMarketPreferredSecuritiesByStockSeriesTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c60"
      decimals="INF"
      id="ixv-23000"
      unitRef="shares">2439</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="c60"
      decimals="INF"
      id="ixv-23001"
      unitRef="shares">2439</us-gaap:SharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c60" decimals="-3" id="ixv-23002" unitRef="usd">52841000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="c60" decimals="-3" id="ixv-23003" unitRef="usd">2439000000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c157"
      decimals="INF"
      id="ixv-23004"
      unitRef="shares">251504</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="c157"
      decimals="INF"
      id="ixv-23005"
      unitRef="shares">137138</us-gaap:SharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="c157"
      decimals="-3"
      id="ixv-23006"
      unitRef="usd">2931000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="c157"
      decimals="-3"
      id="ixv-23007"
      unitRef="usd">11428149000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c155"
      decimals="2"
      id="ixv-23008"
      unitRef="pure">9.99</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c156"
      decimals="2"
      id="ixv-23009"
      unitRef="pure">19.99</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c62"
      decimals="0"
      id="ixv-23010"
      unitRef="shares">545000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c62"
      decimals="0"
      id="ixv-23011"
      unitRef="shares">34988550</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c62"
      decimals="0"
      id="ixv-23012"
      unitRef="shares">2207553</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c0" id="ixv-23013">As
of September 30, 2024, the Company had common stock reserved for future issuance as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issuable on conversion of Company Series A Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,439,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    issuable on conversion of Company Series B Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;11,428,149&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares issuable upon
    exercise of pre-funded warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,202,207&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    and issued stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Outstanding
    and issued employee warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    available for grant under 2024 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4,526,324&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Shares
    available for grant under 2024 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;463,489&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    shares of common stock reserved&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;29,401,287&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c158"
      decimals="INF"
      id="ixv-23014"
      unitRef="shares">2439000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c159"
      decimals="INF"
      id="ixv-23015"
      unitRef="shares">11428149</us-gaap:PreferredStockSharesIssued>
    <orka:SharesIssuableUponExerciseOfPrefundedWarrants
      contextRef="c3"
      decimals="INF"
      id="ixv-23016"
      unitRef="shares">6202207</orka:SharesIssuableUponExerciseOfPrefundedWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-23017"
      unitRef="shares">1287760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-23018"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c160"
      decimals="INF"
      id="ixv-23019"
      unitRef="shares">4526324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c161"
      decimals="INF"
      id="ixv-23020"
      unitRef="shares">463489</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c161"
      decimals="INF"
      id="ixv-23021"
      unitRef="shares">29401287</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-19525">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;8.
Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
2024 Equity Incentive Plan (&#x201c;2024 Plan&#x201d;) was adopted by the board of directors of Pre-Merger Oruka on February&#160;6, 2024.
The 2024 Plan provided for Pre-Merger Oruka to grant stock options, restricted stock awards, restricted stock units, and other stock-based
awards to employees, officers, directors, consultants, and advisors. Equity Incentive Stock options granted under the 2024 Plan generally
vest over four&#160;years, subject to the participant&#x2019;s continued service, and expire after ten&#160;years, although stock options
have been granted with vesting terms less than four&#160;years. As of September 30, 2024, there are no shares of common stock available
for issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;On
August 22, 2024, the 2024 Stock Incentive Plan (&#x201c;2024 Stock Plan&#x201d;) was approved by the Company&#x2019;s stockholders and on
August 29, 2024, the board of directors of the Company (the &#x201c;Board&#x201d;) ratified the 2024 Stock Plan. The 2024 Stock Plan allows
for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, other stockholder-based awards
and incentive bonuses. The 2024 Stock Plan is administered by the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;)
or another committee designated by the Board to administer the Plan. The initial share pool under the 2024 Stock Plan is 4,634,891 shares
of Company Common Stock and as of September 30, 2024, there are 4,526,324 shares available in the pool. The shares that may be issued
under the 2024 Stock Plan will be automatically increased on January 1 of each year beginning in 2025 and ending with a final increase
on January 1, 2034 in an amount equal to 5% of the diluted stock (including Company Common Stock, preferred stock and unexercised pre-funded
warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee. Current or prospective
employees, officers, non-employee directors, and other independent service providers of the Company and its subsidiaries are eligible
to participate in the 2024 Stock Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;2024
Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
2024 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;) was approved by the board of directors of ARCA on July 20, 2024, and by ARCA&#x2019;s
stockholders on August 22, 2024. The ESPP became effective on August 29, 2024, at which time 463,489 shares were reserved for issuance.
The shares that may be issued under the ESPP will be automatically increased on January 1 of each year beginning in 2025 and ending with
a final increase on January 1, 2034 in an amount equal to 1% of the diluted stock (including Company Common Stock, preferred stock and
unexercised pre-funded warrants) on the preceding December 31, unless a lower, or no, increase is determined by the Compensation Committee.
As of September 30, 2024, no shares have been issued out of the ESPP.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock
Option Valuation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period from &lt;br/&gt; February&#160;6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&lt;br/&gt; to &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock
Options&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (in&#160;Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&#160;Thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,507&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,507&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted average grant-date fair value per share of stock options granted during the period from February&#160;6, 2024 (inception) to
September 30, 2024 was $6.44 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the underlying
Company Common Stock and the exercise price of outstanding, in-the-money employee stock options.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Restricted
Stock Awards&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
February 2024 and March&#160;2024, the Company issued 2,207,553 shares of RSAs to certain employees, directors, and consultants at a
price of $0.0001 per share, the then par value of Pre-Merger Oruka Common Stock. Such RSAs have service-based vesting conditions only
and vest over a four-year period, during which time all unvested shares are subject to forfeiture in the event the holder&#x2019;s service
with the Company voluntarily or involuntarily terminates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;br/&gt; RSAs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
                                            Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance
    as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested
    balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Option
Agreements and Paruka Warrant Obligation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;In March&#160;2024, the Company entered into antibody
discovery and option agreements with Paragon and Paruka (the &#x201c;Option Agreements&#x201d;). Under the terms of Option Agreements, Paragon
identifies, evaluates, and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company,
and the Company has the exclusive option to, on a research program-by-research program basis, be granted an exclusive, worldwide license
to all of Paragon&#x2019;s right, title, and interest in and to the intellectual property resulting from the applicable research program
to develop, manufacture and commercialize the antibodies and products directed to the selected target(s). Paruka will be entitled to grants
of warrants to purchase a number of shares equal to 1.00% of then outstanding shares of the Company&#x2019;s stock, on a fully diluted
basis, on December&#160;31, 2024 and December&#160;31, 2025, at the fair market value determined by the Board (the &#x201c;Paruka Warrant
Obligation&#x201d;). The grant dates for the issuance of warrants are expected to be December&#160;31, 2024 and December&#160;31, 2025
as all terms of the award, including number of shares and exercise price, will be known by all parties. The service inception period for
the grant precedes the grant date, with the full award being vested as of the grant date with no post-grant date service requirement.
Accordingly, the warrants expected to be granted to Paruka were accounted for as a liability on the condensed balance sheet and, after
the initial recognition, the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded
in the statement of operations and comprehensive loss as stock-based compensation expenses under research and development expenses. As
of September 30, 2024, the estimated fair value of warrants to be granted on December 31, 2024 was $11.0 million. For the three months
ended September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, $7.3 million and $7.7 million were recognized
as stock-based compensation expenses related to the Paruka Warrant Obligation, respectively.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Employee
Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;As stated above, on July 3, 2024, the Subscription
Agreement was amended and restated, among other things, for employee warrants to be issued to certain Pre-Merger Oruka&#x2019;s employees,
directors, and service providers, immediately prior to the closing of the Merger. Pursuant to this amendment, during the three months
ended September 30, 2024, the Company issued 3,054,358 employee warrants at an exercise price of $7.80 per warrant, which are accounted
as equity in the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (in&#160;Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&#160;Thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,038&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,038&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
weighted average grant-date fair value per share of employee warrants granted during the period from February&#160;6, 2024 (inception)
to September 30, 2024 was $6.27 per share. Aggregate intrinsic value represents the difference between the estimated fair value of the
underlying Company Common Stock and the exercise price of outstanding, in-the-money employee warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) &lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock-Based
Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#x202f;Months
                                            Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period
                                            from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,772&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,229&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,769&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, total unrecognized compensation cost related to the unvested stock options was $7.5 million, which is expected
to be recognized over a weighted average period of approximately 3.4 years. As of September 30, 2024, total unrecognized compensation
cost related to the unvested RSAs was less than $0.1 million, which is expected to be recognized over a weighted average period of 3.4
years. As of September 30, 2024, the unrecognized compensation cost related to the employee warrants was $17.8 million, which is expected
to be recognized over a weighted average period of 3.6 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#160;Months
                                            Ended &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period
                                            from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paruka
    warrant obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,681&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee
    stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,769&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="c162"
      decimals="0"
      id="ixv-23022"
      unitRef="shares">4634891</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c163"
      decimals="0"
      id="ixv-23023"
      unitRef="shares">4526324</us-gaap:CommonStockSharesIssued>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="c164"
      decimals="2"
      id="ixv-23024"
      unitRef="pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c165"
      decimals="0"
      id="ixv-23025"
      unitRef="shares">463489</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c0" decimals="2" id="ixv-23026" unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock contextRef="c0" id="ixv-19592">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the awards for the three months ended
September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&lt;br/&gt; Months Ended &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period from &lt;br/&gt; February&#160;6,&lt;br/&gt; 2024 &lt;br/&gt; (Inception)&lt;br/&gt; to &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;97.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;101.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-113; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-114; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</orka:ScheduleOfFairValueOfTheEmployeeWarrantsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c176" id="ixv-19636">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c177" id="ixv-19645">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c176"
      decimals="3"
      id="ixv-23027"
      unitRef="pure">0.973</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c177"
      decimals="3"
      id="ixv-23028"
      unitRef="pure">1.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c176"
      decimals="3"
      id="ixv-23029"
      unitRef="pure">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c177"
      decimals="3"
      id="ixv-23030"
      unitRef="pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-19715">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the stock option activities under the 2024 Plan and 2024 Stock Plan for the period of February&#160;6, 2024
(inception) through September 30, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Stock Options&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per&lt;br/&gt; Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (in&#160;Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&#160;Thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-115; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-116; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-117; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-118; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-119; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-120; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-121; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-122; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,507&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,287,760&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.97&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;21,507&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-123; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-124; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-125; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-126; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-23031"
      unitRef="shares">1287760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-23032"
      unitRef="usdPershares">7.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-23033"
      unitRef="shares">1287760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-23034"
      unitRef="usdPershares">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-19935">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c3" decimals="-3" id="ixv-23035" unitRef="usd">21507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-23036"
      unitRef="shares">1287760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c3"
      decimals="2"
      id="ixv-23037"
      unitRef="usdPershares">7.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-19971">P9Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c3" decimals="-3" id="ixv-23038" unitRef="usd">21507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c166"
      decimals="2"
      id="ixv-23039"
      unitRef="usdPershares">6.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c167"
      decimals="0"
      id="ixv-23040"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c0"
      decimals="4"
      id="ixv-23041"
      unitRef="usdPershares">0.0001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c0" id="ixv-20052">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the RSAs activity for the period from February&#160;6, 2024 (inception) through September 30, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number
                                            of&lt;br/&gt; RSAs&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt;
                                            Average&lt;br/&gt; Grant Date&lt;br/&gt; Fair Value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested balance
    as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-127; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-128; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-129; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unvested
    balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2,207,553&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-130; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c179"
      decimals="INF"
      id="ixv-23042"
      unitRef="shares">2207553</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c180"
      decimals="INF"
      id="ixv-23043"
      unitRef="shares">2207553</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <orka:SharesOutstandingPercentage contextRef="c0" decimals="4" id="ixv-23044" unitRef="pure">0.01</orka:SharesOutstandingPercentage>
    <orka:EstimatedFairValueOfWarrantsToBeGranted
      contextRef="c168"
      decimals="-5"
      id="ixv-23045"
      unitRef="usd">11000000</orka:EstimatedFairValueOfWarrantsToBeGranted>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c169"
      decimals="-5"
      id="ixv-23046"
      unitRef="usd">7300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c170"
      decimals="-5"
      id="ixv-23047"
      unitRef="usd">7700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c148"
      decimals="0"
      id="ixv-23048"
      unitRef="shares">3054358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c148"
      decimals="2"
      id="ixv-23049"
      unitRef="usdPershares">7.8</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <orka:ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock contextRef="c0" id="ixv-23050">The
following table summarizes the employee warrant activity for the period from February&#160;6, 2024 (inception) through September 30,
2024:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Number of&lt;br/&gt; Warrants&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price Per Share&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term (in&#160;Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value (in&#160;Thousands)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of February&#160;6, 2024 (inception)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-131; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-132; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-133; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-134; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 52%; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-135; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-136; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-137; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-138; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Balance as of September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,038&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and expected to vest, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;3,054,358&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9.8&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;51,038&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Vested and exercisable, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-139; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-140; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-141; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-142; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</orka:ScheduleOfSummarizesTheEmployeeWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-23051"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-23052"
      unitRef="usdPershares">7.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c3"
      decimals="INF"
      id="ixv-23053"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c3"
      decimals="2"
      id="ixv-23054"
      unitRef="usdPershares">7.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c0" id="ixv-20381">P9Y9M18D</orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="c3" decimals="-3" id="ixv-23055" unitRef="usd">51038000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-23056"
      unitRef="shares">3054358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      decimals="2"
      id="ixv-23057"
      unitRef="usdPershares">7.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest contextRef="c0" id="ixv-20417">P9Y9M18D</orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExpectedToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c0" decimals="-3" id="ixv-23058" unitRef="usd">51038000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c171"
      decimals="2"
      id="ixv-23059"
      unitRef="usdPershares">6.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0" id="ixv-20487">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the weighted-average assumptions used in calculating the fair value of the employee warrants for the three
months ended September 30, 2024 and for the period from February&#160;6, 2024 (inception) to September 30, 2024:&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception) &lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected term (in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;99.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-143; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-144; font-family: Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c13" id="ixv-20530">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-20539">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c13" decimals="3" id="ixv-23060" unitRef="pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="3" id="ixv-23061" unitRef="pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c13" decimals="3" id="ixv-23062" unitRef="pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="3" id="ixv-23063" unitRef="pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-20609">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes the classification of the Company&#x2019;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#x202f;Months
                                            Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period
                                            from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,772&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;8,310&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,229&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,459&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,769&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c181"
      decimals="-3"
      id="ixv-23064"
      unitRef="usd">7772000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c182"
      decimals="-3"
      id="ixv-23065"
      unitRef="usd">8310000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c183"
      decimals="-3"
      id="ixv-23066"
      unitRef="usd">1229000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c184"
      decimals="-3"
      id="ixv-23067"
      unitRef="usd">1459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c13" decimals="-3" id="ixv-23068" unitRef="usd">9001000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-23069" unitRef="usd">9769000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c172"
      decimals="-5"
      id="ixv-23070"
      unitRef="usd">7500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c173" id="ixv-23071">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c174"
      decimals="-5"
      id="ixv-23072"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c167" id="ixv-23073">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="c175"
      decimals="-5"
      id="ixv-23074"
      unitRef="usd">17800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c171" id="ixv-23075">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c0" id="ixv-23076">The
following table summarizes the award types of the Company&#x2019;s stock-based compensation expense in the condensed consolidated statement
of operations and comprehensive loss (in thousands):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Three&#160;Months
                                            Ended &lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Period
                                            from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 76%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paruka
    warrant obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,251&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;7,681&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee
    warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,314&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Stock
    options&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;427&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Employee
    stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,001&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;9,769&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <orka:ParukaWarrantObligation contextRef="c13" decimals="-3" id="ixv-23077" unitRef="usd">7251000</orka:ParukaWarrantObligation>
    <orka:ParukaWarrantObligation contextRef="c0" decimals="-3" id="ixv-23078" unitRef="usd">7681000</orka:ParukaWarrantObligation>
    <orka:EmployeeWarrants contextRef="c13" decimals="-3" id="ixv-23079" unitRef="usd">1314000</orka:EmployeeWarrants>
    <orka:EmployeeWarrants contextRef="c0" decimals="-3" id="ixv-23080" unitRef="usd">1314000</orka:EmployeeWarrants>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c13" decimals="-3" id="ixv-23081" unitRef="usd">-427000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" id="ixv-23082" unitRef="usd">-765000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c13" decimals="-3" id="ixv-23083" unitRef="usd">9000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-23084" unitRef="usd">9000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c13" decimals="-3" id="ixv-23085" unitRef="usd">9001000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-23086" unitRef="usd">9769000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0" id="ixv-20841">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;9.
Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;No
provision for income taxes was recorded for the three months ended September 30, 2024 and for the period of February&#160;6, 2024 (inception)
through September 30, 2024. Deferred tax assets generated from the Company&#x2019;s net operating losses have been fully reserved, as
the Company believes it is not more likely than not that the benefit will be realized due to the Company&#x2019;s cumulative losses generated
to date.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c185" decimals="0" id="ixv-23087" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <orka:OptionAgreementsTextBlock contextRef="c0" id="ixv-20868">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;10.
Option Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
March&#160;2024, the Company entered into Option Agreements with Paragon and Paruka. Under the terms of the Option Agreements, Paragon
identifies, evaluates and develops antibodies directed against certain mutually agreed therapeutic targets of interest to the Company.
The Option Agreements include two selected targets, IL-23 (&#x201c;ORKA-001&#x201d;) and IL-17 A/F (&#x201c;ORKA-002&#x201d;). Under the
Option Agreements, the Company has the exclusive options to, on a research program-by-research program basis, be granted an exclusive,
worldwide license to all of Paragon&#x2019;s right, title and interest in and to the intellectual property resulting from the applicable
research program to develop, manufacture and commercialize the antibodies and products directed to the selected targets (each, an &#x201c;Option&#x201d;),
with the exception of pursuing ORKA-001 for the treatment of inflammatory bowel disease. If the Company exercises its options, it will
be required to make non-refundable milestone payments to Paragon of up to $12.0&#160;million under each respective agreement upon the
achievement of certain clinical development milestones, up to $10.0&#160;million under each respective agreement upon the achievement
of certain regulatory milestones as well as tiered royalty payments in the low-to-mid single-digits beginning on the first commercial
sale. From time to time, the Company can choose to add additional targets to the collaboration by mutual agreement with Paragon.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company&#x2019;s exclusive Option with respect to each research program for a particular target initiated by the parties (&#x201c;Research
Program&#x201d;) is exercisable at its sole discretion at any time during the period beginning on the initiation of activities under the
associated Research Program and ending a specified number of&#160;days following (i) with respect to any Research Program other than
ORKA-001, the delivery of the data package from Paragon related to the results of the Research Plan activities, or (ii) with respect
to ORKA-001, the completion of the IL-23 antibody selection process described in the agreement (the &#x201c;Option Period&#x201d;). There
is no payment due upon exercise of an Option pursuant to the Option Agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Unless
terminated earlier, the Option Agreements shall continue in force on a Research Program-by-Research Program basis until the earlier of:
(i)&#160;the end of the Option Period for such Research Program, as applicable, if such Option is not exercised by the Company; (ii)&#160;the
expiration of the 30-day period after the Company exercises its Option with respect to such Research Program, subject to mutually agreed
extension, during the Option Period and the parties are unable to finalize and execute a license agreement, and (iii) the expiration
of the applicable research term (the &#x201c;Term&#x201d;). Upon the expiration of the Term for all then-existing Research Programs, under
the Option Agreements, the Option Agreements will automatically expire in its entirety. The Company may terminate the Option Agreements
or any Research Program at any time for any or no reason upon 30&#160;days&#x2019; prior written notice to Paragon, provided that the
Company must pay certain unpaid fees due to Paragon upon such termination, as well as any non-cancellable obligations reasonably incurred
by Paragon in connection with its activities under any terminated Research Program. Paragon may terminate the Option Agreements or a
Research Program immediately upon written notice to the Company if, as a result of any action or failure to act by the Company or its
affiliates, such Research Program or all material activities under the applicable Research Plan are suspended, discontinued or otherwise
delayed for a certain consecutive number of months. Each party has the right to terminate the Option Agreements or any Research Program
upon (i)&#160;30&#160;days&#x2019; prior written notice of the other party&#x2019;s material breach that remains uncured for the 30-day
period and (ii)&#160;the other party&#x2019;s bankruptcy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Pursuant to the Option Agreements, on a research
program-by-research program basis following the finalization of the research plan for each respective research program, the Company was
required to pay Paragon a one-time, nonrefundable research initiation fee of $0.8&#160;million related to the ORKA-001 program. This amount
was recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. In
June 2024, pursuant to the Option Agreements with Paragon, the Company completed the selection process of its development candidate for
IL-23 antibody for ORKA-001 program. The Company was responsible for 50% of the development costs incurred through the completion of the
IL-23 selection process. The Company received the rights to at least one selected IL-23 antibody in June 2024. During the three months
ended September 30, 2024, the Company exercised its option for ORKA-001 and recorded a $1.5 million milestone payment related to the achievement
of development candidate as research and development expense in the Company&#x2019;s condensed consolidated statements of operations and
comprehensive loss for each of the three months ended September 30, 2024 and for the period from February 6, 2024 (inception) to September
30, 2024. The Company&#x2019;s share of development costs incurred during the three months ended September 30, 3024 and for the period
from February 6, 2024 (inception) to September 30, 2024 was $0.8 million and $13.2 million, respectively, which were recorded as research
and development expenses during the respective periods. An amount of $2.3 million is included in related party accounts payable and other
current liabilities as of September 30, 2024.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The Company was also required to reimburse Paragon
$3.3&#160;million for development costs related to ORKA-002 incurred by Paragon through December&#160;31, 2023 and certain other development
costs incurred by Paragon between January&#160;1, 2024 and March&#160;6, 2024 as stipulated by the Option Agreements. This amount was
recognized as a research and development expense during the period from February&#160;6, 2024 (inception) to September 30, 2024. The Company
is also responsible for the development costs incurred by Paragon from January&#160;1, 2024 through the completion of the IL-17 selection
process. The Company recognized an amount of $0.8&#160;million payable to Paragon for the research initiation fee related to ORKA-002
following the finalization of the ORKA-002 research plan. This was recognized as research and development expenses in the period from
February 6, 2024 (inception) to September 30, 2024. The Company accounted for development costs of $3.8 million and $6.6 million during
the three months ended September 30, 3024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively, as
research and development expenses during the respective periods. An amount of $3.8 million is included in related party accounts payable
and other current liabilities as of September 30, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
part of the Option Agreements, on each of December 31, 2024 and December 31, 2025, the Company will grant warrants to purchase a number
of shares equal to 1.00% of outstanding shares as of the date of the grant on a fully diluted basis with an exercise price equal to the
fair market value of the underlying shares on the grant date. The warrants are liability-classified and after the initial recognition,
the liability is adjusted to fair value at the end of each reporting period, with changes in fair value recorded in the consolidated
statement of operations and comprehensive loss (see Note&#160;8) as stock-based compensation expenses under research and development
expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company expenses the service fees as the associated costs are incurred when the underlying services are rendered. Such amounts are classified
within research and development expenses in the accompanying condensed consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
Company concluded that the rights obtained under the Option Agreements represent an asset acquisition whereby the underlying assets comprise
in-process research and development assets with no alternative future use. The Option Agreements did not qualify as a business combination
because substantially all of the fair value of the assets acquired was concentrated in the exclusive license options, which represent
a group of similar identifiable assets. The research initiation fee represents a one-time cost on a research program-by-research program
basis for accessing research services or resources with benefits that are expected to be consumed in the near term, therefore the amounts
paid are expensed as part of research and development costs immediately. Amounts paid as reimbursements of ongoing development cost,
monthly development cost fee and additional development expenses incurred by Paragon due to work completed for selected targets prior
to the effective date of the Option Agreements that is associated with services being rendered under the related Research Programs are
recognized as research and development expense when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;For
the three months ended September 30, 2024 and the period from February&#160;6, 2024 (inception) to September 30, 2024, the Company recognized
$13.4 million and $33.8 million of expenses, respectively, in connection with services provided by Paragon and Paruka under the Option
Agreements.&lt;/span&gt;&lt;/p&gt;</orka:OptionAgreementsTextBlock>
    <orka:NonRefundableMilestonePayments
      contextRef="c186"
      decimals="-5"
      id="ixv-23088"
      unitRef="usd">12000000</orka:NonRefundableMilestonePayments>
    <orka:NonRefundableMilestonePayments
      contextRef="c187"
      decimals="-5"
      id="ixv-23089"
      unitRef="usd">10000000</orka:NonRefundableMilestonePayments>
    <us-gaap:PaymentsForFees contextRef="c0" decimals="-5" id="ixv-23090" unitRef="usd">800000</us-gaap:PaymentsForFees>
    <orka:DevelopmentCostsPercentage contextRef="c0" decimals="2" id="ixv-23091" unitRef="pure">0.50</orka:DevelopmentCostsPercentage>
    <orka:MilestonePayment
      contextRef="c188"
      decimals="-5"
      id="ixv-23092"
      unitRef="usd">1500000</orka:MilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c183"
      decimals="-5"
      id="ixv-23093"
      unitRef="usd">800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c184"
      decimals="-5"
      id="ixv-23094"
      unitRef="usd">13200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c5" decimals="-5" id="ixv-23095" unitRef="usd">2300000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <orka:OtherDevelopmentCost contextRef="c87" decimals="-5" id="ixv-23096" unitRef="usd">3300000</orka:OtherDevelopmentCost>
    <us-gaap:OtherNotesPayable contextRef="c3" decimals="-5" id="ixv-23097" unitRef="usd">800000</us-gaap:OtherNotesPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c181"
      decimals="-5"
      id="ixv-23098"
      unitRef="usd">3800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c182"
      decimals="-5"
      id="ixv-23099"
      unitRef="usd">6600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities contextRef="c3" decimals="-5" id="ixv-23100" unitRef="usd">3800000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <orka:PercentageOfWarrantPurchare
      contextRef="c189"
      decimals="4"
      id="ixv-23101"
      unitRef="pure">0.01</orka:PercentageOfWarrantPurchare>
    <orka:PercentageOfWarrantPurchare
      contextRef="c190"
      decimals="4"
      id="ixv-23102"
      unitRef="pure">0.01</orka:PercentageOfWarrantPurchare>
    <us-gaap:OtherExpenses contextRef="c13" decimals="-5" id="ixv-23103" unitRef="usd">13400000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-5" id="ixv-23104" unitRef="usd">33800000</us-gaap:OtherExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-20926">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;11.
Commitment and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
April 2024, the Company entered into an operating lease agreement for the Company&#x2019;s headquarters in Menlo Park, California, which
commenced on June 15, 2024 with an initial term of 39.5 months. The Company leases office space under this noncancelable operating lease
agreement. Lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining
the present value of lease payments, the Company used its incremental borrowing rate when measuring operating lease liabilities as discount
rates were not implicit or readily determinable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;As
of September 30, 2024, the Company had $0.9 million of operating lease right-of-use assets, operating lease liability, current of $0.1
million, and operating lease liability, noncurrent of $0.8 million on its condensed consolidated balance sheets. As of September 30,
2024, the operating lease arrangement had a remaining lease term of 36.0 months and a discount rate of 17.95%. For the three months ended
September 30, 2024 and the period from February 6, 2024 (inception) to September 30, 2024, the Company recorded operating and variable
lease expense of $0.1 and $0.2 million, respectively, in general and administrative expenses in its condensed consolidated statements
of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    cash flow from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal
    year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024
    (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;380&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(318&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;988&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(146&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c191" id="ixv-23105">P39M15D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c192"
      decimals="-5"
      id="ixv-23106"
      unitRef="usd">900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-5" id="ixv-23107" unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-5" id="ixv-23108" unitRef="usd">800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3" id="ixv-23109">P36M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c3" decimals="4" id="ixv-23110" unitRef="pure">0.1795</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c13" decimals="-5" id="ixv-23111" unitRef="usd">100000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c0" decimals="-5" id="ixv-23112" unitRef="usd">200000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0" id="ixv-20946">&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s supplemental cash flow information related to leases (in thousands):&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;September
    30, &lt;br/&gt; 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Cash
    paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Operating
    cash flow from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c0" decimals="-3" id="ixv-23113" unitRef="usd">74000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0" id="ixv-23114">The
following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments
as of September 30, 2024 (in thousands):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Fiscal
    year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2024
    (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;63&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;369&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;494&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;380&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1,306&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(318&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total
    discounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;988&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Less:
    current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;(146&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Non-current
    portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;842&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c3" decimals="-3" id="ixv-23115" unitRef="usd">63000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c3" decimals="-3" id="ixv-23116" unitRef="usd">369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c3" decimals="-3" id="ixv-23117" unitRef="usd">494000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c3" decimals="-3" id="ixv-23118" unitRef="usd">380000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c3" decimals="-3" id="ixv-23119" unitRef="usd">1306000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c3" decimals="-3" id="ixv-23120" unitRef="usd">318000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="-3" id="ixv-23121" unitRef="usd">988000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" id="ixv-23122" unitRef="usd">146000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" id="ixv-23123" unitRef="usd">842000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0" id="ixv-21131">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;12.
Net Loss per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss&lt;br/&gt;
 Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Shares&lt;br/&gt;
 Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss Per&lt;br/&gt;
 Share &#x2013;&lt;br/&gt;
 Basic and&lt;br/&gt;
 Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss&lt;br/&gt;
 Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Shares Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss Per&lt;br/&gt;
 Share &#x2013;&lt;br/&gt;
 Basic and&lt;br/&gt;
 Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(21,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;15,013,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(1.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(47,192&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7,765,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(6.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Company Series A Preferred Stock&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(697&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,460.62&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,077.13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Company Series B Preferred Stock&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;49,191&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(121.77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;19,015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(506.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(28,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(57,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was 477,196 and 184,462 for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,099,227 and 1,584,575 for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;For the computation of basic net loss per share
attributable to stockholders, the amount of weighted-average shares outstanding excludes all shares of unvested restricted common stock
as such shares are not considered outstanding for accounting purposes until vested. The amount of weighted-average shares outstanding
includes the pre-funded warrants as the exercise price is negligible and these warrants are fully vested and exercisable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding employee warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding unvested restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and issued common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,287,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,287,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,549,671&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,549,671&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0" id="ixv-23124">Basic and diluted net loss per share attributable
to stockholders were calculated as follows (in thousands, except share and per share data):&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss&lt;br/&gt;
 Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
 Average&lt;br/&gt;
 Shares&lt;br/&gt;
 Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss Per&lt;br/&gt;
 Share &#x2013;&lt;br/&gt;
 Basic and&lt;br/&gt;
 Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss&lt;br/&gt;
 Allocation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted Average Shares Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Loss Per&lt;br/&gt;
 Share &#x2013;&lt;br/&gt;
 Basic and&lt;br/&gt;
 Diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Common Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(21,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;15,013,655&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(1.46&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(47,192&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;7,765,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 7%; text-align: right"&gt;(6.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Company Series A Preferred Stock&lt;sup&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(697&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;477&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,460.62&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,121&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,077.13&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;&lt;span style="font-size: 10pt"&gt;Company Series B Preferred Stock&lt;sup&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,990&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;49,191&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(121.77&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,630&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;19,015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;(506.44&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(28,623&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(57,943&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The weighted-average number of
shares of as-converted Company Series A Preferred Stock used in the loss allocation was 477,196 and 184,462 for the three months ended
September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The weighted-average number of
shares of as-converted Company Series B Preferred Stock used in the loss allocation was 4,099,227 and 1,584,575 for the three months
ended September 30, 2024 and for the period from February 6, 2024 (inception) to September 30, 2024, respectively.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <orka:CommonStockLossAllocation contextRef="c13" decimals="-3" id="ixv-23125" unitRef="usd">-21936000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c13"
      decimals="INF"
      id="ixv-23126"
      unitRef="shares">15013655</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c13"
      decimals="2"
      id="ixv-23127"
      unitRef="usdPershares">-1.46</us-gaap:EarningsPerShareBasic>
    <orka:CommonStockLossAllocation contextRef="c0" decimals="-3" id="ixv-23128" unitRef="usd">-47192000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-23129"
      unitRef="shares">7765381</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-23130"
      unitRef="usdPershares">-6.08</us-gaap:EarningsPerShareBasic>
    <orka:CommonStockLossAllocation
      contextRef="c193"
      decimals="-3"
      id="ixv-23131"
      unitRef="usd">-697000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c193"
      decimals="INF"
      id="ixv-23132"
      unitRef="shares">477</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c193"
      decimals="2"
      id="ixv-23133"
      unitRef="usdPershares">-1460.62</us-gaap:EarningsPerShareBasic>
    <orka:CommonStockLossAllocation
      contextRef="c120"
      decimals="-3"
      id="ixv-23134"
      unitRef="usd">-1121000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c120"
      decimals="INF"
      id="ixv-23135"
      unitRef="shares">184</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c120"
      decimals="2"
      id="ixv-23136"
      unitRef="usdPershares">-6077.13</us-gaap:EarningsPerShareBasic>
    <orka:CommonStockLossAllocation
      contextRef="c194"
      decimals="-3"
      id="ixv-23137"
      unitRef="usd">-5990000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c194"
      decimals="INF"
      id="ixv-23138"
      unitRef="shares">49191</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c194"
      decimals="2"
      id="ixv-23139"
      unitRef="usdPershares">-121.77</us-gaap:EarningsPerShareBasic>
    <orka:CommonStockLossAllocation
      contextRef="c195"
      decimals="-3"
      id="ixv-23140"
      unitRef="usd">-9630000</orka:CommonStockLossAllocation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c195"
      decimals="INF"
      id="ixv-23141"
      unitRef="shares">19015</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c195"
      decimals="2"
      id="ixv-23142"
      unitRef="usdPershares">-506.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss contextRef="c13" decimals="-3" id="ixv-23143" unitRef="usd">-28623000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" id="ixv-23144" unitRef="usd">-57943000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c193"
      decimals="0"
      id="ixv-23145"
      unitRef="shares">477196</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c120"
      decimals="0"
      id="ixv-23146"
      unitRef="shares">184462</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c194"
      decimals="0"
      id="ixv-23147"
      unitRef="shares">4099227</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="c195"
      decimals="0"
      id="ixv-23148"
      unitRef="shares">1584575</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-23149">The potential shares of common stock that were excluded
from the computation of diluted net loss per share attributable to stockholders for the periods presented because including them would
have had an anti-dilutive effect were as follows:&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three&#160;Months Ended&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Period from&lt;br/&gt; February&#160;6,&lt;br/&gt; 2024&lt;br/&gt; (Inception)&lt;br/&gt; to&lt;br/&gt; September&#160;30,&lt;br/&gt; 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Outstanding employee warrants to purchase common stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,054,358&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Outstanding unvested restricted stock awards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,207,553&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and issued common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,287,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,287,760&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,549,671&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,549,671&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c196"
      decimals="INF"
      id="ixv-23150"
      unitRef="shares">3054358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c197"
      decimals="INF"
      id="ixv-23151"
      unitRef="shares">3054358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c198"
      decimals="INF"
      id="ixv-23152"
      unitRef="shares">2207553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c199"
      decimals="INF"
      id="ixv-23153"
      unitRef="shares">2207553</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c200"
      decimals="INF"
      id="ixv-23154"
      unitRef="shares">1287760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c201"
      decimals="INF"
      id="ixv-23155"
      unitRef="shares">1287760</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c13"
      decimals="INF"
      id="ixv-23156"
      unitRef="shares">6549671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-23157"
      unitRef="shares">6549671</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-21382">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;13.
Related Party Transactions&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
and Paruka each beneficially own less than 5% of the Company&#x2019;s capital stock through their respective holdings of Company Common
Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;Fairmount beneficially owns more than 5% of the
Company&#x2019;s capital, currently has one representative appointed to the Board, and beneficially owns more than 5% of Paragon. Fairmount
appointed Paragon&#x2019;s board of directors and has the contractual right to approve the appointment of any executive officers of Paragon.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;The
following is a summary of related party accounts payable and other current liabilities (in thousands):&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable Option Agreements&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable other research expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable patent expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c202"
      decimals="2"
      id="ixv-23158"
      unitRef="pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c203"
      decimals="2"
      id="ixv-23159"
      unitRef="pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="c204"
      decimals="2"
      id="ixv-23160"
      unitRef="pure">0.05</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <srt:ScheduleOfCondensedFinancialStatementsTableTextBlock contextRef="c0" id="ixv-23161">The
following is a summary of related party accounts payable and other current liabilities (in thousands):&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;September&#160;30,&lt;br/&gt;
                                            2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable Option Agreements&#x2019; fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,140&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable other research expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;146&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Paragon
    reimbursable patent expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;71&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font-family: Times New Roman, Times, Serif; vertical-align: bottom; background-color: transparent"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;6,357&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedFinancialStatementsTableTextBlock>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c205"
      decimals="-3"
      id="ixv-23162"
      unitRef="usd">6140000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c206"
      decimals="-3"
      id="ixv-23163"
      unitRef="usd">146000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="c207"
      decimals="-3"
      id="ixv-23164"
      unitRef="usd">71000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c5" decimals="-3" id="ixv-23165" unitRef="usd">6357000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      id="hidden-fact-2"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:SubscriptionReceivables
      contextRef="c3"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c4"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c4"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c4"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableCurrent
      contextRef="c4"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="c4"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c4"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c6"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="c4"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesCurrent
      contextRef="c4"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c4"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="c4"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c4"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c7"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c8"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c7"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c8"
      id="hidden-fact-23"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c7"
      id="hidden-fact-24"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c8"
      id="hidden-fact-25"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c10"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c10"
      id="hidden-fact-27"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c10"
      id="hidden-fact-28"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c10"
      id="hidden-fact-29"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c12"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c12"
      id="hidden-fact-31"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c12"
      id="hidden-fact-32"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c12"
      id="hidden-fact-33"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c4"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c4"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c18"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c19"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c20"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c23"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c25"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c26"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c27"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c30"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c31"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c26"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c27"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c28"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c29"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c30"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c31"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c25"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c26"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c27"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c28"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c30"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c25"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c26"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c27"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c33"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c34"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c39"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c40"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c41"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c42"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c44"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c39"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c40"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c41"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c42"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c43"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c47"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c48"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt
      contextRef="c54"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt
      contextRef="c56"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt
      contextRef="c57"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ExchangeOfSeriesAConvertiblePreferredStockForSeriesBNonvotingConvertiblePreferredSt
      contextRef="c58"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c53"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c54"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c55"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c58"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c53"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c54"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c55"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockAndPrefundedWarrantsInThePreclosingFinancingNetOfOfferingCos
      contextRef="c58"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization
      contextRef="c53"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization
      contextRef="c54"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization
      contextRef="c55"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization
      contextRef="c56"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceCostsOfPreclosingFinancingAndReverseRecapitalization
      contextRef="c58"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger
      contextRef="c53"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger
      contextRef="c54"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger
      contextRef="c55"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:AdjustmentForChangeInCommonStockParValueInConnectionWithTheReverseMerger
      contextRef="c58"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c53"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c55"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:IssuanceOfCommonStockSeriesANonvotingConvertiblePreferredStockAndPrefundedWarr
      contextRef="c58"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c53"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c54"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c55"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c56"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c57"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="c59"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c24"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c129"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c130"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c133"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c134"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="c0" id="hidden-fact-110" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c0"
      id="hidden-fact-111"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="c149"
      id="hidden-fact-112"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c176"
      id="hidden-fact-113"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c177"
      id="hidden-fact-114"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c24"
      id="hidden-fact-115"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c24"
      id="hidden-fact-116"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="c0" id="hidden-fact-117" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c24"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-119"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-120"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      id="hidden-fact-121"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-122"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c3"
      id="hidden-fact-123"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c3"
      id="hidden-fact-124"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-125" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c3"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="c178"
      id="hidden-fact-127"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c178"
      id="hidden-fact-128"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c179"
      id="hidden-fact-129"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c180"
      id="hidden-fact-130"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c24"
      id="hidden-fact-131"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c24"
      id="hidden-fact-132"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="hidden-fact-133" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="c24"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercised
      contextRef="c0"
      id="hidden-fact-135"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-136"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c0"
      id="hidden-fact-137"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-138"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisable
      contextRef="c0"
      id="hidden-fact-139"
      unitRef="shares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableInPeriodWeightedAverageGrantDateFairValue
      contextRef="c0"
      id="hidden-fact-140"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <orka:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisablePeriodWeightedAverageGrantDateFairValue contextRef="c0" id="hidden-fact-141" xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="c0"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c13"
      id="hidden-fact-143"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c0"
      id="hidden-fact-144"
      unitRef="pure"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0" id="ixv-23313">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-23314">0000907654</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $13,537 for the three months ended September 30, 2024 and $33,967 for the period from February 6, 2024 (inception) to September 30, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_2_fact"
          xlink:label="ix_2_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_3_fact"
          xlink:label="ix_3_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $71 for the three months ended September 30, 2024 and $1,339 for the period from February 6, 2024 (inception) to September 30, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_2_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_3_fact"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#ix_4_fact"
          xlink:label="ix_4_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_5_fact"
          xlink:label="ix_5_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_2_footnote" xlink:label="ix_2_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes related party amount of $504 for the three months ended September 30, 2024 and $1,468 for the period from February 6, 2024 (inception) to September 30, 2024</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_4_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_5_fact"
          xlink:to="ix_2_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
